Experiments	0	O
on	0	O
narcotized	0	O
cats	0	O
demonstrated	0	O
that	0	O
the	0	O
derivatives	0	O
of	0	O
2	0	O
-	0	O
mercaptobenzimidazole	0	O
possessing	0	O
the	0	O
properties	0	O
of	0	O
specific	0	O
bradycardic	0	O
agents	0	O
and	0	O
coded	0	O
as	0	O
CM	1	O
-	0	O
251	0	O
,	0	O
CM	1	O
-	0	O
266	0	O
,	0	O
and	0	O
CM	1	O
-	0	O
345	0	O
,	0	O
reduce	0	O
the	0	O
mean	0	O
rise	0	O
of	0	O
segment	0	O
ST	1	O
on	0	O
numerous	0	O
leads	0	O
of	0	O
the	0	O
epicardial	0	O
electrogram	0	O
during	0	O
5	0	O
-	0	O
min	0	O
occlusion	0	O
of	0	O
the	0	O
anterior	0	O
descending	0	O
branch	0	O
of	0	O
the	0	O
left	0	O
coronary	0	O
artery	0	O
.	0	O


Its	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
shows	0	O
extensive	0	O
homology	0	O
to	0	O
those	0	O
of	0	O
Drosophila	1	B
hsp70	0	I
,	0	O
trout	0	B
hsp70	0	I
,	0	O
Xenopus	1	B
hsp70	0	I
,	0	O
yeast	0	B
hsp70	0	I
,	0	O
and	0	O
some	0	O
homology	0	O
to	0	O
the	0	O
heat	0	B
-	0	I
inducible	0	I
dnaK	0	I
gene	0	I
product	0	I
of	0	O
Escherichia	1	O
coli	0	O
.	0	O


A	1	O
chromosome	0	B
transmission	0	I
fidelity	0	I
(	0	O
ctf	0	B
)	0	O
mutant	0	O
,	0	O
s138	0	O
,	0	O
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
was	0	O
identified	0	O
by	0	O
its	0	O
centromere	0	O
(	0	O
CEN	1	O
)	0	O
transcriptional	0	O
readthrough	0	O
phenotype	0	O
,	0	O
suggesting	0	O
perturbed	0	O
kinetochore	0	O
integrity	0	O
in	0	O
vivo	0	O
.	0	O


Spfkh1	0	B
is	0	O
transcribed	0	O
in	0	O
one	0	O
open	0	O
reading	0	O
frame	0	O
that	0	O
contains	0	O
the	0	O
DNA	1	O
binding	0	O
domain	0	O
,	0	O
nuclear	0	O
localization	0	O
signal	0	O
and	0	O
transactivation	0	O
domain	0	O
.	0	O


Antileukoproteinase	0	B
(	0	O
ALP	1	B
)	0	O
is	0	O
a	0	O
low	0	O
mol	0	O
wt	0	O
mucosal	0	O
secretory	0	O
protein	0	O
which	0	O
,	0	O
in	0	O
human	0	O
tissues	0	O
,	0	O
inhibits	0	O
the	0	O
activities	0	O
of	0	O
the	0	O
neutral	0	O
serine	0	B
lysosomal	0	I
proteinases	0	I
elastase	0	I
and	0	O
cathepsin	0	B
-	0	I
G	1	I
.	0	O


Owing	0	O
to	0	O
parental	0	O
attitude	0	O
,	0	O
a	0	O
low	0	O
protein	0	O
diet	0	O
(	0	O
1	0	O
-	0	O
5	0	O
g	0	O
/	0	O
kg	0	O
)	0	O
was	0	O
introduced	0	O
only	0	O
late	0	O
.	0	O


Critical	1	O
evaluation	0	O
of	0	O
various	0	O
methods	0	O
of	0	O
determining	0	O
markers	0	O
of	0	O
fetal	0	O
maturity	0	O
in	0	O
amniotic	0	O
fluid	0	O


Six	0	O
patients	0	O
with	0	O
glomerulonephritis	0	O
in	0	O
association	0	O
with	0	O
a	0	O
ventriculovascular	0	O
shunt	0	O
were	0	O
treated	0	O
with	0	O
three	0	O
basic	0	O
modes	0	O
of	0	O
therapy	0	O
.	0	O


These	0	O
protective	0	O
influences	0	O
were	0	O
observed	0	O
throughout	0	O
the	0	O
range	0	O
of	0	O
filling	0	O
pressures	0	O
measured	0	O
,	0	O
from	0	O
0	0	O
to	0	O
30	0	O
mmHg	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
extracts	0	O
of	0	O
the	0	O
mutant	0	O
virions	0	O
catalyze	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
level	0	O
of	0	O
transcription	0	O
from	0	O
an	0	O
exogenous	0	O
template	0	O
containing	0	O
an	0	O
early	0	O
promoter	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
this	0	O
anatomic	0	O
concept	0	O
,	0	O
the	0	O
brachioplasty	0	O
procedure	0	O
was	0	O
modified	0	O
to	0	O
provide	0	O
secure	0	O
anchoring	0	O
of	0	O
the	0	O
arm	0	O
flap	0	O
to	0	O
the	0	O
axillary	0	O
fascia	0	O
along	0	O
with	0	O
strong	0	O
superficial	0	O
fascial	0	O
system	0	O
repair	0	O
of	0	O
incisions	0	O
,	0	O
reducing	0	O
the	0	O
risk	0	O
of	0	O
widening	0	O
or	0	O
migration	0	O
of	0	O
scars	0	O
and	0	O
unnatural	0	O
contours	0	O
.	0	O


Immunochemical	1	O
studies	0	O
with	0	O
filarial	0	O
antigens	0	O
.	0	O


The	0	O
application	0	O
of	0	O
ultrafiltration	0	O
to	0	O
sample	0	O
preparation	0	O
in	0	O
the	0	O
detection	0	O
and	0	O
quantification	0	O
of	0	O
ethylene	0	O
glycol	0	O
in	0	O
plasma	0	O
by	0	O
gas	0	O
chromatography	0	O
is	0	O
described	0	O
.	0	O


In	1	O
8	0	O
healthy	0	O
volunteers	0	O
there	0	O
were	0	O
no	0	O
significant	0	O
differences	0	O
in	0	O
AUC	1	O
,	0	O
peak	0	O
plasma	0	O
concentrations	0	O
or	0	O
time	0	O
to	0	O
peak	0	O
concentration	0	O
when	0	O
OXC	0	O
was	0	O
administered	0	O
either	0	O
with	0	O
or	0	O
without	0	O
ERY	0	O
.	0	O


The	0	O
subgroup	0	O
innervating	0	O
the	0	O
medial	0	O
rectus	0	O
lies	0	O
exclusively	0	O
along	0	O
the	0	O
medial	0	O
face	0	O
of	0	O
the	0	O
oculomotor	0	O
nucleus	0	O
,	0	O
with	0	O
no	0	O
aberrant	0	O
neurons	0	O
in	0	O
the	0	O
medial	0	O
longitudinal	0	O
fasciculus	0	O
,	0	O
as	0	O
have	0	O
been	0	O
found	0	O
in	0	O
other	0	O
mammals	0	O
.	0	O


The	0	O
imprinted	0	O
expression	0	O
of	0	O
the	0	O
endogenous	0	O
gene	0	O
can	0	O
be	0	O
recapitulated	0	O
in	0	O
mice	0	O
by	0	O
using	0	O
a	0	O
14	0	O
-	0	O
kb	0	O
transgene	0	O
encompassing	0	O
4	0	O
kb	0	O
of	0	O
5	0	O
'-	0	O
flanking	0	O
sequence	0	O
,	0	O
8	0	O
kb	0	O
of	0	O
3	0	O
'-	0	O
flanking	0	O
sequence	0	O
,	0	O
which	0	O
includes	0	O
the	0	O
two	0	O
endoderm	0	O
-	0	O
specific	0	O
enhancers	0	O
,	0	O
and	0	O
an	0	O
internally	0	O
deleted	0	O
structural	0	O
gene	0	O
.	0	O


This	0	O
study	0	O
indicated	0	O
that	0	O
the	0	O
Japanese	0	O
quail	0	O
was	0	O
less	0	O
sensitive	0	O
to	0	O
particulate	0	O
Mn3O4	0	O
exposure	0	O
than	0	O
rodents	0	O
treated	0	O
comparably	0	O
.	0	O


Drug	1	O
and	0	O
nutrient	0	O
interactions	0	O
.	0	O


The	0	O
SH2	0	B
and	0	O
SH3	0	B
domains	0	I
of	0	O
pp60src	0	B
direct	0	O
stable	0	O
association	0	O
with	0	O
tyrosine	0	O
phosphorylated	0	O
proteins	0	O
p130	0	B
and	0	O
p110	0	B
.	0	O


Thus	0	O
,	0	O
VDR	0	B
acts	0	O
selectively	0	O
on	0	O
the	0	O
two	0	O
components	0	O
required	0	O
for	0	O
activation	0	O
of	0	O
this	0	O
promoter	0	O
/	0	O
enhancer	0	O
:	0	O
it	0	O
competes	0	O
with	0	O
NFAT1	0	B
for	0	O
binding	0	O
to	0	O
the	0	O
composite	0	O
site	0	O
,	0	O
positioning	0	O
itself	0	O
adjacent	0	O
to	0	O
Jun	1	B
-	0	O
Fos	1	B
on	0	O
the	0	O
DNA	1	O
.	0	O


The	0	O
RAT3	0	B
gene	0	I
encodes	0	O
an	0	O
1157	0	O
-	0	O
amino	0	O
acid	0	O
protein	0	O
without	0	O
similarity	0	O
to	0	O
other	0	O
known	0	O
proteins	0	O
.	0	O


The	0	O
26S	0	B
rRNA	1	I
binding	0	I
ribosomal	0	I
protein	0	I
equivalent	0	O
to	0	O
bacterial	0	B
protein	0	I
L11	0	I
is	0	O
encoded	0	O
by	0	O
unspliced	0	O
duplicated	0	O
genes	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Four	0	O
putative	0	O
positive	0	O
cDNA	1	O
clones	0	O
were	0	O
isolated	0	O
,	0	O
and	0	O
the	0	O
largest	0	O
insert	0	O
(	0	O
pASB	0	B
-	0	I
1	0	I
)	0	O
was	0	O
sequenced	0	O
in	0	O
both	0	O
orientations	0	O
.	0	O


The	0	O
two	0	O
-	0	O
hybrid	0	O
assay	0	O
was	0	O
then	0	O
performed	0	O
using	0	O
full	0	O
-	0	O
length	0	O
genes	0	O
of	0	O
CI	1	B
,	0	O
HC	1	B
-	0	I
Pro	1	I
,	0	O
P1	1	B
,	0	O
P3	0	B
,	0	O
and	0	O
CP	1	B
,	0	O
but	0	O
no	0	O
heterologous	0	O
interactions	0	O
were	0	O
detected	0	O
.	0	O


Also	0	O
in	0	O
the	0	O
spectrum	0	O
of	0	O
mutants	0	O
with	0	O
TGN	1	O
sorting	0	O
defects	0	O
are	0	O
isolates	0	O
with	0	O
mutations	0	O
in	0	O
the	0	O
following	0	O
:	0	O
RIC1	0	B
,	0	O
encoding	0	O
a	0	O
product	0	O
originally	0	O
proposed	0	O
to	0	O
participate	0	O
in	0	O
ribosome	0	O
biogenesis	0	O
;	0	O
LUV1	0	B
,	0	O
encoding	0	O
a	0	O
product	0	O
potentially	0	O
involved	0	O
in	0	O
vacuole	0	O
and	0	O
microtubule	0	O
organization	0	O
;	0	O
and	0	O
INP53	0	B
,	0	O
encoding	0	O
a	0	O
synaptojanin	0	B
-	0	I
like	0	I
inositol	0	I
polyphosphate	0	I
5	0	I
-	0	I
phosphatase	0	I
.	0	O


AIMS	0	O
:	0	O
To	1	O
evaluate	0	O
the	0	O
role	0	O
of	0	O
environmental	0	O
intra	0	O
-	0	O
uterine	0	O
factors	0	O
in	0	O
determining	0	O
the	0	O
birthweights	0	O
of	0	O
twins	0	O
with	0	O
increased	0	O
susceptibility	0	O
to	0	O
diabetes	0	O
and	0	O
discordant	0	O
for	0	O
abnormal	0	O
responses	0	O
to	0	O
the	0	O
oral	0	O
glucose	0	O
tolerance	0	O
test	0	O
(	0	O
OGTT	1	O
)	0	O
and	0	O
verify	0	O
the	0	O
possible	0	O
association	0	O
of	0	O
within	0	O
-	0	O
pair	0	O
birthweight	0	O
differences	0	O
and	0	O
metabolic	0	O
abnormalities	0	O
in	0	O
adult	0	O
life	0	O
.	0	O


Both	0	O
TRE	0	O
-	0	O
like	0	O
elements	0	O
were	0	O
capable	0	O
of	0	O
binding	0	O
AP1	0	B
.	0	O


S6	0	B
kinase	0	I
activation	0	O
requires	0	O
displacement	0	O
of	0	O
this	0	O
inhibitory	0	O
segment	0	O
,	0	O
which	0	O
is	0	O
proposed	0	O
to	0	O
occur	0	O
consequent	0	O
to	0	O
its	0	O
multiple	0	O
phosphorylation	0	O
.	0	O


Using	0	O
the	0	O
rap1t	0	B
alleles	0	I
to	0	O
generate	0	O
wild	0	O
-	0	O
type	0	O
cells	0	O
differing	0	O
only	0	O
in	0	O
telomere	0	O
tract	0	O
lengths	0	O
,	0	O
we	0	O
also	0	O
show	0	O
that	0	O
telomere	0	O
position	0	O
effects	0	O
are	0	O
highly	0	O
sensitive	0	O
to	0	O
changes	0	O
in	0	O
the	0	O
size	0	O
(	0	O
or	0	O
structure	0	O
)	0	O
of	0	O
the	0	O
telomeric	0	O
tract	0	O
.	0	O


The	0	O
significance	0	O
of	0	O
structural	0	O
integrity	0	O
of	0	O
lymphoid	0	O
tissue	0	O
for	0	O
antibody	0	O
production	0	O
in	0	O
culture	0	O
in	0	O
vivo	0	O


Thus	0	O
,	0	O
the	0	O
inhibition	0	O
of	0	O
pepsin	0	B
in	0	O
human	0	O
gastric	0	O
juice	0	O
does	0	O
not	0	O
appear	0	O
to	0	O
have	0	O
a	0	O
major	0	O
influence	0	O
on	0	O
the	0	O
healing	0	O
of	0	O
duodenal	0	O
ulcer	0	O
.	0	O


It	1	O
was	0	O
argued	0	O
that	0	O
this	0	O
arose	0	O
from	0	O
the	0	O
possibility	0	O
that	0	O
the	0	O
nature	0	O
of	0	O
blue	0	O
collar	0	O
jobs	0	O
was	0	O
physical	0	O
,	0	O
and	0	O
that	0	O
loss	0	O
of	0	O
myocardial	0	O
tissue	0	O
might	0	O
be	0	O
expected	0	O
to	0	O
more	0	O
markedly	0	O
interfere	0	O
with	0	O
their	0	O
work	0	O
efficiency	0	O
(	0	O
on	0	O
returning	0	O
to	0	O
work	0	O
)	0	O
than	0	O
it	0	O
would	0	O
the	0	O
efficiency	0	O
of	0	O
the	0	O
more	0	O
sedentary	0	O
jobs	0	O
of	0	O
white	0	O
collar	0	O
workers	0	O
.	0	O


Certain	0	O
spt10	0	B
spontaneous	0	O
alleles	0	O
are	0	O
good	0	O
suppressors	0	O
but	0	O
have	0	O
a	0	O
normal	0	O
growth	0	O
rate	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
SPT10	0	B
protein	0	I
may	0	O
have	0	O
two	0	O
distinct	0	O
functions	0	O
.	0	O


Zebrafish	0	O
cyclops	0	B
(	0	O
cyc	0	B
)	0	O
encodes	0	O
a	0	O
Transforming	0	B
Growth	1	I
Factor	1	I
beta	0	I
(	0	O
TGFbeta	0	B
)	0	O
signaling	0	O
factor	0	O
closely	0	O
related	0	O
to	0	O
mouse	0	O
Nodal	1	B
.	0	O


Comparison	0	O
of	0	O
the	0	O
deduced	0	O
amino	0	B
acid	0	I
sequence	0	I
of	0	I
gamma	0	I
-	0	I
kafirin	0	I
with	0	O
the	0	O
published	0	O
sequences	0	B
of	0	I
gamma	0	I
-	0	I
prolamins	0	I
of	0	I
maize	0	I
,	0	I
and	0	I
Coix	0	I
revealed	0	O
highly	0	O
conserved	0	O
domains	0	O
.	0	O


The	0	O
proteins	0	O
encoded	0	O
downstream	0	O
of	0	O
rpoN	0	B
are	0	O
known	0	O
to	0	O
negatively	0	O
regulate	0	O
sigma	0	B
54	0	I
activity	0	O
.	0	O


Picture	0	O
the	0	O
smell	0	O
.	0	O


The	0	O
structural	0	O
analysis	0	O
also	0	O
demonstrated	0	O
that	0	O
the	0	O
heterogeneity	0	O
of	0	O
the	0	O
HDC	0	B
mRNA	1	I
is	0	O
caused	0	O
by	0	O
an	0	O
insertion	0	O
of	0	O
the	0	O
seventh	0	O
intron	0	O
sequence	0	O
and	0	O
alternative	0	O
use	0	O
of	0	O
the	0	O
splicing	0	O
acceptor	0	O
site	0	O
at	0	O
the	0	O
12th	0	O
exon	0	O
.	0	O


Most	0	O
patients	0	O
with	0	O
high	0	O
blood	0	O
pressure	0	O
(	0	O
BP	1	O
)	0	O
can	0	O
be	0	O
managed	0	O
by	0	O
using	0	O
one	0	O
of	0	O
4	0	O
classes	0	O
of	0	O
compounds	0	O
:	0	O
a	0	O
diuretic	0	O
,	0	O
beta	0	O
blocker	0	O
,	0	O
converting	0	O
enzyme	0	O
inhibitor	0	O
or	0	O
calcium	0	O
antagonist	0	O
.	0	O


A	1	O
7	0	O
-	0	O
day	0	O
treatment	0	O
of	0	O
amphotericin	0	O
B	1	O
(	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
i	0	O
.	0	O
p	0	O
.)	0	O
significantly	0	O
reduced	0	O
the	0	O
glomerular	0	O
filtration	0	O
rate	0	O
(	0	O
GFR	1	O
)	0	O
measured	0	O
as	0	O
inuline	0	O
clearance	0	O
and	0	O
creatinine	0	O
clearance	0	O
(	0	O
0	0	O
.	0	O
74	0	O
+/-	0	O
0	0	O
.	0	O
29	0	O
and	0	O
0	0	O
.	0	O
16	0	O
+/-	0	O
0	0	O
.	0	O
04	0	O
ml	0	O
/	0	O
min	0	O
,	0	O
respectively	0	O
)	0	O
in	0	O
comparison	0	O
to	0	O
vehicle	0	O
-	0	O
treated	0	O
rats	0	O
(	0	O
2	0	O
.	0	O
04	0	O
+/-	0	O
0	0	O
.	0	O
23	0	O
and	0	O
1	0	O
.	0	O
29	0	O
+/-	0	O
0	0	O
.	0	O
19	0	O
ml	0	O
/	0	O
min	0	O
,	0	O
respectively	0	O
).	0	O


Both	0	O
parents	0	O
are	0	O
clinically	0	O
normal	0	O
and	0	O
unrelated	0	O
.	0	O


A	1	O
portion	0	O
of	0	O
p193	0	B
is	0	O
nuclear	0	O
and	0	O
localizes	0	O
to	0	O
the	0	O
mitotic	0	O
spindle	0	O
.	0	O


As	1	O
was	0	O
observed	0	O
previously	0	O
for	0	O
MATa	0	B
cna1	0	I
cna2	0	I
double	0	O
mutants	0	O
,	0	O
MATa	0	B
cnb1	0	I
mutants	0	I
were	0	O
defective	0	O
in	0	O
their	0	O
ability	0	O
to	0	O
recover	0	O
from	0	O
alpha	0	B
-	0	I
factor	0	I
-	0	O
induced	0	O
growth	0	O
arrest	0	O
.	0	O


The	0	O
5	0	O
'-	0	O
nontranslated	0	O
sequences	0	O
and	0	O
parts	0	O
of	0	O
the	0	O
coding	0	O
sequences	0	O
of	0	O
various	0	O
yeast	0	O
genes	0	O
have	0	O
been	0	O
cloned	0	O
into	0	O
representative	0	O
lacZ	0	B
fusion	0	O
vectors	0	O
.	0	O


Large	0	O
scale	0	O
electronic	0	O
structure	0	O
calculations	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Checkpoint	1	O
pathways	0	O
prevent	0	O
cell	0	O
-	0	O
cycle	0	O
progression	0	O
in	0	O
the	0	O
event	0	O
of	0	O
DNA	1	O
lesions	0	O
.	0	O


Conversely	0	O
,	0	O
activated	0	O
glucocorticoid	0	B
receptors	0	I
suppressed	0	O
the	0	O
transactivation	0	O
function	0	O
of	0	O
p53	0	B
,	0	O
while	0	O
transrepression	0	O
by	0	O
p53	0	B
was	0	O
largely	0	O
unaffected	0	O
.	0	O


The	0	O
studied	0	O
protein	0	O
fragments	0	O
consist	0	O
of	0	O
residues	0	O
Arg183	0	O
-	0	O
His267	0	O
of	0	O
the	0	O
human	0	B
ER	1	I
and	0	O
residues	0	O
Lys438	0	O
-	0	O
Gln520	0	O
of	0	O
the	0	O
rat	0	O
GR	1	B
.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
also	0	O
show	0	O
that	0	O
cdk7	0	B
may	0	O
phosphorylate	0	O
the	0	O
carboxy	0	O
-	0	O
terminal	0	O
domain	0	O
(	0	O
CTD	1	O
)	0	O
of	0	O
RNA	1	B
pol	0	I
II	0	I
in	0	O
the	0	O
absence	0	O
of	0	O
promoter	0	O
opening	0	O
.	0	O


Thus	0	O
,	0	O
growth	0	O
factor	0	O
activation	0	O
of	0	O
ER	1	B
can	0	O
mediate	0	O
transactivation	0	O
vs	0	O
ER	1	B
/	0	O
Sp1	0	B
binding	0	O
to	0	O
GC	1	O
-	0	O
rich	0	O
sites	0	O
and	0	O
represents	0	O
a	0	O
novel	0	O
pathway	0	O
for	0	O
ligand	0	O
-	0	O
independent	0	O
ER	1	B
action	0	O
.	0	O


In	1	O
both	0	O
cities	0	O
,	0	O
HTLV	0	O
-	0	O
I	1	O
/	0	O
II	0	O
prevalence	0	O
increased	0	O
significantly	0	O
with	0	O
age	0	O
,	0	O
and	0	O
the	0	O
New	0	O
Orleans	0	O
age	0	O
-	0	O
and	0	O
sex	0	O
-	0	O
adjusted	0	O
HTLV	0	O
-	0	O
I	1	O
/	0	O
II	0	O
prevalence	0	O
was	0	O
significantly	0	O
higher	0	O
than	0	O
that	0	O
of	0	O
Baltimore	0	O
(	0	O
P	1	O
less	0	O
than	0	O
.	0	O
001	0	O
).	0	O


Since	0	O
1990	0	O
the	0	O
University	0	O
Hospital	1	O
of	0	O
Tromso	0	O
has	0	O
provided	0	O
local	0	O
hospitals	0	O
in	0	O
northern	0	O
Norway	0	O
with	0	O
a	0	O
remote	0	O
frozen	0	O
section	0	O
service	0	O
and	0	O
with	0	O
access	0	O
to	0	O
video	0	O
conferences	0	O
for	0	O
the	0	O
review	0	O
of	0	O
microscopic	0	O
findings	0	O
and	0	O
for	0	O
the	0	O
discussion	0	O
of	0	O
major	0	O
diagnostic	0	O
issues	0	O
.	0	O


The	0	O
ability	0	O
to	0	O
maintain	0	O
expression	0	O
of	0	O
FAS1	0	B
in	0	O
nmt1	0	B
-	0	O
451Dino2	0	B
Delta	1	O
cells	0	O
suggests	0	O
the	0	O
existence	0	O
of	0	O
another	0	O
transcription	0	O
factor	0	O
,	0	O
or	0	O
factors	0	O
,	0	O
whose	0	O
expression	0	O
/	0	O
activity	0	O
is	0	O
inversely	0	O
related	0	O
to	0	O
overall	0	O
levels	0	O
of	0	O
cellular	0	O
protein	0	O
N	1	O
-	0	O
myristoy	0	O
-	0	O
lation	0	O
.	0	O


The	0	O
mortality	0	O
rate	0	O
and	0	O
histopathological	0	O
features	0	O
of	0	O
Nocardia	1	O
asteroides	0	O
and	0	O
Nocardia	1	O
brasiliensis	0	O
infections	0	O
in	0	O
congenitally	0	O
athymic	0	O
(	0	O
nude	0	O
)	0	O
mice	0	O
of	0	O
ICR	0	O
and	0	O
C3H	0	O
/	0	O
eB	1	O
origins	0	O
were	0	O
quite	0	O
different	0	O
from	0	O
what	0	O
we	0	O
found	0	O
for	0	O
Swiss	0	O
white	0	O
mice	0	O
and	0	O
other	0	O
inbred	0	O
mouse	0	O
strains	0	O
(	0	O
namely	0	O
,	0	O
C57	0	O
/	0	O
BL	0	O
/	0	O
6J	0	O
,	0	O
New	0	O
Zealand	0	O
Black	1	O
,	0	O
BALB	0	O
/	0	O
c	0	O
,	0	O
CBA	0	O
/	0	O
LAC	1	O
,	0	O
and	0	O
C3H	0	O
/	0	O
eB	1	O
).	0	O


The	0	O
Cut9	0	B
subunit	0	I
is	0	O
likely	0	O
to	0	O
be	0	O
a	0	O
target	0	O
for	0	O
regulating	0	O
APC	1	B
/	0	I
cyclosome	0	I
function	0	O
through	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
and	0	O
phosphorylation	0	O
.	0	O


Vimentin	1	B
positivity	0	O
was	0	O
noted	0	O
in	0	O
the	0	O
undifferentiated	0	O
and	0	O
fibroblastic	0	O
components	0	O
.	0	O


TNF	1	B
-	0	I
alpha	0	I
induced	0	O
a	0	O
dose	0	O
-	0	O
and	0	O
time	0	O
-	0	O
dependent	0	O
increase	0	O
in	0	O
cyclooxygenase	0	B
-	0	I
2	0	I
(	0	O
COX	1	B
-	0	I
2	0	I
)	0	O
expression	0	O
and	0	O
PGE2	0	O
formation	0	O
in	0	O
human	0	O
NCI	1	O
-	0	O
H292	0	O
epithelial	0	O
cells	0	O
.	0	O


1st	0	O
data	0	O
on	0	O
the	0	O
immunosuppressive	0	O
therapy	0	O
of	0	O
scleroderma	0	O


Glutathione	1	B
S	1	I
-	0	I
transferase	0	I
(	0	O
GST	0	B
)-	0	O
E2F	0	B
and	0	O
GST	0	B
-	0	O
DP	1	B
fusion	0	O
proteins	0	O
were	0	O
found	0	O
to	0	O
cooperate	0	O
in	0	O
binding	0	O
to	0	O
the	0	O
three	0	O
E2F	0	B
sites	0	I
in	0	O
the	0	O
DNA	1	B
polymerase	0	I
alpha	0	I
gene	0	I
promoter	0	I
in	0	O
vitro	0	O
.	0	O


Dorsal	1	O
root	0	O
ganglia	0	O
neuron	0	O
-	0	O
specific	0	O
promoter	0	O
activity	0	O
of	0	O
the	0	O
rabbit	0	B
beta	0	I
-	0	I
galactoside	0	I
alpha1	0	I
,	0	I
2	0	I
-	0	I
fucosyltransferase	0	I
gene	0	I
.	0	O


An	1	O
RME1	0	B
-	0	O
independent	0	O
pathway	0	O
for	0	O
sporulation	0	O
control	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
acts	0	O
through	0	O
IME1	0	B
transcript	0	I
accumulation	0	O
.	0	O


The	0	O
peak	0	O
velocities	0	O
of	0	O
the	0	O
atrial	0	O
systolic	0	O
waves	0	O
of	0	O
the	0	O
transmitral	0	O
and	0	O
pulmonary	0	O
venous	0	O
flow	0	O
velocities	0	O
(	0	O
A	1	O
and	0	O
PVA	1	O
,	0	O
respectively	0	O
)	0	O
and	0	O
first	0	O
systolic	0	O
wave	0	O
(	0	O
PVS1	0	O
)	0	O
of	0	O
pulmonary	0	O
venous	0	O
flow	0	O
,	0	O
durations	0	O
of	0	O
both	0	O
atrial	0	O
systolic	0	O
waves	0	O
,	0	O
and	0	O
amplitude	0	O
of	0	O
interatrial	0	O
septal	0	O
motion	0	O
during	0	O
atrial	0	O
systole	0	O
increased	0	O
significantly	0	O
ten	0	O
days	0	O
after	0	O
cardioversion	0	O
compared	0	O
with	0	O
those	0	O
measured	0	O
within	0	O
a	0	O
day	0	O
of	0	O
cardioversion	0	O
in	0	O
all	0	O
patients	0	O
except	0	O
the	0	O
5	0	O
patients	0	O
with	0	O
dilated	0	O
cardiomyopathy	0	O
.	0	O


In	1	O
vivo	0	O
epiluminescence	0	O
microscopy	0	O
of	0	O
pigmented	0	O
skin	0	O
lesions	0	O
.	0	O


Immunochemotherapy	1	O
with	0	O
schizophyllan	0	O
(	0	O
SPG	0	O
)	0	O
combined	0	O
with	0	O
chemotherapeutic	0	O
agents	0	O
was	0	O
evaluated	0	O
in	0	O
two	0	O
syngeneic	0	O
tumor	0	O
-	0	O
C3H	0	O
/	0	O
He	1	O
mouse	0	O
systems	0	O
.	0	O


The	0	O
negative	0	O
calcium	0	O
balance	0	O
with	0	O
hyperparathyroidemia	0	O
occurred	0	O
after	0	O
continuous	0	O
oral	0	O
administration	0	O
of	0	O
Cd	1	O
and	0	O
developed	0	O
via	0	O
increased	0	O
urinary	0	O
excretion	0	O
of	0	O
calcium	0	O
.	0	O


Anti	0	B
-	0	I
HBc	1	I
production	0	O
of	0	O
PBMC	0	O
was	0	O
enhanced	0	O
remarkably	0	O
in	0	O
this	0	O
case	0	O
.	0	O


Transient	1	O
hyperammonaemia	0	O
in	0	O
an	0	O
adult	0	O
German	0	O
shepherd	0	O
dog	0	O
.	0	O


The	0	O
levels	0	O
of	0	O
galactosyltransferase	0	B
activity	0	O
in	0	O
sera	0	O
from	0	O
normal	0	O
children	0	O
and	0	O
patients	0	O
with	0	O
cystic	0	O
fibrosis	0	O
.	0	O


A	1	O
single	0	O
amino	0	O
acid	0	O
change	0	O
in	0	O
the	0	O
CPY	0	B
vacuolar	0	I
sorting	0	I
signal	0	I
prevents	0	O
this	0	O
interaction	0	O
.	0	O


The	0	O
percutaneous	0	O
absorption	0	O
of	0	O
clindamycin	0	O
was	0	O
studied	0	O
in	0	O
healthy	0	O
male	0	O
volunteers	0	O
,	0	O
comparing	0	O
two	0	O
investigative	0	O
clindamycin	0	O
(%	0	O
w	0	O
/	0	O
v	0	O
)/	0	O
tretinoin	0	O
(	0	O
0	0	O
.	0	O
025	0	O
%	0	O
w	0	O
/	0	O
v	0	O
)	0	O
gels	0	O
,	0	O
containing	0	O
clindamycin	0	O
phosphate	0	O
ester	0	O
and	0	O
clindamycin	0	O
HCl	1	O
,	0	O
respectively	0	O
,	0	O
relative	0	O
to	0	O
a	0	O
clindamycin	0	O
phosphate	0	O
lotion	0	O
(	0	O
1	0	O
%	0	O
clindamycin	0	O
;	0	O
Dalacin	0	O
T	1	O
).	0	O


The	0	O
relationships	0	O
among	0	O
blood	0	O
concentrations	0	O
of	0	O
thyroid	0	O
hormones	0	O
and	0	O
selenium	0	O
,	0	O
zinc	0	O
,	0	O
retinol	0	O
,	0	O
and	0	O
alpha	0	O
-	0	O
tocopherol	0	O
were	0	O
studied	0	O
in	0	O
44	0	O
healthy	0	O
Northern	0	O
Italian	0	O
oldest	0	O
-	0	O
old	0	O
subjects	0	O
(	0	O
age	0	O
range	0	O
,	0	O
90	0	O
-	0	O
107	0	O
yr	0	O
),	0	O
selected	0	O
by	0	O
the	0	O
criteria	0	O
of	0	O
the	0	O
SENIEUR	0	O
protocol	0	O
.	0	O


Topical	1	O
L	1	O
-	0	O
NNA	0	O
attenuated	0	O
the	0	O
hypercapnic	0	O
increase	0	O
of	0	O
CoBF	0	O
by	0	O
52	0	O
+/-	0	O
6	0	O
%	0	O
and	0	O
CeBF	0	O
by	0	O
29	0	O
+/-	0	O
5	0	O
%	0	O
after	0	O
45	0	O
-	0	O
min	0	O
exposure	0	O
.	0	O


The	0	O
secondary	0	O
,	0	O
but	0	O
not	0	O
the	0	O
primary	0	O
,	0	O
antibody	0	O
responses	0	O
of	0	O
male	0	O
C57Bl	0	O
/	0	O
6	0	O
mice	0	O
were	0	O
higher	0	O
among	0	O
mice	0	O
housed	0	O
alone	0	O
compared	0	O
to	0	O
mice	0	O
housed	0	O
in	0	O
groups	0	O
;	0	O
differences	0	O
were	0	O
observed	0	O
for	0	O
both	0	O
IgM	1	B
and	0	O
IgG	1	B
anti	0	I
-	0	I
KLH	0	I
antibodies	0	I
.	0	O


A	1	O
gene	0	O
in	0	O
Drosophila	1	O
melanogaster	0	O
that	0	O
maps	0	O
cytologically	0	O
to	0	O
2C1	0	O
-	0	O
3	0	O
on	0	O
the	0	O
distal	0	O
portion	0	O
of	0	O
the	0	O
X	1	O
-	0	O
chromosome	0	O
encodes	0	O
a	0	O
member	0	O
of	0	O
the	0	O
steroid	0	B
/	0	I
thyroid	0	I
hormone	0	I
receptor	0	I
superfamily	0	I
.	0	O


In	1	O
the	0	O
absence	0	O
of	0	O
histological	0	O
criteria	0	O
,	0	O
which	0	O
it	0	O
is	0	O
difficult	0	O
to	0	O
demand	0	O
in	0	O
view	0	O
of	0	O
the	0	O
variability	0	O
of	0	O
results	0	O
and	0	O
potential	0	O
dangers	0	O
of	0	O
endomyocardial	0	O
biopsy	0	O
involving	0	O
such	0	O
thin	0	O
and	0	O
fragile	0	O
ventricular	0	O
walls	0	O
,	0	O
the	0	O
diagnosis	0	O
of	0	O
ACRV	0	O
is	0	O
based	0	O
upon	0	O
the	0	O
concomitant	0	O
existence	0	O
of	0	O
:	0	O
(	0	O
1	0	O
)	0	O
electrophysiological	0	O
criteria	0	O
:	0	O
ventricular	0	O
arrhythmias	0	O
,	0	O
in	0	O
particular	0	O
sustained	0	O
monomorphous	0	O
VT	1	O
,	0	O
with	0	O
the	0	O
particular	0	O
feature	0	O
of	0	O
a	0	O
very	0	O
high	0	O
degree	0	O
of	0	O
sensitivity	0	O
to	0	O
adrenergic	0	O
stimulation	0	O
(	0	O
exercise	0	O
),	0	O
the	0	O
existence	0	O
of	0	O
late	0	O
potentials	0	O
on	0	O
the	0	O
high	0	O
amplification	0	O
ECG	1	O
,	0	O
a	0	O
highly	0	O
specific	0	O
sign	0	O
,	0	O
though	0	O
unfortunately	0	O
of	0	O
poor	0	O
sensitivity	0	O
in	0	O
localized	0	O
froms	0	O
,	0	O
those	0	O
which	0	O
are	0	O
most	0	O
difficult	0	O
to	0	O
identify	0	O
(	0	O
2	0	O
);	0	O
segmentary	0	O
morphological	0	O
and	0	O
kinetic	0	O
RV	1	O
abnormalities	0	O
,	0	O
most	0	O
often	0	O
resulting	0	O
in	0	O
localized	0	O
akinetic	0	O
or	0	O
dyskinetic	0	O
parietal	0	O
vaulting	0	O
,	0	O
with	0	O
stasis	0	O
"	0	O
in	0	O
situ	0	O
".	0	O


In	1	O
the	0	O
clinical	0	O
study	0	O
,	0	O
the	0	O
defect	0	O
size	0	O
shown	0	O
by	0	O
BMIPP	0	O
imaging	0	O
was	0	O
greater	0	O
in	0	O
anterior	0	O
than	0	O
in	0	O
inferior	0	O
infarcts	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
and	0	O
correlated	0	O
well	0	O
with	0	O
the	0	O
risk	0	O
area	0	O
revealed	0	O
by	0	O
contrast	0	O
ventriculography	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
80	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
0001	0	O
)	0	O
CONCLUSION	0	O
:	0	O
The	0	O
above	0	O
preliminary	0	O
data	0	O
,	0	O
admittedly	0	O
from	0	O
a	0	O
small	0	O
group	0	O
of	0	O
patients	0	O
,	0	O
suggest	0	O
that	0	O
tomographic	0	O
BMIPP	0	O
imaging	0	O
provides	0	O
an	0	O
accurate	0	O
quantification	0	O
of	0	O
defect	0	O
size	0	O
by	0	O
means	0	O
of	0	O
a	0	O
simple	0	O
threshold	0	O
technique	0	O
and	0	O
,	0	O
in	0	O
the	0	O
subacute	0	O
phase	0	O
,	0	O
permits	0	O
determination	0	O
of	0	O
the	0	O
amount	0	O
of	0	O
myocardium	0	O
at	0	O
risk	0	O
after	0	O
acute	0	O
myocardial	0	O
infarction	0	O
.	0	O


A	1	O
second	0	O
peptide	0	O
(	0	O
amino	0	O
acids	0	O
58	0	O
-	0	O
77	0	O
)	0	O
also	0	O
antagonized	0	O
p21	0	B
-	0	O
activity	0	O
,	0	O
but	0	O
this	0	O
peptide	0	O
did	0	O
not	0	O
affect	0	O
the	0	O
ability	0	O
of	0	O
p21	0	B
to	0	O
interact	0	O
with	0	O
cyclin	0	B
E	1	I
/	0	O
Cdk2	0	B
.	0	O


Each	0	O
binding	0	O
site	0	O
,	0	O
however	0	O
,	0	O
was	0	O
different	0	O
in	0	O
its	0	O
preference	0	O
for	0	O
binding	0	O
partners	0	O
.	0	O


When	0	O
multiple	0	O
copies	0	O
of	0	O
the	0	O
IL	1	B
-	0	I
1	0	I
beta	0	I
NF	1	I
-	0	I
kappa	0	I
B	1	I
site	0	I
were	0	O
linked	0	O
to	0	O
an	0	O
enhancerless	0	O
simian	0	B
virus	0	I
40	0	I
promoter	0	I
,	0	O
this	0	O
element	0	O
was	0	O
able	0	O
to	0	O
mediate	0	O
phorbol	0	O
ester	0	O
-	0	O
or	0	O
lipopolysaccharide	0	O
-	0	O
inducible	0	O
gene	0	O
expression	0	O
.	0	O


Finally	0	O
,	0	O
the	0	O
recovery	0	O
indexes	0	O
represented	0	O
by	0	O
the	0	O
times	0	O
required	0	O
for	0	O
T1	1	O
/	0	O
T0	0	O
and	0	O
T4	1	O
/	0	O
T1	1	O
to	0	O
rise	0	O
from	0	O
25	0	O
%	0	O
to	0	O
75	0	O
%	0	O
respectively	0	O
were	0	O
studied	0	O
.	0	O


The	0	O
DNA	1	O
binding	0	O
and	0	O
multimerization	0	O
activities	0	O
of	0	O
c	0	B
-	0	I
Myb	0	I
appear	0	O
to	0	O
be	0	O
unaffected	0	O
by	0	O
the	0	O
S528A	0	O
substitution	0	O
,	0	O
suggesting	0	O
that	0	O
phosphorylation	0	O
of	0	O
serine	0	O
528	0	O
may	0	O
mediate	0	O
its	0	O
effect	0	O
on	0	O
the	0	O
transcription	0	O
transactivating	0	O
activity	0	O
of	0	O
c	0	B
-	0	I
Myb	0	I
by	0	O
regulating	0	O
interactions	0	O
with	0	O
other	0	O
proteins	0	O
.	0	O


In	1	O
transient	0	O
analysis	0	O
using	0	O
particle	0	O
bombardment	0	O
of	0	O
tobacco	0	O
leaf	0	O
sections	0	O
,	0	O
a	0	O
tetramer	0	O
of	0	O
the	0	O
distB	0	O
ABRE	0	O
(	0	O
abscisic	0	O
acid	0	O
-	0	O
responsive	0	O
element	0	O
)	0	O
mediated	0	O
transactivation	0	O
by	0	O
ABI3	0	B
and	0	O
ABI3	0	B
-	0	O
dependent	0	O
response	0	O
to	0	O
ABA	0	O
,	0	O
whereas	0	O
a	0	O
tetramer	0	O
of	0	O
the	0	O
composite	0	O
RY	0	O
/	0	O
G	1	O
complex	0	O
,	0	O
containing	0	O
RY	0	O
repeats	0	O
and	0	O
a	0	O
G	1	O
-	0	O
box	0	O
,	0	O
mediated	0	O
only	0	O
ABA	0	O
-	0	O
independent	0	O
transactivation	0	O
by	0	O
ABI3	0	B
.	0	O


A	1	O
reversed	0	O
-	0	O
phase	0	O
high	0	O
-	0	O
performance	0	O
liquid	0	O
chromatographic	0	O
(	0	O
HPLC	1	O
)	0	O
method	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
cocaine	0	O
metabolites	0	O
produced	0	O
in	0	O
vitro	0	O
by	0	O
serum	0	B
and	0	I
liver	0	I
esterases	0	I
is	0	O
described	0	O
.	0	O


Organisms	0	O
were	0	O
recovered	0	O
from	0	O
the	0	O
conjunctiva	0	O
for	0	O
several	0	O
weeks	0	O
,	0	O
and	0	O
persistent	0	O
genital	0	O
and	0	O
gastrointestinal	0	O
infection	0	O
also	0	O
resulted	0	O
from	0	O
the	0	O
ocular	0	O
infection	0	O
in	0	O
some	0	O
cats	0	O
.	0	O


Results	0	O
obtained	0	O
for	0	O
chloramphenicol	0	O
-	0	O
containing	0	O
preparations	0	O
are	0	O
presented	0	O
,	0	O
and	0	O
both	0	O
dissolution	0	O
curves	0	O
and	0	O
cup	0	O
-	0	O
plate	0	O
assays	0	O
demonstrate	0	O
that	0	O
chloramphenicol	0	O
has	0	O
far	0	O
superior	0	O
release	0	O
(	0	O
and	0	O
hence	0	O
activity	0	O
)	0	O
from	0	O
creams	0	O
than	0	O
from	0	O
ophthalmic	0	O
ointments	0	O
.	0	O


SvO2	1	O
can	0	O
be	0	O
determined	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
.	0	O


VDR	0	B
/	0	O
RXR	0	B
bound	0	O
well	0	O
to	0	O
the	0	O
VDREs	0	O
and	0	O
to	0	O
DR4	0	O
and	0	O
DR5	0	O
using	0	O
the	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assay	0	O
.	0	O


In	1	O
all	0	O
cases	0	O
,	0	O
high	0	O
-	0	O
level	0	O
expression	0	O
of	0	O
the	0	O
truncated	0	B
avian	0	I
integrins	0	I
was	0	O
obtained	0	O
.	0	O


Consequently	0	O
,	0	O
it	0	O
is	0	O
not	0	O
known	0	O
how	0	O
knee	0	O
loading	0	O
changes	0	O
following	0	O
ACL	1	O
transection	0	O
,	0	O
and	0	O
how	0	O
it	0	O
contributes	0	O
to	0	O
cartilage	0	O
degeneration	0	O
.	0	O


Effect	1	O
of	0	O
succimer	0	O
on	0	O
the	0	O
intensity	0	O
of	0	O
tricarboxylic	0	B
acid	0	I
dehydrogenase	0	I
reactions	0	O
in	0	O
the	0	O
brain	0	O
of	0	O
rats	0	O
poisoned	0	O
with	0	O
mercuric	0	O
chloride	0	O


We	0	O
identified	0	O
telSMN	0	B
mutations	0	O
in	0	O
11	0	O
of	0	O
these	0	O
unrelated	0	O
SMA	1	O
-	0	O
like	0	O
individuals	0	O
who	0	O
carry	0	O
a	0	O
single	0	O
copy	0	O
of	0	O
telSMN	0	B
:	0	O
these	0	O
include	0	O
two	0	O
frameshift	0	O
mutations	0	O
(	0	O
800ins11	0	O
and	0	O
542delGT	0	O
)	0	O
and	0	O
three	0	O
missense	0	O
mutations	0	O
(	0	O
A2G	0	O
,	0	O
S262I	0	O
,	0	O
and	0	O
T274I	0	O
).	0	O


We	0	O
also	0	O
compared	0	O
the	0	O
sequence	0	O
with	0	O
the	0	O
partly	0	O
homologous	0	O
products	0	O
of	0	O
the	0	O
S	1	O
.	0	O
cerevisiae	0	O
genes	0	O
TPS2	0	B
and	0	O
TSL1	0	B
which	0	O
code	0	O
for	0	O
the	0	O
larger	0	O
subunits	0	O
of	0	O
the	0	O
trehalose	0	B
synthase	0	I
complex	0	I
and	0	O
with	0	O
a	0	O
TSL1	0	B
homologue	0	I
,	0	O
TPS3	0	B
,	0	O
of	0	O
unknown	0	O
function	0	O
.	0	O


During	0	O
the	0	O
last	0	O
6	0	O
months	0	O
of	0	O
the	0	O
study	0	O
a	0	O
striking	0	O
change	0	O
in	0	O
epidemiology	0	O
concerning	0	O
hepatitis	0	O
A	1	O
was	0	O
seen	0	O
,	0	O
apparently	0	O
caused	0	O
by	0	O
a	0	O
steep	0	O
increase	0	O
in	0	O
the	0	O
incidence	0	O
of	0	O
this	0	O
type	0	O
of	0	O
hepatitis	0	O
among	0	O
drug	0	O
addicts	0	O
.	0	O


We	0	O
have	0	O
earlier	0	O
evolved	0	O
an	0	O
experimental	0	O
model	0	O
by	0	O
means	0	O
of	0	O
which	0	O
changes	0	O
identical	0	O
to	0	O
the	0	O
microembolism	0	O
syndrome	0	O
can	0	O
be	0	O
induced	0	O
from	0	O
a	0	O
reproducible	0	O
musculo	0	O
-	0	O
skeletal	0	O
trauma	0	O
in	0	O
pigs	0	O
observed	0	O
under	0	O
long	0	O
-	0	O
term	0	O
anesthesia	0	O
under	0	O
standardized	0	O
conditions	0	O
.	0	O


The	0	O
CNXA	0	O
domain	0	O
is	0	O
similar	0	O
at	0	O
the	0	O
amino	0	O
acid	0	O
level	0	O
to	0	O
the	0	O
Escherichia	1	B
coli	0	I
moaA	0	I
gene	0	I
product	0	I
,	0	O
while	0	O
CNXC	0	O
is	0	O
similar	0	O
to	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
moaC	0	I
product	0	I
,	0	O
with	0	O
both	0	O
E	1	O
.	0	O
coli	0	O
products	0	O
encoded	0	O
by	0	O
different	0	O
cistrons	0	O
.	0	O


However	0	O
,	0	O
other	0	O
regions	0	O
of	0	O
the	0	O
plasmid	0	O
are	0	O
also	0	O
efficiently	0	O
repaired	0	O
.	0	O


An	1	O
ASIC	0	O
-	0	O
chip	0	O
for	0	O
stereoscopic	0	O
depth	0	O
analysis	0	O
in	0	O
video	0	O
-	0	O
real	0	O
-	0	O
time	0	O
based	0	O
on	0	O
visual	0	O
cortical	0	O
cell	0	O
behavior	0	O
.	0	O


Examination	1	O
of	0	O
the	0	O
MMP	1	B
-	0	I
2	0	I
RE1	0	I
sequence	0	I
revealed	0	O
an	0	O
incomplete	0	O
Y	1	O
-	0	O
box	0	O
sequence	0	O
(	0	O
CTGCTGGGCAAG	0	O
),	0	O
which	0	O
specifically	0	O
interacted	0	O
with	0	O
recombinant	0	B
YB	1	I
-	0	I
1	0	I
on	0	O
DMS	0	O
protection	0	O
footprinting	0	O
analysis	0	O
.	0	O


Serum	1	O
gastrin	0	B
levels	0	O
did	0	O
not	0	O
change	0	O
in	0	O
either	0	O
group	0	O
;	0	O
however	0	O
,	0	O
background	0	O
serum	0	O
gastrin	0	B
concentrations	0	O
were	0	O
significantly	0	O
greater	0	O
for	0	O
V	1	O
&	0	O
P	1	O
patients	0	O
than	0	O
V	1	O
&	0	O
A	1	O
patients	0	O
throughout	0	O
the	0	O
study	0	O
.	0	O


The	0	O
pet56	0	B
and	0	O
his3	0	B
genes	0	I
are	0	O
transcribed	0	O
divergently	0	O
from	0	O
initiation	0	O
sites	0	O
that	0	O
are	0	O
separated	0	O
by	0	O
only	0	O
192	0	O
bp	0	O
.	0	O


We	0	O
recently	0	O
characterized	0	O
a	0	O
single	0	O
yeast	0	B
hnRNP	1	I
methyltransferase	0	I
(	0	O
HMT1	0	B
).	0	O


It	1	O
was	0	O
proposed	0	O
that	0	O
the	0	O
synthetase	0	O
-	0	O
related	0	O
sequences	0	O
of	0	O
GCN2	0	B
stimulate	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
kinase	0	O
by	0	O
interacting	0	O
directly	0	O
with	0	O
uncharged	0	O
tRNA	1	O
that	0	O
accumulates	0	O
during	0	O
amino	0	O
acid	0	O
limitation	0	O
.	0	O


Characterization	0	O
of	0	O
a	0	O
Xenopus	1	B
laevis	0	I
CXC	0	I
chemokine	0	I
receptor	0	I
4	0	I
:	0	O
implications	0	O
for	0	O
hematopoietic	0	O
cell	0	O
development	0	O
in	0	O
the	0	O
vertebrate	0	O
embryo	0	O
.	0	O


No	1	O
significant	0	O
correlations	0	O
of	0	O
peak	0	O
VO2	1	O
were	0	O
observed	0	O
between	0	O
the	0	O
3	0	O
tests	0	O
.	0	O


The	0	O
number	0	O
of	0	O
bacteria	0	O
in	0	O
the	0	O
lung	0	O
,	0	O
peripheral	0	O
white	0	O
blood	0	O
cell	0	O
and	0	O
BAL	1	O
fluid	0	O
cell	0	O
also	0	O
decreased	0	O
by	0	O
the	0	O
administration	0	O
of	0	O
FN	0	B
.	0	O


In	1	O
12	0	O
cases	0	O
(	0	O
3	0	O
.	0	O
1	0	O
%),	0	O
a	0	O
change	0	O
in	0	O
stage	0	O
resulted	0	O
.	0	O


In	1	O
the	0	O
study	0	O
on	0	O
PCI	1	B
mRNA	1	I
expression	0	O
in	0	O
the	0	O
reproductive	0	O
organs	0	O
,	0	O
we	0	O
first	0	O
cloned	0	O
rat	0	B
PCI	1	I
cDNA	1	I
and	0	O
then	0	O
evaluated	0	O
the	0	O
effect	0	O
of	0	O
androgen	0	O
on	0	O
the	0	O
PCI	1	B
mRNA	1	I
expression	0	O
.	0	O


A	1	O
second	0	O
aim	0	O
was	0	O
to	0	O
determine	0	O
whether	0	O
the	0	O
decrease	0	O
in	0	O
muscle	0	O
-	0	O
tendon	0	O
unit	0	O
rest	0	O
length	0	O
produced	0	O
by	0	O
prolonged	0	O
immobilisation	0	O
in	0	O
a	0	O
shortened	0	O
position	0	O
is	0	O
mediated	0	O
primarily	0	O
by	0	O
adaptations	0	O
of	0	O
the	0	O
muscle	0	O
or	0	O
tendon	0	O
.	0	O


Km	1	O
values	0	O
for	0	O
ammonium	0	O
,	0	O
2	0	O
-	0	O
oxoglutarate	0	O
,	0	O
NADH	1	O
,	0	O
glutamate	0	O
and	0	O
NAD	1	O
+	0	O
were	0	O
6	0	O
.	0	O
5	0	O
,	0	O
3	0	O
.	0	O
5	0	O
,	0	O
0	0	O
.	0	O
06	0	O
,	0	O
37	0	O
.	0	O
1	0	O
and	0	O
0	0	O
.	0	O
046	0	O
mM	1	O
,	0	O
respectively	0	O
.	0	O


Measurement	0	O
of	0	O
gastric	0	O
acid	0	O
secretion	0	O
by	0	O
conductivity	0	O
.	0	O


Adult	1	O
H	1	O
,	0	O
but	0	O
not	0	O
R	1	O
,	0	O
manifested	0	O
the	0	O
burrowing	0	O
preference	0	O
whenever	0	O
offered	0	O
the	0	O
opportunity	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
two	0	O
-	0	O
dimensional	0	O
nuclear	0	O
magnetic	0	O
resonance	0	O
studies	0	O
with	0	O
F17A	0	O
,	0	O
K13Q	0	O
,	0	O
F15Y	0	O
and	0	O
F27Y	0	O
revealed	0	O
that	0	O
the	0	O
mutants	0	O
have	0	O
the	0	O
same	0	O
overall	0	O
structure	0	O
as	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
CspB	0	I
protein	0	I
.	0	O


On	1	O
Day	1	O
8	0	O
,	0	O
the	0	O
CIDR	1	O
-	0	O
B	1	O
was	0	O
removed	0	O
and	0	O
500	0	O
micrograms	0	O
cloprostenol	0	O
injected	0	O
,	0	O
IM	1	O
.	0	O


The	0	O
role	0	O
of	0	O
calcitonin	0	B
,	0	O
and	0	O
other	0	O
agonists	0	O
which	0	O
activate	0	O
the	0	O
cAMP	1	O
pathway	0	O
,	0	O
in	0	O
regulating	0	O
transcription	0	O
of	0	O
the	0	O
human	0	B
parathyroid	0	I
hormone	0	I
-	0	I
related	0	I
protein	0	I
(	0	O
PTHrP	0	B
)	0	O
gene	0	O
was	0	O
investigated	0	O
in	0	O
a	0	O
human	0	O
lung	0	O
cancer	0	O
cell	0	O
line	0	O
(	0	O
BEN	0	O
).	0	O


The	0	O
temporal	0	O
component	0	O
lacked	0	O
a	0	O
mandibular	0	O
fossa	0	O
as	0	O
well	0	O
as	0	O
articular	0	O
eminence	0	O
.	0	O


Both	0	O
inhaled	0	O
and	0	O
superfused	0	O
isoflurane	0	O
dilated	0	O
the	0	O
baseline	0	O
vein	0	O
diameter	0	O
before	0	O
stimulation	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
mutL	0	B
,	0	O
miaA	0	B
,	0	O
and	0	O
hfq	0	B
expression	0	O
could	0	O
be	0	O
regulated	0	O
by	0	O
multiple	0	O
mechanisms	0	O
,	0	O
including	0	O
degree	0	O
of	0	O
cotranscription	0	O
from	0	O
upstream	0	O
genes	0	O
,	0	O
modulation	0	O
of	0	O
internal	0	O
promoter	0	O
strength	0	O
,	0	O
and	0	O
by	0	O
RNase	1	B
E	1	I
activity	0	O
.	0	O


SRC	1	B
-	0	I
1	0	I
can	0	O
relieve	0	O
the	0	O
NF	1	B
-	0	I
kappaB	0	I
-	0	O
mediated	0	O
repression	0	O
of	0	O
GR	1	B
activity	0	O
.	0	O


Dosimetric	1	O
estimates	0	O
for	0	O
these	0	O
organs	0	O
were	0	O
2	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
1	0	O
and	0	O
2	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
4	0	O
rad	0	O
(.	0	O
02	0	O
+/-	0	O
.	0	O
01	0	O
Gy	1	O
),	0	O
respectively	0	O
,	0	O
with	0	O
a	0	O
whole	0	O
-	0	O
body	0	O
estimate	0	O
of	0	O
0	0	O
.	0	O
28	0	O
rad	0	O
(.	0	O
003	0	O
Gy	1	O
).	0	O


We	0	O
analyzed	0	O
the	0	O
P	1	O
-	0	O
SAECG	0	O
in	0	O
the	0	O
time	0	O
and	0	O
frequency	0	O
domain	0	O
in	0	O
23	0	O
patients	0	O
with	0	O
Paf	1	O
and	0	O
19	0	O
controls	0	O
.	0	O


Tyrosine	1	O
112	0	O
of	0	O
latent	0	B
membrane	0	I
protein	0	I
2A	0	I
is	0	O
essential	0	O
for	0	O
protein	0	B
tyrosine	0	I
kinase	0	I
loading	0	O
and	0	O
regulation	0	O
of	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
latency	0	O
.	0	O


Administration	1	O
of	0	O
growth	0	B
hormone	0	I
leads	0	O
to	0	O
faster	0	O
growth	0	O
,	0	O
but	0	O
also	0	O
faster	0	O
bone	0	O
maturation	0	O
.	0	O


Gamma	1	B
glutamyl	0	I
transpeptidase	0	I
activity	0	O
was	0	O
increased	0	O
up	0	O
to	0	O
15	0	O
times	0	O
above	0	O
the	0	O
upper	0	O
normal	0	O
limit	0	O
in	0	O
children	0	O
,	0	O
who	0	O
received	0	O
aminopyrine	0	O
for	0	O
two	0	O
weeks	0	O
or	0	O
longer	0	O
.	0	O


Studies	0	O
using	0	O
the	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
system	0	O
also	0	O
did	0	O
not	0	O
provide	0	O
evidence	0	O
for	0	O
the	0	O
formation	0	O
of	0	O
a	0	O
VDR	0	B
-	0	O
TR	1	B
protein	0	O
-	0	O
protein	0	O
interaction	0	O
.	0	O


Neither	0	O
model	0	O
,	0	O
as	0	O
applied	0	O
,	0	O
provided	0	O
a	0	O
satisfactory	0	O
account	0	O
of	0	O
the	0	O
effects	0	O
of	0	O
the	0	O
main	0	O
variables	0	O
of	0	O
number	0	O
of	0	O
tones	0	O
and	0	O
amount	0	O
of	0	O
perturbation	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
400	0	O
WORDS	0	O
)	0	O


Promoter	1	O
analysis	0	O
demonstrated	0	O
that	0	O
the	0	O
sequence	0	O
identical	0	O
to	0	O
consensus	0	O
cAMP	1	O
-	0	O
responsive	0	O
element	0	O
(	0	O
CRE	0	O
)	0	O
located	0	O
at	0	O
-	0	O
481	0	O
of	0	O
the	0	O
SMemb	0	B
promoter	0	I
was	0	O
critical	0	O
for	0	O
Hex	0	B
responsiveness	0	O
.	0	O


It	1	O
also	0	O
contains	0	O
a	0	O
picornaviral	0	B
3C	0	I
-	0	I
like	0	I
protease	0	I
domain	0	I
and	0	O
two	0	O
papain	0	B
-	0	I
like	0	I
protease	0	I
domains	0	I
.	0	O


The	0	O
starting	0	O
point	0	O
is	0	O
the	0	O
consideration	0	O
that	0	O
the	0	O
conceptions	0	O
underlying	0	O
the	0	O
ICIDH	1	O
are	0	O
not	0	O
suitable	0	O
to	0	O
serve	0	O
as	0	O
a	0	O
mainstay	0	O
of	0	O
a	0	O
model	0	O
for	0	O
diagnostics	0	O
in	0	O
rehabilitation	0	O
because	0	O
they	0	O
do	0	O
not	0	O
reflect	0	O
essential	0	O
characteristics	0	O
of	0	O
the	0	O
diagnostic	0	O
process	0	O
which	0	O
is	0	O
the	0	O
basis	0	O
for	0	O
intervention	0	O
.	0	O


No	1	O
case	0	O
of	0	O
SMF	0	O
demonstrated	0	O
expansive	0	O
tumorous	0	O
growth	0	O
.	0	O


To	1	O
determine	0	O
the	0	O
function	0	O
of	0	O
VZV	0	B
gK	0	I
in	0	O
virus	0	O
growth	0	O
,	0	O
a	0	O
series	0	O
of	0	O
gK	0	B
deletion	0	I
mutants	0	I
were	0	O
constructed	0	O
with	0	O
VZV	0	O
cosmid	0	O
DNA	1	O
derived	0	O
from	0	O
the	0	O
Oka	0	O
strain	0	O
.	0	O


The	0	O
upstream	0	O
delta	0	O
-	0	O
alpha	0	O
breakpoint	0	O
is	0	O
flanked	0	O
by	0	O
the	0	O
direct	0	O
repeats	0	O
of	0	O
the	0	O
acceptor	0	O
splice	0	O
site	0	O
,	0	O
whereas	0	O
the	0	O
down	0	O
-	0	O
stream	0	O
alpha	0	O
-	0	O
delta	0	O
breakpoint	0	O
is	0	O
located	0	O
in	0	O
the	0	O
adjacent	0	O
intron	0	O
.	0	O


The	0	O
introns	0	O
are	0	O
1	0	O
.	0	O
6	0	O
-	0	O
1	0	O
.	0	O
9	0	O
kbp	0	O
long	0	O
.	0	O


The	0	O
multiple	0	O
functions	0	O
of	0	O
Pmt3p	0	B
described	0	O
here	0	O
suggest	0	O
that	0	O
several	0	O
nuclear	0	O
proteins	0	O
are	0	O
regulated	0	O
by	0	O
Pmt3p	0	B
conjugation	0	O
.	0	O


Analysis	1	O
of	0	O
a	0	O
set	0	O
of	0	O
deletion	0	O
constructs	0	O
in	0	O
transient	0	O
transfection	0	O
assays	0	O
measuring	0	O
heterologous	0	O
reporter	0	O
gene	0	O
(	0	O
luciferase	0	B
)	0	O
activity	0	O
demonstrated	0	O
that	0	O
the	0	O
182	0	O
-	0	O
bp	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
provides	0	O
full	0	O
promoter	0	O
activity	0	O
in	0	O
IL	1	B
-	0	I
2	0	I
-	0	O
stimulated	0	O
L2	0	O
cells	0	O
.	0	O


Chronic	1	O
hepatitis	0	O
B	1	O
in	0	O
adopted	0	O
Romanian	0	O
children	0	O
.	0	O


The	0	O
exon	0	O
-	0	O
intron	0	O
distribution	0	O
of	0	O
Cdebp	0	B
appears	0	O
strikingly	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
the	0	O
App	1	B
gene	0	I
in	0	O
the	0	O
regions	0	O
encoding	0	O
the	0	O
conserved	0	O
domains	0	O
,	0	O
with	0	O
a	0	O
divergent	0	O
structure	0	O
in	0	O
the	0	O
other	0	O
parts	0	O
.	0	O


We	0	O
have	0	O
visualized	0	O
DNA	1	O
-	0	O
protein	0	O
complexes	0	O
by	0	O
electron	0	O
microscopy	0	O
and	0	O
a	0	O
high	0	O
-	0	O
affinity	0	O
binding	0	O
site	0	O
of	0	O
WDV	0	B
Rep	1	I
protein	0	I
within	0	O
the	0	O
core	0	O
element	0	O
has	0	O
been	0	O
mapped	0	O
to	0	O
approximately	0	O
144	0	O
+/-	0	O
18	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
initiation	0	O
site	0	O
,	0	O
between	0	O
the	0	O
start	0	O
site	0	O
for	0	O
complementary	0	O
-	0	O
sense	0	O
transcription	0	O
and	0	O
the	0	O
TATA	0	O
box	0	O
.	0	O


Significantly	0	O
,	0	O
pPKR	0	B
is	0	O
capable	0	O
of	0	O
specifically	0	O
phosphorylating	0	O
Ser51	0	O
in	0	O
a	0	O
synthetic	0	B
eIF	0	I
-	0	I
2alpha	0	I
peptide	0	I
,	0	O
a	0	O
key	0	O
characteristic	0	O
of	0	O
the	0	O
eIF	0	B
-	0	I
2alpha	0	I
kinase	0	I
family	0	I
.	0	O


Pokeweed	1	B
antiviral	0	I
protein	0	I
(	0	O
PAP	1	B
)	0	O
from	0	O
Phytolacca	1	O
americana	0	O
is	0	O
a	0	O
highly	0	O
specific	0	O
N	1	B
-	0	I
glycosidase	0	I
removing	0	O
adenine	0	O
residues	0	O
(	0	O
A4324	0	O
in	0	O
28S	0	B
rRNA	1	I
and	0	O
A2660	0	O
in	0	O
23S	0	B
rRNA	1	I
)	0	O
from	0	O
intact	0	O
ribosomes	0	O
of	0	O
both	0	O
eukaryotes	0	O
and	0	O
prokaryotes	0	O
.	0	O


A	1	O
particularly	0	O
striking	0	O
HpaII	0	B
tiny	0	O
fragment	0	O
island	0	O
,	0	O
extending	0	O
over	0	O
nearly	0	O
2	0	O
,	0	O
000	0	O
base	0	O
pairs	0	O
,	0	O
surrounds	0	O
the	0	O
USF2	0	B
translation	0	I
initiation	0	I
site	0	I
.	0	O


Pharmacoeconomic	0	O
assessment	0	O
of	0	O
HMG	1	B
-	0	I
CoA	1	I
reductase	0	I
inhibitor	0	O
therapy	0	O
:	0	O
an	0	O
analysis	0	O
based	0	O
on	0	O
the	0	O
CURVES	0	O
study	0	O
.	0	O


These	0	O
mutants	0	O
had	0	O
deletions	0	O
of	0	O
the	0	O
extreme	0	O
amino	0	O
-	0	O
terminal	0	O
residues	0	O
as	0	O
far	0	O
as	0	O
amino	0	O
acid	0	O
residue	0	O
30	0	O
.	0	O


In	1	O
a	0	O
blind	0	O
controlled	0	O
trial	0	O
,	0	O
15	0	O
patients	0	O
with	0	O
COCM	0	O
(	0	O
NYHA	1	O
II	0	O
-	0	O
III	0	O
)	0	O
with	0	O
sinus	0	O
rhythm	0	O
and	0	O
a	0	O
left	0	O
ventricular	0	O
ejection	0	O
fraction	0	O
(	0	O
LV	1	O
-	0	O
EF	1	O
)	0	O
of	0	O
34	0	O
.	0	O
5	0	O
+/-	0	O
2	0	O
.	0	O
6	0	O
%	0	O
received	0	O
consecutively	0	O
D	1	O
(	0	O
0	0	O
.	0	O
25	0	O
-	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
d	0	O
),	0	O
placebo	0	O
(	0	O
PLAC	0	O
),	0	O
P	1	O
(	0	O
slow	0	O
releases	0	O
=	0	O
SR	1	O
)	0	O
(	0	O
80	0	O
mg	0	O
/	0	O
d	0	O
SR	1	O
)	0	O
and	0	O
both	0	O
drugs	0	O
combined	0	O
in	0	O
respective	0	O
doses	0	O
.	0	O


These	0	O
mutants	0	O
were	0	O
tested	0	O
for	0	O
ability	0	O
to	0	O
bind	0	O
each	0	O
of	0	O
the	0	O
Site	1	B
II	0	I
cognate	0	I
proteins	0	I
,	0	O
and	0	O
subsequently	0	O
evaluated	0	O
for	0	O
ability	0	O
to	0	O
confer	0	O
H4	0	B
transcriptional	0	O
activity	0	O
using	0	O
chimeric	0	O
H4	0	B
promoter	0	O
/	0	O
CAT	1	B
fusion	0	O
constructs	0	O
in	0	O
different	0	O
cell	0	O
types	0	O
.	0	O


The	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
contains	0	O
the	0	O
PTP	0	B
-	0	I
like	0	I
domain	0	I
,	0	O
whereas	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
shows	0	O
no	0	O
homology	0	O
to	0	O
any	0	O
known	0	O
mammalian	0	O
protein	0	O
.	0	O


Thyroid	1	O
function	0	O
tests	0	O
were	0	O
performed	0	O
on	0	O
300	0	O
admissions	0	O
,	0	O
leaving	0	O
707	0	O
untested	0	O
.	0	O


These	0	O
findings	0	O
were	0	O
reinforced	0	O
by	0	O
an	0	O
analysis	0	O
that	0	O
was	0	O
restricted	0	O
to	0	O
living	0	O
donor	0	O
transplants	0	O
without	0	O
acute	0	O
rejection	0	O
.	0	O


Sp1	0	B
and	0	O
two	0	O
Sp3	0	B
isoforms	0	I
were	0	O
detected	0	O
as	0	O
the	0	O
primary	0	O
cellular	0	O
constituents	0	O
of	0	O
DNA	1	O
-	0	O
protein	0	O
complexes	0	O
formed	0	O
with	0	O
the	0	O
NF	1	B
-	0	I
kappaB	0	I
-	0	I
proximal	0	I
site	0	I
.	0	O


Normocapnic	1	O
(	0	O
PACO2	1	O
=	0	O
40	0	O
mm	0	O
Hg	1	O
)	0	O
ventilatory	0	O
drive	0	O
increased	0	O
significantly	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
in	0	O
six	0	O
subjects	0	O
(	0	O
Type	1	O
1	0	O
response	0	O
)	0	O
and	0	O
decreased	0	O
substantially	0	O
in	0	O
the	0	O
others	0	O
(	0	O
Type	1	O
2	0	O
response	0	O
);	0	O
with	0	O
hypercapnia	0	O
,	0	O
the	0	O
changes	0	O
in	0	O
drive	0	O
were	0	O
attenuated	0	O
in	0	O
both	0	O
groups	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
its	0	O
elongation	0	O
activity	0	O
,	0	O
ELL	0	B
contains	0	O
a	0	O
novel	0	O
type	0	O
of	0	O
RNA	1	B
polymerase	0	I
II	0	I
interaction	0	I
domain	0	I
that	0	O
is	0	O
capable	0	O
of	0	O
repressing	0	O
polymerase	0	O
activity	0	O
in	0	O
promoter	0	O
-	0	O
specific	0	O
transcription	0	O
.	0	O


447	0	O
microns	0	O
for	0	O
A	1	O
.	0	O
microcephalum	0	O
and	0	O
350	0	O
microns	0	O
for	0	O
A	1	O
.	0	O
wedli	0	O
),	0	O
and	0	O
fewer	0	O
testes	0	O
per	0	O
proglottis	0	O
(	0	O
44	0	O
-	0	O
73	0	O
vs	0	O
.	0	O


Deletion	1	O
analyses	0	O
of	0	O
the	0	O
pCD41	0	B
ORF	1	I
-	0	I
A	1	I
and	0	O
the	0	O
use	0	O
of	0	O
promoter	0	O
constructs	0	O
further	0	O
mapped	0	O
an	0	O
internal	0	O
functional	0	O
promoter	0	O
within	0	O
the	0	O
pCD41	0	B
sequence	0	I
that	0	O
can	0	O
direct	0	O
the	0	O
synthesis	0	O
of	0	O
the	0	O
trans	0	O
-	0	O
activating	0	O
protein	0	O
.	0	O


There	0	O
was	0	O
a	0	O
positive	0	O
correlation	0	O
between	0	O
pyridinium	0	O
cross	0	O
-	0	O
link	0	O
excretion	0	O
and	0	O
thyroid	0	O
hormone	0	O
concentrations	0	O
.	0	O


Cyclin	1	B
D1	1	I
-	0	I
associated	0	I
kinase	0	I
activity	0	O
and	0	O
protein	0	O
levels	0	O
were	0	O
increased	0	O
in	0	O
mammary	0	O
tumors	0	O
from	0	O
murine	0	O
mammary	0	O
tumor	0	O
virus	0	O
-	0	O
pp60	0	B
(	0	O
c	0	B
-	0	I
src527F	0	I
)	0	O
transgenic	0	O
mice	0	O
.	0	O


Catch	0	O
-	0	O
up	0	O
growth	0	O
was	0	O
observed	0	O
only	0	O
for	0	O
a	0	O
12	0	O
-	0	O
month	0	O
period	0	O
in	0	O
4	0	O
children	0	O
with	0	O
a	0	O
bone	0	O
age	0	O
of	0	O
7	0	O
to	0	O
8	0	O
years	0	O
.	0	O


Detailed	0	O
mutagenesis	0	O
of	0	O
the	0	O
element	0	O
'	0	O
s	0	O
rare	0	O
-	0	O
codon	0	O
/	0	O
AU	1	O
-	0	O
rich	0	O
sequence	0	O
boundary	0	O
revealed	0	O
that	0	O
the	0	O
destabilizing	0	O
activity	0	O
of	0	O
the	0	O
MATalpha1	0	B
IE	1	I
is	0	O
observed	0	O
when	0	O
the	0	O
terminal	0	O
codon	0	O
of	0	O
the	0	O
element	0	O
'	0	O
s	0	O
rare	0	O
-	0	O
codon	0	O
interval	0	O
is	0	O
translated	0	O
.	0	O


Although	0	O
diagnostic	0	O
laparoscopy	0	O
is	0	O
still	0	O
considered	0	O
the	0	O
standard	0	O
reference	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
ectopic	0	O
pregnancy	0	O
(	0	O
EP	1	O
),	0	O
use	0	O
of	0	O
high	0	O
-	0	O
resolution	0	O
endovaginal	0	O
sonography	0	O
,	0	O
in	0	O
conjunction	0	O
with	0	O
qualitative	0	O
serum	0	O
assays	0	O
of	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
human	0	B
chorionic	0	I
gonadotropin	0	I
(	0	O
beta	0	B
-	0	I
hCG	1	I
),	0	O
allows	0	O
detection	0	O
of	0	O
earlier	0	O
and	0	O
smaller	0	O
EPs	1	O
.	0	O


Exposure	1	O
of	0	O
endothelium	0	O
to	0	O
pulsatile	0	O
shear	0	O
stresses	0	O
that	0	O
followed	0	O
a	0	O
tape	0	O
recording	0	O
of	0	O
physiological	0	O
flow	0	O
waveforms	0	O
(	0	O
electromagnetic	0	O
flowmeter	0	O
)	0	O
did	0	O
not	0	O
cause	0	O
gross	0	O
injury	0	O
or	0	O
denudation	0	O
even	0	O
when	0	O
peak	0	O
shear	0	O
exceeded	0	O
1500	0	O
dyne	0	O
/	0	O
cm2	0	O
.	0	O


We	0	O
have	0	O
inactivated	0	O
Krox	0	B
-	0	I
20	0	I
by	0	O
homologous	0	O
recombination	0	O
in	0	O
ES	1	O
cells	0	O
and	0	O
demonstrated	0	O
that	0	O
the	0	O
mutation	0	O
leads	0	O
to	0	O
the	0	O
deletion	0	O
of	0	O
r3	0	O
and	0	O
r5	0	O
.	0	O


Range	1	O
behavior	0	O
of	0	O
Hereford	0	O
,	0	O
Hereford	0	O
x	0	O
Holstein	0	O
and	0	O
Holstein	0	O
non	0	O
-	0	O
lactating	0	O
heifers	0	O
.	0	O


Genomic	1	O
Southern	0	O
blot	0	O
analysis	0	O
and	0	O
chromosome	0	O
mapping	0	O
showed	0	O
that	0	O
GPRK6	0	B
hybridizes	0	O
to	0	O
two	0	O
closely	0	O
related	0	O
genes	0	O
located	0	O
on	0	O
chromosomes	0	O
5	0	O
and	0	O
13	0	O
and	0	O
are	0	O
,	0	O
therefore	0	O
,	0	O
distinct	0	O
from	0	O
the	0	O
GPRK	0	B
located	0	O
near	0	O
the	0	O
Huntington	0	B
disease	0	I
locus	0	I
on	0	O
chromosome	0	O
4	0	O
.	0	O


A	1	O
38	0	O
-	0	O
bp	0	O
poly	0	O
(	0	O
dA	1	O
-	0	O
dT	1	O
)	0	O
region	0	O
was	0	O
found	0	O
to	0	O
be	0	O
a	0	O
positive	0	O
regulator	0	O
of	0	O
Act1	0	B
promoter	0	I
activity	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
absence	0	O
of	0	O
residual	0	O
infarct	0	O
-	0	O
zone	0	O
viability	0	O
discriminates	0	O
patients	0	O
who	0	O
develop	0	O
progressive	0	O
left	0	O
ventricular	0	O
dilation	0	O
after	0	O
reperfused	0	O
AMI	1	O
from	0	O
those	0	O
who	0	O
maintain	0	O
normal	0	O
left	0	O
ventricular	0	O
geometry	0	O
.	0	O


The	0	O
inspiratory	0	O
oxygen	0	O
concentration	0	O
needed	0	O
(	0	O
FiO2	1	O
)	0	O
and	0	O
the	0	O
Horowitz	0	O
quotient	0	O
differed	0	O
in	0	O
a	0	O
highly	0	O
significant	0	O
manner	0	O
beginning	0	O
on	0	O
the	0	O
1st	0	O
day	0	O
after	0	O
trauma	0	O
.	0	O


This	0	O
model	0	O
is	0	O
supported	0	O
by	0	O
experiments	0	O
showing	0	O
that	0	O
Cdr2	0	B
associates	0	O
with	0	O
the	0	O
N	1	B
-	0	I
terminal	0	I
regulatory	0	I
domain	0	I
of	0	I
Wee1	0	I
in	0	O
cell	0	O
lysates	0	O
and	0	O
phosphorylates	0	O
Wee1	0	B
in	0	O
vitro	0	O
.	0	O


After	0	O
resection	0	O
of	0	O
the	0	O
proximal	0	O
fragment	0	O
,	0	O
all	0	O
scaphoid	0	O
contact	0	O
area	0	O
and	0	O
pressure	0	O
was	0	O
born	0	O
by	0	O
the	0	O
distal	0	O
scaphoid	0	O
fragment	0	O
.	0	O


The	0	O
dopamine	0	B
D4	0	I
receptor	0	I
as	0	O
well	0	O
as	0	O
many	0	O
other	0	O
catecholaminergic	0	B
receptors	0	I
contain	0	O
several	0	O
putative	0	O
SH3	0	B
binding	0	I
domains	0	I
.	0	O


Courses	0	O
were	0	O
repeated	0	O
monthly	0	O
upon	0	O
recovery	0	O
of	0	O
myelosuppression	0	O
.	0	O


Therefore	0	O
,	0	O
it	0	O
would	0	O
be	0	O
advantageous	0	O
to	0	O
identify	0	O
such	0	O
persons	0	O
and	0	O
treat	0	O
them	0	O
preferentially	0	O
.	0	O


HEED	0	B
was	0	O
found	0	O
to	0	O
bind	0	O
to	0	O
MA	1	B
protein	0	I
in	0	O
vitro	0	O
,	0	O
as	0	O
efficiently	0	O
as	0	O
in	0	O
vivo	0	O
in	0	O
yeast	0	O
cells	0	O
.	0	O


SUMMARY	0	O
BACKGROUND	0	O
DATA	1	O
:	0	O
Melanoma	1	O
care	0	O
has	0	O
not	0	O
changed	0	O
significantly	0	O
in	0	O
the	0	O
last	0	O
20	0	O
years	0	O
,	0	O
and	0	O
the	0	O
controversy	0	O
of	0	O
elective	0	O
lymph	0	O
node	0	O
dissections	0	O
in	0	O
this	0	O
disease	0	O
continues	0	O
to	0	O
be	0	O
discussed	0	O
.	0	O


No	1	O
specific	0	O
subgroup	0	O
of	0	O
clients	0	O
benefited	0	O
more	0	O
from	0	O
URD	0	O
,	0	O
although	0	O
a	0	O
prospective	0	O
study	0	O
employing	0	O
random	0	O
assignment	0	O
might	0	O
be	0	O
more	0	O
successful	0	O
in	0	O
identifying	0	O
such	0	O
a	0	O
group	0	O
.	0	O


The	0	O
gene	0	O
structure	0	O
of	0	O
Elk1	0	B
spans	0	O
15	0	O
.	0	O
2	0	O
kb	0	O
and	0	O
consists	0	O
of	0	O
seven	0	O
exons	0	O
and	0	O
six	0	O
introns	0	O
.	0	O


This	0	O
mechanism	0	O
is	0	O
not	0	O
due	0	O
to	0	O
the	0	O
observed	0	O
grain	0	O
boundary	0	O
precipitates	0	O
.	0	O


Mutant	1	O
enzyme	0	O
forms	0	O
were	0	O
prepared	0	O
to	0	O
eliminate	0	O
the	0	O
initial	0	O
autoprocessing	0	O
site	0	O
and	0	O
thus	0	O
form	0	O
an	0	O
active	0	O
single	0	O
-	0	O
chain	0	O
protein	0	O
for	0	O
structure	0	O
-	0	O
function	0	O
studies	0	O
.	0	O


Until	0	O
now	0	O
,	0	O
each	0	O
of	0	O
these	0	O
loci	0	O
was	0	O
considered	0	O
to	0	O
contain	0	O
three	0	O
genes	0	O
(	0	O
for	0	O
regulator	0	B
,	0	O
permease	0	B
and	0	O
alpha	0	B
-	0	I
glucosidase	0	I
),	0	O
but	0	O
a	0	O
fourth	0	O
gene	0	O
,	0	O
presumably	0	O
an	0	O
extra	0	O
alpha	0	B
-	0	I
glucosidase	0	I
gene	0	I
,	0	O
was	0	O
found	0	O
at	0	O
MAL1	0	B
adjacent	0	O
to	0	O
the	0	O
usual	0	O
cluster	0	O
of	0	O
three	0	O
genes	0	O
.	0	O


Haemodynamic	0	O
responses	0	O
to	0	O
antagonism	0	O
of	0	O
bocurarine	0	O
block	0	O
with	0	O
atropine	0	O
-	0	O
neostigmine	0	O
mixture	0	O
in	0	O
children	0	O
.	0	O


We	0	O
suggest	0	O
that	0	O
sensitivity	0	O
to	0	O
photoperiod	0	O
in	0	O
pallid	0	O
bats	0	O
,	0	O
as	0	O
in	0	O
several	0	O
other	0	O
mammals	0	O
,	0	O
is	0	O
mediated	0	O
by	0	O
the	0	O
pineal	0	O
gland	0	O
.	0	O


Clinical	1	O
nutrition	0	O
of	0	O
adult	0	O
horses	0	O
.	0	O


Analysis	1	O
of	0	O
several	0	O
Tat	1	B
mutants	0	I
indicated	0	O
that	0	O
both	0	O
the	0	O
cysteine	0	O
-	0	O
rich	0	O
and	0	O
the	0	O
core	0	O
domains	0	O
of	0	O
this	0	O
transactivator	0	O
are	0	O
necessary	0	O
and	0	O
sufficient	0	O
to	0	O
activate	0	O
transcription	0	O
when	0	O
TBP	1	B
is	0	O
overexpressed	0	O
.	0	O


Co	1	O
-	0	O
transfection	0	O
of	0	O
a	0	O
tat	0	B
expressing	0	O
plasmid	0	O
with	0	O
these	0	O
viruses	0	O
containing	0	O
the	0	O
tat	0	B
ORF	1	I
mutations	0	O
resulted	0	O
in	0	O
higher	0	O
levels	0	O
of	0	O
virus	0	O
production	0	O
demonstrating	0	O
that	0	O
the	0	O
effects	0	O
of	0	O
both	0	O
mutants	0	O
are	0	O
tat	0	B
specific	0	O
.	0	O


A	1	O
2	0	O
kb	0	O
transcript	0	O
was	0	O
isolated	0	O
from	0	O
brain	0	O
that	0	O
encodes	0	O
a	0	O
approximately	0	O
57	0	O
kDa	1	O
protein	0	O
;	0	O
the	0	O
predicted	0	O
protein	0	O
contains	0	O
the	0	O
known	0	O
N	1	B
-	0	I
terminal	0	I
Ets	1	I
domain	0	I
of	0	O
PE1	0	B
and	0	O
a	0	O
novel	0	O
C	1	O
-	0	O
terminal	0	O
domain	0	O
with	0	O
signficant	0	O
homology	0	O
to	0	O
murine	0	B
ERF	0	I
.	0	O


The	0	O
half	0	O
-	0	O
life	0	O
of	0	O
the	0	O
serum	0	O
-	0	O
induced	0	O
CBP	0	B
/	0	O
tk	0	B
binding	0	O
activity	0	O
was	0	O
estimated	0	O
to	0	O
be	0	O
less	0	O
than	0	O
1	0	O
h	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
400	0	O
WORDS	0	O
)	0	O


This	0	O
gene	0	O
spans	0	O
23	0	O
kb	0	O
and	0	O
is	0	O
composed	0	O
of	0	O
five	0	O
exons	0	O
and	0	O
four	0	O
introns	0	O
.	0	O


Surveillance	1	O
for	0	O
preeclampsia	0	O
was	0	O
conducted	0	O
by	0	O
personnel	0	O
unaware	0	O
of	0	O
treatment	0	O
-	0	O
group	0	O
assignments	0	O
,	0	O
using	0	O
standardized	0	O
measurements	0	O
of	0	O
blood	0	O
pressure	0	O
and	0	O
urinary	0	O
protein	0	O
excretion	0	O
at	0	O
uniformly	0	O
scheduled	0	O
prenatal	0	O
visits	0	O
,	0	O
protocols	0	O
for	0	O
monitoring	0	O
these	0	O
measurements	0	O
during	0	O
the	0	O
hospitalization	0	O
for	0	O
delivery	0	O
,	0	O
and	0	O
reviews	0	O
of	0	O
medical	0	O
records	0	O
of	0	O
unscheduled	0	O
outpatient	0	O
visits	0	O
and	0	O
all	0	O
hospitalizations	0	O
.	0	O


Competition	1	O
needs	0	O
to	0	O
be	0	O
better	0	O
studied	0	O
,	0	O
since	0	O
in	0	O
Central	1	O
America	0	O
and	0	O
Caribean	0	O
islands	0	O
this	0	O
kind	0	O
of	0	O
study	0	O
has	0	O
favored	0	O
the	0	O
biological	0	O
control	0	O
of	0	O
planorbid	0	O
species	0	O
.	0	O


To	1	O
derive	0	O
quantitative	0	O
concentration	0	O
changes	0	O
from	0	O
measurements	0	O
of	0	O
light	0	O
attenuation	0	O
,	0	O
the	0	O
optical	0	O
path	0	O
length	0	O
must	0	O
be	0	O
known	0	O
.	0	O


The	0	O
N3	0	O
wave	0	O
of	0	O
the	0	O
SSEP	0	O
'	0	O
s	0	O
,	0	O
which	0	O
has	0	O
been	0	O
found	0	O
to	0	O
correlate	0	O
best	0	O
with	0	O
neurological	0	O
recovery	0	O
,	0	O
returned	0	O
to	0	O
65	0	O
%	0	O
+/-	0	O
48	0	O
%	0	O
of	0	O
the	0	O
preischemia	0	O
amplitude	0	O
in	0	O
the	0	O
insulin	0	B
-	0	O
treated	0	O
animals	0	O
,	0	O
compared	0	O
to	0	O
40	0	O
%	0	O
+/-	0	O
34	0	O
%	0	O
in	0	O
the	0	O
fasted	0	O
group	0	O
and	0	O
26	0	O
%	0	O
+/-	0	O
24	0	O
%	0	O
in	0	O
the	0	O
control	0	O
animals	0	O
.	0	O


Thus	0	O
,	0	O
a	0	O
critical	0	O
question	0	O
is	0	O
how	0	O
HOX	0	B
proteins	0	I
select	0	O
the	0	O
correct	0	O
sets	0	O
of	0	O
target	0	O
genes	0	O
in	0	O
vivo	0	O
.	0	O


Baseline	1	O
electrocorticography	0	O
over	0	O
the	0	O
surface	0	O
of	0	O
the	0	O
temporal	0	O
lobe	0	O
and	0	O
depth	0	O
electrode	0	O
recordings	0	O
in	0	O
the	0	O
amygdala	0	O
and	0	O
hippocampus	0	O
were	0	O
obtained	0	O
,	0	O
followed	0	O
by	0	O
10	0	O
min	0	O
of	0	O
recording	0	O
before	0	O
and	0	O
after	0	O
the	0	O
i	0	O
.	0	O
v	0	O
.	0	O
administration	0	O
of	0	O
both	0	O
alfentanil	0	O
50	0	O
microg	0	O
/	0	O
kg	0	O
and	0	O
fentanyl	0	O
10	0	O
microg	0	O
/	0	O
kg	0	O
.	0	O


Thus	0	O
,	0	O
two	0	O
very	0	O
different	0	O
regulatory	0	O
elements	0	O
are	0	O
used	0	O
to	0	O
mediate	0	O
estrogen	0	O
induction	0	O
of	0	O
related	0	O
genes	0	O
in	0	O
chickens	0	O
and	0	O
amphibians	0	O
.	0	O


Human	1	B
granulocyte	0	I
-	0	I
macrophage	0	I
colony	0	I
-	0	I
stimulating	0	I
factor	0	I
(	0	O
hGM	0	B
-	0	I
CSF	1	I
)	0	O
activates	0	O
a	0	O
set	0	O
of	0	O
genes	0	O
such	0	O
as	0	O
c	0	B
-	0	I
fos	0	I
,	0	O
jun	0	B
,	0	O
myc	0	B
,	0	O
and	0	O
early	0	B
growth	0	I
response	0	I
gene	0	I
1	0	I
(	0	O
egr	0	B
-	0	I
1	0	I
).	0	O


Skeletal	1	O
muscle	0	O
metaboreceptor	0	O
exercise	0	O
responses	0	O
are	0	O
attenuated	0	O
in	0	O
heart	0	O
failure	0	O
.	0	O


IMPLICATIONS	0	O
:	0	O
Given	0	O
the	0	O
small	0	O
size	0	O
of	0	O
this	0	O
study	0	O
and	0	O
the	0	O
inconsistency	0	O
of	0	O
results	0	O
among	0	O
the	0	O
few	0	O
prospective	0	O
studies	0	O
of	0	O
ovarian	0	O
cancer	0	O
conducted	0	O
to	0	O
test	0	O
these	0	O
associations	0	O
,	0	O
replications	0	O
of	0	O
these	0	O
findings	0	O
are	0	O
highly	0	O
desirable	0	O
.	0	O


Seventeen	0	O
of	0	O
them	0	O
were	0	O
on	0	O
treatment	0	O
with	0	O
systemic	0	O
steroids	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
gene	0	O
also	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
multiple	0	O
TATA	0	O
and	0	O
CAAT	0	O
sequences	0	O
.	0	O


Urease	1	B
activity	0	O
of	0	O
97	0	O
%	0	O
of	0	O
these	0	O
organisms	0	O
became	0	O
evident	0	O
within	0	O
30	0	O
min	0	O
.	0	O


Benign	1	O
intramural	0	O
tumors	0	O
of	0	O
the	0	O
esophagus	0	O


The	0	O
predicted	0	O
DNA	1	O
-	0	O
binding	0	O
,	0	O
zinc	0	B
finger	0	I
domain	0	I
protein	0	I
sequence	0	O
was	0	O
strictly	0	O
conserved	0	O
.	0	O


Conformational	0	O
studies	0	O
combining	0	O
secondary	0	O
structure	0	O
predictions	0	O
,	0	O
CD	1	O
and	0	O
NMR	1	O
spectroscopy	0	O
together	0	O
with	0	O
ELISA	1	O
assays	0	O
,	0	O
showed	0	O
that	0	O
the	0	O
greater	0	O
is	0	O
the	0	O
propensity	0	O
of	0	O
the	0	O
epitope	0	O
for	0	O
helix	0	O
formation	0	O
the	0	O
higher	0	O
is	0	O
the	0	O
recognition	0	O
by	0	O
anti	0	B
-	0	I
K159	0	I
.	0	O


We	0	O
enrolled	0	O
253	0	O
HIV	1	B
-	0	I
antibody	0	I
positive	0	O
heroin	0	O
addicts	0	O
without	0	O
HIV	1	O
-	0	O
related	0	O
disease	0	O
(	0	O
n	0	O
=	0	O
81	0	O
)	0	O
or	0	O
with	0	O
persistent	0	O
generalized	0	O
lymphadenopathy	0	O
(	0	O
n	0	O
=	0	O
172	0	O
)	0	O
in	0	O
a	0	O
prospective	0	O
study	0	O
to	0	O
evaluate	0	O
clinical	0	O
progression	0	O
to	0	O
AIDS	1	O
related	0	O
complex	0	O
(	0	O
ARC	1	O
)	0	O
or	0	O
AIDS	1	O
and	0	O
to	0	O
identify	0	O
factors	0	O
of	0	O
possible	0	O
prognostic	0	O
relevance	0	O
.	0	O


Effects	0	O
of	0	O
a	0	O
perfluorochemical	0	O
blood	0	O
substitute	0	O
on	0	O
diazepam	0	O
binding	0	O
by	0	O
human	0	B
albumin	0	I
.	0	O


Here	0	O
we	0	O
have	0	O
examined	0	O
the	0	O
ability	0	O
of	0	O
the	0	O
cellular	0	O
protein	0	O
YB	1	B
-	0	I
1	0	I
to	0	O
modulate	0	O
transcription	0	O
of	0	O
the	0	O
HIV	1	B
-	0	I
1	0	I
promoter	0	I
in	0	O
a	0	O
human	0	O
astrocytic	0	O
cell	0	O
line	0	O
(	0	O
U	1	O
-	0	O
87MG	0	O
),	0	O
a	0	O
neuronal	0	O
cell	0	O
line	0	O
(	0	O
SK	1	O
-	0	O
N	1	O
-	0	O
MC	1	O
)	0	O
and	0	O
lymphoid	0	O
cells	0	O
(	0	O
Jurkat	0	O
)	0	O
by	0	O
transfection	0	O
assay	0	O
.	0	O


Therefore	0	O
more	0	O
active	0	O
and	0	O
tolerable	0	O
salvage	0	O
regimens	0	O
are	0	O
needed	0	O
.	0	O


To	1	O
identify	0	O
some	0	O
of	0	O
the	0	O
genes	0	O
expressed	0	O
in	0	O
LPS	1	O
-	0	O
activated	0	O
coelomocytes	0	O
,	0	O
we	0	O
sequenced	0	O
randomly	0	O
chosen	0	O
clones	0	O
from	0	O
a	0	O
directionally	0	O
constructed	0	O
cDNA	1	O
library	0	O
to	0	O
produce	0	O
a	0	O
set	0	O
of	0	O
expressed	0	O
sequence	0	O
tags	0	O
(	0	O
ESTs	0	O
).	0	O


The	0	O
thrombolytic	0	O
effects	0	O
of	0	O
native	0	O
tissue	0	B
-	0	I
type	0	I
plasminogen	0	I
activator	0	I
(	0	O
AK	1	B
-	0	I
124	0	I
)	0	O
on	0	O
experimental	0	O
canine	0	O
coronary	0	O
thrombosis	0	O
.	0	O


The	0	O
five	0	O
-	0	O
drug	0	O
combination	0	O
of	0	O
fluorouracil	0	O
imidazole	0	O
carboxamide	0	O
dimethyl	0	O
triazeno	0	O
,	0	O
vincristine	0	O
,	0	O
bis	0	O
-	0	O
chloroethyl	0	O
nitrosourea	0	O
,	0	O
and	0	O
prednisone	0	O
(	0	O
FIVB	0	O
+	0	O
P	1	O
)	0	O
was	0	O
given	0	O
to	0	O
120	0	O
women	0	O
with	0	O
metastatic	0	O
breast	0	O
cancer	0	O
.	0	O


Forty	0	O
4	0	O
-	0	O
month	0	O
old	0	O
SD	1	O
female	0	O
rats	0	O
were	0	O
randomly	0	O
divided	0	O
into	0	O
four	0	O
groups	0	O
,	0	O
namely	0	O
sham	0	O
operation	0	O
,	0	O
bilateral	0	O
ovariectomy	0	O
,	0	O
ovariectomy	0	O
plus	0	O
supplementary	0	O
ethinyl	0	O
estradiol	0	O
(	0	O
0	0	O
.	0	O
2	0	O
microgram	0	O
/	0	O
100	0	O
g	0	O
B	1	O
.	0	O


They	0	O
consisted	0	O
of	0	O
behavioural	0	O
disorders	0	O
,	0	O
tetraparesis	0	O
,	0	O
incontinence	0	O
and	0	O
oculomotor	0	O
paralysis	0	O
.	0	O


The	0	O
PDGFR	0	B
mutants	0	I
that	0	O
failed	0	O
to	0	O
associate	0	O
with	0	O
PLC	0	B
gamma	0	I
were	0	O
not	0	O
able	0	O
to	0	O
mediate	0	O
the	0	O
PDGF	0	B
-	0	O
dependent	0	O
production	0	O
of	0	O
inositol	0	O
phosphates	0	O
.	0	O


Therefore	0	O
,	0	O
both	0	O
the	0	O
Chilean	0	O
and	0	O
the	0	O
Japanese	0	O
samples	0	O
collected	0	O
in	0	O
high	0	O
-	0	O
risk	0	O
areas	0	O
showed	0	O
higher	0	O
mutagenic	0	O
rates	0	O
than	0	O
the	0	O
Japanese	0	O
ones	0	O
in	0	O
a	0	O
low	0	O
-	0	O
risk	0	O
area	0	O
,	0	O
with	0	O
a	0	O
statistical	0	O
significance	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
),	0	O
chi	0	O
-	0	O
square	0	O
test	0	O
).	0	O


In	1	O
HeLa	0	O
cells	0	O
,	0	O
the	0	O
JNKK2	0	B
-	0	O
JNK1	0	B
fusion	0	O
protein	0	O
showed	0	O
significant	0	O
JNK	0	B
activity	0	O
,	0	O
which	0	O
was	0	O
comparable	0	O
with	0	O
that	0	O
of	0	O
JNK1	0	B
activated	0	O
by	0	O
many	0	O
stimuli	0	O
and	0	O
activators	0	O
,	0	O
including	0	O
EGF	1	B
,	0	O
TNF	1	B
-	0	I
alpha	0	I
,	0	O
anisomycin	0	O
,	0	O
UV	1	O
irradiation	0	O
,	0	O
MEKK1	0	B
,	0	O
and	0	O
small	0	B
GTP	1	I
binding	0	I
proteins	0	I
Rac1	0	I
and	0	O
Cdc42Hs	0	B
.	0	O


99Tcm	0	O
-	0	O
DMP	0	O
-	0	O
HSA	1	O
showed	0	O
an	0	O
almost	0	O
identical	0	O
behaviour	0	O
to	0	O
in	0	O
vitro	0	O
labelled	0	O
red	0	O
blood	0	O
cells	0	O
(	0	O
RBCs	0	O
),	0	O
which	0	O
are	0	O
generally	0	O
considered	0	O
the	0	O
reference	0	O
standard	0	O
for	0	O
blood	0	O
pool	0	O
agents	0	O
.	0	O


The	0	O
Abbreviated	0	O
Injury	1	O
Scale	1	O
(	0	O
AIS	1	O
),	0	O
Injury	1	O
Severity	0	O
Scale	1	O
and	0	O
TRISS	1	O
methodology	0	O
comprise	0	O
a	0	O
mathematically	0	O
sound	0	O
system	0	O
for	0	O
the	0	O
analysis	0	O
of	0	O
injuries	0	O
and	0	O
injured	0	O
patients	0	O
.	0	O


Selective	1	O
macrophage	0	O
inhibition	0	O
abolishes	0	O
warfarin	0	O
-	0	O
induced	0	O
reduction	0	O
of	0	O
metastasis	0	O
.	0	O


We	0	O
have	0	O
shown	0	O
that	0	O
the	0	O
epidural	0	O
(	0	O
EPI	0	O
)	0	O
delivery	0	O
of	0	O
morphine	0	O
encapsulated	0	O
in	0	O
multivesicular	0	O
liposomes	0	O
(	0	O
DepoFoam	0	O
drug	0	O
delivery	0	O
system	0	O
)	0	O
produces	0	O
a	0	O
sustained	0	O
clearance	0	O
of	0	O
morphine	0	O
and	0	O
a	0	O
prolonged	0	O
analgesia	0	O
.	0	O


Binding	0	O
affinities	0	O
of	0	O
these	0	O
recombinant	0	O
phages	0	O
as	0	O
determined	0	O
by	0	O
the	0	O
retention	0	O
of	0	O
these	0	O
phages	0	O
by	0	O
a	0	O
His	1	O
-	0	O
tag	0	O
immobilized	0	O
gp17	0	B
column	0	O
,	0	O
and	0	O
by	0	O
co	0	O
-	0	O
immunoprecipitation	0	O
with	0	O
purified	0	O
terminase	0	B
supported	0	O
the	0	O
specific	0	O
nature	0	O
of	0	O
the	0	O
portal	0	B
protein	0	I
and	0	O
terminase	0	B
interaction	0	I
sites	0	I
.	0	O


A	1	O
third	0	O
series	0	O
of	0	O
mice	0	O
were	0	O
given	0	O
a	0	O
single	0	O
injection	0	O
of	0	O
5	0	O
-	0	O
OH	0	O
-	0	O
DA	1	O
,	0	O
sacrificed	0	O
,	0	O
and	0	O
prepared	0	O
for	0	O
ultrastructural	0	O
study	0	O
.	0	O


These	0	O
data	0	O
confirm	0	O
the	0	O
existence	0	O
of	0	O
hyperlipemic	0	O
abdominal	0	O
crisis	0	O
as	0	O
a	0	O
distinct	0	O
entity	0	O
and	0	O
testify	0	O
to	0	O
the	0	O
importance	0	O
of	0	O
recognizing	0	O
this	0	O
syndrome	0	O
in	0	O
order	0	O
to	0	O
avoid	0	O
the	0	O
occurrence	0	O
of	0	O
acute	0	O
pancreatitis	0	O
and	0	O
the	0	O
performance	0	O
of	0	O
unnecessary	0	O
and	0	O
potentially	0	O
harmful	0	O
surgery	0	O
.	0	O


Lac	1	B
operators	0	O
were	0	O
introduced	0	O
into	0	O
several	0	O
positions	0	O
within	0	O
the	0	O
CAB	1	B
promoter	0	I
and	0	O
operator	0	O
-	0	O
free	0	O
plasmid	0	O
was	0	O
used	0	O
as	0	O
control	0	O
.	0	O


IX	0	O
.	0	O


Some	0	O
of	0	O
the	0	O
peptide	0	B
:	0	I
MBP	1	I
fusions	0	I
were	0	O
also	0	O
analyzed	0	O
using	0	O
surface	0	O
plasmon	0	O
resonance	0	O
.	0	O


CONCLUSION	0	O
:	0	O
We	0	O
were	0	O
unable	0	O
to	0	O
identify	0	O
features	0	O
of	0	O
disease	0	O
likely	0	O
to	0	O
be	0	O
associated	0	O
with	0	O
a	0	O
clinically	0	O
useful	0	O
response	0	O
to	0	O
inhaled	0	O
NO	1	O
therapy	0	O
using	0	O
the	0	O
parameters	0	O
studied	0	O
.	0	O


The	0	O
findings	0	O
suggest	0	O
that	0	O
,	0	O
although	0	O
iodine	0	O
deficiency	0	O
is	0	O
the	0	O
most	0	O
probable	0	O
cause	0	O
of	0	O
goiter	0	O
among	0	O
immigrants	0	O
of	0	O
the	0	O
1928	0	O
cohort	0	O
,	0	O
where	0	O
the	0	O
native	0	O
population	0	O
is	0	O
concerned	0	O
(	0	O
both	0	O
men	0	O
and	0	O
women	0	O
),	0	O
some	0	O
other	0	O
goitrogenic	0	O
factor	0	O
(	0	O
s	0	O
)	0	O
must	0	O
be	0	O
involved	0	O
.	0	O


High	0	O
-	0	O
resolution	0	O
structure	0	O
of	0	O
the	0	O
diphtheria	0	B
toxin	0	I
repressor	0	I
complexed	0	O
with	0	O
cobalt	0	O
and	0	O
manganese	0	O
reveals	0	O
an	0	O
SH3	0	B
-	0	I
like	0	I
third	0	O
domain	0	O
and	0	O
suggests	0	O
a	0	O
possible	0	O
role	0	O
of	0	O
phosphate	0	O
as	0	O
co	0	O
-	0	O
corepressor	0	O
.	0	O


The	0	O
latent	0	O
periods	0	O
from	0	O
the	0	O
antral	0	O
exclusion	0	O
to	0	O
the	0	O
occurrence	0	O
of	0	O
anastomotic	0	O
ulcers	0	O
after	0	O
a	0	O
subtotal	0	O
gastrectomy	0	O
with	0	O
Billroth	0	O
'	0	O
s	0	O
type	0	O
II	0	O
reconstruction	0	O
varied	0	O
from	0	O
a	0	O
few	0	O
days	0	O
to	0	O
19	0	O
years	0	O
,	0	O
with	0	O
an	0	O
average	0	O
of	0	O
2	0	O
.	0	O
8	0	O
years	0	O
.	0	O


The	0	O
Menopause	1	O
-	0	O
Rating	0	O
-	0	O
Scale	1	O
(	0	O
MRS	0	O
I	1	O
)	0	O
was	0	O
used	0	O
in	0	O
clinical	0	O
practice	0	O
since	0	O
1992	0	O
.	0	O


The	0	O
CAPLC1	0	B
protein	0	I
also	0	O
exhibited	0	O
several	0	O
unique	0	O
features	0	O
,	0	O
including	0	O
a	0	O
novel	0	O
stretch	0	O
of	0	O
18	0	O
-	0	O
19	0	O
amino	0	O
acid	0	O
residues	0	O
within	0	O
the	0	O
X	1	O
domain	0	O
and	0	O
an	0	O
unusually	0	O
long	0	O
N	1	O
-	0	O
terminus	0	O
which	0	O
did	0	O
not	0	O
contain	0	O
a	0	O
recognizable	0	O
EF	1	O
-	0	O
hand	0	O
Ca	1	O
(	0	O
2	0	O
+)-	0	O
binding	0	O
domain	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
previously	0	O
characterized	0	O
proteophosphoglycans	0	O
,	0	O
the	0	O
ppg1	0	B
gene	0	O
product	0	O
is	0	O
predominantly	0	O
membrane	0	O
-	0	O
associated	0	O
and	0	O
it	0	O
is	0	O
expressed	0	O
on	0	O
the	0	O
promastigote	0	O
cell	0	O
surface	0	O
.	0	O


Labile	1	O
LTR	1	B
-	0	I
binding	0	I
proteins	0	I
appear	0	O
to	0	O
be	0	O
essential	0	O
for	0	O
c	0	B
-	0	I
myc	0	I
hyperexpression	0	O
,	0	O
since	0	O
both	0	O
LTR	1	O
-	0	O
enhanced	0	O
transcription	0	O
and	0	O
the	0	O
activities	0	O
of	0	O
LTR	1	B
-	0	I
binding	0	I
proteins	0	I
are	0	O
specifically	0	O
decreased	0	O
after	0	O
inhibition	0	O
of	0	O
protein	0	O
synthesis	0	O
(	0	O
A	1	O
.	0	O


Comparison	0	O
of	0	O
propofol	0	O
and	0	O
thiopentone	0	O
as	0	O
anaesthetic	0	O
agents	0	O
for	0	O
electroconvulsive	0	O
therapy	0	O
.	0	O


Several	0	O
nuclear	0	O
factors	0	O
that	0	O
interact	0	O
with	0	O
sequences	0	O
in	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
mouse	0	B
tyrosinase	0	I
gene	0	I
were	0	O
identified	0	O
using	0	O
band	0	O
shift	0	O
and	0	O
methylation	0	O
interference	0	O
assays	0	O
.	0	O


Value	1	O
of	0	O
the	0	O
EMG	1	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
a	0	O
cardiomyopathy	0	O
associated	0	O
with	0	O
a	0	O
myotonic	0	O
myopathy	0	O
.	0	O


There	0	O
was	0	O
a	0	O
slight	0	O
increase	0	O
in	0	O
total	0	O
transferrin	0	B
2	0	O
hr	0	O
after	0	O
1	0	O
tablet	0	O
and	0	O
values	0	O
remained	0	O
high	0	O
throughout	0	O
the	0	O
experiment	0	O
.	0	O


Sp1	0	B
can	0	O
activate	0	O
transcription	0	O
through	0	O
immunoglobulin	0	B
kappa	0	I
-	0	I
chain	0	I
enhancer	0	I
or	0	O
P	1	B
-	0	I
selectin	0	I
promoter	0	I
NF	1	I
-	0	I
kappaB	0	I
sites	0	I
.	0	O
p50	0	B
homodimers	0	I
replace	0	O
Sp1	0	B
from	0	O
the	0	O
P	1	B
-	0	I
selectin	0	I
promoter	0	I
by	0	O
binding	0	O
site	0	O
competition	0	O
and	0	O
thereby	0	O
either	0	O
inhibit	0	O
basal	0	O
Sp1	0	B
-	0	O
driven	0	O
expression	0	O
or	0	O
,	0	O
in	0	O
concert	0	O
with	0	O
Bcl	0	B
-	0	I
3	0	I
,	0	O
stimulate	0	O
expression	0	O
.	0	O


In	1	O
the	0	O
presence	0	O
of	0	O
the	0	O
in	0	O
vivo	0	O
reducing	0	O
system	0	O
(	0	O
thioredoxin	0	B
,	0	O
thioredoxin	0	B
reductase	0	I
,	0	O
and	0	O
NADPH	1	O
),	0	O
however	0	O
,	0	O
each	0	O
of	0	O
these	0	O
mutants	0	O
catalyzed	0	O
the	0	O
formation	0	O
of	0	O
only	0	O
0	0	O
.	0	O
6	0	O
-	0	O
0	0	O
.	0	O
8	0	O
dCTPs	0	O
per	0	O
mole	0	O
of	0	O
enzyme	0	O
.	0	O


Premature	1	O
initiation	0	O
of	0	O
mitosis	0	O
in	0	O
yeast	0	O
lacking	0	O
RCC1	0	B
or	0	O
an	0	O
interacting	0	O
GTPase	1	B
.	0	O


Regional	1	O
cerebral	0	O
blood	0	O
flow	0	O
(	0	O
rCBF	1	O
)	0	O
measurements	0	O
and	0	O
psychiatric	0	O
ratings	0	O
were	0	O
performed	0	O
on	0	O
seven	0	O
schizophrenic	0	O
patients	0	O
(	0	O
mean	0	O
age	0	O
=	0	O
41	0	O
.	0	O
4	0	O
years	0	O
)	0	O
who	0	O
had	0	O
been	0	O
examined	0	O
18	0	O
years	0	O
previously	0	O
in	0	O
a	0	O
study	0	O
that	0	O
used	0	O
similar	0	O
psychiatric	0	O
ratings	0	O
and	0	O
a	0	O
comparable	0	O
rCBF	1	O
technique	0	O
.	0	O


Response	1	O
durations	0	O
were	0	O
short	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
the	0	O
P2	1	B
-	0	I
proximal	0	I
CTCF	0	I
binding	0	I
site	0	I
and	0	O
transient	0	O
-	0	O
cotransfection	0	O
experiments	0	O
demonstrate	0	O
that	0	O
CTCF	0	B
is	0	O
a	0	O
transcriptional	0	O
repressor	0	O
of	0	O
the	0	O
human	0	B
c	0	I
-	0	I
myc	0	I
gene	0	I
.	0	O


MSMS	0	O
Council	0	O
hears	0	O
new	0	O
public	0	O
health	0	O
director	0	O
.	0	O


Fusion	1	O
of	0	O
ubiquitin	0	B
to	0	O
pADPRP	0	B
increased	0	O
the	0	O
yield	0	O
of	0	O
pADPRP	0	B
approximately	0	O
10	0	O
-	0	O
fold	0	O
compared	0	O
to	0	O
that	0	O
of	0	O
the	0	O
unfused	0	O
enzyme	0	O
.	0	O


To	1	O
define	0	O
the	0	O
number	0	O
and	0	O
nature	0	O
of	0	O
the	0	O
E6	0	B
and	0	O
E7	0	B
gene	0	I
products	0	O
expressed	0	O
in	0	O
BPV	1	O
-	0	O
1	0	O
-	0	O
transformed	0	O
cells	0	O
,	0	O
we	0	O
performed	0	O
immunoprecipitation	0	O
experiments	0	O
with	0	O
antisera	0	O
raised	0	O
to	0	O
bacterially	0	O
expressed	0	O
BPV	1	B
-	0	I
1	0	I
E6	0	I
and	0	O
E7	0	B
fusion	0	I
proteins	0	I
.	0	O


Study	1	O
of	0	O
the	0	O
physico	0	O
-	0	O
chemical	0	O
state	0	O
of	0	O
plutonium	0	O
-	0	O
239	0	O
in	0	O
a	0	O
citrate	0	O
solution	0	O
-	0	O
blood	0	O
system	0	O


Overexpression	1	O
of	0	O
the	0	O
bZip	0	O
interaction	0	O
domain	0	O
of	0	O
CBP	0	B
specifically	0	O
abolishes	0	O
the	0	O
positive	0	O
cross	0	O
talk	0	O
between	0	O
TR	1	B
and	0	O
p45	0	B
/	0	O
NF	1	B
-	0	I
E2	1	I
.	0	O


Promoter	1	O
activity	0	O
was	0	O
dose	0	O
-	0	O
dependently	0	O
inhibited	0	O
by	0	O
cotransfection	0	O
with	0	O
either	0	O
ras	0	B
or	0	O
mos	0	B
oncogenes	0	I
,	0	O
but	0	O
oncogene	0	O
inhibition	0	O
was	0	O
reversed	0	O
and	0	O
the	0	O
overall	0	O
activity	0	O
increased	0	O
when	0	O
cells	0	O
were	0	O
treated	0	O
with	0	O
the	0	O
MAP	1	B
kinase	0	I
kinase	0	I
(	0	O
MKK	0	B
)	0	O
inhibitor	0	O
PD98059	0	O
.	0	O


The	0	O
underlying	0	O
cirrhosis	0	O
was	0	O
alcoholic	0	O
in	0	O
11	0	O
(	0	O
53	0	O
.	0	O
3	0	O
%),	0	O
cryptogenic	0	O
in	0	O
5	0	O
(	0	O
23	0	O
.	0	O
8	0	O
%),	0	O
and	0	O
hepatitis	0	O
B	1	O
chronic	0	O
infection	0	O
related	0	O
in	0	O
5	0	O
(	0	O
23	0	O
.	0	O
8	0	O
%).	0	O


The	0	O
somatoform	0	O
conundrum	0	O
:	0	O
a	0	O
question	0	O
of	0	O
nosological	0	O
valves	0	O
.	0	O


For	0	O
symptomatic	0	O
relief	0	O
and	0	O
inhibition	0	O
of	0	O
the	0	O
growth	0	O
of	0	O
the	0	O
metastases	0	O
interferon	0	B
-	0	I
a	0	I
and	0	O
somatostatin	0	B
analogues	0	O
can	0	O
be	0	O
employed	0	O
.	0	O


The	0	O
patients	0	O
in	0	O
one	0	O
group	0	O
had	0	O
intrauterine	0	O
catheters	0	O
inserted	0	O
and	0	O
oxytocin	0	B
was	0	O
titrated	0	O
to	0	O
achieve	0	O
the	0	O
75th	0	O
percentile	0	O
of	0	O
uterine	0	O
activity	0	O
observed	0	O
in	0	O
spontaneous	0	O
normal	0	O
labour	0	O
according	0	O
to	0	O
parity	0	O
.	0	O


Our	0	O
data	0	O
complement	0	O
other	0	O
studies	0	O
of	0	O
circumpolar	0	O
populations	0	O
and	0	O
reinforce	0	O
the	0	O
reported	0	O
high	0	O
prevalences	0	O
of	0	O
SPA	1	O
and	0	O
HLA	1	B
-	0	I
B27	0	I
among	0	O
those	0	O
populations	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
have	0	O
more	0	O
closely	0	O
investigated	0	O
transactivation	0	O
of	0	O
the	0	O
human	0	B
HSP70	0	I
promoter	0	I
by	0	O
Myb	0	B
proteins	0	I
.	0	O


After	0	O
giving	0	O
a	0	O
survey	0	O
on	0	O
the	0	O
situation	0	O
of	0	O
antibiotic	0	O
resistance	0	O
in	0	O
the	0	O
region	0	O
of	0	O
Northern	0	O
Bavaria	0	O
during	0	O
1973	0	O
/	0	O
74	0	O
and	0	O
comparing	0	O
the	0	O
activity	0	O
of	0	O
a	0	O
sulfamethoxazole	0	O
(	0	O
SMZ	0	O
)	0	O
trimethoprim	0	O
(	0	O
TMP	1	O
)	0	O
combination	0	O
to	0	O
other	0	O
commonly	0	O
used	0	O
antibiotics	0	O
and	0	O
chemotherapeutic	0	O
agents	0	O
,	0	O
the	0	O
results	0	O
of	0	O
tests	0	O
with	0	O
the	0	O
new	0	O
combination	0	O
of	0	O
N1	0	O
-(	0	O
4	0	O
,	0	O
5	0	O
-	0	O
dimethyl	0	O
-	0	O
2	0	O
-	0	O
oxazolyl	0	O
)-	0	O
sulfanilamide	0	O
)	0	O
(	0	O
sulfamoxole	0	O
)	0	O
and	0	O
2	0	O
,	0	O
4	0	O
-	0	O
diamino	0	O
-	0	O
5	0	O
-(	0	O
3	0	O
,	0	O
4	0	O
,	0	O
5	0	O
-	0	O
trimethoxy	0	O
-	0	O
benzyl	0	O
)-	0	O
pyrimidine	0	O
(	0	O
trimethoprim	0	O
)	0	O
at	0	O
a	0	O
ratio	0	O
of	0	O
5	0	O
:	0	O
1	0	O
(	0	O
CN	1	O
3123	0	O
;	0	O
Nevin	0	O
,	0	O
Supristol	0	O
)	0	O
are	0	O
compared	0	O
to	0	O
those	0	O
of	0	O
tests	0	O
with	0	O
TMP	1	O
/	0	O
SMZ	0	O
.	0	O


An	1	O
8	0	O
-	0	O
h	0	O
exposure	0	O
to	0	O
10	0	O
mg	0	O
DMEA	0	O
/	0	O
m3	0	O
corresponds	0	O
to	0	O
a	0	O
postexposure	0	O
plasma	0	O
concentration	0	O
and	0	O
2	0	O
-	0	O
h	0	O
postexposure	0	O
urinary	0	O
excretion	0	O
of	0	O
4	0	O
.	0	O
9	0	O
mumol	0	O
/	0	O
l	0	O
and	0	O
75	0	O
mmol	0	O
/	0	O
mol	0	O
creatinine	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
promoter	0	O
region	0	O
showed	0	O
no	0	O
consensus	0	O
TATA	0	O
box	0	O
but	0	O
it	0	O
contains	0	O
CCAAT	0	O
and	0	O
CreA	0	B
boxes	0	O
known	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
both	0	O
stress	0	O
and	0	O
carbon	0	O
-	0	O
catabolite	0	O
regulation	0	O
of	0	O
fungal	0	O
promoters	0	O
.	0	O


Cell	1	O
survival	0	O
by	0	O
Epo	0	B
did	0	O
not	0	O
require	0	O
activation	0	O
of	0	O
other	0	O
known	0	O
signaling	0	O
pathways	0	O
including	0	O
PI	1	B
-	0	I
3	0	I
kinase	0	I
,	0	O
PLC	0	B
-	0	I
gamma	0	I
,	0	O
Ras	1	B
or	0	O
Stats	0	B
.	0	O


The	0	O
results	0	O
revealed	0	O
a	0	O
hierarchy	0	O
of	0	O
ligand	0	O
affinities	0	O
that	0	O
mirrored	0	O
their	0	O
adhesive	0	O
activity	0	O
(	0	O
rsVCAM	0	B
-	0	I
1	0	I
>	0	O
fibronectin	0	B
variants	0	I
containing	0	O
CS1	0	B
>>	0	O
other	0	O
fibronectin	0	B
variants	0	I
).	0	O


An	1	O
abnormally	0	O
high	0	O
percentage	0	O
of	0	O
hypertensive	0	O
patients	0	O
(	0	O
approximately	0	O
30	0	O
%)	0	O
undergoing	0	O
cardiac	0	O
catheterization	0	O
because	0	O
of	0	O
anginal	0	O
pain	0	O
and	0	O
/	0	O
or	0	O
exercise	0	O
-	0	O
induced	0	O
ST	1	O
-	0	O
segment	0	O
depressions	0	O
has	0	O
angiographically	0	O
normal	0	O
coronary	0	O
arteries	0	O
.	0	O


The	0	O
neuroprotective	0	O
efficacy	0	O
of	0	O
the	0	O
selective	0	O
N	1	O
-	0	O
type	0	O
voltage	0	O
-	0	O
sensitive	0	O
calcium	0	O
channel	0	O
blocker	0	O
,	0	O
SNX	0	O
-	0	O
111	0	O
,	0	O
was	0	O
evaluated	0	O
in	0	O
spontaneously	0	O
hypertensive	0	O
rats	0	O
subjected	0	O
to	0	O
60	0	O
min	0	O
of	0	O
focal	0	O
cerebral	0	O
ischemia	0	O
by	0	O
permanent	0	O
ligation	0	O
of	0	O
the	0	O
right	0	O
common	0	O
carotid	0	O
artery	0	O
and	0	O
temporary	0	O
occlusion	0	O
of	0	O
the	0	O
right	0	O
middle	0	O
cerebral	0	O
artery	0	O
.	0	O


No	1	O
evidence	0	O
of	0	O
either	0	O
positive	0	O
or	0	O
negative	0	O
chemography	0	O
was	0	O
found	0	O
.	0	O


The	0	O
retinoid	0	B
Z	1	I
receptor	0	I
beta	0	I
(	0	O
RZR	0	B
beta	0	I
),	0	O
an	0	O
orphan	0	O
receptor	0	O
,	0	O
is	0	O
a	0	O
member	0	O
of	0	O
the	0	O
retinoic	0	B
acid	0	I
receptor	0	I
(	0	O
RAR	0	B
)/	0	O
thyroid	0	B
hormone	0	I
receptor	0	I
(	0	O
TR	1	B
)	0	O
subfamily	0	O
of	0	O
nuclear	0	O
receptors	0	O
.	0	O


Franz	0	O
Schubert	0	O
--	0	O
his	0	O
life	0	O
,	0	O
music	0	O
and	0	O
diseases	0	O


Reduction	1	O
in	0	O
dosage	0	O
restored	0	O
normal	0	O
taste	0	O
sense	0	O
in	0	O
all	0	O
three	0	O
,	0	O
but	0	O
in	0	O
two	0	O
the	0	O
drug	0	O
had	0	O
to	0	O
be	0	O
discontinued	0	O
because	0	O
of	0	O
persisting	0	O
high	0	O
transaminase	0	O
levels	0	O
.	0	O


Ultrastructural	0	O
and	0	O
morphometric	0	O
study	0	O
of	0	O
the	0	O
myeloid	0	O
parenchyma	0	O
cells	0	O
of	0	O
mice	0	O
prior	0	O
and	0	O
after	0	O
X	1	O
-	0	O
ray	0	O
exposure	0	O


When	0	O
overexpressed	0	O
in	0	O
an	0	O
appropriate	0	O
cell	0	O
line	0	O
,	0	O
TAN	1	B
-	0	I
1C	0	I
prevented	0	O
kappa	0	B
B	1	I
-	0	O
dependent	0	O
transactivation	0	O
in	0	O
transient	0	O
reporter	0	O
gene	0	O
assays	0	O
in	0	O
a	0	O
fashion	0	O
similar	0	O
to	0	O
the	0	O
structurally	0	O
related	0	O
protein	0	O
,	0	O
Bcl	0	B
-	0	I
3	0	I
.	0	O


The	0	O
fusion	0	O
proteins	0	O
were	0	O
tested	0	O
by	0	O
ELISA	1	O
for	0	O
reactivity	0	O
with	0	O
a	0	O
panel	0	O
of	0	O
human	0	B
anti	0	I
-	0	I
La	1	I
sera	0	I
in	0	O
order	0	O
to	0	O
define	0	O
the	0	O
nature	0	O
of	0	O
the	0	O
epitopes	0	O
.	0	O


This	0	O
-	0	O
2485	0	O
/-	0	O
2458	0	O
element	0	O
bound	0	O
PPARalpha	0	B
and	0	O
PPARgamma	0	B
from	0	O
brown	0	O
fat	0	O
nuclei	0	O
.	0	O


Forskolin	0	O
significantly	0	O
enhanced	0	O
heregulin	0	B
-	0	O
stimulated	0	O
expression	0	O
of	0	O
cyclin	0	B
D	1	I
and	0	O
phosphorylation	0	O
of	0	O
the	0	O
retinoblastoma	0	B
gene	0	I
product	0	I
.	0	O


Hyaluronan	1	O
treatment	0	O
stimulated	0	O
collagen	0	B
remodeling	0	O
in	0	O
the	0	O
peripheral	0	O
region	0	O
and	0	O
inhibited	0	O
swelling	0	O
of	0	O
the	0	O
meniscus	0	O
repaired	0	O
in	0	O
the	0	O
inner	0	O
region	0	O
.	0	O


These	0	O
patients	0	O
failed	0	O
to	0	O
respond	0	O
to	0	O
intravenous	0	O
cyclophosphamide	0	O
and	0	O
steroids	0	O
and	0	O
were	0	O
then	0	O
changed	0	O
to	0	O
receive	0	O
oral	0	O
cyclosporine	0	O
A	1	O
,	0	O
at	0	O
a	0	O
dose	0	O
of	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
.	0	O


Its	0	O
transcription	0	O
product	0	O
,	0	O
a	0	O
1	0	O
.	0	O
3	0	O
kb	0	O
mRNA	1	O
,	0	O
is	0	O
polyadenylated	0	O
at	0	O
a	0	O
site	0	O
containing	0	O
consensus	0	O
eukaryotic	0	O
polyadenylation	0	O
signals	0	O
and	0	O
mapping	0	O
87	0	O
bp	0	O
downstream	0	O
of	0	O
the	0	O
translation	0	O
termination	0	O
codon	0	O
for	0	O
CG30	0	B
.	0	O


The	0	O
two	0	O
contiguous	0	O
IGF2	0	B
(	0	O
human	0	B
insulin	0	I
-	0	I
like	0	I
growth	0	I
factor	0	I
II	0	I
)	0	O
and	0	O
H19	0	B
genes	0	I
are	0	O
reciprocally	0	O
imprinted	0	O
in	0	O
both	0	O
human	0	O
and	0	O
mouse	0	O
.	0	O


Although	0	O
the	0	O
OC	1	B
promoter	0	I
is	0	O
activated	0	O
in	0	O
a	0	O
C	1	O
terminus	0	O
dependent	0	O
manner	0	O
,	0	O
the	0	O
MDR	1	B
,	0	O
LTR	1	O
and	0	O
BSP	0	B
promoters	0	I
are	0	O
repressed	0	O
by	0	O
three	0	O
distinct	0	O
mechanisms	0	O
,	0	O
either	0	O
independent	0	O
of	0	O
or	0	O
involving	0	O
the	0	O
AML	1	B
C	1	I
terminus	0	I
,	0	O
or	0	O
requiring	0	O
only	0	O
the	0	O
conserved	0	O
C	1	O
-	0	O
terminal	0	O
pentapeptide	0	O
VWRPY	0	O
.	0	O


The	0	O
present	0	O
study	0	O
reports	0	O
visual	0	O
evoked	0	O
potential	0	O
responses	0	O
to	0	O
pattern	0	O
reversal	0	O
(	0	O
VEP	1	O
-	0	O
P	1	O
)	0	O
in	0	O
ten	0	O
third	0	O
trimester	0	O
pregnant	0	O
women	0	O
and	0	O
changes	0	O
in	0	O
latency	0	O
of	0	O
NPN	1	O
complex	0	O
when	0	O
compared	0	O
with	0	O
these	0	O
responses	0	O
in	0	O
the	0	O
non	0	O
pregnant	0	O
state	0	O
.	0	O


Together	0	O
,	0	O
these	0	O
results	0	O
indicate	0	O
that	0	O
IL	1	B
-	0	I
1	0	I
beta	0	I
induces	0	O
VEGF	1	B
gene	0	I
expression	0	O
at	0	O
both	0	O
transcriptional	0	O
and	0	O
post	0	O
-	0	O
transcriptional	0	O
levels	0	O
,	0	O
and	0	O
IL	1	B
-	0	I
1	0	I
beta	0	I
evokes	0	O
p38	0	B
MAPK	1	O
and	0	O
JNK	0	B
signalings	0	O
,	0	O
which	0	O
in	0	O
turn	0	O
stimulate	0	O
the	0	O
transcription	0	O
of	0	O
the	0	O
VEGF	1	B
gene	0	I
through	0	O
Sp1	0	B
-	0	I
binding	0	I
sites	0	I
.	0	O


Selective	1	O
visual	0	O
attention	0	O
involves	0	O
dynamic	0	O
interplay	0	O
between	0	O
attentional	0	O
control	0	O
systems	0	O
and	0	O
sensory	0	O
brain	0	O
structures	0	O
.	0	O


Endostatin	1	O
treatment	0	O
for	0	O
10	0	O
minutes	0	O
or	0	O
24	0	O
hours	0	O
induced	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
Shb	0	B
and	0	O
formation	0	O
of	0	O
multiprotein	0	O
complexes	0	O
.	0	O


The	0	O
Authors	0	O
have	0	O
proposed	0	O
to	0	O
develop	0	O
this	0	O
research	0	O
employing	0	O
a	0	O
preparation	0	O
containing	0	O
exclusively	0	O
a	0	O
cortisonic	0	O
,	0	O
the	0	O
desametazone	0	O
,	0	O
in	0	O
order	0	O
to	0	O
evaluate	0	O
the	0	O
alterations	0	O
of	0	O
the	0	O
dentinogenesis	0	O
to	0	O
be	0	O
attributed	0	O
to	0	O
such	0	O
component	0	O
.	0	O


Saturable	0	O
spermidine	0	O
transport	0	O
in	0	O
stk2	0	B
::	0	O
lacZ	0	B
mutants	0	I
had	0	O
an	0	O
approximately	0	O
fivefold	0	O
-	0	O
lower	0	O
affinity	0	O
and	0	O
twofold	0	O
-	0	O
lower	0	O
Vmax	1	O
than	0	O
in	0	O
the	0	O
parental	0	O
strain	0	O
.	0	O


The	0	O
major	0	O
inserted	0	O
DNA	1	O
has	0	O
no	0	O
significant	0	O
homology	0	O
to	0	O
published	0	O
human	0	O
nucleic	0	O
acid	0	O
sequences	0	O
.	0	O


In	1	O
Xenopus	1	O
laevis	0	O
,	0	O
the	0	O
gene	0	O
encoding	0	O
the	0	O
elongation	0	B
factor	0	I
1	0	I
-	0	I
alpha	0	I
variant	0	I
EF	1	I
-	0	I
1	0	I
alpha	0	I
O	1	I
,	0	O
where	0	O
O	1	O
stands	0	O
for	0	O
oocyte	0	O
,	0	O
is	0	O
expressed	0	O
in	0	O
oocytes	0	O
and	0	O
early	0	O
embryos	0	O
.	0	O


The	0	O
present	0	O
study	0	O
highlights	0	O
the	0	O
improvement	0	O
in	0	O
sputum	0	O
amoxycillin	0	O
(	0	O
amoxy	0	O
)	0	O
levels	0	O
when	0	O
a	0	O
combination	0	O
tablet	0	O
,	0	O
amoxy	0	O
500	0	O
mg	0	O
plus	0	O
bromhexeine	0	O
8	0	O
mg	0	O
,	0	O
is	0	O
administered	0	O
as	0	O
compared	0	O
to	0	O
plain	0	O
amoxy	0	O
500	0	O
mg	0	O
.	0	O


Extracellular	1	B
-	0	I
regulated	0	I
kinase	0	I
(	0	O
ERK	0	B
)	0	O
activation	0	O
and	0	O
molecular	0	O
coupling	0	O
of	0	O
the	0	O
adaptor	0	O
proteins	0	O
p130	0	B
Crk	0	I
-	0	I
associated	0	I
substrate	0	I
(	0	O
CAS	1	B
)	0	O
and	0	O
c	0	B
-	0	I
CrkII	0	I
(	0	O
Crk	0	B
)	0	O
represent	0	O
two	0	O
distinct	0	O
pathways	0	O
that	0	O
induce	0	O
cell	0	O
invasion	0	O
and	0	O
protect	0	O
cells	0	O
from	0	O
apoptosis	0	O
in	0	O
a	0	O
three	0	O
-	0	O
dimensional	0	O
collagen	0	B
matrix	0	O
.	0	O


This	0	O
is	0	O
in	0	O
contrast	0	O
with	0	O
the	0	O
classical	0	O
'	0	O
oxygen	0	O
debt	0	O
hypothesis	0	O
',	0	O
which	0	O
states	0	O
that	0	O
the	0	O
oxygen	0	O
debt	0	O
and	0	O
lactate	0	O
clearance	0	O
are	0	O
linked	0	O
.	0	O


Substitution	1	O
of	0	O
bulky	0	O
hydrophobic	0	O
residues	0	O
with	0	O
charged	0	O
residues	0	O
within	0	O
PEP1	0	B
affects	0	O
the	0	O
fusion	0	O
activity	0	O
of	0	O
the	0	O
S	1	B
protein	0	I
without	0	O
affecting	0	O
processing	0	O
and	0	O
surface	0	O
expression	0	O
.	0	O


Thioredoxin	1	B
(	0	O
TR	1	B
)	0	O
is	0	O
a	0	O
small	0	O
ubiquitous	0	O
dithiol	0	B
-	0	I
reductase	0	I
enzyme	0	I
first	0	O
identified	0	O
in	0	O
bacteria	0	O
and	0	O
plants	0	O
.	0	O


Using	0	O
a	0	O
3	0	O
'-	0	O
rapid	0	O
amplification	0	O
of	0	O
cDNA	1	O
ends	0	O
strategy	0	O
,	0	O
we	0	O
have	0	O
cloned	0	O
cDNAs	0	O
representing	0	O
the	0	O
3	0	O
'-	0	O
termini	0	O
of	0	O
both	0	O
the	0	O
native	0	O
and	0	O
mutant	0	O
transcripts	0	O
from	0	O
both	0	O
P388	0	O
/	0	O
ADR	1	O
/	0	O
3	0	O
and	0	O
P388	0	O
/	0	O
ADR	1	O
/	0	O
7	0	O
cells	0	O
.	0	O


The	0	O
method	0	O
involved	0	O
deproteinizing	0	O
samples	0	O
with	0	O
two	0	O
volumes	0	O
of	0	O
acetonitrile	0	O
followed	0	O
by	0	O
injection	0	O
of	0	O
5	0	O
microliters	0	O
of	0	O
deproteinized	0	O
supernatant	0	O
onto	0	O
a	0	O
C18	0	O
reversed	0	O
-	0	O
phase	0	O
column	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
the	0	O
major	0	O
homology	0	O
region	0	O
of	0	O
Mason	0	O
-	0	O
Pfizer	0	O
monkey	0	O
virus	0	O
by	0	O
use	0	O
of	0	O
saturation	0	O
mutagenesis	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
these	0	O
relations	0	O
,	0	O
a	0	O
risk	0	O
factor	0	O
-	0	O
selection	0	O
scale	0	O
(	0	O
RFSS	0	O
)	0	O
(	0	O
range	0	O
,	0	O
0	0	O
to	0	O
10	0	O
)	0	O
was	0	O
developed	0	O
by	0	O
computing	0	O
appropriate	0	O
weights	0	O
for	0	O
each	0	O
risk	0	O
factor	0	O
.	0	O


Activation	1	O
of	0	O
the	0	O
aboral	0	O
ectoderm	0	B
-	0	I
specific	0	I
Spec2a	0	I
gene	0	I
in	0	O
blastula	0	O
-	0	O
stage	0	O
sea	0	O
urchin	0	O
embryos	0	O
requires	0	O
an	0	O
upstream	0	O
regulatory	0	O
region	0	O
that	0	O
is	0	O
part	0	O
of	0	O
a	0	O
repetitive	0	O
sequence	0	O
element	0	O
(	0	O
RSR	0	O
)	0	O
associated	0	O
with	0	O
all	0	O
Spec1	0	B
/	0	O
Spec2	0	B
genes	0	O
.	0	O


Thus	0	O
,	0	O
these	0	O
studies	0	O
indicate	0	O
that	0	O
the	0	O
104	0	O
-	0	O
kDa	1	O
isoform	0	O
is	0	O
required	0	O
for	0	O
normal	0	O
proliferation	0	O
of	0	O
female	0	O
germline	0	O
cells	0	O
and	0	O
perhaps	0	O
for	0	O
oocyte	0	O
differentiation	0	O
.	0	O


Five	0	O
patients	0	O
developed	0	O
metastatic	0	O
spread	0	O
,	0	O
and	0	O
all	0	O
of	0	O
them	0	O
died	0	O
of	0	O
tumor	0	O
.	0	O


Simple	1	O
method	0	O
for	0	O
determination	0	O
of	0	O
the	0	O
cephalosporin	0	O
DQ	0	O
-	0	O
2556	0	O
in	0	O
biological	0	O
fluids	0	O
by	0	O
high	0	O
-	0	O
performance	0	O
liquid	0	O
chromatography	0	O
.	0	O


Oxfendazole	1	O
,	0	O
which	0	O
was	0	O
active	0	O
for	0	O
the	0	O
shortest	0	O
time	0	O
(	0	O
about	0	O
65	0	O
days	0	O
)	0	O
from	0	O
the	0	O
start	0	O
of	0	O
grazing	0	O
(	0	O
May	0	O
1	0	O
),	0	O
produced	0	O
a	0	O
78	0	O
.	0	O
1	0	O
per	0	O
cent	0	O
reduction	0	O
in	0	O
Ostertagia	1	O
species	0	O
and	0	O
an	0	O
84	0	O
.	0	O
4	0	O
per	0	O
cent	0	O
reduction	0	O
in	0	O
D	1	O
viviparus	0	O
.	0	O


Tumor	1	B
necrosis	0	I
factor	0	I
-	0	I
alpha	0	I
(	0	O
TNF	1	B
alpha	0	I
),	0	O
a	0	O
proinflammatory	0	O
cytokine	0	O
,	0	O
inhibits	0	O
cAMP	1	O
-	0	O
stimulated	0	O
testosterone	0	O
production	0	O
in	0	O
mouse	0	O
Leydig	0	O
cells	0	O
.	0	O


It	1	O
suggests	0	O
a	0	O
sequence	0	O
of	0	O
surgical	0	O
planning	0	O
that	0	O
can	0	O
prevent	0	O
them	0	O
and	0	O
also	0	O
offers	0	O
ways	0	O
of	0	O
dealing	0	O
with	0	O
the	0	O
problems	0	O
should	0	O
they	0	O
occur	0	O
.	0	O


All	1	O
three	0	O
NR	0	B
isoforms	0	I
are	0	O
expressed	0	O
in	0	O
cv	0	O
.	0	O


Differentiating	0	O
among	0	O
renal	0	O
stones	0	O
.	0	O


Based	0	O
on	0	O
the	0	O
sequence	0	O
of	0	O
the	0	O
conRTRE	0	B
,	0	O
we	0	O
located	0	O
a	0	O
putative	0	O
RTRE	0	B
,	0	O
referred	0	O
to	0	O
as	0	O
P2	1	B
-	0	I
RE	1	I
,	0	O
in	0	O
the	0	O
5	0	O
'	0	O
promoter	0	O
-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
mouse	0	B
protamine	0	I
2	0	I
gene	0	I
,	0	O
which	0	O
is	0	O
induced	0	O
during	0	O
the	0	O
same	0	O
stage	0	O
of	0	O
spermatogenesis	0	O
as	0	O
RTR	0	B
.	0	O


Standardized	1	O
gastric	0	O
wall	0	O
specimens	0	O
from	0	O
the	0	O
area	0	O
of	0	O
grossly	0	O
healed	0	O
ulcers	0	O
were	0	O
obtained	0	O
,	0	O
processed	0	O
,	0	O
and	0	O
evaluated	0	O
by	0	O
light	0	O
microscopy	0	O
and	0	O
by	0	O
transmission	0	O
electron	0	O
microscopy	0	O
.	0	O


Stable	1	O
expression	0	O
of	0	O
truncated	0	B
inositol	0	I
1	0	I
,	0	I
4	0	I
,	0	I
5	0	I
-	0	I
trisphosphate	0	I
receptor	0	I
subunits	0	I
in	0	O
3T3	0	O
fibroblasts	0	O
.	0	O


The	0	O
LTR	1	O
-	0	O
binding	0	O
activities	0	O
of	0	O
VBP	0	B
,	0	O
a1	0	B
/	0	I
EBP	1	I
,	0	O
and	0	O
B	1	B
-	0	I
cell	0	I
nuclear	0	I
extract	0	I
protein	0	I
were	0	O
compared	0	O
and	0	O
mapped	0	O
by	0	O
gel	0	O
shift	0	O
,	0	O
DNase	1	B
I	1	I
footprinting	0	O
,	0	O
and	0	O
methylation	0	O
interference	0	O
assays	0	O
.	0	O


Two	0	O
-	0	O
way	0	O
analysis	0	O
of	0	O
variance	0	O
was	0	O
used	0	O
to	0	O
determine	0	O
whether	0	O
composite	0	O
knowledge	0	O
score	0	O
differed	0	O
among	0	O
patient	0	O
groups	0	O
.	0	O


Brain	1	O
scan	0	O
with	0	O
99mTc	0	O
-	0	O
labelled	0	O
macroaggregated	0	B
albumin	0	I
(	0	O
MAA	1	B
brain	0	O
scan	0	O
)	0	O
and	0	O
computed	0	O
tomography	0	O
studies	0	O
(	0	O
CT	1	O
)	0	O
were	0	O
performed	0	O
on	0	O
78	0	O
patients	0	O
with	0	O
intracranial	0	O
diseases	0	O
.	0	O


Thus	0	O
,	0	O
prostacyclin	0	O
enhanced	0	O
the	0	O
autoregulative	0	O
property	0	O
of	0	O
the	0	O
inner	0	O
ear	0	O
vessels	0	O
.	0	O


The	0	O
C	1	O
-	0	O
LIP	1	O
also	0	O
was	0	O
compared	0	O
with	0	O
transcather	0	O
arterial	0	O
embolization	0	O
(	0	O
TAE	0	O
;	0	O
C	1	O
-	0	O
LIP	1	O
followed	0	O
by	0	O
gelatin	0	O
sponge	0	O
)	0	O
and	0	O
percutaneous	0	O
ethanol	0	O
injection	0	O
therapy	0	O
(	0	O
PEIT	0	O
).	0	O


A	1	O
Bub2p	0	B
-	0	O
dependent	0	O
spindle	0	O
checkpoint	0	O
pathway	0	O
regulates	0	O
the	0	O
Dbf2p	0	B
kinase	0	I
in	0	I
budding	0	I
yeast	0	I
.	0	O


Lead	1	O
fixation	0	O
in	0	O
dogs	0	O
achieved	0	O
with	0	O
RF	1	O
energy	0	O
.	0	O


Functional	1	O
analysis	0	O
of	0	O
aryl	0	B
hydrocarbon	0	I
receptor	0	I
nuclear	0	I
translocator	0	I
interactions	0	O
with	0	O
aryl	0	B
hydrocarbon	0	I
receptor	0	I
in	0	O
the	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
system	0	O
.	0	O


Recurrence	1	O
of	0	O
oxalate	0	O
deposition	0	O
in	0	O
a	0	O
renal	0	O
transplant	0	O
during	0	O
ciclosporin	0	O
A	1	O
therapy	0	O
.	0	O


In	1	O
vitro	0	O
translation	0	O
experiments	0	O
show	0	O
that	0	O
human	0	O
cDNA	1	O
derived	0	O
RNA	1	O
translates	0	O
into	0	O
a	0	O
protein	0	O
with	0	O
a	0	O
mobility	0	O
of	0	O
44	0	O
-	0	O
46	0	O
kD	1	O
on	0	O
SDS	1	O
polyacrylamide	0	O
gels	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Two	0	O
consecutive	0	O
sets	0	O
of	0	O
transrectal	0	O
ultrasound	0	O
guided	0	O
sextant	0	O
biopsies	0	O
of	0	O
the	0	O
prostate	0	O
performed	0	O
in	0	O
a	0	O
single	0	O
office	0	O
visit	0	O
represent	0	O
a	0	O
cost	0	O
-	0	O
effective	0	O
biopsy	0	O
strategy	0	O
for	0	O
men	0	O
presenting	0	O
with	0	O
an	0	O
abnormal	0	O
digital	0	O
rectal	0	O
examination	0	O
and	0	O
/	0	O
or	0	O
elevated	0	O
serum	0	B
PSA	1	I
.	0	O


E1	1	B
,	0	O
a	0	O
DNA	1	B
helicase	0	I
,	0	O
collaborates	0	O
with	0	O
the	0	O
HPV	1	B
E2	1	I
protein	0	I
in	0	O
ori	0	O
-	0	O
dependent	0	O
replication	0	O
.	0	O


Pentane	1	O
and	0	O
ethane	0	O
,	0	O
which	0	O
arise	0	O
during	0	O
lipid	0	O
peroxidation	0	O
in	0	O
vivo	0	O
,	0	O
were	0	O
measured	0	O
by	0	O
gas	0	O
chromatography	0	O
in	0	O
breath	0	O
samples	0	O
of	0	O
rats	0	O
fed	0	O
for	0	O
8	0	O
weeks	0	O
a	0	O
vitamin	0	O
E	1	O
-	0	O
deficient	0	O
diet	0	O
to	0	O
which	0	O
had	0	O
been	0	O
added	0	O
0	0	O
,	0	O
11	0	O
,	0	O
or	0	O
40	0	O
IU	1	O
vitamin	0	O
E	1	O
acetate	0	O
per	0	O
kg	0	O
.	0	O


Recently	0	O
,	0	O
identical	0	O
RBE	1	B
sequences	0	I
have	0	O
been	0	O
identified	0	O
at	0	O
other	0	O
locations	0	O
in	0	O
the	0	O
human	0	O
genome	0	O
.	0	O


The	0	O
same	0	O
rhythmic	0	O
structure	0	O
enables	0	O
a	0	O
prediction	0	O
to	0	O
be	0	O
made	0	O
concerning	0	O
when	0	O
vowels	0	O
of	0	O
stressed	0	O
syllables	0	O
will	0	O
be	0	O
auditorily	0	O
perceived	0	O
.	0	O


Analysis	1	O
of	0	O
promoter	0	O
and	0	O
androgen	0	O
regulatory	0	O
sequences	0	O
required	0	O
for	0	O
optimal	0	O
transcription	0	O
of	0	O
the	0	O
rat	0	O
androgen	0	B
-	0	I
binding	0	I
protein	0	I
gene	0	O
.	0	O


The	0	O
Trx	0	B
-	0	O
CT	1	B
fusion	0	O
protein	0	O
was	0	O
produced	0	O
less	0	O
efficiently	0	O
(	0	O
20	0	O
%	0	O
of	0	O
total	0	O
soluble	0	O
cellular	0	O
protein	0	O
).	0	O


Aggregation	1	O
of	0	O
vHnf1	0	B
-	0	O
deficient	0	O
embryonic	0	O
stem	0	O
cells	0	O
with	0	O
wild	0	O
-	0	O
type	0	O
tetraploid	0	O
embryos	0	O
,	0	O
which	0	O
contribute	0	O
exclusively	0	O
to	0	O
extraembryonic	0	O
tissues	0	O
,	0	O
rescues	0	O
periimplantation	0	O
lethality	0	O
and	0	O
allows	0	O
development	0	O
to	0	O
progress	0	O
to	0	O
early	0	O
organogenesis	0	O
.	0	O


Animal	1	O
age	0	O
and	0	O
sex	0	O
had	0	O
no	0	O
significant	0	O
effects	0	O
on	0	O
CSF	1	O
composition	0	O
,	0	O
but	0	O
serum	0	O
IgG	1	B
concentration	0	O
increased	0	O
with	0	O
age	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Measurement	0	O
of	0	O
stereoacuity	0	O
at	0	O
varying	0	O
distances	0	O
,	0	O
by	0	O
real	0	O
or	0	O
simulated	0	O
depth	0	O
stereoacuity	0	O
tests	0	O
,	0	O
is	0	O
helpful	0	O
in	0	O
the	0	O
evaluation	0	O
of	0	O
patients	0	O
with	0	O
binocular	0	O
imbalance	0	O
or	0	O
strabismus	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
receptor	0	B
/	0	I
G	1	I
protein	0	I
coupling	0	O
appeared	0	O
unaffected	0	O
by	0	O
expression	0	O
of	0	O
loop	0	O
3i	0	O
domains	0	O
derived	0	O
from	0	O
two	0	O
receptors	0	O
coupled	0	O
to	0	O
G	1	B
(	0	I
i	0	I
/	0	I
o	0	I
)	0	I
proteins	0	I
(	0	O
M2Ach	0	B
-	0	I
muscarinic	0	I
and	0	I
alpha2A	0	I
-	0	I
adrenergic	0	I
receptors	0	I
).	0	O


Substitutions	0	O
of	0	O
region	0	O
I	1	O
with	0	O
synthetic	0	O
sequences	0	O
showed	0	O
that	0	O
no	0	O
specific	0	O
sequence	0	O
but	0	O
rather	0	O
repeats	0	O
of	0	O
three	0	O
or	0	O
more	0	O
consecutive	0	O
adenines	0	O
or	0	O
thymines	0	O
,	0	O
without	0	O
interruption	0	O
by	0	O
guanine	0	O
or	0	O
cytosine	0	O
,	0	O
are	0	O
required	0	O
for	0	O
the	0	O
ARS	1	O
activity	0	O
.	0	O


Additional	0	O
studies	0	O
revealed	0	O
that	0	O
bovine	0	B
brain	0	I
Galpha	0	I
(	0	I
q	0	I
/	0	I
11	0	I
)	0	I
could	0	O
also	0	O
bind	0	O
to	0	O
an	0	O
N	1	O
-	0	O
terminal	0	O
construct	0	O
of	0	O
GRK2	0	B
,	0	O
while	0	O
no	0	O
binding	0	O
of	0	O
Galpha	0	O
(	0	O
q	0	O
/	0	O
11	0	O
),	0	O
Galpha	0	O
(	0	O
s	0	O
),	0	O
Galpha	0	O
(	0	O
i	0	O
),	0	O
or	0	O
Galpha	0	B
(	0	I
12	0	I
/	0	I
13	0	I
)	0	I
to	0	O
comparable	0	O
constructs	0	O
of	0	O
GRK5	0	B
or	0	O
GRK6	0	B
was	0	O
observed	0	O
.	0	O


Dialyzable	1	O
transfer	0	B
factor	0	I
.	0	O


Genotoxic	1	O
activity	0	O
of	0	O
a	0	O
tobacco	0	O
-	0	O
specific	0	O
nitrosamine	0	O
.	0	O


Stoichiometric	1	O
phosphorylation	0	O
of	0	O
human	0	B
p53	0	I
at	0	O
Ser315	0	O
stimulates	0	O
p53	0	B
-	0	O
dependent	0	O
transcription	0	O
.	0	O
p53	0	B
protein	0	I
activity	0	O
as	0	O
a	0	O
transcription	0	O
factor	0	O
can	0	O
be	0	O
activated	0	O
in	0	O
vivo	0	O
by	0	O
antibodies	0	O
that	0	O
target	0	O
its	0	O
C	1	O
-	0	O
terminal	0	O
negative	0	O
regulatory	0	O
domain	0	O
suggesting	0	O
that	0	O
cellular	0	O
enzymes	0	O
that	0	O
target	0	O
this	0	O
domain	0	O
may	0	O
play	0	O
a	0	O
role	0	O
in	0	O
stimulating	0	O
p53	0	B
-	0	O
dependent	0	O
gene	0	O
expression	0	O
.	0	O


Thus	0	O
,	0	O
Pet111p	0	B
could	0	O
play	0	O
dual	0	O
roles	0	O
in	0	O
both	0	O
membrane	0	O
localization	0	O
and	0	O
regulation	0	O
of	0	O
Cox2p	0	B
synthesis	0	O
within	0	O
mitochondria	0	O
.	0	O


Apo	1	B
A	1	I
-	0	I
I	1	I
level	0	O
was	0	O
unrelated	0	O
to	0	O
age	0	O
,	0	O
but	0	O
increased	0	O
with	0	O
ethanol	0	O
consumption	0	O
and	0	O
decreased	0	O
with	0	O
adiposity	0	O
.	0	O


The	0	O
Siglecs	0	B
are	0	O
a	0	O
subfamily	0	O
of	0	O
I	1	B
-	0	I
type	0	I
lectins	0	I
(	0	O
immunoglobulin	0	B
superfamily	0	I
proteins	0	I
that	0	O
bind	0	O
sugars	0	O
)	0	O
that	0	O
specifically	0	O
recognize	0	O
sialic	0	O
acids	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Fluoroquinolones	0	O
(	0	O
FQ	0	O
)	0	O
are	0	O
contraindicated	0	O
in	0	O
children	0	O
because	0	O
of	0	O
the	0	O
risk	0	O
of	0	O
cartilage	0	O
damage	0	O
.	0	O


Recently	0	O
,	0	O
our	0	O
laboratory	0	O
developed	0	O
a	0	O
screen	0	O
that	0	O
identified	0	O
five	0	O
multicopy	0	O
suppressors	0	O
that	0	O
can	0	O
rescue	0	O
lethal	0	O
strains	0	O
of	0	O
clathrin	0	B
heavy	0	O
chain	0	O
-	0	O
deficient	0	O
yeast	0	O
(	0	O
Chc	0	B
-	0	O
scd1	0	B
-	0	I
i	0	I
)	0	O
to	0	O
viability	0	O
.	0	O


Large	0	O
differences	0	O
between	0	O
the	0	O
groups	0	O
were	0	O
not	0	O
observed	0	O
in	0	O
HA	1	B
-	0	I
synthesizing	0	I
enzyme	0	I
activity	0	O
,	0	O
but	0	O
degradative	0	O
enzyme	0	O
activity	0	O
was	0	O
much	0	O
higher	0	O
in	0	O
aspirin	0	O
-	0	O
induced	0	O
asthma	0	O
-	0	O
related	0	O
polyps	0	O
than	0	O
in	0	O
other	0	O
types	0	O
of	0	O
nasal	0	O
polyps	0	O
tested	0	O
.	0	O


Stress	1	B
-	0	I
inducible	0	I
protein	0	I
kinases	0	I
capable	0	O
of	0	O
activating	0	O
c	0	B
-	0	I
jun	0	I
expression	0	O
include	0	O
stress	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
/	0	O
c	0	B
-	0	I
Jun	1	I
N	1	I
-	0	I
terminal	0	I
protein	0	I
kinase	0	I
(	0	O
SAPK	0	B
/	0	O
JNK	0	B
)	0	O
and	0	O
p38	0	B
members	0	O
of	0	O
the	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
(	0	O
MAPK	1	B
)	0	O
superfamily	0	O
of	0	O
signaling	0	O
molecules	0	O
.	0	O


We	0	O
have	0	O
cloned	0	O
cDNA	1	O
and	0	O
genomic	0	O
DNA	1	O
for	0	O
a	0	O
mouse	0	O
gene	0	O
encoding	0	O
a	0	O
protein	0	O
with	0	O
significant	0	O
sequence	0	O
similarity	0	O
to	0	O
conserved	0	O
domains	0	O
found	0	O
in	0	O
proteins	0	O
of	0	O
the	0	O
Spo11p	0	B
family	0	I
.	0	O


This	0	O
was	0	O
performed	0	O
in	0	O
a	0	O
double	0	O
blinded	0	O
,	0	O
randomized	0	O
,	0	O
placebo	0	O
-	0	O
controlled	0	O
study	0	O
.	0	O


A	1	O
comparison	0	O
of	0	O
the	0	O
clinical	0	O
profile	0	O
of	0	O
cavernous	0	O
malformations	0	O
with	0	O
and	0	O
without	0	O
associated	0	O
venous	0	O
malformations	0	O
.	0	O


Intracellular	1	O
activity	0	O
studies	0	O
indicated	0	O
that	0	O
,	0	O
at	0	O
ten	0	O
times	0	O
MBC	1	O
,	0	O
only	0	O
penicillin	0	O
had	0	O
any	0	O
significant	0	O
activity	0	O
against	0	O
intracellular	0	O
staphylococci	0	O
,	0	O
reducing	0	O
survival	0	O
by	0	O
28	0	O
%.	0	O


Patients	0	O
at	0	O
risk	0	O
of	0	O
hypothyroidism	0	O
.	0	O


Thrombocyte	1	O
function	0	O
was	0	O
impaired	0	O
in	0	O
all	0	O
patients	0	O
,	0	O
characterized	0	O
by	0	O
a	0	O
diminished	0	O
platelet	0	O
shape	0	O
change	0	O
.	0	O


In	1	O
the	0	O
chicken	0	O
liver	0	O
,	0	O
levels	0	O
of	0	O
chicken	0	B
MT	1	I
mRNA	1	I
were	0	O
rapidly	0	O
induced	0	O
by	0	O
metals	0	O
(	0	O
Cd2	1	O
+,	0	O
Zn2	0	O
+,	0	O
Cu2	0	O
+),	0	O
glucocorticoids	0	O
and	0	O
lipopolysaccharide	0	O
.	0	O


Efficacy	1	O
was	0	O
determined	0	O
by	0	O
responses	0	O
to	0	O
question	0	O
3	0	O
(	0	O
ability	0	O
to	0	O
achieve	0	O
an	0	O
erection	0	O
)	0	O
and	0	O
question	0	O
4	0	O
(	0	O
ability	0	O
to	0	O
maintain	0	O
an	0	O
erection	0	O
)	0	O
of	0	O
the	0	O
15	0	O
-	0	O
item	0	O
International	0	O
Index	1	O
of	0	O
Erectile	1	O
Function	1	O
(	0	O
IIEF	0	O
).	0	O


The	0	O
antihypertensive	0	O
effect	0	O
of	0	O
Estulic	0	O
has	0	O
been	0	O
examined	0	O
over	0	O
a	0	O
12	0	O
-	0	O
month	0	O
period	0	O
in	0	O
101	0	O
hypertensive	0	O
patients	0	O
.	0	O


SCL	0	O
prolonged	0	O
promptly	0	O
after	0	O
verapamil	0	O
,	0	O
and	0	O
sinus	0	O
arrest	0	O
developed	0	O
in	0	O
two	0	O
of	0	O
10	0	O
group	0	O
2	0	O
and	0	O
two	0	O
of	0	O
five	0	O
group	0	O
3	0	O
animals	0	O
.	0	O


Using	0	O
an	0	O
opsonophagocytic	0	O
bacterial	0	O
assay	0	O
and	0	O
a	0	O
suckling	0	O
rat	0	O
model	0	O
of	0	O
GBS	1	O
sepsis	0	O
,	0	O
we	0	O
analyzed	0	O
a	0	O
modified	0	O
human	0	B
immunoglobulin	0	I
for	0	O
opsonic	0	O
and	0	O
protective	0	O
antibody	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
effects	0	O
of	0	O
father	0	O
absence	0	O
under	0	O
routine	0	O
conditions	0	O
in	0	O
relatively	0	O
healthy	0	O
samples	0	O
may	0	O
exert	0	O
no	0	O
significant	0	O
effects	0	O
independent	0	O
of	0	O
intervening	0	O
family	0	O
stressors	0	O
or	0	O
maternal	0	O
psychopathology	0	O
.	0	O


Endorphins	0	B
at	0	O
the	0	O
approach	0	O
of	0	O
death	0	O
.	0	O


Scotchbond	0	O
2	0	O
showed	0	O
the	0	O
least	0	O
dye	0	O
penetration	0	O
but	0	O
not	0	O
statistically	0	O
less	0	O
than	0	O
the	0	O
XR	0	O
bond	0	O
/	0	O
Silus	0	O
Plus	0	O
combination	0	O
.	0	O


Penicillin	1	O
-	0	O
G	1	O
degradation	0	O
products	0	O
inhibit	0	O
in	0	O
vitro	0	O
granulopoiesis	0	O
.	0	O


However	0	O
,	0	O
inclusion	0	O
of	0	O
the	0	O
neighboring	0	O
CGGAAR	0	O
motifs	0	O
from	0	O
the	0	O
ICP4	0	B
promoter	0	I
,	0	O
which	0	O
bind	0	O
factors	0	O
GABP	0	B
alpha	0	I
and	0	I
beta	0	I
,	0	O
results	0	O
in	0	O
a	0	O
strong	0	O
synergistic	0	O
activation	0	O
.	0	O


This	0	O
points	0	O
to	0	O
a	0	O
specific	0	O
interference	0	O
with	0	O
HSV	1	O
-	0	O
induced	0	O
DNA	1	O
amplification	0	O
.	0	O


Fourteen	0	O
patients	0	O
were	0	O
in	0	O
the	0	O
multifocal	0	O
disease	0	O
group	0	O
;	0	O
13	0	O
were	0	O
detected	0	O
by	0	O
SPECT	1	O
and	0	O
10	0	O
by	0	O
TCT	0	O
.	0	O


Also	0	O
,	0	O
component	0	O
I	1	O
significantly	0	O
correlated	0	O
with	0	O
fasting	0	O
insulin	0	B
and	0	O
VO2	1	O
max	0	O
for	0	O
both	0	O
sexes	0	O
and	0	O
with	0	O
basal	0	O
metabolism	0	O
and	0	O
HDL	1	B
-	0	I
cholesterol	0	I
for	0	O
females	0	O
and	0	O
males	0	O
,	0	O
respectively	0	O
.	0	O


Cbl	1	B
constitutively	0	O
interacts	0	O
with	0	O
the	0	O
SH3	0	B
domains	0	I
of	0	O
Grb2	0	B
,	0	O
with	0	O
a	0	O
preference	0	O
for	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
domain	0	O
,	0	O
and	0	O
is	0	O
in	0	O
this	0	O
way	0	O
recruited	0	O
to	0	O
Shc	0	B
upon	0	O
BCR	0	B
stimulation	0	O
.	0	O


The	0	O
healing	0	O
rate	0	O
in	0	O
HIV	1	O
-	0	O
positive	0	O
patients	0	O
was	0	O
66	0	O
percent	0	O
after	0	O
14	0	O
weeks	0	O
and	0	O
100	0	O
percent	0	O
after	0	O
32	0	O
weeks	0	O
;	0	O
the	0	O
corresponding	0	O
figures	0	O
for	0	O
patients	0	O
with	0	O
acquired	0	O
immunodeficiency	0	O
syndrome	0	O
were	0	O
0	0	O
and	0	O
50	0	O
percent	0	O
.	0	O


Catha	1	O
edulis	0	O
,	0	O
a	0	O
plant	0	O
that	0	O
has	0	O
amphetamine	0	O
effects	0	O
.	0	O


A	1	O
semiautomatic	0	O
digital	0	O
system	0	O
(	0	O
Videoplan	0	O
2	0	O
)	0	O
was	0	O
used	0	O
.	0	O


Recent	0	O
studies	0	O
have	0	O
demonstrated	0	O
that	0	O
the	0	O
U1	0	B
snRNP	1	I
is	0	O
recruited	0	O
to	0	O
the	0	O
5	0	O
'	0	O
splice	0	O
site	0	O
by	0	O
protein	0	O
/	0	O
protein	0	O
interactions	0	O
involving	0	O
the	0	O
SR	1	B
domains	0	O
of	0	O
the	0	O
U1	0	B
-	0	I
70K	0	I
protein	0	I
and	0	O
SF2	0	B
/	0	O
ASF	1	B
.	0	O


Variations	0	O
in	0	O
the	0	O
5	0	O
'	0	O
half	0	O
of	0	O
U3	0	O
were	0	O
primarily	0	O
due	0	O
to	0	O
insertions	0	O
and	0	O
deletions	0	O
.	0	O


Copyright	0	O
2000	0	O
Academic	0	O
Press	0	O
.	0	O


The	0	O
electrically	0	O
induced	0	O
motile	0	O
responses	0	O
were	0	O
not	0	O
suppressed	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
dinitrophenol	0	O
or	0	O
cytochalasin	0	O
B	1	O
.	0	O


In	1	O
short	0	O
-	0	O
term	0	O
cotransfections	0	O
,	0	O
a	0	O
pFRTK	0	B
-	0	O
CAT	1	B
target	0	O
containing	0	O
EBNA	0	B
-	0	I
1	0	I
-	0	I
binding	0	I
sites	0	I
from	0	O
the	0	O
EBV	1	O
origin	0	O
of	0	O
plasmid	0	O
replication	0	O
,	0	O
ori	0	B
-	0	I
P	1	I
,	0	O
was	0	O
transactivated	0	O
by	0	O
a	0	O
carboxy	0	B
-	0	I
terminal	0	I
EBNA	0	I
-	0	I
1	0	I
construction	0	I
(	0	O
amino	0	O
acids	0	O
450	0	O
to	0	O
641	0	O
)	0	O
that	0	O
also	0	O
carried	0	O
a	0	O
c	0	B
-	0	I
myc	0	I
nuclear	0	I
localization	0	I
signal	0	I
.	0	O


The	0	O
urinary	0	O
protein	0	O
,	0	O
serum	0	O
albumin	0	B
,	0	O
BUN	1	O
and	0	O
SCr	1	O
all	0	O
had	0	O
very	0	O
significant	0	O
improvement	0	O
.	0	O


In	1	O
the	0	O
VA	1	O
-	0	O
SMV	0	O
mode	0	O
,	0	O
the	0	O
connection	0	O
was	0	O
made	0	O
with	0	O
valved	0	O
conduits	0	O
from	0	O
the	0	O
LV	1	O
apex	0	O
(	0	O
inflow	0	O
)	0	O
to	0	O
the	0	O
ascending	0	O
aorta	0	O
(	0	O
outflow	0	O
)	0	O
(	0	O
n	0	O
=	0	O
11	0	O
)	0	O
or	0	O
to	0	O
the	0	O
DAo	0	O
(	0	O
n	0	O
=	0	O
12	0	O
).	0	O


The	0	O
present	0	O
data	0	O
also	0	O
indicate	0	O
that	0	O
patients	0	O
with	0	O
TGBM	0	O
nephropathy	0	O
often	0	O
have	0	O
concomitant	0	O
IgA	1	B
nephropathy	0	O
and	0	O
mesangial	0	O
proliferative	0	O
glomerulonephritis	0	O
.	0	O


Effects	0	O
of	0	O
diltiazem	0	O
on	0	O
netilmicin	0	O
-	0	O
induced	0	O
nephrotoxicity	0	O
in	0	O
rabbits	0	O
.	0	O


Various	0	O
companies	0	O
produce	0	O
this	0	O
type	0	O
of	0	O
lens	0	O
.	0	O


Similar	0	O
mechanisms	0	O
leading	0	O
to	0	O
deregulation	0	O
of	0	O
Tcf	0	B
target	0	I
gene	0	I
activity	0	O
are	0	O
likely	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
melanoma	0	O
and	0	O
other	0	O
forms	0	O
of	0	O
cancer	0	O
.	0	O


In	1	O
all	0	O
trials	0	O
,	0	O
antigen	0	O
challenge	0	O
followed	0	O
1	0	O
h	0	O
after	0	O
the	0	O
last	0	O
treatment	0	O
.	0	O


There	0	O
was	0	O
a	0	O
gradual	0	O
increase	0	O
in	0	O
the	0	O
myocyte	0	O
diameter	0	O
according	0	O
to	0	O
age	0	O
in	0	O
the	0	O
biopsy	0	O
and	0	O
autopsy	0	O
specimens	0	O
.	0	O


The	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
altered	0	O
forms	0	O
of	0	O
the	0	O
F	1	B
protein	0	I
were	0	O
expressed	0	O
in	0	O
BHK	0	O
-	0	O
21	0	O
and	0	O
HeLa	0	O
T4	1	O
cells	0	O
by	0	O
use	0	O
of	0	O
the	0	O
recombinant	0	B
vaccinia	0	I
virus	0	I
-	0	I
encoding	0	I
T7	0	I
polymerase	0	I
system	0	O
.	0	O


Statins	1	B
:	0	O
lower	0	O
lipids	0	O
and	0	O
better	0	O
bones	0	O
?	0	O
Although	0	O
statins	0	O
are	0	O
widely	0	O
used	0	O
as	0	O
cholesterol	0	O
-	0	O
lowering	0	O
drugs	0	O
,	0	O
a	0	O
recent	0	O
study	0	O
suggests	0	O
that	0	O
these	0	O
compounds	0	O
have	0	O
anabolic	0	O
effects	0	O
on	0	O
bone	0	O
and	0	O
could	0	O
be	0	O
developed	0	O
into	0	O
new	0	O
treatments	0	O
for	0	O
common	0	O
metabolic	0	O
bone	0	O
diseases	0	O
such	0	O
as	0	O
osteoporosis	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
determine	0	O
the	0	O
efficacy	0	O
and	0	O
safety	0	O
of	0	O
amphotericin	0	O
B	1	O
oral	0	O
suspension	0	O
(	0	O
ABOS	0	O
)	0	O
for	0	O
the	0	O
treatment	0	O
of	0	O
fluconazole	0	O
refractory	0	O
oral	0	O
candidiasis	0	O
in	0	O
persons	0	O
with	0	O
HIV	1	O
infection	0	O
.	0	O


The	0	O
Fis	0	B
protein	0	I
regulates	0	O
site	0	O
-	0	O
specific	0	O
DNA	1	O
inversion	0	O
catalyzed	0	O
by	0	O
a	0	O
family	0	O
of	0	O
DNA	1	B
invertases	0	I
when	0	O
bound	0	O
to	0	O
a	0	O
cis	0	O
-	0	O
acting	0	O
recombinational	0	O
enhancer	0	O
.	0	O


An	1	O
interatrial	0	O
communication	0	O
mitigates	0	O
the	0	O
impairment	0	O
of	0	O
LV	1	O
function	0	O
after	0	O
an	0	O
acute	0	O
and	0	O
sustained	0	O
drop	0	O
of	0	O
intrathoracic	0	O
pressure	0	O
.	0	O


Retrospective	1	O
analyses	0	O
of	0	O
this	0	O
death	0	O
revealed	0	O
a	0	O
significant	0	O
decrease	0	O
of	0	O
the	0	O
left	0	O
ventricular	0	O
(	0	O
LV	1	O
)	0	O
end	0	O
-	0	O
diastolic	0	O
volume	0	O
index	0	O
(	0	O
EDVI	0	O
)	0	O
of	0	O
21	0	O
ml	0	O
/	0	O
m2	0	O
(	0	O
36	0	O
%	0	O
of	0	O
normal	0	O
).	0	O


Adult	1	O
Amblyomma	1	O
lepidum	0	O
ticks	0	O
fed	0	O
as	0	O
nymphs	0	O
on	0	O
this	0	O
goat	0	O
transmitted	0	O
heartwater	0	O
to	0	O
a	0	O
Friesian	0	O
(	0	O
Bos	0	O
taurus	0	O
)	0	O
calf	0	O
.	0	O


While	0	O
mutations	0	O
in	0	O
K	1	B
-	0	I
Rev	0	I
that	0	O
inactivate	0	O
any	0	O
one	0	O
of	0	O
these	0	O
properties	0	O
also	0	O
blocked	0	O
K	1	B
-	0	I
Rev	0	I
-	0	O
dependent	0	O
nuclear	0	O
RNA	1	O
export	0	O
,	0	O
several	0	O
K	1	B
-	0	I
Rev	0	I
mutants	0	I
were	0	O
comparable	0	O
to	0	O
wild	0	O
type	0	O
when	0	O
assayed	0	O
for	0	O
any	0	O
of	0	O
these	0	O
individual	0	O
activities	0	O
yet	0	O
nevertheless	0	O
defective	0	O
for	0	O
RNA	1	O
export	0	O
.	0	O


Hepatocellular	1	O
injury	0	O
during	0	O
preservation	0	O
of	0	O
human	0	O
livers	0	O
with	0	O
UW	0	O
and	0	O
HTK	0	O
solution	0	O
.	0	O


The	0	O
hypBFCDE	0	B
operon	0	I
from	0	O
Rhizobium	1	O
leguminosarum	0	O
biovar	0	O
viciae	0	O
is	0	O
expressed	0	O
from	0	O
an	0	O
Fnr	1	B
-	0	I
type	0	I
promoter	0	I
that	0	O
escapes	0	O
mutagenesis	0	O
of	0	O
the	0	O
fnrN	0	B
gene	0	I
.	0	O


We	0	O
also	0	O
raised	0	O
a	0	O
polyclonal	0	O
antibody	0	O
against	0	O
the	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
fusion	0	I
protein	0	I
containing	0	O
the	0	O
NH2	0	O
-	0	O
terminal	0	O
86	0	O
amino	0	O
acids	0	O
of	0	O
human	0	B
NRAMP2	0	I
.	0	O


Keck	0	O
,	0	O
C	1	O
.	0	O
J	1	O
.	0	O


Here	0	O
we	0	O
report	0	O
the	0	O
cloning	0	O
of	0	O
the	0	O
protein	0	O
that	0	O
binds	0	O
to	0	O
enhancer	0	O
site	0	O
III	0	O
.	0	O


Cell	1	O
.	0	O


This	0	O
study	0	O
confirms	0	O
,	0	O
although	0	O
individual	0	O
reaction	0	O
is	0	O
remarkably	0	O
different	0	O
,	0	O
transportation	0	O
as	0	O
a	0	O
potent	0	O
stressor	0	O
for	0	O
Beagle	0	O
dogs	0	O
.	0	O


Heme	1	B
oxygenase	0	I
1	0	I
is	0	O
an	0	O
essential	0	O
enzyme	0	O
in	0	O
heme	0	O
catabolism	0	O
that	0	O
cleaves	0	O
heme	0	O
to	0	O
form	0	O
biliverdin	0	O
,	0	O
iron	0	O
,	0	O
and	0	O
carbon	0	O
monoxide	0	O
.	0	O


The	0	O
use	0	O
of	0	O
this	0	O
model	0	O
for	0	O
investigating	0	O
pathophysiologically	0	O
significant	0	O
issues	0	O
in	0	O
denervating	0	O
diseases	0	O
is	0	O
illustrated	0	O
with	0	O
five	0	O
different	0	O
sets	0	O
of	0	O
parameters	0	O
.	0	O


This	0	O
accurate	0	O
and	0	O
rapid	0	O
method	0	O
makes	0	O
the	0	O
MLPA	0	O
test	0	O
logistically	0	O
feasible	0	O
for	0	O
large	0	O
-	0	O
scale	0	O
screening	0	O
.	0	O


In	1	O
the	0	O
presence	0	O
of	0	O
inositol	0	O
and	0	O
choline	0	O
(	0	O
repressing	0	O
),	0	O
the	0	O
product	0	O
of	0	O
the	0	O
OPI1	0	B
gene	0	I
represses	0	O
transcription	0	O
dictated	0	O
by	0	O
the	0	O
UASINO	0	O
element	0	O
.	0	O


Besides	0	O
,	0	O
we	0	O
found	0	O
in	0	O
3	0	O
patients	0	O
increased	0	O
serum	0	B
immunoglobulins	0	I
,	0	O
chiefly	0	O
IgG	1	B
,	0	O
as	0	O
first	0	O
Russe	0	O
,	0	O
Busey	0	O
and	0	O
Barbeau	0	O
demonstrated	0	O
in	0	O
a	0	O
large	0	O
French	1	O
-	0	O
Canadian	0	O
family	0	O
.	0	O


Recombinant	1	O
AROM	1	B
-	0	O
p64	0	B
displayed	0	O
high	0	O
binding	0	O
to	0	O
single	0	O
-	0	O
stranded	0	O
DNA	1	O
and	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
homopolymers	0	O
suggesting	0	O
that	0	O
this	0	O
protein	0	O
could	0	O
play	0	O
a	0	O
role	0	O
in	0	O
mRNA	1	O
maturation	0	O
/	0	O
metabolism	0	O
.	0	O


Interestingly	0	O
,	0	O
the	0	O
RNA	1	O
sequences	0	O
selected	0	O
by	0	O
the	0	O
mutated	0	O
zinc	0	B
knuckle	0	I
9G8	0	I
variant	0	I
are	0	O
efficiently	0	O
recognized	0	O
by	0	O
SRp20	0	B
,	0	O
in	0	O
agreement	0	O
with	0	O
the	0	O
fact	0	O
that	0	O
the	0	O
RBD	1	O
of	0	O
9G8	0	B
and	0	O
SRp20	0	B
are	0	O
similar	0	O
.	0	O


Rat	1	B
liver	0	I
catalase	0	I
is	0	O
sorted	0	O
to	0	O
peroxisomes	0	O
by	0	O
its	0	O
C	1	O
-	0	O
terminal	0	O
tripeptide	0	O
Ala	1	O
-	0	O
Asn	1	O
-	0	O
Leu	1	O
,	0	O
not	0	O
by	0	O
the	0	O
internal	0	O
Ser	1	O
-	0	O
Lys	1	O
-	0	O
Leu	1	O
motif	0	O
.	0	O


In	1	O
the	0	O
control	0	O
group	0	O
,	0	O
platelet	0	O
markers	0	O
increased	0	O
1	0	O
h	0	O
after	0	O
surgery	0	O
.	0	O


These	0	O
data	0	O
do	0	O
not	0	O
support	0	O
the	0	O
use	0	O
of	0	O
LDD	0	O
to	0	O
reduce	0	O
risk	0	O
of	0	O
progression	0	O
to	0	O
MSOF	0	O
in	0	O
sepsis	0	O
.	0	O


Cerebral125	0	B
albumin	0	I
was	0	O
increased	0	O
to	0	O
similar	0	O
proportions	0	O
in	0	O
those	0	O
groups	0	O
submitted	0	O
to	0	O
hyperosmolality	0	O
.	0	O


We	0	O
have	0	O
used	0	O
a	0	O
full	0	O
-	0	O
length	0	O
cDNA	1	O
clone	0	O
of	0	O
a	0	O
mouse	0	O
hepatitis	0	O
virus	0	O
strain	0	O
A59	0	O
defective	0	O
interfering	0	O
(	0	O
DI	0	O
)	0	O
RNA	1	O
,	0	O
pMIDI	0	B
-	0	I
C	1	I
,	0	O
and	0	O
cassette	0	O
mutagenesis	0	O
to	0	O
study	0	O
the	0	O
mechanism	0	O
of	0	O
coronavirus	0	O
subgenomic	0	O
mRNA	1	O
synthesis	0	O
.	0	O


Cost	0	O
-	0	O
effectiveness	0	O
analysis	0	O
provides	0	O
a	0	O
rational	0	O
means	0	O
of	0	O
allocating	0	O
limited	0	O
health	0	O
care	0	O
resources	0	O
by	0	O
allowing	0	O
the	0	O
comparison	0	O
of	0	O
the	0	O
costs	0	O
of	0	O
lipid	0	O
-	0	O
lowering	0	O
therapy	0	O
,	0	O
in	0	O
particular	0	O
,	0	O
therapy	0	O
with	0	O
beta	0	B
-	0	I
hydroxy	0	I
-	0	I
beta	0	I
-	0	I
methylglutaryl	0	I
-	0	I
CoA	1	I
(	0	I
coenzyme	0	I
A	1	I
)	0	I
reductase	0	I
inhibitors	0	O
(	0	O
statins	0	O
),	0	O
with	0	O
the	0	O
costs	0	O
of	0	O
atherosclerosis	0	O
that	0	O
could	0	O
be	0	O
prevented	0	O
by	0	O
lowering	0	O
cholesterol	0	O
.	0	O


Interdomain	0	O
signaling	0	O
in	0	O
a	0	O
two	0	O
-	0	O
domain	0	O
fragment	0	O
of	0	O
the	0	O
human	0	B
glucocorticoid	0	I
receptor	0	I
.	0	O


Analysis	1	O
of	0	O
human	0	O
genomic	0	O
DNA	1	O
reveals	0	O
an	0	O
intronless	0	O
sequence	0	O
with	0	O
strong	0	O
homology	0	O
to	0	O
human	0	B
G	1	I
alpha	0	I
q	0	I
cDNA	1	I
.	0	O


Blood	1	O
sampling	0	O
procedures	0	O
were	0	O
videotaped	0	O
.	0	O


With	0	O
a	0	O
sample	0	O
of	0	O
mothers	0	O
of	0	O
healthy	0	O
infants	0	O
,	0	O
all	0	O
three	0	O
subscales	0	O
of	0	O
the	0	O
revised	0	O
instrument	0	O
,	0	O
WPL	0	O
-	0	O
R	1	O
,	0	O
had	0	O
acceptable	0	O
levels	0	O
of	0	O
internal	0	O
consistency	0	O
at	0	O
7	0	O
,	0	O
30	0	O
,	0	O
and	0	O
90	0	O
days	0	O
postpartum	0	O
,	0	O
and	0	O
stability	0	O
across	0	O
administrations	0	O
.	0	O


As	1	O
a	0	O
result	0	O
,	0	O
beta	0	O
-	0	O
apo	0	O
-	0	O
8	0	O
'-	0	O
carotenoic	0	O
acid	0	O
ethyl	0	O
ester	0	O
(	0	O
apo	0	O
-	0	O
EE	1	O
)	0	O
was	0	O
used	0	O
as	0	O
a	0	O
reference	0	O
standard	0	O
in	0	O
Experiments	0	O
4	0	O
to	0	O
6	0	O
.	0	O


The	0	O
-	0	O
64	0	O
/-	0	O
37	0	O
region	0	O
interacted	0	O
with	0	O
purified	0	O
Sp1	0	B
and	0	O
an	0	O
unidentified	0	O
protein	0	O
(	0	O
s	0	O
),	0	O
proximal	0	B
regulatory	0	I
factor	0	I
(	0	I
s	0	I
)	0	I
I	1	I
(	0	O
PRF	1	B
-	0	I
I	1	I
).	0	O


Penicillin	1	B
acylase	0	I
(	0	O
PA	1	B
)	0	O
from	0	O
Escherichia	1	O
coli	0	O
ATCC11105	0	O
is	0	O
a	0	O
periplasmic	0	O
heterodimer	0	O
consisting	0	O
of	0	O
a	0	O
24	0	O
kDa	1	O
small	0	O
subunit	0	O
and	0	O
a	0	O
65	0	O
kDa	1	O
large	0	O
subunit	0	O
.	0	O


Using	0	O
Spurr	0	O
'	0	O
s	0	O
resin	0	O
as	0	O
a	0	O
mounting	0	O
medium	0	O
,	0	O
we	0	O
could	0	O
observe	0	O
thick	0	O
specimens	0	O
with	0	O
oil	0	O
immersion	0	O
objective	0	O
lens	0	O
without	0	O
the	0	O
use	0	O
of	0	O
coverslips	0	O
,	0	O
then	0	O
avoid	0	O
air	0	O
bubbles	0	O
near	0	O
the	0	O
specimen	0	O
.	0	O


Spontaneous	1	O
burst	0	O
firing	0	O
in	0	O
cat	0	O
primary	0	O
auditory	0	O
cortex	0	O
:	0	O
age	0	O
and	0	O
depth	0	O
dependence	0	O
and	0	O
its	0	O
effect	0	O
on	0	O
neural	0	O
interaction	0	O
measures	0	O
.	0	O


When	0	O
introduced	0	O
into	0	O
recJ	0	B
+	0	I
strains	0	O
,	0	O
srjA	0	B
mutations	0	O
conferred	0	O
hyperrecombinational	0	O
and	0	O
hyper	0	B
-	0	I
UVr	0	I
phenotypes	0	O
.	0	O


Intravesical	1	O
chemotherapy	0	O
.	0	O


The	0	O
Pro	1	O
-	0	O
258	0	O
-->	0	O
Leu	1	O
(	0	O
P258L	0	O
)	0	O
mutation	0	O
caused	0	O
constitutive	0	O
receptor	0	O
signaling	0	O
that	0	O
was	0	O
equivalent	0	O
to	0	O
about	0	O
45	0	O
%	0	O
of	0	O
the	0	O
maximum	0	O
level	0	O
observed	0	O
in	0	O
wild	0	O
-	0	O
type	0	O
cells	0	O
stimulated	0	O
with	0	O
alpha	0	B
-	0	I
factor	0	I
.	0	O


The	0	O
nucleotide	0	O
sequence	0	O
of	0	O
3874	0	O
bp	0	O
of	0	O
cloned	0	O
R	1	O
.	0	O
sphaeroides	0	O
chromosomal	0	O
DNA	1	O
,	0	O
including	0	O
the	0	O
three	0	O
structural	0	O
genes	0	O
fbcF	0	B
,	0	O
fbcB	0	B
and	0	O
fbcC	0	B
has	0	O
been	0	O
determined	0	O
.	0	O


The	0	O
most	0	O
frequent	0	O
causes	0	O
of	0	O
the	0	O
meningitis	0	O
was	0	O
the	0	O
external	0	O
ventricular	0	O
drainage	0	O
(	0	O
14	0	O
.	0	O
8	0	O
%),	0	O
post	0	O
-	0	O
neurosurgical	0	O
(	0	O
0	0	O
.	0	O
8	0	O
%)	0	O
and	0	O
head	0	O
injury	0	O
(	0	O
0	0	O
.	0	O
0007	0	O
%).	0	O


However	0	O
,	0	O
tyrA	0	B
can	0	O
be	0	O
expressed	0	O
efficiently	0	O
from	0	O
an	0	O
internal	0	O
promoter	0	O
which	0	O
appears	0	O
to	0	O
lie	0	O
within	0	O
the	0	O
3	0	O
'	0	O
portion	0	O
of	0	O
aroF	0	B
.	0	O


Cardiac	1	B
myosin	0	I
-	0	I
binding	0	I
protein	0	I
C	1	I
(	0	O
MyBP	0	B
-	0	I
C	1	I
):	0	O
identification	0	O
of	0	O
protein	0	B
kinase	0	I
A	1	I
and	0	O
protein	0	B
kinase	0	I
C	1	I
phosphorylation	0	O
sites	0	O
.	0	O


During	0	O
the	0	O
aftermath	0	O
of	0	O
excitation	0	O
of	0	O
the	0	O
skin	0	O
sympathetic	0	O
nerve	0	O
by	0	O
mental	0	O
arithmetics	0	O
,	0	O
3	0	O
/	0	O
12	0	O
A	1	O
delta	0	O
units	0	O
were	0	O
turned	0	O
to	0	O
the	0	O
active	0	O
state	0	O
with	0	O
decreased	0	O
mechanical	0	O
threshold	0	O
.	0	O


Advances	0	O
in	0	O
hemophilia	0	O
treatment	0	O
:	0	O
a	0	O
hepatitis	0	O
-	0	O
safe	0	O
factor	0	B
VIII	0	I
concentrate	0	O


Functional	1	O
studies	0	O
which	0	O
introduced	0	O
a	0	O
mutation	0	O
in	0	O
the	0	O
AP2	0	B
core	0	I
binding	0	I
region	0	I
as	0	O
well	0	O
as	0	O
cotransfection	0	O
experiments	0	O
using	0	O
an	0	O
AP2	0	B
expression	0	O
vector	0	O
revealed	0	O
that	0	O
AP2	0	B
exerts	0	O
a	0	O
repressive	0	O
role	0	O
on	0	O
the	0	O
HGF	1	B
gene	0	I
promoter	0	I
activity	0	O
.	0	O


The	0	O
peroxisome	0	O
biogenesis	0	O
disorders	0	O
(	0	O
PBDs	0	O
)	0	O
are	0	O
a	0	O
set	0	O
of	0	O
lethal	0	O
genetic	0	O
diseases	0	O
characterized	0	O
by	0	O
peroxisomal	0	O
metabolic	0	O
deficiencies	0	O
,	0	O
multisystem	0	O
abnormalities	0	O
,	0	O
mental	0	O
retardation	0	O
,	0	O
and	0	O
premature	0	O
death	0	O
.	0	O


However	0	O
,	0	O
it	0	O
is	0	O
only	0	O
one	0	O
-	0	O
half	0	O
and	0	O
one	0	O
-	0	O
third	0	O
the	0	O
size	0	O
of	0	O
the	0	O
proteolipids	0	O
from	0	O
M	1	O
.	0	O
thermoautotrophicum	0	O
and	0	O
M	1	O
.	0	O
jannaschii	0	O
,	0	O
respectively	0	O
.	0	O
ahaK	0	B
is	0	O
expressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
,	0	O
and	0	O
it	0	O
is	0	O
incorporated	0	O
into	0	O
the	0	O
cytoplasmic	0	O
membrane	0	O
despite	0	O
the	0	O
different	0	O
chemical	0	O
natures	0	O
of	0	O
lipids	0	O
from	0	O
archaea	0	O
and	0	O
bacteria	0	O
.	0	O


The	0	O
comparisons	0	O
revealed	0	O
that	0	O
female	0	O
homicide	0	O
-	0	O
suicide	0	O
perpetrators	0	O
were	0	O
more	0	O
likely	0	O
than	0	O
female	0	O
homicide	0	O
-	0	O
suicide	0	O
victims	0	O
to	0	O
live	0	O
in	0	O
mobile	0	O
homes	0	O
,	0	O
kill	0	O
their	0	O
lover	0	O
or	0	O
ex	0	O
-	0	O
lover	0	O
,	0	O
have	0	O
their	0	O
crime	0	O
accidentally	0	O
discovered	0	O
,	0	O
leave	0	O
a	0	O
suicide	0	O
note	0	O
,	0	O
kill	0	O
on	0	O
a	0	O
weekend	0	O
,	0	O
and	0	O
be	0	O
depressed	0	O
,	0	O
but	0	O
are	0	O
less	0	O
likely	0	O
than	0	O
female	0	O
homicide	0	O
-	0	O
suicide	0	O
victims	0	O
to	0	O
live	0	O
with	0	O
a	0	O
spouse	0	O
.	0	O


These	0	O
mutant	0	O
proteins	0	O
retained	0	O
the	0	O
ability	0	O
to	0	O
competitively	0	O
inhibit	0	O
kappa	0	B
B	1	I
-	0	O
mediated	0	O
transcriptional	0	O
activation	0	O
of	0	O
the	0	O
human	0	B
immunodeficiency	0	I
virus	0	I
long	0	I
terminal	0	I
repeat	0	I
but	0	O
failed	0	O
to	0	O
efficiently	0	O
transform	0	O
chicken	0	O
lymphoid	0	O
cells	0	O
both	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
.	0	O


Patients	0	O
with	0	O
low	0	O
probability	0	O
of	0	O
having	0	O
aluminum	0	O
overload	0	O
(	0	O
serum	0	O
iron	0	O
levels	0	O
<	0	O
40	0	O
micrograms	0	O
/	0	O
L	1	O
and	0	O
DAI	1	O
<	0	O
150	0	O
micrograms	0	O
/	0	O
L	1	O
)	0	O
had	0	O
significantly	0	O
higher	0	O
values	0	O
of	0	O
serum	0	O
iron	0	O
,	0	O
iron	0	O
transferrin	0	B
saturation	0	O
,	0	O
and	0	O
serum	0	B
ferritin	0	I
levels	0	O
compared	0	O
with	0	O
those	0	O
patients	0	O
with	0	O
a	0	O
high	0	O
probability	0	O
of	0	O
having	0	O
aluminum	0	O
overload	0	O
(	0	O
serum	0	O
aluminum	0	O
levels	0	O
>	0	O
40	0	O
micrograms	0	O
/	0	O
L	1	O
and	0	O
DAI	1	O
>	0	O
150	0	O
micrograms	0	O
/	0	O
L	1	O
).	0	O


The	0	O
overall	0	O
results	0	O
of	0	O
this	0	O
paper	0	O
are	0	O
consistent	0	O
with	0	O
the	0	O
conclusion	0	O
that	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
LBD	0	O
is	0	O
not	0	O
sufficient	0	O
for	0	O
mediating	0	O
PR	1	B
dimerization	0	O
and	0	O
that	0	O
multiple	0	O
regions	0	O
,	0	O
including	0	O
the	0	O
hinge	0	O
and	0	O
amino	0	O
-	0	O
terminal	0	O
sequences	0	O
,	0	O
contribute	0	O
either	0	O
directly	0	O
or	0	O
indirectly	0	O
to	0	O
homodimerization	0	O
of	0	O
PR	1	B
.	0	O


We	0	O
conclude	0	O
that	0	O
cAMP	1	O
,	0	O
acting	0	O
through	0	O
PKA	1	B
,	0	O
is	0	O
an	0	O
essential	0	O
regulator	0	O
of	0	O
basal	0	O
CFTR	1	B
gene	0	I
expression	0	O
and	0	O
may	0	O
mediate	0	O
an	0	O
induction	0	O
of	0	O
CFTR	1	B
in	0	O
responsive	0	O
cell	0	O
types	0	O
.	0	O


In	1	O
hemodialyzed	0	O
patients	0	O
(	0	O
Epo	0	B
and	0	O
Non	0	O
-	0	O
Epo	0	B
group	0	O
)	0	O
leptin	0	B
levels	0	O
were	0	O
significantly	0	O
higher	0	O
when	0	O
compared	0	O
to	0	O
CAPD	1	O
patients	0	O
(	0	O
Epo	0	B
and	0	O
Non	0	O
-	0	O
Epo	0	B
group	0	O
,	0	O
respectively	0	O
).	0	O


In	1	O
the	0	O
context	0	O
of	0	O
the	0	O
ADH2	0	B
upstream	0	I
regulatory	0	I
region	0	I
,	0	O
including	0	O
UAS1	0	O
,	0	O
working	0	O
in	0	O
concert	0	O
with	0	O
the	0	O
ADH2	0	B
basal	0	I
promoter	0	I
elements	0	I
,	0	O
UAS2	0	O
-	0	O
dependent	0	O
gene	0	O
activation	0	O
was	0	O
dependent	0	O
on	0	O
orientation	0	O
,	0	O
copy	0	O
number	0	O
,	0	O
and	0	O
helix	0	O
phase	0	O
.	0	O


(	0	O
1996a	0	O
)	0	O
Biochemistry	1	O
35	0	O
,	0	O
1589	0	O
-	0	O
1598	0	O
].	0	O


Here	0	O
we	0	O
report	0	O
the	0	O
cloning	0	O
,	0	O
expression	0	O
,	0	O
and	0	O
biochemical	0	O
characterization	0	O
of	0	O
the	0	O
32	0	O
-	0	O
kDa	1	O
subunit	0	O
of	0	O
human	0	O
(	0	O
h	0	O
)	0	O
TFIID	0	B
,	0	O
termed	0	O
hTAFII32	0	B
.	0	O


Such	0	O
marked	0	O
differences	0	O
are	0	O
found	0	O
occasionally	0	O
in	0	O
the	0	O
literature	0	O
:	0	O
heterophile	0	O
antibodies	0	O
against	0	O
bovine	0	B
gammaglobulin	0	I
are	0	O
regarded	0	O
as	0	O
responsible	0	O
for	0	O
the	0	O
interference	0	O
in	0	O
the	0	O
Sephadex	1	O
system	0	O
of	0	O
RIST	1	O
.	0	O


Object	1	O
relations	0	O
,	0	O
affect	0	O
management	0	O
,	0	O
and	0	O
psychic	0	O
structure	0	O
formation	0	O
.	0	O


NiCl	0	O
(	0	O
2	0	O
)-	0	O
induced	0	O
MCP	1	B
-	0	I
1	0	I
synthesis	0	O
required	0	O
activation	0	O
of	0	O
NF	1	B
-	0	I
kappaB	0	I
since	0	O
mutation	0	O
of	0	O
NF	1	B
-	0	I
kappaB	0	I
-	0	I
binding	0	I
sites	0	I
in	0	O
the	0	O
promoter	0	O
resulted	0	O
in	0	O
complete	0	O
loss	0	O
of	0	O
inducible	0	O
promoter	0	O
activity	0	O
.	0	O


Lyn	0	B
kinase	0	I
immunoprecipitated	0	O
from	0	O
lysates	0	O
of	0	O
irradiated	0	O
BCP	0	O
as	0	O
well	0	O
as	0	O
a	0	O
full	0	O
-	0	O
length	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
(	0	O
GST	0	B
)-	0	O
Lyn	0	B
fusion	0	O
protein	0	O
-	0	O
phosphorylated	0	O
recombinant	0	B
human	0	I
p34cdc2	0	I
on	0	O
tyrosine	0	O
15	0	O
.	0	O


Involvement	0	O
of	0	O
AP	1	B
-	0	I
2	0	I
in	0	O
regulation	0	O
of	0	O
the	0	O
R	1	B
-	0	I
FABP	0	I
gene	0	I
in	0	O
the	0	O
developing	0	O
chick	0	O
retina	0	O
.	0	O


Early	0	O
-	0	O
onset	0	O
scleral	0	O
necrosis	0	O
after	0	O
iodine	0	O
I	1	O
125	0	O
plaque	0	O
radiotherapy	0	O
for	0	O
ciliochoroidal	0	O
melanoma	0	O
.	0	O


The	0	O
actuarial	0	O
local	0	O
control	0	O
rates	0	O
at	0	O
10	0	O
years	0	O
for	0	O
the	0	O
three	0	O
treatment	0	O
groups	0	O
were	0	O
as	0	O
follows	0	O
:	0	O
subtotal	0	O
excision	0	O
alone	0	O
,	0	O
18	0	O
%;	0	O
subtotal	0	O
excision	0	O
plus	0	O
postoperative	0	O
radiation	0	O
therapy	0	O
,	0	O
82	0	O
%;	0	O
and	0	O
total	0	O
excision	0	O
alone	0	O
,	0	O
77	0	O
%.	0	O


Protein	1	O
phosphorylation	0	O
appears	0	O
to	0	O
play	0	O
a	0	O
critical	0	O
role	0	O
in	0	O
uPA	0	B
gene	0	I
expression	0	O
in	0	O
these	0	O
cells	0	O
;	0	O
protein	0	B
kinase	0	I
C	1	I
-	0	O
activating	0	O
phorbol	0	O
esters	0	O
cooperate	0	O
with	0	O
pp60v	0	B
-	0	I
src	0	I
to	0	O
synergistically	0	O
increase	0	O
uPA	0	B
mRNA	1	I
,	0	O
whereas	0	O
cyclic	0	B
AMP	1	I
(	0	I
cAMP	1	I
)-	0	I
dependent	0	I
protein	0	I
kinase	0	I
-	0	O
activating	0	O
agents	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
8	0	O
-	0	O
bromo	0	O
cAMP	1	O
)	0	O
repress	0	O
uPA	0	B
mRNA	1	I
levels	0	O
.	0	O


The	0	O
results	0	O
from	0	O
the	0	O
first	0	O
five	0	O
years	0	O
of	0	O
follow	0	O
up	0	O
in	0	O
1972	0	O
showed	0	O
a	0	O
4	0	O
.	0	O
7	0	O
-	0	O
fold	0	O
excess	0	O
mortality	0	O
for	0	O
ischaemic	0	O
and	0	O
other	0	O
heart	0	O
diseases	0	O
(	0	O
ICD	1	O
A83	0	O
-	0	O
A84	0	O
)	0	O
compared	0	O
with	0	O
a	0	O
comparable	0	O
reference	0	O
cohort	0	O
of	0	O
paper	0	O
mill	0	O
workers	0	O
.	0	O


Propagation	1	O
and	0	O
hormone	0	O
production	0	O
by	0	O
human	0	O
normal	0	O
and	0	O
malignant	0	O
trophoblast	0	O
in	0	O
rats	0	O
.	0	O


Estral	0	O
cycle	0	O
in	0	O
white	0	O
rats	0	O
in	0	O
the	0	O
low	0	O
and	0	O
high	0	O
mountains	0	O
of	0	O
Kirghizia	0	O


RESULTS	0	O
:	0	O
The	0	O
main	0	O
effect	0	O
of	0	O
muscle	0	O
pain	0	O
,	0	O
compared	0	O
to	0	O
non	0	O
-	0	O
painful	0	O
stimulation	0	O
,	0	O
was	0	O
a	0	O
significant	0	O
and	0	O
long	0	O
-	0	O
lasting	0	O
increase	0	O
of	0	O
delta	0	O
(	0	O
1	0	O
-	0	O
3	0	O
Hz	1	O
)	0	O
power	0	O
and	0	O
an	0	O
alpha	0	O
-	0	O
1	0	O
(	0	O
9	0	O
-	0	O
11	0	O
Hz	1	O
)	0	O
power	0	O
increase	0	O
over	0	O
the	0	O
contralateral	0	O
parietal	0	O
locus	0	O
.	0	O


Spinal	1	O
cord	0	O
representation	0	O
of	0	O
the	0	O
micturition	0	O
reflex	0	O
.	0	O


A	1	O
recently	0	O
described	0	O
protein	0	O
,	0	O
metaxin	0	B
1	0	I
,	0	O
serves	0	O
as	0	O
a	0	O
component	0	O
of	0	O
a	0	O
preprotein	0	O
import	0	O
complex	0	O
in	0	O
the	0	O
outer	0	O
membrane	0	O
of	0	O
the	0	O
mammalian	0	O
mitochondrion	0	O
.	0	O


Comparison	0	O
of	0	O
cDNA	1	O
and	0	O
genomic	0	O
sequences	0	O
shows	0	O
that	0	O
the	0	O
ZNF189	0	B
gene	0	I
spans	0	O
approximately	0	O
11	0	O
kb	0	O
and	0	O
is	0	O
organized	0	O
into	0	O
at	0	O
least	0	O
four	0	O
exons	0	O
,	0	O
the	0	O
large	0	O
3	0	O
'-	0	O
end	0	O
exon	0	O
coding	0	O
for	0	O
the	0	O
complete	0	O
zinc	0	O
finger	0	O
domain	0	O
and	0	O
the	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
.	0	O


The	0	O
husband	0	O
in	0	O
one	0	O
of	0	O
the	0	O
married	0	O
couples	0	O
was	0	O
treated	0	O
for	0	O
hepatitis	0	O
of	0	O
unidentified	0	O
etiology	0	O
in	0	O
an	0	O
Infectology	0	O
Department	1	O
four	0	O
years	0	O
ago	0	O
.	0	O


French	1	O
bean	0	O
contains	0	O
a	0	O
small	0	O
family	0	O
of	0	O
genes	0	B
encoding	0	I
PAL	1	I
and	0	O
two	0	O
of	0	O
these	0	O
genes	0	O
,	0	O
PAL2	0	B
and	0	O
PAL3	0	B
,	0	O
have	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
differentially	0	O
expressed	0	O
at	0	O
the	0	O
mRNA	1	O
level	0	O
in	0	O
bean	0	O
tissues	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
different	0	O
models	0	O
of	0	O
intestinal	0	O
ischemia	0	O
have	0	O
different	0	O
cytokine	0	O
profiles	0	O
and	0	O
that	0	O
the	0	O
early	0	O
TNF	1	B
response	0	O
associated	0	O
with	0	O
SMA	1	O
occlusion	0	O
model	0	O
is	0	O
primarily	0	O
due	0	O
to	0	O
the	0	O
laparotomy	0	O
.	0	O


The	0	O
Fas	1	B
receptor	0	I
mediates	0	O
a	0	O
signalling	0	O
cascade	0	O
resulting	0	O
in	0	O
programmed	0	O
cell	0	O
death	0	O
(	0	O
apoptosis	0	O
)	0	O
within	0	O
hours	0	O
of	0	O
receptor	0	O
cross	0	O
-	0	O
linking	0	O
.	0	O


Helicobacter	1	O
pylori	0	O
and	0	O
stomach	0	O
diseases	0	O
:	0	O
from	0	O
clinical	0	O
point	0	O
of	0	O
view	0	O


Type	1	O
IV	1	O
splice	0	O
pattern	0	O
,	0	O
containing	0	O
exon	0	O
U3	0	O
and	0	O
S	1	O
was	0	O
found	0	O
both	0	O
in	0	O
kidney	0	O
and	0	O
ovary	0	O
.	0	O


PKA	1	B
phosphorylated	0	O
WT1	0	B
at	0	O
Ser	1	O
-	0	O
365	0	O
and	0	O
Ser	1	O
-	0	O
393	0	O
in	0	O
vitro	0	O
,	0	O
as	0	O
well	0	O
as	0	O
at	0	O
additional	0	O
sites	0	O
,	0	O
and	0	O
this	0	O
phosphorylation	0	O
abolished	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
activity	0	O
of	0	O
WT1	0	B
in	0	O
vitro	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
reconstitution	0	O
of	0	O
eUSF	0	B
and	0	O
TFIID	0	B
-	0	O
depleted	0	O
transcription	0	O
complexes	0	O
with	0	O
purified	0	O
protein	0	O
fractions	0	O
demonstrate	0	O
that	0	O
not	0	O
only	0	O
TFIID	0	B
but	0	O
also	0	O
eUSF	0	B
essentially	0	O
participates	0	O
in	0	O
complex	0	O
formation	0	O
even	0	O
on	0	O
H5	0	B
promoter	0	I
mutations	0	O
lacking	0	O
the	0	O
TATA	0	O
-	0	O
box	0	O
.	0	O


However	0	O
,	0	O
for	0	O
the	0	O
evaluable	0	O
cases	0	O
,	0	O
the	0	O
performances	0	O
of	0	O
the	0	O
CD3500	0	O
and	0	O
the	0	O
STKS	0	O
were	0	O
broadly	0	O
similar	0	O
and	0	O
generally	0	O
correlated	0	O
well	0	O
with	0	O
the	0	O
manual	0	O
reference	0	O
procedure	0	O
.	0	O


RESULTS	0	O
:	0	O
Cholinergic	1	O
nerves	0	O
are	0	O
mainly	0	O
involved	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
enteric	0	O
nerve	0	O
responses	0	O
to	0	O
EFS	0	O
in	0	O
the	0	O
normal	0	O
IAS	0	O
.	0	O


Cross	1	O
-	0	O
linking	0	O
the	0	O
B	1	B
cell	0	I
Ag	1	I
receptor	0	I
(	0	O
BCR	0	B
)	0	O
to	0	O
surface	0	B
Fc	1	I
receptors	0	I
for	0	O
IgG	1	B
(	0	O
Fc	1	B
gamma	0	I
R	1	I
)	0	O
inhibits	0	O
G1	0	O
-	0	O
to	0	O
-	0	O
S	1	O
progression	0	O
;	0	O
the	0	O
mechanism	0	O
by	0	O
which	0	O
this	0	O
occurs	0	O
is	0	O
not	0	O
completely	0	O
known	0	O
.	0	O


Scapulae	0	O
with	0	O
a	0	O
Type	1	O
I	1	O
configuration	0	O
were	0	O
found	0	O
to	0	O
have	0	O
low	0	O
values	0	O
for	0	O
the	0	O
coraco	0	O
-	0	O
glenoid	0	O
angle	0	O
and	0	O
coracoid	0	O
overlap	0	O
,	0	O
which	0	O
are	0	O
known	0	O
to	0	O
be	0	O
associated	0	O
with	0	O
a	0	O
short	0	O
coraco	0	O
-	0	O
humeral	0	O
distance	0	O
.	0	O


In	1	O
ten	0	O
other	0	O
experiments	0	O
(	0	O
5	0	O
experimental	0	O
and	0	O
5	0	O
control	0	O
rats	0	O
)	0	O
99mTc	0	O
-	0	O
sulfur	0	O
colloid	0	O
was	0	O
injected	0	O
intravenously	0	O
.	0	O


A	1	O
sharp	0	O
outbreak	0	O
of	0	O
influenza	0	O
A	1	O
occurred	0	O
on	0	O
the	0	O
base	0	O
during	0	O
February	0	O
that	0	O
was	0	O
due	0	O
to	0	O
an	0	O
A	1	O
/	0	O
Texas	0	O
/	0	O
1	0	O
/	0	O
77	0	O
-	0	O
like	0	O
virus	0	O
,	0	O
a	0	O
variant	0	O
of	0	O
the	0	O
A	1	O
/	0	O
Victoria	0	O
/	0	O
3	0	O
/	0	O
75	0	O
prototpye	0	O
.	0	O


FDA	1	O
regulations	0	O
for	0	O
growth	0	O
factors	0	O
and	0	O
related	0	O
products	0	O
.	0	O


In	1	O
1993	0	O
and	0	O
1994	0	O
and	0	O
infection	0	O
with	0	O
body	0	O
lice	0	O
was	0	O
registered	0	O
41	0	O
times	0	O
in	0	O
31	0	O
patients	0	O
at	0	O
the	0	O
clinic	0	O
for	0	O
homeless	0	O
of	0	O
the	0	O
Community	1	O
Health	1	O
Service	1	O
of	0	O
Utrecht	0	O
.	0	O


METHODS	0	O
:	0	O
Fifty	0	O
-	0	O
one	0	O
healthy	0	O
eyes	0	O
,	0	O
169	0	O
ocular	0	O
hypertensive	0	O
eyes	0	O
with	0	O
normal	0	O
visual	0	O
fields	0	O
,	0	O
and	0	O
132	0	O
glaucomatous	0	O
eyes	0	O
with	0	O
early	0	O
visual	0	O
field	0	O
defects	0	O
were	0	O
evaluated	0	O
with	0	O
qualitative	0	O
and	0	O
quantitative	0	O
measures	0	O
of	0	O
structural	0	O
damage	0	O
to	0	O
the	0	O
optic	0	O
nerve	0	O
and	0	O
nerve	0	O
fiber	0	O
layer	0	O
.	0	O


DNA	1	O
sequence	0	O
analysis	0	O
of	0	O
a	0	O
3213	0	O
bp	0	O
BamHI	0	B
-	0	O
ClaI	0	B
fragment	0	O
revealed	0	O
that	0	O
three	0	O
open	0	O
reading	0	O
frames	0	O
(	0	O
ORFs	0	O
)	0	O
were	0	O
encoded	0	O
in	0	O
the	0	O
same	0	O
orientation	0	O
.	0	O


Recently	0	O
,	0	O
extremely	0	O
high	0	O
levels	0	O
of	0	O
endothelin	0	B
-	0	I
1	0	I
(	0	O
ET	1	B
-	0	I
1	0	I
)	0	O
were	0	O
detected	0	O
in	0	O
the	0	O
pericardial	0	O
fluid	0	O
of	0	O
patients	0	O
undergoing	0	O
cardiac	0	O
surgery	0	O
.	0	O


Tolerance	1	O
test	0	O
of	0	O
HB	1	O
419	0	O
in	0	O
animal	0	O
experiments	0	O


A	1	O
new	0	O
semi	0	O
-	0	O
automatic	0	O
method	0	O
for	0	O
quantifying	0	O
regional	0	O
cerebral	0	O
uptake	0	O
of	0	O
99m	0	O
technetium	0	O
-	0	O
hexamethylpropylene	0	O
amine	0	O
oxime	0	O
(	0	O
99mTc	0	O
-	0	O
HMPAO	1	O
)	0	O
was	0	O
used	0	O
to	0	O
assess	0	O
single	0	O
photon	0	O
emission	0	O
tomograms	0	O
from	0	O
5	0	O
normal	0	O
subjects	0	O
,	0	O
14	0	O
patients	0	O
with	0	O
Alzheimer	0	O
'	0	O
s	0	O
disease	0	O
,	0	O
14	0	O
patients	0	O
with	0	O
dementia	0	O
of	0	O
frontal	0	O
lobe	0	O
type	0	O
and	0	O
4	0	O
patients	0	O
with	0	O
dementia	0	O
with	0	O
motor	0	O
neurone	0	O
disease	0	O
.	0	O


Amplification	1	O
and	0	O
overexpression	0	O
of	0	O
the	0	O
c	0	B
-	0	I
erbB	0	I
-	0	I
2	0	I
gene	0	I
in	0	O
21MT	0	O
-	0	O
2	0	O
and	0	O
21MT	0	O
-	0	O
1	0	O
human	0	O
breast	0	O
carcinoma	0	O
cells	0	O
results	0	O
in	0	O
progressively	0	O
elevated	0	O
levels	0	O
of	0	O
constitutively	0	O
tyrosine	0	B
-	0	I
phosphorylated	0	I
p185erbB	0	I
-	0	I
2	0	I
and	0	O
is	0	O
associated	0	O
with	0	O
progressive	0	O
insulin	0	B
-	0	I
like	0	I
growth	0	I
factor	0	I
(	0	O
IGF	1	B
)	0	O
and	0	O
combined	0	O
IGF	1	B
/	0	O
epidermal	0	B
growth	0	I
factor	0	I
(	0	O
EGF	1	B
)	0	O
independence	0	O
in	0	O
culture	0	O
.	0	O


Gentamicin	1	O
given	0	O
by	0	O
DPI	0	O
and	0	O
SVN	0	O
significantly	0	O
decreased	0	O
the	0	O
sputum	0	O
Psa	1	O
density	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
),	0	O
by	0	O
almost	0	O
one	0	O
order	0	O
of	0	O
magnitude	0	O
.	0	O


Comparison	0	O
of	0	O
elastase	0	B
-	0	I
1	0	I
with	0	O
amylase	0	B
,	0	O
lipase	0	B
,	0	O
and	0	O
trypsin	0	B
-	0	O
like	0	O
immunoreactivity	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
acute	0	O
pancreatitis	0	O
.	0	O


Based	0	O
on	0	O
subcellular	0	O
fractionation	0	O
,	0	O
the	0	O
47	0	B
-	0	I
kDa	1	I
P	1	I
-	0	I
CIP2	0	I
protein	0	I
is	0	O
mostly	0	O
cytosolic	0	O
.	0	O


Surface	1	O
spin	0	O
waves	0	O
in	0	O
a	0	O
Heisenberg	0	O
ferrimagnet	0	O
with	0	O
a	0	O
single	0	O
-	0	O
ion	0	O
anisotropy	0	O
(	0	O
uniaxial	0	O
and	0	O
nonuniaxial	0	O
).	0	O


The	0	O
spacing	0	O
of	0	O
the	0	O
essential	0	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
(	0	O
END	1	O
)	0	O
relative	0	O
to	0	O
the	0	O
HFD	0	B
can	0	O
be	0	O
changed	0	O
significantly	0	O
without	0	O
an	0	O
apparent	0	O
effect	0	O
on	0	O
Cse4p	0	B
function	0	O
.	0	O


The	0	O
interaction	0	O
between	0	O
piroxicam	0	O
and	0	O
poloxamer	0	O
was	0	O
studied	0	O
by	0	O
x	0	O
-	0	O
ray	0	O
diffractometry	0	O
(	0	O
XRD	0	O
),	0	O
infrared	0	O
(	0	O
IR	1	O
)	0	O
spectroscopy	0	O
and	0	O
differential	0	O
thermal	0	O
analysis	0	O
(	0	O
DTA	0	O
)	0	O
with	0	O
a	0	O
solid	0	O
dispersion	0	O
,	0	O
coprecipitate	0	O
,	0	O
or	0	O
physical	0	O
mixture	0	O
.	0	O


Plasma	1	O
thromboxane	0	O
B2	0	O
levels	0	O
in	0	O
the	0	O
older	0	O
group	0	O
were	0	O
about	0	O
double	0	O
those	0	O
in	0	O
younger	0	O
piglets	0	O
.	0	O


Experiments	0	O
with	0	O
recombinant	0	O
proteins	0	O
showed	0	O
that	0	O
p50	0	B
/	0	O
p65	0	B
and	0	O
high	0	B
-	0	I
mobility	0	I
-	0	I
group	0	I
I	1	I
(	0	I
Y	1	I
)	0	I
protein	0	I
cooperatively	0	O
facilitated	0	O
the	0	O
binding	0	O
of	0	O
IRF	1	B
-	0	I
1	0	I
to	0	O
the	0	O
VCAM1	0	B
IRF	1	I
binding	0	I
site	0	I
and	0	O
that	0	O
IRF	1	B
-	0	I
1	0	I
physically	0	O
interacted	0	O
with	0	O
p50	0	B
and	0	O
with	0	O
high	0	B
-	0	I
mobility	0	I
-	0	I
group	0	I
I	1	I
(	0	I
Y	1	I
)	0	I
protein	0	I
.	0	O


Immunoglobulin	1	B
light	0	I
chain	0	I
(	0	O
IgL	0	B
)	0	O
diversity	0	O
is	0	O
generated	0	O
in	0	O
the	0	O
chicken	0	O
by	0	O
recombination	0	O
between	0	O
the	0	O
single	0	O
functional	0	O
variable	0	O
(	0	O
VL	1	B
)	0	O
and	0	O
joining	0	O
(	0	O
JL	0	B
)	0	O
gene	0	O
segments	0	O
and	0	O
subsequent	0	O
somatic	0	O
diversification	0	O
of	0	O
the	0	O
rearranged	0	O
VL	1	B
region	0	O
.	0	O


The	0	O
activated	0	O
glucocorticoid	0	B
receptor	0	I
forms	0	O
a	0	O
complex	0	O
with	0	O
Stat5	0	B
and	0	O
enhances	0	O
Stat5	0	B
-	0	O
mediated	0	O
transcriptional	0	O
induction	0	O
.	0	O


A	1	O
single	0	O
-	0	O
case	0	O
experimental	0	O
ABAB	0	O
multiple	0	O
baseline	0	O
design	0	O
was	0	O
employed	0	O
to	0	O
test	0	O
for	0	O
treatment	0	O
effectiveness	0	O
.	0	O


Colorectal	1	O
carcinoma	0	O
:	0	O
therapeutic	0	O
approach	0	O
in	0	O
patients	0	O
already	0	O
treated	0	O
with	0	O
metastasis	0	O
resection	0	O


Examples	0	O
are	0	O
using	0	O
more	0	O
subjects	0	O
or	0	O
an	0	O
improved	0	O
research	0	O
design	0	O
,	0	O
developing	0	O
consensus	0	O
statements	0	O
or	0	O
using	0	O
meta	0	O
-	0	O
analysis	0	O
.	0	O


However	0	O
,	0	O
in	0	O
a	0	O
multivariate	0	O
analysis	0	O
considering	0	O
age	0	O
,	0	O
gender	0	O
,	0	O
and	0	O
a	0	O
previous	0	O
history	0	O
of	0	O
cardiovascular	0	O
diseases	0	O
,	0	O
female	0	O
gender	0	O
was	0	O
not	0	O
independently	0	O
associated	0	O
with	0	O
death	0	O
.	0	O


The	0	O
plexiform	0	O
neurofibroma	0	O
and	0	O
multiple	0	O
localized	0	O
neurofibromas	0	O
are	0	O
characteristic	0	O
of	0	O
NF1	1	B
.	0	O


In	1	O
HeLa	0	O
cells	0	O
,	0	O
it	0	O
activated	0	O
transcription	0	O
from	0	O
the	0	O
herpes	0	B
simplex	0	I
virus	0	I
type	0	I
1	0	I
thymidine	0	I
kinase	0	I
promoter	0	I
linked	0	O
to	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
gene	0	I
when	0	O
located	0	O
in	0	O
inverted	0	O
orientation	0	O
upstream	0	O
of	0	O
the	0	O
thymidine	0	B
kinase	0	I
promoter	0	I
or	0	O
downstream	0	O
of	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
gene	0	I
coding	0	I
sequence	0	I
.	0	O


The	0	O
cellular	0	O
rate	0	O
of	0	O
anticoagulant	0	B
heparan	0	I
sulfate	0	I
proteoglycan	0	I
(	0	O
HSPGact	0	B
)	0	O
generation	0	O
is	0	O
determined	0	O
by	0	O
the	0	O
level	0	O
of	0	O
a	0	O
kinetically	0	O
limiting	0	O
microsomal	0	O
activity	0	O
,	0	O
HSact	0	O
conversion	0	O
activity	0	O
,	0	O
which	0	O
is	0	O
predominantly	0	O
composed	0	O
of	0	O
the	0	O
long	0	O
sought	0	O
heparan	0	B
sulfate	0	I
D	1	I
-	0	I
glucosaminyl	0	I
3	0	I
-	0	I
O	1	I
-	0	I
sulfotransferase	0	I
(	0	O
3	0	B
-	0	I
OST	1	I
)	0	O
(	0	O
Shworak	0	O
,	0	O
N	1	O
.	0	O


Mucolipidosis	1	O
type	0	O
IV	1	O
:	0	O
clinical	0	O
spectrum	0	O
and	0	O
natural	0	O
history	0	O
.	0	O


The	0	O
differences	0	O
were	0	O
as	0	O
follows	0	O
:	0	O
for	0	O
overall	0	O
response	0	O
rate	0	O
p	0	O
=	0	O
0	0	O
.	0	O
004	0	O
;	0	O
power	0	O
(	0	O
for	0	O
p	0	O
=	0	O
0	0	O
.	0	O
05	0	O
)	0	O
85	0	O
%;	0	O
for	0	O
survival	0	O
p	0	O
=	0	O
0	0	O
.	0	O
09	0	O
;	0	O
for	0	O
grade	0	O
IV	1	O
granulocytopenia	0	O
p	0	O
=	0	O
0	0	O
.	0	O
3	0	O
;	0	O
and	0	O
for	0	O
febrile	0	O
neutropenia	0	O
p	0	O
=	0	O
0	0	O
.	0	O
61	0	O
.	0	O


During	0	O
an	0	O
8	0	O
-	0	O
wk	0	O
follow	0	O
-	0	O
up	0	O
,	0	O
parasites	0	O
reappeared	0	O
in	0	O
10	0	O
patients	0	O
,	0	O
5	0	O
after	0	O
each	0	O
drug	0	O
,	0	O
between	0	O
1	0	O
and	0	O
7	0	O
wk	0	O
after	0	O
treatment	0	O
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
expression	0	O
of	0	O
TD	1	B
-	0	I
IkappaBalpha	0	I
blocked	0	O
phorbol	0	O
myristate	0	O
acetate	0	B
-	0	I
phytohemagglutinin	0	I
or	0	O
tumor	0	B
necrosis	0	I
factor	0	I
alpha	0	I
-	0	O
induced	0	O
IkappaBalpha	0	B
gene	0	I
transcription	0	O
and	0	O
abolished	0	O
NF	1	B
-	0	I
kappaB	0	I
DNA	1	O
binding	0	O
activity	0	O
,	0	O
due	0	O
to	0	O
the	0	O
continued	0	O
cytoplasmic	0	O
sequestration	0	O
of	0	O
RelA	0	B
(	0	O
p65	0	B
)	0	O
by	0	O
TD	1	B
-	0	I
IkappaBalpha	0	I
.	0	O


The	0	O
new	0	O
FIGO	1	O
definition	0	O
of	0	O
cervical	0	O
cancer	0	O
stage	0	O
IA	1	O
:	0	O
a	0	O
critique	0	O
.	0	O


50	0	O
kDa	1	O
and	0	O
130	0	O
-	0	O
170	0	O
kDa	1	O
were	0	O
detected	0	O
.	0	O


Overexpression	1	O
of	0	O
H411	0	B
cDNA	1	I
in	0	O
the	0	O
RAW	1	O
264	0	O
.	0	O
7	0	O
macrophage	0	O
cell	0	O
line	0	O
promoted	0	O
an	0	O
increased	0	O
growth	0	O
rate	0	O
,	0	O
suggesting	0	O
that	0	O
expression	0	O
of	0	O
H411	0	B
is	0	O
part	0	O
of	0	O
the	0	O
proliferative	0	O
cell	0	O
response	0	O
to	0	O
LPS	1	O
.	0	O


METHODS	0	O
AND	0	O
RESULTS	0	O
:	0	O
We	0	O
prospectively	0	O
compared	0	O
the	0	O
automated	0	O
measurements	0	O
of	0	O
left	0	O
ventricular	0	O
ejection	0	O
fraction	0	O
(	0	O
LVEF	0	O
)	0	O
and	0	O
volumes	0	O
from	0	O
rest	0	O
-	0	O
injected	0	O
gated	0	O
Technetium	1	O
99m	0	O
(	0	O
Tc99m	0	O
)	0	O
perfusion	0	O
SPECT	1	O
with	0	O
equilibrium	0	O
radionuclide	0	O
angiocardiography	0	O
(	0	O
ERNA	0	O
)	0	O
in	0	O
62	0	O
patients	0	O
and	0	O
the	0	O
assessment	0	O
of	0	O
regional	0	O
function	0	O
with	0	O
echocardiography	0	O
in	0	O
22	0	O
patients	0	O
.	0	O


DPA	0	O
attenuated	0	O
the	0	O
increase	0	O
of	0	O
the	0	O
intensity	0	O
of	0	O
the	0	O
ischemic	0	O
and	0	O
pressure	0	O
pain	0	O
components	0	O
with	0	O
increasing	0	O
ischemia	0	O
duration	0	O
,	0	O
but	0	O
only	0	O
the	0	O
effect	0	O
on	0	O
the	0	O
pressure	0	O
pain	0	O
component	0	O
was	0	O
significant	0	O
.	0	O


ORF	1	O
M1	1	O
has	0	O
striking	0	O
homology	0	O
to	0	O
poxvirus	0	O
serpins	0	B
,	0	O
while	0	O
ORF	1	O
M11	0	O
encodes	0	O
a	0	O
potential	0	O
homolog	0	O
of	0	O
Bcl	0	B
-	0	I
2	0	I
-	0	I
like	0	I
molecules	0	I
encoded	0	O
by	0	O
other	0	O
gammaherpesviruses	0	O
(	0	O
gene	0	B
16	0	I
of	0	O
HVS	0	O
and	0	O
KSHV	0	O
and	0	O
the	0	O
BHRF1	0	B
gene	0	I
of	0	O
EBV	1	O
).	0	O


This	0	O
Tbx6	0	B
-	0	I
subfamily	0	I
gene	0	I
is	0	O
likely	0	O
to	0	O
participate	0	O
in	0	O
paraxial	0	O
mesoderm	0	O
formation	0	O
and	0	O
somitogenesis	0	O
in	0	O
human	0	O
embryo	0	O
.	0	O


Vestibular	1	O
adaptation	0	O
exercises	0	O
and	0	O
recovery	0	O
:	0	O
acute	0	O
stage	0	O
after	0	O
acoustic	0	O
neuroma	0	O
resection	0	O
.	0	O


We	0	O
have	0	O
previously	0	O
reported	0	O
that	0	O
expression	0	O
of	0	O
a	0	O
tumour	0	O
derived	0	O
brk	0	B
cDNA	1	I
in	0	O
mouse	0	O
embryonic	0	O
fibroblasts	0	O
and	0	O
human	0	O
mammary	0	O
epithelial	0	O
cells	0	O
supports	0	O
anchorage	0	O
independent	0	O
growth	0	O
,	0	O
and	0	O
in	0	O
the	0	O
latter	0	O
potentiates	0	O
the	0	O
mitogenic	0	O
response	0	O
to	0	O
epidermal	0	B
growth	0	I
factor	0	I
.	0	O


However	0	O
,	0	O
activation	0	O
of	0	O
the	0	O
cAMP	1	O
pathway	0	O
,	0	O
which	0	O
is	0	O
known	0	O
to	0	O
regulate	0	O
inhibin	0	B
alpha	0	I
expression	0	O
,	0	O
greatly	0	O
enhanced	0	O
the	0	O
actions	0	O
of	0	O
SF	1	B
-	0	I
1	0	I
.	0	O


We	0	O
also	0	O
present	0	O
evidence	0	O
for	0	O
a	0	O
negative	0	O
regulatory	0	O
element	0	O
in	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
Mlu	0	B
I	1	I
upstream	0	I
activation	0	I
sequence	0	I
.	0	O


D	1	O
.	0	O


However	0	O
,	0	O
its	0	O
participation	0	O
in	0	O
gagging	0	O
induced	0	O
by	0	O
oropharyngeal	0	O
irritation	0	O
is	0	O
unclear	0	O
.	0	O


A	1	O
new	0	O
method	0	O
for	0	O
the	0	O
in	0	O
vitro	0	O
transfer	0	O
of	0	O
delayed	0	O
hypersensitivity	0	O
by	0	O
dialysed	0	O
transfer	0	B
factor	0	I
.	0	O


Also	0	O
,	0	O
except	0	O
in	0	O
one	0	O
patient	0	O
who	0	O
developed	0	O
gallstones	0	O
following	0	O
institution	0	O
of	0	O
colestipol	0	O
,	0	O
saturation	0	O
of	0	O
gallbladder	0	O
bile	0	O
with	0	O
cholesterol	0	O
was	0	O
not	0	O
markedly	0	O
increased	0	O
by	0	O
this	0	O
drug	0	O
alone	0	O
.	0	O


Furthermore	0	O
,	0	O
bone	0	O
marrow	0	O
-	0	O
derived	0	O
macrophages	0	O
from	0	O
LAT	1	B
-	0	O
deficient	0	O
mice	0	O
displayed	0	O
reduced	0	O
phagocytic	0	O
efficiency	0	O
in	0	O
comparison	0	O
to	0	O
the	0	O
macrophages	0	O
from	0	O
wild	0	O
-	0	O
type	0	O
mice	0	O
.	0	O


Laser	1	O
ablation	0	O
has	0	O
been	0	O
employed	0	O
as	0	O
a	0	O
therapeutic	0	O
measure	0	O
for	0	O
chronic	0	O
pulmonary	0	O
emphysema	0	O
.	0	O


In	1	O
the	0	O
ISO	1	O
group	0	O
,	0	O
at	0	O
pre	0	O
-	0	O
DEX	0	O
,	0	O
CBF	1	O
increased	0	O
from	0	O
86	0	O
+/-	0	O
8	0	O
to	0	O
166	0	O
+/-	0	O
19	0	O
mL	1	O
.	0	O
min	0	O
-	0	O
1	0	O
.	0	O
100	0	O
g	0	O
-	0	O
1	0	O
in	0	O
response	0	O
to	0	O
hypercapnia	0	O
(	0	O
PCO2	1	O
approximately	0	O
90	0	O
mmHg	0	O
).(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Intravenous	1	O
antibiotic	0	O
therapy	0	O
in	0	O
cystic	0	O
fibrosis	0	O
:	0	O
in	0	O
hospital	0	O
or	0	O
at	0	O
home	0	O
?	0	O


Presidential	0	O
address	0	O
1990	0	O
--	0	O
coming	0	O
in	0	O
from	0	O
the	0	O
cold	0	O
.	0	O


An	1	O
examination	0	O
of	0	O
the	0	O
properties	0	O
of	0	O
sequences	0	O
surrounding	0	O
ARS1	0	O
left	0	O
open	0	O
the	0	O
possibility	0	O
that	0	O
ABFI	0	B
enhances	0	O
the	0	O
initiation	0	O
of	0	O
DNA	1	O
replication	0	O
at	0	O
ARS1	0	O
by	0	O
transcriptional	0	O
activation	0	O
.	0	O


The	0	O
decline	0	O
in	0	O
the	0	O
activity	0	O
of	0	O
cytochrome	0	B
oxidase	0	I
,	0	O
peroxidase	0	B
and	0	O
in	0	O
the	0	O
lipid	0	O
content	0	O
of	0	O
peripheral	0	O
neutrophils	0	O
was	0	O
followed	0	O
by	0	O
a	0	O
decrease	0	O
in	0	O
the	0	O
phagocytic	0	O
activity	0	O
.	0	O


A	1	O
reduced	0	O
matrix	0	O
distribution	0	O
and	0	O
enhanced	0	O
cell	0	O
density	0	O
were	0	O
observed	0	O
as	0	O
the	0	O
biofilm	0	O
aged	0	O
.	0	O


For	0	O
comparison	0	O
conventional	0	O
heparin	0	O
was	0	O
used	0	O
during	0	O
18	0	O
dialyses	0	O
in	0	O
the	0	O
same	0	O
patients	0	O
.	0	O


These	0	O
results	0	O
implicate	0	O
a	0	O
precursor	0	O
-	0	O
specific	0	O
base	0	O
-	0	O
paired	0	O
structure	0	O
involving	0	O
sequences	0	O
on	0	O
both	0	O
sides	0	O
of	0	O
the	0	O
mature	0	O
cleavage	0	O
site	0	O
in	0	O
the	0	O
3	0	O
'	0	O
processing	0	O
of	0	O
human	0	B
U2	0	I
RNA	1	I
.	0	O


Unfolding	1	O
can	0	O
be	0	O
described	0	O
by	0	O
a	0	O
two	0	O
-	0	O
state	0	O
process	0	O
since	0	O
a	0	O
ratio	0	O
of	0	O
delta	0	O
Hcalorimetric	0	O
to	0	O
delta	0	O
Hvan	0	O
'	0	O
t	0	O
Hoff	1	O
equals	0	O
0	0	O
.	0	O
96	0	O
.	0	O


Childhood	1	O
misbehavior	0	O
and	0	O
the	0	O
risk	0	O
of	0	O
injecting	0	O
drug	0	O
use	0	O
.	0	O


Codon	1	O
usage	0	O
in	0	O
C	1	O
.	0	O
reinhardtii	0	O
mitochondria	0	O
is	0	O
highly	0	O
biased	0	O
,	0	O
with	0	O
eight	0	O
codons	0	O
entirely	0	O
absent	0	O
from	0	O
all	0	O
protein	0	O
-	0	O
coding	0	O
genes	0	O
;	0	O
however	0	O
,	0	O
even	0	O
though	0	O
codon	0	O
usage	0	O
is	0	O
restricted	0	O
,	0	O
it	0	O
appears	0	O
that	0	O
C	1	O
.	0	O
reinhardtii	0	O
mtDNA	1	O
cannot	0	O
encode	0	O
the	0	O
minimum	0	O
number	0	O
of	0	O
tRNAs	0	O
needed	0	O
to	0	O
support	0	O
mitochondrial	0	O
protein	0	O
synthesis	0	O
.	0	O


Also	0	O
discussed	0	O
is	0	O
the	0	O
possibility	0	O
of	0	O
a	0	O
combined	0	O
genetic	0	O
and	0	O
environmental	0	O
etiology	0	O
.	0	O


High	0	O
-	0	O
level	0	O
gains	0	O
(	0	O
HLGs	0	O
)	0	O
indicative	0	O
of	0	O
gene	0	O
amplifications	0	O
were	0	O
identified	0	O
at	0	O
11q13	0	O
in	0	O
two	0	O
cases	0	O
,	0	O
and	0	O
in	0	O
one	0	O
case	0	O
each	0	O
at	0	O
2q33	0	O
-	0	O
34	0	O
,	0	O
3q25	0	O
-	0	O
29	0	O
,	0	O
5p15	0	O
.	0	O
1	0	O
-	0	O
15	0	O
.	0	O
2	0	O
,	0	O
7q21	0	O
-	0	O
22	0	O
,	0	O
11p11	0	O
.	0	O
2	0	O
,	0	O
12p11	0	O
.	0	O
2	0	O
-	0	O
12	0	O
,	0	O
and	0	O
13q34	0	O
.	0	O


Successive	0	O
abdominal	0	O
scintillation	0	O
with	0	O
131	0	O
-	0	O
I	1	O
-	0	O
tagged	0	O
BSP	0	O
--	0	O
description	0	O
of	0	O
the	0	O
thyroid	0	O
gland	0	O
,	0	O
kidney	0	O
and	0	O
spleen	0	O
(	0	O
comparison	0	O
with	0	O
131	0	O
-	0	O
I	1	O
-	0	O
RB	1	O
)	0	O


Eight	0	O
of	0	O
14	0	O
infectious	0	O
or	0	O
inflammatory	0	O
lesions	0	O
could	0	O
be	0	O
detected	0	O
in	0	O
the	0	O
early	0	O
scan	0	O
(	0	O
4	0	O
-	0	O
6	0	O
h	0	O
p	0	O
.	0	O
i	0	O
.).	0	O


The	0	O
transforming	0	O
protein	0	O
of	0	O
Rous	0	O
sarcoma	0	O
virus	0	O
,	0	O
pp60v	0	B
-	0	I
src	0	I
,	0	O
and	0	O
its	0	O
normal	0	O
cellular	0	O
homolog	0	O
,	0	O
pp60c	0	B
-	0	I
src	0	I
,	0	O
differ	0	O
not	0	O
only	0	O
in	0	O
oncogenic	0	O
potential	0	O
but	0	O
also	0	O
in	0	O
their	0	O
subcellular	0	O
localization	0	O
and	0	O
cytoskeletal	0	O
binding	0	O
ability	0	O
.	0	O
pp60v	0	B
-	0	I
src	0	I
has	0	O
been	0	O
shown	0	O
to	0	O
stably	0	O
associate	0	O
with	0	O
a	0	O
detergent	0	O
-	0	O
insoluble	0	O
cytoskeletal	0	O
matrix	0	O
,	0	O
whereas	0	O
pp60c	0	B
-	0	I
src	0	I
does	0	O
not	0	O
.	0	O


MEF	0	B
and	0	O
AML1B	0	B
synergistically	0	O
transactivated	0	O
an	0	O
interleukin	0	B
3	0	I
promoter	0	I
reporter	0	I
gene	0	I
construct	0	I
,	0	O
yet	0	O
the	0	O
activating	0	O
activity	0	O
of	0	O
MEF	0	B
was	0	O
abolished	0	O
when	0	O
MEF	0	B
was	0	O
coexpressed	0	O
with	0	O
AML1	0	B
/	0	O
ETO	1	B
.	0	O


Each	0	O
dietary	0	O
treatment	0	O
was	0	O
fed	0	O
to	0	O
six	0	O
pen	0	O
replicates	0	O
of	0	O
five	0	O
chicks	0	O
per	0	O
pen	0	O
for	0	O
21	0	O
d	0	O
.	0	O


Association	1	O
of	0	O
stress	0	O
during	0	O
delivery	0	O
with	0	O
increased	0	O
numbers	0	O
of	0	O
nucleated	0	O
cells	0	O
and	0	O
hematopoietic	0	O
progenitor	0	O
cells	0	O
in	0	O
umbilical	0	O
cord	0	O
blood	0	O
.	0	O


In	1	O
humans	0	O
,	0	O
three	0	O
tissue	0	B
-	0	I
specific	0	I
plastin	0	I
isoforms	0	I
have	0	O
been	0	O
identified	0	O
.	0	O


By	0	O
contrast	0	O
,	0	O
PvirE	0	B
or	0	O
Plac	0	B
promoter	0	I
constructs	0	I
yielded	0	O
functional	0	O
VirE2	0	B
only	0	O
if	0	O
virE1	0	B
was	0	O
coexpressed	0	O
with	0	O
virE2	0	B
.	0	O


Histamine	1	O
-	0	O
2	0	O
blockade	0	O
in	0	O
psoriasis	0	O


Recombinant	1	B
human	0	I
TFIID	0	I
supported	0	O
weak	0	O
basal	0	O
transcription	0	O
in	0	O
heat	0	O
-	0	O
treated	0	O
nuclear	0	O
extracts	0	O
whereas	0	O
a	0	O
partially	0	O
purified	0	O
TFIID	0	B
fraction	0	O
from	0	O
HeLa	0	O
cells	0	O
reconstituted	0	O
a	0	O
maximal	0	O
level	0	O
of	0	O
transcription	0	O
.	0	O


The	0	O
novel	0	O
hematopoietic	0	B
growth	0	I
factor	0	I
FLT3	0	I
ligand	0	I
(	0	O
FL	1	B
)	0	O
is	0	O
the	0	O
cognate	0	O
ligand	0	O
for	0	O
the	0	O
FLT3	0	B
,	0	O
tyrosine	0	B
kinase	0	I
receptor	0	I
(	0	O
R	1	B
),	0	O
also	0	O
referred	0	O
to	0	O
as	0	O
FLK	0	B
-	0	I
2	0	I
and	0	O
STK	0	B
-	0	I
1	0	I
.	0	O


Mobilization	1	O
with	0	O
cyclophosphamide	0	O
and	0	O
granulocyte	0	B
-	0	I
colony	0	I
stimulating	0	I
factor	0	I
was	0	O
effective	0	O
in	0	O
terms	0	O
of	0	O
CD34	1	B
+	0	I
cell	0	O
shift	0	O
to	0	O
peripheral	0	O
blood	0	O
and	0	O
the	0	O
good	0	O
quality	0	O
autograft	0	O
reliably	0	O
led	0	O
to	0	O
haematopoetic	0	O
recovery	0	O
after	0	O
megachemotherapy	0	O
.	0	O


The	0	O
present	0	O
study	0	O
sought	0	O
to	0	O
develop	0	O
an	0	O
equation	0	O
to	0	O
estimate	0	O
VO2peak	0	O
in	0	O
peripheral	0	O
arterial	0	O
occlusive	0	O
disease	0	O
(	0	O
PAOD	0	O
)	0	O
patients	0	O
with	0	O
intermittent	0	O
claudication	0	O
and	0	O
to	0	O
determine	0	O
independent	0	O
predictors	0	O
of	0	O
VO2peak	0	O
in	0	O
this	0	O
population	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
correlate	0	O
Dox	0	O
effects	0	O
on	0	O
cell	0	O
cycle	0	O
with	0	O
changes	0	O
of	0	O
E2F	0	B
/	0	O
DP	1	B
complexes	0	O
and	0	O
activity	0	O
in	0	O
differentiating	0	O
C2C12	0	O
myocytes	0	O
.	0	O


The	0	O
degree	0	O
of	0	O
lung	0	O
destruction	0	O
,	0	O
reflected	0	O
by	0	O
interstitial	0	O
hemorrhage	0	O
was	0	O
assessed	0	O
by	0	O
measuring	0	O
hemoglobin	0	B
content	0	O
in	0	O
the	0	O
fluid	0	O
of	0	O
the	0	O
lavaged	0	O
lungs	0	O
.	0	O


Here	0	O
we	0	O
review	0	O
progress	0	O
to	0	O
date	0	O
in	0	O
this	0	O
area	0	O
.	0	O


Mucoepidermoid	1	O
and	0	O
acinous	0	O
cell	0	O
carcinomas	0	O
of	0	O
salivary	0	O
tissues	0	O
.	0	O


Approximately	0	O
50	0	O
%	0	O
of	0	O
the	0	O
ribosomal	0	O
DNA	1	O
(	0	O
rDNA	0	O
)	0	O
units	0	O
of	0	O
Drosophila	1	O
melanogaster	0	O
are	0	O
inactivated	0	O
by	0	O
two	0	O
different	0	O
28	0	B
S	1	I
RNA	1	I
ribosomal	0	I
gene	0	I
insertions	0	O
(	0	O
type	0	O
I	1	O
and	0	O
type	0	O
II	0	O
).	0	O


Transcriptional	1	O
analysis	0	O
of	0	O
a	0	O
series	0	O
of	0	O
deletion	0	O
mutants	0	O
of	0	O
the	0	O
gene	0	O
in	0	O
the	0	O
nuclear	0	O
extracts	0	O
prepared	0	O
from	0	O
the	0	O
middle	0	O
silk	0	O
gland	0	O
of	0	O
2	0	O
-	0	O
day	0	O
-	0	O
old	0	O
fifth	0	O
instar	0	O
larvae	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
multiple	0	O
cis	0	O
-	0	O
regulatory	0	O
elements	0	O
located	0	O
both	0	O
upstream	0	O
and	0	O
downstream	0	O
of	0	O
the	0	O
initiation	0	O
site	0	O
.	0	O


Deglycosylation	0	O
with	0	O
endoglycosidase	0	B
H	1	I
showed	0	O
that	0	O
the	0	O
mutant	0	O
receptors	0	O
had	0	O
mainly	0	O
high	0	O
-	0	O
mannose	0	O
oligosaccharide	0	O
chains	0	O
.	0	O


Self	1	O
-	0	O
heating	0	O
after	0	O
deep	0	O
hypothermia	0	O
(	0	O
20	0	O
degrees	0	O
C	1	O
)	0	O
causes	0	O
a	0	O
considerable	0	O
increase	0	O
in	0	O
the	0	O
brain	0	O
tissues	0	O
glutaminase	0	B
activity	0	O
at	0	O
all	0	O
studied	0	O
incubation	0	O
temperatures	0	O
(	0	O
37	0	O
,	0	O
30	0	O
,	0	O
20	0	O
and	0	O
10	0	O
degrees	0	O
C	1	O
)	0	O
as	0	O
compared	0	O
to	0	O
control	0	O
rats	0	O
and	0	O
rats	0	O
under	0	O
hypothermia	0	O
.	0	O


Low	0	O
-	0	O
dose	0	O
D	1	O
(	0	O
0	0	O
.	0	O
4	0	O
-	0	O
0	0	O
.	0	O
8	0	O
mg	0	O
)	0	O
and	0	O
DB	1	O
(	0	O
1	0	O
.	0	O
0	0	O
-	0	O
5	0	O
.	0	O
0	0	O
mg	0	O
)	0	O
did	0	O
not	0	O
significantly	0	O
alter	0	O
any	0	O
parameter	0	O
from	0	O
control	0	O
.	0	O


Quantum	1	O
-	0	O
statistical	0	O
theory	0	O
of	0	O
high	0	O
-	0	O
field	0	O
transport	0	O
phenomena	0	O
.	0	O


Luteinizing	0	B
hormone	0	I
-	0	I
releasing	0	I
hormone	0	I
analog	0	O
therapy	0	O
of	0	O
uterine	0	O
fibroid	0	O
:	0	O
analysis	0	O
of	0	O
results	0	O
obtained	0	O
with	0	O
buserelin	0	O
administered	0	O
intranasally	0	O
and	0	O
goserelin	0	O
administered	0	O
subcutaneously	0	O
as	0	O
a	0	O
monthly	0	O
depot	0	O
.	0	O


Dipetalonema	1	O
(	0	O
Alafilaria	0	O
)	0	O
hydrochoerus	0	O
subgen	0	O
.	0	O
et	0	O
sp	0	O
.	0	O
n	0	O
.	0	O


The	0	O
epidemic	0	O
occurred	0	O
in	0	O
a	0	O
group	0	O
of	0	O
26	0	O
community	0	O
members	0	O
(	0	O
23	0	O
men	0	O
and	0	O
3	0	O
women	0	O
,	0	O
mean	0	O
age	0	O
,	0	O
28	0	O
.	0	O
9	0	O
--	0	O
3	0	O
years	0	O
)	0	O
living	0	O
and	0	O
working	0	O
together	0	O
,	0	O
who	0	O
underwent	0	O
acute	0	O
and	0	O
convalescent	0	O
serologic	0	O
tests	0	O
for	0	O
Mycoplasma	1	O
pneumoniae	0	O
,	0	O
Legionella	1	O
pneumophila	0	O
,	0	O
cytomegalovirus	0	O
,	0	O
adenovirus	0	O
,	0	O
Coxiella	1	O
burnetii	0	O
,	0	O
and	0	O
Chlamydia	1	O
pneumoniae	0	O
.	0	O


Formation	1	O
of	0	O
hyphae	0	O
and	0	O
chlamydospores	0	O
by	0	O
Cryptococcus	1	O
laurentii	0	O
.	0	O


The	0	O
RAS	1	B
-	0	O
cyclic	0	B
AMP	1	I
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
cAPK	0	I
pathway	0	O
prevents	0	O
the	0	O
UAS	0	O
activity	0	O
of	0	O
IREu	0	B
in	0	O
the	0	O
presence	0	O
of	0	O
glucose	0	O
as	0	O
the	0	O
sole	0	O
carbon	0	O
source	0	O
,	0	O
while	0	O
the	0	O
transcriptional	0	O
activators	0	O
Msn2p	0	B
and	0	O
Msn4p	0	B
promote	0	O
the	0	O
UAS	0	O
activity	0	O
of	0	O
this	0	O
repeat	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
acetate	0	O
.	0	O


The	0	O
ORF	1	O
4	0	O
gene	0	O
was	0	O
minimally	0	O
active	0	O
,	0	O
whereas	0	O
the	0	O
ORF	1	O
62	0	O
gene	0	O
gave	0	O
twofold	0	O
induction	0	O
;	0	O
both	0	O
genes	0	O
,	0	O
acting	0	O
together	0	O
,	0	O
gave	0	O
fivefold	0	O
induction	0	O
.	0	O


The	0	O
results	0	O
of	0	O
this	0	O
study	0	O
demonstrate	0	O
that	0	O
strongyloidiasis	0	O
was	0	O
the	0	O
cause	0	O
of	0	O
sudden	0	O
death	0	O
.	0	O


Experiments	0	O
were	0	O
performed	0	O
in	0	O
which	0	O
brain	0	O
-	0	O
stem	0	O
auditory	0	O
-	0	O
evoked	0	O
responses	0	O
(	0	O
BAERs	0	O
)	0	O
were	0	O
elicited	0	O
by	0	O
two	0	O
types	0	O
of	0	O
pseudorandom	0	O
pulse	0	O
trains	0	O
:	0	O
maximum	0	O
length	0	O
sequences	0	O
(	0	O
MLS	1	O
)	0	O
and	0	O
Legendre	0	O
sequences	0	O
(	0	O
LGS	0	O
).	0	O


Prenatal	1	O
diagnosis	0	O
of	0	O
galactosaemia	0	O
.	0	O


The	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
is	0	O
78	0	O
.	0	O
0	0	O
%	0	O
identical	0	O
to	0	O
the	0	O
cytoplasmic	0	B
dynein	0	I
heavy	0	I
chain	0	I
of	0	I
Neurospora	1	I
crassa	0	I
,	0	O
70	0	O
.	0	O
2	0	O
%	0	O
identical	0	O
to	0	O
that	0	O
of	0	O
Aspergillus	1	O
nidulans	0	O
and	0	O
24	0	O
.	0	O
8	0	O
%	0	O
identical	0	O
to	0	O
that	0	O
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Side	1	O
effect	0	O
including	0	O
subjective	0	O
and	0	O
objective	0	O
symptoms	0	O
were	0	O
strictly	0	O
evaluated	0	O
in	0	O
163	0	O
cases	0	O
(	0	O
KS	1	O
-	0	O
R1	0	O
group	0	O
in	0	O
83	0	O
cases	0	O
,	0	O
oral	0	O
group	0	O
in	0	O
80	0	O
cases	0	O
),	0	O
but	0	O
the	0	O
incidence	0	O
rate	0	O
which	0	O
was	0	O
22	0	O
.	0	O
9	0	O
%	0	O
for	0	O
the	0	O
KS	1	O
-	0	O
R1	0	O
group	0	O
and	0	O
23	0	O
.	0	O
8	0	O
%	0	O
for	0	O
the	0	O
oral	0	O
group	0	O
showed	0	O
no	0	O
significant	0	O
difference	0	O
.	0	O


In	1	O
gel	0	O
mobility	0	O
shift	0	O
assays	0	O
,	0	O
we	0	O
found	0	O
no	0	O
evidence	0	O
for	0	O
VDR	0	B
-	0	O
TR	1	B
heterodimer	0	O
interaction	0	O
with	0	O
any	0	O
tested	0	O
element	0	O
.	0	O


The	0	O
GRE	0	O
at	0	O
nucleotide	0	O
7640	0	O
is	0	O
a	0	O
composite	0	O
GRE	0	O
(	0	O
cGRE	0	O
)	0	O
containing	0	O
an	0	O
overlapping	0	O
activator	0	B
protein	0	I
-	0	I
1	0	I
(	0	O
AP	1	B
-	0	I
1	0	I
)	0	O
motif	0	O
for	0	O
the	0	O
c	0	B
-	0	I
jun	0	I
homodimer	0	I
and	0	O
c	0	B
-	0	I
jun	0	I
/	0	O
c	0	B
-	0	I
fos	0	I
heterodimer	0	O
.	0	O


Among	0	O
blood	0	O
donors	0	O
in	0	O
the	0	O
Republic	0	O
of	0	O
Serbia	0	O
,	0	O
regardless	0	O
the	0	O
number	0	O
of	0	O
blood	0	O
donations	0	O
,	0	O
the	0	O
percentage	0	O
of	0	O
female	0	O
donors	0	O
is	0	O
significantly	0	O
lower	0	O
compared	0	O
to	0	O
the	0	O
percentage	0	O
of	0	O
male	0	O
blood	0	O
donors	0	O
.	0	O


Interspecific	0	O
backcross	0	O
analysis	0	O
using	0	O
progeny	0	O
derived	0	O
from	0	O
matings	0	O
of	0	O
(	0	O
C57BL	0	O
/	0	O
6J	0	O
x	0	O
Mus	1	O
spretus	0	O
)	0	O
F1	0	O
x	0	O
C57BL	0	O
/	0	O
6J	0	O
mice	0	O
indicates	0	O
that	0	O
the	0	O
thrombospondin	0	B
gene	0	I
is	0	O
tightly	0	O
linked	0	O
to	0	O
the	0	O
Fshb	0	B
,	0	O
Actcl	0	B
,	0	O
Ltk	0	B
,	0	O
and	0	O
B2M	0	B
loci	0	I
on	0	O
murine	0	O
chromosome	0	O
2	0	O
.	0	O


In	1	O
cell	0	O
lines	0	O
transformed	0	O
by	0	O
BCR	0	B
/	0	O
ABL	0	B
,	0	O
CRKL	0	B
was	0	O
tyrosine	0	O
phosphorylated	0	O
,	0	O
while	0	O
CRK	0	B
was	0	O
not	0	O
.	0	O


Sex	1	O
of	0	O
calf	0	O
(	0	O
variate	0	O
2	0	O
)	0	O
was	0	O
associated	0	O
most	0	O
closely	0	O
with	0	O
width	0	O
of	0	O
muzzle	0	O
and	0	O
head	0	O
.	0	O


There	0	O
were	0	O
no	0	O
significant	0	O
differences	0	O
in	0	O
EF	1	O
between	0	O
the	0	O
two	0	O
studies	0	O
,	0	O
both	0	O
at	0	O
rest	0	O
(	0	O
56	0	O
.	0	O
0	0	O
+/-	0	O
13	0	O
.	0	O
8	0	O
%	0	O
vs	0	O
58	0	O
.	0	O
2	0	O
+/-	0	O
11	0	O
.	0	O
7	0	O
%,	0	O
p	0	O
=	0	O
NS	1	O
)	0	O
and	0	O
with	0	O
exercise	0	O
(	0	O
51	0	O
.	0	O
1	0	O
+/-	0	O
17	0	O
.	0	O
6	0	O
%	0	O
vs	0	O
54	0	O
.	0	O
3	0	O
+/-	0	O
17	0	O
.	0	O
6	0	O
%,	0	O
p	0	O
=	0	O
NS	1	O
)	0	O
and	0	O
a	0	O
highly	0	O
significant	0	O
correlation	0	O
was	0	O
shown	0	O
between	0	O
the	0	O
two	0	O
groups	0	O
of	0	O
values	0	O
(	0	O
rest	0	O
r	0	O
=	0	O
0	0	O
.	0	O
90	0	O
,	0	O
exercise	0	O
r	0	O
=	0	O
0	0	O
.	0	O
93	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


Emergency	1	O
treatment	0	O
of	0	O
facial	0	O
and	0	O
maxillary	0	O
/	0	O
mandibular	0	O
injuries	0	O


Age	1	O
at	0	O
POI	0	O
and	0	O
asymptote	0	O
were	0	O
achieved	0	O
later	0	O
for	0	O
Line	1	O
RBC2	0	O
than	0	O
for	0	O
Line	1	O
F	1	O
.	0	O


These	0	O
results	0	O
support	0	O
the	0	O
hypothesis	0	O
that	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
tryptophan	0	O
the	0	O
ribosome	0	O
translating	0	O
tnaC	0	B
blocks	0	O
Rho	1	B
'	0	O
s	0	O
access	0	O
to	0	O
the	0	O
boxA	0	B
and	0	O
rut	0	B
sites	0	I
,	0	O
thereby	0	O
preventing	0	O
transcription	0	O
termination	0	O
.	0	O


Upstream	1	O
from	0	O
the	0	O
transcription	0	O
start	0	O
point	0	O
(	0	O
tsp	0	O
),	0	O
a	0	O
nucleotide	0	O
sequence	0	O
highly	0	O
homologous	0	O
to	0	O
the	0	O
consensus	0	B
sequence	0	I
motif	0	I
for	0	I
the	0	I
sigma	0	I
35	0	I
-	0	I
recognized	0	I
promoters	0	I
was	0	O
found	0	O
.	0	O


Chem	0	O
.,	0	O
270	0	O
:	0	O
7117	0	O
-	0	O
7124	0	O
,	0	O
1995	0	O
;	0	O
and	0	O
MT	1	O
Hartsough	0	O
et	0	O
al	0	O
.,	0	O
J	1	O
.	0	O


Eight	0	O
patients	0	O
received	0	O
1	0	O
.	0	O
5	0	O
mg	0	O
of	0	O
adefovir	0	O
dipivoxil	0	O
per	0	O
kg	0	O
of	0	O
body	0	O
weight	0	O
,	0	O
and	0	O
six	0	O
patients	0	O
received	0	O
3	0	O
.	0	O
0	0	O
mg	0	O
of	0	O
adefovir	0	O
dipivoxil	0	O
per	0	O
kg	0	O
.	0	O


We	0	O
examined	0	O
the	0	O
binding	0	O
of	0	O
purified	0	O
T3	1	B
receptor	0	I
alpha	0	I
(	0	O
T3R	0	B
alpha	0	I
),	0	O
overexpressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
,	0	O
to	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
up	0	O
and	0	O
down	0	O
mutations	0	O
of	0	O
the	0	O
rGH	0	B
T3RE	0	I
to	0	O
evaluate	0	O
whether	0	O
transcriptional	0	O
potency	0	O
correlates	0	O
with	0	O
changes	0	O
in	0	O
T3R	0	B
binding	0	O
.	0	O


Teratogenic	1	O
effects	0	O
of	0	O
actinomycin	0	O
D	1	O
in	0	O
rats	0	O


Because	0	O
decreases	0	O
in	0	O
the	0	O
disfluency	0	O
rates	0	O
of	0	O
stutterers	0	O
were	0	O
observed	0	O
during	0	O
the	0	O
presentation	0	O
of	0	O
all	0	O
three	0	O
stimulus	0	O
words	0	O
,	0	O
the	0	O
data	0	O
failed	0	O
to	0	O
support	0	O
the	0	O
operant	0	O
model	0	O
.	0	O


Structure	1	O
,	0	O
promoter	0	O
analysis	0	O
and	0	O
chromosomal	0	O
assignment	0	O
of	0	O
the	0	O
human	0	B
APEX	1	I
gene	0	I
.	0	O


Patients	0	O
with	0	O
psychotropic	0	O
drugs	0	O
showed	0	O
significantly	0	O
higher	0	O
PRL	1	B
levels	0	O
.	0	O


The	0	O
present	0	O
study	0	O
describes	0	O
the	0	O
cell	0	O
volume	0	O
dynamics	0	O
in	0	O
intact	0	O
rat	0	O
hearts	0	O
,	0	O
during	0	O
ischemia	0	O
and	0	O
after	0	O
reperfusion	0	O
.	0	O


We	0	O
show	0	O
that	0	O
IL	1	B
-	0	I
6	0	I
activates	0	O
JRE	0	B
-	0	I
IL6	0	I
through	0	O
an	0	O
H7	0	O
-	0	O
sensitive	0	O
pathway	0	O
that	0	O
does	0	O
not	0	O
involve	0	O
protein	0	B
kinase	0	I
C	1	I
,	0	O
cyclic	0	B
AMP	1	I
-	0	I
dependent	0	I
kinase	0	I
,	0	O
Ca	1	B
(	0	I
2	0	I
+)-	0	I
or	0	I
calmodulin	0	I
-	0	I
dependent	0	I
kinases	0	I
,	0	O
Ras	1	B
,	0	O
Raf	0	B
-	0	I
1	0	I
,	0	O
or	0	O
NF	1	B
-	0	I
IL6	0	I
(	0	O
C	1	B
/	0	I
EBP	1	I
beta	0	I
).	0	O


Yeast	1	B
U1	0	I
snRNP	1	I
is	0	O
considerably	0	O
more	0	O
complex	0	O
than	0	O
its	0	O
metazoan	0	O
counterpart	0	O
,	0	O
which	0	O
suggests	0	O
possible	0	O
differences	0	O
between	0	O
yeast	0	O
and	0	O
metazoa	0	O
in	0	O
early	0	O
splicing	0	O
events	0	O
.	0	O


Specifically	0	O
,	0	O
recombination	0	O
at	0	O
HMR	0	B
was	0	O
used	0	O
to	0	O
produce	0	O
rings	0	O
that	0	O
lacked	0	O
the	0	O
E	1	O
and	0	O
I	1	O
silencers	0	O
.	0	O


SCOB	0	O
testing	0	O
of	0	O
food	0	O
-	0	O
restricted	0	O
animals	0	O
,	0	O
using	0	O
a	0	O
multiple	0	O
fixed	0	O
ratio	0	O
(	0	O
FR	1	O
)/	0	O
fixed	0	O
interval	0	O
(	0	O
FI	0	O
)	0	O
schedule	0	O
(	0	O
FR20	0	O
:	0	O
FI120	0	O
),	0	O
was	0	O
conducted	0	O
prior	0	O
to	0	O
each	0	O
exposure	0	O
to	0	O
maintain	0	O
the	0	O
operant	0	O
behavior	0	O
;	0	O
the	0	O
data	0	O
from	0	O
Weeks	0	O
-	0	O
1	0	O
,	0	O
4	0	O
,	0	O
8	0	O
,	0	O
and	0	O
13	0	O
were	0	O
evaluated	0	O
for	0	O
evidence	0	O
of	0	O
neurotoxicity	0	O
.	0	O


Cat	1	B
proteins	0	I
are	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
when	0	O
co	0	O
-	0	O
expressed	0	O
in	0	O
cells	0	O
with	0	O
the	0	O
focal	0	B
adhesion	0	I
kinase	0	I
Fak	0	I
and	0	O
Src	1	B
.	0	O


Micro	0	O
high	0	O
-	0	O
performance	0	O
liquid	0	O
chromatographic	0	O
system	0	O
with	0	O
micro	0	O
precolumn	0	O
and	0	O
dual	0	O
electrochemical	0	O
detector	0	O
for	0	O
direct	0	O
injection	0	O
analysis	0	O
of	0	O
catecholamines	0	O
in	0	O
body	0	O
fluids	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
a	0	O
catalytically	0	O
inactive	0	O
version	0	O
of	0	O
the	0	O
Src	1	B
family	0	I
member	0	O
,	0	O
Lck	0	B
(	0	O
lymphoid	0	B
cell	0	I
kinase	0	I
),	0	O
was	0	O
expressed	0	O
,	0	O
purified	0	O
,	0	O
and	0	O
evaluated	0	O
as	0	O
a	0	O
Csk	0	B
substrate	0	O
.	0	O


Homodimers	0	O
of	0	O
the	0	O
three	0	O
proteins	0	O
specifically	0	O
recognize	0	O
the	0	O
G	1	O
-	0	O
box	0	O
motif	0	O
,	0	O
with	0	O
GBF1	0	B
and	0	O
GBF3	0	B
binding	0	O
symmetrically	0	O
to	0	O
this	0	O
palindromic	0	O
sequence	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
sought	0	O
to	0	O
test	0	O
the	0	O
hypothesis	0	O
that	0	O
,	0	O
when	0	O
equal	0	O
volumes	0	O
are	0	O
administered	0	O
intrathecally	0	O
,	0	O
significant	0	O
differences	0	O
exist	0	O
in	0	O
the	0	O
potential	0	O
to	0	O
three	0	O
commonly	0	O
used	0	O
anesthetic	0	O
solutions	0	O
to	0	O
induce	0	O
sensory	0	O
impairment	0	O
.	0	O


4	0	O
Five	0	O
patients	0	O
died	0	O
within	0	O
one	0	O
month	0	O
of	0	O
captopril	0	O
and	0	O
five	0	O
between	0	O
four	0	O
and	0	O
seven	0	O
months	0	O
,	0	O
three	0	O
of	0	O
whom	0	O
had	0	O
improved	0	O
to	0	O
class	0	O
IIM	0	O
and	0	O
one	0	O
to	0	O
IIS	0	O
before	0	O
death	0	O
.	0	O


The	0	O
genes	0	O
encoding	0	O
the	0	O
transcription	0	B
factor	0	I
yTAFII60	0	I
,	0	O
the	0	O
G4p1	0	B
protein	0	I
and	0	O
a	0	O
putative	0	O
glucose	0	O
transporter	0	O
are	0	O
contained	0	O
in	0	O
a	0	O
12	0	O
.	0	O
3	0	O
kb	0	O
DNA	1	O
fragment	0	O
on	0	O
the	0	O
left	0	O
arm	0	O
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
chromosome	0	O
VII	0	O
.	0	O


A	1	O
cohort	0	O
of	0	O
Swedish	0	O
children	0	O
was	0	O
monitored	0	O
from	0	O
6	0	O
months	0	O
to	0	O
11	0	O
years	0	O
of	0	O
age	0	O
.	0	O


In	1	O
Denmark	0	O
only	0	O
1	0	O
-	0	O
3	0	O
cases	0	O
of	0	O
transfusion	0	O
-	0	O
associated	0	O
hepatitis	0	O
NANB	0	O
(	0	O
TAH	0	O
-	0	O
NANB	0	O
)	0	O
are	0	O
registered	0	O
annually	0	O
or	0	O
about	0	O
1	0	O
case	0	O
per	0	O
100	0	O
,	0	O
000	0	O
units	0	O
transfused	0	O
.	0	O


Small	0	B
GTPases	0	I
of	0	O
the	0	O
Ypt	0	B
/	0	O
Rab	0	B
family	0	O
are	0	O
involved	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
vesicular	0	O
transport	0	O
.	0	O


The	0	O
hematopoietic	0	B
colony	0	I
-	0	I
stimulating	0	I
factors	0	I
(	0	O
CSF	1	B
)	0	O
have	0	O
been	0	O
introduced	0	O
into	0	O
clinical	0	O
practice	0	O
as	0	O
additional	0	O
supportive	0	O
measures	0	O
that	0	O
can	0	O
reduce	0	O
the	0	O
incidence	0	O
of	0	O
infectious	0	O
complications	0	O
in	0	O
patients	0	O
with	0	O
cancer	0	O
and	0	O
neutropenia	0	O
.	0	O


The	0	O
two	0	O
IL6	0	B
mRNA	1	I
species	0	O
are	0	O
generated	0	O
by	0	O
alternative	0	O
polyadenylation	0	O
at	0	O
sites	0	O
separated	0	O
by	0	O
a	0	O
distance	0	O
of	0	O
1	0	O
.	0	O
2	0	O
kilobases	0	O
.	0	O


A	1	O
receptor	0	B
-	0	I
like	0	I
protein	0	I
kinase	0	I
,	0	O
OsPK10	0	B
,	0	O
has	0	O
been	0	O
cloned	0	O
from	0	O
rice	0	O
(	0	O
Oryza	1	O
sativa	0	O
).	0	O


Mycotoxins	0	O
in	0	O
feeds	0	O
and	0	O
foods	0	O
.	0	O


To	1	O
identify	0	O
factors	0	O
that	0	O
may	0	O
modify	0	O
the	0	O
heterosexual	0	O
transmission	0	O
of	0	O
human	0	O
T	1	O
cell	0	O
leukemia	0	O
/	0	O
lymphoma	0	O
virus	0	O
type	0	O
I	1	O
(	0	O
HTLV	0	O
-	0	O
I	1	O
),	0	O
534	0	O
married	0	O
couples	0	O
enrolled	0	O
in	0	O
the	0	O
Miyazaki	0	O
Cohort	1	O
Study	1	O
between	0	O
November	0	O
1984	0	O
and	0	O
April	0	O
1989	0	O
were	0	O
studied	0	O
:	0	O
95	0	O
husband	0	O
HTLV	0	O
-	0	O
I	1	O
-	0	O
seropositive	0	O
(	0	O
H	1	O
+)/	0	O
wife	0	O
seropositive	0	O
(	0	O
W	1	O
+),	0	O
33	0	O
H	1	O
+/	0	O
W	1	O
-,	0	O
64	0	O
H	1	O
-/	0	O
W	1	O
+,	0	O
and	0	O
342	0	O
H	1	O
-/	0	O
W	1	O
-.	0	O


Using	0	O
anchored	0	O
PCR	1	O
,	0	O
a	0	O
VL	1	B
element	0	I
rearranged	0	O
to	0	O
CL2	0	B
was	0	O
isolated	0	O
.	0	O


Ion	1	O
injection	0	O
.	0	O


Therefore	0	O
,	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
sequence	0	O
of	0	O
the	0	O
purified	0	O
carA	0	B
product	0	I
is	0	O
identical	0	O
to	0	O
that	0	O
derived	0	O
from	0	O
the	0	O
nucleotide	0	O
sequence	0	O
in	0	O
both	0	O
organisms	0	O
,	0	O
P	1	O
.	0	O
stutzeri	0	O
having	0	O
four	0	O
additional	0	O
amino	0	O
acids	0	O
.	0	O


Mechanism	1	O
of	0	O
activation	0	O
of	0	O
the	0	O
vav	0	B
protooncogene	0	I
.	0	O
vav	0	B
is	0	O
a	0	O
human	0	O
locus	0	O
that	0	O
appears	0	O
to	0	O
be	0	O
specifically	0	O
expressed	0	O
in	0	O
cells	0	O
of	0	O
hematopoietic	0	O
origin	0	O
regardless	0	O
of	0	O
their	0	O
differentiation	0	O
lineage	0	O
.	0	O


The	0	O
action	0	O
of	0	O
nef	0	B
was	0	O
specific	0	O
to	0	O
the	0	O
LTR	1	O
,	0	O
as	0	O
expression	0	O
of	0	O
nef	0	B
had	0	O
no	0	O
effect	0	O
on	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
simian	0	O
virus	0	O
40	0	O
,	0	O
c	0	B
-	0	I
fms	0	I
,	0	O
urokinase	0	B
plasminogen	0	I
activator	0	I
,	0	O
or	0	O
type	0	B
5	0	I
acid	0	I
phosphatase	0	I
promoter	0	I
.	0	O
trans	0	O
-	0	O
activating	0	O
activity	0	O
was	0	O
also	0	O
manifested	0	O
by	0	O
a	0	O
frameshift	0	O
mutant	0	O
expressing	0	O
only	0	O
the	0	O
first	0	O
35	0	O
amino	0	O
acids	0	O
of	0	O
the	0	O
protein	0	O
.	0	O


When	0	O
considered	0	O
with	0	O
the	0	O
known	0	O
neurotoxic	0	O
effects	0	O
on	0	O
children	0	O
of	0	O
"	0	O
low	0	O
levels	0	O
"	0	O
of	0	O
exposure	0	O
to	0	O
lead	0	O
,	0	O
these	0	O
results	0	O
also	0	O
suggest	0	O
that	0	O
either	0	O
an	0	O
excessively	0	O
narrow	0	O
margin	0	O
of	0	O
safety	0	O
or	0	O
insufficient	0	O
safety	0	O
is	0	O
provided	0	O
by	0	O
present	0	O
U	1	O
.	0	O
S	1	O
.	0	O
guidelines	0	O
,	0	O
which	0	O
classify	0	O
an	0	O
elevated	0	O
blood	0	O
lead	0	O
concentration	0	O
as	0	O
25	0	O
micrograms	0	O
/	0	O
dl	0	O
or	0	O
greater	0	O
.	0	O


Observers	0	O
with	0	O
brain	0	O
injury	0	O
and	0	O
control	0	O
participants	0	O
performed	0	O
a	0	O
vigilance	0	O
task	0	O
during	0	O
which	0	O
they	0	O
received	0	O
periodic	0	O
whiffs	0	O
of	0	O
unscented	0	O
air	0	O
or	0	O
air	0	O
scented	0	O
with	0	O
peppermint	0	O
.	0	O


Organization	1	O
of	0	O
the	0	O
bovine	0	O
gene	0	O
encoding	0	O
the	0	O
endothelial	0	B
nitric	0	I
oxide	0	I
synthase	0	I
.	0	O


Two	0	O
hundred	0	O
forty	0	O
-	0	O
three	0	O
patients	0	O
have	0	O
received	0	O
WR	0	O
-	0	O
2721	0	O
in	0	O
Phase	1	O
I	1	O
-	0	O
II	0	O
studies	0	O
.	0	O


This	0	O
conclusion	0	O
is	0	O
based	0	O
on	0	O
the	0	O
observations	0	O
of	0	O
the	0	O
immunologic	0	O
changes	0	O
that	0	O
characterize	0	O
the	0	O
acute	0	O
stages	0	O
of	0	O
illness	0	O
as	0	O
well	0	O
as	0	O
on	0	O
the	0	O
demonstrated	0	O
association	0	O
with	0	O
toxin	0	O
-	0	O
producing	0	O
bacteria	0	O
in	0	O
the	0	O
pharynx	0	O
and	0	O
gastrointestinal	0	O
tract	0	O
.	0	O


Site	1	O
-	0	O
directed	0	O
mutagenesis	0	O
showed	0	O
that	0	O
two	0	O
adjacent	0	O
SP1	0	B
sites	0	I
proximal	0	O
to	0	O
exon	0	O
1	0	O
were	0	O
equally	0	O
important	0	O
in	0	O
sustaining	0	O
basal	0	O
promoter	0	O
activity	0	O
.	0	O


There	0	O
was	0	O
no	0	O
correlation	0	O
between	0	O
serum	0	B
LH	1	I
and	0	O
chronological	0	O
or	0	O
bone	0	O
age	0	O
in	0	O
this	0	O
age	0	O
group	0	O
,	0	O
which	0	O
suggests	0	O
that	0	O
the	0	O
correlation	0	O
found	0	O
is	0	O
not	0	O
due	0	O
to	0	O
age	0	O
-	0	O
related	0	O
parallel	0	O
phenomena	0	O
.	0	O


Spores	0	O
from	0	O
Rhizopus	1	O
stolonifer	0	O
were	0	O
suspended	0	O
in	0	O
distilled	0	O
water	0	O
(	0	O
1	0	O
x	0	O
10	0	O
(	0	O
6	0	O
)	0	O
spores	0	O
/	0	O
mL	1	O
)	0	O
and	0	O
used	0	O
as	0	O
starter	0	O
.	0	O


Truncated	0	B
ICSBP	0	I
lacking	0	O
the	0	O
first	0	O
33	0	O
amino	0	O
-	0	O
terminal	0	O
amino	0	O
acids	0	O
fails	0	O
to	0	O
bind	0	O
to	0	O
the	0	O
ICS	1	B
,	0	O
indicating	0	O
that	0	O
at	0	O
least	0	O
part	0	O
of	0	O
the	0	O
DNA	1	O
binding	0	O
domain	0	O
is	0	O
located	0	O
within	0	O
the	0	O
well	0	O
conserved	0	O
amino	0	O
terminus	0	O
.	0	O


During	0	O
a	0	O
disease	0	O
remission	0	O
there	0	O
was	0	O
an	0	O
increase	0	O
in	0	O
GAG	1	O
secretion	0	O
with	0	O
urine	0	O
,	0	O
linked	0	O
with	0	O
hyperheparinuria	0	O
(	0	O
13	0	O
.	0	O
1	0	O
-	0	O
fold	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


A	1	O
significant	0	O
degree	0	O
of	0	O
homology	0	O
was	0	O
also	0	O
found	0	O
among	0	O
these	0	O
genes	0	O
and	0	O
the	0	O
Mtase	0	B
gene	0	I
of	0	O
related	0	O
phage	0	O
SPR	0	O
,	0	O
which	0	O
codes	0	O
for	0	O
an	0	O
enzyme	0	O
with	0	O
different	0	O
modification	0	O
specificity	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
we	0	O
observed	0	O
a	0	O
great	0	O
regeneration	0	O
ability	0	O
following	0	O
mechanical	0	O
injury	0	O
in	0	O
the	0	O
nasal	0	O
mucosa	0	O
.	0	O


A	1	O
mutant	0	O
in	0	O
the	0	O
AAV	1	O
terminal	0	O
resolution	0	O
site	0	O
(	0	O
trs	0	O
)	0	O
was	0	O
defective	0	O
for	0	O
DNA	1	O
replication	0	O
in	0	O
the	0	O
in	0	O
vitro	0	O
assay	0	O
.	0	O


Regulation	1	O
of	0	O
myosin	0	B
phosphatase	0	I
activity	0	O
involves	0	O
changes	0	O
in	0	O
subunit	0	O
interactions	0	O
,	0	O
although	0	O
molecular	0	O
mechanisms	0	O
are	0	O
not	0	O
defined	0	O
.	0	O


Activation	1	O
of	0	O
the	0	O
SH2	0	B
-	0	I
containing	0	I
protein	0	I
tyrosine	0	I
phosphatase	0	I
,	0	O
SH	1	B
-	0	I
PTP2	0	I
,	0	O
by	0	O
phosphotyrosine	0	O
-	0	O
containing	0	O
peptides	0	O
derived	0	O
from	0	O
insulin	0	B
receptor	0	I
substrate	0	I
-	0	I
1	0	I
.	0	O


They	0	O
suggest	0	O
that	0	O
decreased	0	O
steady	0	O
-	0	O
state	0	O
levels	0	O
of	0	O
IME1	0	B
and	0	O
IME2	0	B
mRNA	1	I
were	0	O
not	0	O
merely	0	O
the	0	O
result	0	O
of	0	O
non	0	O
-	0	O
specific	0	O
adverse	0	O
affects	0	O
on	0	O
nucleic	0	O
acid	0	O
metabolism	0	O
caused	0	O
by	0	O
the	0	O
yvh1	0	B
disruption	0	O
.	0	O


The	0	O
six	0	O
commonest	0	O
causes	0	O
of	0	O
death	0	O
varied	0	O
in	0	O
the	0	O
three	0	O
ethnic	0	O
groups	0	O
.	0	O


Prenatal	1	O
exposure	0	O
to	0	O
the	0	O
fungicide	0	O
dinocap	0	O
causes	0	O
behavioral	0	O
torticollis	0	O
,	0	O
ballooning	0	O
and	0	O
cleft	0	O
palate	0	O
in	0	O
mice	0	O
,	0	O
but	0	O
not	0	O
rats	0	O
or	0	O
hamsters	0	O
.	0	O


Grasso	0	O
,	0	O
and	0	O
A	1	O
.	0	O


Interference	1	O
with	0	O
rheumatoid	0	B
factor	0	I
was	0	O
only	0	O
observed	0	O
in	0	O
the	0	O
ELISA	1	O
enzygnost	0	O
if	0	O
sera	0	O
were	0	O
not	0	O
pretreated	0	O
with	0	O
latex	0	O
adsorbents	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
such	0	O
a	0	O
putative	0	O
RNA	1	O
-	0	O
binding	0	O
domain	0	O
suggests	0	O
a	0	O
mechanism	0	O
for	0	O
the	0	O
observed	0	O
autoregulation	0	O
of	0	O
bacteriophage	0	O
T4	1	B
DNA	1	I
polymerase	0	I
synthesis	0	O
by	0	O
binding	0	O
to	0	O
its	0	O
own	0	O
mRNA	1	O
.	0	O


D	1	B
-	0	I
cyclin	0	I
-	0	O
cdk	0	B
activity	0	O
is	0	O
required	0	O
for	0	O
Rb	1	B
phosphorylation	0	O
in	0	O
v	0	B
-	0	I
Jun	1	I
-	0	O
transformed	0	O
cells	0	O
,	0	O
since	0	O
ectopic	0	O
expression	0	O
of	0	O
the	0	O
cdk4	0	B
-	0	O
and	0	O
cdk6	0	B
-	0	O
specific	0	O
inhibitor	0	O
p16	0	B
(	0	O
INK4A	0	B
)	0	O
inhibits	0	O
both	0	O
DNA	1	O
synthesis	0	O
and	0	O
cell	0	O
proliferation	0	O
.	0	O


MAIN	1	O
OUTCOME	1	O
MEASURES	0	O
:	0	O
Associations	0	O
of	0	O
factor	0	O
analysis	0	O
-	0	O
derived	0	O
syndromes	0	O
with	0	O
risk	0	O
factors	0	O
for	0	O
chemical	0	O
interactions	0	O
that	0	O
inhibit	0	O
butyrylcholinesterase	0	B
and	0	O
neuropathy	0	O
target	0	O
esterase	0	B
.	0	O


Northern	0	O
blotting	0	O
showed	0	O
that	0	O
MDMX	0	B
,	0	O
like	0	O
MDM2	0	B
,	0	O
is	0	O
expressed	0	O
in	0	O
all	0	O
tissues	0	O
tested	0	O
,	0	O
and	0	O
that	0	O
several	0	O
mRNAs	0	O
for	0	O
MDMX	0	B
can	0	O
be	0	O
detected	0	O
.	0	O


Twelve	0	O
patients	0	O
had	0	O
stage	0	O
IBG3	0	O
,	0	O
14	0	O
had	0	O
ICG1	0	O
,	0	O
9	0	O
had	0	O
ICG2	0	O
,	0	O
and	0	O
3	0	O
had	0	O
ICG3	0	O
disease	0	O
.	0	O


Bitter	1	O
cassava	0	O
contains	0	O
cyanogenic	0	O
glycosides	0	O
;	0	O
processing	0	O
breaks	0	O
them	0	O
down	0	O
to	0	O
acetone	0	O
cyanohydrin	0	O
and	0	O
hydrogen	0	O
cyanide	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
report	0	O
that	0	O
a	0	O
transfected	0	O
Chinese	0	O
hamster	0	O
ovary	0	O
(	0	O
CHO	1	O
)	0	O
cell	0	O
line	0	O
expressing	0	O
a	0	O
murine	0	B
CD4	1	I
fragment	0	I
containing	0	O
the	0	O
first	0	O
two	0	O
N	1	O
-	0	O
terminal	0	O
domains	0	O
secretes	0	O
both	0	O
monomeric	0	O
molecules	0	O
and	0	O
disulfide	0	O
-	0	O
linked	0	O
multimers	0	O
.	0	O


We	0	O
also	0	O
observed	0	O
that	0	O
the	0	O
predictive	0	O
ability	0	O
of	0	O
the	0	O
selected	0	O
attitudes	0	O
and	0	O
orientations	0	O
increased	0	O
considerably	0	O
from	0	O
1975	0	O
to	0	O
1982	0	O
.	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
was	0	O
highly	0	O
conserved	0	O
across	0	O
the	0	O
wide	0	O
range	0	O
of	0	O
eukaryotes	0	O
(	0	O
vertebrates	0	O
,	0	O
invertebrates	0	O
,	0	O
fungi	0	O
,	0	O
plants	0	O
and	0	O
protozoa	0	O
)	0	O
in	0	O
which	0	O
this	0	O
gene	0	O
has	0	O
now	0	O
been	0	O
identified	0	O
.	0	O


The	0	O
opioid	0	O
antagonist	0	O
naltrexone	0	O
(	0	O
0	0	O
.	0	O
01	0	O
-	0	O
1	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
antagonized	0	O
the	0	O
discriminative	0	O
stimulus	0	O
effects	0	O
of	0	O
heroin	0	O
,	0	O
but	0	O
naltrexone	0	O
at	0	O
doses	0	O
up	0	O
to	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
the	0	O
discriminative	0	O
stimulus	0	O
effects	0	O
of	0	O
cocaine	0	O
.	0	O


Based	0	O
on	0	O
restriction	0	O
enzyme	0	O
analysis	0	O
,	0	O
Southern	0	O
blots	0	O
,	0	O
polymerase	0	O
chain	0	O
reaction	0	O
analysis	0	O
and	0	O
DNA	1	O
sequencing	0	O
,	0	O
it	0	O
was	0	O
confirmed	0	O
that	0	O
the	0	O
three	0	O
overlapping	0	O
clones	0	O
isolated	0	O
cover	0	O
the	0	O
entire	0	O
cHO	1	B
-	0	I
1	0	I
gene	0	I
,	0	O
as	0	O
well	0	O
as	0	O
approximately	0	O
10	0	O
kb	0	O
of	0	O
the	0	O
flanking	0	O
regions	0	O
on	0	O
both	0	O
ends	0	O
.	0	O


The	0	O
expression	0	O
analysis	0	O
of	0	O
the	0	O
KlHIS4	0	B
gene	0	I
under	0	O
phosphate	0	O
starvation	0	O
or	0	O
high	0	O
adenine	0	O
supply	0	O
shows	0	O
that	0	O
factors	0	O
,	0	O
such	0	O
as	0	O
Bas1	0	B
or	0	O
Bas2	0	B
,	0	O
involved	0	O
in	0	O
the	0	O
basal	0	O
control	0	O
may	0	O
also	0	O
operate	0	O
in	0	O
a	0	O
different	0	O
way	0	O
in	0	O
K	1	O
.	0	O
lactis	0	O
.	0	O


In	1	O
vitro	0	O
transcription	0	O
extracts	0	O
from	0	O
ret1	0	B
-	0	I
1	0	I
cells	0	O
terminate	0	O
less	0	O
efficiently	0	O
at	0	O
weak	0	O
transcription	0	O
termination	0	O
signals	0	O
than	0	O
those	0	O
from	0	O
RET1	0	B
cells	0	O
,	0	O
using	0	O
a	0	O
variety	0	O
of	0	O
tRNA	1	O
templates	0	O
.	0	O


Alignment	1	O
of	0	O
the	0	O
selected	0	O
sequences	0	O
allowed	0	O
us	0	O
to	0	O
predict	0	O
a	0	O
consensus	0	O
sequence	0	O
for	0	O
binding	0	O
of	0	O
the	0	O
individual	0	O
homodimeric	0	O
Rel	0	B
-	0	I
related	0	I
proteins	0	I
,	0	O
and	0	O
DNA	1	O
-	0	O
protein	0	O
binding	0	O
analysis	0	O
of	0	O
the	0	O
selected	0	O
DNA	1	O
sequences	0	O
revealed	0	O
sequence	0	O
specificity	0	O
of	0	O
the	0	O
proteins	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
a	0	O
wild	0	O
-	0	O
type	0	O
strain	0	O
containing	0	O
a	0	O
temperature	0	B
-	0	I
sensitive	0	I
threonyl	0	I
-	0	I
tRNA	1	I
synthetase	0	I
mutation	0	I
showed	0	O
increased	0	O
thr	0	B
operon	0	I
expression	0	O
at	0	O
the	0	O
non	0	O
-	0	O
permissive	0	O
temperature	0	O
,	0	O
whereas	0	O
none	0	O
of	0	O
the	0	O
mutants	0	O
showed	0	O
any	0	O
change	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
androgenic	0	O
hormones	0	O
reduce	0	O
HDL	1	B
-	0	I
cholesterol	0	I
concentrations	0	O
and	0	O
the	0	O
HDL2	1	B
-	0	I
cholesterol	0	I
subfraction	0	O
,	0	O
possibly	0	O
by	0	O
enhancing	0	O
hepatic	0	B
triglyceride	0	I
lipase	0	I
activity	0	O
.	0	O


The	0	O
patient	0	O
had	0	O
developed	0	O
left	0	O
-	0	O
sided	0	O
low	0	O
-	0	O
frequency	0	O
tremor	0	O
and	0	O
hemidystonia	0	O
after	0	O
a	0	O
severe	0	O
head	0	O
trauma	0	O
sustained	0	O
at	0	O
15	0	O
years	0	O
of	0	O
age	0	O
.	0	O


Large	0	O
interpatient	0	O
variation	0	O
in	0	O
peak	0	O
PCZ	0	O
plasma	0	O
levels	0	O
(	0	O
91	0	O
-	0	O
3215	0	O
ng	0	O
/	0	O
ml	0	O
)	0	O
was	0	O
seen	0	O
,	0	O
with	0	O
the	0	O
plasma	0	O
half	0	O
-	0	O
life	0	O
(	0	O
t1	0	O
/	0	O
2	0	O
alpha	0	O
)	0	O
being	0	O
approximately	0	O
57	0	O
min	0	O
in	0	O
patients	0	O
given	0	O
135	0	O
-	0	O
180	0	O
mg	0	O
/	0	O
m2	0	O
PCZ	0	O
.	0	O


The	0	O
data	0	O
suggest	0	O
that	0	O
plasminogen	0	B
,	0	O
alpha	0	B
2AP	0	I
,	0	O
and	0	O
C1	1	B
-	0	I
INH	1	I
,	0	O
should	0	O
be	0	O
considered	0	O
equine	0	O
acute	0	O
-	0	O
phase	0	O
proteins	0	O
.	0	O


Cognitive	1	O
visual	0	O
dysfunction	0	O
in	0	O
a	0	O
child	0	O
with	0	O
cerebral	0	O
damage	0	O
.	0	O


Experimental	0	O
adhesion	0	O
prophylaxis	0	O
with	0	O
recombinant	0	B
tissue	0	I
plasminogen	0	I
activator	0	I
.	0	O


Methyl	1	O
formate	0	O
was	0	O
used	0	O
as	0	O
the	0	O
solvent	0	O
of	0	O
biodegradable	0	O
oligoesters	0	O
for	0	O
the	0	O
fabrication	0	O
of	0	O
microspheres	0	O
with	0	O
encapsulated	0	O
bovine	0	B
serum	0	I
albumin	0	I
(	0	O
BSA	1	B
).	0	O


Before	0	O
this	0	O
date	0	O
,	0	O
the	0	O
drug	0	O
directly	0	O
inhibits	0	O
fetal	0	O
weight	0	O
gain	0	O
,	0	O
whereas	0	O
the	0	O
sensitivity	0	O
of	0	O
the	0	O
placenta	0	O
is	0	O
only	0	O
transient	0	O
at	0	O
day	0	O
16	0	O
resulting	0	O
in	0	O
maximum	0	O
weight	0	O
decrease	0	O
of	0	O
this	0	O
organ	0	O
24	0	O
h	0	O
later	0	O
.	0	O


A	1	O
careful	0	O
,	0	O
radiolabelled	0	O
tissue	0	O
-	0	O
distribution	0	O
study	0	O
is	0	O
warranted	0	O
to	0	O
elucidate	0	O
the	0	O
complicated	0	O
metabolic	0	O
fate	0	O
of	0	O
perhexiline	0	O
.	0	O


Cramps	0	O
in	0	O
extrapyramidal	0	O
disorders	0	O
.	0	O


This	0	O
inhibitory	0	O
domain	0	O
has	0	O
been	0	O
deleted	0	O
in	0	O
all	0	O
naturally	0	O
occurring	0	O
AHC	0	B
deletion	0	I
mutants	0	I
described	0	O
to	0	O
date	0	O
.	0	O


Encompassing	0	O
tamponade	0	O
and	0	O
pericardiocentesis	0	O
data	0	O
,	0	O
left	0	O
ventricular	0	O
stroke	0	O
work	0	O
index	0	O
showed	0	O
positive	0	O
correlation	0	O
with	0	O
TMFP1	0	O
(	0	O
r	0	O
=	0	O
.	0	O
59	0	O
)	0	O
and	0	O
TMFP2	0	O
(	0	O
r	0	O
=	0	O
.	0	O
52	0	O
)	0	O
but	0	O
not	0	O
with	0	O
TMFP3	0	O
.	0	O


Nerve	1	O
stimulation	0	O
(	0	O
1	0	O
.	0	O
5	0	O
-	0	O
12	0	O
cycles	0	O
/	0	O
s	0	O
)	0	O
produced	0	O
frequency	0	O
-	0	O
dependent	0	O
reductions	0	O
in	0	O
CBF	1	O
,	0	O
a	0	O
decrease	0	O
of	0	O
50	0	O
percent	0	O
occurring	0	O
with	0	O
the	0	O
highest	0	O
frequency	0	O
.	0	O


To	1	O
investigate	0	O
the	0	O
molecular	0	O
mechanisms	0	O
of	0	O
this	0	O
Tax	0	B
-	0	O
mediated	0	O
inhibition	0	O
,	0	O
we	0	O
analyzed	0	O
its	0	O
effect	0	O
on	0	O
the	0	O
transcriptional	0	O
activity	0	O
of	0	O
the	0	O
myogenic	0	O
MyoD	0	B
protein	0	I
,	0	O
which	0	O
was	0	O
used	0	O
as	0	O
a	0	O
paradigm	0	O
of	0	O
bHLH	0	B
factors	0	I
.	0	O


We	0	O
argue	0	O
that	0	O
the	0	O
primary	0	O
role	0	O
of	0	O
hh	0	B
in	0	O
controlling	0	O
polarity	0	O
is	0	O
to	0	O
cause	0	O
anterior	0	O
compartment	0	O
cells	0	O
to	0	O
reverse	0	O
their	0	O
interpretation	0	O
of	0	O
an	0	O
underlying	0	O
symmetric	0	O
polarization	0	O
.	0	O


Ig	1	B
heavy	0	I
chain	0	I
class	0	O
switching	0	O
is	0	O
directed	0	O
by	0	O
cytokines	0	O
inducing	0	O
transcription	0	O
from	0	O
unrearranged	0	O
CH	1	B
genes	0	I
.	0	O


Of	0	O
the	0	O
serum	0	B
neutralizing	0	I
(	0	I
SN	1	I
)	0	I
antibody	0	I
negative	0	O
calves	0	O
89	0	O
.	0	O
7	0	O
%	0	O
(	0	O
26	0	O
/	0	O
29	0	O
)	0	O
and	0	O
92	0	O
.	0	O
8	0	O
%	0	O
(	0	O
90	0	O
/	0	O
97	0	O
)	0	O
developed	0	O
SN	1	B
antibody	0	I
1	0	O
month	0	O
after	0	O
intranasal	0	O
and	0	O
intramuscular	0	O
vaccination	0	O
,	0	O
respectively	0	O
.	0	O


Three	0	O
different	0	O
techniques	0	O
of	0	O
EA	1	O
analysis	0	O
were	0	O
used	0	O
in	0	O
the	0	O
study	0	O
:	0	O
1	0	O
)	0	O
fast	0	O
Fourier	0	O
transformation	0	O
(	0	O
FFT	1	O
)	0	O
of	0	O
EA	1	O
in	0	O
a	0	O
broad	0	O
band	0	O
,	0	O
2	0	O
)	0	O
developed	0	O
by	0	O
us	0	O
alternative	0	O
method	0	O
of	0	O
non	0	O
-	0	O
harmonic	0	O
expansion	0	O
of	0	O
the	0	O
EEG	1	O
curves	0	O
taking	0	O
into	0	O
account	0	O
their	0	O
shape	0	O
,	0	O
3	0	O
)	0	O
factor	0	O
analysis	0	O
of	0	O
the	0	O
EA	1	O
spectral	0	O
densities	0	O
.	0	O


Molecular	1	O
cloning	0	O
and	0	O
characterization	0	O
of	0	O
a	0	O
new	0	O
member	0	O
of	0	O
the	0	O
rat	0	B
placental	0	I
prolactin	0	I
(	0	O
PRL	1	B
)	0	O
family	0	O
,	0	O
PRL	1	B
-	0	O
like	0	O
protein	0	B
H	1	I
.	0	O


C	1	O
-	0	O
SP	1	O
duration	0	O
was	0	O
significantly	0	O
reduced	0	O
in	0	O
ALS	1	O
patients	0	O
compared	0	O
to	0	O
controls	0	O
at	0	O
low	0	O
stimulation	0	O
intensity	0	O
corresponding	0	O
to	0	O
an	0	O
MEP	1	O
threshold	0	O
increased	0	O
by	0	O
15	0	O
%.	0	O


Thigh	1	O
girth	0	O
correlated	0	O
positively	0	O
with	0	O
HDL	1	B
and	0	O
HDL2	1	B
-	0	I
C	1	I
and	0	O
mass	0	O
,	0	O
and	0	O
with	0	O
LDL	1	B
particle	0	O
size	0	O
among	0	O
women	0	O
.	0	O


The	0	O
activity	0	O
of	0	O
the	0	O
minimal	0	O
promoter	0	O
was	0	O
found	0	O
to	0	O
be	0	O
controlled	0	O
by	0	O
a	0	O
combination	0	O
of	0	O
the	0	O
activities	0	O
of	0	O
the	0	O
transcription	0	O
factors	0	O
Sp1	0	B
,	0	O
Sp3	0	B
,	0	O
and	0	O
NF	1	B
-	0	I
Y	1	I
.	0	O


Bites	0	O
by	0	O
two	0	O
species	0	O
of	0	O
adders	0	O
(	0	O
Vipera	1	O
aspis	0	O
and	0	O
Vipera	1	O
berus	0	O
)	0	O
can	0	O
lead	0	O
to	0	O
extensive	0	O
swelling	0	O
with	0	O
multiorgan	0	O
failure	0	O
.	0	O


BiP670	0	B
retains	0	O
basal	0	O
and	0	O
Ca2	1	O
+	0	O
ionophore	0	O
A23187	0	O
-	0	O
inducible	0	O
activities	0	O
.	0	O


Direct	1	O
and	0	O
inverted	0	O
repeat	0	O
elements	0	O
of	0	O
10	0	O
,	0	O
11	0	O
,	0	O
16	0	O
,	0	O
19	0	O
,	0	O
and	0	O
22	0	O
nucleotides	0	O
(	0	O
nt	0	O
)	0	O
flank	0	O
the	0	O
promoter	0	O
site	0	O
.	0	O


Causes	0	O
of	0	O
death	0	O
found	0	O
in	0	O
an	0	O
epidemiological	0	O
study	0	O
of	0	O
native	0	O
chickens	0	O
in	0	O
Thai	0	O
villages	0	O
.	0	O


The	0	O
IDF	1	O
standard	0	O
method	0	O
for	0	O
the	0	O
detection	0	O
of	0	O
penicillin	0	O
in	0	O
milk	0	O
is	0	O
not	0	O
suitable	0	O
for	0	O
the	0	O
detection	0	O
of	0	O
sulphonamide	0	O
residues	0	O
in	0	O
milk	0	O
.	0	O


We	0	O
analysed	0	O
two	0	O
regions	0	O
involved	0	O
in	0	O
preS2	0	B
/	0	O
S	1	B
gene	0	I
transcription	0	O
of	0	O
the	0	O
HBV	1	O
adw	0	O
subtype	0	O
:	0	O
the	0	O
diverged	0	O
TATA	0	O
box	0	O
and	0	O
a	0	O
putative	0	O
initiator	0	O
element	0	O
.	0	O


Both	0	O
Rep78	0	B
and	0	O
Rep68	0	B
cut	0	O
the	0	O
terminal	0	O
AAV	1	O
sequence	0	O
at	0	O
the	0	O
same	0	O
site	0	O
(	0	O
nucleotide	0	O
124	0	O
).	0	O


During	0	O
a	0	O
single	0	O
LAD	1	O
occlusion	0	O
lasting	0	O
35	0	O
minutes	0	O
(	0	O
series	0	O
I	1	O
,	0	O
n	0	O
=	0	O
10	0	O
)	0	O
9	0	O
microns	0	O
TMs	0	O
were	0	O
infused	0	O
immediately	0	O
and	0	O
30	0	O
minutes	0	O
after	0	O
ligation	0	O
,	0	O
15	0	O
microns	0	O
TMs	0	O
being	0	O
infused	0	O
after	0	O
15	0	O
-	0	O
20	0	O
minutes	0	O
.	0	O


Mutational	1	O
analysis	0	O
shows	0	O
that	0	O
both	0	O
an	0	O
AP	1	B
-	0	I
1	0	I
like	0	I
sequence	0	I
(-	0	O
294	0	O
/-	0	O
285	0	O
,	0	O
TGAATCATCA	0	O
)	0	O
and	0	O
an	0	O
A	1	O
/	0	O
T	1	O
-	0	O
rich	0	O
myocyte	0	B
enhancer	0	I
factor	0	I
(	0	I
MEF	0	I
)-	0	I
2	0	I
like	0	I
sequence	0	I
(-	0	O
310	0	O
/-	0	O
298	0	O
,	0	O
TTAAAAATAAAAA	0	O
)	0	O
in	0	O
the	0	O
33	0	O
-	0	O
bp	0	O
region	0	O
are	0	O
necessary	0	O
for	0	O
the	0	O
OP	1	B
-	0	I
1	0	I
effect	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
HIV	1	O
-	0	O
1	0	O
Gag	1	B
sequences	0	I
can	0	O
influence	0	O
the	0	O
viral	0	B
PR	1	I
-	0	O
mediated	0	O
processing	0	O
of	0	O
the	0	O
MuLV	0	O
TM	1	B
Env	0	I
protein	0	I
p15	0	O
(	0	O
E	1	O
).	0	O


In	1	O
adherent	0	O
macrophages	0	O
,	0	O
absence	0	O
of	0	O
CD45	0	B
led	0	O
to	0	O
the	0	O
hyperphosphorylation	0	O
and	0	O
hyperactivation	0	O
of	0	O
p56	0	B
/	0	I
59	0	I
(	0	O
hck	0	B
)	0	O
and	0	O
p53	0	B
/	0	I
56	0	I
(	0	O
lyn	0	B
),	0	O
but	0	O
not	0	O
of	0	O
p58	0	B
(	0	O
c	0	B
-	0	I
fgr	0	I
).	0	O


We	0	O
further	0	O
demonstrate	0	O
that	0	O
the	0	O
Stress	1	B
-	0	I
Activated	0	I
-	0	I
Protein	1	I
-	0	I
Kinase	1	I
(	0	O
SAPK	0	B
)	0	O
target	0	O
sites	0	O
of	0	O
ATF2	0	B
,	0	O
Thr69	0	O
and	0	O
Thr71	0	O
are	0	O
not	0	O
required	0	O
for	0	O
the	0	O
formation	0	O
of	0	O
the	0	O
p300	0	B
/	0	O
CBP	0	B
-	0	O
ATF2	0	B
multiprotein	0	O
complex	0	O
.	0	O


Stable	1	O
association	0	O
of	0	O
U2	0	B
snRNP	1	I
with	0	O
the	0	O
branchpoint	0	O
sequence	0	O
of	0	O
mammalian	0	O
pre	0	O
-	0	O
mRNAs	0	O
requires	0	O
binding	0	O
of	0	O
a	0	O
non	0	O
-	0	O
snRNP	1	O
protein	0	O
to	0	O
the	0	O
polypyrimidine	0	O
tract	0	O
.	0	O


Although	0	O
the	0	O
extracellular	0	O
domain	0	O
of	0	O
the	0	O
TSH	1	B
-	0	I
R	1	I
is	0	O
sufficient	0	O
for	0	O
high	0	O
affinity	0	O
binding	0	O
of	0	O
TSH	1	B
,	0	O
we	0	O
conclude	0	O
that	0	O
the	0	O
hyt	0	O
mutation	0	O
in	0	O
the	0	O
fourth	0	O
transmembrane	0	O
domain	0	O
eliminates	0	O
TSH	1	B
binding	0	O
.	0	O


The	0	O
IgG	1	B
subclass	0	O
profile	0	O
of	0	O
untreated	0	O
coeliac	0	O
disease	0	O
was	0	O
found	0	O
to	0	O
be	0	O
the	0	O
same	0	O
as	0	O
in	0	O
healthy	0	O
controls	0	O
(	0	O
IgG1	0	B
approximately	0	O
IgG2	0	B
>	0	O
IgG3	0	B
>	0	O
IgG4	0	B
),	0	O
with	0	O
only	0	O
the	0	O
magnitude	0	O
of	0	O
the	0	O
individual	0	O
subclass	0	O
responses	0	O
being	0	O
increased	0	O
in	0	O
coeliac	0	O
patients	0	O
.	0	O


Thus	0	O
,	0	O
methylation	0	O
of	0	O
Pph21p	0	B
is	0	O
important	0	O
for	0	O
formation	0	O
of	0	O
PP2A	0	B
trimeric	0	I
and	0	I
dimeric	0	I
complexes	0	I
,	0	O
and	0	O
consequently	0	O
,	0	O
for	0	O
PP2A	0	B
function	0	O
.	0	O


During	0	O
the	0	O
conditioning	0	O
procedure	0	O
,	0	O
the	0	O
C	1	O
-	0	O
fiber	0	O
reflex	0	O
was	0	O
facilitated	0	O
(	0	O
wind	0	O
-	0	O
up	0	O
)	0	O
in	0	O
a	0	O
stimulus	0	O
-	0	O
dependent	0	O
fashion	0	O
in	0	O
intact	0	O
,	0	O
anesthetized	0	O
animals	0	O
during	0	O
the	0	O
application	0	O
of	0	O
the	0	O
first	0	O
seven	0	O
conditioning	0	O
stimuli	0	O
;	0	O
thereafter	0	O
,	0	O
the	0	O
magnitude	0	O
of	0	O
the	0	O
responses	0	O
reached	0	O
a	0	O
plateau	0	O
and	0	O
then	0	O
decreased	0	O
.	0	O


This	0	O
vector	0	O
transfected	0	O
into	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
directs	0	O
expression	0	O
of	0	O
a	0	O
secreted	0	O
mature	0	O
protein	0	O
at	0	O
levels	0	O
up	0	O
to	0	O
200	0	O
mg	0	O
of	0	O
LAPP	0	O
/	0	O
liter	0	O
of	0	O
culture	0	O
medium	0	O
.	0	O


For	0	O
oral	0	O
administration	0	O
,	0	O
AUC0	0	O
-	0	O
infinity	0	O
was	0	O
58	0	O
.	0	O
47	0	O
+/-	0	O
16	0	O
.	0	O
37	0	O
microg	0	O
x	0	O
h	0	O
/	0	O
ml	0	O
,	0	O
t1	0	O
/	0	O
2beta	0	O
was	0	O
18	0	O
.	0	O
39	0	O
+/-	0	O
0	0	O
.	0	O
06	0	O
hours	0	O
,	0	O
maximum	0	O
concentration	0	O
(	0	O
Cmax	1	O
)	0	O
was	0	O
2	0	O
.	0	O
12	0	O
+/-	0	O
00	0	O
.	0	O
51	0	O
microg	0	O
/	0	O
ml	0	O
,	0	O
time	0	O
to	0	O
Cmax	1	O
was	0	O
2	0	O
.	0	O
20	0	O
+/-	0	O
2	0	O
.	0	O
17	0	O
hours	0	O
,	0	O
mean	0	O
absorption	0	O
time	0	O
was	0	O
2	0	O
.	0	O
09	0	O
+/-	0	O
0	0	O
.	0	O
51	0	O
hours	0	O
,	0	O
and	0	O
bioavailability	0	O
was	0	O
42	0	O
+/-	0	O
0	0	O
.	0	O
42	0	O
%.	0	O


Tensile	0	O
bond	0	O
strengths	0	O
between	0	O
resin	0	O
composite	0	O
and	0	O
bovine	0	O
dentin	0	O
using	0	O
dentin	0	O
adhesive	0	O
systems	0	O
(	0	O
Clearfil	0	O
Liner	1	O
Bond	1	O
II	0	O
:	0	O
LB	1	O
II	0	O
;	0	O
Scotchbond	0	O
Multi	0	O
-	0	O
Purpose	0	O
:	0	O
MP	1	O
)	0	O
bonding	0	O
systems	0	O
showed	0	O
a	0	O
large	0	O
scatter	0	O
among	0	O
students	0	O
and	0	O
dentists	0	O
.	0	O


In	1	O
several	0	O
cell	0	O
lines	0	O
,	0	O
mTOR	0	B
or	0	O
its	0	O
downstream	0	O
targets	0	O
can	0	O
be	0	O
regulated	0	O
by	0	O
phosphatidylinositol	0	B
(	0	I
PI	1	I
)	0	I
3	0	I
-	0	I
kinase	0	I
;	0	O
protein	0	B
kinases	0	I
A	1	I
,	0	I
B	1	I
,	0	I
and	0	I
C	1	I
;	0	O
heterotrimeric	0	B
G	1	I
-	0	I
proteins	0	I
;	0	O
a	0	O
PD98059	0	O
-	0	O
sensitive	0	O
kinase	0	O
or	0	O
calcium	0	O
;	0	O
as	0	O
well	0	O
as	0	O
by	0	O
amino	0	O
acids	0	O
.	0	O


3	0	O
)	0	O
and	0	O
one	0	O
distal	0	O
(-	0	O
11	0	O
.	0	O
8	0	O
/-	0	O
10	0	O
.	0	O
9	0	O
),	0	O
presented	0	O
an	0	O
enhancer	0	O
activity	0	O
in	0	O
pituitary	0	O
cells	0	O
when	0	O
placed	0	O
upstream	0	O
of	0	O
the	0	O
SV40	1	B
promoter	0	I
.	0	O


Effect	1	O
of	0	O
corticosteroid	0	O
-	0	O
containing	0	O
antirheumatic	0	O
combination	0	O
drugs	0	O
on	0	O
endogenous	0	O
ACTH	1	B
and	0	O
cortisol	0	O
production	0	O
.	0	O


The	0	O
transcriptional	0	O
unit	0	O
spans	0	O
a	0	O
chromosomal	0	O
region	0	O
of	0	O
about	0	O
55	0	O
kilobase	0	O
pairs	0	O
(	0	O
kbp	0	O
).	0	O


Conjugated	0	O
estrogens	0	O
shorten	0	O
bleeding	0	O
time	0	O
in	0	O
uraemia	0	O
:	0	O
a	0	O
possible	0	O
role	0	O
of	0	O
serotonin	0	O
?	0	O


Compared	0	O
to	0	O
controls	0	O
,	0	O
both	0	O
UB	0	O
and	0	O
OCS	0	O
rats	0	O
showed	0	O
a	0	O
small	0	O
but	0	O
significant	0	O
post	0	O
-	0	O
operative	0	O
reduction	0	O
in	0	O
the	0	O
nocturnality	0	O
of	0	O
drinking	0	O
.	0	O


This	0	O
study	0	O
suggests	0	O
that	0	O
BSPMs	0	O
are	0	O
useful	0	O
in	0	O
the	0	O
assessment	0	O
of	0	O
AMI	1	O
in	0	O
terms	0	O
of	0	O
diagnosis	0	O
,	0	O
location	0	O
and	0	O
extent	0	O
of	0	O
myocardial	0	O
infarct	0	O
.	0	O


SETTING	0	O
--	0	O
Delhi	0	O
,	0	O
urban	0	O
India	0	O
,	0	O
1985	0	O
-	0	O
6	0	O
.	0	O


Organization	1	O
of	0	O
the	0	O
human	0	B
LU	1	I
gene	0	I
and	0	O
molecular	0	O
basis	0	O
of	0	O
the	0	O
Lu	1	O
(	0	O
a	0	O
)/	0	O
Lu	1	B
(	0	I
b	0	I
)	0	I
blood	0	O
group	0	O
polymorphism	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
this	0	O
new	0	O
measurement	0	O
technique	0	O
provides	0	O
an	0	O
easy	0	O
and	0	O
accurate	0	O
P0	0	O
.	0	O
1	0	O
measurement	0	O
using	0	O
standard	0	O
respiratory	0	O
equipment	0	O
when	0	O
tested	0	O
in	0	O
a	0	O
lung	0	O
model	0	O
.	0	O


Automatic	1	O
view	0	O
box	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
depletion	0	O
of	0	O
Oct	1	B
-	0	I
1	0	I
from	0	O
the	0	O
nuclear	0	O
extract	0	O
by	0	O
using	0	O
Oct	1	B
-	0	I
1	0	I
-	0	O
specific	0	O
antiserum	0	O
or	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
DNA	1	O
affinity	0	O
resin	0	O
decreased	0	O
in	0	O
vitro	0	O
transcription	0	O
from	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
MMTV	0	O
promoter	0	O
to	0	O
a	0	O
level	0	O
identical	0	O
to	0	O
that	0	O
obtained	0	O
from	0	O
a	0	O
promoter	0	O
in	0	O
which	0	O
all	0	O
three	0	O
octamer	0	O
-	0	O
related	0	O
sequences	0	O
were	0	O
mutated	0	O
.	0	O


We	0	O
have	0	O
overexpressed	0	O
,	0	O
purified	0	O
,	0	O
characterized	0	O
,	0	O
and	0	O
crystallized	0	O
the	0	O
BTB	0	B
/	0	O
POZ	0	O
domain	0	O
from	0	O
PLZF	0	B
(	0	O
PLZF	0	B
-	0	O
BTB	0	B
/	0	O
POZ	0	O
).	0	O


Pathogenetic	0	O
relationships	0	O
between	0	O
renal	0	O
tubular	0	O
acidosis	0	O
and	0	O
sodium	0	O
metabolism	0	O
alterations	0	O
in	0	O
liver	0	O
cirrhosis	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
PPSF	0	O
+	0	O
DBP	0	O
side	0	O
showed	0	O
large	0	O
amounts	0	O
of	0	O
bone	0	O
formation	0	O
,	0	O
and	0	O
bone	0	O
almost	0	O
covered	0	O
the	0	O
implant	0	O
.	0	O


One	0	O
of	0	O
these	0	O
genes	0	O
,	0	O
REC114	0	B
,	0	O
is	0	O
described	0	O
here	0	O
,	0	O
and	0	O
the	0	O
data	0	O
confirm	0	O
that	0	O
REC114	0	B
is	0	O
a	0	O
meiosis	0	O
-	0	O
specific	0	O
recombination	0	O
gene	0	O
with	0	O
no	0	O
detectable	0	O
function	0	O
in	0	O
mitosis	0	O
.	0	O


High	0	O
-	0	O
level	0	O
expression	0	O
in	0	O
Escherichia	1	O
coli	0	O
of	0	O
selenocysteine	0	O
-	0	O
containing	0	O
rat	0	B
thioredoxin	0	I
reductase	0	I
utilizing	0	O
gene	0	O
fusions	0	O
with	0	O
engineered	0	O
bacterial	0	O
-	0	O
type	0	O
SECIS	0	O
elements	0	O
and	0	O
co	0	O
-	0	O
expression	0	O
with	0	O
the	0	O
selA	0	B
,	0	O
selB	0	B
and	0	O
selC	0	B
genes	0	I
.	0	O


Idiopathic	1	O
bilateral	0	O
recurrent	0	O
branch	0	O
retinal	0	O
arterial	0	O
occlusion	0	O
(	0	O
IBRBRAO	0	O
)	0	O
is	0	O
a	0	O
rare	0	O
syndrome	0	O
characterized	0	O
by	0	O
migraine	0	O
headaches	0	O
,	0	O
tinnitus	0	O
,	0	O
vertigo	0	O
,	0	O
hearing	0	O
loss	0	O
,	0	O
and	0	O
recurrent	0	O
branch	0	O
retinal	0	O
artery	0	O
occlusion	0	O
of	0	O
unknown	0	O
etiology	0	O
.	0	O


Oligonucleotides	0	O
,	0	O
designed	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
conserved	0	O
flanking	0	O
amino	0	O
acid	0	O
sequence	0	O
segments	0	O
within	0	O
the	0	O
catalytic	0	O
domain	0	O
of	0	O
eukaryotic	0	B
protein	0	I
kinase	0	I
C	1	I
(	0	O
PKC	0	B
)	0	O
proteins	0	O
,	0	O
were	0	O
used	0	O
as	0	O
primers	0	O
for	0	O
polymerase	0	O
chain	0	O
reactions	0	O
to	0	O
amplify	0	O
a	0	O
427	0	O
-	0	O
bp	0	O
chromosomal	0	O
DNA	1	O
fragment	0	O
from	0	O
the	0	O
filamentous	0	O
fungus	0	O
Trichoderma	1	O
reesei	0	O
.	0	O


In	1	O
macrophages	0	O
,	0	O
LPS	1	O
-	0	O
inducible	0	O
HIV	1	O
-	0	O
1	0	O
gene	0	O
expression	0	O
is	0	O
mediated	0	O
in	0	O
part	0	O
by	0	O
binding	0	O
of	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
to	0	O
identical	0	O
tandem	0	O
binding	0	O
sites	0	O
located	0	O
within	0	O
the	0	O
long	0	O
terminal	0	O
repeat	0	O
(	0	O
LTR	1	O
).	0	O


Similar	0	O
results	0	O
were	0	O
also	0	O
obtained	0	O
with	0	O
a	0	O
HepG2	0	O
hepatoblastoma	0	O
cell	0	O
line	0	O
carrying	0	O
wt	0	B
p53	0	I
.	0	O


The	0	O
humanized	0	B
LL2	0	I
(	0	O
hLL2	0	B
),	0	O
lacking	0	O
light	0	B
chain	0	I
variable	0	I
region	0	I
glycosylation	0	O
,	0	O
exhibited	0	O
immunoreactivities	0	O
that	0	O
were	0	O
comparable	0	O
to	0	O
that	0	O
of	0	O
chimeric	0	B
LL2	0	I
(	0	O
cLL2	0	B
),	0	O
which	0	O
was	0	O
shown	0	O
previously	0	O
to	0	O
have	0	O
antigen	0	O
-	0	O
binding	0	O
properties	0	O
similar	0	O
to	0	O
its	0	O
murine	0	O
counterpart	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
VK	0	O
-	0	O
appended	0	O
oligosaccharides	0	O
found	0	O
in	0	O
mLL2	0	B
are	0	O
not	0	O
necessary	0	O
for	0	O
antigen	0	O
binding	0	O
.	0	O


Glucose	1	O
disappearance	0	O
rate	0	O
and	0	O
changes	0	O
in	0	O
plasma	0	O
nutrients	0	O
after	0	O
intravenouly	0	O
injected	0	O
glucose	0	O
in	0	O
normoglycaemic	0	O
and	0	O
hypoglycaemic	0	O
underweight	0	O
newborns	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
dopaminergic	0	O
regulation	0	O
of	0	O
adrenal	0	O
zona	0	O
glomerulosa	0	O
corticosteroid	0	O
and	0	O
renal	0	B
renin	0	I
secretion	0	O
is	0	O
absent	0	O
in	0	O
patients	0	O
with	0	O
high	0	O
spinal	0	O
cord	0	O
transections	0	O
,	0	O
suggesting	0	O
that	0	O
intact	0	O
neural	0	O
pathways	0	O
from	0	O
the	0	O
central	0	O
nervous	0	O
system	0	O
are	0	O
necessary	0	O
for	0	O
metoclopramide	0	O
stimulation	0	O
of	0	O
aldosterone	0	O
and	0	O
renin	0	B
secretion	0	O
in	0	O
men	0	O
.	0	O


Control	1	O
of	0	O
transcription	0	O
of	0	O
the	0	O
erbB	0	B
-	0	I
2	0	I
gene	0	I
is	0	O
an	0	O
important	0	O
determinant	0	O
of	0	O
receptor	0	O
expression	0	O
.	0	O


Air	1	O
ion	0	O
action	0	O
on	0	O
bacteria	0	O
.	0	O


During	0	O
sub	0	O
-	0	O
maximal	0	O
exercise	0	O
,	0	O
DCR	0	O
in	0	O
the	0	O
UT	0	O
dogs	0	O
decreased	0	O
from	0	O
a	0	O
resting	0	O
value	0	O
of	0	O
4	0	O
.	0	O
08	0	O
+/-	0	O
0	0	O
.	0	O
18	0	O
mm	0	O
Hg	1	O
X	1	O
ml	0	O
-	0	O
1	0	O
X	1	O
min	0	O
-	0	O
1	0	O
to	0	O
1	0	O
.	0	O
91	0	O
+/-	0	O
0	0	O
.	0	O
17	0	O
mm	0	O
Hg	1	O
X	1	O
ml	0	O
-	0	O
1	0	O
X	1	O
min	0	O
-	0	O
1	0	O
at	0	O
a	0	O
workload	0	O
of	0	O
6	0	O
.	0	O
4	0	O
kph	0	O
(	0	O
speed	0	O
)/	0	O
16	0	O
%	0	O
(	0	O
grade	0	O
).	0	O


Morphologic	0	O
variables	0	O
included	0	O
cancer	0	O
volume	0	O
,	0	O
histologic	0	O
grade	0	O
,	0	O
capsular	0	O
penetration	0	O
,	0	O
seminal	0	O
vesicle	0	O
invasion	0	O
,	0	O
and	0	O
lymph	0	O
node	0	O
metastasis	0	O
.	0	O


We	0	O
now	0	O
describe	0	O
the	0	O
identification	0	O
of	0	O
DEK	0	B
as	0	O
this	0	O
43	0	B
-	0	I
kDa	1	I
pets	0	I
factor	0	I
.	0	O


The	0	O
yeast	0	B
MMS2	0	I
gene	0	I
was	0	O
cloned	0	O
by	0	O
its	0	O
ability	0	O
to	0	O
complement	0	O
the	0	O
methyl	0	O
methanesulfonate	0	O
sensitivity	0	O
of	0	O
the	0	O
mms2	0	B
-	0	I
1	0	I
mutant	0	I
and	0	O
was	0	O
later	0	O
shown	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
DNA	1	O
post	0	O
-	0	O
replication	0	O
repair	0	O
.	0	O


Indeed	0	O
,	0	O
ERM	1	B
and	0	O
c	0	B
-	0	I
Jun	1	I
synergistically	0	O
activated	0	O
the	0	O
EBS	0	O
-	0	O
CRE	0	O
without	0	O
making	0	O
an	0	O
apparent	0	O
ternary	0	O
complex	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
peak	0	O
filling	0	O
rate	0	O
(	0	O
PFR	0	O
),	0	O
normalized	0	O
to	0	O
end	0	O
diastolic	0	O
volume	0	O
(	0	O
EDV	1	O
),	0	O
or	0	O
stroke	0	O
volume	0	O
(	0	O
SV	1	O
),	0	O
or	0	O
expressed	0	O
as	0	O
the	0	O
ratio	0	O
of	0	O
PFR	0	O
-	0	O
to	0	O
-	0	O
PER	1	O
was	0	O
reduced	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
),	0	O
time	0	O
to	0	O
PFR	0	O
(	0	O
TPFR	0	O
)	0	O
was	0	O
prolonged	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
),	0	O
and	0	O
echocardiographic	0	O
left	0	O
ventricular	0	O
mass	0	O
index	0	O
was	0	O
higher	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
in	0	O
patients	0	O
with	0	O
acromegaly	0	O
compared	0	O
to	0	O
normals	0	O
.	0	O


Finally	0	O
,	0	O
the	0	O
stability	0	O
of	0	O
the	0	O
nucleotide	0	O
binding	0	O
function	0	O
of	0	O
the	0	O
two	0	O
proteins	0	O
is	0	O
similar	0	O
as	0	O
assessed	0	O
by	0	O
sensitivity	0	O
to	0	O
urea	0	O
.	0	O


Constipation	1	O
is	0	O
not	0	O
a	0	O
risk	0	O
factor	0	O
for	0	O
hemorrhoids	0	O
:	0	O
a	0	O
case	0	O
-	0	O
control	0	O
study	0	O
of	0	O
potential	0	O
etiological	0	O
agents	0	O
.	0	O


Plasma	1	O
membranes	0	O
of	0	O
cultured	0	O
cells	0	O
contain	0	O
high	0	O
affinity	0	O
receptors	0	O
for	0	O
high	0	B
density	0	I
lipoprotein	0	I
(	0	O
HDL	1	B
)	0	O
that	0	O
appear	0	O
to	0	O
mediate	0	O
removal	0	O
of	0	O
excess	0	O
intracellular	0	O
cholesterol	0	O
.	0	O


Coexpression	0	O
studies	0	O
indicate	0	O
that	0	O
insulin	0	B
and	0	O
PKB	0	B
suppress	0	O
transactivation	0	O
by	0	O
C	1	B
/	0	I
EBPbeta	0	I
,	0	O
but	0	O
not	0	O
C	1	B
/	0	I
EBPalpha	0	I
,	0	O
and	0	O
that	0	O
N	1	O
-	0	O
terminal	0	O
transactivation	0	O
domains	0	O
in	0	O
C	1	B
/	0	I
EBPbeta	0	I
are	0	O
required	0	O
.	0	O


A	1	O
striking	0	O
feature	0	O
of	0	O
the	0	O
recombinant	0	B
H19	0	I
allele	0	I
is	0	O
the	0	O
occurrence	0	O
of	0	O
a	0	O
parental	0	O
imprint	0	O
set	0	O
on	0	O
the	0	O
neo	0	B
replacement	0	I
cassette	0	I
.	0	O


OBJECTIVE	1	O
:	0	O
Our	0	O
goal	0	O
was	0	O
to	0	O
determine	0	O
whether	0	O
chlamydia	0	O
-	0	O
infected	0	O
women	0	O
have	0	O
a	0	O
higher	0	O
rate	0	O
of	0	O
febrile	0	O
complications	0	O
after	0	O
postpartum	0	O
tubal	0	O
ligation	0	O
.	0	O


A	1	O
single	0	O
i	0	O
.	0	O
p	0	O
.	0	O
injection	0	O
of	0	O
d	0	O
,	0	O
l	0	O
-	0	O
baclofen	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
both	0	O
reduced	0	O
noradrenaline	0	O
(	0	O
NA	1	O
)	0	O
biosynthesis	0	O
in	0	O
vivo	0	O
(	0	O
31	0	O
%)	0	O
and	0	O
the	0	O
endogenous	0	O
concentration	0	O
of	0	O
normetanephrine	0	O
(	0	O
NMN	1	O
)	0	O
(	0	O
32	0	O
%)	0	O
and	0	O
increased	0	O
NA	1	O
levels	0	O
(	0	O
28	0	O
%).	0	O


The	0	O
Bacillus	1	B
subtilis	0	I
phage	0	I
phi	0	I
105	0	I
repressor	0	I
,	0	O
a	0	O
lambda	0	B
repressor	0	I
-	0	O
like	0	O
transcriptional	0	O
regulatory	0	O
protein	0	O
,	0	O
was	0	O
overproduced	0	O
in	0	O
Escherichia	1	O
coli	0	O
and	0	O
purified	0	O
to	0	O
near	0	O
homogeneity	0	O
in	0	O
order	0	O
to	0	O
examine	0	O
its	0	O
in	0	O
vitro	0	O
DNA	1	O
-	0	O
binding	0	O
properties	0	O
.	0	O


Supraventricular	1	O
arrhythmias	0	O
--	0	O
digoxin	0	O
and	0	O
quinidine	0	O
revisited	0	O
.	0	O


However	0	O
,	0	O
at	0	O
lower	0	O
temperature	0	O
the	0	O
positive	0	O
staircase	0	O
was	0	O
not	0	O
clear	0	O
and	0	O
rather	0	O
negative	0	O
staircase	0	O
appeared	0	O
(	0	O
1	0	O
--	0	O
3	0	O
Hz	1	O
).	0	O


We	0	O
have	0	O
identified	0	O
and	0	O
characterized	0	O
the	0	O
structure	0	O
of	0	O
the	0	O
Spec1	0	B
gene	0	I
in	0	O
the	0	O
sea	0	O
urchin	0	O
Strongylocentrotus	0	O
purpuratus	0	O
.	0	O


Biol	0	O
.	0	O


Alternatively	0	O
,	0	O
PC12	0	O
-	0	O
E2	1	O
cells	0	O
were	0	O
submitted	0	O
to	0	O
treatment	0	O
with	0	O
antibodies	0	O
to	0	O
the	0	O
fibroblast	0	B
growth	0	I
factor	0	I
(	0	I
FGF	0	I
)	0	I
receptor	0	I
,	0	O
inhibitors	0	O
of	0	O
the	0	O
nonreceptor	0	B
tyrosine	0	I
kinase	0	I
p59	0	I
(	0	O
fyn	0	B
),	0	O
PLC	0	B
,	0	O
PKC	0	B
and	0	O
MEK	0	B
and	0	O
an	0	O
activator	0	O
of	0	O
PKC	0	B
,	0	O
phorbol	0	O
-	0	O
12	0	O
-	0	O
myristate	0	O
-	0	O
13	0	O
-	0	O
acetate	0	O
(	0	O
PMA	0	O
).	0	O


N	1	O
-	0	O
Substituted	1	O
trimethylsilylcarbamates	0	O
were	0	O
tested	0	O
as	0	O
derivatizing	0	O
reagents	0	O
for	0	O
gas	0	O
chromatographic	0	O
analysis	0	O
.	0	O


These	0	O
transcripts	0	O
have	0	O
a	0	O
unique	0	O
5	0	O
'	0	O
untranslated	0	O
region	0	O
and	0	O
NH2	0	O
-	0	O
terminal	0	O
sequence	0	O
and	0	O
encode	0	O
a	0	O
predicted	0	O
protein	0	O
of	0	O
121	0	O
kD	1	O
.	0	O


In	1	O
a	0	O
prospective	0	O
,	0	O
randomized	0	O
clinical	0	O
trial	0	O
we	0	O
compared	0	O
the	0	O
efficacy	0	O
of	0	O
subcutaneously	0	O
(	0	O
SC	1	O
)	0	O
administered	0	O
(	0	O
every	0	O
8	0	O
h	0	O
)	0	O
calcium	0	O
heparin	0	O
to	0	O
intravenous	0	O
(	0	O
IV	1	O
)	0	O
sodium	0	O
heparin	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
proximal	0	O
deep	0	O
-	0	O
vein	0	O
thrombosis	0	O
(	0	O
DVT	1	O
).	0	O


Children	0	O
with	0	O
defective	0	O
vision	0	O


Nuclear	1	B
factor	0	I
kappa	0	I
B	1	I
(	0	O
NF	1	B
-	0	I
kappaB	0	I
)	0	O
is	0	O
an	0	O
important	0	O
transcription	0	O
factor	0	O
for	0	O
the	0	O
genes	0	O
of	0	O
many	0	O
pro	0	O
-	0	O
inflammatory	0	O
proteins	0	O
and	0	O
is	0	O
strongly	0	O
activated	0	O
by	0	O
the	0	O
cytokines	0	O
interleukin	0	B
-	0	I
1	0	I
and	0	O
tumor	0	B
necrosis	0	I
factor	0	I
(	0	I
TNF	1	I
)	0	I
alpha	0	I
under	0	O
various	0	O
pathological	0	O
conditions	0	O
.	0	O


In	1	O
group	0	O
I	1	O
,	0	O
Paw	1	O
,	0	O
delta	0	O
V	1	O
,	0	O
PaO2	1	O
,	0	O
Vinj	0	O
and	0	O
VT	1	O
significantly	0	O
decreased	0	O
whereas	0	O
operating	0	O
pressure	0	O
and	0	O
E	1	O
significantly	0	O
increased	0	O
when	0	O
the	0	O
internal	0	O
diameter	0	O
of	0	O
the	0	O
injector	0	O
cannula	0	O
was	0	O
reduced	0	O
.	0	O


To	1	O
assess	0	O
the	0	O
relationship	0	O
between	0	O
G	1	O
(	0	O
q	0	O
)/	0	O
G	1	B
(	0	I
11	0	I
)	0	I
function	0	O
with	0	O
the	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
dependent	0	O
pathway	0	O
,	0	O
expression	0	O
of	0	O
a	0	O
dominant	0	O
-	0	O
interfering	0	O
p85	0	B
regulatory	0	I
subunit	0	I
,	0	O
as	0	O
well	0	O
as	0	O
wortmannin	0	O
treatment	0	O
inhibited	0	O
insulin	0	B
-	0	O
stimulated	0	O
but	0	O
not	0	O
G	1	B
(	0	I
q	0	I
)/	0	I
Q209L	0	I
-	0	O
stimulated	0	O
GLUT4	0	B
-	0	O
EGFP	0	B
translocation	0	O
.	0	O


On	1	O
-	0	O
line	0	O
angioscopic	0	O
images	0	O
of	0	O
tissue	0	O
flaps	0	O
floating	0	O
in	0	O
the	0	O
lumen	0	O
,	0	O
recent	0	O
or	0	O
structured	0	O
thrombi	0	O
,	0	O
artery	0	O
wall	0	O
dissections	0	O
,	0	O
plaque	0	O
ruptures	0	O
,	0	O
deep	0	O
fissurations	0	O
and	0	O
sub	0	O
-	0	O
intimal	0	O
haemorrhages	0	O
demonstrate	0	O
,	0	O
in	0	O
live	0	O
colour	0	O
,	0	O
the	0	O
pathophysiological	0	O
mechanisms	0	O
of	0	O
coronary	0	O
artery	0	O
stenosis	0	O
.	0	O


No	1	O
TATA	0	O
box	0	O
was	0	O
found	0	O
in	0	O
the	0	O
putative	0	O
promoter	0	O
region	0	O
,	0	O
but	0	O
multiple	0	O
GC	1	O
boxes	0	O
were	0	O
found	0	O
around	0	O
the	0	O
cap	0	O
sites	0	O
,	0	O
supporting	0	O
the	0	O
previously	0	O
inferred	0	O
housekeeping	0	O
nature	0	O
of	0	O
CYP51	0	B
gene	0	I
and	0	O
the	0	O
existence	0	O
of	0	O
the	0	O
multiple	0	O
transcription	0	O
initiation	0	O
sites	0	O
.	0	O


A	1	O
"	0	O
Level	1	O
A	1	O
"	0	O
in	0	O
vitro	0	O
/	0	O
in	0	O
vivo	0	O
correlation	0	O
was	0	O
established	0	O
for	0	O
a	0	O
sustained	0	O
release	0	O
theophylline	0	O
(	0	O
CAS	1	O
58	0	O
-	0	O
55	0	O
-	0	O
9	0	O
)	0	O
preparation	0	O
(	0	O
Bronchoretard	0	O
)	0	O
under	0	O
investigation	0	O
.	0	O


These	0	O
clones	0	O
overlapped	0	O
and	0	O
contained	0	O
the	0	O
structural	0	O
gene	0	O
encoding	0	O
the	0	O
complete	0	O
C5	1	B
alpha	0	I
-	0	I
chain	0	I
and	0	O
90	0	O
%	0	O
of	0	O
the	0	O
beta	0	O
-	0	O
chain	0	O
.	0	O


In	1	O
one	0	O
of	0	O
these	0	O
tumors	0	O
the	0	O
observed	0	O
rearrangement	0	O
was	0	O
not	0	O
due	0	O
to	0	O
the	0	O
insertion	0	O
of	0	O
an	0	O
intact	0	O
MoMuLV	0	O
provirus	0	O
.	0	O


Angiotensin	1	B
converting	0	I
enzyme	0	I
inhibitors	0	O
enhance	0	O
the	0	O
antihypertensive	0	O
efficacy	0	O
of	0	O
diuretics	0	O
and	0	O
blunt	0	O
or	0	O
prevent	0	O
adverse	0	O
metabolic	0	O
effects	0	O
.	0	O


The	0	O
complete	0	O
exon	0	O
-	0	O
intron	0	O
organization	0	O
of	0	O
the	0	O
murine	0	O
gene	0	O
encoding	0	O
M	1	B
-	0	I
protein	0	I
,	0	O
a	0	O
structural	0	O
protein	0	O
of	0	O
sarcomeric	0	O
myofibrils	0	O
,	0	O
was	0	O
determined	0	O
.	0	O


The	0	O
term	0	O
endovascular	0	O
papillary	0	O
haemangioma	0	O
is	0	O
suggested	0	O
.	0	O


Am	1	O
.	0	O


C	1	B
/	0	I
EBP	1	I
alpha	0	I
also	0	O
activates	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
rat	0	B
class	0	I
-	0	I
I	1	I
ADH	1	I
gene	0	I
in	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
manner	0	O
[	0	O
Potter	0	O
et	0	O
al	0	O
.,	0	O
Arch	1	O
.	0	O


Ribonuclease	1	O
protection	0	O
assays	0	O
revealed	0	O
that	0	O
hmg1	0	B
and	0	O
hmg2	0	B
are	0	O
differentially	0	O
expressed	0	O
in	0	O
a	0	O
developmentally	0	O
-	0	O
and	0	O
spatially	0	O
-	0	O
modulated	0	O
manner	0	O
during	0	O
morphogenesis	0	O
of	0	O
specialized	0	O
terpenoid	0	O
-	0	O
containing	0	O
pigment	0	O
glands	0	O
in	0	O
embryos	0	O
.	0	O


Interestingly	0	O
,	0	O
although	0	O
E	1	O
domains	0	O
of	0	O
these	0	O
two	0	O
receptors	0	O
are	0	O
much	0	O
less	0	O
conserved	0	O
,	0	O
replacement	0	O
of	0	O
this	0	O
domain	0	O
in	0	O
rtER	0	B
by	0	O
its	0	O
human	0	O
counterpart	0	O
resulted	0	O
in	0	O
higher	0	O
estradiol	0	O
sensitivity	0	O
but	0	O
no	0	O
increase	0	O
in	0	O
the	0	O
magnitude	0	O
of	0	O
transactivation	0	O
.	0	O


The	0	O
Schizosaccharomyces	0	B
pombe	0	I
rad1	0	I
+	0	I
cell	0	I
cycle	0	I
checkpoint	0	I
control	0	I
gene	0	I
is	0	O
required	0	O
for	0	O
S	1	O
-	0	O
phase	0	O
and	0	O
G2	0	O
/	0	O
M	1	O
arrest	0	O
in	0	O
response	0	O
to	0	O
both	0	O
DNA	1	O
damage	0	O
and	0	O
incomplete	0	O
DNA	1	O
replication	0	O
.	0	O


Previous	0	O
studies	0	O
have	0	O
suggested	0	O
that	0	O
moderate	0	O
cooling	0	O
increases	0	O
the	0	O
responsiveness	0	O
of	0	O
vascular	0	B
alpha2	0	I
-	0	I
adrenoceptors	0	I
.	0	O


Approximately	0	O
60	0	O
%	0	O
of	0	O
cell	0	O
bodies	0	O
of	0	O
primary	0	O
neurons	0	O
innervating	0	O
the	0	O
intra	0	O
and	0	O
perioral	0	O
structures	0	O
through	0	O
the	0	O
inferior	0	O
alveolar	0	O
,	0	O
lingual	0	O
,	0	O
mental	0	O
,	0	O
and	0	O
buccal	0	O
nerves	0	O
were	0	O
in	0	O
the	0	O
range	0	O
between	0	O
300	0	O
and	0	O
600	0	O
micron	0	O
2	0	O
in	0	O
cross	0	O
-	0	O
sectional	0	O
area	0	O
:	0	O
mean	0	O
+/-	0	O
SD	1	O
509	0	O
+/-	0	O
243	0	O
micron	0	O
2	0	O
,	0	O
420	0	O
+/-	0	O
181	0	O
micron	0	O
2	0	O
,	0	O
469	0	O
+/-	0	O
200	0	O
micron	0	O
2	0	O
,	0	O
and	0	O
444	0	O
+/-	0	O
186	0	O
micron	0	O
2	0	O
,	0	O
respectively	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
a	0	O
Drosophila	1	O
melanogaster	0	O
(	0	O
Dm	1	O
)	0	O
cDNA	1	O
encoding	0	O
a	0	O
polypeptide	0	O
that	0	O
has	0	O
extensive	0	O
sequence	0	O
similarity	0	O
to	0	O
the	0	O
mammalian	0	B
MAPKAPK	0	I
-	0	I
2	0	I
.	0	O


CONCLUSIONS	0	O
:	0	O
Free	1	O
protein	0	B
S	1	I
deficiency	0	O
is	0	O
common	0	O
among	0	O
hospitalized	0	O
patients	0	O
,	0	O
even	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
a	0	O
recognized	0	O
predisposing	0	O
condition	0	O
.	0	O


BACKGROUND	0	O
:	0	O
In	1	O
the	0	O
ubiquitin	0	B
-	0	O
dependent	0	O
proteolysis	0	O
pathway	0	O
,	0	O
a	0	O
ubiquitin	0	B
ligase	0	I
(	0	O
E3	1	B
)	0	O
is	0	O
responsible	0	O
for	0	O
substrate	0	O
selectivity	0	O
and	0	O
timing	0	O
of	0	O
degradation	0	O
.	0	O


2	0	O
cases	0	O
of	0	O
toxic	0	O
lymphomononucleosis	0	O


Results	0	O
demonstrated	0	O
that	0	O
the	0	O
presence	0	O
of	0	O
myofibroblasts	0	O
varied	0	O
considerably	0	O
from	0	O
case	0	O
to	0	O
case	0	O
and	0	O
was	0	O
always	0	O
related	0	O
to	0	O
smooth	0	O
muscle	0	O
cell	0	O
dispersion	0	O
,	0	O
which	0	O
occurred	0	O
around	0	O
medium	0	O
-	0	O
sized	0	O
damaged	0	O
portal	0	O
vein	0	O
branches	0	O
.	0	O


The	0	O
R2	0	O
region	0	O
within	0	O
the	0	O
class	0	O
I	1	O
enhancer	0	O
acts	0	O
as	0	O
a	0	O
negative	0	O
element	0	O
in	0	O
Ad12	0	O
-	0	O
transformed	0	O
cells	0	O
and	0	O
exhibits	0	O
a	0	O
stronger	0	O
binding	0	O
activity	0	O
than	0	O
is	0	O
observed	0	O
in	0	O
nontumorigenic	0	O
Ad5	0	O
-	0	O
transformed	0	O
cells	0	O
,	0	O
which	0	O
are	0	O
not	0	O
reduced	0	O
in	0	O
class	0	O
I	1	O
expression	0	O
.	0	O


This	0	O
report	0	O
substantiates	0	O
that	0	O
at	0	O
least	0	O
two	0	O
of	0	O
the	0	O
18	0	O
kDa	1	O
hsps	0	B
in	0	O
maize	0	O
are	0	O
products	0	O
of	0	O
different	0	O
but	0	O
related	0	O
genes	0	O
.	0	O


The	0	O
most	0	O
common	0	O
cause	0	O
of	0	O
renal	0	O
deterioration	0	O
in	0	O
the	0	O
spinal	0	O
cord	0	O
injured	0	O
patient	0	O
is	0	O
irreversible	0	O
vesicoureteral	0	O
reflux	0	O
.	0	O


Diagnosis	1	O
and	0	O
differential	0	O
diagnosis	0	O


Possible	0	O
roles	0	O
of	0	O
RAD5	0	B
putative	0	O
ATPase	1	B
/	0	O
DNA	1	B
helicase	0	I
activity	0	O
in	0	O
DNA	1	O
repair	0	O
and	0	O
in	0	O
the	0	O
maintenance	0	O
of	0	O
wild	0	O
-	0	O
type	0	O
rates	0	O
of	0	O
instability	0	O
of	0	O
simple	0	O
repetitive	0	O
sequences	0	O
are	0	O
discussed	0	O
.	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
contact	0	O
allergy	0	O
to	0	O
K	1	O
-	0	O
CG	1	O
is	0	O
common	0	O
.	0	O


T	1	O
-	0	O
cell	0	O
hybridomas	0	O
,	0	O
thymocytes	0	O
,	0	O
and	0	O
T	1	O
cells	0	O
can	0	O
be	0	O
induced	0	O
to	0	O
undergo	0	O
apoptotic	0	O
cell	0	O
death	0	O
by	0	O
activation	0	O
through	0	O
the	0	O
T	1	B
-	0	I
cell	0	I
receptor	0	I
.	0	O


The	0	O
drug	0	O
was	0	O
given	0	O
in	0	O
a	0	O
daily	0	O
oral	0	O
dose	0	O
of	0	O
0	0	O
.	0	O
5	0	O
g	0	O
/	0	O
m2	0	O
,	0	O
3	0	O
.	0	O
5	0	O
h	0	O
prior	0	O
to	0	O
each	0	O
radiation	0	O
treatment	0	O
.	0	O


An	1	O
exaggerated	0	O
tissue	0	O
response	0	O
adjacent	0	O
to	0	O
the	0	O
cyanoacrylate	0	O
site	0	O
suggested	0	O
a	0	O
potential	0	O
toxic	0	O
chemical	0	O
or	0	O
thermal	0	O
reaction	0	O
,	0	O
or	0	O
both	0	O
,	0	O
to	0	O
the	0	O
tissue	0	O
adhesive	0	O
,	0	O
but	0	O
there	0	O
was	0	O
no	0	O
evidence	0	O
of	0	O
any	0	O
distant	0	O
ocular	0	O
effects	0	O
.	0	O


Standard	1	O
curve	0	O
correlation	0	O
coefficients	0	O
of	0	O
0	0	O
.	0	O
995	0	O
or	0	O
greater	0	O
were	0	O
obtained	0	O
during	0	O
validation	0	O
experiments	0	O
and	0	O
analysis	0	O
of	0	O
study	0	O
samples	0	O
.	0	O


After	0	O
the	0	O
first	0	O
28	0	O
patients	0	O
vincristine	0	O
was	0	O
replaced	0	O
by	0	O
teniposide	0	O
(	0	O
VM	0	O
-	0	O
26	0	O
)	0	O
due	0	O
to	0	O
neurotoxicity	0	O
.	0	O


Experimental	0	O
ischemic	0	O
heart	0	O
disease	0	O
induced	0	O
by	0	O
thromboxane	0	O
A2	1	O
in	0	O
rabbits	0	O
.	0	O


After	0	O
dopamine	0	O
infusion	0	O
in	0	O
women	0	O
with	0	O
polycystic	0	O
ovary	0	O
syndrome	0	O
and	0	O
in	0	O
matched	0	O
controls	0	O
,	0	O
steady	0	O
state	0	O
levels	0	O
of	0	O
plasma	0	O
dopamine	0	O
,	0	O
norepinephrine	0	O
,	0	O
and	0	O
the	0	O
ratio	0	O
of	0	O
dopamine	0	O
/	0	O
norepinephrine	0	O
were	0	O
similar	0	O
in	0	O
the	0	O
two	0	O
groups	0	O
.	0	O


INTERVENTION	1	O
(	0	O
S	1	O
):	0	O
Twenty	0	O
-	0	O
six	0	O
hemostasis	0	O
parameters	0	O
evaluated	0	O
repeatedly	0	O
in	0	O
patients	0	O
undergoing	0	O
IVF	1	O
-	0	O
ET	1	O
.	0	O


Histamine	1	O
reactivity	0	O
was	0	O
significantly	0	O
reduced	0	O
after	0	O
the	0	O
nifedipine	0	O
aerosol	0	O
,	0	O
the	0	O
geometric	0	O
mean	0	O
provocative	0	O
concentration	0	O
causing	0	O
a	0	O
35	0	O
%	0	O
fall	0	O
in	0	O
specific	0	O
airway	0	O
conductance	0	O
,	0	O
rising	0	O
from	0	O
5	0	O
.	0	O
0	0	O
to	0	O
10	0	O
.	0	O
9	0	O
mg	0	O
/	0	O
ml	0	O
of	0	O
histamine	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Max	0	B
was	0	O
constantly	0	O
transcribed	0	O
at	0	O
a	0	O
relatively	0	O
low	0	O
level	0	O
during	0	O
cell	0	O
cycle	0	O
progression	0	O
.	0	O


Patients	0	O
with	0	O
lesions	0	O
affecting	0	O
the	0	O
PRC	0	O
but	0	O
sparing	0	O
the	0	O
PHC	0	O
,	0	O
and	0	O
patients	0	O
with	0	O
lesions	0	O
affecting	0	O
both	0	O
PRC	0	O
and	0	O
PHC	0	O
,	0	O
performed	0	O
an	0	O
oculomotor	0	O
delayed	0	O
response	0	O
task	0	O
with	0	O
unpredictably	0	O
varied	0	O
memory	0	O
delays	0	O
of	0	O
up	0	O
to	0	O
30	0	O
s	0	O
.	0	O


We	0	O
found	0	O
the	0	O
following	0	O
:	0	O
Specific	1	O
mutations	0	O
affected	0	O
the	0	O
precise	0	O
carbohydrate	0	O
structure	0	O
and	0	O
folding	0	O
of	0	O
the	0	O
HA	1	B
trimer	0	I
.	0	O


Troglitazone	1	O
also	0	O
induced	0	O
an	0	O
endogenous	0	B
PPARgamma	0	I
target	0	I
gene	0	I
in	0	O
T24	0	O
cells	0	O
,	0	O
adipocyte	0	B
-	0	I
type	0	I
fatty	0	I
acid	0	I
binding	0	I
protein	0	I
(	0	O
A	1	B
-	0	I
FABP	0	I
),	0	O
the	0	O
expression	0	O
of	0	O
which	0	O
correlates	0	O
with	0	O
bladder	0	O
cancer	0	O
differentiation	0	O
.	0	O


Most	0	O
of	0	O
the	0	O
patients	0	O
presented	0	O
with	0	O
Transient	1	O
Ischemic	1	O
Attacks	0	O
(	0	O
64	0	O
%)	0	O
or	0	O
Reversible	1	O
Ischemic	1	O
Neurologic	1	O
Deficits	0	O
(	0	O
19	0	O
%).	0	O


The	0	O
overexpressed	0	O
His6	0	B
-	0	I
tagged	0	I
GrsA	0	I
derivatives	0	I
were	0	O
affinity	0	O
-	0	O
purified	0	O
,	0	O
and	0	O
the	0	O
catalytic	0	O
properties	0	O
of	0	O
the	0	O
deletion	0	O
mutants	0	O
were	0	O
examined	0	O
by	0	O
biochemical	0	O
studies	0	O
including	0	O
ATP	1	O
-	0	O
dependent	0	O
amino	0	O
acid	0	O
activation	0	O
,	0	O
carboxyl	0	O
thioester	0	O
formation	0	O
,	0	O
and	0	O
the	0	O
ability	0	O
to	0	O
racemize	0	O
the	0	O
covalently	0	O
bound	0	O
phenylalanine	0	O
from	0	O
L	1	O
-	0	O
to	0	O
the	0	O
D	1	O
-	0	O
isomer	0	O
.	0	O


Further	0	O
investigation	0	O
on	0	O
the	0	O
chemotactic	0	O
influence	0	O
of	0	O
thymic	0	B
hormone	0	I
on	0	O
lymphocytes	0	O


Molecular	1	O
cloning	0	O
of	0	O
a	0	O
novel	0	O
human	0	B
I	1	I
-	0	I
mfa	0	I
domain	0	I
-	0	I
containing	0	I
protein	0	I
that	0	O
differently	0	O
regulates	0	O
human	0	O
T	1	O
-	0	O
cell	0	O
leukemia	0	O
virus	0	O
type	0	O
I	1	O
and	0	O
HIV	1	O
-	0	O
1	0	O
expression	0	O
.	0	O


We	0	O
have	0	O
developed	0	O
a	0	O
new	0	O
method	0	O
for	0	O
estimation	0	O
of	0	O
regional	0	O
CBF	1	O
(	0	O
rCBF	1	O
)	0	O
and	0	O
cerebrovascular	0	O
reserve	0	O
capacity	0	O
on	0	O
a	0	O
pixel	0	O
-	0	O
by	0	O
-	0	O
pixel	0	O
basis	0	O
by	0	O
means	0	O
of	0	O
dynamic	0	O
magnetic	0	O
resonance	0	O
imaging	0	O
(	0	O
MRI	1	O
).	0	O


However	0	O
,	0	O
its	0	O
participation	0	O
in	0	O
collagen	0	B
binding	0	O
has	0	O
not	0	O
been	0	O
shown	0	O
.	0	O


Movement	1	O
programming	0	O
depends	0	O
on	0	O
understanding	0	O
of	0	O
behavioral	0	O
requirements	0	O
.	0	O


The	0	O
TraD	0	B
protein	0	I
(	0	I
83	0	I
,	0	I
899	0	I
Da	1	I
)	0	I
contains	0	O
three	0	O
hydrophobic	0	O
regions	0	O
,	0	O
of	0	O
which	0	O
two	0	O
are	0	O
located	0	O
near	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
region	0	O
.	0	O


Merlie	0	O
,	0	O
Cold	1	O
Spring	1	O
Harbor	0	O
Symp	0	O
.	0	O


Crosstalk	1	O
among	0	O
the	0	O
pathways	0	O
may	0	O
explain	0	O
how	0	O
some	0	O
forms	0	O
of	0	O
stress	0	O
can	0	O
contribute	0	O
to	0	O
the	0	O
development	0	O
of	0	O
a	0	O
malignancy	0	O
.	0	O


A	1	O
water	0	O
-	0	O
vapour	0	O
giga	0	O
-	0	O
maser	0	O
in	0	O
the	0	O
active	0	O
galaxy	0	O
TXFS2226	0	O
-	0	O
184	0	O
.	0	O


We	0	O
have	0	O
demonstrated	0	O
previously	0	O
that	0	O
two	0	O
binding	0	O
sites	0	O
in	0	O
the	0	O
-	0	B
184	0	I
HNF	1	I
-	0	I
3	0	I
beta	0	I
promoter	0	I
are	0	O
recognized	0	O
by	0	O
widely	0	O
distributed	0	O
factors	0	O
and	0	O
that	0	O
there	0	O
is	0	O
also	0	O
a	0	O
critical	0	O
autoregulatory	0	O
site	0	O
,	0	O
we	0	O
identified	0	O
a	0	O
binding	0	O
site	0	O
for	0	O
a	0	O
cell	0	O
-	0	O
specific	0	O
factor	0	O
,	0	O
LF	1	B
-	0	I
H3	0	I
beta	0	I
,	0	O
that	0	O
may	0	O
function	0	O
in	0	O
restricting	0	O
HNF	1	B
-	0	I
3	0	I
beta	0	I
gene	0	I
expression	0	O
to	0	O
hepatocytes	0	O
.	0	O


The	0	O
microcirculatory	0	O
dynamics	0	O
of	0	O
prostaglandin	0	O
E1	1	O
and	0	O
/	0	O
or	0	O
nicardipine	0	O
and	0	O
their	0	O
different	0	O
reactions	0	O
in	0	O
the	0	O
hyper	0	O
-	0	O
and	0	O
hypodynamic	0	O
state	0	O
of	0	O
septic	0	O
shock	0	O
in	0	O
a	0	O
rat	0	O
model	0	O


Four	0	O
out	0	O
of	0	O
10	0	O
patients	0	O
showed	0	O
clinical	0	O
improvement	0	O
according	0	O
to	0	O
Ritchie	0	O
-	0	O
Index	1	O
,	0	O
pain	0	O
score	0	O
,	0	O
ESR	1	O
and	0	O
CRP	1	B
.	0	O


The	0	O
model	0	O
captures	0	O
the	0	O
essence	0	O
of	0	O
predator	0	O
-	0	O
prey	0	O
dynamics	0	O
to	0	O
provide	0	O
reasonable	0	O
predictions	0	O
of	0	O
population	0	O
patterns	0	O
.	0	O


The	0	O
second	0	O
goal	0	O
was	0	O
to	0	O
ascertain	0	O
the	0	O
somatotopic	0	O
arrangement	0	O
of	0	O
the	0	O
GPi	0	O
in	0	O
PD	1	O
.	0	O


The	0	O
malignity	0	O
of	0	O
nevoid	0	O
lentigo	0	O
.	0	O


Rapid	0	O
detection	0	O
of	0	O
this	0	O
mutation	0	O
is	0	O
achieved	0	O
by	0	O
restriction	0	O
digestion	0	O
of	0	O
PCR	1	O
-	0	O
amplified	0	O
genomic	0	O
DNA	1	O
;	0	O
a	0	O
mismatch	0	O
primer	0	O
combined	0	O
with	0	O
the	0	O
point	0	O
mutation	0	O
creates	0	O
a	0	O
Tru9I	0	B
restriction	0	I
site	0	I
.	0	O


Treatment	1	O
also	0	O
led	0	O
to	0	O
a	0	O
significant	0	O
dose	0	O
dependent	0	O
reduction	0	O
in	0	O
the	0	O
sum	0	O
of	0	O
ST	1	O
segment	0	O
depression	0	O
at	0	O
both	0	O
trough	0	O
and	0	O
peak	0	O
concentrations	0	O
.	0	O


[	0	O
Pulmonary	1	O
vascular	0	O
resistance	0	O
(	0	O
PVR	0	O
)	0	O
during	0	O
10	0	O
%	0	O
O2	1	O
-	0	O
PVR	0	O
during	0	O
21	0	O
%	0	O
O2	1	O
/	0	O
PVR	0	O
during	0	O
21	0	O
%	0	O
O2	1	O
]	0	O
x	0	O
100	0	O
was	0	O
termed	0	O
as	0	O
hypoxic	0	O
pulmonary	0	O
vasoconstriction	0	O
(	0	O
HPV	1	O
).	0	O


The	0	O
mechanism	0	O
underlying	0	O
such	0	O
analgesia	0	O
has	0	O
been	0	O
suggested	0	O
to	0	O
involve	0	O
the	0	O
interaction	0	O
between	0	O
the	0	O
two	0	O
separate	0	O
but	0	O
interconnected	0	O
motivational	0	O
systems	0	O
"	0	O
defense	0	O
"	0	O
and	0	O
"	0	O
pain	0	O
."	0	O
To	1	O
determine	0	O
the	0	O
developmental	0	O
course	0	O
of	0	O
defense	0	O
and	0	O
nociception	0	O
,	0	O
these	0	O
processes	0	O
were	0	O
analyzed	0	O
during	0	O
early	0	O
ontogeny	0	O
in	0	O
rats	0	O
.	0	O


The	0	O
gene	0	O
is	0	O
contained	0	O
within	0	O
a	0	O
1	0	O
.	0	O
8	0	O
-	0	O
kilobase	0	O
AccI	0	B
-	0	O
EcoRI	0	B
restriction	0	O
fragment	0	O
mapping	0	O
at	0	O
map	0	O
coordinates	0	O
0	0	O
.	0	O
136	0	O
to	0	O
0	0	O
.	0	O
148	0	O
in	0	O
the	0	O
UL	0	O
region	0	O
of	0	O
the	0	O
EHV	0	O
-	0	O
1	0	O
genome	0	O
and	0	O
is	0	O
transcribed	0	O
from	0	O
right	0	O
to	0	O
left	0	O
.	0	O


The	0	O
character	0	O
of	0	O
specific	0	O
immune	0	O
response	0	O
in	0	O
101	0	O
immunized	0	O
children	0	O
and	0	O
in	0	O
12	0	O
adults	0	O
belonging	0	O
to	0	O
a	0	O
high	0	O
risk	0	O
group	0	O
with	0	O
respect	0	O
to	0	O
VHB	0	O
.	0	O


It	1	O
corresponds	0	O
to	0	O
the	0	O
complete	0	O
mitochondrial	0	O
presequence	0	O
and	0	O
the	0	O
lipoyl	0	O
-	0	O
bearing	0	O
domain	0	O
that	0	O
are	0	O
encoded	0	O
by	0	O
exons	0	O
I	1	O
through	0	O
IV	1	O
of	0	O
the	0	O
functional	0	O
E2	1	B
gene	0	I
.	0	O


The	0	O
linear	0	O
plasmid	0	O
pCLU1	0	O
from	0	O
the	0	O
yeast	0	O
Kluyveromyces	0	O
lactis	0	O
normally	0	O
replicates	0	O
in	0	O
the	0	O
cytoplasm	0	O
,	0	O
with	0	O
the	0	O
aid	0	O
of	0	O
the	0	O
helper	0	O
linear	0	O
plasmid	0	O
pGKL2	0	O
,	0	O
using	0	O
terminal	0	B
protein	0	I
(	0	O
TP	1	B
)	0	O
as	0	O
a	0	O
primer	0	O
.	0	O


Two	0	O
major	0	O
and	0	O
one	0	O
minor	0	O
transcription	0	O
initiation	0	O
sites	0	O
were	0	O
assigned	0	O
to	0	O
positions	0	O
+	0	O
1	0	O
and	0	O
+	0	O
24	0	O
and	0	O
position	0	O
+	0	O
14	0	O
,	0	O
respectively	0	O
,	0	O
by	0	O
a	0	O
combination	0	O
of	0	O
ribonuclease	0	O
protection	0	O
,	0	O
primer	0	O
extension	0	O
,	0	O
and	0	O
5	0	O
'	0	O
RACE	1	O
analyses	0	O
.	0	O


ISIS	0	O
5	0	O
possibilities	0	O
.	0	O


Polysome	1	O
analysis	0	O
further	0	O
indicated	0	O
that	0	O
these	0	O
germ	0	B
cell	0	I
-	0	I
specific	0	I
Sp1	0	I
mRNAs	0	I
are	0	O
translated	0	O
,	0	O
albeit	0	O
with	0	O
a	0	O
lower	0	O
efficiency	0	O
than	0	O
the	0	O
somatic	0	O
transcript	0	O
.	0	O


The	0	O
complete	0	O
circular	0	O
TTV	1	O
genome	0	O
contained	0	O
a	0	O
novel	0	O
sequence	0	O
of	0	O
113	0	O
nt	0	O
(	0	O
nt	0	O
3740	0	O
to	0	O
3852	0	O
[=	0	O
0	0	O
])	0	O
in	0	O
between	0	O
the	0	O
known	0	O
3	0	O
'-	0	O
and	0	O
5	0	O
'-	0	O
end	0	O
arms	0	O
,	0	O
forming	0	O
a	0	O
117	0	O
-	0	O
nt	0	O
GC	1	O
-	0	O
rich	0	O
stretch	0	O
(	0	O
GC	1	O
content	0	O
,	0	O
90	0	O
.	0	O
6	0	O
%	0	O
at	0	O
nt	0	O
3736	0	O
to	0	O
3852	0	O
).	0	O


The	0	O
purpose	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
analyze	0	O
the	0	O
temporal	0	O
characteristics	0	O
and	0	O
the	0	O
spatial	0	O
mapping	0	O
of	0	O
the	0	O
independent	0	O
components	0	O
identified	0	O
by	0	O
ICA	1	O
when	0	O
the	0	O
subject	0	O
performs	0	O
a	0	O
finger	0	O
-	0	O
tapping	0	O
task	0	O
.	0	O


In	1	O
a	0	O
randomized	0	O
double	0	O
-	0	O
blind	0	O
cross	0	O
-	0	O
over	0	O
study	0	O
,	0	O
the	0	O
subjects	0	O
received	0	O
theophylline	0	O
5	0	O
mg	0	O
.	0	O
kg	0	O
-	0	O
1	0	O
per	0	O
day	0	O
with	0	O
omeprazole	0	O
20	0	O
mg	0	O
per	0	O
day	0	O
or	0	O
identical	0	O
placebo	0	O
during	0	O
two	0	O
periods	0	O
,	0	O
each	0	O
of	0	O
7	0	O
days	0	O
,	0	O
separated	0	O
by	0	O
a	0	O
washout	0	O
period	0	O
of	0	O
7	0	O
days	0	O
.	0	O


The	0	O
control	0	O
group	0	O
revealed	0	O
significantly	0	O
higher	0	O
levels	0	O
of	0	O
coagulation	0	B
factors	0	I
II	0	I
,	0	I
V	1	I
and	0	I
VIII	0	I
,	0	O
compared	0	O
to	0	O
the	0	O
index	0	O
group	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Pretreatment	1	O
with	0	O
OCs	0	O
prior	0	O
to	0	O
pituitary	0	O
suppression	0	O
in	0	O
the	0	O
early	0	O
follicular	0	O
phase	0	O
decreases	0	O
ovarian	0	O
cyst	0	O
formation	0	O
,	0	O
without	0	O
an	0	O
apparent	0	O
effect	0	O
on	0	O
subsequent	0	O
follicular	0	O
recruitment	0	O
or	0	O
pregnancy	0	O
rates	0	O
.	0	O


After	0	O
peripheral	0	O
administration	0	O
of	0	O
both	0	O
CRF	1	B
and	0	O
TRH	1	B
,	0	O
ACTH	1	B
levels	0	O
were	0	O
significantly	0	O
higher	0	O
on	0	O
the	0	O
tumor	0	O
side	0	O
in	0	O
all	0	O
patients	0	O
.	0	O


The	0	O
mouse	0	O
extracellular	0	B
signal	0	I
-	0	I
regulated	0	I
kinase	0	I
2	0	I
gene	0	I
.	0	O


However	0	O
,	0	O
the	0	O
requirement	0	O
of	0	O
rev3	0	B
for	0	O
the	0	O
production	0	O
of	0	O
G	1	O
.	0	O
C	1	O
-->	0	O
T	1	O
.	0	O
A	1	O
transversions	0	O
by	0	O
the	0	O
rad18	0	B
mutator	0	I
,	0	O
which	0	O
induces	0	O
only	0	O
these	0	O
substitutions	0	O
,	0	O
was	0	O
similar	0	O
to	0	O
that	0	O
for	0	O
rad6	0	B
-	0	O
mediated	0	O
G	1	O
.	0	O
C	1	O
-->	0	O
T	1	O
.	0	O
A	1	O
transversion	0	O
.	0	O


The	0	O
interaction	0	O
of	0	O
radiation	0	O
and	0	O
hyperthermia	0	O
was	0	O
systematically	0	O
studied	0	O
in	0	O
the	0	O
Dunning	0	O
R3327G	0	O
prostatic	0	O
adenocarcinoma	0	O
,	0	O
the	0	O
preeminent	0	O
animal	0	O
model	0	O
for	0	O
human	0	O
prostatic	0	O
cancer	0	O
.	0	O


Replacement	1	B
variant	0	I
histone	0	I
genes	0	I
contain	0	O
intervening	0	O
sequences	0	O
.	0	O


The	0	O
microdensitometric	0	O
scores	0	O
and	0	O
their	0	O
side	0	O
-	0	O
to	0	O
-	0	O
side	0	O
differences	0	O
in	0	O
patients	0	O
correlated	0	O
negatively	0	O
with	0	O
the	0	O
serum	0	O
25	0	O
-	0	O
OHD	0	O
concentration	0	O
and	0	O
positively	0	O
with	0	O
the	0	O
degree	0	O
of	0	O
paralysis	0	O
.	0	O


The	0	O
case	0	O
described	0	O
is	0	O
that	0	O
of	0	O
a	0	O
72	0	O
-	0	O
year	0	O
-	0	O
old	0	O
man	0	O
with	0	O
ochronosis	0	O
who	0	O
suffered	0	O
a	0	O
hyperextension	0	O
injury	0	O
to	0	O
his	0	O
spine	0	O
in	0	O
a	0	O
fall	0	O
,	0	O
resulting	0	O
in	0	O
a	0	O
fracture	0	O
through	0	O
an	0	O
ankylosed	0	O
L2	0	O
-	0	O
L3	0	O
disk	0	O
space	0	O
.	0	O


The	0	O
partial	0	O
categories	0	O
of	0	O
the	0	O
SIP	1	O
that	0	O
were	0	O
more	0	O
affected	0	O
were	0	O
work	0	O
,	0	O
recreation	0	O
and	0	O
pastimes	0	O
,	0	O
home	0	O
management	0	O
,	0	O
and	0	O
sleep	0	O
and	0	O
rest	0	O
.	0	O


The	0	O
SSB	0	B
-	0	O
poly	0	O
(	0	O
dT	1	O
)	0	O
affinity	0	O
is	0	O
too	0	O
high	0	O
to	0	O
measure	0	O
in	0	O
buffers	0	O
containing	0	O
even	0	O
5	0	O
M	1	O
NaCl	1	O
;	0	O
however	0	O
,	0	O
in	0	O
1	0	O
.	0	O
8	0	O
-	0	O
2	0	O
.	0	O
5	0	O
M	1	O
NaBr	1	O
,	0	O
we	0	O
measure	0	O
alpha	0	O
log	0	O
Kobsd	0	O
/	0	O
alpha	0	O
log	0	O
[	0	O
NaBr	1	O
]	0	O
=	0	O
-	0	O
5	0	O
.	0	O
7	0	O
+/-	0	O
0	0	O
.	0	O
7	0	O
,	0	O
with	0	O
a	0	O
lower	0	O
value	0	O
of	0	O
omega	0	O
T	1	O
/	0	O
O	1	O
=	0	O
130	0	O
+/-	0	O
70	0	O
.	0	O


In	1	O
vivo	0	O
dimethyl	0	O
sulfate	0	O
footprinting	0	O
of	0	O
the	0	O
cyclin	0	B
E	1	I
promoter	0	I
revealed	0	O
several	0	O
regions	0	O
of	0	O
protection	0	O
and	0	O
hypersensitivity	0	O
that	0	O
were	0	O
unique	0	O
to	0	O
infected	0	O
cells	0	O
.	0	O


Before	0	O
birth	0	O
,	0	O
there	0	O
were	0	O
a	0	O
few	0	O
perivascular	0	O
adrenergic	0	O
nerves	0	O
and	0	O
correspondingly	0	O
low	0	O
ovarian	0	O
NE	1	O
levels	0	O
.	0	O


The	0	O
scr	0	B
regulon	0	I
of	0	O
pUR400	0	O
and	0	O
the	0	O
chromosomally	0	B
encoded	0	I
scr	0	I
regulon	0	I
of	0	I
Klebsiella	1	I
pneumoniae	0	I
KAY2026	0	I
are	0	O
both	0	O
negatively	0	O
controlled	0	O
by	0	O
a	0	O
specific	0	O
repressor	0	O
(	0	O
ScrR	0	B
).	0	O


The	0	O
protein	0	O
expressed	0	O
from	0	O
the	0	O
cloned	0	O
cDNA	1	O
is	0	O
secreted	0	O
into	0	O
the	0	O
culture	0	O
medium	0	O
and	0	O
yields	0	O
of	0	O
up	0	O
to	0	O
40	0	O
mg	0	O
per	0	O
litre	0	O
have	0	O
been	0	O
obtained	0	O
.	0	O


To	1	O
measure	0	O
the	0	O
enhancer	0	O
activity	0	O
of	0	O
DR60	0	B
,	0	O
a	0	O
reporter	0	O
plasmid	0	O
was	0	O
constructed	0	O
that	0	O
contained	0	O
DR60	0	B
cloned	0	O
upstream	0	O
of	0	O
the	0	O
reporter	0	O
chloramphenicol	0	B
acetyltransferase	0	I
gene	0	I
under	0	O
the	0	O
control	0	O
of	0	O
the	0	O
delayed	0	O
-	0	O
early	0	O
39K	0	O
promoter	0	O
.	0	O


The	0	O
delta	0	B
srb10	0	I
mutation	0	I
also	0	O
influenced	0	O
on	0	O
the	0	O
transcript	0	O
levels	0	O
of	0	O
meiosis	0	O
-	0	O
inducing	0	O
genes	0	O
called	0	O
IME1	0	B
and	0	O
IME2	0	B
:	0	O
the	0	O
mutation	0	O
elevated	0	O
the	0	O
transcript	0	O
level	0	O
of	0	O
IME1	0	B
but	0	O
reduced	0	O
that	0	O
of	0	O
IME2	0	B
,	0	O
resulting	0	O
in	0	O
partial	0	O
defects	0	O
in	0	O
premeiotic	0	O
DNA	1	O
synthesis	0	O
and	0	O
meiosis	0	O
.	0	O


The	0	O
rhaB	0	B
transcription	0	I
start	0	I
site	0	I
was	0	O
mapped	0	O
to	0	O
-	0	O
24	0	O
relative	0	O
to	0	O
the	0	O
start	0	O
of	0	O
translation	0	O
.	0	O


The	0	O
recombinant	0	O
enzymes	0	O
exist	0	O
as	0	O
monomers	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
grade	0	O
III	0	O
BGCT	0	O
can	0	O
be	0	O
treated	0	O
by	0	O
modified	0	O
intralesional	0	O
excision	0	O
provided	0	O
the	0	O
articular	0	O
surfaces	0	O
and	0	O
part	0	O
of	0	O
the	0	O
metaphysis	0	O
are	0	O
intact	0	O
.	0	O


The	0	O
rate	0	O
of	0	O
enzymic	0	O
stimulation	0	O
induced	0	O
by	0	O
a	0	O
given	0	O
nitrate	0	O
correlates	0	O
closely	0	O
with	0	O
the	0	O
rate	0	O
of	0	O
measured	0	O
NO	1	O
production	0	O
from	0	O
the	0	O
nitrate	0	O
molecule	0	O
.	0	O


Homozygous	1	O
mutation	0	O
in	0	O
two	0	O
children	0	O
led	0	O
to	0	O
amputation	0	O
of	0	O
legs	0	O
due	0	O
to	0	O
purpura	0	O
fulminans	0	O
.	0	O


Biological	1	O
action	0	O
and	0	O
kinetics	0	O
of	0	O
the	0	O
elimination	0	O
of	0	O
tritium	0	O
oxide	0	O
in	0	O
dogs	0	O


However	0	O
,	0	O
ICK1	0	B
was	0	O
induced	0	O
by	0	O
ABA	0	O
,	0	O
and	0	O
along	0	O
with	0	O
ICK1	0	B
induction	0	O
there	0	O
was	0	O
a	0	O
decrease	0	O
in	0	O
Cdc2	0	B
-	0	I
like	0	I
histone	0	I
H1	1	I
kinase	0	I
activity	0	O
.	0	O


The	0	O
sequence	0	O
upstream	0	O
of	0	O
the	0	O
rhlA	0	B
promoter	0	I
contains	0	O
two	0	O
inverted	0	O
repeats	0	O
which	0	O
define	0	O
putative	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
RhlR	0	B
regulator	0	I
.	0	O


The	0	O
level	0	O
of	0	O
serum	0	B
creatine	0	I
kinase	0	I
was	0	O
significantly	0	O
high	0	O
2	0	O
days	0	O
after	0	O
ESWIB	0	O
,	0	O
but	0	O
it	0	O
recovered	0	O
in	0	O
a	0	O
week	0	O
.	0	O


Viruses	0	O
were	0	O
isolated	0	O
from	0	O
9	0	O
lungs	0	O
:	0	O
7	0	O
with	0	O
PI	1	O
-	0	O
3V	0	O
,	0	O
1	0	O
with	0	O
NCP	0	O
BVDV	0	O
type	0	O
1	0	O
,	0	O
and	0	O
1	0	O
with	0	O
both	0	O
BVHV	0	O
-	0	O
1	0	O
and	0	O
BVDV	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
npm3	0	B
,	0	O
which	0	O
is	0	O
usually	0	O
coactivated	0	O
with	0	O
fgf8	0	B
by	0	O
MMTV	0	O
insertion	0	O
,	0	O
was	0	O
not	0	O
up	0	O
-	0	O
regulated	0	O
by	0	O
androgens	0	O
in	0	O
SC	1	O
-	0	O
3	0	O
cells	0	O
.	0	O


MVR	0	O
typing	0	O
of	0	O
rare	0	O
-	0	O
length	0	O
alleles	0	O
indicates	0	O
that	0	O
they	0	O
are	0	O
comprised	0	O
of	0	O
disorganized	0	O
sequences	0	O
,	0	O
although	0	O
they	0	O
usually	0	O
bear	0	O
a	0	O
resemblance	0	O
to	0	O
one	0	O
of	0	O
the	0	O
common	0	O
alleles	0	O
at	0	O
the	0	O
5	0	O
'-	0	O
most	0	O
end	0	O
.	0	O


Moreover	0	O
,	0	O
xTAK1KN	0	B
could	0	O
block	0	O
the	0	O
expression	0	O
of	0	O
ventral	0	O
mesoderm	0	O
marker	0	O
genes	0	O
induced	0	O
by	0	O
Smad1	0	B
or	0	I
5	0	I
.	0	O


The	0	O
method	0	O
described	0	O
may	0	O
prove	0	O
useful	0	O
in	0	O
studying	0	O
the	0	O
physiology	0	O
of	0	O
the	0	O
nasal	0	O
cycle	0	O
.	0	O


Further	0	O
experiments	0	O
will	0	O
be	0	O
required	0	O
to	0	O
highlight	0	O
the	0	O
in	0	O
vivo	0	O
role	0	O
of	0	O
ELE1	0	B
in	0	O
nuclear	0	O
receptor	0	O
functioning	0	O
.	0	O


This	0	O
spindle	0	O
defect	0	O
of	0	O
pds1	0	B
mutants	0	I
results	0	O
from	0	O
a	0	O
temperature	0	O
-	0	O
sensitive	0	O
step	0	O
that	0	O
occurs	0	O
around	0	O
the	0	O
G1	0	O
/	0	O
S	1	O
boundary	0	O
about	0	O
the	0	O
time	0	O
of	0	O
spindle	0	O
assembly	0	O
.	0	O


RESULTS	0	O
:	0	O
The	0	O
diagnostic	0	O
quality	0	O
of	0	O
FDG	1	O
images	0	O
was	0	O
at	0	O
least	0	O
as	0	O
good	0	O
as	0	O
that	0	O
of	0	O
their	0	O
Tl	1	O
-	0	O
201	0	O
counterparts	0	O
,	0	O
with	0	O
less	0	O
liver	0	O
background	0	O
in	0	O
all	0	O
but	0	O
one	0	O
FDG	1	O
study	0	O
.	0	O


In	1	O
order	0	O
to	0	O
examine	0	O
the	0	O
potential	0	O
role	0	O
of	0	O
transcriptional	0	O
silencing	0	O
during	0	O
productive	0	O
HSV	1	O
-	0	O
1	0	O
infection	0	O
,	0	O
recombinant	0	O
viruses	0	O
were	0	O
generated	0	O
in	0	O
which	0	O
wild	0	B
-	0	I
type	0	I
or	0	I
mutant	0	I
ICP34	0	I
.	0	I
5	0	I
promoters	0	I
controlling	0	O
the	0	O
expression	0	O
of	0	O
a	0	O
chloramphenicol	0	B
acetyltransferase	0	I
reporter	0	I
gene	0	I
were	0	O
inserted	0	O
into	0	O
the	0	O
thymidine	0	B
kinase	0	I
gene	0	I
of	0	O
the	0	O
viral	0	O
genome	0	O
.	0	O


This	0	O
article	0	O
reviews	0	O
recent	0	O
information	0	O
on	0	O
the	0	O
frequency	0	O
,	0	O
characteristics	0	O
,	0	O
and	0	O
possible	0	O
pathogenic	0	O
mechanisms	0	O
of	0	O
the	0	O
vasculitides	0	O
occurring	0	O
in	0	O
patients	0	O
with	0	O
the	0	O
main	0	O
connective	0	O
tissue	0	O
diseases	0	O
.	0	O


Further	0	O
studies	0	O
of	0	O
mandibular	0	O
movement	0	O
at	0	O
initial	0	O
tooth	0	O
contact	0	O
.	0	O


These	0	O
results	0	O
further	0	O
support	0	O
an	0	O
important	0	O
role	0	O
for	0	O
CBF2	0	B
in	0	O
mediating	0	O
EBNA2	0	B
transactivation	0	O
;	0	O
they	0	O
identify	0	O
the	0	O
hnRNP	1	B
protein	0	I
AUF1	0	I
as	0	O
a	0	O
major	0	O
component	0	O
of	0	O
CBF2	0	B
and	0	O
are	0	O
also	0	O
the	0	O
first	0	O
evidence	0	O
of	0	O
a	0	O
cis	0	O
-	0	O
acting	0	O
sequence	0	O
other	0	O
than	0	O
a	0	O
CBF1	0	B
binding	0	I
element	0	I
that	0	O
is	0	O
able	0	O
to	0	O
confer	0	O
responsiveness	0	O
to	0	O
EBNA2	0	B
.	0	O


Nocodazole	0	O
arrest	0	O
of	0	O
DU249	0	O
cells	0	O
was	0	O
exploited	0	O
for	0	O
the	0	O
detection	0	O
of	0	O
an	0	O
M	1	O
-	0	O
phase	0	O
-	0	O
activated	0	O
MBP	1	B
kinase	0	I
that	0	O
was	0	O
resolved	0	O
from	0	O
p41	0	B
MAP	1	I
kinase	0	I
by	0	O
phenyl	0	O
-	0	O
Superose	0	O
chromatography	0	O
.	0	O


Latanoprost	1	O
produces	0	O
an	0	O
additional	0	O
reduction	0	O
of	0	O
intraocular	0	O
pressure	0	O
(	0	O
IOP	1	O
)	0	O
when	0	O
used	0	O
in	0	O
combination	0	O
with	0	O
timolol	0	O
,	0	O
pilocarpine	0	O
,	0	O
acetazolamide	0	O
and	0	O
dipivefrin	0	O
.	0	O


Overexpression	1	O
of	0	O
c	0	B
-	0	I
Myc	0	I
in	0	O
serum	0	O
-	0	O
starved	0	O
human	0	O
or	0	O
mouse	0	O
embryonic	0	O
cells	0	O
leads	0	O
to	0	O
apoptosis	0	O
which	0	O
is	0	O
significantly	0	O
reduced	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
growth	0	O
factor	0	O
-	0	O
containing	0	O
serum	0	O
.	0	O
c	0	B
-	0	I
Myc	0	I
-	0	O
induced	0	O
apoptosis	0	O
appears	0	O
to	0	O
be	0	O
deficient	0	O
in	0	O
bax	0	B
-	0	O
null	0	O
as	0	O
compared	0	O
with	0	O
bax	0	B
-	0	O
wild	0	O
-	0	O
type	0	O
mouse	0	O
embryonic	0	O
fibroblasts	0	O
.	0	O


Analysis	1	O
in	0	O
3	0	O
groups	0	O
of	0	O
patients	0	O
suffering	0	O
from	0	O
simple	0	O
acute	0	O
and	0	O
pernicious	0	O
malarial	0	O
flare	0	O
-	0	O
ups	0	O


Alkoxymetgyl	0	O
-	0	O
3	0	O
,	0	O
4	0	O
-	0	O
dimethylpyridinium	0	O
chlorides	0	O
were	0	O
synthetized	0	O
by	0	O
reacting	0	O
3	0	O
,	0	O
4	0	O
-	0	O
dimethylpyridine	0	O
with	0	O
chloromethyl	0	O
alkyl	0	O
ethers	0	O
,	0	O
while	0	O
1	0	O
-	0	O
ethyloxymethyl	0	O
-	0	O
3	0	O
-	0	O
alkylthiomethylimidazolium	0	O
chlorides	0	O
were	0	O
obtained	0	O
in	0	O
reactions	0	O
of	0	O
1	0	O
-	0	O
ethyloxymethylimidazol	0	O
with	0	O
chloromethyl	0	O
alkyl	0	O
sulfides	0	O
.	0	O


Immunolocalization	0	O
of	0	O
Sop1p	0	B
revealed	0	O
a	0	O
cytoplasmic	0	O
distribution	0	O
and	0	O
cell	0	O
fractionation	0	O
studies	0	O
showed	0	O
that	0	O
a	0	O
significant	0	O
fraction	0	O
of	0	O
Sop1p	0	B
was	0	O
recovered	0	O
in	0	O
a	0	O
sedimentable	0	O
fraction	0	O
of	0	O
the	0	O
cytosolic	0	O
material	0	O
.	0	O


Chemotherapy	1	O
was	0	O
administered	0	O
without	0	O
altering	0	O
the	0	O
course	0	O
of	0	O
the	0	O
disorder	0	O
.	0	O


Thus	0	O
,	0	O
in	0	O
stress	0	O
-	0	O
induced	0	O
arrhythmic	0	O
disease	0	O
as	0	O
well	0	O
as	0	O
in	0	O
ischemic	0	O
heart	0	O
disease	0	O
,	0	O
the	0	O
main	0	O
pathogenetic	0	O
links	0	O
are	0	O
outside	0	O
the	0	O
heart	0	O
,	0	O
but	0	O
they	0	O
differ	0	O
from	0	O
those	0	O
observed	0	O
in	0	O
ischemia	0	O
.	0	O


Most	0	O
likely	0	O
they	0	O
might	0	O
represent	0	O
regulatory	0	O
RNAs	0	O
or	0	O
transcribed	0	O
transposable	0	O
elements	0	O
.	0	O


The	0	O
60A	0	B
transcripts	0	I
and	0	O
protein	0	O
are	0	O
first	0	O
detected	0	O
at	0	O
the	0	O
onset	0	O
of	0	O
gastrulation	0	O
,	0	O
primarily	0	O
in	0	O
the	0	O
mesoderm	0	O
of	0	O
the	0	O
extending	0	O
germ	0	O
band	0	O
.	0	O


Cytokine	1	O
-	0	O
induced	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
DNA	1	O
binding	0	O
activity	0	O
,	0	O
RelA	0	B
nuclear	0	O
translocation	0	O
,	0	O
I	1	B
kappa	0	I
B	1	I
alpha	0	I
degradation	0	O
,	0	O
I	1	B
kappa	0	I
B	1	I
serine	0	O
32	0	O
phosphorylation	0	O
,	0	O
and	0	O
I	1	B
kappa	0	I
B	1	I
kinase	0	I
(	0	O
IKK	0	B
)	0	O
activity	0	O
were	0	O
blocked	0	O
by	0	O
curcumin	0	O
treatment	0	O
.	0	O


This	0	O
observation	0	O
cannot	0	O
be	0	O
explained	0	O
by	0	O
the	0	O
scanning	0	O
model	0	O
for	0	O
ribosomal	0	O
initiation	0	O
and	0	O
suggests	0	O
that	0	O
ribosomes	0	O
may	0	O
be	0	O
binding	0	O
directly	0	O
at	0	O
an	0	O
internal	0	O
mRNA	1	O
site	0	O
at	0	O
or	0	O
near	0	O
the	0	O
initiator	0	O
AUG	0	O
codon	0	O
for	0	O
the	0	O
C	1	B
protein	0	I
.	0	O


Similar	0	O
results	0	O
were	0	O
obtained	0	O
with	0	O
xylitol	0	O
,	0	O
an	0	O
activator	0	O
of	0	O
the	0	O
pentose	0	O
phosphate	0	O
pathway	0	O
.	0	O


Blood	1	O
levels	0	O
of	0	O
melatonin	0	O
,	0	O
serotonin	0	O
,	0	O
cortisol	0	O
,	0	O
and	0	O
prolactin	0	B
in	0	O
relation	0	O
to	0	O
the	0	O
circadian	0	O
rhythm	0	O
of	0	O
platelet	0	O
serotonin	0	O
uptake	0	O
.	0	O


Northern	0	O
analyses	0	O
of	0	O
RNAs	0	O
from	0	O
mouse	0	O
tissues	0	O
and	0	O
cell	0	O
lines	0	O
indicated	0	O
that	0	O
p11	0	B
mRNA	1	I
levels	0	O
vary	0	O
widely	0	O
.	0	O


The	0	O
1	0	O
.	0	O
9	0	O
-	0	O
kb	0	O
C	1	B
mu	0	I
RNA	1	O
contains	0	O
the	0	O
3	0	O
'	0	O
sequence	0	O
characteristic	0	O
of	0	O
secreted	0	O
mu	0	B
chain	0	I
,	0	O
whereas	0	O
the	0	O
longer	0	O
species	0	O
bear	0	O
that	0	O
of	0	O
membrane	0	O
-	0	O
bound	0	O
mu	0	B
chin	0	O
.	0	O


Interplane	0	O
coupling	0	O
in	0	O
the	0	O
superconductor	0	O
Y2Ba4Cu7O15	0	O
as	0	O
revealed	0	O
by	0	O
NQR	0	O
spin	0	O
-	0	O
echo	0	O
double	0	O
resonance	0	O
.	0	O


METHODS	0	O
:	0	O
Out	0	O
of	0	O
171	0	O
patients	0	O
receiving	0	O
anticoagulation	0	O
between	0	O
July	0	O
1992	0	O
and	0	O
December	0	O
1993	0	O
,	0	O
83	0	O
patients	0	O
with	0	O
hemispheric	0	O
embolisms	0	O
received	0	O
heparin	0	O
within	0	O
72	0	O
hours	0	O
from	0	O
onset	0	O
(	0	O
activated	0	O
partial	0	O
thromboplastin	0	B
time	0	O
[	0	O
aPTT	1	O
]	0	O
1	0	O
.	0	O
5	0	O
times	0	O
control	0	O
value	0	O
).	0	O


Overall	0	O
,	0	O
our	0	O
results	0	O
suggest	0	O
that	0	O
resistant	0	O
genotypes	0	O
exist	0	O
among	0	O
the	0	O
WAD	0	O
goat	0	O
population	0	O
.	0	O


Ten	0	O
out	0	O
of	0	O
10	0	O
patients	0	O
with	0	O
progressive	0	O
disease	0	O
had	0	O
mast	0	O
cells	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
0	0	O
.	0	O
5	0	O
%,	0	O
hyaluronan	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
50	0	O
micrograms	0	O
.	0	O
l	0	O
-	0	O
1	0	O
and	0	O
fibronectin	0	B
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
350	0	O
micrograms	0	O
.	0	O
l	0	O
-	0	O
1	0	O
compared	0	O
to	0	O
eight	0	O
out	0	O
of	0	O
41	0	O
patients	0	O
with	0	O
stable	0	O
or	0	O
regressive	0	O
disease	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


In	1	O
the	0	O
adult	0	O
mouse	0	O
,	0	O
ERR	0	B
alpha	0	I
is	0	O
most	0	O
highly	0	O
expressed	0	O
in	0	O
kidney	0	O
,	0	O
heart	0	O
,	0	O
and	0	O
brown	0	O
adipocytes	0	O
,	0	O
tissues	0	O
which	0	O
preferentially	0	O
metabolize	0	O
fatty	0	O
acids	0	O
.	0	O


By	0	O
using	0	O
the	0	O
full	0	O
-	0	O
length	0	O
cytoplasmic	0	O
domain	0	O
and	0	O
mutants	0	O
with	0	O
progressive	0	O
carboxy	0	O
-	0	O
terminal	0	O
deletions	0	O
,	0	O
internal	0	O
deletions	0	O
,	0	O
or	0	O
point	0	O
mutations	0	O
,	0	O
we	0	O
identified	0	O
the	0	O
first	0	O
150	0	O
amino	0	O
acid	0	O
residues	0	O
of	0	O
LIFR	0	B
as	0	O
the	0	O
minimal	0	O
region	0	O
necessary	0	O
for	0	O
signaling	0	O
.	0	O


Experiment	1	O
3	0	O
showed	0	O
that	0	O
the	0	O
long	0	O
-	0	O
term	0	O
analgesic	0	O
reaction	0	O
could	0	O
also	0	O
be	0	O
reduced	0	O
by	0	O
administration	0	O
of	0	O
naltrexone	0	O
prior	0	O
to	0	O
reexposure	0	O
to	0	O
shock	0	O
.	0	O


To	1	O
discern	0	O
whether	0	O
these	0	O
disorders	0	O
of	0	O
GnRH	0	B
deficiency	0	O
are	0	O
associated	0	O
with	0	O
altered	0	O
melatonin	0	O
secretion	0	O
profiles	0	O
,	0	O
we	0	O
compared	0	O
untreated	0	O
young	0	O
males	0	O
IGD	1	O
(	0	O
n	0	O
=	0	O
7	0	O
)	0	O
and	0	O
DP	1	O
(	0	O
n	0	O
=	0	O
7	0	O
)	0	O
to	0	O
normal	0	O
pubertal	0	O
male	0	O
controls	0	O
(	0	O
n	0	O
=	0	O
6	0	O
).	0	O


Two	0	O
promoters	0	O
were	0	O
identified	0	O
by	0	O
S1	1	B
nuclease	0	I
mapping	0	O
:	0	O
P1	1	O
,	0	O
which	0	O
lies	0	O
about	0	O
72	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
structural	0	O
gene	0	O
;	0	O
and	0	O
P2	1	O
,	0	O
which	0	O
lies	0	O
about	0	O
35	0	O
bp	0	O
upstream	0	O
.	0	O


Temperature	1	O
dependence	0	O
of	0	O
the	0	O
sublattice	0	O
spontaneous	0	O
magnetization	0	O
of	0	O
YBa2Cu3O6	0	O
.	0	O


Further	0	O
analysis	0	O
of	0	O
this	0	O
domain	0	O
by	0	O
in	0	O
vitro	0	O
mutagenesis	0	O
pointed	0	O
to	0	O
a	0	O
core	0	O
of	0	O
hydrophobic	0	O
and	0	O
acidic	0	O
residues	0	O
as	0	O
critical	0	O
for	0	O
the	0	O
activity	0	O
.	0	O


Effect	1	O
of	0	O
triftazin	0	O
and	0	O
aminazin	0	O
on	0	O
hippocampal	0	O
bioelectric	0	O
activity	0	O


Invited	0	O
editorial	0	O
on	0	O
"	0	O
Acute	1	O
and	0	O
chronic	0	O
effects	0	O
of	0	O
exercise	0	O
on	0	O
leptin	0	B
levels	0	O
in	0	O
humans	0	O
".	0	O


Although	0	O
Pho85	0	B
is	0	O
not	0	O
essential	0	O
for	0	O
viability	0	O
,	0	O
Pcl1	0	B
,	0	I
2	0	I
-	0	O
Pho85	0	B
kinase	0	O
complexes	0	O
become	0	O
essential	0	O
for	0	O
Start	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
Cln1	0	B
,	0	I
2	0	I
-	0	O
Cdc28	0	B
kinases	0	O
.	0	O


The	0	O
p53	0	B
tumor	0	I
suppressor	0	I
gene	0	I
product	0	I
,	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
DNA	1	O
-	0	O
binding	0	O
protein	0	O
,	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
act	0	O
as	0	O
a	0	O
transcriptional	0	O
activator	0	O
and	0	O
repressor	0	O
both	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
data	0	O
indicate	0	O
that	0	O
the	0	O
VirD2	0	B
omega	0	I
domain	0	I
is	0	O
important	0	O
for	0	O
efficient	0	O
T	1	O
-	0	O
DNA	1	O
integration	0	O
.	0	O


This	0	O
apparently	0	O
anomalous	0	O
structure	0	O
/	0	O
activity	0	O
relationship	0	O
raises	0	O
important	0	O
issues	0	O
for	0	O
understanding	0	O
the	0	O
evolution	0	O
of	0	O
regulatory	0	O
peptides	0	O
and	0	O
the	0	O
mechanisms	0	O
that	0	O
control	0	O
their	0	O
expression	0	O
.	0	O


Since	0	O
RCC1p	0	B
acts	0	O
as	0	O
GNRP	0	B
for	0	O
Ran	0	B
,	0	O
a	0	O
small	0	B
nuclear	0	I
GTPase	1	I
of	0	O
the	0	O
ras	0	B
superfamily	0	I
,	0	O
we	0	O
have	0	O
identified	0	O
two	0	O
homologs	0	O
of	0	O
Ran	0	B
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
(	0	O
CNR1	0	B
and	0	O
CNR2	0	B
).	0	O


Examination	1	O
of	0	O
neurohumoral	0	O
factors	0	O
revealed	0	O
a	0	O
hyperactive	0	O
sympathetic	0	O
nervous	0	O
system	0	O
and	0	O
an	0	O
increase	0	O
in	0	O
plasma	0	O
renin	0	B
activity	0	O
.	0	O


Their	0	O
afterglows	0	O
are	0	O
brighter	0	O
than	0	O
supernovae	0	O
and	0	O
therefore	0	O
are	0	O
called	0	O
hypernovae	0	O
.	0	O


A	1	O
novel	0	O
,	0	O
testis	0	B
-	0	I
specific	0	I
mRNA	1	I
transcript	0	I
encoding	0	O
an	0	O
NH2	0	B
-	0	I
terminal	0	I
truncated	0	I
nitric	0	I
-	0	I
oxide	0	I
synthase	0	I
.	0	O
mRNA	1	O
diversity	0	O
represents	0	O
a	0	O
major	0	O
theme	0	O
of	0	O
neuronal	0	B
nitric	0	I
-	0	I
oxide	0	I
synthase	0	I
(	0	O
nNOS	0	B
)	0	O
gene	0	O
expression	0	O
in	0	O
somatic	0	O
cells	0	O
/	0	O
tissues	0	O
.	0	O


All	1	O
corneal	0	O
buttons	0	O
were	0	O
processed	0	O
for	0	O
histopathologic	0	O
and	0	O
electron	0	O
microscopic	0	O
studies	0	O
.	0	O


The	0	O
percentages	0	O
of	0	O
formed	0	O
cysts	0	O
and	0	O
growth	0	O
rates	0	O
were	0	O
monthly	0	O
estimated	0	O
and	0	O
analyzed	0	O
rhythmometrically	0	O
by	0	O
cosinor	0	O
for	0	O
5	0	O
clonal	0	O
cultures	0	O
of	0	O
Scripsiella	0	O
trochoidea	0	O
Stein	0	O
grown	0	O
for	0	O
2	0	O
years	0	O
under	0	O
laboratory	0	O
conditions	0	O
,	0	O
rended	0	O
as	0	O
constant	0	O
as	0	O
possible	0	O
from	0	O
the	0	O
view	0	O
point	0	O
of	0	O
environmental	0	O
temperature	0	O
(	0	O
24	0	O
+/-	0	O
1	0	O
degree	0	O
C	1	O
),	0	O
lighting	0	O
(	0	O
25	0	O
microEin	0	O
m	0	O
-	0	O
2	0	O
s	0	O
-	0	O
1	0	O
),	0	O
and	0	O
artificial	0	O
seawater	0	O
.	0	O


Estrogen	1	B
receptor	0	I
-	0	I
related	0	I
receptor	0	I
alpha	0	I
1	0	I
interacts	0	O
with	0	O
coactivator	0	O
and	0	O
constitutively	0	O
activates	0	O
the	0	O
estrogen	0	O
response	0	O
elements	0	O
of	0	O
the	0	O
human	0	B
lactoferrin	0	I
gene	0	I
.	0	O


8	0	O
%	0	O
(	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
21	0	O
.	0	O
3	0	O
-	0	O
44	0	O
.	0	O
3	0	O
%).	0	O


Hence	0	O
follows	0	O
Kurti	0	O
'	0	O
s	0	O
demand	0	O
to	0	O
mete	0	O
out	0	O
appropriate	0	O
importance	0	O
to	0	O
the	0	O
arguments	0	O
.	0	O


At	1	O
the	0	O
C	1	O
-	0	O
terminus	0	O
of	0	O
the	0	O
protein	0	O
is	0	O
a	0	O
domain	0	O
that	0	O
contains	0	O
sequences	0	O
very	0	O
similar	0	O
to	0	O
those	0	O
found	0	O
in	0	O
the	0	O
breakpoint	0	O
cluster	0	O
region	0	O
gene	0	O
product	0	O
,	0	O
n	0	B
-	0	I
chimerin	0	I
,	0	O
and	0	O
rho	0	B
GAP	1	I
,	0	O
all	0	O
of	0	O
which	0	O
have	0	O
been	0	O
shown	0	O
to	0	O
possess	0	O
intrinsic	0	O
GAP	1	B
activity	0	O
on	0	O
small	0	B
GTPases	0	I
.	0	O


MKK3	0	B
autophosphorylation	0	O
and	0	O
activation	0	O
of	0	O
p38	0	B
was	0	O
also	0	O
observed	0	O
following	0	O
coexpression	0	O
of	0	O
MKK3	0	B
with	0	O
MEKK3	0	B
,	0	O
but	0	O
not	0	O
with	0	O
MEKK2	0	B
.	0	O


In	1	O
contrast	0	O
,	0	O
similar	0	O
rates	0	O
of	0	O
B	1	O
.	0	O
sphaericus	0	O
products	0	O
,	0	O
ABG	1	O
-	0	O
6184	0	O
technical	0	O
powder	0	O
and	0	O
BSP	0	O
-	0	O
2	0	O
flowable	0	O
concentrate	0	O
,	0	O
produced	0	O
no	0	O
significant	0	O
reduction	0	O
.	0	O


Nursing	1	O
home	0	O
discharges	0	O
in	0	O
clinical	0	O
practice	0	O
.	0	O


Treatment	1	O
with	0	O
oxyphenylbutazone	0	O
and	0	O
hydrocortisone	0	O
failed	0	O
to	0	O
inhibit	0	O
the	0	O
raised	0	O
serum	0	B
CPN	0	I
levels	0	O
.	0	O


Utero	0	O
-	0	O
placental	0	O
blood	0	O
flow	0	O
and	0	O
the	0	O
effect	0	O
of	0	O
beta	0	B
2	0	I
-	0	I
adrenoceptor	0	I
stimulating	0	O
drugs	0	O
.	0	O


One	0	O
cDNA	1	O
clone	0	O
designated	0	O
NCoA	0	O
-	0	O
62	0	O
,	0	O
encoded	0	O
a	0	O
62	0	O
,	0	O
000	0	O
-	0	O
Da	1	O
protein	0	O
that	0	O
is	0	O
highly	0	O
related	0	O
to	0	O
BX42	0	B
,	0	O
a	0	O
Drosophila	1	O
melanogaster	0	O
nuclear	0	O
protein	0	O
involved	0	O
in	0	O
ecdysone	0	O
-	0	O
stimulated	0	O
gene	0	O
expression	0	O
.	0	O


They	0	O
were	0	O
called	0	O
PACE4	0	B
and	0	O
PC4	0	B
.	0	O


Surprisingly	0	O
,	0	O
the	0	O
COOH	0	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
RanGAP1	0	B
was	0	O
also	0	O
found	0	O
to	0	O
harbor	0	O
a	0	O
nuclear	0	O
localization	0	O
signal	0	O
.	0	O


Embryo	1	O
coculture	0	O
system	0	O
may	0	O
contribute	0	O
to	0	O
understand	0	O
the	0	O
mechanisms	0	O
underlying	0	O
the	0	O
decrease	0	O
of	0	O
fertility	0	O
with	0	O
aging	0	O
.	0	O


With	0	O
current	0	O
methodology	0	O
beta	0	B
-	0	I
2	0	I
transferrin	0	I
does	0	O
not	0	O
appear	0	O
to	0	O
be	0	O
a	0	O
reliable	0	O
clinical	0	O
marker	0	O
for	0	O
perilymph	0	O
in	0	O
the	0	O
operative	0	O
setting	0	O
.	0	O


Accumulation	0	O
of	0	O
the	0	O
U4	0	B
/	0	O
U6	0	B
duplex	0	O
was	0	O
relieved	0	O
by	0	O
overexpression	0	O
of	0	O
wild	0	B
-	0	I
type	0	I
Prp44p	0	I
.	0	O


Within	0	O
12	0	O
hours	0	O
after	0	O
MR	1	O
tomography	0	O
the	0	O
patients	0	O
were	0	O
surgically	0	O
explored	0	O
,	0	O
biopsied	0	O
and	0	O
if	0	O
necessary	0	O
orchiectomised	0	O
.	0	O


Contingency	0	O
contracting	0	O
between	0	O
clients	0	O
and	0	O
their	0	O
parents	0	O
/	0	O
caregivers	0	O
was	0	O
used	0	O
to	0	O
specify	0	O
consequences	0	O
for	0	O
daily	0	O
self	0	O
-	0	O
monitoring	0	O
,	0	O
reduced	0	O
caloric	0	O
intake	0	O
,	0	O
weight	0	O
loss	0	O
,	0	O
and	0	O
exercise	0	O
.	0	O


Our	0	O
results	0	O
show	0	O
that	0	O
,	0	O
from	0	O
a	0	O
thermodynamical	0	O
standpoint	0	O
,	0	O
melatonin	0	O
may	0	O
directly	0	O
scavenge	0	O
hydroxyl	0	O
radicals	0	O
both	0	O
in	0	O
vacuum	0	O
and	0	O
in	0	O
aqueous	0	O
solution	0	O
.	0	O


Twenty	0	O
-	0	O
one	0	O
percent	0	O
of	0	O
these	0	O
patients	0	O
had	0	O
neurologic	0	O
disease	0	O
that	0	O
appeared	0	O
to	0	O
be	0	O
responsible	0	O
for	0	O
the	0	O
tinnitus	0	O
.	0	O


By	0	O
screening	0	O
a	0	O
Y1	0	O
cell	0	O
cDNA	1	O
library	0	O
with	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
region	0	O
of	0	O
the	0	O
H	1	B
-	0	I
2RIIBP	0	I
nuclear	0	I
hormone	0	I
receptor	0	I
cDNA	1	I
,	0	O
we	0	O
isolated	0	O
a	0	O
cDNA	1	O
that	0	O
is	0	O
selectively	0	O
expressed	0	O
in	0	O
steroidogenic	0	O
cells	0	O
.	0	O


Overexpression	1	O
of	0	O
EFG1	0	B
in	0	O
C	1	O
.	0	O
albicans	0	O
leads	0	O
to	0	O
enhanced	0	O
filamentous	0	O
growth	0	O
in	0	O
the	0	O
form	0	O
of	0	O
extended	0	O
pseudohyphae	0	O
in	0	O
liquid	0	O
and	0	O
on	0	O
solid	0	O
media	0	O
.	0	O


Experimental	0	O
studies	0	O
on	0	O
virus	0	O
excretion	0	O
and	0	O
non	0	O
-	0	O
arthropod	0	O
transmission	0	O
.	0	O


This	0	O
is	0	O
the	0	O
first	0	O
report	0	O
that	0	O
an	0	O
in	0	O
vitro	0	O
-	0	O
synthesized	0	O
alphavirus	0	O
RNA	1	O
lacking	0	O
a	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
tail	0	O
can	0	O
initiate	0	O
infection	0	O
and	0	O
produce	0	O
3	0	O
'	0	O
polyadenylated	0	O
viral	0	O
genome	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
RAD6	0	B
/	0	O
UBC2	0	B
gene	0	O
from	0	O
Saccharomyces	1	O
cerevisiae	0	O
encodes	0	O
a	0	O
ubiquitin	0	B
-	0	I
conjugating	0	I
enzyme	0	I
involved	0	O
in	0	O
DNA	1	O
repair	0	O
,	0	O
induced	0	O
mutagenesis	0	O
,	0	O
and	0	O
sporulation	0	O
.	0	O


A	1	O
human	0	O
cytoplasmic	0	O
signaling	0	O
protein	0	O
has	0	O
been	0	O
cloned	0	O
that	0	O
possesses	0	O
the	0	O
same	0	O
structural	0	O
arrangement	0	O
of	0	O
SH3	0	B
-	0	O
SH2	0	B
-	0	O
SH3	0	B
domains	0	O
as	0	O
Grb2	0	B
.	0	O


The	0	O
amount	0	O
of	0	O
these	0	O
factors	0	O
was	0	O
reduced	0	O
in	0	O
GEO	0	O
cells	0	O
in	0	O
which	0	O
the	0	O
u	0	B
-	0	I
PAR	1	I
gene	0	I
is	0	O
only	0	O
weakly	0	O
transcriptionally	0	O
activated	0	O
.	0	O


Vac1p	0	B
was	0	O
found	0	O
to	0	O
bind	0	O
the	0	O
Sec1p	0	B
homologue	0	I
Vps45p	0	I
.	0	O


The	0	O
role	0	O
of	0	O
supercritical	0	O
fluid	0	O
chromatography	0	O
(	0	O
SFC	0	O
)	0	O
as	0	O
a	0	O
viable	0	O
technique	0	O
for	0	O
analyzing	0	O
agricultural	0	O
products	0	O
has	0	O
been	0	O
investigated	0	O
using	0	O
packed	0	O
and	0	O
capillary	0	O
column	0	O
methodology	0	O
.	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
each	0	O
of	0	O
the	0	O
W3A1	0	B
ETF	1	I
subunits	0	I
exhibit	0	O
only	0	O
approximately	0	O
30	0	O
%	0	O
identity	0	O
with	0	O
the	0	O
corresponding	0	O
subunits	0	O
of	0	O
the	0	O
ETF	1	B
from	0	O
human	0	O
,	0	O
rat	0	O
,	0	O
and	0	O
Paracoccus	0	O
denitrificans	0	O
,	0	O
which	0	O
as	0	O
a	0	O
group	0	O
are	0	O
greater	0	O
than	0	O
50	0	O
%	0	O
identical	0	O
.	0	O


The	0	O
Jem	0	B
peptide	0	O
sequence	0	O
shows	0	O
a	0	O
'	0	O
leucine	0	O
-	0	O
zipper	0	O
'	0	O
dimerisation	0	O
motif	0	O
with	0	O
limited	0	O
homology	0	O
to	0	O
Fos	1	B
/	0	O
Jun	1	B
and	0	O
ATF	0	B
/	0	O
CREB	0	B
proteins	0	O
and	0	O
several	0	O
putative	0	O
phosphorylation	0	O
sites	0	O
.	0	O


All	1	O
carcasses	0	O
resulted	0	O
in	0	O
contamination	0	O
with	0	O
aerobic	0	O
mesophilic	0	O
bacteria	0	O
in	0	O
the	0	O
range	0	O
from	0	O
6	0	O
x	0	O
10	0	O
(	0	O
3	0	O
)	0	O
to	0	O
1	0	O
.	0	O
2	0	O
x	0	O
10	0	O
(	0	O
6	0	O
)	0	O
CFU	1	O
/	0	O
ml	0	O
liquid	0	O
washed	0	O
,	0	O
and	0	O
94	0	O
%	0	O
them	0	O
with	0	O
sporulate	0	O
bacteria	0	O
,	0	O
the	0	O
threshold	0	O
being	0	O
under	0	O
100	0	O
CFU	1	O
/	0	O
ml	0	O
(	0	O
Figure	1	O
1	0	O
).	0	O


Reduced	1	O
NK	1	O
activity	0	O
correlates	0	O
with	0	O
active	0	O
disease	0	O
in	0	O
HIV	1	O
-	0	O
patients	0	O
with	0	O
multidrug	0	O
-	0	O
resistant	0	O
pulmonary	0	O
tuberculosis	0	O
.	0	O


OND	0	O
8	0	O
mg	0	O
tid	0	O
days	0	O
2	0	O
-	0	O
3	0	O
,	0	O
and	0	O
8	0	O
mg	0	O
tid	0	O
prn	0	O
days	0	O
4	0	O
-	0	O
5	0	O
and	0	O
prednisolone	0	O
75	0	O
-	0	O
100	0	O
mg	0	O
qds	0	O
days	0	O
2	0	O
-	0	O
5	0	O
and	0	O
2	0	O
)	0	O
MCP	1	O
30	0	O
mg	0	O
/	0	O
metylprednisolone	0	O
80	0	O
mg	0	O
i	0	O
.	0	O
v	0	O
.	0	O
before	0	O
CT	1	O
and	0	O
MCP	1	O
20	0	O
mg	0	O
p	0	O
.	0	O
r	0	O
.	0	O
after	0	O
4	0	O
and	0	O
8	0	O
h	0	O
respectively	0	O
.	0	O


Functional	1	O
and	0	O
regulatory	0	O
analysis	0	O
of	0	O
the	0	O
two	0	O
copies	0	O
of	0	O
the	0	O
fixNOQP	0	B
operon	0	I
of	0	O
Rhizobium	1	O
leguminosarum	0	O
strain	0	O
VF39	0	O
.	0	O


Growth	1	O
of	0	O
tracheal	0	O
anastomoses	0	O
in	0	O
growing	0	O
animals	0	O


In	1	O
summary	0	O
,	0	O
WT1	0	B
is	0	O
enriched	0	O
by	0	O
oligo	0	O
(	0	O
dT	1	O
)	0	O
chromatography	0	O
,	0	O
as	0	O
are	0	O
U2AF65	0	B
,	0	O
the	0	O
U5	0	B
small	0	I
nuclear	0	I
RNP	1	I
-	0	I
associated	0	I
protein	0	I
p116	0	I
and	0	O
hnRNP	1	O
A1	0	B
.	0	O


The	0	O
former	0	O
group	0	O
did	0	O
excrete	0	O
less	0	O
dry	0	O
fecal	0	O
material	0	O
compared	0	O
to	0	O
both	0	O
other	0	O
groups	0	O
.	0	O


Using	0	O
autoantibodies	0	O
from	0	O
a	0	O
Sjogren	0	O
'	0	O
s	0	O
syndrome	0	O
patient	0	O
,	0	O
we	0	O
have	0	O
previously	0	O
identified	0	O
a	0	O
230	0	O
-	0	O
kDa	1	O
peripheral	0	O
membrane	0	O
protein	0	O
associated	0	O
with	0	O
the	0	O
cytosolic	0	O
face	0	O
of	0	O
the	0	O
trans	0	O
-	0	O
Golgi	0	O
(	0	O
Kooy	0	O
,	0	O
J	1	O
.,	0	O
Toh	0	O
,	0	O
B	1	O
.	0	O


OBJECTIVES	0	O
:	0	O
The	0	O
aim	0	O
of	0	O
the	0	O
study	0	O
was	0	O
to	0	O
analyze	0	O
the	0	O
clinical	0	O
characteristics	0	O
,	0	O
treatment	0	O
and	0	O
outcome	0	O
of	0	O
310	0	O
patients	0	O
with	0	O
hydatidiform	0	O
mole	0	O
.	0	O


In	1	O
both	0	O
these	0	O
respects	0	O
,	0	O
however	0	O
,	0	O
the	0	O
DBP	0	B
mRNA	1	I
resembles	0	O
the	0	O
late	0	O
messengers	0	O
of	0	O
SV40	1	O
and	0	O
polyoma	0	O
viruses	0	O
.	0	O


The	0	O
evidence	0	O
in	0	O
support	0	O
of	0	O
this	0	O
was	0	O
derived	0	O
from	0	O
the	0	O
fact	0	O
that	0	O
the	0	O
affinity	0	O
or	0	O
interaction	0	O
between	0	O
the	0	O
two	0	O
subunits	0	O
was	0	O
impaired	0	O
as	0	O
indicated	0	O
by	0	O
the	0	O
first	0	O
order	0	O
rate	0	O
constant	0	O
of	0	O
hCG	1	B
alpha	0	I
1	0	I
beta	0	I
(	0	O
km	0	O
=	0	O
4	0	O
.	0	O
1	0	O
x	0	O
10	0	O
(-	0	O
2	0	O
)	0	O
min	0	O
-	0	O
1	0	O
)	0	O
at	0	O
pH	1	O
3	0	O
.	0	O
0	0	O
at	0	O
23	0	O
degrees	0	O
C	1	O
which	0	O
is	0	O
one	0	O
order	0	O
of	0	O
magnitude	0	O
greater	0	O
relative	0	O
to	0	O
rehCG	0	B
(	0	O
kw	0	O
=	0	O
4	0	O
.	0	O
6	0	O
x	0	O
10	0	O
(-	0	O
3	0	O
)	0	O
min	0	O
-	0	O
1	0	O
).	0	O


Specific	1	O
class	0	B
I	1	I
and	0	I
II	0	I
histone	0	I
deacetylases	0	I
(	0	O
HDACs	0	B
)	0	O
interact	0	O
in	0	O
vivo	0	O
with	0	O
BCoR	0	B
,	0	O
suggesting	0	O
that	0	O
BCoR	0	B
may	0	O
functionally	0	O
link	0	O
these	0	O
two	0	O
classes	0	O
of	0	O
HDACs	0	B
.	0	O


We	0	O
have	0	O
recently	0	O
shown	0	O
that	0	O
the	0	O
tissue	0	O
-	0	O
specific	0	O
expression	0	O
of	0	O
the	0	O
RAR	0	B
beta	0	I
2	0	I
gene	0	I
in	0	I
mouse	0	I
embryos	0	I
is	0	O
regulated	0	O
at	0	O
the	0	O
translational	0	O
level	0	O
by	0	O
short	0	O
upstream	0	O
open	0	O
reading	0	O
frames	0	O
(	0	O
uORFs	0	O
)	0	O
In	1	O
the	0	O
5	0	O
'-	0	O
untranslated	0	O
region	0	O
(	0	O
Zimmer	0	O
,	0	O
A	1	O
.,	0	O
A	1	O
.	0	O
M	1	O
.	0	O


Vibrio	1	O
fluvialis	0	O
(	0	O
group	0	O
F	1	O
vibrio	0	O
)	0	O
in	0	O
Maharashtra	0	O
.	0	O


Cloning	1	O
by	0	O
complementation	0	O
and	0	O
subsequent	0	O
physical	0	O
and	0	O
genetic	0	O
analysis	0	O
revealed	0	O
that	0	O
it	0	O
maps	0	O
to	0	O
RAF1	0	B
.	0	O


During	0	O
presentation	0	O
of	0	O
happy	0	O
facial	0	O
expressions	0	O
,	0	O
we	0	O
detected	0	O
a	0	O
signal	0	O
increase	0	O
predominantly	0	O
in	0	O
the	0	O
left	0	O
anterior	0	O
cingulate	0	O
gyrus	0	O
,	0	O
bilateral	0	O
posterior	0	O
cingulate	0	O
gyri	0	O
,	0	O
medial	0	O
frontal	0	O
cortex	0	O
and	0	O
right	0	O
supramarginal	0	O
gyrus	0	O
,	0	O
brain	0	O
regions	0	O
previously	0	O
implicated	0	O
in	0	O
visuospatial	0	O
and	0	O
emotion	0	O
processing	0	O
tasks	0	O
.	0	O


Both	0	O
the	0	O
Cmax	1	O
and	0	O
AUC	1	O
values	0	O
were	0	O
almost	0	O
doubled	0	O
with	0	O
doubling	0	O
the	0	O
dose	0	O
.	0	O


During	0	O
the	0	O
dose	0	O
-	0	O
finding	0	O
,	0	O
two	0	O
patients	0	O
were	0	O
temporarily	0	O
withdrawn	0	O
from	0	O
medication	0	O
and	0	O
one	0	O
patient	0	O
was	0	O
excluded	0	O
because	0	O
of	0	O
elevated	0	O
levels	0	O
of	0	O
liver	0	O
enzymes	0	O
.	0	O


In	1	O
connective	0	O
tissue	0	O
,	0	O
cell	0	O
structure	0	O
contributes	0	O
to	0	O
type	0	B
I	1	I
collagen	0	I
expression	0	O
.	0	O


No	1	O
TATA	0	O
or	0	O
Inr	1	O
sequence	0	O
was	0	O
found	0	O
.	0	O


DESIGN	0	O
:	0	O
Serum	1	O
aldosterone	0	O
and	0	O
plasma	0	B
renin	0	I
activity	0	O
were	0	O
measured	0	O
supine	0	O
prior	0	O
to	0	O
and	0	O
60	0	O
,	0	O
90	0	O
,	0	O
120	0	O
minutes	0	O
after	0	O
oral	0	O
captopril	0	O
,	0	O
25	0	O
mg	0	O
.	0	O


Two	0	O
new	0	O
artifacts	0	O
in	0	O
automated	0	O
coagulation	0	O
testing	0	O
.	0	O


For	0	O
HeLa	0	O
,	0	O
293	0	O
,	0	O
U937	0	O
,	0	O
and	0	O
A549	0	O
cells	0	O
,	0	O
participation	0	O
of	0	O
E2F	0	B
-	0	I
1	0	I
,	0	O
DP	1	B
-	0	I
1	0	I
,	0	O
cyclin	0	B
A	1	I
,	0	O
and	0	O
RB	1	B
was	0	O
involved	0	O
in	0	O
formation	0	O
of	0	O
some	0	O
complexes	0	O
only	0	O
,	0	O
assuming	0	O
participation	0	O
of	0	O
factors	0	O
different	0	O
from	0	O
E2F	0	B
-	0	I
1	0	I
or	0	O
DP	1	B
-	0	I
1	0	I
in	0	O
others	0	O
.	0	O


Lewis	0	O
,	0	O
N	1	O
.	0	O


Serum	1	O
levels	0	O
of	0	O
IgG	1	B
and	0	O
IgM	1	B
were	0	O
also	0	O
raised	0	O
,	0	O
but	0	O
contrary	0	O
to	0	O
the	0	O
findings	0	O
of	0	O
other	0	O
observers	0	O
IgA	1	B
levels	0	O
were	0	O
normal	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
inhibition	0	O
of	0	O
Jun	1	B
kinase	0	I
activation	0	O
was	0	O
sufficient	0	O
to	0	O
inhibit	0	O
Ras	1	B
transformation	0	O
even	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
activated	0	O
Erk	0	B
-	0	I
2	0	I
.	0	O


The	0	O
missing	0	O
5	0	O
'	0	O
sequences	0	O
were	0	O
obtained	0	O
by	0	O
5	0	O
'-	0	O
rapid	0	O
amplification	0	O
of	0	O
cDNA	1	O
ends	0	O
and	0	O
by	0	O
analysis	0	O
of	0	O
an	0	O
NHE5	0	B
genomic	0	I
clone	0	I
,	0	O
and	0	O
the	0	O
missing	0	O
3	0	O
'	0	O
sequences	0	O
were	0	O
obtained	0	O
by	0	O
3	0	O
'-	0	O
rapid	0	O
amplification	0	O
of	0	O
cDNA	1	O
ends	0	O
.	0	O


The	0	O
provisional	0	O
reports	0	O
are	0	O
based	0	O
mainly	0	O
upon	0	O
macroscopic	0	O
findings	0	O
,	0	O
whereas	0	O
the	0	O
final	0	O
reports	0	O
include	0	O
the	0	O
information	0	O
provided	0	O
by	0	O
supplementary	0	O
investigations	0	O
such	0	O
as	0	O
microscopy	0	O
,	0	O
histochemistry	0	O
,	0	O
more	0	O
rarely	0	O
electron	0	O
microscopy	0	O
,	0	O
immunohistochemistry	0	O
and	0	O
/	0	O
or	0	O
microbiology	0	O
.	0	O


We	0	O
have	0	O
studied	0	O
the	0	O
biokinetics	0	O
of	0	O
BLM	0	O
labeled	0	O
with	0	O
indium	0	O
-	0	O
111	0	O
(	0	O
In	1	O
-	0	O
111	0	O
).	0	O


Taxonomically	0	O
significant	0	O
colour	0	O
changes	0	O
in	0	O
Brevibacterium	1	O
linens	0	O
probably	0	O
associated	0	O
with	0	O
a	0	O
carotenoid	0	O
-	0	O
like	0	O
pigment	0	O
.	0	O


Unaided	0	O
attempts	0	O
to	0	O
quit	0	O
smoking	0	O
are	0	O
generally	0	O
unsuccessful	0	O
.	0	O


Central	1	O
venous	0	O
catheter	0	O
used	0	O
for	0	O
recording	0	O
intracardiac	0	O
electrocardiogram	0	O
.	0	O


Refugees	0	O
living	0	O
in	0	O
Lund	0	O
and	0	O
repatriated	0	O
to	0	O
Chile	0	O
considered	0	O
their	0	O
health	0	O
as	0	O
bad	0	O
in	0	O
a	0	O
higher	0	O
proportion	0	O
than	0	O
their	0	O
Swedish	0	O
counterparts	0	O
,	0	O
with	0	O
an	0	O
odds	0	O
ratio	0	O
of	0	O
3	0	O
.	0	O
48	0	O
(	0	O
2	0	O
.	0	O
03	0	O
-	0	O
5	0	O
.	0	O
66	0	O
)	0	O
and	0	O
4	0	O
.	0	O
78	0	O
(	0	O
2	0	O
.	0	O
1	0	O
-	0	O
10	0	O
.	0	O
25	0	O
)	0	O
respectively	0	O
.	0	O


Unified	0	O
theory	0	O
of	0	O
segregated	0	O
-	0	O
stack	0	O
organic	0	O
charge	0	O
-	0	O
transfer	0	O
solids	0	O
:	0	O
Magnetic	1	O
properties	0	O
.	0	O


Hybridization	1	O
of	0	O
plasmid	0	O
-	0	O
transformed	0	O
Escherichia	1	O
coli	0	O
RR1	0	O
colonies	0	O
with	0	O
32P	0	O
-	0	O
labeled	0	O
viral	0	O
genome	0	O
RNAs	0	O
demonstrated	0	O
the	0	O
presence	0	O
of	0	O
DNA	1	O
clones	0	O
representative	0	O
of	0	O
each	0	O
of	0	O
the	0	O
10	0	O
reovirus	0	O
RNAs	0	O
and	0	O
10	0	O
of	0	O
the	0	O
11	0	O
constituent	0	O
segments	0	O
of	0	O
the	0	O
rotavirus	0	O
genome	0	O
.	0	O


Developmental	1	O
follow	0	O
-	0	O
up	0	O
at	0	O
age	0	O
2	0	O
years	0	O
was	0	O
performed	0	O
.	0	O


Male	1	O
contraception	0	O
:	0	O
ideas	0	O
for	0	O
the	0	O
future	0	O
.	0	O


From	0	O
two	0	O
inhibitor	0	O
scaffolds	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
potent	0	O
and	0	O
selective	0	O
inhibitors	0	O
for	0	O
sensitized	0	O
kinases	0	O
from	0	O
five	0	O
distinct	0	O
subfamilies	0	O
.	0	O


This	0	O
fragment	0	O
can	0	O
bind	0	O
several	0	O
trans	0	O
-	0	O
acting	0	O
factors	0	O
in	0	O
vitro	0	O
,	0	O
including	0	O
GATA	0	B
-	0	I
1	0	I
and	0	O
members	0	O
of	0	O
the	0	O
Ets	1	B
family	0	I
.	0	O


The	0	O
third	0	O
ORF	1	O
generates	0	O
a	0	O
transcript	0	O
of	0	O
1	0	O
.	0	O
6	0	O
kb	0	O
and	0	O
encodes	0	O
a	0	O
protein	0	O
of	0	O
382	0	O
residues	0	O
including	0	O
a	0	O
perfect	0	O
match	0	O
to	0	O
the	0	O
consensus	0	O
sequence	0	O
of	0	O
a	0	O
C2H2	1	O
zinc	0	O
finger	0	O
domain	0	O
;	0	O
it	0	O
shares	0	O
a	0	O
strong	0	O
homology	0	O
with	0	O
yeast	0	B
Mig1p	0	I
and	0	O
Cre	0	B
-	0	I
A	1	I
from	0	I
Aspergillus	1	I
,	0	I
Emericella	1	I
and	0	I
E	1	I
.	0	I
coli	0	I
.	0	O


Magnetotherapy	1	O
of	0	O
hepatitis	0	O
A	1	O
and	0	O
B	1	O
in	0	O
children	0	O


INTERVENTIONS	0	O
:	0	O
Subcutaneous	1	O
tissue	0	O
PO2	1	O
and	0	O
PCO2	1	O
tensions	0	O
were	0	O
measured	0	O
directly	0	O
in	0	O
patients	0	O
with	0	O
necrotising	0	O
fasciitis	0	O
and	0	O
in	0	O
healthy	0	O
volunteers	0	O
during	0	O
normobaric	0	O
and	0	O
hyperbaric	0	O
conditions	0	O
.	0	O


Intravenous	1	O
injections	0	O
of	0	O
SG	0	O
-	0	O
75	0	O
(	0	O
0	0	O
.	0	O
03	0	O
-	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
decreased	0	O
systemic	0	O
blood	0	O
pressure	0	O
(	0	O
SBP	1	O
)	0	O
and	0	O
increased	0	O
peripheral	0	O
(	0	O
coronary	0	O
,	0	O
renal	0	O
,	0	O
mesenteric	0	O
and	0	O
femoral	0	O
)	0	O
blood	0	O
flow	0	O
(	0	O
PBF	0	O
)	0	O
dose	0	O
-	0	O
dependently	0	O
.	0	O


If	1	O
NCR	0	O
-	0	O
sensitive	0	O
gene	0	O
expression	0	O
occurs	0	O
exclusively	0	O
by	0	O
this	0	O
pathway	0	O
,	0	O
as	0	O
has	0	O
been	0	O
thought	0	O
to	0	O
be	0	O
the	0	O
case	0	O
,	0	O
then	0	O
the	0	O
NCR	0	O
sensitivity	0	O
of	0	O
a	0	O
gene	0	O
'	0	O
s	0	O
expression	0	O
should	0	O
be	0	O
abolished	0	O
by	0	O
a	0	O
ure2	0	B
delta	0	I
mutation	0	I
.	0	O


There	0	O
was	0	O
a	0	O
2	0	O
.	0	O
4	0	O
-	0	O
fold	0	O
difference	0	O
in	0	O
CAT	1	B
produced	0	O
from	0	O
these	0	O
transcripts	0	O
in	0	O
HeLa	0	O
cells	0	O
,	0	O
which	0	O
contain	0	O
a	0	O
greater	0	O
natural	0	O
abundance	0	O
of	0	O
PTB	0	B
.	0	O


This	0	O
survey	0	O
included	0	O
3000	0	O
randomly	0	O
selected	0	O
Norwegians	0	O
above	0	O
18	0	O
years	0	O
of	0	O
age	0	O
who	0	O
received	0	O
the	0	O
European	0	O
Organization	1	O
for	0	O
Research	1	O
and	0	O
Treatment	1	O
of	0	O
Cancer	1	O
Core	1	O
Quality	1	O
of	0	O
Life	1	O
Questionnaire	1	O
(	0	O
EORTC	1	O
QLQ	0	O
-	0	O
C30	0	O
(+	0	O
3	0	O
)	0	O
by	0	O
mail	0	O
.	0	O


An	1	O
anatomical	0	O
and	0	O
histochemical	0	O
study	0	O
has	0	O
been	0	O
undertaken	0	O
and	0	O
as	0	O
a	0	O
result	0	O
emphasis	0	O
is	0	O
given	0	O
to	0	O
recent	0	O
hypotheses	0	O
that	0	O
suggest	0	O
there	0	O
are	0	O
similarities	0	O
with	0	O
Type	1	O
IV	1	O
glycogen	0	O
storage	0	O
disease	0	O
(	0	O
Andersen	0	O
'	0	O
s	0	O
disease	0	O
)	0	O
which	0	O
,	0	O
although	0	O
clinically	0	O
distinct	0	O
,	0	O
has	0	O
the	0	O
same	0	O
enzyme	0	O
defect	0	O
.	0	O


Protein	1	O
sequence	0	O
analysis	0	O
reveals	0	O
that	0	O
MAN1	0	B
shares	0	O
a	0	O
conserved	0	O
globular	0	O
domain	0	O
of	0	O
approximately	0	O
40	0	O
amino	0	O
acids	0	O
,	0	O
which	0	O
we	0	O
term	0	O
the	0	O
LEM	0	B
module	0	I
,	0	O
with	0	O
inner	0	O
nuclear	0	O
membrane	0	O
proteins	0	O
lamina	0	B
-	0	I
associated	0	I
polypeptide	0	I
2	0	I
and	0	O
emerin	0	B
.	0	O


Here	0	O
we	0	O
describe	0	O
the	0	O
optimization	0	O
and	0	O
characterization	0	O
of	0	O
a	0	O
140	0	O
-	0	O
residue	0	O
fragment	0	O
,	0	O
containing	0	O
the	0	O
Runt	1	B
domain	0	I
of	0	O
AML1	0	B
,	0	O
which	0	O
is	0	O
suitable	0	O
for	0	O
structural	0	O
studies	0	O
.	0	O


Finally	0	O
,	0	O
a	0	O
role	0	O
for	0	O
NF	1	B
-	0	I
kappaB	0	I
in	0	O
preventing	0	O
apoptosis	0	O
induced	0	O
by	0	O
ER	1	O
calcium	0	O
release	0	O
was	0	O
demonstrated	0	O
by	0	O
data	0	O
showing	0	O
that	0	O
sAPPalpha	0	B
prevents	0	O
thapsigargin	0	O
-	0	O
induced	0	O
apoptosis	0	O
,	0	O
an	0	O
effect	0	O
blocked	0	O
by	0	O
kappaB	0	B
decoy	0	O
DNA	1	O
.	0	O


Clb	0	B
/	0	O
Cdc28	0	B
kinases	0	O
promote	0	O
nuclear	0	O
export	0	O
of	0	O
the	0	O
replication	0	B
initiator	0	I
proteins	0	I
Mcm2	0	I
-	0	I
7	0	I
.	0	O


We	0	O
describe	0	O
a	0	O
novel	0	O
cytoplasmic	0	B
tyrosine	0	I
kinase	0	I
,	0	O
termed	0	O
BPK	0	B
(	0	O
B	1	B
cell	0	I
progenitor	0	I
kinase	0	I
),	0	O
which	0	O
is	0	O
expressed	0	O
in	0	O
all	0	O
stages	0	O
of	0	O
the	0	O
B	1	O
lineage	0	O
and	0	O
in	0	O
myeloid	0	O
cells	0	O
.	0	O


Basal	1	O
FVR	0	O
was	0	O
reduced	0	O
by	0	O
approximately	0	O
18	0	O
%	0	O
by	0	O
ERT	1	O
and	0	O
HRT	1	O
,	0	O
but	0	O
FVR	0	O
responses	0	O
to	0	O
noradrenaline	0	O
,	0	O
angiotensin	0	B
II	0	I
,	0	O
acetylcholine	0	O
and	0	O
nitroprusside	0	O
were	0	O
unaffected	0	O
.	0	O


Identification	1	O
and	0	O
nucleotide	0	O
sequence	0	O
of	0	O
Rhizobium	1	B
meliloti	0	I
insertion	0	I
sequence	0	I
ISRm3	0	I
:	0	O
similarity	0	O
between	0	O
the	0	O
putative	0	O
transposase	0	B
encoded	0	O
by	0	O
ISRm3	0	B
and	0	O
those	0	O
encoded	0	O
by	0	O
Staphylococcus	1	B
aureus	0	I
IS256	0	I
and	0	O
Thiobacillus	0	B
ferrooxidans	0	I
IST2	0	I
.	0	O


UV	1	O
cross	0	O
-	0	O
linking	0	O
experiments	0	O
show	0	O
that	0	O
TEP	0	B
has	0	O
an	0	O
apparent	0	O
molecular	0	O
mass	0	O
of	0	O
approximately	0	O
65	0	O
kDa	1	O
.	0	O


The	0	O
cleavage	0	O
dipeptides	0	O
of	0	O
C1YVV	0	B
NIa	1	I
protease	0	I
are	0	O
Q	1	O
(	0	O
E	1	O
)/	0	O
S	1	O
(	0	O
A	1	O
,	0	O
G	1	O
).	0	O


Fourteen	0	O
patients	0	O
with	0	O
New	0	O
York	0	O
Heart	1	O
Association	1	O
class	0	O
II	0	O
congestive	0	O
heart	0	O
failure	0	O
were	0	O
enrolled	0	O
in	0	O
a	0	O
double	0	O
-	0	O
blind	0	O
,	0	O
cross	0	O
-	0	O
over	0	O
study	0	O
.	0	O


In	1	O
a	0	O
second	0	O
series	0	O
of	0	O
experiments	0	O
,	0	O
the	0	O
efficacy	0	O
of	0	O
PDC	1	O
/	0	O
HDC	0	O
Ac	1	O
was	0	O
evaluated	0	O
in	0	O
both	0	O
single	0	O
and	0	O
multiple	0	O
dose	0	O
regiments	0	O
.	0	O


The	0	O
potential	0	O
impact	0	O
of	0	O
using	0	O
a	0	O
rapid	0	O
diagnostic	0	O
test	0	O
(	0	O
Strep	0	O
A	1	O
OIA	0	O
)	0	O
on	0	O
detection	0	O
and	0	O
treatment	0	O
of	0	O
group	0	O
A	1	O
beta	0	O
-	0	O
hemolytic	0	O
streptococcal	0	O
(	0	O
GABHS	0	O
)	0	O
pharyngitis	0	O
in	0	O
a	0	O
large	0	O
-	0	O
volume	0	O
pediatric	0	O
and	0	O
adolescent	0	O
clinic	0	O
was	0	O
examined	0	O
.	0	O


Number	1	O
of	0	O
patients	0	O
infected	0	O
with	0	O
nontuberculous	0	O
mycobacteria	0	O
(	0	O
NTM	0	O
)	0	O
is	0	O
increasing	0	O
world	0	O
-	0	O
wide	0	O
in	0	O
recent	0	O
years	0	O
.	0	O


Studies	0	O
of	0	O
lipoproteins	0	O
should	0	O
,	0	O
however	0	O
,	0	O
be	0	O
made	0	O
in	0	O
children	0	O
from	0	O
families	0	O
known	0	O
to	0	O
have	0	O
FH	0	O
or	0	O
early	0	O
coronary	0	O
heart	0	O
disease	0	O
.	0	O


Acad	0	O
.	0	O


Among	0	O
the	0	O
H	1	B
/	0	I
ACA	1	I
snoRNAs	0	I
associated	0	O
with	0	O
Gar1p	0	B
,	0	O
one	0	O
can	0	O
distinguish	0	O
a	0	O
large	0	O
group	0	O
of	0	O
snoRNAs	0	O
that	0	O
are	0	O
not	0	O
essential	0	O
in	0	O
yeast	0	O
and	0	O
serve	0	O
as	0	O
guides	0	O
for	0	O
pseudouridine	0	O
synthesis	0	O
onto	0	O
the	0	O
pre	0	O
-	0	O
rRNA	1	O
molecule	0	O
.	0	O


Mapping	1	O
results	0	O
suggested	0	O
that	0	O
the	0	O
complementation	0	O
group	0	O
identified	0	O
by	0	O
these	0	O
mutants	0	O
is	0	O
allelic	0	O
to	0	O
the	0	O
ag	0	B
alpha	0	I
1	0	I
mutation	0	O
identified	0	O
previously	0	O
.	0	O


In	1	O
a	0	O
Hoosier	0	O
Oncology	1	O
Group	1	O
randomized	0	O
study	0	O
involving	0	O
extensive	0	O
-	0	O
disease	0	O
SCLC	1	O
patients	0	O
,	0	O
VIP	1	O
was	0	O
superior	0	O
to	0	O
etoposide	0	O
/	0	O
cisplatin	0	O
with	0	O
regard	0	O
to	0	O
median	0	O
time	0	O
to	0	O
progression	0	O
(	0	O
6	0	O
.	0	O
6	0	O
v	0	O
5	0	O
.	0	O
8	0	O
months	0	O
),	0	O
median	0	O
survival	0	O
times	0	O
(	0	O
9	0	O
.	0	O
1	0	O
v	0	O
7	0	O
.	0	O
3	0	O
months	0	O
),	0	O
and	0	O
2	0	O
-	0	O
and	0	O
3	0	O
-	0	O
year	0	O
survival	0	O
rates	0	O
(	0	O
13	0	O
%	0	O
v	0	O
5	0	O
%	0	O
and	0	O
5	0	O
%	0	O
v	0	O
0	0	O
%,	0	O
respectively	0	O
).	0	O


The	0	O
concentration	0	O
of	0	O
alpha	0	B
2	0	I
-	0	I
macroglobulin	0	I
,	0	O
alpha	0	B
1	0	I
-	0	I
antitrypsin	0	I
,	0	O
plasminogen	0	B
,	0	O
C3	1	B
-	0	I
complement	0	I
,	0	O
fibrinogen	0	B
degradation	0	I
products	0	I
(	0	O
FDP	1	B
)	0	O
and	0	O
fibrinolytic	0	O
activity	0	O
,	0	O
were	0	O
studied	0	O
in	0	O
the	0	O
aqueous	0	O
humour	0	O
and	0	O
serum	0	O
from	0	O
nine	0	O
patients	0	O
with	0	O
Fuchs	0	O
'	0	O
endothelial	0	O
dystrophy	0	O
,	0	O
17	0	O
patients	0	O
with	0	O
uncomplicated	0	O
senile	0	O
cataract	0	O
and	0	O
in	0	O
the	0	O
secondary	0	O
aqueous	0	O
from	0	O
six	0	O
cataract	0	O
patients	0	O
.	0	O


The	0	O
early	0	O
dg	0	O
.	0	O
of	0	O
rejection	0	O
and	0	O
especially	0	O
acute	0	O
rejection	0	O
,	0	O
it	0	O
'	0	O
s	0	O
adequate	0	O
management	0	O
,	0	O
decreased	0	O
risk	0	O
for	0	O
the	0	O
future	0	O
chronic	0	O
rejection	0	O
nephropathy	0	O
.	0	O


The	0	O
TEA1	0	B
(	0	O
Ty	0	B
enhancer	0	I
activator	0	I
)	0	O
gene	0	O
sequence	0	O
predicts	0	O
a	0	O
protein	0	O
of	0	O
86	0	O
.	0	O
9	0	O
kDa	1	O
whose	0	O
N	1	O
terminus	0	O
contains	0	O
a	0	O
zinc	0	O
cluster	0	O
and	0	O
dimerization	0	O
motif	0	O
typical	0	O
of	0	O
the	0	O
Gal4	0	B
-	0	I
type	0	I
family	0	I
of	0	O
DNA	1	O
-	0	O
binding	0	O
proteins	0	O
.	0	O


The	0	O
serum	0	B
insulin	0	I
response	0	O
cannot	0	O
.	0	O


Accordingly	0	O
,	0	O
no	0	O
Ha	1	B
-	0	I
ras	0	I
codon	0	I
12	0	I
mutations	0	O
are	0	O
found	0	O
in	0	O
the	0	O
EtNU	0	O
-	0	O
induced	0	O
mammary	0	O
tumors	0	O
.	0	O


Anti	0	O
-	0	O
anxiety	0	O
action	0	O
of	0	O
diazepam	0	O
after	0	O
intra	0	O
-	0	O
amygdaloid	0	O
application	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


DNase	1	B
I	1	I
footprinting	0	O
of	0	O
the	0	O
proximal	0	O
promoter	0	O
revealed	0	O
four	0	O
regions	0	O
of	0	O
protection	0	O
.	0	O


At	1	O
Cabras	0	O
(	0	O
Oristano	0	O
),	0	O
a	0	O
town	0	O
characterized	0	O
by	0	O
a	0	O
high	0	O
incidence	0	O
of	0	O
thalassaemia	0	O
and	0	O
G6PD	1	B
deficiency	0	O
less	0	O
than	0	O
half	0	O
the	0	O
people	0	O
between	0	O
18	0	O
and	0	O
35	0	O
have	0	O
a	0	O
fair	0	O
knowledge	0	O
of	0	O
genetic	0	O
diseases	0	O
and	0	O
of	0	O
their	0	O
prevention	0	O
.	0	O


UDP	1	B
-	0	I
GlcNAc	1	I
:	0	O
alpha	0	B
-	0	I
6	0	I
-	0	I
D	1	I
-	0	I
mannoside	0	I
beta	0	I
-	0	I
1	0	I
,	0	I
2	0	I
-	0	I
N	1	I
-	0	I
acetylglucosaminyltransferase	0	I
II	0	I
(	0	O
GnT	0	B
II	0	I
;	0	O
EC	1	B
2	0	I
.	0	I
4	0	I
.	0	I
1	0	I
.	0	I
143	0	I
)	0	O
is	0	O
essential	0	O
for	0	O
the	0	O
normal	0	O
assembly	0	O
of	0	O
complex	0	O
Asn	1	O
-	0	O
linked	0	O
glycans	0	O
.	0	O


The	0	O
gene	0	O
is	0	O
1	0	O
,	0	O
139	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
)	0	O
long	0	O
,	0	O
and	0	O
,	0	O
like	0	O
other	0	O
members	0	O
of	0	O
the	0	O
SIG	1	B
family	0	I
,	0	O
the	0	O
beta	0	B
TG	1	I
gene	0	I
is	0	O
divided	0	O
into	0	O
3	0	O
exons	0	O
.	0	O


Site	1	O
-	0	O
directed	0	O
mutagenesis	0	O
of	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
repressor	0	B
proteins	0	I
BP1	0	I
and	0	O
BP2	0	B
in	0	O
the	0	O
upstream	0	O
portion	0	O
of	0	O
the	0	O
beta	0	B
globin	0	I
gene	0	I
flanking	0	I
region	0	I
led	0	O
to	0	O
a	0	O
4	0	O
-	0	O
6	0	O
fold	0	O
increase	0	O
in	0	O
promoter	0	O
activity	0	O
.	0	O


Electronic	1	O
structure	0	O
of	0	O
a	0	O
buried	0	O
NiSi2	0	O
or	0	O
CoSi2	0	O
layer	0	O
in	0	O
bulk	0	O
Si	1	O
.	0	O


Most	0	O
recently	0	O
,	0	O
the	0	O
use	0	O
of	0	O
the	0	O
product	0	O
of	0	O
brain	0	O
weight	0	O
and	0	O
clearance	0	O
has	0	O
been	0	O
proposed	0	O
.	0	O


To	1	O
determine	0	O
whether	0	O
the	0	O
excess	0	O
prevalence	0	O
of	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
type	0	O
1	0	O
(	0	O
HIV	1	O
-	0	O
1	0	O
)	0	O
infection	0	O
in	0	O
US	1	O
black	0	O
and	0	O
Hispanic	0	O
homosexual	0	O
men	0	O
relative	0	O
to	0	O
white	0	O
men	0	O
can	0	O
be	0	O
explained	0	O
by	0	O
differences	0	O
in	0	O
sociodemographic	0	O
factors	0	O
,	0	O
history	0	O
of	0	O
sexually	0	O
transmitted	0	O
diseases	0	O
,	0	O
or	0	O
sexual	0	O
and	0	O
drug	0	O
-	0	O
use	0	O
behaviors	0	O
,	0	O
the	0	O
authors	0	O
conducted	0	O
a	0	O
cross	0	O
-	0	O
sectional	0	O
analysis	0	O
of	0	O
baseline	0	O
HIV	1	O
-	0	O
1	0	O
seroprevalence	0	O
and	0	O
HIV	1	O
-	0	O
1	0	O
risk	0	O
factors	0	O
among	0	O
4	0	O
,	0	O
475	0	O
non	0	O
-	0	O
Hispanic	0	O
white	0	O
,	0	O
234	0	O
Hispanic	0	O
white	0	O
,	0	O
and	0	O
194	0	O
black	0	O
homosexual	0	O
men	0	O
from	0	O
four	0	O
centers	0	O
in	0	O
the	0	O
United	0	O
States	0	O
(	0	O
Baltimore	0	O
/	0	O
Washington	0	O
,	0	O
DC	1	O
,	0	O
Pittsburgh	0	O
,	0	O
Chicago	0	O
,	0	O
and	0	O
Los	1	O
Angeles	0	O
).	0	O


Heterozygous	1	O
mutation	0	O
in	0	O
the	0	O
G	1	O
+	0	O
5	0	O
position	0	O
of	0	O
intron	0	O
33	0	O
of	0	O
the	0	O
pro	0	B
-	0	I
alpha	0	I
2	0	I
(	0	I
I	1	I
)	0	I
gene	0	I
(	0	O
COL1A2	0	B
)	0	O
that	0	O
causes	0	O
aberrant	0	O
RNA	1	O
splicing	0	O
and	0	O
lethal	0	O
osteogenesis	0	O
imperfecta	0	O
.	0	O


Three	0	O
cDNAs	0	O
encoding	0	O
basic	0	B
leucine	0	I
zipper	0	I
(	0	I
bZIP	0	I
)-	0	I
type	0	I
ABRE	0	I
-	0	I
binding	0	I
proteins	0	I
were	0	O
isolated	0	O
by	0	O
using	0	O
the	0	O
yeast	0	O
one	0	O
-	0	O
hybrid	0	O
system	0	O
and	0	O
were	0	O
designated	0	O
AREB1	0	B
,	0	O
AREB2	0	B
,	0	O
and	0	O
AREB3	0	B
(	0	O
ABA	0	B
-	0	I
responsive	0	I
element	0	I
binding	0	I
protein	0	I
).	0	O


Significant	1	O
alterations	0	O
in	0	O
CBC	1	O
results	0	O
and	0	O
serum	0	B
CRP	1	I
concentration	0	O
,	0	O
compared	0	O
with	0	O
baseline	0	O
values	0	O
,	0	O
were	0	O
lacking	0	O
in	0	O
dogs	0	O
of	0	O
the	0	O
control	0	O
group	0	O
.	0	O


Arterial	1	O
radioactivity	0	O
content	0	O
after	0	O
the	0	O
intravenous	0	O
administration	0	O
of	0	O
HMPAO	1	O
in	0	O
seven	0	O
human	0	O
subjects	0	O
was	0	O
analyzed	0	O
.	0	O


Experiments	0	O
on	0	O
23	0	O
white	0	O
rats	0	O
and	0	O
10	0	O
guinea	0	O
pigs	0	O
have	0	O
shown	0	O
that	0	O
preliminarily	0	O
indomethacin	0	O
-	0	O
induced	0	O
inhibition	0	O
of	0	O
prostaglandins	0	O
synthesis	0	O
prevented	0	O
development	0	O
of	0	O
pulmonary	0	O
oedema	0	O
,	0	O
evoked	0	O
by	0	O
heterologous	0	O
serum	0	O
in	0	O
rats	0	O
and	0	O
by	0	O
vagotomy	0	O
in	0	O
guinea	0	O
pigs	0	O
.	0	O


The	0	O
survival	0	O
rate	0	O
at	0	O
forty	0	O
months	0	O
in	0	O
15	0	O
patients	0	O
with	0	O
N2	0	O
disease	0	O
who	0	O
underwent	0	O
R2b	0	O
operation	0	O
was	0	O
51	0	O
%.	0	O


Use	0	O
of	0	O
radioactive	0	O
isotopes	0	O
in	0	O
the	0	O
chemistry	0	O
of	0	O
proteins	0	O


Here	0	O
we	0	O
report	0	O
the	0	O
complete	0	O
6	0	O
-	0	O
kilobase	0	O
cDNA	1	O
sequence	0	O
coding	0	O
for	0	O
a	0	O
chain	0	O
of	0	O
1775	0	O
amino	0	O
acids	0	O
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
genomic	0	O
structure	0	O
.	0	O


PNT	0	O
,	0	O
ADD	1	O
and	0	O
BSS	1	O
in	0	O
the	0	O
initial	0	O
stage	0	O
of	0	O
kindling	0	O
,	0	O
kindling	0	O
rate	0	O
for	0	O
the	0	O
stage	0	O
-	0	O
3	0	O
and	0	O
-	0	O
5	0	O
seizures	0	O
,	0	O
seizure	0	O
parameters	0	O
at	0	O
the	0	O
first	0	O
stage	0	O
-	0	O
3	0	O
and	0	O
-	0	O
5	0	O
were	0	O
recorded	0	O
and	0	O
compared	0	O
to	0	O
the	0	O
values	0	O
of	0	O
saline	0	O
-	0	O
treated	0	O
,	0	O
control	0	O
group	0	O
.	0	O


Animals	0	O
received	0	O
a	0	O
dose	0	O
of	0	O
dexamethasone	0	O
(	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
p	0	O
.)	0	O
prior	0	O
to	0	O
the	0	O
protein	0	O
-	0	O
free	0	O
surfactant	0	O
preparation	0	O
Exosurf	0	O
(	0	O
pure	0	O
phospholipids	0	O
containing	0	O
surfactant	0	O
,	0	O
Wellcome	0	O
GmbH	0	O
,	0	O
Burgwedel	0	O
,	0	O
Germany	0	O
)	0	O
and	0	O
a	0	O
rSP	1	O
-	0	O
C	1	O
based	0	O
surfactant	0	O
,	0	O
respectively	0	O
.	0	O


A	1	O
series	0	O
of	0	O
5	0	O
'-	0	O
deletions	0	O
revealed	0	O
that	0	O
the	0	O
fragment	0	O
-	0	O
218	0	O
to	0	O
+	0	O
4	0	O
from	0	O
the	0	O
TSS	0	O
had	0	O
the	0	O
highest	0	O
promoter	0	O
activity	0	O
,	0	O
nearly	0	O
1000	0	O
-	0	O
fold	0	O
greater	0	O
than	0	O
the	0	O
promoterless	0	O
chloramphenicol	0	B
acetyltransferase	0	I
construct	0	I
.	0	O


A	1	O
method	0	O
for	0	O
establishing	0	O
stimulus	0	O
control	0	O
of	0	O
ethanol	0	O
responding	0	O
was	0	O
developed	0	O
.	0	O


TPA	1	O
and	0	O
TGF	1	B
-	0	I
beta	0	I
1	0	I
did	0	O
not	0	O
markedly	0	O
affect	0	O
the	0	O
activities	0	O
of	0	O
the	0	O
72	0	O
-	0	O
kDa	1	O
enzyme	0	O
.	0	O


The	0	O
interindividual	0	O
variability	0	O
of	0	O
the	0	O
parameters	0	O
is	0	O
taken	0	O
into	0	O
consideration	0	O
by	0	O
interactively	0	O
determining	0	O
the	0	O
threshold	0	O
levels	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
compare	0	O
pregnancy	0	O
complications	0	O
in	0	O
women	0	O
having	0	O
genetic	0	O
amniocentesis	0	O
at	0	O
11	0	O
-	0	O
14	0	O
weeks	0	O
versus	0	O
those	0	O
undergoing	0	O
amniocentesis	0	O
at	0	O
16	0	O
-	0	O
19	0	O
weeks	0	O
'	0	O
gestation	0	O
.	0	O


It	1	O
has	0	O
also	0	O
been	0	O
shown	0	O
that	0	O
a	0	O
variety	0	O
of	0	O
extracellular	0	O
factors	0	O
stimulate	0	O
a	0	O
pair	0	O
of	0	O
MAPK	1	O
p44	0	B
and	0	O
MAPK	1	O
p42	0	B
of	0	O
MAPK	1	B
family	0	I
members	0	I
.	0	O


Rifabutin	1	O
has	0	O
substantial	0	O
efficacy	0	O
when	0	O
combined	0	O
with	0	O
other	0	O
agents	0	O
.	0	O


Nonvascular	0	O
ophthalmic	0	O
and	0	O
neurologic	0	O
disorders	0	O
that	0	O
can	0	O
be	0	O
confused	0	O
with	0	O
amaurosis	0	O
fugax	0	O
are	0	O
listed	0	O
,	0	O
and	0	O
an	0	O
algorithm	0	O
for	0	O
evaluation	0	O
(	0	O
which	0	O
includes	0	O
ophthalmic	0	O
examination	0	O
,	0	O
laboratory	0	O
studies	0	O
,	0	O
and	0	O
noninvasive	0	O
carotid	0	O
artery	0	O
studies	0	O
)	0	O
is	0	O
given	0	O
.	0	O


Human	1	B
thyroid	0	I
stimulator	0	I
(	0	O
HTS	0	B
)	0	O
in	0	O
thyroid	0	O
diseases	0	O


The	0	O
STE20	0	B
gene	0	I
,	0	O
encoding	0	O
a	0	O
protein	0	O
kinase	0	O
required	0	O
for	0	O
pheromone	0	O
signal	0	O
transduction	0	O
,	0	O
has	0	O
recently	0	O
been	0	O
identified	0	O
in	0	O
a	0	O
genetic	0	O
screen	0	O
for	0	O
high	0	O
-	0	O
gene	0	O
-	0	O
dosage	0	O
suppressors	0	O
of	0	O
a	0	O
partly	0	O
defective	0	O
G	1	B
beta	0	I
mutation	0	O
.	0	O


A	1	O
study	0	O
of	0	O
chromosomes	0	O
of	0	O
lymphocytes	0	O
from	0	O
patients	0	O
treated	0	O
with	0	O
hycanthone	0	O
.	0	O


The	0	O
MCA	1	O
and	0	O
UA	1	O
PI	1	O
values	0	O
showed	0	O
the	0	O
greatest	0	O
deviation	0	O
for	0	O
any	0	O
single	0	O
-	0	O
vessel	0	O
parameter	0	O
.	0	O


In	1	O
this	0	O
paper	0	O
we	0	O
report	0	O
that	0	O
ligand	0	O
binding	0	O
induced	0	O
tyrosine	0	O
phosphorylation	0	O
in	0	O
BaF3	0	O
cells	0	O
engineered	0	O
to	0	O
express	0	O
the	0	O
murine	0	B
Mpl	0	I
receptor	0	I
(	0	O
BaF3	0	O
/	0	O
mMpl	0	B
).	0	O


The	0	O
spectrum	0	O
of	0	O
phenotypes	0	O
caused	0	O
by	0	O
these	0	O
mutations	0	O
was	0	O
strikingly	0	O
different	0	O
than	0	O
mutations	0	O
in	0	O
the	0	O
adaptor	0	O
for	0	O
the	0	O
VP16	0	B
activation	0	I
domain	0	I
.	0	O


The	0	O
p55	0	B
mRNA	1	I
is	0	O
undetectable	0	O
in	0	O
non	0	O
-	0	O
EBV	1	O
-	0	O
infected	0	O
B	1	O
-	0	O
and	0	O
T	1	O
-	0	O
cell	0	O
lines	0	O
or	0	O
in	0	O
a	0	O
myelomonocytic	0	O
cell	0	O
line	0	O
(	0	O
U937	0	O
).	0	O


The	0	O
similar	0	O
phenotypes	0	O
of	0	O
bur6	0	B
and	0	O
bur3	0	B
(	0	O
mot1	0	B
)	0	O
mutations	0	O
suggest	0	O
that	0	O
Bur6p	0	B
and	0	O
Mot1p	0	B
have	0	O
related	0	O
,	0	O
but	0	O
not	0	O
identical	0	O
,	0	O
functions	0	O
in	0	O
modulating	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
general	0	O
transcription	0	O
machinery	0	O
in	0	O
vivo	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
and	0	O
characterized	0	O
the	0	O
GCD6	0	B
and	0	O
GCD7	0	B
genes	0	I
and	0	O
shown	0	O
that	0	O
their	0	O
products	0	O
are	0	O
required	0	O
to	0	O
repress	0	O
GCN4	0	B
translation	0	O
under	0	O
nonstarvation	0	O
conditions	0	O
.	0	O


Three	0	O
subgenomes	0	O
also	0	O
comprised	0	O
15	0	O
to	0	O
75	0	O
nucleotides	0	O
derived	0	O
from	0	O
the	0	O
5	0	O
'	0	O
part	0	O
of	0	O
the	0	O
NS2	0	B
gene	0	I
.	0	O


The	0	O
U17	0	B
/	0	O
U16	0	B
and	0	O
the	0	O
U16	0	B
+	0	I
gene	0	I
products	0	I
transactivated	0	O
the	0	O
HIV	1	B
LTR	1	I
.	0	O


Alternative	0	O
splicing	0	O
of	0	O
fibroblast	0	B
growth	0	I
factor	0	I
receptor	0	I
2	0	I
(	0	O
FGF	0	B
-	0	I
R2	0	I
)	0	O
is	0	O
an	0	O
example	0	O
of	0	O
highly	0	O
regulated	0	O
alternative	0	O
splicing	0	O
in	0	O
which	0	O
exons	0	O
IIIb	0	O
and	0	O
IIIc	0	O
are	0	O
utilized	0	O
in	0	O
a	0	O
mutually	0	O
exclusive	0	O
manner	0	O
in	0	O
different	0	O
cell	0	O
types	0	O
.	0	O


The	0	O
retention	0	O
index	0	O
of	0	O
201Tl	0	O
SPECT	1	O
is	0	O
a	0	O
useful	0	O
indicator	0	O
of	0	O
metastatic	0	O
potential	0	O
,	0	O
thereby	0	O
facilitating	0	O
the	0	O
prediction	0	O
of	0	O
prognosis	0	O
,	0	O
and	0	O
provides	0	O
insight	0	O
into	0	O
the	0	O
relationship	0	O
between	0	O
201Tl	0	O
uptake	0	O
and	0	O
malignancy	0	O
.	0	O


Nucleoprotein	1	O
(	0	O
N	1	O
)	0	O
expressed	0	O
by	0	O
both	0	O
recombinant	0	O
vaccinia	0	O
virus	0	O
and	0	O
TGEV	0	O
had	0	O
a	0	O
relative	0	O
molecular	0	O
mass	0	O
(	0	O
Mr	1	O
)	0	O
of	0	O
47	0	O
,	0	O
000	0	O
and	0	O
was	0	O
susceptible	0	O
to	0	O
degradation	0	O
at	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
yielding	0	O
discrete	0	O
breakdown	0	O
products	0	O
.	0	O


To	1	O
understand	0	O
the	0	O
basis	0	O
for	0	O
the	0	O
increased	0	O
cell	0	O
surface	0	O
stability	0	O
compared	0	O
with	0	O
wild	0	O
-	0	O
type	0	O
peptide	0	O
and	0	O
to	0	O
understand	0	O
the	0	O
differences	0	O
in	0	O
T	1	O
cell	0	O
recognition	0	O
between	0	O
I1Y	0	B
and	0	O
I1F	0	B
,	0	O
we	0	O
determined	0	O
the	0	O
x	0	O
-	0	O
ray	0	O
crystal	0	O
structures	0	O
of	0	O
the	0	O
two	0	O
class	0	B
I	1	I
MHC	1	I
-	0	I
peptide	0	I
complexes	0	I
.	0	O


To	1	O
estimate	0	O
the	0	O
locations	0	O
of	0	O
sources	0	O
with	0	O
the	0	O
TF	1	O
-	0	O
MUSIC	0	O
algorithm	0	O
,	0	O
we	0	O
first	0	O
set	0	O
the	0	O
target	0	O
region	0	O
on	0	O
the	0	O
spectrogram	0	O
of	0	O
the	0	O
somatosensory	0	O
responses	0	O
.	0	O


Relationship	0	O
between	0	O
mitochondrial	0	B
NADH	1	I
-	0	I
ubiquinone	0	I
reductase	0	I
and	0	O
a	0	O
bacterial	0	B
NAD	1	I
-	0	I
reducing	0	I
hydrogenase	0	I
.	0	O


Erythrocytic	1	O
stages	0	O
of	0	O
mammalian	0	O
malarial	0	O
parasites	0	O
contain	0	O
acristate	0	O
mitochondria	0	O
whose	0	O
functions	0	O
are	0	O
not	0	O
well	0	O
understood	0	O
.	0	O


ST	1	O
elevation	0	O
occurs	0	O
in	0	O
5	0	O
patients	0	O
(	0	O
55	0	O
.	0	O
5	0	O
%)	0	O
of	0	O
subgroup	0	O
A	1	O
and	0	O
in	0	O
no	0	O
patient	0	O
of	0	O
the	0	O
subgroup	0	O
B	1	O
.	0	O


In	1	O
calves	0	O
receiving	0	O
milk	0	O
-	0	O
substitute	0	O
diets	0	O
containing	0	O
80	0	O
-	0	O
260	0	O
g	0	O
DM	1	O
/	0	O
kg	0	O
,	0	O
milk	0	O
intakes	0	O
were	0	O
reduced	0	O
by	0	O
up	0	O
to	0	O
30	0	O
%	0	O
on	0	O
the	0	O
1st	0	O
day	0	O
that	0	O
calves	0	O
were	0	O
fed	0	O
once	0	O
daily	0	O
instead	0	O
of	0	O
twice	0	O
daily	0	O
.	0	O


The	0	O
alternative	0	O
exon	0	O
introduces	0	O
the	0	O
novel	0	O
carboxyl	0	O
terminus	0	O
and	0	O
a	0	O
new	0	O
translation	0	O
stop	0	O
signal	0	O
,	0	O
while	0	O
simultaneously	0	O
converting	0	O
the	0	O
coding	0	O
sequence	0	O
for	0	O
40	0	O
carboxyl	0	O
-	0	O
terminal	0	O
residues	0	O
in	0	O
CeCAT	0	B
alpha	0	I
into	0	O
3	0	O
'-	0	O
untranslated	0	O
nucleotides	0	O
.	0	O


Lymphoproliferative	1	O
disorders	0	O
arising	0	O
under	0	O
immunosuppression	0	O
with	0	O
FK	0	O
506	0	O
:	0	O
initial	0	O
observations	0	O
in	0	O
a	0	O
large	0	O
transplant	0	O
population	0	O
.	0	O


Positioning	1	O
this	0	O
uORF	0	O
,	0	O
together	0	O
with	0	O
its	0	O
accompanying	0	O
Kozak	0	O
sequences	0	O
,	0	O
between	0	O
a	0	O
heterologous	0	O
promoter	0	O
from	0	O
SV40	1	O
and	0	O
a	0	O
CAT	1	B
reporter	0	I
gene	0	I
resulted	0	O
in	0	O
marked	0	O
inhibition	0	O
of	0	O
CAT	1	B
protein	0	I
production	0	O
without	0	O
a	0	O
decrease	0	O
in	0	O
CAT	1	B
mRNA	1	I
.	0	O


A	1	O
short	0	O
sequence	0	O
surrounding	0	O
the	0	O
major	0	O
JNK	0	B
phosphorylation	0	O
site	0	O
of	0	O
c	0	B
-	0	I
Jun	1	I
is	0	O
conserved	0	O
in	0	O
c	0	B
-	0	I
Fos	1	I
and	0	O
is	0	O
part	0	O
of	0	O
its	0	O
activation	0	O
domain	0	O
,	0	O
suggesting	0	O
that	0	O
c	0	B
-	0	I
Fos	1	I
may	0	O
be	0	O
similarly	0	O
regulated	0	O
.	0	O


Exon	1	O
A	1	O
is	0	O
located	0	O
approximately	0	O
7	0	O
kb	0	O
5	0	O
'	0	O
to	0	O
the	0	O
HSL	0	B
translation	0	I
start	0	I
site	0	I
.	0	O


However	0	O
,	0	O
calphostin	0	O
C	1	O
,	0	O
a	0	O
specific	0	O
inhibitor	0	O
of	0	O
PKC	0	B
,	0	O
abolished	0	O
the	0	O
TPA	1	O
-	0	O
induced	0	O
increase	0	O
in	0	O
CFI	0	B
mRNA	1	I
levels	0	O
.	0	O


On	1	O
cessation	0	O
of	0	O
steroid	0	O
therapy	0	O
the	0	O
patient	0	O
was	0	O
noted	0	O
to	0	O
have	0	O
radiologic	0	O
manifestations	0	O
of	0	O
hypertrophic	0	O
osteoarthropathy	0	O
(	0	O
HOA	0	O
)	0	O
as	0	O
well	0	O
as	0	O
clinical	0	O
and	0	O
laboratory	0	O
features	0	O
of	0	O
rheumatoid	0	O
arthritis	0	O
(	0	O
RA	1	O
).	0	O


Genomic	1	O
DNA	1	O
hybridization	0	O
suggests	0	O
that	0	O
SpSHR2	0	B
is	0	O
a	0	O
single	0	O
-	0	O
copy	0	O
gene	0	O
in	0	O
the	0	O
S	1	O
.	0	O
purpuratus	0	O
genome	0	O
.	0	O


Many	0	O
eukaryotic	0	O
cell	0	O
surface	0	O
proteins	0	O
are	0	O
anchored	0	O
in	0	O
the	0	O
lipid	0	O
bilayer	0	O
through	0	O
glycosylphosphatidylinositol	0	O
(	0	O
GPI	0	O
).	0	O


Previously	0	O
,	0	O
we	0	O
reported	0	O
the	0	O
sequence	0	O
of	0	O
the	0	O
gene	0	B
encoding	0	I
human	0	I
K14	0	I
(	0	O
D	1	O
.	0	O


Commun	0	O
.	0	O


Analysis	1	O
of	0	O
Standard	1	O
Reference	1	O
Material	1	O
1846	0	O
,	0	O
Infant	1	O
Formula	1	O
,	0	O
gave	0	O
a	0	O
mean	0	O
value	0	O
of	0	O
0	0	O
.	0	O
95	0	O
+/-	0	O
0	0	O
.	0	O
088	0	O
mg	0	O
vitamin	0	O
K	1	O
/	0	O
kg	0	O
(	0	O
K	1	O
or	0	O
K1	0	O
?)	0	O
(	0	O
n	0	O
=	0	O
31	0	O
)	0	O
with	0	O
a	0	O
coefficient	0	O
of	0	O
variation	0	O
of	0	O
9	0	O
.	0	O
26	0	O
.	0	O


DESIGN	0	O
:	0	O
A	1	O
cross	0	O
-	0	O
sectional	0	O
study	0	O
.	0	O


These	0	O
fusions	0	O
are	0	O
contained	0	O
on	0	O
plasmids	0	O
which	0	O
have	0	O
both	0	O
yeast	0	O
and	0	O
E	1	O
.	0	O
coli	0	O
replication	0	O
origins	0	O
and	0	O
selectable	0	O
markers	0	O
and	0	O
,	0	O
therefore	0	O
,	0	O
can	0	O
be	0	O
used	0	O
to	0	O
transform	0	O
either	0	O
yeast	0	O
or	0	O
E	1	O
.	0	O
coli	0	O
cells	0	O
.	0	O


These	0	O
mutations	0	O
create	0	O
stop	0	O
codons	0	O
in	0	O
exon	0	O
7	0	O
and	0	O
8	0	O
,	0	O
respectively	0	O
,	0	O
and	0	O
probably	0	O
result	0	O
in	0	O
truncated	0	O
proteins	0	O
lacking	0	O
HLH	0	O
-	0	O
Zip	0	O
or	0	O
Zip	0	O
structure	0	O
.	0	O


By	0	O
Felix	0	O
Lagrange	0	O
,	0	O
1918	0	O
.	0	O


The	0	O
characteristics	0	O
of	0	O
the	0	O
VirD1	0	B
/	0	O
VirD2	0	B
-	0	O
mediated	0	O
cleavage	0	O
reaction	0	O
strongly	0	O
resemble	0	O
those	0	O
observed	0	O
with	0	O
relaxosomes	0	O
of	0	O
IncP	0	O
plasmids	0	O
involved	0	O
in	0	O
initiation	0	O
of	0	O
transfer	0	O
DNA	1	O
replication	0	O
during	0	O
bacterial	0	O
conjugation	0	O
.	0	O


The	0	O
importance	0	O
of	0	O
these	0	O
sites	0	O
for	0	O
transcriptional	0	O
activation	0	O
was	0	O
studied	0	O
by	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
followed	0	O
by	0	O
promoter	0	O
function	0	O
analysis	0	O
of	0	O
the	0	O
mutants	0	O
with	0	O
a	0	O
chloramphenicol	0	B
acetyltransferase	0	I
reporter	0	I
system	0	O
.	0	O


A	1	O
potential	0	O
TATA	0	O
box	0	O
is	0	O
located	0	O
29	0	O
base	0	O
pairs	0	O
upstream	0	O
of	0	O
the	0	O
first	0	O
transcription	0	O
initiation	0	O
site	0	O
.	0	O


Identification	1	O
of	0	O
dynein	0	B
heavy	0	I
chain	0	I
genes	0	I
expressed	0	O
in	0	O
human	0	O
and	0	O
mouse	0	O
testis	0	O
:	0	O
chromosomal	0	O
localization	0	O
of	0	O
an	0	O
axonemal	0	B
dynein	0	I
gene	0	I
.	0	O


Curiously	0	O
,	0	O
testololactone	0	O
was	0	O
earlier	0	O
and	0	O
more	0	O
widely	0	O
used	0	O
than	0	O
aminoglutethimide	0	O
in	0	O
treating	0	O
advanced	0	O
breast	0	O
carcinoma	0	O
.	0	O


No	1	O
UOxase	0	B
mRNA	1	I
was	0	O
detected	0	O
in	0	O
11	0	O
nonhepatic	0	O
tissues	0	O
of	0	O
rat	0	O
,	0	O
suggesting	0	O
tissue	0	O
specificity	0	O
of	0	O
expression	0	O
of	0	O
this	0	O
UOxase	0	B
gene	0	I
.	0	O


Recent	0	O
application	0	O
of	0	O
recombinant	0	O
canarypox	0	O
ALVAC	0	O
/	0	O
HIV	1	O
-	0	O
1	0	O
vectors	0	O
as	0	O
vaccine	0	O
immunogens	0	O
in	0	O
HIV	1	O
-	0	O
1	0	O
,-	0	O
noninfected	0	O
volunteers	0	O
has	0	O
produced	0	O
CTL	1	O
responses	0	O
in	0	O
a	0	O
significant	0	O
number	0	O
of	0	O
vaccinees	0	O
.	0	O


Manipulation	1	O
of	0	O
the	0	O
checkpoint	0	O
regulators	0	O
involved	0	O
in	0	O
cell	0	O
cycle	0	O
arrest	0	O
and	0	O
apoptosis	0	O
may	0	O
thus	0	O
provide	0	O
a	0	O
novel	0	O
strategy	0	O
to	0	O
cancer	0	O
therapy	0	O
.	0	O


The	0	O
combination	0	O
PIP	1	O
64	0	O
micrograms	0	O
-	0	O
PEF	1	O
4	0	O
micrograms	0	O
prevents	0	O
the	0	O
frequent	0	O
secondary	0	O
regrowth	0	O
seen	0	O
after	0	O
6	0	O
hours	0	O
with	0	O
the	0	O
antibiotics	0	O
used	0	O
alone	0	O
.	0	O


Motivational	1	O
factors	0	O
focusing	0	O
on	0	O
attitudes	0	O
,	0	O
perceived	0	O
susceptibility	0	O
to	0	O
pregnancy	0	O
,	0	O
and	0	O
normative	0	O
factors	0	O
were	0	O
also	0	O
relevant	0	O
.	0	O


Therefore	0	O
,	0	O
in	0	O
conjunction	0	O
with	0	O
a	0	O
positive	0	O
pregnancy	0	O
test	0	O
and	0	O
the	0	O
patient	0	O
'	0	O
s	0	O
clinical	0	O
history	0	O
,	0	O
a	0	O
severely	0	O
depressed	0	O
or	0	O
absent	0	O
serum	0	O
PAPP	0	B
-	0	I
A	1	I
level	0	O
may	0	O
aid	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
extrauterine	0	O
pregnancy	0	O
.	0	O


The	0	O
total	0	O
number	0	O
of	0	O
specimens	0	O
was	0	O
131	0	O
with	0	O
78	0	O
nonsmokers	0	O
and	0	O
53	0	O
smokers	0	O
.	0	O


Interestingly	0	O
,	0	O
one	0	O
IRF	1	B
binding	0	I
site	0	I
was	0	O
found	0	O
within	0	O
the	0	O
IRF	1	B
-	0	I
2	0	I
promoter	0	I
,	0	O
and	0	O
expression	0	O
of	0	O
the	0	O
IRF	1	B
-	0	I
2	0	I
gene	0	I
was	0	O
affected	0	O
by	0	O
both	0	O
transient	0	O
and	0	O
stable	0	O
IRF	1	B
-	0	I
1	0	I
expression	0	O
.	0	O


Effect	1	O
of	0	O
indomethacin	0	O
and	0	O
prostaglandin	0	O
F2	0	O
alpha	0	O
on	0	O
parturition	0	O
in	0	O
swine	0	O
.	0	O


She	0	O
was	0	O
able	0	O
to	0	O
stand	0	O
unaided	0	O
by	0	O
3	0	O
years	0	O
of	0	O
age	0	O
with	0	O
then	0	O
progressive	0	O
worsening	0	O
of	0	O
motor	0	O
abilities	0	O
.	0	O


Electrocardiographic	0	O
right	0	O
ventricular	0	O
hypertrophy	0	O
was	0	O
seen	0	O
in	0	O
4	0	O
,	0	O
and	0	O
biventricular	0	O
hypertrophy	0	O
in	0	O
5	0	O
patients	0	O
.	0	O


One	0	O
of	0	O
these	0	O
is	0	O
located	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
untranslated	0	O
region	0	O
,	0	O
and	0	O
may	0	O
encode	0	O
regulatory	0	O
sequences	0	O
.	0	O


CES4	0	B
on	0	O
a	0	O
multicopy	0	O
plasmid	0	O
was	0	O
unable	0	O
to	0	O
suppress	0	O
tif1	0	B
-	0	I
A79V	0	I
.	0	O


The	0	O
direct	0	O
effects	0	O
of	0	O
transmitter	0	O
release	0	O
were	0	O
(	0	O
a	0	O
)	0	O
an	0	O
early	0	O
fall	0	O
in	0	O
MAP	1	O
followed	0	O
by	0	O
a	0	O
late	0	O
pressor	0	O
effect	0	O
;	0	O
and	0	O
(	0	O
b	0	O
)	0	O
an	0	O
early	0	O
bradycardia	0	O
followed	0	O
by	0	O
a	0	O
late	0	O
tachycardia	0	O
.	0	O


Using	0	O
this	0	O
method	0	O
,	0	O
we	0	O
measured	0	O
absorption	0	O
of	0	O
low	0	O
doses	0	O
of	0	O
vitamin	0	O
A	1	O
,	0	O
which	0	O
may	0	O
provide	0	O
a	0	O
more	0	O
physiological	0	O
approach	0	O
to	0	O
assessment	0	O
of	0	O
fat	0	O
malabsorption	0	O
.	0	O


Our	0	O
data	0	O
,	0	O
combined	0	O
with	0	O
those	0	O
of	0	O
Hershey	0	O
and	0	O
co	0	O
-	0	O
workers	0	O
,	0	O
suggest	0	O
that	0	O
mammalian	0	B
eIF3	0	I
is	0	O
composed	0	O
of	0	O
at	0	O
least	0	O
10	0	O
subunits	0	O
:	0	O
p170	0	B
,	0	O
p116	0	B
(	0	O
hPrt1	0	B
),	0	O
p110	0	B
,	0	O
p66	0	B
,	0	O
p48	0	B
,	0	O
p47	0	B
,	0	O
p44	0	B
,	0	O
p40	0	B
,	0	O
p36	0	B
,	0	O
and	0	O
p35	0	B
.	0	O


Subsequently	0	O
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
reexpression	0	O
of	0	O
the	0	O
r	0	B
-	0	I
PTPeta	0	I
gene	0	I
in	0	O
highly	0	O
malignant	0	O
rat	0	O
thyroid	0	O
cells	0	O
transformed	0	O
by	0	O
retroviruses	0	O
carrying	0	O
the	0	O
v	0	B
-	0	I
mos	0	I
and	0	O
v	0	B
-	0	I
ras	0	I
-	0	I
Ki	1	I
oncogenes	0	I
suppresses	0	O
their	0	O
malignant	0	O
phenotype	0	O
.	0	O


The	0	O
PI3K_68D	0	B
cDNA	1	I
encodes	0	O
a	0	O
protein	0	O
of	0	O
210	0	O
kDa	1	O
,	0	O
which	0	O
lacks	0	O
sequences	0	O
implicated	0	O
in	0	O
linking	0	O
p110	0	B
PI	1	I
3	0	I
-	0	I
kinases	0	I
to	0	O
p85	0	B
adaptor	0	I
proteins	0	I
,	0	O
but	0	O
contains	0	O
an	0	O
amino	0	O
-	0	O
terminal	0	O
proline	0	O
-	0	O
rich	0	O
sequence	0	O
,	0	O
which	0	O
could	0	O
bind	0	O
to	0	O
SH3	0	B
domains	0	I
,	0	O
and	0	O
a	0	O
carboxy	0	O
-	0	O
terminal	0	O
C2	1	B
domain	0	O
.	0	O


The	0	O
CRE	0	O
,	0	O
5	0	O
'-	0	O
TGACGTCA	0	O
-	0	O
3	0	O
',	0	O
has	0	O
been	0	O
described	0	O
as	0	O
the	0	O
consensus	0	O
sequence	0	O
for	0	O
the	0	O
cis	0	O
-	0	O
element	0	O
that	0	O
directs	0	O
cAMP	1	O
-	0	O
regulated	0	O
gene	0	O
expression	0	O
.	0	O


In	1	O
293	0	O
cells	0	O
,	0	O
expression	0	O
of	0	O
the	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
inhibitor	0	O
,	0	O
I	1	B
kappa	0	I
B	1	I
-	0	I
alpha	0	I
,	0	O
reduced	0	O
the	0	O
stimulatory	0	O
activity	0	O
of	0	O
LMP	1	B
.	0	O


These	0	O
results	0	O
also	0	O
suggest	0	O
the	0	O
involvement	0	O
of	0	O
additional	0	O
elements	0	O
in	0	O
the	0	O
UPR	0	O
.	0	O


It	1	O
also	0	O
suggests	0	O
that	0	O
there	0	O
is	0	O
another	0	O
pathway	0	O
which	0	O
can	0	O
activate	0	O
SWI4	0	B
transcription	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
SWI6	0	B
.	0	O


We	0	O
critically	0	O
assess	0	O
current	0	O
systematic	0	O
uncertainties	0	O
and	0	O
determine	0	O
the	0	O
primordial	0	O
Li	1	O
abundance	0	O
within	0	O
new	0	O
,	0	O
much	0	O
tighter	0	O
limits	0	O
:	0	O
&	0	O
amp	0	O
;	0	O
parl0	0	O
;	0	O
Li	1	O
&	0	O
amp	0	O
;	0	O
solm0	0	O
;	0	O
H	1	O
&	0	O
amp	0	O
;	0	O
parr0	0	O
;	0	O
p	0	O
=	0	O
1	0	O
.	0	O
23	0	O
+	0	O
0	0	O
.	0	O
68	0	O
-	0	O
0	0	O
.	0	O
32x10	0	O
-	0	O
10	0	O
.	0	O


RVEF	0	O
and	0	O
LVEF	0	O
both	0	O
increased	0	O
by	0	O
about	0	O
14	0	O
%	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
and	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


LMP2A	0	B
enhances	0	O
Lyn	0	B
and	0	O
Syk	0	B
ubiquitination	0	O
in	0	O
vivo	0	O
in	0	O
a	0	O
fashion	0	O
that	0	O
depends	0	O
on	0	O
the	0	O
activity	0	O
of	0	O
Nedd4	0	B
family	0	O
members	0	O
and	0	O
correlates	0	O
with	0	O
destabilization	0	O
of	0	O
the	0	O
Lyn	0	B
tyrosine	0	I
kinase	0	I
.	0	O


To	1	O
identify	0	O
the	0	O
DNA	1	O
sequences	0	O
that	0	O
cis	0	O
-	0	O
regulate	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
rat	0	B
liver	0	I
pyruvate	0	I
kinase	0	I
(	0	O
L	1	B
-	0	I
PK	1	I
)	0	O
genes	0	O
,	0	O
a	0	O
series	0	O
of	0	O
constructs	0	O
in	0	O
which	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
reporter	0	I
genes	0	I
is	0	O
driven	0	O
by	0	O
various	0	O
deleted	0	O
fragments	0	O
of	0	O
the	0	O
3200	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
)	0	O
upstream	0	O
of	0	O
the	0	O
L	1	B
-	0	I
PK	1	I
gene	0	I
cap	0	I
site	0	I
have	0	O
been	0	O
assayed	0	O
for	0	O
transient	0	O
expression	0	O
after	0	O
introduction	0	O
into	0	O
hepatoma	0	O
HepG2	0	O
cells	0	O
,	0	O
rat	0	O
hepatocytes	0	O
in	0	O
primary	0	O
culture	0	O
,	0	O
fibroblast	0	O
LTK	0	O
-	0	O
cells	0	O
,	0	O
myogenic	0	O
C2C12	0	O
cells	0	O
,	0	O
and	0	O
CHO	1	O
cells	0	O
.	0	O


Fifty	0	O
six	0	O
young	0	O
patients	0	O
(	0	O
age	0	O
<	0	O
45	0	O
yr	0	O
)	0	O
with	0	O
doppler	0	O
-	0	O
proven	0	O
DVT	1	O
were	0	O
investigated	0	O
for	0	O
the	0	O
presence	0	O
of	0	O
resistance	0	O
to	0	O
activated	0	B
protein	0	I
C	1	I
(	0	O
APC	1	B
-	0	I
R	1	I
),	0	O
lupus	0	O
anticoagulant	0	O
(	0	O
LA	1	O
),	0	O
anticardiolipin	0	B
antibodies	0	I
and	0	O
deficiencies	0	O
of	0	O
protein	0	B
C	1	I
,	0	O
protein	0	B
S	1	I
,	0	O
ATIII	0	B
activities	0	O
.	0	O


They	0	O
also	0	O
indicate	0	O
that	0	O
direct	0	O
interactions	0	O
between	0	O
C	1	B
/	0	I
EBPs	0	I
and	0	O
specific	0	O
Ets	1	B
family	0	O
members	0	O
,	0	O
together	0	O
with	0	O
GATA	0	B
-	0	I
1	0	I
,	0	O
are	0	O
important	0	O
for	0	O
eosinophil	0	O
lineage	0	O
determination	0	O
.	0	O


Using	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
RAREoct	0	B
contributes	0	O
to	0	O
the	0	O
transcriptional	0	O
activation	0	O
of	0	O
Oct	1	B
-	0	I
3	0	I
/	0	I
4	0	I
promoter	0	I
in	0	O
P19	0	O
cells	0	O
and	0	O
,	0	O
most	0	O
interestingly	0	O
,	0	O
mediates	0	O
the	0	O
RA	1	O
-	0	O
induced	0	O
repression	0	O
in	0	O
RA	1	O
-	0	O
differentiated	0	O
EC	1	O
cells	0	O
.	0	O


The	0	O
CCAAT	0	O
core	0	O
sequence	0	O
mutants	0	O
in	0	O
which	0	O
both	0	O
CIII	0	O
and	0	O
CI	1	O
/	0	O
CII	0	O
were	0	O
abolished	0	O
,	0	O
also	0	O
increased	0	O
the	0	O
promoter	0	O
activity	0	O
.	0	O


The	0	O
serum	0	O
erythropoietin	0	B
(	0	O
EPO	0	B
)	0	O
concentrations	0	O
of	0	O
15	0	O
male	0	O
triathletes	0	O
(	0	O
26	0	O
.	0	O
3	0	O
U	1	O
.	0	O
ml	0	O
-	0	O
1	0	O
)	0	O
were	0	O
significantly	0	O
lower	0	O
than	0	O
those	0	O
of	0	O
45	0	O
male	0	O
distance	0	O
runners	0	O
(	0	O
31	0	O
.	0	O
6	0	O
U	1	O
.	0	O
ml	0	O
-	0	O
1	0	O
;	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


These	0	O
studies	0	O
serve	0	O
as	0	O
the	0	O
basis	0	O
for	0	O
the	0	O
further	0	O
characterization	0	O
of	0	O
the	0	O
regulatory	0	O
mechanism	0	O
of	0	O
aromatase	0	B
expression	0	O
in	0	O
human	0	O
breast	0	O
cancer	0	O
and	0	O
ASCs	0	O
.	0	O


1	0	O
.	0	O


Point	1	O
mutations	0	O
in	0	O
the	0	O
third	0	O
SH3	0	B
domain	0	I
abolished	0	O
the	0	O
vinexin	0	B
-	0	O
Sos	0	B
interaction	0	O
.	0	O


Growth	1	O
factor	0	O
stimulation	0	O
rapidly	0	O
induces	0	O
a	0	O
reversible	0	O
change	0	O
in	0	O
the	0	O
electrophoretic	0	O
mobility	0	O
of	0	O
the	0	O
ternary	0	O
complex	0	O
,	0	O
accompanied	0	O
by	0	O
increased	0	O
phosphorylation	0	O
of	0	O
the	0	O
Elk	0	B
-	0	I
1	0	I
C	1	I
-	0	I
terminal	0	I
region	0	I
and	0	O
by	0	O
the	0	O
activation	0	O
of	0	O
a	0	O
42	0	B
kd	0	I
cellular	0	I
Elk	0	I
-	0	I
1	0	I
kinase	0	I
.	0	O


Exercise	1	O
training	0	O
has	0	O
become	0	O
increasingly	0	O
important	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
heart	0	O
failure	0	O
patients	0	O
.	0	O


The	0	O
corresponding	0	O
inhibition	0	O
of	0	O
acid	0	B
phosphatase	0	I
activity	0	O
in	0	O
control	0	O
male	0	O
and	0	O
female	0	O
guinea	0	O
pigs	0	O
was	0	O
15	0	O
.	0	O
91	0	O
%	0	O
and	0	O
20	0	O
.	0	O
33	0	O
%	0	O
respectively	0	O
.	0	O


First	0	O
,	0	O
a	0	O
pet54	0	B
::	0	O
LEU2	0	B
cytoductant	0	O
bearing	0	O
the	0	O
'	0	O
short	0	O
'	0	O
mitochondrial	0	O
genome	0	O
that	0	O
lacks	0	O
both	0	O
COX1	0	B
introns	0	I
aI5	0	I
alpha	0	I
and	0	O
aI5	0	B
beta	0	I
is	0	O
defective	0	O
only	0	O
in	0	O
COX3	0	B
gene	0	I
expression	0	O
and	0	O
not	0	O
in	0	O
COX1	0	B
mRNA	1	I
splicing	0	O
or	0	O
mRNA	1	O
translation	0	O
.	0	O


In	1	O
a	0	O
maxicell	0	O
system	0	O
a	0	O
protein	0	O
with	0	O
an	0	O
approximate	0	O
molecular	0	O
weight	0	O
of	0	O
36	0	O
,	0	O
000	0	O
was	0	O
synthesized	0	O
.	0	O


When	0	O
both	0	O
lesions	0	O
were	0	O
complete	0	O
lateral	0	O
hemisections	0	O
in	0	O
weanling	0	O
operates	0	O
,	0	O
little	0	O
behavioral	0	O
recovery	0	O
was	0	O
observed	0	O
,	0	O
similar	0	O
to	0	O
complete	0	O
spinal	0	O
cord	0	O
transection	0	O
(	0	O
N	1	O
=	0	O
3	0	O
).	0	O


Plasma	1	O
lecithin	0	B
/	0	I
cholesterol	0	I
acyltransferase	0	I
(	0	O
LCAT	1	B
)	0	O
activity	0	O
in	0	O
multiple	0	O
-	0	O
organ	0	O
donors	0	O
:	0	O
a	0	O
predictor	0	O
of	0	O
allograft	0	O
viability	0	O
in	0	O
clinical	0	O
liver	0	O
transplantation	0	O
.	0	O


Slowly	0	O
adapting	0	O
type	0	O
I	1	O
mechanoreceptor	0	O
discharge	0	O
as	0	O
a	0	O
function	0	O
of	0	O
dynamic	0	O
force	0	O
versus	0	O
dynamic	0	O
displacement	0	O
of	0	O
glabrous	0	O
skin	0	O
of	0	O
raccoon	0	O
and	0	O
squirrel	0	O
monkey	0	O
hand	0	O
.	0	O


The	0	O
P	1	B
mRNA	1	I
also	0	O
contains	0	O
a	0	O
third	0	O
ORF	1	O
for	0	O
the	0	O
V	1	B
protein	0	I
,	0	O
although	0	O
it	0	O
is	0	O
unclear	0	O
how	0	O
or	0	O
whether	0	O
this	0	O
ORF	1	O
is	0	O
accessed	0	O
.	0	O


Salazopyrine	0	O
desensitization	0	O


Schedule	1	O
2	0	O
,	0	O
in	0	O
which	0	O
2	0	O
.	0	O
4	0	O
mg	0	O
/	0	O
kg	0	O
c	0	O
-	0	O
DDP	1	O
was	0	O
administered	0	O
immediately	0	O
before	0	O
X	1	O
-	0	O
ray	0	O
on	0	O
5	0	O
consecutive	0	O
days	0	O
produced	0	O
the	0	O
highest	0	O
degree	0	O
of	0	O
enhancement	0	O
of	0	O
radiation	0	O
effect	0	O
(	0	O
expressed	0	O
as	0	O
dose	0	O
-	0	O
effect	0	O
factor	0	O
);	0	O
and	0	O
the	0	O
next	0	O
greatest	0	O
enhancement	0	O
was	0	O
produced	0	O
by	0	O
12	0	O
mg	0	O
/	0	O
kg	0	O
c	0	O
-	0	O
DDP	1	O
administered	0	O
24	0	O
h	0	O
before	0	O
the	0	O
start	0	O
of	0	O
fractionated	0	O
daily	0	O
radiotherapy	0	O
.	0	O


Multiple	1	O
SWI6	0	B
-	0	O
dependent	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
control	0	O
SWI4	0	B
transcription	0	O
through	0	O
the	0	O
cell	0	O
cycle	0	O
.	0	O


Selective	1	O
activation	0	O
of	0	O
adrenaline	0	O
secretion	0	O
by	0	O
the	0	O
rat	0	O
adrenal	0	O
in	0	O
neuroglycopenia	0	O
detected	0	O
via	0	O
microdialysis	0	O


Primer	1	O
extension	0	O
and	0	O
mung	0	B
bean	0	I
and	0	I
S1	1	I
nuclease	0	I
mapping	0	O
indicated	0	O
multiple	0	O
transcription	0	O
initiation	0	O
sites	0	O
and	0	O
were	0	O
consistent	0	O
with	0	O
Northern	0	O
analyses	0	O
.	0	O


CONCLUSION	0	O
:	0	O
This	0	O
retrospective	0	O
analysis	0	O
does	0	O
not	0	O
confirm	0	O
the	0	O
efficacy	0	O
of	0	O
one	0	O
course	0	O
of	0	O
simultaneous	0	O
Mitomycin	1	O
-	0	O
C	1	O
and	0	O
5	0	O
-	0	O
fluorouracil	0	O
,	0	O
at	0	O
least	0	O
in	0	O
association	0	O
with	0	O
full	0	O
-	0	O
dose	0	O
radiotherapy	0	O
incorporating	0	O
Iridium	1	O
-	0	O
192	0	O
boost	0	O
.	0	O


For	0	O
higher	0	O
expression	0	O
of	0	O
lipA	0	B
in	0	O
S	1	O
.	0	O
lividans	0	O
,	0	O
the	0	O
gene	0	O
was	0	O
cloned	0	O
next	0	O
to	0	O
the	0	O
strong	0	O
aphII	0	B
promoter	0	I
.	0	O


Mitomycin	1	O
-	0	O
C	1	O
can	0	O
cause	0	O
severe	0	O
necrosis	0	O
and	0	O
ulceration	0	O
when	0	O
extravasated	0	O
inadvertently	0	O
into	0	O
skin	0	O
and	0	O
soft	0	O
tissues	0	O
following	0	O
IV	1	O
drug	0	O
administration	0	O
.	0	O


The	0	O
greatest	0	O
difference	0	O
between	0	O
the	0	O
Ad7	0	B
and	0	I
Ad5	0	I
DBPs	0	I
is	0	O
the	0	O
absence	0	O
,	0	O
in	0	O
the	0	O
Ad7	0	O
protein	0	O
,	0	O
of	0	O
12	0	O
amino	0	O
acids	0	O
located	0	O
between	0	O
the	0	O
two	0	O
functional	0	O
domains	0	O
in	0	O
the	0	O
Ad5	0	O
protein	0	O
(	0	O
amino	0	O
acids	0	O
151	0	O
-	0	O
162	0	O
).	0	O


One	0	O
missense	0	O
allele	0	O
(	0	O
P236S	0	O
)	0	O
with	0	O
complete	0	O
loss	0	O
of	0	O
function	0	O
at	0	O
30	0	O
degreesC	0	O
and	0	O
four	0	O
missense	0	O
alleles	0	O
(	0	O
L173F	0	O
,	0	O
E225K	0	O
,	0	O
S269L	0	O
and	0	O
E274K	0	O
)	0	O
that	0	O
conferred	0	O
a	0	O
temperature	0	O
sensitive	0	O
phenotype	0	O
were	0	O
identified	0	O
.	0	O


In	1	O
XO	1	O
males	0	O
,	0	O
two	0	O
her	0	B
-	0	I
1	0	I
mRNAs	0	I
,	0	O
her	0	B
-	0	I
1a	0	I
and	0	O
her	0	B
-	0	I
1b	0	I
,	0	O
are	0	O
transcribed	0	O
from	0	O
two	0	O
separate	0	O
promoters	0	O
:	0	O
P1	1	O
,	0	O
located	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
,	0	O
and	0	O
P2	1	O
,	0	O
located	0	O
in	0	O
the	0	O
large	0	O
second	0	O
intron	0	O
.	0	O


One	0	O
skull	0	O
does	0	O
not	0	O
a	0	O
species	0	O
make	0	O
.	0	O


Inclusion	1	O
of	0	O
the	0	O
extended	0	O
N	1	O
terminus	0	O
into	0	O
the	0	O
originally	0	O
reported	0	O
protein	0	O
resulted	0	O
in	0	O
a	0	O
striking	0	O
similarity	0	O
to	0	O
the	0	O
lymphoid	0	B
factor	0	I
Lef	0	I
-	0	I
1	0	I
.	0	O


Among	0	O
mucus	0	O
-	0	O
secreting	0	O
cells	0	O
,	0	O
the	0	O
gastric	0	O
gland	0	O
mucous	0	O
cells	0	O
,	0	O
Brunner	0	O
'	0	O
s	0	O
glands	0	O
,	0	O
accessory	0	O
glands	0	O
of	0	O
pancreaticobiliary	0	O
tract	0	O
,	0	O
and	0	O
pancreatic	0	O
ducts	0	O
exhibiting	0	O
gastric	0	O
metaplasia	0	O
are	0	O
unique	0	O
in	0	O
that	0	O
they	0	O
express	0	O
class	0	B
III	0	I
mucin	0	I
identified	0	O
by	0	O
paradoxical	0	O
Con	1	B
A	1	I
staining	0	O
composed	0	O
of	0	O
periodate	0	O
oxidation	0	O
,	0	O
sodium	0	O
borohydride	0	O
reduction	0	O
,	0	O
Con	1	B
A	1	I
,	0	O
and	0	O
horseradish	0	B
peroxidase	0	I
reaction	0	O
.	0	O


On	1	O
the	0	O
other	0	O
hand	0	O
,	0	O
if	0	O
the	0	O
measured	0	O
angle	0	O
ANB	0	O
is	0	O
smaller	0	O
than	0	O
the	0	O
calculated	0	O
angle	0	O
,	0	O
the	0	O
skeletal	0	O
relation	0	O
is	0	O
Class	1	O
III	0	O
.	0	O


Restriction	1	O
enzyme	0	O
mapping	0	O
,	0	O
subcloning	0	O
,	0	O
and	0	O
DNA	1	O
sequencing	0	O
analysis	0	O
of	0	O
recombinant	0	O
phage	0	O
lambda	0	O
and	0	O
P1	1	O
clones	0	O
revealed	0	O
that	0	O
exons	0	O
encoding	0	O
the	0	O
1	0	O
.	0	O
9	0	O
-	0	O
kb	0	O
mouse	0	B
TS	1	I
mRNA	1	I
are	0	O
dispersed	0	O
over	0	O
>	0	O
150	0	O
kb	0	O
genomic	0	O
DNA	1	O
.	0	O


XXI	0	O
.	0	O


The	0	O
sera	0	O
and	0	O
nasal	0	O
secretions	0	O
of	0	O
142	0	O
patients	0	O
,	0	O
who	0	O
were	0	O
positive	0	O
in	0	O
HD	1	O
or	0	O
mites	0	O
skin	0	O
test	0	O
,	0	O
were	0	O
subjected	0	O
to	0	O
a	0	O
radioallergosorbent	0	O
test	0	O
(	0	O
RAST	1	O
)	0	O
for	0	O
estimating	0	O
the	0	O
specific	0	O
IgE	1	B
antibody	0	I
activity	0	O
to	0	O
mites	0	O
.	0	O


P	1	O
.	0	O


The	0	O
Tax	0	B
/	0	O
IKKgamma	0	B
interaction	0	O
serves	0	O
to	0	O
recruit	0	O
Tax	0	B
to	0	O
the	0	O
IKK	0	B
catalytic	0	I
subunits	0	I
,	0	O
IKKalpha	0	B
and	0	O
IKKbeta	0	B
,	0	O
and	0	O
this	0	O
recruitment	0	O
appears	0	O
to	0	O
be	0	O
an	0	O
essential	0	O
mechanism	0	O
by	0	O
which	0	O
Tax	0	B
stimulates	0	O
the	0	O
activity	0	O
of	0	O
IKK	0	B
.	0	O


Both	0	O
HEF1	0	B
and	0	O
Cas	1	B
were	0	O
found	0	O
to	0	O
complex	0	O
with	0	O
the	0	O
related	0	B
adhesion	0	I
focal	0	I
tyrosine	0	I
kinase	0	I
(	0	O
RAFTK	0	B
),	0	O
and	0	O
when	0	O
tyrosine	0	O
phosphorylated	0	O
,	0	O
with	0	O
the	0	O
adapter	0	O
molecule	0	O
CrkL	0	B
.	0	O


The	0	O
promoter	0	O
of	0	O
the	0	O
rat	0	B
PGS	0	I
-	0	I
2	0	I
gene	0	I
contains	0	O
a	0	O
CAAT	0	B
enhancer	0	I
-	0	I
binding	0	I
protein	0	I
consensus	0	I
site	0	I
(	0	I
CAAT	0	I
box	0	I
)	0	I
which	0	O
can	0	O
confer	0	O
hormone	0	O
inducibility	0	O
to	0	O
a	0	O
PGS	0	B
-	0	I
2	0	I
.	0	O
CAT	1	B
reporter	0	O
gene	0	O
,	0	O
as	0	O
well	0	O
as	0	O
a	0	O
putative	0	O
E	1	O
-	0	O
box	0	O
region	0	O
.	0	O


Upon	0	O
analysis	0	O
of	0	O
the	0	O
tissue	0	O
distribution	0	O
of	0	O
AAMP	0	B
,	0	O
it	0	O
was	0	O
found	0	O
to	0	O
be	0	O
expressed	0	O
strongly	0	O
in	0	O
endothelial	0	O
cells	0	O
,	0	O
cytotrophoblasts	0	O
,	0	O
and	0	O
poorly	0	O
differentiated	0	O
colon	0	O
adenocarcinoma	0	O
cells	0	O
found	0	O
in	0	O
lymphatics	0	O
.	0	O


The	0	O
site	0	O
of	0	O
autophosphorylation	0	O
is	0	O
Tyr397	0	O
which	0	O
corresponds	0	O
to	0	O
the	0	O
consensus	0	O
autophosphorylation	0	O
site	0	O
of	0	O
other	0	O
Src	1	B
family	0	I
tyrosine	0	I
kinases	0	I
.	0	O


Estrogen	1	O
replacement	0	O
therapy	0	O
and	0	O
risk	0	O
of	0	O
breast	0	O
cancer	0	O
:	0	O
results	0	O
of	0	O
two	0	O
meta	0	O
-	0	O
analyses	0	O
.	0	O


A	1	O
rise	0	O
of	0	O
hemoglobin	0	B
concentration	0	O
accompanied	0	O
by	0	O
an	0	O
increase	0	O
of	0	O
the	0	O
total	0	O
iron	0	O
in	0	O
the	0	O
blood	0	O
serum	0	O
of	0	O
white	0	O
mice	0	O
was	0	O
found	0	O
under	0	O
oxygen	0	O
pressure	0	O
of	0	O
4	0	O
atm	0	O
for	0	O
an	0	O
hour	0	O
(	0	O
preconvulsive	0	O
state	0	O
)	0	O
and	0	O
6	0	O
atm	0	O
(	0	O
convulsive	0	O
state	0	O
).	0	O


CONCLUSIONS	0	O
:	0	O
We	0	O
obtained	0	O
normal	0	O
EPO	0	B
levels	0	O
for	0	O
mothers	0	O
and	0	O
newborns	0	O
for	0	O
our	0	O
area	0	O
,	0	O
similarly	0	O
to	0	O
the	0	O
previously	0	O
described	0	O
ones	0	O
.	0	O


The	0	O
binding	0	O
of	0	O
PH	1	B
domains	0	I
to	0	O
Gbetagamma	0	B
was	0	O
inhibited	0	O
by	0	O
preincubation	0	O
of	0	O
Gbetagamma	0	B
with	0	O
the	0	O
GDP	1	O
-	0	O
bound	0	O
but	0	O
not	0	O
the	0	O
GTP	1	O
-	0	O
bound	0	O
form	0	O
of	0	O
Gialpha	0	B
.	0	O


The	0	O
median	0	O
levels	0	O
of	0	O
particles	0	O
with	0	O
50	0	O
%	0	O
cut	0	O
-	0	O
off	0	O
aerodynamic	0	O
diameters	0	O
of	0	O
10	0	O
(	0	O
PM10	0	O
)	0	O
and	0	O
2	0	O
.	0	O
5	0	O
microm	0	O
(	0	O
PM2	0	O
.	0	O
5	0	O
)	0	O
were	0	O
170	0	O
(	0	O
range	0	O
103	0	O
-	0	O
613	0	O
)	0	O
and	0	O
95	0	O
(	0	O
range	0	O
61	0	O
-	0	O
218	0	O
)	0	O
micro	0	O
x	0	O
m	0	O
-	0	O
3	0	O
,	0	O
respectively	0	O
.	0	O


HNF	1	B
-	0	I
3	0	I
beta	0	I
amino	0	I
-	0	I
terminal	0	I
sequences	0	I
defined	0	O
by	0	O
conserved	0	O
region	0	O
IV	1	O
also	0	O
contributed	0	O
to	0	O
transactivation	0	O
,	0	O
but	0	O
region	0	O
IV	1	O
activity	0	O
required	0	O
the	0	O
participation	0	O
of	0	O
the	0	O
region	0	O
II	0	O
-	0	O
III	0	O
domain	0	O
.	0	O


Nuclear	1	O
hormone	0	O
receptors	0	O
(	0	O
NRs	0	O
)	0	O
are	0	O
ligand	0	O
-	0	O
inducible	0	O
transcription	0	O
factors	0	O
that	0	O
mediate	0	O
critical	0	O
functions	0	O
in	0	O
many	0	O
species	0	O
.	0	O


The	0	O
kinetics	0	O
of	0	O
kinase	0	O
activity	0	O
within	0	O
these	0	O
complexes	0	O
compared	0	O
to	0	O
CheA	0	B
alone	0	O
indicate	0	O
approximately	0	O
a	0	O
50	0	O
%	0	O
decrease	0	O
in	0	O
the	0	O
KM	1	O
for	0	O
ATP	1	O
and	0	O
a	0	O
100	0	O
-	0	O
fold	0	O
increase	0	O
in	0	O
the	0	O
Vmax	1	O
.	0	O


The	0	O
alternative	0	O
sigma	0	B
factor	0	I
sigmaB	0	I
in	0	I
Staphylococcus	1	I
aureus	0	I
:	0	O
regulation	0	O
of	0	O
the	0	O
sigB	0	B
operon	0	I
in	0	O
response	0	O
to	0	O
growth	0	O
phase	0	O
and	0	O
heat	0	O
shock	0	O


This	0	O
regulation	0	O
requires	0	O
two	0	O
HMG	1	B
-	0	I
box	0	I
proteins	0	I
:	0	O
the	0	O
ubiquitous	0	O
Ste11	0	B
transcription	0	I
factor	0	I
and	0	O
the	0	O
M	1	O
cell	0	O
-	0	O
controlling	0	O
protein	0	O
Mat1	0	B
-	0	I
Mc	1	I
.	0	O


In	1	O
vitro	0	O
translation	0	O
and	0	O
in	0	O
vivo	0	O
polysome	0	O
profile	0	O
analysis	0	O
indicated	0	O
that	0	O
transcripts	0	B
C	1	I
and	0	I
E	1	I
were	0	O
translated	0	O
with	0	O
similar	0	O
translational	0	O
efficiencies	0	O
that	0	O
are	0	O
substantially	0	O
greater	0	O
than	0	O
that	0	O
of	0	O
transcript	0	B
D	1	I
,	0	O
suggesting	0	O
that	0	O
5	0	O
'-	0	O
untranslated	0	O
regions	0	O
play	0	O
a	0	O
role	0	O
in	0	O
translational	0	O
control	0	O
.	0	O


To	1	O
search	0	O
for	0	O
genes	0	O
that	0	O
interact	0	O
with	0	O
the	0	O
SLK1	0	B
-	0	O
SLT2	0	B
pathway	0	O
,	0	O
a	0	O
synthetic	0	O
lethal	0	O
suppression	0	O
screen	0	O
was	0	O
carried	0	O
out	0	O
.	0	O


Comparison	0	O
with	0	O
a	0	O
recently	0	O
described	0	O
c	0	B
-	0	I
sis	0	I
cDNA	1	I
clone	0	I
(	0	O
Collins	0	O
et	0	O
al	0	O
.,	0	O
Nature	0	O
316	0	O
,	0	O
748	0	O
-	0	O
750	0	O
(	0	O
1985	0	O
))	0	O
revealed	0	O
that	0	O
the	0	O
1	0	O
.	0	O
9	0	O
kbp	0	O
DNA	1	O
region	0	O
contained	0	O
a	0	O
large	0	O
5	0	B
'	0	I
c	0	I
-	0	I
sis	0	I
exon	0	I
of	0	O
at	0	O
least	0	O
1050	0	O
bp	0	O
.	0	O


As	1	O
determined	0	O
in	0	O
a	0	O
modified	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
system	0	O
,	0	O
mIRS3	0	B
bound	0	O
strongly	0	O
to	0	O
the	0	O
p85	0	B
subunit	0	I
of	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
.	0	O


A	1	O
third	0	O
is	0	O
a	0	O
partial	0	O
element	0	O
terminating	0	O
at	0	O
a	0	O
probable	0	O
internal	0	O
restriction	0	O
site	0	O
used	0	O
for	0	O
cloning	0	O
.	0	O


Each	0	O
trial	0	O
consisted	0	O
of	0	O
light	0	O
and	0	O
buzzer	0	O
for	0	O
five	0	O
seconds	0	O
as	0	O
conditioned	0	O
stimuli	0	O
and	0	O
electric	0	O
shock	0	O
for	0	O
five	0	O
seconds	0	O
as	0	O
an	0	O
unconditioned	0	O
stimulus	0	O
.	0	O


The	0	O
relative	0	O
R	1	O
-	0	O
and	0	O
L	1	O
-	0	O
brain	0	O
weights	0	O
were	0	O
found	0	O
to	0	O
be	0	O
inversely	0	O
related	0	O
to	0	O
the	0	O
relative	0	O
R	1	O
-	0	O
L	1	O
brain	0	O
weight	0	O
only	0	O
in	0	O
the	0	O
RH	1	O
female	0	O
cats	0	O
with	0	O
R	1	O
-	0	O
L	1	O
brain	0	O
weight	0	O
smaller	0	O
than	0	O
zero	0	O
(	0	O
testosterone	0	O
in	0	O
males	0	O
,	0	O
estrogen	0	O
in	0	O
females	0	O
).	0	O


Two	0	O
disulphide	0	O
bridges	0	O
,	0	O
which	0	O
are	0	O
conserved	0	O
in	0	O
all	0	O
spermadhesin	0	O
molecules	0	O
and	0	O
many	0	O
CUB	0	O
domains	0	O
,	0	O
crosslink	0	O
loop	0	O
LA	1	O
and	0	O
strand	0	O
beta	0	O
4	0	O
and	0	O
loops	0	O
LE	1	O
and	0	O
LG	0	O
,	0	O
respectively	0	O
,	0	O
at	0	O
opposite	0	O
edges	0	O
of	0	O
the	0	O
same	0	O
face	0	O
of	0	O
the	0	O
domain	0	O
.	0	O


Wnt	0	B
-	0	I
1	0	I
overexpression	0	O
in	0	O
mammary	0	O
epithelial	0	O
cells	0	O
induced	0	O
cyclin	0	B
D1	1	I
mRNA	1	I
and	0	O
targeted	0	O
overexpression	0	O
of	0	O
Wnt	0	B
-	0	I
1	0	I
in	0	O
the	0	O
mammary	0	O
gland	0	O
of	0	O
transgenic	0	O
mice	0	O
increased	0	O
both	0	O
ILK	0	B
activity	0	O
and	0	O
cyclin	0	B
D1	1	I
levels	0	O
.	0	O


Samples	0	O
from	0	O
1415	0	O
neurological	0	O
patients	0	O
were	0	O
used	0	O
to	0	O
study	0	O
the	0	O
diagnostic	0	O
value	0	O
of	0	O
acid	0	B
alpha	0	I
1	0	I
-	0	I
glycoprotein	0	I
in	0	O
the	0	O
lumbar	0	O
cerebrospinal	0	O
fluid	0	O
.	0	O


The	0	O
maximum	0	O
induction	0	O
of	0	O
ACC	1	B
-	0	I
oxidase	0	I
transcripts	0	I
occurred	0	O
at	0	O
about	0	O
6	0	O
h	0	O
after	0	O
excision	0	O
,	0	O
while	0	O
the	0	O
maximum	0	O
enzyme	0	O
activity	0	O
was	0	O
observed	0	O
at	0	O
24	0	O
h	0	O
.	0	O


Coronary	1	O
arteries	0	O
--	0	O
old	0	O
and	0	O
new	0	O
.	0	O


High	0	O
plasma	0	O
concentrations	0	O
of	0	O
soluble	0	O
E	1	B
-	0	I
selectin	0	I
were	0	O
closely	0	O
associated	0	O
with	0	O
multiple	0	O
-	0	O
organ	0	O
dysfunction	0	O
and	0	O
death	0	O
.	0	O


The	0	O
frequency	0	O
of	0	O
positive	0	O
anti	0	B
-	0	I
GM1	0	I
antibody	0	I
titers	0	O
in	0	O
the	0	O
Guillain	0	O
-	0	O
Barre	0	O
syndrome	0	O
patients	0	O
with	0	O
PEN	1	O
19	0	O
isolates	0	O
was	0	O
higher	0	O
than	0	O
that	0	O
in	0	O
the	0	O
Guillain	0	O
-	0	O
Barre	0	O
syndrome	0	O
and	0	O
Fisher	0	O
'	0	O
s	0	O
syndrome	0	O
patients	0	O
without	0	O
PEN	1	O
19	0	O
isolates	0	O
.	0	O


This	0	O
constitutes	0	O
evidence	0	O
for	0	O
an	0	O
in	0	O
vivo	0	O
role	0	O
of	0	O
SRC	1	B
-	0	I
1	0	I
in	0	O
dimerization	0	O
-	0	O
induced	0	O
activation	0	O
by	0	O
OR1	0	B
/	0	O
RXRalpha	0	B
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
the	0	O
-	0	O
84	0	O
/-	0	O
55	0	O
DNA	1	O
showed	0	O
that	0	O
JEG	0	O
-	0	O
3	0	O
nuclear	0	O
proteins	0	O
bound	0	O
to	0	O
a	0	O
site	0	O
containing	0	O
,	0	O
but	0	O
not	0	O
identical	0	O
to	0	O
,	0	O
the	0	O
SF	1	B
-	0	I
1	0	I
sequence	0	I
.	0	O


Human	1	O
T	1	O
-	0	O
cell	0	O
leukemia	0	O
virus	0	O
type	0	O
I	1	O
Tax	0	B
activation	0	O
of	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
/	0	O
Rel	0	B
involves	0	O
phosphorylation	0	O
and	0	O
degradation	0	O
of	0	O
I	1	B
kappa	0	I
B	1	I
alpha	0	I
and	0	O
RelA	0	O
(	0	O
p65	0	O
)-	0	O
mediated	0	O
induction	0	O
of	0	O
the	0	O
c	0	B
-	0	I
rel	0	I
gene	0	I
.	0	O


Cardiovascular	1	O
risk	0	O
factors	0	O
were	0	O
measured	0	O
by	0	O
standardized	0	O
techniques	0	O
.	0	O


The	0	O
ARG	1	B
SH2	0	I
domain	0	I
exhibited	0	O
relatively	0	O
weak	0	O
affinity	0	O
for	0	O
BCR	0	B
and	0	O
was	0	O
determined	0	O
to	0	O
bind	0	O
about	0	O
10	0	O
-	0	O
fold	0	O
less	0	O
strongly	0	O
than	0	O
the	0	O
ABL	0	B
SH2	0	I
domain	0	I
.	0	O


There	0	O
is	0	O
a	0	O
cysteine	0	O
clustering	0	O
region	0	O
in	0	O
an	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
the	0	O
c	0	B
-	0	I
raf	0	I
(-	0	I
1	0	I
)	0	I
product	0	I
deduced	0	O
from	0	O
the	0	O
nucleotide	0	O
sequence	0	O
,	0	O
and	0	O
this	0	O
cysteine	0	O
clustering	0	O
region	0	O
was	0	O
found	0	O
to	0	O
be	0	O
highly	0	O
homologous	0	O
to	0	O
that	0	O
present	0	O
in	0	O
an	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
protein	0	B
kinase	0	I
C	1	I
,	0	O
although	0	O
,	0	O
in	0	O
the	0	O
latter	0	O
cysteine	0	O
clusters	0	O
are	0	O
present	0	O
in	0	O
duplicate	0	O
.	0	O


The	0	O
regulatory	0	O
region	0	O
also	0	O
has	0	O
a	0	O
sequence	0	O
similar	0	O
to	0	O
the	0	O
binding	0	O
site	0	O
for	0	O
a	0	O
liver	0	O
-	0	O
specific	0	O
transcription	0	O
factor	0	O
,	0	O
hepatocyte	0	B
nuclear	0	I
factor	0	I
1	0	I
(	0	O
HNF	1	B
-	0	I
1	0	I
),	0	O
at	0	O
positions	0	O
-	0	O
120	0	O
to	0	O
-	0	O
132	0	O
.	0	O


Plasma	1	B
leptin	0	I
concentrations	0	O
were	0	O
higher	0	O
in	0	O
women	0	O
than	0	O
men	0	O
,	0	O
even	0	O
after	0	O
the	0	O
adjustment	0	O
for	0	O
differences	0	O
in	0	O
fat	0	O
mass	0	O
(	0	O
28	0	O
+/-	0	O
3	0	O
ng	0	O
/	0	O
ml	0	O
for	0	O
women	0	O
vs	0	O
.	0	O


The	0	O
number	0	O
of	0	O
elements	0	O
and	0	O
their	0	O
sizes	0	O
relative	0	O
to	0	O
the	0	O
configuration	0	O
were	0	O
varied	0	O
in	0	O
a	0	O
series	0	O
of	0	O
five	0	O
experiments	0	O
.	0	O


The	0	O
E1	1	B
replication	0	I
protein	0	I
of	0	O
bovine	0	O
papillomavirus	0	O
type	0	O
1	0	O
contains	0	O
an	0	O
extended	0	O
nuclear	0	O
localization	0	O
signal	0	O
that	0	O
includes	0	O
a	0	O
p34cdc2	0	B
phosphorylation	0	O
site	0	O
.	0	O


Hepatitis	1	O
C	1	O
virus	0	O
infection	0	O
and	0	O
lymphoproliferative	0	O
diseases	0	O
in	0	O
France	0	O
:	0	O
a	0	O
national	0	O
study	0	O
.	0	O


Homology	1	O
was	0	O
also	0	O
detected	0	O
between	0	O
the	0	O
putative	0	O
transit	0	O
peptide	0	O
sequence	0	O
of	0	O
cysteine	0	B
synthase	0	I
C	1	I
and	0	O
other	0	O
mitochondrion	0	O
-	0	O
targeting	0	O
leader	0	O
sequences	0	O
.	0	O


Since	0	O
the	0	O
integrated	0	O
13h00	0	O
-	0	O
16h00	0	O
plasma	0	O
cortisol	0	O
estimation	0	O
is	0	O
cheaper	0	O
and	0	O
simpler	0	O
than	0	O
the	0	O
mean	0	O
13h00	0	O
-	0	O
16h00	0	O
plasma	0	O
cortisol	0	O
estimation	0	O
,	0	O
we	0	O
recommend	0	O
it	0	O
as	0	O
an	0	O
adjunct	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
Cushing	0	O
'	0	O
s	0	O
syndrome	0	O
.	0	O


In	1	O
recent	0	O
years	0	O
,	0	O
successful	0	O
physiological	0	O
models	0	O
have	0	O
been	0	O
developed	0	O
for	0	O
a	0	O
variety	0	O
of	0	O
volatile	0	O
and	0	O
nonvolatile	0	O
chemicals	0	O
,	0	O
and	0	O
their	0	O
ability	0	O
to	0	O
perform	0	O
the	0	O
extrapolations	0	O
needed	0	O
in	0	O
risk	0	O
assessment	0	O
has	0	O
been	0	O
demonstrated	0	O
.	0	O


To	1	O
determine	0	O
if	0	O
signing	0	O
,	0	O
when	0	O
established	0	O
,	0	O
would	0	O
compete	0	O
with	0	O
SIB	1	O
when	0	O
both	0	O
were	0	O
reinforced	0	O
,	0	O
extinction	0	O
was	0	O
then	0	O
withdrawn	0	O
.	0	O


The	0	O
authors	0	O
describe	0	O
the	0	O
technique	0	O
of	0	O
transverse	0	O
axial	0	O
tomography	0	O
of	0	O
the	0	O
spine	0	O
and	0	O
give	0	O
a	0	O
detailed	0	O
description	0	O
of	0	O
the	0	O
axial	0	O
anatomy	0	O
of	0	O
the	0	O
normal	0	O
lumbar	0	O
spine	0	O
from	0	O
L	1	O
-	0	O
4	0	O
to	0	O
the	0	O
sacrum	0	O
.	0	O


Our	0	O
results	0	O
demonstrate	0	O
the	0	O
importance	0	O
of	0	O
phosphate	0	O
and	0	O
calcium	0	O
in	0	O
influencing	0	O
the	0	O
secretion	0	O
of	0	O
PTH	1	B
and	0	O
CT	1	B
in	0	O
uremia	0	O
.	0	O


Hepatitis	1	O
B	1	O
vaccination	0	O
strategy	0	O
for	0	O
health	0	O
-	0	O
care	0	O
workers	0	O
in	0	O
a	0	O
country	0	O
of	0	O
intermediate	0	O
hepatitis	0	O
B	1	O
endemicity	0	O
.	0	O


Expression	1	O
of	0	O
ME31B	0	B
cDNA	1	I
in	0	O
S	1	O
.	0	O
pombe	0	O
suppresses	0	O
the	0	O
ste13	0	B
mutation	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
a	0	O
global	0	O
assessment	0	O
patients	0	O
showed	0	O
a	0	O
highly	0	O
significant	0	O
preference	0	O
for	0	O
imipramine	0	O
compared	0	O
with	0	O
placebo	0	O
as	0	O
adjunctive	0	O
therapy	0	O
.	0	O


Allagille	0	O
'	0	O
s	0	O
syndrome	0	O
associated	0	O
with	0	O
antenatal	0	O
ascites	0	O


Using	0	O
in	0	O
organello	0	O
footprint	0	O
analysis	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
within	0	O
human	0	O
placental	0	O
mitochondria	0	O
there	0	O
is	0	O
a	0	O
high	0	O
level	0	O
of	0	O
protein	0	O
-	0	O
DNA	1	O
binding	0	O
at	0	O
regularly	0	O
phased	0	O
intervals	0	O
throughout	0	O
a	0	O
500	0	O
-	0	O
bp	0	O
region	0	O
encompassing	0	O
the	0	O
D	1	O
-	0	O
loop	0	O
DNA	1	O
origins	0	O
and	0	O
two	0	O
promoter	0	O
regions	0	O
.	0	O


Analysis	1	O
of	0	O
1	0	O
Mb	1	O
of	0	O
published	0	O
sequence	0	O
from	0	O
the	0	O
region	0	O
of	0	O
conserved	0	O
synteny	0	O
on	0	O
human	0	O
chromosome	0	O
5q31	0	O
-	0	O
q33	0	O
identified	0	O
45	0	O
gene	0	O
candidates	0	O
,	0	O
including	0	O
35	0	O
expressed	0	O
genes	0	O
in	0	O
the	0	O
human	0	B
IL	1	I
-	0	I
4	0	I
cytokine	0	I
gene	0	I
cluster	0	I
.	0	O


Magnetic	1	O
storm	0	O
indicators	0	O
could	0	O
be	0	O
used	0	O
in	0	O
medicine	0	O
,	0	O
in	0	O
geophysics	0	O
and	0	O
for	0	O
special	0	O
purposes	0	O
.	0	O


Despite	0	O
the	0	O
existence	0	O
of	0	O
30	0	O
cysteine	0	O
residues	0	O
,	0	O
carboxymethylation	0	O
prevented	0	O
the	0	O
formation	0	O
of	0	O
most	0	O
if	0	O
not	0	O
all	0	O
disulfide	0	O
bonds	0	O
that	0	O
otherwise	0	O
occurred	0	O
when	0	O
the	0	O
cells	0	O
were	0	O
sonicated	0	O
.	0	O


Biol	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
spontaneous	0	O
recovery	0	O
of	0	O
central	0	O
respiratory	0	O
function	0	O
after	0	O
intoxication	0	O
with	0	O
Soman	1	O
or	0	O
Sarin	1	O
may	0	O
not	0	O
be	0	O
related	0	O
to	0	O
the	0	O
return	0	O
of	0	O
AChE	1	B
activity	0	O
.	0	O


Data	1	O
from	0	O
the	0	O
V	1	O
-	0	O
HeFT	0	O
II	0	O
show	0	O
that	0	O
at	0	O
2	0	O
-	0	O
year	0	O
follow	0	O
-	0	O
up	0	O
,	0	O
a	0	O
progressive	0	O
rise	0	O
of	0	O
plasma	0	O
norepinephrine	0	O
was	0	O
observed	0	O
in	0	O
both	0	O
treatment	0	O
arms	0	O
,	0	O
suggesting	0	O
that	0	O
disease	0	O
progresses	0	O
despite	0	O
treatment	0	O
with	0	O
either	0	O
an	0	O
angiotensin	0	B
-	0	I
converting	0	I
enzyme	0	I
inhibitor	0	O
,	0	O
enalapril	0	O
,	0	O
or	0	O
vasodilator	0	O
therapy	0	O
with	0	O
hydralazine	0	O
/	0	O
isosorbide	0	O
dinitrate	0	O
.	0	O


Reconstitution	1	O
of	0	O
Raf	0	B
-	0	I
1	0	I
activity	0	O
was	0	O
observed	0	O
only	0	O
with	0	O
kinase	0	O
active	0	O
Jak1	0	B
in	0	O
both	0	O
cell	0	O
lines	0	O
.	0	O


Nine	0	O
cats	0	O
received	0	O
PMEA	0	O
at	0	O
a	0	O
dosage	0	O
of	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
body	0	O
weight	0	O
,	0	O
nine	0	O
cats	0	O
received	0	O
FPMPA	0	O
at	0	O
a	0	O
dosage	0	O
of	0	O
25	0	O
mg	0	O
/	0	O
kg	0	O
body	0	O
weight	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
these	0	O
mutations	0	O
on	0	O
protein	0	O
function	0	O
require	0	O
further	0	O
examination	0	O
.	0	O


Substitutions	0	O
introduced	0	O
at	0	O
bases	0	O
surrounding	0	O
the	0	O
ICR2	0	B
motif	0	I
yielded	0	O
levels	0	O
of	0	O
pRNA	0	O
replication	0	O
that	0	O
differed	0	O
,	0	O
depending	0	O
on	0	O
the	0	O
maintenance	0	O
of	0	O
a	0	O
putative	0	O
5	0	O
'	0	O
stem	0	O
-	0	O
loop	0	O
structure	0	O
in	0	O
the	0	O
positive	0	O
strand	0	O
of	0	O
the	0	O
viral	0	O
genome	0	O
.	0	O


In	1	O
an	0	O
effort	0	O
to	0	O
contribute	0	O
to	0	O
the	0	O
transcript	0	O
map	0	O
of	0	O
human	0	O
chromosome	0	O
21	0	O
and	0	O
the	0	O
understanding	0	O
of	0	O
the	0	O
pathophysiology	0	O
of	0	O
trisomy	0	O
21	0	O
,	0	O
we	0	O
have	0	O
used	0	O
exon	0	O
trapping	0	O
to	0	O
identify	0	O
fragments	0	O
of	0	O
chromosome	0	O
21	0	O
genes	0	O
.	0	O


The	0	O
importance	0	O
of	0	O
selective	0	O
renal	0	O
vein	0	O
phlebography	0	O
in	0	O
the	0	O
evaluation	0	O
of	0	O
unexplained	0	O
hematuria	0	O
and	0	O
filing	0	O
defects	0	O
in	0	O
the	0	O
excretory	0	O
urogram	0	O
is	0	O
illustrated	0	O
.	0	O


Our	0	O
laboratory	0	O
and	0	O
others	0	O
have	0	O
shown	0	O
alternative	0	O
splicing	0	O
of	0	O
up	0	O
to	0	O
ten	0	O
exons	0	O
at	0	O
a	0	O
discrete	0	O
extracellular	0	O
site	0	O
to	0	O
be	0	O
primarily	0	O
responsible	0	O
for	0	O
the	0	O
generation	0	O
of	0	O
CD44	0	B
variant	0	I
(	0	O
CD44v	0	B
)	0	O
isoforms	0	O
.	0	O


Lack	0	O
of	0	O
effect	0	O
of	0	O
the	0	O
appetite	0	O
stimulant	0	O
pizotifen	0	O
(	0	O
BC	1	O
105	0	O
)	0	O
on	0	O
the	0	O
absorption	0	O
of	0	O
isonicotinylhydrazine	0	O
.	0	O


However	0	O
,	0	O
parallax	0	O
measurements	0	O
showed	0	O
that	0	O
at	0	O
150K	0	O
,	0	O
collapse	0	O
of	0	O
Epon	1	O
sections	0	O
does	0	O
not	0	O
take	0	O
place	0	O
.	0	O


The	0	O
rate	0	O
of	0	O
resectability	0	O
is	0	O
low	0	O
and	0	O
5	0	O
-	0	O
year	0	O
survival	0	O
is	0	O
very	0	O
poor	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
CPET	0	O
is	0	O
a	0	O
useful	0	O
investigation	0	O
in	0	O
the	0	O
management	0	O
of	0	O
patients	0	O
with	0	O
cardiopulmonary	0	O
disease	0	O
and	0	O
complements	0	O
the	0	O
various	0	O
other	0	O
investigations	0	O
offered	0	O
by	0	O
a	0	O
pulmonary	0	O
function	0	O
laboratory	0	O
.	0	O


The	0	O
most	0	O
frequent	0	O
risk	0	O
factor	0	O
for	0	O
ischaemic	0	O
was	0	O
hypertension	0	O
.	0	O


A	1	O
possible	0	O
decrease	0	O
in	0	O
theophylline	0	O
'	0	O
s	0	O
volume	0	O
of	0	O
distribution	0	O
at	0	O
4	0	O
days	0	O
,	0	O
but	0	O
not	0	O
immediately	0	O
,	0	O
after	0	O
administration	0	O
of	0	O
chloroquine	0	O
was	0	O
suggested	0	O
,	0	O
although	0	O
this	0	O
just	0	O
failed	0	O
to	0	O
achieve	0	O
statistical	0	O
significance	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
055	0	O
).	0	O


Abstracts	0	O
.	0	O


A	1	O
new	0	O
Onchocerca	1	O
species	0	O
,	0	O
a	0	O
parasite	0	O
of	0	O
domestic	0	O
cattle	0	O
,	0	O
in	0	O
Senegal	0	O


Deletion	1	O
of	0	O
fdsR	0	B
revealed	0	O
a	0	O
dual	0	O
regulatory	0	O
effect	0	O
of	0	O
FdsR	0	B
on	0	O
the	0	O
fds	0	B
operon	0	I
by	0	O
acting	0	O
as	0	O
transcriptional	0	O
activator	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
formate	0	O
or	0	O
as	0	O
repressor	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
formate	0	O
.	0	O


So	1	O
far	0	O
15	0	O
children	0	O
have	0	O
been	0	O
studied	0	O
.	0	O


The	0	O
discordant	0	O
behaviour	0	O
in	0	O
weakly	0	O
infected	0	O
mice	0	O
was	0	O
due	0	O
to	0	O
the	0	O
occurrence	0	O
in	0	O
some	0	O
animals	0	O
of	0	O
a	0	O
second	0	O
phase	0	O
of	0	O
more	0	O
rapid	0	O
increase	0	O
of	0	O
the	0	O
parasitemia	0	O
.	0	O


The	0	O
Oct	1	B
-	0	I
2	0	I
glutamine	0	O
-	0	O
rich	0	O
and	0	O
proline	0	O
-	0	O
rich	0	O
activation	0	O
domains	0	O
can	0	O
synergize	0	O
with	0	O
each	0	O
other	0	O
or	0	O
duplicates	0	O
of	0	O
themselves	0	O
to	0	O
activate	0	O
transcription	0	O
.	0	O


Isolation	1	O
and	0	O
characterization	0	O
of	0	O
a	0	O
TATA	0	O
-	0	O
less	0	O
promoter	0	O
for	0	O
the	0	O
human	0	B
beta	0	I
3	0	I
integrin	0	I
gene	0	I
.	0	O


These	0	O
results	0	O
provide	0	O
evidence	0	O
of	0	O
a	0	O
bypass	0	O
of	0	O
p53	0	B
-	0	O
induced	0	O
Waf1	0	B
/	0	O
Cip1	0	B
-	0	O
mediated	0	O
cell	0	O
cycle	0	O
regulatory	0	O
pathways	0	O
by	0	O
a	0	O
member	0	O
of	0	O
the	0	O
myb	0	B
oncogene	0	I
family	0	I
.	0	O


The	0	O
importance	0	O
of	0	O
hepatitis	0	O
C	1	O
virus	0	O
(	0	O
HCV	1	O
)	0	O
infection	0	O
as	0	O
a	0	O
cause	0	O
of	0	O
chronic	0	O
liver	0	O
disease	0	O
has	0	O
become	0	O
clear	0	O
with	0	O
the	0	O
introduction	0	O
of	0	O
serologic	0	O
detection	0	O
methods	0	O
.	0	O


We	0	O
show	0	O
that	0	O
the	0	O
surfaces	0	O
of	0	O
tracheal	0	O
cartilage	0	O
matrix	0	O
are	0	O
collagen	0	B
-	0	O
rich	0	O
and	0	O
surround	0	O
a	0	O
proteoglycan	0	O
-	0	O
rich	0	O
core	0	O
.	0	O


OUTCOME	1	O
:	0	O
Acetylcholine	1	B
receptor	0	I
antibodies	0	I
and	0	O
single	0	O
-	0	O
fibre	0	O
electromyogram	0	O
were	0	O
useful	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
myasthenia	0	O
gravis	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
This	0	O
meta	0	O
-	0	O
analysis	0	O
of	0	O
67	0	O
controlled	0	O
trials	0	O
was	0	O
performed	0	O
to	0	O
quantify	0	O
the	0	O
cholesterol	0	O
-	0	O
lowering	0	O
effect	0	O
of	0	O
major	0	O
dietary	0	O
fibers	0	O
.	0	O


It	1	O
is	0	O
impossible	0	O
to	0	O
define	0	O
only	0	O
one	0	O
clinical	0	O
outline	0	O
because	0	O
both	0	O
symptomatic	0	O
and	0	O
asymptomatic	0	O
infected	0	O
NB	1	O
may	0	O
be	0	O
found	0	O
with	0	O
gestational	0	O
age	0	O
at	0	O
term	0	O
and	0	O
pre	0	O
-	0	O
term	0	O
and	0	O
when	0	O
born	0	O
with	0	O
a	0	O
weight	0	O
above	0	O
or	0	O
below	0	O
2000	0	O
g	0	O
.	0	O


First	0	O
,	0	O
two	0	O
MCTs	0	O
using	0	O
a	0	O
long	0	O
electrode	0	O
,	0	O
3	0	O
cm	0	O
in	0	O
size	0	O
,	0	O
were	0	O
performed	0	O
in	0	O
the	0	O
central	0	O
area	0	O
of	0	O
the	0	O
tumor	0	O
,	0	O
and	0	O
eight	0	O
MCTs	0	O
by	0	O
a	0	O
short	0	O
electrode	0	O
,	0	O
2	0	O
cm	0	O
in	0	O
size	0	O
,	0	O
were	0	O
done	0	O
in	0	O
the	0	O
peripheral	0	O
and	0	O
surrounding	0	O
area	0	O
of	0	O
the	0	O
tumor	0	O
.	0	O


The	0	O
PRB	0	B
-	0	I
1b	0	I
gene	0	I
encodes	0	O
for	0	O
a	0	O
basic	0	O
-	0	O
type	0	O
component	0	O
of	0	O
the	0	O
pathogenesis	0	O
-	0	O
related	0	O
PR	1	B
-	0	I
1	0	I
protein	0	I
family	0	I
.	0	O


These	0	O
results	0	O
support	0	O
the	0	O
view	0	O
that	0	O
clonidine	0	O
and	0	O
6	0	O
-	0	O
OHDA	0	O
,	0	O
but	0	O
not	0	O
alpha	0	O
-	0	O
MD	1	O
,	0	O
have	0	O
central	0	O
pressor	0	O
actions	0	O
in	0	O
the	0	O
rat	0	O
that	0	O
oppose	0	O
their	0	O
antihypertensive	0	O
action	0	O
.	0	O


Mutation	1	O
of	0	O
the	0	O
central	0	O
Tyr497	0	O
to	0	O
Phe	1	O
blocks	0	O
the	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
the	0	O
insulin	0	B
receptor	0	I
substrate	0	I
1	0	I
(	0	O
IRS1	0	B
)	0	O
and	0	O
diminishes	0	O
proliferation	0	O
in	0	O
response	0	O
to	0	O
IL	1	B
-	0	I
4	0	I
.	0	O


IST	0	B
is	0	O
not	0	O
the	0	O
RNA	1	O
target	0	O
(	0	O
TAR	1	O
)	0	O
for	0	O
Tat	1	B
trans	0	O
-	0	O
activation	0	O
;	0	O
however	0	O
,	0	O
because	0	O
it	0	O
relies	0	O
entirely	0	O
on	0	O
cellular	0	O
factors	0	O
for	0	O
activity	0	O
,	0	O
IST	0	B
may	0	O
serve	0	O
to	0	O
provide	0	O
abundant	0	O
RNA	1	O
targets	0	O
for	0	O
Tat	1	B
trans	0	O
-	0	O
activation	0	O
without	0	O
a	0	O
requirement	0	O
for	0	O
full	0	O
-	0	O
length	0	O
viral	0	O
mRNA	1	O
expression	0	O
.	0	O


The	0	O
gene	0	O
encoding	0	O
TRP	1	B
-	0	I
2	0	I
maps	0	O
to	0	O
mouse	0	O
chromosome	0	O
14	0	O
,	0	O
in	0	O
the	0	O
region	0	O
of	0	O
the	0	O
coat	0	B
colour	0	I
mutation	0	I
slaty	0	I
.	0	O


The	0	O
sequence	0	O
of	0	O
the	0	O
pMxL1	0	O
plasmid	0	O
containing	0	O
the	0	O
invertible	0	O
region	0	O
contains	0	O
a	0	O
perfect	0	O
tandem	0	O
repeat	0	O
of	0	O
19	0	O
bp	0	O
in	0	O
the	0	O
orientation	0	O
1	0	O
nonexpressed	0	O
pilin	0	B
gene	0	I
at	0	O
the	0	O
middle	0	O
of	0	O
the	0	O
recombination	0	O
junction	0	O
site	0	O
.	0	O


Evidence	1	O
for	0	O
the	0	O
promoting	0	O
role	0	O
of	0	O
the	0	O
intra	0	B
-	0	I
uterine	0	I
kinin	0	I
release	0	O
in	0	O
the	0	O
development	0	O
of	0	O
late	0	O
hypertonic	0	O
saline	0	O
-	0	O
induced	0	O
abortion	0	O
.	0	O


To	1	O
lower	0	O
the	0	O
current	0	O
high	0	O
incidence	0	O
of	0	O
NANB	0	O
-	0	O
induced	0	O
PTH	1	O
,	0	O
in	0	O
1986	0	O
,	0	O
the	0	O
American	0	O
Association	1	O
of	0	O
Blood	1	O
Banks	0	O
(	0	O
AABB	1	O
)	0	O
recommended	0	O
testing	0	O
for	0	O
these	0	O
PTH	1	O
-	0	O
associated	0	O
"	0	O
surrogate	0	O
"	0	O
markers	0	O
on	0	O
all	0	O
donated	0	O
units	0	O
of	0	O
blood	0	O
.	0	O


Furthermore	0	O
,	0	O
rhoA	0	B
-	0	O
mediated	0	O
SRE	0	O
activation	0	O
was	0	O
blocked	0	O
by	0	O
dominant	0	O
negative	0	O
mutants	0	O
of	0	O
PKC	0	B
-	0	I
alpha	0	I
or	0	O
PKC	0	B
-	0	I
epsilon	0	I
.	0	O


Human	1	O
isoforms	0	O
,	0	O
designated	0	O
1	0	O
to	0	O
4	0	O
,	0	O
differ	0	O
from	0	O
each	0	O
other	0	O
by	0	O
the	0	O
start	0	O
codon	0	O
used	0	O
.	0	O


RESULTS	0	O
:	0	O
Twenty	0	O
-	0	O
two	0	O
(	0	O
26	0	O
%)	0	O
patients	0	O
had	0	O
PHG	1	O
before	0	O
(	0	O
group	0	O
A	1	O
)	0	O
and	0	O
64	0	O
(	0	O
74	0	O
%)	0	O
developed	0	O
PHG	1	O
after	0	O
variceal	0	O
eradication	0	O
(	0	O
group	0	O
B	1	O
).	0	O


19F	0	O
NMR	1	O
studies	0	O
in	0	O
ABF4	0	O
-	0	O
type	0	O
layered	0	O
antiferromagnets	0	O
.	0	O


Intracavitary	1	O
irradiation	0	O
was	0	O
carried	0	O
out	0	O
with	0	O
a	0	O
microSelectron	0	O
HDR	0	O
afterloading	0	O
device	0	O
and	0	O
usually	0	O
22	0	O
.	0	O
5	0	O
Gy	1	O
was	0	O
given	0	O
in	0	O
three	0	O
fractions	0	O
repeated	0	O
weekly	0	O
.	0	O


(	0	O
ii	0	O
)	0	O
An	1	O
AF	1	O
G	1	B
-	0	I
CSF	1	I
level	0	O
>	0	O
2000	0	O
pg	0	O
/	0	O
ml	0	O
is	0	O
a	0	O
strong	0	O
positive	0	O
predictor	0	O
of	0	O
CAM	1	O
.	0	O


Mutation	1	O
of	0	O
TTF	0	B
-	0	I
1	0	I
-	0	I
binding	0	I
sites	0	I
(	0	I
TBE	0	I
)	0	I
1	0	I
,	0	I
3	0	I
,	0	I
and	0	I
4	0	I
in	0	O
combination	0	O
markedly	0	O
decreased	0	O
transcriptional	0	O
activity	0	O
of	0	O
SP	1	B
-	0	I
A	1	I
promoter	0	O
-	0	O
chloramphenicol	0	B
acetyltransferase	0	I
constructs	0	O
containing	0	O
SP	1	B
-	0	I
A	1	I
gene	0	I
sequences	0	O
from	0	O
-	0	O
256	0	O
to	0	O
+	0	O
45	0	O
.	0	O


Recessive	1	O
lethal	0	O
mutations	0	O
were	0	O
isolated	0	O
based	0	O
upon	0	O
failure	0	O
to	0	O
complement	0	O
the	0	O
recessive	0	O
lethality	0	O
of	0	O
Df	0	O
(	0	O
3L	0	O
)	0	O
RR2	0	O
,	0	O
a	0	O
deletion	0	O
of	0	O
the	0	O
DRE	1	O
region	0	O
that	0	O
removes	0	O
16	0	O
-	0	O
18	0	O
polytene	0	O
chromosome	0	O
bands	0	O
.	0	O


Tissue	1	O
samples	0	O
were	0	O
obtained	0	O
either	0	O
from	0	O
rats	0	O
that	0	O
had	0	O
been	0	O
exposed	0	O
to	0	O
opiate	0	O
withdrawal	0	O
following	0	O
a	0	O
seven	0	O
day	0	O
morphine	0	O
infusion	0	O
or	0	O
sham	0	O
treated	0	O
control	0	O
subjects	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
XAB1	0	B
is	0	O
a	0	O
novel	0	O
cytoplasmic	0	B
GTPase	1	I
involved	0	O
in	0	O
nuclear	0	O
localization	0	O
of	0	O
XPA	0	B
.	0	O


Overexpression	1	O
of	0	O
Sed5p	0	B
allowed	0	O
growth	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
Vti1p	0	B
.	0	O


Biol	0	O
.	0	O


We	0	O
also	0	O
localized	0	O
the	0	O
Fra	0	B
-	0	I
2	0	I
phosphorylation	0	I
sites	0	I
by	0	O
MAPK	1	B
to	0	O
three	0	O
threonine	0	O
and	0	O
three	0	O
serine	0	O
residues	0	O
in	0	O
the	0	O
COOH	0	O
-	0	O
terminal	0	O
region	0	O
by	0	O
means	0	O
of	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
and	0	O
showed	0	O
that	0	O
the	0	O
threonine	0	O
residues	0	O
were	0	O
more	0	O
susceptible	0	O
to	0	O
MAPK	1	B
.	0	O


The	0	O
duration	0	O
and	0	O
the	0	O
amplitude	0	O
of	0	O
the	0	O
negative	0	O
potential	0	O
were	0	O
greatest	0	O
for	0	O
completely	0	O
regenerating	0	O
ears	0	O
with	0	O
overgrowth	0	O
,	0	O
smaller	0	O
for	0	O
partially	0	O
regenerating	0	O
ears	0	O
,	0	O
and	0	O
smallest	0	O
for	0	O
the	0	O
nonregenerating	0	O
ears	0	O
.	0	O


By	0	O
negatively	0	O
regulating	0	O
GRK	0	B
-	0	O
mediated	0	O
receptor	0	O
phosphorylation	0	O
,	0	O
beta	0	B
-	0	I
arrestin	0	I
-	0	O
mediated	0	O
processes	0	O
such	0	O
as	0	O
Src	1	B
recruitment	0	O
and	0	O
clathrin	0	B
-	0	O
mediated	0	O
internalization	0	O
,	0	O
which	0	O
are	0	O
required	0	O
for	0	O
GPCR	1	B
-	0	O
mediated	0	O
ERK	0	B
activation	0	O
,	0	O
are	0	O
inhibited	0	O
,	0	O
thus	0	O
dampening	0	O
further	0	O
ERK	0	B
activation	0	O
.	0	O


The	0	O
genome	0	O
of	0	O
avian	0	O
erythroblastosis	0	O
virus	0	O
contains	0	O
two	0	O
independently	0	O
expressed	0	O
genetic	0	O
loci	0	O
(	0	O
v	0	B
-	0	I
erbA	0	I
and	0	O
v	0	B
-	0	I
erbB	0	I
)	0	O
whose	0	O
activities	0	O
are	0	O
probably	0	O
responsible	0	O
for	0	O
oncogenesis	0	O
by	0	O
the	0	O
virus	0	O
.	0	O


We	0	O
cloned	0	O
a	0	O
complete	0	O
cDNA	1	O
(	0	O
2	0	O
.	0	O
9	0	O
kb	0	O
)	0	O
for	0	O
HET	0	B
from	0	O
an	0	O
MCF	1	O
-	0	O
7	0	O
cDNA	1	O
library	0	O
.	0	O


POU	0	B
-	0	O
specific	0	O
and	0	O
POU	0	B
-	0	O
homeo	0	O
domains	0	O
of	0	O
Oct3	0	B
were	0	O
produced	0	O
in	0	O
Echerichia	0	O
coli	0	O
for	0	O
characterization	0	O
of	0	O
DNA	1	O
binding	0	O
to	0	O
the	0	O
octamer	0	O
sequence	0	O
.	0	O


In	1	O
all	0	O
cells	0	O
,	0	O
the	0	O
accumulation	0	O
of	0	O
high	0	O
Dsg	0	B
protein	0	I
levels	0	O
required	0	O
calcium	0	O
and	0	O
was	0	O
not	0	O
observed	0	O
in	0	O
low	0	O
calcium	0	O
(	0	O
0	0	O
.	0	O
05	0	O
-	0	O
0	0	O
.	0	O
07	0	O
mM	1	O
)	0	O
media	0	O
.	0	O


The	0	O
majority	0	O
of	0	O
MRF	0	O
units	0	O
were	0	O
behaviorally	0	O
incongruent	0	O
;	0	O
in	0	O
the	0	O
most	0	O
frequently	0	O
observed	0	O
case	0	O
,	0	O
their	0	O
activity	0	O
failed	0	O
to	0	O
change	0	O
reliably	0	O
when	0	O
behavior	0	O
habituated	0	O
.	0	O


The	0	O
eluting	0	O
solvent	0	O
was	0	O
methanol	0	O
-	0	O
chloroform	0	O
(	0	O
10	0	O
+	0	O
90	0	O
)	0	O
at	0	O
a	0	O
flow	0	O
rate	0	O
of	0	O
2	0	O
.	0	O
0	0	O
ml	0	O
/	0	O
min	0	O
.	0	O


The	0	O
single	0	O
site	0	O
of	0	O
glycosylation	0	O
is	0	O
located	0	O
near	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
in	0	O
the	0	O
N	1	O
-	0	O
glycosylation	0	O
sequon	0	O
-	0	O
Asn	1	O
-	0	O
Cys	1	O
-	0	O
Ser	1	O
-	0	O
in	0	O
which	0	O
Cys	1	O
forms	0	O
part	0	O
of	0	O
a	0	O
disulphide	0	O
bridge	0	O
.	0	O


The	0	O
level	0	O
of	0	O
the	0	O
SUP4A53T61	0	B
transcript	0	I
was	0	O
threefold	0	O
higher	0	O
in	0	O
the	0	O
tap1	0	B
-	0	I
1	0	I
mutant	0	I
than	0	O
in	0	O
the	0	O
wild	0	O
type	0	O
.	0	O


(	0	O
iii	0	O
)	0	O
The	0	O
mRNA	1	O
is	0	O
not	0	O
efficiently	0	O
polyadenylated	0	O
at	0	O
sequences	0	O
in	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
DHFR	1	B
cDNA	1	I
but	0	O
rather	0	O
uses	0	O
polyadenylation	0	O
signals	0	O
downstream	0	O
from	0	O
the	0	O
DHFR	1	B
cDNA	1	I
.	0	O


The	0	O
harpin	0	B
-	0	O
encoding	0	O
hrpZ	0	B
gene	0	I
is	0	O
located	0	O
in	0	O
an	0	O
operon	0	O
that	0	O
also	0	O
encodes	0	O
Hrp	1	B
secretion	0	I
pathway	0	I
components	0	I
and	0	O
is	0	O
part	0	O
of	0	O
the	0	O
functional	0	O
cluster	0	O
of	0	O
hrp	0	B
genes	0	I
carried	0	O
on	0	O
cosmid	0	O
pHIR11	0	O
that	0	O
enables	0	O
saprophytic	0	O
bacteria	0	O
like	0	O
Escherichia	1	O
coli	0	O
and	0	O
Pseudomonas	1	O
fluorescens	0	O
to	0	O
elicit	0	O
the	0	O
HR	1	O
in	0	O
tobacco	0	O
leaves	0	O
.	0	O


Confirmatory	1	O
statistics	0	O
included	0	O
item	0	O
2	0	O
of	0	O
the	0	O
Clinical	1	O
Global	1	O
Impression	1	O
(	0	O
CGI	0	O
),	0	O
the	0	O
total	0	O
score	0	O
of	0	O
the	0	O
Sandoz	0	O
Clinical	1	O
Assessment	1	O
Geriatric	1	O
(	0	O
SCAG	0	O
)	0	O
scale	0	O
,	0	O
the	0	O
subscale	0	O
'	0	O
need	0	O
for	0	O
help	0	O
'	0	O
of	0	O
the	0	O
nurse	0	O
'	0	O
s	0	O
rating	0	O
of	0	O
geriatric	0	O
patients	0	O
(	0	O
Beurteilungsskala	0	O
fur	0	O
geriatrische	0	O
Patienten	0	O
;	0	O
BGP	0	O
)	0	O
and	0	O
the	0	O
total	0	O
score	0	O
of	0	O
the	0	O
Short	0	O
Cognitive	1	O
Performance	1	O
Test	1	O
(	0	O
Syndrom	0	O
-	0	O
Kurztest	0	O
;	0	O
SKT	0	O
).	0	O


Nodular	1	O
involvement	0	O
of	0	O
the	0	O
left	0	O
lung	0	O
and	0	O
infiltration	0	O
of	0	O
the	0	O
mucosa	0	O
of	0	O
the	0	O
left	0	O
lower	0	O
lobe	0	O
bronchus	0	O
followed	0	O
very	0	O
gradually	0	O
and	0	O
a	0	O
monoclonal	0	O
gammopathy	0	O
(	0	O
IgA	1	B
--	0	I
Type	1	I
Kappa	1	I
)	0	O
was	0	O
demonstrated	0	O
.	0	O


We	0	O
found	0	O
that	0	O
120	0	O
bp	0	O
of	0	O
the	0	O
enhancer	0	O
'	0	O
s	0	O
transcriptional	0	O
core	0	O
becomes	0	O
DNase	1	B
I	1	I
hypersensitive	0	O
early	0	O
in	0	O
B	1	O
-	0	O
cell	0	O
development	0	O
.	0	O


Oncological	0	O
,	0	O
clinical	0	O
and	0	O
psychological	0	O
aspects	0	O
are	0	O
evaluated	0	O
according	0	O
to	0	O
experience	0	O
accumulated	0	O
in	0	O
recent	0	O
years	0	O
,	0	O
with	0	O
immediate	0	O
and	0	O
delayed	0	O
reconstruction	0	O
,	0	O
carried	0	O
out	0	O
in	0	O
the	0	O
most	0	O
diverse	0	O
specialized	0	O
centers	0	O
.	0	O


The	0	O
present	0	O
study	0	O
investigates	0	O
whether	0	O
prostaglandins	0	O
"	0	O
cytoprotect	0	O
"	0	O
the	0	O
gastric	0	O
mucosa	0	O
against	0	O
hemorrhage	0	O
-	0	O
induced	0	O
stress	0	O
ulceration	0	O
by	0	O
assessing	0	O
the	0	O
influence	0	O
of	0	O
16	0	O
,	0	O
16	0	O
-	0	O
dimethyl	0	O
prostaglandin	0	O
E2	1	O
(	0	O
16	0	O
,	0	O
16	0	O
-	0	O
dm	0	O
PGE2	0	O
)	0	O
on	0	O
gross	0	O
and	0	O
microscopic	0	O
lesion	0	O
formation	0	O
,	0	O
intramucosal	0	O
tissue	0	O
pH	1	O
,	0	O
H	1	O
+	0	O
back	0	O
-	0	O
diffusion	0	O
,	0	O
and	0	O
mucosal	0	O
blood	0	O
flow	0	O
in	0	O
rat	0	O
gastric	0	O
mucosa	0	O
exposed	0	O
to	0	O
luminal	0	O
acid	0	O
(	0	O
100	0	O
mM	1	O
HCl	1	O
)	0	O
during	0	O
hemorrhagic	0	O
shock	0	O
(	0	O
13	0	O
ml	0	O
/	0	O
kg	0	O
for	0	O
20	0	O
min	0	O
).	0	O


Their	0	O
circadian	0	O
responses	0	O
to	0	O
both	0	O
photic	0	O
and	0	O
non	0	O
-	0	O
photic	0	O
cues	0	O
were	0	O
then	0	O
tested	0	O
.	0	O


All	1	O
patients	0	O
had	0	O
the	0	O
CA	1	B
125	0	I
assay	0	O
performed	0	O
within	0	O
one	0	O
week	0	O
before	0	O
their	0	O
second	0	O
-	0	O
look	0	O
operation	0	O
.	0	O


The	0	O
baroreflex	0	O
latency	0	O
(	0	O
from	0	O
the	0	O
ECG	1	O
R	1	O
-	0	O
wave	0	O
to	0	O
the	0	O
integrated	0	O
MSNA	0	O
burst	0	O
peak	0	O
)	0	O
was	0	O
constant	0	O
at	0	O
approximately	0	O
1	0	O
.	0	O
20	0	O
s	0	O
during	0	O
sleep	0	O
,	0	O
suggesting	0	O
that	0	O
pulse	0	O
-	0	O
synchronicity	0	O
was	0	O
maintained	0	O
.	0	O


These	0	O
include	0	O
the	0	O
CACCC	0	O
and	0	O
CAAT	0	O
motifs	0	O
.	0	O


Nucleotide	1	O
sequence	0	O
,	0	O
genome	0	O
organization	0	O
and	0	O
phylogenetic	0	O
analysis	0	O
of	0	O
pineapple	0	O
mealybug	0	O
wilt	0	O
-	0	O
associated	0	O
virus	0	O
-	0	O
2	0	O
.	0	O


All	1	O
samples	0	O
exhibited	0	O
a	0	O
decline	0	O
in	0	O
ethanol	0	O
concentration	0	O
,	0	O
with	0	O
most	0	O
losses	0	O
falling	0	O
within	0	O
the	0	O
expected	0	O
20	0	O
to	0	O
40	0	O
mg	0	O
%	0	O
range	0	O
.	0	O


135	0	O
students	0	O
had	0	O
a	0	O
count	0	O
of	0	O
less	0	O
than	0	O
50	0	O
eggs	0	O
/	0	O
10	0	O
ml	0	O
.	0	O
urine	0	O
and	0	O
56	0	O
had	0	O
more	0	O
than	0	O
50	0	O
eggs	0	O
/	0	O
10ml	0	O
.	0	O


The	0	O
predicted	0	O
protein	0	O
products	0	O
of	0	O
ORFs	0	B
N2417	0	I
and	0	O
N2403	0	B
present	0	O
similarities	0	O
with	0	O
domains	0	O
from	0	O
proteins	0	O
of	0	O
other	0	O
organisms	0	O
:	0	O
the	0	O
Candida	1	O
maltosa	0	O
cycloheximide	0	B
-	0	I
resistance	0	I
protein	0	I
,	0	O
the	0	O
human	0	O
interleukin	0	B
enhancer	0	I
-	0	I
binding	0	I
factor	0	I
(	0	O
ILF	0	B
-	0	I
2	0	I
).	0	O


Increase	0	O
in	0	O
urinary	0	O
calcium	0	O
and	0	O
oxalate	0	O
after	0	O
fructose	0	O
infusion	0	O
.	0	O


We	0	O
also	0	O
examined	0	O
the	0	O
relationship	0	O
between	0	O
the	0	O
side	0	O
of	0	O
sinusitis	0	O
and	0	O
the	0	O
cleft	0	O
side	0	O
in	0	O
patients	0	O
with	0	O
unilateral	0	O
cleft	0	O
palate	0	O
.	0	O


In	1	O
10	0	O
pentobarbitalized	0	O
dogs	0	O
,	0	O
plasma	0	O
viscosity	0	O
(	0	O
Ep	1	O
)	0	O
was	0	O
raised	0	O
fourfold	0	O
while	0	O
apparent	0	O
blood	0	O
viscosity	0	O
(	0	O
Ea	1	O
)	0	O
increased	0	O
about	0	O
twofold	0	O
by	0	O
two	0	O
steps	0	O
of	0	O
exchange	0	O
transfusion	0	O
of	0	O
200	0	O
ml	0	O
of	0	O
plasma	0	O
with	0	O
plasma	0	O
containing	0	O
high	0	O
molecular	0	O
weight	0	O
dextran	0	O
(	0	O
mol	0	O
wt	0	O
500	0	O
,	0	O
000	0	O
,	0	O
20	0	O
%	0	O
wt	0	O
/	0	O
vol	0	O
).	0	O


Natural	1	O
FL	1	B
protein	0	I
has	0	O
been	0	O
purified	0	O
from	0	O
a	0	O
stromal	0	O
cell	0	O
line	0	O
and	0	O
shown	0	O
to	0	O
be	0	O
a	0	O
65	0	O
kD	1	O
nondisulfide	0	O
-	0	O
linked	0	O
homodimeric	0	O
glycoprotein	0	O
comprised	0	O
of	0	O
30	0	O
kD	1	O
subunits	0	O
,	0	O
each	0	O
containing	0	O
12	0	O
kD	1	O
of	0	O
N	1	O
-	0	O
and	0	O
O	1	O
-	0	O
linked	0	O
sugars	0	O
.	0	O


The	0	O
study	0	O
enrolled	0	O
994	0	O
people	0	O
co	0	O
-	0	O
infected	0	O
with	0	O
CMV	1	O
and	0	O
HIV	1	O
,	0	O
with	0	O
at	0	O
least	0	O
one	0	O
CD4	1	B
count	0	O
recorded	0	O
<	0	O
100	0	O
x	0	O
10	0	O
(	0	O
6	0	O
)	0	O
cells	0	O
/	0	O
l	0	O
.	0	O


Schwab	0	O
and	0	O
England	0	O
ADL	1	O
scores	0	O
in	0	O
the	0	O
"	0	O
off	0	O
"	0	O
state	0	O
were	0	O
improved	0	O
by	0	O
18	0	O
%	0	O
and	0	O
in	0	O
the	0	O
"	0	O
on	0	O
"	0	O
state	0	O
the	0	O
scores	0	O
declined	0	O
by	0	O
2	0	O
%.	0	O


Drugs	0	O
suppressed	0	O
>	0	O
or	0	O
=	0	O
75	0	O
%	0	O
of	0	O
the	0	O
total	0	O
premature	0	O
ventricular	0	O
contractions	0	O
in	0	O
all	0	O
patients	0	O
who	0	O
had	0	O
both	0	O
use	0	O
-	0	O
dependent	0	O
QRS	0	O
prolongation	0	O
and	0	O
reverse	0	O
use	0	O
-	0	O
dependent	0	O
QT	1	O
prolongation	0	O
,	0	O
in	0	O
79	0	O
%	0	O
of	0	O
patients	0	O
with	0	O
use	0	O
-	0	O
dependent	0	O
QRS	0	O
prolongation	0	O
alone	0	O
,	0	O
in	0	O
70	0	O
%	0	O
with	0	O
reverse	0	O
use	0	O
-	0	O
dependent	0	O
QT	1	O
prolongation	0	O
alone	0	O
,	0	O
and	0	O
in	0	O
11	0	O
%	0	O
with	0	O
neither	0	O
use	0	O
-	0	O
dependent	0	O
QRS	0	O
prolongation	0	O
nor	0	O
reverse	0	O
use	0	O
-	0	O
dependent	0	O
QT	1	O
prolongation	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
genomic	0	O
DNA	1	O
sequence	0	O
with	0	O
that	0	O
of	0	O
the	0	O
four	0	O
different	0	O
mRNAs	0	O
indicates	0	O
that	0	O
these	0	O
transcripts	0	O
are	0	O
produced	0	O
by	0	O
alternative	0	O
splicing	0	O
of	0	O
the	0	O
murine	0	O
pre	0	O
-	0	O
mRNA	1	O
according	0	O
to	0	O
a	0	O
cassette	0	O
model	0	O
.	0	O


Studies	0	O
on	0	O
the	0	O
method	0	O
of	0	O
size	0	O
reduction	0	O
of	0	O
medicinal	0	O
compounds	0	O
.	0	O


The	0	O
mapping	0	O
was	0	O
completed	0	O
with	0	O
Southern	0	O
blotting	0	O
and	0	O
restriction	0	O
analysis	0	O
.	0	O


It	1	O
was	0	O
established	0	O
that	0	O
intrathecal	0	O
or	0	O
intraperitoneal	0	O
PTFL	0	O
,	0	O
elevated	0	O
the	0	O
nociceptive	0	O
threshold	0	O
for	0	O
mechanical	0	O
stimuli	0	O
in	0	O
the	0	O
formalin	0	O
test	0	O
in	0	O
rats	0	O
.	0	O


Shift	1	O
-	0	O
down	0	O
experiments	0	O
indicated	0	O
that	0	O
the	0	O
10	0	O
(	0	O
4	0	O
)-	0	O
to	0	O
10	0	O
(	0	O
5	0	O
)-	0	O
fold	0	O
reduction	0	O
in	0	O
virus	0	O
yield	0	O
at	0	O
the	0	O
nonpermissive	0	O
temperature	0	O
was	0	O
due	0	O
to	0	O
the	0	O
disfunction	0	O
of	0	O
alpha	0	B
TIF	0	I
late	0	O
in	0	O
infection	0	O
,	0	O
presumably	0	O
in	0	O
virion	0	O
maturation	0	O
.	0	O


Feeding	1	O
behavior	0	O
,	0	O
circannual	0	O
body	0	O
weight	0	O
and	0	O
hibernation	0	O
rhythms	0	O
in	0	O
European	0	O
hamsters	0	O
lesioned	0	O
in	0	O
the	0	O
noradrenergic	0	O
ascending	0	O
bundles	0	O


We	0	O
have	0	O
reviewed	0	O
the	0	O
experience	0	O
of	0	O
a	0	O
major	0	O
MMT	0	O
general	0	O
practice	0	O
with	0	O
hepatitis	0	O
C	1	O
virus	0	O
(	0	O
HCV	1	O
)	0	O
infection	0	O
from	0	O
1991	0	O
to	0	O
1995	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
UvrA	0	B
protein	0	I
interacts	0	O
with	0	O
the	0	O
UvrB	0	B
protein	0	I
to	0	O
modulate	0	O
its	0	O
activities	0	O
,	0	O
both	0	O
in	0	O
solution	0	O
and	0	O
in	0	O
association	0	O
with	0	O
DNA	1	O
,	0	O
where	0	O
the	0	O
UvrAB	0	B
complex	0	I
possesses	0	O
a	0	O
helicase	0	B
activity	0	O
.	0	O


When	0	O
desipramine	0	O
was	0	O
injected	0	O
16	0	O
hrs	0	O
after	0	O
fluoxetine	0	O
injection	0	O
,	0	O
brain	0	O
levels	0	O
of	0	O
desipramine	0	O
were	0	O
no	0	O
longer	0	O
elevated	0	O
.	0	O


Amino	1	O
acid	0	O
residues	0	O
of	0	O
beta	0	O
1	0	O
',	0	O
alpha	0	O
A	1	O
',	0	O
alpha	0	O
B	1	O
',	0	O
and	0	O
the	0	O
loop	0	O
containing	0	O
His539	0	O
of	0	O
the	0	O
RNase	1	B
H	1	I
domain	0	I
interact	0	O
with	0	O
the	0	O
primer	0	O
strand	0	O
of	0	O
the	0	O
dsDNA	1	O
.	0	O


Allergy	1	O
and	0	O
Tourette	1	O
'	0	O
s	0	O
syndrome	0	O
.	0	O


This	0	O
is	0	O
particularly	0	O
intriguing	0	O
because	0	O
SKUT	0	O
-	0	O
1B	0	O
-	0	O
20	0	O
cells	0	O
lack	0	O
the	0	O
transcription	0	O
factor	0	O
Pit	1	B
-	0	I
1	0	I
.	0	O


TNF	1	B
-	0	I
alpha	0	I
exposure	0	O
markedly	0	O
increased	0	O
activity	0	O
of	0	O
several	0	O
RNA	1	O
-	0	O
binding	0	O
proteins	0	O
,	0	O
especially	0	O
a	0	O
novel	0	O
Mr	1	O
50	0	O
,	0	O
000	0	O
-	0	O
55	0	O
,	0	O
000	0	O
RNA	1	O
-	0	O
binding	0	O
protein	0	O
.	0	O


The	0	O
radiation	0	O
burden	0	O
associated	0	O
with	0	O
the	0	O
majority	0	O
of	0	O
examinations	0	O
in	0	O
nuclear	0	O
medicine	0	O
expressed	0	O
as	0	O
the	0	O
effective	0	O
dose	0	O
is	0	O
comparable	0	O
with	0	O
the	0	O
radiation	0	O
burden	0	O
of	0	O
radiodiagnostic	0	O
examinations	0	O
,	0	O
only	0	O
after	0	O
administration	0	O
of	0	O
preparations	0	O
with	0	O
131I	0	O
,	0	O
201Tl	0	O
,	0	O
67Ga	0	O
and	0	O
111In	0	O
it	0	O
is	0	O
markedly	0	O
higher	0	O
.	0	O


In	1	O
this	0	O
report	0	O
,	0	O
we	0	O
describe	0	O
the	0	O
characterization	0	O
of	0	O
two	0	O
early	0	O
class	0	B
II	0	I
flagellar	0	I
genes	0	I
contained	0	O
in	0	O
the	0	O
orfX	0	O
-	0	O
fliP	0	B
locus	0	O
.	0	O


Tilmicosin	1	O
is	0	O
a	0	O
novel	0	O
macrolide	0	O
antibiotic	0	O
developed	0	O
for	0	O
exclusive	0	O
use	0	O
in	0	O
veterinary	0	O
medicine	0	O
.	0	O


Poly	1	O
(	0	O
dT	1	O
)	0	O
and	0	O
denatured	0	O
calf	0	O
thymus	0	O
DNA	1	O
were	0	O
more	0	O
effective	0	O
than	0	O
were	0	O
other	0	O
polynucleotides	0	O
tested	0	O
in	0	O
promoting	0	O
accumulation	0	O
of	0	O
19	0	O
HDP	1	O
*;	0	O
(	0	O
dT	1	O
)	0	O
8	0	O
was	0	O
as	0	O
effective	0	O
as	0	O
were	0	O
longer	0	O
molecules	0	O
of	0	O
(	0	O
dT	1	O
)	0	O
n	0	O
,	0	O
but	0	O
(	0	O
dT	1	O
)	0	O
4	0	O
and	0	O
(	0	O
dT	1	O
)	0	O
6	0	O
were	0	O
much	0	O
less	0	O
effective	0	O
,	0	O
indicating	0	O
that	0	O
the	0	O
binding	0	O
site	0	O
involved	0	O
in	0	O
19	0	O
HDP	1	B
*	0	I
accumulation	0	O
covered	0	O
between	0	O
6	0	O
and	0	O
8	0	O
residues	0	O
of	0	O
(	0	O
dT	1	O
)	0	O
n	0	O
.	0	O


All	1	O
stimulations	0	O
were	0	O
down	0	O
-	0	O
regulated	0	O
with	0	O
GnRH	0	B
-	0	I
a	0	I
commenced	0	O
on	0	O
day	0	O
21	0	O
in	0	O
a	0	O
long	0	O
protocol	0	O
before	0	O
gonadotropin	0	B
stimulation	0	O
.	0	O


The	0	O
results	0	O
showed	0	O
that	0	O
IFN	1	B
-	0	I
gamma	0	I
stimulated	0	O
the	0	O
rapid	0	O
accumulation	0	O
of	0	O
interferon	0	B
regulated	0	I
factor	0	I
(	0	I
IRF	1	I
)-	0	I
1	0	I
mRNA	1	I
,	0	O
followed	0	O
by	0	O
a	0	O
delayed	0	O
and	0	O
dose	0	O
-	0	O
dependent	0	O
inhibition	0	O
of	0	O
alpha1	0	B
(	0	I
I	1	I
)	0	I
procollagen	0	I
mRNA	1	I
expression	0	O
in	0	O
skin	0	O
fibroblasts	0	O
from	0	O
several	0	O
different	0	O
donors	0	O
.	0	O


Removal	0	O
of	0	O
lipid	0	O
fractions	0	O
of	0	O
plant	0	O
extractions	0	O
with	0	O
hexane	0	O
is	0	O
recommended	0	O
to	0	O
avoid	0	O
damage	0	O
to	0	O
the	0	O
HPLC	1	O
column	0	O
.	0	O


Improvement	0	O
of	0	O
the	0	O
CRT	1	O
display	0	O
of	0	O
an	0	O
averager	0	O
.	0	O


Consequently	0	O
functional	0	O
mRNAs	0	O
can	0	O
be	0	O
produced	0	O
by	0	O
endogenous	0	B
RNA	1	I
polymerase	0	I
I	1	O
.	0	O


These	0	O
results	0	O
establish	0	O
that	0	O
hydroquinones	0	O
lead	0	O
to	0	O
mutagenicity	0	O
and	0	O
carcinogenicity	0	O
.	0	O


When	0	O
the	0	O
E1A	0	B
N	1	I
-	0	I
terminus	0	I
is	0	O
used	0	O
as	0	O
a	0	O
competitor	0	O
in	0	O
squelshing	0	O
experiments	0	O
it	0	O
abolishes	0	O
CBP	0	B
-	0	O
induced	0	O
activation	0	O
of	0	O
E2F1	0	B
/	0	O
DP1	0	B
,	0	O
whereas	0	O
an	0	O
E1A	0	B
mutant	0	I
lacking	0	O
CBP	0	B
binding	0	O
ability	0	O
fails	0	O
to	0	O
do	0	O
so	0	O
.	0	O


A	1	O
brief	0	O
account	0	O
of	0	O
the	0	O
1988	0	O
seminar	0	O
in	0	O
Shanghai	0	O
on	0	O
viral	0	O
hepatitis	0	O
A	1	O


RT	1	O
-	0	O
PCR	1	O
and	0	O
in	0	O
situ	0	O
hybridization	0	O
analyses	0	O
of	0	O
a	0	O
time	0	O
course	0	O
of	0	O
juvenile	0	O
testis	0	O
development	0	O
indicate	0	O
that	0	O
Spo11	0	B
expression	0	O
begins	0	O
in	0	O
early	0	O
meiotic	0	O
Prophase	1	O
I	1	O
,	0	O
prior	0	O
to	0	O
the	0	O
pachytene	0	O
stage	0	O
,	0	O
with	0	O
increasing	0	O
accumulation	0	O
of	0	O
mRNA	1	O
through	0	O
the	0	O
pachytene	0	O
stage	0	O
.	0	O


The	0	O
clinical	0	O
picture	0	O
of	0	O
the	0	O
disease	0	O
was	0	O
significantly	0	O
different	0	O
from	0	O
anthropogenic	0	O
cutaneous	0	O
leishmaniasis	0	O
caused	0	O
by	0	O
L	1	O
.	0	O
tropica	0	O
but	0	O
similar	0	O
to	0	O
cutaneous	0	O
patterns	0	O
caused	0	O
by	0	O
L	1	O
.	0	O
infantum	0	O
which	0	O
was	0	O
a	0	O
prevalent	0	O
pattern	0	O
in	0	O
the	0	O
southern	0	O
France	0	O
.	0	O


SM	1	B
is	0	O
also	0	O
shown	0	O
to	0	O
be	0	O
associated	0	O
in	0	O
vivo	0	O
with	0	O
other	0	O
components	0	O
of	0	O
the	0	O
CRM	1	B
1	0	I
export	0	O
pathway	0	O
,	0	O
including	0	O
the	0	O
small	0	B
GTPase	1	I
Ran	0	I
and	0	O
the	0	O
nucleoporin	0	O
CAN	0	B
/	0	O
Nup214	0	B
.	0	O


Chem	0	O
.	0	O


This	0	O
slope	0	O
tended	0	O
to	0	O
be	0	O
higher	0	O
(	0	O
approximately	0	O
1	0	O
.	0	O
6	0	O
dB	1	O
/	0	O
dB	1	O
)	0	O
for	0	O
L1	0	O
=	0	O
L2	0	O
greater	0	O
than	0	O
80	0	O
dB	1	O
.	0	O


Framingham	0	O
Type	1	O
A	1	O
behavior	0	O
was	0	O
positively	0	O
associated	0	O
with	0	O
diastolic	0	O
blood	0	O
pressure	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
17	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
among	0	O
the	0	O
women	0	O
.	0	O


Gel	1	O
-	0	O
shift	0	O
assays	0	O
identified	0	O
two	0	O
Sp1	0	B
binding	0	I
sites	0	I
within	0	O
this	0	O
element	0	O
.	0	O


1	0	O
,	0	O
among	0	O
which	0	O
nine	0	O
have	0	O
been	0	O
cloned	0	O
and	0	O
two	0	O
(	0	O
potentially	0	O
functional	0	O
)	0	O
sequenced	0	O
.	0	O


Two	0	O
related	0	O
studies	0	O
conducted	0	O
over	0	O
a	0	O
five	0	O
week	0	O
period	0	O
measured	0	O
and	0	O
typed	0	O
HLA	1	B
-	0	I
DQA1	0	I
from	0	O
accumulated	0	O
DNA	1	O
on	0	O
autopsy	0	O
room	0	O
and	0	O
Forensic	1	O
DNA	1	O
Laboratory	1	O
structures	0	O
.	0	O


We	0	O
have	0	O
previously	0	O
shown	0	O
that	0	O
ARNO	0	B
localizes	0	O
to	0	O
the	0	O
plasma	0	O
membrane	0	O
in	0	O
vivo	0	O
and	0	O
efficiently	0	O
catalyzes	0	O
ARF6	0	B
nucleotide	0	O
exchange	0	O
in	0	O
vitro	0	O
.	0	O


The	0	O
variable	0	O
phenotype	0	O
of	0	O
the	0	O
allotetraploids	0	O
could	0	O
not	0	O
be	0	O
explained	0	O
by	0	O
cytological	0	O
abnormalities	0	O
.	0	O


We	0	O
recommend	0	O
that	0	O
paracervical	0	O
block	0	O
with	0	O
lignocaine	0	O
should	0	O
be	0	O
used	0	O
in	0	O
conjunction	0	O
with	0	O
i	0	O
.	0	O
v	0	O
.	0	O
sedation	0	O
/	0	O
analgesia	0	O
during	0	O
egg	0	O
collection	0	O
performed	0	O
through	0	O
the	0	O
transvaginal	0	O
route	0	O
under	0	O
ultrasound	0	O
guidance	0	O
(	0	O
TUGOR	0	O
)	0	O
to	0	O
reduce	0	O
the	0	O
pain	0	O
of	0	O
the	0	O
procedure	0	O
.	0	O


No	1	O
post	0	O
-	0	O
operative	0	O
haemorrhages	0	O
from	0	O
the	0	O
prostheses	0	O
were	0	O
observed	0	O
.	0	O


A	1	O
strong	0	O
correlation	0	O
exists	0	O
between	0	O
the	0	O
numbers	0	O
of	0	O
CFU	1	O
-	0	O
GM	1	O
transfused	0	O
and	0	O
the	0	O
rate	0	O
of	0	O
granulocytes	0	O
and	0	O
platelets	0	O
recovery	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
megabase	0	O
region	0	O
surrounding	0	O
the	0	O
dagA	0	B
locus	0	I
was	0	O
mapped	0	O
.	0	O


Another	0	O
common	0	O
mutation	0	O
involved	0	O
amino	0	O
acids	0	O
that	0	O
are	0	O
thought	0	O
to	0	O
make	0	O
specific	0	O
contacts	0	O
with	0	O
DNA	1	O
.	0	O


In	1	O
mice	0	O
,	0	O
three	0	O
major	0	O
families	0	O
of	0	O
L1	0	O
elements	0	O
,	0	O
termed	0	O
"	0	O
A	1	O
,"	0	O
"	0	O
F	1	O
,"	0	O
and	0	O
"	0	O
V	1	O
,"	0	O
have	0	O
been	0	O
defined	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
the	0	O
sequence	0	O
found	0	O
at	0	O
the	0	O
5	0	O
'	0	O
terminus	0	O
.	0	O


Ongoing	0	O
and	0	O
future	0	O
investigations	0	O
may	0	O
better	0	O
define	0	O
the	0	O
optimal	0	O
approach	0	O
for	0	O
local	0	O
control	0	O
,	0	O
the	0	O
optimal	0	O
duration	0	O
of	0	O
maintenance	0	O
chemotherapy	0	O
,	0	O
and	0	O
the	0	O
possible	0	O
role	0	O
of	0	O
biologic	0	O
response	0	O
modifiers	0	O
and	0	O
growth	0	O
factors	0	O
in	0	O
further	0	O
improving	0	O
the	0	O
outcome	0	O
for	0	O
patients	0	O
with	0	O
this	0	O
disease	0	O
.	0	O


2	0	O
Silastic	1	O
capsules	0	O
,	0	O
each	0	O
containing	0	O
22	0	O
-	0	O
23	0	O
mg	0	O
of	0	O
ethinyl	0	O
estradiol	0	O
,	0	O
were	0	O
inserted	0	O
subcutaneously	0	O
in	0	O
5	0	O
men	0	O
with	0	O
benign	0	O
prostatic	0	O
hypertrophy	0	O
.	0	O


The	0	O
residue	0	O
functions	0	O
,	0	O
R	1	O
(	0	O
t	0	O
),	0	O
for	0	O
C	1	O
-	0	O
11	0	O
CPZ	0	O
and	0	O
In	1	O
-	0	O
113m	0	O
transferrin	0	B
were	0	O
plotted	0	O
against	0	O
time	0	O
for	0	O
selected	0	O
areas	0	O
of	0	O
interest	0	O
,	0	O
and	0	O
the	0	O
CPZ	0	O
area	0	O
-	0	O
weighted	0	O
extraction	0	O
,	0	O
E	1	O
(	0	O
t	0	O
),	0	O
was	0	O
computed	0	O
for	0	O
the	0	O
same	0	O
areas	0	O
every	0	O
250	0	O
msec	0	O
using	0	O
the	0	O
formula	0	O
:	0	O
E	1	O
(	0	O
t	0	O
)	0	O
=	0	O
[	0	O
RT	1	O
(	0	O
t	0	O
)	0	O
-	0	O
RR	0	O
(	0	O
t	0	O
)]/[	0	O
1	0	O
-	0	O
RR	0	O
(	0	O
t	0	O
)],	0	O
where	0	O
RT	1	O
and	0	O
RR	0	O
are	0	O
the	0	O
normalized	0	O
residue	0	O
functions	0	O
for	0	O
CPZ	0	O
and	0	O
transferrin	0	B
,	0	O
respectively	0	O
.	0	O


(	0	O
ii	0	O
)	0	O
ICP27	0	B
binds	0	O
preferentially	0	O
to	0	O
less	0	O
modified	0	O
forms	0	O
of	0	O
ICP4	0	B
,	0	O
a	0	O
protein	0	O
that	0	O
is	0	O
extensively	0	O
modified	0	O
posttranslationally	0	O
.	0	O


Our	0	O
findings	0	O
suggest	0	O
that	0	O
striatal	0	O
FDG	1	O
and	0	O
particularly	0	O
RACLO	0	O
are	0	O
sensitive	0	O
and	0	O
effective	0	O
measures	0	O
of	0	O
striatal	0	O
function	0	O
and	0	O
may	0	O
help	0	O
characterizing	0	O
patients	0	O
with	0	O
multiple	0	O
system	0	O
atrophy	0	O
.	0	O


Diagnostic	1	O
importance	0	O
of	0	O
determining	0	O
the	0	O
complement	0	O
constituents	0	O
in	0	O
children	0	O
with	0	O
autoimmune	0	O
thyroiditis	0	O


Immunofluorescence	1	O
microscopy	0	O
and	0	O
cell	0	O
fractionation	0	O
analyses	0	O
showed	0	O
that	0	O
the	0	O
110	0	O
-	0	O
kDa	1	O
protein	0	O
was	0	O
exclusively	0	O
nuclear	0	O
,	0	O
whereas	0	O
the	0	O
150	0	O
-	0	O
kDa	1	O
protein	0	O
was	0	O
present	0	O
in	0	O
both	0	O
the	0	O
cytoplasm	0	O
and	0	O
nucleus	0	O
of	0	O
human	0	O
cells	0	O
.	0	O


The	0	O
N	1	O
-	0	O
terminal	0	O
115	0	O
amino	0	O
acids	0	O
correspond	0	O
to	0	O
a	0	O
putative	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
and	0	O
show	0	O
significant	0	O
sequence	0	O
similarity	0	O
with	0	O
other	0	O
cloned	0	O
IFN	1	B
response	0	I
factors	0	I
(	0	O
IRF	1	B
-	0	I
1	0	I
and	0	O
IRF	1	B
-	0	I
2	0	I
).	0	O


The	0	O
SCMV	0	B
SNE	0	I
sites	0	I
contain	0	O
potential	0	O
overlapping	0	O
core	0	O
recognition	0	O
binding	0	O
motifs	0	O
for	0	O
SRF	1	B
,	0	O
Rel	0	B
/	0	O
NFkappaB	0	B
,	0	O
ETS	1	B
,	0	O
and	0	O
YY1	0	B
class	0	I
transcription	0	I
factors	0	I
but	0	O
fail	0	O
to	0	O
respond	0	O
to	0	O
either	0	O
serum	0	O
or	0	O
tumor	0	B
necrosis	0	I
factor	0	I
alpha	0	I
.	0	O


Using	0	O
a	0	O
battery	0	O
of	0	O
I	1	B
kappa	0	I
B	1	I
alpha	0	I
mutants	0	I
,	0	O
we	0	O
show	0	O
that	0	O
(	0	O
i	0	O
)	0	O
a	0	O
dimer	0	O
binds	0	O
a	0	O
single	0	O
I	1	B
kappa	0	I
B	1	I
alpha	0	I
molecule	0	I
,	0	O
(	0	O
ii	0	O
)	0	O
the	0	O
acidic	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
I	1	B
kappa	0	I
B	1	I
alpha	0	I
is	0	O
not	0	O
required	0	O
for	0	O
protein	0	O
-	0	O
protein	0	O
binding	0	O
and	0	O
does	0	O
not	0	O
mask	0	O
the	0	O
nuclear	0	O
localization	0	O
signal	0	O
of	0	O
the	0	O
dimer	0	O
,	0	O
(	0	O
iii	0	O
)	0	O
the	0	O
same	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
is	0	O
required	0	O
for	0	O
inhibition	0	O
of	0	O
DNA	1	O
binding	0	O
,	0	O
and	0	O
(	0	O
iv	0	O
)	0	O
this	0	O
inhibition	0	O
may	0	O
be	0	O
accomplished	0	O
by	0	O
direct	0	O
interaction	0	O
between	0	O
the	0	O
PEST	1	O
-	0	O
like	0	O
region	0	O
and	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
region	0	O
of	0	O
one	0	O
of	0	O
the	0	O
subunits	0	O
of	0	O
the	0	O
dimer	0	O
.	0	O


The	0	O
transcription	0	B
factor	0	I
CHOP	1	I
(	0	O
C	1	B
/	0	I
EBP	1	I
homologous	0	I
protein	0	I
10	0	I
)	0	O
is	0	O
a	0	O
bZIP	0	B
protein	0	I
induced	0	O
by	0	O
a	0	O
variety	0	O
of	0	O
stimuli	0	O
that	0	O
evoke	0	O
cellular	0	O
stress	0	O
responses	0	O
and	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
arrest	0	O
cell	0	O
growth	0	O
and	0	O
to	0	O
promote	0	O
programmed	0	O
cell	0	O
death	0	O
.	0	O


The	0	O
risk	0	O
factors	0	O
studied	0	O
were	0	O
male	0	O
sex	0	O
,	0	O
hypertension	0	O
,	0	O
diabetes	0	O
mellitus	0	O
,	0	O
hypercholesterolemia	0	O
,	0	O
cigarette	0	O
smoking	0	O
,	0	O
sedentary	0	O
life	0	O
-	0	O
style	0	O
,	0	O
and	0	O
family	0	O
history	0	O
.	0	O


We	0	O
present	0	O
here	0	O
a	0	O
detailed	0	O
genomic	0	O
sequencing	0	O
analysis	0	O
of	0	O
the	0	O
cytosine	0	O
methylation	0	O
patterns	0	O
of	0	O
the	0	O
transposase	0	B
binding	0	O
sites	0	O
within	0	O
both	0	O
Ac	1	B
ends	0	O
in	0	O
the	0	O
wx	0	B
-	0	I
m9	0	I
::	0	O
Ac	1	B
allele	0	I
,	0	O
where	0	O
Ac	1	B
is	0	O
inserted	0	O
into	0	O
the	0	O
tenth	0	O
exon	0	O
of	0	O
the	0	O
Waxy	1	B
gene	0	I
.	0	O


In	1	O
case	0	O
of	0	O
a	0	O
pathologically	0	O
convoluted	0	O
internal	0	O
carotid	0	O
the	0	O
common	0	O
carotid	0	O
artery	0	O
was	0	O
resected	0	O
with	0	O
an	0	O
end	0	O
-	0	O
to	0	O
-	0	O
end	0	O
anastomosis	0	O
.	0	O


Clinical	1	O
research	0	O
of	0	O
non	0	O
-	0	O
A	1	O
,	0	O
non	0	O
-	0	O
B	1	O
post	0	O
-	0	O
transfusion	0	O
hepatitis	0	O


Thus	0	O
E14	0	O
.	0	O
1TG3B1	0	O
is	0	O
a	0	O
useful	0	O
ES	1	O
cell	0	O
line	0	O
for	0	O
modifying	0	O
the	0	O
mouse	0	O
genome	0	O
using	0	O
the	0	O
HPRT	1	B
gene	0	I
as	0	O
a	0	O
selection	0	O
marker	0	O
and	0	O
for	0	O
transmission	0	O
at	0	O
a	0	O
high	0	O
frequency	0	O
into	0	O
the	0	O
mouse	0	O
germ	0	O
line	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
this	0	O
region	0	O
revealed	0	O
three	0	O
eight	0	O
-	0	O
bp	0	O
repetitive	0	O
elements	0	O
,	0	O
the	0	O
deletion	0	O
of	0	O
which	0	O
restored	0	O
wild	0	O
-	0	O
type	0	O
levels	0	O
of	0	O
luciferase	0	B
activity	0	O
to	0	O
the	0	O
-	0	O
916	0	O
-	0	O
bp	0	O
reporter	0	O
plasmid	0	O
.	0	O


Prevention	1	O
,	0	O
differential	0	O
diagnosis	0	O
and	0	O
therapy	0	O
of	0	O
travel	0	O
diarrhea	0	O


Strikingly	0	O
,	0	O
this	0	O
subdomain	0	O
is	0	O
also	0	O
present	0	O
in	0	O
the	0	O
otherwise	0	O
unrelated	0	O
N	1	O
-	0	O
terminal	0	O
activating	0	O
region	0	O
of	0	O
p58c	0	B
-	0	I
ets	0	I
-	0	I
2	0	I
and	0	O
was	0	O
thus	0	O
named	0	O
BEC	0	B
for	0	O
Ets	1	B
-	0	I
1	0	I
-	0	I
beta	0	I
/	0	O
Ets	1	B
-	0	I
2	0	I
-	0	I
Conserved	0	I
sequence	0	I
.	0	O


A	1	O
cDNA	1	O
library	0	O
of	0	O
tumour	0	O
cells	0	O
was	0	O
screened	0	O
with	0	O
an	0	O
interleukin	0	B
2	0	I
gene	0	O
-	0	O
specific	0	O
probe	0	O
.	0	O


Personal	0	O
satisfaction	0	O
in	0	O
nursing	0	O
:	0	O
an	0	O
encounter	0	O
with	0	O
extremely	0	O
hostile	0	O
patients	0	O


Transcription	1	O
from	0	O
the	0	O
promoter	0	O
containing	0	O
the	0	O
mutated	0	O
direct	0	O
repeats	0	O
was	0	O
increased	0	O
greatly	0	O
,	0	O
consistent	0	O
with	0	O
the	0	O
conclusion	0	O
that	0	O
these	0	O
motifs	0	O
functions	0	O
in	0	O
vivo	0	O
to	0	O
repress	0	O
GPT	1	B
gene	0	I
expression	0	O
.	0	O


CREB	0	B
was	0	O
identified	0	O
as	0	O
one	0	O
of	0	O
the	0	O
protein	0	O
components	0	O
in	0	O
several	0	O
of	0	O
the	0	O
gel	0	O
shift	0	O
complexes	0	O
formed	0	O
with	0	O
the	0	O
variant	0	O
CRE	0	O
.	0	O


A	1	O
single	0	O
N	1	O
-	0	O
glycosylation	0	O
site	0	O
present	0	O
in	0	O
chicken	0	B
gp42	0	I
is	0	O
conserved	0	O
among	0	O
all	0	O
five	0	O
of	0	O
these	0	O
proteins	0	O
:	0	O
carbohydrate	0	O
analysis	0	O
of	0	O
gp42	0	B
revealed	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
complex	0	O
type	0	O
glycan	0	O
chain	0	O
at	0	O
this	0	O
site	0	O
.	0	O


The	0	O
cloned	0	O
genes	0	O
were	0	O
identified	0	O
in	0	O
genetic	0	O
libraries	0	O
by	0	O
hybridization	0	O
screening	0	O
using	0	O
four	0	O
deoxyoligonucleotide	0	O
probes	0	O
which	0	O
corresponded	0	O
to	0	O
the	0	O
partial	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
purified	0	O
enzyme	0	O
.	0	O


TPO	0	B
by	0	O
itself	0	O
did	0	O
not	0	O
activate	0	O
ERK1	0	B
,	0	O
ERK2	0	B
and	0	O
protein	0	B
kinase	0	I
C	1	I
(	0	O
PKC	0	B
),	0	O
whereas	0	O
TPO	0	B
directly	0	O
enhanced	0	O
the	0	O
PKC	0	B
-	0	O
dependent	0	O
activation	0	O
of	0	O
ERKs	0	B
induced	0	O
by	0	O
other	0	O
agonists	0	O
including	0	O
thrombin	0	B
and	0	O
phorbol	0	O
esters	0	O
,	0	O
without	0	O
affecting	0	O
the	0	O
PKC	0	B
activation	0	O
by	0	O
those	0	O
agonists	0	O
.	0	O


When	0	O
the	0	O
coding	0	O
segments	0	O
,	0	O
including	0	O
both	0	O
framework	0	O
and	0	O
complementarity	0	O
-	0	O
determining	0	O
regions	0	O
,	0	O
of	0	O
these	0	O
genes	0	O
and	0	O
the	0	O
murine	0	O
probe	0	O
sequences	0	O
are	0	O
compared	0	O
by	0	O
metric	0	O
analysis	0	O
,	0	O
it	0	O
is	0	O
apparent	0	O
that	0	O
the	0	O
caiman	0	O
genes	0	O
are	0	O
only	0	O
slightly	0	O
more	0	O
related	0	O
to	0	O
each	0	O
other	0	O
than	0	O
to	0	O
the	0	O
mammalian	0	O
sequence	0	O
,	0	O
consistent	0	O
with	0	O
significant	0	O
preservation	0	O
of	0	O
nucleotide	0	O
sequence	0	O
over	0	O
an	0	O
extended	0	O
period	0	O
of	0	O
phylogenetic	0	O
time	0	O
.	0	O


Chenodeoxycholic	0	O
acid	0	O
(	0	O
cheno	0	O
)	0	O
and	0	O
ursodeoxycholic	0	O
acid	0	O
(	0	O
urso	0	O
)	0	O
dissolve	0	O
cholesterol	0	O
gallstones	0	O
in	0	O
man	0	O
.	0	O


The	0	O
stoichiometry	0	O
of	0	O
the	0	O
complexes	0	O
formed	0	O
with	0	O
the	0	O
dodeca	0	O
-	0	O
satellite	0	O
C	1	O
strand	0	O
suggests	0	O
that	0	O
,	0	O
in	0	O
DDP1	0	B
,	0	O
the	0	O
15	0	O
consecutive	0	O
KH	0	O
domains	0	O
are	0	O
organized	0	O
such	0	O
that	0	O
they	0	O
define	0	O
two	0	O
nucleic	0	O
acid	0	O
binding	0	O
surfaces	0	O
.	0	O


The	0	O
induction	0	O
of	0	O
seizures	0	O
in	0	O
"	0	O
Papio	0	O
papio	0	O
"	0	O
following	0	O
allylglycine	0	O
alone	0	O
or	0	O
in	0	O
combination	0	O
with	0	O
intermittent	0	O
photic	0	O
stimulation	0	O


Long	0	O
-	0	O
latency	0	O
:	0	O
locked	0	O
units	0	O
responded	0	O
to	0	O
shocks	0	O
with	0	O
little	0	O
jitter	0	O
and	0	O
long	0	O
latency	0	O
(	0	O
4	0	O
-	0	O
11	0	O
ms	0	O
).	0	O


Immunoreactive	1	O
AR	1	B
content	0	O
in	0	O
transfected	0	O
COS	1	O
-	0	O
1	0	O
cells	0	O
was	0	O
not	0	O
influenced	0	O
by	0	O
exposure	0	O
to	0	O
8	0	O
-	0	O
Br	1	O
-	0	O
cAMP	1	O
.	0	O


This	0	O
enhancer	0	O
activates	0	O
both	0	O
the	0	O
K19	0	B
and	0	O
TK	1	B
basal	0	I
promoters	0	I
in	0	O
HeLa	0	O
cells	0	O
.	0	O


These	0	O
data	0	O
indicate	0	O
that	0	O
RNK	0	B
-	0	I
Met	1	I
-	0	I
1	0	I
is	0	O
a	0	O
serine	0	B
protease	0	I
with	0	O
unique	0	O
activity	0	O
that	0	O
is	0	O
expressed	0	O
in	0	O
the	0	O
granules	0	O
of	0	O
large	0	O
granular	0	O
lymphocytes	0	O
.	0	O


Liquid	1	O
chromatographic	0	O
method	0	O
for	0	O
determination	0	O
of	0	O
citreoviridin	0	O
in	0	O
corn	0	O
and	0	O
rice	0	O
.	0	O


The	0	O
expression	0	O
of	0	O
this	0	O
clone	0	O
in	0	O
a	0	O
wee1	0	B
/	0	O
mik1	0	B
-	0	O
deficient	0	O
mutant	0	O
causes	0	O
an	0	O
elongated	0	O
cell	0	O
phenotype	0	O
under	0	O
non	0	O
-	0	O
permissive	0	O
growth	0	O
conditions	0	O
.	0	O


It	1	O
was	0	O
concluded	0	O
that	0	O
Scotchbond	0	O
2	0	O
and	0	O
Prisma	1	O
Universal	1	O
Bond	1	O
2	0	O
are	0	O
effective	0	O
and	0	O
are	0	O
the	0	O
dentine	0	O
bonding	0	O
agents	0	O
of	0	O
choice	0	O
.	0	O


Green	1	O
fluorescent	0	O
protein	0	O
-	0	O
tagged	0	O
UNC	0	B
-	0	I
49B	0	I
and	0	O
UNC	0	B
-	0	I
49C	0	I
subunits	0	I
are	0	O
coexpressed	0	O
in	0	O
muscle	0	O
cells	0	O
and	0	O
are	0	O
colocalized	0	O
to	0	O
synaptic	0	O
regions	0	O
.	0	O


Asthma	1	O
was	0	O
significantly	0	O
more	0	O
often	0	O
associated	0	O
with	0	O
ASA	1	O
group	0	O
(	0	O
91	0	O
%)	0	O
vs	0	O
46	0	O
%	0	O
at	0	O
AT	1	O
and	0	O
in	0	O
only	0	O
16	0	O
%	0	O
at	0	O
INTR	0	O
group	0	O
.	0	O


Prior	0	O
to	0	O
meals	0	O
2	0	O
to	0	O
3	0	O
times	0	O
daily	0	O
,	0	O
1	0	O
-	0	O
2	0	O
tablespoons	0	O
of	0	O
Alzoon	0	O
are	0	O
recommended	0	O
.	0	O


Well	0	O
-	0	O
visualised	0	O
arteriograms	0	O
of	0	O
the	0	O
limbs	0	O
can	0	O
be	0	O
obtained	0	O
by	0	O
xeroradiography	0	O
after	0	O
rapid	0	O
manual	0	O
injection	0	O
of	0	O
contrast	0	O
-	0	O
medium	0	O
into	0	O
an	0	O
arm	0	O
vein	0	O
,	0	O
as	0	O
demonstrated	0	O
in	0	O
28	0	O
patients	0	O
.	0	O


Finally	0	O
,	0	O
we	0	O
show	0	O
that	0	O
complexes	0	O
similar	0	O
to	0	O
the	0	O
C25	0	B
,	0	O
C30	0	B
and	0	O
C35	0	B
complexes	0	I
are	0	O
formed	0	O
by	0	O
rat	0	O
cortex	0	O
nuclear	0	O
extracts	0	O
and	0	O
the	0	O
SAA	0	O
element	0	O
in	0	O
EMSA	0	O
experiments	0	O
,	0	O
suggesting	0	O
the	0	O
relevance	0	O
of	0	O
our	0	O
in	0	O
vitro	0	O
observations	0	O
to	0	O
the	0	O
in	0	O
vivo	0	O
functioning	0	O
of	0	O
the	0	O
rat	0	B
APP	1	I
promoter	0	I
.	0	O


To	1	O
further	0	O
investigate	0	O
the	0	O
nature	0	O
of	0	O
the	0	O
site	0	O
specificity	0	O
a	0	O
set	0	O
of	0	O
deletion	0	O
mutants	0	O
of	0	O
the	0	O
160	0	O
bp	0	O
sequence	0	O
were	0	O
analysed	0	O
.	0	O


The	0	O
proposed	0	O
algorithm	0	O
consists	0	O
of	0	O
several	0	O
steps	0	O
.	0	O


Acute	1	O
appearance	0	O
of	0	O
hemiparesis	0	O
or	0	O
hemiplegia	0	O
with	0	O
initial	0	O
marked	0	O
spasticity	0	O
was	0	O
observed	0	O
in	0	O
8	0	O
stroke	0	O
patients	0	O
.	0	O


It	1	O
was	0	O
found	0	O
that	0	O
increase	0	O
in	0	O
the	0	O
RH	1	O
level	0	O
boosts	0	O
the	0	O
current	0	O
values	0	O
by	0	O
2	0	O
-	0	O
3	0	O
orders	0	O
of	0	O
magnitude	0	O
;	0	O
contrariwise	0	O
,	0	O
the	0	O
voltage	0	O
values	0	O
rise	0	O
by	0	O
about	0	O
three	0	O
times	0	O
with	0	O
drop	0	O
in	0	O
the	0	O
RH	1	O
.	0	O


Serological	1	O
studies	0	O
of	0	O
antibodies	0	O
to	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
in	0	O
infectious	0	O
mononucleosis	0	O


Among	0	O
the	0	O
v	0	B
-	0	I
myc	0	I
codons	0	O
,	0	O
the	0	O
first	0	O
5	0	O
are	0	O
derived	0	O
from	0	O
the	0	O
noncoding	0	O
5	0	O
'	0	O
terminus	0	O
of	0	O
the	0	O
second	0	O
c	0	B
-	0	I
myc	0	I
exon	0	O
,	0	O
and	0	O
412	0	O
codons	0	O
correspond	0	O
to	0	O
the	0	O
c	0	B
-	0	I
myc	0	I
coding	0	O
region	0	O
.	0	O


Two	0	O
siblings	0	O
with	0	O
hemolytic	0	O
anemia	0	O
caused	0	O
by	0	O
triosephosphate	0	B
isomerase	0	I
deficiency	0	O
developed	0	O
a	0	O
progressive	0	O
neurological	0	O
syndrome	0	O
featuring	0	O
dystonic	0	O
movements	0	O
,	0	O
tremor	0	O
,	0	O
pyramidal	0	O
tract	0	O
signs	0	O
,	0	O
and	0	O
evidence	0	O
of	0	O
spinal	0	O
motor	0	O
neuron	0	O
involvement	0	O
.	0	O


However	0	O
,	0	O
no	0	O
genetic	0	O
alteration	0	O
was	0	O
detected	0	O
in	0	O
any	0	O
of	0	O
the	0	O
cancers	0	O
examined	0	O
.	0	O


RA	1	O
-	0	O
treatment	0	O
of	0	O
these	0	O
transfectants	0	O
induced	0	O
morphologic	0	O
and	0	O
immunophenotypic	0	O
maturation	0	O
,	0	O
changes	0	O
in	0	O
RA	1	O
-	0	O
regulated	0	O
genes	0	O
,	0	O
and	0	O
a	0	O
G1	0	O
cell	0	O
cycle	0	O
arrest	0	O
in	0	O
a	0	O
manner	0	O
similar	0	O
to	0	O
parental	0	O
NT2	0	O
/	0	O
D1	1	O
cells	0	O
.	0	O


The	0	O
RET	0	B
/	0	O
PTC3	0	B
rearrangement	0	O
is	0	O
formed	0	O
by	0	O
fusion	0	O
of	0	O
the	0	O
ELE1	0	B
and	0	O
RET	0	B
genes	0	I
,	0	O
and	0	O
is	0	O
highly	0	O
prevalent	0	O
in	0	O
radiation	0	O
-	0	O
induced	0	O
post	0	O
-	0	O
Chernobyl	0	O
papillary	0	O
thyroid	0	O
carcinomas	0	O
.	0	O


We	0	O
identified	0	O
a	0	O
protein	0	O
,	0	O
termed	0	O
NFIL	0	B
-	0	I
1	0	I
beta	0	I
A	1	I
(	0	O
NF	1	B
beta	0	I
A	1	I
),	0	O
that	0	O
binds	0	O
to	0	O
a	0	O
highly	0	O
conserved	0	O
12	0	O
-	0	O
bp	0	O
DNA	1	O
sequence	0	O
(-	0	O
49	0	O
to	0	O
-	0	O
38	0	O
)	0	O
located	0	O
upstream	0	O
of	0	O
the	0	O
TATA	0	O
box	0	O
motif	0	O
in	0	O
both	0	O
the	0	O
human	0	B
and	0	I
murine	0	I
IL	1	I
-	0	I
1	0	I
beta	0	I
genes	0	I
.	0	O


RESULTS	0	O
:	0	O
Fournier	0	O
'	0	O
s	0	O
gangrene	0	O
occurs	0	O
worldwide	0	O
.	0	O


TAR	1	B
and	0	O
Sp1	0	B
-	0	O
independent	0	O
transactivation	0	O
of	0	O
HIV	1	B
long	0	I
terminal	0	I
repeat	0	I
by	0	O
the	0	O
Tat	1	B
protein	0	I
in	0	O
the	0	O
presence	0	O
of	0	O
human	0	O
cytomegalovirus	0	O
IE1	0	B
/	0	O
IE2	0	B
.	0	O


Another	0	O
stem	0	O
-	0	O
loop	0	O
called	0	O
structure	0	O
III	0	O
near	0	O
the	0	O
3	0	O
'-	0	O
end	0	O
of	0	O
repY	0	B
sequesters	0	O
both	0	O
the	0	O
5	0	O
'-	0	O
rCGCC	0	O
-	0	O
3	0	O
'	0	O
sequence	0	O
and	0	O
the	0	O
repZ	0	B
ribosome	0	I
-	0	I
binding	0	I
site	0	I
.	0	O


The	0	O
Cili	0	B
-	0	I
2	0	I
sequences	0	I
possess	0	O
similarity	0	O
to	0	O
the	0	O
RNaseH	0	B
domain	0	I
of	0	O
Lian	0	B
-	0	O
Aa1	0	B
,	0	O
a	0	O
mosquito	0	B
non	0	I
-	0	I
LTR	1	I
retrotransposon	0	I
.	0	O


High	0	O
expression	0	O
of	0	O
the	0	O
peroxisome	0	B
proliferator	0	I
-	0	I
activated	0	I
receptor	0	I
alpha	0	I
(	0	O
PPARalpha	0	B
)	0	O
differentiates	0	O
brown	0	O
fat	0	O
from	0	O
white	0	O
,	0	O
and	0	O
is	0	O
related	0	O
to	0	O
its	0	O
high	0	O
capacity	0	O
of	0	O
lipid	0	O
oxidation	0	O
.	0	O


The	0	O
bHLH	0	B
proteins	0	I
function	0	O
as	0	O
potent	0	O
transcriptional	0	O
activators	0	O
of	0	O
tissue	0	O
-	0	O
specific	0	O
genes	0	O
by	0	O
forming	0	O
heterodimers	0	O
between	0	O
ubiquitous	0	O
and	0	O
cell	0	O
-	0	O
restricted	0	O
family	0	O
members	0	O
.	0	O


According	0	O
to	0	O
out	0	O
field	0	O
research	0	O
,	0	O
the	0	O
tick	0	O
fauna	0	O
was	0	O
very	0	O
rich	0	O
throughout	0	O
that	0	O
area	0	O
,	0	O
and	0	O
it	0	O
was	0	O
permissible	0	O
enough	0	O
to	0	O
determine	0	O
ticks	0	O
as	0	O
the	0	O
vectors	0	O
,	0	O
based	0	O
on	0	O
arising	0	O
of	0	O
anti	0	B
-	0	I
SF	1	I
group	0	I
rickettsiae	0	I
(	0	O
SFGR	0	B
)	0	O
antibody	0	O
in	0	O
mice	0	O
inoculated	0	O
with	0	O
some	0	O
tick	0	O
emulsions	0	O
,	0	O
findings	0	O
of	0	O
rickettsiae	0	O
reactive	0	O
to	0	O
patient	0	O
sera	0	O
or	0	O
a	0	O
species	0	O
-	0	O
specific	0	O
monoclonal	0	O
antibody	0	O
to	0	O
JSFR	0	B
in	0	O
the	0	O
hemolymph	0	O
cells	0	O
of	0	O
some	0	O
ticks	0	O
,	0	O
and	0	O
electron	0	O
microscopical	0	O
observations	0	O
of	0	O
SFGR	0	B
in	0	O
various	0	O
internal	0	O
organs	0	O
including	0	O
the	0	O
salivary	0	O
gland	0	O
of	0	O
ticks	0	O
.	0	O


Platelet	1	B
activating	0	I
factor	0	I
was	0	O
given	0	O
in	0	O
six	0	O
doses	0	O
at	0	O
15	0	O
minute	0	O
intervals	0	O
and	0	O
airway	0	O
response	0	O
measured	0	O
as	0	O
change	0	O
in	0	O
partial	0	O
expiratory	0	O
flow	0	O
at	0	O
30	0	O
%	0	O
of	0	O
vital	0	O
capacity	0	O
(	0	O
Vp30	0	O
).	0	O


Mutations	0	O
in	0	O
UPF1	0	B
lead	0	O
to	0	O
the	0	O
selective	0	O
stabilization	0	O
of	0	O
mRNAs	0	O
containing	0	O
early	0	O
nonsense	0	O
mutations	0	O
without	0	O
affecting	0	O
the	0	O
decay	0	O
rates	0	O
of	0	O
most	0	O
other	0	O
mRNAs	0	O
.	0	O


ArgR	0	B
was	0	O
shown	0	O
to	0	O
be	0	O
a	0	O
dimer	0	O
of	0	O
two	0	O
equal	0	O
subunits	0	O
,	0	O
each	0	O
with	0	O
a	0	O
molecular	0	O
mass	0	O
of	0	O
37	0	O
,	0	O
000	0	O
Da	1	O
.	0	O


The	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
SGC1	0	B
gene	0	I
product	0	I
includes	0	O
a	0	O
region	0	O
with	0	O
substantial	0	O
similarity	0	O
to	0	O
the	0	O
basic	0	O
-	0	O
helix	0	O
-	0	O
loop	0	O
-	0	O
helix	0	O
domain	0	O
of	0	O
the	0	O
Myc	0	B
family	0	I
of	0	O
DNA	1	O
-	0	O
binding	0	O
proteins	0	O
.	0	O


An	1	O
additional	0	O
advantage	0	O
is	0	O
that	0	O
the	0	O
resin	0	O
can	0	O
be	0	O
removed	0	O
and	0	O
the	0	O
immunoperoxidase	0	B
technique	0	O
carried	0	O
out	0	O
on	0	O
thin	0	O
sections	0	O
.	0	O


The	0	O
chick	0	O
axon	0	O
-	0	O
associated	0	O
surface	0	O
glycoprotein	0	O
neurofascin	0	B
is	0	O
implicated	0	O
in	0	O
axonal	0	O
growth	0	O
and	0	O
fasciculation	0	O
as	0	O
revealed	0	O
by	0	O
antibody	0	O
perturbation	0	O
experiments	0	O
.	0	O


TIP30	0	B
has	0	O
an	0	O
intrinsic	0	O
kinase	0	O
activity	0	O
required	0	O
for	0	O
up	0	O
-	0	O
regulation	0	O
of	0	O
a	0	O
subset	0	O
of	0	O
apoptotic	0	O
genes	0	O
.	0	O


Metastasis	1	O
of	0	O
colon	0	O
carcinoma	0	O
to	0	O
the	0	O
lip	0	O
.	0	O


The	0	O
mutants	0	O
were	0	O
obtained	0	O
by	0	O
substitution	0	O
into	0	O
a	0	O
molecular	0	O
clone	0	O
of	0	O
M	1	O
-	0	O
MuLV	0	O
DNA	1	O
by	0	O
DNA	1	O
from	0	O
two	0	O
acutely	0	O
transforming	0	O
viruses	0	O
,	0	O
Ableson	0	O
MuLV	0	O
(	0	O
Ab	1	O
-	0	O
MuLV	0	O
)	0	O
and	0	O
Moloney	0	O
murine	0	O
sarcoma	0	O
virus	0	O
(	0	O
M	1	O
-	0	O
MSV	1	O
).	0	O


It	1	O
then	0	O
merged	0	O
with	0	O
right	0	O
ventricular	0	O
wavefronts	0	O
ending	0	O
along	0	O
the	0	O
right	0	O
ventricular	0	O
anterior	0	O
atrioventricular	0	O
groove	0	O
and	0	O
outflow	0	O
tract	0	O
.	0	O


This	0	O
open	0	O
reading	0	O
frame	0	O
was	0	O
confirmed	0	O
the	0	O
correct	0	O
one	0	O
by	0	O
direct	0	O
amino	0	O
-	0	O
terminal	0	O
sequence	0	O
analysis	0	O
of	0	O
the	0	O
overproduced	0	O
msgB	0	B
gene	0	I
product	0	I
.	0	O


The	0	O
presence	0	O
of	0	O
cutaneous	0	O
xanthomas	0	O
with	0	O
normal	0	O
serum	0	O
lipid	0	O
levels	0	O
is	0	O
due	0	O
to	0	O
the	0	O
antibetalipoproteic	0	O
activity	0	O
of	0	O
the	0	O
monoclonal	0	B
immunoglobulin	0	I
.	0	O


In	1	O
both	0	O
groups	0	O
there	0	O
were	0	O
5	0	O
management	0	O
failure	0	O
of	0	O
therapy	0	O
,	0	O
so	0	O
that	0	O
alternative	0	O
medication	0	O
or	0	O
a	0	O
cesarean	0	O
section	0	O
lead	0	O
to	0	O
delivery	0	O
.	0	O


To	1	O
identify	0	O
these	0	O
sites	0	O
,	0	O
Cdk2	0	B
-	0	O
phosphorylated	0	O
MARCKS	0	B
was	0	O
digested	0	O
with	0	O
lysyl	0	B
endoprotease	0	I
and	0	O
analysed	0	O
by	0	O
electrospray	0	O
MS	1	O
.	0	O


Endorphins	0	B
and	0	O
legal	0	O
issues	0	O
.	0	O


Psychiatric	1	O
disorders	0	O
in	0	O
children	0	O
and	0	O
adolescents	0	O
carry	0	O
considerable	0	O
morbidity	0	O
,	0	O
impede	0	O
development	0	O
,	0	O
and	0	O
carry	0	O
a	0	O
significant	0	O
mortality	0	O
by	0	O
suicide	0	O
.	0	O


Clinical	1	O
findings	0	O
were	0	O
:	0	O
height	0	O
183	0	O
cm	0	O
,	0	O
weight	0	O
62	0	O
kg	0	O
,	0	O
increased	0	O
length	0	O
of	0	O
lower	0	O
limbs	0	O
,	0	O
P2	1	O
-	0	O
A2	1	O
pilosity	0	O
and	0	O
micropenis	0	O
.	0	O


Using	0	O
a	0	O
conditional	0	O
-	0	O
lethal	0	O
mutant	0	O
allele	0	O
of	0	O
SUP45	0	B
(	0	O
sup45	0	B
-	0	I
2	0	I
)	0	O
and	0	O
a	0	O
combination	0	O
of	0	O
in	0	O
vivo	0	O
and	0	O
in	0	O
vitro	0	O
approaches	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
the	0	O
product	0	O
of	0	O
the	0	O
SUP45	0	B
gene	0	I
(	0	O
Sup45p	0	B
or	0	O
eRF1	0	B
)	0	O
is	0	O
a	0	O
factor	0	O
required	0	O
for	0	O
translation	0	O
termination	0	O
in	0	O
yeast	0	O
.	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
characterization	0	O
is	0	O
given	0	O
of	0	O
clinical	0	O
and	0	O
biochemical	0	O
features	0	O
of	0	O
VH	1	O
B	1	O
course	0	O
against	0	O
the	0	O
background	0	O
of	0	O
narcomania	0	O
.	0	O


Neither	0	O
RD19	0	B
nor	0	O
RD21	0	B
mRNA	1	I
synthesis	0	O
was	0	O
responsive	0	O
to	0	O
cold	0	O
or	0	O
to	0	O
heat	0	O
stress	0	O
.	0	O


Pulmonary	1	O
hypertension	0	O
,	0	O
with	0	O
or	0	O
without	0	O
coronary	0	O
arterial	0	O
narrowing	0	O
,	0	O
is	0	O
the	0	O
major	0	O
condition	0	O
leading	0	O
to	0	O
isolated	0	O
atrial	0	O
infarction	0	O
.	0	O


The	0	O
human	0	B
immunodeficiency	0	I
virus	0	I
type	0	I
-	0	I
1	0	I
(	0	I
HIV	1	I
-	0	I
1	0	I
)	0	I
Tat	1	I
protein	0	I
regulates	0	O
transcription	0	O
by	0	O
stimulating	0	O
RNA	1	B
polymerase	0	I
processivity	0	O
.	0	O


We	0	O
have	0	O
characterized	0	O
a	0	O
panel	0	O
of	0	O
6	0	O
monoclonal	0	O
antibodies	0	O
raised	0	O
against	0	O
human	0	B
platelet	0	I
talin	0	I
by	0	O
Western	0	O
blotting	0	O
,	0	O
immune	0	O
precipitation	0	O
,	0	O
and	0	O
immunofluorescence	0	O
,	0	O
and	0	O
shown	0	O
that	0	O
antibodies	0	B
TA205	0	I
and	0	O
TD77	0	B
disrupt	0	O
actin	0	B
stress	0	O
fibers	0	O
and	0	O
focal	0	O
adhesions	0	O
,	0	O
and	0	O
inhibit	0	O
cell	0	O
motility	0	O
when	0	O
microinjected	0	O
into	0	O
human	0	O
fibroblasts	0	O
.	0	O


We	0	O
have	0	O
thus	0	O
identified	0	O
the	0	O
first	0	O
mammalian	0	B
homolog	0	I
of	0	I
yeast	0	I
UPF1	0	I
,	0	O
a	0	O
protein	0	O
that	0	O
regulates	0	O
levels	0	O
of	0	O
nonsense	0	O
mRNA	1	O
,	0	O
and	0	O
we	0	O
tentatively	0	O
name	0	O
this	0	O
protein	0	O
human	0	B
HUPF1	0	I
(	0	O
for	0	O
human	0	B
homolog	0	I
of	0	I
UPF1	0	I
).	0	O


CYC2	0	B
encodes	0	O
a	0	O
24	0	O
-	0	O
kDa	1	O
protein	0	O
that	0	O
has	0	O
sequence	0	O
identity	0	O
to	0	O
the	0	O
Neurospora	1	B
crassa	0	I
PREG1	0	I
and	0	O
the	0	O
S	1	B
.	0	I
cerevisiae	0	I
PHO80	0	I
cyclin	0	I
.	0	O


This	0	O
report	0	O
focused	0	O
on	0	O
the	0	O
relationship	0	O
between	0	O
Type	1	O
A	1	O
behavior	0	O
and	0	O
eight	0	O
basic	0	O
emotion	0	O
dimensions	0	O
.	0	O


Our	0	O
results	0	O
establish	0	O
GKLF	0	B
as	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
transcription	0	O
factor	0	O
likely	0	O
involved	0	O
in	0	O
regulation	0	O
of	0	O
expression	0	O
of	0	O
endogenous	0	O
genes	0	O
.	0	O


The	0	O
case	0	O
for	0	O
completing	0	O
the	0	O
lymphadenectomy	0	O
when	0	O
positive	0	O
lymph	0	O
nodes	0	O
are	0	O
found	0	O
during	0	O
radical	0	O
hysterectomy	0	O
for	0	O
cervical	0	O
carcinoma	0	O
.	0	O


Judicious	0	O
use	0	O
of	0	O
laboratory	0	O
testing	0	O
,	0	O
including	0	O
monitoring	0	O
of	0	O
CD4	1	B
cell	0	O
counts	0	O
,	0	O
is	0	O
recommended	0	O
.	0	O


CASE	1	O
REPORT	1	O
:	0	O
Referred	1	O
because	0	O
of	0	O
a	0	O
right	0	O
corneal	0	O
perforation	0	O
with	0	O
cellular	0	O
reaction	0	O
in	0	O
anterior	0	O
chamber	0	O
,	0	O
a	0	O
patient	0	O
was	0	O
sutured	0	O
and	0	O
treated	0	O
with	0	O
a	0	O
single	0	O
intravitreal	0	O
injection	0	O
of	0	O
0	0	O
.	0	O
2	0	O
ml	0	O
(	0	O
1	0	O
mg	0	O
)	0	O
Amikacin	1	O
and	0	O
0	0	O
.	0	O
2	0	O
ml	0	O
(	0	O
1	0	O
mg	0	O
)	0	O
Vancomycin	0	O
.	0	O


Transcripts	0	O
for	0	O
both	0	O
ODV	0	B
-	0	I
E18	0	I
and	0	O
ODV	0	B
-	0	I
EC27	0	I
initiate	0	O
from	0	O
conserved	0	O
TAAG	0	O
motifs	0	O
,	0	O
and	0	O
transcripts	0	O
are	0	O
detected	0	O
from	0	O
16	0	O
through	0	O
72	0	O
hr	0	O
p	0	O
.	0	O
i	0	O
.	0	O


Impaction	1	O
of	0	O
gastrostomy	0	O
tube	0	O
in	0	O
the	0	O
abdominal	0	O
wall	0	O
.	0	O


It	1	O
could	0	O
be	0	O
detected	0	O
exclusively	0	O
in	0	O
the	0	O
culture	0	O
medium	0	O
of	0	O
cDNA	1	O
-	0	O
transfected	0	O
COS	1	O
cells	0	O
.	0	O


The	0	O
management	0	O
of	0	O
the	0	O
"	0	O
chronic	0	O
"	0	O
patient	0	O
.	0	O


We	0	O
isolated	0	O
the	0	O
human	0	B
FGF	0	I
-	0	I
BP	1	I
promoter	0	I
and	0	O
determined	0	O
by	0	O
deletion	0	O
analysis	0	O
that	0	O
TPA	1	O
regulatory	0	O
elements	0	O
were	0	O
all	0	O
contained	0	O
in	0	O
the	0	O
first	0	O
118	0	O
base	0	O
pairs	0	O
upstream	0	O
of	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
.	0	O


Is	1	O
nisoldipine	0	O
capable	0	O
of	0	O
reducing	0	O
left	0	O
ventricular	0	O
preload	0	O
?	0	O
In	1	O
ten	0	O
anesthetized	0	O
pigs	0	O
,	0	O
nisoldipine	0	O
(	0	O
2	0	O
-	0	O
4	0	O
micrograms	0	O
X	1	O
kg	0	O
-	0	O
1	0	O
X	1	O
min	0	O
-	0	O
1	0	O
),	0	O
a	0	O
calcium	0	O
channel	0	O
blocker	0	O
structurally	0	O
related	0	O
to	0	O
nifedipine	0	O
,	0	O
reduced	0	O
left	0	O
ventricular	0	O
systolic	0	O
pressure	0	O
(	0	O
40	0	O
%)	0	O
and	0	O
systemic	0	O
vascular	0	O
resistance	0	O
(	0	O
35	0	O
%),	0	O
whereas	0	O
maxLVdP	0	O
/	0	O
dt	0	O
decreased	0	O
by	0	O
20	0	O
%	0	O
and	0	O
cardiac	0	O
output	0	O
was	0	O
unchanged	0	O
.	0	O


The	0	O
genes	0	O
encoding	0	O
(	0	B
2Fe	0	I
-	0	I
2S	0	I
)	0	I
plant	0	I
-	0	I
like	0	I
ferredoxins	0	I
were	0	O
studied	0	O
in	0	O
the	0	O
widely	0	O
used	0	O
cyanobacterium	0	O
Synechocystis	0	O
PCC6803	0	O
.	0	O


Collectively	0	O
,	0	O
the	0	O
results	0	O
suggest	0	O
that	0	O
ARF	1	B
binding	0	O
to	0	O
Mdm2	0	B
induces	0	O
a	0	O
conformational	0	O
change	0	O
that	0	O
facilitates	0	O
nucleolar	0	O
import	0	O
of	0	O
the	0	O
ARF	1	B
-	0	O
Mdm2	0	B
complex	0	O
and	0	O
p53	0	B
-	0	O
dependent	0	O
cell	0	O
cycle	0	O
arrest	0	O
.	0	O


High	0	O
trough	0	O
serum	0	O
TOB	0	O
concentrations	0	O
were	0	O
associated	0	O
with	0	O
death	0	O
and	0	O
very	0	O
low	0	O
levels	0	O
with	0	O
recovery	0	O
.	0	O


As	1	O
no	0	O
complete	0	O
PPARgamma	0	B
antagonists	0	O
have	0	O
been	0	O
described	0	O
hitherto	0	O
,	0	O
we	0	O
have	0	O
constructed	0	O
a	0	O
dominant	0	O
-	0	O
negative	0	O
mutant	0	O
receptor	0	O
to	0	O
inhibit	0	O
wild	0	O
-	0	O
type	0	O
PPARgamma	0	B
action	0	O
.	0	O


Of	0	O
115	0	O
hepatitis	0	O
B	1	O
patients	0	O
seen	0	O
at	0	O
12	0	O
months	0	O
,	0	O
6	0	O
%	0	O
had	0	O
chronic	0	O
hepatitis	0	O
Bs	1	O
antigenaemia	0	O
,	0	O
60	0	O
%	0	O
had	0	O
developed	0	O
anti	0	B
-	0	I
HBs	1	I
antibodies	0	I
,	0	O
and	0	O
7	0	O
.	0	O
3	0	O
%	0	O
still	0	O
had	0	O
abnormal	0	O
liver	0	O
function	0	O
.	0	O


Possible	0	O
relationship	0	O
between	0	O
hyperinsulinemia	0	O
and	0	O
glomerular	0	O
hypertrophy	0	O
in	0	O
nephrosclerosis	0	O
.	0	O


Thromboplastin	1	B
time	0	O
,	0	O
partial	0	O
thromboplastin	0	B
time	0	O
,	0	O
thrombin	0	B
time	0	O
,	0	O
heat	0	O
-	0	O
dependent	0	O
fibrin	0	B
,	0	O
clot	0	O
retraction	0	O
,	0	O
and	0	O
clotting	0	B
factors	0	I
II	0	I
,	0	I
V	1	I
,	0	I
VIII	0	I
,	0	I
IX	0	I
,	0	I
X	1	I
,	0	O
and	0	O
the	0	O
platelet	0	O
count	0	O
were	0	O
determined	0	O
.	0	O


Various	0	O
transcripts	0	O
are	0	O
generated	0	O
from	0	O
the	0	O
VCSA1	0	B
gene	0	I
by	0	O
alternative	0	O
splicing	0	O
and	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
processing	0	O
in	0	O
the	0	O
rat	0	O
submandibular	0	O
gland	0	O
.	0	O


Using	0	O
a	0	O
series	0	O
of	0	O
mutant	0	B
T	1	I
antigens	0	I
expressed	0	O
by	0	O
recombinant	0	O
baculoviruses	0	O
in	0	O
Sf9	0	O
cells	0	O
,	0	O
we	0	O
find	0	O
that	0	O
the	0	O
origin	0	O
unwinding	0	O
activities	0	O
of	0	O
both	0	O
TS677	0	O
-->	0	O
A	1	O
and	0	O
TS677	0	O
,	0	O
679	0	O
-->	0	O
A	1	O
are	0	O
inhibited	0	O
by	0	O
the	0	O
T	1	B
-	0	I
antigen	0	I
kinase	0	I
,	0	O
as	0	O
is	0	O
wild	0	B
-	0	I
type	0	I
T	1	I
antigen	0	I
.	0	O


The	0	O
Cdk2	0	B
-	0	O
cyclin	0	B
-	0	I
D1	1	I
complex	0	O
did	0	O
not	0	O
phosphorylate	0	O
any	0	O
tested	0	O
substrates	0	O
,	0	O
such	0	O
as	0	O
H1	1	B
histone	0	I
,	0	O
pRB	0	B
,	0	O
SV40	1	B
large	0	I
T	1	I
antigen	0	I
,	0	O
p53	0	B
,	0	O
E2F	0	B
-	0	I
1	0	I
or	0	O
a	0	O
preparation	0	O
of	0	O
nuclear	0	O
proteins	0	O
from	0	O
HeLa	0	O
cells	0	O
;	0	O
in	0	O
contrast	0	O
,	0	O
Cdk2	0	B
-	0	O
cyclin	0	B
-	0	I
E	1	I
and	0	O
Cdk2	0	B
-	0	O
cyclin	0	B
-	0	I
A	1	I
phosphorylated	0	O
these	0	O
proteins	0	O
.	0	O


NUP145	0	B
was	0	O
previously	0	O
identified	0	O
by	0	O
using	0	O
a	0	O
genetic	0	O
synthetic	0	O
lethal	0	O
screen	0	O
(	0	O
E	1	O
.	0	O


Shc	0	B
stimulates	0	O
Ras	1	B
/	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
(	0	O
MAPK	1	B
)	0	O
through	0	O
forming	0	O
a	0	O
complex	0	O
with	0	O
Grb2	0	B
at	0	O
the	0	O
phosphorylated	0	O
tyrosine	0	O
(	0	O
Y	1	O
)	0	O
residue	0	O
317	0	O
.	0	O


SFP	0	O
was	0	O
significantly	0	O
elevated	0	O
in	0	O
Hn	0	O
(	0	O
s	0	O
).	0	O


NF	1	B
-	0	I
kappaB	0	I
is	0	O
a	0	O
redox	0	O
-	0	O
sensitive	0	O
transcription	0	O
factor	0	O
known	0	O
to	0	O
be	0	O
activated	0	O
by	0	O
oxidative	0	O
stress	0	O
as	0	O
well	0	O
as	0	O
chemical	0	O
and	0	O
biological	0	O
reductants	0	O
.	0	O


To	1	O
get	0	O
further	0	O
insights	0	O
into	0	O
the	0	O
molecular	0	O
mechanisms	0	O
that	0	O
control	0	O
tal	0	B
-	0	I
1	0	I
expression	0	O
,	0	O
we	0	O
have	0	O
isolated	0	O
5	0	O
'	0	O
sequences	0	O
of	0	O
the	0	O
murine	0	O
gene	0	O
and	0	O
compared	0	O
them	0	O
to	0	O
their	0	O
human	0	O
counterparts	0	O
.	0	O


Genetic	1	O
analysis	0	O
has	0	O
subsequently	0	O
identified	0	O
subpathways	0	O
of	0	O
the	0	O
DNA	1	O
structure	0	O
checkpoints	0	O
,	0	O
including	0	O
the	0	O
reversible	0	O
arrest	0	O
of	0	O
DNA	1	O
synthesis	0	O
.	0	O


This	0	O
mechanism	0	O
is	0	O
in	0	O
contrast	0	O
to	0	O
other	0	O
cases	0	O
of	0	O
splicing	0	O
regulation	0	O
by	0	O
PTB	0	B
,	0	O
in	0	O
which	0	O
the	0	O
protein	0	O
represses	0	O
the	0	O
splice	0	O
site	0	O
to	0	O
which	0	O
it	0	O
binds	0	O
.	0	O


The	0	O
method	0	O
also	0	O
eliminates	0	O
tagging	0	O
of	0	O
venous	0	O
spins	0	O
and	0	O
concern	0	O
about	0	O
asymmetric	0	O
magnetization	0	O
transfer	0	O
effects	0	O
.	0	O


Fraction	1	O
2	0	O
contains	0	O
1	0	O
,	0	O
25	0	O
(	0	O
OH	0	O
)	0	O
2	0	O
-	0	O
vitamin	0	O
D3	0	O
,	0	O
vitamin	0	O
D3	0	O
,	0	O
25	0	O
(	0	O
OH	0	O
)-	0	O
vitamin	0	O
D3	0	O
and	0	O
1	0	O
,	0	O
24	0	O
,	0	O
25	0	O
(	0	O
OH	0	O
)	0	O
3	0	O
-	0	O
vitamin	0	O
D3	0	O
.	0	O


Basal	1	O
midexpiratory	0	O
lower	0	O
esophageal	0	O
sphincter	0	O
pressure	0	O
was	0	O
similar	0	O
in	0	O
the	0	O
study	0	O
group	0	O
(	0	O
mean	0	O
[	0	O
SD	1	O
]	0	O
20	0	O
.	0	O
1	0	O
[	0	O
9	0	O
.	0	O
1	0	O
]	0	O
mmHg	0	O
)	0	O
and	0	O
controls	0	O
(	0	O
17	0	O
.	0	O
6	0	O
[	0	O
6	0	O
.	0	O
0	0	O
]	0	O
mmHg	0	O
);	0	O
the	0	O
pressure	0	O
did	0	O
not	0	O
change	0	O
following	0	O
EVS	0	O
or	0	O
EVL	0	O
.	0	O


E	1	O
.,	0	O
Scott	0	O
,	0	O
J	1	O
.	0	O


Proteolysis	1	O
of	0	O
Mbp1	0	B
and	0	O
Swi4	0	B
DNA	1	I
-	0	I
protein	0	I
complexes	0	I
has	0	O
revealed	0	O
the	0	O
extent	0	O
of	0	O
these	0	O
sequences	0	O
,	0	O
and	0	O
C	1	O
-	0	O
terminally	0	O
extended	0	O
molecules	0	O
with	0	O
substantially	0	O
enhanced	0	O
DNA	1	O
binding	0	O
activity	0	O
compared	0	O
to	0	O
the	0	O
core	0	O
domains	0	O
alone	0	O
have	0	O
been	0	O
produced	0	O
.	0	O


That	0	O
of	0	O
the	0	O
T2	0	B
gene	0	I
contains	0	O
numerous	0	O
potential	0	O
sites	0	O
for	0	O
binding	0	O
the	0	O
mammalian	0	B
transcription	0	I
factor	0	I
SP1	0	I
,	0	O
but	0	O
no	0	O
TATA	0	O
or	0	O
CCAAT	0	O
sequences	0	O
are	0	O
evident	0	O
near	0	O
to	0	O
its	0	O
5	0	O
'	0	O
end	0	O
,	0	O
although	0	O
these	0	O
latter	0	O
features	0	O
are	0	O
associated	0	O
with	0	O
the	0	O
human	0	B
T1	1	I
gene	0	I
.	0	O


The	0	O
genome	0	O
of	0	O
Thogoto	0	O
virus	0	O
comprises	0	O
six	0	O
segments	0	O
of	0	O
single	0	O
-	0	O
stranded	0	O
,	0	O
negative	0	O
sense	0	O
RNA	1	O
.	0	O


Sequencing	1	O
of	0	O
a	0	O
1	0	O
.	0	O
3	0	O
-	0	O
kilobase	0	O
fragment	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
TSG6	0	B
gene	0	I
identified	0	O
TATA	0	O
-	0	O
like	0	O
and	0	O
CAAT	0	O
sequences	0	O
near	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
.	0	O


Similar	0	O
observations	0	O
were	0	O
made	0	O
with	0	O
unilateral	0	O
pneumothorax	0	O
of	0	O
15	0	O
cmH2O	0	O
for	0	O
30	0	O
min	0	O
.	0	O


Hypersplenism	1	O


In	1	O
agreement	0	O
with	0	O
previous	0	O
in	0	O
vitro	0	O
data	0	O
,	0	O
we	0	O
have	0	O
shown	0	O
that	0	O
UmuD	0	B
and	0	O
UmuD	0	B
'	0	I
are	0	O
able	0	O
to	0	O
form	0	O
both	0	O
homodimers	0	O
(	0	O
UmuD	0	B
-	0	O
UmuD	0	B
and	0	O
UmuD	0	O
'-	0	O
UmuD	0	O
')	0	O
and	0	O
a	0	O
heterodimer	0	O
(	0	O
UmuD	0	B
-	0	O
UmuD	0	O
').	0	O


From	0	O
the	0	O
National	0	O
Institutes	0	O
of	0	O
Health	1	O
.	0	O


When	0	O
Hy	0	O
-	0	O
Vac	1	O
SPF	1	O
type	0	O
V	1	O
embryos	0	O
were	0	O
exposed	0	O
to	0	O
either	0	O
0	0	O
.	0	O
20	0	O
ml	0	O
50	0	O
%	0	O
ethanol	0	O
in	0	O
CRS	0	O
or	0	O
to	0	O
0	0	O
.	0	O
20	0	O
ml	0	O
CRS	0	O
(	0	O
controls	0	O
),	0	O
ethanol	0	O
-	0	O
treated	0	O
embryos	0	O
showed	0	O
a	0	O
VSD	1	O
incidence	0	O
of	0	O
34	0	O
.	0	O
1	0	O
%	0	O
compared	0	O
with	0	O
a	0	O
3	0	O
.	0	O
6	0	O
%	0	O
incidence	0	O
in	0	O
the	0	O
controls	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
0017	0	O
).	0	O


Increased	0	O
PTHRP	0	B
production	0	O
by	0	O
a	0	O
tyrosine	0	B
kinase	0	I
oncogene	0	I
,	0	O
Tpr	1	B
-	0	I
Met	1	I
:	0	O
role	0	O
of	0	O
the	0	O
Ras	1	B
signaling	0	O
pathway	0	O
.	0	O


Grade	1	O
3	0	O
mucositis	0	O
was	0	O
reported	0	O
in	0	O
1	0	O
patient	0	O
.	0	O


In	1	O
mammalian	0	O
cells	0	O
,	0	O
phosphorylation	0	O
of	0	O
eIF	0	B
-	0	I
2	0	I
alpha	0	I
inhibits	0	O
the	0	O
activity	0	O
of	0	O
eIF	0	B
-	0	I
2B	0	I
,	0	O
the	0	O
GDP	1	B
-	0	I
GTP	1	I
exchange	0	I
factor	0	I
for	0	O
eIF	0	B
-	0	I
2	0	I
.	0	O


Methods	0	O
used	0	O
include	0	O
Cobb	0	O
angle	0	O
and	0	O
a	0	O
segmental	0	O
evaluation	0	O
(	0	O
T7	0	O
-	0	O
T12	0	O
)	0	O
of	0	O
each	0	O
of	0	O
convex	0	O
and	0	O
concave	0	O
rib	0	O
-	0	O
vertebra	0	O
angles	0	O
(	0	O
RVAs	0	O
),	0	O
rib	0	O
-	0	O
vertebra	0	O
angle	0	O
differences	0	O
(	0	O
RVADs	0	O
),	0	O
vertebral	0	O
rotation	0	O
,	0	O
tilt	0	O
and	0	O
displacement	0	O
.	0	O


Liver	1	O
injuries	0	O


Video	0	O
images	0	O
of	0	O
the	0	O
nostrils	0	O
were	0	O
captured	0	O
and	0	O
then	0	O
analyzed	0	O
for	0	O
area	0	O
,	0	O
perimeter	0	O
,	0	O
centroid	0	O
,	0	O
principal	0	O
axis	0	O
,	0	O
moments	0	O
about	0	O
the	0	O
major	0	O
and	0	O
minor	0	O
axes	0	O
(	0	O
I11	0	O
,	0	O
I22	0	O
),	0	O
anisometry	0	O
,	0	O
bulkiness	0	O
,	0	O
lateral	0	O
offset	0	O
,	0	O
internostril	0	O
angle	0	O
,	0	O
and	0	O
rotational	0	O
angle	0	O
.	0	O


The	0	O
present	0	O
study	0	O
examined	0	O
the	0	O
dependence	0	O
of	0	O
difference	0	O
tone	0	O
level	0	O
[	0	O
L	1	O
(	0	O
f2	0	O
-	0	O
f1	0	O
)]	0	O
on	0	O
the	0	O
following	0	O
parameters	0	O
of	0	O
the	0	O
two	0	O
-	0	O
tone	0	O
input	0	O
:	0	O
f1	0	O
,	0	O
f2	0	O
/	0	O
f1	0	O
(	0	O
f2	0	O
greater	0	O
than	0	O
f1	0	O
),	0	O
L1	0	O
,	0	O
L2	0	O
,	0	O
and	0	O
L1	0	O
=	0	O
L2	0	O
.	0	O


Interferon	1	B
Regulatory	1	I
Factor	1	I
(	0	I
IRF	1	I
)-	0	I
1	0	I
has	0	O
been	0	O
characterized	0	O
as	0	O
an	0	O
important	0	O
growth	0	O
regulatory	0	O
and	0	O
immunomodulatory	0	O
transcription	0	O
factor	0	O
.	0	O


Consistent	0	O
with	0	O
our	0	O
model	0	O
,	0	O
CTCF	0	B
binding	0	O
is	0	O
abolished	0	O
by	0	O
DNA	1	O
methylation	0	O
.	0	O


This	0	O
paper	0	O
reviews	0	O
the	0	O
middleware	0	O
-	0	O
based	0	O
approach	0	O
adopted	0	O
by	0	O
CEN	1	O
ENV	0	O
12967	0	O
-	0	O
1	0	O
and	0	O
the	0	O
specialisation	0	O
necessary	0	O
for	0	O
the	0	O
healthcare	0	O
record	0	O
based	0	O
on	0	O
CEN	1	O
ENV	0	O
12265	0	O
'	0	O
Electronic	1	O
Healthcare	0	O
Record	1	O
Architecture	0	O
'.	0	O


The	0	O
structure	0	O
of	0	O
digiprogenin	0	O
.	0	O


Relatively	0	O
little	0	O
is	0	O
known	0	O
regarding	0	O
the	0	O
role	0	O
of	0	O
5	0	B
-	0	I
HT2	0	I
receptor	0	I
activity	0	O
in	0	O
male	0	O
rat	0	O
sexual	0	O
behavior	0	O
.	0	O


Five	0	O
of	0	O
these	0	O
eight	0	O
patients	0	O
in	0	O
group	0	O
II	0	O
also	0	O
received	0	O
8	0	O
-	0	O
in	0	O
-	0	O
1	0	O
chemotherapy	0	O
.	0	O


The	0	O
results	0	O
point	0	O
to	0	O
the	0	O
effectiveness	0	O
of	0	O
the	0	O
educational	0	O
intervention	0	O
.	0	O


The	0	O
microphthalmia	0	B
-	0	I
TFE	0	I
(	0	O
MiT	1	B
)	0	O
subfamily	0	O
of	0	O
basic	0	B
helix	0	I
-	0	I
loop	0	I
-	0	I
helix	0	I
leucine	0	I
zipper	0	I
(	0	I
bHLH	0	I
-	0	I
ZIP	0	I
)	0	I
transcription	0	I
factors	0	I
,	0	O
including	0	O
TFE3	0	B
,	0	O
TFEB	0	B
,	0	O
TFEC	0	B
,	0	O
and	0	O
Mitf	0	B
,	0	O
has	0	O
been	0	O
implicated	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
tissue	0	O
-	0	O
specific	0	O
gene	0	O
expression	0	O
in	0	O
several	0	O
cell	0	O
lineages	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
G	1	B
beta	0	I
gamma	0	I
-	0	O
stimulated	0	O
Shc	0	B
phosphorylation	0	O
represents	0	O
an	0	O
early	0	O
step	0	O
in	0	O
the	0	O
pathway	0	O
leading	0	O
to	0	O
p21ras	0	B
activation	0	O
,	0	O
similar	0	O
to	0	O
the	0	O
mechanism	0	O
utilized	0	O
by	0	O
growth	0	B
factor	0	I
tyrosine	0	I
kinase	0	I
receptors	0	I
.	0	O


These	0	O
results	0	O
demonstrate	0	O
that	0	O
although	0	O
PI2	0	O
and	0	O
PI3	0	O
viruses	0	O
belong	0	O
to	0	O
the	0	O
same	0	O
parainfluenza	0	O
virus	0	O
genus	0	O
,	0	O
these	0	O
viruses	0	O
show	0	O
marked	0	O
differences	0	O
with	0	O
respect	0	O
to	0	O
functional	0	O
requirements	0	O
for	0	O
the	0	O
cytoplasmic	0	O
tail	0	O
of	0	O
the	0	O
F	1	B
glycoprotein	0	I
.	0	O


The	0	O
histidine	0	O
-	0	O
tagged	0	O
gene	0	O
,	0	O
rpoCHIS	0	B
,	0	O
was	0	O
used	0	O
to	0	O
replace	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
allele	0	O
in	0	O
the	0	O
chromosome	0	O
of	0	O
S	1	O
.	0	O
coelicolor	0	O
and	0	O
S	1	O
.	0	O
lividans	0	O
.	0	O


Sequence	1	O
analysis	0	O
revealed	0	O
that	0	O
in	0	O
addition	0	O
to	0	O
the	0	O
non	0	O
-	0	O
spliced	0	O
variant	0	O
,	0	O
multiple	0	O
mRNA	1	O
species	0	O
were	0	O
generated	0	O
by	0	O
alternative	0	O
splicing	0	O
resulting	0	O
in	0	O
the	0	O
exclusion	0	O
of	0	O
92	0	O
,	0	O
166	0	O
,	0	O
170	0	O
,	0	O
174	0	O
and	0	O
263	0	O
nucleotides	0	O
(	0	O
nt	0	O
),	0	O
respectively	0	O
,	0	O
from	0	O
exon	0	O
1	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
bovine	0	B
PEDF	0	I
cDNA	1	I
isolated	0	O
here	0	O
codes	0	O
for	0	O
a	0	O
functional	0	O
soluble	0	O
secreted	0	B
PEDF	0	I
glycoprotein	0	I
.	0	O


Positive	1	O
correlations	0	O
were	0	O
seen	0	O
between	0	O
the	0	O
measurements	0	O
for	0	O
protein	0	O
intake	0	O
(	0	O
r	0	O
=.	0	O
58	0	O
,	0	O
P	1	O
=.	0	O
0026	0	O
)	0	O
energy	0	O
intake	0	O
(	0	O
r	0	O
=.	0	O
78	0	O
,	0	O
P	1	O
<.	0	O
00001	0	O
),	0	O
with	0	O
mean	0	O
differences	0	O
of	0	O
.	0	O
066	0	O
g	0	O
/	0	O
kg	0	O
/	0	O
d	0	O
(	0	O
SD	1	O
.	0	O
38	0	O
)	0	O
2	0	O
.	0	O
04	0	O
kcal	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
(	0	O
SD	1	O
6	0	O
.	0	O
67	0	O
),	0	O
respectively	0	O
.	0	O


The	0	O
murine	0	B
Mov	1	I
-	0	I
34	0	I
gene	0	I
:	0	O
full	0	O
-	0	O
length	0	O
cDNA	1	O
and	0	O
genomic	0	O
organization	0	O
.	0	O


This	0	O
demonstrates	0	O
that	0	O
treatment	0	O
of	0	O
the	0	O
graft	0	O
recipient	0	O
for	0	O
a	0	O
relatively	0	O
short	0	O
period	0	O
during	0	O
and	0	O
after	0	O
surgery	0	O
has	0	O
a	0	O
favorable	0	O
effect	0	O
on	0	O
the	0	O
survival	0	O
of	0	O
grafted	0	O
dopaminergic	0	O
neurons	0	O
.	0	O


Platelet	1	B
-	0	I
derived	0	I
growth	0	I
factor	0	I
-	0	O
dependent	0	O
activation	0	O
of	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
is	0	O
regulated	0	O
by	0	O
receptor	0	O
binding	0	O
of	0	O
SH2	0	B
-	0	I
domain	0	I
-	0	I
containing	0	I
proteins	0	I
which	0	O
influence	0	O
Ras	1	B
activity	0	O
.	0	O


All	1	O
89	0	O
participating	0	O
household	0	O
members	0	O
were	0	O
anti	0	B
-	0	I
HIV	1	I
seronegative	0	O
,	0	O
and	0	O
78	0	O
who	0	O
were	0	O
tested	0	O
were	0	O
serum	0	B
p24	0	I
antigen	0	I
negative	0	O
.	0	O


Fgd3	0	B
and	0	O
FGD1	0	B
share	0	O
a	0	O
high	0	O
degree	0	O
of	0	O
sequence	0	O
identity	0	O
that	0	O
spans	0	O
>	0	O
560	0	O
contiguous	0	O
amino	0	O
acid	0	O
residues	0	O
.	0	O


PTP	0	B
-	0	I
S3	1	I
differs	0	O
from	0	O
PTP	0	B
-	0	I
S4	1	I
in	0	O
having	0	O
a	0	O
deletion	0	O
of	0	O
19	0	O
amino	0	O
acids	0	O
corresponding	0	O
to	0	O
exon	0	O
E1	1	O
.	0	O


These	0	O
studies	0	O
show	0	O
that	0	O
UCRBP	0	B
binds	0	O
to	0	O
various	0	O
target	0	O
motifs	0	O
that	0	O
are	0	O
distinct	0	O
from	0	O
the	0	O
UCR	0	O
motif	0	O
:	0	O
the	0	O
adeno	0	B
-	0	I
associated	0	I
virus	0	I
P5	0	I
promoter	0	I
and	0	O
elements	0	O
in	0	O
the	0	O
immunoglobulin	0	B
light	0	I
-	0	I
and	0	I
heavy	0	I
-	0	I
chain	0	I
genes	0	O
,	0	O
as	0	O
well	0	O
as	0	O
elements	0	O
in	0	O
ribosomal	0	B
protein	0	I
genes	0	I
.	0	O


Binding	0	O
of	0	O
SSP	0	B
to	0	O
the	0	O
stage	0	B
selector	0	I
element	0	I
(	0	O
SSE	1	B
)	0	O
in	0	O
the	0	O
proximal	0	O
gamma	0	B
-	0	I
globin	0	I
promoter	0	I
is	0	O
integral	0	O
to	0	O
the	0	O
competitive	0	O
silencing	0	O
of	0	O
a	0	O
linked	0	O
beta	0	B
-	0	I
promoter	0	I
in	0	O
embryonic	0	O
/	0	O
fetal	0	O
stage	0	O
erythroleukemia	0	O
(	0	O
K562	0	O
)	0	O
cells	0	O
.	0	O


Following	1	O
the	0	O
results	0	O
of	0	O
toxicological	0	O
experiments	0	O
in	0	O
the	0	O
target	0	O
animals	0	O
"	0	O
Toxicological	0	O
Drinking	0	O
Water	1	O
Standards	0	O
for	0	O
Animals	0	O
"	0	O
can	0	O
be	0	O
established	0	O
.	0	O


A	1	O
distinct	0	O
staining	0	O
pattern	0	O
for	0	O
the	0	O
N	1	B
-	0	I
utrophin	0	I
was	0	O
not	0	O
detectable	0	O
,	0	O
although	0	O
it	0	O
was	0	O
expected	0	O
to	0	O
localise	0	O
at	0	O
the	0	O
actin	0	B
stress	0	O
fibers	0	O
.	0	O


Natl	0	O
.	0	O


Transgenic	1	O
mice	0	O
harboring	0	O
the	0	O
rat	0	O
TnI	0	B
-	0	O
CAT	1	B
fusion	0	O
gene	0	O
expressed	0	O
the	0	O
reporter	0	O
specifically	0	O
in	0	O
the	0	O
skeletal	0	O
muscle	0	O
.	0	O


This	0	O
300	0	O
bp	0	O
5	0	O
'-	0	O
upstream	0	O
sequence	0	O
of	0	O
K3	0	B
keratin	0	I
gene	0	I
,	0	O
which	0	O
can	0	O
function	0	O
in	0	O
vitro	0	O
as	0	O
a	0	O
keratinocyte	0	O
-	0	O
specific	0	O
promoter	0	O
,	0	O
contains	0	O
two	0	O
clusters	0	O
of	0	O
partially	0	O
overlapping	0	O
motifs	0	O
,	0	O
one	0	O
with	0	O
an	0	O
NFkB	0	B
consensus	0	O
sequence	0	O
and	0	O
another	0	O
with	0	O
a	0	O
GC	1	O
box	0	O
.	0	O


These	0	O
repressor	0	O
sites	0	O
are	0	O
pyrimidine	0	O
rich	0	O
and	0	O
bind	0	O
avidly	0	O
to	0	O
the	0	O
polypyrimidine	0	B
tract	0	I
binding	0	I
protein	0	I
(	0	O
PTB	0	B
)	0	O
in	0	O
HeLa	0	O
nuclear	0	O
extracts	0	O
as	0	O
determined	0	O
by	0	O
UV	1	O
crosslinking	0	O
/	0	O
competition	0	O
assays	0	O
.	0	O


We	0	O
investigated	0	O
the	0	O
incidence	0	O
of	0	O
congenital	0	O
color	0	O
deficiency	0	O
among	0	O
Koreans	0	O
by	0	O
the	0	O
use	0	O
of	0	O
H	1	O
-	0	O
R	1	O
-	0	O
R	1	O
pseudoisochromatic	0	O
plates	0	O
.	0	O


Scintigraphic	0	O
visualisation	0	O
of	0	O
Walker	1	O
carcinoma	0	O
-	0	O
256	0	O
in	0	O
Sprague	0	O
-	0	O
Dawley	0	O
rats	0	O
by	0	O
means	0	O
of	0	O
99mTc	0	O
-	0	O
labelled	0	O
monocytes	0	O
.	0	O


Thus	0	O
,	0	O
a	0	O
negative	0	O
test	0	O
is	0	O
compatible	0	O
with	0	O
low	0	O
disease	0	O
activity	0	O
and	0	O
/	0	O
or	0	O
efficacy	0	O
of	0	O
calcium	0	O
antagonist	0	O
treatment	0	O
.	0	O


Chaperones	0	O
/	0	O
HSPs	0	B
thus	0	O
play	0	O
important	0	O
roles	0	O
within	0	O
cell	0	O
cycle	0	O
processes	0	O
.	0	O


Replicating	0	O
simian	0	O
virus	0	O
40	0	O
(	0	O
SV40	1	O
)	0	O
chromosomes	0	O
were	0	O
found	0	O
to	0	O
be	0	O
similar	0	O
to	0	O
other	0	O
eukaryotic	0	O
chromosomes	0	O
in	0	O
that	0	O
the	0	O
rate	0	O
and	0	O
extent	0	O
of	0	O
micrococcal	0	B
nuclease	0	I
(	0	O
MNase	0	B
)	0	O
digestion	0	O
were	0	O
greater	0	O
with	0	O
replicating	0	O
than	0	O
with	0	O
nonreplicating	0	O
mature	0	O
SV40	1	O
chromatin	0	O
.	0	O


A	1	O
pyrazolo	0	O
-	0	O
quinoline	0	O
compound	0	O
,	0	O
6	0	O
-	0	O
methoxy	0	O
-	0	O
4	0	O
-[	0	O
2	0	O
-[(	0	O
2	0	O
-	0	O
hydroxyethoxyl	0	O
)-	0	O
ethyl	0	O
]	0	O
amino	0	O
]-	0	O
3	0	O
-	0	O
methyl	0	O
-	0	O
1M	0	O
-	0	O
pyrazo	0	O
lo	0	O
[	0	O
3	0	O
,	0	O
4	0	O
-	0	O
b	0	O
]	0	O
quinoline	0	O
(	0	O
SCH	0	O
51344	0	O
),	0	O
was	0	O
identified	0	O
based	0	O
on	0	O
its	0	O
ability	0	O
to	0	O
derepress	0	O
human	0	O
smooth	0	O
muscle	0	O
alpha	0	B
-	0	I
actin	0	I
promoter	0	I
activity	0	O
in	0	O
ras	0	B
-	0	O
transformed	0	O
cells	0	O
.	0	O


Ligand	1	O
binding	0	O
to	0	O
the	0	O
receptor	0	O
complex	0	O
leads	0	O
to	0	O
tyrosine	0	O
phosphorylation	0	O
and	0	O
activation	0	O
of	0	O
Janus	0	B
kinases	0	I
(	0	O
Jak	1	B
),	0	O
phosphorylation	0	O
of	0	O
the	0	O
signal	0	B
transducing	0	I
subunit	0	I
gp130	0	I
,	0	O
followed	0	O
by	0	O
recruitment	0	O
and	0	O
phosphorylation	0	O
of	0	O
the	0	O
signal	0	B
transducer	0	I
and	0	I
activator	0	I
of	0	I
transcription	0	I
factors	0	I
STAT3	0	I
and	0	O
STAT1	0	B
and	0	O
the	0	O
src	0	B
homology	0	I
domain	0	I
(	0	O
SH2	0	B
)-	0	O
containing	0	O
protein	0	B
tyrosine	0	I
phosphatase	0	I
(	0	O
SHP2	0	B
).	0	O


The	0	O
findings	0	O
demonstrate	0	O
that	0	O
AMPH	0	O
administration	0	O
induces	0	O
a	0	O
significant	0	O
increase	0	O
in	0	O
the	0	O
height	0	O
of	0	O
a	0	O
major	0	O
electroactive	0	O
peak	0	O
in	0	O
the	0	O
caudate	0	O
nucleus	0	O
of	0	O
pigtail	0	O
monkeys	0	O
,	0	O
and	0	O
further	0	O
that	0	O
such	0	O
amphetamine	0	O
-	0	O
induced	0	O
increases	0	O
can	0	O
be	0	O
manipulated	0	O
by	0	O
altering	0	O
the	0	O
affective	0	O
and	0	O
/	0	O
or	0	O
emotional	0	O
state	0	O
of	0	O
the	0	O
animal	0	O
.	0	O


This	0	O
,	0	O
together	0	O
with	0	O
the	0	O
data	0	O
obtained	0	O
with	0	O
haloperidol	0	O
,	0	O
suggests	0	O
that	0	O
a	0	O
minimal	0	O
increase	0	O
in	0	O
the	0	O
firing	0	O
rate	0	O
of	0	O
LC	0	O
cells	0	O
(+	0	O
140	0	O
%)	0	O
is	0	O
required	0	O
before	0	O
it	0	O
could	0	O
influence	0	O
the	0	O
turnover	0	O
of	0	O
NA	1	O
,	0	O
as	0	O
measured	0	O
by	0	O
DOPAC	0	O
changes	0	O
.	0	O


This	0	O
computerized	0	O
list	0	O
was	0	O
linked	0	O
to	0	O
the	0	O
central	0	O
files	0	O
of	0	O
the	0	O
Massachusetts	0	O
Cancer	1	O
Registry	1	O
and	0	O
cases	0	O
diagnosed	0	O
between	0	O
1982	0	O
and	0	O
1988	0	O
were	0	O
identified	0	O
.	0	O


Alternative	0	O
processing	0	O
of	0	O
the	0	O
tryptophanyl	0	B
-	0	I
tRNA	1	I
synthetase	0	I
mRNA	1	I
from	0	O
interferon	0	B
-	0	O
treated	0	O
human	0	O
cells	0	O
.	0	O


A	1	O
segment	0	O
of	0	O
mRNA	1	O
encoding	0	O
the	0	O
leader	0	O
peptide	0	O
of	0	O
the	0	O
CPA1	0	B
gene	0	I
confers	0	O
repression	0	O
by	0	O
arginine	0	O
on	0	O
a	0	O
heterologous	0	O
yeast	0	O
gene	0	O
transcript	0	O
.	0	O


For	0	O
E2	1	O
,	0	O
each	0	O
cat	0	O
was	0	O
given	0	O
either	0	O
5	0	O
(	0	O
group	0	O
[	0	O
G	1	O
]	0	O
1	0	O
)	0	O
or	0	O
10	0	O
(	0	O
G2	0	O
)	0	O
mg	0	O
of	0	O
itraconazole	0	O
/	0	O
kg	0	O
(	0	O
capsules	0	O
)	0	O
twice	0	O
daily	0	O
for	0	O
6	0	O
weeks	0	O
.	0	O


The	0	O
YccA	0	B
protein	0	I
was	0	O
found	0	O
to	0	O
be	0	O
degraded	0	O
in	0	O
an	0	O
FtsH	0	B
-	0	O
dependent	0	O
manner	0	O
in	0	O
vivo	0	O
and	0	O
in	0	O
vitro	0	O
,	0	O
whereas	0	O
the	0	O
YccA11	0	B
mutant	0	I
protein	0	I
,	0	O
lacking	0	O
eight	0	O
amino	0	O
acid	0	O
residues	0	O
within	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
cytoplasmic	0	O
domain	0	O
,	0	O
was	0	O
refractory	0	O
to	0	O
the	0	O
degradation	0	O
.	0	O


Of	0	O
these	0	O
proteins	0	O
,	0	O
five	0	O
have	0	O
previously	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
phosphorylated	0	O
during	0	O
mitosis	0	O
(	0	O
epithelial	0	B
-	0	I
microtubule	0	I
associated	0	I
protein	0	I
-	0	I
115	0	I
,	0	O
Oct91	0	B
,	0	O
Elongation	1	B
factor	0	I
1gamma	0	I
,	0	O
BRG1	0	B
and	0	O
Ribosomal	0	B
protein	0	I
L18A	0	I
),	0	O
five	0	O
are	0	O
related	0	O
to	0	O
proteins	0	O
postulated	0	O
to	0	O
have	0	O
roles	0	O
in	0	O
mitosis	0	O
(	0	O
epithelial	0	B
-	0	I
microtubule	0	I
associated	0	I
protein	0	I
-	0	I
115	0	I
,	0	O
Schizosaccharomyces	0	B
pombe	0	I
Cdc5	0	I
,	0	O
innercentrosome	0	B
protein	0	I
,	0	O
BRG1	0	B
and	0	O
the	0	O
RNA	1	B
helicase	0	I
WM6	0	I
),	0	O
and	0	O
nine	0	O
are	0	O
related	0	O
to	0	O
transcription	0	O
factors	0	O
(	0	O
BRG1	0	B
,	0	O
negative	0	B
co	0	I
-	0	I
factor	0	I
2alpha	0	I
,	0	O
Oct91	0	B
,	0	O
S	1	O
.	0	O
pombe	0	O
Cdc5	0	B
,	0	O
HoxD1	0	B
,	0	O
Sox3	0	B
,	0	O
Vent2	0	B
,	0	O
and	0	O
two	0	O
isoforms	0	O
of	0	O
Xbr1b	0	B
).	0	O


The	0	O
experimental	0	O
design	0	O
represents	0	O
a	0	O
2	0	O
x	0	O
3	0	O
factorial	0	O
arrangement	0	O
of	0	O
treatments	0	O
with	0	O
three	0	O
dietary	0	O
levels	0	O
of	0	O
incorporation	0	O
of	0	O
RSB	0	O
(	0	O
0	0	O
,	0	O
50	0	O
,	0	O
and	0	O
100	0	O
%),	0	O
and	0	O
chickens	0	O
either	0	O
infected	0	O
or	0	O
uninfected	0	O
.	0	O


We	0	O
have	0	O
determined	0	O
the	0	O
nucleotide	0	O
(	0	O
nt	0	O
)	0	O
sequence	0	O
of	0	O
the	0	O
7	0	B
.	0	I
5	0	I
-	0	I
kb	0	I
COR	1	I
segment	0	I
that	0	O
encompasses	0	O
a	0	O
cluster	0	O
of	0	O
six	0	O
genes	0	O
(	0	O
CYC1	0	B
,	0	O
UTR1	0	B
,	0	O
UTR3	0	B
,	0	O
OSM1	0	B
,	0	O
tRNA	1	B
(	0	I
Gly	1	I
)	0	I
and	0	O
RAD7	0	B
)	0	O
located	0	O
on	0	O
chromosome	0	O
X	1	O
of	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Nuclear	1	B
factor	0	I
III	0	I
(	0	O
NFIII	0	B
)	0	O
is	0	O
a	0	O
protein	0	O
from	0	O
HeLa	0	O
cells	0	O
that	0	O
stimulates	0	O
the	0	O
initiation	0	O
of	0	O
adenovirus	0	O
type	0	O
2	0	O
(	0	O
Ad2	1	O
)	0	O
DNA	1	O
replication	0	O
by	0	O
binding	0	O
to	0	O
a	0	O
specific	0	O
nucleotide	0	O
sequence	0	O
in	0	O
the	0	O
origin	0	O
,	0	O
adjacent	0	O
to	0	O
the	0	O
nuclear	0	B
factor	0	I
I	1	I
recognition	0	I
site	0	I
.	0	O


At	1	O
an	0	O
ambient	0	O
temperature	0	O
of	0	O
25	0	O
degrees	0	O
C	1	O
,	0	O
the	0	O
responses	0	O
to	0	O
spinal	0	O
cooling	0	O
are	0	O
reduced	0	O
during	0	O
the	0	O
dark	0	O
phase	0	O
.	0	O


Antibodies	0	O
against	0	O
this	0	O
purified	0	O
protein	0	O
localize	0	O
RIM1	0	B
to	0	O
mitochondria	0	O
.	0	O


The	0	O
metabolism	0	O
and	0	O
pharmacology	0	O
of	0	O
5	0	O
-	0	O
fluorouracil	0	O
.	0	O


In	1	O
an	0	O
effort	0	O
to	0	O
identify	0	O
the	0	O
USH1C	0	B
disease	0	I
gene	0	I
we	0	O
have	0	O
isolated	0	O
the	0	O
region	0	O
between	0	O
these	0	O
markers	0	O
in	0	O
yeast	0	O
artificial	0	O
chromosomes	0	O
(	0	O
YACs	0	O
)	0	O
using	0	O
a	0	O
combination	0	O
of	0	O
STS	1	O
content	0	O
mapping	0	O
and	0	O
Alu	0	B
-	0	O
PCR	1	O
hybridization	0	O
.	0	O


This	0	O
gene	0	O
encodes	0	O
a	0	O
putative	0	O
transcription	0	O
factor	0	O
with	0	O
regions	0	O
of	0	O
homology	0	O
to	0	O
several	0	O
other	0	O
proteins	0	O
including	0	O
the	0	O
zinc	0	O
fingers	0	O
and	0	O
other	0	O
domains	0	O
of	0	O
the	0	O
Drosophila	1	B
trithorax	0	I
gene	0	I
product	0	I
,	0	O
and	0	O
the	0	O
"	0	O
AT	1	O
-	0	O
hook	0	O
"	0	O
DNA	1	O
-	0	O
binding	0	O
motif	0	O
of	0	O
high	0	B
mobility	0	I
group	0	I
proteins	0	I
.	0	O


The	0	O
data	0	O
provide	0	O
evidence	0	O
both	0	O
for	0	O
a	0	O
signal	0	O
transduction	0	O
pathway	0	O
independent	0	O
of	0	O
JNK	0	B
,	0	O
ERK	0	B
,	0	O
and	0	O
p38	0	B
MAP	1	I
kinase	0	I
to	0	O
be	0	O
involved	0	O
in	0	O
the	0	O
induction	0	O
of	0	O
rhoB	0	B
by	0	O
genotoxic	0	O
stress	0	O
,	0	O
and	0	O
furthermore	0	O
,	0	O
indicate	0	O
autoregulation	0	O
of	0	O
rhoB	0	B
.	0	O


The	0	O
following	0	O
technique	0	O
describes	0	O
a	0	O
modification	0	O
to	0	O
a	0	O
bar	0	O
superstructure	0	O
that	0	O
provided	0	O
the	0	O
advantages	0	O
of	0	O
convenience	0	O
,	0	O
security	0	O
,	0	O
and	0	O
consistent	0	O
positioning	0	O
even	0	O
though	0	O
one	0	O
implant	0	O
was	0	O
lost	0	O
and	0	O
the	0	O
angulation	0	O
of	0	O
implants	0	O
limited	0	O
accuracy	0	O
.	0	O


The	0	O
immuno	0	O
-	0	O
purified	0	O
mRNA	1	O
in	0	O
the	0	O
polysome	0	O
complex	0	O
was	0	O
used	0	O
to	0	O
prepare	0	O
cDNA	1	O
with	0	O
which	0	O
to	0	O
probe	0	O
a	0	O
D	1	O
.	0	O
melanogaster	0	O
genomic	0	O
library	0	O
.	0	O


Stylohyoid	1	O
chain	0	O
ossification	0	O
:	0	O
choice	0	O
of	0	O
the	0	O
surgical	0	O
approach	0	O
.	0	O


Silicosis	1	O
mortality	0	O


33	0	O
out	0	O
of	0	O
90	0	O
neurons	0	O
of	0	O
the	0	O
cat	0	O
medial	0	O
geniculate	0	O
body	0	O
revealed	0	O
the	0	O
selectivity	0	O
of	0	O
their	0	O
afterdischarges	0	O
to	0	O
movement	0	O
of	0	O
sound	0	O
when	0	O
velocity	0	O
of	0	O
the	0	O
movement	0	O
changed	0	O
from	0	O
30	0	O
to	0	O
180	0	O
deg	0	O
/	0	O
s	0	O
.	0	O


TIEG	0	B
expression	0	O
in	0	O
hFOB	0	O
cells	0	O
was	0	O
highly	0	O
induced	0	O
by	0	O
TGF	1	B
-	0	I
beta	0	I
and	0	O
bone	0	B
morphogenetic	0	I
protein	0	I
-	0	I
2	0	I
(	0	O
BMP	1	B
-	0	I
2	0	I
),	0	O
with	0	O
a	0	O
moderate	0	O
induction	0	O
by	0	O
epidermal	0	B
growth	0	I
factor	0	I
(	0	O
EGF	1	B
),	0	O
but	0	O
no	0	O
induction	0	O
by	0	O
other	0	O
growth	0	O
factors	0	O
/	0	O
cytokines	0	O
was	0	O
observed	0	O
.	0	O


Mutations	0	O
in	0	O
the	0	O
RP2	0	B
locus	0	I
at	0	I
Xp11	0	I
.	0	I
3	0	I
were	0	O
found	0	O
in	0	O
a	0	O
further	0	O
10	0	O
-	0	O
20	0	O
%	0	O
of	0	O
XLRP	0	O
patients	0	O
,	0	O
as	0	O
predicted	0	O
from	0	O
linkage	0	O
studies	0	O
.	0	O


Pharmacologic	1	O
doses	0	O
of	0	O
vitamin	0	O
B6	0	O
administered	0	O
to	0	O
lactating	0	O
women	0	O
have	0	O
been	0	O
reported	0	O
to	0	O
suppress	0	O
plasma	0	B
prolactin	0	I
.	0	O


Receptors	0	O
for	0	O
interleukin	0	B
(	0	I
IL	1	I
)-	0	I
10	0	I
and	0	O
IL	1	B
-	0	I
6	0	I
-	0	I
type	0	I
cytokines	0	I
use	0	O
similar	0	O
signaling	0	O
mechanisms	0	O
for	0	O
inducing	0	O
transcription	0	O
through	0	O
IL	1	B
-	0	I
6	0	I
response	0	O
elements	0	O
.	0	O


The	0	O
appropriate	0	O
use	0	O
and	0	O
benefits	0	O
of	0	O
bile	0	O
acid	0	O
sequestrants	0	O
,	0	O
nicotinic	0	O
acid	0	O
,	0	O
fibric	0	O
acids	0	O
,	0	O
3	0	B
-	0	I
hydroxy	0	I
-	0	I
3	0	I
-	0	I
methylglutaryl	0	I
coenzyme	0	I
A	1	I
(	0	I
HMG	1	I
-	0	I
CoA	1	I
)	0	I
reductase	0	I
inhibitors	0	O
,	0	O
and	0	O
probucol	0	O
are	0	O
individually	0	O
discussed	0	O
,	0	O
whereas	0	O
nonpharmacologic	0	O
approaches	0	O
used	0	O
in	0	O
conjunction	0	O
with	0	O
the	0	O
drugs	0	O
are	0	O
recommended	0	O
emphatically	0	O
.	0	O


Epidemiological	1	O
data	0	O
are	0	O
quite	0	O
controversial	0	O
but	0	O
sudden	0	O
death	0	O
occurring	0	O
during	0	O
sporting	0	O
activity	0	O
is	0	O
probably	0	O
not	0	O
a	0	O
rare	0	O
occurrence	0	O
.	0	O


In	1	O
metastasis	0	O
-	0	O
free	0	O
patients	0	O
,	0	O
the	0	O
best	0	O
results	0	O
were	0	O
obtained	0	O
with	0	O
tumor	0	O
diameters	0	O
under	0	O
2	0	O
cm	0	O
regardless	0	O
of	0	O
their	0	O
localization	0	O
in	0	O
lung	0	O
tissue	0	O
and	0	O
with	0	O
2	0	O
--	0	O
4	0	O
.	0	O
9	0	O
cm	0	O
tumors	0	O
embedded	0	O
in	0	O
lung	0	O
parenchyma	0	O
.	0	O


The	0	O
sign	0	O
of	0	O
Leser	0	O
-	0	O
Trelat	0	O
:	0	O
does	0	O
it	0	O
exist	0	O
?	0	O
The	0	O
sign	0	O
of	0	O
Leser	0	O
-	0	O
Trelat	0	O
is	0	O
usually	0	O
regarded	0	O
as	0	O
a	0	O
reliable	0	O
cutaneous	0	O
marker	0	O
of	0	O
internal	0	O
malignancy	0	O
.	0	O


We	0	O
infer	0	O
that	0	O
the	0	O
dominant	0	O
negative	0	O
inhibition	0	O
results	0	O
from	0	O
both	0	O
direct	0	O
proteolysis	0	O
of	0	O
the	0	O
beta	0	B
-	0	I
galactosidase	0	I
tetramer	0	I
by	0	O
the	0	O
fusion	0	O
subunit	0	O
and	0	O
detour	0	O
of	0	O
the	0	O
tetramer	0	O
to	0	O
the	0	O
lysosome	0	O
.	0	O


The	0	O
NarX	0	B
and	0	O
NarQ	0	B
proteins	0	I
with	0	O
amino	0	O
acid	0	O
substitutions	0	O
at	0	O
the	0	O
first	0	O
conserved	0	O
histidine	0	O
position	0	O
were	0	O
also	0	O
unable	0	O
to	0	O
dephosphorylate	0	O
NarL	0	B
-	0	O
phosphate	0	O
in	0	O
vitro	0	O
.	0	O


Complex	1	O
repetitive	0	O
discharges	0	O
were	0	O
observed	0	O
in	0	O
muscles	0	O
of	0	O
mdx	0	O
mice	0	O
but	0	O
no	0	O
complex	0	O
repetitive	0	O
discharges	0	O
or	0	O
other	0	O
abnormalities	0	O
were	0	O
observed	0	O
in	0	O
muscles	0	O
of	0	O
normal	0	O
control	0	O
mice	0	O
.	0	O


Obesity	1	O
was	0	O
strongly	0	O
associated	0	O
with	0	O
the	0	O
proportions	0	O
of	0	O
nonprotein	0	O
-	0	O
bound	0	O
and	0	O
albumin	0	B
-	0	O
bound	0	O
estradiol	0	O
,	0	O
and	0	O
inversely	0	O
associated	0	O
with	0	O
sex	0	B
hormone	0	I
binding	0	I
globulin	0	I
(	0	O
SHBG	1	B
)	0	O
levels	0	O
and	0	O
the	0	O
proportion	0	O
of	0	O
SHBG	1	B
-	0	O
bound	0	O
estradiol	0	O
.	0	O


Polyglactin	1	O
910	0	O
suture	0	O
absorption	0	O
and	0	O
the	0	O
role	0	O
of	0	O
cellular	0	O
enzymes	0	O
.	0	O


A	1	O
full	0	O
-	0	O
length	0	O
cDNA	1	O
clone	0	O
isolated	0	O
from	0	O
a	0	O
rat	0	O
lung	0	O
library	0	O
was	0	O
predicted	0	O
to	0	O
encode	0	O
a	0	O
55	0	O
-	0	O
kDa	1	O
protein	0	O
containing	0	O
at	0	O
its	0	O
amino	0	O
terminus	0	O
a	0	O
targeting	0	O
domain	0	O
that	0	O
binds	0	O
to	0	O
the	0	O
ANP	1	B
-	0	I
receptor	0	I
kinase	0	I
-	0	I
like	0	I
domain	0	I
and	0	O
containing	0	O
at	0	O
its	0	O
carboxyl	0	O
terminus	0	O
a	0	O
putative	0	O
protein	0	B
-	0	I
serine	0	I
phosphatase	0	I
domain	0	O
.	0	O


Wherever	0	O
the	0	O
site	0	O
of	0	O
the	0	O
conditioning	0	O
stimulation	0	O
,	0	O
these	0	O
modifications	0	O
disappeared	0	O
after	0	O
ischaemia	0	O
of	0	O
the	0	O
leg	0	O
.	0	O


E2F	0	B
-	0	I
1	0	I
is	0	O
a	0	O
transcription	0	O
factor	0	O
that	0	O
regulates	0	O
cell	0	O
cycle	0	O
progression	0	O
into	0	O
S	1	O
-	0	O
phase	0	O
.	0	O


The	0	O
high	0	O
density	0	O
of	0	O
tegumental	0	O
spines	0	O
on	0	O
posterior	0	O
half	0	O
of	0	O
the	0	O
body	0	O
and	0	O
the	0	O
distribution	0	O
of	0	O
type	0	O
II	0	O
papillae	0	O
on	0	O
dorsal	0	O
surface	0	O
are	0	O
considered	0	O
to	0	O
be	0	O
characteristic	0	O
of	0	O
C	1	O
.	0	O
armatus	0	O
.	0	O


In	1	O
the	0	O
DNAs	0	O
of	0	O
all	0	O
Ph1	0	O
-	0	O
positive	0	O
chronic	0	O
myelocytic	0	O
leukemia	0	O
patients	0	O
studied	0	O
to	0	O
date	0	O
,	0	O
a	0	O
breakpoint	0	O
on	0	O
chromosome	0	O
22	0	O
(	0	O
the	0	O
Ph1	0	O
chromosome	0	O
)	0	O
can	0	O
be	0	O
demonstrated	0	O
with	0	O
a	0	O
probe	0	O
from	0	O
the	0	O
bcr	0	B
(	0	O
breakpoint	0	B
cluster	0	I
region	0	I
).	0	O


A	1	O
multivariate	0	O
analysis	0	O
of	0	O
risk	0	O
factors	0	O
for	0	O
relapse	0	O
examined	0	O
age	0	O
,	0	O
WBC	1	O
at	0	O
diagnosis	0	O
,	0	O
blast	0	O
count	0	O
at	0	O
diagnosis	0	O
,	0	O
percentage	0	O
of	0	O
marrow	0	O
blasts	0	O
,	0	O
FAB	1	B
subtype	0	O
,	0	O
the	0	O
number	0	O
of	0	O
remission	0	O
induction	0	O
courses	0	O
to	0	O
achieve	0	O
a	0	O
remission	0	O
,	0	O
maintenance	0	O
therapy	0	O
,	0	O
consolidation	0	O
therapy	0	O
,	0	O
marrow	0	O
cell	0	O
dose	0	O
,	0	O
donor	0	O
-	0	O
recipient	0	O
sex	0	O
,	0	O
GVHD	1	O
prophylaxis	0	O
regimen	0	O
and	0	O
isolation	0	O
and	0	O
decontamination	0	O
in	0	O
laminar	0	O
airflow	0	O
rooms	0	O
.	0	O


The	0	O
role	0	O
of	0	O
negative	0	O
regulators	0	O
such	0	O
as	0	O
NCE3	0	B
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
previously	0	O
described	0	O
SIN5	0	B
gene	0	I
,	0	O
in	0	O
determining	0	O
the	0	O
promoter	0	O
specificity	0	O
of	0	O
homologous	0	O
activators	0	O
is	0	O
discussed	0	O
.	0	O


Treatment	1	O
of	0	O
hypertension	0	O
with	0	O
a	0	O
combination	0	O
of	0	O
the	0	O
adrenergic	0	B
beta	0	I
receptor	0	I
blockader	0	O
,	0	O
obsidan	0	O
,	0	O
and	0	O
the	0	O
vasodilator	0	O
,	0	O
apressin	0	O


Heterogeneous	1	B
nuclear	0	I
ribonucleoprotein	0	I
(	0	I
hnRNP	1	I
)	0	I
core	0	I
protein	0	I
A1	0	I
is	0	O
a	0	O
major	0	O
component	0	O
of	0	O
mammalian	0	B
hnRNP	1	I
40	0	I
S	1	I
particles	0	I
.	0	O


Near	0	O
a	0	O
third	0	O
(	0	O
31	0	O
.	0	O
6	0	O
%)	0	O
of	0	O
Insulin	1	B
Dependent	1	O
and	0	O
a	0	O
third	0	O
(	0	O
33	0	O
.	0	O
41	0	O
%)	0	O
for	0	O
Non	0	O
Insulin	1	B
Dependent	1	O
were	0	O
of	0	O
D	1	O
,	0	O
F	1	O
,	0	O
H	1	O
White	1	O
'	0	O
s	0	O
Class	1	O
.	0	O


A	1	O
great	0	O
deal	0	O
of	0	O
information	0	O
is	0	O
available	0	O
on	0	O
the	0	O
morphology	0	O
of	0	O
the	0	O
claustrum	0	O
in	0	O
various	0	O
animal	0	O
species	0	O
,	0	O
as	0	O
well	0	O
as	0	O
on	0	O
its	0	O
neuronal	0	O
distribution	0	O
and	0	O
relationships	0	O
with	0	O
the	0	O
cerebral	0	O
cortex	0	O
and	0	O
other	0	O
nuclei	0	O
.	0	O


The	0	O
HiNF	0	B
-	0	I
D	1	I
(	0	O
CDP	1	B
/	0	O
cut	0	B
)	0	O
complex	0	O
with	0	O
the	0	O
H4	0	B
promoter	0	I
is	0	O
immunoreactive	0	O
with	0	O
antibodies	0	O
against	0	O
CDP	1	B
/	0	O
cut	0	B
and	0	O
pRB	0	B
but	0	O
not	0	O
p107	0	B
,	0	O
whereas	0	O
the	0	O
CDP	1	B
/	0	O
cut	0	B
complex	0	O
with	0	O
a	0	O
nonhistone	0	O
promoter	0	O
(	0	O
gp91	0	B
-	0	O
phox	0	B
)	0	O
reacts	0	O
only	0	O
with	0	O
CDP	1	B
and	0	O
p107	0	B
antibodies	0	O
.	0	O


The	0	O
equivalent	0	O
of	0	O
the	0	O
third	0	O
ligand	0	O
,	0	O
H	1	O
-	0	O
87	0	O
,	0	O
is	0	O
T	1	O
-	0	O
47	0	O
in	0	O
the	0	O
PSTAIRE	0	O
sequence	0	O
motif	0	O
.	0	O


Addition	1	O
of	0	O
synthetic	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
peptides	0	O
derived	0	O
from	0	O
betac	0	O
cytoplasmic	0	O
tyrosines	0	O
prior	0	O
to	0	O
GM	1	B
-	0	I
CSF	1	I
stimulation	0	O
inhibited	0	O
the	0	O
in	0	O
vitro	0	O
activation	0	O
of	0	O
STAT5	0	B
.	0	O


Notice	0	O
of	0	O
retraction	0	O
.	0	O


Upon	0	O
differentiation	0	O
with	0	O
retinoic	0	O
acid	0	O
(	0	O
RA	1	O
),	0	O
transcription	0	O
of	0	O
the	0	O
Rex	0	B
-	0	I
1	0	I
gene	0	I
decreases	0	O
rapidly	0	O
.	0	O


We	0	O
recommend	0	O
that	0	O
ovarian	0	O
stimulation	0	O
is	0	O
done	0	O
only	0	O
if	0	O
there	0	O
is	0	O
a	0	O
valid	0	O
indication	0	O
after	0	O
proper	0	O
assessment	0	O
of	0	O
the	0	O
ovaries	0	O
,	0	O
and	0	O
that	0	O
women	0	O
who	0	O
have	0	O
had	0	O
ovarian	0	O
stimulation	0	O
are	0	O
followed	0	O
for	0	O
longer	0	O
than	0	O
at	0	O
present	0	O
.	0	O


In	1	O
part	0	O
as	0	O
a	0	O
result	0	O
of	0	O
its	0	O
inability	0	O
to	0	O
sustain	0	O
radiative	0	O
loses	0	O
,	0	O
the	0	O
BB	0	O
resonator	0	O
has	0	O
extremely	0	O
low	0	O
RF	1	O
power	0	O
requirements	0	O
.	0	O


A	1	O
highly	0	O
significant	0	O
correlation	0	O
was	0	O
found	0	O
between	0	O
the	0	O
presence	0	O
of	0	O
fibrinolytic	0	O
degradation	0	O
products	0	O
(	0	O
FDP	1	O
)	0	O
and	0	O
the	0	O
incidence	0	O
of	0	O
nephropathy	0	O
and	0	O
renal	0	O
insufficiency	0	O
,	0	O
as	0	O
well	0	O
as	0	O
between	0	O
the	0	O
presence	0	O
of	0	O
fibrin	0	B
monomers	0	I
(	0	O
Godal	0	O
'	0	O
s	0	O
ethanol	0	O
-	0	O
gelification	0	O
test	0	O
)	0	O
and	0	O
the	0	O
evolutive	0	O
signs	0	O
of	0	O
the	0	O
primary	0	O
disease	0	O
(	0	O
fever	0	O
,	0	O
accelerated	0	O
ESR	1	O
).	0	O


Effects	0	O
of	0	O
methylene	0	O
chloride	0	O
,	0	O
trichloroethane	0	O
,	0	O
trichloroethylene	0	O
,	0	O
tetrachloroethylene	0	O
and	0	O
toluene	0	O
on	0	O
the	0	O
development	0	O
of	0	O
chick	0	O
embryos	0	O
.	0	O


Factors	0	O
influencing	0	O
semen	0	O
characteristics	0	O
in	0	O
young	0	O
boars	0	O
reared	0	O
in	0	O
a	0	O
subtropical	0	O
environment	0	O
were	0	O
studied	0	O
.	0	O


The	0	O
elm1	0	B
kinase	0	I
functions	0	O
in	0	O
a	0	O
mitotic	0	O
signaling	0	O
network	0	O
in	0	O
budding	0	O
yeast	0	O
.	0	O


DNA	1	O
sequence	0	O
and	0	O
functions	0	O
of	0	O
the	0	O
actVI	0	B
region	0	I
of	0	O
the	0	O
actinorhodin	0	O
biosynthetic	0	O
gene	0	O
cluster	0	O
of	0	O
Streptomyces	1	O
coelicolor	0	O
A3	0	O
(	0	O
2	0	O
).	0	O


Inactivation	1	O
of	0	O
p53	0	B
but	0	O
not	0	O
p73	0	B
by	0	O
adenovirus	0	B
type	0	I
5	0	I
E1B	0	I
55	0	I
-	0	I
kilodalton	0	I
and	0	I
E4	1	I
34	0	I
-	0	I
kilodalton	0	I
oncoproteins	0	I
.	0	O


Workers	0	O
with	0	O
"	0	O
sensitivity	0	O
"	0	O
to	0	O
toluene	0	O
diisocyanate	0	O
(	0	O
TDI	1	O
)	0	O
studied	0	O
in	0	O
depth	0	O
in	0	O
an	0	O
attempt	0	O
to	0	O
determine	0	O
mechanisms	0	O
of	0	O
bronchial	0	O
hyperreactivity	0	O
.	0	O


Rac	0	B
causes	0	O
uncapping	0	O
of	0	O
actin	0	B
filaments	0	I
(	0	O
F	1	B
-	0	I
actin	0	I
)	0	O
at	0	O
the	0	O
plus	0	O
-	0	O
ends	0	O
,	0	O
through	0	O
phosphatidylinositol	0	O
4	0	O
,	0	O
5	0	O
bisphosphate	0	O
(	0	O
PIP2	1	O
),	0	O
and	0	O
eventually	0	O
induces	0	O
membrane	0	O
ruffling	0	O
.	0	O


These	0	O
studies	0	O
identify	0	O
several	0	O
of	0	O
the	0	O
signal	0	O
-	0	O
transduction	0	O
events	0	O
involved	0	O
in	0	O
the	0	O
apoptosis	0	O
of	0	O
malignant	0	O
B	1	O
cells	0	O
that	0	O
transpire	0	O
following	0	O
ligation	0	O
of	0	O
CD20	1	B
by	0	O
anti	0	B
-	0	I
CD20	1	I
antibodies	0	I
in	0	O
the	0	O
presence	0	O
of	0	O
Fc	1	B
-	0	I
receptor	0	I
-	0	O
expressing	0	O
cells	0	O
or	0	O
secondary	0	O
goat	0	O
anti	0	B
-(	0	I
mouse	0	I
Ig	1	I
)	0	I
antibodies	0	I
and	0	O
which	0	O
may	0	O
contribute	0	O
to	0	O
the	0	O
tumor	0	O
regressions	0	O
observed	0	O
in	0	O
mouse	0	O
models	0	O
and	0	O
clinical	0	O
trials	0	O
.	0	O


We	0	O
provide	0	O
community	0	O
metabolic	0	O
data	0	O
that	0	O
indicate	0	O
that	0	O
large	0	O
changes	0	O
in	0	O
CO2	1	O
concentration	0	O
can	0	O
occur	0	O
in	0	O
coral	0	O
reef	0	O
waters	0	O
via	0	O
biogeochemical	0	O
processes	0	O
not	0	O
directly	0	O
associated	0	O
with	0	O
photosynthesis	0	O
,	0	O
respiration	0	O
,	0	O
calcification	0	O
,	0	O
and	0	O
CaCO3	1	O
dissolution	0	O
.	0	O


Direct	1	O
proof	0	O
that	0	O
the	0	O
heightened	0	O
renal	0	O
cellular	0	O
apoptosis	0	O
in	0	O
PKD	0	O
is	0	O
not	0	O
occurring	0	O
through	0	O
p53	0	B
was	0	O
obtained	0	O
by	0	O
successive	0	O
matings	0	O
between	0	O
SBM	0	O
and	0	O
p53	0	B
(-/-)	0	O
mice	0	O
.	0	O


These	0	O
widely	0	O
expressed	0	O
proteins	0	O
share	0	O
a	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
that	0	O
bears	0	O
significant	0	O
sequence	0	O
homology	0	O
to	0	O
a	0	O
group	0	O
of	0	O
GDP	1	B
/	0	I
GTP	1	I
exchange	0	I
proteins	0	I
for	0	O
the	0	O
Rab3	0	B
family	0	I
of	0	O
small	0	B
GTP	1	I
binding	0	I
proteins	0	I
.	0	O


In	1	O
vivo	0	O
association	0	O
between	0	O
Shb	0	B
-	0	O
SH3	0	B
domain	0	O
proteins	0	O
v	0	B
-	0	I
Src	1	I
and	0	O
Eps8	0	B
was	0	O
detected	0	O
by	0	O
coimmunoprecipitation	0	O
.	0	O


Although	0	O
the	0	O
fertility	0	O
decline	0	O
in	0	O
the	0	O
black	0	O
population	0	O
in	0	O
the	0	O
Mississippi	0	O
Delta	1	O
between	0	O
the	0	O
late	0	O
1870	0	O
'	0	O
s	0	O
and	0	O
early	0	O
1930	0	O
'	0	O
s	0	O
closely	0	O
paralleled	0	O
that	0	O
of	0	O
the	0	O
national	0	O
black	0	O
population	0	O
,	0	O
it	0	O
rose	0	O
much	0	O
more	0	O
dramatically	0	O
in	0	O
the	0	O
1940	0	O
'	0	O
s	0	O
and	0	O
1950	0	O
'	0	O
s	0	O
to	0	O
almost	0	O
1880	0	O
levels	0	O
.	0	O


However	0	O
,	0	O
we	0	O
were	0	O
unable	0	O
to	0	O
identify	0	O
a	0	O
p4	0	B
molecule	0	O
.	0	O


We	0	O
previously	0	O
showed	0	O
that	0	O
v	0	B
-	0	I
Rel	0	I
,	0	O
the	0	O
oncoprotein	0	O
of	0	O
the	0	O
avian	0	O
retrovirus	0	O
Rev	0	O
-	0	O
T	1	O
,	0	O
can	0	O
increase	0	O
expression	0	O
from	0	O
promoters	0	O
containing	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
cellular	0	O
transcription	0	O
factor	0	O
Sp1	0	B
in	0	O
chicken	0	O
embryo	0	O
fibroblasts	0	O
(	0	O
S	1	O
.	0	O


Isolation	1	O
of	0	O
Proteus	1	O
vulgaris	0	O
MC	1	O
-	0	O
63	0	O
from	0	O
carcinoma	0	O
63	0	O
and	0	O
its	0	O
antitumor	0	O
effect	0	O
on	0	O
Crocker	0	O
sarcoma	0	O
180	0	O
and	0	O
Ehrlich	0	O
carcinoma	0	O
.	0	O


The	0	O
ether	0	O
phospholipid	0	O
1	0	O
-	0	O
O	1	O
-	0	O
octadecyl	0	O
-	0	O
2	0	O
-	0	O
O	1	O
-	0	O
methyl	0	O
-	0	O
rac	0	O
-	0	O
glycero	0	O
-	0	O
3	0	O
-	0	O
phosphocholine	0	O
(	0	O
ET	1	O
-	0	O
18	0	O
-	0	O
OCH3	0	O
;	0	O
edelfosine	0	O
)	0	O
is	0	O
a	0	O
potent	0	O
inducer	0	O
of	0	O
apoptosis	0	O
in	0	O
human	0	O
tumor	0	O
cells	0	O
.	0	O


A	1	O
degenerate	0	O
DNA	1	O
transposon	0	O
,	0	O
Pat	1	B
,	0	O
was	0	O
identified	0	O
in	0	O
the	0	O
genomes	0	O
of	0	O
various	0	O
wild	0	O
-	0	O
type	0	O
strains	0	O
of	0	O
the	0	O
filamentous	0	O
fungus	0	O
Podospora	0	O
anserina	0	O
.	0	O


RESULTS	0	O
:	0	O
The	0	O
bovine	0	O
cDNA	1	O
insert	0	O
sequence	0	O
was	0	O
273	0	O
nucleotides	0	O
in	0	O
length	0	O
for	0	O
the	0	O
entire	0	O
mRNA	1	O
coding	0	O
region	0	O
,	0	O
212	0	O
nucleotides	0	O
in	0	O
the	0	O
5	0	O
'	0	O
untranslated	0	O
region	0	O
,	0	O
83	0	O
nucleotides	0	O
in	0	O
the	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
and	0	O
a	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
tail	0	O
.	0	O


U73	0	B
contains	0	O
C	1	O
,	0	O
D	1	O
and	0	O
D	1	O
'	0	O
boxes	0	O
and	0	O
a	0	O
12	0	O
-	0	O
nucleotide	0	O
antisense	0	O
complementarity	0	O
to	0	O
the	0	O
28S	0	B
ribosomal	0	I
RNA	1	I
.	0	O


Biol	0	O
.	0	O


In	1	O
the	0	O
DNA	1	O
recognition	0	O
helix	0	O
of	0	O
finger	0	O
II	0	O
,	0	O
the	0	O
conserved	0	O
Arg	1	O
at	0	O
position	0	O
62	0	O
(	0	O
N	1	O
-	0	O
terminal	0	O
side	0	O
of	0	O
the	0	O
first	0	O
zinc	0	O
-	0	O
coordinating	0	O
histidine	0	O
)	0	O
was	0	O
changed	0	O
to	0	O
a	0	O
Leu	1	O
or	0	O
Gln	1	O
.	0	O


The	0	O
enhanced	0	O
binding	0	O
of	0	O
c	0	B
-	0	I
Abl	0	I
to	0	O
DNA	1	O
containing	0	O
5	0	O
-	0	O
methylcytosine	0	O
residues	0	O
may	0	O
result	0	O
from	0	O
an	0	O
increased	0	O
propensity	0	O
of	0	O
the	0	O
double	0	O
helix	0	O
to	0	O
denature	0	O
locally	0	O
coupled	0	O
with	0	O
a	0	O
protein	0	O
-	0	O
induced	0	O
reduction	0	O
in	0	O
the	0	O
base	0	O
stacking	0	O
interaction	0	O
.	0	O


DDP1	0	B
also	0	O
localizes	0	O
to	0	O
heterochromatin	0	O
in	0	O
interphase	0	O
nuclei	0	O
of	0	O
larval	0	O
neuroblasts	0	O
.	0	O


The	0	O
inhibition	0	O
by	0	O
cytosolic	0	O
Ca2	1	O
+	0	O
was	0	O
caused	0	O
by	0	O
a	0	O
decrease	0	O
in	0	O
cooperativity	0	O
and	0	O
by	0	O
a	0	O
shift	0	O
in	0	O
EC50	0	O
toward	0	O
higher	0	O
InsP3	1	O
concentrations	0	O
.	0	O


The	0	O
brackets	0	O
were	0	O
bonded	0	O
to	0	O
100	0	O
freshly	0	O
extracted	0	O
bovine	0	O
incisors	0	O
,	0	O
and	0	O
,	0	O
after	0	O
storage	0	O
in	0	O
tap	0	O
water	0	O
at	0	O
room	0	O
temperature	0	O
for	0	O
24	0	O
hours	0	O
,	0	O
they	0	O
were	0	O
subsequently	0	O
tested	0	O
in	0	O
a	0	O
shear	0	O
mode	0	O
using	0	O
a	0	O
universal	0	O
testing	0	O
machine	0	O
.	0	O


Transient	1	O
transfection	0	O
assays	0	O
showed	0	O
that	0	O
site	0	O
A	1	O
is	0	O
necessary	0	O
and	0	O
sufficient	0	O
for	0	O
RXR	0	B
alpha	0	I
-	0	O
mediated	0	O
transactivation	0	O
of	0	O
the	0	O
apoAI	0	B
gene	0	I
basal	0	I
promoter	0	I
in	0	O
human	0	O
hepatoma	0	O
HepG2	0	O
cells	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
RA	1	O
and	0	O
that	0	O
this	0	O
transactivation	0	O
is	0	O
abolished	0	O
by	0	O
increasing	0	O
amounts	0	O
of	0	O
cotransfected	0	O
ARP	0	B
-	0	I
1	0	I
.	0	O


A	1	O
transgenic	0	O
complementation	0	O
assay	0	O
was	0	O
used	0	O
to	0	O
test	0	O
whether	0	O
NIa	1	B
supplied	0	O
in	0	O
trans	0	O
could	0	O
rescue	0	O
amplification	0	O
-	0	O
defective	0	O
viral	0	O
genomes	0	O
encoding	0	O
altered	0	O
NIa	1	B
proteins	0	I
.	0	O


Five	0	O
-	0	O
year	0	O
prospective	0	O
study	0	O
of	0	O
peripheral	0	O
white	0	O
blood	0	O
cells	0	O
in	0	O
infectious	0	O
mononucleosis	0	O
.	0	O


Northern	0	O
analysis	0	O
,	0	O
to	0	O
search	0	O
for	0	O
a	0	O
pcbAB	0	B
transcript	0	I
,	0	O
showed	0	O
no	0	O
distinct	0	O
transcript	0	O
and	0	O
indicated	0	O
severely	0	O
degraded	0	O
mRNA	1	O
.	0	O


Propafenone	0	O
is	0	O
well	0	O
tolerated	0	O
in	0	O
the	0	O
majority	0	O
of	0	O
young	0	O
patients	0	O
.	0	O


Oscilloscope	1	O
triggering	0	O
circuit	0	O
for	0	O
recording	0	O
long	0	O
transients	0	O
at	0	O
fast	0	O
sweep	0	O
speeds	0	O
.	0	O


Two	0	O
cDNAs	0	O
encoding	0	O
casein	0	B
kinase	0	I
-	0	I
1	0	I
have	0	O
been	0	O
isolated	0	O
from	0	O
a	0	O
yeast	0	O
cDNA	1	O
library	0	O
and	0	O
termed	0	O
CKI1	0	B
and	0	O
CKI2	0	B
.	0	O


A	1	O
total	0	O
of	0	O
26	0	O
BCG	1	O
strains	0	O
,	0	O
out	0	O
of	0	O
them	0	O
10	0	O
Czechoslovak	0	O
strains	0	O
(	0	O
2	0	O
lyophilized	0	O
cultures	0	O
of	0	O
BCG	1	O
of	0	O
different	0	O
batch	0	O
,	0	O
6	0	O
strains	0	O
isolated	0	O
from	0	O
abscesses	0	O
of	0	O
children	0	O
after	0	O
BCG	1	O
-	0	O
vaccination	0	O
and	0	O
2	0	O
strains	0	O
from	0	O
fatal	0	O
cases	0	O
after	0	O
BCG	1	O
-	0	O
vaccination	0	O
)	0	O
and	0	O
16	0	O
strains	0	O
obtained	0	O
from	0	O
foreign	0	O
laboratories	0	O
,	0	O
were	0	O
used	0	O
.	0	O


EBER1	0	B
mRNA	1	I
,	0	O
a	0	O
consistent	0	O
marker	0	O
of	0	O
viral	0	O
latency	0	O
,	0	O
was	0	O
positive	0	O
in	0	O
all	0	O
PEL	1	O
cases	0	O
,	0	O
although	0	O
at	0	O
lower	0	O
levels	0	O
than	0	O
in	0	O
the	0	O
non	0	O
-	0	O
PEL	1	O
controls	0	O
due	0	O
to	0	O
EBER1	0	B
expression	0	O
by	0	O
only	0	O
a	0	O
variable	0	O
subset	0	O
of	0	O
lymphoma	0	O
cells	0	O
.	0	O


High	0	O
-	0	O
pressure	0	O
effects	0	O
on	0	O
ultrafast	0	O
-	0	O
relaxation	0	O
kinetics	0	O
of	0	O
excitons	0	O
in	0	O
polydiacetylene	0	O
4BCMU	0	O
.	0	O


DNA	1	O
sequence	0	O
analysis	0	O
has	0	O
confirmed	0	O
that	0	O
this	0	O
mutation	0	O
affects	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
the	0	O
alpha	0	O
subunit	0	O
,	0	O
changing	0	O
a	0	O
leucine	0	O
residue	0	O
at	0	O
position	0	O
290	0	O
to	0	O
a	0	O
histidine	0	O
(	0	O
rpoAL290H	0	B
).	0	O


The	0	O
time	0	O
course	0	O
of	0	O
RNA1	0	B
replication	0	O
and	0	O
RNA3	0	B
synthesis	0	O
in	0	O
induced	0	O
yeast	0	O
paralleled	0	O
that	0	O
in	0	O
yeast	0	O
transfected	0	O
with	0	O
natural	0	O
FHV	0	O
virion	0	O
RNA	1	O
.	0	O


Copyright	0	O
1998	0	O
Academic	0	O
Press	0	O
.	0	O


Forty	0	O
-	0	O
eight	0	O
sequences	0	O
,	0	O
30	0	O
not	0	O
previously	0	O
identified	0	O
as	0	O
IR	1	O
-	0	O
responsive	0	O
,	0	O
were	0	O
significantly	0	O
regulated	0	O
by	0	O
IR	1	O
.	0	O


Cloning	1	O
of	0	O
individual	0	O
ZI	0	O
domains	0	O
upstream	0	O
of	0	O
a	0	O
minimal	0	O
promoter	0	O
demonstrated	0	O
that	0	O
the	0	O
ZIA	0	O
,	0	O
ZIC	0	O
,	0	O
and	0	O
ZID	0	O
domains	0	O
,	0	O
but	0	O
not	0	O
the	0	O
ZIB	0	O
domain	0	O
,	0	O
are	0	O
TPA	1	O
responsive	0	O
.	0	O


Although	0	O
a	0	O
carboxyl	0	O
-	0	O
terminal	0	O
HSF	0	B
transcriptional	0	O
activation	0	O
domain	0	O
is	0	O
critical	0	O
for	0	O
the	0	O
activation	0	O
of	0	O
CUP1	0	B
transcription	0	O
in	0	O
response	0	O
to	0	O
both	0	O
heat	0	O
shock	0	O
stress	0	O
and	0	O
glucose	0	O
starvation	0	O
,	0	O
this	0	O
region	0	O
is	0	O
dispensable	0	O
for	0	O
transient	0	O
heat	0	O
shock	0	O
activation	0	O
of	0	O
at	0	O
least	0	O
two	0	O
genes	0	O
encoding	0	O
members	0	O
of	0	O
the	0	O
S	1	O
.	0	O
cerevisiae	0	O
hsp70	0	B
family	0	I
.	0	O


We	0	O
have	0	O
explored	0	O
the	0	O
mechanism	0	O
of	0	O
action	0	O
of	0	O
the	0	O
fibronectin	0	B
splicing	0	I
enhancer	0	I
and	0	O
found	0	O
that	0	O
the	0	O
SE	1	O
element	0	O
is	0	O
required	0	O
for	0	O
efficient	0	O
assembly	0	O
of	0	O
early	0	O
splicing	0	O
complexes	0	O
,	0	O
allowing	0	O
a	0	O
more	0	O
efficient	0	O
interaction	0	O
of	0	O
the	0	O
U2	0	B
snRNP	1	I
with	0	O
branch	0	O
site	0	O
sequences	0	O
.	0	O


The	0	O
ability	0	O
of	0	O
SMRT	0	B
to	0	O
associate	0	O
with	0	O
these	0	O
transcription	0	O
factors	0	O
and	0	O
thereby	0	O
to	0	O
mediate	0	O
repression	0	O
is	0	O
strongly	0	O
inhibited	0	O
by	0	O
activation	0	O
of	0	O
tyrosine	0	B
kinase	0	I
signaling	0	O
pathways	0	O
,	0	O
such	0	O
as	0	O
that	0	O
represented	0	O
by	0	O
the	0	O
epidermal	0	B
growth	0	I
factor	0	I
receptor	0	I
.	0	O


The	0	O
sixth	0	O
nucleotide	0	O
was	0	O
bulged	0	O
out	0	O
to	0	O
allow	0	O
stacking	0	O
of	0	O
this	0	O
U	1	O
.	0	O
G	1	O
pair	0	O
on	0	O
the	0	O
adjacent	0	O
helical	0	O
region	0	O
.	0	O


These	0	O
results	0	O
suggested	0	O
the	0	O
possibility	0	O
that	0	O
the	0	O
fetus	0	O
played	0	O
some	0	O
role	0	O
in	0	O
the	0	O
production	0	O
of	0	O
E3	1	O
-	0	O
16	0	O
-	0	O
G	1	O
in	0	O
early	0	O
pregnancy	0	O
.	0	O


The	0	O
same	0	O
IL	1	B
-	0	I
4	0	I
-	0	O
inducible	0	O
reporter	0	O
gene	0	O
is	0	O
also	0	O
synergistically	0	O
activated	0	O
by	0	O
the	0	O
endogenous	0	B
Stat6	0	I
and	0	O
NF	1	B
-	0	I
kappaB	0	I
proteins	0	I
in	0	O
IL	1	B
-	0	I
4	0	I
-	0	O
stimulated	0	O
I	1	O
.	0	O
29mu	0	O
B	1	O
lymphoma	0	O
cells	0	O
.	0	O


Estrus	1	O
and	0	O
copulative	0	O
abilities	0	O
of	0	O
androgen	0	O
-	0	O
sterilized	0	O
rats	0	O


Another	0	O
full	0	O
ORF	1	O
was	0	O
found	0	O
on	0	O
the	0	O
opposite	0	O
strand	0	O
downstream	0	O
from	0	O
the	0	O
nspC	0	B
gene	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
c	0	B
-	0	I
Src	1	I
-	0	I
derived	0	I
construct	0	I
(	0	O
a	0	B
-	0	I
Src	1	I
),	0	O
that	0	O
was	0	O
excluded	0	O
from	0	O
detergent	0	O
-	0	O
resistant	0	O
membranes	0	O
,	0	O
could	0	O
not	0	O
restore	0	O
the	0	O
series	0	O
of	0	O
phagocytosis	0	O
signaling	0	O
.	0	O


C	1	O
.,	0	O
Sun	0	O
,	0	O
J	1	O
.,	0	O
Hsu	0	O
,	0	O
M	1	O
.-	0	O
Y	1	O
.,	0	O
Vallejo	0	O
-	0	O
Ramirez	0	O
,	0	O
J	1	O
.,	0	O
Inouye	0	O
,	0	O
S	1	O
.,	0	O
and	0	O
Inouye	0	O
,	0	O
M	1	O
.	0	O


Schooling	0	O
is	0	O
found	0	O
to	0	O
be	0	O
related	0	O
to	0	O
good	0	O
health	0	O
even	0	O
after	0	O
controlling	0	O
for	0	O
differences	0	O
in	0	O
observable	0	O
health	0	O
inputs	0	O
.	0	O


Among	0	O
unusual	0	O
features	0	O
,	0	O
we	0	O
report	0	O
numerous	0	O
large	0	O
G	1	O
+	0	O
C	1	O
-	0	O
rich	0	O
conserved	0	O
sequences	0	O
located	0	O
in	0	O
the	0	O
first	0	O
intron	0	O
.	0	O


Although	0	O
previous	0	O
data	0	O
have	0	O
suggested	0	O
that	0	O
Rev	0	B
uses	0	O
the	0	O
same	0	O
export	0	O
pathway	0	O
as	0	O
uracil	0	O
-	0	O
rich	0	O
small	0	O
nuclear	0	O
RNAs	0	O
and	0	O
5S	0	B
ribosomal	0	I
RNA	1	I
,	0	O
the	0	O
CTE	0	O
seems	0	O
to	0	O
interact	0	O
with	0	O
evolutionarily	0	O
conserved	0	O
factors	0	O
that	0	O
are	0	O
essential	0	O
for	0	O
cellular	0	O
mRNA	1	O
export	0	O
.	0	O


A	1	O
triple	0	O
Ser	1	O
-->	0	O
Ala	1	O
mutant	0	O
form	0	O
of	0	O
yeast	0	O
eIF	0	B
-	0	I
2	0	I
alpha	0	I
was	0	O
found	0	O
to	0	O
be	0	O
no	0	O
longer	0	O
phosphorylated	0	O
by	0	O
either	0	O
of	0	O
the	0	O
yeast	0	O
(	0	O
or	0	O
mammalian	0	O
)	0	O
casein	0	B
kinase	0	I
activities	0	O
in	0	O
vitro	0	O
.	0	O


The	0	O
kinase	0	O
inhibitor	0	O
staurosporine	0	O
(	0	O
1	0	O
microM	0	O
)	0	O
blocks	0	O
LPA	0	O
-	0	O
induced	0	O
,	0	O
but	0	O
not	0	O
epidermal	0	O
growth	0	O
factor	0	O
-	0	O
induced	0	O
,	0	O
activation	0	O
of	0	O
p21ras	0	B
and	0	O
MAP	1	B
kinase	0	I
,	0	O
consistent	0	O
with	0	O
an	0	O
intermediate	0	O
protein	0	O
kinase	0	O
linking	0	O
the	0	O
LPA	0	B
receptor	0	I
to	0	O
p21ras	0	B
activation	0	O
.	0	O


Eight	0	O
recombinant	0	O
DNA	1	O
clones	0	O
of	0	O
endogenous	0	O
murine	0	O
leukemia	0	O
virus	0	O
(	0	O
MuLV	0	O
)-	0	O
related	0	O
DNA	1	O
sequences	0	O
have	0	O
been	0	O
isolated	0	O
from	0	O
a	0	O
lambdaphage	0	O
genomic	0	O
library	0	O
of	0	O
Balb	0	O
/	0	O
c	0	O
mouse	0	O
DNA	1	O
.	0	O


By	0	O
treating	0	O
monkey	0	O
COS	1	O
cells	0	O
with	0	O
oligonucleotides	0	O
linked	0	O
to	0	O
psoralen	0	O
,	0	O
we	0	O
have	0	O
generated	0	O
targeted	0	O
mutations	0	O
in	0	O
a	0	O
simian	0	O
virus	0	O
40	0	O
(	0	O
SV40	1	O
)	0	O
vector	0	O
contained	0	O
within	0	O
the	0	O
cells	0	O
via	0	O
intracellular	0	O
triple	0	O
helix	0	O
formation	0	O
.	0	O


After	0	O
declamping	0	O
of	0	O
the	0	O
aorta	0	O
,	0	O
there	0	O
were	0	O
also	0	O
severe	0	O
edema	0	O
,	0	O
local	0	O
fibre	0	O
necrosis	0	O
,	0	O
and	0	O
adhesion	0	O
of	0	O
leucocytes	0	O
,	0	O
whereas	0	O
muscle	0	O
fibre	0	O
areas	0	O
became	0	O
3	0	O
,	0	O
935	0	O
.	0	O
18	0	O
micro	0	O
531	0	O
microm	0	O
(	0	O
2	0	O
)	0	O
for	0	O
type	0	O
I	1	O
and	0	O
5	0	O
,	0	O
804	0	O
+/-	0	O
1	0	O
,	0	O
075	0	O
microm	0	O
(	0	O
2	0	O
)	0	O
for	0	O
type	0	O
II	0	O
.	0	O


When	0	O
phosphorylation	0	O
of	0	O
exogenous	0	O
peptide	0	O
substrates	0	O
was	0	O
measured	0	O
as	0	O
a	0	O
function	0	O
of	0	O
receptor	0	O
self	0	O
-	0	O
phosphorylation	0	O
,	0	O
tyrosine	0	B
kinase	0	I
activity	0	O
was	0	O
found	0	O
to	0	O
be	0	O
enhanced	0	O
two	0	O
to	0	O
threefold	0	O
at	0	O
1	0	O
-	0	O
2	0	O
mol	0	O
of	0	O
phosphate	0	O
per	0	O
mol	0	O
of	0	O
receptor	0	O
.	0	O


Interleukin	1	B
-	0	I
8	0	I
(	0	O
IL	1	B
-	0	I
8	0	I
)	0	O
is	0	O
a	0	O
potent	0	O
inflammatory	0	O
mediator	0	O
that	0	O
belongs	0	O
to	0	O
the	0	O
family	0	O
of	0	O
C	1	B
-	0	I
X	1	I
-	0	I
C	1	I
chemokines	0	I
.	0	O


These	0	O
cell	0	O
lines	0	O
,	0	O
selected	0	O
for	0	O
the	0	O
ability	0	O
to	0	O
support	0	O
the	0	O
replication	0	O
of	0	O
a	0	O
temperature	0	O
-	0	O
sensitive	0	O
VP5	0	B
mutant	0	I
,	0	O
were	0	O
used	0	O
to	0	O
isolate	0	O
VP5	0	B
and	0	O
VP23	0	B
null	0	O
mutants	0	O
.	0	O


Retinal	1	O
changes	0	O
in	0	O
pigmentary	0	O
retinopathy	0	O
in	0	O
children	0	O


Dilutions	0	O
of	0	O
H	1	B
-	0	I
2b	0	I
or	0	I
H	1	I
-	0	I
2d	0	I
NP	1	I
peptides	0	I
indicated	0	O
that	0	O
3	0	O
-	0	O
4	0	O
logs	0	O
less	0	O
H	1	B
-	0	I
2b	0	I
NP	1	I
peptide	0	I
was	0	O
required	0	O
to	0	O
sensitize	0	O
syngeneic	0	O
target	0	O
cells	0	O
for	0	O
CTL	1	O
-	0	O
specific	0	O
lysis	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
differing	0	O
affinities	0	O
of	0	O
H	1	O
-	0	O
2b	0	O
and	0	O
H	1	O
-	0	O
2d	0	O
major	0	B
histocompatibility	0	I
complex	0	I
molecules	0	I
for	0	O
their	0	O
peptides	0	O
likely	0	O
account	0	O
for	0	O
the	0	O
total	0	O
removal	0	O
of	0	O
NP	1	O
CTL	1	O
in	0	O
the	0	O
H	1	O
-	0	O
2b	0	O
mice	0	O
but	0	O
only	0	O
partial	0	O
removal	0	O
in	0	O
H	1	O
-	0	O
2d	0	O
mice	0	O
made	0	O
to	0	O
express	0	O
thymic	0	O
NP	1	O
.	0	O


We	0	O
determined	0	O
whether	0	O
regional	0	O
myocardial	0	O
work	0	O
efficiency	0	O
(	0	O
segment	0	O
work	0	O
/	0	O
regional	0	O
O2	1	O
consumption	0	O
)	0	O
would	0	O
be	0	O
elevated	0	O
by	0	O
surgically	0	O
-	0	O
augmented	0	O
inflow	0	O
.	0	O


The	0	O
highest	0	O
postoperative	0	O
CK	1	B
-	0	I
MB	1	I
level	0	O
was	0	O
less	0	O
after	0	O
BC	1	O
(	0	O
BC	1	O
,	0	O
31	0	O
+/-	0	O
17	0	O
U	1	O
/	0	O
L	1	O
;	0	O
CC	1	O
,	0	O
56	0	O
+/-	0	O
13	0	O
U	1	O
/	0	O
L	1	O
;	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Given	0	O
its	0	O
relative	0	O
longevity	0	O
on	0	O
the	0	O
Web	1	O
,	0	O
TIE	0	O
researchers	0	O
have	0	O
been	0	O
in	0	O
a	0	O
unique	0	O
position	0	O
to	0	O
observe	0	O
trends	0	O
in	0	O
telemedicine	0	O
.	0	O


Repression	1	O
of	0	O
glucocorticoid	0	B
receptor	0	I
-	0	O
mediated	0	O
transcriptional	0	O
activation	0	O
by	0	O
unliganded	0	O
thyroid	0	B
hormone	0	I
receptor	0	I
(	0	O
TR	1	B
)	0	O
is	0	O
TR	1	B
isoform	0	O
-	0	O
specific	0	O
.	0	O


Two	0	O
US	1	O
commercial	0	O
cultivars	0	O
(	0	O
Tehama	0	O
and	0	O
Vina	0	O
),	0	O
three	0	O
European	0	O
commercial	0	O
cultivars	0	O
(	0	O
Esterhazy	0	O
,	0	O
139	0	O
,	0	O
G120	0	O
)	0	O
and	0	O
five	0	O
New	0	O
Zealand	0	O
selections	0	O
(	0	O
Rex	0	O
,	0	O
Dublin	0	O
'	0	O
s	0	O
Glory	0	O
,	0	O
Meyric	0	O
,	0	O
McKinster	0	O
,	0	O
Stanley	0	O
)	0	O
were	0	O
evaluated	0	O
.	0	O


METHODS	0	O
:	0	O
rHb1	0	B
.	0	I
1	0	I
or	0	O
human	0	B
serum	0	I
albumin	0	I
was	0	O
administered	0	O
intravenously	0	O
to	0	O
fasting	0	O
male	0	O
volunteers	0	O
.	0	O


With	0	O
a	0	O
BMI	1	O
cutoff	0	O
of	0	O
27	0	O
,	0	O
mean	0	O
cardiac	0	O
NE	1	O
spillover	0	O
was	0	O
46	0	O
%	0	O
lower	0	O
in	0	O
the	0	O
obese	0	O
subjects	0	O
when	0	O
compared	0	O
with	0	O
the	0	O
lean	0	O
subjects	0	O
(	0	O
P	1	O
=.	0	O
017	0	O
).	0	O


MATERIALS	0	O
AND	0	O
METHODS	0	O
:	0	O
Coronal	1	O
3D	0	O
GRE	0	O
imaging	0	O
was	0	O
used	0	O
to	0	O
study	0	O
the	0	O
volar	0	O
,	0	O
middle	0	O
,	0	O
and	0	O
dorsal	0	O
portions	0	O
of	0	O
the	0	O
SLL	0	O
in	0	O
14	0	O
patients	0	O
with	0	O
an	0	O
arthroscopically	0	O
normal	0	O
SLL	0	O
and	0	O
in	0	O
five	0	O
cadaveric	0	O
wrists	0	O
that	0	O
had	0	O
a	0	O
normal	0	O
SLL	0	O
proved	0	O
with	0	O
dissection	0	O
.	0	O


Prostacyclin	1	O
formation	0	O
,	0	O
reflected	0	O
by	0	O
the	0	O
excretion	0	O
rate	0	O
of	0	O
its	0	O
stable	0	O
metabolite	0	O
6	0	O
-	0	O
keto	0	O
-	0	O
prostaglandin	0	O
F1	0	O
alpha	0	O
,	0	O
was	0	O
measured	0	O
by	0	O
means	0	O
of	0	O
radioimmunoassay	0	O
in	0	O
4	0	O
-	0	O
hour	0	O
urine	0	O
specimens	0	O
obtained	0	O
during	0	O
a	0	O
smoking	0	O
-	0	O
free	0	O
period	0	O
and	0	O
after	0	O
participants	0	O
had	0	O
inhaled	0	O
smoke	0	O
from	0	O
four	0	O
high	0	O
-	0	O
nicotine	0	O
cigarettes	0	O
.	0	O


NH3	1	O
and	0	O
NO	1	O
interaction	0	O
with	0	O
Si	1	O
(	0	O
100	0	O
)-(	0	O
2	0	O
x	0	O
1	0	O
)	0	O
surfaces	0	O
.	0	O


There	0	O
is	0	O
general	0	O
agreement	0	O
that	0	O
the	0	O
hepatitis	0	O
C	1	O
virus	0	O
is	0	O
efficiently	0	O
transmitted	0	O
parenterally	0	O
,	0	O
while	0	O
data	0	O
on	0	O
viral	0	O
transmission	0	O
from	0	O
mothers	0	O
to	0	O
babies	0	O
or	0	O
by	0	O
sexual	0	O
or	0	O
non	0	O
-	0	O
sexual	0	O
household	0	O
contact	0	O
are	0	O
conflicting	0	O
.	0	O


The	0	O
foregoing	0	O
results	0	O
show	0	O
that	0	O
CXD	0	O
has	0	O
high	0	O
efficacy	0	O
and	0	O
safety	0	O
and	0	O
it	0	O
can	0	O
be	0	O
said	0	O
that	0	O
it	0	O
is	0	O
a	0	O
drug	0	O
required	0	O
in	0	O
the	0	O
pediatric	0	O
field	0	O
.	0	O


Identification	1	O
of	0	O
a	0	O
spliced	0	O
gene	0	O
from	0	O
Kaposi	0	O
'	0	O
s	0	O
sarcoma	0	O
-	0	O
associated	0	O
herpesvirus	0	O
encoding	0	O
a	0	O
protein	0	O
with	0	O
similarities	0	O
to	0	O
latent	0	B
membrane	0	I
proteins	0	I
1	0	I
and	0	I
2A	0	I
of	0	I
Epstein	0	I
-	0	I
Barr	0	I
virus	0	I
.	0	O


We	0	O
studied	0	O
GSH	1	O
-	0	O
Px	0	O
enzyme	0	O
activity	0	O
in	0	O
serum	0	O
after	0	O
acute	0	O
myocardial	0	O
infarction	0	O
(	0	O
AMI	1	O
)	0	O
and	0	O
unstable	0	O
angina	0	O
pectoris	0	O
(	0	O
UAP	0	O
).	0	O


Enzyme	1	O
-	0	O
linked	0	O
immunosorbent	0	O
assay	0	O
for	0	O
screening	0	O
aflatoxin	0	O
B1	0	O
in	0	O
cottonseed	0	O
products	0	O
and	0	O
mixed	0	O
feed	0	O
:	0	O
collaborative	0	O
study	0	O
.	0	O


Antithrombin	1	B
III	0	I
deficiency	0	O
:	0	O
when	0	O
substitute	0	O
,	0	O
when	0	O
heparin	0	O
?	0	O
Thrombosis	1	O
ABC	1	O
,	0	O
3	0	O
:	0	O
The	0	O
role	0	O
of	0	O
antithrombin	0	B
III	0	I


Transfection	1	O
with	0	O
a	0	O
CSF	1	B
-	0	I
1R	0	I
expression	0	O
plasmid	0	O
permitted	0	O
CSF	1	B
-	0	I
1	0	I
-	0	O
dependent	0	O
activation	0	O
of	0	O
the	0	O
signalling	0	O
pathway	0	O
targeting	0	O
an	0	O
Ets	1	B
/	0	O
AP1	0	B
(	0	O
activator	0	B
protein	0	I
1	0	I
)	0	O
element	0	O
in	0	O
the	0	O
uPA	0	B
promoter	0	I
that	0	O
has	0	O
been	0	O
shown	0	O
previously	0	O
to	0	O
be	0	O
a	0	O
target	0	O
of	0	O
oncogenic	0	B
ras	0	I
and	0	O
protein	0	O
kinase	0	O
C	1	O
pathways	0	O
.	0	O


Biol	0	O
.	0	O


Altogether	0	O
,	0	O
our	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
transcriptional	0	O
activity	0	O
of	0	O
Cut	1	B
proteins	0	I
is	0	O
modulated	0	O
by	0	O
PKC	0	B
.	0	O


The	0	O
structural	0	O
similarity	0	O
between	0	O
Vav	0	B
and	0	O
other	0	O
guanine	0	B
nucleotide	0	I
exchange	0	I
factors	0	I
for	0	O
small	0	B
GTP	1	I
-	0	I
binding	0	I
proteins	0	I
,	0	O
together	0	O
with	0	O
the	0	O
recent	0	O
identification	0	O
of	0	O
biochemical	0	O
routes	0	O
specific	0	O
for	0	O
members	0	O
of	0	O
the	0	O
Ras	1	B
and	0	O
Rho	1	B
family	0	I
of	0	O
GTPases	0	B
,	0	O
prompted	0	O
us	0	O
to	0	O
explore	0	O
whether	0	O
MAPK	1	B
or	0	O
JNK	0	B
are	0	O
downstream	0	O
components	0	O
of	0	O
the	0	O
Vav	0	B
signaling	0	O
pathways	0	O
.	0	O


The	0	O
class	0	B
II	0	I
Escherichia	1	I
coli	0	I
alanine	0	I
tRNA	1	I
synthetase	0	I
aminoacylates	0	I
RNA	1	I
miniduplexes	0	I
,	0	O
which	0	O
reconstruct	0	O
the	0	O
acceptor	0	O
end	0	O
of	0	O
alanine	0	B
tRNA	1	I
with	0	O
the	0	O
critical	0	O
G3	0	O
:	0	O
U70	0	O
base	0	O
pair	0	O
.	0	O


We	0	O
show	0	O
that	0	O
the	0	O
en	0	B
stripes	0	O
expand	0	O
anteriorly	0	O
in	0	O
slp	0	B
mutant	0	O
embryos	0	O
and	0	O
that	0	O
slp	0	B
activity	0	O
is	0	O
an	0	O
absolute	0	O
requirement	0	O
for	0	O
maintenance	0	O
of	0	O
wg	0	B
expression	0	O
at	0	O
the	0	O
same	0	O
time	0	O
that	0	O
wg	0	B
transcription	0	O
is	0	O
dependent	0	O
on	0	O
hh	0	B
.	0	O


The	0	O
MMPI	1	O
-	0	O
A	1	O
(	0	O
Butcher	0	O
et	0	O
al	0	O
.,	0	O
1992	0	O
),	0	O
like	0	O
the	0	O
older	0	O
MMPI	1	O
(	0	O
Hathaway	0	O
&	0	O
McKinley	0	O
,	0	O
1983	0	O
),	0	O
distinguishes	0	O
between	0	O
anorexia	0	O
and	0	O
bulimia	0	O
.	0	O


Constructs	0	O
were	0	O
made	0	O
in	0	O
which	0	O
an	0	O
AATAAA	0	O
and	0	O
the	0	O
GT	1	O
-	0	O
rich	0	O
region	0	O
were	0	O
separated	0	O
by	0	O
various	0	O
distances	0	O
ranging	0	O
from	0	O
7	0	O
to	0	O
43	0	O
bp	0	O
.	0	O


Functional	1	O
analysis	0	O
of	0	O
DNase	1	B
-	0	I
I	1	I
hypersensitive	0	O
sites	0	O
at	0	O
the	0	O
mouse	0	B
porphobilinogen	0	I
deaminase	0	I
gene	0	I
locus	0	I
.	0	O


HBB	0	O
concentration	0	O
in	0	O
the	0	O
fetuses	0	O
indicated	0	O
little	0	O
,	0	O
if	0	O
any	0	O
accumulation	0	O
.	0	O


At	1	O
maximum	0	O
photosensitivity	0	O
the	0	O
inhibitory	0	O
amino	0	O
acids	0	O
gamma	0	O
-	0	O
aminobutyric	0	O
acid	0	O
and	0	O
taurine	0	O
were	0	O
lower	0	O
,	0	O
and	0	O
those	0	O
of	0	O
asparagine	0	O
(	0	O
metabolite	0	O
of	0	O
the	0	O
excitatory	0	O
amino	0	O
acid	0	O
aspartate	0	O
)	0	O
were	0	O
higher	0	O
,	0	O
than	0	O
when	0	O
the	0	O
animals	0	O
were	0	O
not	0	O
photosensitive	0	O
.	0	O


In	1	O
serum	0	O
-	0	O
stimulated	0	O
cells	0	O
,	0	O
the	0	O
binding	0	O
of	0	O
NF	1	B
-	0	I
Y	1	I
/	0	O
CBF	1	B
to	0	O
TKC1	0	B
increased	0	O
gradually	0	O
,	0	O
reaching	0	O
a	0	O
plateau	0	O
at	0	O
the	0	O
S	1	O
phase	0	O
.	0	O


Institution	0	O
of	0	O
both	0	O
intravenous	0	O
and	0	O
intracisternal	0	O
administration	0	O
of	0	O
amphotericin	0	O
B	1	O
and	0	O
possibly	0	O
concomitant	0	O
intravenous	0	O
administration	0	O
of	0	O
dexamethasone	0	O
may	0	O
be	0	O
warranted	0	O
in	0	O
situations	0	O
in	0	O
which	0	O
the	0	O
association	0	O
of	0	O
C	1	O
.	0	O
immitis	0	O
with	0	O
CNS	1	O
vasculitis	0	O
or	0	O
encephalitis	0	O
appears	0	O
likely	0	O
before	0	O
serologic	0	O
or	0	O
cultural	0	O
confirmation	0	O
of	0	O
C	1	O
.	0	O
immitis	0	O
infection	0	O
involving	0	O
the	0	O
CNS	1	O
is	0	O
available	0	O
.	0	O


Studies	0	O
of	0	O
lipogenesis	0	O
by	0	O
labelled	0	O
precursors	0	O
in	0	O
the	0	O
pregnant	0	O
rat	0	O
.	0	O


This	0	O
repression	0	O
was	0	O
mediated	0	O
through	0	O
binding	0	O
to	0	O
the	0	O
E2	1	B
DNA	1	I
-	0	I
binding	0	I
site	0	I
immediately	0	O
upstream	0	O
of	0	O
the	0	O
P105	0	B
promoter	0	O
TATA	0	O
box	0	O
and	0	O
could	0	O
be	0	O
abrogated	0	O
by	0	O
preincubation	0	O
of	0	O
the	0	O
HPV	1	B
-	0	I
18	0	I
P105	0	I
promoter	0	I
template	0	O
with	0	O
the	0	O
nuclear	0	O
extract	0	O
allowing	0	O
the	0	O
formation	0	O
of	0	O
the	0	O
preinitiation	0	O
complex	0	O
.	0	O


DNase	1	B
I	1	I
footprinting	0	O
and	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assays	0	O
indicate	0	O
that	0	O
PBP	0	B
binds	0	O
to	0	O
the	0	O
half	0	O
-	0	O
site	0	O
of	0	O
each	0	O
palindrome	0	O
with	0	O
the	0	O
core	0	O
recognition	0	O
sequence	0	O
TGGGAG	0	O
.	0	O


Total	0	O
cholesterol	0	O
was	0	O
measured	0	O
in	0	O
amniotic	0	O
fluids	0	O
collected	0	O
at	0	O
different	0	O
stages	0	O
of	0	O
gestation	0	O
.	0	O


HER2	1	B
overexpressing	0	O
cells	0	O
showed	0	O
a	0	O
single	0	O
prominent	0	O
DNase	1	B
I	1	I
hypersensitive	0	O
site	0	O
near	0	O
a	0	O
conserved	0	O
and	0	O
hitherto	0	O
unrecognized	0	O
ets	0	B
response	0	O
element	0	O
(	0	O
GAGGAA	0	O
),	0	O
located	0	O
38	0	O
bases	0	O
down	0	O
-	0	O
stream	0	O
from	0	O
the	0	O
CAAT	0	O
box	0	O
and	0	O
directly	0	O
5	0	O
'	0	O
of	0	O
the	0	O
TATA	0	O
box	0	O
in	0	O
the	0	O
human	0	B
HER2	1	I
promoter	0	I
.	0	O


They	0	O
self	0	O
-	0	O
completed	0	O
the	0	O
SF	1	O
-	0	O
36	0	O
questionnaire	0	O
and	0	O
their	0	O
QoL	0	O
was	0	O
described	0	O
and	0	O
retrospectively	0	O
compared	0	O
to	0	O
that	0	O
of	0	O
historical	0	O
controls	0	O
.	0	O


Although	0	O
it	0	O
has	0	O
been	0	O
shown	0	O
that	0	O
it	0	O
is	0	O
possible	0	O
to	0	O
use	0	O
orally	0	O
administered	0	O
testosterone	0	O
to	0	O
maintain	0	O
se	0	O
-	0	O
T	1	O
levels	0	O
in	0	O
the	0	O
normal	0	O
male	0	O
range	0	O
,	0	O
the	0	O
convenience	0	O
to	0	O
the	0	O
patient	0	O
must	0	O
be	0	O
balanced	0	O
against	0	O
the	0	O
cost	0	O
and	0	O
possible	0	O
side	0	O
effects	0	O
of	0	O
the	0	O
large	0	O
doses	0	O
required	0	O
.	0	O


All	1	O
tumors	0	O
proved	0	O
histologically	0	O
to	0	O
be	0	O
neuroendocrine	0	O
in	0	O
origin	0	O
.	0	O


66	0	O
:	0	O
469	0	O
-	0	O
479	0	O
,	0	O
1992	0	O
).	0	O


J	1	O
.	0	O


Serial	1	O
measurements	0	O
of	0	O
total	0	O
serum	0	O
IgE	1	B
appears	0	O
to	0	O
be	0	O
a	0	O
useful	0	O
index	0	O
of	0	O
disease	0	O
activity	0	O
in	0	O
ABPA	0	O
.	0	O


To	1	O
facilitate	0	O
manipulation	0	O
of	0	O
large	0	O
genomic	0	O
sequences	0	O
,	0	O
we	0	O
developed	0	O
a	0	O
method	0	O
of	0	O
converting	0	O
Escherichia	1	O
coli	0	O
P1	1	O
artificial	0	O
chromosomes	0	O
(	0	O
PACs	1	O
)	0	O
into	0	O
yeast	0	O
artificial	0	O
chromosomes	0	O
(	0	O
YACs	0	O
).	0	O


Here	0	O
we	0	O
show	0	O
that	0	O
these	0	O
synthetic	0	O
binding	0	O
sites	0	O
have	0	O
a	0	O
more	0	O
restricted	0	O
and	0	O
specific	0	O
ability	0	O
to	0	O
enhance	0	O
transcription	0	O
when	0	O
assayed	0	O
in	0	O
transformed	0	O
embryos	0	O
.	0	O


On	1	O
the	0	O
other	0	O
hand	0	O
,	0	O
neither	0	O
phosphate	0	O
buffered	0	O
saline	0	O
injection	0	O
into	0	O
the	0	O
ES	1	O
nor	0	O
primary	0	O
KLH	0	B
challenges	0	O
of	0	O
the	0	O
ES	1	O
were	0	O
capable	0	O
of	0	O
elevating	0	O
the	0	O
threshold	0	O
level	0	O
and	0	O
changing	0	O
the	0	O
latency	0	O
.	0	O


Ketanserin	0	O
,	0	O
a	0	O
hypotensive	0	O
drug	0	O
with	0	O
5	0	B
-	0	I
HT2	0	I
receptor	0	I
antagonism	0	O
,	0	O
when	0	O
administered	0	O
by	0	O
topical	0	O
infusion	0	O
of	0	O
a	0	O
0	0	O
.	0	O
25	0	O
%	0	O
w	0	O
/	0	O
v	0	O
solution	0	O
by	0	O
corneal	0	O
and	0	O
scleral	0	O
applications	0	O
,	0	O
was	0	O
found	0	O
to	0	O
lower	0	O
intraocular	0	O
pressure	0	O
with	0	O
four	0	O
times	0	O
more	0	O
activity	0	O
than	0	O
its	0	O
metabolite	0	O
,	0	O
ketanserinol	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
salmon	0	B
calcitonin	0	I
nasal	0	O
spray	0	O
in	0	O
women	0	O
with	0	O
established	0	O
osteoporosis	0	O
has	0	O
also	0	O
been	0	O
studied	0	O
.	0	O


Varieties	0	O
of	0	O
envious	0	O
experience	0	O
.	0	O


Brief	1	O
report	0	O
.	0	O


Plasma	1	O
levels	0	O
of	0	O
protein	0	B
C	1	I
,	0	O
protein	0	B
S	1	I
,	0	O
and	0	O
antithrombin	0	B
III	0	I
in	0	O
patients	0	O
with	0	O
subarachnoid	0	O
haemorrhage	0	O
.	0	O


Development	1	O
of	0	O
a	0	O
yeast	0	O
system	0	O
to	0	O
assay	0	O
mutational	0	O
specificity	0	O
.	0	O


Calcinosis	1	O
cutis	0	O
following	0	O
intravenous	0	O
infusion	0	O
of	0	O
calcium	0	O
gluconate	0	O
.	0	O


To	1	O
compare	0	O
the	0	O
PAX3	0	B
and	0	O
putative	0	O
PAX3	0	B
-	0	O
FKHR	0	B
transactivation	0	O
domains	0	O
,	0	O
we	0	O
fused	0	O
C	1	O
-	0	O
terminal	0	O
test	0	O
fragments	0	O
to	0	O
the	0	O
heterologous	0	O
GAL4	0	B
DNA	1	I
-	0	I
binding	0	I
domain	0	I
and	0	O
tested	0	O
activation	0	O
of	0	O
a	0	O
reporter	0	O
gene	0	O
co	0	O
-	0	O
transfected	0	O
into	0	O
four	0	O
cell	0	O
types	0	O
.	0	O


Nuclease	1	O
footprinting	0	O
revealed	0	O
that	0	O
purified	0	O
glucocorticoid	0	B
receptor	0	I
bound	0	O
at	0	O
multiple	0	O
discrete	0	O
sites	0	O
within	0	O
and	0	O
at	0	O
the	0	O
borders	0	O
of	0	O
the	0	O
tandemly	0	O
repeated	0	O
sequence	0	O
motif	0	O
that	0	O
defines	0	O
Sa	1	B
.	0	O


Instead	0	O
,	0	O
they	0	O
contained	0	O
dendritic	0	O
cells	0	O
that	0	O
express	0	O
melanogenic	0	O
marker	0	O
proteins	0	O
such	0	O
as	0	O
tyrosinase	0	B
and	0	O
tyrosinase	0	B
-	0	I
related	0	I
protein	0	I
1	0	I
.	0	O


The	0	O
location	0	O
of	0	O
multiple	0	O
GRK2	0	B
and	0	O
GRK5	0	B
phosphoacceptor	0	I
sites	0	I
at	0	O
the	0	O
extreme	0	O
carboxyl	0	O
terminus	0	O
of	0	O
the	0	O
beta2AR	0	B
is	0	O
highly	0	O
reminiscent	0	O
of	0	O
GRK1	0	B
-	0	O
mediated	0	O
phosphorylation	0	O
of	0	O
rhodopsin	0	B
.	0	O


Surprisingly	0	O
,	0	O
there	0	O
is	0	O
no	0	O
sequence	0	O
homology	0	O
between	0	O
this	0	O
region	0	O
of	0	O
Ly	1	B
-	0	I
6E	0	I
and	0	O
the	0	O
established	0	O
consensus	0	O
for	0	O
the	0	O
interferon	0	B
-	0	I
stimulated	0	I
response	0	I
element	0	I
,	0	O
which	0	O
has	0	O
been	0	O
shown	0	O
functionally	0	O
important	0	O
to	0	O
all	0	O
previously	0	O
characterized	0	O
alpha	0	B
/	0	I
beta	0	I
interferon	0	I
-	0	O
inducible	0	O
promoters	0	O
.	0	O


Elimination	1	O
of	0	O
ETH1	0	B
in	0	O
apn1	0	B
strains	0	O
also	0	O
increased	0	O
spontaneous	0	O
mutation	0	O
rates	0	O
9	0	O
-	0	O
or	0	O
31	0	O
-	0	O
fold	0	O
compared	0	O
to	0	O
the	0	O
wild	0	O
type	0	O
as	0	O
determined	0	O
by	0	O
reversion	0	O
to	0	O
adenine	0	O
or	0	O
lysine	0	O
prototrophy	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
experiments	0	O
show	0	O
that	0	O
it	0	O
is	0	O
the	0	O
micromilieu	0	O
of	0	O
the	0	O
alveoli	0	O
and	0	O
the	0	O
condition	0	O
of	0	O
the	0	O
AM	1	O
(	0	O
certain	0	O
physiological	0	O
activation	0	O
states	0	O
,	0	O
such	0	O
as	0	O
phagocytic	0	O
activity	0	O
)	0	O
that	0	O
essentially	0	O
determine	0	O
the	0	O
degree	0	O
of	0	O
recovery	0	O
.	0	O


A	1	O
major	0	O
mechanism	0	O
whereby	0	O
steroid	0	B
hydroxylase	0	I
gene	0	I
transcription	0	O
is	0	O
regulated	0	O
in	0	O
the	0	O
adrenal	0	O
cortex	0	O
requires	0	O
the	0	O
pituitary	0	O
peptide	0	O
hormone	0	O
,	0	O
ACTH	1	B
,	0	O
which	0	O
acts	0	O
via	0	O
cAMP	1	O
.	0	O


An	1	O
expression	0	O
library	0	O
was	0	O
constructed	0	O
by	0	O
inserting	0	O
5	0	O
'	0	O
portion	0	O
-	0	O
enriched	0	O
cDNAs	0	O
from	0	O
phytohemagglutinin	0	B
-	0	O
stimulated	0	O
peripheral	0	O
blood	0	O
mononuclear	0	O
cells	0	O
into	0	O
upstream	0	O
of	0	O
signal	0	B
sequence	0	I
-	0	I
deleted	0	I
CD4	1	I
cDNA	1	I
in	0	O
an	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
shuttle	0	O
vector	0	O
.	0	O


Primers	0	O
for	0	O
subsequent	0	O
rounds	0	O
of	0	O
RACE	1	O
were	0	O
designed	0	O
from	0	O
the	0	O
5	0	O
'-	0	O
ends	0	O
of	0	O
amplified	0	O
RACE	1	O
products	0	O
.	0	O


The	0	O
nucleolin	0	B
gene	0	I
extends	0	O
over	0	O
9000	0	O
base	0	O
-	0	O
pairs	0	O
and	0	O
is	0	O
split	0	O
into	0	O
14	0	O
exons	0	O
that	0	O
encode	0	O
the	0	O
706	0	O
amino	0	O
acid	0	O
residues	0	O
of	0	O
the	0	O
protein	0	O
.	0	O


Crohn	0	O
'	0	O
s	0	O
disease	0	O
in	0	O
prolonged	0	O
remission	0	O
:	0	O
should	0	O
one	0	O
augment	0	O
protein	0	O
-	0	O
calorie	0	O
intake	0	O
as	0	O
compared	0	O
to	0	O
healthy	0	O
subjects	0	O
?]	0	O
The	0	O
aim	0	O
of	0	O
our	0	O
two	0	O
year	0	O
prospective	0	O
study	0	O
was	0	O
to	0	O
evaluate	0	O
whether	0	O
adult	0	O
Crohn	0	O
'	0	O
s	0	O
disease	0	O
patients	0	O
in	0	O
prolonged	0	O
remission	0	O
(	0	O
CDAI	0	O
<	0	O
150	0	O
),	0	O
in	0	O
order	0	O
to	0	O
maintain	0	O
their	0	O
body	0	O
weight	0	O
as	0	O
close	0	O
as	0	O
possible	0	O
to	0	O
the	0	O
ideal	0	O
one	0	O
,	0	O
need	0	O
a	0	O
protein	0	O
-	0	O
calorie	0	O
intake	0	O
higher	0	O
than	0	O
the	0	O
predicted	0	O
one	0	O
and	0	O
that	0	O
of	0	O
healthy	0	O
controls	0	O
.	0	O


[	0	B
Ala85	0	I
]	0	I
Dk	1	I
(	0	I
69	0	I
-	0	I
85	0	I
)	0	I
retains	0	O
full	0	O
biological	0	O
activity	0	O
.	0	O


Mouse	1	B
mast	0	I
cell	0	I
protease	0	I
9	0	I
,	0	O
a	0	O
novel	0	O
member	0	O
of	0	O
the	0	O
chromosome	0	O
14	0	O
family	0	O
of	0	O
serine	0	B
proteases	0	I
that	0	O
is	0	O
selectively	0	O
expressed	0	O
in	0	O
uterine	0	O
mast	0	O
cells	0	O
.	0	O


There	0	O
were	0	O
differences	0	O
between	0	O
males	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
for	0	O
most	0	O
of	0	O
the	0	O
characteristics	0	O
studied	0	O
.	0	O


The	0	O
study	0	O
disclosed	0	O
generalized	0	O
atrophy	0	O
and	0	O
diffuse	0	O
symmetric	0	O
white	0	O
matter	0	O
hypodensities	0	O
.	0	O


Oleate	1	O
induced	0	O
steady	0	O
-	0	O
state	0	O
levels	0	O
of	0	O
M	1	B
-	0	I
CPT	1	I
I	1	I
mRNA	1	I
4	0	O
.	0	O
5	0	O
-	0	O
fold	0	O
.	0	O


OBJECTIVES	0	O
:	0	O
1	0	O
)	0	O
to	0	O
determine	0	O
serum	0	B
ACE	1	I
activity	0	O
in	0	O
patients	0	O
with	0	O
COPD	1	O
treated	0	O
with	0	O
and	0	O
without	0	O
continuous	0	O
ambulatory	0	O
oxygen	0	O
therapy	0	O
(	0	O
CAOT	1	O
);	0	O
2	0	O
)	0	O
to	0	O
verify	0	O
whether	0	O
there	0	O
is	0	O
a	0	O
correlation	0	O
between	0	O
ACE	1	B
and	0	O
any	0	O
hematological	0	O
,	0	O
spirometric	0	O
or	0	O
gasometric	0	O
parameter	0	O
.	0	O


Thus	0	O
,	0	O
this	0	O
study	0	O
provides	0	O
evidence	0	O
that	0	O
a	0	O
novel	0	O
,	0	O
ubiquitous	0	O
factor	0	O
(	0	O
HF	1	B
-	0	I
1a	0	I
)	0	O
and	0	O
a	0	O
muscle	0	O
factor	0	O
(	0	O
HF	1	B
-	0	I
1b	0	I
/	0	O
MEF	0	B
-	0	I
2	0	I
)	0	O
can	0	O
form	0	O
a	0	O
novel	0	O
,	0	O
E	1	O
-	0	O
box	0	O
-	0	O
independent	0	O
pathway	0	O
for	0	O
muscle	0	O
-	0	O
specific	0	O
expression	0	O
in	0	O
ventricular	0	O
cardiac	0	O
muscle	0	O
cells	0	O
.	0	O


Determinants	0	O
of	0	O
recurrent	0	O
ischaemia	0	O
and	0	O
revascularisation	0	O
procedures	0	O
after	0	O
thrombolysis	0	O
with	0	O
recombinant	0	O
tissue	0	B
plasminogen	0	I
activator	0	I
in	0	O
primary	0	O
coronary	0	O
occlusion	0	O
.	0	O


Adrenergic	1	O
nerve	0	O
function	0	O
,	0	O
noradrenaline	0	O
level	0	O
and	0	O
noradrenaline	0	O
uptake	0	O
in	0	O
cat	0	O
nictitating	0	O
membrane	0	O
after	0	O
reserpine	0	O
treatment	0	O
.	0	O


We	0	O
characterized	0	O
cDNA	1	O
clones	0	O
specific	0	O
for	0	O
the	0	O
extracellular	0	O
matrix	0	O
glycoprotein	0	O
undulin	0	B
.	0	O


An	1	O
outbreak	0	O
of	0	O
hepatitis	0	O
A	1	O
among	0	O
homosexual	0	O
men	0	O
in	0	O
Amsterdam	0	O
,	0	O
1991	0	O
-	0	O
1993	0	O
.	0	O


An	1	O
unusual	0	O
cysteine	0	O
triplet	0	O
conserved	0	O
in	0	O
the	0	O
sequences	0	O
of	0	O
TB	1	B
domains	0	I
is	0	O
localized	0	O
to	0	O
the	0	O
hydrophobic	0	O
core	0	O
,	0	O
at	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
of	0	O
an	0	O
alpha	0	O
-	0	O
helix	0	O
.	0	O


Analysis	1	O
of	0	O
this	0	O
sequence	0	O
combined	0	O
with	0	O
that	0	O
previously	0	O
reported	0	O
for	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
directly	0	O
proximal	0	O
to	0	O
the	0	O
start	0	O
of	0	O
transcription	0	O
revealed	0	O
several	0	O
putative	0	O
regulatory	0	O
sequences	0	O
.	0	O


SCFFWD1	0	B
may	0	O
be	0	O
critical	0	O
for	0	O
tumor	0	O
development	0	O
and	0	O
suppression	0	O
through	0	O
regulation	0	O
of	0	O
beta	0	B
-	0	I
catenin	0	I
protein	0	I
stability	0	O
.	0	O


Analysis	1	O
of	0	O
homologous	0	O
DNA	1	O
sequences	0	O
within	0	O
the	0	O
first	0	O
intron	0	O
of	0	O
the	0	O
mouse	0	B
and	0	I
human	0	I
mts1	0	I
genes	0	I
:	0	O
kB	1	B
-	0	I
like	0	I
site	0	I
and	0	O
microsatellite	0	O
DNA	1	O


Plate	1	O
luting	0	O
,	0	O
a	0	O
technique	0	O
that	0	O
uses	0	O
polymethylmethacrylate	0	O
(	0	O
PMMA	1	O
)	0	O
interposed	0	O
between	0	O
the	0	O
plate	0	O
and	0	O
the	0	O
bone	0	O
,	0	O
as	0	O
well	0	O
as	0	O
between	0	O
the	0	O
screw	0	O
heads	0	O
and	0	O
the	0	O
plate	0	O
,	0	O
to	0	O
improve	0	O
the	0	O
stability	0	O
of	0	O
internal	0	O
fixation	0	O
was	0	O
tested	0	O
in	0	O
vitro	0	O
using	0	O
20	0	O
paired	0	O
equine	0	O
third	0	O
metacarpal	0	O
bones	0	O
with	0	O
mid	0	O
-	0	O
diaphyseal	0	O
osteotomies	0	O
plated	0	O
with	0	O
six	0	O
-	0	O
hole	0	O
broad	0	O
ASIF	0	O
compression	0	O
plates	0	O
.	0	O


The	0	O
potency	0	O
of	0	O
the	0	O
effect	0	O
of	0	O
Nim	0	O
(	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
.	0	O
kg	0	O
-	0	O
1	0	O
i	0	O
.	0	O
p	0	O
.)	0	O
was	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
NBP	0	O
(	0	O
10	0	O
mg	0	O
.	0	O
kg	0	O
-	0	O
1	0	O
i	0	O
.	0	O
p	0	O
.).	0	O


To	1	O
characterize	0	O
the	0	O
expression	0	O
of	0	O
this	0	O
DNA	1	B
repair	0	I
enzyme	0	I
,	0	O
we	0	O
have	0	O
isolated	0	O
the	0	O
corresponding	0	O
genomic	0	O
clone	0	O
.	0	O


In	1	O
invertebrates	0	O
,	0	O
Fhit	0	B
is	0	O
encoded	0	O
as	0	O
a	0	O
fusion	0	O
protein	0	O
with	0	O
Nit	1	B
,	0	O
a	0	O
member	0	O
of	0	O
the	0	O
nitrilase	0	B
superfamily	0	I
.	0	O


Continued	1	O
development	0	O
of	0	O
the	0	O
rat	0	O
conditioning	0	O
paradigm	0	O
is	0	O
especially	0	O
warranted	0	O
because	0	O
of	0	O
the	0	O
ability	0	O
to	0	O
record	0	O
sympathetic	0	O
nerve	0	O
activity	0	O
in	0	O
intact	0	O
,	0	O
awake	0	O
subjects	0	O
and	0	O
the	0	O
large	0	O
number	0	O
of	0	O
readily	0	O
available	0	O
genetic	0	O
strains	0	O
,	0	O
which	0	O
model	0	O
human	0	O
pathological	0	O
states	0	O
.	0	O


The	0	O
N	1	O
terminus	0	O
of	0	O
beta	0	O
(	0	O
95	0	O
kDa	1	O
)	0	O
corresponds	0	O
to	0	O
alpha	0	O
with	0	O
the	0	O
integrase	0	B
domain	0	I
attached	0	O
to	0	O
the	0	O
C	1	O
terminus	0	O
(	0	O
32	0	O
kDa	1	O
).	0	O


However	0	O
,	0	O
a	0	O
clear	0	O
difference	0	O
exists	0	O
between	0	O
myoblasts	0	O
and	0	O
10T1	0	O
/	0	O
2	0	O
cells	0	O
(	0	O
and	0	O
other	0	O
non	0	O
-	0	O
muscle	0	O
cell	0	O
types	0	O
)	0	O
in	0	O
the	0	O
chromatin	0	O
structure	0	O
of	0	O
the	0	O
chromosomal	0	O
myoD	0	B
core	0	I
enhancer	0	I
,	0	O
suggesting	0	O
that	0	O
the	0	O
myoD	0	B
enhancer	0	I
is	0	O
repressed	0	O
by	0	O
epigenetic	0	O
mechanisms	0	O
in	0	O
10T1	0	O
/	0	O
2	0	O
cells	0	O
.	0	O


The	0	O
plasmin	0	B
-	0	I
derived	0	I
D	1	I
(	0	I
approximately	0	I
105	0	I
-	0	I
kDa	1	I
)	0	I
product	0	I
,	0	O
however	0	O
,	0	O
could	0	O
be	0	O
cross	0	O
-	0	O
linked	0	O
into	0	O
DD	0	O
dimers	0	O
.	0	O


Number	1	O
and	0	O
size	0	O
of	0	O
the	0	O
myelin	0	O
structures	0	O
in	0	O
the	0	O
pneumocytes	0	O
typ	0	O
II	0	O
increased	0	O
simultaneously	0	O
.	0	O


The	0	O
transcription	0	B
factor	0	I
AP	1	I
-	0	I
2	0	I
is	0	O
encoded	0	O
by	0	O
a	0	O
gene	0	O
located	0	O
on	0	O
chromosome	0	O
6	0	O
near	0	O
the	0	O
HLA	1	B
locus	0	I
.	0	O


Using	0	O
a	0	O
high	0	O
-	0	O
copy	0	O
suppression	0	O
strategy	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
a	0	O
yeast	0	O
gene	0	O
(	0	O
UBS1	0	B
)	0	O
whose	0	O
elevated	0	O
expression	0	O
suppresses	0	O
the	0	O
conditional	0	O
cell	0	O
cycle	0	O
defects	0	O
associated	0	O
with	0	O
cdc34	0	B
mutations	0	O
.	0	O


Additional	0	O
studies	0	O
with	0	O
new	0	O
and	0	O
reprocessed	0	O
regenerated	0	O
cellulose	0	O
dialyzers	0	O
comparing	0	O
450	0	O
and	0	O
220	0	O
mL	1	O
/	0	O
min	0	O
blood	0	O
flow	0	O
rates	0	O
at	0	O
10	0	O
minutes	0	O
showed	0	O
no	0	O
change	0	O
in	0	O
BTG	0	O
.	0	O


Preliminary	0	O
use	0	O
of	0	O
the	0	O
Nottingham	0	O
Eczema	1	O
Severity	0	O
Score	1	O
would	0	O
support	0	O
further	0	O
development	0	O
as	0	O
a	0	O
research	0	O
tool	0	O
for	0	O
a	0	O
simple	0	O
assessment	0	O
of	0	O
disease	0	O
severity	0	O
that	0	O
could	0	O
be	0	O
used	0	O
in	0	O
epidemiological	0	O
studies	0	O
.	0	O


This	0	O
implies	0	O
that	0	O
the	0	O
groups	0	O
do	0	O
not	0	O
just	0	O
differ	0	O
along	0	O
one	0	O
dimension	0	O
,	0	O
but	0	O
along	0	O
three	0	O
dimensions	0	O
.	0	O


NIK	0	O
-	0	O
244	0	O
suppressed	0	O
coronary	0	O
ligation	0	O
-	0	O
and	0	O
digitalis	0	O
-	0	O
induced	0	O
arrhythmias	0	O
,	0	O
and	0	O
the	0	O
minimum	0	O
effective	0	O
plasma	0	O
concentrations	0	O
for	0	O
arrhythmias	0	O
induced	0	O
by	0	O
24	0	O
-	0	O
h	0	O
and	0	O
48	0	O
-	0	O
h	0	O
coronary	0	O
ligation	0	O
and	0	O
digitalis	0	O
were	0	O
0	0	O
.	0	O
41	0	O
+/-	0	O
0	0	O
.	0	O
10	0	O
(	0	O
by	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.),	0	O
0	0	O
.	0	O
70	0	O
+/-	0	O
0	0	O
.	0	O
13	0	O
(	0	O
by	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.),	0	O
and	0	O
0	0	O
.	0	O
21	0	O
+/-	0	O
0	0	O
.	0	O
08	0	O
(	0	O
by	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.)	0	O
microgram	0	O
/	0	O
ml	0	O
,	0	O
respectively	0	O
(	0	O
mean	0	O
+/-	0	O
SD	1	O
of	0	O
the	0	O
mean	0	O
,	0	O
n	0	O
=	0	O
6	0	O
).	0	O


The	0	O
first	0	O
group	0	O
of	0	O
sequential	0	O
BMB	0	O
showed	0	O
a	0	O
significant	0	O
progress	0	O
to	0	O
myelofibrosis	0	O
in	0	O
so	0	O
-	0	O
called	0	O
"	0	O
Chronic	1	O
Megakaryocytic	0	O
-	0	O
Granulocytic	1	O
Myelosis	1	O
"--	0	O
CMGM	0	O
-,	0	O
which	0	O
corresponds	0	O
to	0	O
Agnogenic	1	O
Myeloid	1	O
Metaplasia	1	O
-	0	O
AMM	0	O
-	0	O
in	0	O
72	0	O
.	0	O
4	0	O
%	0	O
(	0	O
21	0	O
/	0	O
29	0	O
patients	0	O
),	0	O
as	0	O
well	0	O
as	0	O
in	0	O
CML	1	O
with	0	O
megakaryocytic	0	O
increase	0	O
-	0	O
CML	1	O
.	0	O
MI	1	O
-	0	O
in	0	O
39	0	O
.	0	O
2	0	O
%	0	O
(	0	O
20	0	O
/	0	O
51	0	O
).	0	O


The	0	O
pathogenesis	0	O
of	0	O
Dupuytren	0	O
'	0	O
s	0	O
contracture	0	O


Diagnostic	1	O
value	0	O
of	0	O
serum	0	B
myoglobin	0	I
in	0	O
cases	0	O
of	0	O
neuromuscular	0	O
disease	0	O


A	1	O
third	0	O
ORF	1	O
,	0	O
ORF5	0	O
,	0	O
shows	0	O
homology	0	O
with	0	O
gene	0	B
agrB	0	I
from	0	O
Staphylococcus	1	O
aureus	0	O
,	0	O
which	0	O
is	0	O
involved	0	O
in	0	O
the	0	O
mechanism	0	O
of	0	O
regulation	0	O
of	0	O
the	0	O
virulence	0	O
phenotype	0	O
in	0	O
this	0	O
species	0	O
.	0	O


Similar	0	O
waves	0	O
were	0	O
seen	0	O
on	0	O
cross	0	O
-	0	O
correlating	0	O
a	0	O
motor	0	O
unit	0	O
with	0	O
an	0	O
electronic	0	O
oscillator	0	O
,	0	O
confirming	0	O
that	0	O
their	0	O
occurrence	0	O
does	0	O
not	0	O
necessarily	0	O
demonstrate	0	O
the	0	O
existence	0	O
of	0	O
active	0	O
neural	0	O
interactions	0	O
.	0	O


The	0	O
resulting	0	O
mutants	0	O
were	0	O
coexpressed	0	O
with	0	O
gE	1	B
in	0	O
the	0	O
vaccinia	0	O
virus	0	O
-	0	O
based	0	O
vTF7	0	O
-	0	O
3	0	O
system	0	O
,	0	O
and	0	O
the	0	O
formation	0	O
and	0	O
endoplasmic	0	O
reticulum	0	O
(	0	O
ER	1	O
)-	0	O
to	0	O
-	0	O
Golgi	0	O
transport	0	O
of	0	O
the	0	O
hetero	0	O
-	0	O
oligomeric	0	O
complex	0	O
were	0	O
monitored	0	O
.	0	O


The	0	O
Oct	1	B
-	0	I
3	0	I
/	0	I
4	0	I
gene	0	I
product	0	I
,	0	O
which	0	O
belongs	0	O
to	0	O
the	0	O
POU	0	B
family	0	I
of	0	I
transcription	0	I
factors	0	I
,	0	O
is	0	O
a	0	O
good	0	O
candidate	0	O
for	0	O
regulating	0	O
initial	0	O
differentiation	0	O
decisions	0	O
.	0	O


Our	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
crucial	0	O
role	0	O
of	0	O
the	0	O
mutations	0	O
activating	0	O
v	0	B
-	0	I
erbA	0	I
as	0	O
an	0	O
oncogene	0	O
is	0	O
to	0	O
'	0	O
freeze	0	O
'	0	O
c	0	B
-	0	I
ErbA	0	I
/	0	O
TRalpha	0	B
in	0	O
its	0	O
non	0	O
-	0	O
liganded	0	O
,	0	O
repressive	0	O
conformation	0	O
and	0	O
to	0	O
facilitate	0	O
its	0	O
overexpression	0	O
.	0	O


Management	1	O
often	0	O
involves	0	O
beta	0	O
-	0	O
and	0	O
calcium	0	O
channel	0	O
blocking	0	O
drugs	0	O
or	0	O
type	0	O
IC	1	O
antiarrhythmic	0	O
drugs	0	O
.	0	O


Optically	0	O
detected	0	O
librons	0	O
and	0	O
phonons	0	O
in	0	O
crystalline	0	O
C60	0	O
.	0	O


Determination	1	O
of	0	O
20	0	O
alpha	0	O
-	0	O
hydroxy	0	O
-	0	O
9	0	O
beta	0	O
,	0	O
10	0	O
alpha	0	O
-	0	O
pregna	0	O
-	0	O
4	0	O
,	0	O
6	0	O
-	0	O
dien	0	O
-	0	O
3	0	O
-	0	O
one	0	O
in	0	O
plasma	0	O
by	0	O
selected	0	O
ion	0	O
monitoring	0	O
.	0	O


Transcriptional	1	O
blockade	0	O
was	0	O
reversed	0	O
by	0	O
co	0	O
-	0	O
transfections	0	O
of	0	O
a	0	O
wild	0	B
-	0	I
type	0	I
SRF	1	I
expression	0	O
vector	0	O
,	0	O
but	0	O
was	0	O
not	0	O
rescued	0	O
by	0	O
the	0	O
expression	0	O
of	0	O
other	0	O
myogenic	0	O
factors	0	O
,	0	O
such	0	O
as	0	O
MyoD	0	B
and	0	O
Mef	0	B
-	0	I
2C	0	I
.	0	O


Mutational	1	O
studies	0	O
provide	0	O
evidence	0	O
to	0	O
this	0	O
end	0	O
and	0	O
indicate	0	O
that	0	O
the	0	O
side	0	O
chains	0	O
of	0	O
subdomain	0	O
4	0	O
.	0	O
2	0	O
make	0	O
specific	0	O
contacts	0	O
with	0	O
the	0	O
nucleotides	0	O
at	0	O
-	0	O
35	0	O
.	0	O


In	1	O
order	0	O
to	0	O
infer	0	O
shape	0	O
from	0	O
contour	0	O
,	0	O
the	0	O
human	0	O
visual	0	O
system	0	O
must	0	O
selectively	0	O
integrate	0	O
fragments	0	O
projecting	0	O
from	0	O
a	0	O
common	0	O
object	0	O
while	0	O
keeping	0	O
fragments	0	O
from	0	O
different	0	O
objects	0	O
separate	0	O
.	0	O


APOE	0	B
-	0	O
epsilon4	0	O
count	0	O
predicts	0	O
age	0	O
when	0	O
prevalence	0	O
of	0	O
AD	1	O
increases	0	O
,	0	O
then	0	O
declines	0	O
:	0	O
the	0	O
Cache	1	O
County	0	O
Study	1	O
.	0	O


To	1	O
examine	0	O
the	0	O
possibility	0	O
that	0	O
LNNB	0	O
performance	0	O
of	0	O
the	0	O
schizophrenic	0	O
groups	0	O
may	0	O
have	0	O
been	0	O
related	0	O
to	0	O
neuroleptic	0	O
medication	0	O
,	0	O
analyses	0	O
were	0	O
completed	0	O
on	0	O
the	0	O
relationship	0	O
between	0	O
medication	0	O
levels	0	O
and	0	O
LNNB	0	O
scores	0	O
.	0	O


As	1	O
an	0	O
initial	0	O
step	0	O
towards	0	O
the	0	O
characterization	0	O
of	0	O
replicative	0	O
DNA	1	B
polymerases	0	I
of	0	I
trypanosomes	0	I
,	0	O
we	0	O
have	0	O
cloned	0	O
,	0	O
sequenced	0	O
and	0	O
examined	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
Trypanosoma	1	O
(	0	O
Trypanozoon	1	O
)	0	O
brucei	0	O
brucei	0	O
gene	0	O
that	0	O
encodes	0	O
the	0	O
DNA	1	B
polymerase	0	I
alpha	0	I
catalytic	0	I
core	0	I
(	0	O
pol	0	B
alpha	0	I
).	0	O


An	1	O
important	0	O
mechanism	0	O
by	0	O
which	0	O
the	0	O
tumor	0	O
suppressor	0	O
p53	0	B
maintains	0	O
genomic	0	O
stability	0	O
is	0	O
to	0	O
induce	0	O
cell	0	O
cycle	0	O
arrest	0	O
through	0	O
activation	0	O
of	0	O
the	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinase	0	I
inhibitor	0	O
p21	0	B
(	0	O
WAF1	0	B
/	0	O
Cip1	0	B
)	0	O
gene	0	O
.	0	O


The	0	O
PCr	1	O
resynthesis	0	O
rate	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
)	0	O
and	0	O
the	0	O
effective	0	O
maximal	0	O
rate	0	O
of	0	O
mitochondrial	0	O
ATP	1	O
synthesis	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
also	0	O
improved	0	O
.	0	O


During	0	O
flexion	0	O
whiplash	0	O
,	0	O
the	0	O
torque	0	O
at	0	O
the	0	O
occipital	0	O
condyle	0	O
reverses	0	O
its	0	O
direction	0	O
at	0	O
about	0	O
25	0	O
ms	0	O
after	0	O
impact	0	O
.	0	O


This	0	O
finding	0	O
is	0	O
the	0	O
first	0	O
example	0	O
of	0	O
utilization	0	O
of	0	O
noncomplementary	0	O
dinucleotide	0	O
primer	0	O
by	0	O
an	0	O
RNA	1	B
polymerase	0	I
.	0	O


Monitoring	0	O
of	0	O
rheumatoid	0	O
arthritis	0	O
.	0	O


IL	1	B
-	0	I
1beta	0	I
(	0	O
10	0	O
ng	0	O
/	0	O
ml	0	O
)	0	O
drastically	0	O
increased	0	O
both	0	O
PDGFalphaR	0	B
and	0	O
CCAAT	0	B
/	0	I
enhancer	0	I
-	0	I
binding	0	I
protein	0	I
delta	0	I
(	0	O
C	1	B
/	0	I
EBPdelta	0	I
)	0	O
mRNA	1	O
levels	0	O
in	0	O
a	0	O
time	0	O
dependent	0	O
manner	0	O
.	0	O


Evaluation	1	O
of	0	O
the	0	O
Du	1	O
Pont	0	O
aca	0	O
ammonia	0	O
procedure	0	O
.	0	O


Sensitivity	1	O
and	0	O
specificity	0	O
was	0	O
established	0	O
for	0	O
the	0	O
Pharmacia	0	O
CAP	1	O
System	1	O
and	0	O
the	0	O
DPC	0	O
AlaSTAT	0	O
System	1	O
by	0	O
comparison	0	O
with	0	O
results	0	O
of	0	O
the	0	O
skin	0	O
prick	0	O
test	0	O
.	0	O


The	0	O
human	0	O
U4	0	B
/	0	O
U6	0	B
snRNP	1	O
contains	0	O
60	0	O
and	0	O
90kD	0	O
proteins	0	O
that	0	O
are	0	O
structurally	0	O
homologous	0	O
to	0	O
the	0	O
yeast	0	O
splicing	0	O
factors	0	O
Prp4p	0	B
and	0	O
Prp3p	0	B
.	0	O


A	1	O
statistically	0	O
significant	0	O
improvement	0	O
due	0	O
to	0	O
the	0	O
administration	0	O
of	0	O
Bromergon	0	O
was	0	O
observed	0	O
in	0	O
symptoms	0	O
associated	0	O
with	0	O
overreactiveness	0	O
to	0	O
normal	0	O
prolactin	0	B
levels	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
abdominal	0	O
tension	0	O
,	0	O
edema	0	O
,	0	O
weight	0	O
gain	0	O
and	0	O
breast	0	O
tenderness	0	O
.	0	O


STUDY	1	O
DESIGN	0	O
AND	0	O
METHODS	0	O
:	0	O
A	1	O
study	0	O
was	0	O
initiated	0	O
to	0	O
compare	0	O
the	0	O
collection	0	O
of	0	O
PBPCs	0	O
with	0	O
the	0	O
new	0	O
device	0	O
,	0	O
the	0	O
AutoPBSC	0	O
(	0	O
version	0	O
[	0	O
V	1	O
]	0	O
6	0	O
.	0	O
0	0	O
with	0	O
AutoPBSC	0	O
tubing	0	O
set	0	O
),	0	O
and	0	O
that	0	O
with	0	O
the	0	O
MNC	0	O
(	0	O
mononuclear	0	O
cell	0	O
)	0	O
procedure	0	O
(	0	O
V4	0	O
.	0	O
7	0	O
with	0	O
white	0	O
cell	0	O
tubing	0	O
set	0	O
),	0	O
for	0	O
patients	0	O
and	0	O
healthy	0	O
donors	0	O
.	0	O


Nonetheless	0	O
,	0	O
that	0	O
ventricular	0	O
afferents	0	O
,	0	O
in	0	O
certain	0	O
special	0	O
settings	0	O
,	0	O
are	0	O
able	0	O
to	0	O
induce	0	O
e	0	O
.	0	O
g	0	O
.	0	O
generalised	0	O
vasodilation	0	O
and	0	O
hypotension	0	O
cannot	0	O
be	0	O
excluded	0	O
.	0	O


The	0	O
extraction	0	O
measurements	0	O
were	0	O
used	0	O
to	0	O
test	0	O
for	0	O
extracerebral	0	O
contamination	0	O
of	0	O
venous	0	O
outflow	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
we	0	O
observed	0	O
high	0	O
concentrations	0	O
in	0	O
29	0	O
of	0	O
75	0	O
patients	0	O
with	0	O
tumors	0	O
of	0	O
the	0	O
central	0	O
nervous	0	O
system	0	O
,	0	O
especially	0	O
in	0	O
meningioma	0	O
(	0	O
6	0	O
/	0	O
9	0	O
),	0	O
glioblastoma	0	O
(	0	O
9	0	O
/	0	O
23	0	O
),	0	O
and	0	O
neurinoma	0	O
(	0	O
5	0	O
/	0	O
5	0	O
).	0	O


Mean	1	O
intake	0	O
of	0	O
vitamin	0	O
A	1	O
amounted	0	O
to	0	O
1	0	O
.	0	O
1	0	O
and	0	O
0	0	O
.	0	O
9	0	O
mg	0	O
RE	1	O
/	0	O
day	0	O
for	0	O
men	0	O
and	0	O
women	0	O
,	0	O
respectively	0	O
;	0	O
the	0	O
contributions	0	O
of	0	O
meat	0	O
,	0	O
fats	0	O
and	0	O
oils	0	O
,	0	O
vegetables	0	O
and	0	O
dairy	0	O
products	0	O
to	0	O
total	0	O
intake	0	O
were	0	O
35	0	O
%,	0	O
24	0	O
%,	0	O
16	0	O
%,	0	O
and	0	O
16	0	O
%,	0	O
respectively	0	O
.	0	O


Because	0	O
of	0	O
serious	0	O
infections	0	O
(	0	O
fever	0	O
larger	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
101	0	O
degrees	0	O
F	1	O
.	0	O
granulocytes	0	O
less	0	O
than	0	O
1	0	O
,	0	O
000	0	O
/	0	O
mm	0	O
,	0	O
3	0	O
and	0	O
hospitalization	0	O
)	0	O
and	0	O
1	0	O
drug	0	O
death	0	O
in	0	O
the	0	O
first	0	O
4	0	O
patients	0	O
,	0	O
oral	0	O
calcium	0	O
leucovorin	0	O
,	0	O
20	0	O
to	0	O
30	0	O
mg	0	O
/	0	O
m2	0	O
orally	0	O
,	0	O
was	0	O
given	0	O
2	0	O
days	0	O
after	0	O
methotrexate	0	O
in	0	O
subsequent	0	O
treatment	0	O
cycles	0	O
.	0	O


Here	0	O
we	0	O
report	0	O
the	0	O
cloning	0	O
and	0	O
characterization	0	O
of	0	O
Xenopus	1	B
Pax	0	I
-	0	I
5	0	I
and	0	O
Pax	0	B
-	0	I
8	0	I
,	0	O
two	0	O
orthologues	0	O
of	0	O
the	0	O
Pax	0	B
-	0	I
2	0	I
/	0	I
5	0	I
/	0	I
8	0	I
gene	0	I
family	0	I
.	0	O


INTERVENTIONS	0	O
:	0	O
Patients	0	O
received	0	O
rt	0	B
-	0	I
PA	1	I
,	0	O
heparin	0	O
,	0	O
and	0	O
aspirin	0	O
.	0	O


An	1	O
end	0	O
-	0	O
to	0	O
-	0	O
end	0	O
pancreaticojejunostomy	0	O
using	0	O
a	0	O
mechanical	0	O
purse	0	O
-	0	O
string	0	O
device	0	O
.	0	O


Vocal	1	O
cord	0	O
abduction	0	O
rehabilitation	0	O
by	0	O
nervous	0	O
selective	0	O
anastomosis	0	O
.	0	O


The	0	O
diagnostic	0	O
value	0	O
of	0	O
blood	0	O
serum	0	O
and	0	O
urinary	0	B
amylase	0	I
,	0	O
lipase	0	B
,	0	O
and	0	O
trypsin	0	B
in	0	O
exacerbations	0	O
of	0	O
chronic	0	O
relapsing	0	O
pancreatitis	0	O
is	0	O
discussed	0	O
.	0	O


The	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
SAP	1	B
-	0	I
1	0	I
cDNA	1	I
showed	0	O
that	0	O
mature	0	B
SAP	1	I
-	0	I
1	0	I
consisted	0	O
of	0	O
1093	0	O
amino	0	O
acids	0	O
and	0	O
a	0	O
transmembrane	0	B
-	0	I
type	0	I
PTP	0	I
,	0	O
which	0	O
possessed	0	O
a	0	O
single	0	O
PTP	0	B
-	0	I
conserved	0	I
domain	0	I
in	0	O
the	0	O
cytoplasmic	0	O
region	0	O
.	0	O


Perceptions	0	O
of	0	O
illness	0	O
intrusiveness	0	O
were	0	O
significantly	0	O
higher	0	O
when	0	O
both	0	O
muscle	0	O
cramp	0	O
and	0	O
headache	0	O
symptoms	0	O
occurred	0	O
during	0	O
one	0	O
or	0	O
more	0	O
assessment	0	O
intervals	0	O
as	0	O
compared	0	O
to	0	O
when	0	O
muscle	0	O
cramps	0	O
or	0	O
headaches	0	O
,	0	O
only	0	O
,	0	O
occurred	0	O
.	0	O


The	0	O
disturbance	0	O
of	0	O
pulmonary	0	O
gas	0	O
exchange	0	O
,	0	O
as	0	O
revealed	0	O
by	0	O
the	0	O
high	0	O
value	0	O
of	0	O
AaDO2	0	O
,	0	O
existed	0	O
without	0	O
left	0	O
ventricular	0	O
dysfunction	0	O
,	0	O
and	0	O
AaDO2	0	O
had	0	O
no	0	O
significant	0	O
relationship	0	O
with	0	O
any	0	O
of	0	O
the	0	O
hemodynamic	0	O
parameters	0	O
including	0	O
the	0	O
difference	0	O
between	0	O
plasma	0	O
colloid	0	O
osmotic	0	O
pressure	0	O
and	0	O
PCW	0	O
.	0	O


Clinical	1	O
value	0	O
of	0	O
the	0	O
estimation	0	O
of	0	O
growth	0	O
kinetics	0	O
of	0	O
primary	0	O
ovarian	0	O
cancer	0	O
recurrences	0	O
by	0	O
CA125	0	B
doubling	0	O
time	0	O


Co	1	O
-	0	O
immunoprecipitation	0	O
and	0	O
DNA	1	O
affinity	0	O
chromatography	0	O
prove	0	O
that	0	O
Sp1	0	B
heterodimerizes	0	O
with	0	O
ZBP	0	B
-	0	I
89	0	I
when	0	O
bound	0	O
to	0	O
the	0	O
silencer	0	O
element	0	O
to	0	O
yield	0	O
a	0	O
DNA	1	O
-	0	O
protein	0	O
complex	0	O
whose	0	O
mobility	0	O
is	0	O
indistinguishable	0	O
from	0	O
that	0	O
displayed	0	O
by	0	O
HeLa	0	O
nuclear	0	O
extract	0	O
in	0	O
band	0	O
shift	0	O
assays	0	O
.	0	O


These	0	O
characteristic	0	O
structural	0	O
features	0	O
were	0	O
used	0	O
to	0	O
create	0	O
the	0	O
abbreviation	0	O
AZF1	0	B
(	0	O
Asparagine	1	B
-	0	I
rich	0	I
Zinc	1	I
Finger	1	I
protein	0	I
).	0	O


Regression	1	O
analyses	0	O
identified	0	O
7	0	O
risk	0	O
and	0	O
7	0	O
protective	0	O
factors	0	O
with	0	O
minimal	0	O
overlap	0	O
.	0	O


The	0	O
data	0	O
indicate	0	O
that	0	O
etr	0	B
-	0	I
1	0	I
is	0	O
essential	0	O
for	0	O
muscle	0	O
development	0	O
in	0	O
C	1	O
.	0	O
elegans	0	O
,	0	O
perhaps	0	O
by	0	O
playing	0	O
a	0	O
role	0	O
in	0	O
post	0	O
-	0	O
transcriptional	0	O
processing	0	O
of	0	O
some	0	O
muscle	0	O
component	0	O
,	0	O
and	0	O
thus	0	O
suggesting	0	O
a	0	O
possible	0	O
conservation	0	O
of	0	O
gene	0	O
function	0	O
with	0	O
human	0	B
CUG	0	I
-	0	I
bp	0	I
.	0	O


Results	0	O
indicate	0	O
that	0	O
KNM	0	O
-	0	O
LU	1	O
335	0	O
differs	0	O
from	0	O
both	0	O
human	0	O
and	0	O
chimpanzee	0	O
M1s	0	O
in	0	O
relative	0	O
distances	0	O
(	0	O
measured	0	O
in	0	O
three	0	O
dimensions	0	O
)	0	O
between	0	O
crown	0	O
fissure	0	O
termini	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
Our	0	O
purpose	0	O
was	0	O
to	0	O
determine	0	O
the	0	O
simultaneous	0	O
concentrations	0	O
of	0	O
serum	0	O
cotinine	0	O
in	0	O
both	0	O
fetal	0	O
and	0	O
maternal	0	O
blood	0	O
.	0	O


The	0	O
influence	0	O
of	0	O
patient	0	O
-	0	O
related	0	O
factors	0	O
on	0	O
inter	0	O
-	0	O
observer	0	O
variability	0	O
in	0	O
the	0	O
evaluation	0	O
of	0	O
neurological	0	O
signs	0	O
was	0	O
investigated	0	O
.	0	O


Cardiac	1	B
endothelin	0	I
release	0	O
and	0	O
infarct	0	O
size	0	O
,	0	O
myocardial	0	O
blood	0	O
flow	0	O
,	0	O
and	0	O
ventricular	0	O
function	0	O
in	0	O
canine	0	O
infarction	0	O
and	0	O
reperfusion	0	O
.	0	O


The	0	O
behavior	0	O
of	0	O
different	0	O
types	0	O
of	0	O
polytetrafluoroethylene	0	O
(	0	O
PTFE	1	O
)	0	O
prostheses	0	O
in	0	O
the	0	O
reparative	0	O
scarring	0	O
process	0	O
of	0	O
abdominal	0	O
wall	0	O
defects	0	O
.	0	O


Furthermore	0	O
,	0	O
although	0	O
the	0	O
regional	0	O
distribution	0	O
of	0	O
lean	0	O
tissue	0	O
mass	0	O
in	0	O
the	0	O
trunk	0	O
and	0	O
legs	0	O
remained	0	O
fairly	0	O
constant	0	O
at	0	O
different	0	O
pubertal	0	O
stages	0	O
,	0	O
the	0	O
regional	0	O
distribution	0	O
of	0	O
fat	0	O
was	0	O
altered	0	O
significantly	0	O
,	0	O
becoming	0	O
more	0	O
central	0	O
and	0	O
less	0	O
peripheral	0	O
.	0	O


Calmodulin	1	B
-	0	I
binding	0	I
peptide	0	I
(	0	O
CBP	0	B
),	0	O
a	0	O
peptide	0	O
of	0	O
26	0	O
amino	0	O
acids	0	O
derived	0	O
from	0	O
muscle	0	B
myosin	0	I
light	0	I
chain	0	I
kinase	0	I
(	0	O
MLCK	0	B
),	0	O
binds	0	O
to	0	O
calmodulin	0	B
with	0	O
nanomolar	0	O
affinity	0	O
.	0	O


Antibodies	0	O
to	0	O
the	0	O
human	0	B
PTS1R	0	I
recognize	0	O
this	0	O
protein	0	O
in	0	O
human	0	O
,	0	O
monkey	0	O
,	0	O
rat	0	O
,	0	O
and	0	O
hamster	0	O
cells	0	O
.	0	O


The	0	O
rates	0	O
of	0	O
total	0	O
energy	0	O
use	0	O
(	0	O
mean	0	O
+/-	0	O
SD	1	O
=	0	O
39	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
2	0	O
vs	0	O
35	0	O
.	0	O
7	0	O
+/-	0	O
1	0	O
.	0	O
3	0	O
kJ	1	O
X	1	O
min	0	O
-	0	O
1	0	O
;	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
were	0	O
significantly	0	O
higher	0	O
at	0	O
-	0	O
10	0	O
degrees	0	O
C	1	O
than	0	O
at	0	O
22	0	O
degrees	0	O
C	1	O
.	0	O


These	0	O
studies	0	O
suggest	0	O
an	0	O
additional	0	O
component	0	O
or	0	O
cellular	0	O
environment	0	O
is	0	O
required	0	O
for	0	O
SPRK	0	B
activation	0	O
by	0	O
Cdc42	0	B
.	0	O


Using	0	O
this	0	O
reporter	0	O
gene	0	O
system	0	O
,	0	O
we	0	O
previously	0	O
showed	0	O
that	0	O
EPO	0	B
-	0	O
induced	0	O
activation	0	O
of	0	O
the	0	O
c	0	B
-	0	I
fos	0	I
promoter	0	I
can	0	O
be	0	O
detected	0	O
rapidly	0	O
and	0	O
sensitively	0	O
as	0	O
an	0	O
elevation	0	O
of	0	O
cellular	0	B
luciferase	0	I
activity	0	O
.	0	O


SRE	0	O
activity	0	O
is	0	O
dependent	0	O
upon	0	O
the	0	O
activation	0	O
by	0	O
phosphorylation	0	O
of	0	O
a	0	O
ternary	0	O
complex	0	O
factor	0	O
;	0	O
included	0	O
among	0	O
the	0	O
ternary	0	O
complex	0	O
factors	0	O
is	0	O
Elk	0	B
-	0	I
1	0	I
.	0	O


In	1	O
PC12	0	O
cells	0	O
,	0	O
nerve	0	B
growth	0	I
factor	0	I
induces	0	O
neuronal	0	O
differentiation	0	O
and	0	O
repressed	0	O
expression	0	O
of	0	O
nrg	0	B
-	0	I
1	0	I
.	0	O


Serum	1	B
amylase	0	I
became	0	O
markedly	0	O
elevated	0	O
(	0	O
2	0	O
,	0	O
624	0	O
CU	1	O
/	0	O
100	0	O
ml	0	O
),	0	O
as	0	O
did	0	O
the	0	O
serum	0	O
FFA	1	O
(	0	O
29	0	O
.	0	O
19	0	O
mEq	1	O
/	0	O
liter	0	O
).	0	O


Dopamine	1	O
neurons	0	O
in	0	O
subjects	0	O
that	0	O
received	0	O
6	0	O
-	0	O
OHDA	0	O
were	0	O
protected	0	O
by	0	O
pre	0	O
-	0	O
treatment	0	O
with	0	O
GBR	0	O
-	0	O
12909	0	O
.	0	O


Vitamin	1	O
D3	0	O
plus	0	O
nicotine	0	O
treatment	0	O
produced	0	O
parallel	0	O
increases	0	O
in	0	O
cardiac	0	O
mass	0	O
and	0	O
elastic	0	O
modulus	0	O
,	0	O
with	0	O
a	0	O
significant	0	O
correlation	0	O
between	0	O
the	0	O
two	0	O
.	0	O


A	1	O
cDNA	1	O
encoding	0	O
a	0	O
putative	0	O
RNA	1	B
and	0	I
/	0	I
or	0	I
DNA	1	I
helicase	0	I
has	0	O
been	0	O
isolated	0	O
from	0	O
Arabidopsis	0	O
thaliana	0	O
cDNA	1	O
libraries	0	O
.	0	O


Thyrotoxicosis	1	O
due	0	O
to	0	O
amiodarone	0	O
is	0	O
difficult	0	O
to	0	O
treat	0	O
and	0	O
is	0	O
further	0	O
complicated	0	O
by	0	O
the	0	O
pro	0	O
-	0	O
arrhythmic	0	O
potential	0	O
of	0	O
thyrotoxicosis	0	O
and	0	O
the	0	O
fading	0	O
antiarrhythmic	0	O
effect	0	O
after	0	O
amiodarone	0	O
withdrawal	0	O
.	0	O


IL	1	B
-	0	I
12	0	I
production	0	O
was	0	O
correlated	0	O
with	0	O
C3a	1	O
concentration	0	O
measured	0	O
at	0	O
the	0	O
outlet	0	O
of	0	O
hemodialyzer	0	O
after	0	O
15	0	O
min	0	O
of	0	O
dialysis	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
69	0	O
,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Seventeen	0	O
of	0	O
the	0	O
35	0	O
patients	0	O
were	0	O
randomly	0	O
chosen	0	O
to	0	O
receive	0	O
a	0	O
training	0	O
program	0	O
(	0	O
lasting	0	O
approximately	0	O
1	0	O
month	0	O
)	0	O
designed	0	O
to	0	O
establish	0	O
a	0	O
systematic	0	O
strategy	0	O
of	0	O
organizing	0	O
complex	0	O
visual	0	O
material	0	O
.	0	O


Natl	0	O
.	0	O


In	1	O
order	0	O
to	0	O
better	0	O
characterize	0	O
the	0	O
distribution	0	O
of	0	O
ML	1	O
and	0	O
MAP	1	O
estimates	0	O
under	0	O
these	0	O
conditions	0	O
,	0	O
we	0	O
derive	0	O
a	0	O
point	0	O
approximation	0	O
to	0	O
density	0	O
values	0	O
of	0	O
the	0	O
conditional	0	O
distribution	0	O
of	0	O
such	0	O
estimates	0	O
.	0	O


Here	0	O
we	0	O
describe	0	O
an	0	O
in	0	O
vitro	0	O
assay	0	O
where	0	O
the	0	O
NS3	0	B
-	0	I
4A	0	I
polyprotein	0	I
,	0	O
NS3	0	B
,	0	O
the	0	O
serine	0	O
proteinase	0	O
domain	0	O
(	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
181	0	O
residues	0	O
of	0	O
NS3	0	O
),	0	O
and	0	O
the	0	O
NS4A	0	B
cofactor	0	I
were	0	O
produced	0	O
by	0	O
cell	0	O
-	0	O
free	0	O
translation	0	O
and	0	O
tested	0	O
for	0	O
trans	0	O
-	0	O
processing	0	O
of	0	O
radiolabeled	0	O
substrates	0	O
.	0	O


Fifty	0	O
-	0	O
seven	0	O
patients	0	O
aged	0	O
<	0	O
55	0	O
years	0	O
with	0	O
acute	0	O
lymphoblastic	0	O
leukemia	0	O
(	0	O
ALL	1	O
)	0	O
in	0	O
second	0	O
or	0	O
third	0	O
bone	0	O
marrow	0	O
(	0	O
BM	1	O
)	0	O
relapse	0	O
or	0	O
refractory	0	O
to	0	O
first	0	O
-	0	O
line	0	O
therapy	0	O
were	0	O
enrolled	0	O
in	0	O
an	0	O
Italian	0	O
cooperative	0	O
study	0	O
.	0	O


Conservative	1	O
treatment	0	O
of	0	O
central	0	O
nervous	0	O
system	0	O
injuries	0	O


Dietetics	1	O
of	0	O
childhood	0	O
-	0	O
and	0	O
juvenile	0	O
diabetes	0	O


We	0	O
observed	0	O
abundant	0	O
levels	0	O
of	0	O
Rev	0	B
-	0	O
erbA	0	B
alpha	0	I
mRNA	1	O
in	0	O
dividing	0	O
C2C12	0	O
myoblasts	0	O
,	0	O
which	0	O
were	0	O
suppressed	0	O
when	0	O
the	0	O
cells	0	O
differentiated	0	O
into	0	O
postmitotic	0	O
multinucleated	0	O
myotubes	0	O
.	0	O


The	0	O
models	0	O
accurately	0	O
localized	0	O
the	0	O
common	0	O
boundaries	0	O
between	0	O
the	0	O
PBB	1	O
and	0	O
CN	1	O
.	0	O


The	0	O
contribution	0	O
that	0	O
alternative	0	O
splicing	0	O
events	0	O
in	0	O
c	0	B
-	0	I
myb	0	I
expression	0	O
may	0	O
make	0	O
on	0	O
c	0	B
-	0	I
myb	0	I
function	0	O
remains	0	O
to	0	O
be	0	O
elucidated	0	O
.	0	O


The	0	O
primary	0	O
pancreatic	0	O
insult	0	O
seemed	0	O
to	0	O
be	0	O
unaffected	0	O
by	0	O
the	0	O
treatment	0	O
,	0	O
because	0	O
neither	0	O
the	0	O
rise	0	O
in	0	O
plasma	0	B
lipase	0	I
nor	0	O
the	0	O
development	0	O
of	0	O
ascites	0	O
or	0	O
the	0	O
extension	0	O
of	0	O
the	0	O
pancreatic	0	O
necrosis	0	O
were	0	O
diminished	0	O
.	0	O


In	1	O
vitro	0	O
expression	0	O
of	0	O
four	0	O
different	0	O
naturally	0	O
occurring	0	O
nonsense	0	O
and	0	O
missense	0	O
mutations	0	O
revealed	0	O
a	0	O
dramatically	0	O
altered	0	O
subcellular	0	O
location	0	O
of	0	O
the	0	O
protein	0	O
in	0	O
cultured	0	O
cells	0	O
.	0	O


In	1	O
vivo	0	O
,	0	O
MyoD	0	B
requires	0	O
this	0	O
tryptophan	0	O
motif	0	O
to	0	O
evoke	0	O
chromatin	0	O
remodeling	0	O
in	0	O
the	0	O
Myogenin	0	B
promoter	0	I
and	0	O
to	0	O
activate	0	O
Myogenin	0	B
transcription	0	O
.	0	O


They	0	O
were	0	O
found	0	O
to	0	O
be	0	O
seropositive	0	O
for	0	O
antibodies	0	O
to	0	O
hepatitis	0	O
C	1	O
virus	0	O
by	0	O
second	0	O
-	0	O
generation	0	O
testing	0	O
(	0	O
RIBA	0	O
2	0	O
,	0	O
Ortho	0	O
Diagnostic	1	O
Systems	0	O
Inc	0	O
,	0	O
Westwood	0	O
,	0	O
MA	1	O
).	0	O


They	0	O
are	0	O
subdivided	0	O
into	0	O
two	0	O
types	0	O
that	0	O
activate	0	O
transduction	0	O
pathways	0	O
via	0	O
different	0	O
cell	0	O
surface	0	O
receptors	0	O
.	0	O


The	0	O
IgA	1	B
deficiency	0	O
is	0	O
combined	0	O
with	0	O
the	0	O
IgE	1	B
one	0	O
.	0	O


We	0	O
describe	0	O
the	0	O
identification	0	O
and	0	O
initial	0	O
characterization	0	O
of	0	O
neurobeachin	0	B
,	0	O
a	0	O
neuron	0	O
-	0	O
specific	0	O
multidomain	0	O
protein	0	O
of	0	O
327	0	O
kDa	1	O
with	0	O
a	0	O
high	0	O
-	0	O
affinity	0	O
binding	0	O
site	0	O
(	0	O
K	1	O
(	0	O
d	0	O
),	0	O
10	0	O
nm	0	O
)	0	O
for	0	O
the	0	O
type	0	B
II	0	I
regulatory	0	I
subunit	0	I
of	0	I
protein	0	I
kinase	0	I
A	1	I
(	0	O
PKA	1	B
RII	0	I
).	0	O


Ten	0	O
males	0	O
performed	0	O
both	0	O
test	0	O
conditions	0	O
and	0	O
oxygen	0	O
uptake	0	O
VO2	1	O
,	0	O
heart	0	O
rate	0	O
,	0	O
minute	0	O
ventilation	0	O
VE	0	O
,	0	O
perceived	0	O
exertion	0	O
and	0	O
spinal	0	O
shrinkage	0	O
were	0	O
recorded	0	O
.	0	O


A	1	O
prospective	0	O
trial	0	O
was	0	O
carried	0	O
out	0	O
in	0	O
156	0	O
unselected	0	O
patients	0	O
(	0	O
41	0	O
men	0	O
,	0	O
mean	0	O
age	0	O
67	0	O
.	0	O
5	0	O
years	0	O
,	0	O
115	0	O
women	0	O
,	0	O
mean	0	O
age	0	O
71	0	O
.	0	O
4	0	O
years	0	O
)	0	O
who	0	O
had	0	O
undergone	0	O
total	0	O
hip	0	O
joint	0	O
replacement	0	O
because	0	O
of	0	O
degenerative	0	O
or	0	O
inflammatory	0	O
arthritis	0	O
or	0	O
fracture	0	O
of	0	O
the	0	O
neck	0	O
of	0	O
the	0	O
femur	0	O
.	0	O


With	0	O
only	0	O
purified	0	O
T	1	B
antigen	0	I
in	0	O
the	0	O
presence	0	O
of	0	O
topoisomerase	0	B
I	1	I
to	0	O
unwind	0	O
purified	0	O
DNA	1	O
,	0	O
ori	0	O
-	0	O
auxiliary	0	O
sequences	0	O
strongly	0	O
facilitated	0	O
T	1	B
-	0	I
antigen	0	I
-	0	O
dependent	0	O
DNA	1	O
conformational	0	O
changes	0	O
consistent	0	O
with	0	O
melting	0	O
the	0	O
first	0	O
50	0	O
base	0	O
pairs	0	O
.	0	O


Reagent	1	O
strips	0	O
are	0	O
frequently	0	O
used	0	O
in	0	O
the	0	O
practice	0	O
of	0	O
laboratory	0	O
medicine	0	O
as	0	O
well	0	O
as	0	O
outside	0	O
the	0	O
professional	0	O
laboratories	0	O
.	0	O


S	1	O
.,	0	O
and	0	O
Walter	0	O
,	0	O
P	1	O
.	0	O


Similarly	0	O
,	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
cytoplasmic	0	O
domain	0	O
of	0	O
the	0	O
latent	0	B
membrane	0	I
protein	0	I
2A	0	I
(	0	O
LMP2A	0	B
)	0	O
of	0	O
the	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
(	0	O
EBV	1	O
)	0	O
contains	0	O
a	0	O
single	0	O
copy	0	O
of	0	O
the	0	O
Tyr	1	O
-	0	O
X	1	O
-	0	O
X	1	O
-	0	O
Leu	1	O
/	0	O
Ile	1	O
-	0	O
containing	0	O
motif	0	O
which	0	O
could	0	O
play	0	O
a	0	O
critical	0	O
role	0	O
in	0	O
B	1	O
cell	0	O
transformation	0	O
.	0	O


From	0	O
the	0	O
15	0	O
-	0	O
kb	0	O
clone	0	O
a	0	O
4	0	B
-	0	I
kb	0	I
EcoRI	0	I
fragment	0	I
containing	0	O
the	0	O
first	0	O
two	0	O
exons	0	O
and	0	O
2	0	O
.	0	O
6	0	O
kb	0	O
of	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
opn	0	B
gene	0	I
was	0	O
sequenced	0	O
,	0	O
and	0	O
the	0	O
transcriptional	0	O
start	0	O
site	0	O
determined	0	O
by	0	O
primer	0	O
extension	0	O
analysis	0	O
and	0	O
S1	1	B
nuclease	0	I
mapping	0	O
.	0	O


Improvement	0	O
of	0	O
nursing	0	O
instruction	0	O
to	0	O
be	0	O
given	0	O
at	0	O
the	0	O
time	0	O
of	0	O
discharge	0	O
from	0	O
the	0	O
ward	0	O
for	0	O
premature	0	O
infants	0	O


Restarting	0	O
time	0	O
was	0	O
not	0	O
affected	0	O
by	0	O
magnesium	0	O
cardioplegia	0	O
.	0	O


Validity	1	O
of	0	O
immunohistology	0	O
and	0	O
in	0	O
situ	0	O
hybridization	0	O
in	0	O
the	0	O
differential	0	O
diagnosis	0	O
of	0	O
cytomegalovirus	0	O
pneumonia	0	O
and	0	O
idiopathic	0	O
interstitial	0	O
pneumonia	0	O
after	0	O
allogenic	0	O
bone	0	O
marrow	0	O
transplantation	0	O


Tiaprofenic	0	O
acid	0	O
overdose	0	O
.	0	O


Note	1	O
on	0	O
Slot	0	O
'	0	O
s	0	O
method	0	O
for	0	O
the	0	O
specific	0	O
determination	0	O
of	0	O
creatinine	0	O
.	0	O


Triumph	0	O
of	0	O
Leninist	0	O
national	0	O
policy	0	O


Plasma	1	O
and	0	O
bladder	0	O
platinum	0	O
concentration	0	O
were	0	O
measured	0	O
following	0	O
intravesical	0	O
DDP	1	O
,	0	O
and	0	O
also	0	O
histopathological	0	O
examination	0	O
,	0	O
urinalysis	0	O
,	0	O
complete	0	O
blood	0	O
count	0	O
and	0	O
blood	0	O
chemistry	0	O
were	0	O
performed	0	O
in	0	O
order	0	O
to	0	O
know	0	O
the	0	O
toxicity	0	O
of	0	O
intravesical	0	O
DDP	1	O
.	0	O


At	1	O
the	0	O
time	0	O
of	0	O
the	0	O
seizure	0	O
,	0	O
the	0	O
patient	0	O
was	0	O
asked	0	O
to	0	O
read	0	O
a	0	O
test	0	O
phrase	0	O
aloud	0	O
until	0	O
it	0	O
was	0	O
read	0	O
correctly	0	O
and	0	O
clearly	0	O
.	0	O


BACKGROUND	0	O
AND	0	O
DESIGN	0	O
:	0	O
Fifty	0	O
-	0	O
nine	0	O
melanocytic	0	O
nevi	0	O
with	0	O
eccentric	0	O
foci	0	O
of	0	O
hyperpigmentation	0	O
("	0	O
small	0	O
dark	0	O
dots	0	O
")	0	O
that	0	O
measured	0	O
primarily	0	O
1	0	O
to	0	O
2	0	O
mm	0	O
in	0	O
diameter	0	O
were	0	O
prospectively	0	O
examined	0	O
to	0	O
determine	0	O
the	0	O
histologic	0	O
correlates	0	O
of	0	O
the	0	O
dark	0	O
dots	0	O
.	0	O


Homozygous	1	O
mutant	0	O
mice	0	O
,	0	O
designated	0	O
Cux	0	B
/	0	O
CDPDeltaCR1	0	B
,	0	O
display	0	O
a	0	O
phenotype	0	O
characterized	0	O
by	0	O
curly	0	O
vibrissae	0	O
and	0	O
wavy	0	O
hair	0	O
.	0	O


Aneurysmal	1	O
bone	0	O
cyst	0	O
of	0	O
the	0	O
jaws	0	O
:	0	O
analysis	0	O
of	0	O
11	0	O
cases	0	O
.	0	O


The	0	O
pp90rsk	0	B
-	0	I
protein	0	I
kinase	0	I
activity	0	O
(	0	O
referred	0	O
to	0	O
as	0	O
rsk	0	B
-	0	I
kinase	0	I
)	0	O
is	0	O
also	0	O
not	0	O
related	0	O
to	0	O
cofactor	0	O
-	0	O
dependent	0	O
signal	0	O
transducing	0	O
protein	0	O
kinases	0	O
such	0	O
as	0	O
the	0	O
cyclic	0	B
AMP	1	I
-	0	I
dependent	0	I
protein	0	I
kinases	0	I
,	0	O
members	0	O
of	0	O
the	0	O
protein	0	B
kinase	0	I
C	1	I
family	0	I
,	0	O
or	0	O
other	0	O
Ca2	1	B
(+)-	0	I
dependent	0	I
protein	0	I
kinases	0	I
.	0	O


We	0	O
also	0	O
show	0	O
that	0	O
zygotically	0	O
activated	0	O
Xretpos	0	O
transcripts	0	O
are	0	O
restricted	0	O
to	0	O
ventro	0	O
-	0	O
posterior	0	O
specific	0	O
regions	0	O
and	0	O
induced	0	O
by	0	O
UV	1	O
-	0	O
irradiation	0	O
and	0	O
BMP	1	B
-	0	I
4	0	I
overexpression	0	O
in	0	O
cycloheximide	0	O
-	0	O
dependent	0	O
way	0	O
.	0	O
genesis	0	O
26	0	O
:	0	O
198	0	O
-	0	O
207	0	O
,	0	O
2000	0	O
.	0	O


By	0	O
using	0	O
lambda	0	O
gt11	0	O
expression	0	O
cloning	0	O
with	0	O
oligonucleotides	0	O
corresponding	0	O
to	0	O
the	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
1	0	O
TATA	0	O
element	0	O
,	0	O
we	0	O
report	0	O
the	0	O
identification	0	O
of	0	O
a	0	O
cellular	0	O
protein	0	O
with	0	O
a	0	O
calculated	0	O
molecular	0	O
mass	0	O
of	0	O
123	0	O
kDa	1	O
that	0	O
we	0	O
designate	0	O
TATA	0	B
element	0	I
modulatory	0	I
factor	0	I
(	0	O
TMF	0	B
).	0	O


Molecular	1	O
cloning	0	O
and	0	O
characterisation	0	O
of	0	O
the	0	O
two	0	O
homologous	0	O
genes	0	O
coding	0	O
for	0	O
nitrate	0	B
reductase	0	I
in	0	I
tobacco	0	I
.	0	O


A	1	O
method	0	O
for	0	O
determining	0	O
cumulative	0	O
behavioral	0	O
toxicity	0	O
after	0	O
chronic	0	O
oral	0	O
administration	0	O
of	0	O
l	0	O
-	0	O
alpha	0	O
-	0	O
acetylmethadol	0	O
to	0	O
female	0	O
rats	0	O
.	0	O


It	1	O
was	0	O
postulated	0	O
that	0	O
persistent	0	O
challenge	0	O
by	0	O
M	1	O
.	0	O
leprae	0	O
or	0	O
its	0	O
antigens	0	O
to	0	O
the	0	O
IgA	1	B
immunocytes	0	O
of	0	O
the	0	O
intestinal	0	O
epithelium	0	O
might	0	O
have	0	O
induced	0	O
tolerance	0	O
leading	0	O
to	0	O
IgA	1	B
deficiency	0	O
and	0	O
subsequent	0	O
subtotal	0	O
atrophy	0	O
of	0	O
the	0	O
intestinal	0	O
villi	0	O
in	0	O
the	0	O
patients	0	O
with	0	O
lepromatous	0	O
leprosy	0	O
.	0	O


Common	1	O
history	0	O
and	0	O
prospects	0	O
in	0	O
surgical	0	O
gynecology	0	O
of	0	O
the	0	O
Charite	0	O
and	0	O
the	0	O
Vienna	0	O
University	0	O
Clinic	1	O


The	0	O
proofreading	0	O
domain	0	O
of	0	O
Escherichia	1	B
coli	0	I
DNA	1	I
polymerase	0	I
I	1	I
and	0	O
other	0	O
DNA	1	B
and	0	I
/	0	I
or	0	I
RNA	1	I
exonuclease	0	I
domains	0	I
.	0	O


Consistent	0	O
with	0	O
previous	0	O
reports	0	O
,	0	O
addition	0	O
of	0	O
a	0	O
myristoylation	0	O
signal	0	O
to	0	O
mSos1	0	B
(	0	O
MyrSos1	0	B
)	0	O
rendered	0	O
it	0	O
transforming	0	O
for	0	O
NIH	1	O
3T3	0	O
cells	0	O
and	0	O
deletion	0	O
of	0	O
the	0	O
mSos	0	B
C	1	I
terminus	0	I
(	0	O
MyrSos1	0	B
-	0	I
deltaC	0	I
)	0	O
did	0	O
not	0	O
interfere	0	O
with	0	O
this	0	O
activity	0	O
.	0	O


10	0	O
long	0	O
-	0	O
term	0	O
hemodialysis	0	O
patients	0	O
had	0	O
immediate	0	O
and	0	O
redistribution	0	O
thallium	0	O
-	0	O
201	0	O
myocardial	0	O
imaging	0	O
performed	0	O
after	0	O
a	0	O
course	0	O
of	0	O
hemodialysis	0	O
.	0	O


Supplementation	1	O
was	0	O
stopped	0	O
when	0	O
pl	0	B
-	0	I
ALB	0	I
reached	0	O
2	0	O
.	0	O
0	0	O
g	0	O
/	0	O
dL	1	O
.	0	O


N	1	O
.,	0	O
and	0	O
Fanning	0	O
,	0	O
E	1	O
.	0	O


In	1	O
patients	0	O
with	0	O
osteomyelitis	0	O
and	0	O
joint	0	O
empyema	0	O
(	0	O
n	0	O
=	0	O
48	0	O
)	0	O
PMN	1	B
elastase	0	I
had	0	O
a	0	O
sensitivity	0	O
of	0	O
77	0	O
%,	0	O
which	0	O
was	0	O
only	0	O
exceeded	0	O
by	0	O
that	0	O
of	0	O
the	0	O
unspecific	0	O
erythrocyte	0	O
sedimentation	0	O
rate	0	O
(	0	O
sensitivity	0	O
89	0	O
%).	0	O


The	0	O
proteasome	0	O
is	0	O
a	0	O
large	0	O
complex	0	O
consisting	0	O
of	0	O
two	0	O
multisubunit	0	O
structures	0	O
,	0	O
the	0	O
20S	0	B
and	0	O
19S	0	B
(	0	O
PA700	0	B
)	0	O
or	0	O
P28	0	B
complexes	0	I
,	0	O
that	0	O
combine	0	O
to	0	O
form	0	O
the	0	O
26S	0	B
particles	0	I
.	0	O


Irradiation	1	O
of	0	O
human	0	O
blood	0	O
platelets	0	O
with	0	O
UV	1	O
-	0	O
A	1	O
in	0	O
vitro	0	O
impairs	0	O
their	0	O
ability	0	O
to	0	O
aggregate	0	O
after	0	O
challenge	0	O
with	0	O
collagen	0	B
.	0	O


The	0	O
gp330	0	B
/	0	O
Megalin	0	B
/	0	O
LRP	0	B
-	0	I
2	0	I
protein	0	O
belongs	0	O
to	0	O
the	0	O
low	0	B
-	0	I
density	0	I
lipoprotein	0	I
receptor	0	I
gene	0	I
family	0	I
and	0	O
is	0	O
believed	0	O
to	0	O
function	0	O
as	0	O
an	0	O
endocytic	0	O
receptor	0	O
for	0	O
the	0	O
uptake	0	O
of	0	O
lipoproteins	0	O
and	0	O
many	0	O
other	0	O
ligands	0	O
.	0	O


Sites	0	O
1	0	O
and	0	O
4	0	O
in	0	O
lumican	0	B
and	0	O
keratocan	0	B
are	0	O
in	0	O
a	0	O
homologous	0	O
location	0	O
.	0	O


Significance	0	O
of	0	O
delta	0	O
-	0	O
aminolevulinic	0	O
acid	0	O
analysis	0	O
in	0	O
clinical	0	O
tests	0	O


The	0	O
Myc	0	B
LZ	1	I
was	0	O
found	0	O
to	0	O
prevent	0	O
homodimeric	0	O
interactions	0	O
,	0	O
thus	0	O
explaining	0	O
Myc	0	B
inability	0	O
to	0	O
homodimerize	0	O
efficiently	0	O
.	0	O


Using	0	O
Ki	1	B
-	0	I
ras	0	I
-	0	O
transformed	0	O
3T3	0	O
cells	0	O
as	0	O
a	0	O
model	0	O
system	0	O
,	0	O
we	0	O
show	0	O
that	0	O
both	0	O
RA	1	O
and	0	O
the	0	O
'	0	O
dissociating	0	O
'	0	O
retinoids	0	O
inhibit	0	O
anchorage	0	O
-	0	O
independent	0	O
cell	0	O
proliferation	0	O
,	0	O
suggesting	0	O
that	0	O
retinoid	0	O
-	0	O
induced	0	O
growth	0	O
inhibition	0	O
may	0	O
be	0	O
related	0	O
to	0	O
AP1	0	B
transrepression	0	O
.	0	O


Prevalence	1	O
of	0	O
sleep	0	O
-	0	O
disordered	0	O
breathing	0	O
(	0	O
SDB	0	O
)	0	O
is	0	O
reported	0	O
to	0	O
increase	0	O
in	0	O
menopausal	0	O
women	0	O
.	0	O


They	0	O
were	0	O
checked	0	O
for	0	O
anti	0	B
-	0	I
HCV	1	I
(	0	O
anti	0	B
-	0	I
C100	0	I
-	0	I
3	0	I
)	0	O
with	0	O
HCV	1	O
EIA	1	O
kit	0	O
(	0	O
Abbott	0	O
Lab	1	O
.,	0	O
North	0	O
Chicago	0	O
,	0	O
IL	1	O
).	0	O


This	0	O
suggested	0	O
that	0	O
delta	0	O
6	0	O
and	0	O
delta	0	O
5	0	O
desaturation	0	O
activities	0	O
are	0	O
normal	0	O
in	0	O
these	0	O
conditions	0	O
with	0	O
this	0	O
C18	0	O
:	0	O
2w6	0	O
supply	0	O
.	0	O


A	1	O
method	0	O
for	0	O
determining	0	O
optimal	0	O
development	0	O
conditions	0	O
by	0	O
summary	0	O
oxygen	0	O
consumption	0	O


We	0	O
have	0	O
previously	0	O
shown	0	O
that	0	O
LBP	1	B
-	0	I
1	0	I
represses	0	O
HIV	1	O
-	0	O
1	0	O
transcription	0	O
by	0	O
inhibiting	0	O
the	0	O
binding	0	O
of	0	O
TFIID	0	B
to	0	O
the	0	O
TATA	0	O
box	0	O
.	0	O


This	0	O
report	0	O
has	0	O
reviewed	0	O
some	0	O
of	0	O
the	0	O
reasons	0	O
for	0	O
treatment	0	O
failures	0	O
and	0	O
has	0	O
presented	0	O
a	0	O
philosophy	0	O
for	0	O
their	0	O
management	0	O
.	0	O


It	1	O
is	0	O
shown	0	O
that	0	O
the	0	O
(	0	O
G	1	O
+	0	O
C	1	O
)-	0	O
rich	0	O
element	0	O
of	0	O
the	0	O
aldolase	0	B
C	1	I
promoter	0	I
directs	0	O
transcription	0	O
in	0	O
neuronal	0	O
as	0	O
well	0	O
as	0	O
in	0	O
nonneuronal	0	O
cells	0	O
.	0	O


Four	0	O
patients	0	O
(	0	O
group	0	O
1	0	O
)	0	O
had	0	O
type	0	O
I	1	O
basement	0	O
membrane	0	O
nephropathy	0	O
,	0	O
characterized	0	O
by	0	O
marked	0	O
thickening	0	O
and	0	O
lamellation	0	O
of	0	O
the	0	O
basement	0	O
membrane	0	O
in	0	O
a	0	O
pattern	0	O
resembling	0	O
that	0	O
of	0	O
Alport	0	O
'	0	O
s	0	O
syndrome	0	O
.	0	O


Serum	1	O
and	0	O
peritoneal	0	O
dialysis	0	O
fluid	0	O
(	0	O
PDF	0	O
)	0	O
were	0	O
collected	0	O
for	0	O
assay	0	O
throughout	0	O
the	0	O
course	0	O
of	0	O
the	0	O
study	0	O
and	0	O
for	0	O
5	0	O
days	0	O
thereafter	0	O
.	0	O


These	0	O
data	0	O
provide	0	O
evidence	0	O
that	0	O
the	0	O
2	0	B
.	0	I
0	0	I
-	0	I
kb	0	I
LAT	1	I
is	0	O
an	0	O
intron	0	O
of	0	O
the	0	O
mLAT	0	B
pre	0	I
-	0	I
mRNA	1	I
with	0	O
a	0	O
unique	0	O
branch	0	O
point	0	O
.	0	O


Tyrosine	1	B
kinase	0	I
oncogenes	0	O
abrogate	0	O
interleukin	0	B
-	0	I
3	0	I
dependence	0	O
of	0	O
murine	0	O
myeloid	0	O
cells	0	O
through	0	O
signaling	0	O
pathways	0	O
involving	0	O
c	0	B
-	0	I
myc	0	I
:	0	O
conditional	0	O
regulation	0	O
of	0	O
c	0	B
-	0	I
myc	0	I
transcription	0	O
by	0	O
temperature	0	O
-	0	O
sensitive	0	O
v	0	B
-	0	I
abl	0	I
.	0	O


The	0	O
amino	0	O
-	0	O
terminal	0	O
region	0	O
of	0	O
E1A	0	B
binds	0	O
several	0	O
high	0	O
molecular	0	O
weight	0	O
proteins	0	O
and	0	O
inhibits	0	O
the	0	O
transcriptional	0	O
coactivator	0	O
function	0	O
of	0	O
p300	0	B
and	0	O
the	0	O
homologous	0	O
cAMP	1	B
response	0	I
element	0	I
(	0	I
CRE	0	I
)-	0	I
binding	0	I
protein	0	I
.	0	O


The	0	O
present	0	O
study	0	O
shows	0	O
that	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
-	0	O
dependent	0	O
p38	0	B
kinase	0	I
activation	0	O
regulates	0	O
Akt	0	B
phosphorylation	0	O
and	0	O
activity	0	O
in	0	O
human	0	O
neutrophils	0	O
.	0	O


The	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
contains	0	O
potential	0	O
binding	0	O
sites	0	O
for	0	O
TATA	0	B
-	0	I
binding	0	I
protein	0	I
,	0	O
Sp1	0	B
,	0	O
nuclear	0	B
factor	0	I
1	0	I
(	0	O
NF1	1	B
),	0	O
CAAT	0	B
-	0	I
box	0	I
binding	0	I
protein	0	I
(	0	O
C	1	B
/	0	I
EBP	1	I
),	0	O
hepatocyte	0	B
nuclear	0	I
factors	0	I
1	0	I
and	0	I
5	0	I
(	0	O
HNF1	0	B
,	0	O
HNF5	0	B
)	0	O
and	0	O
activator	0	B
proteins	0	I
1	0	I
and	0	I
2	0	I
(	0	O
AP1	0	B
,	0	O
AP2	0	B
).	0	O


The	0	O
human	0	B
MSH	1	I
-	0	I
2	0	I
gene	0	I
product	0	I
is	0	O
a	0	O
member	0	O
of	0	O
a	0	O
highly	0	O
conserved	0	O
family	0	O
of	0	O
proteins	0	O
which	0	O
are	0	O
involved	0	O
in	0	O
post	0	O
-	0	O
replication	0	O
mismatch	0	O
repair	0	O
.	0	O
hMSH	0	B
-	0	I
2	0	I
is	0	O
homologous	0	O
to	0	O
Escherichia	1	O
coli	0	O
(	0	O
E	1	O
.	0	O
coli	0	O
)	0	O
MutS	0	B
and	0	O
Sacchromyces	0	B
cerevisiae	0	I
MSH	1	I
-	0	I
1	0	I
and	0	O
MSH	1	B
-	0	I
2	0	I
proteins	0	I
,	0	O
which	0	O
recognise	0	O
heteroduplex	0	O
DNA	1	O
at	0	O
the	0	O
sites	0	O
of	0	O
all	0	O
single	0	O
base	0	O
mismatches	0	O
and	0	O
deletions	0	O
or	0	O
insertions	0	O
up	0	O
to	0	O
4	0	O
base	0	O
pairs	0	O
.	0	O
hMSH	0	B
-	0	I
2	0	I
is	0	O
one	0	O
of	0	O
the	0	O
hereditary	0	B
non	0	I
-	0	I
polyposis	0	I
colorectal	0	I
cancer	0	I
(	0	I
HNPCC	1	I
)	0	I
tumor	0	I
suppressor	0	I
genes	0	I
,	0	O
and	0	O
maps	0	O
to	0	O
human	0	O
chromosome	0	O
2p16	0	O
.	0	O


McCann	0	O
III	0	O
,	0	O
F	1	O
.	0	O


Both	0	O
immunophilins	0	B
may	0	O
have	0	O
important	0	O
roles	0	O
in	0	O
receptor	0	O
assembly	0	O
and	0	O
may	0	O
represent	0	O
a	0	O
new	0	O
category	0	O
of	0	O
ligand	0	O
-	0	O
and	0	O
calcium	0	O
-	0	O
dependent	0	O
modulators	0	O
of	0	O
protein	0	O
function	0	O
.	0	O


Hyperthyroidism	1	O


Inhibition	1	O
of	0	O
the	0	O
Raf	0	B
-	0	I
1	0	I
kinase	0	I
by	0	O
cyclic	0	O
AMP	1	O
agonists	0	O
causes	0	O
apoptosis	0	O
of	0	O
v	0	B
-	0	I
abl	0	I
-	0	O
transformed	0	O
cells	0	O
.	0	O


The	0	O
possibility	0	O
of	0	O
a	0	O
hereditary	0	O
disorder	0	O
leading	0	O
to	0	O
a	0	O
minor	0	O
defect	0	O
in	0	O
elastic	0	O
fibre	0	O
structure	0	O
which	0	O
could	0	O
be	0	O
responsible	0	O
for	0	O
the	0	O
spontaneous	0	O
lesions	0	O
is	0	O
discussed	0	O
.	0	O


This	0	O
may	0	O
account	0	O
,	0	O
at	0	O
least	0	O
in	0	O
part	0	O
,	0	O
for	0	O
the	0	O
ability	0	O
of	0	O
excess	0	O
wt	0	B
p53	0	I
to	0	O
inhibit	0	O
cell	0	O
proliferation	0	O
and	0	O
to	0	O
interfere	0	O
with	0	O
neoplastic	0	O
processes	0	O
.	0	O


The	0	O
American	0	O
Burkitt	0	O
Lymphoma	1	O
Registry	1	O
:	0	O
a	0	O
progress	0	O
report	0	O
.	0	O


Ischemic	1	O
stroke	0	O
due	0	O
to	0	O
protein	0	B
C	1	I
deficiency	0	O
.	0	O


It	1	O
was	0	O
also	0	O
suggested	0	O
that	0	O
the	0	O
biological	0	O
activities	0	O
of	0	O
5	0	O
-	0	O
FU	0	O
,	0	O
ADM	0	O
and	0	O
MMC	0	O
in	0	O
FAMLIP	0	O
were	0	O
stable	0	O
in	0	O
FULIP	0	O
,	0	O
ADRLIP	0	O
and	0	O
MMCLIP	0	O
.	0	O


An	1	O
apparent	0	O
N	1	O
-	0	O
terminal	0	O
transit	0	O
peptide	0	O
in	0	O
the	0	O
coding	0	O
region	0	O
and	0	O
a	0	O
3	0	O
'	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
tail	0	O
exist	0	O
in	0	O
the	0	O
cDNA	1	O
clone	0	O
indicated	0	O
that	0	O
this	0	O
chloroplast	0	O
protein	0	O
as	0	O
nuclear	0	O
encoded	0	O
.	0	O


These	0	O
findings	0	O
suggest	0	O
that	0	O
fodrin	0	B
proteolysis	0	O
in	0	O
vivo	0	O
may	0	O
reflect	0	O
the	0	O
activity	0	O
of	0	O
multiple	0	O
ICE	1	B
/	0	O
Ced	0	B
-	0	I
3	0	I
proteases	0	O
whose	0	O
partial	0	O
sensitivity	0	O
to	0	O
DEVD	0	O
-	0	O
CHO	1	O
reflects	0	O
a	0	O
limited	0	O
contribution	0	O
from	0	O
CPP32	0	B
,	0	O
or	0	O
an	0	O
ICE	1	B
/	0	O
Ced	0	B
-	0	I
3	0	I
protease	0	O
less	0	O
sensitive	0	O
than	0	O
CPP32	0	B
to	0	O
DEVD	0	O
-	0	O
CHO	1	O
inhibition	0	O
.	0	O


Sequence	1	O
comparisons	0	O
of	0	O
prokaryotic	0	B
RCR	0	I
initiators	0	I
has	0	O
revealed	0	O
a	0	O
set	0	O
of	0	O
three	0	O
common	0	O
motifs	0	O
,	0	O
two	0	O
of	0	O
which	0	O
,	0	O
a	0	O
putative	0	O
metal	0	O
coordination	0	O
site	0	O
and	0	O
a	0	O
downstream	0	O
active	0	O
-	0	O
site	0	O
tyrosine	0	O
motif	0	O
,	0	O
could	0	O
be	0	O
tentatively	0	O
identified	0	O
in	0	O
parvoviral	0	B
replicator	0	I
proteins	0	I
.	0	O


The	0	O
human	0	B
RAD30B	0	I
and	0	O
mouse	0	B
Rad30b	0	I
mRNA	1	I
transcripts	0	I
,	0	O
like	0	O
many	0	O
repair	0	O
proteins	0	O
,	0	O
are	0	O
highly	0	O
expressed	0	O
in	0	O
the	0	O
testis	0	O
.	0	O


METHODS	0	O
AND	0	O
RESULTS	0	O
:	0	O
In	1	O
25	0	O
open	0	O
-	0	O
chest	0	O
,	0	O
anesthetized	0	O
dogs	0	O
,	0	O
progressive	0	O
circumflex	0	O
artery	0	O
stenosis	0	O
led	0	O
to	0	O
a	0	O
concordant	0	O
decrease	0	O
of	0	O
circumflex	0	O
artery	0	O
resting	0	O
and	0	O
hyperemic	0	O
flow	0	O
,	0	O
coronary	0	O
flow	0	O
reserve	0	O
,	0	O
and	0	O
inverse	0	O
angiographic	0	O
mean	0	O
transit	0	O
time	0	O
Tmicro	0	O
-	0	O
1	0	O
(	0	O
P	1	O
<	0	O
.	0	O
01	0	O
).	0	O


These	0	O
genetic	0	O
alterations	0	O
do	0	O
not	0	O
affect	0	O
synthesis	0	O
of	0	O
the	0	O
major	0	O
c	0	B
-	0	I
myc	0	I
protein	0	I
,	0	O
p64	0	B
,	0	O
which	0	O
is	0	O
initiated	0	O
from	0	O
the	0	O
first	0	O
AUG	0	O
codon	0	O
in	0	O
exon	0	O
2	0	O
.	0	O


VP5	0	B
,	0	O
which	0	O
encodes	0	O
the	0	O
major	0	B
capsid	0	I
protein	0	I
,	0	O
each	0	O
fused	0	O
to	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
gene	0	I
.	0	O


The	0	O
second	0	O
and	0	O
third	0	O
responded	0	O
similarly	0	O
to	0	O
either	0	O
a	0	O
combined	0	O
cyclophosphamide	0	O
+	0	O
antilymphocyte	0	B
globulin	0	I
(	0	O
ALG	1	B
)	0	O
treatment	0	O
or	0	O
to	0	O
ALG	1	B
administration	0	O
preceded	0	O
by	0	O
a	0	O
small	0	O
dosage	0	O
of	0	O
cyclophosphamide	0	O
,	0	O
which	0	O
had	0	O
proved	0	O
ineffective	0	O
when	0	O
administered	0	O
alone	0	O
.	0	O


Horseradish	1	B
peroxidase	0	I
as	0	O
a	0	O
permeability	0	O
marker	0	O
in	0	O
injured	0	O
rat	0	O
caudal	0	O
and	0	O
iliac	0	O
arteries	0	O
.	0	O


Pregnant	1	O
rats	0	O
were	0	O
exposed	0	O
to	0	O
one	0	O
of	0	O
the	0	O
following	0	O
:	0	O
(	0	O
1	0	O
)	0	O
10	0	O
%	0	O
O2	1	O
in	0	O
N2	0	O
or	0	O
100	0	O
%	0	O
O2	1	O
for	0	O
2	0	O
days	0	O
beginning	0	O
at	0	O
day	0	O
7	0	O
,	0	O
11	0	O
,	0	O
14	0	O
,	0	O
or	0	O
18	0	O
of	0	O
pregnancy	0	O
;	0	O
(	0	O
2	0	O
)	0	O
10	0	O
%	0	O
O2	1	O
in	0	O
N2	0	O
or	0	O
100	0	O
%	0	O
O2	1	O
for	0	O
10	0	O
h	0	O
/	0	O
day	0	O
beginning	0	O
at	0	O
day	0	O
7	0	O
;	0	O
or	0	O
(	0	O
3	0	O
)	0	O
14	0	O
-	0	O
11	0	O
%	0	O
O2	1	O
in	0	O
N2	0	O
continuously	0	O
beginning	0	O
at	0	O
day	0	O
14	0	O
till	0	O
day	0	O
21	0	O
when	0	O
they	0	O
were	0	O
sacrificed	0	O
.	0	O


The	0	O
IPL1	0	B
gene	0	I
is	0	O
required	0	O
for	0	O
high	0	O
-	0	O
fidelity	0	O
chromosome	0	O
segregation	0	O
in	0	O
the	0	O
budding	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
diltiazem	0	O
were	0	O
stereoselective	0	O
,	0	O
thus	0	O
the	0	O
potentiation	0	O
induced	0	O
by	0	O
d	0	O
-	0	O
cis	0	O
diltiazem	0	O
was	0	O
significantly	0	O
greater	0	O
in	0	O
all	0	O
cases	0	O
than	0	O
that	0	O
induced	0	O
by	0	O
l	0	O
-	0	O
cis	0	O
diltiazem	0	O
,	0	O
which	0	O
suggests	0	O
that	0	O
calcium	0	O
channel	0	O
blockade	0	O
plays	0	O
a	0	O
role	0	O
in	0	O
these	0	O
interactions	0	O
.	0	O


Second	1	O
,	0	O
when	0	O
the	0	O
NBF1	0	B
+	0	I
R	1	I
protein	0	I
,	0	O
the	0	O
NBF2	0	B
protein	0	I
,	0	O
and	0	O
a	0	O
mixture	0	O
of	0	O
the	0	O
two	0	O
proteins	0	O
were	0	O
folded	0	O
separately	0	O
and	0	O
analyzed	0	O
by	0	O
molecular	0	O
sieve	0	O
chomatography	0	O
,	0	O
the	0	O
mixture	0	O
was	0	O
found	0	O
to	0	O
elute	0	O
prior	0	O
to	0	O
either	0	O
NBF1	0	B
+	0	I
R	1	I
or	0	O
NBF2	0	B
.	0	O


Its	0	O
vasodilatory	0	O
,	0	O
anti	0	O
-	0	O
vasopressor	0	O
,	0	O
and	0	O
platelet	0	O
stabilizing	0	O
effects	0	O
could	0	O
be	0	O
expected	0	O
to	0	O
counteract	0	O
the	0	O
placental	0	O
ischemia	0	O
,	0	O
hypertension	0	O
and	0	O
excessive	0	O
coagulation	0	O
that	0	O
are	0	O
seen	0	O
in	0	O
pre	0	O
-	0	O
eclampsia	0	O
.	0	O


Truncations	0	O
composed	0	O
of	0	O
78	0	O
and	0	O
64	0	O
amino	0	O
acids	0	O
were	0	O
translocated	0	O
across	0	O
the	0	O
endoplasmic	0	O
reticulum	0	O
membrane	0	O
,	0	O
and	0	O
translocation	0	O
was	0	O
found	0	O
to	0	O
be	0	O
strictly	0	O
co	0	O
-	0	O
translational	0	O
and	0	O
SRP	0	B
-	0	O
dependent	0	O
.	0	O


These	0	O
cells	0	O
averaged	0	O
17	0	O
microns	0	O
in	0	O
diameter	0	O
and	0	O
reproduced	0	O
by	0	O
fission	0	O
,	0	O
forming	0	O
clusters	0	O
of	0	O
two	0	O
or	0	O
four	0	O
daughter	0	O
cells	0	O
.	0	O


Both	0	O
classes	0	O
of	0	O
MHBst	0	B
proteins	0	I
were	0	O
found	0	O
to	0	O
form	0	O
dimers	0	O
;	0	O
an	0	O
which	0	O
is	0	O
involved	0	O
in	0	O
mediating	0	O
the	0	O
dimerization	0	O
.	0	O


Two	0	O
protease	0	O
-	0	O
resistant	0	O
fragments	0	O
spanning	0	O
the	0	O
N	1	O
-	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
halves	0	O
of	0	O
the	0	O
nuclease	0	O
were	0	O
identified	0	O
using	0	O
different	0	O
proteases	0	O
which	0	O
cleave	0	O
the	0	O
protein	0	O
in	0	O
the	0	O
same	0	O
region	0	O
.	0	O


The	0	O
potential	0	O
for	0	O
highly	0	O
reactive	0	O
nanoparticles	0	O
(	0	O
RNP	1	O
)	0	O
to	0	O
absorb	0	O
destructively	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
to	0	O
neutralize	0	O
highly	0	O
toxic	0	O
substances	0	O
such	0	O
as	0	O
the	0	O
warfare	0	O
agents	0	O
GA	1	O
,	0	O
GB	1	O
,	0	O
HD	1	O
and	0	O
VX	1	O
,	0	O
has	0	O
been	0	O
demonstrated	0	O
in	0	O
the	0	O
laboratory	0	O
.	0	O


Regulators	0	O
responsible	0	O
for	0	O
the	0	O
pervasive	0	O
,	0	O
nonsex	0	O
-	0	O
specific	0	O
alternative	0	O
pre	0	O
-	0	O
mRNA	1	O
splicing	0	O
characteristic	0	O
of	0	O
metazoans	0	O
are	0	O
almost	0	O
entirely	0	O
unknown	0	O
or	0	O
uncertain	0	O
.	0	O


The	0	O
impact	0	O
of	0	O
social	0	O
support	0	O
on	0	O
the	0	O
relationships	0	O
of	0	O
gay	0	O
male	0	O
couples	0	O
is	0	O
examined	0	O
.	0	O


The	0	O
incidence	0	O
of	0	O
cardiac	0	O
death	0	O
(	0	O
one	0	O
per	0	O
group	0	O
),	0	O
Q	1	O
wave	0	O
MI	1	O
(	0	O
propofol	0	O
,	0	O
n	0	O
=	0	O
7	0	O
;	0	O
midazolam	0	O
,	0	O
n	0	O
=	0	O
3	0	O
;	0	O
P	1	O
=	0	O
0	0	O
.	0	O
27	0	O
),	0	O
or	0	O
non	0	O
Q	1	O
wave	0	O
MI	1	O
(	0	O
propofol	0	O
,	0	O
n	0	O
=	0	O
16	0	O
;	0	O
midazolam	0	O
,	0	O
n	0	O
=	0	O
18	0	O
;	0	O
P	1	O
=	0	O
0	0	O
.	0	O
81	0	O
)	0	O
did	0	O
not	0	O
differ	0	O
between	0	O
treatment	0	O
groups	0	O
.	0	O


In	1	O
vitro	0	O
binding	0	O
studies	0	O
using	0	O
GST	0	B
fusion	0	O
proteins	0	O
and	0	O
yeast	0	O
extracts	0	O
defined	0	O
distinct	0	O
binding	0	O
sites	0	O
on	0	O
yAP180A	0	B
for	0	O
Pan1p	0	B
and	0	O
clathrin	0	B
.	0	O
yAP180	0	B
proteins	0	I
and	0	O
Pan1p	0	B
,	0	O
like	0	O
actin	0	B
,	0	O
localize	0	O
to	0	O
peripheral	0	O
patches	0	O
along	0	O
the	0	O
plasma	0	O
membrane	0	O
.	0	O


We	0	O
show	0	O
here	0	O
that	0	O
the	0	O
binding	0	O
of	0	O
C1F	0	B
in	0	O
vitro	0	O
is	0	O
sensitive	0	O
to	0	O
the	0	O
concentration	0	O
of	0	O
calcium	0	O
ions	0	O
.	0	O


The	0	O
preferences	0	O
were	0	O
for	0	O
intact	0	O
vis	0	O
-	0	O
a	0	O
-	0	O
vis	0	O
castrated	0	O
males	0	O
,	0	O
though	0	O
injections	0	O
of	0	O
TP	1	O
restored	0	O
the	0	O
castrates	0	O
'	0	O
attractiveness	0	O
to	0	O
the	0	O
females	0	O
.	0	O


Innervation	1	O
of	0	O
the	0	O
ventral	0	O
diaphragm	0	O
of	0	O
the	0	O
locust	0	O
(	0	O
Locusta	0	O
migratoria	0	O
).	0	O


On	1	O
the	0	O
amount	0	O
and	0	O
significance	0	O
of	0	O
the	0	O
effective	0	O
glucose	0	O
level	0	O
in	0	O
tumors	0	O
.	0	O


Whereas	0	O
the	0	O
mutant	0	O
enzymes	0	O
terminate	0	O
normally	0	O
at	0	O
the	0	O
late	0	O
terminator	0	O
in	0	O
T7	0	O
DNA	1	O
(	0	O
T	1	O
(	0	O
phi	0	O
))	0	O
and	0	O
rrnB	0	B
T2	0	O
,	0	O
they	0	O
fail	0	O
to	0	O
terminate	0	O
at	0	O
one	0	O
of	0	O
the	0	O
termination	0	O
sites	0	O
of	0	O
rrnB	0	B
T1	1	O
,	0	O
and	0	O
also	0	O
fail	0	O
to	0	O
recognize	0	O
the	0	O
PTH	1	B
and	0	O
CJ	0	O
signals	0	O
.	0	O


Following	1	O
2	0	O
.	0	O
5	0	O
Gy	1	O
,	0	O
HbO2	1	B
changes	0	O
were	0	O
minimal	0	O
.	0	O


Liver	1	O
regional	0	O
blood	0	O
volume	0	O
(	0	O
LRBV	0	O
)	0	O
is	0	O
altered	0	O
by	0	O
several	0	O
disease	0	O
states	0	O
and	0	O
various	0	O
drugs	0	O
.	0	O


The	0	O
spectrum	0	O
of	0	O
age	0	O
-	0	O
associated	0	O
brain	0	O
abnormalities	0	O
:	0	O
their	0	O
measurement	0	O
and	0	O
histopathological	0	O
correlates	0	O
.	0	O


Expression	1	O
of	0	O
this	0	O
cDNA	1	O
in	0	O
vitro	0	O
yields	0	O
a	0	O
peptide	0	O
which	0	O
comigrates	0	O
with	0	O
natural	0	B
eIF	0	I
-	0	I
2B	0	I
alpha	0	I
in	0	O
SDS	1	O
/	0	O
polyacrylamide	0	O
gels	0	O
.	0	O


Twelve	0	O
patients	0	O
without	0	O
abnormalities	0	O
in	0	O
the	0	O
PTT	1	O
are	0	O
assumed	0	O
to	0	O
harbor	0	O
missense	0	O
mutations	0	O
,	0	O
probably	0	O
in	0	O
TSC2	0	B
.	0	O


Physical	1	O
analysis	0	O
maps	0	O
SAL6	0	B
to	0	O
chromosome	0	O
XVI	0	O
between	0	O
TPK2	0	B
and	0	O
spt14	0	B
.	0	O


In	1	O
one	0	O
,	0	O
exploratory	0	O
behavior	0	O
(	0	O
assessed	0	O
by	0	O
hole	0	O
pokes	0	O
)	0	O
and	0	O
locomotion	0	O
were	0	O
assessed	0	O
during	0	O
a	0	O
10	0	O
-	0	O
min	0	O
test	0	O
session	0	O
.	0	O


cDNA	1	O
encoding	0	O
a	0	O
functional	0	O
feline	0	B
liver	0	I
/	0	I
bone	0	I
/	0	I
kidney	0	I
-	0	I
type	0	I
alkaline	0	I
phosphatase	0	I
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
utility	0	O
of	0	O
beta	0	B
2	0	I
transferrin	0	I
assay	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
cerebrospinal	0	O
fluid	0	O
otorrhea	0	O
is	0	O
presented	0	O
.	0	O


The	0	O
patient	0	O
was	0	O
treated	0	O
with	0	O
benzathine	0	O
penicillin	0	O
,	0	O
2	0	O
,	0	O
400	0	O
,	0	O
000	0	O
U	1	O
weekly	0	O
for	0	O
three	0	O
weeks	0	O
.	0	O


We	0	O
have	0	O
now	0	O
shown	0	O
that	0	O
in	0	O
vivo	0	O
phosphorylation	0	O
of	0	O
14	0	B
-	0	I
3	0	I
-	0	I
3	0	I
zeta	0	I
at	0	O
the	0	O
CKIalpha	0	B
site	0	I
(	0	I
Thr	1	I
-	0	I
233	0	I
)	0	I
negatively	0	O
regulates	0	O
its	0	O
binding	0	O
to	0	O
c	0	B
-	0	I
Raf	0	I
,	0	O
and	0	O
may	0	O
be	0	O
important	0	O
in	0	O
Raf	0	B
-	0	O
mediated	0	O
signal	0	O
transduction	0	O
.	0	O


These	0	O
cell	0	O
lines	0	O
displayed	0	O
methylation	0	O
of	0	O
the	0	O
CpG	0	O
island	0	O
surrounding	0	O
the	0	O
first	0	O
exon	0	O
of	0	O
p16INK4A	0	B
and	0	O
expressed	0	O
abundant	0	O
levels	0	O
of	0	O
a	0	O
nontranslated	0	O
mRNA	1	O
containing	0	O
an	0	O
alternative	0	O
first	0	O
exon	0	O
(	0	O
E1	1	O
beta	0	O
),	0	O
as	0	O
did	0	O
all	0	O
other	0	O
cell	0	O
lines	0	O
in	0	O
which	0	O
the	0	O
p16INK4A	0	B
locus	0	I
was	0	O
not	0	O
deleted	0	O
.	0	O


ACE	1	B
-	0	I
2	0	I
has	0	O
a	0	O
hydrophobic	0	O
C	1	O
terminus	0	O
of	0	O
H	1	O
type	0	O
.	0	O


Using	0	O
5	0	O
ng	0	O
/	0	O
mL	1	O
as	0	O
the	0	O
cutoff	0	O
,	0	O
the	0	O
sensitivity	0	O
of	0	O
CEA	1	B
was	0	O
68	0	O
%.	0	O


Group	1	O
psychometric	0	O
functions	0	O
for	0	O
listeners	0	O
with	0	O
hearing	0	O
loss	0	O
do	0	O
not	0	O
show	0	O
a	0	O
decrease	0	O
in	0	O
performance	0	O
at	0	O
the	0	O
largest	0	O
values	0	O
of	0	O
delta	0	O
f	0	O
included	0	O
in	0	O
this	0	O
study	0	O
.	0	O


Utilization	1	O
of	0	O
alternative	0	O
polyadenylation	0	O
signals	0	O
was	0	O
previously	0	O
shown	0	O
to	0	O
generate	0	O
two	0	O
sialophorin	0	B
mRNAs	0	I
of	0	I
1	0	I
.	0	I
9	0	I
and	0	I
4	0	I
.	0	I
3	0	I
kb	0	I
,	0	O
which	0	O
differ	0	O
in	0	O
the	0	O
length	0	O
of	0	O
their	0	O
3	0	O
'	0	O
untranslated	0	O
regions	0	O
.	0	O


Behavioral	0	O
and	0	O
electrographic	0	O
expression	0	O
of	0	O
natural	0	O
sleep	0	O
and	0	O
wakefulness	0	O
in	0	O
reptiles	0	O


The	0	O
M	1	O
-	0	O
3	0	O
subtype	0	O
was	0	O
an	0	O
adverse	0	O
prognostic	0	O
factor	0	O
.	0	O


Canadian	0	O
survey	0	O
reveals	0	O
widespread	0	O
dissatisfaction	0	O
among	0	O
physicians	0	O
.	0	O


Neural	1	O
blockade	0	O
in	0	O
chronic	0	O
and	0	O
cancer	0	O
pain	0	O
.	0	O


Simian	1	O
immunodeficiency	0	O
virus	0	O
(	0	O
SIV	1	O
)	0	O
is	0	O
a	0	O
lentivirus	0	O
with	0	O
morphological	0	O
and	0	O
antigenic	0	O
similarities	0	O
to	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
,	0	O
the	0	O
causative	0	O
agent	0	O
of	0	O
acquired	0	O
immunodeficiency	0	O
syndrome	0	O
(	0	O
AIDS	1	O
)	0	O
of	0	O
humans	0	O
.	0	O


US	1	O
-	0	O
Doppler	1	O
has	0	O
recently	0	O
gained	0	O
attention	0	O
as	0	O
a	0	O
noninvasive	0	O
method	0	O
for	0	O
the	0	O
functional	0	O
evaluation	0	O
of	0	O
arteriovenous	0	O
fistulas	0	O
(	0	O
FAV	0	O
).	0	O


Phosphocreatine	1	O
hydrolysis	0	O
during	0	O
submaximal	0	O
exercise	0	O
:	0	O
the	0	O
effect	0	O
of	0	O
FIO2	1	O
.	0	O


Most	0	O
of	0	O
them	0	O
were	0	O
situated	0	O
at	0	O
Sylvius	1	O
fissure	0	O
(	0	O
13	0	O
cases	0	O
).	0	O


Finally	0	O
,	0	O
we	0	O
determined	0	O
the	0	O
genomic	0	O
organization	0	O
of	0	O
the	0	O
human	0	B
TrxR2	0	I
gene	0	I
,	0	O
which	0	O
consists	0	O
of	0	O
18	0	O
exons	0	O
spanning	0	O
about	0	O
67	0	O
kb	0	O
,	0	O
and	0	O
its	0	O
chromosomal	0	O
localization	0	O
at	0	O
position	0	O
22q11	0	O
.	0	O
2	0	O
.	0	O


Relapse	1	O
of	0	O
leukemia	0	O
after	0	O
prolonged	0	O
remission	0	O
.	0	O


Insertional	0	O
inactivation	0	O
of	0	O
sms	0	B
led	0	O
to	0	O
increased	0	O
sensitivity	0	O
to	0	O
the	0	O
alkylating	0	O
agent	0	O
methylmethane	0	O
sulfonate	0	O
,	0	O
but	0	O
not	0	O
to	0	O
a	0	O
requirement	0	O
for	0	O
serine	0	O
or	0	O
other	0	O
metabolites	0	O
.	0	O


Furthermore	0	O
,	0	O
we	0	O
notice	0	O
two	0	O
potential	0	O
consensus	0	O
motifs	0	O
which	0	O
are	0	O
also	0	O
found	0	O
in	0	O
corresponding	0	O
positions	0	O
in	0	O
the	0	O
genes	0	O
for	0	O
the	0	O
nerve	0	B
growth	0	I
factor	0	I
receptor	0	I
and	0	O
the	0	O
68	0	B
-	0	I
kDa	1	I
neurofilament	0	I
protein	0	I
.	0	O


We	0	O
report	0	O
here	0	O
the	0	O
identification	0	O
of	0	O
HSF	0	B
in	0	O
the	0	O
fission	0	O
yeast	0	O
Schizosaccharomyces	0	O
pombe	0	O
.	0	O


These	0	O
cognitive	0	O
deficits	0	O
were	0	O
prevented	0	O
in	0	O
animals	0	O
treated	0	O
with	0	O
MK	1	O
-	0	O
801	0	O
during	0	O
SE	1	O
.	0	O


To	1	O
further	0	O
understand	0	O
the	0	O
role	0	O
of	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
in	0	O
these	0	O
regulatory	0	O
mechanisms	0	O
,	0	O
we	0	O
have	0	O
characterized	0	O
a	0	O
transcriptional	0	O
promoter	0	O
that	0	O
drives	0	O
germline	0	O
expression	0	O
of	0	O
TCR	1	B
beta	0	I
gene	0	I
segments	0	I
in	0	O
vivo	0	O
.	0	O


Nucleotide	1	O
sequencing	0	O
indicates	0	O
that	0	O
this	0	O
E1	1	B
alpha	0	I
cDNA	1	I
clone	0	O
is	0	O
1821	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
)	0	O
in	0	O
length	0	O
with	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
of	0	O
1365	0	O
bp	0	O
and	0	O
a	0	O
3	0	O
'-	0	O
untranslated	0	O
region	0	O
of	0	O
356	0	O
bp	0	O
.	0	O


Surgical	1	O
treatment	0	O
of	0	O
pulmonary	0	O
metastases	0	O
.	0	O


Dynamic	1	O
decision	0	O
making	0	O
:	0	O
human	0	O
control	0	O
of	0	O
complex	0	O
systems	0	O
.	0	O


This	0	O
structure	0	O
interconnects	0	O
specific	0	O
triplets	0	O
of	0	O
the	0	O
basal	0	O
bodies	0	O
with	0	O
the	0	O
microtubular	0	O
bundles	0	O
that	0	O
emerge	0	O
from	0	O
the	0	O
basal	0	O
apparatus	0	O
.	0	O


Neither	0	O
ethanol	0	O
nor	0	O
estrogen	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
cause	0	O
UROD	0	B
-	0	O
deficiency	0	O
in	0	O
animals	0	O
.	0	O


The	0	O
functions	0	O
of	0	O
isolated	0	O
portions	0	O
of	0	O
the	0	O
insulin	0	B
,	0	O
IAPP	1	B
,	0	O
and	0	O
beta	0	B
GK	0	I
promoters	0	I
were	0	O
studied	0	O
by	0	O
using	0	O
transient	0	O
expression	0	O
and	0	O
DNA	1	O
binding	0	O
assays	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
this	0	O
100	0	O
-	0	O
bp	0	O
Col2a1	0	B
enhancer	0	I
revealed	0	O
several	0	O
sequence	0	O
motifs	0	O
similar	0	O
to	0	O
motifs	0	O
present	0	O
within	0	O
the	0	O
regulatory	0	O
region	0	O
of	0	O
the	0	O
link	0	B
protein	0	I
gene	0	I
,	0	O
another	0	O
cartilage	0	O
gene	0	O
.	0	O


327	0	O
and	0	O
736	0	O
protocols	0	O
of	0	O
postmortem	0	O
examinations	0	O
from	0	O
Moscow	0	O
hospitals	0	O
N	1	O
31	0	O
and	0	O
57	0	O
,	0	O
respectively	0	O
,	0	O
were	0	O
evaluated	0	O
statistically	0	O
.	0	O


A	1	O
brief	0	O
discussion	0	O
of	0	O
color	0	O
deficiencies	0	O
.	0	O


Synergistic	1	O
transactivation	0	O
of	0	O
the	0	O
BMRF1	0	B
promoter	0	I
by	0	O
the	0	O
Z	1	B
/	0	O
c	0	B
-	0	I
myb	0	I
combination	0	O
appears	0	O
to	0	O
involve	0	O
direct	0	O
binding	0	O
by	0	O
the	0	O
Z	1	B
protein	0	I
but	0	O
not	0	O
the	0	O
c	0	B
-	0	I
myb	0	I
protein	0	I
.	0	O


S2F	0	B
,	0	O
a	0	O
leaf	0	O
-	0	O
specific	0	O
trans	0	O
-	0	O
acting	0	O
factor	0	O
,	0	O
binds	0	O
to	0	O
a	0	O
novel	0	O
cis	0	O
-	0	O
acting	0	O
element	0	O
and	0	O
differentially	0	O
activates	0	O
the	0	O
RPL21	0	B
gene	0	I
.	0	O


Lung	1	O
prostacyclin	0	O
production	0	O
may	0	O
be	0	O
related	0	O
to	0	O
flow	0	O
.	0	O


We	0	O
studied	0	O
120	0	O
male	0	O
and	0	O
42	0	O
female	0	O
patients	0	O
with	0	O
early	0	O
CAD	1	O
who	0	O
were	0	O
unrelated	0	O
to	0	O
each	0	O
other	0	O
but	0	O
were	0	O
from	0	O
families	0	O
in	0	O
which	0	O
at	0	O
least	0	O
one	0	O
other	0	O
sibling	0	O
had	0	O
early	0	O
CAD	1	O
.	0	O


In	1	O
the	0	O
pRb	0	B
(-)	0	I
SAOS	0	O
-	0	O
2	0	O
cell	0	O
line	0	O
transiently	0	O
transfected	0	O
with	0	O
a	0	O
reporter	0	O
plasmid	0	O
containing	0	O
six	0	O
tal	0	B
-	0	I
1	0	I
binding	0	I
site	0	I
,	0	O
pRb	0	B
enhances	0	O
the	0	O
transcriptional	0	O
activity	0	O
of	0	O
tal	0	B
-	0	I
1	0	I
-	0	O
E12	0	B
-	0	O
Lmo2	0	B
and	0	O
tal	0	B
-	0	I
1	0	I
-	0	O
E12	0	B
-	0	O
Lmo2	0	B
-	0	O
Ldb1	0	B
complexes	0	O
but	0	O
not	0	O
that	0	O
of	0	O
a	0	O
tal	0	B
-	0	I
1	0	I
-	0	O
E12	0	B
heterodimer	0	O
.	0	O


The	0	O
network	0	O
evolution	0	O
was	0	O
interpreted	0	O
by	0	O
an	0	O
approach	0	O
based	0	O
on	0	O
the	0	O
Flory	0	O
model	0	O
.	0	O


A	1	O
total	0	O
number	0	O
of	0	O
1628	0	O
cases	0	O
were	0	O
collected	0	O
from	0	O
135	0	O
medical	0	O
institutions	0	O
.	0	O


It	1	O
is	0	O
transparent	0	O
,	0	O
cheap	0	O
to	0	O
be	0	O
made	0	O
,	0	O
and	0	O
easy	0	O
to	0	O
empty	0	O
and	0	O
was	0	O
tested	0	O
in	0	O
118	0	O
animals	0	O
for	0	O
two	0	O
and	0	O
four	0	O
weeks	0	O
.	0	O


The	0	O
results	0	O
confirm	0	O
and	0	O
extend	0	O
previous	0	O
work	0	O
by	0	O
other	0	O
researchers	0	O
.	0	O


Furthermore	0	O
,	0	O
analysis	0	O
of	0	O
the	0	O
E2	1	B
proteins	0	I
present	0	O
in	0	O
various	0	O
cell	0	O
lines	0	O
harboring	0	O
specific	0	O
BPV	1	O
-	0	O
1	0	O
mutants	0	O
,	0	O
including	0	O
the	0	O
2558	0	O
acceptor	0	O
mutant	0	O
,	0	O
proves	0	O
that	0	O
alternate	0	O
modes	0	O
of	0	O
E2	1	B
expression	0	O
exist	0	O
.	0	O


Control	1	O
subjects	0	O
'	0	O
evoked	0	O
potentials	0	O
(	0	O
EPs	1	O
)	0	O
were	0	O
characterized	0	O
by	0	O
an	0	O
initial	0	O
positivity	0	O
in	0	O
the	0	O
90	0	O
-	0	O
140	0	O
ms	0	O
range	0	O
(	0	O
P1	1	O
)	0	O
at	0	O
the	0	O
temporo	0	O
-	0	O
occipital	0	O
site	0	O
.	0	O


We	0	O
isolated	0	O
a	0	O
complementary	0	O
DNA	1	O
(	0	O
cDNA	1	O
)	0	O
clone	0	O
from	0	O
an	0	O
RL95	0	O
-	0	O
2	0	O
expression	0	O
library	0	O
that	0	O
encodes	0	O
the	0	O
C1	1	B
site	0	I
-	0	I
binding	0	I
protein	0	I
.	0	O


It	1	O
is	0	O
mainly	0	O
transcribed	0	O
in	0	O
neural	0	O
structures	0	O
and	0	O
in	0	O
developing	0	O
organs	0	O
characterized	0	O
by	0	O
epithelial	0	O
-	0	O
mesenchymal	0	O
interactions	0	O
.	0	O


Recent	0	O
work	0	O
in	0	O
this	0	O
laboratory	0	O
has	0	O
shown	0	O
that	0	O
the	0	O
gene	0	O
coding	0	O
for	0	O
acetate	0	B
kinase	0	I
(	0	O
ackA	0	B
)	0	O
in	0	O
Sinorhizobium	0	O
meliloti	0	O
is	0	O
up	0	O
-	0	O
regulated	0	O
in	0	O
response	0	O
to	0	O
phosphate	0	O
limitation	0	O
.	0	O


67	0	O
393	0	O
bp	0	O
of	0	O
contiguous	0	O
DNA	1	O
located	0	O
between	0	O
markers	0	O
cdc18	0	B
and	0	O
cdc14	0	B
on	0	O
the	0	O
right	0	O
arm	0	O
of	0	O
fission	0	O
yeast	0	O
chromosome	0	O
II	0	O
has	0	O
been	0	O
sequenced	0	O
as	0	O
part	0	O
of	0	O
the	0	O
European	0	O
Union	1	O
Schizosaccharomyces	0	O
pombe	0	O
genome	0	O
sequencing	0	O
project	0	O
.	0	O


PATIENTS	0	O
AND	0	O
METHODS	0	O
:	0	O
One	0	O
hundred	0	O
eighty	0	O
-	0	O
four	0	O
chemotherapy	0	O
-	0	O
naive	0	O
patients	0	O
receiving	0	O
high	0	O
-	0	O
dose	0	O
cisplatin	0	O
(	0	O
81	0	O
to	0	O
120	0	O
mg	0	O
/	0	O
m2	0	O
)	0	O
were	0	O
randomized	0	O
to	0	O
receive	0	O
one	0	O
of	0	O
four	0	O
granisetron	0	O
doses	0	O
(	0	O
5	0	O
,	0	O
10	0	O
,	0	O
20	0	O
,	0	O
or	0	O
40	0	O
micrograms	0	O
/	0	O
kg	0	O
)	0	O
administered	0	O
before	0	O
chemotherapy	0	O
.	0	O


Consistent	0	O
with	0	O
these	0	O
findings	0	O
,	0	O
relatively	0	O
weak	0	O
transcriptional	0	O
silencing	0	O
by	0	O
the	0	O
native	0	O
VDR	0	B
was	0	O
observed	0	O
using	0	O
the	0	O
osteopontin	0	B
VDRE	0	O
.	0	O


In	1	O
controls	0	O
,	0	O
most	0	O
of	0	O
the	0	O
output	0	O
from	0	O
the	0	O
conduit	0	O
occurred	0	O
during	0	O
type	0	O
I	1	O
activity	0	O
(	0	O
73	0	O
+/-	0	O
14	0	O
%).	0	O


The	0	O
deduced	0	O
96	0	O
-	0	O
residue	0	O
amino	0	O
acid	0	O
coding	0	O
sequence	0	O
of	0	O
the	0	O
murine	0	O
HMG	1	B
-	0	I
I	1	I
(	0	I
Y	1	I
)	0	I
cDNA	1	O
is	0	O
very	0	O
similar	0	O
to	0	O
the	0	O
reported	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
human	0	O
HMG	1	B
-	0	I
I	1	I
,	0	O
except	0	O
that	0	O
it	0	O
lacks	0	O
11	0	O
internal	0	O
amino	0	O
acids	0	O
reported	0	O
in	0	O
the	0	O
human	0	O
protein	0	O
.	0	O


End	1	O
-	0	O
tidal	0	O
PO2	1	O
and	0	O
the	0	O
ratio	0	O
of	0	O
minute	0	O
ventilation	0	O
to	0	O
oxygen	0	O
consumption	0	O
(	0	O
VE	0	O
/	0	O
VO2	1	O
)	0	O
were	0	O
lower	0	O
while	0	O
PETCO2	1	O
was	0	O
higher	0	O
for	0	O
Hyp	0	O
(	0	O
P	1	O
<	0	O
or	0	O
=	0	O
0	0	O
.	0	O
01	0	O
).	0	O


METHODS	0	O
:	0	O
Ten	0	O
influenza	0	O
A	1	O
(	0	O
H3N2	0	O
)	0	O
viruses	0	O
isolated	0	O
during	0	O
the	0	O
outbreaks	0	O
were	0	O
examined	0	O
for	0	O
resistance	0	O
to	0	O
amantadine	0	O
and	0	O
rimantadine	0	O
by	0	O
means	0	O
of	0	O
an	0	O
enzyme	0	O
immunoassay	0	O
and	0	O
by	0	O
sequencing	0	O
of	0	O
the	0	O
viral	0	O
nucleic	0	O
acid	0	O
that	0	O
encodes	0	O
the	0	O
transmembrane	0	O
domain	0	O
of	0	O
the	0	O
M2	1	B
protein	0	I
.	0	O


Antithrombin	1	B
III	0	I
in	0	O
hip	0	O
surgery	0	O


EBNA	0	B
-	0	I
2	0	I
and	0	O
the	0	O
cis	0	O
-	0	O
acting	0	O
CD23	0	B
element	0	I
increased	0	O
TK	1	B
-	0	O
promoted	0	O
mRNA	1	O
and	0	O
did	0	O
not	0	O
alter	0	O
the	0	O
herpes	0	B
simplex	0	I
virus	0	I
TK	1	I
promoter	0	I
transcription	0	I
start	0	I
site	0	I
.	0	O


We	0	O
propose	0	O
that	0	O
refeeding	0	O
may	0	O
be	0	O
an	0	O
important	0	O
mechanism	0	O
for	0	O
activation	0	O
of	0	O
certain	0	O
viral	0	O
infections	0	O
previously	0	O
suppressed	0	O
by	0	O
famine	0	O
.	0	O


All	1	O
of	0	O
the	0	O
basal	0	O
TPN	1	O
solutions	0	O
were	0	O
isonitrogenous	0	O
and	0	O
identical	0	O
in	0	O
nutrient	0	O
composition	0	O
,	0	O
except	0	O
for	0	O
the	0	O
difference	0	O
in	0	O
energy	0	O
level	0	O
,	0	O
which	0	O
was	0	O
adjusted	0	O
with	0	O
glucose	0	O
.	0	O


Purified	0	O
PLB	0	B
showed	0	O
optimal	0	O
lyase	0	B
activity	0	O
at	0	O
pH	1	O
10	0	O
.	0	O
0	0	O
.	0	O


0	0	O
.	0	O
61	0	O
+/-	0	O
0	0	O
.	0	O
04	0	O
).	0	O


This	0	O
protein	0	O
,	0	O
designated	0	O
p532	0	B
based	0	O
on	0	O
its	0	O
predicted	0	O
molecular	0	O
weight	0	O
(	0	O
EMBO	0	O
J	1	O
15	0	O
:	0	O
5738	0	O
,	0	O
1996	0	O
),	0	O
contains	0	O
multiple	0	O
structural	0	O
domains	0	O
including	0	O
two	0	O
regions	0	O
of	0	O
seven	0	O
internal	0	O
repeats	0	O
highly	0	O
related	0	O
to	0	O
the	0	O
cell	0	O
cycle	0	O
regulator	0	O
RCC1	0	B
,	0	O
a	0	O
guanine	0	B
nucleotide	0	I
exchange	0	I
factor	0	I
for	0	O
the	0	O
small	0	B
GTP	1	I
-	0	I
binding	0	I
protein	0	I
Ran	0	I
,	0	O
seven	0	O
beta	0	O
-	0	O
repeat	0	O
domains	0	O
characteristic	0	O
of	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
heterotrimeric	0	B
G	1	I
proteins	0	I
,	0	O
three	0	O
putative	0	O
SH3	0	B
binding	0	I
sites	0	I
,	0	O
a	0	O
putative	0	O
leucine	0	O
-	0	O
zipper	0	O
and	0	O
a	0	O
carboxy	0	B
-	0	I
terminal	0	I
HECT	0	I
domain	0	I
characteristic	0	O
of	0	O
E3	1	B
ubiquitin	0	I
-	0	I
protein	0	I
ligases	0	I
.	0	O


Analysis	1	O
of	0	O
intragenic	0	O
revertants	0	O
shows	0	O
that	0	O
this	0	O
function	0	O
depends	0	O
on	0	O
the	0	O
amino	0	O
acid	0	O
preceding	0	O
the	0	O
first	0	O
cysteine	0	O
residue	0	O
of	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
of	0	O
Hap1p	0	B
.	0	O


Estrogen	1	O
treatment	0	O
in	0	O
high	0	O
doses	0	O
is	0	O
effective	0	O
in	0	O
reducing	0	O
adult	0	O
stature	0	O
in	0	O
constitutionally	0	O
tall	0	O
girls	0	O
.	0	O


Human	1	B
thymine	0	I
-	0	I
DNA	1	I
glycosylase	0	I
maps	0	O
at	0	O
chromosome	0	O
12q22	0	O
-	0	O
q24	0	O
.	0	O
1	0	O
:	0	O
a	0	O
region	0	O
of	0	O
high	0	O
loss	0	O
of	0	O
heterozygosity	0	O
in	0	O
gastric	0	O
cancer	0	O
.	0	O


The	0	O
HOI	0	O
induced	0	O
a	0	O
nearly	0	O
fourfold	0	O
increase	0	O
in	0	O
ANF	1	B
in	0	O
the	0	O
elderly	0	O
,	0	O
whereas	0	O
that	0	O
for	0	O
the	0	O
young	0	O
was	0	O
threefold	0	O
.	0	O


Members	0	O
of	0	O
the	0	O
myocyte	0	B
-	0	I
specific	0	I
enhancer	0	I
-	0	I
binding	0	I
factor	0	I
2	0	I
(	0	O
MEF2	0	B
)	0	O
family	0	O
of	0	O
transcription	0	O
factors	0	O
bind	0	O
a	0	O
conserved	0	O
A	1	O
/	0	O
T	1	O
-	0	O
rich	0	O
sequence	0	O
in	0	O
the	0	O
control	0	O
regions	0	O
of	0	O
numerous	0	O
muscle	0	O
-	0	O
specific	0	O
genes	0	O
.	0	O


Two	0	O
XPG	0	B
regions	0	I
with	0	O
putative	0	O
NLS	0	O
[	0	O
amino	0	O
acid	0	O
(	0	O
AA	1	O
)	0	O
coordinates	0	O
:	0	O
NLS	0	O
-	0	O
B	1	O
(	0	O
AA	1	O
1057	0	O
-	0	O
1074	0	O
)	0	O
and	0	O
NLS	0	O
-	0	O
C	1	O
(	0	O
AA	1	O
1171	0	O
-	0	O
1185	0	O
)]	0	O
were	0	O
each	0	O
shown	0	O
to	0	O
independently	0	O
localize	0	O
the	0	O
beta	0	B
-	0	I
gal	0	I
extensively	0	O
(>	0	O
80	0	O
%)	0	O
to	0	O
the	0	O
nucleus	0	O
of	0	O
HeLa	0	O
cells	0	O
.	0	O


Decreased	0	O
levels	0	O
of	0	O
alpha2	0	B
-	0	I
antiplasmin	0	I
were	0	O
also	0	O
observed	0	O
in	0	O
the	0	O
mediastinum	0	O
(	0	O
0	0	O
.	0	O
50	0	O
versus	0	O
0	0	O
.	0	O
61	0	O
U	1	O
/	0	O
mL	1	O
;	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


In	1	O
angiodysplasia	0	O
,	0	O
ectatic	0	O
vessels	0	O
in	0	O
the	0	O
mucosa	0	O
appeared	0	O
to	0	O
contain	0	O
less	0	O
collagen	0	B
type	0	I
IV	1	I
than	0	O
similarly	0	O
sized	0	O
vessels	0	O
in	0	O
the	0	O
submucosa	0	O
,	0	O
and	0	O
perforating	0	O
vessels	0	O
appeared	0	O
in	0	O
many	0	O
cases	0	O
to	0	O
lose	0	O
staining	0	O
at	0	O
the	0	O
level	0	O
of	0	O
the	0	O
muscularis	0	O
mucosae	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
interpretation	0	O
,	0	O
recombinant	0	B
CREB	0	I
and	0	O
activating	0	B
transcription	0	I
factor	0	I
proteins	0	I
bound	0	O
the	0	O
junB	0	B
CRE	0	O
-	0	O
like	0	O
site	0	O
,	0	O
but	0	O
did	0	O
not	0	O
interact	0	O
with	0	O
a	0	O
mutant	0	O
CRE	0	O
-	0	O
like	0	O
site	0	O
.	0	O


(	0	O
1988	0	O
)	0	O
J	1	O
.	0	O


Molecular	1	O
structure	0	O
and	0	O
evolutionary	0	O
origin	0	O
of	0	O
human	0	B
cardiac	0	I
muscle	0	I
actin	0	I
gene	0	I
.	0	O


The	0	O
human	0	B
immunodeficiency	0	I
virus	0	I
type	0	I
1	0	I
(	0	I
HIV	1	I
-	0	I
1	0	I
)	0	I
Rev	0	I
protein	0	I
is	0	O
a	0	O
positive	0	O
posttranscriptional	0	O
regulator	0	O
of	0	O
viral	0	O
structural	0	O
gene	0	O
expression	0	O
and	0	O
essential	0	O
for	0	O
virus	0	O
replication	0	O
.	0	O


Time	1	O
shifts	0	O
increase	0	O
growth	0	B
hormone	0	I
release	0	O
.	0	O


Indeed	0	O
,	0	O
significant	0	O
level	0	O
of	0	O
CAT	1	B
activity	0	O
was	0	O
observed	0	O
in	0	O
human	0	O
lung	0	O
adenocarcinoma	0	O
(	0	O
A549	0	O
-	0	O
1	0	O
)	0	O
cells	0	O
which	0	O
had	0	O
been	0	O
incubated	0	O
with	0	O
a	0	O
complex	0	O
of	0	O
T7	0	B
RNA	1	I
polymerase	0	I
,	0	O
pT7	0	B
-	0	I
EMC	1	I
-	0	I
CAT	1	I
DNA	1	I
and	0	O
DC	1	O
-	0	O
chol	0	O
cationic	0	O
liposomes	0	O
.	0	O


A	1	O
direct	0	O
role	0	O
for	0	O
sterol	0	B
regulatory	0	I
element	0	I
binding	0	I
protein	0	I
in	0	O
activation	0	O
of	0	O
3	0	B
-	0	I
hydroxy	0	I
-	0	I
3	0	I
-	0	I
methylglutaryl	0	I
coenzyme	0	I
A	1	I
reductase	0	I
gene	0	I
.	0	O


Thus	0	O
,	0	O
the	0	O
association	0	O
of	0	O
PS1	0	B
fragments	0	I
may	0	O
be	0	O
maintained	0	O
during	0	O
cycles	0	O
of	0	O
phosphorylation	0	O
/	0	O
dephosphorylation	0	O
of	0	O
the	0	O
PS1	0	B
CTF	0	I
.	0	O


The	0	O
yeast	0	O
C	1	B
-	0	I
type	0	I
cyclin	0	I
Ume3p	0	I
/	0	O
Srb11p	0	B
and	0	O
its	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinase	0	I
(	0	O
Cdk	1	B
)	0	O
Ume5p	0	B
are	0	O
required	0	O
for	0	O
the	0	O
full	0	O
repression	0	O
of	0	O
genes	0	O
involved	0	O
in	0	O
the	0	O
stress	0	O
response	0	O
or	0	O
meiosis	0	O
.	0	O


Moreover	0	O
,	0	O
moderate	0	O
overexpression	0	O
of	0	O
Chk1	0	B
suppresses	0	O
the	0	O
phenotypes	0	O
of	0	O
cut5	0	B
and	0	O
crb2	0	B
mutants	0	I
.	0	O


The	0	O
result	0	O
suggests	0	O
that	0	O
this	0	O
non	0	O
-	0	O
invasive	0	O
TTD	0	O
method	0	O
is	0	O
easily	0	O
available	0	O
and	0	O
useful	0	O
in	0	O
monitoring	0	O
the	0	O
intraoperative	0	O
cardiac	0	O
output	0	O
.	0	O


This	0	O
up	0	O
-	0	O
grading	0	O
of	0	O
the	0	O
final	0	O
score	0	O
by	0	O
the	0	O
CA	1	O
component	0	O
is	0	O
greater	0	O
(	0	O
3	0	O
-	0	O
8	0	O
%)	0	O
in	0	O
the	0	O
less	0	O
able	0	O
students	0	O
with	0	O
scores	0	O
below	0	O
the	0	O
mean	0	O
level	0	O
.	0	O


Because	0	O
endogenous	0	O
HSF	0	B
DNA	1	O
-	0	O
binding	0	O
activity	0	O
is	0	O
low	0	O
and	0	O
anti	0	B
-	0	I
hHSF1	0	I
antibody	0	I
does	0	O
not	0	O
recognize	0	O
Xenopus	1	B
HSF	0	I
,	0	O
we	0	O
employed	0	O
this	0	O
system	0	O
for	0	O
mapping	0	O
regions	0	O
in	0	O
hHSF1	0	B
that	0	O
are	0	O
required	0	O
for	0	O
the	0	O
maintenance	0	O
of	0	O
the	0	O
monomeric	0	O
state	0	O
.	0	O


The	0	O
importance	0	O
of	0	O
this	0	O
new	0	O
epidemiological	0	O
profile	0	O
of	0	O
schistosomiasis	0	O
in	0	O
the	0	O
State	1	O
of	0	O
Pernambuco	0	O
relies	0	O
on	0	O
the	0	O
fact	0	O
that	0	O
it	0	O
can	0	O
be	0	O
related	0	O
with	0	O
the	0	O
drastic	0	O
human	0	O
interference	0	O
on	0	O
the	0	O
environment	0	O
.	0	O


The	0	O
interaction	0	O
between	0	O
U	1	O
(	0	O
L	1	O
)	0	O
3	0	O
.	0	O


Stimulation	1	O
of	0	O
the	0	O
caudate	0	O
nucleus	0	O
'	0	O
dophamine	0	O
-	0	O
reactive	0	O
system	0	O
in	0	O
dogs	0	O
by	0	O
means	0	O
of	0	O
administration	0	O
of	0	O
dophamine	0	O
(	0	O
60	0	O
micrograms	0	O
)	0	O
and	0	O
phenamine	0	O
led	0	O
to	0	O
deterioration	0	O
of	0	O
conditioned	0	O
and	0	O
unconditioned	0	O
components	0	O
of	0	O
feeding	0	O
behaviour	0	O
.	0	O


Genomic	1	O
Southern	0	O
blot	0	O
analysis	0	O
of	0	O
rat	0	B
EFIA	0	I
(	0	O
gene	0	O
encoding	0	O
enhancer	0	B
factor	0	I
I	1	I
subunit	0	I
A	1	I
)	0	O
reveals	0	O
a	0	O
complex	0	O
band	0	O
pattern	0	O
when	0	O
cDNA	1	O
subfragment	0	O
probes	0	O
are	0	O
used	0	O
.	0	O


Based	0	O
on	0	O
these	0	O
data	0	O
,	0	O
we	0	O
conclude	0	O
that	0	O
transcription	0	O
of	0	O
prgX	0	B
is	0	O
initiated	0	O
from	0	O
the	0	O
Qa	1	B
promoter	0	I
in	0	O
prgQ	0	B
,	0	O
and	0	O
PrgX	0	B
autoregulates	0	O
its	0	O
transcription	0	O
either	0	O
by	0	O
mediating	0	O
transcriptional	0	O
readthrough	0	O
or	0	O
increasing	0	O
mRNA	1	O
stability	0	O
.	0	O


Deletion	1	O
of	0	O
the	0	O
POR2	0	B
gene	0	I
alone	0	O
had	0	O
no	0	O
detectable	0	O
phenotype	0	O
,	0	O
while	0	O
yeasts	0	O
with	0	O
deletions	0	O
of	0	O
both	0	O
the	0	O
POR1	0	B
and	0	O
POR2	0	B
genes	0	I
were	0	O
viable	0	O
and	0	O
able	0	O
to	0	O
grow	0	O
on	0	O
glycerol	0	O
at	0	O
30	0	O
degrees	0	O
C	1	O
,	0	O
albeit	0	O
more	0	O
slowly	0	O
than	0	O
delta	0	B
por1	0	I
single	0	I
mutants	0	I
.	0	O


These	0	O
studies	0	O
point	0	O
to	0	O
the	0	O
involvement	0	O
of	0	O
the	0	O
MAP	1	B
kinase	0	I
pathway	0	O
in	0	O
the	0	O
activation	0	O
of	0	O
monocytic	0	O
cells	0	O
during	0	O
transmigration	0	O
to	0	O
inflammatory	0	O
sites	0	O
.	0	O


The	0	O
E1	1	B
nuclear	0	I
transport	0	I
motif	0	I
is	0	O
highly	0	O
conserved	0	O
in	0	O
the	0	O
animal	0	O
and	0	O
human	0	O
papillomaviruses	0	O
and	0	O
is	0	O
encoded	0	O
in	0	O
a	0	O
similar	0	O
region	0	O
in	0	O
the	0	O
related	0	O
E1	1	B
genes	0	I
.	0	O


Thrombosis	1	O
of	0	O
the	0	O
renal	0	O
vein	0	O
may	0	O
be	0	O
dramatic	0	O
and	0	O
include	0	O
renal	0	O
failure	0	O
.	0	O


Both	0	O
betaAPP	0	B
mRNA	1	I
and	0	O
Abeta	0	B
levels	0	O
are	0	O
increased	0	O
in	0	O
trisomy	0	O
21	0	O
.	0	O


The	0	O
granules	0	O
grew	0	O
as	0	O
the	0	O
melted	0	O
material	0	O
immersed	0	O
into	0	O
the	0	O
void	0	O
space	0	O
among	0	O
the	0	O
adhered	0	O
particles	0	O
.	0	O


Ammonia	1	O
concentration	0	O
dropped	0	O
significantly	0	O
in	0	O
all	0	O
treatments	0	O
,	0	O
a	0	O
finding	0	O
which	0	O
suggests	0	O
a	0	O
protective	0	O
effect	0	O
on	0	O
protein	0	O
nitrogen	0	O
degradation	0	O
to	0	O
non	0	O
-	0	O
protein	0	O
nitrogen	0	O
(	0	O
NH3	1	O
).	0	O


However	0	O
,	0	O
there	0	O
were	0	O
some	0	O
properties	0	O
of	0	O
Rak	0	B
that	0	O
are	0	O
distinct	0	O
from	0	O
Src	1	B
-	0	I
like	0	I
kinases	0	I
:	0	O
(	0	O
a	0	O
)	0	O
expression	0	O
of	0	O
Rak	0	B
was	0	O
predominantly	0	O
in	0	O
epithelial	0	O
-	0	O
derived	0	O
cell	0	O
lines	0	O
and	0	O
tissues	0	O
,	0	O
especially	0	O
normal	0	O
liver	0	O
and	0	O
kidney	0	O
,	0	O
and	0	O
cell	0	O
lines	0	O
of	0	O
breast	0	O
and	0	O
colon	0	O
origin	0	O
;	0	O
(	0	O
b	0	O
)	0	O
Rak	0	B
does	0	O
not	0	O
harbor	0	O
the	0	O
NH2	0	O
-	0	O
terminal	0	O
glycine	0	O
essential	0	O
for	0	O
myristylation	0	O
and	0	O
membrane	0	O
localization	0	O
;	0	O
and	0	O
(	0	O
c	0	O
)	0	O
Rak	0	B
possesses	0	O
a	0	O
putative	0	O
bipartite	0	O
nuclear	0	O
localization	0	O
signal	0	O
in	0	O
the	0	O
SH2	0	B
domain	0	I
,	0	O
and	0	O
subcellular	0	O
fractionation	0	O
studies	0	O
revealed	0	O
that	0	O
p54rak	0	B
resides	0	O
predominantly	0	O
in	0	O
the	0	O
nucleus	0	O
.	0	O


Sex	1	O
selection	0	O
via	0	O
albumin	0	B
columns	0	O
:	0	O
20	0	O
years	0	O
of	0	O
results	0	O
.	0	O


Dermatology	1	O
is	0	O
no	0	O
exception	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Monitoring	0	O
SpO2	1	O
at	0	O
the	0	O
nasal	0	O
septum	0	O
site	0	O
is	0	O
more	0	O
reliable	0	O
than	0	O
monitoring	0	O
it	0	O
at	0	O
the	0	O
finger	0	O
site	0	O
in	0	O
hypothermic	0	O
patients	0	O
.	0	O


Strontium	1	O
chloride	0	O
Sr	1	O
89	0	O
is	0	O
costly	0	O
,	0	O
but	0	O
preliminary	0	O
analysis	0	O
indicates	0	O
that	0	O
it	0	O
may	0	O
reduce	0	O
management	0	O
expenditures	0	O
overall	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
residue	0	O
266	0	O
serves	0	O
as	0	O
a	0	O
"	0	O
protein	0	O
sensor	0	O
"	0	O
of	0	O
altered	0	O
minor	0	O
groove	0	O
interactions	0	O
and	0	O
identifies	0	O
which	0	O
base	0	O
pair	0	O
interactions	0	O
are	0	O
altered	0	O
by	0	O
these	0	O
lesions	0	O
.	0	O


Expression	1	O
,	0	O
nucleotide	0	O
sequence	0	O
and	0	O
mutational	0	O
analysis	0	O
of	0	O
two	0	O
open	0	O
reading	0	O
frames	0	O
in	0	O
the	0	O
nif	0	B
gene	0	I
region	0	I
of	0	I
Anabaena	1	I
sp	0	I
.	0	I
strain	0	I
PCC7120	0	I
.	0	O


Comparison	0	O
of	0	O
the	0	O
deduced	0	O
amino	0	O
acid	0	O
sequences	0	O
with	0	O
protein	0	O
sequences	0	O
of	0	O
T	1	O
.	0	O
pyriformis	0	O
H2As	0	B
showed	0	O
only	0	O
two	0	O
and	0	O
three	0	O
differences	0	O
respectively	0	O
,	0	O
in	0	O
a	0	O
total	0	O
of	0	O
137	0	O
amino	0	O
acids	0	O
for	0	O
H2A1	0	B
,	0	O
and	0	O
132	0	O
amino	0	O
acids	0	O
for	0	O
H2A2	0	B
,	0	O
indicating	0	O
the	0	O
two	0	O
genes	0	O
arose	0	O
before	0	O
the	0	O
divergence	0	O
of	0	O
these	0	O
two	0	O
species	0	O
.	0	O


The	0	O
members	0	O
of	0	O
the	0	O
Myb	0	B
family	0	I
of	0	I
transcription	0	I
factors	0	I
are	0	O
defined	0	O
by	0	O
homology	0	O
in	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
;	0	O
all	0	O
bind	0	O
the	0	O
Myb	0	B
-	0	I
binding	0	I
site	0	I
(	0	O
MBS	0	B
)	0	O
sequence	0	O
(	0	O
YG	0	O
(	0	O
A	1	O
/	0	O
G	1	O
)	0	O
C	1	O
(	0	O
A	1	O
/	0	O
C	1	O
/	0	O
G	1	O
)	0	O
GTT	1	O
(	0	O
G	1	O
/	0	O
A	1	O
)).	0	O


Determination	1	O
of	0	O
an	0	O
RNA	1	O
structure	0	O
involved	0	O
in	0	O
splicing	0	O
inhibition	0	O
of	0	O
a	0	O
muscle	0	O
-	0	O
specific	0	O
exon	0	O
.	0	O


Hovenitin	0	O
I	1	O
and	0	O
(+)-	0	O
ampelopsin	0	O
,	0	O
both	0	O
of	0	O
which	0	O
were	0	O
principal	0	O
ingredients	0	O
of	0	O
the	0	O
active	0	O
fractions	0	O
from	0	O
this	0	O
natural	0	O
medicine	0	O
,	0	O
were	0	O
found	0	O
to	0	O
show	0	O
an	0	O
inhibitory	0	O
activity	0	O
on	0	O
the	0	O
ethanol	0	O
-	0	O
induced	0	O
muscle	0	O
relaxation	0	O
in	0	O
rats	0	O
.	0	O


The	0	O
absorbable	0	O
perisplenic	0	O
mesh	0	O
is	0	O
an	0	O
important	0	O
improvement	0	O
,	0	O
and	0	O
in	0	O
some	0	O
cases	0	O
it	0	O
may	0	O
replace	0	O
other	0	O
techniques	0	O
for	0	O
arresting	0	O
splenic	0	O
bleeding	0	O
.	0	O


To	1	O
clarify	0	O
whether	0	O
seizure	0	O
-	0	O
offset	0	O
patterns	0	O
are	0	O
reliable	0	O
in	0	O
predicting	0	O
seizure	0	O
outcome	0	O
,	0	O
we	0	O
studied	0	O
SEEG	0	O
/	0	O
ECoG	1	O
in	0	O
a	0	O
similar	0	O
group	0	O
of	0	O
patients	0	O
with	0	O
temporal	0	O
lobe	0	O
epilepsy	0	O
(	0	O
TLE	0	O
).	0	O


The	0	O
femoral	0	O
artery	0	O
/	0	O
vein	0	O
and	0	O
the	0	O
soleus	0	O
and	0	O
gastrocnemius	0	O
muscles	0	O
were	0	O
examined	0	O
in	0	O
healthy	0	O
human	0	O
male	0	O
volunteers	0	O
.	0	O


By	0	O
analyzing	0	O
the	0	O
RanGAP	0	B
activity	0	O
of	0	O
a	0	O
series	0	O
of	0	O
recombinantly	0	O
expressed	0	O
rna1p	0	B
mutant	0	I
derivatives	0	O
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
highly	0	O
acidic	0	O
sequence	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
both	0	O
yeast	0	O
proteins	0	O
is	0	O
indispensable	0	O
for	0	O
activating	0	O
Ran	0	B
-	0	O
mediated	0	O
GTP	1	O
hydrolysis	0	O
.	0	O


The	0	O
biochemical	0	O
and	0	O
molecular	0	O
spectrum	0	O
of	0	O
ornithine	0	B
transcarbamylase	0	I
deficiency	0	O
.	0	O


The	0	O
MET4	0	B
gene	0	O
was	0	O
cloned	0	O
,	0	O
and	0	O
its	0	O
sequence	0	O
reveals	0	O
that	0	O
it	0	O
encodes	0	O
a	0	O
protein	0	O
related	0	O
to	0	O
the	0	O
family	0	O
of	0	O
the	0	O
bZIP	0	B
transcriptional	0	I
activators	0	I
.	0	O


To	1	O
facilitate	0	O
the	0	O
availability	0	O
of	0	O
important	0	O
new	0	O
therapeutic	0	O
agents	0	O
,	0	O
the	0	O
Food	1	O
and	0	O
Drug	1	O
Administration	1	O
(	0	O
FDA	1	O
)	0	O
in	0	O
the	0	O
mid	0	O
-	0	O
1970s	0	O
began	0	O
assigning	0	O
therapeutic	0	O
ratings	0	O
to	0	O
investigational	0	O
new	0	O
drugs	0	O
and	0	O
holding	0	O
end	0	O
-	0	O
of	0	O
-	0	O
phase	0	O
II	0	O
conferences	0	O
with	0	O
drug	0	O
sponsors	0	O
.	0	O


Furthermore	0	O
,	0	O
beta	0	B
2	0	I
-	0	I
adrenoceptor	0	I
sensitivity	0	O
appears	0	O
to	0	O
be	0	O
unaltered	0	O
in	0	O
BHT	1	O
.	0	O


Triton	0	O
-	0	O
disrupted	0	O
cells	0	O
retained	0	O
capacity	0	O
for	0	O
activation	0	O
of	0	O
the	0	O
pathway	0	O
by	0	O
both	0	O
peptide	0	O
growth	0	O
factors	0	O
and	0	O
by	0	O
addition	0	O
of	0	O
GTP	1	O
-	0	O
loaded	0	O
p21	0	B
rasVal12	0	I
.	0	O


Copyright	0	O
2000	0	O
Academic	0	O
Press	0	O
.	0	O


Moreover	0	O
,	0	O
Western	0	O
blots	0	O
demonstrated	0	O
at	0	O
least	0	O
six	0	O
types	0	O
of	0	O
Ypt	0	B
in	0	O
both	0	O
Cr	1	O
and	0	O
Vc	1	O
,	0	O
suggesting	0	O
that	0	O
these	0	O
Ypt	0	B
are	0	O
used	0	O
for	0	O
household	0	O
functions	0	O
responsible	0	O
for	0	O
vesicle	0	O
transport	0	O
rather	0	O
than	0	O
for	0	O
cellular	0	O
differentiation	0	O
.	0	O


Spatiotemporal	0	O
expression	0	O
of	0	O
the	0	O
PAX3	0	B
gene	0	I
is	0	O
tightly	0	O
regulated	0	O
during	0	O
development	0	O
.	0	O


Lower	0	O
extremity	0	O
weight	0	O
bearing	0	O
under	0	O
various	0	O
standing	0	O
conditions	0	O
in	0	O
independently	0	O
ambulatory	0	O
patients	0	O
with	0	O
hemiparesis	0	O
.	0	O


Patients	0	O
with	0	O
more	0	O
than	0	O
250	0	O
PVC	1	O
/	0	O
24	0	O
hours	0	O
were	0	O
selected	0	O
for	0	O
distribution	0	O
of	0	O
PVC	1	O
and	0	O
CI	1	O
evaluation	0	O
.	0	O


Middle	0	O
-	0	O
latency	0	O
auditory	0	O
evoked	0	O
potentials	0	O
(	0	O
MAEPs	0	O
)	0	O
were	0	O
recorded	0	O
in	0	O
controls	0	O
and	0	O
patients	0	O
with	0	O
focal	0	O
lesions	0	O
in	0	O
dorsolateral	0	O
prefrontal	0	O
cortex	0	O
.	0	O


Irmiere	0	O
,	0	O
and	0	O
W	1	O
.	0	O


Direct	1	O
approach	0	O
to	0	O
the	0	O
study	0	O
of	0	O
soliton	0	O
perturbations	0	O
.	0	O


This	0	O
activity	0	O
is	0	O
stimulated	0	O
by	0	O
complex	0	O
formation	0	O
with	0	O
the	0	O
other	0	O
eIF2B	0	B
subunits	0	I
.	0	O


1	0	O
.	0	O


The	0	O
sites	0	O
targeted	0	O
for	0	O
mutagenesis	0	O
,	0	O
residues	0	O
60	0	O
,	0	O
61	0	O
,	0	O
and	0	O
66	0	O
,	0	O
are	0	O
located	0	O
within	0	O
a	0	O
putative	0	O
helical	0	O
loop	0	O
structure	0	O
which	0	O
may	0	O
be	0	O
involved	0	O
in	0	O
substrate	0	O
recognition	0	O
by	0	O
the	0	O
enzyme	0	O
.	0	O


Chem	0	O
.	0	O


These	0	O
six	0	O
amino	0	O
acids	0	O
are	0	O
part	0	O
of	0	O
an	0	O
amphipathic	0	O
helix	0	O
that	0	O
is	0	O
highly	0	O
conserved	0	O
among	0	O
nuclear	0	B
hormone	0	I
receptors	0	I
and	0	O
contains	0	O
the	0	O
core	0	O
domain	0	O
of	0	O
the	0	O
ligand	0	O
-	0	O
dependent	0	O
transactivation	0	O
function	0	O
,	0	O
AF	1	O
-	0	O
2	0	O
.	0	O


The	0	O
pel	0	B
gene	0	I
from	0	O
an	0	O
Amycolata	0	O
sp	0	O
.	0	O
encoding	0	O
a	0	O
pectate	0	B
lyase	0	I
(	0	O
EC	1	B
4	0	I
.	0	I
2	0	I
.	0	I
2	0	I
.	0	I
2	0	I
)	0	O
was	0	O
isolated	0	O
by	0	O
activity	0	O
screening	0	O
a	0	O
genomic	0	O
DNA	1	O
library	0	O
in	0	O
Streptomyces	1	O
lividans	0	O
TK24	0	O
.	0	O


This	0	O
computation	0	O
is	0	O
performed	0	O
by	0	O
a	0	O
parallel	0	O
network	0	O
of	0	O
locally	0	O
connected	0	O
neuron	0	O
-	0	O
like	0	O
elements	0	O
.	0	O


The	0	O
treatment	0	O
group	0	O
also	0	O
showed	0	O
in	0	O
vivo	0	O
T	1	O
-	0	O
cell	0	O
activation	0	O
with	0	O
an	0	O
initial	0	O
lymphopenia	0	O
followed	0	O
by	0	O
a	0	O
rebound	0	O
lymphocytosis	0	O
and	0	O
upregulation	0	O
of	0	O
the	0	O
subset	0	O
markers	0	O
CD25	1	B
(	0	O
interleukin	0	B
2	0	I
receptor	0	I
)	0	O
and	0	O
CD45RO	0	B
(	0	O
T	1	O
-	0	O
memory	0	O
cells	0	O
).	0	O


The	0	O
non	0	O
-	0	O
homologous	0	O
sequences	0	O
in	0	O
the	0	O
5	0	O
'	0	O
untranslated	0	O
regions	0	O
might	0	O
be	0	O
acquired	0	O
at	0	O
or	0	O
after	0	O
transcription	0	O
during	0	O
retrotransposition	0	O
of	0	O
the	0	O
ATLN	0	O
elements	0	O
.	0	O


Fentanyl	0	O
,	0	O
a	0	O
prototypic	0	O
mu	0	B
-	0	I
opiate	0	I
receptor	0	I
agonist	0	O
,	0	O
has	0	O
been	0	O
previously	0	O
shown	0	O
to	0	O
produce	0	O
a	0	O
syndrome	0	O
characterized	0	O
by	0	O
marked	0	O
analgesia	0	O
and	0	O
locomotor	0	O
stimulation	0	O
as	0	O
well	0	O
as	0	O
tachycardia	0	O
,	0	O
tachypnoea	0	O
and	0	O
behavioural	0	O
arousal	0	O
.	0	O


The	0	O
interpretation	0	O
of	0	O
antibiotic	0	O
disc	0	O
sensitivities	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
The	0	O
purpose	0	O
of	0	O
this	0	O
article	0	O
is	0	O
to	0	O
review	0	O
balance	0	O
instruments	0	O
developed	0	O
within	0	O
the	0	O
past	0	O
10	0	O
years	0	O
that	0	O
can	0	O
be	0	O
used	0	O
in	0	O
the	0	O
clinic	0	O
or	0	O
home	0	O
environment	0	O
.	0	O


During	0	O
transcript	0	O
elongation	0	O
,	0	O
the	0	O
sizes	0	O
of	0	O
the	0	O
DNA	1	O
footprint	0	O
and	0	O
the	0	O
single	0	O
-	0	O
stranded	0	O
transcription	0	O
bubble	0	O
vary	0	O
markedly	0	O
among	0	O
transcription	0	O
complexes	0	O
halted	0	O
at	0	O
different	0	O
template	0	O
positions	0	O
.	0	O


Otte	0	O
,	0	O
Mol	1	O
.	0	O


Sodium	1	O
dodecyl	0	O
sulphate	0	O
-	0	O
induced	0	O
cleavage	0	O
by	0	O
eukaryotic	0	B
topoisomerase	0	I
I	1	I
is	0	O
known	0	O
to	0	O
yield	0	O
enzyme	0	O
covalently	0	O
attached	0	O
to	0	O
the	0	O
3	0	O
'	0	O
cut	0	O
end	0	O
of	0	O
the	0	O
DNA	1	O
.	0	O


Thus	0	O
,	0	O
the	0	O
pol	0	B
alpha	0	I
-	0	O
primase	0	B
complex	0	O
appears	0	O
to	0	O
act	0	O
processively	0	O
for	0	O
only	0	O
a	0	O
short	0	O
distance	0	O
.	0	O


Using	0	O
one	0	O
of	0	O
the	0	O
six	0	O
fragments	0	O
(	0	O
CPK3	0	B
-	0	I
8	0	I
),	0	O
we	0	O
isolated	0	O
a	0	O
2022	0	B
bp	0	I
cDNA	1	I
(	0	I
VrCDPK	0	I
-	0	I
1	0	I
)	0	I
from	0	O
a	0	O
Vigna	0	O
radiata	0	O
lambda	0	O
gt11	0	O
library	0	O
.	0	O


Likewise	0	O
,	0	O
at	0	O
150	0	O
degrees	0	O
C	1	O
with	0	O
2	0	O
%	0	O
APS	1	O
the	0	O
surface	0	O
density	0	O
of	0	O
NH2	0	O
groups	0	O
reached	0	O
a	0	O
maximum	0	O
at	0	O
24	0	O
hr	0	O
and	0	O
remained	0	O
relatively	0	O
constant	0	O
up	0	O
to	0	O
96	0	O
hr	0	O
.	0	O


However	0	O
,	0	O
the	0	O
favored	0	O
,	0	O
parallel	0	O
beta	0	O
helix	0	O
model	0	O
is	0	O
a	0	O
compact	0	O
coil	0	O
of	0	O
ten	0	O
helically	0	O
arranged	0	O
beta	0	O
strands	0	O
forming	0	O
two	0	O
parallel	0	O
beta	0	O
sheet	0	O
faces	0	O
.	0	O


Urinary	1	O
LTE4	0	O
increased	0	O
after	0	O
both	0	O
challenges	0	O
the	0	O
rise	0	O
being	0	O
higher	0	O
following	0	O
oral	0	O
as	0	O
compared	0	O
to	0	O
inhalation	0	O
provocation	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
0001	0	O
).	0	O


The	0	O
organization	0	O
of	0	O
SPP1	0	B
genes	0	I
involved	0	O
in	0	O
the	0	O
replication	0	O
,	0	O
DNA	1	O
packaging	0	O
and	0	O
phage	0	O
assembly	0	O
proteins	0	O
resembles	0	O
the	0	O
organization	0	O
of	0	O
genes	0	O
of	0	O
equivalent	0	O
regions	0	O
of	0	O
different	0	O
E	1	O
.	0	O
coli	0	O
double	0	O
-	0	O
stranded	0	O
DNA	1	O
phages	0	O
.	0	O


Based	0	O
on	0	O
the	0	O
current	0	O
literature	0	O
,	0	O
the	0	O
mechanisms	0	O
involved	0	O
in	0	O
the	0	O
toxicity	0	O
of	0	O
OA	1	B
indicate	0	O
three	0	O
major	0	O
effects	0	O
:	0	O
(	0	O
1	0	O
)	0	O
inhibition	0	O
of	0	O
mitochondrial	0	O
respiration	0	O
correlated	0	O
with	0	O
a	0	O
depletion	0	O
of	0	O
ATP	1	O
;	0	O
(	0	O
2	0	O
)	0	O
inhibition	0	O
of	0	O
tRNA	1	B
-	0	I
synthetase	0	I
accompanied	0	O
by	0	O
a	0	O
reduced	0	O
protein	0	O
synthesis	0	O
;	0	O
and	0	O
(	0	O
3	0	O
)	0	O
enhanced	0	O
lipid	0	O
peroxidation	0	O
.	0	O


Such	0	O
an	0	O
intervention	0	O
may	0	O
be	0	O
of	0	O
considerable	0	O
use	0	O
for	0	O
the	0	O
treatment	0	O
of	0	O
angiogenesis	0	O
-	0	O
dependent	0	O
diseases	0	O
involving	0	O
FGF	0	B
-	0	I
2	0	I
.	0	O


In	1	O
gel	0	O
retardation	0	O
assays	0	O
,	0	O
an	0	O
RCS	1	O
cell	0	O
-	0	O
specific	0	O
protein	0	O
and	0	O
another	0	O
closely	0	O
related	0	O
protein	0	O
expressed	0	O
only	0	O
in	0	O
RCS	1	O
cells	0	O
and	0	O
primary	0	O
chondrocytes	0	O
bound	0	O
to	0	O
a	0	O
10	0	O
-	0	O
bp	0	O
sequence	0	O
within	0	O
the	0	O
18	0	O
-	0	O
mer	0	O
.	0	O


Less	0	O
antibacterial	0	O
activity	0	O
was	0	O
shown	0	O
toward	0	O
the	0	O
Gram	1	O
-	0	O
negative	0	O
bacilli	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
Pseudomonas	1	O
,	0	O
Klebsiella	1	O
-	0	O
Enterobacter	1	O
,	0	O
Shigella	1	O
,	0	O
Escherichia	1	O
coli	0	O
,	0	O
Serratia	1	O
marcescens	0	O
and	0	O
Proteus	1	O
.	0	O


Hemolytic	1	O
jaundice	0	O
due	0	O
to	0	O
G6PD	1	B
deficiency	0	O
causing	0	O
kernicterus	0	O
in	0	O
a	0	O
female	0	O
newborn	0	O
.	0	O


Glycogen	1	O
synthesis	0	O
and	0	O
catabolism	0	O
,	0	O
gluconeogenesis	0	O
,	0	O
glycolysis	0	O
,	0	O
motility	0	O
,	0	O
cell	0	O
surface	0	O
properties	0	O
and	0	O
adherence	0	O
are	0	O
modulated	0	O
by	0	O
csrA	0	B
in	0	I
Escherichia	1	I
coli	0	I
,	0	O
while	0	O
the	0	O
production	0	O
of	0	O
several	0	O
secreted	0	O
virulence	0	O
factors	0	O
,	0	O
the	0	O
plant	0	O
hypersensitive	0	O
response	0	O
elicitor	0	O
HrpN	0	B
(	0	O
Ecc	1	B
)	0	O
and	0	O
,	0	O
potentially	0	O
,	0	O
other	0	O
secondary	0	O
metabolites	0	O
are	0	O
regulated	0	O
by	0	O
rsmA	0	B
in	0	I
Erwinia	1	I
carotovora	0	I
.	0	O


Induction	1	O
in	0	O
AP	1	B
-	0	I
1	0	I
DNA	1	O
binding	0	O
correlates	0	O
with	0	O
a	0	O
concomitant	0	O
GH	1	B
trans	0	O
-	0	O
activation	0	O
of	0	O
c	0	B
-	0	I
jun	0	I
and	0	O
c	0	B
-	0	I
fos	0	I
genes	0	I
described	0	O
previously	0	O
.	0	O


Our	0	O
findings	0	O
also	0	O
provide	0	O
the	0	O
basis	0	O
for	0	O
the	0	O
development	0	O
of	0	O
assays	0	O
to	0	O
screen	0	O
for	0	O
the	0	O
ligands	0	O
to	0	O
testis	0	B
receptor	0	I
2	0	I
and	0	O
hERR1	0	B
.	0	O


From	0	O
S3	1	O
(	0	O
CBF	1	O
:	0	O
79	0	O
-	0	O
60	0	O
%)	0	O
to	0	O
S5	0	O
(	0	O
CBF	1	O
:	0	O
39	0	O
-	0	O
0	0	O
%),	0	O
%	0	O
WTh	0	O
,	0	O
1	0	O
/	0	O
TPC	0	O
and	0	O
1	0	O
/	0	O
T	1	O
were	0	O
significantly	0	O
decreased	0	O
from	0	O
those	0	O
of	0	O
the	0	O
control	0	O
levels	0	O
(	0	O
all	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Structure	1	O
and	0	O
regulation	0	O
of	0	O
the	0	O
gene	0	O
encoding	0	O
the	0	O
neuron	0	O
-	0	O
specific	0	O
protein	0	B
kinase	0	I
C	1	I
substrate	0	O
neurogranin	0	B
(	0	O
RC3	0	B
protein	0	I
).	0	O


Doxorubicin	1	O
,	0	O
dacarbazine	0	O
,	0	O
vincristine	0	O
,	0	O
and	0	O
cyclophosphamide	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
advanced	0	O
gastrointestinal	0	O
leiomyosarcoma	0	O
.	0	O


The	0	O
study	0	O
of	0	O
calcium	0	O
metabolism	0	O
in	0	O
ten	0	O
thalassaemic	0	O
children	0	O
comperatively	0	O
with	0	O
controls	0	O
after	0	O
oral	0	O
administration	0	O
of	0	O
47Ca	0	O
has	0	O
shown	0	O
diminished	0	O
intestinal	0	O
absorption	0	O
.	0	O


In	1	O
patients	0	O
in	0	O
group	0	O
A	1	O
("	0	O
normal	0	O
"	0	O
CI	1	O
),	0	O
the	0	O
CI	1	O
,	0	O
heart	0	O
rate	0	O
and	0	O
the	0	O
mean	0	O
circumferential	0	O
fiber	0	O
shortening	0	O
velocity	0	O
(	0	O
mVCF	0	O
)	0	O
were	0	O
normal	0	O
,	0	O
but	0	O
the	0	O
TPR	1	O
was	0	O
increased	0	O
significantly	0	O
.	0	O


The	0	O
specific	0	O
electrical	0	O
resistance	0	O
of	0	O
the	0	O
cerebrospinal	0	O
fluid	0	O
was	0	O
measured	0	O
by	0	O
means	0	O
of	0	O
conductometry	0	O
in	0	O
14	0	O
cases	0	O
of	0	O
meningitis	0	O
purulenta	0	O
,	0	O
17	0	O
cases	0	O
of	0	O
meningitis	0	O
serosa	0	O
,	0	O
10	0	O
cases	0	O
of	0	O
encephalitis	0	O
and	0	O
in	0	O
32	0	O
control	0	O
subjects	0	O
.	0	O


The	0	O
results	0	O
also	0	O
showed	0	O
that	0	O
although	0	O
oyster	0	O
shell	0	O
supplementation	0	O
generally	0	O
increased	0	O
alkaline	0	B
phosphatase	0	I
activity	0	O
,	0	O
bone	0	O
mineralization	0	O
was	0	O
relatively	0	O
uninfluenced	0	O
as	0	O
judged	0	O
by	0	O
the	0	O
low	0	O
coefficients	0	O
of	0	O
variation	0	O
(	0	O
CV	1	O
)	0	O
of	0	O
3	0	O
.	0	O
14	0	O
-	0	O
3	0	O
.	0	O
51	0	O
%	0	O
and	0	O
3	0	O
.	0	O
39	0	O
-	0	O
4	0	O
.	0	O
82	0	O
%	0	O
for	0	O
calcium	0	O
and	0	O
phosphorus	0	O
content	0	O
in	0	O
the	0	O
femur	0	O
and	0	O
tibia	0	O
respectively	0	O
.	0	O


Replacement	1	O
of	0	O
the	0	O
CRE	0	O
with	0	O
a	0	O
second	0	O
copy	0	O
of	0	O
the	0	O
AP	1	B
-	0	I
1	0	I
site	0	I
results	0	O
in	0	O
a	0	O
level	0	O
of	0	O
transcriptional	0	O
activity	0	O
comparable	0	O
with	0	O
that	0	O
of	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
sequence	0	O
,	0	O
but	0	O
replacement	0	O
of	0	O
the	0	O
AP	1	B
-	0	I
1	0	I
site	0	I
with	0	O
a	0	O
CRE	0	O
abolishes	0	O
activity	0	O
.	0	O


Each	0	O
sample	0	O
was	0	O
analysed	0	O
as	0	O
soon	0	O
as	0	O
possible	0	O
,	0	O
and	0	O
repeated	0	O
15	0	O
,	0	O
30	0	O
,	0	O
60	0	O
and	0	O
120	0	O
min	0	O
after	0	O
sampling	0	O
.	0	O


Spliced	0	O
exons	0	O
of	0	O
adenovirus	0	O
late	0	O
RNAs	0	O
colocalize	0	O
with	0	O
snRNP	1	O
in	0	O
a	0	O
specific	0	O
nuclear	0	O
domain	0	O
.	0	O


Neither	0	O
is	0	O
it	0	O
a	0	O
major	0	O
cause	0	O
of	0	O
rehydration	0	O
-	0	O
induced	0	O
renal	0	O
Na	1	O
retention	0	O
.	0	O


GW	0	O
Gamma	1	O
approximation	0	O
for	0	O
electron	0	O
self	0	O
-	0	O
energies	0	O
in	0	O
semiconductors	0	O
and	0	O
insulators	0	O
.	0	O


The	0	O
HBP	0	B
gene	0	I
is	0	O
composed	0	O
of	0	O
eight	0	O
exons	0	O
covering	0	O
19	0	O
.	0	O
5	0	O
kb	0	O
on	0	O
the	0	O
short	0	O
arm	0	O
of	0	O
chromosome	0	O
4	0	O
.	0	O


Preferential	0	O
heterodimeric	0	O
parallel	0	O
coiled	0	O
-	0	O
coil	0	O
formation	0	O
by	0	O
synthetic	0	B
Max	0	I
and	0	O
c	0	B
-	0	I
Myc	0	I
leucine	0	I
zippers	0	I
:	0	O
a	0	O
description	0	O
of	0	O
putative	0	O
electrostatic	0	O
interactions	0	O
responsible	0	O
for	0	O
the	0	O
specificity	0	O
of	0	O
heterodimerization	0	O
.	0	O


A	1	O
fusion	0	O
protein	0	O
composed	0	O
of	0	O
beta	0	B
-	0	I
galactosidase	0	I
and	0	O
full	0	B
-	0	I
length	0	I
Ahr	0	I
translocates	0	O
from	0	O
the	0	O
cytoplasm	0	O
to	0	O
the	0	O
nucleus	0	O
in	0	O
a	0	O
ligand	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


A	1	O
2	0	O
.	0	O
3	0	O
-	0	O
kb	0	O
full	0	O
-	0	O
length	0	O
cDNA	1	O
clone	0	O
of	0	O
an	0	O
Atlantic	0	B
halibut	0	I
Mx	1	I
gene	0	I
was	0	O
isolated	0	O
from	0	O
a	0	O
liver	0	O
cDNA	1	O
library	0	O
.	0	O


Role	1	O
of	0	O
NH	0	O
(	0	O
2	0	O
)-	0	O
and	0	O
COOH	0	O
-	0	O
terminal	0	O
domains	0	O
of	0	O
the	0	O
P	1	B
protein	0	I
of	0	O
human	0	O
parainfluenza	0	O
virus	0	O
type	0	O
3	0	O
in	0	O
transcription	0	O
and	0	O
replication	0	O
.	0	O


A	1	O
third	0	O
prominent	0	O
component	0	O
of	0	O
apparent	0	O
molecular	0	O
mass	0	O
16	0	O
kDa	1	O
displayed	0	O
several	0	O
properties	0	O
,	0	O
including	0	O
ability	0	O
to	0	O
bind	0	O
45Ca2	0	O
+,	0	O
that	0	O
are	0	O
characteristic	0	O
of	0	O
the	0	O
regulatory	0	O
(	0	O
B	1	O
)	0	O
subunit	0	O
of	0	O
mammalian	0	B
calcineurin	0	I
and	0	O
was	0	O
recognized	0	O
by	0	O
an	0	O
antiserum	0	O
raised	0	O
against	0	O
bovine	0	B
calcineurin	0	I
.	0	O


The	0	O
effect	0	O
of	0	O
a	0	O
beta	0	B
-	0	I
adrenoceptor	0	I
antagonist	0	O
,	0	O
pindolol	0	O
,	0	O
on	0	O
uterine	0	O
smooth	0	O
muscle	0	O
in	0	O
term	0	O
pregnant	0	O
women	0	O
was	0	O
studied	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
(	0	O
in	0	O
hypertensive	0	O
women	0	O
).	0	O


Post	1	O
-	0	O
translational	0	O
modifications	0	O
such	0	O
as	0	O
glycosylation	0	O
and	0	O
phosphorylation	0	O
could	0	O
be	0	O
excluded	0	O
as	0	O
potential	0	O
explanations	0	O
for	0	O
the	0	O
protein	0	O
heterogeneity	0	O
.	0	O


DNA	1	B
-	0	I
STAT	1	I
complexes	0	I
were	0	O
detected	0	O
in	0	O
all	0	O
Bcr	0	B
/	0	O
Abl	0	B
-	0	O
transformed	0	O
cell	0	O
lines	0	O
and	0	O
they	0	O
were	0	O
supershifted	0	O
by	0	O
antibodies	0	O
against	0	O
STAT1	0	B
and	0	O
STAT5	0	B
.	0	O


Both	0	O
the	0	O
intact	0	B
A1	0	I
protein	0	I
and	0	O
its	0	O
proteolytic	0	O
fragment	0	O
,	0	O
the	0	O
UP1	0	B
protein	0	I
,	0	O
can	0	O
be	0	O
cleaved	0	O
by	0	O
Staphylococcus	1	B
aureus	0	I
V	1	I
-	0	I
8	0	I
protease	0	I
to	0	O
produce	0	O
two	0	O
polypeptides	0	O
of	0	O
92	0	O
amino	0	O
acids	0	O
.	0	O


Organ	1	O
transplantation	0	O
in	0	O
Denmark	0	O
.	0	O


A	1	O
high	0	O
mean	0	O
intensity	0	O
of	0	O
CLTPA	0	O
(	0	O
standardized	0	O
multivariate	0	O
regression	0	O
coefficient	0	O
beta	0	O
-	0	O
0	0	O
.	0	O
059	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
020	0	O
)	0	O
and	0	O
a	0	O
high	0	O
maximal	0	O
oxygen	0	O
uptake	0	O
(	0	O
beta	0	O
-	0	O
0	0	O
.	0	O
163	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
were	0	O
associated	0	O
with	0	O
reduced	0	O
plasma	0	B
fibrinogen	0	I
when	0	O
adjusting	0	O
for	0	O
the	0	O
strongest	0	O
covariates	0	O
.	0	O


A	1	O
conserved	0	O
role	0	O
for	0	O
L1	0	B
as	0	O
a	0	O
transmembrane	0	O
link	0	O
between	0	O
neuronal	0	O
adhesion	0	O
and	0	O
membrane	0	O
cytoskeleton	0	O
assembly	0	O
.	0	O


Even	0	O
when	0	O
the	0	O
inoculum	0	O
size	0	O
was	0	O
reduced	0	O
sixfold	0	O
(	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
6	0	O
x	0	O
10	0	O
(	0	O
6	0	O
)	0	O
CFU	1	O
/	0	O
mouse	0	O
),	0	O
50	0	O
%	0	O
of	0	O
the	0	O
RB6	0	B
-	0	I
8C5	0	I
-	0	O
treated	0	O
animals	0	O
died	0	O
within	0	O
6	0	O
days	0	O
.	0	O


We	0	O
also	0	O
present	0	O
evidence	0	O
that	0	O
human	0	B
HYAL1	0	I
is	0	O
identical	0	O
to	0	O
an	0	O
uncharacterized	0	O
gene	0	O
positionally	0	O
cloned	0	O
by	0	O
others	0	O
from	0	O
chromosome	0	O
3p21	0	O
.	0	O
3	0	O
that	0	O
is	0	O
homozygously	0	O
deleted	0	O
in	0	O
several	0	O
small	0	O
-	0	O
cell	0	O
lung	0	O
carcinoma	0	O
cell	0	O
lines	0	O
.	0	O


Multizone	0	O
PRK	1	O
has	0	O
been	0	O
suggested	0	O
to	0	O
increase	0	O
the	0	O
predictability	0	O
of	0	O
higher	0	O
myopic	0	O
corrections	0	O
.	0	O


These	0	O
probable	0	O
border	0	O
sequences	0	O
are	0	O
closely	0	O
related	0	O
to	0	O
those	0	O
of	0	O
other	0	O
known	0	O
T	1	O
-	0	O
regions	0	O
and	0	O
define	0	O
a	0	O
second	0	O
T	1	O
-	0	O
region	0	O
of	0	O
pTiChry5	0	O
,	0	O
called	0	O
T	1	O
-	0	O
right	0	O
(	0	O
TR	1	O
),	0	O
that	0	O
confers	0	O
production	0	O
of	0	O
the	0	O
Amadoriopines	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
over	0	O
-	0	O
expression	0	O
of	0	O
RAR	0	B
beta	0	I
only	0	O
poorly	0	O
restored	0	O
differentiation	0	O
,	0	O
although	0	O
it	0	O
could	0	O
replace	0	O
RAR	0	B
gamma	0	I
for	0	O
the	0	O
activation	0	O
of	0	O
target	0	O
genes	0	O
.	0	O


Gel	1	O
-	0	O
mobility	0	O
-	0	O
shift	0	O
assays	0	O
confirmed	0	O
that	0	O
the	0	O
Raji	0	O
nuclear	0	O
proteins	0	O
that	0	O
bound	0	O
to	0	O
W	1	O
and	0	O
V	1	O
elements	0	O
were	0	O
competed	0	O
with	0	O
by	0	O
an	0	O
HLA	1	B
-	0	I
DRA	0	I
X	1	I
-	0	I
box	0	I
oligonucleotide	0	I
.	0	O


To	1	O
investigate	0	O
the	0	O
requirements	0	O
for	0	O
CBF2	0	B
binding	0	O
,	0	O
we	0	O
synthesized	0	O
a	0	O
series	0	O
of	0	O
oligonucleotides	0	O
carrying	0	O
double	0	O
transversion	0	O
mutations	0	O
spanning	0	O
both	0	O
the	0	O
conserved	0	O
core	0	O
sequence	0	O
and	0	O
outside	0	O
flanking	0	O
sequences	0	O
.	0	O


In	1	O
concert	0	O
with	0	O
the	0	O
coactivator	0	O
CREB	0	B
binding	0	I
protein	0	I
/	0	O
p300	0	B
,	0	O
which	0	O
interacts	0	O
with	0	O
GABPalpha	0	B
,	0	O
the	0	O
binding	0	O
of	0	O
GABPalpha	0	B
and	0	I
-	0	I
beta	0	I
to	0	O
the	0	O
dyad	0	O
symmetry	0	O
element	0	O
controls	0	O
the	0	O
induction	0	O
of	0	O
IL	1	B
-	0	I
16	0	I
promoter	0	I
in	0	O
T	1	O
cells	0	O
.	0	O


NF	1	B
-	0	I
kappaB	0	I
,	0	O
which	0	O
is	0	O
probably	0	O
important	0	O
for	0	O
basal	0	O
activity	0	O
of	0	O
the	0	O
human	0	B
NOS	1	I
II	0	I
promoter	0	I
,	0	O
is	0	O
unlikely	0	O
to	0	O
function	0	O
as	0	O
a	0	O
major	0	O
effector	0	O
of	0	O
CM	1	O
in	0	O
DLD	0	O
-	0	O
1	0	O
cells	0	O
.	0	O


Analysis	1	O
of	0	O
hematopoietic	0	B
growth	0	I
factor	0	I
prescriptions	0	O
in	0	O
19	0	O
french	0	O
cancer	0	O
centers	0	O


One	0	O
class	0	O
of	0	O
plasmids	0	O
contained	0	O
tRNA	1	B
(	0	I
His	1	I
)	0	I
genes	0	I
and	0	O
conferred	0	O
efficient	0	O
suppression	0	O
only	0	O
when	0	O
cells	0	O
were	0	O
starved	0	O
for	0	O
histidine	0	O
;	0	O
these	0	O
plasmids	0	O
suppressed	0	O
a	0	O
gcn2	0	B
deletion	0	O
much	0	O
less	0	O
efficiently	0	O
than	0	O
they	0	O
suppressed	0	O
gcn2	0	B
-	0	I
507	0	I
.	0	O


Recent	0	O
studies	0	O
have	0	O
demonstrated	0	O
that	0	O
Cbl	1	B
,	0	O
the	0	O
120	0	O
-	0	O
kDa	1	O
protein	0	O
product	0	O
of	0	O
the	0	O
c	0	B
-	0	I
cbl	0	I
proto	0	I
-	0	I
oncogene	0	I
,	0	O
serves	0	O
as	0	O
a	0	O
substrate	0	O
of	0	O
a	0	O
number	0	O
of	0	O
receptor	0	B
-	0	I
coupled	0	I
tyrosine	0	I
kinases	0	I
and	0	O
forms	0	O
complexes	0	O
with	0	O
SH3	0	B
and	0	O
SH2	0	B
domain	0	O
-	0	O
containing	0	O
proteins	0	O
,	0	O
pointing	0	O
to	0	O
its	0	O
role	0	O
in	0	O
signal	0	O
transduction	0	O
.	0	O


In	1	O
summary	0	O
,	0	O
the	0	O
efficacies	0	O
of	0	O
adjuvant	0	O
carboplatin	0	O
and	0	O
of	0	O
abdominal	0	O
radiotherapy	0	O
seem	0	O
to	0	O
be	0	O
identical	0	O
.	0	O


Most	0	O
other	0	O
end	0	O
points	0	O
were	0	O
highly	0	O
significant	0	O
,	0	O
and	0	O
death	0	O
,	0	O
which	0	O
was	0	O
monitored	0	O
across	0	O
the	0	O
U	1	O
.	0	O
S	1	O
.	0	O
program	0	O
,	0	O
was	0	O
different	0	O
with	0	O
p	0	O
<	0	O
0	0	O
.	0	O
0001	0	O
.	0	O


Similarly	0	O
,	0	O
expression	0	O
of	0	O
a	0	O
transiently	0	O
transfected	0	O
wild	0	B
-	0	I
type	0	I
prothymosin	0	I
alpha	0	I
gene	0	I
as	0	O
the	0	O
reporter	0	O
was	0	O
not	0	O
affected	0	O
by	0	O
a	0	O
repertoire	0	O
of	0	O
myc	0	B
-	0	I
derived	0	I
genes	0	I
,	0	O
including	0	O
myc	0	B
itself	0	O
and	0	O
dominant	0	O
or	0	O
recessive	0	O
negative	0	O
myc	0	B
mutants	0	I
.	0	O


Cardiovascular	1	O
risk	0	O
factors	0	O
and	0	O
antihypertensive	0	O
treatment	0	O
.	0	O


Peroxisome	1	B
proliferator	0	I
-	0	I
activated	0	I
receptors	0	I
(	0	O
PPAR	0	B
)	0	O
modulate	0	O
transcription	0	O
by	0	O
binding	0	O
to	0	O
specific	0	O
peroxisome	0	O
proliferator	0	O
-	0	O
response	0	O
elements	0	O
(	0	O
PPRE	0	O
)	0	O
through	0	O
heterodimerization	0	O
with	0	O
the	0	O
9	0	B
-	0	I
cis	0	I
retinoic	0	I
acid	0	I
receptor	0	I
(	0	O
RXR	0	B
).	0	O


We	0	O
have	0	O
now	0	O
located	0	O
the	0	O
5	0	O
'	0	O
ends	0	O
of	0	O
the	0	O
two	0	O
remaining	0	O
late	0	O
mRNAs	0	O
.	0	O


271	0	O
:	0	O
31290	0	O
-	0	O
31295	0	O
,	0	O
1996	0	O
).	0	O


A	1	O
3	0	O
-	0	O
week	0	O
regimen	0	O
of	0	O
erythropoietin	0	B
may	0	O
help	0	O
prevent	0	O
the	0	O
donor	0	O
'	0	O
s	0	O
need	0	O
to	0	O
receive	0	O
allogeneic	0	O
blood	0	O
transfusion	0	O
,	0	O
when	0	O
the	0	O
initial	0	O
Hb	1	B
levels	0	O
were	0	O
below	0	O
130	0	O
milligrams	0	O
.	0	O


The	0	O
average	0	O
deviations	0	O
in	0	O
the	0	O
X	1	O
-	0	O
ray	0	O
counts	0	O
of	0	O
the	0	O
constant	0	O
elements	0	O
from	0	O
the	0	O
series	0	O
means	0	O
were	0	O
used	0	O
to	0	O
correct	0	O
the	0	O
recorded	0	O
count	0	O
of	0	O
the	0	O
variable	0	O
element	0	O
in	0	O
each	0	O
block	0	O
.	0	O


To	1	O
investigate	0	O
the	0	O
mechanisms	0	O
involved	0	O
in	0	O
the	0	O
transcriptional	0	O
control	0	O
of	0	O
retinoid	0	B
X	1	I
receptor	0	I
(	0	O
RXR	0	B
)	0	O
gene	0	O
expression	0	O
,	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
human	0	B
RXRgamma2	0	I
isoform	0	I
was	0	O
characterized	0	O
.	0	O


Measurements	0	O
were	0	O
done	0	O
with	0	O
a	0	O
commercial	0	O
haematofluorometer	0	O
Buchler	0	O
ZF	0	O
which	0	O
was	0	O
calibrated	0	O
to	0	O
the	0	O
average	0	O
haematocrit	0	O
value	0	O
of	0	O
0	0	O
.	0	O
42	0	O
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
,	0	O
we	0	O
characterized	0	O
cis	0	O
-	0	O
elements	0	O
of	0	O
the	0	O
human	0	B
PCI	1	I
gene	0	I
required	0	O
for	0	O
expression	0	O
in	0	O
the	0	O
hepatoma	0	O
-	0	O
derived	0	O
cell	0	O
line	0	O
,	0	O
HepG2	0	O
cells	0	O
,	0	O
and	0	O
also	0	O
evaluated	0	O
rat	0	B
PCI	1	I
mRNA	1	I
expression	0	O
,	0	O
particularly	0	O
on	0	O
the	0	O
effect	0	O
of	0	O
androgen	0	O
in	0	O
rat	0	O
reproductive	0	O
tissues	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
the	0	O
situation	0	O
in	0	O
mammalian	0	O
cells	0	O
,	0	O
prolonged	0	O
exposure	0	O
of	0	O
the	0	O
agonist	0	O
(	0	O
24	0	O
h	0	O
)	0	O
does	0	O
not	0	O
result	0	O
in	0	O
down	0	O
regulation	0	O
of	0	O
the	0	O
remaining	0	O
70	0	O
%	0	O
of	0	O
the	0	O
receptors	0	O
.	0	O


However	0	O
,	0	O
C3	1	B
toxin	0	I
alone	0	O
or	0	O
in	0	O
combination	0	O
with	0	O
growth	0	O
factors	0	O
did	0	O
not	0	O
stimulate	0	O
AP	1	B
-	0	I
1	0	I
:	0	O
Luc	0	B
activity	0	O
and	0	O
actually	0	O
antagonized	0	O
the	0	O
synergistic	0	O
activation	0	O
of	0	O
AP	1	B
-	0	I
1	0	I
:	0	O
Luc	0	B
observed	0	O
in	0	O
response	0	O
to	0	O
co	0	O
-	0	O
stimulation	0	O
with	0	O
growth	0	O
factors	0	O
and	0	O
Ro	0	O
-	0	O
31	0	O
-	0	O
8220	0	O
.	0	O


Phylogenetic	1	O
analysis	0	O
gave	0	O
evidence	0	O
for	0	O
a	0	O
close	0	O
evolutionary	0	O
relationship	0	O
between	0	O
PhHV	0	O
-	0	O
1	0	O
and	0	O
members	0	O
of	0	O
the	0	O
Varicellovirus	1	O
genus	0	O
of	0	O
the	0	O
alpha	0	O
-	0	O
Herpesvirinae	0	O
and	0	O
canid	0	O
herpesvirus	0	O
in	0	O
particular	0	O
.	0	O


She	0	O
had	0	O
been	0	O
receiving	0	O
MTX	1	O
7	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
week	0	O
for	0	O
2	0	O
.	0	O
5	0	O
months	0	O
because	0	O
of	0	O
her	0	O
vasculitis	0	O
symptoms	0	O
.	0	O


Most	0	O
smokers	0	O
would	0	O
prefer	0	O
to	0	O
quit	0	O
smoking	0	O
on	0	O
their	0	O
own	0	O
.	0	O


In	1	O
the	0	O
lattice	0	O
,	0	O
23	0	O
%	0	O
of	0	O
the	0	O
sites	0	O
are	0	O
occupied	0	O
,	0	O
95	0	O
%	0	O
of	0	O
the	0	O
atoms	0	O
are	0	O
in	0	O
the	0	O
lowest	0	O
energy	0	O
magnetic	0	O
sublevel	0	O
,	0	O
and	0	O
37	0	O
%	0	O
are	0	O
in	0	O
the	0	O
lowest	0	O
3D	0	O
vibrational	0	O
state	0	O
.	0	O


No	1	O
significant	0	O
differences	0	O
were	0	O
found	0	O
between	0	O
the	0	O
TS	1	O
and	0	O
the	0	O
PTS	1	O
.	0	O


The	0	O
inhibition	0	O
by	0	O
the	0	O
RIalpha	0	B
subunit	0	I
is	0	O
reversed	0	O
by	0	O
addition	0	O
of	0	O
nanomolar	0	O
concentrations	0	O
of	0	O
cAMP	1	O
(	0	O
Ka	1	O
=	0	O
40	0	O
nM	1	O
),	0	O
thus	0	O
demonstrating	0	O
that	0	O
PrKX	0	B
is	0	O
a	0	O
novel	0	O
,	0	O
type	0	B
I	1	I
cAMP	1	I
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
that	0	O
is	0	O
activated	0	O
at	0	O
lower	0	O
cAMP	1	O
concentrations	0	O
than	0	O
the	0	O
holoenzyme	0	O
with	0	O
the	0	O
Calpha	0	B
subunit	0	I
of	0	O
cAMP	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
.	0	O


Three	0	O
radiologists	0	O
without	0	O
knowledge	0	O
of	0	O
patients	0	O
'	0	O
data	0	O
and	0	O
treatment	0	O
analyzed	0	O
30	0	O
angiograms	0	O
with	0	O
and	0	O
30	0	O
examinations	0	O
without	0	O
PGF	0	O
.	0	O


The	0	O
TTG	0	B
-	0	I
2	0	I
gene	0	I
has	0	O
been	0	O
identified	0	O
at	0	O
the	0	O
site	0	O
of	0	O
chromosomal	0	O
translocations	0	O
in	0	O
acute	0	O
T	1	O
-	0	O
cell	0	O
leukemia	0	O
'	0	O
s	0	O
(	0	O
T	1	O
-	0	O
ALL	1	O
).	0	O


A	1	O
prospective	0	O
trail	0	O
comparing	0	O
hysterectomy	0	O
,	0	O
hysterectomy	0	O
plus	0	O
vaginal	0	O
radium	0	O
,	0	O
and	0	O
uterine	0	O
radium	0	O
plus	0	O
hysterectomy	0	O
in	0	O
stage	0	O
I	1	O
endometrial	0	O
carcinoma	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
beta	0	B
-	0	I
1	0	I
may	0	O
act	0	O
as	0	O
a	0	O
tissue	0	O
-	0	O
specific	0	O
,	0	O
trans	0	O
-	0	O
acting	0	O
regulator	0	O
of	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
beta	0	B
-	0	I
zein	0	I
gene	0	I
in	0	O
developing	0	O
maize	0	O
endosperm	0	O
.	0	O


RESULTS	0	O
:	0	O
Glaucoma	1	O
suspects	0	O
were	0	O
divided	0	O
into	0	O
two	0	O
groups	0	O
according	0	O
to	0	O
their	0	O
SWAP	0	O
results	0	O
:	0	O
high	0	O
risk	0	O
(	0	O
with	0	O
SWAP	0	O
abnormalities	0	O
)	0	O
and	0	O
low	0	O
risk	0	O
(	0	O
with	0	O
normal	0	O
SWAP	0	O
result	0	O
).	0	O


Laboratory	1	O
studies	0	O
using	0	O
Ca45	0	O
labeled	0	O
teeth	0	O
and	0	O
biologically	0	O
stained	0	O
teeth	0	O
confirmed	0	O
that	0	O
the	0	O
dentifrice	0	O
did	0	O
not	0	O
decalcify	0	O
enamel	0	O
or	0	O
bleach	0	O
teeth	0	O
.	0	O


By	0	O
using	0	O
lacZ	0	B
fusions	0	I
,	0	O
it	0	O
was	0	O
possible	0	O
to	0	O
localize	0	O
the	0	O
DNA	1	O
sequences	0	O
required	0	O
to	0	O
mediate	0	O
nitrate	0	O
repression	0	O
to	0	O
the	0	O
pfl	0	B
promoter	0	I
-	0	I
regulatory	0	I
region	0	I
.	0	O


In	1	O
addition	0	O
,	0	O
mapping	0	O
of	0	O
the	0	O
promoter	0	O
region	0	O
and	0	O
the	0	O
identification	0	O
of	0	O
putative	0	O
promoter	0	O
regulatory	0	O
sequences	0	O
should	0	O
give	0	O
insight	0	O
into	0	O
the	0	O
transcriptional	0	O
regulation	0	O
of	0	O
UCP2	0	B
expression	0	O
--	0	O
in	0	O
particular	0	O
by	0	O
anyone	0	O
of	0	O
the	0	O
above	0	O
mentioned	0	O
factors	0	O
--	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
.	0	O


3	0	O
'	0	O
RNA	1	O
boundary	0	O
experiments	0	O
indicate	0	O
that	0	O
the	0	O
5	0	O
'	0	O
structure	0	O
reduces	0	O
the	0	O
number	0	O
of	0	O
(	0	O
G	1	O
/	0	O
U	1	O
)	0	O
AG	1	O
repeats	0	O
required	0	O
for	0	O
stable	0	O
TRAP	1	B
-	0	O
trp	0	B
leader	0	O
RNA	1	O
association	0	O
.	0	O


There	0	O
has	0	O
been	0	O
similar	0	O
improvement	0	O
in	0	O
treating	0	O
ampullary	0	O
and	0	O
periampullary	0	O
cancer	0	O
,	0	O
gallbladder	0	O
cancer	0	O
,	0	O
or	0	O
extrahepatic	0	O
bile	0	O
duct	0	O
cancer	0	O
.	0	O


Kidney	1	O
length	0	O
did	0	O
not	0	O
significantly	0	O
differ	0	O
between	0	O
right	0	O
and	0	O
left	0	O
,	0	O
however	0	O
,	0	O
kidney	0	O
width	0	O
,	0	O
cortical	0	O
thickness	0	O
and	0	O
size	0	O
did	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


XII	0	O
.	0	O


A	1	O
narrow	0	O
zone	0	O
of	0	O
myelin	0	O
-	0	O
axonal	0	O
dissociation	0	O
was	0	O
also	0	O
observed	0	O
.	0	O


Compared	0	O
to	0	O
those	0	O
with	0	O
normal	0	O
renal	0	O
functions	0	O
,	0	O
these	0	O
patients	0	O
were	0	O
older	0	O
(	0	O
P	1	O
<	0	O
or	0	O
=	0	O
0	0	O
.	0	O
01	0	O
),	0	O
had	0	O
significantly	0	O
elevated	0	O
blood	0	O
pressures	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
or	0	O
P	1	O
=	0	O
0	0	O
.	0	O
0001	0	O
),	0	O
and	0	O
in	0	O
the	0	O
case	0	O
of	0	O
Type	1	O
1	0	O
DM	1	O
,	0	O
with	0	O
a	0	O
higher	0	O
body	0	O
mass	0	O
index	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
0001	0	O
)	0	O
and	0	O
waist	0	O
-	0	O
hip	0	O
ratio	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
).	0	O


A	1	O
polypeptide	0	O
chain	0	O
of	0	O
34	0	O
residues	0	O
of	0	O
the	0	O
deduced	0	O
yeast	0	O
amino	0	O
acid	0	O
sequence	0	O
closely	0	O
resembles	0	O
a	0	O
peptide	0	O
sequence	0	O
at	0	O
the	0	O
ADP	1	O
binding	0	O
site	0	O
of	0	O
bovine	0	B
muscle	0	I
pyruvate	0	I
kinase	0	I
.	0	O


We	0	O
also	0	O
identified	0	O
an	0	O
alternative	0	O
spliced	0	O
form	0	O
of	0	O
Lyp	0	B
RNA	1	I
,	0	O
Lyp2	0	B
.	0	O


9	0	O
,	0	O
1498	0	O
-	0	O
1506	0	O
).	0	O


These	0	O
case	0	O
reports	0	O
provide	0	O
further	0	O
evidence	0	O
that	0	O
LiCO3	0	O
can	0	O
be	0	O
a	0	O
useful	0	O
medication	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
aggressive	0	O
behavior	0	O
and	0	O
affective	0	O
instability	0	O
after	0	O
brain	0	O
injury	0	O
,	0	O
but	0	O
that	0	O
it	0	O
has	0	O
significant	0	O
potential	0	O
for	0	O
neurotoxicity	0	O
in	0	O
this	0	O
population	0	O
,	0	O
particularly	0	O
when	0	O
used	0	O
in	0	O
conjunction	0	O
with	0	O
neuroleptic	0	O
agents	0	O
.	0	O


Characterization	0	O
of	0	O
an	0	O
EcR	0	B
/	0	O
USP	1	B
heterodimer	0	O
target	0	O
site	0	O
that	0	O
mediates	0	O
ecdysone	0	O
responsiveness	0	O
of	0	O
the	0	O
Drosophila	1	B
Lsp	1	I
-	0	I
2	0	I
gene	0	I
.	0	O


We	0	O
evaluated	0	O
the	0	O
likelihood	0	O
of	0	O
tissues	0	O
to	0	O
be	0	O
positive	0	O
for	0	O
carcinoembryonic	0	B
antigen	0	I
and	0	O
the	0	O
intensity	0	O
of	0	O
carcinoembryonic	0	B
antigen	0	I
staining	0	O
in	0	O
specimens	0	O
of	0	O
villous	0	O
adenomas	0	O
,	0	O
mixed	0	O
polypoid	0	O
villous	0	O
adenomas	0	O
,	0	O
polypoid	0	O
adenomas	0	O
,	0	O
and	0	O
diverticulitis	0	O
using	0	O
the	0	O
peroxidase	0	B
-	0	O
antiperoxidase	0	B
technique	0	O
.	0	O


As	1	O
demonstrated	0	O
by	0	O
gel	0	O
mobility	0	O
shift	0	O
analysis	0	O
and	0	O
supershift	0	O
experiments	0	O
,	0	O
FIRE1	0	B
,	0	O
located	0	O
between	0	O
-	0	O
516	0	O
and	0	O
-	0	O
498	0	O
,	0	O
is	0	O
responsible	0	O
for	0	O
binding	0	O
NF	1	B
-	0	I
Y	1	I
.	0	O


Response	1	O
to	0	O
treatment	0	O
was	0	O
better	0	O
in	0	O
patients	0	O
with	0	O
less	0	O
pretreatment	0	O
(	0	O
one	0	O
-	0	O
two	0	O
prior	0	O
treatments	0	O
)	0	O
than	0	O
in	0	O
heavily	0	O
pretreated	0	O
ones	0	O
(	0	O
more	0	O
than	0	O
three	0	O
)	0	O
and	0	O
this	0	O
relation	0	O
was	0	O
found	0	O
to	0	O
be	0	O
statistically	0	O
significant	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Prognostic	1	O
value	0	O
of	0	O
a	0	O
treadmill	0	O
exercise	0	O
score	0	O
in	0	O
symptomatic	0	O
patients	0	O
with	0	O
nonspecific	0	O
ST	1	O
-	0	O
T	1	O
abnormalities	0	O
on	0	O
resting	0	O
ECG	1	O
.	0	O


The	0	O
hydrophobicity	0	O
plot	0	O
of	0	O
NHE	0	B
-	0	I
3	0	I
is	0	O
very	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
NHE	0	B
-	0	I
1	0	I
and	0	O
NHE	0	B
-	0	I
2	0	I
.	0	O


Posttranslational	1	O
regulation	0	O
of	0	O
Ty1	0	B
retrotransposition	0	O
by	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
Fus3	0	I
.	0	O


The	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
that	0	O
control	0	O
promoter	0	O
activity	0	O
include	0	O
binding	0	O
sites	0	O
for	0	O
transcription	0	O
factors	0	O
Sp1	0	B
and	0	O
alphaCbf	0	B
,	0	O
a	0	O
60	0	B
-	0	I
kDa	1	I
CCAAT	0	I
box	0	I
-	0	I
binding	0	I
protein	0	I
.	0	O


Considerably	0	O
high	0	O
levels	0	O
of	0	O
IgE	1	B
antibodies	0	I
was	0	O
also	0	O
established	0	O
while	0	O
other	0	O
pollens	0	O
did	0	O
not	0	O
show	0	O
such	0	O
correspondence	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
the	0	O
Ca	1	O
entry	0	O
blocker	0	O
nitrendipine	0	O
,	0	O
the	0	O
antioxidant	0	O
superoxide	0	B
dismutase	0	I
(	0	O
SOD	0	B
),	0	O
and	0	O
a	0	O
combination	0	O
of	0	O
nitrendipine	0	O
and	0	O
superoxide	0	B
dismutase	0	I
on	0	O
postischemic	0	O
renal	0	O
function	0	O
was	0	O
studied	0	O
in	0	O
four	0	O
groups	0	O
(	0	O
n	0	O
=	0	O
24	0	O
)	0	O
of	0	O
rats	0	O
.	0	O


Structural	1	O
basis	0	O
for	0	O
activation	0	O
of	0	O
human	0	B
lymphocyte	0	I
kinase	0	I
Lck	0	I
upon	0	O
tyrosine	0	O
phosphorylation	0	O
.	0	O


Zinc	1	O
fingers	0	O
(	0	O
Zf	0	O
)	0	O
are	0	O
a	0	O
common	0	O
structural	0	O
motif	0	O
found	0	O
in	0	O
many	0	O
nucleic	0	O
acid	0	O
-	0	O
binding	0	O
proteins	0	O
.	0	O


Two	0	O
episodes	0	O
of	0	O
peritonitis	0	O
occurred	0	O
while	0	O
the	0	O
patient	0	O
received	0	O
CAPD	1	O
(	0	O
1	0	O
episode	0	O
/	0	O
3	0	O
.	0	O
5	0	O
patient	0	O
-	0	O
months	0	O
).	0	O


These	0	O
rearrangements	0	O
result	0	O
in	0	O
the	0	O
formation	0	O
of	0	O
chimeric	0	O
genes	0	O
showing	0	O
the	0	O
tyrosine	0	B
kinase	0	I
domain	0	I
of	0	O
ret	0	B
fused	0	O
with	0	O
the	0	O
5	0	O
'	0	O
end	0	O
sequences	0	O
of	0	O
different	0	O
genes	0	O
.	0	O


S1	1	B
nuclease	0	I
analysis	0	O
of	0	O
RNA	1	O
from	0	O
chemically	0	O
induced	0	O
B95	0	O
-	0	O
8	0	O
cells	0	O
and	0	O
from	0	O
Vero	0	O
cells	0	O
cotransfected	0	O
with	0	O
NotI	0	B
repeat	0	I
promoter	0	I
-	0	O
CAT	1	B
and	0	O
Z	1	B
showed	0	O
that	0	O
Z	1	B
transactivation	0	O
increased	0	O
the	0	O
level	0	O
of	0	O
correctly	0	O
initiated	0	O
,	0	O
stable	0	O
RNA	1	O
transcripts	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
expression	0	O
of	0	O
individual	0	O
members	0	O
of	0	O
one	0	O
subfamily	0	O
of	0	O
KRAB	0	B
zinc	0	I
finger	0	I
genes	0	I
is	0	O
restricted	0	O
to	0	O
specific	0	O
hematopoietic	0	O
cell	0	O
lineages	0	O
.	0	O


These	0	O
techniques	0	O
have	0	O
been	0	O
used	0	O
by	0	O
many	0	O
people	0	O
for	0	O
many	0	O
years	0	O
and	0	O
no	0	O
claim	0	O
is	0	O
being	0	O
made	0	O
for	0	O
any	0	O
innovation	0	O
in	0	O
this	0	O
regard	0	O
.	0	O


Restriction	1	O
enzyme	0	O
and	0	O
heteroduplex	0	O
analyses	0	O
confirmed	0	O
that	0	O
sequences	0	O
unique	0	O
to	0	O
FeSV	0	O
(	0	O
src	0	B
sequences	0	I
)	0	O
are	0	O
located	0	O
at	0	O
the	0	O
center	0	O
of	0	O
the	0	O
FeSV	0	O
genome	0	O
and	0	O
are	0	O
approximately	0	O
1	0	O
.	0	O
5	0	O
kilobase	0	O
pairs	0	O
in	0	O
length	0	O
.	0	O


These	0	O
natural	0	O
antisense	0	O
S	1	B
transcripts	0	I
co	0	O
-	0	O
exist	0	O
with	0	O
several	0	O
less	0	O
abundant	0	O
sense	0	O
S	1	B
transcripts	0	I
.	0	O


We	0	O
determined	0	O
whether	0	O
a	0	O
single	0	O
injection	0	O
of	0	O
slow	0	O
-	0	O
release	0	O
estradiol	0	O
-	0	O
17beta	0	O
(	0	O
SRE2	0	O
)	0	O
would	0	O
induce	0	O
pseudopregnancy	0	O
in	0	O
gilts	0	O
and	0	O
whether	0	O
PGF2alpha	0	O
would	0	O
regress	0	O
the	0	O
corpora	0	O
lutea	0	O
(	0	O
CL	1	O
)	0	O
of	0	O
pseudopregnancy	0	O
.	0	O


Autorosette	0	O
-	0	O
forming	0	O
cells	0	O
are	0	O
characterized	0	O
by	0	O
a	0	O
high	0	O
activity	0	O
of	0	O
alkaline	0	B
and	0	I
acid	0	I
phosphatases	0	I
and	0	O
low	0	O
NBT	1	O
-	0	O
test	0	O
values	0	O
.	0	O


The	0	O
2	0	O
kb	0	O
of	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
and	0	O
the	0	O
1	0	O
.	0	O
1	0	O
kb	0	O
of	0	O
the	0	O
entire	0	O
sGTH	0	B
alpha	0	I
subunit	0	I
coding	0	O
region	0	O
were	0	O
sequenced	0	O
from	0	O
the	0	O
genomic	0	O
clone	0	O
,	0	O
sGTH	0	B
alpha	0	I
-	0	I
G1	0	I
.	0	O


The	0	O
cDNA	1	O
of	0	O
cpm7	0	B
encodes	0	O
a	0	O
closely	0	O
related	0	O
protein	0	O
of	0	O
36	0	O
.	0	O
8	0	O
kDa	1	O
.	0	O


Heating	0	O
cells	0	O
to	0	O
43	0	O
degrees	0	O
C	1	O
decreased	0	O
the	0	O
amount	0	O
of	0	O
newly	0	O
synthesized	0	O
rRNA	1	O
to	0	O
less	0	O
than	0	O
5	0	O
%	0	O
of	0	O
the	0	O
control	0	O
level	0	O
and	0	O
led	0	O
to	0	O
greater	0	O
than	0	O
95	0	O
%	0	O
inhibition	0	O
of	0	O
transcription	0	O
termination	0	O
at	0	O
a	0	O
region	0	O
355	0	O
to	0	O
362	0	O
nucleotides	0	O
downstream	0	O
of	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
28S	0	B
rRNA	1	I
,	0	O
with	0	O
readthrough	0	O
continuing	0	O
into	0	O
the	0	O
next	0	O
transcription	0	O
unit	0	O
.	0	O


The	0	O
standard	0	O
principles	0	O
of	0	O
surgical	0	O
management	0	O
must	0	O
be	0	O
adhered	0	O
to	0	O
when	0	O
using	0	O
Sandostatin	1	O
to	0	O
treat	0	O
patients	0	O
with	0	O
these	0	O
disorders	0	O
.	0	O


Inhibitor	1	B
-	0	I
1	0	I
(	0	O
I	1	B
-	0	I
1	0	I
)	0	O
and	0	O
inhibitor	0	B
-	0	I
2	0	I
(	0	O
I	1	B
-	0	I
2	0	I
)	0	O
selectively	0	O
inhibit	0	O
type	0	B
1	0	I
protein	0	I
serine	0	I
/	0	I
threonine	0	I
phosphatases	0	I
(	0	O
PP1	0	B
).	0	O


A	1	O
clinical	0	O
,	0	O
serological	0	O
and	0	O
prognostic	0	O
study	0	O


A	1	O
high	0	O
-	0	O
resolution	0	O
restriction	0	O
map	0	O
of	0	O
over	0	O
200	0	O
kb	0	O
of	0	O
contiguous	0	O
DNA	1	O
containing	0	O
N	1	B
-	0	I
myc	0	I
has	0	O
been	0	O
generated	0	O
by	0	O
subcloning	0	O
YACs	0	O
into	0	O
cosmids	0	O
.	0	O


However	0	O
,	0	O
using	0	O
ATL	1	O
-	0	O
16T	0	O
nuclear	0	O
extract	0	O
,	0	O
we	0	O
demonstrated	0	O
that	0	O
GATA	0	B
-	0	I
4	0	I
is	0	O
the	0	O
only	0	O
GATA	0	B
-	0	I
binding	0	I
protein	0	I
that	0	O
forms	0	O
specific	0	O
DNA	1	O
-	0	O
protein	0	O
complex	0	O
with	0	O
the	0	O
-	0	O
70	0	O
GATA	0	O
site	0	O
.	0	O


The	0	O
ORF1	0	O
protein	0	O
was	0	O
found	0	O
to	0	O
be	0	O
highly	0	O
homologous	0	O
to	0	O
the	0	O
putative	0	O
potexvirus	0	B
RNA	1	I
replicases	0	I
;	0	O
ORF2	0	O
,	0	O
-	0	O
3	0	O
,	0	O
-	0	O
5	0	O
and	0	O
-	0	O
6	0	O
proteins	0	O
also	0	O
have	0	O
analogues	0	O
among	0	O
the	0	O
potex	0	O
-	0	O
and	0	O
/	0	O
or	0	O
carlavirus	0	O
-	0	O
encoded	0	O
proteins	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
maternal	0	O
ingestion	0	O
of	0	O
the	0	O
reduced	0	O
energy	0	O
sweetener	0	O
erythritol	0	O
was	0	O
investigated	0	O
in	0	O
KBL	0	O
:	0	O
JW	0	O
strain	0	O
pregnant	0	O
rabbits	0	O
.	0	O


A	1	O
genomic	0	O
clone	0	O
,	0	O
pTt21	0	O
,	0	O
containing	0	O
DNA	1	O
apparently	0	O
transcribed	0	O
specifically	0	O
in	0	O
Trypanosoma	1	O
cruzi	0	O
trypomastigotes	0	O
,	0	O
was	0	O
obtained	0	O
by	0	O
differentially	0	O
screening	0	O
a	0	O
genomic	0	O
library	0	O
with	0	O
trypomastigote	0	O
and	0	O
epimastigote	0	O
cDNA	1	O
.	0	O


Application	1	O
of	0	O
different	0	O
criteria	0	O
of	0	O
cure	0	O
revealed	0	O
that	0	O
19	0	O
patients	0	O
(	0	O
66	0	O
%)	0	O
had	0	O
basal	0	O
GH	1	B
levels	0	O
below	0	O
5	0	O
ng	0	O
/	0	O
ml	0	O
,	0	O
17	0	O
patients	0	O
(	0	O
59	0	O
%)	0	O
had	0	O
normal	0	O
somatomedin	0	B
-	0	I
C	1	I
values	0	O
,	0	O
16	0	O
patients	0	O
(	0	O
55	0	O
%)	0	O
had	0	O
complete	0	O
GH	1	B
suppression	0	O
(	0	O
less	0	O
than	0	O
1	0	O
ng	0	O
/	0	O
ml	0	O
)	0	O
during	0	O
OGTT	1	O
,	0	O
and	0	O
13	0	O
patients	0	O
(	0	O
45	0	O
%)	0	O
met	0	O
the	0	O
above	0	O
-	0	O
mentioned	0	O
criteria	0	O
with	0	O
disappearance	0	O
of	0	O
the	0	O
paradoxical	0	O
GH	1	B
response	0	O
to	0	O
TRH	1	B
/	0	O
GnRH	0	B
test	0	O
.	0	O


UVA	1	O
-	0	O
induced	0	O
melanocytic	0	O
lesions	0	O
.	0	O


A	1	O
stable	0	O
heterologous	0	O
cell	0	O
line	0	O
containing	0	O
the	0	O
mouse	0	B
TRH	1	I
receptor	0	I
was	0	O
constructed	0	O
by	0	O
transfection	0	O
of	0	O
nonexcitable	0	O
293	0	O
cells	0	O
,	0	O
which	0	O
lack	0	O
L	1	O
channel	0	O
activity	0	O
.	0	O


Osteosarcoma	1	O
caused	0	O
by	0	O
3	0	O
,	0	O
4	0	O
-	0	O
benzopyrene	0	O


There	0	O
were	0	O
15	0	O
deaths	0	O
,	0	O
seven	0	O
of	0	O
which	0	O
were	0	O
felt	0	O
to	0	O
be	0	O
avoidable	0	O
.	0	O


DNA	1	O
binding	0	O
and	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
pull	0	O
-	0	O
down	0	O
assays	0	O
demonstrate	0	O
that	0	O
binding	0	O
requires	0	O
Elk	0	B
-	0	I
1	0	I
(	0	I
1	0	I
-	0	I
212	0	I
)	0	I
but	0	O
not	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
transactivation	0	O
domain	0	O
.	0	O


During	0	O
activity	0	O
III	0	O
,	0	O
one	0	O
patient	0	O
developed	0	O
angina	0	O
.	0	O


Expression	1	O
of	0	O
the	0	O
proapoptotic	0	B
protein	0	I
Bax	0	I
under	0	O
the	0	O
control	0	O
of	0	O
a	0	O
GAL10	0	B
promoter	0	I
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
resulted	0	O
in	0	O
galactose	0	O
-	0	O
inducible	0	O
cell	0	O
death	0	O
.	0	O


In	1	O
this	0	O
report	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
hGCN5	0	B
is	0	O
also	0	O
an	0	O
HAT	1	B
and	0	O
has	0	O
the	0	O
same	0	O
substrate	0	O
specificity	0	O
as	0	O
yGCN5	0	B
.	0	O


A	1	O
complementary	0	O
DNA	1	O
was	0	O
isolated	0	O
from	0	O
Caenorhabditis	0	O
elegans	0	O
that	0	O
encoded	0	O
a	0	O
polypeptide	0	O
of	0	O
1438	0	O
amino	0	O
acid	0	O
residues	0	O
,	0	O
CeGAP	0	B
,	0	O
which	0	O
contains	0	O
a	0	O
domain	0	O
with	0	O
sequence	0	O
similarity	0	O
to	0	O
the	0	O
COOH	0	B
-	0	I
terminal	0	I
segment	0	I
(	0	I
GTPase	1	I
-	0	I
activating	0	I
protein	0	I
region	0	I
)	0	I
of	0	O
Bcr	0	B
and	0	O
other	0	O
known	0	O
GTPase	1	B
-	0	I
activating	0	I
proteins	0	I
of	0	O
the	0	O
Rho	1	B
subfamily	0	I
.	0	O


The	0	O
preferential	0	O
heterodimerization	0	O
of	0	O
USF	0	B
subunits	0	I
was	0	O
reproduced	0	O
ex	0	O
vivo	0	O
,	0	O
while	0	O
the	0	O
in	0	O
vitro	0	O
association	0	O
of	0	O
cotranslated	0	O
subunits	0	O
,	0	O
or	0	O
recombinant	0	B
USF	0	I
proteins	0	I
,	0	O
appeared	0	O
to	0	O
be	0	O
random	0	O
.	0	O


In	1	O
literature	0	O
,	0	O
the	0	O
HBE	1	O
has	0	O
been	0	O
displayed	0	O
by	0	O
application	0	O
of	0	O
the	0	O
averaging	0	O
method	0	O
.	0	O


The	0	O
apparatus	0	O
consists	0	O
of	0	O
an	0	O
Am	1	O
-	0	O
241	0	O
exciting	0	O
source	0	O
(	0	O
300	0	O
mCi	1	O
)	0	O
and	0	O
pure	0	O
Ge	1	O
detector	0	O
(	0	O
50	0	O
mm2	0	O
X	1	O
5	0	O
mm	0	O
)	0	O
for	0	O
measuring	0	O
K	1	O
alpha	0	O
fluorescent	0	O
x	0	O
-	0	O
rays	0	O
(	0	O
28	0	O
.	0	O
3	0	O
and	0	O
28	0	O
.	0	O
6	0	O
KeV	1	O
)	0	O
emitted	0	O
from	0	O
exited	0	O
iodine	0	O
.	0	O


The	0	O
applicability	0	O
of	0	O
laparoscopic	0	O
donor	0	O
nephrectomy	0	O
(	0	O
LDN	0	O
)	0	O
has	0	O
not	0	O
been	0	O
assessed	0	O
in	0	O
the	0	O
obese	0	O
donor	0	O
.	0	O


67	0	O
393	0	O
bp	0	O
of	0	O
contiguous	0	O
DNA	1	O
located	0	O
between	0	O
markers	0	O
cdc18	0	B
and	0	O
cdc14	0	B
on	0	O
the	0	O
right	0	O
arm	0	O
of	0	O
fission	0	O
yeast	0	O
chromosome	0	O
II	0	O
has	0	O
been	0	O
sequenced	0	O
as	0	O
part	0	O
of	0	O
the	0	O
European	0	O
Union	1	O
Schizosaccharomyces	0	O
pombe	0	O
genome	0	O
sequencing	0	O
project	0	O
.	0	O


A	1	O
much	0	O
less	0	O
expensive	0	O
solution	0	O
than	0	O
UW	0	O
,	0	O
containing	0	O
only	0	O
K	1	O
(+)-	0	O
lactobionate	0	O
,	0	O
KH2PO4	0	O
,	0	O
MgSO4	0	O
and	0	O
raffinose	0	O
,	0	O
can	0	O
be	0	O
used	0	O
successfully	0	O
for	0	O
preservation	0	O
of	0	O
rat	0	O
hepatocytes	0	O
for	0	O
24	0	O
hr	0	O
for	0	O
drug	0	O
transport	0	O
studies	0	O
.	0	O


The	0	O
N	1	O
-	0	O
terminal	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
Mop	0	B
has	0	O
sequence	0	O
homology	0	O
with	0	O
DNA	1	O
binding	0	O
proteins	0	O
.	0	O


The	0	O
titer	0	O
of	0	O
anti	0	B
HSV	1	I
type	0	I
1	0	I
and	0	O
anti	0	B
HSV	1	I
type	0	I
2	0	I
antibodies	0	I
in	0	O
the	0	O
mothers	0	O
'	0	O
and	0	O
cord	0	O
blood	0	O
was	0	O
determined	0	O
and	0	O
compared	0	O
.	0	O


The	0	O
plasmatic	0	B
albumin	0	I
concentration	0	O
(	0	O
3	0	O
.	0	O
5	0	O
-	0	O
4	0	O
.	0	O
5	0	O
g	0	O
/	0	O
dl	0	O
)	0	O
represents	0	O
about	0	O
60	0	O
%	0	O
of	0	O
the	0	O
total	0	O
plasma	0	O
protein	0	O
.	0	O


Weight	1	O
and	0	O
height	0	O
z	0	O
-	0	O
scores	0	O
were	0	O
significantly	0	O
associated	0	O
with	0	O
BMD	1	O
z	0	O
-	0	O
scores	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Significant	1	O
elevations	0	O
of	0	O
IL	1	B
-	0	I
1alpha	0	I
and	0	O
IL	1	B
-	0	I
1beta	0	I
occur	0	O
in	0	O
patients	0	O
with	0	O
bacterial	0	O
cystitis	0	O
and	0	O
microscopic	0	O
hematuria	0	O
.	0	O


The	0	O
volume	0	O
of	0	O
blood	0	O
to	0	O
the	0	O
flap	0	O
ranges	0	O
from	0	O
1	0	O
to	0	O
2	0	O
ml	0	O
/	0	O
min	0	O
,	0	O
collateral	0	O
circulation	0	O
to	0	O
the	0	O
flap	0	O
exists	0	O
,	0	O
but	0	O
is	0	O
negligible	0	O
,	0	O
and	0	O
there	0	O
is	0	O
little	0	O
change	0	O
in	0	O
the	0	O
capillary	0	O
blood	0	O
flow	0	O
as	0	O
the	0	O
flap	0	O
ages	0	O
.	0	O


The	0	O
initial	0	O
phase	0	O
of	0	O
increased	0	O
vascular	0	O
permeability	0	O
in	0	O
the	0	O
peritoneal	0	O
cavity	0	O
and	0	O
LTB4	0	O
production	0	O
was	0	O
dose	0	O
dependently	0	O
inhibited	0	O
by	0	O
the	0	O
5	0	O
-	0	O
LO	0	O
inhibitors	0	O
phenidone	0	O
,	0	O
BW	1	O
A4C	1	O
,	0	O
A63162	0	O
,	0	O
and	0	O
ICI	0	O
207	0	O
968	0	O
but	0	O
not	0	O
by	0	O
dexamethasone	0	O
or	0	O
colchicine	0	O
.	0	O


Based	0	O
on	0	O
these	0	O
results	0	O
and	0	O
because	0	O
Cdc68	0	B
has	0	O
been	0	O
implicated	0	O
as	0	O
a	0	O
regulator	0	O
of	0	O
chromatin	0	O
structure	0	O
,	0	O
we	0	O
postulate	0	O
that	0	O
polymerase	0	B
alpha	0	I
may	0	O
interact	0	O
with	0	O
these	0	O
proteins	0	O
to	0	O
gain	0	O
access	0	O
to	0	O
its	0	O
template	0	O
or	0	O
to	0	O
origins	0	O
of	0	O
replication	0	O
in	0	O
vivo	0	O
.	0	O


Liquid	1	O
chromatography	0	O
with	0	O
amperometric	0	O
detection	0	O
(	0	O
LC	0	O
/	0	O
AD	1	O
)	0	O
is	0	O
used	0	O
to	0	O
determine	0	O
fluazifop	0	O
acid	0	O
produced	0	O
from	0	O
the	0	O
metabolism	0	O
or	0	O
base	0	O
hydrolysis	0	O
of	0	O
fluazifop	0	O
-	0	O
butyl	0	O
in	0	O
soybeans	0	O
and	0	O
soybean	0	O
oil	0	O
.	0	O


Tobacco	1	O
mosaic	0	O
virus	0	O
-	0	O
infected	0	O
tobacco	0	O
(	0	O
Nicotiana	1	O
tabacum	0	O
var	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
lumenal	0	O
domains	0	O
of	0	O
Sec12p	0	B
,	0	O
Stl1p	0	B
and	0	O
Stl2p	0	B
are	0	O
very	0	O
different	0	O
in	0	O
size	0	O
and	0	O
do	0	O
not	0	O
show	0	O
any	0	O
appreciable	0	O
homology	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
have	0	O
used	0	O
specific	0	O
antibody	0	O
to	0	O
identify	0	O
and	0	O
characterize	0	O
the	0	O
SSN6	0	B
protein	0	I
.	0	O


A	1	O
portion	0	O
of	0	O
Region	1	O
II	0	O
also	0	O
resembles	0	O
part	0	O
of	0	O
the	0	O
human	0	O
c	0	B
-	0	I
jun	0	I
oncoprotein	0	O
'	0	O
s	0	O
leucine	0	O
zipper	0	O
,	0	O
which	0	O
in	0	O
turn	0	O
,	0	O
has	0	O
been	0	O
demonstrated	0	O
to	0	O
be	0	O
the	0	O
heterodimerization	0	O
site	0	O
between	0	O
the	0	O
jun	0	B
and	0	O
fos	0	B
oncoproteins	0	I
.	0	O


The	0	O
inserted	0	O
region	0	O
,	0	O
which	0	O
represents	0	O
an	0	O
intron	0	O
in	0	O
brain	0	O
and	0	O
muscle	0	O
,	0	O
is	0	O
expressed	0	O
in	0	O
the	0	O
tumor	0	O
cell	0	O
lines	0	O
either	0	O
as	0	O
a	0	O
"	0	O
readthrough	0	O
"	0	O
form	0	O
or	0	O
with	0	O
78	0	O
residues	0	O
deleted	0	O
from	0	O
its	0	O
5	0	O
'	0	O
end	0	O
.	0	O


An	1	O
essential	0	O
role	0	O
of	0	O
c	0	B
-	0	I
Jun	1	I
and	0	O
c	0	B
-	0	I
Fos	1	I
in	0	O
basal	0	O
and	0	O
PMA	0	O
-	0	O
stimulated	0	O
transcription	0	O
of	0	O
the	0	O
PAI	1	B
-	0	I
1	0	I
gene	0	I
is	0	O
demonstrated	0	O
by	0	O
our	0	O
finding	0	O
that	0	O
antisense	0	O
c	0	B
-	0	I
jun	0	I
and	0	O
c	0	B
-	0	I
fos	0	I
oligodeoxynucleotides	0	O
both	0	O
strongly	0	O
reduced	0	O
basal	0	O
and	0	O
PMA	0	O
-	0	O
stimulated	0	O
PAI	1	B
-	0	I
1	0	I
synthesis	0	O
.	0	O


Because	0	O
there	0	O
is	0	O
great	0	O
need	0	O
for	0	O
iron	0	O
in	0	O
the	0	O
EPO	0	B
-	0	O
stimulated	0	O
erythroid	0	O
progenitors	0	O
,	0	O
it	0	O
is	0	O
essential	0	O
that	0	O
serum	0	B
ferritin	0	I
and	0	O
transferrin	0	B
saturation	0	O
levels	0	O
should	0	O
be	0	O
maintained	0	O
over	0	O
300	0	O
microg	0	O
/	0	O
liter	0	O
and	0	O
30	0	O
%,	0	O
respectively	0	O
.	0	O


By	0	O
deletion	0	O
analysis	0	O
of	0	O
the	0	O
MLS1	0	B
control	0	O
region	0	O
,	0	O
we	0	O
identified	0	O
two	0	O
sites	0	O
,	0	O
UAS1	0	O
and	0	O
UAS2	0	O
,	0	O
as	0	O
important	0	O
for	0	O
efficient	0	O
derepression	0	O
of	0	O
the	0	O
gene	0	O
.	0	O


In	1	O
this	0	O
case	0	O
the	0	O
degree	0	O
of	0	O
promoter	0	O
methylation	0	O
,	0	O
which	0	O
could	0	O
extend	0	O
beyond	0	O
the	0	O
T	1	O
-	0	O
DNA	1	O
borders	0	O
,	0	O
was	0	O
not	0	O
correlated	0	O
with	0	O
the	0	O
reduction	0	O
in	0	O
steady	0	O
-	0	O
state	0	O
poly	0	O
(	0	O
A	1	O
)+	0	O
mRNA	1	O
levels	0	O
,	0	O
the	0	O
silenced	0	O
state	0	O
was	0	O
transmitted	0	O
through	0	O
meiosis	0	O
and	0	O
reactivation	0	O
lasted	0	O
several	0	O
generations	0	O
.	0	O


A	1	O
centromere	0	O
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
consists	0	O
of	0	O
a	0	O
region	0	O
of	0	O
DNA	1	O
,	0	O
approximately	0	O
150	0	O
bp	0	O
in	0	O
length	0	O
,	0	O
containing	0	O
three	0	O
important	0	O
sequence	0	O
elements	0	O
,	0	O
which	0	O
are	0	O
folded	0	O
with	0	O
proteins	0	O
into	0	O
a	0	O
specific	0	O
conformation	0	O
in	0	O
the	0	O
chromatin	0	O
(	0	O
the	0	O
yeast	0	O
kinetochore	0	O
).	0	O


2	0	O
new	0	O
Algerian	0	O
cases	0	O


Comparison	0	O
of	0	O
immunoassay	0	O
kits	0	O
for	0	O
detection	0	O
of	0	O
staphylococcal	0	B
enterotoxins	0	I
produced	0	O
by	0	O
Staphylococcus	1	O
aureus	0	O


The	0	O
ventilation	0	O
did	0	O
not	0	O
increase	0	O
when	0	O
PACO2	1	O
was	0	O
increased	0	O
.	0	O


Newcastle	0	O
disease	0	O
virus	0	O
surveillance	0	O
in	0	O
Hong	0	O
Kong	0	O
on	0	O
local	0	O
and	0	O
imported	0	O
poultry	0	O
.	0	O


The	0	O
interferon	0	B
(	0	O
IFN	1	B
)-	0	O
induced	0	O
double	0	B
-	0	I
stranded	0	I
RNA	1	I
(	0	I
dsRNA	1	I
)-	0	I
activated	0	I
Ser	1	I
/	0	I
Thr	1	I
protein	0	I
kinase	0	I
(	0	O
PKR	0	B
)	0	O
plays	0	O
a	0	O
role	0	O
in	0	O
the	0	O
antiviral	0	O
and	0	O
antiproliferative	0	O
effects	0	O
of	0	O
IFN	1	B
.	0	O


In	1	O
cases	0	O
of	0	O
1	0	O
degrees	0	O
HPT	0	O
,	0	O
the	0	O
plasma	0	O
1	0	O
,	0	O
25	0	O
-(	0	O
OH	0	O
)	0	O
2D	0	O
level	0	O
rose	0	O
significantly	0	O
in	0	O
all	0	O
cases	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
),	0	O
although	0	O
the	0	O
pattern	0	O
of	0	O
the	0	O
increase	0	O
was	0	O
not	0	O
uniform	0	O
.	0	O


The	0	O
pre	0	O
-	0	O
and	0	O
postoperative	0	O
haemoglobin	0	B
concentrations	0	O
in	0	O
the	0	O
autologous	0	O
group	0	O
were	0	O
lower	0	O
by	0	O
15	0	O
and	0	O
10	0	O
g	0	O
/	0	O
L	1	O
,	0	O
respectively	0	O
,	0	O
after	0	O
primary	0	O
THR	1	O
and	0	O
by	0	O
10	0	O
g	0	O
/	0	O
L	1	O
in	0	O
both	0	O
instances	0	O
after	0	O
revision	0	O
THR	1	O
.	0	O


The	0	O
Rlm1	0	B
protein	0	I
,	0	O
a	0	O
member	0	O
of	0	O
the	0	O
MADS	0	B
box	0	I
family	0	I
of	0	O
transcription	0	O
factors	0	O
,	0	O
functions	0	O
downstream	0	O
of	0	O
Mpk1	0	B
in	0	O
the	0	O
pathway	0	O
.	0	O


This	0	O
region	0	O
of	0	O
60	0	O
amino	0	O
acids	0	O
may	0	O
be	0	O
involved	0	O
in	0	O
coiled	0	O
-	0	O
coil	0	O
interactions	0	O
similar	0	O
to	0	O
those	0	O
that	0	O
facilitate	0	O
the	0	O
filament	0	O
formation	0	O
in	0	O
the	0	O
rod	0	O
region	0	O
.	0	O


PBSX	0	B
is	0	O
induced	0	O
by	0	O
agents	0	O
which	0	O
elicit	0	O
the	0	O
SOS	0	O
response	0	O
.	0	O


Riboflavin	1	O
did	0	O
not	0	O
affect	0	O
the	0	O
percentage	0	O
of	0	O
aflatoxin	0	O
-	0	O
treated	0	O
animals	0	O
with	0	O
abnormal	0	O
urinary	0	O
excretion	0	O
patterns	0	O
,	0	O
but	0	O
did	0	O
increase	0	O
the	0	O
magnitude	0	O
of	0	O
the	0	O
disturbances	0	O
in	0	O
elimination	0	O
of	0	O
kynurenic	0	O
and	0	O
xanthurenic	0	O
acids	0	O
.	0	O


RESULT	0	O
(	0	O
S	1	O
):	0	O
In	1	O
patients	0	O
with	0	O
elevated	0	O
FSH	1	B
levels	0	O
on	0	O
cycle	0	O
day	0	O
3	0	O
,	0	O
a	0	O
low	0	O
oocyte	0	O
yield	0	O
was	0	O
achieved	0	O
(	0	O
7	0	O
versus	0	O
11	0	O
)	0	O
and	0	O
a	0	O
high	0	O
number	0	O
of	0	O
ampules	0	O
of	0	O
hMG	1	B
was	0	O
necessary	0	O
(	0	O
56	0	O
versus	0	O
33	0	O
).	0	O


The	0	O
oral	0	O
temperature	0	O
rose	0	O
and	0	O
the	0	O
serum	0	B
creatine	0	I
kinase	0	I
levels	0	O
fell	0	O
only	0	O
in	0	O
those	0	O
patients	0	O
who	0	O
were	0	O
actively	0	O
warmed	0	O
.	0	O


Nuclease	1	O
probing	0	O
and	0	O
structure	0	O
-	0	O
directed	0	O
mutagenesis	0	O
revealed	0	O
that	0	O
the	0	O
105	0	O
-	0	O
nt	0	O
TE	1	O
(	0	O
TE105	0	O
)	0	O
forms	0	O
a	0	O
cruciform	0	O
secondary	0	O
structure	0	O
containing	0	O
four	0	O
helices	0	O
connected	0	O
by	0	O
single	0	O
-	0	O
stranded	0	O
regions	0	O
.	0	O


However	0	O
,	0	O
in	0	O
some	0	O
of	0	O
them	0	O
either	0	O
pattern	0	O
may	0	O
predominate	0	O
or	0	O
be	0	O
exclusively	0	O
present	0	O
.	0	O


The	0	O
roles	0	O
of	0	O
phorbol	0	O
esters	0	O
and	0	O
cyclic	0	O
AMP	1	O
in	0	O
mediating	0	O
the	0	O
GnRH	0	B
response	0	O
were	0	O
also	0	O
investigated	0	O
.	0	O


CONCLUSION	0	O
:	0	O
In	1	O
Cdks	0	B
functioning	0	O
throughout	0	O
the	0	O
cell	0	O
cycle	0	O
,	0	O
tyrosine	0	O
phosphorylation	0	O
is	0	O
inhibitory	0	O
to	0	O
the	0	O
activation	0	O
of	0	O
kinase	0	O
,	0	O
whereas	0	O
the	0	O
phosphorylation	0	O
of	0	O
threonine	0	O
in	0	O
the	0	O
T	1	O
-	0	O
loop	0	O
is	0	O
essential	0	O
for	0	O
activation	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
system	0	O
can	0	O
be	0	O
used	0	O
to	0	O
detect	0	O
and	0	O
study	0	O
dynamic	0	O
perfusion	0	O
changes	0	O
from	0	O
the	0	O
brain	0	O
surface	0	O
with	0	O
minimal	0	O
tissue	0	O
damage	0	O
.	0	O


Neonatal	1	O
lupus	0	O
erythematosus	0	O
is	0	O
most	0	O
often	0	O
associated	0	O
with	0	O
autoantibodies	0	O
against	0	O
Ro	0	B
and	0	O
La	1	B
antigens	0	O
.	0	O


Eighteen	0	O
patients	0	O
were	0	O
untreated	0	O
,	0	O
and	0	O
8	0	O
had	0	O
been	0	O
given	0	O
previous	0	O
treatment	0	O
with	0	O
depot	0	O
testosterone	0	O
100	0	O
mg	0	O
intramuscularly	0	O
every	0	O
2	0	O
-	0	O
3	0	O
weeks	0	O
for	0	O
an	0	O
average	0	O
duration	0	O
of	0	O
4	0	O
.	0	O
7	0	O
years	0	O
.	0	O


When	0	O
the	0	O
degree	0	O
of	0	O
exercise	0	O
was	0	O
maximal	0	O
,	0	O
mPAP	0	O
was	0	O
maintained	0	O
,	0	O
SVI	0	O
decreased	0	O
,	0	O
HR	1	O
was	0	O
unchanged	0	O
,	0	O
and	0	O
CO	1	O
and	0	O
VO2	1	O
decreased	0	O
.	0	O


Chemical	1	O
uptake	0	O
into	0	O
human	0	O
stratum	0	O
corneum	0	O
in	0	O
vivo	0	O
from	0	O
volatile	0	O
and	0	O
non	0	O
-	0	O
volatile	0	O
solvents	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
entire	0	O
16	0	O
.	0	O
7	0	O
-	0	O
kb	0	O
mt	0	O
genome	0	O
determined	0	O
that	0	O
a	0	O
MDP1	1	B
mediates	0	O
cleavage	0	O
of	0	O
chick	0	O
mtDNA	1	O
in	0	O
vitro	0	O
at	0	O
three	0	O
H	1	O
-	0	O
and	0	O
two	0	O
L	1	O
-	0	O
strand	0	O
sequence	0	O
-	0	O
specific	0	O
target	0	O
sites	0	O
located	0	O
within	0	O
a	0	O
90	0	O
-	0	O
bp	0	O
A	1	O
+	0	O
T	1	O
-	0	O
rich	0	O
genomic	0	O
tract	0	O
,	0	O
theoretically	0	O
capable	0	O
of	0	O
forming	0	O
stable	0	O
secondary	0	O
structures	0	O
,	0	O
approximately	0	O
200	0	O
bases	0	O
upstream	0	O
from	0	O
the	0	O
H	1	O
-	0	O
strand	0	O
origin	0	O
(	0	O
OH	0	O
)	0	O
of	0	O
replication	0	O
.	0	O


Gene	1	O
constructs	0	O
possessing	0	O
the	0	O
complete	0	B
tat	0	I
,	0	O
rev	0	B
(	0	O
tat	0	B
+	0	I
rev	0	O
+)	0	O
and	0	O
env	0	B
genes	0	I
were	0	O
transiently	0	O
expressed	0	O
in	0	O
COS	1	O
-	0	O
1	0	O
cells	0	O
as	0	O
precursor	0	B
SU	0	I
-	0	I
TM	1	I
(	0	O
gp160	0	B
),	0	O
SU	0	B
.	0	I
TM	1	I
(	0	O
gp120	0	B
x	0	I
41	0	I
),	0	O
and	0	O
nucleolar	0	B
rev	0	I
protein	0	I
.	0	O


Having	0	O
an	0	O
LRR	1	B
domain	0	I
and	0	O
an	0	O
SH3	0	B
-	0	I
binding	0	I
domain	0	I
,	0	O
Acan125	0	B
and	0	O
the	0	O
C	1	O
.	0	O
elegans	0	O
homologue	0	O
define	0	O
a	0	O
novel	0	O
family	0	O
of	0	O
bifunctional	0	O
binding	0	O
proteins	0	O
.	0	O


From	0	O
250	0	O
g	0	O
of	0	O
cells	0	O
,	0	O
we	0	O
isolated	0	O
1	0	O
mg	0	O
of	0	O
PDH	0	B
complex	0	I
with	0	O
a	0	O
specific	0	O
activity	0	O
of	0	O
12	0	O
.	0	O
6	0	O
U	1	O
/	0	O
mg	0	O
of	0	O
protein	0	O
.	0	O


Mechanistically	0	O
,	0	O
the	0	O
presence	0	O
of	0	O
the	0	O
GRR	0	O
appears	0	O
to	0	O
stop	0	O
further	0	O
degradation	0	O
of	0	O
p50	0	B
and	0	O
to	0	O
stabilize	0	O
the	0	O
molecule	0	O
.	0	O


TDEYA	0	O
at	0	O
doses	0	O
of	0	O
200	0	O
to	0	O
500	0	O
mg	0	O
/	0	O
kg	0	O
significantly	0	O
suppressed	0	O
xanthine	0	B
oxidase	0	I
(	0	O
XO	1	B
)	0	O
activity	0	O
in	0	O
the	0	O
stomach	0	O
tissue	0	O
following	0	O
its	0	O
oral	0	O
administration	0	O
.	0	O


Delayed	0	O
mortality	0	O
of	0	O
mice	0	O
following	0	O
inhalation	0	O
of	0	O
acute	0	O
doses	0	O
of	0	O
CH2O	0	O
,	0	O
SO2Cl2	0	O
,	0	O
and	0	O
Br2	0	O
.	0	O


The	0	O
sequence	0	O
-	0	O
specific	0	O
interaction	0	O
of	0	O
nuclear	0	B
factor	0	I
HiNF	0	I
-	0	I
D	1	I
with	0	O
this	0	O
key	0	O
proximal	0	O
promoter	0	O
element	0	O
of	0	O
the	0	O
H4	0	B
-	0	I
FO108	0	I
gene	0	I
is	0	O
cell	0	O
cycle	0	O
regulated	0	O
in	0	O
normal	0	O
diploid	0	O
cells	0	O
(	0	O
J	1	O
.	0	O


Neurons	0	O
were	0	O
held	0	O
at	0	O
-	0	O
67	0	O
mV	1	O
to	0	O
equate	0	O
voltage	0	O
-	0	O
dependent	0	O
effects	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
3	0	O
'-	0	O
untranslated	0	O
regions	0	O
of	0	O
pmGT10	0	B
display	0	O
a	0	O
marked	0	O
degree	0	O
of	0	O
homology	0	O
to	0	O
the	0	O
3	0	O
'	0	O
region	0	O
of	0	O
the	0	O
rat	0	B
Yb1	0	I
gene	0	I
,	0	O
while	0	O
this	0	O
region	0	O
of	0	O
pmGT2	0	B
displays	0	O
marked	0	O
homology	0	O
to	0	O
the	0	O
corresponding	0	O
region	0	O
of	0	O
the	0	O
rat	0	B
Yb2	0	I
gene	0	I
.	0	O


None	0	O
had	0	O
a	0	O
past	0	O
history	0	O
of	0	O
opportunistic	0	O
infections	0	O
;	0	O
neither	0	O
did	0	O
any	0	O
have	0	O
lymphopenia	0	O
.	0	O


Phagocytosis	1	O
of	0	O
tubercle	0	O
bacilli	0	O
by	0	O
macrophages	0	O
.	0	O


A	1	O
hospital	0	O
-	0	O
based	0	O
study	0	O
of	0	O
the	0	O
relationship	0	O
between	0	O
retained	0	O
placenta	0	O
and	0	O
mastitis	0	O
in	0	O
dairy	0	O
cows	0	O
.	0	O


The	0	O
encoded	0	O
amino	0	O
acid	0	O
sequences	0	O
in	0	O
the	0	O
full	0	O
-	0	O
length	0	O
bovine	0	O
and	0	O
porcine	0	O
cDNAs	0	O
were	0	O
identical	0	O
,	0	O
consisting	0	O
of	0	O
209	0	O
amino	0	O
acid	0	O
residues	0	O
,	0	O
and	0	O
were	0	O
nearly	0	O
the	0	O
same	0	O
as	0	O
the	0	O
published	0	O
sequence	0	O
determined	0	O
by	0	O
Edman	0	O
degradation	0	O
.	0	O


Cells	0	O
differentiate	0	O
in	0	O
response	0	O
to	0	O
various	0	O
extracellular	0	O
stimuli	0	O
.	0	O


Morphine	1	O
-	0	O
dependent	0	O
and	0	O
control	0	O
rats	0	O
in	0	O
an	0	O
oral	0	O
free	0	O
-	0	O
choice	0	O
protocol	0	O
were	0	O
treated	0	O
with	0	O
gamma	0	O
-	0	O
vinyl	0	O
GABA	1	O
(	0	O
GVG	0	O
),	0	O
60	0	O
,	0	O
120	0	O
and	0	O
240	0	O
mg	0	O
/	0	O
kg	0	O
IP	1	O
,	0	O
for	0	O
3	0	O
days	0	O
over	0	O
three	0	O
successive	0	O
periods	0	O
.	0	O


Clipping	0	O
resulted	0	O
in	0	O
a	0	O
serious	0	O
mislocalization	0	O
of	0	O
the	0	O
position	0	O
of	0	O
the	0	O
peak	0	O
of	0	O
the	0	O
epicortical	0	O
potential	0	O
field	0	O
.	0	O


Psychological	1	O
examinations	0	O
in	0	O
patients	0	O
with	0	O
chronic	0	O
kidney	0	O
insufficiency	0	O


Glutathione	1	B
peroxidase	0	I
in	0	O
human	0	O
red	0	O
cells	0	O
in	0	O
health	0	O
and	0	O
disease	0	O
.	0	O


High	0	O
levels	0	O
of	0	O
IC	1	O
coincided	0	O
with	0	O
relative	0	O
hypocomplementemia	0	O
.	0	O


Gab2	0	B
,	0	O
a	0	O
new	0	O
pleckstrin	0	B
homology	0	O
domain	0	O
-	0	O
containing	0	O
adapter	0	O
protein	0	O
,	0	O
acts	0	O
to	0	O
uncouple	0	O
signaling	0	O
from	0	O
ERK	0	B
kinase	0	I
to	0	O
Elk	0	B
-	0	I
1	0	I
.	0	O


This	0	O
result	0	O
suggested	0	O
that	0	O
mutant	0	O
I299	0	O
has	0	O
diminished	0	O
cap	0	O
-	0	O
binding	0	O
activity	0	O
.	0	O


Second	1	O
,	0	O
the	0	O
transcription	0	B
factor	0	I
Gal	0	I
-	0	I
ER	1	I
was	0	O
rendered	0	O
more	0	O
potent	0	O
and	0	O
less	0	O
susceptible	0	O
to	0	O
cell	0	O
type	0	O
-	0	O
specific	0	O
variation	0	O
by	0	O
fusing	0	O
the	0	O
strong	0	O
activating	0	O
domain	0	O
of	0	O
the	0	O
herpesvirus	0	B
protein	0	I
VP16	0	I
onto	0	O
its	0	O
C	1	O
terminus	0	O
.	0	O


We	0	O
find	0	O
that	0	O
beta	0	B
II	0	I
PKC	0	I
phosphorylates	0	O
nuclear	0	B
envelope	0	I
lamin	0	I
B	1	I
at	0	O
10	0	O
-	0	O
20	0	O
times	0	O
the	0	O
rate	0	O
of	0	O
alpha	0	B
PKC	0	I
,	0	O
whereas	0	O
both	0	O
kinases	0	O
phosphorylate	0	O
soluble	0	B
lamin	0	I
B	1	I
at	0	O
similar	0	O
rates	0	O
.	0	O


This	0	O
is	0	O
predicted	0	O
to	0	O
encode	0	O
a	0	O
315	0	O
-	0	O
residue	0	O
protein	0	O
containing	0	O
seven	0	O
hydrophobic	0	O
helical	0	O
regions	0	O
and	0	O
a	0	O
17	0	O
amino	0	O
acid	0	O
motif	0	O
characteristic	0	O
of	0	O
the	0	O
R7G	0	B
family	0	I
of	0	O
G	1	B
-	0	I
protein	0	I
coupled	0	I
membrane	0	I
-	0	I
bound	0	I
receptors	0	I
.	0	O


Lesions	0	O
were	0	O
made	0	O
by	0	O
pressure	0	O
injection	0	O
of	0	O
kainic	0	O
acid	0	O
into	0	O
the	0	O
SOC	0	O
through	0	O
a	0	O
stereotaxically	0	O
positioned	0	O
glass	0	O
micropipette	0	O
.	0	O


Moreover	0	O
,	0	O
increasing	0	O
the	0	O
dosage	0	O
of	0	O
wild	0	B
-	0	I
type	0	I
Fus3	0	I
intensifies	0	O
the	0	O
inhibition	0	O
of	0	O
both	0	O
Ty1	0	B
transposition	0	O
and	0	O
invasive	0	O
growth	0	O
.	0	O


Current	1	O
status	0	O
of	0	O
chemotherapy	0	O
for	0	O
Hodgkin	0	O
'	0	O
s	0	O
disease	0	O


Although	0	O
stone	0	O
-	0	O
formers	0	O
were	0	O
not	0	O
found	0	O
to	0	O
display	0	O
any	0	O
features	0	O
of	0	O
magnesium	0	O
metabolism	0	O
that	0	O
were	0	O
different	0	O
from	0	O
those	0	O
in	0	O
the	0	O
control	0	O
group	0	O
,	0	O
their	0	O
lower	0	O
urinary	0	O
excretion	0	O
of	0	O
magnesium	0	O
in	0	O
relation	0	O
to	0	O
calcium	0	O
may	0	O
be	0	O
a	0	O
factor	0	O
in	0	O
their	0	O
increased	0	O
stone	0	O
-	0	O
forming	0	O
propensity	0	O
.	0	O


Cerebrospinal	1	O
fluid	0	O
transferrin	0	B
II	0	I
studies	0	O
in	0	O
ischemic	0	O
disorders	0	O
of	0	O
the	0	O
central	0	O
nervous	0	O
system	0	O
.	0	O


The	0	O
envelope	0	O
glycoproteins	0	O
of	0	O
Rous	0	O
sarcoma	0	O
virus	0	O
(	0	O
RSV	1	O
),	0	O
gp85	0	B
and	0	O
gp37	0	B
,	0	O
are	0	O
anchored	0	O
in	0	O
the	0	O
membrane	0	O
by	0	O
a	0	O
27	0	O
-	0	O
amino	0	O
acid	0	O
,	0	O
hydrophobic	0	O
domain	0	O
that	0	O
lies	0	O
adjacent	0	O
to	0	O
a	0	O
22	0	O
-	0	O
amino	0	O
acid	0	O
,	0	O
cytoplasmic	0	O
domain	0	O
at	0	O
the	0	O
carboxy	0	O
terminus	0	O
of	0	O
gp37	0	B
.	0	O


In	1	O
this	0	O
paper	0	O
we	0	O
describe	0	O
properties	0	O
of	0	O
the	0	O
cdc10	0	B
-	0	O
C4	1	O
mutant	0	O
of	0	O
the	0	O
fission	0	O
yeast	0	O
Schizosaccharomyces	0	O
pombe	0	O
.	0	O


In	1	O
PB	1	O
mice	0	O
,	0	O
there	0	O
was	0	O
only	0	O
a	0	O
small	0	O
deficit	0	O
in	0	O
the	0	O
number	0	O
of	0	O
the	0	O
hippocampal	0	O
pyramidal	0	O
neurons	0	O
compared	0	O
to	0	O
controls	0	O
(	0	O
15	0	O
%,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
),	0	O
and	0	O
no	0	O
deficit	0	O
in	0	O
the	0	O
granule	0	O
cells	0	O
.	0	O


A	1	O
novel	0	O
gene	0	O
designated	0	O
cmr	0	B
,	0	O
which	0	O
mapped	0	O
to	0	O
18	0	O
.	0	O
8	0	O
min	0	O
of	0	O
the	0	O
Escherichia	1	O
coli	0	O
K	1	O
-	0	O
12	0	O
genome	0	O
,	0	O
was	0	O
shown	0	O
to	0	O
mediate	0	O
resistance	0	O
to	0	O
chloramphenicol	0	O
when	0	O
it	0	O
was	0	O
expressed	0	O
from	0	O
a	0	O
multicopy	0	O
vector	0	O
.	0	O


In	1	O
the	0	O
face	0	O
of	0	O
the	0	O
outbreak	0	O
,	0	O
there	0	O
was	0	O
a	0	O
delay	0	O
before	0	O
vaccination	0	O
was	0	O
able	0	O
to	0	O
stop	0	O
deaths	0	O
.	0	O


The	0	O
distribution	0	O
of	0	O
patients	0	O
was	0	O
as	0	O
follows	0	O
:	0	O
group	0	O
1	0	O
--	0	O
complex	0	O
gamma	0	O
-	0	O
therapy	0	O
(	0	O
55	0	O
cases	0	O
),	0	O
group	0	O
2	0	O
--	0	O
complex	0	O
gamma	0	O
-	0	O
therapy	0	O
plus	0	O
iliac	0	O
lymphadenectomy	0	O
(	0	O
50	0	O
cases	0	O
)	0	O
and	0	O
group	0	O
3	0	O
--	0	O
complex	0	O
radiation	0	O
treatment	0	O
with	0	O
megavolt	0	O
bremsstrahlung	0	O
beam	0	O
from	0	O
the	0	O
luc	0	O
type	0	O
installation	0	O
and	0	O
iliac	0	O
lymphadenectomy	0	O
(	0	O
50	0	O
cases	0	O
).	0	O


The	0	O
requirement	0	O
for	0	O
proteolytic	0	O
activity	0	O
of	0	O
both	0	O
FVIIa	0	B
and	0	O
FXa	0	B
suggests	0	O
that	0	O
protease	0	O
-	0	O
activated	0	O
receptors	0	O
may	0	O
be	0	O
involved	0	O
.	0	O


The	0	O
Sarns	0	O
51F	0	O
cavoatrial	0	O
cannula	0	O
decompressed	0	O
the	0	O
venous	0	O
system	0	O
as	0	O
efficiently	0	O
as	0	O
the	0	O
double	0	O
caval	0	O
cannulas	0	O
.	0	O


In	1	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assay	0	O
(	0	O
EMSA	0	O
),	0	O
this	0	O
GLUT4	0	B
repressor	0	I
element	0	I
(	0	O
G4RE	0	B
)	0	O
generated	0	O
specific	0	O
bands	0	O
with	0	O
nuclear	0	O
extracts	0	O
from	0	O
preadipocytes	0	O
,	0	O
but	0	O
not	0	O
from	0	O
adipocytes	0	O
.	0	O


B	1	O
cell	0	O
-	0	O
specific	0	O
mb	0	B
-	0	I
1	0	I
and	0	O
B29	0	B
genes	0	I
encode	0	O
the	0	O
alpha	0	O
/	0	O
beta	0	O
components	0	O
of	0	O
the	0	O
BCR	0	B
-	0	I
associated	0	I
complex	0	I
in	0	O
mature	0	O
sIgM	0	B
+	0	I
B	1	O
cells	0	O
.	0	O


Phosphorylation	1	O
and	0	O
spindle	0	O
pole	0	O
body	0	O
localization	0	O
of	0	O
the	0	O
Cdc15p	0	B
mitotic	0	I
regulatory	0	I
protein	0	I
kinase	0	I
in	0	I
budding	0	I
yeast	0	I
.	0	O


BSE	1	O
and	0	O
farmworkers	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
DNA	1	O
from	0	O
15	0	O
cases	0	O
of	0	O
sporadic	0	O
and	0	O
familial	0	O
Wilms	0	O
'	0	O
tumor	0	O
did	0	O
not	0	O
reveal	0	O
any	0	O
changes	0	O
,	0	O
indicating	0	O
that	0	O
the	0	O
translocation	0	O
breakpoint	0	O
does	0	O
not	0	O
reside	0	O
in	0	O
this	0	O
gene	0	O
.	0	O


Evidence	1	O
for	0	O
two	0	O
distinctive	0	O
clinical	0	O
,	0	O
epidemiological	0	O
,	0	O
and	0	O
immunological	0	O
types	0	O
of	0	O
infection	0	O
.	0	O


RESULTS	0	O
:	0	O
In	1	O
an	0	O
18	0	O
moth	0	O
period	0	O
and	0	O
out	0	O
of	0	O
a	0	O
total	0	O
of	0	O
284	0	O
positive	0	O
blood	0	O
cultures	0	O
(	0	O
154	0	O
significant	0	O
isolations	0	O
)	0	O
14	0	O
episodes	0	O
of	0	O
bacteremia	0	O
by	0	O
M	1	O
.	0	O
tuberculosis	0	O
were	0	O
studied	0	O
in	0	O
12	0	O
prison	0	O
patients	0	O
coinfected	0	O
by	0	O
the	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
with	0	O
associated	0	O
severe	0	O
immunosuppression	0	O
(	0	O
mean	0	O
of	0	O
CD4	1	B
=	0	O
0	0	O
.	0	O
068	0	O
x	0	O
10	0	O
(	0	O
9	0	O
)/	0	O
l	0	O
).	0	O


During	0	O
the	0	O
following	0	O
pregnancy	0	O
ultrasonographic	0	O
studies	0	O
of	0	O
the	0	O
male	0	O
fetus	0	O
in	0	O
the	0	O
16th	0	O
week	0	O
of	0	O
gestation	0	O
revealed	0	O
severe	0	O
micrognathia	0	O
,	0	O
short	0	O
and	0	O
wide	0	O
thumbs	0	O
,	0	O
and	0	O
big	0	O
toes	0	O
,	0	O
and	0	O
bowed	0	O
tibiae	0	O
.	0	O


The	0	O
following	0	O
evidence	0	O
indicates	0	O
that	0	O
the	0	O
69	0	O
-	0	O
kD	1	O
protein	0	O
is	0	O
a	0	O
common	0	O
,	0	O
rather	0	O
than	0	O
a	0	O
U1	0	B
-	0	O
specific	0	O
,	0	O
protein	0	O
,	0	O
possibly	0	O
associating	0	O
with	0	O
the	0	O
snRNP	1	O
core	0	O
particles	0	O
by	0	O
protein	0	O
-	0	O
protein	0	O
interaction	0	O
.	0	O


Genetic	1	O
abnormalities	0	O
that	0	O
could	0	O
lead	0	O
to	0	O
mutagenesis	0	O
include	0	O
chromosomal	0	O
abnormalities	0	O
and	0	O
single	0	O
-	0	O
gene	0	O
mutations	0	O
.	0	O


An	1	O
approximately	0	O
2	0	B
-	0	I
kilobase	0	I
B2	0	I
transcript	0	I
was	0	O
expressed	0	O
in	0	O
all	0	O
alfalfa	0	O
organs	0	O
tested	0	O
.	0	O


Antenatal	1	O
diagnosis	0	O
of	0	O
haematological	0	O
disorders	0	O
--'	0	O
1978	0	O
'.	0	O


In	1	O
cerebrospinal	0	O
fluid	0	O
,	0	O
an	0	O
ADA	1	B
catalytic	0	O
concentration	0	O
above	0	O
0	0	O
.	0	O
15	0	O
mu	0	O
kat	0	O
/	0	O
L	1	O
strongly	0	O
suggests	0	O
tuberculous	0	O
meningitis	0	O
in	0	O
patients	0	O
older	0	O
than	0	O
7	0	O
years	0	O
(	0	O
sensitivity	0	O
1	0	O
.	0	O
00	0	O
,	0	O
specificity	0	O
0	0	O
.	0	O
99	0	O
and	0	O
efficiency	0	O
0	0	O
.	0	O
99	0	O
).	0	O


The	0	O
RNA	1	O
transcripts	0	O
structurally	0	O
equivalent	0	O
to	0	O
I	1	B
(	0	I
2	0	I
)	0	I
sgRNAs	0	I
of	0	O
TMV	0	B
U1	0	I
and	0	O
crTMV	0	O
,	0	O
but	0	O
containing	0	O
a	0	O
hairpin	0	O
structure	0	O
(	0	O
H	1	O
)	0	O
immediately	0	O
upstream	0	O
of	0	O
IRES	0	B
(	0	I
MP	1	I
,	0	I
75	0	I
)	0	I
(	0	I
HIRES	0	I
(	0	I
MP	1	I
),	0	I
(	0	I
75	0	I
)(	0	I
CR	1	I
)-	0	I
MP	1	I
-	0	I
CP	1	I
-	0	I
3	0	I
'	0	I
UTR	0	I
;	0	O
HIRES	0	B
(	0	I
MP	1	I
,	0	I
75	0	I
)(	0	I
U1	0	I
)-	0	I
MP	1	I
-	0	I
CP	1	I
-	0	I
3	0	I
'	0	I
UTR	0	I
),	0	O
were	0	O
able	0	O
to	0	O
express	0	O
the	0	O
MP	1	B
gene	0	I
in	0	O
vitro	0	O
.	0	O


A	1	O
one	0	O
-	0	O
way	0	O
analysis	0	O
of	0	O
variance	0	O
,	0	O
performed	0	O
separately	0	O
for	0	O
men	0	O
and	0	O
women	0	O
for	0	O
differences	0	O
among	0	O
the	0	O
three	0	O
phobic	0	O
groups	0	O
on	0	O
field	0	O
dependence	0	O
,	0	O
showed	0	O
significance	0	O
(	0	O
rho	0	O
less	0	O
than	0	O
.	0	O
05	0	O
)	0	O
for	0	O
the	0	O
females	0	O
,	0	O
with	0	O
the	0	O
famale	0	O
agoraphobic	0	O
being	0	O
more	0	O
field	0	O
dependent	0	O
than	0	O
the	0	O
female	0	O
simple	0	O
phobic	0	O
groups	0	O
,	0	O
but	0	O
not	0	O
for	0	O
the	0	O
males	0	O
.	0	O


In	1	O
a	0	O
gel	0	O
retardation	0	O
assay	0	O
using	0	O
HepG2	0	O
nuclear	0	O
extracts	0	O
,	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
sequence	0	O
from	0	O
-	0	O
74	0	O
to	0	O
-	0	O
46	0	O
showed	0	O
a	0	O
shifted	0	O
band	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
emotional	0	O
-	0	O
painful	0	O
stress	0	O
(	0	O
EPS	1	O
)	0	O
on	0	O
myocardial	0	O
extensibility	0	O
and	0	O
contractility	0	O
was	0	O
studied	0	O
on	0	O
an	0	O
isolated	0	O
rat	0	O
atrium	0	O
.	0	O


The	0	O
pheromone	0	O
response	0	O
pathway	0	O
activates	0	O
transcription	0	O
of	0	O
Ty5	0	B
retrotransposons	0	I
located	0	O
within	0	O
silent	0	O
chromatin	0	O
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


After	0	O
2	0	O
min	0	O
of	0	O
dobutamine	0	O
injection	0	O
,	0	O
or	0	O
after	0	O
20	0	O
min	0	O
of	0	O
pimobendan	0	O
injection	0	O
,	0	O
the	0	O
myocardium	0	O
was	0	O
removed	0	O
,	0	O
and	0	O
used	0	O
for	0	O
determination	0	O
of	0	O
the	0	O
tissue	0	O
levels	0	O
of	0	O
metabolites	0	O
of	0	O
energy	0	O
and	0	O
carbohydrate	0	O
metabolism	0	O
.	0	O


Likewise	0	O
,	0	O
whether	0	O
or	0	O
not	0	O
the	0	O
hypotensive	0	O
action	0	O
of	0	O
converting	0	O
enzyme	0	O
inhibitors	0	O
is	0	O
age	0	O
-	0	O
related	0	O
is	0	O
as	0	O
yet	0	O
unknown	0	O
.	0	O


The	0	O
peptide	0	O
sequence	0	O
contains	0	O
a	0	O
region	0	O
of	0	O
80	0	O
amino	0	O
acids	0	O
that	0	O
shows	0	O
similarity	0	O
to	0	O
bcl	0	B
-	0	I
2	0	I
and	0	O
to	0	O
the	0	O
recently	0	O
described	0	O
bcl	0	B
-	0	I
2	0	I
-	0	I
related	0	I
gene	0	I
,	0	O
MCL1	0	B
.	0	O


They	0	O
were	0	O
then	0	O
subjected	0	O
to	0	O
whole	0	O
-	0	O
body	0	O
heat	0	O
stress	0	O
(	0	O
water	0	O
-	0	O
perfused	0	O
suits	0	O
),	0	O
and	0	O
the	0	O
3	0	O
minutes	0	O
of	0	O
LBNP	0	O
was	0	O
repeated	0	O
.	0	O


Ischaemia	0	O
was	0	O
induced	0	O
by	0	O
a	0	O
low	0	O
flow	0	O
rate	0	O
of	0	O
0	0	O
.	0	O
8	0	O
mL	1	O
min	0	O
-	0	O
1	0	O
for	0	O
30	0	O
min	0	O
,	0	O
and	0	O
was	0	O
followed	0	O
by	0	O
a	0	O
40	0	O
-	0	O
minute	0	O
reperfusion	0	O
.	0	O


The	0	O
evaluation	0	O
was	0	O
performed	0	O
using	0	O
a	0	O
retrospective	0	O
study	0	O
design	0	O
with	0	O
newborn	0	O
blood	0	O
samples	0	O
from	0	O
three	0	O
screening	0	O
centres	0	O
.	0	O


Imposed	0	O
angular	0	O
displacements	0	O
of	0	O
monkey	0	O
'	0	O
s	0	O
wrist	0	O
produce	0	O
three	0	O
major	0	O
peaks	0	O
of	0	O
activity	0	O
(	0	O
terms	0	O
M1	1	O
,	0	O
M2	1	O
,	0	O
and	0	O
M3	1	O
peaks	0	O
)	0	O
in	0	O
the	0	O
averaged	0	O
gross	0	O
EMG	1	O
activity	0	O
ot	0	O
the	0	O
stretched	0	O
muscles	0	O
.	0	O


All	1	O
lambs	0	O
with	0	O
B	1	O
breeding	0	O
had	0	O
significantly	0	O
higher	0	O
Hb	1	B
levels	0	O
at	0	O
the	0	O
end	0	O
of	0	O
the	0	O
experiment	0	O
than	0	O
did	0	O
NB	1	O
lambs	0	O
.	0	O
b	0	O
and	0	O
S	1	O
x	0	O
B	1	O
lambs	0	O
had	0	O
higher	0	O
(	0	O
P	1	O
<	0	O
.	0	O
05	0	O
)	0	O
Hb	1	B
levels	0	O
than	0	O
the	0	O
D	1	O
x	0	O
B	1	O
lambs	0	O
,	0	O
and	0	O
B	1	O
lambs	0	O
had	0	O
the	0	O
highest	0	O
(	0	O
P	1	O
<	0	O
.	0	O
05	0	O
)	0	O
mean	0	O
corpuscular	0	O
hemoglobin	0	B
concentrations	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
Anabaena	1	O
strain	0	O
7120	0	O
leuA	0	B
gene	0	O
did	0	O
not	0	O
complement	0	O
the	0	O
nifV	0	B
mutation	0	I
of	0	O
R229I	0	O
efficiently	0	O
.	0	O


Electrophoretic	1	O
mobility	0	O
shift	0	O
assays	0	O
(	0	O
EMSAs	0	O
)	0	O
using	0	O
purified	0	O
glucocorticoid	0	B
receptor	0	I
DNA	1	I
binding	0	I
domain	0	I
(	0	O
DBD	0	O
)	0	O
demonstrated	0	O
that	0	O
both	0	O
GRE	0	B
-	0	I
2	0	I
and	0	I
-	0	I
3	0	I
motifs	0	I
interact	0	O
with	0	O
DBD	0	O
and	0	O
oligonucleotide	0	O
competition	0	O
experiments	0	O
established	0	O
that	0	O
these	0	O
have	0	O
different	0	O
affinities	0	O
for	0	O
DBD	0	O
.	0	O


Collagen	1	B
was	0	O
extracted	0	O
from	0	O
the	0	O
skin	0	O
,	0	O
and	0	O
the	0	O
lack	0	O
of	0	O
type	0	B
III	0	I
collagen	0	I
was	0	O
determined	0	O
by	0	O
means	0	O
of	0	O
sodium	0	O
dodecyl	0	O
sulfate	0	O
-	0	O
polyacrylamide	0	O
gel	0	O
electrophoresis	0	O
(	0	O
SDS	1	O
-	0	O
PAGE	1	O
).	0	O


However	0	O
,	0	O
D8	0	B
binding	0	O
was	0	O
observed	0	O
by	0	O
nuclease	0	O
protection	0	O
with	0	O
lactotroph	0	B
-	0	I
as	0	I
well	0	I
as	0	I
somatotroph	0	I
-	0	I
like	0	I
cell	0	I
nuclear	0	I
protein	0	I
.	0	O


The	0	O
present	0	O
data	0	O
also	0	O
suggest	0	O
that	0	O
when	0	O
compared	0	O
to	0	O
the	0	O
systemic	0	O
vascular	0	O
bed	0	O
,	0	O
the	0	O
pulmonary	0	O
vascular	0	O
bed	0	O
is	0	O
less	0	O
responsive	0	O
to	0	O
bolus	0	O
administration	0	O
of	0	O
ET	1	B
-	0	I
1	0	I
.	0	O


It	1	O
was	0	O
shown	0	O
that	0	O
administration	0	O
of	0	O
immunomodulator	0	O
neurotropin	0	B
(	0	O
NSP	0	B
)	0	O
results	0	O
in	0	O
more	0	O
steady	0	O
consolidation	0	O
and	0	O
retention	0	O
of	0	O
feeding	0	O
and	0	O
avoidance	0	O
behavior	0	O
,	0	O
and	0	O
some	0	O
neurophysiological	0	O
mechanisms	0	O
of	0	O
that	0	O
phenomena	0	O
were	0	O
revealed	0	O
.	0	O


We	0	O
have	0	O
generated	0	O
a	0	O
computer	0	O
model	0	O
of	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
the	0	O
434	0	O
repressor	0	O
based	0	O
on	0	O
the	0	O
crystal	0	O
structure	0	O
of	0	O
the	0	O
homologous	0	B
UmuD	0	I
'	0	I
protein	0	I
.	0	O


Vbeta	0	B
segments	0	O
are	0	O
appended	0	O
to	0	O
DJbeta	0	B
rearrangements	0	O
,	0	O
with	0	O
little	0	O
or	0	O
no	0	O
direct	0	O
Vbeta	0	B
to	0	O
Jbeta	0	B
joining	0	O
,	0	O
despite	0	O
12	0	O
/	0	O
23	0	O
compatibility	0	O
of	0	O
Vbeta	0	B
23	0	I
-	0	I
RSSs	0	I
and	0	O
Jbeta12	0	B
-	0	I
RSSs	0	I
.	0	O


To	1	O
gain	0	O
insight	0	O
into	0	O
the	0	O
possible	0	O
involvement	0	O
of	0	O
p21	0	B
in	0	O
liver	0	O
cell	0	O
growth	0	O
,	0	O
the	0	O
expression	0	O
and	0	O
regulation	0	O
of	0	O
the	0	O
p21	0	B
gene	0	I
was	0	O
evaluated	0	O
in	0	O
rodent	0	O
models	0	O
of	0	O
liver	0	O
regeneration	0	O
and	0	O
specimens	0	O
of	0	O
human	0	O
liver	0	O
diseases	0	O
.	0	O


Radiosensitive	1	O
nature	0	O
of	0	O
paravascular	0	O
infiltrate	0	O
-	0	O
producing	0	O
potential	0	O
of	0	O
parental	0	O
spleen	0	O
cells	0	O
.	0	O


Midge	1	O
control	0	O
in	0	O
flood	0	O
channels	0	O
.	0	O


Patients	0	O
with	0	O
detectable	0	O
serum	0	O
TNF	1	B
levels	0	O
had	0	O
significantly	0	O
lower	0	O
serum	0	O
T3	1	O
concentrations	0	O
compared	0	O
to	0	O
those	0	O
with	0	O
undetectable	0	O
levels	0	O
[	0	O
1	0	O
.	0	O
072	0	O
+/-	0	O
0	0	O
.	0	O
588	0	O
vs	0	O
.	0	O


Further	0	O
studies	0	O
in	0	O
T	1	O
-	0	O
24	0	O
cells	0	O
demonstrated	0	O
that	0	O
HA	1	O
fragments	0	O
also	0	O
induced	0	O
I	1	B
kappa	0	I
B	1	I
alpha	0	I
phosphorylation	0	O
and	0	O
degradation	0	O
,	0	O
kappa	0	B
B	1	I
-	0	I
linked	0	I
reporter	0	I
gene	0	I
expression	0	O
,	0	O
and	0	O
ICAM	1	B
-	0	I
1	0	I
promoter	0	I
activity	0	O
in	0	O
an	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
-	0	O
dependent	0	O
manner	0	O
.	0	O


M	1	B
-	0	I
Ras	1	I
interacted	0	O
poorly	0	O
in	0	O
a	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
assay	0	O
with	0	O
multiple	0	O
Ras	1	B
effectors	0	O
,	0	O
including	0	O
c	0	B
-	0	I
Raf	0	I
-	0	I
1	0	I
,	0	O
A	1	B
-	0	I
Raf	0	I
,	0	O
B	1	B
-	0	I
Raf	0	I
,	0	O
phosphoinositol	0	B
-	0	I
3	0	I
kinase	0	I
delta	0	I
,	0	O
RalGDS	0	B
,	0	O
and	0	O
Rin1	0	B
.	0	O


Besides	0	O
the	0	O
characterization	0	O
and	0	O
discussion	0	O
of	0	O
the	0	O
experimental	0	O
setup	0	O
used	0	O
,	0	O
the	0	O
rate	0	O
constants	0	O
obtained	0	O
are	0	O
discussed	0	O
and	0	O
compared	0	O
with	0	O
estimated	0	O
values	0	O
.	0	O


Measurement	0	O
of	0	O
magnesium	0	O
absorption	0	O
in	0	O
man	0	O
using	0	O
stable	0	O
26Mg	0	O
as	0	O
a	0	O
tracer	0	O
.	0	O


A	1	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
RA	1	O
-	0	O
mediated	0	O
repression	0	O
of	0	O
the	0	O
hMGP	0	B
gene	0	I
is	0	O
due	0	O
to	0	O
binding	0	O
of	0	O
liganded	0	O
RAR	0	B
/	0	O
RXR	0	B
to	0	O
a	0	O
novel	0	O
negative	0	O
RA	1	O
response	0	O
element	0	O
.	0	O


There	0	O
were	0	O
18	0	O
patients	0	O
with	0	O
Group	1	O
II	0	O
(	0	O
a	0	O
)	0	O
tumors	0	O
;	0	O
although	0	O
tumor	0	O
biopsy	0	O
was	0	O
attempted	0	O
on	0	O
eight	0	O
of	0	O
these	0	O
,	0	O
pathological	0	O
diagnosis	0	O
at	0	O
the	0	O
time	0	O
of	0	O
surgery	0	O
was	0	O
made	0	O
in	0	O
only	0	O
one	0	O
case	0	O
.	0	O


In	1	O
general	0	O
,	0	O
the	0	O
values	0	O
obtained	0	O
by	0	O
the	0	O
two	0	O
methods	0	O
were	0	O
in	0	O
agreement	0	O
for	0	O
each	0	O
species	0	O
of	0	O
epidermal	0	B
growth	0	I
factor	0	I
and	0	O
followed	0	O
the	0	O
order	0	O
:	0	O
wild	0	O
type	0	O
greater	0	O
than	0	O
Glu24	0	O
----	0	O
Gly	1	O
greater	0	O
than	0	O
Asp27	0	O
----	0	O
Gly	1	O
much	0	O
greater	0	O
than	0	O
Pro7	0	O
----	0	O
Thr	1	O
greater	0	O
than	0	O
Tyr29	0	O
----	0	O
Gly	1	O
greater	0	O
than	0	O
Leu47	0	O
----	0	O
His	1	O
.	0	O


Additionally	0	O
,	0	O
the	0	O
mouse	0	O
promoter	0	O
contains	0	O
22	0	O
copies	0	O
of	0	O
a	0	O
CT	1	O
dinucleotide	0	O
repeat	0	O
sequence	0	O
located	0	O
approximately	0	O
155	0	O
bp	0	O
5	0	O
'	0	O
to	0	O
exon	0	O
1	0	O
.	0	O


Competition	1	O
analysis	0	O
by	0	O
gel	0	O
mobility	0	O
shift	0	O
electrophoresis	0	O
indicates	0	O
that	0	O
this	0	O
DNA	1	O
-	0	O
protein	0	O
interaction	0	O
is	0	O
novel	0	O
and	0	O
not	0	O
related	0	O
to	0	O
many	0	O
transcription	0	O
factors	0	O
previously	0	O
reported	0	O
.	0	O


Here	0	O
we	0	O
characterize	0	O
an	0	O
S	1	B
.	0	I
cerevisiae	0	I
Swi3	0	I
homolog	0	I
(	0	O
Swh3	0	B
)	0	O
and	0	O
present	0	O
evidence	0	O
that	0	O
it	0	O
associates	0	O
in	0	O
a	0	O
complex	0	O
with	0	O
a	0	O
Snf2	0	B
homolog	0	I
,	0	O
Sthl	0	B
.	0	O


Elevated	0	O
IOP	1	O
developed	0	O
in	0	O
35	0	O
patients	0	O
(	0	O
44	0	O
eyes	0	O
)	0	O
during	0	O
the	0	O
study	0	O
.	0	O


In	1	O
a	0	O
third	0	O
experiment	0	O
,	0	O
crossover	0	O
AM	1	O
between	0	O
dissimilar	0	O
textures	0	O
was	0	O
investigated	0	O
,	0	O
and	0	O
it	0	O
was	0	O
found	0	O
that	0	O
the	0	O
more	0	O
salient	0	O
textures	0	O
carried	0	O
the	0	O
AM	1	O
.	0	O


Phosphorylation	1	O
of	0	O
tyrosine	0	O
residues	0	O
in	0	O
the	0	O
kinase	0	O
domain	0	O
and	0	O
juxtamembrane	0	O
region	0	O
regulates	0	O
the	0	O
biological	0	O
and	0	O
catalytic	0	O
activities	0	O
of	0	O
Eph	0	B
receptors	0	I
.	0	O


Similarly	0	O
approximately	0	O
300	0	O
bp	0	O
of	0	O
sequence	0	O
downstream	0	O
of	0	O
the	0	O
translation	0	O
terminator	0	O
TGA	0	O
of	0	O
the	0	O
beta	0	B
-	0	I
tubulin	0	I
2	0	I
(	0	O
BTU2	0	B
)	0	O
gene	0	O
could	0	O
substitute	0	O
for	0	O
the	0	O
3	0	O
'	0	O
region	0	O
of	0	O
the	0	O
H4	0	B
-	0	I
I	1	I
gene	0	I
.	0	O


A	1	O
rapid	0	O
staining	0	O
technique	0	O
for	0	O
Leishmania	1	O
parasites	0	O
in	0	O
splenic	0	O
aspirate	0	O
smears	0	O
.	0	O


In	1	O
NASCIS	0	O
III	0	O
,	0	O
a	0	O
randomization	0	O
imbalance	0	O
occurred	0	O
that	0	O
allocated	0	O
a	0	O
disproportionate	0	O
number	0	O
of	0	O
patients	0	O
with	0	O
no	0	O
motor	0	O
deficit	0	O
(	0	O
and	0	O
therefore	0	O
no	0	O
chance	0	O
for	0	O
recovery	0	O
)	0	O
to	0	O
the	0	O
lower	0	O
dose	0	O
control	0	O
group	0	O
.	0	O


A	1	O
5	0	O
'	0	O
RNA	1	O
stem	0	O
-	0	O
loop	0	O
participates	0	O
in	0	O
the	0	O
transcription	0	O
attenuation	0	O
mechanism	0	O
that	0	O
controls	0	O
expression	0	O
of	0	O
the	0	O
Bacillus	1	B
subtilis	0	I
trpEDCFBA	0	I
operon	0	I
.	0	O


The	0	O
availability	0	O
of	0	O
sequence	0	O
from	0	O
multiple	0	O
species	0	O
has	0	O
permitted	0	O
us	0	O
to	0	O
determine	0	O
that	0	O
the	0	O
UBE	0	O
site	0	O
has	0	O
close	0	O
similarity	0	O
to	0	O
motifs	0	O
that	0	O
bind	0	O
members	0	O
of	0	O
the	0	O
NF	1	B
-	0	I
1	0	I
family	0	I
of	0	I
transcription	0	I
factors	0	I
.	0	O


The	0	O
corresponding	0	O
differences	0	O
in	0	O
FVIIa	0	B
and	0	O
PAI	1	B
-	0	I
1	0	I
were	0	O
not	0	O
statistically	0	O
significant	0	O
.	0	O


Terminal	1	B
deoxynucleotidyl	0	I
transferase	0	I
-	0	O
mediated	0	O
nick	0	O
end	0	O
labeling	0	O
assays	0	O
revealed	0	O
that	0	O
hormonal	0	O
activation	0	O
of	0	O
the	0	O
PAX3	0	B
repressors	0	I
induced	0	O
extensive	0	O
apoptosis	0	O
that	0	O
correlated	0	O
with	0	O
down	0	O
-	0	O
regulation	0	O
of	0	O
BCL	0	B
-	0	I
X	1	I
(	0	I
L	1	I
)	0	I
expression	0	O
.	0	O


The	0	O
gene	0	O
sequence	0	O
also	0	O
identified	0	O
a	0	O
340	0	O
-	0	O
nucleotide	0	O
RNA	1	O
in	0	O
total	0	O
yeast	0	O
RNA	1	O
and	0	O
in	0	O
purified	0	O
RNase	1	B
MRP	0	I
enzyme	0	I
preparations	0	O
.	0	O


Comparisons	0	O
with	0	O
the	0	O
available	0	O
amino	0	O
acid	0	O
residue	0	O
(	0	O
aa	0	O
)	0	O
sequence	0	O
information	0	O
from	0	O
the	0	O
complete	0	O
CPMV	0	B
RNA	1	I
1	0	I
sequence	0	I
and	0	O
the	0	O
partial	0	O
sequence	0	O
of	0	O
red	0	B
clover	0	I
mottle	0	I
virus	0	I
RNA	1	I
1	0	I
suggest	0	O
that	0	O
CPSMV	0	B
RNA	1	I
1	0	I
specifies	0	O
the	0	O
expected	0	O
set	0	O
of	0	O
five	0	O
mature	0	O
proteins	0	O
:	0	O
32K	0	B
proteinase	0	I
cofactor	0	I
,	0	O
58K	0	B
presumed	0	I
helicase	0	I
,	0	O
VPg	0	B
5	0	I
'-	0	I
linked	0	I
protein	0	I
of	0	O
the	0	O
genomic	0	O
RNAs	0	O
,	0	O
24K	0	B
proteinase	0	I
,	0	O
and	0	O
87K	0	B
presumed	0	I
polymerase	0	I
,	0	O
separated	0	O
by	0	O
four	0	O
cleavage	0	O
sites	0	O
.	0	O


Both	0	O
carbachol	0	O
(	0	O
100	0	O
microM	0	O
)	0	O
and	0	O
EGF	1	B
(	0	O
10	0	O
nM	1	O
)	0	O
induced	0	O
Ras	1	B
activation	0	O
.	0	O


Age	1	O
>/=	0	O
50	0	O
years	0	O
(	0	O
odds	0	O
ratio	0	O
[	0	O
OR	1	O
],	0	O
14	0	O
.	0	O
1	0	O
),	0	O
BMI	1	O
>/=	0	O
28	0	O
kg	0	O
/	0	O
m	0	O
(	0	O
2	0	O
)	0	O
(	0	O
OR	1	O
,	0	O
5	0	O
.	0	O
7	0	O
),	0	O
triglycerides	0	O
>/=	0	O
1	0	O
.	0	O
7	0	O
mmol	0	O
/	0	O
L	1	O
(	0	O
OR	1	O
,	0	O
5	0	O
),	0	O
and	0	O
alanine	0	B
aminotransferase	0	I
(	0	O
ALT	1	B
)	0	O
>/=	0	O
2N	0	O
(	0	O
OR	1	O
,	0	O
4	0	O
.	0	O
6	0	O
)	0	O
were	0	O
independently	0	O
associated	0	O
with	0	O
septal	0	O
fibrosis	0	O
.	0	O


In	1	O
Rat	1	O
-	0	O
1a	0	O
cells	0	O
the	0	O
expression	0	O
of	0	O
human	0	B
c	0	I
-	0	I
jun	0	I
mRNA	1	I
was	0	O
associated	0	O
with	0	O
the	0	O
ability	0	O
to	0	O
clone	0	O
in	0	O
soft	0	O
agarose	0	O
and	0	O
form	0	O
tumors	0	O
in	0	O
nude	0	O
mice	0	O
.	0	O


There	0	O
was	0	O
however	0	O
,	0	O
no	0	O
significant	0	O
difference	0	O
in	0	O
the	0	O
prevalence	0	O
of	0	O
chronic	0	O
respiratory	0	O
symptoms	0	O
between	0	O
animal	0	O
food	0	O
workers	0	O
with	0	O
positive	0	O
and	0	O
negative	0	O
skin	0	O
tests	0	O
to	0	O
house	0	O
dust	0	O
or	0	O
to	0	O
fish	0	O
flour	0	O
or	0	O
among	0	O
those	0	O
with	0	O
increased	0	O
or	0	O
normal	0	O
IgE	1	B
(	0	O
except	0	O
for	0	O
dyspnea	0	O
).	0	O


Type	1	O
I	1	O
position	0	O
-	0	O
vestibular	0	O
-	0	O
pause	0	O
(	0	O
PVP	1	O
I	1	O
)	0	O
and	0	O
vestibular	0	O
-	0	O
only	0	O
(	0	O
V	1	O
I	1	O
)	0	O
neurons	0	O
,	0	O
as	0	O
well	0	O
as	0	O
a	0	O
smaller	0	O
number	0	O
of	0	O
other	0	O
type	0	O
I	1	O
and	0	O
type	0	O
II	0	O
eye	0	O
-	0	O
plus	0	O
-	0	O
vestibular	0	O
neurons	0	O
were	0	O
studied	0	O
.	0	O


Both	0	O
BG	1	O
and	0	O
IRI	0	B
concentrations	0	O
during	0	O
the	0	O
OGTT	1	O
were	0	O
the	0	O
lowest	0	O
in	0	O
body	0	O
builders	0	O
,	0	O
medium	0	O
in	0	O
controls	0	O
,	0	O
and	0	O
the	0	O
highest	0	O
in	0	O
obese	0	O
men	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
these	0	O
sequences	0	O
located	0	O
immediately	0	O
3	0	O
'	0	O
to	0	O
the	0	O
breakpoint	0	O
of	0	O
the	0	O
HPFH	0	B
-	0	I
3	0	I
deletion	0	I
,	0	O
exhibit	0	O
both	0	O
the	0	O
structure	0	O
and	0	O
the	0	O
function	0	O
of	0	O
an	0	O
enhancer	0	O
,	0	O
and	0	O
can	0	O
modify	0	O
the	0	O
developmental	0	O
specificity	0	O
of	0	O
the	0	O
fetal	0	B
gamma	0	I
-	0	I
globin	0	I
genes	0	I
,	0	O
resulting	0	O
in	0	O
their	0	O
continued	0	O
expression	0	O
during	0	O
adult	0	O
life	0	O
.	0	O


Mutation	1	O
of	0	O
the	0	O
Sp1	0	B
element	0	I
,	0	O
which	0	O
abolishes	0	O
Sp1	0	B
binding	0	O
,	0	O
results	0	O
in	0	O
a	0	O
6	0	O
-	0	O
10	0	O
-	0	O
fold	0	O
reduction	0	O
in	0	O
reporter	0	O
activity	0	O
.	0	O


The	0	O
high	0	O
selectivity	0	O
of	0	O
arrestins	0	B
for	0	O
this	0	O
particular	0	O
functional	0	O
form	0	O
of	0	O
receptor	0	O
ensures	0	O
their	0	O
timely	0	O
binding	0	O
and	0	O
dissociation	0	O
.	0	O


Immunohistochemically	0	O
,	0	O
anticytokeratin	0	B
19	0	I
antibody	0	I
revealed	0	O
strong	0	O
staining	0	O
in	0	O
both	0	O
epithelial	0	O
and	0	O
sarcomatous	0	O
MPM	1	O
tissues	0	O
.	0	O


Use	0	O
of	0	O
free	0	O
-	0	O
access	0	O
minerals	0	O
.	0	O


The	0	O
Saccharomyces	1	B
cerevisiae	0	I
GAL1	0	I
and	0	O
GAL10	0	B
genes	0	I
are	0	O
controlled	0	O
in	0	O
response	0	O
to	0	O
the	0	O
availability	0	O
of	0	O
galactose	0	O
and	0	O
glucose	0	O
by	0	O
multiple	0	O
activating	0	O
and	0	O
repressing	0	O
proteins	0	O
bound	0	O
at	0	O
adjacent	0	O
or	0	O
overlapping	0	O
sites	0	O
in	0	O
UASG	0	O
.	0	O


Only	0	O
one	0	O
of	0	O
these	0	O
bands	0	O
was	0	O
supershifted	0	O
by	0	O
antibody	0	O
to	0	O
p50	0	B
,	0	O
whereas	0	O
antibodies	0	O
to	0	O
p65	0	B
or	0	O
other	0	O
NF	1	B
-	0	I
kappaB	0	I
proteins	0	I
had	0	O
no	0	O
effect	0	O
.	0	O


The	0	O
evidence	0	O
presented	0	O
here	0	O
suggests	0	O
that	0	O
the	0	O
p40	0	B
complex	0	I
is	0	O
a	0	O
ribonucleoprotein	0	O
complex	0	O
containing	0	O
L1Hs	0	B
RNA	1	I
(	0	I
s	0	I
)	0	I
and	0	O
that	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
in	0	O
which	0	O
alpha	0	O
-	0	O
helix	0	O
structures	0	O
participate	0	O
,	0	O
for	0	O
example	0	O
coiled	0	O
-	0	O
coils	0	O
,	0	O
may	0	O
occur	0	O
in	0	O
the	0	O
complex	0	O
.	0	O


San	0	O
Martin	0	O
'	0	O
s	0	O
psychological	0	O
traits	0	O
coupled	0	O
to	0	O
his	0	O
work	0	O
with	0	O
masonic	0	O
lodges	0	O
that	0	O
allowed	0	O
him	0	O
to	0	O
display	0	O
his	0	O
abilities	0	O
as	0	O
strategist	0	O
and	0	O
political	0	O
ruler	0	O
.	0	O


The	0	O
number	0	O
of	0	O
polymerases	0	O
active	0	O
in	0	O
vitro	0	O
at	0	O
the	0	O
E	1	O
strand	0	O
promoter	0	O
was	0	O
similar	0	O
to	0	O
the	0	O
number	0	O
of	0	O
polymerases	0	O
at	0	O
the	0	O
L	1	O
strand	0	O
promoter	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Local	1	O
control	0	O
was	0	O
highest	0	O
with	0	O
Preop	0	O
in	0	O
patients	0	O
presenting	0	O
primarily	0	O
with	0	O
gross	0	O
disease	0	O
,	0	O
and	0	O
with	0	O
Postop	0	O
in	0	O
patients	0	O
presenting	0	O
primarily	0	O
following	0	O
gross	0	O
total	0	O
excision	0	O
.	0	O


The	0	O
ability	0	O
of	0	O
sodium	0	O
phenobarbital	0	O
(	0	O
60	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
and	0	O
sodium	0	O
barbital	0	O
(	0	O
80	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
to	0	O
produce	0	O
a	0	O
taste	0	O
aversion	0	O
in	0	O
23	0	O
hr	0	O
fluid	0	O
deprived	0	O
rats	0	O
was	0	O
examined	0	O
using	0	O
a	0	O
discrimination	0	O
or	0	O
two	0	O
bottle	0	O
taste	0	O
aversion	0	O
task	0	O
(	0	O
0	0	O
.	0	O
125	0	O
%	0	O
sodium	0	O
saccharin	0	O
solution	0	O
or	0	O
water	0	O
).	0	O


A	1	O
cDNA	1	O
cloning	0	O
vector	0	O
that	0	O
permits	0	O
expression	0	O
of	0	O
cDNA	1	O
inserts	0	O
in	0	O
mammalian	0	O
cells	0	O
.	0	O


This	0	O
approach	0	O
places	0	O
gHoxb	0	B
-	0	I
1	0	I
into	0	O
the	0	O
normal	0	O
embryonic	0	O
spatiotemporal	0	O
context	0	O
in	0	O
which	0	O
lab	0	O
acts	0	O
.	0	O


SUMMARY	0	O
OF	0	O
REVIEW	0	O
:	0	O
We	0	O
discuss	0	O
the	0	O
criteria	0	O
that	0	O
make	0	O
such	0	O
studies	0	O
comparable	0	O
,	0	O
drawing	0	O
on	0	O
the	0	O
experiences	0	O
of	0	O
recent	0	O
studies	0	O
performed	0	O
around	0	O
the	0	O
world	0	O
.	0	O


2	0	O
.	0	O


Pao2	1	O
increased	0	O
from	0	O
15	0	O
.	0	O
5	0	O
+/-	0	O
5	0	O
.	0	O
6	0	O
kPa	0	O
(	0	O
116	0	O
+/-	0	O
42	0	O
mm	0	O
Hg	1	O
)	0	O
to	0	O
17	0	O
.	0	O
3	0	O
+/-	0	O
6	0	O
.	0	O
3	0	O
kPa	0	O
(	0	O
130	0	O
+/-	0	O
47	0	O
mm	0	O
Hg	1	O
)	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


The	0	O
Lp	1	B
mouse	0	I
mutant	0	I
provides	0	O
a	0	O
model	0	O
for	0	O
the	0	O
severe	0	O
human	0	O
neural	0	O
tube	0	O
defect	0	O
(	0	O
NTD	1	O
),	0	O
cranio	0	O
-	0	O
rachischisis	0	O
.	0	O


Ligand	1	O
-	0	O
independent	0	O
activation	0	O
of	0	O
platelet	0	B
-	0	I
derived	0	I
growth	0	I
factor	0	I
receptor	0	I
is	0	O
a	0	O
necessary	0	O
intermediate	0	O
in	0	O
lysophosphatidic	0	O
,	0	O
acid	0	O
-	0	O
stimulated	0	O
mitogenic	0	O
activity	0	O
in	0	O
L	1	O
cells	0	O
.	0	O


Genetic	1	O
and	0	O
molecular	0	O
complexity	0	O
of	0	O
the	0	O
position	0	O
effect	0	O
variegation	0	O
modifier	0	O
mod	0	B
(	0	O
mdg4	0	B
)	0	O
in	0	O
Drosophila	1	O
.	0	O
mod	0	B
(	0	O
mdg4	0	B
),	0	O
also	0	O
known	0	O
as	0	O
E	1	B
(	0	I
var	0	I
)	0	I
3	0	I
-	0	I
93D	0	I
,	0	O
is	0	O
involved	0	O
in	0	O
a	0	O
variety	0	O
of	0	O
processes	0	O
,	0	O
such	0	O
as	0	O
gene	0	O
silencing	0	O
in	0	O
position	0	O
effect	0	O
variegation	0	O
(	0	O
PEV	0	O
),	0	O
the	0	O
control	0	O
of	0	O
gypsy	0	B
insulator	0	I
sequences	0	I
,	0	O
regulation	0	O
of	0	O
homeotic	0	B
gene	0	I
expression	0	O
,	0	O
and	0	O
programmed	0	O
cell	0	O
death	0	O
.	0	O


Vesicles	0	O
could	0	O
be	0	O
induced	0	O
only	0	O
with	0	O
multiple	0	O
exposures	0	O
to	0	O
UVA	1	O
.	0	O


Defective	1	O
provirus	0	O
genomes	0	O
of	0	O
human	0	O
T	1	O
-	0	O
cell	0	O
leukemia	0	O
virus	0	O
type	0	O
I	1	O
are	0	O
frequently	0	O
detected	0	O
in	0	O
lymphocytes	0	O
from	0	O
infected	0	O
individuals	0	O
and	0	O
in	0	O
infected	0	O
cell	0	O
lines	0	O
.	0	O


The	0	O
bactericidal	0	O
effect	0	O
of	0	O
disinfectants	0	O
against	0	O
biofilm	0	O
cells	0	O
was	0	O
found	0	O
to	0	O
be	0	O
considerably	0	O
enhanced	0	O
by	0	O
increasing	0	O
the	0	O
concentrations	0	O
of	0	O
the	0	O
disinfectants	0	O
.	0	O


A	1	O
1	0	O
.	0	O
5	0	O
-	0	O
kb	0	O
HindIII	0	B
genomic	0	O
fragment	0	O
carrying	0	O
the	0	O
vspA	0	B
gene	0	O
from	0	O
M	1	O
.	0	O
bovis	0	O
PG45	0	O
was	0	O
cloned	0	O
and	0	O
sequenced	0	O
.	0	O


Citrate	1	B
synthase	0	I
activity	0	O
was	0	O
increased	0	O
in	0	O
the	0	O
medial	0	O
head	0	O
(	0	O
81	0	O
%,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
and	0	O
the	0	O
red	0	O
long	0	O
head	0	O
(	0	O
88	0	O
%,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
of	0	O
the	0	O
triceps	0	O
brachii	0	O
muscle	0	O
in	0	O
R	1	O
rats	0	O
but	0	O
not	0	O
in	0	O
the	0	O
white	0	O
long	0	O
head	0	O
(	0	O
25	0	O
%,	0	O
P	1	O
=	0	O
0	0	O
.	0	O
06	0	O
).	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
negative	0	O
inotropic	0	O
action	0	O
of	0	O
nicorandil	0	O
is	0	O
caused	0	O
by	0	O
inhibition	0	O
of	0	O
Ca	1	O
influx	0	O
and	0	O
intracellular	0	O
mobilization	0	O
of	0	O
Ca	1	O
.	0	O


Auditory	1	O
threshold	0	O
shifts	0	O
,	0	O
as	0	O
measured	0	O
by	0	O
the	0	O
auditory	0	O
evoked	0	O
brainstem	0	O
response	0	O
,	0	O
were	0	O
measured	0	O
at	0	O
2	0	O
,	0	O
4	0	O
,	0	O
8	0	O
,	0	O
12	0	O
,	0	O
16	0	O
,	0	O
20	0	O
and	0	O
24	0	O
kHz	1	O
.	0	O


A	1	O
further	0	O
mechanism	0	O
increasing	0	O
specific	0	O
activation	0	O
was	0	O
cooperation	0	O
of	0	O
receptors	0	O
at	0	O
multiple	0	O
and	0	O
weak	0	O
HREs	0	O
,	0	O
which	0	O
was	0	O
accentuated	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
both	0	O
the	0	O
AR	1	B
N	1	O
terminus	0	O
and	0	O
ligand	0	O
binding	0	O
domain	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
PCE	1	B
binds	0	O
a	0	O
Pbx	0	B
dimer	0	I
partner	0	I
that	0	O
behaves	0	O
unlike	0	O
Class	1	B
I	1	I
Hox	0	I
proteins	0	I
.	0	O


This	0	O
observation	0	O
suggests	0	O
that	0	O
the	0	O
methyl	0	O
-	0	O
directed	0	O
repair	0	O
system	0	O
utilizes	0	O
the	0	O
proximal	0	O
d	0	O
(	0	O
GATC	0	O
)	0	O
sequence	0	O
to	0	O
direct	0	O
correction	0	O
.	0	O


When	0	O
cotransfected	0	O
in	0	O
fibroblasts	0	O
with	0	O
a	0	O
C	1	B
/	0	I
EBP	1	I
alpha	0	I
expression	0	O
vector	0	O
,	0	O
reporter	0	O
gene	0	O
expression	0	O
increased	0	O
3	0	O
-	0	O
fold	0	O
only	0	O
in	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
constructs	0	O
.	0	O


Constructs	0	O
designed	0	O
and	0	O
expressed	0	O
were	0	O
E2L1	0	O
(	0	O
1	0	O
-	0	O
98	0	O
),	0	O
E2L1	0	O
.	0	O
H1	1	O
(	0	O
1	0	O
-	0	O
128	0	O
),	0	O
E2L2	0	O
(	0	O
120	0	O
-	0	O
233	0	O
),	0	O
E2H1	0	O
.	0	O
L2	0	O
(	0	O
98	0	O
-	0	O
233	0	O
),	0	O
and	0	O
E2L1	0	O
.	0	O
H1	1	O
.	0	O
L2	0	O
(	0	O
1	0	O
-	0	O
233	0	O
),	0	O
where	0	O
numbers	0	O
in	0	O
parentheses	0	O
give	0	O
the	0	O
amino	0	O
acid	0	O
sequence	0	O
for	0	O
the	0	O
portions	0	O
of	0	O
the	0	O
E2	1	B
component	0	O
incorporated	0	O
into	0	O
a	0	O
construct	0	O
.	0	O


Employing	0	O
this	0	O
sequence	0	O
information	0	O
from	0	O
c11	0	O
/	0	O
1	0	O
,	0	O
the	0	O
c11	0	O
/	0	O
1	0	O
-	0	O
specific	0	O
cDNA	1	O
was	0	O
generated	0	O
from	0	O
poly	0	O
(	0	O
A	1	O
)+	0	O
RNA	1	O
of	0	O
bovine	0	O
PMNLs	0	O
by	0	O
reverse	0	O
transcription	0	O
and	0	O
a	0	O
combination	0	O
of	0	O
polymerase	0	O
chain	0	O
reaction	0	O
(	0	O
PCR	1	O
)	0	O
methods	0	O
.	0	O


A	1	O
partial	0	O
cDNA	1	O
sequence	0	O
indicated	0	O
that	0	O
the	0	O
T	1	B
lymphocyte	0	I
early	0	I
-	0	I
activation	0	I
gene	0	I
(	0	O
Tea	1	B
)	0	O
encodes	0	O
a	0	O
protein	0	O
related	0	O
to	0	O
the	0	O
dual	0	O
-	0	O
function	0	O
ecotropic	0	B
retrovirus	0	I
receptor	0	I
/	0	O
cationic	0	B
amino	0	I
acid	0	I
transporter	0	I
(	0	O
ecoR	0	B
/	0	O
CAT1	0	B
),	0	O
and	0	O
RNA	1	O
blots	0	O
suggested	0	O
highest	0	O
Tea	1	B
expression	0	O
in	0	O
T	1	O
lymphocytes	0	O
and	0	O
liver	0	O
(	0	O
MacLeod	0	O
,	0	O
C	1	O
.	0	O
L	1	O
.,	0	O
Finley	0	O
,	0	O
K	1	O
.,	0	O
Kakuda	0	O
,	0	O
D	1	O
.	0	O


This	0	O
region	0	O
contains	0	O
a	0	O
motif	0	O
with	0	O
partial	0	O
identity	0	O
with	0	O
the	0	O
binding	0	O
site	0	O
for	0	O
the	0	O
ubiquitous	0	O
transcription	0	O
factor	0	O
upstream	0	B
stimulatory	0	I
factor	0	I
(	0	O
USF	0	B
),	0	O
which	0	O
binds	0	O
to	0	O
the	0	O
human	0	B
insulin	0	I
promoter	0	I
.	0	O


Uracil	1	B
DNA	1	I
glycosylase	0	I
catalyzes	0	O
the	0	O
initial	0	O
step	0	O
in	0	O
the	0	O
repair	0	O
pathway	0	O
that	0	O
removes	0	O
potentially	0	O
mutagenic	0	O
uracil	0	O
from	0	O
duplex	0	O
DNA	1	O
.	0	O


Epitopes	0	O
of	0	O
adhesion	0	O
-	0	O
perturbing	0	O
monoclonal	0	O
antibodies	0	O
map	0	O
within	0	O
a	0	O
predicted	0	O
alpha	0	O
-	0	O
helical	0	O
domain	0	O
of	0	O
the	0	O
integrin	0	B
beta	0	I
1	0	I
subunit	0	I
.	0	O


Whether	0	O
or	0	O
not	0	O
there	0	O
are	0	O
sequences	0	O
conferring	0	O
cAMP	1	O
responsiveness	0	O
which	0	O
are	0	O
common	0	O
both	0	O
to	0	O
P	1	B
-	0	I
450scc	0	I
and	0	O
the	0	O
other	0	O
steroidogenic	0	O
P	1	B
-	0	I
450	0	I
genes	0	I
remains	0	O
to	0	O
be	0	O
established	0	O
.	0	O


Serine	1	O
528	0	O
is	0	O
phosphorylated	0	O
in	0	O
vivo	0	O
in	0	O
several	0	O
cell	0	O
lines	0	O
,	0	O
and	0	O
substitution	0	O
of	0	O
serine	0	O
528	0	O
to	0	O
alanine	0	O
(	0	O
S528A	0	O
)	0	O
resulted	0	O
in	0	O
an	0	O
increased	0	O
ability	0	O
of	0	O
Myb	0	B
to	0	O
transactivate	0	O
a	0	O
synthetic	0	O
promoter	0	O
containing	0	O
five	0	O
copies	0	O
of	0	O
the	0	O
mim	0	B
-	0	I
1A	0	I
Myb	0	I
-	0	O
responsive	0	O
element	0	O
and	0	O
a	0	O
minimal	0	O
herpes	0	B
tk	0	I
promoter	0	I
.	0	O


Following	1	O
extended	0	O
recovery	0	O
hippocampal	0	O
EEG	1	O
was	0	O
normal	0	O
despite	0	O
extensive	0	O
cellular	0	O
loss	0	O
in	0	O
areas	0	O
CA3	0	O
and	0	O
CA4	0	O
.	0	O


The	0	O
study	0	O
suggests	0	O
the	0	O
presence	0	O
of	0	O
an	0	O
anatomical	0	O
sphincter	0	O
at	0	O
the	0	O
RSJ	0	O
which	0	O
seems	0	O
to	0	O
regulate	0	O
the	0	O
passage	0	O
of	0	O
stools	0	O
from	0	O
the	0	O
sigmoid	0	O
colon	0	O
to	0	O
the	0	O
rectum	0	O
.	0	O


Sequence	1	O
analysis	0	O
indicates	0	O
that	0	O
in	0	O
addition	0	O
to	0	O
an	0	O
ATA	1	O
and	0	O
GC	1	O
box	0	O
,	0	O
this	0	O
region	0	O
contains	0	O
domains	0	O
that	0	O
have	0	O
been	0	O
implicated	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
other	0	O
muscle	0	O
-	0	O
specific	0	O
genes	0	O
:	0	O
a	0	O
CArG	0	O
box	0	O
at	0	O
-	0	O
91	0	O
bp	0	O
;	0	O
myocyte	0	B
-	0	I
specific	0	I
enhancer	0	I
-	0	I
binding	0	I
nuclear	0	I
factor	0	I
1	0	I
binding	0	I
site	0	I
homologies	0	O
at	0	O
-	0	O
58	0	O
,	0	O
-	0	O
535	0	O
,	0	O
and	0	O
-	0	O
583	0	O
bp	0	O
;	0	O
and	0	O
a	0	O
muscle	0	O
-	0	O
CAAT	0	O
consensus	0	O
sequence	0	O
at	0	O
-	0	O
394	0	O
bp	0	O
relative	0	O
to	0	O
the	0	O
cap	0	O
site	0	O
.	0	O


A	1	O
second	0	O
even	0	O
more	0	O
significant	0	O
match	0	O
to	0	O
this	0	O
E	1	O
.	0	O
coli	0	O
region	0	O
was	0	O
found	0	O
in	0	O
the	0	O
retroviral	0	B
ribonuclease	0	I
H	1	I
(	0	O
RNase	1	B
H	1	I
)	0	O
domain	0	O
,	0	O
and	0	O
corresponds	0	O
precisely	0	O
to	0	O
a	0	O
region	0	O
that	0	O
has	0	O
been	0	O
aligned	0	O
by	0	O
previous	0	O
investigators	0	O
with	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
RNase	1	I
H	1	I
,	0	O
suggesting	0	O
that	0	O
Pol	0	B
I	1	I
helices	0	O
O	1	O
and	0	O
P	1	O
are	0	O
homologous	0	O
to	0	O
helices	0	O
A	1	O
and	0	O
D	1	O
of	0	O
the	0	O
RNase	1	B
H	1	I
crystal	0	O
structure	0	O
,	0	O
respectively	0	O
.	0	O


Changes	0	O
in	0	O
immunologic	0	O
reactivity	0	O
in	0	O
subjects	0	O
receiving	0	O
transfer	0	B
factor	0	I
could	0	O
not	0	O
be	0	O
distinguished	0	O
from	0	O
those	0	O
in	0	O
subjects	0	O
receiving	0	O
placebo	0	O
.	0	O


Synaptic	1	O
targeting	0	O
of	0	O
the	0	O
postsynaptic	0	B
density	0	I
protein	0	I
PSD	0	I
-	0	I
95	0	I
mediated	0	O
by	0	O
a	0	O
tyrosine	0	O
-	0	O
based	0	O
trafficking	0	O
signal	0	O
.	0	O


The	0	O
spontaneous	0	O
mutation	0	O
blocking	0	O
pca	0	B
gene	0	I
expression	0	O
was	0	O
located	0	O
in	0	O
the	0	O
promoter	0	O
for	0	O
the	0	O
pca	0	B
operon	0	I
.	0	O


Histopathologically	0	O
,	0	O
a	0	O
cystic	0	O
lymphangioma	0	O
was	0	O
diagnosed	0	O
because	0	O
of	0	O
the	0	O
morphological	0	O
features	0	O
and	0	O
the	0	O
immunohistochemical	0	O
stainings	0	O
of	0	O
CD34	1	B
and	0	O
Factor	1	B
VIII	0	I
related	0	I
antigen	0	I
which	0	O
were	0	O
observed	0	O
positive	0	O
reactions	0	O
in	0	O
endothelial	0	O
cells	0	O
of	0	O
the	0	O
cysts	0	O
.	0	O


Malignant	1	O
lymphoma	0	O
is	0	O
very	0	O
heterogeneous	0	O
in	0	O
terms	0	O
of	0	O
its	0	O
biological	0	O
behavior	0	O
.	0	O


In	1	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
,	0	O
copper	0	O
levels	0	O
exert	0	O
some	0	O
control	0	O
over	0	O
the	0	O
level	0	O
of	0	O
SOD1	0	B
expression	0	O
.	0	O


The	0	O
examination	0	O
was	0	O
focused	0	O
on	0	O
assessment	0	O
of	0	O
different	0	O
types	0	O
of	0	O
drusen	0	O
,	0	O
on	0	O
evaluation	0	O
of	0	O
the	0	O
development	0	O
and	0	O
incidence	0	O
of	0	O
risk	0	O
factors	0	O
leading	0	O
to	0	O
complications	0	O
and	0	O
loss	0	O
of	0	O
central	0	O
vision	0	O
.	0	O


The	0	O
kinase	0	O
is	0	O
essential	0	O
in	0	O
vivo	0	O
for	0	O
normal	0	O
phosphorylation	0	O
of	0	O
the	0	O
CTD	1	O
and	0	O
for	0	O
normal	0	O
growth	0	O
and	0	O
differentiation	0	O
.	0	O


With	0	O
constructs	0	O
containing	0	O
the	0	O
binding	0	O
site	0	O
of	0	O
one	0	O
gene	0	O
fused	0	O
to	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
other	0	O
,	0	O
we	0	O
demonstrated	0	O
that	0	O
the	0	O
positional	0	O
requirements	0	O
are	0	O
a	0	O
function	0	O
of	0	O
the	0	O
specific	0	O
binding	0	O
site	0	O
,	0	O
not	0	O
the	0	O
promoter	0	O
.	0	O


The	0	O
sacT	0	B
gene	0	I
regulating	0	O
the	0	O
sacPA	0	B
operon	0	I
in	0	I
Bacillus	1	I
subtilis	0	I
shares	0	O
strong	0	O
homology	0	O
with	0	O
transcriptional	0	O
antiterminators	0	O
.	0	O


The	0	O
protein	0	O
is	0	O
composed	0	O
of	0	O
a	0	O
central	0	O
alpha	0	O
-	0	O
helical	0	O
portion	0	O
with	0	O
globular	0	O
domains	0	O
at	0	O
both	0	O
NH2	0	O
and	0	O
COOH	0	O
termini	0	O
,	0	O
and	0	O
the	0	O
epitope	0	O
to	0	O
the	0	O
monoclonal	0	O
antibody	0	O
resides	0	O
in	0	O
the	0	O
central	0	O
alpha	0	O
-	0	O
helical	0	O
stalk	0	O
.	0	O


While	0	O
daily	0	O
food	0	O
intake	0	O
was	0	O
almost	0	O
constant	0	O
regardless	0	O
of	0	O
the	0	O
dietary	0	O
protein	0	O
level	0	O
,	0	O
water	0	O
intake	0	O
and	0	O
urine	0	O
volume	0	O
increased	0	O
with	0	O
increasing	0	O
the	0	O
dietary	0	O
protein	0	O
.	0	O


For	0	O
sputum	0	B
interleukin	0	I
-	0	I
8	0	I
there	0	O
was	0	O
an	0	O
estimated	0	O
true	0	O
treatment	0	O
median	0	O
difference	0	O
of	0	O
142	0	O
pg	0	O
/	0	O
ml	0	O
(	0	O
95	0	O
%	0	O
confidence	0	O
interval	0	O
(	0	O
CI	1	O
)	0	O
8	0	O
to	0	O
2866	0	O
pg	0	O
/	0	O
ml	0	O
)	0	O
in	0	O
favour	0	O
of	0	O
placebo	0	O
;	0	O
while	0	O
for	0	O
maximal	0	O
expiratory	0	O
flow	0	O
at	0	O
25	0	O
%	0	O
(	0	O
MEF25	0	O
%)	0	O
remaining	0	O
forced	0	O
vital	0	O
capacity	0	O
predicted	0	O
for	0	O
sex	0	O
and	0	O
height	0	O
there	0	O
was	0	O
a	0	O
15	0	O
percentage	0	O
points	0	O
(	0	O
pp	0	O
)	0	O
(	0	O
95	0	O
%	0	O
CI	1	O
4	0	O
to	0	O
26	0	O
pp	0	O
)	0	O
mean	0	O
treatment	0	O
difference	0	O
in	0	O
favour	0	O
of	0	O
placebo	0	O
.	0	O


Yeast	1	O
mutants	0	O
assigned	0	O
to	0	O
the	0	O
pet	0	B
complementation	0	O
group	0	O
G104	0	O
were	0	O
found	0	O
to	0	O
lack	0	O
alpha	0	B
-	0	I
ketoglutarate	0	I
dehydrogenase	0	I
activity	0	O
as	0	O
a	0	O
result	0	O
of	0	O
mutations	0	O
in	0	O
the	0	O
dihydrolipoyl	0	B
transsuccinylase	0	I
(	0	O
KE2	0	B
)	0	O
component	0	O
of	0	O
the	0	O
complex	0	O
.	0	O


The	0	O
GALT	1	O
-	0	O
primed	0	O
calves	0	O
had	0	O
increased	0	O
serum	0	O
IgG	1	B
,	0	O
lavage	0	O
IgG	1	B
and	0	O
IgA	1	B
and	0	O
increased	0	O
LNA	0	B
titers	0	O
in	0	O
both	0	O
lavage	0	O
fluids	0	O
and	0	O
serum	0	O
following	0	O
the	0	O
SC	1	O
dose	0	O
of	0	O
killed	0	O
bacteria	0	O
.	0	O


We	0	O
report	0	O
here	0	O
that	0	O
out	0	O
of	0	O
the	0	O
major	0	O
pro	0	O
-	0	O
inflammatory	0	O
cytokines	0	O
examined	0	O
,	0	O
IL	1	B
-	0	I
1alpha	0	I
,	0	O
IL	1	B
-	0	I
1beta	0	I
,	0	O
TNF	1	B
-	0	I
alpha	0	I
and	0	O
IL	1	B
-	0	I
6	0	I
,	0	O
only	0	O
IL	1	B
-	0	I
6	0	I
was	0	O
generated	0	O
and	0	O
secreted	0	O
in	0	O
PKCeta	0	B
-	0	O
expressing	0	O
cells	0	O
without	0	O
any	0	O
additional	0	O
inducer	0	O
in	0	O
serum	0	O
-	0	O
supplemented	0	O
cultures	0	O
(	0	O
10	0	O
%	0	O
FCS	0	O
).	0	O


Immediate	1	O
-	0	O
early	0	O
transcription	0	O
from	0	O
the	0	O
channel	0	O
catfish	0	O
virus	0	O
genome	0	O
:	0	O
characterization	0	O
of	0	O
two	0	O
immediate	0	B
-	0	I
early	0	I
transcripts	0	I
.	0	O


CONCLUSION	0	O
:	0	O
TNF	1	B
alpha	0	I
,	0	O
TGF	1	B
beta	0	I
,	0	O
PDGF	0	B
and	0	O
IL	1	B
-	0	I
1beta	0	I
increased	0	O
LDLr	0	B
gene	0	I
expression	0	O
by	0	O
increasing	0	O
sterol	0	O
-	0	O
independent	0	O
and	0	O
mitogenesis	0	O
-	0	O
independent	0	O
gene	0	O
transcription	0	O
.	0	O


CD3	0	B
cross	0	O
-	0	O
linking	0	O
induced	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
Sam68	0	B
in	0	O
uninfected	0	O
T	1	O
cells	0	O
.	0	O


Analysis	1	O
with	0	O
additional	0	O
anti	0	O
-	0	O
peptide	0	O
antibodies	0	O
specific	0	O
for	0	O
alpha	0	B
,	0	I
beta	0	I
,	0	I
or	0	I
gamma	0	I
PKC	0	I
indicated	0	O
that	0	O
all	0	O
three	0	O
types	0	O
of	0	O
PKC	0	B
are	0	O
expressed	0	O
in	0	O
JK	0	O
cells	0	O
;	0	O
however	0	O
,	0	O
JKPE	0	O
cells	0	O
lost	0	O
a	0	O
major	0	O
approximately	0	O
82	0	O
kDa	1	O
immunoreactive	0	O
cytosolic	0	O
protein	0	O
detectable	0	O
with	0	O
anti	0	B
-	0	I
PKC	0	I
alpha	0	I
antibody	0	I
.	0	O


Furthermore	0	O
,	0	O
the	0	O
potency	0	O
of	0	O
Dacarbacine	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
carcinoid	0	O
tumors	0	O
seems	0	O
to	0	O
be	0	O
underestimated	0	O
up	0	O
to	0	O
now	0	O
.	0	O


The	0	O
size	0	O
of	0	O
the	0	O
mutant	0	O
molecule	0	O
corresponds	0	O
to	0	O
the	0	O
unprocessed	0	O
cytoplasmic	0	O
precursor	0	O
(	0	O
pre	0	B
-	0	I
super	0	I
-	0	I
pro	0	I
-	0	I
PrB	0	I
),	0	O
as	0	O
detected	0	O
in	0	O
sec61	0	B
mutants	0	I
,	0	O
when	0	O
translocation	0	O
into	0	O
the	0	O
endoplasmic	0	O
reticulum	0	O
is	0	O
blocked	0	O
.	0	O


The	0	O
RNA	1	O
aptamer	0	O
contains	0	O
three	0	O
stems	0	O
separated	0	O
by	0	O
a	0	O
pair	0	O
of	0	O
two	0	O
-	0	O
base	0	O
bulges	0	O
,	0	O
and	0	O
adopts	0	O
an	0	O
unanticipated	0	O
fold	0	O
in	0	O
which	0	O
both	0	O
junctional	0	O
sites	0	O
are	0	O
anchored	0	O
through	0	O
base	0	O
triple	0	O
formation	0	O
.	0	O


LH	1	B
/	0	I
CG	1	I
receptor	0	I
activation	0	O
of	0	O
ARNO	0	B
is	0	O
not	0	O
mediated	0	O
by	0	O
activation	0	O
of	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
(	0	O
PI	1	B
3	0	I
-	0	I
kinase	0	I
)	0	O
or	0	O
by	0	O
G	1	B
protein	0	I
beta	0	I
gamma	0	I
subunits	0	I
.	0	O


This	0	O
intracellular	0	O
signaling	0	O
,	0	O
known	0	O
as	0	O
the	0	O
unfolded	0	O
protein	0	O
response	0	O
(	0	O
UPR	0	O
),	0	O
is	0	O
mediated	0	O
by	0	O
the	0	O
cis	0	O
-	0	O
acting	0	O
ER	1	O
stress	0	O
response	0	O
element	0	O
(	0	O
ERSE	0	O
)	0	O
in	0	O
mammals	0	O
.	0	O


Furthermore	0	O
,	0	O
addition	0	O
of	0	O
B	1	B
-	0	I
Myb	0	I
-	0	O
glutathionine	0	B
S	1	I
-	0	I
transferase	0	I
fusion	0	O
protein	0	O
inhibited	0	O
complex	0	O
formation	0	O
.	0	O


This	0	O
interaction	0	O
involved	0	O
the	0	O
SH3	0	B
region	0	I
of	0	O
p50	0	B
(	0	O
csk	0	B
)	0	O
and	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
region	0	O
(	0	O
PPPLPERTPESFVLADM	0	O
)	0	O
outside	0	O
the	0	O
catalytic	0	O
region	0	O
of	0	O
PTP	0	B
-	0	O
PEST	1	O
.	0	O


Low	0	O
molecular	0	O
weight	0	O
heparins	0	O
have	0	O
stimulated	0	O
much	0	O
interest	0	O
because	0	O
of	0	O
their	0	O
supposedly	0	O
more	0	O
selective	0	O
action	0	O
on	0	O
Xa	0	B
factor	0	I
.	0	O


Egd1p	0	B
is	0	O
homologous	0	O
to	0	O
human	0	B
BTF3b	0	I
,	0	O
recently	0	O
identified	0	O
as	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
the	0	O
heterodimeric	0	B
nascent	0	I
-	0	I
polypeptide	0	I
-	0	I
associated	0	I
complex	0	I
(	0	O
NAC	0	B
)	0	O
involved	0	O
in	0	O
ensuring	0	O
signal	0	O
-	0	O
sequence	0	O
-	0	O
specific	0	O
protein	0	O
sorting	0	O
and	0	O
translocation	0	O
[	0	O
Wiedmann	0	O
et	0	O
al	0	O
.,	0	O
Nature	0	O
370	0	O
(	0	O
1994	0	O
)	0	O
434	0	O
-	0	O
440	0	O
].	0	O


Motile	1	O
nocardoid	0	O
Actinomycetales	1	O
.	0	O


The	0	O
scores	0	O
are	0	O
dependent	0	O
in	0	O
part	0	O
on	0	O
the	0	O
reliability	0	O
of	0	O
faculty	0	O
evaluations	0	O
.	0	O


Formalin	1	O
activated	0	O
both	0	O
SNO	0	O
NS	1	O
and	0	O
NnS	0	O
neurones	0	O
,	0	O
but	0	O
,	0	O
when	0	O
they	0	O
responded	0	O
,	0	O
NS	1	O
neurones	0	O
(	0	O
n	0	O
=	0	O
5	0	O
)	0	O
showed	0	O
only	0	O
the	0	O
first	0	O
phase	0	O
of	0	O
activity	0	O
while	0	O
NnS	0	O
neurones	0	O
showed	0	O
either	0	O
one	0	O
(	0	O
n	0	O
=	0	O
13	0	O
)	0	O
or	0	O
two	0	O
phases	0	O
(	0	O
n	0	O
=	0	O
6	0	O
).	0	O


There	0	O
was	0	O
no	0	O
competition	0	O
between	0	O
activin	0	B
A	1	I
and	0	O
OP	1	B
-	0	I
1	0	I
for	0	O
availability	0	O
of	0	O
Smad4	0	B
,	0	O
indicating	0	O
that	0	O
the	0	O
concentration	0	O
of	0	O
this	0	O
common	0	O
signal	0	O
transducer	0	O
is	0	O
not	0	O
limiting	0	O
for	0	O
generating	0	O
the	0	O
observed	0	O
biological	0	O
responses	0	O
.	0	O


FASEB	0	O
Federal	0	O
Funding	0	O
Consensus	1	O
Conference	0	O
FY	0	O
2000	0	O
.	0	O


Calcitonin	1	B
simultaneously	0	O
regulates	0	O
both	0	O
periosteal	0	O
hyperostosis	0	O
and	0	O
trabecular	0	O
osteopenia	0	O
in	0	O
the	0	O
spinal	0	O
hyperostotic	0	O
mouse	0	O
(	0	O
twy	0	B
/	0	O
twy	0	B
)	0	O
in	0	O
vivo	0	O
.	0	O


Drug	1	O
inhibition	0	O
of	0	O
whole	0	O
blood	0	O
aspirin	0	B
esterase	0	I
.	0	O


Cattaneo	0	O
,	0	O
and	0	O
J	1	O
.	0	O


In	1	O
the	0	O
region	0	O
Walgau	0	O
with	0	O
mixed	0	O
industrial	0	O
-	0	O
rural	0	O
population	0	O
an	0	O
iodine	0	O
deficiency	0	O
I	1	O
was	0	O
found	0	O
in	0	O
81	0	O
%	0	O
and	0	O
an	0	O
iodine	0	O
deficiency	0	O
II	0	O
in	0	O
45	0	O
%.	0	O


The	0	O
growing	0	O
drug	0	O
problem	0	O
is	0	O
also	0	O
reflected	0	O
in	0	O
the	0	O
increasing	0	O
number	0	O
of	0	O
cases	0	O
of	0	O
hepatitis	0	O
B	1	O
and	0	O
of	0	O
drug	0	O
-	0	O
related	0	O
deaths	0	O
.	0	O


356	0	O
,	0	O
93	0	O
-	0	O
98	0	O
].	0	O


The	0	O
Drosophila	1	B
melanogaster	0	I
suppressor	0	I
of	0	I
sable	0	I
gene	0	I
,	0	O
su	0	O
(	0	O
s	0	O
),	0	O
encodes	0	O
a	0	O
novel	0	O
,	0	O
150	0	O
-	0	O
kDa	1	O
nuclear	0	O
RNA	1	O
binding	0	O
protein	0	O
,	0	O
SU	0	O
(	0	O
S	1	O
),	0	O
that	0	O
negatively	0	O
regulates	0	O
RNA	1	O
accumulation	0	O
from	0	O
mutant	0	O
alleles	0	O
of	0	O
other	0	O
genes	0	O
that	0	O
have	0	O
transposon	0	O
insertions	0	O
in	0	O
the	0	O
5	0	O
'	0	O
transcribed	0	O
region	0	O
.	0	O


Taking	0	O
into	0	O
consideration	0	O
weight	0	O
and	0	O
seasonal	0	O
changes	0	O
in	0	O
bone	0	O
mass	0	O
,	0	O
total	0	O
(	0	O
TBBMC	0	O
)	0	O
and	0	O
regional	0	O
body	0	O
bone	0	O
mineral	0	O
content	0	O
were	0	O
measured	0	O
in	0	O
38	0	O
women	0	O
treated	0	O
with	0	O
GnRH	0	B
agonists	0	O
for	0	O
6	0	O
months	0	O
for	0	O
endometriosis	0	O
or	0	O
leiomyomata	0	O
.	0	O


V	1	O
.	0	O


Previous	0	O
studies	0	O
have	0	O
demonstrated	0	O
that	0	O
the	0	O
TATA	0	O
element	0	O
is	0	O
critical	0	O
for	0	O
basal	0	O
and	0	O
Tat	1	B
-	0	O
induced	0	O
HIV	1	O
-	0	O
1	0	O
gene	0	O
expression	0	O
.	0	O


Chronic	1	O
E	1	O
-	0	O
B	1	O
virus	0	O
infection	0	O
terminated	0	O
in	0	O
malignant	0	O
lymphoma	0	O
:	0	O
a	0	O
case	0	O
report	0	O


This	0	O
finding	0	O
is	0	O
consistent	0	O
with	0	O
the	0	O
notion	0	O
that	0	O
the	0	O
dsRNA	1	O
binding	0	O
domains	0	O
may	0	O
be	0	O
composed	0	O
of	0	O
two	0	O
separate	0	O
functional	0	O
subdomains	0	O
.	0	O


These	0	O
temperature	0	O
-	0	O
and	0	O
cold	0	O
-	0	O
sensitive	0	O
strains	0	O
were	0	O
used	0	O
to	0	O
prepare	0	O
extracts	0	O
deficient	0	O
in	0	O
BRF1	0	B
activity	0	O
and	0	O
were	0	O
tested	0	O
for	0	O
transcriptional	0	O
activity	0	O
by	0	O
RNA	1	B
polymerases	0	I
I	1	I
,	0	I
II	0	I
,	0	I
and	0	I
III	0	I
in	0	O
vitro	0	O
.	0	O


Our	0	O
results	0	O
demonstrate	0	O
that	0	O
cis	0	O
elements	0	O
positioned	0	O
between	0	O
the	0	O
alpha	0	B
3	0	I
and	0	O
beta	0	B
4	0	I
coding	0	O
regions	0	O
are	0	O
important	0	O
for	0	O
establishing	0	O
part	0	O
of	0	O
the	0	O
restricted	0	O
CNS	1	O
patterns	0	O
of	0	O
beta	0	B
4	0	I
,	0	O
alpha	0	B
3	0	I
,	0	O
and	0	O
alpha	0	B
5	0	I
gene	0	I
transcription	0	O
.	0	O


On	1	O
long	0	O
-	0	O
term	0	O
follow	0	O
-	0	O
up	0	O
,	0	O
there	0	O
was	0	O
no	0	O
significant	0	O
difference	0	O
in	0	O
the	0	O
incidence	0	O
of	0	O
hospitalizations	0	O
(	0	O
1	0	O
per	0	O
2	0	O
.	0	O
1	0	O
vs	0	O
.	0	O


In	1	O
none	0	O
of	0	O
the	0	O
44	0	O
type	0	O
I	1	O
attacks	0	O
and	0	O
29	0	O
type	0	O
II	0	O
attacks	0	O
which	0	O
were	0	O
recorded	0	O
did	0	O
circulatory	0	O
changes	0	O
;	0	O
the	0	O
latter	0	O
were	0	O
different	0	O
in	0	O
the	0	O
two	0	O
groups	0	O
.	0	O


Complementary	1	O
DNAs	0	O
encompassing	0	O
the	0	O
coat	0	B
protein	0	I
coding	0	O
and	0	O
adjacent	0	O
regions	0	O
of	0	O
Agropyron	0	O
mosaic	0	O
virus	0	O
(	0	O
AgMV	0	O
)	0	O
and	0	O
Hordeum	0	O
mosaic	0	O
virus	0	O
(	0	O
HoMV	0	O
)	0	O
were	0	O
cloned	0	O
and	0	O
sequenced	0	O
.	0	O


Coexpression	0	O
of	0	O
mouse	0	O
PKR	0	B
(	0	I
1	0	I
-	0	I
515	0	I
)	0	I
WT	1	I
as	0	O
a	0	O
Gal4	0	B
DNA	1	O
-	0	O
binding	0	O
domain	0	O
fusion	0	O
with	0	O
either	0	O
the	0	O
catalytic	0	O
-	0	O
deficient	0	O
human	0	O
PKR	0	B
(	0	I
1	0	I
-	0	I
551	0	I
)	0	I
K296R	0	O
mutant	0	O
,	0	O
the	0	O
RNA	1	O
-	0	O
binding	0	O
-	0	O
deficient	0	O
human	0	O
PKR	0	B
(	0	I
1	0	I
-	0	I
551	0	I
)	0	I
K64E	0	I
/	0	I
K296R	0	I
double	0	O
mutant	0	O
,	0	O
or	0	O
wild	0	O
-	0	O
type	0	O
mouse	0	O
PKR	0	B
(	0	I
1	0	I
-	0	I
515	0	I
)	0	I
WT	1	I
as	0	O
full	0	O
-	0	O
length	0	O
PKR	0	B
-	0	O
Gal4	0	B
activation	0	O
domain	0	O
fusions	0	O
resulted	0	O
in	0	O
activation	0	O
of	0	O
the	0	O
HIS3	0	B
and	0	O
lacZ	0	B
reporters	0	O
.	0	O


Plasma	1	O
glucose	0	O
,	0	O
immunoreactive	0	B
insulin	0	I
(	0	O
IRI	0	B
),	0	O
C	1	B
-	0	I
peptide	0	I
,	0	O
glucagon	0	B
,	0	O
and	0	O
GLP	1	B
-	0	I
1	0	I
levels	0	O
at	0	O
each	0	O
time	0	O
point	0	O
during	0	O
OGTT	1	O
were	0	O
measured	0	O
.	0	O


Despite	0	O
total	0	O
tumor	0	O
resection	0	O
,	0	O
multiple	0	O
intraperitoneal	0	O
tumor	0	O
nodules	0	O
of	0	O
varying	0	O
sizes	0	O
were	0	O
found	0	O
and	0	O
resected	0	O
six	0	O
months	0	O
and	0	O
one	0	O
year	0	O
later	0	O
.	0	O


Isolated	0	O
calcaneal	0	O
tuberculous	0	O
osteomyelitis	0	O
.	0	O


The	0	O
wavenumbers	0	O
corresponding	0	O
to	0	O
the	0	O
normal	0	O
modes	0	O
of	0	O
vibration	0	O
were	0	O
calculated	0	O
using	0	O
the	0	O
DFT	1	O
(	0	O
B3LYP	0	O
/	0	O
6	0	O
-	0	O
31G	0	O
**)	0	O
approximation	0	O
and	0	O
their	0	O
agreement	0	O
with	0	O
the	0	O
measured	0	O
values	0	O
improved	0	O
after	0	O
scaling	0	O
of	0	O
the	0	O
associated	0	O
force	0	O
field	0	O
.	0	O


Furthermore	0	O
,	0	O
Rac1	0	B
activation	0	O
of	0	O
JNK	0	B
or	0	O
SRF	1	B
,	0	O
or	0	O
induction	0	O
of	0	O
lamellipodia	0	O
,	0	O
was	0	O
neither	0	O
necessary	0	O
nor	0	O
sufficient	0	O
for	0	O
Rac1	0	B
transforming	0	O
activity	0	O
.	0	O


Application	1	O
of	0	O
the	0	O
method	0	O
to	0	O
a	0	O
representative	0	O
set	0	O
of	0	O
50	0	O
known	0	O
genes	0	O
from	0	O
Arabidopsis	0	O
thaliana	0	O
showed	0	O
significant	0	O
improvement	0	O
in	0	O
prediction	0	O
accuracy	0	O
compared	0	O
to	0	O
previous	0	O
spliced	0	O
alignment	0	O
methods	0	O
.	0	O


A	1	O
positive	0	O
correlation	0	O
between	0	O
serum	0	B
myoglobin	0	I
and	0	O
CA	1	B
III	0	I
concentrations	0	O
(	0	O
rs	0	O
=	0	O
0	0	O
.	0	O
933	0	O
,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
was	0	O
observed	0	O
in	0	O
hemodialyzed	0	O
patients	0	O
with	0	O
chronic	0	O
renal	0	O
failure	0	O
.	0	O


M	1	B
.	0	I
leprae	0	I
OxyR	0	I
was	0	O
overproduced	0	O
and	0	O
purified	0	O
,	0	O
and	0	O
its	0	O
binding	0	O
to	0	O
the	0	O
oxyR	0	B
-	0	O
ahpC	0	B
intergenic	0	O
region	0	O
of	0	O
M	1	O
.	0	O
leprae	0	O
was	0	O
demonstrated	0	O
.	0	O


Administration	1	O
of	0	O
a	0	O
second	0	O
dose	0	O
of	0	O
vaccine	0	O
during	0	O
the	0	O
outbreak	0	O
was	0	O
not	0	O
protective	0	O
.	0	O


However	0	O
,	0	O
when	0	O
a	0	O
second	0	O
,	0	O
upstream	0	B
IRE	0	I
-	0	I
like	0	I
sequence	0	I
was	0	O
evaluated	0	O
by	0	O
EMSA	0	O
,	0	O
a	0	O
DNA	1	O
binding	0	O
pattern	0	O
distinct	0	O
from	0	O
that	0	O
seen	0	O
following	0	O
exposure	0	O
to	0	O
IFN	1	B
-	0	I
gamma	0	I
alone	0	O
was	0	O
observed	0	O
after	0	O
prolonged	0	O
stimulation	0	O
with	0	O
both	0	O
IFN	1	B
-	0	I
alpha	0	I
and	0	O
IFN	1	B
-	0	I
gamma	0	I
.	0	O


By	0	O
using	0	O
reporter	0	O
gene	0	O
constructs	0	O
,	0	O
it	0	O
is	0	O
shown	0	O
that	0	O
upstream	0	O
sequences	0	O
of	0	O
the	0	O
P1	1	O
promoter	0	O
contain	0	O
several	0	O
regions	0	O
that	0	O
modulate	0	O
the	0	O
expression	0	O
either	0	O
positively	0	O
or	0	O
negatively	0	O
.	0	O


The	0	O
sequence	0	O
of	0	O
this	0	O
region	0	O
shows	0	O
high	0	O
G	1	O
+	0	O
C	1	O
content	0	O
(	0	O
62	0	O
%),	0	O
which	0	O
is	0	O
particularly	0	O
emphasized	0	O
in	0	O
the	0	O
200	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
mRNA	1	O
start	0	O
(	0	O
80	0	O
%	0	O
G	1	O
+	0	O
C	1	O
).	0	O


We	0	O
report	0	O
a	0	O
case	0	O
of	0	O
pheochromocytoma	0	O
manifesting	0	O
during	0	O
the	0	O
third	0	O
trimester	0	O
of	0	O
pregnancy	0	O
.	0	O


Effect	1	O
of	0	O
thrombotic	0	O
and	0	O
antithrombotic	0	O
drugs	0	O
on	0	O
the	0	O
surface	0	O
charge	0	O
characteristics	0	O
of	0	O
canine	0	O
blood	0	O
vessels	0	O
:	0	O
in	0	O
vivo	0	O
and	0	O
in	0	O
vitro	0	O
studies	0	O
.	0	O


A	1	O
single	0	O
NMSC	0	O
was	0	O
present	0	O
in	0	O
69	0	O
.	0	O
4	0	O
%,	0	O
two	0	O
in	0	O
16	0	O
%,	0	O
three	0	O
in	0	O
6	0	O
.	0	O
4	0	O
%,	0	O
four	0	O
in	0	O
3	0	O
.	0	O
5	0	O
%,	0	O
five	0	O
to	0	O
nine	0	O
in	0	O
4	0	O
.	0	O
2	0	O
%,	0	O
and	0	O
0	0	O
.	0	O
5	0	O
%	0	O
had	0	O
ten	0	O
or	0	O
more	0	O
.	0	O


Immunogenicity	1	O
of	0	O
various	0	O
mycobacteria	0	O
and	0	O
the	0	O
corresponding	0	O
levels	0	O
of	0	O
cross	0	O
-	0	O
protection	0	O
developed	0	O
between	0	O
species	0	O
.	0	O


Expression	1	O
of	0	O
a	0	O
dominant	0	B
-	0	I
negative	0	I
ras	0	I
gene	0	I
also	0	O
blocks	0	O
TIS10	0	B
/	0	O
PGS2	0	B
induction	0	O
by	0	O
v	0	B
-	0	I
src	0	I
.	0	O


In	1	O
comparison	0	O
with	0	O
the	0	O
16	0	O
introns	0	O
reported	0	O
in	0	O
AHA3	0	B
,	0	O
AHA2	0	B
is	0	O
missing	0	O
one	0	O
intron	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
untranslated	0	O
region	0	O
and	0	O
a	0	O
second	0	O
intron	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
coding	0	O
region	0	O
.	0	O


Sensory	1	O
evoked	0	O
field	0	O
potentials	0	O
were	0	O
recorded	0	O
from	0	O
the	0	O
mesencephalic	0	O
reticular	0	O
formation	0	O
(	0	O
MRF	0	O
),	0	O
central	0	O
gray	0	O
(	0	O
CG	1	O
)	0	O
and	0	O
somatosensory	0	O
cortex	0	O
(	0	O
SCX	0	O
),	0	O
following	0	O
incremental	0	O
doses	0	O
of	0	O
halothane	0	O
in	0	O
freely	0	O
-	0	O
moving	0	O
rats	0	O
.	0	O


Lack	0	O
of	0	O
sufficient	0	O
data	0	O
on	0	O
vibration	0	O
measurements	0	O
and	0	O
employment	0	O
durations	0	O
add	0	O
to	0	O
the	0	O
uncertainty	0	O
,	0	O
as	0	O
do	0	O
variations	0	O
in	0	O
tool	0	O
conditions	0	O
(	0	O
grinder	0	O
wheels	0	O
,	0	O
etc	0	O
)	0	O
and	0	O
inherent	0	O
difficulties	0	O
in	0	O
measurement	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
a	0	O
tissue	0	O
emulsion	0	O
,	0	O
vitamin	0	O
A	1	O
and	0	O
nonspecific	0	O
gamma	0	B
-	0	I
globulin	0	I
on	0	O
the	0	O
blood	0	O
clearance	0	O
in	0	O
rabbits	0	O


The	0	O
c	0	B
-	0	I
myc	0	I
and	0	O
skeletal	0	B
alpha	0	I
-	0	I
actin	0	I
gene	0	I
promoters	0	I
contain	0	O
YY1	0	B
binding	0	I
sites	0	I
thought	0	O
to	0	O
act	0	O
either	0	O
as	0	O
positive	0	O
or	0	O
negative	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
.	0	O


The	0	O
use	0	O
of	0	O
CRF	1	B
-	0	I
41	0	I
in	0	O
the	0	O
differential	0	O
diagnosis	0	O
of	0	O
Cushing	0	O
'	0	O
s	0	O
syndrome	0	O
and	0	O
obesity	0	O
.	0	O


Kinase	1	O
-	0	O
deficient	0	O
erbB	0	B
proteins	0	I
reduced	0	O
epidermal	0	B
growth	0	I
factor	0	I
(	0	O
EGF	1	B
)-	0	O
induced	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
endogenous	0	O
Shc	0	B
proteins	0	I
and	0	O
also	0	O
reduced	0	O
immediate	0	O
and	0	O
sustained	0	O
EGF	1	B
-	0	I
induced	0	I
ERK	0	I
MAPK	1	I
activities	0	O
in	0	O
human	0	O
glioblastoma	0	O
cells	0	O
,	0	O
although	0	O
basal	0	O
ERK	0	B
MAPK	1	I
activities	0	O
were	0	O
unaffected	0	O
.	0	O


When	0	O
excluding	0	O
children	0	O
with	0	O
ocular	0	O
and	0	O
cerebral	0	O
pathology	0	O
,	0	O
32	0	O
matched	0	O
pairs	0	O
of	0	O
premature	0	O
and	0	O
control	0	O
children	0	O
remained	0	O
.	0	O


PURPOSE	0	O
:	0	O
Previous	0	O
WR	0	O
-	0	O
2721	0	O
human	0	O
pharmacokinetic	0	O
studies	0	O
were	0	O
limited	0	O
to	0	O
plasma	0	O
levels	0	O
in	0	O
patients	0	O
receiving	0	O
platinum	0	O
-	0	O
based	0	O
compounds	0	O
,	0	O
and	0	O
none	0	O
includes	0	O
the	0	O
effects	0	O
of	0	O
WR	0	O
-	0	O
2721	0	O
on	0	O
endogenous	0	O
thiols	0	O
.	0	O


To	1	O
investigate	0	O
the	0	O
functions	0	O
of	0	O
GE	1	O
,	0	O
IG	1	O
,	0	O
and	0	O
GS	0	O
sequences	0	O
in	0	O
transcription	0	O
,	0	O
we	0	O
constructed	0	O
plasmids	0	O
containing	0	O
cDNAs	0	O
of	0	O
the	0	O
full	0	O
-	0	O
length	0	O
SV5	0	O
genome	0	O
in	0	O
which	0	O
the	0	O
gene	0	O
junction	0	O
sequences	0	O
(	0	O
GE	1	O
,	0	O
IG	1	O
,	0	O
and	0	O
GS	0	O
sequences	0	O
)	0	O
located	0	O
between	0	O
the	0	O
hemagglutinin	0	B
-	0	I
neuraminidase	0	I
(	0	O
HN	0	B
)	0	O
and	0	O
the	0	O
polymerase	0	B
(	0	I
L	1	I
)	0	I
genes	0	I
were	0	O
replaced	0	O
with	0	O
the	0	O
counterpart	0	O
sequences	0	O
from	0	O
other	0	O
gene	0	O
junctions	0	O
.	0	O


Cord	1	O
swelling	0	O
was	0	O
observed	0	O
in	0	O
2	0	O
patients	0	O
who	0	O
developed	0	O
complete	0	O
lesions	0	O
.	0	O


A	1	O
simple	0	O
registration	0	O
as	0	O
an	0	O
incentive	0	O
for	0	O
improvement	0	O


Serological	1	O
studies	0	O
at	0	O
the	0	O
early	0	O
relapse	0	O
stage	0	O
of	0	O
this	0	O
disease	0	O
showed	0	O
increased	0	O
serum	0	B
ANA	1	I
,	0	O
IgA	1	B
and	0	O
IgM	1	B
level	0	O
with	0	O
normal	0	O
IgG	1	B
and	0	O
decrease	0	O
of	0	O
C3	1	B
and	0	O
C4	1	B
.	0	O


The	0	O
technique	0	O
of	0	O
the	0	O
TEE	1	O
visualization	0	O
of	0	O
the	0	O
proximal	0	O
coronary	0	O
arteries	0	O
is	0	O
described	0	O
.	0	O


The	0	O
first	0	O
symptoms	0	O
of	0	O
enzootic	0	O
calcinosis	0	O
were	0	O
noted	0	O
in	0	O
March	1	O
1998	0	O
,	0	O
when	0	O
some	0	O
of	0	O
the	0	O
cows	0	O
developed	0	O
locomotor	0	O
abnormalities	0	O
.	0	O


These	0	O
factors	0	O
belong	0	O
to	0	O
a	0	O
set	0	O
of	0	O
genetically	0	O
distinct	0	O
molecules	0	O
,	0	O
including	0	O
AP	1	B
-	0	I
4	0	I
and	0	O
MLTF	0	B
,	0	O
that	0	O
bind	0	O
to	0	O
the	0	O
CACCTGTC	0	O
motif	0	O
or	0	O
related	0	O
sequences	0	O
.	0	O


(	0	O
1994	0	O
,	0	O
Hum	1	O
.	0	O


The	0	O
COP	1	O
-	0	O
PAWP	1	O
gradient	0	O
was	0	O
markedly	0	O
decreased	0	O
in	0	O
both	0	O
shock	0	O
and	0	O
non	0	O
-	0	O
shock	0	O
patients	0	O
with	0	O
pulmonary	0	O
edema	0	O
.	0	O


Carbohydrate	1	O
metabolism	0	O
and	0	O
the	0	O
semen	0	O
profile	0	O
:	0	O
glucose	0	O
,	0	O
insulin	0	B
,	0	O
and	0	O
sperm	0	O
studies	0	O
.	0	O


Lars	0	O
has	0	O
AIDS	1	O
--	0	O
a	0	O
more	0	O
dignified	0	O
life	0	O
with	0	O
care	0	O
at	0	O
home	0	O
.	0	O


When	0	O
combined	0	O
with	0	O
serum	0	O
ferritin	0	B
and	0	O
hemoglobin	0	B
determinations	0	O
,	0	O
the	0	O
serum	0	O
transferrin	0	B
receptor	0	I
assay	0	O
is	0	O
a	0	O
valuable	0	O
addition	0	O
in	0	O
epidemiologic	0	O
surveys	0	O
because	0	O
it	0	O
provides	0	O
a	0	O
quantitative	0	O
measure	0	O
of	0	O
functional	0	O
iron	0	O
deficiency	0	O
and	0	O
it	0	O
distinguishes	0	O
true	0	O
IDA	1	O
from	0	O
the	0	O
anemia	0	O
of	0	O
chronic	0	O
disease	0	O
.	0	O


Treatment	1	O
and	0	O
care	0	O
of	0	O
adult	0	O
diabetes	0	O
mellitus	0	O
without	0	O
coma	0	O


The	0	O
ratio	0	O
of	0	O
the	0	O
activity	0	O
of	0	O
arogenate	0	B
dehydrogenase	0	I
to	0	O
that	0	O
of	0	O
prephenate	0	B
dehydrogenase	0	I
(	0	O
approximately	0	O
3	0	O
:	0	O
1	0	O
)	0	O
remained	0	O
constant	0	O
throughout	0	O
purification	0	O
,	0	O
and	0	O
the	0	O
two	0	O
activities	0	O
were	0	O
therefore	0	O
inseparable	0	O
.	0	O


A	1	O
high	0	O
degree	0	O
of	0	O
correlation	0	O
in	0	O
the	0	O
sense	0	O
of	0	O
the	0	O
classic	0	O
conception	0	O
of	0	O
brain	0	O
localization	0	O
of	0	O
neuropsychological	0	O
syndromes	0	O
was	0	O
found	0	O
.	0	O


Most	0	O
important	0	O
,	0	O
infection	0	O
of	0	O
the	0	O
cells	0	O
with	0	O
an	0	O
adenoviral	0	O
construct	0	O
expressing	0	O
this	0	O
mutant	0	O
inhibited	0	O
the	0	O
induction	0	O
of	0	O
VEGF	1	B
mRNA	1	I
under	0	O
conditions	0	O
that	0	O
mimic	0	O
hypoxia	0	O
.	0	O


Studies	0	O
of	0	O
MPO	1	B
gene	0	I
regulation	0	O
can	0	O
help	0	O
to	0	O
elucidate	0	O
the	0	O
mechanism	0	O
of	0	O
normal	0	O
and	0	O
abnormal	0	O
myeloid	0	O
differentiation	0	O
.	0	O


Paradoxically	0	O
,	0	O
coexpression	0	O
of	0	O
the	0	O
transcriptionally	0	O
inactive	0	O
,	0	O
amino	0	O
-	0	O
terminally	0	O
deleted	0	O
IDX	0	B
-	0	I
1	0	I
mutant	0	I
proteins	0	I
,	0	O
either	0	O
with	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
IDX	0	I
-	0	I
1	0	I
or	0	O
with	0	O
themselves	0	O
,	0	O
results	0	O
in	0	O
a	0	O
marked	0	O
enhancement	0	O
of	0	O
transactivation	0	O
of	0	O
the	0	O
transcriptional	0	O
TAAT	0	B
-	0	I
1	0	I
element	0	I
reporter	0	I
.	0	O


205	0	O
,	0	O
285	0	O
-	0	O
290	0	O
]	0	O
and	0	O
was	0	O
subsequently	0	O
cloned	0	O
and	0	O
sequenced	0	O
[	0	O
J	1	O
.	0	O


Ovarian	1	O
allotransplantation	0	O
in	0	O
human	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
loss	0	O
of	0	O
MAD2	0	B
staining	0	O
in	0	O
meiosis	0	O
was	0	O
not	0	O
correlated	0	O
with	0	O
initial	0	O
microtubule	0	O
attachment	0	O
but	0	O
was	0	O
correlated	0	O
with	0	O
a	0	O
measure	0	O
of	0	O
tension	0	O
:	0	O
the	0	O
distance	0	O
between	0	O
homologous	0	O
or	0	O
sister	0	O
kinetochores	0	O
(	0	O
in	0	O
meiosis	0	O
I	1	O
and	0	O
II	0	O
,	0	O
respectively	0	O
).	0	O


Removal	0	O
of	0	O
beta	0	B
2	0	I
-	0	I
microglobulin	0	I
by	0	O
hemodialysis	0	O
and	0	O
hemofiltration	0	O
:	0	O
a	0	O
four	0	O
year	0	O
follow	0	O
up	0	O
.	0	O


Calcification	1	O
of	0	O
a	0	O
cariogenic	0	O
Streptococcus	1	O
and	0	O
of	0	O
Corynebacterium	1	O
(	0	O
Bacterionema	0	O
)	0	O
matruchotii	0	O
.	0	O


Functional	1	O
rearranged	0	O
antibody	0	O
genes	0	O
were	0	O
detected	0	O
with	0	O
JH	0	B
and	0	O
VH	1	B
heavy	0	I
chain	0	I
probes	0	O
and	0	O
with	0	O
Jk	0	B
and	0	O
Vk	0	B
light	0	I
chain	0	I
probes	0	O
.	0	O


The	0	O
TCF	0	B
-	0	I
1	0	I
alpha	0	I
binding	0	I
site	0	I
was	0	O
also	0	O
required	0	O
for	0	O
TCR	1	B
alpha	0	I
enhancer	0	I
activity	0	O
in	0	O
transcriptionally	0	O
active	0	O
extracts	0	O
from	0	O
Jurkat	0	O
but	0	O
not	0	O
HeLa	0	O
cells	0	O
,	0	O
confirming	0	O
that	0	O
TCF	0	B
-	0	I
1	0	I
alpha	0	I
is	0	O
a	0	O
T	1	B
-	0	I
cell	0	I
-	0	I
specific	0	I
transcription	0	I
factor	0	I
.	0	O


Proteinuria	1	O
in	0	O
a	0	O
young	0	O
man	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
mammalian	0	B
translation	0	I
initiation	0	I
factor	0	I
5	0	I
(	0	O
eIF5	0	B
):	0	O
role	0	O
of	0	O
interaction	0	O
between	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
eIF2	0	B
and	0	O
eIF5	0	B
in	0	O
eIF5	0	B
function	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
.	0	O


Treatment	1	O
of	0	O
unstable	0	O
angina	0	O
:	0	O
role	0	O
of	0	O
antithrombotic	0	O
therapy	0	O
.	0	O


When	0	O
the	0	O
73	0	O
-	0	O
bp	0	O
fragment	0	O
was	0	O
fused	0	O
to	0	O
an	0	O
alpha1	0	B
-	0	I
globin	0	I
promoter	0	O
-	0	O
CAT	1	B
construct	0	O
and	0	O
cotransfected	0	O
with	0	O
CCAAT	0	B
transcription	0	I
factor	0	I
1	0	I
(	0	O
CTF1	0	B
)/	0	O
NF1	1	B
into	0	O
Drosophila	1	O
Schneider	0	O
SL2	0	O
insect	0	O
cells	0	O
(	0	O
which	0	O
lack	0	O
NF1	1	B
-	0	I
like	0	I
proteins	0	I
)	0	O
trans	0	O
-	0	O
activation	0	O
of	0	O
CAT	1	B
activity	0	O
was	0	O
observed	0	O
.	0	O


Southern	0	O
blot	0	O
analysis	0	O
using	0	O
probes	0	O
from	0	O
the	0	O
3	0	O
'	0	O
portions	0	O
of	0	O
the	0	O
genomic	0	O
and	0	O
B	1	B
.	0	I
napus	0	I
MA	1	I
and	0	O
MB	1	B
cDNA	1	I
clones	0	O
showed	0	O
that	0	O
MA	1	B
type	0	I
myrosinases	0	I
are	0	O
encoded	0	O
by	0	O
approximately	0	O
4	0	O
genes	0	O
,	0	O
while	0	O
MB	1	B
type	0	I
myrosinases	0	I
are	0	O
encoded	0	O
by	0	O
more	0	O
than	0	O
10	0	O
genes	0	O
in	0	O
B	1	O
.	0	O
napus	0	O
.	0	O


Analysis	1	O
of	0	O
mRNA	1	O
expression	0	O
shows	0	O
that	0	O
AT	1	B
-	0	I
BP1	0	I
and	0	O
AT	1	B
-	0	I
BP2	0	I
are	0	O
expressed	0	O
in	0	O
all	0	O
the	0	O
tissues	0	O
examined	0	O
.	0	O


Overexpression	1	O
of	0	O
wild	0	B
-	0	I
type	0	I
p53	0	I
also	0	O
induces	0	O
apoptosis	0	O
in	0	O
an	0	O
LCL	0	O
.	0	O


It	1	O
has	0	O
been	0	O
established	0	O
that	0	O
preoperative	0	O
irradiation	0	O
in	0	O
the	0	O
form	0	O
of	0	O
the	0	O
fractionation	0	O
of	0	O
a	0	O
single	0	O
focal	0	O
dose	0	O
of	0	O
6	0	O
Gy	1	O
every	0	O
other	0	O
day	0	O
,	0	O
the	0	O
summary	0	O
dose	0	O
of	0	O
24	0	O
Gy	1	O
within	0	O
8	0	O
-	0	O
10	0	O
days	0	O
followed	0	O
by	0	O
surgery	0	O
1	0	O
-	0	O
3	0	O
days	0	O
after	0	O
irradiation	0	O
does	0	O
not	0	O
either	0	O
complicate	0	O
its	0	O
performance	0	O
or	0	O
the	0	O
course	0	O
of	0	O
the	0	O
postoperative	0	O
period	0	O
,	0	O
and	0	O
by	0	O
the	0	O
short	0	O
-	0	O
and	0	O
long	0	O
-	0	O
term	0	O
results	0	O
it	0	O
is	0	O
no	0	O
worse	0	O
than	0	O
the	0	O
routine	0	O
dose	0	O
fractionation	0	O
.	0	O


In	1	O
the	0	O
Oct	1	B
-	0	I
1	0	I
crystal	0	O
,	0	O
the	0	O
POU	0	B
-	0	I
specific	0	I
domain	0	I
recognizes	0	O
a	0	O
GCAT	0	O
half	0	O
-	0	O
site	0	O
,	0	O
while	0	O
the	0	O
corresponding	0	O
sequence	0	O
recognized	0	O
by	0	O
the	0	O
Pit	1	B
-	0	I
1	0	I
POU	0	I
-	0	O
specific	0	O
domain	0	O
,	0	O
GTAT	0	O
,	0	O
is	0	O
on	0	O
the	0	O
opposing	0	O
strand	0	O
.	0	O


The	0	O
failures	0	O
frequently	0	O
were	0	O
related	0	O
to	0	O
patient	0	O
intolerance	0	O
or	0	O
poor	0	O
mechanical	0	O
fit	0	O
and	0	O
occurred	0	O
in	0	O
the	0	O
first	0	O
few	0	O
days	0	O
or	0	O
first	0	O
few	0	O
months	0	O
after	0	O
insertion	0	O
.	0	O


We	0	O
analyzed	0	O
data	0	O
from	0	O
56	0	O
patients	0	O
with	0	O
Systemic	1	O
Lupus	1	O
Erythematosus	0	O
(	0	O
SLE	1	O
)	0	O
in	0	O
whom	0	O
renal	0	O
biopsies	0	O
were	0	O
done	0	O
systematically	0	O
.	0	O


Paper	1	O
alert	0	O
.	0	O


But	0	O
no	0	O
influence	0	O
was	0	O
observed	0	O
at	0	O
lower	0	O
concentrations	0	O
than	0	O
1	0	O
/	0	O
4	0	O
MIC	1	O
of	0	O
AMK	0	O
.	0	O


A	1	O
single	0	O
five	0	O
minute	0	O
period	0	O
of	0	O
rapid	0	O
atrial	0	O
pacing	0	O
fails	0	O
to	0	O
limit	0	O
infarct	0	O
size	0	O
in	0	O
the	0	O
in	0	O
situ	0	O
rabbit	0	O
heart	0	O
.	0	O


We	0	O
linked	0	O
hypersensitivity	0	O
site	0	O
2	0	O
(	0	O
HS2	0	O
)	0	O
from	0	O
the	0	O
locus	0	O
control	0	O
region	0	O
(	0	O
LCR	1	O
)	0	O
to	0	O
a	0	O
A	1	B
gamma	0	I
-	0	I
globin	0	I
gene	0	O
(	0	O
A	1	O
gamma	0	O
*)	0	O
mutationally	0	O
marked	0	O
to	0	O
allow	0	O
its	0	O
transcript	0	O
to	0	O
be	0	O
distinguished	0	O
from	0	O
endogenous	0	O
gamma	0	B
-	0	I
globin	0	I
mRNA	1	O
.	0	O


After	0	O
hepatitis	0	O
B	1	O
vaccine	0	O
immunization	0	O
,	0	O
serum	0	O
antibody	0	O
response	0	O
was	0	O
of	0	O
primary	0	O
type	0	O
in	0	O
33	0	O
cases	0	O
with	0	O
anti	0	B
-	0	I
HBs	1	I
less	0	O
than	0	O
2	0	O
.	0	O
1	0	O
S	1	O
/	0	O
N	1	O
(	0	O
S	1	O
/	0	O
N	1	O
Ratio	1	O
Unit	1	O
)	0	O
at	0	O
T0	0	O
,	0	O
the	0	O
anti	0	B
-	0	I
HBs	1	I
positive	0	O
rate	0	O
was	0	O
39	0	O
.	0	O
4	0	O
%,	0	O
84	0	O
.	0	O
8	0	O
%,	0	O
96	0	O
.	0	O
7	0	O
%	0	O
and	0	O
96	0	O
.	0	O
7	0	O
%	0	O
in	0	O
T1	1	O
,	0	O
T2	0	O
,	0	O
T0	0	O
and	0	O
T12	0	O
respectively	0	O
.	0	O


The	0	O
transmembrane	0	O
topology	0	O
of	0	O
Na	1	O
(+)/	0	O
H	1	O
(+)	0	O
exchanger	0	O
NHE3	0	B
has	0	O
been	0	O
studied	0	O
using	0	O
in	0	O
vitro	0	O
transcription	0	O
/	0	O
translation	0	O
of	0	O
two	0	O
types	0	O
of	0	O
fusion	0	O
vectors	0	O
designed	0	O
to	0	O
test	0	O
membrane	0	O
insertion	0	O
properties	0	O
of	0	O
cDNA	1	O
sequences	0	O
encoding	0	O
putative	0	O
NHE3	0	B
membrane	0	O
spanning	0	O
domains	0	O
(	0	O
msds	0	O
).	0	O


Lung	1	O
density	0	O
increased	0	O
in	0	O
quartz	0	O
-	0	O
exposed	0	O
,	0	O
but	0	O
not	0	O
in	0	O
volcanic	0	O
-	0	O
ash	0	O
-	0	O
exposed	0	O
animals	0	O
.	0	O


The	0	O
pia	0	O
mater	0	O
at	0	O
the	0	O
site	0	O
of	0	O
the	0	O
entry	0	O
of	0	O
blood	0	O
vessels	0	O
into	0	O
the	0	O
central	0	O
nervous	0	O
system	0	O
.	0	O


To	1	O
identify	0	O
these	0	O
sites	0	O
,	0	O
the	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
3T3	0	O
-	0	O
L1	0	O
adipocyte	0	B
insulin	0	I
receptor	0	I
of	0	O
the	0	O
mouse	0	O
was	0	O
determined	0	O
.	0	O


The	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
human	0	B
lactoferrin	0	I
gene	0	I
was	0	O
isolated	0	O
from	0	O
a	0	O
human	0	O
placental	0	O
genomic	0	O
library	0	O
.	0	O


From	0	O
February	0	O
1991	0	O
to	0	O
August	0	O
1997	0	O
,	0	O
124	0	O
patients	0	O
with	0	O
endometrial	0	O
carcinoma	0	O
were	0	O
treated	0	O
postoperatively	0	O
with	0	O
high	0	O
-	0	O
dose	0	O
-	0	O
rate	0	O
vaginal	0	O
vault	0	O
brachytherapy	0	O
as	0	O
the	0	O
only	0	O
adjuvant	0	O
treatment	0	O
.	0	O


The	0	O
results	0	O
suggested	0	O
that	0	O
,	0	O
depending	0	O
upon	0	O
the	0	O
cell	0	O
type	0	O
,	0	O
gene	0	O
cotransfer	0	O
using	0	O
aminoglycoside	0	O
resistance	0	O
as	0	O
a	0	O
selectable	0	O
marker	0	O
may	0	O
seriously	0	O
perturb	0	O
important	0	O
cellular	0	O
control	0	O
mechanisms	0	O
such	0	O
as	0	O
the	0	O
PKC	0	B
pathway	0	O
leading	0	O
to	0	O
activation	0	O
of	0	O
gene	0	O
expression	0	O
.	0	O


After	0	O
the	0	O
application	0	O
of	0	O
RS	1	O
86	0	O
,	0	O
REM	1	O
latency	0	O
was	0	O
shortened	0	O
in	0	O
all	0	O
groups	0	O
under	0	O
investigation	0	O
.	0	O


Resting	1	O
plasma	0	O
norepinephrine	0	O
(	0	O
NE	1	O
)	0	O
and	0	O
epinephrine	0	O
(	0	O
E	1	O
)	0	O
levels	0	O
were	0	O
lower	0	O
during	0	O
active	0	O
therapy	0	O
than	0	O
2	0	O
wk	0	O
after	0	O
withdrawal	0	O
(	0	O
guanfacine	0	O
and	0	O
control	0	O
:	0	O
plasma	0	O
NE	1	O
,	0	O
0	0	O
.	0	O
27	0	O
+/-	0	O
0	0	O
.	0	O
03	0	O
/	0	O
0	0	O
.	0	O
64	0	O
+/-	0	O
0	0	O
.	0	O
13	0	O
ng	0	O
/	0	O
ml	0	O
;	0	O
plasma	0	O
E	1	O
,	0	O
0	0	O
.	0	O
09	0	O
+/-	0	O
0	0	O
.	0	O
02	0	O
/	0	O
0	0	O
.	0	O
17	0	O
+/-	0	O
0	0	O
.	0	O
05	0	O
ng	0	O
/	0	O
ml	0	O
).	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
examine	0	O
the	0	O
effects	0	O
of	0	O
Msx2	0	B
expression	0	O
on	0	O
OC	1	B
promoter	0	I
activation	0	O
(	0	O
luciferase	0	B
reporter	0	I
)	0	O
by	0	O
FGF2	0	B
/	0	O
FSK	0	B
and	0	O
calcitriol	0	O
in	0	O
MC3T3	0	O
-	0	O
E1	1	O
osteoblasts	0	O
.	0	O


This	0	O
study	0	O
tested	0	O
the	0	O
hypothesis	0	O
that	0	O
sodium	0	O
channel	0	O
blocking	0	O
drugs	0	O
selectively	0	O
prolong	0	O
the	0	O
late	0	O
potential	0	O
,	0	O
or	0	O
terminal	0	O
low	0	O
amplitude	0	O
signal	0	O
,	0	O
portion	0	O
of	0	O
the	0	O
signal	0	O
-	0	O
averaged	0	O
QRS	0	O
complex	0	O
and	0	O
that	0	O
prolongation	0	O
of	0	O
the	0	O
late	0	O
potential	0	O
would	0	O
correlate	0	O
with	0	O
slowing	0	O
of	0	O
ventricular	0	O
tachycardia	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
perform	0	O
a	0	O
cost	0	O
-	0	O
effectiveness	0	O
analysis	0	O
(	0	O
CEA	1	O
)	0	O
between	0	O
a	0	O
standard	0	O
antiemetic	0	O
regimen	0	O
-	0	O
chlorpromazine	0	O
+	0	O
dexamethasone	0	O
(	0	O
CPM	1	O
-	0	O
DEX	0	O
)-	0	O
and	0	O
a	0	O
5	0	B
-	0	I
HT3	0	I
receptor	0	I
antagonist	0	O
-	0	O
tropisetron	0	O
(	0	O
TROP	0	O
)--	0	O
in	0	O
the	0	O
control	0	O
of	0	O
acute	0	O
emesis	0	O
induced	0	O
by	0	O
highly	0	O
emetogenic	0	O
chemotherapy	0	O
in	0	O
children	0	O
,	0	O
considering	0	O
two	0	O
analytic	0	O
perspectives	0	O
:	0	O
hospital	0	O
and	0	O
patients	0	O
.	0	O


Previous	0	O
investigators	0	O
have	0	O
suggested	0	O
that	0	O
subretinal	0	O
blood	0	O
damages	0	O
the	0	O
retina	0	O
in	0	O
part	0	O
because	0	O
of	0	O
its	0	O
solid	0	O
fibrin	0	B
meshwork	0	O
.	0	O


We	0	O
show	0	O
here	0	O
that	0	O
RA	1	O
and	0	O
E1A	0	B
induce	0	O
phosphorylation	0	O
of	0	O
the	0	O
E1A	0	B
-	0	I
associated	0	I
300	0	I
kDa	1	I
protein	0	I
(	0	O
p300	0	B
)	0	O
during	0	O
the	0	O
differentiation	0	O
of	0	O
F9	0	O
cells	0	O
.	0	O


The	0	O
examinations	0	O
were	0	O
performed	0	O
on	0	O
two	0	O
groups	0	O
of	0	O
20	0	O
(	0	O
using	0	O
AmF	0	O
/	0	O
SnF2	0	O
)-,	0	O
resp	0	O
.	0	O


The	0	O
other	0	O
model	0	O
was	0	O
a	0	O
continuous	0	O
exponential	0	O
plus	0	O
constant	0	O
of	0	O
the	0	O
form	0	O
La	1	O
-	0	O
=	0	O
a	0	O
+	0	O
b	0	O
[	0	O
exp	0	O
(	0	O
cVO2	0	O
)].	0	O


To	1	O
study	0	O
the	0	O
regulation	0	O
of	0	O
mdr2	0	B
expression	0	O
,	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
mdr2	0	B
gene	0	I
has	0	O
been	0	O
isolated	0	O
from	0	O
a	0	O
murine	0	O
vinblastine	0	O
-	0	O
resistant	0	O
cell	0	O
line	0	O
,	0	O
J7	0	O
.	0	O
V2	0	O
-	0	O
1	0	O
,	0	O
and	0	O
characterized	0	O
.	0	O


Sera	1	O
from	0	O
euthyroid	0	O
post	0	O
-	0	O
menopausal	0	O
or	0	O
pregnant	0	O
women	0	O
yielded	0	O
TSH	1	B
levels	0	O
within	0	O
the	0	O
normal	0	O
range	0	O
.	0	O


The	0	O
PDE4A	0	B
-	0	I
subfamily	0	I
-	0	I
specific	0	I
linker	0	I
region	0	I
LR1	0	O
,	0	O
which	0	O
joins	0	O
UCR1	0	O
and	0	O
UCR2	0	O
,	0	O
is	0	O
encoded	0	O
by	0	O
two	0	O
exons	0	O
,	0	O
whereas	0	O
LR2	0	O
,	0	O
which	0	O
joins	0	O
UCR2	0	O
to	0	O
the	0	O
catalytic	0	O
unit	0	O
,	0	O
is	0	O
encoded	0	O
by	0	O
a	0	O
single	0	O
exon	0	O
.	0	O


This	0	O
region	0	O
also	0	O
contains	0	O
a	0	O
gene	0	O
specifying	0	O
a	0	O
Leu	1	B
-	0	I
tRNA	1	I
precursor	0	I
and	0	O
a	0	O
remnant	0	O
of	0	O
a	0	O
tau	0	O
element	0	O
.	0	O


An	1	O
exon	0	O
that	0	O
prevents	0	O
transport	0	O
of	0	O
a	0	O
mature	0	O
mRNA	1	O
.	0	O


Slowed	0	O
lysosomal	0	B
enzyme	0	I
release	0	O
and	0	O
its	0	O
normalization	0	O
by	0	O
drugs	0	O
in	0	O
adjuvant	0	O
-	0	O
induced	0	O
polyarthritis	0	O
.	0	O


How	0	O
does	0	O
a	0	O
nurse	0	O
go	0	O
about	0	O
maintaining	0	O
her	0	O
level	0	O
of	0	O
competence	0	O
when	0	O
she	0	O
is	0	O
one	0	O
of	0	O
the	0	O
few	0	O
local	0	O
practitioners	0	O
in	0	O
her	0	O
field	0	O
?	0	O
Vancouver	0	O
sex	0	O
therapist	0	O
Bianca	0	O
Rucker	0	O
is	0	O
doing	0	O
it	0	O
by	0	O
cultivating	0	O
a	0	O
network	0	O
of	0	O
colleagues	0	O
and	0	O
mentors	0	O
in	0	O
related	0	O
fields	0	O
both	0	O
at	0	O
home	0	O
and	0	O
across	0	O
the	0	O
continent	0	O
.	0	O


Each	0	O
immunoprecipitate	0	O
contained	0	O
a	0	O
complex	0	O
of	0	O
N1	0	B
(	0	I
deltaEC	0	I
)	0	I
and	0	O
CBF1	0	B
.	0	O


81	0	O
milk	0	O
samples	0	O
collected	0	O
from	0	O
35	0	O
donors	0	O
3	0	O
days	0	O
to	0	O
7	0	O
months	0	O
after	0	O
delivery	0	O
were	0	O
examined	0	O
for	0	O
the	0	O
occurrence	0	O
of	0	O
cytomegalovirus	0	O
(	0	O
CMV	1	O
).	0	O


Analysis	1	O
of	0	O
the	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
mouse	0	B
Elavl1	0	I
(	0	O
mHuA	0	B
)	0	O
gene	0	O
reveals	0	O
a	0	O
transcriptional	0	O
regulatory	0	O
element	0	O
and	0	O
evidence	0	O
for	0	O
conserved	0	O
genomic	0	O
organization	0	O
.	0	O
mHuA	0	B
(	0	O
Elavl1	0	B
)	0	O
belongs	0	O
to	0	O
a	0	O
highly	0	O
conserved	0	O
family	0	O
of	0	O
genes	0	O
encoding	0	O
RNA	1	O
-	0	O
binding	0	O
proteins	0	O
and	0	O
has	0	O
been	0	O
linked	0	O
to	0	O
cell	0	O
growth	0	O
and	0	O
proliferation	0	O
through	0	O
its	0	O
regulation	0	O
of	0	O
mRNA	1	O
stability	0	O
.	0	O


The	0	O
functional	0	O
homology	0	O
of	0	O
Cwg2	0	B
with	0	O
Cdc43	0	B
,	0	O
which	0	O
has	0	O
been	0	O
implicated	0	O
in	0	O
the	0	O
control	0	O
of	0	O
cell	0	O
polarity	0	O
,	0	O
suggests	0	O
a	0	O
link	0	O
between	0	O
two	0	O
morphogenetic	0	O
events	0	O
such	0	O
as	0	O
establishment	0	O
of	0	O
cell	0	O
polarity	0	O
and	0	O
cell	0	O
wall	0	O
biosynthesis	0	O
.	0	O


HCV	1	O
infection	0	O
acquired	0	O
during	0	O
or	0	O
after	0	O
BMT	1	O
caused	0	O
only	0	O
mild	0	O
acute	0	O
hepatitis	0	O
C	1	O
,	0	O
which	0	O
progressed	0	O
to	0	O
chronic	0	O
hepatitis	0	O
C	1	O
in	0	O
one	0	O
patient	0	O
surviving	0	O
10	0	O
years	0	O
after	0	O
BMT	1	O
.	0	O


Subsequent	0	O
to	0	O
their	0	O
secretion	0	O
,	0	O
the	0	O
IGF	1	B
-	0	I
II	0	I
in	0	O
xz97	0	O
and	0	O
G11	0	O
cells	0	O
accumulated	0	O
in	0	O
the	0	O
conditioned	0	O
medium	0	O
mostly	0	O
as	0	O
two	0	O
partially	0	O
processed	0	O
species	0	O
with	0	O
appMr	0	O
,	0	O
of	0	O
17K	0	O
and	0	O
14K	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
data	0	O
further	0	O
indicate	0	O
that	0	O
the	0	O
IL	1	B
-	0	I
7R	0	I
alpha	0	I
chains	0	I
are	0	O
directly	0	O
involved	0	O
in	0	O
the	0	O
activation	0	O
of	0	O
JAKs	0	B
and	0	O
STATs	0	B
and	0	O
have	0	O
a	0	O
major	0	O
role	0	O
in	0	O
proliferative	0	O
signaling	0	O
in	0	O
precursor	0	O
B	1	O
cells	0	O
.	0	O


Human	1	O
adenovirus	0	O
type	0	O
41	0	O
contains	0	O
two	0	O
fibers	0	O
.	0	O


Unlike	0	O
ARF	1	B
,	0	O
the	0	O
ARP	0	B
immunoreactivity	0	O
was	0	O
detected	0	O
in	0	O
plasma	0	O
membranes	0	O
but	0	O
not	0	O
in	0	O
cytosol	0	O
of	0	O
fractionated	0	O
3T3	0	O
-	0	O
L1	0	O
cells	0	O
.	0	O


An	1	O
anchored	0	O
AFLP	0	O
-	0	O
and	0	O
retrotransposon	0	O
-	0	O
based	0	O
map	0	O
of	0	O
diploid	0	O
Avena	1	O
.	0	O


Toluene	1	O
is	0	O
the	0	O
chemical	0	O
most	0	O
frequently	0	O
present	0	O
in	0	O
cases	0	O
involving	0	O
volatile	0	O
solvents	0	O
.	0	O


A	1	O
position	0	O
-	0	O
independent	0	O
activation	0	O
domain	0	O
which	0	O
contained	0	O
conserved	0	O
regions	0	O
II	0	O
and	0	O
III	0	O
was	0	O
identified	0	O
at	0	O
the	0	O
carboxyl	0	O
terminus	0	O
of	0	O
the	0	O
HNF	1	B
-	0	I
3	0	I
beta	0	I
protein	0	I
(	0	O
amino	0	O
acids	0	O
361	0	O
to	0	O
458	0	O
).	0	O


CONCLUSIONS	0	O
:	0	O
Use	0	O
of	0	O
the	0	O
first	0	O
method	0	O
was	0	O
associated	0	O
with	0	O
a	0	O
reduction	0	O
in	0	O
the	0	O
time	0	O
patients	0	O
remained	0	O
in	0	O
the	0	O
ICU	1	O
before	0	O
transfer	0	O
to	0	O
another	0	O
unit	0	O
and	0	O
savings	0	O
in	0	O
nursing	0	O
time	0	O
,	0	O
but	0	O
the	0	O
two	0	O
methods	0	O
did	0	O
not	0	O
differ	0	O
according	0	O
to	0	O
clinical	0	O
outcomes	0	O
.	0	O


This	0	O
work	0	O
unravels	0	O
a	0	O
new	0	O
model	0	O
for	0	O
the	0	O
ets	0	B
-	0	I
1	0	I
/	0	O
ets	0	B
-	0	I
2	0	I
gene	0	I
'	0	O
s	0	O
evolution	0	O
,	0	O
based	0	O
for	0	O
the	0	O
first	0	O
time	0	O
on	0	O
both	0	O
structural	0	O
and	0	O
functional	0	O
evidences	0	O
.	0	O


The	0	O
deduced	0	O
bovine	0	O
EFIA	0	B
#	0	I
1	0	I
amino	0	O
acid	0	O
(	0	O
aa	0	O
)	0	O
sequence	0	O
is	0	O
98	0	O
%	0	O
identical	0	O
to	0	O
rat	0	O
EFIA	0	B
and	0	O
100	0	O
%	0	O
identical	0	O
to	0	O
human	0	O
EFIA	0	B
/	0	O
DbpB	0	B
/	0	O
YB	1	B
-	0	I
1	0	I
family	0	O
member	0	O
DNA	1	B
-	0	I
binding	0	I
protein	0	I
B	1	I
(	0	O
DbpB	0	B
).	0	O


Molecular	1	O
cloning	0	O
and	0	O
expression	0	O
of	0	O
RPE65	0	B
,	0	O
a	0	O
novel	0	O
retinal	0	O
pigment	0	O
epithelium	0	O
-	0	O
specific	0	O
microsomal	0	O
protein	0	O
that	0	O
is	0	O
post	0	O
-	0	O
transcriptionally	0	O
regulated	0	O
in	0	O
vitro	0	O
.	0	O


The	0	O
seventh	0	O
cysteine	0	O
residue	0	O
of	0	O
CTSE	0	B
is	0	O
located	0	O
within	0	O
the	0	O
activation	0	O
peptide	0	O
region	0	O
of	0	O
the	0	O
proenzyme	0	O
.	0	O


Systematic	1	O
functional	0	O
analysis	0	O
of	0	O
V1a	0	B
/	0	I
V2	0	I
hybrid	0	I
receptors	0	I
showed	0	O
that	0	O
the	0	O
second	0	O
intracellular	0	O
loop	0	O
of	0	O
the	0	O
V1a	0	B
receptor	0	I
is	0	O
required	0	O
and	0	O
sufficient	0	O
for	0	O
efficient	0	O
coupling	0	O
to	0	O
Gq	0	B
/	0	I
11	0	I
,	0	O
whereas	0	O
the	0	O
third	0	O
intracellular	0	O
loop	0	O
of	0	O
the	0	O
V2	0	B
receptor	0	I
is	0	O
required	0	O
and	0	O
sufficient	0	O
for	0	O
coupling	0	O
to	0	O
Gs	0	B
.	0	O


The	0	O
exogenous	0	O
fos	0	B
gene	0	I
was	0	O
rapidly	0	O
induced	0	O
to	0	O
maximal	0	O
levels	0	O
within	0	O
1	0	O
-	0	O
2	0	O
hr	0	O
of	0	O
estrogen	0	O
addition	0	O
.	0	O


Since	0	O
general	0	B
regulatory	0	I
factor	0	I
I	1	I
(	0	O
GRFI	0	B
)/	0	O
repressor	0	B
/	0	I
activator	0	I
site	0	I
binding	0	I
protein	0	I
1	0	I
(	0	O
RAP1	0	B
)/	0	O
translation	0	B
upstream	0	I
factor	0	I
(	0	O
TUF	0	B
)	0	O
is	0	O
believed	0	O
to	0	O
be	0	O
an	0	O
activator	0	O
of	0	O
MAT	1	B
alpha	0	I
expression	0	O
,	0	O
we	0	O
examined	0	O
whether	0	O
PYK1	0	B
,	0	O
which	0	O
is	0	O
known	0	O
to	0	O
be	0	O
regulated	0	O
by	0	O
GRFI	0	B
/	0	O
RAP1	0	B
/	0	O
TUF	0	B
,	0	O
is	0	O
also	0	O
affected	0	O
by	0	O
the	0	O
gal11	0	B
mutation	0	I
.	0	O


65	0	O
,	0	O
3829	0	O
-	0	O
3838	0	O
,	0	O
1991	0	O
),	0	O
a	0	O
truncated	0	O
form	0	O
of	0	O
the	0	O
IE	1	B
polypeptide	0	I
lacking	0	O
IE	1	B
amino	0	I
acid	0	I
residues	0	I
1	0	I
-	0	I
322	0	I
(	0	O
and	0	O
,	0	O
therefore	0	O
lacks	0	O
the	0	O
deduced	0	O
transcriptional	0	O
activation	0	O
domain	0	O
),	0	O
fails	0	O
to	0	O
transactivate	0	O
the	0	O
EHV	0	B
-	0	I
1	0	I
tk	0	I
promoter	0	I
,	0	O
but	0	O
retains	0	O
the	0	O
ability	0	O
to	0	O
down	0	O
-	0	O
regulate	0	O
the	0	O
EHV	0	B
-	0	I
1	0	I
IE	1	I
promoter	0	I
.	0	O


RESULTS	0	O
:	0	O
Soluble	1	O
CD23	0	B
levels	0	O
were	0	O
significantly	0	O
higher	0	O
in	0	O
women	0	O
with	0	O
endometriosis	0	O
before	0	O
treatment	0	O
than	0	O
in	0	O
ten	0	O
normal	0	O
controls	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
oral	0	O
vanadyl	0	O
sulfate	0	O
(	0	O
VOSO4	0	O
)	0	O
(	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
)	0	O
on	0	O
anthropometry	0	O
,	0	O
body	0	O
composition	0	O
,	0	O
and	0	O
performance	0	O
were	0	O
investigated	0	O
in	0	O
a	0	O
12	0	O
-	0	O
week	0	O
,	0	O
double	0	O
-	0	O
blind	0	O
,	0	O
placebo	0	O
-	0	O
controlled	0	O
trial	0	O
involving	0	O
weight	0	O
-	0	O
training	0	O
volunteers	0	O
.	0	O


Polymyxin	1	O
B	1	O
was	0	O
given	0	O
intravenously	0	O
for	0	O
1	0	O
week	0	O
postburn	0	O
in	0	O
doses	0	O
designed	0	O
to	0	O
neutralize	0	O
circulating	0	O
endotoxemia	0	O
.	0	O


Intraoperative	1	O
measurement	0	O
of	0	O
activated	0	O
partial	0	O
thromboplastin	0	B
time	0	O
and	0	O
prothrombin	0	B
time	0	O
with	0	O
a	0	O
new	0	O
compact	0	O
monitor	0	O
.	0	O


However	0	O
,	0	O
Southern	0	O
blot	0	O
and	0	O
karyotype	0	O
analyses	0	O
did	0	O
not	0	O
reveal	0	O
any	0	O
significant	0	O
changes	0	O
in	0	O
copy	0	O
number	0	O
or	0	O
gross	0	O
rearrangements	0	O
of	0	O
the	0	O
p53	0	B
gene	0	I
in	0	O
any	0	O
of	0	O
the	0	O
p53	0	B
-	0	I
cell	0	O
lines	0	O
.	0	O


Aggravating	0	O
process	0	O
induced	0	O
by	0	O
indomethacin	0	O
on	0	O
chronic	0	O
gastric	0	O
lesion	0	O
in	0	O
rat	0	O
.	0	O


Multiple	1	O
regression	0	O
analyses	0	O
revealed	0	O
that	0	O
WAIS	1	O
-	0	O
R	1	O
factor	0	O
scores	0	O
Verbal	1	O
Comprehension	0	O
and	0	O
Freedom	0	O
from	0	O
Distractibility	1	O
accounted	0	O
for	0	O
up	0	O
to	0	O
42	0	O
%	0	O
of	0	O
the	0	O
variance	0	O
in	0	O
WMS	1	O
-	0	O
R	1	O
and	0	O
CVLT	0	O
indices	0	O
.	0	O


This	0	O
in	0	O
turn	0	O
will	0	O
further	0	O
enhance	0	O
the	0	O
role	0	O
of	0	O
meta	0	O
-	0	O
analysis	0	O
in	0	O
helping	0	O
clinicians	0	O
and	0	O
policy	0	O
makers	0	O
answer	0	O
clinical	0	O
questions	0	O
.	0	O


Tumor	1	B
necrosis	0	I
factor	0	I
(	0	O
TNF	1	B
)	0	O
is	0	O
reported	0	O
to	0	O
cause	0	O
a	0	O
shock	0	O
syndrome	0	O
similar	0	O
to	0	O
that	0	O
produced	0	O
by	0	O
endotoxin	0	O
(	0	O
LPS	1	O
).	0	O


After	0	O
profound	0	O
normovolemic	0	O
hemodilution	0	O
(	0	O
Hct	1	O
9	0	O
%)	0	O
superiority	0	O
of	0	O
LV	1	O
MC	1	O
and	0	O
LV	1	O
diastolic	0	O
properties	0	O
was	0	O
found	0	O
,	0	O
when	0	O
myocardial	0	O
oxygenation	0	O
was	0	O
supported	0	O
by	0	O
i	0	O
.	0	O
v	0	O
.	0	O
perflubron	0	O
emulsion	0	O
,	0	O
a	0	O
temporary	0	O
O2	1	O
carrier	0	O
.	0	O


Five	0	O
healthy	0	O
male	0	O
subjects	0	O
inspired	0	O
air	0	O
for	0	O
20	0	O
min	0	O
and	0	O
then	0	O
5	0	O
%	0	O
CO2	1	O
/	0	O
95	0	O
%	0	O
O2	1	O
for	0	O
30	0	O
min	0	O
,	0	O
of	0	O
which	0	O
the	0	O
first	0	O
10	0	O
min	0	O
was	0	O
used	0	O
to	0	O
achieve	0	O
a	0	O
steady	0	O
-	0	O
state	0	O
end	0	O
-	0	O
tidal	0	O
CO2	1	O
measurement	0	O
.	0	O


Expression	1	O
and	0	O
regulation	0	O
by	0	O
interferon	0	B
of	0	O
a	0	O
double	0	B
-	0	I
stranded	0	I
-	0	I
RNA	1	I
-	0	I
specific	0	I
adenosine	0	I
deaminase	0	I
from	0	O
human	0	O
cells	0	O
:	0	O
evidence	0	O
for	0	O
two	0	O
forms	0	O
of	0	O
the	0	O
deaminase	0	O
.	0	O


New	0	O
and	0	O
successful	0	O
steps	0	O
have	0	O
been	0	O
made	0	O
in	0	O
immunodiagnostics	0	O
,	0	O
immunotherapy	0	O
,	0	O
and	0	O
immunoprophylaxis	0	O
of	0	O
immunologically	0	O
conditioned	0	O
infertility	0	O
.	0	O


The	0	O
monkey	0	B
LHR	0	I
cDNA	1	I
displayed	0	O
83	0	O
-	0	O
94	0	O
%	0	O
overall	0	O
sequence	0	O
homology	0	O
with	0	O
the	0	O
other	0	O
mammalian	0	B
LHR	0	I
cDNAs	0	I
.	0	O


Dry	1	O
matter	0	O
intake	0	O
,	0	O
apparent	0	O
nutrient	0	O
digestibilities	0	O
,	0	O
serum	0	O
chemistry	0	O
profiles	0	O
,	0	O
sphingolipid	0	O
concentrations	0	O
,	0	O
and	0	O
persistency	0	O
of	0	O
FB1	0	O
in	0	O
tissues	0	O
were	0	O
evaluated	0	O
.	0	O


We	0	O
now	0	O
provide	0	O
evidence	0	O
for	0	O
physical	0	O
and	0	O
functional	0	O
interaction	0	O
between	0	O
Doa4	0	B
and	0	O
the	0	O
proteasome	0	O
.	0	O


Revascularization	1	O
after	0	O
anterior	0	O
maxillary	0	O
and	0	O
mandibular	0	O
osteotomy	0	O


Although	0	O
upstream	0	O
regulators	0	O
of	0	O
Tec	0	B
family	0	I
kinases	0	I
are	0	O
relatively	0	O
well	0	O
characterized	0	O
,	0	O
little	0	O
is	0	O
known	0	O
of	0	O
the	0	O
downstream	0	O
effectors	0	O
of	0	O
these	0	O
enzymes	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
the	0	O
levels	0	O
of	0	O
oxygen	0	O
free	0	O
radicals	0	O
were	0	O
increased	0	O
in	0	O
hepatocytes	0	O
and	0	O
mitochondria	0	O
.	0	O


Glucagon	1	B
also	0	O
induced	0	O
LUC	0	B
activity	0	O
very	0	O
strongly	0	O
when	0	O
the	0	O
CRE1	0	O
and	0	O
CRE2	0	O
sites	0	O
were	0	O
combined	0	O
;	0	O
induction	0	O
of	0	O
the	0	O
(	0	O
CRE1	0	O
)	0	O
3	0	O
(	0	O
CRE2	0	O
)	0	O
2SV40	0	O
-	0	O
LUC	0	B
constructs	0	O
was	0	O
positively	0	O
modulated	0	O
by	0	O
the	0	O
pO2	1	O
.	0	O


The	0	O
Ntl1	0	B
gene	0	I
is	0	O
present	0	O
as	0	O
a	0	O
unique	0	O
copy	0	O
in	0	O
the	0	O
diploid	0	O
N	1	O
.	0	O
plumbaginifolia	0	O
species	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
present	0	O
evidence	0	O
for	0	O
a	0	O
model	0	O
in	0	O
which	0	O
mRNA	1	O
sequences	0	O
up	0	O
to	0	O
around	0	O
100	0	O
nucleotides	0	O
downstream	0	O
from	0	O
the	0	O
start	0	O
codon	0	O
of	0	O
21K	0	O
fold	0	O
back	0	O
and	0	O
base	0	O
-	0	O
pair	0	O
to	0	O
the	0	O
21K	0	O
translation	0	O
initiation	0	O
region	0	O
,	0	O
thereby	0	O
decreasing	0	O
the	0	O
translation	0	O
initiation	0	O
frequency	0	O
.	0	O


Similarity	0	O
is	0	O
most	0	O
striking	0	O
in	0	O
the	0	O
zinc	0	O
knuckle	0	O
region	0	O
,	0	O
a	0	O
region	0	O
characteristic	0	O
of	0	O
gag	0	B
genes	0	I
of	0	O
most	0	O
replication	0	O
-	0	O
competent	0	O
retroelements	0	O
.	0	O


It	1	O
has	0	O
repeatedly	0	O
been	0	O
shown	0	O
that	0	O
HCMV	0	O
IE1	0	B
/	0	O
IE2	0	B
can	0	O
independently	0	O
transactivate	0	O
HIV	1	B
-	0	I
1	0	I
LTR	1	I
.	0	O


In	1	O
a	0	O
randomized	0	O
study	0	O
on	0	O
150	0	O
patients	0	O
(	0	O
ASA	1	O
1	0	O
)	0	O
undergoing	0	O
induction	0	O
of	0	O
anaesthesia	0	O
,	0	O
the	0	O
effects	0	O
of	0	O
Fentanyl	0	O
(	0	O
0	0	O
.	0	O
1	0	O
mg	0	O
),	0	O
the	0	O
combination	0	O
of	0	O
Fentanyl	0	O
(	0	O
0	0	O
.	0	O
1	0	O
mg	0	O
)	0	O
and	0	O
Droperidol	1	O
(	0	O
5	0	O
mg	0	O
)	0	O
(	0	O
Innovar	1	O
,	0	O
Thalamonal	0	O
)	0	O
and	0	O
Atropine	1	O
(	0	O
0	0	O
.	0	O
01	0	O
mg	0	O
/	0	O
kg	0	O
b	0	O
.	0	O
w	0	O
.)	0	O
alone	0	O
on	0	O
cardiocirculatory	0	O
parameters	0	O
were	0	O
studied	0	O
.	0	O


R	1	O
-	0	O
wave	0	O
voltage	0	O
in	0	O
the	0	O
right	0	O
precordial	0	O
leads	0	O
in	0	O
anthracycline	0	O
cardiomyopathy	0	O
:	0	O
a	0	O
clinical	0	O
study	0	O
.	0	O


Of	0	O
7	0	O
patients	0	O
treated	0	O
with	0	O
cyclophosphamide	0	O
,	0	O
hexamethylmelamine	0	O
,	0	O
adriamycin	0	O
and	0	O
cisplatin	0	O
(	0	O
CHAP	0	O
-	0	O
5	0	O
),	0	O
6	0	O
had	0	O
measurable	0	O
disease	0	O
,	0	O
of	0	O
whom	0	O
5	0	O
yielded	0	O
a	0	O
response	0	O
(	0	O
2	0	O
complete	0	O
responses	0	O
for	0	O
19	0	O
+	0	O
and	0	O
40	0	O
months	0	O
and	0	O
3	0	O
partial	0	O
responses	0	O
for	0	O
4	0	O
,	0	O
7	0	O
and	0	O
8	0	O
months	0	O
).	0	O


Current	1	O
status	0	O
and	0	O
future	0	O
perspectives	0	O


The	0	O
systolic	0	O
pressure	0	O
gradient	0	O
(	0	O
SPG	0	O
)	0	O
between	0	O
the	0	O
left	0	O
ventricle	0	O
(	0	O
LV	1	O
)	0	O
and	0	O
left	0	O
atrium	0	O
(	0	O
LA	1	O
)	0	O
was	0	O
obtained	0	O
from	0	O
high	0	O
-	0	O
fidelity	0	O
pressure	0	O
transducers	0	O
.	0	O


The	0	O
femoroarterial	0	O
coronary	0	O
sinus	0	O
difference	0	O
in	0	O
lactate	0	O
turned	0	O
negative	0	O
,	0	O
and	0	O
pH	1	O
,	0	O
PCO2	1	O
and	0	O
potassium	0	O
differences	0	O
increased	0	O
in	0	O
group	0	O
2	0	O
during	0	O
pacing	0	O
.	0	O


In	1	O
a	0	O
third	0	O
experiment	0	O
,	0	O
a	0	O
Chessmaster	0	O
gradually	0	O
increases	0	O
the	0	O
number	0	O
of	0	O
boards	0	O
he	0	O
can	0	O
reproduce	0	O
with	0	O
higher	0	O
than	0	O
70	0	O
%	0	O
average	0	O
accuracy	0	O
to	0	O
nine	0	O
,	0	O
replacing	0	O
as	0	O
many	0	O
as	0	O
160	0	O
pieces	0	O
correctly	0	O
.	0	O


These	0	O
regions	0	O
contain	0	O
inverted	0	O
E	1	O
-	0	O
box	0	O
palindromic	0	O
or	0	O
direct	0	O
repeat	0	O
motifs	0	O
and	0	O
bind	0	O
SREBP	0	B
-	0	I
1	0	I
with	0	O
different	0	O
affinities	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
low	0	O
-	0	O
profile	0	O
serine	0	O
substitutions	0	O
in	0	O
the	0	O
V3	0	B
loop	0	O
of	0	O
HIV	1	O
-	0	O
1	0	O
gp120	0	B
IIIB	0	I
/	0	O
LAI	0	B
on	0	O
the	0	O
immunogenicity	0	O
of	0	O
the	0	O
envelope	0	B
protein	0	O
.	0	O


Drug	1	O
-	0	O
drug	0	O
interactions	0	O
are	0	O
most	0	O
likely	0	O
to	0	O
occur	0	O
in	0	O
patients	0	O
receiving	0	O
multiple	0	O
medications	0	O
and	0	O
with	0	O
drugs	0	O
that	0	O
have	0	O
a	0	O
narrow	0	O
therapeutic	0	O
window	0	O
.	0	O


The	0	O
induction	0	O
by	0	O
pseudorabies	0	O
virus	0	O
of	0	O
an	0	O
IL	1	B
-	0	I
6	0	I
construct	0	I
containing	0	O
the	0	O
IL	1	B
-	0	I
6	0	I
TATA	0	I
box	0	I
and	0	O
the	0	O
RNA	1	O
start	0	O
site	0	O
("	0	O
initiator	0	O
"	0	O
or	0	O
Inr	1	O
element	0	O
)	0	O
but	0	O
not	0	O
the	0	O
MRE	0	O
region	0	O
was	0	O
also	0	O
repressed	0	O
by	0	O
Dex	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
wild	0	B
-	0	I
type	0	I
GR	1	I
.	0	O


There	0	O
were	0	O
no	0	O
significant	0	O
changes	0	O
in	0	O
either	0	O
the	0	O
fatty	0	O
acid	0	O
composition	0	O
of	0	O
biliary	0	O
lecithin	0	O
or	0	O
in	0	O
the	0	O
bile	0	O
acid	0	O
composition	0	O
of	0	O
bile	0	O
.	0	O


Under	0	O
halothane	0	O
anesthesia	0	O
,	0	O
the	0	O
flow	0	O
pneumocardiogram	0	O
(	0	O
PnCG	0	O
)	0	O
and	0	O
its	0	O
time	0	O
derivative	0	O
(	0	O
acceleration	0	O
pneumocardiogram	0	O
or	0	O
dPn	0	O
/	0	O
dt	0	O
)	0	O
were	0	O
transduced	0	O
during	0	O
apnea	0	O
by	0	O
a	0	O
small	0	O
high	0	O
-	0	O
gain	0	O
pneumotachograph	0	O
.	0	O


Cytogenetic	1	O
and	0	O
molecular	0	O
characterization	0	O
of	0	O
random	0	O
chromosomal	0	O
rearrangements	0	O
activating	0	O
the	0	O
drug	0	O
resistance	0	O
gene	0	O
,	0	O
MDR1	0	B
/	0	O
P	1	B
-	0	I
glycoprotein	0	I
,	0	O
in	0	O
drug	0	O
-	0	O
selected	0	O
cell	0	O
lines	0	O
and	0	O
patients	0	O
with	0	O
drug	0	O
refractory	0	O
ALL	1	O
.	0	O


Since	0	O
1970	0	O
the	0	O
frequency	0	O
of	0	O
potassium	0	O
-	0	O
induced	0	O
ulceration	0	O
has	0	O
been	0	O
low	0	O
--	0	O
3	0	O
cases	0	O
per	0	O
100	0	O
000	0	O
patient	0	O
-	0	O
years	0	O
of	0	O
slow	0	O
-	0	O
release	0	O
tablet	0	O
use	0	O
.	0	O


Cardiac	1	O
disease	0	O
was	0	O
not	0	O
detected	0	O
with	0	O
M	1	O
-	0	O
mode	0	O
,	0	O
2	0	O
-	0	O
dimensional	0	O
real	0	O
-	0	O
time	0	O
or	0	O
pulsed	0	O
-	0	O
wave	0	O
Doppler	1	O
echocardiography	0	O
.	0	O


The	0	O
Dox	0	B
-	0	I
A2	1	I
locus	0	I
is	0	O
within	0	O
3	0	O
.	0	O
4	0	O
to	0	O
4	0	O
.	0	O
4	0	O
kb	0	O
of	0	O
the	0	O
Df	0	B
(	0	I
2L	0	I
)	0	I
OD15	0	I
breakpoint	0	I
,	0	O
placing	0	O
four	0	O
of	0	O
the	0	O
vital	0	O
loci	0	O
within	0	O
a	0	O
maximum	0	O
of	0	O
15	0	O
.	0	O
5	0	O
kb	0	O
.	0	O


Connector	1	B
enhancer	0	I
of	0	I
KSR	0	I
(	0	O
CNK	0	B
)	0	O
is	0	O
a	0	O
multidomain	0	O
protein	0	O
required	0	O
for	0	O
RAS	1	B
signaling	0	O
.	0	O


Effects	0	O
of	0	O
intramammary	0	O
endotoxin	0	O
infusion	0	O
on	0	O
milking	0	O
-	0	O
induced	0	O
oxytocin	0	B
release	0	O
.	0	O


Sixty	0	O
days	0	O
after	0	O
the	0	O
intervention	0	O
,	0	O
twitch	0	O
and	0	O
tetanic	0	O
tensions	0	O
remained	0	O
dependent	0	O
upon	0	O
the	0	O
extracellular	0	O
Ca2	1	O
+	0	O
concentration	0	O
([	0	O
Ca	1	O
]	0	O
o	0	O
)	0	O
both	0	O
in	0	O
groups	0	O
A	1	O
and	0	O
B	1	O
.	0	O


Most	0	O
,	0	O
however	0	O
,	0	O
would	0	O
tell	0	O
the	0	O
spouse	0	O
the	0	O
full	0	O
truth	0	O
about	0	O
both	0	O
diagnosis	0	O
and	0	O
prognosis	0	O
.	0	O


The	0	O
sensitivity	0	O
of	0	O
the	0	O
vas	0	O
deferens	0	O
to	0	O
adrenaline	0	O
was	0	O
also	0	O
reduced	0	O
in	0	O
scorbutic	0	O
guinea	0	O
pigs	0	O
,	0	O
thus	0	O
decreasing	0	O
their	0	O
fertility	0	O
rate	0	O
.	0	O


Hence	0	O
,	0	O
the	0	O
uPA	0	B
promoter	0	I
contains	0	O
multiple	0	O
weak	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
distributed	0	O
over	0	O
7	0	O
.	0	O
0	0	O
kb	0	O
5	0	O
'	0	O
to	0	O
the	0	O
translation	0	O
start	0	O
site	0	O
.	0	O


Levels	0	O
of	0	O
the	0	O
MEK	0	B
inhibitor	0	O
PD98059	0	O
that	0	O
block	0	O
EGF	1	B
-	0	O
induced	0	O
mitogenesis	0	O
and	0	O
MAP	1	B
kinase	0	I
phosphorylation	0	O
also	0	O
abrogate	0	O
EGF	1	B
-	0	O
induced	0	O
focal	0	O
adhesion	0	O
disassembly	0	O
and	0	O
cell	0	O
motility	0	O
.	0	O


The	0	O
Oct	1	B
and	0	O
HMG2	0	B
proteins	0	I
also	0	O
interact	0	O
in	0	O
vivo	0	O
.	0	O


Lipid	1	O
concentration	0	O
and	0	O
lipase	0	B
activity	0	O
in	0	O
the	0	O
epiphysis	0	O
of	0	O
adrenalectomized	0	O
rats	0	O
consuming	0	O
food	0	O
with	0	O
different	0	O
sodium	0	O
content	0	O


This	0	O
study	0	O
analyzed	0	O
whether	0	O
the	0	O
localization	0	O
of	0	O
an	0	O
accessory	0	O
pathway	0	O
could	0	O
be	0	O
predicted	0	O
by	0	O
using	0	O
the	0	O
polarity	0	O
of	0	O
the	0	O
QRS	0	O
complex	0	O
during	0	O
sinus	0	O
rhythm	0	O
on	0	O
the	0	O
surface	0	O
ECG	1	O
,	0	O
instead	0	O
of	0	O
the	0	O
delta	0	O
wave	0	O
polarity	0	O
as	0	O
used	0	O
in	0	O
many	0	O
reports	0	O
.	0	O


Transient	1	O
transfection	0	O
assays	0	O
using	0	O
P19	0	O
cells	0	O
revealed	0	O
that	0	O
expression	0	O
of	0	O
NDRF	0	B
/	0	O
NeuroD2	0	B
increased	0	O
the	0	O
transactivation	0	O
of	0	O
the	0	O
rat	0	B
insulin	0	I
promoter	0	I
element	0	I
3	0	I
(	0	O
RIPE3	0	B
)	0	O
enhancer	0	O
up	0	O
to	0	O
approximately	0	O
12	0	O
-	0	O
fold	0	O
and	0	O
that	0	O
co	0	O
-	0	O
expression	0	O
of	0	O
catalytically	0	O
active	0	O
form	0	O
of	0	O
PKN	0	B
,	0	O
but	0	O
not	0	O
kinase	0	O
-	0	O
deficient	0	O
derivative	0	O
,	0	O
resulted	0	O
in	0	O
a	0	O
further	0	O
threefold	0	O
increase	0	O
of	0	O
NDRF	0	B
/	0	O
NeuroD2	0	B
-	0	O
mediated	0	O
transcription	0	O
.	0	O


RNase	1	B
MRP	0	I
is	0	O
a	0	O
ribonucleoprotein	0	O
endoribonuclease	0	O
that	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
have	0	O
roles	0	O
in	0	O
both	0	O
mitochondrial	0	O
DNA	1	O
replication	0	O
and	0	O
nuclear	0	B
5	0	I
.	0	I
8S	0	I
rRNA	1	I
processing	0	O
.	0	O


Disruption	1	O
of	0	O
the	0	O
HOG1	0	B
and	0	O
PBS2	0	B
genes	0	I
leads	0	O
to	0	O
a	0	O
dramatic	0	O
decrease	0	O
of	0	O
the	0	O
HSP12	0	B
inducibility	0	O
in	0	O
osmostressed	0	O
cells	0	O
,	0	O
whereas	0	O
overproduction	0	O
of	0	O
Hog1	0	B
produces	0	O
a	0	O
fivefold	0	O
increase	0	O
in	0	O
wild	0	O
-	0	O
type	0	O
induced	0	O
levels	0	O
upon	0	O
a	0	O
shift	0	O
to	0	O
a	0	O
high	0	O
salt	0	O
concentration	0	O
.	0	O


The	0	O
structural	0	O
genes	0	O
encoding	0	O
glyceraldehyde	0	B
-	0	I
3	0	I
-	0	I
phosphate	0	I
dehydrogenase	0	I
(	0	O
GAPDH	0	B
),	0	O
3	0	B
-	0	I
phosphoglycerate	0	I
kinase	0	I
(	0	O
PGK	0	B
)	0	O
and	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
part	0	O
of	0	O
triosephosphate	0	B
isomerase	0	I
(	0	O
TIM	0	B
)	0	O
from	0	O
mesophilic	0	O
Bacillus	1	O
megaterium	0	O
DSM319	0	O
have	0	O
been	0	O
cloned	0	O
as	0	O
a	0	O
gene	0	O
cluster	0	O
(	0	O
gap	0	B
operon	0	I
)	0	O
by	0	O
complementation	0	O
of	0	O
an	0	O
Escherichia	1	O
coli	0	O
gap	0	B
amber	0	I
mutant	0	I
.	0	O


A	1	O
crucial	0	O
transcription	0	O
factor	0	O
in	0	O
this	0	O
process	0	O
is	0	O
STAT6	0	B
,	0	O
which	0	O
binds	0	O
to	0	O
a	0	O
specific	0	O
DNA	1	O
element	0	O
upon	0	O
cytokine	0	O
activation	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
insulin	0	B
response	0	O
had	0	O
returned	0	O
to	0	O
the	0	O
non	0	O
-	0	O
pregnant	0	O
value	0	O
by	0	O
the	0	O
second	0	O
day	0	O
of	0	O
the	0	O
puerperium	0	O
.	0	O


We	0	O
propose	0	O
that	0	O
noi	0	B
/	0	O
pax2	0	B
.	0	I
1	0	I
participates	0	O
in	0	O
sequential	0	O
signaling	0	O
processes	0	O
as	0	O
a	0	O
key	0	O
integrator	0	O
of	0	O
midbrain	0	O
-	0	O
hindbrain	0	O
boundary	0	O
development	0	O
.	0	O


The	0	O
PAC	1	O
clone	0	O
with	0	O
an	0	O
insert	0	O
size	0	O
of	0	O
120kb	0	O
was	0	O
isolated	0	O
and	0	O
mapped	0	O
by	0	O
restriction	0	O
analysis	0	O
.	0	O


The	0	O
origins	0	O
of	0	O
reflected	0	O
light	0	O
changes	0	O
associated	0	O
with	0	O
neuronal	0	O
activity	0	O
(	0	O
optical	0	O
signals	0	O
)	0	O
were	0	O
investigated	0	O
in	0	O
rat	0	O
somatosensory	0	O
cortex	0	O
with	0	O
optical	0	O
imaging	0	O
,	0	O
microspectrophotometry	0	O
,	0	O
and	0	O
laser	0	O
-	0	O
Doppler	1	O
flowmetry	0	O
,	0	O
and	0	O
dynamic	0	O
changes	0	O
in	0	O
local	0	O
hemoglobin	0	B
concentration	0	O
and	0	O
oxygenation	0	O
were	0	O
focused	0	O
on	0	O
.	0	O


Silencing	1	O
can	0	O
be	0	O
restored	0	O
by	0	O
creation	0	O
of	0	O
a	0	O
telomere	0	O
at	0	O
13	0	O
kb	0	O
from	0	O
the	0	O
reporter	0	O
construct	0	O
,	0	O
or	0	O
by	0	O
insertion	0	O
of	0	O
340	0	O
bp	0	O
of	0	O
yeast	0	O
telomeric	0	O
repeat	0	O
sequence	0	O
at	0	O
this	0	O
site	0	O
without	0	O
chromosomal	0	O
truncation	0	O
.	0	O


BCR	0	B
cross	0	O
-	0	O
linking	0	O
also	0	O
led	0	O
to	0	O
increased	0	O
MAPK	1	B
-	0	O
activated	0	O
protein	0	B
kinase	0	I
-	0	I
2	0	I
activity	0	O
,	0	O
an	0	O
enzyme	0	O
that	0	O
lies	0	O
immediately	0	O
downstream	0	O
from	0	O
p38	0	B
MAPK	1	I
;	0	O
MAPK	1	B
-	0	O
activated	0	O
protein	0	B
kinase	0	I
-	0	I
2	0	I
immune	0	O
complexes	0	O
phosphorylated	0	O
a	0	O
peptide	0	O
substrate	0	O
containing	0	O
the	0	O
CREB	0	B
serine	0	I
133	0	I
phosphoacceptor	0	I
motif	0	I
.	0	O


The	0	O
effect	0	O
of	0	O
CBZ	0	O
and	0	O
DPH	1	O
can	0	O
be	0	O
explained	0	O
by	0	O
interference	0	O
with	0	O
thyroid	0	O
hormone	0	O
binding	0	O
to	0	O
TBG	1	B
combined	0	O
with	0	O
enzyme	0	O
-	0	O
induced	0	O
increased	0	O
metabolic	0	O
clearance	0	O
rate	0	O
of	0	O
thyroid	0	O
hormones	0	O
without	0	O
homeostatic	0	O
maintenance	0	O
of	0	O
premedication	0	O
levels	0	O
of	0	O
FT4	0	O
and	0	O
FT3	0	O
.	0	O


99mTc	0	O
-	0	O
HMPAO	1	O
was	0	O
distributed	0	O
in	0	O
the	0	O
territories	0	O
of	0	O
the	0	O
ACA	1	O
and	0	O
MCA	1	O
in	0	O
the	0	O
two	0	O
patients	0	O
who	0	O
were	0	O
treated	0	O
with	0	O
intraarterial	0	O
infusion	0	O
of	0	O
papaverine	0	O
from	0	O
the	0	O
C4	1	O
segment	0	O
,	0	O
but	0	O
was	0	O
distributed	0	O
only	0	O
to	0	O
the	0	O
territory	0	O
of	0	O
the	0	O
ACA	1	O
in	0	O
four	0	O
patients	0	O
who	0	O
were	0	O
treated	0	O
with	0	O
intraarterial	0	O
infusion	0	O
of	0	O
papaverine	0	O
from	0	O
the	0	O
C1	1	O
segment	0	O
at	0	O
1	0	O
ml	0	O
/	0	O
min	0	O
.	0	O


E2F	0	B
activity	0	O
is	0	O
regulated	0	O
in	0	O
part	0	O
by	0	O
the	0	O
retinoblastoma	0	B
family	0	I
of	0	I
tumor	0	I
suppressor	0	I
proteins	0	I
.	0	O


The	0	O
spectrum	0	O
of	0	O
histologically	0	O
diagnosed	0	O
malignant	0	O
neoplasms	0	O
in	0	O
Sabah	0	O
,	0	O
1983	0	O
-	0	O
1988	0	O
.	0	O


Thus	0	O
,	0	O
Esigma54	0	B
promoters	0	I
are	0	O
responsive	0	O
to	0	O
CRP	1	B
,	0	O
a	0	O
protein	0	O
unrelated	0	O
to	0	O
sigma54	0	B
activators	0	I
,	0	O
and	0	O
the	0	O
repression	0	O
exerted	0	O
is	0	O
the	0	O
direct	0	O
result	0	O
of	0	O
an	0	O
interaction	0	O
between	0	O
Esigma54	0	B
and	0	O
the	0	O
CRP	1	B
-	0	I
cAMP	1	I
complex	0	I
.	0	O


We	0	O
emphasize	0	O
that	0	O
ANCA	1	B
-	0	O
associated	0	O
vasculitis	0	O
is	0	O
another	0	O
important	0	O
complication	0	O
of	0	O
RA	1	O
.	0	O


Early	0	O
heparin	0	O
therapy	0	O
in	0	O
60	0	O
children	0	O
with	0	O
acute	0	O
meningococcemia	0	O
.	0	O


Post	1	O
-	0	O
operative	0	O
functional	0	O
outcome	0	O
is	0	O
related	0	O
to	0	O
pre	0	O
-	0	O
operative	0	O
functional	0	O
status	0	O
.	0	O


State	1	O
-	0	O
approved	0	O
schools	0	O
of	0	O
nursing	0	O
--	0	O
R	1	O
.	0	O
N	1	O
.,	0	O
1972	0	O
.	0	O


Sulfhydryl	1	O
titration	0	O
with	0	O
iodoacetamide	0	O
,	0	O
monitored	0	O
by	0	O
quantitating	0	O
the	0	O
residual	0	O
thiols	0	O
after	0	O
reaction	0	O
with	0	O
a	0	O
maleimide	0	O
derivative	0	O
of	0	O
biotin	0	O
,	0	O
revealed	0	O
a	0	O
striking	0	O
difference	0	O
in	0	O
the	0	O
apparent	0	O
pK	1	O
(	0	O
a	0	O
)	0	O
values	0	O
of	0	O
the	0	O
cysteines	0	O
at	0	O
the	0	O
two	0	O
splice	0	O
junctions	0	O
.	0	O


After	0	O
two	0	O
successive	0	O
rounds	0	O
of	0	O
selection	0	O
by	0	O
focus	0	O
formation	0	O
assay	0	O
,	0	O
a	0	O
transforming	0	O
ribozyme	0	O
(	0	O
Rz007	0	B
)	0	O
was	0	O
identified	0	O
.	0	O


Increasing	0	O
the	0	O
RH	1	O
beyond	0	O
32	0	O
%	0	O
resulted	0	O
in	0	O
solvation	0	O
of	0	O
the	0	O
peroxy	0	O
radical	0	O
,	0	O
sterically	0	O
hindering	0	O
the	0	O
radical	0	O
from	0	O
entering	0	O
the	0	O
propagation	0	O
transition	0	O
state	0	O
.	0	O


The	0	O
imino	0	O
proton	0	O
of	0	O
T3	1	O
in	0	O
the	0	O
O6meG	0	O
.	0	O
T	1	O
12	0	O
-	0	O
mer	0	O
and	0	O
G3	0	O
in	0	O
the	0	O
O6meG	0	O
.	0	O
N	1	O
12	0	O
-	0	O
mer	0	O
helix	0	O
,	0	O
which	0	O
are	0	O
associated	0	O
with	0	O
the	0	O
modification	0	O
site	0	O
,	0	O
resonate	0	O
at	0	O
unusually	0	O
high	0	O
field	0	O
(	0	O
8	0	O
.	0	O
5	0	O
to	0	O
9	0	O
.	0	O
0	0	O
ppm	0	O
)	0	O
compared	0	O
to	0	O
imino	0	O
protons	0	O
in	0	O
Watson	0	O
-	0	O
Crick	1	O
base	0	O
pairs	0	O
(	0	O
12	0	O
.	0	O
5	0	O
to	0	O
14	0	O
.	0	O
5	0	O
ppm	0	O
).	0	O


Spasmus	1	O
nutans	0	O
:	0	O
a	0	O
syndrome	0	O
of	0	O
auto	0	O
-	0	O
arousal	0	O
.	0	O


Heparin	1	O
had	0	O
no	0	O
effect	0	O
on	0	O
rAC	0	B
-	0	I
st	0	I
myosin	0	I
light	0	I
chain	0	I
phosphatase	0	I
activity	0	O
,	0	O
while	0	O
the	0	O
B	1	O
subunit	0	O
-	0	O
containing	0	O
forms	0	O
were	0	O
stimulated	0	O
2	0	O
-	0	O
3	0	O
-	0	O
fold	0	O
.	0	O


Insulin	1	B
stimulation	0	O
promoted	0	O
the	0	O
association	0	O
of	0	O
mIRS3	0	B
with	0	O
p85	0	B
,	0	O
SHP2	0	B
,	0	O
Nck	0	B
,	0	O
and	0	O
Shc	0	B
.	0	O


Differentiation	1	O
was	0	O
not	0	O
observed	0	O
after	0	O
cellular	0	O
expression	0	O
of	0	O
GTPase	1	B
-	0	O
deficient	0	O
forms	0	O
of	0	O
alpha	0	B
i2	0	I
or	0	O
alpha	0	B
0	0	I
,	0	O
indicating	0	O
selectivity	0	O
for	0	O
the	0	O
Gq	0	B
family	0	I
of	0	O
G	1	B
proteins	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
cotransfection	0	O
of	0	O
TFIIB	0	B
and	0	O
IRF	1	B
-	0	I
1	0	I
into	0	O
NIH	1	O
3T3	0	O
cells	0	O
resulted	0	O
in	0	O
a	0	O
dose	0	O
-	0	O
dependent	0	O
repression	0	O
of	0	O
promoter	0	O
activation	0	O
which	0	O
occurred	0	O
in	0	O
a	0	O
TATA	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


Products	0	O
of	0	O
immune	0	O
cells	0	O
such	0	O
as	0	O
transfer	0	B
factor	0	I
and	0	O
lymphokines	0	O
form	0	O
the	0	O
third	0	O
and	0	O
possibly	0	O
most	0	O
important	0	O
group	0	O
of	0	O
immune	0	O
-	0	O
stimulating	0	O
agents	0	O
.	0	O


However	0	O
,	0	O
little	0	O
was	0	O
understood	0	O
about	0	O
the	0	O
normal	0	O
function	0	O
of	0	O
CREB	0	B
-	0	I
2	0	I
in	0	O
mammalian	0	O
development	0	O
or	0	O
organ	0	O
physiology	0	O
.	0	O


Droperidol	1	O
-	0	O
induced	0	O
extrapyramidal	0	O
symptoms	0	O
in	0	O
an	0	O
adolescent	0	O
following	0	O
strabismus	0	O
surgery	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
taloximine	0	O
and	0	O
aminophylline	0	O
on	0	O
isolated	0	O
human	0	O
smooth	0	O
muscle	0	O
.	0	O


To	1	O
identify	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
that	0	O
target	0	O
c	0	B
-	0	I
myc	0	I
mRNA	1	I
for	0	O
downregulation	0	O
during	0	O
myogenesis	0	O
,	0	O
we	0	O
stably	0	O
transfected	0	O
C2C12	0	O
cells	0	O
with	0	O
mutant	0	B
myc	0	I
genes	0	I
or	0	O
chimeric	0	O
genes	0	O
in	0	O
which	0	O
various	0	O
myc	0	B
sequences	0	I
were	0	O
fused	0	O
to	0	O
the	0	O
human	0	B
beta	0	I
-	0	I
globin	0	I
gene	0	I
or	0	O
to	0	O
the	0	O
bacterial	0	B
chloramphenicol	0	I
acetyltransferase	0	I
(	0	O
CAT	1	B
)	0	O
gene	0	O
.	0	O


However	0	O
,	0	O
a	0	O
cosmid	0	O
clone	0	O
containing	0	O
the	0	O
entire	0	O
mouse	0	B
alpha	0	I
1	0	I
(	0	I
I	1	I
)	0	I
gene	0	I
,	0	O
including	0	O
3	0	O
.	0	O
7	0	O
kb	0	O
of	0	O
5	0	O
'-	0	O
and	0	O
4	0	O
kb	0	O
of	0	O
3	0	O
'-	0	O
flanking	0	O
DNA	1	O
,	0	O
was	0	O
expressed	0	O
at	0	O
reduced	0	O
levels	0	O
in	0	O
fibroblasts	0	O
overexpressing	0	O
oncogenic	0	B
ras	0	I
.	0	O


Controlled	1	O
versus	0	O
uncontrolled	0	O
reperfusion	0	O
of	0	O
ischemic	0	O
myocardium	0	O
after	0	O
experimental	0	O
coronary	0	O
artery	0	O
occlusion	0	O
was	0	O
studied	0	O
to	0	O
determine	0	O
the	0	O
effect	0	O
on	0	O
regional	0	O
ventricular	0	O
wall	0	O
motion	0	O
and	0	O
associated	0	O
biochemical	0	O
alterations	0	O
.	0	O


This	0	O
action	0	O
is	0	O
dependent	0	O
on	0	O
helix	0	B
-	0	I
loop	0	I
-	0	I
helix	0	I
factors	0	I
bound	0	O
to	0	O
the	0	O
E1	1	B
element	0	O
.	0	O


Once	0	O
more	0	O
Hong	0	O
Kong	0	O
influenza	0	O
in	0	O
the	0	O
Netherlands	0	O


Systemic	1	O
lupus	0	O
erythematosus	0	O
was	0	O
diagnosed	0	O
.	0	O


In	1	O
reviewing	0	O
a	0	O
number	0	O
of	0	O
the	0	O
most	0	O
intensely	0	O
studied	0	O
environmentally	0	O
inducible	0	O
promoters	0	O
it	0	O
becomes	0	O
clear	0	O
that	0	O
the	0	O
presence	0	O
of	0	O
two	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
are	0	O
critical	0	O
for	0	O
promoter	0	O
activity	0	O
,	0	O
one	0	O
of	0	O
which	0	O
is	0	O
the	0	O
G	1	O
-	0	O
box	0	O
(	0	O
CCACGTGG	0	O
).	0	O


Based	0	O
on	0	O
these	0	O
results	0	O
the	0	O
minimal	0	O
control	0	O
element	0	O
(	0	O
AX	0	O
470	0	O
)	0	O
specifying	0	O
the	0	O
anterior	0	O
boundary	0	O
of	0	O
Hox	0	B
expression	0	O
was	0	O
designated	0	O
as	0	O
Hoxa	0	B
-	0	I
7	0	I
enhancer	0	I
.	0	O


Because	0	O
of	0	O
this	0	O
latter	0	O
phenomenon	0	O
,	0	O
we	0	O
were	0	O
able	0	O
to	0	O
identify	0	O
a	0	O
particular	0	O
cysteine	0	O
motif	0	O
that	0	O
was	0	O
repeated	0	O
multiple	0	O
times	0	O
in	0	O
Dfurin2	0	B
but	0	O
present	0	O
only	0	O
twice	0	O
in	0	O
mammalian	0	B
furin	0	I
.	0	O


In	1	O
contrast	0	O
to	0	O
the	0	O
signaling	0	O
triggered	0	O
by	0	O
surface	0	O
Ig	1	B
engagement	0	O
in	0	O
B	1	O
lymphocytes	0	O
,	0	O
CD38	0	B
ligation	0	O
did	0	O
not	0	O
appear	0	O
to	0	O
induce	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
the	0	O
src	0	B
-	0	I
like	0	I
protein	0	I
tyrosine	0	I
kinases	0	I
lyn	0	I
,	0	O
fyn	0	B
,	0	O
and	0	O
btk	0	B
,	0	O
or	0	O
of	0	O
vav	0	B
-	0	I
and	0	I
ras	0	I
-	0	I
GTPase	1	I
-	0	I
activating	0	I
protein	0	I
,	0	O
nor	0	O
did	0	O
it	0	O
induce	0	O
detectable	0	O
changes	0	O
in	0	O
cytosolic	0	O
CA2	1	O
+	0	O
concentrations	0	O
.	0	O


Vascular	1	O
endothelial	0	O
cells	0	O
undergo	0	O
profound	0	O
changes	0	O
upon	0	O
cellular	0	O
activation	0	O
including	0	O
expression	0	O
of	0	O
a	0	O
spectrum	0	O
of	0	O
cell	0	O
activation	0	O
-	0	O
associated	0	O
genes	0	O
.	0	O


Identification	1	O
and	0	O
estimation	0	O
of	0	O
monosaccharides	0	O
and	0	O
disaccharides	0	O
in	0	O
urine	0	O
by	0	O
gas	0	O
-	0	O
liquid	0	O
chromatography	0	O
.	0	O


The	0	O
above	0	O
results	0	O
mean	0	O
that	0	O
the	0	O
increase	0	O
in	0	O
alpha	0	B
-	0	I
adrenergic	0	I
receptors	0	I
makes	0	O
the	0	O
prostate	0	O
,	0	O
which	0	O
has	0	O
been	0	O
already	0	O
hypertrophied	0	O
,	0	O
less	0	O
elastic	0	O
,	0	O
inhibiting	0	O
external	0	O
urinary	0	O
sphincter	0	O
function	0	O
.	0	O


However	0	O
,	0	O
it	0	O
remains	0	O
an	0	O
open	0	O
question	0	O
whether	0	O
vertebrate	0	B
Hox	0	I
genes	0	I
expressed	0	O
under	0	O
the	0	O
control	0	O
of	0	O
Drosophila	1	O
regulatory	0	O
sequences	0	O
can	0	O
substitute	0	O
the	0	O
function	0	O
of	0	O
Drosophila	1	B
Hox	0	I
genes	0	I
.	0	O


Rinit	0	O
reflects	0	O
the	0	O
Newtonian	0	O
resistances	0	O
and	0	O
Rdiff	0	O
represents	0	O
the	0	O
viscoelastic	0	O
/	0	O
inhomogeneous	0	O
pressure	0	O
dissipations	0	O
in	0	O
the	0	O
system	0	O
.	0	O


Pronounced	0	O
microangiopathy	0	O
characterized	0	O
by	0	O
avascular	0	O
fields	0	O
,	0	O
enlarged	0	O
and	0	O
tortuous	0	O
capillaries	0	O
and	0	O
increased	0	O
transcapillary	0	O
diffusion	0	O
of	0	O
sodium	0	O
fluorescein	0	O
,	0	O
was	0	O
clearly	0	O
demonstrable	0	O
in	0	O
the	0	O
area	0	O
of	0	O
the	0	O
nodules	0	O
.	0	O


These	0	O
lesions	0	O
may	0	O
be	0	O
treated	0	O
by	0	O
propranolol	0	O
or	0	O
phentolamine	0	O
.	0	O


Dual	0	O
innervation	0	O
of	0	O
fast	0	O
fibers	0	O
in	0	O
trunk	0	O
muscles	0	O
of	0	O
lamprey	0	O
larvae	0	O


All	1	O
patients	0	O
in	0	O
the	0	O
control	0	O
group	0	O
showed	0	O
a	0	O
significant	0	O
improvement	0	O
in	0	O
their	0	O
PEFR	1	O
while	0	O
only	0	O
3	0	O
patients	0	O
in	0	O
the	0	O
treated	0	O
group	0	O
showed	0	O
an	0	O
improvement	0	O
.	0	O


Mutations	0	O
in	0	O
genes	0	O
encoding	0	O
PR65	0	B
/	0	I
A	1	I
subunits	0	I
have	0	O
been	0	O
identified	0	O
in	0	O
several	0	O
different	0	O
human	0	O
cancers	0	O
and	0	O
the	0	O
PP2A	0	B
inhibitor	0	O
,	0	O
termed	0	O
fostriecin	0	O
,	0	O
is	0	O
being	0	O
tested	0	O
as	0	O
an	0	O
anticancer	0	O
drug	0	O
.	0	O


We	0	O
also	0	O
isolated	0	O
two	0	O
alternatively	0	O
spliced	0	O
forms	0	O
of	0	O
human	0	B
CD6	0	I
cDNA	1	I
lacking	0	O
sequences	0	O
encoding	0	O
membrane	0	O
-	0	O
proximal	0	O
regions	0	O
of	0	O
the	0	O
cytoplasmic	0	O
domain	0	O
which	0	O
maintain	0	O
the	0	O
same	0	O
reading	0	O
frame	0	O
as	0	O
CD6	0	B
-	0	O
PB1	0	B
.	0	O


Activation	1	O
of	0	O
the	0	O
mitogen	0	B
activated	0	I
protein	0	I
(	0	I
MAP	1	I
)	0	I
kinase	0	I
is	0	O
a	0	O
primary	0	O
consequence	0	O
of	0	O
Ras	1	B
activation	0	O
and	0	O
plays	0	O
a	0	O
key	0	O
role	0	O
in	0	O
mediating	0	O
Ras	1	B
signal	0	O
transduction	0	O
.	0	O


The	0	O
second	0	O
primary	0	O
mutant	0	O
contained	0	O
a	0	O
proline	0	O
-	0	O
to	0	O
-	0	O
leucine	0	O
change	0	O
at	0	O
position	0	O
243	0	O
(	0	O
P243L	0	O
).	0	O


The	0	O
frequency	0	O
of	0	O
integrations	0	O
that	0	O
led	0	O
to	0	O
transcription	0	O
of	0	O
the	0	O
lacZ	0	B
gene	0	I
was	0	O
estimated	0	O
to	0	O
be	0	O
0	0	O
.	0	O
5	0	O
%	0	O
of	0	O
all	0	O
integrations	0	O
,	0	O
of	0	O
which	0	O
14	0	O
%	0	O
were	0	O
downregulated	0	O
on	0	O
differentiation	0	O
of	0	O
32D	0	O
cells	0	O
towards	0	O
neutrophils	0	O
.	0	O


Ultrasound	1	O
effect	0	O
on	0	O
the	0	O
cytochrome	0	B
oxidase	0	I
activity	0	O


The	0	O
routine	0	O
administration	0	O
of	0	O
fat	0	O
-	0	O
soluble	0	O
vitamins	0	O
appears	0	O
unnecessary	0	O
but	0	O
it	0	O
is	0	O
prudent	0	O
to	0	O
measure	0	O
prothrombin	0	B
time	0	O
and	0	O
serum	0	O
vitamins	0	O
A	1	O
and	0	O
E	1	O
at	0	O
intervals	0	O
.	0	O


A	1	O
retrospective	0	O
study	0	O
of	0	O
banked	0	O
sera	0	O
from	0	O
19	0	O
cats	0	O
with	0	O
the	0	O
eosinophilic	0	O
granuloma	0	O
complex	0	O
revealed	0	O
that	0	O
68	0	O
%	0	O
of	0	O
affected	0	O
cats	0	O
had	0	O
circulating	0	O
antibodies	0	O
to	0	O
components	0	O
of	0	O
normal	0	O
cat	0	O
epithelium	0	O
.	0	O


This	0	O
sequence	0	O
,	0	O
Thr	1	O
-	0	O
Gly	1	O
-	0	O
X	1	O
-	0	O
X	1	O
-	0	O
Gly	1	O
-	0	O
Asp	1	O
-	0	O
Gly	1	O
-	0	O
Lys	1	O
-	0	O
Ile	1	O
-	0	O
Phe	1	O
,	0	O
forms	0	O
part	0	O
of	0	O
the	0	O
B	1	O
-	0	O
loop	0	O
and	0	O
is	0	O
conserved	0	O
in	0	O
a	0	O
wide	0	O
variety	0	O
of	0	O
organisms	0	O
that	0	O
include	0	O
bacteria	0	O
,	0	O
algae	0	O
and	0	O
archeabacteria	0	O
.	0	O


Acute	1	O
pancreatitis	0	O
:	0	O
a	0	O
multisystem	0	O
disease	0	O
.	0	O


The	0	O
negative	0	O
regulatory	0	O
activity	0	O
of	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
was	0	O
antagonized	0	O
by	0	O
a	0	O
C	1	O
-	0	O
terminal	0	O
segment	0	O
of	0	O
Pho81p	0	B
supplied	0	O
in	0	O
trans	0	O
.	0	O


The	0	O
transcription	0	O
initiation	0	O
site	0	O
was	0	O
determined	0	O
by	0	O
S1	1	B
nuclease	0	I
mapping	0	O
.	0	O


DNA	1	O
sequence	0	O
and	0	O
evolution	0	O
of	0	O
the	0	O
CPS	1	B
domain	0	I
of	0	O
the	0	O
Syrian	0	B
hamster	0	I
multifunctional	0	I
protein	0	I
CAD	1	I
.	0	O


A	1	O
double	0	O
-	0	O
blind	0	O
trial	0	O
of	0	O
half	0	O
-	0	O
strength	0	O
Polybactrin	0	O
Soluble	1	O
GU	1	O
bladder	0	O
irrigation	0	O
in	0	O
cystoscopy	0	O
.	0	O


Overlapping	0	O
cDNA	1	O
clones	0	O
were	0	O
isolated	0	O
and	0	O
sequenced	0	O
.	0	O


Deletion	1	O
studies	0	O
identified	0	O
a	0	O
distal	0	O
response	0	O
element	0	O
that	0	O
is	0	O
responsible	0	O
for	0	O
the	0	O
cytokine	0	O
response	0	O
and	0	O
has	0	O
properties	0	O
of	0	O
an	0	O
inducible	0	O
transcriptional	0	O
enhancer	0	O
.	0	O


Evolutionary	0	O
relationships	0	O
among	0	O
putative	0	O
RNA	1	B
-	0	I
dependent	0	I
RNA	1	I
polymerases	0	I
encoded	0	O
by	0	O
a	0	O
mitochondrial	0	O
virus	0	O
-	0	O
like	0	O
RNA	1	O
in	0	O
the	0	O
Dutch	0	O
elm	0	O
disease	0	O
fungus	0	O
,	0	O
Ophiostoma	0	O
novo	0	O
-	0	O
ulmi	0	O
,	0	O
by	0	O
other	0	O
viruses	0	O
and	0	O
virus	0	O
-	0	O
like	0	O
RNAs	0	O
and	0	O
by	0	O
the	0	O
Arabidopsis	0	O
mitochondrial	0	O
genome	0	O
.	0	O


H	1	O
-	0	O
7	0	O
,	0	O
which	0	O
specifically	0	O
,	0	O
although	0	O
weakly	0	O
,	0	O
inhibited	0	O
PKC	0	B
activation	0	O
,	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
tyrosine	0	O
phosphorylation	0	O
and	0	O
PtdIns	0	O
(	0	O
3	0	O
,	0	O
4	0	O
)	0	O
P2	1	O
production	0	O
.	0	O


GGS1	0	B
is	0	O
the	0	O
same	0	O
gene	0	O
as	0	O
TPS1	0	B
which	0	O
was	0	O
identified	0	O
as	0	O
encoding	0	O
a	0	O
subunit	0	O
of	0	O
the	0	O
trehalose	0	B
-	0	I
6	0	I
-	0	I
phosphate	0	I
synthase	0	I
/	0	I
phosphatase	0	I
complex	0	I
and	0	O
it	0	O
is	0	O
allelic	0	O
to	0	O
the	0	O
fdp1	0	B
,	0	O
byp1	0	B
,	0	O
glc6	0	B
and	0	O
cif1	0	O
mutations	0	O
.	0	O


Sixty	0	O
-	0	O
five	0	O
patients	0	O
(	0	O
aged	0	O
between	0	O
3	0	O
years	0	O
5	0	O
months	0	O
and	0	O
60	0	O
years	0	O
)	0	O
suffering	0	O
from	0	O
medically	0	O
resistant	0	O
temporal	0	O
lobe	0	O
epilepsy	0	O
(	0	O
TLE	0	O
)	0	O
were	0	O
operated	0	O
on	0	O
over	0	O
a	0	O
period	0	O
of	0	O
33	0	O
months	0	O
in	0	O
Bethel	0	O
Epilepsy	1	O
Center	1	O
.	0	O


Finally	0	O
,	0	O
we	0	O
determined	0	O
that	0	O
the	0	O
P68	0	B
amino	0	O
terminus	0	O
was	0	O
both	0	O
necessary	0	O
and	0	O
sufficient	0	O
for	0	O
binding	0	O
dsRNA	1	O
as	0	O
we	0	O
were	0	O
able	0	O
to	0	O
transfer	0	O
dsRNA	1	O
-	0	O
binding	0	O
properties	0	O
to	0	O
a	0	O
reporter	0	O
gene	0	O
product	0	O
previously	0	O
unable	0	O
to	0	O
bind	0	O
RNA	1	O
.	0	O


The	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
type	0	O
1	0	O
(	0	O
HIV	1	O
-	0	O
1	0	O
)	0	O
preferentially	0	O
infects	0	O
CD4	1	B
+	0	I
T	1	O
lymphocytes	0	O
and	0	O
may	0	O
exist	0	O
as	0	O
a	0	O
latent	0	O
provirus	0	O
within	0	O
these	0	O
cells	0	O
for	0	O
extended	0	O
periods	0	O
.	0	O


For	0	O
this	0	O
purpose	0	O
,	0	O
the	0	O
writhing	0	O
test	0	O
,	0	O
capsaicin	0	O
and	0	O
formalin	0	O
induced	0	O
-	0	O
pain	0	O
in	0	O
mice	0	O
were	0	O
used	0	O
.	0	O


From	0	O
transient	0	O
expression	0	O
studies	0	O
,	0	O
we	0	O
could	0	O
demonstrate	0	O
that	0	O
the	0	O
SH3	0	B
domain	0	I
of	0	O
PLC	0	B
-	0	I
gamma1	0	I
is	0	O
necessary	0	O
for	0	O
the	0	O
association	0	O
with	0	O
SOS1	0	B
in	0	O
vivo	0	O
.	0	O


The	0	O
nucleotide	0	O
sequences	0	O
of	0	O
these	0	O
genes	0	O
differ	0	O
at	0	O
only	0	O
nine	0	O
positions	0	O
,	0	O
resulting	0	O
in	0	O
three	0	O
amino	0	O
acid	0	O
differences	0	O
.	0	O


Antiviral	1	O
agents	0	O
.	0	O


The	0	O
12S	0	B
E1A	0	I
product	0	I
does	0	O
not	0	O
activate	0	O
a	0	O
TRE	0	O
sequence	0	O
,	0	O
but	0	O
cotransfection	0	O
with	0	O
c	0	B
-	0	I
jun	0	I
circumvents	0	O
this	0	O
lack	0	O
of	0	O
stimulation	0	O
.	0	O


MPO	1	B
was	0	O
labeled	0	O
with	0	O
1	0	O
mCi	1	O
125I	0	O
by	0	O
a	0	O
technique	0	O
of	0	O
self	0	O
-	0	O
labeling	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
10	0	O
(-	0	O
4	0	O
)	0	O
M	1	O
hydrogen	0	O
peroxide	0	O
.	0	O


The	0	O
authors	0	O
present	0	O
the	0	O
only	0	O
two	0	O
studies	0	O
that	0	O
have	0	O
proved	0	O
successful	0	O
in	0	O
treating	0	O
animal	0	O
models	0	O
of	0	O
osteoarthritis	0	O
using	0	O
gene	0	O
therapy	0	O
,	0	O
and	0	O
propose	0	O
an	0	O
overview	0	O
of	0	O
several	0	O
strategies	0	O
for	0	O
the	0	O
development	0	O
of	0	O
gene	0	O
therapy	0	O
in	0	O
osteoarthritis	0	O
treatment	0	O
in	0	O
the	0	O
future	0	O
.	0	O


The	0	O
loss	0	O
of	0	O
avirulence	0	O
activity	0	O
because	0	O
of	0	O
mutations	0	O
in	0	O
the	0	O
acidic	0	O
transcriptional	0	O
activation	0	O
domain	0	O
was	0	O
restored	0	O
by	0	O
addition	0	O
of	0	O
the	0	O
activation	0	O
domain	0	O
from	0	O
the	0	O
herpes	0	B
simplex	0	I
viral	0	I
protein	0	I
VP16	0	I
.	0	O


Consciousness	1	O
is	0	O
connected	0	O
with	0	O
attention	0	O
,	0	O
working	0	O
memory	0	O
and	0	O
perception	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
describe	0	O
the	0	O
isolation	0	O
of	0	O
bovine	0	B
and	0	I
rat	0	I
GHF	0	I
-	0	I
1	0	I
cDNA	1	I
clones	0	O
.	0	O


Eastern	0	O
Cooperative	0	O
Oncology	1	O
Group	1	O
trial	0	O
E3186	0	O
was	0	O
initiated	0	O
to	0	O
explore	0	O
this	0	O
question	0	O
.	0	O


In	1	O
contrast	0	O
with	0	O
previous	0	O
two	0	O
-	0	O
pool	0	O
models	0	O
,	0	O
provisions	0	O
were	0	O
made	0	O
for	0	O
folate	0	O
turnover	0	O
by	0	O
urinary	0	O
folate	0	O
excretion	0	O
(	0	O
as	0	O
measured	0	O
here	0	O
)	0	O
and	0	O
by	0	O
fecal	0	O
excretion	0	O
and	0	O
catabolic	0	O
processes	0	O
.	0	O


The	0	O
relatively	0	O
high	0	O
level	0	O
transcription	0	O
from	0	O
this	0	O
gene	0	O
shows	0	O
that	0	O
the	0	O
polymorphic	0	O
chromosome	0	O
ends	0	O
of	0	O
P	1	O
.	0	O
falciparum	0	O
,	0	O
which	0	O
have	0	O
been	0	O
proposed	0	O
to	0	O
be	0	O
transcriptionally	0	O
silent	0	O
,	0	O
can	0	O
be	0	O
active	0	O
expression	0	O
sites	0	O
for	0	O
var	0	B
genes	0	I
.	0	O


Proximal	1	O
CBD	0	O
was	0	O
inversely	0	O
correlated	0	O
with	0	O
bone	0	B
alkaline	0	I
phosphatase	0	I
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
71	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
)	0	O
and	0	O
intact	0	O
PTH	1	B
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
59	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Comparison	0	O
of	0	O
genomic	0	O
sequence	0	O
shows	0	O
that	0	O
the	0	O
ph	0	B
locus	0	I
has	0	O
been	0	O
duplicated	0	O
,	0	O
and	0	O
that	0	O
it	0	O
contains	0	O
proximal	0	O
and	0	O
distal	0	O
transcription	0	O
units	0	O
.	0	O


32Pi	0	O
labeling	0	O
or	0	O
isoelectric	0	O
focusing	0	O
analysis	0	O
of	0	O
eIF	0	B
-	0	I
2	0	I
alpha	0	I
from	0	O
conditional	0	O
casein	0	B
kinase	0	I
II	0	I
mutants	0	I
indicated	0	O
that	0	O
phosphorylation	0	O
of	0	O
eIF	0	B
-	0	I
2	0	I
alpha	0	I
is	0	O
abolished	0	O
or	0	O
dephosphorylated	0	O
forms	0	O
of	0	O
eIF	0	B
-	0	I
2	0	I
alpha	0	I
are	0	O
detected	0	O
when	0	O
these	0	O
strains	0	O
are	0	O
grown	0	O
at	0	O
the	0	O
restrictive	0	O
growth	0	O
conditions	0	O
.	0	O


Signaling	1	O
by	0	O
tyrosine	0	B
kinases	0	I
involves	0	O
direct	0	O
associations	0	O
between	0	O
proteins	0	O
with	0	O
Src	1	B
homology	0	I
2	0	I
(	0	O
SH2	0	B
)	0	O
domains	0	O
and	0	O
sites	0	O
of	0	O
tyrosine	0	O
phosphorylation	0	O
.	0	O


Closure	1	O
of	0	O
the	0	O
patent	0	O
ductus	0	O
arteriosus	0	O
with	0	O
a	0	O
Ligaclip	0	O
through	0	O
a	0	O
minithoracotomy	0	O
.	0	O


Disruption	1	O
of	0	O
RB	1	B
/	0	O
E2F	0	B
-	0	I
1	0	I
interaction	0	O
by	0	O
single	0	O
point	0	O
mutations	0	O
in	0	O
E2F	0	B
-	0	I
1	0	I
enhances	0	O
S	1	O
-	0	O
phase	0	O
entry	0	O
and	0	O
apoptosis	0	O
.	0	O


Effect	1	O
of	0	O
time	0	O
and	0	O
dose	0	O
on	0	O
alterations	0	O
following	0	O
inhalation	0	O
of	0	O
plutonium	0	O
-	0	O
239	0	O
dioxide	0	O
aerosol	0	O
in	0	O
rat	0	O
.	0	O


In	1	O
a	0	O
similar	0	O
experiment	0	O
,	0	O
simultaneous	0	O
nitrofurazone	0	O
administration	0	O
and	0	O
S	1	O
.	0	O
enteritidis	0	O
challenge	0	O
resulted	0	O
in	0	O
no	0	O
significant	0	O
differences	0	O
in	0	O
S	1	O
.	0	O
enteritidis	0	O
isolation	0	O
frequency	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
5	0	O
'	0	O
deletions	0	O
removing	0	O
all	0	O
but	0	O
34	0	O
bp	0	O
upstream	0	O
of	0	O
the	0	O
transcription	0	O
start	0	O
point	0	O
retained	0	O
greater	0	O
than	0	O
90	0	O
%	0	O
promoter	0	O
activity	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
-	0	O
35	0	O
hexamer	0	O
was	0	O
not	0	O
essential	0	O
for	0	O
promoter	0	O
activity	0	O
.	0	O


The	0	O
data	0	O
indicate	0	O
that	0	O
the	0	O
minimal	0	O
catalytic	0	O
domain	0	O
of	0	O
Nmt1p	0	B
is	0	O
located	0	O
between	0	O
Ile59	0	O
-->	0	O
Phe96	0	O
and	0	O
Gly451	0	O
-->	0	O
Leu455	0	O
.	0	O


TRAF2	0	B
is	0	O
a	0	O
potent	0	O
activator	0	O
of	0	O
a	0	O
95	0	B
-	0	I
kDa	1	I
serine	0	I
/	0	I
threonine	0	I
kinase	0	I
termed	0	O
germinal	0	B
center	0	I
kinase	0	I
related	0	I
(	0	O
GCKR	0	B
,	0	O
also	0	O
referred	0	O
to	0	O
as	0	O
KHS1	0	B
),	0	O
which	0	O
signals	0	O
activation	0	O
of	0	O
the	0	O
SAPK	0	B
pathway	0	O
.	0	O


Molecular	1	O
cloning	0	O
,	0	O
expression	0	O
pattern	0	O
,	0	O
and	0	O
chromosomal	0	O
localization	0	O
of	0	O
human	0	O
CDKN2D	0	B
/	0	O
INK4d	0	B
,	0	O
an	0	O
inhibitor	0	O
of	0	O
cyclin	0	B
D	1	I
-	0	I
dependent	0	I
kinases	0	I
.	0	O


We	0	O
show	0	O
,	0	O
by	0	O
injection	0	O
of	0	O
synthetic	0	O
mRNAs	0	O
,	0	O
that	0	O
the	0	O
cis	0	O
-	0	O
acting	0	O
sequences	0	O
responsible	0	O
for	0	O
repression	0	O
of	0	O
cyclin	0	B
B1	0	I
mRNA	1	I
reside	0	O
within	0	O
its	0	O
3	0	O
'	0	O
UTR	0	O
.	0	O


The	0	O
highly	0	O
restrained	0	O
girls	0	O
had	0	O
a	0	O
significantly	0	O
higher	0	O
EAT	1	O
score	0	O
than	0	O
the	0	O
low	0	O
-	0	O
restrained	0	O
girls	0	O
,	0	O
and	0	O
shared	0	O
with	0	O
their	0	O
mothers	0	O
a	0	O
susceptibility	0	O
to	0	O
the	0	O
disinhibitory	0	O
effects	0	O
of	0	O
negative	0	O
mood	0	O
states	0	O
on	0	O
their	0	O
eating	0	O
behaviour	0	O
.	0	O


Analysis	1	O
of	0	O
mig	0	B
/	0	O
CAT	1	B
chimeric	0	O
constructs	0	O
transiently	0	O
transfected	0	O
into	0	O
the	0	O
RAW	1	O
264	0	O
.	0	O
7	0	O
mouse	0	O
monocytic	0	O
cell	0	O
line	0	O
revealed	0	O
a	0	O
unique	0	O
IFN	1	B
-	0	I
gamma	0	I
-	0	I
responsive	0	I
element	0	I
(	0	O
gamma	0	B
RE	1	I
-	0	I
1	0	I
).	0	O


Our	0	O
results	0	O
,	0	O
when	0	O
combined	0	O
with	0	O
previously	0	O
published	0	O
in	0	O
vitro	0	O
results	0	O
,	0	O
support	0	O
a	0	O
direct	0	O
role	0	O
for	0	O
Prp44p	0	B
in	0	O
unwinding	0	O
of	0	O
the	0	O
U4	0	B
/	0	O
U6	0	B
helix	0	O
.	0	O


Our	0	O
findings	0	O
suggest	0	O
that	0	O
the	0	O
mtr	0	B
product	0	I
causes	0	O
both	0	O
transcription	0	O
attenuation	0	O
and	0	O
inhibition	0	O
of	0	O
translation	0	O
of	0	O
trpE	0	B
mRNA	1	I
.	0	O


Enhancement	1	O
of	0	O
the	0	O
immune	0	O
response	0	O
by	0	O
aspecific	0	O
action	0	O
of	0	O
vaccine	0	O
additives	0	O
in	0	O
the	0	O
aerogenic	0	O
immunization	0	O
of	0	O
swine	0	O
against	0	O
swine	0	O
plague	0	O


Effects	0	O
of	0	O
spatial	0	O
and	0	O
temporal	0	O
smoothing	0	O
on	0	O
stimulated	0	O
brillouin	0	O
scattering	0	O
in	0	O
the	0	O
independent	0	O
-	0	O
hot	0	O
-	0	O
spot	0	O
model	0	O
limit	0	O
The	0	O
influence	0	O
of	0	O
laser	0	O
beam	0	O
smoothing	0	O
on	0	O
stimulated	0	O
Brillouin	0	O
backscattering	0	O
(	0	O
SBBS	0	O
)	0	O
is	0	O
studied	0	O
analytically	0	O
in	0	O
the	0	O
limit	0	O
of	0	O
the	0	O
independent	0	O
hot	0	O
spot	0	O
model	0	O
.	0	O


Umweltchem	0	O
.	0	O


We	0	O
then	0	O
demonstrated	0	O
that	0	O
1	0	O
)	0	O
GAL4	0	B
-	0	O
REV	0	B
-	0	O
erbA	0	B
alpha	0	I
chimeras	0	O
that	0	O
contain	0	O
the	0	O
'	0	O
AB	1	O
'	0	O
region	0	O
and	0	O
lack	0	O
the	0	O
'	0	O
E	1	O
'	0	O
region	0	O
activated	0	O
transcription	0	O
of	0	O
GAL4	0	B
response	0	I
elements	0	I
in	0	O
the	0	O
presence	0	O
of	0	O
8	0	O
-	0	O
Br	1	O
-	0	O
cAMP	1	O
and	0	O
2	0	O
)	0	O
the	0	O
ligand	0	O
-	0	O
binding	0	O
domain	0	O
(	0	O
LBD	0	O
)	0	O
contains	0	O
an	0	O
active	0	O
transcriptional	0	O
silencer	0	O
.	0	O


Although	0	O
both	0	O
transcripts	0	O
share	0	O
the	0	O
first	0	O
nine	0	O
exons	0	O
,	0	O
exon	0	O
10	0	O
of	0	O
ZIS	0	B
-	0	I
2	0	I
is	0	O
lacking	0	O
in	0	O
ZIS	0	B
-	0	I
1	0	I
,	0	O
and	0	O
instead	0	O
,	0	O
exon	0	O
11	0	O
(	0	O
10th	0	O
exon	0	O
)	0	O
of	0	O
ZIS	0	B
-	0	I
1	0	I
is	0	O
larger	0	O
in	0	O
size	0	O
,	0	O
leading	0	O
to	0	O
the	0	O
longer	0	O
3	0	O
'-	0	O
UTR	0	O
.	0	O


Drug	1	O
effect	0	O
,	0	O
measured	0	O
as	0	O
postural	0	O
sway	0	O
,	0	O
was	0	O
also	0	O
similar	0	O
in	0	O
the	0	O
patients	0	O
with	0	O
cirrhosis	0	O
and	0	O
control	0	O
subjects	0	O
;	0	O
therefore	0	O
the	0	O
ratio	0	O
of	0	O
effect	0	O
area	0	O
under	0	O
the	0	O
curve	0	O
to	0	O
concentration	0	O
area	0	O
under	0	O
the	0	O
curve	0	O
,	0	O
a	0	O
measure	0	O
of	0	O
sensitivity	0	O
,	0	O
did	0	O
not	0	O
differ	0	O
significantly	0	O
between	0	O
the	0	O
patients	0	O
with	0	O
cirrhosis	0	O
and	0	O
the	0	O
control	0	O
subjects	0	O
.	0	O


The	0	O
binding	0	O
site	0	O
for	0	O
OxyR	0	B
overlapped	0	O
P1oxyR	0	B
,	0	O
reminiscent	0	O
of	0	O
the	0	O
autoregulatory	0	O
loops	0	O
controlling	0	O
expression	0	O
of	0	O
oxyR	0	B
in	0	O
enteric	0	O
bacteria	0	O
and	0	O
characteristic	0	O
of	0	O
the	0	O
LysR	0	B
superfamily	0	I
in	0	O
general	0	O
.	0	O


YAC	1	O
and	0	O
cosmid	0	O
contigs	0	O
spanning	0	O
the	0	O
Batten	0	B
disease	0	I
(	0	O
CLN3	0	B
)	0	O
region	0	O
at	0	O
16p12	0	O
.	0	O
1	0	O
-	0	O
p11	0	O
.	0	O
2	0	O
.	0	O


These	0	O
transcripts	0	O
contain	0	O
the	0	O
5	0	O
'	0	O
ends	0	O
of	0	O
mature	0	O
UbCRBP	0	B
mRNAs	0	I
;	0	O
extend	0	O
through	0	O
UbCRBP	0	B
,	0	O
across	0	O
the	0	O
intergenic	0	O
region	0	O
,	0	O
and	0	O
a	0	O
significant	0	O
distance	0	O
3	0	O
'	0	O
into	0	O
the	0	O
enolase	0	B
gene	0	I
.	0	O


The	0	O
requirement	0	O
of	0	O
different	0	O
essential	0	O
fatty	0	O
acids	0	O
in	0	O
patients	0	O
with	0	O
total	0	O
parenteral	0	O
nutrition	0	O
after	0	O
heavy	0	O
injury	0	O
is	0	O
of	0	O
special	0	O
interest	0	O
with	0	O
respect	0	O
to	0	O
the	0	O
development	0	O
and	0	O
prognosis	0	O
of	0	O
shock	0	O
,	0	O
sepsis	0	O
or	0	O
adult	0	O
respiratory	0	O
distress	0	O
syndrome	0	O
.	0	O


We	0	O
further	0	O
demonstrate	0	O
that	0	O
RU486	0	O
-	0	O
PR	1	B
-	0	I
B	1	I
interacts	0	O
physically	0	O
with	0	O
NCoR	0	B
in	0	O
vitro	0	O
.	0	O


It	1	O
bound	0	O
to	0	O
vitamin	0	B
D	1	I
receptor	0	I
(	0	O
VDR	0	B
)	0	O
but	0	O
not	0	O
retinoic	0	B
acid	0	I
Xalpha	0	I
receptor	0	I
(	0	O
RXRalpha	0	B
)	0	O
in	0	O
the	0	O
human	0	O
T	1	O
cell	0	O
line	0	O
MT2	0	O
cells	0	O
.	0	O


Substitution	1	O
of	0	O
a	0	O
threonine	0	O
residue	0	O
by	0	O
an	0	O
alanine	0	O
residue	0	O
at	0	O
position	0	O
-	0	O
2	0	O
(	0	O
P2	1	O
)	0	O
of	0	O
this	0	O
cleavage	0	O
site	0	O
abolished	0	O
cleavage	0	O
,	0	O
whereas	0	O
substitution	0	O
of	0	O
a	0	O
tyrosine	0	O
residue	0	O
by	0	O
a	0	O
phenylalanine	0	O
residue	0	O
at	0	O
amino	0	O
acid	0	O
position	0	O
-	0	O
1	0	O
(	0	O
P1	1	O
)	0	O
of	0	O
the	0	O
cleavage	0	O
site	0	O
did	0	O
not	0	O
influence	0	O
processing	0	O
.	0	O


A	1	O
similar	0	O
phenomenon	0	O
has	0	O
been	0	O
reported	0	O
in	0	O
a	0	O
few	0	O
humans	0	O
.	0	O


These	0	O
data	0	O
establish	0	O
Smd1p	0	B
as	0	O
a	0	O
required	0	O
component	0	O
of	0	O
the	0	O
cellular	0	O
splicing	0	O
apparatus	0	O
and	0	O
a	0	O
factor	0	O
in	0	O
snRNA	1	O
maturation	0	O
and	0	O
stability	0	O
.	0	O


K	1	O
.	0	O


Practical	0	O
use	0	O
and	0	O
interpretation	0	O
of	0	O
viral	0	O
hepatitis	0	O
B	1	O
markers	0	O
and	0	O
hepatic	0	O
biopsy	0	O
in	0	O
HBs	1	B
Ag	1	I
carriers	0	O
and	0	O
at	0	O
the	0	O
chronic	0	O
hepatitis	0	O
stage	0	O


MDS1	0	B
/	0	O
EVI1	0	B
,	0	O
located	0	O
on	0	O
chromosome	0	O
3	0	O
band	0	O
q26	0	O
,	0	O
encodes	0	O
a	0	O
zinc	0	B
-	0	I
finger	0	I
DNA	1	I
-	0	I
binding	0	I
transcription	0	I
activator	0	I
not	0	O
detected	0	O
in	0	O
normal	0	O
hematopoietic	0	O
cells	0	O
but	0	O
expressed	0	O
in	0	O
several	0	O
normal	0	O
tissues	0	O
.	0	O


Capsular	1	O
antigens	0	O
of	0	O
Staphylococcus	1	O
aureus	0	O


These	0	O
studies	0	O
support	0	O
the	0	O
view	0	O
that	0	O
HMG	1	B
I	1	I
(	0	I
Y	1	I
)	0	I
is	0	O
an	0	O
important	0	O
cofactor	0	O
for	0	O
HLA	1	B
-	0	I
DRA	0	I
gene	0	I
activation	0	O
by	0	O
Oct	1	B
-	0	I
2A	0	I
and	0	O
provide	0	O
insights	0	O
into	0	O
its	0	O
mechanism	0	O
of	0	O
action	0	O
.	0	O


This	0	O
study	0	O
shows	0	O
that	0	O
C	1	B
/	0	I
EBPbeta	0	I
is	0	O
the	0	O
predominant	0	O
C	1	B
/	0	I
EBP	1	I
isoform	0	I
found	0	O
in	0	O
activated	0	O
stellate	0	O
cells	0	O
and	0	O
that	0	O
increased	0	O
C	1	B
/	0	I
EBPbeta	0	I
protein	0	I
and	0	O
C	1	B
/	0	I
EBPbeta	0	I
binding	0	O
to	0	O
a	0	O
proximal	0	O
C	1	B
/	0	I
EBP	1	I
binding	0	I
site	0	I
in	0	O
the	0	O
promoter	0	O
mediates	0	O
the	0	O
activating	0	O
effect	0	O
of	0	O
acetaldehyde	0	O
.	0	O


A	1	O
cDNA	1	O
,	0	O
cak1At	0	B
,	0	O
was	0	O
isolated	0	O
that	0	O
suppressed	0	O
the	0	O
CAK	0	B
mutation	0	I
in	0	O
budding	0	O
yeast	0	O
,	0	O
and	0	O
it	0	O
also	0	O
complemented	0	O
a	0	O
fission	0	B
yeast	0	I
CAK	0	I
mutant	0	I
.	0	O
cak1At	0	B
encodes	0	O
a	0	O
protein	0	O
related	0	O
to	0	O
animal	0	B
CAKs	0	I
.	0	O


The	0	O
present	0	O
results	0	O
demonstrate	0	O
that	0	O
rats	0	O
with	0	O
relatively	0	O
small	0	O
remnants	0	O
of	0	O
one	0	O
olfactory	0	O
bulb	0	O
can	0	O
perform	0	O
a	0	O
variety	0	O
of	0	O
odor	0	O
detection	0	O
and	0	O
discrimination	0	O
tasks	0	O
as	0	O
well	0	O
or	0	O
nearly	0	O
as	0	O
well	0	O
as	0	O
controls	0	O
.	0	O


An	1	O
approach	0	O
to	0	O
a	0	O
biomathematical	0	O
model	0	O
of	0	O
lymphocytopoiesis	0	O
.	0	O


Dose	1	O
standardisation	0	O
of	0	O
botulinum	0	B
toxin	0	I
.	0	O


She	0	O
improved	0	O
with	0	O
a	0	O
combination	0	O
of	0	O
benzodiazepines	0	O
and	0	O
the	0	O
acetylcholinesterase	0	B
inhibitor	0	O
physostigmine	0	O
.	0	O


Identical	1	O
c	0	B
-	0	I
erbB3	0	I
transcripts	0	I
are	0	O
expressed	0	O
in	0	O
normal	0	O
human	0	O
placental	0	O
tissues	0	O
.	0	O


Measurements	0	O
of	0	O
activity	0	O
with	0	O
the	0	O
radioprotective	0	O
chamber	0	O
VA	1	O
-	0	O
K	1	O
-	0	O
254	0	O
of	0	O
the	0	O
osimeter	0	O
VA	1	O
-	0	O
J18	0	O


GR63178A	0	O
is	0	O
a	0	O
water	0	O
-	0	O
soluble	0	O
analogue	0	O
of	0	O
mitoquidone	0	O
,	0	O
a	0	O
pentacyclic	0	O
pyrroloquinone	0	O
.	0	O


Engagement	1	O
of	0	O
human	0	B
CD2	1	I
by	0	O
mitogenic	0	O
pairs	0	O
of	0	O
anti	0	B
-	0	I
CD2	1	I
mAb	0	I
induces	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
a	0	O
number	0	O
of	0	O
intracellular	0	O
proteins	0	O
including	0	O
a	0	O
120	0	O
kDa	1	O
phosphoprotein	0	O
that	0	O
we	0	O
identify	0	O
as	0	O
the	0	O
proto	0	B
-	0	I
oncogene	0	I
c	0	I
-	0	I
Cbl	1	I
.	0	O


Peroxisome	1	B
proliferator	0	I
-	0	I
activated	0	I
receptors	0	I
(	0	O
PPARs	0	B
)	0	O
and	0	O
retinoid	0	B
X	1	I
receptors	0	I
(	0	O
RXRs	0	B
)	0	O
are	0	O
nuclear	0	B
hormone	0	I
receptors	0	I
that	0	O
are	0	O
activated	0	O
by	0	O
fatty	0	O
acids	0	O
and	0	O
9	0	O
-	0	O
cis	0	O
-	0	O
retinoic	0	O
acid	0	O
,	0	O
respectively	0	O
.	0	O


ORF	1	B
E8	0	I
colinear	0	O
with	0	O
ORF	1	B
E6	0	I
,	0	O
which	0	O
could	0	O
generate	0	O
a	0	O
50	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
protein	0	O
with	0	O
a	0	O
hydrophobic	0	O
segment	0	O
,	0	O
did	0	O
not	0	O
transform	0	O
cells	0	O
when	0	O
cloned	0	O
into	0	O
the	0	O
pZipNeo	0	O
vector	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
targeting	0	O
partially	0	O
assembled	0	O
Ti	1	B
alpha	0	I
-	0	I
beta	0	I
CD3	0	I
gamma	0	I
delta	0	I
epsilon	0	I
TCR	1	I
complexes	0	I
to	0	O
the	0	O
cell	0	O
surface	0	O
,	0	O
CD3	0	B
zeta	0	I
appears	0	O
to	0	O
be	0	O
essential	0	O
for	0	O
interleukin	0	B
-	0	I
2	0	I
production	0	O
after	0	O
TCR	1	B
stimulation	0	O
with	0	O
antigen	0	B
/	0	I
major	0	I
histocompatibility	0	I
complex	0	I
.	0	O


However	0	O
,	0	O
there	0	O
is	0	O
still	0	O
a	0	O
subset	0	O
of	0	O
tumors	0	O
that	0	O
displayed	0	O
no	0	O
changes	0	O
in	0	O
these	0	O
genes	0	O
.	0	O


New	0	O
Langevin	0	O
equations	0	O
for	0	O
a	0	O
translating	0	O
and	0	O
simultaneously	0	O
rotating	0	O
asymmetric	0	O
top	0	O
.	0	O


On	1	O
the	0	O
other	0	O
hand	0	O
factor	0	B
IX	0	I
activity	0	O
is	0	O
decreased	0	O
in	0	O
coumarin	0	O
treatment	0	O
with	0	O
factor	0	B
IX	0	I
antigen	0	O
remaining	0	O
normal	0	O
.	0	O


Positive	1	O
shifts	0	O
of	0	O
basal	0	O
skin	0	O
potentials	0	O
during	0	O
human	0	O
sleep	0	O
.	0	O


Nevertheless	0	O
,	0	O
they	0	O
are	0	O
functionally	0	O
distinct	0	O
in	0	O
that	0	O
FcalphaRI	0	B
binds	0	O
human	0	B
IgA	1	I
(	0	O
hIgA	0	B
)	0	O
but	0	O
not	0	O
bovine	0	B
IgG2	0	I
(	0	O
bIgG2	0	B
),	0	O
whereas	0	O
bFcgamma2R	0	B
binds	0	O
bIgG2	0	B
but	0	O
not	0	O
hIgA	0	B
.	0	O


Quantitative	1	O
assays	0	O
in	0	O
which	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
synthetic	0	B
alpha	0	I
s	0	I
-	0	I
1	0	I
was	0	O
compared	0	O
to	0	O
that	0	O
of	0	O
native	0	O
purified	0	O
human	0	B
erythrocyte	0	I
type	0	I
-	0	I
1	0	I
Gs	0	I
,	0	O
indicated	0	O
that	0	O
the	0	O
two	0	O
products	0	O
are	0	O
equipotent	0	O
within	0	O
a	0	O
2	0	O
-	0	O
fold	0	O
margin	0	O
of	0	O
error	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
ligustrazine	0	O
hydrochloride	0	O
(	0	O
LTH	1	O
)	0	O
on	0	O
depressing	0	O
pulmonary	0	O
artery	0	O
hypertension	0	O
has	0	O
been	0	O
proved	0	O
in	0	O
recent	0	O
studies	0	O
.	0	O


Catch	0	O
-	0	O
up	0	O
growth	0	O
and	0	O
craniofacial	0	O
dimensions	0	O
following	0	O
administration	0	O
of	0	O
the	0	O
antineoplastic	0	O
agent	0	O
vincristine	0	O
to	0	O
young	0	O
rats	0	O
.	0	O


The	0	O
method	0	O
has	0	O
been	0	O
satisfactorily	0	O
applied	0	O
to	0	O
the	0	O
determination	0	O
of	0	O
paracetamol	0	O
in	0	O
pharmaceutical	0	O
formulations	0	O
and	0	O
biological	0	O
fluids	0	O
.	0	O


Magnetic	1	O
resonance	0	O
imaging	0	O
(	0	O
MRI	1	O
)	0	O
has	0	O
enabled	0	O
us	0	O
to	0	O
see	0	O
the	0	O
spinal	0	O
intramedullary	0	O
pathology	0	O
as	0	O
differences	0	O
in	0	O
signal	0	O
intensity	0	O
.	0	O


We	0	O
report	0	O
an	0	O
odd	0	O
case	0	O
of	0	O
marked	0	O
enlargement	0	O
of	0	O
suprapineal	0	O
recess	0	O
in	0	O
a	0	O
patient	0	O
with	0	O
triventricular	0	O
hydrocephalus	0	O
.	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
attention	0	O
to	0	O
these	0	O
issues	0	O
can	0	O
substantially	0	O
improve	0	O
the	0	O
quality	0	O
of	0	O
research	0	O
on	0	O
AIDS	1	O
related	0	O
behaviors	0	O
on	0	O
Black	1	O
communities	0	O
.	0	O


PET	1	O
activation	0	O
studies	0	O
are	0	O
performed	0	O
widely	0	O
to	0	O
study	0	O
human	0	O
brain	0	O
function	0	O
.	0	O


Peptide	1	O
sequences	0	O
of	0	O
the	0	O
zinc	0	B
finger	0	I
protein	0	I
Ttk	0	I
and	0	O
the	0	O
transcription	0	B
factor	0	I
Adf	0	I
-	0	I
1	0	I
were	0	O
obtained	0	O
.	0	O


A	1	O
chicken	0	B
paxillin	0	I
cDNA	1	I
was	0	O
also	0	O
cloned	0	O
and	0	O
is	0	O
predicted	0	O
to	0	O
encode	0	O
a	0	O
protein	0	O
approximately	0	O
90	0	O
%	0	O
identical	0	O
to	0	O
human	0	B
paxil	0	I
-	0	I
lin	0	I
.	0	O


Comparison	0	O
of	0	O
the	0	O
nucleotide	0	O
sequences	0	O
between	0	O
the	0	O
human	0	O
and	0	O
bovine	0	O
DNA	1	O
showed	0	O
that	0	O
the	0	O
sequence	0	O
similarity	0	O
extended	0	O
2400	0	O
bp	0	O
downstream	0	O
from	0	O
the	0	O
coding	0	O
region	0	O
.	0	O


Study	1	O
of	0	O
the	0	O
energy	0	O
metabolism	0	O
of	0	O
the	0	O
sensomotor	0	O
cortex	0	O
and	0	O
hippocampus	0	O
by	0	O
the	0	O
(	0	O
14C	0	O
)	0	O
2	0	O
-	0	O
deoxyglucose	0	O
method	0	O
during	0	O
the	0	O
development	0	O
of	0	O
dissociated	0	O
states	0	O


Replacement	1	O
of	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
5	0	O
'-	0	O
regulatory	0	O
region	0	O
with	0	O
either	0	O
of	0	O
the	0	O
mutants	0	O
'	0	O
cis	0	O
-	0	O
acting	0	O
regulatory	0	O
element	0	O
resulted	0	O
in	0	O
the	0	O
anaerobic	0	O
expression	0	O
of	0	O
active	0	B
Mn	1	I
-	0	I
superoxide	0	I
dismutase	0	I
.	0	O


We	0	O
report	0	O
here	0	O
on	0	O
the	0	O
molecular	0	O
nature	0	O
of	0	O
an	0	O
EMS	1	O
-	0	O
induced	0	O
mutant	0	O
,	0	O
mn1	0	B
-	0	I
89	0	I
,	0	O
a	0	O
leaky	0	O
semidominant	0	O
allele	0	O
of	0	O
the	0	O
Miniature1	0	B
(	0	O
Mn1	0	B
)	0	O
seed	0	O
locus	0	O
that	0	O
encodes	0	O
a	0	O
seed	0	B
-	0	I
specific	0	I
cell	0	I
wall	0	I
invertase	0	I
,	0	O
INCW2	0	B
.	0	O


Osteocalcin	1	B
(	0	O
serum	0	B
bone	0	I
-	0	I
Gla	0	I
protein	0	I
,	0	O
sBGP	0	B
),	0	O
serum	0	B
alkaline	0	I
phosphatase	0	I
(	0	O
sAP	1	B
)	0	O
and	0	O
urinary	0	O
hydroxyproline	0	O
/	0	O
creatinine	0	O
ratio	0	O
(	0	O
uOH	0	O
-	0	O
Prol	0	O
/	0	O
creatinine	0	O
)	0	O
have	0	O
been	0	O
measured	0	O
in	0	O
21	0	O
patients	0	O
with	0	O
primary	0	O
hyperparathyroidism	0	O
(	0	O
PHPT	0	O
)	0	O
and	0	O
in	0	O
nine	0	O
patients	0	O
with	0	O
hypercalcaemia	0	O
of	0	O
malignancy	0	O
(	0	O
HM	1	O
).	0	O


Two	0	O
distinct	0	O
Salmonella	1	B
fimbrins	0	I
,	0	O
AgfA	0	B
and	0	O
SefA	0	B
,	0	O
comprising	0	O
thin	0	O
aggregative	0	O
fimbriae	0	O
SEF17	0	B
and	0	O
SEF14	0	B
,	0	O
respectively	0	O
,	0	O
were	0	O
each	0	O
genetically	0	O
engineered	0	O
to	0	O
carry	0	O
PT3	0	B
,	0	O
an	0	O
alpha	0	O
-	0	O
helical	0	O
16	0	O
-	0	O
amino	0	O
acid	0	O
Leishmania	1	O
T	1	O
-	0	O
cell	0	O
epitope	0	O
derived	0	O
from	0	O
the	0	O
metalloprotease	0	B
gp63	0	I
.	0	O


In	1	O
addition	0	O
,	0	O
a	0	O
potent	0	O
splicing	0	O
enhancer	0	O
sequence	0	O
isolated	0	O
in	0	O
the	0	O
selection	0	O
specifically	0	O
binds	0	O
a	0	O
20	0	B
-	0	I
kDa	1	I
SR	1	I
protein	0	I
.	0	O


Sequence	1	O
analysis	0	O
identified	0	O
some	0	O
of	0	O
these	0	O
cDNA	1	O
clones	0	O
as	0	O
Dlc	0	B
-	0	I
1	0	I
,	0	O
a	0	O
sequence	0	O
encoding	0	O
a	0	O
small	0	O
,	0	O
9	0	B
-	0	I
kDa	1	I
human	0	I
homolog	0	I
of	0	I
the	0	I
outer	0	I
-	0	I
arm	0	I
dynein	0	I
light	0	I
-	0	I
chain	0	I
protein	0	O
.	0	O


Processing	1	O
of	0	O
the	0	O
polycistronic	0	O
precursor	0	O
requires	0	O
nucleases	0	O
also	0	O
involved	0	O
in	0	O
rRNA	1	O
processing	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
Rnt1p	0	B
and	0	O
Rat1p	0	B
.	0	O


Model	1	O
IV	1	O
:	0	O
primary	0	O
abutments	0	O
with	0	O
the	0	O
lateral	0	O
incisor	0	O
and	0	O
the	0	O
second	0	O
molar	0	O
as	0	O
secondary	0	O
abutments	0	O
.	0	O


A	1	O
reassessment	0	O
of	0	O
the	0	O
prevalence	0	O
data	0	O
was	0	O
carried	0	O
out	0	O
in	0	O
the	0	O
southern	0	O
province	0	O
of	0	O
Uusimaa	0	O
and	0	O
in	0	O
the	0	O
western	0	O
province	0	O
of	0	O
Vaasa	0	O
,	0	O
the	0	O
prevalence	0	O
day	0	O
being	0	O
January	0	O
1	0	O
,	0	O
1979	0	O
.	0	O


Ampicillin	1	O
(	0	O
AMP	1	O
)	0	O
alone	0	O
or	0	O
with	0	O
an	0	O
aminoglycoside	0	O
(	0	O
AMI	1	O
)	0	O
was	0	O
the	0	O
treatment	0	O
in	0	O
9	0	O
and	0	O
16	0	O
cases	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
subepicardial	0	O
lymphatic	0	O
capillaries	0	O
were	0	O
ramified	0	O
and	0	O
anastomosed	0	O
with	0	O
each	0	O
other	0	O
to	0	O
form	0	O
a	0	O
relatively	0	O
dense	0	O
network	0	O
which	0	O
extended	0	O
over	0	O
the	0	O
entire	0	O
surface	0	O
of	0	O
both	0	O
ventricles	0	O
.	0	O


Although	0	O
the	0	O
DSK2	0	B
-	0	I
1	0	I
mutation	0	I
alters	0	O
a	0	O
conserved	0	O
residue	0	O
in	0	O
the	0	O
Dsk2p	0	B
ubiquitin	0	I
-	0	I
like	0	I
domain	0	I
,	0	O
we	0	O
detect	0	O
no	0	O
differences	0	O
in	0	O
Dsk2p	0	B
or	0	O
Cdc31p	0	B
stability	0	O
.	0	O


The	0	O
new	0	O
semi	0	O
-	0	O
synthetic	0	O
oral	0	O
cephalosporin	0	O
,	0	O
CGP	0	O
9	0	O
,	0	O
000	0	O
,	0	O
has	0	O
been	0	O
evaluated	0	O
in	0	O
a	0	O
large	0	O
number	0	O
of	0	O
hospitalized	0	O
patients	0	O
with	0	O
urinary	0	O
infections	0	O
.	0	O


12	0	O
:	0	O
2684	0	O
-	0	O
2697	0	O
,	0	O
1998	0	O
):	0	O
a	0	O
key	0	O
step	0	O
of	0	O
this	0	O
model	0	O
is	0	O
the	0	O
activation	0	O
of	0	O
the	0	O
MAPK	1	B
Fus3p	0	I
through	0	O
the	0	O
G	1	O
(	0	O
betagamma	0	O
)-	0	O
dependent	0	O
relocalization	0	O
of	0	O
the	0	O
Ste5p	0	B
-	0	O
MAPK	1	B
cascade	0	O
to	0	O
the	0	O
plasma	0	O
membrane	0	O
.	0	O


Although	0	O
E2FBP1	0	B
lacks	0	O
the	0	O
transactivation	0	O
domain	0	O
,	0	O
it	0	O
stimulates	0	O
E2F	0	B
site	0	O
-	0	O
dependent	0	O
transcription	0	O
in	0	O
cooperation	0	O
with	0	O
E2F	0	B
-	0	I
1	0	I
.	0	O


Respondents	0	O
who	0	O
lived	0	O
with	0	O
a	0	O
spouse	0	O
/	0	O
partner	0	O
only	0	O
were	0	O
less	0	O
likely	0	O
to	0	O
have	0	O
an	0	O
unfavorable	0	O
BMI	1	O
status	0	O
than	0	O
people	0	O
in	0	O
the	0	O
other	0	O
two	0	O
groups	0	O
.	0	O


The	0	O
DNA	1	O
sequences	0	O
upstream	0	O
of	0	O
these	0	O
termini	0	O
exhibit	0	O
homology	0	O
to	0	O
plant	0	O
mitochondrial	0	O
-	0	O
processing	0	O
sites	0	O
,	0	O
therefore	0	O
the	0	O
proximal	0	O
5	0	O
'	0	O
ends	0	O
are	0	O
most	0	O
probably	0	O
generated	0	O
by	0	O
RNA	1	O
processing	0	O
.	0	O


Truncated	0	O
mammalian	0	B
Notch1	0	I
activates	0	O
CBF1	0	B
/	0	O
RBPJk	0	B
-	0	O
repressed	0	O
genes	0	O
by	0	O
a	0	O
mechanism	0	O
resembling	0	O
that	0	O
of	0	O
Epstein	0	B
-	0	I
Barr	0	I
virus	0	I
EBNA2	0	I
.	0	O


Efficacy	1	O
of	0	O
a	0	O
three	0	O
-	0	O
versus	0	O
a	0	O
five	0	O
-	0	O
week	0	O
alcohol	0	O
treatment	0	O
program	0	O
.	0	O


A	1	O
suspected	0	O
hypothalamic	0	O
dysfunction	0	O
and	0	O
a	0	O
slightly	0	O
impaired	0	O
pituitary	0	O
function	0	O
manifested	0	O
as	0	O
GH	1	B
deficiency	0	O
were	0	O
their	0	O
common	0	O
endocrinological	0	O
features	0	O
.	0	O


Such	0	O
transgenic	0	O
plants	0	O
should	0	O
enable	0	O
not	0	O
only	0	O
the	0	O
mutational	0	O
analysis	0	O
of	0	O
sequence	0	O
elements	0	O
within	0	O
the	0	O
replication	0	O
origin	0	O
region	0	O
,	0	O
but	0	O
also	0	O
the	0	O
construction	0	O
of	0	O
a	0	O
new	0	O
generation	0	O
of	0	O
vectors	0	O
for	0	O
gene	0	O
amplification	0	O
in	0	O
plants	0	O
,	0	O
based	0	O
on	0	O
a	0	O
minimal	0	O
virus	0	O
replicon	0	O
.	0	O


Here	0	O
we	0	O
report	0	O
on	0	O
the	0	O
isolation	0	O
of	0	O
ICK2	0	B
,	0	O
and	0	O
show	0	O
that	0	O
it	0	O
interacts	0	O
with	0	O
Cdc2aAt	0	B
,	0	O
but	0	O
not	0	O
with	0	O
a	0	O
second	0	O
CDK	1	B
from	0	I
Arabidopsis	0	I
,	0	O
Cdc2bAt	0	B
.	0	O


Treatment	1	O
of	0	O
meat	0	O
muscle	0	O
800	0	O
V	1	O
for	0	O
45	0	O
s	0	O
reduced	0	O
weeping	0	O
but	0	O
increased	0	O
slightly	0	O
the	0	O
rate	0	O
of	0	O
autoxidation	0	O
of	0	O
lipids	0	O
.	0	O


The	0	O
patients	0	O
who	0	O
presented	0	O
with	0	O
mucocutaneous	0	O
disease	0	O
also	0	O
had	0	O
low	0	O
CD4	1	B
+	0	I
T	1	O
lymphocyte	0	O
counts	0	O
,	0	O
and	0	O
most	0	O
of	0	O
them	0	O
had	0	O
AIDS	1	O
defining	0	O
illnesses	0	O
.	0	O


In	1	O
comparison	0	O
with	0	O
normal	0	O
pregnant	0	O
women	0	O
and	0	O
normal	0	O
non	0	O
-	0	O
pregnant	0	O
women	0	O
,	0	O
women	0	O
with	0	O
PIH	1	O
showed	0	O
an	0	O
increase	0	O
in	0	O
heart	0	O
rate	0	O
,	0	O
suggesting	0	O
an	0	O
increased	0	O
peripheral	0	O
sympathetic	0	O
tone	0	O
,	0	O
and	0	O
an	0	O
initial	0	O
derangement	0	O
in	0	O
renal	0	O
function	0	O
as	0	O
shown	0	O
by	0	O
the	0	O
increase	0	O
in	0	O
serum	0	O
uric	0	O
acid	0	O
and	0	O
reduction	0	O
in	0	O
sodium	0	O
excretion	0	O
and	0	O
total	0	O
and	0	O
fractional	0	O
calcium	0	O
excretion	0	O
at	0	O
any	0	O
given	0	O
level	0	O
of	0	O
sodium	0	O
excretion	0	O
.	0	O


Since	0	O
the	0	O
regulation	0	O
of	0	O
SWI4	0	B
is	0	O
required	0	O
for	0	O
normal	0	O
cell	0	O
cycle	0	O
progression	0	O
,	0	O
we	0	O
have	0	O
characterized	0	O
cis	0	O
-	0	O
and	0	O
trans	0	O
-	0	O
acting	0	O
regulators	0	O
of	0	O
SWI4	0	B
transcription	0	O
.	0	O


A	1	O
method	0	O
is	0	O
described	0	O
for	0	O
the	0	O
simultaneous	0	O
determination	0	O
of	0	O
1	0	O
,	0	O
alpha	0	O
-	0	O
acetylmethadol	0	O
(	0	O
LAAM	0	O
)	0	O
and	0	O
five	0	O
active	0	O
metabolites	0	O
--	0	O
noracetylmethadol	0	O
,	0	O
dinoracetylmethadol	0	O
,	0	O
methadol	0	O
,	0	O
normethadol	0	O
,	0	O
and	0	O
dinormethadol	0	O
--	0	O
in	0	O
biofluids	0	O
by	0	O
high	0	O
-	0	O
performance	0	O
liquid	0	O
chromatography	0	O
using	0	O
a	0	O
normal	0	O
-	0	O
phase	0	O
column	0	O
and	0	O
a	0	O
UV	1	O
detector	0	O
at	0	O
218	0	O
nm	0	O
.	0	O


Progression	1	O
after	0	O
first	0	O
-	0	O
line	0	O
chemotherapy	0	O
was	0	O
associated	0	O
with	0	O
significantly	0	O
worse	0	O
survival	0	O
for	0	O
patients	0	O
with	0	O
metastasis	0	O
.	0	O


The	0	O
epidermal	0	B
growth	0	I
factor	0	I
(	0	I
EGF	1	I
)	0	I
receptor	0	I
,	0	O
which	0	O
exhibits	0	O
intrinsic	0	O
protein	0	B
tyrosine	0	I
kinase	0	I
activity	0	O
,	0	O
undergoes	0	O
a	0	O
rapid	0	O
,	0	O
intramolecular	0	O
self	0	O
-	0	O
phosphorylation	0	O
reaction	0	O
following	0	O
EGF	1	B
activation	0	O
.	0	O


Thirty	0	O
minutes	0	O
of	0	O
supine	0	O
restraint	0	O
decreased	0	O
DOPAC	0	O
concentrations	0	O
in	0	O
the	0	O
median	0	O
eminence	0	O
of	0	O
female	0	O
rats	0	O
that	0	O
were	0	O
not	0	O
exposed	0	O
to	0	O
ether	0	O
,	0	O
and	0	O
brief	0	O
exposure	0	O
to	0	O
ether	0	O
enhanced	0	O
this	0	O
effect	0	O
.	0	O


BACKGROUND	0	O
AND	0	O
OBJECTIVES	0	O
:	0	O
The	0	O
sexually	0	O
transmitted	0	O
diseases	0	O
(	0	O
STD	1	O
)	0	O
control	0	O
program	0	O
for	0	O
female	0	O
sex	0	O
workers	0	O
(	0	O
FSW	0	O
)	0	O
in	0	O
Lima	0	O
,	0	O
Peru	0	O
,	0	O
provided	0	O
periodic	0	O
serological	0	O
tests	0	O
for	0	O
syphilis	0	O
and	0	O
cervical	0	O
smears	0	O
for	0	O
gonococci	0	O
,	0	O
but	0	O
not	0	O
medication	0	O
for	0	O
STD	1	O
or	0	O
condoms	0	O
.	0	O


Glucocorticoid	1	O
induced	0	O
hypertension	0	O
has	0	O
been	0	O
regarded	0	O
as	0	O
independent	0	O
of	0	O
sodium	0	O
(	0	O
Na	1	O
),	0	O
in	0	O
contrast	0	O
to	0	O
mineralocorticoid	0	O
induced	0	O
hypertension	0	O
,	0	O
which	0	O
is	0	O
Na	1	O
+-	0	O
dependent	0	O
.	0	O


Contrary	0	O
to	0	O
expectations	0	O
,	0	O
we	0	O
find	0	O
a	0	O
relatively	0	O
high	0	O
level	0	O
of	0	O
variation	0	O
in	0	O
the	0	O
stripe	0	B
2	0	I
enhancer	0	O
region	0	O
,	0	O
including	0	O
point	0	O
substitutions	0	O
and	0	O
insertion	0	O
/	0	O
deletions	0	O
in	0	O
binding	0	O
sites	0	O
,	0	O
and	0	O
a	0	O
comparable	0	O
level	0	O
of	0	O
variation	0	O
in	0	O
the	0	O
other	0	O
noncoding	0	O
regions	0	O
.	0	O


By	0	O
contrast	0	O
,	0	O
mTRAP100	0	B
coprecipitates	0	O
in	0	O
vivo	0	O
with	0	O
another	0	O
component	0	O
of	0	O
the	0	O
TRAP	1	B
complex	0	I
(	0	O
TRAP220	0	B
),	0	O
which	0	O
directly	0	O
contacts	0	O
TR	1	B
and	0	O
the	0	O
vitamin	0	B
D	1	I
receptor	0	I
in	0	O
a	0	O
ligand	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


Two	0	O
of	0	O
these	0	O
resulted	0	O
in	0	O
increased	0	O
levels	0	O
of	0	O
the	0	O
alpha	0	O
subunit	0	O
,	0	O
and	0	O
one	0	O
caused	0	O
a	0	O
substitution	0	O
of	0	O
glycine	0	O
for	0	O
the	0	O
aspartic	0	O
acid	0	O
residue	0	O
at	0	O
position	0	O
171	0	O
,	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
.	0	O


(	0	O
iv	0	O
)	0	O
Although	0	O
UCRBP	0	B
has	0	O
been	0	O
previously	0	O
shown	0	O
to	0	O
act	0	O
as	0	O
a	0	O
transcriptional	0	O
repressor	0	O
,	0	O
we	0	O
show	0	O
here	0	O
that	0	O
UCRBP	0	B
can	0	O
also	0	O
act	0	O
as	0	O
a	0	O
positive	0	O
transactivator	0	O
of	0	O
a	0	O
reporter	0	O
driven	0	O
by	0	O
UCR	0	O
elements	0	O
when	0	O
used	0	O
in	0	O
co	0	O
-	0	O
transfection	0	O
assays	0	O
.	0	O


A	1	O
marked	0	O
decrease	0	O
in	0	O
the	0	O
type	0	B
1	0	I
insulin	0	I
-	0	I
like	0	I
growth	0	I
factor	0	I
(	0	I
IGF	1	I
)	0	I
receptor	0	I
(	0	O
IGF	1	B
-	0	I
IR	1	I
)	0	O
occurs	0	O
in	0	O
prostate	0	O
epithelial	0	O
cells	0	O
during	0	O
transformation	0	O
from	0	O
the	0	O
benign	0	O
to	0	O
the	0	O
metastatic	0	O
state	0	O
.	0	O


Oncogenic	1	O
signalling	0	O
by	0	O
E2F1	0	B
has	0	O
recently	0	O
been	0	O
linked	0	O
to	0	O
stabilization	0	O
and	0	O
activation	0	O
of	0	O
the	0	O
tumour	0	O
suppressor	0	O
p53	0	B
(	0	O
refs	0	O
1	0	O
,	0	O
3	0	O
,	0	O
4	0	O
).	0	O


The	0	O
deleted	0	O
nucleotide	0	O
sequence	0	O
corresponded	0	O
to	0	O
sequences	0	O
that	0	O
,	0	O
by	0	O
analogy	0	O
to	0	O
the	0	O
organization	0	O
of	0	O
the	0	O
type	0	B
I	1	I
collagen	0	I
genes	0	I
,	0	O
should	0	O
be	0	O
precisely	0	O
encoded	0	O
by	0	O
exon	0	O
41	0	O
of	0	O
the	0	O
COL3A1	0	B
gene	0	I
.	0	O


Unlike	0	O
most	0	O
other	0	O
small	0	B
G	1	I
proteins	0	I
which	0	O
are	0	O
expressed	0	O
ubiquitously	0	O
,	0	O
TTF	0	B
was	0	O
transcribed	0	O
only	0	O
in	0	O
hemopoietic	0	O
cells	0	O
as	0	O
a	0	O
2	0	O
.	0	O
2	0	O
kb	0	O
transcript	0	O
.	0	O


Accumulations	0	O
of	0	O
Tl	1	O
+	0	O
1	0	O
(	0	O
202Tl	0	O
label	0	O
)	0	O
were	0	O
6	0	O
times	0	O
those	0	O
for	0	O
Ga	1	O
or	0	O
In	1	O
in	0	O
the	0	O
brain	0	O
and	0	O
muscles	0	O
,	0	O
and	0	O
.	0	O
1	0	O
times	0	O
in	0	O
plasma	0	O
.	0	O


Furthermore	0	O
,	0	O
cpxA	0	B
*	0	I
mutations	0	O
suppress	0	O
the	0	O
toxicity	0	O
conferred	0	O
by	0	O
the	0	O
LamB	0	B
-	0	O
LacZ	0	B
hybrid	0	O
protein	0	O
,	0	O
which	0	O
exerts	0	O
its	0	O
effects	0	O
in	0	O
the	0	O
cytoplasm	0	O
,	0	O
sequestered	0	O
from	0	O
DegP	0	B
.	0	O


Both	0	O
4	0	O
,	0	O
8	0	O
-	0	O
DiMeIQx	0	O
and	0	O
A	1	O
alpha	0	O
C	1	O
were	0	O
found	0	O
at	0	O
<	0	O
1	0	O
p	0	O
.	0	O
p	0	O
.	0	O
b	0	O
.	0	O


Susceptibilities	0	O
of	0	O
540	0	O
anaerobic	0	O
gram	0	O
-	0	O
negative	0	O
bacilli	0	O
to	0	O
amoxicillin	0	O
,	0	O
amoxicillin	0	O
-	0	O
BRL	0	O
42715	0	O
,	0	O
amoxicillin	0	O
-	0	O
clavulanate	0	O
,	0	O
temafloxacin	0	O
,	0	O
and	0	O
clindamycin	0	O
.	0	O


After	0	O
infection	0	O
of	0	O
293	0	O
cells	0	O
(	0	O
which	0	O
provide	0	O
complementary	0	O
E1a	0	B
-	0	O
E1b	0	B
functions	0	O
),	0	O
both	0	O
viruses	0	O
directed	0	O
equal	0	O
amounts	0	O
of	0	O
P	1	B
/	0	I
C	1	I
-	0	I
specific	0	I
mRNA	1	I
transcription	0	O
.	0	O


Our	0	O
results	0	O
,	0	O
however	0	O
,	0	O
were	0	O
obtained	0	O
for	0	O
Z	1	O
itself	0	O
and	0	O
not	0	O
for	0	O
[	0	O
Z	1	O
].	0	O


Following	1	O
the	0	O
injection	0	O
of	0	O
PGF2	0	O
alpha	0	O
,	0	O
heifers	0	O
were	0	O
observed	0	O
visually	0	O
for	0	O
signs	0	O
of	0	O
estrus	0	O
at	0	O
0730	0	O
and	0	O
1630	0	O
(	0	O
45	0	O
min	0	O
each	0	O
).	0	O


A	1	O
note	0	O
on	0	O
some	0	O
consequences	0	O
of	0	O
UV	1	O
vision	0	O
in	0	O
birds	0	O
.	0	O


The	0	O
Functional	1	O
Independence	0	O
Measure	1	O
:	0	O
a	0	O
comparative	0	O
study	0	O
of	0	O
clinician	0	O
and	0	O
self	0	O
ratings	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
visna	0	O
-	0	O
maedi	0	O
in	0	O
Italy	0	O
is	0	O
reported	0	O
for	0	O
the	0	O
first	0	O
time	0	O
.	0	O


The	0	O
response	0	O
properties	0	O
of	0	O
cat	0	O
horizontal	0	O
canal	0	O
afferents	0	O
(	0	O
N	1	O
=	0	O
81	0	O
)	0	O
were	0	O
characterized	0	O
by	0	O
three	0	O
parameters	0	O
:	0	O
their	0	O
long	0	O
time	0	O
constants	0	O
(	0	O
tau	0	O
),	0	O
low	0	O
frequency	0	O
gain	0	O
constants	0	O
(	0	O
G1	0	O
),	0	O
and	0	O
middle	0	O
frequency	0	O
gain	0	O
constants	0	O
(	0	O
Gm	1	O
).	0	O


Transcription	1	O
readthrough	0	O
into	0	O
the	0	O
inverted	0	O
repeats	0	O
has	0	O
little	0	O
effect	0	O
on	0	O
this	0	O
event	0	O
.	0	O


Intron	1	O
8	0	O
harbored	0	O
a	0	O
strong	0	O
erythroid	0	O
-	0	O
specific	0	O
enhancer	0	O
activity	0	O
which	0	O
was	0	O
orientation	0	O
-	0	O
dependent	0	O
.	0	O


Group	1	O
A	1	O
was	0	O
treated	0	O
with	0	O
three	0	O
or	0	O
four	0	O
doses	0	O
of	0	O
hepatitis	0	B
B	1	I
immune	0	I
globulin	0	I
(	0	O
HBIG	0	B
)	0	O
in	0	O
one	0	O
of	0	O
three	0	O
different	0	O
schedules	0	O
.	0	O


Consanguinity	1	O
and	0	O
migration	0	O
in	0	O
the	0	O
marriages	0	O
of	0	O
the	0	O
region	0	O
of	0	O
Nunoa	0	O
,	0	O
Santiago	0	O
,	0	O
1850	0	O
-	0	O
1960	0	O


State	1	O
-	0	O
approved	0	O
schools	0	O
of	0	O
nursing	0	O
R	1	O
.	0	O
N	1	O
.	0	O


Neither	0	O
class	0	O
II	0	O
nor	0	O
IV	1	O
infections	0	O
precluded	0	O
transplantation	0	O
.	0	O


Post	1	O
and	0	O
core	0	O
fabrication	0	O
for	0	O
divergent	0	O
canals	0	O
with	0	O
a	0	O
cast	0	O
post	0	O
and	0	O
core	0	O
and	0	O
a	0	O
prefabricated	0	O
dowel	0	O
.	0	O


A	1	O
candidate	0	O
gene	0	O
for	0	O
Bcg	1	B
,	0	O
designated	0	O
natural	0	B
resistance	0	I
-	0	I
associated	0	I
macrophage	0	I
protein	0	I
(	0	O
Nramp	0	B
),	0	O
has	0	O
been	0	O
isolated	0	O
and	0	O
shown	0	O
to	0	O
encode	0	O
a	0	O
novel	0	O
macrophage	0	O
-	0	O
specific	0	O
membrane	0	O
protein	0	O
,	0	O
which	0	O
is	0	O
altered	0	O
in	0	O
susceptible	0	O
animals	0	O
.	0	O


KAR1	0	B
encodes	0	O
an	0	O
essential	0	O
component	0	O
of	0	O
the	0	O
yeast	0	O
spindle	0	O
pole	0	O
body	0	O
(	0	O
SPB	0	O
)	0	O
that	0	O
is	0	O
required	0	O
for	0	O
karyogamy	0	O
and	0	O
SPB	0	O
duplication	0	O
.	0	O


Thus	0	O
,	0	O
hypoxia	0	O
-	0	O
inducible	0	O
nuclear	0	O
import	0	O
and	0	O
transactivation	0	O
by	0	O
recruitment	0	O
of	0	O
CBP	0	B
can	0	O
be	0	O
functionally	0	O
separated	0	O
from	0	O
one	0	O
another	0	O
and	0	O
play	0	O
critical	0	O
roles	0	O
in	0	O
signal	0	O
transduction	0	O
by	0	O
HIF	0	B
-	0	I
1alpha	0	I
.	0	O


Arm	1	O
function	0	O
tests	0	O
.	0	O


PATIENTS	0	O
AND	0	O
METHOD	1	O
:	0	O
Since	0	O
1986	0	O
,	0	O
62	0	O
patients	0	O
were	0	O
irradiated	0	O
stereotactically	0	O
.	0	O


Using	0	O
bovine	0	B
and	0	I
murine	0	I
c	0	I
-	0	I
myb	0	I
clones	0	O
,	0	O
no	0	O
change	0	O
in	0	O
the	0	O
rate	0	O
of	0	O
c	0	B
-	0	I
myb	0	I
gene	0	I
transcription	0	O
or	0	O
mRNA	1	O
stability	0	O
was	0	O
detected	0	O
during	0	O
the	0	O
cell	0	O
cycle	0	O
.	0	O


Therefore	0	O
,	0	O
recombinant	0	O
human	0	O
Ads	0	O
that	0	O
express	0	O
noninfectious	0	O
HIV	1	O
or	0	O
other	0	O
microbial	0	O
proteins	0	O
are	0	O
attractive	0	O
vaccine	0	O
candidates	0	O
.	0	O


The	0	O
prominent	0	O
lesions	0	O
were	0	O
confined	0	O
to	0	O
the	0	O
cerebral	0	O
surface	0	O
layer	0	O
and	0	O
leptomeningeal	0	O
tissue	0	O
including	0	O
the	0	O
arachnoid	0	O
vessels	0	O
,	0	O
which	0	O
were	0	O
all	0	O
bathed	0	O
in	0	O
the	0	O
cerebrospinal	0	O
fluid	0	O
,	0	O
suggesting	0	O
that	0	O
some	0	O
necrotizing	0	O
toxins	0	O
had	0	O
been	0	O
secreted	0	O
into	0	O
the	0	O
fluid	0	O
by	0	O
the	0	O
B	1	O
.	0	O
cereus	0	O
.	0	O


We	0	O
propose	0	O
a	0	O
model	0	O
in	0	O
which	0	O
Sro7	0	B
function	0	O
is	0	O
involved	0	O
in	0	O
the	0	O
targeting	0	O
of	0	O
the	0	O
myosin	0	B
proteins	0	I
to	0	O
their	0	O
intrinsic	0	O
pathways	0	O
.	0	O


Parasitological	0	O
and	0	O
pathological	0	O
findings	0	O
in	0	O
capuchin	0	O
monkeys	0	O
infected	0	O
with	0	O
Schistosoma	1	O
japonicum	0	O
or	0	O
Schistosoma	1	O
mansoni	0	O
.	0	O


Glucose	1	B
-	0	I
6	0	I
-	0	I
phosphate	0	I
dehydrogenase	0	I
(	0	O
G	1	B
-	0	I
6	0	I
-	0	I
PD	1	I
)	0	O
deficiency	0	O
in	0	O
the	0	O
newborn	0	O
.	0	O


The	0	O
characterized	0	O
Y	1	B
'	0	I
repeated	0	I
sequence	0	I
families	0	I
provide	0	O
an	0	O
experimental	0	O
system	0	O
in	0	O
which	0	O
repeated	0	O
sequence	0	O
interactions	0	O
and	0	O
subsequent	0	O
evolution	0	O
can	0	O
be	0	O
studied	0	O
.	0	O


They	0	O
observed	0	O
depressed	0	O
protein	0	B
C	1	I
activity	0	O
that	0	O
significantly	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
005	0	O
)	0	O
increased	0	O
and	0	O
became	0	O
normal	0	O
immediately	0	O
after	0	O
hemodialysis	0	O
while	0	O
factor	0	B
X	1	I
and	0	O
factor	0	B
VII	0	I
increased	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
;	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
despite	0	O
heparinization	0	O
together	0	O
with	0	O
amount	0	O
of	0	O
serum	0	O
lipoprotein	0	O
(	0	O
a	0	O
).	0	O


To	1	O
test	0	O
the	0	O
feasibility	0	O
of	0	O
using	0	O
liposomes	0	O
to	0	O
deliver	0	O
therapeutic	0	O
agents	0	O
to	0	O
the	0	O
lungs	0	O
,	0	O
the	0	O
effect	0	O
of	0	O
liposome	0	O
-	0	O
encapsulated	0	O
superoxide	0	B
dismutase	0	I
(	0	O
SOD	0	B
)	0	O
or	0	O
catalase	0	B
on	0	O
pulmonary	0	O
oxygen	0	O
toxicity	0	O
was	0	O
studied	0	O
in	0	O
rats	0	O
.	0	O


Comprising	0	O
a	0	O
126	0	O
-	0	O
nucleotide	0	O
5	0	O
'	0	O
untranscribed	0	O
genomic	0	O
sequence	0	O
and	0	O
a	0	O
466	0	O
-	0	O
nucleotide	0	O
5	0	O
'	0	O
noncoding	0	O
cDNA	1	O
sequence	0	O
,	0	O
the	0	O
592	0	O
-	0	O
nucleotide	0	O
5	0	O
'	0	O
CpG	0	O
island	0	O
lacked	0	O
TATA	0	O
and	0	O
CAAT	0	O
boxes	0	O
but	0	O
displayed	0	O
a	0	O
high	0	O
G	1	O
+	0	O
C	1	O
content	0	O
,	0	O
was	0	O
enriched	0	O
for	0	O
CpG	0	O
dinucleotides	0	O
,	0	O
and	0	O
contained	0	O
a	0	O
potential	0	O
Sp1	0	B
-	0	I
binding	0	I
site	0	I
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
features	0	O
compatible	0	O
with	0	O
a	0	O
housekeeping	0	O
gene	0	O
.	0	O


99mTc	0	O
phytate	0	O
,	0	O
198Au	0	O
colloid	0	O
,	0	O
and	0	O
99mTc	0	O
antimony	0	O
sulfide	0	O
have	0	O
been	0	O
used	0	O
;	0	O
the	0	O
last	0	O
appears	0	O
to	0	O
have	0	O
been	0	O
the	0	O
most	0	O
satisfactory	0	O
.	0	O


Who	1	O
says	0	O
'	0	O
National	0	O
Health	1	O
Dis	1	O
-	0	O
service	0	O
'.	0	O


Current	1	O
world	0	O
literature	0	O
.	0	O


IgM	1	B
and	0	O
IgG	1	B
anti	0	I
A	1	I
and	0	O
anti	0	B
B	1	I
antibody	0	I
status	0	O
of	0	O
100	0	O
antenatal	0	O
O	1	O
group	0	O
mothers	0	O
(	0	O
who	0	O
had	0	O
non	0	O
O	1	O
group	0	O
husbands	0	O
)	0	O
were	0	O
studied	0	O
.	0	O


Grossly	0	O
,	0	O
the	0	O
experimental	0	O
vulvitis	0	O
was	0	O
identical	0	O
to	0	O
the	0	O
field	0	O
condition	0	O
,	0	O
and	0	O
bacteria	0	O
indistinguishable	0	O
from	0	O
the	0	O
inoculated	0	O
strains	0	O
were	0	O
reisolated	0	O
.	0	O


Regulation	1	O
of	0	O
Gax	0	B
homeobox	0	I
gene	0	I
transcription	0	O
by	0	O
a	0	O
combination	0	O
of	0	O
positive	0	O
factors	0	O
including	0	O
myocyte	0	B
-	0	I
specific	0	I
enhancer	0	I
factor	0	I
2	0	I
.	0	O


No	1	O
changes	0	O
were	0	O
evident	0	O
in	0	O
the	0	O
FR	1	O
-	0	O
task	0	O
performance	0	O
of	0	O
controls	0	O
that	0	O
received	0	O
daily	0	O
saline	0	O
injections	0	O
.	0	O


All	1	O
subsequent	0	O
patients	0	O
were	0	O
treated	0	O
at	0	O
the	0	O
maximal	0	O
tolerated	0	O
dose	0	O
of	0	O
EDXR	0	O
(	0	O
35	0	O
mg	0	O
/	0	O
m2	0	O
/	0	O
day	0	O
).	0	O


This	0	O
work	0	O
,	0	O
therefore	0	O
,	0	O
also	0	O
emphasizes	0	O
the	0	O
importance	0	O
of	0	O
careful	0	O
choice	0	O
of	0	O
oligonucleotide	0	O
and	0	O
cDNA	1	O
probes	0	O
to	0	O
study	0	O
PKC	0	B
zeta	0	I
mRNA	1	I
.	0	O


The	0	O
current	0	O
study	0	O
defines	0	O
the	0	O
vinculin	0	B
-	0	O
and	0	O
FAK	0	B
-	0	I
interaction	0	I
domains	0	I
on	0	O
paxillin	0	B
and	0	O
identifies	0	O
the	0	O
principal	0	O
paxillin	0	B
focal	0	O
adhesion	0	O
targeting	0	O
motif	0	O
.	0	O


MpB	0	B
GroEL	0	I
has	0	O
extensive	0	O
sequence	0	O
similarity	0	O
(	0	O
92	0	O
%)	0	O
with	0	O
Escherichia	1	B
coli	0	I
GroEL	0	I
and	0	O
other	0	O
members	0	O
of	0	O
the	0	O
chaperonin	0	B
-	0	I
60	0	I
family	0	I
.	0	O


3	0	O
.	0	O


Monkeys	0	O
were	0	O
evaluated	0	O
before	0	O
and	0	O
after	0	O
unilateral	0	O
and	0	O
serial	0	O
bilateral	0	O
removal	0	O
of	0	O
superior	0	O
temporal	0	O
cortex	0	O
.	0	O


Two	0	O
alternatively	0	O
spliced	0	O
5	0	O
'	0	O
UTRs	0	O
,	0	O
designated	0	O
type	0	O
I	1	O
and	0	O
type	0	O
II	0	O
,	0	O
of	0	O
222	0	O
and	0	O
115	0	O
bp	0	O
,	0	O
respectively	0	O
,	0	O
were	0	O
found	0	O
associated	0	O
with	0	O
PFP	1	B
.	0	O


Disulfiram	1	O
and	0	O
the	0	O
drug	0	O
-	0	O
induced	0	O
effects	0	O
on	0	O
motility	0	O
.	0	O


HLA	1	B
-	0	I
A	1	I
and	0	I
B	1	I
phenotypes	0	O
of	0	O
105	0	O
patients	0	O
suffering	0	O
from	0	O
malignant	0	O
melanomas	0	O
were	0	O
determined	0	O
,	0	O
with	0	O
special	0	O
regard	0	O
for	0	O
metastatic	0	O
form	0	O
or	0	O
relapse	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
used	0	O
footprinting	0	O
and	0	O
gel	0	O
mobility	0	O
retardation	0	O
assays	0	O
to	0	O
reveal	0	O
that	0	O
bacterially	0	O
synthesized	0	O
Zta	0	B
fusion	0	I
proteins	0	I
bound	0	O
directly	0	O
to	0	O
six	0	O
TGTGCAA	0	O
-	0	O
like	0	O
motifs	0	O
within	0	O
DSL	0	B
.	0	O


At	1	O
a	0	O
PaCO2	1	O
of	0	O
40	0	O
mmHg	0	O
,	0	O
baseline	0	O
brain	0	O
pHi	1	O
measured	0	O
7	0	O
.	0	O
03	0	O
+/-	0	O
0	0	O
.	0	O
04	0	O
,	0	O
while	0	O
regional	0	O
cortical	0	O
blood	0	O
flow	0	O
was	0	O
47	0	O
.	0	O
0	0	O
+/-	0	O
4	0	O
.	0	O
3	0	O
ml	0	O
.	0	O
100	0	O
g	0	O
-	0	O
1	0	O
.	0	O
min	0	O
-	0	O
1	0	O
.	0	O


Tranilast	0	O
in	0	O
the	0	O
Therapy	1	O
of	0	O
Coronary	1	O
Artery	1	O
Disease	1	O
.	0	O


The	0	O
present	0	O
research	0	O
evaluated	0	O
the	0	O
possibility	0	O
that	0	O
polyethylene	0	O
glycol	0	O
400	0	O
(	0	O
PEG	1	O
400	0	O
)	0	O
might	0	O
be	0	O
efficacious	0	O
,	0	O
toxic	0	O
,	0	O
or	0	O
both	0	O
.	0	O


17	0	O
volunteer	0	O
deaf	0	O
Ss	1	O
were	0	O
compared	0	O
with	0	O
18	0	O
volunteer	0	O
hearing	0	O
Ss	1	O
on	0	O
the	0	O
Stanford	0	O
Hypnotic	1	O
Clinical	1	O
Scale	1	O
(	0	O
SHCS	0	O
)	0	O
of	0	O
Morgan	1	O
and	0	O
J	1	O
.	0	O


We	0	O
have	0	O
also	0	O
found	0	O
that	0	O
the	0	O
in	0	O
vitro	0	O
interaction	0	O
between	0	O
the	0	O
SV40	1	O
octamer	0	O
motif	0	O
and	0	O
the	0	O
lymphoid	0	B
cell	0	I
-	0	I
specific	0	I
protein	0	I
oct	0	I
-	0	I
B2	0	I
was	0	O
negatively	0	O
modulated	0	O
by	0	O
a	0	O
component	0	O
present	0	O
in	0	O
the	0	O
nuclear	0	O
extracts	0	O
from	0	O
several	0	O
lymphoid	0	O
cell	0	O
lines	0	O
.	0	O


The	0	O
cDNA	1	O
contained	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
of	0	O
1392	0	O
bp	0	O
that	0	O
predicted	0	O
a	0	O
protein	0	O
of	0	O
464	0	O
amino	0	O
acids	0	O
and	0	O
a	0	O
molecular	0	O
mass	0	O
of	0	O
52	0	O
kDa	1	O
;	0	O
this	0	O
protein	0	O
has	0	O
97	0	O
%	0	O
identity	0	O
to	0	O
rat	0	B
liver	0	I
glucokinase	0	I
.	0	O


This	0	O
protein	0	O
-	0	O
protein	0	O
interaction	0	O
does	0	O
not	0	O
require	0	O
the	0	O
simultaneous	0	O
binding	0	O
of	0	O
Oct	1	B
proteins	0	I
to	0	O
DNA	1	O
,	0	O
and	0	O
high	0	O
resolution	0	O
footprinting	0	O
of	0	O
the	0	O
Oct	1	B
-	0	I
DNA	1	I
interaction	0	O
reveals	0	O
that	0	O
binding	0	O
of	0	O
BOB	0	B
.	0	I
1	0	I
/	0	O
OBF	0	B
.	0	I
1	0	I
to	0	O
Oct1	0	B
or	0	O
Oct2	0	B
does	0	O
not	0	O
alter	0	O
the	0	O
interaction	0	O
with	0	O
DNA	1	O
.	0	O


Use	0	O
of	0	O
the	0	O
vena	0	O
cava	0	O
to	0	O
extend	0	O
the	0	O
right	0	O
renal	0	O
vein	0	O
for	0	O
cadaver	0	O
transplantation	0	O
is	0	O
controversial	0	O
.	0	O


Two	0	O
studies	0	O
on	0	O
the	0	O
relationship	0	O
between	0	O
taking	0	O
a	0	O
commercial	0	O
coaching	0	O
course	0	O
and	0	O
performance	0	O
on	0	O
the	0	O
Medical	1	O
College	0	O
Admission	1	O
Test	1	O
(	0	O
MCAT	0	O
)	0	O
are	0	O
reported	0	O
.	0	O


On	1	O
d	0	O
112	0	O
,	0	O
progesterone	0	O
was	0	O
higher	0	O
(	0	O
P	1	O
less	0	O
than	0	O
.	0	O
05	0	O
)	0	O
in	0	O
hysterectomized	0	O
heifers	0	O
than	0	O
in	0	O
other	0	O
treatment	0	O
groups	0	O
.	0	O


We	0	O
exploit	0	O
the	0	O
properties	0	O
of	0	O
LexA	0	B
fusion	0	I
proteins	0	I
to	0	O
study	0	O
the	0	O
dimerization	0	O
and	0	O
DNA	1	O
-	0	O
contacting	0	O
domains	0	O
of	0	O
cRel	0	B
.	0	O


2	0	O
.	0	O


Together	0	O
,	0	O
these	0	O
data	0	O
support	0	O
a	0	O
model	0	O
in	0	O
which	0	O
Tax	0	B
anchors	0	O
CBP	0	B
to	0	O
the	0	O
HTLV	0	B
-	0	I
1	0	I
promoter	0	I
,	0	O
with	0	O
strong	0	O
transcriptional	0	O
activation	0	O
resulting	0	O
from	0	O
the	0	O
CBP	0	B
-	0	O
associated	0	O
activities	0	O
of	0	O
nucleosome	0	O
remodeling	0	O
and	0	O
recruitment	0	O
of	0	O
the	0	O
general	0	O
transcription	0	O
machinery	0	O
.	0	O


To	1	O
our	0	O
knowledge	0	O
,	0	O
type	0	O
IV	1	O
renal	0	O
tubular	0	O
acidosis	0	O
has	0	O
not	0	O
been	0	O
reported	0	O
previously	0	O
in	0	O
association	0	O
with	0	O
Alport	0	O
'	0	O
s	0	O
syndrome	0	O
in	0	O
an	0	O
adult	0	O
patient	0	O
.	0	O


The	0	O
domain	0	O
structure	0	O
of	0	O
bovine	0	B
LTBP	0	I
-	0	I
2	0	I
is	0	O
very	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
the	0	O
human	0	B
LTBP	0	I
-	0	I
2	0	I
,	0	O
containing	0	O
20	0	O
examples	0	O
of	0	O
6	0	O
-	0	O
cysteine	0	O
epidermal	0	B
growth	0	I
factor	0	I
-	0	I
like	0	I
repeats	0	I
,	0	O
16	0	O
of	0	O
which	0	O
have	0	O
the	0	O
consensus	0	O
sequence	0	O
for	0	O
calcium	0	O
binding	0	O
,	0	O
together	0	O
with	0	O
4	0	O
examples	0	O
of	0	O
8	0	O
-	0	O
cysteine	0	O
motifs	0	O
characteristic	0	O
of	0	O
fibrillins	0	B
and	0	O
LTBP	0	B
-	0	I
1	0	I
.	0	O


We	0	O
have	0	O
previously	0	O
identified	0	O
,	0	O
by	0	O
screening	0	O
a	0	O
lambda	0	O
gt11	0	O
expression	0	O
library	0	O
,	0	O
murine	0	B
protein	0	I
mXBP	0	I
,	0	O
which	0	O
binds	0	O
to	0	O
a	0	O
sequence	0	O
which	0	O
overlaps	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
murine	0	B
class	0	I
II	0	I
major	0	I
histocompatibility	0	I
complex	0	I
A	1	I
alpha	0	I
gene	0	I
X	1	I
box	0	I
,	0	O
a	0	O
conserved	0	O
transcription	0	O
element	0	O
found	0	O
upstream	0	O
of	0	O
all	0	O
class	0	O
II	0	O
genes	0	O
.	0	O


Antithrombin	1	B
III	0	I
prevents	0	O
60	0	O
min	0	O
warm	0	O
intestinal	0	O
ischemia	0	O
reperfusion	0	O
injury	0	O
in	0	O
rats	0	O
.	0	O


The	0	O
nucleotide	0	O
sequence	0	O
of	0	O
22	0	O
,	0	O
846	0	O
bp	0	O
of	0	O
the	0	O
left	0	O
arm	0	O
of	0	O
chromosome	0	O
IV	1	O
is	0	O
described	0	O
.	0	O


Indium	1	O
-	0	O
111	0	O
OncoScint	0	O
CR	1	O
/	0	O
OV	0	O
and	0	O
F	1	O
-	0	O
18	0	O
FDG	1	O
in	0	O
colorectal	0	O
and	0	O
ovarian	0	O
carcinoma	0	O
recurrences	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
cDNAs	0	O
for	0	O
a	0	O
gene	0	O
coding	0	O
for	0	O
a	0	O
G	1	B
protein	0	I
alpha	0	I
subunit	0	I
from	0	I
tomato	0	I
(	0	O
Lycopersicon	0	O
esculentum	0	O
,	0	O
cv	0	O
.	0	O


The	0	O
first	0	O
gene	0	O
,	0	O
NSR1	0	B
,	0	O
a	0	O
previously	0	O
identified	0	O
gene	0	O
,	0	O
encodes	0	O
a	0	O
protein	0	O
involved	0	O
in	0	O
ribosomal	0	O
RNA	1	O
maturation	0	O
and	0	O
possibly	0	O
in	0	O
transport	0	O
of	0	O
proteins	0	O
into	0	O
the	0	O
nucleus	0	O
.	0	O


Solution	1	O
structure	0	O
of	0	O
the	0	O
IRF	1	B
-	0	I
2	0	I
DNA	1	I
-	0	I
binding	0	I
domain	0	I
:	0	O
a	0	O
novel	0	O
subgroup	0	O
of	0	O
the	0	O
winged	0	B
helix	0	I
-	0	I
turn	0	I
-	0	I
helix	0	I
family	0	I
.	0	O


This	0	O
tendency	0	O
is	0	O
likely	0	O
due	0	O
to	0	O
the	0	O
biased	0	O
nucleotide	0	O
composition	0	O
of	0	O
the	0	O
asparagus	0	O
genome	0	O
,	0	O
rather	0	O
than	0	O
to	0	O
the	0	O
translational	0	O
selection	0	O
for	0	O
specific	0	O
codons	0	O
.	0	O


Analysis	1	O
of	0	O
various	0	O
deletion	0	O
mutants	0	O
indicates	0	O
that	0	O
the	0	O
sequence	0	O
requirements	0	O
for	0	O
binding	0	O
by	0	O
QBP	0	B
in	0	O
vitro	0	O
are	0	O
indistinguishable	0	O
from	0	O
those	0	O
necessary	0	O
for	0	O
Q	1	O
activity	0	O
in	0	O
vivo	0	O
,	0	O
strongly	0	O
suggesting	0	O
that	0	O
QBP	0	B
is	0	O
required	0	O
for	0	O
the	0	O
function	0	O
of	0	O
this	0	O
TATA	0	O
-	0	O
independent	0	O
promoter	0	O
.	0	O


Yap1p	0	B
is	0	O
constitutively	0	O
nuclear	0	O
in	0	O
a	0	O
crm1	0	B
mutant	0	I
,	0	O
and	0	O
Crm1p	0	B
binds	0	O
to	0	O
a	0	O
nuclear	0	O
export	0	O
sequence	0	O
(	0	O
NES	0	O
)-	0	O
like	0	O
sequence	0	O
in	0	O
Yap1p	0	B
in	0	O
the	0	O
presence	0	O
of	0	O
RanGTP	0	B
.	0	O


A	1	O
.	0	O


Genetic	1	O
experiments	0	O
using	0	O
mutants	0	O
defective	0	O
in	0	O
apontic	0	B
and	0	O
bruno	0	B
reveal	0	O
a	0	O
functional	0	O
interaction	0	O
between	0	O
these	0	O
genes	0	O
.	0	O


Two	0	O
out	0	O
of	0	O
five	0	O
patients	0	O
undergoing	0	O
selective	0	O
spinal	0	O
arteriography	0	O
developed	0	O
transient	0	O
neurological	0	O
complications	0	O
during	0	O
the	0	O
injection	0	O
of	0	O
Urografin	1	O
310	0	O
M	1	O
.	0	O


In	1	O
rats	0	O
anaesthetized	0	O
with	0	O
+-	0	O
chloralose	0	O
the	0	O
changes	0	O
in	0	O
extracellular	0	O
pH	1	O
and	0	O
K	1	O
+	0	O
in	0	O
spinal	0	O
cord	0	O
dorsal	0	O
horn	0	O
were	0	O
studied	0	O
using	0	O
pH	1	O
and	0	O
K	1	O
+	0	O
ion	0	O
-	0	O
selective	0	O
electrodes	0	O
.	0	O


These	0	O
introns	0	O
contain	0	O
only	0	O
single	0	O
snoRNA	1	B
genes	0	I
and	0	O
their	0	O
processing	0	O
involves	0	O
exonucleolytic	0	O
release	0	O
of	0	O
the	0	O
snoRNA	1	O
from	0	O
debranched	0	O
intron	0	O
lariats	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
echothiophate	0	O
on	0	O
the	0	O
biphasic	0	O
response	0	O
of	0	O
rabbit	0	O
ocular	0	O
pressure	0	O
to	0	O
dipivefrin	0	O
.	0	O


High	0	O
fibrinogen	0	B
levels	0	O
could	0	O
thus	0	O
be	0	O
a	0	O
risk	0	O
for	0	O
perioperative	0	O
thrombosis	0	O
.	0	O


Strategic	0	O
change	0	O
in	0	O
the	0	O
NHS	1	O
.	0	O


Aplastic	1	O
crisis	0	O
in	0	O
sickle	0	O
cell	0	O
disorders	0	O
:	0	O
bone	0	O
marrow	0	O
necrosis	0	O
and	0	O
human	0	O
parvovirus	0	O
infection	0	O
.	0	O


BACKGROUND	0	O
:	0	O
The	0	O
Bazett	0	O
-	0	O
corrected	0	O
QT	1	O
(	0	O
QTc	1	O
)	0	O
interval	0	O
during	0	O
exercise	0	O
has	0	O
been	0	O
used	0	O
as	0	O
a	0	O
marker	0	O
for	0	O
ischemic	0	O
disease	0	O
,	0	O
arrhythmogenic	0	O
substrate	0	O
and	0	O
the	0	O
long	0	O
QT	1	O
syndrome	0	O
.	0	O


Restoration	1	O
of	0	O
impaired	0	O
immune	0	O
functions	0	O
in	0	O
aging	0	O
animals	0	O
.	0	O


Little	0	O
is	0	O
known	0	O
about	0	O
the	0	O
mechanism	0	O
,	0	O
but	0	O
the	0	O
availability	0	O
of	0	O
rapid	0	O
facile	0	O
assays	0	O
for	0	O
monitoring	0	O
immunoglobulin	0	B
hypermutation	0	O
would	0	O
greatly	0	O
aid	0	O
the	0	O
development	0	O
of	0	O
culture	0	O
systems	0	O
for	0	O
hypermutating	0	O
B	1	O
cells	0	O
as	0	O
well	0	O
as	0	O
the	0	O
screening	0	O
for	0	O
individuals	0	O
deficient	0	O
in	0	O
the	0	O
process	0	O
.	0	O


Ten	0	O
selenocysteine	0	O
residues	0	O
(	0	O
deduced	0	O
)	0	O
are	0	O
present	0	O
.	0	O


The	0	O
highest	0	O
prevalence	0	O
of	0	O
reported	0	O
pet	0	O
allergy	0	O
,	0	O
chronic	0	O
cough	0	O
,	0	O
wheeze	0	O
,	0	O
attacks	0	O
of	0	O
shortness	0	O
of	0	O
breath	0	O
with	0	O
wheezing	0	O
,	0	O
and	0	O
doctor	0	O
-	0	O
diagnosed	0	O
asthma	0	O
was	0	O
found	0	O
in	0	O
children	0	O
who	0	O
had	0	O
pets	0	O
in	0	O
the	0	O
past	0	O
but	0	O
not	0	O
anymore	0	O
.	0	O


Partial	0	O
sequencing	0	O
of	0	O
the	0	O
region	0	O
downstream	0	O
of	0	O
ORF	1	B
-	0	I
Pto	0	I
revealed	0	O
homology	0	O
to	0	O
the	0	O
ru	0	B
/	0	I
AB	1	I
genes	0	I
,	0	O
involved	0	O
in	0	O
UV	1	O
resistance	0	O
,	0	O
from	0	O
plasmid	0	O
pPSR1	0	O
.	0	O


All	1	O
other	0	O
changes	0	O
at	0	O
the	0	O
3	0	O
-,	0	O
5	0	O
-,	0	O
and	0	O
6	0	O
-	0	O
positions	0	O
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
replacement	0	O
of	0	O
the	0	O
phenyl	0	O
group	0	O
at	0	O
position	0	O
2	0	O
,	0	O
caused	0	O
a	0	O
marked	0	O
decrease	0	O
of	0	O
activity	0	O
.	0	O


Additionally	0	O
,	0	O
the	0	O
enzyme	0	O
shows	0	O
activity	0	O
towards	0	O
triglycerides	0	O
such	0	O
as	0	O
olive	0	O
oil	0	O
and	0	O
tributyrin	0	O
and	0	O
towards	0	O
egg	0	O
-	0	O
yolk	0	O
emulsions	0	O
.	0	O


Our	0	O
results	0	O
demonstrate	0	O
that	0	O
distinct	0	O
cytoplasmic	0	O
domains	0	O
of	0	O
these	0	O
cytokine	0	O
receptors	0	O
elicit	0	O
convergent	0	O
signaling	0	O
pathways	0	O
and	0	O
provide	0	O
evidence	0	O
that	0	O
beta	0	B
c	0	I
and	0	O
IL	1	B
-	0	I
2R	0	I
beta	0	I
function	0	O
as	0	O
a	0	O
complete	0	O
signal	0	O
transducer	0	O
.	0	O


Isolation	1	O
of	0	O
T	1	O
.	0	O
gambiense	0	O
strains	0	O
in	0	O
Zaire	0	O
and	0	O
their	0	O
adaptation	0	O
to	0	O
laboratory	0	O
animals	0	O


Epileptiform	1	O
activity	0	O
recorded	0	O
from	0	O
superficial	0	O
laminae	0	O
bordering	0	O
layer	0	O
4	0	O
,	0	O
and	0	O
into	0	O
which	0	O
layer	0	O
4	0	O
'	0	O
s	0	O
primary	0	O
projections	0	O
terminate	0	O
,	0	O
is	0	O
suppressed	0	O
preferentially	0	O
by	0	O
phenytoin	0	O
.	0	O


The	0	O
biosynthesis	0	O
and	0	O
stability	0	O
of	0	O
the	0	O
three	0	O
mutant	0	O
proteins	0	O
were	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
erbB	0	I
protein	0	I
,	0	O
and	0	O
all	0	O
three	0	O
retained	0	O
the	0	O
ability	0	O
to	0	O
transform	0	O
chicken	0	O
embryo	0	O
fibroblasts	0	O
.	0	O


From	0	O
March	1	O
5	0	O
through	0	O
October	0	O
26	0	O
,	0	O
1991	0	O
,	0	O
eight	0	O
persons	0	O
were	0	O
diagnosed	0	O
with	0	O
elevated	0	O
blood	0	O
lead	0	O
levels	0	O
(	0	O
BLLs	0	O
)	0	O
at	0	O
a	0	O
local	0	O
hospital	0	O
and	0	O
were	0	O
reported	0	O
to	0	O
the	0	O
notifiable	0	O
disease	0	O
surveillance	0	O
system	0	O
maintained	0	O
by	0	O
the	0	O
Alabama	0	O
Department	1	O
of	0	O
Public	0	O
Health	1	O
(	0	O
ADPH	0	O
).	0	O


Significant	1	O
correlations	0	O
were	0	O
obtained	0	O
between	0	O
changes	0	O
in	0	O
SSEP	0	O
in	0	O
response	0	O
to	0	O
AS	1	O
and	0	O
the	0	O
presence	0	O
of	0	O
not	0	O
deep	0	O
residual	0	O
-	0	O
organic	0	O
disturbances	0	O
,	0	O
so	0	O
-	0	O
called	0	O
"	0	O
ground	0	O
"	0	O
in	0	O
psychogenic	0	O
disorders	0	O
.	0	O


We	0	O
have	0	O
now	0	O
identified	0	O
,	0	O
after	0	O
21	0	O
serial	0	O
undiluted	0	O
passages	0	O
of	0	O
MHV	0	O
,	0	O
a	0	O
small	0	B
DI	0	I
RNA	1	I
,	0	O
DIssF	0	B
,	0	O
which	0	O
is	0	O
efficiently	0	O
packaged	0	O
into	0	O
virions	0	O
.	0	O


Demonstration	0	O
of	0	O
fine	0	O
structure	0	O
of	0	O
the	0	O
guinea	0	O
pig	0	O
organ	0	O
of	0	O
Corti	0	O
after	0	O
electron	0	O
microscopic	0	O
silver	0	O
staining	0	O


Here	0	O
,	0	O
we	0	O
describe	0	O
the	0	O
isolation	0	O
of	0	O
MdPin1	0	B
,	0	O
a	0	O
Pin1	0	B
homologue	0	O
from	0	O
the	0	O
plant	0	O
species	0	O
apple	0	O
(	0	O
Malus	1	O
domestica	0	O
)	0	O
and	0	O
show	0	O
that	0	O
it	0	O
has	0	O
the	0	O
same	0	O
phosphorylation	0	O
-	0	O
specific	0	O
substrate	0	O
specificity	0	O
and	0	O
can	0	O
be	0	O
inhibited	0	O
by	0	O
juglone	0	O
in	0	O
vitro	0	O
,	0	O
as	0	O
is	0	O
the	0	O
case	0	O
for	0	O
Pin1	0	B
.	0	O


In	1	O
the	0	O
artificial	0	O
lung	0	O
,	0	O
like	0	O
in	0	O
the	0	O
natural	0	O
lung	0	O
and	0	O
peripheral	0	O
tissues	0	O
,	0	O
gas	0	O
exchanges	0	O
depend	0	O
on	0	O
several	0	O
parameters	0	O
:	0	O
blood	0	O
inlet	0	O
conditions	0	O
,	0	O
blood	0	O
flow	0	O
rate	0	O
,	0	O
temperature	0	O
,	0	O
composition	0	O
of	0	O
the	0	O
gas	0	O
mixture	0	O
used	0	O
for	0	O
ventilation	0	O
,	0	O
blood	0	O
tissue	0	O
perfusion	0	O
,	0	O
O2	1	O
consumption	0	O
,	0	O
etc	0	O
.	0	O


Brain	1	B
cholinesterase	0	I
activity	0	O
of	0	O
nestling	0	O
great	0	O
egrets	0	O
,	0	O
snowy	0	O
egrets	0	O
and	0	O
black	0	O
-	0	O
crowned	0	O
night	0	O
-	0	O
herons	0	O
.	0	O
inhibition	0	O
of	0	O
brain	0	B
cholinesterase	0	I
(	0	O
ChE	1	B
)	0	O
activity	0	O
in	0	O
birds	0	O
is	0	O
often	0	O
used	0	O
to	0	O
diagnose	0	O
exposure	0	O
or	0	O
death	0	O
from	0	O
organophosphorus	0	O
or	0	O
carbamate	0	O
pesticides	0	O
.	0	O


40	0	O
patients	0	O
with	0	O
chronic	0	O
osteomyelitis	0	O
were	0	O
treated	0	O
per	0	O
os	0	O
with	0	O
the	0	O
bactericidal	0	O
beta	0	O
-	0	O
lactam	0	O
-	0	O
antibiotic	0	O
cephalexin	0	O
during	0	O
3	0	O
to	0	O
60	0	O
weeks	0	O
.	0	O


The	0	O
terminator	0	O
region	0	O
supported	0	O
termination	0	O
of	0	O
transcripts	0	O
initiated	0	O
by	0	O
RNA	1	B
polymerase	0	I
I	1	I
in	0	O
vivo	0	O
.	0	O


Dr	1	O
.	0	O


A	1	O
15	0	O
.	0	O
1	0	O
kb	0	O
fragment	0	O
of	0	O
the	0	O
yeast	0	O
genome	0	O
was	0	O
allocated	0	O
to	0	O
the	0	O
centromeric	0	O
region	0	O
of	0	O
chromosome	0	O
XIV	0	O
by	0	O
genetic	0	O
mapping	0	O
.	0	O


Typical	1	O
configurations	0	O
of	0	O
psychosocial	0	O
stress	0	O
factors	0	O
of	0	O
psychiatrically	0	O
conspicuous	0	O
children	0	O
and	0	O
adolescents	0	O


An	1	O
immunologic	0	O
test	0	O
using	0	O
stomach	0	O
and	0	O
tumor	0	O
antigens	0	O
for	0	O
screening	0	O
of	0	O
those	0	O
at	0	O
high	0	O
risk	0	O
for	0	O
stomach	0	O
cancer	0	O
is	0	O
suggested	0	O
.	0	O


This	0	O
report	0	O
provides	0	O
further	0	O
evidence	0	O
for	0	O
the	0	O
riMLF	0	O
in	0	O
the	0	O
control	0	O
of	0	O
downgaze	0	O
,	0	O
and	0	O
a	0	O
synkinesis	0	O
is	0	O
postulated	0	O
for	0	O
the	0	O
development	0	O
of	0	O
the	0	O
convergence	0	O
retraction	0	O
nystagmus	0	O
.	0	O


The	0	O
distribution	0	O
of	0	O
the	0	O
sites	0	O
of	0	O
recombinational	0	O
resolution	0	O
is	0	O
inversely	0	O
correlated	0	O
with	0	O
that	0	O
of	0	O
the	0	O
gradient	0	O
of	0	O
sequence	0	O
divergence	0	O
,	0	O
with	0	O
only	0	O
approximately	0	O
7	0	O
%	0	O
of	0	O
the	0	O
X	1	O
recombinants	0	O
resolved	0	O
within	0	O
the	0	O
3	0	O
'	0	O
third	0	O
of	0	O
the	0	O
X	1	O
blocks	0	O
where	0	O
two	0	O
diverged	0	O
Alu	0	B
family	0	O
repeats	0	O
reside	0	O
.	0	O


The	0	O
HMG	1	B
CoA	1	I
reductase	0	I
inhibitors	0	O
are	0	O
the	0	O
most	0	O
effective	0	O
cholesterol	0	O
-	0	O
lowering	0	O
agents	0	O
currently	0	O
available	0	O
.	0	O


The	0	O
diagnostic	0	O
significance	0	O
of	0	O
creatine	0	B
phosphokinase	0	I
antibodies	0	O
in	0	O
the	0	O
cardiac	0	O
muscle	0	O
in	0	O
non	0	O
-	0	O
coronarogenic	0	O
myocardial	0	O
diseases	0	O


Predictors	0	O
of	0	O
success	0	O
in	0	O
pharmacy	0	O
school	0	O
:	0	O
PCAT	0	O
vs	0	O
.	0	O
other	0	O
admission	0	O
criteria	0	O
.	0	O


Because	0	O
the	0	O
hcf109	0	B
locus	0	I
was	0	O
mapped	0	O
at	0	O
a	0	O
distance	0	O
<	0	O
0	0	O
.	0	O
1	0	O
centimorgans	0	O
from	0	O
the	0	O
phytochrome	0	B
C	1	I
gene	0	I
,	0	O
its	0	O
molecular	0	O
characterization	0	O
by	0	O
positional	0	O
cloning	0	O
is	0	O
possible	0	O
.	0	O


The	0	O
fepA	0	B
-	0	O
entD	0	B
and	0	O
fes	0	B
-	0	O
entF	0	B
operons	0	O
in	0	O
the	0	O
enterobactin	0	O
synthesis	0	O
and	0	O
transport	0	O
system	0	O
are	0	O
divergently	0	O
transcribed	0	O
from	0	O
overlapping	0	O
promoters	0	O
,	0	O
and	0	O
both	0	O
are	0	O
inhibited	0	O
by	0	O
the	0	O
Fur	0	B
repressor	0	I
protein	0	I
under	0	O
iron	0	O
-	0	O
replete	0	O
conditions	0	O
.	0	O


267	0	O
,	0	O
4870	0	O
-	0	O
4877	0	O
))	0	O
indicates	0	O
an	0	O
overall	0	O
identity	0	O
of	0	O
58	0	O
and	0	O
56	0	O
%,	0	O
respectively	0	O
,	0	O
with	0	O
a	0	O
91	0	O
and	0	O
92	0	O
%	0	O
identity	0	O
in	0	O
the	0	O
highly	0	O
conserved	0	O
transmembrane	0	O
and	0	O
cytoplasmic	0	O
domains	0	O
.	0	O


Quantitative	1	O
predictions	0	O
are	0	O
confirmed	0	O
for	0	O
the	0	O
positive	0	O
responses	0	O
,	0	O
but	0	O
not	0	O
for	0	O
the	0	O
negatives	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
SSTS	0	O
model	0	O
is	0	O
incorrect	0	O
.	0	O


Azithromycin	1	O
is	0	O
a	0	O
new	0	O
generation	0	O
macrolide	0	O
antibiotic	0	O
with	0	O
unusual	0	O
and	0	O
favorable	0	O
pharmacokinetics	0	O
,	0	O
and	0	O
seems	0	O
to	0	O
be	0	O
a	0	O
very	0	O
promising	0	O
agent	0	O
for	0	O
innovative	0	O
anti	0	O
-	0	O
H	1	O
.	0	O
pylori	0	O
regimens	0	O
.	0	O


Preface	0	O
.	0	O


Potential	1	O
indicators	0	O
were	0	O
assessed	0	O
for	0	O
the	0	O
two	0	O
classifications	0	O
of	0	O
protein	0	O
-	0	O
energy	0	O
malnutrition	0	O
in	0	O
the	0	O
guidelines	0	O
for	0	O
integrated	0	O
management	0	O
of	0	O
childhood	0	O
illness	0	O
:	0	O
severe	0	O
malnutrition	0	O
,	0	O
which	0	O
requires	0	O
immediate	0	O
referral	0	O
to	0	O
hospital	0	O
,	0	O
and	0	O
very	0	O
low	0	O
weight	0	O
,	0	O
which	0	O
calls	0	O
for	0	O
feeding	0	O
assessment	0	O
,	0	O
nutritional	0	O
counselling	0	O
and	0	O
follow	0	O
-	0	O
up	0	O
.	0	O


Positive	1	O
genetic	0	O
selections	0	O
for	0	O
inhibition	0	O
of	0	O
cyclin	0	B
/	0	O
CDK	1	B
function	0	O
were	0	O
characterized	0	O
using	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
neo	0	I
and	0	O
yeast	0	B
LEU2	0	I
genes	0	I
.	0	O


This	0	O
study	0	O
represents	0	O
the	0	O
first	0	O
published	0	O
long	0	O
-	0	O
term	0	O
follow	0	O
-	0	O
up	0	O
regarding	0	O
this	0	O
mode	0	O
of	0	O
treatment	0	O
in	0	O
patients	0	O
with	0	O
alveolar	0	O
hypoventilation	0	O
.	0	O


The	0	O
expression	0	O
pattern	0	O
of	0	O
GL2	0	B
,	0	O
as	0	O
demonstrated	0	O
by	0	O
in	0	O
situ	0	O
hybridization	0	O
,	0	O
indicated	0	O
that	0	O
the	0	O
gene	0	O
is	0	O
expressed	0	O
in	0	O
trichome	0	O
progenitor	0	O
cells	0	O
and	0	O
at	0	O
stages	0	O
associated	0	O
with	0	O
trichome	0	O
development	0	O
.	0	O


Five	0	O
of	0	O
the	0	O
patients	0	O
with	0	O
increased	0	O
L	1	O
-	0	O
L	1	O
size	0	O
had	0	O
a	0	O
normal	0	O
A	1	O
-	0	O
P	1	O
diameter	0	O
.	0	O


State	1	O
of	0	O
the	0	O
body	0	O
in	0	O
disorders	0	O
of	0	O
diurnal	0	O
physiological	0	O
rhythms	0	O
and	0	O
long	0	O
-	0	O
term	0	O
hypokinesia	0	O


The	0	O
lysozyme	0	B
FEF	1	I
site	0	O
is	0	O
immediately	0	O
5	0	O
'	0	O
to	0	O
a	0	O
PU	1	B
.	0	O


Human	1	B
ULK1	0	I
,	0	O
a	0	O
novel	0	O
serine	0	B
/	0	I
threonine	0	I
kinase	0	I
related	0	O
to	0	O
UNC	0	B
-	0	I
51	0	I
kinase	0	I
of	0	O
Caenorhabditis	0	O
elegans	0	O
:	0	O
cDNA	1	O
cloning	0	O
,	0	O
expression	0	O
,	0	O
and	0	O
chromosomal	0	O
assignment	0	O
.	0	O


We	0	O
also	0	O
show	0	O
that	0	O
in	0	O
fusions	0	O
with	0	O
the	0	O
DNA	1	O
binding	0	O
domain	0	O
of	0	O
GAL4	0	B
,	0	O
full	0	O
activity	0	O
requires	0	O
the	0	O
entire	0	O
BHV	0	B
-	0	I
alpha	0	I
TIF	0	I
,	0	O
although	0	O
both	0	O
amino	0	O
and	0	O
carboxyl	0	O
termini	0	O
display	0	O
some	0	O
activity	0	O
on	0	O
their	0	O
own	0	O
.	0	O


Tolterodine	0	O
users	0	O
were	0	O
7	0	O
.	0	O
5	0	O
times	0	O
more	0	O
likely	0	O
to	0	O
have	0	O
received	0	O
another	0	O
spasmolytic	0	O
drug	0	O
(	0	O
RR	0	O
7	0	O
.	0	O
5	0	O
,	0	O
95	0	O
%	0	O
CI	1	O
4	0	O
.	0	O
8	0	O
to	0	O
11	0	O
.	0	O
9	0	O
).	0	O


The	0	O
combination	0	O
of	0	O
Pitx2	0	B
and	0	O
another	0	O
homeodomain	0	B
protein	0	I
,	0	O
Pit	1	B
-	0	I
1	0	I
,	0	O
yielded	0	O
a	0	O
synergistic	0	O
55	0	O
-	0	O
fold	0	O
activation	0	O
of	0	O
the	0	O
prolactin	0	B
promoter	0	I
in	0	O
transfection	0	O
assays	0	O
.	0	O


Dopamine	1	O
caused	0	O
a	0	O
prominent	0	O
potassium	0	O
efflux	0	O
measured	0	O
as	0	O
86Rb	0	O
+	0	O
efflux	0	O
from	0	O
control	0	O
glands	0	O
,	0	O
but	0	O
was	0	O
without	0	O
effect	0	O
in	0	O
denervated	0	O
glands	0	O
.	0	O


Upstream	1	O
activating	0	O
sequences	0	O
(	0	O
UASs	0	O
)	0	O
derived	0	O
from	0	O
known	0	O
Ste12p	0	B
-	0	O
dependent	0	O
genes	0	O
have	0	O
previously	0	O
been	0	O
characterized	0	O
to	0	O
require	0	O
either	0	O
multiple	0	O
PREs	0	O
or	0	O
a	0	O
single	0	O
PRE	0	O
coupled	0	O
to	0	O
a	0	O
binding	0	O
site	0	O
for	0	O
a	0	O
second	0	O
protein	0	O
.	0	O


These	0	O
data	0	O
demonstrate	0	O
that	0	O
DMVA	0	O
does	0	O
not	0	O
cause	0	O
more	0	O
myocardial	0	O
trauma	0	O
than	0	O
CPB	0	O
when	0	O
used	0	O
to	0	O
provide	0	O
resuscitative	0	O
circulatory	0	O
support	0	O
.	0	O


Basic	1	B
fibroblast	0	I
growth	0	I
factor	0	I
(	0	O
bFGF	0	B
)	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
induce	0	O
angiogenesis	0	O
in	0	O
various	0	O
animal	0	O
models	0	O
,	0	O
but	0	O
the	0	O
methods	0	O
of	0	O
administration	0	O
used	0	O
experimentally	0	O
are	0	O
not	0	O
clinically	0	O
feasible	0	O
.	0	O


The	0	O
transactivation	0	O
function	0	O
of	0	O
EBNA2	0	B
was	0	O
also	0	O
observed	0	O
in	0	O
the	0	O
HeLa	0	O
epithelial	0	O
cell	0	O
line	0	O
,	0	O
which	0	O
suggests	0	O
that	0	O
EBV	1	O
and	0	O
HIV	1	O
-	0	O
1	0	O
infection	0	O
of	0	O
non	0	O
-	0	O
B	1	O
cells	0	O
may	0	O
result	0	O
in	0	O
HIV	1	B
-	0	I
1	0	I
promoter	0	I
activation	0	O
.	0	O


Previous	0	O
analysis	0	O
of	0	O
the	0	O
98	0	O
-	0	O
bp	0	O
sequence	0	O
has	0	O
delineated	0	O
several	0	O
protein	0	O
-	0	O
binding	0	O
domains	0	O
that	0	O
are	0	O
recognized	0	O
by	0	O
nuclear	0	O
factors	0	O
present	0	O
in	0	O
human	0	O
brain	0	O
cells	0	O
.	0	O


In	1	O
one	0	O
acromegalic	0	O
patient	0	O
visual	0	O
improvement	0	O
was	0	O
obtained	0	O
while	0	O
the	0	O
abnormal	0	O
GH	1	B
secretion	0	O
remained	0	O
unaltered	0	O
.	0	O


Hypoglycemic	1	O
action	0	O
of	0	O
"	0	O
he	0	O
xiang	0	O
zhuang	0	O
qi	0	O
gong	0	O
"	0	O
and	0	O
its	0	O
mechanism	0	O
on	0	O
diabetes	0	O
mellitus	0	O


High	0	O
concentrations	0	O
of	0	O
tumor	0	O
-	0	O
associated	0	O
trypsin	0	B
inhibitor	0	O
in	0	O
hemodialyzed	0	O
patients	0	O
.	0	O


All	1	O
three	0	O
NR	0	B
isoforms	0	O
are	0	O
expressed	0	O
in	0	O
cv	0	O
.	0	O


Collectively	0	O
,	0	O
our	0	O
findings	0	O
demonstrate	0	O
that	0	O
SF	1	B
-	0	I
1	0	I
plays	0	O
a	0	O
key	0	O
role	0	O
in	0	O
controlling	0	O
the	0	O
basal	0	O
and	0	O
cAMP	1	O
-	0	O
stimulated	0	O
expression	0	O
of	0	O
the	0	O
StAR	1	B
gene	0	I
.	0	O


Caution	0	O
should	0	O
be	0	O
exercised	0	O
in	0	O
the	0	O
use	0	O
of	0	O
these	0	O
dyes	0	O
for	0	O
lymphograms	0	O
.	0	O


The	0	O
implications	0	O
for	0	O
estimates	0	O
of	0	O
cortical	0	O
magnification	0	O
and	0	O
possible	0	O
differences	0	O
in	0	O
the	0	O
specializations	0	O
of	0	O
foveal	0	O
and	0	O
peripheral	0	O
vision	0	O
are	0	O
discussed	0	O
.	0	O


The	0	O
variations	0	O
were	0	O
caused	0	O
by	0	O
opposite	0	O
shifts	0	O
in	0	O
TSH	1	B
frequency	0	O
distribution	0	O
in	0	O
mothers	0	O
and	0	O
neonates	0	O
.	0	O


The	0	O
method	0	O
is	0	O
applied	0	O
to	0	O
determine	0	O
aberration	0	O
constants	0	O
of	0	O
a	0	O
CM300	0	O
FEG	0	O
/	0	O
UT	0	O
microscope	0	O
with	0	O
correction	0	O
of	0	O
the	0	O
three	0	O
-	0	O
fold	0	O
astigmatism	0	O
.	0	O


The	0	O
modalities	0	O
for	0	O
using	0	O
reference	0	O
values	0	O
for	0	O
individual	0	O
subjects	0	O
as	0	O
well	0	O
as	0	O
for	0	O
groups	0	O
are	0	O
then	0	O
discussed	0	O
and	0	O
the	0	O
main	0	O
points	0	O
of	0	O
research	0	O
which	0	O
must	0	O
be	0	O
faced	0	O
in	0	O
the	0	O
near	0	O
future	0	O
regarding	0	O
reference	0	O
values	0	O
are	0	O
highlighted	0	O
.	0	O


The	0	O
uterine	0	O
response	0	O
to	0	O
prostaglandin	0	O
E2	1	O
(	0	O
PGE2	0	O
)	0	O
and	0	O
prostaglandin	0	O
F2alpha	0	O
(	0	O
administered	0	O
by	0	O
intravenous	0	O
and	0	O
intrauterine	0	O
routes	0	O
)	0	O
was	0	O
evaluated	0	O
during	0	O
different	0	O
phases	0	O
of	0	O
the	0	O
menstrual	0	O
cycle	0	O
in	0	O
five	0	O
functionally	0	O
infertile	0	O
women	0	O
.	0	O


Platelet	1	O
aggregation	0	O
and	0	O
metabolic	0	O
control	0	O
are	0	O
not	0	O
affected	0	O
by	0	O
calcium	0	O
antagonist	0	O
treatment	0	O
in	0	O
type	0	O
II	0	O
diabetes	0	O
mellitus	0	O
.	0	O


Magnetically	0	O
induced	0	O
optical	0	O
self	0	O
-	0	O
pulsing	0	O
in	0	O
a	0	O
nonlinear	0	O
resonator	0	O
.	0	O


Human	1	B
LAF	0	I
-	0	I
4	0	I
readily	0	O
hybridized	0	O
with	0	O
genes	0	O
in	0	O
mouse	0	O
and	0	O
chicken	0	O
,	0	O
thus	0	O
showing	0	O
that	0	O
this	0	O
gene	0	O
family	0	O
has	0	O
been	0	O
highly	0	O
conserved	0	O
during	0	O
vertebrate	0	O
evolution	0	O
.	0	O


Pb	1	O
foil	0	O
(	0	O
0	0	O
.	0	O
55	0	O
gcm	0	O
-	0	O
2	0	O
)	0	O
provided	0	O
the	0	O
best	0	O
overall	0	O
improvement	0	O
.	0	O


Possible	0	O
pathogenetic	0	O
mechanisms	0	O
of	0	O
hemopoietic	0	O
changes	0	O
in	0	O
response	0	O
to	0	O
space	0	O
flight	0	O
effects	0	O
are	0	O
described	0	O
.	0	O


Vam7p	0	B
,	0	O
a	0	O
SNAP	1	B
-	0	I
25	0	I
-	0	I
like	0	I
molecule	0	I
,	0	O
and	0	O
Vam3p	0	B
,	0	O
a	0	O
syntaxin	0	B
homolog	0	I
,	0	O
function	0	O
together	0	O
in	0	O
yeast	0	O
vacuolar	0	O
protein	0	O
trafficking	0	O
.	0	O


From	0	O
day	0	O
30	0	O
after	0	O
turnout	0	O
,	0	O
the	0	O
PFB	0	O
-	0	O
group	0	O
had	0	O
significantly	0	O
lower	0	O
serum	0	B
pepsinogen	0	I
levels	0	O
,	0	O
which	0	O
reflects	0	O
the	0	O
low	0	O
degree	0	O
of	0	O
abomasal	0	O
damage	0	O
in	0	O
these	0	O
animals	0	O
.	0	O


These	0	O
data	0	O
demonstrate	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
single	0	O
binding	0	O
site	0	O
for	0	O
vinculin	0	B
,	0	O
and	0	O
at	0	O
least	0	O
two	0	O
binding	0	O
sites	0	O
for	0	O
FAK	0	B
that	0	O
are	0	O
separated	0	O
by	0	O
an	0	O
intervening	0	O
stretch	0	O
of	0	O
100	0	O
amino	0	O
acids	0	O
.	0	O


The	0	O
status	0	O
of	0	O
education	0	O
and	0	O
training	0	O
programs	0	O
in	0	O
speech	0	O
pathology	0	O
and	0	O
audiology	0	O
--	0	O
1971	0	O
-	0	O
72	0	O
.	0	O


As	1	O
expected	0	O
,	0	O
the	0	O
heparin	0	O
did	0	O
produce	0	O
increased	0	O
recalcification	0	O
times	0	O
and	0	O
the	0	O
development	0	O
of	0	O
occasional	0	O
subcutaneous	0	O
hematomas	0	O
.	0	O


The	0	O
pulmonary	0	O
effects	0	O
observed	0	O
,	0	O
became	0	O
more	0	O
pronounced	0	O
with	0	O
increasing	0	O
NO2	0	O
concentrations	0	O
(	0	O
0	0	O
,	0	O
25	0	O
,	0	O
75	0	O
,	0	O
125	0	O
,	0	O
175	0	O
or	0	O
200	0	O
ppm	0	O
,	0	O
1	0	O
ppm	0	O
NO2	0	O
=	0	O
1	0	O
.	0	O
88	0	O
mg	0	O
m	0	O
-	0	O
3	0	O
NO2	0	O
)	0	O
and	0	O
exposure	0	O
times	0	O
(	0	O
5	0	O
,	0	O
10	0	O
,	0	O
20	0	O
or	0	O
30	0	O
min	0	O
).	0	O


Translational	0	O
fusions	0	O
of	0	O
the	0	O
aroF	0	B
regulatory	0	I
regions	0	I
to	0	O
lacZ	0	B
were	0	O
constructed	0	O
and	0	O
then	0	O
introduced	0	O
in	0	O
single	0	O
copy	0	O
into	0	O
the	0	O
E	1	O
.	0	O
coli	0	O
chromosome	0	O
.	0	O
beta	0	B
-	0	I
Galactosidase	1	I
assays	0	O
for	0	O
tyrR	0	O
-	0	O
mediated	0	O
regulation	0	O
of	0	O
aroF	0	B
-	0	O
lacZ	0	B
expression	0	O
revealed	0	O
that	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
TyrR	0	I
repressor	0	I
apparently	0	O
recognizes	0	O
the	0	O
operators	0	O
of	0	O
both	0	O
organisms	0	O
with	0	O
about	0	O
equal	0	O
efficiency	0	O
.	0	O


Overproduction	1	O
,	0	O
purification	0	O
and	0	O
characterization	0	O
of	0	O
M	1	B
.	0	I
HinfI	0	I
methyltransferase	0	I
and	0	O
its	0	O
deletion	0	O
mutant	0	O
.	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
we	0	O
have	0	O
analyzed	0	O
the	0	O
structure	0	O
of	0	O
human	0	O
gene	0	O
for	0	O
Gx	0	B
alpha	0	I
,	0	O
which	0	O
spans	0	O
more	0	O
than	0	O
60	0	O
kilobases	0	O
.	0	O


The	0	O
protein	0	B
ELT	0	I
-	0	I
1	0	I
,	0	O
encoded	0	O
by	0	O
a	0	O
single	0	O
-	0	O
copy	0	O
gene	0	O
homologous	0	O
to	0	O
the	0	O
GATA	0	B
family	0	I
of	0	I
vertebrate	0	I
transcription	0	I
factors	0	I
,	0	O
is	0	O
potentially	0	O
capable	0	O
of	0	O
interacting	0	O
with	0	O
this	0	O
element	0	O
.	0	O


Hydrocortisone	1	O
caused	0	O
lymphopenia	0	O
and	0	O
inhibited	0	O
the	0	O
blastogenic	0	O
response	0	O
of	0	O
peripheral	0	O
blood	0	O
lymphocytes	0	O
to	0	O
phytohemagglutinin	0	B
and	0	O
concanavalin	0	B
A	1	I
mitogens	0	O
.	0	O


Preheparin	0	O
LPL	0	B
mass	0	O
level	0	O
did	0	O
not	0	O
significantly	0	O
differ	0	O
in	0	O
individuals	0	O
from	0	O
19	0	O
to	0	O
70	0	O
years	0	O
old	0	O
,	0	O
for	0	O
both	0	O
men	0	O
and	0	O
women	0	O
.	0	O


The	0	O
catalytic	0	O
site	0	O
has	0	O
an	0	O
S1	1	O
pocket	0	O
lined	0	O
with	0	O
conserved	0	O
hydrophobic	0	O
residues	0	O
to	0	O
accommodate	0	O
the	0	O
pyroglutamyl	0	O
residue	0	O
.	0	O


The	0	O
mean	0	O
total	0	O
white	0	O
cell	0	O
count	0	O
increased	0	O
from	0	O
a	0	O
baseline	0	O
of	0	O
11	0	O
.	0	O
3	0	O
x	0	O
10	0	O
(	0	O
9	0	O
)/	0	O
L	1	O
(	0	O
SD	1	O
2	0	O
.	0	O
3	0	O
)	0	O
to	0	O
16	0	O
.	0	O
2	0	O
x	0	O
10	0	O
(	0	O
9	0	O
)/	0	O
L	1	O
(	0	O
SD	1	O
4	0	O
.	0	O
6	0	O
)	0	O
on	0	O
day	0	O
1	0	O
,	0	O
normalising	0	O
thereafter	0	O
.	0	O


Production	1	O
of	0	O
C	1	B
mu	0	I
RNAs	0	I
,	0	O
unlike	0	O
mu	0	B
mRNAs	0	I
,	0	O
does	0	O
not	0	O
require	0	O
recombination	0	O
with	0	O
the	0	O
joining	0	B
region	0	I
(	0	O
JH	0	B
)	0	O
locus	0	O
.	0	O


The	0	O
term	0	O
osteomesopycnosis	0	O
is	0	O
proposed	0	O
for	0	O
a	0	O
sclerosing	0	O
bone	0	O
disease	0	O
with	0	O
dominant	0	O
inheritance	0	O
that	0	O
has	0	O
been	0	O
discovered	0	O
in	0	O
five	0	O
members	0	O
of	0	O
four	0	O
different	0	O
families	0	O
.	0	O


One	0	O
of	0	O
these	0	O
is	0	O
surrounded	0	O
by	0	O
an	0	O
adenine	0	O
-	0	O
uridine	0	O
rich	0	O
region	0	O
that	0	O
can	0	O
form	0	O
an	0	O
11	0	O
-	0	O
base	0	O
pair	0	O
stem	0	O
structure	0	O
.	0	O


Auditory	1	O
-	0	O
visual	0	O
interaction	0	O
in	0	O
the	0	O
generation	0	O
of	0	O
saccades	0	O
in	0	O
man	0	O
.	0	O


RESULTS	0	O
:	0	O
No	1	O
significant	0	O
deformation	0	O
in	0	O
vertebral	0	O
artery	0	O
flow	0	O
was	0	O
noted	0	O
in	0	O
the	0	O
flexion	0	O
-	0	O
distraction	0	O
Stage	1	O
I	1	O
injuries	0	O
within	0	O
the	0	O
physiologic	0	O
range	0	O
of	0	O
cervical	0	O
flexion	0	O
.	0	O


Transient	1	O
expression	0	O
of	0	O
human	0	B
and	0	I
chicken	0	I
progesterone	0	I
receptors	0	I
does	0	O
not	0	O
support	0	O
alternative	0	O
translational	0	O
initiation	0	O
from	0	O
a	0	O
single	0	O
mRNA	1	O
as	0	O
the	0	O
mechanism	0	O
generating	0	O
two	0	O
receptor	0	O
isoforms	0	O
.	0	O


Dynamics	1	O
of	0	O
hospital	0	O
stay	0	O
in	0	O
peptic	0	O
ulcer	0	O
patients	0	O


In	1	O
this	0	O
study	0	O
,	0	O
a	0	O
common	0	O
mechanism	0	O
has	0	O
been	0	O
identified	0	O
to	0	O
coordinate	0	O
the	0	O
growth	0	O
-	0	O
and	0	O
FC	1	O
-	0	O
dependent	0	O
expression	0	O
of	0	O
caveolin	0	B
.	0	O


More	0	O
recently	0	O
,	0	O
however	0	O
,	0	O
a	0	O
number	0	O
of	0	O
developments	0	O
such	0	O
as	0	O
the	0	O
successful	0	O
use	0	O
of	0	O
the	0	O
inhaled	0	O
steroid	0	O
budesonide	0	O
and	0	O
oral	0	O
dexamethasone	0	O
have	0	O
reinforced	0	O
the	0	O
argument	0	O
for	0	O
using	0	O
steroids	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
ability	0	O
to	0	O
selectivity	0	O
arrest	0	O
elongation	0	O
by	0	O
polIII	0	B
at	0	O
defined	0	O
positions	0	O
within	0	O
the	0	O
tRNA	1	O
gene	0	O
transcription	0	O
unit	0	O
has	0	O
permitted	0	O
the	0	O
identification	0	O
of	0	O
discrete	0	O
functional	0	O
properties	0	O
of	0	O
paused	0	O
mammalian	0	B
polIII	0	I
ternary	0	I
complexes	0	I
.	0	O


Thrombolytic	1	O
therapy	0	O
in	0	O
spontaneous	0	O
coronary	0	O
artery	0	O
dissection	0	O
.	0	O


Ischemia	1	O
and	0	O
reperfusion	0	O
markedly	0	O
increased	0	O
the	0	O
release	0	O
of	0	O
6	0	O
-	0	O
keto	0	O
-	0	O
PGF1	0	O
alpha	0	O
and	0	O
TXB2	0	O
.	0	O


Greater	0	O
attenuation	0	O
of	0	O
the	0	O
N1	0	O
-	0	O
P2	1	O
and	0	O
baseline	0	O
-	0	O
P2	1	O
amplitude	0	O
of	0	O
the	0	O
probe	0	O
EPs	1	O
was	0	O
observed	0	O
when	0	O
the	0	O
probe	0	O
stimulus	0	O
was	0	O
presented	0	O
to	0	O
the	0	O
right	0	O
ear	0	O
and	0	O
the	0	O
verbal	0	O
material	0	O
presented	0	O
to	0	O
the	0	O
left	0	O
ear	0	O
than	0	O
when	0	O
the	0	O
opposite	0	O
stimulation	0	O
arrangement	0	O
was	0	O
used	0	O
.	0	O


These	0	O
studies	0	O
have	0	O
shown	0	O
that	0	O
the	0	O
majority	0	O
of	0	O
tested	0	O
staphylococci	0	O
were	0	O
resistant	0	O
to	0	O
penicillin	0	O
G	1	O
,	0	O
erythromycin	0	O
,	0	O
and	0	O
produced	0	O
beta	0	B
-	0	I
lactamase	0	I
.	0	O


Ectopic	1	O
ACTH	1	B
syndrome	0	O
and	0	O
medullary	0	O
thyroid	0	O
carcinoma	0	O
.	0	O


Dopamine	1	B
receptor	0	I
blockade	0	O
and	0	O
the	0	O
neuroleptics	0	O
,	0	O
a	0	O
crystallographic	0	O
study	0	O
.	0	O


Plasma	1	O
NE	1	O
was	0	O
also	0	O
low	0	O
in	0	O
the	0	O
anephric	0	O
group	0	O
(	0	O
289	0	O
mg	0	O
/	0	O
liter	0	O
+/-	0	O
126	0	O
(	0	O
1	0	O
SD	1	O
)	0	O
vs	0	O
612	0	O
+/-	0	O
189	0	O
,	0	O
P	1	O
=	0	O
0	0	O
.	0	O
033	0	O
,	0	O
resting	0	O
).(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


The	0	O
latter	0	O
method	0	O
adds	0	O
clamping	0	O
of	0	O
the	0	O
inferior	0	O
vena	0	O
cava	0	O
,	0	O
which	0	O
results	0	O
in	0	O
hypotension	0	O
,	0	O
requiring	0	O
invasive	0	O
anesthetic	0	O
management	0	O
.	0	O


Inactivation	1	O
of	0	O
MAP	1	B
kinases	0	I
occurs	0	O
via	0	O
a	0	O
specific	0	O
phosphatase	0	O
,	0	O
MKP	0	B
-	0	I
1	0	I
.	0	O


Like	0	O
scrotal	0	O
testes	0	O
,	0	O
undescended	0	O
testes	0	O
were	0	O
hypointense	0	O
to	0	O
fat	0	O
on	0	O
sequences	0	O
with	0	O
a	0	O
short	0	O
repetition	0	O
time	0	O
(	0	O
TR	1	O
)	0	O
and	0	O
echo	0	O
time	0	O
(	0	O
TE	1	O
)	0	O
in	0	O
all	0	O
cases	0	O
,	0	O
and	0	O
hyperintense	0	O
or	0	O
isointense	0	O
to	0	O
fat	0	O
on	0	O
long	0	O
TR	1	O
/	0	O
TE	1	O
sequences	0	O
in	0	O
all	0	O
but	0	O
two	0	O
cases	0	O
.	0	O


CKII	0	B
as	0	O
a	0	O
CD44	0	B
-	0	I
associated	0	I
serine	0	I
kinase	0	I
therefore	0	O
may	0	O
serve	0	O
as	0	O
an	0	O
important	0	O
molecule	0	O
in	0	O
a	0	O
signaling	0	O
cascade	0	O
that	0	O
produces	0	O
a	0	O
variety	0	O
of	0	O
cellular	0	O
responses	0	O
in	0	O
MDA231	0	O
breast	0	O
cancer	0	O
cells	0	O
.	0	O


Renal	1	O
response	0	O
to	0	O
captopril	0	O
in	0	O
severe	0	O
heart	0	O
failure	0	O
:	0	O
role	0	O
of	0	O
furosemide	0	O
in	0	O
natriuresis	0	O
and	0	O
reversal	0	O
of	0	O
hyponatremia	0	O
.	0	O


The	0	O
results	0	O
demonstrate	0	O
that	0	O
(	0	O
i	0	O
)	0	O
no	0	O
intact	0	O
capsids	0	O
were	0	O
assembled	0	O
when	0	O
the	0	O
full	0	O
-	0	O
length	0	O
or	0	O
a	0	O
truncated	0	O
(	0	O
missing	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
65	0	O
amino	0	O
acids	0	O
)	0	O
UL80	0	B
.	0	I
5	0	I
protein	0	I
was	0	O
tested	0	O
;	0	O
(	0	O
ii	0	O
)	0	O
when	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
65	0	O
amino	0	O
acids	0	O
of	0	O
the	0	O
UL80	0	B
.	0	I
5	0	I
protein	0	I
were	0	O
replaced	0	O
with	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
25	0	O
amino	0	O
acids	0	O
of	0	O
the	0	O
UL26	0	B
.	0	I
5	0	I
protein	0	I
,	0	O
intact	0	O
capsids	0	O
were	0	O
made	0	O
and	0	O
direct	0	O
interaction	0	O
of	0	O
the	0	O
UL80	0	B
.	0	I
5	0	I
protein	0	I
with	0	O
VP5	0	B
was	0	O
detected	0	O
;	0	O
(	0	O
iii	0	O
)	0	O
assembly	0	O
of	0	O
intact	0	O
capsids	0	O
was	0	O
demonstrated	0	O
when	0	O
the	0	O
sequence	0	O
of	0	O
the	0	O
last	0	O
12	0	O
amino	0	O
acids	0	O
of	0	O
the	0	O
UL80	0	B
.	0	I
5	0	I
protein	0	I
was	0	O
changed	0	O
from	0	O
RRIFVA	0	O
ALNKLE	0	O
to	0	O
RRIFVAAMMKLE	0	O
;	0	O
(	0	O
iv	0	O
)	0	O
self	0	O
-	0	O
interaction	0	O
of	0	O
the	0	O
scaffold	0	O
proteins	0	O
is	0	O
mediated	0	O
by	0	O
sequences	0	O
N	1	O
terminal	0	O
to	0	O
the	0	O
maturation	0	O
cleavage	0	O
site	0	O
;	0	O
and	0	O
(	0	O
v	0	O
)	0	O
the	0	O
UL26	0	B
.	0	I
5	0	I
and	0	O
UL80	0	B
.	0	I
5	0	I
proteins	0	I
will	0	O
not	0	O
coassemble	0	O
into	0	O
scaffold	0	O
structures	0	O
.	0	O


Promoter	1	O
activities	0	O
were	0	O
estimated	0	O
using	0	O
beta	0	B
-	0	I
glucuronidase	0	I
and	0	O
neomycin	0	B
phosphotransferase	0	I
II	0	I
reporter	0	I
gene	0	I
systems	0	I
.	0	O


Transcervical	1	O
amnioinfusion	0	O
.	0	O


Therefore	0	O
,	0	O
with	0	O
a	0	O
biopsy	0	O
from	0	O
the	0	O
stoma	0	O
site	0	O
there	0	O
is	0	O
a	0	O
risk	0	O
of	0	O
missing	0	O
early	0	O
rejection	0	O
.	0	O


Fourth	0	O
,	0	O
sometime	0	O
between	0	O
4	0	O
and	0	O
24	0	O
hours	0	O
of	0	O
recovery	0	O
is	0	O
necessary	0	O
to	0	O
reverse	0	O
the	0	O
effect	0	O
of	0	O
chronic	0	O
hypoxia	0	O
on	0	O
cerebral	0	O
blood	0	O
flow	0	O
.	0	O


Different	0	O
cortical	0	O
malformations	0	O
were	0	O
produced	0	O
in	0	O
rats	0	O
by	0	O
a	0	O
single	0	O
dose	0	O
of	0	O
X	1	O
-	0	O
rays	0	O
(	0	O
200	0	O
cGy	1	O
)	0	O
given	0	O
on	0	O
different	0	O
days	0	O
during	0	O
gestation	0	O
.	0	O


High	0	O
-	0	O
affinity	0	O
binding	0	O
sites	0	O
for	0	O
both	0	O
GR	1	B
and	0	O
AP	1	B
-	0	I
1	0	I
nucleoproteins	0	I
were	0	O
identified	0	O
at	0	O
adjacent	0	O
elements	0	O
within	0	O
the	0	O
nGRE	0	O
.	0	O


Where	0	O
UMDNJ	0	O
is	0	O
headed	0	O
.	0	O


Relation	1	O
between	0	O
mixing	0	O
ratio	0	O
of	0	O
raw	0	O
materials	0	O
and	0	O
composition	0	O
of	0	O
products	0	O
in	0	O
the	0	O
synthesis	0	O
of	0	O
aluminosilicates	0	O


In	1	O
a	0	O
prospective	0	O
randomized	0	O
study	0	O
,	0	O
287	0	O
patients	0	O
with	0	O
advanced	0	O
non	0	O
-	0	O
small	0	O
cell	0	O
lung	0	O
cancer	0	O
(	0	O
NSCLC	1	O
)	0	O
stage	0	O
IIIb	0	O
or	0	O
IV	1	O
with	0	O
ECOG	1	O
performance	0	O
status	0	O
(	0	O
PS	1	O
)	0	O
0	0	O
-	0	O
1	0	O
or	0	O
2	0	O
were	0	O
randomly	0	O
assigned	0	O
to	0	O
receive	0	O
either	0	O
best	0	O
supportive	0	O
care	0	O
(	0	O
BSC	0	O
)	0	O
or	0	O
supportive	0	O
care	0	O
plus	0	O
combination	0	O
chemotherapy	0	O
(	0	O
IEP	1	O
regimen	0	O
:	0	O
ifosfamide	0	O
3	0	O
gm	0	O
/	0	O
m2	0	O
IV	1	O
with	0	O
mesna	0	O
uroprotection	0	O
,	0	O
epirubicin	0	O
60	0	O
mg	0	O
/	0	O
m2	0	O
IV	1	O
on	0	O
day	0	O
1	0	O
and	0	O
cisplatin	0	O
60	0	O
mg	0	O
/	0	O
m2	0	O
IV	1	O
on	0	O
day	0	O
2	0	O
;	0	O
or	0	O
MVP	1	O
regimen	0	O
:	0	O
mitomycin	0	O
-	0	O
C	1	O
8	0	O
mg	0	O
/	0	O
m2	0	O
,	0	O
cisplatin	0	O
100	0	O
mg	0	O
/	0	O
m2	0	O
IV	1	O
on	0	O
day	0	O
1	0	O
,	0	O
vinblastine	0	O
4	0	O
mg	0	O
/	0	O
m2	0	O
IV	1	O
on	0	O
days	0	O
1	0	O
and	0	O
15	0	O
).	0	O


It	1	O
is	0	O
suggested	0	O
that	0	O
the	0	O
observed	0	O
clinical	0	O
phenomena	0	O
in	0	O
response	0	O
to	0	O
morphine	0	O
can	0	O
be	0	O
explained	0	O
by	0	O
differences	0	O
in	0	O
expression	0	O
and	0	O
sensitivity	0	O
of	0	O
some	0	O
opioid	0	B
receptor	0	I
subtypes	0	O
in	0	O
migraine	0	O
.	0	O


Sweet	1	O
oranges	0	O
,	0	O
mandarin	0	O
,	0	O
grapefruit	0	O
,	0	O
lemon	0	O
,	0	O
and	0	O
lime	0	O
are	0	O
generally	0	O
used	0	O
for	0	O
processing	0	O
.	0	O


Also	0	O
,	0	O
the	0	O
BALB	0	B
/	0	I
c	0	I
gene	0	I
contains	0	O
a	0	O
single	0	O
substitution	0	O
in	0	O
a	0	O
conserved	0	O
octamer	0	O
sequence	0	O
approximately	0	O
equal	0	O
to	0	O
100	0	O
nucleotides	0	O
upstream	0	O
of	0	O
the	0	O
coding	0	O
region	0	O
,	0	O
which	0	O
could	0	O
affect	0	O
its	0	O
expression	0	O
.	0	O


Sequence	1	O
conservation	0	O
is	0	O
greatest	0	O
for	0	O
residues	0	O
located	0	O
near	0	O
the	0	O
active	0	O
centers	0	O
of	0	O
the	0	O
exo	0	B
and	0	O
pol	0	B
domains	0	I
of	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
DNA	1	I
polymerase	0	I
I	1	I
structure	0	O
.	0	O


Prostaglandin	1	O
synthesis	0	O
inhibitors	0	O
have	0	O
been	0	O
shown	0	O
to	0	O
delay	0	O
healing	0	O
of	0	O
bone	0	O
and	0	O
this	0	O
has	0	O
led	0	O
to	0	O
limitations	0	O
on	0	O
their	0	O
use	0	O
clinically	0	O
in	0	O
some	0	O
situations	0	O
.	0	O


The	0	O
neurohypophysial	0	O
vasopressin	0	B
and	0	O
oxytocin	0	B
content	0	O
was	0	O
bioassayed	0	O
by	0	O
pressor	0	O
effect	0	O
following	0	O
Dekanski	0	O
or	0	O
milk	0	O
-	0	O
ejection	0	O
activity	0	O
in	0	O
vitro	0	O
following	0	O
van	0	O
Dongen	0	O
and	0	O
Hays	0	O
,	0	O
respectively	0	O
.	0	O


Two	0	O
experiments	0	O
(	0	O
N	1	O
=	0	O
20	0	O
each	0	O
)	0	O
were	0	O
carried	0	O
out	0	O
to	0	O
explore	0	O
the	0	O
nature	0	O
of	0	O
ERP	1	O
negativities	0	O
in	0	O
a	0	O
visuospatial	0	O
memory	0	O
task	0	O
and	0	O
in	0	O
an	0	O
auditory	0	O
spatial	0	O
memory	0	O
task	0	O
,	0	O
respectively	0	O
.	0	O


A	1	O
mutant	0	B
areA	1	I
product	0	I
truncated	0	O
immediately	0	O
after	0	O
the	0	O
last	0	O
residue	0	O
of	0	O
the	0	O
highly	0	O
conserved	0	O
GATA	0	B
(	0	I
DNA	1	I
-	0	I
binding	0	I
)	0	I
domain	0	I
retains	0	O
partial	0	O
function	0	O
.	0	O


Endometrial	1	O
biopsies	0	O
and	0	O
plasma	0	O
oestradiol	0	O
(	0	O
E2	1	O
)	0	O
and	0	O
progesterone	0	O
(	0	O
P4	0	O
)	0	O
levels	0	O
in	0	O
23	0	O
patients	0	O
were	0	O
evaluated	0	O
during	0	O
26	0	O
replacement	0	O
therapy	0	O
cycles	0	O
for	0	O
premature	0	O
ovarian	0	O
failure	0	O
.	0	O


Clin	0	O
.	0	O


Synthesis	1	O
of	0	O
antisense	0	O
RNA	1	O
and	0	O
S	1	O
phase	0	O
-	0	O
dependent	0	O
binding	0	O
of	0	O
E2F	0	B
complexes	0	I
in	0	O
intron	0	O
1	0	O
.	0	O


A	1	O
TATA	0	O
-	0	O
less	0	O
promoter	0	O
containing	0	O
binding	0	O
sites	0	O
for	0	O
ubiquitous	0	O
transcription	0	O
factors	0	O
mediates	0	O
cell	0	O
type	0	O
-	0	O
specific	0	O
regulation	0	O
of	0	O
the	0	O
gene	0	O
for	0	O
transcription	0	B
enhancer	0	I
factor	0	I
-	0	I
1	0	I
(	0	O
TEF	0	B
-	0	I
1	0	I
).	0	O


Gaucher	0	O
'	0	O
s	0	O
disease	0	O
is	0	O
a	0	O
rare	0	O
metabolic	0	O
disorder	0	O
characterized	0	O
by	0	O
the	0	O
lack	0	O
of	0	O
beta	0	B
-	0	I
glucocerebrosidase	0	I
enzyme	0	I
.	0	O


Endogenous	1	O
RMP	1	B
was	0	O
immunologically	0	O
detected	0	O
interacting	0	O
with	0	O
assembled	0	O
RPB5	0	B
in	0	O
RNA	1	B
polymerase	0	I
in	0	O
mammalian	0	O
cells	0	O
.	0	O


Notably	0	O
,	0	O
SRF	1	B
has	0	O
been	0	O
found	0	O
to	0	O
be	0	O
a	0	O
key	0	O
regulator	0	O
of	0	O
members	0	O
of	0	O
a	0	O
class	0	O
of	0	O
cellular	0	O
response	0	O
genes	0	O
termed	0	O
immediate	0	B
-	0	I
early	0	I
genes	0	I
(	0	O
IEGs	0	B
),	0	O
many	0	O
of	0	O
which	0	O
are	0	O
believed	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
regulating	0	O
cell	0	O
growth	0	O
and	0	O
differentiation	0	O
.	0	O


A	1	O
total	0	O
of	0	O
281	0	O
patients	0	O
were	0	O
divided	0	O
into	0	O
groups	0	O
according	0	O
to	0	O
their	0	O
clinical	0	O
diagnosis	0	O
and	0	O
were	0	O
examined	0	O
using	0	O
capnography	0	O
,	0	O
spirometry	0	O
and	0	O
blood	0	O
-	0	O
gas	0	O
analysis	0	O
.	0	O


We	0	O
discuss	0	O
the	0	O
need	0	O
to	0	O
use	0	O
animals	0	O
older	0	O
than	0	O
3	0	O
months	0	O
for	0	O
the	0	O
study	0	O
of	0	O
'	0	O
adult	0	O
'	0	O
regeneration	0	O
phenomena	0	O
since	0	O
3	0	O
-	0	O
month	0	O
-	0	O
old	0	O
rats	0	O
may	0	O
be	0	O
somewhat	0	O
immature	0	O
.	0	O


Purified	0	O
spleen	0	O
GAP	1	B
accelerated	0	O
hydrolysis	0	O
of	0	O
GTP	1	O
bound	0	O
to	0	O
recombinant	0	B
ARF1	0	I
,	0	O
ARF3	0	B
,	0	O
ARF5	0	B
,	0	O
and	0	O
ARF6	0	B
;	0	O
no	0	O
effect	0	O
of	0	O
NH2	0	O
-	0	O
terminal	0	O
myristoylation	0	O
was	0	O
observed	0	O
.	0	O


The	0	O
active	0	O
site	0	O
includes	0	O
the	0	O
acidic	0	O
triad	0	O
Asp53	0	O
(	0	O
the	0	O
site	0	O
of	0	O
phosphorylation	0	O
),	0	O
Asp10	0	O
and	0	O
Glu9	0	O
.	0	O


The	0	O
1489	0	O
-	0	O
base	0	O
pair	0	O
EFIA	0	B
cDNA	1	O
encodes	0	O
a	0	O
322	0	O
-	0	O
amino	0	O
acid	0	O
protein	0	O
which	0	O
is	0	O
nearly	0	O
identical	0	O
to	0	O
two	0	O
previously	0	O
described	0	O
human	0	O
DNA	1	O
binding	0	O
proteins	0	O
.	0	O


Extramedullary	1	O
relapse	0	O
in	0	O
childhood	0	O
leukemia	0	O
.	0	O


The	0	O
human	0	O
gene	0	O
fragment	0	O
ligated	0	O
to	0	O
the	0	O
minimal	0	O
rat	0	O
liver	0	O
glucokinase	0	B
promoter	0	O
was	0	O
shown	0	O
to	0	O
work	0	O
as	0	O
an	0	O
enhancer	0	O
in	0	O
the	0	O
hepatocyte	0	O
transfection	0	O
system	0	O
.	0	O


BIAcore	0	O
analysis	0	O
gave	0	O
a	0	O
Kaff	0	O
of	0	O
4	0	O
.	0	O
4	0	O
x	0	O
10	0	O
(	0	O
10	0	O
)	0	O
M	1	O
-	0	O
1	0	O
for	0	O
the	0	O
binding	0	O
of	0	O
N	1	B
-	0	I
A3	0	I
to	0	O
T84	0	B
.	0	I
1	0	I
and	0	O
2	0	O
.	0	O
2	0	O
x	0	O
10	0	O
(	0	O
10	0	O
)	0	O
M	1	O
-	0	O
1	0	O
for	0	O
the	0	O
binding	0	O
of	0	O
N	1	B
-	0	I
A3	0	I
to	0	O
T84	0	B
.	0	I
66	0	I
.	0	O


The	0	O
assay	0	O
exhibits	0	O
a	0	O
dynamic	0	O
range	0	O
of	0	O
0	0	O
.	0	O
1	0	O
-	0	O
100	0	O
micrograms	0	O
l	0	O
-	0	O
1	0	O
using	0	O
a	0	O
monoclonal	0	O
antibody	0	O
or	0	O
alternatively	0	O
10	0	O
micrograms	0	O
l	0	O
-	0	O
1	0	O
to	0	O
10	0	O
mg	0	O
l	0	O
-	0	O
1	0	O
using	0	O
commercially	0	O
available	0	O
antiserum	0	O
.	0	O


Factor	1	B
XI	1	I
deficiency	0	O
is	0	O
a	0	O
rare	0	O
hereditary	0	O
bleeding	0	O
disorder	0	O
affecting	0	O
the	0	O
intrinsic	0	O
pathway	0	O
.	0	O


Mutations	0	O
in	0	O
the	0	O
small	0	O
subunit	0	O
of	0	O
ribulosebisphosphate	0	B
carboxylase	0	I
affect	0	O
subunit	0	O
binding	0	O
and	0	O
catalysis	0	O
.	0	O


Advances	0	O
in	0	O
the	0	O
management	0	O
of	0	O
gynecologic	0	O
cancer	0	O
--	0	O
radiation	0	O
therapy	0	O
.	0	O


Acetoin	1	O
-	0	O
dependent	0	O
expression	0	O
of	0	O
the	0	O
acoABCD	0	B
operon	0	I
could	0	O
be	0	O
restored	0	O
in	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
acoK	0	I
mutants	0	I
by	0	O
supplying	0	O
a	0	O
plasmid	0	O
carrying	0	O
an	0	O
intact	0	O
acoK	0	B
,	0	O
suggesting	0	O
a	0	O
transactivating	0	O
function	0	O
of	0	O
the	0	O
gene	0	O
product	0	O
.	0	O


PURPOSE	0	O
:	0	O
To	1	O
introduce	0	O
an	0	O
image	0	O
analysis	0	O
of	0	O
the	0	O
cornea	0	O
in	0	O
photorefractive	0	O
keratectomy	0	O
(	0	O
PRK	1	O
)	0	O
for	0	O
preoperative	0	O
and	0	O
early	0	O
postoperative	0	O
determination	0	O
of	0	O
changes	0	O
in	0	O
the	0	O
condition	0	O
of	0	O
the	0	O
cornea	0	O
.	0	O


A	1	O
genetic	0	O
screen	0	O
applied	0	O
to	0	O
mutants	0	O
in	0	O
the	0	O
branch	0	O
site	0	O
region	0	O
shows	0	O
that	0	O
all	0	O
positions	0	O
in	0	O
the	0	O
conserved	0	O
TACTAAC	0	O
sequence	0	O
are	0	O
important	0	O
for	0	O
intron	0	O
recognition	0	O
.	0	O


Its	0	O
potential	0	O
as	0	O
a	0	O
diagnostic	0	O
tool	0	O
for	0	O
epidemiological	0	O
surveillance	0	O
was	0	O
assessed	0	O
in	0	O
comparison	0	O
with	0	O
three	0	O
other	0	O
diagnostic	0	O
tests	0	O
:	0	O
stool	0	O
examination	0	O
,	0	O
ELISA	1	O
with	0	O
soluble	0	B
egg	0	I
antigen	0	I
(	0	O
SEA	1	B
)	0	O
and	0	O
the	0	O
circumoval	0	O
precipitin	0	B
test	0	O
(	0	O
COPT	0	O
).	0	O


However	0	O
,	0	O
a	0	O
specific	0	O
ICE	1	B
/	0	O
caspase	0	B
-	0	I
1	0	I
inhibitor	0	O
called	0	O
N1445	0	O
completely	0	O
abolished	0	O
the	0	O
CK	1	B
-	0	O
induced	0	O
apoptosis	0	O
by	0	O
reactivating	0	O
PKB	0	B
,	0	O
but	0	O
without	0	O
affecting	0	O
the	0	O
CK	1	B
-	0	O
induced	0	O
suppression	0	O
of	0	O
Ras	1	B
transformation	0	O
.	0	O


As	1	O
in	0	O
Tb	1	O
,	0	O
U6	0	B
is	0	O
a	0	O
single	0	O
-	0	O
copy	0	O
gene	0	O
and	0	O
two	0	O
tRNA	1	O
genes	0	O
,	0	O
tRNAGln	0	B
and	0	O
tRNAIle	0	B
,	0	O
are	0	O
found	0	O
upstream	0	O
to	0	O
the	0	O
gene	0	O
.	0	O


A	1	O
215	0	O
-	0	O
base	0	O
-	0	O
pair	0	O
(	0	O
bp	0	O
)	0	O
region	0	O
of	0	O
the	0	O
mouse	0	B
MOPC	0	I
41	0	I
kappa	0	I
light	0	I
-	0	I
chain	0	I
immunoglobulin	0	I
gene	0	I
enhancer	0	I
has	0	O
been	0	O
analyzed	0	O
for	0	O
specific	0	O
binding	0	O
of	0	O
lymphoid	0	O
and	0	O
nonlymphoid	0	O
nuclear	0	O
factors	0	O
.	0	O


The	0	O
Mean	1	O
was	0	O
74	0	O
,	0	O
3	0	O
+/-	0	O
53	0	O
,	0	O
6	0	O
micrograms	0	O
J	1	O
/	0	O
g	0	O
Cr	1	O
,	0	O
the	0	O
Median	1	O
61	0	O
micrograms	0	O
J	1	O
/	0	O
g	0	O
Cr	1	O
.	0	O


PCR	1	O
-	0	O
derived	0	O
fragments	0	O
were	0	O
used	0	O
as	0	O
probes	0	O
for	0	O
the	0	O
isolation	0	O
of	0	O
the	0	O
U3	0	B
snRNA	1	I
genes	0	I
from	0	O
a	0	O
genomic	0	O
library	0	O
of	0	O
Arabidopsis	0	O
.	0	O


Human	1	O
synovial	0	O
fluid	0	O
:	0	O
detection	0	O
of	0	O
a	0	O
new	0	O
component	0	O
.	0	O


Five	0	O
of	0	O
the	0	O
PDP1	0	B
isoforms	0	I
differ	0	O
by	0	O
the	0	O
substitution	0	O
or	0	O
insertion	0	O
of	0	O
amino	0	O
acids	0	O
at	0	O
or	0	O
near	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
of	0	O
the	0	O
protein	0	O
.	0	O


During	0	O
coronary	0	O
stenosis	0	O
,	0	O
on	0	O
the	0	O
contrary	0	O
,	0	O
intracoronary	0	O
procaterol	0	O
at	0	O
the	0	O
same	0	O
dose	0	O
significantly	0	O
deteriorated	0	O
regional	0	O
myocardial	0	O
dysfunction	0	O
without	0	O
changing	0	O
LCX	0	O
flow	0	O
,	0	O
global	0	O
hemodynamics	0	O
and	0	O
cardiac	0	O
lactate	0	O
metabolism	0	O
.	0	O


As	1	O
a	0	O
result	0	O
,	0	O
we	0	O
have	0	O
defined	0	O
two	0	O
arginine	0	O
-	0	O
rich	0	O
motifs	0	O
(	0	O
ARM1	0	O
and	0	O
ARM2	0	O
)	0	O
that	0	O
mediate	0	O
the	0	O
RNA	1	O
binding	0	O
activity	0	O
of	0	O
SU	0	O
(	0	O
S	1	O
).	0	O


This	0	O
report	0	O
presents	0	O
an	0	O
analysis	0	O
of	0	O
the	0	O
vocal	0	O
repertoire	0	O
of	0	O
howler	0	O
monkeys	0	O
(	0	O
Alouatta	0	O
palliata	0	O
)	0	O
observed	0	O
during	0	O
a	0	O
field	0	O
study	0	O
in	0	O
southwestern	0	O
Panama	0	O
.	0	O


DtxR	0	B
is	0	O
an	0	O
iron	0	O
-	0	O
dependent	0	O
sequence	0	O
-	0	O
specific	0	O
DNA	1	O
-	0	O
binding	0	O
protein	0	O
that	0	O
binds	0	O
to	0	O
the	0	O
tox	0	B
operator	0	I
,	0	O
an	0	O
inverted	0	O
-	0	O
repeat	0	O
nucleotide	0	O
sequence	0	O
located	0	O
upstream	0	O
from	0	O
the	0	O
diphtheria	0	B
toxin	0	I
gene	0	I
.	0	O


Expression	1	O
of	0	O
a	0	O
novel	0	O
murine	0	B
phospholipase	0	I
D	1	I
homolog	0	I
coincides	0	O
with	0	O
late	0	O
neuronal	0	O
development	0	O
in	0	O
the	0	O
forebrain	0	O
.	0	O


Are	0	O
low	0	O
P300	0	O
amplitudes	0	O
a	0	O
marker	0	O
for	0	O
schizophrenia	0	O
.	0	O


It	1	O
was	0	O
shown	0	O
that	0	O
estradiol	0	O
concentrations	0	O
obtained	0	O
after	0	O
estradiol	0	O
valerate	0	O
and	0	O
micronized	0	O
estradiol	0	O
ingestion	0	O
were	0	O
dependent	0	O
on	0	O
the	0	O
patient	0	O
'	0	O
s	0	O
age	0	O
as	0	O
well	0	O
as	0	O
on	0	O
the	0	O
constitutional	0	O
type	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Our	0	O
findings	0	O
suggest	0	O
that	0	O
endometriosis	0	O
increases	0	O
soluble	0	O
CD23	0	B
levels	0	O
,	0	O
which	0	O
can	0	O
be	0	O
suppressed	0	O
with	0	O
either	0	O
danazol	0	O
or	0	O
leuprolide	0	O
acetate	0	O
injection	0	O
.	0	O


Diclofenac	1	O
sodium	0	O
-	0	O
chlormezanone	0	O
poisoning	0	O
.	0	O


The	0	O
population	0	O
of	0	O
between	0	O
75	0	O
,	0	O
000	0	O
and	0	O
100	0	O
,	0	O
000	0	O
was	0	O
largely	0	O
unstable	0	O
,	0	O
and	0	O
cost	0	O
per	0	O
capita	0	O
was	0	O
$	0	O
0	0	O
.	0	O
95	0	O
to	0	O
$	0	O
1	0	O
.	0	O
21	0	O
.	0	O


Hepatitis	1	O
-	0	O
B	1	O
vaccination	0	O
in	0	O
the	0	O
elderly	0	O
.	0	O


An	1	O
AP	1	B
-	0	I
1	0	I
binding	0	I
sequence	0	I
is	0	O
essential	0	O
for	0	O
regulation	0	O
of	0	O
the	0	O
human	0	B
alpha2	0	I
(	0	I
I	1	I
)	0	I
collagen	0	I
(	0	O
COL1A2	0	B
)	0	O
promoter	0	O
activity	0	O
by	0	O
transforming	0	B
growth	0	I
factor	0	I
-	0	I
beta	0	I
.	0	O


This	0	O
machine	0	O
drift	0	O
,	0	O
which	0	O
was	0	O
not	0	O
associated	0	O
with	0	O
a	0	O
rise	0	O
in	0	O
water	0	O
phantom	0	O
temperature	0	O
and	0	O
did	0	O
not	0	O
consistently	0	O
correlate	0	O
with	0	O
estimated	0	O
x	0	O
-	0	O
ray	0	O
tube	0	O
heat	0	O
,	0	O
could	0	O
result	0	O
in	0	O
a	0	O
significant	0	O
overestimation	0	O
of	0	O
regional	0	O
cerebral	0	O
blood	0	O
flow	0	O
(	0	O
rCBF	1	O
)	0	O
for	0	O
a	0	O
xenon	0	O
/	0	O
CT	1	O
rCBF	1	O
protocol	0	O
involving	0	O
5	0	O
-	0	O
7	0	O
sequential	0	O
scans	0	O
obtained	0	O
at	0	O
1	0	O
-	0	O
min	0	O
interscan	0	O
intervals	0	O
.	0	O


For	0	O
this	0	O
purpose	0	O
,	0	O
a	0	O
simple	0	O
respiration	0	O
-	0	O
control	0	O
device	0	O
has	0	O
been	0	O
developed	0	O
that	0	O
enables	0	O
the	0	O
patient	0	O
to	0	O
monitor	0	O
breath	0	O
-	0	O
holding	0	O
during	0	O
successive	0	O
scans	0	O
.	0	O


These	0	O
characteristics	0	O
of	0	O
N22	0	O
/	0	O
P22	0	O
indicate	0	O
that	0	O
it	0	O
is	0	O
a	0	O
localized	0	O
synaptically	0	O
dependent	0	O
event	0	O
conforming	0	O
to	0	O
a	0	O
transverse	0	O
dipole	0	O
with	0	O
dorsal	0	O
negativity	0	O
and	0	O
a	0	O
simultaneous	0	O
anterior	0	O
positivity	0	O
.	0	O


Three	0	O
pyridoxine	0	O
derivatives	0	O
have	0	O
been	0	O
isolated	0	O
from	0	O
the	0	O
fresh	0	O
stem	0	O
bark	0	O
of	0	O
Albizzia	0	O
julibrissin	0	O
DURAZZ	0	O
..	0	O


Spectrophotometric	1	O
microanalysis	0	O
of	0	O
ethylenediaminotetracetic	0	O
acid	0	O
in	0	O
pharmaceutical	0	O
preparations	0	O


The	0	O
mechanism	0	O
of	0	O
peroxisome	0	O
proliferation	0	O
is	0	O
poorly	0	O
understood	0	O
.	0	O


Azygos	1	O
vein	0	O
abutting	0	O
the	0	O
posterior	0	O
wall	0	O
of	0	O
the	0	O
right	0	O
main	0	O
and	0	O
upper	0	O
lobe	0	O
bronchi	0	O
:	0	O
a	0	O
normal	0	O
CT	1	O
variant	0	O
.	0	O


The	0	O
geometric	0	O
mean	0	O
hemagglutination	0	O
-	0	O
inhibition	0	O
antibody	0	O
titers	0	O
(	0	O
GMT	0	O
)	0	O
of	0	O
non	0	O
-	0	O
immunized	0	O
,	0	O
once	0	O
-	0	O
immunized	0	O
,	0	O
and	0	O
twice	0	O
-	0	O
immunized	0	O
chickens	0	O
were	0	O
compared	0	O
at	0	O
2	0	O
-	0	O
week	0	O
intervals	0	O
following	0	O
primary	0	O
immunization	0	O
,	0	O
secondary	0	O
immunization	0	O
,	0	O
and	0	O
challenge	0	O
.	0	O


Consistently	0	O
,	0	O
activation	0	O
of	0	O
c	0	B
-	0	I
Jun	1	I
N	1	I
-	0	I
terminal	0	I
kinase	0	I
downstream	0	O
of	0	O
Rho	1	B
family	0	I
GTP	1	I
-	0	I
binding	0	I
proteins	0	I
was	0	O
also	0	O
enhanced	0	O
when	0	O
Dbl	0	B
was	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
.	0	O


We	0	O
have	0	O
introduced	0	O
a	0	O
mutation	0	O
(	0	O
Ser36	0	O
-->	0	O
Asn	1	O
)	0	O
into	0	O
this	0	O
domain	0	O
of	0	O
p190	0	B
that	0	O
decreased	0	O
its	0	O
ability	0	O
to	0	O
bind	0	O
guanine	0	O
nucleotide	0	O
when	0	O
expressed	0	O
as	0	O
a	0	O
hemagglutinin	0	B
(	0	O
HA	1	B
)-	0	O
tagged	0	O
protein	0	O
in	0	O
COS	1	O
cells	0	O
.	0	O


Chronic	1	O
dose	0	O
effects	0	O
of	0	O
methyl	0	O
parathion	0	O
on	0	O
nuthatches	0	O
:	0	O
cholinesterase	0	B
and	0	O
ptilochronology	0	O
.	0	O


This	0	O
compound	0	O
is	0	O
the	0	O
main	0	O
bioactive	0	O
metabolite	0	O
of	0	O
trimebutine	0	O
II	0	O
(	0	O
Debridat	0	O
,	0	O
CAS	1	O
39133	0	O
-	0	O
31	0	O
-	0	O
8	0	O
),	0	O
an	0	O
antispasmodic	0	O
widely	0	O
used	0	O
for	0	O
intestinal	0	O
diseases	0	O
since	0	O
1969	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
similarity	0	O
,	0	O
the	0	O
cdc28	0	B
-	0	O
P8	0	O
mutant	0	O
accumulates	0	O
unspliced	0	O
precursors	0	O
at	0	O
the	0	O
restrictive	0	O
temperature	0	O
.	0	O


Immunocytochemical	0	O
analysis	0	O
demonstrated	0	O
the	0	O
presence	0	O
of	0	O
DREF	0	B
polypeptide	0	I
in	0	O
nuclei	0	O
after	0	O
the	0	O
eighth	0	O
nuclear	0	O
division	0	O
cycle	0	O
,	0	O
suggesting	0	O
that	0	O
nuclear	0	O
accumulation	0	O
of	0	O
DREF	0	B
is	0	O
important	0	O
for	0	O
the	0	O
coordinate	0	O
zygotic	0	O
expression	0	O
of	0	O
DNA	1	O
replication	0	O
-	0	O
related	0	O
genes	0	O
carrying	0	O
DRE	1	O
sequences	0	O
.	0	O


The	0	O
characterized	0	O
Aplysia	0	B
Afurin2	0	I
is	0	O
a	0	O
candidate	0	O
PC	1	B
that	0	O
may	0	O
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
processing	0	O
of	0	O
egg	0	B
-	0	I
laying	0	I
hormone	0	I
(	0	O
ELH	0	B
)-	0	O
related	0	O
precursors	0	O
in	0	O
the	0	O
secretory	0	O
cells	0	O
of	0	O
the	0	O
atrial	0	O
gland	0	O
.	0	O


The	0	O
0	0	O
.	0	O
22	0	O
-	0	O
kb	0	O
NheI	0	B
/	0	O
BglII	0	B
promoter	0	O
exhibited	0	O
PMA	0	O
inducibility	0	O
in	0	O
myeloid	0	O
cells	0	O
and	0	O
contained	0	O
a	0	O
PMA	0	O
-	0	O
responsive	0	O
element	0	O
recognized	0	O
by	0	O
Sp1	0	B
and	0	O
EGR	0	B
-	0	I
1	0	I
transcription	0	I
factors	0	I
.	0	O


Mutation	1	O
of	0	O
the	0	O
presumptive	0	O
phosphorylated	0	O
tyrosine	0	O
and	0	O
threonine	0	O
residues	0	O
of	0	O
Mpk1p	0	B
individually	0	O
to	0	O
phenylalanine	0	O
and	0	O
alanine	0	O
,	0	O
respectively	0	O
,	0	O
severely	0	O
impaired	0	O
Mpk1p	0	B
function	0	O
.	0	O


The	0	O
RFX	0	B
protein	0	I
family	0	I
includes	0	O
members	0	O
from	0	O
yeast	0	O
to	0	O
humans	0	O
,	0	O
which	0	O
function	0	O
in	0	O
various	0	O
biological	0	O
systems	0	O
,	0	O
and	0	O
share	0	O
a	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
and	0	O
a	0	O
conserved	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
.	0	O


Basing	0	O
on	0	O
experimental	0	O
toxicity	0	O
research	0	O
it	0	O
was	0	O
established	0	O
that	0	O
,	0	O
out	0	O
of	0	O
50	0	O
atmosphere	0	O
metal	0	O
corrosion	0	O
inhibitors	0	O
,	0	O
some	0	O
14	0	O
per	0	O
cent	0	O
were	0	O
found	0	O
extremely	0	O
hazardous	0	O
,	0	O
42	0	O
per	0	O
cent	0	O
--	0	O
of	0	O
high	0	O
level	0	O
hazardous	0	O
,	0	O
33	0	O
percent	0	O
--	0	O
of	0	O
moderate	0	O
and	0	O
11	0	O
per	0	O
cent	0	O
--	0	O
of	0	O
low	0	O
hazardous	0	O
.	0	O


Children	0	O
'	0	O
s	0	O
temperament	0	O
and	0	O
maternal	0	O
socialization	0	O
at	0	O
Time	1	O
1	0	O
(	0	O
n	0	O
=	0	O
103	0	O
,	0	O
aged	0	O
2	0	O
-	0	O
3	0	O
years	0	O
)	0	O
were	0	O
considered	0	O
predictors	0	O
of	0	O
future	0	O
conscience	0	O
,	0	O
assessed	0	O
using	0	O
new	0	O
observational	0	O
and	0	O
narrative	0	O
measures	0	O
.	0	O


With	0	O
the	0	O
human	0	B
Rhotekin	0	I
cDNA	1	I
as	0	O
a	0	O
probe	0	O
,	0	O
Northern	0	O
hybridization	0	O
revealed	0	O
that	0	O
a	0	O
4	0	O
.	0	O
0	0	O
-	0	O
kb	0	O
transcript	0	O
was	0	O
expressed	0	O
at	0	O
a	0	O
high	0	O
level	0	O
in	0	O
prostate	0	O
and	0	O
at	0	O
a	0	O
middle	0	O
level	0	O
in	0	O
13	0	O
of	0	O
16	0	O
tissues	0	O
examined	0	O
,	0	O
but	0	O
it	0	O
cannot	0	O
be	0	O
detected	0	O
in	0	O
liver	0	O
and	0	O
lung	0	O
tissues	0	O
.	0	O


Chick	0	B
brain	0	I
actin	0	I
depolymerizing	0	I
factor	0	I
(	0	O
ADF	0	B
)	0	O
is	0	O
a	0	O
19	0	O
-	0	O
kDa	1	O
protein	0	O
that	0	O
severs	0	O
actin	0	B
filaments	0	I
and	0	O
binds	0	O
actin	0	B
monomers	0	I
.	0	O


Propranolol	1	O
(	0	O
Inderal	1	O
)	0	O
administered	0	O
in	0	O
a	0	O
dose	0	O
which	0	O
blocks	0	O
the	0	O
beta	0	O
-	0	O
adrenergic	0	O
apparatus	0	O
of	0	O
the	0	O
heart	0	O
prevents	0	O
the	0	O
development	0	O
of	0	O
the	0	O
positive	0	O
inotropic	0	O
effect	0	O
of	0	O
therapeutic	0	O
doses	0	O
of	0	O
strophanthin	0	O
K	1	O
on	0	O
a	0	O
hypodynamic	0	O
left	0	O
ventricular	0	O
myocardium	0	O
.	0	O


These	0	O
children	0	O
were	0	O
grouped	0	O
into	0	O
four	0	O
diagnostic	0	O
categories	0	O
:	0	O
1	0	O
)	0	O
idiopathic	0	O
GH	1	B
deficiency	0	O
(	0	O
n	0	O
=	0	O
10	0	O
);	0	O
2	0	O
)	0	O
organic	0	O
hypopituitarism	0	O
(	0	O
n	0	O
=	0	O
7	0	O
);	0	O
3	0	O
)	0	O
intrauterine	0	O
growth	0	O
retardation	0	O
(	0	O
n	0	O
=	0	O
5	0	O
);	0	O
and	0	O
4	0	O
)	0	O
constitutional	0	O
delay	0	O
of	0	O
growth	0	O
and	0	O
/	0	O
or	0	O
familial	0	O
short	0	O
stature	0	O
(	0	O
n	0	O
=	0	O
18	0	O
),	0	O
by	0	O
standard	0	O
clinical	0	O
criteria	0	O
and	0	O
physiological	0	O
and	0	O
pharmacological	0	O
tests	0	O
of	0	O
GH	1	B
reserve	0	O
.	0	O


DNA	1	O
from	0	O
PCR	1	O
was	0	O
labeled	0	O
and	0	O
used	0	O
to	0	O
isolate	0	O
several	0	O
lambda	0	O
gt11	0	O
cDNA	1	O
clones	0	O
,	0	O
including	0	O
one	0	O
full	0	O
-	0	O
length	0	O
one	0	O
(	0	O
Dd	0	B
kinase	0	I
-	0	I
2	0	I
).	0	O


Thus	0	O
,	0	O
this	0	O
reading	0	O
frame	0	O
was	0	O
concluded	0	O
to	0	O
encode	0	O
the	0	O
precursor	0	O
of	0	O
mitochondrial	0	B
fumarase	0	I
.	0	O


Hybridization	1	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
size	0	O
of	0	O
the	0	O
mRNA	1	O
is	0	O
about	0	O
1	0	O
.	0	O
4	0	O
kilobases	0	O
.	0	O


The	0	O
study	0	O
made	0	O
to	0	O
define	0	O
the	0	O
ability	0	O
of	0	O
lipid	0	B
A	1	I
monoclonal	0	I
antibodies	0	I
to	0	O
correct	0	O
hemodynamic	0	O
disturbances	0	O
due	0	O
to	0	O
endotoxemia	0	O
in	0	O
dog	0	O
experiments	0	O
showed	0	O
the	0	O
efficacy	0	O
of	0	O
the	0	O
antibodies	0	O
administration	0	O
.	0	O


The	0	O
epitope	0	O
-	0	O
protected	0	O
lysine	0	O
(	0	O
K	1	O
)	0	O
was	0	O
present	0	O
in	0	O
a	0	O
30	0	B
-	0	I
aa	0	I
TPO	0	I
fragment	0	I
that	0	O
,	0	O
by	0	O
N	1	O
-	0	O
terminal	0	O
sequencing	0	O
,	0	O
was	0	O
found	0	O
to	0	O
be	0	O
K713	0	O
.	0	O


Northern	0	O
(	0	O
RNA	1	O
)	0	O
analysis	0	O
demonstrated	0	O
expression	0	O
of	0	O
human	0	O
PI	1	B
3	0	I
-	0	I
kinase	0	I
in	0	O
all	0	O
tissues	0	O
and	0	O
cell	0	O
lines	0	O
tested	0	O
.	0	O


Muscle	1	B
GSH	1	I
-	0	I
Px	0	I
activity	0	O
after	0	O
prolonged	0	O
exercise	0	O
,	0	O
training	0	O
,	0	O
and	0	O
selenium	0	O
supplementation	0	O
.	0	O


The	0	O
selenium	0	O
level	0	O
and	0	O
glutathione	0	B
peroxidase	0	I
activity	0	O
in	0	O
the	0	O
blood	0	O
,	0	O
liver	0	O
,	0	O
and	0	O
stomach	0	O
mucosa	0	O
were	0	O
significantly	0	O
higher	0	O
in	0	O
the	0	O
high	0	O
-	0	O
selenium	0	O
diet	0	O
group	0	O
than	0	O
in	0	O
the	0	O
low	0	O
-	0	O
selenium	0	O
diet	0	O
group	0	O
.	0	O


DNA	1	O
sequence	0	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
gene	0	O
was	0	O
525	0	O
bp	0	O
long	0	O
and	0	O
encoded	0	O
a	0	O
175	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
protein	0	O
with	0	O
a	0	O
molecular	0	O
weight	0	O
of	0	O
19	0	O
,	0	O
094	0	O
containing	0	O
a	0	O
21	0	O
-	0	O
residue	0	O
typical	0	O
lipoprotein	0	O
signal	0	O
peptide	0	O
and	0	O
consensus	0	O
prolipoprotein	0	O
processing	0	O
site	0	O
.	0	O


The	0	O
bZP2	0	O
cDNA	1	O
(	0	O
115	0	O
-	0	O
1914	0	O
nt	0	O
,	0	O
1	0	O
.	0	O
8	0	O
kb	0	O
),	0	O
excluding	0	O
sequences	0	O
coding	0	O
for	0	O
N	1	O
-	0	O
terminal	0	O
signal	0	O
sequence	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
transmembranelike	0	O
domain	0	O
,	0	O
was	0	O
PCR	1	O
amplified	0	O
and	0	O
Sac1	0	B
-	0	O
Sal1	0	B
restricted	0	O
fragment	0	O
cloned	0	O
in	0	O
frame	0	O
downstream	0	O
of	0	O
the	0	O
T5	0	O
promoter	0	O
under	0	O
the	0	O
lac	0	B
operator	0	I
control	0	O
in	0	O
a	0	O
pQE	0	O
-	0	O
30	0	O
vector	0	O
.	0	O


This	0	O
binary	0	O
repeat	0	O
contains	0	O
repetitive	0	O
DNA	1	O
elements	0	O
that	0	O
include	0	O
LINES	0	O
,	0	O
SINES	0	O
,	0	O
medium	0	O
reiteration	0	O
frequency	0	O
repeats	0	O
,	0	O
and	0	O
a	0	O
transposon	0	O
-	0	O
like	0	O
element	0	O
.	0	O


Human	1	O
neutrophil	0	O
response	0	O
to	0	O
short	0	O
-	0	O
term	0	O
exposure	0	O
to	0	O
F	1	O
-	0	O
75	0	O
cobalt	0	O
-	0	O
based	0	O
alloy	0	O
.	0	O


Five	0	O
women	0	O
(	0	O
15	0	O
.	0	O
6	0	O
%)	0	O
met	0	O
criteria	0	O
for	0	O
PMS	1	O
.	0	O


It	1	O
contains	0	O
a	0	O
5	0	O
'-	0	O
noncoding	0	O
region	0	O
(	0	O
NCR	0	O
)	0	O
of	0	O
73	0	O
nucleotides	0	O
,	0	O
five	0	O
open	0	O
reading	0	O
frames	0	O
(	0	O
ORFs	0	O
1	0	O
to	0	O
5	0	O
)	0	O
which	0	O
encode	0	O
proteins	0	O
with	0	O
M	1	O
(	0	O
r	0	O
)	0	O
160	0	O
kDa	1	O
RNA	1	O
-	0	O
dependent	0	O
RNA	1	O
polymerase	0	O
(	0	O
ORF1	0	O
),	0	O
26	0	O
kDa	1	O
movement	0	O
protein	0	O
1	0	O
(	0	O
ORF2	0	O
),	0	O
13	0	O
kDa	1	O
movement	0	O
protein	0	O
2	0	O
(	0	O
ORF3	0	O
),	0	O
10	0	O
kDa	1	O
movement	0	O
protein	0	O
3	0	O
(	0	O
ORF4	0	O
),	0	O
24	0	O
kDa	1	O
coat	0	O
protein	0	O
(	0	O
OFR5	0	O
),	0	O
and	0	O
a	0	O
3	0	O
'	0	O
NCR	0	O
of	0	O
76	0	O
nucleotides	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
IgM	1	B
can	0	O
be	0	O
absent	0	O
in	0	O
children	0	O
with	0	O
congenital	0	O
toxoplasmosis	0	O
or	0	O
subjects	0	O
with	0	O
secondary	0	O
reactivation	0	O
.	0	O


Analyses	1	O
of	0	O
hGMR	0	B
beta	0	I
subunit	0	I
mutants	0	I
revealed	0	O
two	0	O
cytoplasmic	0	O
regions	0	O
involved	0	O
in	0	O
activation	0	O
of	0	O
the	0	O
c	0	B
-	0	I
myc	0	I
promoter	0	I
,	0	O
one	0	O
is	0	O
essential	0	O
and	0	O
the	0	O
other	0	O
is	0	O
dispensable	0	O
but	0	O
enhances	0	O
the	0	O
activity	0	O
.	0	O


Reverse	0	O
transcription	0	O
(	0	O
RT	1	O
)-	0	O
PCR	1	O
products	0	O
were	0	O
synthesized	0	O
with	0	O
two	0	O
degenerate	0	O
primers	0	O
derived	0	O
from	0	O
the	0	O
conserved	0	O
motifs	0	O
of	0	O
various	0	O
tyrosine	0	B
kinases	0	I
.	0	O


Oxygen	1	O
tension	0	O
of	0	O
the	0	O
small	0	O
lymph	0	O
vessels	0	O
(	0	O
PLO2	0	O
)	0	O
of	0	O
the	0	O
rabbit	0	O
hind	0	O
limb	0	O
was	0	O
measured	0	O
with	0	O
both	0	O
a	0	O
flow	0	O
-	0	O
through	0	O
micro	0	O
chamber	0	O
and	0	O
a	0	O
polarographic	0	O
catheter	0	O
-	0	O
tip	0	O
oxygen	0	O
electrode	0	O
to	0	O
obtain	0	O
experimental	0	O
data	0	O
on	0	O
the	0	O
source	0	O
of	0	O
oxygen	0	O
in	0	O
the	0	O
lymph	0	O
.	0	O


In	1	O
diethyl	0	O
ether	0	O
solution	0	O
the	0	O
main	0	O
peak	0	O
is	0	O
that	0	O
of	0	O
2	0	O
-	0	O
benzylidenamio	0	O
-	0	O
1	0	O
-	0	O
phenylpropane	0	O
,	0	O
which	0	O
has	0	O
a	0	O
retention	0	O
time	0	O
of	0	O
23	0	O
,	0	O
2	0	O
minutes	0	O
under	0	O
the	0	O
condition	0	O
delineated	0	O
.	0	O


The	0	O
5	0	O
'	0	O
region	0	O
of	0	O
ADH5	0	B
contains	0	O
consensus	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
transcriptional	0	O
regulatory	0	O
proteins	0	O
,	0	O
Sp1	0	B
,	0	O
AP2	0	B
,	0	O
LF	1	B
-	0	I
A1	0	I
,	0	O
NF	1	B
-	0	I
1	0	I
,	0	O
NF	1	B
-	0	I
A2	1	I
,	0	O
and	0	O
NF	1	B
-	0	I
E1	1	I
.	0	O


Insert2	1	O
contains	0	O
repetitive	0	O
non	0	O
-	0	O
Ig	1	B
-	0	O
related	0	O
sequences	0	O
and	0	O
a	0	O
small	0	B
Ig	1	I
-	0	I
related	0	I
sequence	0	I
.	0	O


We	0	O
conclude	0	O
that	0	O
common	0	O
upstream	0	O
signals	0	O
cause	0	O
activation	0	O
of	0	O
Ras	1	B
and	0	O
TC21	0	B
,	0	O
but	0	O
activated	0	O
TC21	0	B
controls	0	O
cell	0	O
growth	0	O
via	0	O
distinct	0	O
Raf	0	B
-	0	O
independent	0	O
downstream	0	O
signaling	0	O
pathways	0	O
.	0	O


Here	0	O
we	0	O
demonstrate	0	O
that	0	O
another	0	O
cellular	0	O
protein	0	O
linked	0	O
to	0	O
BCR	0	B
/	0	O
ABL	0	B
through	0	O
the	0	O
CRKL	0	B
-	0	O
SH2	0	B
domain	0	O
is	0	O
p130	0	B
(	0	O
CAS	1	B
).	0	O
p130	0	B
(	0	O
CAS	1	B
)	0	O
was	0	O
found	0	O
to	0	O
be	0	O
tyrosine	0	O
phosphorylated	0	O
and	0	O
associated	0	O
with	0	O
CRKL	0	B
in	0	O
BCR	0	B
/	0	O
ABL	0	B
expressing	0	O
cell	0	O
lines	0	O
and	0	O
in	0	O
samples	0	O
obtained	0	O
from	0	O
CML	1	O
and	0	O
ALL	1	O
patients	0	O
,	0	O
but	0	O
not	0	O
in	0	O
samples	0	O
from	0	O
controls	0	O
.	0	O


The	0	O
primary	0	O
structure	0	O
of	0	O
each	0	O
of	0	O
the	0	O
three	0	O
proteins	0	O
has	0	O
about	0	O
70	0	O
%	0	O
homology	0	O
with	0	O
that	0	O
of	0	O
mouse	0	B
contrapsin	0	I
,	0	O
in	0	O
contrast	0	O
to	0	O
43	0	O
-	0	O
46	0	O
%	0	O
homology	0	O
with	0	O
that	0	O
of	0	O
rat	0	B
alpha	0	I
1	0	I
-	0	I
protease	0	I
inhibitor	0	O
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
open	0	O
-	0	O
section	0	O
effect	0	O
decreases	0	O
the	0	O
torsional	0	O
stiffness	0	O
and	0	O
stress	0	O
concentration	0	O
effects	0	O
decrease	0	O
the	0	O
torsional	0	O
strength	0	O
of	0	O
a	0	O
long	0	O
bone	0	O
with	0	O
a	0	O
longitudinal	0	O
defect	0	O
.	0	O


By	0	O
in	0	O
vitro	0	O
immunoprecipitations	0	O
and	0	O
gel	0	O
shift	0	O
assays	0	O
,	0	O
we	0	O
identified	0	O
two	0	O
classes	0	O
of	0	O
high	0	O
affinity	0	O
Engrailed	0	B
-	0	I
binding	0	I
sites	0	I
upstream	0	O
of	0	O
each	0	O
of	0	O
the	0	O
two	0	O
polyhomeotic	0	O
transcription	0	O
units	0	O
.	0	O


The	0	O
nucleotide	0	O
sequence	0	O
of	0	O
the	0	O
gene	0	O
predicts	0	O
a	0	O
polypeptide	0	O
of	0	O
215	0	O
amino	0	O
acids	0	O
(	0	O
25	0	O
.	0	O
2	0	O
kDa	1	O
)	0	O
with	0	O
two	0	O
putative	0	O
membrane	0	O
-	0	O
spanning	0	O
domains	0	O
.	0	O


In	1	O
one	0	O
mechanism	0	O
,	0	O
a	0	O
specialized	0	O
ubiquitin	0	B
-	0	O
dependent	0	O
proteolytic	0	O
system	0	O
(	0	O
called	0	O
the	0	O
APC	1	O
-	0	O
dependent	0	O
proteolysis	0	O
machinery	0	O
)	0	O
degrades	0	O
the	0	O
mitotic	0	O
(	0	O
Clb	0	B
)	0	O
cyclin	0	B
subunit	0	I
.	0	O


Two	0	O
closely	0	O
related	0	O
variants	0	O
of	0	O
Stat5	0	B
,	0	O
Stat5a	0	B
and	0	O
Stat5b	0	B
,	0	O
are	0	O
encoded	0	O
by	0	O
distinct	0	O
genes	0	O
.	0	O


Cloning	1	O
and	0	O
sequencing	0	O
of	0	O
the	0	O
upstream	0	O
region	0	O
of	0	O
pepX	0	B
revealed	0	O
the	0	O
presence	0	O
of	0	O
two	0	O
ORFs	0	O
of	0	O
360	0	O
and	0	O
1	0	O
,	0	O
338	0	O
bp	0	O
that	0	O
were	0	O
shown	0	O
to	0	O
be	0	O
able	0	O
to	0	O
encode	0	O
proteins	0	O
with	0	O
high	0	O
homology	0	O
to	0	O
GlnR	0	B
and	0	O
GlnA	0	B
proteins	0	I
,	0	O
respectively	0	O
.	0	O


The	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
presence	0	O
or	0	O
absence	0	O
per	0	O
se	0	O
of	0	O
keratan	0	O
sulfate	0	O
on	0	O
native	0	O
G1	0	O
-	0	O
G2	0	O
does	0	O
not	0	O
affect	0	O
the	0	O
activity	0	O
of	0	O
atrolysin	0	O
C	1	O
toward	0	O
the	0	O
two	0	O
sites	0	O
.	0	O


Thus	0	O
our	0	O
observations	0	O
establish	0	O
a	0	O
functional	0	O
link	0	O
between	0	O
the	0	O
PKC	0	B
and	0	O
retinoid	0	O
pathways	0	O
,	0	O
which	0	O
are	0	O
generally	0	O
considered	0	O
to	0	O
have	0	O
antagonistic	0	O
activities	0	O
on	0	O
differentiation	0	O
processes	0	O
.	0	O


Gonadotropin	1	B
levels	0	O
in	0	O
mothers	0	O
who	0	O
have	0	O
had	0	O
two	0	O
sets	0	O
of	0	O
DZ	0	O
twins	0	O
.	0	O


No	1	O
therapy	0	O
exists	0	O
for	0	O
halting	0	O
the	0	O
progression	0	O
of	0	O
the	0	O
disease	0	O
with	0	O
the	0	O
possible	0	O
exception	0	O
of	0	O
laser	0	O
photocoagulation	0	O
treatment	0	O
used	0	O
to	0	O
ablate	0	O
subretinal	0	O
neovascular	0	O
membranes	0	O
in	0	O
an	0	O
attempt	0	O
to	0	O
avoid	0	O
complications	0	O
of	0	O
subretinal	0	O
hemorrhages	0	O
.	0	O


The	0	O
B	1	B
cell	0	I
antigen	0	I
receptor	0	I
activates	0	O
the	0	O
Akt	0	B
(	0	O
protein	0	B
kinase	0	I
B	1	I
)/	0	O
glycogen	0	B
synthase	0	I
kinase	0	I
-	0	I
3	0	I
signaling	0	O
pathway	0	O
via	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
.	0	O


It	1	O
is	0	O
largely	0	O
predicted	0	O
by	0	O
lupus	0	O
anticoagulant	0	O
(	0	O
estimated	0	O
by	0	O
activated	0	O
partial	0	O
thromboplastin	0	B
time	0	O
)	0	O
and	0	O
/	0	O
or	0	O
antibody	0	O
to	0	O
cardiolipin	0	O
.	0	O


Thus	0	O
,	0	O
cibenzoline	0	O
is	0	O
an	0	O
effective	0	O
antiarrhythmic	0	O
agent	0	O
with	0	O
a	0	O
favourable	0	O
pharmacokinetic	0	O
profile	0	O
that	0	O
may	0	O
be	0	O
considered	0	O
with	0	O
other	0	O
class	0	O
I	1	O
drugs	0	O
in	0	O
patients	0	O
requiring	0	O
therapy	0	O
for	0	O
high	0	O
risk	0	O
arrhythmias	0	O
.	0	O


This	0	O
construct	0	O
,	0	O
termed	0	O
pDeltaCREC	0	B
/	0	O
EBP	1	B
,	0	O
binds	0	O
C	1	B
/	0	I
EBPalpha	0	I
and	0	I
beta	0	I
but	0	O
not	0	O
CREB	0	B
,	0	O
yet	0	O
it	0	O
confers	0	O
a	0	O
nearly	0	O
complete	0	O
glucocorticoid	0	O
response	0	O
when	0	O
transiently	0	O
transfected	0	O
into	0	O
H4IIE	0	O
rat	0	O
hepatoma	0	O
cells	0	O
.	0	O


The	0	O
initial	0	O
inpatient	0	O
experience	0	O
for	0	O
individuals	0	O
with	0	O
HIV	1	O
-	0	O
related	0	O
TB	1	O
may	0	O
be	0	O
pivotal	0	O
to	0	O
the	0	O
acceptance	0	O
of	0	O
and	0	O
participation	0	O
in	0	O
ongoing	0	O
TB	1	O
care	0	O
.	0	O


THE	0	O
SCALING	1	O
OF	0	O
SONG	0	O
FREQUENCY	1	O
IN	1	O
CICADAS	0	O


At	1	O
this	0	O
stage	0	O
,	0	O
the	0	O
eventual	0	O
high	0	O
mortality	0	O
of	0	O
acute	0	O
ischemia	0	O
is	0	O
established	0	O
whatever	0	O
the	0	O
urgency	0	O
of	0	O
the	0	O
operation	0	O
or	0	O
the	0	O
skill	0	O
with	0	O
which	0	O
it	0	O
is	0	O
performed	0	O
.	0	O


Release	1	O
of	0	O
this	0	O
selective	0	O
pressure	0	O
,	0	O
however	0	O
,	0	O
gave	0	O
way	0	O
to	0	O
homologous	0	O
resolution	0	O
of	0	O
the	0	O
cointegrate	0	O
structures	0	O
.	0	O


In	1	O
the	0	O
BF	1	O
ECT	1	O
group	0	O
the	0	O
-	0	O
age	0	O
based	0	O
dose	0	O
would	0	O
have	0	O
been	0	O
similarly	0	O
dependent	0	O
on	0	O
the	0	O
initial	0	O
seizure	0	O
threshold	0	O
level	0	O
.	0	O


The	0	O
results	0	O
demonstrate	0	O
(	0	O
i	0	O
)	0	O
that	0	O
the	0	O
selenocysteine	0	O
-	0	O
specific	0	O
UGA	0	O
codon	0	O
is	0	O
readily	0	O
suppressed	0	O
under	0	O
conditions	0	O
where	0	O
the	0	O
homologous	0	B
SelB	0	I
protein	0	I
is	0	O
absent	0	O
and	0	O
(	0	O
ii	0	O
)	0	O
that	0	O
apart	0	O
from	0	O
the	0	O
specificity	0	O
of	0	O
the	0	O
SelB	0	B
-	0	I
mRNA	1	I
interaction	0	O
,	0	O
a	0	O
structural	0	O
compatibility	0	O
of	0	O
the	0	O
quaternary	0	O
complex	0	O
with	0	O
the	0	O
ribosome	0	O
is	0	O
required	0	O
.	0	O


The	0	O
HPLC	1	O
method	0	O
involves	0	O
an	0	O
octadecylsilane	0	O
column	0	O
at	0	O
55	0	O
degrees	0	O
C	1	O
,	0	O
a	0	O
mixture	0	O
of	0	O
water	0	O
-	0	O
acetonitrile	0	O
-	0	O
orthophosphoric	0	O
acid	0	O
(	0	O
779	0	O
:	0	O
220	0	O
:	0	O
1	0	O
,	0	O
v	0	O
/	0	O
v	0	O
)	0	O
as	0	O
mobile	0	O
phase	0	O
and	0	O
detection	0	O
at	0	O
226	0	O
nm	0	O
.	0	O


They	0	O
also	0	O
occur	0	O
in	0	O
similar	0	O
locations	0	O
in	0	O
the	0	O
promoters	0	O
of	0	O
several	0	O
other	0	O
ribosomal	0	B
protein	0	I
genes	0	I
.	0	O


Identity	1	O
of	0	O
GABP	0	B
with	0	O
NRF	0	B
-	0	I
2	0	I
,	0	O
a	0	O
multisubunit	0	O
activator	0	O
of	0	O
cytochrome	0	B
oxidase	0	I
expression	0	O
,	0	O
reveals	0	O
a	0	O
cellular	0	O
role	0	O
for	0	O
an	0	O
ETS	1	B
domain	0	I
activator	0	O
of	0	O
viral	0	O
promoters	0	O
.	0	O


We	0	O
also	0	O
show	0	O
that	0	O
p65	0	B
binds	0	O
to	0	O
these	0	O
targets	0	O
with	0	O
almost	0	O
equal	0	O
affinity	0	O
and	0	O
that	0	O
different	0	O
residues	0	O
have	0	O
variable	0	O
roles	0	O
in	0	O
binding	0	O
different	0	O
kappaB	0	B
targets	0	I
.	0	O


Contrary	0	O
to	0	O
the	0	O
observation	0	O
made	0	O
with	0	O
other	0	O
S	1	O
.	0	O
pombe	0	O
genes	0	O
transcribed	0	O
in	0	O
the	0	O
budding	0	O
yeast	0	O
,	0	O
the	0	O
heterologous	0	O
actin	0	B
gene	0	I
transcript	0	I
is	0	O
initiated	0	O
39	0	O
nucleotides	0	O
upstream	0	O
of	0	O
the	0	O
initiation	0	O
start	0	O
site	0	O
used	0	O
in	0	O
the	0	O
homologous	0	O
yeast	0	O
.	0	O


After	0	O
surgery	0	O
,	0	O
patients	0	O
self	0	O
administered	0	O
one	0	O
of	0	O
three	0	O
possible	0	O
postsurgical	0	O
medications	0	O
,	0	O
which	0	O
included	0	O
placebo	0	O
,	0	O
codeine	0	O
60	0	O
mg	0	O
,	0	O
and	0	O
ibuprofen	0	O
400	0	O
mg	0	O
,	0	O
when	0	O
their	0	O
pain	0	O
reached	0	O
a	0	O
moderate	0	O
or	0	O
severe	0	O
intensity	0	O
.	0	O


Clinicopathologic	1	O
studies	0	O
in	0	O
feminizing	0	O
tumors	0	O
of	0	O
the	0	O
ovary	0	O
.	0	O


Maximum	1	O
number	0	O
of	0	O
strains	0	O
(	0	O
39	0	O
.	0	O
1	0	O
%)	0	O
were	0	O
resistant	0	O
in	0	O
S	1	O
.	0	O
bareilly	0	O
serotype	0	O
,	0	O
followed	0	O
by	0	O
S	1	O
.	0	O
typhimurium	0	O
(	0	O
21	0	O
.	0	O
7	0	O
%)	0	O
and	0	O
least	0	O
in	0	O
S	1	O
.	0	O
typhi	0	O
(	0	O
17	0	O
.	0	O
4	0	O
%).	0	O


We	0	O
have	0	O
screened	0	O
the	0	O
elastin	0	B
gene	0	I
for	0	O
mutations	0	O
responsible	0	O
for	0	O
supravalvular	0	O
aortic	0	O
stenosis	0	O
(	0	O
SVAS	0	O
)	0	O
in	0	O
two	0	O
large	0	O
,	0	O
independently	0	O
collected	0	O
families	0	O
with	0	O
isolated	0	O
(	0	O
nonsyndromic	0	O
)	0	O
SVAS	0	O
.	0	O


4	0	O
.	0	O


The	0	O
role	0	O
of	0	O
DNA	1	O
rearrangement	0	O
and	0	O
alternative	0	O
RNA	1	O
processing	0	O
in	0	O
the	0	O
expression	0	O
of	0	O
immunoglobulin	0	B
delta	0	I
genes	0	I
.	0	O


Left	1	O
atrial	0	O
volumes	0	O
were	0	O
greater	0	O
in	0	O
old	0	O
compared	0	O
with	0	O
young	0	O
subjects	0	O
(	0	O
maximal	0	O
:	0	O
31	0	O
+/-	0	O
10	0	O
cm3	0	O
/	0	O
m2	0	O
vs	0	O
24	0	O
+/-	0	O
8	0	O
cm3	0	O
/	0	O
m2	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
02	0	O
;	0	O
at	0	O
onset	0	O
of	0	O
atrial	0	O
systole	0	O
:	0	O
23	0	O
+/-	0	O
8	0	O
cm3	0	O
/	0	O
m2	0	O
vs	0	O
15	0	O
+/-	0	O
5	0	O
cm3	0	O
/	0	O
m2	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
0002	0	O
;	0	O
minimal	0	O
:	0	O
13	0	O
+/-	0	O
5	0	O
cm3	0	O
/	0	O
m2	0	O
vs	0	O
9	0	O
+/-	0	O
4	0	O
cm3	0	O
/	0	O
m2	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
001	0	O
).	0	O


2	0	O
patients	0	O
(	0	O
11	0	O
%)	0	O
had	0	O
significant	0	O
morbidity	0	O
502	0	O
and	0	O
529	0	O
days	0	O
respectively	0	O
after	0	O
transplantation	0	O
.	0	O


We	0	O
studied	0	O
the	0	O
role	0	O
of	0	O
prostaglandins	0	O
in	0	O
acid	0	O
-	0	O
induced	0	O
esophagitis	0	O
and	0	O
the	0	O
associated	0	O
LES	1	O
hypotension	0	O
by	0	O
simultaneous	0	O
treatment	0	O
of	0	O
some	0	O
animals	0	O
with	0	O
indomethacin	0	O
(	0	O
150	0	O
micrograms	0	O
/	0	O
kg	0	O
intravenous	0	O
),	0	O
a	0	O
specific	0	O
inhibitor	0	O
of	0	O
prostaglandin	0	O
synthesis	0	O
,	0	O
either	0	O
during	0	O
production	0	O
of	0	O
esophagitis	0	O
or	0	O
during	0	O
recovery	0	O
.	0	O


The	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
mouse	0	B
Met	1	I
-	0	I
ase	0	I
-	0	I
1	0	I
gene	0	I
also	0	O
shares	0	O
considerable	0	O
regions	0	O
of	0	O
identity	0	O
with	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
rat	0	B
Met	1	I
-	0	I
ase	0	I
-	0	I
1	0	I
gene	0	I
.	0	O


Except	0	O
for	0	O
nonperfusion	0	O
of	0	O
neurosensory	0	O
retinal	0	O
vessels	0	O
at	0	O
a	0	O
light	0	O
dose	0	O
of	0	O
150	0	O
J	1	O
/	0	O
cm2	0	O
,	0	O
no	0	O
other	0	O
adverse	0	O
events	0	O
were	0	O
of	0	O
concern	0	O
.	0	O


Occupational	1	O
exposure	0	O
to	0	O
hepatitis	0	O
B	1	O
virus	0	O
and	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
:	0	O
a	0	O
comparative	0	O
risk	0	O
analysis	0	O
.	0	O


Behaviorally	0	O
,	0	O
a	0	O
pain	0	O
-	0	O
tolerant	0	O
group	0	O
(	0	O
PT	1	O
=	0	O
29	0	O
Ss	1	O
)	0	O
tolerated	0	O
the	0	O
entire	0	O
3	0	O
-	0	O
min	0	O
test	0	O
(	0	O
means	0	O
=	0	O
180	0	O
+/-	0	O
0	0	O
sec	0	O
),	0	O
while	0	O
a	0	O
pain	0	O
-	0	O
sensitive	0	O
group	0	O
(	0	O
PS	1	O
=	0	O
13	0	O
Ss	1	O
)	0	O
averaged	0	O
only	0	O
50	0	O
.	0	O
31	0	O
+/-	0	O
20	0	O
.	0	O
81	0	O
sec	0	O
of	0	O
the	0	O
cold	0	O
-	0	O
pressor	0	O
test	0	O
(	0	O
t	0	O
=	0	O
16	0	O
.	0	O
75	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
0001	0	O
),	0	O
replicating	0	O
our	0	O
earlier	0	O
studies	0	O
.	0	O


Sp1	0	B
'	0	O
s	0	O
role	0	O
in	0	O
transactivation	0	O
of	0	O
the	0	O
pgp2	0	B
/	0	O
mdr1b	0	B
promoter	0	O
was	0	O
tested	0	O
in	0	O
Drosophila	1	O
Schneider	0	O
cells	0	O
.	0	O


Commutative	0	O
saccadic	0	O
generator	0	O
is	0	O
sufficient	0	O
to	0	O
control	0	O
a	0	O
3	0	O
-	0	O
D	1	O
ocular	0	O
plant	0	O
with	0	O
pulleys	0	O
.	0	O


Therefore	0	O
,	0	O
PC	1	B
-	0	I
PLC	0	I
is	0	O
a	0	O
component	0	O
of	0	O
a	0	O
signal	0	O
transduction	0	O
pathway	0	O
leading	0	O
to	0	O
transcription	0	O
of	0	O
c	0	B
-	0	I
fos	0	I
and	0	O
junB	0	B
that	0	O
collaborates	0	O
with	0	O
c	0	B
-	0	I
myc	0	I
and	0	O
is	0	O
independent	0	O
of	0	O
PKC	0	B
-	0	I
delta	0	I
and	0	O
Ras	1	B
activation	0	O
.	0	O


Determination	1	O
of	0	O
potassium	0	O
iodide	0	O
in	0	O
Polish	0	O
edible	0	O
salt	0	O


Univariate	1	O
statistical	0	O
analysis	0	O
based	0	O
on	0	O
Kaplan	0	O
-	0	O
Meier	0	O
-	0	O
estimates	0	O
and	0	O
Log	1	O
-	0	O
Rank	1	O
-	0	O
Test	1	O
showed	0	O
the	0	O
following	0	O
prognostically	0	O
beneficial	0	O
factors	0	O
:	0	O
Limited	0	O
disease	0	O
stage	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
009	0	O
),	0	O
NSE	0	B
serum	0	O
level	0	O
less	0	O
than	0	O
25	0	O
micrograms	0	O
/	0	O
l	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
016	0	O
),	0	O
serum	0	O
alkaline	0	B
phosphatase	0	I
less	0	O
than	0	O
200	0	O
U	1	O
/	0	O
l	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
035	0	O
),	0	O
normal	0	O
serum	0	O
albumin	0	B
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
003	0	O
)	0	O
and	0	O
activity	0	O
index	0	O
of	0	O
minimum	0	O
of	0	O
70	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
).	0	O


CDDP	1	O
is	0	O
active	0	O
as	0	O
a	0	O
single	0	O
agent	0	O
in	0	O
non	0	O
-	0	O
Hodgkin	0	O
'	0	O
s	0	O
lymphoma	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
narZ	0	B
expression	0	O
was	0	O
induced	0	O
approximately	0	O
20	0	O
-	0	O
fold	0	O
intracellularly	0	O
in	0	O
Madin	0	O
-	0	O
Darby	0	O
canine	0	O
kidney	0	O
epithelial	0	O
cells	0	O
and	0	O
16	0	O
-	0	O
fold	0	O
in	0	O
intracellular	0	O
salts	0	O
medium	0	O
,	0	O
which	0	O
is	0	O
believed	0	O
to	0	O
mimic	0	O
the	0	O
intracellular	0	O
milieu	0	O
.	0	O


Abnormal	1	O
technetium	0	O
Tc	1	O
99m	0	O
medronate	0	O
scans	0	O
in	0	O
patients	0	O
with	0	O
previously	0	O
undiagnosed	0	O
polyarthralgias	0	O
suggested	0	O
inflammatory	0	O
arthropathy	0	O
and	0	O
influenced	0	O
management	0	O
decisions	0	O
with	0	O
favorable	0	O
therapeutic	0	O
outcomes	0	O
.	0	O


Effects	0	O
of	0	O
prostaglandin	0	O
inhibitors	0	O
on	0	O
the	0	O
onset	0	O
of	0	O
proteinuria	0	O
and	0	O
stroke	0	O
in	0	O
stroke	0	O
-	0	O
prone	0	O
spontaneously	0	O
hypertensive	0	O
rats	0	O
.	0	O


Genomic	1	O
structure	0	O
and	0	O
chromosomal	0	O
location	0	O
of	0	O
the	0	O
mouse	0	B
pre	0	I
-	0	I
T	1	I
-	0	I
cell	0	I
receptor	0	I
alpha	0	I
gene	0	I
.	0	O


The	0	O
risk	0	O
factors	0	O
for	0	O
hematuria	0	O
in	0	O
patients	0	O
with	0	O
renal	0	O
hypouricemia	0	O
are	0	O
the	0	O
elevation	0	O
of	0	O
urinary	0	O
urate	0	O
concentration	0	O
and	0	O
the	0	O
subtypes	0	O
of	0	O
Post	1	O
and	0	O
Secretion	1	O
.	0	O


Zn	1	O
(	0	O
II	0	O
)	0	O
coordination	0	O
domain	0	O
mutants	0	O
of	0	O
T4	1	O
gene	0	B
32	0	I
protein	0	O
.	0	O


Influence	0	O
of	0	O
cigarette	0	O
smoking	0	O
on	0	O
some	0	O
blood	0	O
coagulation	0	O
tests	0	O
.	0	O


Interestingly	0	O
,	0	O
virions	0	O
also	0	O
contained	0	O
smaller	0	O
proteins	0	O
that	0	O
reacted	0	O
with	0	O
antibodies	0	O
specific	0	O
for	0	O
the	0	O
accessory	0	O
proteins	0	O
as	0	O
well	0	O
as	0	O
SN	1	B
and	0	O
CAT	1	B
fusion	0	I
partners	0	O
.	0	O


All	1	O
patients	0	O
then	0	O
received	0	O
suxamethonium	0	O
1	0	O
.	0	O
5	0	O
mg	0	O
kg	0	O
-	0	O
1	0	O
i	0	O
.	0	O
v	0	O
.	0	O


Similarly	0	O
,	0	O
a	0	O
human	0	O
but	0	O
not	0	O
a	0	O
bovine	0	B
alpha	0	I
transgene	0	I
was	0	O
expressed	0	O
in	0	O
placenta	0	O
in	0	O
transgenic	0	O
mice	0	O
.	0	O


In	1	O
Experiment	1	O
II	0	O
,	0	O
as	0	O
performing	0	O
moderate	0	O
supine	0	O
cycling	0	O
(	0	O
55	0	O
%	0	O
VO2	1	O
max	0	O
)	0	O
for	0	O
50	0	O
minutes	0	O
under	0	O
several	0	O
LBNP	0	O
conditions	0	O
in	0	O
5	0	O
sedentary	0	O
women	0	O
,	0	O
there	0	O
were	0	O
correspondingly	0	O
similar	0	O
changing	0	O
manners	0	O
of	0	O
the	0	O
cardiovascular	0	O
adjustments	0	O
to	0	O
each	0	O
of	0	O
the	0	O
phases	0	O
given	0	O
in	0	O
Experiment	1	O
I	1	O
.	0	O


Detection	1	O
of	0	O
anti	0	O
-	0	O
lymphocyte	0	O
antibodies	0	O
using	0	O
the	0	O
immunoperoxidase	0	B
antiglobulin	0	I
technic	0	O
.	0	O


A	1	O
highly	0	O
hydrophobic	0	O
sequence	0	O
located	0	O
near	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
extremity	0	O
of	0	O
the	0	O
molecule	0	O
most	0	O
likely	0	O
constitutes	0	O
the	0	O
anchor	0	O
to	0	O
the	0	O
plasma	0	O
membrane	0	O
.	0	O


Of	0	O
254	0	O
children	0	O
with	0	O
neuroblastoma	0	O
treated	0	O
at	0	O
St	1	O
.	0	O


It	1	O
is	0	O
suggested	0	O
that	0	O
the	0	O
use	0	O
of	0	O
endogenous	0	O
creatinine	0	O
clearance	0	O
to	0	O
estimate	0	O
the	0	O
glomerular	0	O
filtration	0	O
rate	0	O
(	0	O
GFR	1	O
)	0	O
requires	0	O
caution	0	O
and	0	O
the	0	O
recognition	0	O
of	0	O
the	0	O
limitations	0	O
of	0	O
the	0	O
method	0	O
,	0	O
and	0	O
that	0	O
simpler	0	O
techniques	0	O
(	0	O
serum	0	O
creatinine	0	O
or	0	O
estimated	0	O
endogenous	0	O
creatinine	0	O
clearance	0	O
)	0	O
are	0	O
preferable	0	O
in	0	O
routine	0	O
practice	0	O
.	0	O


Structural	1	O
characteristics	0	O
of	0	O
the	0	O
erythrocyte	0	O
membrane	0	O
,	0	O
peroxidation	0	O
processes	0	O
and	0	O
antioxidant	0	O
function	0	O
in	0	O
children	0	O
with	0	O
diffuse	0	O
glomerulonephritis	0	O


The	0	O
acids	0	O
were	0	O
obtained	0	O
by	0	O
hydrolysis	0	O
of	0	O
the	0	O
corresponding	0	O
esters	0	O
,	0	O
and	0	O
their	0	O
anti	0	O
-	0	O
inflammatory	0	O
activity	0	O
was	0	O
tested	0	O
.	0	O


However	0	O
,	0	O
the	0	O
inability	0	O
to	0	O
export	0	O
RNA	1	O
from	0	O
the	0	O
nucleus	0	O
to	0	O
the	0	O
cytoplasm	0	O
was	0	O
not	0	O
limited	0	O
to	0	O
a	0	O
particular	0	O
phase	0	O
of	0	O
the	0	O
cell	0	O
division	0	O
cycle	0	O
.	0	O


The	0	O
differentiation	0	O
and	0	O
maintenance	0	O
of	0	O
a	0	O
neurotransmitter	0	O
phenotype	0	O
is	0	O
guided	0	O
by	0	O
the	0	O
interaction	0	O
of	0	O
exogenous	0	O
cues	0	O
with	0	O
intrinsic	0	O
genetic	0	O
machinery	0	O
.	0	O


III	0	O
.	0	O


Simple	1	O
models	0	O
of	0	O
bimolecular	0	O
interaction	0	O
did	0	O
not	0	O
fully	0	O
account	0	O
for	0	O
the	0	O
kinetic	0	O
profiles	0	O
obtained	0	O
with	0	O
the	0	O
parental	0	O
antibodies	0	O
and	0	O
the	0	O
hybrids	0	O
,	0	O
and	0	O
this	0	O
complexity	0	O
suggested	0	O
the	0	O
existence	0	O
of	0	O
a	0	O
conformational	0	O
heterogeneity	0	O
in	0	O
these	0	O
molecules	0	O
.	0	O


An	1	O
endogenous	0	O
mammalian	0	O
regulator	0	O
of	0	O
this	0	O
process	0	O
,	0	O
named	0	O
Usurpin	0	B
,	0	O
has	0	O
been	0	O
identified	0	O
(	0	O
aliases	0	O
for	0	O
Usurpin	0	B
include	0	O
CASH	0	B
,	0	O
Casper	0	B
,	0	O
CLARP	0	B
,	0	O
FLAME	1	B
-	0	I
1	0	I
,	0	O
FLIP	0	B
,	0	O
I	1	B
-	0	I
FLICE	0	I
and	0	O
MRIT	0	B
).	0	O


Several	0	O
lines	0	O
of	0	O
evidence	0	O
presented	0	O
here	0	O
suggest	0	O
that	0	O
PKC	0	B
-	0	I
zeta	0	I
plays	0	O
a	0	O
role	0	O
in	0	O
alpha	0	B
2	0	I
integrin	0	I
gene	0	I
expression	0	O
.	0	O


Mouse	1	B
Impact	1	I
is	0	O
a	0	O
paternally	0	O
expressed	0	O
gene	0	O
encoding	0	O
an	0	O
evolutionarily	0	O
conserved	0	O
protein	0	O
of	0	O
unknown	0	O
function	0	O
.	0	O


V	1	O
.	0	O


Immunohistochemical	0	O
studies	0	O
revealed	0	O
positive	0	O
staining	0	O
for	0	O
S100	0	B
protein	0	I
in	0	O
all	0	O
the	0	O
granular	0	O
cell	0	O
tumors	0	O
of	0	O
the	0	O
adult	0	O
but	0	O
in	0	O
none	0	O
of	0	O
the	0	O
congenital	0	O
granular	0	O
cell	0	O
epulides	0	O
.	0	O


Interestingly	0	O
,	0	O
the	0	O
IR5	0	B
ORF	1	I
of	0	O
EHV	0	O
-	0	O
1	0	O
possesses	0	O
a	0	O
sequence	0	O
of	0	O
13	0	O
amino	0	O
acids	0	O
(	0	O
CAYWCCLGHAFAC	0	O
)	0	O
that	0	O
is	0	O
a	0	O
perfect	0	O
match	0	O
to	0	O
the	0	O
consensus	0	O
zinc	0	O
finger	0	O
motif	0	O
(	0	O
C	1	O
-	0	O
X2	0	O
-	0	O
4	0	O
-	0	O
C	1	O
-	0	O
X2	0	O
-	0	O
15	0	O
-	0	O
C	1	O
/	0	O
H	1	O
-	0	O
X2	0	O
-	0	O
4	0	O
-	0	O
C	1	O
/	0	O
H	1	O
).	0	O


Three	0	O
of	0	O
these	0	O
subunits	0	O
are	0	O
also	0	O
homologous	0	O
to	0	O
the	0	O
dimeric	0	O
POR	1	B
from	0	O
a	0	O
mesophilic	0	O
archaeon	0	O
,	0	O
Halobacterium	0	O
halobium	0	O
(	0	O
21	0	O
%	0	O
identity	0	O
).	0	O


RT	1	O
-	0	O
PCR	1	O
indicated	0	O
that	0	O
p21	0	B
mRNA	1	I
was	0	O
induced	0	O
1	0	O
.	0	O
4	0	O
-,	0	O
2	0	O
.	0	O
0	0	O
-,	0	O
and	0	O
3	0	O
.	0	O
1	0	O
-	0	O
fold	0	O
in	0	O
the	0	O
2	0	O
-	0	O
day	0	O
neonatal	0	O
,	0	O
7	0	O
-	0	O
day	0	O
neonatal	0	O
,	0	O
and	0	O
adult	0	O
stages	0	O
,	0	O
respectively	0	O
,	0	O
compared	0	O
to	0	O
the	0	O
17	0	O
-	0	O
day	0	O
fetal	0	O
stage	0	O
.	0	O


Ten	0	O
days	0	O
of	0	O
cefadroxil	0	O
therapy	0	O
was	0	O
used	0	O
to	0	O
treat	0	O
44	0	O
children	0	O
with	0	O
urinary	0	O
tract	0	O
infection	0	O
and	0	O
CRP	1	B
values	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
28	0	O
microgram	0	O
/	0	O
ml	0	O
(	0	O
CRP	1	B
-	0	O
positive	0	O
group	0	O
).	0	O


This	0	O
indicates	0	O
that	0	O
under	0	O
certain	0	O
experimental	0	O
conditions	0	O
cdc2	0	B
/	0	O
p58	0	B
and	0	O
cdc2	0	B
/	0	O
p62	0	B
may	0	O
express	0	O
some	0	O
differences	0	O
in	0	O
their	0	O
catalytic	0	O
activity	0	O
.	0	O


The	0	O
predominant	0	O
sensitizing	0	O
allergens	0	O
in	0	O
Swedish	0	O
asthmatic	0	O
children	0	O
are	0	O
furred	0	O
pet	0	O
animals	0	O
.	0	O


Transcriptional	1	O
regulation	0	O
of	0	O
fbp1	0	B
promoter	0	I
constructs	0	I
containing	0	O
only	0	O
UAS1	0	O
or	0	O
UAS2	0	O
confirms	0	O
that	0	O
the	0	O
PKA	1	B
and	0	O
MAPK	1	B
regulation	0	O
is	0	O
targeted	0	O
to	0	O
both	0	O
sites	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Gamma	1	O
knife	0	O
radiosurgery	0	O
(	0	O
GKR	0	O
)	0	O
is	0	O
a	0	O
safe	0	O
and	0	O
effective	0	O
alternative	0	O
to	0	O
surgery	0	O
for	0	O
intracranial	0	O
lesions	0	O
.	0	O


Svensson	0	O
et	0	O
al	0	O
.	0	O


Up	0	O
to	0	O
now	0	O
the	0	O
number	0	O
of	0	O
patients	0	O
examined	0	O
is	0	O
about	0	O
300	0	O
,	0	O
additionally	0	O
6	0	O
persons	0	O
who	0	O
underwent	0	O
binephrectomy	0	O
.	0	O


E2F	0	B
-	0	I
6	0	I
shares	0	O
significant	0	O
homology	0	O
with	0	O
E2Fs	0	B
1	0	I
-	0	I
5	0	I
,	0	O
especially	0	O
within	0	O
the	0	O
DNA	1	O
binding	0	O
,	0	O
heterodimerization	0	O
and	0	O
marked	0	O
box	0	O
domains	0	O
.	0	O


Here	0	O
we	0	O
report	0	O
that	0	O
the	0	O
proline	0	O
-	0	O
rich	0	O
region	0	O
of	0	O
CAP	1	B
is	0	O
recognized	0	O
by	0	O
the	0	O
SH3	0	B
domains	0	I
of	0	O
several	0	O
proteins	0	O
,	0	O
including	0	O
the	0	O
yeast	0	B
actin	0	I
-	0	I
associated	0	I
protein	0	I
Abp1p	0	I
.	0	O


A	1	O
significant	0	O
relationship	0	O
existed	0	O
during	0	O
the	0	O
evolution	0	O
of	0	O
the	0	O
disease	0	O
between	0	O
CRS	0	O
/	0	O
BW	1	O
and	0	O
gas	0	O
exchange	0	O
parameters	0	O
(	0	O
FIO2	1	O
and	0	O
a	0	O
/	0	O
AO2	0	O
ratio	0	O
)	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
),	0	O
but	0	O
gas	0	O
exchange	0	O
improved	0	O
earlier	0	O
than	0	O
lung	0	O
mechanics	0	O
.	0	O


Tributyltin	0	O
and	0	O
its	0	O
breakdown	0	O
products	0	O
,	0	O
mono	0	O
-	0	O
and	0	O
di	0	O
-	0	O
butyltin	0	O
,	0	O
were	0	O
determined	0	O
in	0	O
water	0	O
birds	0	O
collected	0	O
from	0	O
Lake	1	O
Huron	0	O
(	0	O
the	0	O
Great	0	O
Lakes	0	O
),	0	O
marine	0	O
coastal	0	O
United	0	O
States	0	O
,	0	O
and	0	O
the	0	O
west	0	O
coast	0	O
of	0	O
British	0	O
Columbia	0	O
,	0	O
Canada	0	O
.	0	O


Animal	1	O
experimental	0	O
and	0	O
clinical	0	O
applications	0	O
of	0	O
plates	0	O
,	0	O
screws	0	O
and	0	O
spinal	0	O
segmental	0	O
replacement	0	O
implants	0	O
made	0	O
of	0	O
this	0	O
composite	0	O
material	0	O
have	0	O
shown	0	O
good	0	O
results	0	O
so	0	O
far	0	O
.	0	O


Secretion	1	O
in	0	O
milk	0	O
and	0	O
transplacental	0	O
transfer	0	O
of	0	O
two	0	O
iodized	0	O
oils	0	O
,	0	O
Lipiodol	0	O
UF	0	O
and	0	O
Oriodol	0	O
,	0	O
in	0	O
rabbits	0	O
.	0	O


We	0	O
report	0	O
the	0	O
isolation	0	O
of	0	O
human	0	O
cDNAs	0	O
homologous	0	O
to	0	O
the	0	O
Drosophila	1	B
dishevelled	0	I
(	0	O
dsh	0	B
)	0	O
segment	0	O
-	0	O
polarity	0	O
gene	0	O
.	0	O


In	1	O
mammals	0	O
,	0	O
the	0	O
Rb	1	B
protein	0	I
interacts	0	O
specifically	0	O
with	0	O
D	1	B
-	0	I
type	0	I
cyclins	0	I
and	0	O
regulates	0	O
cell	0	O
proliferation	0	O
by	0	O
binding	0	O
and	0	O
inhibiting	0	O
E2F	0	B
transcription	0	I
factors	0	I
.	0	O


ROS	1	B
x	0	O
SRC	1	B
(	0	O
R	1	B
)	0	O
contains	0	O
a	0	O
16	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
deletion	0	O
that	0	O
includes	0	O
the	0	O
3	0	O
'	0	O
half	0	O
of	0	O
the	0	O
transmembrane	0	O
domain	0	O
of	0	O
ros	0	B
.	0	O


The	0	O
mean	0	O
marginal	0	O
discrepancy	0	O
of	0	O
provisional	0	O
restorations	0	O
was	0	O
compared	0	O
for	0	O
restorations	0	O
fabricated	0	O
from	0	O
stone	0	O
,	0	O
low	0	O
-	0	O
viscosity	0	O
poly	0	O
(	0	O
vinyl	0	O
siloxane	0	O
),	0	O
and	0	O
medium	0	O
-	0	O
viscosity	0	O
poly	0	O
(	0	O
vinyl	0	O
siloxane	0	O
).	0	O


Analysis	1	O
of	0	O
the	0	O
binding	0	O
of	0	O
Lrp	0	B
to	0	O
a	0	O
set	0	O
of	0	O
circularly	0	O
permuted	0	O
DNA	1	O
fragments	0	O
from	0	O
this	0	O
region	0	O
indicates	0	O
that	0	O
Lrp	0	B
induces	0	O
DNA	1	O
bending	0	O
.	0	O


Thus	0	O
,	0	O
chronic	0	O
hematocrit	0	O
decrease	0	O
induced	0	O
by	0	O
H	1	O
or	0	O
P	1	O
resulted	0	O
in	0	O
a	0	O
significant	0	O
fall	0	O
in	0	O
blood	0	O
pressure	0	O
compared	0	O
to	0	O
control	0	O
(	0	O
201	0	O
+/-	0	O
3	0	O
v	0	O
175	0	O
+/-	0	O
4	0	O
,	0	O
167	0	O
+/-	0	O
4	0	O
mm	0	O
Hg	1	O
,	0	O
respectively	0	O
;	0	O
P	1	O
<	0	O
.	0	O
05	0	O
).	0	O


To	1	O
define	0	O
the	0	O
minimal	0	O
VDRE	0	O
binding	0	O
domain	0	O
for	0	O
human	0	B
VDR	0	I
(	0	O
hVDR	0	B
),	0	O
a	0	O
series	0	O
of	0	O
C	1	O
-	0	O
terminally	0	O
truncated	0	O
hVDR	0	B
mutants	0	I
(	0	O
Delta134	0	O
,	0	O
Delta113	0	O
,	0	O
Delta102	0	O
,	0	O
Delta90	0	O
,	0	O
Delta84	0	O
,	0	O
Delta80	0	O
,	0	O
and	0	O
Delta60	0	O
)	0	O
was	0	O
generated	0	O
and	0	O
expressed	0	O
in	0	O
bacteria	0	O
.	0	O


Lactation	1	O
of	0	O
baboons	0	O
fed	0	O
a	0	O
low	0	O
protein	0	O
maintenance	0	O
diet	0	O
.	0	O


IRF	1	B
-	0	I
1	0	I
acts	0	O
as	0	O
a	0	O
transcriptional	0	O
activator	0	O
,	0	O
while	0	O
IRF	1	B
-	0	I
2	0	I
acts	0	O
as	0	O
a	0	O
repressor	0	O
.	0	O


Linking	0	O
continuous	0	O
community	0	O
-	0	O
based	0	O
morbidity	0	O
recording	0	O
of	0	O
influenza	0	O
-	0	O
like	0	O
illness	0	O
(	0	O
ILI	1	O
)	0	O
with	0	O
virological	0	O
sampling	0	O
has	0	O
consistently	0	O
proved	0	O
its	0	O
value	0	O
as	0	O
one	0	O
of	0	O
the	0	O
earliest	0	O
indicators	0	O
of	0	O
circulating	0	O
influenza	0	O
activity	0	O
.	0	O


Antimicrobial	1	O
Susceptibility	1	O
of	0	O
Klebsiella	1	O
pneumoniae	0	O
Producing	0	O
Extended	0	B
-	0	I
Spectrum	1	I
beta	0	I
-	0	I
lactamase	0	I
(	0	O
ESBL	0	B
)	0	O
Isolated	0	O
in	0	O
Hospitals	0	O
in	0	O
Brazil	0	O
.	0	O


Among	0	O
the	0	O
LE6	0	B
deletions	0	O
,	0	O
only	0	O
one	0	O
had	0	O
a	0	O
reduced	0	O
transformation	0	O
efficiency	0	O
,	0	O
while	0	O
seven	0	O
transformed	0	O
cells	0	O
at	0	O
least	0	O
as	0	O
efficiently	0	O
as	0	O
wild	0	B
-	0	I
type	0	I
LE6	0	I
.	0	O


Electrophoretic	1	O
mobility	0	O
shift	0	O
assays	0	O
and	0	O
competition	0	O
experiments	0	O
showed	0	O
that	0	O
site	0	O
A	1	O
is	0	O
recognized	0	O
by	0	O
an	0	O
NF1	1	B
protein	0	I
.	0	O


The	0	O
level	0	O
of	0	O
carboxyl	0	B
-	0	I
terminal	0	I
parathyroid	0	I
hormone	0	I
in	0	O
the	0	O
patients	0	O
with	0	O
thyroid	0	O
carcinoma	0	O
was	0	O
higher	0	O
than	0	O
that	0	O
in	0	O
the	0	O
patients	0	O
without	0	O
thyroid	0	O
carcinoma	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


This	0	O
strategy	0	O
was	0	O
used	0	O
to	0	O
place	0	O
both	0	O
the	0	O
Tn903	0	B
neo	0	I
gene	0	I
and	0	O
the	0	O
Rhodosporidium	0	B
toruloides	0	I
phenylalanine	0	I
ammonia	0	I
lyase	0	I
(	0	O
PAL	1	B
)-	0	O
encoding	0	O
gene	0	O
under	0	O
the	0	O
transcriptional	0	O
control	0	O
of	0	O
pPGK	0	B
::	0	O
REP2	0	B
.	0	O


PATIENTS	0	O
OR	1	O
OTHER	0	O
PARTICIPANTS	0	O
:	0	O
Twenty	0	O
children	0	O
met	0	O
the	0	O
criteria	0	O
for	0	O
being	0	O
learning	0	O
disabled	0	O
.	0	O


Analysis	1	O
of	0	O
proteins	0	O
synthesized	0	O
by	0	O
plasmids	0	O
containing	0	O
deleted	0	O
forms	0	O
of	0	O
the	0	O
trfA	0	B
region	0	I
indicates	0	O
that	0	O
the	0	O
A2	1	B
protein	0	I
is	0	O
the	0	O
essential	0	O
trfA	0	B
-	0	I
encoded	0	I
replication	0	I
protein	0	I
of	0	O
plasmid	0	O
RK2	0	O
.	0	O


Assessment	1	O
of	0	O
the	0	O
carcinogenicity	0	O
of	0	O
non	0	O
-	0	O
nutritive	0	O
sweetners	0	O
II	0	O
:	0	O
Cyclamates	0	O
and	0	O
cyclohexylamine	0	O
.	0	O


These	0	O
data	0	O
indicate	0	O
that	0	O
the	0	O
largest	0	O
subunit	0	O
of	0	O
RNA	1	B
polymerase	0	I
II	0	I
and	0	O
TFIIB	0	B
are	0	O
important	0	O
determinants	0	O
of	0	O
transcription	0	O
start	0	O
site	0	O
selection	0	O
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
and	0	O
suggest	0	O
that	0	O
this	0	O
function	0	O
might	0	O
be	0	O
conferred	0	O
by	0	O
interaction	0	O
between	0	O
these	0	O
two	0	O
proteins	0	O
.	0	O


Successful	0	O
treatment	0	O
with	0	O
nasal	0	O
continuous	0	O
positive	0	O
airway	0	O
pressure	0	O
(	0	O
8	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
5	0	O
cmH2O	0	O
)	0	O
for	0	O
3	0	O
days	0	O
caused	0	O
a	0	O
significant	0	O
decrease	0	O
in	0	O
mean	0	O
blood	0	O
pressure	0	O
in	0	O
OSAS	1	O
.	0	O


Val	1	O
-->	0	O
Ala	1	O
mutations	0	O
selectively	0	O
alter	0	O
helix	0	O
-	0	O
helix	0	O
packing	0	O
in	0	O
the	0	O
transmembrane	0	O
segment	0	O
of	0	O
phage	0	B
M13	0	I
coat	0	I
protein	0	I
.	0	O


Serum	1	O
prostatic	0	B
acid	0	I
phosphatase	0	I
levels	0	O
showed	0	O
a	0	O
significantly	0	O
weaker	0	O
correlation	0	O
with	0	O
cancer	0	O
volume	0	O
(	0	O
r	0	O
equals	0	O
0	0	O
.	0	O
51	0	O
)	0	O
and	0	O
every	0	O
other	0	O
pathological	0	O
parameter	0	O
.	0	O


FTF	0	B
is	0	O
also	0	O
abundantly	0	O
expressed	0	O
in	0	O
the	0	O
pancreas	0	O
and	0	O
may	0	O
exert	0	O
differentiation	0	O
functions	0	O
in	0	O
endodermal	0	O
sublineages	0	O
,	0	O
similar	0	O
to	0	O
SF	1	B
-	0	I
1	0	I
in	0	O
steroidogenic	0	O
tissues	0	O
.	0	O


The	0	O
ubiquitously	0	O
expressed	0	O
hypoxia	0	B
-	0	I
inducible	0	I
factor	0	I
-	0	I
1	0	I
(	0	O
HIF	0	B
-	0	I
1	0	I
)	0	O
is	0	O
involved	0	O
in	0	O
expression	0	O
of	0	O
a	0	O
large	0	O
number	0	O
of	0	O
oxygen	0	O
-	0	O
regulated	0	O
genes	0	O
.	0	O


As	1	O
pleural	0	O
thickening	0	O
is	0	O
seen	0	O
commonly	0	O
in	0	O
asbestosis	0	O
and	0	O
may	0	O
influence	0	O
lung	0	O
volumes	0	O
and	0	O
the	0	O
ratio	0	O
of	0	O
transfer	0	B
factor	0	I
to	0	O
effective	0	O
alveolar	0	O
volume	0	O
,	0	O
the	0	O
results	0	O
of	0	O
these	0	O
measurements	0	O
were	0	O
compared	0	O
only	0	O
in	0	O
the	0	O
cases	0	O
showing	0	O
absent	0	O
or	0	O
minimal	0	O
pleural	0	O
thickening	0	O
.	0	O


Intra	0	O
-	0	O
operative	0	O
ultrasound	0	O
(	0	O
IOUS	0	O
)	0	O
has	0	O
been	0	O
widely	0	O
used	0	O
in	0	O
an	0	O
attempt	0	O
to	0	O
overcome	0	O
these	0	O
difficulties	0	O
,	0	O
but	0	O
is	0	O
limited	0	O
by	0	O
its	0	O
two	0	O
-	0	O
dimensional	0	O
nature	0	O
,	0	O
inter	0	O
-	0	O
user	0	O
variability	0	O
,	0	O
and	0	O
image	0	O
obliteration	0	O
with	0	O
ablative	0	O
or	0	O
resectional	0	O
techniques	0	O
.	0	O


The	0	O
absence	0	O
of	0	O
H4PteGlun	0	O
bound	0	O
to	0	O
the	0	O
T	1	B
protein	0	I
in	0	O
our	0	O
experimental	0	O
conditions	0	O
demonstrates	0	O
that	0	O
H4PteGlun	0	O
is	0	O
not	0	O
covalently	0	O
linked	0	O
to	0	O
the	0	O
T	1	B
protein	0	I
.	0	O


Synchronous	1	O
extracts	0	O
showed	0	O
no	0	O
significant	0	O
migration	0	O
inhibition	0	O
in	0	O
allogeneic	0	O
assays	0	O
.	0	O


In	1	O
the	0	O
TLE	0	O
patients	0	O
the	0	O
NAA	0	O
:	0	O
Cr	1	O
ratios	0	O
were	0	O
reduced	0	O
in	0	O
the	0	O
seizure	0	O
focus	0	O
,	0	O
while	0	O
in	0	O
the	0	O
FLE	0	O
patients	0	O
they	0	O
were	0	O
not	0	O
always	0	O
reduced	0	O
in	0	O
the	0	O
seizure	0	O
focus	0	O
.	0	O


Therefore	0	O
,	0	O
homozygous	0	O
co	0	O
-	0	O
deletions	0	O
of	0	O
CDKN2A	0	B
and	0	O
CDKN2B	0	B
rather	0	O
than	0	O
mutations	0	O
targeting	0	O
individual	0	O
transcripts	0	O
are	0	O
frequently	0	O
selected	0	O
for	0	O
in	0	O
these	0	O
tumors	0	O
.	0	O


Chem	0	O
.	0	O


Structure	1	O
and	0	O
expression	0	O
of	0	O
a	0	O
gene	0	O
from	0	O
Arabidopsis	0	O
thaliana	0	O
encoding	0	O
a	0	O
protein	0	O
related	0	O
to	0	O
SNF1	0	B
protein	0	O
kinase	0	O
.	0	O


An	1	O
implant	0	O
may	0	O
release	0	O
a	0	O
drug	0	O
either	0	O
by	0	O
diffusion	0	O
concurrent	0	O
with	0	O
dissolution	0	O
of	0	O
the	0	O
polymeric	0	O
implant	0	O
material	0	O
without	0	O
depolymerization	0	O
(	0	O
Type	1	O
A	1	O
)	0	O
or	0	O
by	0	O
bioerosion	0	O
involving	0	O
depolymerization	0	O
(	0	O
Type	1	O
B	1	O
).	0	O


The	0	O
requirement	0	O
of	0	O
Tyr	1	O
-	0	O
19	0	O
dephosphorylation	0	O
for	0	O
spindle	0	O
assembly	0	O
is	0	O
also	0	O
observed	0	O
under	0	O
conditions	0	O
in	0	O
which	0	O
spindle	0	O
formation	0	O
is	0	O
independent	0	O
of	0	O
mitosis	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
involvement	0	O
of	0	O
Cdc28	0	B
/	0	O
Clb	0	B
kinase	0	O
in	0	O
SPB	0	O
separation	0	O
is	0	O
direct	0	O
.	0	O


Additional	0	O
exonuclease	0	B
III	0	I
protection	0	O
was	0	O
observed	0	O
beyond	0	O
the	0	O
core	0	O
region	0	O
on	0	O
both	0	O
the	0	O
5	0	O
'	0	O
and	0	O
3	0	O
'	0	O
sides	0	O
,	0	O
suggesting	0	O
that	0	O
E1	1	B
interacted	0	O
with	0	O
more	0	O
distal	0	O
sequences	0	O
as	0	O
well	0	O
.	0	O


16	0	O
,	0	O
99	0	O
-	0	O
104	0	O
).	0	O


Furthermore	0	O
,	0	O
we	0	O
demonstrated	0	O
that	0	O
Galpha11	0	B
Q209L	0	I
stimulated	0	O
Src	1	B
family	0	I
kinase	0	O
activity	0	O
and	0	O
induced	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
several	0	O
proteins	0	O
in	0	O
HEK	1	O
-	0	O
293	0	O
cells	0	O
.	0	O


One	0	O
millimolar	0	O
ouabain	0	O
completely	0	O
inhibited	0	O
net	0	O
HCO3	0	O
-	0	O
secretion	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
AP	1	B
-	0	I
2	0	I
binding	0	O
activity	0	O
was	0	O
significantly	0	O
greater	0	O
in	0	O
T47D	0	O
cells	0	O
,	0	O
and	0	O
Western	0	O
blots	0	O
confirmed	0	O
increased	0	O
AP	1	B
-	0	I
2	0	I
protein	0	I
levels	0	O
in	0	O
these	0	O
cells	0	O
.	0	O


A	1	O
value	0	O
of	0	O
1	0	O
.	0	O
1	0	O
l	0	O
/	0	O
kg	0	O
was	0	O
used	0	O
for	0	O
V	1	O
in	0	O
calculating	0	O
all	0	O
single	0	O
sample	0	O
estimates	0	O
of	0	O
clearance	0	O
(	0	O
CL	1	O
),	0	O
and	0	O
a	0	O
value	0	O
of	0	O
4	0	O
.	0	O
3	0	O
l	0	O
/	0	O
kg	0	O
was	0	O
used	0	O
to	0	O
calculate	0	O
single	0	O
sample	0	O
estimates	0	O
of	0	O
clearance	0	O
of	0	O
plasma	0	O
unbound	0	O
drug	0	O
(	0	O
CLunb	0	O
).	0	O


We	0	O
conclude	0	O
that	0	O
(	0	O
i	0	O
)	0	O
we	0	O
have	0	O
identified	0	O
several	0	O
candidate	0	O
latency	0	O
genes	0	O
of	0	O
murine	0	O
gammaHV68	0	O
,	0	O
(	0	O
ii	0	O
)	0	O
expression	0	O
of	0	O
genes	0	O
during	0	O
latency	0	O
may	0	O
be	0	O
different	0	O
in	0	O
different	0	O
organs	0	O
,	0	O
consistent	0	O
with	0	O
multiple	0	O
latency	0	O
programs	0	O
and	0	O
/	0	O
or	0	O
multiple	0	O
cellular	0	O
sites	0	O
of	0	O
latency	0	O
,	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
regions	0	O
of	0	O
the	0	O
viral	0	O
genome	0	O
(	0	O
v	0	B
-	0	I
bcl	0	I
-	0	I
2	0	I
gene	0	I
,	0	O
v	0	B
-	0	I
GCR	0	I
gene	0	I
,	0	O
and	0	O
gene	0	B
73	0	I
)	0	O
are	0	O
transcribed	0	O
during	0	O
latency	0	O
with	0	O
both	0	O
gammaHV68	0	O
and	0	O
primate	0	O
gammaherpesviruses	0	O
.	0	O


Polysome	1	O
and	0	O
40S	0	B
ribosome	0	I
fractions	0	O
were	0	O
severely	0	O
decreased	0	O
in	0	O
the	0	O
krr1	0	B
mutant	0	I
and	0	O
Kri1p	0	B
-	0	O
depleted	0	O
cells	0	O
.	0	O


Development	1	O
of	0	O
a	0	O
provisional	0	O
information	0	O
-	0	O
retrieval	0	O
descriptor	0	O
language	0	O
for	0	O
"	0	O
Roentgenology	1	O
and	0	O
Medical	1	O
Radiology	1	O
"	0	O
for	0	O
use	0	O
in	0	O
the	0	O
Medinform	0	O
system	0	O


Our	0	O
data	0	O
show	0	O
also	0	O
that	0	O
phagocytic	0	O
killing	0	O
of	0	O
meningococci	0	O
is	0	O
probably	0	O
a	0	O
more	0	O
consistent	0	O
assay	0	O
than	0	O
antibody	0	O
titer	0	O
levels	0	O
for	0	O
antimeningococcal	0	O
immunity	0	O
,	0	O
especially	0	O
in	0	O
LCC	0	O
-	0	O
deficient	0	O
patients	0	O
.	0	O


Mutation	1	O
analysis	0	O
implicated	0	O
multiple	0	O
segments	0	O
of	0	O
the	0	O
5	0	O
'	0	O
untranslated	0	O
region	0	O
as	0	O
contributing	0	O
to	0	O
the	0	O
inhibitory	0	O
effect	0	O
.	0	O


Calibration	1	O
and	0	O
a	0	O
correction	0	O
of	0	O
blood	0	O
O2	1	O
content	0	O
measured	0	O
by	0	O
Po2	1	O
and	0	O
CO	1	O
saturation	0	O
.	0	O


Toxicities	0	O
included	0	O
:	0	O
nausea	0	O
/	0	O
vomiting	0	O
(	0	O
69	0	O
%),	0	O
headache	0	O
(	0	O
25	0	O
%),	0	O
chills	0	O
(	0	O
69	0	O
%),	0	O
pain	0	O
at	0	O
tumor	0	O
sites	0	O
(	0	O
63	0	O
%),	0	O
hypotension	0	O
(	0	O
31	0	O
%),	0	O
and	0	O
hypertension	0	O
(	0	O
38	0	O
%).	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
determine	0	O
the	0	O
impact	0	O
of	0	O
the	0	O
introduction	0	O
of	0	O
clarithromycin	0	O
and	0	O
azithromycin	0	O
on	0	O
the	0	O
treatment	0	O
and	0	O
survival	0	O
of	0	O
patients	0	O
with	0	O
AIDS	1	O
and	0	O
disseminated	0	O
Mycobacterium	1	O
avium	0	O
complex	0	O
(	0	O
DMAC	0	O
).	0	O


The	0	O
muskox	0	O
is	0	O
a	0	O
new	0	O
host	0	O
record	0	O
for	0	O
T	1	O
.	0	O
gondii	0	O
.	0	O


Chordoma	1	O
of	0	O
the	0	O
spinal	0	O
cord	0	O
in	0	O
a	0	O
F344	0	O
rat	0	O
.	0	O


The	0	O
solubility	0	O
of	0	O
all	0	O
the	0	O
mutated	0	O
proteins	0	O
was	0	O
remarkably	0	O
reduced	0	O
.	0	O


Furthermore	0	O
,	0	O
as	0	O
in	0	O
the	0	O
human	0	O
gene	0	O
,	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
Cacna1f	0	B
gene	0	I
maps	0	O
within	0	O
5	0	O
kb	0	O
of	0	O
the	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
mouse	0	B
synaptophysin	0	I
gene	0	I
in	0	O
a	0	O
region	0	O
orthologous	0	O
to	0	O
Xp11	0	O
.	0	O
23	0	O
.	0	O


Tendon	1	O
also	0	O
shows	0	O
a	0	O
degree	0	O
of	0	O
extensibility	0	O
.	0	O


Biological	1	O
activities	0	O
of	0	O
hematopoietic	0	B
growth	0	I
factors	0	I
that	0	O
lead	0	O
to	0	O
future	0	O
clinical	0	O
application	0	O
.	0	O


Antibodies	0	O
raised	0	O
against	0	O
a	0	O
bacterially	0	O
produced	0	O
beta	0	B
gal	0	I
-	0	O
trk	0	B
receptor	0	O
kinase	0	O
fusion	0	O
protein	0	O
recognized	0	O
a	0	O
44	0	O
kd	0	O
phosphoprotein	0	O
phosphorylated	0	O
on	0	O
serine	0	O
,	0	O
threonine	0	O
and	0	O
tyrosine	0	O
in	0	O
extracts	0	O
of	0	O
trk	0	B
-	0	I
2h	0	I
transformed	0	O
NIH3T3	0	O
cells	0	O
.	0	O


We	0	O
found	0	O
that	0	O
TCR	1	B
signaling	0	O
induces	0	O
AP	1	B
-	0	I
1	0	I
binding	0	O
to	0	O
this	0	O
site	0	O
and	0	O
regulates	0	O
the	0	O
fasl	0	B
promoter	0	I
function	0	O
in	0	O
a	0	O
fashion	0	O
dependent	0	O
on	0	O
NF	1	B
-	0	I
kappaB	0	I
binding	0	O
.	0	O


Sequential	1	O
MR	1	O
examinations	0	O
of	0	O
the	0	O
nasal	0	O
cavity	0	O
and	0	O
paranasal	0	O
sinuses	0	O
were	0	O
performed	0	O
within	0	O
a	0	O
6	0	O
-	0	O
8	0	O
h	0	O
period	0	O
in	0	O
five	0	O
normal	0	O
volunteers	0	O
.	0	O


Immunohistochemical	0	O
staining	0	O
was	0	O
positive	0	O
for	0	O
S	1	B
-	0	I
100	0	I
in	0	O
all	0	O
9	0	O
cases	0	O
stained	0	O
,	0	O
positive	0	O
for	0	O
HMB	0	B
-	0	I
45	0	I
in	0	O
9	0	O
(	0	O
90	0	O
%)	0	O
of	0	O
10	0	O
,	0	O
and	0	O
negative	0	O
for	0	O
cytokeratin	0	B
in	0	O
all	0	O
9	0	O
cases	0	O
in	0	O
which	0	O
myxoid	0	O
melanoma	0	O
remained	0	O
in	0	O
the	0	O
block	0	O
after	0	O
previous	0	O
sections	0	O
.	0	O


Research	1	O
on	0	O
ethylene	0	O
glycol	0	O
and	0	O
diethylene	0	O
glycol	0	O
for	0	O
carcinogenic	0	O
effects	0	O


Transcriptional	1	O
regulators	0	O
utilizing	0	O
the	0	O
POU	0	B
domain	0	I
DNA	1	I
-	0	I
binding	0	I
motif	0	I
have	0	O
been	0	O
shown	0	O
to	0	O
form	0	O
multi	0	O
-	0	O
protein	0	O
complexes	0	O
dependent	0	O
on	0	O
the	0	O
POU	0	B
domain	0	I
itself	0	O
and	0	O
its	0	O
flexible	0	O
recognition	0	O
of	0	O
various	0	O
octamer	0	O
sequence	0	O
elements	0	O
.	0	O


Deletion	1	O
of	0	O
the	0	O
apeA	0	B
gene	0	I
,	0	O
either	0	O
with	0	O
or	0	O
without	0	O
deletion	0	O
of	0	O
other	0	O
proteinases	0	O
(	0	O
protease	0	B
IV	1	I
and	0	O
aminopeptidase	0	B
N	1	I
),	0	O
did	0	O
not	0	O
have	0	O
any	0	O
effect	0	O
on	0	O
cell	0	O
growth	0	O
in	0	O
the	0	O
various	0	O
media	0	O
tested	0	O
.	0	O


Phosphatidylinositol	1	B
3	0	I
-	0	I
kinase	0	I
requirement	0	O
in	0	O
activation	0	O
of	0	O
the	0	O
ras	0	B
/	0	O
C	1	B
-	0	I
raf	0	I
-	0	I
1	0	I
/	0	O
MEK	0	B
/	0	O
ERK	0	B
and	0	O
p70	0	B
(	0	O
s6k	0	B
)	0	O
signaling	0	O
cascade	0	O
by	0	O
the	0	O
insulinomimetic	0	O
agent	0	O
vanadyl	0	O
sulfate	0	O
.	0	O


Effects	0	O
of	0	O
beta	0	B
-	0	I
adrenergic	0	I
receptor	0	I
blockade	0	O
on	0	O
airway	0	O
conductance	0	O
and	0	O
lung	0	O
volume	0	O
in	0	O
normal	0	O
and	0	O
asthmatic	0	O
subjects	0	O
.	0	O


After	0	O
description	0	O
of	0	O
his	0	O
short	0	O
life	0	O
and	0	O
an	0	O
explanation	0	O
of	0	O
the	0	O
light	0	O
conductor	0	O
Bozzini	0	O
'	0	O
s	0	O
merit	0	O
is	0	O
emphasized	0	O
,	0	O
by	0	O
his	0	O
invention	0	O
as	0	O
first	0	O
physician	0	O
to	0	O
have	0	O
made	0	O
accessible	0	O
to	0	O
medicine	0	O
endoscopic	0	O
diagnostic	0	O
possibilities	0	O
.	0	O


Cultivation	1	O
technics	0	O
for	0	O
Codonopsis	0	O
pilosula	0	O


The	0	O
expression	0	O
of	0	O
the	0	O
pilin	0	B
gene	0	I
,	0	O
tcpA	0	B
,	0	O
is	0	O
dependent	0	O
upon	0	O
ToxR	0	B
and	0	O
upon	0	O
ToxT	0	B
.	0	O


Furthermore	0	O
,	0	O
in	0	O
vitro	0	O
decay	0	O
reaction	0	O
mixtures	0	O
supplemented	0	O
with	0	O
the	0	O
20	0	O
-	0	O
nt	0	O
sense	0	O
RNA	1	O
transcript	0	O
resulted	0	O
in	0	O
stabilization	0	O
of	0	O
R2	0	B
message	0	I
.	0	O


The	0	O
present	0	O
investigation	0	O
conducted	0	O
in	0	O
a	0	O
population	0	O
of	0	O
258	0	O
dentally	0	O
aware	0	O
individuals	0	O
in	0	O
the	0	O
age	0	O
range	0	O
20	0	O
-	0	O
69	0	O
years	0	O
,	0	O
was	0	O
initiated	0	O
to	0	O
elucidate	0	O
the	0	O
relationship	0	O
between	0	O
tobacco	0	O
smoking	0	O
and	0	O
supragingival	0	O
calculus	0	O
,	0	O
taking	0	O
into	0	O
account	0	O
possible	0	O
confounding	0	O
factors	0	O
such	0	O
as	0	O
age	0	O
,	0	O
gender	0	O
,	0	O
oral	0	O
hygiene	0	O
and	0	O
gingival	0	O
inflammation	0	O
.	0	O


The	0	O
mEmBP	0	B
-	0	I
1	0	I
protein	0	I
can	0	O
activate	0	O
transcription	0	O
from	0	O
a	0	O
truncated	0	O
promoter	0	O
containing	0	O
a	0	O
pentamer	0	O
of	0	O
the	0	O
O2	1	B
site	0	I
in	0	O
yeast	0	O
cells	0	O
;	0	O
however	0	O
,	0	O
it	0	O
inhibited	0	O
regulated	0	O
transcription	0	O
of	0	O
a	0	O
22	0	B
kDa	1	I
zein	0	I
promoter	0	I
in	0	O
a	0	O
transient	0	O
expression	0	O
assay	0	O
using	0	O
cultured	0	O
maize	0	O
endosperm	0	O
cells	0	O
.	0	O


Molecular	1	O
characterization	0	O
of	0	O
the	0	O
50	0	O
-	0	O
and	0	O
57	0	O
-	0	O
kDa	1	O
subunits	0	O
of	0	O
the	0	O
bovine	0	B
vacuolar	0	I
proton	0	I
pump	0	I
.	0	O


The	0	O
incidence	0	O
of	0	O
DNCB	1	O
reactions	0	O
was	0	O
78	0	O
per	0	O
cent	0	O
for	0	O
Stage	1	O
I	1	O
and	0	O
II	0	O
cancers	0	O
(	0	O
37	0	O
patinets	0	O
),	0	O
73	0	O
per	0	O
cent	0	O
for	0	O
resectable	0	O
Stage	1	O
III	0	O
cancer	0	O
(	0	O
22	0	O
patients	0	O
),	0	O
and	0	O
66	0	O
per	0	O
cent	0	O
in	0	O
patients	0	O
with	0	O
unresectable	0	O
or	0	O
inoperable	0	O
Stage	1	O
III	0	O
cancer	0	O
.	0	O


However	0	O
,	0	O
in	0	O
a	0	O
new	0	O
experiment	0	O
in	0	O
which	0	O
the	0	O
deletion	0	O
task	0	O
was	0	O
presented	0	O
as	0	O
a	0	O
puppet	0	O
game	0	O
,	0	O
and	0	O
with	0	O
pretraining	0	O
and	0	O
selection	0	O
on	0	O
vowel	0	O
deletion	0	O
,	0	O
a	0	O
significantly	0	O
higher	0	O
level	0	O
of	0	O
success	0	O
was	0	O
achieved	0	O
by	0	O
the	0	O
children	0	O
working	0	O
with	0	O
the	0	O
CVCC	0	O
material	0	O
.	0	O


An	1	O
experiment	0	O
examined	0	O
the	0	O
effects	0	O
of	0	O
treatment	0	O
with	0	O
gonadotrophin	0	B
releasing	0	I
hormone	0	I
(	0	O
100	0	O
micrograms	0	O
GnRH	0	B
injected	0	O
24	0	O
h	0	O
after	0	O
progestagen	0	O
sponge	0	O
removal	0	O
),	0	O
season	0	O
of	0	O
treatment	0	O
(	0	O
autumn	0	O
v	0	O
.	0	O
spring	0	O
),	0	O
the	0	O
effect	0	O
of	0	O
supplementary	0	O
feeding	0	O
with	0	O
lupin	0	O
grain	0	O
(	0	O
in	0	O
autumn	0	O
only	0	O
,	0	O
from	0	O
12	0	O
days	0	O
before	0	O
until	0	O
8	0	O
days	0	O
after	0	O
sponge	0	O
removal	0	O
)	0	O
on	0	O
the	0	O
time	0	O
of	0	O
ovulation	0	O
in	0	O
182	0	O
mature	0	O
Merino	0	O
ewes	0	O
superovulated	0	O
with	0	O
a	0	O
combination	0	O
of	0	O
400	0	O
I	1	O
.	0	O
U	1	O
.	0	O
pregnant	0	B
mare	0	I
serum	0	I
gonadotrophin	0	I
(	0	O
PMSG	1	B
)	0	O
and	0	O
12	0	O
mg	0	O
follicle	0	B
stimulating	0	I
hormone	0	I
(	0	O
FSH	1	B
-	0	I
P	1	I
).	0	O


A	1	O
platelet	0	B
-	0	I
derived	0	I
growth	0	I
factor	0	I
receptor	0	I
(	0	O
PDGF	0	B
-	0	I
R	1	I
)	0	O
phosphopeptide	0	O
containing	0	O
Tyr	1	O
-	0	O
857	0	O
does	0	O
not	0	O
bind	0	O
appreciably	0	O
to	0	O
the	0	O
Src	1	B
SH2	0	I
domain	0	I
,	0	O
suggesting	0	O
it	0	O
is	0	O
not	0	O
the	0	O
PDGF	0	B
-	0	I
R	1	I
binding	0	O
site	0	O
for	0	O
Src	1	B
as	0	O
previously	0	O
reported	0	O
.	0	O


This	0	O
study	0	O
examines	0	O
the	0	O
effects	0	O
of	0	O
hypovolemia	0	O
on	0	O
the	0	O
extracellular	0	O
ptO2	0	O
and	0	O
ptH	1	O
distributions	0	O
at	0	O
multiple	0	O
tissue	0	O
sites	0	O
using	0	O
a	0	O
recently	0	O
developed	0	O
multipoint	0	O
microelectrode	0	O
,	0	O
that	0	O
provides	0	O
simultaneous	0	O
measurements	0	O
of	0	O
ptO2	0	O
and	0	O
ptH	1	O
.	0	O


The	0	O
mHIF	0	B
-	0	I
1	0	I
alpha	0	I
structural	0	I
gene	0	I
is	0	O
composed	0	O
of	0	O
15	0	O
exons	0	O
.	0	O


PFK	0	B
-	0	I
A	1	I
mRNA	1	O
was	0	O
more	0	O
abundantly	0	O
expressed	0	O
in	0	O
all	0	O
tissues	0	O
than	0	O
were	0	O
the	0	O
PFK	0	B
-	0	I
B	1	I
and	0	O
PFK	0	B
-	0	I
C	1	I
genes	0	I
.	0	O


Our	0	O
data	0	O
suggest	0	O
that	0	O
,	0	O
at	0	O
least	0	O
at	0	O
high	0	O
temperature	0	O
,	0	O
a	0	O
critical	0	O
minimal	0	O
level	0	O
of	0	O
Ypt	0	B
protein	0	I
prenylation	0	O
is	0	O
required	0	O
for	0	O
maintaining	0	O
vesicle	0	O
polarization	0	O
.	0	O


PATIENTS	0	O
AND	0	O
METHODS	0	O
:	0	O
In	1	O
807	0	O
consecutive	0	O
patients	0	O
from	0	O
the	0	O
Chilean	0	O
National	0	O
Registry	1	O
of	0	O
Acute	1	O
Myocardial	0	O
Infarction	1	O
we	0	O
analyzed	0	O
the	0	O
resolution	0	O
of	0	O
chest	0	O
pain	0	O
and	0	O
ST	1	O
segment	0	O
elevation	0	O
over	0	O
50	0	O
%	0	O
within	0	O
the	0	O
first	0	O
90	0	O
min	0	O
,	0	O
abrupt	0	O
CK	1	B
rise	0	O
within	0	O
8	0	O
h	0	O
and	0	O
T	1	O
wave	0	O
inversion	0	O
in	0	O
infarct	0	O
related	0	O
EKG	1	O
leads	0	O
within	0	O
the	0	O
first	0	O
24	0	O
h	0	O
after	0	O
thrombolysis	0	O
.	0	O


In	1	O
light	0	O
of	0	O
the	0	O
importance	0	O
of	0	O
GnRHR	0	B
,	0	O
the	0	O
molecular	0	O
mechanisms	0	O
underlying	0	O
the	0	O
transcriptional	0	O
regulation	0	O
of	0	O
the	0	O
human	0	B
GnRHR	0	I
(	0	O
hGnRHR	0	B
)	0	O
gene	0	O
become	0	O
a	0	O
key	0	O
issue	0	O
in	0	O
understanding	0	O
human	0	O
reproduction	0	O
.	0	O


Diagnosis	1	O
of	0	O
prostatic	0	O
carcinoma	0	O
:	0	O
the	0	O
yield	0	O
of	0	O
serum	0	B
prostate	0	I
specific	0	I
antigen	0	I
,	0	O
digital	0	O
rectal	0	O
examination	0	O
and	0	O
transrectal	0	O
ultrasonography	0	O
.	0	O


Anastrozole	1	O
is	0	O
the	0	O
first	0	O
aromatase	0	B
inhibitor	0	O
to	0	O
show	0	O
a	0	O
significant	0	O
survival	0	O
advantage	0	O
over	0	O
megestrol	0	O
acetate	0	O
in	0	O
post	0	O
-	0	O
menopausal	0	O
women	0	O
with	0	O
advanced	0	O
breast	0	O
cancer	0	O
.	0	O


Among	0	O
three	0	O
isoforms	0	O
,	0	O
the	0	O
beta	0	O
isoform	0	O
has	0	O
the	0	O
greatest	0	O
Vmax	1	O
value	0	O
for	0	O
the	0	O
PtdIns	0	B
(	0	I
4	0	I
)	0	I
P	1	I
kinase	0	I
activity	0	O
and	0	O
the	0	O
gamma	0	O
isoform	0	O
is	0	O
most	0	O
markedly	0	O
stimulated	0	O
by	0	O
phosphatidic	0	O
acid	0	O
.	0	O


Evaluating	0	O
dietary	0	O
department	0	O
management	0	O
.	0	O


Effects	0	O
of	0	O
nitrogen	0	O
(	0	O
PN2	0	O
:	0	O
5	0	O
and	0	O
14	0	O
MPa	0	O
)	0	O
and	0	O
helium	0	O
(	0	O
PHe	1	O
:	0	O
13	0	O
and	0	O
14	0	O
MPa	0	O
)	0	O
were	0	O
also	0	O
tested	0	O
.	0	O


The	0	O
test	0	O
for	0	O
alpha	0	B
-	0	I
naphthyl	0	I
esterase	0	I
and	0	O
quantitation	0	O
of	0	O
macrophages	0	O
(	0	O
absolute	0	O
number	0	O
)	0	O
per	0	O
infiltration	0	O
area	0	O
unit	0	O
adjacent	0	O
to	0	O
the	0	O
abscess	0	O
suggest	0	O
a	0	O
direct	0	O
correlation	0	O
between	0	O
the	0	O
absolute	0	O
number	0	O
of	0	O
macrophages	0	O
and	0	O
the	0	O
width	0	O
of	0	O
the	0	O
capsule	0	O
.	0	O


Aspirin	1	O
causes	0	O
peptic	0	O
ulcers	0	O
predominately	0	O
by	0	O
reducing	0	O
gastric	0	B
mucosal	0	I
cyclooxygenase	0	I
(	0	O
COX	1	B
)	0	O
activity	0	O
and	0	O
prostaglandin	0	O
synthesis	0	O
.	0	O


In	1	O
the	0	O
ileum	0	O
,	0	O
enterotoxin	0	O
increased	0	O
the	0	O
luminal	0	O
disappearance	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
and	0	O
peripheral	0	O
blood	0	O
appearance	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
)	0	O
of	0	O
chloroquine	0	O
.	0	O


The	0	O
authors	0	O
report	0	O
the	0	O
results	0	O
of	0	O
a	0	O
series	0	O
of	0	O
toxicological	0	O
tests	0	O
conducted	0	O
on	0	O
plastic	0	O
materials	0	O
(	0	O
polyethylene	0	O
)	0	O
activated	0	O
with	0	O
tetraphenylbutadiene	0	O
(	0	O
TPB	0	O
)	0	O
an	0	O
additive	0	O
recently	0	O
proposed	0	O
as	0	O
a	0	O
sensitizer	0	O
capable	0	O
of	0	O
photodegrading	0	O
plastic	0	O
materials	0	O
.	0	O


Resistance	1	O
to	0	O
thyroid	0	O
hormone	0	O
:	0	O
implications	0	O
for	0	O
neurodevelopmental	0	O
research	0	O
on	0	O
the	0	O
effects	0	O
of	0	O
thyroid	0	O
hormone	0	O
disruptors	0	O
.	0	O


Molecular	1	O
cloning	0	O
of	0	O
an	0	O
amphibian	0	B
insulin	0	I
receptor	0	I
substrate	0	I
1	0	I
-	0	I
like	0	I
cDNA	1	I
and	0	O
involvement	0	O
of	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
in	0	O
insulin	0	B
-	0	O
induced	0	O
Xenopus	1	O
oocyte	0	O
maturation	0	O
.	0	O


As	1	O
in	0	O
mammals	0	O
,	0	O
considerable	0	O
nucleotide	0	O
diversity	0	O
was	0	O
observed	0	O
at	0	O
the	0	O
junctions	0	O
of	0	O
the	0	O
variable	0	O
,	0	O
diversity	0	O
,	0	O
and	0	O
joining	0	O
elements	0	O
in	0	O
chicken	0	B
TCR	1	I
beta	0	I
cDNAs	0	I
.	0	O


The	0	O
protein	0	O
was	0	O
associated	0	O
with	0	O
purified	0	O
vaccinia	0	O
virus	0	O
particles	0	O
and	0	O
with	0	O
membranes	0	O
of	0	O
immature	0	O
and	0	O
mature	0	O
virions	0	O
that	0	O
were	0	O
visualized	0	O
by	0	O
electron	0	O
microscopy	0	O
of	0	O
infected	0	O
cells	0	O
.	0	O


The	0	O
aim	0	O
of	0	O
the	0	O
study	0	O
was	0	O
to	0	O
correlate	0	O
the	0	O
responsiveness	0	O
to	0	O
bronchoprovocation	0	O
with	0	O
methacholine	0	O
in	0	O
subjects	0	O
a	0	O
with	0	O
allergic	0	O
rhinitis	0	O
during	0	O
and	0	O
out	0	O
of	0	O
the	0	O
pollen	0	O
season	0	O
with	0	O
total	0	O
serum	0	O
IgE	1	B
and	0	O
blood	0	O
eosinophils	0	O
.	0	O


When	0	O
BFDS	0	O
was	0	O
taken	0	O
as	0	O
the	0	O
reference	0	O
,	0	O
W	1	O
/	0	O
A	1	O
Z	1	O
scores	0	O
showed	0	O
consistent	0	O
positive	0	O
increments	0	O
,	0	O
from	0	O
birth	0	O
in	0	O
girls	0	O
and	0	O
1	0	O
mo	0	O
in	0	O
boys	0	O
.	0	O


Beta	1	O
blocking	0	O
agents	0	O
.	0	O


EGF	1	B
acts	0	O
primarily	0	O
by	0	O
means	0	O
of	0	O
transactivation	0	O
domain	0	O
AF	1	O
-	0	O
1	0	O
,	0	O
whereas	0	O
cAMP	1	O
acts	0	O
via	0	O
transactivation	0	O
domain	0	O
AF	1	O
-	0	O
2	0	O
of	0	O
the	0	O
ER	1	B
.	0	O


We	0	O
cloned	0	O
the	0	O
third	0	O
human	0	O
gene	0	O
for	0	O
the	0	O
LD78	0	B
,	0	O
termed	0	O
LD78	0	B
gamma	0	I
and	0	O
the	0	O
sequence	0	O
analysis	0	O
showed	0	O
that	0	O
it	0	O
is	0	O
a	0	O
5	0	O
'-	0	O
truncated	0	O
pseudogene	0	O
.	0	O


The	0	O
initial	0	O
translation	0	O
protein	0	O
encoded	0	O
by	0	O
the	0	O
cDNA	1	O
is	0	O
53	0	O
,	0	O
932	0	O
kDa	1	O
and	0	O
possesses	0	O
a	0	O
hydrophilic	0	O
amino	0	O
acid	0	O
composition	0	O
with	0	O
glutamic	0	O
acid	0	O
comprising	0	O
22	0	O
%	0	O
of	0	O
the	0	O
total	0	O
amino	0	O
acid	0	O
residues	0	O
.	0	O


Evidence	1	O
that	0	O
therapeutic	0	O
alterations	0	O
of	0	O
a	0	O
circadian	0	O
rhythm	0	O
for	0	O
gastric	0	O
emptying	0	O
response	0	O
may	0	O
be	0	O
possible	0	O
.	0	O


Deletions	0	O
in	0	O
each	0	O
of	0	O
these	0	O
regions	0	O
abolish	0	O
membrane	0	O
localization	0	O
of	0	O
Tiam1	0	B
and	0	O
membrane	0	O
ruffling	0	O
,	0	O
suggesting	0	O
that	0	O
they	0	O
function	0	O
cooperatively	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
a	0	O
Maf	1	B
-	0	I
related	0	I
protein	0	I
,	0	O
Nrl	0	B
,	0	O
completely	0	O
mimicked	0	O
c	0	B
-	0	I
Maf	1	I
actions	0	O
.	0	O


This	0	O
protein	0	O
can	0	O
bind	0	O
to	0	O
a	0	O
region	0	O
of	0	O
the	0	O
promoter	0	O
of	0	O
an	0	O
Arabidopsis	0	B
light	0	I
-	0	I
harvesting	0	I
chlorophyll	0	I
a	0	I
/	0	I
b	0	I
protein	0	I
gene	0	I
,	0	O
Lhcb1	0	B
*	0	I
3	0	I
,	0	O
which	0	O
is	0	O
necessary	0	O
for	0	O
its	0	O
regulation	0	O
by	0	O
phytochrome	0	B
.	0	O


These	0	O
data	0	O
indicate	0	O
that	0	O
activation	0	O
of	0	O
these	0	O
enzymes	0	O
is	0	O
not	0	O
sufficient	0	O
for	0	O
the	0	O
acute	0	O
stimulation	0	O
of	0	O
glucose	0	O
transport	0	O
.	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
LvUSF2	0	B
is	0	O
nearly	0	O
identical	0	O
to	0	O
LvUSF1	0	B
except	0	O
at	0	O
the	0	O
amino	0	O
end	0	O
,	0	O
where	0	O
they	0	O
are	0	O
sharply	0	O
divergent	0	O
.	0	O


Characterization	0	O
of	0	O
the	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
growth	0	O
-	0	O
regulated	0	O
Syrian	0	B
hamster	0	I
CAD	1	I
gene	0	I
.	0	O


Results	0	O
from	0	O
transient	0	O
assays	0	O
using	0	O
these	0	O
mutants	0	O
showed	0	O
that	0	O
the	0	O
DE1	0	O
received	0	O
signals	0	O
from	0	O
phytochromes	0	B
A	1	I
and	0	I
B	1	I
,	0	O
demonstrating	0	O
that	0	O
this	0	O
element	0	O
is	0	O
indeed	0	O
a	0	O
light	0	O
-	0	O
responsive	0	O
element	0	O
.	0	O


In	1	O
Experiment	1	O
2	0	O
scopolamine	0	O
hydrobromide	0	O
,	0	O
0	0	O
.	0	O
5	0	O
and	0	O
1	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
p	0	O
.,	0	O
was	0	O
administered	0	O
1	0	O
h	0	O
before	0	O
each	0	O
electrical	0	O
stimulation	0	O
until	0	O
each	0	O
rat	0	O
showed	0	O
the	0	O
stage	0	O
-	0	O
3	0	O
seizure	0	O
.	0	O


Also	0	O
,	0	O
samples	0	O
of	0	O
serum	0	O
were	0	O
absorbed	0	O
with	0	O
the	0	O
various	0	O
solid	0	O
-	0	O
phase	0	O
allergens	0	O
and	0	O
the	0	O
reactivity	0	O
of	0	O
the	0	O
remaining	0	O
IgE	1	B
antibodies	0	I
was	0	O
determined	0	O
.	0	O


Granisetron	0	O
,	0	O
but	0	O
not	0	O
saline	0	O
,	0	O
abolished	0	O
vomiting	0	O
and	0	O
nausea	0	O
when	0	O
given	0	O
as	0	O
intervention	0	O
after	0	O
this	0	O
combined	0	O
emetic	0	O
regimen	0	O
.	0	O


Concomitant	1	O
chronic	0	O
lymphocytic	0	O
leukemia	0	O
,	0	O
acute	0	O
myeloid	0	O
leukemia	0	O
,	0	O
and	0	O
thrombosis	0	O
with	0	O
protein	0	B
C	1	I
deficiency	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
restoring	0	O
checkpoint	0	O
control	0	O
,	0	O
overexpression	0	O
of	0	O
sum1	0	B
+	0	I
inhibits	0	O
the	0	O
normal	0	O
cell	0	O
cycle	0	O
response	0	O
to	0	O
osmotic	0	O
stress	0	O
.	0	O


Effect	1	O
of	0	O
biliary	0	O
obstruction	0	O
and	0	O
cholangitis	0	O
on	0	O
serum	0	B
SPan	1	I
-	0	I
1	0	I
level	0	O


Yeast	1	B
Gal11	0	I
protein	0	I
mediates	0	O
the	0	O
transcriptional	0	O
activation	0	O
signal	0	O
of	0	O
two	0	O
different	0	O
transacting	0	O
factors	0	O
,	0	O
Gal4	0	B
and	0	O
general	0	B
regulatory	0	I
factor	0	I
I	1	I
/	0	O
repressor	0	B
/	0	I
activator	0	I
site	0	I
binding	0	I
protein	0	I
1	0	I
/	0	I
translation	0	I
upstream	0	I
factor	0	I
.	0	O


Aviators	0	O
from	0	O
the	0	O
Light	1	O
Attack	1	O
Wing	1	O
,	0	O
Pacific	0	O
were	0	O
surveyed	0	O
and	0	O
the	0	O
results	0	O
were	0	O
categorized	0	O
by	0	O
aircraft	0	O
type	0	O
.	0	O


The	0	O
cryptococcal	0	B
antigen	0	I
test	0	O
was	0	O
positive	0	O
at	0	O
1	0	O
:	0	O
125	0	O
by	0	O
latex	0	O
agglutination	0	O
.	0	O


3	0	O
Significant	1	O
reductions	0	O
in	0	O
lying	0	O
mean	0	O
arterial	0	O
blood	0	O
pressure	0	O
were	0	O
observed	0	O
with	0	O
daily	0	O
doses	0	O
of	0	O
200	0	O
mg	0	O
(-	0	O
9	0	O
%),	0	O
400	0	O
mg	0	O
(-	0	O
10	0	O
%)	0	O
and	0	O
800	0	O
mg	0	O
(-	0	O
14	0	O
%),	0	O
and	0	O
were	0	O
associated	0	O
with	0	O
significant	0	O
decreases	0	O
in	0	O
heart	0	O
rate	0	O
and	0	O
plasma	0	B
renin	0	I
activity	0	O
.	0	O


Infarct	1	O
regional	0	O
ejection	0	O
fraction	0	O
improved	0	O
by	0	O
10	0	O
.	0	O
1	0	O
+/-	0	O
2	0	O
.	0	O
1	0	O
%	0	O
between	0	O
early	0	O
and	0	O
late	0	O
studies	0	O
when	0	O
the	0	O
infarct	0	O
-	0	O
related	0	O
artery	0	O
was	0	O
patent	0	O
and	0	O
by	0	O
4	0	O
.	0	O
8	0	O
+/-	0	O
1	0	O
.	0	O
4	0	O
%	0	O
if	0	O
it	0	O
was	0	O
occluded	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
048	0	O
);	0	O
changes	0	O
in	0	O
global	0	O
and	0	O
noninfarct	0	O
regional	0	O
ejection	0	O
fraction	0	O
were	0	O
similar	0	O
irrespective	0	O
of	0	O
perfusion	0	O
status	0	O
.	0	O


On	1	O
the	0	O
constituents	0	O
of	0	O
Dryopteris	1	O
polylepis	0	O


Interferon	1	B
stimulated	0	I
gene	0	I
factor	0	I
3	0	I
(	0	O
ISGF3	0	B
)	0	O
is	0	O
a	0	O
trimeric	0	O
transcription	0	O
factor	0	O
activated	0	O
on	0	O
treatment	0	O
of	0	O
cells	0	O
with	0	O
interferon	0	B
-	0	I
alpha	0	I
and	0	I
beta	0	I
(	0	O
type	0	B
I	1	I
IFNs	0	I
).	0	O


This	0	O
is	0	O
the	0	O
first	0	O
description	0	O
,	0	O
to	0	O
our	0	O
knowledge	0	O
,	0	O
of	0	O
regulatory	0	O
elements	0	O
that	0	O
control	0	O
expression	0	O
of	0	O
a	0	O
gene	0	O
encoding	0	O
a	0	O
B7	0	B
costimulatory	0	I
molecule	0	I
.	0	O


Self	1	O
or	0	O
foreign	0	O
cellular	0	O
proteins	0	O
provide	0	O
peptides	0	O
for	0	O
presentation	0	O
by	0	O
major	0	B
histocompatibility	0	I
complex	0	I
(	0	I
MHC	1	I
)	0	I
class	0	I
I	1	I
molecules	0	I
on	0	O
the	0	O
surface	0	O
of	0	O
antigen	0	O
presenting	0	O
cells	0	O
(	0	O
APC	1	O
).	0	O


This	0	O
conclusion	0	O
was	0	O
confirmed	0	O
by	0	O
Northern	0	O
blotting	0	O
analysis	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
CAD	1	B
gene	0	I
.	0	O


The	0	O
insulin	0	B
-	0	O
induced	0	O
DNA	1	O
-	0	O
binding	0	O
complex	0	O
was	0	O
identified	0	O
as	0	O
the	0	O
p50	0	B
/	0	O
p65	0	B
heterodimer	0	O
.	0	O


Outcome	1	O
of	0	O
severe	0	O
congenital	0	O
hypothyroidism	0	O
.	0	O


Conversely	0	O
,	0	O
activation	0	O
of	0	O
this	0	O
signaling	0	O
pathway	0	O
by	0	O
expression	0	O
of	0	O
a	0	O
constitutively	0	O
active	0	O
MKK1	0	B
mutant	0	I
dramatically	0	O
increased	0	O
cyclin	0	B
D1	1	I
promoter	0	O
activity	0	O
and	0	O
cyclin	0	B
D1	1	I
protein	0	I
expression	0	O
,	0	O
in	0	O
a	0	O
growth	0	O
factor	0	O
-	0	O
independent	0	O
manner	0	O
.	0	O


Suggestive	1	O
evidence	0	O
was	0	O
obtained	0	O
that	0	O
cstA	0	B
is	0	O
involved	0	O
in	0	O
peptide	0	O
utilization	0	O
.	0	O


A	1	O
phylogenetic	0	O
analysis	0	O
with	0	O
the	0	O
TK	1	B
domains	0	I
from	0	O
these	0	O
sequences	0	O
and	0	O
a	0	O
fourth	0	O
,	0	O
from	0	O
a	0	O
novel	0	O
scavenger	0	B
RTK	0	I
(	0	O
all	0	O
domains	0	O
comprise	0	O
the	0	O
signature	0	O
for	0	O
the	0	O
TK	1	B
class	0	I
II	0	I
receptors	0	I
),	0	O
showed	0	O
that	0	O
they	0	O
are	0	O
distantly	0	O
related	0	O
to	0	O
the	0	O
insulin	0	B
and	0	O
insulin	0	B
-	0	I
like	0	I
receptors	0	I
.	0	O


The	0	O
presence	0	O
in	0	O
such	0	O
patients	0	O
of	0	O
antibodies	0	O
to	0	O
adrenaline	0	O
and	0	O
noradrenaline	0	O
is	0	O
indicative	0	O
of	0	O
considerable	0	O
disruption	0	O
of	0	O
catecholamine	0	O
biotransformation	0	O
.	0	O


Large	0	O
genomic	0	O
constructs	0	O
integrate	0	O
at	0	O
the	0	O
endogenous	0	O
locus	0	O
by	0	O
homologous	0	O
recombination	0	O
,	0	O
but	0	O
cDNA	1	O
-	0	O
derived	0	O
sequences	0	O
lacking	0	O
long	0	O
stretches	0	O
of	0	O
contiguous	0	O
genomic	0	O
DNA	1	O
(	0	O
due	0	O
to	0	O
intron	0	O
excision	0	O
)	0	O
typically	0	O
integrate	0	O
into	0	O
chromosomal	0	O
DNA	1	O
by	0	O
nonhomologous	0	O
recombination	0	O
.	0	O


The	0	O
MMA	1	B
,	0	I
DMA	0	I
,	0	I
and	0	I
TMA	1	I
methyltransferases	0	I
are	0	O
not	0	O
homologs	0	O
;	0	O
however	0	O
,	0	O
like	0	O
the	0	O
MMA	1	B
methyltransferase	0	I
gene	0	I
,	0	O
the	0	O
genes	0	O
encoding	0	O
the	0	O
DMA	0	B
and	0	I
TMA	1	I
methyltransferases	0	I
each	0	O
contain	0	O
a	0	O
single	0	O
in	0	O
-	0	O
frame	0	O
amber	0	O
codon	0	O
.	0	O


Thus	0	O
,	0	O
SAG	0	B
appears	0	O
to	0	O
control	0	O
cell	0	O
cycle	0	O
progression	0	O
in	0	O
yeast	0	O
by	0	O
promoting	0	O
ubiquitination	0	O
and	0	O
degradation	0	O
of	0	O
cell	0	O
cycle	0	O
regulatory	0	O
proteins	0	O
.	0	O


Dual	0	O
roles	0	O
of	0	O
p82	0	B
,	0	O
the	0	O
clam	0	O
CPEB	0	B
homolog	0	I
,	0	O
in	0	O
cytoplasmic	0	O
polyadenylation	0	O
and	0	O
translational	0	O
masking	0	O
.	0	O


Pentobarbital	1	O
(	0	O
1	0	O
,	0	O
3	0	O
,	0	O
10	0	O
,	0	O
and	0	O
17	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
was	0	O
also	0	O
tested	0	O
in	0	O
combination	0	O
with	0	O
rate	0	O
-	0	O
decreasing	0	O
doses	0	O
of	0	O
normeperidine	0	O
(	0	O
17	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
),	0	O
anileridine	0	O
(	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
),	0	O
alphaprodine	0	O
(	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
),	0	O
and	0	O
fentanyl	0	O
(	0	O
0	0	O
.	0	O
3	0	O
mg	0	O
/	0	O
kg	0	O
).	0	O


We	0	O
measured	0	O
basal	0	O
plasma	0	O
prolactin	0	B
concentrations	0	O
(	0	O
in	0	O
samples	0	O
obtained	0	O
during	0	O
the	0	O
early	0	O
follicular	0	O
phase	0	O
)	0	O
in	0	O
25	0	O
normal	0	O
(	0	O
control	0	O
)	0	O
women	0	O
and	0	O
in	0	O
a	0	O
similar	0	O
group	0	O
of	0	O
40	0	O
patients	0	O
with	0	O
a	0	O
long	0	O
-	0	O
standing	0	O
history	0	O
of	0	O
infertility	0	O
.	0	O


In	1	O
Saccharomyces	1	O
cerevisiae	0	O
,	0	O
PHO85	0	B
encodes	0	O
a	0	O
cyclin	0	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	O
Cdk	1	B
)	0	O
catalytic	0	O
subunit	0	O
with	0	O
multiple	0	O
regulatory	0	O
roles	0	O
thought	0	O
to	0	O
be	0	O
specified	0	O
by	0	O
association	0	O
with	0	O
different	0	O
cyclin	0	B
partners	0	O
(	0	O
Pcls	0	B
).	0	O


GCD10	0	B
binds	0	O
RNA	1	O
in	0	O
vitro	0	O
and	0	O
we	0	O
present	0	O
strong	0	O
biochemical	0	O
evidence	0	O
that	0	O
it	0	O
is	0	O
identical	0	O
to	0	O
the	0	O
RNA	1	O
-	0	O
binding	0	O
subunit	0	O
of	0	O
yeast	0	B
initiation	0	I
factor	0	I
-	0	I
3	0	I
(	0	O
eIF	0	B
-	0	I
3	0	I
).	0	O
eIF	0	B
-	0	I
3	0	I
is	0	O
a	0	O
multisubunit	0	O
complex	0	O
that	0	O
stimulates	0	O
translation	0	O
initiation	0	O
in	0	O
vitro	0	O
at	0	O
several	0	O
different	0	O
steps	0	O
.	0	O


We	0	O
describe	0	O
here	0	O
17	0	O
dominant	0	B
GCN2	0	I
mutations	0	I
that	0	O
lead	0	O
to	0	O
derepression	0	O
of	0	O
GCN4	0	B
expression	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
amino	0	O
acid	0	O
starvation	0	O
.	0	O


Refined	0	O
Cox	1	O
models	0	O
using	0	O
a	0	O
CD4	1	B
count	0	O
of	0	O
150	0	O
/	0	O
microL	1	O
rather	0	O
than	0	O
200	0	O
/	0	O
microL	1	O
to	0	O
distinguish	0	O
I0	0	O
and	0	O
I1	0	O
yielded	0	O
a	0	O
simplified	0	O
model	0	O
with	0	O
better	0	O
fit	0	O
to	0	O
the	0	O
observed	0	O
data	0	O
.	0	O


Furthermore	0	O
,	0	O
interactions	0	O
were	0	O
identified	0	O
between	0	O
endogenous	0	B
E	1	I
-	0	I
cadherin	0	I
and	0	O
the	0	O
chimera	0	O
containing	0	O
the	0	O
E	1	B
-	0	I
cadherin	0	I
extracellular	0	I
domain	0	I
and	0	O
the	0	O
desmoglein	0	B
1	0	I
intracellular	0	I
domain	0	I
providing	0	O
in	0	O
vivo	0	O
evidence	0	O
for	0	O
previously	0	O
predicted	0	O
lateral	0	O
interactions	0	O
of	0	O
E	1	B
-	0	I
cadherin	0	I
extracellular	0	I
domains	0	I
.	0	O


A	1	O
possible	0	O
role	0	O
for	0	O
the	0	O
mixed	0	O
function	0	O
oxidase	0	B
enzyme	0	O
system	0	O
in	0	O
the	0	O
requirement	0	O
for	0	O
selenium	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


This	0	O
sequence	0	O
similarity	0	O
raises	0	O
the	0	O
possibility	0	O
that	0	O
GCN1	0	B
interacts	0	O
with	0	O
ribosomes	0	O
or	0	O
tRNA	1	O
molecules	0	O
and	0	O
functions	0	O
in	0	O
conjunction	0	O
with	0	O
GCN2	0	B
in	0	O
monitoring	0	O
uncharged	0	O
tRNA	1	O
levels	0	O
during	0	O
the	0	O
process	0	O
of	0	O
translation	0	O
elongation	0	O
.	0	O


With	0	O
histology	0	O
and	0	O
Evans	0	O
blue	0	O
injections	0	O
,	0	O
blood	0	O
-	0	O
brain	0	O
barrier	0	O
alterations	0	O
were	0	O
seen	0	O
as	0	O
early	0	O
as	0	O
4	0	O
days	0	O
after	0	O
a	0	O
dose	0	O
of	0	O
50	0	O
Gy	1	O
.	0	O


Although	0	O
IL	1	B
-	0	I
2	0	I
and	0	O
IFN	1	B
-	0	I
alpha	0	I
activated	0	O
STAT1	0	B
alpha	0	I
and	0	O
STAT5	0	B
,	0	O
IL	1	B
-	0	I
2	0	I
predominantly	0	O
activated	0	O
STAT5	0	B
,	0	O
while	0	O
IFN	1	B
-	0	I
alpha	0	I
predominantly	0	O
activated	0	O
STAT1	0	B
alpha	0	I
.	0	O


These	0	O
genes	0	O
were	0	O
expressed	0	O
in	0	O
a	0	O
Saccharomyces	1	O
cerevisiae	0	O
mutant	0	O
in	0	O
which	0	O
the	0	O
endogenous	0	B
ferrochelatase	0	I
gene	0	I
(	0	O
HEM15	0	B
)	0	O
had	0	O
been	0	O
deleted	0	O
,	0	O
and	0	O
the	0	O
phenotypes	0	O
of	0	O
the	0	O
transformants	0	O
were	0	O
characterized	0	O
.	0	O


Coactivation	0	O
of	0	O
endogenous	0	O
or	0	O
exogenous	0	O
G	1	B
(	0	I
q	0	I
)-	0	I
coupled	0	I
receptors	0	I
with	0	O
the	0	O
delta	0	B
-	0	I
opioid	0	I
receptor	0	I
produced	0	O
strong	0	O
stimulations	0	O
of	0	O
PLCbeta	0	B
and	0	O
such	0	O
responses	0	O
could	0	O
be	0	O
partially	0	O
blocked	0	O
by	0	O
pertussis	0	B
toxin	0	I
.	0	O


157	0	O
+/-	0	O
16	0	O
mg	0	O
/	0	O
dl	0	O
;	0	O
NS	1	O
),	0	O
glucose	0	O
levels	0	O
,	0	O
and	0	O
basal	0	O
(	0	O
17	0	O
+/-	0	O
4	0	O
vs	0	O
.	0	O


Purified	0	B
Pra	1	I
was	0	O
also	0	O
shown	0	O
to	0	O
physically	0	O
interact	0	O
with	0	O
pyruvate	0	B
kinase	0	I
(	0	O
Pk	1	B
);	0	O
Pk	1	B
and	0	O
Pra	1	B
can	0	O
form	0	O
a	0	O
complex	0	O
,	0	O
but	0	O
when	0	O
the	0	O
12	0	B
-	0	I
kDa	1	I
Ndk	0	I
,	0	O
Pk	1	B
,	0	O
and	0	O
Pra	1	B
are	0	O
all	0	O
present	0	O
,	0	O
Pk	1	B
has	0	O
a	0	O
higher	0	O
affinity	0	O
than	0	O
Pra	1	B
for	0	O
forming	0	O
a	0	O
complex	0	O
with	0	O
the	0	O
12	0	B
-	0	I
kDa	1	I
Ndk	0	I
.	0	O


The	0	O
effects	0	O
of	0	O
cardioselective	0	O
beta	0	O
-	0	O
1	0	O
adrenergic	0	O
agonist	0	O
,	0	O
1	0	O
-(	0	O
4	0	O
-	0	O
hydroxyphenoxy	0	O
)-	0	O
isopropylamino	0	O
-	0	O
2	0	O
-	0	O
propanol	0	O
),	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
prenalterol	0	O
,	0	O
were	0	O
examined	0	O
on	0	O
direct	0	O
and	0	O
continuous	0	O
measurements	0	O
of	0	O
left	0	O
ventricular	0	O
(	0	O
LV	1	O
)	0	O
pressure	0	O
,	0	O
diameter	0	O
,	0	O
dP	1	O
/	0	O
dt	0	O
,	0	O
velocity	0	O
of	0	O
shortening	0	O
,	0	O
arterial	0	O
pressure	0	O
,	0	O
iliac	0	O
blood	0	O
flow	0	O
and	0	O
heart	0	O
rate	0	O
in	0	O
10	0	O
conscious	0	O
dogs	0	O
.	0	O


The	0	O
proliferation	0	O
-	0	O
specific	0	O
HNF	1	B
-	0	I
3	0	I
/	0	O
fork	0	B
head	0	I
homolog	0	I
-	0	I
11B	0	I
protein	0	O
(	0	O
HFH	0	B
-	0	I
11B	0	I
;	0	O
also	0	O
known	0	O
as	0	O
Trident	1	B
and	0	O
Win	0	B
)	0	O
is	0	O
a	0	O
family	0	O
member	0	O
of	0	O
the	0	O
winged	0	B
helix	0	I
/	0	O
fork	0	B
head	0	I
transcription	0	O
factors	0	O
and	0	O
in	0	O
regenerating	0	O
liver	0	O
its	0	O
expression	0	O
is	0	O
reactivated	0	O
prior	0	O
to	0	O
hepatocyte	0	O
entry	0	O
into	0	O
DNA	1	O
replication	0	O
(	0	O
S	1	O
phase	0	O
).	0	O


CPDs	0	O
at	0	O
these	0	O
three	0	O
sites	0	O
may	0	O
partially	0	O
displace	0	O
TFIIIA	0	B
,	0	O
thereby	0	O
enabling	0	O
rapid	0	O
repair	0	O
.	0	O


Deltamethrin	1	O
was	0	O
most	0	O
effective	0	O
on	0	O
the	0	O
thatched	0	O
surface	0	O
and	0	O
produced	0	O
100	0	O
%	0	O
mortality	0	O
of	0	O
An	1	O
.	0	O
culicifacies	0	O
adults	0	O
up	0	O
to	0	O
12	0	O
weeks	0	O
,	0	O
even	0	O
when	0	O
exposed	0	O
at	0	O
the	0	O
lowest	0	O
dose	0	O
/	0	O
12	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
m2	0	O
.	0	O


Analysis	1	O
of	0	O
a	0	O
Mac1p	0	B
mutant	0	I
,	0	O
refractile	0	O
for	0	O
copper	0	O
-	0	O
dependent	0	O
repression	0	O
of	0	O
the	0	O
Cu	1	B
(	0	I
I	1	I
)	0	I
transport	0	I
genes	0	I
,	0	O
showed	0	O
an	0	O
aberrant	0	O
pattern	0	O
of	0	O
CUP1	0	B
expression	0	O
and	0	O
copper	0	O
sensitivity	0	O
.	0	O


An	1	O
interaction	0	O
screen	0	O
with	0	O
the	0	O
repression	0	O
domain	0	O
of	0	O
the	0	O
orphan	0	B
receptor	0	I
RevErb	0	I
identified	0	O
N	1	B
-	0	I
CoR	1	I
,	0	O
the	0	O
corepressor	0	O
for	0	O
thyroid	0	B
hormone	0	I
receptor	0	I
(	0	O
TR	1	B
)	0	O
and	0	O
retinoic	0	B
acid	0	I
receptor	0	I
(	0	O
RAR	0	B
).	0	O


Nevertheless	0	O
,	0	O
antibodies	0	O
directed	0	O
against	0	O
an	0	O
epitope	0	O
-	0	O
tagged	0	O
version	0	O
of	0	O
Prp42p	0	B
specifically	0	O
precipitate	0	O
U1	0	B
snRNA	1	I
from	0	O
yeast	0	O
extracts	0	O
.	0	O


In	1	O
view	0	O
of	0	O
the	0	O
short	0	O
t1	0	O
/	0	O
2	0	O
,	0	O
we	0	O
used	0	O
three	0	O
doses	0	O
/	0	O
day	0	O
.	0	O


Early	0	O
disagnosis	0	O
of	0	O
cancer	0	O
--	0	O
50	0	O
per	0	O
cent	0	O
of	0	O
all	0	O
patients	0	O
could	0	O
be	0	O
cured	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
MAN	1	O
showed	0	O
a	0	O
unimodal	0	O
,	0	O
skewed	0	O
distribution	0	O
,	0	O
with	0	O
a	0	O
range	0	O
from	0	O
approximately	0	O
1	0	O
to	0	O
14	0	O
micron	0	O
and	0	O
a	0	O
maximum	0	O
at	0	O
3	0	O
-	0	O
4	0	O
micron	0	O
.	0	O


The	0	O
interaction	0	O
of	0	O
AF	1	O
-	0	O
1	0	O
with	0	O
proteins	0	O
that	0	O
regulate	0	O
distinct	0	O
steps	0	O
of	0	O
transcription	0	O
may	0	O
provide	0	O
a	0	O
mechanism	0	O
for	0	O
synergistic	0	O
activation	0	O
of	0	O
gene	0	O
expression	0	O
by	0	O
AF	1	O
-	0	O
1	0	O
.	0	O


Two	0	O
-	0	O
Channel	1	O
Kondo	0	O
Lattice	1	O
:	0	O
An	1	O
Incoherent	1	O
Metal	1	O
.	0	O


Structure	1	O
of	0	O
the	0	O
gene	0	O
encoding	0	O
the	0	O
human	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinase	0	I
inhibitor	0	O
p18	0	B
and	0	O
mutational	0	O
analysis	0	O
in	0	O
breast	0	O
cancer	0	O
.	0	O


The	0	O
rate	0	O
-	0	O
limiting	0	O
step	0	O
for	0	O
telomerase	0	B
activity	0	O
seems	0	O
to	0	O
be	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
catalytic	0	O
subunit	0	O
of	0	O
the	0	O
enzyme	0	O
,	0	O
encoded	0	O
by	0	O
the	0	O
human	0	B
telomerase	0	I
reverse	0	I
transcriptase	0	I
(	0	O
hTERT	0	B
)	0	O
gene	0	O
.	0	O


Significant	1	O
treatment	0	O
-	0	O
related	0	O
problems	0	O
appeared	0	O
during	0	O
the	0	O
second	0	O
decade	0	O
in	0	O
5	0	O
patients	0	O
,	0	O
including	0	O
one	0	O
chest	0	O
wall	0	O
sarcoma	0	O
;	0	O
all	0	O
of	0	O
these	0	O
patients	0	O
had	0	O
received	0	O
at	0	O
least	0	O
60	0	O
Gy	1	O
to	0	O
breast	0	O
and	0	O
regional	0	O
nodal	0	O
areas	0	O
.	0	O


Underestimations	0	O
by	0	O
as	0	O
much	0	O
as	0	O
35	0	O
%	0	O
may	0	O
occur	0	O
due	0	O
to	0	O
the	0	O
problems	0	O
in	0	O
the	0	O
existing	0	O
methodologies	0	O
.	0	O


When	0	O
the	0	O
cervical	0	O
Pap	1	O
smear	0	O
is	0	O
positive	0	O
.	0	O


The	0	O
third	0	O
domain	0	O
had	0	O
the	0	O
motif	0	O
of	0	O
a	0	O
cAMP	1	O
response	0	O
element	0	O
(	0	O
CRE	0	O
).	0	O


A	1	O
herpesvirus	0	O
proteinase	0	O
activity	0	O
has	0	O
been	0	O
identified	0	O
and	0	O
partially	0	O
characterized	0	O
by	0	O
using	0	O
the	0	O
cloned	0	O
enzyme	0	O
and	0	O
substrate	0	O
genes	0	O
in	0	O
transient	0	O
transfection	0	O
assays	0	O
.	0	O


Altogether	0	O
,	0	O
the	0	O
results	0	O
demonstrate	0	O
that	0	O
the	0	O
two	0	O
isoforms	0	O
elicit	0	O
similar	0	O
responses	0	O
in	0	O
vivo	0	O
despite	0	O
differences	0	O
in	0	O
their	0	O
regulation	0	O
.	0	O


We	0	O
found	0	O
sequences	0	O
related	0	O
to	0	O
this	0	O
insertion	0	O
in	0	O
wild	0	O
-	0	O
type	0	O
strains	0	O
of	0	O
N	1	O
.	0	O
crassa	0	O
and	0	O
other	0	O
Neurospora	1	O
species	0	O
.	0	O


For	0	O
patients	0	O
with	0	O
recurrent	0	O
or	0	O
metastatic	0	O
disease	0	O
,	0	O
the	0	O
data	0	O
suggest	0	O
that	0	O
I	1	O
-	0	O
131	0	O
MIBG	1	O
scintigraphy	0	O
is	0	O
the	0	O
examination	0	O
of	0	O
choice	0	O
.	0	O


In	1	O
the	0	O
normal	0	O
,	0	O
basal	0	O
(	0	O
unstimulated	0	O
)	0	O
condition	0	O
there	0	O
were	0	O
no	0	O
significant	0	O
correlations	0	O
(	0	O
p	0	O
greater	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
between	0	O
the	0	O
systolic	0	O
blood	0	O
pressure	0	O
and	0	O
dopamine	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
09	0	O
),	0	O
norepinephrine	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
26	0	O
),	0	O
or	0	O
epinephrine	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
27	0	O
),	0	O
nor	0	O
were	0	O
there	0	O
significant	0	O
correlations	0	O
between	0	O
melatonin	0	O
and	0	O
dopamine	0	O
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
01	0	O
),	0	O
norepinephrine	0	O
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
26	0	O
),	0	O
or	0	O
growth	0	B
hormone	0	I
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
17	0	O
).	0	O


We	0	O
report	0	O
here	0	O
that	0	O
constitutively	0	O
active	0	O
Mek1	0	B
could	0	O
activate	0	O
p96h2bk	0	B
in	0	O
the	0	O
absence	0	O
of	0	O
oncogenic	0	B
Ras	1	I
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
less	0	O
antidopaminergic	0	O
activity	0	O
of	0	O
RHAL	0	O
in	0	O
this	0	O
neuroleptic	0	O
test	0	O
might	0	O
be	0	O
explained	0	O
by	0	O
the	0	O
lesser	0	O
conversion	0	O
of	0	O
RHAL	0	O
to	0	O
HAL	0	O
.	0	O


Twenty	0	O
-	0	O
five	0	O
patients	0	O
(	0	O
80	0	O
,	0	O
6	0	O
%)	0	O
with	0	O
mixed	0	O
neoplasms	0	O
were	0	O
operated	0	O
on	0	O
by	0	O
total	0	O
conservative	0	O
parotidectomy	0	O
(	0	O
T	1	O
.	0	O
C	1	O
.	0	O
P	1	O
.),	0	O
3	0	O
(	0	O
9	0	O
,	0	O
7	0	O
%)	0	O
by	0	O
S	1	O
.	0	O
P	1	O
.	0	O
and	0	O
3	0	O
(	0	O
9	0	O
,	0	O
7	0	O
%)	0	O
by	0	O
En	0	O
.	0	O


The	0	O
N	1	O
-	0	O
terminal	0	O
sequence	0	O
of	0	O
one	0	O
hydrophilic	0	O
peptide	0	O
of	0	O
the	0	O
FeS	1	B
protein	0	I
has	0	O
been	0	O
also	0	O
obtained	0	O
confirming	0	O
the	0	O
fbcF	0	B
reading	0	O
frame	0	O
.	0	O


Histological	1	O
signs	0	O
of	0	O
the	0	O
flare	0	O
-	0	O
up	0	O
reaction	0	O
were	0	O
already	0	O
present	0	O
at	0	O
6	0	O
hr	0	O
after	0	O
i	0	O
.	0	O
v	0	O
.	0	O
challenge	0	O
and	0	O
lasted	0	O
for	0	O
at	0	O
least	0	O
4	0	O
days	0	O
.	0	O


We	0	O
and	0	O
others	0	O
have	0	O
demonstrated	0	O
that	0	O
the	0	O
c	0	B
-	0	I
cbl	0	I
proto	0	I
-	0	I
oncogene	0	I
product	0	I
is	0	O
one	0	O
of	0	O
the	0	O
earliest	0	O
targets	0	O
of	0	O
tyrosine	0	O
phosphorylation	0	O
upon	0	O
T	1	B
cell	0	I
receptor	0	I
stimulation	0	O
.	0	O


He	1	O
was	0	O
administered	0	O
recombinant	0	B
IFN	1	I
alpha	0	I
-	0	I
2b	0	I
under	0	O
the	0	O
diagnosis	0	O
of	0	O
chronic	0	O
hepatitis	0	O
C	1	O
.	0	O


We	0	O
have	0	O
isolated	0	O
a	0	O
cosmid	0	O
containing	0	O
DNA	1	O
that	0	O
corresponds	0	O
to	0	O
the	0	O
site	0	O
of	0	O
transposon	0	O
insertion	0	O
in	0	O
257DH4	0	O
and	0	O
have	0	O
localized	0	O
Tn5	0	B
on	0	O
an	0	O
8	0	B
.	0	I
0	0	I
kb	0	I
EcoRI	0	I
fragment	0	I
.	0	O


Erratum	0	O
:	0	O
Absence	1	O
of	0	O
precursor	0	O
effects	0	O
above	0	O
the	0	O
martensitic	0	O
transformation	0	O
in	0	O
a	0	O
virgin	0	O
crystal	0	O
of	0	O
Li	1	O
metal	0	O


This	0	O
philosophy	0	O
was	0	O
instituted	0	O
for	0	O
the	0	O
compound	0	O
RP	1	O
73401	0	O
,	0	O
a	0	O
specific	0	O
phosphodiesterase	0	B
IV	1	I
inhibitor	0	O
,	0	O
that	0	O
was	0	O
being	0	O
developed	0	O
simultaneously	0	O
for	0	O
delivery	0	O
by	0	O
both	0	O
oral	0	O
and	0	O
pulmonary	0	O
routes	0	O
of	0	O
administration	0	O
.	0	O


We	0	O
determined	0	O
whether	0	O
the	0	O
human	0	B
StAR	1	I
promoter	0	I
is	0	O
responsive	0	O
to	0	O
sterol	0	B
regulatory	0	I
element	0	I
-	0	I
binding	0	I
proteins	0	I
(	0	O
SREBPs	0	B
).	0	O


EB	1	B
-	0	I
1	0	I
,	0	O
a	0	O
tyrosine	0	B
kinase	0	I
signal	0	I
transduction	0	I
gene	0	I
,	0	O
is	0	O
transcriptionally	0	O
activated	0	O
in	0	O
the	0	O
t	0	O
(	0	O
1	0	O
;	0	O
19	0	O
)	0	O
subset	0	O
of	0	O
pre	0	O
-	0	O
B	1	O
ALL	1	O
,	0	O
which	0	O
express	0	O
oncoprotein	0	O
E2a	0	B
-	0	O
Pbx1	0	B
.	0	O


Effects	0	O
of	0	O
negative	0	O
pleural	0	O
pressure	0	O
on	0	O
left	0	O
ventricular	0	O
hemodynamics	0	O
.	0	O


Elimination	1	O
of	0	O
Haemophilus	1	O
influenzae	0	O
type	0	O
b	0	O
meningitis	0	O
after	0	O
introduction	0	O
of	0	O
vaccination	0	O


We	0	O
have	0	O
subcloned	0	O
into	0	O
pBR322	0	O
deoxyribonucleic	0	O
acid	0	O
(	0	O
DNA	1	O
)	0	O
sequences	0	O
mapping	0	O
either	0	O
in	0	O
the	0	O
coding	0	O
region	0	O
,	0	O
the	0	O
5	0	O
'	0	O
spacer	0	O
,	0	O
or	0	O
the	0	O
3	0	O
'	0	O
spacer	0	O
of	0	O
the	0	O
H2B	0	B
histone	0	I
gene	0	I
.	0	O


Grossly	0	O
,	0	O
the	0	O
incidence	0	O
of	0	O
a	0	O
type	0	O
IIc	0	O
carcinoma	0	O
was	0	O
46	0	O
.	0	O
5	0	O
%	0	O
and	0	O
that	0	O
of	0	O
a	0	O
IIc	0	O
+	0	O
III	0	O
type	0	O
was	0	O
20	0	O
.	0	O
5	0	O
%,	0	O
respectively	0	O
.	0	O


The	0	O
influence	0	O
of	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
seropositivity	0	O
on	0	O
the	0	O
efficacy	0	O
of	0	O
intravenous	0	O
immune	0	B
globulin	0	I
in	0	O
children	0	O
with	0	O
immune	0	O
thrombocytopenic	0	O
purpura	0	O
.	0	O


The	0	O
SEN1	0	B
gene	0	I
corresponds	0	O
to	0	O
a	0	O
6	0	O
,	0	O
336	0	O
-	0	O
bp	0	O
open	0	O
reading	0	O
frame	0	O
coding	0	O
for	0	O
a	0	O
2	0	O
,	0	O
112	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
protein	0	O
(	0	O
molecular	0	O
mass	0	O
,	0	O
239	0	O
kDa	1	O
).	0	O


Northern	0	O
(	0	O
RNA	1	O
)	0	O
blot	0	O
analyses	0	O
indicated	0	O
that	0	O
the	0	O
cdh	0	B
genes	0	I
encoding	0	O
the	0	O
five	0	O
subunits	0	O
and	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
ORF1	0	O
)	0	O
with	0	O
unknown	0	O
function	0	O
are	0	O
cotranscribed	0	O
during	0	O
growth	0	O
on	0	O
acetate	0	O
.	0	O


A	1	O
combination	0	O
of	0	O
cisplatin	0	O
and	0	O
5	0	O
-	0	O
fluorouracil	0	O
,	0	O
both	0	O
administered	0	O
4	0	O
days	0	O
continuously	0	O
as	0	O
infusion	0	O
,	0	O
was	0	O
assessed	0	O
in	0	O
advanced	0	O
head	0	O
and	0	O
neck	0	O
cancer	0	O
.	0	O


Independent	0	O
protrudor	0	O
muscle	0	O
stimulation	0	O
increased	0	O
VI	0	O
,	0	O
max	0	O
(	0	O
peak	0	O
increase	0	O
61	0	O
%,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
),	0	O
did	0	O
not	0	O
change	0	O
Pcrit	1	O
,	0	O
and	0	O
decreased	0	O
Rn	1	O
(	0	O
peak	0	O
decrease	0	O
of	0	O
41	0	O
%,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


In	1	O
both	0	O
settings	0	O
,	0	O
it	0	O
can	0	O
be	0	O
phosphorylated	0	O
by	0	O
cyclin	0	B
D	1	I
-	0	I
dependent	0	I
kinases	0	I
,	0	O
suggesting	0	O
that	0	O
its	0	O
transcriptional	0	O
activity	0	O
may	0	O
normally	0	O
be	0	O
regulated	0	O
through	0	O
such	0	O
mechanisms	0	O
.	0	O


An	1	O
ELISA	1	O
procedure	0	O
was	0	O
developed	0	O
for	0	O
monitoring	0	O
the	0	O
specific	0	O
IgE	1	B
response	0	O
in	0	O
dogs	0	O
to	0	O
Dirofilaria	1	O
immitis	0	O
infection	0	O
.	0	O


Therefore	0	O
,	0	O
we	0	O
have	0	O
developed	0	O
a	0	O
system	0	O
to	0	O
study	0	O
nuclear	0	O
targeting	0	O
in	0	O
plants	0	O
and	0	O
have	0	O
established	0	O
that	0	O
the	0	O
nuclear	0	O
transport	0	O
machinery	0	O
is	0	O
similar	0	O
in	0	O
monocots	0	O
and	0	O
dicots	0	O
.	0	O


Anesthesiologists	0	O
often	0	O
use	0	O
more	0	O
than	0	O
one	0	O
drug	0	O
in	0	O
a	0	O
patient	0	O
to	0	O
achieve	0	O
a	0	O
target	0	O
response	0	O
,	0	O
such	0	O
as	0	O
a	0	O
desired	0	O
blood	0	O
pressure	0	O
.	0	O


The	0	O
interaction	0	O
of	0	O
U1	0	B
-	0	I
70K	0	I
with	0	O
the	0	O
SRZ	0	B
proteins	0	I
is	0	O
confirmed	0	O
further	0	O
in	0	O
vitro	0	O
using	0	O
a	0	O
blot	0	O
overlay	0	O
assay	0	O
.	0	O


An	1	O
even	0	O
greater	0	O
inflammatory	0	O
response	0	O
was	0	O
observed	0	O
after	0	O
intratracheal	0	O
instillation	0	O
of	0	O
ufCB	0	O
,	0	O
but	0	O
not	0	O
after	0	O
CB	1	O
instillation	0	O
.	0	O


Recent	0	O
studies	0	O
have	0	O
suggested	0	O
that	0	O
SHP	0	B
-	0	I
1	0	I
regulates	0	O
the	0	O
function	0	O
of	0	O
Jak	1	B
family	0	O
tyrosine	0	B
kinases	0	I
,	0	O
as	0	O
shown	0	O
by	0	O
its	0	O
constitutive	0	O
association	0	O
with	0	O
the	0	O
Tyk2	0	B
kinase	0	I
and	0	O
the	0	O
hyperphosphorylation	0	O
of	0	O
Jak	1	B
kinases	0	I
in	0	O
the	0	O
motheaten	0	O
cells	0	O
that	0	O
lack	0	O
functional	0	O
SHP	0	B
-	0	I
1	0	I
.	0	O


Here	0	O
,	0	O
we	0	O
report	0	O
the	0	O
complete	0	O
structure	0	O
of	0	O
the	0	O
human	0	B
topoisomerase	0	I
IIalpha	0	I
gene	0	I
,	0	O
which	0	O
consists	0	O
of	0	O
35	0	O
exons	0	O
spanning	0	O
27	0	O
.	0	O
5	0	O
kb	0	O
.	0	O


We	0	O
previously	0	O
described	0	O
the	0	O
purification	0	O
of	0	O
an	0	O
83	0	B
-	0	I
kDa	1	I
phosphatidic	0	I
acid	0	I
phosphatase	0	I
(	0	O
PAP	1	B
)	0	O
from	0	O
the	0	O
porcine	0	O
thymus	0	O
membranes	0	O
(	0	O
Kanoh	0	O
,	0	O
H	1	O
.,	0	O
Imai	0	O
,	0	O
S	1	O
.-	0	O
i	0	O
.,	0	O
Yamada	0	O
,	0	O
K	1	O
.	0	O
and	0	O
Sakane	0	O
,	0	O
F	1	O
.(	0	O
1992	0	O
)	0	O
J	1	O
.	0	O


There	0	O
was	0	O
no	0	O
clear	0	O
correlation	0	O
between	0	O
the	0	O
MFA	0	O
and	0	O
the	0	O
severity	0	O
of	0	O
the	0	O
UTS	0	O
phenotype	0	O
.	0	O


Effects	0	O
of	0	O
alterations	0	O
of	0	O
primer	0	O
-	0	O
binding	0	O
site	0	O
sequences	0	O
on	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
type	0	O
1	0	O
replication	0	O
.	0	O


The	0	O
experimental	0	O
design	0	O
incorporated	0	O
a	0	O
multiple	0	O
regression	0	O
model	0	O
,	0	O
sequential	0	O
treatments	0	O
and	0	O
a	0	O
proportional	0	O
end	0	O
point	0	O
(	0	O
95	0	O
%)	0	O
for	0	O
protection	0	O
time	0	O
.	0	O


The	0	O
5	0	O
'	0	O
external	0	O
transcribed	0	O
spacer	0	O
(	0	O
ETS	1	O
)	0	O
region	0	O
of	0	O
the	0	O
pre	0	O
-	0	O
rRNA	1	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
contains	0	O
a	0	O
sequence	0	O
with	0	O
10	0	O
bp	0	O
of	0	O
perfect	0	O
complementarity	0	O
to	0	O
the	0	O
U3	0	B
snoRNA	1	I
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
essential	0	O
IncP	0	O
alpha	0	O
plasmid	0	O
transfer	0	O
genes	0	O
traF	0	B
and	0	O
traG	0	B
and	0	O
involvement	0	O
of	0	O
traF	0	B
in	0	O
phage	0	O
sensitivity	0	O
.	0	O


Functional	1	O
analysis	0	O
of	0	O
the	0	O
sGTH	0	B
alpha	0	I
subunit	0	I
promoter	0	I
by	0	O
the	0	O
transient	0	O
transfection	0	O
of	0	O
several	0	O
sGTH	0	B
alpha	0	I
/	0	O
CAT	1	B
chimeric	0	O
plasmids	0	O
into	0	O
rainbow	0	O
trout	0	O
pituitary	0	O
cells	0	O
suggests	0	O
that	0	O
its	0	O
pituitary	0	O
-	0	O
specific	0	O
expression	0	O
is	0	O
GSE	1	B
-	0	O
dependent	0	O
.	0	O


The	0	O
human	0	O
cDNA	1	O
was	0	O
used	0	O
to	0	O
demonstrate	0	O
that	0	O
tumor	0	B
necrosis	0	I
factor	0	I
-	0	I
alpha	0	I
could	0	O
rapidly	0	O
stimulate	0	O
MARCKS	0	B
gene	0	I
transcription	0	O
in	0	O
the	0	O
human	0	O
promyelocytic	0	O
leukemia	0	O
cell	0	O
line	0	O
HL60	0	O
.	0	O


The	0	O
resurgence	0	O
of	0	O
drug	0	O
-	0	O
resistant	0	O
malaria	0	O
makes	0	O
urgent	0	O
the	0	O
evaluation	0	O
of	0	O
new	0	O
antimalarial	0	O
agents	0	O
.	0	O


The	0	O
9	0	O
;	0	O
22	0	O
chromosomal	0	O
translocation	0	O
characteristic	0	O
of	0	O
CML	1	O
results	0	O
in	0	O
a	0	O
fused	0	O
bcr	0	B
/	0	O
abl	0	B
gene	0	O
and	0	O
an	0	O
abnormal	0	O
fusion	0	O
protein	0	O
,	0	O
p210bcr	0	B
/	0	O
abl	0	B
.	0	O


Genes	0	O
belonging	0	O
to	0	O
the	0	O
ras	0	B
superfamily	0	I
encode	0	O
low	0	B
-	0	I
molecular	0	I
-	0	I
weight	0	I
GTP	1	I
/	0	I
GDP	1	I
-	0	I
binding	0	I
proteins	0	I
that	0	O
are	0	O
highly	0	O
conserved	0	O
in	0	O
wide	0	O
variety	0	O
of	0	O
organisms	0	O
.	0	O


Dopaminergic	1	O
modulation	0	O
of	0	O
transcallosal	0	O
activity	0	O
of	0	O
cat	0	O
motor	0	O
cortical	0	O
neurons	0	O
.	0	O


It	1	O
thus	0	O
appears	0	O
that	0	O
MAPK	1	B
functions	0	O
in	0	O
meiotic	0	O
maturation	0	O
by	0	O
preventing	0	O
unfertilized	0	O
eggs	0	O
from	0	O
proceeding	0	O
into	0	O
parthenogenetic	0	O
development	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
the	0	O
abilities	0	O
of	0	O
constitutive	0	O
and	0	O
conditional	0	O
forms	0	O
of	0	O
the	0	O
three	0	O
Raf	0	B
kinases	0	I
to	0	O
abrogate	0	O
the	0	O
cytokine	0	O
dependency	0	O
of	0	O
FDC	0	O
-	0	O
P1	1	O
cells	0	O
were	0	O
examined	0	O
.	0	O


Based	0	O
on	0	O
the	0	O
occurrence	0	O
of	0	O
several	0	O
transcription	0	O
signals	0	O
in	0	O
the	0	O
Thermus	0	B
pyr	0	I
promoter	0	I
region	0	I
and	0	O
strong	0	O
amino	0	O
acid	0	O
sequence	0	O
identities	0	O
(	0	O
about	0	O
60	0	O
%)	0	O
between	0	O
Thermus	0	B
PyrR	0	I
and	0	O
the	0	O
PyrR	0	B
attenuation	0	I
proteins	0	I
of	0	O
two	0	O
Bacillus	1	O
sp	0	O
.,	0	O
we	0	O
propose	0	O
a	0	O
regulatory	0	O
mechanism	0	O
involving	0	O
transcriptional	0	O
attenuation	0	O
to	0	O
control	0	O
pyr	0	B
gene	0	I
expression	0	O
in	0	O
Thermus	0	O
.	0	O


The	0	O
experimental	0	O
end	0	O
points	0	O
were	0	O
the	0	O
time	0	O
required	0	O
for	0	O
treated	0	O
tumors	0	O
to	0	O
reach	0	O
3	0	O
times	0	O
their	0	O
treatment	0	O
size	0	O
,	0	O
the	0	O
survival	0	O
of	0	O
stem	0	O
cells	0	O
in	0	O
the	0	O
duodenal	0	O
crypts	0	O
,	0	O
and	0	O
the	0	O
breathing	0	O
rate	0	O
measured	0	O
early	0	O
(	0	O
19	0	O
-	0	O
23	0	O
weeks	0	O
)	0	O
and	0	O
late	0	O
(	0	O
41	0	O
-	0	O
46	0	O
weeks	0	O
)	0	O
after	0	O
treatment	0	O
.	0	O


However	0	O
,	0	O
changing	0	O
the	0	O
half	0	O
-	0	O
site	0	O
to	0	O
the	0	O
consensus	0	O
sequence	0	O
AGGTCA	0	O
(	0	O
IRper	0	O
-	0	O
1	0	O
)	0	O
increased	0	O
binding	0	O
of	0	O
AaEcR	0	B
.	0	I
AaUSP	0	I
10	0	O
-	0	O
fold	0	O
over	0	O
IRhsp	0	O
-	0	O
1	0	O
and	0	O
,	0	O
at	0	O
the	0	O
same	0	O
time	0	O
,	0	O
reduced	0	O
the	0	O
stringency	0	O
of	0	O
the	0	O
spacer	0	O
length	0	O
requirement	0	O
,	0	O
with	0	O
IRper	0	O
-	0	O
0	0	O
to	0	O
IRper	0	O
-	0	O
5	0	O
showing	0	O
detectable	0	O
binding	0	O
.	0	O


Effect	1	O
of	0	O
separate	0	O
and	0	O
combined	0	O
effects	0	O
of	0	O
plutonium	0	O
-	0	O
239	0	O
,	0	O
hexachlorobutadiene	0	O
and	0	O
tributyl	0	O
phosphate	0	O
on	0	O
the	0	O
thymus	0	O
gland	0	O
of	0	O
rats	0	O


This	0	O
generalization	0	O
of	0	O
MFP	0	O
involves	0	O
defining	0	O
an	0	O
appropriate	0	O
high	0	O
-	0	O
resolution	0	O
cost	0	O
function	0	O
,	0	O
parametrizing	0	O
the	0	O
search	0	O
space	0	O
of	0	O
the	0	O
environment	0	O
and	0	O
source	0	O
,	0	O
constructing	0	O
solutions	0	O
of	0	O
the	0	O
wave	0	O
equation	0	O
,	0	O
and	0	O
utilizing	0	O
a	0	O
nonlinear	0	O
optimization	0	O
method	0	O
to	0	O
search	0	O
the	0	O
parameter	0	O
landscape	0	O
for	0	O
the	0	O
global	0	O
minimum	0	O
of	0	O
the	0	O
cost	0	O
function	0	O
.	0	O


Our	0	O
analysis	0	O
of	0	O
nonsense	0	O
mutations	0	O
indicates	0	O
that	0	O
the	0	O
C	1	O
terminus	0	O
of	0	O
eIF2Bepsilon	0	B
(	0	I
residues	0	I
518	0	I
to	0	I
712	0	I
)	0	I
is	0	O
required	0	O
for	0	O
both	0	O
catalytic	0	O
activity	0	O
and	0	O
interaction	0	O
with	0	O
eIF2	0	B
.	0	O


The	0	O
model	0	O
is	0	O
able	0	O
to	0	O
anticipate	0	O
why	0	O
the	0	O
effect	0	O
of	0	O
water	0	O
fluoridation	0	O
on	0	O
caries	0	O
prevalence	0	O
is	0	O
most	0	O
pronounced	0	O
when	0	O
caries	0	O
is	0	O
diagnosed	0	O
at	0	O
cavity	0	O
level	0	O
.	0	O


Pharmacokinetics	1	O
of	0	O
FK	0	O
506	0	O
in	0	O
transplant	0	O
patients	0	O
.	0	O


Routinely	0	O
collected	0	O
,	0	O
processed	0	O
and	0	O
stored	0	O
breast	0	O
cancer	0	O
tissue	0	O
blocks	0	O
recovered	0	O
from	0	O
the	0	O
archives	0	O
of	0	O
the	0	O
Pathology	1	O
laboratory	0	O
in	0	O
Dar	0	O
es	0	O
Salaam	0	O
after	0	O
storage	0	O
of	0	O
up	0	O
to	0	O
3	0	O
years	0	O
were	0	O
analysed	0	O
by	0	O
a	0	O
flow	0	O
cytometry	0	O
for	0	O
DNA	1	O
ploidy	0	O
and	0	O
S	1	O
-	0	O
phase	0	O
fraction	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
xtRNA	0	B
(	0	O
Sec	0	B
)	0	O
gene	0	O
needs	0	O
the	0	O
binding	0	O
of	0	O
the	0	O
seven	0	O
Staf	0	B
zinc	0	I
fingers	0	I
,	0	O
but	0	O
not	0	O
Oct	1	B
-	0	I
1	0	I
,	0	O
for	0	O
optimal	0	O
transcriptional	0	O
capacity	0	O
.	0	O


High	0	O
resolution	0	O
computed	0	O
tomography	0	O
of	0	O
the	0	O
lungs	0	O
in	0	O
patients	0	O
with	0	O
rheumatoid	0	O
arthritis	0	O
.	0	O


The	0	O
histological	0	O
grading	0	O
was	0	O
certified	0	O
in	0	O
68	0	O
cases	0	O
:	0	O
12	0	O
G1	0	O
,	0	O
39	0	O
G2	0	O
,	0	O
17	0	O
G3	0	O
;	0	O
extracapsular	0	O
spread	0	O
was	0	O
found	0	O
in	0	O
20	0	O
/	0	O
54	0	O
cases	0	O
(	0	O
37	0	O
%).	0	O


Mean	1	O
rCBF	1	O
increased	0	O
in	0	O
some	0	O
patients	0	O
4	0	O
-	0	O
8	0	O
weeks	0	O
after	0	O
surgery	0	O
on	0	O
the	0	O
ipsilateral	0	O
side	0	O
.	0	O


The	0	O
volume	0	O
fraction	0	O
(	0	O
Vv	1	O
)	0	O
and	0	O
number	0	O
/	0	O
mm2	0	O
(	0	O
Na	1	O
)	0	O
of	0	O
all	0	O
capillaries	0	O
(	0	O
perfused	0	O
and	0	O
nonperfused	0	O
)	0	O
in	0	O
a	0	O
given	0	O
area	0	O
of	0	O
brain	0	O
were	0	O
determined	0	O
after	0	O
staining	0	O
for	0	O
alkaline	0	B
phosphatase	0	I
.	0	O


3	0	O
--	0	O
It	1	O
is	0	O
necessary	0	O
to	0	O
think	0	O
about	0	O
cosmetic	0	O
consequences	0	O
of	0	O
the	0	O
chinese	0	O
flap	0	O
and	0	O
consider	0	O
other	0	O
possibilities	0	O
of	0	O
the	0	O
flap	0	O
choice	0	O
.	0	O


The	0	O
influenza	0	O
virus	0	O
NS1	0	B
protein	0	O
is	0	O
a	0	O
unique	0	O
posttranscriptional	0	O
regulator	0	O
that	0	O
has	0	O
two	0	O
activities	0	O
:	0	O
inhibition	0	O
of	0	O
the	0	O
nuclear	0	O
export	0	O
of	0	O
poly	0	O
A	1	O
-	0	O
containing	0	O
mRNAs	0	O
and	0	O
inhibition	0	O
of	0	O
pre	0	O
-	0	O
mRNA	1	O
splicing	0	O
.	0	O


Nucleotide	1	O
sequence	0	O
analysis	0	O
revealed	0	O
that	0	O
TAR	1	B
-	0	I
binding	0	I
protein	0	I
is	0	O
very	0	O
similar	0	O
to	0	O
the	0	O
CREB2	0	B
protein	0	I
.	0	O


The	0	O
three	0	O
isoforms	0	O
purified	0	O
with	0	O
anti	0	B
-	0	I
FLAG	0	I
antibody	0	I
affinity	0	O
column	0	O
transferred	0	O
sulfate	0	O
to	0	O
heparan	0	O
sulfate	0	O
and	0	O
heparin	0	O
but	0	O
not	0	O
to	0	O
other	0	O
glycosaminoglycans	0	O
.	0	O


HRES	0	O
has	0	O
been	0	O
found	0	O
to	0	O
be	0	O
clinically	0	O
useful	0	O
in	0	O
assessing	0	O
histologic	0	O
damage	0	O
following	0	O
pneumatic	0	O
dilatation	0	O
and	0	O
in	0	O
localizing	0	O
the	0	O
LES	1	O
during	0	O
the	0	O
administration	0	O
of	0	O
intrasphincter	0	O
botulinum	0	B
toxin	0	I
injection	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
achalasia	0	O
.	0	O


PSI	1	B
-	0	I
G	1	I
and	0	O
PSI	1	B
-	0	I
K	1	I
probably	0	O
have	0	O
evolved	0	O
from	0	O
a	0	O
gene	0	O
duplication	0	O
of	0	O
an	0	O
ancestral	0	O
gene	0	O
.	0	O


The	0	O
mean	0	O
values	0	O
of	0	O
protease	0	O
activity	0	O
were	0	O
significantly	0	O
higher	0	O
in	0	O
the	0	O
test	0	O
groups	0	O
than	0	O
in	0	O
the	0	O
control	0	O
group	0	O
at	0	O
baseline	0	O
.	0	O


The	0	O
lengths	0	O
of	0	O
the	0	O
complete	0	O
polypeptide	0	O
chain	0	O
of	0	O
the	0	O
recombinant	0	O
enzyme	0	O
and	0	O
its	0	O
transit	0	O
peptide	0	O
are	0	O
388	0	O
and	0	O
53	0	O
residues	0	O
,	0	O
respectively	0	O
.	0	O


Neither	0	O
gene	0	O
possesses	0	O
a	0	O
distinct	0	O
transcriptional	0	O
start	0	O
site	0	O
as	0	O
shown	0	O
by	0	O
nuclease	0	B
S1	1	I
analysis	0	O
.	0	O


Cross	1	O
-	0	O
reaction	0	O
between	0	O
a	0	O
monoclonal	0	O
antibody	0	O
and	0	O
two	0	O
alpha	0	B
beta	0	I
T	1	I
cell	0	I
receptors	0	I
.	0	O


Protein	1	B
S	1	I
levels	0	O
were	0	O
virtually	0	O
undetectable	0	O
at	0	O
the	0	O
time	0	O
of	0	O
admission	0	O
and	0	O
failed	0	O
to	0	O
respond	0	O
to	0	O
infusions	0	O
of	0	O
fresh	0	O
frozen	0	O
plasma	0	O
,	0	O
despite	0	O
correction	0	O
of	0	O
other	0	O
procoagulant	0	O
and	0	O
anticoagulant	0	O
factors	0	O
.	0	O


The	0	O
influence	0	O
of	0	O
adrenergic	0	O
nerves	0	O
of	0	O
the	0	O
response	0	O
of	0	O
blood	0	O
vessels	0	O
in	0	O
the	0	O
rabbit	0	O
ear	0	O
to	0	O
2	0	B
--	0	I
phenylalanine	0	I
-	0	I
8	0	I
-	0	I
lysine	0	I
vasopressin	0	I
(	0	O
Octapressin	0	B
).	0	O


Water	1	O
content	0	O
and	0	O
equilibrium	0	O
water	0	O
partition	0	O
in	0	O
immature	0	O
cartilage	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
they	0	O
display	0	O
common	0	O
features	0	O
that	0	O
make	0	O
them	0	O
strikingly	0	O
related	0	O
to	0	O
snoRNA	1	B
U14	0	I
.	0	O


A	1	O
decamer	0	O
sequence	0	O
,	0	O
5	0	O
'-	0	O
CGA	0	O
-	0	O
CCCCUCC	0	O
-	0	O
3	0	O
',	0	O
complementary	0	O
to	0	O
a	0	O
conserved	0	O
sequence	0	O
adjacent	0	O
to	0	O
the	0	O
enzymatic	0	O
cleavage	0	O
site	0	O
on	0	O
the	0	O
mitochondrial	0	O
RNA	1	O
substrate	0	O
,	0	O
is	0	O
present	0	O
in	0	O
the	0	O
RNAase	0	B
MRP	0	I
RNA	1	I
.	0	O


Overall	0	O
least	0	O
-	0	O
squares	0	O
means	0	O
for	0	O
uncooked	0	O
and	0	O
cooked	0	O
longissimus	0	O
muscle	0	O
and	0	O
subcutaneous	0	O
fat	0	O
were	0	O
63	0	O
.	0	O
32	0	O
,	0	O
80	0	O
.	0	O
27	0	O
and	0	O
98	0	O
.	0	O
90	0	O
mg	0	O
of	0	O
cholesterol	0	O
/	0	O
100	0	O
g	0	O
of	0	O
tissue	0	O
,	0	O
respectively	0	O
.	0	O


Other	0	O
properties	0	O
of	0	O
Hg	1	O
-	0	O
and	0	O
Cd	1	O
-	0	O
spores	0	O
were	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
control	0	O
spores	0	O
.	0	O


At	1	O
physiological	0	O
doses	0	O
,	0	O
either	0	O
insulin	0	B
-	0	I
like	0	I
growth	0	I
factor	0	I
I	1	I
(	0	O
IGF	1	B
-	0	I
I	1	I
)	0	O
or	0	O
insulin	0	B
turned	0	O
out	0	O
to	0	O
be	0	O
as	0	O
potent	0	O
as	0	O
dibutyryl	0	O
cAMP	1	O
(	0	O
dbcAMP	0	O
)	0	O
in	0	O
increasing	0	O
UCP1	0	B
gene	0	I
transcription	0	O
rate	0	O
(	0	O
1	0	O
h	0	O
)	0	O
and	0	O
also	0	O
UCP1	0	B
mRNA	1	I
accumulation	0	O
(	0	O
3	0	O
h	0	O
),	0	O
their	0	O
maximal	0	O
effect	0	O
(	0	O
15	0	O
-	0	O
fold	0	O
increase	0	O
)	0	O
reached	0	O
upon	0	O
treatment	0	O
for	0	O
24	0	O
h	0	O
.	0	O


To	1	O
further	0	O
our	0	O
knowledge	0	O
about	0	O
the	0	O
systemic	0	O
humoral	0	O
immune	0	O
system	0	O
response	0	O
to	0	O
weak	0	O
hapten	0	O
-	0	O
syngeneic	0	O
or	0	O
allogeneic	0	O
protein	0	O
conjugates	0	O
(	0	O
corrosion	0	O
and	0	O
wear	0	O
products	0	O
of	0	O
metallic	0	O
orthopedic	0	O
devices	0	O
),	0	O
a	0	O
sensitive	0	O
enzyme	0	O
-	0	O
linked	0	O
immunosorbent	0	O
assay	0	O
(	0	O
ELISA	1	O
)	0	O
method	0	O
for	0	O
testing	0	O
for	0	O
antibody	0	O
(	0	O
humoral	0	O
immunity	0	O
)	0	O
to	0	O
metals	0	O
was	0	O
developed	0	O
.	0	O


Although	0	O
basal	0	O
vessels	0	O
may	0	O
constrict	0	O
distal	0	O
parenchymal	0	O
vessels	0	O
tend	0	O
to	0	O
dilate	0	O
after	0	O
SAH	0	O
.	0	O


Harmful	0	O
effects	0	O
in	0	O
animals	0	O
and	0	O
man	0	O
may	0	O
result	0	O
from	0	O
both	0	O
deficient	0	O
or	0	O
excessive	0	O
amounts	0	O
of	0	O
intake	0	O
.	0	O


Myocardial	0	O
infarction	0	O
in	0	O
patients	0	O
with	0	O
previous	0	O
bypass	0	O
surgery	0	O
.	0	O


Using	0	O
adenoviral	0	O
transfer	0	O
of	0	O
IkappaBalpha	0	B
(	0	O
IkappaBalpha	0	B
overexpression	0	O
),	0	O
the	0	O
production	0	O
of	0	O
TNF	1	B
-	0	I
alpha	0	I
induced	0	O
by	0	O
whole	0	O
GBS	1	O
was	0	O
inhibited	0	O
by	0	O
only	0	O
20	0	O
%.	0	O


Analysis	1	O
of	0	O
SRE	0	O
oligonucleotide	0	O
gel	0	O
mobility	0	O
shift	0	O
assays	0	O
with	0	O
nuclear	0	O
extracts	0	O
from	0	O
Sertoli	0	O
cells	0	O
demonstrated	0	O
the	0	O
presence	0	O
of	0	O
both	0	O
the	0	O
SRF	1	B
and	0	O
the	0	O
ubiquitously	0	O
expressed	0	O
bHLH	0	O
protein	0	O
E12	0	B
/	0	O
E47	0	B
.	0	O


Also	0	O
,	0	O
HR21ap	0	B
as	0	O
well	0	O
as	0	O
HR21Xap	0	B
are	0	O
specific	0	O
in	0	O
their	0	O
inhibition	0	O
of	0	O
Sp1	0	B
binding	0	O
.	0	O


Studies	0	O
are	0	O
necessary	0	O
to	0	O
assess	0	O
the	0	O
source	0	O
of	0	O
contamination	0	O
and	0	O
potential	0	O
role	0	O
of	0	O
MRSA	1	O
-	0	O
contaminated	0	O
milk	0	O
in	0	O
the	0	O
transmission	0	O
of	0	O
MRSA	1	O
to	0	O
neonates	0	O
.	0	O


The	0	O
transcription	0	O
factor	0	O
Sp1	0	B
bound	0	O
to	0	O
eight	0	O
sites	0	O
,	0	O
as	0	O
demonstrated	0	O
by	0	O
footprinting	0	O
assays	0	O
and	0	O
gel	0	O
shift	0	O
analysis	0	O
with	0	O
purified	0	O
Sp1	0	B
.	0	O


The	0	O
minus	0	O
-	0	O
end	0	O
-	0	O
directed	0	O
microtubule	0	O
motors	0	O
,	0	O
the	0	O
dyneins	0	B
,	0	O
may	0	O
also	0	O
constitute	0	O
a	0	O
superfamily	0	O
of	0	O
force	0	O
-	0	O
generating	0	O
proteins	0	O
with	0	O
distinct	0	O
attachment	0	O
domains	0	O
.	0	O


Thus	0	O
,	0	O
Fis	0	B
acts	0	O
as	0	O
an	0	O
accessory	0	O
transcriptional	0	O
activator	0	O
at	0	O
the	0	O
mar	0	B
promoter	0	I
.	0	O


A	1	O
full	0	B
-	0	I
length	0	I
PRL	1	I
receptor	0	I
(	0	O
PRLR	0	B
)	0	O
complementary	0	O
DNA	1	O
from	0	O
pigeons	0	O
was	0	O
obtained	0	O
by	0	O
screening	0	O
pigeon	0	O
crop	0	O
sac	0	O
libraries	0	O
and	0	O
by	0	O
reverse	0	O
transcription	0	O
coupled	0	O
with	0	O
polymerase	0	O
chain	0	O
reaction	0	O
.	0	O


Fibrin	1	B
cloaking	0	O
along	0	O
the	0	O
catheter	0	O
was	0	O
found	0	O
in	0	O
20	0	O
patients	0	O
studied	0	O
by	0	O
pull	0	O
-	0	O
out	0	O
arteriography	0	O
and	0	O
was	0	O
unassociated	0	O
with	0	O
clinical	0	O
symptoms	0	O
.	0	O


Respiratory	1	O
interaction	0	O
after	0	O
spinal	0	O
anesthesia	0	O
and	0	O
sedation	0	O
with	0	O
midazolam	0	O
.	0	O


Further	0	O
studies	0	O
established	0	O
that	0	O
the	0	O
Ep	1	B
-	0	O
induced	0	O
increase	0	O
in	0	O
beta	0	B
-	0	I
globin	0	I
mRNA	1	I
could	0	O
be	0	O
inhibited	0	O
by	0	O
the	0	O
tyrosine	0	B
kinase	0	I
inhibitor	0	O
genistein	0	O
and	0	O
the	0	O
protein	0	B
kinase	0	I
C	1	I
inhibitor	0	O
Compound	1	O
3	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Oligodeoxynucleotides	0	O
antisense	0	O
to	0	O
the	0	O
predicted	0	O
translation	0	O
initiation	0	O
regions	0	O
of	0	O
ICP4	0	B
and	0	O
pp38	0	B
mRNAs	0	I
inhibited	0	O
proliferation	0	O
of	0	O
MSB1	0	O
cells	0	O
but	0	O
not	0	O
MDCC	0	O
-	0	O
CU91	0	O
(	0	O
CU91	0	O
)	0	O
reticuloendotheliosis	0	O
virus	0	O
-	0	O
transformed	0	O
cells	0	O
.	0	O


Additionally	0	O
,	0	O
putative	0	O
CF1	0	B
/	0	O
USP	1	B
and	0	O
Broad	0	B
Complex	1	I
Z2	0	I
transcription	0	O
factor	0	O
elements	0	O
were	0	O
found	0	O
in	0	O
the	0	O
upstream	0	O
regions	0	O
of	0	O
MIH	0	B
and	0	O
MO	1	B
-	0	I
IH	1	I
genes	0	O
respectively	0	O
.	0	O


During	0	O
early	0	O
neurogenesis	0	O
,	0	O
Vnd	0	B
protein	0	I
is	0	O
restricted	0	O
to	0	O
ventral	0	O
column	0	O
neuroectoderm	0	O
and	0	O
neuroblasts	0	O
;	0	O
later	0	O
it	0	O
is	0	O
detected	0	O
in	0	O
a	0	O
complex	0	O
pattern	0	O
of	0	O
neurons	0	O
.	0	O


To	1	O
assess	0	O
the	0	O
ability	0	O
of	0	O
the	0	O
atria	0	O
to	0	O
maintain	0	O
elevated	0	O
plasma	0	O
concentrations	0	O
of	0	O
atrial	0	B
natriuretic	0	I
peptide	0	I
(	0	O
ANP	1	B
),	0	O
the	0	O
temporal	0	O
changes	0	O
in	0	O
plasma	0	B
ANP	1	I
concentrations	0	O
were	0	O
studied	0	O
in	0	O
seven	0	O
chloralose	0	O
-	0	O
anaesthetized	0	O
dogs	0	O
during	0	O
4	0	O
h	0	O
of	0	O
sustained	0	O
rapid	0	O
cardiac	0	O
pacing	0	O
.	0	O


If	1	O
this	0	O
is	0	O
present	0	O
,	0	O
such	0	O
patients	0	O
should	0	O
be	0	O
closely	0	O
monitored	0	O
,	0	O
and	0	O
any	0	O
atypical	0	O
lesions	0	O
biopsied	0	O
.	0	O


The	0	O
weak	0	O
base	0	O
ketoconazole	0	O
showed	0	O
complete	0	O
dissolution	0	O
from	0	O
a	0	O
tablet	0	O
formulation	0	O
in	0	O
Simulated	0	O
Gastric	1	O
Fluid	1	O
without	0	O
pepsin	0	B
(	0	O
SGFsp	0	O
)	0	O
within	0	O
30	0	O
minutes	0	O
,	0	O
70	0	O
%	0	O
dissolution	0	O
in	0	O
2	0	O
hours	0	O
under	0	O
fed	0	O
state	0	O
simulated	0	O
upper	0	O
jejunal	0	O
conditions	0	O
but	0	O
only	0	O
6	0	O
%	0	O
dissolution	0	O
in	0	O
2	0	O
hours	0	O
under	0	O
fasted	0	O
state	0	O
conditions	0	O
.	0	O


The	0	O
Drosophila	1	B
melanogaster	0	I
Gart	1	I
gene	0	I
encodes	0	O
three	0	O
enzymatic	0	O
activities	0	O
in	0	O
the	0	O
pathway	0	O
for	0	O
purine	0	O
de	0	O
novo	0	O
synthesis	0	O
.	0	O


Three	0	O
group	0	O
1	0	O
patients	0	O
developed	0	O
CMV	1	O
disease	0	O
;	0	O
1	0	O
group	0	O
2	0	O
patient	0	O
developed	0	O
CMV	1	O
hepatitis	0	O
.	0	O


Trials	0	O
of	0	O
sevine	0	O
activity	0	O
against	0	O
mosquito	0	O
larvae	0	O


Treatment	1	O
of	0	O
human	0	O
myeloid	0	O
cell	0	O
lines	0	O
HL	1	O
-	0	O
60	0	O
and	0	O
U937	0	O
with	0	O
phorbol	0	O
12	0	O
-	0	O
myristate	0	O
13	0	O
-	0	O
acetate	0	O
(	0	O
PMA	0	O
)	0	O
increased	0	O
within	0	O
2	0	O
h	0	O
cellular	0	O
levels	0	O
of	0	O
the	0	O
RNA	1	O
hybridizable	0	O
to	0	O
LD78	0	B
cDNA	1	I
.	0	O


EMSA	0	O
with	0	O
crude	0	O
nuclear	0	O
extracts	0	O
demonstrated	0	O
that	0	O
stimulation	0	O
with	0	O
CD40L	0	B
results	0	O
in	0	O
the	0	O
induction	0	O
of	0	O
NF	1	B
-	0	I
kappaB	0	I
complexes	0	I
that	0	O
bind	0	O
to	0	O
each	0	O
of	0	O
the	0	O
three	0	O
NF	1	B
-	0	I
kappaB	0	I
sites	0	I
and	0	O
are	0	O
composed	0	O
mainly	0	O
of	0	O
p50	0	B
and	0	O
RelB	0	B
,	0	O
but	0	O
also	0	O
include	0	O
c	0	B
-	0	I
Rel	0	I
and	0	O
p65	0	B
.	0	O


Epithelial	1	O
nerve	0	O
fiber	0	O
defects	0	O
included	0	O
absence	0	O
or	0	O
distorted	0	O
architecture	0	O
of	0	O
the	0	O
basal	0	O
epithelial	0	O
plexus	0	O
and	0	O
intra	0	O
-	0	O
epithelial	0	O
terminals	0	O
.	0	O


Although	0	O
eight	0	O
contiguous	0	O
genes	0	O
necessary	0	O
for	0	O
urease	0	B
activity	0	O
have	0	O
been	0	O
cloned	0	O
and	0	O
sequenced	0	O
,	0	O
the	0	O
transcriptional	0	O
organization	0	O
and	0	O
regulation	0	O
of	0	O
specific	0	O
genes	0	O
within	0	O
the	0	O
Proteus	1	B
gene	0	I
cluster	0	I
has	0	O
not	0	O
been	0	O
investigated	0	O
in	0	O
detail	0	O
.	0	O


Paf1p	0	B
may	0	O
therefore	0	O
be	0	O
required	0	O
for	0	O
both	0	O
positive	0	O
and	0	O
negative	0	O
regulation	0	O
of	0	O
subsets	0	O
of	0	O
yeast	0	O
genes	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
describe	0	O
a	0	O
mammalian	0	O
cell	0	O
-	0	O
free	0	O
transcription	0	O
system	0	O
reconstituted	0	O
with	0	O
only	0	O
recombinant	0	O
proteins	0	O
and	0	O
epitope	0	O
-	0	O
tagged	0	O
multiprotein	0	O
complexes	0	O
.	0	O


Pseudomembranous	1	O
conjunctivitis	0	O
following	0	O
bone	0	O
marrow	0	O
transplantation	0	O
:	0	O
immunopathological	0	O
and	0	O
ultrastructural	0	O
study	0	O
of	0	O
one	0	O
case	0	O
.	0	O


Two	0	O
of	0	O
these	0	O
six	0	O
cases	0	O
showed	0	O
mucosal	0	O
spread	0	O
without	0	O
stromal	0	O
invasion	0	O
(	0	O
type	0	O
A	1	O
);	0	O
the	0	O
remaining	0	O
four	0	O
cases	0	O
presented	0	O
a	0	O
direct	0	O
extension	0	O
(	0	O
type	0	O
B	1	O
)	0	O
from	0	O
muscle	0	O
-	0	O
invasive	0	O
carcinomas	0	O
of	0	O
the	0	O
bladder	0	O
.	0	O


Familial	1	O
autoimmune	0	O
hepatitis	0	O
and	0	O
C4	1	B
deficiency	0	O


RUSH	1	B
-	0	I
1	0	I
beta	0	I
is	0	O
a	0	O
95	0	O
-	0	O
kDa	1	O
truncated	0	O
version	0	O
of	0	O
RUSH	1	B
-	0	I
1	0	I
alpha	0	I
that	0	O
results	0	O
from	0	O
alternative	0	O
splicing	0	O
of	0	O
a	0	O
57	0	O
-	0	O
bp	0	O
exon	0	O
as	0	O
confirmed	0	O
by	0	O
genomic	0	O
cloning	0	O
.	0	O


Their	0	O
function	0	O
is	0	O
not	0	O
only	0	O
to	0	O
recruit	0	O
Pho2	0	B
to	0	O
the	0	O
promoter	0	O
but	0	O
to	0	O
allow	0	O
cooperative	0	O
binding	0	O
of	0	O
Pho4	0	B
together	0	O
with	0	O
Pho2	0	B
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
the	0	O
effect	0	O
of	0	O
acute	0	O
administration	0	O
of	0	O
various	0	O
doses	0	O
of	0	O
malathion	0	O
via	0	O
oral	0	O
and	0	O
dermal	0	O
routes	0	O
to	0	O
mice	0	O
and	0	O
rats	0	O
on	0	O
serum	0	O
levels	0	O
of	0	O
histamine	0	O
was	0	O
evaluated	0	O
.	0	O


A	1	O
multicentre	0	O
study	0	O
involving	0	O
9	0	O
Italian	0	O
institutions	0	O
was	0	O
carried	0	O
out	0	O
to	0	O
compare	0	O
the	0	O
efficacy	0	O
and	0	O
safety	0	O
of	0	O
ranitidine	0	O
150	0	O
mg	0	O
b	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.	0	O
and	0	O
ranitidine	0	O
300	0	O
mg	0	O
nocte	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
reflux	0	O
oesophagitis	0	O
.	0	O


H19	0	B
and	0	O
Igf2	0	B
monoallelic	0	O
expression	0	O
is	0	O
regulated	0	O
in	0	O
two	0	O
distinct	0	O
ways	0	O
by	0	O
a	0	O
shared	0	O
cis	0	O
acting	0	O
regulatory	0	O
region	0	O
upstream	0	O
of	0	O
H19	0	B
.	0	O


MED1	0	B
has	0	O
a	0	O
weak	0	O
glycosylase	0	B
activity	0	O
on	0	O
the	0	O
mutagenic	0	O
adduct	0	O
3	0	O
,	0	O
N	1	O
(	0	O
4	0	O
)-	0	O
ethenocytosine	0	O
,	0	O
a	0	O
metabolite	0	O
of	0	O
vinyl	0	O
chloride	0	O
and	0	O
ethyl	0	O
carbamate	0	O
.	0	O


These	0	O
changes	0	O
correlate	0	O
directly	0	O
with	0	O
an	0	O
increase	0	O
in	0	O
the	0	O
acetylation	0	O
levels	0	O
of	0	O
all	0	O
four	0	O
core	0	B
histones	0	I
in	0	O
vivo	0	O
.	0	O


John	0	O
leonard	0	O
dawson	0	O


PMEK1	0	B
displays	0	O
96	0	O
and	0	O
80	0	O
%	0	O
identity	0	O
respectively	0	O
with	0	O
the	0	O
tobacco	0	B
NTF3	0	I
and	0	O
Arabidopsis	0	B
ATMPK1	0	I
kinases	0	I
,	0	O
and	0	O
only	0	O
50	0	O
%	0	O
to	0	O
the	0	O
more	0	O
distantly	0	O
related	0	O
plant	0	O
MAP	1	O
kinase	0	O
MsERK1	0	B
from	0	O
alfalfa	0	O
.	0	O


2	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
L45	0	O
sequence	0	O
between	0	O
kinase	0	O
subdomains	0	O
IV	1	O
and	0	O
V	1	O
specifies	0	O
TGF	1	B
-	0	I
beta	0	I
responsiveness	0	O
of	0	O
the	0	O
type	0	B
I	1	I
receptor	0	I
.	0	O


The	0	O
core	0	B
enzyme	0	I
is	0	O
homologous	0	O
to	0	O
those	0	O
of	0	O
bacteriophages	0	O
T3	1	O
,	0	O
T7	0	O
and	0	O
SP6	0	O
whereas	0	O
the	0	O
specificity	0	O
factor	0	O
shows	0	O
similarities	0	O
with	0	O
bacterial	0	B
sigma	0	I
factors	0	I
.	0	O


Spatial	1	O
zones	0	O
for	0	O
muscle	0	O
coactivation	0	O
and	0	O
the	0	O
control	0	O
of	0	O
postural	0	O
stability	0	O
.	0	O


Epithelial	1	O
and	0	O
corneal	0	O
thickness	0	O
measurements	0	O
by	0	O
in	0	O
vivo	0	O
confocal	0	O
microscopy	0	O
through	0	O
focusing	0	O
(	0	O
CMTF	0	O
).	0	O


JCAHO	1	O
revised	0	O
interpretation	0	O


The	0	O
corticosterone	0	O
synthesis	0	O
inhibitor	0	O
metyrapone	0	O
(	0	O
75	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
p	0	O
.)	0	O
was	0	O
given	0	O
to	0	O
attenuate	0	O
the	0	O
rise	0	O
of	0	O
corticosterone	0	O
to	0	O
a	0	O
level	0	O
typical	0	O
of	0	O
stressed	0	O
males	0	O
.	0	O


Because	0	O
of	0	O
the	0	O
increased	0	O
CPK	1	B
activity	0	O
found	0	O
in	0	O
normal	0	O
newborns	0	O
,	0	O
screening	0	O
for	0	O
Duchenne	0	O
-	0	O
type	0	O
muscular	0	O
dystrophy	0	O
should	0	O
be	0	O
postponed	0	O
for	0	O
a	0	O
few	0	O
weeks	0	O
after	0	O
delivery	0	O
.	0	O


We	0	O
show	0	O
here	0	O
that	0	O
the	0	O
LIM	0	B
domain	0	I
homeobox	0	I
protein	0	I
isl	0	I
-	0	I
1	0	I
activates	0	O
the	0	O
rat	0	B
amylin	0	I
promoter	0	I
in	0	O
both	0	O
fibroblast	0	O
and	0	O
islet	0	O
cell	0	O
lines	0	O
.	0	O


PRL	1	B
receptor	0	I
also	0	O
activates	0	O
SHP	0	B
-	0	I
2	0	I
,	0	O
a	0	O
cytosolic	0	B
tyrosine	0	I
phosphatase	0	I
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
both	0	O
PKC	0	B
alpha	0	I
(	0	O
calcium	0	O
dependent	0	O
)	0	O
and	0	O
PKC	0	B
delta	0	I
(	0	O
calcium	0	O
independent	0	O
)	0	O
may	0	O
mediate	0	O
the	0	O
transcription	0	O
of	0	O
TPA	1	O
-	0	O
inducible	0	O
genes	0	O
through	0	O
both	0	O
AP	1	B
-	0	I
1	0	I
and	0	O
non	0	O
-	0	O
AP	1	B
-	0	I
1	0	I
sequences	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
evaluate	0	O
the	0	O
relationship	0	O
between	0	O
blood	0	O
flow	0	O
in	0	O
the	0	O
tumor	0	O
assessed	0	O
by	0	O
color	0	O
Doppler	1	O
ultrasound	0	O
,	0	O
microvessel	0	O
density	0	O
,	0	O
and	0	O
vascular	0	B
endothelial	0	I
growth	0	I
factor	0	I
levels	0	O
in	0	O
endometrial	0	O
carcinoma	0	O
.	0	O


The	0	O
patient	0	O
'	0	O
s	0	O
role	0	O
,	0	O
organized	0	O
by	0	O
the	0	O
prerequisites	0	O
of	0	O
expressive	0	O
freedom	0	O
,	0	O
is	0	O
counter	0	O
posed	0	O
with	0	O
the	0	O
psychoanalyst	0	O
'	0	O
s	0	O
,	0	O
which	0	O
is	0	O
structured	0	O
to	0	O
empower	0	O
listening	0	O
and	0	O
understanding	0	O
.	0	O


Selected	0	O
topics	0	O
in	0	O
pediatric	0	O
ultrasonography	0	O
--	0	O
1992	0	O
.	0	O


Severe	0	O
hemolysis	0	O
resulted	0	O
in	0	O
statistically	0	O
significant	0	O
changes	0	O
in	0	O
the	0	O
mean	0	O
values	0	O
of	0	O
the	0	O
above	0	O
analytes	0	O
in	0	O
addition	0	O
to	0	O
the	0	O
following	0	O
increases	0	O
:	0	O
alanine	0	B
aminotransferase	0	I
,	0	O
calcium	0	O
,	0	O
and	0	O
serum	0	B
globulins	0	I
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
and	0	O
albumin	0	B
and	0	O
total	0	O
protein	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
).	0	O


The	0	O
difficulties	0	O
to	0	O
analyse	0	O
prostaglandins	0	O
(	0	O
PG	1	O
)	0	O
by	0	O
gas	0	O
-	0	O
liquid	0	O
chromatography	0	O
are	0	O
mainly	0	O
due	0	O
to	0	O
the	0	O
lack	0	O
of	0	O
sensitivity	0	O
of	0	O
the	0	O
gas	0	O
-	0	O
chromatograph	0	O
itself	0	O
(	0	O
higher	0	O
than	0	O
200	0	O
ng	0	O
)	0	O
and	0	O
to	0	O
the	0	O
poor	0	O
resolution	0	O
of	0	O
the	0	O
packed	0	O
columns	0	O
.	0	O


We	0	O
studied	0	O
the	0	O
GR	1	B
in	0	O
DMS	0	O
-	0	O
79	0	O
cells	0	O
derived	0	O
from	0	O
a	0	O
human	0	O
ACTH	1	B
-	0	O
secreting	0	O
small	0	O
cell	0	O
lung	0	O
cancer	0	O
.	0	O


The	0	O
results	0	O
suggest	0	O
that	0	O
,	0	O
although	0	O
both	0	O
the	0	O
N	1	O
-	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
regions	0	O
of	0	O
talin	0	B
bind	0	O
actin	0	B
,	0	O
the	0	O
properties	0	O
of	0	O
these	0	O
two	0	O
regions	0	O
of	0	O
the	0	O
protein	0	O
are	0	O
distinct	0	O
.	0	O


PARTICIPANTS	0	O
:	0	O
Convenience	0	O
sample	0	O
of	0	O
ambulatory	0	O
outpatients	0	O
with	0	O
hereditary	0	O
motor	0	O
and	0	O
sensory	0	O
neuropathy	0	O
,	0	O
type	0	O
I	1	O
(	0	O
n	0	O
=	0	O
9	0	O
),	0	O
myotonic	0	O
muscular	0	O
dystrophy	0	O
(	0	O
n	0	O
=	0	O
10	0	O
),	0	O
and	0	O
able	0	O
-	0	O
bodied	0	O
controls	0	O
(	0	O
n	0	O
=	0	O
11	0	O
).	0	O


Small	0	B
Maf	1	I
proteins	0	I
heterodimerize	0	O
with	0	O
Fos	1	B
and	0	O
may	0	O
act	0	O
as	0	O
competitive	0	O
repressors	0	O
of	0	O
the	0	O
NF	1	B
-	0	I
E2	1	I
transcription	0	I
factor	0	I
.	0	O


Mutations	0	O
in	0	O
seven	0	O
other	0	O
lts	0	B
genes	0	I
do	0	O
not	0	O
result	0	O
in	0	O
the	0	O
mak	0	B
-	0	I
phenotype	0	I
.	0	O


The	0	O
'	0	O
Newcastle	0	O
'	0	O
model	0	O
,	0	O
which	0	O
is	0	O
based	0	O
on	0	O
Hotelling	0	O
'	0	O
s	0	O
T2	0	O
statistic	0	O
,	0	O
proved	0	O
to	0	O
be	0	O
more	0	O
sensitive	0	O
and	0	O
diagnosed	0	O
a	0	O
systematic	0	O
displacement	0	O
for	0	O
three	0	O
prostate	0	O
patients	0	O
.	0	O


The	0	O
major	0	O
type	0	O
involves	0	O
activator	0	O
proteins	0	O
that	0	O
bind	0	O
to	0	O
DNA	1	O
adjacent	0	O
to	0	O
where	0	O
the	0	O
RNA	1	B
polymerase	0	I
(	0	O
RNAP	0	B
)	0	O
holoenzyme	0	O
binds	0	O
,	0	O
usually	0	O
assisting	0	O
in	0	O
recruitment	0	O
of	0	O
the	0	O
RNAP	0	B
to	0	O
the	0	O
promoter	0	O
.	0	O


Exchange	1	O
of	0	O
the	0	O
LPL	0	B
and	0	O
HL	1	B
lids	0	O
resulted	0	O
in	0	O
a	0	O
reversal	0	O
of	0	O
the	0	O
phospholipase	0	B
/	0	O
neutral	0	O
lipase	0	B
ratio	0	O
,	0	O
establishing	0	O
the	0	O
important	0	O
role	0	O
of	0	O
this	0	O
region	0	O
in	0	O
mediating	0	O
substrate	0	O
specificity	0	O
.	0	O


The	0	O
intensity	0	O
of	0	O
the	0	O
SSTEs	0	O
is	0	O
an	0	O
order	0	O
of	0	O
magnitude	0	O
larger	0	O
than	0	O
that	0	O
of	0	O
the	0	O
MSEs	0	O
and	0	O
determines	0	O
the	0	O
signal	0	O
contrast	0	O
if	0	O
both	0	O
effects	0	O
are	0	O
selected	0	O
simultaneously	0	O
.	0	O


The	0	O
peroxisome	0	B
proliferator	0	I
-	0	I
activated	0	I
receptors	0	I
(	0	O
PPARs	0	B
)	0	O
are	0	O
members	0	O
of	0	O
the	0	O
nuclear	0	B
hormone	0	I
receptor	0	I
superfamily	0	I
.	0	O


The	0	O
clinical	0	O
and	0	O
laboratory	0	O
features	0	O
of	0	O
72	0	O
children	0	O
with	0	O
Henoch	0	O
-	0	O
Schonlein	0	O
purpura	0	O
(	0	O
HSP	0	O
)	0	O
were	0	O
examined	0	O
to	0	O
determine	0	O
if	0	O
there	0	O
were	0	O
associations	0	O
between	0	O
the	0	O
laboratory	0	O
indices	0	O
--	0	O
including	0	O
white	0	O
blood	0	O
cell	0	O
(	0	O
WBC	1	O
)	0	O
counts	0	O
,	0	O
serum	0	B
C	1	I
-	0	I
reactive	0	I
protein	0	I
(	0	O
CRP	1	B
)	0	O
levels	0	O
,	0	O
platelet	0	O
(	0	O
PLT	1	O
)	0	O
counts	0	O
--	0	O
and	0	O
the	0	O
clinical	0	O
manifestations	0	O
of	0	O
acute	0	O
HSP	0	O
.	0	O


Tetrad	1	O
analysis	0	O
and	0	O
mitotic	0	O
recombination	0	O
experiments	0	O
localized	0	O
the	0	O
PEP4	0	B
gene	0	I
proximal	0	O
to	0	O
GAL4	0	B
on	0	O
chromosome	0	O
XVI	0	O
.	0	O


Our	0	O
findings	0	O
support	0	O
the	0	O
view	0	O
of	0	O
a	0	O
multifactorial	0	O
genesis	0	O
of	0	O
the	0	O
cardiac	0	O
involvement	0	O
in	0	O
uremic	0	O
patients	0	O
.	0	O


Ultrastructure	1	O
of	0	O
the	0	O
tumor	0	O
in	0	O
1	0	O
patient	0	O
in	0	O
whom	0	O
transurethral	0	O
resection	0	O
was	0	O
performed	0	O
2	0	O
weeks	0	O
after	0	O
alum	0	O
irrigation	0	O
revealed	0	O
well	0	O
preserved	0	O
nuclear	0	O
chromatin	0	O
,	0	O
thus	0	O
,	0	O
suggesting	0	O
that	0	O
whatever	0	O
changes	0	O
occur	0	O
after	0	O
alum	0	O
irrigation	0	O
are	0	O
short	0	O
-	0	O
lived	0	O
.	0	O


To	1	O
assess	0	O
the	0	O
effects	0	O
of	0	O
alveolar	0	O
hypoxia	0	O
and	0	O
angiotensin	0	B
II	0	I
infusion	0	O
on	0	O
distribution	0	O
of	0	O
blood	0	O
flow	0	O
to	0	O
the	0	O
lung	0	O
we	0	O
performed	0	O
perfusion	0	O
lung	0	O
scans	0	O
on	0	O
anesthetized	0	O
mechanically	0	O
ventilated	0	O
lambs	0	O
.	0	O


FK	0	O
33	0	O
-	0	O
824	0	O
,	0	O
a	0	O
methionine	0	O
-	0	O
enkephalin	0	B
analogue	0	O
,	0	O
suppressed	0	O
plasma	0	O
ACTH	1	B
to	0	O
85	0	O
%	0	O
of	0	O
basal	0	O
level	0	O
,	0	O
while	0	O
bromocriptine	0	O
(	0	O
CB	1	O
-	0	O
154	0	O
)	0	O
caused	0	O
no	0	O
significant	0	O
change	0	O
.	0	O


Although	0	O
pathological	0	O
thyroid	0	O
function	0	O
is	0	O
related	0	O
to	0	O
changes	0	O
in	0	O
energy	0	O
expenditure	0	O
and	0	O
body	0	O
composition	0	O
,	0	O
its	0	O
possible	0	O
influence	0	O
on	0	O
leptin	0	B
levels	0	O
remains	0	O
to	0	O
be	0	O
determined	0	O
.	0	O


The	0	O
toxicological	0	O
evaluation	0	O
of	0	O
chlorofluorocarbon	0	O
22	0	O
(	0	O
CFC	1	O
22	0	O
).	0	O


In	1	O
co	0	O
-	0	O
transfection	0	O
studies	0	O
,	0	O
the	0	O
expression	0	O
of	0	O
c	0	B
-	0	I
Jun	1	I
plus	0	O
c	0	B
-	0	I
Fos	1	I
enhanced	0	O
the	0	O
transactivation	0	O
of	0	O
oIFNtau	0	B
-	0	O
CAT	1	B
but	0	O
the	0	O
expression	0	O
of	0	O
GATA	0	B
-	0	I
1	0	I
,	0	O
GATA	0	B
-	0	I
2	0	I
or	0	O
GATA	0	B
-	0	I
3	0	I
did	0	O
not	0	O
.	0	O


Thus	0	O
,	0	O
as	0	O
expected	0	O
,	0	O
trans	0	O
-	0	O
splicing	0	O
depends	0	O
on	0	O
the	0	O
integrity	0	O
of	0	O
U2	0	B
,	0	O
U4	0	B
,	0	O
and	0	O
U6	0	B
snRNAs	0	I
.	0	O


In	1	O
a	0	O
man	0	O
with	0	O
myelomonocytic	0	O
leukemia	0	O
,	0	O
the	0	O
association	0	O
of	0	O
increased	0	O
prostatic	0	B
acid	0	I
phosphatase	0	I
activity	0	O
in	0	O
serum	0	O
and	0	O
the	0	O
presence	0	O
of	0	O
typical	0	O
bone	0	O
lesions	0	O
on	0	O
roentgenography	0	O
suggested	0	O
the	0	O
existence	0	O
of	0	O
disseminated	0	O
prostatic	0	O
carcinoma	0	O
.	0	O


A	1	O
local	0	O
,	0	O
high	0	O
-	0	O
density	0	O
,	0	O
single	0	O
-	0	O
nucleotide	0	O
polymorphism	0	O
map	0	O
used	0	O
to	0	O
clone	0	O
Caenorhabditis	0	B
elegans	0	I
cdf	0	I
-	0	I
1	0	I
.	0	O


Modification	1	O
of	0	O
enteral	0	O
resorption	0	O
by	0	O
cytostatic	0	O
therapy	0	O


The	0	O
DNA	1	O
binding	0	O
activities	0	O
of	0	O
the	0	O
three	0	O
repressor	0	O
preparations	0	O
were	0	O
studied	0	O
using	0	O
fragments	0	O
containing	0	O
CIRs	0	O
(	0	O
CIR3	0	O
-	0	O
CIR6	0	O
)	0	O
from	0	O
the	0	O
essential	0	O
early	0	O
region	0	O
as	0	O
templates	0	O
for	0	O
DNase	1	B
I	1	I
footprinting	0	O
.	0	O


Oncogenic	1	O
activation	0	O
of	0	O
the	0	O
tyrosine	0	B
kinase	0	I
domain	0	I
of	0	O
the	0	O
human	0	B
trk	0	I
proto	0	I
-	0	I
oncogene	0	I
by	0	O
fusion	0	O
to	0	O
a	0	O
cell	0	O
adhesion	0	O
molecule	0	O
.	0	O


The	0	O
amino	0	O
-	0	O
terminal	0	O
third	0	O
of	0	O
the	0	O
protein	0	O
contains	0	O
a	0	O
high	0	B
-	0	I
mobility	0	I
-	0	I
group	0	I
motif	0	I
characteristic	0	O
of	0	O
DNA	1	O
-	0	O
binding	0	O
proteins	0	O
.	0	O


The	0	O
decrease	0	O
of	0	O
TNF	1	B
receptors	0	I
by	0	O
IL	1	B
-	0	I
4	0	I
was	0	O
accompanied	0	O
by	0	O
down	0	O
-	0	O
regulation	0	O
of	0	O
TNF	1	B
-	0	O
induced	0	O
activities	0	O
,	0	O
including	0	O
cytotoxicity	0	O
,	0	O
caspase	0	B
-	0	I
3	0	I
activation	0	O
,	0	O
NF	1	B
-	0	I
kappaB	0	I
and	0	O
AP	1	B
-	0	I
1	0	I
activation	0	O
,	0	O
and	0	O
c	0	B
-	0	I
Jun	1	I
N	1	I
-	0	I
terminal	0	I
kinase	0	I
induction	0	O
.	0	O


Counter	1	O
-	0	O
current	0	O
heat	0	O
exchange	0	O
in	0	O
the	0	O
respiratory	0	O
passages	0	O
:	0	O
effect	0	O
on	0	O
water	0	O
and	0	O
heat	0	O
balance	0	O
.	0	O


The	0	O
concentration	0	O
of	0	O
PGI2	0	O
on	0	O
the	0	O
newly	0	O
-	0	O
formed	0	O
luminal	0	O
surface	0	O
remained	0	O
low	0	O
.	0	O


Scientific	0	O
cooperation	0	O
of	0	O
CMEA	0	O
member	0	O
countries	0	O
has	0	O
been	0	O
carried	0	O
out	0	O
since	0	O
1974	0	O
under	0	O
the	0	O
sponsorship	0	O
of	0	O
the	0	O
Cancer	1	O
Research	1	O
Institute	0	O
,	0	O
Slovak	0	O
Academy	0	O
of	0	O
Sciences	0	O
(	0	O
Czechoslovakia	0	O
)	0	O
within	0	O
the	0	O
framework	0	O
of	0	O
CMEA	0	O
.	0	O


When	0	O
expressed	0	O
per	0	O
kilogram	0	O
body	0	O
weight	0	O
,	0	O
mean	0	O
GIT	0	O
increased	0	O
in	0	O
the	0	O
dF	0	O
group	0	O
from	0	O
0	0	O
.	0	O
14	0	O
%	0	O
to	0	O
0	0	O
.	0	O
16	0	O
%	0	O
above	0	O
RMR	0	O
,	0	O
with	0	O
a	0	O
significant	0	O
decrease	0	O
from	0	O
0	0	O
.	0	O
15	0	O
%	0	O
to	0	O
0	0	O
.	0	O
13	0	O
%	0	O
in	0	O
the	0	O
P	1	O
group	0	O
.	0	O


Increasing	0	O
the	0	O
phosphorus	0	O
content	0	O
of	0	O
the	0	O
diet	0	O
improved	0	O
the	0	O
reabsorption	0	O
of	0	O
calcium	0	O
and	0	O
magnesium	0	O
.	0	O


The	0	O
murine	0	B
MHC	1	I
class	0	I
I	1	I
genes	0	I
,	0	O
H	1	B
-	0	I
2Dq	0	I
and	0	O
H	1	B
-	0	I
2Lq	0	I
,	0	O
are	0	O
strikingly	0	O
homologous	0	O
to	0	O
each	0	O
other	0	O
,	0	O
H	1	B
-	0	I
2Ld	0	I
,	0	O
and	0	O
two	0	O
genes	0	O
reported	0	O
to	0	O
encode	0	O
tumor	0	O
-	0	O
specific	0	O
antigens	0	O
.	0	O


Further	0	O
observations	0	O
on	0	O
resorption	0	O
in	0	O
guinea	0	O
pigs	0	O
following	0	O
injections	0	O
of	0	O
trypan	0	O
blue	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
p33	0	B
subunit	0	I
of	0	O
eIF3	0	B
plays	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
initiation	0	O
phase	0	O
of	0	O
protein	0	O
synthesis	0	O
and	0	O
that	0	O
its	0	O
RNA	1	O
-	0	O
binding	0	O
domain	0	O
is	0	O
required	0	O
for	0	O
optimal	0	O
activity	0	O
.	0	O


The	0	O
rationale	0	O
for	0	O
continuous	0	O
dopaminergic	0	O
stimulation	0	O
in	0	O
patients	0	O
with	0	O
Parkinson	0	O
'	0	O
s	0	O
disease	0	O
.	0	O


JNK	0	B
and	0	O
p38	0	B
are	0	O
constitutively	0	O
present	0	O
in	0	O
the	0	O
nucleus	0	O
,	0	O
and	0	O
DNA	1	O
-	0	O
bound	0	O
c	0	B
-	0	I
JUN	1	I
and	0	O
ATF	0	B
-	0	I
2	0	I
are	0	O
stably	0	O
contacted	0	O
by	0	O
JNK	0	B
and	0	O
p38	0	B
,	0	O
respectively	0	O
.	0	O


Botulinum	0	B
toxin	0	I
A	1	I
in	0	O
the	0	O
treatment	0	O
of	0	O
hemiplegic	0	O
spastic	0	O
foot	0	O
drop	0	O
--	0	O
clinical	0	O
and	0	O
functional	0	O
outcomes	0	O
.	0	O


The	0	O
serum	0	O
concentration	0	O
of	0	O
iP	1	O
before	0	O
dialysis	0	O
(	0	O
HD	1	O
)	0	O
was	0	O
on	0	O
average	0	O
3	0	O
.	0	O
06	0	O
(+/-	0	O
0	0	O
.	0	O
81	0	O
)	0	O
mmol	0	O
/	0	O
l	0	O
and	0	O
D	1	O
was	0	O
on	0	O
average	0	O
55	0	O
.	0	O
6	0	O
(+/-	0	O
10	0	O
.	0	O
0	0	O
)	0	O
mmol	0	O
.	0	O


M	1	O
.	0	O


Hex	0	B
is	0	O
expressed	0	O
in	0	O
the	0	O
developing	0	O
liver	0	O
coincident	0	O
with	0	O
the	0	O
forkhead	0	B
/	0	O
winged	0	B
helix	0	I
transcription	0	O
factor	0	O
,	0	O
Hepatocyte	1	B
Nuclear	1	I
Factor	1	I
3beta	0	I
(	0	O
HNF3beta	0	B
).	0	O


With	0	O
certain	0	O
exceptions	0	O
the	0	O
method	0	O
was	0	O
considered	0	O
suitable	0	O
in	0	O
the	0	O
routine	0	O
intravenous	0	O
cholangiography	0	O
.	0	O


A	1	O
reduction	0	O
of	0	O
the	0	O
aspartate	0	B
aminotransferase	0	I
activity	0	O
was	0	O
observed	0	O
from	0	O
800	0	O
mg	0	O
/	0	O
kg	0	O
b	0	O
.	0	O
w	0	O
./	0	O
d	0	O
onwards	0	O
.	0	O


As	1	O
PP2A	0	B
exerts	0	O
a	0	O
range	0	O
of	0	O
cellular	0	O
functions	0	O
including	0	O
cell	0	O
cycle	0	O
regulation	0	O
and	0	O
cell	0	O
fate	0	O
determination	0	O
,	0	O
we	0	O
were	0	O
surprised	0	O
to	0	O
find	0	O
that	0	O
these	0	O
embryos	0	O
develop	0	O
normally	0	O
until	0	O
postimplantation	0	O
,	0	O
around	0	O
embryonic	0	O
day	0	O
5	0	O
.	0	O
5	0	O
/	0	O
6	0	O
.	0	O
0	0	O
.	0	O


Biologically	0	O
significant	0	O
amounts	0	O
of	0	O
platelet	0	B
activating	0	I
factor	0	I
were	0	O
eluted	0	O
from	0	O
the	0	O
sorbent	0	O
during	0	O
the	0	O
entire	0	O
treatment	0	O
time	0	O
.	0	O


Differences	0	O
in	0	O
profiles	0	O
of	0	O
viscosity	0	O
variables	0	O
between	0	O
subgroups	0	O
of	0	O
EAD	1	O
in	0	O
RA	1	O
patients	0	O
were	0	O
observed	0	O
.	0	O


Differential	1	O
drawing	0	O
size	0	O
associated	0	O
with	0	O
unilateral	0	O
brain	0	O
damage	0	O
.	0	O


Following	1	O
the	0	O
patients	0	O
during	0	O
a	0	O
course	0	O
of	0	O
therapy	0	O
with	0	O
a	0	O
selective	0	O
vasodilator	0	O
calcium	0	O
antagonist	0	O
,	0	O
the	0	O
beta	0	O
-	0	O
adrenergic	0	O
reflex	0	O
vasodilation	0	O
became	0	O
substantially	0	O
attenuated	0	O
but	0	O
was	0	O
preserved	0	O
during	0	O
a	0	O
placebo	0	O
course	0	O
of	0	O
therapy	0	O
.	0	O


The	0	O
results	0	O
presented	0	O
suggest	0	O
that	0	O
TIQ	0	O
reduces	0	O
the	0	O
turnover	0	O
rate	0	O
of	0	O
the	0	O
nigrostriatal	0	O
dopamine	0	O
neurons	0	O
after	0	O
repeated	0	O
administration	0	O
for	0	O
a	0	O
long	0	O
period	0	O
in	0	O
mice	0	O
.	0	O


In	1	O
a	0	O
longitudinal	0	O
study	0	O
,	0	O
14	0	O
low	0	O
-	0	O
risk	0	O
fetuses	0	O
were	0	O
studied	0	O
at	0	O
2	0	O
-	0	O
week	0	O
intervals	0	O
from	0	O
32	0	O
weeks	0	O
of	0	O
gestation	0	O
onward	0	O
.	0	O


Copyright	0	O
2000	0	O
Academic	0	O
Press	0	O
.	0	O


CCAAT	0	B
displacement	0	I
protein	0	I
binds	0	O
to	0	O
and	0	O
negatively	0	O
regulates	0	O
human	0	O
papillomavirus	0	O
type	0	O
6	0	O
E6	0	B
,	0	O
E7	0	B
,	0	O
and	0	O
E1	1	B
promoters	0	O
.	0	O


METHODS	0	O
:	0	O
Four	0	O
hundred	0	O
fifty	0	O
patients	0	O
with	0	O
the	0	O
diagnosis	0	O
of	0	O
squamous	0	O
cell	0	O
carcinoma	0	O
of	0	O
the	0	O
oral	0	O
cavity	0	O
received	0	O
their	0	O
primary	0	O
treatment	0	O
at	0	O
Roswell	0	O
Park	0	O
Cancer	1	O
Center	1	O
(	0	O
RPCI	0	O
)	0	O
from	0	O
1971	0	O
to	0	O
1991	0	O
.	0	O


The	0	O
yeast	0	B
SSS1	0	I
gene	0	I
is	0	O
essential	0	O
for	0	O
secretory	0	O
protein	0	O
translocation	0	O
and	0	O
encodes	0	O
a	0	O
conserved	0	O
protein	0	O
of	0	O
the	0	O
endoplasmic	0	O
reticulum	0	O
.	0	O


Oculus	1	O
-	0	O
500	0	O
is	0	O
a	0	O
group	0	O
of	0	O
high	0	O
resolution	0	O
imaging	0	O
boards	0	O
for	0	O
use	0	O
with	0	O
IBM	0	O
-	0	O
AT	1	O
and	0	O
compatible	0	O
computers	0	O
.	0	O


Although	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
4E	0	B
-	0	I
BP1	0	I
gene	0	I
alone	0	O
has	0	O
not	0	O
yet	0	O
been	0	O
accomplished	0	O
,	0	O
the	0	O
gene	0	O
was	0	O
expressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
[	0	O
BL21	0	O
(	0	O
DE3	0	O
)]	0	O
as	0	O
a	0	O
fusion	0	O
gene	0	O
with	0	O
the	0	O
glutathione	0	B
-	0	I
S	1	I
-	0	I
transferase	0	I
(	0	O
GST	0	B
)	0	O
gene	0	O
using	0	O
a	0	O
prokaryotic	0	O
gene	0	O
fusion	0	O
vector	0	O
(	0	O
pGEX	0	O
-	0	O
4T	0	O
-	0	O
2	0	O
),	0	O
which	0	O
contains	0	O
a	0	O
gene	0	O
sequence	0	O
coding	0	O
the	0	O
cleavage	0	O
site	0	O
for	0	O
a	0	O
specific	0	O
protease	0	O
,	0	O
alpha	0	B
-	0	I
thrombin	0	I
.	0	O


Regulatory	1	O
regions	0	O
in	0	O
the	0	O
promoter	0	O
and	0	O
third	0	O
intron	0	O
of	0	O
the	0	O
growth	0	B
hormone	0	I
gene	0	I
in	0	I
rainbow	0	I
trout	0	I
,	0	O
Oncorhynchus	0	O
mykiss	0	O
walbaum	0	O
.	0	O


The	0	O
purified	0	O
recombinant	0	O
enzyme	0	O
catalyzed	0	O
specific	0	O
phosphoryl	0	O
transfer	0	O
from	0	O
ATP	1	O
to	0	O
UMP	1	O
and	0	O
CMP	1	O
.	0	O


220	0	O
,	0	O
263	0	O
-	0	O
273	0	O
).	0	O


The	0	O
eluent	0	O
from	0	O
the	0	O
column	0	O
was	0	O
mixed	0	O
with	0	O
the	0	O
chemiluminescent	0	O
solution	0	O
containing	0	O
lucigenin	0	B
and	0	O
Triton	0	O
X	1	O
-	0	O
100	0	O
and	0	O
a	0	O
0	0	O
.	0	O
28	0	O
M	1	O
KOH	1	O
solution	0	O
by	0	O
pumps	0	O
and	0	O
monitored	0	O
by	0	O
a	0	O
chemiluminescence	0	O
detector	0	O
.	0	O


Ceftazidime	1	O
shows	0	O
promise	0	O
as	0	O
single	0	O
-	0	O
agent	0	O
therapy	0	O
for	0	O
serious	0	O
gram	0	O
-	0	O
negative	0	O
bacillary	0	O
infections	0	O
.	0	O


These	0	O
findings	0	O
suggest	0	O
that	0	O
intraarterial	0	O
neoadjuvant	0	O
chemotherapy	0	O
should	0	O
be	0	O
effective	0	O
on	0	O
advanced	0	O
cervical	0	O
cancer	0	O
.	0	O


Such	0	O
studied	0	O
acquired	0	O
with	0	O
low	0	O
energy	0	O
or	0	O
medium	0	O
energy	0	O
collimation	0	O
and	0	O
a	0	O
window	0	O
centered	0	O
on	0	O
the	0	O
159	0	O
keV	1	O
123I	0	O
photopeak	0	O
contain	0	O
appreciable	0	O
septal	0	O
breakthrough	0	O
signals	0	O
originating	0	O
from	0	O
Compton	0	O
scatter	0	O
of	0	O
high	0	O
energy	0	O
photons	0	O
primarily	0	O
from	0	O
124I	0	O
.	0	O


Thirty	0	O
seven	0	O
patients	0	O
(	0	O
amitriptyline	0	O
n	0	O
=	0	O
16	0	O
,	0	O
moclobemide	0	O
n	0	O
=	0	O
21	0	O
)	0	O
completed	0	O
the	0	O
six	0	O
week	0	O
protocol	0	O
,	0	O
which	0	O
was	0	O
conducted	0	O
under	0	O
double	0	O
blind	0	O
conditions	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
second	0	O
RCC1	0	B
-	0	I
like	0	I
motif	0	I
located	0	O
at	0	O
the	0	O
amino	0	O
-	0	O
terminus	0	O
of	0	O
p619	0	B
stimulates	0	O
guanine	0	O
nucleotide	0	O
exchange	0	O
on	0	O
ARF1	0	B
and	0	O
on	0	O
members	0	O
of	0	O
the	0	O
related	0	O
Rab	0	B
proteins	0	I
,	0	O
but	0	O
not	0	O
on	0	O
other	0	O
small	0	B
GTP	1	I
binding	0	I
proteins	0	I
such	0	O
as	0	O
Ran	0	B
or	0	O
R	1	B
-	0	I
Ras2	1	I
/	0	O
TC21	0	B
.	0	O


Carnitine	1	B
palmitoyltransferase	0	I
(	0	I
CPT	1	I
)	0	I
II	0	I
deficiency	0	O
is	0	O
the	0	O
most	0	O
common	0	O
inherited	0	O
disorder	0	O
of	0	O
lipid	0	O
metabolism	0	O
affecting	0	O
skeletal	0	O
muscle	0	O
.	0	O


G	1	B
-	0	I
CSF	1	I
was	0	O
started	0	O
on	0	O
day	0	O
3	0	O
of	0	O
each	0	O
cycle	0	O
(	0	O
5	0	O
microg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
)	0	O
and	0	O
was	0	O
stopped	0	O
the	0	O
day	0	O
before	0	O
the	0	O
last	0	O
apheresis	0	O
or	0	O
when	0	O
absolute	0	O
neutrophil	0	O
count	0	O
was	0	O
above	0	O
0	0	O
.	0	O
5	0	O
x	0	O
10	0	O
(	0	O
9	0	O
)/	0	O
l	0	O
.	0	O


The	0	O
C18	0	O
:	0	O
1	0	O
:	0	O
C10	0	O
value	0	O
is	0	O
a	0	O
convenient	0	O
measure	0	O
of	0	O
these	0	O
changes	0	O
and	0	O
can	0	O
be	0	O
determined	0	O
more	0	O
rapidly	0	O
than	0	O
determining	0	O
all	0	O
the	0	O
lower	0	O
fatty	0	O
acids	0	O
.	0	O


Residues	0	O
removed	0	O
from	0	O
transcripts	0	O
by	0	O
splicing	0	O
were	0	O
identified	0	O
.	0	O


Integrated	0	O
mapping	0	O
analysis	0	O
of	0	O
the	0	O
Werner	0	O
syndrome	0	O
region	0	O
of	0	O
chromosome	0	O
8	0	O
.	0	O


However	0	O
,	0	O
in	0	O
the	0	O
subgroup	0	O
with	0	O
normal	0	O
Ht	1	O
(<	0	O
0	0	O
.	0	O
45	0	O
l	0	O
/	0	O
l	0	O
;	0	O
n	0	O
=	0	O
201	0	O
)	0	O
there	0	O
was	0	O
a	0	O
significant	0	O
reduction	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
of	0	O
the	0	O
mortality	0	O
after	0	O
3	0	O
months	0	O
(	0	O
27	0	O
%	0	O
and	0	O
16	0	O
%,	0	O
respectively	0	O
)	0	O
and	0	O
an	0	O
increase	0	O
of	0	O
independence	0	O
at	0	O
home	0	O
(	0	O
35	0	O
%	0	O
and	0	O
48	0	O
%,	0	O
respectively	0	O
)	0	O
due	0	O
to	0	O
a	0	O
reduction	0	O
of	0	O
the	0	O
viscosity	0	O
by	0	O
means	0	O
of	0	O
haemodilution	0	O
with	0	O
albumin	0	B
(	0	O
a	0	O
specific	0	O
viscosity	0	O
effect	0	O
in	0	O
the	0	O
normovolaemic	0	O
group	0	O
).	0	O


The	0	O
MAP	1	B
kinase	0	I
cascade	0	O
is	0	O
highly	0	O
conserved	0	O
in	0	O
all	0	O
eukaryotes	0	O
and	0	O
involved	0	O
in	0	O
numerous	0	O
cellular	0	O
responses	0	O
.	0	O


Further	0	O
analysis	0	O
of	0	O
this	0	O
DNA	1	O
fragment	0	O
showed	0	O
that	0	O
four	0	O
genes	0	O
are	0	O
present	0	O
encoding	0	O
proteins	0	O
of	0	O
16	0	O
,	0	O
18	0	O
.	0	O
5	0	O
,	0	O
21	0	O
and	0	O
89	0	O
kDal	0	O
.	0	O


In	1	O
electromobility	0	O
shift	0	O
assays	0	O
,	0	O
EWS	1	B
-	0	O
FLI	0	B
-	0	I
1	0	I
binding	0	O
to	0	O
the	0	O
SRE	0	O
is	0	O
detectable	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
SRF	1	B
whereas	0	O
the	0	O
binding	0	O
of	0	O
FLI	0	B
-	0	I
1	0	I
is	0	O
not	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
interaction	0	O
with	0	O
DNA	1	O
is	0	O
the	0	O
step	0	O
which	0	O
limits	0	O
ternary	0	O
complex	0	O
formation	0	O
by	0	O
FLI	0	B
-	0	I
1	0	I
.	0	O


Like	0	O
the	0	O
elicitors	0	O
of	0	O
the	0	O
hypersensitive	0	O
reaction	0	O
(	0	O
HR	1	O
)	0	O
produced	0	O
by	0	O
E	1	O
.	0	O
chrysanthemi	0	O
(	0	O
HarpinEch	0	O
)	0	O
and	0	O
E	1	O
.	0	O
amylovora	0	O
(	0	O
HarpinEa	0	O
),	0	O
the	0	O
deduced	0	O
36	0	O
-	0	O
kDa	1	O
protein	0	O
does	0	O
not	0	O
possess	0	O
a	0	O
typical	0	O
signal	0	O
sequence	0	O
,	0	O
but	0	O
it	0	O
contains	0	O
a	0	O
putative	0	O
membrane	0	O
-	0	O
spanning	0	O
domain	0	O
.	0	O


Study	1	O
on	0	O
the	0	O
evagination	0	O
of	0	O
Cysticercus	1	O
pisiformis	0	O
.	0	O


Histogenetic	1	O
aspects	0	O
of	0	O
mesoblastic	0	O
nephroma	0	O
.	0	O


Chronic	1	O
thyroiditis	0	O
as	0	O
a	0	O
risk	0	O
factor	0	O
of	0	O
B	1	O
-	0	O
cell	0	O
lymphoma	0	O
in	0	O
the	0	O
thyroid	0	O
gland	0	O
.	0	O


Takayasu	0	O
'	0	O
s	0	O
disease	0	O
:	0	O
association	0	O
with	0	O
HLA	1	B
-	0	I
B5	0	I
.	0	O


A	1	O
.,	0	O
Swift	0	O
,	0	O
A	1	O
.	0	O


XXI	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
negatively	0	O
regulatory	0	O
region	0	O
may	0	O
exist	0	O
from	0	O
-	0	O
1782	0	O
to	0	O
-	0	O
1295	0	O
bp	0	O
.	0	O


The	0	O
cDNA	1	O
clone	0	O
was	0	O
used	0	O
as	0	O
a	0	O
homologous	0	O
probe	0	O
to	0	O
isolate	0	O
a	0	O
truncated	0	O
genomic	0	O
clone	0	O
encoding	0	O
H2A1	0	B
.	0	O


In	1	O
this	0	O
study	0	O
we	0	O
examined	0	O
hepatic	0	O
stellate	0	O
cell	0	O
regulation	0	O
of	0	O
M6P	0	B
/	0	O
IGFIIR	0	B
expression	0	O
and	0	O
found	0	O
that	0	O
M6P	0	B
/	0	O
IGFIIR	0	B
mRNA	1	O
transcript	0	O
levels	0	O
increased	0	O
in	0	O
stellate	0	O
cells	0	O
from	0	O
rats	0	O
exposed	0	O
to	0	O
carbon	0	O
tetrachloride	0	O
(	0	O
CCl4	0	O
),	0	O
a	0	O
potent	0	O
fibrogenic	0	O
stimulant	0	O
.	0	O


Ten	0	O
weeks	0	O
after	0	O
reconstruction	0	O
,	0	O
the	0	O
regenerating	0	O
nerves	0	O
already	0	O
resembled	0	O
normal	0	O
nerves	0	O
.	0	O


We	0	O
also	0	O
report	0	O
that	0	O
AHR	0	B
interacts	0	O
with	0	O
COUP	1	B
-	0	I
TF	1	I
in	0	O
transfected	0	O
CV	1	O
-	0	O
1	0	O
cells	0	O
.	0	O


To	1	O
investigate	0	O
the	0	O
potential	0	O
role	0	O
of	0	O
SP1	0	B
,	0	O
we	0	O
examined	0	O
nuclear	0	O
extracts	0	O
from	0	O
HCMV	0	O
-	0	O
infected	0	O
cells	0	O
.	0	O


T2	0	O
cancers	0	O
should	0	O
not	0	O
be	0	O
excluded	0	O
from	0	O
the	0	O
benefit	0	O
of	0	O
preoperative	0	O
irradiation	0	O
.	0	O


When	0	O
differentiated	0	O
G0	0	O
-	0	O
arrested	0	O
leaf	0	O
cells	0	O
were	0	O
induced	0	O
to	0	O
resume	0	O
cell	0	O
division	0	O
by	0	O
treatment	0	O
with	0	O
plant	0	O
hormones	0	O
,	0	O
cycMs4	0	B
transcription	0	O
was	0	O
induced	0	O
before	0	O
the	0	O
onset	0	O
of	0	O
DNA	1	O
synthesis	0	O
.	0	O


Since	0	O
considerable	0	O
variations	0	O
in	0	O
length	0	O
and	0	O
primary	0	O
sequence	0	O
in	0	O
the	0	O
CDR3	0	B
(	0	O
complementarity	0	B
determining	0	I
region	0	I
)	0	O
peptides	0	O
of	0	O
all	0	O
the	0	O
H	1	B
-	0	I
chains	0	I
are	0	O
evident	0	O
,	0	O
conservation	0	O
of	0	O
the	0	O
D	1	B
-	0	I
region	0	I
structure	0	O
does	0	O
not	0	O
appear	0	O
to	0	O
be	0	O
necessary	0	O
for	0	O
effective	0	O
hapten	0	O
binding	0	O
.	0	O


The	0	O
4	0	O
degrees	0	O
stimuli	0	O
were	0	O
found	0	O
to	0	O
elicit	0	O
scalp	0	O
distributions	0	O
for	0	O
the	0	O
pattern	0	O
reversal	0	O
P100	0	O
and	0	O
the	0	O
pattern	0	O
onset	0	O
C1	1	O
consistent	0	O
with	0	O
striate	0	O
and	0	O
extrastriate	0	O
visual	0	O
cortical	0	O
origins	0	O
respectively	0	O
.	0	O


Removal	0	O
of	0	O
beta	0	B
2	0	I
-	0	I
microglobulin	0	I
by	0	O
hemodialysis	0	O
and	0	O
hemofiltration	0	O
:	0	O
a	0	O
four	0	O
year	0	O
follow	0	O
up	0	O
.	0	O


Genomic	1	O
organization	0	O
of	0	O
the	0	O
human	0	O
phosphodiesterase	0	B
PDE11A	0	I
gene	0	I
.	0	O


Alanine	1	B
aminotransferase	0	I
(	0	O
ALT	1	B
)	0	O
levels	0	O
had	0	O
been	0	O
elevated	0	O
for	0	O
six	0	O
months	0	O
in	0	O
all	0	O
patients	0	O
and	0	O
hepatitis	0	O
B	1	O
viral	0	O
infection	0	O
was	0	O
replicative	0	O
.	0	O


The	0	O
protein	0	O
coding	0	O
region	0	O
,	0	O
1	0	O
,	0	O
696	0	O
bps	0	O
long	0	O
,	0	O
is	0	O
divided	0	O
by	0	O
an	0	O
intron	0	O
into	0	O
two	0	O
exons	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
found	0	O
differences	0	O
in	0	O
the	0	O
binding	0	O
of	0	O
nuclear	0	O
factors	0	O
from	0	O
shoots	0	O
versus	0	O
from	0	O
roots	0	O
,	0	O
in	0	O
agreement	0	O
with	0	O
the	0	O
different	0	O
activities	0	O
of	0	O
the	0	O
promoter	0	O
in	0	O
these	0	O
two	0	O
organs	0	O
.	0	O


Effects	0	O
of	0	O
alcoholism	0	O
on	0	O
the	0	O
family	0	O


A	1	O
single	0	O
amino	0	O
acid	0	O
difference	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
influences	0	O
dominant	0	O
negative	0	O
activity	0	O
and	0	O
receptor	0	O
dimer	0	O
formation	0	O
.	0	O


Two	0	O
evolutionarily	0	O
conserved	0	O
kinases	0	O
,	0	O
the	0	O
cyclin	0	B
B	1	I
(	0	O
Clb	0	B
)/	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinase	0	I
(	0	O
Cdk	1	B
/	0	O
Cdc28p	0	B
)	0	O
and	0	O
Cdc7p	0	B
along	0	O
with	0	O
its	0	O
interacting	0	O
factor	0	O
Dbf4p	0	B
,	0	O
are	0	O
required	0	O
late	0	O
in	0	O
G1	0	O
to	0	O
initiate	0	O
DNA	1	O
replication	0	O
.	0	O


The	0	O
centromeric	0	O
YAC	1	O
contig	0	O
,	0	O
which	0	O
consists	0	O
of	0	O
23	0	O
overlapping	0	O
YACs	0	O
and	0	O
orders	0	O
19	0	O
sequence	0	O
-	0	O
tagged	0	O
sites	0	O
(	0	O
STSs	0	O
),	0	O
covers	0	O
a	0	O
minimum	0	O
of	0	O
2	0	O
.	0	O
2	0	O
Mb	1	O
and	0	O
spans	0	O
the	0	O
Ewing	0	O
sarcoma	0	O
breakpoint	0	O
.	0	O
c	0	B
-	0	I
ets	0	I
1	0	I
and	0	O
Fli	0	B
-	0	I
1	0	I
,	0	O
two	0	O
members	0	O
of	0	O
the	0	O
ets	0	B
family	0	I
,	0	O
have	0	O
been	0	O
linked	0	O
within	0	O
400	0	O
kb	0	O
of	0	O
intervening	0	O
DNA	1	O
within	0	O
this	0	O
contig	0	O
,	0	O
which	0	O
also	0	O
comprises	0	O
a	0	O
polymorphic	0	O
microsatellite	0	O
,	0	O
D11S912	0	B
(	0	O
CA	1	O
)	0	O
n	0	O
,	0	O
which	0	O
we	0	O
have	0	O
localized	0	O
within	0	O
the	0	O
Fli	0	B
-	0	I
1	0	I
gene	0	I
.	0	O


During	0	O
the	0	O
period	0	O
from	0	O
May	0	O
to	0	O
August	0	O
,	0	O
1978	0	O
,	0	O
an	0	O
epidemic	0	O
of	0	O
hand	0	O
,	0	O
foot	0	O
and	0	O
mouth	0	O
disease	0	O
(	0	O
HFMD	0	O
)	0	O
occurred	0	O
in	0	O
Gifu	0	O
prefecture	0	O
.	0	O


Fluorescence	1	O
in	0	O
situ	0	O
hybridization	0	O
of	0	O
metaphase	0	O
spreads	0	O
of	0	O
chromosome	0	O
8	0	O
,	0	O
containing	0	O
hybrid	0	O
cell	0	O
line	0	O
706	0	O
-	0	O
B6	0	O
clone	0	O
17	0	O
(	0	O
CL	1	O
-	0	O
17	0	O
)	0	O
with	0	O
cosmid	0	O
c101F1	0	O
,	0	O
placed	0	O
the	0	O
9804	0	B
gene	0	I
close	0	O
to	0	O
the	0	O
telomere	0	O
at	0	O
8q24	0	O
.	0	O
3	0	O
.	0	O


No	1	O
local	0	O
destruction	0	O
by	0	O
tumor	0	O
or	0	O
infection	0	O
could	0	O
be	0	O
demonstrated	0	O
apart	0	O
from	0	O
HIV	1	O
infection	0	O
.	0	O


Immunodepression	1	O
was	0	O
combined	0	O
with	0	O
the	0	O
increase	0	O
of	0	O
glucocorticoid	0	O
activity	0	O
of	0	O
adrenal	0	O
cortex	0	O
,	0	O
while	0	O
no	0	O
significant	0	O
changes	0	O
in	0	O
thyroid	0	O
hormones	0	O
were	0	O
registered	0	O
.	0	O


Polypeptide	1	O
growth	0	O
factors	0	O
and	0	O
cytokines	0	O
mediate	0	O
their	0	O
biochemical	0	O
functions	0	O
through	0	O
their	0	O
responsive	0	O
receptors	0	O
.	0	O


Depletion	1	O
of	0	O
dopamine	0	O
in	0	O
the	0	O
nucleus	0	O
accumbens	0	O
led	0	O
to	0	O
a	0	O
dramatic	0	O
shift	0	O
in	0	O
behavior	0	O
in	0	O
which	0	O
there	0	O
was	0	O
a	0	O
significant	0	O
decrease	0	O
in	0	O
lever	0	O
pressing	0	O
but	0	O
a	0	O
significant	0	O
increase	0	O
in	0	O
consumption	0	O
of	0	O
lab	0	O
chow	0	O
.	0	O


A	1	O
critical	0	O
heart	0	O
rate	0	O
and	0	O
/	0	O
or	0	O
appropriate	0	O
sympathetic	0	O
state	0	O
was	0	O
found	0	O
to	0	O
provoke	0	O
all	0	O
instances	0	O
of	0	O
reentrant	0	O
or	0	O
automatic	0	O
atrial	0	O
tachycardia	0	O
and	0	O
atypical	0	O
junctional	0	O
tachycardia	0	O
.	0	O


Regions	0	O
of	0	O
the	0	O
translated	0	O
open	0	O
reading	0	O
frames	0	O
of	0	O
cobA	0	B
and	0	O
the	0	O
third	0	O
intron	0	O
of	0	O
the	0	O
cob	0	B
gene	0	I
in	0	I
yeast	0	I
show	0	O
high	0	O
amino	0	O
acid	0	O
homology	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
have	0	O
examined	0	O
the	0	O
regulation	0	O
of	0	O
B	1	B
-	0	I
Myb	0	I
activity	0	O
by	0	O
cyclin	0	B
-	0	O
Cdks	0	B
.	0	O


The	0	O
[	0	O
18F	0	O
]	0	O
FMISO	0	O
TMRR	0	O
is	0	O
a	0	O
simple	0	O
and	0	O
clinically	0	O
useful	0	O
index	0	O
for	0	O
detecting	0	O
tumour	0	O
hypoxia	0	O
in	0	O
NPC	0	O
.	0	O


Rheumatoid	1	B
factor	0	I
and	0	O
antinuclear	0	O
antibody	0	O
tests	0	O
were	0	O
frequently	0	O
positive	0	O
,	0	O
and	0	O
reactions	0	O
to	0	O
gold	0	O
therapy	0	O
were	0	O
more	0	O
frequent	0	O
than	0	O
in	0	O
other	0	O
rheumatoid	0	O
populations	0	O
.	0	O


Light	1	B
regulatory	0	I
unit	0	I
1	0	I
(	0	O
LRU1	0	B
)	0	O
is	0	O
necessary	0	O
for	0	O
and	0	O
sufficient	0	O
to	0	O
mediate	0	O
light	0	O
-	0	O
dependent	0	O
activation	0	O
of	0	O
the	0	O
chalcone	0	B
synthase	0	I
(	0	I
CHS	1	I
)	0	I
minimal	0	I
promoter	0	I
in	0	O
Petroselinum	0	O
crispum	0	O
.	0	O


This	0	O
paper	0	O
presents	0	O
the	0	O
reasons	0	O
why	0	O
countries	0	O
to	0	O
which	0	O
Chagas	0	O
disease	0	O
is	0	O
endemic	0	O
should	0	O
carry	0	O
out	0	O
the	0	O
relevant	0	O
research	0	O
themselves	0	O
.	0	O


Factors	0	O
affecting	0	O
the	0	O
inhibition	0	O
of	0	O
phagocytosis	0	O
by	0	O
chlorpromazine	0	O
.	0	O


Gel	1	O
mobility	0	O
shift	0	O
assays	0	O
indicated	0	O
that	0	O
at	0	O
least	0	O
four	0	O
nuclear	0	O
proteins	0	O
with	0	O
distinct	0	O
biochemical	0	O
and	0	O
binding	0	O
properties	0	O
possess	0	O
the	0	O
ability	0	O
to	0	O
bind	0	O
the	0	O
3	0	O
beta	0	O
I	1	O
-	0	O
A	1	O
element	0	O
to	0	O
produce	0	O
four	0	O
DNA	1	O
-	0	O
protein	0	O
complexes	0	O
(	0	O
R1	0	O
to	0	O
R4	0	O
).	0	O


Such	0	O
a	0	O
mechanism	0	O
may	0	O
allow	0	O
acceleration	0	O
of	0	O
degenerative	0	O
joint	0	O
conditions	0	O
,	0	O
and	0	O
may	0	O
account	0	O
for	0	O
the	0	O
increased	0	O
prevalence	0	O
of	0	O
such	0	O
conditions	0	O
seen	0	O
with	0	O
HMS	1	O
subjects	0	O
.	0	O


100	0	O
more	0	O
than	0	O
in	0	O
the	0	O
summer	0	O
coat	0	O
).	0	O


In	1	O
silicosis	0	O
,	0	O
significant	0	O
relationships	0	O
between	0	O
patients	0	O
and	0	O
sons	0	O
were	0	O
not	0	O
seen	0	O
with	0	O
respect	0	O
to	0	O
arterial	0	O
blood	0	O
gas	0	O
determinations	0	O
and	0	O
ventilatory	0	O
responses	0	O
except	0	O
for	0	O
Paco2	1	O
of	0	O
patients	0	O
and	0	O
hypercapnic	0	O
ventilatory	0	O
responses	0	O
of	0	O
sons	0	O
.	0	O


To	1	O
begin	0	O
to	0	O
characterize	0	O
the	0	O
role	0	O
of	0	O
the	0	O
RNA	1	O
subunits	0	O
in	0	O
enzyme	0	O
function	0	O
and	0	O
substrate	0	O
specificity	0	O
,	0	O
we	0	O
swapped	0	O
two	0	O
hairpin	0	O
structures	0	O
(	0	O
MRP3	0	O
and	0	O
P3	0	O
)	0	O
between	0	O
RNase	1	B
MRP	0	I
RNA	1	I
and	0	O
RNase	1	B
P	1	I
RNA	1	I
of	0	I
S	1	I
.	0	I
cerevisiae	0	I
.	0	O


Temafloxacin	0	O
400	0	O
mg	0	O
b	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.	0	O
administered	0	O
orally	0	O
for	0	O
28	0	O
days	0	O
represents	0	O
a	0	O
safe	0	O
and	0	O
effective	0	O
treatment	0	O
for	0	O
chronic	0	O
bacterial	0	O
prostatitis	0	O
.	0	O


All	1	O
injections	0	O
of	0	O
CSF	1	B
were	0	O
given	0	O
after	0	O
the	0	O
initiation	0	O
of	0	O
neutropenia	0	O
and	0	O
continued	0	O
until	0	O
the	0	O
occurrence	0	O
of	0	O
an	0	O
absolute	0	O
neutrophil	0	O
recovery	0	O
.	0	O
rHu	0	B
GM	1	I
-	0	I
CSF	1	I
and	0	O
rHu	0	B
G	1	I
-	0	I
CSF	1	I
,	0	O
administered	0	O
once	0	O
daily	0	O
at	0	O
the	0	O
250	0	O
microg	0	O
m	0	O
(-	0	O
2	0	O
)	0	O
day	0	O
(-	0	O
1	0	O
)	0	O
and	0	O
5	0	O
microg	0	O
kg	0	O
(-	0	O
1	0	O
)	0	O
day	0	O
(-	0	O
1	0	O
)	0	O
level	0	O
,	0	O
were	0	O
effective	0	O
in	0	O
increasing	0	O
the	0	O
absolute	0	O
neutrophil	0	O
count	0	O
and	0	O
neutrophil	0	O
function	0	O
,	0	O
as	0	O
measured	0	O
by	0	O
an	0	O
automated	0	O
chemiluminescence	0	O
system	0	O
.	0	O


Grade	1	O
3	0	O
-	0	O
4	0	O
mucositis	0	O
was	0	O
present	0	O
in	0	O
13	0	O
%	0	O
of	0	O
the	0	O
cycles	0	O
.	0	O


The	0	O
murine	0	O
chromosomal	0	O
locations	0	O
of	0	O
the	0	O
five	0	O
NMDA	1	B
receptor	0	I
channel	0	I
subunits	0	I
,	0	O
the	0	O
epsilon	0	B
1	0	I
(	0	O
Grin2a	0	B
),	0	O
epsilon	0	B
2	0	I
(	0	O
Grin2b	0	B
),	0	O
epsilon	0	B
3	0	I
(	0	O
Grin2c	0	B
),	0	O
epsilon	0	B
4	0	I
(	0	O
Grin2d	0	B
)	0	O
and	0	O
zeta	0	B
1	0	I
(	0	O
Grinl	0	B
)	0	O
subunits	0	O
,	0	O
were	0	O
determined	0	O
using	0	O
an	0	O
interspecific	0	O
backcross	0	O
mapping	0	O
panel	0	O
derived	0	O
from	0	O
crosses	0	O
of	0	O
[(	0	O
C57BL	0	O
/	0	O
6JxM	0	O
.	0	O
spretus	0	O
)	0	O
F1xC57BL	0	O
/	0	O
6J	0	O
]	0	O
mice	0	O
.	0	O


The	0	O
ZnF20	0	B
cDNA	1	I
hybridized	0	O
to	0	O
multiple	0	O
transcripts	0	O
in	0	O
a	0	O
thyroid	0	O
cancer	0	O
cell	0	O
line	0	O
(	0	O
8	0	O
.	0	O
0	0	O
,	0	O
4	0	O
.	0	O
5	0	O
and	0	O
2	0	O
kb	0	O
)	0	O
that	0	O
increased	0	O
after	0	O
cycloheximide	0	O
treatment	0	O
and	0	O
decayed	0	O
<	0	O
2	0	O
h	0	O
after	0	O
addition	0	O
of	0	O
actinomycin	0	O
D	1	O
.	0	O


The	0	O
DNA	1	O
sequences	0	O
predict	0	O
proteins	0	O
for	0	O
SRP54sc	0	B
and	0	O
SRP54sp	0	B
that	0	O
are	0	O
47	0	O
%	0	O
and	0	O
52	0	O
%	0	O
identical	0	O
to	0	O
SRP54mam	0	B
,	0	O
respectively	0	O
.	0	O


Identification	1	O
of	0	O
an	0	O
immediate	0	B
-	0	I
early	0	I
gene	0	I
in	0	O
the	0	O
Marek	0	O
'	0	O
s	0	O
disease	0	O
virus	0	O
long	0	O
internal	0	O
repeat	0	O
region	0	O
which	0	O
encodes	0	O
a	0	O
unique	0	O
14	0	O
-	0	O
kilodalton	0	O
polypeptide	0	O
.	0	O


Differential	1	O
expression	0	O
of	0	O
AP	1	B
-	0	I
2alpha	0	I
and	0	O
AP	1	B
-	0	I
2beta	0	I
in	0	O
the	0	O
developing	0	O
chick	0	O
retina	0	O
:	0	O
repression	0	O
of	0	O
R	1	B
-	0	I
FABP	0	I
promoter	0	I
activity	0	O
by	0	O
AP	1	B
-	0	I
2	0	I
.	0	O


Teratological	0	O
studies	0	O
on	0	O
SF	1	O
-	0	O
837	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
systemic	0	O
glucose	0	O
concentration	0	O
on	0	O
brain	0	O
metabolism	0	O
following	0	O
repeated	0	O
brain	0	O
ischemia	0	O
.	0	O


Induction	1	O
of	0	O
AtP5CS1	0	B
mRNA	1	I
accumulation	0	O
in	0	O
salt	0	O
-	0	O
treated	0	O
seedlings	0	O
involves	0	O
an	0	O
immediate	0	O
early	0	O
transcriptional	0	O
response	0	O
regulated	0	O
by	0	O
ABA	0	O
signalling	0	O
that	0	O
is	0	O
not	0	O
inhibited	0	O
by	0	O
cycloheximide	0	O
,	0	O
but	0	O
abolished	0	O
by	0	O
the	0	O
deficiency	0	O
of	0	O
ABA	0	O
biosynthesis	0	O
in	0	O
the	0	O
aba1	0	B
Arabidopsis	0	I
mutant	0	I
.	0	O


Here	0	O
we	0	O
demonstrate	0	O
that	0	O
the	0	O
mechanism	0	O
of	0	O
activation	0	O
of	0	O
HIF	0	B
-	0	I
1alpha	0	I
is	0	O
a	0	O
multi	0	O
-	0	O
step	0	O
process	0	O
which	0	O
includes	0	O
hypoxia	0	O
-	0	O
dependent	0	O
nuclear	0	O
import	0	O
and	0	O
activation	0	O
(	0	O
derepression	0	O
)	0	O
of	0	O
the	0	O
transactivation	0	O
domain	0	O
,	0	O
resulting	0	O
in	0	O
recruitment	0	O
of	0	O
the	0	O
CREB	0	B
-	0	I
binding	0	I
protein	0	I
(	0	O
CBP	0	B
)/	0	O
p300	0	B
coactivator	0	I
.	0	O


Sternocleidomastoid	1	O
,	0	O
neck	0	O
or	0	O
facial	0	O
muscles	0	O
wasting	0	O
were	0	O
also	0	O
found	0	O
in	0	O
three	0	O
cases	0	O
.	0	O


It	1	O
can	0	O
also	0	O
be	0	O
used	0	O
to	0	O
examine	0	O
various	0	O
laryngeal	0	O
parameters	0	O
obtained	0	O
from	0	O
videotaped	0	O
endoscopic	0	O
and	0	O
stroboscopic	0	O
examinations	0	O
.	0	O


Molecular	1	O
characterization	0	O
of	0	O
a	0	O
large	0	O
Borrelia	1	O
burgdorferi	0	O
motility	0	O
operon	0	O
which	0	O
is	0	O
initiated	0	O
by	0	O
a	0	O
consensus	0	O
sigma70	0	B
promoter	0	I
.	0	O


Under	0	O
resting	0	O
conditions	0	O
,	0	O
activity	0	O
levels	0	O
of	0	O
cardiac	0	O
vagal	0	O
and	0	O
sympathetic	0	O
outflows	0	O
are	0	O
not	0	O
related	0	O
across	0	O
young	0	O
,	0	O
healthy	0	O
human	0	O
subjects	0	O
and	0	O
peripheral	0	O
interaction	0	O
is	0	O
not	0	O
manifest	0	O
between	0	O
the	0	O
autonomic	0	O
divisions	0	O
.	0	O


PURPOSE	0	O
/	0	O
OBJECTIVES	0	O
:	0	O
To	1	O
examine	0	O
the	0	O
question	0	O
of	0	O
whether	0	O
an	0	O
early	0	O
first	0	O
full	0	O
-	0	O
term	0	O
pregnancy	0	O
(	0	O
FFTP	0	O
)	0	O
protects	0	O
against	0	O
breast	0	O
cancer	0	O
and	0	O
whether	0	O
interruption	0	O
of	0	O
the	0	O
pregnancy	0	O
with	0	O
an	0	O
induced	0	O
abortion	0	O
increases	0	O
breast	0	O
cancer	0	O
risk	0	O
.	0	O


USA	0	O
80	0	O
,	0	O
802	0	O
-	0	O
806	0	O
]	0	O
was	0	O
used	0	O
to	0	O
isolate	0	O
a	0	O
genomic	0	O
clone	0	O
lambda	0	O
PGK	0	B
-	0	I
1	0	I
containing	0	O
a	0	O
portion	0	O
of	0	O
an	0	O
autosomal	0	O
locus	0	O
for	0	O
phosphoglycerate	0	B
kinase	0	I
(	0	O
PGK	0	B
).	0	O


The	0	O
results	0	O
imply	0	O
that	0	O
kindling	0	O
does	0	O
not	0	O
produce	0	O
its	0	O
facilitating	0	O
effect	0	O
on	0	O
acquisition	0	O
of	0	O
HPC	0	O
SS	1	O
by	0	O
removing	0	O
a	0	O
disruptive	0	O
effect	0	O
of	0	O
the	0	O
stimulation	0	O
.	0	O


In	1	O
Schizosaccharomyces	0	O
pombe	0	O
,	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
M	1	O
-	0	O
phase	0	O
-	0	O
inducing	0	O
Cdc2	0	B
/	0	O
Cdc13	0	B
cyclin	0	O
-	0	O
dependent	0	O
kinase	0	O
is	0	O
inhibited	0	O
by	0	O
Wee1	0	B
and	0	O
Mik1	0	B
tyrosine	0	I
kinases	0	I
,	0	O
and	0	O
activated	0	O
by	0	O
Cdc25	0	B
and	0	O
Pyp3	0	B
tyrosine	0	I
phosphatases	0	I
.	0	O


Rarely	0	O
,	0	O
patients	0	O
with	0	O
locally	0	O
advanced	0	O
,	0	O
uncontrollable	0	O
,	0	O
non	0	O
-	0	O
metastatic	0	O
prostatic	0	O
cancer	0	O
enjoy	0	O
prolonged	0	O
survival	0	O
.	0	O


The	0	O
hormonal	0	O
response	0	O
to	0	O
a	0	O
standardized	0	O
bicycle	0	O
exercise	0	O
test	0	O
was	0	O
studied	0	O
in	0	O
11	0	O
male	0	O
cadets	0	O
exposed	0	O
to	0	O
a	0	O
course	0	O
of	0	O
107	0	O
h	0	O
of	0	O
continuous	0	O
activity	0	O
with	0	O
less	0	O
than	0	O
2	0	O
h	0	O
sleep	0	O
.	0	O


Risk	1	O
of	0	O
infection	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
fractures	0	O


Delayed	0	O
hypersensitivity	0	O
in	0	O
man	0	O
:	0	O
effects	0	O
of	0	O
systemic	0	O
anticoagulation	0	O
.	0	O


We	0	O
have	0	O
cloned	0	O
and	0	O
sequenced	0	O
a	0	O
region	0	O
encoding	0	O
a	0	O
lipase	0	B
operon	0	I
and	0	O
a	0	O
putative	0	O
,	0	O
previously	0	O
uncharacterized	0	O
metalloprotease	0	B
of	0	I
Vibrio	1	I
cholerae	0	I
O1	0	I
.	0	O


It	1	O
contains	0	O
three	0	O
putative	0	O
binding	0	O
sites	0	O
for	0	O
transcription	0	B
factor	0	I
Sp1	0	I
as	0	O
well	0	O
as	0	O
several	0	O
short	0	O
sequences	0	O
that	0	O
are	0	O
similar	0	O
to	0	O
known	0	O
cis	0	O
-	0	O
acting	0	O
enhancers	0	O
or	0	O
binding	0	O
sites	0	O
for	0	O
transcription	0	O
factors	0	O
.	0	O


Inhibition	1	O
assays	0	O
performed	0	O
with	0	O
over	0	O
30	0	O
different	0	O
natural	0	O
and	0	O
synthetic	0	O
sialylated	0	O
and	0	O
/	0	O
or	0	O
sulfated	0	O
compounds	0	O
are	0	O
utilized	0	O
to	0	O
define	0	O
in	0	O
greater	0	O
detail	0	O
specific	0	O
structural	0	O
features	0	O
involved	0	O
in	0	O
oligosaccharide	0	O
-	0	O
protein	0	O
binding	0	O
.	0	O


The	0	O
primary	0	O
CT	1	O
findings	0	O
were	0	O
misinterpreted	0	O
as	0	O
a	0	O
brain	0	O
infarct	0	O
or	0	O
possibly	0	O
a	0	O
tumour	0	O
.	0	O


RESULTS	0	O
:	0	O
Surprisingly	0	O
,	0	O
PAF	1	B
blockade	0	O
increased	0	O
mortality	0	O
after	0	O
trauma	0	O
(	0	O
5	0	O
of	0	O
11	0	O
WEB	1	O
-	0	O
2086	0	O
animals	0	O
versus	0	O
1	0	O
of	0	O
9	0	O
vehicle	0	O
animals	0	O
;	0	O
p	0	O
=	0	O
0	0	O
.	0	O
15	0	O
)	0	O
and	0	O
depressed	0	O
cardiac	0	O
index	0	O
and	0	O
O2	1	O
delivery	0	O
at	0	O
72	0	O
hours	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


UK	1	O
'	0	O
s	0	O
biotechnology	0	O
lacking	0	O
specialists	0	O
.	0	O


In	1	O
the	0	O
course	0	O
of	0	O
a	0	O
study	0	O
of	0	O
low	0	O
dose	0	O
X	1	O
-	0	O
rays	0	O
effects	0	O
,	0	O
we	0	O
found	0	O
that	0	O
male	0	O
ICR	0	O
white	0	O
Swiss	0	O
mice	0	O
showed	0	O
remarkable	0	O
suppression	0	O
of	0	O
mounting	0	O
behavior	0	O
after	0	O
whole	0	O
body	0	O
irradiation	0	O
by	0	O
5	0	O
to	0	O
15	0	O
cGy	1	O
X	1	O
-	0	O
rays	0	O
.	0	O


In	1	O
the	0	O
studies	0	O
described	0	O
in	0	O
this	0	O
report	0	O
,	0	O
we	0	O
have	0	O
investigated	0	O
the	0	O
signaling	0	O
pathway	0	O
(	0	O
s	0	O
)	0	O
that	0	O
are	0	O
responsible	0	O
for	0	O
CREB	0	B
activation	0	O
in	0	O
normal	0	O
T	1	O
cells	0	O
.	0	O


Althoug	0	O
RBF	0	O
tended	0	O
to	0	O
increase	0	O
after	0	O
the	0	O
therapy	0	O
,	0	O
there	0	O
was	0	O
no	0	O
statistically	0	O
significant	0	O
change	0	O
in	0	O
RBF	0	O
,	0	O
GFR	1	O
and	0	O
cardiac	0	O
output	0	O
.	0	O


Soft	1	O
-	0	O
x	0	O
-	0	O
ray	0	O
lasing	0	O
at	0	O
32	0	O
.	0	O
6	0	O
nm	0	O
in	0	O
Ne	1	O
-	0	O
like	0	O
Ti	1	O
ions	0	O
driven	0	O
by	0	O
40	0	O
J	1	O
of	0	O
energy	0	O
from	0	O
two	0	O
650	0	O
-	0	O
ps	0	O
laser	0	O
pulses	0	O
.	0	O


Efforts	0	O
were	0	O
made	0	O
to	0	O
determine	0	O
the	0	O
amount	0	O
of	0	O
time	0	O
required	0	O
for	0	O
kidney	0	O
lesions	0	O
to	0	O
develop	0	O
and	0	O
,	0	O
if	0	O
possible	0	O
,	0	O
to	0	O
delineate	0	O
the	0	O
potential	0	O
site	0	O
of	0	O
action	0	O
of	0	O
PBB	1	O
.	0	O


The	0	O
neuroleptic	0	O
-	0	O
induced	0	O
increase	0	O
in	0	O
central	0	O
DA	1	O
turnover	0	O
(	0	O
an	0	O
indicator	0	O
for	0	O
the	0	O
degree	0	O
of	0	O
DA	1	B
receptor	0	I
blocking	0	O
)	0	O
was	0	O
found	0	O
to	0	O
be	0	O
positively	0	O
correlated	0	O
with	0	O
the	0	O
therapeutic	0	O
effect	0	O
of	0	O
neuroleptics	0	O
and	0	O
the	0	O
development	0	O
of	0	O
hypokinetic	0	O
-	0	O
rigid	0	O
symptoms	0	O
.	0	O


Pretreatment	1	O
of	0	O
cells	0	O
or	0	O
mouse	0	O
skin	0	O
with	0	O
antisense	0	O
oligonucleotides	0	O
of	0	O
PKCzeta	0	B
impaired	0	O
UV	1	O
-	0	O
induced	0	O
activation	0	O
of	0	O
AP	1	B
-	0	I
1	0	I
in	0	O
JB6	0	O
cells	0	O
as	0	O
well	0	O
as	0	O
in	0	O
AP	1	B
-	0	I
1	0	I
-	0	O
luciferase	0	B
transgenic	0	O
mice	0	O
.	0	O


Targeted	0	O
disruption	0	O
of	0	O
the	0	O
OGG1	0	B
gene	0	I
in	0	O
yeast	0	O
revealed	0	O
a	0	O
second	0	O
OG	0	B
glycosylase	0	I
/	0	I
lyase	0	I
protein	0	I
,	0	O
tentatively	0	O
named	0	O
Ogg2	0	B
,	0	O
which	0	O
differs	0	O
from	0	O
Ogg1	0	B
in	0	O
that	0	O
it	0	O
preferentially	0	O
acts	0	O
on	0	O
OG	0	O
:	0	O
G	1	O
.	0	O


Specialized	0	O
actin	0	B
tails	0	O
that	0	O
propel	0	O
IEV	0	O
particles	0	O
to	0	O
the	0	O
periphery	0	O
and	0	O
virus	0	O
-	0	O
tipped	0	O
microvilli	0	O
(	0	O
both	0	O
common	0	O
in	0	O
wild	0	O
-	0	O
type	0	O
-	0	O
infected	0	O
cells	0	O
)	0	O
were	0	O
absent	0	O
in	0	O
cells	0	O
infected	0	O
with	0	O
vA33delta	0	O
.	0	O


Chimaeric	0	O
VP16	0	B
-	0	O
E2	1	B
molecules	0	O
suggest	0	O
that	0	O
the	0	O
epithelial	0	O
specific	0	O
transcriptional	0	O
activation	0	O
of	0	O
the	0	O
BPV	1	B
-	0	I
4	0	I
LCR	1	I
promoter	0	I
is	0	O
mediated	0	O
by	0	O
the	0	O
E2	1	B
transactivation	0	I
domain	0	I
.	0	O


Our	0	O
previous	0	O
study	0	O
suggested	0	O
that	0	O
pertussis	0	B
toxin	0	I
(	0	O
IAP	1	B
)-	0	O
sensitive	0	O
GTP	1	B
-	0	I
binding	0	I
protein	0	I
(	0	I
s	0	I
)	0	I
(	0	O
G	1	B
-	0	I
protein	0	I
)	0	O
is	0	O
involved	0	O
in	0	O
the	0	O
process	0	O
of	0	O
differentiation	0	O
by	0	O
hormones	0	O
/	0	O
IBMX	0	O
,	0	O
accompanied	0	O
by	0	O
c	0	B
-	0	I
fos	0	I
induction	0	O
.	0	O


Restriction	1	O
enzyme	0	O
mapping	0	O
and	0	O
Southern	0	O
analysis	0	O
indicated	0	O
further	0	O
that	0	O
the	0	O
human	0	B
MZF	0	I
-	0	I
1	0	I
gene	0	I
is	0	O
a	0	O
single	0	O
-	0	O
copy	0	O
gene	0	O
.	0	O


Seventy	0	O
-	0	O
one	0	O
percent	0	O
of	0	O
patients	0	O
treated	0	O
with	0	O
ticarcillin	0	O
alone	0	O
responded	0	O
favorably	0	O
.	0	O


Repeated	0	O
efforts	0	O
to	0	O
isolate	0	O
recombinant	0	O
baculoviruses	0	O
containing	0	O
a	0	O
wild	0	O
-	0	O
type	0	O
kinase	0	O
failed	0	O
,	0	O
whereas	0	O
recombinants	0	O
expressing	0	O
a	0	O
nonfunctional	0	O
kinase	0	O
with	0	O
a	0	O
catalytic	0	O
domain	0	O
II	0	O
mutation	0	O
were	0	O
readily	0	O
isolated	0	O
.	0	O


Using	0	O
an	0	O
oligomer	0	O
duplex	0	O
5	0	O
'-	0	O
A	1	O
(	0	O
GGGTTA	0	O
)(	0	O
5	0	O
)-	0	O
3	0	O
'/	0	O
5	0	O
'-(	0	O
TAACCC	0	O
)(	0	O
5	0	O
)	0	O
T	1	O
-	0	O
3	0	O
'	0	O
as	0	O
a	0	O
template	0	O
-	0	O
primer	0	O
,	0	O
we	0	O
show	0	O
that	0	O
both	0	O
the	0	O
Klenow	0	B
fragment	0	I
of	0	I
Escherichia	1	I
coli	0	I
DNA	1	I
polymerase	0	I
I	1	I
and	0	O
HIV	1	B
reverse	0	I
transcriptase	0	I
could	0	O
expand	0	O
telomere	0	O
DNA	1	O
sequences	0	O
as	0	O
well	0	O
,	0	O
giving	0	O
products	0	O
greater	0	O
than	0	O
the	0	O
size	0	O
of	0	O
the	0	O
template	0	O
DNA	1	O
.	0	O


Induction	1	O
of	0	O
both	0	O
potential	0	O
transcripts	0	O
follows	0	O
heat	0	O
shock	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
present	0	O
treatment	0	O
strategy	0	O
in	0	O
progressive	0	O
disorders	0	O
is	0	O
mainly	0	O
based	0	O
on	0	O
the	0	O
complementary	0	O
effect	0	O
of	0	O
intensive	0	O
radiochemotherapy	0	O
,	0	O
autologous	0	O
stem	0	O
-	0	O
cell	0	O
transplantation	0	O
and	0	O
the	0	O
rational	0	O
use	0	O
of	0	O
cytokines	0	O
,	0	O
mostly	0	O
colony	0	B
-	0	I
stimulating	0	I
factors	0	I
.	0	O


The	0	O
Psc2	0	B
cDNA	1	I
contained	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
homologous	0	O
to	0	O
CP2	0	B
family	0	I
proteins	0	I
.	0	O


We	0	O
conclude	0	O
from	0	O
these	0	O
studies	0	O
that	0	O
CKII	0	B
may	0	O
act	0	O
as	0	O
a	0	O
positive	0	O
regulator	0	O
of	0	O
myogenesis	0	O
by	0	O
preventing	0	O
E	1	B
protein	0	I
homodimers	0	I
from	0	O
binding	0	O
to	0	O
muscle	0	O
gene	0	O
regulatory	0	O
elements	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
no	0	O
change	0	O
was	0	O
detected	0	O
in	0	O
the	0	O
phenotype	0	O
of	0	O
'	0	O
unstressed	0	O
'	0	O
clones	0	O
,	0	O
with	0	O
respect	0	O
to	0	O
any	0	O
of	0	O
the	0	O
following	0	O
parameters	0	O
:	0	O
proliferation	0	O
rate	0	O
in	0	O
monolayer	0	O
,	0	O
serum	0	O
-	0	O
dependence	0	O
for	0	O
proliferation	0	O
or	0	O
survival	0	O
,	0	O
tumorigenicity	0	O
,	0	O
cellular	0	O
morphology	0	O
,	0	O
or	0	O
tissue	0	O
-	0	O
specific	0	O
differentiation	0	O
markers	0	O
.	0	O


Deletion	1	O
analysis	0	O
indicates	0	O
that	0	O
TBP	1	B
and	0	O
hTAFII18	0	B
bind	0	O
to	0	O
distinct	0	O
domains	0	O
of	0	O
hTAFII28	0	B
.	0	O
hTAFII18	0	B
also	0	O
interacts	0	O
with	0	O
TBP	1	B
,	0	O
but	0	O
it	0	O
interacts	0	O
more	0	O
strongly	0	O
with	0	O
hTAFII28	0	B
and	0	O
hTAFII30	0	B
.	0	O


Cooperative	0	O
dimerization	0	O
of	0	O
paired	0	B
class	0	O
homeo	0	O
domains	0	O
on	0	O
DNA	1	O
.	0	O


The	0	O
p20	0	B
-	0	I
CGGBP	0	I
gene	0	I
is	0	O
conserved	0	O
among	0	O
mammals	0	O
but	0	O
shows	0	O
no	0	O
homology	0	O
to	0	O
non	0	O
-	0	O
vertebrate	0	O
species	0	O
.	0	O


Recently	0	O
,	0	O
an	0	O
alternatively	0	O
spliced	0	O
form	0	O
of	0	O
c	0	B
-	0	I
myb	0	I
-	0	I
encoded	0	I
mRNA	1	I
has	0	O
been	0	O
identified	0	O
in	0	O
murine	0	O
cells	0	O
containing	0	O
either	0	O
normal	0	O
or	0	O
rearranged	0	O
c	0	B
-	0	I
myb	0	I
genes	0	I
.	0	O


Thus	0	O
,	0	O
although	0	O
p28	0	B
may	0	O
play	0	O
only	0	O
a	0	O
limited	0	O
role	0	O
during	0	O
the	0	O
early	0	O
embryonic	0	O
cleavages	0	O
,	0	O
it	0	O
may	0	O
function	0	O
later	0	O
in	0	O
development	0	O
to	0	O
establish	0	O
a	0	O
somatic	0	O
type	0	O
of	0	O
cell	0	O
cycle	0	O
.	0	O


Recently	0	O
,	0	O
cell	0	O
-	0	O
surface	0	O
TRAIL	0	B
has	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
expressed	0	O
by	0	O
activated	0	O
human	0	O
and	0	O
mouse	0	O
T	1	O
lymphocytes	0	O
,	0	O
raising	0	O
the	0	O
possibility	0	O
that	0	O
TRAIL	0	B
might	0	O
be	0	O
involved	0	O
in	0	O
T	1	O
cell	0	O
-	0	O
mediated	0	O
cytotoxicity	0	O
and	0	O
/	0	O
or	0	O
immune	0	O
regulation	0	O
.	0	O


Furthermore	0	O
,	0	O
MOM	0	B
-	0	I
4	0	I
and	0	O
TAK1	0	B
bind	0	O
related	0	O
proteins	0	O
that	0	O
promote	0	O
their	0	O
kinase	0	O
activities	0	O
.	0	O


Infect	1	O
.	0	O


Neuro	0	O
-	0	O
otological	0	O
examinations	0	O
revealed	0	O
spontaneous	0	O
downbeat	0	O
nystagmus	0	O
,	0	O
bilateral	0	O
gaze	0	O
nystagmus	0	O
and	0	O
rebound	0	O
nystagmus	0	O
.	0	O


Both	0	O
of	0	O
these	0	O
domains	0	O
have	0	O
striking	0	O
sequence	0	O
homology	0	O
with	0	O
human	0	O
SIM	0	B
and	0	O
Drosophila	1	O
SIM	0	B
proteins	0	O
.	0	O


PaO2	1	O
threshold	0	O
was	0	O
determined	0	O
through	0	O
an	0	O
indwelling	0	O
O2	1	O
sensor	0	O
catheter	0	O
.	0	O


Hybridization	1	O
data	0	O
indicate	0	O
that	0	O
6F6	0	B
.	0	I
2	0	I
corresponds	0	O
to	0	O
the	0	O
previously	0	O
characterized	0	O
m6F6	0	B
cDNA	1	I
clone	0	I
and	0	O
that	0	O
6F6	0	B
.	0	I
1	0	I
and	0	O
6F6	0	B
.	0	I
3	0	I
,	0	O
but	0	O
not	0	O
6F6	0	B
.	0	I
2	0	I
,	0	O
are	0	O
adjacent	0	O
to	0	O
alpha	0	B
-	0	I
type	0	I
genes	0	I
.	0	O


This	0	O
result	0	O
suggests	0	O
that	0	O
phosphorylation	0	O
of	0	O
Thr	1	O
14	0	O
and	0	O
/	0	O
or	0	O
Tyr	1	O
15	0	O
inhibits	0	O
p34cdc2	0	B
kinase	0	I
activity	0	O
,	0	O
in	0	O
line	0	O
with	0	O
the	0	O
location	0	O
of	0	O
these	0	O
residues	0	O
within	0	O
the	0	O
putative	0	O
ATP	1	O
binding	0	O
site	0	O
of	0	O
the	0	O
kinase	0	O
.	0	O


The	0	O
hyperacute	0	O
phase	0	O
of	0	O
posterolateral	0	O
myocardial	0	O
infarction	0	O
.	0	O


Epitope	1	O
mapping	0	O
revealed	0	O
that	0	O
these	0	O
three	0	O
clones	0	O
appear	0	O
to	0	O
recognize	0	O
an	0	O
identical	0	O
epitope	0	O
domain	0	O
present	0	O
on	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
RNP	1	O
motif	0	O
of	0	O
the	0	O
U1A	0	B
protein	0	I
.	0	O


Staining	1	O
with	0	O
IF	1	O
MoAB	1	O
alone	0	O
of	0	O
BAL	1	O
fluid	0	O
only	0	O
seemed	0	O
to	0	O
be	0	O
even	0	O
more	0	O
sensitive	0	O
than	0	O
silver	0	O
methenamine	0	O
staining	0	O
of	0	O
BAL	1	O
,	0	O
TBB	0	O
and	0	O
brushing	0	O
material	0	O
.	0	O


Effects	0	O
of	0	O
posteroventral	0	O
pallidotomy	0	O
on	0	O
Parkinson	0	O
'	0	O
s	0	O
disease	0	O
.	0	O


Quantitation	0	O
of	0	O
exocrine	0	B
IgA	1	I
in	0	O
human	0	O
serum	0	O
in	0	O
health	0	O
and	0	O
disease	0	O
.	0	O


Convulsive	1	O
status	0	O
epilepticus	0	O
after	0	O
infusion	0	O
of	0	O
cisplatin	0	O


The	0	O
perioperative	0	O
mortality	0	O
of	0	O
all	0	O
patients	0	O
was	0	O
1	0	O
.	0	O
9	0	O
%,	0	O
the	0	O
mortality	0	O
of	0	O
patients	0	O
older	0	O
than	0	O
70	0	O
years	0	O
was	0	O
4	0	O
.	0	O
3	0	O
%.	0	O


These	0	O
findings	0	O
suggest	0	O
that	0	O
late	0	O
MYO	0	O
/	0	O
M	1	O
is	0	O
more	0	O
useful	0	O
than	0	O
washout	0	O
rate	0	O
to	0	O
assess	0	O
the	0	O
effect	0	O
of	0	O
treatment	0	O
on	0	O
heart	0	O
failure	0	O
due	0	O
to	0	O
DCM	0	O
.	0	O


All	1	O
six	0	O
genes	0	O
were	0	O
cloned	0	O
and	0	O
characterised	0	O
.	0	O


During	0	O
the	0	O
febrile	0	O
period	0	O
,	0	O
pleocytosis	0	O
was	0	O
associated	0	O
with	0	O
high	0	O
levels	0	O
of	0	O
IgG	1	B
,	0	O
IL	1	B
-	0	I
6	0	I
,	0	O
TNF	1	B
-	0	I
alpha	0	I
,	0	O
and	0	O
PGE2	0	O
in	0	O
the	0	O
cerebrospinal	0	O
fluid	0	O
.	0	O


Mapping	1	O
the	0	O
cAMP	1	B
receptor	0	I
protein	0	I
contact	0	I
site	0	I
on	0	O
the	0	O
alpha	0	O
subunit	0	O
of	0	O
Escherichia	1	B
coli	0	I
RNA	1	I
polymerase	0	I
.	0	O


Gene	1	O
expression	0	O
occurs	0	O
in	0	O
a	0	O
circadian	0	O
rhythm	0	O
and	0	O
induced	0	O
by	0	O
light	0	O
in	0	O
leaves	0	O
of	0	O
dark	0	O
-	0	O
adapted	0	O
plants	0	O
.	0	O


Our	0	O
study	0	O
was	0	O
designed	0	O
to	0	O
investigate	0	O
the	0	O
effect	0	O
of	0	O
MMF	1	O
on	0	O
in	0	O
vivo	0	O
bone	0	O
mineral	0	O
metabolism	0	O
.	0	O


Disability	1	O
insurance	0	O
under	0	O
social	0	O
security	0	O
.	0	O


A	1	O
dose	0	O
-	0	O
dependent	0	O
fall	0	O
in	0	O
GABA	1	O
content	0	O
was	0	O
observed	0	O
;	0	O
GABA	1	O
decrease	0	O
was	0	O
evident	0	O
15	0	O
min	0	O
after	0	O
the	0	O
administration	0	O
,	0	O
reached	0	O
its	0	O
nadir	0	O
at	0	O
60	0	O
min	0	O
and	0	O
disappeared	0	O
at	0	O
120	0	O
minutes	0	O
.	0	O


Electrophile	1	O
Response	1	O
Elements	0	O
(	0	O
EpREs	0	O
),	0	O
located	0	O
in	0	O
5	0	O
'-	0	O
flanking	0	O
sequences	0	O
of	0	O
both	0	O
the	0	O
GCSh	0	B
and	0	O
GCSl	0	B
subunit	0	I
genes	0	I
,	0	O
are	0	O
hypothesized	0	O
to	0	O
at	0	O
least	0	O
partially	0	O
mediate	0	O
gene	0	O
induction	0	O
following	0	O
xenobiotic	0	O
exposure	0	O
.	0	O


One	0	O
gene	0	O
appears	0	O
ubiquitously	0	O
expressed	0	O
while	0	O
the	0	O
other	0	O
is	0	O
prominently	0	O
expressed	0	O
in	0	O
muscle	0	O
.	0	O


The	0	O
distribution	0	O
of	0	O
the	0	O
various	0	O
repeats	0	O
suggests	0	O
its	0	O
organization	0	O
is	0	O
similar	0	O
to	0	O
the	0	O
beta	0	O
-	0	O
heterochromatic	0	O
regions	0	O
near	0	O
the	0	O
base	0	O
of	0	O
the	0	O
major	0	O
chromosome	0	O
arms	0	O
.	0	O


Many	0	O
mammary	0	O
tumors	0	O
induced	0	O
by	0	O
mouse	0	O
mammary	0	O
tumor	0	O
virus	0	O
(	0	O
MMTV	0	O
)	0	O
contain	0	O
a	0	O
provirus	0	O
in	0	O
the	0	O
same	0	O
region	0	O
of	0	O
the	0	O
host	0	O
-	0	O
cell	0	O
genome	0	O
,	0	O
leading	0	O
to	0	O
expression	0	O
of	0	O
a	0	O
putative	0	O
cellular	0	O
oncogene	0	O
called	0	O
int	0	B
-	0	I
1	0	I
.	0	O


These	0	O
results	0	O
with	0	O
clozapine	0	O
illustrate	0	O
that	0	O
LI	1	O
is	0	O
sensitive	0	O
to	0	O
antipsychotics	0	O
which	0	O
differ	0	O
in	0	O
their	0	O
mode	0	O
of	0	O
action	0	O
and	0	O
furthermore	0	O
emphasize	0	O
the	0	O
value	0	O
of	0	O
LI	1	O
as	0	O
a	0	O
test	0	O
model	0	O
for	0	O
detecting	0	O
the	0	O
antipsychotic	0	O
potential	0	O
of	0	O
novel	0	O
drugs	0	O
.	0	O


In	1	O
support	0	O
of	0	O
a	0	O
role	0	O
at	0	O
the	0	O
spindle	0	O
,	0	O
two	0	O
-	0	O
hybrid	0	O
library	0	O
screening	0	O
with	0	O
HEF1	0	B
identifies	0	O
the	0	O
human	0	O
homolog	0	O
of	0	O
the	0	O
G2	0	B
/	0	I
M	1	I
spindle	0	I
-	0	I
regulatory	0	I
protein	0	I
Dim1p	0	I
as	0	O
a	0	O
specific	0	O
interactor	0	O
with	0	O
a	0	O
region	0	O
of	0	O
HEF1	0	B
encompassed	0	O
in	0	O
p55	0	B
(	0	O
HEF1	0	B
).	0	O


Conversely	0	O
,	0	O
the	0	O
inactive	0	O
dAK	0	B
subunit	0	I
is	0	O
progressively	0	O
activated	0	O
by	0	O
1	0	O
)	0	O
association	0	O
with	0	O
a	0	O
dGK	0	B
or	0	O
dCK	0	B
subunit	0	I
and	0	O
2	0	O
)	0	O
the	0	O
conformationally	0	O
driven	0	O
heterotropic	0	O
affect	0	O
of	0	O
dGuo	0	B
or	0	O
dCyd	0	B
bound	0	O
to	0	O
the	0	O
opposing	0	O
subunit	0	O
.	0	O


In	1	O
order	0	O
to	0	O
determine	0	O
which	0	O
sequences	0	O
in	0	O
the	0	O
GATA	0	B
-	0	I
1	0	I
promoter	0	I
are	0	O
crucial	0	O
for	0	O
activation	0	O
by	0	O
the	0	O
ME26	0	B
viral	0	I
protein	0	I
,	0	O
we	0	O
made	0	O
deletions	0	O
of	0	O
the	0	O
promoter	0	O
,	0	O
cloned	0	O
them	0	O
into	0	O
a	0	O
luciferase	0	B
expression	0	O
vector	0	O
and	0	O
tested	0	O
their	0	O
activity	0	O
in	0	O
mouse	0	O
fibroblasts	0	O
,	0	O
which	0	O
do	0	O
not	0	O
express	0	O
GATA	0	B
-	0	I
1	0	I
.	0	O


This	0	O
exon	0	O
,	0	O
here	0	O
named	0	O
exon	0	O
0	0	O
,	0	O
contained	0	O
the	0	O
entire	0	O
5	0	O
'	0	O
untranslated	0	O
region	0	O
and	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
signal	0	O
sequence	0	O
of	0	O
the	0	O
polypeptide	0	O
.	0	O


We	0	O
speculate	0	O
that	0	O
these	0	O
tumors	0	O
may	0	O
represent	0	O
congenital	0	O
hamartomatous	0	O
growths	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
NH2	0	O
-	0	O
terminal	0	O
portion	0	O
of	0	O
the	0	O
homologue	0	O
was	0	O
not	0	O
translocated	0	O
into	0	O
the	0	O
outer	0	O
membrane	0	O
without	0	O
its	0	O
COOH	0	O
-	0	O
terminal	0	O
part	0	O
.	0	O


Patients	0	O
were	0	O
assessed	0	O
for	0	O
cardiac	0	O
MIBG	1	O
uptake	0	O
,	0	O
circulating	0	O
norepinephrine	0	O
concentration	0	O
,	0	O
LVEF	0	O
,	0	O
peak	0	O
Vo2	1	O
,	0	O
x	0	O
-	0	O
ray	0	O
cardiothoracic	0	O
ratio	0	O
,	0	O
M	1	O
-	0	O
mode	0	O
echographic	0	O
end	0	O
-	0	O
diastolic	0	O
diameter	0	O
and	0	O
right	0	O
-	0	O
sided	0	O
heart	0	O
catheterization	0	O
parameters	0	O
.	0	O


Tissue	1	O
-	0	O
specific	0	O
expression	0	O
of	0	O
the	0	O
tmy	0	B
-	0	I
1	0	I
gene	0	I
was	0	O
determined	0	O
by	0	O
microinjection	0	O
of	0	O
a	0	O
promoter	0	B
/	0	I
lacZ	0	I
fusion	0	I
gene	0	I
and	0	O
with	0	O
immunohistochemistry	0	O
by	0	O
using	0	O
affinity	0	O
-	0	O
purified	0	O
tissue	0	B
-	0	I
specific	0	I
anti	0	I
-	0	I
tropomyosins	0	I
.	0	O


Goodpasture	0	O
'	0	O
s	0	O
-	0	O
like	0	O
syndrome	0	O
and	0	O
effect	0	O
of	0	O
extracorporeal	0	O
membrane	0	O
oxygenator	0	O
support	0	O
.	0	O


These	0	O
findings	0	O
indicate	0	O
that	0	O
autophosphorylation	0	O
of	0	O
Thr286	0	O
(	0	O
alpha	0	O
subunit	0	O
)	0	O
and	0	O
Thr287	0	O
(	0	O
beta	0	O
subunit	0	O
)	0	O
is	0	O
responsible	0	O
for	0	O
transition	0	O
of	0	O
CaM	1	B
-	0	I
kinase	0	I
II	0	I
to	0	O
the	0	O
Ca2	1	O
+-	0	O
independent	0	O
form	0	O
.	0	O


We	0	O
investigated	0	O
the	0	O
diagnostic	0	O
value	0	O
of	0	O
a	0	O
new	0	O
in	0	O
vitro	0	O
test	0	O
,	0	O
Pharmacia	0	O
CAP	1	O
System	1	O
(	0	O
Pharmacia	0	O
Diagnostics	1	O
AB	1	O
,	0	O
Uppsala	0	O
,	0	O
Sweden	0	O
),	0	O
for	0	O
the	0	O
quantitative	0	O
measurement	0	O
of	0	O
allergen	0	B
-	0	I
specific	0	I
IgE	1	I
antibodies	0	I
by	0	O
comparison	0	O
with	0	O
RAST	1	O
in	0	O
2	0	O
groups	0	O
of	0	O
patients	0	O
,	0	O
71	0	O
atopic	0	O
and	0	O
48	0	O
non	0	O
-	0	O
atopic	0	O
.	0	O


The	0	O
central	0	O
visual	0	O
fields	0	O
of	0	O
2165	0	O
normal	0	O
and	0	O
106	0	O
glaucoma	0	O
eyes	0	O
were	0	O
measured	0	O
using	0	O
a	0	O
threshold	0	O
related	0	O
suprathreshold	0	O
strategy	0	O
.	0	O


PURPOSE	0	O
:	0	O
The	0	O
role	0	O
interleukin	0	B
-	0	I
6	0	I
(	0	O
IL	1	B
-	0	I
6	0	I
)	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
congenital	0	O
thrombocytopenias	0	O
is	0	O
unknown	0	O
.	0	O


It	1	O
has	0	O
a	0	O
grave	0	O
prognosis	0	O
with	0	O
>	0	O
70	0	O
%	0	O
mortality	0	O
in	0	O
3	0	O
months	0	O
,	0	O
despite	0	O
mechanical	0	O
ventilation	0	O
.	0	O


This	0	O
investigation	0	O
was	0	O
undertaken	0	O
to	0	O
determine	0	O
whether	0	O
consuming	0	O
several	0	O
small	0	O
feedings	0	O
of	0	O
preexercise	0	O
carbohydrate	0	O
(	0	O
CHO	1	O
),	0	O
rather	0	O
than	0	O
a	0	O
single	0	O
bolus	0	O
,	0	O
would	0	O
affect	0	O
blood	0	O
glucose	0	O
and	0	O
insulin	0	B
responses	0	O
during	0	O
rest	0	O
and	0	O
exercise	0	O
.	0	O


It	1	O
is	0	O
likely	0	O
that	0	O
the	0	O
sequence	0	O
similarities	0	O
reflect	0	O
a	0	O
common	0	O
molecular	0	O
architecture	0	O
of	0	O
the	0	O
two	0	O
heme	0	O
binding	0	O
sites	0	O
and	0	O
of	0	O
a	0	O
copper	0	O
binding	0	O
site	0	O
in	0	O
these	0	O
enzymes	0	O
.	0	O


Yeast	1	B
U1	0	I
snRNP	1	I
therefore	0	O
contains	0	O
16	0	O
different	0	O
proteins	0	O
,	0	O
including	0	O
seven	0	O
snRNP	1	B
core	0	I
proteins	0	I
,	0	O
three	0	O
homologues	0	O
of	0	O
the	0	O
metazoan	0	B
U1	0	I
snRNP	1	I
-	0	I
specific	0	I
proteins	0	I
,	0	O
and	0	O
six	0	O
yeast	0	B
-	0	I
specific	0	I
U1	0	I
snRNP	1	I
proteins	0	I
.	0	O


Further	0	O
investigations	0	O
are	0	O
necessary	0	O
to	0	O
elucidate	0	O
the	0	O
biochemical	0	O
and	0	O
physiological	0	O
properties	0	O
of	0	O
DLIS	0	O
.	0	O


RESULTS	0	O
:	0	O
Transpulmonary	0	O
passage	0	O
of	0	O
contrast	0	O
occurred	0	O
in	0	O
sufficient	0	O
amounts	0	O
to	0	O
enhance	0	O
the	0	O
intensity	0	O
of	0	O
the	0	O
Doppler	1	O
signal	0	O
significantly	0	O
,	0	O
but	0	O
the	0	O
duration	0	O
of	0	O
this	0	O
effect	0	O
was	0	O
short	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
In	1	O
addition	0	O
to	0	O
the	0	O
superiority	0	O
of	0	O
octafluoropropane	0	O
-	0	O
filled	0	O
microspheres	0	O
to	0	O
air	0	O
-	0	O
filled	0	O
microspheres	0	O
for	0	O
LV	1	O
opacification	0	O
,	0	O
the	0	O
efficacy	0	O
of	0	O
OCTA	0	O
is	0	O
relatively	0	O
unaffected	0	O
by	0	O
impaired	0	O
LV	1	O
function	0	O
and	0	O
is	0	O
less	0	O
susceptible	0	O
to	0	O
the	0	O
effects	0	O
of	0	O
poor	0	O
echogenicity	0	O
than	0	O
AIR	1	O
.	0	O


A	1	O
comparison	0	O
among	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
regions	0	O
encompassing	0	O
the	0	O
presumptive	0	O
HS	1	B
promoter	0	I
of	0	O
the	0	O
soybean	0	B
HS	1	I
-	0	I
protein	0	I
genes	0	I
demonstrated	0	O
this	0	O
region	0	O
to	0	O
be	0	O
extremely	0	O
homologous	0	O
.	0	O


Estradiol	1	O
is	0	O
known	0	O
to	0	O
induce	0	O
expression	0	O
of	0	O
certain	0	O
proto	0	O
-	0	O
oncogenes	0	O
,	0	O
and	0	O
this	0	O
led	0	O
us	0	O
to	0	O
examine	0	O
potential	0	O
regulatory	0	O
regions	0	O
of	0	O
the	0	O
cellular	0	B
c	0	I
-	0	I
fos	0	I
oncogene	0	I
.	0	O


Many	0	O
cells	0	O
were	0	O
negative	0	O
for	0	O
endothelial	0	O
-	0	O
cell	0	O
markers	0	O
,	0	O
and	0	O
they	0	O
reacted	0	O
with	0	O
a	0	O
monoclonal	0	O
antibody	0	O
against	0	O
muscle	0	O
actin	0	B
.	0	O


UPMC	0	O
is	0	O
not	0	O
the	0	O
only	0	O
organization	0	O
pursuing	0	O
controlled	0	O
NHBC	0	O
organ	0	O
procurement	0	O
,	0	O
however	0	O
.	0	O


The	0	O
high	0	O
degree	0	O
of	0	O
sequence	0	O
identity	0	O
(	0	O
96	0	O
%)	0	O
between	0	O
hydrolase	0	B
B	1	I
and	0	I
C	1	I
,	0	O
particularly	0	O
in	0	O
the	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
,	0	O
suggests	0	O
that	0	O
the	0	O
genes	0	O
encoding	0	O
these	0	O
two	0	O
carboxylesterases	0	B
evolved	0	O
by	0	O
duplication	0	O
and	0	O
divergence	0	O
of	0	O
a	0	O
common	0	O
ancestral	0	O
gene	0	O
.	0	O


Supplementary	0	O
Phase	1	O
Contraste	0	O
RSE	0	O
("	0	O
Rapid	0	O
Sequential	1	O
Excitation	1	O
")	0	O
sequences	0	O
were	0	O
carried	0	O
out	0	O
in	0	O
29	0	O
patients	0	O
.	0	O


The	0	O
sequence	0	O
data	0	O
now	0	O
permit	0	O
a	0	O
detailed	0	O
interpretation	0	O
of	0	O
the	0	O
X	1	O
-	0	O
ray	0	O
crystallographic	0	O
structure	0	O
of	0	O
the	0	O
enzyme	0	O
and	0	O
the	0	O
cloning	0	O
and	0	O
expression	0	O
of	0	O
the	0	O
clostridial	0	O
gene	0	O
will	0	O
facilitate	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
.	0	O


Substrates	0	O
for	0	O
p210	0	B
(	0	O
bcr	0	B
-	0	O
abl	0	B
)	0	O
are	0	O
likely	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
the	0	O
pathogenesis	0	O
of	0	O
CML	1	O
.	0	O


Testosterone	1	O
,	0	O
free	0	O
testosterone	0	O
,	0	O
non	0	B
-	0	I
sex	0	I
hormone	0	I
-	0	I
binding	0	I
globulin	0	I
-	0	O
bound	0	O
testosterone	0	O
,	0	O
and	0	O
free	0	O
androgen	0	O
index	0	O
:	0	O
which	0	O
testosterone	0	O
measurement	0	O
is	0	O
most	0	O
relevant	0	O
to	0	O
reproductive	0	O
and	0	O
sexual	0	O
function	0	O
in	0	O
men	0	O
with	0	O
epilepsy	0	O
?	0	O


Although	0	O
the	0	O
mechanism	0	O
of	0	O
action	0	O
of	0	O
ICRF	0	O
-	0	O
159	0	O
and	0	O
187	0	O
has	0	O
not	0	O
been	0	O
clearly	0	O
defined	0	O
,	0	O
it	0	O
is	0	O
evident	0	O
from	0	O
both	0	O
preclinical	0	O
and	0	O
early	0	O
clinical	0	O
studies	0	O
that	0	O
these	0	O
compounds	0	O
are	0	O
of	0	O
interest	0	O
.	0	O


Heterogeneity	1	O
of	0	O
human	0	B
serum	0	I
albumin	0	I
.	0	O


We	0	O
found	0	O
that	0	O
total	0	O
PSA	1	B
can	0	O
be	0	O
detected	0	O
in	0	O
all	0	O
cyst	0	O
fluids	0	O
and	0	O
in	0	O
about	0	O
75	0	O
%	0	O
of	0	O
female	0	O
sera	0	O
.	0	O


The	0	O
data	0	O
presented	0	O
in	0	O
this	0	O
work	0	O
indicate	0	O
that	0	O
thi1	0	B
may	0	O
also	0	O
be	0	O
involved	0	O
in	0	O
DNA	1	O
damage	0	O
tolerance	0	O
in	0	O
plant	0	O
cells	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
serum	0	B
alpha1AT	0	I
quantitation	0	O
,	0	O
newborn	0	O
infants	0	O
may	0	O
be	0	O
separated	0	O
into	0	O
two	0	O
groups	0	O
,	0	O
characterized	0	O
respectively	0	O
by	0	O
concentrations	0	O
above	0	O
or	0	O
below	0	O
150	0	O
mg	0	O
%.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
also	0	O
constructed	0	O
and	0	O
expressed	0	O
chimeric	0	O
fusion	0	O
protein	0	O
that	0	O
contains	0	O
HIV	1	B
-	0	I
2	0	I
gag	0	I
with	0	O
V3	0	B
domains	0	O
of	0	O
HIV	1	O
-	0	O
1IIIB	0	O
,	0	O
HIV	1	O
-	0	O
1MN	0	O
,	0	O
HIV	1	O
-	0	O
1SF2	0	O
and	0	O
HIV	1	O
-	0	O
1RF	0	O
.	0	O


Transfection	1	O
experiments	0	O
demonstrated	0	O
that	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
(-	0	O
1894	0	O
to	0	O
+	0	O
37	0	O
)	0	O
of	0	O
the	0	O
mStaf	0	B
gene	0	I
drives	0	O
transcription	0	O
in	0	O
mouse	0	O
NMuMG	0	O
cells	0	O
and	0	O
that	0	O
a	0	O
construct	0	O
containing	0	O
a	0	O
fragment	0	O
from	0	O
-	0	O
387	0	O
to	0	O
+	0	O
37	0	O
showed	0	O
the	0	O
highest	0	O
transcriptional	0	O
activity	0	O
.	0	O


Hemolytic	1	O
disease	0	O
of	0	O
African	0	O
newborn	0	O
.	0	O


The	0	O
asymmetric	0	O
methylation	0	O
was	0	O
associated	0	O
with	0	O
tissue	0	O
-	0	O
specific	0	O
disruption	0	O
of	0	O
H19	0	B
genomic	0	O
imprinting	0	O
in	0	O
fetal	0	O
brain	0	O
.	0	O


The	0	O
swa2	0	B
-	0	I
1	0	I
allele	0	I
recovered	0	O
from	0	O
the	0	O
original	0	O
screen	0	O
carries	0	O
a	0	O
point	0	O
mutation	0	O
in	0	O
its	0	O
tetratricopeptide	0	O
repeat	0	O
(	0	O
TPR	1	O
)	0	O
domain	0	O
,	0	O
a	0	O
motif	0	O
not	0	O
found	0	O
in	0	O
auxilin	0	B
but	0	O
known	0	O
in	0	O
other	0	O
proteins	0	O
to	0	O
mediate	0	O
interaction	0	O
with	0	O
heat	0	B
-	0	I
shock	0	I
proteins	0	I
.	0	O


Significant	1	O
correlations	0	O
existed	0	O
between	0	O
FEV1	1	O
and	0	O
the	0	O
corresponding	0	O
values	0	O
of	0	O
Raw	1	O
,	0	O
MEF50	0	O
and	0	O
MEF25	0	O
,	0	O
although	0	O
there	0	O
were	0	O
considerable	0	O
individual	0	O
differences	0	O
between	0	O
test	0	O
results	0	O
.	0	O


Doppler	1	O
ultrasound	0	O
studies	0	O
of	0	O
long	0	O
-	0	O
term	0	O
follow	0	O
-	0	O
up	0	O
of	0	O
children	0	O
with	0	O
hemolytic	0	O
-	0	O
uremic	0	O
syndrome	0	O


A	1	O
deletion	0	O
mutation	0	O
analysis	0	O
of	0	O
the	0	O
recombinant	0	O
protein	0	O
has	0	O
shown	0	O
that	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
and	0	O
the	0	O
two	0	O
leucine	0	O
zippers	0	O
are	0	O
necessary	0	O
for	0	O
the	0	O
binding	0	O
.	0	O


The	0	O
SR	1	B
protein	0	I
family	0	I
is	0	O
involved	0	O
in	0	O
constitutive	0	O
and	0	O
regulated	0	O
pre	0	O
-	0	O
mRNA	1	O
splicing	0	O
and	0	O
has	0	O
been	0	O
found	0	O
to	0	O
be	0	O
evolutionarily	0	O
conserved	0	O
in	0	O
metazoan	0	O
organisms	0	O
.	0	O


Role	1	O
of	0	O
biocenosis	0	O
in	0	O
the	0	O
manifestation	0	O
of	0	O
Shigella	1	O
virulence	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
the	0	O
unique	0	O
suppository	0	O
formulation	0	O
of	0	O
CZX	0	O
-	0	O
S	1	O
is	0	O
useful	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
infections	0	O
in	0	O
children	0	O
with	0	O
heavy	0	O
psychophysiologic	0	O
disorders	0	O
and	0	O
in	0	O
children	0	O
who	0	O
cannot	0	O
take	0	O
oral	0	O
drugs	0	O
because	0	O
of	0	O
severe	0	O
vomiting	0	O
.	0	O


Previously	0	O
,	0	O
we	0	O
reported	0	O
that	0	O
scanthrough	0	O
translation	0	O
,	0	O
where	0	O
the	0	O
initiating	0	O
AUG	0	O
of	0	O
a	0	O
primary	0	O
open	0	O
reading	0	O
frame	0	O
is	0	O
bypassed	0	O
,	0	O
is	0	O
most	0	O
likely	0	O
to	0	O
account	0	O
for	0	O
the	0	O
presentation	0	O
of	0	O
cryptic	0	O
epitopes	0	O
from	0	O
alternative	0	O
reading	0	O
frames	0	O
within	0	O
the	0	O
influenza	0	B
A	1	I
PR	1	I
/	0	I
8	0	I
/	0	I
34	0	I
nucleoprotein	0	I
gene	0	I
.	0	O


Both	0	O
alleles	0	O
are	0	O
functionally	0	O
expressed	0	O
and	0	O
are	0	O
distributed	0	O
within	0	O
CD4	1	B
+/	0	O
CD8	0	B
+	0	O
T	1	O
cell	0	O
subsets	0	O
.	0	O


Furthermore	0	O
,	0	O
overexpression	0	O
of	0	O
AML3	0	B
/	0	O
CBFalpha1	0	B
could	0	O
rescue	0	O
the	0	O
AML1	0	B
-	0	O
ETO	1	B
repression	0	O
.	0	O


This	0	O
report	0	O
presents	0	O
the	0	O
isolation	0	O
and	0	O
characterization	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
(	0	O
1	0	O
.	0	O
2	0	O
kb	0	O
)	0	O
and	0	O
exon	0	O
1	0	O
of	0	O
the	0	O
human	0	B
RII	0	I
alpha	0	I
gene	0	I
.	0	O


Molecules	0	O
of	0	O
NH3	1	O
are	0	O
capable	0	O
of	0	O
emitting	0	O
stimulated	0	O
radiation	0	O
(	0	O
MASER	1	O
).	0	O


We	0	O
have	0	O
examined	0	O
the	0	O
regulation	0	O
of	0	O
the	0	O
FGFR	0	B
-	0	I
1	0	I
gene	0	I
(	0	O
cek	0	B
-	0	I
1	0	I
)	0	O
in	0	O
avian	0	O
myogenic	0	O
cultures	0	O
by	0	O
immunocytochemistry	0	O
and	0	O
Northern	0	O
blot	0	O
analysis	0	O
.	0	O


Measurement	0	O
of	0	O
open	0	O
-	0	O
loop	0	O
responses	0	O
to	0	O
electrical	0	O
stimulation	0	O
in	0	O
olfactory	0	O
bulb	0	O
of	0	O
cat	0	O
.	0	O


Schizosaccharomyces	0	O
pombe	0	O
cells	0	O
respond	0	O
to	0	O
nutrient	0	O
deprivation	0	O
by	0	O
altering	0	O
G2	0	O
/	0	O
M	1	O
cell	0	O
size	0	O
control	0	O
.	0	O


Eight	0	O
cats	0	O
infected	0	O
with	0	O
H	1	O
.	0	O
pylori	0	O
were	0	O
used	0	O
in	0	O
the	0	O
study	0	O
.	0	O


The	0	O
Harleco	0	O
apparatus	0	O
is	0	O
a	0	O
simple	0	O
,	0	O
useful	0	O
,	0	O
cost	0	O
-	0	O
effective	0	O
adjunct	0	O
to	0	O
the	0	O
diagnosis	0	O
and	0	O
treatment	0	O
of	0	O
this	0	O
life	0	O
-	0	O
threatening	0	O
condition	0	O
.	0	O


Stimulation	1	O
of	0	O
macrophage	0	O
function	0	O
by	0	O
killed	0	O
Bordetella	1	O
pertussis	0	O
cells	0	O
did	0	O
not	0	O
show	0	O
any	0	O
beneficial	0	O
effect	0	O
as	0	O
an	0	O
increased	0	O
susceptibility	0	O
became	0	O
apparent	0	O
.	0	O


Reperfusion	1	O
caused	0	O
a	0	O
transient	0	O
reduction	0	O
in	0	O
lactate	0	O
production	0	O
and	0	O
a	0	O
significant	0	O
increase	0	O
in	0	O
LDH	1	B
release	0	O
.	0	O


PLUS	0	O
-	0	O
3	0	O
is	0	O
a	0	O
new	0	O
Swedish	0	O
protocol	0	O
of	0	O
natural	0	O
speech	0	O
in	0	O
3	0	O
-	0	O
year	0	O
-	0	O
old	0	O
children	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
this	0	O
mRNA	1	O
,	0	O
90	0	O
%	0	O
of	0	O
alpha	0	B
and	0	I
beta	0	I
actin	0	I
mRNAs	0	I
were	0	O
translated	0	O
in	0	O
both	0	O
myoblasts	0	O
and	0	O
myotubes	0	O
.	0	O


The	0	O
PDH	0	B
complex	0	I
-	0	I
encoding	0	I
genes	0	I
were	0	O
identified	0	O
by	0	O
hybridization	0	O
experiments	0	O
and	0	O
sequence	0	O
analysis	0	O
in	0	O
two	0	O
separate	0	O
gene	0	O
regions	0	O
in	0	O
the	0	O
genome	0	O
of	0	O
Z	1	O
.	0	O
mobilis	0	O
.	0	O


The	0	O
"	0	O
cracked	0	O
-	0	O
tooth	0	O
"	0	O
syndrome	0	O
.	0	O


Neurospora	1	O
crassa	0	O
CYT	0	B
-	0	I
18	0	I
,	0	O
can	0	O
rescue	0	O
the	0	O
exonic	0	O
trap	0	O
and	0	O
intron	0	O
mutants	0	O
which	0	O
cause	0	O
a	0	O
structural	0	O
defect	0	O
.	0	O


It	1	O
acts	0	O
on	0	O
Cdks	0	B
in	0	O
the	0	O
G1	0	O
and	0	O
S	1	O
phases	0	O
of	0	O
the	0	O
cell	0	O
cycle	0	O
,	0	O
and	0	O
also	0	O
binds	0	O
to	0	O
proliferating	0	B
cell	0	I
nuclear	0	I
antigen	0	I
(	0	O
PCNA	1	B
),	0	O
blocking	0	O
DNA	1	O
replication	0	O
in	0	O
vitro	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
1998	0	O
Surveillance	1	O
,	0	O
Epidemiology	1	O
,	0	O
and	0	O
End	1	O
Results	0	O
(	0	O
SEER	0	O
)	0	O
data	0	O
estimate	0	O
an	0	O
83	0	O
.	0	O
1	0	O
%	0	O
5	0	O
-	0	O
year	0	O
survival	0	O
rate	0	O
for	0	O
corpus	0	O
uteri	0	O
adenocarcinoma	0	O
FIGO	1	O
stage	0	O
II	0	O
.	0	O


Reward	1	O
value	0	O
of	0	O
prosodic	0	O
features	0	O
of	0	O
language	0	O
for	0	O
autistic	0	O
,	0	O
mentally	0	O
retarded	0	O
,	0	O
and	0	O
normal	0	O
children	0	O
.	0	O


Angionephroscintigraphy	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
diseases	0	O
of	0	O
the	0	O
kidney	0	O


Novel	0	O
8	0	O
-	0	O
base	0	O
pair	0	O
sequence	0	O
(	0	O
Drosophila	1	O
DNA	1	O
replication	0	O
-	0	O
related	0	O
element	0	O
)	0	O
and	0	O
specific	0	O
binding	0	O
factor	0	O
involved	0	O
in	0	O
the	0	O
expression	0	O
of	0	O
Drosophila	1	O
genes	0	O
for	0	O
DNA	1	B
polymerase	0	I
alpha	0	I
and	0	O
proliferating	0	B
cell	0	I
nuclear	0	I
antigen	0	I
.	0	O


We	0	O
also	0	O
found	0	O
that	0	O
the	0	O
same	0	O
males	0	O
,	0	O
breeding	0	O
in	0	O
different	0	O
years	0	O
on	0	O
the	0	O
same	0	O
territories	0	O
,	0	O
had	0	O
significantly	0	O
larger	0	O
harems	0	O
in	0	O
the	0	O
years	0	O
they	0	O
had	0	O
familiar	0	O
neighbors	0	O
.	0	O


The	0	O
IL	1	B
-	0	I
8	0	I
receptor	0	I
is	0	O
a	0	O
seven	0	O
-	0	O
transmembrane	0	O
spanning	0	O
receptor	0	O
coupled	0	O
to	0	O
specific	0	O
heterotrimeric	0	B
G	1	I
proteins	0	I
including	0	O
Gi	1	B
and	0	O
G16	0	B
.	0	O


Induction	1	O
of	0	O
the	0	O
CINC	0	B
promoter	0	I
by	0	O
IL	1	B
-	0	I
17	0	I
in	0	O
IEC	0	O
-	0	O
6	0	O
cells	0	O
was	0	O
TNF	1	B
receptor	0	I
-	0	I
associated	0	I
factor	0	I
-	0	I
6	0	I
(	0	O
TRAF6	0	B
),	0	O
but	0	O
not	0	O
TRAF2	0	B
,	0	O
dependent	0	O
.	0	O


Study	1	O
of	0	O
bacterial	0	O
motility	0	O
and	0	O
rate	0	O
of	0	O
movement	0	O
using	0	O
a	0	O
closed	0	O
circuit	0	O
television	0	O


Importantly	0	O
,	0	O
concomitant	0	O
expression	0	O
of	0	O
constitutive	0	O
activated	0	O
Raf	0	B
and	0	O
V12N38	0	B
Ras	1	I
results	0	O
in	0	O
almost	0	O
complete	0	O
loss	0	O
of	0	O
TTF	0	B
-	0	I
1	0	I
activity	0	O
.	0	O


Characterization	0	O
of	0	O
the	0	O
human	0	B
gene	0	I
encoding	0	I
cytokeratin	0	I
17	0	I
and	0	O
its	0	O
expression	0	O
pattern	0	O
.	0	O


Determination	1	O
of	0	O
diquat	0	O
in	0	O
biological	0	O
materials	0	O
by	0	O
electron	0	O
spin	0	O
resonance	0	O
spectroscopy	0	O
.	0	O


The	0	O
weak	0	O
relationships	0	O
between	0	O
F	1	O
and	0	O
Zn	1	O
to	0	O
Mg	1	O
clearly	0	O
have	0	O
no	0	O
significant	0	O
effect	0	O
on	0	O
the	0	O
contents	0	O
of	0	O
these	0	O
elements	0	O
in	0	O
bone	0	O
.	0	O


Western	0	O
blot	0	O
analyses	0	O
detect	0	O
anti	0	B
-	0	I
E	1	I
-	0	O
specific	0	O
immunoreactivity	0	O
in	0	O
affinity	0	O
-	0	O
purified	0	O
extracts	0	O
derived	0	O
from	0	O
the	0	O
bacterial	0	O
expression	0	O
of	0	O
a	0	O
truncated	0	B
AMPD3	0	I
cDNA	1	I
.	0	O


Studies	0	O
on	0	O
the	0	O
pathogenicity	0	O
of	0	O
ECHO	1	O
9	0	O
(	0	O
HILL	0	O
)	0	O
virus	0	O
and	0	O
its	0	O
mutants	0	O
for	0	O
suckling	0	O
mice	0	O


Three	0	O
mutants	0	O
(	0	O
pms1	0	B
,	0	O
pms2	0	B
and	0	O
pms3	0	B
)	0	O
isolated	0	O
earlier	0	O
from	0	O
MW104	0	O
-	0	O
1B	0	O
were	0	O
shown	0	O
to	0	O
correct	0	O
in	0	O
vitro	0	O
constructed	0	O
plasmids	0	O
with	0	O
defined	0	O
DNA	1	O
mismatches	0	O
(	0	O
G	1	O
/	0	O
T	1	O
,	0	O
A	1	O
/	0	O
C	1	O
,	0	O
G	1	O
/	0	O
G	1	O
,	0	O
etc	0	O
.)	0	O
poorly	0	O
(	0	O
Kramer	0	O
et	0	O
al	0	O
.,	0	O
1989a	0	O
).	0	O


The	0	O
platelet	0	O
adhesion	0	O
rate	0	O
on	0	O
these	0	O
layers	0	O
were	0	O
tested	0	O
concerning	0	O
the	0	O
valuation	0	O
of	0	O
the	0	O
haemocompatibility	0	O
of	0	O
the	0	O
basic	0	O
-	0	O
polymers	0	O
polyurethane	0	O
(	0	O
PUR	0	O
),	0	O
polyvinylchloride	0	O
(	0	O
PVC	1	O
),	0	O
and	0	O
polystyrene	0	O
(	0	O
PS	1	O
)	0	O
in	0	O
two	0	O
different	0	O
worked	0	O
test	0	O
chambers	0	O
.	0	O


R	1	O
.,	0	O
Fleischmann	0	O
,	0	O
R	1	O
.,	0	O
Venter	1	O
,	0	O
J	1	O
.	0	O


The	0	O
association	0	O
of	0	O
p255	0	B
with	0	O
splicing	0	O
complexes	0	O
is	0	O
suggested	0	O
by	0	O
the	0	O
finding	0	O
that	0	O
mAb	0	B
CC3	0	I
can	0	O
inhibit	0	O
in	0	O
vitro	0	O
splicing	0	O
and	0	O
immunoprecipitate	0	O
pre	0	O
-	0	O
messenger	0	O
RNA	1	O
and	0	O
splicing	0	O
products	0	O
.	0	O


Catecholamines	0	O
and	0	O
aversive	0	O
learning	0	O
:	0	O
a	0	O
review	0	O
.	0	O


Interestingly	0	O
,	0	O
an	0	O
increase	0	O
of	0	O
distance	0	O
per	0	O
se	0	O
did	0	O
not	0	O
have	0	O
a	0	O
deleterious	0	O
effect	0	O
on	0	O
translation	0	O
efficiency	0	O
.	0	O


Both	0	O
groups	0	O
rejected	0	O
pops	0	O
with	0	O
added	0	O
SOA	0	O
,	0	O
decreasing	0	O
mouthing	0	O
times	0	O
as	0	O
SOA	0	O
concentration	0	O
increased	0	O
.	0	O


We	0	O
compared	0	O
the	0	O
volume	0	O
of	0	O
the	0	O
pulmonary	0	O
extravascular	0	O
,	0	O
extracellular	0	O
water	0	O
space	0	O
using	0	O
sodium	0	O
and	0	O
sucrose	0	O
indicators	0	O
in	0	O
8	0	O
normal	0	O
and	0	O
11	0	O
edematous	0	O
rabbit	0	O
lungs	0	O
by	0	O
steady	0	O
-	0	O
state	0	O
techniques	0	O
.	0	O


General	1	O
formulae	0	O
for	0	O
estimating	0	O
heritability	0	O
in	0	O
a	0	O
population	0	O
with	0	O
related	0	O
parents	0	O
.	0	O


The	0	O
two	0	O
mouse	0	O
lines	0	O
carrying	0	O
the	0	O
unfragmented	0	O
Hnf3g	0	B
-	0	O
lacZ	0	B
YAC	1	O
showed	0	O
tissue	0	O
-	0	O
specific	0	O
,	0	O
copy	0	O
number	0	O
-	0	O
dependent	0	O
and	0	O
position	0	O
-	0	O
independent	0	O
expression	0	O
,	0	O
proving	0	O
that	0	O
170	0	O
kb	0	O
of	0	O
the	0	O
Hnf3g	0	B
locus	0	O
contain	0	O
all	0	O
elements	0	O
important	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
Hnf3g	0	B
.	0	O


Clinico	0	O
-	0	O
physiological	0	O
experiment	0	O


During	0	O
ISO	1	O
+	0	O
AT	1	O
infusion	0	O
,	0	O
abdominal	0	O
fat	0	O
blood	0	O
flow	0	O
was	0	O
still	0	O
significantly	0	O
increased	0	O
as	0	O
compared	0	O
with	0	O
control	0	O
values	0	O
in	0	O
lean	0	O
and	0	O
obese	0	O
subjects	0	O
.	0	O


We	0	O
have	0	O
separated	0	O
a	0	O
dermatan	0	O
sulfate	0	O
proteoglycan	0	O
,	0	O
epiphycan	0	O
,	0	O
from	0	O
decorin	0	B
and	0	O
biglycan	0	O
by	0	O
using	0	O
dissociative	0	O
extraction	0	O
of	0	O
bovine	0	O
fetal	0	O
epiphyseal	0	O
cartilage	0	O
,	0	O
followed	0	O
by	0	O
sequential	0	O
ion	0	O
-	0	O
exchange	0	O
,	0	O
gel	0	O
permeation	0	O
,	0	O
hydrophobic	0	O
,	0	O
and	0	O
Zn2	0	O
+	0	O
chelate	0	O
chromatographic	0	O
steps	0	O
.	0	O


Effects	0	O
of	0	O
perceptual	0	O
salience	0	O
on	0	O
the	0	O
matrix	0	O
task	0	O
performance	0	O
of	0	O
four	0	O
-	0	O
and	0	O
six	0	O
-	0	O
year	0	O
-	0	O
old	0	O
children	0	O
.	0	O


The	0	O
DNase	1	B
I	1	I
footprint	0	O
extended	0	O
5	0	O
'	0	O
in	0	O
the	0	O
silencer	0	O
region	0	O
to	0	O
include	0	O
an	0	O
inverted	0	O
repeat	0	O
of	0	O
a	0	O
six	0	O
-	0	O
nucleotide	0	O
motif	0	O
(	0	O
epsilon	0	O
-	0	O
267	0	O
to	0	O
-	0	O
278	0	O
bp	0	O
)	0	O
which	0	O
shares	0	O
5	0	O
of	0	O
6	0	O
bases	0	O
with	0	O
the	0	O
GATA	0	B
-	0	I
1	0	I
consensus	0	I
sequence	0	I
.	0	O


The	0	O
circadian	0	O
rhythmicity	0	O
of	0	O
sleep	0	O
was	0	O
pronounced	0	O
.	0	O


Both	0	O
genes	0	O
comprise	0	O
three	0	O
exons	0	O
,	0	O
two	0	O
introns	0	O
and	0	O
an	0	O
unusually	0	O
long	0	O
3	0	O
'-	0	O
untranslated	0	O
region	0	O
(	0	O
3	0	O
.	0	O
2	0	O
kilobase	0	O
pairs	0	O
),	0	O
specificying	0	O
a	0	O
mRNA	1	O
of	0	O
approximately	0	O
4	0	O
.	0	O
1	0	O
kilobases	0	O
.	0	O


The	0	O
PSS	0	B
gene	0	I
was	0	O
subcloned	0	O
into	0	O
a	0	O
1	0	O
.	0	O
1	0	O
-	0	O
kb	0	O
fragment	0	O
of	0	O
the	0	O
yeast	0	O
DNA	1	O
on	0	O
the	0	O
YEp13	0	O
vector	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
Y239	0	B
/	0	I
240F	0	I
Shc	0	I
,	0	O
but	0	O
not	0	O
Y317F	0	B
Shc	0	I
,	0	O
reduced	0	O
the	0	O
EGF	1	B
-	0	O
induced	0	O
c	0	B
-	0	I
myc	0	I
message	0	O
.	0	O


An	1	O
intravenous	0	O
drip	0	O
infusion	0	O
of	0	O
AMK	0	O
in	0	O
adequate	0	O
dosage	0	O
would	0	O
be	0	O
beneficial	0	O
to	0	O
use	0	O
against	0	O
some	0	O
infectious	0	O
diseases	0	O
of	0	O
otorhinolaryngologic	0	O
field	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
revealed	0	O
several	0	O
GC	1	O
boxes	0	O
but	0	O
no	0	O
identifiable	0	O
TATA	0	O
box	0	O
.	0	O


The	0	O
C	1	O
-	0	O
terminal	0	O
mutants	0	O
were	0	O
strongly	0	O
dominant	0	O
over	0	O
TraR	0	B
,	0	O
suggesting	0	O
that	0	O
they	0	O
can	0	O
form	0	O
heteromultimers	0	O
with	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
activator	0	O
.	0	O


No	1	O
somatic	0	O
mutations	0	O
were	0	O
found	0	O
in	0	O
any	0	O
of	0	O
the	0	O
samples	0	O
,	0	O
suggesting	0	O
that	0	O
ING1	0	B
is	0	O
not	0	O
a	0	O
tumor	0	O
suppressor	0	O
gene	0	O
target	0	O
in	0	O
head	0	O
and	0	O
neck	0	O
cancer	0	O
.	0	O


These	0	O
kinases	0	O
belong	0	O
to	0	O
a	0	O
new	0	O
subfamily	0	O
related	0	O
to	0	O
the	0	O
Trk	0	B
subfamily	0	I
.	0	O


CONCLUSION	0	O
:	0	O
Our	0	O
study	0	O
shows	0	O
that	0	O
(	0	O
1	0	O
)	0	O
total	0	O
body	0	O
BMD	1	O
and	0	O
femoral	0	O
neck	0	O
BMD	1	O
were	0	O
significantly	0	O
higher	0	O
in	0	O
the	0	O
study	0	O
group	0	O
that	0	O
performed	0	O
weight	0	O
-	0	O
bearing	0	O
exercises	0	O
than	0	O
in	0	O
control	0	O
subjects	0	O
,	0	O
(	0	O
2	0	O
)	0	O
swimming	0	O
exercise	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
BMD	1	O
,	0	O
and	0	O
(	0	O
3	0	O
)	0	O
although	0	O
swimming	0	O
is	0	O
not	0	O
a	0	O
bone	0	O
-	0	O
building	0	O
exercise	0	O
,	0	O
it	0	O
can	0	O
significantly	0	O
improve	0	O
shoulder	0	O
,	0	O
back	0	O
,	0	O
and	0	O
grip	0	O
muscle	0	O
strength	0	O
.	0	O


By	0	O
applying	0	O
the	0	O
potentiometric	0	O
method	0	O
,	0	O
in	0	O
aqueous	0	O
medium	0	O
of	0	O
ionic	0	O
strength	0	O
mu	0	O
=	0	O
0	0	O
.	0	O
2	0	O
,	0	O
the	0	O
stability	0	O
constants	0	O
,	0	O
log	0	O
beta	0	O
1	0	O
=	0	O
4	0	O
.	0	O
42	0	O
and	0	O
log	0	O
beta	0	O
2	0	O
=	0	O
8	0	O
.	0	O
57	0	O
were	0	O
obtained	0	O
.	0	O


To	1	O
characterize	0	O
this	0	O
effect	0	O
,	0	O
we	0	O
looked	0	O
for	0	O
targets	0	O
of	0	O
NS1	0	B
influenza	0	I
virus	0	I
protein	0	I
among	0	O
cellular	0	O
translation	0	O
factors	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
CCAAT	0	O
box	0	O
also	0	O
has	0	O
tissue	0	O
-	0	O
specific	0	O
characteristics	0	O
that	0	O
assist	0	O
in	0	O
targeting	0	O
expression	0	O
of	0	O
the	0	O
alpha	0	B
-	0	I
subunit	0	I
gene	0	I
to	0	O
trophoblasts	0	O
.	0	O


The	0	O
dichloromethane	0	O
is	0	O
removed	0	O
,	0	O
mobile	0	O
phase	0	O
solvent	0	O
is	0	O
added	0	O
,	0	O
and	0	O
aliquots	0	O
are	0	O
injected	0	O
onto	0	O
a	0	O
PRP	1	O
-	0	O
1	0	O
liquid	0	O
chromatographic	0	O
column	0	O
;	0	O
fluazifop	0	O
acid	0	O
is	0	O
separated	0	O
from	0	O
coextracted	0	O
compounds	0	O
and	0	O
detected	0	O
at	0	O
an	0	O
applied	0	O
potential	0	O
of	0	O
+	0	O
1	0	O
.	0	O
25	0	O
V	1	O
,	0	O
using	0	O
an	0	O
amperometric	0	O
electrochemical	0	O
detector	0	O
in	0	O
the	0	O
oxidation	0	O
mode	0	O
.	0	O


Calcifications	0	O
in	0	O
the	0	O
thoracic	0	O
aorta	0	O
at	0	O
the	0	O
level	0	O
of	0	O
the	0	O
11th	0	O
and	0	O
the	0	O
12th	0	O
thoracic	0	O
vertebrae	0	O
in	0	O
592	0	O
men	0	O
and	0	O
333	0	O
women	0	O
were	0	O
studied	0	O
using	0	O
computed	0	O
tomography	0	O
.	0	O


Aeromonas	1	O
salmonicida	0	O
possesses	0	O
two	0	O
genes	0	O
encoding	0	O
homologs	0	O
of	0	O
the	0	O
major	0	B
outer	0	I
membrane	0	I
protein	0	I
,	0	O
OmpA	1	B
.	0	O


Our	0	O
data	0	O
provide	0	O
a	0	O
biochemical	0	O
explanation	0	O
for	0	O
the	0	O
similarity	0	O
in	0	O
phenotype	0	O
between	0	O
A	1	O
-	0	O
T	1	O
and	0	O
NBS	0	O
.	0	O


Issues	0	O
of	0	O
distribution	0	O
of	0	O
kinetic	0	O
energy	0	O
of	0	O
traumatizing	0	O
object	0	O
in	0	O
direct	0	O
contact	0	O
interaction	0	O
with	0	O
head	0	O
during	0	O
impact	0	O
are	0	O
discussed	0	O
from	0	O
position	0	O
of	0	O
biomechanics	0	O
.	0	O


Characterization	0	O
of	0	O
the	0	O
microtubule	0	O
binding	0	O
domain	0	O
of	0	O
microtubule	0	B
actin	0	I
crosslinking	0	I
factor	0	I
(	0	O
MACF	0	B
):	0	O
identification	0	O
of	0	O
a	0	O
novel	0	O
group	0	O
of	0	O
microtubule	0	B
associated	0	I
proteins	0	I
.	0	O


The	0	O
colony	0	B
-	0	I
stimulating	0	I
factors	0	I
(	0	O
CSFs	0	B
)	0	O
principally	0	O
involved	0	O
in	0	O
the	0	O
production	0	O
of	0	O
neutrophils	0	O
and	0	O
monocytes	0	O
are	0	O
granulocyte	0	B
CSF	1	I
,	0	O
granulocyte	0	B
-	0	I
macrophage	0	I
CSF	1	I
,	0	O
macrophage	0	B
CSF	1	I
,	0	O
and	0	O
interleukin	0	B
3	0	I
(	0	O
sometimes	0	O
called	0	O
multi	0	B
-	0	I
CSF	1	I
).	0	O


Previous	0	O
studies	0	O
characterized	0	O
a	0	O
cytokine	0	O
-	0	O
inducible	0	O
,	0	O
functional	0	O
nuclear	0	B
factor	0	I
(	0	I
NF	1	I
)-	0	I
kappaB	0	I
consensus	0	I
element	0	I
in	0	O
the	0	O
immediate	0	O
5	0	O
'	0	O
regulatory	0	O
region	0	O
of	0	O
the	0	O
MGSA	0	B
/	0	O
GRO	0	B
-	0	I
alpha	0	I
gene	0	O
at	0	O
-	0	O
78	0	O
bp	0	O
.	0	O


Marked	0	O
thrombocytopenia	0	O
,	0	O
depletion	0	O
of	0	O
serum	0	B
fibrinogen	0	I
and	0	O
prolonged	0	O
prothrombin	0	B
and	0	O
activated	0	O
partial	0	O
thromboplastin	0	B
time	0	O
,	0	O
were	0	O
recorded	0	O
at	0	O
5	0	O
to	0	O
10	0	O
and	0	O
30	0	O
to	0	O
40	0	O
minutes	0	O
after	0	O
intravenous	0	O
envenomation	0	O
.	0	O


After	0	O
phosphorylation	0	O
,	0	O
STAT	1	B
proteins	0	I
are	0	O
transported	0	O
into	0	O
the	0	O
nucleus	0	O
and	0	O
exhibit	0	O
transcriptional	0	O
activity	0	O
.	0	O


After	0	O
recovery	0	O
,	0	O
a	0	O
hypertonic	0	O
saline	0	O
challenge	0	O
was	0	O
performed	0	O
.	0	O


Hydrocortisone	1	O
seems	0	O
to	0	O
be	0	O
unable	0	O
to	0	O
hinder	0	O
the	0	O
postdenervation	0	O
changes	0	O
in	0	O
the	0	O
muscle	0	O
membrane	0	O
whereas	0	O
high	0	O
doses	0	O
of	0	O
the	0	O
hormone	0	O
are	0	O
able	0	O
to	0	O
induce	0	O
changes	0	O
in	0	O
the	0	O
muscle	0	O
membrane	0	O
.	0	O


Whole	0	O
blood	0	O
serotonin	0	O
levels	0	O
were	0	O
investigated	0	O
in	0	O
a	0	O
control	0	O
group	0	O
(	0	O
n	0	O
=	0	O
35	0	O
)	0	O
and	0	O
in	0	O
a	0	O
group	0	O
of	0	O
chronic	0	O
renal	0	O
failure	0	O
patients	0	O
(	0	O
n	0	O
=	0	O
127	0	O
)	0	O
on	0	O
various	0	O
treatment	0	O
regimen	0	O
i	0	O
.	0	O
e	0	O
.	0	O
conservative	0	O
treatment	0	O
(	0	O
n	0	O
=	0	O
39	0	O
),	0	O
maintenance	0	O
haemodialysis	0	O
(	0	O
n	0	O
=	0	O
35	0	O
)	0	O
and	0	O
after	0	O
renal	0	O
transplantation	0	O
(	0	O
n	0	O
=	0	O
53	0	O
).	0	O


From	0	O
these	0	O
results	0	O
,	0	O
we	0	O
concluded	0	O
that	0	O
this	0	O
ORF	1	O
is	0	O
the	0	O
FRDS	0	B
gene	0	I
.	0	O


Initial	1	O
results	0	O
indicate	0	O
that	0	O
this	0	O
23S	0	B
pre	0	I
-	0	I
rRNA	1	I
is	0	O
the	0	O
same	0	O
as	0	O
the	0	O
species	0	O
detected	0	O
on	0	O
depletion	0	O
of	0	O
the	0	O
small	0	B
nucleolar	0	I
RNA	1	I
-	0	I
associated	0	I
proteins	0	I
NOP1	0	I
and	0	O
GAR1	0	B
and	0	O
in	0	O
an	0	O
snr10	0	B
mutant	0	I
strain	0	O
.	0	O


We	0	O
found	0	O
that	0	O
T3	1	O
(	0	O
10	0	O
(-	0	O
8	0	O
)	0	O
M	1	O
)	0	O
selectively	0	O
stimulates	0	O
transcription	0	O
from	0	O
rGH	0	B
-	0	O
TRE	0	O
-	0	O
and	0	O
TREpal	0	O
-,	0	O
but	0	O
not	0	O
ME	1	O
-	0	O
TRE	0	O
-	0	O
and	0	O
F2	0	O
-	0	O
TRE	0	O
-,	0	O
containing	0	O
templates	0	O
in	0	O
which	0	O
these	0	O
TREs	0	O
are	0	O
linked	0	O
in	0	O
front	0	O
of	0	O
the	0	O
rGH	0	B
minimal	0	I
promoter	0	I
containing	0	O
only	0	O
the	0	O
TATA	0	B
box	0	I
binding	0	I
protein	0	I
,	0	O
but	0	O
not	0	O
any	0	O
other	0	O
proximal	0	O
binding	0	O
protein	0	O
,	0	O
sequence	0	O
.	0	O


Enhancer	1	O
and	0	O
promoter	0	O
elements	0	O
directing	0	O
activation	0	O
and	0	O
glucocorticoid	0	O
repression	0	O
of	0	O
the	0	O
alpha	0	B
1	0	I
-	0	I
fetoprotein	0	I
gene	0	I
in	0	O
hepatocytes	0	O
.	0	O


PATIENTS	0	O
AND	0	O
METHODS	0	O
:	0	O
Semen	1	O
analyses	0	O
were	0	O
performed	0	O
on	0	O
58	0	O
patients	0	O
with	0	O
stages	0	O
I	1	O
-	0	O
III	0	O
HD	1	O
before	0	O
,	0	O
during	0	O
,	0	O
and	0	O
after	0	O
chemotherapy	0	O
and	0	O
after	0	O
the	0	O
sperm	0	O
count	0	O
recovered	0	O
from	0	O
the	0	O
effects	0	O
of	0	O
abdominal	0	O
radiotherapy	0	O
that	0	O
was	0	O
given	0	O
after	0	O
chemotherapy	0	O
.	0	O


For	0	O
this	0	O
,	0	O
cDNAs	0	O
containing	0	O
the	0	O
60K	0	O
,	0	O
87K	0	O
,	0	O
110K	0	O
and	0	O
170K	0	O
protein	0	O
coding	0	O
sequences	0	O
were	0	O
each	0	O
provided	0	O
with	0	O
an	0	O
ATG	1	O
start	0	O
codon	0	O
and	0	O
the	0	O
cDNA	1	O
containing	0	O
the	0	O
60K	0	O
coding	0	O
sequence	0	O
with	0	O
a	0	O
TAA	1	O
stop	0	O
codon	0	O
immediately	0	O
downstream	0	O
of	0	O
the	0	O
coding	0	O
sequence	0	O
.	0	O


Extreme	0	O
potency	0	O
of	0	O
botulinum	0	B
toxin	0	I
.	0	O


Analysis	1	O
of	0	O
liver	0	O
biopsy	0	O
specimens	0	O
from	0	O
patients	0	O
with	0	O
hepatitis	0	O
showed	0	O
a	0	O
large	0	O
variation	0	O
in	0	O
the	0	O
mean	0	O
iron	0	O
content	0	O
of	0	O
the	0	O
liver	0	O
ferritin	0	B
molecules	0	O
.	0	O


Since	0	O
one	0	O
group	0	O
of	0	O
adolescents	0	O
more	0	O
difficult	0	O
to	0	O
influence	0	O
are	0	O
those	0	O
whose	0	O
parents	0	O
smoke	0	O
,	0	O
parental	0	O
involvement	0	O
in	0	O
smoking	0	O
prevention	0	O
may	0	O
be	0	O
a	0	O
powerful	0	O
enhancer	0	O
.	0	O


ATF1	0	B
transcription	0	O
is	0	O
negatively	0	O
regulated	0	O
by	0	O
unsaturated	0	O
fatty	0	O
acids	0	O
and	0	O
oxygen	0	O
.	0	O


Strain	1	O
CFN037	0	O
is	0	O
an	0	O
R	1	O
.	0	O
etli	0	O
mutant	0	O
induced	0	O
by	0	O
a	0	O
single	0	O
Tn5mob	0	B
insertion	0	O
in	0	O
the	0	O
promoter	0	O
region	0	O
of	0	O
the	0	O
thiCOGE	0	B
gene	0	I
cluster	0	I
.	0	O


Here	0	O
we	0	O
report	0	O
that	0	O
expression	0	O
of	0	O
the	0	O
I	1	B
-	0	I
POU	0	I
/	0	O
tI	1	B
-	0	I
POU	0	I
message	0	O
is	0	O
maximal	0	O
late	0	O
in	0	O
the	0	O
embryonic	0	O
phase	0	O
of	0	O
Drosophila	1	O
development	0	O
,	0	O
and	0	O
I	1	B
-	0	I
POU	0	I
is	0	O
the	0	O
preferred	0	O
splice	0	O
variant	0	O
.	0	O


Thirty	0	O
percent	0	O
of	0	O
patients	0	O
were	0	O
tapered	0	O
off	0	O
all	0	O
steroids	0	O
,	0	O
and	0	O
the	0	O
average	0	O
steroid	0	O
dose	0	O
in	0	O
the	0	O
group	0	O
who	0	O
received	0	O
steroids	0	O
was	0	O
8	0	O
.	0	O
6	0	O
mg	0	O
of	0	O
prednisone	0	O
per	0	O
day	0	O
.	0	O


The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
assess	0	O
the	0	O
reproducibility	0	O
of	0	O
a	0	O
number	0	O
of	0	O
simplified	0	O
clearance	0	O
methods	0	O
using	0	O
chromium	0	O
-	0	O
51	0	O
ethylenediamine	0	O
tetraacetic	0	O
acid	0	O
(	0	O
51Cr	0	O
-	0	O
EDTA	1	O
)	0	O
and	0	O
to	0	O
compare	0	O
these	0	O
with	0	O
the	0	O
multiple	0	O
blood	0	O
sample	0	O
technique	0	O
.	0	O


The	0	O
hybridizing	0	O
clone	0	O
of	0	O
V	1	O
.	0	O
vulnificus	0	O
chromosomal	0	O
DNA	1	O
complemented	0	O
a	0	O
V	1	B
.	0	I
cholerae	0	I
fur	0	I
mutant	0	I
.	0	O


Recurrence	1	O
of	0	O
bladder	0	O
tumors	0	O
among	0	O
the	0	O
original	0	O
9	0	O
cases	0	O
has	0	O
occurred	0	O
only	0	O
among	0	O
the	0	O
5	0	O
whose	0	O
properdin	0	B
levels	0	O
remained	0	O
below	0	O
the	0	O
median	0	O
.	0	O


At	1	O
pH	1	O
6	0	O
.	0	O
9	0	O
,	0	O
the	0	O
same	0	O
lidocaine	0	O
concentrations	0	O
significantly	0	O
reduced	0	O
resting	0	O
potential	0	O
(	0	O
3	0	O
-	0	O
10	0	O
%),	0	O
action	0	O
potential	0	O
amplitude	0	O
(	0	O
3	0	O
-	0	O
8	0	O
%)	0	O
and	0	O
Vmax	1	O
(	0	O
14	0	O
-	0	O
22	0	O
%).	0	O


The	0	O
congenital	0	O
forms	0	O
(	0	O
7	0	O
cases	0	O
)	0	O
all	0	O
occurred	0	O
in	0	O
female	0	O
infants	0	O
and	0	O
involved	0	O
the	0	O
mucosa	0	O
overlying	0	O
either	0	O
the	0	O
anterior	0	O
ridge	0	O
of	0	O
the	0	O
maxilla	0	O
or	0	O
the	0	O
mandible	0	O
.	0	O


On	1	O
physical	0	O
examination	0	O
a	0	O
mild	0	O
symmetrical	0	O
polyarthritis	0	O
of	0	O
small	0	O
and	0	O
large	0	O
joints	0	O
was	0	O
seen	0	O
.	0	O


Saccharomyces	1	O
cerevisiae	0	O
has	0	O
been	0	O
used	0	O
widely	0	O
both	0	O
as	0	O
a	0	O
model	0	O
system	0	O
for	0	O
unraveling	0	O
the	0	O
biochemical	0	O
,	0	O
genetic	0	O
,	0	O
and	0	O
molecular	0	O
details	0	O
of	0	O
gene	0	O
expression	0	O
and	0	O
the	0	O
secretion	0	O
process	0	O
,	0	O
and	0	O
as	0	O
a	0	O
host	0	O
for	0	O
the	0	O
production	0	O
of	0	O
heterologous	0	O
proteins	0	O
of	0	O
biotechnological	0	O
interest	0	O
.	0	O


Spore	1	O
inocula	0	O
(	0	O
approximately	0	O
10	0	O
(	0	O
6	0	O
)/	0	O
coupon	0	O
)	0	O
were	0	O
dried	0	O
onto	0	O
0	0	O
.	0	O
5	0	O
-	0	O
in	0	O
.	0	O


Alena	0	O
is	0	O
a	0	O
nurse	0	O
in	0	O
Prague	0	O
--	0	O
she	0	O
dreams	0	O
of	0	O
higher	0	O
wages	0	O
and	0	O
a	0	O
trip	0	O
across	0	O
the	0	O
ocean	0	O


After	0	O
the	0	O
first	0	O
cycle	0	O
,	0	O
18	0	O
cases	0	O
were	0	O
treated	0	O
at	0	O
dose	0	O
level	0	O
1	0	O
,	0	O
after	0	O
a	0	O
second	0	O
cycle	0	O
,	0	O
13	0	O
cases	0	O
were	0	O
treated	0	O
at	0	O
dose	0	O
level	0	O
2	0	O
.	0	O


Pneumothorax	1	O
complicated	0	O
by	0	O
chronic	0	O
steroid	0	O
treatment	0	O
.	0	O


The	0	O
proliferation	0	B
potential	0	I
protein	0	I
-	0	I
related	0	I
(	0	O
P2P	0	B
-	0	I
R	1	I
)	0	O
gene	0	O
with	0	O
domains	0	O
encoding	0	O
heterogeneous	0	O
nuclear	0	O
ribonucleoprotein	0	O
association	0	O
and	0	O
Rb1	0	B
binding	0	O
shows	0	O
repressed	0	O
expression	0	O
during	0	O
terminal	0	O
differentiation	0	O
.	0	O


We	0	O
have	0	O
elucidated	0	O
the	0	O
exon	0	O
-	0	O
intron	0	O
organization	0	O
of	0	O
the	0	O
entire	0	O
human	0	O
CD58	0	B
gene	0	I
,	0	O
including	0	O
approximately	0	O
2	0	O
.	0	O
5	0	O
kilobases	0	O
(	0	O
kb	0	O
)	0	O
of	0	O
5	0	O
'-	0	O
flanking	0	O
DNA	1	O
.	0	O


35	0	O
patients	0	O
with	0	O
acute	0	O
arterial	0	O
occlusions	0	O
[	0	O
27	0	O
]	0	O
and	0	O
graft	0	O
thromboses	0	O
[	0	O
8	0	O
],	0	O
responsible	0	O
for	0	O
severe	0	O
and	0	O
recent	0	O
ischemia	0	O
,	0	O
were	0	O
treated	0	O
by	0	O
fibrinolytic	0	O
therapy	0	O
(	0	O
Urokinase	1	B
:	0	O
1	0	O
000	0	O
units	0	O
/	0	O
kg	0	O
/	0	O
hour	0	O
,	0	O
and	0	O
Lys	1	O
Plasminogen	1	B
).	0	O


The	0	O
other	0	O
transmembrane	0	O
regions	0	O
as	0	O
well	0	O
as	0	O
the	0	O
nucleoplasmic	0	O
domain	0	O
are	0	O
not	0	O
required	0	O
for	0	O
sorting	0	O
.	0	O


Second	1	O
,	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
m8	0	I
3	0	I
'	0	I
UTR	0	I
strongly	0	O
reduces	0	O
accumulation	0	O
of	0	O
heterologous	0	O
transcripts	0	O
in	0	O
vivo	0	O
,	0	O
an	0	O
activity	0	O
that	0	O
requires	0	O
its	0	O
K	1	O
box	0	O
sequences	0	O
.	0	O


To	1	O
determine	0	O
what	0	O
role	0	O
eIF4E	0	B
might	0	O
play	0	O
in	0	O
c	0	B
-	0	I
myc	0	I
expression	0	O
,	0	O
the	0	O
c	0	B
-	0	I
myc	0	I
5	0	I
'	0	I
untranslated	0	I
region	0	I
(	0	I
UTR	0	I
)	0	I
was	0	O
fused	0	O
in	0	O
-	0	O
frame	0	O
to	0	O
CAT	1	B
reporters	0	I
,	0	O
and	0	O
several	0	O
more	0	O
derivative	0	O
constructs	0	O
were	0	O
made	0	O
.	0	O


In	1	O
this	0	O
model	0	O
,	0	O
eltoprazine	0	O
has	0	O
a	0	O
very	0	O
specific	0	O
anti	0	O
-	0	O
aggressive	0	O
(	0	O
serenic	0	O
)	0	O
profile	0	O
,	0	O
inhibiting	0	O
aggression	0	O
while	0	O
social	0	O
interaction	0	O
and	0	O
exploration	0	O
are	0	O
not	0	O
decreased	0	O
but	0	O
even	0	O
enhanced	0	O
;	0	O
inactivity	0	O
,	0	O
a	0	O
measure	0	O
for	0	O
sedation	0	O
,	0	O
is	0	O
not	0	O
affected	0	O
.	0	O


We	0	O
use	0	O
the	0	O
term	0	O
corticosteroid	0	O
-	0	O
dependent	0	O
IA	1	O
to	0	O
refer	0	O
to	0	O
the	0	O
serious	0	O
problem	0	O
of	0	O
chronic	0	O
IA	1	O
requiring	0	O
maintenance	0	O
prednisone	0	O
therapy	0	O
.	0	O


Increased	0	O
urinary	0	O
riboflavin	0	O
excretion	0	O
resulting	0	O
from	0	O
boric	0	O
acid	0	O
ingestion	0	O
.	0	O


To	1	O
study	0	O
the	0	O
role	0	O
of	0	O
heavy	0	O
chain	0	O
motifs	0	O
in	0	O
substrate	0	O
recognition	0	O
,	0	O
secreted	0	O
variants	0	O
of	0	O
recombinant	0	B
bovine	0	I
proenteropeptidase	0	I
were	0	O
constructed	0	O
by	0	O
replacing	0	O
the	0	O
transmembrane	0	O
domain	0	O
with	0	O
a	0	O
signal	0	O
peptide	0	O
.	0	O


Binding	0	O
site	0	O
selection	0	O
using	0	O
in	0	O
vitro	0	O
-	0	O
synthesized	0	O
proteins	0	O
reveals	0	O
that	0	O
the	0	O
ROR	0	B
alpha	0	I
1	0	I
and	0	O
ROR	0	B
alpha	0	I
2	0	I
isoforms	0	I
bind	0	O
DNA	1	O
as	0	O
monomers	0	O
to	0	O
hormone	0	O
response	0	O
elements	0	O
composed	0	O
of	0	O
a	0	O
6	0	O
-	0	O
bp	0	O
AT	1	O
-	0	O
rich	0	O
sequence	0	O
preceding	0	O
a	0	O
half	0	O
-	0	O
site	0	O
core	0	O
motif	0	O
PuGGTCA	0	O
(	0	O
RORE	0	B
).	0	O


Comparison	0	O
of	0	O
beta	0	B
2	0	I
-	0	I
microglobulin	0	I
removal	0	O
using	0	O
the	0	O
same	0	O
polysulphone	0	O
membrane	0	O
for	0	O
haemodialysis	0	O
and	0	O
haemofiltration	0	O
shows	0	O
that	0	O
beta	0	B
2	0	I
-	0	I
microglobulin	0	I
is	0	O
more	0	O
effectively	0	O
removed	0	O
by	0	O
convection	0	O
than	0	O
by	0	O
diffusion	0	O
when	0	O
both	0	O
treatment	0	O
modes	0	O
are	0	O
matched	0	O
for	0	O
blood	0	O
flow	0	O
and	0	O
urea	0	O
clearance	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
N	1	B
-	0	O
Nus	0	B
complex	0	O
may	0	O
be	0	O
affected	0	O
through	0	O
contacts	0	O
with	0	O
the	0	O
CTD	1	O
of	0	O
the	0	O
alpha	0	O
subunit	0	O
of	0	O
RNA	1	B
polymerase	0	I
,	0	O
as	0	O
is	0	O
a	0	O
group	0	O
of	0	O
regulatory	0	O
proteins	0	O
that	0	O
influences	0	O
initiation	0	O
of	0	O
transcription	0	O
.	0	O


However	0	O
,	0	O
limited	0	O
comparisons	0	O
reveal	0	O
domains	0	O
in	0	O
the	0	O
NH2	0	O
and	0	O
COOH	0	O
termini	0	O
that	0	O
have	0	O
a	0	O
high	0	O
degree	0	O
of	0	O
similarity	0	O
suggesting	0	O
functional	0	O
conservation	0	O
.	0	O


Chimeras	0	O
containing	0	O
IE1	0	B
peptides	0	I
dramatically	0	O
activated	0	O
transcription	0	O
of	0	O
the	0	O
basal	0	O
promoter	0	O
only	0	O
when	0	O
lac	0	B
operator	0	I
sequences	0	I
were	0	O
present	0	O
.	0	O


Asthmatic	1	O
patients	0	O
showed	0	O
greater	0	O
responses	0	O
of	0	O
both	0	O
parameters	0	O
to	0	O
adrenaline	0	O
than	0	O
controls	0	O
indicating	0	O
that	0	O
long	0	O
-	0	O
term	0	O
corticosteroid	0	O
treatment	0	O
enhances	0	O
the	0	O
acute	0	O
responses	0	O
of	0	O
plasminogen	0	B
activator	0	I
and	0	O
clotting	0	B
factor	0	I
VIII	0	I
to	0	O
adrenaline	0	O
infusion	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
sequences	0	O
of	0	O
attP	0	B
,	0	O
attB	0	B
and	0	O
bacteria	0	O
-	0	O
prophage	0	O
junctions	0	O
attL	0	B
and	0	O
attR	0	B
showed	0	O
a	0	O
26	0	O
bp	0	O
common	0	O
core	0	O
sequence	0	O
,	0	O
where	0	O
recombination	0	O
takes	0	O
place	0	O
,	0	O
near	0	O
the	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
integrase	0	B
gene	0	I
.	0	O


Confocal	1	O
fluorescence	0	O
microscopy	0	O
in	0	O
modern	0	O
cell	0	O
biology	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
tri	0	O
-	0	O
snRNP	1	O
-	0	O
specific	0	O
27K	0	O
protein	0	O
could	0	O
potentially	0	O
be	0	O
involved	0	O
in	0	O
SR	1	B
protein	0	O
-	0	O
mediated	0	O
protein	0	O
/	0	O
protein	0	O
interactions	0	O
and	0	O
,	0	O
additionally	0	O
,	0	O
its	0	O
phosphorylation	0	O
state	0	O
could	0	O
modulate	0	O
pre	0	O
-	0	O
mRNA	1	O
splicing	0	O
.	0	O


Two	0	O
classes	0	O
of	0	O
inactive	0	O
receptors	0	O
were	0	O
identified	0	O
:	0	O
one	0	O
in	0	O
which	0	O
both	0	O
transcriptional	0	O
activation	0	O
and	0	O
dimerization	0	O
were	0	O
compromised	0	O
and	0	O
a	0	O
second	0	O
in	0	O
which	0	O
only	0	O
transcriptional	0	O
activation	0	O
was	0	O
abolished	0	O
.	0	O


Oxygen	1	O
delivery	0	O
and	0	O
base	0	O
excess	0	O
decreased	0	O
significantly	0	O
and	0	O
four	0	O
pigs	0	O
died	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
loading	0	O
the	0	O
respiratory	0	O
pumps	0	O
on	0	O
the	0	O
oxygen	0	O
consumption	0	O
of	0	O
Callionymus	0	O
lyra	0	O
.	0	O


Sensitive	1	O
fluorometric	0	O
method	0	O
of	0	O
determining	0	O
SH	1	O
-	0	O
and	0	O
S	1	O
-	0	O
S	1	O
-	0	O
groups	0	O
when	0	O
jointly	0	O
present	0	O


Sputum	1	B
IL	1	I
-	0	I
8	0	I
and	0	O
MPO	1	B
were	0	O
significantly	0	O
increased	0	O
after	0	O
BPT	0	O
in	0	O
both	0	O
TDI	1	O
-	0	O
and	0	O
grain	0	O
dust	0	O
-	0	O
asthma	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Both	0	O
in	0	O
vitro	0	O
-	0	O
synthesized	0	O
S2	1	B
protein	0	I
and	0	O
synthetic	0	O
peptides	0	O
corresponding	0	O
to	0	O
S2	1	B
are	0	O
shown	0	O
to	0	O
react	0	O
positively	0	O
with	0	O
sera	0	O
obtained	0	O
from	0	O
EIAV	0	O
-	0	O
infected	0	O
horses	0	O
,	0	O
providing	0	O
the	0	O
first	0	O
direct	0	O
evidence	0	O
of	0	O
expression	0	O
of	0	O
this	0	O
protein	0	O
in	0	O
infected	0	O
animals	0	O
.	0	O


Exposure	1	O
of	0	O
peripheral	0	O
blood	0	O
T	1	O
cells	0	O
from	0	O
young	0	O
subjects	0	O
to	0	O
PHA	1	B
or	0	O
cross	0	O
-	0	O
linked	0	O
anti	0	B
-	0	I
CD3	0	I
monoclonal	0	I
antibodies	0	I
stimulated	0	O
rapid	0	O
increases	0	O
in	0	O
MAPK	1	B
and	0	O
MEK	0	B
enzymatic	0	O
activity	0	O
.	0	O


Urine	1	O
antibodies	0	O
could	0	O
not	0	O
be	0	O
demonstrated	0	O
in	0	O
any	0	O
other	0	O
cases	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
and	0	O
characterised	0	O
a	0	O
differentially	0	O
-	0	O
regulated	0	O
gene	0	O
family	0	O
in	0	O
the	0	O
protozoan	0	O
parasite	0	O
Leishmania	1	O
major	0	O
.	0	O


Private	0	O
hospital	0	O
accreditation	0	O
.	0	O


Oseltamivir	0	O
(	0	O
GS4104	0	O
),	0	O
which	0	O
can	0	O
be	0	O
administered	0	O
orally	0	O
,	0	O
is	0	O
the	0	O
prodrug	0	O
of	0	O
GS4071	0	O
,	0	O
a	0	O
potent	0	O
and	0	O
selective	0	O
inhibitor	0	O
of	0	O
influenzavirus	0	B
neuraminidases	0	I
.	0	O


Six	0	O
patients	0	O
with	0	O
human	0	O
T	1	O
-	0	O
cell	0	O
lymphotropic	0	O
virus	0	O
type	0	O
I	1	O
(	0	O
HTLV	0	O
-	0	O
I	1	O
)-	0	O
associated	0	O
myelopathy	0	O
(	0	O
HAM	1	O
)	0	O
were	0	O
studied	0	O
by	0	O
electrophysiologic	0	O
methods	0	O
.	0	O


In	1	O
the	0	O
brain	0	O
,	0	O
muscarinic	0	B
receptors	0	I
mediate	0	O
motor	0	O
and	0	O
memory	0	O
function	0	O
by	0	O
interaction	0	O
with	0	O
their	0	O
ligand	0	O
acetylcholine	0	O
.	0	O


In	1	O
49	0	O
patients	0	O
in	0	O
whom	0	O
gated	0	O
equilibrium	0	O
ventriculography	0	O
and	0	O
cardiac	0	O
catheterization	0	O
were	0	O
performed	0	O
within	0	O
a	0	O
6	0	O
day	0	O
interval	0	O
,	0	O
total	0	O
and	0	O
fractional	0	O
portions	0	O
of	0	O
global	0	O
and	0	O
regional	0	O
right	0	O
ventricular	0	O
ejection	0	O
fraction	0	O
(	0	O
RVEF	0	O
)	0	O
were	0	O
correlated	0	O
with	0	O
pulmonary	0	O
arterial	0	O
systolic	0	O
pressure	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
the	0	O
mechanism	0	O
of	0	O
action	0	O
,	0	O
two	0	O
groups	0	O
of	0	O
inodilators	0	O
are	0	O
distinguished	0	O
,	0	O
the	0	O
phosphodiesterase	0	O
inhibitors	0	O
and	0	O
the	0	O
dopaminergic	0	O
agents	0	O
.	0	O


These	0	O
include	0	O
NPF	0	O
repeats	0	O
,	0	O
a	0	O
leucine	0	O
heptad	0	O
repeat	0	O
enriched	0	O
in	0	O
charged	0	O
residues	0	O
,	0	O
and	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
SH3	0	B
-	0	I
like	0	I
and	0	O
/	0	O
or	0	O
WW	0	O
domain	0	O
-	0	O
binding	0	O
site	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
,	0	O
which	0	O
is	0	O
followed	0	O
by	0	O
a	0	O
membrane	0	O
core	0	O
containing	0	O
four	0	O
putative	0	O
transmembrane	0	O
spans	0	O
and	0	O
three	0	O
amphiphilic	0	O
segments	0	O
that	0	O
are	0	O
the	0	O
most	0	O
highly	0	O
conserved	0	O
structural	0	O
elements	0	O
.	0	O


The	0	O
homeobox	0	B
gene	0	I
ATK1	0	I
of	0	O
Arabidopsis	0	O
thaliana	0	O
is	0	O
expressed	0	O
in	0	O
the	0	O
shoot	0	O
apex	0	O
of	0	O
the	0	O
seedling	0	O
and	0	O
in	0	O
flowers	0	O
and	0	O
inflorescence	0	O
stems	0	O
of	0	O
mature	0	O
plants	0	O
.	0	O


Thus	0	O
,	0	O
despite	0	O
the	0	O
potential	0	O
for	0	O
common	0	O
regulatory	0	O
mechanisms	0	O
,	0	O
the	0	O
available	0	O
evidence	0	O
indicates	0	O
that	0	O
the	0	O
Mtx	1	B
minimal	0	I
promoter	0	I
does	0	O
not	0	O
significantly	0	O
affect	0	O
Thbs3	0	B
gene	0	I
expression	0	O
.	0	O


Transfection	1	O
analyses	0	O
indicate	0	O
that	0	O
mutation	0	O
of	0	O
any	0	O
one	0	O
of	0	O
these	0	O
TGACCT	0	O
motifs	0	O
or	0	O
truncation	0	O
of	0	O
the	0	O
entire	0	O
HD	1	B
PPRE	0	O
into	0	O
a	0	O
separate	0	O
DR1	0	O
and	0	O
DR2	0	O
element	0	O
significantly	0	O
reduced	0	O
the	0	O
transcriptional	0	O
response	0	O
of	0	O
HD	1	B
PPRE	0	O
to	0	O
peroxisome	0	O
proliferators	0	O
.	0	O


Intron	1	O
K1	0	B
cox1	0	I
.	0	I
2	0	I
is	0	O
not	0	O
found	0	O
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
and	0	O
appears	0	O
at	0	O
an	0	O
unique	0	O
location	0	O
in	0	O
K	1	O
.	0	O
lactis	0	O
.	0	O


It	1	O
is	0	O
reported	0	O
that	0	O
,	0	O
at	0	O
present	0	O
,	0	O
most	0	O
of	0	O
the	0	O
MRSAs	0	O
spreading	0	O
in	0	O
Japan	0	O
are	0	O
acceleratedly	0	O
acquiring	0	O
resistance	0	O
to	0	O
many	0	O
drugs	0	O
,	0	O
and	0	O
especially	0	O
,	0	O
they	0	O
are	0	O
developing	0	O
high	0	O
resistance	0	O
against	0	O
beta	0	O
-	0	O
lactams	0	O
.	0	O


Armed	0	O
with	0	O
a	0	O
clear	0	O
understanding	0	O
of	0	O
the	0	O
pathophysiologic	0	O
pathways	0	O
that	0	O
may	0	O
cause	0	O
and	0	O
/	0	O
or	0	O
contribute	0	O
to	0	O
the	0	O
development	0	O
of	0	O
unconjugated	0	O
hyperbilirubinemia	0	O
and	0	O
the	0	O
associated	0	O
jaundice	0	O
,	0	O
the	0	O
practitioner	0	O
will	0	O
be	0	O
successful	0	O
in	0	O
helping	0	O
the	0	O
family	0	O
understand	0	O
their	0	O
child	0	O
'	0	O
s	0	O
illness	0	O
.	0	O


EMSA	0	O
showed	0	O
that	0	O
nuclear	0	O
proteins	0	O
from	0	O
PC12	0	O
but	0	O
not	0	O
C6	1	O
or	0	O
Rat2	0	O
cells	0	O
bind	0	O
the	0	O
CRE	0	O
as	0	O
a	0	O
complex	0	O
containing	0	O
activating	0	B
transcription	0	I
factor	0	I
(	0	I
ATF	0	I
)-	0	I
4	0	I
and	0	O
CCAAT	0	B
enhancer	0	I
-	0	I
binding	0	I
protein	0	I
beta	0	I
,	0	O
while	0	O
both	0	O
PC12	0	O
and	0	O
C6	1	O
cell	0	O
nuclear	0	O
extracts	0	O
were	0	O
recruited	0	O
by	0	O
the	0	O
CCAAT	0	O
-	0	O
box	0	O
as	0	O
a	0	O
complex	0	O
containing	0	O
nuclear	0	B
factor	0	I
Y	1	I
.	0	O


Recombinant	1	O
expression	0	O
of	0	O
a	0	O
chimeric	0	O
EGFR	1	B
/	0	O
ErbB	0	B
-	0	I
3	0	I
receptor	0	I
in	0	O
NIH	1	O
3T3	0	O
fibroblasts	0	O
allowed	0	O
us	0	O
to	0	O
investigate	0	O
cytoplasmic	0	O
events	0	O
associated	0	O
with	0	O
ErbB	0	B
-	0	I
3	0	I
signal	0	O
transduction	0	O
upon	0	O
ligand	0	O
activation	0	O
.	0	O


Replacing	0	O
residues	0	O
405	0	O
-	0	O
419	0	O
on	0	O
delta419	0	O
with	0	O
the	0	O
conserved	0	O
AF	1	O
-	0	O
2	0	O
domain	0	O
from	0	O
the	0	O
vitamin	0	B
D3	0	I
receptor	0	I
or	0	O
the	0	O
estrogen	0	B
receptor	0	I
results	0	O
in	0	O
a	0	O
receptor	0	O
with	0	O
wild	0	O
-	0	O
type	0	O
or	0	O
low	0	O
transcriptional	0	O
activity	0	O
,	0	O
respectively	0	O
.	0	O


Prevention	1	O
of	0	O
acute	0	O
paraquat	0	O
toxicity	0	O
in	0	O
rats	0	O
by	0	O
superoxide	0	B
dismutase	0	I
.	0	O


Thrombolysis	1	O
was	0	O
followed	0	O
by	0	O
a	0	O
similar	0	O
increase	0	O
of	0	O
platelet	0	O
activity	0	O
with	0	O
maximal	0	O
values	0	O
reached	0	O
at	0	O
the	0	O
3rd	0	O
hour	0	O
in	0	O
both	0	O
groups	0	O
(	0	O
196	0	O
+/-	0	O
43	0	O
IU	1	O
/	0	O
ml	0	O
in	0	O
Group	1	O
1	0	O
and	0	O
192	0	O
+/-	0	O
39	0	O
in	0	O
Group	1	O
2	0	O
:	0	O
p	0	O
&	0	O
lt	0	O
;	0	O
001versus	0	O
baseline	0	O
and	0	O
p	0	O
NS	1	O
between	0	O
the	0	O
groups	0	O
).	0	O


Scanning	1	O
electron	0	O
microscopic	0	O
investigations	0	O
on	0	O
the	0	O
formation	0	O
of	0	O
Reissner	0	O
'	0	O
s	0	O
fiber	0	O
in	0	O
Rattus	1	O
rattus	0	O


Blood	1	O
samples	0	O
were	0	O
obtained	0	O
daily	0	O
during	0	O
this	0	O
supplementation	0	O
period	0	O
and	0	O
5	0	O
d	0	O
thereafter	0	O
(	0	O
d	0	O
11	0	O
to	0	O
15	0	O
).	0	O


A	1	O
rabbit	0	O
antiserum	0	O
was	0	O
raised	0	O
against	0	O
a	0	O
synthetic	0	O
peptide	0	O
corresponding	0	O
to	0	O
a	0	O
hydrophilic	0	O
portion	0	O
of	0	O
the	0	O
translated	0	O
murine	0	O
cDNA	1	O
sequence	0	O
.	0	O


We	0	O
analyzed	0	O
the	0	O
modular	0	O
organization	0	O
of	0	O
DNA	1	B
polymerase	0	I
beta	0	I
and	0	O
found	0	O
that	0	O
residues	0	O
making	0	O
contact	0	O
with	0	O
DNA	1	O
phosphates	0	O
were	0	O
localized	0	O
to	0	O
five	0	O
modules	0	O
.	0	O


Some	0	O
studies	0	O
of	0	O
exercise	0	O
have	0	O
associated	0	O
beta	0	B
-	0	I
endorphin	0	I
release	0	O
with	0	O
increased	0	O
exertion	0	O
levels	0	O
,	0	O
but	0	O
other	0	O
evidence	0	O
suggests	0	O
that	0	O
acidosis	0	O
may	0	O
stimulate	0	O
the	0	O
release	0	O
of	0	O
beta	0	B
-	0	I
endorphin	0	I
.	0	O


Subsequent	0	O
cloning	0	O
and	0	O
nucleotide	0	O
sequence	0	O
analysis	0	O
of	0	O
the	0	O
S	1	B
.	0	I
pombe	0	I
adenylate	0	I
kinase	0	I
gene	0	I
,	0	O
adk1	0	B
,	0	O
revealed	0	O
a	0	O
coding	0	O
region	0	O
of	0	O
660	0	O
nucleotides	0	O
.	0	O


We	0	O
here	0	O
demonstrate	0	O
that	0	O
a	0	O
temperature	0	O
-	0	O
sensitive	0	O
fission	0	O
yeast	0	O
mutant	0	O
which	0	O
has	0	O
a	0	O
mutation	0	O
in	0	O
a	0	O
homologous	0	O
gene	0	O
,	0	O
and	0	O
two	0	O
of	0	O
three	0	O
additional	0	O
(	0	O
mtr1	0	B
/	0	O
prp20	0	B
/	0	O
srm1	0	B
)	0	O
mutants	0	O
accumulate	0	O
nuclear	0	O
poly	0	O
(	0	O
A	1	O
)+	0	O
RNA	1	O
at	0	O
37	0	O
degrees	0	O
C	1	O
.	0	O


After	0	O
gamma	0	O
-	0	O
irradiation	0	O
,	0	O
the	0	O
majority	0	O
of	0	O
F9	0	O
cells	0	O
undergo	0	O
apoptosis	0	O
implying	0	O
that	0	O
wt	0	B
-	0	I
p53	0	I
likely	0	O
triggers	0	O
pro	0	O
-	0	O
apoptotic	0	O
gene	0	O
expression	0	O
in	0	O
DNA	1	O
damaged	0	O
cells	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
alter	0	O
the	0	O
dimerization	0	O
specificity	0	O
of	0	O
Fos	1	B
by	0	O
precisely	0	O
replacing	0	O
its	0	O
leucine	0	O
zipper	0	O
with	0	O
that	0	O
from	0	O
GCN4	0	B
.	0	O


Expression	1	O
of	0	O
the	0	O
phenylalanine	0	B
hydroxylase	0	I
gene	0	I
in	0	O
livers	0	O
and	0	O
kidneys	0	O
of	0	O
rodents	0	O
is	0	O
activated	0	O
at	0	O
birth	0	O
and	0	O
is	0	O
induced	0	O
by	0	O
glucocorticoids	0	O
and	0	O
cyclic	0	O
AMP	1	O
in	0	O
the	0	O
liver	0	O
.	0	O


Model	1	O
of	0	O
spatiotemporal	0	O
dynamics	0	O
of	0	O
stick	0	O
-	0	O
slip	0	O
motion	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
describe	0	O
a	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
nuclear	0	O
protein	0	O
,	0	O
YT521	0	B
-	0	I
B	1	I
,	0	O
and	0	O
show	0	O
that	0	O
it	0	O
interacts	0	O
with	0	O
the	0	O
nuclear	0	B
transcriptosomal	0	I
component	0	I
scaffold	0	I
attachment	0	I
factor	0	I
B	1	I
,	0	O
and	0	O
the	0	O
68	0	B
-	0	I
kDa	1	I
Src	1	I
substrate	0	O
associated	0	O
during	0	O
mitosis	0	O
,	0	O
Sam68	0	B
.	0	O


On	1	O
the	0	O
other	0	O
hand	0	O
,	0	O
cells	0	O
containing	0	O
a	0	O
PTP1C	0	B
in	0	O
which	0	O
the	0	O
catalytic	0	O
site	0	O
had	0	O
been	0	O
inactivated	0	O
through	0	O
mutagenesis	0	O
,	0	O
stably	0	O
phosphorylated	0	O
the	0	O
phosphatase	0	O
.	0	O


The	0	O
various	0	O
forms	0	O
of	0	O
sickle	0	O
cell	0	O
disease	0	O
share	0	O
the	0	O
common	0	O
feature	0	O
of	0	O
an	0	O
abnormal	0	O
globin	0	B
chain	0	I
that	0	O
,	0	O
under	0	O
certain	0	O
conditions	0	O
such	0	O
as	0	O
hypoxia	0	O
,	0	O
results	0	O
in	0	O
the	0	O
sickling	0	O
of	0	O
red	0	O
blood	0	O
cells	0	O
and	0	O
obstruction	0	O
of	0	O
blood	0	O
vessels	0	O
.	0	O


Abbreviations	0	O
:	0	O
CAS	1	B
,	0	O
CRK	0	B
-	0	I
associated	0	I
substrate	0	I
;	0	O
CH	1	B
,	0	O
calponin	0	B
-	0	I
homology	0	I
domain	0	I
;	0	O
CSK	0	B
,	0	O
C	1	B
-	0	I
terminal	0	I
SRC	1	I
kinase	0	I
;	0	O
E6	0	B
,	0	O
Papillomavirus	1	B
E6	0	I
protein	0	I
;	0	O
FAK	0	B
,	0	O
focal	0	B
adhesion	0	I
kinase	0	I
;	0	O
GIT	0	B
,	0	O
GRK	0	B
interacter	0	I
;	0	O
GPCR	1	B
,	0	O
heterotrimeric	0	B
-	0	I
G	1	I
-	0	I
protein	0	I
-	0	I
coupled	0	I
receptor	0	I
;	0	O
GRK	0	B
,	0	O
G	1	B
-	0	I
protein	0	I
-	0	I
coupled	0	I
-	0	I
receptor	0	I
kinase	0	I
;	0	O
MAPK	1	B
,	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
(	0	O
ERK	0	B
,	0	O
p38	0	B
,	0	O
JNK	0	B
);	0	O
PAK	0	B
,	0	O
p21	0	B
-	0	I
activated	0	I
kinase	0	I
;	0	O
PBS	0	B
,	0	O
paxillin	0	B
-	0	I
binding	0	I
subdomain	0	I
;	0	O
PIX	1	B
,	0	O
PAK	0	B
-	0	I
interacting	0	I
exchange	0	I
factor	0	I
;	0	O
PKL	0	B
,	0	O
paxillin	0	B
kinase	0	I
linker	0	I
;	0	O
POR1	0	B
,	0	O
partner	0	B
of	0	I
Rac	0	I
;	0	O
PS	1	O
,	0	O
phosphoserine	0	O
;	0	O
PT	1	O
,	0	O
phosphothreonine	0	O
;	0	O
PY	0	O
,	0	O
phosphotyrosine	0	O
;	0	O
RTK	0	B
,	0	O
growth	0	B
factor	0	I
receptor	0	I
tyrosine	0	I
kinase	0	I
;	0	O
SH	1	B
,	0	O
SRC	1	B
-	0	I
homology	0	I
domain	0	I
.	0	O


In	1	O
the	0	O
B6	0	O
-	0	O
derived	0	O
Db	1	B
mutant	0	I
B6	0	I
.	0	I
CH	1	I
-	0	I
2bm13	0	I
(	0	I
bm13	0	I
)	0	I
strain	0	O
,	0	O
part	0	O
of	0	O
the	0	O
class	0	B
I	1	I
Db	1	I
antigen	0	I
-	0	I
presenting	0	I
groove	0	I
is	0	O
shaped	0	O
by	0	O
a	0	O
class	0	B
I	1	I
Kb	1	I
-	0	I
encoded	0	I
sequence	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
dig1	0	B
dig2	0	I
cells	0	O
constitutively	0	O
invade	0	O
agar	0	O
medium	0	O
,	0	O
whereas	0	O
a	0	O
dig1	0	B
dig2	0	I
ste12	0	I
triple	0	O
mutant	0	O
does	0	O
not	0	O
,	0	O
indicating	0	O
that	0	O
Dig1	0	B
and	0	O
Dig2	0	B
share	0	O
a	0	O
role	0	O
in	0	O
negatively	0	O
regulating	0	O
the	0	O
invasive	0	O
growth	0	O
pathway	0	O
.	0	O


Papers	0	O
of	0	O
the	0	O
Society	0	O
for	0	O
Clinical	1	O
Vascular	1	O
Surgery	1	O
.	0	O


Survival	1	O
of	0	O
111	0	O
Indium	1	O
-	0	O
labelled	0	O
autologous	0	O
platelets	0	O
was	0	O
studied	0	O
in	0	O
2	0	O
patients	0	O
after	0	O
correction	0	O
of	0	O
platelet	0	O
count	0	O
and	0	O
was	0	O
still	0	O
found	0	O
shortened	0	O
.	0	O


Thus	0	O
RV	1	O
O2	1	O
demand	0	O
fell	0	O
when	0	O
RC	0	O
O2	1	O
supply	0	O
was	0	O
reduced	0	O
,	0	O
although	0	O
a	0	O
flow	0	O
reserve	0	O
was	0	O
available	0	O
.	0	O


This	0	O
c	0	B
-	0	I
Jun	1	I
activity	0	O
is	0	O
inhibited	0	O
by	0	O
c	0	B
-	0	I
Fos	1	I
,	0	O
another	0	O
protooncoprotein	0	O
that	0	O
can	0	O
dimerize	0	O
with	0	O
c	0	B
-	0	I
Jun	1	I
to	0	O
form	0	O
the	0	O
transcription	0	O
factor	0	O
AP	1	B
-	0	I
1	0	I
.	0	O


RESULTS	0	O
:	0	O
In	1	O
the	0	O
pregnant	0	O
group	0	O
,	0	O
serum	0	O
PP14	0	B
concentrations	0	O
were	0	O
markedly	0	O
increased	0	O
after	0	O
ET	1	O
,	0	O
and	0	O
a	0	O
significant	0	O
difference	0	O
between	0	O
the	0	O
pregnant	0	O
group	0	O
and	0	O
the	0	O
nonpregnant	0	O
group	0	O
was	0	O
observed	0	O
8	0	O
days	0	O
following	0	O
ET	1	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
).	0	O


They	0	O
share	0	O
many	0	O
downstream	0	O
targets	0	O
,	0	O
including	0	O
remodeling	0	O
of	0	O
the	0	O
actin	0	B
cytoskeleton	0	O
,	0	O
activation	0	O
of	0	O
p70	0	B
(	0	I
S6	0	I
)	0	I
kinase	0	I
and	0	O
c	0	B
-	0	I
jun	0	I
N	1	I
-	0	I
terminal	0	I
kinase	0	I
(	0	O
JNK	0	B
),	0	O
and	0	O
regulation	0	O
of	0	O
transcription	0	O
and	0	O
cell	0	O
proliferation	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
our	0	O
data	0	O
suggest	0	O
that	0	O
PecS	0	B
attenuates	0	O
pelD	0	B
and	0	O
pelE	0	B
expression	0	O
rather	0	O
than	0	O
acting	0	O
as	0	O
a	0	O
true	0	O
repressor	0	O
like	0	O
KdgR	0	B
.	0	O


Cholesterol	1	B
side	0	I
-	0	I
chain	0	I
cleavage	0	I
cytochrome	0	I
P450	0	I
(	0	O
CYP11A	0	B
;	0	O
P450scc	1	B
)	0	O
gene	0	O
expression	0	O
is	0	O
regulated	0	O
by	0	O
gonadotropins	0	B
via	0	O
cAMP	1	O
in	0	O
the	0	O
ovary	0	O
and	0	O
by	0	O
ACTH	1	B
via	0	O
cAMP	1	O
in	0	O
adrenal	0	O
cortical	0	O
cells	0	O
.	0	O


Study	1	O
groups	0	O
were	0	O
control	0	O
,	0	O
and	0	O
those	0	O
treated	0	O
with	0	O
the	0	O
alpha1	0	B
-	0	I
adrenoceptor	0	I
-	0	I
subtype	0	I
blockers	0	O
WB4101	0	O
(	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.)	0	O
or	0	O
chloroethylclonidine	0	O
(	0	O
1	0	O
.	0	O
9	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.).	0	O


3	0	O
.	0	O


Conversely	0	O
,	0	O
the	0	O
central	0	O
regions	0	O
are	0	O
highly	0	O
variable	0	O
.	0	O


Characterization	0	O
of	0	O
FIII	0	B
/	0	O
YY1	0	B
,	0	O
a	0	O
Xenopus	1	B
laevis	0	I
conserved	0	I
zinc	0	I
-	0	I
finger	0	I
protein	0	I
binding	0	O
to	0	O
the	0	O
first	0	O
exon	0	O
of	0	O
L1	0	B
and	0	O
L14	0	B
ribosomal	0	I
protein	0	I
genes	0	I
.	0	O


The	0	O
patients	0	O
are	0	O
two	0	O
healthy	0	O
adult	0	O
males	0	O
.	0	O


All	1	O
four	0	O
doubly	0	O
tyrosine	0	O
phosphorylated	0	O
TAM	0	O
peptides	0	O
cross	0	O
-	0	O
compete	0	O
with	0	O
each	0	O
other	0	O
for	0	O
binding	0	O
to	0	O
the	0	O
tandem	0	O
SH2	0	B
domains	0	I
of	0	O
ZAP	0	B
-	0	I
70	0	I
.	0	O


By	0	O
contrast	0	O
,	0	O
d	0	B
(	0	I
T2AG3T	0	I
)	0	I
and	0	O
d	0	B
(	0	I
T2G4T	0	I
)	0	I
form	0	O
only	0	O
the	0	O
G	1	O
-	0	O
quadruplex	0	O
monomer	0	O
structures	0	O
independent	0	O
of	0	O
K	1	O
cation	0	O
concentration	0	O
as	0	O
reported	0	O
previously	0	O
[	0	O
Sen	1	O
,	0	O
D	1	O
.,	0	O
&	0	O
Gilbert	0	O
,	0	O
W	1	O
.	0	O


Splice	1	O
variations	0	O
in	0	O
genes	0	O
coding	0	O
for	0	O
the	0	O
transmembrane	0	B
FGF	0	I
receptor	0	I
(	0	O
FGFR	0	B
)	0	O
result	0	O
in	0	O
isoforms	0	O
that	0	O
vary	0	O
in	0	O
the	0	O
ectodomain	0	O
,	0	O
intracellular	0	O
juxtamembrane	0	O
domain	0	O
,	0	O
and	0	O
the	0	O
intracellular	0	O
kinase	0	O
domain	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
mouse	0	O
ortholog	0	O
(	0	O
Mharp	0	B
/	0	O
Smarcal1	0	B
)	0	O
was	0	O
cloned	0	O
,	0	O
and	0	O
the	0	O
Caenorhabditis	0	O
elegans	0	O
ortholog	0	O
(	0	O
CEHARP	0	B
)	0	O
was	0	O
identified	0	O
in	0	O
the	0	O
GenBank	0	O
database	0	O
.	0	O


Of	0	O
those	0	O
injuries	0	O
,	0	O
143	0	O
cases	0	O
were	0	O
snowboard	0	O
related	0	O
and	0	O
158	0	O
cases	0	O
were	0	O
ski	0	O
related	0	O
.	0	O


Specifically	0	O
,	0	O
by	0	O
oligonucleotide	0	O
-	0	O
directed	0	O
site	0	O
-	0	O
specific	0	O
mutagenesis	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
of	0	O
10	0	O
cysteine	0	O
residues	0	O
in	0	O
the	0	O
ORF4	0	O
polypeptide	0	O
,	0	O
only	0	O
C	1	O
-	0	O
421	0	O
and	0	O
C	1	O
-	0	O
426	0	O
are	0	O
essential	0	O
for	0	O
transactivator	0	O
function	0	O
and	0	O
suggest	0	O
that	0	O
these	0	O
cysteine	0	O
residues	0	O
may	0	O
participate	0	O
in	0	O
critical	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
rather	0	O
than	0	O
protein	0	O
-	0	O
nucleic	0	O
acid	0	O
interactions	0	O
to	0	O
mediate	0	O
ORF4	0	O
inducibility	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
total	0	O
number	0	O
of	0	O
subunit	0	O
c	0	O
in	0	O
F0	0	B
should	0	O
be	0	O
a	0	O
multiple	0	O
of	0	O
2	0	O
and	0	O
3	0	O
.	0	O


Thus	0	O
,	0	O
SPECT	1	O
was	0	O
not	0	O
as	0	O
sensitive	0	O
as	0	O
PET	1	O
in	0	O
this	0	O
activation	0	O
task	0	O
.	0	O


Ovulation	1	O
was	0	O
induced	0	O
in	0	O
8	0	O
(	0	O
56	0	O
.	0	O
7	0	O
%)	0	O
patients	0	O
who	0	O
conceived	0	O
.	0	O


Adverse	0	O
foetal	0	O
outcome	0	O
in	0	O
specific	0	O
IgM	1	B
positive	0	O
Chlamydia	1	O
trachomatis	0	O
infection	0	O
in	0	O
pregnancy	0	O
.	0	O


The	0	O
regional	0	O
blockade	0	O
of	0	O
H1R	0	B
was	0	O
observed	0	O
mainly	0	O
in	0	O
the	0	O
frontal	0	O
,	0	O
temporal	0	O
and	0	O
anterior	0	O
cingulate	0	O
cortices	0	O
,	0	O
and	0	O
the	0	O
intravenous	0	O
administration	0	O
of	0	O
d	0	O
-	0	O
chlorpheniramine	0	O
as	0	O
a	0	O
therapeutic	0	O
dose	0	O
(	0	O
2	0	O
mg	0	O
)	0	O
blocked	0	O
over	0	O
60	0	O
%	0	O
of	0	O
H1R	0	B
in	0	O
the	0	O
frontal	0	O
cortices	0	O
.	0	O


cDNA	1	O
cloning	0	O
,	0	O
expression	0	O
analysis	0	O
,	0	O
and	0	O
chromosomal	0	O
localization	0	O
of	0	O
a	0	O
gene	0	O
with	0	O
high	0	O
homology	0	O
to	0	O
wheat	0	B
eIF	0	I
-(	0	I
iso	0	I
)	0	I
4F	0	I
and	0	O
mammalian	0	B
eIF	0	I
-	0	I
4G	0	I
.	0	O


The	0	O
discussion	0	O
focuses	0	O
primarily	0	O
on	0	O
the	0	O
newer	0	O
drugs	0	O
like	0	O
angiotensin	0	B
converting	0	I
enzyme	0	I
inhibitors	0	O
,	0	O
alpha	0	B
-	0	I
adrenergic	0	I
receptor	0	I
blockers	0	O
,	0	O
and	0	O
calcium	0	O
antagonists	0	O
.	0	O


In	1	O
the	0	O
local	0	O
geomagnetic	0	O
field	0	O
,	0	O
the	0	O
animals	0	O
preferred	0	O
the	0	O
SE	1	O
-	0	O
sector	0	O
.	0	O


A	1	O
reciprocal	0	O
binding	0	O
assay	0	O
using	0	O
IM	1	O
-	0	O
9	0	O
cells	0	O
as	0	O
a	0	O
source	0	O
of	0	O
SHP	0	B
-	0	I
1	0	I
and	0	O
SHP	0	B
-	0	I
2	0	I
revealed	0	O
specific	0	O
association	0	O
of	0	O
SHP	0	B
-	0	I
2	0	I
(	0	O
but	0	O
not	0	O
SHP	0	B
-	0	I
1	0	I
)	0	O
with	0	O
a	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
fusion	0	I
incorporating	0	O
GHR	0	B
cytoplasmic	0	I
domain	0	I
residues	0	I
485	0	I
-	0	I
620	0	I
,	0	O
but	0	O
only	0	O
if	0	O
the	0	O
fusion	0	O
was	0	O
first	0	O
rendered	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
.	0	O


The	0	O
application	0	O
of	0	O
these	0	O
microelectrodes	0	O
to	0	O
the	0	O
measurement	0	O
of	0	O
rapid	0	O
,	0	O
transient	0	O
changes	0	O
in	0	O
retinal	0	O
[	0	O
K	1	O
+]	0	O
o	0	O
is	0	O
presented	0	O
.	0	O


We	0	O
present	0	O
the	0	O
preliminary	0	O
results	0	O
obtained	0	O
on	0	O
36	0	O
patients	0	O
which	0	O
were	0	O
followed	0	O
for	0	O
a	0	O
mean	0	O
period	0	O
of	0	O
12	0	O
months	0	O
.	0	O


For	0	O
SMX	0	O
at	0	O
pH	1	O
7	0	O
.	0	O
0	0	O
,	0	O
a	0	O
1	0	O
:	0	O
1	0	O
complex	0	O
is	0	O
formed	0	O
,	0	O
but	0	O
at	0	O
pH	1	O
7	0	O
.	0	O
5	0	O
HPCD	0	O
has	0	O
little	0	O
effect	0	O
on	0	O
the	0	O
solubility	0	O
of	0	O
the	0	O
highly	0	O
ionized	0	O
SMX	0	O
,	0	O
presumably	0	O
since	0	O
only	0	O
un	0	O
-	0	O
ionized	0	O
molecules	0	O
can	0	O
form	0	O
inclusion	0	O
complexes	0	O
with	0	O
the	0	O
HPCD	0	O
.	0	O


However	0	O
,	0	O
in	0	O
those	0	O
studies	0	O
due	0	O
to	0	O
the	0	O
presence	0	O
of	0	O
thiol	0	O
agents	0	O
in	0	O
the	0	O
PKC	0	B
preparations	0	O
,	0	O
the	0	O
sensitive	0	O
reaction	0	O
of	0	O
BPO	0	O
with	0	O
redox	0	O
-	0	O
active	0	O
cysteine	0	O
residues	0	O
in	0	O
PKC	0	B
was	0	O
not	0	O
observed	0	O
.	0	O


Both	0	O
functional	0	O
analyses	0	O
in	0	O
undifferentiated	0	O
and	0	O
differentiated	0	O
F9	0	O
cells	0	O
and	0	O
characterization	0	O
of	0	O
DNA	1	O
-	0	O
protein	0	O
complexes	0	O
in	0	O
vitro	0	O
have	0	O
identified	0	O
the	0	O
sequence	0	O
motifs	0	O
GTGACT	0	O
(	0	O
C	1	O
),	0	O
ATTGT	0	O
,	0	O
and	0	O
GATA	0	O
as	0	O
the	0	O
key	0	O
transcription	0	O
factor	0	O
binding	0	O
sites	0	O
.	0	O


Increased	0	O
granulocyte	0	B
-	0	I
colony	0	I
stimulating	0	I
factor	0	I
(	0	O
G	1	B
-	0	I
CSF	1	I
)	0	O
levels	0	O
in	0	O
neonates	0	O
with	0	O
perinatal	0	O
complications	0	O
.	0	O


Inhibition	1	O
of	0	O
the	0	O
Mek	0	B
/	0	O
Erk	0	B
pathway	0	O
in	0	O
Rat1	0	O
/	0	O
ras	0	B
cells	0	O
,	0	O
using	0	O
the	0	O
Mek	0	B
inhibitor	0	O
,	0	O
PD98059	0	O
,	0	O
resulted	0	O
in	0	O
complete	0	O
cytoskeletal	0	O
recovery	0	O
,	0	O
indistinguishable	0	O
from	0	O
that	0	O
induced	0	O
by	0	O
HR12	0	O
.	0	O


One	0	O
is	0	O
to	0	O
act	0	O
within	0	O
the	0	O
visceral	0	O
endoderm	0	O
to	0	O
promote	0	O
proper	0	O
streak	0	O
morphogenesis	0	O
.	0	O


Teicoplanin	1	O
was	0	O
given	0	O
most	0	O
often	0	O
because	0	O
of	0	O
persistent	0	O
fever	0	O
or	0	O
initial	0	O
Gram	1	O
-	0	O
positive	0	O
bacteraemia	0	O
and	0	O
only	0	O
one	0	O
-	0	O
third	0	O
of	0	O
these	0	O
cases	0	O
responded	0	O
.	0	O


RESULTS	0	O
:	0	O
Looking	0	O
at	0	O
the	0	O
question	0	O
of	0	O
its	0	O
benefits	0	O
,	0	O
we	0	O
were	0	O
unable	0	O
to	0	O
find	0	O
any	0	O
methodologically	0	O
sound	0	O
studies	0	O
that	0	O
have	0	O
shown	0	O
efficacy	0	O
for	0	O
EMDR	1	O
in	0	O
eating	0	O
disorders	0	O
,	0	O
or	0	O
,	0	O
indeed	0	O
,	0	O
any	0	O
psychiatric	0	O
disorder	0	O
.	0	O


As	1	O
normal	0	O
B	1	O
cells	0	O
also	0	O
present	0	O
this	0	O
variant	0	O
,	0	O
the	0	O
mechanism	0	O
of	0	O
CD79b	0	B
posttranscriptional	0	O
regulation	0	O
might	0	O
reflect	0	O
the	0	O
activation	0	O
stage	0	O
of	0	O
the	0	O
normal	0	O
B	1	O
cell	0	O
from	0	O
which	0	O
B	1	O
-	0	O
CLL	1	O
derives	0	O
.	0	O


Distal	1	O
tubular	0	O
acidification	0	O
and	0	O
the	0	O
threshold	0	O
for	0	O
proximal	0	O
tubular	0	O
bicarbonate	0	O
reabsorption	0	O
were	0	O
normal	0	O
,	0	O
as	0	O
was	0	O
urine	0	O
concentrating	0	O
capacity	0	O
.	0	O


A	1	O
role	0	O
for	0	O
the	0	O
small	0	B
GTPase	1	I
Rac	0	I
in	0	O
polyomavirus	0	B
middle	0	I
-	0	I
T	1	I
antigen	0	I
-	0	O
mediated	0	O
activation	0	O
of	0	O
the	0	O
serum	0	O
response	0	O
element	0	O
and	0	O
in	0	O
cell	0	O
transformation	0	O
.	0	O


The	0	O
SV40	1	B
enhancer	0	I
augmented	0	O
replication	0	O
1	0	O
.	0	O
5	0	O
-	0	O
10	0	O
fold	0	O
.	0	O


Molecular	1	O
cloning	0	O
of	0	O
the	0	O
polypeptide	0	O
component	0	O
of	0	O
the	0	O
Rel	0	B
-	0	I
related	0	I
human	0	I
p75	0	I
nucleoprotein	0	I
complex	0	I
has	0	O
revealed	0	O
its	0	O
identity	0	O
with	0	O
the	0	O
65	0	O
-	0	O
kDa	1	O
(	0	O
p65	0	B
)	0	O
subunit	0	O
of	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
.	0	O


The	0	O
mRNAs	0	O
of	0	O
the	0	O
GRF	0	B
genes	0	I
are	0	O
encoded	0	O
by	0	O
six	0	O
exons	0	O
interrupted	0	O
by	0	O
five	0	O
introns	0	O
.	0	O


The	0	O
afferents	0	O
'	0	O
phase	0	O
of	0	O
response	0	O
was	0	O
unmodified	0	O
by	0	O
electrical	0	O
EVS	0	O
stimulation	0	O
.	0	O


Is	1	O
desensitization	0	O
'	0	O
for	0	O
ragweed	0	O
hay	0	O
fever	0	O
immunologically	0	O
specific	0	O
?	0	O


Of	0	O
the	0	O
117	0	O
patients	0	O
(	0	O
out	0	O
of	0	O
the	0	O
136	0	O
)	0	O
with	0	O
serologic	0	O
evidence	0	O
of	0	O
chronic	0	O
thyroiditis	0	O
who	0	O
could	0	O
be	0	O
studied	0	O
,	0	O
eight	0	O
(	0	O
7	0	O
%)	0	O
had	0	O
hyperthyroidism	0	O
and	0	O
45	0	O
(	0	O
38	0	O
%)	0	O
were	0	O
hypothyroid	0	O
.	0	O


Comparison	0	O
of	0	O
sequences	0	O
of	0	O
ovine	0	O
and	0	O
bovine	0	O
,	0	O
rat	0	O
and	0	O
guinea	0	B
-	0	I
pig	0	I
alpha	0	I
s1	0	I
-	0	I
casein	0	I
mRNAs	0	I
has	0	O
revealed	0	O
a	0	O
greater	0	O
homology	0	O
in	0	O
the	0	O
3	0	O
'	0	O
and	0	O
especially	0	O
5	0	O
'	0	O
non	0	O
coding	0	O
regions	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
identified	0	O
two	0	O
mutations	0	O
,	0	O
Delta	1	O
M1281	0	O
and	0	O
IVS51	0	O
+	0	O
5G	0	O
-->	0	O
A	1	O
,	0	O
in	0	O
a	0	O
German	0	O
USH1	0	B
patient	0	O
.	0	O


Identification	1	O
of	0	O
this	0	O
region	0	O
as	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
tmk	0	I
gene	0	I
was	0	O
confirmed	0	O
by	0	O
functional	0	O
complementation	0	O
of	0	O
a	0	O
yeast	0	B
dTMP	1	I
kinase	0	I
temperature	0	O
-	0	O
sensitive	0	O
mutant	0	O
and	0	O
by	0	O
in	0	O
vitro	0	O
enzyme	0	O
assay	0	O
of	0	O
the	0	O
thymidylate	0	B
kinase	0	I
activity	0	O
in	0	O
cell	0	O
extracts	0	O
of	0	O
E	1	O
.	0	O
coli	0	O
by	0	O
use	0	O
of	0	O
tmk	0	B
-	0	O
overproducing	0	O
plasmids	0	O
.	0	O


However	0	O
,	0	O
if	0	O
the	0	O
spatial	0	O
resolution	0	O
is	0	O
not	0	O
critical	0	O
and	0	O
interest	0	O
is	0	O
to	0	O
compare	0	O
a	0	O
pathologic	0	O
area	0	O
with	0	O
a	0	O
contralateral	0	O
VOI	0	O
,	0	O
then	0	O
the	0	O
acquisition	0	O
of	0	O
two	0	O
single	0	O
-	0	O
voxel	0	O
spectra	0	O
may	0	O
be	0	O
preferred	0	O
.	0	O


RNA	1	O
blot	0	O
hybridizations	0	O
identified	0	O
an	0	O
1	0	O
.	0	O
8	0	O
-	0	O
kb	0	O
mRNA	1	O
common	0	O
to	0	O
cytochrome	0	B
b6	0	I
and	0	O
subunit	0	O
IV	1	O
,	0	O
and	0	O
an	0	O
intensely	0	O
hybridizing	0	O
0	0	O
.	0	O
8	0	O
-	0	O
kb	0	O
mRNA	1	O
specific	0	O
to	0	O
the	0	O
subunit	0	O
IV	1	O
gene	0	O
probe	0	O
.	0	O


Human	1	B
rIL	0	I
-	0	I
3	0	I
expressed	0	O
in	0	O
COS7	0	O
cells	0	O
has	0	O
multipotential	0	O
CSF	1	B
activity	0	O
in	0	O
semisolid	0	O
cultures	0	O
of	0	O
bone	0	O
marrow	0	O
cells	0	O
,	0	O
and	0	O
selectively	0	O
induced	0	O
the	0	O
proliferation	0	O
of	0	O
My	1	O
-	0	O
10	0	O
+	0	O
marrow	0	O
or	0	O
cord	0	O
blood	0	O
cells	0	O
in	0	O
liquid	0	O
cultures	0	O
.	0	O


(	0	O
3	0	O
).	0	O


We	0	O
have	0	O
cloned	0	O
and	0	O
characterized	0	O
a	0	O
55	0	O
-	0	O
kb	0	O
region	0	O
of	0	O
DNA	1	O
surrounding	0	O
HRAS1	0	B
.	0	O


Isoform	1	B
C	1	I
beta	0	I
2	0	I
,	0	O
an	0	O
unusual	0	O
form	0	O
of	0	O
the	0	O
bovine	0	O
catalytic	0	O
subunit	0	O
of	0	O
cAMP	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
.	0	O


For	0	O
this	0	O
purpose	0	O
,	0	O
a	0	O
segment	0	O
of	0	O
dxr	0	B
was	0	O
amplified	0	O
from	0	O
Synechococcus	0	O
leopoliensis	0	O
SAUG	0	O
1402	0	O
-	0	O
1	0	O
DNA	1	O
via	0	O
PCR	1	O
using	0	O
oligonucleotides	0	O
for	0	O
conserved	0	O
regions	0	O
.	0	O


Of	0	O
49	0	O
receptors	0	O
which	0	O
fired	0	O
in	0	O
phase	0	O
with	0	O
ventilation	0	O
,	0	O
13	0	O
behaved	0	O
like	0	O
mammalian	0	O
rapidly	0	O
adapting	0	O
pulmonary	0	O
stretch	0	O
receptors	0	O
,	0	O
19	0	O
like	0	O
mammalian	0	O
slowly	0	O
adapting	0	O
pulmonary	0	O
stretch	0	O
receptors	0	O
(	0	O
PSR	0	O
),	0	O
and	0	O
17	0	O
like	0	O
avian	0	O
intrapulmonary	0	O
CO2	1	O
-	0	O
sensitive	0	O
chemoreceptors	0	O
(	0	O
IPC	0	O
).	0	O


The	0	O
patients	0	O
were	0	O
divided	0	O
into	0	O
ischaemia	0	O
and	0	O
non	0	O
-	0	O
ischaemia	0	O
groups	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
the	0	O
change	0	O
in	0	O
lactate	0	O
extraction	0	O
ratio	0	O
during	0	O
balloon	0	O
inflation	0	O
.	0	O


With	0	O
the	0	O
help	0	O
of	0	O
a	0	O
nomogram	0	O
one	0	O
can	0	O
read	0	O
off	0	O
the	0	O
refraction	0	O
,	0	O
when	0	O
axis	0	O
length	0	O
and	0	O
corneal	0	O
curvature	0	O
are	0	O
known	0	O
.	0	O


The	0	O
infection	0	O
rate	0	O
was	0	O
five	0	O
times	0	O
greater	0	O
in	0	O
patients	0	O
with	0	O
Hickman	0	O
catheters	0	O
than	0	O
in	0	O
those	0	O
with	0	O
Broviac	0	O
catheters	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Anesthesia	1	O
with	0	O
M	1	O
/	0	O
K	1	O
was	0	O
reversed	0	O
after	0	O
41	0	O
.	0	O
6	0	O
min	0	O
of	0	O
immobilization	0	O
with	0	O
atipamezole	0	O
.	0	O


Lung	1	O
function	0	O
tests	0	O
(	0	O
EFR	0	O
)	0	O
were	0	O
performed	0	O
on	0	O
these	0	O
patients	0	O
for	0	O
a	0	O
period	0	O
of	0	O
19	0	O
.	0	O
2	0	O
+/-	0	O
3	0	O
.	0	O
4	0	O
months	0	O
.	0	O


Specifically	0	O
,	0	O
the	0	O
deduced	0	O
FR	1	B
-	0	I
19	0	I
amino	0	I
acid	0	I
sequence	0	I
has	0	O
approximately89	0	O
,	0	O
77	0	O
,	0	O
and	0	O
68	0	O
%	0	O
overall	0	O
identity	0	O
to	0	O
chicken	0	B
TEF	0	I
-	0	I
1A	0	I
,	0	O
mouse	0	B
TEF	0	I
-	0	I
1	0	I
,	0	O
and	0	O
mouse	0	B
embryonic	0	I
TEA	1	I
domain	0	I
-	0	I
containing	0	I
factor	0	I
,	0	O
respectively	0	O
.	0	O


40	0	O
.	0	O
3	0	O
+/-	0	O
10	0	O
.	0	O
1	0	O
mg	0	O
/	0	O
l	0	O
(	0	O
SD	1	O
)	0	O
vs	0	O
31	0	O
.	0	O
2	0	O
+/-	0	O
8	0	O
.	0	O
0	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O
beta	0	B
2m	0	I
was	0	O
not	0	O
significantly	0	O
higher	0	O
in	0	O
patients	0	O
with	0	O
bone	0	O
cysts	0	O
(	0	O
37	0	O
.	0	O
7	0	O
+/-	0	O
11	0	O
.	0	O
4	0	O
mg	0	O
/	0	O
l	0	O
vs	0	O
37	0	O
.	0	O
0	0	O
+/-	0	O
10	0	O
.	0	O
0	0	O
),	0	O
but	0	O
median	0	O
duration	0	O
of	0	O
dialysis	0	O
was	0	O
significantly	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
)	0	O
longer	0	O
in	0	O
patients	0	O
with	0	O
bone	0	O
cysts	0	O
(	0	O
90	0	O
vs	0	O
57	0	O
months	0	O
).	0	O
beta	0	B
2m	0	I
was	0	O
lower	0	O
in	0	O
patients	0	O
maintained	0	O
on	0	O
dialysis	0	O
for	0	O
less	0	O
than	0	O
1	0	O
year	0	O
and	0	O
whose	0	O
residual	0	O
urine	0	O
volume	0	O
was	0	O
greater	0	O
than	0	O
0	0	O
.	0	O
1	0	O
litre	0	O
per	0	O
day	0	O
.	0	O


E	1	O
50	0	O
,	0	O
843	0	O
(	0	O
1994	0	O
)].	0	O


Complete	0	O
sequences	0	O
were	0	O
obtained	0	O
for	0	O
the	0	O
three	0	O
large	0	O
thrombic	0	O
peptides	0	O
,	0	O
and	0	O
these	0	O
were	0	O
aligned	0	O
by	0	O
using	0	O
peptides	0	O
from	0	O
the	0	O
V8	0	B
protease	0	I
digest	0	O
.	0	O


The	0	O
suppression	0	O
was	0	O
also	0	O
demonstrated	0	O
in	0	O
a	0	O
transient	0	O
expression	0	O
assay	0	O
in	0	O
vivo	0	O
using	0	O
isolated	0	O
barley	0	O
endosperms	0	O
.	0	O


Interestingly	0	O
,	0	O
these	0	O
response	0	O
elements	0	O
display	0	O
dramatically	0	O
reduced	0	O
affinity	0	O
for	0	O
retinoic	0	B
acid	0	I
receptor	0	I
-	0	O
retinoid	0	B
-	0	I
X	1	I
receptor	0	I
heterodimers	0	O
.	0	O


Auto	0	O
-	0	O
and	0	O
isotopy	0	O
of	0	O
the	0	O
conjunctiva	0	O


Comparison	0	O
with	0	O
alkaline	0	B
phosphatases	0	I
and	0	O
5	0	B
-	0	I
nucleotidase	0	I
.	0	O


Transcriptional	1	O
regulation	0	O
of	0	O
the	0	O
yeast	0	B
PHO8	0	I
promoter	0	I
in	0	O
comparison	0	O
to	0	O
the	0	O
coregulated	0	O
PHO5	0	B
promoter	0	I
.	0	O


Expression	1	O
of	0	O
the	0	O
wt1	0	B
gene	0	I
via	0	O
transient	0	O
transfection	0	O
in	0	O
COS	1	O
-	0	O
1	0	O
cells	0	O
revealed	0	O
a	0	O
52	0	O
kDa	1	O
protein	0	O
which	0	O
was	0	O
immunoprecipitated	0	O
by	0	O
both	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
-	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
-	0	O
specific	0	O
antisera	0	O
.	0	O


The	0	O
SUP44	0	B
suppressor	0	I
mutation	0	I
occurs	0	O
near	0	O
a	0	O
region	0	O
of	0	O
the	0	O
protein	0	O
that	0	O
corresponds	0	O
to	0	O
the	0	O
known	0	O
positions	0	O
of	0	O
alterations	0	O
in	0	O
E	1	B
.	0	I
coli	0	I
S5	0	I
ram	0	I
mutations	0	I
.	0	O


Deadenylation	0	O
and	0	O
decay	0	O
of	0	O
beta	0	B
-	0	I
globin	0	I
mRNA	1	I
in	0	O
K562	0	O
cells	0	O
is	0	O
extraordinarily	0	O
slow	0	O
compared	0	O
with	0	O
NIH	1	O
3T3	0	O
cells	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
increased	0	O
stability	0	O
gained	0	O
by	0	O
beta	0	B
-	0	I
globin	0	I
mRNA	1	I
in	0	O
K562	0	O
cells	0	O
is	0	O
mainly	0	O
controlled	0	O
at	0	O
the	0	O
deadenylation	0	O
step	0	O
.	0	O


The	0	O
cell	0	O
cycle	0	O
and	0	O
transcriptional	0	O
defects	0	O
caused	0	O
by	0	O
taf17	0	B
(	0	O
slm7	0	B
-	0	I
1	0	I
)	0	O
are	0	O
consistent	0	O
with	0	O
the	0	O
role	0	O
of	0	O
TAF	0	B
(	0	I
II	0	I
)	0	I
s	0	I
as	0	O
modulators	0	O
of	0	O
transcriptional	0	O
activation	0	O
and	0	O
may	0	O
reflect	0	O
a	0	O
role	0	O
for	0	O
TAF17	0	B
in	0	O
regulating	0	O
activation	0	O
by	0	O
SBF	0	B
and	0	O
MBF	0	B
.	0	O


A	1	O
unified	0	O
approach	0	O
to	0	O
the	0	O
standardization	0	O
of	0	O
allergens	0	O
.	0	O


Ang	0	B
II	0	I
-	0	O
induced	0	O
fibronectin	0	B
mRNA	1	O
was	0	O
not	0	O
affected	0	O
by	0	O
PKC	0	B
inhibitors	0	O
or	0	O
PKC	0	B
depletion	0	O
,	0	O
whereas	0	O
specific	0	O
inhibition	0	O
of	0	O
EGF	1	B
-	0	I
R	1	I
function	0	O
by	0	O
a	0	O
dominant	0	B
negative	0	I
EGF	1	I
-	0	I
R	1	I
mutant	0	I
and	0	O
tyrphostin	0	O
AG1478	0	O
abolished	0	O
induction	0	O
of	0	O
fibronectin	0	B
mRNA	1	I
.	0	O


Binding	0	O
of	0	O
meAda	0	B
is	0	O
necessary	0	O
to	0	O
activate	0	O
transcription	0	O
of	0	O
the	0	O
adaptive	0	O
response	0	O
genes	0	O
;	0	O
accordingly	0	O
,	0	O
in	0	O
vitro	0	O
transcription	0	O
of	0	O
aidB	0	B
is	0	O
dependent	0	O
on	0	O
the	0	O
presence	0	O
of	0	O
meAda	0	B
.	0	O


The	0	O
lowest	0	O
culture	0	O
failure	0	O
rate	0	O
of	0	O
0	0	O
.	0	O
2	0	O
per	0	O
cent	0	O
was	0	O
found	0	O
after	0	O
EAF	0	O
compared	0	O
with	0	O
0	0	O
.	0	O
9	0	O
per	0	O
cent	0	O
among	0	O
CVS	1	O
.	0	O


Deletion	1	O
mapping	0	O
of	0	O
the	0	O
human	0	B
presenilin	0	I
-	0	I
1	0	I
(	0	O
PS1	0	B
)	0	O
promoter	0	O
delineated	0	O
the	0	O
most	0	O
active	0	O
fragment	0	O
from	0	O
-	0	O
118	0	O
to	0	O
+	0	O
178	0	O
in	0	O
relation	0	O
to	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
mapped	0	O
in	0	O
this	0	O
study	0	O
,	0	O
in	0	O
both	0	O
human	0	O
neuroblastoma	0	O
SK	1	O
-	0	O
N	1	O
-	0	O
SH	1	O
and	0	O
hepatoma	0	O
HepG2	0	O
cells	0	O
.	0	O


How	0	O
many	0	O
embryos	0	O
to	0	O
transfer	0	O
in	0	O
patients	0	O
undergoing	0	O
IVF	1	O
?	0	O


The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
investigate	0	O
the	0	O
spontaneous	0	O
reports	0	O
of	0	O
suspected	0	O
adverse	0	O
drug	0	O
reactions	0	O
,	0	O
observed	0	O
in	0	O
elderly	0	O
patients	0	O
(	0	O
over	0	O
65	0	O
years	0	O
of	0	O
age	0	O
)	0	O
in	0	O
Sicily	0	O
(	0	O
Italy	0	O
)	0	O
during	0	O
the	0	O
period	0	O
from	0	O
1	0	O
January	0	O
1995	0	O
to	0	O
31	0	O
December	0	O
1997	0	O
.	0	O


Frozen	1	O
/	0	O
thawed	0	O
extensor	0	O
digitorum	0	O
longus	0	O
muscle	0	O
tendon	0	O
units	0	O
had	0	O
significantly	0	O
lower	0	O
values	0	O
for	0	O
load	0	O
to	0	O
failure	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
),	0	O
energy	0	O
absorbed	0	O
to	0	O
failure	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
),	0	O
and	0	O
strain	0	O
at	0	O
failure	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
),	0	O
and	0	O
they	0	O
tended	0	O
to	0	O
fail	0	O
at	0	O
a	0	O
different	0	O
anatomic	0	O
location	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
)	0	O
(	0	O
broadly	0	O
at	0	O
the	0	O
fascia	0	O
-	0	O
muscle	0	O
interface	0	O
as	0	O
compared	0	O
with	0	O
horizontally	0	O
at	0	O
the	0	O
musculotendinous	0	O
junction	0	O
)	0	O
than	0	O
fresh	0	O
units	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Fission	1	B
yeast	0	I
SCF	0	I
is	0	O
composed	0	O
of	0	O
Pop1	0	B
and	0	O
Pop2	0	B
,	0	O
two	0	O
structurally	0	O
related	0	O
but	0	O
functionally	0	O
independent	0	O
F	1	B
-	0	I
box	0	I
/	0	I
WD	0	I
-	0	I
repeat	0	I
proteins	0	I
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
both	0	O
naturally	0	O
acquired	0	O
and	0	O
passive	0	O
(	0	O
modified	0	O
immune	0	B
serum	0	I
globulin	0	I
)	0	O
antibodies	0	O
to	0	O
type	0	B
III	0	I
group	0	I
B	1	I
Streptococcus	1	I
antigen	0	I
are	0	O
partially	0	O
protective	0	O
against	0	O
intra	0	O
-	0	O
amniotic	0	O
infection	0	O
.	0	O


The	0	O
triple	0	O
combination	0	O
of	0	O
nizatidine	0	O
,	0	O
clarithromycin	0	O
,	0	O
and	0	O
bismuth	0	O
subcitrate	0	O
resulted	0	O
in	0	O
an	0	O
ulcer	0	O
healing	0	O
rate	0	O
of	0	O
98	0	O
%	0	O
and	0	O
an	0	O
H	1	O
.	0	O
pylori	0	O
eradication	0	O
rate	0	O
of	0	O
90	0	O
%.	0	O


The	0	O
responses	0	O
of	0	O
the	0	O
"	0	O
stress	0	O
hormones	0	O
"	0	O
cortisol	0	O
,	0	O
11	0	O
-	0	O
deoxycortisol	0	O
,	0	O
ACTH	1	B
,	0	O
vasopressin	0	B
(	0	O
AVP	1	B
),	0	O
and	0	O
corticotropin	0	B
releasing	0	I
factor	0	I
(	0	O
CRF	1	B
)	0	O
were	0	O
studied	0	O
in	0	O
6	0	O
normal	0	O
males	0	O
in	0	O
response	0	O
to	0	O
acute	0	O
cortisol	0	O
deficiency	0	O
induced	0	O
by	0	O
the	0	O
11	0	B
-	0	I
beta	0	I
-	0	I
hydroxylase	0	I
inhibitor	0	O
,	0	O
metyrapone	0	O
.	0	O


The	0	O
invasive	0	O
pattern	0	O
of	0	O
squamous	0	O
cell	0	O
carcinoma	0	O
in	0	O
the	0	O
mandibular	0	O
gingiva	0	O


The	0	O
cDNA	1	O
was	0	O
expressed	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
under	0	O
the	0	O
control	0	O
of	0	O
the	0	O
yeast	0	B
triose	0	I
phosphate	0	I
isomerase	0	I
promoter	0	I
.	0	O


Similarly	0	O
,	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
activity	0	O
of	0	O
activator	0	B
protein	0	I
1	0	I
(	0	O
AP	1	B
-	0	I
1	0	I
)	0	O
is	0	O
modified	0	O
by	0	O
a	0	O
DNA	1	B
repair	0	I
enzyme	0	I
,	0	O
redox	0	B
factor	0	I
1	0	I
(	0	O
Ref	0	B
-	0	I
1	0	I
),	0	O
which	0	O
is	0	O
identical	0	O
to	0	O
a	0	O
DNA	1	B
repair	0	I
enzyme	0	I
,	0	O
AP	1	B
endonuclease	0	I
.	0	O


When	0	O
RNA	1	O
encoding	0	O
the	0	O
tail	0	O
domain	0	O
of	0	O
desmoglein	0	B
was	0	O
coinjected	0	O
with	0	O
plakoglobin	0	B
RNA	1	I
,	0	O
both	0	O
the	0	O
dorsalizing	0	O
effect	0	O
and	0	O
nuclear	0	O
accumulation	0	O
of	0	O
plakoglobin	0	B
were	0	O
suppressed	0	O
.	0	O


All	1	O
control	0	O
persons	0	O
had	0	O
a	0	O
normal	0	O
reaction	0	O
to	0	O
DNFB	1	O
.	0	O


The	0	O
original	0	O
technique	0	O
was	0	O
developed	0	O
in	0	O
the	0	O
1960	0	O
'	0	O
s	0	O
to	0	O
analyze	0	O
the	0	O
inner	0	O
ear	0	O
fluid	0	O
as	0	O
a	0	O
diagnostic	0	O
procedure	0	O
(	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
diagnostic	0	O
labyrinthotomy	0	O
)	0	O
in	0	O
acoustic	0	O
neuroma	0	O
suspects	0	O
.	0	O


Second	1	O
report	0	O
of	0	O
the	0	O
Norwegian	0	O
Cancer	1	O
Society	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
the	0	O
sMtCK	0	B
genomic	0	I
upstream	0	I
sequences	0	I
reveals	0	O
a	0	O
typical	0	O
TATAA	0	O
box	0	O
within	0	O
the	0	O
80	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
)	0	O
that	0	O
,	0	O
by	0	O
transfection	0	O
experiments	0	O
,	0	O
are	0	O
sufficient	0	O
to	0	O
promote	0	O
expression	0	O
of	0	O
chimeric	0	O
plasmids	0	O
with	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
reporter	0	I
.	0	O


Plasma	1	B
secretin	0	I
,	0	O
pancreozymin	0	B
,	0	O
and	0	O
somatostatin	0	B
-	0	I
like	0	I
hormone	0	I
in	0	O
chronic	0	O
renal	0	O
failure	0	O
patients	0	O
.	0	O


In	1	O
the	0	O
commercially	0	O
available	0	O
intravenous	0	O
formulation	0	O
of	0	O
Cyclosporin	0	O
A	1	O
(	0	O
Sandimmun	0	O
),	0	O
polyoxyethylated	0	O
castor	0	O
oil	0	O
(	0	O
Cremophor	1	O
EL	0	O
)	0	O
is	0	O
used	0	O
as	0	O
a	0	O
solubilizing	0	O
agent	0	O
.	0	O


None	0	O
of	0	O
the	0	O
cystometrograms	0	O
showed	0	O
uninhibited	0	O
detrusor	0	O
contractions	0	O
.	0	O


Biochemical	1	O
characterization	0	O
of	0	O
valosin	0	B
-	0	I
containing	0	I
protein	0	I
,	0	O
a	0	O
protein	0	B
tyrosine	0	I
kinase	0	I
substrate	0	O
in	0	O
hematopoietic	0	O
cells	0	O
.	0	O


ZIOS	0	O
was	0	O
significantly	0	O
more	0	O
sensitive	0	O
than	0	O
all	0	O
subsequent	0	O
methods	0	O
,	0	O
and	0	O
Ptc	1	O
,	0	O
O2	1	O
was	0	O
significantly	0	O
more	0	O
sensitive	0	O
than	0	O
FEV1	1	O
.	0	O


Time	1	O
-	0	O
activity	0	O
curves	0	O
from	0	O
the	0	O
gastric	0	O
region	0	O
of	0	O
interest	0	O
were	0	O
used	0	O
,	0	O
after	0	O
subjection	0	O
to	0	O
appropriate	0	O
corrective	0	O
procedures	0	O
,	0	O
to	0	O
calculate	0	O
the	0	O
mean	0	O
gastric	0	O
transit	0	O
time	0	O
(	0	O
MTT	0	O
90	0	O
)	0	O
and	0	O
the	0	O
fraction	0	O
of	0	O
the	0	O
test	0	O
meal	0	O
retained	0	O
in	0	O
the	0	O
stomach	0	O
after	0	O
90	0	O
min	0	O
(	0	O
F90	0	O
).	0	O


RESULTS	0	O
:	0	O
In	1	O
this	0	O
group	0	O
of	0	O
patients	0	O
,	0	O
male	0	O
gender	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O


Hepatitis	1	O
B	1	O
vaccine	0	O


Williams	0	O
,	0	O
2	0	O
August	0	O
1977	0	O
.	0	O


To	1	O
quantify	0	O
any	0	O
mechanical	0	O
inhibitory	0	O
effect	0	O
of	0	O
nasal	0	O
intermittent	0	O
positive	0	O
pressure	0	O
ventilation	0	O
(	0	O
IPPV	1	O
)	0	O
on	0	O
inspiratory	0	O
activity	0	O
of	0	O
the	0	O
diaphragm	0	O
we	0	O
ventilated	0	O
five	0	O
conscious	0	O
relaxed	0	O
subjects	0	O
on	0	O
two	0	O
occasions	0	O
at	0	O
respiratory	0	O
rates	0	O
similar	0	O
to	0	O
quiet	0	O
breathing	0	O
(	0	O
QB	0	O
)	0	O
and	0	O
at	0	O
three	0	O
levels	0	O
of	0	O
applied	0	O
pressure	0	O
(	0	O
Pappl	0	O
)--	0	O
6	0	O
,	0	O
9	0	O
and	0	O
12	0	O
cmH2O	0	O
,	0	O
each	0	O
during	0	O
hypocapnia	0	O
(	0	O
P	1	O
(	0	O
CO2	1	O
)	0	O
allowed	0	O
to	0	O
decrease	0	O
)	0	O
and	0	O
eucapnia	0	O
(	0	O
CO2	1	O
added	0	O
to	0	O
inspired	0	O
gas	0	O
).	0	O


These	0	O
findings	0	O
indicate	0	O
that	0	O
the	0	O
t	0	O
(	0	O
4	0	O
;	0	O
14	0	O
)(	0	O
p16	0	O
.	0	O
3	0	O
;	0	O
q32	0	O
)	0	O
represents	0	O
a	0	O
novel	0	O
,	0	O
recurrent	0	O
chromosomal	0	O
translocation	0	O
in	0	O
MM	1	O
,	0	O
and	0	O
suggest	0	O
that	0	O
the	0	O
FGFR3	0	B
gene	0	I
may	0	O
be	0	O
the	0	O
target	0	O
of	0	O
this	0	O
abnormality	0	O
and	0	O
thus	0	O
contribute	0	O
to	0	O
tumorigenesis	0	O
in	0	O
MM	1	O
.	0	O


Transcription	1	O
of	0	O
the	0	O
vascular	0	B
cell	0	I
adhesion	0	I
molecule	0	I
1	0	I
(	0	O
VCAM	0	B
-	0	I
1	0	I
)	0	O
gene	0	O
in	0	O
endothelial	0	O
cells	0	O
is	0	O
induced	0	O
by	0	O
lipopolysaccharide	0	O
and	0	O
the	0	O
inflammatory	0	O
cytokines	0	B
interleukin	0	I
-	0	I
1	0	I
beta	0	I
and	0	O
tumor	0	B
necrosis	0	I
factor	0	I
alpha	0	I
(	0	O
TNF	1	B
-	0	I
alpha	0	I
).	0	O


We	0	O
show	0	O
here	0	O
that	0	O
the	0	O
third	0	O
SH3	0	B
domain	0	I
binds	0	O
to	0	O
Sos	0	B
,	0	O
a	0	O
guanine	0	B
nucleotide	0	I
exchange	0	I
factor	0	I
for	0	O
Ras	1	B
and	0	O
Rac	0	B
,	0	O
both	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
transforming	0	O
gene	0	O
of	0	O
the	0	O
avian	0	B
sarcoma	0	I
virus	0	I
CT10	0	I
encodes	0	O
a	0	O
fusion	0	O
protein	0	O
(	0	O
p47gag	0	B
-	0	O
crk	0	B
or	0	O
v	0	B
-	0	I
Crk	0	I
)	0	O
containing	0	O
viral	0	B
Gag	1	I
sequences	0	I
fused	0	O
to	0	O
cellular	0	O
sequences	0	O
consisting	0	O
primarily	0	O
of	0	O
Src	1	B
homology	0	I
regions	0	I
2	0	I
and	0	I
3	0	I
(	0	O
SH2	0	B
and	0	O
SH3	0	B
sequences	0	I
).	0	O


We	0	O
have	0	O
cloned	0	O
a	0	O
novel	0	O
protein	0	O
kinase	0	O
,	0	O
termed	0	O
hematopoietic	0	B
progenitor	0	I
kinase	0	I
1	0	I
(	0	O
HPK1	0	B
),	0	O
that	0	O
is	0	O
expressed	0	O
predominantly	0	O
in	0	O
hematopoietic	0	O
cells	0	O
,	0	O
including	0	O
early	0	O
progenitor	0	O
cells	0	O
.	0	O


DNA	1	O
strand	0	O
exchange	0	O
catalyzed	0	O
by	0	O
Rad51	0	B
protein	0	I
is	0	O
also	0	O
greatly	0	O
stimulated	0	O
by	0	O
RPA	0	B
.	0	O


The	0	O
SEB1	0	B
homologue	0	O
thus	0	O
isolated	0	O
,	0	O
SEB2	0	B
,	0	O
encodes	0	O
a	0	O
protein	0	O
53	0	O
%	0	O
identical	0	O
to	0	O
Seb1p	0	B
.	0	O


Indeed	0	O
the	0	O
predicted	0	O
folding	0	O
of	0	O
the	0	O
5	0	O
'	0	O
and	0	O
3	0	O
'-	0	O
untranslated	0	O
regions	0	O
revealed	0	O
patterns	0	O
of	0	O
stem	0	O
and	0	O
loop	0	O
structures	0	O
conserved	0	O
for	0	O
all	0	O
tick	0	O
-	0	O
borne	0	O
flaviviruses	0	O
suggesting	0	O
a	0	O
purifying	0	O
selection	0	O
for	0	O
preservation	0	O
of	0	O
essential	0	O
RNA	1	O
secondary	0	O
structures	0	O
which	0	O
could	0	O
be	0	O
involved	0	O
in	0	O
translational	0	O
control	0	O
and	0	O
replication	0	O
.	0	O


EUK	0	O
-	0	O
8	0	O
is	0	O
a	0	O
novel	0	O
,	0	O
synthetic	0	O
,	0	O
low	0	O
-	0	O
molecular	0	O
-	0	O
weight	0	O
salen	0	O
-	0	O
manganese	0	O
complex	0	O
that	0	O
exhibits	0	O
both	0	O
superoxide	0	B
dismutase	0	I
and	0	O
catalase	0	B
activities	0	O
in	0	O
vitro	0	O
.	0	O


The	0	O
results	0	O
suggest	0	O
that	0	O
GATA	0	B
-	0	I
5	0	I
may	0	O
have	0	O
specific	0	O
downstream	0	O
targets	0	O
and	0	O
that	0	O
GATA	0	B
-	0	I
4	0	I
,	0	I
-	0	I
5	0	I
,	0	I
and	0	I
-	0	I
6	0	I
can	0	O
only	0	O
partially	0	O
substitute	0	O
for	0	O
each	0	O
other	0	O
in	0	O
cardiogenesis	0	O
.	0	O


An	1	O
infectious	0	O
origin	0	O
should	0	O
always	0	O
be	0	O
excluded	0	O
since	0	O
specific	0	O
etiologic	0	O
therapy	0	O
may	0	O
be	0	O
implemented	0	O
.	0	O


i	0	O
.	0	O


Atmospheric	1	O
benzene	0	O
,	0	O
urinary	0	O
muconic	0	O
acid	0	O
(	0	O
tt	0	O
-	0	O
MA	1	O
)	0	O
and	0	O
leukocyte	0	B
alkaline	0	I
phosphatase	0	I
activity	0	O
(	0	O
LAPA	0	O
)	0	O
were	0	O
evaluated	0	O
among	0	O
66	0	O
car	0	O
mechanics	0	O
,	0	O
34	0	O
road	0	O
tanker	0	O
drivers	0	O
,	0	O
and	0	O
28	0	O
nonexposed	0	O
workers	0	O
.	0	O


In	1	O
experiments	0	O
with	0	O
the	0	O
D1	1	O
antagonist	0	O
SCH	0	O
23390	0	O
,	0	O
buprenorphine	0	O
-	0	O
induced	0	O
depression	0	O
was	0	O
consistently	0	O
blocked	0	O
,	0	O
but	0	O
facilitation	0	O
was	0	O
unaffected	0	O
.	0	O


55	0	O
+/-	0	O
11	0	O
%),	0	O
all	0	O
other	0	O
parameters	0	O
showed	0	O
a	0	O
significant	0	O
increase	0	O
:	0	O
RS	1	O
index	0	O
5	0	O
.	0	O
4	0	O
+/-	0	O
1	0	O
.	0	O
4	0	O
mVolt	0	O
to	0	O
6	0	O
.	0	O
0	0	O
+/-	0	O
1	0	O
.	0	O
7	0	O
mVolt	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
);	0	O
EDD	1	O
6	0	O
.	0	O
3	0	O
+/-	0	O
0	0	O
.	0	O
7	0	O
to	0	O
6	0	O
.	0	O
8	0	O
+/-	0	O
0	0	O
.	0	O
9	0	O
cm	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
);	0	O
HV	0	O
1017	0	O
+/-	0	O
151	0	O
ml	0	O
to	0	O
1099	0	O
+/-	0	O
261	0	O
ml	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
);	0	O
EDV	1	O
371	0	O
+/-	0	O
131	0	O
ml	0	O
to	0	O
441	0	O
+/-	0	O
175	0	O
ml	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
);	0	O
RBV	0	O
117	0	O
+/-	0	O
57	0	O
ml	0	O
to	0	O
151	0	O
+/-	0	O
77	0	O
ml	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


These	0	O
results	0	O
illuminate	0	O
a	0	O
hitherto	0	O
unanticipated	0	O
function	0	O
of	0	O
U6	0	B
RNA	1	I
:	0	O
the	0	O
modulation	0	O
of	0	O
a	0	O
phosphorylation	0	O
-	0	O
dephosphorylation	0	O
cycle	0	O
of	0	O
C1	1	B
hnRNP	1	I
protein	0	I
that	0	O
influences	0	O
the	0	O
binding	0	O
affinity	0	O
of	0	O
this	0	O
protein	0	O
for	0	O
pre	0	O
-	0	O
mRNA	1	O
.	0	O


To	1	O
prepare	0	O
for	0	O
analyses	0	O
with	0	O
the	0	O
family	0	O
variables	0	O
,	0	O
we	0	O
next	0	O
present	0	O
descriptive	0	O
data	0	O
based	0	O
on	0	O
separate	0	O
principal	0	O
components	0	O
analysis	0	O
(	0	O
PCA	1	O
)	0	O
and	0	O
multidimensional	0	O
scaling	0	O
analysis	0	O
(	0	O
MDS	1	O
)	0	O
of	0	O
14	0	O
self	0	O
-	0	O
reported	0	O
health	0	O
scores	0	O
for	0	O
husbands	0	O
and	0	O
for	0	O
wives	0	O
.	0	O


Marine	0	O
oils	0	O
and	0	O
cardiovascular	0	O
reactivity	0	O
.	0	O


To	1	O
dissect	0	O
these	0	O
mechanisms	0	O
,	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
mutant	0	B
Raf	0	I
-	0	I
1	0	I
proteins	0	I
were	0	O
studied	0	O
in	0	O
an	0	O
in	0	O
vitro	0	O
system	0	O
with	0	O
purified	0	O
plasma	0	O
membranes	0	O
from	0	O
v	0	B
-	0	I
Ras	1	I
-	0	O
and	0	O
v	0	B
-	0	I
Src	1	I
-	0	O
transformed	0	O
cells	0	O
(	0	O
transformed	0	O
membranes	0	O
).	0	O


Data	1	O
were	0	O
processed	0	O
with	0	O
a	0	O
semi	0	O
-	0	O
automatic	0	O
computer	0	O
program	0	O
which	0	O
develops	0	O
an	0	O
averaged	0	O
-	0	O
volume	0	O
curve	0	O
from	0	O
an	0	O
assigned	0	O
LV	1	O
region	0	O
-	0	O
of	0	O
-	0	O
interest	0	O
.	0	O


Transcriptional	1	O
activation	0	O
by	0	O
thyroid	0	O
hormone	0	O
(	0	O
T3	1	O
)	0	O
requires	0	O
interactions	0	O
between	0	O
the	0	O
T3	1	B
receptor	0	I
(	0	O
TR	1	B
)	0	O
and	0	O
T3	1	O
response	0	O
elements	0	O
(	0	O
TREs	0	O
)	0	O
composed	0	O
of	0	O
two	0	O
copies	0	O
of	0	O
sequences	0	O
related	0	O
to	0	O
AGGTCA	0	O
.	0	O


Functional	1	O
analysis	0	O
of	0	O
the	0	O
mutant	0	B
desmin	0	I
in	0	O
SW13	0	O
(	0	O
vim	0	B
-)	0	O
cells	0	O
showed	0	O
aggregation	0	O
of	0	O
abnormal	0	O
coarse	0	O
clumps	0	O
of	0	O
desmin	0	B
positive	0	O
material	0	O
dispersed	0	O
throughout	0	O
the	0	O
cytoplasm	0	O
.	0	O


Growth	1	O
factor	0	O
stimulation	0	O
of	0	O
cells	0	O
causes	0	O
the	0	O
phosphorylation	0	O
of	0	O
the	0	O
c	0	B
-	0	I
Myc	0	I
transcriptional	0	I
activation	0	I
domain	0	I
at	0	O
Ser62	0	O
within	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
region	0	O
that	0	O
is	0	O
highly	0	O
conserved	0	O
among	0	O
members	0	O
of	0	O
the	0	O
Myc	0	B
family	0	I
(	0	O
Alvarez	0	O
,	0	O
E	1	O
.,	0	O
Northwood	0	O
,	0	O
I	1	O
.	0	O
C	1	O
.,	0	O
Gonzalez	0	O
,	0	O
F	1	O
.	0	O


Influence	0	O
of	0	O
diet	0	O
on	0	O
urinary	0	O
VMA	1	O
excretion	0	O
.	0	O


One	0	O
site	0	O
,	0	O
PAL	1	B
,	0	O
occurs	0	O
within	0	O
the	0	O
10	0	O
bp	0	O
sequence	0	O
GGGGAGGAGG	0	O
.	0	O


The	0	O
interrelation	0	O
of	0	O
the	0	O
levels	0	O
of	0	O
glucocorticoids	0	O
and	0	O
insulin	0	B
in	0	O
the	0	O
blood	0	O
of	0	O
irradiated	0	O
animals	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
has	0	O
the	0	O
greatest	0	O
homology	0	O
(	0	O
61	0	O
%)	0	O
to	0	O
the	0	O
green	0	B
alga	0	I
Scenedemus	0	I
obliquus	0	I
plastocyanin	0	I
.	0	O


CONCLUSION	0	O
:	0	O
The	0	O
authors	0	O
emphasize	0	O
that	0	O
the	0	O
initial	0	O
management	0	O
of	0	O
primary	0	O
STS	1	O
should	0	O
be	0	O
adequate	0	O
and	0	O
suggest	0	O
that	0	O
safty	0	O
margin	0	O
of	0	O
>	0	O
or	0	O
=	0	O
2	0	O
cm	0	O
should	0	O
be	0	O
adhered	0	O
to	0	O
.	0	O


Rev	0	B
-	0	O
erbAalpha	0	B
/	0	I
beta	0	I
),	0	O
Mxi	0	B
-	0	I
1	0	I
and	0	O
Mad	1	B
bHLH	0	O
-	0	O
zip	0	O
proteins	0	O
and	0	O
the	0	O
oncoproteins	0	O
PLZF	0	B
and	0	O
LAZ3	0	B
/	0	O
BCL6	0	B
is	0	O
mediated	0	O
by	0	O
the	0	O
corepressors	0	O
N	1	B
-	0	I
CoR	1	I
and	0	O
SMRT	0	B
.	0	O


Chrispeels	0	O
[	0	O
1993	0	O
]	0	O
EMBO	0	O
J	1	O
12	0	O
:	0	O
2241	0	O
-	0	O
2247	0	O
).	0	O


Splenectomized	0	O
patients	0	O
are	0	O
predisposed	0	O
toward	0	O
developing	0	O
overwhelming	0	O
bacterial	0	O
infections	0	O
.	0	O


Patients	0	O
received	0	O
either	0	O
diltiazem	0	O
CD	1	O
180	0	O
mg	0	O
or	0	O
placebo	0	O
once	0	O
/	0	O
day	0	O
in	0	O
combination	0	O
with	0	O
existing	0	O
antianginal	0	O
therapy	0	O
.	0	O


Blood	1	O
eosinophils	0	O
in	0	O
patients	0	O
with	0	O
Taenia	1	O
saginata	0	O
taeniasis	0	O
.	0	O


Drosophila	1	O
230	0	O
-	0	O
kD	1	O
TFIID	0	B
subunit	0	O
,	0	O
a	0	O
functional	0	O
homolog	0	O
of	0	O
the	0	O
human	0	O
cell	0	O
cycle	0	O
gene	0	O
product	0	O
,	0	O
negatively	0	O
regulates	0	O
DNA	1	O
binding	0	O
of	0	O
the	0	O
TATA	0	B
box	0	I
-	0	I
binding	0	I
subunit	0	I
of	0	I
TFIID	0	I
.	0	O


These	0	O
cells	0	O
fail	0	O
to	0	O
generate	0	O
the	0	O
signals	0	O
to	0	O
phosphorylate	0	O
CREB	0	B
and	0	O
produce	0	O
significantly	0	O
less	0	O
of	0	O
the	0	O
cytokine	0	O
Interleukin	1	B
-	0	I
2	0	I
(	0	O
IL	1	B
-	0	I
2	0	I
)	0	O
in	0	O
response	0	O
to	0	O
agents	0	O
that	0	O
either	0	O
increase	0	O
intracellular	0	O
Ca2	1	O
+	0	O
and	0	O
/	0	O
or	0	O
activate	0	O
protein	0	B
kinase	0	I
C	1	I
.	0	O


Longitudinal	1	O
force	0	O
-	0	O
length	0	O
relationships	0	O
of	0	O
guinea	0	O
pig	0	O
ureter	0	O
were	0	O
studied	0	O
in	0	O
vitro	0	O
in	0	O
animals	0	O
3	0	O
weeks	0	O
,	0	O
3	0	O
months	0	O
,	0	O
and	0	O
3	0	O
years	0	O
of	0	O
age	0	O
.	0	O


We	0	O
studied	0	O
the	0	O
functional	0	O
interaction	0	O
between	0	O
human	0	O
embryonic	0	O
zeta	0	B
2	0	I
globin	0	I
promoter	0	O
and	0	O
the	0	O
alpha	0	B
globin	0	I
regulatory	0	I
element	0	I
(	0	O
HS	1	B
-	0	I
40	0	I
)	0	O
located	0	O
40	0	O
kb	0	O
upstream	0	O
of	0	O
the	0	O
zeta	0	B
2	0	I
globin	0	I
gene	0	I
.	0	O


Three	0	O
mog	0	B
-	0	I
1	0	I
alleles	0	I
possess	0	O
premature	0	O
stop	0	O
codons	0	O
and	0	O
are	0	O
likely	0	O
to	0	O
be	0	O
null	0	O
alleles	0	O
,	0	O
and	0	O
one	0	O
is	0	O
a	0	O
missense	0	O
mutation	0	O
and	0	O
is	0	O
likely	0	O
to	0	O
retain	0	O
residual	0	O
activity	0	O
.	0	O
mog	0	B
-	0	I
1	0	I
mRNA	1	I
is	0	O
expressed	0	O
in	0	O
both	0	O
germ	0	O
line	0	O
and	0	O
somatic	0	O
tissues	0	O
and	0	O
appears	0	O
to	0	O
be	0	O
ubiquitous	0	O
.	0	O


Fatal	1	O
apneusis	0	O
was	0	O
observed	0	O
under	0	O
following	0	O
conditions	0	O
:	0	O
(	0	O
1	0	O
)	0	O
Persistent	0	O
apnea	0	O
was	0	O
produced	0	O
after	0	O
a	0	O
single	0	O
KA	1	O
microinjection	0	O
in	0	O
one	0	O
side	0	O
of	0	O
the	0	O
VRG	0	O
-	0	O
Apa	1	O
(	0	O
5	0	O
animals	0	O
).	0	O


In	1	O
2	0	O
subjects	0	O
the	0	O
phytomitogen	0	O
reactivity	0	O
of	0	O
the	0	O
lymphocytes	0	O
was	0	O
improved	0	O
after	0	O
treatment	0	O
.	0	O


The	0	O
existence	0	O
of	0	O
threshold	0	O
concentrations	0	O
,	0	O
above	0	O
which	0	O
certain	0	O
phenomena	0	O
may	0	O
occur	0	O
,	0	O
strengthens	0	O
the	0	O
role	0	O
of	0	O
sentinels	0	O
.	0	O


Here	0	O
we	0	O
localize	0	O
a	0	O
transferable	0	O
40	0	O
-	0	O
amino	0	O
acid	0	O
region	0	O
within	0	O
the	0	O
LBDs	0	B
of	0	O
RXR	0	B
,	0	O
RAR	0	B
,	0	O
TR	1	B
,	0	O
and	0	O
chicken	0	B
ovalbumin	0	I
upstream	0	I
promoter	0	I
transcription	0	I
factor	0	I
that	0	O
is	0	O
critical	0	O
for	0	O
determining	0	O
identity	0	O
in	0	O
the	0	O
heterodimeric	0	O
interaction	0	O
and	0	O
for	0	O
high	0	O
-	0	O
affinity	0	O
DNA	1	O
binding	0	O
.	0	O


Patients	0	O
with	0	O
acute	0	O
myocardial	0	O
infarction	0	O
had	0	O
higher	0	O
plasma	0	O
concentrations	0	O
of	0	O
neutrophil	0	B
elastase	0	I
and	0	O
the	0	O
non	0	O
-	0	O
peroxide	0	O
diene	0	O
conjugated	0	O
isomer	0	O
of	0	O
linoleic	0	O
acid	0	O
than	0	O
normal	0	O
volunteers	0	O
or	0	O
patients	0	O
with	0	O
stable	0	O
ischaemic	0	O
heart	0	O
disease	0	O
.	0	O


Role	1	O
of	0	O
secondary	0	O
structure	0	O
in	0	O
discrimination	0	O
between	0	O
constitutive	0	O
and	0	O
inducible	0	O
activators	0	O
.	0	O


The	0	O
plasmid	0	O
shuffle	0	O
technique	0	O
was	0	O
used	0	O
to	0	O
replace	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
gene	0	O
with	0	O
the	0	O
mutant	0	O
form	0	O
,	0	O
resulting	0	O
in	0	O
failure	0	O
of	0	O
the	0	O
yeast	0	O
cells	0	O
to	0	O
grow	0	O
.	0	O


Drug	1	O
and	0	O
personnel	0	O
costs	0	O
were	0	O
reduced	0	O
when	0	O
batch	0	O
manufacturing	0	O
with	0	O
40	0	O
-	0	O
mL	1	O
multidose	0	O
vials	0	O
was	0	O
compared	0	O
with	0	O
extemporaneous	0	O
compounding	0	O
with	0	O
unit	0	O
-	0	O
dose	0	O
vials	0	O
.	0	O


Gel	1	O
shift	0	O
analysis	0	O
indicates	0	O
that	0	O
the	0	O
full	0	B
-	0	I
length	0	I
ERM	1	I
protein	0	I
is	0	O
able	0	O
to	0	O
bind	0	O
specifically	0	O
to	0	O
an	0	O
oligonucleotide	0	O
containing	0	O
the	0	O
consensus	0	O
nucleotide	0	O
core	0	O
sequence	0	O
GGAA	0	O
recognized	0	O
by	0	O
the	0	O
Ets	1	B
proteins	0	O
.	0	O


Sequential	1	O
cleavage	0	O
by	0	O
metallopeptidases	0	B
and	0	O
proteasomes	0	O
is	0	O
involved	0	O
in	0	O
processing	0	O
HIV	1	B
-	0	I
1	0	I
ENV	0	I
epitope	0	I
for	0	O
endogenous	0	O
MHC	1	B
class	0	I
I	1	I
antigen	0	I
presentation	0	O
.	0	O


The	0	O
mobility	0	O
shift	0	O
assay	0	O
of	0	O
the	0	O
65	0	O
bp	0	O
(-	0	O
318	0	O
/	0	O
-	0	O
254	0	O
)	0	O
fragment	0	O
with	0	O
nuclear	0	O
extract	0	O
from	0	O
the	0	O
dark	0	O
-	0	O
adapted	0	O
sample	0	O
showed	0	O
an	0	O
additional	0	O
band	0	O
,	0	O
not	0	O
seen	0	O
with	0	O
the	0	O
light	0	O
-	0	O
grown	0	O
sample	0	O
.	0	O


The	0	O
level	0	O
of	0	O
contamination	0	O
in	0	O
the	0	O
wound	0	O
can	0	O
be	0	O
determined	0	O
with	0	O
the	0	O
rapid	0	O
biopsy	0	O
fixation	0	O
technique	0	O
.	0	O


The	0	O
former	0	O
procedure	0	O
is	0	O
economical	0	O
but	0	O
complicated	0	O
,	0	O
whereas	0	O
the	0	O
latter	0	O
is	0	O
simple	0	O
and	0	O
labour	0	O
-	0	O
saving	0	O
,	0	O
but	0	O
a	0	O
special	0	O
ultrafiltration	0	O
tube	0	O
is	0	O
required	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
Rho1p	0	B
regulates	0	O
cytoskeletal	0	O
reorganization	0	O
at	0	O
least	0	O
through	0	O
Bni1p	0	B
and	0	O
Pkc1p	0	B
.	0	O


The	0	O
presence	0	O
of	0	O
PDZ	0	B
and	0	O
SAM	0	O
domains	0	O
in	0	O
the	0	O
KS5	0	B
protein	0	I
suggests	0	O
that	0	O
it	0	O
may	0	O
act	0	O
as	0	O
a	0	O
molecular	0	O
adaptor	0	O
,	0	O
promoting	0	O
and	0	O
relaying	0	O
information	0	O
in	0	O
a	0	O
signal	0	O
transduction	0	O
pathway	0	O
.	0	O


After	0	O
determining	0	O
isoflurane	0	O
MAC	1	O
in	0	O
triplicate	0	O
,	0	O
birds	0	O
were	0	O
given	0	O
a	0	O
mu	0	O
-	0	O
opioid	0	O
agonist	0	O
(	0	O
morphine	0	O
,	0	O
n	0	O
=	0	O
9	0	O
)	0	O
or	0	O
a	0	O
kappa	0	O
-	0	O
opioid	0	O
agonist	0	O
(	0	O
U50488H	0	O
,	0	O
n	0	O
=	0	O
9	0	O
).	0	O


In	1	O
patients	0	O
who	0	O
were	0	O
not	0	O
vented	0	O
,	0	O
there	0	O
was	0	O
overall	0	O
significant	0	O
depression	0	O
of	0	O
function	0	O
(	0	O
67	0	O
+/-	0	O
5	0	O
%	0	O
of	0	O
control	0	O
;	0	O
range	0	O
,	0	O
91	0	O
--	0	O
45	0	O
%,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Moxidectin	0	O
(	0	O
at	0	O
3	0	O
times	0	O
the	0	O
therapeutic	0	O
dose	0	O
)	0	O
did	0	O
not	0	O
have	0	O
deleterious	0	O
effects	0	O
on	0	O
cow	0	O
reproductive	0	O
performance	0	O
as	0	O
examined	0	O
(	0	O
eg	0	O
,	0	O
at	0	O
folliculogenesis	0	O
,	0	O
ovulation	0	O
,	0	O
and	0	O
the	0	O
early	0	O
embryonic	0	O
phase	0	O
of	0	O
development	0	O
).	0	O


RNase	1	B
protection	0	O
analyses	0	O
indicate	0	O
that	0	O
either	0	O
61	0	B
-	0	I
kDa	1	I
CaM	1	I
PDE	1	I
mRNA	1	I
or	0	O
structurally	0	O
related	0	O
transcripts	0	O
encoding	0	O
different	0	O
CaM	1	B
PDE	1	I
isoforms	0	I
are	0	O
expressed	0	O
in	0	O
a	0	O
tissue	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


The	0	O
antibodies	0	O
inhibited	0	O
specifically	0	O
the	0	O
transcription	0	O
of	0	O
DNA	1	B
polymerase	0	I
alpha	0	I
promoter	0	O
in	0	O
vitro	0	O
.	0	O


Purified	0	O
Hsk1	0	B
phosphorylates	0	O
the	0	O
Cdc19	0	B
(	0	O
Mcm2	0	B
)	0	O
subunit	0	O
of	0	O
the	0	O
six	0	B
-	0	I
member	0	I
minichromosome	0	I
maintenance	0	I
protein	0	I
complex	0	I
purified	0	O
from	0	O
fission	0	O
yeast	0	O
.	0	O


This	0	O
study	0	O
was	0	O
aimed	0	O
at	0	O
assessing	0	O
whether	0	O
c	0	O
-	0	O
DDP	1	O
administration	0	O
immediately	0	O
before	0	O
radiotherapy	0	O
could	0	O
increase	0	O
frequency	0	O
and	0	O
duration	0	O
of	0	O
objective	0	O
responses	0	O
,	0	O
as	0	O
well	0	O
as	0	O
survival	0	O
,	0	O
in	0	O
patients	0	O
affected	0	O
with	0	O
locally	0	O
advanced	0	O
stages	0	O
of	0	O
squamous	0	O
carcinomas	0	O
of	0	O
the	0	O
head	0	O
and	0	O
neck	0	O
.	0	O


The	0	O
steepness	0	O
of	0	O
the	0	O
standard	0	O
O2	1	O
dissociation	0	O
curve	0	O
becomes	0	O
greater	0	O
during	0	O
the	0	O
training	0	O
period	0	O
(	0	O
increase	0	O
in	0	O
Hill	0	O
'	0	O
s	0	O
n	0	O
from	0	O
2	0	O
.	0	O
68	0	O
+/-	0	O
0	0	O
.	0	O
10	0	O
to	0	O
2	0	O
.	0	O
96	0	O
+/-	0	O
0	0	O
.	0	O
15	0	O
).	0	O


A	1	O
correlation	0	O
coefficient	0	O
was	0	O
used	0	O
for	0	O
assessing	0	O
the	0	O
similarity	0	O
of	0	O
each	0	O
map	0	O
pattern	0	O
with	0	O
the	0	O
normal	0	O
mean	0	O
IQRST	0	O
map	0	O
.	0	O


Biometric	0	O
analysis	0	O
of	0	O
intraocular	0	O
lens	0	O
power	0	O
required	0	O
to	0	O
produce	0	O
emmetropia	0	O
:	0	O
results	0	O
of	0	O
450	0	O
implants	0	O
.	0	O


We	0	O
tried	0	O
amphotericin	0	O
B	1	O
(	0	O
AmB	0	O
),	0	O
and	0	O
remission	0	O
of	0	O
the	0	O
tumor	0	O
was	0	O
obtained	0	O
.	0	O


Studies	0	O
on	0	O
the	0	O
life	0	O
cycle	0	O
of	0	O
Haplorchis	1	O
pumilio	0	O
(	0	O
Looss	0	O
,	0	O
1896	0	O
)	0	O
Looss	0	O
,	0	O
1899	0	O
with	0	O
morphological	0	O
redescription	0	O
of	0	O
larval	0	O
and	0	O
adult	0	O
stages	0	O
.	0	O


The	0	O
ultrastructure	0	O
of	0	O
retinal	0	O
vessels	0	O
was	0	O
examined	0	O
in	0	O
three	0	O
eyes	0	O
from	0	O
diabetic	0	O
patients	0	O
and	0	O
two	0	O
eyes	0	O
from	0	O
control	0	O
subjects	0	O
.	0	O


Multivariate	1	O
Cox	1	O
survival	0	O
analysis	0	O
identified	0	O
baseline	0	O
EF	1	O
<	0	O
or	0	O
=	0	O
30	0	O
%,	0	O
presence	0	O
of	0	O
significant	0	O
mitral	0	O
regurgitation	0	O
(>	0	O
2	0	O
+)	0	O
before	0	O
ablation	0	O
,	0	O
and	0	O
failure	0	O
to	0	O
exhibit	0	O
improved	0	O
cardiac	0	O
performance	0	O
by	0	O
1	0	O
month	0	O
after	0	O
ablation	0	O
as	0	O
the	0	O
only	0	O
independent	0	O
predictors	0	O
of	0	O
death	0	O
.	0	O


Histological	1	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
neuronal	0	O
loss	0	O
in	0	O
the	0	O
DHED	0	O
-	0	O
treated	0	O
group	0	O
was	0	O
notably	0	O
reduced	0	O
in	0	O
the	0	O
hippocampal	0	O
area	0	O
(	0	O
CA1	0	O
)	0	O
of	0	O
ischemic	0	O
rats	0	O
and	0	O
in	0	O
the	0	O
dentate	0	O
gyrus	0	O
and	0	O
hippocampal	0	O
area	0	O
(	0	O
CA1	0	O
and	0	O
CA3	0	O
)	0	O
of	0	O
EC	1	O
-	0	O
lesioned	0	O
rats	0	O
compared	0	O
with	0	O
the	0	O
nontreated	0	O
group	0	O
.	0	O


Experiments	0	O
with	0	O
epitope	0	O
-	0	O
tagged	0	O
proteins	0	O
show	0	O
that	0	O
UEV1A	0	B
is	0	O
a	0	O
nuclear	0	O
protein	0	O
,	0	O
whereas	0	O
both	0	O
Kua	0	B
and	0	O
Kua	0	B
-	0	O
UEV	0	B
localize	0	O
to	0	O
cytoplasmic	0	O
structures	0	O
,	0	O
indicating	0	O
that	0	O
the	0	O
Kua	0	B
domain	0	I
determines	0	O
the	0	O
cytoplasmic	0	O
localization	0	O
of	0	O
Kua	0	B
-	0	O
UEV	0	B
.	0	O


M	1	O
.,	0	O
and	0	O
D	1	O
.	0	O


Transcription	1	O
start	0	O
sites	0	O
of	0	O
the	0	O
plastid	0	O
ACCase	0	B
genes	0	I
were	0	O
estimated	0	O
from	0	O
the	0	O
longest	0	O
cDNA	1	O
clones	0	O
obtained	0	O
by	0	O
5	0	O
'-	0	O
RACE	1	O
(	0	O
rapid	0	O
amplification	0	O
of	0	O
cDNA	1	O
ends	0	O
).	0	O


Immunity	1	O
acquired	0	O
by	0	O
mice	0	O
during	0	O
I	1	O
.	0	O
scapularis	0	O
nymphal	0	O
activity	0	O
in	0	O
early	0	O
summer	0	O
may	0	O
exclude	0	O
a	0	O
large	0	O
proportion	0	O
of	0	O
the	0	O
mouse	0	O
population	0	O
from	0	O
maintaining	0	O
E	1	O
.	0	O
phagocytophila	0	O
during	0	O
the	0	O
period	0	O
of	0	O
larval	0	O
activity	0	O
later	0	O
in	0	O
the	0	O
season	0	O
.	0	O


3	0	O
.	0	O
04	0	O
+/-	0	O
1	0	O
.	0	O
2	0	O
,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
0001	0	O
),	0	O
large	0	O
accelerations	0	O
/	0	O
30	0	O
min	0	O
(	0	O
1	0	O
.	0	O
46	0	O
+/-	0	O
1	0	O
.	0	O
96	0	O
vs	0	O
.	0	O


A	1	O
large	0	O
deletion	0	O
in	0	O
the	0	O
CTD	1	B
-	0	I
binding	0	I
motif	0	I
blocks	0	O
down	0	O
-	0	O
regulation	0	O
but	0	O
does	0	O
not	0	O
affect	0	O
the	0	O
essential	0	O
function	0	O
of	0	O
Nrd1	0	B
.	0	O


Following	1	O
EPI	0	O
-	0	O
C0401	0	O
,	0	O
but	0	O
not	0	O
saline	0	O
or	0	O
DepoFoam	0	O
vehicle	0	O
,	0	O
there	0	O
were	0	O
transient	0	O
(<	0	O
72	0	O
hr	0	O
)	0	O
decreases	0	O
in	0	O
food	0	O
consumption	0	O
,	0	O
arousal	0	O
,	0	O
hindlimb	0	O
muscle	0	O
tone	0	O
,	0	O
and	0	O
body	0	O
temperature	0	O
.	0	O


Instead	0	O
,	0	O
mRNA	1	O
of	0	O
2	0	O
.	0	O
0	0	O
and	0	O
2	0	O
.	0	O
8	0	O
kb	0	O
are	0	O
detected	0	O
in	0	O
varying	0	O
abundance	0	O
.	0	O


After	0	O
clofelin	0	O
administration	0	O
the	0	O
autoregulation	0	O
borders	0	O
shifted	0	O
to	0	O
the	0	O
right	0	O
i	0	O
.	0	O
e	0	O
.	0	O
towards	0	O
higher	0	O
AP	1	O
levels	0	O
.	0	O


Chloramphenicol	1	B
acetyltransferase	0	I
assays	0	O
examining	0	O
the	0	O
ability	0	O
of	0	O
IE86	0	B
to	0	O
repress	0	O
activity	0	O
from	0	O
the	0	O
HCMV	0	O
major	0	O
IE	1	B
promoter	0	I
or	0	O
activate	0	O
the	0	O
HCMV	0	B
early	0	I
promoter	0	I
for	0	O
the	0	O
2	0	O
.	0	O
2	0	O
-	0	O
kb	0	O
class	0	O
of	0	O
RNAs	0	O
demonstrated	0	O
the	0	O
functional	0	O
integrity	0	O
of	0	O
the	0	O
IE86	0	B
protein	0	I
.	0	O


The	0	O
effect	0	O
of	0	O
pure	0	O
natural	0	O
porcine	0	B
secretin	0	I
on	0	O
endocrine	0	O
and	0	O
exocrine	0	O
pancreatic	0	O
secretion	0	O
was	0	O
studied	0	O
in	0	O
the	0	O
totally	0	O
isolated	0	O
perfused	0	O
porcine	0	O
pancreas	0	O
.	0	O


Role	1	O
of	0	O
the	0	O
infectious	0	O
-	0	O
disease	0	O
specialist	0	O
of	0	O
a	0	O
polyclinic	0	O
in	0	O
reducing	0	O
the	0	O
incidence	0	O
of	0	O
communicable	0	O
diseases	0	O


In	1	O
the	0	O
premating	0	O
period	0	O
male	0	O
rate	0	O
of	0	O
aggression	0	O
was	0	O
not	0	O
significantly	0	O
correlated	0	O
with	0	O
testosterone	0	O
level	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
the	0	O
myoD	0	B
promoter	0	I
,	0	O
the	0	O
myoD	0	B
enhancer	0	I
shows	0	O
striking	0	O
conservation	0	O
between	0	O
humans	0	O
and	0	O
mice	0	O
both	0	O
in	0	O
its	0	O
sequence	0	O
and	0	O
its	0	O
distal	0	O
position	0	O
.	0	O


Spectroscopy	1	O
of	0	O
negative	0	O
ions	0	O
utilizing	0	O
multiphoton	0	O
detachment	0	O
in	0	O
a	0	O
Raman	0	O
coupling	0	O
regime	0	O
.	0	O


Complete	0	O
nucleotide	0	O
sequence	0	O
of	0	O
the	0	O
bacteriophage	0	B
K1F	0	I
tail	0	I
gene	0	I
encoding	0	O
endo	0	B
-	0	I
N	1	I
-	0	I
acylneuraminidase	0	I
(	0	O
endo	0	B
-	0	I
N	1	I
)	0	O
and	0	O
comparison	0	O
to	0	O
an	0	O
endo	0	B
-	0	I
N	1	I
homolog	0	I
in	0	O
bacteriophage	0	O
PK1E	0	O
.	0	O


In	1	O
HCMV	0	O
(	0	O
Towne	0	O
)-	0	O
infected	0	O
HF	1	O
cells	0	O
at	0	O
24	0	O
to	0	O
48	0	O
h	0	O
,	0	O
IE2	0	B
also	0	O
accumulated	0	O
in	0	O
newly	0	O
formed	0	O
viral	0	O
DNA	1	O
replication	0	O
compartments	0	O
containing	0	O
the	0	O
polymerase	0	B
processivity	0	I
factor	0	I
(	0	O
UL44	0	B
),	0	O
the	0	O
single	0	B
-	0	I
stranded	0	I
DNA	1	I
binding	0	I
protein	0	I
(	0	O
SSB	0	B
;	0	O
UL57	0	B
),	0	O
the	0	O
UL112	0	B
-	0	I
113	0	I
accessory	0	I
protein	0	I
,	0	O
and	0	O
newly	0	O
incorporated	0	O
bromodeoxyuridine	0	O
(	0	O
BrdU	1	O
).	0	O


Four	0	O
p53	0	B
DNA	1	I
-	0	I
binding	0	I
domain	0	I
peptides	0	I
bind	0	O
natural	0	O
p53	0	B
-	0	I
response	0	I
elements	0	I
and	0	O
bend	0	O
the	0	O
DNA	1	O
.	0	O


One	0	O
form	0	O
of	0	O
the	0	O
SBEI	0	B
gene	0	I
transcript	0	I
in	0	O
12	0	O
-	0	O
day	0	O
old	0	O
kernels	0	O
contained	0	O
the	0	O
exon	0	O
I	1	O
+	0	O
II	0	O
+	0	O
III	0	O
combination	0	O
at	0	O
the	0	O
5	0	O
'	0	O
end	0	O
,	0	O
whereas	0	O
other	0	O
forms	0	O
differed	0	O
by	0	O
inclusion	0	O
of	0	O
intron	0	O
1	0	O
or	0	O
exclusion	0	O
of	0	O
exon	0	O
II	0	O
sequences	0	O
.	0	O


Evaluation	1	O
of	0	O
1	0	O
,	0	O
10	0	O
-	0	O
phenanthroline	0	O
as	0	O
a	0	O
reagent	0	O
for	0	O
sialic	0	O
acid	0	O
determinations	0	O
.	0	O


However	0	O
,	0	O
with	0	O
the	0	O
alpha1	0	O
antagonist	0	O
prazosin	0	O
(	0	O
5	0	O
x	0	O
10	0	O
(-	0	O
8	0	O
)-	0	O
5	0	O
x	0	O
10	0	O
(-	0	O
7	0	O
)	0	O
M	1	O
),	0	O
no	0	O
relaxation	0	O
occurred	0	O
.	0	O


The	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
genomic	0	O
RNA	1	O
of	0	O
rubella	0	O
virus	0	O
(	0	O
RUB	1	O
)	0	O
contains	0	O
a	0	O
14	0	O
-	0	O
nucleotide	0	O
(	0	O
nt	0	O
)	0	O
single	0	O
-	0	O
stranded	0	O
leader	0	O
(	0	O
ss	0	O
-	0	O
leader	0	O
)	0	O
followed	0	O
by	0	O
a	0	O
stem	0	O
-	0	O
and	0	O
-	0	O
loop	0	O
structure	0	O
[	0	O
5	0	O
'(+)	0	O
SL	1	O
]	0	O
(	0	O
nt	0	O
15	0	O
to	0	O
65	0	O
),	0	O
the	0	O
complement	0	O
of	0	O
which	0	O
at	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
minus	0	O
-	0	O
strand	0	O
RNA	1	O
[	0	O
3	0	O
'(-)	0	O
SL	1	O
]	0	O
has	0	O
been	0	O
proposed	0	O
to	0	O
function	0	O
as	0	O
a	0	O
promoter	0	O
for	0	O
synthesis	0	O
of	0	O
genomic	0	O
plus	0	O
strands	0	O
.	0	O


The	0	O
MSY2	0	B
associated	0	O
kinase	0	O
is	0	O
not	0	O
casein	0	B
kinase	0	I
2	0	I
,	0	O
the	0	O
kinase	0	O
believed	0	O
to	0	O
phosphorylate	0	O
mRNP3	0	B
+	0	I
4	0	I
in	0	O
oocytes	0	O
,	0	O
but	0	O
a	0	O
yet	0	O
unidentified	0	O
kinase	0	O
.	0	O


Similar	0	O
results	0	O
were	0	O
seen	0	O
on	0	O
Western	0	O
blots	0	O
of	0	O
Autographa	0	O
californica	0	O
MNPV	0	O
(	0	O
AcMNPV	0	O
)-	0	O
infected	0	O
Spodoptera	0	O
frugiperda	0	O
cells	0	O
.	0	O


Unfortunately	0	O
,	0	O
these	0	O
preservatives	0	O
may	0	O
also	0	O
interfere	0	O
with	0	O
microbiological	0	O
assays	0	O
used	0	O
to	0	O
determine	0	O
product	0	O
sterility	0	O
or	0	O
bioburden	0	O
levels	0	O
.	0	O


Fenfluramine	0	O
(	0	O
in	0	O
doses	0	O
ranging	0	O
from	0	O
0	0	O
.	0	O
0625	0	O
-	0	O
4	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
infusion	0	O
)	0	O
did	0	O
not	0	O
maintain	0	O
self	0	O
-	0	O
administration	0	O
behavior	0	O
at	0	O
or	0	O
above	0	O
the	0	O
minimum	0	O
requirement	0	O
(	0	O
FR	1	O
30	0	O
).	0	O


Of	0	O
these	0	O
179	0	O
samples	0	O
,	0	O
Mobiluncus	1	O
SP	1	O
was	0	O
observed	0	O
in	0	O
35	0	O
(	0	O
19	0	O
.	0	O
6	0	O
%)	0	O
using	0	O
Gram	1	O
staining	0	O
and	0	O
in	0	O
18	0	O
(	0	O
10	0	O
.	0	O
1	0	O
%)	0	O
this	0	O
microorganism	0	O
was	0	O
isolated	0	O
in	0	O
agar	0	O
RLK	0	O
and	0	O
anaerobic	0	O
atmosphere	0	O
.	0	O


N	1	O
.	0	O
van	0	O
Hoek	0	O
,	0	O
and	0	O
M	1	O
.	0	O


The	0	O
absolute	0	O
configuration	0	O
at	0	O
C	1	O
-	0	O
2	0	O
in	0	O
monocrotalic	0	O
acid	0	O
.	0	O


Thus	0	O
,	0	O
ZNF74	0	B
sublocalization	0	O
in	0	O
nuclear	0	O
domains	0	O
enriched	0	O
in	0	O
pre	0	O
-	0	O
mRNA	1	O
maturating	0	O
factors	0	O
,	0	O
its	0	O
RNA	1	O
binding	0	O
activity	0	O
,	0	O
and	0	O
its	0	O
direct	0	O
phosphodependent	0	O
interaction	0	O
with	0	O
the	0	O
pol	0	B
IIo	0	I
,	0	O
a	0	O
form	0	O
of	0	O
the	0	O
RNA	1	B
polymerase	0	I
functionally	0	O
associated	0	O
with	0	O
pre	0	O
-	0	O
mRNA	1	O
processing	0	O
,	0	O
suggest	0	O
a	0	O
role	0	O
for	0	O
this	0	O
member	0	O
of	0	O
the	0	O
KRAB	0	B
multifinger	0	I
protein	0	I
family	0	I
in	0	O
RNA	1	O
processing	0	O
.	0	O


Acute	1	O
pancreatitis	0	O
as	0	O
a	0	O
complication	0	O
of	0	O
polyarteritis	0	O
nodosa	0	O
.	0	O


We	0	O
did	0	O
not	0	O
observe	0	O
any	0	O
changes	0	O
in	0	O
Bcl	0	B
-	0	I
2	0	I
or	0	O
Bcl	0	B
-	0	I
2	0	I
-	0	I
related	0	I
proteins	0	I
(	0	O
Bcl	0	B
-	0	I
x	0	I
,	0	O
Bax	0	B
,	0	O
and	0	O
Bad	0	B
)	0	O
in	0	O
control	0	O
or	0	O
KCREB	0	B
-	0	O
transfected	0	O
cells	0	O
before	0	O
or	0	O
after	0	O
treatment	0	O
with	0	O
Tg	1	O
.	0	O


In	1	O
consequence	0	O
,	0	O
the	0	O
gpI	0	B
derived	0	O
from	0	O
cells	0	O
infected	0	O
with	0	O
mO74	0	O
showed	0	O
antigenic	0	O
characteristics	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
gpI	0	B
from	0	O
VZV	0	O
-	0	O
infected	0	O
cells	0	O
as	0	O
determined	0	O
from	0	O
the	0	O
immunoprecipitation	0	O
pattern	0	O
,	0	O
although	0	O
the	0	O
molecular	0	O
weight	0	O
of	0	O
each	0	O
polypeptide	0	O
was	0	O
different	0	O
,	0	O
and	0	O
antibody	0	O
produced	0	O
in	0	O
rabbits	0	O
infected	0	O
with	0	O
recombinant	0	O
virus	0	O
had	0	O
a	0	O
high	0	O
neutralizing	0	O
activity	0	O
,	0	O
when	0	O
the	0	O
reaction	0	O
was	0	O
performed	0	O
with	0	O
complement	0	O
.	0	O


Supershift	0	O
assays	0	O
,	0	O
using	0	O
Jun	1	B
and	0	I
Fos	1	I
family	0	I
member	0	I
-	0	I
specific	0	I
antibodies	0	I
,	0	O
showed	0	O
that	0	O
protein	0	O
complexes	0	O
formed	0	O
by	0	O
AtT	0	O
-	0	O
20	0	O
cell	0	O
nuclear	0	O
extracts	0	O
bound	0	O
to	0	O
the	0	O
c	0	B
-	0	I
jun	0	I
AP	1	I
-	0	I
1	0	I
site	0	I
were	0	O
comprised	0	O
of	0	O
Jun	1	B
family	0	O
members	0	O
,	0	O
JunD	0	B
,	0	O
JunB	0	B
,	0	O
and	0	O
cJun	0	B
.	0	O


Hybridization	1	O
of	0	O
a	0	O
probe	0	O
from	0	O
this	0	O
region	0	O
to	0	O
electrophoretic	0	O
blots	0	O
of	0	O
RNAs	0	O
from	0	O
different	0	O
human	0	O
tissues	0	O
showed	0	O
a	0	O
predominant	0	O
2	0	O
.	0	O
8	0	O
-	0	O
kilobase	0	O
(	0	O
kb	0	O
)	0	O
message	0	O
accompanied	0	O
by	0	O
weaker	0	O
bands	0	O
4	0	O
.	0	O
1	0	O
and	0	O
2	0	O
.	0	O
1	0	O
kb	0	O
in	0	O
size	0	O
.	0	O


Behind	0	O
the	0	O
ATPase	1	B
cluster	0	I
,	0	O
two	0	O
open	0	O
reading	0	O
frames	0	O
were	0	O
detected	0	O
that	0	O
are	0	O
not	0	O
homologous	0	O
to	0	O
any	0	O
known	0	O
chloroplast	0	O
gene	0	O
.	0	O


Here	0	O
we	0	O
show	0	O
that	0	O
calpeptin	0	B
inhibits	0	O
tyrosine	0	B
phosphatases	0	I
,	0	O
enhancing	0	O
tyrosine	0	O
phosphorylation	0	O
particularly	0	O
of	0	O
paxillin	0	B
.	0	O


The	0	O
three	0	O
-	0	O
dimensional	0	O
structure	0	O
of	0	O
RT	1	B
shows	0	O
that	0	O
it	0	O
is	0	O
a	0	O
strikingly	0	O
asymmetric	0	O
heterodimer	0	O
consisting	0	O
of	0	O
two	0	O
differently	0	O
folded	0	O
subunits	0	O
(	0	O
molecular	0	O
weights	0	O
66	0	O
kDa	1	O
and	0	O
51	0	O
kDa	1	O
)	0	O
with	0	O
identical	0	O
amino	0	O
-	0	O
terminal	0	O
amino	0	O
acid	0	O
sequences	0	O
(	0	O
residues	0	O
1	0	O
-	0	O
428	0	O
).	0	O


In	1	O
vitro	0	O
DNase	1	B
I	1	I
footprinting	0	O
showed	0	O
that	0	O
OxyR	0	B
-	0	I
C199S	0	I
protected	0	O
Pmom	0	B
from	0	O
-	0	O
104	0	O
to	0	O
-	0	O
46	0	O
on	0	O
the	0	O
top	0	O
strand	0	O
and	0	O
produced	0	O
a	0	O
protection	0	O
pattern	0	O
characteristic	0	O
of	0	O
reduced	0	B
wild	0	I
-	0	I
type	0	I
OxyR	0	I
.	0	O


Similar	0	O
memory	0	O
impairments	0	O
found	0	O
in	0	O
medial	0	O
septal	0	O
-	0	O
vertical	0	O
diagonal	0	O
band	0	O
of	0	O
Broca	0	O
and	0	O
nucleus	0	O
basalis	0	O
lesioned	0	O
rats	0	O
:	0	O
are	0	O
memory	0	O
defects	0	O
induced	0	O
by	0	O
nucleus	0	O
basalis	0	O
lesions	0	O
related	0	O
to	0	O
the	0	O
degree	0	O
of	0	O
non	0	O
-	0	O
specific	0	O
subcortical	0	O
cell	0	O
loss	0	O
?	0	O
The	0	O
function	0	O
of	0	O
nucleus	0	O
basalis	0	O
(	0	O
NB	1	O
)	0	O
and	0	O
medial	0	O
septal	0	O
-	0	O
vertical	0	O
diagonal	0	O
band	0	O
of	0	O
Broca	0	O
(	0	O
MS	1	O
-	0	O
VDBB	0	O
)	0	O
in	0	O
a	0	O
place	0	O
navigation	0	O
task	0	O
requiring	0	O
reference	0	O
memory	0	O
was	0	O
investigated	0	O
.	0	O


Combination	0	O
of	0	O
a	0	O
Shwachman	0	O
syndrome	0	O
and	0	O
a	0	O
complex	0	O
granulocyte	0	O
function	0	O
disorder	0	O
in	0	O
a	0	O
girl	0	O


Due	0	O
to	0	O
its	0	O
relatively	0	O
soluble	0	O
chemical	0	O
form	0	O
,	0	O
90Sr	0	O
was	0	O
rapidly	0	O
translocated	0	O
from	0	O
lung	0	O
to	0	O
bone	0	O
where	0	O
a	0	O
substantial	0	O
portion	0	O
was	0	O
retained	0	O
for	0	O
a	0	O
long	0	O
period	0	O
of	0	O
time	0	O
.	0	O


An	1	O
in	0	O
vitro	0	O
binding	0	O
site	0	O
selection	0	O
procedure	0	O
was	0	O
used	0	O
to	0	O
determine	0	O
DNA	1	O
sequences	0	O
preferentially	0	O
bound	0	O
by	0	O
wild	0	B
-	0	I
type	0	I
HLF	0	I
and	0	O
chimeric	0	O
E2A	0	B
-	0	O
HLF	0	B
proteins	0	O
isolated	0	O
from	0	O
various	0	O
t	0	O
(	0	O
17	0	O
;	0	O
19	0	O
)-	0	O
bearing	0	O
leukemias	0	O
.	0	O


1972	0	O
.	0	O


The	0	O
Ishasha	0	O
samples	0	O
show	0	O
a	0	O
range	0	O
encompassing	0	O
three	0	O
trophic	0	O
levels	0	O
.	0	O


Results	0	O
support	0	O
the	0	O
hypothesis	0	O
that	0	O
endogenous	0	B
corticotropin	0	I
-	0	I
releasing	0	I
factor	0	I
,	0	O
perhaps	0	O
acting	0	O
at	0	O
a	0	O
peripheral	0	O
binding	0	O
site	0	O
,	0	O
suppresses	0	O
the	0	O
active	0	O
behavioral	0	O
response	0	O
characteristic	0	O
of	0	O
pups	0	O
during	0	O
the	0	O
early	0	O
phase	0	O
of	0	O
isolation	0	O
in	0	O
novel	0	O
surroundings	0	O
.	0	O


Evidence	1	O
forthe	0	O
electroosmosis	0	O
theory	0	O
of	0	O
transport	0	O
in	0	O
the	0	O
phloem	0	O
.	0	O


The	0	O
mRNA	1	O
was	0	O
converted	0	O
to	0	O
cDNA	1	O
and	0	O
amplified	0	O
by	0	O
the	0	O
polymerase	0	O
chain	0	O
reaction	0	O
technique	0	O
.	0	O


While	0	O
the	0	O
latter	0	O
corresponded	0	O
to	0	O
a	0	O
protein	0	O
of	0	O
824	0	O
amino	0	O
acids	0	O
,	0	O
an	0	O
upstream	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
uORF	0	O
)	0	O
within	0	O
the	0	O
5	0	O
'	0	O
leader	0	O
could	0	O
potentially	0	O
encode	0	O
a	0	O
54	0	O
amino	0	O
acid	0	O
peptide	0	O
.	0	O


Ultimate	1	O
strengthes	0	O
seem	0	O
to	0	O
be	0	O
reached	0	O
for	0	O
cast	0	O
cobalt	0	O
alloys	0	O
,	0	O
whereas	0	O
titanium	0	O
alloys	0	O
,	0	O
such	0	O
as	0	O
Ta	1	O
6	0	O
V	1	O
,	0	O
present	0	O
very	0	O
high	0	O
fatigue	0	O
limit	0	O
under	0	O
corrosion	0	O
.	0	O


With	0	O
both	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
the	0	O
mutant	0	O
enzymes	0	O
,	0	O
ATP	1	O
activates	0	O
both	0	O
[	0	O
14C	0	O
]	0	O
Asp	1	O
in	0	O
equilibrium	0	O
N	1	O
-	0	O
carbamyl	0	O
-	0	O
L	1	O
-	0	O
aspartate	0	O
(	0	O
C	1	O
-	0	O
Asp	1	O
)	0	O
and	0	O
the	0	O
[	0	O
32P	0	O
]	0	O
carbamyl	0	O
phosphate	0	O
(	0	O
C	1	O
-	0	O
P	1	O
)	0	O
in	0	O
equilibrium	0	O
Pi	1	O
exchanges	0	O
.	0	O


To	1	O
determine	0	O
which	0	O
region	0	O
of	0	O
SulA	0	B
is	0	O
essential	0	O
for	0	O
the	0	O
inhibition	0	O
of	0	O
cell	0	O
division	0	O
,	0	O
we	0	O
constructed	0	O
a	0	O
series	0	O
of	0	O
N	1	O
-	0	O
terminal	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
deletions	0	O
of	0	O
SulA	0	B
and	0	O
a	0	O
series	0	O
of	0	O
alanine	0	O
substitution	0	O
mutants	0	O
.	0	O


Northern	0	O
analysis	0	O
revealed	0	O
no	0	O
detectable	0	O
expression	0	O
of	0	O
the	0	O
transcript	0	O
in	0	O
diapause	0	O
-	0	O
or	0	O
nondiapause	0	O
-	0	O
programmed	0	O
wandering	0	O
larvae	0	O
,	0	O
and	0	O
only	0	O
trace	0	O
expression	0	O
in	0	O
nondiapausing	0	O
pupae	0	O
.	0	O


Three	0	O
mutants	0	O
were	0	O
isolated	0	O
from	0	O
the	0	O
widely	0	O
used	0	O
strain	0	O
,	0	O
PAO1	0	O
.	0	O


We	0	O
propose	0	O
that	0	O
two	0	O
pathways	0	O
regulate	0	O
Stat5	0	B
serine	0	O
phosphorylation	0	O
,	0	O
one	0	O
that	0	O
is	0	O
prolactin	0	B
-	0	O
activated	0	O
and	0	O
PD98059	0	O
-	0	O
resistant	0	O
and	0	O
one	0	O
that	0	O
is	0	O
constitutively	0	O
active	0	O
and	0	O
PD98059	0	O
-	0	O
sensitive	0	O
and	0	O
preferentially	0	O
targets	0	O
Stat5a	0	B
.	0	O


These	0	O
results	0	O
were	0	O
compared	0	O
with	0	O
those	0	O
obtained	0	O
in	0	O
-	0	O
D	1	O
mothers	0	O
and	0	O
pups	0	O
,	0	O
after	0	O
giving	0	O
the	0	O
mothers	0	O
an	0	O
oral	0	O
supplement	0	O
(	0	O
10	0	O
i	0	O
.	0	O
u	0	O
.	0	O
vitamin	0	O
D3	0	O
/	0	O
day	0	O
)	0	O
during	0	O
the	0	O
period	0	O
of	0	O
lactation	0	O
(	0	O
20	0	O
days	0	O
).	0	O


Phosphopeptide	0	O
mapping	0	O
revealed	0	O
the	0	O
same	0	O
autophosphorylation	0	O
sites	0	O
utilized	0	O
by	0	O
EGFR	1	B
-	0	I
IC	1	I
as	0	O
those	0	O
identified	0	O
in	0	O
wild	0	B
-	0	I
type	0	I
EGFR	1	I
.	0	O


Eleven	0	O
biopsy	0	O
specimens	0	O
(	0	O
five	0	O
papules	0	O
and	0	O
six	0	O
dusky	0	O
or	0	O
crusted	0	O
lesions	0	O
)	0	O
from	0	O
four	0	O
patients	0	O
with	0	O
pityriasis	0	O
lichenoides	0	O
et	0	O
varioliformis	0	O
acuta	0	O
(	0	O
PLEVA	1	O
)	0	O
were	0	O
studied	0	O
by	0	O
direct	0	O
immunofluorescence	0	O
and	0	O
immunoperoxidase	0	B
technics	0	O
.	0	O


Rearrangements	0	O
of	0	O
the	0	O
NFKB2	0	B
gene	0	I
are	0	O
associated	0	O
with	0	O
lymphoid	0	O
malignancies	0	O
,	0	O
but	0	O
the	0	O
functional	0	O
significance	0	O
of	0	O
these	0	O
alterations	0	O
is	0	O
not	0	O
known	0	O
.	0	O


In	1	O
gel	0	O
mobility	0	O
shift	0	O
assays	0	O
,	0	O
factors	0	O
present	0	O
in	0	O
nuclear	0	O
extracts	0	O
derived	0	O
from	0	O
differentiated	0	O
osteoblast	0	O
bound	0	O
to	0	O
oligonucleotide	0	O
probes	0	O
containing	0	O
the	0	O
E	1	O
-	0	O
box	0	O
1	0	O
and	0	O
E	1	O
-	0	O
box	0	O
2	0	O
elements	0	O
.	0	O


Only	0	O
fully	0	O
processed	0	O
Pra	1	B
(	0	O
N0	0	O
and	0	O
Nb	1	O
)	0	O
and	0	O
ICP35	0	B
(	0	O
ICP35	0	B
e	0	I
,	0	I
f	0	I
)	0	O
are	0	O
present	0	O
in	0	O
B	1	O
capsids	0	O
,	0	O
which	0	O
are	0	O
believed	0	O
to	0	O
be	0	O
precursors	0	O
of	0	O
mature	0	O
virions	0	O
.	0	O


The	0	O
carboxy	0	O
terminus	0	O
of	0	O
Mbp1	0	B
is	0	O
sufficient	0	O
for	0	O
interaction	0	O
with	0	O
Swi6	0	B
,	0	O
and	0	O
the	0	O
carboxy	0	O
terminus	0	O
of	0	O
Swi6	0	B
is	0	O
required	0	O
for	0	O
interaction	0	O
with	0	O
Mbp1	0	B
.	0	O


Fifty	0	O
-	0	O
four	0	O
patients	0	O
were	0	O
divided	0	O
into	0	O
groups	0	O
according	0	O
to	0	O
their	0	O
clinical	0	O
presentation	0	O
;	0	O
seven	0	O
asymptomatic	0	O
volunteers	0	O
,	0	O
20	0	O
patients	0	O
with	0	O
duodenal	0	O
-	0	O
gastric	0	O
reflux	0	O
gastropathy	0	O
(	0	O
DRG	1	O
),	0	O
16	0	O
patients	0	O
with	0	O
recurrent	0	O
ulcers	0	O
of	0	O
the	0	O
duodenal	0	O
bulb	0	O
(	0	O
RUD	0	O
),	0	O
and	0	O
11	0	O
patients	0	O
with	0	O
Moynihan	0	O
'	0	O
s	0	O
disease	0	O
.	0	O


These	0	O
observations	0	O
of	0	O
elevated	0	O
serum	0	B
lipase	0	I
and	0	O
serum	0	O
CA	1	B
19	0	I
-	0	I
9	0	I
in	0	O
Sjogren	0	O
'	0	O
s	0	O
syndrome	0	O
without	0	O
evidence	0	O
of	0	O
malignancy	0	O
may	0	O
reflect	0	O
pancreatic	0	O
involvement	0	O
in	0	O
this	0	O
disorder	0	O
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
:	0	O
1	0	O
)	0	O
the	0	O
initial	0	O
response	0	O
to	0	O
tethering	0	O
varies	0	O
according	0	O
to	0	O
previous	0	O
penning	0	O
and	0	O
handling	0	O
experience	0	O
,	0	O
2	0	O
)	0	O
although	0	O
the	0	O
circadian	0	O
rhythm	0	O
of	0	O
cortisol	0	O
was	0	O
either	0	O
altered	0	O
or	0	O
disrupted	0	O
during	0	O
estrus	0	O
,	0	O
such	0	O
disruptions	0	O
were	0	O
not	0	O
influenced	0	O
by	0	O
type	0	O
of	0	O
penning	0	O
and	0	O
3	0	O
)	0	O
tether	0	O
stalls	0	O
may	0	O
chronically	0	O
increase	0	O
cortisol	0	O
concentrations	0	O
in	0	O
gilts	0	O
.	0	O


Regulation	1	O
of	0	O
embryonic	0	O
growth	0	O
and	0	O
lysosomal	0	O
targeting	0	O
by	0	O
the	0	O
imprinted	0	O
Igf2	0	B
/	0	O
Mpr	0	B
gene	0	O
.	0	O


HIV	1	O
infectiousness	0	O
and	0	O
the	0	O
AIDS	1	O
epidemic	0	O
.	0	O


Sucrose	1	O
-	0	O
specific	0	O
regulation	0	O
of	0	O
scrB	0	B
was	0	O
also	0	O
lost	0	O
upon	0	O
deletion	0	O
of	0	O
4	0	O
bp	0	O
of	0	O
a	0	O
palindromic	0	O
sequence	0	O
(	0	O
OB	1	O
)	0	O
covering	0	O
positions	0	O
+	0	O
6	0	O
to	0	O
+	0	O
21	0	O
downstream	0	O
of	0	O
the	0	O
scrB	0	B
transcriptional	0	O
start	0	O
site	0	O
.	0	O


Deglutition	1	O
is	0	O
considered	0	O
to	0	O
be	0	O
immature	0	O
in	0	O
infants	0	O
and	0	O
to	0	O
mature	0	O
postnatally	0	O
.	0	O


Diary	1	O
.	0	O


Expression	1	O
of	0	O
the	0	O
mouse	0	B
TSH	1	I
beta	0	I
gene	0	I
,	0	O
therefore	0	O
,	0	O
gives	0	O
rise	0	O
to	0	O
multiple	0	O
mRNAs	0	O
,	0	O
each	0	O
with	0	O
a	0	O
unique	0	O
5	0	O
'-	0	O
untranslated	0	O
region	0	O
.	0	O


The	0	O
evaluation	0	O
of	0	O
amniotic	0	O
fluid	0	O
delta	0	O
OD450	0	O
is	0	O
considered	0	O
to	0	O
be	0	O
the	0	O
cornerstone	0	O
of	0	O
clinical	0	O
management	0	O
.	0	O


Secondary	1	O
cleavage	0	O
of	0	O
RT	1	B
at	0	O
Trp	1	O
-	0	O
595	0	O
-	0	O
Tyr	1	O
-	0	O
596	0	O
of	0	O
Pol	0	B
yields	0	O
a	0	O
truncated	0	O
form	0	O
lacking	0	O
the	0	O
C	1	B
-	0	I
terminal	0	I
RNase	1	I
H	1	I
domain	0	I
.	0	O


The	0	O
results	0	O
of	0	O
the	0	O
ISIS	0	O
-	0	O
2	0	O
trial	0	O
and	0	O
the	0	O
data	0	O
from	0	O
the	0	O
Antiplatelet	1	O
Trialists	0	O
'	0	O
Collaboration	0	O
indicated	0	O
that	0	O
aspirin	0	O
is	0	O
mandatory	0	O
in	0	O
patients	0	O
with	0	O
acute	0	O
myocardial	0	O
infarction	0	O
and	0	O
for	0	O
secondary	0	O
prevention	0	O
.	0	O


The	0	O
optimal	0	O
care	0	O
of	0	O
CHF	1	O
patient	0	O
includes	0	O
the	0	O
recognition	0	O
and	0	O
management	0	O
of	0	O
these	0	O
electrolyte	0	O
disturbances	0	O
.	0	O


Feed	0	O
intake	0	O
and	0	O
BW	1	O
gains	0	O
were	0	O
decreased	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
by	0	O
dietary	0	O
treatments	0	O
containing	0	O
M	1	O
.	0	O


Gastrin	1	B
secretion	0	O
during	0	O
food	0	O
stimulation	0	O
in	0	O
digestive	0	O
system	0	O
diseases	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
phenotype	0	O
of	0	O
XLP	0	O
may	0	O
result	0	O
from	0	O
perturbed	0	O
signaling	0	O
not	0	O
only	0	O
through	0	O
SLAM	0	B
,	0	O
but	0	O
also	0	O
other	0	O
cell	0	O
surface	0	O
molecules	0	O
that	0	O
utilize	0	O
SAP	1	B
as	0	O
a	0	O
signaling	0	O
adaptor	0	O
protein	0	O
.	0	O


The	0	O
segmental	0	O
and	0	O
regional	0	O
projections	0	O
of	0	O
the	0	O
sciatic	0	O
,	0	O
tibial	0	O
and	0	O
common	0	O
peroneal	0	O
nerves	0	O
to	0	O
the	0	O
substantia	0	O
gelatinosa	0	O
of	0	O
the	0	O
spinal	0	O
cord	0	O
in	0	O
rats	0	O
--	0	O
an	0	O
experimental	0	O
study	0	O
by	0	O
means	0	O
of	0	O
an	0	O
acid	0	B
phosphatase	0	I
(	0	O
ACP	1	B
)	0	O
method	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
findings	0	O
show	0	O
that	0	O
16K	0	B
hPRL	0	I
inhibits	0	O
the	0	O
VEGF	1	B
-	0	O
induced	0	O
Ras	1	B
activation	0	O
;	0	O
this	0	O
antagonism	0	O
represents	0	O
a	0	O
novel	0	O
and	0	O
potentially	0	O
important	0	O
mechanism	0	O
for	0	O
the	0	O
control	0	O
of	0	O
angiogenesis	0	O
.	0	O


Endo16	0	B
transcripts	0	I
are	0	O
confined	0	O
to	0	O
the	0	O
definitive	0	O
vegetal	0	O
plate	0	O
in	0	O
blastula	0	O
stage	0	O
embryos	0	O
;	0	O
at	0	O
gastrula	0	O
stage	0	O
this	0	O
gene	0	O
is	0	O
expressed	0	O
throughout	0	O
the	0	O
archenteron	0	O
,	0	O
but	0	O
later	0	O
only	0	O
in	0	O
the	0	O
midgut	0	O
.	0	O


GlcNAc	1	O
-	0	O
and	0	O
GlcNAc2	0	O
-	0	O
PP	1	O
-	0	O
Dolichol	1	O
biosynthesis	0	O
could	0	O
be	0	O
shown	0	O
with	0	O
isolated	0	O
S	1	O
.	0	O
cerevisiae	0	O
membranes	0	O
from	0	O
cells	0	O
harboring	0	O
the	0	O
recombinant	0	O
plasmid	0	O
and	0	O
grown	0	O
on	0	O
glucose	0	O
thus	0	O
suppressing	0	O
transcription	0	O
of	0	O
the	0	O
endogenous	0	O
gene	0	O
.	0	O


CDK4	0	B
kinase	0	I
activities	0	O
were	0	O
unaffected	0	O
,	0	O
as	0	O
were	0	O
the	0	O
levels	0	O
of	0	O
the	0	O
CDK	1	B
inhibitor	0	O
p21Cip1	0	B
present	0	O
in	0	O
cyclin	0	B
E	1	I
immunocomplexes	0	I
.	0	O


RNA	1	O
gel	0	O
retardation	0	O
and	0	O
competition	0	O
analyses	0	O
indicate	0	O
that	0	O
TRP	1	B
-	0	I
185	0	I
binding	0	O
is	0	O
strongly	0	O
dependent	0	O
on	0	O
the	0	O
TAR	1	O
RNA	1	O
loop	0	O
sequences	0	O
.	0	O


T7	0	O
transcription	0	O
could	0	O
be	0	O
manipulated	0	O
to	0	O
achieve	0	O
different	0	O
levels	0	O
of	0	O
constitutive	0	O
expression	0	O
,	0	O
through	0	O
the	0	O
use	0	O
of	0	O
promoter	0	O
mutations	0	O
.	0	O


SETTING	0	O
:	0	O
University	0	O
of	0	O
Paris	0	O
VII	0	O
hospital	0	O
.	0	O
Patient	1	O
(	0	O
s	0	O
):	0	O
Nine	0	O
women	0	O
had	0	O
embolization	0	O
for	0	O
symptomatic	0	O
myoma	0	O
,	0	O
with	0	O
12	0	O
pregnancies	0	O
observed	0	O
.	0	O


Acute	1	O
feasibility	0	O
and	0	O
safety	0	O
of	0	O
a	0	O
smoking	0	O
reduction	0	O
strategy	0	O
for	0	O
smokers	0	O
with	0	O
schizophrenia	0	O
.	0	O


3	0	O
.	0	O


IFI	0	B
16	0	I
mRNA	1	I
was	0	O
found	0	O
to	0	O
be	0	O
constitutively	0	O
expressed	0	O
in	0	O
lymphoid	0	O
cells	0	O
and	0	O
in	0	O
cell	0	O
lines	0	O
of	0	O
both	0	O
the	0	O
T	1	O
and	0	O
B	1	O
lineages	0	O
.	0	O


Sensitization	1	O
to	0	O
hyperlactatemia	0	O
induced	0	O
by	0	O
phenformin	0	O
after	0	O
subtotal	0	O
ablation	0	O
of	0	O
the	0	O
pancreas	0	O
.	0	O


Solution	1	O
structure	0	O
and	0	O
mechanism	0	O
of	0	O
the	0	O
MutT	0	B
pyrophosphohydrolase	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
mutations	0	O
affecting	0	O
the	0	O
other	0	O
two	0	O
Nim1p	0	B
-	0	I
related	0	I
kinases	0	I
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
,	0	O
Hsl1p	0	B
and	0	O
Kcc4p	0	B
,	0	O
produce	0	O
no	0	O
detectable	0	O
effect	0	O
on	0	O
septin	0	B
organization	0	O
.	0	O


Insertion	1	O
of	0	O
short	0	O
oligonucleotides	0	O
encoding	0	O
the	0	O
basic	0	O
amino	0	O
acid	0	O
motifs	0	O
726	0	O
-	0	O
GRKRKSP	0	O
-	0	O
732	0	O
from	0	O
IE175	0	B
and	0	O
500	0	O
-	0	O
VRPRKRR	0	O
-	0	O
506	0	O
from	0	O
IE110	0	B
into	0	O
deleted	0	O
cytoplasmic	0	O
forms	0	O
of	0	O
the	0	O
two	0	O
proteins	0	O
restored	0	O
the	0	O
karyophilic	0	O
phenotype	0	O
and	0	O
confirmed	0	O
that	0	O
these	0	O
motifs	0	O
are	0	O
both	0	O
necessary	0	O
and	0	O
sufficient	0	O
for	0	O
proper	0	O
nuclear	0	O
localization	0	O
.	0	O


The	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
the	0	O
150	0	O
-	0	O
kDa	1	O
protein	0	O
contains	0	O
an	0	O
NTP	1	O
-	0	O
binding	0	O
helicase	0	B
motif	0	I
and	0	O
the	0	O
readthrough	0	O
region	0	O
,	0	O
an	0	O
RNA	1	B
polymerase	0	I
motif	0	I
,	0	O
indicating	0	O
that	0	O
these	0	O
two	0	O
overlapping	0	O
proteins	0	O
may	0	O
form	0	O
an	0	O
RNA	1	O
replication	0	O
complex	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
tobamo	0	O
-	0	O
and	0	O
tobraviruses	0	O
.	0	O


Semidominant	0	O
mutations	0	O
in	0	O
the	0	O
yeast	0	B
Rad51	0	I
protein	0	I
and	0	O
their	0	O
relationships	0	O
with	0	O
the	0	O
Srs2	0	B
helicase	0	I
.	0	O


Fifteen	0	O
light	0	O
for	0	O
dates	0	O
infants	0	O
and	0	O
their	0	O
placentae	0	O
were	0	O
compared	0	O
to	0	O
15	0	O
well	0	O
-	0	O
grown	0	O
infants	0	O
and	0	O
their	0	O
placentae	0	O
.	0	O


Ten	0	O
out	0	O
-	0	O
patients	0	O
with	0	O
pustulosis	0	O
palmaris	0	O
et	0	O
plantaris	0	O
were	0	O
examined	0	O
with	0	O
direct	0	O
immunofluorescence	0	O
(	0	O
IF	1	O
)	0	O
technique	0	O
for	0	O
deposition	0	O
of	0	O
fibrinogen	0	B
,	0	O
fibrin	0	B
or	0	O
its	0	O
degradation	0	O
products	0	O
(	0	O
FR	1	B
-	0	I
antigen	0	I
)	0	O
in	0	O
affected	0	O
and	0	O
unaffected	0	O
skin	0	O
,	0	O
together	0	O
with	0	O
heparin	0	O
-	0	O
precipitable	0	O
fraction	0	O
(	0	O
HPF	1	O
),	0	O
cryoglobulin	0	B
and	0	O
total	0	O
plasma	0	O
fibrinogen	0	B
in	0	O
the	0	O
blood	0	O
.	0	O


The	0	O
relation	0	O
between	0	O
VE	0	O
/	0	O
VO2	1	O
and	0	O
Q	1	O
/	0	O
VO2	1	O
showed	0	O
a	0	O
significant	0	O
negative	0	O
correlation	0	O
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
93	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


The	0	O
relative	0	O
tumor	0	O
FDG	1	O
-	0	O
uptake	0	O
(	0	O
Q	1	O
-	0	O
MRGlu	0	O
)	0	O
(	0	O
tumor	0	O
/	0	O
contralateral	0	O
cortex	0	O
)	0	O
of	0	O
all	0	O
meningiomas	0	O
was	0	O
calculated	0	O
with	0	O
0	0	O
.	0	O
73	0	O
+/-	0	O
0	0	O
.	0	O
37	0	O
(	0	O
0	0	O
.	0	O
24	0	O
-	0	O
1	0	O
.	0	O
79	0	O
).	0	O


Although	0	O
the	0	O
RAD23	0	B
equivalents	0	O
are	0	O
well	0	O
conserved	0	O
during	0	O
evolution	0	O
,	0	O
the	0	O
mammalian	0	O
genes	0	O
did	0	O
not	0	O
express	0	O
the	0	O
UV	1	O
-	0	O
inducible	0	O
phenotype	0	O
of	0	O
their	0	O
yeast	0	O
counterpart	0	O
.	0	O


Characterization	0	O
of	0	O
the	0	O
alpha	0	B
4	0	I
integrin	0	I
gene	0	I
promoter	0	I
.	0	O


Osteoadherin	1	B
is	0	O
a	0	O
recently	0	O
described	0	O
bone	0	O
proteoglycan	0	O
containing	0	O
keratan	0	O
sulfate	0	O
.	0	O


Pretreatment	1	O
of	0	O
cells	0	O
with	0	O
the	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
-	0	I
extracellular	0	I
signal	0	I
-	0	I
regulated	0	I
kinase	0	I
kinase	0	I
(	0	O
MEK	0	B
)	0	O
inhibitor	0	O
U0126	0	O
inhibited	0	O
S6K2	0	B
activation	0	O
to	0	O
a	0	O
greater	0	O
extent	0	O
than	0	O
S6K1	0	B
.	0	O


All	1	O
9	0	O
untreated	0	O
patients	0	O
underwent	0	O
laparoscopy	0	O
,	0	O
which	0	O
identified	0	O
3	0	O
intra	0	O
-	0	O
abdominal	0	O
,	0	O
3	0	O
vanished	0	O
and	0	O
2	0	O
peeping	0	O
testes	0	O
,	0	O
and	0	O
1	0	O
atrophic	0	O
testis	0	O
in	0	O
the	0	O
inguinal	0	O
canal	0	O
.	0	O


The	0	O
sequence	0	O
of	0	O
the	0	O
putative	0	O
RBP1	0	B
protein	0	I
contains	0	O
two	0	O
copies	0	O
of	0	O
an	0	O
RNA	1	O
recognition	0	O
motif	0	O
,	0	O
two	0	O
glutamine	0	O
stretches	0	O
,	0	O
an	0	O
asparagine	0	O
-	0	O
rich	0	O
region	0	O
,	0	O
a	0	O
methionine	0	O
-	0	O
rich	0	O
region	0	O
,	0	O
and	0	O
two	0	O
long	0	O
potential	0	O
alpha	0	O
-	0	O
helixes	0	O
.	0	O


Iodine	1	O
metabolism	0	O
in	0	O
chronic	0	O
thyroiditis	0	O
.	0	O


Copyright	0	O
2000	0	O
Academic	0	O
Press	0	O
.	0	O


Two	0	O
estrogen	0	B
receptor	0	I
(	0	O
ER	1	B
)	0	O
isoforms	0	O
with	0	O
different	0	O
estrogen	0	O
dependencies	0	O
are	0	O
generated	0	O
from	0	O
the	0	O
trout	0	B
ER	1	I
gene	0	I
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
in	0	O
addition	0	O
to	0	O
Grb2	0	B
-	0	O
mediated	0	O
activation	0	O
of	0	O
Ras	1	B
,	0	O
PLC	0	B
-	0	I
gamma1	0	I
-	0	O
mediated	0	O
DAG	1	O
production	0	O
is	0	O
required	0	O
for	0	O
EGF	1	B
-	0	O
and	0	O
PDGF	0	B
-	0	O
induced	0	O
S	1	O
-	0	O
phase	0	O
entry	0	O
and	0	O
gene	0	O
expression	0	O
,	0	O
possibly	0	O
through	0	O
activation	0	O
of	0	O
PKC	0	B
.	0	O


Levels	0	O
of	0	O
TSG	0	B
-	0	I
14	0	I
protein	0	I
(	0	O
also	0	O
termed	0	O
PTX	0	B
-	0	I
3	0	I
)	0	O
become	0	O
elevated	0	O
in	0	O
the	0	O
serum	0	O
of	0	O
mice	0	O
and	0	O
humans	0	O
after	0	O
injection	0	O
with	0	O
bacterial	0	O
lipopolysaccharide	0	O
,	0	O
but	0	O
in	0	O
contrast	0	O
to	0	O
conventional	0	O
acute	0	O
phase	0	O
proteins	0	O
,	0	O
the	0	O
bulk	0	O
of	0	O
TSG	0	B
-	0	I
14	0	I
synthesis	0	O
in	0	O
the	0	O
intact	0	O
organism	0	O
occurs	0	O
outside	0	O
the	0	O
liver	0	O
.	0	O


Nhp2p	0	B
is	0	O
a	0	O
highly	0	O
basic	0	O
protein	0	O
that	0	O
belongs	0	O
to	0	O
a	0	O
family	0	O
of	0	O
putative	0	O
RNA	1	O
-	0	O
binding	0	O
proteins	0	O
.	0	O


By	0	O
contrast	0	O
,	0	O
secretory	0	B
HI	1	I
antibodies	0	I
were	0	O
not	0	O
demonstrated	0	O
at	0	O
the	0	O
onset	0	O
of	0	O
illness	0	O
in	0	O
any	0	O
of	0	O
the	0	O
patients	0	O
,	0	O
but	0	O
their	0	O
formation	0	O
started	0	O
early	0	O
and	0	O
the	0	O
antibodies	0	O
reached	0	O
maximal	0	O
levels	0	O
about	0	O
10	0	O
days	0	O
after	0	O
onset	0	O
of	0	O
illness	0	O
.	0	O


Null	1	O
mutations	0	O
in	0	O
daf	0	B
-	0	I
3	0	I
suppress	0	O
mutations	0	O
in	0	O
genes	0	O
encoding	0	O
this	0	O
TGF	1	B
-	0	I
beta	0	I
signal	0	O
,	0	O
its	0	O
receptors	0	O
,	0	O
and	0	O
associated	0	O
Smad	0	B
signal	0	I
transduction	0	I
proteins	0	I
.	0	O
daf	0	B
-	0	I
3	0	I
encodes	0	O
a	0	O
Smad	0	B
protein	0	I
that	0	O
is	0	O
most	0	O
closely	0	O
related	0	O
to	0	O
mammalian	0	B
DPC4	0	I
,	0	O
and	0	O
is	0	O
expressed	0	O
throughout	0	O
development	0	O
in	0	O
many	0	O
of	0	O
the	0	O
tissues	0	O
that	0	O
are	0	O
remodeled	0	O
during	0	O
dauer	0	O
development	0	O
.	0	O


Full	0	B
-	0	I
length	0	I
FLAP	1	I
clones	0	O
were	0	O
isolated	0	O
from	0	O
a	0	O
mouse	0	O
skeletal	0	O
muscle	0	O
cDNA	1	O
library	0	O
.	0	O


The	0	O
expression	0	O
of	0	O
chloramphenicol	0	B
acetyltransferase	0	I
was	0	O
detected	0	O
within	0	O
1	0	O
h	0	O
after	0	O
infection	0	O
of	0	O
cells	0	O
with	0	O
recombinant	0	O
virus	0	O
,	0	O
reflecting	0	O
the	0	O
early	0	O
nature	0	O
of	0	O
the	0	O
promoters	0	O
used	0	O
.	0	O


First	0	O
,	0	O
each	0	O
lung	0	O
was	0	O
cut	0	O
into	0	O
slices	0	O
,	0	O
from	0	O
which	0	O
primary	0	O
disectors	0	O
were	0	O
sampled	0	O
systematically	0	O
with	0	O
a	0	O
known	0	O
sampling	0	O
fraction	0	O
.	0	O


Studies	0	O
of	0	O
biochemical	0	O
and	0	O
morphological	0	O
changes	0	O
(	0	O
between	0	O
normal	0	O
and	0	O
treated	0	O
animals	0	O
)	0	O
show	0	O
that	0	O
chrysotile	0	O
induces	0	O
an	0	O
increase	0	O
in	0	O
the	0	O
lung	0	O
free	0	O
cell	0	O
population	0	O
and	0	O
pulmonary	0	O
surfactant	0	O
levels	0	O
.	0	O


Of	0	O
the	0	O
drugs	0	O
orally	0	O
administered	0	O
,	0	O
WR	0	O
-	0	O
168643	0	O
was	0	O
the	0	O
best	0	O
protector	0	O
with	0	O
a	0	O
DMF	1	O
of	0	O
1	0	O
.	0	O
51	0	O
.	0	O


Alternative	0	O
splicing	0	O
of	0	O
ClC	1	B
-	0	I
6	0	I
(	0	O
a	0	O
member	0	O
of	0	O
the	0	O
CIC	0	B
chloride	0	I
-	0	I
channel	0	I
family	0	I
)	0	O
transcripts	0	O
generates	0	O
three	0	O
truncated	0	O
isoforms	0	O
one	0	O
of	0	O
which	0	O
,	0	O
ClC	1	B
-	0	I
6c	0	I
,	0	O
is	0	O
kidney	0	O
-	0	O
specific	0	O
.	0	O


Abnormal	1	O
characteristics	0	O
and	0	O
verticillation	0	O
in	0	O
Platynothrus	0	O
peltifer	0	O


The	0	O
DNA	1	O
sequence	0	O
of	0	O
the	0	O
sulfate	0	B
activation	0	I
locus	0	I
from	0	O
Escherichia	1	O
coli	0	O
K	1	O
-	0	O
12	0	O
has	0	O
been	0	O
determined	0	O
.	0	O


We	0	O
show	0	O
that	0	O
the	0	O
mouse	0	O
genome	0	O
contains	0	O
four	0	O
copies	0	O
of	0	O
the	0	O
ubc	0	B
-	0	I
9	0	I
gene	0	I
.	0	O


Location	0	O
and	0	O
orientation	0	O
of	0	O
an	0	O
activating	0	O
region	0	O
in	0	O
the	0	O
Escherichia	1	O
coli	0	O
transcription	0	O
factor	0	O
,	0	O
FNR	1	B
.	0	O


The	0	O
isolated	0	O
POT1	0	B
clones	0	O
hybridized	0	O
to	0	O
a	0	O
1	0	O
.	0	O
4	0	O
kb	0	O
RNA	1	O
species	0	O
,	0	O
which	0	O
was	0	O
induced	0	O
approximately	0	O
30	0	O
-	0	O
fold	0	O
when	0	O
oleate	0	O
was	0	O
the	0	O
carbon	0	O
source	0	O
.	0	O


The	0	O
murine	0	B
mutation	0	I
dominant	0	I
white	0	I
spotting	0	I
(	0	O
W	1	B
)	0	O
is	0	O
in	0	O
the	0	O
proto	0	O
-	0	O
oncogene	0	O
,	0	O
c	0	B
-	0	I
kit	0	I
.	0	O


Investigation	0	O
of	0	O
the	0	O
structural	0	O
basis	0	O
of	0	O
the	0	O
interaction	0	O
between	0	O
human	0	B
Igs	0	I
and	0	O
gp120	0	B
shows	0	O
that	0	O
the	0	O
viral	0	B
gp120	0	I
SAg	0	I
can	0	O
interact	0	O
only	0	O
with	0	O
a	0	O
subset	0	O
of	0	O
human	0	B
V	1	I
(	0	I
H	1	I
)	0	I
3	0	I
+	0	I
Igs	0	I
.	0	O


Each	0	O
of	0	O
these	0	O
spliced	0	O
mRNAs	0	O
has	0	O
an	0	O
untranslated	0	O
leader	0	O
sequence	0	O
of	0	O
249	0	O
bases	0	O
and	0	O
a	0	O
single	0	O
intron	0	O
of	0	O
approximately	0	O
540	0	O
bases	0	O
which	0	O
are	0	O
contained	0	O
entirely	0	O
within	0	O
TRs	0	O
/	0	O
IRs	0	O
sequences	0	O
.	0	O


Flavonoids	0	O
from	0	O
Brosimum	0	O
acutifolium	0	O
.	0	O


A	1	O
polymorphic	0	O
bipartite	0	O
motif	0	O
signals	0	O
nuclear	0	O
targeting	0	O
of	0	O
early	0	O
auxin	0	O
-	0	O
inducible	0	O
proteins	0	O
related	0	O
to	0	O
PS	1	O
-	0	O
IAA4	0	O
from	0	O
pea	0	O
(	0	O
Pisum	1	O
sativum	0	O
).	0	O


It	1	O
is	0	O
present	0	O
in	0	O
the	0	O
nucleus	0	O
of	0	O
the	0	O
cells	0	O
in	0	O
which	0	O
it	0	O
is	0	O
expressed	0	O
and	0	O
can	0	O
phosphorylate	0	O
and	0	O
activate	0	O
the	0	O
cyclic	0	B
AMP	1	I
response	0	I
element	0	I
binding	0	I
proteins	0	I
CREB	0	I
and	0	O
CREM	0	B
tau	0	I
in	0	O
a	0	O
manner	0	O
analogous	0	O
to	0	O
protein	0	B
kinase	0	I
A	1	I
.	0	O


Infection	1	O
with	0	O
Neisseria	1	O
meningitidis	0	O
group	0	O
B	1	O
has	0	O
been	0	O
difficult	0	O
to	0	O
detect	0	O
,	0	O
partly	0	O
because	0	O
this	0	O
bacterial	0	O
group	0	O
'	0	O
s	0	O
polysaccharide	0	O
is	0	O
a	0	O
weak	0	O
immunogen	0	O
.	0	O


To	1	O
those	0	O
of	0	O
us	0	O
who	0	O
are	0	O
not	0	O
satisfied	0	O
with	0	O
the	0	O
present	0	O
outlook	0	O
there	0	O
is	0	O
much	0	O
to	0	O
be	0	O
investigated	0	O
and	0	O
much	0	O
to	0	O
be	0	O
contributed	0	O
.	0	O


To	1	O
study	0	O
the	0	O
sensitivity	0	O
of	0	O
some	0	O
central	0	O
brain	0	O
structures	0	O
to	0	O
the	0	O
action	0	O
of	0	O
an	0	O
electromagnetic	0	O
field	0	O
of	0	O
decimeter	0	O
waves	0	O
(	0	O
EMF	1	O
of	0	O
DW	0	O
)	0	O
a	0	O
dynamic	0	O
investigation	0	O
of	0	O
single	0	O
unit	0	O
activity	0	O
was	0	O
undertaken	0	O
.	0	O


IE2	0	B
-	0	O
IE2	0	B
interactions	0	O
were	0	O
mapped	0	O
to	0	O
a	0	O
domain	0	O
containing	0	O
a	0	O
putative	0	O
helix	0	O
-	0	O
turn	0	O
-	0	O
helix	0	O
motif	0	O
located	0	O
near	0	O
the	0	O
C	1	O
terminus	0	O
of	0	O
IE2	0	B
,	0	O
between	0	O
amino	0	O
acids	0	O
456	0	O
and	0	O
539	0	O
.	0	O


There	0	O
were	0	O
gene	0	O
clusters	0	O
encoding	0	O
photosynthesis	0	O
components	0	O
such	0	O
as	0	O
the	0	O
psbB	0	B
-	0	O
psbH	0	B
-	0	O
petB	0	B
-	0	O
petD	0	B
and	0	O
the	0	O
psbE	0	O
-	0	O
psbF	0	O
clusters	0	O
.	0	O


To	1	O
identify	0	O
nuclear	0	O
regulatory	0	O
factors	0	O
,	0	O
we	0	O
have	0	O
located	0	O
and	0	O
functionally	0	O
characterized	0	O
the	0	O
CCR5	0	B
gene	0	I
promoter	0	I
.	0	O


Binding	0	O
specificity	0	O
and	0	O
modulation	0	O
of	0	O
the	0	O
ApoA	0	B
-	0	I
I	1	I
promoter	0	I
activity	0	O
by	0	O
homo	0	O
-	0	O
and	0	O
heterodimers	0	O
of	0	O
nuclear	0	O
receptors	0	O
.	0	O


Apart	0	O
from	0	O
iron	0	O
regulation	0	O
,	0	O
sodA	1	B
expression	0	O
was	0	O
affected	0	O
by	0	O
changes	0	O
in	0	O
DNA	1	O
topology	0	O
induced	0	O
by	0	O
coumermycin	0	O
A	1	O
but	0	O
not	0	O
by	0	O
the	0	O
global	0	O
virulence	0	O
regulatory	0	O
Bvg	0	B
system	0	I
.	0	O


These	0	O
combined	0	O
observations	0	O
define	0	O
a	0	O
promoter	0	O
and	0	O
an	0	O
enhancer	0	O
for	0	O
the	0	O
chicken	0	B
L	1	I
-	0	I
CAM	1	I
gene	0	I
.	0	O


Mapping	1	O
of	0	O
the	0	O
mouse	0	B
ornithine	0	I
decarboxylase	0	I
-	0	I
related	0	I
sequence	0	I
family	0	I
.	0	O


Recombination	1	O
,	0	O
replication	0	O
,	0	O
repair	0	O
:	0	O
from	0	O
complexity	0	O
to	0	O
harmony	0	O
.	0	O


The	0	O
hydrophobicity	0	O
profile	0	O
of	0	O
the	0	O
methyltransferase	0	O
reveals	0	O
the	0	O
presence	0	O
of	0	O
at	0	O
least	0	O
five	0	O
potential	0	O
transmembrane	0	O
domains	0	O
.	0	O


Restriction	1	O
maps	0	O
of	0	O
the	0	O
cloned	0	O
plasmids	0	O
revealed	0	O
that	0	O
their	0	O
chromosomal	0	O
inserts	0	O
consisted	0	O
of	0	O
overlapping	0	O
fragments	0	O
.	0	O


Furthermore	0	O
,	0	O
a	0	O
mutant	0	O
receptor	0	O
(	0	O
Y977F	0	O
/	0	O
Y989F	0	O
[	0	O
PLC	0	B
gamma	0	I
-	0	O
binding	0	O
sites	0	O
])	0	O
could	0	O
fully	0	O
activate	0	O
Ras	1	B
,	0	O
and	0	O
the	0	O
direct	0	O
activation	0	O
of	0	O
protein	0	B
kinase	0	I
C	1	I
and	0	O
calcium	0	O
mobilization	0	O
had	0	O
almost	0	O
no	0	O
effect	0	O
on	0	O
the	0	O
GDP	1	O
/	0	O
GTP	1	O
state	0	O
of	0	O
Ras	1	B
in	0	O
this	0	O
cell	0	O
line	0	O
.	0	O


Dll3	0	B
is	0	O
mutated	0	O
in	0	O
the	0	O
X	1	O
-	0	O
ray	0	O
-	0	O
induced	0	O
mouse	0	B
mutant	0	I
pudgy	0	I
(	0	O
pu	0	B
),	0	O
causing	0	O
a	0	O
variety	0	O
of	0	O
vertebrocostal	0	O
defects	0	O
similar	0	O
to	0	O
SD	1	O
phenotypes	0	O
.	0	O


Twenty	0	O
-	0	O
two	0	O
consecutive	0	O
patients	0	O
with	0	O
ischaemic	0	O
ulcers	0	O
had	0	O
tcPO2	0	O
measured	0	O
and	0	O
the	0	O
ankle	0	O
/	0	O
brachial	0	O
(	0	O
ABI	1	O
)	0	O
and	0	O
toe	0	O
/	0	O
brachial	0	O
(	0	O
TBI	1	O
)	0	O
indices	0	O
calculated	0	O
.	0	O


The	0	O
AGM	0	B
and	0	I
NIH	1	I
/	0	I
Swiss	0	I
mouse	0	I
CCR5	0	I
proteins	0	I
are	0	O
97	0	O
.	0	O
7	0	O
to	0	O
98	0	O
.	0	O
3	0	O
%	0	O
and	0	O
79	0	O
.	0	O
8	0	O
%	0	O
identical	0	O
to	0	O
the	0	O
human	0	O
protein	0	O
,	0	O
respectively	0	O
.	0	O


Cloning	1	O
of	0	O
a	0	O
human	0	O
cDNA	1	O
encoding	0	O
a	0	O
CDC2	0	B
-	0	I
related	0	I
kinase	0	I
by	0	O
complementation	0	O
of	0	O
a	0	O
budding	0	B
yeast	0	I
cdc28	0	I
mutation	0	O
.	0	O


A	1	O
recent	0	O
index	0	O
(	0	O
Fluorosis	1	O
Risk	1	O
Index	1	O
)	0	O
developed	0	O
by	0	O
Pendrys	0	O
(	0	O
1990	0	O
)	0	O
is	0	O
also	0	O
included	0	O
in	0	O
this	0	O
review	0	O
.	0	O


Several	0	O
PTPases	0	B
were	0	O
expressed	0	O
abundantly	0	O
in	0	O
the	0	O
5	0	O
-	0	O
FU	0	O
-	0	O
treated	0	O
bone	0	O
marrow	0	O
stem	0	O
cells	0	O
.	0	O


This	0	O
study	0	O
assesses	0	O
the	0	O
feasibility	0	O
and	0	O
toxicity	0	O
of	0	O
adoptive	0	O
immunotherapy	0	O
with	0	O
tumor	0	O
infiltrating	0	O
lymphocytes	0	O
and	0	O
recombinant	0	B
interleukin	0	I
-	0	I
2	0	I
in	0	O
29	0	O
patients	0	O
who	0	O
underwent	0	O
resection	0	O
for	0	O
stage	0	O
III	0	O
non	0	O
-	0	O
small	0	O
-	0	O
cell	0	O
lung	0	O
cancer	0	O
.	0	O


The	0	O
second	0	O
transcriptional	0	O
unit	0	O
,	0	O
designated	0	O
UL26	0	B
.	0	I
5	0	I
,	0	O
predicted	0	O
to	0	O
specify	0	O
a	0	O
protein	0	O
of	0	O
329	0	O
amino	0	O
acids	0	O
,	0	O
encodes	0	O
the	0	O
family	0	B
35	0	I
proteins	0	I
;	0	O
it	0	O
is	0	O
transcribed	0	O
by	0	O
an	0	O
mRNA	1	O
which	0	O
initiates	0	O
at	0	O
approximately	0	O
nucleotide	0	O
+	0	O
1000	0	O
of	0	O
the	0	O
UL26	0	B
transcription	0	O
initiation	0	O
site	0	O
and	0	O
is	0	O
translated	0	O
from	0	O
the	0	O
methionine	0	O
initiation	0	O
codon	0	O
located	0	O
at	0	O
position	0	O
+	0	O
1099	0	O
of	0	O
the	0	O
UL26	0	B
transcriptional	0	I
unit	0	I
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
Thr115	0	O
may	0	O
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
MyoD	0	B
function	0	O
under	0	O
conditions	0	O
of	0	O
high	0	O
mitogenesis	0	O
.	0	O


The	0	O
two	0	O
most	0	O
recent	0	O
patients	0	O
(	0	O
35	0	O
and	0	O
132	0	O
days	0	O
)	0	O
received	0	O
only	0	O
oral	0	O
dipyridamole	0	O
(	0	O
75	0	O
mg	0	O
X	1	O
3	0	O
/	0	O
day	0	O
)	0	O
and	0	O
aspirin	0	O
(	0	O
80	0	O
mg	0	O
/	0	O
day	0	O
)	0	O
after	0	O
the	0	O
early	0	O
recovery	0	O
period	0	O
(	0	O
four	0	O
-	0	O
six	0	O
days	0	O
),	0	O
resulting	0	O
in	0	O
normal	0	O
prothrombin	0	B
and	0	O
partial	0	O
thromboplastin	0	B
times	0	O
.	0	O


Relative	0	O
to	0	O
coherent	0	O
control	0	O
words	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
quick	0	O
),	0	O
these	0	O
discourse	0	O
-	0	O
dependent	0	O
semantic	0	O
anomalies	0	O
elicited	0	O
a	0	O
large	0	O
N400	0	O
effect	0	O
that	0	O
began	0	O
at	0	O
about	0	O
200	0	O
to	0	O
250	0	O
msec	0	O
after	0	O
word	0	O
onset	0	O
.	0	O


Human	1	B
acid	0	I
ceramidase	0	I
((	0	O
AC	1	O
)	0	O
N	1	O
-	0	O
acylsphingosine	0	O
amidohydrolase	0	O
,	0	O
EC	1	B
3	0	I
.	0	I
5	0	I
.	0	O


Although	0	O
no	0	O
differences	0	O
were	0	O
noted	0	O
in	0	O
the	0	O
decrease	0	O
in	0	O
platelet	0	O
counts	0	O
between	0	O
the	0	O
two	0	O
groups	0	O
,	0	O
fibrinogen	0	B
levels	0	O
and	0	O
alpha	0	B
2	0	I
-	0	I
antiplasmin	0	I
levels	0	O
declined	0	O
less	0	O
drastically	0	O
in	0	O
the	0	O
antithrombin	0	B
-	0	O
treated	0	O
group	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Sonographic	1	O
angiography	0	O
has	0	O
a	0	O
possible	0	O
role	0	O
in	0	O
the	0	O
detection	0	O
of	0	O
small	0	O
nodules	0	O
in	0	O
patients	0	O
with	0	O
CRF	1	O
.	0	O


There	0	O
were	0	O
122	0	O
cases	0	O
of	0	O
tuberculosis	0	O
over	0	O
an	0	O
average	0	O
10	0	O
.	0	O
3	0	O
yr	0	O
of	0	O
follow	0	O
-	0	O
up	0	O
(	0	O
crude	0	O
annual	0	O
incidence	0	O
,	0	O
76	0	O
.	0	O
2	0	O
/	0	O
100	0	O
,	0	O
000	0	O
).	0	O


5	0	O
micrograms	0	O
/	0	O
l	0	O
was	0	O
detected	0	O
in	0	O
urine	0	O
from	0	O
some	0	O
non	0	O
-	0	O
occupationally	0	O
exposed	0	O
persons	0	O
.	0	O


The	0	O
protector	0	O
doubled	0	O
the	0	O
estimated	0	O
fall	0	O
distance	0	O
for	0	O
fracture	0	O
of	0	O
the	0	O
trochanter	0	O
.	0	O


Primer	1	O
extension	0	O
experiments	0	O
showed	0	O
that	0	O
there	0	O
are	0	O
two	0	O
transcription	0	O
initiation	0	O
sites	0	O
16	0	O
bp	0	O
apart	0	O
in	0	O
the	0	O
mouse	0	B
type	0	I
2	0	I
receptor	0	I
gene	0	I
.	0	O


The	0	O
controversy	0	O
of	0	O
significance	0	O
testing	0	O
:	0	O
misconceptions	0	O
and	0	O
alternatives	0	O
.	0	O


Data	1	O
collection	0	O
was	0	O
made	0	O
with	0	O
a	0	O
query	0	O
language	0	O
,	0	O
and	0	O
data	0	O
analysis	0	O
performed	0	O
with	0	O
an	0	O
interactive	0	O
knowledge	0	O
-	0	O
based	0	O
statistical	0	O
tool	0	O
,	0	O
MAXITAB	0	O
,	0	O
employing	0	O
a	0	O
multivariate	0	O
tabular	0	O
analysis	0	O
technique	0	O
.	0	O


272	0	O
,	0	O
19107	0	O
-	0	O
19110	0	O
).	0	O


During	0	O
the	0	O
2h	0	O
resuscitation	0	O
period	0	O
,	0	O
extracellular	0	O
aspartate	0	O
and	0	O
glutamate	0	O
concentrations	0	O
in	0	O
the	0	O
cerebral	0	O
striatum	0	O
were	0	O
higher	0	O
during	0	O
hypoxaemic	0	O
resuscitation	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
044	0	O
and	0	O
p	0	O
=	0	O
0	0	O
.	0	O
055	0	O
,	0	O
respectively	0	O
)	0	O
than	0	O
during	0	O
resuscitation	0	O
with	0	O
21	0	O
%	0	O
O2	1	O
or	0	O
100	0	O
%	0	O
O2	1	O
,	0	O
suggesting	0	O
an	0	O
unfavourable	0	O
accumulation	0	O
of	0	O
potent	0	O
excitotoxins	0	O
during	0	O
hypoxaemic	0	O
resuscitation	0	O
.	0	O


Finally	0	O
,	0	O
we	0	O
show	0	O
that	0	O
PhLP	0	B
complexes	0	O
,	0	O
at	0	O
least	0	O
partially	0	O
,	0	O
with	0	O
Gbetagamma	0	B
in	0	O
vivo	0	O
.	0	O


The	0	O
tip	0	O
of	0	O
the	0	O
button	0	O
caused	0	O
a	0	O
perforation	0	O
of	0	O
the	0	O
posterior	0	O
stomach	0	O
wall	0	O
,	0	O
leading	0	O
to	0	O
death	0	O
.	0	O


We	0	O
cloned	0	O
and	0	O
sequenced	0	O
the	0	O
cDNAs	0	O
against	0	O
genomic	0	O
RNA	1	O
and	0	O
mRNA	1	O
for	0	O
phosphoprotein	0	B
(	0	I
P	1	I
)	0	I
of	0	O
human	0	O
parainfluenza	0	O
type	0	O
2	0	O
virus	0	O
(	0	O
PIV	0	O
-	0	O
2	0	O
).	0	O
cDNA	1	O
clone	0	O
from	0	O
genomic	0	O
RNA	1	O
was	0	O
1439	0	O
nucleotides	0	O
in	0	O
length	0	O
excluding	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
and	0	O
was	0	O
found	0	O
to	0	O
have	0	O
two	0	O
small	0	O
open	0	O
reading	0	O
frames	0	O
encoding	0	O
proteins	0	O
of	0	O
233	0	O
and	0	O
249	0	O
amino	0	O
acids	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
marmoset	0	B
monkey	0	I
LHR	0	I
seems	0	O
to	0	O
lack	0	O
the	0	O
sequence	0	O
corresponding	0	O
to	0	O
exon	0	O
10	0	O
of	0	O
the	0	O
LHR	0	B
gene	0	I
in	0	O
other	0	O
mammalian	0	O
species	0	O
.	0	O


No	1	O
evidence	0	O
for	0	O
the	0	O
presence	0	O
of	0	O
introns	0	O
within	0	O
the	0	O
acvA	0	B
gene	0	I
has	0	O
been	0	O
found	0	O
.	0	O


Acad	0	O
.	0	O


The	0	O
MRS	0	O
II	0	O
meets	0	O
a	0	O
high	0	O
methodological	0	O
standard	0	O
as	0	O
an	0	O
instrument	0	O
standardized	0	O
in	0	O
the	0	O
population	0	O
.	0	O


Isolation	1	O
of	0	O
a	0	O
near	0	O
full	0	O
-	0	O
length	0	O
cDNA	1	O
from	0	O
a	0	O
human	0	O
fetal	0	O
brain	0	O
cDNA	1	O
library	0	O
revealed	0	O
a	0	O
protein	0	B
serine	0	I
-	0	I
threonine	0	I
phosphatase	0	I
with	0	O
a	0	O
tetratricopeptide	0	O
motif	0	O
,	0	O
almost	0	O
identical	0	O
to	0	O
human	0	B
PPP5C	0	I
(	0	O
PP5	0	B
)	0	O
and	0	O
highly	0	O
homologous	0	O
to	0	O
rat	0	B
PPT	1	I
.	0	O


We	0	O
find	0	O
that	0	O
BCL	0	B
-	0	I
6	0	I
POZ	0	O
domain	0	O
mutations	0	O
that	0	O
disrupt	0	O
the	0	O
interaction	0	O
with	0	O
N	1	B
-	0	I
CoR	1	I
and	0	O
SMRT	0	B
no	0	O
longer	0	O
repress	0	O
transcription	0	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
serum	0	B
BGP	0	I
is	0	O
a	0	O
valuable	0	O
measurement	0	O
of	0	O
bone	0	O
metabolism	0	O
.	0	O


Stress	1	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
1	0	I
(	0	O
SAPK1	0	B
),	0	O
also	0	O
called	0	O
c	0	B
-	0	I
Jun	1	I
N	1	I
-	0	I
terminal	0	I
kinase	0	I
(	0	O
JNK	0	B
),	0	O
becomes	0	O
activated	0	O
in	0	O
vivo	0	O
in	0	O
response	0	O
to	0	O
pro	0	O
-	0	O
inflammatory	0	O
cytokines	0	O
or	0	O
cellular	0	O
stresses	0	O
.	0	O


Sources	0	O
of	0	O
noise	0	O
in	0	O
these	0	O
signals	0	O
were	0	O
evaluated	0	O
in	0	O
preparations	0	O
stained	0	O
with	0	O
the	0	O
potentiometric	0	O
probe	0	O
RH	1	O
-	0	O
414	0	O
.	0	O


1	0	O
.	0	O


Endoscopic	1	O
transthoracic	0	O
sympathectomy	0	O
as	0	O
adjuvant	0	O
treatment	0	O
for	0	O
critical	0	O
upper	0	O
-	0	O
limb	0	O
ischaemia	0	O
.	0	O


Further	0	O
outbreaks	0	O
of	0	O
ocular	0	O
disease	0	O
in	0	O
farmed	0	O
red	0	O
deer	0	O
calves	0	O
caused	0	O
by	0	O
HVC	0	O
-	0	O
1	0	O
were	0	O
investigated	0	O
.	0	O


Whereas	0	O
a	0	O
PR55	0	B
beta	0	I
transcript	0	I
of	0	O
about	0	O
2	0	O
.	0	O
3	0	O
kb	0	O
was	0	O
detected	0	O
at	0	O
high	0	O
levels	0	O
in	0	O
the	0	O
neuroblastoma	0	O
derived	0	O
cell	0	O
line	0	O
LA	1	O
-	0	O
N	1	O
-	0	O
1	0	O
,	0	O
the	0	O
level	0	O
of	0	O
the	0	O
mRNA	1	O
was	0	O
very	0	O
low	0	O
in	0	O
the	0	O
other	0	O
human	0	O
cell	0	O
lines	0	O
analyzed	0	O
.	0	O


Similarly	0	O
,	0	O
maternal	0	B
serum	0	I
somatomedin	0	I
A	1	I
was	0	O
significantly	0	O
reduced	0	O
in	0	O
rats	0	O
nursing	0	O
large	0	O
litters	0	O
.	0	O


When	0	O
the	0	O
LCx	0	O
was	0	O
partially	0	O
occluded	0	O
,	0	O
mild	0	O
PM	1	O
-	0	O
induced	0	O
tachycardia	0	O
resulted	0	O
in	0	O
decreased	0	O
AoP	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
045	0	O
)	0	O
as	0	O
well	0	O
as	0	O
in	0	O
decreased	0	O
SV	1	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
048	0	O
);	0	O
the	0	O
LVEDP	1	O
remained	0	O
high	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
002	0	O
).	0	O


Subcellular	0	O
localizations	0	O
of	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
CBFbeta	0	I
and	0	O
the	0	O
CBFbeta	0	B
-	0	O
SMMHC	0	B
fusion	0	O
protein	0	O
were	0	O
determined	0	O
by	0	O
immunofluorescence	0	O
of	0	O
NIH	1	O
3T3	0	O
cells	0	O
that	0	O
overexpress	0	O
wild	0	O
-	0	O
type	0	O
or	0	O
fusion	0	O
protein	0	O
.	0	O


In	1	O
vitro	0	O
translation	0	O
of	0	O
the	0	O
mTRF1	0	B
cDNA	1	I
resulted	0	O
in	0	O
a	0	O
56	0	O
kDa	1	O
protein	0	O
that	0	O
binds	0	O
to	0	O
TTAGGG	0	O
repeat	0	O
arrays	0	O
.	0	O
mTRF1	0	B
displayed	0	O
the	0	O
same	0	O
sequence	0	O
specificity	0	O
as	0	O
hTRF1	0	B
,	0	O
preferring	0	O
arrays	0	O
of	0	O
TTAGGG	0	O
repeats	0	O
as	0	O
a	0	O
binding	0	O
substrate	0	O
over	0	O
TTAGGC	0	O
and	0	O
TTGGGG	0	O
repeats	0	O
.	0	O


In	1	O
another	0	O
study	0	O
,	0	O
intravenous	0	O
administration	0	O
of	0	O
devazepide	0	O
,	0	O
a	0	O
specific	0	O
cholecystokinin	0	B
-	0	I
A	1	I
receptor	0	I
antagonist	0	O
,	0	O
at	0	O
a	0	O
dose	0	O
of	0	O
0	0	O
.	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
hr	0	O
was	0	O
begun	0	O
15	0	O
min	0	O
before	0	O
postprandial	0	O
saline	0	O
intake	0	O
and	0	O
continued	0	O
for	0	O
1	0	O
hr	0	O
.	0	O


This	0	O
is	0	O
the	0	O
first	0	O
example	0	O
of	0	O
a	0	O
eukaryotic	0	O
transcription	0	O
factor	0	O
complex	0	O
containing	0	O
both	0	O
a	0	O
MADS	0	B
-	0	I
box	0	I
and	0	O
a	0	O
forkhead	0	B
protein	0	I
,	0	O
and	0	O
it	0	O
has	0	O
important	0	O
implications	0	O
for	0	O
the	0	O
regulation	0	O
of	0	O
mammalian	0	O
gene	0	O
expression	0	O
.	0	O


Immuno	0	O
-	0	O
cytochemistry	0	O
,	0	O
using	0	O
antisera	0	O
against	0	O
Campylobacter	1	O
jejuni	0	O
,	0	O
showed	0	O
that	0	O
the	0	O
positive	0	O
staining	0	O
in	0	O
altered	0	O
epithelial	0	O
cells	0	O
were	0	O
restricted	0	O
to	0	O
intracellular	0	O
organisms	0	O
having	0	O
a	0	O
structure	0	O
resembling	0	O
Campylobacter	1	O
spp	0	O
.	0	O


Internal	1	O
modes	0	O
of	0	O
a	0	O
soliton	0	O
.	0	O


Thus	0	O
adaptation	0	O
to	0	O
continuous	0	O
mild	0	O
stress	0	O
has	0	O
a	0	O
potent	0	O
antiarrhythmic	0	O
effect	0	O
which	0	O
occurs	0	O
due	0	O
to	0	O
the	0	O
increased	0	O
vagal	0	O
tone	0	O
.	0	O


RESULTS	0	O
:	0	O
Patients	0	O
in	0	O
Group	1	O
A	1	O
had	0	O
a	0	O
higher	0	O
incidence	0	O
of	0	O
posterolateral	0	O
wall	0	O
motion	0	O
abnormalities	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
on	0	O
radionuclide	0	O
ventriculography	0	O
,	0	O
a	0	O
larger	0	O
infarct	0	O
area	0	O
(	0	O
as	0	O
evidenced	0	O
by	0	O
higher	0	O
peak	0	O
creatine	0	B
kinase	0	I
levels	0	O
)	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
02	0	O
)	0	O
and	0	O
a	0	O
lower	0	O
left	0	O
ventricular	0	O
ejection	0	O
fraction	0	O
(	0	O
LVEF	0	O
)	0	O
at	0	O
hospital	0	O
discharge	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
008	0	O
)	0	O
than	0	O
those	0	O
in	0	O
Group	1	O
B	1	O
.	0	O


In	1	O
transient	0	O
assays	0	O
,	0	O
using	0	O
rice	0	O
suspension	0	O
-	0	O
cultured	0	O
cells	0	O
transformed	0	O
by	0	O
particle	0	O
bombardment	0	O
,	0	O
we	0	O
showed	0	O
previously	0	O
that	0	O
Oshox1	0	B
can	0	O
transcriptionally	0	O
repress	0	O
the	0	O
activity	0	O
of	0	O
reporter	0	O
gene	0	O
constructs	0	O
with	0	O
upstream	0	O
HD	1	B
-	0	I
Zip	0	I
binding	0	O
sites	0	O
.	0	O


However	0	O
,	0	O
the	0	O
elderly	0	O
group	0	O
showed	0	O
significantly	0	O
longer	0	O
mean	0	O
residence	0	O
times	0	O
(	0	O
MRTs	0	O
)	0	O
and	0	O
lower	0	O
plasma	0	O
clearance	0	O
of	0	O
lidocaine	0	O
during	0	O
the	0	O
period	0	O
compared	0	O
with	0	O
the	0	O
adult	0	O
group	0	O
(	0	O
P	1	O
<	0	O
.	0	O
05	0	O
).	0	O


We	0	O
have	0	O
measured	0	O
the	0	O
release	0	O
of	0	O
interleukin	0	B
-	0	I
1	0	I
beta	0	I
(	0	O
IL	1	B
-	0	I
1	0	I
)	0	O
and	0	O
tumour	0	B
necrosis	0	I
factor	0	I
-	0	I
alpha	0	I
(	0	O
TNF	1	B
)	0	O
by	0	O
unstimulated	0	O
monocytes	0	O
and	0	O
monocytes	0	O
stimulated	0	O
with	0	O
lipopolysaccharide	0	O
(	0	O
LPS	1	O
)	0	O
isolated	0	O
from	0	O
the	0	O
peripheral	0	O
blood	0	O
of	0	O
two	0	O
patients	0	O
with	0	O
acute	0	O
poststreptococcal	0	O
glomerulonephritis	0	O
(	0	O
AGN	0	O
)	0	O
and	0	O
16	0	O
healthy	0	O
controls	0	O
.	0	O


Hydrophobicity	0	O
analysis	0	O
indicated	0	O
that	0	O
the	0	O
KlaA	0	B
and	0	O
KlaB	0	B
polypeptides	0	I
are	0	O
likely	0	O
to	0	O
be	0	O
soluble	0	O
,	0	O
whereas	0	O
the	0	O
KlaC	0	B
polypeptide	0	I
was	0	O
predicted	0	O
to	0	O
have	0	O
four	0	O
potential	0	O
membrane	0	O
-	0	O
spanning	0	O
domains	0	O
.	0	O


Although	0	O
most	0	O
SFV	0	O
genes	0	O
have	0	O
homologs	0	O
encoded	0	O
by	0	O
other	0	O
Chordopoxvirinae	1	O
,	0	O
the	0	O
SFV	0	O
genome	0	O
lacks	0	O
a	0	O
key	0	O
gene	0	O
required	0	O
for	0	O
the	0	O
production	0	O
of	0	O
extracellular	0	O
enveloped	0	O
virus	0	O
.	0	O


TOR2	0	B
is	0	O
part	0	O
of	0	O
two	0	O
related	0	O
signaling	0	O
pathways	0	O
coordinating	0	O
cell	0	O
growth	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


In	1	O
overdoses	0	O
up	0	O
to	0	O
2	0	O
g	0	O
fluvoxamine	0	O
no	0	O
lasting	0	O
toxic	0	O
effects	0	O
were	0	O
observed	0	O
.	0	O


Double	1	O
-	0	O
staining	0	O
confirmed	0	O
that	0	O
there	0	O
were	0	O
separate	0	O
populations	0	O
of	0	O
CD68	1	B
-	0	O
positive	0	O
macrophages	0	O
and	0	O
XIIIa	0	B
-	0	O
positive	0	O
dendrocytes	0	O
.	0	O


However	0	O
the	0	O
sequence	0	O
surrounding	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
CTCA	0	O
(+	0	O
1	0	O
)	0	O
TTCC	0	O
was	0	O
similar	0	O
to	0	O
the	0	O
consensus	0	O
CTCA	0	O
(+	0	O
1	0	O
)	0	O
NTCT	0	O
(	0	O
N	1	O
is	0	O
any	0	O
nucleoside	0	O
)	0	O
for	0	O
an	0	O
initiator	0	O
element	0	O
found	0	O
in	0	O
terminal	0	B
deoxynucleotidyltransferase	0	I
and	0	O
a	0	O
number	0	O
of	0	O
other	0	O
highly	0	O
regulated	0	O
genes	0	O
.	0	O


A	1	O
five	0	O
-	0	O
phase	0	O
experiment	0	O
was	0	O
designed	0	O
to	0	O
investigate	0	O
(	0	O
a	0	O
)	0	O
whether	0	O
contingent	0	O
music	0	O
-	0	O
listening	0	O
would	0	O
act	0	O
as	0	O
a	0	O
reinforcer	0	O
to	0	O
increase	0	O
arithmetic	0	O
performance	0	O
of	0	O
EMR	1	O
children	0	O
and	0	O
(	0	O
b	0	O
)	0	O
whether	0	O
this	0	O
contingent	0	O
reinforcement	0	O
would	0	O
affect	0	O
preference	0	O
for	0	O
that	0	O
reinforcer	0	O
.	0	O


This	0	O
association	0	O
was	0	O
independently	0	O
significant	0	O
for	0	O
patients	0	O
treated	0	O
primarily	0	O
(	0	O
not	0	O
for	0	O
recurrence	0	O
).	0	O


The	0	O
mobility	0	O
shift	0	O
of	0	O
both	0	O
of	0	O
these	0	O
proteins	0	O
is	0	O
abolished	0	O
by	0	O
treatment	0	O
with	0	O
inhibitors	0	O
of	0	O
PKC	0	B
or	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
/	0	O
extracellular	0	B
signal	0	I
-	0	I
related	0	I
kinase	0	I
kinase	0	I
.	0	O


When	0	O
the	0	O
coronary	0	O
sinus	0	O
pressure	0	O
reached	0	O
15	0	O
torr	0	O
,	0	O
there	0	O
was	0	O
a	0	O
significant	0	O
decrease	0	O
in	0	O
cardiac	0	O
index	0	O
(	0	O
3	0	O
.	0	O
60	0	O
+/-	0	O
0	0	O
.	0	O
5	0	O
to	0	O
2	0	O
.	0	O
70	0	O
+/-	0	O
0	0	O
.	0	O
6	0	O
L	1	O
/	0	O
min	0	O
/	0	O
m2	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
),	0	O
coronary	0	O
blood	0	O
flow	0	O
(	0	O
13	0	O
.	0	O
7	0	O
+/-	0	O
3	0	O
.	0	O
1	0	O
to	0	O
7	0	O
.	0	O
0	0	O
+/-	0	O
2	0	O
.	0	O
1	0	O
ml	0	O
/	0	O
min	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
),	0	O
rate	0	O
of	0	O
rise	0	O
of	0	O
left	0	O
ventricular	0	O
pressure	0	O
(	0	O
1	0	O
,	0	O
567	0	O
+/-	0	O
275	0	O
to	0	O
1	0	O
,	0	O
331	0	O
+/-	0	O
314	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
),	0	O
and	0	O
an	0	O
increase	0	O
in	0	O
coronary	0	O
arteriovenous	0	O
difference	0	O
(	0	O
62	0	O
.	0	O
8	0	O
%	0	O
+/-	0	O
9	0	O
.	0	O
3	0	O
%	0	O
to	0	O
70	0	O
.	0	O
5	0	O
%	0	O
+/-	0	O
5	0	O
.	0	O
4	0	O
%	0	O
saturation	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
03	0	O
).	0	O


Attenuation	1	O
from	0	O
the	0	O
vit	0	B
A2	1	I
consensus	0	O
ERE	0	O
is	0	O
not	0	O
necessarily	0	O
dependent	0	O
on	0	O
DNA	1	O
binding	0	O
as	0	O
the	0	O
TR	1	B
alpha	0	I
DNA	1	O
binding	0	O
mutant	0	O
was	0	O
still	0	O
able	0	O
to	0	O
inhibit	0	O
E	1	O
-	0	O
dependent	0	O
transactivation	0	O
.	0	O


Basal	1	O
plasma	0	O
renin	0	B
activity	0	O
(	0	O
PRA	1	O
)	0	O
was	0	O
slightly	0	O
raised	0	O
prior	0	O
to	0	O
training	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
07	0	O
)	0	O
compared	0	O
to	0	O
the	0	O
controls	0	O
and	0	O
post	0	O
-	0	O
training	0	O
.	0	O


To	1	O
understand	0	O
further	0	O
the	0	O
expression	0	O
and	0	O
regulation	0	O
of	0	O
the	0	O
V1aR	0	B
,	0	O
we	0	O
now	0	O
describe	0	O
the	0	O
genomic	0	O
characteristics	0	O
,	0	O
tissue	0	O
expression	0	O
,	0	O
chromosomal	0	O
localization	0	O
,	0	O
and	0	O
regional	0	O
mapping	0	O
of	0	O
the	0	O
human	0	B
V1aR	0	I
gene	0	I
,	0	O
AVPR1A	0	B
.	0	O


We	0	O
suggest	0	O
that	0	O
the	0	O
ER	1	O
lumenal	0	O
variable	0	O
domain	0	O
of	0	O
gp19K	0	B
has	0	O
a	0	O
specific	0	O
tertiary	0	O
structure	0	O
that	0	O
is	0	O
important	0	O
for	0	O
binding	0	O
to	0	O
the	0	O
polymorphic	0	O
alpha	0	O
1	0	O
and	0	O
alpha	0	O
2	0	O
domains	0	O
of	0	O
class	0	B
I	1	I
heavy	0	I
(	0	I
alpha	0	I
)	0	I
chains	0	I
.	0	O


Mining	1	O
the	0	O
diagnostic	0	O
iron	0	O
ore	0	O
.	0	O


As	1	O
retinoic	0	O
acid	0	O
and	0	O
thyroid	0	O
hormone	0	O
are	0	O
frequently	0	O
involved	0	O
in	0	O
developmental	0	O
regulatory	0	O
processes	0	O
,	0	O
it	0	O
is	0	O
possible	0	O
that	0	O
this	0	O
element	0	O
may	0	O
be	0	O
important	0	O
in	0	O
the	0	O
process	0	O
of	0	O
islet	0	O
cell	0	O
differentiation	0	O
.	0	O


GTPase	1	B
activating	0	O
specificity	0	O
of	0	O
RGS12	0	B
and	0	O
binding	0	O
specificity	0	O
of	0	O
an	0	O
alternatively	0	O
spliced	0	O
PDZ	0	B
(	0	O
PSD	0	B
-	0	I
95	0	I
/	0	O
Dlg	0	B
/	0	O
ZO	0	B
-	0	I
1	0	I
)	0	O
domain	0	O
.	0	O


Histopathologic	0	O
response	0	O
of	0	O
gingival	0	O
tissues	0	O
to	0	O
hemodent	0	O
and	0	O
aluminum	0	O
chloride	0	O
solutions	0	O
as	0	O
tissue	0	O
displacement	0	O
materials	0	O
.	0	O


Dystonic	1	O
movement	0	O
of	0	O
the	0	O
left	0	O
upper	0	O
limb	0	O
in	0	O
a	0	O
case	0	O
of	0	O
the	0	O
right	0	O
pontine	0	O
hemorrhage	0	O


These	0	O
changes	0	O
may	0	O
be	0	O
the	0	O
result	0	O
of	0	O
,	0	O
on	0	O
the	0	O
one	0	O
hand	0	O
,	0	O
an	0	O
increased	0	O
sensitivity	0	O
of	0	O
the	0	O
neuromuscular	0	O
transmission	0	O
and	0	O
/	0	O
or	0	O
decreased	0	O
muscle	0	O
contractility	0	O
and	0	O
,	0	O
on	0	O
the	0	O
other	0	O
hand	0	O
,	0	O
the	0	O
result	0	O
of	0	O
a	0	O
reduced	0	O
plasma	0	O
clearance	0	O
during	0	O
hypothermia	0	O
.	0	O


The	0	O
c	0	B
-	0	I
myc	0	I
gene	0	I
is	0	O
overexpressed	0	O
in	0	O
a	0	O
variety	0	O
of	0	O
tumor	0	O
types	0	O
and	0	O
appears	0	O
to	0	O
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
abnormal	0	O
growth	0	O
of	0	O
a	0	O
number	0	O
of	0	O
cell	0	O
types	0	O
.	0	O


Transcripts	0	O
from	0	O
a	0	O
second	0	O
POU	0	B
-	0	I
domain	0	I
gene	0	I
,	0	O
Oct	1	B
-	0	I
25	0	I
,	0	O
were	0	O
present	0	O
at	0	O
low	0	O
levels	0	O
in	0	O
oocytes	0	O
and	0	O
early	0	O
embryos	0	O
and	0	O
were	0	O
dramatically	0	O
upregulated	0	O
during	0	O
early	0	O
gastrulation	0	O
.	0	O


In	1	O
order	0	O
to	0	O
decipher	0	O
the	0	O
pathway	0	O
that	0	O
leads	0	O
to	0	O
Hox	0	B
gene	0	I
induction	0	O
,	0	O
we	0	O
have	0	O
investigated	0	O
whether	0	O
a	0	O
Hox	0	B
gene	0	I
regulator	0	O
,	0	O
the	0	O
leucine	0	O
zipper	0	O
transcription	0	O
factor	0	O
MafB	0	B
/	0	O
Kr	1	B
,	0	O
is	0	O
itself	0	O
transcriptionally	0	O
regulated	0	O
by	0	O
the	0	O
environmental	0	O
signals	0	O
.	0	O


The	0	O
strategy	0	O
has	0	O
been	0	O
used	0	O
to	0	O
determine	0	O
2	0	O
.	0	O
6	0	O
kilobases	0	O
of	0	O
nucleotide	0	O
sequence	0	O
in	0	O
the	0	O
Saccharomyces	1	B
cerevisiae	0	I
ADE	0	I
1	0	I
locus	0	I
.	0	O


In	1	O
the	0	O
absence	0	O
of	0	O
E1A243	0	B
,	0	O
YY1	0	B
represses	0	O
CRE	0	O
-	0	O
dependent	0	O
transcription	0	O
of	0	O
c	0	B
-	0	I
fos	0	I
by	0	O
physically	0	O
interacting	0	O
with	0	O
ATF	0	B
/	0	O
CREB	0	B
proteins	0	O
bound	0	O
to	0	O
the	0	O
-	0	O
67	0	O
CRE	0	O
.	0	O


The	0	O
catenins	0	B
bind	0	O
to	0	O
APC	1	B
and	0	O
E	1	B
-	0	I
cadherin	0	I
in	0	O
a	0	O
similar	0	O
fashion	0	O
,	0	O
but	0	O
APC	1	B
and	0	O
E	1	B
-	0	I
cadherin	0	I
do	0	O
not	0	O
associate	0	O
with	0	O
each	0	O
other	0	O
either	0	O
in	0	O
the	0	O
presence	0	O
or	0	O
absence	0	O
of	0	O
catenins	0	B
.	0	O


The	0	O
T	1	B
-	0	I
cyt	0	I
promoter	0	I
,	0	O
although	0	O
of	0	O
bacterial	0	O
origin	0	O
is	0	O
active	0	O
in	0	O
planta	0	O
and	0	O
the	0	O
30	0	B
bp	0	I
cyt	0	I
-	0	I
1	0	I
element	0	I
is	0	O
located	0	O
within	0	O
a	0	O
region	0	O
that	0	O
is	0	O
essential	0	O
for	0	O
T	1	B
-	0	I
cyt	0	I
promotor	0	I
activity	0	O
in	0	O
leaf	0	O
,	0	O
stem	0	O
and	0	O
root	0	O
cells	0	O
of	0	O
tobacco	0	O
plants	0	O
.	0	O


Besides	0	O
,	0	O
it	0	O
was	0	O
considered	0	O
that	0	O
the	0	O
NPF	0	O
was	0	O
a	0	O
useful	0	O
tool	0	O
for	0	O
activation	0	O
of	0	O
velopharyngeal	0	O
activity	0	O
by	0	O
way	0	O
of	0	O
visual	0	O
feed	0	O
-	0	O
back	0	O
control	0	O
.	0	O


Adenylosuccinate	1	B
synthetase	0	I
(	0	O
IMP	0	O
:	0	O
L	1	B
-	0	I
aspartate	0	I
ligase	0	I
(	0	O
GDP	1	O
),	0	O
EC	1	B
6	0	I
.	0	I
3	0	I
.	0	I
4	0	I
.	0	I
4	0	I
)	0	O
plays	0	O
an	0	O
important	0	O
role	0	O
in	0	O
purine	0	O
biosynthesis	0	O
catalyzing	0	O
the	0	O
GTP	1	O
-	0	O
dependent	0	O
conversion	0	O
of	0	O
IMP	0	O
to	0	O
AMP	1	O
.	0	O


Bacteriol	0	O
.	0	O


Therefore	0	O
,	0	O
use	0	O
of	0	O
presaturation	0	O
is	0	O
recommended	0	O
for	0	O
myocardial	0	O
motion	0	O
studies	0	O
using	0	O
cine	0	O
PC	1	O
velocity	0	O
data	0	O
.	0	O


This	0	O
phenomenon	0	O
may	0	O
be	0	O
regarded	0	O
as	0	O
a	0	O
variant	0	O
of	0	O
selective	0	O
individual	0	O
cell	0	O
death	0	O
,	0	O
currently	0	O
referred	0	O
to	0	O
as	0	O
apoptosis	0	O
,	0	O
which	0	O
has	0	O
not	0	O
been	0	O
previously	0	O
reported	0	O
in	0	O
a	0	O
case	0	O
of	0	O
embryonal	0	O
rhabdomyosarcoma	0	O
.	0	O


These	0	O
results	0	O
provide	0	O
the	0	O
first	0	O
demonstration	0	O
that	0	O
an	0	O
SR	1	B
protein	0	I
can	0	O
influence	0	O
splicing	0	O
of	0	O
specific	0	O
pre	0	O
-	0	O
mRNAs	0	O
in	0	O
vivo	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
follow	0	O
-	0	O
up	0	O
prospectively	0	O
patients	0	O
with	0	O
arthritis	0	O
after	0	O
infection	0	O
with	0	O
beta	0	O
-	0	O
haemolytic	0	O
streptococci	0	O
of	0	O
Lancefield	0	O
group	0	O
A	1	O
(	0	O
beta	0	O
HSA	1	O
),	0	O
with	0	O
emphasis	0	O
on	0	O
clinical	0	O
characteristics	0	O
and	0	O
serological	0	O
features	0	O
.	0	O


Neural	1	O
-	0	O
specific	0	O
expression	0	O
,	0	O
genomic	0	O
structure	0	O
,	0	O
and	0	O
chromosomal	0	O
localization	0	O
of	0	O
the	0	O
gene	0	O
encoding	0	O
the	0	O
zinc	0	B
-	0	I
finger	0	I
transcription	0	I
factor	0	I
NGFI	0	I
-	0	I
C	1	I
.	0	O


The	0	O
results	0	O
suggest	0	O
followings	0	O
--	0	O
1	0	O
)	0	O
both	0	O
eosinophils	0	O
and	0	O
neutrophils	0	O
participate	0	O
in	0	O
hypersecretion	0	O
of	0	O
type	0	O
Ib	1	O
in	0	O
atopic	0	O
cases	0	O
,	0	O
and	0	O
only	0	O
eosinophils	0	O
in	0	O
non	0	O
-	0	O
atopic	0	O
cases	0	O
.	0	O


Further	0	O
evidence	0	O
for	0	O
a	0	O
clustered	0	O
organization	0	O
of	0	O
FAX	0	B
-	0	O
ZFP	0	B
transcription	0	O
units	0	O
is	0	O
provided	0	O
by	0	O
Southern	0	O
blot	0	O
analysis	0	O
of	0	O
large	0	O
genomic	0	O
restriction	0	O
fragments	0	O
separated	0	O
by	0	O
transverse	0	O
field	0	O
gel	0	O
electrophoresis	0	O
,	0	O
and	0	O
by	0	O
in	0	O
situ	0	O
hybridization	0	O
on	0	O
intact	0	O
chromosomes	0	O
.	0	O


To	1	O
evaluate	0	O
the	0	O
hepatic	0	O
regenerative	0	O
response	0	O
in	0	O
patients	0	O
with	0	O
alcoholic	0	O
liver	0	O
disease	0	O
,	0	O
sera	0	O
from	0	O
263	0	O
patients	0	O
with	0	O
severe	0	O
alcoholic	0	O
hepatitis	0	O
and	0	O
/	0	O
or	0	O
cirrhosis	0	O
were	0	O
analyzed	0	O
for	0	O
hepatocyte	0	B
growth	0	I
factor	0	I
(	0	O
HGF	1	B
)	0	O
and	0	O
alpha	0	B
-	0	I
fetoprotein	0	I
(	0	O
AFP	1	B
).	0	O


Immunohistochemical	0	O
analysis	0	O
of	0	O
several	0	O
rat	0	O
organs	0	O
also	0	O
showed	0	O
staining	0	O
in	0	O
epithelial	0	O
cells	0	O
.	0	O


Interestingly	0	O
,	0	O
we	0	O
find	0	O
that	0	O
the	0	O
interaction	0	O
between	0	O
Tat	1	B
and	0	O
hCycT1	0	B
requires	0	O
zinc	0	O
as	0	O
well	0	O
as	0	O
essential	0	O
cysteine	0	O
residues	0	O
in	0	O
both	0	O
proteins	0	O
.	0	O


The	0	O
sub	0	O
-	0	O
acute	0	O
inhalation	0	O
toxicity	0	O
of	0	O
furfural	0	O
was	0	O
studied	0	O
in	0	O
Syrian	0	O
golden	0	O
hamsters	0	O
.	0	O


In	1	O
the	0	O
absence	0	O
of	0	O
MHC	1	B
class	0	I
II	0	I
,	0	O
purified	0	B
soluble	0	I
D10	0	I
TCR	1	I
bound	0	O
to	0	O
Staphylococcus	1	B
aureus	0	I
enterotoxin	0	I
C2	1	I
with	0	O
an	0	O
association	0	O
rate	0	O
of	0	O
1	0	O
.	0	O
69	0	O
+/-	0	O
0	0	O
.	0	O
12	0	O
x	0	O
10	0	O
(	0	O
4	0	O
)	0	O
M	1	O
(-	0	O
1	0	O
)	0	O
sec	0	O
(-	0	O
1	0	O
)	0	O
and	0	O
a	0	O
dissociation	0	O
rate	0	O
of	0	O
1	0	O
.	0	O
9	0	O
+/-	0	O
0	0	O
.	0	O
47	0	O
x	0	O
10	0	O
(-	0	O
2	0	O
)	0	O
sec	0	O
(-	0	O
1	0	O
),	0	O
giving	0	O
a	0	O
dissociation	0	O
constant	0	O
of	0	O
1	0	O
.	0	O
1	0	O
microM	0	O
.	0	O


Both	0	O
fusion	0	O
proteins	0	O
form	0	O
stable	0	O
specific	0	O
complexes	0	O
with	0	O
a	0	O
short	0	O
DNA	1	O
duplex	0	O
harboring	0	O
the	0	O
CTGT	0	O
(	0	O
at	0	O
)	0	O
4ACAG	0	O
consensus	0	O
sequence	0	O
of	0	O
the	0	O
LexA	0	B
repressor	0	I
.	0	O


Testing	1	O
for	0	O
serum	0	B
IgM	1	I
binding	0	O
to	0	O
GM1	0	O
ganglioside	0	O
in	0	O
clinical	0	O
practice	0	O
.	0	O


Preimmune	0	B
IgG	1	I
,	0	O
anti	0	B
-	0	I
GalT	1	I
Fab	1	I
fragments	0	I
,	0	O
irrelevant	0	O
polymers	0	O
and	0	O
monomeric	0	O
N	1	O
-	0	O
acetylglucosamine	0	O
had	0	O
no	0	O
effect	0	O
.	0	O


A	1	O
comparison	0	O
of	0	O
physical	0	O
and	0	O
cytogenetic	0	O
estimates	0	O
of	0	O
radiation	0	O
dose	0	O
in	0	O
patients	0	O
treated	0	O
with	0	O
iodine	0	O
-	0	O
131	0	O
for	0	O
thyroid	0	O
carcinoma	0	O
.	0	O


The	0	O
osmotic	0	O
diuretic	0	O
mannitol	0	O
was	0	O
administered	0	O
to	0	O
21	0	O
patients	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
use	0	O
of	0	O
zero	0	O
-	0	O
loss	0	O
filtering	0	O
in	0	O
combination	0	O
with	0	O
exit	0	O
wavefront	0	O
reconstruction	0	O
is	0	O
considerably	0	O
more	0	O
effective	0	O
at	0	O
removing	0	O
the	0	O
effects	0	O
of	0	O
multiple	0	O
elastic	0	O
and	0	O
inelastic	0	O
scattering	0	O
and	0	O
microscope	0	O
objective	0	O
lens	0	O
aberrations	0	O
than	0	O
either	0	O
technique	0	O
by	0	O
itself	0	O
.	0	O


In	1	O
the	0	O
SPK	0	O
and	0	O
PTA	1	O
category	0	O
,	0	O
anti	0	O
-	0	O
T	1	O
-	0	O
cell	0	O
therapy	0	O
significantly	0	O
lowered	0	O
the	0	O
risk	0	O
of	0	O
graft	0	O
loss	0	O
.	0	O


Pacing	1	O
the	0	O
Roux	0	O
limb	0	O
abolished	0	O
the	0	O
ectopic	0	O
pacemakers	0	O
,	0	O
restored	0	O
the	0	O
slow	0	O
emptying	0	O
of	0	O
liquids	0	O
to	0	O
the	0	O
more	0	O
rapid	0	O
rate	0	O
found	0	O
in	0	O
the	0	O
Billroth	0	O
dogs	0	O
(	0	O
t1	0	O
/	0	O
2	0	O
:	0	O
paced	0	O
Roux	0	O
,	0	O
72	0	O
+/-	0	O
15	0	O
minutes	0	O
;	0	O
Billroth	0	O
,	0	O
43	0	O
+/-	0	O
9	0	O
minutes	0	O
;	0	O
p	0	O
greater	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
and	0	O
did	0	O
not	0	O
change	0	O
emptying	0	O
of	0	O
solids	0	O
.	0	O


And	0	O
the	0	O
natural	0	O
barriers	0	O
?	0	O


Renal	1	O
cell	0	O
carcinoma	0	O
in	0	O
children	0	O
:	0	O
a	0	O
single	0	O
institution	0	O
'	0	O
s	0	O
experience	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
prediction	0	O
,	0	O
transfections	0	O
into	0	O
the	0	O
hematopoietic	0	O
cell	0	O
line	0	O
Jurkat	0	O
showed	0	O
a	0	O
9	0	O
.	0	O
0	0	O
-	0	O
and	0	O
2	0	O
.	0	O
5	0	O
-	0	O
fold	0	O
activation	0	O
of	0	O
the	0	O
mim	0	B
-	0	I
1	0	I
promoter	0	I
by	0	O
the	0	O
p32	0	B
and	0	O
p30	0	B
isoforms	0	I
,	0	O
respectively	0	O
.	0	O


Mutations	0	O
within	0	O
conserved	0	O
region	0	O
2	0	O
(	0	O
CR2	1	O
)	0	O
of	0	O
E1A	0	B
that	0	O
inhibit	0	O
the	0	O
binding	0	O
of	0	O
E1A	0	B
to	0	O
the	0	O
retinoblastoma	0	B
gene	0	I
product	0	I
(	0	O
pRb	0	B
)	0	O
further	0	O
enhanced	0	O
the	0	O
stimulation	0	O
of	0	O
transcription	0	O
from	0	O
the	0	O
PEPCK	0	B
promoter	0	I
by	0	O
2	0	O
3	0	O
-	0	O
fold	0	O
compared	0	O
with	0	O
wild	0	B
type	0	I
E1A	0	I
.	0	O


The	0	O
ORF	1	O
was	0	O
analyzed	0	O
for	0	O
secondary	0	O
structural	0	O
features	0	O
,	0	O
and	0	O
the	0	O
sequence	0	O
data	0	O
bases	0	O
were	0	O
searched	0	O
for	0	O
homologies	0	O
.	0	O


Our	0	O
evidence	0	O
derives	0	O
from	0	O
three	0	O
principal	0	O
observations	0	O
:	0	O
1	0	O
)	0	O
a	0	O
transfection	0	O
construct	0	O
containing	0	O
only	0	O
122	0	O
nucleotides	0	O
(	0	O
nt	0	O
)	0	O
of	0	O
promoter	0	O
1	0	O
and	0	O
328	0	O
nt	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
UTR	0	O
retained	0	O
full	0	O
PGE2	0	O
-	0	O
stimulated	0	O
reporter	0	O
expression	0	O
;	0	O
2	0	O
)	0	O
maximal	0	O
PGE2	0	O
-	0	O
driven	0	O
reporter	0	O
expression	0	O
required	0	O
the	0	O
presence	0	O
of	0	O
nt	0	O
196	0	O
to	0	O
328	0	O
of	0	O
exon	0	O
1	0	O
when	0	O
tested	0	O
within	0	O
the	0	O
context	0	O
of	0	O
IGF	1	B
-	0	I
I	1	I
promoter	0	I
1	0	I
;	0	O
3	0	O
)	0	O
cotransfection	0	O
of	0	O
IGF	1	B
-	0	I
I	1	I
promoter	0	I
-	0	O
luciferase	0	B
-	0	O
reporter	0	O
constructs	0	O
with	0	O
a	0	O
plasmid	0	O
encoding	0	O
the	0	O
alpha	0	O
-	0	O
isoform	0	O
of	0	O
the	0	O
catalytic	0	O
subunit	0	O
of	0	O
murine	0	B
cAMP	1	I
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	O
PKA	1	B
)	0	O
produced	0	O
results	0	O
comparable	0	O
to	0	O
those	0	O
seen	0	O
with	0	O
PGE2	0	O
treatment	0	O
,	0	O
whereas	0	O
cotransfection	0	O
with	0	O
a	0	O
plasmid	0	O
encoding	0	O
a	0	O
mutant	0	O
regulatory	0	O
subunit	0	O
of	0	O
PKA	1	B
that	0	O
cannot	0	O
bind	0	O
cAMP	1	O
blocked	0	O
PGE2	0	O
-	0	O
induced	0	O
reporter	0	O
expression	0	O
.	0	O


The	0	O
slower	0	O
-	0	O
electrophoretic	0	O
-	0	O
mobility	0	O
form	0	O
of	0	O
p68	0	B
was	0	O
absent	0	O
in	0	O
human	0	O
cells	0	O
in	0	O
G1	0	O
/	0	O
S	1	O
and	0	O
appeared	0	O
as	0	O
the	0	O
cells	0	O
entered	0	O
G2	0	O
/	0	O
M	1	O
.	0	O


Sibling	1	O
aggregation	0	O
of	0	O
low	0	B
-	0	I
and	0	I
high	0	I
-	0	I
density	0	I
lipoprotein	0	I
cholesterol	0	I
and	0	O
apolipoproteins	0	B
B	1	I
and	0	I
A	1	I
-	0	I
I	1	I
levels	0	O
in	0	O
black	0	O
and	0	O
white	0	O
children	0	O
:	0	O
the	0	O
Bogalusa	0	O
Heart	1	O
Study	1	O
.	0	O


Finally	0	O
,	0	O
in	0	O
situ	0	O
RNA	1	O
hybridization	0	O
studies	0	O
revealed	0	O
a	0	O
very	0	O
specific	0	O
pattern	0	O
of	0	O
EphA8	0	B
gene	0	I
expression	0	O
restricted	0	O
to	0	O
the	0	O
rostral	0	O
region	0	O
of	0	O
midbrain	0	O
tectum	0	O
during	0	O
embryonic	0	O
development	0	O
.	0	O


Induction	1	O
of	0	O
proto	0	B
-	0	I
oncogene	0	I
fos	0	I
transcription	0	O
through	0	O
the	0	O
adenylate	0	B
cyclase	0	I
pathway	0	O
:	0	O
characterization	0	O
of	0	O
a	0	O
cAMP	1	O
-	0	O
responsive	0	O
element	0	O
.	0	O


Multiple	1	O
chemical	0	O
sensitivity	0	O
(	0	O
MCS	1	O
)	0	O
is	0	O
a	0	O
syndrome	0	O
in	0	O
which	0	O
multiple	0	O
symptoms	0	O
reportedly	0	O
occur	0	O
with	0	O
low	0	O
-	0	O
level	0	O
chemical	0	O
exposure	0	O
.	0	O


J	1	O
.	0	O


EEA1	0	B
is	0	O
a	0	O
conserved	0	O
alpha	0	O
-	0	O
helical	0	O
peripheral	0	O
membrane	0	O
protein	0	O
flanked	0	O
by	0	O
cysteine	0	O
"	0	O
fingers	0	O
"	0	O
and	0	O
contains	0	O
a	0	O
calmodulin	0	B
-	0	I
binding	0	I
IQ	1	I
motif	0	I
.	0	O


There	0	O
was	0	O
a	0	O
trend	0	O
in	0	O
all	0	O
studies	0	O
favouring	0	O
PVI	0	O
.	0	O


Transient	1	O
transfection	0	O
experiments	0	O
revealed	0	O
that	0	O
Pax	0	B
-	0	I
8	0	I
isoforms	0	I
a	0	I
and	0	I
b	0	I
,	0	O
but	0	O
not	0	O
c	0	O
and	0	O
d	0	O
,	0	O
strongly	0	O
stimulate	0	O
transcription	0	O
from	0	O
a	0	O
promoter	0	O
containing	0	O
six	0	O
copies	0	O
of	0	O
a	0	O
paired	0	B
-	0	I
domain	0	I
recognition	0	I
sequence	0	I
.	0	O


A	1	O
total	0	O
of	0	O
90	0	O
patients	0	O
were	0	O
randomly	0	O
allocated	0	O
either	0	O
to	0	O
an	0	O
MY	1	O
-	0	O
1	0	O
treated	0	O
or	0	O
an	0	O
untreated	0	O
group	0	O
.	0	O


Changes	0	O
following	0	O
periodontal	0	O
surgery	0	O
.	0	O


These	0	O
studies	0	O
indicate	0	O
that	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
electrical	0	O
stimulation	0	O
generate	0	O
reactive	0	O
oxygen	0	O
species	0	O
and	0	O
affect	0	O
SOD	0	B
activity	0	O
,	0	O
which	0	O
in	0	O
part	0	O
are	0	O
responsible	0	O
for	0	O
decreased	0	O
sperm	0	O
motion	0	O
and	0	O
viability	0	O
.	0	O


This	0	O
protein	0	O
encoded	0	O
by	0	O
this	0	O
cDNA	1	O
,	0	O
which	0	O
we	0	O
have	0	O
termed	0	O
p150TSP	0	B
(	0	O
for	0	O
TPR	1	O
-	0	O
containing	0	O
,	0	O
SH2	0	B
-	0	I
binding	0	I
phosphoprotein	0	I
),	0	O
is	0	O
located	0	O
predominantly	0	O
in	0	O
the	0	O
nucleus	0	O
and	0	O
is	0	O
highly	0	O
conserved	0	O
in	0	O
evolution	0	O
.	0	O


A	1	O
mutation	0	O
in	0	O
the	0	O
5	0	O
'	0	O
C2U4	0	O
repeat	0	O
causes	0	O
underaccumulation	0	O
of	0	O
snR13F	0	B
,	0	O
whereas	0	O
mutations	0	O
in	0	O
the	0	O
3	0	O
'	0	O
C2U4	0	O
repeat	0	O
cause	0	O
the	0	O
accumulation	0	O
of	0	O
two	0	O
novel	0	O
RNAs	0	O
that	0	O
migrate	0	O
in	0	O
the	0	O
500	0	O
-	0	O
nt	0	O
range	0	O
.	0	O


In	1	O
the	0	O
formalin	0	O
test	0	O
,	0	O
however	0	O
,	0	O
naloxone	0	O
attenuated	0	O
morphine	0	O
analgesia	0	O
at	0	O
the	0	O
lower	0	O
doses	0	O
(	0	O
0	0	O
.	0	O
1	0	O
and	0	O
0	0	O
.	0	O
3	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
and	0	O
potentiated	0	O
morphine	0	O
analgesia	0	O
at	0	O
the	0	O
highest	0	O
dose	0	O
(	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
).	0	O


All	1	O
of	0	O
the	0	O
indigo	0	O
-	0	O
producing	0	O
bacteria	0	O
had	0	O
an	0	O
indoxyl	0	B
phosphatase	0	I
with	0	O
a	0	O
pI	1	O
of	0	O
6	0	O
.	0	O
4	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
present	0	O
genetic	0	O
evidence	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
for	0	O
a	0	O
functional	0	O
interaction	0	O
between	0	O
the	0	O
DEAH	0	B
protein	0	I
Prp16	0	I
,	0	O
and	0	O
the	0	O
U6	0	B
and	0	O
U2	0	B
spliceosomal	0	I
snRNAs	0	I
.	0	O


Functional	1	O
magnetic	0	O
resonance	0	O
imaging	0	O
(	0	O
fMRI	1	O
)	0	O
has	0	O
been	0	O
increasingly	0	O
used	0	O
in	0	O
studying	0	O
human	0	O
brain	0	O
function	0	O
given	0	O
its	0	O
non	0	O
-	0	O
invasive	0	O
feature	0	O
and	0	O
good	0	O
spatial	0	O
resolution	0	O
.	0	O


According	0	O
to	0	O
the	0	O
changes	0	O
of	0	O
perfusion	0	O
defects	0	O
between	0	O
Ex	0	O
,	0	O
RD	1	O
and	0	O
ReI	0	O
images	0	O
,	0	O
they	0	O
were	0	O
classified	0	O
into	0	O
3	0	O
types	0	O
:	0	O
Type	1	O
I	1	O
;	0	O
perfusion	0	O
defect	0	O
on	0	O
the	0	O
RD	1	O
image	0	O
was	0	O
identical	0	O
to	0	O
ReI	0	O
image	0	O
(	0	O
75	0	O
%)	0	O
Type	1	O
I	1	O
was	0	O
divided	0	O
into	0	O
2	0	O
subgroups	0	O
whether	0	O
perfusion	0	O
defect	0	O
at	0	O
Ex	0	O
was	0	O
unchanged	0	O
(	0	O
Ia	1	O
,	0	O
42	0	O
%)	0	O
or	0	O
improved	0	O
(	0	O
Ib	1	O
,	0	O
33	0	O
%)	0	O
on	0	O
the	0	O
RD	1	O
image	0	O
.	0	O


(	0	O
GUT	1	O
)	0	O
Sera	1	O
of	0	O
30	0	O
montoux	0	O
negative	0	O
healthy	0	O
adults	0	O
(	0	O
age	0	O
/	0	O
sex	0	O
matched	0	O
)	0	O
were	0	O
taken	0	O
as	0	O
control	0	O
by	0	O
detecting	0	O
IgG	1	B
anti	0	I
bodies	0	I
to	0	O
A60	0	B
antigen	0	I
.	0	O


The	0	O
GTPase	1	B
activity	0	O
of	0	O
CDC42Ce	0	B
is	0	O
moderately	0	O
stimulated	0	O
by	0	O
human	0	B
n	0	I
-	0	I
chimaerin	0	I
,	0	O
a	0	O
GTPase	1	B
-	0	I
activating	0	I
protein	0	I
for	0	O
the	0	O
related	0	O
p21	0	B
rac1	0	I
.	0	O


Biol	0	O
.	0	O


Ischemic	1	O
heart	0	O
disease	0	O
evaluated	0	O
by	0	O
exercise	0	O
stress	0	O
thallium	0	O
-	0	O
201	0	O
myocardial	0	O
scintigraphy	0	O
:	0	O
a	0	O
comparison	0	O
of	0	O
SPECT	1	O
and	0	O
bull	0	O
'	0	O
s	0	O
eye	0	O
display	0	O


Higher	0	O
CYP3A23	0	B
basal	0	O
activity	0	O
appears	0	O
to	0	O
be	0	O
due	0	O
to	0	O
an	0	O
E	1	O
-	0	O
box	0	O
in	0	O
3A23SiteA	0	B
that	0	O
interacts	0	O
with	0	O
USF1	0	B
,	0	O
a	0	O
ubiquitous	0	O
bHLH	0	B
/	0	I
leucine	0	I
zipper	0	I
transcription	0	I
factor	0	I
.	0	O


The	0	O
lines	0	O
also	0	O
differed	0	O
in	0	O
postsynaptic	0	O
,	0	O
but	0	O
not	0	O
presynaptic	0	O
,	0	O
5	0	B
-	0	I
HT1A	0	I
receptors	0	I
.	0	O


The	0	O
nucleosomal	0	O
response	0	O
associated	0	O
with	0	O
immediate	0	B
-	0	I
early	0	I
gene	0	I
induction	0	O
is	0	O
mediated	0	O
via	0	O
alternative	0	O
MAP	1	B
kinase	0	I
cascades	0	I
:	0	O
MSK1	0	B
as	0	O
a	0	O
potential	0	O
histone	0	B
H3	0	I
/	0	O
HMG	1	B
-	0	I
14	0	I
kinase	0	O
.	0	O


Although	0	O
it	0	O
is	0	O
well	0	O
known	0	O
that	0	O
calcium	0	O
channel	0	O
blockers	0	O
can	0	O
influence	0	O
contraction	0	O
of	0	O
vascular	0	O
smooth	0	O
muscle	0	O
,	0	O
there	0	O
is	0	O
less	0	O
knowledge	0	O
on	0	O
its	0	O
effect	0	O
on	0	O
excitation	0	O
contraction	0	O
coupling	0	O
in	0	O
the	0	O
endocrine	0	O
glands	0	O
and	0	O
more	0	O
specifically	0	O
on	0	O
insulin	0	B
and	0	O
glucagon	0	B
release	0	O
.	0	O


Follow	0	O
-	0	O
up	0	O
study	0	O
showed	0	O
85	0	O
%	0	O
of	0	O
these	0	O
patients	0	O
with	0	O
effectiveness	0	O
.	0	O


Identification	1	O
of	0	O
an	0	O
AfsA	0	B
homologue	0	I
(	0	O
BarX	0	B
)	0	O
from	0	O
Streptomyces	1	O
virginiae	0	O
as	0	O
a	0	O
pleiotropic	0	O
regulator	0	O
controlling	0	O
autoregulator	0	O
biosynthesis	0	O
,	0	O
virginiamycin	0	O
biosynthesis	0	O
and	0	O
virginiamycin	0	O
M1	1	O
resistance	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
a	0	O
novel	0	O
human	0	B
cyclin	0	I
,	0	O
cyclin	0	B
E2	1	I
,	0	O
that	0	O
contains	0	O
significant	0	O
homology	0	O
to	0	O
cyclin	0	B
E	1	I
.	0	O


Subhuman	0	O
primates	0	O
appear	0	O
to	0	O
be	0	O
more	0	O
sensitive	0	O
to	0	O
reproductive	0	O
and	0	O
other	0	O
adverse	0	O
effects	0	O
of	0	O
PCBs	0	O
than	0	O
humans	0	O
.	0	O


Those	0	O
radiological	0	O
aspects	0	O
were	0	O
distributed	0	O
in	0	O
two	0	O
categories	0	O
:	0	O
1	0	O
)	0	O
type	0	O
I	1	O
-	0	O
presenting	0	O
variable	0	O
sinusoidal	0	O
filling	0	O
.	0	O


4	0	O
.	0	O
26	0	O
+/-	0	O
1	0	O
.	0	O
54	0	O
mmol	0	O
/	0	O
l	0	O
,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
),	0	O
and	0	O
systolic	0	O
BP	1	O
responses	0	O
to	0	O
intravenous	0	O
norepinephrine	0	O
and	0	O
angiotensin	0	B
II	0	I
were	0	O
significantly	0	O
higher	0	O
on	0	O
glibenclamide	0	O
than	0	O
on	0	O
metformin	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
02	0	O
and	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
,	0	O
respectively	0	O
).	0	O


Nucleotide	1	O
sequence	0	O
analysis	0	O
of	0	O
the	0	O
HA	1	B
gene	0	I
in	0	O
these	0	O
two	0	O
mutants	0	O
confirmed	0	O
the	0	O
HA	1	B
-	0	I
phenotype	0	O
.	0	O


The	0	O
immune	0	O
response	0	O
of	0	O
past	0	O
-	0	O
infection	0	O
of	0	O
cytomegalovirus	0	O
in	0	O
the	0	O
patients	0	O
of	0	O
RTID	0	O
is	0	O
rather	0	O
remarkable	0	O
.	0	O


The	0	O
gene	0	O
is	0	O
separated	0	O
into	0	O
four	0	O
exons	0	O
by	0	O
three	0	O
short	0	O
introns	0	O
,	0	O
and	0	O
the	0	O
open	0	O
reading	0	O
frame	0	O
consists	0	O
of	0	O
6660	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
)	0	O
capable	0	O
of	0	O
encoding	0	O
a	0	O
polypeptide	0	O
of	0	O
2220	0	O
amino	0	O
acid	0	O
residues	0	O
.	0	O


The	0	O
domains	0	O
involved	0	O
in	0	O
superactivation	0	O
appear	0	O
to	0	O
be	0	O
a	0	O
subset	0	O
of	0	O
those	0	O
necessary	0	O
to	0	O
achieve	0	O
synergistic	0	O
activation	0	O
.	0	O


The	0	O
consensus	0	O
highlights	0	O
the	0	O
importance	0	O
of	0	O
residues	0	O
other	0	O
than	0	O
the	0	O
eight	0	O
motifs	0	O
that	0	O
are	0	O
often	0	O
associated	0	O
with	0	O
DEAD	1	B
-	0	I
box	0	I
RNA	1	I
helicases	0	I
,	0	O
as	0	O
well	0	O
as	0	O
de	0	O
-	0	O
emphasising	0	O
the	0	O
importance	0	O
of	0	O
the	0	O
"	0	O
A	1	O
"	0	O
residue	0	O
within	0	O
the	0	O
"	0	O
DEAD	1	O
"	0	O
motif	0	O
.	0	O


Organisms	0	O
were	0	O
not	0	O
observed	0	O
in	0	O
the	0	O
5	0	O
bobcats	0	O
trapped	0	O
in	0	O
2	0	O
other	0	O
counties	0	O
.	0	O


METHODS	0	O
:	0	O
We	0	O
determined	0	O
an	0	O
odds	0	O
ratio	0	O
(	0	O
OR	1	O
),	0	O
as	0	O
a	0	O
measure	0	O
of	0	O
the	0	O
relative	0	O
risk	0	O
of	0	O
being	0	O
exposed	0	O
to	0	O
a	0	O
potential	0	O
interaction	0	O
,	0	O
comparing	0	O
the	0	O
use	0	O
of	0	O
the	0	O
H2	0	B
-	0	I
receptor	0	I
antagonist	0	O
,	0	O
cimetidine	0	O
,	0	O
with	0	O
that	0	O
of	0	O
the	0	O
noninteracting	0	O
agents	0	O
ranitidine	0	O
,	0	O
famotidine	0	O
and	0	O
nizatidine	0	O
in	0	O
users	0	O
and	0	O
nonusers	0	O
of	0	O
warfarin	0	O
,	0	O
phenytoin	0	O
and	0	O
theophylline	0	O
.	0	O


Expression	1	O
is	0	O
exclusively	0	O
limited	0	O
to	0	O
the	0	O
CNS	1	O
at	0	O
this	0	O
and	0	O
later	0	O
stages	0	O
.	0	O


When	0	O
the	0	O
entire	0	O
diet	0	O
consisted	0	O
of	0	O
SBF	0	O
,	0	O
voluntary	0	O
feed	0	O
intake	0	O
was	0	O
reduced	0	O
,	0	O
indicating	0	O
that	0	O
SBF	0	O
should	0	O
not	0	O
be	0	O
fed	0	O
to	0	O
ponies	0	O
as	0	O
the	0	O
sole	0	O
dietary	0	O
ingredient	0	O
.	0	O


OKT3	1	B
prophylaxis	0	O
improves	0	O
long	0	O
-	0	O
term	0	O
renal	0	O
graft	0	O
survival	0	O
in	0	O
high	0	O
-	0	O
risk	0	O
patients	0	O
as	0	O
compared	0	O
to	0	O
cyclosporine	0	O
:	0	O
combined	0	O
results	0	O
from	0	O
the	0	O
prospective	0	O
,	0	O
randomized	0	O
Belgian	0	O
and	0	O
US	1	O
studies	0	O
.	0	O


This	0	O
paper	0	O
describes	0	O
the	0	O
advantages	0	O
and	0	O
limitations	0	O
of	0	O
the	0	O
main	0	O
study	0	O
approaches	0	O
used	0	O
.	0	O


These	0	O
results	0	O
demonstrate	0	O
that	0	O
EKLF	0	B
provides	0	O
a	0	O
crucial	0	O
transactivation	0	O
function	0	O
for	0	O
globin	0	B
expression	0	O
and	0	O
further	0	O
reinforce	0	O
the	0	O
idea	0	O
that	0	O
EKLF	0	B
is	0	O
an	0	O
important	0	O
regulator	0	O
of	0	O
CACCC	0	O
element	0	O
-	0	O
directed	0	O
transcription	0	O
in	0	O
erythroid	0	O
cells	0	O
.	0	O


Cloning	1	O
and	0	O
sequencing	0	O
revealed	0	O
that	0	O
dMax	0	B
contains	0	O
a	0	O
deletion	0	O
spanning	0	O
the	0	O
basic	0	O
region	0	O
and	0	O
helix	0	O
1	0	O
and	0	O
the	0	O
loop	0	O
of	0	O
the	0	O
helix	0	O
-	0	O
loop	0	O
-	0	O
helix	0	O
region	0	O
,	0	O
presumably	0	O
as	0	O
a	0	O
result	0	O
of	0	O
alternative	0	O
splicing	0	O
of	0	O
max	0	B
RNA	1	I
.	0	O


Patients	0	O
had	0	O
to	0	O
have	0	O
adequate	0	O
liver	0	O
,	0	O
renal	0	O
,	0	O
and	0	O
marrow	0	O
functions	0	O
.	0	O


Stimulation	1	O
with	0	O
MCh	1	O
produced	0	O
a	0	O
Ca	1	O
-	0	O
dependent	0	O
transient	0	O
elevation	0	O
of	0	O
cGMP	1	O
level	0	O
from	0	O
10	0	O
to	0	O
80	0	O
fmol	0	O
/	0	O
gland	0	O
,	0	O
peaking	0	O
at	0	O
1	0	O
-	0	O
2	0	O
min	0	O
but	0	O
returning	0	O
to	0	O
the	0	O
basal	0	O
level	0	O
by	0	O
5	0	O
min	0	O
.	0	O


The	0	O
repression	0	O
domain	0	O
,	0	O
and	0	O
indeed	0	O
the	0	O
entire	0	O
Cdc68	0	B
protein	0	I
,	0	O
is	0	O
highly	0	O
conserved	0	O
,	0	O
as	0	O
shown	0	O
by	0	O
the	0	O
sequence	0	O
of	0	O
the	0	O
Cdc68	0	B
functional	0	I
homolog	0	I
from	0	O
the	0	O
yeast	0	O
Kluyveromyces	0	O
lactis	0	O
and	0	O
by	0	O
database	0	O
searches	0	O
.	0	O


These	0	O
data	0	O
support	0	O
a	0	O
possible	0	O
biological	0	O
significance	0	O
of	0	O
the	0	O
frameshift	0	O
to	0	O
occur	0	O
at	0	O
this	0	O
position	0	O
of	0	O
the	0	O
large	0	O
overlap	0	O
by	0	O
including	0	O
the	0	O
putative	0	O
RNA	1	O
template	0	O
-	0	O
binding	0	O
site	0	O
of	0	O
the	0	O
PLRV	0	B
replicase	0	I
in	0	O
the	0	O
ORF2a	0	B
/	0	I
ORF2b	0	I
transframe	0	I
protein	0	I
.	0	O


Tryptic	1	O
cleavage	0	O
and	0	O
peptide	0	O
sequence	0	O
analysis	0	O
demonstrated	0	O
that	0	O
the	0	O
98	0	O
-	0	O
kD	1	O
protein	0	O
is	0	O
identical	0	O
to	0	O
a	0	O
recently	0	O
cloned	0	O
protein	0	O
,	0	O
special	0	B
A	1	I
-	0	I
T	1	I
-	0	I
rich	0	I
binding	0	I
protein	0	I
1	0	I
(	0	O
SATB1	0	B
),	0	O
that	0	O
binds	0	O
selectively	0	O
to	0	O
nuclear	0	O
matrix	0	O
/	0	O
scaffold	0	O
-	0	O
associated	0	O
regions	0	O
of	0	O
DNA	1	O
(	0	O
MARs	1	O
/	0	O
SARs	1	O
).	0	O


Both	0	O
antidepressants	0	O
elevated	0	O
the	0	O
pain	0	O
threshold	0	O
acutely	0	O
,	0	O
while	0	O
pretreatment	0	O
with	0	O
pCPA	0	O
largely	0	O
blocked	0	O
the	0	O
analgesia	0	O
.	0	O


The	0	O
B	1	O
-	0	O
oligomer	0	O
of	0	O
pertussis	0	B
toxin	0	I
deactivates	0	O
CC	1	B
chemokine	0	I
receptor	0	I
5	0	I
and	0	O
blocks	0	O
entry	0	O
of	0	O
M	1	O
-	0	O
tropic	0	O
HIV	1	O
-	0	O
1	0	O
strains	0	O
.	0	O


Interestingly	0	O
,	0	O
however	0	O
,	0	O
it	0	O
is	0	O
homologous	0	O
to	0	O
several	0	O
expressed	0	O
sequence	0	O
tags	0	O
(	0	O
EST	1	O
)	0	O
of	0	O
unknown	0	O
function	0	O
from	0	O
Caenorhabditis	0	O
elegans	0	O
,	0	O
Oryza	1	O
sativa	0	O
and	0	O
Homo	1	O
sapiens	0	O
.	0	O


Estrogen	1	O
replacement	0	O
,	0	O
either	0	O
as	0	O
17	0	O
beta	0	O
-	0	O
estradiol	0	O
or	0	O
beta	0	O
-	0	O
estradiol	0	O
-	0	O
3	0	O
-	0	O
benzoate	0	O
via	0	O
subcutaneous	0	O
Silastic	1	O
capsules	0	O
,	0	O
was	0	O
associated	0	O
with	0	O
elevated	0	O
rates	0	O
of	0	O
heat	0	O
production	0	O
and	0	O
dry	0	O
heat	0	O
loss	0	O
relative	0	O
to	0	O
untreated	0	O
ovariectomized	0	O
controls	0	O
.	0	O


Comparison	0	O
with	0	O
the	0	O
crystal	0	O
structure	0	O
of	0	O
Desulfovibrio	1	O
gigas	0	O
,	0	O
Dg	1	O
,	0	O
Fd	1	B
(	0	O
Kissinger	0	O
et	0	O
al	0	O
.,	0	O
1991	0	O
)	0	O
reveals	0	O
a	0	O
very	0	O
similar	0	O
folding	0	O
topology	0	O
,	0	O
although	0	O
several	0	O
secondary	0	O
structural	0	O
elements	0	O
are	0	O
extended	0	O
in	0	O
Pf	1	O
relative	0	O
to	0	O
Dg	1	O
Fd	1	B
.	0	O


Tele	0	O
-	0	O
Talk	0	O
has	0	O
the	0	O
extra	0	O
capability	0	O
of	0	O
operating	0	O
in	0	O
live	0	O
conference	0	O
situations	0	O
using	0	O
microphone	0	O
input	0	O
.	0	O


The	0	O
transport	0	O
of	0	O
a	0	O
genetically	0	O
engineered	0	O
chimeric	0	O
transmembrane	0	O
protein	0	O
connected	0	O
to	0	O
this	0	O
ER	1	O
leader	0	O
sequence	0	O
was	0	O
as	0	O
efficient	0	O
as	0	O
that	0	O
of	0	O
the	0	O
original	0	O
protein	0	O
from	0	O
which	0	O
the	0	O
ER	1	O
sequence	0	O
has	0	O
been	0	O
derived	0	O
.	0	O


By	0	O
comparing	0	O
the	0	O
abundances	0	O
of	0	O
many	0	O
yeast	0	O
transcripts	0	O
in	0	O
isogenic	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
paf1	0	B
mutant	0	I
strains	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
genes	0	O
whose	0	O
expression	0	O
is	0	O
affected	0	O
by	0	O
PAF1	0	B
.	0	O


Optical	1	O
-	0	O
absorption	0	O
spectra	0	O
,	0	O
crystal	0	O
-	0	O
field	0	O
energy	0	O
levels	0	O
,	0	O
and	0	O
transition	0	O
line	0	O
strengths	0	O
of	0	O
holmium	0	O
in	0	O
trigonal	0	O
Na3	0	O


Most	0	O
apneic	0	O
events	0	O
occurred	0	O
during	0	O
Stages	0	O
I	1	O
and	0	O
II	0	O
,	0	O
and	0	O
REM	1	O
,	0	O
but	0	O
this	0	O
proportion	0	O
was	0	O
less	0	O
during	0	O
the	0	O
gamma	0	O
OH	0	O
study	0	O
(	0	O
77	0	O
.	0	O
9	0	O
+/-	0	O
8	0	O
.	0	O
9	0	O
%)	0	O
than	0	O
during	0	O
the	0	O
control	0	O
studies	0	O
(	0	O
92	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
9	0	O
and	0	O
95	0	O
.	0	O
9	0	O
+/-	0	O
2	0	O
.	0	O
2	0	O
%),	0	O
apneas	0	O
occurring	0	O
even	0	O
during	0	O
SWS	0	O
with	0	O
gamma	0	O
OH	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Blood	1	O
pressure	0	O
also	0	O
was	0	O
increased	0	O
by	0	O
lidocaine	0	O
(	0	O
6	0	O
mg	0	O
kg	0	O
-	0	O
1	0	O
).	0	O


A	1	O
study	0	O
in	0	O
vivo	0	O
of	0	O
adrenergic	0	B
receptors	0	I
in	0	O
the	0	O
rectum	0	O
and	0	O
in	0	O
the	0	O
internal	0	O
and	0	O
sphincter	0	O
of	0	O
the	0	O
cat	0	O
.	0	O


Fas	1	B
-	0	O
resistant	0	O
DT	1	O
-	0	O
40	0	O
lymphoma	0	O
B	1	O
-	0	O
cells	0	O
rendered	0	O
BTK	1	B
-	0	O
deficient	0	O
through	0	O
targeted	0	O
disruption	0	O
of	0	O
the	0	O
btk	0	B
gene	0	I
by	0	O
homologous	0	O
recombination	0	O
knockout	0	O
underwent	0	O
apoptosis	0	O
after	0	O
Fas	1	B
ligation	0	O
,	0	O
but	0	O
wild	0	O
-	0	O
type	0	O
DT	1	O
-	0	O
40	0	O
cells	0	O
or	0	O
BTK	1	B
-	0	O
deficient	0	O
DT	1	O
-	0	O
40	0	O
cells	0	O
reconstituted	0	O
with	0	O
wild	0	B
-	0	I
type	0	I
human	0	I
btk	0	I
gene	0	I
did	0	O
not	0	O
.	0	O


HPLC	1	O
phosphopeptide	0	O
mapping	0	O
,	0	O
amino	0	O
acid	0	O
sequencing	0	O
,	0	O
and	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
determined	0	O
that	0	O
NCLK	0	B
phosphorylates	0	O
Ser	1	O
(	0	O
67	0	O
)	0	O
of	0	O
I	1	B
-	0	I
1	0	I
.	0	O


Sestamibi	1	O
scintigraphy	0	O
,	0	O
performed	0	O
in	0	O
70	0	O
patients	0	O
,	0	O
was	0	O
less	0	O
sensitive	0	O
than	0	O
ultrasonography	0	O
(	0	O
80	0	O
%).	0	O


Appropriate	1	O
restriction	0	O
sites	0	O
allow	0	O
one	0	O
to	0	O
insert	0	O
virtually	0	O
any	0	O
desired	0	O
cDNA	1	O
fragment	0	O
directly	0	O
behind	0	O
the	0	O
epitope	0	O
-	0	O
specific	0	O
sequence	0	O
and	0	O
before	0	O
a	0	O
long	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
tail	0	O
.	0	O


Similarly	0	O
,	0	O
overexpression	0	O
of	0	O
increasing	0	O
concentration	0	O
of	0	O
COUP	1	B
-	0	I
TFI	0	I
,	0	O
but	0	O
not	0	O
COUP	1	B
-	0	I
TFI	0	I
delta35	0	I
,	0	O
can	0	O
squelch	0	O
the	0	O
silencing	0	O
activity	0	O
of	0	O
the	0	O
unliganded	0	O
TRbeta	0	B
.	0	O


These	0	O
findings	0	O
indicate	0	O
that	0	O
hypergastrinemia	0	O
induced	0	O
by	0	O
surgical	0	O
removal	0	O
of	0	O
acid	0	O
-	0	O
producing	0	O
mucosa	0	O
in	0	O
the	0	O
rat	0	O
has	0	O
the	0	O
same	0	O
effects	0	O
on	0	O
oxyntical	0	O
mucosal	0	B
HDC	0	I
activity	0	O
,	0	O
histamine	0	O
concentration	0	O
and	0	O
ECL	0	O
cell	0	O
density	0	O
as	0	O
hypergastrinemia	0	O
induced	0	O
by	0	O
continuous	0	O
gastrin	0	B
infusion	0	O
or	0	O
by	0	O
long	0	O
-	0	O
term	0	O
treatment	0	O
with	0	O
effective	0	O
antisecretagogues	0	O
.	0	O


Thus	0	O
,	0	O
YMIP	0	B
is	0	O
a	0	O
functional	0	O
homolog	0	O
of	0	O
RMIP	0	B
and	0	O
represents	0	O
a	0	O
new	0	O
component	0	O
of	0	O
the	0	O
yeast	0	O
mitochondrial	0	O
import	0	O
machinery	0	O
.	0	O


WR	0	O
-	0	O
2721	0	O
(	0	O
S	1	O
-	0	O
2	0	O
-(	0	O
3	0	O
aminopropylamino	0	O
)	0	O
ethylphosphorothioic	0	O
acid	0	O
)	0	O
has	0	O
been	0	O
investigated	0	O
for	0	O
its	0	O
ability	0	O
to	0	O
protect	0	O
gut	0	O
,	0	O
lung	0	O
,	0	O
and	0	O
testis	0	O
,	0	O
as	0	O
well	0	O
as	0	O
fibrosarcoma	0	O
(	0	O
FSa	0	O
)	0	O
tumor	0	O
nodules	0	O
,	0	O
in	0	O
the	0	O
lungs	0	O
of	0	O
mice	0	O
from	0	O
gamma	0	O
-	0	O
radiation	0	O
injury	0	O
.	0	O


We	0	O
took	0	O
advantage	0	O
of	0	O
the	0	O
high	0	O
degree	0	O
of	0	O
aa	0	O
sequence	0	O
homology	0	O
between	0	O
DAHPSs	0	B
from	0	O
several	0	O
species	0	O
to	0	O
isolate	0	O
ARO3	0	B
homologues	0	I
from	0	O
the	0	O
pathogenic	0	O
yeast	0	O
Candida	1	O
albicans	0	O
.	0	O


Vasopressin	1	B
(	0	O
AVP	1	B
),	0	O
the	0	O
antidiuretic	0	O
hormone	0	O
,	0	O
is	0	O
a	0	O
cyclic	0	O
nonapeptide	0	O
that	0	O
acts	0	O
through	0	O
binding	0	O
to	0	O
G	1	B
protein	0	I
-	0	I
coupled	0	I
specific	0	I
membrane	0	I
receptors	0	I
pharmacologically	0	O
divided	0	O
into	0	O
three	0	O
subtypes	0	O
(	0	O
V1a	0	B
,	0	O
V1b	0	B
,	0	O
and	0	O
V2	0	B
)	0	O
linked	0	O
to	0	O
distinct	0	O
second	0	O
messengers	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
observations	0	O
indicate	0	O
that	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
24	0	O
amino	0	O
acids	0	O
are	0	O
sufficient	0	O
for	0	O
NodO	0	B
secretion	0	O
although	0	O
the	0	O
region	0	O
adjacent	0	O
to	0	O
this	0	O
domain	0	O
appears	0	O
to	0	O
affect	0	O
secretion	0	O
efficiency	0	O
.	0	O


Twenty	0	O
food	0	O
products	0	O
were	0	O
contaminated	0	O
with	0	O
V	1	O
.	0	O
cholerae	0	O
O1	0	O
,	0	O
Ogawa	0	O
,	0	O
toxigenic	0	O
and	0	O
not	0	O
toxigenic	0	O
strains	0	O
:	0	O
yoghurt	0	O
,	0	O
cream	0	O
cheese	0	O
,	0	O
apricot	0	O
marmelade	0	O
,	0	O
hip	0	O
rose	0	O
marmelade	0	O
,	0	O
mayonnaise	0	O
,	0	O
italian	0	O
pasta	0	O
for	0	O
"	0	O
empanadas	0	O
",	0	O
"	0	O
dulce	0	O
de	0	O
leche	0	O
",	0	O
meat	0	O
sausage	0	O
,	0	O
meat	0	O
and	0	O
spinach	0	O
ravioli	0	O
,	0	O
margarine	0	O
,	0	O
milk	0	O
dessert	0	O
(	0	O
made	0	O
with	0	O
cocoa	0	O
,	0	O
milk	0	O
confiture	0	O
,	0	O
starch	0	O
and	0	O
additives	0	O
),	0	O
lettuce	0	O
,	0	O
tuna	0	O
fish	0	O
,	0	O
ricotta	0	O
and	0	O
sterilized	0	O
milk	0	O
.	0	O


In	1	O
spite	0	O
of	0	O
much	0	O
effort	0	O
,	0	O
no	0	O
one	0	O
has	0	O
succeeded	0	O
in	0	O
isolating	0	O
and	0	O
characterizing	0	O
the	0	O
enzyme	0	O
(	0	O
s	0	O
)	0	O
responsible	0	O
for	0	O
synthesis	0	O
of	0	O
cellulose	0	O
,	0	O
the	0	O
major	0	O
cell	0	O
wall	0	O
polymer	0	O
of	0	O
plants	0	O
.	0	O


Piroxicam	1	O
produced	0	O
a	0	O
lower	0	O
incidence	0	O
of	0	O
gastric	0	O
ulcers	0	O
than	0	O
equivalent	0	O
doses	0	O
of	0	O
indomethacin	0	O
.	0	O


Ras2p	0	B
activates	0	O
invasive	0	O
growth	0	O
using	0	O
either	0	O
of	0	O
two	0	O
downstream	0	O
signaling	0	O
pathways	0	O
,	0	O
the	0	O
filamentation	0	O
MAPK	1	B
(	0	O
Cdc42p	0	B
/	0	O
Ste20p	0	B
/	0	O
MAPK	1	B
)	0	O
cascade	0	O
or	0	O
the	0	O
cAMP	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	O
Cyr1p	0	B
/	0	O
cAMP	1	O
/	0	O
PKA	1	B
)	0	O
pathway	0	O
.	0	O


In	1	O
particular	0	O
,	0	O
unc	0	B
-	0	I
86	0	I
encodes	0	O
a	0	O
POU	0	B
-	0	I
type	0	I
homeodomain	0	I
protein	0	I
needed	0	O
for	0	O
the	0	O
production	0	O
of	0	O
the	0	O
touch	0	O
cells	0	O
,	0	O
while	0	O
mec	0	B
-	0	I
3	0	I
encodes	0	O
a	0	O
LIM	0	B
-	0	I
type	0	I
homeodomain	0	I
protein	0	I
needed	0	O
for	0	O
the	0	O
differentiation	0	O
of	0	O
the	0	O
touch	0	O
cells	0	O
.	0	O


Efficacy	1	O
of	0	O
cervical	0	O
spine	0	O
immobilization	0	O
methods	0	O
.	0	O


Using	0	O
either	0	O
a	0	O
p50	0	B
-	0	O
or	0	O
p65	0	B
-	0	I
selected	0	I
kappa	0	I
B	1	I
motif	0	I
,	0	O
which	0	O
displayed	0	O
differential	0	O
binding	0	O
with	0	O
respect	0	O
to	0	O
the	0	O
other	0	O
protein	0	O
,	0	O
little	0	O
to	0	O
no	0	O
binding	0	O
was	0	O
observed	0	O
with	0	O
the	0	O
heterodimeric	0	B
NF	1	I
-	0	I
kappa	0	I
B	1	I
complex	0	I
.	0	O


Trial	1	O
3	0	O
broiler	0	O
chickens	0	O
were	0	O
maintained	0	O
on	0	O
control	0	O
feed	0	O
until	0	O
they	0	O
reached	0	O
3	0	O
weeks	0	O
of	0	O
age	0	O
at	0	O
which	0	O
time	0	O
they	0	O
were	0	O
taken	0	O
off	0	O
of	0	O
feed	0	O
for	0	O
2	0	O
.	0	O
5	0	O
hr	0	O
and	0	O
then	0	O
placed	0	O
on	0	O
either	0	O
control	0	O
feed	0	O
or	0	O
feed	0	O
containing	0	O
4	0	O
.	0	O
0	0	O
ppm	0	O
ochratoxin	0	O
A	1	O
,	0	O
and	0	O
heart	0	O
rate	0	O
and	0	O
blood	0	O
pressure	0	O
were	0	O
measured	0	O
every	0	O
half	0	O
hour	0	O
through	0	O
7	0	O
hr	0	O
.	0	O


Recently	0	O
,	0	O
a	0	O
protein	0	O
designated	0	O
GF14	0	B
has	0	O
been	0	O
isolated	0	O
that	0	O
is	0	O
associated	0	O
with	0	O
the	0	O
GBF	0	B
protein	0	I
complex	0	I
.	0	O


Rho	1	B
GDP	1	I
/	0	I
GTP	1	I
exchange	0	I
inhibitor	0	I
,	0	O
Rho	1	B
GDI	0	I
,	0	O
comigrated	0	O
with	0	O
Rac2	0	B
and	0	O
RhoA	0	B
,	0	O
but	0	O
not	0	O
Rac1	0	B
.	0	O


Many	0	O
studies	0	O
have	0	O
pointed	0	O
out	0	O
the	0	O
possibility	0	O
of	0	O
"	0	O
masked	0	O
"	0	O
organic	0	O
factors	0	O
in	0	O
erectile	0	O
impotence	0	O
,	0	O
detectable	0	O
only	0	O
by	0	O
means	0	O
of	0	O
laboratory	0	O
investigations	0	O
:	0	O
mild	0	O
hypogonadism	0	O
,	0	O
hyperprolactinemia	0	O
,	0	O
occlusions	0	O
selectively	0	O
located	0	O
at	0	O
the	0	O
site	0	O
of	0	O
the	0	O
sexual	0	O
arteries	0	O
,	0	O
venous	0	O
incompetence	0	O
,	0	O
subclinical	0	O
neuropathies	0	O
.	0	O


AGO1	0	B
is	0	O
similar	0	O
to	0	O
QDE	0	B
-	0	I
2	0	I
required	0	O
for	0	O
quelling	0	O
and	0	O
RDE	1	B
-	0	I
1	0	I
required	0	O
for	0	O
RNAi	1	O
.	0	O


A	1	O
lambda	0	O
gt10	0	O
cDNA	1	O
library	0	O
was	0	O
constructed	0	O
from	0	O
poly	0	O
(	0	O
A	1	O
)+	0	O
RNA	1	O
of	0	O
young	0	O
green	0	O
leaves	0	O
of	0	O
spinach	0	O
.	0	O


Previous	0	O
studies	0	O
have	0	O
indicated	0	O
that	0	O
a	0	O
hamster	0	O
cell	0	O
line	0	O
(	0	O
ts13	0	O
)	0	O
with	0	O
a	0	O
point	0	O
mutation	0	O
in	0	O
the	0	O
TAF	0	B
(	0	I
II	0	I
)	0	I
250	0	I
/	0	O
CCG1	0	B
(	0	O
TAF	0	B
(	0	I
II	0	I
)	0	I
250	0	I
)	0	O
gene	0	O
shows	0	O
temperature	0	O
-	0	O
sensitive	0	O
expression	0	O
of	0	O
a	0	O
subset	0	O
of	0	O
genes	0	O
and	0	O
arrests	0	O
in	0	O
late	0	O
G1	0	O
at	0	O
39	0	O
.	0	O
5	0	O
degrees	0	O
C	1	O
.	0	O


Gluzman	0	O
,	0	O
EMBO	0	O
J	1	O
.	0	O


The	0	O
eating	0	O
and	0	O
drinking	0	O
patterns	0	O
of	0	O
pygmy	0	O
goats	0	O
fed	0	O
ad	0	O
lib	0	O
and	0	O
kept	0	O
on	0	O
a	0	O
12	0	O
h	0	O
light	0	O
/	0	O
12	0	O
h	0	O
dark	0	O
cycle	0	O
were	0	O
recorded	0	O
and	0	O
analyzed	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
contrast	0	O
media	0	O
on	0	O
coagulation	0	B
factor	0	I
XII	0	I
.	0	O


In	1	O
an	0	O
ongoing	0	O
study	0	O
the	0	O
performance	0	O
of	0	O
the	0	O
SMSP	0	O
is	0	O
being	0	O
compared	0	O
with	0	O
that	0	O
of	0	O
the	0	O
Mini	0	O
Speech	1	O
Processor	1	O
(	0	O
MSP	0	O
).	0	O


Specifically	0	O
,	0	O
I	1	O
use	0	O
molecular	0	O
markers	0	O
that	0	O
identify	0	O
particular	0	O
neuroectodermal	0	O
domains	0	O
,	0	O
all	0	O
neuroblasts	0	O
or	0	O
individual	0	O
neuroblasts	0	O
,	0	O
to	0	O
show	0	O
that	0	O
in	0	O
DER	0	B
mutant	0	I
embryos	0	O
(	0	O
1	0	O
)	0	O
intermediate	0	O
column	0	O
neuroblasts	0	O
do	0	O
not	0	O
form	0	O
,	0	O
(	0	O
2	0	O
)	0	O
medial	0	O
column	0	O
neuroblasts	0	O
often	0	O
acquire	0	O
identities	0	O
inappropriate	0	O
for	0	O
their	0	O
position	0	O
,	0	O
while	0	O
(	0	O
3	0	O
)	0	O
lateral	0	O
neuroblasts	0	O
develop	0	O
normally	0	O
.	0	O


In	1	O
Xenopus	1	O
embryos	0	O
,	0	O
the	0	O
engineered	0	B
PDGF	0	I
receptor	0	I
protein	0	I
induced	0	O
the	0	O
formation	0	O
of	0	O
mesoderm	0	O
from	0	O
animal	0	O
-	0	O
pole	0	O
explants	0	O
in	0	O
an	0	O
FK1012	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


The	0	O
RING	1	O
finger	0	O
,	0	O
B2	0	O
box	0	O
,	0	O
and	0	O
coiled	0	O
-	0	O
coil	0	O
region	0	O
are	0	O
required	0	O
for	0	O
oligomerization	0	O
of	0	O
KAP	0	B
-	0	I
1	0	I
-	0	O
RBCC	0	B
and	0	O
KRAB	0	B
binding	0	O
,	0	O
as	0	O
mutations	0	O
in	0	O
these	0	O
domains	0	O
concomitantly	0	O
abolished	0	O
these	0	O
functions	0	O
.	0	O


The	0	O
available	0	O
data	0	O
suggest	0	O
that	0	O
the	0	O
NF	1	B
kappa	0	I
B2	0	I
nucleoprotein	0	I
complex	0	I
may	0	O
cooperate	0	O
with	0	O
DNA	1	O
-	0	O
bound	0	O
STAT6	0	B
to	0	O
achieve	0	O
IL	1	B
-	0	I
4	0	I
-	0	O
dependent	0	O
activation	0	O
of	0	O
the	0	O
human	0	B
IgE	1	I
germline	0	I
gene	0	I
.	0	O


Carbonic	1	B
anhydrase	0	I
V	1	I
(	0	O
CA	1	B
V	1	I
)	0	O
is	0	O
expressed	0	O
in	0	O
mitochondrial	0	O
matrix	0	O
in	0	O
liver	0	O
and	0	O
several	0	O
other	0	O
tissues	0	O
.	0	O


Accumulated	0	O
evidence	0	O
indicates	0	O
that	0	O
,	0	O
upon	0	O
stimulation	0	O
with	0	O
interferon	0	B
-	0	I
gamma	0	I
(	0	O
IFN	1	B
-	0	I
gamma	0	I
),	0	O
three	0	O
beta	0	O
-	0	O
type	0	O
subunits	0	O
,	0	O
designated	0	O
LMP2	0	B
,	0	O
LMP7	0	B
,	0	O
and	0	O
PSMB10	0	B
,	0	O
are	0	O
incorporated	0	O
into	0	O
the	0	O
20S	0	B
proteasome	0	I
by	0	O
displacing	0	O
the	0	O
housekeeping	0	O
beta	0	O
-	0	O
type	0	O
subunits	0	O
designated	0	O
PSMB6	0	B
,	0	O
PSMB5	0	B
,	0	O
and	0	O
PSMB7	0	B
,	0	O
respectively	0	O
.	0	O


Pharmacology	1	O
studies	0	O
with	0	O
potassium	0	O
chloride	0	O
and	0	O
acetylcholine	0	O
suggest	0	O
that	0	O
raveron	0	O
acts	0	O
as	0	O
a	0	O
calcium	0	O
antagonist	0	O
by	0	O
blocking	0	O
the	0	O
influx	0	O
of	0	O
extracellular	0	O
calcium	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
the	0	O
disposition	0	O
of	0	O
venlafaxine	0	O
and	0	O
O	1	O
-	0	O
desmethylvenlafaxine	0	O
is	0	O
markedly	0	O
altered	0	O
in	0	O
renal	0	O
disease	0	O
;	0	O
therefore	0	O
dosage	0	O
adjustment	0	O
is	0	O
warranted	0	O
for	0	O
patients	0	O
with	0	O
creatinine	0	O
clearance	0	O
values	0	O
below	0	O
30	0	O
ml	0	O
/	0	O
min	0	O
.	0	O


Patients	0	O
with	0	O
moderate	0	O
PDDAT	0	O
were	0	O
impaired	0	O
on	0	O
all	0	O
serial	0	O
positions	0	O
for	0	O
both	0	O
spatial	0	O
order	0	O
and	0	O
spatial	0	O
recognition	0	O
memory	0	O
.	0	O


Maize	1	B
rbcS	0	I
promoter	0	I
activity	0	O
depends	0	O
on	0	O
sequence	0	O
elements	0	O
not	0	O
found	0	O
in	0	O
dicot	0	B
rbcS	0	I
promoters	0	I
.	0	O


Therefore	0	O
,	0	O
it	0	O
is	0	O
hoped	0	O
that	0	O
by	0	O
defining	0	O
the	0	O
transcriptional	0	O
control	0	O
of	0	O
the	0	O
L7	0	B
gene	0	I
insights	0	O
into	0	O
the	0	O
mechanisms	0	O
that	0	O
control	0	O
functional	0	O
fate	0	O
and	0	O
organization	0	O
in	0	O
the	0	O
nervous	0	O
system	0	O
can	0	O
be	0	O
gained	0	O
.	0	O


The	0	O
ORFII	0	B
gene	0	I
product	0	I
is	0	O
targeted	0	O
to	0	O
the	0	O
chloroplast	0	O
,	0	O
which	0	O
is	0	O
consistent	0	O
with	0	O
previous	0	O
data	0	O
indicating	0	O
the	0	O
presence	0	O
of	0	O
PMSR	0	B
activity	0	O
in	0	O
the	0	O
chloroplast	0	O
.	0	O


Phase	1	O
II	0	O
study	0	O
of	0	O
VP	1	O
-	0	O
16	0	O
(	0	O
capsule	0	O
)	0	O
in	0	O
solid	0	O
tumors	0	O
.	0	O


Studies	0	O
using	0	O
a	0	O
reporter	0	O
plasmid	0	O
with	0	O
a	0	O
functionally	0	O
disrupted	0	O
sterol	0	O
-	0	O
responsive	0	O
element	0	O
(	0	O
SRE	0	O
)-	0	O
1	0	O
revealed	0	O
a	0	O
reduced	0	O
stimulatory	0	O
response	0	O
to	0	O
IL	1	B
-	0	I
6	0	I
.	0	O


Uptake	1	O
of	0	O
ofloxacin	0	O
by	0	O
Escherichia	1	O
coli	0	O


Copyright	0	O
1998	0	O
Academic	0	O
Press	0	O
.	0	O


Reaction	1	O
of	0	O
human	0	O
organism	0	O
to	0	O
exercise	0	O
.	0	O


Examination	1	O
of	0	O
ANCA	1	B
is	0	O
not	0	O
only	0	O
a	0	O
significant	0	O
contribution	0	O
towards	0	O
a	0	O
more	0	O
accurate	0	O
diagnosis	0	O
of	0	O
renal	0	O
vasculitis	0	O
,	0	O
but	0	O
also	0	O
an	0	O
indicator	0	O
of	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
disease	0	O
and	0	O
thus	0	O
of	0	O
the	0	O
effectiveness	0	O
of	0	O
immunosuppressive	0	O
treatment	0	O
.	0	O


Another	0	O
sequence	0	O
,	0	O
GGGXGGAG	0	O
,	0	O
which	0	O
is	0	O
repeated	0	O
several	0	O
times	0	O
in	0	O
many	0	O
polyomaviruses	0	O
and	0	O
adenoviruses	0	O
,	0	O
and	0	O
which	0	O
is	0	O
thought	0	O
to	0	O
play	0	O
a	0	O
role	0	O
in	0	O
DNA	1	O
replication	0	O
and	0	O
/	0	O
or	0	O
transcription	0	O
,	0	O
is	0	O
not	0	O
found	0	O
in	0	O
the	0	O
JCV	0	O
sequence	0	O
presented	0	O
.	0	O


The	0	O
prothrombin	0	B
gene	0	I
G20210A	0	I
mutation	0	I
is	0	O
not	0	O
found	0	O
among	0	O
Japanese	0	O
patients	0	O
with	0	O
deep	0	O
vein	0	O
thrombosis	0	O
and	0	O
healthy	0	O
individuals	0	O
.	0	O


PPAR	0	B
gamma	0	I
mRNA	1	I
levels	0	O
were	0	O
reduced	0	O
by	0	O
95	0	O
%	0	O
with	0	O
3	0	O
nM	1	O
TNF	1	B
alpha	0	I
treatment	0	O
for	0	O
24	0	O
h	0	O
.	0	O


Oncogenic	1	B
Raf	0	I
-	0	I
1	0	I
activates	0	O
p70	0	B
S6	0	I
kinase	0	I
via	0	O
a	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
-	0	O
independent	0	O
pathway	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
RPF	1	B
-	0	I
1	0	I
is	0	O
likely	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
early	0	O
steps	0	O
in	0	O
the	0	O
differentiation	0	O
of	0	O
amacrine	0	O
and	0	O
ganglion	0	O
cells	0	O
.	0	O


Merosin	1	B
positive	0	O
congenital	0	O
muscular	0	O
dystrophy	0	O
with	0	O
mental	0	O
deficiency	0	O
,	0	O
epilepsy	0	O
and	0	O
MRI	1	O
changes	0	O
in	0	O
the	0	O
cerebral	0	O
white	0	O
matter	0	O
.	0	O


The	0	O
color	0	O
-	0	O
word	0	O
interference	0	O
effect	0	O
previously	0	O
reported	0	O
with	0	O
normal	0	O
populations	0	O
when	0	O
given	0	O
the	0	O
Stroop	0	O
test	0	O
was	0	O
demonstrated	0	O
for	0	O
this	0	O
retarded	0	O
sample	0	O
using	0	O
a	0	O
special	0	O
format	0	O
.	0	O


Interaction	1	O
of	0	O
H	1	B
-	0	I
2Eb	0	I
with	0	O
an	0	O
IAP	1	B
retrotransposon	0	I
in	0	O
the	0	O
A20	0	O
/	0	O
2J	0	O
B	1	O
cell	0	O
lymphoma	0	O
.	0	O


In	1	O
the	0	O
present	0	O
report	0	O
,	0	O
66	0	O
hemochromatosis	0	O
families	0	O
yielding	0	O
151	0	O
hemochromatosis	0	O
chromosomes	0	O
and	0	O
182	0	O
normal	0	O
chromosomes	0	O
were	0	O
RFLP	1	O
-	0	O
typed	0	O
with	0	O
a	0	O
battery	0	O
of	0	O
probes	0	O
,	0	O
including	0	O
two	0	O
newly	0	O
derived	0	O
polymorphic	0	O
markers	0	O
from	0	O
the	0	O
6	0	O
.	0	O
7	0	O
and	0	O
HLA	1	B
-	0	I
F	1	I
loci	0	I
located	0	O
150	0	O
and	0	O
250	0	O
kb	0	O
telomeric	0	O
to	0	O
HLA	1	B
-	0	I
A	1	I
,	0	O
respectively	0	O
.	0	O


Flow	1	O
cytomery	0	O
was	0	O
used	0	O
for	0	O
cell	0	O
cycle	0	O
analysis	0	O
.	0	O


Space	1	O
limitations	0	O
prevent	0	O
an	0	O
exhaustive	0	O
review	0	O
of	0	O
all	0	O
biologic	0	O
pharmaceuticals	0	O
,	0	O
such	0	O
as	0	O
tissue	0	B
plasminogen	0	I
activating	0	I
substance	0	I
,	0	O
hormones	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
thyroid	0	O
,	0	O
insulin	0	B
,	0	O
growth	0	B
hormone	0	I
,	0	O
erythropoietin	0	B
),	0	O
clotting	0	O
factors	0	O
,	0	O
and	0	O
blood	0	O
products	0	O
.	0	O


Endosonography	1	O
accurately	0	O
assessed	0	O
tumor	0	O
extension	0	O
in	0	O
two	0	O
T2	0	O
tumors	0	O
,	0	O
14	0	O
T3	1	O
tumors	0	O
,	0	O
and	0	O
seven	0	O
T4	1	O
tumors	0	O
.	0	O


A	1	O
--	0	O
A	1	O
natural	0	O
hydrostatic	0	O
phenomenon	0	O
,	0	O
at	0	O
the	0	O
level	0	O
of	0	O
the	0	O
ends	0	O
of	0	O
the	0	O
plantar	0	O
arcs	0	O
,	0	O
diffuses	0	O
body	0	O
weight	0	O
,	0	O
as	0	O
PAIN	1	O
plays	0	O
the	0	O
role	0	O
of	0	O
outsentry	0	O
(	0	O
fig	0	O
.--	0	O
1	0	O
)	0	O
(	0	O
5	0	O
);	0	O
B	1	O
--	0	O
Plantar	1	O
perforating	0	O
ulceration	0	O
(	0	O
PPU	0	O
)	0	O
is	0	O
caused	0	O
by	0	O
a	0	O
combination	0	O
of	0	O
INSENSITIVITY	1	O
and	0	O
TRAUMATIS	0	O
(	0	O
1	0	O
);	0	O
C	1	O
--	0	O
The	0	O
patient	0	O
reposing	0	O
,	0	O
as	0	O
body	0	O
weight	0	O
(	0	O
traumatism	0	O
)	0	O
effects	0	O
disappear	0	O
,	0	O
cicatrization	0	O
process	0	O
can	0	O
be	0	O
easily	0	O
observed	0	O
;	0	O
D	1	O
--	0	O
PNEUMATIC	1	O
INSOLE	0	O
,	0	O
being	0	O
elastic	0	O
,	0	O
diffuses	0	O
localized	0	O
compression	0	O
at	0	O
the	0	O
ends	0	O
of	0	O
the	0	O
plantar	0	O
arcs	0	O
,	0	O
reduces	0	O
attrition	0	O
,	0	O
makes	0	O
easier	0	O
blood	0	O
circulation	0	O
,	0	O
as	0	O
well	0	O
as	0	O
cure	0	O
and	0	O
prophylaxis	0	O
of	0	O
PPU	0	O
(	0	O
fig	0	O
.--	0	O
6	0	O
)	0	O
(	0	O
3	0	O
).	0	O


Preparation	1	O
of	0	O
a	0	O
stable	0	O
phospholipid	0	O
reagent	0	O
for	0	O
coagulation	0	O
assays	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
further	0	O
investigated	0	O
the	0	O
regulation	0	O
of	0	O
the	0	O
synthesis	0	O
of	0	O
the	0	O
c	0	B
-	0	I
mos	0	I
oncogene	0	I
product	0	I
,	0	O
which	0	O
is	0	O
necessary	0	O
for	0	O
the	0	O
activation	0	O
of	0	O
Cdc2	0	B
.	0	O


At	1	O
different	0	O
times	0	O
of	0	O
the	0	O
surgical	0	O
procedures	0	O
(	0	O
thorax	0	O
opening	0	O
and	0	O
closure	0	O
,	0	O
period	0	O
of	0	O
cardiopulmonary	0	O
bypass	0	O
)	0	O
67	0	O
to	0	O
100	0	O
%	0	O
of	0	O
the	0	O
patients	0	O
in	0	O
group	0	O
1	0	O
had	0	O
vancomycin	0	O
concentrations	0	O
in	0	O
the	0	O
studied	0	O
tissues	0	O
above	0	O
the	0	O
MIC	1	O
90	0	O
for	0	O
Staphylococcus	1	O
aureus	0	O
(	0	O
1	0	O
microgram	0	O
/	0	O
g	0	O
)	0	O
and	0	O
Staphylococcus	1	O
epidermidis	0	O
(	0	O
2	0	O
micrograms	0	O
/	0	O
g	0	O
).	0	O


CONCLUSION	0	O
:	0	O
The	0	O
probability	0	O
of	0	O
cardiopulmonary	0	O
complications	0	O
increases	0	O
significantly	0	O
when	0	O
patients	0	O
develop	0	O
class	0	O
1	0	O
HELLP	1	O
syndrome	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
,	0	O
with	0	O
autonomic	0	O
nervous	0	O
system	0	O
activity	0	O
intact	0	O
,	0	O
carotid	0	O
chemoreceptor	0	O
reflex	0	O
activation	0	O
can	0	O
elicit	0	O
an	0	O
absolute	0	O
reflexly	0	O
mediated	0	O
reduction	0	O
in	0	O
coronary	0	O
blood	0	O
flow	0	O
in	0	O
the	0	O
normal	0	O
,	0	O
conscious	0	O
dog	0	O
,	0	O
despite	0	O
an	0	O
increase	0	O
in	0	O
arterial	0	O
pressure	0	O
.	0	O


Furthermore	0	O
,	0	O
unlike	0	O
the	0	O
case	0	O
for	0	O
HIS3	0	B
where	0	O
only	0	O
a	0	O
limited	0	O
subset	0	O
of	0	O
TATA	0	O
-	0	O
like	0	O
sequences	0	O
can	0	O
activate	0	O
transcription	0	O
in	0	O
conjunction	0	O
with	0	O
GCN4p	0	B
,	0	O
many	0	O
divergent	0	O
TATA	0	O
-	0	O
like	0	O
sequences	0	O
allowed	0	O
GCN4p	0	B
activation	0	O
of	0	O
TRP3	0	B
.	0	O


Additionally	0	O
,	0	O
I	1	B
kappa	0	I
B	1	I
beta	0	I
,	0	O
but	0	O
not	0	O
I	1	B
kappa	0	I
B	1	I
alpha	0	I
,	0	O
also	0	O
prevented	0	O
the	0	O
binding	0	O
of	0	O
Rel	0	B
to	0	O
the	0	O
kappa	0	B
B	1	I
site	0	I
.	0	O


An	1	O
increase	0	O
in	0	O
bone	0	O
mineral	0	O
density	0	O
at	0	O
the	0	O
spine	0	O
,	0	O
total	0	O
hip	0	O
,	0	O
and	0	O
total	0	O
body	0	O
has	0	O
been	0	O
reported	0	O
with	0	O
raloxifene	0	O
but	0	O
seems	0	O
to	0	O
be	0	O
less	0	O
than	0	O
that	0	O
seen	0	O
with	0	O
estrogen	0	O
or	0	O
alendronate	0	O
therapy	0	O
.	0	O


We	0	O
have	0	O
therefore	0	O
evaluated	0	O
the	0	O
efficacy	0	O
and	0	O
safety	0	O
of	0	O
doxazosin	0	O
,	0	O
a	0	O
new	0	O
orally	0	O
active	0	O
selective	0	O
alpha	0	B
1	0	I
blocker	0	O
,	0	O
in	0	O
patients	0	O
with	0	O
systemic	0	O
hypertension	0	O
with	0	O
concomitant	0	O
airflow	0	O
limitation	0	O
.	0	O


Molecular	1	O
mimicry	0	O
of	0	O
human	0	O
cytokine	0	O
and	0	O
cytokine	0	O
response	0	O
pathway	0	O
genes	0	O
by	0	O
KSHV	0	O
.	0	O


A	1	O
family	0	O
of	0	O
RNA	1	O
molecules	0	O
in	0	O
the	0	O
2	0	O
.	0	O
0	0	O
-	0	O
2	0	O
.	0	O
2	0	O
-	0	O
kilobase	0	O
range	0	O
identified	0	O
with	0	O
a	0	O
probe	0	O
from	0	O
this	0	O
gene	0	O
was	0	O
overexpressed	0	O
in	0	O
the	0	O
resistant	0	O
cells	0	O
.	0	O


The	0	O
majority	0	O
of	0	O
PI	1	B
kinase	0	I
activity	0	O
appeared	0	O
to	0	O
be	0	O
cbl	0	B
-	0	O
associated	0	O
after	0	O
PRL	1	B
stimulation	0	O
.	0	O


The	0	O
HMG	1	B
domain	0	I
of	0	O
both	0	O
HMG20	0	B
proteins	0	I
is	0	O
most	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
yeast	0	B
NHP6A	0	I
(	0	O
38	0	O
%	0	O
to	0	O
42	0	O
%).	0	O


Visidex	0	O
I	1	O
is	0	O
unsuitable	0	O
for	0	O
storage	0	O
and	0	O
re	0	O
-	0	O
reading	0	O
.	0	O


On	1	O
the	0	O
transport	0	O
of	0	O
mucus	0	O
and	0	O
its	0	O
rheologic	0	O
simulants	0	O
in	0	O
ciliated	0	O
systems	0	O
.	0	O


A	1	O
mutation	0	O
linked	0	O
to	0	O
the	0	O
SOC1	0	B
gene	0	I
,	0	O
previously	0	O
defined	0	O
by	0	O
recessive	0	O
mutations	0	O
that	0	O
suppress	0	O
cbp1	0	B
ts	0	I
alleles	0	I
and	0	O
stabilize	0	O
many	0	O
mitochondrial	0	O
mRNAs	0	O
,	0	O
was	0	O
also	0	O
isolated	0	O
.	0	O


Modulation	1	O
of	0	O
25	0	B
-	0	I
hydroxyvitamin	0	I
D3	0	I
-	0	I
24	0	I
-	0	I
hydroxylase	0	I
by	0	O
aminophylline	0	O
:	0	O
a	0	O
cytochrome	0	B
P	1	I
-	0	I
450	0	I
monooxygenase	0	I
system	0	O
.	0	O


Bilateral	1	O
Charnley	0	O
arthroplasty	0	O
as	0	O
a	0	O
single	0	O
procedure	0	O
.	0	O


No	1	O
reflow	0	O
occurred	0	O
in	0	O
approximately	0	O
30	0	O
percent	0	O
of	0	O
the	0	O
muscle	0	O
microvasculature	0	O
upon	0	O
reperfusion	0	O
.	0	O


Scanning	1	O
mutations	0	O
throughout	0	O
the	0	O
AC	1	O
element	0	O
interfered	0	O
with	0	O
induction	0	O
but	0	O
allowed	0	O
us	0	O
to	0	O
define	0	O
five	0	O
overlapping	0	O
sites	0	O
for	0	O
regulatory	0	O
factors	0	O
in	0	O
AC	1	O
and	0	O
to	0	O
design	0	O
probes	0	O
binding	0	O
just	0	O
one	0	O
or	0	O
two	0	O
factors	0	O
.	0	O


Studies	0	O
on	0	O
the	0	O
intracutaneous	0	O
infection	0	O
of	0	O
rabbits	0	O
by	0	O
Staphylococcus	1	O
aureus	0	O
.	0	O


Identification	1	O
of	0	O
mutations	0	O
in	0	O
the	0	O
coding	0	O
sequence	0	O
of	0	O
the	0	O
proto	0	B
-	0	I
oncogene	0	I
c	0	I
-	0	I
kit	0	I
in	0	O
a	0	O
human	0	O
mast	0	O
cell	0	O
leukemia	0	O
cell	0	O
line	0	O
causing	0	O
ligand	0	O
-	0	O
independent	0	O
activation	0	O
of	0	O
c	0	B
-	0	I
kit	0	I
product	0	I
.	0	O


In	1	O
Group	1	O
IV	1	O
dogs	0	O
that	0	O
received	0	O
alpha	0	B
-	0	I
MSH	1	I
only	0	O
during	0	O
reperfusion	0	O
,	0	O
BAEPs	0	O
were	0	O
increased	0	O
approximately	0	O
10	0	O
to	0	O
14	0	O
%	0	O
more	0	O
than	0	O
in	0	O
Group	1	O
II	0	O
during	0	O
the	0	O
late	0	O
reperfusion	0	O
period	0	O
.	0	O


Because	0	O
of	0	O
a	0	O
rapid	0	O
development	0	O
of	0	O
the	0	O
connective	0	O
tissue	0	O
scars	0	O
,	0	O
however	0	O
,	0	O
at	0	O
the	0	O
place	0	O
of	0	O
the	0	O
destroyed	0	O
glandular	0	O
parenchyma	0	O
areas	0	O
,	0	O
there	0	O
is	0	O
no	0	O
normalization	0	O
of	0	O
the	0	O
organ	0	O
'	0	O
s	0	O
structure	0	O
and	0	O
function	0	O
by	0	O
the	0	O
42d	0	O
day	0	O
.	0	O


Members	0	O
of	0	O
the	0	O
Ras	1	B
subfamily	0	I
of	0	O
small	0	B
GTP	1	I
-	0	I
binding	0	I
proteins	0	I
have	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
promiscuous	0	O
towards	0	O
a	0	O
variety	0	O
of	0	O
putative	0	O
effector	0	O
molecules	0	O
such	0	O
as	0	O
the	0	O
protein	0	B
kinase	0	I
c	0	I
-	0	I
Raf	0	I
and	0	O
the	0	O
Ral	0	B
-	0	I
specific	0	I
guanine	0	I
nucleotide	0	I
exchange	0	I
factor	0	I
(	0	O
Ral	0	B
-	0	I
GEF	0	I
).	0	O


Dermoid	1	O
cyst	0	O
in	0	O
a	0	O
free	0	O
skin	0	O
flap	0	O
as	0	O
the	0	O
complication	0	O
after	0	O
treatment	0	O
of	0	O
recurring	0	O
hernia	0	O


The	0	O
small	0	B
GTPase	1	I
Rho	1	I
is	0	O
implicated	0	O
in	0	O
physiological	0	O
functions	0	O
associated	0	O
with	0	O
actin	0	B
-	0	O
myosin	0	B
filaments	0	O
such	0	O
as	0	O
cytokinesis	0	O
,	0	O
cell	0	O
motility	0	O
,	0	O
and	0	O
smooth	0	O
muscle	0	O
contraction	0	O
.	0	O


The	0	O
E1	1	B
gene	0	I
is	0	O
located	0	O
within	0	O
the	0	O
first	0	O
intron	0	O
of	0	O
the	0	O
gene	0	O
for	0	O
RCC1	0	B
,	0	O
a	0	O
protein	0	O
that	0	O
regulates	0	O
onset	0	O
of	0	O
mitosis	0	O
.	0	O


The	0	O
heterogeneity	0	O
of	0	O
bovine	0	B
IgG2	0	I
--	0	I
VIII	0	I
.	0	O


Study	1	O
on	0	O
re	0	O
-	0	O
establishment	0	O
of	0	O
ovulation	0	O
after	0	O
termination	0	O
of	0	O
sex	0	O
-	0	O
steroidal	0	O
treatment	0	O
--	0	O
compared	0	O
with	0	O
re	0	O
-	0	O
appearance	0	O
of	0	O
ovulation	0	O
after	0	O
abortion	0	O
and	0	O
premature	0	O
delivery	0	O
.	0	O


Tctex	0	B
-	0	I
1	0	I
binding	0	O
required	0	O
the	0	O
first	0	O
19	0	O
amino	0	O
acids	0	O
of	0	O
Fyn	0	B
and	0	O
integrity	0	O
of	0	O
two	0	O
lysine	0	O
residues	0	O
within	0	O
this	0	O
sequence	0	O
that	0	O
were	0	O
previously	0	O
shown	0	O
to	0	O
be	0	O
important	0	O
for	0	O
Fyn	0	B
interactions	0	O
with	0	O
the	0	O
immunoreceptor	0	O
tyrosine	0	O
-	0	O
based	0	O
activation	0	O
motifs	0	O
(	0	O
ITAMs	0	O
)	0	O
of	0	O
lymphocyte	0	B
Ag	1	I
receptors	0	I
.	0	O


The	0	O
Wnt	0	B
signaling	0	O
pathway	0	O
functions	0	O
reiteratively	0	O
during	0	O
animal	0	O
development	0	O
to	0	O
control	0	O
cell	0	O
fate	0	O
decisions	0	O
.	0	O


Pediatric	1	O
medical	0	O
emergencies	0	O
in	0	O
a	0	O
regional	0	O
hospital	0	O
:	0	O
appropriate	0	O
locale	0	O
?	0	O


An	1	O
epidemic	0	O
of	0	O
hepatitis	0	O
B	1	O
virus	0	O
infection	0	O
among	0	O
intravenous	0	O
drug	0	O
users	0	O
in	0	O
Iceland	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
a	0	O
noncanonical	0	O
C	1	B
/	0	I
EBP	1	I
-	0	I
binding	0	I
site	0	I
within	0	O
the	0	O
Gadd45gamma	0	B
promoter	0	I
where	0	O
C	1	B
/	0	I
EBPbeta	0	I
and	0	O
C	1	B
/	0	I
EBPdelta	0	I
could	0	O
bind	0	O
,	0	O
was	0	O
identified	0	O
by	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assay	0	O
(	0	O
EMSA	0	O
)	0	O
and	0	O
reporter	0	O
gene	0	O
analysis	0	O
.	0	O


With	0	O
stepwise	0	O
reductions	0	O
in	0	O
flow	0	O
,	0	O
the	0	O
peak	0	O
(	0	O
S	1	O
)	0	O
and	0	O
trough	0	O
(	0	O
D	1	O
)	0	O
points	0	O
of	0	O
the	0	O
maximum	0	O
shifted	0	O
-	0	O
frequency	0	O
envelope	0	O
fell	0	O
in	0	O
parallel	0	O
in	0	O
a	0	O
linear	0	O
fashion	0	O
until	0	O
D	1	O
reached	0	O
zero	0	O
.	0	O


Patient	1	O
characteristics	0	O
associated	0	O
with	0	O
deep	0	O
wounds	0	O
as	0	O
well	0	O
as	0	O
patient	0	O
and	0	O
wound	0	O
characteristics	0	O
predictive	0	O
of	0	O
the	0	O
extent	0	O
of	0	O
healing	0	O
and	0	O
time	0	O
required	0	O
for	0	O
healing	0	O
were	0	O
identified	0	O
.	0	O


Recombinant	1	B
Leishmania	1	I
surface	0	I
glycoprotein	0	I
GP63	0	I
is	0	O
secreted	0	O
in	0	O
the	0	O
baculovirus	0	O
expression	0	O
system	0	O
as	0	O
a	0	O
latent	0	O
metalloproteinase	0	B
.	0	O


All	1	O
patients	0	O
received	0	O
VCR	0	O
1	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
m2	0	O
weekly	0	O
for	0	O
6	0	O
weeks	0	O
with	0	O
dose	0	O
modification	0	O
for	0	O
neurotoxicity	0	O
.	0	O


In	1	O
sorted	0	O
bone	0	O
marrow	0	O
cells	0	O
expression	0	O
of	0	O
both	0	O
VpreB	0	B
genes	0	I
was	0	O
detected	0	O
in	0	O
pro	0	O
-	0	O
B	1	O
/	0	O
pre	0	O
-	0	O
BI	1	O
and	0	O
large	0	O
pre	0	O
-	0	O
BII	0	O
cells	0	O
,	0	O
while	0	O
the	0	O
RNA	1	O
steady	0	O
state	0	O
levels	0	O
were	0	O
at	0	O
least	0	O
100	0	O
-	0	O
fold	0	O
lower	0	O
in	0	O
small	0	O
pre	0	O
-	0	O
BII	0	O
and	0	O
immature	0	O
/	0	O
mature	0	O
B	1	O
cells	0	O
.	0	O


Morphological	1	O
features	0	O
of	0	O
Jat	0	O
dentition	0	O
.	0	O


This	0	O
study	0	O
proposes	0	O
an	0	O
estimator	0	O
for	0	O
such	0	O
global	0	O
synchronizing	0	O
effects	0	O
upon	0	O
unit	0	O
-	0	O
pair	0	O
correlations	0	O
based	0	O
on	0	O
local	0	O
field	0	O
potentials	0	O
(	0	O
LFPs	0	O
).	0	O


The	0	O
association	0	O
of	0	O
clopamide	0	O
and	0	O
hydergine	0	O
(	0	O
Brinedine	0	O
)	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
the	0	O
vasculo	0	O
-	0	O
renal	0	O
syndromes	0	O
of	0	O
pregnancy	0	O


In	1	O
situ	0	O
hybridization	0	O
analysis	0	O
in	0	O
adult	0	O
rat	0	O
tissue	0	O
reveals	0	O
good	0	O
correlation	0	O
with	0	O
this	0	O
pattern	0	O
and	0	O
indicates	0	O
that	0	O
drm	0	B
mRNA	1	I
is	0	O
most	0	O
highly	0	O
expressed	0	O
in	0	O
nondividing	0	O
and	0	O
terminally	0	O
differentiated	0	O
cells	0	O
,	0	O
such	0	O
as	0	O
neurons	0	O
,	0	O
type	0	O
1	0	O
lung	0	O
cells	0	O
,	0	O
and	0	O
goblet	0	O
cells	0	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
periseizure	0	O
lipid	0	O
accumulation	0	O
is	0	O
related	0	O
to	0	O
cortical	0	O
oxygenation	0	O
.	0	O


Here	0	O
we	0	O
show	0	O
that	0	O
a	0	O
novel	0	O
isoform	0	O
of	0	O
Rapl	0	B
GTPase	1	I
-	0	I
activating	0	I
protein	0	I
,	0	O
called	0	O
rap1GAPII	0	B
,	0	O
binds	0	O
specifically	0	O
to	0	O
the	0	O
alpha	0	O
-	0	O
subunits	0	O
of	0	O
the	0	O
G	1	B
(	0	I
i	0	I
)	0	I
family	0	I
of	0	O
heterotrimeric	0	B
G	1	I
-	0	I
proteins	0	I
.	0	O


This	0	O
shows	0	O
that	0	O
the	0	O
characteristically	0	O
diffuse	0	O
banding	0	O
pattern	0	O
of	0	O
plant	0	O
nuclear	0	O
proteins	0	O
interacting	0	O
with	0	O
the	0	O
G	1	O
-	0	O
box	0	O
is	0	O
also	0	O
observed	0	O
in	0	O
a	0	O
binding	0	O
assay	0	O
using	0	O
only	0	O
one	0	O
recombinant	0	B
GBF	0	I
.	0	O


The	0	O
clinical	0	O
efficacy	0	O
rates	0	O
evaluated	0	O
in	0	O
151	0	O
cases	0	O
(	0	O
KS	1	O
-	0	O
R1	0	O
group	0	O
in	0	O
77	0	O
cases	0	O
,	0	O
oral	0	O
group	0	O
in	0	O
74	0	O
cases	0	O
)	0	O
on	0	O
standard	0	O
criteria	0	O
of	0	O
committee	0	O
members	0	O
were	0	O
88	0	O
.	0	O
3	0	O
%	0	O
for	0	O
the	0	O
KS	1	O
-	0	O
R1	0	O
group	0	O
and	0	O
86	0	O
.	0	O
5	0	O
%	0	O
for	0	O
the	0	O
oral	0	O
group	0	O
,	0	O
respectively	0	O
.	0	O


Also	0	O
,	0	O
transient	0	O
overexpression	0	O
of	0	O
this	0	O
protein	0	O
in	0	O
C2C12	0	O
cells	0	O
reduced	0	O
the	0	O
transcription	0	O
of	0	O
a	0	O
CAT	1	B
-	0	O
reporter	0	O
regulated	0	O
by	0	O
an	0	O
E12	0	B
/	0	O
MyoD	0	B
driven	0	O
enhancer	0	O
.	0	O


Abnormal	1	O
calcium	0	O
metabolism	0	O
in	0	O
normocalcaemic	0	O
sarcoidosis	0	O
.	0	O


Carboxy	0	O
-	0	O
terminal	0	O
Spc110p	0	B
truncations	0	O
lacking	0	O
the	0	O
calmodulin	0	B
binding	0	O
site	0	O
can	0	O
support	0	O
growth	0	O
and	0	O
are	0	O
also	0	O
phosphorylated	0	O
in	0	O
a	0	O
cell	0	O
cycle	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
bradycardic	0	O
agents	0	O
alinidine	0	O
and	0	O
zatebradine	0	O
do	0	O
not	0	O
exert	0	O
antiarrhythmic	0	O
efficacy	0	O
against	0	O
SVT	1	O
induced	0	O
during	0	O
subacute	0	O
myocardial	0	O
infarction	0	O
in	0	O
conscious	0	O
dogs	0	O
.	0	O


The	0	O
neural	0	O
mechanism	0	O
of	0	O
parkinsonian	0	O
motor	0	O
symptoms	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
rigidity	0	O
,	0	O
tremor	0	O
and	0	O
akinesia	0	O
,	0	O
which	0	O
are	0	O
the	0	O
result	0	O
of	0	O
nigrostriatal	0	O
dopamine	0	O
deficiency	0	O
,	0	O
is	0	O
interpreted	0	O
from	0	O
long	0	O
-	0	O
term	0	O
observations	0	O
on	0	O
the	0	O
effect	0	O
of	0	O
surgical	0	O
and	0	O
pharmacological	0	O
treatment	0	O
of	0	O
the	0	O
disease	0	O
in	0	O
relation	0	O
to	0	O
the	0	O
neuropathological	0	O
findings	0	O
within	0	O
the	0	O
substantia	0	O
nigra	0	O
zona	0	O
compacta	0	O
(	0	O
SNc	0	O
).	0	O


The	0	O
leader	0	O
sequence	0	O
of	0	O
the	0	O
isolated	0	O
cDNA	1	O
clone	0	O
contains	0	O
several	0	O
small	0	O
open	0	O
reading	0	O
frames	0	O
upstream	0	O
of	0	O
the	0	O
initiation	0	O
codon	0	O
of	0	O
the	0	O
largest	0	O
open	0	O
reading	0	O
frame	0	O
coding	0	O
for	0	O
the	0	O
homeodomain	0	B
protein	0	I
.	0	O


Because	0	O
Trp53	0	B
(	0	O
the	0	O
mouse	0	B
homolog	0	I
of	0	I
human	0	I
TP53	0	I
)	0	O
is	0	O
located	0	O
with	0	O
Tk1	0	B
on	0	O
chromosome	0	O
11	0	O
and	0	O
is	0	O
critical	0	O
in	0	O
regulating	0	O
cellular	0	O
responses	0	O
following	0	O
exposure	0	O
to	0	O
DNA	1	O
damaging	0	O
agents	0	O
,	0	O
we	0	O
wanted	0	O
to	0	O
determine	0	O
if	0	O
these	0	O
mouse	0	O
lymphoma	0	O
cells	0	O
harbor	0	O
mutations	0	O
in	0	O
Trp53	0	B
.	0	O


HTLV	0	O
-	0	O
1	0	O
gene	0	O
expression	0	O
by	0	O
defective	0	O
proviruses	0	O
in	0	O
an	0	O
infected	0	O
T	1	O
-	0	O
cell	0	O
line	0	O
.	0	O


There	0	O
were	0	O
35	0	O
boys	0	O
and	0	O
15	0	O
girls	0	O
,	0	O
with	0	O
a	0	O
mean	0	O
age	0	O
of	0	O
five	0	O
and	0	O
a	0	O
half	0	O
years	0	O
.	0	O


Twelve	0	O
out	0	O
of	0	O
43	0	O
renal	0	O
failure	0	O
patients	0	O
had	0	O
troponin	0	B
I	1	I
0	0	O
.	0	O
13	0	O
-	0	O
0	0	O
.	0	O
9	0	O
microg	0	O
/	0	O
l	0	O
using	0	O
Axsym	0	O
method	0	O
and	0	O
4	0	O
had	0	O
levels	0	O
of	0	O
0	0	O
.	0	O
07	0	O
-	0	O
0	0	O
.	0	O
13	0	O
microg	0	O
/	0	O
l	0	O
using	0	O
Immuno	0	O
1	0	O
.	0	O


DNA	1	O
-	0	O
binding	0	O
activity	0	O
was	0	O
not	0	O
increased	0	O
by	0	O
the	0	O
addition	0	O
of	0	O
forskolin	0	O
to	0	O
thecal	0	O
or	0	O
luteal	0	O
cells	0	O
.	0	O


The	0	O
amplitudes	0	O
of	0	O
DPOAE	0	O
also	0	O
recovered	0	O
to	0	O
a	0	O
greater	0	O
extent	0	O
and	0	O
outer	0	O
hair	0	O
cell	0	O
losses	0	O
were	0	O
less	0	O
severe	0	O
in	0	O
the	0	O
R	1	O
-	0	O
PIA	1	O
-	0	O
treated	0	O
ears	0	O
.	0	O


Raman	0	O
investigation	0	O
of	0	O
YBa2	0	O
-	0	O
xLaxCu3O7	0	O
ceramics	0	O
.	0	O


Expression	1	O
of	0	O
h6	0	O
.	0	O
1	0	O
in	0	O
COS	1	O
-	0	O
1	0	O
cells	0	O
led	0	O
to	0	O
the	0	O
production	0	O
of	0	O
a	0	O
typical	0	O
type	0	B
IV	1	I
PDE	1	I
activity	0	O
in	0	O
that	0	O
cAMP	1	O
,	0	O
but	0	O
not	0	O
cGMP	1	O
,	0	O
served	0	O
as	0	O
substrate	0	O
and	0	O
its	0	O
activity	0	O
was	0	O
insensitive	0	O
to	0	O
either	0	O
Ca2	1	O
+/	0	O
CaM	1	B
or	0	O
cGMP	1	O
but	0	O
was	0	O
inhibited	0	O
by	0	O
low	0	O
concentrations	0	O
of	0	O
rolipram	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
400	0	O
WORDS	0	O
)	0	O


Intrastriatal	0	O
grafts	0	O
of	0	O
nigral	0	O
and	0	O
adrenal	0	O
tissues	0	O
have	0	O
been	0	O
found	0	O
to	0	O
be	0	O
effective	0	O
in	0	O
alleviating	0	O
many	0	O
of	0	O
the	0	O
simple	0	O
motor	0	O
and	0	O
sensorimotor	0	O
deficits	0	O
associated	0	O
with	0	O
lesions	0	O
of	0	O
the	0	O
nigrostriatal	0	O
dopamine	0	O
system	0	O
.	0	O


Studies	0	O
on	0	O
the	0	O
hereditary	0	O
nature	0	O
of	0	O
sole	0	O
prints	0	O
--	0	O
with	0	O
special	0	O
reference	0	O
to	0	O
interdigital	0	O
and	0	O
triradii	0	O


We	0	O
found	0	O
that	0	O
the	0	O
3	0	O
'-	0	O
end	0	O
-	0	O
adjacent	0	O
sequence	0	O
CA	1	O
(	0	O
N	1	O
)	0	O
3	0	O
-	0	O
10AGTNNAA	0	O
,	0	O
conserved	0	O
in	0	O
plant	0	O
Pol	0	B
II	0	I
-	0	O
specific	0	O
U	1	B
snRNA	1	I
genes	0	I
,	0	O
is	0	O
essential	0	O
for	0	O
the	0	O
3	0	O
'-	0	O
end	0	O
formation	0	O
of	0	O
U2	0	B
transcripts	0	I
and	0	O
,	0	O
similar	0	O
to	0	O
the	0	O
vertebrate	0	O
3	0	O
'	0	O
box	0	O
,	0	O
is	0	O
highly	0	O
tolerant	0	O
to	0	O
mutation	0	O
.	0	O


There	0	O
was	0	O
a	0	O
significant	0	O
but	0	O
similar	0	O
elevation	0	O
of	0	O
mean	0	O
O2	1	O
uptake	0	O
during	0	O
40	0	O
min	0	O
postexercise	0	O
by	0	O
13	0	O
.	0	O
6	0	O
%	0	O
in	0	O
both	0	O
the	0	O
fasted	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
)	0	O
and	0	O
fed	0	O
state	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


The	0	O
findings	0	O
are	0	O
compatible	0	O
with	0	O
the	0	O
idea	0	O
that	0	O
the	0	O
genes	0	O
encoding	0	O
PDGF	0	B
receptors	0	I
in	0	O
glioma	0	O
cells	0	O
are	0	O
regulated	0	O
in	0	O
concert	0	O
with	0	O
other	0	O
genes	0	O
,	0	O
the	0	O
expression	0	O
of	0	O
which	0	O
may	0	O
reflect	0	O
the	0	O
developmental	0	O
program	0	O
of	0	O
normal	0	O
glia	0	O
cell	0	O
lineages	0	O
.	0	O


Like	0	O
many	0	O
eukaryotic	0	O
transcription	0	O
factors	0	O
,	0	O
these	0	O
proteins	0	O
bind	0	O
to	0	O
DNA	1	O
as	0	O
dimers	0	O
.	0	O


UDP	1	B
-	0	I
Gal	0	I
:	0	I
Gal	0	I
beta	0	I
1	0	I
----	0	I
4GlcNAc	0	I
alpha	0	I
1	0	I
----	0	I
3	0	I
-	0	I
galactosyltransferase	0	I
is	0	O
a	0	O
terminal	0	B
glycosyltransferase	0	I
that	0	O
is	0	O
widely	0	O
expressed	0	O
in	0	O
a	0	O
variety	0	O
of	0	O
mammalian	0	O
species	0	O
,	0	O
with	0	O
the	0	O
notable	0	O
exception	0	O
of	0	O
man	0	O
,	0	O
apes	0	O
,	0	O
and	0	O
Old	0	O
World	0	O
monkeys	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
transcription	0	O
of	0	O
c	0	B
-	0	I
IAP2	0	I
promoter	0	I
was	0	O
strongly	0	O
up	0	O
-	0	O
regulated	0	O
when	0	O
CD40	0	B
or	0	O
Epstein	0	B
-	0	I
Barr	0	I
virus	0	I
latent	0	I
membrane	0	I
protein	0	I
1	0	I
was	0	O
overexpressed	0	O
.	0	O


The	0	O
major	0	O
myosin	0	B
-	0	I
binding	0	I
domain	0	I
of	0	O
skeletal	0	B
muscle	0	I
MyBP	0	I
-	0	I
C	1	I
(	0	O
C	1	B
protein	0	I
)	0	O
resides	0	O
in	0	O
the	0	O
COOH	0	O
-	0	O
terminal	0	O
,	0	O
immunoglobulin	0	B
C2	1	I
motif	0	I
.	0	O


The	0	O
fibrinogen	0	B
,	0	O
serum	0	O
proteins	0	O
,	0	O
sodium	0	O
heparin	0	O
and	0	O
membrane	0	O
contributed	0	O
to	0	O
Cm	1	O
by	0	O
20	0	O
%,	0	O
14	0	O
%,	0	O
2	0	O
%	0	O
and	0	O
64	0	O
%,	0	O
respectively	0	O
.	0	O


Cholangiography	1	O
was	0	O
performed	0	O
in	0	O
all	0	O
cases	0	O
and	0	O
classified	0	O
by	0	O
a	0	O
scoring	0	O
system	0	O
specifically	0	O
developed	0	O
for	0	O
pediatric	0	O
patients	0	O
.	0	O


Most	0	O
eukaryotic	0	O
mRNAs	0	O
are	0	O
translated	0	O
by	0	O
a	0	O
"	0	O
scanning	0	O
ribosome	0	O
"	0	O
mechanism	0	O
.	0	O


This	0	O
study	0	O
demonstrates	0	O
secretion	0	O
of	0	O
bicarbonate	0	O
by	0	O
the	0	O
human	0	O
stomach	0	O
in	0	O
vivo	0	O
at	0	O
a	0	O
rate	0	O
equivalent	0	O
to	0	O
10	0	O
--	0	O
20	0	O
%	0	O
of	0	O
basal	0	O
acid	0	O
secretion	0	O
.	0	O


The	0	O
84	0	B
.	0	I
1C	0	I
mAb	0	I
recognizes	0	O
a	0	O
site	0	O
on	0	O
IgE	1	B
which	0	O
is	0	O
identical	0	O
or	0	O
very	0	O
close	0	O
to	0	O
the	0	O
Fc	1	B
epsilon	0	I
R	1	I
binding	0	I
site	0	I
,	0	O
and	0	O
95	0	O
.	0	O
3	0	O
recognizes	0	O
a	0	O
site	0	O
on	0	O
IgE	1	B
which	0	O
is	0	O
related	0	O
,	0	O
but	0	O
not	0	O
identical	0	O
to	0	O
the	0	O
Fc	1	B
epsilon	0	I
R	1	I
binding	0	I
site	0	I
.	0	O


UV	1	O
cross	0	O
-	0	O
linking	0	O
experiments	0	O
demonstrated	0	O
that	0	O
HSV	1	O
infection	0	O
caused	0	O
enhanced	0	O
binding	0	O
of	0	O
protein	0	O
factors	0	O
,	0	O
including	0	O
the	0	O
64	0	B
-	0	I
kDa	1	I
component	0	I
of	0	I
cleavage	0	I
stimulation	0	I
factor	0	I
(	0	O
CstF	0	B
),	0	O
to	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
site	0	O
RNAs	0	O
from	0	O
virus	0	O
genes	0	O
of	0	O
all	0	O
temporal	0	O
classes	0	O
and	0	O
that	0	O
this	0	O
enhanced	0	O
binding	0	O
required	0	O
expression	0	O
of	0	O
IE63	0	B
.	0	O


The	0	O
carcinogen	0	O
bioassay	0	O
therefore	0	O
is	0	O
a	0	O
very	0	O
important	0	O
component	0	O
of	0	O
the	0	O
battery	0	O
of	0	O
toxicological	0	O
tests	0	O
used	0	O
in	0	O
hazard	0	O
evaluation	0	O
.	0	O


All	1	O
these	0	O
processes	0	O
were	0	O
fully	0	O
developed	0	O
during	0	O
the	0	O
last	0	O
month	0	O
of	0	O
pregnancy	0	O
,	0	O
offering	0	O
the	0	O
same	0	O
picture	0	O
as	0	O
the	0	O
controls	0	O
.	0	O


The	0	O
favourable	0	O
effect	0	O
of	0	O
thymic	0	O
shielding	0	O
was	0	O
also	0	O
reflected	0	O
in	0	O
a	0	O
significant	0	O
increase	0	O
of	0	O
LD50	1	O
/	0	O
30	0	O
,	0	O
and	0	O
the	0	O
dose	0	O
reduction	0	O
factor	0	O
was	0	O
equal	0	O
to	0	O
2	0	O
.	0	O


The	0	O
1	0	O
.	0	O
7	0	O
kb	0	O
cloned	0	O
fragment	0	O
was	0	O
sequenced	0	O
and	0	O
shown	0	O
to	0	O
contain	0	O
the	0	O
entire	0	O
fliA	0	B
gene	0	I
.	0	O


To	1	O
do	0	O
this	0	O
,	0	O
segments	0	O
of	0	O
DNA	1	O
from	0	O
the	0	O
5	0	O
'	0	O
flank	0	O
of	0	O
the	0	O
initiation	0	O
sites	0	O
for	0	O
germline	0	O
epsilon	0	O
RNA	1	O
were	0	O
ligated	0	O
to	0	O
a	0	O
luciferase	0	B
reporter	0	I
gene	0	I
and	0	O
transfected	0	O
into	0	O
two	0	O
mouse	0	O
B	1	O
cell	0	O
lines	0	O
,	0	O
one	0	O
of	0	O
which	0	O
can	0	O
be	0	O
induced	0	O
to	0	O
switch	0	O
to	0	O
IgE	1	B
.	0	O


The	0	O
exploratory	0	O
behaviour	0	O
in	0	O
normal	0	O
and	0	O
aggressive	0	O
mice	0	O
.	0	O


In	1	O
vitro	0	O
protein	0	O
retention	0	O
experiments	0	O
in	0	O
which	0	O
Hsp90	0	B
heterocomplexes	0	I
were	0	O
precipitated	0	O
resulted	0	O
in	0	O
coprecipitation	0	O
of	0	O
Cns1	0	B
.	0	O


In	1	O
reperfusion	0	O
B	1	O
,	0	O
only	0	O
the	0	O
diabetic	0	O
group	0	O
demonstrated	0	O
a	0	O
significant	0	O
increase	0	O
in	0	O
IL	1	B
-	0	I
8	0	I
concentrations	0	O
at	0	O
1	0	O
and	0	O
15	0	O
min	0	O
compared	0	O
to	0	O
nondiabetics	0	O
.	0	O


These	0	O
results	0	O
suggested	0	O
that	0	O
the	0	O
GG	0	O
motifs	0	O
contributed	0	O
to	0	O
the	0	O
cell	0	O
-	0	O
specific	0	O
transcription	0	O
of	0	O
the	0	O
human	0	B
insulin	0	I
gene	0	I
in	0	O
association	0	O
with	0	O
the	0	O
binding	0	O
of	0	O
the	0	O
sequence	0	O
-	0	O
specific	0	O
nuclear	0	O
factor	0	O
.	0	O


In	1	O
the	0	O
absence	0	O
of	0	O
enhancer	0	O
sequences	0	O
,	0	O
the	0	O
adenovirus	0	B
E1A	0	I
gene	0	I
can	0	O
not	0	O
stimulate	0	O
CATase	0	B
synthesis	0	O
.	0	O


This	0	O
compares	0	O
favorably	0	O
to	0	O
results	0	O
of	0	O
similarly	0	O
sized	0	O
melanomas	0	O
treated	0	O
by	0	O
enucleation	0	O
.	0	O


The	0	O
addition	0	O
of	0	O
an	0	O
equimolar	0	O
complex	0	O
of	0	O
the	0	O
fourth	0	O
and	0	O
seventh	0	O
largest	0	O
subunits	0	O
,	0	O
purified	0	O
from	0	O
pol	0	B
II	0	I
holoenzyme	0	I
by	0	O
ion	0	O
-	0	O
exchange	0	O
chromatography	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
urea	0	O
,	0	O
restored	0	O
promoter	0	O
-	0	O
directed	0	O
initiation	0	O
activity	0	O
to	0	O
pol	0	B
II	0	I
delta	0	I
4	0	I
/	0	I
7	0	I
.	0	O


Recent	0	O
studies	0	O
have	0	O
shown	0	O
that	0	O
the	0	O
Src	1	B
homology	0	I
-	0	I
2	0	I
(	0	O
SH2	0	B
)	0	O
domain	0	O
-	0	O
containing	0	O
protein	0	B
-	0	I
tyrosine	0	I
phosphatase	0	I
,	0	O
SHP	0	B
-	0	I
2	0	I
,	0	O
associates	0	O
with	0	O
the	0	O
cytoplasmic	0	O
domain	0	O
of	0	O
PECAM	0	B
-	0	I
1	0	I
as	0	O
it	0	O
becomes	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
during	0	O
platelet	0	O
aggregation	0	O
:	0	O
a	0	O
process	0	O
that	0	O
can	0	O
be	0	O
mimicked	0	O
in	0	O
part	0	O
by	0	O
small	0	O
synthetic	0	O
phosphopeptides	0	O
corresponding	0	O
to	0	O
the	0	O
cytoplasmic	0	O
domain	0	O
of	0	O
PECAM	0	B
-	0	I
1	0	I
encompassing	0	O
tyrosine	0	O
residues	0	O
Tyr	1	O
-	0	O
663	0	O
or	0	O
Tyr	1	O
-	0	O
686	0	O
.	0	O


Serum	1	B
alkaline	0	I
phosphatase	0	I
activity	0	O
,	0	O
bone	0	O
mass	0	O
measurements	0	O
,	0	O
dual	0	O
energy	0	O
x	0	O
-	0	O
ray	0	O
absortiometric	0	O
analysis	0	O
of	0	O
mineral	0	O
density	0	O
,	0	O
and	0	O
mechanical	0	O
testing	0	O
values	0	O
in	0	O
vertebrae	0	O
and	0	O
femora	0	O
of	0	O
the	0	O
-	0	O
D	1	O
Sal	1	O
animals	0	O
did	0	O
not	0	O
significantly	0	O
differ	0	O
from	0	O
those	0	O
in	0	O
+	0	O
D	1	O
Sal	1	O
animals	0	O
.	0	O


The	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
S	1	O
.	0	O
aureus	0	O
peptide	0	O
carrying	0	O
the	0	O
phosphoryl	0	O
group	0	O
was	0	O
found	0	O
to	0	O
be	0	O
Gln	1	O
-	0	O
Val	1	O
-	0	O
Val	1	O
-	0	O
Ser	1	O
-	0	O
Thr	1	O
-	0	O
Phe	1	O
-	0	O
Met	1	O
-	0	O
Gly	1	O
-	0	O
Asn	1	O
-	0	O
Gly	1	O
-	0	O
Leu	1	O
-	0	O
Ala	1	O
-	0	O
Ile	1	O
-	0	O
Pro	1	O
-	0	O
His	1	O
-	0	O
Gly	1	O
-	0	O
Thr	1	O
-	0	O
Asp	1	O
-	0	O
Asp	1	O
.	0	O


Taken	0	O
together	0	O
,	0	O
our	0	O
data	0	O
suggest	0	O
that	0	O
the	0	O
antagonistic	0	O
effects	0	O
of	0	O
CRP	1	B
and	0	O
KdgR	0	B
on	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
pectinolysis	0	B
genes	0	I
occur	0	O
by	0	O
different	0	O
mechanisms	0	O
,	0	O
including	0	O
direct	0	O
competition	0	O
between	0	O
the	0	O
two	0	O
regulators	0	O
or	0	O
between	0	O
the	0	O
repressor	0	O
and	0	O
RNA	1	B
polymerase	0	I
for	0	O
the	0	O
occupation	0	O
of	0	O
a	0	O
common	0	O
DNA	1	O
region	0	O
on	0	O
the	0	O
target	0	O
genes	0	O
.	0	O


A	1	O
combined	0	O
series	0	O
of	0	O
patients	0	O
experienced	0	O
a	0	O
TOL	0	O
after	0	O
two	0	O
or	0	O
more	0	O
previous	0	O
cesarean	0	O
deliveries	0	O
;	0	O
the	0	O
rate	0	O
of	0	O
vaginal	0	O
delivery	0	O
was	0	O
66	0	O
%,	0	O
and	0	O
there	0	O
was	0	O
virtually	0	O
no	0	O
morbidity	0	O
.	0	O


Halothane	1	O
is	0	O
metabolized	0	O
by	0	O
an	0	O
oxidative	0	O
pathway	0	O
to	0	O
stable	0	O
,	0	O
nonvolatile	0	O
end	0	O
products	0	O
,	0	O
trifluoroacetic	0	O
acid	0	O
(	0	O
TFAA	0	O
)	0	O
and	0	O
bromide	0	O
(	0	O
Br	1	O
-),	0	O
and	0	O
by	0	O
reductive	0	O
pathways	0	O
to	0	O
Br	1	O
-	0	O
and	0	O
inorganic	0	O
fluoride	0	O
(	0	O
F	1	O
-).	0	O


These	0	O
findings	0	O
suggest	0	O
that	0	O
a	0	O
range	0	O
of	0	O
microenvironmental	0	O
conditions	0	O
exist	0	O
within	0	O
purified	0	O
water	0	O
systems	0	O
,	0	O
leading	0	O
to	0	O
variable	0	O
populations	0	O
of	0	O
bacteria	0	O
.	0	O


Functional	1	O
postnatal	0	O
development	0	O
of	0	O
the	0	O
rat	0	O
primary	0	O
visual	0	O
cortex	0	O
and	0	O
the	0	O
role	0	O
of	0	O
visual	0	O
experience	0	O
:	0	O
dark	0	O
rearing	0	O
and	0	O
monocular	0	O
deprivation	0	O
.	0	O


Nor	1	O
is	0	O
such	0	O
adjustment	0	O
possible	0	O
unless	0	O
one	0	O
posits	0	O
a	0	O
model	0	O
that	0	O
relates	0	O
the	0	O
missing	0	O
observations	0	O
to	0	O
other	0	O
observed	0	O
information	0	O
for	0	O
each	0	O
subject	0	O
-	0	O
models	0	O
that	0	O
are	0	O
inherently	0	O
untestable	0	O
.	0	O


Oestrogen	0	O
implant	0	O
overdose	0	O
.	0	O


Angiographic	1	O
work	0	O
-	0	O
up	0	O
in	0	O
a	0	O
patient	0	O
with	0	O
late	0	O
vaginal	0	O
metastasis	0	O
from	0	O
a	0	O
renal	0	O
carcinoma	0	O
.	0	O


Mus81p	0	B
also	0	O
shares	0	O
homology	0	O
with	0	O
motifs	0	O
found	0	O
in	0	O
the	0	O
XPF	0	B
endonuclease	0	I
superfamily	0	I
.	0	O


Molecular	1	O
characterization	0	O
and	0	O
expression	0	O
of	0	O
the	0	O
Erwinia	1	B
carotovora	0	I
hrpNEcc	0	I
gene	0	I
,	0	O
which	0	O
encodes	0	O
an	0	O
elicitor	0	O
of	0	O
the	0	O
hypersensitive	0	O
reaction	0	O
.	0	O


The	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
protein	0	O
in	0	O
the	0	O
region	0	O
of	0	O
the	0	O
specificity	0	O
pocket	0	O
is	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
S	1	B
.	0	I
griseus	0	I
proteases	0	I
A	1	I
,	0	I
B	1	I
,	0	I
and	0	I
C	1	I
.	0	O


CDNA	1	O
cloning	0	O
of	0	O
chick	0	B
brain	0	I
alpha	0	I
-	0	I
amino	0	I
-	0	I
3	0	I
-	0	I
hydroxy	0	I
-	0	I
5	0	I
-	0	I
methyl	0	I
-	0	I
4	0	I
-	0	I
isoxazolepropionic	0	I
acid	0	I
receptors	0	I
reveals	0	O
conservation	0	O
of	0	O
structure	0	O
,	0	O
function	0	O
and	0	O
post	0	O
-	0	O
transcriptional	0	O
processes	0	O
with	0	O
mammalian	0	O
receptors	0	O
.	0	O


In	1	O
lean	0	O
mice	0	O
,	0	O
the	0	O
fat	0	O
/	0	O
water	0	O
intensity	0	O
ratio	0	O
was	0	O
about	0	O
1	0	O
:	0	O
4	0	O
,	0	O
about	0	O
half	0	O
that	0	O
in	0	O
normal	0	O
mice	0	O
.	0	O


Multistep	0	O
transformation	0	O
by	0	O
defined	0	O
fragments	0	O
of	0	O
herpes	0	O
simplex	0	O
virus	0	O
type	0	O
2	0	O
DNA	1	O
:	0	O
oncogenic	0	O
region	0	O
and	0	O
its	0	O
gene	0	O
product	0	O
.	0	O


PM	1	O
12	0	O
or	0	O
18	0	O
mg	0	O
/	0	O
kg	0	O
daily	0	O
plus	0	O
a	0	O
standard	0	O
dose	0	O
of	0	O
SB	1	O
for	0	O
21	0	O
days	0	O
was	0	O
statistically	0	O
more	0	O
effective	0	O
than	0	O
SB	1	O
in	0	O
producing	0	O
a	0	O
final	0	O
cure	0	O
for	0	O
patients	0	O
with	0	O
VL	1	O
in	0	O
Bihar	0	O
,	0	O
India	0	O
.	0	O


Pseudomonas	1	O
aeruginosa	0	O
strains	0	O
infecting	0	O
patients	0	O
with	0	O
cystic	0	O
fibrosis	0	O
(	0	O
CF	1	O
)	0	O
acquire	0	O
a	0	O
mucoid	0	O
phenotype	0	O
due	0	O
to	0	O
overproduction	0	O
of	0	O
alginate	0	O
.	0	O


Conservative	1	O
treatment	0	O
of	0	O
bladder	0	O
carcinoma	0	O
by	0	O
partial	0	O
cystectomy	0	O
and	0	O
interstitial	0	O
iridium	0	O
192	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
at	0	O
steady	0	O
state	0	O
the	0	O
timing	0	O
of	0	O
a	0	O
light	0	O
meal	0	O
is	0	O
unlikely	0	O
to	0	O
alter	0	O
in	0	O
any	0	O
clinically	0	O
important	0	O
manner	0	O
the	0	O
pharmacokinetics	0	O
of	0	O
nifedipine	0	O
released	0	O
from	0	O
'	0	O
biphasic	0	O
'	0	O
tablets	0	O
.	0	O


In	1	O
most	0	O
subjects	0	O
,	0	O
markers	0	O
of	0	O
bone	0	O
formation	0	O
and	0	O
resorption	0	O
were	0	O
normal	0	O
.	0	O


An	1	O
E	1	O
box	0	O
element	0	O
is	0	O
required	0	O
for	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
ad4bp	0	B
gene	0	I
,	0	O
a	0	O
mammalian	0	B
homologue	0	I
of	0	I
ftz	0	I
-	0	I
f1	0	I
gene	0	I
,	0	O
which	0	O
is	0	O
essential	0	O
for	0	O
adrenal	0	O
and	0	O
gonadal	0	O
development	0	O
.	0	O


Antimicrobial	1	O
substance	0	O
isolated	0	O
from	0	O
an	0	O
acorn	0	O
extract	0	O
.	0	O


The	0	O
dorsal	0	O
nerves	0	O
of	0	O
the	0	O
penis	0	O
were	0	O
anesthetized	0	O
bilaterally	0	O
with	0	O
lidocaine	0	O
.	0	O


Transformation	1	O
blocks	0	O
differentiation	0	O
-	0	O
induced	0	O
inhibition	0	O
of	0	O
serum	0	B
response	0	I
factor	0	I
interactions	0	O
with	0	O
serum	0	O
response	0	O
elements	0	O
.	0	O


Results	0	O
were	0	O
supported	0	O
by	0	O
the	0	O
agar	0	O
diffusion	0	O
method	0	O
for	0	O
Y	1	O
.	0	O
enterocolitica	0	O
,	0	O
whereas	0	O
inhibition	0	O
activity	0	O
was	0	O
not	0	O
found	0	O
for	0	O
A	1	O
.	0	O
hydrophila	0	O
.	0	O


Km	1	O
and	0	O
Vmax	1	O
for	0	O
two	0	O
substrates	0	O
,	0	O
src	0	B
-	0	I
related	0	I
peptide	0	I
and	0	O
poly	0	O
(	0	O
Glu	1	O
,	0	O
Tyr	1	O
)	0	O
(	0	O
4	0	O
:	0	O
1	0	O
),	0	O
were	0	O
2	0	O
.	0	O
4	0	O
mM	1	O
and	0	O
2	0	O
.	0	O
5	0	O
mumol	0	O
min	0	O
-	0	O
1	0	O
mg	0	O
-	0	O
1	0	O
and	0	O
0	0	O
.	0	O
26	0	O
mM	1	O
and	0	O
1	0	O
.	0	O
2	0	O
mumol	0	O
min	0	O
-	0	O
1	0	O
mg	0	O
-	0	O
1	0	O
,	0	O
respectively	0	O
.	0	O


Altogether	0	O
46	0	O
phase	0	O
III	0	O
activities	0	O
were	0	O
recorded	0	O
.	0	O


Sulfuric	0	O
acid	0	O
concentration	0	O
in	0	O
the	0	O
catalyzed	0	O
breathalyzer	0	O
ampules	0	O
.	0	O


Thus	0	O
,	0	O
CHOP	1	B
not	0	O
only	0	O
is	0	O
a	0	O
negative	0	O
or	0	O
a	0	O
positive	0	O
regulator	0	O
of	0	O
C	1	B
/	0	I
EBP	1	I
target	0	O
genes	0	O
but	0	O
also	0	O
,	0	O
when	0	O
tethered	0	O
to	0	O
AP	1	B
-	0	I
1	0	I
factors	0	I
,	0	O
can	0	O
activate	0	O
AP	1	B
-	0	I
1	0	I
target	0	O
genes	0	O
.	0	O


The	0	O
side	0	O
-	0	O
to	0	O
-	0	O
side	0	O
difference	0	O
was	0	O
statistically	0	O
significant	0	O
at	0	O
EXT	1	O
30	0	O
degrees	0	O
/	0	O
s	0	O
and	0	O
60	0	O
degrees	0	O
/	0	O
s	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


When	0	O
cysteine	0	O
is	0	O
scanned	0	O
through	0	O
the	0	O
helices	0	O
,	0	O
characteristic	0	O
repeating	0	O
patterns	0	O
of	0	O
solvent	0	O
exposure	0	O
and	0	O
burial	0	O
are	0	O
observed	0	O
.	0	O


Five	0	O
-	0	O
year	0	O
survivals	0	O
amounted	0	O
to	0	O
100	0	O
%,	0	O
86	0	O
.	0	O
2	0	O
%,	0	O
59	0	O
.	0	O
4	0	O
%,	0	O
29	0	O
.	0	O
8	0	O
%,	0	O
and	0	O
20	0	O
%	0	O
for	0	O
stages	0	O
I	1	O
,	0	O
II	0	O
,	0	O
III	0	O
,	0	O
IVA	0	O
and	0	O
IVB	0	O
respectively	0	O
.	0	O


Hematopoietic	1	O
system	0	O
in	0	O
streptococcal	0	O
allergy	0	O
.	0	O


The	0	O
two	0	O
drugs	0	O
increase	0	O
the	0	O
rate	0	O
of	0	O
early	0	O
diastolic	0	O
filling	0	O
.	0	O


A	1	O
transformation	0	O
-	0	O
competent	0	O
mutant	0	O
,	0	O
like	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
E5	0	I
protein	0	I
,	0	O
bound	0	O
the	0	O
receptor	0	O
and	0	O
induced	0	O
receptor	0	O
tyrosine	0	O
phosphorylation	0	O
and	0	O
down	0	O
-	0	O
regulation	0	O
.	0	O


Abp1	0	B
preferentially	0	O
binds	0	O
to	0	O
multiple	0	O
sites	0	O
in	0	O
ARS	1	B
3002	0	I
and	0	O
to	0	O
the	0	O
DNA	1	O
polymer	0	O
poly	0	O
[	0	O
d	0	O
(	0	O
A	1	O
.	0	O
T	1	O
)].	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
BOX	1	O
DNA	1	O
enhances	0	O
transcription	0	O
from	0	O
the	0	O
thymidine	0	B
kinase	0	I
(	0	O
TK	1	B
)	0	O
promoter	0	O
in	0	O
various	0	O
EC	1	O
cells	0	O
.	0	O


Overexpression	1	O
of	0	O
CARP	1	B
in	0	O
cardiomyocytes	0	O
suppresses	0	O
cardiac	0	B
troponin	0	I
C	1	I
and	0	O
atrial	0	B
natriuretic	0	I
factor	0	I
transcription	0	O
.	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
we	0	O
show	0	O
that	0	O
,	0	O
like	0	O
BAP2	0	B
,	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
BAP3	0	B
gene	0	I
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
is	0	O
induced	0	O
by	0	O
the	0	O
addition	0	O
of	0	O
branched	0	O
-	0	O
chain	0	O
amino	0	O
acids	0	O
to	0	O
the	0	O
medium	0	O
.	0	O


HL	1	B
-	0	I
A	1	I
antibodies	0	I
in	0	O
polytransfused	0	O
patients	0	O


Comparison	0	O
of	0	O
the	0	O
p50	0	B
sequence	0	I
to	0	O
other	0	O
cloned	0	O
proteins	0	O
revealed	0	O
89	0	O
%	0	O
homology	0	O
with	0	O
a	0	O
glycosaminoglycan	0	O
-	0	O
binding	0	O
protein	0	O
and	0	O
54	0	O
%	0	O
homology	0	O
with	0	O
Drosophila	1	B
cell	0	I
cycle	0	I
control	0	I
protein	0	I
(	0	I
cdc	0	I
)	0	I
37	0	O
.	0	O


Stable	1	O
patients	0	O
have	0	O
mucous	0	O
hypersecretion	0	O
and	0	O
little	0	O
evidence	0	O
of	0	O
acute	0	O
inflammation	0	O
.	0	O


(	0	O
5	0	O
)	0	O
An	1	O
increase	0	O
in	0	O
leukocyte	0	O
-	0	O
counts	0	O
occurred	0	O
on	0	O
the	0	O
administration	0	O
of	0	O
serum	0	O
obtained	0	O
from	0	O
rabbit	0	O
during	0	O
phase	0	O
-	0	O
2	0	O
.	0	O


The	0	O
sequence	0	O
of	0	O
monkey	0	B
opsin	0	I
closely	0	O
resembles	0	O
the	0	O
human	0	O
sequence	0	O
at	0	O
the	0	O
nucleotide	0	O
and	0	O
the	0	O
amino	0	O
acid	0	O
levels	0	O
,	0	O
with	0	O
the	0	O
latter	0	O
having	0	O
only	0	O
7	0	O
differences	0	O
out	0	O
of	0	O
348	0	O
residues	0	O
.	0	O


Areas	0	O
with	0	O
significantly	0	O
greater	0	O
rCBF	1	O
for	0	O
targeting	0	O
were	0	O
the	0	O
left	0	O
motor	0	O
cortex	0	O
,	0	O
left	0	O
intraparietal	0	O
sulcus	0	O
,	0	O
and	0	O
left	0	O
caudate	0	O
.	0	O


When	0	O
O2	1	O
therapy	0	O
was	0	O
controlled	0	O
for	0	O
,	0	O
the	0	O
association	0	O
between	0	O
RBT	0	O
and	0	O
RLF	1	O
did	0	O
not	0	O
achieve	0	O
statistical	0	O
significance	0	O
(	0	O
P	1	O
=	0	O
.	0	O
07	0	O
).	0	O


A	1	O
flow	0	O
rate	0	O
of	0	O
at	0	O
least	0	O
5	0	O
mL	1	O
/	0	O
h	0	O
is	0	O
required	0	O
through	0	O
the	0	O
receptor	0	O
(	0	O
volume	0	O
,	0	O
0	0	O
.	0	O
4	0	O
mL	1	O
)	0	O
for	0	O
accurate	0	O
results	0	O
.	0	O


Electrophoretic	1	O
mobility	0	O
shift	0	O
assays	0	O
with	0	O
each	0	O
of	0	O
these	0	O
sequences	0	O
demonstrated	0	O
complexes	0	O
with	0	O
mobilities	0	O
identical	0	O
to	0	O
those	0	O
of	0	O
the	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
site	0	I
from	0	O
the	0	O
kappa	0	B
light	0	I
-	0	I
chain	0	I
gene	0	I
.	0	O


The	0	O
cis	0	O
-	0	O
acting	0	O
regulatory	0	O
properties	0	O
of	0	O
an	0	O
872	0	O
bp	0	O
promoter	0	O
fragment	0	O
of	0	O
a	0	O
B	1	O
.	0	O
napus	0	O
oleosin	0	B
gene	0	I
were	0	O
examined	0	O
by	0	O
analysis	0	O
of	0	O
beta	0	B
-	0	I
glucuronidase	0	I
(	0	O
GUS	0	B
)	0	O
expression	0	O
in	0	O
transgenic	0	O
tobacco	0	O
plants	0	O
containing	0	O
an	0	O
oleosin	0	B
promoter	0	I
-	0	O
GUS	0	B
transcriptional	0	O
fusion	0	O
.	0	O


Cyclophilins	0	B
are	0	O
cis	0	B
-	0	I
trans	0	I
-	0	I
peptidyl	0	I
-	0	I
prolyl	0	I
isomerases	0	I
that	0	O
bind	0	O
to	0	O
and	0	O
are	0	O
inhibited	0	O
by	0	O
the	0	O
immunosuppressant	0	O
cyclosporin	0	O
A	1	O
(	0	O
CsA	0	O
).	0	O


15	0	O
,	0	O
2500	0	O
-	0	O
2508	0	O
;	0	O
O	1	O
'	0	O
Neill	0	O
,	0	O
T	1	O
.	0	O


Thus	0	O
,	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
active	0	B
S	1	I
-	0	I
CDKs	0	I
and	0	O
Dbf4	0	B
/	0	O
Cdc7	0	B
,	0	O
Mcms	0	B
may	0	O
open	0	O
origins	0	O
and	0	O
thereby	0	O
facilitate	0	O
the	0	O
loading	0	O
of	0	O
RPA	0	B
.	0	O


NH2	0	O
-	0	O
and	0	O
COOH	0	O
-	0	O
terminal	0	O
deletion	0	O
analysis	0	O
revealed	0	O
that	0	O
both	0	O
the	0	O
PH	1	B
and	0	O
putative	0	O
guanine	0	B
nucleotide	0	I
exchange	0	I
factor	0	I
domains	0	I
are	0	O
required	0	O
,	0	O
but	0	O
the	0	O
zinc	0	O
butterfly	0	O
is	0	O
dispensable	0	O
,	0	O
for	0	O
transformation	0	O
.	0	O


Significant	1	O
increases	0	O
in	0	O
mean	0	O
serum	0	O
E2	1	O
concentration	0	O
(	0	O
100	0	O
to	0	O
150	0	O
pg	0	O
/	0	O
ml	0	O
)	0	O
were	0	O
noted	0	O
at	0	O
6	0	O
and	0	O
8	0	O
hours	0	O
after	0	O
administration	0	O
on	0	O
day	0	O
1	0	O
and	0	O
at	0	O
8	0	O
hours	0	O
on	0	O
day	0	O
4	0	O
.	0	O


RESULTS	0	O
:	0	O
Factors	0	O
associated	0	O
with	0	O
significantly	0	O
(	0	O
P	1	O
<.	0	O
05	0	O
)	0	O
increased	0	O
risk	0	O
of	0	O
treatment	0	O
failure	0	O
in	0	O
a	0	O
Cox	1	O
multivariate	0	O
analysis	0	O
included	0	O
age	0	O
older	0	O
than	0	O
45	0	O
years	0	O
(	0	O
relative	0	O
hazard	0	O
,	0	O
1	0	O
.	0	O
17	0	O
;	0	O
95	0	O
%	0	O
confidence	0	O
interval	0	O
[	0	O
CI	1	O
],	0	O
1	0	O
.	0	O
02	0	O
-	0	O
1	0	O
.	0	O
33	0	O
),	0	O
Karnofsky	0	O
performance	0	O
score	0	O
less	0	O
than	0	O
90	0	O
%	0	O
(	0	O
1	0	O
.	0	O
27	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
1	0	O
.	0	O
07	0	O
-	0	O
1	0	O
.	0	O
51	0	O
),	0	O
absence	0	O
of	0	O
hormone	0	O
receptors	0	O
(	0	O
1	0	O
.	0	O
31	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
1	0	O
.	0	O
15	0	O
-	0	O
1	0	O
.	0	O
51	0	O
),	0	O
prior	0	O
use	0	O
of	0	O
adjuvant	0	O
chemotherapy	0	O
(	0	O
1	0	O
.	0	O
31	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
1	0	O
.	0	O
10	0	O
-	0	O
1	0	O
.	0	O
56	0	O
),	0	O
initial	0	O
disease	0	O
-	0	O
free	0	O
survival	0	O
interval	0	O
after	0	O
adjuvant	0	O
treatment	0	O
of	0	O
no	0	O
more	0	O
than	0	O
18	0	O
months	0	O
(	0	O
1	0	O
.	0	O
99	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
1	0	O
.	0	O
62	0	O
-	0	O
2	0	O
.	0	O
43	0	O
),	0	O
metastases	0	O
in	0	O
the	0	O
liver	0	O
(	0	O
1	0	O
.	0	O
47	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
1	0	O
.	0	O
20	0	O
-	0	O
1	0	O
.	0	O
80	0	O
)	0	O
or	0	O
central	0	O
nervous	0	O
system	0	O
(	0	O
1	0	O
.	0	O
56	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
0	0	O
.	0	O
99	0	O
-	0	O
2	0	O
.	0	O
46	0	O
[	0	O
approaches	0	O
significance	0	O
])	0	O
vs	0	O
soft	0	O
tissue	0	O
,	0	O
bone	0	O
,	0	O
or	0	O
lung	0	O
,	0	O
3	0	O
or	0	O
more	0	O
sites	0	O
of	0	O
metastatic	0	O
disease	0	O
(	0	O
1	0	O
.	0	O
32	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
1	0	O
.	0	O
13	0	O
-	0	O
1	0	O
.	0	O
54	0	O
),	0	O
and	0	O
incomplete	0	O
response	0	O
vs	0	O
complete	0	O
response	0	O
to	0	O
standard	0	O
-	0	O
dose	0	O
chemotherapy	0	O
(	0	O
1	0	O
.	0	O
65	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
,	0	O
1	0	O
.	0	O
36	0	O
-	0	O
1	0	O
.	0	O
99	0	O
).	0	O


GTRE	0	O
,	0	O
TRE	0	O
,	0	O
and	0	O
CRE	0	O
oligonucleotides	0	O
all	0	O
compete	0	O
more	0	O
efficiently	0	O
for	0	O
protein	0	O
binding	0	O
to	0	O
their	0	O
labeled	0	O
congeners	0	O
than	0	O
for	0	O
protein	0	O
binding	0	O
to	0	O
either	0	O
of	0	O
the	0	O
other	0	O
labeled	0	O
oligonucleotides	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
GTRE	0	O
,	0	O
TRE	0	O
,	0	O
and	0	O
CRE	0	O
oligonucleotides	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
GTRE	0	O
,	0	O
TRE	0	O
,	0	O
and	0	O
CRE	0	O
oligonucleotides	0	O
each	0	O
bind	0	O
unique	0	O
as	0	O
well	0	O
as	0	O
common	0	O
proteins	0	O
,	0	O
likely	0	O
to	0	O
be	0	O
members	0	O
of	0	O
the	0	O
Jun	1	B
/	0	O
Fos	1	B
and	0	O
cAMP	1	B
-	0	I
responsive	0	I
element	0	I
-	0	I
binding	0	I
protein	0	I
/	0	O
activating	0	B
transcription	0	I
factors	0	I
(	0	O
CREB	0	B
/	0	O
ATF	0	B
)	0	O
families	0	O
of	0	O
transcription	0	O
factors	0	O
,	0	O
in	0	O
chromaffin	0	O
cells	0	O
.	0	O


A	1	O
thermal	0	O
Kubo	0	O
-	0	O
Martin	0	O
-	0	O
Schwinger	0	O
condition	0	O
arises	0	O
due	0	O
to	0	O
the	0	O
coupling	0	O
of	0	O
a	0	O
computer	0	O
to	0	O
a	0	O
strong	0	O
periodic	0	O
source	0	O
,	0	O
namely	0	O
,	0	O
the	0	O
daily	0	O
and	0	O
weekly	0	O
usage	0	O
patterns	0	O
of	0	O
the	0	O
system	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
circulating	0	O
platelet	0	O
aggregates	0	O
and	0	O
elevated	0	O
levels	0	O
of	0	O
fibrinopeptide	0	B
A	1	I
(	0	O
a	0	O
cleavage	0	O
product	0	O
of	0	O
fibrin	0	B
)	0	O
suggests	0	O
that	0	O
platelet	0	O
activation	0	O
and	0	O
fibrin	0	B
deposition	0	O
may	0	O
play	0	O
a	0	O
role	0	O
in	0	O
the	0	O
pathogenesis	0	O
of	0	O
this	0	O
disorder	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
six	0	O
arginine	0	O
mutations	0	O
of	0	O
oxidative	0	O
phosphorylation	0	O
and	0	O
AAC	0	B
expression	0	O
.	0	O


However	0	O
,	0	O
little	0	O
is	0	O
known	0	O
regarding	0	O
the	0	O
genomic	0	O
organization	0	O
and	0	O
developmental	0	O
expression	0	O
of	0	O
the	0	O
caveolin	0	B
gene	0	I
family	0	I
.	0	O


T4	1	O
and	0	O
FT4I	0	O
followed	0	O
parallel	0	O
courses	0	O
in	0	O
both	0	O
groups	0	O
;	0	O
during	0	O
the	0	O
first	0	O
45	0	O
days	0	O
,	0	O
however	0	O
,	0	O
the	0	O
values	0	O
were	0	O
significantly	0	O
lower	0	O
in	0	O
premature	0	O
infants	0	O
under	0	O
34	0	O
weeks	0	O
'	0	O
EGA	0	O
than	0	O
in	0	O
term	0	O
infants	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


Effect	1	O
of	0	O
the	0	O
methods	0	O
of	0	O
cutaneous	0	O
administration	0	O
of	0	O
methyl	0	O
isobutyl	0	O
ketone	0	O
on	0	O
its	0	O
toxicity	0	O


To	1	O
elucidate	0	O
the	0	O
regulatory	0	O
mechanism	0	O
of	0	O
human	0	B
AM	1	I
gene	0	I
expression	0	O
,	0	O
functional	0	O
elements	0	O
of	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
AM	1	B
gene	0	I
were	0	O
studied	0	O
in	0	O
human	0	O
aortic	0	O
endothelial	0	O
cells	0	O
(	0	O
HAEC	0	O
).	0	O


An	1	O
abundant	0	O
1	0	O
.	0	O
1	0	O
-	0	O
kb	0	O
virion	0	O
-	0	O
sense	0	O
polyadenylated	0	O
RNA	1	O
and	0	O
four	0	O
complementary	0	O
-	0	O
sense	0	O
polyadenylated	0	O
RNAs	0	O
of	0	O
1	0	O
.	0	O
7	0	O
,	0	O
1	0	O
.	0	O
5	0	O
,	0	O
1	0	O
.	0	O
3	0	O
,	0	O
and	0	O
0	0	O
.	0	O
7	0	O
kb	0	O
have	0	O
been	0	O
identified	0	O
by	0	O
northern	0	O
blot	0	O
hybridization	0	O
,	0	O
confirming	0	O
the	0	O
bidirectional	0	O
transcription	0	O
strategy	0	O
implied	0	O
by	0	O
the	0	O
arrangement	0	O
of	0	O
ORFs	0	O
.	0	O


Mutating	0	O
the	0	O
Fcp1p	0	B
-	0	O
binding	0	O
motif	0	O
KEFGK	0	O
in	0	O
the	0	O
RAP74	0	B
(	0	O
Tfg1p	0	B
)	0	O
subunit	0	O
of	0	O
TFIIF	0	B
to	0	O
EEFGE	0	O
led	0	O
to	0	O
both	0	O
synthetic	0	O
phenotypes	0	O
in	0	O
certain	0	O
fcp1	0	B
tfg1	0	I
double	0	O
mutants	0	O
and	0	O
a	0	O
reduced	0	O
ability	0	O
of	0	O
Fcp1p	0	B
to	0	O
activate	0	O
transcription	0	O
when	0	O
it	0	O
is	0	O
artificially	0	O
tethered	0	O
to	0	O
a	0	O
promoter	0	O
.	0	O


As	1	O
shown	0	O
previously	0	O
,	0	O
EBNA2	0	B
transactivates	0	O
the	0	O
promoters	0	O
of	0	O
the	0	O
viral	0	B
latent	0	I
membrane	0	I
proteins	0	I
.	0	O


Electron	1	O
microscopic	0	O
picture	0	O
of	0	O
the	0	O
cerebral	0	O
cortex	0	O
in	0	O
rats	0	O
cooled	0	O
to	0	O
22	0	O
degrees	0	O
C	1	O


The	0	O
Ras	1	B
-	0	I
related	0	I
GTPases	0	I
are	0	O
small	0	O
,	0	O
20	0	O
-	0	O
to	0	O
25	0	O
-	0	O
kDa	1	O
proteins	0	O
which	0	O
cycle	0	O
between	0	O
an	0	O
inactive	0	O
GDP	1	O
-	0	O
bound	0	O
form	0	O
and	0	O
an	0	O
active	0	O
GTP	1	O
-	0	O
bound	0	O
state	0	O
.	0	O


HEF1	0	B
,	0	O
p130	0	B
(	0	O
Cas	1	B
),	0	O
and	0	O
Efs	0	B
/	0	O
Sin	0	B
constitute	0	O
a	0	O
family	0	O
of	0	O
multidomain	0	O
docking	0	O
proteins	0	O
that	0	O
have	0	O
been	0	O
implicated	0	O
in	0	O
coordinating	0	O
the	0	O
regulation	0	O
of	0	O
cell	0	O
adhesion	0	O
.	0	O


After	0	O
hemodynamic	0	O
stabilization	0	O
,	0	O
the	0	O
goal	0	O
of	0	O
therapy	0	O
is	0	O
to	0	O
diminish	0	O
the	0	O
chance	0	O
that	0	O
an	0	O
ulcer	0	O
will	0	O
continue	0	O
to	0	O
bleed	0	O
or	0	O
will	0	O
rebleed	0	O
.	0	O


Combined	0	O
intravenous	0	O
and	0	O
intra	0	O
-	0	O
arterial	0	O
recombinant	0	O
tissue	0	B
plasminogen	0	I
activator	0	I
in	0	O
acute	0	O
ischemic	0	O
stroke	0	O
.	0	O


Beta	1	B
-	0	I
endorphin	0	I
,	0	O
ACTH	1	B
and	0	O
cortisol	0	O
secretion	0	O
were	0	O
measured	0	O
in	0	O
twelve	0	O
healthy	0	O
adult	0	O
males	0	O
after	0	O
nasal	0	O
spray	0	O
administration	0	O
200	0	O
IU	1	O
salmon	0	B
calcitonin	0	I
.	0	O


Surprisingly	0	O
,	0	O
calf	0	B
thymus	0	I
CstF	0	I
contained	0	O
an	0	O
additional	0	O
,	0	O
novel	0	O
form	0	O
of	0	O
the	0	O
64	0	O
-	0	O
kDa	1	O
subunit	0	O
with	0	O
a	0	O
molecular	0	O
mass	0	O
of	0	O
70	0	O
kDa	1	O
.	0	O


The	0	O
effects	0	O
of	0	O
coenzyme	0	O
Q10	1	O
(	0	O
CoQ	0	O
)	0	O
and	0	O
captopril	0	O
on	0	O
functional	0	O
capacity	0	O
,	0	O
hemodynamics	0	O
and	0	O
survival	0	O
were	0	O
studied	0	O
in	0	O
154	0	O
rats	0	O
that	0	O
recovered	0	O
after	0	O
experimental	0	O
myocardial	0	O
infarction	0	O
.	0	O


One	0	O
hundred	0	O
fifty	0	O
patients	0	O
were	0	O
reviewed	0	O
at	0	O
1	0	O
year	0	O
after	0	O
arthroplasty	0	O
.	0	O


Suppression	1	O
of	0	O
food	0	O
intake	0	O
in	0	O
the	0	O
rat	0	O
by	0	O
tung	0	O
oil	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
REP21	0	O
plants	0	O
were	0	O
resistant	0	O
to	0	O
an	0	O
unusually	0	O
broad	0	O
range	0	O
of	0	O
tobamoviruses	0	O
including	0	O
tomato	0	O
mosaic	0	O
virus	0	O
,	0	O
tobacco	0	O
mild	0	O
green	0	O
mosaic	0	O
virus	0	O
,	0	O
TMV	0	O
-	0	O
U5	0	O
,	0	O
green	0	O
tomato	0	O
atypical	0	O
mosaic	0	O
virus	0	O
,	0	O
and	0	O
ribgrass	0	O
mosaic	0	O
virus	0	O
.	0	O


Mucin	1	B
gene	0	I
expression	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
altered	0	O
in	0	O
many	0	O
intestinal	0	O
diseases	0	O
and	0	O
especially	0	O
cancers	0	O
of	0	O
the	0	O
gastrointestinal	0	O
tract	0	O
.	0	O


In	1	O
the	0	O
duodenum	0	O
a	0	O
small	0	O
part	0	O
of	0	O
the	0	O
administered	0	O
dose	0	O
was	0	O
transformed	0	O
to	0	O
3H	0	O
-	0	O
alpha	0	O
-	0	O
acetyldigoxin	0	O
.	0	O


Nevertheless	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
the	0	O
entire	0	O
three	0	O
-	0	O
component	0	O
yeast	0	O
capping	0	O
apparatus	0	O
,	0	O
consisting	0	O
of	0	O
RNA	1	B
5	0	I
'-	0	I
triphosphatase	0	I
(	0	O
Cet1p	0	B
),	0	O
RNA	1	B
guanylyltransferase	0	I
(	0	O
Ceg1p	0	B
),	0	O
and	0	O
Abd1p	0	B
could	0	O
be	0	O
replaced	0	O
in	0	O
vivo	0	O
by	0	O
the	0	O
two	0	O
-	0	O
component	0	O
mammalian	0	O
apparatus	0	O
consisting	0	O
of	0	O
a	0	O
bifunctional	0	O
triphosphatase	0	B
-	0	I
guanylyltransferase	0	I
Mce1p	0	I
and	0	O
the	0	O
methyltransferase	0	B
Hcm1	0	I
(	0	I
121	0	I
-	0	I
476	0	I
)	0	I
p	0	I
.	0	O


The	0	O
c	0	B
-	0	I
myc	0	I
/	0	O
TGF	1	B
-	0	I
alpha	0	I
HCCs	0	O
were	0	O
also	0	O
characterized	0	O
by	0	O
a	0	O
particularly	0	O
strong	0	O
expression	0	O
of	0	O
TGF	1	B
-	0	I
alpha	0	I
and	0	O
very	0	O
low	0	O
apoptotic	0	O
index	0	O
in	0	O
contrast	0	O
to	0	O
high	0	O
levels	0	O
of	0	O
apoptosis	0	O
in	0	O
peritumorous	0	O
tissues	0	O
and	0	O
c	0	B
-	0	I
myc	0	I
HCCs	0	O
.	0	O


Bile	1	O
bilirubin	0	O
did	0	O
not	0	O
rise	0	O
within	0	O
12	0	O
h	0	O
after	0	O
haem	0	O
infusion	0	O
a	0	O
finding	0	O
which	0	O
warrants	0	O
further	0	O
investigation	0	O
.	0	O


Identification	1	O
,	0	O
purification	0	O
,	0	O
and	0	O
molecular	0	O
cloning	0	O
of	0	O
autonomously	0	B
replicating	0	I
sequence	0	I
-	0	I
binding	0	I
protein	0	I
1	0	I
from	0	I
fission	0	I
yeast	0	I
Schizosaccharomyces	0	I
pombe	0	I
.	0	O


The	0	O
experimental	0	O
group	0	O
consisted	0	O
of	0	O
61	0	O
examinees	0	O
class	0	O
II	0	O
/	0	O
2	0	O
orthodontic	0	O
anomalies	0	O
.	0	O


Fourteen	0	O
different	0	O
species	0	O
(	0	O
eight	0	O
Platyhelmintha	0	O
,	0	O
one	0	O
Nematoda	1	O
and	0	O
five	0	O
Crustacea	1	O
)	0	O
have	0	O
been	0	O
inventorized	0	O
.	0	O


The	0	O
ability	0	O
of	0	O
U6	0	B
-	0	O
U57	0	B
mutants	0	O
to	0	O
influence	0	O
the	0	O
fidelity	0	O
of	0	O
both	0	O
branch	0	O
site	0	O
and	0	O
3	0	O
'	0	O
splice	0	O
site	0	O
recognition	0	O
suggests	0	O
that	0	O
this	0	O
nucleotide	0	O
may	0	O
participate	0	O
in	0	O
the	0	O
formation	0	O
of	0	O
the	0	O
active	0	O
site	0	O
(	0	O
s	0	O
)	0	O
of	0	O
the	0	O
spliceosome	0	O
.	0	O


J	1	O
.	0	O


During	0	O
latency	0	O
,	0	O
more	0	O
than	0	O
1	0	O
%	0	O
of	0	O
neurons	0	O
in	0	O
ganglia	0	O
that	0	O
innervate	0	O
the	0	O
footpad	0	O
expressed	0	O
beta	0	B
-	0	I
galactosidase	0	I
,	0	O
with	0	O
the	0	O
number	0	O
of	0	O
positive	0	O
cells	0	O
remaining	0	O
constant	0	O
for	0	O
at	0	O
least	0	O
5	0	O
months	0	O
.	0	O


The	0	O
fracture	0	O
groups	0	O
were	0	O
significantly	0	O
older	0	O
and	0	O
had	0	O
more	0	O
years	0	O
since	0	O
menopause	0	O
than	0	O
the	0	O
control	0	O
groups	0	O
.	0	O


TSA	1	O
treatment	0	O
,	0	O
however	0	O
,	0	O
did	0	O
not	0	O
detectably	0	O
alter	0	O
enhancer	0	O
factor	0	O
binding	0	O
or	0	O
the	0	O
positioning	0	O
of	0	O
nuc	0	B
-	0	I
1	0	I
on	0	O
the	0	O
majority	0	O
of	0	O
the	0	O
chromatin	0	O
templates	0	O
indicating	0	O
that	0	O
protein	0	O
acetylation	0	O
and	0	O
chromatin	0	O
remodeling	0	O
may	0	O
be	0	O
limiting	0	O
steps	0	O
that	0	O
occur	0	O
only	0	O
on	0	O
transcriptionally	0	O
competent	0	O
templates	0	O
,	0	O
or	0	O
that	0	O
remodeling	0	O
of	0	O
nuc	0	B
-	0	I
1	0	I
requires	0	O
additional	0	O
factors	0	O
.	0	O


R	1	O
.	0	O


Dual	0	O
radionuclide	0	O
subtraction	0	O
imaging	0	O
of	0	O
the	0	O
spleen	0	O
using	0	O
67Ga	0	O
citrate	0	O
and	0	O
99mTc	0	O
is	0	O
useful	0	O
in	0	O
further	0	O
delineating	0	O
lesions	0	O
that	0	O
are	0	O
identified	0	O
on	0	O
either	0	O
a	0	O
routine	0	O
radiogallium	0	O
survey	0	O
or	0	O
on	0	O
a	0	O
conventional	0	O
sulfur	0	O
colloid	0	O
liver	0	O
-	0	O
spleen	0	O
image	0	O
.	0	O


Wave	1	O
cybernetics	0	O
:	0	O
A	1	O
simple	0	O
model	0	O
of	0	O
wave	0	O
-	0	O
controlled	0	O
nonlinear	0	O
and	0	O
nonlocal	0	O
cooperative	0	O
phenomena	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
proportion	0	O
of	0	O
nonsynonymous	0	O
(	0	O
pN	0	O
)	0	O
and	0	O
synonymous	0	O
(	0	O
pS	1	O
)	0	O
substitutions	0	O
occurring	0	O
per	0	O
site	0	O
within	0	O
tamarin	0	B
variable	0	I
region	0	I
genes	0	I
demonstrated	0	O
a	0	O
reduction	0	O
in	0	O
pN	0	O
in	0	O
the	0	O
framework	0	O
regions	0	O
compared	0	O
with	0	O
pN	0	O
in	0	O
the	0	O
presumed	0	O
MHC	1	B
contact	0	I
regions	0	I
(	0	O
CDR1	0	B
and	0	O
CDR2	0	B
).	0	O


Kodak	0	O
XV	0	O
-	0	O
2	0	O
film	0	O
is	0	O
wrapped	0	O
around	0	O
a	0	O
cylindrical	0	O
water	0	O
-	0	O
filled	0	O
phantom	0	O
and	0	O
the	0	O
dose	0	O
distribution	0	O
is	0	O
recorded	0	O
.	0	O


We	0	O
postulate	0	O
that	0	O
CaM	1	B
binding	0	O
by	0	O
HIV	1	B
envelope	0	I
proteins	0	I
is	0	O
likely	0	O
to	0	O
exert	0	O
diverse	0	O
modulatory	0	O
effects	0	O
,	0	O
and	0	O
the	0	O
mechanism	0	O
for	0	O
HIV	1	O
-	0	O
induced	0	O
cytotoxicity	0	O
may	0	O
involve	0	O
,	0	O
in	0	O
part	0	O
,	0	O
inhibition	0	O
of	0	O
CaM	1	B
-	0	O
regulated	0	O
cellular	0	O
functions	0	O
.	0	O


The	0	O
FMN	1	O
moiety	0	O
but	0	O
not	0	O
the	0	O
[	0	O
3Fe	0	O
-	0	O
4S	0	O
]	0	O
cluster	0	O
of	0	O
the	0	O
subunit	0	O
appears	0	O
to	0	O
participate	0	O
in	0	O
this	0	O
reaction	0	O
.	0	O


Thus	0	O
,	0	O
Sir	0	B
proteins	0	I
from	0	O
K	1	O
.	0	O
lactis	0	O
have	0	O
roles	0	O
in	0	O
both	0	O
silencing	0	O
and	0	O
telomere	0	O
length	0	O
maintenance	0	O
,	0	O
reflecting	0	O
conserved	0	O
functional	0	O
themes	0	O
.	0	O


A	1	O
total	0	O
of	0	O
57	0	O
patients	0	O
with	0	O
Hodgkin	0	O
'	0	O
s	0	O
disease	0	O
limited	0	O
to	0	O
above	0	O
the	0	O
diaphragm	0	O
(	0	O
Stages	0	O
I	1	O
and	0	O
II	0	O
,	0	O
A	1	O
and	0	O
B	1	O
)	0	O
were	0	O
treated	0	O
with	0	O
radiation	0	O
therapy	0	O
alone	0	O
at	0	O
the	0	O
University	0	O
of	0	O
Florida	0	O
between	0	O
1964	0	O
and	0	O
1974	0	O
.	0	O


Involvement	0	O
of	0	O
early	0	B
growth	0	I
response	0	I
factor	0	I
Egr	0	I
-	0	I
1	0	I
in	0	O
apolipoprotein	0	B
AI	1	I
gene	0	I
transcription	0	O
.	0	O


Editorial	0	O
:	0	O
Low	0	O
-	0	O
dose	0	O
heparin	0	O
and	0	O
the	0	O
prevention	0	O
of	0	O
venous	0	O
thromboembolic	0	O
disease	0	O
.	0	O


Only	0	O
seven	0	O
patients	0	O
,	0	O
five	0	O
of	0	O
whom	0	O
have	0	O
metastatic	0	O
disease	0	O
,	0	O
survive	0	O
more	0	O
than	0	O
10	0	O
years	0	O
after	0	O
first	0	O
presentation	0	O
;	0	O
nine	0	O
patients	0	O
,	0	O
one	0	O
of	0	O
whom	0	O
has	0	O
secondaries	0	O
,	0	O
survive	0	O
for	0	O
5	0	O
years	0	O
or	0	O
less	0	O
.	0	O


MSSPs	0	B
are	0	O
believed	0	O
to	0	O
regulate	0	O
DNA	1	O
replication	0	O
,	0	O
transcription	0	O
,	0	O
apopotosis	0	O
and	0	O
cell	0	O
cycle	0	O
progression	0	O
by	0	O
interacting	0	O
with	0	O
the	0	O
C	1	B
-	0	I
MYC	0	I
protein	0	I
.	0	O


In	1	O
two	0	O
further	0	O
cases	0	O
(	0	O
one	0	O
type	0	O
I	1	O
and	0	O
one	0	O
type	0	O
III	0	O
SMA	1	O
),	0	O
de	0	O
novo	0	O
deletions	0	O
of	0	O
only	0	O
one	0	O
copy	0	O
of	0	O
Ag1	0	B
-	0	I
CA	1	I
and	0	O
C212	0	B
were	0	O
found	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
a	0	O
6	0	O
.	0	O
3	0	O
-	0	O
kbp	0	O
genomic	0	O
EcoRI	0	B
-	0	O
fragment	0	O
of	0	O
Alcaligenes	1	O
eutrophus	0	O
,	0	O
which	0	O
was	0	O
recently	0	O
identified	0	O
by	0	O
using	0	O
a	0	O
dihydrolipoamide	0	B
dehydrogenase	0	I
-	0	O
specific	0	O
DNA	1	O
probe	0	O
(	0	O
A	1	O
.	0	O


Previously	0	O
,	0	O
we	0	O
characterized	0	O
a	0	O
DNA	1	O
-	0	O
binding	0	O
protein	0	O
,	0	O
HS2NF5	0	B
,	0	O
that	0	O
bound	0	O
tightly	0	O
to	0	O
a	0	O
conserved	0	O
region	0	O
within	0	O
hypersensitive	0	O
site	0	O
2	0	O
(	0	O
HS2	0	O
)	0	O
of	0	O
the	0	O
human	0	B
beta	0	I
-	0	I
globin	0	I
locus	0	I
control	0	I
region	0	I
(	0	O
LCR	1	O
)	0	O
(	0	O
Lam	1	O
,	0	O
L	1	O
.	0	O


For	0	O
this	0	O
reason	0	O
,	0	O
the	0	O
particle	0	O
forming	0	O
capacity	0	O
of	0	O
derivatives	0	O
of	0	O
the	0	O
HIV	1	B
-	0	I
1	0	I
group	0	I
specific	0	I
core	0	I
antigen	0	I
p55	0	I
gag	0	I
was	0	O
assayed	0	O
and	0	O
compared	0	O
dependent	0	O
on	0	O
various	0	O
expression	0	O
systems	0	O
:	0	O
recombinant	0	O
bacteria	0	O
,	0	O
vaccinia	0	O
-	0	O
and	0	O
baculoviruses	0	O
were	0	O
established	0	O
encoding	0	O
the	0	O
entire	0	O
core	0	B
protein	0	I
p55	0	I
either	0	O
in	0	O
its	0	O
authentic	0	O
sequence	0	O
or	0	O
lacking	0	O
the	0	O
myristylation	0	O
consensus	0	O
signal	0	O
.	0	O


The	0	O
subjects	0	O
of	0	O
the	0	O
study	0	O
were	0	O
10	0	O
normal	0	O
subjects	0	O
and	0	O
64	0	O
patients	0	O
with	0	O
gastroduodenal	0	O
disease	0	O
.	0	O


Galphaq	0	B
,	0	O
Galpha12	0	B
,	0	O
and	0	O
Galpha13	0	B
,	0	O
but	0	O
not	0	O
Galphai	0	B
,	0	O
activate	0	O
SRF	1	B
through	0	O
RhoA	0	B
.	0	O


Working	0	O
session	0	O
report	0	O
:	0	O
in	0	O
vivo	0	O
-	0	O
in	0	O
vitro	0	O
screening	0	O
.	0	O


Nonreplicating	0	O
vaccinia	0	O
vector	0	O
efficiently	0	O
expresses	0	O
recombinant	0	O
genes	0	O
.	0	O


DNA	1	O
blot	0	O
hybridization	0	O
suggests	0	O
that	0	O
the	0	O
rat	0	O
genome	0	O
may	0	O
contain	0	O
more	0	O
than	0	O
one	0	O
gene	0	O
encoding	0	O
PtdIns	0	B
transfer	0	I
protein	0	I
.	0	O


Pneumonia	1	O
in	0	O
children	0	O


The	0	O
yeast	0	B
LPD1	0	I
gene	0	I
encoding	0	O
lipoamide	0	B
dehydrogenase	0	I
is	0	O
subject	0	O
to	0	O
the	0	O
general	0	O
control	0	O
of	0	O
amino	0	O
acid	0	O
biosynthesis	0	O
mediated	0	O
by	0	O
the	0	O
GCN4	0	B
transcription	0	I
factor	0	I
.	0	O


Dosage	1	O
in	0	O
both	0	O
cases	0	O
was	0	O
0	0	O
.	0	O
2	0	O
g	0	O
/	0	O
m2	0	O
.	0	O


The	0	O
diagnosis	0	O
of	0	O
metachromatic	0	O
leukodystrophy	0	O
(	0	O
MLD	1	O
)	0	O
was	0	O
confirmed	0	O
by	0	O
the	0	O
finding	0	O
of	0	O
low	0	O
arylsulfatase	0	B
A	1	I
(	0	O
ASA	1	B
)	0	O
levels	0	O
in	0	O
cultured	0	O
fibroblasts	0	O
in	0	O
both	0	O
sisters	0	O
.	0	O


Corticosteroid	1	O
therapy	0	O
is	0	O
known	0	O
to	0	O
be	0	O
hazardous	0	O
in	0	O
patients	0	O
with	0	O
occult	0	O
infection	0	O
but	0	O
the	0	O
mechanism	0	O
by	0	O
which	0	O
the	0	O
host	0	O
parasite	0	O
relationship	0	O
is	0	O
altered	0	O
by	0	O
steroids	0	O
is	0	O
not	0	O
known	0	O
.	0	O
We	0	O
have	0	O
used	0	O
an	0	O
intestinal	0	O
protozoal	0	O
parasite	0	O
,	0	O
Giardia	1	O
muris	0	O
,	0	O
to	0	O
examine	0	O
the	0	O
effects	0	O
of	0	O
corticosteroids	0	O
on	0	O
the	0	O
number	0	O
of	0	O
parasites	0	O
in	0	O
the	0	O
intestine	0	O
in	0	O
the	0	O
course	0	O
of	0	O
a	0	O
primary	0	O
infection	0	O
.	0	O


Over	0	O
-	0	O
expression	0	O
of	0	O
Azf1p	0	B
in	0	O
the	0	O
yeast	0	O
cell	0	O
does	0	O
not	0	O
influence	0	O
the	0	O
expression	0	O
level	0	O
of	0	O
the	0	O
mitochondrial	0	B
transcription	0	I
factor	0	I
Mtf1p	0	I
,	0	O
indicating	0	O
that	0	O
the	0	O
influence	0	O
of	0	O
Azf1p	0	B
on	0	O
the	0	O
suppression	0	O
of	0	O
the	0	O
special	0	O
mitochondrial	0	B
RNA	1	I
polymerase	0	I
mutant	0	I
is	0	O
an	0	O
indirect	0	O
one	0	O
.	0	O


One	0	O
P1	1	O
genomic	0	O
clone	0	O
and	0	O
six	0	O
subsequent	0	O
plasmid	0	O
subclones	0	O
were	0	O
isolated	0	O
and	0	O
analyzed	0	O
for	0	O
the	0	O
exon	0	O
-	0	O
intron	0	O
organization	0	O
of	0	O
the	0	O
Ctpct	0	B
gene	0	I
.	0	O


Haemodilution	0	O
in	0	O
cardiopulmonary	0	O
bypass	0	O
using	0	O
a	0	O
gelatine	0	O
derivative	0	O
for	0	O
priming	0	O
.	0	O


Cotransfection	1	O
of	0	O
Ets	1	B
-	0	I
2	0	I
and	0	O
p44	0	B
mitogen	0	I
-	0	I
activated	0	I
protein	0	I
(	0	I
MAP	1	I
)	0	I
kinase	0	I
expression	0	O
vectors	0	O
strongly	0	O
potentiated	0	O
HB	1	B
-	0	O
EGF	1	B
promoter	0	O
activation	0	O
in	0	O
response	0	O
to	0	O
deltaRaf	0	B
-	0	I
1	0	I
:	0	O
ER	1	B
.	0	O


Epidemiology	1	O
and	0	O
prevention	0	O
of	0	O
hospital	0	O
infections	0	O
in	0	O
the	0	O
Local	1	O
Health	1	O
Unit	1	O
of	0	O
Sassari	0	O
:	0	O
profile	0	O
of	0	O
bacterial	0	O
resistance	0	O
and	0	O
antimicrobial	0	O
agents	0	O
of	0	O
large	0	O
usage	0	O
.	0	O


BRCA1	0	B
,	0	O
a	0	O
familial	0	O
breast	0	O
and	0	O
ovarian	0	O
cancer	0	O
susceptibility	0	O
gene	0	O
encodes	0	O
nuclear	0	O
phosphoproteins	0	O
that	0	O
function	0	O
as	0	O
tumor	0	O
suppressors	0	O
in	0	O
human	0	O
breast	0	O
cancer	0	O
cells	0	O
.	0	O


Acupuncture	1	O
effect	0	O
on	0	O
deep	0	O
receptors	0	O
was	0	O
not	0	O
limited	0	O
to	0	O
one	0	O
point	0	O
but	0	O
within	0	O
a	0	O
certain	0	O
area	0	O
,	0	O
namely	0	O
distant	0	O
effect	0	O
existed	0	O
.	0	O


We	0	O
measured	0	O
serum	0	B
hepatocyte	0	I
growth	0	I
factor	0	I
(	0	O
HGF	1	B
)	0	O
in	0	O
patients	0	O
with	0	O
acute	0	O
myocardial	0	O
infarction	0	O
,	0	O
angina	0	O
pectoris	0	O
,	0	O
and	0	O
other	0	O
heart	0	O
diseases	0	O
.	0	O


The	0	O
position	0	O
,	0	O
transcription	0	O
orientation	0	O
,	0	O
and	0	O
imprinted	0	O
status	0	O
of	0	O
the	0	O
genes	0	O
immediately	0	O
flanking	0	O
Igf2r	0	B
have	0	O
been	0	O
assessed	0	O
.	0	O


Also	0	O
,	0	O
the	0	O
anti	0	O
-	0	O
inflammatory	0	O
activities	0	O
of	0	O
an	0	O
aqueous	0	O
extract	0	O
of	0	O
Buddleia	0	O
cordata	0	O
and	0	O
its	0	O
principal	0	O
glycoside	0	O
linarin	0	O
were	0	O
evaluated	0	O
.	0	O


The	0	O
alpha	0	O
7A	0	O
form	0	O
RNA	1	O
contains	0	O
an	0	O
additional	0	O
113	0	O
nucleotides	0	O
compared	0	O
to	0	O
the	0	O
B	1	O
form	0	O
,	0	O
and	0	O
a	0	O
common	0	O
coding	0	O
region	0	O
in	0	O
the	0	O
A	1	O
and	0	O
B	1	O
form	0	O
RNAs	0	O
is	0	O
used	0	O
in	0	O
alternate	0	O
reading	0	O
frames	0	O
.	0	O


Mg2	0	O
+	0	O
and	0	O
Mn2	0	O
+	0	O
compete	0	O
for	0	O
binding	0	O
sites	0	O
,	0	O
with	0	O
the	0	O
former	0	O
having	0	O
lower	0	O
affinity	0	O
.	0	O


In	1	O
ischemic	0	O
and	0	O
hypoxic	0	O
hypoxia	0	O
,	0	O
a	0	O
strong	0	O
correlation	0	O
was	0	O
found	0	O
between	0	O
cyt	0	O
a	0	O
,	0	O
a3	0	O
oxidation	0	O
level	0	O
and	0	O
VO2	1	O
in	0	O
both	0	O
ischemic	0	O
and	0	O
hypoxic	0	O
hypoxia	0	O
(	0	O
r2	0	O
=.	0	O
90	0	O
and	0	O
.	0	O
87	0	O
,	0	O
respectively	0	O
).	0	O


Here	0	O
we	0	O
demonstrate	0	O
that	0	O
the	0	O
protein	0	O
product	0	O
of	0	O
the	0	O
ref	0	B
-	0	I
1	0	I
gene	0	I
stimulates	0	O
the	0	O
DNA	1	O
binding	0	O
activity	0	O
of	0	O
Fos	1	B
-	0	O
Jun	1	B
heterodimers	0	O
,	0	O
Jun	1	B
-	0	O
Jun	1	B
homodimers	0	O
and	0	O
Hela	0	O
cell	0	O
AP	1	B
-	0	I
1	0	I
proteins	0	I
as	0	O
well	0	O
as	0	O
that	0	O
of	0	O
several	0	O
other	0	O
transcription	0	O
factors	0	O
including	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
,	0	O
Myb	0	B
and	0	O
members	0	O
of	0	O
the	0	O
ATF	0	B
/	0	O
CREB	0	B
family	0	O
.	0	O


16	0	O
women	0	O
were	0	O
treated	0	O
with	0	O
methadone	0	O
to	0	O
prevent	0	O
withdrawal	0	O
symptoms	0	O
.	0	O


Fenoldopam	0	O
,	0	O
a	0	O
dopamine	0	B
receptor	0	I
agonist	0	O
,	0	O
has	0	O
been	0	O
shown	0	O
,	0	O
in	0	O
animal	0	O
experiments	0	O
,	0	O
to	0	O
improve	0	O
renal	0	O
perfusion	0	O
.	0	O


These	0	O
incisors	0	O
were	0	O
studied	0	O
by	0	O
scanning	0	O
electron	0	O
microscopy	0	O
-	0	O
energy	0	O
dispersive	0	O
spectroscopy	0	O
analysis	0	O
(	0	O
SEM	0	O
-	0	O
EDS	0	O
)	0	O
and	0	O
light	0	O
microscopy	0	O
to	0	O
examine	0	O
the	0	O
calciotraumatic	0	O
lines	0	O
of	0	O
strontium	0	O
in	0	O
the	0	O
rat	0	O
incisor	0	O
labial	0	O
dentin	0	O
.	0	O


CONCLUSION	0	O
:	0	O
The	0	O
alpha2	0	O
-	0	O
adrenergic	0	O
antagonist	0	O
idazoxan	0	O
increases	0	O
glucose	0	O
-	0	O
induced	0	O
sympathetic	0	O
activity	0	O
but	0	O
not	0	O
energy	0	O
expenditure	0	O
in	0	O
obese	0	O
subjects	0	O
.	0	O


Protamine	1	B
and	0	O
heparin	0	O
doses	0	O
,	0	O
their	0	O
sum	0	O
(	0	O
Sigma	1	O
-	0	O
dose	0	O
)	0	O
and	0	O
differential	0	O
(	0	O
Delta	1	O
-	0	O
dose	0	O
)	0	O
doses	0	O
,	0	O
and	0	O
activated	0	O
clotting	0	O
times	0	O
were	0	O
tabulated	0	O
.	0	O


Receptor	1	B
protein	0	I
tyrosine	0	I
phosphatases	0	I
(	0	O
RPTPs	0	B
)	0	O
comprise	0	O
a	0	O
family	0	O
of	0	O
proteins	0	O
that	0	O
feature	0	O
intracellular	0	O
phosphatase	0	O
domains	0	O
and	0	O
an	0	O
ectodomain	0	O
with	0	O
putative	0	O
ligand	0	O
-	0	O
binding	0	O
motifs	0	O
.	0	O


Antisense	1	O
transcription	0	O
of	0	O
a	0	O
murine	0	B
FGFR	0	I
-	0	I
3	0	I
psuedogene	0	I
during	0	O
fetal	0	O
developement	0	O
.	0	O


Intron	1	O
-	0	O
exon	0	O
structure	0	O
of	0	O
the	0	O
porcine	0	B
I	1	I
kappa	0	I
B	1	I
alpha	0	I
-	0	I
encoding	0	I
gene	0	I
.	0	O


Promoter	1	O
elements	0	O
include	0	O
an	0	O
atypical	0	O
TATA	0	O
box	0	O
(	0	O
GTTA	0	O
),	0	O
one	0	O
CCAAT	0	O
box	0	O
much	0	O
further	0	O
from	0	O
the	0	O
initiation	0	O
site	0	O
,	0	O
three	0	O
reverse	0	O
compliments	0	O
of	0	O
CCAAT	0	O
(	0	O
ATTGG	0	O
),	0	O
and	0	O
two	0	O
pyrimidine	0	O
-	0	O
rich	0	O
nucleotide	0	O
stretches	0	O
.	0	O


Campomelic	0	O
dysplasia	0	O
translocation	0	O
breakpoints	0	O
are	0	O
scattered	0	O
over	0	O
1	0	O
Mb	1	O
proximal	0	O
to	0	O
SOX9	0	B
:	0	O
evidence	0	O
for	0	O
an	0	O
extended	0	O
control	0	O
region	0	O
.	0	O


The	0	O
next	0	O
twenty	0	O
years	0	O
of	0	O
prevention	0	O
in	0	O
Indian	0	O
country	0	O
:	0	O
visionary	0	O
,	0	O
complex	0	O
,	0	O
and	0	O
practical	0	O
.	0	O


Upstream	1	O
activation	0	O
sites	0	O
of	0	O
the	0	O
CYC1	0	B
gene	0	I
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
are	0	O
active	0	O
when	0	O
inverted	0	O
but	0	O
not	0	O
when	0	O
placed	0	O
downstream	0	O
of	0	O
the	0	O
"	0	O
TATA	0	O
box	0	O
".	0	O


Transcriptional	1	O
control	0	O
of	0	O
a	0	O
nuclear	0	O
gene	0	O
encoding	0	O
a	0	O
mitochondrial	0	O
fatty	0	O
acid	0	O
oxidation	0	O
enzyme	0	O
in	0	O
transgenic	0	O
mice	0	O
:	0	O
role	0	O
for	0	O
nuclear	0	O
receptors	0	O
in	0	O
cardiac	0	O
and	0	O
brown	0	O
adipose	0	O
expression	0	O
.	0	O


Out	0	O
of	0	O
40	0	O
patients	0	O
,	0	O
who	0	O
initially	0	O
did	0	O
not	0	O
show	0	O
eye	0	O
complications	0	O
due	0	O
to	0	O
leprosy	0	O
,	0	O
37	0	O
patients	0	O
were	0	O
essentially	0	O
the	0	O
same	0	O
10	0	O
years	0	O
later	0	O
.	0	O


Competition	1	O
EMSA	0	O
established	0	O
that	0	O
constitutively	0	O
expressed	0	O
nuclear	0	O
proteins	0	O
bound	0	O
the	0	O
KCS	0	B
element	0	I
selectively	0	O
;	0	O
KCS	0	B
protein	0	I
binding	0	O
activity	0	O
correlated	0	O
with	0	O
promoter	0	O
activity	0	O
in	0	O
the	0	O
transient	0	O
transfection	0	O
reporter	0	O
assay	0	O
.	0	O


In	1	O
memory	0	O
of	0	O
Magdelaine	0	O
Comtesse	0	O


No	1	O
difference	0	O
in	0	O
elastin	0	B
peptide	0	I
concentration	0	O
was	0	O
observed	0	O
between	0	O
emphysematous	0	O
patients	0	O
and	0	O
control	0	O
subjects	0	O
(	0	O
mean	0	O
+/-	0	O
SD	1	O
=	0	O
2	0	O
.	0	O
39	0	O
+/-	0	O
1	0	O
.	0	O
18	0	O
micrograms	0	O
/	0	O
ml	0	O
in	0	O
patients	0	O
versus	0	O
2	0	O
.	0	O
55	0	O
+/-	0	O
1	0	O
.	0	O
34	0	O
micrograms	0	O
/	0	O
ml	0	O
in	0	O
policemen	0	O
and	0	O
2	0	O
.	0	O
59	0	O
+/-	0	O
1	0	O
.	0	O
20	0	O
micrograms	0	O
/	0	O
ml	0	O
in	0	O
coal	0	O
miners	0	O
).	0	O


All	1	O
patients	0	O
with	0	O
deterioriation	0	O
in	0	O
mental	0	O
status	0	O
showed	0	O
a	0	O
marked	0	O
increase	0	O
in	0	O
liver	0	O
enzymes	0	O
(	0	O
aspartate	0	B
and	0	I
alanine	0	I
aminotransaminases	0	I
)	0	O
and	0	O
severe	0	O
coagulopathy	0	O
.	0	O


A	1	O
mutant	0	O
(	0	O
residues	0	O
1	0	O
-	0	O
332	0	O
)	0	O
showed	0	O
complete	0	O
Ca2	1	O
+/	0	O
CaM	1	B
-	0	O
dependent	0	O
activity	0	O
.	0	O


Because	0	O
the	0	O
Pit	1	B
-	0	I
1	0	I
sites	0	I
in	0	O
the	0	O
hGH	1	B
-	0	I
N	1	I
gene	0	I
promoter	0	I
are	0	O
insufficient	0	O
for	0	O
such	0	O
gene	0	O
activation	0	O
in	0	O
vivo	0	O
,	0	O
these	0	O
data	0	O
suggested	0	O
a	0	O
unique	0	O
chromatin	0	O
-	0	O
mediated	0	O
developmental	0	O
role	0	O
for	0	O
Pit	1	B
-	0	I
1	0	I
in	0	O
the	0	O
hGH	1	B
LCR	1	I
.	0	O


Envelope	1	O
-	0	O
function	0	O
matching	0	O
conditions	0	O
for	0	O
GaAs	0	O
/(	0	O
Al	1	O
,	0	O
Ga	1	O
)	0	O
As	1	O
heterojunctions	0	O
.	0	O


Demographic	1	O
characteristics	0	O
and	0	O
risk	0	O
factor	0	O
data	0	O
for	0	O
76	0	O
,	0	O
672	0	O
clients	0	O
were	0	O
studied	0	O
to	0	O
characterize	0	O
the	0	O
distribution	0	O
of	0	O
infection	0	O
with	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
(	0	O
HIV	1	O
)	0	O
and	0	O
the	0	O
use	0	O
of	0	O
counseling	0	O
and	0	O
testing	0	O
facilities	0	O
in	0	O
Houston	0	O
,	0	O
Tex	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
identified	0	O
Sp1	0	B
and	0	O
Sp3	0	B
as	0	O
major	0	O
factors	0	O
binding	0	O
to	0	O
the	0	O
Sp1	0	B
sites	0	I
of	0	O
the	0	O
p21	0	B
/	0	O
WAF1	0	B
/	0	O
Cip1	0	B
promoter	0	O
in	0	O
MG63	0	O
cells	0	O
through	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assays	0	O
and	0	O
showed	0	O
that	0	O
TSA	1	O
treatment	0	O
did	0	O
not	0	O
change	0	O
their	0	O
binding	0	O
activities	0	O
.	0	O


Of	0	O
the	0	O
21	0	O
quadrants	0	O
positive	0	O
in	0	O
the	0	O
controls	0	O
,	0	O
17	0	O
were	0	O
correlated	0	O
with	0	O
previously	0	O
detected	0	O
jaw	0	O
pathoses	0	O
.	0	O


These	0	O
motifs	0	O
include	0	O
a	0	O
Chi	1	O
motif	0	O
and	0	O
a	0	O
Chi	1	O
-	0	O
like	0	O
element	0	O
previously	0	O
found	0	O
in	0	O
the	0	O
recombination	0	O
hotspot	0	O
region	0	O
of	0	O
the	0	O
Bcl	0	B
-	0	I
2	0	I
proto	0	I
-	0	I
oncogene	0	I
and	0	O
close	0	O
to	0	O
chromosomal	0	O
breakpoints	0	O
in	0	O
T	1	O
-	0	O
ALL	1	O
lines	0	O
.	0	O


None	0	O
of	0	O
these	0	O
organic	0	O
manifestations	0	O
was	0	O
discovered	0	O
by	0	O
scintigraphic	0	O
means	0	O
.	0	O


CONCLUSION	0	O
:	0	O
During	0	O
chronic	0	O
treatment	0	O
,	0	O
the	0	O
haemodynamic	0	O
response	0	O
to	0	O
oral	0	O
cilazapril	0	O
was	0	O
attenuated	0	O
,	0	O
indicating	0	O
that	0	O
continued	0	O
clinical	0	O
improvement	0	O
in	0	O
patients	0	O
with	0	O
CHF	1	O
on	0	O
CLZ	0	O
is	0	O
independent	0	O
of	0	O
to	0	O
its	0	O
acute	0	O
haemodynamic	0	O
effects	0	O
.	0	O


The	0	O
transposon	0	O
-	0	O
inactivated	0	O
gene	0	O
,	0	O
designated	0	O
pilP	0	B
,	0	O
is	0	O
525	0	O
bp	0	O
long	0	O
,	0	O
potentially	0	O
encoding	0	O
a	0	O
19	0	O
.	0	O
1	0	O
-	0	O
kDa	1	O
protein	0	O
precursor	0	O
that	0	O
contains	0	O
a	0	O
typical	0	O
membrane	0	O
lipoprotein	0	O
leader	0	O
sequence	0	O
.	0	O


Total	0	O
cholesterol	0	O
was	0	O
also	0	O
reduced	0	O
at	0	O
week	0	O
12	0	O
by	0	O
17	0	O
.	0	O
0	0	O
%	0	O
(	0	O
20	0	O
mg	0	O
/	0	O
day	0	O
)	0	O
and	0	O
15	0	O
.	0	O
7	0	O
%	0	O
(	0	O
20	0	O
-	0	O
30	0	O
mg	0	O
/	0	O
day	0	O
),	0	O
and	0	O
at	0	O
week	0	O
52	0	O
by	0	O
20	0	O
.	0	O
4	0	O
%	0	O
(<	0	O
or	0	O
=	0	O
20	0	O
mg	0	O
/	0	O
day	0	O
)	0	O
and	0	O
19	0	O
.	0	O
2	0	O
%	0	O
(>	0	O
or	0	O
=	0	O
30	0	O
mg	0	O
/	0	O
day	0	O
).	0	O


In	1	O
F42A	0	O
-	0	O
stimulated	0	O
internalization	0	O
assays	0	O
on	0	O
forskolin	0	O
-	0	O
induced	0	O
YT	0	O
-	0	O
1	0	O
cells	0	O
,	0	O
the	0	O
IL	1	B
-	0	I
2R	0	I
alpha	0	I
chain	0	I
is	0	O
consistently	0	O
endocytosed	0	O
together	0	O
with	0	O
the	0	O
IL	1	B
-	0	I
2R	0	I
beta	0	I
subunit	0	I
indicating	0	O
that	0	O
IL	1	B
-	0	I
2R	0	I
alpha	0	I
is	0	O
stably	0	O
associated	0	O
with	0	O
the	0	O
F42A	0	B
-	0	I
IL	1	I
-	0	I
2R	0	I
beta	0	I
complex	0	I
even	0	O
though	0	O
the	0	O
alpha	0	O
-	0	O
subunit	0	O
contributes	0	O
little	0	O
if	0	O
any	0	O
affinity	0	O
to	0	O
the	0	O
F42A	0	O
binding	0	O
reaction	0	O
.	0	O


Transfection	1	O
of	0	O
increasing	0	O
amounts	0	O
of	0	O
delta5ERalpha	0	B
expression	0	O
vector	0	O
into	0	O
[	0	O
ERalpha	0	B
+]	0	O
OS	1	O
cells	0	O
resulted	0	O
in	0	O
potentiation	0	O
of	0	O
E2	1	O
-	0	O
stimulated	0	O
ERELuc	0	B
activity	0	O
in	0	O
a	0	O
synergistic	0	O
,	0	O
dose	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


Laser	1	O
therapy	0	O
of	0	O
penile	0	O
carcinoma	0	O


Marker	1	O
rescue	0	O
analysis	0	O
has	0	O
localized	0	O
ts8	0	B
to	0	O
a	0	O
910	0	O
-	0	O
bp	0	O
internal	0	O
segment	0	O
of	0	O
rpoB	0	B
that	0	O
encodes	0	O
the	0	O
Rif	1	B
domain	0	I
.	0	O


Haycocknema	0	O
perplexum	0	O
n	0	O
.	0	O
g	0	O
.,	0	O
n	0	O
.	0	O
sp	0	O
.	0	O


Although	0	O
not	0	O
common	0	O
,	0	O
the	0	O
disorder	0	O
is	0	O
the	0	O
most	0	O
frequently	0	O
diagnosed	0	O
disturbance	0	O
of	0	O
porphyrin	0	O
metabolism	0	O
in	0	O
many	0	O
countries	0	O
,	0	O
and	0	O
further	0	O
insight	0	O
into	0	O
its	0	O
unusual	0	O
pathogenesis	0	O
may	0	O
clarify	0	O
the	0	O
hepatotoxic	0	O
effects	0	O
of	0	O
the	0	O
4	0	O
etiologic	0	O
agents	0	O
.	0	O


The	0	O
defined	0	O
length	0	O
of	0	O
the	0	O
mRNA	1	O
,	0	O
1	0	O
,	0	O
838	0	O
nucleotides	0	O
,	0	O
was	0	O
in	0	O
agreement	0	O
with	0	O
that	0	O
of	0	O
a	0	O
1	0	O
.	0	O
9	0	O
-	0	O
kb	0	O
RNA	1	O
expressed	0	O
throughout	0	O
the	0	O
replication	0	O
cycle	0	O
,	0	O
starting	0	O
at	0	O
the	0	O
early	0	O
stages	0	O
of	0	O
infection	0	O
.	0	O


Estimation	0	O
of	0	O
L	1	O
-	0	O
alanine	0	O
in	0	O
serum	0	O
or	0	O
plasma	0	O
using	0	O
the	0	O
LKB	0	O
reaction	0	O
rate	0	O
analyser	0	O
.	0	O


Problems	0	O
remain	0	O
to	0	O
be	0	O
resolved	0	O
in	0	O
the	0	O
area	0	O
of	0	O
quantitative	0	O
risk	0	O
assessment	0	O
.	0	O


In	1	O
B	1	O
cells	0	O
,	0	O
HEF1	0	B
is	0	O
phosphorylated	0	O
by	0	O
a	0	O
cytoskeleton	0	O
-	0	O
dependent	0	O
mechanism	0	O
that	0	O
is	0	O
triggered	0	O
by	0	O
integrin	0	B
ligation	0	O
.	0	O


Interestingly	0	O
,	0	O
an	0	O
antibody	0	O
against	0	O
N	1	B
-	0	I
SMase	0	I
can	0	O
abrogate	0	O
Ox	1	B
-	0	I
LDL	1	I
-	0	O
and	0	O
TNF	1	B
-	0	I
alpha	0	I
-	0	O
induced	0	O
apoptosis	0	O
and	0	O
therefore	0	O
may	0	O
be	0	O
useful	0	O
for	0	O
in	0	O
vivo	0	O
studies	0	O
of	0	O
apoptosis	0	O
in	0	O
experimental	0	O
animals	0	O
.	0	O


Sci	1	O
.	0	O


The	0	O
effectiveness	0	O
of	0	O
alpha	0	O
-	0	O
mercapto	0	O
-	0	O
beta	0	O
-(	0	O
2	0	O
-	0	O
furyl	0	O
)	0	O
acrylic	0	O
acid	0	O
(	0	O
MFA	0	O
)	0	O
and	0	O
N	1	O
-	0	O
benzyl	0	O
-	0	O
N	1	O
-	0	O
dithiocarboxy	0	O
-	0	O
D	1	O
-	0	O
glucamine	0	O
(	0	O
NaB	0	O
),	0	O
used	0	O
in	0	O
combination	0	O
,	0	O
in	0	O
the	0	O
mobilization	0	O
and	0	O
excretion	0	O
of	0	O
lead	0	O
was	0	O
investigated	0	O
in	0	O
rats	0	O
.	0	O


Strontium	1	O
-	0	O
90	0	O
was	0	O
inject	0	O
i	0	O
.	0	O
v	0	O
.	0	O
into	0	O
pregnant	0	O
rats	0	O
on	0	O
day	0	O
18	0	O
post	0	O
conception	0	O
(	0	O
p	0	O
.	0	O
c	0	O
.).	0	O


These	0	O
results	0	O
demonstrate	0	O
that	0	O
sequences	0	O
in	0	O
the	0	O
SH2	0	B
/	0	O
SH3	0	B
/	0	O
SH2	0	B
region	0	O
of	0	O
p120	0	B
GAP	1	I
are	0	O
required	0	O
for	0	O
full	0	O
catalytic	0	O
activity	0	O
toward	0	O
Ras	1	B
.	0	O


The	0	O
frequency	0	O
of	0	O
previous	0	O
transfusion	0	O
in	0	O
chronic	0	O
hepatitis	0	O
,	0	O
cirrhosis	0	O
and	0	O
hepatocellular	0	O
carcinoma	0	O
of	0	O
type	0	O
NANB	0	O
was	0	O
42	0	O
.	0	O
8	0	O
,	0	O
37	0	O
.	0	O
1	0	O
and	0	O
15	0	O
.	0	O
1	0	O
%,	0	O
respectively	0	O
,	0	O
whereas	0	O
the	0	O
incidence	0	O
of	0	O
early	0	O
posttransfusion	0	O
hepatitis	0	O
was	0	O
8	0	O
.	0	O
5	0	O
,	0	O
8	0	O
.	0	O
6	0	O
and	0	O
7	0	O
.	0	O
5	0	O
%,	0	O
respectively	0	O
.	0	O
in	0	O
chronic	0	O
liver	0	O
diseases	0	O
with	0	O
a	0	O
history	0	O
of	0	O
jaundice	0	O
and	0	O
/	0	O
or	0	O
hepatitis	0	O
,	0	O
previous	0	O
transfusions	0	O
are	0	O
more	0	O
frequently	0	O
associated	0	O
with	0	O
type	0	O
NANB	0	O
than	0	O
with	0	O
type	0	O
B	1	O
disease	0	O
.	0	O


Lithium	1	O
delays	0	O
the	0	O
circadian	0	O
rhythm	0	O
of	0	O
wheel	0	O
-	0	O
running	0	O
in	0	O
Syrian	0	O
hamsters	0	O
at	0	O
plasma	0	O
concentrations	0	O
(	0	O
0	0	O
.	0	O
59	0	O
-	0	O
0	0	O
.	0	O
74	0	O
mM	1	O
)	0	O
that	0	O
also	0	O
cause	0	O
toxic	0	O
weight	0	O
loss	0	O
.	0	O


Two	0	O
mutations	0	O
that	0	O
affect	0	O
larval	0	B
cuticle	0	I
protein	0	I
gene	0	I
expression	0	O
in	0	O
the	0	O
2	0	O
/	0	O
3	0	O
variant	0	O
Drosophila	1	O
melanogaster	0	O
strain	0	O
were	0	O
investigated	0	O
.	0	O


It	1	O
can	0	O
be	0	O
concluded	0	O
that	0	O
in	0	O
normotensive	0	O
subjects	0	O
,	0	O
uric	0	O
acid	0	O
and	0	O
xanthine	0	B
oxidase	0	I
have	0	O
significant	0	O
association	0	O
with	0	O
blood	0	O
pressure	0	O
and	0	O
thus	0	O
are	0	O
one	0	O
of	0	O
the	0	O
many	0	O
factors	0	O
which	0	O
are	0	O
involved	0	O
in	0	O
the	0	O
cause	0	O
or	0	O
effect	0	O
of	0	O
hypertension	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
Rb	1	B
protein	0	I
is	0	O
interacting	0	O
with	0	O
some	0	O
component	0	O
(	0	O
s	0	O
)	0	O
of	0	O
the	0	O
cell	0	O
cycle	0	O
-	0	O
regulatory	0	O
machinery	0	O
during	0	O
G2	0	O
phase	0	O
.	0	O


The	0	O
predominant	0	O
binding	0	O
activity	0	O
was	0	O
not	0	O
Ets	1	B
-	0	I
1	0	I
but	0	O
rather	0	O
two	0	O
independent	0	O
DNA	1	O
-	0	O
protein	0	O
complexes	0	O
that	0	O
comigrated	0	O
in	0	O
mobility	0	O
shift	0	O
assays	0	O
.	0	O


Plasma	1	B
renin	0	I
activity	0	O
rose	0	O
and	0	O
the	0	O
plasma	0	O
aldosterone	0	O
level	0	O
fell	0	O
after	0	O
taking	0	O
lisinopril	0	O
.	0	O


This	0	O
gave	0	O
rise	0	O
to	0	O
RNA	1	O
molecules	0	O
with	0	O
3	0	O
'-	0	O
untranslated	0	O
regions	0	O
of	0	O
roughly	0	O
375	0	O
,	0	O
655	0	O
,	0	O
and	0	O
945	0	O
base	0	O
pairs	0	O
.	0	O


Effect	1	O
of	0	O
trauma	0	O
on	0	O
plasma	0	B
glucagon	0	I
and	0	O
insulin	0	B
concentrations	0	O
in	0	O
sheep	0	O
.	0	O


A	1	O
short	0	O
history	0	O
of	0	O
dermatology	0	O
in	0	O
Lagos	0	O
,	0	O
Nigeria	0	O
.	0	O


The	0	O
nucleotide	0	O
sequence	0	O
of	0	O
the	0	O
region	0	O
upstream	0	O
from	0	O
M	1	B
.	0	I
voltae	0	I
ORFtrpA	0	I
was	0	O
determined	0	O
and	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
an	0	O
ORF	1	O
of	0	O
1227	0	O
nucleotides	0	O
(	0	O
ORFtrpB	0	B
)	0	O
encoding	0	O
a	0	O
409	0	O
amino	0	O
acid	0	O
polypeptide	0	O
of	0	O
mol	0	O
.	0	O
wt	0	O
.	0	O


The	0	O
10	0	O
kDa	1	O
polypeptide	0	O
was	0	O
phosphorylated	0	O
in	0	O
vitro	0	O
by	0	O
incubating	0	O
wheat	0	O
etioplast	0	O
membranes	0	O
with	0	O
[	0	O
gamma	0	O
32P	0	O
]	0	O
ATP	1	O
.	0	O


Re	1	O
-	0	O
examination	0	O
of	0	O
the	0	O
ED01	0	O
study	0	O
.	0	O


A	1	O
major	0	O
task	0	O
for	0	O
sports	0	O
scientists	0	O
may	0	O
be	0	O
to	0	O
verify	0	O
empirically	0	O
the	0	O
nature	0	O
of	0	O
an	0	O
integrated	0	O
model	0	O
of	0	O
the	0	O
sport	0	O
performer	0	O
.	0	O


In	1	O
the	0	O
final	0	O
model	0	O
,	0	O
grade	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
0002	0	O
),	0	O
peritoneal	0	O
cytologic	0	O
results	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
0002	0	O
),	0	O
progesterone	0	B
receptor	0	I
status	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
004	0	O
),	0	O
and	0	O
age	0	O
as	0	O
a	0	O
continuous	0	O
variable	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
008	0	O
)	0	O
were	0	O
most	0	O
closely	0	O
associated	0	O
with	0	O
disease	0	O
-	0	O
free	0	O
survival	0	O
.	0	O


Tightly	0	O
ordered	0	O
proteasomal	0	O
degradation	0	O
of	0	O
proteins	0	O
critical	0	O
for	0	O
cell	0	O
cycle	0	O
control	0	O
implies	0	O
a	0	O
role	0	O
of	0	O
the	0	O
proteasome	0	O
in	0	O
maintaining	0	O
cell	0	O
proliferation	0	O
and	0	O
cell	0	O
survival	0	O
.	0	O


Thiopentone	1	O
sodium	0	O
administered	0	O
at	0	O
30	0	O
and	0	O
10	0	O
min	0	O
before	0	O
or	0	O
5	0	O
,	0	O
10	0	O
and	0	O
15	0	O
min	0	O
after	0	O
exposure	0	O
to	0	O
NOC	0	O
-	0	O
5	0	O
,	0	O
but	0	O
not	0	O
thereafter	0	O
,	0	O
significantly	0	O
attenuated	0	O
NO	1	O
-	0	O
induced	0	O
neurotoxicity	0	O
compared	0	O
with	0	O
controls	0	O
.	0	O


In	1	O
nucleus	0	O
ventralis	0	O
anterior	0	O
thalami	0	O
-	0	O
nucleus	0	O
ventralis	0	O
lateralis	0	O
thalami	0	O
neurons	0	O
with	0	O
an	0	O
inhibitory	0	O
input	0	O
from	0	O
nucleus	0	O
entopeduncularis	0	O
,	0	O
a	0	O
shortening	0	O
of	0	O
inhibition	0	O
from	0	O
17	0	O
.	0	O
5	0	O
+/-	0	O
3	0	O
.	0	O
6	0	O
to	0	O
9	0	O
.	0	O
1	0	O
+/-	0	O
1	0	O
.	0	O
8	0	O
ms	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
under	0	O
the	0	O
haloperidol	0	O
influence	0	O
was	0	O
evident	0	O
.	0	O


The	0	O
PETCO2	1	O
measurement	0	O
during	0	O
precordial	0	O
compression	0	O
predicted	0	O
the	0	O
success	0	O
of	0	O
defibrillation	0	O
with	0	O
return	0	O
of	0	O
spontaneous	0	O
circulation	0	O
.	0	O


A	1	O
promoter	0	O
sequence	0	O
(	0	O
Goldberg	0	O
-	0	O
Hogness	0	O
or	0	O
TATA	0	O
box	0	O
)	0	O
is	0	O
situated	0	O
28	0	O
base	0	O
pairs	0	O
upstream	0	O
from	0	O
the	0	O
point	0	O
of	0	O
initiation	0	O
of	0	O
transcription	0	O
which	0	O
was	0	O
found	0	O
by	0	O
S1	1	B
nuclease	0	I
mapping	0	O
and	0	O
by	0	O
oligonucleotide	0	O
-	0	O
primed	0	O
reverse	0	O
transcription	0	O
of	0	O
rat	0	B
PTH	1	I
mRNA	1	I
.	0	O


The	0	O
C	1	O
-	0	O
terminal	0	O
peptide	0	O
sequences	0	O
of	0	O
the	0	O
human	0	B
lymphocyte	0	I
-	0	I
specific	0	I
high	0	I
mobility	0	I
group	0	I
(	0	I
HMG	1	I
)-	0	I
box	0	I
transcription	0	I
factor	0	I
TCF	0	I
-	0	I
1	0	I
are	0	O
determined	0	O
by	0	O
alternative	0	O
splice	0	O
mechanisms	0	O
affecting	0	O
the	0	O
exons	0	O
VIII	0	O
to	0	O
X	1	O
.	0	O


Transfection	1	O
and	0	O
in	0	O
vitro	0	O
binding	0	O
studies	0	O
identified	0	O
within	0	O
HEFT1	0	B
a	0	I
promoter	0	I
whose	0	O
basal	0	O
activity	0	O
required	0	O
a	0	O
GC	1	O
box	0	O
activated	0	O
by	0	O
Sp1	0	B
or	0	O
Sp3	0	B
.	0	O


The	0	O
methylation	0	O
of	0	O
nuclear	0	O
and	0	O
chloroplast	0	O
DNAs	0	O
has	0	O
been	0	O
examined	0	O
in	0	O
relation	0	O
to	0	O
the	0	O
known	0	O
differential	0	O
expression	0	O
of	0	O
C4	1	B
photosynthesis	0	I
genes	0	I
in	0	O
the	0	O
bundle	0	O
sheath	0	O
and	0	O
mesophyll	0	O
cells	0	O
of	0	O
etiolated	0	O
,	0	O
greening	0	O
,	0	O
and	0	O
fully	0	O
green	0	O
maize	0	O
leaves	0	O
.	0	O


The	0	O
stimulus	0	O
threshold	0	O
for	0	O
EER	0	O
showed	0	O
a	0	O
less	0	O
individual	0	O
variation	0	O
than	0	O
amplitude	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
investigated	0	O
STAT	1	B
activation	0	O
in	0	O
a	0	O
panel	0	O
of	0	O
rodent	0	O
fibroblast	0	O
cell	0	O
lines	0	O
stably	0	O
transformed	0	O
by	0	O
diverse	0	O
viral	0	O
oncoproteins	0	O
.	0	O


These	0	O
findings	0	O
suggest	0	O
that	0	O
the	0	O
increase	0	O
in	0	O
V	1	O
O2	1	O
may	0	O
have	0	O
been	0	O
a	0	O
consequence	0	O
of	0	O
the	0	O
increase	0	O
in	0	O
Q	1	O
O2	1	O
rather	0	O
than	0	O
a	0	O
response	0	O
to	0	O
the	0	O
procedure	0	O
itself	0	O
.	0	O


Stable	1	O
transfection	0	O
of	0	O
the	0	O
truncated	0	O
reduced	0	B
folate	0	I
carrier	0	I
cDNA	1	I
into	0	O
mouse	0	O
L1210	0	O
leukemia	0	O
cells	0	O
:	0	O
increased	0	O
folate	0	O
accumulation	0	O
,	0	O
decreased	0	O
their	0	O
leucovorin	0	O
and	0	O
folic	0	O
acid	0	O
growth	0	O
requirements	0	O
,	0	O
and	0	O
increased	0	O
their	0	O
sensitivity	0	O
to	0	O
methotrexate	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
HAPE	1	O
-	0	O
S	1	O
-	0	O
S	1	O
are	0	O
prone	0	O
to	0	O
irregular	0	O
nocturnal	0	O
breathing	0	O
patterns	0	O
at	0	O
high	0	O
altitude	0	O
,	0	O
which	0	O
is	0	O
associated	0	O
with	0	O
the	0	O
development	0	O
of	0	O
AMS	1	O
,	0	O
but	0	O
it	0	O
was	0	O
not	0	O
possible	0	O
to	0	O
determine	0	O
whether	0	O
these	0	O
abnormal	0	O
breathing	0	O
patterns	0	O
are	0	O
a	0	O
cause	0	O
or	0	O
an	0	O
effect	0	O
of	0	O
AMS	1	O
.	0	O


Each	0	O
group	0	O
received	0	O
15	0	O
ml	0	O
/	0	O
kg	0	O
of	0	O
either	0	O
6	0	O
%	0	O
pentafraction	0	O
,	0	O
6	0	O
%	0	O
pentastarch	0	O
,	0	O
or	0	O
plasma	0	O
followed	0	O
two	0	O
hours	0	O
later	0	O
by	0	O
1	0	O
.	0	O
5	0	O
micrograms	0	O
/	0	O
kg	0	O
/	0	O
0	0	O
.	0	O
5	0	O
hr	0	O
E	1	O
.	0	O


Dotarizine	0	O
produced	0	O
arterial	0	O
dilation	0	O
in	0	O
both	0	O
systemic	0	O
and	0	O
pulmonary	0	O
circulation	0	O
:	0	O
the	0	O
total	0	O
peripheral	0	O
resistance	0	O
dropped	0	O
,	0	O
and	0	O
femoral	0	O
artery	0	O
flow	0	O
rose	0	O
;	0	O
aortic	0	O
and	0	O
pulmonary	0	O
artery	0	O
mean	0	O
and	0	O
diastolic	0	O
pressures	0	O
declined	0	O
,	0	O
and	0	O
systolic	0	O
pressures	0	O
remained	0	O
almost	0	O
stable	0	O
.	0	O


Recent	0	O
target	0	O
BP	1	O
goals	0	O
promulgated	0	O
by	0	O
the	0	O
Sixth	0	O
Report	1	O
from	0	O
the	0	O
Joint	1	O
National	0	O
Committee	0	O
(	0	O
JNC	0	O
VI	0	O
)	0	O
are	0	O
based	0	O
on	0	O
the	0	O
premise	0	O
that	0	O
the	0	O
intensity	0	O
of	0	O
treatment	0	O
directly	0	O
corresponds	0	O
to	0	O
the	0	O
magnitude	0	O
of	0	O
pretreatment	0	O
risk	0	O
.	0	O


Surprisingly	0	O
,	0	O
the	0	O
full	0	O
-	0	O
deletion	0	O
mutant	0	O
showed	0	O
a	0	O
strong	0	O
block	0	O
in	0	O
virus	0	O
release	0	O
,	0	O
suggesting	0	O
that	0	O
NC	0	B
is	0	O
involved	0	O
in	0	O
virus	0	O
assembly	0	O
.	0	O


We	0	O
report	0	O
here	0	O
that	0	O
,	0	O
for	0	O
a	0	O
constant	0	O
amount	0	O
of	0	O
transfected	0	O
DNA	1	O
,	0	O
the	0	O
level	0	O
of	0	O
chloramphenicol	0	B
acetyltransferase	0	I
(	0	O
CAT	1	B
)	0	O
mRNA	1	O
is	0	O
increased	0	O
in	0	O
Vpr	0	B
-	0	O
expressing	0	O
cells	0	O
using	0	O
either	0	O
HIV	1	O
-	0	O
1	0	O
or	0	O
a	0	O
murine	0	O
leukemia	0	B
virus	0	I
(	0	I
MLV	0	I
)	0	I
SL3	0	I
-	0	I
3	0	I
LTR	1	I
-	0	O
CAT	1	B
reporter	0	O
construct	0	O
.	0	O


At	1	O
the	0	O
carboxyl	0	O
terminus	0	O
,	0	O
deletion	0	O
as	0	O
far	0	O
as	0	O
residue	0	O
388	0	O
did	0	O
not	0	O
affect	0	O
in	0	O
vitro	0	O
TRF	0	B
.	0	I
C	1	I
assembly	0	O
,	0	O
although	0	O
trans	0	O
-	0	O
activating	0	O
activity	0	O
was	0	O
abolished	0	O
.	0	O


Palindromic	1	O
rheumatism	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
CRE	0	O
of	0	O
the	0	O
human	0	B
c	0	I
-	0	I
fos	0	I
promoter	0	I
located	0	O
at	0	O
-	0	O
60	0	O
was	0	O
weakly	0	O
induced	0	O
by	0	O
cAMP	1	O
and	0	O
E1a	0	B
in	0	O
both	0	O
HeLa	0	O
and	0	O
PC12	0	O
cells	0	O
.	0	O


Isolation	1	O
of	0	O
a	0	O
temperature	0	O
-	0	O
sensitive	0	O
mutant	0	O
with	0	O
an	0	O
altered	0	O
tRNA	1	B
nucleotidyltransferase	0	I
and	0	O
cloning	0	O
of	0	O
the	0	O
gene	0	B
encoding	0	I
tRNA	1	I
nucleotidyltransferase	0	I
in	0	I
the	0	I
yeast	0	I
Saccharomyces	1	I
cerevisiae	0	I
.	0	O


The	0	O
mean	0	O
values	0	O
of	0	O
the	0	O
concentrations	0	O
of	0	O
the	0	O
components	0	O
due	0	O
to	0	O
tobacco	0	O
smoke	0	O
are	0	O
:	0	O
CO	1	O
=	0	O
1	0	O
.	0	O
1	0	O
ppm	0	O
,	0	O
NO	1	O
=	0	O
32	0	O
ppb	0	O
,	0	O
NO2	0	O
=	0	O
24	0	O
ppb	0	O
,	0	O
nicotine	0	O
=	0	O
0	0	O
.	0	O
9	0	O
micrograms	0	O
/	0	O
m3	0	O
,	0	O
particulate	0	O
matter	0	O
=	0	O
133	0	O
micrograms	0	O
/	0	O
m3	0	O
.	0	O


Combined	0	O
therapy	0	O
with	0	O
MK	1	O
-	0	O
801	0	O
and	0	O
nimodipine	0	O
for	0	O
protection	0	O
of	0	O
ischemic	0	O
brain	0	O
damage	0	O
.	0	O


Characteristics	0	O
of	0	O
anesthesia	0	O
and	0	O
resuscitation	0	O
in	0	O
emergency	0	O
lung	0	O
surgery	0	O


The	0	O
duration	0	O
of	0	O
diabetes	0	O
mellitus	0	O
in	0	O
these	0	O
patients	0	O
was	0	O
from	0	O
5	0	O
months	0	O
to	0	O
6	0	O
years	0	O
,	0	O
and	0	O
in	0	O
all	0	O
patients	0	O
this	0	O
was	0	O
the	0	O
first	0	O
myocardial	0	O
infarction	0	O
.	0	O


Within	0	O
this	0	O
sequence	0	O
the	0	O
MSAS	0	B
gene	0	I
was	0	O
identified	0	O
as	0	O
a	0	O
5322	0	O
-	0	O
bp	0	O
-	0	O
long	0	O
open	0	O
reading	0	O
frame	0	O
coding	0	O
for	0	O
a	0	O
protein	0	O
of	0	O
1774	0	O
amino	0	O
acids	0	O
and	0	O
190	0	O
,	0	O
731	0	O
Da	1	O
molecular	0	O
mass	0	O
.	0	O


No	1	O
systematic	0	O
L	1	O
-	0	O
R	1	O
differences	0	O
were	0	O
observed	0	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
Shh	1	B
can	0	O
drive	0	O
continued	0	O
cycling	0	O
in	0	O
immature	0	O
,	0	O
proliferating	0	O
CGNPs	0	O
.	0	O


Comparison	0	O
of	0	O
sequences	0	O
from	0	O
-	0	O
215	0	O
to	0	O
+	0	O
1	0	O
bp	0	O
identified	0	O
consensus	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
homeodomain	0	B
transcription	0	I
factor	0	I
thyroid	0	I
transcription	0	I
factor	0	I
-	0	I
1	0	I
(	0	O
TTF	0	B
-	0	I
1	0	I
).	0	O


Fourth	0	O
,	0	O
the	0	O
3	0	O
'-	0	O
region	0	O
splice	0	O
junctions	0	O
of	0	O
the	0	O
MSRs	0	B
during	0	O
latent	0	O
and	0	O
productive	0	O
infection	0	O
were	0	O
determined	0	O
by	0	O
sequencing	0	O
RNA	1	O
-	0	O
PCR	1	O
products	0	O
generated	0	O
with	0	O
primers	0	O
that	0	O
flank	0	O
the	0	O
3	0	O
'	0	O
splice	0	O
region	0	O
.	0	O


Data	1	O
from	0	O
119	0	O
men	0	O
and	0	O
40	0	O
women	0	O
undergoing	0	O
coronary	0	O
angiography	0	O
provide	0	O
an	0	O
opportunity	0	O
to	0	O
compare	0	O
these	0	O
associations	0	O
in	0	O
relation	0	O
to	0	O
a	0	O
direct	0	O
and	0	O
continuous	0	O
measure	0	O
of	0	O
atherosclerosis	0	O
while	0	O
controlling	0	O
for	0	O
age	0	O
,	0	O
sex	0	O
,	0	O
income	0	O
,	0	O
hypertension	0	O
,	0	O
serum	0	O
cholesterol	0	O
,	0	O
smoking	0	O
,	0	O
angina	0	O
,	0	O
diabetes	0	O
,	0	O
family	0	O
history	0	O
of	0	O
heart	0	O
disease	0	O
,	0	O
Type	1	O
A	1	O
behavior	0	O
pattern	0	O
,	0	O
and	0	O
hostility	0	O
.	0	O


A	1	O
significant	0	O
herd	0	O
X	1	O
period	0	O
interaction	0	O
existed	0	O
for	0	O
liver	0	O
TG	1	O
and	0	O
serum	0	O
dextran	0	O
precipitable	0	O
cholesterol	0	O
concentrations	0	O
.	0	O


Three	0	O
women	0	O
have	0	O
had	0	O
abnormal	0	O
endocervical	0	O
follow	0	O
up	0	O
cytology	0	O
suggestive	0	O
of	0	O
residual	0	O
disease	0	O
.	0	O


On	1	O
catabolism	0	O
of	0	O
aminoketones	0	O
in	0	O
climacteric	0	O
age	0	O


Using	0	O
the	0	O
polymerase	0	O
chain	0	O
reaction	0	O
,	0	O
Whipple	0	O
-	0	O
specific	0	O
DNA	1	O
fragments	0	O
of	0	O
284	0	O
base	0	O
pairs	0	O
from	0	O
the	0	O
genome	0	O
of	0	O
the	0	O
Whipple	0	O
bacterium	0	O
(	0	O
Tropheryma	1	O
whippelii	0	O
)	0	O
were	0	O
demonstrated	0	O
.	0	O


CONTEXT	0	O
:	0	O
ThinPrep	0	O
,	0	O
AutoPap	1	O
,	0	O
and	0	O
Papnet	0	O
are	0	O
3	0	O
new	0	O
technologies	0	O
that	0	O
increase	0	O
the	0	O
sensitivity	0	O
and	0	O
cost	0	O
of	0	O
cervical	0	O
cancer	0	O
screening	0	O
.	0	O


The	0	O
viral	0	B
oncoprotein	0	I
E1A	0	I
inhibits	0	O
NFAT	0	B
-	0	O
dependent	0	O
transactivation	0	O
in	0	O
a	0	O
p300	0	B
-	0	O
dependent	0	O
manner	0	O
.	0	O


Use	0	O
of	0	O
the	0	O
immunofluorescence	0	O
method	0	O
for	0	O
identification	0	O
of	0	O
enteroviruses	0	O
in	0	O
cell	0	O
cultures	0	O


We	0	O
conclude	0	O
that	0	O
the	0	O
gp54	0	B
structural	0	I
gene	0	I
is	0	O
required	0	O
for	0	O
initiation	0	O
or	0	O
amplification	0	O
of	0	O
the	0	O
splenic	0	O
erythroblast	0	O
hyperplasia	0	O
which	0	O
characterizes	0	O
the	0	O
preleukemic	0	O
phase	0	O
of	0	O
Rauscher	0	O
disease	0	O
.	0	O


In	1	O
early	0	O
Xenopus	1	O
embryos	0	O
,	0	O
the	0	O
transforming	0	B
growth	0	I
factor	0	I
-	0	I
beta	0	I
member	0	O
activin	0	B
induces	0	O
the	0	O
gene	0	B
Mix	1	I
.	0	I
2	0	I
by	0	O
stimulating	0	O
the	0	O
formation	0	O
of	0	O
a	0	O
multiprotein	0	O
complex	0	O
,	0	O
activin	0	B
-	0	I
responsive	0	I
factor	0	I
(	0	O
ARF	1	B
).	0	O


The	0	O
tryptase	0	B
locus	0	I
also	0	O
contains	0	O
at	0	O
least	0	O
four	0	O
tryptase	0	B
-	0	I
like	0	I
pseudogenes	0	I
,	0	O
including	0	O
mastin	0	B
,	0	O
a	0	O
gene	0	O
expressed	0	O
in	0	O
dogs	0	O
but	0	O
not	0	O
in	0	O
humans	0	O
.	0	O


The	0	O
coding	0	O
sequence	0	O
for	0	O
a	0	O
260	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
residue	0	O
polypeptide	0	O
was	0	O
interrupted	0	O
by	0	O
a	0	O
single	0	O
short	0	O
intron	0	O
of	0	O
60	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
),	0	O
and	0	O
about	0	O
70	0	O
%	0	O
of	0	O
the	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
Drosophila	1	B
PCNA	1	I
was	0	O
identical	0	O
to	0	O
the	0	O
rat	0	O
and	0	O
human	0	B
PCNA	1	I
polypeptides	0	I
,	0	O
with	0	O
conserved	0	O
unique	0	O
repeats	0	O
of	0	O
leucine	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
.	0	O


AF154055	0	B
.	0	O


Circulating	0	O
oxytocin	0	B
in	0	O
male	0	O
guinea	0	O
pigs	0	O
affected	0	O
by	0	O
the	0	O
female	0	O
cohabitation	0	O
and	0	O
reproductive	0	O
condition	0	O
.	0	O


Control	1	O
of	0	O
fatty	0	O
liver	0	O
syndrome	0	O
in	0	O
a	0	O
Jersey	0	O
herd	0	O
by	0	O
a	0	O
change	0	O
of	0	O
diet	0	O
and	0	O
the	0	O
use	0	O
of	0	O
recombinant	0	O
bovine	0	O
somatotrophin	0	B
.	0	O


Comparison	0	O
of	0	O
three	0	O
different	0	O
preparations	0	O
of	0	O
disodium	0	O
cromoglycate	0	O
in	0	O
the	0	O
prevention	0	O
of	0	O
exercise	0	O
-	0	O
induced	0	O
bronchospasm	0	O
:	0	O
a	0	O
double	0	O
-	0	O
blind	0	O
study	0	O
.	0	O


Genomic	1	O
and	0	O
cDNA	1	O
clones	0	O
homologous	0	O
to	0	O
the	0	O
yeast	0	O
GCN2	0	B
eIF	0	I
-	0	I
2alpha	0	I
kinase	0	O
(	0	O
yGCN2	0	O
)	0	O
were	0	O
isolated	0	O
from	0	O
Drosophila	1	O
melanogaster	0	O
.	0	O


In	1	O
a	0	O
randomized	0	O
single	0	O
-	0	O
blind	0	O
3	0	O
x	0	O
3	0	O
Latin	0	O
-	0	O
square	0	O
study	0	O
with	0	O
corrections	0	O
for	0	O
any	0	O
carryover	0	O
effects	0	O
,	0	O
27	0	O
males	0	O
and	0	O
30	0	O
females	0	O
consumed	0	O
supplements	0	O
containing	0	O
glucose	0	O
or	0	O
resistant	0	O
starch	0	O
(	0	O
RS	1	O
)	0	O
from	0	O
raw	0	O
high	0	O
-	0	O
amylose	0	O
cornstarch	0	O
(	0	O
RS2	0	O
)	0	O
or	0	O
from	0	O
retrograded	0	O
high	0	O
-	0	O
amylose	0	O
cornstarch	0	O
(	0	O
RS3	0	O
).	0	O


Over	0	O
-	0	O
expression	0	O
of	0	O
the	0	O
cofactor	0	O
p300	0	B
,	0	O
which	0	O
functions	0	O
as	0	O
a	0	O
coactivator	0	O
of	0	O
myoD	0	B
-	0	O
mediated	0	O
transcription	0	O
,	0	O
alleviated	0	O
repression	0	O
by	0	O
COUP	1	B
-	0	I
TF	1	I
II	0	I
.	0	O


Whereas	0	O
cDNA	1	O
hybridization	0	O
to	0	O
genomic	0	O
DNA	1	O
blots	0	O
indicated	0	O
a	0	O
small	0	O
subfamily	0	O
of	0	O
G0S19	0	B
genes	0	I
,	0	O
simple	0	O
patterns	0	O
of	0	O
bands	0	O
indicated	0	O
that	0	O
most	0	O
cDNAs	0	O
,	0	O
including	0	O
G0S30	0	B
cDNA	1	I
,	0	O
corresponded	0	O
to	0	O
single	0	O
-	0	O
copy	0	O
genes	0	O
.	0	O


Kinetic	1	O
experiments	0	O
revealed	0	O
that	0	O
within	0	O
10	0	O
min	0	O
this	0	O
radiolabeled	0	O
precursor	0	O
protein	0	O
was	0	O
converted	0	O
in	0	O
HL	1	O
-	0	O
60	0	O
cells	0	O
into	0	O
an	0	O
Mr	1	O
approximately	0	O
150	0	O
,	0	O
000	0	O
chondroitin	0	O
sulfate	0	O
proteoglycan	0	O
intermediate	0	O
.	0	O


In	1	O
this	0	O
situation	0	O
the	0	O
convlusion	0	O
threshold	0	O
for	0	O
the	0	O
8	0	O
substances	0	O
is	0	O
as	0	O
follows	0	O
:	0	O
pethidine	0	O
20	0	O
mg	0	O
.	0	O
kg	0	O
-	0	O
1	0	O
I	1	O
.	0	O
V	1	O
.,	0	O
piritramide	0	O
30	0	O
,	0	O
morphine	0	O
180	0	O
,	0	O
phenoperidine	0	O
4	0	O
,	0	O
R	1	O
39	0	O
209	0	O
5	0	O
,	0	O
fentanyl	0	O
4	0	O
,	0	O
sufentanil	0	O
4	0	O
and	0	O
R	1	O
34	0	O
995	0	O
10	0	O
mg	0	O
.	0	O
kg	0	O
-	0	O
1	0	O
I	1	O
.	0	O
V	1	O
.	0	O


One	0	O
hundred	0	O
twenty	0	O
units	0	O
of	0	O
deglycerolized	0	O
red	0	O
blood	0	O
cells	0	O
,	0	O
some	0	O
with	0	O
glycerol	0	O
added	0	O
so	0	O
as	0	O
to	0	O
exceed	0	O
an	0	O
acceptable	0	O
1	0	O
%	0	O
glycerol	0	O
content	0	O
,	0	O
had	0	O
measurements	0	O
made	0	O
of	0	O
the	0	O
post	0	O
-	0	O
wash	0	O
supernatant	0	O
fluid	0	O
by	0	O
refractive	0	O
index	0	O
and	0	O
osmometry	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
the	0	O
morphological	0	O
criteria	0	O
,	0	O
the	0	O
few	0	O
data	0	O
available	0	O
from	0	O
recent	0	O
studies	0	O
at	0	O
the	0	O
genetic	0	O
level	0	O
have	0	O
suggested	0	O
that	0	O
EPVs	0	O
infecting	0	O
different	0	O
insect	0	O
orders	0	O
are	0	O
phylogenetically	0	O
distant	0	O
.	0	O


Expression	1	O
of	0	O
six	0	O
genes	0	O
,	0	O
ipaB	0	B
,	0	O
ipaC	0	B
,	0	O
invE	0	B
,	0	O
invG	0	B
,	0	O
invJ	0	B
,	0	O
and	0	O
invK	0	B
,	0	O
was	0	O
apparently	0	O
regulated	0	O
by	0	O
the	0	O
positive	0	O
regulator	0	O
virF	0	B
.	0	O


Flap	1	O
survival	0	O
depends	0	O
on	0	O
the	0	O
development	0	O
of	0	O
a	0	O
small	0	O
number	0	O
of	0	O
vascular	0	O
connections	0	O
between	0	O
vessels	0	O
arising	0	O
from	0	O
the	0	O
pedicle	0	O
and	0	O
preexisting	0	O
dermal	0	O
vessels	0	O
.	0	O


Angiotensin	1	B
effect	0	O
in	0	O
the	0	O
human	0	O
kidney	0	O
.	0	O


A	1	O
transcript	0	O
of	0	O
about	0	O
2	0	O
kb	0	O
is	0	O
expected	0	O
for	0	O
each	0	O
PPO	0	B
.	0	O


Failure	1	O
of	0	O
stapedius	0	O
reflexometry	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
myasthenia	0	O
gravis	0	O
.	0	O


Two	0	O
distinct	0	O
recessive	0	O
susceptibility	0	O
loci	0	O
for	0	O
vasculitis	0	O
were	0	O
mapped	0	O
on	0	O
chromosome	0	O
(	0	O
Chr	1	O
)	0	O
4	0	O
at	0	O
D4Mit89	0	B
and	0	O
D4Mit147	0	B
in	0	O
both	0	O
progenies	0	O
.	0	O


The	0	O
relatively	0	O
mild	0	O
defects	0	O
observed	0	O
in	0	O
Rpd3	0	B
mutants	0	I
suggest	0	O
that	0	O
the	0	O
recently	0	O
identified	0	O
Groucho	0	B
and	0	O
dCtBP	0	B
corepressor	0	I
proteins	0	I
do	0	O
not	0	O
function	0	O
solely	0	O
through	0	O
the	0	O
recruitment	0	O
of	0	O
histone	0	B
deacetylases	0	I
.	0	O


Previous	0	O
experience	0	O
and	0	O
contextual	0	O
cues	0	O
are	0	O
essential	0	O
elements	0	O
in	0	O
the	0	O
generation	0	O
of	0	O
a	0	O
subjective	0	O
prediction	0	O
.	0	O


Existence	0	O
and	0	O
uniqueness	0	O
of	0	O
solutions	0	O
of	0	O
the	0	O
appropriate	0	O
boundary	0	O
value	0	O
problems	0	O
are	0	O
established	0	O
,	0	O
in	0	O
the	0	O
case	0	O
of	0	O
small	0	O
permeability	0	O
coefficients	0	O
and	0	O
transport	0	O
rates	0	O
,	0	O
or	0	O
large	0	O
diffusion	0	O
coefficients	0	O
and	0	O
small	0	O
resistance	0	O
to	0	O
flow	0	O
constants	0	O
.	0	O


Angiography	1	O
of	0	O
aneurysmal	0	O
bone	0	O
cyst	0	O
.	0	O


Interspecific	0	O
mouse	0	O
back	0	O
-	0	O
cross	0	O
analysis	0	O
identified	0	O
the	0	O
loci	0	O
for	0	O
mouse	0	B
3Ost	0	I
genes	0	I
and	0	O
syntenic	0	O
assignments	0	O
of	0	O
corresponding	0	O
human	0	O
isologs	0	O
were	0	O
confirmed	0	O
by	0	O
the	0	O
identification	0	O
of	0	O
mapped	0	O
sequence	0	O
-	0	O
tagged	0	O
site	0	O
markers	0	O
.	0	O


(	0	O
1980	0	O
):	0	O
Science	1	O
210	0	O
,	0	O
77	0	O
-	0	O
72	0	O
)	0	O
that	0	O
stimulating	0	O
the	0	O
crossed	0	O
olivocochlear	0	O
bundle	0	O
(	0	O
COCB	0	O
)	0	O
can	0	O
change	0	O
the	0	O
magnitude	0	O
of	0	O
the	0	O
distortion	0	O
product	0	O
(	0	O
f2	0	O
-	0	O
f1	0	O
)	0	O
in	0	O
the	0	O
ear	0	O
-	0	O
canal	0	O
sound	0	O
pressure	0	O
.	0	O


In	1	O
one	0	O
patient	0	O
with	0	O
severe	0	O
diarrhea	0	O
the	0	O
estriol	0	O
concentration	0	O
in	0	O
serum	0	O
was	0	O
low	0	O
until	0	O
the	0	O
intestinal	0	O
function	0	O
normalised	0	O
and	0	O
the	0	O
estriol	0	O
concentration	0	O
went	0	O
up	0	O
exactly	0	O
when	0	O
the	0	O
diarrhea	0	O
stopped	0	O
.	0	O


Pathology	1	O
of	0	O
neuritis	0	O
caudae	0	O
equinae	0	O
in	0	O
the	0	O
horse	0	O


Effect	1	O
of	0	O
intraventricular	0	O
administration	0	O
of	0	O
streptolysin	0	B
O	1	I
on	0	O
the	0	O
electroencephalogram	0	O
of	0	O
rabbits	0	O
.	0	O


One	0	O
possible	0	O
solution	0	O
is	0	O
a	0	O
thin	0	O
radial	0	O
forearm	0	O
free	0	O
flap	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
two	0	O
levels	0	O
of	0	O
caffeine	0	O
ingestion	0	O
on	0	O
excess	0	O
postexercise	0	O
oxygen	0	O
consumption	0	O
in	0	O
untrained	0	O
women	0	O
.	0	O


During	0	O
both	0	O
encephalopathy	0	O
episodes	0	O
,	0	O
CSF	1	O
protein	0	O
and	0	O
immunoglobulin	0	B
G	1	I
(	0	O
IgG	1	B
)	0	O
levels	0	O
were	0	O
elevated	0	O
without	0	O
an	0	O
increased	0	O
IgG	1	B
index	0	O
or	0	O
IgG	1	B
synthesis	0	O
rate	0	O
.	0	O


Plasma	1	O
concentrations	0	O
of	0	O
ANF	1	B
(	0	O
pANF	0	B
),	0	O
aldosterone	0	O
(	0	O
PAC	1	O
)	0	O
and	0	O
renin	0	B
(	0	O
PRC	0	B
)	0	O
were	0	O
measured	0	O
daily	0	O
,	0	O
as	0	O
were	0	O
hemodynamic	0	O
parameters	0	O
.	0	O


The	0	O
most	0	O
striking	0	O
difference	0	O
in	0	O
the	0	O
birch	0	B
NAD	1	I
(	0	I
P	1	I
)	0	I
H	1	I
-	0	I
NR	0	I
sequence	0	I
in	0	O
comparison	0	O
to	0	O
NADH	1	B
-	0	I
NR	0	I
sequences	0	I
was	0	O
found	0	O
at	0	O
the	0	O
putative	0	O
pyridine	0	O
nucleotide	0	O
binding	0	O
site	0	O
.	0	O


Subsets	0	O
of	0	O
patients	0	O
were	0	O
performed	0	O
according	0	O
to	0	O
the	0	O
severity	0	O
of	0	O
trauma	0	O
(	0	O
ISS	0	O
<	0	O
9	0	O
;	0	O
9	0	O
-	0	O
17	0	O
;	0	O
18	0	O
-	0	O
31	0	O
;	0	O
>	0	O
32	0	O
),	0	O
based	0	O
on	0	O
the	0	O
different	0	O
injury	0	O
pattern	0	O
,	0	O
and	0	O
survivors	0	O
versus	0	O
nonsurvivors	0	O
as	0	O
well	0	O
.	0	O


To	1	O
determine	0	O
the	0	O
relationship	0	O
of	0	O
these	0	O
viruses	0	O
,	0	O
the	0	O
complete	0	O
DNA	1	O
sequence	0	O
of	0	O
KV	1	O
consisting	0	O
of	0	O
4754	0	O
bp	0	O
was	0	O
determined	0	O
.	0	O


The	0	O
background	0	O
processes	0	O
depending	0	O
on	0	O
the	0	O
etiological	0	O
factor	0	O
and	0	O
the	0	O
character	0	O
of	0	O
lesion	0	O
of	0	O
the	0	O
epithelium	0	O
are	0	O
divided	0	O
into	0	O
dyshormonal	0	O
,	0	O
inflammatory	0	O
,	0	O
and	0	O
posttraumatic	0	O
.	0	O


The	0	O
structural	0	O
gene	0	O
encoding	0	O
the	0	O
novel	0	O
lantibiotic	0	O
epilancin	0	B
K7	0	I
from	0	O
Staphylococcus	1	O
epidermidis	0	O
K7	0	O
was	0	O
cloned	0	O
and	0	O
its	0	O
nucleotide	0	O
sequence	0	O
was	0	O
determined	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
both	0	O
Sp1	0	B
and	0	O
ETS	1	B
proteins	0	I
are	0	O
required	0	O
to	0	O
bring	0	O
about	0	O
full	0	O
promoter	0	O
activity	0	O
in	0	O
the	0	O
Surf	0	B
-	0	I
1	0	I
direction	0	O
.	0	O


Pure	1	O
T1	1	O
and	0	O
dual	0	O
-	0	O
T1	1	O
images	0	O
were	0	O
visually	0	O
evaluated	0	O
for	0	O
image	0	O
quality	0	O
(	0	O
IQ	1	O
)	0	O
on	0	O
a	0	O
five	0	O
-	0	O
point	0	O
scale	0	O
(	0	O
0	0	O
=	0	O
unacceptable	0	O
to	0	O
4	0	O
=	0	O
excellent	0	O
).	0	O


Gains	0	O
increased	0	O
3	0	O
.	0	O
5	0	O
%	0	O
(	0	O
P	1	O
less	0	O
than	0	O
.	0	O
10	0	O
)	0	O
and	0	O
feed	0	O
conversion	0	O
improved	0	O
5	0	O
.	0	O
9	0	O
%	0	O
(	0	O
P	1	O
less	0	O
than	0	O
.	0	O
07	0	O
)	0	O
in	0	O
steers	0	O
fed	0	O
.	0	O
28	0	O
%	0	O
AS	1	O
-	0	O
VFA	0	O
compared	0	O
with	0	O
gain	0	O
and	0	O
feed	0	O
conversion	0	O
of	0	O
the	0	O
control	0	O
steers	0	O
.	0	O


Freezing	1	O
of	0	O
plasma	0	O
to	0	O
obtain	0	O
better	0	O
yield	0	O
of	0	O
factor	0	B
VIII	0	I
:	0	O
C	1	O
.	0	O


Ficat	0	O
and	0	O
Bizou	0	O
'	0	O
s	0	O
condylar	0	O
depth	0	O
index	0	O
and	0	O
the	0	O
condylar	0	O
-	0	O
joint	0	O
surface	0	O
angle	0	O
of	0	O
Brattstrom	0	O
are	0	O
recommended	0	O
as	0	O
especially	0	O
suitable	0	O
methods	0	O
of	0	O
measurement	0	O
.	0	O


Sulphur	0	O
amino	0	O
acids	0	O
(	0	O
g	0	O
/	0	O
16	0	O
g	0	O
N	1	O
)	0	O
were	0	O
higher	0	O
in	0	O
the	0	O
isolates	0	O
than	0	O
in	0	O
the	0	O
flours	0	O
.	0	O


Control	1	O
Tmuscle	0	O
was	0	O
35	0	O
.	0	O
8	0	O
+/-	0	O
0	0	O
.	0	O
7	0	O
degrees	0	O
C	1	O
,	0	O
with	0	O
control	0	O
Wi	0	O
,	0	O
max	0	O
being	0	O
51	0	O
.	0	O
6	0	O
(	0	O
SD	1	O
8	0	O
.	0	O
7	0	O
)	0	O
W	1	O
.	0	O
kg	0	O
-	0	O
1	0	O
.	0	O


A	1	O
hydrodynamic	0	O
description	0	O
of	0	O
the	0	O
osmotic	0	O
reflection	0	O
coefficient	0	O
with	0	O
application	0	O
to	0	O
the	0	O
pore	0	O
theory	0	O
of	0	O
transcapillary	0	O
exchange	0	O
.	0	O


New	0	O
beta	0	O
-	0	O
blocking	0	O
drugs	0	O
have	0	O
been	0	O
introduced	0	O
which	0	O
may	0	O
prove	0	O
beneficial	0	O
in	0	O
certain	0	O
clinical	0	O
situations	0	O
since	0	O
they	0	O
exert	0	O
more	0	O
selective	0	O
blockade	0	O
of	0	O
the	0	O
cardiac	0	B
receptors	0	I
(	0	O
beta1	0	B
)	0	O
as	0	O
opposed	0	O
to	0	O
smooth	0	B
muscle	0	I
receptors	0	I
(	0	O
beta2	0	B
).	0	O


The	0	O
hTERT	0	B
gene	0	I
encompasses	0	O
more	0	O
than	0	O
37kb	0	O
and	0	O
consists	0	O
of	0	O
16	0	O
exons	0	O
.	0	O


Conditions	0	O
influencing	0	O
inhibitors	0	O
of	0	O
the	0	O
colony	0	B
-	0	I
stimulating	0	I
factor	0	I
(	0	O
CSF	1	B
).	0	O


Recombination	1	O
between	0	O
feline	0	O
leukemia	0	O
virus	0	O
subgroup	0	O
B	1	O
or	0	O
C	1	O
and	0	O
endogenous	0	O
env	0	B
elements	0	O
alters	0	O
the	0	O
in	0	O
vitro	0	O
biological	0	O
activities	0	O
of	0	O
the	0	O
viruses	0	O
.	0	O


In	1	O
these	0	O
cases	0	O
,	0	O
asbestos	0	O
or	0	O
erionite	0	O
-	0	O
tissue	0	O
burden	0	O
followed	0	O
by	0	O
fibrosis	0	O
was	0	O
frequently	0	O
observed	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Studies	0	O
in	0	O
lean	0	O
men	0	O
show	0	O
poor	0	O
regulation	0	O
of	0	O
energy	0	O
(	0	O
EB	1	O
)	0	O
and	0	O
fat	0	O
balance	0	O
(	0	O
FB	0	O
)	0	O
during	0	O
manipulation	0	O
of	0	O
dietary	0	O
ratios	0	O
of	0	O
fat	0	O
to	0	O
carbohydrate	0	O
.	0	O


Thus	0	O
,	0	O
dpp	0	B
and	0	O
omb	0	B
promote	0	O
both	0	O
dorsal	0	O
leg	0	O
cell	0	O
fate	0	O
as	0	O
well	0	O
as	0	O
transdetermination	0	O
-	0	O
competent	0	O
leg	0	O
disc	0	O
cells	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
tobacco	0	B
GS	0	I
-	0	I
2	0	I
is	0	O
composed	0	O
of	0	O
subunits	0	O
of	0	O
identical	0	O
size	0	O
in	0	O
all	0	O
organs	0	O
examined	0	O
.	0	O


The	0	O
genome	0	O
of	0	O
the	0	O
human	0	O
herpesvirus	0	O
8	0	O
(	0	O
HHV	0	O
-	0	O
8	0	O
)	0	O
contains	0	O
a	0	O
cluster	0	O
of	0	O
open	0	O
reading	0	O
frames	0	O
(	0	O
ORFs	0	O
)	0	O
encoding	0	O
proteins	0	O
with	0	O
homology	0	O
to	0	O
the	0	O
cellular	0	O
transcription	0	O
factors	0	O
of	0	O
the	0	O
interferon	0	B
regulatory	0	I
factor	0	I
(	0	O
IRF	1	B
)	0	O
family	0	O
.	0	O


Randomly	0	O
selected	0	O
300	0	O
children	0	O
aged	0	O
3	0	O
months	0	O
-	0	O
3	0	O
yr	0	O
were	0	O
analysed	0	O
over	0	O
a	0	O
period	0	O
of	0	O
one	0	O
year	0	O
for	0	O
estimating	0	O
prevalence	0	O
of	0	O
nutritional	0	O
anaemia	0	O
.	0	O


The	0	O
lytic	0	O
cycle	0	O
of	0	O
KSHV	0	O
,	0	O
probably	0	O
under	0	O
the	0	O
initial	0	O
control	0	O
of	0	O
the	0	O
KSHV	0	B
/	0	I
Rta	1	I
gene	0	I
,	0	O
may	0	O
directly	0	O
contribute	0	O
to	0	O
tumor	0	O
pathogenesis	0	O
.	0	O


The	0	O
activation	0	O
of	0	O
the	0	O
HIV	1	O
promoter	0	O
required	0	O
the	0	O
nuclear	0	O
localization	0	O
of	0	O
c	0	B
-	0	I
Abl	0	I
and	0	O
could	0	O
be	0	O
correlated	0	O
with	0	O
increased	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
RNA	1	B
polymerase	0	I
II	0	I
.	0	O


This	0	O
study	0	O
was	0	O
undertaken	0	O
to	0	O
define	0	O
the	0	O
mechanism	0	O
for	0	O
the	0	O
respiratory	0	O
inhibition	0	O
observed	0	O
during	0	O
high	0	O
-	0	O
frequency	0	O
oscillatory	0	O
ventilation	0	O
(	0	O
HFOV	1	O
).	0	O


Depending	0	O
on	0	O
the	0	O
location	0	O
and	0	O
size	0	O
of	0	O
the	0	O
mass	0	O
,	0	O
a	0	O
wide	0	O
range	0	O
of	0	O
clinical	0	O
presentations	0	O
is	0	O
associated	0	O
with	0	O
the	0	O
lesion	0	O
.	0	O


Immediately	0	O
after	0	O
surgery	0	O
,	0	O
dialysate	0	O
PGE2	0	O
and	0	O
adenosine	0	O
concentrations	0	O
were	0	O
3	0	O
.	0	O
7	0	O
+/-	0	O
0	0	O
.	0	O
7	0	O
and	0	O
296	0	O
+/-	0	O
127	0	O
nM	1	O
,	0	O
respectively	0	O
.	0	O


Direct	1	O
binding	0	O
and	0	O
competition	0	O
assays	0	O
using	0	O
30	0	O
-	0	O
mer	0	O
oligonucleotide	0	O
probes	0	O
representing	0	O
the	0	O
individual	0	O
CBF1	0	B
binding	0	I
sites	0	I
indicated	0	O
that	0	O
CBF1	0	B
bound	0	O
less	0	O
efficiently	0	O
to	0	O
the	0	O
CD23	0	B
promoter	0	I
and	0	O
the	0	O
EBV	1	B
LMP	1	I
-	0	I
1	0	I
promoter	0	I
sites	0	I
than	0	O
to	0	O
the	0	O
Cp	1	B
site	0	I
.	0	O


Finally	0	O
,	0	O
we	0	O
present	0	O
evidence	0	O
that	0	O
fimbrin	0	B
is	0	O
a	0	O
third	0	O
distinct	0	O
plastin	0	B
isoform	0	I
which	0	O
is	0	O
specifically	0	O
expressed	0	O
at	0	O
high	0	O
levels	0	O
in	0	O
the	0	O
small	0	O
intestine	0	O
.	0	O


Paxillin	1	B
acts	0	O
as	0	O
an	0	O
adaptor	0	O
molecule	0	O
in	0	O
integrin	0	B
signaling	0	O
.	0	O


Amino	1	O
acid	0	O
sequence	0	O
comparison	0	O
revealed	0	O
significant	0	O
homology	0	O
between	0	O
the	0	O
yeast	0	B
and	0	I
Escherichia	1	I
coli	0	I
gamma	0	I
-	0	I
glutamyl	0	I
kinases	0	I
throughout	0	O
their	0	O
lengths	0	O
.	0	O


Two	0	O
overlapping	0	O
clones	0	O
contained	0	O
the	0	O
complete	0	O
Adh	1	B
-	0	I
2	0	I
gene	0	I
composed	0	O
of	0	O
nine	0	O
exons	0	O
in	0	O
a	0	O
12	0	O
-	0	O
kb	0	O
region	0	O
,	0	O
with	0	O
the	0	O
placement	0	O
of	0	O
introns	0	O
matching	0	O
that	0	O
observed	0	O
in	0	O
other	0	O
mammalian	0	B
ADH	1	I
genes	0	I
.	0	O


Productive	1	O
growth	0	O
of	0	O
phage	0	O
P22	0	O
in	0	O
wild	0	O
-	0	O
type	0	O
Salmonella	1	O
typhimurium	0	O
correlates	0	O
with	0	O
the	0	O
presence	0	O
of	0	O
Abc2	0	B
,	0	O
but	0	O
is	0	O
independent	0	O
of	0	O
the	0	O
absolute	0	O
level	0	O
of	0	O
ATP	1	B
-	0	I
dependent	0	I
nuclease	0	I
activity	0	O
,	0	O
suggesting	0	O
a	0	O
qualitative	0	O
change	0	O
in	0	O
the	0	O
nature	0	O
of	0	O
Abc2	0	B
-	0	O
modified	0	O
RecBCD	0	B
nuclease	0	I
activity	0	O
relative	0	O
to	0	O
the	0	O
native	0	O
enzyme	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
amount	0	O
of	0	O
tRNA	1	B
(	0	I
3Lys	0	I
)	0	I
that	0	O
was	0	O
placed	0	O
onto	0	O
viral	0	O
RNA	1	O
in	0	O
mutated	0	O
viruses	0	O
was	0	O
significantly	0	O
less	0	O
than	0	O
that	0	O
placed	0	O
in	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
virus	0	O
.	0	O


The	0	O
efficacy	0	O
of	0	O
these	0	O
immunosuppressive	0	O
drugs	0	O
is	0	O
clinical	0	O
proven	0	O
.	0	O


Immobilized	0	O
dimers	0	O
of	0	O
N	1	B
-	0	I
cadherin	0	I
-	0	O
Fc	1	B
chimera	0	O
mimic	0	O
cadherin	0	O
-	0	O
mediated	0	O
cell	0	O
contact	0	O
formation	0	O
:	0	O
contribution	0	O
of	0	O
both	0	O
outside	0	O
-	0	O
in	0	O
and	0	O
inside	0	O
-	0	O
out	0	O
signals	0	O
.	0	O


Sequencing	1	O
analysis	0	O
revealed	0	O
that	0	O
the	0	O
0	0	O
.	0	O
54	0	O
-	0	O
and	0	O
0	0	O
.	0	O
4	0	O
-	0	O
kb	0	O
fragments	0	O
are	0	O
identical	0	O
except	0	O
for	0	O
150	0	O
nucleotides	0	O
missing	0	O
at	0	O
the	0	O
5	0	O
'	0	O
region	0	O
of	0	O
the	0	O
0	0	O
.	0	O
4	0	O
-	0	O
kb	0	O
fragment	0	O
.	0	O


By	0	O
directly	0	O
interacting	0	O
with	0	O
both	0	O
Arfs	0	B
and	0	O
tyrosine	0	B
kinases	0	I
involved	0	O
in	0	O
regulating	0	O
cell	0	O
growth	0	O
and	0	O
cytoskeletal	0	O
organization	0	O
,	0	O
ASAP1	0	B
could	0	O
coordinate	0	O
membrane	0	O
remodeling	0	O
events	0	O
with	0	O
these	0	O
processes	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
validity	0	O
of	0	O
this	0	O
new	0	O
subset	0	O
of	0	O
questions	0	O
was	0	O
shown	0	O
to	0	O
be	0	O
significant	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
037	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
for	0	O
the	0	O
correlation	0	O
between	0	O
a	0	O
measure	0	O
of	0	O
the	0	O
severity	0	O
of	0	O
binocular	0	O
visual	0	O
field	0	O
loss	0	O
and	0	O
the	0	O
mean	0	O
score	0	O
of	0	O
the	0	O
variables	0	O
used	0	O
in	0	O
the	0	O
glaucoma	0	O
specific	0	O
subgroup	0	O
of	0	O
questions	0	O
.	0	O


The	0	O
cDNA	1	O
corresponding	0	O
to	0	O
the	0	O
FPS1	0	B
gene	0	I
was	0	O
isolated	0	O
by	0	O
functional	0	O
complementation	0	O
of	0	O
a	0	O
mutant	0	O
yeast	0	O
strain	0	O
defective	0	O
in	0	O
FPS	0	B
activity	0	O
(	0	O
Delourme	0	O
,	0	O
D	1	O
.,	0	O
Lacroute	0	O
,	0	O
F	1	O
.,	0	O
and	0	O
Karst	0	O
,	0	O
F	1	O
.	0	O


Cortical	1	O
dysplasias	0	O
,	0	O
genetics	0	O
,	0	O
and	0	O
epileptogenesis	0	O
.	0	O


The	0	O
coding	0	O
region	0	O
of	0	O
mkh1	0	B
is	0	O
contained	0	O
within	0	O
a	0	O
single	0	O
exon	0	O
encoding	0	O
a	0	O
1	0	O
,	0	O
116	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
protein	0	O
.	0	O


The	0	O
sympathetic	0	O
neuroeffector	0	O
influence	0	O
on	0	O
the	0	O
myocardium	0	O
with	0	O
ATCI	0	O
depends	0	O
to	0	O
a	0	O
large	0	O
measure	0	O
on	0	O
the	0	O
intensity	0	O
of	0	O
the	0	O
neurotransmitter	0	O
biosynthesis	0	O
and	0	O
function	0	O
of	0	O
cardiomyocyte	0	O
adrenoreceptors	0	O
.	0	O


In	1	O
17	0	O
patients	0	O
with	0	O
deletions	0	O
,	0	O
the	0	O
parental	0	O
origin	0	O
of	0	O
deletion	0	O
was	0	O
determined	0	O
.	0	O


Cp	1	B
is	0	O
normally	0	O
the	0	O
main	0	O
promoter	0	O
for	0	O
EBNA	0	B
mRNA	1	I
initiation	0	O
,	0	O
so	0	O
it	0	O
appears	0	O
that	0	O
EBNA3C	0	B
contributes	0	O
to	0	O
a	0	O
negative	0	O
autoregulatory	0	O
control	0	O
loop	0	O
.	0	O


Unique	1	O
to	0	O
this	0	O
system	0	O
,	0	O
the	0	O
activity	0	O
of	0	O
TraR	0	B
is	0	O
negatively	0	O
modulated	0	O
by	0	O
an	0	O
antiactivator	0	O
called	0	O
TraM	1	B
.	0	O


SNAP	1	B
-	0	I
23	0	I
plays	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
vesicle	0	O
trafficking	0	O
in	0	O
mammalian	0	O
cells	0	O
.	0	O


In	1	O
insulin	0	B
-	0	O
responsive	0	O
cells	0	O
,	0	O
Akt	0	B
phosphorylates	0	O
and	0	O
inactivates	0	O
the	0	O
serine	0	B
/	0	I
threonine	0	I
kinase	0	I
glycogen	0	I
synthase	0	I
kinase	0	I
-	0	I
3	0	I
(	0	O
GSK	0	B
-	0	I
3	0	I
).	0	O


Lack	0	O
of	0	O
cyclin	0	B
D	1	I
-	0	O
Cdk	1	B
complexes	0	O
in	0	O
Rb	1	B
-	0	O
negative	0	O
cells	0	O
correlates	0	O
with	0	O
high	0	O
levels	0	O
of	0	O
p16INK4	0	B
/	0	O
MTS1	0	B
tumour	0	O
suppressor	0	O
gene	0	O
product	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
virulence	0	O
-	0	O
associated	0	O
genes	0	O
and	0	O
their	0	O
overall	0	O
chromosomal	0	O
arrangement	0	O
are	0	O
relatively	0	O
well	0	O
conserved	0	O
between	0	O
B	1	O
.	0	O
henselae	0	O
and	0	O
other	0	O
gram	0	O
-	0	O
negative	0	O
bacteria	0	O
such	0	O
as	0	O
A	1	O
.	0	O
tumefaciens	0	O
.	0	O


The	0	O
human	0	B
2	0	I
',	0	I
5	0	I
'-	0	I
oligoadenylate	0	I
(	0	I
2	0	I
-	0	I
5A	0	I
)	0	I
synthetases	0	I
are	0	O
members	0	O
of	0	O
a	0	O
family	0	O
interferon	0	B
(	0	O
IFN	1	B
)-	0	O
inducible	0	O
anti	0	B
-	0	I
viral	0	I
proteins	0	I
.	0	O


The	0	O
LMW	0	B
FGF	0	I
-	0	I
2	0	I
up	0	O
-	0	O
regulated	0	O
the	0	O
PKC	0	B
epsilon	0	I
levels	0	O
by	0	O
1	0	O
.	0	O
6	0	O
-	0	O
fold	0	O
;	0	O
by	0	O
contrast	0	O
the	0	O
HMW	0	B
isoform	0	I
down	0	O
-	0	O
regulated	0	O
the	0	O
level	0	O
of	0	O
this	0	O
PKC	0	B
isotype	0	I
by	0	O
about	0	O
3	0	O
-	0	O
fold	0	O
and	0	O
increased	0	O
the	0	O
amount	0	O
of	0	O
PKC	0	B
delta	0	I
by	0	O
1	0	O
.	0	O
7	0	O
-	0	O
fold	0	O
.	0	O


The	0	O
costs	0	O
were	0	O
DM	1	O
11	0	O
,	0	O
562	0	O
for	0	O
a	0	O
PE	1	O
,	0	O
DM	1	O
12	0	O
,	0	O
477	0	O
for	0	O
a	0	O
VR	1	O
and	0	O
DM	1	O
7	0	O
,	0	O
532	0	O
for	0	O
a	0	O
MR	1	O
.	0	O


New	0	O
-	0	O
onset	0	O
angina	0	O
preceding	0	O
acute	0	O
myocardial	0	O
infarction	0	O
is	0	O
associated	0	O
with	0	O
improved	0	O
contractile	0	O
recovery	0	O
after	0	O
thrombolysis	0	O
.	0	O


This	0	O
conformer	0	O
features	0	O
a	0	O
Type	1	O
I	1	O
beta	0	O
-	0	O
turn	0	O
and	0	O
has	0	O
extensive	0	O
hydrophobic	0	O
contacts	0	O
with	0	O
the	0	O
FKBP12	0	B
binding	0	O
surface	0	O
.	0	O


Intravenous	1	O
administration	0	O
(	0	O
25	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
of	0	O
carbonic	0	B
anhydrase	0	I
inhibitors	0	O
(	0	O
acetazolamide	0	O
,	0	O
methazolamide	0	O
,	0	O
dichlorphenamide	0	O
,	0	O
sulthiame	0	O
)	0	O
induced	0	O
an	0	O
early	0	O
important	0	O
rise	0	O
of	0	O
cortical	0	O
p	0	O
O2	1	O
,	0	O
which	0	O
is	0	O
not	0	O
dependent	0	O
on	0	O
increase	0	O
of	0	O
p	0	O
O2	1	O
and	0	O
p	0	O
CO2	1	O
and	0	O
decrease	0	O
of	0	O
pH	1	O
in	0	O
arterial	0	O
blood	0	O
.	0	O


We	0	O
have	0	O
also	0	O
identified	0	O
a	0	O
functional	0	O
domain	0	O
in	0	O
the	0	O
ORF	1	O
50	0	O
protein	0	O
,	0	O
an	0	O
immediate	0	B
-	0	I
early	0	I
gene	0	I
product	0	I
that	0	O
is	0	O
mainly	0	O
encoded	0	O
by	0	O
ORF	1	O
50	0	O
.	0	O


This	0	O
region	0	O
binds	0	O
two	0	O
ubiquitous	0	O
nuclear	0	O
factors	0	O
,	0	O
USF	0	B
/	0	O
MLTF	0	B
and	0	O
the	0	O
CAAT	0	B
-	0	I
binding	0	I
transcription	0	I
factor	0	I
/	0	O
nuclear	0	B
factor	0	I
1	0	I
(	0	O
CTF	0	B
/	0	O
NF1	1	B
).	0	O


The	0	O
persistence	0	O
of	0	O
members	0	O
of	0	O
the	0	O
prostigmatid	0	O
families	0	O
Tydeidae	0	O
,	0	O
Nanorchestidae	0	O
and	0	O
Tarsonemidae	0	O
in	0	O
the	0	O
moisture	0	O
-	0	O
deficient	0	O
90	0	O
%-	0	O
concentration	0	O
treatments	0	O
supports	0	O
previous	0	O
evidence	0	O
of	0	O
adaptations	0	O
to	0	O
low	0	O
-	0	O
water	0	O
-	0	O
content	0	O
habitats	0	O
.	0	O


To	1	O
address	0	O
the	0	O
biological	0	O
effect	0	O
of	0	O
specific	0	O
isoform	0	O
expression	0	O
,	0	O
NIH3T3	0	O
cells	0	O
were	0	O
transfected	0	O
with	0	O
a	0	O
eukaryotic	0	O
expression	0	O
vector	0	O
containing	0	O
cDNA	1	O
for	0	O
FGF8a	0	B
,	0	O
FGF8b	0	B
,	0	O
or	0	O
FGF8e	0	B
.	0	O


Amikacin	1	O
concentrations	0	O
in	0	O
serum	0	O
and	0	O
blister	0	O
fluid	0	O
in	0	O
healthy	0	O
volunteers	0	O
and	0	O
in	0	O
patients	0	O
with	0	O
renal	0	O
impairment	0	O
.	0	O


Paradoxically	0	O
,	0	O
however	0	O
,	0	O
the	0	O
GH	1	B
receptor	0	I
cloned	0	O
from	0	O
liver	0	O
exhibits	0	O
no	0	O
sequence	0	O
similarity	0	O
to	0	O
receptors	0	O
with	0	O
known	0	O
signal	0	O
transduction	0	O
mechanisms	0	O
,	0	O
including	0	O
those	0	O
exhibiting	0	O
ligand	0	O
-	0	O
activated	0	O
tyrosine	0	B
kinase	0	I
activity	0	O
.	0	O


Survival	1	O
rates	0	O
for	0	O
the	0	O
original	0	O
treatment	0	O
group	0	O
were	0	O
84	0	O
.	0	O
5	0	O
%	0	O
and	0	O
57	0	O
.	0	O
6	0	O
%	0	O
at	0	O
12	0	O
and	0	O
21	0	O
months	0	O
,	0	O
respectively	0	O
;	0	O
for	0	O
the	0	O
delayed	0	O
treatment	0	O
group	0	O
,	0	O
78	0	O
.	0	O
8	0	O
%	0	O
and	0	O
64	0	O
.	0	O
6	0	O
%	0	O
at	0	O
12	0	O
and	0	O
21	0	O
months	0	O
,	0	O
respectively	0	O
,	0	O
and	0	O
78	0	O
.	0	O
8	0	O
%	0	O
and	0	O
47	0	O
.	0	O
5	0	O
%	0	O
at	0	O
12	0	O
and	0	O
21	0	O
months	0	O
,	0	O
respectively	0	O
,	0	O
for	0	O
77	0	O
subjects	0	O
with	0	O
AIDS	1	O
and	0	O
93	0	O
.	0	O
0	0	O
%	0	O
and	0	O
71	0	O
.	0	O
8	0	O
%,	0	O
respectively	0	O
,	0	O
for	0	O
50	0	O
subjects	0	O
with	0	O
AIDS	1	O
-	0	O
related	0	O
complex	0	O
in	0	O
the	0	O
original	0	O
treatment	0	O
group	0	O
.	0	O


However	0	O
,	0	O
there	0	O
has	0	O
not	0	O
been	0	O
any	0	O
evidence	0	O
of	0	O
A	1	O
.	0	O
salmonicida	0	O
infections	0	O
,	0	O
specifically	0	O
furunculosis	0	O
,	0	O
associated	0	O
with	0	O
the	0	O
fish	0	O
in	0	O
this	0	O
loch	0	O
.	0	O


The	0	O
ED30	0	O
values	0	O
were	0	O
2	0	O
.	0	O
4	0	O
and	0	O
2	0	O
.	0	O
2	0	O
mg	0	O
/	0	O
kg	0	O
and	0	O
similar	0	O
to	0	O
the	0	O
respective	0	O
values	0	O
of	0	O
nifedipine	0	O
(	0	O
ED	1	O
30	0	O
:	0	O
2	0	O
.	0	O
4	0	O
,	0	O
2	0	O
.	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
).	0	O


Re	1	O
-	0	O
examining	0	O
methylbenzene	0	O
(	0	O
toluene	0	O
)	0	O
as	0	O
a	0	O
treatment	0	O
for	0	O
Ancylostomum	1	O
caninum	0	O
.	0	O


The	0	O
pseudolymphoma	0	O
syndrome	0	O
is	0	O
a	0	O
reversible	0	O
reactive	0	O
condition	0	O
consisting	0	O
of	0	O
fever	0	O
,	0	O
lymphadenopathy	0	O
and	0	O
generalized	0	O
rash	0	O
.	0	O


The	0	O
second	0	O
method	0	O
,	0	O
the	0	O
"	0	O
macro	0	O
"	0	O
assay	0	O
,	0	O
has	0	O
a	0	O
sensitivity	0	O
range	0	O
of	0	O
0	0	O
.	0	O
03	0	O
-	0	O
5	0	O
.	0	O
0	0	O
micrograms	0	O
phosphorus	0	O
with	0	O
100	0	O
-	0	O
500	0	O
microliters	0	O
HClO4	0	O
.	0	O


Data	1	O
are	0	O
presented	0	O
hinting	0	O
that	0	O
the	0	O
15	0	O
beta	0	O
-	0	O
hydroxy	0	O
-,	0	O
metabolite	0	O
of	0	O
CPA	1	O
may	0	O
actually	0	O
be	0	O
the	0	O
biologically	0	O
active	0	O
agent	0	O
.	0	O


Sequences	0	O
required	0	O
for	0	O
interaction	0	O
of	0	O
mu2	0	B
and	0	O
CTLA	0	B
-	0	I
4	0	I
were	0	O
localized	0	O
to	0	O
residues	0	O
,	0	O
161TTGVY	0	O
in	0	O
CTLA	0	B
-	0	I
4	0	I
;	0	O
this	0	O
sequence	0	O
is	0	O
N	1	O
-	0	O
terminal	0	O
to	0	O
,	0	O
but	0	O
overlaps	0	O
with	0	O
,	0	O
a	0	O
previously	0	O
identified	0	O
SH2	0	B
binding	0	I
motif	0	I
,	0	O
165YVKM	0	O
,	0	O
involved	0	O
in	0	O
CTLA	0	B
-	0	I
4	0	I
signaling	0	O
.	0	O


The	0	O
pharmacokinetic	0	O
parameters	0	O
which	0	O
helped	0	O
predict	0	O
these	0	O
toxicities	0	O
included	0	O
area	0	O
under	0	O
the	0	O
curve	0	O
and	0	O
peak	0	O
plasma	0	O
level	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
to	0	O
study	0	O
and	0	O
overcome	0	O
TI	1	O
region	0	O
-	0	O
based	0	O
expression	0	O
problems	0	O
it	0	O
is	0	O
worthwhile	0	O
to	0	O
start	0	O
out	0	O
with	0	O
a	0	O
versatile	0	O
vector	0	O
containing	0	O
exhaustive	0	O
mutations	0	O
in	0	O
the	0	O
periShine	0	O
-	0	O
Dalgarno	0	O
sequences	0	O
;	0	O
as	0	O
a	0	O
rule	0	O
the	0	O
coding	0	O
MTI	0	O
subregion	0	O
can	0	O
be	0	O
kept	0	O
unchanged	0	O
.	0	O


Resources	0	O
for	0	O
helping	0	O
patients	0	O
to	0	O
quit	0	O
smoking	0	O
.	0	O


These	0	O
sequences	0	O
were	0	O
then	0	O
used	0	O
to	0	O
clone	0	O
the	0	O
full	0	O
-	0	O
length	0	O
genes	0	O
from	0	O
a	0	O
yeast	0	O
genomic	0	O
library	0	O
.	0	O


Splicing	1	O
of	0	O
the	0	O
K	1	B
-	0	I
SAM	0	I
alternative	0	O
exon	0	O
of	0	O
the	0	O
fibroblast	0	B
growth	0	I
factor	0	I
receptor	0	I
2	0	I
gene	0	I
is	0	O
heavily	0	O
dependent	0	O
on	0	O
the	0	O
U	1	O
-	0	O
rich	0	O
sequence	0	O
IAS1	0	B
lying	0	O
immediately	0	O
downstream	0	O
from	0	O
its	0	O
5	0	O
'	0	O
splice	0	O
site	0	O
.	0	O


At	1	O
baseline	0	O
,	0	O
serum	0	O
levels	0	O
of	0	O
lycopene	0	O
and	0	O
FLOP	0	O
were	0	O
abnormally	0	O
high	0	O
and	0	O
serum	0	O
FLOP	0	O
was	0	O
correlated	0	O
significantly	0	O
with	0	O
plasma	0	O
cyclosporine	0	O
levels	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
646	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
016	0	O
).	0	O


The	0	O
isolated	0	O
plasmin	0	B
fragments	0	O
of	0	O
VEGF	1	B
were	0	O
compared	0	O
with	0	O
respect	0	O
to	0	O
heparin	0	O
binding	0	O
,	0	O
interaction	0	O
with	0	O
soluble	0	O
VEGF	1	B
receptors	0	I
,	0	O
and	0	O
ability	0	O
to	0	O
promote	0	O
endothelial	0	O
cell	0	O
mitogenesis	0	O
.	0	O


However	0	O
,	0	O
the	0	O
serum	0	B
TNF	1	I
-	0	I
a	0	I
concentration	0	O
decreased	0	O
significantly	0	O
in	0	O
patients	0	O
receiving	0	O
pentoxifylline	0	O
(	0	O
basal	0	O
623	0	O
+/-	0	O
366	0	O
pg	0	O
/	0	O
ml	0	O
;	0	O
6th	0	O
month	0	O
562	0	O
+/-	0	O
358	0	O
pg	0	O
/	0	O
ml	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
),	0	O
but	0	O
not	0	O
in	0	O
the	0	O
control	0	O
group	0	O
.	0	O


Denaturation	1	O
of	0	O
the	0	O
simian	0	O
virus	0	O
40	0	O
origin	0	O
of	0	O
replication	0	O
mediated	0	O
by	0	O
human	0	B
replication	0	I
protein	0	I
A	1	I
.	0	O


We	0	O
found	0	O
that	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
protein	0	O
was	0	O
maximum	0	O
in	0	O
mitosis	0	O
and	0	O
minimum	0	O
in	0	O
G1	0	O
,	0	O
which	0	O
correlated	0	O
with	0	O
the	0	O
expression	0	O
of	0	O
its	0	O
messenger	0	O
RNA	1	O
.	0	O


Nonteratogenicity	0	O
in	0	O
rats	0	O
of	0	O
blighted	0	O
potatoes	0	O
and	0	O
compounds	0	O
contained	0	O
in	0	O
them	0	O
.	0	O


An	1	O
examination	0	O
of	0	O
the	0	O
role	0	O
of	0	O
the	0	O
carboxyl	0	O
terminus	0	O
in	0	O
regulating	0	O
NGFI	0	B
-	0	I
B	1	I
transcriptional	0	O
activity	0	O
revealed	0	O
that	0	O
,	0	O
in	0	O
accordance	0	O
with	0	O
other	0	O
nuclear	0	O
receptors	0	O
,	0	O
mutants	0	O
lacking	0	O
portions	0	O
of	0	O
the	0	O
carboxyl	0	O
terminus	0	O
had	0	O
greatly	0	O
decreased	0	O
activity	0	O
.	0	O


A	1	O
cDNA	1	O
clone	0	O
corresponding	0	O
to	0	O
the	0	O
putative	0	O
GA	1	B
20	0	I
-	0	O
oxidase	0	B
genomic	0	O
sequence	0	O
was	0	O
constructed	0	O
with	0	O
the	0	O
reverse	0	O
transcription	0	O
-	0	O
PCR	1	O
method	0	O
,	0	O
and	0	O
the	0	O
identity	0	O
of	0	O
the	0	O
cDNA	1	O
clone	0	O
was	0	O
confirmed	0	O
by	0	O
analyzing	0	O
the	0	O
capability	0	O
of	0	O
the	0	O
fusion	0	O
protein	0	O
expressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
to	0	O
convert	0	O
GA53	0	B
to	0	O
GA44	0	B
and	0	O
GA19	0	B
to	0	O
GA20	0	B
.	0	O


A	1	O
patient	0	O
matches	0	O
a	0	O
PIC	0	O
patient	0	O
if	0	O
both	0	O
have	0	O
the	0	O
same	0	O
mechanism	0	O
of	0	O
injury	0	O
,	0	O
the	0	O
same	0	O
coding	0	O
of	0	O
Revised	0	O
Trauma	1	O
Score	1	O
variables	0	O
(	0	O
Glascow	0	O
Coma	1	O
Scale	1	O
score	0	O
,	0	O
systolic	0	O
blood	0	O
pressure	0	O
,	0	O
respiratory	0	O
rate	0	O
),	0	O
the	0	O
same	0	O
coded	0	O
age	0	O
per	0	O
A	1	O
Severity	0	O
Characterization	0	O
of	0	O
Trauma	1	O
)	0	O
(	0	O
ASCOT	1	O
),	0	O
and	0	O
if	0	O
they	0	O
differ	0	O
by	0	O
no	0	O
more	0	O
than	0	O
0	0	O
.	0	O
5	0	O
for	0	O
A	1	O
,	0	O
B	1	O
,	0	O
and	0	O
C	1	O
(	0	O
the	0	O
ASCOT	1	O
components	0	O
for	0	O
serious	0	O
injuries	0	O
).	0	O


Cost	0	O
-	0	O
effectiveness	0	O
of	0	O
interferon	0	B
beta	0	I
-	0	I
1b	0	I
in	0	O
slowing	0	O
multiple	0	O
sclerosis	0	O
disability	0	O
progression	0	O
.	0	O


For	0	O
functional	0	O
studies	0	O
,	0	O
two	0	O
promoter	0	O
regions	0	O
were	0	O
cloned	0	O
upstream	0	O
of	0	O
the	0	O
reporter	0	O
gene	0	O
,	0	O
chloramphenicol	0	B
acetyl	0	I
transferase	0	I
(	0	O
CAT	1	B
):	0	O
(	0	O
i	0	O
)	0	O
phbetaE	0	O
-	0	O
B	1	O
-	0	O
the	0	O
plasmid	0	O
that	0	O
contains	0	O
the	0	O
human	0	O
(	0	O
h	0	O
)	0	O
promoter	0	O
region	0	O
(-	0	O
2832	0	O
to	0	O
+	0	O
101	0	O
)	0	O
including	0	O
URE	0	O
,	0	O
and	0	O
(	0	O
ii	0	O
)	0	O
prhbetaE	0	O
-	0	O
B	1	O
-	0	O
the	0	O
plasmid	0	O
that	0	O
contains	0	O
the	0	O
rhesus	0	O
(	0	O
rh	0	O
)	0	O
promoter	0	O
region	0	O
excluding	0	O
URE	0	O
as	0	O
it	0	O
lacks	0	O
a	0	O
270	0	O
bp	0	O
region	0	O
of	0	O
the	0	O
hbetaAPP	0	B
promoter	0	I
(-	0	O
2435	0	O
to	0	O
-	0	O
2165	0	O
).	0	O


We	0	O
also	0	O
observed	0	O
that	0	O
cell	0	O
surface	0	O
CD4	1	B
(-)	0	O
CD8	0	B
(-)	0	O
CD3	0	B
(-)	0	O
cells	0	O
with	0	O
rearranged	0	B
TCR	1	I
genes	0	I
developed	0	O
from	0	O
Id3	0	B
-	0	O
transduced	0	O
but	0	O
not	0	O
from	0	O
control	0	O
-	0	O
transduced	0	O
pre	0	O
-	0	O
T	1	O
cells	0	O
in	0	O
an	0	O
FTOC	0	O
.	0	O


We	0	O
also	0	O
show	0	O
that	0	O
activation	0	O
of	0	O
protein	0	B
kinase	0	I
A	1	I
(	0	O
PKA	1	B
)	0	O
signaling	0	O
is	0	O
sufficient	0	O
to	0	O
down	0	O
-	0	O
regulate	0	O
caveolin	0	B
-	0	I
1	0	I
protein	0	I
expression	0	O
and	0	O
promoter	0	O
activity	0	O
.	0	O


Recognition	1	O
mechanisms	0	O
of	0	O
the	0	O
minus	0	O
-	0	O
strand	0	O
origin	0	O
of	0	O
phage	0	O
f1	0	O
by	0	O
Escherichia	1	B
coli	0	I
RNA	1	I
polymerase	0	I
.	0	O


Identification	1	O
and	0	O
characterization	0	O
of	0	O
the	0	O
promoter	0	O
for	0	O
the	0	O
cytotactin	0	B
gene	0	I
.	0	O


Furthermore	0	O
,	0	O
RING1	0	B
overexpression	0	O
results	0	O
in	0	O
enhanced	0	O
expression	0	O
of	0	O
the	0	O
proto	0	O
-	0	O
oncogenes	0	O
c	0	B
-	0	I
jun	0	I
and	0	O
c	0	B
-	0	I
fos	0	I
.	0	O


A	1	O
second	0	O
large	0	O
group	0	O
of	0	O
disorders	0	O
in	0	O
pregnancy	0	O
is	0	O
caused	0	O
by	0	O
effects	0	O
of	0	O
infections	0	O
of	0	O
the	0	O
mother	0	O
without	0	O
pathogens	0	O
being	0	O
transmitted	0	O
to	0	O
the	0	O
embryo	0	O
or	0	O
the	0	O
placenta	0	O
.	0	O


Wnt	0	B
-	0	I
1	0	I
(	0	O
int	0	B
-	0	I
1	0	I
)	0	O
is	0	O
a	0	O
cellular	0	O
oncogene	0	O
often	0	O
activated	0	O
by	0	O
insertion	0	O
of	0	O
proviral	0	O
DNA	1	O
of	0	O
the	0	O
mouse	0	O
mammary	0	O
tumor	0	O
virus	0	O
.	0	O


More	0	O
specific	0	O
adverse	0	O
events	0	O
,	0	O
also	0	O
frequently	0	O
considered	0	O
as	0	O
dose	0	O
-	0	O
limiting	0	O
toxicities	0	O
,	0	O
include	0	O
hypotension	0	O
with	0	O
IL	1	B
-	0	I
1	0	I
,	0	O
severe	0	O
headache	0	O
or	0	O
skin	0	O
rash	0	O
with	0	O
IL	1	B
-	0	I
3	0	I
,	0	O
and	0	O
nasal	0	O
congestion	0	O
and	0	O
gastroduodenal	0	O
lesions	0	O
with	0	O
IL	1	B
-	0	I
4	0	I
.	0	O


Supplementing	0	O
a	0	O
soybean	0	O
protein	0	O
and	0	O
sucrose	0	O
-	0	O
based	0	O
diet	0	O
with	0	O
levels	0	O
of	0	O
2	0	O
.	0	O
2	0	O
,	0	O
11	0	O
,	0	O
and	0	O
55	0	O
ppm	0	O
of	0	O
the	0	O
antibiotic	0	O
,	0	O
from	0	O
the	0	O
two	0	O
sources	0	O
each	0	O
with	0	O
two	0	O
different	0	O
purities	0	O
,	0	O
improved	0	O
weight	0	O
gain	0	O
of	0	O
chicks	0	O
an	0	O
average	0	O
of	0	O
23	0	O
%	0	O
and	0	O
improved	0	O
feed	0	O
efficiency	0	O
an	0	O
average	0	O
of	0	O
13	0	O
%	0	O
at	0	O
the	0	O
higher	0	O
levels	0	O
(	0	O
all	0	O
P	1	O
less	0	O
than	0	O
.	0	O
01	0	O
).	0	O


Molecular	1	O
cloning	0	O
of	0	O
a	0	O
cDNA	1	O
encoding	0	O
rat	0	B
NADH	1	I
-	0	I
cytochrome	0	I
b5	0	I
reductase	0	I
and	0	O
the	0	O
corresponding	0	O
gene	0	O
.	0	O


Characterization	0	O
of	0	O
CR1	1	B
repeat	0	O
random	0	O
PCR	1	O
markers	0	O
for	0	O
mapping	0	O
the	0	O
chicken	0	O
genome	0	O
.	0	O


The	0	O
disease	0	O
ran	0	O
an	0	O
atypical	0	O
course	0	O
;	0	O
with	0	O
early	0	O
jaundice	0	O
syndrome	0	O
,	0	O
severe	0	O
enterorrhagia	0	O
and	0	O
late	0	O
appearance	0	O
of	0	O
roseola	0	O
.	0	O


SELECTION	1	O
CRITERIA	1	O
:	0	O
All	1	O
controlled	0	O
trials	0	O
where	0	O
adults	0	O
with	0	O
schizophrenia	0	O
or	0	O
similar	0	O
illnesses	0	O
were	0	O
randomised	0	O
to	0	O
quetiapine	0	O
,	0	O
placebo	0	O
or	0	O
other	0	O
neuroleptic	0	O
drugs	0	O
and	0	O
where	0	O
clinically	0	O
relevant	0	O
outcomes	0	O
were	0	O
reported	0	O
.	0	O


Mutations	0	O
in	0	O
the	0	O
yeast	0	B
RNA14	0	I
and	0	O
RNA15	0	B
genes	0	I
result	0	O
in	0	O
an	0	O
abnormal	0	O
mRNA	1	O
decay	0	O
rate	0	O
;	0	O
sequence	0	O
analysis	0	O
reveals	0	O
an	0	O
RNA	1	O
-	0	O
binding	0	O
domain	0	O
in	0	O
the	0	O
RNA15	0	B
protein	0	I
.	0	O


PATIENTS	0	O
and	0	O
METHODS	0	O
:	0	O
Thallium	1	O
-	0	O
201	0	O
myocardial	0	O
scintigraphy	0	O
was	0	O
performed	0	O
at	0	O
rest	0	O
and	0	O
after	0	O
0	0	O
.	0	O
56	0	O
mg	0	O
/	0	O
kg	0	O
intravenous	0	O
dipyridamole	0	O
during	0	O
four	0	O
minutes	0	O
in	0	O
16	0	O
patients	0	O
with	0	O
sarcoidosis	0	O
.	0	O


Structure	1	O
and	0	O
expression	0	O
of	0	O
the	0	O
alternative	0	O
sigma	0	B
factor	0	I
,	0	O
RpoN	0	B
,	0	O
in	0	O
Rhodobacter	0	O
capsulatus	0	O
;	0	O
physiological	0	O
relevance	0	O
of	0	O
an	0	O
autoactivated	0	O
nifU2	0	B
-	0	O
rpoN	0	B
superoperon	0	O
.	0	O


A	1	O
patient	0	O
of	0	O
Group	1	O
B	1	O
had	0	O
severe	0	O
athetoid	0	O
CP	1	O
with	0	O
spasticity	0	O
,	0	O
being	0	O
unable	0	O
to	0	O
right	0	O
his	0	O
trunk	0	O
and	0	O
neck	0	O
.	0	O


Aryl	1	B
hydrocarbon	0	I
receptor	0	I
nuclear	0	I
translocator	0	I
(	0	O
ARNT	0	B
)	0	O
is	0	O
a	0	O
component	0	O
of	0	O
the	0	O
transcription	0	O
factors	0	O
,	0	O
aryl	0	B
hydrocarbon	0	I
receptor	0	I
(	0	O
AhR	0	B
)	0	O
and	0	O
hypoxia	0	B
-	0	I
inducible	0	I
factor	0	I
1	0	I
,	0	O
which	0	O
transactivate	0	O
their	0	O
target	0	O
genes	0	O
,	0	O
such	0	O
as	0	O
CYP1A1	0	B
and	0	O
erythropoietin	0	B
,	0	O
in	0	O
response	0	O
to	0	O
xenobiotic	0	O
aromatic	0	O
hydrocarbons	0	O
and	0	O
to	0	O
low	0	O
O2	1	O
concentration	0	O
,	0	O
respectively	0	O
.	0	O


In	1	O
this	0	O
regard	0	O
,	0	O
we	0	O
have	0	O
recently	0	O
observed	0	O
that	0	O
a	0	O
constitutively	0	O
active	0	O
G	1	B
protein	0	I
-	0	I
coupled	0	I
receptor	0	I
(	0	O
GPCR	1	B
)	0	O
encoded	0	O
by	0	O
the	0	O
Kaposi	0	O
'	0	O
s	0	O
sarcoma	0	O
-	0	O
associated	0	O
herpes	0	O
virus	0	O
(	0	O
KSHV	0	O
)/	0	O
human	0	O
herpes	0	O
virus	0	O
8	0	O
is	0	O
oncogenic	0	O
and	0	O
stimulates	0	O
angiogenesis	0	O
by	0	O
increasing	0	O
the	0	O
secretion	0	O
of	0	O
vascular	0	B
endothelial	0	I
growth	0	I
factor	0	I
(	0	O
VEGF	1	B
),	0	O
which	0	O
is	0	O
a	0	O
key	0	O
angiogenic	0	O
stimulator	0	O
and	0	O
a	0	O
critical	0	O
mitogen	0	O
for	0	O
the	0	O
development	0	O
of	0	O
Kaposi	0	O
'	0	O
s	0	O
sarcoma	0	O
.	0	O


The	0	O
transit	0	O
time	0	O
was	0	O
significantly	0	O
shortened	0	O
.	0	O


A	1	O
pathway	0	O
for	0	O
regulation	0	O
of	0	O
B	1	B
lymphocyte	0	I
antigen	0	I
receptor	0	I
-	0	O
induced	0	O
calcium	0	O
flux	0	O
.	0	O


Interestingly	0	O
,	0	O
dTFIIA	0	B
-	0	I
L	1	I
/	0	I
S	1	I
is	0	O
also	0	O
able	0	O
to	0	O
significantly	0	O
enhance	0	O
transcriptional	0	O
activation	0	O
by	0	O
upstream	0	O
transcription	0	O
factors	0	O
including	0	O
Sp1	0	B
,	0	O
VP16	0	B
,	0	O
and	0	O
NTF	0	B
-	0	I
1	0	I
.	0	O


The	0	O
trk	0	B
-	0	I
2h	0	I
oncogene	0	I
,	0	O
isolated	0	O
from	0	O
the	0	O
human	0	O
breast	0	O
carcinoma	0	O
cell	0	O
line	0	O
MDA	1	O
-	0	O
MB	1	O
231	0	O
by	0	O
genomic	0	O
DNA	1	O
-	0	O
transfection	0	O
into	0	O
NIH3T3	0	O
cells	0	O
,	0	O
consists	0	O
of	0	O
the	0	O
trk	0	B
proto	0	I
-	0	I
oncogene	0	I
receptor	0	I
kinase	0	I
domain	0	I
fused	0	O
to	0	O
a	0	O
N	1	O
-	0	O
terminal	0	O
41	0	O
amino	0	O
acid	0	O
activating	0	O
sequence	0	O
(	0	O
Kozma	0	O
,	0	O
S	1	O
.	0	O
C	1	O
.,	0	O
Redmond	0	O
,	0	O
S	1	O
.	0	O
M	1	O
.	0	O
S	1	O
.,	0	O
Xiao	0	O
-	0	O
Chang	0	O
,	0	O
F	1	O
.,	0	O
Saurer	0	O
,	0	O
S	1	O
.	0	O
M	1	O
.,	0	O
Groner	0	O
,	0	O
B	1	O
.	0	O
and	0	O
Hynes	0	O
,	0	O
N	1	O
.	0	O
E	1	O
.	0	O


The	0	O
nit	0	B
-	0	I
3	0	I
gene	0	I
of	0	I
the	0	I
filamentous	0	I
fungus	0	I
Neurospora	1	I
crassa	0	I
encodes	0	O
nitrate	0	B
reductase	0	I
,	0	O
the	0	O
enzyme	0	O
which	0	O
catalyzes	0	O
the	0	O
first	0	O
step	0	O
in	0	O
nitrate	0	O
assimilation	0	O
.	0	O


The	0	O
p130	0	B
and	0	O
p62	0	B
tyrosine	0	O
-	0	O
phosphorylated	0	O
proteins	0	O
that	0	O
complexed	0	O
v	0	B
-	0	I
Src	1	I
SH2	0	I
in	0	O
vitro	0	O
also	0	O
associated	0	O
with	0	O
v	0	B
-	0	I
Src	1	I
in	0	O
v	0	B
-	0	I
src	0	I
-	0	O
transformed	0	O
Rat	1	O
-	0	O
2	0	O
cells	0	O
;	0	O
this	0	O
in	0	O
vivo	0	O
binding	0	O
was	0	O
dependent	0	O
on	0	O
the	0	O
v	0	B
-	0	I
Src	1	I
SH2	0	I
domain	0	O
.	0	O


HFA	0	O
134a	0	O
had	0	O
a	0	O
greater	0	O
tendency	0	O
to	0	O
take	0	O
up	0	O
moisture	0	O
from	0	O
the	0	O
environment	0	O
than	0	O
did	0	O
HFA	0	O
227	0	O
.	0	O


Antibodies	0	O
raised	0	O
to	0	O
the	0	O
expressed	0	O
NS3	0	B
by	0	O
immunization	0	O
of	0	O
mice	0	O
detected	0	O
both	0	O
NS3	0	B
and	0	O
NS3A	0	B
in	0	O
BTV	0	O
-	0	O
10	0	O
-	0	O
infected	0	O
BHK	0	O
cells	0	O
but	0	O
not	0	O
in	0	O
purified	0	O
BTV	0	O
-	0	O
10	0	O
virus	0	O
particles	0	O
.	0	O


Recently	0	O
,	0	O
roles	0	O
also	0	O
have	0	O
been	0	O
suggested	0	O
for	0	O
the	0	O
nuclear	0	O
trans	0	O
-	0	O
factor	0	O
GATA	0	B
-	0	I
1	0	I
in	0	O
regulating	0	O
progenitor	0	O
cell	0	O
proliferation	0	O
.	0	O


C	1	O
.	0	O
D2	0	O
-	0	O
Chr	1	O
4	0	O
congenic	0	O
strains	0	O
harboring	0	O
DBA	1	O
/	0	O
2	0	O
alleles	0	O
associated	0	O
with	0	O
the	0	O
Pctr1	0	B
locus	0	I
contained	0	O
DBA	1	O
/	0	O
2	0	O
"	0	O
resistant	0	O
"	0	O
alleles	0	O
of	0	O
the	0	O
CDK4	0	B
/	0	O
CDK6	0	B
inhibitors	0	O
p16	0	B
and	0	O
p15	0	B
.	0	O


Antipyretic	1	O
therapy	0	O
:	0	O
physiologic	0	O
rationale	0	O
,	0	O
diagnostic	0	O
implications	0	O
,	0	O
and	0	O
clinical	0	O
consequences	0	O
.	0	O


The	0	O
3ASubE	0	O
cells	0	O
expressing	0	O
CXCR2	0	B
with	0	O
mutation	0	O
of	0	O
Ser	1	O
-	0	O
346	0	O
,	0	O
-	0	O
347	0	O
,	0	O
and	0	O
-	0	O
348	0	O
to	0	O
alanine	0	O
,	0	O
or	0	O
with	0	O
mutation	0	O
of	0	O
only	0	O
one	0	O
serine	0	O
in	0	O
this	0	O
domain	0	O
,	0	O
continue	0	O
to	0	O
be	0	O
phosphorylated	0	O
in	0	O
response	0	O
to	0	O
ligand	0	O
and	0	O
are	0	O
60	0	O
-	0	O
70	0	O
%	0	O
desensitized	0	O
following	0	O
the	0	O
initial	0	O
ligand	0	O
challenge	0	O
.	0	O


The	0	O
therapy	0	O
time	0	O
to	0	O
deliver	0	O
the	0	O
NCS	1	O
therapeutic	0	O
dose	0	O
of	0	O
10000	0	O
RBE	1	O
-	0	O
cGy	1	O
,	0	O
is	0	O
27	0	O
times	0	O
longer	0	O
when	0	O
157Gd	0	O
is	0	O
used	0	O
instead	0	O
of	0	O
10B	0	O
.	0	O


Diagnosis	1	O
of	0	O
primary	0	O
sclerosing	0	O
cholangitis	0	O
in	0	O
a	0	O
blood	0	O
donor	0	O
with	0	O
elevated	0	O
serum	0	B
alanine	0	I
aminotransferase	0	I
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
ULK2	0	B
is	0	O
involved	0	O
in	0	O
a	0	O
previously	0	O
uncharacterized	0	O
signaling	0	O
pathway	0	O
in	0	O
mammalian	0	O
cells	0	O
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
carbon	0	O
-	0	O
perfused	0	O
areas	0	O
and	0	O
MBF	0	O
in	0	O
the	0	O
liver	0	O
,	0	O
renal	0	O
cortex	0	O
,	0	O
spleen	0	O
,	0	O
and	0	O
small	0	O
intestinal	0	O
serosa	0	O
(	0	O
only	0	O
MBF	0	O
)	0	O
increased	0	O
significantly	0	O
5	0	O
h	0	O
after	0	O
CLP	0	O
.	0	O


Ritanserin	0	O
is	0	O
a	0	O
new	0	O
substance	0	O
with	0	O
highly	0	O
selective	0	O
blocking	0	O
activity	0	O
on	0	O
S2	1	B
receptors	0	I
for	0	O
5	0	O
-	0	O
HT	1	O
in	0	O
the	0	O
central	0	O
nervous	0	O
system	0	O
.	0	O


The	0	O
investigation	0	O
was	0	O
apt	0	O
at	0	O
studying	0	O
the	0	O
relationship	0	O
between	0	O
urinary	0	O
metabolites	0	O
of	0	O
serotonin	0	O
and	0	O
catecholamine	0	O
(	0	O
5	0	O
-	0	O
HIAA	0	O
and	0	O
VMA	1	O
),	0	O
T	1	O
-	0	O
cells	0	O
(	0	O
OKT3	1	O
+),	0	O
T	1	O
-	0	O
helper	0	O
(	0	O
OKT4	0	O
+),	0	O
T	1	O
-	0	O
suppressor	0	O
(	0	O
OKT8	0	O
+)	0	O
and	0	O
B	1	O
-	0	O
cells	0	O
(	0	O
EAC	1	O
-	0	O
rosette	0	O
forming	0	O
cells	0	O
)	0	O
in	0	O
normal	0	O
(	0	O
10	0	O
subjects	0	O
,	0	O
1	0	O
female	0	O
,	0	O
9	0	O
male	0	O
,	0	O
age	0	O
21	0	O
+/-	0	O
5	0	O
years	0	O
)	0	O
and	0	O
stress	0	O
administered	0	O
subjects	0	O
(	0	O
20	0	O
subjects	0	O
,	0	O
3	0	O
female	0	O
,	0	O
17	0	O
male	0	O
,	0	O
age	0	O
20	0	O
+/-	0	O
4	0	O
years	0	O
).	0	O


Thus	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
an	0	O
activation	0	O
target	0	O
of	0	O
a	0	O
human	0	O
activator	0	O
,	0	O
Oct	1	B
-	0	I
1	0	I
,	0	O
within	0	O
its	0	O
cognate	0	O
basal	0	O
transcription	0	O
complex	0	O
.	0	O


VaI	0	O
and	0	O
VaII	0	O
co	0	O
-	0	O
immunoprecipitated	0	O
with	0	O
ErbB2	0	B
,	0	O
but	0	O
not	0	O
with	0	O
ErbB1	0	B
,	0	O
ErbB3	0	B
,	0	O
or	0	O
ErbB4	0	B
.	0	O


Regulation	1	O
of	0	O
mitochondrial	0	O
single	0	O
-	0	O
stranded	0	O
DNA	1	O
-	0	O
binding	0	O
protein	0	O
gene	0	O
expression	0	O
links	0	O
nuclear	0	O
and	0	O
mitochondrial	0	O
DNA	1	O
replication	0	O
in	0	O
drosophila	0	O
.	0	O


Necrosis	1	O
appears	0	O
6	0	O
h	0	O
after	0	O
TA	1	O
infusion	0	O
,	0	O
being	0	O
5	0	O
.	0	O
77	0	O
%	0	O
in	0	O
extent	0	O
after	0	O
12	0	O
h	0	O
,	0	O
14	0	O
.	0	O
9	0	O
%	0	O
after	0	O
24	0	O
h	0	O
and	0	O
animals	0	O
die	0	O
with	0	O
an	0	O
area	0	O
of	0	O
29	0	O
.	0	O
5	0	O
%	0	O
necrosis	0	O
.	0	O


We	0	O
suggest	0	O
that	0	O
such	0	O
occlusions	0	O
occurred	0	O
at	0	O
the	0	O
time	0	O
of	0	O
the	0	O
infarction	0	O
.	0	O


The	0	O
gene	0	B
lac	0	I
-	0	I
1	0	I
,	0	O
encoding	0	O
the	0	O
enzyme	0	O
laccase	0	B
,	0	O
is	0	O
the	0	O
best	0	O
characterized	0	O
of	0	O
a	0	O
number	0	O
of	0	O
genes	0	O
in	0	O
the	0	O
chestnut	0	O
blight	0	O
fungus	0	O
,	0	O
Cryphonectria	0	O
parasitica	0	O
,	0	O
that	0	O
are	0	O
repressed	0	O
by	0	O
hypoviruses	0	O
,	0	O
a	0	O
group	0	O
of	0	O
virulence	0	O
-	0	O
attenuating	0	O
mycoviruses	0	O
.	0	O
lac	0	B
-	0	I
1	0	I
has	0	O
also	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
transcriptionally	0	O
activated	0	O
by	0	O
low	0	O
concentrations	0	O
of	0	O
the	0	O
translational	0	O
inhibitor	0	O
cycloheximide	0	O
(	0	O
CHX	0	O
)	0	O
and	0	O
by	0	O
the	0	O
immunosuppressant	0	O
cyclosporin	0	O
A	1	O
.	0	O


The	0	O
records	0	O
from	0	O
1948	0	O
through	0	O
1967	0	O
of	0	O
344	0	O
previously	0	O
untreated	0	O
patients	0	O
with	0	O
squamous	0	O
cell	0	O
carcinoma	0	O
of	0	O
the	0	O
oral	0	O
cavity	0	O
,	0	O
oropharynx	0	O
,	0	O
supraglottic	0	O
larynx	0	O
and	0	O
hypopharynx	0	O
who	0	O
had	0	O
clinically	0	O
positive	0	O
cervical	0	O
lymph	0	O
node	0	O
metastases	0	O
staged	0	O
N1	0	O
,	0	O
N2A	0	O
,	0	O
or	0	O
N2B	0	O
,	0	O
and	0	O
whose	0	O
initial	0	O
neck	0	O
treatment	0	O
consisted	0	O
of	0	O
external	0	O
radiation	0	O
therapy	0	O
alone	0	O
were	0	O
reviewed	0	O
.	0	O


Hyperthyroidism	1	O
is	0	O
one	0	O
of	0	O
the	0	O
numerous	0	O
causes	0	O
of	0	O
infertility	0	O
and	0	O
recurrent	0	O
abortion	0	O
.	0	O


A	1	O
sterol	0	O
-	0	O
regulated	0	O
protease	0	O
initiates	0	O
release	0	O
of	0	O
the	0	O
NH2	0	O
-	0	O
terminal	0	O
segments	0	O
of	0	O
sterol	0	B
regulatory	0	I
element	0	I
-	0	I
binding	0	I
proteins	0	I
(	0	O
SREBPs	0	B
)	0	O
from	0	O
cell	0	O
membranes	0	O
,	0	O
thereby	0	O
allowing	0	O
them	0	O
to	0	O
enter	0	O
the	0	O
nucleus	0	O
and	0	O
to	0	O
stimulate	0	O
transcription	0	O
of	0	O
genes	0	O
involved	0	O
in	0	O
the	0	O
uptake	0	O
and	0	O
synthesis	0	O
of	0	O
cholesterol	0	O
and	0	O
fatty	0	O
acids	0	O
.	0	O


The	0	O
cost	0	O
per	0	O
test	0	O
is	0	O
less	0	O
than	0	O
those	0	O
for	0	O
CC	1	O
,	0	O
kEIA	0	O
and	0	O
PACE2	0	O
.	0	O


The	0	O
PC2	0	B
protein	0	I
also	0	O
shows	0	O
great	0	O
similarity	0	O
to	0	O
the	0	O
incomplete	0	O
NH2	0	O
-	0	O
terminal	0	O
sequence	0	O
of	0	O
the	0	O
human	0	B
furin	0	I
gene	0	I
product	0	I
,	0	O
a	0	O
putative	0	O
membrane	0	O
-	0	O
inserted	0	O
receptor	0	O
-	0	O
like	0	O
molecule	0	O
.	0	O


This	0	O
interaction	0	O
is	0	O
mediated	0	O
by	0	O
the	0	O
SH2	0	B
domain	0	I
of	0	O
Crk	0	B
and	0	O
can	0	O
be	0	O
inhibited	0	O
with	0	O
a	0	O
phosphopeptide	0	O
containing	0	O
the	0	O
Crk	0	B
-	0	O
SH2	0	B
binding	0	O
motif	0	O
.	0	O


The	0	O
responsive	0	O
region	0	O
of	0	O
the	0	O
alpha	0	B
2	0	I
(	0	I
V	1	I
)	0	I
collagen	0	I
gene	0	I
was	0	O
localized	0	O
to	0	O
a	0	O
fragment	0	O
including	0	O
100	0	O
bp	0	O
of	0	O
basal	0	O
promoter	0	O
and	0	O
150	0	O
bp	0	O
of	0	O
exon	0	O
1	0	O
sequences	0	O
,	0	O
which	0	O
contained	0	O
two	0	O
CRE	0	O
-	0	O
like	0	O
elements	0	O
.	0	O


In	1	O
the	0	O
electrophoresis	0	O
mobility	0	O
shift	0	O
assay	0	O
using	0	O
nuclear	0	O
extracts	0	O
of	0	O
the	0	O
myogenic	0	O
cells	0	O
,	0	O
MyoD	0	B
and	0	O
myogenin	0	B
bound	0	O
to	0	O
the	0	O
right	0	O
E	1	O
-	0	O
box	0	O
in	0	O
the	0	O
enhancer	0	O
region	0	O
of	0	O
the	0	O
MCK	0	B
gene	0	I
even	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
BMP	1	B
-	0	I
2	0	I
.	0	O


They	0	O
include	0	O
genes	0	O
encoding	0	O
three	0	O
subunits	0	O
of	0	O
the	0	O
cytochrome	0	B
oxidase	0	I
(	0	O
cox1	0	B
to	0	I
3	0	I
),	0	O
apocytochrome	0	B
b	0	I
(	0	O
cob	0	B
),	0	O
seven	0	O
subunits	0	O
of	0	O
the	0	O
NADH	1	B
dehydrogenase	0	I
complex	0	I
(	0	O
nad1	0	B
to	0	I
6	0	I
,	0	O
nad4L	0	B
),	0	O
two	0	O
ATPase	1	B
subunits	0	O
(	0	O
atp6	0	B
and	0	O
atp9	0	B
),	0	O
three	0	O
ribosomal	0	O
RNAs	0	O
(	0	O
rrn5	0	B
,	0	O
srn	0	B
and	0	O
lrn	0	B
),	0	O
23	0	O
tRNAs	0	O
and	0	O
four	0	O
ribosomal	0	O
proteins	0	O
(	0	O
rps3	0	B
,	0	O
rps11	0	B
,	0	O
rps12	0	B
and	0	O
rpl16	0	B
).	0	O


5	0	O
-(	0	O
Dimethylaminopropyl	0	O
)-	0	O
19	0	O
,	0	O
11	0	O
-	0	O
dihydro	0	O
-	0	O
5H	0	O
-	0	O
benzo	0	O
[	0	O
2	0	O
,	0	O
3	0	O
]	0	O
pyrido	0	O
[	0	O
6	0	O
,	0	O
7	0	O
-	0	O
b	0	O
]	0	O
azepine	0	O
.	0	O


Further	0	O
,	0	O
the	0	O
PIP2	1	O
content	0	O
of	0	O
the	0	O
85	0	O
-	0	O
90	0	O
kDa	1	O
protein	0	O
appeared	0	O
to	0	O
decrease	0	O
with	0	O
CSF	1	B
-	0	I
1	0	I
treatment	0	O
.	0	O


An	1	O
overexpression	0	O
of	0	O
the	0	O
betaAPP	0	B
gene	0	I
in	0	O
certain	0	O
areas	0	O
of	0	O
the	0	O
AD	1	O
brain	0	O
has	0	O
been	0	O
suggested	0	O
to	0	O
be	0	O
an	0	O
important	0	O
factor	0	O
in	0	O
the	0	O
neuropathology	0	O
of	0	O
AD	1	O
.	0	O


Toward	0	O
absolute	0	O
methods	0	O
in	0	O
clinical	0	O
chemistry	0	O
:	0	O
application	0	O
of	0	O
mass	0	O
fragmentography	0	O
to	0	O
high	0	O
-	0	O
accuracy	0	O
analyses	0	O
.	0	O


Endothelial	1	O
cell	0	O
seeding	0	O
.	0	O


Increased	0	O
dietary	0	O
energy	0	O
decreased	0	O
PAB	1	O
and	0	O
the	0	O
use	0	O
of	0	O
added	0	O
dietary	0	O
CO	1	O
rather	0	O
than	0	O
PF	1	O
decreased	0	O
PSHL	0	O
in	0	O
broiler	0	O
breeders	0	O
between	0	O
26	0	O
and	0	O
47	0	O
wk	0	O
of	0	O
age	0	O
.	0	O


The	0	O
enzymatic	0	O
response	0	O
of	0	O
neutrophils	0	O
and	0	O
monocytes	0	O
was	0	O
similar	0	O
although	0	O
the	0	O
magnitude	0	O
of	0	O
the	0	O
NADPH	1	B
oxidase	0	I
activity	0	O
was	0	O
significantly	0	O
higher	0	O
in	0	O
neutrophils	0	O
than	0	O
in	0	O
monocytes	0	O
.	0	O


To	1	O
address	0	O
this	0	O
issue	0	O
,	0	O
the	0	O
gene	0	O
for	0	O
factor	0	B
Y	1	I
has	0	O
been	0	O
cloned	0	O
molecularly	0	O
and	0	O
its	0	O
DNA	1	O
sequence	0	O
has	0	O
been	0	O
determined	0	O
.	0	O


These	0	O
observed	0	O
drug	0	O
interactions	0	O
,	0	O
plus	0	O
the	0	O
known	0	O
effect	0	O
of	0	O
probenecid	0	O
to	0	O
block	0	O
secretion	0	O
of	0	O
PZA	1	O
,	0	O
have	0	O
to	0	O
be	0	O
considered	0	O
in	0	O
evaluating	0	O
the	0	O
effect	0	O
of	0	O
the	0	O
two	0	O
drugs	0	O
given	0	O
together	0	O
,	0	O
compared	0	O
to	0	O
the	0	O
effect	0	O
of	0	O
each	0	O
drug	0	O
given	0	O
separately	0	O
.	0	O


I	1	O
.	0	O


A23187	0	O
did	0	O
not	0	O
induce	0	O
any	0	O
modifications	0	O
of	0	O
the	0	O
endolymphatic	0	O
potential	0	O
,	0	O
the	0	O
ampullar	0	O
direct	0	O
current	0	O
or	0	O
the	0	O
frequency	0	O
of	0	O
the	0	O
evoked	0	O
afferent	0	O
spikes	0	O
.	0	O


Eleven	0	O
patients	0	O
tested	0	O
positive	0	O
for	0	O
the	0	O
hepatitis	0	B
B	1	I
surface	0	I
antigen	0	I
(	0	O
HBsAg	1	B
).	0	O


As	1	O
with	0	O
VP16	0	B
,	0	O
the	0	O
transactivation	0	O
function	0	O
of	0	O
Luman	0	B
is	0	O
also	0	O
regulated	0	O
by	0	O
HCF	0	B
.	0	O


Looming	0	O
detectors	0	O
in	0	O
the	0	O
human	0	O
visual	0	O
pathway	0	O
.	0	O


Appl	0	O
.	0	O


Autoimmune	1	O
manipulation	0	O
aids	0	O
juvenile	0	O
diabetes	0	O
management	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
transcription	0	O
initiating	0	O
from	0	O
opuE	0	B
P	1	I
-	0	I
1	0	I
(	0	O
sigma	0	B
A	1	I
)	0	O
rose	0	O
in	0	O
proportion	0	O
to	0	O
the	0	O
external	0	O
osmolarity	0	O
and	0	O
was	0	O
maintained	0	O
at	0	O
high	0	O
levels	0	O
.	0	O


Consistent	0	O
with	0	O
the	0	O
hypothesis	0	O
that	0	O
it	0	O
acts	0	O
as	0	O
transcriptional	0	O
regulator	0	O
,	0	O
wild	0	B
-	0	I
type	0	I
p53	0	I
protein	0	I
binds	0	O
DNA	1	O
and	0	O
activates	0	O
transcription	0	O
of	0	O
several	0	O
promoters	0	O
.	0	O


In	1	O
this	0	O
method	0	O
,	0	O
PLP	1	O
in	0	O
plasma	0	O
can	0	O
be	0	O
determined	0	O
with	0	O
high	0	O
sensitivity	0	O
using	0	O
derivatization	0	O
with	0	O
sodium	0	O
bisulfite	0	O
in	0	O
the	0	O
mobile	0	O
phase	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Physiologic	1	O
pacing	0	O
provides	0	O
little	0	O
benefit	0	O
over	0	O
ventricular	0	O
pacing	0	O
for	0	O
the	0	O
prevention	0	O
of	0	O
stroke	0	O
or	0	O
death	0	O
due	0	O
to	0	O
cardiovascular	0	O
causes	0	O
.	0	O


The	0	O
E	1	O
-	0	O
box	0	O
sequence	0	O
in	0	O
the	0	O
SE2	0	B
fragment	0	I
of	0	O
the	0	O
transferrin	0	B
promoter	0	I
was	0	O
CATCTG	0	O
and	0	O
was	0	O
similar	0	O
in	0	O
gel	0	O
shifts	0	O
to	0	O
the	0	O
consensus	0	O
E	1	O
-	0	O
box	0	O
elements	0	O
(	0	O
CANNTG	0	O
)	0	O
previously	0	O
characterized	0	O
.	0	O


Surprisingly	0	O
,	0	O
the	0	O
RXR	0	B
-	0	O
specific	0	O
ligand	0	O
9	0	O
-	0	O
cis	0	O
-	0	O
retinoic	0	O
acid	0	O
induced	0	O
binding	0	O
of	0	O
SRC	1	B
-	0	I
1	0	I
to	0	O
the	0	O
RXR	0	B
component	0	I
of	0	O
the	0	O
TRE	0	O
-	0	O
bound	0	O
heterodimer	0	O
.	0	O


Our	0	O
findings	0	O
provide	0	O
the	0	O
first	0	O
evidence	0	O
that	0	O
the	0	O
function	0	O
of	0	O
WT1	0	B
can	0	O
be	0	O
modulated	0	O
by	0	O
its	0	O
phosphorylation	0	O
in	0	O
vivo	0	O
.	0	O


Intracranial	1	O
arachnoid	0	O
cyst	0	O
of	0	O
the	0	O
middle	0	O
fossa	0	O
demonstrated	0	O
by	0	O
positive	0	O
99mTc	0	O
brainscintigraphy	0	O
.	0	O


The	0	O
lowest	0	O
detectable	0	O
concentration	0	O
was	0	O
1	0	O
.	0	O
0	0	O
ng	0	O
/	0	O
ml	0	O
in	0	O
the	0	O
serum	0	O
.	0	O


Senior	0	O
systems	0	O
--	0	O
45	0	O
;	0	O
Mental	1	O
health	0	O
and	0	O
illness	0	O
in	0	O
old	0	O
age	0	O
--	0	O
3	0	O
.	0	O


X	1	O
-	0	O
linked	0	O
liver	0	O
glycogenosis	0	O
:	0	O
localization	0	O
and	0	O
isolation	0	O
of	0	O
a	0	O
candidate	0	O
gene	0	O
.	0	O


METHODS	0	O
AND	0	O
RESULTS	0	O
:	0	O
A	1	O
64	0	O
-	0	O
year	0	O
-	0	O
old	0	O
woman	0	O
with	0	O
confirmed	0	O
AV	1	O
nodal	0	O
reentrant	0	O
tachycardia	0	O
underwent	0	O
a	0	O
successful	0	O
"	0	O
slow	0	O
pathway	0	O
"	0	O
AV	1	O
modification	0	O
with	0	O
a	0	O
single	0	O
radiofrequency	0	O
application	0	O
.	0	O


Removal	0	O
of	0	O
the	0	O
carboxyl	0	O
region	0	O
severely	0	O
reduced	0	O
transcriptional	0	O
activation	0	O
.	0	O


Also	0	O
,	0	O
the	0	O
deduced	0	O
amino	0	O
acids	0	O
of	0	O
the	0	O
antigenic	0	B
regions	0	I
A	1	I
,	0	I
B	1	I
and	0	I
C	1	I
of	0	I
VP7	0	I
were	0	O
nearly	0	O
conserved	0	O
within	0	O
the	0	O
phylogenetic	0	O
lineages	0	O
.	0	O


The	0	O
locus	0	O
encoding	0	O
the	0	O
XD	0	B
gene	0	I
(	0	O
designated	0	O
Xd	0	B
)	0	O
was	0	O
mapped	0	O
to	0	O
the	0	O
distal	0	O
part	0	O
of	0	O
mouse	0	O
chromosome	0	O
17	0	O
by	0	O
haplotype	0	O
analysis	0	O
of	0	O
114	0	O
interspecific	0	O
backcross	0	O
mice	0	O
.	0	O


The	0	O
various	0	O
muscles	0	O
of	0	O
the	0	O
pelvic	0	O
floor	0	O
region	0	O
could	0	O
be	0	O
reflexly	0	O
activated	0	O
either	0	O
individually	0	O
or	0	O
as	0	O
a	0	O
mass	0	O
unit	0	O
depending	0	O
on	0	O
the	0	O
intensity	0	O
of	0	O
stimulation	0	O
.	0	O


This	0	O
study	0	O
examines	0	O
the	0	O
cooperative	0	O
effects	0	O
of	0	O
a	0	O
human	0	O
estrogen	0	B
receptor	0	I
-	0	I
alpha	0	I
(	0	O
ERalpha	0	B
)	0	O
isoform	0	O
on	0	O
estrogen	0	O
(	0	O
E2	1	O
)-	0	O
mediated	0	O
gene	0	O
activation	0	O
in	0	O
U2	0	O
-	0	O
OS	1	O
osteosarcoma	0	O
cells	0	O
.	0	O


This	0	O
study	0	O
was	0	O
performed	0	O
to	0	O
clarify	0	O
the	0	O
location	0	O
of	0	O
a	0	O
transesophageal	0	O
echocardiographic	0	O
(	0	O
TEE	1	O
)	0	O
transducer	0	O
when	0	O
obtaining	0	O
the	0	O
short	0	O
-	0	O
axis	0	O
view	0	O
of	0	O
the	0	O
left	0	O
ventricle	0	O
(	0	O
S	1	O
-	0	O
LV	1	O
).	0	O


A	1	O
new	0	O
vector	0	O
,	0	O
pHBK280	0	O
,	0	O
was	0	O
designed	0	O
to	0	O
facilitate	0	O
this	0	O
analysis	0	O
.	0	O


We	0	O
present	0	O
evidence	0	O
that	0	O
YY1	0	B
,	0	O
a	0	O
ubiquitously	0	O
expressed	0	O
DNA	1	O
-	0	O
binding	0	O
protein	0	O
,	0	O
regulates	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
c	0	B
-	0	I
fos	0	I
promoter	0	I
primarily	0	O
through	0	O
an	0	O
effect	0	O
on	0	O
DNA	1	O
structure	0	O
.	0	O


This	0	O
stimulatory	0	O
effect	0	O
could	0	O
also	0	O
be	0	O
elicited	0	O
by	0	O
c	0	B
-	0	I
Jun	1	I
,	0	O
which	0	O
interacts	0	O
with	0	O
topo	0	B
II	0	I
,	0	O
but	0	O
not	0	O
by	0	O
c	0	B
-	0	I
Fos	1	I
,	0	O
which	0	O
does	0	O
not	0	O
bind	0	O
topo	0	B
II	0	I
in	0	O
our	0	O
in	0	O
vitro	0	O
assay	0	O
.	0	O


Anesthesia	1	O
was	0	O
maintained	0	O
with	0	O
isoflurane	0	O
(	0	O
ISO	1	O
)/	0	O
N2O	1	O
/	0	O
O2	1	O
inhalation	0	O
.	0	O


A	1	O
coiled	0	B
-	0	I
coil	0	I
related	0	I
protein	0	I
specific	0	O
for	0	O
synapsed	0	O
regions	0	O
of	0	O
meiotic	0	O
prophase	0	O
chromosomes	0	O
.	0	O


A	1	O
secondary	0	O
spread	0	O
of	0	O
an	0	O
imported	0	O
methicillin	0	O
-	0	O
resistant	0	O
Staphylococcus	1	O
aureus	0	O
strain	0	O
(	0	O
MRSA	1	O
)	0	O
to	0	O
two	0	O
other	0	O
patients	0	O
occurred	0	O
within	0	O
a	0	O
Danish	0	O
surgical	0	O
ward	0	O
in	0	O
spite	0	O
of	0	O
isolation	0	O
of	0	O
a	0	O
multitraumatized	0	O
index	0	O
-	0	O
patient	0	O
immediately	0	O
after	0	O
arrival	0	O
from	0	O
a	0	O
hospital	0	O
in	0	O
the	0	O
Mediterranean	0	O
area	0	O
.	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
stereotypy	0	O
can	0	O
be	0	O
evoked	0	O
also	0	O
in	0	O
the	0	O
case	0	O
when	0	O
the	0	O
striatal	0	O
dopaminergic	0	O
tone	0	O
is	0	O
normal	0	O
or	0	O
even	0	O
below	0	O
normal	0	O
:	0	O
it	0	O
is	0	O
the	0	O
equilibrium	0	O
of	0	O
the	0	O
striatal	0	O
cholinergic	0	O
-	0	O
dopaminergic	0	O
systems	0	O
which	0	O
must	0	O
be	0	O
shifted	0	O
towards	0	O
dopamine	0	O
,	0	O
which	0	O
is	0	O
necessary	0	O
for	0	O
the	0	O
development	0	O
of	0	O
this	0	O
behavioral	0	O
manifestation	0	O
.	0	O


The	0	O
IC50	0	O
values	0	O
for	0	O
rat	0	O
and	0	O
dog	0	O
urinary	0	O
bladder	0	O
were	0	O
3	0	O
.	0	O
9	0	O
x	0	O
10	0	O
(-	0	O
6	0	O
)	0	O
M	1	O
and	0	O
3	0	O
.	0	O
8	0	O
x	0	O
10	0	O
(-	0	O
6	0	O
)	0	O
M	1	O
,	0	O
respectively	0	O
.	0	O


Recently	0	O
,	0	O
studies	0	O
of	0	O
agents	0	O
that	0	O
disrupt	0	O
collagen	0	B
synthesis	0	O
and	0	O
deposition	0	O
have	0	O
yielded	0	O
several	0	O
new	0	O
angiogenesis	0	O
inhibitors	0	O
.	0	O


Copper	1	O
treatments	0	O
were	0	O
assigned	0	O
to	0	O
simulate	0	O
the	0	O
different	0	O
levels	0	O
of	0	O
copper	0	O
intake	0	O
that	0	O
might	0	O
result	0	O
from	0	O
differences	0	O
in	0	O
daily	0	O
feed	0	O
intake	0	O
similar	0	O
to	0	O
the	0	O
practice	0	O
followed	0	O
with	0	O
commercial	0	O
industry	0	O
.	0	O


Following	1	O
seven	0	O
days	0	O
'	0	O
incubation	0	O
both	0	O
at	0	O
20	0	O
degrees	0	O
C	1	O
and	0	O
28	0	O
degrees	0	O
C	1	O
,	0	O
Ae	1	O
.	0	O
vexans	0	O
nip	0	O
.	0	O
was	0	O
capable	0	O
of	0	O
transmitting	0	O
the	0	O
virus	0	O
.	0	O


Neuregulin	1	B
stimulates	0	O
ErbB2	0	B
,	0	O
ErbB3	0	B
,	0	O
and	0	O
ErbB4	0	B
,	0	O
members	0	O
of	0	O
the	0	O
ErbB	0	B
family	0	I
of	0	O
receptor	0	B
tyrosine	0	I
kinases	0	I
.	0	O


Subjects	0	O
with	0	O
a	0	O
short	0	O
postexposure	0	O
time	0	O
and	0	O
a	0	O
dioxin	0	O
burden	0	O
>	0	O
0	0	O
.	0	O
6	0	O
pg	0	O
/	0	O
m3	0	O
had	0	O
a	0	O
significantly	0	O
higher	0	O
risk	0	O
of	0	O
hypoergy	0	O
than	0	O
unexposed	0	O
subjects	0	O
(	0	O
hypoergy	0	O
I	1	O
:	0	O
OR	1	O
=	0	O
9	0	O
.	0	O
51	0	O
,	0	O
95	0	O
%	0	O
CI	1	O
=	0	O
1	0	O
.	0	O
96	0	O
-	0	O
42	0	O
.	0	O
02	0	O
;	0	O
hypoergy	0	O
II	0	O
:	0	O
OR	1	O
=	0	O
2	0	O
.	0	O
92	0	O
,	0	O
95	0	O
%	0	O
CI	1	O
=	0	O
1	0	O
.	0	O
14	0	O
-	0	O
7	0	O
.	0	O
5	0	O
).	0	O


To	1	O
modulate	0	O
transcription	0	O
,	0	O
regulatory	0	O
factors	0	O
communicate	0	O
with	0	O
basal	0	O
transcription	0	O
factors	0	O
and	0	O
/	0	O
or	0	O
RNA	1	B
polymerases	0	I
in	0	O
a	0	O
variety	0	O
of	0	O
ways	0	O
.	0	O


While	0	O
determination	0	O
of	0	O
the	0	O
protein	0	O
content	0	O
of	0	O
the	0	O
formulae	0	O
gave	0	O
no	0	O
valid	0	O
information	0	O
,	0	O
RAST	1	O
/	0	O
EAST	0	O
inhibition	0	O
was	0	O
highest	0	O
for	0	O
cow	0	O
'	0	O
s	0	O
milk	0	O
,	0	O
followed	0	O
by	0	O
the	0	O
partially	0	O
hydrolysed	0	O
whey	0	O
formula	0	O
,	0	O
partially	0	O
hydrolysed	0	O
whey	0	O
/	0	O
casein	0	B
formula	0	O
,	0	O
soy	0	B
/	0	I
pork	0	I
collagen	0	I
formula	0	O
,	0	O
and	0	O
the	0	O
amino	0	O
acid	0	O
formula	0	O
.	0	O


Altogether	0	O
these	0	O
results	0	O
suggest	0	O
that	0	O
,	0	O
in	0	O
KG1a	0	O
cells	0	O
,	0	O
TNFalpha	0	B
can	0	O
stimulate	0	O
in	0	O
parallel	0	O
PC	1	B
-	0	I
PLC	0	I
and	0	O
PLD	0	B
,	0	O
whose	0	O
lipid	0	O
products	0	O
activate	0	O
in	0	O
turn	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
(	0	O
MAP	1	B
kinase	0	I
)	0	O
and	0	O
NF	1	B
-	0	I
kappaB	0	I
signalling	0	O
respectively	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
a	0	O
21	0	O
-	0	O
mer	0	O
subrepeat	0	O
structure	0	O
is	0	O
also	0	O
present	0	O
in	0	O
each	0	O
unit	0	O
.	0	O


The	0	O
authors	0	O
have	0	O
tested	0	O
the	0	O
interference	0	O
of	0	O
the	0	O
hemoglobin	0	B
by	0	O
two	0	O
routine	0	O
methods	0	O
(	0	O
Berthelot	0	O
classic	0	O
and	0	O
Berthelot	0	O
modified	0	O
)	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
plasmatic	0	O
urea	0	O
.	0	O


To	1	O
study	0	O
a	0	O
possible	0	O
functional	0	O
role	0	O
of	0	O
this	0	O
putative	0	O
chicken	0	O
ICS	1	B
,	0	O
an	0	O
oligonucleotide	0	O
spanning	0	O
the	0	O
upstream	0	O
sequences	0	O
of	0	O
the	0	O
BF	1	B
-	0	I
IV	1	I
gene	0	I
(-	0	O
174	0	O
/-	0	O
194	0	O
)	0	O
was	0	O
cloned	0	O
singly	0	O
or	0	O
in	0	O
multiple	0	O
copies	0	O
before	0	O
the	0	O
herpes	0	O
TK	1	B
promoter	0	I
controlling	0	O
the	0	O
chloramphenicol	0	B
acetyl	0	I
transferase	0	I
(	0	O
CAT	1	B
)	0	O
gene	0	O
(	0	O
pBLCAT2	0	B
).	0	O


RNA	1	B
polymerase	0	I
II	0	I
inhibition	0	O
increased	0	O
the	0	O
binding	0	O
of	0	O
ARE	0	O
(	0	O
AUBP	0	O
activity	0	O
)	0	O
and	0	O
poly	0	O
(	0	O
U	1	O
)-	0	O
Sepharose	0	O
by	0	O
cytoplasmic	0	B
hnRNP	1	I
A1	0	I
,	0	O
while	0	O
nuclear	0	B
hnRNP	1	I
A1	0	I
binding	0	O
was	0	O
unaffected	0	O
.	0	O


However	0	O
,	0	O
the	0	O
few	0	O
studies	0	O
that	0	O
address	0	O
antimicrobial	0	O
prophylaxis	0	O
in	0	O
bone	0	O
marrow	0	O
transplantation	0	O
have	0	O
not	0	O
always	0	O
shown	0	O
a	0	O
survival	0	O
benefit	0	O
.	0	O


Short	0	O
therapy	0	O
with	0	O
omeprazole	0	O
20	0	O
mg	0	O
/	0	O
b	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.,	0	O
clarithromycin	0	O
500	0	O
mg	0	O
/	0	O
b	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.,	0	O
and	0	O
CBS	0	O
120	0	O
mg	0	O
/	0	O
q	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.	0	O
is	0	O
a	0	O
safe	0	O
,	0	O
well	0	O
tolerated	0	O
combination	0	O
that	0	O
achieves	0	O
a	0	O
80	0	O
.	0	O
6	0	O
%	0	O
eradication	0	O
rate	0	O
of	0	O
H	1	O
.	0	O
pylori	0	O
and	0	O
duodenal	0	O
ulcer	0	O
healing	0	O
rates	0	O
as	0	O
good	0	O
as	0	O
those	0	O
achieved	0	O
by	0	O
omeprazole	0	O
20	0	O
mg	0	O
/	0	O
d	0	O
when	0	O
given	0	O
for	0	O
4	0	O
wk	0	O
.	0	O


All	1	O
were	0	O
tested	0	O
for	0	O
serum	0	O
ferritin	0	B
(	0	O
SF	1	B
),	0	O
hemoglobin	0	B
(	0	O
Hb	1	B
)	0	O
level	0	O
and	0	O
asked	0	O
for	0	O
detailed	0	O
histories	0	O
of	0	O
donations	0	O
and	0	O
iron	0	O
supplementation	0	O
.	0	O


The	0	O
latter	0	O
domain	0	O
appears	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
targeting	0	O
Num1p	0	B
to	0	O
the	0	O
mother	0	O
cell	0	O
cortex	0	O
.	0	O


Comparative	0	O
studies	0	O
of	0	O
the	0	O
antithrombin	0	B
III	0	I
level	0	O
and	0	O
plasminogen	0	B
activator	0	I
activity	0	O
in	0	O
patients	0	O
with	0	O
thrombophlebitis	0	O


12	0	O
healthy	0	O
women	0	O
(	0	O
age	0	O
18	0	O
-	0	O
38	0	O
years	0	O
)	0	O
were	0	O
examined	0	O
using	0	O
the	0	O
2	0	O
-	0	O
hour	0	O
'	0	O
s	0	O
method	0	O
of	0	O
passive	0	O
leg	0	O
rising	0	O
(	0	O
PLR	0	O
)	0	O
in	0	O
follicular	0	O
(	0	O
FP	1	O
)	0	O
and	0	O
luteal	0	O
(	0	O
LP	1	O
)	0	O
phases	0	O
of	0	O
normal	0	O
ovulatory	0	O
cycle	0	O
.	0	O


Patulin	1	O
is	0	O
extracted	0	O
from	0	O
apple	0	O
butter	0	O
samples	0	O
with	0	O
ethyl	0	O
acetate	0	O
and	0	O
the	0	O
extract	0	O
is	0	O
cleaned	0	O
up	0	O
on	0	O
a	0	O
silica	0	O
gel	0	O
column	0	O
,	0	O
using	0	O
benzene	0	O
-	0	O
ethyl	0	O
acetate	0	O
(	0	O
75	0	O
+	0	O
25	0	O
)	0	O
as	0	O
the	0	O
eluant	0	O
.	0	O


Prostate	1	B
specific	0	I
antigen	0	I
shows	0	O
the	0	O
metastatic	0	O
cases	0	O
better	0	O
[	0	O
correction	0	O
of	0	O
worse	0	O
]	0	O
than	0	O
prostatic	0	B
acid	0	I
phosphatase	0	I
.	0	O


However	0	O
,	0	O
regional	0	O
MVO2	0	O
increased	0	O
to	0	O
about	0	O
the	0	O
same	0	O
extent	0	O
in	0	O
the	0	O
CFX	0	O
(	0	O
from	0	O
6	0	O
.	0	O
0	0	O
+/-	0	O
0	0	O
.	0	O
7	0	O
to	0	O
12	0	O
.	0	O
4	0	O
+/-	0	O
0	0	O
.	0	O
9	0	O
ml	0	O
O2	1	O
.	0	O
min	0	O
-	0	O
1	0	O
times	0	O
100	0	O
g	0	O
-	0	O
1	0	O
)	0	O
and	0	O
the	0	O
LAD	1	O
region	0	O
(	0	O
from	0	O
7	0	O
.	0	O
0	0	O
+/-	0	O
0	0	O
.	0	O
6	0	O
to	0	O
14	0	O
.	0	O
5	0	O
+/-	0	O
1	0	O
.	0	O
3	0	O
ml	0	O
O2	1	O
.	0	O
min	0	O
-	0	O
1	0	O
times	0	O
100	0	O
g	0	O
-	0	O
1	0	O
).	0	O


Expression	1	O
of	0	O
a	0	O
dominant	0	O
-	0	O
negative	0	O
mutant	0	O
of	0	O
JNK1	0	B
also	0	O
suppressed	0	O
glucose	0	O
deprivation	0	O
-	0	O
induced	0	O
JNK1	0	B
activation	0	O
as	0	O
well	0	O
as	0	O
HSP70	0	B
gene	0	I
expression	0	O
.	0	O


Alterations	0	O
in	0	O
DNase	1	B
I	1	I
reactivity	0	O
of	0	O
the	0	O
GC	1	O
-	0	O
response	0	O
element	0	O
region	0	O
suggest	0	O
that	0	O
GC	1	B
receptor	0	I
-	0	I
GC	1	I
complexes	0	I
may	0	O
associate	0	O
,	0	O
in	0	O
a	0	O
transient	0	O
manner	0	O
,	0	O
with	0	O
the	0	O
promoter	0	O
in	0	O
the	0	O
actively	0	O
transcribing	0	O
control	0	O
state	0	O
.	0	O


Foveating	0	O
saccades	0	O
,	0	O
therefore	0	O
,	0	O
can	0	O
be	0	O
distinguished	0	O
from	0	O
other	0	O
FEMs	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
speed	0	O
.	0	O


The	0	O
importance	0	O
of	0	O
posttranslational	0	O
regulation	0	O
of	0	O
p15INK4B	0	B
by	0	O
TGF	1	B
-	0	I
beta	0	I
is	0	O
underlined	0	O
by	0	O
the	0	O
observation	0	O
that	0	O
in	0	O
TGF	1	B
-	0	I
beta	0	I
-	0	O
resistant	0	O
184A1L5R	0	O
,	0	O
although	0	O
the	0	O
p15	0	B
transcript	0	I
increased	0	O
,	0	O
p15INK4B	0	B
protein	0	I
was	0	O
not	0	O
stabilized	0	O
and	0	O
did	0	O
not	0	O
accumulate	0	O
,	0	O
and	0	O
cyclin	0	B
D1	1	I
-	0	O
cdk	0	B
association	0	O
and	0	O
kinase	0	O
activation	0	O
were	0	O
not	0	O
inhibited	0	O
.	0	O


This	0	O
is	0	O
based	0	O
on	0	O
partitioning	0	O
an	0	O
underlying	0	O
multivariate	0	O
normal	0	O
distribution	0	O
.	0	O


Hand	1	O
-	0	O
held	0	O
,	0	O
continuous	0	O
-	0	O
wave	0	O
Doppler	1	O
probes	0	O
,	0	O
coupled	0	O
with	0	O
sound	0	O
spectral	0	O
analysis	0	O
,	0	O
can	0	O
successfully	0	O
predict	0	O
carotid	0	O
artery	0	O
stenosis	0	O
.	0	O


Moreover	0	O
,	0	O
in	0	O
one	0	O
patient	0	O
with	0	O
a	0	O
sarcoma	0	O
who	0	O
underwent	0	O
a	0	O
leg	0	O
-	0	O
sparing	0	O
procedure	0	O
,	0	O
no	0	O
sciatic	0	O
nerve	0	O
enlargement	0	O
was	0	O
seen	0	O
postoperatively	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Delineation	0	O
of	0	O
the	0	O
morphologic	0	O
aspects	0	O
of	0	O
age	0	O
-	0	O
related	0	O
macular	0	O
degeneration	0	O
(	0	O
ARMD	1	O
)	0	O
is	0	O
helpful	0	O
in	0	O
correlation	0	O
with	0	O
the	0	O
clinical	0	O
features	0	O
and	0	O
may	0	O
contribute	0	O
to	0	O
understanding	0	O
the	0	O
pathogenesis	0	O
.	0	O


In	1	O
adulthood	0	O
these	0	O
rats	0	O
were	0	O
hyperactive	0	O
and	0	O
learned	0	O
the	0	O
active	0	O
avoidance	0	O
response	0	O
later	0	O
than	0	O
the	0	O
controls	0	O
.	0	O


A	1	O
cDNA	1	O
encoding	0	O
a	0	O
MYC	0	B
-	0	I
related	0	I
DNA	1	I
binding	0	I
protein	0	I
was	0	O
isolated	0	O
by	0	O
DNA	1	O
-	0	O
ligand	0	O
binding	0	O
screening	0	O
,	0	O
using	0	O
the	0	O
67	0	O
-	0	O
bp	0	O
region	0	O
as	0	O
a	0	O
probe	0	O
,	0	O
and	0	O
designated	0	O
rd22BP1	0	B
.	0	O


The	0	O
comparison	0	O
of	0	O
the	0	O
expression	0	O
patterns	0	O
of	0	O
the	0	O
known	0	O
Kv4	0	B
family	0	I
members	0	I
shows	0	O
subtype	0	O
specificity	0	O
with	0	O
significant	0	O
overlaps	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
TGF	1	B
-	0	I
betaf	0	I
potentiates	0	O
the	0	O
c	0	B
-	0	I
fos	0	I
SRE	0	O
activated	0	O
by	0	O
PKC	0	B
through	0	O
the	0	O
SRF	1	B
binding	0	I
site	0	I
.	0	O


We	0	O
describe	0	O
a	0	O
case	0	O
of	0	O
acetaminophen	0	O
overdose	0	O
that	0	O
was	0	O
treated	0	O
with	0	O
both	0	O
hemodialysis	0	O
(	0	O
HD	1	O
)	0	O
and	0	O
NAC	0	O
due	0	O
to	0	O
severe	0	O
intoxication	0	O
and	0	O
slow	0	O
drug	0	O
clearance	0	O
.	0	O


Acta	0	O
572	0	O
,	0	O
113	0	O
-	0	O
120	0	O
].	0	O


Overall	0	O
prevalences	0	O
of	0	O
antibody	0	O
were	0	O
70	0	O
per	0	O
cent	0	O
in	0	O
cattle	0	O
,	0	O
67	0	O
per	0	O
cent	0	O
in	0	O
sheep	0	O
and	0	O
76	0	O
per	0	O
cent	0	O
in	0	O
goats	0	O
as	0	O
assessed	0	O
by	0	O
an	0	O
immunodiffusion	0	O
test	0	O
.	0	O


The	0	O
long	0	O
terminal	0	O
repeat	0	O
(	0	O
LTR	1	O
)	0	O
of	0	O
the	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
(	0	O
HIV	1	O
)	0	O
contains	0	O
three	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
transcriptional	0	O
factor	0	O
Sp1	0	B
.	0	O


PURPOSE	0	O
:	0	O
A	1	O
two	0	O
-	0	O
generation	0	O
consanguineous	0	O
Pakistani	0	O
family	0	O
with	0	O
autosomal	0	O
recessive	0	O
Leber	0	O
congenital	0	O
amaurosis	0	O
(	0	O
LCA	1	O
,	0	O
MIM	0	O
204	0	O
,	0	O
000	0	O
)	0	O
and	0	O
keratoconus	0	O
was	0	O
identified	0	O
.	0	O


Syndecan	1	B
-	0	I
4	0	I
is	0	O
a	0	O
focal	0	O
adhesion	0	O
component	0	O
,	0	O
and	0	O
this	0	O
interaction	0	O
may	0	O
both	0	O
localize	0	O
PKC	0	B
and	0	O
amplify	0	O
its	0	O
activity	0	O
at	0	O
sites	0	O
of	0	O
forming	0	O
adhesions	0	O
.	0	O


The	0	O
Babcock	0	O
Surgical	1	O
Clinic	1	O
.	0	O


Using	0	O
a	0	O
polymerase	0	O
chain	0	O
reaction	0	O
-	0	O
based	0	O
approach	0	O
,	0	O
we	0	O
cloned	0	O
a	0	O
150	0	O
-	0	O
base	0	O
pair	0	O
fragment	0	O
of	0	O
a	0	O
new	0	O
sialymotif	0	O
from	0	O
human	0	O
placenta	0	O
mRNA	1	O
,	0	O
which	0	O
was	0	O
then	0	O
used	0	O
as	0	O
a	0	O
probe	0	O
to	0	O
clone	0	O
the	0	O
complete	0	O
coding	0	O
sequence	0	O
of	0	O
the	0	O
corresponding	0	O
gene	0	O
from	0	O
a	0	O
cDNA	1	O
library	0	O
.	0	O


These	0	O
results	0	O
illustrate	0	O
an	0	O
important	0	O
role	0	O
for	0	O
La	1	B
in	0	O
RNA	1	O
production	0	O
by	0	O
demonstrating	0	O
its	0	O
ability	0	O
to	0	O
clear	0	O
the	0	O
termination	0	O
sites	0	O
of	0	O
class	0	O
III	0	O
templates	0	O
,	0	O
thereby	0	O
promoting	0	O
efficient	0	O
use	0	O
of	0	O
transcription	0	O
complexes	0	O
by	0	O
pol	0	B
III	0	I
.	0	O


Studies	0	O
in	0	O
mammalian	0	O
cells	0	O
have	0	O
correlated	0	O
induction	0	O
of	0	O
inhibitory	0	O
tyrosine	0	O
15	0	O
(	0	O
Y15	0	O
)	0	O
phosphorylation	0	O
on	0	O
p34cdc2	0	B
with	0	O
the	0	O
response	0	O
to	0	O
DNA	1	O
damage	0	O
.	0	O


FK506	0	O
is	0	O
10	0	O
-	0	O
to	0	O
100	0	O
-	0	O
fold	0	O
more	0	O
potent	0	O
than	0	O
cyclosporin	0	O
A	1	O
in	0	O
preventing	0	O
organ	0	O
rejection	0	O
and	0	O
in	0	O
toxicity	0	O
.	0	O


Six	0	O
healthy	0	O
male	0	O
subjects	0	O
received	0	O
single	0	O
oral	0	O
doses	0	O
of	0	O
regular	0	O
release	0	O
(	0	O
RR	0	O
)	0	O
quinidine	0	O
sulfate	0	O
,	0	O
sustained	0	O
release	0	O
(	0	O
SR	1	O
)	0	O
quinidine	0	O
bisulfate	0	O
and	0	O
the	0	O
same	0	O
dose	0	O
of	0	O
the	0	O
SR	1	O
product	0	O
with	0	O
food	0	O
(	0	O
SR	1	O
-	0	O
F	1	O
).	0	O


Members	0	O
of	0	O
the	0	O
titin	0	B
/	0	O
myosin	0	B
light	0	I
chain	0	I
kinase	0	I
family	0	O
play	0	O
an	0	O
essential	0	O
role	0	O
in	0	O
the	0	O
organization	0	O
of	0	O
the	0	O
actin	0	B
/	0	O
myosin	0	B
cytoskeleton	0	O
,	0	O
especially	0	O
in	0	O
sarcomere	0	O
assembly	0	O
and	0	O
function	0	O
.	0	O


Src	1	B
homology	0	I
(	0	O
SH	1	B
)	0	O
domain	0	O
dependent	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
are	0	O
important	0	O
to	0	O
tyrosine	0	B
kinase	0	I
receptor	0	I
signal	0	O
transduction	0	O
.	0	O


Only	0	O
after	0	O
a	0	O
pretreatment	0	O
aimed	0	O
at	0	O
increasing	0	O
its	0	O
oxide	0	O
surface	0	O
layer	0	O
was	0	O
titanium	0	O
powder	0	O
found	0	O
to	0	O
accelerate	0	O
the	0	O
precipitation	0	O
from	0	O
solutions	0	O
containing	0	O
2	0	O
mmol	0	O
/	0	O
L	1	O
CaCl2	1	O
,	0	O
2	0	O
mmol	0	O
/	0	O
L	1	O
KH2PO4	0	O
,	0	O
50	0	O
mmol	0	O
/	0	O
L	1	O
Hepes	0	O
,	0	O
pH	1	O
7	0	O
.	0	O
2	0	O
,	0	O
and	0	O
to	0	O
induce	0	O
precipitation	0	O
from	0	O
metastable	0	O
solutions	0	O
containing	0	O
1	0	O
.	0	O
2	0	O
mmol	0	O
/	0	O
L	1	O
CaCl2	1	O
,	0	O
1	0	O
.	0	O
2	0	O
mmol	0	O
/	0	O
L	1	O
KH2PO4	0	O
,	0	O
50	0	O
mmol	0	O
/	0	O
L	1	O
Hepes	0	O
,	0	O
pH	1	O
7	0	O
.	0	O
2	0	O
,	0	O
at	0	O
37	0	O
degrees	0	O
C	1	O
.	0	O


Identification	1	O
and	0	O
characterization	0	O
of	0	O
IS2404	0	B
and	0	O
IS2606	0	B
:	0	O
two	0	O
distinct	0	O
repeated	0	O
sequences	0	O
for	0	O
detection	0	O
of	0	O
Mycobacterium	1	O
ulcerans	0	O
by	0	O
PCR	1	O
.	0	O


Ex	0	O
vivo	0	O
MAO	1	B
inhibition	0	O
data	0	O
indicated	0	O
DPGPEA	0	O
to	0	O
be	0	O
an	0	O
inhibitor	0	O
of	0	O
MAO	1	B
-	0	I
B	1	I
,	0	O
although	0	O
the	0	O
effect	0	O
was	0	O
much	0	O
weaker	0	O
than	0	O
seen	0	O
with	0	O
tranylcypromine	0	O
or	0	O
pargyline	0	O
.	0	O


We	0	O
used	0	O
the	0	O
Toshiba	0	O
IIDR	0	O
system	0	O
,	0	O
which	0	O
is	0	O
composed	0	O
of	0	O
an	0	O
X	1	O
-	0	O
ray	0	O
TV	1	O
system	0	O
and	0	O
a	0	O
digital	0	O
image	0	O
managing	0	O
circuit	0	O
.	0	O


A	1	O
constitutive	0	O
allele	0	O
of	0	O
GPA2	0	B
could	0	O
stimulate	0	O
growth	0	O
of	0	O
a	0	O
strain	0	O
lacking	0	O
both	0	O
RAS	1	B
genes	0	I
.	0	O


The	0	O
extents	0	O
of	0	O
phosphorylation	0	O
of	0	O
Ser44	0	O
and	0	O
Ser64	0	O
were	0	O
1	0	O
:	0	O
1	0	O
,	0	O
whereas	0	O
those	0	O
of	0	O
the	0	O
four	0	O
minor	0	O
sites	0	O
all	0	O
together	0	O
were	0	O
<	0	O
30	0	O
%	0	O
of	0	O
the	0	O
major	0	O
one	0	O
.	0	O


The	0	O
abundance	0	O
of	0	O
transcripts	0	O
from	0	O
several	0	O
unrelated	0	O
genes	0	O
is	0	O
decreased	0	O
in	0	O
cdc68	0	B
-	0	I
1	0	I
mutant	0	I
cells	0	O
after	0	O
transfer	0	O
to	0	O
the	0	O
restrictive	0	O
temperature	0	O
,	0	O
while	0	O
at	0	O
least	0	O
one	0	O
transcript	0	O
,	0	O
from	0	O
the	0	O
HSP82	0	B
gene	0	I
,	0	O
persists	0	O
in	0	O
an	0	O
aberrant	0	O
fashion	0	O
.	0	O


Roux	0	O
-	0	O
en	0	O
-	0	O
Y	1	O
gastroenterostomy	0	O
severely	0	O
disturbs	0	O
emptying	0	O
of	0	O
the	0	O
gallbladder	0	O
.	0	O


Overexpression	1	O
of	0	O
PTTG	0	B
in	0	O
transfected	0	O
NIH	1	O
3T3	0	O
cells	0	O
also	0	O
stimulated	0	O
expression	0	O
and	0	O
secretion	0	O
of	0	O
basic	0	B
fibroblast	0	I
growth	0	I
factor	0	I
,	0	O
a	0	O
human	0	B
pituitary	0	I
tumor	0	I
growth	0	I
-	0	I
regulating	0	I
factor	0	I
.	0	O


We	0	O
have	0	O
shown	0	O
previously	0	O
that	0	O
in	0	O
contrast	0	O
to	0	O
other	0	O
extracellular	0	O
matrix	0	O
molecules	0	O
pepsin	0	B
-	0	O
solubilized	0	O
collagen	0	B
VI	0	I
(	0	O
CVI	0	B
)	0	O
can	0	O
stimulate	0	O
DNA	1	O
synthesis	0	O
of	0	O
various	0	O
mesenchymal	0	O
cell	0	O
types	0	O
,	0	O
apparently	0	O
independent	0	O
of	0	O
integrin	0	B
-	0	O
mediated	0	O
signal	0	O
transduction	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Although	0	O
quantitative	0	O
and	0	O
qualitative	0	O
criteria	0	O
for	0	O
diagnosing	0	O
fatty	0	O
liver	0	O
on	0	O
helical	0	O
CT	1	O
can	0	O
be	0	O
determined	0	O
,	0	O
they	0	O
are	0	O
protocol	0	O
-	0	O
specific	0	O
.	0	O


No	1	O
difference	0	O
in	0	O
telomere	0	O
length	0	O
was	0	O
seen	0	O
in	0	O
mutants	0	O
affected	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
Cdc2	0	B
,	0	O
whereas	0	O
some	0	O
of	0	O
the	0	O
DNA	1	O
repair	0	O
mutants	0	O
examined	0	O
had	0	O
slightly	0	O
longer	0	O
telomeres	0	O
than	0	O
did	0	O
the	0	O
wild	0	O
type	0	O
.	0	O


The	0	O
recovery	0	O
index	0	O
(	0	O
T25	0	O
-	0	O
T75	0	O
)	0	O
after	0	O
the	0	O
infusion	0	O
stopped	0	O
was	0	O
similar	0	O
in	0	O
patients	0	O
who	0	O
received	0	O
mivacurium	0	O
and	0	O
those	0	O
who	0	O
received	0	O
suxamethonium	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
,	0	O
we	0	O
show	0	O
that	0	O
peptides	0	O
representing	0	O
docking	0	O
sites	0	O
within	0	O
the	0	O
target	0	O
substrates	0	O
Elk	0	B
-	0	I
1	0	I
and	0	O
p90	0	B
(	0	O
rsk	0	B
)	0	O
inhibit	0	O
ERK	0	B
-	0	O
dependent	0	O
activation	0	O
of	0	O
MKP	0	B
-	0	I
3	0	I
.	0	O


The	0	O
injection	0	O
of	0	O
XDRP1	0	B
protein	0	I
into	0	O
fertilized	0	O
Xenopus	1	O
eggs	0	O
blocked	0	O
embryonic	0	O
cell	0	O
division	0	O
.	0	O


The	0	O
inferred	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
cyanobacterial	0	B
HemB	0	I
protein	0	I
indicates	0	O
a	0	O
significant	0	O
difference	0	O
in	0	O
the	0	O
metal	0	O
cofactor	0	O
requirement	0	O
from	0	O
the	0	O
higher	0	O
-	0	O
plant	0	O
enzymes	0	O
,	0	O
which	0	O
was	0	O
confirmed	0	O
by	0	O
overexpression	0	O
and	0	O
biochemical	0	O
analysis	0	O
.	0	O


The	0	O
ICBF	0	O
in	0	O
the	0	O
ischaemic	0	O
cortex	0	O
revealed	0	O
a	0	O
graded	0	O
reduction	0	O
from	0	O
the	0	O
ischaemic	0	O
centre	0	O
to	0	O
the	0	O
surrounding	0	O
tissues	0	O
.	0	O


Restriction	1	O
mapping	0	O
analysis	0	O
localized	0	O
this	0	O
cDNA	1	O
to	0	O
the	0	O
HHV	0	B
-	0	I
6A	0	I
(	0	I
U1102	0	I
)	0	I
genomic	0	I
BamHI	0	I
G	1	I
fragment	0	I
,	0	O
at	0	O
the	0	O
right	0	O
end	0	O
of	0	O
the	0	O
unique	0	O
long	0	O
segment	0	O
of	0	O
the	0	O
genome	0	O
and	0	O
to	0	O
the	0	O
SalI	0	B
L	1	I
and	0	O
SalI	0	B
O	1	I
fragments	0	I
within	0	O
the	0	O
left	0	O
and	0	O
right	0	O
terminal	0	O
direct	0	O
repeat	0	O
regions	0	O
,	0	O
respectively	0	O
.	0	O


Angiotensin	1	B
II	0	I
induces	0	O
nuclear	0	B
factor	0	I
(	0	I
NF	1	I
)-	0	I
kappaB1	0	I
isoforms	0	I
to	0	O
bind	0	O
the	0	O
angiotensinogen	0	B
gene	0	I
acute	0	O
-	0	O
phase	0	O
response	0	O
element	0	O
:	0	O
a	0	O
stimulus	0	O
-	0	O
specific	0	O
pathway	0	O
for	0	O
NF	1	B
-	0	I
kappaB	0	I
activation	0	O
.	0	O


Mechanism	1	O
of	0	O
immunogenesis	0	O
in	0	O
vaccination	0	O
with	0	O
streptomycin	0	O
-	0	O
dependent	0	O
mutants	0	O
of	0	O
salmonellae	0	O
and	0	O
shigellae	0	O
.	0	O


Morphometrical	0	O
quantification	0	O
of	0	O
brain	0	O
edema	0	O
related	0	O
to	0	O
experimental	0	O
multiple	0	O
micro	0	O
-	0	O
infarcts	0	O
in	0	O
mice	0	O
:	0	O
assessment	0	O
of	0	O
neurotropin	0	B
effect	0	O
.	0	O


Evidence	1	O
for	0	O
a	0	O
role	0	O
of	0	O
endogenous	0	B
corticotropin	0	I
-	0	I
releasing	0	I
factor	0	I
in	0	O
cold	0	O
,	0	O
ether	0	O
,	0	O
immobilization	0	O
,	0	O
and	0	O
traumatic	0	O
stress	0	O
.	0	O


With	0	O
regard	0	O
to	0	O
nonhematologic	0	O
toxicities	0	O
,	0	O
diarrhea	0	O
,	0	O
infection	0	O
and	0	O
elevated	0	O
serum	0	B
alkaline	0	I
phosphatase	0	I
of	0	O
grade	0	O
3	0	O
or	0	O
over	0	O
were	0	O
observed	0	O
in	0	O
2	0	O
%	0	O
of	0	O
cycles	0	O
,	0	O
but	0	O
were	0	O
tolerable	0	O
and	0	O
reversible	0	O
.	0	O


Laboratory	1	O
studies	0	O
showed	0	O
that	0	O
the	0	O
direct	0	O
fluorescent	0	O
-	0	O
antibody	0	O
kits	0	O
were	0	O
the	0	O
least	0	O
sensitive	0	O
in	0	O
this	0	O
case	0	O
and	0	O
did	0	O
not	0	O
detect	0	O
fewer	0	O
than	0	O
10	0	O
(	0	O
4	0	O
)	0	O
elementary	0	O
bodies	0	O
per	0	O
ml	0	O
,	0	O
while	0	O
most	0	O
ELISA	1	O
kits	0	O
detected	0	O
between	0	O
130	0	O
and	0	O
600	0	O
elementary	0	O
bodies	0	O
per	0	O
ml	0	O
.	0	O


The	0	O
patients	0	O
were	0	O
divided	0	O
into	0	O
3	0	O
subgroups	0	O
:	0	O
1	0	O
)	0	O
13	0	O
N	1	O
+	0	O
patients	0	O
with	0	O
multiple	0	O
hot	0	O
spots	0	O
(	0	O
greater	0	O
than	0	O
2	0	O
)	0	O
(	0	O
N	1	O
+	0	O
IM	1	O
);	0	O
2	0	O
)	0	O
24	0	O
N	1	O
+	0	O
patients	0	O
with	0	O
single	0	O
hot	0	O
spots	0	O
(	0	O
less	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
2	0	O
)	0	O
(	0	O
N	1	O
+	0	O
IS	1	O
);	0	O
3	0	O
)	0	O
12	0	O
N	1	O
-	0	O
patients	0	O
with	0	O
single	0	O
hot	0	O
spots	0	O
(	0	O
less	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
2	0	O
)	0	O
(	0	O
N	1	O
-	0	O
IS	1	O
).	0	O


Analysis	1	O
of	0	O
the	0	O
sequence	0	O
identified	0	O
four	0	O
open	0	O
reading	0	O
frames	0	O
(	0	O
ORFs	0	O
)	0	O
which	0	O
are	0	O
designated	0	O
UL1	0	B
,	0	O
UL2	0	B
,	0	O
UL3	0	B
,	0	O
and	0	O
UL3	0	B
.	0	I
5	0	I
based	0	O
on	0	O
their	0	O
homology	0	O
with	0	O
proteins	0	O
of	0	O
herpes	0	O
simplex	0	O
virus	0	O
-	0	O
1	0	O
(	0	O
HSV	1	O
-	0	O
1	0	O
),	0	O
pseudorabies	0	O
virus	0	O
(	0	O
PRV	0	O
),	0	O
equine	0	O
herpesvirus	0	O
-	0	O
1	0	O
,	0	O
and	0	O
varicella	0	O
-	0	O
zoster	0	O
virus	0	O
.	0	O


We	0	O
report	0	O
here	0	O
the	0	O
isolation	0	O
of	0	O
a	0	O
full	0	O
-	0	O
length	0	O
cDNA	1	O
clone	0	O
coding	0	O
for	0	O
a	0	O
hitherto	0	O
undiscovered	0	O
isoform	0	O
of	0	O
the	0	O
bovine	0	B
C	1	I
-	0	I
subunit	0	I
.	0	O


The	0	O
potentially	0	O
SLE	1	O
-	0	O
inducing	0	O
drugs	0	O
are	0	O
reviewed	0	O
.	0	O


European	0	O
Community	1	O
Huntington	0	O
'	0	O
s	0	O
Disease	1	O
Collaborative	0	O
Study	1	O
Group	1	O
.	0	O


Malaria	1	O
,	0	O
anaemia	0	O
,	0	O
and	0	O
HIV	1	O
-	0	O
1	0	O
transmission	0	O
in	0	O
central	0	O
Africa	0	O
.	0	O


The	0	O
RI	1	B
alpha	0	I
gene	0	I
is	0	O
composed	0	O
of	0	O
nine	0	O
coding	0	O
exons	0	O
of	0	O
varying	0	O
lengths	0	O
,	0	O
separated	0	O
by	0	O
introns	0	O
,	0	O
giving	0	O
the	0	O
gene	0	O
a	0	O
total	0	O
length	0	O
of	0	O
at	0	O
least	0	O
21	0	O
kb	0	O
.	0	O
our	0	O
recent	0	O
cloning	0	O
of	0	O
a	0	O
processed	0	O
RI	1	B
alpha	0	I
pseudogene	0	I
with	0	O
a	0	O
5	0	O
'-	0	O
noncoding	0	O
region	0	O
different	0	O
from	0	O
the	0	O
previously	0	O
reported	0	O
RI	1	B
alpha	0	I
complementary	0	I
RNA	1	I
indicated	0	O
that	0	O
the	0	O
RI	1	B
alpha	0	I
gene	0	I
may	0	O
have	0	O
multiple	0	O
leader	0	O
exons	0	O
giving	0	O
rise	0	O
to	0	O
alternately	0	O
spliced	0	O
messenger	0	O
RNAs	0	O
(	0	O
mRNAs	0	O
).	0	O


The	0	O
nucleotide	0	O
sequences	0	O
of	0	O
the	0	O
human	0	B
and	0	I
murine	0	I
ornithine	0	I
decarboxylase	0	I
mRNAs	0	I
share	0	O
an	0	O
85	0	O
%	0	O
homology	0	O
,	0	O
even	0	O
in	0	O
their	0	O
3	0	O
'-	0	O
noncoding	0	O
regions	0	O
.	0	O


Similarity	0	O
of	0	O
DNA	1	O
binding	0	O
and	0	O
transcriptional	0	O
regulation	0	O
by	0	O
Caenorhabditis	0	B
elegans	0	I
MAB	0	I
-	0	I
3	0	I
and	0	O
Drosophila	1	B
melanogaster	0	I
DSX	0	I
suggests	0	O
conservation	0	O
of	0	O
sex	0	O
determining	0	O
mechanisms	0	O
.	0	O


The	0	O
complete	0	O
exon	0	O
-	0	O
intron	0	O
structure	0	O
of	0	O
the	0	O
156	0	B
-	0	I
kb	0	I
human	0	I
gene	0	I
NFKB1	0	I
,	0	O
which	0	O
encodes	0	O
the	0	O
p105	0	B
and	0	O
p50	0	B
proteins	0	I
of	0	O
transcription	0	O
factors	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
and	0	O
I	1	B
kappa	0	I
B	1	I
-	0	I
gamma	0	I
:	0	O
implications	0	O
for	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
-	0	O
mediated	0	O
signal	0	O
transduction	0	O
.	0	O


Changes	0	O
in	0	O
xanthine	0	B
oxidase	0	I
activity	0	O
in	0	O
patients	0	O
with	0	O
circulatory	0	O
failure	0	O


One	0	O
group	0	O
of	0	O
six	0	O
cDNA	1	O
clones	0	O
was	0	O
derived	0	O
from	0	O
a	0	O
2	0	O
.	0	O
9	0	O
-	0	O
kilobase	0	O
early	0	O
transcript	0	O
encoded	0	O
by	0	O
the	0	O
IR2	0	O
repeat	0	O
element	0	O
and	0	O
showed	0	O
restriction	0	O
site	0	O
polymorphism	0	O
for	0	O
the	0	O
enzyme	0	B
SmaI	0	I
.	0	O


The	0	O
11	0	O
;	0	O
22	0	O
chromosomal	0	O
translocation	0	O
specifically	0	O
linked	0	O
to	0	O
Ewing	0	O
sarcoma	0	O
and	0	O
primitive	0	O
neuroectodermal	0	O
tumor	0	O
results	0	O
in	0	O
a	0	O
chimeric	0	O
molecule	0	O
fusing	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
-	0	O
encoding	0	O
portion	0	O
of	0	O
the	0	O
EWS	1	B
gene	0	I
to	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
encoded	0	O
by	0	O
the	0	O
FLI1	0	B
gene	0	I
.	0	O


Karger	0	O
AG	1	O
,	0	O
Basel	0	O


Six	0	O
(	0	O
four	0	O
FAP	1	O
;	0	O
two	0	O
primary	0	O
amyloidosis	0	O
)	0	O
also	0	O
had	0	O
diffusely	0	O
positive	0	O
myocardial	0	O
uptakes	0	O
,	0	O
but	0	O
the	0	O
intensity	0	O
was	0	O
less	0	O
than	0	O
that	0	O
of	0	O
the	0	O
sternum	0	O
.	0	O


Those	0	O
dosages	0	O
that	0	O
inhibited	0	O
mean	0	O
NTE	0	B
activity	0	O
in	0	O
spinal	0	O
cord	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
72	0	O
%	0	O
and	0	O
brain	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
66	0	O
%	0	O
of	0	O
control	0	O
values	0	O
within	0	O
44	0	O
hr	0	O
postexposure	0	O
produced	0	O
marked	0	O
spinal	0	O
cord	0	O
pathology	0	O
14	0	O
days	0	O
postexposure	0	O
in	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
90	0	O
%	0	O
of	0	O
similarly	0	O
dosed	0	O
animals	0	O
.	0	O


The	0	O
codon	0	O
usage	0	O
is	0	O
particularly	0	O
marked	0	O
for	0	O
the	0	O
gag	0	B
,	0	O
pol	0	B
,	0	O
and	0	O
env	0	B
genes	0	I
.	0	O


CPAP	1	O
reduced	0	O
isotime	0	O
(	0	O
defined	0	O
as	0	O
the	0	O
last	0	O
common	0	O
minute	0	O
of	0	O
exercise	0	O
)	0	O
VO2	1	O
and	0	O
dyspnea	0	O
in	0	O
those	0	O
patients	0	O
with	0	O
more	0	O
severe	0	O
lung	0	O
disease	0	O
,	0	O
but	0	O
these	0	O
values	0	O
tended	0	O
to	0	O
increase	0	O
slightly	0	O
in	0	O
the	0	O
patients	0	O
with	0	O
only	0	O
mild	0	O
lung	0	O
disease	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
the	0	O
conservation	0	O
of	0	O
nucleotides	0	O
154	0	O
to	0	O
156	0	O
is	0	O
likely	0	O
to	0	O
be	0	O
a	0	O
consequence	0	O
of	0	O
their	0	O
role	0	O
as	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
recognition	0	O
element	0	O
for	0	O
the	0	O
SRP54	0	B
protein	0	I
.	0	O


Responsiveness	0	O
to	0	O
beta	0	O
-	0	O
2	0	O
agonist	0	O
therapy	0	O
was	0	O
retained	0	O
with	0	O
both	0	O
agents	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


GCN4	0	B
encodes	0	O
a	0	O
transcriptional	0	O
activator	0	O
of	0	O
amino	0	O
acid	0	O
biosynthetic	0	O
genes	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


In	1	O
10	0	O
control	0	O
sheep	0	O
mean	0	O
plasma	0	O
TXB2	0	O
concentration	0	O
increased	0	O
from	0	O
0	0	O
.	0	O
39	0	O
ng	0	O
/	0	O
ml	0	O
prebypass	0	O
to	0	O
about	0	O
1	0	O
.	0	O
1	0	O
ng	0	O
/	0	O
ml	0	O
at	0	O
8	0	O
and	0	O
16	0	O
min	0	O
of	0	O
bypass	0	O
.	0	O


In	1	O
several	0	O
cases	0	O
of	0	O
definite	0	O
SjS	0	O
,	0	O
labial	0	O
salivary	0	O
gland	0	O
examinations	0	O
after	0	O
more	0	O
than	0	O
a	0	O
one	0	O
year	0	O
interval	0	O
were	0	O
performed	0	O
on	0	O
two	0	O
occasions	0	O
,	0	O
and	0	O
the	0	O
clinical	0	O
and	0	O
histopathological	0	O
changes	0	O
were	0	O
investigated	0	O
.	0	O


ELISA	1	O
was	0	O
found	0	O
to	0	O
make	0	O
a	0	O
contribution	0	O
to	0	O
the	0	O
diagnosis	0	O
of	0	O
tuberculosis	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
sputum	0	O
smear	0	O
.	0	O


Significantly	0	O
,	0	O
two	0	O
proximal	0	O
GATA	0	B
-	0	I
1	0	I
-	0	I
binding	0	I
sites	0	I
(-	0	O
118	0	O
/-	0	O
113	0	O
and	0	O
-	0	O
98	0	O
/-	0	O
93	0	O
)	0	O
and	0	O
a	0	O
region	0	O
located	0	O
within	0	O
-	0	O
518	0	O
to	0	O
-	0	O
315bp	0	O
of	0	O
the	0	O
mouse	0	B
ALAS2	0	I
promoter	0	I
were	0	O
essential	0	O
for	0	O
transcriptional	0	O
activation	0	O
during	0	O
chemically	0	O
induced	0	O
differentiation	0	O
of	0	O
MEL	1	O
cells	0	O
,	0	O
implying	0	O
their	0	O
importance	0	O
in	0	O
conferring	0	O
erythroid	0	O
specificity	0	O
to	0	O
the	0	O
ALAS2	0	B
transcriptional	0	O
activation	0	O
.	0	O


To	1	O
better	0	O
understand	0	O
the	0	O
role	0	O
of	0	O
Ets	1	B
proteins	0	I
in	0	O
Ras	1	B
transformation	0	O
,	0	O
we	0	O
have	0	O
now	0	O
analyzed	0	O
the	0	O
effects	0	O
of	0	O
stably	0	O
expressing	0	O
a	0	O
variety	0	O
of	0	O
Ets2	0	B
constructs	0	I
in	0	O
Ras	1	B
-	0	O
transformed	0	O
NIH3T3	0	O
(	0	O
DT	1	O
)	0	O
cells	0	O
.	0	O


Low	0	O
-	0	O
dose	0	O
aspirin	0	O
and	0	O
recurrent	0	O
miscarriage	0	O
.	0	O


She	0	O
also	0	O
had	0	O
slight	0	O
weakness	0	O
of	0	O
the	0	O
upper	0	O
extremities	0	O
.	0	O


Different	0	O
doses	0	O
of	0	O
15	0	O
-	0	O
methyl	0	O
-	0	O
PGF2	0	O
alpha	0	O
(	0	O
0	0	O
.	0	O
125	0	O
-	0	O
10	0	O
mg	0	O
)	0	O
were	0	O
used	0	O
to	0	O
induce	0	O
luteolysis	0	O
and	0	O
oestrus	0	O
in	0	O
7	0	O
heifers	0	O
with	0	O
28	0	O
treatments	0	O
on	0	O
day	0	O
8	0	O
-	0	O
12	0	O
of	0	O
the	0	O
oestrous	0	O
cycle	0	O
.	0	O


The	0	O
remaining	0	O
80	0	O
patients	0	O
underwent	0	O
recordings	0	O
of	0	O
ECG	1	O
,	0	O
beat	0	O
-	0	O
to	0	O
-	0	O
beat	0	O
arterial	0	O
oxygen	0	O
saturation	0	O
(	0	O
SaO2	1	O
),	0	O
and	0	O
respiration	0	O
during	0	O
both	0	O
spontaneous	0	O
and	0	O
controlled	0	O
breathing	0	O
.	0	O


Phylogenetic	1	O
position	0	O
of	0	O
the	0	O
Phacotaceae	0	O
within	0	O
the	0	O
Chlamydophyceaeas	0	O
revealed	0	O
by	0	O
analysis	0	O
of	0	O
18S	0	B
rDNA	0	I
and	0	O
rbcL	0	B
sequences	0	I
.	0	O


The	0	O
progress	0	O
of	0	O
morphological	0	O
research	0	O
on	0	O
the	0	O
parabrachial	0	O
nucleus	0	O


Circulatory	1	O
arrest	0	O
in	0	O
the	0	O
operating	0	O
room	0	O
.	0	O


We	0	O
show	0	O
also	0	O
that	0	O
RA	1	O
represses	0	O
the	0	O
transcriptional	0	O
activity	0	O
of	0	O
a	0	O
reporter	0	O
gene	0	O
containing	0	O
a	0	O
TPA	1	O
responding	0	O
AP1	0	B
binding	0	I
site	0	I
driving	0	O
the	0	O
HSV	1	B
tk	0	I
promoter	0	I
.	0	O


Applications	0	O
of	0	O
three	0	O
-	0	O
dimensional	0	O
analysis	0	O
to	0	O
the	0	O
auditory	0	O
P300	0	O
.	0	O


This	0	O
paper	0	O
gives	0	O
an	0	O
overview	0	O
of	0	O
the	0	O
global	0	O
pattern	0	O
of	0	O
casualties	0	O
in	0	O
earthquakes	0	O
which	0	O
occurred	0	O
during	0	O
the	0	O
30	0	O
-	0	O
month	0	O
period	0	O
from	0	O
1	0	O
September	0	O
1993	0	O
to	0	O
29	0	O
February	0	O
1996	0	O
.	0	O


Recently	0	O
,	0	O
a	0	O
mutation	0	O
in	0	O
the	0	O
amino	0	O
-	0	O
terminus	0	O
of	0	O
IB1	0	B
was	0	O
associated	0	O
with	0	O
diabetes	0	O
.	0	O


The	0	O
COL7A1	0	B
gene	0	I
,	0	O
which	0	O
encodes	0	O
type	0	B
VII	0	I
collagen	0	I
,	0	O
has	0	O
been	0	O
implicated	0	O
as	0	O
a	0	O
candidate	0	O
gene	0	O
for	0	O
dominantly	0	O
and	0	O
recessively	0	O
inherited	0	O
forms	0	O
of	0	O
dystrophic	0	O
epidermolysis	0	O
bullosa	0	O
.	0	O


This	0	O
finding	0	O
represents	0	O
both	0	O
a	0	O
potentially	0	O
important	0	O
mechanism	0	O
by	0	O
which	0	O
HPV	1	O
gene	0	O
expression	0	O
can	0	O
be	0	O
regulated	0	O
and	0	O
an	0	O
interesting	0	O
model	0	O
for	0	O
the	0	O
study	0	O
of	0	O
transcriptional	0	O
cooperativity	0	O
.	0	O


Mutations	0	O
in	0	O
a	0	O
region	0	O
located	0	O
15	0	O
to	0	O
30	0	O
bp	0	O
downstream	0	O
from	0	O
the	0	O
major	0	O
transcription	0	O
start	0	O
site	0	O
that	0	O
shows	0	O
good	0	O
homology	0	O
to	0	O
a	0	O
sequence	0	O
in	0	O
the	0	O
first	0	O
exon	0	O
of	0	O
c	0	B
-	0	I
fos	0	I
implicated	0	O
as	0	O
a	0	O
negative	0	O
regulatory	0	O
element	0	O
resulted	0	O
in	0	O
a	0	O
significant	0	O
increase	0	O
in	0	O
basal	0	O
gene	0	O
expression	0	O
but	0	O
did	0	O
not	0	O
affect	0	O
regulation	0	O
.	0	O


Adaptation	1	O
of	0	O
taurocholate	0	O
transport	0	O
maximum	0	O
to	0	O
increased	0	O
secretory	0	O
load	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


In	1	O
the	0	O
diabetics	0	O
,	0	O
Ca2	1	O
+	0	O
infusions	0	O
induced	0	O
a	0	O
rise	0	O
of	0	O
plasma	0	O
Ca2	1	O
+	0	O
up	0	O
to	0	O
3	0	O
.	0	O
2	0	O
+/-	0	O
0	0	O
.	0	O
1	0	O
mmol	0	O
/	0	O
1	0	O
and	0	O
a	0	O
fall	0	O
of	0	O
circulating	0	O
glucagon	0	B
(-	0	O
26	0	O
.	0	O
4	0	O
+/-	0	O
5	0	O
.	0	O
7	0	O
%;	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
)	0	O
and	0	O
glucose	0	O
(-	0	O
23	0	O
.	0	O
3	0	O
+/-	0	O
3	0	O
.	0	O
6	0	O
%;	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


After	0	O
14	0	O
d	0	O
of	0	O
overfeeding	0	O
,	0	O
hepatic	0	O
PL	0	O
profiles	0	O
were	0	O
identical	0	O
in	0	O
the	0	O
two	0	O
breeds	0	O
and	0	O
similar	0	O
to	0	O
that	0	O
in	0	O
control	0	O
livers	0	O
;	0	O
choline	0	O
-	0	O
containing	0	O
PL	0	O
accounted	0	O
for	0	O
95	0	O
%	0	O
of	0	O
total	0	O
PL	0	O
.	0	O


Serum	1	O
gastrin	0	B
and	0	O
AFP	1	B
levels	0	O
had	0	O
the	0	O
same	0	O
evolution	0	O
and	0	O
appear	0	O
to	0	O
have	0	O
the	0	O
same	0	O
interest	0	O
to	0	O
follow	0	O
the	0	O
course	0	O
of	0	O
the	0	O
disease	0	O
.	0	O


All	1	O
nuclear	0	O
receptors	0	O
have	0	O
several	0	O
well	0	O
-	0	O
characterized	0	O
structural	0	O
domains	0	O
,	0	O
including	0	O
a	0	O
conserved	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
,	0	O
and	0	O
a	0	O
ligand	0	O
binding	0	O
domain	0	O
at	0	O
the	0	O
carboxyl	0	O
terminus	0	O
of	0	O
the	0	O
receptor	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
T	1	O
.	0	O
C	1	O
.,	0	O
LDL	1	B
-	0	I
C	1	I
.,	0	O
HDL	1	B
-	0	I
C	1	I
.,	0	O
HDL2	1	B
-	0	I
C	1	I
.,	0	O
apo	0	B
B	1	I
,	0	O
apo	0	B
A	1	I
-	0	I
I	1	I
/	0	I
B	1	I
ratio	0	O
and	0	O
apo	0	B
A	1	I
-	0	I
II	0	I
/	0	I
B	1	I
ratio	0	O
are	0	O
predictive	0	O
risk	0	O
factors	0	O
of	0	O
the	0	O
coronary	0	O
heart	0	O
disease	0	O
.	0	O


Resistance	1	O
training	0	O
shifts	0	O
the	0	O
power	0	O
curve	0	O
in	0	O
a	0	O
positive	0	O
direction	0	O
when	0	O
the	0	O
measurements	0	O
are	0	O
determined	0	O
with	0	O
absolute	0	O
loads	0	O
,	0	O
but	0	O
the	0	O
increased	0	O
power	0	O
may	0	O
not	0	O
be	0	O
transferred	0	O
to	0	O
an	0	O
absolute	0	O
performance	0	O
task	0	O
like	0	O
the	0	O
SSP	0	O
.	0	O


Using	0	O
mutated	0	B
IL2R	0	I
alpha	0	I
promoter	0	I
constructs	0	I
in	0	O
transient	0	O
transfection	0	O
and	0	O
DNA	1	O
binding	0	O
assays	0	O
,	0	O
we	0	O
now	0	O
demonstrate	0	O
that	0	O
sequences	0	O
located	0	O
immediately	0	O
upstream	0	O
and	0	O
downstream	0	O
of	0	O
the	0	O
kappa	0	B
B	1	I
enhancer	0	I
also	0	O
contribute	0	O
to	0	O
the	0	O
regulation	0	O
of	0	O
IL2R	0	B
alpha	0	I
gene	0	I
expression	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
sought	0	O
to	0	O
identify	0	O
mechanisms	0	O
that	0	O
could	0	O
account	0	O
for	0	O
the	0	O
antimitogenic	0	O
effects	0	O
of	0	O
IL	1	B
-	0	I
4	0	I
.	0	O


Delayed	0	O
or	0	O
paradoxically	0	O
emptying	0	O
regions	0	O
of	0	O
the	0	O
left	0	O
ventricle	0	O
were	0	O
detected	0	O
by	0	O
a	0	O
relatively	0	O
new	0	O
nuclear	0	O
technique	0	O
--	0	O
phase	0	O
imaging	0	O
.	0	O


Two	0	O
closely	0	O
related	0	O
IgH	0	B
constant	0	O
region	0	O
genes	0	O
,	0	O
CHA	0	B
and	0	O
CHB	1	B
,	0	O
have	0	O
been	0	O
sequenced	0	O
completely	0	O
.	0	O


But	0	O
the	0	O
application	0	O
solutions	0	O
of	0	O
instrument	0	O
disinfectants	0	O
should	0	O
not	0	O
be	0	O
used	0	O
longer	0	O
than	0	O
one	0	O
day	0	O
.	0	O


We	0	O
have	0	O
identified	0	O
two	0	O
Marek	0	O
'	0	O
s	0	O
Disease	1	O
Virus	1	O
(	0	O
MDV	0	O
)	0	O
genes	0	O
within	0	O
the	0	O
EcoRI	0	B
-	0	I
B	1	I
fragment	0	I
of	0	O
MDV	0	O
-	0	O
GA	1	O
genomic	0	O
DNA	1	O
.	0	O


HeLa	0	O
and	0	O
Jurkat	0	O
cell	0	O
lines	0	O
carrying	0	O
the	0	O
nef	0	B
gene	0	I
linked	0	O
to	0	O
the	0	O
CMV	1	O
promoter	0	O
or	0	O
the	0	O
HIV	1	B
-	0	I
1	0	I
LTR	1	I
were	0	O
isolated	0	O
by	0	O
coselection	0	O
for	0	O
neomycin	0	O
resistance	0	O
.	0	O


LDL	1	B
cholesterol	0	I
decreased	0	O
from	0	O
4	0	O
.	0	O
74	0	O
+/-	0	O
0	0	O
.	0	O
87	0	O
to	0	O
3	0	O
.	0	O
78	0	O
+/-	0	O
0	0	O
.	0	O
78	0	O
mmol	0	O
/	0	O
l	0	O
after	0	O
8	0	O
weeks	0	O
on	0	O
simvastatin	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
),	0	O
and	0	O
apo	0	B
B	1	I
fell	0	O
from	0	O
142	0	O
+/-	0	O
31	0	O
to	0	O
112	0	O
+/-	0	O
22	0	O
mg	0	O
/	0	O
dl	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
).	0	O


Identification	1	O
of	0	O
a	0	O
new	0	O
gene	0	O
in	0	O
the	0	O
streptococcal	0	O
plasmid	0	O
pLS1	0	O
:	0	O
the	0	O
rnaI	1	B
gene	0	I
.	0	O


However	0	O
,	0	O
as	0	O
determined	0	O
by	0	O
PCR	1	O
with	0	O
primers	0	O
specific	0	O
for	0	O
the	0	O
26	0	O
-	0	O
kDa	1	O
product	0	O
,	0	O
the	0	O
majority	0	O
of	0	O
cats	0	O
at	0	O
2	0	O
and	0	O
4	0	O
weeks	0	O
p	0	O
.	0	O
t	0	O
.	0	O
had	0	O
gastric	0	O
fluid	0	O
samples	0	O
which	0	O
were	0	O
positive	0	O
for	0	O
H	1	O
.	0	O
pylori	0	O
and	0	O
three	0	O
of	0	O
three	0	O
cats	0	O
at	0	O
2	0	O
weeks	0	O
p	0	O
.	0	O
t	0	O
.	0	O
had	0	O
dental	0	O
plaque	0	O
which	0	O
was	0	O
positive	0	O
for	0	O
H	1	O
.	0	O
pylori	0	O
.	0	O


On	1	O
transition	0	O
from	0	O
high	0	O
to	0	O
low	0	O
voltage	0	O
there	0	O
was	0	O
a	0	O
significant	0	O
fall	0	O
in	0	O
arterial	0	O
pressure	0	O
(	0	O
7	0	O
%)	0	O
and	0	O
an	0	O
increase	0	O
in	0	O
flow	0	O
(	0	O
19	0	O
-	0	O
38	0	O
%)	0	O
to	0	O
areas	0	O
of	0	O
the	0	O
brain	0	O
corresponding	0	O
to	0	O
the	0	O
arborization	0	O
of	0	O
the	0	O
reticular	0	O
formation	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
excluding	0	O
the	0	O
cerebrum	0	O
and	0	O
cerebellum	0	O
.	0	O


In	1	O
untreated	0	O
mice	0	O
,	0	O
bactericidal	0	O
activity	0	O
of	0	O
peritoneal	0	O
macrophages	0	O
decreased	0	O
from	0	O
one	0	O
day	0	O
to	0	O
3	0	O
days	0	O
after	0	O
ip	0	O
injection	0	O
of	0	O
killed	0	O
L	1	O
.	0	O
monocytogenes	0	O
.	0	O


New	0	O
technologies	0	O
in	0	O
diagnosis	0	O
and	0	O
classification	0	O
of	0	O
malignancy	0	O
.	0	O


We	0	O
now	0	O
describe	0	O
a	0	O
second	0	O
RIM	1	B
protein	0	I
,	0	O
called	0	O
RIM2	0	B
,	0	O
that	0	O
is	0	O
highly	0	O
homologous	0	O
to	0	O
RIM1	0	B
and	0	O
also	0	O
expressed	0	O
primarily	0	O
in	0	O
brain	0	O
.	0	O


Rats	0	O
underwent	0	O
either	0	O
a	0	O
90	0	O
-	0	O
95	0	O
%	0	O
JIB	0	O
or	0	O
a	0	O
sham	0	O
operation	0	O
.	0	O


M	1	O
.	0	O
M	1	O
.	0	O
C	1	O
.	0	O
was	0	O
used	0	O
for	0	O
2	0	O
.	0	O
5	0	O
minutes	0	O
in	0	O
44	0	O
cases	0	O
(	0	O
20	0	O
HR	1	O
patients	0	O
,	0	O
24	0	O
LR	1	O
patients	0	O
),	0	O
and	0	O
for	0	O
5	0	O
minutes	0	O
in	0	O
66	0	O
cases	0	O
(	0	O
46	0	O
HR	1	O
patients	0	O
,	0	O
20	0	O
LR	1	O
patients	0	O
).	0	O


To	1	O
elucidate	0	O
the	0	O
functional	0	O
significance	0	O
of	0	O
Fyn	0	B
in	0	O
the	0	O
expression	0	O
of	0	O
viral	0	O
promoters	0	O
,	0	O
we	0	O
transfected	0	O
a	0	O
Fyn	0	B
-	0	O
expression	0	O
vector	0	O
together	0	O
with	0	O
a	0	O
reporter	0	O
plasmid	0	O
containing	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
gene	0	I
driven	0	O
by	0	O
HIV	1	B
LTR	1	I
into	0	O
a	0	O
human	0	O
T	1	O
cell	0	O
line	0	O
,	0	O
Jurkat	0	O
.	0	O


Analysis	1	O
for	0	O
DNA	1	O
-	0	O
protein	0	O
interactions	0	O
by	0	O
in	0	O
vitro	0	O
DNase	1	B
-	0	I
I	1	I
footprinting	0	O
identified	0	O
a	0	O
broad	0	O
region	0	O
of	0	O
protection	0	O
extending	0	O
from	0	O
nt	0	O
-	0	O
12	0	O
to	0	O
+	0	O
38	0	O
.	0	O


As	1	O
a	0	O
result	0	O
,	0	O
the	0	O
subendocardial	0	O
/	0	O
subepicardial	0	O
blood	0	O
flow	0	O
ratio	0	O
(	0	O
ENDO	0	O
/	0	O
EPI	0	O
)	0	O
increased	0	O
from	0	O
0	0	O
.	0	O
44	0	O
+/-	0	O
0	0	O
.	0	O
09	0	O
during	0	O
control	0	O
stenosis	0	O
to	0	O
0	0	O
.	0	O
85	0	O
+/-	0	O
0	0	O
.	0	O
13	0	O
after	0	O
ITF	0	O
1129	0	O
(	0	O
10	0	O
micrograms	0	O
/	0	O
kg	0	O
/	0	O
min	0	O
i	0	O
.	0	O
v	0	O
.)	0	O
and	0	O
to	0	O
0	0	O
.	0	O
81	0	O
+/-	0	O
0	0	O
.	0	O
12	0	O
after	0	O
NTG	1	O
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
we	0	O
have	0	O
investigated	0	O
the	0	O
regulatory	0	O
mechanism	0	O
for	0	O
CD95L	0	B
expression	0	O
.	0	O


Sensing	0	O
with	0	O
chemically	0	O
and	0	O
biologically	0	O
modified	0	O
carbon	0	O
electrodes	0	O
.	0	O


These	0	O
results	0	O
show	0	O
that	0	O
the	0	O
CAAT	0	O
-	0	O
region	0	O
is	0	O
involved	0	O
in	0	O
upregulating	0	O
the	0	O
MDR1	0	B
promoter	0	I
in	0	O
HL60	0	O
/	0	O
VCR	0	O
cells	0	O
.	0	O


Genetic	1	O
and	0	O
phenotypic	0	O
analysis	0	O
indicates	0	O
that	0	O
NHP6A	0	B
and	0	O
NHP6B	0	B
function	0	O
downstream	0	O
of	0	O
SLT2	0	B
.	0	O


The	0	O
subjects	0	O
from	0	O
the	0	O
two	0	O
regions	0	O
with	0	O
a	0	O
higher	0	O
pollution	0	O
level	0	O
had	0	O
lower	0	O
FVC	1	O
and	0	O
FEV1	1	O
values	0	O
than	0	O
those	0	O
from	0	O
the	0	O
Viskovo	0	O
region	0	O
.	0	O


This	0	O
experimental	0	O
design	0	O
was	0	O
used	0	O
to	0	O
determine	0	O
the	0	O
effect	0	O
of	0	O
displacement	0	O
of	0	O
the	0	O
alpha	0	B
4	0	I
-	0	I
2	0	I
binding	0	I
site	0	I
on	0	O
the	0	O
repression	0	O
of	0	O
alpha	0	B
4	0	I
gene	0	I
transcription	0	O
by	0	O
ICP4	0	B
.	0	O


Ultrastructural	0	O
studies	0	O
of	0	O
retinopathy	0	O
of	0	O
premature	0	O
infants	0	O


A	1	O
consensus	0	O
binding	0	O
site	0	O
for	0	O
the	0	O
transcription	0	O
factor	0	O
SP1	0	B
was	0	O
identified	0	O
in	0	O
intron	0	O
As	1	O
downstream	0	O
of	0	O
the	0	O
proenkephalin	0	B
germ	0	I
cell	0	I
cap	0	I
site	0	I
region	0	I
.	0	O


This	0	O
two	0	O
-	0	O
helix	0	O
motif	0	O
is	0	O
thought	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
specific	0	O
DNA	1	O
sequence	0	O
recognition	0	O
by	0	O
CAP	1	B
.	0	O


These	0	O
observations	0	O
lead	0	O
to	0	O
the	0	O
proposal	0	O
that	0	O
the	0	O
RNAP	0	B
II	0	I
CTD	1	I
might	0	O
be	0	O
an	0	O
in	0	O
vivo	0	O
target	0	O
for	0	O
the	0	O
activated	0	O
p42mapk	0	B
and	0	O
p44mapk	0	B
MAP	1	I
kinases	0	I
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
,	0	O
we	0	O
transiently	0	O
expressed	0	O
in	0	O
primary	0	O
cultures	0	O
of	0	O
rat	0	O
hepatocytes	0	O
plasmids	0	O
consisting	0	O
of	0	O
CYP3A1	0	B
5	0	I
'-	0	I
flanking	0	I
sequences	0	I
fused	0	O
to	0	O
a	0	O
chloramphenicol	0	B
acetyltransferase	0	I
reporter	0	I
plasmid	0	O
.	0	O


We	0	O
present	0	O
this	0	O
case	0	O
because	0	O
of	0	O
the	0	O
rarity	0	O
of	0	O
left	0	O
ventricular	0	O
involvement	0	O
associated	0	O
with	0	O
ARVD	0	O
.	0	O


X2	0	O
test	0	O
,	0	O
with	0	O
Yates	0	O
correction	0	O
if	0	O
need	0	O
,	0	O
was	0	O
used	0	O
as	0	O
statistical	0	O
.	0	O
method	0	O
.	0	O


This	0	O
generally	0	O
means	0	O
an	0	O
energy	0	O
intake	0	O
of	0	O
1	0	O
.	0	O
4	0	O
to	0	O
1	0	O
.	0	O
6	0	O
times	0	O
the	0	O
energy	0	O
expenditure	0	O
,	0	O
with	0	O
a	0	O
N	1	O
intake	0	O
of	0	O
250	0	O
to	0	O
400	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
tested	0	O
this	0	O
notion	0	O
by	0	O
using	0	O
ligation	0	O
-	0	O
mediated	0	O
PCR	1	O
to	0	O
assess	0	O
the	0	O
formation	0	O
of	0	O
recombination	0	B
-	0	I
activating	0	I
gene	0	I
(	0	O
RAG	0	B
)-	0	O
dependent	0	O
double	0	O
-	0	O
strand	0	O
breaks	0	O
(	0	O
DSBs	0	O
)	0	O
at	0	O
RSSs	0	O
3	0	O
'	0	O
of	0	O
Ddelta3	0	B
and	0	O
5	0	O
'	0	O
of	0	O
Jdelta1	0	B
.	0	O


The	0	O
tetraphasic	0	O
action	0	O
of	0	O
lidocaine	0	O
on	0	O
CNS	1	O
electrical	0	O
activity	0	O
and	0	O
behavior	0	O
in	0	O
cats	0	O
.	0	O


Effects	0	O
of	0	O
estrogen	0	O
and	0	O
glucocorticoids	0	O
on	0	O
the	0	O
adrenal	0	O
development	0	O
of	0	O
the	0	O
fetus	0	O
.	0	O


A	1	O
more	0	O
complete	0	O
analysis	0	O
of	0	O
dose	0	O
response	0	O
,	0	O
time	0	O
and	0	O
mode	0	O
of	0	O
Ga	1	O
administration	0	O
(	0	O
preinjury	0	O
or	0	O
postinjury	0	O
),	0	O
and	0	O
availability	0	O
of	0	O
Ga	1	O
across	0	O
the	0	O
blood	0	O
-	0	O
brain	0	O
barrier	0	O
is	0	O
needed	0	O
to	0	O
further	0	O
evaluate	0	O
the	0	O
efficacy	0	O
of	0	O
this	0	O
compound	0	O
.	0	O


Disruption	1	O
of	0	O
ARF2	0	B
causes	0	O
no	0	O
detectable	0	O
phenotype	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
gluconeogenic	0	O
genes	0	O
are	0	O
derepressed	0	O
upon	0	O
binding	0	O
of	0	O
Cat8p	0	B
,	0	O
whose	0	O
synthesis	0	O
depends	0	O
on	0	O
the	0	O
release	0	O
of	0	O
Cat4p	0	B
(	0	O
Mig1p	0	B
)	0	O
from	0	O
the	0	O
CAT8	0	B
promoter	0	I
.	0	O


The	0	O
sequence	0	O
contains	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
of	0	O
1744	0	O
nt	0	O
in	0	O
the	0	O
virus	0	O
-	0	O
sense	0	O
strand	0	O
,	0	O
a	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
of	0	O
1360	0	O
nt	0	O
and	0	O
a	0	O
3	0	O
'	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
tail	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
,	0	O
for	0	O
the	0	O
HML	0	B
ARS	1	O
cluster	0	O
(	0	O
ARS303	0	B
,	0	O
ARS320	0	B
,	0	O
and	0	O
ARS302	0	B
),	0	O
inactivity	0	O
of	0	O
origins	0	O
is	0	O
independent	0	O
of	0	O
local	0	O
transcriptional	0	O
silencing	0	O
,	0	O
even	0	O
though	0	O
origins	0	O
and	0	O
silencers	0	O
share	0	O
key	0	O
cis	0	O
-	0	O
and	0	O
trans	0	O
-	0	O
acting	0	O
components	0	O
.	0	O


Intrapocket	0	O
chemotherapy	0	O
in	0	O
adult	0	O
periodontitis	0	O
using	0	O
a	0	O
new	0	O
controlled	0	O
-	0	O
release	0	O
insert	0	O
containing	0	O
ofloxacin	0	O
(	0	O
PT	1	O
-	0	O
01	0	O
).	0	O


The	0	O
RS447	0	B
human	0	I
megasatellite	0	I
tandem	0	I
repetitive	0	I
sequence	0	I
encodes	0	O
a	0	O
novel	0	O
deubiquitinating	0	O
enzyme	0	O
with	0	O
a	0	O
functional	0	O
promoter	0	O
.	0	O


A	1	O
Chinese	0	O
(	0	O
HK	0	O
)	0	O
SF	1	O
-	0	O
36	0	O
survey	0	O
form	0	O
was	0	O
developed	0	O
by	0	O
an	0	O
iterative	0	O
translation	0	O
process	0	O
.	0	O


The	0	O
Jenkins	0	O
Activity	1	O
Survey	1	O
and	0	O
the	0	O
CPI	1	O
-	0	O
revised	0	O
:	0	O
further	0	O
evidence	0	O
of	0	O
adaptive	0	O
and	0	O
maladaptive	0	O
type	0	O
A	1	O
traits	0	O
.	0	O


It	1	O
is	0	O
suggested	0	O
that	0	O
a	0	O
raised	0	O
hydroxykynurenine	0	O
/	0	O
hydroxyanthranilic	0	O
acid	0	O
ratio	0	O
does	0	O
not	0	O
necessarily	0	O
indicate	0	O
vitamin	0	O
B6	0	O
deficiency	0	O
but	0	O
may	0	O
represent	0	O
a	0	O
nonspecific	0	O
response	0	O
of	0	O
tryptophan	0	O
metabolism	0	O
to	0	O
stress	0	O
.	0	O


Both	0	O
the	0	O
MVBF	0	O
and	0	O
the	0	O
maximum	0	O
EMG	1	O
activity	0	O
in	0	O
the	0	O
right	0	O
masseter	0	O
and	0	O
the	0	O
left	0	O
anterior	0	O
temporalis	0	O
muscles	0	O
were	0	O
significantly	0	O
decreased	0	O
during	0	O
muscle	0	O
pain	0	O
when	0	O
the	0	O
subjects	0	O
bit	0	O
on	0	O
the	0	O
painful	0	O
side	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Mitosis	1	O
is	0	O
regulated	0	O
by	0	O
MPF	0	B
(	0	O
maturation	0	B
promoting	0	I
factor	0	I
),	0	O
the	0	O
active	0	O
form	0	O
of	0	O
Cdc2	0	B
/	0	I
28	0	I
-	0	O
cyclin	0	B
B	1	I
complexes	0	O
.	0	O


DNA	1	B
polymerase	0	I
E	1	I
,	0	O
DNA	1	B
ligase	0	I
III	0	I
and	0	O
a	0	O
DNA	1	O
structure	0	O
-	0	O
specific	0	O
endonuclease	0	O
co	0	O
-	0	O
purify	0	O
with	0	O
the	0	O
five	0	O
polypeptide	0	O
complex	0	O
.	0	O


We	0	O
previously	0	O
demonstrated	0	O
that	0	O
acute	0	O
expression	0	O
of	0	O
the	0	O
bovine	0	O
papillomavirus	0	O
type	0	O
1	0	O
(	0	O
BPV1	0	O
)	0	O
E2	1	B
protein	0	I
in	0	O
HeLa	0	O
and	0	O
HT	1	O
-	0	O
3	0	O
cervical	0	O
carcinoma	0	O
cell	0	O
lines	0	O
greatly	0	O
reduced	0	O
cellular	0	O
proliferation	0	O
by	0	O
imposing	0	O
a	0	O
specific	0	O
G1	0	O
/	0	O
S	1	O
phase	0	O
growth	0	O
arrest	0	O
.	0	O


Immunoprecipitation	1	O
experiments	0	O
using	0	O
DokR	0	B
-	0	I
specific	0	I
antibodies	0	I
revealed	0	O
an	0	O
interaction	0	O
between	0	O
endogenous	0	B
DokR	0	I
and	0	O
a	0	O
150	0	O
-	0	O
kDa	1	O
protein	0	O
that	0	O
is	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
in	0	O
EGF	1	B
-	0	O
stimulated	0	O
BaF	0	O
/	0	O
3	0	O
cells	0	O
.	0	O


Observations	0	O
on	0	O
the	0	O
flight	0	O
activities	0	O
of	0	O
Chrysops	1	O
caecutiens	0	O
L	1	O
.	0	O


A	1	O
p21	0	B
peptide	0	I
spanning	0	O
amino	0	O
acids	0	O
139	0	O
-	0	O
164	0	O
was	0	O
found	0	O
to	0	O
bind	0	O
PCNA	1	B
in	0	O
a	0	O
filter	0	O
binding	0	O
assay	0	O
and	0	O
this	0	O
peptide	0	O
suppressed	0	O
recombinant	0	O
p21	0	B
-	0	O
PCNA	1	B
interaction	0	O
.	0	O


We	0	O
report	0	O
two	0	O
patients	0	O
receiving	0	O
maintenance	0	O
valproate	0	O
,	0	O
one	0	O
with	0	O
resolving	0	O
acute	0	O
hepatitis	0	O
C	1	O
and	0	O
the	0	O
other	0	O
with	0	O
chronic	0	O
persistent	0	O
hepatitis	0	O
C	1	O
,	0	O
with	0	O
incidental	0	O
microvesicular	0	O
steatosis	0	O
demonstrated	0	O
on	0	O
oil	0	O
-	0	O
red	0	O
O	1	O
stains	0	O
.	0	O


Four	0	O
short	0	O
nucleotide	0	O
sequences	0	O
(	0	O
boxes	0	O
I	1	O
to	0	O
IV	1	O
)	0	O
contribute	0	O
to	0	O
the	0	O
light	0	O
responsiveness	0	O
of	0	O
the	0	O
parsley	0	B
chalcone	0	I
synthase	0	I
promoter	0	I
.	0	O


Sequence	1	O
analysis	0	O
reveals	0	O
that	0	O
the	0	O
DNA	1	O
binding	0	O
domain	0	O
of	0	O
ILF	0	B
has	0	O
strong	0	O
homology	0	O
to	0	O
the	0	O
recently	0	O
described	0	O
fork	0	B
head	0	I
DNA	1	I
binding	0	I
domain	0	I
found	0	O
in	0	O
the	0	O
Drosophila	1	B
homeotic	0	I
protein	0	I
fork	0	I
head	0	I
and	0	O
a	0	O
family	0	O
of	0	O
hepatocyte	0	B
nuclear	0	I
factors	0	I
,	0	O
HNF	1	B
-	0	I
3	0	I
.	0	O


Androgens	0	O
and	0	O
growth	0	O
.	0	O


Sequencing	1	O
of	0	O
the	0	O
three	0	O
pag	0	B
-	0	I
3	0	I
alleles	0	I
showed	0	O
that	0	O
two	0	O
apparent	0	O
null	0	O
alleles	0	O
encode	0	O
a	0	O
nonsense	0	O
mutation	0	O
before	0	O
the	0	O
zinc	0	O
fingers	0	O
and	0	O
a	0	O
missense	0	O
mutation	0	O
in	0	O
the	0	O
fourth	0	O
zinc	0	O
finger	0	O
that	0	O
changes	0	O
a	0	O
coordinating	0	O
histidine	0	O
to	0	O
a	0	O
tyrosine	0	O
.	0	O


Multiple	1	O
dosing	0	O
four	0	O
times	0	O
daily	0	O
for	0	O
7	0	O
days	0	O
of	0	O
indoprofen	0	O
200	0	O
mg	0	O
,	0	O
a	0	O
non	0	O
-	0	O
steroidal	0	O
anti	0	O
-	0	O
inflammatory	0	O
drug	0	O
with	0	O
a	0	O
short	0	O
half	0	O
-	0	O
life	0	O
(	0	O
t1	0	O
/	0	O
2	0	O
),	0	O
revealed	0	O
drug	0	O
accumulation	0	O
in	0	O
eight	0	O
elderly	0	O
subjects	0	O
.	0	O


Finding	1	O
of	0	O
Rhodnius	1	O
prolixus	0	O
Stal	0	O
,	0	O
1859	0	O
,	0	O
in	0	O
babassu	0	O
palm	0	O
trees	0	O


Analysis	1	O
of	0	O
the	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
suggests	0	O
that	0	O
CHIP28	0	B
protein	0	I
contains	0	O
six	0	O
bilayer	0	O
-	0	O
spanning	0	O
domains	0	O
,	0	O
two	0	O
exofacial	0	O
potential	0	O
N	1	O
-	0	O
glycosylation	0	O
sites	0	O
,	0	O
and	0	O
intracellular	0	O
N	1	O
and	0	O
C	1	O
termini	0	O
.	0	O


Mild	0	O
orbital	0	O
discomfort	0	O
occurred	0	O
in	0	O
some	0	O
patients	0	O
.	0	O


Duration	1	O
of	0	O
remission	0	O
in	0	O
advanced	0	O
gastric	0	O
cancer	0	O
patients	0	O
responding	0	O
to	0	O
sequential	0	O
dose	0	O
of	0	O
MTX	1	O
and	0	O
5	0	O
-	0	O
FU	0	O


LY290181	0	O
appears	0	O
to	0	O
inhibit	0	O
uPA	0	B
promoter	0	I
activation	0	O
by	0	O
blocking	0	O
phorbol	0	O
ester	0	O
-	0	O
stimulated	0	O
binding	0	O
of	0	O
nuclear	0	O
proteins	0	O
to	0	O
the	0	O
uPA	0	B
PEA3	0	I
/	0	O
12	0	O
-	0	O
0	0	O
-	0	O
tetradecanoylphorbol	0	O
13	0	O
-	0	O
acetate	0	O
responsive	0	O
element	0	O
(	0	O
TRE	0	O
).	0	O


Monotherapy	1	O
with	0	O
ceftazidime	0	O
was	0	O
clinically	0	O
and	0	O
bacteriologically	0	O
as	0	O
effective	0	O
as	0	O
a	0	O
combination	0	O
therapy	0	O
with	0	O
cefazolin	0	O
and	0	O
tobramycin	0	O
.	0	O


Inhibition	1	O
of	0	O
erythromycin	0	O
synthesis	0	O
by	0	O
disruption	0	O
of	0	O
malonyl	0	B
-	0	I
coenzyme	0	I
A	1	I
decarboxylase	0	I
gene	0	I
eryM	0	I
in	0	O
Saccharopolyspora	1	O
erythraea	0	O
.	0	O


Quantitative	1	O
evaluation	0	O
of	0	O
the	0	O
steady	0	O
state	0	O
kinetics	0	O
of	0	O
MEK	0	B
inhibition	0	O
by	0	O
these	0	O
compounds	0	O
reveals	0	O
that	0	O
U0126	0	O
has	0	O
approximately	0	O
100	0	O
-	0	O
fold	0	O
higher	0	O
affinity	0	O
for	0	O
deltaN3	0	B
-	0	I
S218E	0	I
/	0	I
S222D	0	I
MEK	0	I
than	0	O
does	0	O
PD098059	0	O
.	0	O


Oncogenic	1	O
capacity	0	O
of	0	O
the	0	O
E2F1	0	B
gene	0	I
.	0	O


The	0	O
C	1	O
-	0	O
terminal	0	O
mature	0	O
region	0	O
is	0	O
highly	0	O
conserved	0	O
in	0	O
other	0	O
serine	0	B
carboxypeptidases	0	I
.	0	O


Cloning	1	O
,	0	O
expression	0	O
,	0	O
and	0	O
nucleotide	0	O
sequence	0	O
of	0	O
rat	0	B
liver	0	I
sterol	0	I
carrier	0	I
protein	0	I
2	0	I
cDNAs	0	I
.	0	O


The	0	O
7	0	O
-	0	O
kb	0	O
mRNA	1	O
differs	0	O
by	0	O
alternative	0	O
splicing	0	O
such	0	O
that	0	O
it	0	O
encodes	0	O
a	0	O
protein	0	O
with	0	O
a	0	O
distinct	0	O
amino	0	O
terminus	0	O
.	0	O


Transient	1	O
co	0	O
-	0	O
transfection	0	O
assays	0	O
involving	0	O
NFKB2	0	B
expression	0	O
vectors	0	O
and	0	O
kappa	0	B
B	1	I
-	0	O
driven	0	O
reporter	0	O
plasmids	0	O
indicate	0	O
that	0	O
NFKB2	0	B
p85	0	I
has	0	O
lost	0	O
the	0	O
transcriptional	0	O
repressor	0	O
functions	0	O
typical	0	O
of	0	O
normal	0	O
NFKB2	0	B
p52	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
injection	0	O
of	0	O
a	0	O
plasmid	0	O
encoding	0	O
simian	0	B
virus	0	I
40	0	I
small	0	I
t	0	I
antigen	0	I
,	0	O
which	0	O
interacts	0	O
with	0	O
PP2A	0	B
to	0	O
inhibit	0	O
its	0	O
activity	0	O
towards	0	O
several	0	O
phosphoprotein	0	O
substrates	0	O
,	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
the	0	O
phosphorylation	0	O
state	0	O
of	0	O
CREB	0	B
in	0	O
stimulated	0	O
or	0	O
unstimulated	0	O
NIH	1	O
3T3	0	O
cells	0	O
.	0	O


Transcription	1	O
factor	0	O
binding	0	O
sites	0	O
downstream	0	O
of	0	O
the	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
type	0	O
1	0	O
transcription	0	O
start	0	O
site	0	O
are	0	O
important	0	O
for	0	O
virus	0	O
infectivity	0	O
.	0	O


Depending	0	O
on	0	O
treatment	0	O
exposures	0	O
,	0	O
this	0	O
at	0	O
-	0	O
risk	0	O
population	0	O
may	0	O
experience	0	O
life	0	O
-	0	O
threatening	0	O
late	0	O
effects	0	O
,	0	O
such	0	O
as	0	O
cirrhosis	0	O
secondary	0	O
to	0	O
hepatitis	0	O
C	1	O
or	0	O
late	0	O
-	0	O
onset	0	O
anthracycline	0	O
-	0	O
induced	0	O
cardiomyopathy	0	O
,	0	O
or	0	O
life	0	O
-	0	O
changing	0	O
late	0	O
effects	0	O
,	0	O
such	0	O
as	0	O
cognitive	0	O
dysfunction	0	O
.	0	O


Three	0	O
-	0	O
dimensional	0	O
structural	0	O
studies	0	O
using	0	O
electron	0	O
cryomicroscopy	0	O
showed	0	O
that	0	O
the	0	O
binding	0	O
of	0	O
one	0	O
Fab	1	B
(	0	O
8H2	0	O
/	0	O
G5	0	O
)	0	O
does	0	O
not	0	O
affect	0	O
the	0	O
conformation	0	O
of	0	O
the	0	O
capsid	0	O
,	0	O
and	0	O
the	0	O
efficiency	0	O
of	0	O
mRNA	1	O
production	0	O
is	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
the	0	O
native	0	O
subviral	0	O
particle	0	O
.	0	O


Leukemia	1	B
-	0	I
inhibitory	0	I
factor	0	I
(	0	O
LIF	1	B
)	0	O
is	0	O
a	0	O
neuropoietin	0	B
able	0	O
to	0	O
regulate	0	O
the	0	O
differentiation	0	O
and	0	O
the	0	O
survival	0	O
of	0	O
many	0	O
cell	0	O
types	0	O
,	0	O
which	0	O
include	0	O
some	0	O
neuronal	0	O
populations	0	O
.	0	O


An	1	O
amino	0	O
-	0	O
acid	0	O
sequence	0	O
comparison	0	O
revealed	0	O
that	0	O
Bacillus	1	B
YM55	0	I
-	0	I
1	0	I
aspartase	0	I
shared	0	O
71	0	O
%	0	O
homology	0	O
with	0	O
Bacillus	1	B
subtilis	0	I
aspartase	0	I
and	0	O
49	0	O
%	0	O
with	0	O
Escherichia	1	O
coli	0	O
and	0	O
Pseudomonas	1	B
fluorescens	0	I
aspartases	0	I
.	0	O


Molecular	1	O
cloning	0	O
and	0	O
functional	0	O
characterization	0	O
of	0	O
murine	0	B
sphingosine	0	I
kinase	0	I
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
,	0	O
in	0	O
this	0	O
experimental	0	O
model	0	O
,	0	O
ACE	1	B
inhibitors	0	O
limit	0	O
the	0	O
arrhythmias	0	O
following	0	O
ischemia	0	O
-	0	O
reperfusion	0	O
and	0	O
free	0	O
radical	0	O
scavenging	0	O
action	0	O
of	0	O
these	0	O
drugs	0	O
does	0	O
not	0	O
have	0	O
a	0	O
major	0	O
contributory	0	O
role	0	O
in	0	O
their	0	O
protective	0	O
effect	0	O
.	0	O


The	0	O
Nur77	0	B
protein	0	I
can	0	O
act	0	O
as	0	O
a	0	O
potent	0	O
transcription	0	O
activator	0	O
and	0	O
may	0	O
function	0	O
to	0	O
regulate	0	O
the	0	O
expression	0	O
of	0	O
downstream	0	O
genes	0	O
in	0	O
response	0	O
to	0	O
extracellular	0	O
stimuli	0	O
.	0	O


In	1	O
a	0	O
series	0	O
of	0	O
patients	0	O
with	0	O
neuroinfection	0	O
,	0	O
Lyme	0	O
disease	0	O
,	0	O
Guillain	0	O
Barre	0	O
syndrome	0	O
,	0	O
demyelinization	0	O
,	0	O
partial	0	O
or	0	O
generalized	0	O
,	0	O
epilepsy	0	O
,	0	O
we	0	O
have	0	O
investigated	0	O
antiphospholipid	0	O
antibodies	0	O
of	0	O
IgG	1	B
and	0	O
IgM	1	B
subtypes	0	O
,	0	O
together	0	O
with	0	O
anticoagulant	0	O
factors	0	O
,	0	O
member	0	O
of	0	O
thrombocytes	0	O
,	0	O
sedimentation	0	O
rate	0	O
of	0	O
erythrocytes	0	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
interaction	0	O
between	0	O
Jak2	0	B
and	0	O
PRLR	0	B
requires	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
sequence	0	O
in	0	O
the	0	O
membrane	0	O
proximal	0	O
region	0	O
of	0	O
the	0	O
receptor	0	O
,	0	O
which	0	O
is	0	O
conserved	0	O
among	0	O
the	0	O
different	0	O
members	0	O
of	0	O
the	0	O
cytokine	0	B
receptor	0	I
superfamily	0	I
.	0	O


We	0	O
also	0	O
provide	0	O
evidence	0	O
that	0	O
gar2	0	B
is	0	O
phosphorylated	0	O
in	0	O
vitro	0	O
by	0	O
a	0	O
p13	0	B
(	0	O
suc1	0	B
)-	0	O
Sepharose	0	O
-	0	O
bound	0	O
kinase	0	O
from	0	O
Schizosaccharomyces	0	O
pombe	0	O
extracts	0	O
that	0	O
displays	0	O
cell	0	O
cycle	0	O
-	0	O
regulated	0	O
activity	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
the	0	O
p34	0	B
(	0	O
cdc2	0	B
(	0	O
kinase	0	O
.	0	O


However	0	O
,	0	O
when	0	O
domain	0	O
I	1	O
and	0	O
domain	0	O
II	0	O
were	0	O
linked	0	O
on	0	O
the	0	O
same	0	O
plasmid	0	O
,	0	O
high	0	O
levels	0	O
of	0	O
replication	0	O
were	0	O
observed	0	O
.	0	O


During	0	O
the	0	O
observation	0	O
period	0	O
of	0	O
0	0	O
.	0	O
4	0	O
-	0	O
30	0	O
weeks	0	O
,	0	O
cardiac	0	O
white	0	O
spots	0	O
on	0	O
the	0	O
right	0	O
ventricle	0	O
of	0	O
BALB	0	O
/	0	O
c	0	O
mice	0	O
were	0	O
first	0	O
detected	0	O
at	0	O
three	0	O
weeks	0	O
(	0	O
6	0	O
of	0	O
20	0	O
mice	0	O
;	0	O
30	0	O
%),	0	O
and	0	O
the	0	O
maximal	0	O
incidence	0	O
of	0	O
cardiac	0	O
white	0	O
spots	0	O
was	0	O
obtained	0	O
at	0	O
nine	0	O
weeks	0	O
(	0	O
39	0	O
of	0	O
44	0	O
mice	0	O
;	0	O
88	0	O
%).	0	O


Differences	0	O
in	0	O
the	0	O
clinical	0	O
presentation	0	O
and	0	O
the	0	O
gross	0	O
appearance	0	O
of	0	O
the	0	O
two	0	O
cases	0	O
are	0	O
described	0	O
,	0	O
and	0	O
similarities	0	O
in	0	O
the	0	O
microscopic	0	O
features	0	O
are	0	O
discussed	0	O
.	0	O


Circulating	0	O
platelets	0	O
may	0	O
be	0	O
activated	0	O
by	0	O
exposed	0	O
triple	0	O
-	0	O
helical	0	O
collagen	0	B
in	0	O
atherosclerotic	0	O
lesions	0	O
in	0	O
Mg	1	O
-	0	O
deficient	0	O
ruminants	0	O
.	0	O


This	0	O
DNA	1	O
motif	0	O
represents	0	O
a	0	O
novel	0	O
protein	0	O
-	0	O
binding	0	O
sequence	0	O
.	0	O


The	0	O
rho	0	B
genes	0	I
comprise	0	O
an	0	O
evolutionarily	0	O
conserved	0	O
family	0	O
with	0	O
significant	0	O
homology	0	O
to	0	O
the	0	O
ras	0	B
oncogene	0	I
family	0	I
.	0	O


The	0	O
S229A	0	O
variant	0	O
can	0	O
better	0	O
flip	0	O
modified	0	O
bases	0	O
but	0	O
does	0	O
not	0	O
tightly	0	O
lock	0	O
the	0	O
flipped	0	O
base	0	O
into	0	O
the	0	O
adenine	0	O
-	0	O
binding	0	O
pocket	0	O
,	0	O
suggesting	0	O
that	0	O
Ser229	0	O
could	0	O
form	0	O
a	0	O
contact	0	O
to	0	O
the	0	O
flipped	0	O
adenine	0	O
.	0	O


Hypoxic	1	O
ventilatory	0	O
responses	0	O
were	0	O
-	0	O
1	0	O
.	0	O
99	0	O
+/-	0	O
0	0	O
.	0	O
37	0	O
L	1	O
/	0	O
min	0	O
/%	0	O
SaO2	1	O
in	0	O
the	0	O
relatives	0	O
and	0	O
-	0	O
1	0	O
.	0	O
54	0	O
+/-	0	O
0	0	O
.	0	O
25	0	O
L	1	O
/	0	O
min	0	O
/%	0	O
SaO2	1	O
in	0	O
the	0	O
control	0	O
subjects	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Primer	1	O
extension	0	O
and	0	O
S1	1	B
nuclease	0	I
mapping	0	O
experiments	0	O
were	0	O
used	0	O
to	0	O
locate	0	O
the	0	O
transcription	0	O
initiation	0	O
site	0	O
of	0	O
Nramp1	0	B
and	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
one	0	O
major	0	O
and	0	O
several	0	O
minor	0	O
initiation	0	O
sites	0	O
.	0	O


Convulsive	1	O
seizure	0	O
during	0	O
a	0	O
treatment	0	O
with	0	O
interferon	0	B
alpha	0	I
for	0	O
chronic	0	O
viral	0	O
hepatitis	0	O
C	1	O


A	1	O
miracle	0	O
cure	0	O
and	0	O
its	0	O
solution	0	O


Serial	1	O
levels	0	O
of	0	O
troponin	0	B
T	1	I
and	0	O
the	0	O
activity	0	O
of	0	O
CK	1	B
-	0	I
MB	1	I
were	0	O
measured	0	O
6	0	O
,	0	O
12	0	O
,	0	O
24	0	O
and	0	O
48	0	O
h	0	O
after	0	O
aortic	0	O
unclamping	0	O
.	0	O


Deletion	1	O
of	0	O
both	0	O
prfA	0	B
and	0	O
ponA	0	B
resulted	0	O
in	0	O
extremely	0	O
slow	0	O
growth	0	O
and	0	O
a	0	O
reduction	0	O
in	0	O
sporulation	0	O
efficiency	0	O
.	0	O


Genomic	1	O
organization	0	O
of	0	O
the	0	O
human	0	B
beta	0	I
-	0	I
catenin	0	I
gene	0	I
(	0	O
CTNNB1	0	B
).	0	O


Rolandic	1	O
spikes	0	O
and	0	O
cognitive	0	O
function	0	O
.	0	O


NERVTRACK	0	O
contains	0	O
4000	0	O
anatomical	0	O
data	0	O
items	0	O
arranged	0	O
in	0	O
a	0	O
tree	0	O
-	0	O
like	0	O
manner	0	O
reflecting	0	O
structural	0	O
and	0	O
functional	0	O
relationships	0	O
.	0	O


In	1	O
a	0	O
gntR	0	B
deletion	0	I
mutant	0	I
,	0	O
the	0	O
expression	0	O
of	0	O
a	0	O
chromosomal	0	O
gntT	0	B
::	0	O
lacZ	0	B
fusion	0	O
is	0	O
both	0	O
high	0	O
and	0	O
constitutive	0	O
,	0	O
confirming	0	O
that	0	O
GntR	0	B
is	0	O
the	0	O
negative	0	O
regulator	0	O
of	0	O
gntT	0	B
.	0	O


Overexpression	1	O
of	0	O
MDR1	0	B
has	0	O
been	0	O
demonstrated	0	O
in	0	O
many	0	O
cancers	0	O
,	0	O
both	0	O
in	0	O
patient	0	O
tumors	0	O
and	0	O
in	0	O
cell	0	O
lines	0	O
selected	0	O
with	0	O
a	0	O
variety	0	O
of	0	O
chemotherapeutic	0	O
agents	0	O
.	0	O


The	0	O
intron	0	O
RNA	1	O
consists	0	O
of	0	O
2492	0	O
nucleotides	0	O
which	0	O
can	0	O
be	0	O
folded	0	O
into	0	O
a	0	O
secondary	0	O
structure	0	O
with	0	O
all	0	O
the	0	O
expected	0	O
sequence	0	O
motifs	0	O
of	0	O
subgroup	0	O
-	0	O
IIA1	0	O
introns	0	O
(	0	O
Michel	0	O
et	0	O
al	0	O
.	0	O


Results	0	O
of	0	O
the	0	O
recognition	0	O
task	0	O
revealed	0	O
significant	0	O
effects	0	O
of	0	O
consonant	0	O
voicing	0	O
,	0	O
position	0	O
and	0	O
vowel	0	O
context	0	O
on	0	O
syllable	0	O
recognition	0	O
.	0	O


Expression	1	O
of	0	O
various	0	O
FAK	0	B
mutants	0	I
in	0	O
the	0	O
FAK	0	B
-	0	O
cells	0	O
showed	0	O
that	0	O
FAK	0	B
kinase	0	I
activity	0	O
,	0	O
the	0	O
Tyr	1	B
-	0	I
397	0	I
/	0	I
SH2	0	I
domain	0	I
binding	0	I
site	0	I
,	0	O
and	0	O
the	0	O
first	0	O
proline	0	O
-	0	O
rich	0	O
SH3	0	B
binding	0	I
region	0	I
in	0	O
the	0	O
FAK	0	B
C	1	I
-	0	I
terminal	0	I
domain	0	I
were	0	O
individually	0	O
needed	0	O
to	0	O
promote	0	O
full	0	O
FAK	0	B
-	0	O
mediated	0	O
FAK	0	B
-	0	O
cell	0	O
migration	0	O
to	0	O
FN	0	B
whereas	0	O
direct	0	O
paxillin	0	B
binding	0	O
to	0	O
FAK	0	B
was	0	O
not	0	O
required	0	O
.	0	O


The	0	O
mean	0	O
blood	0	O
flow	0	O
in	0	O
the	0	O
penile	0	O
foreskin	0	O
was	0	O
estimated	0	O
to	0	O
be	0	O
15	0	O
ml	0	O
/	0	O
min	0	O
/	0	O
100	0	O
g	0	O
and	0	O
it	0	O
increased	0	O
to	0	O
150	0	O
-	0	O
200	0	O
%	0	O
after	0	O
the	0	O
induction	0	O
of	0	O
anesthesia	0	O
,	0	O
and	0	O
then	0	O
decreased	0	O
to	0	O
72	0	O
%	0	O
at	0	O
the	0	O
tip	0	O
of	0	O
the	0	O
created	0	O
parameatal	0	O
foreskin	0	O
flap	0	O
.	0	O


If	1	O
this	0	O
is	0	O
unavailable	0	O
,	0	O
then	0	O
Supramid	0	O
has	0	O
a	0	O
proven	0	O
record	0	O
for	0	O
good	0	O
tissue	0	O
compatibility	0	O
and	0	O
resistance	0	O
to	0	O
infection	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
acetazolamide	0	O
(	0	O
ACZ	0	O
)	0	O
on	0	O
HCO3	0	O
-	0	O
and	0	O
Cl	1	O
-	0	O
activities	0	O
in	0	O
inner	0	O
ear	0	O
fluid	0	O
was	0	O
investigated	0	O
by	0	O
ion	0	O
-	0	O
selective	0	O
microelectrode	0	O
methods	0	O
.	0	O


There	0	O
were	0	O
5	0	O
treatments	0	O
:	0	O
control	0	O
(	0	O
C	1	O
);	0	O
a	0	O
wooden	0	O
surround	0	O
in	0	O
one	0	O
rear	0	O
corner	0	O
of	0	O
the	0	O
cage	0	O
(	0	O
S	1	O
);	0	O
a	0	O
fiberglass	0	O
rollaway	0	O
hollow	0	O
in	0	O
one	0	O
rear	0	O
corner	0	O
of	0	O
the	0	O
cage	0	O
(	0	O
H	1	O
);	0	O
a	0	O
hollow	0	O
and	0	O
a	0	O
surround	0	O
(	0	O
H	1	O
/	0	O
S	1	O
);	0	O
a	0	O
nest	0	O
box	0	O
attached	0	O
to	0	O
the	0	O
back	0	O
of	0	O
the	0	O
cage	0	O
,	0	O
containing	0	O
a	0	O
hollow	0	O
(	0	O
N	1	O
).	0	O


The	0	O
availability	0	O
of	0	O
cryoprecipitate	0	O
and	0	O
DDAVP	1	O
offers	0	O
an	0	O
alternative	0	O
and	0	O
effective	0	O
treatment	0	O
for	0	O
the	0	O
temporary	0	O
reversal	0	O
of	0	O
uremic	0	O
bleeding	0	O
in	0	O
patients	0	O
who	0	O
require	0	O
urgent	0	O
invasive	0	O
procedures	0	O
.	0	O


Finally	0	O
,	0	O
using	0	O
in	0	O
vitro	0	O
binding	0	O
studies	0	O
,	0	O
we	0	O
showed	0	O
that	0	O
SREBP2	0	B
was	0	O
able	0	O
to	0	O
displace	0	O
ADD1	0	B
/	0	O
SREBP1	0	B
binding	0	O
from	0	O
the	0	O
sterol	0	O
regulatory	0	O
element	0	O
(	0	O
SRE	0	O
)	0	O
site	0	O
.	0	O


Nine	0	O
DNA	1	O
fragments	0	O
that	0	O
were	0	O
specifically	0	O
recognized	0	O
and	0	O
bound	0	O
by	0	O
histidine	0	O
-	0	O
tagged	0	O
AdpA	0	B
were	0	O
isolated	0	O
by	0	O
cycles	0	O
of	0	O
a	0	O
gel	0	O
mobility	0	O
shift	0	O
-	0	O
PCR	1	O
method	0	O
.	0	O


Interferon	1	B
type	0	I
I	1	I
in	0	O
protective	0	O
body	0	O
reactions	0	O
in	0	O
an	0	O
experimental	0	O
Klebsiella	1	O
infection	0	O


The	0	O
respiratory	0	O
rate	0	O
was	0	O
13	0	O
+/-	0	O
1	0	O
breaths	0	O
/	0	O
min	0	O
with	0	O
52	0	O
+/-	0	O
4	0	O
%	0	O
of	0	O
the	0	O
respiratory	0	O
cycle	0	O
spent	0	O
in	0	O
inspiration	0	O
;	0	O
end	0	O
-	0	O
tidal	0	O
CO2	1	O
pressure	0	O
increased	0	O
by	0	O
3	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
0	0	O
Torr	1	O
during	0	O
runs	0	O
at	0	O
SIP	1	O
.	0	O


The	0	O
TYAC	0	O
/	0	O
P1	1	O
resource	0	O
,	0	O
derivative	0	O
STSs	0	O
,	0	O
and	0	O
polymorphisms	0	O
constitute	0	O
an	0	O
enabling	0	O
resource	0	O
to	0	O
further	0	O
studies	0	O
of	0	O
telomere	0	O
structure	0	O
and	0	O
function	0	O
and	0	O
a	0	O
means	0	O
for	0	O
physical	0	O
and	0	O
genetic	0	O
map	0	O
integration	0	O
and	0	O
closure	0	O
.	0	O


Analysis	1	O
of	0	O
viral	0	O
mutants	0	O
in	0	O
vivo	0	O
demonstrated	0	O
that	0	O
the	0	O
NFIII	0	B
/	0	O
OCT	1	B
-	0	I
1	0	I
binding	0	O
site	0	O
and	0	O
a	0	O
conserved	0	O
ATF	0	B
motif	0	I
were	0	O
important	0	O
for	0	O
efficient	0	O
viral	0	O
growth	0	O
.	0	O


Recombinant	1	B
Ffh	0	I
has	0	O
a	0	O
melting	0	O
point	0	O
of	0	O
tm	0	O
=	0	O
89	0	O
degreesC	0	O
.	0	O


Then	0	O
we	0	O
correlated	0	O
HRCT	1	O
findings	0	O
with	0	O
the	0	O
clinical	0	O
features	0	O
,	0	O
pulmonary	0	O
functions	0	O
and	0	O
methacholine	0	O
PC20	0	O
(	0	O
PC20M	0	O
)	0	O
and	0	O
studied	0	O
their	0	O
clinical	0	O
significance	0	O
.	0	O


The	0	O
performance	0	O
of	0	O
three	0	O
commonly	0	O
used	0	O
chemical	0	O
cartridge	0	O
respirators	0	O
for	0	O
SO2	0	O
was	0	O
measured	0	O
under	0	O
working	0	O
conditions	0	O
in	0	O
a	0	O
copper	0	O
smelter	0	O
.	0	O


Determination	1	O
of	0	O
lead	0	O
in	0	O
blood	0	O
.	0	O


Several	0	O
different	0	O
oncogenes	0	O
and	0	O
growth	0	O
factors	0	O
promote	0	O
G1	0	O
phase	0	O
progression	0	O
.	0	O


Because	0	O
of	0	O
its	0	O
wide	0	O
spectrum	0	O
of	0	O
activity	0	O
particularly	0	O
against	0	O
ampicillin	0	O
resistant	0	O
strains	0	O
of	0	O
H	1	O
.	0	O
influenzae	0	O
and	0	O
because	0	O
of	0	O
its	0	O
good	0	O
tolerance	0	O
Cefaclor	1	O
is	0	O
very	0	O
useful	0	O
in	0	O
treatment	0	O
of	0	O
respiratory	0	O
tract	0	O
infections	0	O
in	0	O
children	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
mRNA	1	B
capping	0	I
enzyme	0	I
identifies	0	O
amino	0	O
acids	0	O
involved	0	O
in	0	O
GTP	1	O
binding	0	O
,	0	O
enzyme	0	O
-	0	O
guanylate	0	O
formation	0	O
,	0	O
and	0	O
GMP	1	O
transfer	0	O
to	0	O
RNA	1	O
.	0	O


To	1	O
assess	0	O
the	0	O
functional	0	O
importance	0	O
of	0	O
these	0	O
NBS	0	O
in	0	O
the	0	O
overall	0	O
drug	0	O
resistance	0	O
phenotype	0	O
conferred	0	O
by	0	O
mdr1	0	B
,	0	O
we	0	O
introduced	0	O
amino	0	O
acid	0	O
substitutions	0	O
in	0	O
the	0	O
core	0	O
consensus	0	O
sequence	0	O
for	0	O
nucleotide	0	O
binding	0	O
,	0	O
GXGKST	0	O
.	0	O


Moreover	0	O
,	0	O
radiolabeled	0	O
EFI	0	B
,	0	O
NF	1	B
-	0	I
Y	1	I
,	0	O
or	0	O
CBF	1	B
DNAs	0	I
give	0	O
rise	0	O
to	0	O
identical	0	O
gel	0	O
retardation	0	O
patterns	0	O
in	0	O
extracts	0	O
from	0	O
a	0	O
variety	0	O
of	0	O
different	0	O
cell	0	O
types	0	O
.	0	O


The	0	O
lacS	0	B
gene	0	I
was	0	O
cloned	0	O
in	0	O
an	0	O
E	1	O
.	0	O
coli	0	O
-	0	O
Streptococcus	1	O
shuttle	0	O
vector	0	O
and	0	O
was	0	O
expressed	0	O
both	0	O
in	0	O
a	0	O
lacS	0	B
deletion	0	O
derivative	0	O
of	0	O
S	1	O
.	0	O
thermophilus	0	O
and	0	O
in	0	O
a	0	O
pNZ63	0	O
-	0	O
cured	0	O
strain	0	O
,	0	O
L	1	O
.	0	O
lactis	0	O
NZ6091	0	O
.	0	O


The	0	O
repetitive	0	O
ETn	0	B
(	0	O
early	0	B
transposon	0	I
)	0	O
family	0	O
of	0	O
sequences	0	O
represents	0	O
an	0	O
active	0	O
"	0	O
mobile	0	O
mutagen	0	O
"	0	O
in	0	O
the	0	O
mouse	0	O
genome	0	O
.	0	O


Histopathology	1	O
and	0	O
pathogenesis	0	O
of	0	O
exanthematous	0	O
viroses	0	O


An	1	O
explanation	0	O
explored	0	O
for	0	O
this	0	O
lack	0	O
of	0	O
gene	0	O
expression	0	O
was	0	O
that	0	O
increased	0	O
levels	0	O
of	0	O
RAR	0	B
alpha	0	I
or	0	O
PML	1	B
might	0	O
suppress	0	O
APL	0	O
cell	0	O
growth	0	O
.	0	O


Roizman	0	O
,	0	O
J	1	O
.	0	O


Identification	1	O
of	0	O
a	0	O
consensus	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinase	0	I
phosphorylation	0	I
site	0	I
unique	0	O
to	0	O
the	0	O
nuclear	0	O
form	0	O
of	0	O
human	0	B
deoxyuridine	0	I
triphosphate	0	I
nucleotidohydrolase	0	I
.	0	O


Isolation	1	O
by	0	O
PCR	1	O
of	0	O
a	0	O
cDNA	1	O
clone	0	O
from	0	O
pea	0	O
petals	0	O
with	0	O
similarity	0	O
to	0	O
petunia	0	O
and	0	O
wheat	0	B
zinc	0	I
finger	0	I
proteins	0	I
.	0	O


Sequence	1	O
analyses	0	O
of	0	O
sos2	0	B
mutant	0	I
alleles	0	I
reveal	0	O
that	0	O
both	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
catalytic	0	O
domain	0	O
and	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
regulatory	0	O
domain	0	O
of	0	O
SOS2	0	B
are	0	O
functionally	0	O
essential	0	O
.	0	O


Technique	1	O
for	0	O
obtaining	0	O
refined	0	O
ceramics	0	O
with	0	O
dense	0	O
mass	0	O


Blood	1	B
serum	0	I
erythropoietin	0	I
level	0	O
and	0	O
basic	0	O
hematological	0	O
indices	0	O
during	0	O
the	0	O
adaptation	0	O
of	0	O
healthy	0	O
newborn	0	O
infants	0	O


The	0	O
protein	0	O
first	0	O
identified	0	O
by	0	O
the	0	O
monoclonal	0	B
antibody	0	I
Q18	0	I
is	0	O
encoded	0	O
by	0	O
a	0	O
gene	0	O
located	0	O
in	0	O
57A	0	O
on	0	O
polytene	0	O
chromosomes	0	O
and	0	O
has	0	O
been	0	O
consequently	0	O
named	0	O
Hrb57A	0	B
.	0	O


In	1	O
addition	0	O
,	0	O
media	0	O
containing	0	O
F	1	B
beta	0	I
alpha	0	I
/	0	O
CG	1	B
beta	0	I
displayed	0	O
high	0	O
-	0	O
affinity	0	O
binding	0	O
to	0	O
both	0	O
CG	1	B
and	0	I
FSH	1	I
receptors	0	I
.	0	O


CIITA	0	B
mRNA	1	I
is	0	O
normally	0	O
inducible	0	O
by	0	O
IFN	1	B
-	0	I
gamma	0	I
in	0	O
class	0	O
II	0	O
non	0	O
-	0	O
inducible	0	O
,	0	O
RB	1	O
-	0	O
defective	0	O
lines	0	O
,	0	O
and	0	O
in	0	O
one	0	O
line	0	O
,	0	O
re	0	O
-	0	O
expression	0	O
of	0	O
RB	1	B
has	0	O
no	0	O
effect	0	O
on	0	O
CIITA	0	B
mRNA	1	I
induction	0	O
levels	0	O
.	0	O


These	0	O
data	0	O
indicate	0	O
that	0	O
the	0	O
third	0	O
intracellular	0	O
loop	0	O
of	0	O
the	0	O
rat	0	B
GnRH	0	I
-	0	I
R	1	I
is	0	O
involved	0	O
in	0	O
receptor	0	B
G	1	I
(	0	I
q	0	I
/	0	I
11	0	I
)	0	I
protein	0	I
coupling	0	O
and	0	O
/	0	O
or	0	O
selectivity	0	O
,	0	O
and	0	O
in	0	O
the	0	O
GGH	0	O
(	0	O
3	0	O
)	0	O
1	0	O
'	0	O
cell	0	O
line	0	O
,	0	O
this	0	O
loop	0	O
is	0	O
also	0	O
involved	0	O
in	0	O
signal	0	O
transduction	0	O
mediated	0	O
through	0	O
the	0	O
Gs	0	B
protein	0	O
pathway	0	O
.	0	O


We	0	O
have	0	O
identified	0	O
two	0	O
overlapping	0	O
expressed	0	O
sequence	0	O
tag	0	O
clones	0	O
,	0	O
which	0	O
contain	0	O
the	0	O
missing	0	O
4	0	O
.	0	O
4	0	O
-	0	O
kb	0	O
3	0	O
'-	0	O
UTR	0	O
of	0	O
the	0	O
human	0	B
D2	0	I
(	0	O
hD2	0	B
)	0	O
cDNA	1	O
.	0	O


Bacterial	1	O
recovery	0	O
of	0	O
SA	1	O
from	0	O
the	0	O
liver	0	O
/	0	O
spleen	0	O
and	0	O
the	0	O
cecal	0	O
tonsil	0	O
in	0	O
contact	0	O
poults	0	O
and	0	O
SG	0	O
from	0	O
contact	0	O
chicks	0	O
treated	0	O
with	0	O
ILK	0	B
was	0	O
dramatically	0	O
reduced	0	O
when	0	O
compared	0	O
to	0	O
non	0	O
-	0	O
treated	0	O
contact	0	O
poults	0	O
and	0	O
chicks	0	O
.	0	O


Therefore	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
a	0	O
cis	0	O
-	0	O
acting	0	O
element	0	O
,	0	O
the	0	O
E1	1	O
E	1	O
-	0	O
box	0	O
,	0	O
located	0	O
in	0	O
the	0	O
GAP	1	B
-	0	I
43	0	I
promoter	0	O
region	0	O
that	0	O
modulates	0	O
either	0	O
positively	0	O
or	0	O
negatively	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
GAP	1	B
-	0	I
43	0	I
gene	0	I
depending	0	O
on	0	O
which	0	O
E	1	B
-	0	I
box	0	I
-	0	I
binding	0	I
proteins	0	I
occupy	0	O
this	0	O
site	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
N	1	O
-	0	O
nitroso	0	O
compounds	0	O
can	0	O
be	0	O
formed	0	O
in	0	O
vivo	0	O
in	0	O
the	0	O
infected	0	O
bladder	0	O
,	0	O
which	0	O
could	0	O
explain	0	O
the	0	O
association	0	O
between	0	O
urinary	0	O
-	0	O
tract	0	O
infections	0	O
and	0	O
increased	0	O
risk	0	O
for	0	O
bladder	0	O
cancer	0	O
.	0	O


This	0	O
study	0	O
utilizes	0	O
the	0	O
mammalian	0	O
two	0	O
-	0	O
hybrid	0	O
system	0	O
to	0	O
examine	0	O
the	0	O
role	0	O
of	0	O
ligand	0	O
in	0	O
the	0	O
dimerization	0	O
of	0	O
human	0	B
progesterone	0	I
receptor	0	I
(	0	O
hPR	0	B
).	0	O


Parasitological	0	O
post	0	O
-	0	O
mortem	0	O
examination	0	O
of	0	O
all	0	O
seropositive	0	O
animals	0	O
showed	0	O
five	0	O
and	0	O
seven	0	O
false	0	O
-	0	O
positive	0	O
animals	0	O
when	0	O
E	1	B
/	0	I
S	1	I
and	0	I
CWE	0	I
antigens	0	I
were	0	O
used	0	O
,	0	O
respectively	0	O
.	0	O


We	0	O
examined	0	O
Akt	0	B
activation	0	O
in	0	O
Lyn	0	B
-,	0	O
Syk	0	B
-	0	O
and	0	O
Btk	1	B
-	0	O
deficient	0	O
DT40	0	O
cells	0	O
and	0	O
B	1	O
cells	0	O
from	0	O
Lyn	0	B
(-/-)	0	I
mice	0	O
.	0	O


Studies	0	O
suggest	0	O
that	0	O
the	0	O
DGOR	0	O
without	0	O
acid	0	O
reflux	0	O
may	0	O
result	0	O
in	0	O
symptoms	0	O
but	0	O
unless	0	O
acid	0	O
reflux	0	O
is	0	O
present	0	O
simultaneously	0	O
,	0	O
it	0	O
does	0	O
not	0	O
cause	0	O
oesophagitis	0	O
.	0	O


An	1	O
industry	0	O
-	0	O
wide	0	O
retrospective	0	O
cohort	0	O
mortality	0	O
study	0	O
was	0	O
conducted	0	O
on	0	O
6	0	O
,	0	O
152	0	O
chemical	0	O
workers	0	O
(	0	O
2	0	O
,	0	O
460	0	O
exposed	0	O
and	0	O
3	0	O
,	0	O
692	0	O
nonexposed	0	O
)	0	O
engaged	0	O
in	0	O
chloromethyl	0	O
ether	0	O
manufacture	0	O
at	0	O
7	0	O
major	0	O
U	1	O
.	0	O
S	1	O
.	0	O
companies	0	O
between	0	O
1948	0	O
and	0	O
1980	0	O
.	0	O


Autoionization	0	O
rates	0	O
and	0	O
energy	0	O
levels	0	O
of	0	O
triplet	0	O
nf	0	O
,	0	O
v	0	O
=	0	O
1	0	O
Rydberg	0	O
states	0	O
of	0	O
H2	0	O
.	0	O


In	1	O
the	0	O
control	0	O
group	0	O
the	0	O
histological	0	O
picture	0	O
resembled	0	O
osteoarthritis	0	O
.	0	O


The	0	O
96	0	O
-	0	O
bp	0	O
insert	0	O
contained	0	O
a	0	O
termination	0	O
signal	0	O
which	0	O
caused	0	O
the	0	O
premature	0	O
termination	0	O
of	0	O
the	0	O
protein	0	O
,	0	O
leading	0	O
to	0	O
the	0	O
generation	0	O
of	0	O
a	0	O
p53	0	B
product	0	I
9	0	O
amino	0	O
acids	0	O
shorter	0	O
than	0	O
usual	0	O
.	0	O


METHODS	0	O
:	0	O
In	1	O
the	0	O
current	0	O
study	0	O
the	0	O
authors	0	O
reported	0	O
on	0	O
PPB	1	O
cases	0	O
from	0	O
a	0	O
national	0	O
retrospective	0	O
search	0	O
performed	0	O
in	0	O
18	0	O
Italian	0	O
Associations	0	O
for	0	O
Pediatric	1	O
Hematology	1	O
and	0	O
Oncology	1	O
centers	0	O
.	0	O


L	1	O
-	0	O
canavanine	0	O
,	0	O
a	0	O
selective	0	O
inhibitor	0	O
of	0	O
the	0	O
inducible	0	O
nitric	0	B
oxide	0	I
synthase	0	I
,	0	O
increases	0	O
the	0	O
mean	0	O
systemic	0	O
filling	0	O
pressure	0	O
,	0	O
thereby	0	O
improving	0	O
venous	0	O
return	0	O
,	0	O
under	0	O
these	0	O
conditions	0	O
.	0	O


HDL	1	B
-	0	I
cholesterol	0	I
(+	0	O
6	0	O
%,	0	O
P	1	O
less	0	O
than	0	O
.	0	O
01	0	O
)	0	O
and	0	O
apolipoprotein	0	B
A	1	I
-	0	I
I	1	I
(+	0	O
6	0	O
%,	0	O
P	1	O
less	0	O
than	0	O
.	0	O
01	0	O
)	0	O
concentrations	0	O
increased	0	O
significantly	0	O
only	0	O
in	0	O
the	0	O
young	0	O
.	0	O


This	0	O
led	0	O
to	0	O
the	0	O
conclusion	0	O
that	0	O
the	0	O
metatarsal	0	O
artery	0	O
should	0	O
be	0	O
used	0	O
for	0	O
toe	0	O
MP	1	O
joint	0	O
grafts	0	O
,	0	O
while	0	O
the	0	O
unilateral	0	O
proper	0	O
digital	0	O
artery	0	O
is	0	O
suitable	0	O
for	0	O
toe	0	O
PIP	1	O
joint	0	O
grafts	0	O
,	0	O
together	0	O
with	0	O
concomitant	0	O
or	0	O
dorsal	0	O
cutaneous	0	O
vein	0	O
.	0	O


However	0	O
,	0	O
in	0	O
contrast	0	O
with	0	O
previous	0	O
in	0	O
vitro	0	O
cell	0	O
-	0	O
free	0	O
integration	0	O
studies	0	O
,	0	O
alteration	0	O
of	0	O
the	0	O
highly	0	O
conserved	0	O
CA	1	O
dinucleotide	0	O
resulted	0	O
in	0	O
a	0	O
mutant	0	O
which	0	O
still	0	O
retained	0	O
40	0	O
%	0	O
of	0	O
wild	0	O
-	0	O
type	0	O
integration	0	O
activity	0	O
.	0	O


Giant	1	O
pilomatrix	0	O
carcinoma	0	O
:	0	O
report	0	O
and	0	O
review	0	O
of	0	O
the	0	O
literature	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
calbindin	0	B
-	0	I
D28K	0	I
promoter	0	I
is	0	O
composed	0	O
of	0	O
a	0	O
variety	0	O
of	0	O
simple	0	O
repeated	0	O
sequences	0	O
,	0	O
some	0	O
of	0	O
which	0	O
are	0	O
components	0	O
of	0	O
putative	0	O
regulatory	0	O
signals	0	O
.	0	O


The	0	O
size	0	O
discrepancy	0	O
is	0	O
not	0	O
due	0	O
to	0	O
glycosylation	0	O
or	0	O
phosphorylation	0	O
of	0	O
Ag35	0	B
but	0	O
may	0	O
result	0	O
from	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
sequence	0	O
which	0	O
occurs	0	O
in	0	O
this	0	O
polypeptide	0	O
.	0	O


Serum	1	O
induction	0	O
of	0	O
a	0	O
MEF2	0	B
reporter	0	I
gene	0	I
was	0	O
not	0	O
observed	0	O
in	0	O
a	0	O
line	0	O
of	0	O
NIH	1	O
3T3	0	O
cells	0	O
which	0	O
contain	0	O
low	0	O
MEF2	0	B
site	0	I
binding	0	O
activity	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
Although	0	O
the	0	O
preponderance	0	O
of	0	O
findings	0	O
offer	0	O
support	0	O
for	0	O
transient	0	O
(	0	O
where	0	O
is	0	O
it	0	O
?)	0	O
as	0	O
opposed	0	O
to	0	O
sustained	0	O
(	0	O
what	0	O
is	0	O
it	0	O
?)	0	O
deficit	0	O
,	0	O
a	0	O
need	0	O
remains	0	O
for	0	O
specific	0	O
depiction	0	O
of	0	O
the	0	O
deficit	0	O
.	0	O


Frog	1	O
type	0	O
I	1	O
(	0	O
Ft	1	O
I	1	O
)	0	O
and	0	O
frog	0	O
type	0	O
II	0	O
(	0	O
Ft	1	O
II	0	O
)	0	O
slowly	0	O
adapting	0	O
(	0	O
SA	1	O
)	0	O
units	0	O
produced	0	O
spikes	0	O
only	0	O
at	0	O
the	0	O
indentation	0	O
phase	0	O
,	0	O
and	0	O
the	0	O
threshold	0	O
response	0	O
phase	0	O
(	0	O
TRP	1	O
),	0	O
i	0	O
.	0	O
e	0	O
..	0	O
the	0	O
phase	0	O
of	0	O
the	0	O
first	0	O
spike	0	O
was	0	O
for	0	O
ca	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
the	0	O
beta	0	O
-	0	O
adrenergic	0	O
agonist	0	O
,	0	O
isoproterenol	0	O
,	0	O
has	0	O
little	0	O
influence	0	O
on	0	O
vascular	0	O
capacitance	0	O
or	0	O
liver	0	O
volume	0	O
of	0	O
dogs	0	O
,	0	O
unless	0	O
the	0	O
hepatic	0	O
outflow	0	O
resistance	0	O
is	0	O
elevated	0	O
by	0	O
agents	0	O
such	0	O
as	0	O
histamine	0	O
.	0	O


Diazepam	1	O
(	0	O
3	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
generalized	0	O
to	0	O
Ro	0	O
11	0	O
-	0	O
6896	0	O
whereas	0	O
the	0	O
structurally	0	O
related	0	O
Ro	0	O
5	0	O
-	0	O
4864	0	O
(	0	O
3	0	O
mg	0	O
/	0	O
kg	0	O
and	0	O
30	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
did	0	O
not	0	O
.	0	O


By	0	O
an	0	O
induced	0	O
-	0	O
fit	0	O
mechanism	0	O
,	0	O
contacts	0	O
with	0	O
the	0	O
anticodon	0	O
can	0	O
activate	0	O
formation	0	O
of	0	O
a	0	O
robust	0	O
transition	0	O
state	0	O
at	0	O
a	0	O
site	0	O
over	0	O
70	0	O
A	1	O
away	0	O
.	0	O


Administration	1	O
of	0	O
anticoagulants	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
heparin	0	O
,	0	O
prostaglandin	0	O
E1	1	O
and	0	O
ticlopidine	0	O
seems	0	O
to	0	O
be	0	O
effective	0	O
in	0	O
alleviating	0	O
symptoms	0	O
and	0	O
might	0	O
prevent	0	O
further	0	O
deterioration	0	O
.	0	O


Protein	1	B
kinase	0	I
C	1	I
(	0	O
PKC	0	B
),	0	O
a	0	O
widely	0	O
-	0	O
distributed	0	O
enzyme	0	O
implicated	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
many	0	O
physiological	0	O
processes	0	O
,	0	O
consists	0	O
of	0	O
a	0	O
family	0	O
of	0	O
at	0	O
least	0	O
twelve	0	O
isoenzymes	0	O
which	0	O
differ	0	O
in	0	O
tissue	0	O
distribution	0	O
,	0	O
subcellular	0	O
localization	0	O
,	0	O
regulatory	0	O
properties	0	O
,	0	O
etc	0	O
.	0	O


The	0	O
central	0	O
(	0	O
R	1	O
)	0	O
domain	0	O
is	0	O
responsible	0	O
for	0	O
receptor	0	O
-	0	O
binding	0	O
activity	0	O
whereas	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
(	0	O
T	1	O
)	0	O
domain	0	O
mediates	0	O
translocation	0	O
,	0	O
the	0	O
process	0	O
by	0	O
which	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
cytotoxic	0	O
domain	0	O
is	0	O
transported	0	O
from	0	O
the	0	O
receptor	0	O
to	0	O
the	0	O
site	0	O
of	0	O
its	0	O
cytotoxicity	0	O
.	0	O


Wrist	1	O
measurement	0	O
of	0	O
blood	0	O
pressure	0	O
:	0	O
some	0	O
critical	0	O
remarks	0	O
to	0	O
oscillometry	0	O
.	0	O


Cardiac	1	O
output	0	O
(	0	O
CO	1	O
)	0	O
was	0	O
significantly	0	O
higher	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
0005	0	O
)	0	O
in	0	O
the	0	O
MBBF	0	O
group	0	O
.	0	O


The	0	O
interaction	0	O
between	0	O
DDB	0	B
and	0	O
E2F1	0	B
can	0	O
also	0	O
be	0	O
detected	0	O
by	0	O
coimmunoprecipitation	0	O
experiments	0	O
.	0	O


Account	1	O
was	0	O
taken	0	O
of	0	O
noncellular	0	O
and	0	O
nonhuman	0	O
elements	0	O
in	0	O
the	0	O
smears	0	O
;	0	O
they	0	O
included	0	O
mucus	0	O
,	0	O
Charcot	0	O
-	0	O
Layden	0	O
crystals	0	O
,	0	O
pollen	0	O
grains	0	O
,	0	O
vegetal	0	O
fragments	0	O
and	0	O
fungi	0	O
.	0	O


However	0	O
,	0	O
the	0	O
presence	0	O
of	0	O
effacement	0	O
seems	0	O
to	0	O
be	0	O
a	0	O
more	0	O
reliable	0	O
and	0	O
practical	0	O
parameter	0	O
that	0	O
will	0	O
be	0	O
preferred	0	O
in	0	O
that	0	O
prediction	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Intravenous	1	O
diazepam	0	O
administration	0	O
before	0	O
EGD	1	O
produces	0	O
a	0	O
significant	0	O
fall	0	O
in	0	O
SpO2	1	O
during	0	O
the	0	O
procedure	0	O
,	0	O
and	0	O
so	0	O
should	0	O
be	0	O
avoided	0	O
;	0	O
continuous	0	O
monitoring	0	O
of	0	O
SpO2	1	O
should	0	O
be	0	O
done	0	O
during	0	O
EGD	1	O
.	0	O


Nursing	1	O
of	0	O
patients	0	O
with	0	O
gynecological	0	O
diseases	0	O


Cell	1	O
lines	0	O
are	0	O
checked	0	O
to	0	O
find	0	O
out	0	O
whether	0	O
they	0	O
develop	0	O
tumors	0	O
in	0	O
nude	0	O
mice	0	O
followed	0	O
by	0	O
an	0	O
analysis	0	O
of	0	O
the	0	O
karyotype	0	O
.	0	O


This	0	O
interaction	0	O
occurs	0	O
over	0	O
a	0	O
wide	0	O
range	0	O
of	0	O
both	0	O
parameters	0	O
;	0	O
for	0	O
charge	0	O
density	0	O
from	0	O
at	0	O
least	0	O
10	0	O
to	0	O
800	0	O
microC	0	O
/	0	O
cm2	0	O
and	0	O
,	0	O
for	0	O
charge	0	O
per	0	O
phase	0	O
,	0	O
from	0	O
at	0	O
least	0	O
0	0	O
.	0	O
05	0	O
to	0	O
5	0	O
.	0	O
0	0	O
microC	0	O
per	0	O
phase	0	O
.	0	O


The	0	O
PEBP2	0	B
alpha	0	I
proteins	0	I
contain	0	O
a	0	O
128	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
(	0	O
aa	0	O
)	0	O
region	0	O
highly	0	O
homologous	0	O
to	0	O
the	0	O
Drosophila	1	B
melanogaster	0	I
segmentation	0	I
gene	0	I
runt	0	I
.	0	O


CD7	1	B
+/	0	O
CD3	0	B
-	0	O
T	1	O
-	0	O
cell	0	O
precursors	0	O
exhibit	0	O
V	1	B
delta	0	I
2D	0	I
delta	0	I
3	0	I
rearrangements	0	I
.	0	O


To	1	O
evaluate	0	O
the	0	O
effects	0	O
of	0	O
HRT	1	O
on	0	O
those	0	O
factors	0	O
in	0	O
end	0	O
-	0	O
stage	0	O
renal	0	O
disease	0	O
(	0	O
ESRD	1	O
)	0	O
patients	0	O
,	0	O
we	0	O
evaluated	0	O
the	0	O
changes	0	O
of	0	O
lipid	0	O
profile	0	O
,	0	O
coagulation	0	O
and	0	O
fibrinolysis	0	O
markers	0	O
,	0	O
and	0	O
plasma	0	O
homocysteine	0	O
levels	0	O
after	0	O
treatment	0	O
.	0	O


The	0	O
core	0	O
of	0	O
this	0	O
enhancer	0	O
contains	0	O
two	0	O
evolutionarily	0	O
conserved	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
homeodomain	0	B
protein	0	I
Tinman	0	I
(	0	O
Tin	1	B
),	0	O
expressed	0	O
in	0	O
developing	0	O
cardiac	0	O
,	0	O
somatic	0	O
,	0	O
and	0	O
visceral	0	O
muscle	0	O
lineages	0	O
.	0	O


Interestingly	0	O
,	0	O
the	0	O
activated	0	O
PDGF	0	B
beta	0	I
-	0	I
receptor	0	I
was	0	O
found	0	O
not	0	O
to	0	O
bind	0	O
Crk	0	B
proteins	0	I
.	0	O


The	0	O
present	0	O
study	0	O
investigated	0	O
dose	0	O
dependence	0	O
and	0	O
time	0	O
course	0	O
effects	0	O
of	0	O
the	0	O
benzodiazepine	0	O
(	0	O
BDZ	0	O
)	0	O
partial	0	O
inverse	0	O
agonist	0	O
,	0	O
RO19	0	O
-	0	O
4603	0	O
(	0	O
0	0	O
.	0	O
005	0	O
-	0	O
0	0	O
.	0	O
30	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
alone	0	O
,	0	O
and	0	O
in	0	O
combination	0	O
with	0	O
the	0	O
BDZ	0	B
receptor	0	I
antagonists	0	O
flumazenil	0	O
,	0	O
ZK	0	O
93426	0	O
,	0	O
and	0	O
CGS	1	O
8216	0	O
(	0	O
20	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
in	0	O
selectively	0	O
bred	0	O
alcohol	0	O
-	0	O
preferring	0	O
(	0	O
P	1	O
)	0	O
rats	0	O
provided	0	O
a	0	O
two	0	O
-	0	O
bottle	0	O
choice	0	O
test	0	O
between	0	O
ethanol	0	O
(	0	O
EtOH	1	O
)	0	O
(	0	O
10	0	O
%	0	O
v	0	O
/	0	O
v	0	O
),	0	O
and	0	O
a	0	O
palatable	0	O
saccharin	0	O
(	0	O
0	0	O
.	0	O
0125	0	O
%	0	O
g	0	O
/	0	O
v	0	O
)	0	O
solution	0	O
.	0	O


Intestinal	1	O
adaptation	0	O
(	0	O
first	0	O
of	0	O
two	0	O
parts	0	O
).	0	O


Each	0	O
repeat	0	O
consists	0	O
of	0	O
12	0	O
nt	0	O
,	0	O
coding	0	O
for	0	O
the	0	O
reiterated	0	O
sequence	0	O
,	0	O
K	1	O
/	0	O
NPAG	0	O
.	0	O


All	1	O
other	0	O
ejaculate	0	O
parameters	0	O
(	0	O
density	0	O
,	0	O
motility	0	O
,	0	O
swelling	0	O
test	0	O
,	0	O
penetration	0	O
test	0	O
)	0	O
remained	0	O
unchanged	0	O
,	0	O
and	0	O
there	0	O
was	0	O
only	0	O
one	0	O
post	0	O
-	0	O
therapeutic	0	O
pregnancy	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
contractile	0	O
action	0	O
of	0	O
arachidonic	0	O
acid	0	O
,	0	O
via	0	O
a	0	O
presumed	0	O
cyclooxygenase	0	B
product	0	O
that	0	O
mediated	0	O
the	0	O
contractions	0	O
caused	0	O
by	0	O
both	0	O
TF	1	B
and	0	O
EGF	1	B
,	0	O
was	0	O
not	0	O
blocked	0	O
by	0	O
any	0	O
of	0	O
the	0	O
signal	0	O
pathway	0	O
probe	0	O
inhibitors	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
tap	0	O
(	0	O
TW	0	O
)	0	O
or	0	O
carbonated	0	O
(	0	O
CW	0	O
)	0	O
water	0	O
on	0	O
arterial	0	O
pH	1	O
,	0	O
partial	0	O
pressure	0	O
of	0	O
carbon	0	O
dioxide	0	O
(	0	O
PCO2	1	O
)	0	O
and	0	O
plasma	0	O
lactate	0	O
were	0	O
determined	0	O
in	0	O
heat	0	O
-	0	O
stressed	0	O
broilers	0	O
.	0	O


Nip7p	0	B
-	0	O
depleted	0	O
cells	0	O
exhibited	0	O
the	0	O
same	0	O
defects	0	O
as	0	O
Nop8p	0	B
-	0	O
depleted	0	O
cells	0	O
,	0	O
except	0	O
that	0	O
they	0	O
accumulated	0	O
27S	0	B
precursors	0	I
.	0	O


Stability	1	O
of	0	O
pyrimethamine	0	O
in	0	O
a	0	O
liquid	0	O
dosage	0	O
formulation	0	O
stored	0	O
for	0	O
three	0	O
months	0	O
.	0	O


Microstructure	0	O
and	0	O
conductivity	0	O
of	0	O
hierarchical	0	O
laminate	0	O
composites	0	O
.	0	O


Patients	0	O
with	0	O
types	0	O
I	1	O
and	0	O
III	0	O
MPGN	0	O
did	0	O
not	0	O
differ	0	O
in	0	O
age	0	O
at	0	O
apparent	0	O
onset	0	O
,	0	O
age	0	O
at	0	O
diagnosis	0	O
,	0	O
or	0	O
interval	0	O
from	0	O
apparent	0	O
onset	0	O
of	0	O
symptoms	0	O
to	0	O
diagnosis	0	O
(	0	O
biopsy	0	O
).	0	O


RNP1	0	B
,	0	O
a	0	O
new	0	O
ribonucleoprotein	0	O
gene	0	O
of	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


These	0	O
results	0	O
support	0	O
the	0	O
diagnostic	0	O
validity	0	O
of	0	O
NFPD	0	O
in	0	O
CP	1	O
/	0	O
NCA	0	O
patients	0	O
,	0	O
because	0	O
such	0	O
patients	0	O
had	0	O
a	0	O
family	0	O
history	0	O
of	0	O
panic	0	O
disorder	0	O
similar	0	O
to	0	O
patients	0	O
with	0	O
a	0	O
more	0	O
classical	0	O
panic	0	O
disorder	0	O
presentation	0	O
.	0	O


Cloning	1	O
of	0	O
higher	0	B
plant	0	I
omega	0	I
-	0	I
3	0	I
fatty	0	I
acid	0	I
desaturases	0	I
.	0	O


The	0	O
mechanism	0	O
by	0	O
which	0	O
E2	1	B
-	0	I
C	1	I
represses	0	O
E2	1	B
-	0	I
dependent	0	I
enhancer	0	I
activity	0	O
most	0	O
likely	0	O
involves	0	O
competition	0	O
with	0	O
E2	1	B
for	0	O
binding	0	O
to	0	O
a	0	O
common	0	O
transcriptional	0	O
regulatory	0	O
site	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
400	0	O
WORDS	0	O
)	0	O


These	0	O
results	0	O
demonstrate	0	O
a	0	O
specific	0	O
association	0	O
of	0	O
SIV	1	O
and	0	O
HIV	1	B
-	0	I
2	0	I
nef	0	I
,	0	O
but	0	O
not	0	O
HIV	1	B
-	0	I
1	0	I
nef	0	I
,	0	O
with	0	O
TCRzeta	0	B
.	0	O


However	0	O
,	0	O
the	0	O
presence	0	O
of	0	O
Tax	0	B
I	1	I
increased	0	O
the	0	O
extent	0	O
and	0	O
altered	0	O
the	0	O
profile	0	O
of	0	O
proteins	0	O
binding	0	O
TRE	0	B
-	0	I
2	0	I
in	0	O
vivo	0	O
.	0	O


An	1	O
ASSEMBLER	0	O
routine	0	O
for	0	O
on	0	O
-	0	O
line	0	O
graphic	0	O
display	0	O
and	0	O
averaging	0	O
of	0	O
data	0	O
acquired	0	O
on	0	O
a	0	O
personal	0	O
microcomputer	0	O
.	0	O


Effect	1	O
of	0	O
single	0	O
base	0	O
substitutions	0	O
at	0	O
glycine	0	O
-	0	O
870	0	O
codon	0	O
of	0	O
gramicidin	0	B
S	1	I
synthetase	0	I
2	0	I
gene	0	I
on	0	O
proline	0	O
activation	0	O
.	0	O


Internal	1	O
biliary	0	O
drainage	0	O
,	0	O
unlike	0	O
external	0	O
drainage	0	O
,	0	O
does	0	O
not	0	O
suppress	0	O
the	0	O
regeneration	0	O
of	0	O
cholestatic	0	O
rat	0	O
liver	0	O
after	0	O
partial	0	O
hepatectomy	0	O
.	0	O


(	0	O
1986	0	O
)	0	O
method	0	O
of	0	O
separation	0	O
of	0	O
Cryptosporidium	1	O
spp	0	O
.	0	O
oocysts	0	O
from	0	O
feces	0	O
by	0	O
using	0	O
a	0	O
percoll	0	O
discontinuous	0	O
density	0	O
gradient	0	O
appeared	0	O
a	0	O
method	0	O
of	0	O
choice	0	O
for	0	O
obtaining	0	O
large	0	O
numbers	0	O
of	0	O
oocysts	0	O
of	0	O
C	1	O
.	0	O
parvum	0	O
free	0	O
of	0	O
fecal	0	O
contamination	0	O
.	0	O


Relationship	0	O
of	0	O
CDK	1	B
-	0	I
activating	0	I
kinase	0	I
and	0	O
RNA	1	B
polymerase	0	I
II	0	I
CTD	1	O
kinase	0	O
TFIIH	0	B
/	0	O
TFIIK	0	B
.	0	O


In	1	O
addition	0	O
serum	0	B
IgE	1	I
concentrations	0	O
were	0	O
not	0	O
statistically	0	O
different	0	O
.	0	O


Artificial	1	O
ventilation	0	O
was	0	O
conducted	0	O
using	0	O
a	0	O
tidal	0	O
volume	0	O
of	0	O
10	0	O
ml	0	O
X	1	O
kg	0	O
-	0	O
1	0	O
and	0	O
a	0	O
rate	0	O
of	0	O
10	0	O
to	0	O
12	0	O
c	0	O
X	1	O
min	0	O
-	0	O
1	0	O
.	0	O


Although	0	O
further	0	O
studies	0	O
are	0	O
required	0	O
to	0	O
determine	0	O
the	0	O
precise	0	O
role	0	O
of	0	O
PEBP2	0	B
in	0	O
the	0	O
GM	1	B
-	0	I
CSF	1	I
promoter	0	I
activity	0	O
,	0	O
the	0	O
present	0	O
findings	0	O
suggested	0	O
the	0	O
importance	0	O
of	0	O
the	0	O
relative	0	O
ratio	0	O
of	0	O
different	0	O
PEBP2	0	B
isoforms	0	I
in	0	O
regulating	0	O
the	0	O
levels	0	O
of	0	O
the	0	O
promoter	0	O
activity	0	O
.	0	O


Such	0	O
mutations	0	O
are	0	O
thought	0	O
to	0	O
exert	0	O
their	0	O
dominant	0	O
phenotype	0	O
by	0	O
sequestration	0	O
of	0	O
the	0	O
guanine	0	B
nucleotide	0	I
exchange	0	I
factor	0	I
(	0	O
GNEF	0	B
).	0	O


The	0	O
presence	0	O
of	0	O
an	0	O
unusual	0	O
transcript	0	O
possessing	0	O
IVS2C	0	B
beta	0	I
1	0	I
at	0	O
the	0	O
5	0	O
'	0	O
terminus	0	O
suggests	0	O
that	0	O
cleavage	0	O
of	0	O
its	0	O
splice	0	O
acceptor	0	O
is	0	O
inefficient	0	O
or	0	O
negatively	0	O
regulated	0	O
.	0	O


HL	1	O
02	0	O
type	0	O
oculomotor	0	O
stimulator	0	O
.	0	O


The	0	O
UV	1	O
absorption	0	O
spectrum	0	O
revealed	0	O
a	0	O
shoulder	0	O
at	0	O
250	0	O
nm	0	O
,	0	O
characteristic	0	O
of	0	O
CysS	0	O
-	0	O
Cd	1	O
(	0	O
II	0	O
)	0	O
ligand	0	O
-	0	O
to	0	O
-	0	O
metal	0	O
charge	0	O
-	0	O
transfer	0	O
transitions	0	O
,	0	O
and	0	O
the	0	O
difference	0	O
absorption	0	O
coefficient	0	O
after	0	O
acidification	0	O
(	0	O
delta	0	O
epsilon	0	O
248	0	O
,	0	O
24	0	O
mM	1	O
-	0	O
1	0	O
cm	0	O
-	0	O
1	0	O
)	0	O
indicated	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
Cd	1	O
(	0	O
Cys	1	O
-	0	O
S	1	O
)	0	O
4	0	O
center	0	O
.	0	O


Indeed	0	O
,	0	O
it	0	O
is	0	O
shown	0	O
that	0	O
it	0	O
mediates	0	O
the	0	O
formation	0	O
of	0	O
disulfide	0	O
-	0	O
linked	0	O
homodimers	0	O
and	0	O
that	0	O
the	0	O
formation	0	O
of	0	O
homo	0	O
-	0	O
and	0	O
heterodimers	0	O
are	0	O
mutually	0	O
excluded	0	O
.	0	O


By	0	O
progressive	0	O
5	0	O
'-	0	O
deletion	0	O
studies	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
a	0	O
248	0	O
-	0	O
bp	0	O
DNA	1	O
fragment	0	O
(-	0	O
1018	0	O
to	0	O
-	0	O
771	0	O
,	0	O
relative	0	O
to	0	O
the	0	O
translation	0	O
start	0	O
site	0	O
)	0	O
at	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
human	0	B
GnRHR	0	I
gene	0	I
that	0	O
is	0	O
responsible	0	O
for	0	O
the	0	O
GnRHa	0	O
-	0	O
mediated	0	O
down	0	O
-	0	O
regulation	0	O
of	0	O
human	0	B
GnRHR	0	I
promoter	0	I
activity	0	O
.	0	O


Furthermore	0	O
,	0	O
p150	0	B
suppresses	0	O
actin	0	B
gelation	0	O
,	0	O
which	0	O
is	0	O
induced	0	O
by	0	O
smooth	0	B
muscle	0	I
alpha	0	I
-	0	I
actinin	0	I
.	0	O


The	0	O
protein	0	O
kinase	0	O
domains	0	O
of	0	O
LIMK1	0	B
and	0	O
LIMK2	0	B
are	0	O
unique	0	O
in	0	O
that	0	O
they	0	O
contain	0	O
an	0	O
unusual	0	O
sequence	0	O
motif	0	O
Asp	1	O
-	0	O
Leu	1	O
-	0	O
Asn	1	O
-	0	O
Ser	1	O
-	0	O
His	1	O
-	0	O
Asn	1	O
in	0	O
subdomain	0	O
VIB	0	O
and	0	O
a	0	O
highly	0	O
basic	0	O
insert	0	O
between	0	O
subdomains	0	O
VII	0	O
and	0	O
VIII	0	O
.	0	O


However	0	O
,	0	O
if	0	O
EMPD	0	O
involves	0	O
the	0	O
glans	0	O
penis	0	O
or	0	O
perianal	0	O
area	0	O
,	0	O
a	0	O
search	0	O
for	0	O
internal	0	O
malignancy	0	O
is	0	O
still	0	O
warranted	0	O
.	0	O


Redistribution	1	O
of	0	O
mannosidase	0	B
I	1	I
was	0	O
also	0	O
observed	0	O
in	0	O
cells	0	O
incubated	0	O
at	0	O
15	0	O
degrees	0	O
C	1	O
.	0	O


In	1	O
flies	0	O
,	0	O
the	0	O
dShc	0	B
protein	0	I
physically	0	O
associates	0	O
with	0	O
the	0	O
activated	0	O
Drosophila	1	B
epidermal	0	I
growth	0	I
factor	0	I
receptor	0	I
homolog	0	I
(	0	O
DER	0	B
)	0	O
and	0	O
is	0	O
inducibly	0	O
phosphorylated	0	O
on	0	O
tyrosine	0	O
by	0	O
DER	0	B
.	0	O


Hematopoietic	1	B
growth	0	I
factors	0	I
have	0	O
already	0	O
had	0	O
an	0	O
enormous	0	O
impact	0	O
on	0	O
transfusion	0	O
practice	0	O
by	0	O
eliminating	0	O
or	0	O
reducing	0	O
the	0	O
need	0	O
for	0	O
red	0	O
blood	0	O
cell	0	O
transfusions	0	O
in	0	O
a	0	O
variety	0	O
of	0	O
anemic	0	O
states	0	O
characterized	0	O
by	0	O
an	0	O
absolute	0	O
or	0	O
relative	0	O
decrease	0	O
in	0	O
erythropoietin	0	B
.	0	O


Cestode	1	O
invasion	0	O
in	0	O
irradiated	0	O
host	0	O
organism	0	O
increases	0	O
the	0	O
negative	0	O
effect	0	O
of	0	O
ionizing	0	O
radiation	0	O
on	0	O
the	0	O
hamster	0	O
immune	0	O
system	0	O
.	0	O


Repair	1	O
of	0	O
this	0	O
insertion	0	O
by	0	O
homologous	0	O
recombination	0	O
restores	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
hprt	0	B
locus	0	I
,	0	O
thus	0	O
confirming	0	O
the	0	O
site	0	O
of	0	O
mutation	0	O
.	0	O


Three	0	O
chromosomal	0	B
crsA	0	I
mutations	0	I
,	0	O
crsA1	0	B
,	0	O
crsA4	0	B
,	0	O
and	0	O
crsA47	0	B
,	0	O
were	0	O
transferred	0	O
by	0	O
the	0	O
"	0	O
gene	0	O
conversion	0	O
"	0	O
process	0	O
to	0	O
B	1	O
.	0	O
subtilis	0	O
plasmid	0	O
pRPD11	0	O
,	0	O
which	0	O
consists	0	O
of	0	O
the	0	O
entire	0	O
wild	0	B
-	0	I
type	0	I
rpoD	0	I
coding	0	I
sequence	0	I
,	0	O
encoding	0	O
the	0	O
major	0	B
sigma	0	I
43	0	I
factor	0	I
of	0	I
B	1	I
.	0	I
subtilis	0	I
RNA	1	I
polymerase	0	I
,	0	O
and	0	O
pUB110	0	O
.	0	O


Renal	1	O
pathology	0	O
and	0	O
long	0	O
-	0	O
term	0	O
outcome	0	O
in	0	O
childhood	0	O
SLE	1	O
.	0	O


Identification	1	O
of	0	O
a	0	O
cis	0	O
-	0	O
acting	0	O
element	0	O
in	0	O
the	0	O
class	0	B
I	1	I
major	0	I
histocompatibility	0	I
complex	0	I
gene	0	I
promoter	0	I
responsive	0	O
to	0	O
activation	0	O
by	0	O
retroviral	0	O
sequences	0	O
.	0	O


Because	0	O
RNase	1	B
III	0	I
host	0	I
mutants	0	I
are	0	O
defective	0	O
in	0	O
sib	0	B
regulation	0	O
,	0	O
processing	0	O
of	0	O
the	0	O
PL	0	B
mRNA	1	I
at	0	O
sib	0	B
by	0	O
this	0	O
endoribonuclease	0	O
may	0	O
cause	0	O
int	0	B
mRNA	1	I
decay	0	O
and	0	O
decrease	0	O
int	0	B
synthesis	0	O
.	0	O


The	0	O
ORF3	0	O
mutant	0	O
produced	0	O
reduced	0	O
levels	0	O
of	0	O
tabtoxin	0	B
,	0	O
indicating	0	O
that	0	O
ORF3	0	O
may	0	O
have	0	O
a	0	O
role	0	O
in	0	O
T	1	B
beta	0	I
L	1	I
biosynthesis	0	O
.	0	O


The	0	O
requirement	0	O
of	0	O
3	0	O
'	0	O
complementarity	0	O
for	0	O
a	0	O
ligation	0	O
reaction	0	O
is	0	O
reaffirmed	0	O
by	0	O
results	0	O
from	0	O
1	0	O
nt	0	O
insertions	0	O
on	0	O
either	0	O
the	0	O
3	0	O
'-	0	O
or	0	O
5	0	O
'-	0	O
side	0	O
of	0	O
the	0	O
nick	0	O
.	0	O


A	1	O
subset	0	O
of	0	O
mutations	0	O
in	0	O
the	0	O
Psi	1	B
synthase	0	I
domain	0	I
impairs	0	O
association	0	O
of	0	O
the	0	O
altered	0	O
Cbf5p	0	B
proteins	0	I
with	0	O
selected	0	O
box	0	O
H	1	B
/	0	I
ACA	1	I
snoRNAs	0	I
,	0	O
suggesting	0	O
that	0	O
the	0	O
functional	0	O
catalytic	0	O
domain	0	O
is	0	O
essential	0	O
for	0	O
that	0	O
interaction	0	O
.	0	O


Serum	1	B
TNF	1	I
concentrations	0	O
were	0	O
elevated	0	O
at	0	O
diagnosis	0	O
and	0	O
gradually	0	O
decreased	0	O
toward	0	O
the	0	O
reference	0	O
limits	0	O
by	0	O
week	0	O
16	0	O
.	0	O


Element	1	O
B	1	O
(-	0	O
249	0	O
/-	0	O
229	0	O
)	0	O
shows	0	O
more	0	O
than	0	O
80	0	O
%	0	O
homology	0	O
to	0	O
a	0	O
consensus	0	B
c	0	I
-	0	I
myb	0	I
element	0	I
,	0	O
but	0	O
formed	0	O
two	0	O
specific	0	O
complexes	0	O
that	0	O
differed	0	O
from	0	O
that	0	O
of	0	O
c	0	B
-	0	I
myb	0	I
in	0	O
the	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assay	0	O
.	0	O


However	0	O
,	0	O
expression	0	O
of	0	O
sigma	0	B
3	0	I
from	0	O
S4	1	B
(	0	O
3	0	B
'	0	I
UTR	0	I
/	0	I
S1	1	I
),	0	O
which	0	O
included	0	O
the	0	O
PKR	0	B
activator	0	I
sequence	0	I
from	0	O
S1	1	B
within	0	O
the	0	O
3	0	B
'-	0	I
UTR	0	I
of	0	I
S4	1	I
,	0	O
was	0	O
comparable	0	O
to	0	O
that	0	O
from	0	O
wild	0	B
-	0	I
type	0	I
S4	1	I
.	0	O


RESULTS	0	O
:	0	O
256	0	O
Periods	0	O
of	0	O
TTP	0	O
or	0	O
PUNP	0	O
were	0	O
reported	0	O
by	0	O
men	0	O
and	0	O
174	0	O
by	0	O
women	0	O
.	0	O


One	0	O
of	0	O
the	0	O
most	0	O
relevant	0	O
aspects	0	O
in	0	O
achieving	0	O
the	0	O
consistent	0	O
survival	0	O
of	0	O
an	0	O
animal	0	O
undergoing	0	O
the	0	O
experimental	0	O
implantation	0	O
of	0	O
a	0	O
total	0	O
artificial	0	O
heart	0	O
is	0	O
obviously	0	O
related	0	O
to	0	O
the	0	O
correct	0	O
anatomic	0	O
placement	0	O
of	0	O
prosthetic	0	O
ventricles	0	O
inside	0	O
the	0	O
chest	0	O
.	0	O


Biol	0	O
.	0	O


Although	0	O
not	0	O
consistently	0	O
identified	0	O
in	0	O
all	0	O
samples	0	O
,	0	O
secondary	0	O
Academic	0	O
,	0	O
Personal	0	O
Responsibility	1	O
,	0	O
and	0	O
Community	1	O
/	0	O
Vocational	0	O
dimensions	0	O
were	0	O
also	0	O
identified	0	O
.	0	O


In	1	O
TNF	1	B
-	0	O
resistant	0	O
T24	0	O
bladder	0	O
carcinoma	0	O
cells	0	O
,	0	O
TNF	1	B
failed	0	O
to	0	O
alter	0	O
EGF	1	B
-	0	I
R	1	I
tyrosine	0	I
protein	0	I
kinase	0	I
activity	0	O
although	0	O
both	0	O
EGF	1	B
and	0	O
phorbol	0	O
ester	0	O
were	0	O
shown	0	O
to	0	O
modulate	0	O
the	0	O
enzymatic	0	O
activity	0	O
of	0	O
the	0	O
receptor	0	O
in	0	O
these	0	O
cells	0	O
.	0	O


Compensative	0	O
justice	0	O
and	0	O
moral	0	O
investment	0	O
among	0	O
Japanese	0	O
,	0	O
Chinese	0	O
,	0	O
and	0	O
Koreans	0	O
.	0	O


Problems	0	O
in	0	O
the	0	O
determination	0	O
of	0	O
the	0	O
antigenic	0	O
content	0	O
of	0	O
influenza	0	O
vaccines	0	O
.	0	O


Radiogallium	0	O
imaging	0	O
is	0	O
thus	0	O
of	0	O
limited	0	O
use	0	O
in	0	O
evaluation	0	O
of	0	O
suspected	0	O
giant	0	O
cell	0	O
tumors	0	O
of	0	O
bone	0	O
.	0	O


Five	0	O
of	0	O
the	0	O
Aeromonas	1	O
strains	0	O
and	0	O
one	0	O
of	0	O
V	1	O
cholerae	0	O
non	0	O
-	0	O
O1	0	O
were	0	O
positive	0	O
for	0	O
enterotoxin	0	O
activity	0	O
.	0	O


Since	0	O
the	0	O
UfAP	0	B
and	0	O
UTMP	0	B
share	0	O
many	0	O
biosynthetic	0	O
and	0	O
structural	0	O
features	0	O
that	0	O
include	0	O
site	0	O
of	0	O
biosynthesis	0	O
in	0	O
the	0	O
endometrium	0	O
,	0	O
P4	0	O
-	0	O
responsiveness	0	O
,	0	O
the	0	O
presence	0	O
of	0	O
the	0	O
mannose	0	O
6	0	O
-	0	O
phosphate	0	O
lysosomal	0	O
recognition	0	O
marker	0	O
,	0	O
and	0	O
considerable	0	O
sequence	0	O
similarity	0	O
,	0	O
the	0	O
UfAP	0	B
and	0	O
the	0	O
UTMP	0	B
may	0	O
have	0	O
homologous	0	O
function	0	O
which	0	O
for	0	O
both	0	O
still	0	O
remains	0	O
obscure	0	O
.	0	O


Between	0	O
the	0	O
subgroups	0	O
of	0	O
dementia	0	O
disorders	0	O
there	0	O
were	0	O
no	0	O
significant	0	O
differences	0	O
in	0	O
basal	0	O
cortisol	0	O
levels	0	O
.	0	O


This	0	O
laser	0	O
provided	0	O
sufficient	0	O
power	0	O
in	0	O
an	0	O
amniotic	0	O
fluid	0	O
medium	0	O
to	0	O
occlude	0	O
placental	0	O
vessels	0	O
as	0	O
large	0	O
as	0	O
7	0	O
mm	0	O
in	0	O
diameter	0	O
within	0	O
6	0	O
seconds	0	O
at	0	O
a	0	O
power	0	O
density	0	O
of	0	O
2000	0	O
W	1	O
/	0	O
cm2	0	O
.	0	O


Primary	1	O
infection	0	O
is	0	O
usually	0	O
managed	0	O
conservatively	0	O
.	0	O


In	1	O
an	0	O
effort	0	O
to	0	O
isolate	0	O
genes	0	O
with	0	O
down	0	O
-	0	O
regulated	0	O
expression	0	O
at	0	O
the	0	O
mRNA	1	O
level	0	O
during	0	O
oncogenic	0	O
transformation	0	O
of	0	O
human	0	O
mammary	0	O
epithelial	0	O
cells	0	O
(	0	O
MECs	0	O
),	0	O
we	0	O
performed	0	O
subtractive	0	O
hybridization	0	O
between	0	O
normal	0	O
MEC	0	O
strain	0	O
76N	0	O
and	0	O
its	0	O
radiation	0	O
-	0	O
transformed	0	O
tumorigenic	0	O
derivative	0	O
76R	0	O
-	0	O
30	0	O
.	0	O


Furthermore	0	O
,	0	O
LB1	0	B
gene	0	I
mapped	0	O
to	0	O
chromosome	0	O
13q14	0	O
,	0	O
a	0	O
region	0	O
that	0	O
has	0	O
been	0	O
involved	0	O
as	0	O
a	0	O
chromosomal	0	O
breakpoint	0	O
in	0	O
DLBL	0	O
.	0	O


Furthermore	0	O
,	0	O
an	0	O
upstream	0	O
element	0	O
,	0	O
collagen	0	O
element	0	O
I	1	O
(-	0	O
370	0	O
/-	0	O
344	0	O
),	0	O
which	0	O
shares	0	O
homology	0	O
with	0	O
the	0	O
LAP	1	B
binding	0	O
cis	0	O
-	0	O
element	0	O
of	0	O
the	0	O
albumin	0	B
promoter	0	I
(	0	O
9	0	O
of	0	O
13	0	O
bp	0	O
)	0	O
is	0	O
described	0	O
.	0	O


This	0	O
multimodality	0	O
treatment	0	O
for	0	O
locally	0	O
advanced	0	O
gynecologic	0	O
tumors	0	O
appears	0	O
feasible	0	O
with	0	O
modification	0	O
,	0	O
and	0	O
continued	0	O
work	0	O
exploring	0	O
this	0	O
approach	0	O
is	0	O
encouraged	0	O
.	0	O


Our	0	O
data	0	O
therefore	0	O
indicate	0	O
that	0	O
it	0	O
is	0	O
possible	0	O
to	0	O
engineer	0	O
the	0	O
HA	1	B
envelope	0	I
glycoprotein	0	I
by	0	O
fusing	0	O
ligands	0	O
to	0	O
its	0	O
amino	0	O
-	0	O
terminal	0	O
end	0	O
without	0	O
affecting	0	O
its	0	O
fusion	0	O
activity	0	O
.	0	O


Fibrin	1	B
gels	0	O
and	0	O
their	0	O
possible	0	O
implication	0	O
for	0	O
surface	0	O
hemorheology	0	O
in	0	O
health	0	O
and	0	O
disease	0	O
.	0	O


Members	0	O
of	0	O
the	0	O
meis1	0	B
and	0	O
pbx	0	B
homeodomain	0	I
protein	0	I
families	0	I
cooperatively	0	O
bind	0	O
a	0	O
cAMP	1	O
-	0	O
responsive	0	O
sequence	0	O
(	0	O
CRS1	0	O
)	0	O
from	0	O
bovine	0	B
CYP17	0	I
.	0	O


The	0	O
CANNTG	0	O
motifs	0	O
were	0	O
found	0	O
to	0	O
bind	0	O
MyoD	0	B
and	0	O
myogenin	0	B
fusion	0	I
proteins	0	I
and	0	O
to	0	O
interact	0	O
with	0	O
proteins	0	O
in	0	O
nuclear	0	O
extracts	0	O
from	0	O
cultured	0	O
myotubes	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
unidentified	0	O
macroscopic	0	O
or	0	O
microscopic	0	O
clusters	0	O
of	0	O
neoplastic	0	O
cells	0	O
,	0	O
lying	0	O
around	0	O
,	0	O
more	0	O
or	0	O
less	0	O
close	0	O
to	0	O
,	0	O
the	0	O
line	0	O
of	0	O
insertion	0	O
of	0	O
lesion	0	O
,	0	O
could	0	O
render	0	O
any	0	O
attempt	0	O
to	0	O
gain	0	O
a	0	O
"	0	O
radical	0	O
"	0	O
excision	0	O
useless	0	O
.	0	O


It	1	O
may	0	O
be	0	O
time	0	O
to	0	O
reevaluate	0	O
the	0	O
dichotomy	0	O
between	0	O
AD	1	O
and	0	O
VaD	1	O
.	0	O


Cytohesin	0	B
-	0	I
1	0	I
,	0	O
a	0	O
protein	0	O
abundant	0	O
in	0	O
cells	0	O
of	0	O
the	0	O
immune	0	O
system	0	O
,	0	O
has	0	O
been	0	O
proposed	0	O
to	0	O
be	0	O
a	0	O
human	0	O
homolog	0	O
of	0	O
the	0	O
Saccharomyces	1	B
cerevisiae	0	I
Sec7	0	I
gene	0	I
product	0	I
,	0	O
which	0	O
is	0	O
crucial	0	O
in	0	O
protein	0	O
transport	0	O
.	0	O


Surprisingly	0	O
,	0	O
double	0	O
mutants	0	O
of	0	O
the	0	O
shy2	0	B
-	0	I
1D	0	I
mutant	0	I
with	0	O
the	0	O
phytochrome	0	B
-	0	O
deficient	0	O
mutants	0	O
hy2	0	B
,	0	O
hy3	0	B
(	0	O
phyB	0	B
-	0	I
1	0	I
)	0	O
and	0	O
fre1	0	B
-	0	I
1	0	I
(	0	O
phyA	0	B
-	0	I
201	0	I
)	0	O
showed	0	O
reduced	0	O
photomorphogenic	0	O
response	0	O
in	0	O
darkness	0	O
with	0	O
a	0	O
longer	0	O
hypocotyl	0	O
,	0	O
a	0	O
longer	0	O
inflorescence	0	O
stem	0	O
,	0	O
and	0	O
a	0	O
lower	0	O
level	0	O
expression	0	O
of	0	O
the	0	O
CAB	1	B
gene	0	I
than	0	O
the	0	O
shy2	0	B
-	0	I
1D	0	I
single	0	I
mutant	0	I
.	0	O


In	1	O
patients	0	O
with	0	O
type	0	O
IA	1	O
maple	0	O
syrup	0	O
urine	0	O
disease	0	O
,	0	O
the	0	O
E1alpha	0	B
subunit	0	I
is	0	O
affected	0	O
,	0	O
resulting	0	O
in	0	O
the	0	O
loss	0	O
of	0	O
E1	1	B
and	0	O
branched	0	B
-	0	I
chain	0	I
ketoacid	0	I
dehydrogenase	0	I
catalytic	0	O
activities	0	O
.	0	O


New	0	O
diagnostic	0	O
strategies	0	O
for	0	O
lupus	0	O
anticoagulants	0	O
and	0	O
antiphospholipid	0	O
antibodies	0	O
.	0	O


Guinea	0	O
pigs	0	O
weighing	0	O
300	0	O
approximately	0	O
350	0	O
g	0	O
were	0	O
used	0	O
.	0	O


Discordance	1	O
on	0	O
the	0	O
cost	0	O
dimension	0	O
correlated	0	O
negatively	0	O
with	0	O
G	1	B
Hb	1	I
,	0	O
suggesting	0	O
better	0	O
glycemic	0	O
control	0	O
with	0	O
greater	0	O
disagreement	0	O
.	0	O


To	1	O
elucidate	0	O
whether	0	O
potential	0	O
endocrine	0	O
changes	0	O
resulted	0	O
from	0	O
acute	0	O
hypoxaemia	0	O
alone	0	O
,	0	O
the	0	O
underlying	0	O
disease	0	O
,	0	O
or	0	O
unspecific	0	O
influences	0	O
connected	0	O
with	0	O
the	0	O
ICU	1	O
setting	0	O
,	0	O
all	0	O
measurements	0	O
were	0	O
compared	0	O
to	0	O
those	0	O
of	0	O
a	0	O
completely	0	O
healthy	0	O
reference	0	O
group	0	O
(	0	O
REF	0	O
)	0	O
with	0	O
comparable	0	O
acute	0	O
experimental	0	O
hypoxaemia	0	O
.	0	O


We	0	O
have	0	O
cloned	0	O
the	0	O
single	0	O
-	0	O
copy	0	O
gene	0	O
for	0	O
the	0	O
trans	0	B
-	0	I
spliceosomal	0	I
U5	0	I
snRNA	1	I
from	0	O
the	0	O
trypanosomatid	0	O
species	0	O
Leptomonas	1	O
seymouri	0	O
,	0	O
using	0	O
U5	0	B
RNA	1	I
affinity	0	O
selection	0	O
and	0	O
cDNA	1	O
cloning	0	O
.	0	O


Parathyroid	1	B
hormone	0	I
regulation	0	O
of	0	O
bone	0	B
sialoprotein	0	I
(	0	O
BSP	0	B
)	0	O
gene	0	O
transcription	0	O
is	0	O
mediated	0	O
through	0	O
a	0	O
pituitary	0	B
-	0	I
specific	0	I
transcription	0	I
factor	0	I
-	0	I
1	0	I
(	0	O
Pit	1	B
-	0	I
1	0	I
)	0	O
motif	0	O
in	0	O
the	0	O
rat	0	B
BSP	0	I
gene	0	I
promoter	0	I
.	0	O


Diallylnitrosamine	0	O
(	0	O
DAN	0	O
),	0	O
one	0	O
of	0	O
the	0	O
few	0	O
nitrosamines	0	O
tested	0	O
thus	0	O
far	0	O
that	0	O
has	0	O
not	0	O
induced	0	O
neoplasms	0	O
in	0	O
rats	0	O
,	0	O
caused	0	O
a	0	O
high	0	O
incidence	0	O
of	0	O
respiratory	0	O
tract	0	O
tumors	0	O
in	0	O
Syrian	0	O
golden	0	O
hamsters	0	O
treated	0	O
sc	0	O
with	0	O
single	0	O
or	0	O
weekly	0	O
doses	0	O
of	0	O
the	0	O
compound	0	O
.	0	O


A	1	O
DNA	1	O
fragment	0	O
encoding	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
(	0	O
amino	0	O
acids	0	O
1	0	O
-	0	O
60	0	O
)	0	O
of	0	O
the	0	O
Escherichia	1	B
coli	0	I
fru	0	I
transcriptional	0	I
regulator	0	I
was	0	O
cloned	0	O
into	0	O
the	0	O
pGEX	0	O
-	0	O
KT	0	O
vector	0	O
and	0	O
expressed	0	O
in	0	O
frame	0	O
with	0	O
the	0	O
fused	0	O
gene	0	O
encoding	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
.	0	O


Unusual	0	O
course	0	O
of	0	O
plasmocytosis	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
TA	1	O
caused	0	O
a	0	O
specific	0	O
decrease	0	O
in	0	O
AGD	1	O
on	0	O
GD	1	O
20	0	O
that	0	O
was	0	O
largely	0	O
reversed	0	O
by	0	O
PCD	1	O
23	0	O
.	0	O


A	1	O
single	0	O
rectal	0	O
dose	0	O
of	0	O
25	0	O
mg	0	O
/	0	O
kg	0	O
will	0	O
obtain	0	O
this	0	O
lower	0	O
concentration	0	O
within	0	O
1	0	O
h	0	O
of	0	O
administration	0	O
and	0	O
maintain	0	O
it	0	O
for	0	O
up	0	O
to	0	O
6	0	O
h	0	O
.	0	O


A	1	O
false	0	O
positive	0	O
marker	0	O
screen	0	O
was	0	O
associated	0	O
with	0	O
the	0	O
occurrence	0	O
of	0	O
hand	0	O
-	0	O
foot	0	O
syndrome	0	O
even	0	O
when	0	O
the	0	O
effect	0	O
of	0	O
regimen	0	O
was	0	O
accounted	0	O
for	0	O
by	0	O
stratification	0	O
(	0	O
p	0	O
=	0	O
.	0	O
01	0	O
).	0	O


The	0	O
effect	0	O
of	0	O
water	0	O
deprivation	0	O
for	0	O
19	0	O
h	0	O
on	0	O
renal	0	O
Na	1	O
excretion	0	O
of	0	O
conscious	0	O
adrenalectomized	0	O
(	0	O
ADX	0	O
)	0	O
sheep	0	O
maintained	0	O
on	0	O
a	0	O
constant	0	O
intravenous	0	O
infusion	0	O
of	0	O
aldosterone	0	O
and	0	O
cortisol	0	O
(	0	O
ADX	0	O
-	0	O
constant	0	O
steroid	0	O
sheep	0	O
)	0	O
was	0	O
investigated	0	O
.	0	O


272	0	O
,	0	O
1904	0	O
].	0	O


These	0	O
results	0	O
support	0	O
a	0	O
model	0	O
in	0	O
which	0	O
p53	0	B
protein	0	I
contributes	0	O
to	0	O
the	0	O
maintenance	0	O
of	0	O
genomic	0	O
integrity	0	O
through	0	O
recombinational	0	O
repair	0	O
.	0	O


The	0	O
structure	0	O
of	0	O
the	0	O
enhancer	0	O
was	0	O
also	0	O
probed	0	O
by	0	O
inserting	0	O
a	0	O
pair	0	O
of	0	O
complementary	0	O
synthetic	0	O
oligodeoxynucleotides	0	O
which	0	O
represented	0	O
the	0	O
region	0	O
between	0	O
nt	0	O
positions	0	O
-	0	O
235	0	O
and	0	O
-	0	O
215	0	O
into	0	O
a	0	O
truncated	0	O
template	0	O
which	0	O
lacked	0	O
the	0	O
enhancer	0	O
.	0	O


Identification	1	O
of	0	O
an	0	O
enhancer	0	O
and	0	O
an	0	O
alternative	0	O
promoter	0	O
in	0	O
the	0	O
first	0	O
intron	0	O
of	0	O
the	0	O
alpha	0	B
-	0	I
fetoprotein	0	I
gene	0	I
.	0	O


Multilayer	0	O
-	0	O
relaxation	0	O
geometry	0	O
and	0	O
electronic	0	O
structure	0	O
of	0	O
a	0	O
W	1	O
(	0	O
111	0	O
)	0	O
surface	0	O
.	0	O


A	1	O
gapped	0	O
search	0	O
with	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
CDED	0	B
/	0	O
LIOR	0	B
revealed	0	O
a	0	O
36	0	O
-	0	O
41	0	O
%	0	O
similarity	0	O
to	0	O
several	0	O
proteins	0	O
related	0	O
to	0	O
signal	0	O
transduction	0	O
and	0	O
cell	0	O
replication	0	O
,	0	O
such	0	O
as	0	O
ORC1	0	B
and	0	O
KSR	0	B
.	0	O


A	1	O
third	0	O
one	0	O
is	0	O
homologous	0	O
in	0	O
half	0	O
of	0	O
its	0	O
length	0	O
to	0	O
the	0	O
prokaryotic	0	B
hydantoinase	0	I
HyuA	0	I
and	0	O
in	0	O
the	0	O
other	0	O
half	0	O
to	0	O
hydatoinase	0	B
HyuB	0	I
.	0	O


Aluminium	1	O
resin	0	O
for	0	O
the	0	O
treatment	0	O
of	0	O
the	0	O
hyperkalamia	0	O
of	0	O
renal	0	O
failure	0	O
.	0	O


Involvement	0	O
of	0	O
AP1	0	B
and	0	O
PEA3	0	B
binding	0	I
sites	0	I
in	0	O
the	0	O
regulation	0	O
of	0	O
murine	0	B
tissue	0	I
inhibitor	0	I
of	0	I
metalloproteinases	0	I
-	0	I
1	0	I
(	0	O
TIMP	0	B
-	0	I
1	0	I
)	0	O
transcription	0	O
.	0	O


cDNA	1	O
and	0	O
structural	0	O
organization	0	O
of	0	O
the	0	O
gene	0	B
Pole1	0	I
for	0	O
the	0	O
mouse	0	B
DNA	1	I
polymerase	0	I
epsilon	0	I
catalytic	0	I
subunit	0	I
.	0	O


Expression	1	O
of	0	O
this	0	O
protein	0	O
in	0	O
E	1	O
.	0	O
coli	0	O
demonstrated	0	O
that	0	O
tyrosine	0	O
was	0	O
incorporated	0	O
during	0	O
suppression	0	O
and	0	O
that	0	O
yeast	0	B
cytoplasmic	0	I
TyrRS	0	I
activity	0	O
was	0	O
produced	0	O
.	0	O


Mean	1	O
(+/-	0	O
SE	1	O
)	0	O
measurements	0	O
of	0	O
clearance	0	O
(	0	O
24	0	O
.	0	O
5	0	O
+/-	0	O
2	0	O
.	0	O
06	0	O
v	0	O
26	0	O
.	0	O
5	0	O
+/-	0	O
2	0	O
.	0	O
05	0	O
mL	1	O
/	0	O
min	0	O
/	0	O
m2	0	O
),	0	O
half	0	O
-	0	O
life	0	O
(	0	O
5	0	O
.	0	O
7	0	O
+/-	0	O
0	0	O
.	0	O
5	0	O
v	0	O
6	0	O
.	0	O
4	0	O
+/-	0	O
0	0	O
.	0	O
5	0	O
hours	0	O
),	0	O
and	0	O
volume	0	O
of	0	O
distribution	0	O
(	0	O
12	0	O
.	0	O
4	0	O
+/-	0	O
1	0	O
.	0	O
1	0	O
v	0	O
13	0	O
.	0	O
7	0	O
+/-	0	O
1	0	O
.	0	O
6	0	O
L	1	O
/	0	O
m2	0	O
)	0	O
were	0	O
not	0	O
significantly	0	O
different	0	O
in	0	O
patients	0	O
with	0	O
jaundice	0	O
when	0	O
compared	0	O
with	0	O
controls	0	O
.	0	O


However	0	O
,	0	O
kidneys	0	O
perfused	0	O
for	0	O
72	0	O
hr	0	O
demonstrated	0	O
more	0	O
similar	0	O
renal	0	O
functions	0	O
when	0	O
tested	0	O
by	0	O
either	0	O
IMPK	0	O
or	0	O
IBPK	0	O
.	0	O


A	1	O
randomized	0	O
,	0	O
multicenter	0	O
study	0	O
comparing	0	O
the	0	O
efficacy	0	O
and	0	O
tolerability	0	O
of	0	O
tropisetron	0	O
,	0	O
a	0	O
new	0	O
5	0	B
-	0	I
HT3	0	I
receptor	0	I
antagonist	0	O
,	0	O
with	0	O
a	0	O
metoclopramide	0	O
-	0	O
containing	0	O
antiemetic	0	O
cocktail	0	O
in	0	O
the	0	O
prevention	0	O
of	0	O
cisplatin	0	O
-	0	O
induced	0	O
emesis	0	O
.	0	O


The	0	O
assessment	0	O
using	0	O
7	0	O
H	1	O
9	0	O
liquid	0	O
medium	0	O
by	0	O
the	0	O
former	0	O
author	0	O
demonstrated	0	O
the	0	O
potent	0	O
activities	0	O
of	0	O
both	0	O
CS	1	O
-	0	O
940	0	O
*	0	O
and	0	O
sparfloxacin	0	O
(	0	O
SPFX	0	O
),	0	O
followed	0	O
by	0	O
AM	1	O
-	0	O
1155	0	O
*,	0	O
ciprofloxacin	0	O
(	0	O
CPFX	0	O
),	0	O
levofloxacin	0	O
(	0	O
LVFX	0	O
),	0	O
OPC	1	O
-	0	O
17116	0	O
*,	0	O
NM	1	O
-	0	O
394	0	O
*	0	O
in	0	O
sequence	0	O
.	0	O


We	0	O
estimate	0	O
that	0	O
the	0	O
protease	0	O
activity	0	O
is	0	O
at	0	O
least	0	O
35	0	O
-	0	O
fold	0	O
greater	0	O
in	0	O
mature	0	O
B	1	O
cells	0	O
than	0	O
in	0	O
pre	0	O
-	0	O
B	1	O
cells	0	O
.	0	O


In	1	O
this	0	O
report	0	O
we	0	O
describe	0	O
for	0	O
the	0	O
first	0	O
time	0	O
the	0	O
complete	0	O
primary	0	O
structure	0	O
of	0	O
type	0	B
X	1	I
collagen	0	I
,	0	O
based	0	O
on	0	O
cloning	0	O
and	0	O
sequencing	0	O
of	0	O
cDNA	1	O
and	0	O
genomic	0	O
DNA	1	O
.	0	O


Incorporation	1	O
of	0	O
0	0	O
.	0	O
1	0	O
or	0	O
0	0	O
.	0	O
2	0	O
M	1	O
sodium	0	O
dihydrogen	0	O
phosphate	0	O
in	0	O
the	0	O
sugar	0	O
solutions	0	O
resulted	0	O
in	0	O
a	0	O
decrease	0	O
in	0	O
the	0	O
shelf	0	O
-	0	O
life	0	O
of	0	O
diltiazem	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
DNA	1	O
ploidy	0	O
is	0	O
a	0	O
major	0	O
objective	0	O
prognostic	0	O
factor	0	O
and	0	O
therapeutic	0	O
determinant	0	O
for	0	O
endometrial	0	O
carcinoma	0	O
.	0	O


Tumor	1	O
stages	0	O
were	0	O
IIB	0	O
(	0	O
T3	1	O
N0	0	O
)	0	O
in	0	O
52	0	O
%,	0	O
IIIA	0	O
in	0	O
15	0	O
%,	0	O
and	0	O
IIIB	0	O
in	0	O
27	0	O
%	0	O
of	0	O
patients	0	O
.	0	O


A	1	O
phylogenetic	0	O
analysis	0	O
of	0	O
the	0	O
reverse	0	B
transcriptase	0	I
domain	0	I
confirms	0	O
our	0	O
differential	0	O
genetic	0	O
assessment	0	O
that	0	O
Cyclops	1	B
from	0	O
pea	0	O
is	0	O
a	0	O
novel	0	O
element	0	O
with	0	O
no	0	O
specific	0	O
relationship	0	O
to	0	O
the	0	O
previously	0	O
described	0	O
Gypsy	0	B
-	0	I
like	0	I
elements	0	I
from	0	O
plants	0	O
.	0	O


Feline	1	O
leukemia	0	O
viruses	0	O
(	0	O
FeLVs	0	O
),	0	O
which	0	O
are	0	O
replication	0	O
-	0	O
competent	0	O
oncoretroviruses	0	O
of	0	O
the	0	O
domestic	0	O
cat	0	O
species	0	O
,	0	O
are	0	O
contagiously	0	O
transmitted	0	O
in	0	O
natural	0	O
environments	0	O
.	0	O


The	0	O
gene	0	O
was	0	O
uniquely	0	O
mapped	0	O
with	0	O
odds	0	O
>	0	O
1	0	O
,	0	O
000	0	O
:	0	O
1	0	O
on	0	O
chromosome	0	O
3p	0	O
in	0	O
Centre	1	O
d	0	O
'	0	O
Etude	0	O
du	0	O
Polymorphisme	0	O
Humain	0	O
pedigrees	0	O
.	0	O


The	0	O
ewes	0	O
were	0	O
returned	0	O
to	0	O
normoxia	0	O
,	0	O
and	0	O
monitoring	0	O
was	0	O
continued	0	O
for	0	O
1	0	O
h	0	O
.	0	O


Increased	0	O
p53	0	B
activity	0	O
induced	0	O
by	0	O
OP	1	O
is	0	O
not	0	O
due	0	O
to	0	O
elevated	0	O
p53	0	B
mRNA	1	I
nor	0	O
to	0	O
protein	0	O
levels	0	O
.	0	O


The	0	O
intracellular	0	O
basic	0	B
region	0	I
/	0	I
helix	0	I
-	0	I
loop	0	I
-	0	I
helix	0	I
(	0	I
bHLH	0	I
)	0	I
dioxin	0	I
receptor	0	I
mediates	0	O
signal	0	O
transduction	0	O
by	0	O
dioxin	0	O
(	0	O
2	0	O
,	0	O
3	0	O
,	0	O
7	0	O
,	0	O
8	0	O
-	0	O
tetrachlorodibenzo	0	O
-	0	O
p	0	O
-	0	O
dioxin	0	O
)	0	O
and	0	O
functions	0	O
as	0	O
a	0	O
ligand	0	O
-	0	O
activated	0	O
DNA	1	O
binding	0	O
protein	0	O
directly	0	O
interacting	0	O
with	0	O
target	0	O
genes	0	O
by	0	O
binding	0	O
to	0	O
dioxin	0	O
response	0	O
elements	0	O
.	0	O


Our	0	O
data	0	O
show	0	O
that	0	O
multiple	0	O
MLSN1	0	B
transcripts	0	I
,	0	O
both	0	O
constitutively	0	O
expressed	0	O
and	0	O
inducible	0	O
,	0	O
are	0	O
present	0	O
in	0	O
cultured	0	O
pigmented	0	O
melanoma	0	O
cells	0	O
,	0	O
and	0	O
suggest	0	O
that	0	O
MLSN1	0	B
expression	0	O
can	0	O
be	0	O
regulated	0	O
at	0	O
the	0	O
level	0	O
of	0	O
both	0	O
transcription	0	O
and	0	O
mRNA	1	O
processing	0	O
.	0	O


We	0	O
could	0	O
demonstrate	0	O
the	0	O
involvement	0	O
of	0	O
cAMP	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	O
PKA	1	B
)	0	O
in	0	O
the	0	O
phosphorylation	0	O
of	0	O
CDC25Mm	0	B
in	0	O
fibroblasts	0	O
overexpressing	0	O
this	0	O
RasGEF	0	B
as	0	O
well	0	O
as	0	O
in	0	O
mouse	0	O
brain	0	O
synaptosomal	0	O
membranes	0	O
.	0	O


Thus	0	O
,	0	O
these	0	O
studies	0	O
on	0	O
rat	0	B
Std	1	I
promoter	0	I
function	0	O
indicate	0	O
that	0	O
(	0	O
i	0	O
)	0	O
HNF1	0	B
and	0	O
C	1	B
/	0	I
EBP	1	I
are	0	O
responsible	0	O
for	0	O
liver	0	O
specificity	0	O
of	0	O
the	0	O
rat	0	B
Std	1	I
gene	0	I
;	0	O
(	0	O
ii	0	O
)	0	O
androgenic	0	O
repression	0	O
of	0	O
the	0	O
gene	0	O
requires	0	O
the	0	O
presence	0	O
of	0	O
all	0	O
of	0	O
the	0	O
OCT	1	B
-	0	I
1	0	I
and	0	O
C	1	B
/	0	I
EBP	1	I
elements	0	I
between	0	O
positions	0	O
-	0	O
231	0	O
and	0	O
-	0	O
292	0	O
;	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
AR	1	B
may	0	O
exert	0	O
its	0	O
negative	0	O
regulatory	0	O
effect	0	O
indirectly	0	O
through	0	O
transcriptional	0	O
interference	0	O
of	0	O
OCT	1	B
-	0	I
1	0	I
and	0	O
C	1	B
/	0	I
EBP	1	I
rather	0	O
than	0	O
through	0	O
a	0	O
direct	0	O
DNA	1	B
-	0	I
AR	1	I
interaction	0	O
.	0	O


In	1	O
group	0	O
III	0	O
,	0	O
patients	0	O
also	0	O
received	0	O
their	0	O
own	0	O
mediastinal	0	O
drainage	0	O
blood	0	O
,	0	O
shed	0	O
for	0	O
6	0	O
hours	0	O
after	0	O
operation	0	O
,	0	O
after	0	O
concentration	0	O
and	0	O
washing	0	O
in	0	O
a	0	O
MBRS	0	O
.	0	O


Despite	0	O
i	0	O
.	0	O
v	0	O
.	0	O
steroid	0	O
therapy	0	O
,	0	O
[	0	O
NOexh	0	O
]	0	O
remained	0	O
elevated	0	O
throughout	0	O
recovery	0	O
(	0	O
37	0	O
.	0	O
9	0	O
+/-	0	O
4	0	O
.	0	O
8	0	O
ppb	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
until	0	O
discharge	0	O
(	0	O
40	0	O
.	0	O
9	0	O
+/-	0	O
4	0	O
.	0	O
3	0	O
ppb	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
).	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
haloperidol	0	O
selectively	0	O
reduced	0	O
the	0	O
animal	0	O
'	0	O
s	0	O
capacity	0	O
to	0	O
'	0	O
programme	0	O
non	0	O
-	0	O
stimulus	0	O
directed	0	O
motor	0	O
behaviour	0	O
'.	0	O


Deletion	1	O
of	0	O
a	0	O
53	0	O
-	0	O
bp	0	O
early	0	O
promoter	0	O
region	0	O
containing	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
and	0	O
a	0	O
putative	0	O
TATA	0	O
box	0	O
completely	0	O
abolishes	0	O
the	0	O
ability	0	O
of	0	O
upstream	0	O
elements	0	O
to	0	O
drive	0	O
transcription	0	O
of	0	O
the	0	O
luciferase	0	B
cDNA	1	I
.	0	O


The	0	O
effect	0	O
of	0	O
L	1	O
-	0	O
methionine	0	O
supplementation	0	O
on	0	O
the	0	O
utilization	0	O
of	0	O
a	0	O
soy	0	O
protein	0	O
isolate	0	O
(	0	O
SPI	0	O
)	0	O
was	0	O
evaluated	0	O
by	0	O
short	0	O
-	0	O
term	0	O
nitrogen	0	O
balance	0	O
studies	0	O
in	0	O
young	0	O
women	0	O
.	0	O


Weak	1	O
allergenicity	0	O
of	0	O
recombinant	0	B
hirudin	0	I
CGP	0	I
39393	0	I
(	0	O
REVASC	0	O
)	0	O
in	0	O
immunocompetent	0	O
volunteers	0	O
.	0	O


Pitfalls	0	O
in	0	O
the	0	O
use	0	O
of	0	O
chromosome	0	O
aberration	0	O
analysis	0	O
for	0	O
biological	0	O
radiation	0	O
dosimetry	0	O
.	0	O


P	1	B
-	0	I
CIP1	0	I
,	0	O
a	0	O
novel	0	O
protein	0	O
that	0	O
interacts	0	O
with	0	O
the	0	O
cytosolic	0	O
domain	0	O
of	0	O
peptidylglycine	0	B
alpha	0	I
-	0	I
amidating	0	I
monooxygenase	0	I
,	0	O
is	0	O
associated	0	O
with	0	O
endosomes	0	O
.	0	O


Among	0	O
six	0	O
different	0	O
library	0	O
isolates	0	O
containing	0	O
6	0	B
.	0	I
5	0	I
-	0	I
to	0	I
7	0	I
-	0	I
kb	0	I
IAP	1	I
units	0	I
,	0	O
some	0	O
restriction	0	O
sites	0	O
were	0	O
highly	0	O
conserved	0	O
whereas	0	O
others	0	O
varied	0	O
in	0	O
both	0	O
occurrence	0	O
and	0	O
position	0	O
.	0	O


Rss1p	0	B
encodes	0	O
a	0	O
novel	0	O
essential	0	O
protein	0	O
of	0	O
538	0	O
amino	0	O
acids	0	O
,	0	O
which	0	O
contains	0	O
an	0	O
extended	0	O
predicted	0	O
coiled	0	O
-	0	O
coil	0	O
domain	0	O
and	0	O
is	0	O
located	0	O
both	0	O
at	0	O
nuclear	0	O
pore	0	O
complexes	0	O
(	0	O
NPCs	0	O
)	0	O
and	0	O
in	0	O
the	0	O
cytoplasm	0	O
.	0	O


The	0	O
experiment	0	O
results	0	O
showed	0	O
:	0	O
(	0	O
i	0	O
)	0	O
not	0	O
only	0	O
1O2	0	O
,	0	O
but	0	O
also	0	O
free	0	O
radicals	0	O
(	0	O
O2	1	O
-.	0	O
.	0	O
OH	0	O
and	0	O
YHPD	0	O
-.)	0	O
can	0	O
be	0	O
formed	0	O
by	0	O
the	0	O
aid	0	O
of	0	O
YHPD	0	O
;	0	O
and	0	O
(	0	O
ii	0	O
)	0	O
as	0	O
to	0	O
the	0	O
ability	0	O
of	0	O
producing	0	O
1O2	0	O
,	0	O
YHPD	0	O
less	0	O
than	0	O
BHPD	0	O
,	0	O
while	0	O
for	0	O
generating	0	O
O2	1	O
-.	0	O
and	0	O
.	0	O
OH	0	O
,	0	O
YHPD	0	O
greater	0	O
than	0	O
BHPD	0	O
.	0	O


Intra	0	O
-	0	O
articular	0	O
dislocation	0	O
of	0	O
the	0	O
patella	0	O
.	0	O


Clinical	1	O
use	0	O
of	0	O
absorbable	0	O
polyglycolic	0	O
acid	0	O
suture	0	O
in	0	O
Blalock	0	O
-	0	O
Taussig	0	O
'	0	O
s	0	O
operation	0	O


The	0	O
authors	0	O
report	0	O
the	0	O
clinicopathologic	0	O
findings	0	O
in	0	O
four	0	O
cases	0	O
of	0	O
adult	0	O
women	0	O
with	0	O
rhabdomyosarcomas	0	O
that	0	O
originated	0	O
in	0	O
the	0	O
endometrium	0	O
or	0	O
cervix	0	O
,	0	O
or	0	O
both	0	O
.	0	O


Sequence	1	O
divergence	0	O
is	0	O
observed	0	O
in	0	O
untranslated	0	O
regions	0	O
which	0	O
allows	0	O
the	0	O
definition	0	O
of	0	O
gene	0	O
-	0	O
specific	0	O
probes	0	O
.	0	O


With	0	O
a	0	O
view	0	O
to	0	O
identifying	0	O
other	0	O
important	0	O
U14	0	B
interactions	0	O
,	0	O
a	0	O
stem	0	O
-	0	O
loop	0	O
domain	0	O
required	0	O
for	0	O
activity	0	O
of	0	O
Saccharomyces	1	B
cerevisiae	0	I
U14	0	I
RNAs	0	I
(	0	O
the	0	O
Y	1	O
domain	0	O
)	0	O
was	0	O
first	0	O
subjected	0	O
to	0	O
detailed	0	O
mutational	0	O
analysis	0	O
.	0	O


Here	0	O
we	0	O
show	0	O
that	0	O
IIIa	0	O
pre	0	O
-	0	O
mRNA	1	O
splicing	0	O
is	0	O
activated	0	O
more	0	O
than	0	O
200	0	O
-	0	O
fold	0	O
in	0	O
nuclear	0	O
extracts	0	O
prepared	0	O
from	0	O
late	0	O
adenovirus	0	O
-	0	O
infected	0	O
cells	0	O
(	0	O
Ad	1	O
-	0	O
NE	1	O
)	0	O
compared	0	O
to	0	O
uninfected	0	O
HeLa	0	O
cell	0	O
nuclear	0	O
extracts	0	O
(	0	O
HeLa	0	O
-	0	O
NE	1	O
).	0	O


DNA	1	O
-	0	O
protein	0	O
UV	1	O
cross	0	O
-	0	O
linking	0	O
studies	0	O
indicated	0	O
that	0	O
UHF	0	B
-	0	I
1	0	I
has	0	O
an	0	O
electrophoretic	0	O
mobility	0	O
on	0	O
sodium	0	O
dodecyl	0	O
sulfate	0	O
-	0	O
acrylamide	0	O
gels	0	O
of	0	O
approximately	0	O
85	0	O
kDa	1	O
and	0	O
suggested	0	O
that	0	O
additional	0	O
proteins	0	O
,	0	O
specific	0	O
to	0	O
each	0	O
promoter	0	O
,	0	O
bind	0	O
to	0	O
each	0	O
site	0	O
.	0	O


Improved	0	O
methods	0	O
have	0	O
been	0	O
developed	0	O
for	0	O
maintaining	0	O
and	0	O
breeding	0	O
the	0	O
neotropical	0	O
short	0	O
-	0	O
tailed	0	O
fruit	0	O
bat	0	O
,	0	O
Carollia	0	O
perspicillata	0	O
,	0	O
in	0	O
an	0	O
easily	0	O
-	0	O
reproduced	0	O
,	0	O
laboratory	0	O
setting	0	O
.	0	O


When	0	O
nifA	0	B
mRNA	1	I
5	0	O
'	0	O
start	0	O
points	0	O
were	0	O
mapped	0	O
by	0	O
primer	0	O
extension	0	O
,	0	O
both	0	O
a	0	O
minor	0	O
upstream	0	O
transcript	0	O
(	0	O
s	0	O
)	0	O
starting	0	O
45	0	O
bp	0	O
distal	0	O
to	0	O
the	0	O
anaerobox	0	O
and	0	O
a	0	O
major	0	O
downstream	0	O
transcript	0	O
starting	0	O
10	0	O
bp	0	O
distal	0	O
to	0	O
the	0	O
sigma	0	B
54	0	I
box	0	O
were	0	O
observed	0	O
.	0	O


G	1	B
-	0	I
CSF	1	I
(	0	O
480	0	O
micrograms	0	O
subcutaneously	0	O
(	0	O
s	0	O
.	0	O
c	0	O
.))	0	O
were	0	O
used	0	O
in	0	O
55	0	O
and	0	O
GM	1	B
-	0	I
CSF	1	I
(	0	O
400	0	O
micrograms	0	O
s	0	O
.	0	O
c	0	O
.)	0	O
in	0	O
28	0	O
chemotherapeutic	0	O
cycles	0	O
.	0	O


The	0	O
oxygen	0	O
uptake	0	O
(	0	O
VO2	1	O
),	0	O
carbon	0	O
dioxide	0	O
output	0	O
(	0	O
VCO2	0	O
),	0	O
respiratory	0	O
rate	0	O
(	0	O
fR	1	O
),	0	O
minute	0	O
ventilation	0	O
(	0	O
VE	0	O
),	0	O
alveolar	0	O
ventilation	0	O
(	0	O
VA	1	O
),	0	O
alveolar	0	O
oxygen	0	O
pressure	0	O
(	0	O
PAO2	1	O
),	0	O
and	0	O
VE	0	O
/	0	O
VO2	1	O
ratio	0	O
were	0	O
higher	0	O
in	0	O
the	0	O
cows	0	O
,	0	O
while	0	O
the	0	O
tidal	0	O
volume	0	O
(	0	O
VT	1	O
)	0	O
and	0	O
physiological	0	O
dead	0	O
space	0	O
(	0	O
VD	1	O
)	0	O
were	0	O
larger	0	O
in	0	O
the	0	O
horses	0	O
.	0	O


Increased	0	O
levels	0	O
of	0	O
anticardiolipin	0	B
immunoglobulin	0	I
G	1	I
may	0	O
also	0	O
cause	0	O
bleeding	0	O
.	0	O


Although	0	O
there	0	O
are	0	O
no	0	O
octamer	0	O
elements	0	O
in	0	O
the	0	O
adenovirus	0	O
genome	0	O
that	0	O
are	0	O
known	0	O
to	0	O
be	0	O
important	0	O
for	0	O
transcription	0	O
,	0	O
there	0	O
are	0	O
octamer	0	O
elements	0	O
in	0	O
the	0	O
viral	0	O
terminal	0	O
repeat	0	O
sequences	0	O
.	0	O


Myocardial	0	O
perfusion	0	O
was	0	O
evaluated	0	O
using	0	O
the	0	O
enhanced	0	O
gray	0	O
level	0	O
after	0	O
contrast	0	O
injection	0	O
,	0	O
and	0	O
the	0	O
level	0	O
was	0	O
compared	0	O
with	0	O
the	0	O
morphology	0	O
and	0	O
degree	0	O
of	0	O
collateral	0	O
development	0	O
.	0	O


French	1	O
,	0	O
M	1	O
.	0	O


The	0	O
results	0	O
were	0	O
as	0	O
follows	0	O
:	0	O
1	0	O
)	0	O
Total	0	O
integrated	0	O
EMG	1	O
activity	0	O
of	0	O
FB	0	O
group	0	O
was	0	O
approximately	0	O
equal	0	O
in	0	O
any	0	O
occluded	0	O
position	0	O
,	0	O
whereas	0	O
that	0	O
of	0	O
CG	1	O
and	0	O
GF	0	O
group	0	O
varied	0	O
from	0	O
position	0	O
to	0	O
position	0	O
.	0	O


The	0	O
transcription	0	O
of	0	O
most	0	O
RP	1	B
genes	0	I
is	0	O
activated	0	O
by	0	O
two	0	O
Rap1p	0	B
binding	0	I
sites	0	I
,	0	O
250	0	O
to	0	O
400	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
initiation	0	O
of	0	O
transcription	0	O
.	0	O


The	0	O
emerging	0	O
complexity	0	O
of	0	O
the	0	O
5	0	O
'	0	O
regulatory	0	O
region	0	O
of	0	O
the	0	O
GH	1	B
receptor	0	I
gene	0	I
was	0	O
emphasised	0	O
by	0	O
the	0	O
observation	0	O
that	0	O
probes	0	O
derived	0	O
from	0	O
exon	0	O
1B	0	O
and	0	O
the	0	O
distal	0	O
3	0	O
'	0	O
intron	0	O
boundary	0	O
do	0	O
not	0	O
hybridise	0	O
with	0	O
previously	0	O
cloned	0	O
genomic	0	O
sequences	0	O
that	0	O
span	0	O
the	0	O
liver	0	O
-	0	O
specific	0	O
P1	1	O
promoter	0	O
and	0	O
exon	0	O
2	0	O
.	0	O


The	0	O
prevalence	0	O
of	0	O
CPAF	0	O
was	0	O
similar	0	O
in	0	O
type	0	O
1	0	O
and	0	O
type	0	O
2	0	O
diabetes	0	O
,	0	O
was	0	O
greater	0	O
in	0	O
women	0	O
than	0	O
in	0	O
men	0	O
,	0	O
and	0	O
was	0	O
significantly	0	O
greater	0	O
after	0	O
repeated	0	O
administrations	0	O
than	0	O
after	0	O
one	0	O
single	0	O
administration	0	O
of	0	O
chlorpropamide	0	O
.	0	O


This	0	O
TC	1	B
-	0	I
II	0	I
enhanson	0	I
,	0	O
which	0	O
is	0	O
identical	0	O
to	0	O
the	0	O
kappa	0	B
B	1	I
motif	0	I
from	0	O
the	0	O
kappa	0	B
chain	0	I
enhancer	0	I
,	0	O
was	0	O
active	0	O
in	0	O
both	0	O
lymphoid	0	O
and	0	O
non	0	O
-	0	O
lymphoid	0	O
cells	0	O
,	0	O
which	0	O
contrasts	0	O
with	0	O
the	0	O
previously	0	O
reported	0	O
lymphoid	0	O
cell	0	O
specificity	0	O
of	0	O
the	0	O
kappa	0	B
B	1	I
motif	0	I
.	0	O


Recovery	1	O
was	0	O
characterized	0	O
by	0	O
rapid	0	O
improvement	0	O
such	0	O
that	0	O
all	0	O
measured	0	O
parameters	0	O
normalized	0	O
by	0	O
1	0	O
week	0	O
,	0	O
except	0	O
for	0	O
cross	0	O
-	0	O
sectional	0	O
cardiac	0	O
area	0	O
which	0	O
remained	0	O
dilated	0	O
up	0	O
to	0	O
4	0	O
weeks	0	O
(	0	O
14	0	O
+/-	0	O
3	0	O
cm2	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
versus	0	O
control	0	O
).(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Respiratory	1	O
chain	0	O
enzyme	0	O
activity	0	O
was	0	O
normal	0	O
.	0	O


Implication	0	O
of	0	O
PAF	1	B
and	0	O
acetylhydrolase	0	B
(	0	O
PAF	1	B
-	0	I
AH	1	I
)	0	O
activity	0	O
in	0	O
periodontal	0	O
disease	0	O
.	0	O


Nutritional	1	O
cataracts	0	O
in	0	O
timber	0	O
wolves	0	O
.	0	O


Folded	0	O
tissue	0	O
and	0	O
crimped	0	O
collagen	0	B
fibers	0	O
in	0	O
the	0	O
tunica	0	O
albuginea	0	O
permit	0	O
its	0	O
expansion	0	O
during	0	O
erection	0	O
.	0	O


Only	0	O
two	0	O
of	0	O
27	0	O
participants	0	O
(	0	O
7	0	O
.	0	O
4	0	O
%)	0	O
with	0	O
definite	0	O
POAG	0	O
had	0	O
been	0	O
previously	0	O
diagnosed	0	O
and	0	O
treated	0	O
,	0	O
and	0	O
66	0	O
.	0	O
7	0	O
%	0	O
of	0	O
the	0	O
previously	0	O
undiagnosed	0	O
had	0	O
IOP	1	O
less	0	O
than	0	O
22	0	O
mmHg	0	O
.	0	O


The	0	O
protein	0	O
expressed	0	O
by	0	O
F2771	0	B
cDNA	1	I
in	0	O
transfected	0	O
COS	1	O
cells	0	O
is	0	O
localized	0	O
in	0	O
the	0	O
cytoplasm	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
have	0	O
cloned	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
human	0	B
nidogen	0	I
gene	0	I
.	0	O


Whereas	0	O
creatine	0	B
kinase	0	I
activity	0	O
declined	0	O
exponentially	0	O
from	0	O
a	0	O
single	0	O
peak	0	O
,	0	O
myoglobin	0	B
appeared	0	O
in	0	O
multiple	0	O
episodes	0	O
inadequately	0	O
represented	0	O
by	0	O
a	0	O
single	0	O
peak	0	O
value	0	O
and	0	O
having	0	O
no	0	O
clear	0	O
clinical	0	O
correlation	0	O
.	0	O


Overexpression	1	O
of	0	O
either	0	O
DAP	0	B
-	0	I
1	0	I
or	0	O
sentrin	0	B
causes	0	O
apoptosis	0	O
of	0	O
TNF	1	B
-	0	O
sensitive	0	O
L929	0	O
fibroblast	0	O
cell	0	O
line	0	O
,	0	O
as	0	O
well	0	O
as	0	O
TNF	1	B
-	0	O
resistant	0	O
osteosarcoma	0	O
cell	0	O
line	0	O
,	0	O
U2OS	0	O
.	0	O


Functional	1	O
tests	0	O
using	0	O
a	0	O
reporter	0	O
gene	0	O
,	0	O
containing	0	O
Stat5	0	B
-	0	I
binding	0	I
elements	0	I
,	0	O
confirmed	0	O
that	0	O
while	0	O
the	0	O
variant	0	O
form	0	O
was	0	O
inactive	0	O
by	0	O
itself	0	O
,	0	O
it	0	O
could	0	O
inhibit	0	O
the	0	O
function	0	O
of	0	O
the	0	O
full	0	O
-	0	O
length	0	O
receptor	0	O
.	0	O


The	0	O
mechanism	0	O
by	0	O
which	0	O
large	0	O
molecules	0	O
,	0	O
such	0	O
as	0	O
the	0	O
diphosphonate	0	O
99mTc	0	O
-	0	O
labeled	0	O
EHDP	1	O
or	0	O
99mTc	0	O
-	0	O
labeled	0	O
pyrophosphate	0	O
,	0	O
pass	0	O
through	0	O
capillaries	0	O
in	0	O
bone	0	O
is	0	O
by	0	O
passive	0	O
diffusion	0	O
.	0	O


To	1	O
identify	0	O
additional	0	O
non	0	O
-	0	O
Sir	0	B
factors	0	I
that	0	O
affect	0	O
rDNA	0	O
silencing	0	O
,	0	O
we	0	O
performed	0	O
a	0	O
genetic	0	O
screen	0	O
designed	0	O
to	0	O
isolate	0	O
mutations	0	O
which	0	O
alter	0	O
the	0	O
expression	0	O
of	0	O
reporter	0	O
genes	0	O
integrated	0	O
within	0	O
the	0	O
rDNA	0	O
.	0	O


It	1	O
may	0	O
be	0	O
dependent	0	O
on	0	O
location	0	O
of	0	O
a	0	O
focus	0	O
(	0	O
according	0	O
to	0	O
EEG	1	O
)	0	O
as	0	O
well	0	O
as	0	O
on	0	O
the	0	O
character	0	O
and	0	O
manifestation	0	O
of	0	O
the	0	O
accompanying	0	O
neuropsychologic	0	O
symptomatology	0	O
.	0	O


Protein	1	B
phosphatase	0	I
2A	0	I
is	0	O
a	0	O
critical	0	O
regulator	0	O
of	0	O
protein	0	B
kinase	0	I
C	1	I
zeta	0	I
signaling	0	O
targeted	0	O
by	0	O
SV40	1	B
small	0	I
t	0	I
to	0	O
promote	0	O
cell	0	O
growth	0	O
and	0	O
NF	1	B
-	0	I
kappaB	0	I
activation	0	O
.	0	O


Interferon	1	B
beta	0	I
therapy	0	O
was	0	O
discontinued	0	O
for	0	O
4	0	O
weeks	0	O
.	0	O


It	1	O
was	0	O
concluded	0	O
,	0	O
that	0	O
on	0	O
a	0	O
given	0	O
section	0	O
,	0	O
75	0	O
,	0	O
7	0	O
per	0	O
cent	0	O
of	0	O
the	0	O
trabeculae	0	O
were	0	O
in	0	O
contact	0	O
with	0	O
vascular	0	O
cavities	0	O
.	0	O


Reverse	0	B
transcriptase	0	I
and	0	O
protease	0	O
activities	0	O
of	0	O
avian	0	O
leukosis	0	O
virus	0	O
Gag	1	B
-	0	O
Pol	0	B
fusion	0	O
proteins	0	O
expressed	0	O
in	0	O
insect	0	O
cells	0	O
.	0	O


Clone	1	O
pSRc200	0	O
hybrid	0	O
selected	0	O
an	0	O
mRNA	1	O
that	0	O
on	0	O
cell	0	O
-	0	O
free	0	O
translation	0	O
produced	0	O
a	0	O
38	0	O
-	0	O
kDa	1	O
polypeptide	0	O
.	0	O


This	0	O
distinction	0	O
was	0	O
based	0	O
upon	0	O
whether	0	O
the	0	O
diagnosis	0	O
provided	0	O
a	0	O
straightforward	0	O
range	0	O
of	0	O
prognoses	0	O
or	0	O
an	0	O
ambiguous	0	O
clinical	0	O
implication	0	O
.	0	O


It	1	O
has	0	O
been	0	O
calculated	0	O
that	0	O
600	0	O
,	0	O
000	0	O
new	0	O
cases	0	O
of	0	O
lung	0	O
cancer	0	O
occur	0	O
worldwide	0	O
every	0	O
year	0	O
,	0	O
most	0	O
of	0	O
them	0	O
due	0	O
to	0	O
smoking	0	O
.	0	O


Effect	1	O
of	0	O
heparin	0	O
on	0	O
the	0	O
inactivation	0	O
of	0	O
serum	0	B
lipoprotein	0	I
lipase	0	I
by	0	O
the	0	O
liver	0	O
in	0	O
unanesthetized	0	O
dogs	0	O
.	0	O


The	0	O
incompatibility	0	O
group	0	O
W	1	O
plasmid	0	O
pSa	1	O
suppresses	0	O
Agrobacterium	1	O
tumefaciens	0	O
oncogenicity	0	O
(	0	O
J	1	O
.	0	O


Menstrual	1	O
-	0	O
cycle	0	O
phase	0	O
did	0	O
not	0	O
significantly	0	O
affect	0	O
personality	0	O
variables	0	O
in	0	O
either	0	O
group	0	O
.	0	O


A	1	O
poor	0	O
correlation	0	O
was	0	O
also	0	O
observed	0	O
between	0	O
PbB	1	O
and	0	O
ALAD	0	B
activity	0	O
of	0	O
the	0	O
stearate	0	O
workers	0	O
.	0	O


Estimation	0	O
of	0	O
renin	0	B
secretion	0	O
rate	0	O
and	0	O
renal	0	O
plasma	0	O
flow	0	O
from	0	O
peripheral	0	O
and	0	O
renal	0	B
vein	0	I
renin	0	I
levels	0	O
.	0	O


NuA4	0	B
has	0	O
an	0	O
apparent	0	O
molecular	0	O
mass	0	O
of	0	O
1	0	O
.	0	O
3	0	O
MDa	1	O
.	0	O


The	0	O
correct	0	O
termination	0	O
of	0	O
retroviral	0	O
transcripts	0	O
at	0	O
the	0	O
3	0	O
'	0	O
LTR	1	O
R	1	O
/	0	O
U5	0	O
junction	0	O
is	0	O
primarily	0	O
dependent	0	O
on	0	O
the	0	O
canonical	0	O
AAUAAA	0	O
polyadenylation	0	O
signal	0	O
,	0	O
so	0	O
we	0	O
have	0	O
analyzed	0	O
the	0	O
effect	0	O
of	0	O
mutating	0	O
the	0	O
polyadenylation	0	O
signal	0	O
sequences	0	O
on	0	O
the	0	O
properties	0	O
of	0	O
a	0	O
selectable	0	O
murine	0	O
retroviral	0	O
vector	0	O
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
we	0	O
demonstrated	0	O
a	0	O
unique	0	O
mechanism	0	O
of	0	O
action	0	O
of	0	O
8	0	O
-	0	O
Cl	1	O
-	0	O
cAMP	1	O
in	0	O
the	0	O
regulation	0	O
of	0	O
these	0	O
kinase	0	O
isozymes	0	O
in	0	O
HL	1	O
-	0	O
60	0	O
human	0	O
promyelocytic	0	O
leukemia	0	O
cells	0	O
.	0	O


According	0	O
to	0	O
pilot	0	O
experiments	0	O
which	0	O
considered	0	O
various	0	O
durations	0	O
of	0	O
global	0	O
no	0	O
-	0	O
flow	0	O
ischemia	0	O
ranging	0	O
from	0	O
10	0	O
to	0	O
20	0	O
minutes	0	O
,	0	O
two	0	O
durations	0	O
were	0	O
chosen	0	O
for	0	O
the	0	O
present	0	O
study	0	O
:	0	O
20	0	O
minutes	0	O
(	0	O
group	0	O
20	0	O
)	0	O
in	0	O
which	0	O
ventricular	0	O
fibrillation	0	O
(	0	O
VF	1	O
)	0	O
was	0	O
the	0	O
predominant	0	O
form	0	O
of	0	O
arrhythmias	0	O
,	0	O
and	0	O
18	0	O
minutes	0	O
(	0	O
group	0	O
18	0	O
)	0	O
in	0	O
which	0	O
the	0	O
prevalence	0	O
of	0	O
VF	1	O
was	0	O
markedly	0	O
lower	0	O
despite	0	O
the	0	O
small	0	O
difference	0	O
in	0	O
the	0	O
duration	0	O
of	0	O
ischemia	0	O
.	0	O


Our	0	O
study	0	O
cohorts	0	O
consisted	0	O
of	0	O
15	0	O
patients	0	O
who	0	O
received	0	O
SC	1	O
rIL	0	B
-	0	I
2	0	I
at	0	O
doses	0	O
of	0	O
4	0	O
.	0	O
8	0	O
-	0	O
14	0	O
.	0	O
4	0	O
million	0	O
IU	1	O
/	0	O
m2	0	O
/	0	O
day	0	O
on	0	O
5	0	O
days	0	O
per	0	O
week	0	O
for	0	O
a	0	O
total	0	O
of	0	O
8	0	O
weeks	0	O
,	0	O
20	0	O
patients	0	O
who	0	O
received	0	O
rIFN	0	B
-	0	I
alpha	0	I
2b	0	I
at	0	O
3	0	O
.	0	O
0	0	O
-	0	O
6	0	O
.	0	O
0	0	O
million	0	O
U	1	O
/	0	O
m2	0	O
/	0	O
day	0	O
thrice	0	O
weekly	0	O
for	0	O
a	0	O
total	0	O
of	0	O
6	0	O
weeks	0	O
,	0	O
and	0	O
72	0	O
patients	0	O
who	0	O
were	0	O
given	0	O
SC	1	O
rIFN	0	B
-	0	I
alpha	0	I
2b	0	I
at	0	O
6	0	O
.	0	O
0	0	O
million	0	O
U	1	O
/	0	O
m2	0	O
/	0	O
day	0	O
thrice	0	O
weekly	0	O
plus	0	O
SC	1	O
rIL	0	B
-	0	I
2	0	I
at	0	O
14	0	O
.	0	O
4	0	O
-	0	O
18	0	O
.	0	O
0	0	O
million	0	O
IU	1	O
/	0	O
m2	0	O
/	0	O
day	0	O
on	0	O
days	0	O
1	0	O
and	0	O
2	0	O
,	0	O
followed	0	O
by	0	O
4	0	O
.	0	O
8	0	O
million	0	O
IU	1	O
/	0	O
m2	0	O
/	0	O
day	0	O
,	0	O
5	0	O
days	0	O
per	0	O
week	0	O
for	0	O
6	0	O
consecutive	0	O
weeks	0	O
.	0	O


In	1	O
serum	0	O
-	0	O
free	0	O
media	0	O
,	0	O
p50E4F	0	B
accelerated	0	O
E1A	0	B
-	0	O
induced	0	O
apoptosis	0	O
.	0	O


Absorption	1	O
of	0	O
electrolytes	0	O
from	0	O
the	0	O
colon	0	O
in	0	O
cases	0	O
of	0	O
ulcerative	0	O
colitis	0	O
and	0	O
in	0	O
control	0	O
subjects	0	O
.	0	O


This	0	O
coat	0	B
protein	0	I
consists	0	O
of	0	O
Sar1p	0	B
,	0	O
the	0	O
Sec23p	0	B
protein	0	I
complex	0	I
containing	0	O
Sec23p	0	B
and	0	O
Sec24p	0	B
,	0	O
and	0	O
the	0	O
Sec13p	0	B
protein	0	I
complex	0	I
containing	0	O
Sec13p	0	B
and	0	O
a	0	O
novel	0	O
150	0	B
-	0	I
kDa	1	I
protein	0	I
,	0	I
p150	0	I
.	0	O


This	0	O
report	0	O
describes	0	O
the	0	O
identification	0	O
of	0	O
a	0	O
gene	0	O
of	0	O
related	0	O
function	0	O
,	0	O
SMD1	0	B
,	0	O
located	0	O
immediately	0	O
3	0	O
'	0	O
to	0	O
PRP38	0	B
.	0	O


These	0	O
data	0	O
provide	0	O
strong	0	O
evidence	0	O
that	0	O
E2F	0	B
or	0	O
an	0	O
E2F	0	B
-	0	I
related	0	I
transcription	0	I
factor	0	I
is	0	O
involved	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
nonmuscle	0	B
myosin	0	I
expression	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
predicted	0	O
CD30v	0	B
protein	0	I
retains	0	O
most	0	O
of	0	O
the	0	O
cytoplasmic	0	O
region	0	O
,	0	O
but	0	O
lacks	0	O
the	0	O
extracellular	0	O
and	0	O
transmembrane	0	O
domains	0	O
.	0	O


Full	0	B
-	0	I
length	0	I
AT	1	I
-	0	I
PHH1	0	I
,	0	O
and	0	O
both	0	O
AT	1	B
-	0	I
PHH1	0	I
and	0	O
AT	1	B
-	0	I
PHH1	0	I
delta	0	I
C	1	I
-	0	I
513	0	I
(	0	O
truncated	0	O
to	0	O
be	0	O
approximately	0	O
the	0	O
size	0	O
of	0	O
microbial	0	B
photolyase	0	I
genes	0	I
)	0	O
cDNAs	0	O
,	0	O
were	0	O
overexpressed	0	O
,	0	O
respectively	0	O
,	0	O
in	0	O
yeast	0	O
and	0	O
Escherichia	1	O
coli	0	O
mutants	0	O
hypersensitive	0	O
to	0	O
ultraviolet	0	O
light	0	O
.	0	O


The	0	O
results	0	O
of	0	O
induced	0	O
coexpression	0	O
were	0	O
also	0	O
supported	0	O
by	0	O
rapid	0	O
generation	0	O
of	0	O
FeLV	0	O
recombinants	0	O
when	0	O
FeLV	0	O
-	0	O
C	1	O
was	0	O
used	0	O
to	0	O
infect	0	O
the	0	O
feline	0	O
3201B	0	O
cell	0	O
line	0	O
that	0	O
constitutively	0	O
expresses	0	O
high	0	O
levels	0	O
of	0	O
endogenous	0	O
FeLV	0	O
-	0	O
specific	0	O
mRNAs	0	O
.	0	O


The	0	O
method	0	O
is	0	O
accurate	0	O
,	0	O
with	0	O
good	0	O
precision	0	O
and	0	O
adequate	0	O
sensitivity	0	O
.	0	O


Incidences	0	O
of	0	O
nonfatal	0	O
stroke	0	O
,	0	O
myocardial	0	O
infarction	0	O
,	0	O
angina	0	O
pectoris	0	O
und	0	O
left	0	O
ventricular	0	O
hypertrophy	0	O
could	0	O
also	0	O
be	0	O
lowered	0	O
.	0	O


Antidepressant	1	O
-	0	O
like	0	O
properties	0	O
of	0	O
some	0	O
serotonin	0	B
receptor	0	I
ligands	0	O
and	0	O
calcium	0	O
channel	0	O
antagonists	0	O
measured	0	O
with	0	O
the	0	O
forced	0	O
swimming	0	O
test	0	O
in	0	O
mice	0	O
.	0	O


Interspecific	0	O
complementation	0	O
tests	0	O
showed	0	O
that	0	O
the	0	O
P7	0	B
proteins	0	I
are	0	O
unable	0	O
to	0	O
complement	0	O
P1	1	B
parA	1	I
or	0	O
parB	0	B
mutants	0	I
,	0	O
and	0	O
the	0	O
P1	1	B
proteins	0	I
fail	0	O
to	0	O
complement	0	O
the	0	O
P7	0	B
mutations	0	I
.	0	O


One	0	O
hundred	0	O
and	0	O
four	0	O
(	0	O
14	0	O
per	0	O
cent	0	O
)	0	O
second	0	O
primary	0	O
tumours	0	O
were	0	O
reported	0	O
.	0	O


The	0	O
cellular	0	O
part	0	O
of	0	O
the	0	O
third	0	O
chimeric	0	O
clone	0	O
shows	0	O
significant	0	O
homology	0	O
to	0	O
an	0	O
exon	0	O
of	0	O
the	0	O
human	0	B
tyrosine	0	I
phosphatase	0	I
1	0	I
gene	0	I
,	0	O
although	0	O
oriented	0	O
in	0	O
the	0	O
antisense	0	O
direction	0	O
compared	0	O
to	0	O
the	0	O
adjacent	0	O
LTR	1	O
.	0	O


The	0	O
genomic	0	O
structure	0	O
and	0	O
chromosomal	0	O
location	0	O
of	0	O
the	0	O
human	0	B
TR2	0	I
orphan	0	I
receptor	0	I
,	0	O
a	0	O
member	0	O
of	0	O
the	0	O
steroid	0	B
receptor	0	I
superfamily	0	I
.	0	O


Tissues	0	O
and	0	O
exudates	0	O
contain	0	O
sufficient	0	O
thymidine	0	O
for	0	O
growth	0	O
of	0	O
anaerobic	0	O
bacteria	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
inhibitory	0	O
levels	0	O
of	0	O
trimethoprim	0	O
-	0	O
sulfamethoxazole	0	O
.	0	O


In	1	O
contrast	0	O
with	0	O
the	0	O
previously	0	O
reported	0	O
HMGR1	0	B
mRNA	1	I
(	0	O
HMGR1S	0	B
mRNA	1	I
),	0	O
which	0	O
is	0	O
detected	0	O
at	0	O
high	0	O
levels	0	O
in	0	O
all	0	O
tissues	0	O
of	0	O
the	0	O
plant	0	O
,	0	O
HMGR1L	0	B
mRNA	1	I
is	0	O
present	0	O
at	0	O
relatively	0	O
low	0	O
levels	0	O
and	0	O
its	0	O
expression	0	O
is	0	O
restricted	0	O
mostly	0	O
to	0	O
seedlings	0	O
,	0	O
roots	0	O
and	0	O
inflorescences	0	O
.	0	O


Structural	1	O
changes	0	O
in	0	O
the	0	O
kinetically	0	O
more	0	O
damaged	0	O
E44D	0	O
mutant	0	O
detected	0	O
in	0	O
(	0	O
1	0	O
)	0	O
H	1	O
-(	0	O
15	0	O
)	0	O
N	1	O
HSQC	0	O
spectra	0	O
were	0	O
largely	0	O
limited	0	O
to	0	O
the	0	O
loop	0	O
I	1	O
-	0	O
helix	0	O
I	1	O
motif	0	O
,	0	O
suggesting	0	O
that	0	O
Glu	1	O
-	0	O
44	0	O
stabilizes	0	O
the	0	O
active	0	O
site	0	O
region	0	O
.	0	O


Both	0	O
HERV	1	O
-	0	O
K	1	O
type	0	O
1	0	O
and	0	O
2	0	O
clones	0	O
were	0	O
isolated	0	O
.	0	O


When	0	O
tethered	0	O
to	0	O
a	0	O
heterologous	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
,	0	O
PSU1	0	B
can	0	O
activate	0	O
transcription	0	O
on	0	O
its	0	O
own	0	O
.	0	O


The	0	O
grandfather	0	O
and	0	O
the	0	O
granddaughter	0	O
both	0	O
had	0	O
microtia	0	O
and	0	O
meatal	0	O
atresia	0	O
,	0	O
whereas	0	O
the	0	O
daughter	0	O
had	0	O
a	0	O
normal	0	O
outer	0	O
ear	0	O
except	0	O
for	0	O
a	0	O
narrow	0	O
meatus	0	O
and	0	O
auricular	0	O
appendages	0	O
.	0	O


Ent	1	B
-	0	I
kaurene	0	I
synthase	0	I
from	0	I
the	0	I
fungus	0	I
Phaeosphaeria	0	I
sp	0	O
.	0	O


Activation	1	O
of	0	O
alpha	0	B
4	0	I
beta	0	I
1	0	I
with	0	O
TS2	0	B
/	0	I
16	0	I
inhibited	0	O
the	0	O
cytoplasmic	0	O
protrusions	0	O
and	0	O
cell	0	O
migration	0	O
but	0	O
did	0	O
not	0	O
affect	0	O
the	0	O
pattern	0	O
of	0	O
phosphorylation	0	O
.	0	O


In	1	O
throttling	0	O
valves	0	O
,	0	O
the	0	O
aim	0	O
is	0	O
to	0	O
correlate	0	O
the	0	O
effect	0	O
of	0	O
shear	0	O
to	0	O
a	0	O
parameter	0	O
related	0	O
to	0	O
the	0	O
inner	0	O
geometry	0	O
of	0	O
the	0	O
valve	0	O
and	0	O
to	0	O
operating	0	O
conditions	0	O
.	0	O


Sequencing	1	O
of	0	O
a	0	O
40	0	O
-	0	O
kb	0	O
DNA	1	O
segment	0	O
of	0	O
the	0	O
FK506	0	O
gene	0	O
cluster	0	O
from	0	O
Streptomyces	1	O
sp	0	O
.	0	O


Experimental	0	O
pancreatitis	0	O
in	0	O
pigs	0	O
.	0	O


Do	1	O
overall	0	O
treatment	0	O
time	0	O
,	0	O
field	0	O
size	0	O
,	0	O
and	0	O
treatment	0	O
energy	0	O
influence	0	O
local	0	O
control	0	O
of	0	O
T1	1	O
-	0	O
T2	0	O
squamous	0	O
cell	0	O
carcinomas	0	O
of	0	O
the	0	O
glottic	0	O
larynx	0	O
?	0	O
PURPOSE	0	O
:	0	O
To	1	O
evaluate	0	O
treatment	0	O
and	0	O
patient	0	O
related	0	O
prognostic	0	O
factors	0	O
that	0	O
may	0	O
influence	0	O
local	0	O
control	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
T1	1	O
-	0	O
T2	0	O
squamous	0	O
cell	0	O
carcinoma	0	O
of	0	O
the	0	O
glottic	0	O
larynx	0	O
.	0	O


The	0	O
paramyxovirus	0	B
fusion	0	I
(	0	I
F	1	I
)	0	I
protein	0	I
mediates	0	O
membrane	0	O
fusion	0	O
.	0	O


All	1	O
were	0	O
experienced	0	O
hearing	0	O
aid	0	O
users	0	O
who	0	O
wore	0	O
linear	0	O
Class	1	O
D	1	O
instruments	0	O
with	0	O
input	0	O
compression	0	O
limiting	0	O
at	0	O
the	0	O
time	0	O
of	0	O
their	0	O
enrollment	0	O
in	0	O
this	0	O
study	0	O
.	0	O


Heterodimers	0	O
of	0	O
myogenin	0	B
and	0	O
E12	0	B
(	0	O
or	0	O
MyoD	0	B
and	0	O
E12	0	B
)	0	O
specifically	0	O
bound	0	O
a	0	O
restriction	0	O
fragment	0	O
extending	0	O
from	0	O
-	0	O
200	0	O
to	0	O
-	0	O
103	0	O
relative	0	O
to	0	O
the	0	O
start	0	O
of	0	O
cardiac	0	B
alpha	0	I
-	0	I
actin	0	I
transcription	0	O
.	0	O


The	0	O
p73pct1	0	B
/	0	O
p85cdc10	0	B
complex	0	O
binds	0	O
both	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
to	0	O
MCB	0	B
but	0	O
not	0	O
SCB	0	B
or	0	O
E2F	0	B
sites	0	I
.	0	O


Activation	1	O
of	0	O
nuclear	0	B
factor	0	I
(	0	I
NF	1	I
)-	0	I
kappaB	0	I
and	0	O
subsequent	0	O
proinflammatory	0	O
gene	0	O
expression	0	O
in	0	O
human	0	O
airway	0	O
epithelial	0	O
cells	0	O
can	0	O
be	0	O
evoked	0	O
by	0	O
oxidative	0	O
stress	0	O
.	0	O


Pneumoscrotum	1	O
is	0	O
a	0	O
rare	0	O
condition	0	O
that	0	O
receives	0	O
little	0	O
discussion	0	O
in	0	O
standard	0	O
texts	0	O
of	0	O
urology	0	O
.	0	O


Nernst	0	O
--	0	O
Planck	0	O
analog	0	O
equations	0	O
and	0	O
stationary	0	O
state	0	O
membrane	0	O
electric	0	O
potentials	0	O
.	0	O


A	1	O
high	0	O
reactor	0	O
pH	1	O
(+/-	0	O
8	0	O
),	0	O
a	0	O
short	0	O
solid	0	O
retention	0	O
time	0	O
(<	0	O
150	0	O
days	0	O
),	0	O
and	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
substantial	0	O
SRB	0	O
population	0	O
in	0	O
the	0	O
inoculum	0	O
may	0	O
considerably	0	O
reduce	0	O
the	0	O
time	0	O
required	0	O
for	0	O
acetate	0	O
-	0	O
utilising	0	O
SRB	0	O
to	0	O
outcompete	0	O
MB	1	O
.	0	O


Detection	1	O
of	0	O
poisoning	0	O
by	0	O
Impila	0	O
(	0	O
Callilepis	0	O
laureola	0	O
)	0	O
in	0	O
a	0	O
mother	0	O
and	0	O
child	0	O
.	0	O


Human	1	O
recombinant	0	O
DNA	1	O
-	0	O
derived	0	O
antihemophilic	0	B
factor	0	I
(	0	O
factor	0	B
VIII	0	I
)	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
hemophilia	0	O
A	1	O
.	0	O
recombinant	0	O
Factor	1	B
VIII	0	I
Study	1	O
Group	1	O
.	0	O


In	1	O
order	0	O
to	0	O
characterize	0	O
the	0	O
functional	0	O
elements	0	O
of	0	O
the	0	O
promoter	0	O
that	0	O
in	0	O
some	0	O
way	0	O
must	0	O
respond	0	O
to	0	O
these	0	O
regulatory	0	O
signals	0	O
,	0	O
a	0	O
number	0	O
of	0	O
promoter	0	O
mutations	0	O
were	0	O
constructed	0	O
,	0	O
including	0	O
a	0	O
set	0	O
of	0	O
linker	0	O
-	0	O
scanning	0	O
mutations	0	O
across	0	O
the	0	O
entire	0	O
promoter	0	O
region	0	O
.	0	O


Mycobacterium	1	O
avium	0	O
-	0	O
intracellulare	0	O
complex	0	O
infections	0	O
in	0	O
the	0	O
acquired	0	O
immunodeficiency	0	O
syndrome	0	O
.	0	O


Most	0	O
pituitary	0	O
hormone	0	O
-	0	O
coding	0	O
gene	0	O
promoters	0	O
are	0	O
activated	0	O
by	0	O
Ptx1	0	B
.	0	O


In	1	O
addition	0	O
to	0	O
the	0	O
nine	0	O
and	0	O
51	0	O
terminal	0	O
amino	0	O
acid	0	O
forms	0	O
already	0	O
known	0	O
,	0	O
we	0	O
identified	0	O
a	0	O
third	0	O
with	0	O
43	0	O
terminal	0	O
amino	0	O
acids	0	O
predicted	0	O
to	0	O
encode	0	O
a	0	O
novel	0	O
RET	0	B
protein	0	I
isoform	0	I
.	0	O


At	1	O
the	0	O
time	0	O
of	0	O
the	0	O
13	0	O
latest	0	O
BPVs	0	O
,	0	O
age	0	O
ranged	0	O
from	0	O
three	0	O
days	0	O
to	0	O
13	0	O
.	0	O
1	0	O
years	0	O
(	0	O
mean	0	O
5	0	O
.	0	O
7	0	O
+/-	0	O
SD	1	O
4	0	O
.	0	O
8	0	O
years	0	O
).	0	O


No	1	O
mutations	0	O
were	0	O
found	0	O
in	0	O
follicular	0	O
adenomas	0	O
.	0	O


Changes	0	O
in	0	O
body	0	O
weight	0	O
and	0	O
agonistic	0	O
behavior	0	O
were	0	O
also	0	O
recorded	0	O
.	0	O


Infant	1	O
aged	0	O
3	0	O
.	0	O
5	0	O
years	0	O
presents	0	O
persistence	0	O
of	0	O
primordial	0	O
vitreous	0	O
body	0	O
with	0	O
crystalline	0	O
dislocation	0	O
in	0	O
the	0	O
camera	0	O
aquosa	0	O
and	0	O
secondary	0	O
buphthalmos	0	O
of	0	O
the	0	O
left	0	O
eye	0	O
and	0	O
microphthalmos	0	O
with	0	O
dislocation	0	O
of	0	O
the	0	O
crystalline	0	O
in	0	O
the	0	O
vitreous	0	O
body	0	O
of	0	O
the	0	O
right	0	O
eye	0	O
.	0	O


To	1	O
date	0	O
,	0	O
two	0	O
such	0	O
proteins	0	O
,	0	O
PLZF	0	B
and	0	O
LAZ	0	B
-	0	I
3	0	I
/	0	O
BCL	0	B
-	0	I
6	0	I
,	0	O
have	0	O
been	0	O
implicated	0	O
in	0	O
oncogenesis	0	O
.	0	O


Steroids	0	O
in	0	O
germfree	0	O
and	0	O
conventional	0	O
rats	0	O
.	0	O


The	0	O
feed	0	O
given	0	O
to	0	O
young	0	O
broiler	0	O
chickens	0	O
was	0	O
contaminated	0	O
artificially	0	O
with	0	O
Salmonella	1	O
kedougou	0	O
,	0	O
a	0	O
serotype	0	O
associated	0	O
with	0	O
both	0	O
subclinical	0	O
infections	0	O
in	0	O
commercially	0	O
reared	0	O
chickens	0	O
and	0	O
food	0	O
poisoning	0	O
in	0	O
humans	0	O
.	0	O


It	1	O
appears	0	O
that	0	O
the	0	O
pulmonary	0	O
gas	0	O
exchange	0	O
parenchyma	0	O
of	0	O
these	0	O
smallest	0	O
mammals	0	O
is	0	O
well	0	O
suited	0	O
to	0	O
supply	0	O
the	0	O
organism	0	O
with	0	O
the	0	O
comparatively	0	O
high	0	O
levels	0	O
of	0	O
O2	1	O
required	0	O
by	0	O
the	0	O
high	0	O
metabolic	0	O
rates	0	O
,	0	O
exhibiting	0	O
a	0	O
structural	0	O
adaptation	0	O
of	0	O
the	0	O
lung	0	O
to	0	O
higher	0	O
VO2	1	O
.	0	O


Rabbits	0	O
developed	0	O
profound	0	O
hypocalcemia	0	O
,	0	O
with	0	O
levels	0	O
falling	0	O
from	0	O
15	0	O
.	0	O
5	0	O
+/-	0	O
0	0	O
.	0	O
2	0	O
to	0	O
7	0	O
.	0	O
6	0	O
+/-	0	O
0	0	O
.	0	O
4	0	O
mg	0	O
/	0	O
dl	0	O
under	0	O
the	0	O
influence	0	O
of	0	O
TSST	0	B
-	0	I
1	0	I
.	0	O


The	0	O
abscess	0	O
was	0	O
debrided	0	O
and	0	O
the	0	O
septum	0	O
was	0	O
patched	0	O
with	0	O
a	0	O
single	0	O
layer	0	O
of	0	O
autologous	0	O
pericardium	0	O
.	0	O


The	0	O
pea	0	B
rps10	0	I
intron	0	I
is	0	O
homologous	0	O
to	0	O
introns	0	O
in	0	O
rrn26	0	B
and	0	O
cox3	0	B
in	0	O
the	0	O
Marchantia	0	O
mitochondrial	0	O
genome	0	O
,	0	O
while	0	O
the	0	O
Marchantia	0	B
rps10	0	I
gene	0	I
lacks	0	O
an	0	O
intron	0	O
.	0	O


Elementary	1	O
visual	0	O
hallucinations	0	O
in	0	O
migraine	0	O
and	0	O
epilepsy	0	O
.	0	O


This	0	O
last	0	O
includes	0	O
tissue	0	O
O2	1	O
transfer	0	O
(	0	O
Ft	1	O
')	0	O
and	0	O
mitochondrial	0	O
O2	1	O
utilization	0	O
(	0	O
Fm	1	O
').	0	O


CONCLUSION	0	O
:	0	O
NBP	0	O
pre	0	O
-	0	O
treatment	0	O
or	0	O
post	0	O
-	0	O
treatment	0	O
markedly	0	O
enhanced	0	O
the	0	O
rCBF	1	O
to	0	O
striatum	0	O
in	0	O
RMCAO	0	O
rats	0	O
.	0	O


The	0	O
data	0	O
indicate	0	O
that	0	O
calcitonin	0	B
induced	0	O
a	0	O
beta	0	B
-	0	I
endorphin	0	I
increase	0	O
independent	0	O
of	0	O
enhanced	0	O
corticotrophin	0	B
-	0	O
cortisol	0	O
release	0	O
.	0	O


The	0	O
ARX2	0	O
procedure	0	O
models	0	O
the	0	O
recorded	0	O
signal	0	O
as	0	O
the	0	O
sum	0	O
of	0	O
three	0	O
signals	0	O
:	0	O
(	0	O
a	0	O
)	0	O
the	0	O
background	0	O
EEG	1	O
activity	0	O
,	0	O
modelled	0	O
as	0	O
an	0	O
autoregressive	0	O
process	0	O
driven	0	O
by	0	O
a	0	O
white	0	O
noise	0	O
;	0	O
(	0	O
b	0	O
)	0	O
a	0	O
filtered	0	O
version	0	O
of	0	O
a	0	O
reference	0	O
signal	0	O
carrying	0	O
the	0	O
average	0	O
information	0	O
contained	0	O
in	0	O
each	0	O
sweep	0	O
;	0	O
(	0	O
c	0	O
)	0	O
a	0	O
signal	0	O
due	0	O
to	0	O
the	0	O
ocular	0	O
artefact	0	O
propagation	0	O
.	0	O


Histamine	1	O
reactivity	0	O
had	0	O
returned	0	O
to	0	O
normal	0	O
in	0	O
half	0	O
the	0	O
workers	0	O
who	0	O
had	0	O
left	0	O
their	0	O
original	0	O
factories	0	O
,	0	O
but	0	O
in	0	O
only	0	O
one	0	O
worker	0	O
who	0	O
had	0	O
moved	0	O
within	0	O
her	0	O
original	0	O
factory	0	O
.	0	O


The	0	O
inflation	0	O
hub	0	O
of	0	O
the	0	O
probe	0	O
is	0	O
recreated	0	O
by	0	O
modifying	0	O
a	0	O
standard	0	O
USCI	0	O
Tuohy	0	O
-	0	O
Borst	0	O
Y	1	O
adaptor	0	O
and	0	O
attaching	0	O
this	0	O
to	0	O
the	0	O
transected	0	O
probe	0	O
hypotube	0	O
.	0	O


Within	0	O
-	0	O
subject	0	O
BP	1	O
differences	0	O
between	0	O
fish	0	O
oil	0	O
and	0	O
corn	0	O
oil	0	O
treatment	0	O
were	0	O
similar	0	O
for	0	O
Dinamap	0	O
(	0	O
3	0	O
.	0	O
2	0	O
+/-	0	O
1	0	O
.	0	O
8	0	O
/	0	O
2	0	O
.	0	O
5	0	O
+/-	0	O
1	0	O
.	0	O
0	0	O
mm	0	O
Hg	1	O
)	0	O
and	0	O
for	0	O
24	0	O
-	0	O
h	0	O
ABP	1	O
(	0	O
2	0	O
.	0	O
5	0	O
+/-	0	O
1	0	O
.	0	O
0	0	O
/	0	O
2	0	O
.	0	O
3	0	O
+/-	0	O
0	0	O
.	0	O
8	0	O
mm	0	O
Hg	1	O
),	0	O
but	0	O
were	0	O
more	0	O
significant	0	O
with	0	O
the	0	O
latter	0	O
.	0	O


To	1	O
assess	0	O
the	0	O
health	0	O
significance	0	O
of	0	O
the	0	O
early	0	O
renal	0	O
changes	0	O
after	0	O
chronic	0	O
exposure	0	O
to	0	O
cadmium	0	O
,	0	O
23	0	O
workers	0	O
removed	0	O
from	0	O
exposure	0	O
because	0	O
of	0	O
the	0	O
discovery	0	O
of	0	O
an	0	O
increased	0	O
urinary	0	O
excretion	0	O
of	0	O
beta	0	B
2	0	I
-	0	I
microglobulin	0	I
or	0	O
retinol	0	B
binding	0	I
protein	0	I
,	0	O
or	0	O
both	0	O
,	0	O
have	0	O
been	0	O
examined	0	O
once	0	O
a	0	O
year	0	O
for	0	O
five	0	O
years	0	O
.	0	O


Site	1	O
S	1	O
-	0	O
II	0	O
also	0	O
spans	0	O
a	0	O
23	0	O
bp	0	O
sequence	0	O
containing	0	O
two	0	O
tandem	0	O
consensus	0	O
binding	0	O
sites	0	O
with	0	O
three	0	O
base	0	O
pair	0	O
mismatches	0	O
in	0	O
each	0	O
and	0	O
a	0	O
one	0	O
base	0	O
pair	0	O
deletion	0	O
.	0	O


Virol	0	O
.	0	O


Termination	1	O
of	0	O
induced	0	O
VT	1	O
on	0	O
the	0	O
first	0	O
attempt	0	O
was	0	O
comparable	0	O
with	0	O
BV	1	O
pacing	0	O
(	0	O
87	0	O
.	0	O
4	0	O
%)	0	O
versus	0	O
RV	1	O
pacing	0	O
(	0	O
89	0	O
.	0	O
6	0	O
%).	0	O


Pups	0	O
placed	0	O
into	0	O
the	0	O
novel	0	O
environment	0	O
with	0	O
their	0	O
mothers	0	O
exhibited	0	O
an	0	O
intermediate	0	O
level	0	O
of	0	O
DA	1	O
turnover	0	O
.	0	O


Studied	0	O
groups	0	O
were	0	O
(	0	O
1	0	O
)	0	O
untreated	0	O
control	0	O
,	0	O
n	0	O
=	0	O
12	0	O
;	0	O
(	0	O
2	0	O
)	0	O
FK	0	O
-	0	O
1	0	O
,	0	O
n	0	O
=	0	O
8	0	O
;	0	O
(	0	O
3	0	O
)	0	O
FK	0	O
-	0	O
3	0	O
,	0	O
n	0	O
=	0	O
8	0	O
.	0	O


A	1	O
4	0	O
.	0	O
8	0	O
-	0	O
kilobase	0	O
BamHI	0	B
-	0	O
HindIII	0	B
fragment	0	O
encoding	0	O
the	0	O
entire	0	B
Neurospora	1	I
crassa	0	I
CuZn	0	I
superoxide	0	I
dismutase	0	I
gene	0	I
(	0	O
herein	0	O
designated	0	O
sod	0	B
-	0	I
1	0	I
)	0	O
was	0	O
isolated	0	O
from	0	O
a	0	O
genomic	0	O
library	0	O
using	0	O
two	0	O
60	0	O
-	0	O
base	0	O
deoxyoligonucleotide	0	O
probes	0	O
corresponding	0	O
to	0	O
the	0	O
published	0	O
N	1	O
.	0	O
crassa	0	O
amino	0	O
acid	0	O
sequence	0	O
.	0	O


Chronic	1	O
renal	0	O
failure	0	O
patients	0	O
essentially	0	O
die	0	O
from	0	O
cardiovascular	0	O
causes	0	O
,	0	O
and	0	O
the	0	O
frequency	0	O
of	0	O
malignant	0	O
disease	0	O
responsible	0	O
for	0	O
death	0	O
is	0	O
estimated	0	O
to	0	O
be	0	O
10	0	O
%.	0	O


The	0	O
findings	0	O
suggest	0	O
that	0	O
ERP	1	O
effects	0	O
of	0	O
distinct	0	O
memory	0	O
processes	0	O
are	0	O
differentially	0	O
influenced	0	O
by	0	O
the	0	O
encoding	0	O
instructions	0	O
.	0	O


The	0	O
cwg2	0	B
-	0	I
1	0	I
mutation	0	I
was	0	O
identified	0	O
as	0	O
a	0	O
guanine	0	O
to	0	O
adenine	0	O
substitution	0	O
at	0	O
nucleotide	0	O
604	0	O
of	0	O
the	0	O
coding	0	O
region	0	O
,	0	O
originating	0	O
the	0	O
change	0	O
A202T	0	O
in	0	O
the	0	O
cwg2p	0	B
.	0	O


Major	1	O
clinical	0	O
symptoms	0	O
of	0	O
the	0	O
disease	0	O
were	0	O
defined	0	O
in	0	O
this	0	O
group	0	O
of	0	O
patients	0	O
.	0	O


Efferent	1	O
projections	0	O
of	0	O
the	0	O
ventral	0	O
portion	0	O
of	0	O
the	0	O
putamen	0	O
to	0	O
the	0	O
frontal	0	O
,	0	O
parietal	0	O
and	0	O
temporal	0	O
regions	0	O
of	0	O
the	0	O
cat	0	O
cerebral	0	O
cortex	0	O


Bacteriostatic	1	O
and	0	O
bacteriacidal	0	O
activity	0	O
of	0	O
hydroxy	0	O
-	0	O
9	0	O
ellipticine	0	O
in	0	O
vitro	0	O


In	1	O
the	0	O
present	0	O
article	0	O
,	0	O
the	0	O
causes	0	O
of	0	O
death	0	O
or	0	O
ill	0	O
-	0	O
being	0	O
as	0	O
found	0	O
in	0	O
10	0	O
consecutive	0	O
carcinogenicity	0	O
studies	0	O
--	0	O
5	0	O
studies	0	O
with	0	O
2400	0	O
OFA	0	O
(	0	O
Sprague	0	O
-	0	O
Dawley	0	O
-	0	O
derived	0	O
)	0	O
and	0	O
Wistar	0	O
rats	0	O
and	0	O
5	0	O
studies	0	O
with	0	O
2400	0	O
OF1	0	O
and	0	O
NMRI	1	O
mice	0	O
--	0	O
were	0	O
re	0	O
-	0	O
examined	0	O
.	0	O


Here	0	O
we	0	O
describe	0	O
the	0	O
identification	0	O
and	0	O
characterization	0	O
of	0	O
several	0	O
Sp100	0	B
splice	0	I
variant	0	I
proteins	0	I
and	0	O
support	0	O
their	0	O
existence	0	O
by	0	O
elucidation	0	O
of	0	O
the	0	O
3	0	O
'-	0	O
end	0	O
of	0	O
the	0	O
Sp100	0	B
gene	0	I
.	0	O


Pokeweed	1	B
mitogen	0	I
(	0	O
PWM	1	B
)	0	O
or	0	O
anti	0	B
-	0	I
CD3	0	I
significantly	0	O
increases	0	O
c	0	B
-	0	I
jun	0	I
messenger	0	I
RNA	1	I
(	0	I
mRNA	1	I
)	0	I
levels	0	O
in	0	O
T	1	O
cells	0	O
.	0	O


Apparent	1	O
loss	0	O
of	0	O
differentiation	0	O
markers	0	O
characterizes	0	O
advanced	0	O
malignant	0	O
neoplasms	0	O
.	0	O


Surprisingly	0	O
,	0	O
the	0	O
CSF1R	0	B
/	0	O
IRDelta960	0	B
was	0	O
as	0	O
effective	0	O
as	0	O
the	0	O
CSF1R	0	B
/	0	O
IR	1	B
in	0	O
mediating	0	O
CSF	1	B
-	0	I
1	0	I
protection	0	O
of	0	O
cells	0	O
from	0	O
staurosporine	0	O
-	0	O
induced	0	O
apoptosis	0	O
.	0	O


All	1	O
Cu	1	O
values	0	O
obtained	0	O
from	0	O
the	0	O
organs	0	O
investigated	0	O
had	0	O
reached	0	O
a	0	O
saturation	0	O
level	0	O
at	0	O
8	0	O
mug	0	O
Cu	1	O
/	0	O
g	0	O
diet	0	O
with	0	O
the	0	O
exception	0	O
of	0	O
the	0	O
values	0	O
for	0	O
body	0	O
Cu	1	O
found	0	O
in	0	O
the	0	O
dams	0	O
that	0	O
were	0	O
killed	0	O
on	0	O
the	0	O
day	0	O
of	0	O
delivery	0	O
.	0	O


IL	1	B
-	0	I
2	0	I
is	0	O
accepted	0	O
as	0	O
a	0	O
standard	0	O
treatment	0	O
used	0	O
alone	0	O
,	0	O
or	0	O
in	0	O
combination	0	O
with	0	O
chemotherapy	0	O
or	0	O
biotherapy	0	O
in	0	O
the	0	O
management	0	O
of	0	O
metastatic	0	O
melanoma	0	O
and	0	O
metastatic	0	O
renal	0	O
cell	0	O
carcinoma	0	O
.	0	O


Creutzfeldt	0	O
-	0	O
Jakob	0	O
disease	0	O
and	0	O
lyophilised	0	O
dura	0	O
mater	0	O
grafts	0	O
:	0	O
report	0	O
of	0	O
two	0	O
cases	0	O
.	0	O


The	0	O
clinical	0	O
application	0	O
of	0	O
the	0	O
antibody	0	O
-	0	O
targeted	0	O
Phthalocyanine	0	O
was	0	O
performed	0	O
in	0	O
3	0	O
patients	0	O
suffering	0	O
from	0	O
an	0	O
advanced	0	O
ovarian	0	O
carcinoma	0	O
(	0	O
FIGO	1	O
III	0	O
).	0	O


The	0	O
juxtamembrane	0	O
region	0	O
of	0	O
the	0	O
insulin	0	B
receptor	0	I
(	0	I
IR	1	I
)	0	I
beta	0	I
-	0	I
subunit	0	I
contains	0	O
an	0	O
unphosphorylated	0	O
tyrosyl	0	O
residue	0	O
(	0	O
Tyr960	0	O
)	0	O
that	0	O
is	0	O
essential	0	O
for	0	O
insulin	0	B
-	0	O
stimulated	0	O
tyrosyl	0	O
phosphorylation	0	O
of	0	O
some	0	O
endogenous	0	O
substrates	0	O
and	0	O
certain	0	O
biological	0	O
responses	0	O
(	0	O
White	1	O
,	0	O
M	1	O
.	0	O
F	1	O
.,	0	O
Livingston	0	O
,	0	O
J	1	O
.	0	O
N	1	O
.,	0	O
Backer	0	O
,	0	O
J	1	O
.	0	O
M	1	O
.,	0	O
Lauris	0	O
,	0	O
V	1	O
.,	0	O
Dull	1	O
,	0	O
T	1	O
.	0	O
J	1	O
.,	0	O
Ullrich	0	O
,	0	O
A	1	O
.,	0	O
and	0	O
Kahn	0	O
,	0	O
C	1	O
.	0	O
R	1	O
.	0	O


This	0	O
core	0	O
sequence	0	O
,	0	O
along	0	O
with	0	O
additional	0	O
nonspecific	0	O
downstream	0	O
nucleotides	0	O
,	0	O
is	0	O
sufficient	0	O
for	0	O
partial	0	O
suppression	0	O
of	0	O
spliceosome	0	O
assembly	0	O
and	0	O
splicing	0	O
of	0	O
BPV	1	O
-	0	O
1	0	O
pre	0	O
-	0	O
mRNAs	0	O
.	0	O


Nitrogen	1	O
-	0	O
hydrogen	0	O
tautomerism	0	O
in	0	O
porphyrins	0	O
and	0	O
chlorins	0	O
.	0	O


The	0	O
pyrR	0	B
and	0	O
pyrP	0	B
genes	0	I
encoded	0	O
polypeptides	0	O
with	0	O
calculated	0	O
molecular	0	O
masses	0	O
of	0	O
19	0	O
.	0	O
9	0	O
and	0	O
45	0	O
.	0	O
2	0	O
kDa	1	O
,	0	O
respectively	0	O
.	0	O


RESULTS	0	O
:	0	O
Acetabular	1	O
index	0	O
returned	0	O
to	0	O
normal	0	O
gradually	0	O
as	0	O
the	0	O
time	0	O
went	0	O
by	0	O
and	0	O
significantly	0	O
within	0	O
one	0	O
year	0	O
after	0	O
the	0	O
reduction	0	O
of	0	O
developmental	0	O
dislocation	0	O
of	0	O
the	0	O
hip	0	O
.	0	O


However	0	O
,	0	O
we	0	O
could	0	O
not	0	O
find	0	O
the	0	O
homologous	0	O
regions	0	O
with	0	O
guanine	0	B
nucleotide	0	I
exchange	0	I
factors	0	I
or	0	O
GTPase	1	B
-	0	I
activating	0	I
proteins	0	I
in	0	O
the	0	O
c	0	B
-	0	I
cbl	0	I
gene	0	I
.	0	O


The	0	O
minimal	0	O
region	0	O
of	0	O
overlap	0	O
of	0	O
Langer	0	O
-	0	O
Giedion	0	O
syndrome	0	O
deletions	0	O
,	0	O
previously	0	O
identified	0	O
by	0	O
analysis	0	O
of	0	O
15	0	O
patients	0	O
,	0	O
was	0	O
placed	0	O
on	0	O
the	0	O
map	0	O
by	0	O
analysis	0	O
of	0	O
2	0	O
patients	0	O
whose	0	O
deletions	0	O
define	0	O
the	0	O
endpoints	0	O
.	0	O


Familial	1	O
glutathione	0	B
reductase	0	I
deficiency	0	O
and	0	O
disorder	0	O
of	0	O
glutathione	0	O
synthesis	0	O
in	0	O
the	0	O
erythrocyte	0	O


D	1	O
.	0	O


Biochemical	1	O
analysis	0	O
demonstrates	0	O
that	0	O
the	0	O
BJ1	0	B
protein	0	I
is	0	O
associated	0	O
with	0	O
nucleosomes	0	O
and	0	O
is	0	O
released	0	O
from	0	O
chromatin	0	O
by	0	O
agents	0	O
which	0	O
intercalate	0	O
into	0	O
DNA	1	O
,	0	O
as	0	O
previously	0	O
shown	0	O
for	0	O
the	0	O
high	0	B
mobility	0	I
group	0	I
proteins	0	I
(	0	O
HMGs	0	B
).	0	O


The	0	O
TA	1	O
muscle	0	O
was	0	O
fatigued	0	O
by	0	O
four	0	O
forms	0	O
of	0	O
repeated	0	O
isometric	0	O
contractions	0	O
:	0	O
(	0	O
1	0	O
)	0	O
maximal	0	O
voluntary	0	O
contractions	0	O
(	0	O
MVC	1	O
),	0	O
(	0	O
2	0	O
)	0	O
MVC	1	O
with	0	O
circulation	0	O
occluded	0	O
,	0	O
(	0	O
3	0	O
)	0	O
electrically	0	O
evoked	0	O
contractions	0	O
with	0	O
20	0	O
Hz	1	O
supramaximal	0	O
voltage	0	O
stimulation	0	O
and	0	O
(	0	O
4	0	O
)	0	O
electrically	0	O
evoked	0	O
contractions	0	O
with	0	O
circulation	0	O
occluded	0	O
.	0	O


The	0	O
Arabidopsis	0	B
FAD7	0	I
gene	0	I
encodes	0	O
a	0	O
chloroplast	0	B
omega	0	I
-	0	I
3	0	I
fatty	0	I
acid	0	I
desaturase	0	I
that	0	O
catalyzes	0	O
the	0	O
desaturation	0	O
of	0	O
lipid	0	O
-	0	O
linked	0	O
dienoic	0	O
fatty	0	O
acids	0	O
(	0	O
18	0	O
:	0	O
2	0	O
and	0	O
16	0	O
:	0	O
2	0	O
).	0	O


An	1	O
ion	0	O
chromatographic	0	O
method	0	O
was	0	O
used	0	O
to	0	O
determine	0	O
Br	1	O
ion	0	O
in	0	O
the	0	O
urine	0	O
of	0	O
Greyhounds	0	O
.	0	O


A	1	O
limited	0	O
study	0	O
in	0	O
a	0	O
glassware	0	O
factory	0	O
(	0	O
As2O3	0	O
exposure	0	O
)	0	O
involving	0	O
the	0	O
measurement	0	O
of	0	O
total	0	O
airborne	0	O
arsenic	0	O
,	0	O
the	0	O
determination	0	O
of	0	O
urinary	0	O
arsenic	0	O
,	0	O
and	0	O
the	0	O
evaluation	0	O
of	0	O
hand	0	O
and	0	O
mouth	0	O
contamination	0	O
by	0	O
arsenic	0	O
before	0	O
and	0	O
after	0	O
the	0	O
workshift	0	O
suggests	0	O
that	0	O
the	0	O
high	0	O
urinary	0	O
arsenic	0	O
levels	0	O
(	0	O
300	0	O
microgram	0	O
/	0	O
g	0	O
creatinine	0	O
)	0	O
are	0	O
likely	0	O
to	0	O
be	0	O
more	0	O
related	0	O
to	0	O
an	0	O
increased	0	O
oral	0	O
intake	0	O
from	0	O
contaminated	0	O
hands	0	O
than	0	O
to	0	O
an	0	O
increased	0	O
absorption	0	O
from	0	O
the	0	O
lungs	0	O
.	0	O


The	0	O
second	0	O
functional	0	O
pair	0	O
of	0	O
CreA	0	B
sites	0	I
is	0	O
located	0	O
between	0	O
the	0	O
two	0	O
transcription	0	O
initiation	0	O
sites	0	O
.	0	O


Cutaneous	1	O
necrosis	0	O
associated	0	O
with	0	O
protein	0	B
S	1	I
deficiency	0	O
.	0	O


Whole	0	O
bowel	0	O
irrigation	0	O
is	0	O
a	0	O
recently	0	O
described	0	O
technique	0	O
to	0	O
enhance	0	O
the	0	O
passage	0	O
of	0	O
drugs	0	O
already	0	O
beyond	0	O
the	0	O
pylorus	0	O
.	0	O


SSG1	0	B
,	0	O
a	0	O
gene	0	O
encoding	0	O
a	0	O
sporulation	0	B
-	0	I
specific	0	I
1	0	I
,	0	I
3	0	I
-	0	I
beta	0	I
-	0	I
glucanase	0	I
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Transcriptional	1	O
activity	0	O
was	0	O
measured	0	O
by	0	O
slot	0	O
-	0	O
blot	0	O
hybridization	0	O
with	0	O
steady	0	O
-	0	O
state	0	O
RNA	1	O
isolated	0	O
from	0	O
lacZ	0	B
+	0	I
M	1	I
.	0	I
smegmatis	0	I
clones	0	O
.	0	O


Using	0	O
immunogold	0	O
electron	0	O
microscopy	0	O
,	0	O
we	0	O
found	0	O
that	0	O
p58	0	B
/	0	O
p45	0	B
and	0	O
p54	0	B
are	0	O
localized	0	O
on	0	O
both	0	O
sides	0	O
of	0	O
the	0	O
nuclear	0	O
pore	0	O
complex	0	O
,	0	O
like	0	O
p62	0	B
.	0	O


Two	0	O
techniques	0	O
based	0	O
on	0	O
assay	0	O
coefficients	0	O
of	0	O
variation	0	O
were	0	O
employed	0	O
to	0	O
characterize	0	O
a	0	O
normal	0	O
circadian	0	O
pattern	0	O
of	0	O
cortisol	0	O
.	0	O


Induced	1	O
expression	0	O
of	0	O
Rnd3	0	B
is	0	O
associated	0	O
with	0	O
transformation	0	O
of	0	O
polarized	0	O
epithelial	0	O
cells	0	O
by	0	O
the	0	O
Raf	0	B
-	0	O
MEK	0	B
-	0	O
extracellular	0	O
signal	0	O
-	0	O
regulated	0	O
kinase	0	O
pathway	0	O
.	0	O


The	0	O
experience	0	O
of	0	O
the	0	O
lateral	0	O
rhinotomy	0	O
approach	0	O
in	0	O
transsphenoidal	0	O
surgery	0	O
of	0	O
acromegaly	0	O
has	0	O
been	0	O
favourable	0	O
.	0	O


Previous	0	O
studies	0	O
demonstrated	0	O
that	0	O
the	0	O
flavin	0	B
-	0	I
containing	0	I
monooxygenases	0	I
(	0	O
FMO	0	B
)	0	O
are	0	O
expressed	0	O
in	0	O
a	0	O
tissue	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


As	1	O
opposed	0	O
to	0	O
in	0	O
vitro	0	O
co	0	O
-	0	O
precipitation	0	O
studies	0	O
,	0	O
the	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
screen	0	O
reveals	0	O
in	0	O
vivo	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
.	0	O


We	0	O
have	0	O
recently	0	O
detected	0	O
high	0	O
levels	0	O
of	0	O
CKB	0	B
mRNA	1	I
in	0	O
HeLa	0	O
cells	0	O
and	0	O
,	0	O
in	0	O
this	0	O
study	0	O
,	0	O
have	0	O
tested	0	O
whether	0	O
this	0	O
may	0	O
be	0	O
due	0	O
to	0	O
the	0	O
extremely	0	O
low	0	O
amounts	0	O
of	0	O
p53	0	B
protein	0	I
present	0	O
in	0	O
HeLa	0	O
cells	0	O
.	0	O


Different	0	O
sequence	0	O
elements	0	O
of	0	O
both	0	O
the	0	O
retroviral	0	O
vectors	0	O
and	0	O
the	0	O
c	0	B
-	0	I
myc	0	I
gene	0	I
recombined	0	O
during	0	O
genesis	0	O
of	0	O
highly	0	O
oncogenic	0	O
retroviruses	0	O
CMII	0	O
,	0	O
MC29	0	O
,	0	O
or	0	O
MH2	0	O
.	0	O


Three	0	O
cases	0	O
of	0	O
primary	0	O
signet	0	O
-	0	O
ring	0	O
cell	0	O
carcinoma	0	O
of	0	O
the	0	O
rectum	0	O
are	0	O
described	0	O
.	0	O


Regulation	1	O
of	0	O
the	0	O
Raf	0	B
kinase	0	I
in	0	O
T	1	O
cells	0	O
differs	0	O
from	0	O
findings	0	O
with	0	O
a	0	O
variety	0	O
of	0	O
cell	0	O
lines	0	O
that	0	O
the	0	O
catalytic	0	B
domain	0	I
of	0	I
Raf	0	I
(	0	O
Raf	0	B
(	0	O
delta26	0	O
-	0	O
303	0	O
))	0	O
shows	0	O
no	0	O
activity	0	O
.	0	O


The	0	O
galactose	0	B
transporter	0	I
shows	0	O
both	0	O
sequence	0	O
and	0	O
structural	0	O
homology	0	O
with	0	O
a	0	O
superfamily	0	O
of	0	O
sugar	0	B
transporters	0	I
which	0	O
includes	0	O
the	0	O
human	0	B
HepG2	0	I
-	0	I
erythrocyte	0	I
and	0	I
fetal	0	I
muscle	0	I
glucose	0	I
transporters	0	I
,	0	O
the	0	O
rat	0	B
brain	0	I
and	0	I
liver	0	I
glucose	0	I
transporters	0	I
,	0	O
the	0	O
Escherichia	1	B
coli	0	I
xylose	0	I
and	0	I
arabinose	0	I
permeases	0	I
,	0	O
and	0	O
the	0	O
S	1	B
.	0	I
cerevisiae	0	I
glucose	0	I
,	0	I
maltose	0	I
,	0	I
and	0	I
galactose	0	I
transporters	0	I
.	0	O


Adverse	0	O
reaction	0	O
of	0	O
the	0	O
apparently	0	O
healthy	0	O
partner	0	O
in	0	O
response	0	O
to	0	O
improvement	0	O
in	0	O
the	0	O
overtly	0	O
dysfunctional	0	O
partner	0	O
.	0	O


These	0	O
data	0	O
show	0	O
that	0	O
PTH	1	B
and	0	O
cAMP	1	O
can	0	O
repress	0	O
collagen	0	B
promoter	0	I
activity	0	O
in	0	O
calvariae	0	O
from	0	O
transgenic	0	O
mice	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
alpha	0	B
1	0	I
(	0	I
I	1	I
)	0	I
collagen	0	I
promoter	0	I
may	0	O
contain	0	O
cis	0	O
elements	0	O
down	0	O
-	0	O
stream	0	O
of	0	O
-	0	O
2	0	O
.	0	O
3	0	O
kilobases	0	O
that	0	O
mediate	0	O
PTH	1	B
and	0	O
cAMP	1	O
repression	0	O
of	0	O
collagen	0	B
gene	0	I
expression	0	O
in	0	O
bone	0	O
.	0	O


Specific	1	O
clotting	0	O
factor	0	O
assays	0	O
showed	0	O
an	0	O
isolated	0	O
deficiency	0	O
of	0	O
factor	0	B
X	1	I
ranging	0	O
from	0	O
7	0	O
to	0	O
12	0	O
per	0	O
cent	0	O
on	0	O
three	0	O
determinations	0	O
.	0	O


A	1	O
coiled	0	O
-	0	O
coil	0	O
domain	0	O
,	0	O
conserved	0	O
within	0	O
each	0	O
encoded	0	O
protein	0	O
,	0	O
serves	0	O
as	0	O
a	0	O
potential	0	O
interaction	0	O
motif	0	O
for	0	O
FLI	0	B
LRR	1	I
.	0	O


During	0	O
the	0	O
past	0	O
decade	0	O
,	0	O
different	0	O
types	0	O
of	0	O
endogenous	0	O
retroviral	0	O
sequences	0	O
have	0	O
been	0	O
defined	0	O
in	0	O
the	0	O
human	0	O
genome	0	O
usually	0	O
by	0	O
low	0	O
stringency	0	O
hybridization	0	O
employing	0	O
DNA	1	O
probes	0	O
of	0	O
evolutionary	0	O
conserved	0	O
animal	0	O
retrovirus	0	O
genes	0	O
.	0	O


Of	0	O
the	0	O
three	0	O
known	0	O
C	1	B
/	0	I
EBP	1	I
family	0	I
inhibitors	0	O
,	0	O
Ig	1	B
/	0	I
EBP	1	I
,	0	O
LIP	1	B
and	0	O
CHOP	1	B
-	0	I
10	0	I
,	0	O
only	0	O
Ig	1	B
/	0	I
EBP	1	I
is	0	O
ubiquitously	0	O
expressed	0	O
.	0	O


Facioscapulohumeral	1	O
muscular	0	O
dystrophy	0	O
(	0	O
FSHD	0	O
)	0	O
is	0	O
an	0	O
autosomal	0	O
dominant	0	O
,	0	O
neuromuscular	0	O
disorder	0	O
characterized	0	O
by	0	O
progressive	0	O
weakness	0	O
of	0	O
muscles	0	O
in	0	O
the	0	O
face	0	O
,	0	O
shoulder	0	O
and	0	O
upper	0	O
arm	0	O
.	0	O


The	0	O
TIMP	0	B
(-	0	O
59	0	O
/	0	O
-	0	O
53	0	O
)	0	O
AP1	0	B
site	0	O
is	0	O
a	0	O
promiscuous	0	O
motif	0	O
that	0	O
binds	0	O
c	0	B
-	0	I
Fos	1	I
/	0	O
c	0	B
-	0	I
Jun	1	I
AP1	0	I
translated	0	O
in	0	O
vitro	0	O
and	0	O
is	0	O
an	0	O
effective	0	O
competitor	0	O
for	0	O
binding	0	O
of	0	O
nuclear	0	B
AP1	0	I
factors	0	I
to	0	O
the	0	O
consensus	0	O
TRE	0	O
,	0	O
but	0	O
in	0	O
addition	0	O
it	0	O
binds	0	O
factors	0	O
that	0	O
do	0	O
not	0	O
associate	0	O
with	0	O
the	0	O
consensus	0	O
TRE	0	O
.	0	O


Western	0	O
blotting	0	O
(	0	O
immunoblotting	0	O
)	0	O
with	0	O
an	0	O
antiserum	0	O
to	0	O
a	0	O
partial	0	O
SOD	0	B
expressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
revealed	0	O
two	0	O
proteins	0	O
with	0	O
estimated	0	O
molecular	0	O
masses	0	O
of	0	O
19	0	O
and	0	O
29	0	O
kDa	1	O
.	0	O


The	0	O
resulting	0	O
integrated	0	O
physical	0	O
,	0	O
genetic	0	O
,	0	O
and	0	O
cytogenetic	0	O
map	0	O
constitutes	0	O
a	0	O
resource	0	O
for	0	O
the	0	O
characterization	0	O
of	0	O
genes	0	O
that	0	O
may	0	O
be	0	O
involved	0	O
in	0	O
the	0	O
WAGR	0	O
syndrome	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
induction	0	O
of	0	O
E2F	0	B
binding	0	O
to	0	O
the	0	O
E2F	0	B
-	0	I
1	0	I
promoter	0	I
by	0	O
the	0	O
E4	1	B
-	0	I
6	0	I
/	0	I
7	0	I
protein	0	I
observed	0	O
in	0	O
vitro	0	O
correlates	0	O
with	0	O
transactivation	0	O
of	0	O
E2F	0	B
-	0	I
1	0	I
promoter	0	I
activity	0	O
in	0	O
vivo	0	O
.	0	O


In	1	O
eight	0	O
groups	0	O
of	0	O
subjects	0	O
operating	0	O
various	0	O
hand	0	O
-	0	O
held	0	O
vibrating	0	O
tools	0	O
and	0	O
aged	0	O
from	0	O
30	0	O
to	0	O
59	0	O
years	0	O
,	0	O
the	0	O
prevalence	0	O
rates	0	O
of	0	O
vibration	0	O
-	0	O
induced	0	O
white	0	O
finger	0	O
(	0	O
VWF	1	O
)	0	O
and	0	O
numbness	0	O
,	0	O
pain	0	O
,	0	O
or	0	O
stiffness	0	O
in	0	O
the	0	O
upper	0	O
and	0	O
lower	0	O
extremities	0	O
were	0	O
investigated	0	O
.	0	O


Smoking	0	O
history	0	O
and	0	O
awake	0	O
oxygen	0	O
saturation	0	O
(	0	O
SaO2	1	O
)	0	O
was	0	O
recorded	0	O
in	0	O
all	0	O
of	0	O
them	0	O
.	0	O


Negatively	0	O
supercoiled	0	O
plasmid	0	O
pUC19	0	O
did	0	O
not	0	O
compete	0	O
,	0	O
whereas	0	O
an	0	O
otherwise	0	O
identical	0	O
plasmid	0	O
pUC19	0	O
(	0	O
CG	1	O
),	0	O
which	0	O
contained	0	O
a	0	O
(	0	O
dG	1	O
-	0	O
dC	1	O
)	0	O
7	0	O
segment	0	O
in	0	O
the	0	O
Z	1	O
-	0	O
form	0	O
was	0	O
an	0	O
excellent	0	O
competitor	0	O
.	0	O


Hematopoietic	1	B
growth	0	I
factors	0	I
are	0	O
being	0	O
used	0	O
to	0	O
accelerate	0	O
the	0	O
recovery	0	O
of	0	O
myelopoiesis	0	O
following	0	O
high	0	O
-	0	O
dose	0	O
chemotherapy	0	O
in	0	O
cancer	0	O
patients	0	O
.	0	O


Modern	0	O
studies	0	O
,	0	O
conducted	0	O
with	0	O
Delta	1	O
-	0	O
9	0	O
-	0	O
THC	1	O
,	0	O
in	0	O
healthy	0	O
voluntaries	0	O
,	0	O
again	0	O
suggest	0	O
the	0	O
comparison	0	O
or	0	O
even	0	O
the	0	O
identity	0	O
of	0	O
the	0	O
modifications	0	O
caused	0	O
by	0	O
cannabis	0	O
with	0	O
sleep	0	O
and	0	O
dream	0	O
.	0	O


Oxidative	1	O
degradation	0	O
of	0	O
adrenaline	0	O
solutions	0	O
:	0	O
study	0	O
of	0	O
the	0	O
intermediate	0	O
stages	0	O
and	0	O
their	0	O
analytic	0	O
value	0	O
for	0	O
the	0	O
control	0	O
of	0	O
this	0	O
solute	0	O


These	0	O
responses	0	O
were	0	O
compared	0	O
with	0	O
others	0	O
in	0	O
the	0	O
same	0	O
subjects	0	O
under	0	O
the	0	O
same	0	O
conditions	0	O
and	0	O
it	0	O
was	0	O
concluded	0	O
that	0	O
the	0	O
antihypertensive	0	O
effect	0	O
of	0	O
labetalol	0	O
is	0	O
explained	0	O
by	0	O
concurrent	0	O
blockade	0	O
of	0	O
alpha	0	B
-	0	I
and	0	I
beta	0	I
-	0	I
adrenoceptors	0	I
.	0	O


Technetium	1	O
-	0	O
99m	0	O
methylene	0	O
diphosphonate	0	O
scintimammography	0	O
for	0	O
evaluation	0	O
of	0	O
palpable	0	O
breast	0	O
masses	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
Vpu	0	B
on	0	O
class	0	O
I	1	O
biogenesis	0	O
was	0	O
analyzed	0	O
in	0	O
more	0	O
detail	0	O
using	0	O
a	0	O
Vpu	0	B
-	0	O
expressing	0	O
recombinant	0	O
vaccinia	0	O
virus	0	O
(	0	O
VV	1	O
).	0	O


Experiences	0	O
with	0	O
the	0	O
clinical	0	O
and	0	O
experimental	0	O
use	0	O
of	0	O
Urat	0	O
-	0	O
I	1	O
lithotriptor	0	O
.	0	O


Among	0	O
38	0	O
patients	0	O
with	0	O
inducible	0	O
reentrant	0	O
VTs	0	O
who	0	O
underwent	0	O
electrophysiologic	0	O
study	0	O
(	0	O
EPS	1	O
),	0	O
10	0	O
VTs	0	O
of	0	O
six	0	O
patients	0	O
were	0	O
selected	0	O
.	0	O


The	0	O
membrane	0	O
-	0	O
distal	0	O
cytoplasmic	0	O
region	0	O
of	0	O
human	0	B
granulocyte	0	I
colony	0	I
-	0	I
stimulating	0	I
factor	0	I
receptor	0	I
is	0	O
required	0	O
for	0	O
STAT3	0	B
but	0	O
not	0	O
STAT1	0	B
homodimer	0	I
formation	0	O
.	0	O


MutY	0	B
is	0	O
an	0	O
adenine	0	B
-	0	I
DNA	1	I
glycosylase	0	I
with	0	O
specificity	0	O
for	0	O
mismatches	0	O
involving	0	O
8	0	O
-	0	O
oxoguanine	0	O
(	0	O
oG	0	O
.	0	O
A	1	O
)	0	O
or	0	O
guanine	0	O
(	0	O
G	1	O
.	0	O
A	1	O
).	0	O


No	1	O
significant	0	O
differences	0	O
were	0	O
identified	0	O
between	0	O
groups	0	O
for	0	O
pH	1	O
,	0	O
PaCO2	1	O
,	0	O
intracranial	0	O
pressure	0	O
,	0	O
heart	0	O
rate	0	O
,	0	O
brain	0	O
temperature	0	O
,	0	O
or	0	O
glucose	0	O
levels	0	O
.	0	O


Reproductive	1	O
period	0	O
affects	0	O
water	0	O
intake	0	O
in	0	O
heat	0	O
-	0	O
stressed	0	O
dehydrated	0	O
goats	0	O
.	0	O


Animals	0	O
may	0	O
be	0	O
immunized	0	O
by	0	O
oral	0	O
vaccination	0	O
,	0	O
but	0	O
natural	0	O
mechanisms	0	O
that	0	O
also	0	O
can	0	O
terminate	0	O
outbreaks	0	O
are	0	O
discussed	0	O
.	0	O


Although	0	O
a	0	O
wide	0	O
range	0	O
of	0	O
cognitive	0	O
functions	0	O
had	0	O
been	0	O
tested	0	O
,	0	O
all	0	O
but	0	O
one	0	O
seizure	0	O
occurred	0	O
during	0	O
assessment	0	O
of	0	O
memory	0	O
performance	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
model	0	O
,	0	O
a	0	O
synthetic	0	O
construct	0	O
containing	0	O
three	0	O
tandem	0	O
copies	0	O
of	0	O
the	0	O
native	0	O
LDL	1	B
receptor	0	I
SREBP	0	I
site	0	O
linked	0	O
to	0	O
a	0	O
single	0	O
Sp1	0	B
site	0	I
was	0	O
also	0	O
significantly	0	O
activated	0	O
in	0	O
a	0	O
buttonhead	0	B
-	0	O
independent	0	O
fashion	0	O
.	0	O


The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
investigate	0	O
the	0	O
effects	0	O
of	0	O
nebulized	0	O
ipratropium	0	O
in	0	O
patients	0	O
with	0	O
acute	0	O
asthma	0	O
in	0	O
order	0	O
to	0	O
determine	0	O
whether	0	O
it	0	O
augments	0	O
the	0	O
bronchodilator	0	O
effect	0	O
of	0	O
a	0	O
beta	0	O
agonist	0	O
drug	0	O
.	0	O


DATA	1	O
SYNTHESIS	1	O
:	0	O
Intracoronary	1	O
ultrasound	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
improve	0	O
upon	0	O
demonstrated	0	O
weaknesses	0	O
of	0	O
coronary	0	O
angiography	0	O
.	0	O


The	0	O
recognition	0	O
specificity	0	O
of	0	O
the	0	O
p55	0	B
PDZ	0	I
domain	0	I
appears	0	O
to	0	O
be	0	O
unique	0	O
,	0	O
since	0	O
the	0	O
three	0	O
PDZ	0	B
domains	0	I
of	0	O
hDlg	0	B
(	0	O
human	0	O
lymphocyte	0	O
homologue	0	O
of	0	O
the	0	O
Drosophila	1	B
discs	0	I
large	0	I
tumor	0	I
suppressor	0	I
)	0	O
do	0	O
not	0	O
bind	0	O
the	0	O
cytoplasmic	0	O
domain	0	O
of	0	O
glycophorin	0	B
C	1	I
.	0	O


Only	0	O
one	0	O
ADR	1	O
was	0	O
related	0	O
definitely	0	O
to	0	O
ciprofloxacin	0	O
therapy	0	O
.	0	O


Both	0	O
normal	0	O
and	0	O
transforming	0	O
PCPH	0	B
proteins	0	I
have	0	O
guanosine	0	B
diphosphatase	0	I
activity	0	O
but	0	O
only	0	O
the	0	O
oncoprotein	0	O
cooperates	0	O
with	0	O
Ras	1	B
in	0	O
activating	0	O
extracellular	0	B
signal	0	I
-	0	I
regulated	0	I
kinase	0	I
ERK1	0	I
.	0	O


Sparfloxacin	1	O
and	0	O
clinafloxacin	0	O
were	0	O
evaluated	0	O
against	0	O
Enterococcus	1	O
faecium	0	O
SF2149	0	O
and	0	O
Enterococcus	1	O
faecalis	0	O
WH245	0	O
,	0	O
respectively	0	O
.	0	O


Furthermore	0	O
,	0	O
analysis	0	O
of	0	O
deletion	0	O
promoter	0	O
-	0	O
reporter	0	O
constructs	0	O
found	0	O
that	0	O
the	0	O
basal	0	O
activity	0	O
of	0	O
P2	1	O
resided	0	O
in	0	O
the	0	O
proximal	0	O
region	0	O
of	0	O
P2	1	O
.	0	O


This	0	O
scFv	0	O
was	0	O
therefore	0	O
used	0	O
as	0	O
control	0	O
in	0	O
experiments	0	O
where	0	O
another	0	O
anti	0	B
-	0	I
Ras	1	I
scFv	0	I
(	0	O
Y259	0	B
scFv	0	I
,	0	O
derived	0	O
from	0	O
the	0	O
neutralizing	0	O
anti	0	B
-	0	I
Ras	1	I
mAb	0	I
Y13	0	I
-	0	I
259	0	I
)	0	O
blocked	0	O
the	0	O
Ras	1	B
pathway	0	O
in	0	O
vitro	0	O
and	0	O
led	0	O
to	0	O
tumor	0	O
regression	0	O
in	0	O
a	0	O
nude	0	O
mouse	0	O
model	0	O
[	0	O
Cochet	0	O
,	0	O
O	1	O
.,	0	O
Kenigsberg	0	O
,	0	O
M	1	O
.,	0	O
Delumeau	0	O
,	0	O
I	1	O
.,	0	O
Virone	0	O
-	0	O
Oddos	0	O
,	0	O
A	1	O
.,	0	O
Multon	0	O
,	0	O
M	1	O
.	0	O
C	1	O
.,	0	O
Fridman	0	O
,	0	O
W	1	O
.	0	O
H	1	O
.,	0	O
Schweighoffer	0	O
,	0	O
F	1	O
.,	0	O
Teillaud	0	O
,	0	O
J	1	O
.	0	O
L	1	O
.,	0	O
Tocque	0	O
,	0	O
B	1	O
.,	0	O
1998	0	O
.	0	O


The	0	O
junctions	0	O
between	0	O
viral	0	O
and	0	O
cellular	0	O
sequences	0	O
were	0	O
determined	0	O
by	0	O
DNA	1	O
sequence	0	O
analysis	0	O
to	0	O
be	0	O
517	0	O
nucleotides	0	O
into	0	O
the	0	O
p30	0	B
sequence	0	I
and	0	O
1	0	O
,	0	O
920	0	O
nucleotides	0	O
into	0	O
the	0	O
polymerase	0	O
sequence	0	O
.	0	O


There	0	O
were	0	O
significant	0	O
differences	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
between	0	O
the	0	O
fracture	0	O
and	0	O
nonfracture	0	O
groups	0	O
in	0	O
the	0	O
total	0	O
femur	0	O
BMD	1	O
(	0	O
13	0	O
%),	0	O
trabecular	0	O
BMD	1	O
in	0	O
the	0	O
distal	0	O
radius	0	O
(	0	O
4	0	O
%),	0	O
and	0	O
the	0	O
fractal	0	O
dimension	0	O
in	0	O
the	0	O
radiographs	0	O
(	0	O
FD2	0	O
)	0	O
(	0	O
3	0	O
%).	0	O


Molecular	1	O
cloning	0	O
of	0	O
mouse	0	B
glycolate	0	I
oxidase	0	I
.	0	O


We	0	O
report	0	O
here	0	O
that	0	O
microinjection	0	O
of	0	O
an	0	O
anti	0	B
-	0	I
CBP	0	I
antiserum	0	I
into	0	O
fibroblasts	0	O
can	0	O
inhibit	0	O
transcription	0	O
from	0	O
a	0	O
cAMP	1	O
responsive	0	O
promoter	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
c	0	B
-	0	I
Myb	0	I
regulates	0	O
the	0	O
RAG	0	B
-	0	I
2	0	I
promoter	0	I
in	0	O
T	1	O
cells	0	O
by	0	O
binding	0	O
to	0	O
this	0	O
consensus	0	B
c	0	I
-	0	I
Myb	0	I
binding	0	I
site	0	I
.	0	O


Paraneoplastic	1	O
rheumatic	0	O
syndromes	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
A	1	O
50	0	O
-	0	O
mg	0	O
daily	0	O
dose	0	O
of	0	O
bicalutamide	0	O
is	0	O
sufficient	0	O
when	0	O
given	0	O
in	0	O
combination	0	O
with	0	O
an	0	O
agent	0	O
,	0	O
such	0	O
as	0	O
a	0	O
LHRH	1	B
-	0	O
A	1	O
,	0	O
that	0	O
lowers	0	O
serum	0	O
testosterone	0	O
,	0	O
but	0	O
higher	0	O
doses	0	O
of	0	O
bicalutamide	0	O
may	0	O
be	0	O
needed	0	O
when	0	O
the	0	O
drug	0	O
is	0	O
given	0	O
as	0	O
monotherapy	0	O
.	0	O


Induction	1	O
of	0	O
CD86	0	B
expression	0	O
by	0	O
stimulation	0	O
of	0	O
U937	0	O
cells	0	O
with	0	O
IFN	1	B
-	0	I
gamma	0	I
revealed	0	O
the	0	O
presence	0	O
of	0	O
two	0	O
functional	0	O
GAS	1	B
(	0	O
gamma	0	B
-	0	I
interferon	0	I
activation	0	I
site	0	I
)	0	O
elements	0	O
.	0	O


Specific	1	O
hyperimmune	0	B
globulins	0	I
to	0	O
pathogens	0	O
such	0	O
as	0	O
Haemophilus	1	O
influenzae	0	O
and	0	O
Streptococcus	1	O
pneumoniae	0	O
have	0	O
also	0	O
been	0	O
studied	0	O
.	0	O


We	0	O
describe	0	O
a	0	O
genetic	0	O
system	0	O
for	0	O
further	0	O
characterizing	0	O
the	0	O
role	0	O
of	0	O
the	0	O
extreme	0	O
C	1	O
-	0	O
terminus	0	O
of	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
E	1	B
.	0	I
coli	0	I
RNA	1	I
polymerase	0	I
.	0	O


There	0	O
is	0	O
no	0	O
correlation	0	O
between	0	O
C2	1	O
-	0	O
C3	1	O
disk	0	O
morphology	0	O
and	0	O
the	0	O
diskographically	0	O
provoked	0	O
response	0	O
.	0	O


OODG	0	O
is	0	O
a	0	O
diagnostic	0	O
method	0	O
permitting	0	O
assessment	0	O
of	0	O
ocular	0	O
pulse	0	O
curves	0	O
and	0	O
objective	0	O
determination	0	O
of	0	O
blood	0	O
pressures	0	O
in	0	O
the	0	O
ophthalmic	0	O
circulatory	0	O
system	0	O
(	0	O
retinal	0	O
and	0	O
ciliary	0	O
arterial	0	O
blood	0	O
pressures	0	O
)	0	O
simultaneously	0	O
for	0	O
both	0	O
eyes	0	O
,	0	O
without	0	O
dilatation	0	O
of	0	O
the	0	O
pupils	0	O
.	0	O


The	0	O
pharmacological	0	O
effects	0	O
of	0	O
the	0	O
novel	0	O
compound	0	O
WEB	1	O
1881	0	O
FU	0	O
(	0	O
4	0	O
-	0	O
amino	0	O
-	0	O
methyl	0	O
-	0	O
1	0	O
-	0	O
benzyl	0	O
-	0	O
pyrrolidine	0	O
-	0	O
2	0	O
-	0	O
one	0	O
-	0	O
fumarate	0	O
)	0	O
were	0	O
investigated	0	O
.	0	O


However	0	O
,	0	O
L	1	B
-	0	I
plastin	0	I
has	0	O
been	0	O
found	0	O
in	0	O
many	0	O
types	0	O
of	0	O
malignant	0	O
human	0	O
cells	0	O
of	0	O
non	0	O
-	0	O
hemopoietic	0	O
origin	0	O
suggesting	0	O
that	0	O
its	0	O
expression	0	O
is	0	O
induced	0	O
accompanying	0	O
tumorigenesis	0	O
in	0	O
solid	0	O
tissues	0	O
.	0	O


PURPOSE	0	O
:	0	O
The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
evaluate	0	O
the	0	O
bony	0	O
anchorage	0	O
of	0	O
a	0	O
new	0	O
implant	0	O
(	0	O
orderly	0	O
wired	0	O
surface	0	O
effect	0	O
with	0	O
alloy	0	O
Ti	1	O
Al	1	O
Va	1	O
and	0	O
ordered	0	O
pores	0	O
of	0	O
488	0	O
mu	0	O
).	0	O


National	0	O
certification	0	O
:	0	O
a	0	O
vital	0	O
component	0	O
of	0	O
quality	0	O
assurance	0	O
.	0	O


This	0	O
GAP	1	B
activity	0	O
was	0	O
observed	0	O
in	0	O
3T3	0	O
-	0	O
L1	0	O
adipocyte	0	O
lysates	0	O
,	0	O
and	0	O
was	0	O
able	0	O
to	0	O
accelerate	0	O
the	0	O
hydrolysis	0	O
of	0	O
the	0	O
[	0	O
alpha	0	O
-	0	O
32P	0	O
]	0	O
GTP	1	O
bound	0	O
to	0	O
GST	0	B
-	0	O
Rab4	0	B
into	0	O
[	0	O
alpha	0	O
-	0	O
32P	0	O
]	0	O
GDP	1	O
.	0	O


Furthermore	0	O
,	0	O
45Ca	0	O
-	0	O
binding	0	O
assays	0	O
revealed	0	O
that	0	O
CCaMK	0	B
directly	0	O
binds	0	O
Ca2	1	O
+.	0	O


IFN	1	B
-	0	I
stimulated	0	I
gene	0	I
factor	0	I
-	0	I
3	0	I
and	0	O
STAT1	0	B
homodimers	0	I
formed	0	O
and	0	O
bound	0	O
an	0	O
IFN	1	B
-	0	I
stimulated	0	I
response	0	I
element	0	I
(	0	O
ISRE	0	B
)	0	O
and	0	O
gamma	0	B
-	0	I
activated	0	I
sequence	0	I
(	0	O
GAS	1	B
)	0	O
element	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
5	0	O
'	0	O
regions	0	O
of	0	O
these	0	O
two	0	O
soybean	0	B
actin	0	I
genes	0	I
contain	0	O
many	0	O
unusual	0	O
features	0	O
including	0	O
(	0	O
CT	1	O
)	0	O
repeats	0	O
and	0	O
long	0	O
stretches	0	O
of	0	O
pyrimidine	0	O
-	0	O
rich	0	O
DNA	1	O
.	0	O


5	0	O
microU	0	O
/	0	O
l	0	O
thyrotropin	0	B
:	0	O
75	0	O
%	0	O
(	0	O
1974	0	O
),	0	O
45	0	O
%	0	O
(	0	O
1977	0	O
)	0	O
and	0	O
20	0	O
%	0	O
(	0	O
1980	0	O
).	0	O


We	0	O
have	0	O
determined	0	O
that	0	O
these	0	O
nicks	0	O
occur	0	O
in	0	O
both	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
the	0	O
mutant	0	O
sites	0	O
.	0	O


Aneurysmectomy	1	O
and	0	O
the	0	O
performance	0	O
of	0	O
CABG	1	O
were	0	O
not	0	O
significantly	0	O
associated	0	O
with	0	O
postoperative	0	O
ECG	1	O
changes	0	O
,	0	O
but	0	O
more	0	O
bypass	0	O
grafts	0	O
per	0	O
patient	0	O
grafted	0	O
appeared	0	O
in	0	O
the	0	O
group	0	O
with	0	O
postoperative	0	O
ECG	1	O
changes	0	O
,	0	O
suggesting	0	O
that	0	O
coronary	0	O
artery	0	O
disease	0	O
may	0	O
be	0	O
more	0	O
severe	0	O
in	0	O
that	0	O
group	0	O
.	0	O


Chernoff	0	O
,	0	O
submitted	0	O
for	0	O
publication	0	O
).	0	O


The	0	O
encoded	0	O
polypeptide	0	O
is	0	O
similar	0	O
in	0	O
sequence	0	O
to	0	O
the	0	O
ABA	0	B
-	0	I
1	0	I
allergen	0	I
of	0	I
Ascaris	1	I
,	0	O
the	0	O
gp15	0	B
/	0	I
400	0	I
'	0	I
ladder	0	I
'	0	I
protein	0	I
of	0	I
Brugia	1	I
malayi	0	I
,	0	I
Brugia	1	I
pahangi	0	I
and	0	I
Wuchereria	1	I
bancrofti	0	I
,	0	O
and	0	O
a	0	O
15	0	B
-	0	I
kDa	1	I
antigen	0	I
of	0	I
Dirofilaria	1	I
immitis	0	I
.	0	O


To	1	O
test	0	O
the	0	O
hypothesis	0	O
that	0	O
progestin	0	O
-	0	O
mediated	0	O
increases	0	O
in	0	O
resting	0	O
core	0	O
temperature	0	O
and	0	O
the	0	O
core	0	O
temperature	0	O
threshold	0	O
for	0	O
sweating	0	O
onset	0	O
are	0	O
counteracted	0	O
by	0	O
estrogen	0	O
,	0	O
we	0	O
studied	0	O
eight	0	O
women	0	O
(	0	O
24	0	O
+/-	0	O
2	0	O
yr	0	O
)	0	O
at	0	O
27	0	O
degrees	0	O
C	1	O
rest	0	O
,	0	O
during	0	O
20	0	O
min	0	O
of	0	O
passive	0	O
heating	0	O
(	0	O
35	0	O
degrees	0	O
C	1	O
),	0	O
and	0	O
during	0	O
40	0	O
min	0	O
of	0	O
exercise	0	O
at	0	O
35	0	O
degrees	0	O
C	1	O
.	0	O


A	1	O
new	0	O
technique	0	O
to	0	O
create	0	O
an	0	O
artificial	0	O
stenosis	0	O
in	0	O
the	0	O
native	0	O
LAD	1	O
using	0	O
a	0	O
hemoclip	0	O
.	0	O


Effects	0	O
of	0	O
single	0	O
and	0	O
combined	0	O
maltose	0	O
tetrapalmitate	0	O
immunotherapy	0	O
,	0	O
cyclophosphamide	0	O
chemotherapy	0	O
and	0	O
radiotherapy	0	O
on	0	O
ethyl	0	O
carbamate	0	O
accelerated	0	O
primary	0	O
lung	0	O
cancer	0	O
in	0	O
A	1	O
/	0	O
J	1	O
mice	0	O
.	0	O


However	0	O
,	0	O
although	0	O
deletion	0	O
of	0	O
Fp1	0	B
in	0	O
the	0	O
hCRBP1	0	B
gene	0	I
yielded	0	O
increased	0	O
CAT	1	B
activity	0	O
,	0	O
pointing	0	O
toward	0	O
a	0	O
negative	0	O
regulatory	0	O
function	0	O
exerted	0	O
by	0	O
this	0	O
element	0	O
,	0	O
its	0	O
insertion	0	O
upstream	0	O
of	0	O
the	0	O
p12	0	B
basal	0	I
promoter	0	I
results	0	O
in	0	O
an	0	O
impressive	0	O
positive	0	O
stimulation	0	O
of	0	O
CAT	1	B
gene	0	I
expression	0	O
.	0	O


The	0	O
appearance	0	O
of	0	O
dyskinetic	0	O
movement	0	O
disorders	0	O
in	0	O
humans	0	O
following	0	O
the	0	O
chronic	0	O
use	0	O
of	0	O
levodopa	0	O
or	0	O
amphetamine	0	O
may	0	O
be	0	O
a	0	O
manifestation	0	O
of	0	O
similarly	0	O
increased	0	O
dopamine	0	B
receptor	0	I
site	0	I
sensitivity	0	O
within	0	O
the	0	O
striatum	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
cDNA	1	O
-	0	O
predicted	0	O
avian	0	B
TnIcardiac	0	I
amino	0	I
acid	0	I
sequences	0	I
with	0	O
known	0	O
TnI	0	B
sequences	0	I
indicated	0	O
1	0	O
)	0	O
that	0	O
the	0	O
presence	0	O
of	0	O
an	0	O
N	1	O
-	0	O
terminal	0	O
extension	0	O
sequence	0	O
carrying	0	O
a	0	O
dual	0	O
protein	0	B
kinase	0	I
A	1	I
phosphorylation	0	O
target	0	O
site	0	O
and	0	O
an	0	O
adjacent	0	O
proline	0	O
-	0	O
rich	0	O
segment	0	O
is	0	O
an	0	O
ancient	0	O
cardiac	0	O
-	0	O
specific	0	O
feature	0	O
of	0	O
TnI	0	B
which	0	O
has	0	O
been	0	O
conserved	0	O
since	0	O
the	0	O
bird	0	O
/	0	O
mammal	0	O
divergence	0	O
,	0	O
2	0	O
)	0	O
that	0	O
features	0	O
of	0	O
the	0	O
near	0	O
-	0	O
N	1	O
-	0	O
terminal	0	O
troponin	0	B
C	1	I
(	0	O
TnC	0	B
)-	0	O
binding	0	O
site	0	O
sequence	0	O
suggest	0	O
isoform	0	O
-	0	O
specific	0	O
adaptation	0	O
of	0	O
TnI	0	B
and	0	O
TnC	0	B
,	0	O
and	0	O
3	0	O
)	0	O
that	0	O
the	0	O
avian	0	O
TnIcardiac	0	B
internal	0	O
actin	0	B
/	0	I
TnC	0	I
-	0	I
binding	0	I
,	0	I
actomyosin	0	I
-	0	I
inhibitory	0	I
,	0	I
domain	0	I
shows	0	O
significant	0	O
sequence	0	O
divergence	0	O
from	0	O
mammalian	0	B
TnIcardiac	0	I
sequences	0	I
,	0	O
including	0	O
the	0	O
absence	0	O
of	0	O
a	0	O
protein	0	B
kinase	0	I
C	1	I
target	0	O
site	0	O
which	0	O
is	0	O
a	0	O
cardiac	0	O
-	0	O
specific	0	O
feature	0	O
of	0	O
TnI	0	B
in	0	O
mammals	0	O
.	0	O


Thirty	0	O
Class	1	O
I	1	O
and	0	O
Class	1	O
II	0	O
recessions	0	O
in	0	O
30	0	O
patients	0	O
were	0	O
treated	0	O
with	0	O
a	0	O
modified	0	O
subepithelial	0	O
connective	0	O
tissue	0	O
graft	0	O
procedure	0	O
.	0	O


The	0	O
predictive	0	O
value	0	O
of	0	O
a	0	O
positive	0	O
flag	0	O
was	0	O
77	0	O
.	0	O
7	0	O
%.	0	O


Mutations	0	O
of	0	O
the	0	O
RET	0	B
gene	0	I
,	0	O
encoding	0	O
a	0	O
receptor	0	B
tyrosine	0	I
kinase	0	I
,	0	O
have	0	O
been	0	O
associated	0	O
with	0	O
the	0	O
inherited	0	O
cancer	0	O
syndromes	0	O
MEN	1	O
2A	0	O
and	0	O
MEN	1	O
2B	0	O
.	0	O


However	0	O
,	0	O
the	0	O
use	0	O
of	0	O
cyclosporin	0	O
A	1	O
is	0	O
associated	0	O
with	0	O
an	0	O
increased	0	O
prevalence	0	O
of	0	O
hypertension	0	O
in	0	O
kidney	0	O
transplant	0	O
recipients	0	O
.	0	O


A	1	O
study	0	O
was	0	O
performed	0	O
to	0	O
compare	0	O
the	0	O
ONLINE	0	O
and	0	O
EMIT	1	O
II	0	O
immunoassays	0	O
with	0	O
gas	0	O
chromatographic	0	O
/	0	O
mass	0	O
spectrometric	0	O
(	0	O
GC	1	O
/	0	O
MS	1	O
)	0	O
analysis	0	O
of	0	O
methaqualone	0	O
metabolites	0	O
on	0	O
urine	0	O
using	0	O
samples	0	O
obtained	0	O
from	0	O
a	0	O
clinical	0	O
study	0	O
.	0	O


Since	0	O
the	0	O
morphology	0	O
of	0	O
the	0	O
lesions	0	O
can	0	O
mimic	0	O
that	0	O
of	0	O
other	0	O
cutaneous	0	O
disorders	0	O
,	0	O
Bowen	0	O
'	0	O
s	0	O
disease	0	O
is	0	O
often	0	O
not	0	O
recognized	0	O
initially	0	O
.	0	O


IgE	1	B
levels	0	O
showed	0	O
higher	0	O
values	0	O
compared	0	O
to	0	O
normal	0	O
individuals	0	O
and	0	O
IgE	1	B
levels	0	O
were	0	O
higher	0	O
in	0	O
children	0	O
groups	0	O
than	0	O
in	0	O
adults	0	O
regardless	0	O
of	0	O
the	0	O
intensity	0	O
of	0	O
infection	0	O
.	0	O


This	0	O
sequenced	0	O
region	0	O
of	0	O
the	0	O
V	1	O
beta	0	O
locus	0	O
contains	0	O
an	0	O
average	0	O
number	0	O
of	0	O
repetitive	0	O
DNA	1	O
elements	0	O
(	0	O
21	0	O
Alu	0	B
,	0	O
three	0	O
L1	0	B
,	0	O
three	0	O
MER	1	O
,	0	O
and	0	O
three	0	O
retrovirus	0	O
-	0	O
related	0	O
elements	0	O
.	0	O


The	0	O
mucosal	0	O
defence	0	O
capacity	0	O
against	0	O
proteolytic	0	O
leukocyte	0	O
enzymes	0	O
.	0	O


Distribution	1	O
and	0	O
correlations	0	O
of	0	O
serum	0	O
uric	0	O
-	0	O
acid	0	O
in	0	O
two	0	O
French	1	O
adult	0	O
populations	0	O
:	0	O
13	0	O
,	0	O
885	0	O
men	0	O
and	0	O
6	0	O
,	0	O
861	0	O
women	0	O


The	0	O
p53	0	B
-	0	I
homolog	0	I
p73beta	0	I
also	0	O
activated	0	O
the	0	O
PIG3	0	B
promoter	0	I
,	0	O
but	0	O
in	0	O
contrast	0	O
to	0	O
p53	0	B
,	0	O
the	0	O
proline	0	O
-	0	O
rich	0	O
domain	0	O
of	0	O
p73beta	0	B
(	0	I
residues	0	I
81	0	I
-	0	I
113	0	I
)	0	I
was	0	O
dispensable	0	O
to	0	O
induce	0	O
the	0	O
PIG3	0	B
promoter	0	I
.	0	O


However	0	O
,	0	O
it	0	O
is	0	O
not	0	O
known	0	O
whether	0	O
the	0	O
recently	0	O
identified	0	O
isoforms	0	O
Vav2	0	B
and	0	O
Vav3	0	B
,	0	O
which	0	O
are	0	O
broadly	0	O
expressed	0	O
,	0	O
can	0	O
couple	0	O
with	0	O
similar	0	O
classes	0	O
of	0	O
receptors	0	O
,	0	O
nor	0	O
is	0	O
it	0	O
known	0	O
whether	0	O
all	0	O
Vav	0	B
isoforms	0	I
possess	0	O
identical	0	O
functional	0	O
activities	0	O
.	0	O


Expression	1	O
in	0	O
early	0	O
postnatal	0	O
pituitary	0	O
and	0	O
in	0	O
pre	0	O
-	0	O
somatotrophic	0	O
cells	0	O
suggests	0	O
that	0	O
Zn	1	B
-	0	I
16	0	I
could	0	O
play	0	O
a	0	O
role	0	O
in	0	O
pituitary	0	O
development	0	O
prior	0	O
to	0	O
somatotroph	0	O
differentiation	0	O
.	0	O


Determination	1	O
of	0	O
three	0	O
-	0	O
dimensional	0	O
imaging	0	O
properties	0	O
of	0	O
a	0	O
light	0	O
microscope	0	O
system	0	O
.	0	O


The	0	O
article	0	O
deals	0	O
with	0	O
the	0	O
diagnosing	0	O
and	0	O
correction	0	O
of	0	O
reversible	0	O
ischemia	0	O
of	0	O
the	0	O
intestine	0	O
.	0	O


In	1	O
18	0	O
%	0	O
lymphography	0	O
was	0	O
clearly	0	O
positive	0	O
and	0	O
CT	1	O
negative	0	O
.	0	O


Orientation	1	O
of	0	O
the	0	O
nuclear	0	O
spin	0	O
system	0	O
by	0	O
optical	0	O
pumping	0	O
causes	0	O
an	0	O
Overhauser	0	O
shift	0	O
of	0	O
the	0	O
excitonic	0	O
energy	0	O
levels	0	O
proportional	0	O
to	0	O
the	0	O
degree	0	O
of	0	O
nuclear	0	O
orientation	0	O
.	0	O


Five	0	O
control	0	O
subjects	0	O
with	0	O
COPD	1	O
,	0	O
who	0	O
performed	0	O
the	0	O
same	0	O
sequence	0	O
of	0	O
tests	0	O
without	0	O
breathing	0	O
30	0	O
%	0	O
O2	1	O
,	0	O
showed	0	O
no	0	O
change	0	O
in	0	O
flow	0	O
rates	0	O
or	0	O
density	0	O
dependence	0	O
.	0	O


The	0	O
final	0	O
screening	0	O
yielded	0	O
a	0	O
clone	0	O
containing	0	O
a	0	O
2	0	O
kilobase	0	O
(	0	O
kb	0	O
)	0	O
insert	0	O
.	0	O


Overexpression	1	O
of	0	O
mcl	0	B
-	0	I
1	0	I
is	0	O
sufficient	0	O
to	0	O
protect	0	O
against	0	O
apoptosis	0	O
,	0	O
while	0	O
transfection	0	O
of	0	O
a	0	O
mcl	0	B
-	0	I
1	0	I
antisense	0	O
plasmid	0	O
causes	0	O
cell	0	O
death	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
resensitization	0	O
of	0	O
a	0	O
sequestration	0	O
-	0	O
impaired	0	O
beta2AR	0	B
mutant	0	O
(	0	O
Y326A	0	O
)	0	O
was	0	O
reestablished	0	O
following	0	O
the	0	O
overexpression	0	O
of	0	O
either	0	O
GRK2	0	B
or	0	O
beta	0	B
-	0	I
arrestin	0	I
1	0	I
.	0	O


A	1	O
specific	0	O
distal	0	O
promoter	0	O
controls	0	O
gamma	0	B
-	0	I
glutamyl	0	I
transpeptidase	0	I
gene	0	I
expression	0	O
in	0	O
undifferentiated	0	O
rat	0	O
transformed	0	O
liver	0	O
cells	0	O
.	0	O


The	0	O
location	0	O
of	0	O
the	0	O
IBS	1	O
within	0	O
the	0	O
catB	0	B
structural	0	I
gene	0	I
,	0	O
the	0	O
cooperativity	0	O
observed	0	O
in	0	O
footprinting	0	O
studies	0	O
and	0	O
phasing	0	O
studies	0	O
suggest	0	O
that	0	O
the	0	O
IBS	1	O
participates	0	O
in	0	O
the	0	O
interaction	0	O
of	0	O
CatR	0	B
with	0	O
the	0	O
upstream	0	O
binding	0	O
sites	0	O
by	0	O
looping	0	O
out	0	O
the	0	O
intervening	0	O
DNA	1	O
.	0	O


A	1	O
73	0	O
bp	0	O
fragment	0	O
(	0	O
X1	0	O
region	0	O
)	0	O
of	0	O
the	0	O
PRB	0	B
-	0	I
1b	0	I
promoter	0	I
,	0	O
located	0	O
between	0	O
positions	0	O
-	0	O
213	0	O
and	0	O
-	0	O
141	0	O
,	0	O
was	0	O
sufficient	0	O
to	0	O
confer	0	O
ethylene	0	O
responsiveness	0	O
to	0	O
the	0	O
reporter	0	O
gene	0	O
.	0	O


In	1	O
Saccharomyces	1	O
cerevisiae	0	O
the	0	O
cAMP	1	B
-	0	I
dependent	0	I
kinases	0	I
(	0	O
PKAs	0	B
)	0	O
promote	0	O
cytoplasmic	0	O
growth	0	O
and	0	O
modulate	0	O
the	0	O
growth	0	O
-	0	O
regulated	0	O
mechanism	0	O
triggering	0	O
the	0	O
begin	0	O
of	0	O
DNA	1	O
synthesis	0	O
.	0	O


In	1	O
patients	0	O
who	0	O
had	0	O
received	0	O
no	0	O
previous	0	O
drug	0	O
treatment	0	O
,	0	O
log	0	O
baseline	0	O
plasma	0	B
renin	0	I
activity	0	O
and	0	O
change	0	O
in	0	O
mean	0	O
blood	0	O
pressure	0	O
after	0	O
SQ	1	O
20881	0	O
correlated	0	O
significantly	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
651	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


In	1	O
vitro	0	O
studies	0	O
with	0	O
blood	0	O
cells	0	O
incubated	0	O
with	0	O
acetate	0	O
or	0	O
bicarbonate	0	O
ions	0	O
in	0	O
concentrations	0	O
,	0	O
which	0	O
are	0	O
observed	0	O
in	0	O
vivo	0	O
during	0	O
hemodialysis	0	O
,	0	O
suggest	0	O
that	0	O
probably	0	O
these	0	O
ions	0	O
do	0	O
not	0	O
directly	0	O
affect	0	O
superoxide	0	O
anions	0	O
generation	0	O
,	0	O
erythrocyte	0	O
SOD	0	B
-	0	I
1	0	I
and	0	O
catalase	0	B
activities	0	O
and	0	O
erythrocyte	0	O
membrane	0	O
lipid	0	O
peroxidation	0	O
.	0	O


Characterisation	0	O
of	0	O
the	0	O
chicken	0	B
apolipoprotein	0	I
A	1	I
-	0	I
I	1	I
gene	0	I
5	0	O
'-	0	O
flanking	0	O
region	0	O
.	0	O


The	0	O
bile	0	O
acid	0	O
sequestrants	0	O
(	0	O
cholestyramine	0	O
and	0	O
colestipol	0	O
),	0	O
nicotinic	0	O
acid	0	O
,	0	O
fenofibrate	0	O
and	0	O
inhibitors	0	O
of	0	O
hydroxymethylglutaryl	0	B
coenzyme	0	I
A	1	I
(	0	I
HMG	1	I
CoA	1	I
)	0	I
reductase	0	I
(	0	O
e	0	O
.	0	O
g	0	O
.	0	O
lovastatin	0	O
or	0	O
simvastatin	0	O
)	0	O
are	0	O
the	0	O
most	0	O
effective	0	O
drugs	0	O
for	0	O
use	0	O
in	0	O
patients	0	O
with	0	O
primary	0	O
hypercholesterolaemia	0	O
;	0	O
these	0	O
agents	0	O
reduce	0	O
plasma	0	O
concentrations	0	O
of	0	O
total	0	O
and	0	O
LDL	1	B
-	0	I
cholesterol	0	I
by	0	O
15	0	O
to	0	O
45	0	O
%.	0	O


The	0	O
customary	0	O
coupling	0	O
reagent	0	O
sulfanilic	0	O
acid	0	O
has	0	O
been	0	O
replaced	0	O
by	0	O
1	0	O
,	0	O
3	0	O
-	0	O
dimethylbarbituric	0	O
acid	0	O
;	0	O
CNCl	0	O
is	0	O
produced	0	O
in	0	O
the	0	O
flow	0	O
through	0	O
system	0	O
directly	0	O
from	0	O
KCN	0	O
and	0	O
chloramine	0	O
T	1	O
.	0	O


Some	0	O
of	0	O
the	0	O
PCR	1	O
products	0	O
contained	0	O
mutations	0	O
in	0	O
ATG1	0	B
and	0	O
/	0	O
or	0	O
ATG2	0	B
.	0	O


GCR1	0	B
gene	0	I
function	0	O
is	0	O
required	0	O
for	0	O
high	0	O
-	0	O
level	0	O
glycolytic	0	O
gene	0	O
expression	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


These	0	O
results	0	O
demonstrate	0	O
that	0	O
a	0	O
class	0	O
of	0	O
proline	0	O
-	0	O
rich	0	O
activator	0	O
proteins	0	O
and	0	O
RNA	1	B
polymerase	0	I
II	0	I
possess	0	O
a	0	O
common	0	O
structural	0	O
and	0	O
functional	0	O
component	0	O
which	0	O
can	0	O
interact	0	O
with	0	O
the	0	O
same	0	O
target	0	O
in	0	O
the	0	O
general	0	O
transcription	0	O
machinery	0	O
.	0	O


The	0	O
latency	0	O
time	0	O
for	0	O
the	0	O
lactate	0	O
concentration	0	O
to	0	O
reach	0	O
the	0	O
top	0	O
values	0	O
was	0	O
reduced	0	O
by	0	O
aerobic	0	O
training	0	O
(	0	O
T2	0	O
).	0	O


A	1	O
comparative	0	O
analysis	0	O
of	0	O
the	0	O
reported	0	O
MOCT	0	O
-	0	O
associated	0	O
malignant	0	O
melanomas	0	O
emphasizes	0	O
the	0	O
singularity	0	O
of	0	O
our	0	O
case	0	O
in	0	O
the	0	O
amelanotic	0	O
character	0	O
of	0	O
the	0	O
melanoma	0	O
,	0	O
its	0	O
lymphotropism	0	O
and	0	O
the	0	O
coexistence	0	O
of	0	O
invasive	0	O
squamous	0	O
cell	0	O
carcinoma	0	O
.	0	O


Allergenic	1	O
activity	0	O
of	0	O
allergen	0	O
extract	0	O
Ambrosia	1	O
elatior	0	O
(	0	O
AE	1	O
)	0	O
was	0	O
tested	0	O
in	0	O
fifteen	0	O
volunteers	0	O
extremely	0	O
sensitive	0	O
to	0	O
the	0	O
allergen	0	O
.	0	O


Comparable	0	O
amounts	0	O
of	0	O
alpha	0	B
5	0	I
beta	0	I
1	0	I
integrin	0	I
were	0	O
isolated	0	O
from	0	O
these	0	O
cells	0	O
by	0	O
chromatography	0	O
of	0	O
detergent	0	O
extracts	0	O
on	0	O
a	0	O
fibronectin	0	B
cell	0	O
-	0	O
binding	0	O
fragment	0	O
affinity	0	O
column	0	O
and	0	O
elution	0	O
with	0	O
EDTA	1	O
.	0	O


These	0	O
observations	0	O
provide	0	O
strong	0	O
support	0	O
for	0	O
the	0	O
idea	0	O
that	0	O
expression	0	O
of	0	O
mutant	0	O
tRNA	1	O
can	0	O
confer	0	O
a	0	O
mutator	0	O
phenotype	0	O
,	0	O
including	0	O
the	0	O
UVM	0	O
-	0	O
constitutive	0	O
phenotype	0	O
observed	0	O
in	0	O
mutA	0	B
and	0	O
mutC	0	B
cells	0	O
.	0	O


These	0	O
offspring	0	O
of	0	O
the	0	O
alpha	0	B
-	0	I
MSH	1	I
treated	0	O
mothers	0	O
were	0	O
less	0	O
sensitive	0	O
to	0	O
pain	0	O
and	0	O
as	0	O
adults	0	O
showed	0	O
a	0	O
reduced	0	O
analgesic	0	O
response	0	O
to	0	O
morphine	0	O
.	0	O


Finally	0	O
,	0	O
a	0	O
complementary	0	O
footprinting	0	O
analysis	0	O
of	0	O
the	0	O
upstream	0	O
region	0	O
of	0	O
the	0	O
constitutively	0	O
expressed	0	O
HSC82	0	B
gene	0	I
reveals	0	O
the	0	O
presence	0	O
of	0	O
three	0	O
discrete	0	O
protein	0	O
complexes	0	O
.	0	O


In	1	O
marked	0	O
contrast	0	O
to	0	O
AgfA	0	B
,	0	O
none	0	O
of	0	O
the	0	O
chimeric	0	B
SefA	0	I
proteins	0	I
were	0	O
expressed	0	O
or	0	O
assembled	0	O
into	0	O
fimbriae	0	O
.	0	O


These	0	O
two	0	O
mAbs	0	O
used	0	O
the	0	O
same	0	O
V	1	O
(	0	O
H	1	O
)	0	O
and	0	O
J	1	O
(	0	O
H	1	O
)	0	O
gene	0	O
segments	0	O
,	0	O
but	0	O
different	0	O
D	1	O
,	0	O
Vkappa	0	O
,	0	O
and	0	O
Jkappa	0	O
genes	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
identified	0	O
three	0	O
cis	0	O
-	0	O
elements	0	O
required	0	O
for	0	O
replication	0	O
within	0	O
the	0	O
200	0	O
bp	0	O
promoter	0	O
,	0	O
using	0	O
autonomously	0	O
replicating	0	O
plasmids	0	O
carrying	0	O
various	0	O
mutations	0	O
and	0	O
deletions	0	O
.	0	O


No	1	O
difference	0	O
in	0	O
the	0	O
clinical	0	O
acceptability	0	O
could	0	O
be	0	O
ascertained	0	O
between	0	O
the	0	O
two	0	O
groups	0	O
.	0	O


(	0	O
1989	0	O
),	0	O
which	0	O
is	0	O
identical	0	O
to	0	O
the	0	O
SSC1	0	B
gene	0	I
(	0	O
Smith	0	O
et	0	O
al	0	O
.,	0	O
1988	0	O
).	0	O


Genomic	1	O
DNA	1	O
sequencing	0	O
in	0	O
the	0	O
vicinity	0	O
of	0	O
methylmalonyl	0	B
-	0	I
CoA	1	I
mutase	0	I
gene	0	I
(	0	O
mutAB	0	B
)	0	O
from	0	O
a	0	O
rifamycin	0	O
SV	1	O
-	0	O
producing	0	O
Amycolatopsis	1	O
mediterranei	0	O
U32	0	O
allowed	0	O
us	0	O
to	0	O
clone	0	O
,	0	O
sequence	0	O
,	0	O
and	0	O
identify	0	O
a	0	O
gene	0	O
encoding	0	O
a	0	O
novel	0	O
serine	0	B
/	0	I
threonine	0	I
protein	0	I
kinase	0	I
(	0	O
amk	0	B
).	0	O


We	0	O
show	0	O
that	0	O
c	0	B
-	0	I
Fos	1	I
(	0	O
the	0	O
c	0	B
-	0	I
fos	0	I
protooncogene	0	I
product	0	I
),	0	O
which	0	O
is	0	O
an	0	O
intrinsically	0	O
unstable	0	O
nuclear	0	O
protein	0	O
,	0	O
is	0	O
metabolically	0	O
highly	0	O
stabilized	0	O
,	0	O
and	0	O
greatly	0	O
enhances	0	O
the	0	O
transforming	0	O
efficiency	0	O
of	0	O
NIH	1	O
3T3	0	O
cells	0	O
,	0	O
by	0	O
Mos	1	B
.	0	O


Theory	1	O
and	0	O
applications	0	O
of	0	O
pulse	0	O
dosing	0	O
:	0	O
a	0	O
summary	0	O
of	0	O
the	0	O
symposium	0	O
.	0	O


Hb	1	B
levels	0	O
remained	0	O
adequate	0	O
(	0	O
Hb	1	B
=	0	O
10	0	O
.	0	O
68	0	O
+/-	0	O
0	0	O
.	0	O
77	0	O
g	0	O
/	0	O
dl	0	O
)	0	O
after	0	O
14	0	O
.	0	O
6	0	O
+/-	0	O
7	0	O
.	0	O
64	0	O
months	0	O
.	0	O


Processing	1	O
of	0	O
the	0	O
NS3	0	O
'-	0	O
5B	0	B
polyprotein	0	O
was	0	O
complex	0	O
and	0	O
occurred	0	O
rapidly	0	O
.	0	O


The	0	O
maximal	0	O
effect	0	O
was	0	O
seen	0	O
at	0	O
100	0	O
ng	0	O
/	0	O
ml	0	O
EGF	1	B
,	0	O
with	0	O
a	0	O
time	0	O
lag	0	O
of	0	O
about	0	O
5	0	O
h	0	O
.	0	O


To	1	O
determine	0	O
whether	0	O
food	0	O
and	0	O
/	0	O
or	0	O
water	0	O
in	0	O
the	0	O
gastrointestinal	0	O
tract	0	O
affects	0	O
restitution	0	O
of	0	O
blood	0	O
volume	0	O
and	0	O
plasma	0	O
protein	0	O
after	0	O
hemorrhage	0	O
,	0	O
fed	0	O
and	0	O
24	0	O
-	0	O
h	0	O
-	0	O
fasted	0	O
awake	0	O
rats	0	O
received	0	O
a	0	O
20	0	O
ml	0	O
.	0	O
kg	0	O
-	0	O
1	0	O
x	0	O
3	0	O
min	0	O
-	0	O
1	0	O
hemorrhage	0	O
,	0	O
and	0	O
restitution	0	O
of	0	O
blood	0	O
volume	0	O
was	0	O
measured	0	O
by	0	O
Evans	0	O
blue	0	O
dye	0	O
and	0	O
dilution	0	O
of	0	O
hematocrit	0	O
.	0	O


Two	0	O
polyadenylation	0	O
sites	0	O
were	0	O
used	0	O
,	0	O
one	0	O
at	0	O
the	0	O
end	0	O
of	0	O
the	0	O
early	0	B
(	0	I
E	1	I
)	0	I
region	0	I
of	0	O
the	0	O
viral	0	O
DNA	1	O
,	0	O
the	0	O
other	0	O
at	0	O
the	0	O
end	0	O
of	0	O
the	0	O
late	0	B
(	0	I
L	1	I
)	0	I
region	0	I
.	0	O


This	0	O
article	0	O
will	0	O
briefly	0	O
review	0	O
the	0	O
published	0	O
data	0	O
on	0	O
the	0	O
morphology	0	O
,	0	O
function	0	O
,	0	O
and	0	O
biochemistry	0	O
of	0	O
the	0	O
normal	0	O
renal	0	O
medulla	0	O
and	0	O
the	0	O
pathology	0	O
associated	0	O
with	0	O
RPN	0	O
,	0	O
together	0	O
with	0	O
the	0	O
secondary	0	O
changes	0	O
which	0	O
give	0	O
rise	0	O
to	0	O
cortical	0	O
degeneration	0	O
or	0	O
epithelial	0	O
carcinoma	0	O
.	0	O


Here	0	O
we	0	O
describe	0	O
a	0	O
mutant	0	O
alpha	0	O
subunit	0	O
designed	0	O
to	0	O
inhibit	0	O
receptor	0	O
-	0	O
mediated	0	O
hormonal	0	O
activation	0	O
of	0	O
Gs	0	B
,	0	O
the	0	O
stimulatory	0	O
regulator	0	O
of	0	O
adenylyl	0	B
cyclase	0	I
.	0	O


The	0	O
second	0	O
class	0	O
of	0	O
cDNA	1	O
hybridized	0	O
to	0	O
a	0	O
13	0	O
kb	0	O
transcript	0	O
,	0	O
which	0	O
was	0	O
approximately	0	O
twice	0	O
as	0	O
large	0	O
as	0	O
the	0	O
mammalian	0	B
lactase	0	I
mRNA	1	I
.	0	O


Mo	1	O
+	0	O
SV	1	O
M	1	O
-	0	O
MuLV	0	O
-	0	O
inoculated	0	O
animals	0	O
became	0	O
moribund	0	O
at	0	O
3	0	O
to	0	O
13	0	O
months	0	O
postinoculation	0	O
,	0	O
whereas	0	O
delta	0	O
Mo	1	O
+	0	O
SV	1	O
M	1	O
-	0	O
MuLV	0	O
-	0	O
inoculated	0	O
animals	0	O
became	0	O
moribund	0	O
at	0	O
6	0	O
to	0	O
24	0	O
months	0	O
postinoculation	0	O
.	0	O


PATIENTS	0	O
AND	0	O
METHODS	0	O
:	0	O
We	0	O
report	0	O
our	0	O
experience	0	O
with	0	O
seven	0	O
children	0	O
with	0	O
active	0	O
small	0	O
bowel	0	O
Crohn	0	O
'	0	O
s	0	O
disease	0	O
given	0	O
a	0	O
casein	0	B
-	0	O
based	0	O
,	0	O
polymeric	0	O
feed	0	O
rich	0	O
in	0	O
TGF	1	B
-	0	I
beta	0	I
2	0	I
(	0	O
Specific	1	O
Polymeric	1	O
Diet	1	O
;	0	O
Nestle	0	O
-	0	O
Clintec	0	O
;	0	O
Vevey	0	O
,	0	O
Switzerland	0	O
)	0	O
as	0	O
complete	0	O
nutrition	0	O
for	0	O
8	0	O
weeks	0	O
.	0	O


Our	0	O
analysis	0	O
suggests	0	O
that	0	O
Upf1p	0	B
is	0	O
a	0	O
multifunctional	0	O
protein	0	O
with	0	O
separable	0	O
activities	0	O
that	0	O
can	0	O
affect	0	O
mRNA	1	O
turnover	0	O
and	0	O
nonsense	0	O
suppression	0	O
.	0	O


Transforming	0	B
growth	0	I
factor	0	I
(	0	I
TGF	1	I
)-	0	I
beta1	0	I
induces	0	O
extracellular	0	O
matrix	0	O
deposition	0	O
and	0	O
proliferation	0	O
of	0	O
mesenchymal	0	O
cells	0	O
.	0	O


He	1	O
visited	0	O
our	0	O
hospital	0	O
and	0	O
left	0	O
solitary	0	O
renal	0	O
cyst	0	O
was	0	O
suspected	0	O
.	0	O


The	0	O
coexpression	0	O
of	0	O
full	0	O
-	0	O
length	0	O
expression	0	O
constructs	0	O
for	0	O
both	0	O
DBP	0	B
and	0	O
hepatic	0	B
leukemia	0	I
factor	0	I
resulted	0	O
in	0	O
a	0	O
dramatic	0	O
increase	0	O
in	0	O
activation	0	O
mediated	0	O
by	0	O
the	0	O
GAL4	0	B
-	0	O
DBP	0	B
fusion	0	O
proteins	0	O
,	0	O
suggesting	0	O
the	0	O
involvement	0	O
of	0	O
a	0	O
regulated	0	O
coactivator	0	O
in	0	O
this	0	O
process	0	O
.	0	O


Two	0	O
Pax2	0	B
/	0	I
5	0	I
/	0	I
8	0	I
-	0	I
binding	0	I
sites	0	I
in	0	O
Engrailed2	0	B
are	0	O
required	0	O
for	0	O
proper	0	O
initiation	0	O
of	0	O
endogenous	0	O
mid	0	O
-	0	O
hindbrain	0	O
expression	0	O
.	0	O


Such	0	O
a	0	O
change	0	O
may	0	O
involve	0	O
increased	0	O
mammary	0	O
utilization	0	O
of	0	O
pre	0	O
-	0	O
formed	0	O
long	0	O
-	0	O
chain	0	O
fatty	0	O
acid	0	O
and	0	O
increased	0	O
metabolism	0	O
of	0	O
glucose	0	O
via	0	O
glycolysis	0	O
.	0	O


Most	0	O
of	0	O
the	0	O
prepeptide	0	O
portion	0	O
of	0	O
the	0	O
precursor	0	O
polypeptide	0	O
is	0	O
encoded	0	O
by	0	O
the	0	O
next	0	O
three	0	O
exons	0	O
,	0	O
and	0	O
the	0	O
mature	0	O
form	0	O
of	0	O
IL	1	B
-	0	I
1	0	I
alpha	0	I
is	0	O
encoded	0	O
by	0	O
the	0	O
remaining	0	O
three	0	O
exons	0	O
.	0	O


The	0	O
5	0	O
'	0	O
flanking	0	O
regions	0	O
of	0	O
both	0	O
pelA	0	B
and	0	O
pelB	0	B
were	0	O
translationally	0	O
fused	0	O
to	0	O
the	0	O
beta	0	B
-	0	I
glucuronidase	0	I
gene	0	I
and	0	O
introduced	0	O
into	0	O
F	1	O
.	0	O
solani	0	O
f	0	O
.	0	O
sp	0	O
.	0	O
pisi	0	O
,	0	O
and	0	O
beta	0	B
-	0	I
glucuronidase	0	I
activities	0	O
of	0	O
the	0	O
transformants	0	O
were	0	O
measured	0	O
.	0	O


Endotoxemia	1	O
induced	0	O
by	0	O
gram	0	O
-	0	O
negative	0	O
bacteria	0	O
leads	0	O
to	0	O
endotoxic	0	O
shock	0	O
pathogenetically	0	O
stemming	0	O
from	0	O
the	0	O
integral	0	O
component	0	O
of	0	O
the	0	O
bacterial	0	O
wall	0	O
--	0	O
lipid	0	O
A	1	O
.	0	O


Relief	1	O
from	0	O
autoinhibition	0	O
and	0	O
a	0	O
subsequent	0	O
10	0	O
-	0	O
60	0	O
-	0	O
fold	0	O
increase	0	O
in	0	O
V	1	O
(	0	O
max	0	O
)	0	O
have	0	O
been	0	O
observed	0	O
upon	0	O
N	1	B
-	0	I
SH2	0	I
domain	0	I
engagement	0	O
by	0	O
a	0	O
specific	0	O
phosphotyrosyl	0	O
ligand	0	O
or	0	O
upon	0	O
deletion	0	O
of	0	O
the	0	O
SH2	0	B
domains	0	I
to	0	O
yield	0	O
the	0	O
catalytic	0	O
PTPase	0	B
domain	0	I
.	0	O


1	0	O
,	0	O
3	0	O
-	0	O
bis	0	O
(	0	O
2	0	O
-	0	O
chloroethyl	0	O
)-	0	O
1	0	O
-	0	O
nitrosourea	0	O
(	0	O
bcnu	0	O
)	0	O
and	0	O
other	0	O
nitrosoureas	0	O
in	0	O
cancer	0	O
treatment	0	O
:	0	O
a	0	O
review	0	O
.	0	O


For	0	O
example	0	O
,	0	O
introduction	0	O
of	0	O
immunogenic	0	O
and	0	O
purification	0	O
tag	0	O
sequences	0	O
into	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
coding	0	O
region	0	O
significantly	0	O
decreased	0	O
bop	0	B
gene	0	I
mRNA	1	I
and	0	O
protein	0	O
accumulation	0	O
.	0	O


Neither	0	O
CES1	0	B
nor	0	O
CES4	0	B
is	0	O
essential	0	O
for	0	O
cell	0	O
growth	0	O
,	0	O
and	0	O
a	0	O
double	0	O
deletion	0	O
mutant	0	O
is	0	O
viable	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
our	0	O
data	0	O
indicate	0	O
that	0	O
multiple	0	O
survival	0	O
pathways	0	O
are	0	O
triggered	0	O
via	0	O
this	0	O
receptor	0	O
,	0	O
whereas	0	O
NF	1	B
-	0	I
kappaB	0	I
/	0	O
Rel	0	B
and	0	O
PI	1	B
-	0	I
3K	0	I
are	0	O
crucial	0	O
for	0	O
CD40	0	B
-	0	O
induced	0	O
proliferation	0	O
.	0	O


Two	0	O
patients	0	O
were	0	O
treated	0	O
with	0	O
both	0	O
regimens	0	O
.	0	O


Selection	1	O
was	0	O
based	0	O
on	0	O
expression	0	O
of	0	O
an	0	O
integrated	0	O
DNA	1	O
fragment	0	O
containing	0	O
the	0	O
con	0	B
-	0	I
10	0	I
promoter	0	I
-	0	I
regulatory	0	I
region	0	I
followed	0	O
by	0	O
the	0	O
initial	0	O
segment	0	O
of	0	O
the	0	O
con	0	B
-	0	I
10	0	I
open	0	I
reading	0	I
frame	0	I
fused	0	O
in	0	O
frame	0	O
with	0	O
the	0	O
bacterial	0	B
hygromycin	0	I
B	1	I
phosphotransferase	0	I
structural	0	I
gene	0	I
(	0	O
con10	0	B
'-'	0	I
hph	0	I
).	0	O


Anamnestic	1	O
data	0	O
were	0	O
obtained	0	O
from	0	O
case	0	O
history	0	O
,	0	O
smoking	0	O
habits	0	O
were	0	O
not	0	O
known	0	O
in	0	O
collective	0	O
A	1	O
and	0	O
C	1	O
.	0	O


No	1	O
patient	0	O
had	0	O
a	0	O
history	0	O
of	0	O
excess	0	O
alcohol	0	O
intake	0	O
,	0	O
or	0	O
prolonged	0	O
intake	0	O
of	0	O
hepatotoxic	0	O
drugs	0	O
and	0	O
steroids	0	O
,	0	O
and	0	O
were	0	O
not	0	O
obese	0	O
or	0	O
malnourished	0	O
.	0	O


Absence	1	O
of	0	O
action	0	O
potentials	0	O
in	0	O
frog	0	O
slow	0	O
muscle	0	O
fibres	0	O
paralysed	0	O
by	0	O
botulinum	0	B
toxin	0	I
.	0	O


Neomycin	1	O
is	0	O
fairly	0	O
effective	0	O
against	0	O
staphylococci	0	O
,	0	O
less	0	O
effective	0	O
against	0	O
streptococci	0	O
,	0	O
and	0	O
fairly	0	O
effective	0	O
against	0	O
gram	0	O
-	0	O
negative	0	O
intestinal	0	O
organisms	0	O
.	0	O


Ha	1	B
-	0	I
RasV12	0	I
and	0	O
activated	0	O
proteins	0	O
in	0	O
both	0	O
the	0	O
extra	0	B
-	0	I
cellular	0	I
regulated	0	I
kinase	0	I
(	0	O
ERK	0	B
)	0	O
and	0	O
the	0	O
stress	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
(	0	O
SAPK	0	B
)	0	O
or	0	O
Jun	1	B
N	1	I
-	0	I
terminal	0	I
kinase	0	I
(	0	O
JNK	0	B
)	0	O
cascades	0	O
independently	0	O
stimulated	0	O
PEA3	0	B
-	0	O
mediated	0	O
gene	0	O
expression	0	O
.	0	O


Differential	1	O
regulation	0	O
of	0	O
the	0	O
alpha	0	B
/	0	I
beta	0	I
interferon	0	I
-	0	O
stimulated	0	O
Jak	1	B
/	0	O
Stat	1	B
pathway	0	O
by	0	O
the	0	O
SH2	0	B
domain	0	O
-	0	O
containing	0	O
tyrosine	0	B
phosphatase	0	I
SHPTP1	0	I
.	0	O


The	0	O
backbone	0	O
dynamics	0	O
of	0	O
residues	0	O
located	0	O
in	0	O
the	0	O
folded	0	O
part	0	O
of	0	O
CRP2	0	B
(	0	O
LIM2	0	B
)	0	O
R122A	0	B
have	0	O
been	0	O
characterized	0	O
by	0	O
proton	0	O
-	0	O
detected	0	O
(	0	O
15	0	O
)	0	O
N	1	O
NMR	1	O
spectroscopy	0	O
.	0	O


Clinical	1	O
aspects	0	O
and	0	O
therapy	0	O


Another	0	O
group	0	O
of	0	O
HIPP	0	O
-	0	O
and	0	O
HCX	0	O
-	0	O
lesioned	0	O
animals	0	O
trained	0	O
on	0	O
the	0	O
tasks	0	O
after	0	O
the	0	O
lesion	0	O
showed	0	O
reduced	0	O
impairments	0	O
of	0	O
the	0	O
type	0	O
described	0	O
above	0	O
,	0	O
suggesting	0	O
that	0	O
extrahippocampal	0	O
structures	0	O
trained	0	O
after	0	O
the	0	O
lesion	0	O
can	0	O
assume	0	O
the	0	O
role	0	O
of	0	O
the	0	O
hippocampus	0	O
to	0	O
some	0	O
degree	0	O
.	0	O


Here	0	O
we	0	O
show	0	O
that	0	O
the	0	O
type	0	O
of	0	O
tyrosine	0	B
kinase	0	I
receptor	0	I
stimulated	0	O
also	0	O
participates	0	O
in	0	O
the	0	O
nature	0	O
of	0	O
the	0	O
cAMP	1	O
effect	0	O
.	0	O


Competition	1	O
with	0	O
a	0	O
putative	0	O
MADS	0	B
box	0	I
consensus	0	O
binding	0	O
site	0	O
from	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
coordinately	0	O
regulated	0	O
opaque	0	B
-	0	I
phase	0	I
-	0	I
specific	0	I
gene	0	I
PEP1	0	I
(	0	O
SAP1	0	B
)	0	O
and	0	O
the	0	O
human	0	B
MADS	0	I
box	0	I
consensus	0	I
binding	0	I
site	0	I
for	0	O
serum	0	B
response	0	I
factor	0	I
demonstrated	0	O
that	0	O
one	0	O
of	0	O
the	0	O
three	0	O
complexes	0	O
formed	0	O
was	0	O
specific	0	O
to	0	O
the	0	O
OP4	0	B
sequence	0	I
.	0	O


Lesion	1	O
diameters	0	O
of	0	O
greater	0	O
than	0	O
20	0	O
mm	0	O
and	0	O
the	0	O
large	0	O
sessile	0	O
-	0	O
type	0	O
configurations	0	O
were	0	O
factors	0	O
that	0	O
were	0	O
associated	0	O
with	0	O
incomplete	0	O
removal	0	O
.	0	O


Response	1	O
was	0	O
extremely	0	O
poor	0	O
in	0	O
African	0	O
Americans	0	O
and	0	O
those	0	O
with	0	O
HCV	1	O
genotype	0	O
1	0	O
.	0	O


Consistent	0	O
with	0	O
its	0	O
role	0	O
in	0	O
p53	0	B
ubiquitination	0	O
,	0	O
mE6	0	B
-	0	I
AP	1	I
was	0	O
found	0	O
both	0	O
in	0	O
the	0	O
nucleus	0	O
and	0	O
cytosol	0	O
,	0	O
while	0	O
Nedd	0	B
-	0	I
4	0	I
was	0	O
found	0	O
only	0	O
in	0	O
the	0	O
cytosol	0	O
.	0	O


The	0	O
prevalence	0	O
of	0	O
opportunistic	0	O
infection	0	O
among	0	O
surviving	0	O
AIDS	1	O
patients	0	O
and	0	O
the	0	O
probability	0	O
of	0	O
being	0	O
in	0	O
tumour	0	O
response	0	O
following	0	O
cancer	0	O
therapy	0	O
conditional	0	O
on	0	O
being	0	O
alive	0	O
are	0	O
two	0	O
examples	0	O
of	0	O
such	0	O
functions	0	O
.	0	O


Bacteriologic	0	O
culture	0	O
of	0	O
pancreatic	0	O
tissue	0	O
was	0	O
positive	0	O
in	0	O
6	0	O
/	0	O
8	0	O
IB	1	O
and	0	O
3	0	O
/	0	O
17	0	O
NIB	1	O
rats	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


On	1	O
admission	0	O
to	0	O
the	0	O
ICU	1	O
,	0	O
117	0	O
patients	0	O
(	0	O
61	0	O
percent	0	O
)	0	O
had	0	O
hypomagnesemia	0	O
(	0	O
serum	0	O
Mg	1	O
less	0	O
than	0	O
1	0	O
.	0	O
5	0	O
mEq	1	O
/	0	O
dl	0	O
),	0	O
66	0	O
patients	0	O
(	0	O
34	0	O
percent	0	O
)	0	O
had	0	O
normomagnesemia	0	O
(	0	O
1	0	O
.	0	O
5	0	O
to	0	O
2	0	O
.	0	O
0	0	O
mEq	1	O
/	0	O
dl	0	O
),	0	O
and	0	O
ten	0	O
patients	0	O
(	0	O
5	0	O
percent	0	O
)	0	O
had	0	O
hypermagnesemia	0	O
(	0	O
greater	0	O
than	0	O
2	0	O
.	0	O
0	0	O
mEq	1	O
/	0	O
dl	0	O
).	0	O


Genomic	1	O
locus	0	O
of	0	O
chCTCF	0	B
contains	0	O
a	0	O
GC	1	O
-	0	O
rich	0	O
untranslated	0	O
exon	0	O
separated	0	O
from	0	O
seven	0	O
coding	0	O
exons	0	O
by	0	O
a	0	O
long	0	O
intron	0	O
.	0	O


Simultaneous	0	O
,	0	O
bilateral	0	O
and	0	O
permanent	0	O
ventilation	0	O
with	0	O
a	0	O
diaphragm	0	O
pacing	0	O
in	0	O
childhood	0	O
:	0	O
the	0	O
implantation	0	O
technique	0	O
and	0	O
indications	0	O


Results	0	O
confirmed	0	O
that	0	O
stress	0	O
produced	0	O
CA3	0	O
dendritic	0	O
atrophy	0	O
and	0	O
tianeptine	0	O
prevented	0	O
it	0	O
.	0	O


From	0	O
May	0	O
1985	0	O
to	0	O
May	0	O
1989	0	O
,	0	O
126	0	O
necropsies	0	O
were	0	O
performed	0	O
at	0	O
the	0	O
Sao	0	O
Paulo	0	O
City	0	O
Morgue	1	O
on	0	O
cadavers	0	O
of	0	O
individuals	0	O
AIDS	1	O
victims	0	O
whose	0	O
unnatural	0	O
deaths	0	O
had	0	O
prompted	0	O
police	0	O
investigations	0	O
.	0	O


Parodoxical	0	O
rise	0	O
in	0	O
urinary	0	B
albumin	0	I
levels	0	O
after	0	O
treatment	0	O
of	0	O
essential	0	O
hypertension	0	O
.	0	O


Bepridil	0	O
,	0	O
a	0	O
calcium	0	O
antagonist	0	O
with	0	O
a	0	O
half	0	O
-	0	O
life	0	O
of	0	O
approximately	0	O
42	0	O
hours	0	O
,	0	O
was	0	O
compared	0	O
with	0	O
placebo	0	O
in	0	O
a	0	O
double	0	O
-	0	O
blind	0	O
,	0	O
randomized	0	O
,	0	O
crossover	0	O
trial	0	O
.	0	O


Serine	1	O
phosphorylation	0	O
of	0	O
STAT3	0	B
was	0	O
only	0	O
apparent	0	O
after	0	O
somatostatin	0	B
treatment	0	O
and	0	O
was	0	O
abolished	0	O
by	0	O
pertussis	0	B
toxin	0	I
or	0	O
PD	1	O
98059	0	O
,	0	O
together	0	O
with	0	O
the	0	O
associated	0	O
increases	0	O
in	0	O
proliferation	0	O
.	0	O


Within	0	O
the	0	O
Strep	0	O
.	0	O
mutans	0	O
group	0	O
there	0	O
was	0	O
a	0	O
highly	0	O
-	0	O
significant	0	O
difference	0	O
between	0	O
Strep	0	O
.	0	O
mutans	0	O
/	0	O
Strep	0	O
.	0	O
cricetus	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
)	0	O
with	0	O
respect	0	O
to	0	O
mean	0	O
clump	0	O
size	0	O
.	0	O


Protein	1	B
tyrosine	0	I
phosphatases	0	I
(	0	O
PTPs	1	B
),	0	O
together	0	O
with	0	O
protein	0	B
tyrosine	0	I
kinases	0	I
(	0	O
PTKs	0	B
),	0	O
are	0	O
involved	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
cell	0	O
activation	0	O
,	0	O
growth	0	O
,	0	O
and	0	O
differentiation	0	O
.	0	O


Intermediate	1	O
levels	0	O
of	0	O
gene	0	O
activity	0	O
were	0	O
observed	0	O
for	0	O
TnI	0	B
enhancers	0	I
containing	0	O
E	1	O
-	0	O
boxes	0	O
derived	0	O
from	0	O
the	0	O
MCK	0	B
left	0	I
E	1	I
-	0	I
box	0	I
site	0	I
or	0	O
from	0	O
the	0	O
Ig	1	B
kappa	0	I
E2	1	I
E	1	I
-	0	I
box	0	I
.	0	O


The	0	O
percentages	0	O
of	0	O
recovery	0	O
decreased	0	O
with	0	O
storage	0	O
time	0	O
,	0	O
although	0	O
the	0	O
addition	0	O
of	0	O
dispersant	0	O
(	0	O
Tris	1	O
-	0	O
Tween	1	O
80	0	O
)	0	O
before	0	O
storage	0	O
appeared	0	O
to	0	O
partially	0	O
prevent	0	O
adhesion	0	O
.	0	O


Beyond	0	O
the	0	O
Tower	0	O
of	0	O
Babel	0	O
:	0	O
a	0	O
nomenclature	0	O
for	0	O
suicidology	0	O
.	0	O


LPO	1	O
and	0	O
SOD	0	B
levels	0	O
were	0	O
measured	0	O
at	0	O
five	0	O
points	0	O
before	0	O
and	0	O
during	0	O
the	0	O
operation	0	O
.	0	O


OKA	0	O
and	0	O
calyculin	0	O
A	1	O
do	0	O
not	0	O
decrease	0	O
OCFRE	0	B
DNA	1	O
-	0	O
protein	0	O
interactions	0	O
,	0	O
suggesting	0	O
that	0	O
important	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
are	0	O
phosphatase	0	O
regulated	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
While	0	O
INR	1	O
correction	0	O
may	0	O
be	0	O
achieved	0	O
by	0	O
all	0	O
the	0	O
above	0	O
methods	0	O
,	0	O
that	0	O
relating	0	O
log	0	O
reference	0	O
INR	1	O
to	0	O
log	0	O
local	0	O
prothrombin	0	B
time	0	O
by	0	O
linear	0	O
regression	0	O
analysis	0	O
is	0	O
the	0	O
simplest	0	O
to	0	O
perform	0	O
.	0	O


Recording	1	O
of	0	O
the	0	O
digital	0	O
sphygmic	0	O
activity	0	O
in	0	O
the	0	O
lower	0	O
extremities	0	O
with	0	O
the	0	O
photoplethysmographic	0	O
and	0	O
strain	0	O
-	0	O
gauge	0	O
methods	0	O
.	0	O


The	0	O
effectiveness	0	O
of	0	O
the	0	O
haemodialysate	0	O
Solcoseryl	0	O
for	0	O
second	0	O
-	0	O
intention	0	O
wound	0	O
healing	0	O
in	0	O
horses	0	O
and	0	O
ponies	0	O
.	0	O


Its	0	O
interaction	0	O
with	0	O
RFX5	0	B
and	0	O
RFXAP	0	B
is	0	O
essential	0	O
for	0	O
binding	0	O
of	0	O
the	0	O
RFX	0	B
complex	0	I
to	0	O
MHC	1	B
-	0	I
II	0	I
promoters	0	I
.	0	O


We	0	O
identify	0	O
the	0	O
"	0	O
M	1	O
region	0	O
"	0	O
of	0	O
the	0	O
muscle	0	B
-	0	I
specific	0	I
Xenopus	1	I
cardiac	0	I
actin	0	I
gene	0	I
promoter	0	I
from	0	O
-	0	O
282	0	O
to	0	O
-	0	O
348	0	O
as	0	O
necessary	0	O
for	0	O
the	0	O
embryonic	0	O
expression	0	O
of	0	O
a	0	O
cardiac	0	O
actin	0	B
-	0	O
beta	0	B
-	0	I
globin	0	I
reporter	0	O
gene	0	O
injected	0	O
into	0	O
fertilized	0	O
eggs	0	O
.	0	O


The	0	O
Laser	1	O
Scanning	1	O
Ophthalmoscope	1	O
enables	0	O
a	0	O
fundus	0	O
-	0	O
based	0	O
examination	0	O
and	0	O
therefore	0	O
allows	0	O
exact	0	O
comparison	0	O
between	0	O
morphologic	0	O
appearance	0	O
and	0	O
corresponding	0	O
function	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
both	0	O
the	0	O
exon	0	O
1	0	O
-	0	O
and	0	O
exon	0	O
2	0	O
-	0	O
initiated	0	O
forms	0	O
of	0	O
the	0	O
c	0	B
-	0	I
Myc	0	I
protein	0	I
stimulated	0	O
transcription	0	O
of	0	O
a	0	O
Myc	0	B
/	0	O
Max	0	B
-	0	O
responsive	0	O
reporter	0	O
construct	0	O
to	0	O
a	0	O
similar	0	O
level	0	O
.	0	O


We	0	O
show	0	O
that	0	O
other	0	O
cdc33	0	B
mutants	0	I
also	0	O
arrest	0	O
in	0	O
G1	0	O
.	0	O


Further	0	O
studies	0	O
on	0	O
a	0	O
"	0	O
new	0	O
"	0	O
human	0	O
isoprecipitin	0	B
system	0	O
(	0	O
Australia	0	O
antigen	0	O
).	0	O


Effects	0	O
of	0	O
dopamine	0	O
and	0	O
of	0	O
a	0	O
dopaminergic	0	O
blocker	0	O
,	0	O
haloperidol	0	O
,	0	O
on	0	O
the	0	O
responses	0	O
of	0	O
carotid	0	O
body	0	O
chemoreceptors	0	O
to	0	O
hypoxia	0	O
and	0	O
hypercapnia	0	O
were	0	O
investigated	0	O
in	0	O
16	0	O
anesthetized	0	O
cats	0	O
.	0	O


ATP	1	O
by	0	O
itself	0	O
also	0	O
reduced	0	O
polypeptide	0	O
binding	0	O
to	0	O
Ssb1	0	B
/	0	I
2p	0	I
to	0	O
a	0	O
level	0	O
that	0	O
was	0	O
intermediate	0	O
between	0	O
that	0	O
observed	0	O
for	0	O
the	0	O
Ssa	0	B
Hsp70	0	I
proteins	0	I
tested	0	O
and	0	O
BiP	0	B
and	0	O
DnaK	0	B
.	0	O


Serum	1	O
concentrations	0	O
of	0	O
E2	1	O
and	0	O
TBOH	0	O
were	0	O
measured	0	O
on	0	O
d	0	O
0	0	O
,	0	O
1	0	O
,	0	O
3	0	O
,	0	O
5	0	O
,	0	O
7	0	O
,	0	O
13	0	O
,	0	O
21	0	O
,	0	O
28	0	O
,	0	O
42	0	O
,	0	O
56	0	O
,	0	O
84	0	O
,	0	O
112	0	O
,	0	O
and	0	O
140	0	O
in	0	O
finishing	0	O
heifers	0	O
administered	0	O
the	0	O
following	0	O
treatments	0	O
:	0	O
1	0	O
)	0	O
control	0	O
;	0	O
2	0	O
)	0	O
MGA	0	O
,	0	O
.	0	O
5	0	O
mg	0	O
per	0	O
heifer	0	O
daily	0	O
;	0	O
3	0	O
)	0	O
Revalor	0	O
-	0	O
H	1	O
(	0	O
140	0	O
mg	0	O
TBA	0	O
+	0	O
14	0	O
mg	0	O
E2	1	O
);	0	O
4	0	O
)	0	O
Revalor	0	O
-	0	O
H	1	O
+	0	O
MGA	0	O
;	0	O
5	0	O
)	0	O
Finaplix	0	O
-	0	O
H	1	O
(	0	O
200	0	O
mg	0	O
TBA	0	O
);	0	O
and	0	O
6	0	O
)	0	O
Finaplix	0	O
-	0	O
H	1	O
+	0	O
MGA	0	O
.	0	O


Differential	1	O
expression	0	O
and	0	O
regulation	0	O
by	0	O
20	0	O
-	0	O
hydroxyecdysone	0	O
of	0	O
mosquito	0	O
ultraspiracle	0	O
isoforms	0	O
.	0	O


Action	1	O
of	0	O
strontium	0	O
-	0	O
90	0	O
and	0	O
metaphos	0	O
on	0	O
Cyprinus	0	O
carpio	0	O


The	0	O
percentage	0	O
RFR	0	O
reduction	0	O
at	0	O
the	0	O
end	0	O
of	0	O
CPB	0	O
showed	0	O
significant	0	O
correlation	0	O
with	0	O
1	0	O
)	0	O
CPB	0	O
duration	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
49	0	O
),	0	O
2	0	O
)	0	O
oxygen	0	O
flow	0	O
rate	0	O
index	0	O
(	0	O
OFRI	0	O
),	0	O
i	0	O
.	0	O
e	0	O
.	0	O
flow	0	O
/	0	O
min	0	O
in	0	O
the	0	O
bubble	0	O
oxygenator	0	O
/	0	O
m2	0	O
bsa	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
38	0	O
),	0	O
and	0	O
3	0	O
)	0	O
blood	0	O
flow	0	O
rate	0	O
index	0	O
(	0	O
BFRI	0	O
),	0	O
i	0	O
.	0	O
e	0	O
.	0	O
average	0	O
volume	0	O
of	0	O
blood	0	O
pumped	0	O
through	0	O
the	0	O
heart	0	O
-	0	O
lung	0	O
machine	0	O
/	0	O
min	0	O
CPB	0	O
time	0	O
/	0	O
m2	0	O
bsa	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
51	0	O
).	0	O


Since	0	O
proteins	0	O
containing	0	O
TPR	1	O
elements	0	O
are	0	O
typically	0	O
involved	0	O
in	0	O
multiple	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
,	0	O
we	0	O
suggest	0	O
that	0	O
the	0	O
102kD	0	O
protein	0	O
interacts	0	O
within	0	O
the	0	O
tri	0	O
-	0	O
snRNP	1	O
with	0	O
both	0	O
the	0	O
U5	0	B
and	0	O
U4	0	B
/	0	O
U6	0	B
snRNPs	0	O
,	0	O
thus	0	O
bridging	0	O
the	0	O
two	0	O
particles	0	O
.	0	O


This	0	O
brief	0	O
hypercapnic	0	O
challenge	0	O
induced	0	O
a	0	O
rapid	0	O
increase	0	O
in	0	O
CBF	1	O
in	0	O
the	0	O
absence	0	O
of	0	O
any	0	O
change	0	O
in	0	O
MABP	0	O
.	0	O


Atopic	1	O
allergy	0	O
and	0	O
other	0	O
hypersensitivities	0	O
.	0	O


Ectopic	1	O
expression	0	O
of	0	O
Apo	1	B
-	0	I
3	0	I
in	0	O
HEK293	0	O
or	0	O
HeLa	0	O
cells	0	O
induced	0	O
marked	0	O
apoptosis	0	O
.	0	O


Today	0	O
there	0	O
is	0	O
no	0	O
doubt	0	O
that	0	O
elevated	0	O
plasma	0	O
cholesterol	0	O
levels	0	O
should	0	O
be	0	O
lowered	0	O
first	0	O
by	0	O
dietary	0	O
modification	0	O
even	0	O
in	0	O
early	0	O
childhood	0	O
,	0	O
beginning	0	O
at	0	O
the	0	O
age	0	O
of	0	O
two	0	O
years	0	O
.	0	O


Validation	1	O
of	0	O
automated	0	O
systems	0	O
--	0	O
system	0	O
definition	0	O
.	0	O


The	0	O
activity	0	O
of	0	O
6	0	O
-	0	O
fluoroquinolones	0	O
and	0	O
their	0	O
nonfluorinated	0	O
derivatives	0	O
is	0	O
compared	0	O
in	0	O
general	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
A	1	O
comparison	0	O
of	0	O
the	0	O
LysU	0	B
crystal	0	O
structure	0	O
with	0	O
the	0	O
structures	0	O
of	0	O
seryl	0	B
-	0	I
and	0	I
aspartyl	0	I
-	0	I
tRNA	1	I
synthetases	0	I
enables	0	O
a	0	O
conserved	0	O
core	0	O
to	0	O
be	0	O
identified	0	O
.	0	O


Copyright	0	O
1998	0	O
Elsevier	0	O
Science	1	O
B	1	O
.	0	O
V	1	O
.	0	O


As	1	O
a	0	O
result	0	O
of	0	O
alternative	0	O
splicing	0	O
,	0	O
the	0	O
BGP	0	B
gene	0	I
is	0	O
transcribed	0	O
into	0	O
at	0	O
least	0	O
seven	0	O
distinct	0	O
mRNA	1	O
species	0	O
.	0	O


These	0	O
data	0	O
demonstrate	0	O
that	0	O
paxillin	0	B
localizes	0	O
to	0	O
focal	0	O
adhesions	0	O
independent	0	O
of	0	O
interactions	0	O
with	0	O
vinculin	0	B
and	0	O
/	0	O
or	0	O
FAK	0	B
,	0	O
and	0	O
represents	0	O
the	0	O
first	0	O
definitive	0	O
demonstration	0	O
of	0	O
LIM	0	B
domains	0	I
functioning	0	O
as	0	O
a	0	O
primary	0	O
determinant	0	O
of	0	O
protein	0	O
subcellular	0	O
localization	0	O
to	0	O
focal	0	O
adhesions	0	O
.	0	O


Despite	0	O
supraphysiologic	0	O
E2	1	O
concentrations	0	O
,	0	O
however	0	O
,	0	O
cervical	0	O
mucus	0	O
scores	0	O
were	0	O
significantly	0	O
reduced	0	O
in	0	O
the	0	O
CC	1	O
-	0	O
treated	0	O
group	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Badcock	0	O
and	0	O
Westheimer	0	O
(	0	O
Spatial	1	O
Vision	1	O
1	0	O
(	0	O
1	0	O
),	0	O
3	0	O
-	0	O
11	0	O
,	0	O
1985	0	O
)	0	O
showed	0	O
that	0	O
a	0	O
thin	0	O
vertical	0	O
line	0	O
induces	0	O
nearby	0	O
zones	0	O
of	0	O
attraction	0	O
and	0	O
repulsion	0	O
;	0	O
this	0	O
study	0	O
extends	0	O
those	0	O
results	0	O
by	0	O
more	0	O
closely	0	O
examining	0	O
the	0	O
horizontal	0	O
and	0	O
vertical	0	O
extents	0	O
of	0	O
the	0	O
repulsion	0	O
zone	0	O
and	0	O
by	0	O
using	0	O
an	0	O
illusory	0	O
contour	0	O
to	0	O
induce	0	O
repulsion	0	O
.	0	O


In	1	O
both	0	O
experiments	0	O
,	0	O
average	0	O
daily	0	O
gain	0	O
and	0	O
gain	0	O
-	0	O
to	0	O
-	0	O
feed	0	O
ratio	0	O
were	0	O
similar	0	O
for	0	O
TR	1	O
and	0	O
CR	1	O
.	0	O


Whole	0	O
-	0	O
mount	0	O
in	0	O
situ	0	O
hybridization	0	O
to	0	O
early	0	O
mouse	0	O
embryos	0	O
of	0	O
9	0	O
.	0	O
5	0	O
-	0	O
10	0	O
.	0	O
5	0	O
days	0	O
indicated	0	O
a	0	O
complex	0	O
pattern	0	O
of	0	O
Arp1	0	B
expression	0	O
spatially	0	O
overlapping	0	O
with	0	O
the	0	O
expression	0	O
of	0	O
All1	0	B
.	0	O


Expression	1	O
of	0	O
the	0	O
human	0	B
heat	0	I
shock	0	I
protein	0	I
70	0	I
gene	0	I
(	0	O
hsp70	0	B
)	0	O
is	0	O
induced	0	O
by	0	O
various	0	O
kinds	0	O
of	0	O
stress	0	O
and	0	O
by	0	O
oncogenes	0	O
.	0	O


The	0	O
data	0	O
indicate	0	O
a	0	O
three	0	O
-	0	O
phase	0	O
reaction	0	O
after	0	O
B1	0	O
injection	0	O
:	0	O
Phase	1	O
1	0	O
--	0	O
shortly	0	O
after	0	O
injection	0	O
there	0	O
is	0	O
a	0	O
drop	0	O
of	0	O
all	0	O
parameters	0	O
lasting	0	O
for	0	O
30	0	O
sec	0	O
.	0	O


In	1	O
the	0	O
mouse	0	O
,	0	O
CtBP1	0	B
is	0	O
expressed	0	O
from	0	O
embryo	0	O
to	0	O
adult	0	O
,	0	O
but	0	O
CtBP2	0	B
is	0	O
mainly	0	O
expressed	0	O
during	0	O
embryogenesis	0	O
.	0	O


Within	0	O
Stage	1	O
IA	1	O
,	0	O
141	0	O
patients	0	O
had	0	O
well	0	O
differentiated	0	O
tumor	0	O
(	0	O
G1	0	O
),	0	O
20	0	O
had	0	O
moderately	0	O
well	0	O
differentiated	0	O
tumor	0	O
(	0	O
G2	0	O
),	0	O
and	0	O
12	0	O
patients	0	O
had	0	O
poorly	0	O
differentiated	0	O
(	0	O
G3	0	O
).	0	O


Comparative	0	O
study	0	O
of	0	O
the	0	O
differential	0	O
white	0	O
blood	0	O
cell	0	O
count	0	O
using	0	O
three	0	O
automated	0	O
analyzers	0	O
:	0	O
Coulter	0	O
STKS	0	O
,	0	O
Sysmex	0	O
NE	1	O
8000	0	O
and	0	O
Technicon	0	O
H	1	O
-	0	O
1	0	O
.	0	O


To	1	O
explore	0	O
the	0	O
function	0	O
of	0	O
human	0	O
SINA	0	B
-	0	I
homologous	0	I
(	0	I
Siah	0	I
)	0	I
proteins	0	I
,	0	O
expression	0	O
plasmids	0	O
encoding	0	O
Siah	0	B
-	0	I
1A	0	I
were	0	O
transiently	0	O
transfected	0	O
into	0	O
293	0	O
epithelial	0	O
cells	0	O
and	0	O
GM701	0	O
fibroblast	0	O
cells	0	O
,	0	O
resulting	0	O
in	0	O
growth	0	O
arrest	0	O
without	0	O
induction	0	O
of	0	O
apoptosis	0	O
.	0	O


Modification	1	O
by	0	O
this	0	O
latter	0	O
compound	0	O
was	0	O
so	0	O
extensive	0	O
that	0	O
the	0	O
amount	0	O
of	0	O
membrane	0	O
-	0	O
associated	0	O
N	1	O
-	0	O
myristoylated	0	O
protein	0	O
was	0	O
decreased	0	O
.	0	O


The	0	O
skp1	0	B
+	0	I
gene	0	I
is	0	O
not	0	O
essential	0	O
.	0	O


Phosphorylation	1	O
of	0	O
myosin	0	B
-	0	I
binding	0	I
subunit	0	I
(	0	O
MBS	0	B
)	0	O
of	0	O
myosin	0	B
phosphatase	0	I
by	0	O
Rho	1	B
-	0	I
kinase	0	I
in	0	O
vivo	0	O
.	0	O


RESULTS	0	O
:	0	O
The	0	O
binding	0	O
of	0	O
99mTc	0	O
d	0	O
,	0	O
1	0	O
-	0	O
HMPAO	1	O
to	0	O
human	0	O
placenta	0	O
ranged	0	O
from	0	O
2	0	O
.	0	O
95	0	O
%	0	O
+/-	0	O
1	0	O
.	0	O
5	0	O
%	0	O
to	0	O
5	0	O
.	0	O
82	0	O
%	0	O
+/-	0	O
0	0	O
.	0	O
3	0	O
%	0	O
per	0	O
1	0	O
ml	0	O
standard	0	O
solution	0	O
.	0	O


Finally	0	O
,	0	O
nonphotosynthetic	0	O
mutants	0	O
,	0	O
including	0	O
the	0	O
tscA	0	B
-	0	I
lacking	0	I
photosystem	0	I
I	1	I
mutant	0	I
,	0	O
H13	0	O
,	0	O
did	0	O
not	0	O
show	0	O
evidence	0	O
of	0	O
light	0	O
-	0	O
stimulated	0	O
RNA	1	O
processing	0	O
.	0	O


Internally	0	O
oriented	0	O
patients	0	O
'	0	O
scores	0	O
on	0	O
Rotter	0	O
'	0	O
s	0	O
Internal	1	O
-	0	O
External	1	O
Locus	1	O
of	0	O
Control	1	O
Scale	1	O
remained	0	O
the	0	O
same	0	O
over	0	O
treatment	0	O
but	0	O
those	0	O
of	0	O
externally	0	O
oriented	0	O
patients	0	O
shifted	0	O
toward	0	O
greater	0	O
internal	0	O
control	0	O
.	0	O


All	1	O
of	0	O
these	0	O
data	0	O
suggest	0	O
that	0	O
replication	0	O
of	0	O
UV	1	O
-	0	O
damaged	0	O
templates	0	O
occurs	0	O
in	0	O
vitro	0	O
as	0	O
it	0	O
does	0	O
in	0	O
vivo	0	O
and	0	O
that	0	O
this	0	O
replication	0	O
results	0	O
in	0	O
mutation	0	O
fixation	0	O
.	0	O


Ciprofloxacin	1	O
:	0	O
an	0	O
overview	0	O
of	0	O
adverse	0	O
experiences	0	O
.	0	O


Cloning	1	O
and	0	O
sequence	0	O
analyses	0	O
revealed	0	O
a	0	O
second	0	O
cDNA	1	O
with	0	O
a	0	O
95	0	O
-	0	O
nt	0	O
deletion	0	O
in	0	O
the	0	O
region	0	O
coding	0	O
for	0	O
the	0	O
putative	0	O
second	0	O
intracellular	0	O
loop	0	O
and	0	O
the	0	O
fourth	0	O
transmembrane	0	O
domain	0	O
of	0	O
the	0	O
5	0	B
-	0	I
HT2C	0	I
-	0	I
R	1	I
.	0	O


Down	1	O
-	0	O
regulation	0	O
of	0	O
IRS	0	B
-	0	I
1	0	I
is	0	O
linked	0	O
to	0	O
its	0	O
serine	0	O
phosphorylation	0	O
dependent	0	O
on	0	O
PI	1	B
3	0	I
-	0	I
kinase	0	I
activity	0	O
and	0	O
appears	0	O
required	0	O
for	0	O
differentiation	0	O
to	0	O
occur	0	O
,	0	O
as	0	O
IRS	0	B
-	0	I
1	0	I
is	0	O
not	0	O
modified	0	O
and	0	O
continues	0	O
to	0	O
accumulate	0	O
in	0	O
a	0	O
nondifferentiating	0	O
myoblast	0	O
cell	0	O
line	0	O
.	0	O


Objective	1	O
:	0	O
To	1	O
evaluate	0	O
endometrial	0	O
thickness	0	O
and	0	O
the	0	O
incidence	0	O
of	0	O
uterine	0	O
bleeding	0	O
in	0	O
postmenopausal	0	O
women	0	O
using	0	O
either	0	O
tibolone	0	O
2	0	O
.	0	O
5	0	O
mg	0	O
or	0	O
continuous	0	O
combined	0	O
2	0	O
mg	0	O
estradiol	0	O
and	0	O
1	0	O
mg	0	O
norethisterone	0	O
acetate	0	O
(	0	O
E	1	O
+	0	O
NETA	0	O
)	0	O
daily	0	O
as	0	O
hormone	0	O
replacement	0	O
therapy	0	O
.	0	O


CONCLUSION	0	O
:	0	O
The	0	O
results	0	O
demonstrate	0	O
that	0	O
at	0	O
the	0	O
site	0	O
of	0	O
lumbar	0	O
disc	0	O
herniation	0	O
,	0	O
inflammatory	0	O
cytokines	0	O
such	0	O
as	0	O
interleukin	0	B
-	0	I
1	0	I
alpha	0	I
are	0	O
produced	0	O
,	0	O
which	0	O
increases	0	O
prostaglandin	0	O
E2	1	O
production	0	O
.	0	O


Seven	0	O
out	0	O
of	0	O
34	0	O
patients	0	O
died	0	O
,	0	O
giving	0	O
a	0	O
mortality	0	O
rate	0	O
of	0	O
21	0	O
%.	0	O


Linkage	1	O
studies	0	O
have	0	O
shown	0	O
locus	0	O
heterogeneity	0	O
with	0	O
one	0	O
TSC	1	B
gene	0	I
mapped	0	O
to	0	O
chromosome	0	O
9q34	0	O
and	0	O
a	0	O
second	0	O
to	0	O
16p13	0	O
.	0	O
3	0	O
.	0	O


In	1	O
DNase	1	B
I	1	I
footprinting	0	O
protection	0	O
analysis	0	O
,	0	O
both	0	O
SFRE	0	B
and	0	O
ERE	0	O
regions	0	O
were	0	O
protected	0	O
by	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
-	0	O
ERRalpha1	0	B
fusion	0	O
protein	0	O
.	0	O


Screening	1	O
of	0	O
asthma	0	O
patients	0	O
by	0	O
determination	0	O
of	0	O
IgE	1	B
and	0	O
by	0	O
comprehension	0	O
of	0	O
spectrum	0	O
of	0	O
allergospecific	0	B
IgE	1	I
antibodies	0	I


One	0	O
-	0	O
third	0	O
of	0	O
the	0	O
men	0	O
with	0	O
azoospermia	0	O
and	0	O
with	0	O
sperm	0	O
density	0	O
of	0	O
less	0	O
than	0	O
10	0	O
million	0	O
had	0	O
marked	0	O
FSH	1	B
elevation	0	O
and	0	O
our	0	O
experience	0	O
confirms	0	O
the	0	O
work	0	O
of	0	O
others	0	O
that	0	O
this	0	O
indicates	0	O
a	0	O
poor	0	O
prognosis	0	O
.	0	O


The	0	O
incidence	0	O
of	0	O
second	0	O
malignant	0	O
neoplasms	0	O
was	0	O
lower	0	O
(	0	O
1	0	O
.	0	O
3	0	O
%)	0	O
in	0	O
the	0	O
group	0	O
treated	0	O
with	0	O
5	0	O
-	0	O
fluorouracil	0	O
,	0	O
doxorubicin	0	O
,	0	O
and	0	O
cyclophosphamide	0	O
than	0	O
in	0	O
the	0	O
historical	0	O
control	0	O
group	0	O
(	0	O
4	0	O
.	0	O
8	0	O
%).	0	O


100	0	O
of	0	O
the	0	O
patients	0	O
who	0	O
would	0	O
have	0	O
died	0	O
survive	0	O
.	0	O


Gel	1	O
-	0	O
mobility	0	O
shift	0	O
analysis	0	O
was	0	O
also	0	O
performed	0	O
for	0	O
the	0	O
CCAAT	0	O
motif	0	O
at	0	O
-	0	O
67	0	O
.	0	O


Constrictive	1	O
pericarditis	0	O
and	0	O
pleuropulmonary	0	O
disease	0	O
linked	0	O
to	0	O
ergot	0	O
dopamine	0	O
agonist	0	O
therapy	0	O
(	0	O
cabergoline	0	O
)	0	O
for	0	O
Parkinson	0	O
'	0	O
s	0	O
disease	0	O
.	0	O


Cloning	1	O
and	0	O
characterization	0	O
of	0	O
human	0	B
Lnk	0	I
,	0	O
an	0	O
adaptor	0	O
protein	0	O
with	0	O
pleckstrin	0	B
homology	0	O
and	0	O
Src	1	B
homology	0	I
2	0	I
domains	0	I
that	0	O
can	0	O
inhibit	0	O
T	1	O
cell	0	O
activation	0	O
.	0	O


Several	0	O
secondary	0	O
structure	0	O
elements	0	O
were	0	O
identified	0	O
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
folate	0	O
compounds	0	O
decrease	0	O
formate	0	O
accumulation	0	O
after	0	O
methanol	0	O
by	0	O
stimulating	0	O
formate	0	O
oxidation	0	O
or	0	O
utilization	0	O
and	0	O
suggest	0	O
a	0	O
possible	0	O
use	0	O
for	0	O
folates	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
certain	0	O
cases	0	O
of	0	O
human	0	O
methanol	0	O
poisoning	0	O
.	0	O


In	1	O
support	0	O
of	0	O
this	0	O
interpretation	0	O
we	0	O
demonstrate	0	O
that	0	O
MQ9b	0	B
binds	0	O
strongly	0	O
5	0	O
of	0	O
17	0	O
motif	0	O
-	0	O
positive	0	O
,	0	O
pathogen	0	O
-	0	O
derived	0	O
synthetic	0	O
peptides	0	O
.	0	O


When	0	O
expressed	0	O
in	0	O
COS	1	O
-	0	O
7	0	O
cells	0	O
,	0	O
MKP	0	B
-	0	I
4	0	I
blocks	0	O
activation	0	O
of	0	O
MAP	1	B
kinases	0	I
with	0	O
the	0	O
selectivity	0	O
ERK	0	B
>	0	O
p38	0	B
=	0	O
JNK	0	B
/	0	O
SAPK	0	B
.	0	O


We	0	O
report	0	O
a	0	O
case	0	O
of	0	O
vasculitis	0	O
(	0	O
cutaneous	0	O
and	0	O
neurologic	0	O
)	0	O
which	0	O
led	0	O
to	0	O
the	0	O
discovery	0	O
of	0	O
a	0	O
selective	0	O
immunodeficit	0	O
towards	0	O
EBV	1	O
,	0	O
similar	0	O
to	0	O
Purtilo	0	O
'	0	O
s	0	O
syndrome	0	O
.	0	O


Ten	0	O
-	0	O
year	0	O
experience	0	O
with	0	O
one	0	O
-	0	O
stage	0	O
proctocolectomy	0	O
and	0	O
anal	0	O
ileostomy	0	O
.	0	O


Two	0	O
of	0	O
these	0	O
motifs	0	O
are	0	O
part	0	O
of	0	O
a	0	O
highly	0	O
conserved	0	O
and	0	O
inducible	0	O
dyad	0	O
symmetry	0	O
element	0	O
shown	0	O
previously	0	O
to	0	O
control	0	O
a	0	O
remote	0	O
IL	1	B
-	0	I
2	0	I
enhancer	0	I
and	0	O
the	0	O
CD18	0	B
promoter	0	I
.	0	O


This	0	O
0	0	O
.	0	O
74	0	O
kb	0	O
cDNA	1	O
contains	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
ORF	1	O
)	0	O
of	0	O
477	0	O
bp	0	O
encoding	0	O
a	0	O
polypeptide	0	O
of	0	O
159	0	O
amino	0	O
acids	0	O
(	0	O
aa	0	O
)	0	O
which	0	O
differs	0	O
at	0	O
only	0	O
one	0	O
position	0	O
(	0	O
position	0	O
65	0	O
)	0	O
from	0	O
the	0	O
human	0	B
U1	0	I
-	0	I
C	1	I
protein	0	I
.	0	O


Interferon	1	B
-	0	I
alpha	0	I
may	0	O
exacerbate	0	O
cryoblobulinemia	0	O
-	0	O
related	0	O
ischemic	0	O
manifestations	0	O
:	0	O
an	0	O
adverse	0	O
effect	0	O
potentially	0	O
related	0	O
to	0	O
its	0	O
anti	0	O
-	0	O
angiogenic	0	O
activity	0	O
.	0	O


Risks	0	O
of	0	O
chronicity	0	O
following	0	O
acute	0	O
hepatitis	0	O
B	1	O
virus	0	O
infection	0	O
:	0	O
a	0	O
review	0	O
.	0	O


Identical	1	O
results	0	O
were	0	O
obtained	0	O
when	0	O
transfections	0	O
and	0	O
mobility	0	O
shift	0	O
assays	0	O
were	0	O
performed	0	O
in	0	O
primary	0	O
rat	0	O
hepatocytes	0	O
in	0	O
which	0	O
the	0	O
endogenous	0	O
ALS	1	B
gene	0	I
is	0	O
expressed	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
Codonopsis	0	O
pilosula	0	O
oral	0	O
liquor	0	O
(	0	O
CPOL	0	O
)	0	O
on	0	O
tissue	0	B
-	0	I
type	0	I
plasminogen	0	I
activator	0	I
(	0	O
t	0	B
-	0	I
PA	1	I
)	0	O
and	0	O
plasminogen	0	B
activator	0	I
inhibitor	0	I
(	0	O
PAI	1	B
)	0	O
in	0	O
the	0	O
plasma	0	O
of	0	O
25	0	O
patients	0	O
of	0	O
coronary	0	O
heart	0	O
disease	0	O
with	0	O
blood	0	O
stasis	0	O
were	0	O
studied	0	O
.	0	O


176	0	O
:	0	O
787	0	O
-	0	O
792	0	O
,	0	O
1992	0	O
;	0	O
M	1	O
.	0	O


The	0	O
efficacy	0	O
of	0	O
a	0	O
Propionibacterium	1	O
acnes	0	O
product	0	O
for	0	O
treatment	0	O
of	0	O
coliform	0	O
mastitis	0	O
was	0	O
evaluated	0	O
following	0	O
intramammary	0	O
infusion	0	O
of	0	O
Escherichia	1	O
coli	0	O
.	0	O


The	0	O
other	0	O
patients	0	O
continued	0	O
the	0	O
trial	0	O
with	0	O
single	0	O
daily	0	O
doses	0	O
of	0	O
monotherapy	0	O
.	0	O


Total	0	O
body	0	O
water	0	O
,	0	O
rhodanide	0	O
space	0	O
and	0	O
I	1	B
-	0	I
131	0	I
-	0	I
albumin	0	I
space	0	O
under	0	O
the	0	O
acute	0	O
effect	0	O
of	0	O
furosemide	0	O


Localization	1	O
of	0	O
the	0	O
brachial	0	O
plexus	0	O
with	0	O
the	0	O
nerve	0	O
stimulator	0	O
is	0	O
equally	0	O
effective	0	O
at	0	O
the	0	O
interscalene	0	O
,	0	O
supraclavicular	0	O
,	0	O
and	0	O
axillary	0	O
sites	0	O
.	0	O


The	0	O
manifestations	0	O
often	0	O
include	0	O
a	0	O
moderate	0	O
thrombocytopenia	0	O
and	0	O
,	0	O
less	0	O
commonly	0	O
,	0	O
hemolysis	0	O
.	0	O


Tissue	1	O
pressure	0	O
,	0	O
rCBF	1	O
,	0	O
and	0	O
water	0	O
content	0	O
were	0	O
measured	0	O
from	0	O
gray	0	O
matter	0	O
in	0	O
the	0	O
central	0	O
core	0	O
and	0	O
the	0	O
peripheral	0	O
margin	0	O
of	0	O
the	0	O
MCA	1	O
territory	0	O
over	0	O
6	0	O
h	0	O
after	0	O
MCAO	0	O
.	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
binding	0	O
of	0	O
the	0	O
GA	1	B
-	0	I
binding	0	I
protein	0	I
(	0	O
GABP	0	B
)	0	O
to	0	O
ets	0	B
sequence	0	I
motifs	0	I
within	0	O
each	0	O
repeated	0	O
unit	0	O
is	0	O
required	0	O
for	0	O
transcriptional	0	O
activation	0	O
of	0	O
the	0	O
COXIV	0	B
promoter	0	I
.	0	O


The	0	O
test	0	O
was	0	O
not	0	O
performed	0	O
in	0	O
3923	0	O
patients	0	O
because	0	O
of	0	O
contraindications	0	O
.	0	O


LCBF	0	O
in	0	O
normal	0	O
and	0	O
hypoxic	0	O
puppies	0	O
was	0	O
correlated	0	O
with	0	O
local	0	O
cerebral	0	O
glucose	0	O
utilization	0	O
(	0	O
LCGU	0	O
)	0	O
obtained	0	O
under	0	O
the	0	O
same	0	O
experimental	0	O
conditions	0	O
(	0	O
Duffy	0	O
et	0	O
al	0	O
,	0	O
1982	0	O
).	0	O


Cleavage	1	O
by	0	O
the	0	O
intron	0	O
-	0	O
encoded	0	O
enzyme	0	O
(	0	O
I	1	B
-	0	I
CreI	0	I
)	0	O
occurs	0	O
5	0	O
bp	0	O
and	0	O
1	0	O
bp	0	O
3	0	O
'	0	O
to	0	O
the	0	O
intron	0	O
insertion	0	O
site	0	O
(	0	O
in	0	O
the	0	O
3	0	O
'-	0	O
exon	0	O
)	0	O
in	0	O
the	0	O
top	0	O
(/)	0	O
and	0	O
bottom	0	O
(,)	0	O
strands	0	O
,	0	O
respectively	0	O
,	0	O
resulting	0	O
in	0	O
4	0	O
-	0	O
nt	0	O
single	0	O
-	0	O
stranded	0	O
overhangs	0	O
with	0	O
3	0	O
'-	0	O
OH	0	O
termini	0	O
.	0	O


In	1	O
a	0	O
group	0	O
of	0	O
13	0	O
patients	0	O
with	0	O
obliterative	0	O
arteriopathies	0	O
of	0	O
the	0	O
lower	0	O
limbs	0	O
the	0	O
plasma	0	O
levels	0	O
of	0	O
thrombomodulin	0	B
(	0	O
TM	1	B
),	0	O
betathromboglobulin	0	B
(	0	O
beta	0	B
-	0	I
TG	1	I
),	0	O
D	1	O
-	0	O
dimer	0	O
(	0	O
DD	0	O
)	0	O
and	0	O
plasminogen	0	B
activator	0	I
-	0	I
inhibitor	0	I
(	0	O
pAI	1	B
-	0	I
1	0	I
)	0	O
were	0	O
measured	0	O
,	0	O
and	0	O
compared	0	O
to	0	O
the	0	O
values	0	O
obtained	0	O
from	0	O
10	0	O
healthy	0	O
volunteers	0	O
.	0	O


RNA	1	O
of	0	O
GBV	0	O
-	0	O
C	1	O
was	0	O
detected	0	O
in	0	O
14	0	O
(	0	O
18	0	O
%)	0	O
patients	0	O
before	0	O
BMT	1	O
.	0	O


Coliphage	1	B
186	0	I
B	1	I
is	0	O
a	0	O
72	0	O
-	0	O
amino	0	O
acid	0	O
protein	0	O
belonging	0	O
to	0	O
the	0	O
Ogr	0	B
family	0	O
of	0	O
analogous	0	O
transcription	0	O
factors	0	O
present	0	O
in	0	O
P2	1	O
-	0	O
like	0	O
phage	0	O
,	0	O
which	0	O
contain	0	O
a	0	O
Cys	1	O
-	0	O
X2	0	O
-	0	O
Cys	1	O
-	0	O
X22	0	O
-	0	O
Cys	1	O
-	0	O
X4	0	O
-	0	O
Cys	1	O
presumptive	0	O
zinc	0	O
-	0	O
finger	0	O
motif	0	O
.	0	O


Deletion	1	O
or	0	O
inactivation	0	O
of	0	O
CRY1	0	B
leads	0	O
to	0	O
5	0	O
-	0	O
to	0	O
10	0	O
-	0	O
fold	0	O
-	0	O
increased	0	O
levels	0	O
of	0	O
CRY2	0	B
mRNA	1	I
.	0	O


Histopathological	0	O
examination	0	O
revealed	0	O
dose	0	O
-	0	O
related	0	O
proliferation	0	O
of	0	O
type	0	O
II	0	O
pneumocytes	0	O
in	0	O
dams	0	O
and	0	O
proliferation	0	O
of	0	O
interstitial	0	O
cells	0	O
and	0	O
delayed	0	O
septal	0	O
/	0	O
capillary	0	O
development	0	O
in	0	O
neonates	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


The	0	O
growth	0	O
of	0	O
Aer	0	O
.	0	O
hydrophila	0	O
in	0	O
filter	0	O
-	0	O
sterilized	0	O
lettuce	0	O
extract	0	O
was	0	O
completely	0	O
inhibited	0	O
by	0	O
0	0	O
.	0	O
1	0	O
%	0	O
(	0	O
v	0	O
/	0	O
v	0	O
)	0	O
BMC	0	O
whereas	0	O
that	0	O
of	0	O
Ps	1	O
.	0	O
fluorescens	0	O
was	0	O
not	0	O
significantly	0	O
affected	0	O
by	0	O
1	0	O
%	0	O
(	0	O
v	0	O
/	0	O
v	0	O
)	0	O
BMC	0	O
.	0	O


Though	0	O
the	0	O
BACTEC	0	O
9000	0	O
MB	1	O
system	0	O
is	0	O
recommended	0	O
for	0	O
respiratory	0	O
specimens	0	O
,	0	O
we	0	O
demonstrated	0	O
that	0	O
it	0	O
can	0	O
be	0	O
successfully	0	O
used	0	O
also	0	O
for	0	O
recovery	0	O
of	0	O
mycobacteria	0	O
from	0	O
clinical	0	O
specimens	0	O
from	0	O
various	0	O
extrapulmonary	0	O
sites	0	O
.	0	O


Among	0	O
them	0	O
,	0	O
26	0	O
cases	0	O
were	0	O
benign	0	O
and	0	O
34	0	O
malignant	0	O
.	0	O


Removal	0	O
of	0	O
PDMP	0	O
from	0	O
the	0	O
cell	0	O
medium	0	O
resulted	0	O
in	0	O
reversal	0	O
of	0	O
the	0	O
cell	0	O
cycle	0	O
changes	0	O
,	0	O
with	0	O
cells	0	O
re	0	O
-	0	O
entering	0	O
the	0	O
S	1	O
phase	0	O
.	0	O


The	0	O
present	0	O
study	0	O
was	0	O
designed	0	O
to	0	O
evaluate	0	O
the	0	O
sensitivity	0	O
and	0	O
specificity	0	O
of	0	O
AMP	1	O
CT	1	O
(	0	O
Gen	0	O
-	0	O
Probe	1	O
Incorporated	0	O
,	0	O
San	0	O
Diego	0	O
,	0	O
CA	1	O
,	0	O
USA	0	O
)	0	O
on	0	O
urogenital	0	O
specimens	0	O
taken	0	O
from	0	O
symptomatic	0	O
patients	0	O
and	0	O
on	0	O
first	0	O
void	0	O
urine	0	O
(	0	O
FVU	0	O
)	0	O
specimens	0	O
from	0	O
asymptomatic	0	O
patients	0	O
.	0	O


Fasting	1	O
plasma	0	O
and	0	O
lipoprotein	0	O
lipid	0	O
concentrations	0	O
,	0	O
adipose	0	B
tissue	0	I
lipoprotein	0	I
lipase	0	I
activity	0	O
,	0	O
anthropometric	0	O
data	0	O
,	0	O
alcohol	0	O
consumption	0	O
,	0	O
smoking	0	O
habits	0	O
,	0	O
weekly	0	O
mileage	0	O
run	0	O
and	0	O
performance	0	O
on	0	O
a	0	O
bicycle	0	O
ergometer	0	O
were	0	O
recorded	0	O
before	0	O
and	0	O
after	0	O
the	0	O
training	0	O
period	0	O
.	0	O


There	0	O
were	0	O
45	0	O
to	0	O
56	0	O
nt	0	O
differences	0	O
between	0	O
the	0	O
virulent	0	O
and	0	O
avirulent	0	O
groups	0	O
while	0	O
there	0	O
were	0	O
6	0	O
to	0	O
14	0	O
nt	0	O
differences	0	O
among	0	O
four	0	O
avirulent	0	O
strains	0	O
.	0	O


He	1	O
is	0	O
well	0	O
,	0	O
five	0	O
years	0	O
after	0	O
relapse	0	O
.	0	O


Such	0	O
multisensory	0	O
interactions	0	O
can	0	O
be	0	O
significant	0	O
for	0	O
behavior	0	O
.	0	O


Thus	0	O
,	0	O
NART	0	O
-	0	O
R	1	O
performance	0	O
may	0	O
not	0	O
be	0	O
a	0	O
valid	0	O
estimate	0	O
of	0	O
baseline	0	O
IQ	1	O
for	0	O
patients	0	O
with	0	O
neurologic	0	O
disorders	0	O
with	0	O
suspected	0	O
language	0	O
impairment	0	O
.	0	O


The	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
is	0	O
highly	0	O
GC	1	O
rich	0	O
,	0	O
with	0	O
multiple	0	O
CpG	0	O
doublets	0	O
,	0	O
and	0	O
contains	0	O
multiple	0	O
binding	0	O
sites	0	O
for	0	O
Sp1	0	B
.	0	O


Platelet	1	O
counts	0	O
and	0	O
function	0	O
as	0	O
well	0	O
as	0	O
fibrinogen	0	B
and	0	O
von	0	B
Willebrand	0	I
factor	0	I
(	0	O
vWF	1	B
)	0	O
levels	0	O
were	0	O
determined	0	O
in	0	O
each	0	O
sample	0	O
.	0	O


Class	1	B
I	1	I
alpha1	0	I
,	0	I
2	0	I
-	0	I
mannosidases	0	I
play	0	O
an	0	O
essential	0	O
role	0	O
in	0	O
the	0	O
elaboration	0	O
of	0	O
complex	0	O
and	0	O
hybrid	0	O
N	1	O
-	0	O
glycans	0	O
in	0	O
mammalian	0	O
cells	0	O
.	0	O


Furthermore	0	O
,	0	O
microinjection	0	O
of	0	O
dominant	0	O
negative	0	O
forms	0	O
of	0	O
Rac	0	B
and	0	O
Cdc42	0	B
or	0	O
of	0	O
the	0	O
Rho	1	B
inhibitor	0	O
C3	1	B
transferase	0	I
blocked	0	O
serum	0	O
-	0	O
induced	0	O
DNA	1	O
synthesis	0	O
.	0	O


Northern	0	O
-	0	O
blot	0	O
analysis	0	O
of	0	O
mRNA	1	O
from	0	O
Avicel	0	O
-	0	O
grown	0	O
N	1	O
.	0	O
patriciarum	0	O
showed	0	O
that	0	O
xynB	0	B
hybridized	0	O
to	0	O
a	0	O
3	0	O
.	0	O
4	0	O
kb	0	O
mRNA	1	O
species	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
changes	0	O
in	0	O
carotid	0	O
sinus	0	O
stimulation	0	O
alters	0	O
blood	0	O
flow	0	O
to	0	O
the	0	O
hindlimb	0	O
through	0	O
changes	0	O
in	0	O
both	0	O
Pcrit	1	O
and	0	O
Ra	1	O
.	0	O


Regional	1	O
cerebral	0	O
blood	0	O
flow	0	O
was	0	O
measured	0	O
using	0	O
N	1	O
-	0	O
isopropyl	0	O
-	0	O
123I	0	O
-	0	O
iodoamphetamine	0	O
with	0	O
single	0	O
-	0	O
photon	0	O
emission	0	O
computed	0	O
tomography	0	O
(	0	O
CT	1	O
)	0	O
in	0	O
16	0	O
aged	0	O
patients	0	O
with	0	O
noninsulin	0	O
-	0	O
dependent	0	O
diabetes	0	O
mellitus	0	O
(	0	O
NIDDM	1	O
,	0	O
average	0	O
age	0	O
72	0	O
.	0	O
8	0	O
years	0	O
,	0	O
average	0	O
fasting	0	O
plasma	0	O
glucose	0	O
7	0	O
.	0	O
7	0	O
mmol	0	O
/	0	O
L	1	O
),	0	O
and	0	O
12	0	O
nondiabetic	0	O
subjects	0	O
(	0	O
71	0	O
.	0	O
6	0	O
years	0	O
,	0	O
5	0	O
.	0	O
3	0	O
mmol	0	O
/	0	O
L	1	O
).	0	O


Conversely	0	O
,	0	O
E1A	0	B
binding	0	O
to	0	O
only	0	O
p300	0	B
/	0	O
CBP	0	B
results	0	O
in	0	O
an	0	O
increase	0	O
in	0	O
PARP	0	B
enzyme	0	I
activity	0	O
and	0	O
consequently	0	O
in	0	O
cell	0	O
death	0	O
susceptibility	0	O
to	0	O
irradiation	0	O
,	0	O
which	0	O
is	0	O
effectively	0	O
counteracted	0	O
by	0	O
the	0	O
PARP	0	B
chemical	0	O
inhibitor	0	O
3	0	O
-	0	O
aminobenzamide	0	O
.	0	O


The	0	O
CD4	1	B
count	0	O
at	0	O
which	0	O
remission	0	O
occurs	0	O
may	0	O
reflect	0	O
severe	0	O
immunodeficiency	0	O
such	0	O
that	0	O
risk	0	O
for	0	O
AIDS	1	O
-	0	O
related	0	O
infection	0	O
is	0	O
high	0	O
.	0	O


Radiation	1	O
-	0	O
induced	0	O
changes	0	O
in	0	O
the	0	O
area	0	O
of	0	O
alveoli	0	O
and	0	O
septa	0	O
as	0	O
well	0	O
as	0	O
collagen	0	B
content	0	O
were	0	O
seen	0	O
11	0	O
weeks	0	O
after	0	O
irradiation	0	O
.	0	O


Therapy	1	O
with	0	O
dietary	0	O
modification	0	O
and	0	O
triglyceride	0	O
lowering	0	O
drugs	0	O
resulted	0	O
in	0	O
resolution	0	O
of	0	O
symptoms	0	O
and	0	O
parotid	0	O
swelling	0	O
in	0	O
one	0	O
patient	0	O
.	0	O


All	1	O
clones	0	O
and	0	O
strains	0	O
produced	0	O
have	0	O
been	0	O
deposited	0	O
in	0	O
the	0	O
EUROFAN	0	O
genetic	0	O
stock	0	O
centre	0	O
(	0	O
EUROSCARF	0	O
,	0	O
Frankfurt	0	O
).	0	O


Although	0	O
both	0	O
transfected	0	O
cell	0	O
lines	0	O
contain	0	O
FGF	0	B
-	0	I
1	0	I
cell	0	I
surface	0	I
receptors	0	I
as	0	O
judged	0	O
by	0	O
crosslinking	0	O
studies	0	O
,	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
transfectants	0	O
are	0	O
refractory	0	O
to	0	O
exogenous	0	O
FGF	0	B
-	0	I
1	0	I
,	0	O
whereas	0	O
the	0	O
mutant	0	O
transfectants	0	O
respond	0	O
normally	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


At	1	O
4	0	O
wk	0	O
however	0	O
,	0	O
tumor	0	O
relapse	0	O
was	0	O
noted	0	O
in	0	O
6	0	O
of	0	O
7	0	O
group	0	O
4	0	O
responders	0	O
,	0	O
10	0	O
of	0	O
12	0	O
in	0	O
group	0	O
5	0	O
,	0	O
13	0	O
of	0	O
16	0	O
in	0	O
group	0	O
7	0	O
,	0	O
but	0	O
only	0	O
4	0	O
of	0	O
19	0	O
group	0	O
8	0	O
responders	0	O
(	0	O
p	0	O
less	0	O
than	0	O
.	0	O
001	0	O
group	0	O
8	0	O
versus	0	O
4	0	O
,	0	O
5	0	O
,	0	O
7	0	O
).	0	O


Plasma	1	O
was	0	O
tested	0	O
before	0	O
and	0	O
after	0	O
(	0	O
14	0	O
+/-	0	O
7	0	O
.	0	O
5	0	O
[	0	O
SD	1	O
]	0	O
days	0	O
)	0	O
surgery	0	O
for	0	O
IgG	1	B
antibodies	0	I
to	0	O
the	0	O
complex	0	O
of	0	O
heparin	0	B
/	0	I
platelet	0	I
factor	0	I
4	0	I
,	0	O
using	0	O
a	0	O
standardized	0	O
,	0	O
validated	0	O
enzyme	0	O
-	0	O
linked	0	O
immunosorbent	0	O
assay	0	O
(	0	O
ELISA	1	O
).	0	O


Competitive	0	O
mobility	0	O
shift	0	O
assays	0	O
using	0	O
either	0	O
alphaT3	0	O
-	0	O
1	0	O
nuclear	0	O
extract	0	O
or	0	O
recombinant	0	B
SF	1	I
-	0	I
1	0	I
protein	0	I
clearly	0	O
indicated	0	O
that	0	O
SF	1	B
-	0	I
1	0	I
is	0	O
able	0	O
to	0	O
interact	0	O
specifically	0	O
with	0	O
this	0	O
GSE	1	B
element	0	I
positioned	0	O
at	0	O
-	0	O
134	0	O
.	0	O


Interestingly	0	O
,	0	O
the	0	O
positions	0	O
of	0	O
these	0	O
introns	0	O
have	0	O
been	0	O
conserved	0	O
in	0	O
comparison	0	O
with	0	O
the	0	O
genes	0	O
of	0	O
two	0	O
other	0	O
transglutaminase	0	O
-	0	O
like	0	O
activities	0	O
described	0	O
in	0	O
the	0	O
literature	0	O
,	0	O
but	0	O
the	0	O
TGM1	0	B
gene	0	I
is	0	O
by	0	O
far	0	O
the	0	O
smallest	0	O
characterized	0	O
to	0	O
date	0	O
because	0	O
its	0	O
introns	0	O
are	0	O
relatively	0	O
smaller	0	O
.	0	O


Zatebradine	0	O
weakly	0	O
depressed	0	O
the	0	O
ectopic	0	O
ventricular	0	O
rate	0	O
but	0	O
not	0	O
the	0	O
arrhythmic	0	O
ratio	0	O
of	0	O
the	0	O
ventricular	0	O
arrhythmias	0	O
induced	0	O
by	0	O
two	0	O
-	0	O
stage	0	O
coronary	0	O
ligation	0	O
24	0	O
h	0	O
after	0	O
the	0	O
ligation	0	O
in	0	O
conscious	0	O
dogs	0	O
.	0	O


This	0	O
may	0	O
result	0	O
in	0	O
more	0	O
reabsorption	0	O
and	0	O
hence	0	O
reduced	0	O
renal	0	O
clearance	0	O
.	0	O


The	0	O
region	0	O
of	0	O
plasmid	0	O
pCM2	0	O
encoding	0	O
the	0	O
pathogenicity	0	B
locus	0	I
pat	0	I
-	0	I
1	0	I
was	0	O
mapped	0	O
by	0	O
deletion	0	O
analysis	0	O
and	0	O
complementation	0	O
studies	0	O
to	0	O
a	0	O
1	0	O
.	0	O
5	0	O
-	0	O
kb	0	O
Bg	1	B
/	0	I
II	0	I
/	0	O
SmaI	0	B
DNA	1	O
fragment	0	O
.	0	O


In	1	O
PC	1	O
,	0	O
rare	0	O
MNGCs	0	O
had	0	O
intranuclear	0	O
inclusions	0	O
and	0	O
grooves	0	O
.	0	O


These	0	O
results	0	O
provide	0	O
direct	0	O
evidence	0	O
for	0	O
differential	0	O
susceptibility	0	O
to	0	O
endonuclease	0	O
-	0	O
mediated	0	O
mRNA	1	O
decay	0	O
resulting	0	O
from	0	O
the	0	O
differential	0	O
affinity	0	O
of	0	O
a	0	O
RNA	1	O
-	0	O
binding	0	O
protein	0	O
for	0	O
cis	0	O
-	0	O
acting	0	O
stability	0	O
determinants	0	O
.	0	O


Alignment	1	O
of	0	O
the	0	O
cervical	0	O
spine	0	O
,	0	O
vertebral	0	O
abnormalities	0	O
,	0	O
and	0	O
disc	0	O
changes	0	O
also	0	O
were	0	O
evaluated	0	O
.	0	O


Current	1	O
status	0	O
of	0	O
zinc	0	O
deficiency	0	O
in	0	O
the	0	O
pathogenesis	0	O
of	0	O
neurological	0	O
,	0	O
dermatological	0	O
and	0	O
musculoskeletal	0	O
disorders	0	O
.	0	O


Demyelinating	0	O
diseases	0	O
involving	0	O
the	0	O
grey	0	O
matter	0	O
were	0	O
very	0	O
rare	0	O
,	0	O
but	0	O
we	0	O
must	0	O
consider	0	O
the	0	O
presence	0	O
of	0	O
symmetrical	0	O
thalamic	0	O
involvement	0	O
in	0	O
patients	0	O
with	0	O
ADEM	1	O
.	0	O


Employing	0	O
fluorescence	0	O
spectroscopy	0	O
and	0	O
circular	0	O
dichroism	0	O
,	0	O
we	0	O
showed	0	O
that	0	O
the	0	O
binding	0	O
of	0	O
Ca2	1	O
+	0	O
to	0	O
ALG	1	B
-	0	I
2	0	I
induced	0	O
significant	0	O
conformational	0	O
changes	0	O
in	0	O
both	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
domains	0	O
of	0	O
the	0	O
protein	0	O
.	0	O


GLUT5	0	B
mRNA	1	I
is	0	O
expressed	0	O
at	0	O
highest	0	O
levels	0	O
in	0	O
small	0	O
intestine	0	O
and	0	O
at	0	O
much	0	O
lower	0	O
levels	0	O
in	0	O
kidney	0	O
,	0	O
skeletal	0	O
muscle	0	O
,	0	O
and	0	O
adipose	0	O
tissue	0	O
.	0	O


Eight	0	O
patients	0	O
with	0	O
ARC	1	O
and	0	O
renal	0	O
failure	0	O
were	0	O
recently	0	O
evaluated	0	O
.	0	O


MAIN	1	O
OUTCOME	1	O
MEASURES	0	O
:	0	O
Systemic	1	O
and	0	O
pulmonary	0	O
hemodynamics	0	O
,	0	O
arterial	0	O
blood	0	O
gas	0	O
determination	0	O
,	0	O
bronchoalveolar	0	O
lavage	0	O
protein	0	O
and	0	O
neutrophil	0	O
content	0	O
,	0	O
neutrophil	0	O
oxidant	0	O
burst	0	O
,	0	O
lung	0	B
myeloperoxidase	0	I
content	0	O
,	0	O
and	0	O
scanning	0	O
electron	0	O
micrographic	0	O
studies	0	O
.	0	O


The	0	O
C4BP	0	B
alpha	0	I
gene	0	I
is	0	O
organized	0	O
as	0	O
follows	0	O
:	0	O
the	0	O
first	0	O
exon	0	O
codes	0	O
for	0	O
the	0	O
first	0	O
198	0	O
nucleotides	0	O
of	0	O
the	0	O
5	0	O
'	0	O
UTR	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
gel	0	O
mobility	0	O
shift	0	O
experiments	0	O
have	0	O
failed	0	O
to	0	O
reveal	0	O
that	0	O
HAP2	0	B
or	0	O
HAP3	0	B
binds	0	O
to	0	O
domain	0	O
1	0	O
or	0	O
that	0	O
hap3	0	B
mutations	0	O
affect	0	O
the	0	O
complexes	0	O
bound	0	O
to	0	O
it	0	O
.	0	O


1	0	O
)	0	O
CFDN	0	O
,	0	O
AMPC	0	O
and	0	O
MNZ	0	O
showed	0	O
a	0	O
potent	0	O
antimicrobial	0	O
activity	0	O
against	0	O
H	1	O
.	0	O
pylori	0	O
,	0	O
and	0	O
especially	0	O
,	0	O
AMPC	0	O
showed	0	O
a	0	O
marked	0	O
bactericidal	0	O
activity	0	O
in	0	O
a	0	O
short	0	O
time	0	O
.	0	O


Topical	1	O
1	0	O
percent	0	O
isoproterenol	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
the	0	O
phosphodiesterase	0	O
inhibitor	0	O
theophylline	0	O
was	0	O
tested	0	O
for	0	O
its	0	O
ability	0	O
to	0	O
stimulate	0	O
the	0	O
rate	0	O
of	0	O
aqueous	0	O
humor	0	O
flow	0	O
through	0	O
the	0	O
anterior	0	O
chamber	0	O
of	0	O
the	0	O
normal	0	O
and	0	O
the	0	O
partially	0	O
adrenergically	0	O
denervated	0	O
human	0	O
eye	0	O
(	0	O
Horner	0	O
'	0	O
s	0	O
syndrome	0	O
).	0	O


Here	0	O
we	0	O
report	0	O
that	0	O
Dbp5p	0	B
and	0	O
Rat7p	0	B
interact	0	O
through	0	O
their	0	O
Nterminal	0	O
domains	0	O
.	0	O


A	1	O
possible	0	O
mechanism	0	O
is	0	O
that	0	O
elevated	0	O
alveolar	0	O
pressure	0	O
and	0	O
decreased	0	O
cardiac	0	O
output	0	O
eliminate	0	O
blood	0	O
flow	0	O
from	0	O
corner	0	O
vessels	0	O
in	0	O
nondependent	0	O
high	0	O
VA	1	O
/	0	O
Q	1	O
regions	0	O
.	0	O


Alternative	0	O
splicing	0	O
of	0	O
CDC25B	0	B
may	0	O
therefore	0	O
contribute	0	O
to	0	O
the	0	O
control	0	O
of	0	O
cell	0	O
proliferation	0	O
.	0	O


The	0	O
results	0	O
of	0	O
these	0	O
studies	0	O
demonstrate	0	O
that	0	O
the	0	O
rat	0	O
HDL	1	O
receptor	0	O
SR	1	B
-	0	I
BI	1	I
promoter	0	O
contains	0	O
two	0	O
sterol	0	O
response	0	O
elements	0	O
(	0	O
pSRE	0	O
and	0	O
dSRE	0	O
)	0	O
through	0	O
which	0	O
SREBP	0	B
-	0	I
1a	0	I
can	0	O
bind	0	O
and	0	O
activate	0	O
transcription	0	O
of	0	O
this	0	O
gene	0	O
.	0	O


The	0	O
P131	0	O
ORF	1	O
is	0	O
followed	0	O
in	0	O
-	0	O
frame	0	O
by	0	O
a	0	O
second	0	O
ORF	1	O
which	0	O
is	0	O
probably	0	O
expressed	0	O
by	0	O
partial	0	O
readthrough	0	O
of	0	O
the	0	O
UGA	0	O
termination	0	O
codon	0	O
of	0	O
the	0	O
P131	0	O
ORF	1	O
to	0	O
produce	0	O
a	0	O
polypeptide	0	O
of	0	O
M	1	O
(	0	O
r	0	O
)	0	O
191044	0	O
(	0	O
P191	0	O
).	0	O


RU486	0	O
and	0	O
ONO	0	O
802	0	O
in	0	O
combination	0	O
have	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
effective	0	O
in	0	O
early	0	O
termination	0	O
of	0	O
pregnancy	0	O
.	0	O


Northern	0	O
blot	0	O
analysis	0	O
indicates	0	O
that	0	O
AHA2	0	B
mRNA	1	I
relative	0	O
to	0	O
total	0	O
cellular	0	O
RNA	1	O
is	0	O
expressed	0	O
at	0	O
significantly	0	O
higher	0	O
levels	0	O
in	0	O
root	0	O
tissue	0	O
as	0	O
compared	0	O
with	0	O
shoot	0	O
tissue	0	O
.	0	O


The	0	O
strategies	0	O
by	0	O
which	0	O
hepatitis	0	O
B	1	O
and	0	O
hepatitis	0	O
D	1	O
can	0	O
be	0	O
diminished	0	O
and	0	O
eventually	0	O
eliminated	0	O
are	0	O
:	0	O
immunization	0	O
,	0	O
measures	0	O
to	0	O
prevent	0	O
exposure	0	O
to	0	O
infective	0	O
blood	0	O
or	0	O
blood	0	O
derivatives	0	O
and	0	O
education	0	O
(	0	O
in	0	O
particular	0	O
awareness	0	O
that	0	O
hepatitis	0	O
B	1	O
is	0	O
a	0	O
sexually	0	O
transmitted	0	O
disease	0	O
).	0	O


Precipitating	0	O
antibodies	0	O
for	0	O
Thermophilic	1	O
actinomycetes	0	O
and	0	O
M	1	O
.	0	O
f	0	O
.	0	O
were	0	O
negative	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
homologues	0	O
of	0	O
the	0	O
human	0	B
genes	0	I
PSMB5	0	I
through	0	O
PSMB9	0	B
,	0	O
two	0	O
new	0	O
genes	0	O
,	0	O
PSMB11	0	B
and	0	O
PSMB12	0	B
,	0	O
have	0	O
been	0	O
found	0	O
for	0	O
which	0	O
there	0	O
are	0	O
no	0	O
known	0	O
corresponding	0	O
genes	0	O
in	0	O
humans	0	O
.	0	O


New	0	O
techniques	0	O
for	0	O
the	0	O
mass	0	O
spectrometry	0	O
of	0	O
natural	0	O
products	0	O
.	0	O


DNase	1	B
I	1	I
footprinting	0	O
and	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
analyses	0	O
revealed	0	O
two	0	O
hepatocyte	0	B
nuclear	0	I
factor	0	I
-	0	I
1	0	I
(	0	O
HNF1	0	B
),	0	O
three	0	O
CCAAT	0	B
/	0	I
enhancer	0	I
-	0	I
binding	0	I
protein	0	I
(	0	O
C	1	B
/	0	I
EBP	1	I
),	0	O
and	0	O
one	0	O
consensus	0	O
palindromic	0	O
thyroid	0	O
hormone	0	O
response	0	O
elements	0	O
within	0	O
the	0	O
first	0	O
215	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
)	0	O
of	0	O
the	0	O
promoter	0	O
sequence	0	O
of	0	O
rat	0	B
Std	1	I
.	0	O


The	0	O
Cr	1	B
.	0	I
psbA	0	I
-	0	I
4	0	I
ORF	1	I
contains	0	O
an	0	O
H	1	O
-	0	O
N	1	O
-	0	O
H	1	O
motif	0	O
,	0	O
and	0	O
possibly	0	O
a	0	O
GIY	0	O
-	0	O
YIG	0	O
motif	0	O
.	0	O


A	1	O
comparison	0	O
of	0	O
the	0	O
predicted	0	O
polypeptide	0	O
sequence	0	O
of	0	O
the	0	O
Drosophila	1	O
protein	0	O
with	0	O
the	0	O
equivalent	0	O
subunits	0	O
from	0	O
mouse	0	O
and	0	O
yeast	0	O
suggests	0	O
that	0	O
they	0	O
are	0	O
closely	0	O
related	0	O
and	0	O
defines	0	O
three	0	O
conserved	0	O
regions	0	O
which	0	O
are	0	O
likely	0	O
to	0	O
be	0	O
important	0	O
for	0	O
enzyme	0	O
activity	0	O
.	0	O


In	1	O
vivo	0	O
,	0	O
selective	0	O
activation	0	O
of	0	O
SAPKs	0	B
stimulates	0	O
formation	0	O
of	0	O
the	0	O
ternary	0	O
complex	0	O
containing	0	O
Elk	0	B
-	0	I
1	0	I
,	0	O
serum	0	B
response	0	I
factor	0	I
and	0	O
the	0	O
serum	0	O
response	0	O
element	0	O
,	0	O
and	0	O
enhances	0	O
Elk	0	B
-	0	I
1	0	I
-	0	O
dependent	0	O
transcription	0	O
.	0	O


Agranulocytosis	1	O
treatment	0	O
with	0	O
rhGM	0	B
-	0	I
CSF	1	I


We	0	O
have	0	O
been	0	O
able	0	O
to	0	O
map	0	O
specific	0	O
DNA	1	O
fragments	0	O
at	0	O
the	0	O
bases	0	O
of	0	O
chromatin	0	O
loops	0	O
with	0	O
the	0	O
help	0	O
of	0	O
a	0	O
novel	0	O
extraction	0	O
procedure	0	O
by	0	O
using	0	O
lithium	0	O
-	0	O
3	0	O
',	0	O
5	0	O
'-	0	O
diiodosalicylate	0	O
.	0	O


However	0	O
,	0	O
primary	0	O
transcripts	0	O
of	0	O
a	0	O
variant	0	B
tRNA	1	I
(	0	I
Val	1	I
)(	0	I
UAC	0	I
)	0	I
gene	0	I
are	0	O
processing	0	O
deficient	0	O
under	0	O
standard	0	O
growth	0	O
conditions	0	O
(	0	O
30	0	O
degrees	0	O
C	1	O
),	0	O
due	0	O
to	0	O
a	0	O
slightly	0	O
altered	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
.	0	O


Precipitation	1	O
using	0	O
GST	0	B
fusion	0	I
proteins	0	I
containing	0	O
Fyn	0	B
SH2	0	I
,	0	O
SH3	0	B
,	0	O
and	0	O
SH2	0	B
/	0	O
SH3	0	B
domains	0	O
revealed	0	O
that	0	O
PI	1	B
3	0	I
-	0	I
kinase	0	I
bound	0	O
principally	0	O
to	0	O
the	0	O
SH3	0	B
domain	0	I
of	0	O
Fyn	0	B
.	0	O


Hydrallazine	0	O
also	0	O
caused	0	O
a	0	O
slight	0	O
increase	0	O
in	0	O
plasma	0	B
renin	0	I
activity	0	O
and	0	O
urinary	0	O
excretion	0	O
of	0	O
noradrenaline	0	O
.	0	O


Cis	1	O
-	0	O
regulation	0	O
downstream	0	O
of	0	O
cell	0	O
type	0	O
specification	0	O
:	0	O
a	0	O
single	0	O
compact	0	O
element	0	O
controls	0	O
the	0	O
complex	0	O
expression	0	O
of	0	O
the	0	O
CyIIa	0	B
gene	0	I
in	0	O
sea	0	O
urchin	0	O
embryos	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
the	0	O
sMtCK	0	B
genomic	0	I
upstream	0	I
sequences	0	I
reveals	0	O
a	0	O
typical	0	O
TATAA	0	O
box	0	O
within	0	O
the	0	O
80	0	O
base	0	O
pairs	0	O
(	0	O
bp	0	O
)	0	O
that	0	O
,	0	O
by	0	O
transfection	0	O
experiments	0	O
,	0	O
are	0	O
sufficient	0	O
to	0	O
promote	0	O
expression	0	O
of	0	O
chimeric	0	O
plasmids	0	O
with	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
reporter	0	I
.	0	O


Patients	0	O
with	0	O
apparently	0	O
minor	0	O
CT	1	O
abnormalities	0	O
may	0	O
have	0	O
significant	0	O
epidural	0	O
disease	0	O
.	0	O


Here	0	O
we	0	O
show	0	O
that	0	O
messenger	0	O
RNAs	0	O
encoding	0	O
trans	0	O
-	0	O
sialidases	0	O
containing	0	O
the	0	O
repeats	0	O
are	0	O
not	0	O
present	0	O
in	0	O
epimastigotes	0	O
but	0	O
are	0	O
abundant	0	O
in	0	O
trypomastigotes	0	O
.	0	O


Extramedullary	1	O
plasmacytoma	0	O
of	0	O
the	0	O
parotid	0	O
gland	0	O


DNase	1	B
I	1	I
footprint	0	O
analysis	0	O
identified	0	O
a	0	O
protected	0	O
region	0	O
from	0	O
-	0	O
37	0	O
to	0	O
-	0	O
53	0	O
.	0	O


Separate	0	O
experiments	0	O
measured	0	O
AIB	0	O
and	0	O
86RbCl	0	O
uptake	0	O
in	0	O
36B	0	O
-	0	O
10	0	O
cells	0	O
in	0	O
vitro	0	O
1	0	O
and	0	O
2	0	O
days	0	O
following	0	O
20	0	O
Gy	1	O
irradiation	0	O
to	0	O
assess	0	O
whether	0	O
this	0	O
radiation	0	O
dose	0	O
reduced	0	O
the	0	O
capacity	0	O
of	0	O
tumor	0	O
cells	0	O
to	0	O
trap	0	O
AIB	0	O
or	0	O
Rb	1	O
+.	0	O


We	0	O
have	0	O
mapped	0	O
the	0	O
human	0	B
STAG3	0	I
gene	0	I
to	0	O
the	0	O
7q22	0	O
region	0	O
of	0	O
chromosome	0	O
7	0	O
;	0	O
six	0	O
human	0	B
STAG3	0	I
-	0	I
related	0	I
genes	0	I
have	0	O
also	0	O
been	0	O
mapped	0	O
:	0	O
two	0	O
at	0	O
7q22	0	O
near	0	O
the	0	O
functional	0	O
gene	0	O
,	0	O
one	0	O
at	0	O
7q11	0	O
.	0	O
22	0	O
,	0	O
and	0	O
three	0	O
at	0	O
7q11	0	O
.	0	O
23	0	O
,	0	O
two	0	O
of	0	O
them	0	O
flanking	0	O
the	0	O
breakpoints	0	O
commonly	0	O
associated	0	O
with	0	O
the	0	O
Williams	0	B
-	0	I
Beuren	0	I
syndrome	0	I
(	0	I
WBS	0	I
)	0	I
deletion	0	I
.	0	O


Deformities	0	O
of	0	O
the	0	O
tip	0	O
of	0	O
the	0	O
olecranon	0	O
and	0	O
of	0	O
the	0	O
coronoid	0	O
process	0	O
are	0	O
also	0	O
described	0	O
(	0	O
De	0	O
Palma	1	O
1956	0	O
,	0	O
Jordan	0	O
1958	0	O
,	0	O
Ahlberg	0	O
1965	0	O
,	0	O
Weseloh	0	O
1973	0	O
).	0	O


The	0	O
tramtrack	0	B
(	0	O
ttk	0	B
)	0	O
gene	0	O
of	0	O
Drosophila	1	O
encodes	0	O
69	0	O
-	0	O
kDa	1	O
and	0	O
88	0	O
-	0	O
kDa	1	O
proteins	0	O
through	0	O
alternative	0	O
splicing	0	O
of	0	O
the	0	O
primary	0	O
ttk	0	B
transcript	0	I
.	0	O


L3	0	O
-	0	O
L4	0	O
compressive	0	O
load	0	O
was	0	O
calculated	0	O
using	0	O
a	0	O
model	0	O
of	0	O
the	0	O
anatomy	0	O
of	0	O
the	0	O
trunk	0	O
musculoskeletal	0	O
system	0	O
.	0	O


Nevertheless	0	O
,	0	O
protein	0	B
kinase	0	I
A	1	I
stimulation	0	O
induces	0	O
CREMalpha	0	B
to	0	O
activate	0	O
the	0	O
complex	0	O
native	0	O
promoter	0	O
in	0	O
the	0	O
phosphoenolpyruvate	0	B
carboxykinase	0	I
(	0	O
PEPCK	0	B
)	0	O
gene	0	O
.	0	O


In	1	O
agreement	0	O
with	0	O
these	0	O
data	0	O
,	0	O
western	0	O
blot	0	O
experiments	0	O
using	0	O
an	0	O
antibody	0	O
directed	0	O
against	0	O
the	0	O
carboxy	0	O
-	0	O
terminal	0	O
portion	0	O
of	0	O
the	0	O
mouse	0	O
c	0	B
-	0	I
kit	0	I
protein	0	I
showed	0	O
that	0	O
a	0	O
polypeptide	0	O
,	0	O
of	0	O
the	0	O
size	0	O
predicted	0	O
by	0	O
the	0	O
open	0	O
reading	0	O
frame	0	O
of	0	O
the	0	O
spermatid	0	B
-	0	I
specific	0	I
c	0	I
-	0	I
kit	0	I
cDNA	1	I
,	0	O
accumulates	0	O
in	0	O
the	0	O
latest	0	O
stages	0	O
of	0	O
spermatogenesis	0	O
and	0	O
in	0	O
epididymal	0	O
spermatozoa	0	O
.	0	O


The	0	O
calculated	0	O
pD2	0	O
values	0	O
were	0	O
8	0	O
.	0	O
8	0	O
for	0	O
E	1	O
,	0	O
8	0	O
.	0	O
6	0	O
for	0	O
DHE	0	O
and	0	O
6	0	O
.	0	O
6	0	O
for	0	O
M	1	O
.	0	O


Regulation	1	O
of	0	O
HIV	1	O
-	0	O
1	0	O
transcription	0	O
.	0	O


The	0	O
pre	0	O
-	0	O
mRNA	1	O
splicing	0	O
factor	0	O
U2AF	0	B
(	0	O
U2	0	B
small	0	I
nuclear	0	I
ribonucleoprotein	0	I
particle	0	I
[	0	I
snRNP	1	I
]	0	I
auxiliary	0	I
factor	0	I
)	0	O
plays	0	O
a	0	O
critical	0	O
role	0	O
in	0	O
3	0	O
'	0	O
splice	0	O
site	0	O
selection	0	O
.	0	O


PATIENTS	0	O
AND	0	O
METHODS	0	O
:	0	O
Immediately	0	O
before	0	O
radical	0	O
prostatectomy	0	O
,	0	O
bone	0	O
marrow	0	O
aspirates	0	O
from	0	O
both	0	O
sides	0	O
of	0	O
the	0	O
iliac	0	O
crest	0	O
were	0	O
taken	0	O
from	0	O
287	0	O
patients	0	O
.	0	O


However	0	O
,	0	O
the	0	O
ratio	0	O
M	1	O
/	0	O
Pc	1	O
provides	0	O
a	0	O
useful	0	O
index	0	O
that	0	O
seems	0	O
to	0	O
be	0	O
independent	0	O
of	0	O
the	0	O
metabolic	0	O
demand	0	O
.	0	O


Twenty	0	O
-	0	O
three	0	O
sequence	0	O
-	0	O
tagged	0	O
sites	0	O
(	0	O
STSs	0	O
)	0	O
were	0	O
mapped	0	O
within	0	O
the	0	O
contig	0	O
,	0	O
a	0	O
density	0	O
of	0	O
approximately	0	O
1	0	O
per	0	O
200	0	O
kb	0	O
.	0	O


Paleoceanographic	0	O
data	0	O
from	0	O
the	0	O
Laurentian	0	O
Fan	1	O
,	0	O
used	0	O
as	0	O
a	0	O
proxy	0	O
for	0	O
sea	0	O
surface	0	O
temperature	0	O
,	0	O
reveal	0	O
that	0	O
surface	0	O
slope	0	O
waters	0	O
north	0	O
of	0	O
the	0	O
Gulf	0	O
Stream	1	O
experienced	0	O
warming	0	O
during	0	O
the	0	O
Little	0	O
Ice	1	O
Age	1	O
of	0	O
the	0	O
16th	0	O
to	0	O
19th	0	O
centuries	0	O
and	0	O
support	0	O
the	0	O
notion	0	O
of	0	O
an	0	O
NAO	0	O
-	0	O
driven	0	O
coupled	0	O
system	0	O
.	0	O


A	1	O
model	0	O
with	0	O
age	0	O
and	0	O
weight	0	O
described	0	O
the	0	O
best	0	O
fit	0	O
for	0	O
TBBMD	0	O
,	0	O
whereas	0	O
age	0	O
,	0	O
weight	0	O
,	0	O
and	0	O
height	0	O
described	0	O
the	0	O
best	0	O
fit	0	O
for	0	O
total	0	O
body	0	O
TBBMC	0	O
.	0	O


A	1	O
neuropsychological	0	O
test	0	O
battery	0	O
was	0	O
used	0	O
that	0	O
contained	0	O
the	0	O
Wisconsin	0	O
card	0	O
sorting	0	O
test	0	O
,	0	O
Street	0	O
completion	0	O
test	0	O
,	0	O
Stroop	0	O
test	0	O
,	0	O
a	0	O
dichotic	0	O
memory	0	O
listening	0	O
test	0	O
,	0	O
and	0	O
a	0	O
facial	0	O
recognition	0	O
test	0	O
.	0	O


Activation	1	O
of	0	O
T	1	O
cells	0	O
via	0	O
the	0	O
TCR	1	B
and	0	O
other	0	O
costimulatory	0	O
receptors	0	O
triggers	0	O
a	0	O
number	0	O
of	0	O
signaling	0	O
cascades	0	O
.	0	O


However	0	O
,	0	O
there	0	O
was	0	O
a	0	O
difference	0	O
in	0	O
the	0	O
quality	0	O
of	0	O
immunity	0	O
:	0	O
fever	0	O
and	0	O
body	0	O
weight	0	O
loss	0	O
were	0	O
seen	0	O
in	0	O
hamsters	0	O
vaccinated	0	O
with	0	O
the	0	O
killed	0	O
-	0	O
toxoplasma	0	O
vaccine	0	O
after	0	O
they	0	O
were	0	O
challenge	0	O
exposed	0	O
with	0	O
T	1	O
-	0	O
1	0	O
strain	0	O
,	0	O
whereas	0	O
these	0	O
changes	0	O
were	0	O
rarely	0	O
seen	0	O
in	0	O
hamsters	0	O
given	0	O
the	0	O
live	0	O
-	0	O
toxoplasma	0	O
vaccine	0	O
and	0	O
then	0	O
challenge	0	O
exposed	0	O
with	0	O
RH	1	O
strain	0	O
.	0	O


In	1	O
this	0	O
report	0	O
,	0	O
we	0	O
identify	0	O
and	0	O
characterize	0	O
two	0	O
overlapping	0	O
ELL	0	B
functional	0	I
domains	0	I
that	0	O
govern	0	O
its	0	O
interaction	0	O
with	0	O
RNA	1	B
polymerase	0	I
II	0	I
and	0	O
the	0	O
ternary	0	O
elongation	0	O
complex	0	O
.	0	O


The	0	O
properties	0	O
of	0	O
the	0	O
phi	0	O
29	0	O
SSB	0	B
-	0	I
ssDNA	1	I
complex	0	O
are	0	O
described	0	O
.	0	O


We	0	O
investigated	0	O
the	0	O
smoking	0	O
habits	0	O
of	0	O
relapsers	0	O
1	0	O
year	0	O
after	0	O
quitting	0	O
in	0	O
a	0	O
smoking	0	O
cessation	0	O
trial	0	O
using	0	O
nicotine	0	O
or	0	O
placebo	0	O
patches	0	O
.	0	O


RPA190	0	B
encodes	0	O
a	0	O
polypeptide	0	O
chain	0	O
of	0	O
186	0	O
,	0	O
270	0	O
daltons	0	O
in	0	O
a	0	O
large	0	O
uninterrupted	0	O
reading	0	O
frame	0	O
.	0	O


Large	0	O
ones	0	O
were	0	O
similar	0	O
in	0	O
size	0	O
to	0	O
the	0	O
main	0	O
lobe	0	O
and	0	O
small	0	O
ones	0	O
were	0	O
approximately	0	O
1	0	O
/	0	O
4	0	O
of	0	O
the	0	O
length	0	O
of	0	O
the	0	O
main	0	O
lobe	0	O
.	0	O


Mothers	0	O
with	0	O
severe	0	O
anatomical	0	O
abnormalities	0	O
,	0	O
who	0	O
are	0	O
HIV	1	O
positive	0	O
,	0	O
have	0	O
active	0	O
TB	1	O
or	0	O
whose	0	O
children	0	O
have	0	O
inherited	0	O
mono	0	O
-	0	O
or	0	O
disaccharide	0	O
intolerances	0	O
should	0	O
not	0	O
breastfeed	0	O
.	0	O


The	0	O
diagnostic	0	O
accuracy	0	O
of	0	O
serum	0	O
PE	1	B
-	0	I
1	0	I
was	0	O
0	0	O
.	0	O
80	0	O
,	0	O
and	0	O
that	0	O
of	0	O
amylase	0	B
0	0	O
.	0	O
97	0	O
.	0	O


In	1	O
all	0	O
tissues	0	O
examined	0	O
only	0	O
transcripts	0	O
positive	0	O
for	0	O
insert	0	O
3	0	O
,	0	O
an	0	O
18	0	O
bp	0	O
insertion	0	O
in	0	O
repeat	0	O
21	0	O
,	0	O
were	0	O
amplified	0	O
,	0	O
even	0	O
under	0	O
conditions	0	O
in	0	O
which	0	O
a	0	O
30	0	O
%	0	O
level	0	O
of	0	O
insert	0	O
3	0	O
negative	0	O
transcript	0	O
could	0	O
be	0	O
easily	0	O
detected	0	O
in	0	O
artificially	0	O
prepared	0	O
control	0	O
samples	0	O
.	0	O


Selenium	1	O
(.	0	O
1	0	O
ppm	0	O
)	0	O
and	0	O
E	1	O
(	0	O
50	0	O
IU	1	O
/	0	O
kg	0	O
)	0	O
supplementation	0	O
of	0	O
the	0	O
diet	0	O
of	0	O
the	0	O
sow	0	O
increased	0	O
plasma	0	O
tocopherol	0	O
and	0	O
Se	1	O
concentrations	0	O
,	0	O
but	0	O
did	0	O
not	0	O
increase	0	O
plasma	0	B
glutathione	0	I
peroxidase	0	I
(	0	O
GSH	1	B
-	0	I
Px	0	I
)	0	O
activity	0	O
.	0	O


Effect	1	O
of	0	O
variations	0	O
in	0	O
time	0	O
interval	0	O
between	0	O
treatment	0	O
with	0	O
BCG	1	O
and	0	O
quartz	0	O
dust	0	O
on	0	O
translocation	0	O
of	0	O
quartz	0	O
dust	0	O
from	0	O
the	0	O
lungs	0	O
to	0	O
their	0	O
regional	0	O
lymph	0	O
nodes	0	O
.	0	O


Two	0	O
BASIC	1	O
computer	0	O
programs	0	O
using	0	O
logit	0	O
transformation	0	O
for	0	O
the	0	O
analysis	0	O
of	0	O
S	1	O
-	0	O
shaped	0	O
curves	0	O
are	0	O
presented	0	O
.	0	O


Sip1	0	B
was	0	O
initially	0	O
identified	0	O
by	0	O
virtue	0	O
of	0	O
its	0	O
interaction	0	O
with	0	O
SC35	0	B
,	0	O
a	0	O
splicing	0	O
factor	0	O
of	0	O
the	0	O
SR	1	B
family	0	I
.	0	O


Sequence	1	O
comparisons	0	O
strongly	0	O
suggest	0	O
that	0	O
the	0	O
S27a	0	B
and	0	O
the	0	O
ubiquitin	0	B
coding	0	O
sequences	0	O
found	0	O
in	0	O
the	0	O
genome	0	O
of	0	O
CP	1	O
Rit	0	O
were	0	O
both	0	O
derived	0	O
from	0	O
a	0	O
bovine	0	O
mRNA	1	O
encoding	0	O
a	0	O
hybrid	0	O
protein	0	O
with	0	O
the	0	O
structure	0	O
NH2	0	O
-	0	O
ubiquitin	0	B
-	0	O
S27a	0	B
-	0	O
COOH	0	O
.	0	O


This	0	O
relatively	0	O
simple	0	O
and	0	O
easily	0	O
performed	0	O
technique	0	O
of	0	O
measuring	0	O
deep	0	O
muscle	0	O
temperature	0	O
appears	0	O
to	0	O
be	0	O
a	0	O
useful	0	O
adjunct	0	O
in	0	O
choosing	0	O
the	0	O
amputation	0	O
level	0	O
.	0	O


A	1	O
recombinant	0	O
with	0	O
a	0	O
5	0	O
'	0	O
end	0	O
from	0	O
src	0	B
and	0	O
a	0	O
3	0	O
'	0	O
end	0	O
from	0	O
ros	0	B
,	0	O
called	0	O
SRC	1	B
x	0	O
ROS	1	B
,	0	O
transformed	0	O
chicken	0	O
embryo	0	O
fibroblasts	0	O
(	0	O
CEF	0	O
)	0	O
to	0	O
a	0	O
spindle	0	O
shape	0	O
morphology	0	O
,	0	O
mimicking	0	O
that	0	O
of	0	O
UR2	0	B
.	0	O


Mis3	0	B
is	0	O
needed	0	O
for	0	O
the	0	O
formation	0	O
of	0	O
18S	0	B
ribosome	0	I
RNA	1	I
,	0	O
and	0	O
may	0	O
hence	0	O
direct	0	O
the	0	O
level	0	O
of	0	O
proteins	0	O
required	0	O
for	0	O
the	0	O
coupling	0	O
.	0	O


None	0	O
of	0	O
the	0	O
five	0	O
proprotein	0	O
processing	0	O
proteases	0	O
tested	0	O
were	0	O
capable	0	O
of	0	O
cleaving	0	O
human	0	B
pro	0	I
-	0	I
LPH	1	I
,	0	O
strongly	0	O
suggesting	0	O
that	0	O
they	0	O
are	0	O
not	0	O
involved	0	O
in	0	O
the	0	O
maturation	0	O
of	0	O
this	0	O
enzyme	0	O
.	0	O


Additionally	0	O
,	0	O
observations	0	O
that	0	O
patients	0	O
with	0	O
mitral	0	O
versus	0	O
aortic	0	O
regurgitation	0	O
respond	0	O
differently	0	O
to	0	O
valve	0	O
replacement	0	O
suggest	0	O
that	0	O
differences	0	O
exist	0	O
preoperatively	0	O
between	0	O
these	0	O
two	0	O
types	0	O
of	0	O
volume	0	O
overload	0	O
.	0	O


Downregulation	1	O
of	0	O
FUS	1	B
expression	0	O
in	0	O
BCR	0	B
/	0	O
ABL	0	B
-	0	O
expressing	0	O
32Dcl3	0	O
cells	0	O
was	0	O
associated	0	O
with	0	O
suppression	0	O
of	0	O
growth	0	O
factor	0	O
-	0	O
independent	0	O
colony	0	O
formation	0	O
,	0	O
restoration	0	O
of	0	O
G	1	B
-	0	I
CSF	1	I
-	0	O
induced	0	O
granulocytic	0	O
differentiation	0	O
and	0	O
reduced	0	O
tumorigenic	0	O
potential	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
calcium	0	O
antagonist	0	O
,	0	O
diltiazem	0	O
,	0	O
may	0	O
modify	0	O
the	0	O
effects	0	O
of	0	O
isoflurane	0	O
on	0	O
myocardial	0	O
function	0	O
.	0	O


Of	0	O
419	0	O
persons	0	O
surveyed	0	O
,	0	O
207	0	O
(	0	O
49	0	O
.	0	O
4	0	O
%)	0	O
were	0	O
antigen	0	O
-	0	O
positive	0	O
with	0	O
the	0	O
Og4C3	0	B
assay	0	O
.	0	O


Xenopus	1	B
homolog	0	I
of	0	I
the	0	I
mos	0	I
protooncogene	0	I
transforms	0	O
mammalian	0	O
fibroblasts	0	O
and	0	O
induces	0	O
maturation	0	O
of	0	O
Xenopus	1	O
oocytes	0	O
.	0	O


Both	0	O
filters	0	O
equally	0	O
contributed	0	O
to	0	O
elevation	0	O
of	0	O
iliac	0	O
venous	0	O
pressure	0	O
(	0	O
median	0	O
,	0	O
9	0	O
.	0	O
3	0	O
and	0	O
7	0	O
.	0	O
2	0	O
mm	0	O
Hg	1	O
[	0	O
n	0	O
=	0	O
9	0	O
]	0	O
with	0	O
the	0	O
spring	0	O
filter	0	O
and	0	O
RF02	0	O
filter	0	O
,	0	O
respectively	0	O
).	0	O


The	0	O
efficacy	0	O
and	0	O
safety	0	O
of	0	O
a	0	O
novel	0	O
percutaneous	0	O
anaesthetic	0	O
preparation	0	O
based	0	O
on	0	O
amethocaine	0	O
has	0	O
been	0	O
investigated	0	O
in	0	O
the	0	O
paediatric	0	O
clinical	0	O
environment	0	O
.	0	O


Imaging	1	O
features	0	O
of	0	O
splenic	0	O
epidermoid	0	O
cyst	0	O
with	0	O
pathologic	0	O
correlation	0	O
.	0	O


PCR	1	O
/	0	O
Southern	0	O
blot	0	O
analysis	0	O
of	0	O
human	0	O
kidney	0	O
cDNA	1	O
using	0	O
primers	0	O
flanking	0	O
the	0	O
hKID	0	B
coding	0	I
sequence	0	I
revealed	0	O
expression	0	O
of	0	O
a	0	O
full	0	O
-	0	O
length	0	O
mRNA	1	O
and	0	O
short	0	O
transcripts	0	O
with	0	O
partial	0	O
exon	0	O
1	0	O
and	0	O
partial	0	O
exon	0	O
4	0	O
deletions	0	O
.	0	O


The	0	O
mean	0	O
values	0	O
of	0	O
the	0	O
first	0	O
three	0	O
components	0	O
were	0	O
not	0	O
significantly	0	O
different	0	O
in	0	O
ARVD	0	O
patients	0	O
and	0	O
control	0	O
subjects	0	O
.	0	O


The	0	O
5	0	O
-	0	O
year	0	O
OS	1	O
for	0	O
stage	0	O
IIIB	0	O
was	0	O
30	0	O
.	0	O
9	0	O
%,	0	O
compared	0	O
to	0	O
7	0	O
.	0	O
8	0	O
%	0	O
for	0	O
stage	0	O
IV	1	O
.	0	O


Collectively	0	O
,	0	O
these	0	O
results	0	O
show	0	O
that	0	O
the	0	O
differential	0	O
utilization	0	O
of	0	O
Staf	0	B
zinc	0	I
finger	0	I
1	0	I
represents	0	O
a	0	O
new	0	O
,	0	O
critical	0	O
determinant	0	O
of	0	O
the	0	O
transcriptional	0	O
activation	0	O
mechanism	0	O
for	0	O
the	0	O
Xenopus	1	B
tRNA	1	I
(	0	O
Sec	0	B
)	0	O
and	0	O
human	0	B
U6	0	I
snRNA	1	I
genes	0	I
.	0	O


The	0	O
lack	0	O
of	0	O
change	0	O
in	0	O
the	0	O
ratio	0	O
of	0	O
the	0	O
two	0	O
spliced	0	O
products	0	O
expressed	0	O
from	0	O
either	0	O
the	0	O
normal	0	O
or	0	O
the	0	O
5	0	B
'-	0	I
rearranged	0	I
myb	0	I
further	0	O
indicates	0	O
that	0	O
the	0	O
insertion	0	O
of	0	O
the	0	O
unique	0	O
121	0	O
amino	0	O
acids	0	O
in	0	O
the	0	O
larger	0	O
myb	0	B
transcripts	0	I
is	0	O
not	0	O
a	0	O
consequence	0	O
of	0	O
tumor	0	O
-	0	O
specific	0	O
activation	0	O
of	0	O
the	0	O
mouse	0	B
myb	0	I
oncogene	0	I
.	0	O


Substitution	1	O
of	0	O
the	0	O
Ser	1	O
-	0	O
Thr	1	O
sites	0	O
with	0	O
the	0	O
phosphomimetic	0	O
Asp	1	O
generated	0	O
a	0	O
constitutively	0	O
active	0	O
form	0	O
of	0	O
IRF	1	B
-	0	I
3	0	I
that	0	O
functioned	0	O
as	0	O
a	0	O
very	0	O
strong	0	O
activator	0	O
of	0	O
promoters	0	O
containing	0	O
PRDI	0	B
-	0	O
PRDIII	0	B
or	0	O
ISRE	0	B
regulatory	0	I
elements	0	I
.	0	O


A	1	O
safe	0	O
and	0	O
simple	0	O
system	0	O
for	0	O
the	0	O
detection	0	O
of	0	O
sudden	0	O
infant	0	O
death	0	O
syndrome	0	O
(	0	O
SIDS	1	O
)	0	O
is	0	O
proposed	0	O
.	0	O


The	0	O
absolute	0	O
concentrations	0	O
of	0	O
alpha	0	B
2	0	I
-	0	I
plasmin	0	I
inhibitor	0	O
,	0	O
alpha	0	B
2	0	I
-	0	I
macroglobulin	0	I
,	0	O
and	0	O
antithrombin	0	B
III	0	I
increased	0	O
with	0	O
exercise	0	O
(	0	O
all	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
005	0	O
),	0	O
but	0	O
when	0	O
concentrations	0	O
were	0	O
corrected	0	O
for	0	O
acute	0	O
shifts	0	O
of	0	O
plasma	0	O
water	0	O
during	0	O
exercise	0	O
,	0	O
the	0	O
quantity	0	O
of	0	O
these	0	O
inhibitors	0	O
actually	0	O
decreased	0	O
(	0	O
all	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
005	0	O
).	0	O


Like	0	O
pineal	0	O
melatonin	0	O
,	0	O
serum	0	O
melatonin	0	O
was	0	O
high	0	O
at	0	O
mid	0	O
-	0	O
dark	0	O
and	0	O
low	0	O
at	0	O
mid	0	O
-	0	O
light	0	O
.	0	O


Disruption	1	O
of	0	O
the	0	O
IRA2	0	B
gene	0	I
resulted	0	O
in	0	O
(	0	O
i	0	O
)	0	O
increased	0	O
sensitivity	0	O
to	0	O
heat	0	O
shock	0	O
and	0	O
nitrogen	0	O
starvation	0	O
,	0	O
(	0	O
ii	0	O
)	0	O
sporulation	0	O
defects	0	O
,	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
suppression	0	O
of	0	O
the	0	O
lethality	0	O
of	0	O
the	0	O
cdc25	0	B
mutant	0	I
.	0	O


The	0	O
"	0	O
tobacco	0	O
issue	0	O
".	0	O


The	0	O
loss	0	O
of	0	O
SKO1	0	B
completely	0	O
restored	0	O
ENA1	0	B
expression	0	O
in	0	O
a	0	O
hog1	0	B
mutant	0	I
and	0	O
partially	0	O
suppressed	0	O
the	0	O
osmotic	0	O
stress	0	O
sensitivity	0	O
,	0	O
qualifying	0	O
Sko1p	0	B
as	0	O
a	0	O
downstream	0	O
effector	0	O
of	0	O
the	0	O
HOG	0	B
pathway	0	O
.	0	O


GETS	0	B
-	0	I
1	0	I
is	0	O
expressed	0	O
in	0	O
many	0	O
tissues	0	O
,	0	O
but	0	O
is	0	O
enriched	0	O
in	0	O
retina	0	O
and	0	O
brain	0	O
.	0	O


Our	0	O
findings	0	O
demonstrate	0	O
a	0	O
dose	0	O
-	0	O
dependent	0	O
blockade	0	O
of	0	O
the	0	O
mechanical	0	O
sensitivity	0	O
caused	0	O
by	0	O
a	0	O
mild	0	O
thermal	0	O
injury	0	O
by	0	O
both	0	O
GBP	0	O
and	0	O
IBG	0	O
.	0	O


RESULTS	0	O
:	0	O
Nodular	1	O
opacities	0	O
,	0	O
mainly	0	O
centrilobular	0	O
in	0	O
distribution	0	O
,	0	O
were	0	O
the	0	O
most	0	O
common	0	O
finding	0	O
,	0	O
seen	0	O
in	0	O
21	0	O
(	0	O
72	0	O
%)	0	O
and	0	O
15	0	O
(	0	O
65	0	O
%)	0	O
of	0	O
patients	0	O
with	0	O
MTB	0	O
and	0	O
NTMB	0	O
,	0	O
respectively	0	O
.	0	O


Regulation	1	O
of	0	O
ASN1	0	B
and	0	O
ASN2	0	B
expression	0	O
was	0	O
studied	0	O
using	0	O
lacZ	0	B
fusions	0	I
and	0	O
both	0	O
genes	0	O
were	0	O
found	0	O
to	0	O
be	0	O
several	0	O
times	0	O
less	0	O
expressed	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
the	0	O
transcription	0	O
activator	0	O
Gcn4p	0	B
.	0	O


Swim	0	O
-	0	O
over	0	O
:	0	O
an	0	O
alternative	0	O
method	0	O
for	0	O
harvesting	0	O
motile	0	O
spermatozoa	0	O
.	0	O


METHODS	0	O
:	0	O
Rats	0	O
received	0	O
continuous	0	O
intragastric	0	O
infusion	0	O
of	0	O
elemental	0	O
diet	0	O
or	0	O
with	0	O
supplementation	0	O
of	0	O
oatbase	0	O
,	0	O
Lactobacillus	1	O
reuteri	0	O
R2LC	0	O
,	0	O
and	0	O
Lactobacillus	1	O
plantarum	0	O
DSM	1	O
9843	0	O
,	0	O
with	0	O
and	0	O
without	0	O
fermentation	0	O
,	0	O
from	0	O
the	0	O
beginning	0	O
of	0	O
the	0	O
study	0	O
.	0	O


As	1	O
the	0	O
rate	0	O
of	0	O
protein	0	O
synthesis	0	O
decreases	0	O
during	0	O
late	0	O
embryogenesis	0	O
,	0	O
levels	0	O
of	0	O
SEC	0	B
-	0	I
1	0	I
and	0	O
its	0	O
cognate	0	O
mRNA	1	O
decline	0	O
precipitously	0	O
.	0	O


Cloning	1	O
and	0	O
expression	0	O
of	0	O
two	0	O
genes	0	O
encoding	0	O
auxin	0	B
-	0	I
binding	0	I
proteins	0	I
from	0	O
tobacco	0	O
.	0	O


Judge	0	O
OKs	0	O
docs	0	O
'	0	O
bid	0	O
for	0	O
Chicago	0	O
hospital	0	O
.	0	O


Abnormal	1	O
intrapulmonary	0	O
shunting	0	O
(	0	O
IPS	0	O
),	0	O
which	0	O
was	0	O
proved	0	O
in	0	O
4	0	O
cases	0	O
by	0	O
whole	0	O
-	0	O
body	0	O
radionuclide	0	O
scanning	0	O
with	0	O
99mTc	0	O
-	0	O
MAA	1	O
,	0	O
is	0	O
suggested	0	O
as	0	O
the	0	O
major	0	O
cause	0	O
of	0	O
cyanosis	0	O
in	0	O
liver	0	O
cirrhosis	0	O
.	0	O


In	1	O
these	0	O
constructs	0	O
,	0	O
GUS	0	B
expression	0	O
was	0	O
driven	0	O
by	0	O
promoter	0	O
regions	0	O
derived	0	O
from	0	O
the	0	O
Arabidopsis	0	B
alcohol	0	I
dehydrogenase	0	I
(	0	O
Adh1	0	B
),	0	O
maize	0	B
ubiquitin	0	I
(	0	O
Ubi1	0	B
),	0	O
rice	0	B
actin	0	I
(	0	O
Act1	0	B
)	0	O
and	0	O
CaMV	0	B
35S	0	I
genes	0	I
.	0	O


At	1	O
all	0	O
time	0	O
-	0	O
points	0	O
,	0	O
most	0	O
patients	0	O
(>/=	0	O
87	0	O
%)	0	O
were	0	O
receiving	0	O
irbesartan	0	O
/	0	O
HCTZ	0	O
alone	0	O
.	0	O


The	0	O
nm23	0	B
-	0	I
H1	1	I
/	0	O
nm23	0	B
-	0	I
H2	0	I
gene	0	O
transcriptional	0	O
activity	0	O
ratio	0	O
varied	0	O
depending	0	O
on	0	O
the	0	O
cell	0	O
line	0	O
.	0	O


Once	0	O
P	1	B
-	0	I
450scc	0	I
mRNA	1	I
is	0	O
induced	0	O
as	0	O
a	0	O
consequence	0	O
of	0	O
the	0	O
LH	1	B
/	0	O
hCG	1	B
surge	0	O
it	0	O
is	0	O
constitutively	0	O
maintained	0	O
by	0	O
luteinized	0	O
cells	0	O
in	0	O
vivo	0	O
(	0	O
0	0	O
-	0	O
4	0	O
days	0	O
)	0	O
and	0	O
in	0	O
vitro	0	O
(	0	O
0	0	O
-	0	O
9	0	O
days	0	O
)	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
gonadotropins	0	B
,	0	O
is	0	O
susceptible	0	O
to	0	O
modulation	0	O
by	0	O
prolactin	0	B
and	0	O
is	0	O
no	0	O
longer	0	O
regulated	0	O
by	0	O
cAMP	1	O
.	0	O


A	1	O
single	0	O
exon	0	O
encodes	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
26	0	O
amino	0	O
acids	0	O
of	0	O
the	0	O
ssd	0	B
chain	0	I
and	0	O
the	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
of	0	O
its	0	O
mRNA	1	O
,	0	O
ending	0	O
with	0	O
a	0	O
poly	0	O
(	0	O
A	1	O
)-	0	O
addition	0	O
site	0	O
.	0	O


Nucleotide	1	O
sequences	0	O
of	0	O
the	0	O
clones	0	O
revealed	0	O
that	0	O
one	0	O
clone	0	O
,	0	O
cap3	0	B
,	0	O
contained	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
ORF	1	O
)	0	O
that	0	O
would	0	O
code	0	O
for	0	O
a	0	O
26	0	O
-	0	O
amino	0	O
acid	0	O
,	0	O
cysteine	0	O
-	0	O
rich	0	O
peptide	0	O
with	0	O
significant	0	O
homology	0	O
to	0	O
Neurospora	1	B
crassa	0	I
copper	0	I
metallothionein	0	I
.	0	O


The	0	O
pen	0	O
can	0	O
heal	0	O
.	0	O


Early	0	O
cirrhosis	0	O
,	0	O
an	0	O
early	0	O
modality	0	O
of	0	O
the	0	O
evolution	0	O
of	0	O
acute	0	O
hepatitis	0	O
.	0	O


Therefore	0	O
,	0	O
in	0	O
our	0	O
in	0	O
vitro	0	O
model	0	O
,	0	O
the	0	O
localization	0	O
of	0	O
the	0	O
mutation	0	O
in	0	O
the	0	O
K	1	B
-	0	I
ras	0	I
gene	0	I
predisposes	0	O
to	0	O
a	0	O
different	0	O
level	0	O
of	0	O
aggressiveness	0	O
in	0	O
the	0	O
transforming	0	O
phenotype	0	O
.	0	O


In	1	O
a	0	O
country	0	O
where	0	O
general	0	O
HIV	1	O
prevalence	0	O
is	0	O
low	0	O
,	0	O
the	0	O
strategy	0	O
is	0	O
cost	0	O
-	0	O
effective	0	O
for	0	O
location	0	O
and	0	O
counselling	0	O
of	0	O
unknowingly	0	O
seropositive	0	O
individuals	0	O
.	0	O


Relatively	0	O
large	0	O
DNA	1	O
rearrangements	0	O
spanning	0	O
the	0	O
region	0	O
with	0	O
tandem	0	O
direct	0	O
repeats	0	O
encoding	0	O
the	0	O
carboxy	0	O
-	0	O
terminal	0	O
histone	0	B
H1	1	I
-	0	I
like	0	I
structure	0	O
of	0	O
AlgP	0	B
were	0	O
detected	0	O
in	0	O
several	0	O
strains	0	O
upon	0	O
conversion	0	O
from	0	O
the	0	O
mucoid	0	O
to	0	O
the	0	O
nonmucoid	0	O
phenotype	0	O
.	0	O


Mapping	1	O
of	0	O
RNA	1	O
-	0	O
temperature	0	B
-	0	I
sensitive	0	I
mutants	0	I
of	0	I
Sindbis	0	I
virus	0	I
:	0	I
complementation	0	I
group	0	I
F	1	I
mutants	0	I
have	0	O
lesions	0	O
in	0	O
nsP4	0	B
.	0	O


In	1	O
spite	0	O
of	0	O
this	0	O
and	0	O
other	0	O
complications	0	O
of	0	O
corticosteroids	0	O
,	0	O
she	0	O
made	0	O
a	0	O
full	0	O
recovery	0	O
from	0	O
the	0	O
fungal	0	O
infection	0	O
following	0	O
treatment	0	O
with	0	O
amphotericin	0	O
B	1	O
and	0	O
surgical	0	O
excision	0	O
of	0	O
the	0	O
lung	0	O
abscess	0	O
.	0	O


The	0	O
protein	0	O
folds	0	O
correctly	0	O
with	0	O
two	0	O
disulfide	0	O
bonds	0	O
and	0	O
a	0	O
free	0	O
thiol	0	O
group	0	O
at	0	O
Cys25	0	O
.	0	O


Total	0	O
VO2	1	O
was	0	O
decreased	0	O
in	0	O
both	0	O
groups	0	O
during	0	O
severe	0	O
hypoxia	0	O
but	0	O
limb	0	O
VO2	1	O
was	0	O
maintained	0	O
in	0	O
the	0	O
beta	0	O
-	0	O
block	0	O
group	0	O
.	0	O
beta	0	O
-	0	O
Block	1	O
prevented	0	O
the	0	O
fall	0	O
in	0	O
total	0	O
and	0	O
limb	0	O
peripheral	0	O
resistance	0	O
seen	0	O
in	0	O
severe	0	O
hypoxia	0	O
but	0	O
did	0	O
not	0	O
alter	0	O
the	0	O
consistently	0	O
more	0	O
efficient	0	O
utilization	0	O
of	0	O
total	0	O
O2	1	O
delivery	0	O
shown	0	O
by	0	O
the	0	O
limb	0	O
in	0	O
comparison	0	O
to	0	O
the	0	O
whole	0	O
body	0	O
by	0	O
higher	0	O
O2	1	O
extraction	0	O
ratios	0	O
and	0	O
lower	0	O
venous	0	O
O2	1	O
pressure	0	O
.	0	O
beta	0	B
-	0	I
Vasodilator	1	I
receptors	0	I
evidently	0	O
played	0	O
an	0	O
active	0	O
part	0	O
in	0	O
the	0	O
vasodilatation	0	O
seen	0	O
during	0	O
severe	0	O
hypoxia	0	O
.	0	O


Transcription	1	O
factor	0	O
recognition	0	O
surface	0	O
on	0	O
the	0	O
RNA	1	B
polymerase	0	I
alpha	0	I
subunit	0	I
is	0	O
involved	0	O
in	0	O
contact	0	O
with	0	O
the	0	O
DNA	1	O
enhancer	0	O
element	0	O
.	0	O


Ivermectin	1	O
uptake	0	O
and	0	O
distribution	0	O
in	0	O
the	0	O
plasma	0	O
and	0	O
tissue	0	O
of	0	O
Sudanese	0	O
and	0	O
Mexican	0	O
patients	0	O
infected	0	O
with	0	O
Onchocerca	1	O
volvulus	0	O
.	0	O


Plasma	1	O
thrombomodulin	0	B
:	0	O
a	0	O
marker	0	O
for	0	O
microvascular	0	O
complications	0	O
in	0	O
diabetes	0	O
mellitus	0	O
.	0	O


The	0	O
feed	0	O
consumed	0	O
which	0	O
was	0	O
lowered	0	O
by	0	O
25	0	O
%	0	O
initially	0	O
,	0	O
did	0	O
not	0	O
alter	0	O
later	0	O
.	0	O


These	0	O
data	0	O
should	0	O
be	0	O
useful	0	O
in	0	O
developing	0	O
reagents	0	O
for	0	O
heterozygote	0	O
detection	0	O
and	0	O
prenatal	0	O
diagnosis	0	O
of	0	O
11	0	B
beta	0	I
-	0	I
hydroxylase	0	I
deficiency	0	O
,	0	O
the	0	O
second	0	O
most	0	O
frequent	0	O
cause	0	O
of	0	O
congenital	0	O
adrenal	0	O
hyperplasia	0	O
.	0	O


A	1	O
DNA	1	O
fragment	0	O
carrying	0	O
1	0	O
,	0	O
100	0	O
nucleotides	0	O
derived	0	O
from	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
UGT1A1	0	B
gene	0	I
was	0	O
enough	0	O
for	0	O
MC	1	O
induction	0	O
.	0	O


High	0	O
radial	0	O
r	0	O
values	0	O
with	0	O
small	0	O
standard	0	O
deviations	0	O
were	0	O
observed	0	O
in	0	O
normal	0	O
LV	1	O
(	0	O
0	0	O
.	0	O
972	0	O
+/-	0	O
0	0	O
.	0	O
016	0	O
)	0	O
and	0	O
in	0	O
non	0	O
-	0	O
MI	1	O
regions	0	O
(	0	O
0	0	O
.	0	O
964	0	O
+/-	0	O
0	0	O
.	0	O
018	0	O
),	0	O
indicating	0	O
temporally	0	O
homogeneous	0	O
radial	0	O
shortening	0	O
.	0	O


The	0	O
extraction	0	O
recovery	0	O
of	0	O
Amphotericin	0	O
B	1	O
from	0	O
the	0	O
cerebrospinal	0	O
fluid	0	O
is	0	O
higher	0	O
than	0	O
90	0	O
%	0	O
over	0	O
the	0	O
entire	0	O
linear	0	O
range	0	O
.	0	O


In	1	O
44	0	O
evaluable	0	O
patients	0	O
the	0	O
response	0	O
rate	0	O
was	0	O
50	0	O
%,	0	O
with	0	O
one	0	O
complete	0	O
response	0	O
.	0	O


The	0	O
obtained	0	O
results	0	O
were	0	O
compared	0	O
with	0	O
control	0	O
group	0	O
(	0	O
10	0	O
female	0	O
volunteers	0	O
).	0	O


Distribution	1	O
and	0	O
changing	0	O
morphological	0	O
course	0	O


Through	0	O
transient	0	O
transfection	0	O
of	0	O
NIH3T3	0	O
fibroblast	0	O
cells	0	O
and	0	O
gel	0	O
mobility	0	O
shift	0	O
assays	0	O
,	0	O
the	0	O
functional	0	O
binding	0	O
site	0	O
was	0	O
localized	0	O
to	0	O
a	0	O
short	0	O
region	0	O
(-	0	O
318	0	O
to	0	O
-	0	O
303	0	O
bp	0	O
from	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
)	0	O
which	0	O
has	0	O
a	0	O
CTCCC	0	O
sequence	0	O
.	0	O


Mae	0	O
West	0	O
and	0	O
the	0	O
doctor	0	O
shortage	0	O
.	0	O


Therefore	0	O
,	0	O
we	0	O
conclude	0	O
that	0	O
DnaA	0	B
may	0	O
contact	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
RNA	1	B
polymerase	0	I
during	0	O
activation	0	O
of	0	O
the	0	O
pR	1	B
promoter	0	I
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
,	0	O
we	0	O
have	0	O
isolated	0	O
and	0	O
sequenced	0	O
several	0	O
p15E	0	B
cDNA	1	I
gene	0	I
fragments	0	I
amplified	0	O
by	0	O
means	0	O
of	0	O
polymerase	0	O
chain	0	O
reaction	0	O
(	0	O
PCR	1	O
)	0	O
from	0	O
parental	0	O
(	0	O
P815	0	O
)	0	O
and	0	O
xenogenized	0	O
(	0	O
P815	0	O
/	0	O
DTIC	1	O
)	0	O
tumour	0	O
cells	0	O
.	0	O


Cotransfection	1	O
of	0	O
either	0	O
construct	0	O
with	0	O
plasmids	0	O
encoding	0	O
PKI	0	B
(	0	I
1	0	I
-	0	I
31	0	I
)	0	I
inhibits	0	O
cAMP	1	O
-	0	O
stimulated	0	O
but	0	O
not	0	O
basal	0	O
-	0	O
or	0	O
phorbol	0	O
ester	0	O
-	0	O
stimulated	0	O
expression	0	O
.	0	O


In	1	O
our	0	O
studies	0	O
,	0	O
we	0	O
utilized	0	O
HIV	1	O
-	0	O
1	0	O
HXB2	0	B
and	0	O
HIV	1	O
-	0	O
1	0	O
Z2Z6	0	B
core	0	I
enhancers	0	I
because	0	O
the	0	O
Z2Z6	0	B
strain	0	O
has	0	O
a	0	O
single	0	O
point	0	O
mutation	0	O
flanking	0	O
the	0	O
right	0	O
ETS	1	B
-	0	I
binding	0	I
site	0	I
.	0	O


Diagnosis	1	O
and	0	O
treatment	0	O
planning	0	O
in	0	O
Class	1	O
II	0	O
,	0	O
division	0	O
2	0	O


RESULTS	0	O
:	0	O
For	0	O
E1	1	O
,	0	O
itraconazole	0	O
plasma	0	O
drug	0	O
concentration	0	O
extrapolated	0	O
to	0	O
time	0	O
zero	0	O
(	0	O
IV	1	O
dose	0	O
)	0	O
was	0	O
5	0	O
.	0	O
2	0	O
+/-	0	O
1	0	O
.	0	O
4	0	O
micrograms	0	O
/	0	O
ml	0	O
,	0	O
and	0	O
mean	0	O
residence	0	O
time	0	O
(	0	O
MRT	1	O
)	0	O
was	0	O
37	0	O
+/-	0	O
16	0	O
hours	0	O
.	0	O


The	0	O
recruitment	0	O
of	0	O
constitutively	0	O
phosphorylated	0	O
p185	0	B
(	0	O
neu	0	B
)	0	O
and	0	O
the	0	O
activated	0	O
mitogenic	0	O
pathway	0	O
proteins	0	O
to	0	O
this	0	O
membrane	0	O
-	0	O
microfilament	0	O
interaction	0	O
site	0	O
provides	0	O
a	0	O
physical	0	O
model	0	O
for	0	O
integrating	0	O
the	0	O
assembly	0	O
of	0	O
the	0	O
mitogenic	0	O
pathway	0	O
with	0	O
the	0	O
transmission	0	O
of	0	O
growth	0	O
factor	0	O
signal	0	O
to	0	O
the	0	O
cytoskeleton	0	O
.	0	O


Xenopus	1	B
Ran	0	I
-	0	I
binding	0	I
protein	0	I
1	0	I
:	0	O
molecular	0	O
interactions	0	O
and	0	O
effects	0	O
on	0	O
nuclear	0	O
assembly	0	O
in	0	O
Xenopus	1	O
egg	0	O
extracts	0	O
.	0	O


According	0	O
to	0	O
the	0	O
results	0	O
of	0	O
assays	0	O
obtained	0	O
with	0	O
the	0	O
use	0	O
of	0	O
assay	0	O
systems	0	O
ORTHO	0	O
ELISA	1	O
and	0	O
ABBOTT	0	O
HCV	1	O
EIA	1	O
(	0	O
USA	0	O
),	0	O
the	0	O
detection	0	O
rate	0	O
of	0	O
anti	0	B
-	0	I
HCV	1	I
-	0	I
C100	0	I
-	0	I
3	0	I
among	0	O
primary	0	O
blood	0	O
donors	0	O
in	0	O
Moscow	0	O
was	0	O
1	0	O
.	0	O
37	0	O
%	0	O
and	0	O
was	0	O
not	0	O
different	0	O
from	0	O
that	0	O
among	0	O
HBsAg	1	B
carriers	0	O
(	0	O
1	0	O
.	0	O
8	0	O
%)	0	O
and	0	O
among	0	O
donors	0	O
with	0	O
anti	0	B
-	0	I
HCV	1	I
-	0	I
C100	0	I
-	0	I
3	0	I
in	0	O
the	0	O
blood	0	O
(	0	O
1	0	O
.	0	O
6	0	O
%)	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Thyroid	1	O
disease	0	O
and	0	O
pregnancy	0	O
.	0	O


X	1	O
-	0	O
ray	0	O
crystallographic	0	O
data	0	O
show	0	O
that	0	O
the	0	O
PLZF	0	B
BTB	0	I
/	0	O
POZ	0	O
domain	0	O
forms	0	O
an	0	O
obligate	0	O
homodimer	0	O
via	0	O
an	0	O
extensive	0	O
interface	0	O
.	0	O


These	0	O
lesions	0	O
were	0	O
asymptomatic	0	O
,	0	O
but	0	O
both	0	O
were	0	O
characterized	0	O
clinically	0	O
by	0	O
central	0	O
ulceration	0	O
.	0	O


Band	1	O
-	0	O
shift	0	O
assays	0	O
and	0	O
DNase	1	B
I	1	I
footprinting	0	O
experiments	0	O
using	0	O
purified	0	O
42	0	O
kDa	1	O
repressor	0	O
isoform	0	O
confirmed	0	O
that	0	O
CIRs	0	B
5	0	I
and	0	I
6	0	I
were	0	O
indeed	0	O
the	0	O
targets	0	O
for	0	O
binding	0	O
of	0	O
this	0	O
protein	0	O
.	0	O


These	0	O
well	0	O
-	0	O
characterized	0	O
brain	0	O
regions	0	O
may	0	O
provide	0	O
a	0	O
basis	0	O
for	0	O
future	0	O
studies	0	O
of	0	O
RPTP	0	B
-	0	I
kappa	0	I
function	0	O
.	0	O


Improvement	0	O
of	0	O
the	0	O
polypyrimidine	0	O
tract	0	O
also	0	O
increased	0	O
the	0	O
splicing	0	O
efficiency	0	O
,	0	O
but	0	O
to	0	O
a	0	O
degree	0	O
slightly	0	O
less	0	O
than	0	O
that	0	O
obtained	0	O
with	0	O
the	0	O
branchpoint	0	O
mutation	0	O
.	0	O


Some	0	O
artificial	0	O
promoter	0	O
constructs	0	O
containing	0	O
multiple	0	O
Sp1	0	B
sites	0	I
were	0	O
highly	0	O
responsive	0	O
to	0	O
ethanol	0	O
,	0	O
but	0	O
others	0	O
were	0	O
not	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
organization	0	O
of	0	O
the	0	O
proximal	0	O
promoter	0	O
region	0	O
was	0	O
an	0	O
additional	0	O
factor	0	O
that	0	O
affected	0	O
the	0	O
ethanol	0	O
response	0	O
.	0	O


During	0	O
the	0	O
biosynthesis	0	O
of	0	O
all	0	O
three	0	O
mutant	0	O
polypeptides	0	O
,	0	O
the	0	O
signal	0	O
peptide	0	O
is	0	O
efficiently	0	O
and	0	O
accurately	0	O
cleaved	0	O
from	0	O
the	0	O
nascent	0	O
protein	0	O
,	0	O
even	0	O
though	0	O
in	0	O
mutants	0	O
X2	0	O
and	0	O
X3	0	O
the	0	O
cleavage	0	O
site	0	O
itself	0	O
has	0	O
been	0	O
altered	0	O
.	0	O


EMSA	0	O
competition	0	O
experiments	0	O
showed	0	O
that	0	O
mutations	0	O
within	0	O
the	0	O
direct	0	O
repeats	0	O
failed	0	O
to	0	O
compete	0	O
for	0	O
binding	0	O
of	0	O
the	0	O
nuclear	0	O
proteins	0	O
to	0	O
labeled	0	O
wild	0	O
type	0	O
oligonucleotide	0	O
.	0	O


Mean	1	O
longitudinal	0	O
extension	0	O
of	0	O
the	0	O
epidural	0	O
lesion	0	O
was	0	O
2	0	O
.	0	O
6	0	O
vertebral	0	O
segments	0	O
.	0	O


Cardiac	1	O
taurine	0	O
levels	0	O
and	0	O
sarcolemmal	0	O
calcium	0	O
binding	0	O
activity	0	O
in	0	O
furazolidone	0	O
-	0	O
induced	0	O
cardiomyopathy	0	O
.	0	O


The	0	O
interleukin	0	B
2	0	I
receptor	0	I
alpha	0	I
-	0	I
chain	0	I
(	0	O
IL	1	B
-	0	I
2R	0	I
alpha	0	I
)	0	O
gene	0	O
is	0	O
rapidly	0	O
and	0	O
potently	0	O
induced	0	O
in	0	O
T	1	O
cells	0	O
in	0	O
response	0	O
to	0	O
mitogenic	0	O
stimuli	0	O
.	0	O


We	0	O
previously	0	O
delineated	0	O
a	0	O
region	0	O
in	0	O
the	0	O
fatty	0	B
-	0	I
acid	0	I
synthase	0	I
promoter	0	I
,	0	O
which	0	O
was	0	O
responsible	0	O
for	0	O
obesity	0	O
-	0	O
related	0	O
overexpression	0	O
of	0	O
the	0	O
fatty	0	B
-	0	I
acid	0	I
synthase	0	I
(	0	O
FAS	1	B
)	0	O
gene	0	O
,	0	O
by	0	O
negatively	0	O
regulating	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
downstream	0	O
promoter	0	O
in	0	O
lean	0	O
but	0	O
not	0	O
obese	0	O
rat	0	O
fat	0	O
cells	0	O
.	0	O


Solitary	1	O
thyroid	0	O
nodule	0	O
.	0	O


The	0	O
C	1	O
-	0	O
terminal	0	O
end	0	O
of	0	O
this	0	O
polypeptide	0	O
harbors	0	O
three	0	O
types	0	O
of	0	O
repeated	0	O
sequences	0	O
.	0	O


Radioimmunoassays	0	O
of	0	O
pregnenolone	0	O
,	0	O
progesterone	0	O
,	0	O
dehydroepiandrosterone	0	O
(	0	O
DHA	1	O
)	0	O
16	0	O
alpha	0	O
-	0	O
hydroxy	0	O
-	0	O
DHA	1	O
,	0	O
estriol	0	O
,	0	O
and	0	O
cortisol	0	O
were	0	O
performed	0	O
on	0	O
a	0	O
total	0	O
of	0	O
0	0	O
;	0	O
1	0	O
ml	0	O
;	0	O
of	0	O
fetal	0	O
plasma	0	O
,	0	O
collected	0	O
during	0	O
the	0	O
course	0	O
of	0	O
normal	0	O
vaginal	0	O
delivery	0	O
.	0	O


Thus	0	O
the	0	O
present	0	O
data	0	O
also	0	O
suggest	0	O
that	0	O
BP	1	O
and	0	O
HR	1	O
measurements	0	O
are	0	O
influenced	0	O
not	0	O
only	0	O
by	0	O
state	0	O
-	0	O
dependent	0	O
factors	0	O
but	0	O
also	0	O
by	0	O
at	0	O
least	0	O
three	0	O
different	0	O
factors	0	O
that	0	O
are	0	O
each	0	O
independent	0	O
of	0	O
the	0	O
state	0	O
:	0	O
one	0	O
leads	0	O
to	0	O
BP	1	O
and	0	O
HR	1	O
values	0	O
that	0	O
are	0	O
influenced	0	O
by	0	O
the	0	O
cycle	0	O
the	0	O
animal	0	O
is	0	O
in	0	O
and	0	O
the	0	O
other	0	O
two	0	O
influence	0	O
,	0	O
respectively	0	O
,	0	O
the	0	O
ranking	0	O
of	0	O
the	0	O
individual	0	O
'	0	O
s	0	O
BP	1	O
and	0	O
HR	1	O
levels	0	O
within	0	O
the	0	O
population	0	O
.	0	O


The	0	O
mature	0	O
chromosome	0	O
4	0	O
FRG1	0	B
transcript	0	I
is	0	O
1042	0	O
bp	0	O
in	0	O
length	0	O
and	0	O
contains	0	O
nine	0	O
exons	0	O
which	0	O
encode	0	O
a	0	O
putative	0	O
protein	0	O
of	0	O
258	0	O
amino	0	O
acid	0	O
residues	0	O
.	0	O


Northern	0	O
blotting	0	O
with	0	O
a	0	O
unique	0	O
17	0	O
-	0	O
mer	0	O
oligonucleotide	0	O
demonstrated	0	O
the	0	O
absence	0	O
of	0	O
the	0	O
mutant	0	O
sequence	0	O
in	0	O
the	0	O
mRNA	1	O
from	0	O
which	0	O
the	0	O
cDNA	1	O
library	0	O
giving	0	O
rise	0	O
to	0	O
the	0	O
mutant	0	O
cDNA	1	O
was	0	O
constructed	0	O
.	0	O


The	0	O
arrangement	0	O
of	0	O
these	0	O
cutoff	0	O
-	0	O
levels	0	O
leads	0	O
to	0	O
a	0	O
sensitivity	0	O
of	0	O
85	0	O
%	0	O
at	0	O
a	0	O
specificity	0	O
of	0	O
55	0	O
%	0	O
for	0	O
Protein	1	B
S100	0	I
when	0	O
measured	0	O
by	0	O
RIA	1	O
,	0	O
and	0	O
to	0	O
a	0	O
sensitivity	0	O
of	0	O
77	0	O
%	0	O
at	0	O
a	0	O
specificity	0	O
of	0	O
61	0	O
%	0	O
when	0	O
measured	0	O
by	0	O
LIA	1	O
.	0	O


RESULTS	0	O
:	0	O
Using	0	O
information	0	O
in	0	O
the	0	O
dbEST	0	O
database	0	O
of	0	O
expressed	0	O
sequence	0	O
tags	0	O
,	0	O
we	0	O
isolated	0	O
an	0	O
Arabidopsis	0	O
thaliana	0	O
gene	0	O
(	0	O
GCR1	0	B
)	0	O
that	0	O
encodes	0	O
a	0	O
protein	0	O
with	0	O
seven	0	O
predicted	0	O
membrane	0	O
-	0	O
spanning	0	O
domains	0	O
and	0	O
other	0	O
features	0	O
characteristic	0	O
of	0	O
7TM	0	B
receptors	0	I
.	0	O


As	1	O
with	0	O
the	0	O
murine	0	B
and	0	I
human	0	I
mb	0	I
-	0	I
1	0	I
genes	0	I
,	0	O
the	0	O
5	0	O
'	0	O
region	0	O
of	0	O
the	0	O
bovine	0	B
mb	0	I
-	0	I
1	0	I
gene	0	I
lacked	0	O
a	0	O
TATA	0	O
box	0	O
.	0	O


We	0	O
show	0	O
that	0	O
the	0	O
Sm	1	B
-	0	I
binding	0	I
site	0	I
and	0	O
stem	0	O
-	0	O
loop	0	O
III	0	O
structures	0	O
are	0	O
necessary	0	O
for	0	O
correct	0	O
3	0	O
'-	0	O
end	0	O
formation	0	O
.	0	O


The	0	O
yeast	0	O
gene	0	O
that	0	O
encodes	0	O
eIF	0	B
-	0	I
5	0	I
,	0	O
designated	0	O
TIF5	0	B
,	0	O
has	0	O
been	0	O
isolated	0	O
and	0	O
expressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
to	0	O
yield	0	O
a	0	O
catalytically	0	O
active	0	O
eIF	0	B
-	0	I
5	0	I
protein	0	I
.	0	O


Deletion	1	O
analysis	0	O
was	0	O
carried	0	O
out	0	O
within	0	O
a	0	O
part	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
showing	0	O
homology	0	O
to	0	O
the	0	O
upstream	0	O
region	0	O
of	0	O
the	0	O
yeast	0	B
CYC1	0	I
gene	0	I
.	0	O


While	0	O
no	0	O
significant	0	O
differences	0	O
in	0	O
the	0	O
tensile	0	O
responses	0	O
or	0	O
failure	0	O
characteristics	0	O
were	0	O
noted	0	O
for	0	O
irradiated	0	O
and	0	O
nonirradiated	0	O
grafts	0	O
in	0	O
the	0	O
drip	0	O
,	0	O
in	0	O
the	0	O
bath	0	O
environment	0	O
the	0	O
nonirradiated	0	O
tissues	0	O
had	0	O
greater	0	O
strength	0	O
and	0	O
modulus	0	O
.	0	O


By	0	O
adapting	0	O
a	0	O
method	0	O
for	0	O
DNA	1	O
-	0	O
footprinting	0	O
using	0	O
impure	0	O
extracts	0	O
of	0	O
ner	0	B
overproducing	0	O
cells	0	O
,	0	O
we	0	O
were	0	O
able	0	O
to	0	O
determine	0	O
that	0	O
the	0	O
ner	0	B
-	0	I
binding	0	I
sites	0	I
are	0	O
located	0	O
between	0	O
nucleotides	0	O
1026	0	O
and	0	O
1058	0	O
from	0	O
the	0	O
Mu	1	O
left	0	O
end	0	O
.	0	O


Comparison	0	O
of	0	O
promoters	0	O
repressed	0	O
by	0	O
c	0	B
-	0	I
myc	0	I
reveals	0	O
a	0	O
weak	0	O
consensus	0	O
sequence	0	O
of	0	O
the	0	O
initiator	0	O
(	0	O
Inr	1	O
)	0	O
element	0	O
:	0	O
TCA	1	O
(+	0	O
1	0	O
)	0	O
YYYNY	0	O
.	0	O


The	0	O
sequence	0	O
of	0	O
four	0	O
clones	0	O
was	0	O
sufficient	0	O
to	0	O
construct	0	O
a	0	O
3018	0	B
-	0	I
bp	0	I
BAL	1	I
cDNA	1	I
structure	0	O
.	0	O


Mutagenesis	1	O
of	0	O
the	0	O
pecT	0	B
regulatory	0	O
region	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
two	0	O
sites	0	O
in	0	O
which	0	O
insertions	0	O
reproduced	0	O
the	0	O
pec	0	B
-	0	I
1	0	I
phenotype	0	O
.	0	O


The	0	O
introduction	0	O
of	0	O
an	0	O
acidic	0	O
residue	0	O
at	0	O
the	0	O
second	0	O
site	0	O
was	0	O
essential	0	O
for	0	O
suppression	0	O
of	0	O
the	0	O
Asn	1	O
-	0	O
285	0	O
mutation	0	O
because	0	O
Lys	1	O
-	0	O
220	0	O
and	0	O
Gln	1	O
-	0	O
220	0	O
second	0	O
-	0	O
site	0	O
mutants	0	O
of	0	O
the	0	O
Asn	1	O
-	0	O
285	0	O
mutant	0	O
showed	0	O
very	0	O
low	0	O
tetracycline	0	O
resistance	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Persistent	0	O
acantholytic	0	O
dermatosis	0	O
with	0	O
increased	0	O
light	0	O
sensitivity	0	O


Following	1	O
20	0	O
min	0	O
of	0	O
steady	0	O
state	0	O
anaesthesia	0	O
during	0	O
which	0	O
measurements	0	O
of	0	O
IOP	1	O
,	0	O
arterial	0	O
pressure	0	O
,	0	O
heart	0	O
rate	0	O
,	0	O
FIO2	1	O
,	0	O
FE	1	O
'	0	O
CO2	1	O
and	0	O
CVP	1	O
were	0	O
recorded	0	O
,	0	O
one	0	O
group	0	O
of	0	O
patients	0	O
received	0	O
atracurium	0	O
0	0	O
.	0	O
45	0	O
mg	0	O
kg	0	O
-	0	O
1	0	O
and	0	O
the	0	O
other	0	O
pancuronium	0	O
0	0	O
.	0	O
1	0	O
mg	0	O
kg	0	O
-	0	O
1	0	O
.	0	O


A	1	O
data	0	O
base	0	O
homology	0	O
search	0	O
revealed	0	O
that	0	O
the	0	O
predicted	0	O
ER1	0	B
amino	0	O
acid	0	O
sequence	0	O
contains	0	O
three	0	O
regions	0	O
of	0	O
similarity	0	O
to	0	O
the	0	O
rat	0	O
and	0	O
human	0	O
proteins	0	O
encoded	0	O
by	0	O
the	0	O
metastasis	0	O
-	0	O
associated	0	O
gene	0	O
,	0	O
mta1	0	B
,	0	O
and	0	O
two	0	O
regions	0	O
of	0	O
similarity	0	O
to	0	O
the	0	O
Caenorhabditis	0	O
elegans	0	O
sequence	0	O
that	0	O
is	0	O
similar	0	O
to	0	O
mta1	0	B
.	0	O


B	1	B
cell	0	I
antigen	0	I
receptor	0	I
(	0	O
BCR	0	B
)-	0	O
mediated	0	O
formation	0	O
of	0	O
a	0	O
SHP	0	B
-	0	I
2	0	I
-	0	O
pp120	0	B
complex	0	O
and	0	O
its	0	O
inhibition	0	O
by	0	O
Fc	1	B
gamma	0	I
RIIB1	0	I
-	0	O
BCR	0	B
coligation	0	O
.	0	O


The	0	O
subunit	0	B
-	0	I
a	0	I
gene	0	I
is	0	O
preceded	0	O
by	0	O
a	0	O
gene	0	O
coding	0	O
for	0	O
a	0	O
small	0	O
hydrophobic	0	O
protein	0	O
,	0	O
as	0	O
has	0	O
been	0	O
observed	0	O
previously	0	O
in	0	O
the	0	O
atp	0	B
operons	0	I
in	0	O
E	1	O
.	0	O
coli	0	O
,	0	O
bacterium	0	O
PS3	0	O
and	0	O
cyanobacteria	0	O
.	0	O


They	0	O
were	0	O
found	0	O
to	0	O
stimulate	0	O
at	0	O
nanomolar	0	O
concentrations	0	O
the	0	O
turnover	0	O
of	0	O
biosynthetically	0	O
labeled	0	O
ceramide	0	O
,	0	O
glucosylceramide	0	O
,	0	O
and	0	O
lactosylceramide	0	O
.	0	O


Accordingly	0	O
,	0	O
we	0	O
designated	0	O
this	0	O
gene	0	B
CTL1	0	I
(	0	O
capping	0	B
enzyme	0	I
RNAtriphosphatase	0	I
-	0	I
like	0	I
1	0	I
).	0	O


The	0	O
RNA	1	O
genome	0	O
of	0	O
rabbit	0	O
hemorrhagic	0	O
disease	0	O
virus	0	O
(	0	O
RHDV	0	O
)	0	O
was	0	O
molecularly	0	O
cloned	0	O
.	0	O


It	1	O
is	0	O
likely	0	O
that	0	O
other	0	O
pathways	0	O
involve	0	O
alternate	0	O
signal	0	O
transduction	0	O
events	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
calcium	0	O
mobilization	0	O
)	0	O
and	0	O
promoter	0	O
response	0	O
elements	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
SRE	0	O
).	0	O


Although	0	O
heart	0	O
rate	0	O
and	0	O
diastolic	0	O
pressure	0	O
rose	0	O
in	0	O
some	0	O
degree	0	O
1	0	O
min	0	O
after	0	O
intubation	0	O
,	0	O
free	0	O
and	0	O
total	0	O
CA	1	O
concentrations	0	O
did	0	O
not	0	O
increase	0	O
during	0	O
study	0	O
period	0	O
.	0	O


These	0	O
RZR	0	B
subtypes	0	O
represent	0	O
members	0	O
of	0	O
a	0	O
new	0	O
family	0	O
of	0	O
orphan	0	B
nuclear	0	I
receptors	0	I
that	0	O
most	0	O
likely	0	O
regulate	0	O
specific	0	O
gene	0	O
expression	0	O
.	0	O


The	0	O
human	0	B
T	1	I
cell	0	I
leukemia	0	I
/	0	I
lymphotropic	0	I
virus	0	I
type	0	I
1	0	I
Tax	0	I
protein	0	I
represses	0	O
MyoD	0	B
-	0	O
dependent	0	O
transcription	0	O
by	0	O
inhibiting	0	O
MyoD	0	B
-	0	O
binding	0	O
to	0	O
the	0	O
KIX	0	B
domain	0	I
of	0	O
p300	0	B
.	0	O


Detection	1	O
of	0	O
congenital	0	O
hypothyroidism	0	O
in	0	O
26	0	O
,	0	O
282	0	O
newborn	0	O
infants	0	O


Female	1	O
mice	0	O
were	0	O
significantly	0	O
more	0	O
resistant	0	O
to	0	O
infection	0	O
than	0	O
males	0	O
.	0	O


Human	1	B
GATA	0	I
-	0	I
3	0	I
:	0	O
a	0	O
lineage	0	O
-	0	O
restricted	0	O
transcription	0	O
factor	0	O
that	0	O
regulates	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
T	1	B
cell	0	I
receptor	0	I
alpha	0	I
gene	0	I
.	0	O


We	0	O
have	0	O
determined	0	O
that	0	O
several	0	O
E1	1	B
mutants	0	I
mapping	0	O
in	0	O
both	0	O
the	0	O
M	1	O
and	0	O
R	1	O
regions	0	O
and	0	O
a	0	O
single	0	O
mutant	0	O
of	0	O
the	0	O
upstream	0	O
regulatory	0	O
region	0	O
have	0	O
a	0	O
higher	0	O
transforming	0	O
activity	0	O
on	0	O
mouse	0	O
C127	0	O
cells	0	O
than	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
genome	0	O
does	0	O
.	0	O


One	0	O
complex	0	O
most	0	O
likely	0	O
contained	0	O
Sp1	0	B
,	0	O
and	0	O
another	0	O
complex	0	O
showed	0	O
S	1	O
-	0	O
phase	0	O
-	0	O
specific	0	O
binding	0	O
,	0	O
suggesting	0	O
a	0	O
direct	0	O
role	0	O
in	0	O
the	0	O
cell	0	O
-	0	O
cycle	0	O
-	0	O
dependent	0	O
R1	0	B
gene	0	I
expression	0	O
.	0	O


DR1	0	B
molecules	0	I
purified	0	O
from	0	O
human	0	O
lymphoblastoid	0	O
cell	0	O
lines	0	O
could	0	O
specifically	0	O
bind	0	O
to	0	O
these	0	O
peptide	0	O
sequences	0	O
expressed	0	O
on	0	O
the	0	O
phage	0	O
surface	0	O
.	0	O


This	0	O
analysis	0	O
revealed	0	O
an	0	O
intact	0	O
gene	0	O
(	0	O
arg4	0	B
)	0	O
showing	0	O
a	0	O
high	0	O
degree	0	O
of	0	O
homology	0	O
with	0	O
the	0	O
Saccharomyces	1	B
cerevisiae	0	I
CPA2	0	I
gene	0	I
encoding	0	O
the	0	O
large	0	O
subunit	0	O
of	0	O
carbamoyl	0	B
-	0	I
phosphate	0	I
synthetase	0	I
(	0	O
CPS	1	B
-	0	I
A	1	I
).	0	O


The	0	O
v	0	B
-	0	I
ets	0	I
oncogene	0	I
of	0	O
the	0	O
avian	0	O
retrovirus	0	O
E26	0	O
differs	0	O
from	0	O
its	0	O
cellular	0	O
progenitor	0	O
p68c	0	B
-	0	I
ets	0	I
-	0	I
1	0	I
by	0	O
two	0	O
amino	0	O
acid	0	O
substitutions	0	O
(	0	O
alanine	0	O
285	0	O
and	0	O
isoleucine	0	O
445	0	O
in	0	O
c	0	B
-	0	I
ets	0	I
-	0	I
1	0	I
both	0	O
substituted	0	O
by	0	O
valine	0	O
in	0	O
v	0	B
-	0	I
ets	0	I
,	0	O
mutations	0	O
A	1	O
and	0	O
B	1	O
respectively	0	O
)	0	O
and	0	O
its	0	O
carboxy	0	O
-	0	O
terminal	0	O
end	0	O
(	0	O
mutation	0	O
C	1	O
).	0	O


Therefore	0	O
,	0	O
a	0	O
prospective	0	O
Phase	1	O
II	0	O
trial	0	O
was	0	O
conducted	0	O
to	0	O
determine	0	O
the	0	O
safety	0	O
and	0	O
efficacy	0	O
of	0	O
cryosurgery	0	O
following	0	O
radiation	0	O
therapy	0	O
in	0	O
men	0	O
with	0	O
local	0	O
recurrence	0	O
.	0	O


(	0	O
2	0	O
)	0	O
Diffusion	1	O
limitation	0	O
in	0	O
the	0	O
heterogeneous	0	O
model	0	O
sets	0	O
in	0	O
at	0	O
a	0	O
lower	0	O
O2	1	O
requirement	0	O
value	0	O
,	0	O
and	0	O
increases	0	O
more	0	O
gradually	0	O
with	0	O
increasing	0	O
O2	1	O
requirement	0	O
,	0	O
than	0	O
in	0	O
the	0	O
corresponding	0	O
homogeneous	0	O
models	0	O
with	0	O
the	0	O
same	0	O
average	0	O
cylinder	0	O
diameter	0	O
.	0	O


Static	1	O
magnetic	0	O
fields	0	O
affect	0	O
the	0	O
diffusion	0	O
of	0	O
biological	0	O
particles	0	O
in	0	O
solutions	0	O
through	0	O
the	0	O
Lorentz	0	O
force	0	O
and	0	O
Maxwell	1	O
stress	0	O
.	0	O


Minor	1	O
initiation	0	O
sites	0	O
were	0	O
found	0	O
at	0	O
positions	0	O
-	0	O
128	0	O
,	0	O
-	0	O
111	0	O
,	0	O
-	0	O
91	0	O
,	0	O
and	0	O
-	0	O
74	0	O
.	0	O


To	1	O
explore	0	O
the	0	O
functional	0	O
significance	0	O
of	0	O
these	0	O
subdomains	0	O
in	0	O
PRL	1	B
binding	0	O
and	0	O
signal	0	O
transduction	0	O
,	0	O
deletion	0	O
mutants	0	O
of	0	O
S1	1	O
or	0	O
/	0	O
and	0	O
S2	1	O
subdomains	0	O
were	0	O
constructed	0	O
.	0	O


Its	0	O
application	0	O
in	0	O
Madagascar	0	O
:	0	O
advantages	0	O
and	0	O
disadvantages	0	O


Altogether	0	O
our	0	O
data	0	O
indicate	0	O
that	0	O
PEDF	0	B
belongs	0	O
to	0	O
the	0	O
subgroup	0	O
of	0	O
noninhibitory	0	O
serpins	0	B
and	0	O
that	0	O
its	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
confers	0	O
a	0	O
neurite	0	O
-	0	O
promoting	0	O
activity	0	O
to	0	O
the	0	O
protein	0	O
.	0	O


When	0	O
CSF	1	O
[	0	O
HCO3	0	O
-]	0	O
is	0	O
shown	0	O
as	0	O
a	0	O
function	0	O
of	0	O
CSF	1	O
PCO2	1	O
the	0	O
data	0	O
of	0	O
K	1	O
-	0	O
depleted	0	O
rats	0	O
are	0	O
no	0	O
longer	0	O
displaced	0	O
when	0	O
compared	0	O
to	0	O
controls	0	O
but	0	O
still	0	O
have	0	O
a	0	O
significantly	0	O
greater	0	O
slope	0	O
(	0	O
1	0	O
.	0	O
21	0	O
+/-	0	O
0	0	O
.	0	O
23	0	O
vs	0	O
.	0	O


We	0	O
report	0	O
here	0	O
the	0	O
discovery	0	O
of	0	O
a	0	O
new	0	O
actin	0	B
-	0	I
related	0	I
gene	0	I
in	0	O
this	0	O
organism	0	O
,	0	O
which	0	O
we	0	O
have	0	O
named	0	O
ACT4	0	B
.	0	O


DNA	1	O
sequencing	0	O
of	0	O
a	0	O
17	0	O
-	0	O
kb	0	O
segment	0	O
encompassing	0	O
a	0	O
gammaherpesvirus	0	O
divergent	0	O
locus	0	O
(	0	O
DL	1	O
-	0	O
B	1	O
)	0	O
between	0	O
ORF11	0	O
and	0	O
ORF17	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
nine	0	O
viral	0	O
ORFs	0	O
with	0	O
predicted	0	O
gene	0	O
products	0	O
related	0	O
to	0	O
cellular	0	O
proteins	0	O
.	0	O


The	0	O
newly	0	O
recognised	0	O
skeletogenital	0	O
syndrome	0	O
.	0	O


Distant	0	O
spread	0	O
was	0	O
found	0	O
in	0	O
46	0	O
patients	0	O
(	0	O
34	0	O
%),	0	O
42	0	O
of	0	O
whom	0	O
had	0	O
serum	0	O
Tg	1	B
greater	0	O
than	0	O
10	0	O
micrograms	0	O
/	0	O
l	0	O
.	0	O


The	0	O
SCH9	0	B
protein	0	I
kinase	0	I
mRNA	1	I
contains	0	O
a	0	O
long	0	O
5	0	O
'	0	O
leader	0	O
with	0	O
a	0	O
small	0	O
open	0	O
reading	0	O
frame	0	O
.	0	O


Together	0	O
,	0	O
these	0	O
data	0	O
identify	0	O
ERK2	0	B
as	0	O
a	0	O
specific	0	O
and	0	O
direct	0	O
target	0	O
of	0	O
HePTP	0	B
and	0	O
are	0	O
consistent	0	O
with	0	O
a	0	O
model	0	O
in	0	O
which	0	O
HePTP	0	B
negatively	0	O
regulates	0	O
ERK2	0	B
activity	0	O
as	0	O
part	0	O
of	0	O
a	0	O
feedback	0	O
mechanism	0	O
.	0	O


A	1	O
motif	0	O
(	0	O
TGATGTCA	0	O
)	0	O
which	0	O
matches	0	O
a	0	O
CREB	0	B
site	0	I
and	0	O
is	0	O
similar	0	O
to	0	O
an	0	O
AP	1	B
-	0	I
1	0	I
site	0	I
is	0	O
embedded	0	O
within	0	O
ER2	0	B
.	0	O


A	1	O
13	0	O
-	0	O
bp	0	O
cis	0	O
-	0	O
regulatory	0	O
element	0	O
in	0	O
the	0	O
LTR	1	O
promoter	0	O
of	0	O
the	0	O
tobacco	0	B
retrotransposon	0	I
Tto1	0	I
is	0	O
involved	0	O
in	0	O
responsiveness	0	O
to	0	O
tissue	0	O
culture	0	O
,	0	O
wounding	0	O
,	0	O
methyl	0	O
jasmonate	0	O
and	0	O
fungal	0	O
elicitors	0	O
.	0	O


We	0	O
report	0	O
the	0	O
successful	0	O
use	0	O
of	0	O
electroconvulsive	0	O
therapy	0	O
for	0	O
treatment	0	O
of	0	O
severe	0	O
depression	0	O
in	0	O
a	0	O
young	0	O
man	0	O
with	0	O
adult	0	O
GM2	0	O
gangliosidosis	0	O
.	0	O


However	0	O
,	0	O
neu	0	B
differentiation	0	O
factor	0	O
-	0	O
induced	0	O
heterodimers	0	O
of	0	O
ErbB2	0	B
and	0	O
ErbB4	0	B
activated	0	O
Stat5	0	B
.	0	O


These	0	O
two	0	O
mRNA	1	O
species	0	O
are	0	O
produced	0	O
by	0	O
differential	0	O
polyadenylation	0	O
site	0	O
usage	0	O
.	0	O


A	1	O
review	0	O
of	0	O
studies	0	O
published	0	O
between	0	O
1983	0	O
and	0	O
1995	0	O
shows	0	O
that	0	O
there	0	O
are	0	O
some	0	O
common	0	O
factors	0	O
as	0	O
regards	0	O
the	0	O
psychological	0	O
distress	0	O
and	0	O
social	0	O
and	0	O
functional	0	O
limitations	0	O
this	0	O
group	0	O
of	0	O
patients	0	O
has	0	O
to	0	O
deal	0	O
with	0	O
.	0	O


Transient	1	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
Crk	0	B
in	0	O
fibroblast	0	B
growth	0	I
factor	0	I
-	0	I
2	0	I
-	0	O
stimulated	0	O
endothelial	0	O
cells	0	O
was	0	O
dependent	0	O
on	0	O
the	0	O
juxtamembrane	0	O
tyrosine	0	O
residue	0	O
463	0	O
in	0	O
FGFR	0	B
-	0	I
1	0	I
,	0	O
and	0	O
a	0	O
Crk	0	B
SH2	0	I
domain	0	I
precipitated	0	O
FGFR	0	B
-	0	I
1	0	I
via	0	O
phosphorylated	0	O
Tyr	1	O
-	0	O
463	0	O
,	0	O
indicating	0	O
direct	0	O
complex	0	O
formation	0	O
between	0	O
Crk	0	B
and	0	O
FGFR	0	B
-	0	I
1	0	I
.	0	O


In	1	O
an	0	O
effort	0	O
to	0	O
separate	0	O
domains	0	O
of	0	O
FadR	0	B
required	0	O
for	0	O
DNA	1	O
binding	0	O
,	0	O
dimerization	0	O
,	0	O
and	0	O
ligand	0	O
binding	0	O
,	0	O
chimeric	0	O
protein	0	O
fusions	0	O
between	0	O
the	0	O
DNA	1	O
binding	0	O
domain	0	O
of	0	O
LexA	0	B
and	0	O
different	0	O
regions	0	O
of	0	O
FadR	0	B
were	0	O
constructed	0	O
.	0	O


3	0	O
'-	0	O
Methyl	1	O
,	0	O
8	0	O
-	0	O
methyl	0	O
,	0	O
and	0	O
8	0	O
-	0	O
phenyl	0	O
derivatives	0	O
of	0	O
5	0	O
,	0	O
9	0	O
-	0	O
dimethyl	0	O
-	0	O
6	0	O
,	0	O
7	0	O
-	0	O
benzomorphans	0	O
.	0	O


In	1	O
a	0	O
highly	0	O
select	0	O
group	0	O
of	0	O
stable	0	O
hypertensive	0	O
patients	0	O
,	0	O
we	0	O
have	0	O
assessed	0	O
the	0	O
strength	0	O
of	0	O
association	0	O
between	0	O
various	0	O
blood	0	O
pressure	0	O
measurements	0	O
(	0	O
24	0	O
h	0	O
average	0	O
automated	0	O
ambulatory	0	O
blood	0	O
pressure	0	O
,	0	O
4	0	O
h	0	O
automated	0	O
ambulatory	0	O
morning	0	O
average	0	O
blood	0	O
pressure	0	O
,	0	O
multiple	0	O
office	0	O
visit	0	O
average	0	O
blood	0	O
pressure	0	O
,	0	O
and	0	O
a	0	O
single	0	O
office	0	O
visit	0	O
average	0	O
blood	0	O
pressure	0	O
)	0	O
and	0	O
various	0	O
echocardiographic	0	O
indices	0	O
of	0	O
hypertensive	0	O
cardiac	0	O
target	0	O
organ	0	O
damage	0	O
(	0	O
left	0	O
atrial	0	O
diameter	0	O
,	0	O
left	0	O
ventricular	0	O
end	0	O
diastolic	0	O
diameter	0	O
,	0	O
posterior	0	O
wall	0	O
thickness	0	O
,	0	O
combined	0	O
wall	0	O
thickness	0	O
,	0	O
relative	0	O
wall	0	O
thickness	0	O
,	0	O
left	0	O
ventricular	0	O
mass	0	O
and	0	O
mass	0	O
index	0	O
,	0	O
and	0	O
combined	0	O
wall	0	O
thickness	0	O
/	0	O
left	0	O
ventricular	0	O
diastolic	0	O
diameter	0	O
ratio	0	O
).	0	O


The	0	O
recently	0	O
developed	0	O
gamma	0	B
-	0	I
interferon	0	I
(	0	O
IFN	1	B
-	0	I
gamma	0	I
)	0	O
assay	0	O
system	0	O
for	0	O
the	0	O
diagnosis	0	O
of	0	O
bovine	0	O
tuberculosis	0	O
in	0	O
cattle	0	O
has	0	O
been	0	O
accredited	0	O
by	0	O
the	0	O
Standing	0	O
Committee	0	O
on	0	O
Agriculture	0	O
for	0	O
use	0	O
in	0	O
Australia	0	O
.	0	O


Molecular	1	O
cloning	0	O
of	0	O
a	0	O
cysteine	0	B
synthase	0	I
cDNA	1	I
from	0	O
Citrullus	1	O
vulgaris	0	O
(	0	O
watermelon	0	O
)	0	O
by	0	O
genetic	0	O
complementation	0	O
in	0	O
an	0	O
Escherichia	1	O
coli	0	O
Cys	1	O
-	0	O
auxotroph	0	O
.	0	O


COGLAB	0	O
includes	0	O
measures	0	O
of	0	O
preattentional	0	O
,	0	O
attentional	0	O
,	0	O
conceptual	0	O
,	0	O
and	0	O
psychomotor	0	O
performance	0	O
.	0	O


The	0	O
cochlear	0	O
compromise	0	O
.	0	O


All	1	O
62	0	O
isolates	0	O
were	0	O
resistant	0	O
to	0	O
lincomycin	0	O
,	0	O
colistin	0	O
,	0	O
nystatin	0	O
,	0	O
amphotericin	0	O
B	1	O
,	0	O
trimethoprim	0	O
lactate	0	O
,	0	O
polymyxin	0	O
B	1	O
,	0	O
and	0	O
anisomycin	0	O
.	0	O


Certain	0	O
characteristics	0	O
of	0	O
eye	0	O
changes	0	O
in	0	O
patients	0	O
with	0	O
pheochromocytoma	0	O
including	0	O
Sipple	0	O
'	0	O
s	0	O
syndrome	0	O


However	0	O
,	0	O
bilateral	0	O
diffuse	0	O
pulmonary	0	O
infiltrations	0	O
developed	0	O
21	0	O
days	0	O
later	0	O
.	0	O


They	0	O
also	0	O
reported	0	O
that	0	O
E	1	B
mu	0	I
pim	0	I
-	0	I
1	0	I
transgenic	0	O
mice	0	O
show	0	O
greatly	0	O
accelerated	0	O
lymphoma	0	O
development	0	O
when	0	O
infected	0	O
with	0	O
wild	0	O
-	0	O
type	0	O
M	1	O
-	0	O
MuLV	0	O
at	0	O
birth	0	O
.	0	O


New	0	O
alkaloids	0	O
from	0	O
bark	0	O
of	0	O
Erythrophleum	0	O
ivorense	0	O
.	0	O


Allelic	1	O
variation	0	O
in	0	O
HLA	1	B
-	0	I
B	1	I
and	0	O
HLA	1	B
-	0	I
C	1	I
sequences	0	I
and	0	O
the	0	O
evolution	0	O
of	0	O
the	0	O
HLA	1	B
-	0	I
B	1	I
alleles	0	I
.	0	O


In	1	O
conclusion	0	O
:	0	O
(	0	O
i	0	O
)	0	O
TECRA	0	O
kit	0	O
is	0	O
suggested	0	O
to	0	O
be	0	O
used	0	O
for	0	O
screening	0	O
SE	1	O
producing	0	O
strains	0	O
;	0	O
(	0	O
ii	0	O
)	0	O
SET	1	O
-	0	O
RPLA	0	O
and	0	O
RIDASCREEN	0	O
kits	0	O
are	0	O
suitable	0	O
for	0	O
epidemiological	0	O
investigation	0	O
of	0	O
SE	1	O
types	0	O
,	0	O
but	0	O
the	0	O
lack	0	O
of	0	O
ability	0	O
for	0	O
detecting	0	O
SEE	0	O
,	0	O
long	0	O
time	0	O
required	0	O
for	0	O
testing	0	O
with	0	O
SET	1	O
-	0	O
RPLA	0	O
kit	0	O
and	0	O
high	0	O
background	0	O
when	0	O
using	0	O
RIDASCREEN	0	O
kit	0	O
must	0	O
be	0	O
overcome	0	O
;	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
because	0	O
of	0	O
the	0	O
complicated	0	O
test	0	O
procedures	0	O
and	0	O
the	0	O
lack	0	O
of	0	O
ability	0	O
for	0	O
detecting	0	O
SEE	0	O
,	0	O
the	0	O
practicality	0	O
of	0	O
SET	1	O
-	0	O
EIA	1	O
kit	0	O
in	0	O
screening	0	O
and	0	O
epidemiological	0	O
research	0	O
purposes	0	O
is	0	O
low	0	O
.	0	O


Since	0	O
September	0	O
1980	0	O
to	0	O
June	0	O
1983	0	O
we	0	O
have	0	O
treated	0	O
32	0	O
patients	0	O
with	0	O
ovarian	0	O
cancer	0	O
.	0	O


The	0	O
"	0	O
28	0	O
percent	0	O
"	0	O
Venturi	0	O
mask	0	O
in	0	O
obstructive	0	O
airway	0	O
disease	0	O
.	0	O


National	0	O
abortion	0	O
laws	0	O
usually	0	O
do	0	O
not	0	O
allow	0	O
abortion	0	O
when	0	O
a	0	O
foetus	0	O
is	0	O
independently	0	O
viable	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
from	0	O
a	0	O
gestational	0	O
age	0	O
of	0	O
about	0	O
24	0	O
weeks	0	O
.	0	O


For	0	O
the	0	O
first	0	O
time	0	O
we	0	O
describe	0	O
deletion	0	O
and	0	O
point	0	O
mutations	0	O
within	0	O
the	0	O
plasma	0	B
membrane	0	I
family	0	I
of	0	I
guanylyl	0	I
cyclase	0	I
receptors	0	I
that	0	O
result	0	O
in	0	O
the	0	O
formation	0	O
of	0	O
effective	0	O
dominant	0	O
negative	0	O
proteins	0	O
.	0	O


Various	0	O
assays	0	O
demonstrate	0	O
promoter	0	O
activity	0	O
in	0	O
this	0	O
sequence	0	O
that	0	O
reproduces	0	O
the	0	O
normal	0	O
control	0	O
of	0	O
E2F2	0	B
expression	0	O
during	0	O
a	0	O
growth	0	O
stimulation	0	O
.	0	O


INO2	0	B
,	0	O
a	0	O
regulatory	0	O
gene	0	O
in	0	O
yeast	0	O
phospholipid	0	O
biosynthesis	0	O
,	0	O
affects	0	O
nuclear	0	O
segregation	0	O
and	0	O
bud	0	O
pattern	0	O
formation	0	O
.	0	O


During	0	O
heat	0	O
exposure	0	O
,	0	O
chicks	0	O
that	0	O
had	0	O
been	0	O
subjected	0	O
to	0	O
early	0	O
60	0	O
%	0	O
restriction	0	O
with	0	O
non	0	O
-	0	O
metyrapone	0	O
-	0	O
treated	0	O
food	0	O
had	0	O
lower	0	O
H	1	O
/	0	O
L	1	O
ratios	0	O
and	0	O
improved	0	O
resistance	0	O
to	0	O
marble	0	O
spleen	0	O
disease	0	O
infection	0	O
.	0	O


Degradation	1	O
of	0	O
the	0	O
soybean	0	B
ribulose	0	I
-	0	I
1	0	I
,	0	I
5	0	I
-	0	I
bisphosphate	0	I
carboxylase	0	I
small	0	I
-	0	I
subunit	0	I
mRNA	1	I
,	0	O
SRS4	0	B
,	0	O
initiates	0	O
with	0	O
endonucleolytic	0	O
cleavage	0	O
.	0	O


The	0	O
non	0	O
-	0	O
role	0	O
of	0	O
fluoride	0	O
in	0	O
the	0	O
control	0	O
of	0	O
plasma	0	O
calcium	0	O
in	0	O
the	0	O
parathyroidectomized	0	O
rat	0	O
.	0	O


Deletion	1	O
of	0	O
the	0	O
RVH	1	B
domain	0	I
resulted	0	O
in	0	O
loss	0	O
of	0	O
Ca	1	O
(	0	O
2	0	O
+)-	0	O
dependent	0	O
activation	0	O
.	0	O


31	0	O
,	0	O
1997	0	O
,	0	O
40	0	O
patients	0	O
had	0	O
died	0	O
(	0	O
35	0	O
in	0	O
the	0	O
ERA	0	O
-	0	O
II	0	O
group	0	O
and	0	O
5	0	O
in	0	O
the	0	O
ERA	0	O
-	0	O
III	0	O
group	0	O
),	0	O
for	0	O
a	0	O
crude	0	O
mortality	0	O
rate	0	O
of	0	O
8	0	O
.	0	O
0	0	O
%.	0	O


Repair	1	O
of	0	O
double	0	O
-	0	O
strand	0	O
breaks	0	O
(	0	O
DSBs	0	O
)	0	O
in	0	O
chromosomal	0	O
DNA	1	O
by	0	O
nonhomologous	0	O
end	0	O
-	0	O
joining	0	O
(	0	O
NHEJ	0	O
)	0	O
is	0	O
not	0	O
well	0	O
characterized	0	O
in	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Insulin	1	B
receptor	0	I
substrate	0	I
-	0	I
1	0	I
-	0	O
mediated	0	O
enhancement	0	O
of	0	O
growth	0	B
hormone	0	I
-	0	O
induced	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
activation	0	O
.	0	O


Methods	0	O
included	0	O
24	0	O
-	0	O
hour	0	O
dietary	0	O
recall	0	O
,	0	O
menu	0	O
weights	0	O
,	0	O
and	0	O
recipe	0	O
analysis	0	O
.	0	O


We	0	O
recently	0	O
reported	0	O
a	0	O
placenta	0	O
-	0	O
specific	0	O
enhancer	0	O
in	0	O
the	0	O
human	0	B
leukemia	0	I
inhibitory	0	I
factor	0	I
receptor	0	I
(	0	O
LIFR	0	B
)	0	O
gene	0	O
and	0	O
now	0	O
show	0	O
detailed	0	O
characterization	0	O
of	0	O
the	0	O
226	0	O
-	0	O
base	0	O
pair	0	O
enhancer	0	O
(-	0	O
4625	0	O
/-	0	O
4400	0	O
nucleotides	0	O
).	0	O


Krox	0	B
-	0	I
20	0	I
,	0	O
a	0	O
zinc	0	B
finger	0	I
gene	0	I
,	0	O
has	0	O
a	0	O
highly	0	O
conserved	0	O
pattern	0	O
of	0	O
expression	0	O
in	0	O
r3	0	O
and	0	O
r5	0	O
and	0	O
is	0	O
functionally	0	O
required	0	O
for	0	O
their	0	O
maintenance	0	O
in	0	O
mouse	0	O
embryos	0	O
.	0	O


Viral	1	O
infections	0	O
have	0	O
long	0	O
been	0	O
suspected	0	O
to	0	O
be	0	O
causative	0	O
agents	0	O
in	0	O
a	0	O
number	0	O
of	0	O
inner	0	O
ear	0	O
dysfunctions	0	O
.	0	O


This	0	O
hypothesis	0	O
was	0	O
tested	0	O
by	0	O
introducing	0	O
mutations	0	O
at	0	O
each	0	O
of	0	O
the	0	O
three	0	O
histidine	0	O
pairs	0	O
,	0	O
the	0	O
H382	0	O
-	0	O
X2	0	O
-	0	O
H385	0	O
pair	0	O
,	0	O
the	0	O
H411	0	O
-	0	O
X2	0	O
-	0	O
H414	0	O
pair	0	O
and	0	O
the	0	O
H430	0	O
-	0	O
X5	0	O
-	0	O
H436	0	O
pair	0	O
,	0	O
which	0	O
constitute	0	O
the	0	O
histidine	0	O
-	0	O
rich	0	O
region	0	O
near	0	O
the	0	O
C	1	O
terminus	0	O
of	0	O
gp17	0	B
.	0	O


Similar	0	O
experiments	0	O
with	0	O
TR	1	B
support	0	O
the	0	O
high	0	O
affinity	0	O
of	0	O
RIP140	0	B
to	0	O
the	0	O
RXR	0	B
subunit	0	I
and	0	O
also	0	O
suggest	0	O
that	0	O
either	0	O
partner	0	O
in	0	O
the	0	O
TR	1	B
/	0	O
RXR	0	B
heterodimer	0	O
can	0	O
independently	0	O
respond	0	O
to	0	O
ligand	0	O
.	0	O


The	0	O
Hagen	0	O
-	0	O
Poiseuille	0	O
equation	0	O
is	0	O
used	0	O
to	0	O
assess	0	O
the	0	O
effects	0	O
of	0	O
attached	0	O
parasites	0	O
in	0	O
the	0	O
foregut	0	O
of	0	O
Leishmania	1	O
-	0	O
infected	0	O
sandflies	0	O
on	0	O
blood	0	O
flow	0	O
.	0	O


The	0	O
3	0	O
.	0	O
3	0	O
-	0	O
fold	0	O
higher	0	O
expression	0	O
in	0	O
the	0	O
fetal	0	O
heart	0	O
than	0	O
in	0	O
the	0	O
adult	0	O
heart	0	O
suggests	0	O
that	0	O
HFHZ	0	B
mRNA	1	I
is	0	O
downregulated	0	O
in	0	O
the	0	O
process	0	O
of	0	O
development	0	O
.	0	O


The	0	O
existence	0	O
of	0	O
these	0	O
two	0	O
categories	0	O
of	0	O
strains	0	O
offers	0	O
a	0	O
new	0	O
genetic	0	O
system	0	O
in	0	O
which	0	O
the	0	O
properties	0	O
of	0	O
a	0	O
potential	0	O
invertebrate	0	O
retrovirus	0	O
can	0	O
be	0	O
tested	0	O
.	0	O


Cells	0	O
respond	0	O
to	0	O
the	0	O
accumulation	0	O
of	0	O
unfolded	0	O
proteins	0	O
in	0	O
the	0	O
endoplasmic	0	O
reticulum	0	O
(	0	O
ER	1	O
)	0	O
by	0	O
increasing	0	O
the	0	O
transcription	0	O
of	0	O
the	0	O
genes	0	O
encoding	0	O
ER	1	B
-	0	I
resident	0	I
chaperone	0	I
proteins	0	I
.	0	O


Resting	1	O
VE	0	O
in	0	O
the	0	O
luteal	0	O
phase	0	O
was	0	O
7	0	O
.	0	O
8	0	O
%	0	O
greater	0	O
than	0	O
that	0	O
in	0	O
the	0	O
follicular	0	O
phase	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Hepatic	1	O
encephalopathy	0	O
is	0	O
a	0	O
neuropsychiatric	0	O
syndrome	0	O
associated	0	O
with	0	O
acute	0	O
liver	0	O
failure	0	O
,	0	O
chronic	0	O
parenchymal	0	O
liver	0	O
disease	0	O
or	0	O
portal	0	O
systemic	0	O
anastomosis	0	O
.	0	O


Cicatricial	1	O
pemphigoid	0	O
is	0	O
an	0	O
autoimmune	0	O
systemic	0	O
disease	0	O
characterized	0	O
by	0	O
chronic	0	O
conjunctival	0	O
cicatrization	0	O
.	0	O


Family	1	O
environment	0	O
was	0	O
an	0	O
important	0	O
influence	0	O
on	0	O
interpersonal	0	O
relationships	0	O
,	0	O
substance	0	O
use	0	O
,	0	O
and	0	O
social	0	O
support	0	O
.	0	O


Within	0	O
the	0	O
span	0	O
of	0	O
attenuator	0	O
region	0	O
encoding	0	O
the	0	O
three	0	O
stem	0	O
-	0	O
loop	0	O
structures	0	O
of	0	O
mRNA	1	O
secondary	0	O
configuration	0	O
,	0	O
hot	0	O
spots	0	O
of	0	O
base	0	O
-	0	O
residue	0	O
divergence	0	O
were	0	O
localized	0	O
to	0	O
looped	0	O
-	0	O
out	0	O
regions	0	O
.	0	O


Sequence	1	O
comparison	0	O
of	0	O
the	0	O
0	0	O
.	0	O
38	0	O
kb	0	O
promoter	0	O
sequence	0	O
with	0	O
the	0	O
promoters	0	O
of	0	O
the	0	O
Sm	1	B
-	0	I
E	1	I
gene	0	O
and	0	O
U1	0	B
snRNA	1	I
genes	0	I
revealed	0	O
several	0	O
homologous	0	O
motifs	0	O
,	0	O
suggesting	0	O
that	0	O
genes	0	O
encoding	0	O
the	0	O
snRNP	1	O
components	0	O
may	0	O
be	0	O
coordinately	0	O
regulated	0	O
.	0	O


Disruption	1	O
of	0	O
the	0	O
chromosomal	0	B
AAR1	0	I
gene	0	I
in	0	O
alpha	0	O
and	0	O
a	0	O
/	0	O
alpha	0	O
cells	0	O
conferred	0	O
the	0	O
nonmating	0	O
phenotype	0	O
,	0	O
and	0	O
the	0	O
a	0	O
/	0	O
alpha	0	O
diploids	0	O
could	0	O
not	0	O
sporulate	0	O
.	0	O


Bacterial	1	O
meningitis	0	O
secondary	0	O
to	0	O
abscess	0	O
of	0	O
the	0	O
nasal	0	O
septum	0	O
.	0	O


ALT	1	B
levels	0	O
in	0	O
responders	0	O
were	0	O
lowered	0	O
by	0	O
46	0	O
%	0	O
and	0	O
AST	1	B
levels	0	O
were	0	O
lowered	0	O
by	0	O
35	0	O
%	0	O
after	0	O
12	0	O
weeks	0	O
of	0	O
vitamin	0	O
E	1	O
treatment	0	O
.	0	O


Control	1	O
intact	0	O
rats	0	O
were	0	O
age	0	O
-	0	O
matched	0	O
to	0	O
the	0	O
different	0	O
treated	0	O
groups	0	O
.	0	O


The	0	O
degree	0	O
of	0	O
hypoperfusion	0	O
was	0	O
slightly	0	O
related	0	O
to	0	O
decrease	0	O
in	0	O
FEV1	1	O
.	0	O
0	0	O
%,	0	O
V25	0	O
and	0	O
PaO2	1	O
and	0	O
increase	0	O
in	0	O
circulating	0	O
blood	0	O
volume	0	O
and	0	O
peripheral	0	O
red	0	O
blood	0	O
cell	0	O
counts	0	O
.	0	O


Most	0	O
of	0	O
the	0	O
patients	0	O
had	0	O
locally	0	O
advanced	0	O
lesions	0	O
(	0	O
63	0	O
T3	1	O
-	0	O
4	0	O
:	0	O
91	0	O
.	0	O
5	0	O
%)	0	O
according	0	O
to	0	O
the	0	O
adopted	0	O
TNM	1	O
system	0	O
(	0	O
Lederman	0	O
-	0	O
Gadeberg	0	O
,	0	O
Sisson	0	O
-	0	O
Jesse	0	O
).	0	O


Recently	0	O
,	0	O
a	0	O
distantly	0	O
related	0	O
UmuC	0	B
-	0	I
homolog	0	I
,	0	O
DinB	0	B
,	0	O
has	0	O
also	0	O
been	0	O
identified	0	O
in	0	O
E	1	O
.	0	O
coli	0	O
.	0	O


Potentiation	1	O
of	0	O
the	0	O
thrombolytic	0	O
efficacy	0	O
of	0	O
single	0	B
-	0	I
chain	0	I
urokinase	0	I
(	0	O
Pro	1	B
-	0	I
urokinase	0	I
)	0	O
by	0	O
heparin	0	O
.	0	O


Expression	1	O
of	0	O
class	0	B
IV	1	I
ADH	1	I
mRNA	1	I
was	0	O
detected	0	O
in	0	O
human	0	O
stomach	0	O
but	0	O
not	0	O
liver	0	O
.	0	O


Year	0	O
one	0	O
of	0	O
the	0	O
first	0	O
general	0	O
practitioner	0	O
medical	0	O
unit	0	O
in	0	O
the	0	O
greater	0	O
Glasgow	0	O
area	0	O
.	0	O


Using	0	O
sequence	0	O
information	0	O
from	0	O
human	0	B
BMAL1	0	I
(	0	O
hBMAL1	0	B
)	0	O
cDNAs	0	O
previously	0	O
reported	0	O
by	0	O
our	0	O
laboratory	0	O
,	0	O
we	0	O
have	0	O
isolated	0	O
and	0	O
characterized	0	O
cDNAs	0	O
encoding	0	O
three	0	O
splice	0	O
variants	0	O
of	0	O
the	0	O
mouse	0	B
BMAL1	0	I
(	0	O
mBMAL1	0	B
)	0	O
gene	0	O
.	0	O


Logistic	0	O
regression	0	O
analysis	0	O
revealed	0	O
that	0	O
physicians	0	O
were	0	O
3	0	O
.	0	O
6	0	O
times	0	O
more	0	O
likely	0	O
to	0	O
detect	0	O
thin	0	O
lesions	0	O
(</=	0	O
0	0	O
.	0	O
75	0	O
mm	0	O
)	0	O
compared	0	O
with	0	O
nonphysician	0	O
detectors	0	O
(	0	O
95	0	O
%	0	O
confidence	0	O
interval	0	O
[	0	O
95	0	O
%	0	O
CI	1	O
],	0	O
2	0	O
.	0	O
1	0	O
,	0	O
6	0	O
.	0	O
5	0	O
;	0	O
P	1	O
=	0	O
0	0	O
.	0	O
0001	0	O
).	0	O


Furthermore	0	O
the	0	O
median	0	O
increase	0	O
in	0	O
cyclosporine	0	O
DR	1	O
/	0	O
C	1	O
(	0	O
SS	1	O
trough	0	O
)	0	O
was	0	O
18	0	O
l	0	O
h	0	O
-	0	O
1	0	O
(-	0	O
3	0	O
.	0	O
1	0	O
to	0	O
42	0	O
.	0	O
1	0	O
l	0	O
h	0	O
-	0	O
1	0	O
,	0	O
interquartile	0	O
range	0	O
).	0	O


In	1	O
Malmo	0	O
,	0	O
Sweden	0	O
,	0	O
17	0	O
,	0	O
181	0	O
school	0	O
children	0	O
born	0	O
in	0	O
the	0	O
years	0	O
1961	0	O
-	0	O
1965	0	O
were	0	O
screened	0	O
for	0	O
scoliosis	0	O
once	0	O
a	0	O
year	0	O
between	0	O
the	0	O
ages	0	O
of	0	O
7	0	O
and	0	O
16	0	O
years	0	O
,	0	O
during	0	O
1971	0	O
-	0	O
1980	0	O
.	0	O


Malaria	1	O
had	0	O
diminished	0	O
significantly	0	O
by	0	O
the	0	O
early	0	O
1940s	0	O
,	0	O
and	0	O
this	0	O
paper	0	O
queries	0	O
whether	0	O
that	0	O
reduction	0	O
was	0	O
due	0	O
to	0	O
the	0	O
control	0	O
projects	0	O
of	0	O
the	0	O
thirties	0	O
,	0	O
and	0	O
,	0	O
if	0	O
so	0	O
,	0	O
whether	0	O
such	0	O
projects	0	O
should	0	O
be	0	O
a	0	O
model	0	O
for	0	O
the	0	O
current	0	O
developing	0	O
world	0	O
,	0	O
where	0	O
malaria	0	O
is	0	O
a	0	O
growing	0	O
problem	0	O
today	0	O
.	0	O


The	0	O
objective	0	O
of	0	O
our	0	O
study	0	O
was	0	O
to	0	O
evaluate	0	O
the	0	O
age	0	O
,	0	O
sex	0	O
,	0	O
clinical	0	O
conditions	0	O
,	0	O
family	0	O
history	0	O
,	0	O
site	0	O
,	0	O
catheter	0	O
association	0	O
,	0	O
means	0	O
of	0	O
radiologic	0	O
evaluation	0	O
,	0	O
development	0	O
of	0	O
pulmonary	0	O
involvement	0	O
,	0	O
prevalence	0	O
of	0	O
antithrombin	0	B
III	0	I
,	0	O
protein	0	B
C	1	I
and	0	O
protein	0	B
S	1	I
deficiencies	0	O
,	0	O
and	0	O
lupus	0	O
anticoagulants	0	O
in	0	O
children	0	O
who	0	O
suffered	0	O
a	0	O
thrombotic	0	O
event	0	O
.	0	O


Detailed	0	O
molecular	0	O
organization	0	O
of	0	O
the	0	O
coding	0	O
and	0	O
upstream	0	O
regulatory	0	O
regions	0	O
of	0	O
the	0	O
murine	0	O
homeodomain	0	B
-	0	I
containing	0	I
gene	0	I
,	0	O
Msx	0	B
-	0	I
1	0	I
,	0	O
is	0	O
reported	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
results	0	O
are	0	O
consistent	0	O
with	0	O
the	0	O
possibility	0	O
that	0	O
p202	0	B
protein	0	I
contributes	0	O
to	0	O
the	0	O
cell	0	O
growth	0	O
retardation	0	O
activity	0	O
of	0	O
the	0	O
IFNs	0	B
,	0	O
at	0	O
least	0	O
in	0	O
part	0	O
,	0	O
by	0	O
modulating	0	O
p21	0	B
protein	0	I
levels	0	O
.	0	O


Sequence	1	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
upstream	0	O
to	0	O
the	0	O
ATG	1	O
codon	0	O
did	0	O
not	0	O
contain	0	O
a	0	O
conventional	0	O
TATA	0	O
box	0	O
.	0	O


In	1	O
epithelial	0	O
cells	0	O
,	0	O
the	0	O
PH	1	B
domain	0	I
of	0	O
Akt	0	B
/	0	O
PKB	0	B
localised	0	O
to	0	O
sites	0	O
of	0	O
cell	0	O
-	0	O
cell	0	O
and	0	O
cell	0	O
-	0	O
matrix	0	O
contact	0	O
,	0	O
distinct	0	O
from	0	O
focal	0	O
contacts	0	O
,	0	O
even	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
serum	0	O
.	0	O


Neither	0	O
mutant	0	O
exhibited	0	O
derepression	0	O
of	0	O
the	0	O
silent	0	B
mating	0	I
type	0	I
loci	0	I
.	0	O


A	1	O
bacteriological	0	O
relapse	0	O
requiring	0	O
treatment	0	O
occurred	0	O
by	0	O
5	0	O
years	0	O
in	0	O
16	0	O
.	0	O
8	0	O
%	0	O
of	0	O
113	0	O
R3	0	O
,	0	O
5	0	O
.	0	O
2	0	O
%	0	O
of	0	O
97	0	O
R5	0	O
,	0	O
and	0	O
20	0	O
.	0	O
0	0	O
%	0	O
of	0	O
115	0	O
Z5	0	O
patients	0	O
with	0	O
organisms	0	O
sensitive	0	O
to	0	O
streptomycin	0	O
and	0	O
isoniazid	0	O
initially	0	O
.	0	O


The	0	O
mRNAs	0	O
of	0	O
these	0	O
genes	0	O
contain	0	O
respectively	0	O
one	0	O
(	0	O
YAP1	0	B
uORF	0	I
)	0	O
and	0	O
two	0	O
(	0	O
YAP2	0	B
uORF1	0	I
and	0	O
uORF2	0	O
)	0	O
upstream	0	O
open	0	O
reading	0	O
frames	0	O
.	0	O
uORF	0	O
-	0	O
mediated	0	O
modulation	0	O
of	0	O
post	0	O
-	0	O
termination	0	O
events	0	O
on	0	O
the	0	O
5	0	O
'-	0	O
untranslated	0	O
region	0	O
(	0	O
5	0	O
'-	0	O
UTR	0	O
)	0	O
directs	0	O
differential	0	O
control	0	O
not	0	O
only	0	O
of	0	O
translation	0	O
but	0	O
also	0	O
of	0	O
mRNA	1	O
decay	0	O
.	0	O


The	0	O
kappa	0	O
coefficient	0	O
of	0	O
agreement	0	O
between	0	O
the	0	O
Patho	0	O
Dx	1	O
Kit	0	O
and	0	O
the	0	O
standard	0	O
method	0	O
was	0	O
0	0	O
.	0	O
958	0	O
.	0	O


This	0	O
growth	0	O
arrest	0	O
is	0	O
partly	0	O
suppressed	0	O
on	0	O
minimal	0	O
medium	0	O
or	0	O
under	0	O
conditions	0	O
in	0	O
which	0	O
the	0	O
cells	0	O
are	0	O
less	0	O
dependent	0	O
on	0	O
mitochondrial	0	O
metabolism	0	O
.	0	O


Intraperitoneal	1	O
administration	0	O
of	0	O
L	1	O
-	0	O
5	0	O
-	0	O
hydroxytryptophan	0	O
(	0	O
L	1	O
-	0	O
5	0	O
-	0	O
HTP	0	O
)	0	O
at	0	O
doses	0	O
of	0	O
25	0	O
to	0	O
100	0	O
mg	0	O
/	0	O
kg	0	O
dramatically	0	O
increase	0	O
defecation	0	O
in	0	O
mice	0	O
.	0	O


In	1	O
a	0	O
second	0	O
experiment	0	O
involving	0	O
an	0	O
18	0	O
-	0	O
h	0	O
lung	0	O
clearance	0	O
assay	0	O
,	0	O
we	0	O
used	0	O
the	0	O
mAb	0	B
3	0	I
.	0	I
2	0	I
.	0	I
3	0	I
to	0	O
deplete	0	O
rats	0	O
of	0	O
LGL	0	O
/	0	O
NK	1	O
cells	0	O
with	0	O
the	0	O
following	0	O
rationale	0	O
:	0	O
if	0	O
LGL	0	O
/	0	O
NK	1	O
cells	0	O
are	0	O
necessary	0	O
to	0	O
mediate	0	O
an	0	O
event	0	O
,	0	O
then	0	O
in	0	O
their	0	O
absence	0	O
,	0	O
that	0	O
event	0	O
should	0	O
not	0	O
occur	0	O
.	0	O


Using	0	O
avidin	0	B
-	0	I
biotin	0	I
complex	0	O
DNA	1	O
binding	0	O
assays	0	O
,	0	O
a	0	O
series	0	O
of	0	O
overlapping	0	O
alpha	0	B
promoter	0	I
DNA	1	I
sequences	0	I
between	0	O
-	0	O
170	0	O
to	0	O
29	0	O
basepairs	0	O
were	0	O
tested	0	O
,	0	O
but	0	O
each	0	O
failed	0	O
to	0	O
bind	0	O
GR	1	B
,	0	O
whereas	0	O
a	0	O
control	0	O
GRE	0	O
avidly	0	O
bound	0	O
receptor	0	O
.	0	O


Ten	0	O
volunteers	0	O
were	0	O
tested	0	O
at	0	O
18	0	O
,	0	O
000	0	O
ft	0	O
(	0	O
5	0	O
,	0	O
486	0	O
m	0	O
),	0	O
and	0	O
through	0	O
12	0	O
,	0	O
000	0	O
,	0	O
8	0	O
,	0	O
000	0	O
,	0	O
and	0	O
5	0	O
,	0	O
000	0	O
ft	0	O
(	0	O
3	0	O
,	0	O
657	0	O
,	0	O
2	0	O
,	0	O
438	0	O
,	0	O
and	0	O
1	0	O
,	0	O
524	0	O
m	0	O
)	0	O
with	0	O
directional	0	O
sounds	0	O
recorded	0	O
via	0	O
a	0	O
dummy	0	O
head	0	O
microphone	0	O
and	0	O
presented	0	O
binaurally	0	O
.	0	O


ECG	1	O
-	0	O
gated	0	O
myocardial	0	O
Technetium	1	O
-	0	O
99m	0	O
sestamibi	0	O
SPECT	1	O
is	0	O
a	0	O
useful	0	O
technique	0	O
to	0	O
measure	0	O
myocardial	0	O
perfusion	0	O
and	0	O
function	0	O
simultaneously	0	O
.	0	O


Parkinsonian	1	O
patients	0	O
had	0	O
a	0	O
significantly	0	O
lower	0	O
prevalence	0	O
of	0	O
alcohol	0	O
use	0	O
.	0	O


Panlobular	1	O
emphysema	0	O


Two	0	O
homologues	0	O
of	0	O
the	0	O
rhombotin	0	B
gene	0	I
have	0	O
now	0	O
been	0	O
isolated	0	O
.	0	O


Anti	0	B
-	0	I
NPROSP	0	I
-	0	I
C	1	I
also	0	O
exclusively	0	O
detected	0	O
time	0	O
-	0	O
dependent	0	O
appearances	0	O
of	0	O
5	0	B
-	0	I
10	0	I
-	0	I
kDa	1	I
proSP	0	I
-	0	I
C	1	I
forms	0	O
in	0	O
lamellar	0	O
bodies	0	O
and	0	O
homogenates	0	O
.	0	O


These	0	O
results	0	O
demonstrate	0	O
Ras	1	B
-	0	O
and	0	O
Raf	0	B
-	0	O
independent	0	O
ERK	0	B
MAPK	1	O
activation	0	O
maintains	0	O
cell	0	O
viability	0	O
following	0	O
heat	0	O
shock	0	O
.	0	O


A	1	O
rapid	0	O
fluorimetric	0	O
procedure	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
the	0	O
fungicide	0	O
5	0	O
-	0	O
fluorocytosine	0	O
in	0	O
serum	0	O
is	0	O
described	0	O
.	0	O


Genome	1	O
plasticity	0	O
in	0	O
the	0	O
distal	0	O
tail	0	O
fiber	0	O
locus	0	O
of	0	O
the	0	O
T	1	O
-	0	O
even	0	O
bacteriophage	0	O
:	0	O
recombination	0	O
between	0	O
conserved	0	O
motifs	0	O
swaps	0	O
adhesin	0	B
specificity	0	O
.	0	O


Recombinant	1	B
erythropoietin	0	I
(	0	O
r	0	B
-	0	I
HuEPO	0	I
)	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
anemia	0	O
in	0	O
multiple	0	O
myeloma	0	O


Measurement	0	O
of	0	O
SaO2	1	O
at	0	O
moderate	0	O
altitude	0	O
can	0	O
be	0	O
helpful	0	O
in	0	O
the	0	O
care	0	O
of	0	O
both	0	O
healthy	0	O
and	0	O
ill	0	O
newborns	0	O
or	0	O
infants	0	O
.	0	O


The	0	O
zta	0	B
transactivator	0	I
involved	0	O
in	0	O
induction	0	O
of	0	O
lytic	0	O
cycle	0	O
gene	0	O
expression	0	O
in	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
-	0	O
infected	0	O
lymphocytes	0	O
binds	0	O
to	0	O
both	0	O
AP	1	B
-	0	I
1	0	I
and	0	O
ZRE	0	B
sites	0	I
in	0	O
target	0	O
promoter	0	O
and	0	O
enhancer	0	O
regions	0	O
.	0	O


Since	0	O
AP	1	B
-	0	I
1	0	I
is	0	O
an	0	O
important	0	O
mediator	0	O
of	0	O
tumor	0	O
promoter	0	O
action	0	O
,	0	O
these	0	O
findings	0	O
may	0	O
explain	0	O
the	0	O
anti	0	O
-	0	O
tumor	0	O
-	0	O
promoting	0	O
activity	0	O
of	0	O
phenolic	0	O
antioxidants	0	O
.	0	O


Using	0	O
reference	0	O
probes	0	O
as	0	O
internal	0	O
standards	0	O
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
ost	0	B
transcription	0	I
unit	0	I
is	0	O
located	0	O
within	0	O
the	0	O
cytogenetic	0	O
band	0	O
interval	0	O
89A1	0	O
,	0	O
2	0	O
on	0	O
the	0	O
right	0	O
arm	0	O
of	0	O
the	0	O
third	0	O
chromosome	0	O
,	0	O
and	0	O
that	0	O
it	0	O
exerts	0	O
diagnostic	0	O
segmentation	0	O
gene	0	O
expression	0	O
patterns	0	O
in	0	O
the	0	O
embryo	0	O
.	0	O


This	0	O
study	0	O
was	0	O
designed	0	O
to	0	O
compare	0	O
the	0	O
efficacy	0	O
of	0	O
efegatran	0	O
plus	0	O
streptokinase	0	B
versus	0	O
heparin	0	O
plus	0	O
accelerated	0	O
tissue	0	B
plasminogen	0	I
activator	0	I
(	0	O
TPA	1	B
)	0	O
in	0	O
coronary	0	O
reperfusion	0	O
in	0	O
acute	0	O
MI	1	O
.	0	O


This	0	O
suggests	0	O
that	0	O
while	0	O
underpredictions	0	O
of	0	O
pain	0	O
do	0	O
not	0	O
hurt	0	O
more	0	O
,	0	O
disruption	0	O
on	0	O
primary	0	O
tasks	0	O
and	0	O
physiological	0	O
impact	0	O
are	0	O
higher	0	O
.	0	O


Effects	0	O
of	0	O
a	0	O
selective	0	O
monoamine	0	B
oxidase	0	I
(	0	I
MAO	1	I
)--	0	I
A	1	I
inhibitor	0	O
,	0	O
clorgyline	0	O
,	0	O
a	0	O
selective	0	O
MAO	1	B
-	0	I
B	1	I
inhibitor	0	O
,	0	O
deprenyl	0	O
,	0	O
and	0	O
a	0	O
non	0	O
-	0	O
selective	0	O
MAO	1	B
inhibitor	0	O
,	0	O
nialamide	0	O
,	0	O
were	0	O
investigated	0	O
on	0	O
footshock	0	O
-	0	O
induced	0	O
aggression	0	O
(	0	O
FIA	1	O
)	0	O
in	0	O
paired	0	O
rats	0	O
.	0	O


Overall	0	O
agreement	0	O
between	0	O
rest	0	O
/	0	O
postnitroglycerin	0	O
technetium	0	O
-	0	O
99m	0	O
tetrofosmin	0	O
SPET	0	O
studies	0	O
and	0	O
rest	0	O
/	0	O
redistribution	0	O
or	0	O
rest	0	O
/	0	O
reinjection	0	O
thallium	0	O
-	0	O
201	0	O
SPET	0	O
studies	0	O
,	0	O
regarding	0	O
the	0	O
presence	0	O
of	0	O
myocardial	0	O
viability	0	O
,	0	O
was	0	O
87	0	O
%	0	O
and	0	O
90	0	O
%,	0	O
respectively	0	O
.	0	O


This	0	O
observation	0	O
calls	0	O
for	0	O
careful	0	O
monitoring	0	O
of	0	O
calcium	0	O
and	0	O
alkaline	0	B
phosphatase	0	I
values	0	O
and	0	O
possible	0	O
adjustments	0	O
of	0	O
vitamin	0	O
D	1	O
intake	0	O
when	0	O
fortifiers	0	O
are	0	O
used	0	O
for	0	O
extended	0	O
periods	0	O
.	0	O


We	0	O
have	0	O
mutated	0	O
to	0	O
cysteine	0	O
,	0	O
one	0	O
at	0	O
a	0	O
time	0	O
,	0	O
21	0	O
consecutive	0	O
residues	0	O
in	0	O
the	0	O
fourth	0	O
TMS	0	O
(	0	O
TM4	0	O
).	0	O


Sequence	1	O
analysis	0	O
suggests	0	O
that	0	O
TtrA	0	B
contains	0	O
a	0	O
molybdopterin	0	O
guanine	0	O
dinucleotide	0	O
cofactor	0	O
and	0	O
a	0	O
[	0	O
4Fe	0	O
-	0	O
4S	0	O
]	0	O
cluster	0	O
,	0	O
that	0	O
TtrB	0	B
binds	0	O
four	0	O
[	0	O
4Fe	0	O
-	0	O
4S	0	O
]	0	O
clusters	0	O
,	0	O
and	0	O
that	0	O
TtrC	0	B
is	0	O
an	0	O
integral	0	O
membrane	0	O
protein	0	O
containing	0	O
a	0	O
quinol	0	O
oxidation	0	O
site	0	O
.	0	O


With	0	O
this	0	O
bisected	0	O
diastolic	0	O
driving	0	O
,	0	O
the	0	O
abnormal	0	O
echo	0	O
disappeared	0	O
completely	0	O
.	0	O


The	0	O
factor	0	O
designated	0	O
B	1	O
formed	0	O
a	0	O
complex	0	O
centered	0	O
on	0	O
the	0	O
sequence	0	O
TGTGGT	0	O
,	0	O
a	0	O
core	0	O
motif	0	O
recognized	0	O
by	0	O
members	0	O
of	0	O
the	0	O
AML	1	B
/	0	I
CBFalpha	0	I
transcription	0	I
factor	0	I
family	0	I
.	0	O


To	1	O
test	0	O
whether	0	O
or	0	O
not	0	O
SOCS	0	B
-	0	I
3	0	I
also	0	O
binds	0	O
to	0	O
the	0	O
IGFIR	0	B
,	0	O
we	0	O
cloned	0	O
human	0	B
SOCS	0	I
-	0	I
3	0	I
by	0	O
reverse	0	O
transcription	0	O
-	0	O
polymerase	0	O
chain	0	O
reaction	0	O
from	0	O
human	0	O
skeletal	0	O
muscle	0	O
mRNA	1	O
.	0	O


The	0	O
gene	0	O
includes	0	O
three	0	O
exons	0	O
and	0	O
two	0	O
introns	0	O
within	0	O
1	0	O
.	0	O
6	0	O
kilobases	0	O
of	0	O
DNA	1	O
,	0	O
and	0	O
the	0	O
entire	0	O
open	0	O
reading	0	O
frame	0	O
for	0	O
glycoprotein	0	B
IX	0	I
is	0	O
included	0	O
within	0	O
the	0	O
third	0	O
exon	0	O
.	0	O


GHB	1	O
,	0	O
2	0	O
CB	1	O
,	0	O
HMB	0	O
,	0	O
are	0	O
some	0	O
of	0	O
these	0	O
recent	0	O
substances	0	O
.	0	O


IGF	1	B
I	1	I
and	0	O
insulin	0	B
receptors	0	I
are	0	O
homologous	0	O
proteins	0	O
that	0	O
function	0	O
in	0	O
distinct	0	O
physiological	0	O
pathways	0	O
.	0	O


Area	1	O
under	0	O
the	0	O
drug	0	O
concentration	0	O
-	0	O
time	0	O
curves	0	O
(	0	O
AUC0	0	O
-	0	O
24	0	O
hr	0	O
)	0	O
for	0	O
MTX	1	O
were	0	O
2379	0	O
and	0	O
3534	0	O
ng	0	O
*	0	O
hr	0	O
/	0	O
ml	0	O
from	0	O
PG	1	O
-	0	O
2	0	O
.	0	O
5	0	O
%	0	O
Azone	0	O
and	0	O
PG	1	O
-	0	O
7	0	O
.	0	O
5	0	O
%	0	O
Azone	0	O
systems	0	O
respectively	0	O
.	0	O


Pharmacological	1	O
and	0	O
pharmacokinetic	0	O
characteristics	0	O
of	0	O
the	0	O
non	0	O
-	0	O
ionic	0	O
monomeric	0	O
X	1	O
-	0	O
ray	0	O
contrast	0	O
agent	0	O
iopromide	0	O
(	0	O
Ultravist	1	O
,	0	O
CAS	1	O
73334	0	O
-	0	O
07	0	O
-	0	O
3	0	O
)	0	O
were	0	O
evaluated	0	O
in	0	O
preclinical	0	O
studies	0	O
.	0	O


The	0	O
stability	0	O
of	0	O
isoniazid	0	O
solutions	0	O
increases	0	O
markedly	0	O
with	0	O
increasing	0	O
NTA	0	O
or	0	O
EDTA	1	O
concentration	0	O
up	0	O
to	0	O
1	0	O
mmol	0	O
/	0	O
l	0	O
.	0	O


The	0	O
control	0	O
group	0	O
included	0	O
8	0	O
afterbirth	0	O
samples	0	O
from	0	O
physiological	0	O
full	0	O
-	0	O
term	0	O
pregnancies	0	O
.	0	O


Based	0	O
on	0	O
these	0	O
results	0	O
,	0	O
a	0	O
new	0	O
model	0	O
for	0	O
the	0	O
regulation	0	O
of	0	O
nif	0	B
/	0	O
fix	0	B
gene	0	O
expression	0	O
in	0	O
A	1	O
.	0	O
caulinodans	0	O
is	0	O
proposed	0	O
.	0	O


Responses	0	O
to	0	O
brainstem	0	O
of	0	O
nuclei	0	O
medialis	0	O
dorsalis	0	O
,	0	O
lateralis	0	O
posterior	0	O
were	0	O
of	0	O
considerably	0	O
longer	0	O
latency	0	O
.	0	O


Lastly	0	O
,	0	O
there	0	O
are	0	O
multiple	0	O
instances	0	O
in	0	O
which	0	O
short	0	O
oligonucleotide	0	O
direct	0	O
repeats	0	O
flank	0	O
a	0	O
region	0	O
absent	0	O
from	0	O
either	0	O
variola	0	O
or	0	O
vaccinia	0	O
virus	0	O
.	0	O


The	0	O
gene	0	O
organization	0	O
of	0	O
CRSV	0	B
RNA	1	I
-	0	I
1	0	I
is	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
red	0	O
clover	0	O
necrotic	0	O
mosaic	0	O
(	0	O
RCNMV	0	O
)	0	O
and	0	O
sweet	0	O
clover	0	O
necrotic	0	O
mosaic	0	O
(	0	O
SCNMV	0	O
)	0	O
dianthoviruses	0	O
with	0	O
the	0	O
exception	0	O
that	0	O
CRSV	0	B
RNA	1	I
-	0	I
1	0	I
contains	0	O
the	0	O
additional	0	O
3	0	O
'-	0	O
terminal	0	O
ORF	1	O
.	0	O


PKC	0	B
-	0	I
gamma	0	I
,	0	O
which	0	O
is	0	O
not	0	O
present	0	O
in	0	O
keratinocytes	0	O
,	0	O
also	0	O
induces	0	O
involucrin	0	B
gene	0	I
expression	0	O
in	0	O
a	0	O
TPA	1	O
-	0	O
independent	0	O
manner	0	O
,	0	O
when	0	O
introduced	0	O
into	0	O
SVHK	0	O
cells	0	O
.	0	O


2	0	O
.--	0	O
concepts	0	O
of	0	O
higher	0	O
nervous	0	O
function	0	O
in	0	O
the	0	O
USSR	0	O
.	0	O


A	1	O
genetic	0	O
screen	0	O
in	0	O
yeast	0	O
has	0	O
allowed	0	O
us	0	O
to	0	O
identify	0	O
a	0	O
novel	0	O
transcriptional	0	O
factor	0	O
binding	0	O
to	0	O
the	0	O
GlRE	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
the	0	O
chicken	0	B
ovalbumin	0	I
upstream	0	I
promoter	0	I
-	0	I
transcription	0	I
factor	0	I
II	0	I
(	0	O
COUP	1	B
-	0	I
TFII	0	I
).	0	O


Bilateral	1	O
basal	0	O
arteries	0	O
were	0	O
measured	0	O
by	0	O
the	0	O
transtemporal	0	O
approach	0	O
with	0	O
a	0	O
2	0	O
MHz	1	O
pulsed	0	O
Doppler	1	O
instrument	0	O
(	0	O
TC	1	O
-	0	O
2	0	O
64B	0	O
EME	0	O
).	0	O


In	1	O
the	0	O
evening	0	O
,	0	O
the	0	O
amplitude	0	O
of	0	O
the	0	O
responses	0	O
to	0	O
both	0	O
O2	1	O
and	0	O
CO2	1	O
increased	0	O
but	0	O
the	0	O
increase	0	O
in	0	O
CO2	1	O
sensitivity	0	O
was	0	O
proportionally	0	O
more	0	O
important	0	O
.	0	O


DNA	1	O
hybridization	0	O
analysis	0	O
revealed	0	O
that	0	O
both	0	O
pigmented	0	O
and	0	O
nonpigmented	0	O
cells	0	O
of	0	O
Y	1	O
.	0	O
pestis	0	O
possess	0	O
a	0	O
DNA	1	O
locus	0	O
homologous	0	O
to	0	O
the	0	O
Escherichia	1	B
coli	0	I
fur	0	I
gene	0	I
.	0	O


Records	0	O
of	0	O
31	0	O
children	0	O
with	0	O
AIDS	1	O
or	0	O
AIDS	1	O
-	0	O
related	0	O
complex	0	O
admitted	0	O
to	0	O
the	0	O
pediatric	0	O
intensive	0	O
care	0	O
unit	0	O
for	0	O
acute	0	O
respiratory	0	O
failure	0	O
throughout	0	O
a	0	O
46	0	O
-	0	O
month	0	O
period	0	O
were	0	O
reviewed	0	O
.	0	O


Cdk2	0	B
formed	0	O
a	0	O
complex	0	O
with	0	O
cyclin	0	B
D1	1	I
in	0	O
this	0	O
system	0	O
.	0	O


Finally	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
C	1	B
/	0	I
EBP	1	I
alpha	0	I
can	0	O
also	0	O
active	0	O
the	0	O
GM	1	B
-	0	I
CSF	1	I
receptor	0	I
alpha	0	I
promoter	0	O
in	0	O
nonmyeloid	0	O
cells	0	O
.	0	O


Plasma	1	B
secretin	0	I
levels	0	O
also	0	O
augmented	0	O
after	0	O
the	0	O
administration	0	O
of	0	O
ethanol	0	O
solutions	0	O
,	0	O
with	0	O
a	0	O
delay	0	O
of	0	O
about	0	O
one	0	O
hour	0	O
after	0	O
the	0	O
onset	0	O
of	0	O
acid	0	O
secretion	0	O
.	0	O


The	0	O
serum	0	O
levels	0	O
of	0	O
IgE	1	B
,	0	O
and	0	O
asIgE	1	B
and	0	O
IgG	1	B
-	0	I
4	0	I
against	0	O
14	0	O
common	0	O
food	0	O
allergens	0	O
were	0	O
determined	0	O
.	0	O


Children	0	O
with	0	O
ADD	1	O
showed	0	O
an	0	O
attenuated	0	O
frontal	0	O
CNV	1	O
-	0	O
1	0	O
amplitude	0	O
and	0	O
a	0	O
trend	0	O
towards	0	O
increased	0	O
CNV	1	O
-	0	O
1	0	O
and	0	O
CNV	1	O
-	0	O
2	0	O
occipital	0	O
amplitudes	0	O
.	0	O


Expression	1	O
of	0	O
activated	0	O
Cdc42	0	B
results	0	O
in	0	O
the	0	O
translocation	0	O
of	0	O
PKClambda	0	B
from	0	O
the	0	O
nucleus	0	O
into	0	O
the	0	O
cytosol	0	O
,	0	O
and	0	O
Cdc42	0	B
and	0	O
PKClambda	0	B
colocalize	0	O
at	0	O
the	0	O
plasma	0	O
membrane	0	O
and	0	O
in	0	O
the	0	O
cytoplasm	0	O
.	0	O


Experimentally	0	O
in	0	O
green	0	O
monkeys	0	O
,	0	O
Syrian	0	O
hamsters	0	O
and	0	O
white	0	O
mice	0	O
the	0	O
authors	0	O
studied	0	O
the	0	O
pathogenic	0	O
properties	0	O
of	0	O
a	0	O
new	0	O
virus	0	O
Issyk	0	O
-	0	O
Kul	0	O
.	0	O


The	0	O
remaining	0	O
RAD	1	B
+	0	I
cells	0	O
progressed	0	O
to	0	O
form	0	O
microcolonies	0	O
(<	0	O
30	0	O
cells	0	O
)	0	O
containing	0	O
aberrantly	0	O
shaped	0	O
inviable	0	O
cells	0	O
.	0	O


Patterns	0	O
of	0	O
connections	0	O
underlying	0	O
cross	0	O
-	0	O
modality	0	O
integration	0	O
were	0	O
studied	0	O
by	0	O
injecting	0	O
distinguishable	0	O
,	0	O
retrograde	0	O
tracers	0	O
(	0	O
Fluoro	0	O
-	0	O
Gold	1	O
and	0	O
diamidino	0	O
yellow	0	O
)	0	O
in	0	O
pairwise	0	O
manner	0	O
into	0	O
different	0	O
sensory	0	O
representations	0	O
(	0	O
visual	0	O
,	0	O
somatosensory	0	O
,	0	O
and	0	O
auditory	0	O
)	0	O
in	0	O
the	0	O
cerebral	0	O
cortex	0	O
of	0	O
the	0	O
rat	0	O
.	0	O


However	0	O
,	0	O
Cbf5p	0	B
was	0	O
found	0	O
to	0	O
be	0	O
nucleolar	0	O
and	0	O
is	0	O
highly	0	O
homologous	0	O
to	0	O
the	0	O
rat	0	B
nucleolar	0	I
protein	0	I
NAP57	0	I
,	0	O
which	0	O
coimmunoprecipitates	0	O
with	0	O
Nopp140	0	B
and	0	O
which	0	O
is	0	O
postulated	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
nucleolar	0	O
-	0	O
cytoplasmic	0	O
shuttling	0	O
(	0	O
U	1	O
.	0	O


Echocardiography	1	O
revealed	0	O
right	0	O
ventricular	0	O
diastolic	0	O
collapse	0	O
(	0	O
RVDC	0	O
)	0	O
without	0	O
physical	0	O
signs	0	O
of	0	O
cardiac	0	O
tamponade	0	O
.	0	O


PAO	1	O
blocks	0	O
turnover	0	O
of	0	O
the	0	O
phosphoryl	0	O
group	0	O
of	0	O
pp15	0	B
,	0	O
causing	0	O
its	0	O
accumulation	0	O
,	0	O
and	0	O
thereby	0	O
appears	0	O
to	0	O
interrupt	0	O
signal	0	O
transmission	0	O
from	0	O
the	0	O
receptor	0	O
to	0	O
the	0	O
glucose	0	O
-	0	O
transport	0	O
system	0	O
.	0	O


The	0	O
alpha	0	B
inhibin	0	I
promoter	0	I
containing	0	O
a	0	O
mutated	0	O
CRE	0	O
was	0	O
not	0	O
regulated	0	O
by	0	O
forskolin	0	O
in	0	O
granulosa	0	O
cells	0	O
and	0	O
did	0	O
not	0	O
bind	0	O
the	0	O
CREB	0	B
protein	0	I
.	0	O


A	1	O
deletion	0	O
series	0	O
of	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
was	0	O
created	0	O
from	0	O
position	0	O
-	0	O
1329	0	O
to	0	O
-	0	O
74	0	O
relative	0	O
to	0	O
the	0	O
transcriptional	0	O
initiation	0	O
site	0	O
and	0	O
similarly	0	O
examined	0	O
in	0	O
transgenic	0	O
tobacco	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
our	0	O
data	0	O
suggest	0	O
that	0	O
prostate	0	O
carcinomas	0	O
with	0	O
the	0	O
Ras	1	B
/	0	O
MAPK	1	B
pathway	0	O
activation	0	O
might	0	O
have	0	O
a	0	O
selective	0	O
growth	0	O
advantage	0	O
by	0	O
autocrine	0	O
TGF	1	B
-	0	I
beta1	0	I
production	0	O
.	0	O


Responses	0	O
to	0	O
the	0	O
Plowright	0	O
Rinderpest	1	O
vaccine	0	O
by	0	O
43	0	O
calves	0	O
and	0	O
70	0	O
adult	0	O
cattle	0	O
in	0	O
Uganda	0	O
in	0	O
1990	0	O
,	0	O
through	0	O
the	0	O
production	0	O
of	0	O
IgG	1	B
antibodies	0	I
,	0	O
were	0	O
monitored	0	O
for	0	O
4	0	O
weeks	0	O
using	0	O
the	0	O
ELISA	1	O
assay	0	O
.	0	O


Specifically	0	O
,	0	O
they	0	O
were	0	O
performed	0	O
to	0	O
determine	0	O
whether	0	O
detection	0	O
of	0	O
envelope	0	O
phase	0	O
disparity	0	O
was	0	O
consistent	0	O
with	0	O
processing	0	O
within	0	O
a	0	O
single	0	O
channel	0	O
in	0	O
which	0	O
the	0	O
AM	1	O
tones	0	O
were	0	O
simply	0	O
added	0	O
.	0	O


Interestingly	0	O
,	0	O
this	0	O
activation	0	O
occurred	0	O
only	0	O
when	0	O
the	0	O
regions	0	O
were	0	O
cloned	0	O
in	0	O
the	0	O
same	0	O
relative	0	O
orientation	0	O
in	0	O
which	0	O
they	0	O
exist	0	O
on	0	O
wild	0	O
-	0	O
type	0	O
pCF10	0	O
.	0	O


No	1	O
effect	0	O
was	0	O
found	0	O
on	0	O
grooming	0	O
behavior	0	O
.	0	O


Induction	1	O
of	0	O
Jurkat	0	O
leukemic	0	O
T	1	O
cells	0	O
with	0	O
phorbol	0	O
12	0	O
-	0	O
myristate	0	O
13	0	O
-	0	O
acetate	0	O
and	0	O
ionomycin	0	O
did	0	O
not	0	O
affect	0	O
the	0	O
level	0	O
of	0	O
FKBP	0	B
mRNA	1	I
.	0	O


Importantly	0	O
,	0	O
in	0	O
HeLa	0	O
and	0	O
293	0	O
cells	0	O
,	0	O
endogenous	0	O
and	0	O
transfected	0	O
I	1	B
kappaB	0	I
alpha	0	I
coimmunoprecipitated	0	O
with	0	O
Myc	0	B
-	0	O
tagged	0	O
or	0	O
endogenous	0	O
Dlc	0	B
-	0	I
1	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
overproduction	0	O
of	0	O
Der3p	0	B
is	0	O
lethal	0	O
in	0	O
a	0	O
sec61	0	B
-	0	I
2	0	I
strain	0	O
at	0	O
the	0	O
permissive	0	O
temperature	0	O
of	0	O
25	0	O
degrees	0	O
C	1	O
.	0	O


Characterization	0	O
and	0	O
hormonal	0	O
regulation	0	O
of	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
rat	0	B
prostaglandin	0	I
endoperoxide	0	I
synthase	0	I
2	0	I
gene	0	I
in	0	O
granulosa	0	O
cells	0	O
.	0	O


Resistance	1	O
ratios	0	O
for	0	O
the	0	O
other	0	O
field	0	O
strains	0	O
obtained	0	O
by	0	O
comparison	0	O
with	0	O
the	0	O
R5	0	O
strain	0	O
ranged	0	O
from	0	O
24	0	O
.	0	O
5	0	O
to	0	O
239	0	O
for	0	O
topical	0	O
application	0	O
and	0	O
from	0	O
1	0	O
.	0	O
2	0	O
to	0	O
9	0	O
.	0	O
8	0	O
for	0	O
the	0	O
glass	0	O
jar	0	O
method	0	O
.	0	O


Cell	1	O
lines	0	O
derived	0	O
from	0	O
the	0	O
tumors	0	O
were	0	O
examined	0	O
by	0	O
fluorescent	0	O
in	0	O
situ	0	O
hybridization	0	O
for	0	O
the	0	O
status	0	O
of	0	O
the	0	O
transferred	0	O
human	0	O
chromosome	0	O
and	0	O
by	0	O
PCR	1	O
for	0	O
marker	0	O
loss	0	O
.	0	O


Salivary	1	O
sodium	0	O
,	0	O
calcium	0	O
,	0	O
and	0	O
magnesium	0	O
concentrations	0	O
were	0	O
significantly	0	O
higher	0	O
in	0	O
the	0	O
SLE	1	O
patients	0	O
with	0	O
systemic	0	O
lupus	0	O
erythematosus	0	O
,	0	O
whereas	0	O
potassium	0	O
and	0	O
total	0	O
protein	0	O
concentrations	0	O
and	0	O
amylase	0	B
activity	0	O
did	0	O
not	0	O
differ	0	O
significantly	0	O
from	0	O
the	0	O
controls	0	O
.	0	O


Mutations	0	O
in	0	O
the	0	O
alpha	0	B
-	0	I
amanitin	0	I
conserved	0	O
domain	0	O
of	0	O
the	0	O
largest	0	O
subunit	0	O
of	0	O
yeast	0	B
RNA	1	I
polymerase	0	I
III	0	I
affect	0	O
pausing	0	O
,	0	O
RNA	1	O
cleavage	0	O
and	0	O
transcriptional	0	O
transitions	0	O
.	0	O


This	0	O
approach	0	O
was	0	O
examined	0	O
utilizing	0	O
the	0	O
fetal	0	O
protein	0	O
,	0	O
HGB	1	B
F	1	I
.	0	O


Consequently	0	O
,	0	O
significant	0	O
differences	0	O
between	0	O
the	0	O
measured	0	O
and	0	O
calculated	0	O
methods	0	O
were	0	O
noted	0	O
in	0	O
oxygen	0	O
uptake	0	O
(	0	O
213	0	O
+/-	0	O
41	0	O
ml	0	O
/	0	O
min	0	O
vs	0	O
193	0	O
+/-	0	O
25	0	O
ml	0	O
/	0	O
min	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
),	0	O
oxygen	0	O
delivery	0	O
(	0	O
780	0	O
+/-	0	O
297	0	O
ml	0	O
/	0	O
min	0	O
vs	0	O
716	0	O
+/-	0	O
296	0	O
ml	0	O
/	0	O
min	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
),	0	O
and	0	O
cardiac	0	O
output	0	O
(	0	O
5	0	O
.	0	O
8	0	O
+/-	0	O
2	0	O
.	0	O
2	0	O
L	1	O
/	0	O
min	0	O
vs	0	O
5	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
8	0	O
L	1	O
/	0	O
min	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
).	0	O


There	0	O
was	0	O
significant	0	O
correlation	0	O
of	0	O
LVM	0	O
/	0	O
M2	1	O
and	0	O
PWVn	0	O
for	0	O
pre	0	O
-	0	O
AVR	0	O
and	0	O
post	0	O
AVR	0	O
studies	0	O
.	0	O


To	1	O
evaluate	0	O
whether	0	O
the	0	O
human	0	O
gene	0	O
is	0	O
also	0	O
a	0	O
target	0	O
of	0	O
thyroid	0	O
hormone	0	O
we	0	O
have	0	O
searched	0	O
for	0	O
T3	1	O
-	0	O
responsive	0	O
elements	0	O
in	0	O
NRGN	0	B
cloned	0	O
genomic	0	O
fragments	0	O
spanning	0	O
the	0	O
whole	0	O
gene	0	O
.	0	O


Multiple	1	O
transcription	0	O
start	0	O
sites	0	O
were	0	O
revealed	0	O
by	0	O
primer	0	O
extension	0	O
analysis	0	O
of	0	O
the	0	O
mouse	0	O
gene	0	O
,	0	O
and	0	O
transfection	0	O
constructs	0	O
containing	0	O
the	0	O
prospective	0	O
promoter	0	O
generated	0	O
transcriptional	0	O
activity	0	O
comparable	0	O
to	0	O
that	0	O
of	0	O
the	0	O
SV40	1	B
promoter	0	I
.	0	O


The	0	O
patient	0	O
initially	0	O
attained	0	O
complete	0	O
remission	0	O
(	0	O
CR1	1	O
)	0	O
with	0	O
conventional	0	O
chemotherapy	0	O
and	0	O
then	0	O
relapsed	0	O
14	0	O
months	0	O
later	0	O
.	0	O


We	0	O
have	0	O
shown	0	O
previously	0	O
that	0	O
GH3	0	O
cells	0	O
transfected	0	O
with	0	O
the	0	O
rat	0	B
GnRH	0	I
receptor	0	I
cDNA	1	I
(	0	O
GGH3	0	O
-	0	O
1	0	O
'	0	O
cells	0	O
)	0	O
support	0	O
the	0	O
expression	0	O
of	0	O
a	0	O
cotransfected	0	O
fusion	0	O
gene	0	O
composed	0	O
of	0	O
797	0	O
base	0	O
pairs	0	O
of	0	O
rat	0	B
LHbeta	0	I
gene	0	I
5	0	I
'-	0	I
flanking	0	I
sequence	0	I
and	0	O
the	0	O
first	0	O
5	0	O
base	0	O
pairs	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
untranslated	0	O
region	0	O
fused	0	O
to	0	O
a	0	O
luciferase	0	B
reporter	0	I
(-	0	I
797	0	I
/+	0	I
5LHbetaLUC	0	I
)	0	I
and	0	O
respond	0	O
to	0	O
a	0	O
GnRH	0	B
agonist	0	O
with	0	O
a	0	O
10	0	O
-	0	O
fold	0	O
stimulation	0	O
of	0	O
activity	0	O
.	0	O


The	0	O
participants	0	O
were	0	O
homosexual	0	O
men	0	O
in	0	O
hepatitis	0	O
B	1	O
vaccine	0	O
trials	0	O
in	0	O
Amsterdam	0	O
(	0	O
n	0	O
=	0	O
74	0	O
),	0	O
New	0	O
York	0	O
City	0	O
(	0	O
n	0	O
=	0	O
120	0	O
),	0	O
and	0	O
San	0	O
Francisco	0	O
(	0	O
n	0	O
=	0	O
168	0	O
).	0	O


Complexes	0	O
containing	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
either	0	O
his175	0	B
or	0	I
his273	0	I
mutant	0	I
p53	0	I
proteins	0	I
are	0	O
completely	0	O
unable	0	O
to	0	O
bind	0	O
to	0	O
the	0	O
RGC	0	B
DNA	1	I
sequence	0	I
.	0	O


Lack	0	O
of	0	O
controlled	0	O
prospective	0	O
studies	0	O
of	0	O
sleep	0	O
electroencephalograms	0	O
(	0	O
EEG	1	O
),	0	O
and	0	O
the	0	O
use	0	O
of	0	O
medication	0	O
,	0	O
in	0	O
children	0	O
with	0	O
developmental	0	O
dysphasia	0	O
,	0	O
may	0	O
deny	0	O
appropriate	0	O
treatment	0	O
strategies	0	O
to	0	O
children	0	O
with	0	O
severe	0	O
developmental	0	O
speech	0	O
and	0	O
language	0	O
disorders	0	O
.	0	O


Further	0	O
support	0	O
for	0	O
a	0	O
direct	0	O
interaction	0	O
of	0	O
Tub4p	0	B
,	0	O
Spc98p	0	B
and	0	O
Spc97p	0	B
comes	0	O
from	0	O
the	0	O
toxicity	0	O
of	0	O
strong	0	O
SPC97	0	B
overexpression	0	O
which	0	O
is	0	O
suppressed	0	O
by	0	O
co	0	O
-	0	O
overexpression	0	O
of	0	O
TUB4	0	B
or	0	O
SPC98	0	B
.	0	O


Endocytosis	1	O
and	0	O
vacuolar	0	O
degradation	0	O
of	0	O
the	0	O
plasma	0	O
membrane	0	O
-	0	O
localized	0	O
Pdr5	0	B
ATP	1	I
-	0	I
binding	0	I
cassette	0	I
multidrug	0	I
transporter	0	I
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Typical	1	O
and	0	O
atypical	0	O
clinical	0	O
features	0	O
of	0	O
this	0	O
lacrimal	0	O
sac	0	O
cyst	0	O
are	0	O
emphasized	0	O
.	0	O


Pigs	0	O
were	0	O
switched	0	O
from	0	O
the	0	O
growing	0	O
to	0	O
the	0	O
finishing	0	O
diet	0	O
at	0	O
57	0	O
and	0	O
61	0	O
kg	0	O
in	0	O
Exp	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
cooperation	0	O
of	0	O
transcription	0	B
factors	0	I
NF	1	I
-	0	I
kappaB	0	I
and	0	O
AP	1	B
-	0	I
1	0	I
is	0	O
essential	0	O
for	0	O
transactivation	0	O
of	0	O
IL	1	B
-	0	I
8	0	I
gene	0	I
by	0	O
HTLV	0	B
-	0	I
I	1	I
Tax	0	I
.	0	O


Although	0	O
L	1	O
-	0	O
threo	0	O
-	0	O
dihydroxyphenylserine	0	O
(	0	O
DOPS	0	O
),	0	O
an	0	O
artificial	0	O
norepinephrine	0	O
(	0	O
NE	1	O
)	0	O
precursor	0	O
,	0	O
did	0	O
not	0	O
change	0	O
immobility	0	O
in	0	O
intact	0	O
mice	0	O
,	0	O
DOPS	0	O
significantly	0	O
reduced	0	O
immobility	0	O
in	0	O
mice	0	O
pretreated	0	O
with	0	O
the	0	O
selective	0	O
NE	1	O
neurotoxin	0	O
DSP4	0	O
.	0	O


METHODS	0	O
:	0	O
Von	0	B
Willebrand	0	I
factor	0	I
(	0	O
vWF	1	B
)	0	O
and	0	O
the	0	O
fibrinolytic	0	O
factors	0	O
tissue	0	B
plasminogen	0	I
activator	0	I
(	0	O
tPA	1	B
),	0	O
measured	0	O
as	0	O
tPA	1	B
capacity	0	O
,	0	O
and	0	O
plasminogen	0	B
activator	0	I
inhibitor	0	I
1	0	I
(	0	O
PAI	1	B
-	0	I
1	0	I
),	0	O
platelets	0	O
,	0	O
fibrinogen	0	B
,	0	O
and	0	O
inflammatory	0	O
markers	0	O
were	0	O
measured	0	O
in	0	O
74	0	O
patients	0	O
with	0	O
active	0	O
seropositive	0	O
RA	1	O
.	0	O


The	0	O
TATA	0	B
box	0	I
-	0	I
binding	0	I
protein	0	I
(	0	O
TBP	1	B
)	0	O
plays	0	O
an	0	O
essential	0	O
role	0	O
in	0	O
transcription	0	O
by	0	O
all	0	O
three	0	O
eukaryotic	0	O
nuclear	0	B
RNA	1	I
polymerases	0	I
,	0	O
polymerases	0	B
(	0	I
Pol	0	I
)	0	I
I	1	I
,	0	I
II	0	I
,	0	I
and	0	I
III	0	I
.	0	O


Hence	0	O
,	0	O
scs32	0	B
only	0	O
partially	0	O
suppressed	0	O
the	0	O
ts	0	O
phenotype	0	O
and	0	O
was	0	O
unable	0	O
to	0	O
suppress	0	O
the	0	O
Ino	0	O
-	0	O
phenotype	0	O
of	0	O
rpo26	0	B
-	0	I
31	0	I
.	0	O


Takahashi	0	O
,	0	O
H	1	O
.	0	O


The	0	O
Ng	1	B
/	0	I
RC3	0	I
and	0	O
PKC	0	B
-	0	I
gamma	0	I
genes	0	I
have	0	O
a	0	O
similar	0	O
expression	0	O
pattern	0	O
in	0	O
the	0	O
brain	0	O
during	0	O
development	0	O
.	0	O


Evidence	1	O
that	0	O
opiate	0	O
addiction	0	O
is	0	O
in	0	O
part	0	O
an	0	O
immune	0	O
response	0	O
.	0	O


When	0	O
combined	0	O
with	0	O
independent	0	O
activating	0	O
mutations	0	O
in	0	O
the	0	O
c	0	B
-	0	I
abl	0	I
kinase	0	I
domain	0	I
or	0	O
NH2	0	O
-	0	O
terminus	0	O
,	0	O
the	0	O
G128R	0	B
mutation	0	O
blocked	0	O
transformation	0	O
by	0	O
the	0	O
double	0	O
mutant	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
G128R	0	B
mutant	0	I
was	0	O
unable	0	O
to	0	O
transform	0	O
cells	0	O
for	0	O
trivial	0	O
reasons	0	O
.	0	O


Roentgenographically	0	O
,	0	O
the	0	O
lesion	0	O
was	0	O
usually	0	O
a	0	O
well	0	O
-	0	O
defined	0	O
and	0	O
benign	0	O
appearing	0	O
one	0	O
,	0	O
either	0	O
purely	0	O
lytic	0	O
(	0	O
3	0	O
cases	0	O
)	0	O
or	0	O
with	0	O
central	0	O
radiodensity	0	O
(	0	O
2	0	O
cases	0	O
).	0	O


MEK	0	B
itself	0	O
is	0	O
activated	0	O
via	0	O
serine	0	O
phosphorylation	0	O
by	0	O
upstream	0	B
activator	0	I
kinases	0	I
,	0	O
including	0	O
c	0	B
-	0	I
raf	0	I
,	0	O
mos	0	B
and	0	O
MEK	0	B
kinase	0	I
.	0	O


The	0	O
high	0	O
sequence	0	O
homology	0	O
,	0	O
similar	0	O
genomic	0	O
structure	0	O
,	0	O
and	0	O
identical	0	O
chromosomal	0	O
loci	0	O
of	0	O
hKID	0	B
,	0	O
MIP	1	B
,	0	O
and	0	O
AQP	0	B
-	0	I
2	0	I
suggest	0	O
a	0	O
MIP	1	B
family	0	I
gene	0	I
cluster	0	I
at	0	O
chromosome	0	O
locus	0	O
12q13	0	O
.	0	O


An	1	O
experimental	0	O
long	0	O
-	0	O
term	0	O
study	0	O
.	0	O


These	0	O
genes	0	O
may	0	O
represent	0	O
interesting	0	O
targets	0	O
for	0	O
new	0	O
therapeutic	0	O
strategies	0	O
.	0	O


The	0	O
gene	0	O
encodes	0	O
an	0	O
ATP	1	B
-	0	I
binding	0	I
cassette	0	I
,	0	O
ABC	1	B
transporter	0	I
.	0	O


Variable	1	O
FHR	0	O
decelerations	0	O
or	0	O
bradycardias	0	O
were	0	O
encountered	0	O
on	0	O
95	0	O
nonstress	0	O
tests	0	O
(	0	O
18	0	O
.	0	O
8	0	O
%)	0	O
in	0	O
80	0	O
(	0	O
33	0	O
.	0	O
5	0	O
%)	0	O
postdate	0	O
patients	0	O
.	0	O


A	1	O
new	0	O
set	0	O
of	0	O
cDNA	1	O
clones	0	O
spanning	0	O
approximately	0	O
3	0	O
.	0	O
2	0	O
kb	0	O
was	0	O
isolated	0	O
from	0	O
a	0	O
lambda	0	O
-	0	O
ZAP	0	O
goose	0	O
liver	0	O
cDNA	1	O
library	0	O
using	0	O
the	0	O
5	0	O
'-	0	O
most	0	O
exon	0	O
-	0	O
containing	0	O
fragment	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
most	0	O
genomic	0	O
DNA	1	O
clone	0	O
.	0	O


GCD10	0	B
was	0	O
first	0	O
identified	0	O
genetically	0	O
as	0	O
a	0	O
translational	0	O
repressor	0	O
of	0	O
GCN4	0	B
.	0	O


Thromboelastography	1	O
is	0	O
a	0	O
test	0	O
that	0	O
could	0	O
potentially	0	O
correlate	0	O
with	0	O
the	0	O
degree	0	O
of	0	O
anticoagulation	0	O
produced	0	O
by	0	O
low	0	O
molecular	0	O
weight	0	O
heparin	0	O
.	0	O


Moreover	0	O
,	0	O
unlike	0	O
control	0	O
rats	0	O
operated	0	O
animals	0	O
did	0	O
not	0	O
show	0	O
aversion	0	O
to	0	O
the	0	O
highest	0	O
concentrations	0	O
of	0	O
saccharin	0	O
solutions	0	O
.	0	O


A	1	O
high	0	O
efficacy	0	O
of	0	O
the	0	O
combined	0	O
use	0	O
of	0	O
nontoxic	0	O
doses	0	O
of	0	O
two	0	O
pharmaceuticals	0	O
:	0	O
cystamine	0	O
(	0	O
50	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
and	0	O
mexamine	0	O
(	0	O
25	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
under	0	O
the	0	O
conditions	0	O
of	0	O
short	0	O
-	0	O
term	0	O
exogenous	0	O
hypoxia	0	O
(	0	O
7	0	O
.	0	O
5	0	O
%	0	O
O2	1	O
)	0	O
was	0	O
found	0	O
in	0	O
(	0	O
CBA	0	O
X	1	O
C57Bl	0	O
)	0	O
F1	0	O
mice	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
presence	0	O
of	0	O
the	0	O
Cln2	0	B
PEST	1	I
domain	0	I
was	0	O
sufficient	0	O
to	0	O
destabilize	0	O
a	0	O
heterologous	0	O
protein	0	O
.	0	O


The	0	O
pattern	0	O
of	0	O
RNase	1	B
E	1	I
digestion	0	O
of	0	O
finP305	0	B
RNA	1	I
differed	0	O
from	0	O
FinP	0	B
,	0	O
and	0	O
GST	0	B
-	0	O
FinO	0	B
did	0	O
not	0	O
protect	0	O
finP305	0	B
RNA	1	I
from	0	O
cleavage	0	O
in	0	O
vitro	0	O
.	0	O


Crystal	1	O
structure	0	O
of	0	O
an	0	O
oligomer	0	O
of	0	O
proteolytic	0	O
zymogens	0	O
:	0	O
detailed	0	O
conformational	0	O
analysis	0	O
of	0	O
the	0	O
bovine	0	O
ternary	0	O
complex	0	O
and	0	O
implications	0	O
for	0	O
their	0	O
activation	0	O
.	0	O


Maximum	1	O
induction	0	O
of	0	O
AP	1	B
-	0	I
1	0	I
was	0	O
reached	0	O
at	0	O
a	0	O
concentration	0	O
of	0	O
250	0	O
nmol	0	O
/	0	O
L	1	O
of	0	O
CalC	0	O
.	0	O


AgMNPV	0	O
and	0	O
Orgyia	0	O
pseudotsugata	0	O
MNPV	0	O
(	0	O
OpMNPV	0	O
)	0	O
are	0	O
similar	0	O
in	0	O
terms	0	O
of	0	O
promoter	0	O
structure	0	O
and	0	O
polyhedrin	0	B
primary	0	I
sequence	0	I
,	0	O
and	0	O
the	0	O
polyhedrin	0	B
gene	0	I
of	0	O
both	0	O
viruses	0	O
is	0	O
transcribed	0	O
in	0	O
the	0	O
anti	0	O
-	0	O
clockwise	0	O
direction	0	O
in	0	O
relation	0	O
to	0	O
their	0	O
physical	0	O
maps	0	O
.	0	O


These	0	O
data	0	O
provide	0	O
the	0	O
molecular	0	O
tools	0	O
for	0	O
the	0	O
final	0	O
identification	0	O
of	0	O
the	0	O
MKS	1	B
and	0	O
the	0	O
MUL	0	B
genes	0	I
.	0	O


The	0	O
effect	0	O
of	0	O
iron	0	O
intake	0	O
on	0	O
59Fe	0	O
absorption	0	O
throughout	0	O
pregnancy	0	O
,	0	O
and	0	O
on	0	O
maternal	0	O
and	0	O
fetal	0	O
Fe	1	O
status	0	O
towards	0	O
the	0	O
end	0	O
of	0	O
pregnancy	0	O
,	0	O
was	0	O
investigated	0	O
in	0	O
rats	0	O
.	0	O


Many	0	O
human	0	O
viruses	0	O
are	0	O
able	0	O
to	0	O
develop	0	O
suitable	0	O
strategies	0	O
for	0	O
modifying	0	O
apoptosis	0	O
in	0	O
virus	0	O
-	0	O
infected	0	O
cells	0	O
and	0	O
in	0	O
virus	0	O
-	0	O
primed	0	O
T	1	O
cells	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
the	0	O
protein	0	B
-	0	I
tyrosine	0	I
kinase	0	I
domain	0	I
,	0	O
p56lck	0	B
possesses	0	O
Src	1	B
homology	0	I
2	0	I
and	0	I
3	0	I
(	0	O
SH2	0	B
and	0	O
SH3	0	B
)	0	O
domains	0	O
as	0	O
well	0	O
as	0	O
a	0	O
unique	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
.	0	O


Among	0	O
booked	0	O
patients	0	O
the	0	O
maternal	0	O
mortality	0	O
rate	0	O
was	0	O
0	0	O
.	0	O
32	0	O
and	0	O
among	0	O
unbooked	0	O
patients	0	O
11	0	O
.	0	O
13	0	O
per	0	O
1000	0	O
deliveries	0	O
.	0	O


Mutational	1	O
studies	0	O
revealed	0	O
that	0	O
it	0	O
was	0	O
the	0	O
homeodomain	0	B
binding	0	I
site	0	I
II	0	I
sequence	0	I
that	0	O
was	0	O
required	0	O
for	0	O
this	0	O
regulation	0	O
.	0	O


The	0	O
statistical	0	O
analysis	0	O
consist	0	O
of	0	O
the	0	O
F	1	O
test	0	O
followed	0	O
by	0	O
Snedecor	0	O
'	0	O
s	0	O
contrast	0	O
test	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
locus	0	O
-	0	O
specific	0	O
residues	0	O
throughout	0	O
the	0	O
entire	0	O
promoter	0	O
region	0	O
strongly	0	O
suggests	0	O
that	0	O
the	0	O
various	0	O
HLA	1	B
class	0	I
I	1	I
loci	0	I
are	0	O
differentially	0	O
regulated	0	O
.	0	O


Handling	0	O
on	0	O
PND	1	O
9	0	O
did	0	O
not	0	O
result	0	O
in	0	O
elevated	0	O
CORT	0	O
levels	0	O
in	0	O
any	0	O
of	0	O
the	0	O
groups	0	O
.	0	O


PAI	1	B
-	0	I
1	0	I
levels	0	O
increased	0	O
significantly	0	O
in	0	O
patients	0	O
who	0	O
received	0	O
iohexol	0	O
but	0	O
not	0	O
in	0	O
those	0	O
who	0	O
received	0	O
ioxaglate	0	O
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
,	0	O
beta	0	O
-	0	O
funaltrexamine	0	O
(	0	O
beta	0	O
-	0	O
FNA	0	O
)	0	O
and	0	O
naltrindole	0	O
(	0	O
NTI	0	O
)	0	O
(	0	O
nonequilibrium	0	O
mu	0	O
-	0	O
and	0	O
delta	0	O
-	0	O
antagonist	0	O
,	0	O
respectively	0	O
)	0	O
were	0	O
used	0	O
to	0	O
precipitate	0	O
withdrawal	0	O
in	0	O
butorphanol	0	O
-	0	O
dependent	0	O
rats	0	O
.	0	O


The	0	O
mean	0	O
change	0	O
in	0	O
HbA1	0	B
,	0	O
adjusted	0	O
for	0	O
the	0	O
initial	0	O
value	0	O
,	0	O
was	0	O
-	0	O
0	0	O
.	0	O
4	0	O
%	0	O
in	0	O
the	0	O
experimental	0	O
and	0	O
+	0	O
0	0	O
.	0	O
5	0	O
%	0	O
in	0	O
the	0	O
control	0	O
group	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


To	1	O
begin	0	O
to	0	O
understand	0	O
this	0	O
role	0	O
,	0	O
we	0	O
overexpressed	0	O
ATF	0	B
-	0	I
2	0	I
in	0	O
a	0	O
human	0	O
cancer	0	O
cell	0	O
line	0	O
.	0	O


We	0	O
propose	0	O
that	0	O
the	0	O
reduced	0	O
responsiveness	0	O
of	0	O
CYP3A2	0	B
is	0	O
the	0	O
result	0	O
of	0	O
preferential	0	O
binding	0	O
of	0	O
COUP	1	B
-	0	I
TF	1	I
at	0	O
the	0	O
CYP3A2	0	B
DexRE	0	I
-	0	I
1	0	I
site	0	I
.	0	O


Animals	0	O
that	0	O
received	0	O
DSP	0	O
-	0	O
4	0	O
were	0	O
significantly	0	O
retarded	0	O
in	0	O
motor	0	O
recovery	0	O
compared	0	O
with	0	O
the	0	O
saline	0	O
group	0	O
.	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
exhibited	0	O
98	0	O
%	0	O
identity	0	O
to	0	O
the	0	O
human	0	O
cellular	0	O
transglutaminase	0	O
sequence	0	O
.	0	O


Human	1	O
and	0	O
Chinese	0	B
hamster	0	I
S14	0	I
protein	0	I
sequences	0	I
deduced	0	O
from	0	O
the	0	O
cDNAs	0	O
are	0	O
identical	0	O
.	0	O


The	0	O
incidence	0	O
of	0	O
tumours	0	O
in	0	O
young	0	O
chickens	0	O
.	0	O


We	0	O
showed	0	O
that	0	O
Stat3	0	B
and	0	O
Stat3beta	0	B
were	0	O
affinity	0	O
purified	0	O
using	0	O
phosphopeptides	0	O
containing	0	O
Y704	0	O
and	0	O
Y744	0	O
but	0	O
not	0	O
by	0	O
nonphosphorylated	0	O
peptide	0	O
analogues	0	O
or	0	O
by	0	O
phosphopeptides	0	O
containing	0	O
Y729	0	O
and	0	O
Y764	0	O
.	0	O


MEASUREMENTS	0	O
AND	0	O
MAIN	1	O
RESULTS	0	O
:	0	O
The	0	O
two	0	O
groups	0	O
were	0	O
similar	0	O
on	0	O
entry	0	O
into	0	O
the	0	O
study	0	O
,	0	O
including	0	O
mean	0	O
FEV1	1	O
measurements	0	O
(	0	O
0	0	O
.	0	O
70	0	O
L	1	O
atropine	0	O
/	0	O
0	0	O
.	0	O
60	0	O
L	1	O
metaproterenol	0	O
,	0	O
P	1	O
greater	0	O
than	0	O
.	0	O
05	0	O
).	0	O


When	0	O
blood	0	O
samples	0	O
of	0	O
patients	0	O
with	0	O
hyperbilirubinemia	0	O
were	0	O
analyzed	0	O
,	0	O
direct	0	O
measurement	0	O
of	0	O
ZPP	0	O
by	0	O
this	0	O
fluorimeter	0	O
yielded	0	O
significantly	0	O
higher	0	O
levels	0	O
than	0	O
did	0	O
an	0	O
alternate	0	O
extraction	0	O
method	0	O
.	0	O


A	1	O
tobacco	0	O
homologue	0	O
(	0	O
trolC	0	B
)	0	O
of	0	O
the	0	O
rolC	0	B
gene	0	I
of	0	I
the	0	I
Agrobacterium	1	I
rhizogenes	0	I
Ri	1	I
-	0	I
plasmid	0	I
was	0	O
cloned	0	O
and	0	O
sequenced	0	O
from	0	O
Nicotiana	1	O
tabacum	0	O
L	1	O
.	0	O
cv	0	O
.	0	O


Copyright	0	O
2000	0	O
The	0	O
Royal	0	O
College	0	O
of	0	O
Radiologists	0	O
.	0	O


Schlegel	0	O
,	0	O
J	1	O
.	0	O


A	1	O
potential	0	O
outcome	0	O
of	0	O
these	0	O
biochemical	0	O
effects	0	O
may	0	O
include	0	O
the	0	O
limited	0	O
responsiveness	0	O
of	0	O
infected	0	O
T	1	O
cells	0	O
to	0	O
antigenic	0	O
stimulation	0	O
observed	0	O
during	0	O
HIV	1	O
-	0	O
1	0	O
infection	0	O
.	0	O


Primer	1	O
extension	0	O
experiments	0	O
indicated	0	O
that	0	O
the	0	O
transcription	0	O
initiation	0	O
site	0	O
mapped	0	O
to	0	O
a	0	O
position	0	O
on	0	O
gene	0	B
IV	1	I
that	0	O
was	0	O
analogous	0	O
to	0	O
that	0	O
reported	0	O
for	0	O
the	0	O
structurally	0	O
similar	0	O
P	1	B
-	0	I
450e	0	I
gene	0	I
.	0	O


The	0	O
growth	0	O
-	0	O
promoting	0	O
properties	0	O
of	0	O
the	0	O
retroviral	0	B
v	0	I
-	0	I
erbA	0	I
oncogene	0	I
,	0	O
a	0	O
highly	0	O
mutated	0	O
version	0	O
of	0	O
the	0	O
chicken	0	B
thyroid	0	I
hormone	0	I
receptor	0	I
(	0	I
TR	1	I
)	0	I
alpha	0	I
,	0	O
have	0	O
so	0	O
far	0	O
exclusively	0	O
been	0	O
linked	0	O
to	0	O
dominant	0	O
repression	0	O
of	0	O
the	0	O
antimitogenic	0	O
roles	0	O
of	0	O
TR	1	B
and	0	O
retinoic	0	B
acid	0	I
receptors	0	I
.	0	O


Regulation	1	O
of	0	O
the	0	O
human	0	O
p21	0	B
/	0	O
WAF1	0	B
/	0	O
Cip1	0	B
promoter	0	O
in	0	O
hepatic	0	O
cells	0	O
by	0	O
functional	0	O
interactions	0	O
between	0	O
Sp1	0	B
and	0	O
Smad	0	B
family	0	I
members	0	I
.	0	O


To	1	O
circumvent	0	O
this	0	O
problem	0	O
,	0	O
a	0	O
simple	0	O
two	0	O
-	0	O
step	0	O
strategy	0	O
was	0	O
devised	0	O
by	0	O
which	0	O
essential	0	O
cis	0	O
-	0	O
acting	0	O
sites	0	O
like	0	O
the	0	O
a	0	O
sequence	0	O
can	0	O
be	0	O
readily	0	O
deleted	0	O
from	0	O
their	0	O
natural	0	O
loci	0	O
in	0	O
large	0	O
viral	0	O
DNA	1	O
genomes	0	O
.	0	O


Viral	1	O
RNA	1	O
,	0	O
molecularly	0	O
cloned	0	O
proviral	0	O
DNA	1	O
,	0	O
and	0	O
virus	0	O
-	0	O
specific	0	O
protein	0	O
of	0	O
avian	0	O
retrovirus	0	O
MH2	0	O
were	0	O
analyzed	0	O
.	0	O


The	0	O
possible	0	O
benefits	0	O
of	0	O
LMW	0	O
heparin	0	O
(	0	O
reduced	0	O
frequency	0	O
of	0	O
bleeding	0	O
,	0	O
alleviation	0	O
of	0	O
hypertriglyceridemia	0	O
)	0	O
were	0	O
not	0	O
,	0	O
however	0	O
,	0	O
apparent	0	O
,	0	O
possibly	0	O
because	0	O
of	0	O
the	0	O
short	0	O
observation	0	O
period	0	O
and	0	O
the	0	O
low	0	O
incidence	0	O
of	0	O
hemorrhagic	0	O
complications	0	O
in	0	O
routine	0	O
dialyses	0	O
.	0	O


A	1	O
second	0	O
isotype	0	O
of	0	O
Raja	0	B
immunoglobulin	0	I
heavy	0	I
chain	0	I
genes	0	I
has	0	O
been	0	O
detected	0	O
by	0	O
screening	0	O
a	0	O
spleen	0	O
cDNA	1	O
library	0	O
with	0	O
homologous	0	O
Raja	0	B
VH	1	I
-	0	O
and	0	O
CH1	0	B
-	0	O
specific	0	O
probes	0	O
complementing	0	O
the	0	O
respective	0	O
regions	0	O
of	0	O
the	0	O
mu	0	B
-	0	I
like	0	I
isotype	0	I
.	0	O


One	0	O
of	0	O
these	0	O
factors	0	O
,	0	O
IRF	1	B
-	0	I
2	0	I
,	0	O
was	0	O
initially	0	O
cloned	0	O
as	0	O
an	0	O
antagonistic	0	O
counterpart	0	O
to	0	O
IRF	1	B
-	0	I
1	0	I
with	0	O
oncogenic	0	O
potential	0	O
.	0	O


In	1	O
these	0	O
experiments	0	O
we	0	O
begin	0	O
to	0	O
study	0	O
the	0	O
potential	0	O
functions	0	O
of	0	O
the	0	O
alpha	0	B
7	0	I
cytoplasmic	0	I
domain	0	I
by	0	O
analyzing	0	O
homologies	0	O
between	0	O
the	0	O
rat	0	O
and	0	O
human	0	O
sequences	0	O
,	0	O
by	0	O
immunologic	0	O
studies	0	O
using	0	O
an	0	O
anti	0	O
-	0	O
cytoplasmic	0	O
domain	0	O
antiserum	0	O
,	0	O
and	0	O
by	0	O
identifying	0	O
two	0	O
alternate	0	O
forms	0	O
.	0	O


Concussion	1	O
of	0	O
the	0	O
spinal	0	O
cord	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
identified	0	O
a	0	O
novel	0	O
type	0	O
of	0	O
inhibitory	0	O
domain	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
60	0	O
amino	0	O
acids	0	O
of	0	O
IRF	1	B
-	0	I
1	0	I
which	0	O
strongly	0	O
inhibits	0	O
its	0	O
transcriptional	0	O
activity	0	O
.	0	O


A	1	O
decrease	0	O
of	0	O
the	0	O
lysozyme	0	B
activity	0	O
coincided	0	O
with	0	O
the	0	O
clinical	0	O
improvement	0	O
of	0	O
the	0	O
bacterial	0	O
meningitis	0	O
.	0	O


Filter	1	O
and	0	O
cytocentrifuge	0	O
preparations	0	O
of	0	O
the	0	O
urine	0	O
were	0	O
studied	0	O
and	0	O
all	0	O
cases	0	O
displayed	0	O
numerous	0	O
scattered	0	O
aggregates	0	O
or	0	O
single	0	O
tumor	0	O
cells	0	O
in	0	O
an	0	O
inflammatory	0	O
background	0	O
.	0	O


The	0	O
flow	0	O
rate	0	O
of	0	O
phosphate	0	O
buffered	0	O
saline	0	O
through	0	O
dermis	0	O
was	0	O
measured	0	O
as	0	O
a	0	O
function	0	O
of	0	O
applied	0	O
pressure	0	O
.	0	O


We	0	O
have	0	O
previously	0	O
identified	0	O
mouse	0	B
and	0	I
human	0	I
cDNAs	0	I
encoding	0	I
UNC	0	I
-	0	I
51	0	I
-	0	I
like	0	I
kinase	0	I
(	0	O
ULK1	0	B
).	0	O


20	0	O
%	0	O
of	0	O
total	0	O
HSL	0	B
transcripts	0	I
in	0	O
human	0	O
subcutaneous	0	O
adipocytes	0	O
.	0	O


Lipid	1	O
hydroperoxide	0	O
levels	0	O
in	0	O
plasma	0	O
and	0	O
LDL	1	B
remained	0	O
unchanged	0	O
throughout	0	O
the	0	O
study	0	O
.	0	O


Human	1	B
Duo	0	I
contains	0	O
a	0	O
guanine	0	B
nucleotide	0	I
exchange	0	I
factor	0	I
(	0	O
GEF	0	B
)	0	O
domain	0	O
that	0	O
is	0	O
likely	0	O
to	0	O
be	0	O
rac1	0	B
-	0	O
specific	0	O
,	0	O
a	0	O
pleckstrin	0	B
homology	0	I
(	0	O
PH	1	B
)	0	O
domain	0	O
and	0	O
spectrin	0	B
-	0	I
like	0	I
repeat	0	I
units	0	I
.	0	O


However	0	O
,	0	O
cotransfection	0	O
studies	0	O
indicate	0	O
that	0	O
RVR	0	B
does	0	O
not	0	O
activate	0	O
transcription	0	O
when	0	O
this	0	O
hormone	0	O
response	0	O
element	0	O
is	0	O
linked	0	O
to	0	O
a	0	O
reporter	0	O
gene	0	O
but	0	O
rather	0	O
acts	0	O
as	0	O
a	0	O
potent	0	O
competitive	0	O
repressor	0	O
of	0	O
ROR	0	B
alpha	0	I
function	0	O
.	0	O


A	1	O
noncatalytic	0	O
domain	0	O
conserved	0	O
among	0	O
cytoplasmic	0	B
protein	0	I
-	0	I
tyrosine	0	I
kinases	0	I
modifies	0	O
the	0	O
kinase	0	O
function	0	O
and	0	O
transforming	0	O
activity	0	O
of	0	O
Fujinami	0	B
sarcoma	0	I
virus	0	I
P130gag	0	I
-	0	O
fps	0	B
.	0	O


A	1	O
P22	0	O
R17	0	O
derivative	0	O
with	0	O
an	0	O
OcRNA	0	O
site	0	O
(	0	O
P22	0	O
R17	0	O
[	0	O
A	1	O
(-	0	O
10	0	O
)	0	O
U	1	O
])	0	O
develops	0	O
lytically	0	O
following	0	O
infection	0	O
of	0	O
these	0	O
strains	0	O
.	0	O


Forty	0	O
-	0	O
one	0	O
ASA	1	O
physical	0	O
status	0	O
I	1	O
or	0	O
II	0	O
adult	0	O
patients	0	O
undergoing	0	O
a	0	O
variety	0	O
of	0	O
1	0	O
-	0	O
1	0	O
.	0	O
5	0	O
h	0	O
surgical	0	O
procedures	0	O
were	0	O
randomly	0	O
allocated	0	O
to	0	O
receive	0	O
CCA	1	O
with	0	O
desflurane	0	O
or	0	O
isoflurane	0	O
with	0	O
ventilation	0	O
being	0	O
either	0	O
spontaneous	0	O
or	0	O
controlled	0	O
.	0	O


The	0	O
mean	0	O
day	0	O
of	0	O
diagnosis	0	O
of	0	O
periventricular	0	O
echodensities	0	O
was	0	O
3	0	O
+/-	0	O
2	0	O
days	0	O
(	0	O
range	0	O
1	0	O
-	0	O
11	0	O
days	0	O
),	0	O
and	0	O
of	0	O
cystic	0	O
PVL	1	O
21	0	O
+/-	0	O
8	0	O
days	0	O
(	0	O
range	0	O
2	0	O
-	0	O
47	0	O
days	0	O
).	0	O


In	1	O
vitro	0	O
evaluation	0	O
of	0	O
the	0	O
mucolytic	0	O
action	0	O
of	0	O
urea	0	O
.	0	O


Radionuclide	1	O
angiography	0	O
and	0	O
static	0	O
whole	0	O
body	0	O
imaging	0	O
performed	0	O
with	0	O
technetium	0	O
-	0	O
99m	0	O
-	0	O
labeled	0	O
particulates	0	O
can	0	O
clearly	0	O
demonstrate	0	O
differential	0	O
shunting	0	O
in	0	O
patients	0	O
with	0	O
patent	0	O
ductus	0	O
arteriosus	0	O
(	0	O
PDA	1	O
)	0	O
with	0	O
Eisenmenger	0	O
physiology	0	O
.	0	O


IFN	1	B
-	0	I
gamma	0	I
was	0	O
elevated	0	O
during	0	O
active	0	O
TB	1	O
when	0	O
compared	0	O
with	0	O
healthy	0	O
controls	0	O
,	0	O
declining	0	O
during	0	O
and	0	O
after	0	O
treatment	0	O
.	0	O


Domain	1	O
switch	0	O
experiments	0	O
reveal	0	O
that	0	O
C	1	B
/	0	I
EBP	1	I
beta	0	I
proteins	0	I
containing	0	O
either	0	O
the	0	O
leucine	0	O
zipper	0	O
or	0	O
the	0	O
activation	0	O
domain	0	O
of	0	O
C	1	B
/	0	I
EBP	1	I
alpha	0	I
are	0	O
unable	0	O
to	0	O
stimulate	0	O
the	0	O
2D5	0	B
promoter	0	I
yet	0	O
are	0	O
fully	0	O
capable	0	O
of	0	O
transactivating	0	O
an	0	O
artificial	0	O
promoter	0	O
bearing	0	O
a	0	O
high	0	O
-	0	O
affinity	0	O
C	1	B
/	0	I
EBP	1	I
site	0	I
.	0	O


SRF	1	B
-	0	O
deficient	0	O
embryos	0	O
(	0	O
Srf	1	B
-/-)	0	O
have	0	O
a	0	O
severe	0	O
gastrulation	0	O
defect	0	O
and	0	O
do	0	O
not	0	O
develop	0	O
to	0	O
term	0	O
.	0	O


Lithium	1	O
-	0	O
carbonate	0	O
action	0	O
during	0	O
radiation	0	O
therapy	0	O
has	0	O
been	0	O
studied	0	O
,	0	O
valuing	0	O
the	0	O
positive	0	O
effect	0	O
on	0	O
leukopoiesis	0	O
and	0	O
the	0	O
consequent	0	O
better	0	O
clinical	0	O
conditions	0	O
of	0	O
the	0	O
patients	0	O
in	0	O
course	0	O
of	0	O
treatment	0	O
.	0	O


A	1	O
hybridoma	0	O
clone	0	O
(	0	O
7H1	0	O
)	0	O
resulting	0	O
from	0	O
the	0	O
fusion	0	O
between	0	O
CEMLAI	0	O
/	0	O
NP	1	O
and	0	O
human	0	O
embryonic	0	O
fibroblasts	0	O
MRC5	0	O
cells	0	O
produced	0	O
very	0	O
large	0	O
amounts	0	O
of	0	O
P47	0	B
that	0	O
was	0	O
purified	0	O
using	0	O
Jacalin	0	B
lectin	0	I
(	0	O
specific	0	O
for	0	O
O	1	O
-	0	O
glycans	0	O
)	0	O
and	0	O
microsequenced	0	O
.	0	O


It	1	O
was	0	O
shown	0	O
by	0	O
transient	0	O
expression	0	O
assay	0	O
that	0	O
HS	1	B
-	0	I
40	0	I
behaved	0	O
as	0	O
an	0	O
authentic	0	O
enhancer	0	O
for	0	O
high	0	O
-	0	O
level	0	O
zeta	0	B
2	0	I
globin	0	I
promoter	0	I
activity	0	O
in	0	O
K562	0	O
cells	0	O
,	0	O
an	0	O
erythroid	0	O
cell	0	O
line	0	O
of	0	O
embryonic	0	O
and	0	O
/	0	O
or	0	O
fetal	0	O
origin	0	O
.	0	O


Crisis	1	O
of	0	O
the	0	O
therapeutic	0	O
community	0	O
in	0	O
Great	0	O
Britain	0	O


Surprisingly	0	O
,	0	O
3	0	O
full	0	B
-	0	I
length	0	I
murine	0	I
survivin	0	I
cDNA	1	I
clones	0	O
were	0	O
isolated	0	O
,	0	O
predicting	0	O
the	0	O
existence	0	O
of	0	O
3	0	O
distinct	0	O
survivin	0	B
proteins	0	I
.	0	O


Similar	0	O
to	0	O
Hp140	0	B
,	0	O
isolated	0	O
Hp55	0	B
binds	0	O
DNA	1	O
with	0	O
moderate	0	O
strength	0	O
and	0	O
was	0	O
a	0	O
specificity	0	O
for	0	O
double	0	O
-	0	O
stranded	0	O
primer	0	O
-	0	O
template	0	O
DNA	1	O
.	0	O


The	0	O
human	0	B
eps15	0	I
gene	0	I
,	0	O
encoding	0	O
a	0	O
tyrosine	0	B
kinase	0	I
substrate	0	O
,	0	O
is	0	O
conserved	0	O
in	0	O
evolution	0	O
and	0	O
maps	0	O
to	0	O
1p31	0	O
-	0	O
p32	0	O
.	0	O


Significance	0	O
of	0	O
thin	0	O
glomerular	0	O
basement	0	O
membranes	0	O
in	0	O
hematuric	0	O
children	0	O
.	0	O


Diagnosis	1	O
:	0	O
progressive	0	O
multifocal	0	O
leukoencephalopathy	0	O
.	0	O


Deregulation	0	O
of	0	O
their	0	O
expression	0	O
may	0	O
contribute	0	O
to	0	O
malignant	0	O
transformation	0	O
associated	0	O
with	0	O
HTLV	0	O
-	0	O
1	0	O
infection	0	O
.	0	O


The	0	O
frequency	0	O
of	0	O
PPNG	0	O
strains	0	O
increased	0	O
from	0	O
1	0	O
.	0	O
7	0	O
%	0	O
in	0	O
1981	0	O
to	0	O
6	0	O
.	0	O
7	0	O
%	0	O
in	0	O
1985	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
full	0	O
mu	0	O
-	0	O
opioid	0	O
agonists	0	O
fentanyl	0	O
,	0	O
morphine	0	O
,	0	O
I	1	O
-	0	O
methadone	0	O
and	0	O
levorphanol	0	O
produced	0	O
50	0	O
%	0	O
fentanyl	0	O
-	0	O
appropriate	0	O
responding	0	O
at	0	O
doses	0	O
only	0	O
1	0	O
.	0	O
3	0	O
to	0	O
10	0	O
.	0	O
9	0	O
times	0	O
smaller	0	O
than	0	O
those	0	O
required	0	O
to	0	O
decrease	0	O
response	0	O
rates	0	O
by	0	O
50	0	O
%.	0	O


All	1	O
groups	0	O
were	0	O
challenged	0	O
subsequently	0	O
with	0	O
naloxone	0	O
(	0	O
0	0	O
.	0	O
4	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
in	0	O
the	0	O
distinctive	0	O
environment	0	O
and	0	O
then	0	O
observed	0	O
for	0	O
signs	0	O
of	0	O
opiate	0	O
withdrawal	0	O
.	0	O


Guiding	1	O
patients	0	O
in	0	O
the	0	O
decision	0	O
should	0	O
involve	0	O
a	0	O
multidisciplinary	0	O
team	0	O
composed	0	O
of	0	O
a	0	O
surgical	0	O
oncologist	0	O
,	0	O
geneticist	0	O
,	0	O
pathologist	0	O
,	0	O
psychotherapist	0	O
and	0	O
plastic	0	O
surgeon	0	O
.	0	O


Among	0	O
eight	0	O
graminaceous	0	O
species	0	O
tested	0	O
,	0	O
Ids3	0	B
expression	0	O
was	0	O
observed	0	O
only	0	O
in	0	O
Fe	1	O
-	0	O
deficient	0	O
roots	0	O
of	0	O
H	1	O
.	0	O
vulgare	0	O
and	0	O
Secale	1	O
cereale	0	O
.	0	O
which	0	O
not	0	O
only	0	O
secrete	0	O
2	0	O
'-	0	O
deoxymugineic	0	O
acid	0	O
(	0	O
DMA	0	O
),	0	O
but	0	O
also	0	O
mugineic	0	O
acid	0	O
(	0	O
MA	1	O
)	0	O
and	0	O
3	0	O
-	0	O
epihydroxymugineic	0	O
acid	0	O
(	0	O
epiHMA	0	O
,	0	O
H	1	O
.	0	O
vulgare	0	O
),	0	O
and	0	O
3	0	O
-	0	O
hydroxymugineic	0	O
acid	0	O
(	0	O
HMA	0	O
,	0	O
S	1	O
.	0	O
cereale	0	O
).	0	O


IgG	1	B
levels	0	O
of	0	O
1	0	O
/	0	O
100	0	O
were	0	O
present	0	O
in	0	O
only	0	O
four	0	O
out	0	O
of	0	O
ten	0	O
samples	0	O
obtained	0	O
150	0	O
days	0	O
after	0	O
the	0	O
clinical	0	O
onset	0	O
.	0	O


Atherosclerosis	1	O


Letter	0	O
:	0	O
Lactose	1	O
tolerance	0	O
tests	0	O
as	0	O
a	0	O
predictor	0	O
of	0	O
milk	0	O
tolerance	0	O
.	0	O


The	0	O
RNase	1	B
MRP	0	I
RNA	1	I
gene	0	I
was	0	O
deleted	0	O
by	0	O
insertional	0	O
replacement	0	O
and	0	O
found	0	O
to	0	O
be	0	O
essential	0	O
for	0	O
cellular	0	O
viability	0	O
,	0	O
indicating	0	O
a	0	O
critical	0	O
nuclear	0	O
role	0	O
for	0	O
RNase	1	B
MRP	0	I
.	0	O


The	0	O
avidin	0	B
-	0	I
biotin	0	I
complex	0	I
peroxidase	0	I
(	0	O
ABC	1	B
-	0	I
P	1	I
)	0	O
method	0	O
was	0	O
used	0	O
to	0	O
detect	0	O
Mycobacterium	1	O
bovis	0	O
,	0	O
and	0	O
the	0	O
results	0	O
were	0	O
compared	0	O
with	0	O
those	0	O
obtained	0	O
by	0	O
the	0	O
Ziehl	0	O
-	0	O
Neelsen	0	O
(	0	O
ZN	1	O
)	0	O
technique	0	O
.	0	O


We	0	O
now	0	O
report	0	O
the	0	O
isolation	0	O
and	0	O
expression	0	O
of	0	O
cDNAs	0	O
encoding	0	O
PTF	0	B
gamma	0	I
and	0	O
PTF	0	B
delta	0	I
,	0	O
as	0	O
well	0	O
as	0	O
functional	0	O
studies	0	O
with	0	O
cognate	0	O
antibodies	0	O
that	0	O
recognize	0	O
the	0	O
native	0	O
PTF	0	B
complex	0	I
in	0	O
HeLa	0	O
extracts	0	O
.	0	O


The	0	O
promoter	0	O
mutation	0	O
is	0	O
complemented	0	O
in	0	O
trans	0	O
by	0	O
E1A	0	B
products	0	O
of	0	O
the	0	O
heterologous	0	O
helper	0	O
adenovirus	0	O
type	0	O
5	0	O
(	0	O
Ad5	0	O
).	0	O


Remarkably	0	O
,	0	O
both	0	O
TTD	0	O
-	0	O
A	1	O
and	0	O
XP	1	O
-	0	O
D	1	O
defects	0	O
are	0	O
associated	0	O
with	0	O
subunits	0	O
of	0	O
TFIIH	0	B
,	0	O
a	0	O
basal	0	O
transcription	0	O
factor	0	O
with	0	O
a	0	O
second	0	O
function	0	O
in	0	O
DNA	1	O
repair	0	O
.	0	O


We	0	O
have	0	O
previously	0	O
reported	0	O
that	0	O
depletion	0	O
of	0	O
protein	0	B
kinase	0	I
C	1	I
by	0	O
long	0	O
-	0	O
term	0	O
treatment	0	O
of	0	O
B16	0	O
mouse	0	O
melanoma	0	O
cells	0	O
with	0	O
phorbol	0	O
dibutyrate	0	O
(	0	O
PDBu	0	O
)	0	O
prevented	0	O
cell	0	O
density	0	O
-	0	O
dependent	0	O
melanogenesis	0	O
.	0	O


These	0	O
results	0	O
are	0	O
the	0	O
first	0	O
to	0	O
demonstrate	0	O
the	0	O
structural	0	O
organization	0	O
of	0	O
a	0	O
vertebrate	0	O
gene	0	O
encoding	0	O
an	0	O
integral	0	O
membrane	0	O
protein	0	O
of	0	O
the	0	O
nuclear	0	O
envelope	0	O
that	0	O
may	0	O
be	0	O
a	0	O
member	0	O
of	0	O
a	0	O
family	0	O
of	0	O
polypeptides	0	O
conserved	0	O
in	0	O
evolution	0	O
.	0	O


Other	0	O
uncertainties	0	O
in	0	O
the	0	O
dosimetry	0	O
at	0	O
Y	1	O
-	0	O
12	0	O
and	0	O
Vinca	1	O
are	0	O
unaltered	0	O
.	0	O


A	1	O
5	0	O
.	0	O
3	0	O
-	0	O
kb	0	O
DNA	1	O
fragment	0	O
,	0	O
which	0	O
included	0	O
the	0	O
entire	0	O
structural	0	O
porin	0	B
gene	0	I
(	0	O
named	0	O
porCa	0	B
)	0	O
and	0	O
its	0	O
flanking	0	O
regions	0	O
,	0	O
was	0	O
identified	0	O
.	0	O


Primary	1	O
invasive	0	O
Haemophilus	1	O
influenzae	0	O
type	0	O
b	0	O
disease	0	O
:	0	O
a	0	O
population	0	O
-	0	O
based	0	O
assessment	0	O
of	0	O
risk	0	O
factors	0	O
.	0	O


However	0	O
,	0	O
the	0	O
a1	0	O
isoform	0	O
is	0	O
expressed	0	O
most	0	O
heavily	0	O
in	0	O
brain	0	O
and	0	O
heart	0	O
,	0	O
a2	0	O
in	0	O
liver	0	O
and	0	O
kidney	0	O
,	0	O
and	0	O
a3	0	O
in	0	O
liver	0	O
,	0	O
lung	0	O
,	0	O
heart	0	O
,	0	O
brain	0	O
,	0	O
spleen	0	O
,	0	O
and	0	O
kidney	0	O
.	0	O


Patterns	0	O
defined	0	O
by	0	O
combinations	0	O
of	0	O
normal	0	O
and	0	O
abnormal	0	O
laboratory	0	O
results	0	O
had	0	O
decreased	0	O
the	0	O
likelihood	0	O
of	0	O
PEM	1	O
from	0	O
an	0	O
all	0	O
-	0	O
2	0	O
to	0	O
all	0	O
-	0	O
0	0	O
pattern	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
interpretation	0	O
,	0	O
a	0	O
mutant	0	O
form	0	O
of	0	O
XRN1	0	B
,	0	O
which	0	O
encodes	0	O
a	0	O
5	0	O
'-	0	O
3	0	O
'	0	O
exonuclease	0	O
,	0	O
was	0	O
identified	0	O
as	0	O
an	0	O
extragenic	0	O
suppressor	0	O
that	0	O
increases	0	O
the	0	O
half	0	O
-	0	O
life	0	O
of	0	O
rhis4	0	B
mRNA	1	I
,	0	O
leading	0	O
to	0	O
a	0	O
10	0	O
-	0	O
fold	0	O
increase	0	O
in	0	O
steady	0	O
-	0	O
state	0	O
mRNA	1	O
levels	0	O
compared	0	O
to	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
HIS4	0	I
mRNA	1	I
level	0	O
.	0	O


Intravenous	1	O
glucose	0	O
tolerance	0	O
tests	0	O
were	0	O
performed	0	O
before	0	O
operation	0	O
,	0	O
before	0	O
starting	0	O
CyA	0	O
and	0	O
after	0	O
3	0	O
weeks	0	O
.	0	O


A	1	O
case	0	O
of	0	O
chronic	0	O
hepatitis	0	O
C	1	O
with	0	O
primary	0	O
hypothyroidism	0	O
manifested	0	O
during	0	O
interferon	0	B
treatment	0	O


Thus	0	O
,	0	O
included	0	O
in	0	O
the	0	O
KG1a	0	O
EST	1	O
dataset	0	O
are	0	O
candidates	0	O
for	0	O
new	0	O
human	0	O
genes	0	O
that	0	O
may	0	O
play	0	O
roles	0	O
in	0	O
hematopoietic	0	O
differentiative	0	O
progression	0	O
and	0	O
lineage	0	O
commitment	0	O
.	0	O


Epidemiologic	1	O
evidence	0	O
indicates	0	O
that	0	O
estrogen	0	O
replacement	0	O
therapy	0	O
after	0	O
menopause	0	O
increases	0	O
breast	0	O
cancer	0	O
risk	0	O
.	0	O


In	1	O
experiment	0	O
2	0	O
,	0	O
no	0	O
difference	0	O
in	0	O
gastric	0	O
emptying	0	O
of	0	O
40	0	O
%	0	O
peptone	0	O
or	0	O
25	0	O
%	0	O
glucose	0	O
was	0	O
found	0	O
between	0	O
rats	0	O
receiving	0	O
TPN	1	O
and	0	O
those	0	O
receiving	0	O
intragastric	0	O
nutrition	0	O
for	0	O
10	0	O
to	0	O
12	0	O
days	0	O
.	0	O


The	0	O
already	0	O
elevated	0	O
prolactin	0	B
levels	0	O
in	0	O
nursing	0	O
women	0	O
were	0	O
not	0	O
influenced	0	O
by	0	O
chronic	0	O
oestradiol	0	O
administration	0	O
.	0	O


The	0	O
transcription	0	O
and	0	O
alternative	0	O
splicing	0	O
of	0	O
human	0	B
ORL1	0	I
and	0	O
GAIP	0	B
are	0	O
cell	0	O
-	0	O
type	0	O
specific	0	O
.	0	O


We	0	O
consider	0	O
that	0	O
DIL	0	O
-	0	O
CP	1	O
is	0	O
a	0	O
safe	0	O
and	0	O
excellent	0	O
CP	1	O
in	0	O
CABG	1	O
surgery	0	O
and	0	O
we	0	O
are	0	O
now	0	O
utilizing	0	O
this	0	O
CP	1	O
in	0	O
all	0	O
patients	0	O
requiring	0	O
CABG	1	O
surgery	0	O
.	0	O


Immobilization	1	O
of	0	O
the	0	O
fracture	0	O
in	0	O
a	0	O
collar	0	O
and	0	O
cuff	0	O
sling	0	O
was	0	O
as	0	O
effective	0	O
as	0	O
more	0	O
elaborate	0	O
methods	0	O
.	0	O


The	0	O
yeast	0	O
retrotransposon	0	B
Ty5	0	I
preferentially	0	O
integrates	0	O
into	0	O
regions	0	O
of	0	O
silent	0	O
chromatin	0	O
.	0	O


Circulating	0	O
thrombomodulin	0	B
:	0	O
current	0	O
knowledge	0	O
and	0	O
future	0	O
prospects	0	O


Several	0	O
lines	0	O
of	0	O
evidence	0	O
demonstrate	0	O
that	0	O
this	0	O
growth	0	O
inhibition	0	O
requires	0	O
active	0	O
PKA	1	B
subunits	0	I
and	0	O
cAMP	1	O
:	0	O
(	0	O
i	0	O
)	0	O
this	0	O
phenotype	0	O
is	0	O
dependent	0	O
on	0	O
cAMP	1	O
since	0	O
it	0	O
is	0	O
not	0	O
seen	0	O
in	0	O
a	0	O
strain	0	O
lacking	0	O
adenylyl	0	B
cyclase	0	I
activity	0	O
,	0	O
but	0	O
the	0	O
growth	0	O
rate	0	O
of	0	O
these	0	O
transformants	0	O
is	0	O
slower	0	O
when	0	O
exogenous	0	O
cAMP	1	O
is	0	O
added	0	O
;	0	O
(	0	O
ii	0	O
)	0	O
normal	0	O
growth	0	O
occurs	0	O
when	0	O
wild	0	O
-	0	O
type	0	O
RI	1	B
cDNA	1	O
is	0	O
replaced	0	O
by	0	O
a	0	O
mutant	0	B
RI	1	I
cDNA	1	I
encoding	0	O
a	0	O
RI	1	B
protein	0	I
with	0	O
reduced	0	O
cAMP	1	O
binding	0	O
;	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
the	0	O
growth	0	O
-	0	O
inhibited	0	O
phenotype	0	O
of	0	O
the	0	O
transformed	0	O
BL21	0	O
(	0	O
DE3	0	O
)	0	O
cells	0	O
requires	0	O
soluble	0	O
,	0	O
active	0	O
C	1	B
alpha	0	I
protein	0	I
.	0	O


The	0	O
prescription	0	O
for	0	O
apoplexy	0	O
includes	0	O
C1	1	O
-	0	O
7	0	O
,	0	O
T1	1	O
-	0	O
9	0	O
and	0	O
L2	0	O
-	0	O
4	0	O
.	0	O


Liposomal	0	O
Amphotericin	0	O
-	0	O
B	1	O
failed	0	O
in	0	O
6	0	O
/	0	O
7	0	O
patients	0	O
with	0	O
culture	0	O
-	0	O
proven	0	O
mycosis	0	O
who	0	O
died	0	O
from	0	O
infection	0	O
with	0	O
Aspergillus	1	O
(	0	O
n	0	O
=	0	O
2	0	O
)	0	O
and	0	O
Candida	1	O
(	0	O
n	0	O
=	0	O
4	0	O
),	0	O
respectively	0	O
.	0	O


To	1	O
begin	0	O
to	0	O
examine	0	O
the	0	O
mechanism	0	O
controlling	0	O
expression	0	O
of	0	O
this	0	O
gene	0	O
during	0	O
the	0	O
cell	0	O
-	0	O
cycle	0	O
,	0	O
a	0	O
mouse	0	B
B	1	I
-	0	I
myb	0	I
5	0	I
'	0	I
flanking	0	I
sequence	0	I
was	0	O
isolated	0	O
from	0	O
a	0	O
cosmid	0	O
library	0	O
and	0	O
shown	0	O
to	0	O
promote	0	O
efficiently	0	O
the	0	O
transcription	0	O
of	0	O
a	0	O
luciferase	0	B
reporter	0	I
gene	0	I
when	0	O
transfected	0	O
into	0	O
NIH3T3	0	O
fibroblasts	0	O
.	0	O


Although	0	O
YopH	0	B
is	0	O
a	0	O
highly	0	O
active	0	O
PTP	0	B
,	0	O
it	0	O
preferentially	0	O
targets	0	O
a	0	O
subset	0	O
of	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
proteins	0	O
in	0	O
host	0	O
cells	0	O
,	0	O
including	0	O
p130Cas	0	B
.	0	O


This	0	O
study	0	O
is	0	O
a	0	O
further	0	O
and	0	O
more	0	O
extensive	0	O
validation	0	O
of	0	O
the	0	O
clinician	0	O
rated	0	O
NIMH	1	O
-	0	O
LCM	1	O
-	0	O
p	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
combined	0	O
lesions	0	O
of	0	O
cholinergic	0	O
and	0	O
serotonergic	0	O
neurons	0	O
in	0	O
the	0	O
rat	0	O
brain	0	O
do	0	O
not	0	O
alter	0	O
olfactory	0	O
perception	0	O
or	0	O
olfactory	0	O
short	0	O
-	0	O
term	0	O
memory	0	O
.	0	O


An	1	O
analysis	0	O
of	0	O
synthetic	0	O
peptides	0	O
revealed	0	O
a	0	O
minimal	0	O
CTD	1	O
sequence	0	O
that	0	O
is	0	O
sufficient	0	O
to	0	O
bind	0	O
to	0	O
the	0	O
second	0	O
Rsp5	0	B
WW	0	I
domain	0	I
(	0	O
Rsp5	0	B
WW2	0	I
)	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
assays	0	O
.	0	O


Dietary	1	O
supplement	0	O
with	0	O
fish	0	O
oil	0	O
and	0	O
related	0	O
n	0	O
-	0	O
3	0	O
EFAs	0	O
has	0	O
been	0	O
used	0	O
to	0	O
study	0	O
their	0	O
antihypertensive	0	O
property	0	O
in	0	O
animals	0	O
and	0	O
humans	0	O
with	0	O
borderline	0	O
and	0	O
essential	0	O
hypertension	0	O
.	0	O


B	1	B
cell	0	I
antigen	0	I
receptor	0	I
(	0	O
BCR	0	B
)-	0	O
induced	0	O
apoptosis	0	O
in	0	O
the	0	O
WEHI	0	O
-	0	O
231	0	O
B	1	O
lymphoma	0	O
cell	0	O
line	0	O
can	0	O
be	0	O
prevented	0	O
by	0	O
engaging	0	O
CD40	0	B
.	0	O


Activated	0	O
PKR	0	B
may	0	O
exist	0	O
as	0	O
a	0	O
dimer	0	O
and	0	O
phosphorylates	0	O
the	0	O
eukaryotic	0	B
translation	0	I
initiation	0	I
factor	0	I
2	0	I
alpha	0	I
subunit	0	I
(	0	O
cIF	0	B
-	0	I
2	0	I
alpha	0	I
)	0	O
to	0	O
inhibit	0	O
polypeptide	0	O
chain	0	O
initiation	0	O
.	0	O


Topoisomerase	1	B
II	0	I
is	0	O
a	0	O
major	0	O
target	0	O
of	0	O
the	0	O
protein	0	B
kinase	0	I
casein	0	I
kinase	0	I
2	0	I
(	0	O
PK	1	B
CK2	0	I
)	0	O
in	0	O
vivo	0	O
.	0	O


We	0	O
have	0	O
examined	0	O
by	0	O
in	0	O
vitro	0	O
footprinting	0	O
a	0	O
region	0	O
located	0	O
downstream	0	O
of	0	O
the	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
,	0	O
type	0	O
1	0	O
(	0	O
HIV	1	O
-	0	O
1	0	O
)	0	O
promoter	0	O
found	0	O
to	0	O
be	0	O
hypersensitive	0	O
to	0	O
DNase	1	B
I	1	I
digestion	0	O
in	0	O
vivo	0	O
.	0	O


Expression	1	O
of	0	O
SREBP	0	B
-	0	I
1a	0	I
stimulated	0	O
StAR	1	B
promoter	0	I
activity	0	O
in	0	O
the	0	O
context	0	O
of	0	O
COS	1	O
-	0	O
1	0	O
cells	0	O
and	0	O
human	0	O
granulosa	0	O
-	0	O
lutein	0	O
cells	0	O
.	0	O


The	0	O
amino	0	O
-	0	O
terminal	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
of	0	O
Pip	1	B
exhibits	0	O
a	0	O
high	0	O
degree	0	O
of	0	O
homology	0	O
to	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domains	0	O
of	0	O
members	0	O
of	0	O
the	0	O
interferon	0	B
regulatory	0	I
factor	0	I
(	0	O
IRF	1	B
)	0	O
family	0	O
,	0	O
which	0	O
includes	0	O
IRF	1	B
-	0	I
1	0	I
,	0	O
IRF	1	B
-	0	I
2	0	I
,	0	O
ICSBP	0	B
,	0	O
and	0	O
ISGF3	0	B
gamma	0	I
.	0	O


In	1	O
humans	0	O
,	0	O
four	0	O
AMP	1	B
deaminase	0	I
variants	0	I
,	0	O
termed	0	O
M	1	B
(	0	O
muscle	0	O
),	0	O
L	1	B
(	0	O
liver	0	O
),	0	O
E1	1	B
,	0	O
and	0	O
E2	1	B
(	0	O
erythrocyte	0	O
)	0	O
can	0	O
be	0	O
distinguished	0	O
by	0	O
a	0	O
variety	0	O
of	0	O
biochemical	0	O
and	0	O
immunological	0	O
criteria	0	O
.	0	O


The	0	O
psychological	0	O
tests	0	O
consisted	0	O
of	0	O
a	0	O
free	0	O
-	0	O
recall	0	O
task	0	O
,	0	O
a	0	O
test	0	O
for	0	O
visuomotor	0	O
coordination	0	O
and	0	O
a	0	O
recognition	0	O
task	0	O
.	0	O


Instead	0	O
,	0	O
the	0	O
results	0	O
support	0	O
the	0	O
idea	0	O
that	0	O
Pc	1	B
group	0	I
products	0	I
provide	0	O
stable	0	O
memory	0	O
or	0	O
imprinting	0	O
of	0	O
boundaries	0	O
which	0	O
are	0	O
initially	0	O
specified	0	O
by	0	O
gap	0	O
and	0	O
pair	0	O
-	0	O
rule	0	O
regulators	0	O
.	0	O


Possibly	0	O
,	0	O
the	0	O
scr1	0	B
-	0	I
1	0	I
mutation	0	I
does	0	O
not	0	O
affect	0	O
signal	0	O
recognition	0	O
or	0	O
translational	0	O
arrest	0	O
but	0	O
instead	0	O
results	0	O
in	0	O
maintenance	0	O
of	0	O
translational	0	O
arrest	0	O
of	0	O
AEP	1	B
synthesis	0	O
.	0	O


Successful	0	O
use	0	O
of	0	O
transureteroureterostomy	0	O
to	0	O
salvage	0	O
ureterosigmoidostomy	0	O
after	0	O
anastomotic	0	O
failure	0	O
.	0	O


Prominent	0	O
protein	0	O
kinase	0	O
cascades	0	O
are	0	O
those	0	O
that	0	O
activate	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
(	0	I
MAP	1	I
)	0	I
kinases	0	I
.	0	O


The	0	O
distribution	0	O
phase	0	O
is	0	O
followed	0	O
by	0	O
an	0	O
elimination	0	O
phase	0	O
with	0	O
a	0	O
much	0	O
longer	0	O
half	0	O
-	0	O
life	0	O
(	0	O
mean	0	O
value	0	O
375	0	O
min	0	O
)	0	O
and	0	O
a	0	O
volume	0	O
of	0	O
distribution	0	O
of	0	O
approximately	0	O
200	0	O
-	0	O
400	0	O
l	0	O
.	0	O


Regulation	1	O
at	0	O
37	0	O
degrees	0	O
C	1	O
,	0	O
therefore	0	O
,	0	O
involves	0	O
the	0	O
action	0	O
of	0	O
three	0	O
protein	0	O
kinase	0	O
cascades	0	O
that	0	O
repress	0	O
HSF1	0	B
through	0	O
phosphorylation	0	O
of	0	O
serine	0	O
residues	0	O
303	0	O
,	0	O
307	0	O
,	0	O
and	0	O
363	0	O
and	0	O
may	0	O
promote	0	O
growth	0	O
by	0	O
suppressing	0	O
the	0	O
heat	0	O
shock	0	O
response	0	O
.	0	O


We	0	O
have	0	O
identified	0	O
a	0	O
strong	0	O
Tas	0	B
-	0	I
responsive	0	I
element	0	I
,	0	O
designated	0	O
TRE	0	B
(	0	O
GP	1	B
),	0	O
near	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
gag	0	B
gene	0	I
and	0	O
preceding	0	O
the	0	O
pol	0	B
gene	0	I
of	0	O
SFV	0	O
-	0	O
1	0	O
.	0	O


In	1	O
whole	0	O
sardine	0	O
,	0	O
domoic	0	O
acid	0	O
was	0	O
detected	0	O
in	0	O
levels	0	O
exceeding	0	O
sometimes	0	O
the	0	O
regulatory	0	O
limit	0	O
.	0	O


Dentalplaque	0	O
was	0	O
controlled	0	O
by	0	O
the	0	O
oral	0	O
higienic	0	O
index	0	O
of	0	O
the	0	O
whole	0	O
dentition	0	O
daily	0	O
,	0	O
after	0	O
staining	0	O
with	0	O
1	0	O
per	0	O
cent	0	O
alkaline	0	O
fuxin	0	O
.	0	O


Magnetic	1	O
resonance	0	O
imaging	0	O
in	0	O
coccidioidal	0	O
arthritis	0	O
.	0	O


II	0	O
.	0	O


The	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
segment	0	O
of	0	O
the	0	O
RNA	1	O
was	0	O
selectively	0	O
cross	0	O
-	0	O
linked	0	O
to	0	O
the	0	O
72	0	O
,	0	O
000	0	O
-	0	O
molecular	0	O
-	0	O
weight	0	O
protein	0	O
(	0	O
72K	0	O
protein	0	O
).	0	O


The	0	O
patient	0	O
was	0	O
homozygous	0	O
for	0	O
the	0	O
underlying	0	O
mutation	0	O
,	0	O
which	0	O
was	0	O
found	0	O
to	0	O
be	0	O
a	0	O
G	1	O
-->	0	O
T	1	O
transversion	0	O
within	0	O
the	0	O
acceptor	0	O
splice	0	O
site	0	O
between	0	O
intron	0	O
e	0	O
and	0	O
exon	0	O
6	0	O
,	0	O
abolishing	0	O
normal	0	O
RNA	1	O
splicing	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
regulation	0	O
of	0	O
Glvr	0	B
-	0	I
1	0	I
gene	0	I
expression	0	O
also	0	O
has	0	O
potential	0	O
applications	0	O
to	0	O
gene	0	O
therapy	0	O
,	0	O
since	0	O
retroviral	0	O
vectors	0	O
carrying	0	O
gibbon	0	B
ape	0	I
leukemia	0	I
virus	0	I
envelope	0	I
proteins	0	I
are	0	O
used	0	O
for	0	O
gene	0	O
delivery	0	O
into	0	O
different	0	O
cell	0	O
types	0	O
.	0	O


These	0	O
cells	0	O
produced	0	O
P2Y	0	B
(	0	I
11	0	I
)	0	I
mRNA	1	I
during	0	O
culture	0	O
.	0	O


Microcomputer	0	O
management	0	O
of	0	O
chronic	0	O
hepatitis	0	O
B	1	O
virus	0	O
asymptomatic	0	O
patients	0	O


For	0	O
wild	0	O
type	0	O
MutT	0	B
and	0	O
its	0	O
E53D	0	B
and	0	O
E44D	0	B
mutants	0	I
,	0	O
plots	0	O
of	0	O
log	0	O
(	0	O
k	0	O
(	0	O
cat	0	O
))	0	O
versus	0	O
pH	1	O
exhibited	0	O
a	0	O
limiting	0	O
slope	0	O
of	0	O
1	0	O
on	0	O
the	0	O
ascending	0	O
limb	0	O
and	0	O
then	0	O
a	0	O
hump	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
a	0	O
sharply	0	O
defined	0	O
maximum	0	O
near	0	O
pH	1	O
8	0	O
followed	0	O
by	0	O
a	0	O
plateau	0	O
,	0	O
yielding	0	O
apparent	0	O
pK	1	O
(	0	O
a	0	O
)	0	O
values	0	O
of	0	O
7	0	O
.	0	O
6	0	O
+/-	0	O
0	0	O
.	0	O
3	0	O
and	0	O
8	0	O
.	0	O
4	0	O
+/-	0	O
0	0	O
.	0	O
4	0	O
for	0	O
an	0	O
essential	0	O
base	0	O
and	0	O
a	0	O
nonessential	0	O
acid	0	O
catalyst	0	O
,	0	O
respectively	0	O
,	0	O
in	0	O
the	0	O
active	0	O
quaternary	0	O
MutT	0	B
-	0	O
Mg	1	O
(	0	O
2	0	O
+)-	0	O
dGTP	1	O
-	0	O
Mg	1	O
(	0	O
2	0	O
+)	0	O
complex	0	O
.	0	O


Conventionally	0	O
,	0	O
four	0	O
nominal	0	O
allotypic	0	O
variants	0	O
,	0	O
b4	0	O
,	0	O
b5	0	O
,	0	O
b6	0	O
and	0	O
b9	0	O
have	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
co	0	O
-	0	O
dominantly	0	O
expressed	0	O
at	0	O
the	0	O
Ckappa1	0	B
gene	0	I
locus	0	I
.	0	O


Naval	0	O
personnel	0	O
who	0	O
exceed	0	O
standards	0	O
for	0	O
%	0	O
BF	1	O
can	0	O
be	0	O
separated	0	O
from	0	O
active	0	O
duty	0	O
.	0	O


Ninety	0	O
-	0	O
four	0	O
percent	0	O
of	0	O
the	0	O
EPs	1	O
were	0	O
tubal	0	O
,	0	O
and	0	O
90	0	O
%	0	O
of	0	O
the	0	O
tubes	0	O
exhibited	0	O
some	0	O
pathologic	0	O
changes	0	O
,	0	O
including	0	O
chronic	0	O
salpingitis	0	O
(	0	O
49	0	O
.	0	O
5	0	O
%)	0	O
and	0	O
follicular	0	O
salpingitis	0	O
(	0	O
10	0	O
%),	0	O
among	0	O
others	0	O
.	0	O


Upon	0	O
induction	0	O
of	0	O
SOS	0	O
,	0	O
viability	0	O
increased	0	O
2	0	O
-	0	O
6	0	O
-	0	O
fold	0	O
.	0	O


We	0	O
remain	0	O
convinced	0	O
that	0	O
antilymphocyte	0	B
globulin	0	I
(	0	O
ALG	1	B
)	0	O
is	0	O
a	0	O
potent	0	O
immunosuppressive	0	O
agent	0	O
in	0	O
humans	0	O
.	0	O


Clinical	1	O
trials	0	O
with	0	O
1	0	O
,	0	O
3	0	O
-	0	O
bis	0	O
(	0	O
2	0	O
-	0	O
chloroethyl	0	O
)-	0	O
1	0	O
-	0	O
nitrosourea	0	O
,	0	O
NSC	0	O
-	0	O
409962	0	O
.	0	O


These	0	O
elements	0	O
comprise	0	O
a	0	O
binding	0	O
site	0	O
for	0	O
Krox	0	B
proteins	0	I
,	0	O
one	0	O
for	0	O
nuclear	0	B
factor	0	I
1	0	I
,	0	O
an	0	O
octamer	0	O
motif	0	O
that	0	O
binds	0	O
POU	0	B
-	0	I
homeodomain	0	I
proteins	0	I
,	0	O
and	0	O
a	0	O
novel	0	O
TN	1	B
control	0	I
element	0	I
.	0	O


Chimeric	0	O
phage	0	O
-	0	O
plasmid	0	O
expression	0	O
vectors	0	O
were	0	O
constructed	0	O
from	0	O
pUC18	0	O
/	0	O
19	0	O
plasmids	0	O
by	0	O
cloning	0	O
a	0	O
single	0	O
-	0	O
stranded	0	O
DNA	1	O
(	0	O
ssDNA	1	O
)	0	O
origin	0	O
of	0	O
replication	0	O
from	0	O
bacteriophage	0	O
f1	0	O
and	0	O
inserting	0	O
a	0	O
bacteriophage	0	O
T7	0	O
promoter	0	O
within	0	O
the	0	O
beta	0	B
-	0	I
galactosidase	0	I
gene	0	I
.	0	O


The	0	O
topology	0	O
and	0	O
chain	0	O
folding	0	O
of	0	O
the	0	O
beta	0	O
subunits	0	O
in	0	O
the	0	O
artifactual	0	O
beta	0	O
60	0	O
capsid	0	O
are	0	O
similar	0	O
to	0	O
the	0	O
native	0	B
alpha	0	I
3	0	I
beta	0	I
60	0	I
enzyme	0	I
.	0	O


Furthermore	0	O
,	0	O
plasma	0	O
fibrinogen	0	B
levels	0	O
increased	0	O
by	0	O
a	0	O
mean	0	O
of	0	O
17	0	O
.	0	O
6	0	O
%,	0	O
a	0	O
potentially	0	O
adverse	0	O
effect	0	O
of	0	O
gemfibrozil	0	O
that	0	O
has	0	O
not	0	O
been	0	O
previously	0	O
reported	0	O
.	0	O


Renal	1	O
and	0	O
extrarenal	0	O
arterial	0	O
fibromuscular	0	O
hyperplasia	0	O
with	0	O
hypertension	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
two	0	O
internal	0	O
promoters	0	O
,	0	O
PmiaA	0	B
and	0	O
P1hfq	0	B
were	0	O
identified	0	O
and	0	O
mapped	0	O
to	0	O
201	0	O
and	0	O
837	0	O
nucleotides	0	O
upstream	0	O
from	0	O
the	0	O
respective	0	O
translation	0	O
start	0	O
sites	0	O
.	0	O


We	0	O
failed	0	O
to	0	O
find	0	O
these	0	O
data	0	O
to	0	O
be	0	O
useful	0	O
in	0	O
predicting	0	O
the	0	O
time	0	O
of	0	O
onset	0	O
of	0	O
initial	0	O
seizures	0	O
after	0	O
acute	0	O
ischemic	0	O
stroke	0	O
and	0	O
recurrence	0	O
.	0	O


Prazosin	0	O
alone	0	O
was	0	O
effective	0	O
in	0	O
volume	0	O
responsive	0	O
patients	0	O
at	0	O
a	0	O
dose	0	O
of	0	O
5	0	O
+/-	0	O
1	0	O
.	0	O
0	0	O
mg	0	O
daily	0	O
.	0	O


The	0	O
yeast	0	B
RER2	0	I
gene	0	I
,	0	O
identified	0	O
by	0	O
endoplasmic	0	O
reticulum	0	O
protein	0	O
localization	0	O
mutations	0	O
,	0	O
encodes	0	O
cis	0	B
-	0	I
prenyltransferase	0	I
,	0	O
a	0	O
key	0	O
enzyme	0	O
in	0	O
dolichol	0	O
synthesis	0	O
.	0	O


Thus	0	O
,	0	O
we	0	O
have	0	O
produced	0	O
lipoyl	0	O
domain	0	O
constructs	0	O
that	0	O
can	0	O
be	0	O
employed	0	O
in	0	O
sorting	0	O
the	0	O
specific	0	O
roles	0	O
of	0	O
E2L1	0	B
and	0	O
E2L2	0	B
in	0	O
facilitating	0	O
catalytic	0	O
and	0	O
regulatory	0	O
processes	0	O
.	0	O


These	0	O
findings	0	O
demonstrate	0	O
that	0	O
haemodialysis	0	O
patients	0	O
with	0	O
chronic	0	O
hepatitis	0	O
C	1	O
respond	0	O
well	0	O
to	0	O
interferon	0	B
treatment	0	O
and	0	O
that	0	O
a	0	O
long	0	O
-	0	O
term	0	O
response	0	O
is	0	O
achieved	0	O
in	0	O
a	0	O
high	0	O
proportion	0	O
of	0	O
patients	0	O
.	0	O


VIII	0	O
in	0	O
doses	0	O
2	0	O
-	0	O
3	0	O
times	0	O
higher	0	O
than	0	O
usually	0	O
used	0	O
in	0	O
haemophiliacs	0	O
without	0	O
inhibitor	0	O
were	0	O
successful	0	O
.	0	O


In	1	O
Experiments	0	O
1	0	O
and	0	O
2	0	O
,	0	O
infants	0	O
,	0	O
like	0	O
adults	0	O
,	0	O
initially	0	O
categorized	0	O
novel	0	O
objects	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
physical	0	O
appearance	0	O
,	0	O
but	0	O
only	0	O
if	0	O
trained	0	O
with	0	O
multiple	0	O
exemplars	0	O
,	0	O
after	0	O
delays	0	O
of	0	O
1	0	O
and	0	O
7	0	O
days	0	O
.	0	O


The	0	O
mechanism	0	O
of	0	O
action	0	O
is	0	O
explored	0	O
in	0	O
some	0	O
detail	0	O
,	0	O
specifically	0	O
as	0	O
it	0	O
relates	0	O
to	0	O
reticuloendothelial	0	O
system	0	O
(	0	O
RES	1	O
)	0	O
Fc	1	B
receptor	0	I
blockade	0	O
and	0	O
suppression	0	O
of	0	O
antiplatelet	0	O
antibody	0	O
synthesis	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
using	0	O
biochemical	0	O
activity	0	O
assays	0	O
for	0	O
Rho	1	B
-	0	O
like	0	O
GTPases	0	B
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
expression	0	O
of	0	O
beta1A	0	B
,	0	O
beta1D	0	B
,	0	O
or	0	O
IL2R	0	B
-	0	O
beta1A	0	B
in	0	O
GE11	0	O
or	0	O
GD25	0	O
cells	0	O
triggers	0	O
activation	0	O
of	0	O
both	0	O
RhoA	0	B
and	0	O
Rac1	0	B
,	0	O
but	0	O
not	0	O
of	0	O
Cdc42	0	B
.	0	O


Overexpression	1	O
of	0	O
CDP	1	B
/	0	O
cut	0	B
in	0	O
ROS	1	O
17	0	O
/	0	O
2	0	O
.	0	O
8	0	O
osteosarcoma	0	O
cells	0	O
results	0	O
in	0	O
repression	0	O
of	0	O
OC	1	B
promoter	0	I
activity	0	O
;	0	O
this	0	O
repression	0	O
is	0	O
abrogated	0	O
by	0	O
mutating	0	O
OC	1	B
box	0	I
I	1	I
.	0	O


Their	0	O
effect	0	O
on	0	O
the	0	O
guinea	0	O
pig	0	O
vas	0	O
deferens	0	O
.	0	O


Commercially	0	O
available	0	O
formulations	0	O
of	0	O
2	0	O
.	0	O
5	0	O
%	0	O
and	0	O
5	0	O
%	0	O
lambdacyhalothrin	0	O
can	0	O
be	0	O
diluted	0	O
either	0	O
with	0	O
water	0	O
for	0	O
ULV	0	O
cold	0	O
aerosol	0	O
space	0	O
-	0	O
spraying	0	O
or	0	O
with	0	O
diesel	0	O
/	0	O
kerosene	0	O
for	0	O
thermal	0	O
fogging	0	O
at	0	O
recommended	0	O
application	0	O
rates	0	O
of	0	O
0	0	O
.	0	O
5	0	O
-	0	O
1	0	O
g	0	O
ai	0	O
/	0	O
ha	0	O
for	0	O
mosquito	0	O
control	0	O
and	0	O
2	0	O
g	0	O
ai	0	O
/	0	O
ha	0	O
for	0	O
housefly	0	O
control	0	O
.	0	O


XYL1	0	B
was	0	O
isolated	0	O
as	0	O
a	0	O
highly	0	O
expressed	0	O
fusion	0	O
clone	0	O
from	0	O
a	0	O
'	0	B
lacZ	0	I
translational	0	O
fusion	0	O
library	0	O
.	0	O


Venkatesan	0	O
,	0	O
and	0	O
D	1	O
.	0	O


Theories	0	O
proffered	0	O
to	0	O
account	0	O
for	0	O
the	0	O
modality	0	O
shift	0	O
effect	0	O
are	0	O
critically	0	O
evaluated	0	O
.	0	O


Osteocalcin	1	B
(	0	O
OC	1	B
)	0	O
is	0	O
a	0	O
matrix	0	B
calcium	0	I
-	0	I
binding	0	I
protein	0	I
expressed	0	O
in	0	O
osteoblasts	0	O
and	0	O
odontoblasts	0	O
undergoing	0	O
mineralization	0	O
.	0	O


The	0	O
distribution	0	O
of	0	O
body	0	O
fluids	0	O
following	0	O
hemorrhage	0	O
and	0	O
resuscitation	0	O
in	0	O
combat	0	O
casualties	0	O
.	0	O


Follow	0	O
-	0	O
up	0	O
controls	0	O
of	0	O
luteinizing	0	B
hormone	0	I
(	0	O
LH	1	B
),	0	O
follicle	0	B
stimulating	0	I
hormone	0	I
(	0	O
FSH	1	B
),	0	O
prolactin	0	B
(	0	O
HPRL	0	B
),	0	O
oestradiol	0	O
(	0	O
E2	1	O
),	0	O
progesterone	0	O
(	0	O
P	1	O
)	0	O
and	0	O
testosterone	0	O
(	0	O
T	1	O
)	0	O
in	0	O
the	0	O
catabolic	0	O
and	0	O
healing	0	O
phase	0	O
of	0	O
burn	0	O
disease	0	O
.	0	O


Like	0	O
other	0	O
members	0	O
of	0	O
this	0	O
family	0	O
,	0	O
the	0	O
AP	1	B
-	0	I
4	0	I
HLH	0	O
motif	0	O
and	0	O
the	0	O
adjacent	0	O
basic	0	O
domain	0	O
are	0	O
necessary	0	O
and	0	O
sufficient	0	O
to	0	O
confer	0	O
site	0	O
-	0	O
specific	0	O
DNA	1	O
binding	0	O
.	0	O


The	0	O
cglIM	0	B
gene	0	I
is	0	O
organized	0	O
in	0	O
an	0	O
unusual	0	O
operon	0	O
which	0	O
contains	0	O
,	0	O
in	0	O
addition	0	O
,	0	O
two	0	O
genes	0	O
encoding	0	O
stress	0	O
-	0	O
sensitive	0	O
restriction	0	O
enzymes	0	O
.	0	O


Addition	1	O
of	0	O
sucralfate	0	O
or	0	O
De	0	O
-	0	O
Nol	0	O
resulted	0	O
in	0	O
increments	0	O
of	0	O
gastric	0	O
HCO3	0	O
secretion	0	O
,	0	O
reaching	0	O
about	0	O
45	0	O
%	0	O
and	0	O
59	0	O
%,	0	O
respectively	0	O
,	0	O
of	0	O
the	0	O
maximal	0	O
HCO3	0	O
response	0	O
to	0	O
16	0	O
,	0	O
16	0	O
-	0	O
dimethyl	0	O
PGE2	0	O
(	0	O
dmPGE2	0	O
).	0	O


16	0	O
subjects	0	O
were	0	O
repatch	0	O
tested	0	O
to	0	O
ethylmercury	0	O
chloride	0	O
(	0	O
EtHgCl	0	O
)	0	O
and	0	O
to	0	O
solutions	0	O
containing	0	O
EtHgCl	0	O
mixed	0	O
with	0	O
L	1	O
-	0	O
cysteine	0	O
and	0	O
glutathione	0	O
,	0	O
respectively	0	O
.	0	O


An	1	O
inverted	0	O
Alu	0	B
repeat	0	O
element	0	O
,	0	O
flanked	0	O
by	0	O
nonamer	0	O
direct	0	O
repeats	0	O
,	0	O
was	0	O
identified	0	O
within	0	O
the	0	O
region	0	O
-	0	O
913	0	O
/-	0	O
620	0	O
,	0	O
relative	0	O
to	0	O
the	0	O
cap	0	O
site	0	O
.	0	O


Several	0	O
new	0	O
techniques	0	O
are	0	O
available	0	O
for	0	O
monitoring	0	O
control	0	O
of	0	O
diabetes	0	O
.	0	O


Thus	0	O
,	0	O
IRF	1	B
-	0	I
7	0	I
exhibits	0	O
functional	0	O
similarity	0	O
to	0	O
IRF	1	B
-	0	I
3	0	I
;	0	O
however	0	O
,	0	O
the	0	O
preferential	0	O
expression	0	O
of	0	O
IRF	1	B
-	0	I
7	0	I
in	0	O
lymphoid	0	O
cells	0	O
(	0	O
the	0	O
cell	0	O
type	0	O
that	0	O
expresses	0	O
IFNA	0	B
)	0	O
suggests	0	O
that	0	O
IRF	1	B
-	0	I
7	0	I
may	0	O
play	0	O
a	0	O
critical	0	O
role	0	O
in	0	O
regulating	0	O
the	0	O
IFNA	0	B
gene	0	I
expression	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
an	0	O
amino	0	O
-	0	O
terminal	0	O
fragment	0	O
containing	0	O
the	0	O
C	1	O
/	0	O
H1	1	O
domain	0	O
was	0	O
sufficient	0	O
for	0	O
coactivation	0	O
of	0	O
Zta	0	B
transcription	0	O
and	0	O
viral	0	O
reactivation	0	O
function	0	O
.	0	O


Transcription	1	O
initiation	0	O
occurred	0	O
predominantly	0	O
at	0	O
the	0	O
putative	0	O
sigmaA	0	B
-	0	I
dependent	0	I
promoter	0	I
in	0	O
exponentially	0	O
growing	0	O
cells	0	O
and	0	O
was	0	O
induced	0	O
under	0	O
stress	0	O
conditions	0	O
.	0	O


A	1	O
36	0	O
year	0	O
-	0	O
old	0	O
woman	0	O
was	0	O
given	0	O
Ergotamine	1	O
Tartrate	1	O
4	0	O
.	0	O
5	0	O
mg	0	O
p	0	O
.	0	O
d	0	O
.	0	O
during	0	O
seven	0	O
days	0	O
,	0	O
after	0	O
an	0	O
abortion	0	O
(	0	O
a	0	O
still	0	O
birth	0	O
).	0	O


Sinusoidal	1	O
oscillations	0	O
of	0	O
a	0	O
gas	0	O
dilution	0	O
indicator	0	O


The	0	O
aim	0	O
of	0	O
our	0	O
study	0	O
was	0	O
to	0	O
evaluate	0	O
the	0	O
level	0	O
of	0	O
oxidative	0	O
stress	0	O
in	0	O
healthy	0	O
controls	0	O
(	0	O
CTL	1	O
)	0	O
compared	0	O
with	0	O
CRF	1	O
and	0	O
HD	1	O
patients	0	O
before	0	O
(	0	O
pre	0	O
-	0	O
HD	1	O
)	0	O
and	0	O
after	0	O
(	0	O
post	0	O
-	0	O
HD	1	O
)	0	O
the	0	O
dialysis	0	O
session	0	O
,	0	O
carried	0	O
out	0	O
on	0	O
a	0	O
high	0	O
biocompatible	0	O
polyacrylonitrile	0	O
membrane	0	O
AN69	0	O
.	0	O


To	1	O
further	0	O
define	0	O
the	0	O
structural	0	O
requirements	0	O
for	0	O
ZAP	0	B
-	0	I
70	0	I
interaction	0	O
with	0	O
the	0	O
TCR	1	B
,	0	O
we	0	O
developed	0	O
a	0	O
binding	0	O
assay	0	O
using	0	O
immobilized	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
fusion	0	I
proteins	0	I
containing	0	O
the	0	O
NH2	0	O
-	0	O
and	0	O
/	0	O
or	0	O
COOH	0	B
-	0	I
terminal	0	I
SH2	0	I
domains	0	I
of	0	O
ZAP	0	B
-	0	I
70	0	I
,	0	O
and	0	O
soluble	0	O
synthetic	0	O
peptides	0	O
with	0	O
the	0	O
sequence	0	O
of	0	O
the	0	O
cytoplasmic	0	O
region	0	O
of	0	O
the	0	O
TCR	1	B
zeta	0	I
chain	0	I
(	0	O
TCR	1	B
zeta	0	I
cyt	0	I
)	0	O
or	0	O
individual	0	O
TCR	1	B
zeta	0	I
and	0	O
CD3	0	B
epsilon	0	I
TAM	0	I
motifs	0	I
.	0	O


BRCA1	0	B
protein	0	I
contains	0	O
an	0	O
amino	0	O
-	0	O
terminal	0	O
zinc	0	O
finger	0	O
motif	0	O
and	0	O
a	0	O
carboxy	0	O
-	0	O
terminal	0	O
acidic	0	O
region	0	O
.	0	O


The	0	O
quantitative	0	O
determination	0	O
of	0	O
HBSAG	1	B
--	0	O
a	0	O
valuable	0	O
aid	0	O
in	0	O
evaluating	0	O
the	0	O
infectiousness	0	O
of	0	O
hepatitis	0	O
B	1	O
virus	0	O
carriers	0	O


Preflight	0	O
,	0	O
inflight	0	O
,	0	O
and	0	O
postflight	0	O
exercise	0	O
response	0	O
tests	0	O
were	0	O
conducted	0	O
on	0	O
the	0	O
astronauts	0	O
of	0	O
the	0	O
second	0	O
Skylab	0	O
mission	0	O
(	0	O
Skylab	0	O
3	0	O
)	0	O
as	0	O
part	0	O
of	0	O
an	0	O
evaluation	0	O
of	0	O
physiological	0	O
adaptation	0	O
to	0	O
long	0	O
-	0	O
term	0	O
weightlessness	0	O
.	0	O


The	0	O
best	0	O
endometrial	0	O
ablation	0	O
was	0	O
seen	0	O
when	0	O
SnET2	0	O
was	0	O
given	0	O
by	0	O
intrauterine	0	O
administration	0	O
with	0	O
light	0	O
treatment	0	O
at	0	O
150	0	O
J	1	O
/	0	O
cm	0	O
24	0	O
hours	0	O
later	0	O
.	0	O


Escherichia	1	O
coli	0	O
BL21	0	O
(	0	O
DE3	0	O
)	0	O
plysS	0	O
,	0	O
harbouring	0	O
a	0	O
recombinant	0	O
plasmid	0	O
containing	0	O
the	0	O
catalase	0	B
-	0	O
peroxidase	0	B
gene	0	O
,	0	O
produced	0	O
a	0	O
large	0	O
amount	0	O
of	0	O
proteins	0	O
that	0	O
co	0	O
-	0	O
migrated	0	O
on	0	O
SDS	1	O
/	0	O
PAGE	1	O
with	0	O
the	0	O
native	0	O
enzyme	0	O
.	0	O


In	1	O
the	0	O
8	0	O
patients	0	O
the	0	O
difference	0	O
betweent	0	O
he	0	O
mean	0	O
diastolic	0	O
values	0	O
of	0	O
delta	0	O
PU	1	O
and	0	O
delta	0	O
PM	1	O
was	0	O
-	0	O
0	0	O
.	0	O
54	0	O
+/-	0	O
1	0	O
.	0	O
0	0	O
(	0	O
SD	1	O
)	0	O
mmHg	0	O
.	0	O


No	1	O
significant	0	O
differences	0	O
were	0	O
found	0	O
in	0	O
relation	0	O
to	0	O
Type	1	O
A	1	O
behaviour	0	O
and	0	O
beta	0	B
-	0	I
adrenoceptor	0	I
blockade	0	O
.	0	O


The	0	O
latter	0	O
was	0	O
determined	0	O
as	0	O
follows	0	O
:	0	O
Type	1	O
I	1	O
-	0	O
solid	0	O
tumor	0	O
tissue	0	O
without	0	O
significant	0	O
peripheral	0	O
isolated	0	O
tumor	0	O
cells	0	O
;	0	O
Type	1	O
II	0	O
-	0	O
solid	0	O
tumor	0	O
tissue	0	O
associated	0	O
with	0	O
peripheral	0	O
isolated	0	O
tumor	0	O
cells	0	O
;	0	O
Type	1	O
III	0	O
-	0	O
isolated	0	O
tumor	0	O
cells	0	O
only	0	O
.	0	O


Radiation	1	O
decreased	0	O
the	0	O
levels	0	O
of	0	O
T4	1	O
and	0	O
T3	1	O
6	0	O
h	0	O
and	0	O
72	0	O
h	0	O
in	0	O
group	0	O
C	1	O
,	0	O
in	0	O
group	0	O
A	1	O
at	0	O
72	0	O
h	0	O
,	0	O
in	0	O
group	0	O
B	1	O
at	0	O
24	0	O
h	0	O
postexposure	0	O
.	0	O


A	1	O
comparison	0	O
of	0	O
the	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
T	1	O
.	0	O
thermophilus	0	O
enzyme	0	O
with	0	O
that	0	O
of	0	O
the	0	O
Escherichia	1	O
coli	0	O
enzyme	0	O
showed	0	O
(	0	O
i	0	O
)	0	O
a	0	O
37	0	O
%	0	O
overall	0	O
similarity	0	O
;	0	O
(	0	O
ii	0	O
)	0	O
the	0	O
conservation	0	O
of	0	O
the	0	O
Ser	1	O
residue	0	O
,	0	O
which	0	O
is	0	O
known	0	O
to	0	O
be	0	O
phosphorylated	0	O
in	0	O
the	0	O
E	1	O
.	0	O
coli	0	O
enzyme	0	O
,	0	O
and	0	O
of	0	O
the	0	O
surrounding	0	O
sequence	0	O
;	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
the	0	O
presence	0	O
of	0	O
141	0	O
extra	0	O
residues	0	O
at	0	O
the	0	O
C	1	O
terminus	0	O
of	0	O
the	0	O
T	1	O
.	0	O
thermophilus	0	O
enzyme	0	O
.	0	O


Both	0	O
domains	0	O
were	0	O
required	0	O
for	0	O
specific	0	O
DNA	1	O
binding	0	O
to	0	O
the	0	O
beta	0	B
-	0	I
retinoic	0	I
acid	0	I
receptor	0	I
element	0	I
,	0	O
producing	0	O
a	0	O
DNase	1	B
I	1	I
footprint	0	O
covering	0	O
predominantly	0	O
one	0	O
strand	0	O
.	0	O


EGV	0	O
had	0	O
no	0	O
detectable	0	O
effect	0	O
on	0	O
PP	1	B
secretion	0	O
under	0	O
basal	0	O
or	0	O
stimulated	0	O
conditions	0	O
.	0	O


The	0	O
authors	0	O
report	0	O
a	0	O
case	0	O
in	0	O
which	0	O
stereotactic	0	O
irrigation	0	O
of	0	O
a	0	O
brain	0	O
cyst	0	O
was	0	O
temporally	0	O
associated	0	O
with	0	O
respiratory	0	O
distress	0	O
.	0	O


The	0	O
interaction	0	O
of	0	O
caffeine	0	O
,	0	O
theophylline	0	O
and	0	O
theobromine	0	O
with	0	O
monoamine	0	B
oxidase	0	I
inhibitors	0	O
.	0	O


A	1	O
study	0	O
of	0	O
the	0	O
comparative	0	O
efficacy	0	O
of	0	O
diflucortolone	0	O
valerate	0	O
0	0	O
.	0	O
3	0	O
%	0	O
ointment	0	O
and	0	O
clobetasol	0	O
propionate	0	O
0	0	O
.	0	O
05	0	O
%	0	O
ointment	0	O
.	0	O


However	0	O
,	0	O
the	0	O
rtFc	0	B
gamma	0	I
R	1	I
alpha	0	I
cDNA	1	I
clone	0	O
is	0	O
complementary	0	O
to	0	O
at	0	O
least	0	O
two	0	O
different	0	O
-	0	O
sized	0	O
mRNAs	0	O
expressed	0	O
by	0	O
CRNK	0	O
-	0	O
16	0	O
cells	0	O
,	0	O
contrasting	0	O
the	0	O
single	0	O
Fc	1	B
gamma	0	I
R	1	I
-	0	I
related	0	I
mRNA	1	I
species	0	O
expressed	0	O
by	0	O
human	0	O
and	0	O
mouse	0	O
natural	0	O
killer	0	O
cells	0	O
.	0	O


195mPt	0	O
-	0	O
labeled	0	O
cisplatin	0	O
was	0	O
administered	0	O
iv	0	O
and	0	O
ip	0	O
to	0	O
control	0	O
mice	0	O
and	0	O
to	0	O
mice	0	O
bearing	0	O
Sarcoma	1	O
180	0	O
.	0	O


Diuretics	0	O
:	0	O
basic	0	O
clinical	0	O
pharmacology	0	O
and	0	O
therapeutic	0	O
use	0	O
.	0	O


Ethylene	1	O
is	0	O
involved	0	O
in	0	O
endosperm	0	O
rupture	0	O
and	0	O
high	0	O
-	0	O
level	0	O
betaGLU	0	B
I	1	I
expression	0	O
;	0	O
but	0	O
,	0	O
it	0	O
does	0	O
not	0	O
affect	0	O
the	0	O
spatial	0	O
and	0	O
temporal	0	O
pattern	0	O
of	0	O
betaGLU	0	B
I	1	I
expression	0	O
.	0	O


Mutations	0	O
at	0	O
three	0	O
sites	0	O
have	0	O
larger	0	O
effects	0	O
in	0	O
muscle	0	O
than	0	O
nonmuscle	0	O
cells	0	O
;	0	O
an	0	O
A	1	O
/	0	O
T	1	O
-	0	O
rich	0	O
site	0	O
mutation	0	O
has	0	O
a	0	O
pronounced	0	O
effect	0	O
in	0	O
both	0	O
striated	0	O
muscle	0	O
types	0	O
,	0	O
mutations	0	O
at	0	O
the	0	O
MEF1	0	B
(	0	I
Right	1	I
E	1	I
-	0	I
box	0	I
)	0	I
site	0	I
are	0	O
relatively	0	O
specific	0	O
to	0	O
expression	0	O
in	0	O
skeletal	0	O
muscle	0	O
,	0	O
and	0	O
mutations	0	O
at	0	O
the	0	O
CArG	0	O
site	0	O
are	0	O
relatively	0	O
specific	0	O
to	0	O
expression	0	O
in	0	O
cardiac	0	O
muscle	0	O
.	0	O


To	1	O
determine	0	O
whether	0	O
the	0	O
NTP	1	O
-	0	O
binding	0	O
motif	0	O
is	0	O
important	0	O
for	0	O
Rad24	0	B
function	0	O
,	0	O
we	0	O
mutated	0	O
the	0	O
conserved	0	O
lysine	0	O
(	0	O
115	0	O
)	0	O
residue	0	O
in	0	O
this	0	O
motif	0	O
.	0	O


Fine	0	O
analysis	0	O
at	0	O
the	0	O
nucleotide	0	O
level	0	O
of	0	O
the	0	O
early	0	O
events	0	O
in	0	O
the	0	O
digestion	0	O
with	0	O
nuclease	0	B
S1	1	I
shows	0	O
that	0	O
the	0	O
enzyme	0	O
attacks	0	O
preferentially	0	O
the	0	O
sequence	0	O
(	0	O
G	1	O
-	0	O
A	1	O
)	0	O
12	0	O
on	0	O
the	0	O
message	0	O
complementary	0	O
strand	0	O
.	0	O


Previously	0	O
,	0	O
we	0	O
showed	0	O
that	0	O
the	0	O
APRE	0	O
is	0	O
a	0	O
cytokine	0	O
[	0	O
tumor	0	B
necrosis	0	I
factor	0	I
-	0	I
alpha	0	I
(	0	O
TNFalpha	0	B
)]-	0	O
inducible	0	O
enhancer	0	O
by	0	O
binding	0	O
the	0	O
heterodimeric	0	B
nuclear	0	I
factor	0	I
-	0	I
kappaB	0	I
(	0	O
NF	1	B
-	0	I
kappaB	0	I
)	0	O
complex	0	O
Rel	0	B
A	1	I
x	0	O
NF	1	B
-	0	I
kappaB1	0	I
.	0	O


MotA	0	B
also	0	O
binds	0	O
a	0	O
DNA	1	O
sequence	0	O
(	0	O
a	0	O
MotA	0	B
box	0	I
),	0	O
centered	0	O
at	0	O
position	0	O
-	0	O
30	0	O
.	0	O


The	0	O
fragments	0	O
of	0	O
each	0	O
region	0	O
were	0	O
amplified	0	O
by	0	O
polymerase	0	O
chain	0	O
reaction	0	O
and	0	O
analyzed	0	O
by	0	O
gel	0	O
electrophoresis	0	O
to	0	O
detect	0	O
single	0	O
-	0	O
strand	0	O
conformation	0	O
polymorphism	0	O
.	0	O


Substrates	0	O
include	0	O
the	0	O
p21	0	B
(	0	O
ras	0	B
)	0	O
proteins	0	O
,	0	O
nuclear	0	B
lamins	0	I
,	0	O
and	0	O
a	0	O
series	0	O
of	0	O
retinal	0	O
proteins	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
sequences	0	O
with	0	O
the	0	O
BLAST	1	O
and	0	O
GRAIL	0	O
programs	0	O
provided	0	O
additional	0	O
independent	0	O
evidence	0	O
that	0	O
15	0	O
of	0	O
these	0	O
17	0	O
clones	0	O
contain	0	O
coding	0	O
sequences	0	O
and	0	O
that	0	O
nine	0	O
other	0	O
clones	0	O
are	0	O
likely	0	O
to	0	O
contain	0	O
sequences	0	O
coding	0	O
for	0	O
portions	0	O
of	0	O
new	0	O
genes	0	O
.	0	O


The	0	O
ultrastructural	0	O
findings	0	O
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
urinary	0	O
C	1	B
-	0	I
peptide	0	I
excretion	0	O
,	0	O
confirmed	0	O
that	0	O
the	0	O
glycemic	0	O
effects	0	O
should	0	O
not	0	O
be	0	O
thought	0	O
to	0	O
be	0	O
due	0	O
to	0	O
a	0	O
direct	0	O
action	0	O
of	0	O
the	0	O
drugs	0	O
used	0	O
on	0	O
the	0	O
endocrine	0	O
pancreas	0	O
.	0	O


MAIN	1	O
OUTCOME	1	O
MEASURES	0	O
:	0	O
Percentage	0	O
change	0	O
in	0	O
the	0	O
apnea	0	O
-	0	O
hypopnea	0	O
index	0	O
(	0	O
AHI	0	O
;	0	O
apnea	0	O
events	0	O
+	0	O
hypopnea	0	O
events	0	O
per	0	O
hour	0	O
of	0	O
sleep	0	O
)	0	O
and	0	O
odds	0	O
of	0	O
developing	0	O
moderate	0	O
-	0	O
to	0	O
-	0	O
severe	0	O
SDB	0	O
(	0	O
defined	0	O
by	0	O
an	0	O
AHI	0	O
>	0	O
or	0	O
=	0	O
15	0	O
events	0	O
per	0	O
hour	0	O
of	0	O
sleep	0	O
),	0	O
with	0	O
respect	0	O
to	0	O
change	0	O
in	0	O
weight	0	O
.	0	O


Cloning	1	O
and	0	O
primary	0	O
structure	0	O
of	0	O
neurocan	0	O
,	0	O
a	0	O
developmentally	0	O
regulated	0	O
,	0	O
aggregating	0	O
chondroitin	0	O
sulfate	0	O
proteoglycan	0	O
of	0	O
brain	0	O
.	0	O


As	1	O
with	0	O
the	0	O
heterologous	0	O
DNA	1	O
binding	0	O
domain	0	O
,	0	O
MZF	0	B
-	0	I
1	0	I
represses	0	O
reporter	0	O
gene	0	O
expression	0	O
in	0	O
nonhematopoietic	0	O
cell	0	O
lines	0	O
and	0	O
activates	0	O
expression	0	O
in	0	O
hematopoietic	0	O
cell	0	O
lines	0	O
.	0	O


The	0	O
model	0	O
indicates	0	O
that	0	O
a	0	O
0	0	O
.	0	O
076	0	O
%	0	O
reduction	0	O
in	0	O
cigarette	0	O
consumption	0	O
is	0	O
associated	0	O
with	0	O
the	0	O
availability	0	O
of	0	O
nicotine	0	O
patches	0	O
after	0	O
1992	0	O
.	0	O


Since	0	O
MEK	0	B
acts	0	O
as	0	O
a	0	O
cytoplasmic	0	O
anchor	0	O
for	0	O
the	0	O
ERKs	0	B
,	0	O
the	0	O
lack	0	O
of	0	O
a	0	O
MEK	0	B
interaction	0	O
resulted	0	O
in	0	O
the	0	O
aberrant	0	O
nuclear	0	O
localization	0	O
of	0	O
ERK2	0	B
-	0	O
Delta19	0	B
-	0	I
25	0	I
mutants	0	O
in	0	O
serum	0	O
-	0	O
starved	0	O
cells	0	O
.	0	O


We	0	O
introduced	0	O
the	0	O
gel	0	O
technique	0	O
as	0	O
a	0	O
routine	0	O
assay	0	O
for	0	O
antibody	0	O
detection	0	O
and	0	O
identification	0	O
in	0	O
1993	0	O
.	0	O


The	0	O
investigation	0	O
was	0	O
thereafter	0	O
continued	0	O
in	0	O
an	0	O
open	0	O
fashion	0	O
by	0	O
administering	0	O
a	0	O
single	0	O
10	0	O
mg	0	O
dose	0	O
of	0	O
the	0	O
MAO	1	B
-	0	I
B	1	I
inhibitor	0	O
deprenyl	0	O
to	0	O
the	0	O
same	0	O
subjects	0	O
.	0	O


When	0	O
the	0	O
first	0	O
twitch	0	O
of	0	O
TOF	1	O
spontaneously	0	O
recovered	0	O
to	0	O
10	0	O
%	0	O
of	0	O
control	0	O
value	0	O
,	0	O
neostigmine	0	O
was	0	O
injected	0	O
(	0	O
40	0	O
micrograms	0	O
/	0	O
kg	0	O
in	0	O
adults	0	O
,	0	O
30	0	O
micrograms	0	O
/	0	O
kg	0	O
in	0	O
infants	0	O
and	0	O
children	0	O
).	0	O


All	1	O
of	0	O
the	0	O
elements	0	O
exhibited	0	O
a	0	O
uniform	0	O
structure	0	O
.	0	O


The	0	O
median	0	O
age	0	O
was	0	O
33	0	O
years	0	O
(	0	O
range	0	O
17	0	O
-	0	O
56	0	O
years	0	O
).	0	O


CONCLUSIONS	0	O
:	0	O
Valproate	0	O
appears	0	O
to	0	O
inhibit	0	O
the	0	O
glucuronidation	0	O
of	0	O
carbamazepine	0	O
-	0	O
10	0	O
,	0	O
11	0	O
-	0	O
trans	0	O
-	0	O
diol	0	O
,	0	O
and	0	O
probably	0	O
also	0	O
inhibits	0	O
the	0	O
conversion	0	O
of	0	O
carbamazepine	0	O
-	0	O
10	0	O
,	0	O
11	0	O
-	0	O
epoxide	0	O
to	0	O
this	0	O
trans	0	O
-	0	O
diol	0	O
derivative	0	O
,	0	O
rather	0	O
than	0	O
simply	0	O
inhibiting	0	O
the	0	O
latter	0	O
reaction	0	O
only	0	O
.	0	O


A	1	O
novel	0	O
Drosophila	1	B
A	1	I
kinase	0	I
anchor	0	I
protein	0	I
,	0	O
Drosophila	1	B
A	1	I
kinase	0	I
anchor	0	I
protein	0	I
200	0	I
(	0	O
DAKAP200	0	B
),	0	O
is	0	O
predicted	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
routing	0	O
,	0	O
mediating	0	O
,	0	O
and	0	O
integrating	0	O
signals	0	O
carried	0	O
by	0	O
cAMP	1	O
,	0	O
Ca	1	O
(	0	O
2	0	O
+),	0	O
and	0	O
diacylglycerol	0	O
(	0	O
Li	1	O
,	0	O
Z	1	O
.,	0	O
Rossi	0	O
,	0	O
E	1	O
.	0	O


Chinese	0	O
Spring	1	O
(	0	O
CS	1	O
)	0	O
carrying	0	O
the	0	O
Q	1	B
gene	0	I
to	0	O
those	0	O
of	0	O
a	0	O
chromosome	0	O
deletion	0	O
line	0	O
of	0	O
CS	1	O
,	0	O
namely	0	O
,	0	O
q5	0	O
,	0	O
which	0	O
lacks	0	O
15	0	O
%	0	O
of	0	O
5AL	0	O
including	0	O
the	0	O
Q	1	B
gene	0	I
.	0	O


Two	0	O
mammalian	0	O
enzymes	0	O
,	0	O
the	0	O
haem	0	B
-	0	I
controlled	0	I
repressor	0	I
(	0	O
HCR	0	B
)	0	O
and	0	O
the	0	O
double	0	B
-	0	I
stranded	0	I
RNA	1	I
-	0	I
activated	0	I
inhibitor	0	I
(	0	O
dsI	0	B
),	0	O
phosphorylate	0	O
Ser	1	O
-	0	O
51	0	O
of	0	O
the	0	O
alpha	0	O
subunit	0	O
,	0	O
thereby	0	O
inhibiting	0	O
the	0	O
exchange	0	O
of	0	O
bound	0	O
nucleotides	0	O
on	0	O
,	0	O
and	0	O
thus	0	O
the	0	O
recycling	0	O
of	0	O
,	0	O
eIF	0	B
-	0	I
2	0	I
.	0	O


RESULTS	0	O
:	0	O
We	0	O
identified	0	O
a	0	O
full	0	O
-	0	O
length	0	O
cDNA	1	O
with	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
of	0	O
2883	0	O
bp	0	O
corresponding	0	O
to	0	O
a	0	O
predicted	0	O
protein	0	O
of	0	O
961	0	O
amino	0	O
acids	0	O
that	0	O
shares	0	O
greater	0	O
than	0	O
95	0	O
%	0	O
homology	0	O
with	0	O
the	0	O
rat	0	B
gamma	0	I
-	0	I
aminobutyric	0	I
acid	0	I
B	1	I
(	0	I
GABAB	0	I
)	0	I
receptor	0	I
.	0	O


The	0	O
prevalence	0	O
of	0	O
malnutrition	0	O
was	0	O
30	0	O
%	0	O
in	0	O
the	0	O
47	0	O
patients	0	O
without	0	O
CVD	1	O
and	0	O
was	0	O
significantly	0	O
higher	0	O
(	0	O
70	0	O
%,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
in	0	O
the	0	O
70	0	O
patients	0	O
with	0	O
CVD	1	O
,	0	O
who	0	O
also	0	O
had	0	O
lower	0	O
tHcy	0	O
,	0	O
SAlb	0	O
,	0	O
plasma	0	B
IGF	1	I
-	0	I
1	0	I
,	0	O
serum	0	O
creatinine	0	O
(	0	O
SCr	1	O
),	0	O
and	0	O
blood	0	B
hemoglobin	0	I
.	0	O


Composites	0	O
as	0	O
restoration	0	O
materials	0	O


A	1	O
major	0	O
pool	0	O
of	0	O
Dsg	0	B
-	0	O
plakoglobin	0	B
complexes	0	O
sedimented	0	O
at	0	O
8S	0	O
and	0	O
exhibited	0	O
a	0	O
1	0	O
:	0	O
1	0	O
stoichiometry	0	O
.	0	O


This	0	O
region	0	O
of	0	O
hsp90	0	B
mediates	0	O
ATP	1	O
-	0	O
independent	0	O
chaperone	0	O
activity	0	O
,	0	O
overlaps	0	O
the	0	O
hsp90	0	B
dimerization	0	I
domain	0	I
,	0	O
and	0	O
includes	0	O
structural	0	O
elements	0	O
important	0	O
for	0	O
steroid	0	B
receptor	0	I
interaction	0	O
.	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
in	0	O
patients	0	O
with	0	O
first	0	O
-	0	O
attack	0	O
genital	0	O
herpes	0	O
,	0	O
the	0	O
type	0	O
of	0	O
HSV	1	O
is	0	O
the	0	O
most	0	O
important	0	O
determinant	0	O
of	0	O
subsequent	0	O
recurrences	0	O
and	0	O
that	0	O
intravenous	0	O
acyclovir	0	O
has	0	O
little	0	O
effect	0	O
on	0	O
subsequent	0	O
recurrences	0	O
.	0	O


CXCR4	0	B
is	0	O
a	0	O
chemokine	0	O
receptor	0	O
and	0	O
a	0	O
coreceptor	0	O
for	0	O
T	1	O
-	0	O
cell	0	O
-	0	O
line	0	O
-	0	O
tropic	0	O
(	0	O
X4	0	O
)	0	O
and	0	O
dual	0	O
-	0	O
tropic	0	O
(	0	O
R5X4	0	O
)	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
type	0	O
1	0	O
(	0	O
HIV	1	O
-	0	O
1	0	O
)	0	O
isolates	0	O
.	0	O


Setting	0	O
takes	0	O
place	0	O
through	0	O
complex	0	O
formation	0	O
of	0	O
(	0	O
NH4Mg	0	O
PO4	0	O
.	0	O
6H2O	0	O
)	0	O
n	0	O
,	0	O
excess	0	O
reactants	0	O
,	0	O
and	0	O
water	0	O
.	0	O


Therefore	0	O
,	0	O
the	0	O
impaired	0	O
floor	0	O
plate	0	O
development	0	O
in	0	O
oep	0	B
mutants	0	I
is	0	O
not	0	O
caused	0	O
by	0	O
the	0	O
absence	0	O
of	0	O
the	0	O
floor	0	B
plate	0	I
inducer	0	I
shh	0	I
.	0	O


Taurine	1	O
deficiency	0	O
significantly	0	O
depressed	0	O
the	0	O
amplitude	0	O
of	0	O
OP1	0	O
and	0	O
OP4	0	O
.	0	O


The	0	O
RanQ69L	0	B
preincubation	0	O
leads	0	O
to	0	O
accumulation	0	O
of	0	O
CRM1	0	B
at	0	O
the	0	O
cytoplasmic	0	O
periphery	0	O
of	0	O
the	0	O
nuclear	0	O
pore	0	O
complex	0	O
(	0	O
NPC	0	O
)	0	O
in	0	O
association	0	O
with	0	O
the	0	O
p62	0	B
complex	0	I
and	0	O
Can	0	B
/	0	O
Nup214	0	B
.	0	O


This	0	O
article	0	O
describes	0	O
the	0	O
collaborative	0	O
care	0	O
of	0	O
the	0	O
woman	0	O
participating	0	O
in	0	O
maternal	0	O
blood	0	O
donation	0	O
for	0	O
intrauterine	0	O
transfusion	0	O
.	0	O


The	0	O
exon	0	O
:	0	O
intron	0	O
structure	0	O
of	0	O
chicken	0	B
IL8	0	I
corresponds	0	O
almost	0	O
exactly	0	O
to	0	O
that	0	O
of	0	O
human	0	B
IL8	0	I
and	0	O
differs	0	O
from	0	O
those	0	O
of	0	O
other	0	O
known	0	O
mammalian	0	B
CXC	0	I
chemokine	0	I
genes	0	I
.	0	O


The	0	O
mean	0	O
percentage	0	O
of	0	O
linoleic	0	O
acid	0	O
in	0	O
the	0	O
triglycerides	0	O
of	0	O
the	0	O
subcutaneous	0	O
adipose	0	O
tissue	0	O
(	0	O
PLASAT	0	O
)	0	O
of	0	O
these	0	O
subjects	0	O
was	0	O
substantially	0	O
higher	0	O
than	0	O
that	0	O
in	0	O
a	0	O
similar	0	O
group	0	O
examined	0	O
in	0	O
1975	0	O
-	0	O
1976	0	O
.	0	O


Computer	0	O
assisted	0	O
mapping	0	O
in	0	O
quantitative	0	O
analysis	0	O
of	0	O
cerebral	0	O
positron	0	O
emission	0	O
tomograms	0	O
.	0	O


The	0	O
data	0	O
show	0	O
conclusively	0	O
that	0	O
phosphorylation	0	O
of	0	O
His	1	O
-	0	O
304	0	O
is	0	O
not	0	O
essential	0	O
for	0	O
any	0	O
of	0	O
the	0	O
known	0	O
functions	0	O
of	0	O
A	1	B
.	0	I
vinelandii	0	I
NifL	0	I
.	0	O


Bone	1	O
and	0	O
bones	0	O
.	0	O


Expression	1	O
of	0	O
PTPRO	0	B
was	0	O
also	0	O
observed	0	O
in	0	O
human	0	B
CD34	1	I
+	0	I
bone	0	O
marrow	0	O
cells	0	O
and	0	O
5	0	O
-	0	O
FU	0	O
-	0	O
treated	0	O
murine	0	O
primitive	0	O
stem	0	O
cells	0	O
.	0	O


Both	0	O
the	0	O
presence	0	O
of	0	O
arginine	0	O
and	0	O
anaerobiosis	0	O
are	0	O
needed	0	O
to	0	O
trigger	0	O
induction	0	O
of	0	O
the	0	O
pathway	0	O
.	0	O


Biochemical	1	O
studies	0	O
revealed	0	O
the	0	O
expected	0	O
loss	0	O
of	0	O
ChAT	0	B
activity	0	O
in	0	O
the	0	O
dorsal	0	O
and	0	O
ventral	0	O
hippocampi	0	O
of	0	O
lesioned	0	O
animals	0	O
along	0	O
with	0	O
elevated	0	O
levels	0	O
of	0	O
norepinephrine	0	O
(	0	O
NE	1	O
)	0	O
in	0	O
the	0	O
dorsal	0	O
hippocampus	0	O
of	0	O
MS	1	O
/	0	O
HSI	0	O
animals	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


The	0	O
bearing	0	O
of	0	O
season	0	O
and	0	O
sequence	0	O
of	0	O
calving	0	O
on	0	O
frequency	0	O
of	0	O
male	0	O
,	0	O
female	0	O
and	0	O
total	0	O
calvings	0	O
in	0	O
Hariana	0	O
cows	0	O
.	0	O


In	1	O
particular	0	O
,	0	O
the	0	O
S1	1	B
'	0	I
specificity	0	I
site	0	I
is	0	O
a	0	O
deep	0	O
and	0	O
highly	0	O
hydrophobic	0	O
cavity	0	O
.	0	O


Previous	0	O
experimental	0	O
evidence	0	O
had	0	O
indicated	0	O
that	0	O
Reg1	0	B
might	0	O
target	0	O
Glc7	0	B
to	0	O
nuclear	0	O
substrates	0	O
such	0	O
as	0	O
the	0	O
Snf1	0	B
kinase	0	I
complex	0	I
.	0	O


In	1	O
the	0	O
current	0	O
model	0	O
,	0	O
Wingless	0	B
/	0	O
Wnt	0	B
signal	0	O
stabilizes	0	O
Armadillo	1	B
/	0	O
beta	0	B
-	0	I
catenin	0	I
,	0	O
which	0	O
then	0	O
accumulates	0	O
in	0	O
nuclei	0	O
and	0	O
binds	0	O
TCF	0	B
/	0	O
LEF	0	B
family	0	O
proteins	0	O
,	0	O
forming	0	O
bipartite	0	O
transcription	0	O
factors	0	O
which	0	O
activate	0	O
transcription	0	O
of	0	O
Wingless	0	B
/	0	O
Wnt	0	B
responsive	0	O
genes	0	O
.	0	O


The	0	O
differential	0	O
investigation	0	O
of	0	O
lipoproteins	0	O
,	0	O
however	0	O
,	0	O
showed	0	O
that	0	O
the	0	O
high	0	B
-	0	I
density	0	I
lipoprotein	0	I
(	0	O
HDL	1	B
)	0	O
fractions	0	O
are	0	O
absolutely	0	O
or	0	O
relatively	0	O
decreased	0	O
with	0	O
respect	0	O
to	0	O
low	0	B
-	0	I
density	0	I
lipoproteins	0	I
(	0	O
LDL	1	B
)	0	O
in	0	O
cerebral	0	O
infarcts	0	O
and	0	O
in	0	O
transient	0	O
ischaemic	0	O
attacks	0	O
.	0	O


Of	0	O
165	0	O
women	0	O
with	0	O
non	0	O
-	0	O
malignant	0	O
diagnoses	0	O
26	0	O
(	0	O
16	0	O
%)	0	O
had	0	O
CA	1	B
125	0	I
levels	0	O
in	0	O
excess	0	O
of	0	O
35	0	O
U	1	O
/	0	O
ml	0	O
and	0	O
8	0	O
(	0	O
5	0	O
%)	0	O
greater	0	O
than	0	O
65	0	O
U	1	O
/	0	O
ml	0	O
.	0	O


Periodic	1	O
breathing	0	O
and	0	O
apnea	0	O
in	0	O
preterm	0	O
infants	0	O
.	0	O


A	1	O
stratified	0	O
random	0	O
sample	0	O
of	0	O
20	0	O
active	0	O
employees	0	O
from	0	O
a	0	O
cohort	0	O
of	0	O
phenoxy	0	O
herbicide	0	O
workers	0	O
was	0	O
selected	0	O
in	0	O
1995	0	O
for	0	O
determining	0	O
PCDD	0	O
and	0	O
PCDF	0	O
congeners	0	O
in	0	O
blood	0	O
lipids	0	O
to	0	O
assess	0	O
the	0	O
extent	0	O
of	0	O
past	0	O
PCDD	0	O
and	0	O
PCDF	0	O
exposure	0	O
in	0	O
this	0	O
cohort	0	O
and	0	O
whether	0	O
that	0	O
exposure	0	O
might	0	O
explain	0	O
site	0	O
-	0	O
specific	0	O
cancer	0	O
findings	0	O
in	0	O
the	0	O
total	0	O
cohort	0	O
.	0	O


Vascular	1	O
responses	0	O
to	0	O
reactive	0	O
hyperemia	0	O
(	0	O
with	0	O
flow	0	O
increase	0	O
leading	0	O
to	0	O
endothelium	0	O
-	0	O
dependent	0	O
dilation	0	O
)	0	O
and	0	O
to	0	O
sublingual	0	O
glyceryl	0	O
trinitrate	0	O
(	0	O
GTN	1	O
;	0	O
endothelium	0	O
-	0	O
independent	0	O
dilation	0	O
)	0	O
were	0	O
recorded	0	O
.	0	O


SV	1	O
increased	0	O
less	0	O
in	0	O
SHR	0	O
,	0	O
mainly	0	O
reflecting	0	O
the	0	O
reduced	0	O
diastolic	0	O
compliance	0	O
of	0	O
the	0	O
hypertrophied	0	O
SHR	0	O
left	0	O
ventricle	0	O
and	0	O
the	0	O
consequent	0	O
rightward	0	O
shift	0	O
of	0	O
its	0	O
Frank	1	O
-	0	O
Starling	0	O
curve	0	O
.	0	O


The	0	O
mean	0	O
weight	0	O
and	0	O
height	0	O
velocities	0	O
were	0	O
148	0	O
%	0	O
and	0	O
122	0	O
%	0	O
of	0	O
the	0	O
standard	0	O
,	0	O
respectively	0	O
.	0	O


Dissociative	0	O
anesthetics	0	O
2	0	O
-(	0	O
o	0	O
-	0	O
chlorophenyl	0	O
)-	0	O
2	0	O
-	0	O
methyl	0	O
-	0	O
amino	0	O
cyclohexane	0	O
HCL	1	O
(	0	O
CI	1	O
-	0	O
581	0	O
)	0	O


The	0	O
major	0	O
phenotypes	0	O
resulting	0	O
from	0	O
Fab1p	0	B
kinase	0	I
inactivation	0	O
include	0	O
temperature	0	O
-	0	O
sensitive	0	O
growth	0	O
,	0	O
vacuolar	0	O
acidification	0	O
defects	0	O
,	0	O
and	0	O
dramatic	0	O
increases	0	O
in	0	O
vacuolar	0	O
size	0	O
.	0	O


100	0	O
years	0	O
of	0	O
dentistry	0	O
at	0	O
the	0	O
Friedrich	0	O
Schiller	0	O
University	0	O
in	0	O
Jena	0	O


Following	1	O
iv	0	O
injection	0	O
of	0	O
0	0	O
.	0	O
5	0	O
g	0	O
galactose	0	O
per	0	O
kg	0	O
body	0	O
weight	0	O
,	0	O
together	0	O
with	0	O
2	0	O
mu	0	O
Ci	1	O
generally	0	O
14C	0	O
-	0	O
labelled	0	O
galactose	0	O
,	0	O
14CO2	0	O
is	0	O
collected	0	O
in	0	O
regular	0	O
intervals	0	O
during	0	O
one	0	O
hour	0	O
.	0	O


A	1	O
promising	0	O
new	0	O
cement	0	O
,	0	O
4	0	O
-	0	O
META	0	O
/	0	O
MMA	1	O
-	0	O
TBB	0	O
opaque	0	O
resin	0	O
,	0	O
has	0	O
shown	0	O
remarkable	0	O
adhesive	0	O
properties	0	O
as	0	O
a	0	O
bone	0	O
cement	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
interferon	0	B
-	0	O
induced	0	O
RNA	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	O
PKR	0	B
)	0	O
is	0	O
considered	0	O
to	0	O
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
cellular	0	O
defense	0	O
against	0	O
viral	0	O
infection	0	O
and	0	O
,	0	O
in	0	O
addition	0	O
,	0	O
has	0	O
been	0	O
suggested	0	O
to	0	O
be	0	O
a	0	O
tumor	0	O
suppressor	0	O
gene	0	O
because	0	O
of	0	O
its	0	O
growth	0	O
-	0	O
suppressive	0	O
properties	0	O
.	0	O


The	0	O
first	0	O
involved	0	O
measurements	0	O
of	0	O
the	0	O
steady	0	O
state	0	O
levels	0	O
of	0	O
mRNAs	0	O
for	0	O
subunit	0	O
5	0	O
of	0	O
cytochrome	0	B
oxidase	0	I
and	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
F1	0	B
ATPase	1	I
in	0	O
wild	0	O
type	0	O
and	0	O
in	0	O
a	0	O
hem2	0	B
mutant	0	I
.	0	O


As	1	O
for	0	O
31	0	O
stage	0	O
I	1	O
-	0	O
II	0	O
lung	0	O
cancer	0	O
patients	0	O
,	0	O
CR	1	O
has	0	O
been	0	O
observed	0	O
in	0	O
82	0	O
.	0	O
8	0	O
%	0	O
of	0	O
them	0	O
and	0	O
PR	1	O
in	0	O
13	0	O
.	0	O
8	0	O
%;	0	O
the	0	O
response	0	O
was	0	O
always	0	O
assessed	0	O
with	0	O
chest	0	O
radiography	0	O
,	0	O
CT	1	O
,	0	O
FBS	0	O
,	0	O
cytology	0	O
and	0	O
/	0	O
or	0	O
histology	0	O
.	0	O


The	0	O
210	0	O
kDa	1	O
precursor	0	O
is	0	O
converted	0	O
slowly	0	O
(	0	O
t	0	O
1	0	O
/	0	O
2	0	O
=	0	O
2	0	O
h	0	O
)	0	O
by	0	O
proteolytic	0	O
processing	0	O
into	0	O
a	0	O
125	0	O
kDa	1	O
(	0	O
alpha	0	O
')	0	O
and	0	O
83	0	O
kDa	1	O
(	0	O
beta	0	O
')	0	O
species	0	O
.	0	O


Twenty	0	O
-	0	O
eight	0	O
were	0	O
excluded	0	O
as	0	O
gallstones	0	O
were	0	O
not	0	O
proved	0	O
:	0	O
of	0	O
the	0	O
remainder	0	O
,	0	O
21	0	O
patients	0	O
received	0	O
glucagon	0	B
and	0	O
22	0	O
placebo	0	O
.	0	O


The	0	O
single	0	O
strandedness	0	O
is	0	O
manifested	0	O
as	0	O
a	0	O
terminal	0	O
extension	0	O
of	0	O
the	0	O
G	1	O
-	0	O
rich	0	O
strand	0	O
(	0	O
G	1	O
tails	0	O
)	0	O
that	0	O
can	0	O
occur	0	O
independently	0	O
of	0	O
telomerase	0	B
,	0	O
suggesting	0	O
that	0	O
cdc17	0	B
/	0	O
pol1	0	B
mutants	0	O
exhibit	0	O
defects	0	O
in	0	O
telomeric	0	O
lagging	0	O
-	0	O
strand	0	O
synthesis	0	O
.	0	O


6	0	O
.	0	O


Specific	1	O
IgG	1	B
,	0	O
specific	0	O
IgE	1	B
and	0	O
total	0	O
IgE	1	B
immunoglobulins	0	I
against	0	O
Toxocara	1	B
canis	0	I
excretory	0	I
/	0	I
secretory	0	I
antigens	0	I
(	0	O
TES	0	B
)	0	O
were	0	O
detected	0	O
by	0	O
using	0	O
ELISA	1	O
technique	0	O
.	0	O


Treatment	1	O
is	0	O
instituted	0	O
with	0	O
prednisone	0	O
and	0	O
cyclophosphamide	0	O
.	0	O


The	0	O
alternative	0	O
splice	0	O
sites	0	O
for	0	O
the	0	O
smallest	0	O
adducin	0	B
isoform	0	O
,	0	O
beta	0	B
-	0	I
3	0	I
,	0	O
are	0	O
alternative	0	O
donor	0	O
and	0	O
acceptor	0	O
sites	0	O
within	0	O
exons	0	O
7	0	O
and	0	O
12	0	O
.	0	O


GAP	1	B
-	0	I
N	1	I
bound	0	O
constitutively	0	O
to	0	O
p190	0	B
in	0	O
both	0	O
serum	0	O
-	0	O
deprived	0	O
and	0	O
growth	0	O
factor	0	O
-	0	O
stimulated	0	O
cells	0	O
.	0	O


The	0	O
ARF	1	B
promoter	0	I
was	0	O
also	0	O
found	0	O
to	0	O
be	0	O
highly	0	O
responsive	0	O
to	0	O
E2F1	0	B
expression	0	O
,	0	O
in	0	O
keeping	0	O
with	0	O
previous	0	O
results	0	O
at	0	O
the	0	O
RNA	1	O
level	0	O
.	0	O


Reliability	1	O
of	0	O
cervical	0	O
range	0	O
of	0	O
motion	0	O
using	0	O
the	0	O
OSI	0	O
CA	1	O
6000	0	O
spine	0	O
motion	0	O
analyser	0	O
on	0	O
asymptomatic	0	O
and	0	O
symptomatic	0	O
subjects	0	O
.	0	O


Recent	0	O
studies	0	O
have	0	O
revealed	0	O
unconventional	0	O
myosin	0	B
V	1	I
to	0	O
be	0	O
an	0	O
important	0	O
actin	0	B
-	0	O
based	0	O
molecular	0	O
motor	0	O
involved	0	O
in	0	O
vesicular	0	O
movement	0	O
.	0	O


Our	0	O
results	0	O
concluded	0	O
that	0	O
1	0	O
)	0	O
the	0	O
two	0	O
inhibin	0	B
/	0	O
activin	0	B
beta	0	O
B	1	O
-	0	O
subunit	0	O
mRNAs	0	O
were	0	O
transcribed	0	O
from	0	O
different	0	O
initiation	0	O
sites	0	O
;	0	O
2	0	O
)	0	O
both	0	O
promoters	0	O
may	0	O
be	0	O
controlled	0	O
by	0	O
up	0	O
-	0	O
stream	0	O
negative	0	O
regulatory	0	O
elements	0	O
;	0	O
and	0	O
3	0	O
)	0	O
neither	0	O
of	0	O
these	0	O
promoters	0	O
is	0	O
responsive	0	O
to	0	O
cAMP	1	O
and	0	O
/	0	O
or	0	O
phorbol	0	O
esters	0	O
under	0	O
the	0	O
conditions	0	O
employed	0	O
.	0	O


L	1	O
/	0	O
H	1	O
>	0	O
0	0	O
.	0	O
61	0	O
(	0	O
chi	0	O
(	0	O
2	0	O
)=	0	O
10	0	O
.	0	O
8	0	O
;	0	O
P	1	O
:<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
and	0	O
a	0	O
restrictive	0	O
filling	0	O
pattern	0	O
(	0	O
chi	0	O
(	0	O
2	0	O
)=	0	O
3	0	O
.	0	O
6	0	O
;	0	O
P	1	O
:<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
were	0	O
independent	0	O
predictors	0	O
of	0	O
events	0	O
.	0	O


Greek	0	O
classicism	0	O
in	0	O
living	0	O
structure	0	O
?	0	O
Some	0	O
deductive	0	O
pathways	0	O
in	0	O
animal	0	O
morphology	0	O
.	0	O


RNase	1	B
protection	0	O
and	0	O
primer	0	O
extension	0	O
assays	0	O
confirmed	0	O
that	0	O
the	0	O
5	0	O
'	0	O
non	0	O
-	0	O
coding	0	O
exon	0	O
is	0	O
included	0	O
in	0	O
the	0	O
DDT1	0	O
aFGF	0	B
mRNA	1	I
and	0	O
that	0	O
a	0	O
major	0	O
transcription	0	O
start	0	O
site	0	O
is	0	O
approximately	0	O
136	0	O
bp	0	O
upstream	0	O
of	0	O
the	0	O
5	0	O
'	0	O
non	0	O
-	0	O
coding	0	O
splice	0	O
junction	0	O
of	0	O
this	0	O
exon	0	O
.	0	O


To	1	O
confirm	0	O
the	0	O
binding	0	O
of	0	O
protein	0	O
to	0	O
these	0	O
sites	0	O
in	0	O
cells	0	O
,	0	O
we	0	O
carried	0	O
out	0	O
an	0	O
in	0	O
vivo	0	O
genomic	0	O
footprinting	0	O
analysis	0	O
of	0	O
this	0	O
portion	0	O
of	0	O
the	0	O
TGF	1	B
alpha	0	I
promoter	0	I
in	0	O
normal	0	O
and	0	O
transformed	0	O
rat	0	O
liver	0	O
epithelial	0	O
cell	0	O
lines	0	O
that	0	O
express	0	O
the	0	O
endogenous	0	O
gene	0	O
at	0	O
varying	0	O
levels	0	O
.	0	O


Immediately	0	O
before	0	O
surgery	0	O
patients	0	O
received	0	O
either	0	O
intravenous	0	O
hydrocortisone	0	O
100	0	O
mg	0	O
or	0	O
placebo	0	O
in	0	O
random	0	O
,	0	O
double	0	O
-	0	O
blind	0	O
order	0	O
.	0	O


The	0	O
response	0	O
of	0	O
serum	0	B
GH	1	I
to	0	O
arginine	0	O
infusion	0	O
was	0	O
normal	0	O
,	0	O
while	0	O
that	0	O
to	0	O
insulin	0	B
-	0	O
induced	0	O
hypoglycemia	0	O
was	0	O
poor	0	O
.	0	O


A	1	O
site	0	O
-	0	O
directed	0	O
R618K	0	O
mutation	0	O
in	0	O
the	0	O
Stat5	0	B
SH2	0	I
domain	0	I
abolished	0	O
the	0	O
phosphorylation	0	O
by	0	O
Jak2	0	B
,	0	O
while	0	O
deletion	0	O
of	0	O
the	0	O
C	1	O
terminus	0	O
led	0	O
to	0	O
Stat5	0	B
hyperphosphorylation	0	O
.	0	O


By	0	O
DNase	1	B
I	1	I
footprint	0	O
analysis	0	O
of	0	O
the	0	O
PNR	0	O
element	0	O
,	0	O
a	0	O
palindrome	0	O
of	0	O
two	0	O
high	0	O
-	0	O
affinity	0	O
Ets	1	B
-	0	I
binding	0	I
sites	0	I
(	0	O
CTTCCCTGGAAG	0	O
)	0	O
was	0	O
identified	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
These	0	O
routinely	0	O
collected	0	O
data	0	O
provided	0	O
quantitative	0	O
estimates	0	O
of	0	O
changes	0	O
in	0	O
CBZ	0	O
Cl	1	O
/	0	O
F	1	O
due	0	O
to	0	O
comedication	0	O
and	0	O
an	0	O
age	0	O
-	0	O
related	0	O
decrease	0	O
in	0	O
Cl	1	O
/	0	O
F	1	O
The	0	O
derived	0	O
regression	0	O
equations	0	O
reasonably	0	O
predicted	0	O
concentrations	0	O
in	0	O
a	0	O
separate	0	O
validation	0	O
set	0	O
.	0	O


In	1	O
particular	0	O
,	0	O
the	0	O
potential	0	O
for	0	O
prostate	0	O
cancer	0	O
chemoprevention	0	O
using	0	O
nonsteroidal	0	O
anti	0	O
-	0	O
inflammatory	0	O
drugs	0	O
(	0	O
cyclo	0	B
-	0	I
oxygenase	0	I
inhibitors	0	O
;	0	O
NSAIDs	0	O
)	0	O
has	0	O
received	0	O
little	0	O
attention	0	O
.	0	O


Significance	0	O
of	0	O
the	0	O
pulmonary	0	O
gas	0	O
exchange	0	O
reaction	0	O
to	0	O
physical	0	O
loading	0	O
in	0	O
evaluating	0	O
the	0	O
effectiveness	0	O
of	0	O
mitral	0	O
commissurotomy	0	O


The	0	O
indoor	0	O
radon	0	O
concentration	0	O
in	0	O
the	0	O
summer	0	O
(	0	O
1990	0	O
)	0	O
period	0	O
ranged	0	O
between	0	O
8	0	O
and	0	O
81	0	O
Bq	1	O
m	0	O
-	0	O
3	0	O
,	0	O
while	0	O
in	0	O
the	0	O
winter	0	O
(	0	O
1989	0	O
-	0	O
1990	0	O
)	0	O
it	0	O
ranged	0	O
between	0	O
20	0	O
and	0	O
143	0	O
Bq	1	O
m	0	O
-	0	O
3	0	O
for	0	O
the	0	O
first	0	O
year	0	O
of	0	O
measurements	0	O
or	0	O
between	0	O
8	0	O
and	0	O
92	0	O
Bq	1	O
m	0	O
-	0	O
3	0	O
in	0	O
the	0	O
summer	0	O
(	0	O
1991	0	O
)	0	O
period	0	O
and	0	O
between	0	O
12	0	O
and	0	O
119	0	O
Bq	1	O
m	0	O
-	0	O
3	0	O
in	0	O
the	0	O
winter	0	O
(	0	O
1990	0	O
-	0	O
1991	0	O
)	0	O
for	0	O
the	0	O
second	0	O
year	0	O
of	0	O
measurements	0	O
.	0	O


This	0	O
phosphorylation	0	O
can	0	O
be	0	O
catalyzed	0	O
by	0	O
a	0	O
break	0	O
-	0	O
ended	0	O
double	0	O
-	0	O
stranded	0	O
DNA	1	O
-	0	O
activated	0	O
protein	0	O
kinase	0	O
activity	0	O
from	0	O
the	0	O
sea	0	O
urchin	0	O
nucleus	0	O
in	0	O
vitro	0	O
.	0	O


A	1	O
unique	0	O
leucine	0	O
-	0	O
proline	0	O
repeat	0	O
element	0	O
found	0	O
N	1	O
-	0	O
terminal	0	O
to	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
of	0	O
EmBP	0	B
-	0	I
1	0	I
does	0	O
not	0	O
appear	0	O
to	0	O
play	0	O
a	0	O
role	0	O
in	0	O
DNA	1	O
-	0	O
binding	0	O
or	0	O
dimerization	0	O
.	0	O


The	0	O
modification	0	O
of	0	O
P32	0	O
uptake	0	O
into	0	O
the	0	O
Jensen	0	O
sarcoma	0	O
in	0	O
vitro	0	O
by	0	O
adding	0	O
of	0	O
peroxide	0	O
to	0	O
the	0	O
nutritive	0	O
medium	0	O


We	0	O
reviewed	0	O
the	0	O
records	0	O
of	0	O
151	0	O
patients	0	O
with	0	O
optic	0	O
neuritis	0	O
examined	0	O
over	0	O
an	0	O
eight	0	O
-	0	O
year	0	O
period	0	O
.	0	O


Kindling	1	O
of	0	O
the	0	O
primary	0	O
visual	0	O
cortex	0	O
(	0	O
VC	1	O
)	0	O
was	0	O
compared	0	O
with	0	O
that	0	O
of	0	O
the	0	O
amygdala	0	O
in	0	O
cats	0	O
.	0	O


The	0	O
GEF	0	B
and	0	O
GAP	1	B
activities	0	O
for	0	O
Ypt1p	0	B
localize	0	O
to	0	O
particulate	0	O
cellular	0	O
fractions	0	O
.	0	O


Interestingly	0	O
,	0	O
addition	0	O
of	0	O
purified	0	O
CBP	0	B
to	0	O
the	0	O
nuclear	0	O
extracts	0	O
of	0	O
T47D	0	O
cells	0	O
markedly	0	O
stimulated	0	O
progesterone	0	O
-	0	O
and	0	O
PR	1	B
-	0	O
dependent	0	O
transcription	0	O
from	0	O
a	0	O
nucleosome	0	O
-	0	O
free	0	O
,	0	O
progesterone	0	O
response	0	O
element	0	O
(	0	O
PRE	0	O
)-	0	O
linked	0	O
reporter	0	O
DNA	1	O
template	0	O
.	0	O


Synthetic	1	O
enantiomers	0	O
of	0	O
drugs	0	O


Although	0	O
most	0	O
SH2	0	B
-	0	O
pTyr	0	B
interactions	0	O
occur	0	O
between	0	O
two	0	O
different	0	O
types	0	O
of	0	O
molecules	0	O
,	0	O
some	0	O
appear	0	O
to	0	O
involve	0	O
only	0	O
a	0	O
single	0	O
molecular	0	O
type	0	O
.	0	O


Osteogenesis	1	O
imperfecta	0	O


Our	0	O
data	0	O
suggest	0	O
that	0	O
trans	0	O
-	0	O
activation	0	O
from	0	O
the	0	O
prothymosin	0	B
intron	0	I
enhancer	0	I
is	0	O
a	0	O
faithful	0	O
reflection	0	O
of	0	O
the	0	O
transforming	0	O
properties	0	O
of	0	O
the	0	O
Myc	0	B
protein	0	I
.	0	O


Ectopic	1	O
expression	0	O
of	0	O
d	0	B
-	0	I
axin	0	I
inhibited	0	O
Wingless	0	B
signaling	0	O
.	0	O


Thrombotic	1	O
thrombocytopenic	0	O
purpura	0	O
in	0	O
systemic	0	O
lupus	0	O
erythematosus	0	O
.	0	O


We	0	O
recently	0	O
characterized	0	O
a	0	O
single	0	O
yeast	0	B
hnRNP	1	I
methyltransferase	0	I
(	0	O
HMT1	0	B
).	0	O


Regarding	0	O
"	0	O
the	0	O
relation	0	O
between	0	O
sexual	0	O
orientation	0	O
and	0	O
penile	0	O
size	0	O
,"	0	O
by	0	O
A	1	O
.	0	O


Angiography	1	O
was	0	O
performed	0	O
following	0	O
the	0	O
rCBF	1	O
study	0	O
and	0	O
the	0	O
degree	0	O
of	0	O
vasospasm	0	O
was	0	O
measured	0	O
on	0	O
the	0	O
angiograms	0	O
.	0	O


These	0	O
data	0	O
indicate	0	O
that	0	O
although	0	O
218leu	0	O
retains	0	O
normal	0	O
transactivation	0	O
activity	0	O
on	0	O
a	0	O
p53	0	B
promoter	0	I
in	0	O
yeast	0	O
at	0	O
physiological	0	O
temperatures	0	O
,	0	O
it	0	O
is	0	O
not	0	O
capable	0	O
of	0	O
normal	0	O
p53	0	B
function	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
248trp	0	B
allele	0	I
in	0	O
SNU	0	O
-	0	O
C5	1	O
cells	0	O
.	0	O


Host	1	O
lipids	0	O
in	0	O
tuberculous	0	O
infection	0	O
.	0	O


Binding	0	O
of	0	O
NusA	0	B
to	0	O
RNA	1	O
in	0	O
the	0	O
presence	0	O
of	0	O
alpha	0	O
or	0	O
N	1	O
involves	0	O
an	0	O
amino	0	B
-	0	I
terminal	0	I
S1	1	I
homology	0	I
region	0	I
that	0	O
is	0	O
otherwise	0	O
inactive	0	O
in	0	O
full	0	B
-	0	I
length	0	I
NusA	0	I
.	0	O


The	0	O
lemdr1	0	B
gene	0	I
was	0	O
cloned	0	O
in	0	O
the	0	O
expression	0	O
vector	0	O
pALTNEO	0	O
and	0	O
transfected	0	O
into	0	O
wild	0	O
-	0	O
type	0	O
L	1	O
.	0	O
enriettii	0	O
and	0	O
the	0	O
resulting	0	O
transfected	0	O
cells	0	O
were	0	O
resistant	0	O
to	0	O
vinblastine	0	O
but	0	O
at	0	O
lower	0	O
levels	0	O
than	0	O
in	0	O
the	0	O
selected	0	O
mutant	0	O
cells	0	O
.	0	O


Inspection	1	O
of	0	O
enhancer	0	O
mutants	0	O
suggests	0	O
that	0	O
trans	0	O
-	0	O
activation	0	O
by	0	O
hLEF	0	B
/	0	O
GAL4	0	B
is	0	O
especially	0	O
dependent	0	O
on	0	O
TCF	0	B
-	0	I
2	0	I
,	0	O
a	0	O
distinct	0	O
T	1	O
-	0	O
cell	0	O
-	0	O
enriched	0	O
protein	0	O
that	0	O
binds	0	O
to	0	O
sequences	0	O
flanking	0	O
the	0	O
hLEF	0	B
-	0	I
binding	0	I
site	0	I
in	0	O
the	0	O
enhancer	0	O
.	0	O


Relationship	0	O
of	0	O
mast	0	O
cells	0	O
to	0	O
sarcoidosis	0	O
granuloma	0	O
of	0	O
the	0	O
skin	0	O


Structure	1	O
and	0	O
regulation	0	O
of	0	O
a	0	O
nuclear	0	O
gene	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
that	0	O
specifies	0	O
MRP13	0	B
,	0	O
a	0	O
protein	0	O
of	0	O
the	0	O
small	0	O
subunit	0	O
of	0	O
the	0	O
mitochondrial	0	O
ribosome	0	O
.	0	O


Identification	1	O
and	0	O
characterization	0	O
of	0	O
two	0	O
putative	0	O
human	0	B
arginine	0	I
methyltransferases	0	I
(	0	O
HRMT1L1	0	B
and	0	O
HRMT1L2	0	B
).	0	O


Liquid	1	O
chromatographic	0	O
separation	0	O
was	0	O
achieved	0	O
on	0	O
a	0	O
Zorbax	0	O
RX	1	O
C8	1	O
analytical	0	O
column	0	O
using	0	O
gradient	0	O
elution	0	O
.	0	O


Using	0	O
an	0	O
RNase	1	B
H	1	I
-	0	O
mediated	0	O
mapping	0	O
technique	0	O
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
64	0	O
-	0	O
kDa	1	O
subunit	0	O
of	0	O
CstF	0	B
can	0	O
be	0	O
photo	0	O
cross	0	O
-	0	O
linked	0	O
to	0	O
pre	0	O
-	0	O
mRNAs	0	O
at	0	O
U	1	O
-	0	O
rich	0	O
regions	0	O
located	0	O
downstream	0	O
of	0	O
the	0	O
cleavage	0	O
site	0	O
of	0	O
the	0	O
simian	0	O
virus	0	O
40	0	O
late	0	O
and	0	O
adenovirus	0	B
L3	0	I
pre	0	I
-	0	I
mRNAs	0	I
.	0	O


Therefore	0	O
,	0	O
it	0	O
is	0	O
important	0	O
to	0	O
control	0	O
hypertension	0	O
and	0	O
keep	0	O
appropriate	0	O
renal	0	O
blood	0	O
flow	0	O
during	0	O
living	0	O
renal	0	O
transplantation	0	O
surgery	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
synergistic	0	O
effects	0	O
of	0	O
HNF	1	B
-	0	I
1beta	0	I
and	0	O
the	0	O
GR	1	B
on	0	O
dexamethasone	0	O
-	0	O
stimulated	0	O
promoter	0	O
activity	0	O
require	0	O
that	0	O
they	0	O
are	0	O
bound	0	O
to	0	O
the	0	O
HNF	1	B
-	0	I
1	0	I
site	0	I
and	0	O
the	0	O
GRE	0	O
,	0	O
respectively	0	O
,	0	O
and	0	O
may	0	O
involve	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
between	0	O
the	0	O
transcription	0	O
factors	0	O
,	0	O
or	0	O
between	0	O
them	0	O
and	0	O
the	0	O
basal	0	O
transcription	0	O
machinery	0	O
or	0	O
a	0	O
steroid	0	B
receptor	0	I
coactivator	0	I
.	0	O


Ea	1	O
value	0	O
was	0	O
calculated	0	O
as	0	O
the	0	O
ratio	0	O
of	0	O
the	0	O
steady	0	O
-	0	O
state	0	O
end	0	O
-	0	O
systolic	0	O
aortic	0	O
pressure	0	O
(	0	O
ESAP	0	O
)	0	O
to	0	O
stroke	0	O
volume	0	O
(	0	O
thermodilution	0	O
).	0	O


Furthermore	0	O
,	0	O
the	0	O
DNA	1	B
polymerase	0	I
II	0	I
complex	0	I
was	0	O
difficult	0	O
to	0	O
obtain	0	O
from	0	O
dpb2	0	B
-	0	I
1	0	I
mutant	0	O
cells	0	O
,	0	O
suggesting	0	O
that	0	O
a	0	O
stable	0	O
DNA	1	B
polymerase	0	I
II	0	I
complex	0	I
requires	0	O
DPB2	0	B
and	0	O
is	0	O
essential	0	O
for	0	O
chromosomal	0	O
replication	0	O
.	0	O


L	1	O
-	0	O
735	0	O
,	0	O
524	0	O
free	0	O
base	0	O
or	0	O
sulfate	0	O
salt	0	O
was	0	O
administered	0	O
orally	0	O
as	0	O
suspension	0	O
,	0	O
solution	0	O
or	0	O
in	0	O
solid	0	O
dosage	0	O
forms	0	O
to	0	O
fasted	0	O
or	0	O
fed	0	O
Beagle	0	O
dogs	0	O
.	0	O


At	1	O
each	0	O
level	0	O
of	0	O
PaO2	1	O
we	0	O
obtained	0	O
simultaneous	0	O
measures	0	O
of	0	O
arterial	0	O
and	0	O
venous	0	O
blood	0	O
gases	0	O
,	0	O
venous	0	O
lactate	0	O
concentration	0	O
,	0	O
and	0	O
changes	0	O
in	0	O
the	0	O
relative	0	O
concentrations	0	O
of	0	O
inorganic	0	O
phosphate	0	O
,	0	O
phosphocreatine	0	O
,	0	O
and	0	O
ATP	1	O
measured	0	O
with	0	O
31P	0	O
magnetic	0	O
resonance	0	O
spectroscopy	0	O
.	0	O


Our	0	O
studies	0	O
also	0	O
excluded	0	O
the	0	O
possibility	0	O
that	0	O
the	0	O
phosphorylation	0	O
of	0	O
Ser	1	O
-	0	O
2	0	O
,	0	O
Ser	1	O
-	0	O
123	0	O
,	0	O
or	0	O
Ser	1	O
-	0	O
210	0	O
,	0	O
had	0	O
roles	0	O
in	0	O
the	0	O
trans	0	O
-	0	O
suppression	0	O
activity	0	O
of	0	O
the	0	O
large	0	B
HDAg	1	I
,	0	O
in	0	O
the	0	O
assembly	0	O
of	0	O
empty	0	O
virus	0	B
-	0	I
like	0	I
HDAg	1	I
particle	0	I
,	0	O
and	0	O
in	0	O
the	0	O
nuclear	0	O
transport	0	O
of	0	O
HDAgs	0	B
.	0	O


Combining	0	O
multiple	0	O
laboratory	0	O
studies	0	O
may	0	O
be	0	O
of	0	O
value	0	O
in	0	O
predetermining	0	O
the	0	O
eventual	0	O
outcome	0	O
in	0	O
near	0	O
-	0	O
drowning	0	O
.	0	O


Etiopathogenetic	0	O
and	0	O
therapeutic	0	O
problems	0	O
in	0	O
acute	0	O
orbital	0	O
inflammation	0	O


DAF16	0	B
is	0	O
known	0	O
to	0	O
be	0	O
a	0	O
component	0	O
of	0	O
a	0	O
signaling	0	O
pathway	0	O
that	0	O
has	0	O
been	0	O
partially	0	O
dissected	0	O
genetically	0	O
and	0	O
includes	0	O
homologues	0	O
of	0	O
the	0	O
insulin	0	B
/	0	O
IGF	1	B
-	0	I
1	0	I
receptor	0	I
,	0	O
PtdIns	0	B
3	0	I
-	0	I
kinase	0	I
and	0	O
PKB	0	B
.	0	O


The	0	O
median	0	O
durations	0	O
for	0	O
response	0	O
and	0	O
survival	0	O
time	0	O
in	0	O
the	0	O
late	0	O
phase	0	O
II	0	O
trial	0	O
were	0	O
2	0	O
.	0	O
3	0	O
months	0	O
and	0	O
5	0	O
.	0	O
8	0	O
months	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
Prolactin	1	B
levels	0	O
were	0	O
within	0	O
the	0	O
physiological	0	O
norms	0	O
;	0	O
the	0	O
responses	0	O
to	0	O
TRH	1	B
were	0	O
normal	0	O
,	0	O
and	0	O
elevated	0	O
only	0	O
in	0	O
a	0	O
few	0	O
cases	0	O
.	0	O


Once	0	O
HIT	1	O
II	0	O
is	0	O
suspected	0	O
,	0	O
heparin	0	O
(	0	O
and	0	O
low	0	O
-	0	O
molecular	0	O
-	0	O
weight	0	O
heparins	0	O
)	0	O
should	0	O
be	0	O
stopped	0	O
immediately	0	O
.	0	O


The	0	O
inhibitory	0	O
response	0	O
to	0	O
taps	0	O
is	0	O
essentially	0	O
a	0	O
protective	0	O
reflex	0	O
which	0	O
probably	0	O
serves	0	O
to	0	O
reduce	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
jaw	0	O
-	0	O
closing	0	O
muscles	0	O
when	0	O
one	0	O
bites	0	O
unexpectedly	0	O
on	0	O
hard	0	O
objects	0	O
.	0	O


The	0	O
cloned	0	O
alcR	0	B
gene	0	I
provided	0	O
in	0	O
trans	0	O
restored	0	O
these	0	O
siderophore	0	O
system	0	O
activities	0	O
to	0	O
the	0	O
mutants	0	O
.	0	O


A	1	O
DNase	1	B
I	1	I
-	0	I
hypersensitive	0	I
site	0	I
has	0	O
also	0	O
been	0	O
mapped	0	O
in	0	O
the	0	O
258	0	O
-	0	O
base	0	O
pair	0	O
enhancer	0	O
region	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
ethanol	0	O
on	0	O
human	0	O
sensorimotor	0	O
reactivity	0	O
was	0	O
assessed	0	O
by	0	O
examining	0	O
the	0	O
acoustic	0	O
startle	0	O
response	0	O
.	0	O


The	0	O
promoter	0	O
of	0	O
the	0	O
first	0	O
gene	0	O
,	0	O
epiF	0	B
,	0	O
responded	0	O
to	0	O
the	0	O
activator	0	B
protein	0	I
EpiQ	0	I
and	0	O
contained	0	O
a	0	O
palindromic	0	O
sequence	0	O
similar	0	O
to	0	O
the	0	O
EpiQ	0	B
binding	0	I
site	0	I
of	0	O
the	0	O
epiA	0	B
promoter	0	I
,	0	O
which	0	O
is	0	O
also	0	O
activated	0	O
by	0	O
EpiQ	0	B
.	0	O


The	0	O
signalling	0	O
molecules	0	O
Wnt1	0	B
and	0	O
Sonic	1	B
hedgehog	0	I
,	0	O
implicated	0	O
in	0	O
the	0	O
activation	0	O
of	0	O
Myf5	0	B
in	0	O
myogenic	0	O
progenitor	0	O
cells	0	O
in	0	O
the	0	O
somite	0	O
,	0	O
are	0	O
also	0	O
produced	0	O
in	0	O
the	0	O
viscinity	0	O
of	0	O
the	0	O
Myf5	0	B
expression	0	I
domain	0	I
in	0	O
the	0	O
mesencephalon	0	O
.	0	O


Transformations	0	O
in	0	O
the	0	O
morphine	0	O
series	0	O
.	0	O


Proteinuria	1	O
--	0	O
selected	0	O
physiopathological	0	O
and	0	O
clinical	0	O
problems	0	O


Neither	0	O
the	0	O
p42	0	B
/	0	I
44	0	I
nor	0	O
the	0	O
JNK	0	B
pathway	0	O
was	0	O
involved	0	O
in	0	O
the	0	O
action	0	O
of	0	O
IL	1	B
-	0	I
1beta	0	I
.	0	O


The	0	O
unilateral	0	O
vestibular	0	O
hypofunction	0	O
.	0	O


Limited	0	O
role	0	O
for	0	O
PCR	1	O
-	0	O
based	0	O
diagnosis	0	O
of	0	O
Whipple	0	O
'	0	O
s	0	O
disease	0	O
from	0	O
peripheral	0	O
blood	0	O
mononuclear	0	O
cells	0	O
.	0	O


A	1	O
dose	0	O
of	0	O
3	0	O
and	0	O
6	0	O
micrograms	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
GM	1	B
-	0	I
CSF	1	I
reduces	0	O
the	0	O
severity	0	O
of	0	O
neutropenia	0	O
and	0	O
thrombocytopenia	0	O
after	0	O
carboplatin	0	O
-	0	O
cyclophosphamide	0	O
chemotherapy	0	O
,	0	O
which	0	O
may	0	O
lead	0	O
to	0	O
more	0	O
effective	0	O
chemotherapy	0	O
for	0	O
ovarian	0	O
cancer	0	O
in	0	O
the	0	O
future	0	O
.	0	O


Disturbance	1	O
of	0	O
regeneration	0	O
in	0	O
the	0	O
above	0	O
pathological	0	O
condition	0	O
results	0	O
from	0	O
the	0	O
damage	0	O
to	0	O
tunica	0	O
propria	0	O
and	0	O
loss	0	O
of	0	O
its	0	O
function	0	O
for	0	O
the	0	O
support	0	O
of	0	O
structural	0	O
homeostasis	0	O
.	0	O


In	1	O
a	0	O
similar	0	O
fashion	0	O
to	0	O
adipose	0	O
stromal	0	O
cells	0	O
,	0	O
serum	0	O
potentiated	0	O
the	0	O
response	0	O
to	0	O
dexamethasone	0	O
but	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
phorbol	0	O
ester	0	O
-	0	O
stimulated	0	O
activity	0	O
.	0	O


Disruption	1	O
mutations	0	O
have	0	O
been	0	O
constructed	0	O
in	0	O
the	0	O
SLK1	0	B
gene	0	I
.	0	O
slk1	0	B
null	0	I
mutants	0	I
cannot	0	O
grow	0	O
at	0	O
37	0	O
degrees	0	O
C	1	O
,	0	O
but	0	O
many	0	O
cells	0	O
can	0	O
grow	0	O
at	0	O
30	0	O
,	0	O
24	0	O
,	0	O
and	0	O
17	0	O
degrees	0	O
C	1	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
histopathological	0	O
findings	0	O
,	0	O
the	0	O
origin	0	O
of	0	O
amyloid	0	O
appeared	0	O
to	0	O
be	0	O
closely	0	O
related	0	O
to	0	O
the	0	O
fibroblasts	0	O
.	0	O


C	1	B
/	0	I
EBP	1	I
alpha	0	I
also	0	O
activates	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
rat	0	B
class	0	I
-	0	I
I	1	I
ADH	1	I
gene	0	I
in	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
manner	0	O
[	0	O
Potter	0	O
et	0	O
al	0	O
.,	0	O
Arch	1	O
.	0	O


Elevated	0	O
expression	0	O
of	0	O
a	0	O
previously	0	O
uncharacterized	0	O
gene	0	O
,	0	O
SPP381	0	B
,	0	O
efficiently	0	O
suppresses	0	O
the	0	O
growth	0	O
and	0	O
splicing	0	O
defects	0	O
of	0	O
a	0	O
temperature	0	O
-	0	O
sensitive	0	O
(	0	O
Ts	1	O
)	0	O
mutant	0	B
prp38	0	I
-	0	I
1	0	I
.	0	O


Acute	1	O
type	0	O
A	1	O
hepatitis	0	O
in	0	O
three	0	O
patients	0	O
with	0	O
chronic	0	O
HBV	1	O
infection	0	O
.	0	O


Thin	0	O
melanomas	0	O
can	0	O
metastasize	0	O
and	0	O
be	0	O
lethal	0	O
.	0	O


This	0	O
motif	0	O
is	0	O
similar	0	O
to	0	O
but	0	O
distinct	0	O
from	0	O
the	0	O
LIM	0	B
domain	0	I
and	0	O
the	0	O
RING	1	B
finger	0	I
family	0	I
,	0	O
and	0	O
is	0	O
reminiscent	0	O
of	0	O
known	0	O
metal	0	O
-	0	O
binding	0	O
regions	0	O
.	0	O


This	0	O
protein	0	O
with	0	O
a	0	O
hydrophobic	0	O
amino	0	O
terminus	0	O
appears	0	O
to	0	O
be	0	O
a	0	O
secreted	0	O
protein	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
the	0	O
signals	0	O
obtained	0	O
by	0	O
ligation	0	O
of	0	O
the	0	O
TCR	1	B
,	0	O
T	1	O
cells	0	O
need	0	O
additional	0	O
,	0	O
co	0	O
-	0	O
stimulatory	0	O
signals	0	O
to	0	O
be	0	O
activated	0	O
.	0	O


We	0	O
found	0	O
that	0	O
multiple	0	O
tumor	0	O
suppressor	0	O
genes	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
p53	0	B
,	0	O
DCC	1	B
,	0	O
APC	1	B
,	0	O
MCC	0	B
,	0	O
BRCA1	0	B
,	0	O
and	0	O
WAF1	0	B
/	0	O
CIP1	0	B
)	0	O
were	0	O
inactivated	0	O
at	0	O
different	0	O
frequencies	0	O
via	0	O
various	0	O
mechanisms	0	O
[	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
loss	0	O
of	0	O
heterozygosity	0	O
(	0	O
LOH	1	O
),	0	O
loss	0	O
of	0	O
expression	0	O
(	0	O
LOE	0	O
),	0	O
mutation	0	O
,	0	O
and	0	O
inactivation	0	O
by	0	O
cellular	0	O
binding	0	O
protein	0	O
].	0	O


The	0	O
mysteries	0	O
of	0	O
geographic	0	O
variability	0	O
in	0	O
nonmelanoma	0	O
skin	0	O
cancer	0	O
incidence	0	O
.	0	O


We	0	O
further	0	O
studied	0	O
the	0	O
effects	0	O
of	0	O
SIE	0	B
-	0	I
1	0	I
hypermethylation	0	O
on	0	O
p21WAF1	0	B
induction	0	O
by	0	O
STAT	1	B
activation	0	O
.	0	O


The	0	O
dominant	0	O
negative	0	O
mutant	0	O
of	0	O
SHP	0	B
-	0	I
2	0	I
was	0	O
found	0	O
to	0	O
inhibit	0	O
the	0	O
induction	0	O
of	0	O
tyrosine	0	O
phosphorylation	0	O
and	0	O
DNA	1	O
-	0	O
binding	0	O
activity	0	O
of	0	O
m	0	B
-	0	I
Stat5a	0	I
,	0	O
m	0	B
-	0	I
Stat5b	0	I
,	0	O
and	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
deletion	0	O
variant	0	O
m	0	B
-	0	I
Stat5adelta749	0	I
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
transactivation	0	O
potential	0	O
of	0	O
m	0	B
-	0	I
Stat5a	0	I
and	0	O
m	0	B
-	0	I
Stat5b	0	I
.	0	O


Drug	1	O
use	0	O
in	0	O
trauma	0	O
victims	0	O
.	0	O


The	0	O
P13	0	O
and	0	O
N22	0	O
of	0	O
ppSEPs	0	O
had	0	O
phase	0	O
reversal	0	O
relationship	0	O
with	0	O
the	0	O
P2	1	O
and	0	O
N2	0	O
recorded	0	O
from	0	O
the	0	O
PES	1	O
,	0	O
respectively	0	O
.	0	O


Key	1	O
areas	0	O
of	0	O
the	0	O
selection	0	O
process	0	O
including	0	O
medical	0	O
and	0	O
surgical	0	O
alternatives	0	O
to	0	O
transplantation	0	O
,	0	O
the	0	O
composition	0	O
of	0	O
the	0	O
transplant	0	O
work	0	O
-	0	O
up	0	O
,	0	O
specific	0	O
inclusion	0	O
criteria	0	O
as	0	O
well	0	O
as	0	O
specific	0	O
psychosocial	0	O
factors	0	O
and	0	O
specific	0	O
disease	0	O
etiologies	0	O
and	0	O
co	0	O
-	0	O
morbidities	0	O
that	0	O
might	0	O
represent	0	O
contraindications	0	O
were	0	O
extensively	0	O
reviewed	0	O
.	0	O


Particularly	0	O
striking	0	O
was	0	O
the	0	O
conservation	0	O
of	0	O
an	0	O
AP	1	B
-	0	I
4	0	I
binding	0	I
site	0	I
within	0	O
100	0	O
nucleotides	0	O
upstream	0	O
of	0	O
the	0	O
transcription	0	O
initiation	0	O
site	0	O
in	0	O
both	0	O
Aal	0	B
-	0	O
rpL34	0	B
and	0	O
Aal	0	B
-	0	O
rpL8	0	B
genes	0	O
.	0	O


Colorimetric	0	O
method	0	O
of	0	O
determining	0	O
glycerin	0	O
in	0	O
the	0	O
blood	0	O


We	0	O
propose	0	O
that	0	O
CTS1	0	B
and	0	I
CTS2	0	I
of	0	I
Ci	1	I
are	0	O
members	0	O
of	0	O
two	0	O
distinct	0	O
classes	0	O
of	0	O
fungal	0	B
chitinases	0	I
,	0	O
an	0	O
observation	0	O
not	0	O
previously	0	O
reported	0	O
for	0	O
a	0	O
single	0	O
fungus	0	O
.	0	O


Changing	0	O
and	0	O
predicting	0	O
doses	0	O
of	0	O
Cs137	0	O
irradiation	0	O


Two	0	O
new	0	O
temperature	0	O
-	0	O
sensitive	0	O
alleles	0	O
of	0	O
SEC3	0	B
,	0	O
1	0	O
of	0	O
10	0	O
late	0	O
-	0	O
acting	0	O
SEC	0	B
genes	0	I
required	0	O
for	0	O
targeting	0	O
or	0	O
fusion	0	O
of	0	O
post	0	O
-	0	O
Golgi	0	O
secretory	0	O
vesicles	0	O
to	0	O
the	0	O
plasma	0	O
membrane	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
,	0	O
were	0	O
isolated	0	O
in	0	O
a	0	O
screen	0	O
for	0	O
temperature	0	O
-	0	O
sensitive	0	O
secretory	0	O
mutants	0	O
that	0	O
are	0	O
synthetically	0	O
lethal	0	O
with	0	O
sec4	0	B
-	0	I
8	0	I
.	0	O


These	0	O
analyses	0	O
demonstrate	0	O
that	0	O
the	0	O
dUTPase	0	B
isoforms	0	O
are	0	O
encoded	0	O
by	0	O
the	0	O
same	0	O
gene	0	O
with	0	O
isoform	0	O
-	0	O
specific	0	O
transcripts	0	O
arising	0	O
through	0	O
the	0	O
use	0	O
of	0	O
alternative	0	O
5	0	O
'	0	O
exons	0	O
.	0	O


Like	0	O
humans	0	O
,	0	O
the	0	O
PITSLRE	0	B
PK	1	I
genes	0	I
in	0	I
chickens	0	I
must	0	O
be	0	O
closely	0	O
linked	0	O
,	0	O
based	0	O
on	0	O
fluorescent	0	O
in	0	O
situ	0	O
hybridization	0	O
(	0	O
FISH	1	O
)	0	O
localization	0	O
of	0	O
these	0	O
genes	0	O
to	0	O
a	0	O
single	0	O
chicken	0	O
microchromosome	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
pancreatic	0	O
polypeptide	0	O
and	0	O
motilin	0	B
responses	0	O
to	0	O
a	0	O
meal	0	O
are	0	O
different	0	O
in	0	O
encopretic	0	O
children	0	O
than	0	O
in	0	O
children	0	O
in	0	O
the	0	O
control	0	O
group	0	O
.	0	O


Twenty	0	O
patients	0	O
aged	0	O
45	0	O
or	0	O
older	0	O
with	0	O
the	0	O
diagnosis	0	O
of	0	O
endogenous	0	O
depression	0	O
were	0	O
evaluated	0	O
in	0	O
terms	0	O
of	0	O
safety	0	O
and	0	O
efficacy	0	O
in	0	O
their	0	O
response	0	O
to	0	O
multiple	0	O
monitored	0	O
electroconvulsive	0	O
therapy	0	O
(	0	O
MMECT	0	O
)	0	O
versus	0	O
single	0	O
electroconvulsive	0	O
therapy	0	O
(	0	O
SECT	0	O
).	0	O


The	0	O
outcome	0	O
of	0	O
the	0	O
optimization	0	O
of	0	O
the	0	O
seven	0	O
-	0	O
field	0	O
plan	0	O
prompted	0	O
an	0	O
investigation	0	O
into	0	O
the	0	O
best	0	O
results	0	O
that	0	O
could	0	O
be	0	O
achieved	0	O
by	0	O
an	0	O
"	0	O
ideal	0	O
"	0	O
conformal	0	O
radiotherapy	0	O
technique	0	O
.	0	O


2	0	O
.	0	O


Immunological	1	O
testing	0	O
was	0	O
performed	0	O
on	0	O
all	0	O
brewery	0	O
workers	0	O
and	0	O
some	0	O
control	0	O
volunteers	0	O
using	0	O
skin	0	O
prick	0	O
testing	0	O
with	0	O
hops	0	O
,	0	O
barley	0	O
,	0	O
and	0	O
yeast	0	O
antigens	0	O
as	0	O
well	0	O
as	0	O
other	0	O
nonoccupational	0	O
allergens	0	O
,	0	O
and	0	O
by	0	O
determining	0	O
total	0	O
serum	0	B
IgE	1	I
levels	0	O
.	0	O


Several	0	O
genes	0	O
or	0	O
transcriptional	0	O
units	0	O
were	0	O
identified	0	O
,	0	O
including	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
ribosomal	0	B
s6	0	I
kinase	0	I
(	0	O
Rsk3	0	B
);	0	O
two	0	O
apparently	0	O
intronless	0	O
and	0	O
ORF	1	O
-	0	O
less	0	O
genes	0	O
;	0	O
and	0	O
Gpr31	0	B
,	0	O
an	0	O
intronless	0	O
,	0	O
putative	0	O
G	1	B
-	0	I
protein	0	I
coupled	0	I
receptor	0	I
.	0	O


These	0	O
findings	0	O
show	0	O
that	0	O
EBP50	0	B
is	0	O
a	0	O
physiologically	0	O
relevant	0	O
ezrin	0	B
binding	0	I
protein	0	I
.	0	O


Baseline	1	O
measurements	0	O
of	0	O
forced	0	O
expiratory	0	O
volume	0	O
in	0	O
1	0	O
s	0	O
(	0	O
FEV1	1	O
),	0	O
specific	0	O
airway	0	O
conductance	0	O
(	0	O
SGaw	0	O
)	0	O
and	0	O
the	0	O
provocative	0	O
dose	0	O
of	0	O
carbachol	0	O
causing	0	O
a	0	O
35	0	O
%	0	O
reduction	0	O
in	0	O
SGaw	0	O
(	0	O
PD35	0	O
),	0	O
and	0	O
a	0	O
20	0	O
%	0	O
reduction	0	O
in	0	O
FEV1	1	O
(	0	O
PD20	0	O
)	0	O
were	0	O
established	0	O
on	0	O
entry	0	O
while	0	O
each	0	O
subject	0	O
was	0	O
still	0	O
smoking	0	O
.	0	O


To	1	O
assess	0	O
the	0	O
function	0	O
(	0	O
s	0	O
)	0	O
of	0	O
E74	0	B
during	0	O
metamorphosis	0	O
,	0	O
we	0	O
have	0	O
isolated	0	O
and	0	O
characterized	0	O
recessive	0	O
loss	0	O
-	0	O
of	0	O
-	0	O
function	0	O
mutations	0	O
specific	0	O
to	0	O
each	0	O
transcription	0	O
unit	0	O
.	0	O


Regulation	1	O
of	0	O
avian	0	B
fibroblast	0	I
growth	0	I
factor	0	I
receptor	0	I
1	0	I
(	0	O
FGFR	0	B
-	0	I
1	0	I
)	0	O
gene	0	O
expression	0	O
during	0	O
skeletal	0	O
muscle	0	O
differentiation	0	O
.	0	O


Fission	1	B
yeast	0	I
mal2	0	I
+	0	I
is	0	O
required	0	O
for	0	O
chromosome	0	O
segregation	0	O
.	0	O


SSF	0	O
experiments	0	O
were	0	O
carried	0	O
out	0	O
in	0	O
bench	0	O
-	0	O
scale	0	O
bioreactors	0	O
(	0	O
equipped	0	O
with	0	O
CO2	1	O
and	0	O
volatile	0	O
organic	0	O
traps	0	O
)	0	O
containing	0	O
a	0	O
mixture	0	O
of	0	O
lignocellulosic	0	O
materials	0	O
and	0	O
a	0	O
radiolabeled	0	O
pesticide	0	O
.	0	O


Northern	0	O
blot	0	O
analysis	0	O
of	0	O
LeMT	0	B
(	0	I
A	1	I
)	0	I
and	0	O
LeMT	0	B
(	0	I
B	1	I
)	0	I
showed	0	O
that	0	O
transcripts	0	O
of	0	O
both	0	O
MT	1	B
-	0	I
like	0	I
genes	0	I
were	0	O
more	0	O
abundant	0	O
in	0	O
leaves	0	O
than	0	O
roots	0	O
in	0	O
tomato	0	O
plants	0	O
grown	0	O
without	0	O
addition	0	O
of	0	O
extra	0	O
metal	0	O
ions	0	O
,	0	O
a	0	O
characteristic	0	O
of	0	O
type	0	B
II	0	I
MTs	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
distribution	0	O
of	0	O
endocytic	0	O
markers	0	O
is	0	O
not	0	O
affected	0	O
.	0	O


Both	0	O
GH	1	B
deficiency	0	O
and	0	O
impaired	0	O
spinal	0	O
growth	0	O
may	0	O
result	0	O
in	0	O
short	0	O
stature	0	O
,	0	O
whereas	0	O
the	0	O
occurrence	0	O
of	0	O
early	0	O
puberty	0	O
in	0	O
association	0	O
with	0	O
GH	1	B
deficiency	0	O
reduces	0	O
the	0	O
time	0	O
available	0	O
for	0	O
GH	1	B
therapy	0	O
.	0	O


The	0	O
topography	0	O
and	0	O
trajectories	0	O
of	0	O
the	0	O
commissural	0	O
fibers	0	O
of	0	O
the	0	O
superior	0	O
temporal	0	O
region	0	O
(	0	O
STR	1	O
)	0	O
are	0	O
studied	0	O
using	0	O
the	0	O
autoradiographic	0	O
technique	0	O
.	0	O


Effects	0	O
of	0	O
verapamil	0	O
and	0	O
propranolol	0	O
on	0	O
early	0	O
afterdepolarizations	0	O
and	0	O
ventricular	0	O
arrhythmias	0	O
induced	0	O
by	0	O
epinephrine	0	O
in	0	O
congenital	0	O
long	0	O
QT	1	O
syndrome	0	O
.	0	O


(	0	O
3	0	O
).	0	O


Removal	0	O
of	0	O
all	0	O
core	0	B
histone	0	I
tail	0	O
domains	0	O
by	0	O
limited	0	O
trypsin	0	B
proteolysis	0	O
or	0	O
acetylation	0	O
of	0	O
the	0	O
core	0	B
histone	0	I
tails	0	O
significantly	0	O
relieves	0	O
this	0	O
inhibition	0	O
and	0	O
allows	0	O
TFIIIA	0	B
to	0	O
exhibit	0	O
high	0	O
-	0	O
affinity	0	O
binding	0	O
to	0	O
nucleosomal	0	O
DNA	1	O
.	0	O


To	1	O
this	0	O
end	0	O
,	0	O
we	0	O
analyzed	0	O
the	0	O
phosphorylation	0	O
status	0	O
of	0	O
a	0	O
universal	0	O
tyrosine	0	B
kinase	0	I
substrate	0	O
,	0	O
the	0	O
transforming	0	O
Shc	0	B
adapter	0	I
protein	0	I
,	0	O
in	0	O
fibroblasts	0	O
expressing	0	O
the	0	O
viral	0	O
oncogene	0	O
.	0	O


Its	0	O
hydropathy	0	O
profile	0	O
predicts	0	O
seven	0	O
transmembrane	0	O
spans	0	O
and	0	O
a	0	O
hydrophilic	0	O
amino	0	O
terminus	0	O
of	0	O
approximately	0	O
100	0	O
residues	0	O
,	0	O
and	0	O
it	0	O
suggests	0	O
the	0	O
presence	0	O
of	0	O
an	0	O
amphiphilic	0	O
alpha	0	O
-	0	O
helix	0	O
(	0	O
L	1	O
-	0	O
61	0	O
to	0	O
F	1	O
-	0	O
97	0	O
)	0	O
in	0	O
close	0	O
proximity	0	O
to	0	O
the	0	O
first	0	O
strongly	0	O
hydrophobic	0	O
segment	0	O
of	0	O
ProW	0	B
.	0	O


Transcriptional	1	O
control	0	O
signals	0	O
of	0	O
a	0	O
herpes	0	B
simplex	0	I
virus	0	I
type	0	I
1	0	I
late	0	I
(	0	I
gamma	0	I
2	0	I
)	0	I
gene	0	I
lie	0	O
within	0	O
bases	0	O
-	0	O
34	0	O
to	0	O
+	0	O
124	0	O
relative	0	O
to	0	O
the	0	O
5	0	O
'	0	O
terminus	0	O
of	0	O
the	0	O
mRNA	1	O
.	0	O


A	1	O
stochastic	0	O
version	0	O
of	0	O
Kernell	0	O
'	0	O
s	0	O
(	0	O
1968	0	O
,	0	O
1972	0	O
)	0	O
model	0	O
with	0	O
cumulative	0	O
afterhyperpolarization	0	O
(	0	O
AHP	0	O
)	0	O
was	0	O
simulated	0	O
.	0	O


The	0	O
results	0	O
show	0	O
that	0	O
ROS	1	O
production	0	O
by	0	O
viable	0	O
spermatozoa	0	O
is	0	O
highly	0	O
correlated	0	O
with	0	O
the	0	O
concentration	0	O
of	0	O
PMN	1	B
elastase	0	I
and	0	O
the	0	O
number	0	O
of	0	O
both	0	O
peroxidase	0	B
-	0	O
positive	0	O
and	0	O
round	0	O
cells	0	O
.	0	O


We	0	O
have	0	O
measured	0	O
the	0	O
MBF	0	O
on	0	O
incisors	0	O
and	0	O
its	0	O
direction	0	O
in	0	O
three	0	O
dimensions	0	O
for	0	O
different	0	O
jaw	0	O
openings	0	O
in	0	O
ten	0	O
subjects	0	O
.	0	O


The	0	O
highly	0	O
conserved	0	O
ninth	0	O
heptad	0	O
,	0	O
which	0	O
is	0	O
involved	0	O
in	0	O
heterodimerization	0	O
,	0	O
appears	0	O
to	0	O
participate	0	O
in	0	O
the	0	O
receptor	0	O
-	0	O
inhibitor	0	O
interaction	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
inhibitor	0	O
is	0	O
a	0	O
related	0	O
member	0	O
of	0	O
the	0	O
receptor	0	O
gene	0	O
family	0	O
.	0	O


Various	0	O
mutant	0	B
HN	0	I
genes	0	I
were	0	O
constructed	0	O
to	0	O
examine	0	O
the	0	O
role	0	O
of	0	O
residues	0	O
flanking	0	O
the	0	O
signal	0	O
-	0	O
anchor	0	O
domain	0	O
,	0	O
including	0	O
the	0	O
cytoplasmic	0	O
tail	0	O
,	0	O
on	0	O
assembly	0	O
and	0	O
intracellular	0	O
transport	0	O
of	0	O
the	0	O
HN	0	B
glycoprotein	0	I
.	0	O


Further	0	O
analysis	0	O
of	0	O
AP	1	B
-	0	I
1	0	I
DNA	1	O
binding	0	O
activities	0	O
in	0	O
7	0	O
-	0	O
to	0	O
14	0	O
-	0	O
day	0	O
culture	0	O
activated	0	O
HSCs	0	O
led	0	O
to	0	O
the	0	O
discovery	0	O
of	0	O
high	0	B
mobility	0	I
AP	1	I
-	0	I
1	0	I
complexes	0	I
(	0	O
HMAP	0	B
-	0	I
1	0	I
).	0	O


Sequence	1	O
analysis	0	O
and	0	O
identification	0	O
of	0	O
two	0	O
hyp	0	B
regulatory	0	I
mutants	0	I
.	0	O


This	0	O
inhibition	0	O
can	0	O
be	0	O
overcome	0	O
by	0	O
mutating	0	O
either	0	O
the	0	O
exon	0	O
'	0	O
s	0	O
5	0	O
'	0	O
or	0	O
3	0	O
'	0	O
splice	0	O
site	0	O
to	0	O
make	0	O
it	0	O
correspond	0	O
more	0	O
closely	0	O
to	0	O
the	0	O
relevant	0	O
consensus	0	O
sequence	0	O
.	0	O


To	1	O
determine	0	O
whether	0	O
interaction	0	O
of	0	O
arsenite	0	O
with	0	O
the	0	O
hormone	0	O
-	0	O
binding	0	O
domain	0	O
results	0	O
in	0	O
receptor	0	O
activation	0	O
,	0	O
COS	1	O
-	0	O
1	0	O
cells	0	O
were	0	O
transiently	0	O
cotransfected	0	O
with	0	O
the	0	O
chimeric	0	B
receptors	0	I
GAL	0	I
-	0	I
ER	1	I
,	0	O
which	0	O
contains	0	O
the	0	O
hormone	0	O
-	0	O
binding	0	O
domain	0	O
of	0	O
ERalpha	0	B
and	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
of	0	O
the	0	O
transcription	0	O
factor	0	O
GAL4	0	B
,	0	O
and	0	O
a	0	O
GAL4	0	B
-	0	O
responsive	0	O
CAT	1	B
reporter	0	I
gene	0	I
.	0	O


Breast	1	O
-	0	O
fed	0	O
newborn	0	O
infants	0	O
synthesize	0	O
n	0	O
-	0	O
6	0	O
long	0	O
-	0	O
chain	0	O
polyunsaturated	0	O
fatty	0	O
acids	0	O
already	0	O
during	0	O
the	0	O
first	0	O
week	0	O
of	0	O
life	0	O
,	0	O
but	0	O
the	0	O
contribution	0	O
of	0	O
endogenous	0	O
synthesis	0	O
to	0	O
the	0	O
total	0	O
plasma	0	O
long	0	O
-	0	O
chain	0	O
polyunsaturated	0	O
pool	0	O
is	0	O
small	0	O
.	0	O


Anisotropic	1	O
heat	0	O
transport	0	O
in	0	O
the	0	O
octylcyanobiphenyl	0	O
(	0	O
8CB	0	O
)	0	O
liquid	0	O
crystal	0	O
.	0	O


A	1	O
similar	0	O
chimera	0	O
was	0	O
assembled	0	O
from	0	O
the	0	O
two	0	O
halves	0	O
of	0	O
the	0	O
molecule	0	O
expressed	0	O
separately	0	O
in	0	O
different	0	O
bacteria	0	O
and	0	O
refolded	0	O
together	0	O
.	0	O


Type	1	O
2	0	O
genomes	0	O
containing	0	O
this	0	O
sequence	0	O
presumably	0	O
more	0	O
closely	0	O
reflect	0	O
the	0	O
structure	0	O
of	0	O
the	0	O
infectious	0	O
,	0	O
replication	0	O
-	0	O
competent	0	O
retrovirus	0	O
ancestors	0	O
of	0	O
the	0	O
HERV	1	O
-	0	O
K	1	O
family	0	O
than	0	O
do	0	O
type	0	O
1	0	O
genomes	0	O
that	0	O
lack	0	O
the	0	O
sequence	0	O
.	0	O


Toxicity	1	O
during	0	O
the	0	O
therapeutic	0	O
period	0	O
was	0	O
not	0	O
significant	0	O
in	0	O
the	0	O
study	0	O
group	0	O
compared	0	O
with	0	O
the	0	O
historical	0	O
control	0	O
,	0	O
treated	0	O
with	0	O
the	0	O
same	0	O
regimen	0	O
without	0	O
G	1	B
-	0	I
CSF	1	I
.	0	O


The	0	O
concomitant	0	O
interaction	0	O
of	0	O
mSTI1	0	B
with	0	O
hsp70	0	B
and	0	O
hsp90	0	B
at	0	O
its	0	O
N	1	O
-	0	O
and	0	O
C	1	O
-	0	O
termini	0	O
respectively	0	O
is	0	O
mediated	0	O
by	0	O
the	0	O
tetratricopeptide	0	O
repeat	0	O
(	0	O
TPR	1	O
)	0	O
motifs	0	O
in	0	O
these	0	O
regions	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
initial	0	O
plasma	0	O
retinol	0	O
level	0	O
in	0	O
conjunction	0	O
with	0	O
RBP	1	B
was	0	O
found	0	O
to	0	O
be	0	O
even	0	O
lower	0	O
in	0	O
12	0	O
patients	0	O
(	0	O
35	0	O
.	0	O
1	0	O
micrograms	0	O
dl	0	O
-	0	O
1	0	O
,	0	O
3	0	O
.	0	O
7	0	O
mg	0	O
dl	0	O
-	0	O
1	0	O
)	0	O
who	0	O
subsequently	0	O
had	0	O
cancer	0	O
recurrence	0	O
than	0	O
in	0	O
those	0	O
who	0	O
remained	0	O
free	0	O
of	0	O
apparent	0	O
cancer	0	O
(	0	O
44	0	O
.	0	O
5	0	O
micrograms	0	O
dl	0	O
-	0	O
1	0	O
,	0	O
4	0	O
.	0	O
6	0	O
mg	0	O
dl	0	O
-	0	O
1	0	O
).	0	O


CT	1	O
abnormalities	0	O
noted	0	O
in	0	O
term	0	O
babies	0	O
included	0	O
hemorrhage	0	O
(	0	O
subarachnoid	0	O
5	0	O
.	0	O
8	0	O
%,	0	O
intracerebral	0	O
11	0	O
.	0	O
6	0	O
%),	0	O
hypodensity	0	O
(	0	O
mild	0	O
23	0	O
.	0	O
2	0	O
%,	0	O
moderate	0	O
11	0	O
.	0	O
6	0	O
%	0	O
severe	0	O
5	0	O
.	0	O
8	0	O
%);	0	O
hypodensity	0	O
with	0	O
hemorrhage	0	O
5	0	O
.	0	O
8	0	O
%	0	O
and	0	O
cerebral	0	O
atrophy	0	O
5	0	O
.	0	O
8	0	O
%.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
hGCSFR	0	B
gene	0	I
was	0	O
chromosomally	0	O
localized	0	O
by	0	O
Southern	0	O
blot	0	O
analysis	0	O
of	0	O
its	0	O
segregation	0	O
pattern	0	O
in	0	O
a	0	O
panel	0	O
of	0	O
rodent	0	O
-	0	O
human	0	O
hybrid	0	O
DNAs	0	O
using	0	O
the	0	O
radiolabeled	0	O
cDNA	1	O
probe	0	O
.	0	O


Solving	0	O
an	0	O
age	0	O
old	0	O
problem	0	O
.	0	O


Glutamic	0	O
acid	0	O
in	0	O
a	0	O
dose	0	O
of	0	O
1	0	O
/	0	O
100	0	O
of	0	O
the	0	O
LD50	1	O
was	0	O
injected	0	O
in	0	O
the	0	O
form	0	O
of	0	O
sodium	0	O
salt	0	O
into	0	O
male	0	O
and	0	O
female	0	O
Wistar	0	O
rats	0	O
for	0	O
7	0	O
days	0	O
after	0	O
8	0	O
-	0	O
and	0	O
12	0	O
-	0	O
day	0	O
injections	0	O
of	0	O
dexazone	0	O
.	0	O


Thomas	0	O
'	0	O
Hospital	1	O
solution	0	O
(	0	O
with	0	O
95	0	O
%	0	O
O2	1	O
:	0	O
5	0	O
%	0	O
CO2	1	O
)	0	O
can	0	O
meet	0	O
the	0	O
metabolic	0	O
demand	0	O
of	0	O
the	0	O
ischaemic	0	O
myocardium	0	O
and	0	O
thus	0	O
increase	0	O
the	0	O
safe	0	O
duration	0	O
of	0	O
cardiac	0	O
arrest	0	O
.	0	O


The	0	O
role	0	O
of	0	O
pharmacological	0	O
profiling	0	O
in	0	O
safety	0	O
assessment	0	O
.	0	O


Use	0	O
of	0	O
Medi	0	O
-	0	O
Jector	0	O
EZ	0	O
dermojet	0	O
for	0	O
anesthesia	0	O
in	0	O
minor	0	O
surgery	0	O


The	0	O
qualitative	0	O
concentrations	0	O
of	0	O
HCG	1	B
had	0	O
a	0	O
sensitivity	0	O
of	0	O
37	0	O
.	0	O
5	0	O
%	0	O
and	0	O
a	0	O
specificity	0	O
of	0	O
100	0	O
%.	0	O


In	1	O
7	0	O
of	0	O
9	0	O
cases	0	O
,	0	O
the	0	O
enhancer	0	O
is	0	O
fused	0	O
to	0	O
the	0	O
c	0	B
-	0	I
myc	0	I
bearing	0	I
sequences	0	I
of	0	O
chromosome	0	O
8	0	O
.	0	O


In	1	O
the	0	O
eight	0	O
patients	0	O
with	0	O
persistent	0	O
generalized	0	O
lymph	0	O
-	0	O
adenopathy	0	O
(	0	O
PGL	1	O
)	0	O
and	0	O
nontender	0	O
,	0	O
nonenlarging	0	O
nodes	0	O
,	0	O
pathologic	0	O
analysis	0	O
revealed	0	O
lymphoid	0	O
hyperplasia	0	O
.	0	O


Fractionation	1	O
of	0	O
crude	0	O
nuclear	0	O
extracts	0	O
by	0	O
heparin	0	O
-	0	O
agarose	0	O
chromatography	0	O
indicates	0	O
that	0	O
PCAT	0	B
-	0	I
1	0	I
is	0	O
more	0	O
prevalent	0	O
in	0	O
extracts	0	O
prepared	0	O
from	0	O
salt	0	O
-	0	O
stressed	0	O
leaf	0	O
tissue	0	O
.	0	O


The	0	O
protein	0	O
encoded	0	O
is	0	O
114	0	O
kDa	1	O
and	0	O
contains	0	O
eight	0	O
zinc	0	O
finger	0	O
motifs	0	O
,	0	O
seven	0	O
of	0	O
which	0	O
are	0	O
present	0	O
in	0	O
two	0	O
clusters	0	O
at	0	O
opposite	0	O
ends	0	O
of	0	O
the	0	O
molecule	0	O
.	0	O


Thyroid	1	O
lymphoma	0	O
and	0	O
its	0	O
management	0	O
.	0	O


These	0	O
single	0	O
mutational	0	O
defects	0	O
in	0	O
the	0	O
eRF1	0	B
-	0	O
eRF3	0	B
interaction	0	O
became	0	O
evident	0	O
when	0	O
either	0	O
truncated	0	O
protein	0	O
eRF3C	0	B
or	0	O
C	1	O
-	0	O
terminally	0	O
altered	0	O
eRF1	0	B
proteins	0	O
were	0	O
used	0	O
for	0	O
the	0	O
authentic	0	O
protein	0	O
,	0	O
providing	0	O
further	0	O
support	0	O
for	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
C	1	O
-	0	O
terminal	0	O
interaction	0	O
.	0	O


Albumin	1	B
and	0	O
cyclic	0	O
AMP	1	O
levels	0	O
in	0	O
peritoneal	0	O
fluids	0	O
in	0	O
the	0	O
child	0	O


Only	0	O
17	0	O
%	0	O
of	0	O
all	0	O
patients	0	O
admitted	0	O
it	0	O
at	0	O
all	0	O
times	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
the	0	O
isolated	0	O
genomic	0	O
clone	0	O
revealed	0	O
that	0	O
the	0	O
DNA	1	O
binding	0	O
domain	0	O
of	0	O
this	0	O
orphan	0	O
receptor	0	O
is	0	O
most	0	O
homologous	0	O
to	0	O
the	0	O
human	0	B
TR2	0	I
receptor	0	I
.	0	O


The	0	O
promoter	0	O
and	0	O
upstream	0	O
region	0	O
of	0	O
the	0	O
Brassica	1	B
napus	0	I
2S	0	I
storage	0	I
protein	0	I
napA	0	I
gene	0	I
were	0	O
studied	0	O
to	0	O
identify	0	O
cis	0	O
-	0	O
acting	0	O
sequences	0	O
involved	0	O
in	0	O
developmental	0	O
seed	0	O
-	0	O
specific	0	O
expression	0	O
.	0	O


Collectively	0	O
,	0	O
these	0	O
results	0	O
suggest	0	O
that	0	O
components	0	O
of	0	O
the	0	O
protein	0	B
kinase	0	I
A	1	I
signaling	0	O
pathway	0	O
are	0	O
recruited	0	O
by	0	O
mIg	0	B
to	0	O
induce	0	O
junB	0	B
transcription	0	O
.	0	O


All	1	O
clinical	0	O
isolates	0	O
were	0	O
concomitantly	0	O
tested	0	O
by	0	O
disk	0	O
diffusion	0	O
and	0	O
agar	0	O
dilution	0	O
procedures	0	O
as	0	O
outlined	0	O
by	0	O
the	0	O
National	0	O
Committee	0	O
for	0	O
Clinical	1	O
Laboratory	1	O
Standards	0	O
.	0	O


Molecular	1	O
cloning	0	O
and	0	O
characterization	0	O
of	0	O
a	0	O
cDNA	1	O
,	0	O
CHEMR1	0	B
,	0	O
encoding	0	O
a	0	O
chemokine	0	O
receptor	0	O
with	0	O
a	0	O
homology	0	O
to	0	O
the	0	O
human	0	B
C	1	I
-	0	I
C	1	I
chemokine	0	I
receptor	0	I
,	0	O
CCR	1	B
-	0	I
4	0	I
.	0	O


This	0	O
paper	0	O
describes	0	O
the	0	O
genomic	0	O
organization	0	O
of	0	O
mouse	0	O
gC1qBP	0	B
and	0	O
the	0	O
characterization	0	O
of	0	O
its	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
.	0	O


Pathophysiology	1	O
of	0	O
bone	0	O
loss	0	O
in	0	O
castrated	0	O
animals	0	O
.	0	O


Therefore	0	O
the	0	O
procedure	0	O
of	0	O
Lich	0	O
-	0	O
Gregoir	0	O
is	0	O
not	0	O
to	0	O
be	0	O
recommended	0	O
in	0	O
adults	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
report	0	O
the	0	O
isolation	0	O
and	0	O
characterization	0	O
of	0	O
the	0	O
entire	0	O
rat	0	B
GSTA3	0	I
(	0	O
rGST	0	B
Yc1	0	I
)	0	O
subunit	0	O
gene	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
these	0	O
observations	0	O
demonstrated	0	O
that	0	O
stratification	0	O
of	0	O
acute	0	O
MI	1	O
patients	0	O
by	0	O
plasma	0	O
ANF	1	B
level	0	O
is	0	O
a	0	O
useful	0	O
non	0	O
-	0	O
invasive	0	O
method	0	O
for	0	O
predicting	0	O
prognosis	0	O
and	0	O
for	0	O
identifying	0	O
individuals	0	O
at	0	O
high	0	O
risk	0	O
of	0	O
cardiac	0	O
death	0	O
.	0	O


Cheung	0	O
and	0	O
S	1	O
.	0	O


In	1	O
terms	0	O
of	0	O
sequence	0	O
repetitions	0	O
,	0	O
seven	0	O
tandemly	0	O
repeated	0	O
copies	0	O
of	0	O
the	0	O
hexanucleotide	0	O
ATTGTT	0	O
and	0	O
three	0	O
flanking	0	O
regions	0	O
of	0	O
dyad	0	O
symmetry	0	O
were	0	O
detected	0	O
,	0	O
all	0	O
in	0	O
ORF	1	O
T3C	0	O
.	0	O


Pre	0	B
-	0	I
beta	0	I
-	0	I
1	0	I
lipoprotein	0	I
and	0	O
early	0	O
detection	0	O
of	0	O
risk	0	O
factors	0	O
for	0	O
coronary	0	O
heart	0	O
disease	0	O
.	0	O


However	0	O
,	0	O
no	0	O
studies	0	O
have	0	O
been	0	O
conducted	0	O
to	0	O
further	0	O
investigate	0	O
this	0	O
potentially	0	O
hazardous	0	O
effect	0	O
of	0	O
lidocaine	0	O
.	0	O


Copyright	0	O
2000	0	O
Academic	0	O
Press	0	O
.	0	O


Our	0	O
results	0	O
suggest	0	O
that	0	O
proteasome	0	O
inhibition	0	O
leads	0	O
to	0	O
upregulation	0	O
of	0	O
specific	0	O
members	0	O
of	0	O
transcription	0	O
factor	0	O
families	0	O
controlling	0	O
cellular	0	O
stress	0	O
response	0	O
and	0	O
proliferation	0	O
.	0	O


TRAF2	0	B
is	0	O
known	0	O
to	0	O
associate	0	O
with	0	O
TRADD	0	B
,	0	O
and	0	O
expression	0	O
of	0	O
a	0	O
dominant	0	O
-	0	O
negative	0	O
N	1	O
-	0	O
terminal	0	O
deletion	0	O
TRAF2	0	B
mutant	0	I
was	0	O
found	0	O
to	0	O
partially	0	O
inhibit	0	O
LMP1	0	B
-	0	O
induced	0	O
JNK	0	B
activation	0	O
in	0	O
293	0	O
cells	0	O
.	0	O


Piroximone	0	O
is	0	O
a	0	O
new	0	O
phosphodiesterase	0	B
III	0	I
inhibitor	0	O
that	0	O
combines	0	O
inotropic	0	O
and	0	O
vasodilator	0	O
properties	0	O
.	0	O


Groups	0	O
dicker	0	O
for	0	O
price	0	O
breaks	0	O
as	0	O
anesthetic	0	O
gas	0	O
goes	0	O
multi	0	O
-	0	O
source	0	O
.	0	O


The	0	O
importin	0	B
alpha	0	I
.	0	I
beta	0	I
heterodimer	0	I
mediates	0	O
nuclear	0	O
import	0	O
of	0	O
proteins	0	O
containing	0	O
classical	0	O
nuclear	0	O
localization	0	O
signals	0	O
.	0	O


The	0	O
activation	0	O
and	0	O
injury	0	O
of	0	O
endothelial	0	O
cells	0	O
induced	0	O
by	0	O
TNF	1	B
and	0	O
other	0	O
proinflammatory	0	O
cytokines	0	O
may	0	O
underlie	0	O
the	0	O
local	0	O
effects	0	O
of	0	O
these	0	O
mediators	0	O
in	0	O
vivo	0	O
.	0	O


Troubled	0	O
CareNetwork	0	O
gets	0	O
pact	0	O
from	0	O
largest	0	O
teacher	0	O
union	0	O
in	0	O
Wis	0	O
.	0	O


CREST	1	O
syndrome	0	O
;	0	O
a	0	O
changing	0	O
clinical	0	O
significance	0	O


5	0	O
'-	0	O
RACE	1	O
analysis	0	O
suggested	0	O
a	0	O
single	0	O
transcription	0	O
initiation	0	O
site	0	O
187	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
translational	0	O
start	0	O
site	0	O
.	0	O


Although	0	O
isl	0	B
-	0	I
1	0	I
binds	0	O
to	0	O
both	0	O
the	0	O
insulin	0	B
and	0	O
amylin	0	B
gene	0	I
promoter	0	I
elements	0	I
in	0	O
vitro	0	O
,	0	O
these	0	O
sequences	0	O
display	0	O
marked	0	O
differences	0	O
in	0	O
their	0	O
relative	0	O
transcriptional	0	O
properties	0	O
when	0	O
ligated	0	O
adjacent	0	O
to	0	O
a	0	O
heterologous	0	O
promoter	0	O
and	0	O
transfected	0	O
into	0	O
InR1	0	O
-	0	O
G9	0	O
islet	0	O
cells	0	O
.	0	O


3	0	O
.	0	O


Therefore	0	O
,	0	O
the	0	O
rbcL	0	B
-	0	O
rbcS	0	B
locus	0	O
seems	0	O
to	0	O
be	0	O
barely	0	O
expressed	0	O
under	0	O
a	0	O
standard	0	O
condition	0	O
for	0	O
photoautotrophic	0	O
growth	0	O
.	0	O


We	0	O
isolated	0	O
several	0	O
overlapping	0	O
A	1	O
-	0	O
phage	0	O
and	0	O
cosmid	0	O
clones	0	O
that	0	O
cover	0	O
more	0	O
than	0	O
100	0	O
kb	0	O
of	0	O
human	0	O
DNA	1	O
and	0	O
contained	0	O
the	0	O
entire	0	O
VDR	0	B
gene	0	I
.	0	O


The	0	O
rear	0	O
silver	0	O
liquid	0	O
chamber	0	O
was	0	O
threefold	0	O
thick	0	O
to	0	O
17	0	O
MeV	1	O
protons	0	O
in	0	O
water	0	O
and	0	O
it	0	O
efficiently	0	O
produced	0	O
either	0	O
13N	0	O
by	0	O
the	0	O
16O	0	O
(	0	O
p	0	O
,	0	O
alpha	0	O
)	0	O
13N	0	O
reaction	0	O
or	0	O
[	0	O
18F	0	O
]	0	O
fluoride	0	O
ion	0	O
by	0	O
the	0	O
18O	0	O
(	0	O
p	0	O
,	0	O
n	0	O
)	0	O
18F	0	O
reaction	0	O
.	0	O


Van	0	O
der	0	O
Ende	0	O
,	0	O
R	1	O
.	0	O


Another	0	O
cis	0	O
-	0	O
acting	0	O
element	0	O
,	0	O
exonic	0	O
splicing	0	O
suppressor	0	O
1	0	O
(	0	O
ESS1	0	O
),	0	O
represses	0	O
use	0	O
of	0	O
the	0	O
nt	0	O
3225	0	O
3	0	O
'	0	O
splice	0	O
site	0	O
.	0	O


It	1	O
is	0	O
exclusively	0	O
observed	0	O
in	0	O
smooth	0	O
muscle	0	O
cells	0	O
by	0	O
Northern	0	O
blotting	0	O
and	0	O
immunohistochemical	0	O
analysis	0	O
and	0	O
therefore	0	O
designated	0	O
"	0	B
smoothelin	0	I
."	0	I
A	1	O
human	0	O
smooth	0	O
muscle	0	O
cDNA	1	O
library	0	O
was	0	O
screened	0	O
with	0	O
the	0	O
monoclonal	0	B
antibody	0	I
R4A	0	I
,	0	O
and	0	O
a	0	O
full	0	O
-	0	O
size	0	O
cDNA	1	O
of	0	O
the	0	O
protein	0	O
was	0	O
selected	0	O
.	0	O


Single	1	O
-	0	O
alanine	0	O
-	0	O
substitution	0	O
mutations	0	O
had	0	O
minimal	0	O
,	0	O
if	0	O
any	0	O
,	0	O
effects	0	O
on	0	O
S	1	O
-	0	O
induced	0	O
cell	0	O
-	0	O
to	0	O
-	0	O
cell	0	O
fusion	0	O
.	0	O


We	0	O
suggest	0	O
that	0	O
apart	0	O
from	0	O
the	0	O
World	0	O
Summit	1	O
for	0	O
Children	0	O
'	0	O
s	0	O
under	0	O
-	0	O
five	0	O
mortality	0	O
target	0	O
for	0	O
the	0	O
year	0	O
2000	0	O
,	0	O
intraregional	0	O
targets	0	O
to	0	O
reduce	0	O
geographical	0	O
inequalities	0	O
in	0	O
under	0	O
-	0	O
five	0	O
mortality	0	O
should	0	O
be	0	O
specified	0	O
.	0	O


The	0	O
case	0	O
for	0	O
neutrinos	0	O
from	0	O
SN	1	O
1987A	0	O
.	0	O


Electroglottography	1	O
is	0	O
a	0	O
useful	0	O
,	0	O
non	0	O
-	0	O
invasive	0	O
technique	0	O
that	0	O
can	0	O
assist	0	O
in	0	O
the	0	O
assessment	0	O
of	0	O
vocal	0	O
fold	0	O
dysfunction	0	O
.	0	O


Histological	1	O
slides	0	O
of	0	O
one	0	O
biopsy	0	O
of	0	O
each	0	O
patient	0	O
(	0	O
formalin	0	O
-	0	O
fixed	0	O
and	0	O
paraffin	0	O
-	0	O
embedded	0	O
)	0	O
were	0	O
stained	0	O
with	0	O
a	0	O
Modified	0	O
Giemsa	0	O
(	0	O
MG	1	O
),	0	O
the	0	O
Warthin	0	O
-	0	O
Starry	0	O
(	0	O
WS	1	O
),	0	O
and	0	O
an	0	O
immunohistochemical	0	O
method	0	O
(	0	O
IMM	0	O
)	0	O
using	0	O
purified	0	O
polyclonal	0	O
H	1	O
.	0	O
pylori	0	O
antiserum	0	O
(	0	O
DAKO	0	O
B471	0	O
).	0	O


Nucleotide	1	O
sequence	0	O
of	0	O
DNA	1	O
controlling	0	O
expression	0	O
of	0	O
genes	0	O
for	0	O
maltosaccharide	0	O
utilization	0	O
in	0	O
Streptococcus	1	O
pneumoniae	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
neu	0	B
proto	0	I
-	0	I
oncogene	0	I
did	0	O
not	0	O
show	0	O
kinase	0	O
activity	0	O
or	0	O
transforming	0	O
properties	0	O
when	0	O
expressed	0	O
at	0	O
similar	0	O
levels	0	O
in	0	O
NIH	1	O
3T3	0	O
cells	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Furthermore	0	O
,	0	O
our	0	O
novel	0	O
observation	0	O
that	0	O
expression	0	O
of	0	O
a	0	O
highly	0	O
activated	0	O
FGFR3	0	B
kinase	0	I
domain	0	I
is	0	O
able	0	O
to	0	O
morphologically	0	O
transform	0	O
fibroblasts	0	O
suggests	0	O
that	0	O
dysregulation	0	O
of	0	O
FGFR3	0	B
has	0	O
the	0	O
potential	0	O
to	0	O
play	0	O
a	0	O
role	0	O
in	0	O
human	0	O
neoplasia	0	O
.	0	O


The	0	O
Italian	0	O
Lung	1	O
Cancer	1	O
Task	0	O
Force	1	O
(	0	O
FONICAP	0	O
).	0	O


Jembrana	0	O
disease	0	O
virus	0	O
(	0	O
JDV	0	O
)	0	O
is	0	O
a	0	O
newly	0	O
identified	0	O
bovine	0	O
lentivirus	0	O
that	0	O
is	0	O
closely	0	O
related	0	O
to	0	O
the	0	O
bovine	0	O
immunodeficiency	0	O
virus	0	O
(	0	O
BIV	0	O
).	0	O


It	1	O
applies	0	O
Udry	0	O
'	0	O
s	0	O
biosocial	0	O
perspective	0	O
,	0	O
which	0	O
attempts	0	O
to	0	O
reconcile	0	O
the	0	O
biological	0	O
and	0	O
sociological	0	O
models	0	O
of	0	O
premarital	0	O
sexual	0	O
and	0	O
reproductive	0	O
behaviour	0	O
.	0	O


Effects	0	O
of	0	O
repeated	0	O
exposures	0	O
of	0	O
hydrogen	0	O
sulphide	0	O
on	0	O
rat	0	O
hippocampal	0	O
EEG	1	O
.	0	O


Here	0	O
we	0	O
present	0	O
genetic	0	O
evidence	0	O
suggesting	0	O
that	0	O
PP2A	0	B
functions	0	O
downstream	0	O
of	0	O
Ras1	1	B
in	0	O
the	0	O
Sevenless	0	B
receptor	0	I
tyrosine	0	I
kinase	0	I
(	0	O
RTK	0	B
)	0	O
signal	0	O
transduction	0	O
pathway	0	O
that	0	O
specifies	0	O
R7	0	O
photoreceptor	0	O
cell	0	O
fate	0	O
in	0	O
the	0	O
developing	0	O
Drosophila	1	O
eye	0	O
.	0	O


Growth	1	O
factor	0	O
allows	0	O
effective	0	O
dose	0	O
-	0	O
intensive	0	O
regimen	0	O
in	0	O
advanced	0	O
breast	0	O
cancer	0	O
patients	0	O
.	0	O


Of	0	O
the	0	O
43	0	O
infants	0	O
with	0	O
a	0	O
(	0	O
probable	0	O
)	0	O
loss	0	O
18	0	O
were	0	O
examined	0	O
again	0	O
at	0	O
3	0	O
months	0	O
corrected	0	O
age	0	O
.	0	O


Vitrectomy	1	O
with	0	O
an	0	O
alternative	0	O
instrument	0	O
system	0	O
.	0	O


Recombinant	1	B
human	0	I
erythropoietin	0	I
(	0	O
epoetin	0	B
)	0	O
is	0	O
approved	0	O
to	0	O
be	0	O
administered	0	O
by	0	O
the	0	O
intravenous	0	O
(	0	O
i	0	O
.	0	O
v	0	O
.)	0	O
or	0	O
subcutaneous	0	O
(	0	O
SC	1	O
)	0	O
route	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Patients	0	O
wit	0	O
clinically	0	O
palpable	0	O
neck	0	O
disease	0	O
(	0	O
N1	0	O
-	0	O
3	0	O
),	0	O
histological	0	O
evidence	0	O
of	0	O
metastatic	0	O
nodal	0	O
disease	0	O
,	0	O
extracapsular	0	O
spread	0	O
,	0	O
and	0	O
three	0	O
or	0	O
more	0	O
positive	0	O
lymph	0	O
nodes	0	O
are	0	O
at	0	O
greater	0	O
risk	0	O
of	0	O
developing	0	O
failure	0	O
at	0	O
distant	0	O
sites	0	O
.	0	O


Effect	1	O
of	0	O
aging	0	O
on	0	O
respiratory	0	O
skeletal	0	O
muscles	0	O
.	0	O


The	0	O
T	1	O
-	0	O
box	0	O
motif	0	O
is	0	O
present	0	O
in	0	O
a	0	O
family	0	O
of	0	O
genes	0	O
whose	0	O
structural	0	O
features	0	O
and	0	O
expression	0	O
patterns	0	O
support	0	O
their	0	O
involvement	0	O
in	0	O
developmental	0	O
gene	0	O
regulation	0	O
.	0	O


Diverse	0	O
endogenous	0	O
light	0	O
chains	0	O
contribute	0	O
to	0	O
basement	0	O
membrane	0	O
reactivity	0	O
in	0	O
nonautoimmune	0	O
mice	0	O
transgenic	0	O
for	0	O
an	0	O
anti	0	B
-	0	I
laminin	0	I
Ig	1	I
heavy	0	I
chain	0	I
.	0	O


Effect	1	O
of	0	O
indomethacin	0	O
on	0	O
coronary	0	O
circulation	0	O
:	0	O
effect	0	O
on	0	O
ECG	1	O
tracing	0	O


Endothelial	1	O
cells	0	O
stored	0	O
with	0	O
University	0	O
of	0	O
Wisconsin	0	O
solution	0	O
excluded	0	O
trypan	0	O
blue	0	O
better	0	O
(	0	O
1	0	O
.	0	O
0	0	O
%	0	O
+/-	0	O
0	0	O
.	0	O
5	0	O
%	0	O
cells	0	O
stained	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
.	0	O


Nitrogen	1	O
balance	0	O
was	0	O
compared	0	O
,	0	O
and	0	O
metabolic	0	O
complications	0	O
were	0	O
monitored	0	O
by	0	O
evaluating	0	O
BUN	1	O
,	0	O
serum	0	O
creatinine	0	O
,	0	O
creatinine	0	O
clearance	0	O
,	0	O
serum	0	O
CO2	1	O
,	0	O
SGOT	1	B
,	0	O
SGPT	1	B
,	0	O
serum	0	B
LDH	1	I
,	0	O
and	0	O
serum	0	B
alkaline	0	I
phosphatase	0	I
.	0	O


Since	0	O
high	0	O
levels	0	O
of	0	O
immunoglobulin	0	B
G	1	I
were	0	O
demonstrated	0	O
against	0	O
the	0	O
surface	0	O
of	0	O
the	0	O
NVS	1	O
after	0	O
immunization	0	O
,	0	O
passive	0	O
transfer	0	O
experiments	0	O
were	0	O
initiated	0	O
.	0	O


Here	0	O
we	0	O
present	0	O
evidence	0	O
that	0	O
major	0	B
IE	1	I
proteins	0	I
IE86	0	I
,	0	O
IE72	0	B
,	0	O
and	0	O
IE55	0	B
are	0	O
capable	0	O
of	0	O
trans	0	O
-	0	O
activating	0	O
the	0	O
HIV	1	B
LTR	1	I
in	0	O
a	0	O
T	1	O
-	0	O
cell	0	O
line	0	O
,	0	O
HUT	0	O
-	0	O
78	0	O
.	0	O


The	0	O
mean	0	O
(+/-	0	O
SD	1	O
)	0	O
PaO2	1	O
increased	0	O
from	0	O
80	0	O
.	0	O
8	0	O
+/-	0	O
26	0	O
.	0	O
9	0	O
mmHg	0	O
before	0	O
to	0	O
89	0	O
.	0	O
8	0	O
+/-	0	O
27	0	O
.	0	O
3	0	O
mmHg	0	O
after	0	O
the	0	O
infusion	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
and	0	O
the	0	O
PaCO2	1	O
decreased	0	O
from	0	O
42	0	O
.	0	O
4	0	O
+/-	0	O
8	0	O
.	0	O
3	0	O
to	0	O
39	0	O
.	0	O
6	0	O
+/-	0	O
7	0	O
.	0	O
9	0	O
mmHg	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


A	1	O
pre	0	O
-	0	O
boutonniere	0	O
deformity	0	O
was	0	O
simulated	0	O
by	0	O
dividing	0	O
the	0	O
central	0	O
slip	0	O
.	0	O


The	0	O
author	0	O
gives	0	O
an	0	O
account	0	O
of	0	O
antipsychotic	0	O
,	0	O
analgetic	0	O
,	0	O
myorelaxing	0	O
and	0	O
vasodilatating	0	O
effects	0	O
of	0	O
some	0	O
calcium	0	O
antagonists	0	O
,	0	O
and	0	O
their	0	O
clinical	0	O
application	0	O
is	0	O
discussed	0	O
.	0	O


TREB7	0	B
and	0	O
TREB36	0	B
protected	0	O
all	0	O
three	0	O
repeats	0	O
of	0	O
the	0	O
21	0	O
bp	0	O
,	0	O
but	0	O
TREB5	0	B
protected	0	O
only	0	O
the	0	O
second	0	O
repeat	0	O
.	0	O


Identification	1	O
of	0	O
a	0	O
promoter	0	O
-	0	O
specific	0	O
transactivation	0	O
domain	0	O
in	0	O
the	0	O
herpes	0	B
simplex	0	I
virus	0	I
regulatory	0	I
protein	0	I
ICP4	0	I
.	0	O


"	0	O
In	1	O
vitro	0	O
"	0	O
study	0	O
of	0	O
dentin	0	O
adhesion	0	O
to	0	O
adhesives	0	O
made	0	O
from	0	O
urethane	0	O
molecules	0	O
with	0	O
free	0	O
groups	0	O
of	0	O
isocyanate	0	O


The	0	O
maximum	0	O
deflections	0	O
of	0	O
phase	0	O
IV	1	O
for	0	O
Ar	1	O
and	0	O
N2	0	O
from	0	O
extrapolated	0	O
phase	0	O
III	0	O
slopes	0	O
were	0	O
smaller	0	O
in	0	O
the	0	O
prone	0	O
position	0	O
,	0	O
suggesting	0	O
more	0	O
uniform	0	O
tracer	0	O
gas	0	O
concentrations	0	O
across	0	O
the	0	O
lungs	0	O
.	0	O


The	0	O
diagnosis	0	O
of	0	O
amyloidosis	0	O
was	0	O
determined	0	O
from	0	O
a	0	O
labial	0	O
salivary	0	O
gland	0	O
biopsy	0	O
.	0	O


A	1	O
2	0	O
years	0	O
and	0	O
9	0	O
months	0	O
old	0	O
female	0	O
patient	0	O
,	0	O
with	0	O
the	0	O
diagnosis	0	O
of	0	O
Weaver	0	O
syndrome	0	O
is	0	O
reported	0	O
.	0	O


Mutations	0	O
affecting	0	O
only	0	O
CD4	1	B
regulation	0	O
mapped	0	O
to	0	O
residues	0	O
previously	0	O
shown	0	O
to	0	O
mediate	0	O
the	0	O
binding	0	O
of	0	O
Nef	0	B
to	0	O
this	0	O
receptor	0	O
,	0	O
such	0	O
as	0	O
W57	0	O
and	0	O
L58	0	O
,	0	O
as	0	O
well	0	O
as	0	O
to	0	O
an	0	O
AP	1	B
-	0	I
recruiting	0	I
dileucine	0	I
motif	0	I
and	0	O
to	0	O
an	0	O
acidic	0	O
dipeptide	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
the	0	O
protein	0	O
.	0	O


Human	1	O
SRF	1	B
-	0	I
related	0	I
proteins	0	I
:	0	O
DNA	1	O
-	0	O
binding	0	O
properties	0	O
and	0	O
potential	0	O
regulatory	0	O
targets	0	O
.	0	O


It	1	O
was	0	O
found	0	O
that	0	O
the	0	O
ROSP	0	O
undergoes	0	O
a	0	O
number	0	O
of	0	O
fluctuations	0	O
in	0	O
the	0	O
negative	0	O
and	0	O
positive	0	O
directions	0	O
with	0	O
a	0	O
gradually	0	O
decreasing	0	O
amplitude	0	O
in	0	O
the	0	O
course	0	O
of	0	O
5	0	O
-	0	O
25	0	O
days	0	O
following	0	O
the	0	O
operation	0	O
,	0	O
after	0	O
which	0	O
relatively	0	O
stable	0	O
negative	0	O
values	0	O
of	0	O
the	0	O
ROSP	0	O
are	0	O
established	0	O
on	0	O
the	0	O
average	0	O
in	0	O
electrodes	0	O
implanted	0	O
to	0	O
the	0	O
level	0	O
of	0	O
the	0	O
dura	0	O
mater	0	O
,	0	O
and	0	O
positive	0	O
values	0	O
in	0	O
electrodes	0	O
implanted	0	O
to	0	O
the	0	O
level	0	O
of	0	O
the	0	O
pia	0	O
mater	0	O
.	0	O


Manganese	1	O
ions	0	O
were	0	O
found	0	O
to	0	O
be	0	O
essential	0	O
for	0	O
autophosphorylation	0	O
of	0	O
BGLF4	0	B
,	0	O
and	0	O
magnesium	0	O
can	0	O
stimulate	0	O
the	0	O
activity	0	O
.	0	O


BACKGROUND	0	O
:	0	O
The	0	O
effectiveness	0	O
of	0	O
monoamine	0	B
oxidase	0	I
inhibitors	0	O
(	0	O
MAOIs	0	O
)	0	O
in	0	O
tricyclic	0	O
resistant	0	O
depression	0	O
has	0	O
received	0	O
surprisingly	0	O
little	0	O
systematic	0	O
study	0	O
.	0	O


Valuing	0	O
families	0	O
:	0	O
social	0	O
work	0	O
practice	0	O
with	0	O
families	0	O
from	0	O
a	0	O
strengths	0	O
perspective	0	O
.	0	O


A	1	O
surgical	0	O
technique	0	O
for	0	O
correcting	0	O
this	0	O
problem	0	O
is	0	O
described	0	O
.	0	O


A	1	O
simplified	0	O
thin	0	O
-	0	O
layer	0	O
chromatographic	0	O
determination	0	O
of	0	O
hippuric	0	O
acid	0	O
and	0	O
methylhippuric	0	O
acids	0	O
.	0	O


Genomic	1	O
DNA	1	O
clones	0	O
containing	0	O
the	0	O
T	1	B
-	0	I
cell	0	I
-	0	I
specific	0	I
human	0	I
MAL	1	I
gene	0	I
were	0	O
isolated	0	O
.	0	O


The	0	O
first	0	O
algorithm	0	O
,	0	O
FOREPROJ	0	O
,	0	O
is	0	O
a	0	O
fast	0	O
-	0	O
forward	0	O
projection	0	O
algorithm	0	O
that	0	O
allows	0	O
calculation	0	O
of	0	O
the	0	O
3	0	O
-	0	O
D	1	O
attenuation	0	O
correction	0	O
factors	0	O
(	0	O
ACF	0	O
'	0	O
s	0	O
)	0	O
directly	0	O
from	0	O
a	0	O
two	0	O
-	0	O
dimensional	0	O
(	0	O
2	0	O
-	0	O
D	1	O
)	0	O
transmission	0	O
scan	0	O
,	0	O
without	0	O
first	0	O
reconstructing	0	O
the	0	O
attenuation	0	O
map	0	O
and	0	O
then	0	O
performing	0	O
a	0	O
3	0	O
-	0	O
D	1	O
forward	0	O
projection	0	O
.	0	O


Simultaneous	0	O
right	0	O
and	0	O
left	0	O
adrenal	0	O
and	0	O
peripheral	0	O
blood	0	O
samples	0	O
were	0	O
collected	0	O
for	0	O
determination	0	O
of	0	O
oestrone	0	O
(	0	O
E1	1	O
)	0	O
and	0	O
oestradiol	0	O
(	0	O
E2	1	O
).	0	O


Comparison	0	O
of	0	O
the	0	O
sequences	0	O
of	0	O
the	0	O
xFxFG	0	O
repeat	0	O
regions	0	O
of	0	O
p62	0	B
and	0	O
Nsplp	0	B
indicated	0	O
that	0	O
NTF2	0	B
was	0	O
probably	0	O
interacting	0	O
with	0	O
the	0	O
phenylalanine	0	O
-	0	O
containing	0	O
core	0	O
of	0	O
these	0	O
repeats	0	O
and	0	O
not	0	O
the	0	O
intervening	0	O
hydrophilic	0	O
linkers	0	O
.	0	O


Both	0	O
factors	0	O
demonstrated	0	O
significant	0	O
correlations	0	O
with	0	O
rCBF	1	O
in	0	O
the	0	O
medial	0	O
prefrontal	0	O
cortex	0	O
and	0	O
frontal	0	O
polar	0	O
cortex	0	O
while	0	O
for	0	O
each	0	O
factor	0	O
there	0	O
were	0	O
also	0	O
unique	0	O
patterns	0	O
of	0	O
correlations	0	O
with	0	O
posterior	0	O
brain	0	O
regions	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
its	0	O
effect	0	O
in	0	O
augmenting	0	O
the	0	O
neutrophil	0	O
response	0	O
to	0	O
eccentric	0	O
exercise	0	O
,	0	O
vitamin	0	O
E	1	O
causes	0	O
a	0	O
greater	0	O
increase	0	O
in	0	O
circulating	0	O
creatine	0	B
kinase	0	I
activity	0	O
,	0	O
perhaps	0	O
indicating	0	O
increased	0	O
skeletal	0	O
muscle	0	O
repair	0	O
.	0	O


The	0	O
maximum	0	O
stress	0	O
due	0	O
to	0	O
the	0	O
hygroscopic	0	O
examination	0	O
of	0	O
the	0	O
composite	0	O
was	0	O
0	0	O
.	0	O
74	0	O
kg	0	O
/	0	O
mm2	0	O
at	0	O
equilibrium	0	O
of	0	O
the	0	O
water	0	O
absorbed	0	O
of	0	O
the	0	O
composite	0	O
.	0	O


The	0	O
objective	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
examine	0	O
the	0	O
influence	0	O
of	0	O
HHCA	0	O
and	0	O
other	0	O
serological	0	O
factors	0	O
upon	0	O
the	0	O
development	0	O
of	0	O
VGS	0	O
.	0	O


The	0	O
administration	0	O
of	0	O
the	0	O
GnRH	0	B
agonist	0	O
reduced	0	O
the	0	O
bone	0	O
mineral	0	O
density	0	O
in	0	O
the	0	O
whole	0	O
femur	0	O
to	0	O
91	0	O
.	0	O
0	0	O
%	0	O
of	0	O
that	0	O
in	0	O
the	0	O
control	0	O
group	0	O
.	0	O


RNAs	0	O
are	0	O
not	0	O
only	0	O
essential	0	O
components	0	O
of	0	O
both	0	O
ribosomal	0	O
subunits	0	O
but	0	O
also	0	O
transiently	0	O
interacting	0	O
factors	0	O
during	0	O
particle	0	O
formation	0	O
.	0	O


These	0	O
observations	0	O
have	0	O
led	0	O
us	0	O
to	0	O
conclude	0	O
that	0	O
an	0	O
elevated	0	O
VIII	0	O
-	0	O
ratio	0	O
is	0	O
a	0	O
very	0	O
sensitive	0	O
indicator	0	O
of	0	O
intravascular	0	O
coagulation	0	O
.	0	O


The	0	O
sequence	0	O
of	0	O
the	0	O
repressor	0	O
locus	0	O
,	0	O
c	0	O
,	0	O
of	0	O
the	0	O
Streptomyces	1	O
temperate	0	O
phage	0	O
,	0	O
phi	0	O
C31	0	O
,	0	O
was	0	O
shown	0	O
previously	0	O
to	0	O
contain	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
encoding	0	O
a	0	O
74	0	O
kDa	1	O
protein	0	O
.	0	O


"	0	O
Let	1	O
the	0	O
hundred	0	O
flowers	0	O
bloom	0	O
".	0	O


Botulinum	0	B
toxin	0	I
:	0	O
preferred	0	O
treatment	0	O
for	0	O
hemifacial	0	O
spasm	0	O
.	0	O


Our	0	O
results	0	O
suggest	0	O
that	0	O
while	0	O
many	0	O
muscle	0	O
gene	0	O
E	1	O
-	0	O
boxes	0	O
are	0	O
capable	0	O
of	0	O
binding	0	O
the	0	O
previously	0	O
characterized	0	O
spectrum	0	O
of	0	O
MDF	1	B
/	0	I
bH	0	I
-	0	I
L	1	I
-	0	I
H	1	I
heterodimers	0	I
in	0	O
vitro	0	O
,	0	O
MCK	0	B
-	0	I
L	1	I
type	0	O
E	1	O
-	0	O
boxes	0	O
probably	0	O
bind	0	O
qualitatively	0	O
different	0	O
factors	0	O
in	0	O
vivo	0	O
.	0	O


In	1	O
this	0	O
report	0	O
,	0	O
we	0	O
present	0	O
two	0	O
lines	0	O
of	0	O
evidence	0	O
that	0	O
all	0	O
ribosomes	0	O
which	0	O
synthesize	0	O
GCN4	0	B
have	0	O
previously	0	O
translated	0	O
uORF1	0	O
,	0	O
resumed	0	O
scanning	0	O
,	0	O
and	0	O
reinitiated	0	O
at	0	O
the	0	O
GCN4	0	B
start	0	O
site	0	O
.	0	O


Normal	1	O
rates	0	O
of	0	O
weight	0	O
gain	0	O
were	0	O
seen	0	O
once	0	O
absorbed	0	O
energy	0	O
intakes	0	O
reached	0	O
100	0	O
-	0	O
110	0	O
%	0	O
of	0	O
requirements	0	O
.	0	O


Young	0	O
fish	0	O
(	0	O
Oreochromis	0	O
mossambicus	0	O
)	0	O
were	0	O
exposed	0	O
to	0	O
microgravity	0	O
(	0	O
micro	0	O
g	0	O
)	0	O
for	0	O
9	0	O
to	0	O
10	0	O
days	0	O
during	0	O
space	0	O
missions	0	O
STS	1	O
-	0	O
55	0	O
and	0	O
STS	1	O
-	0	O
84	0	O
,	0	O
or	0	O
to	0	O
hypergravity	0	O
(	0	O
hg	0	O
)	0	O
for	0	O
9	0	O
days	0	O
.	0	O


Correlation	1	O
of	0	O
skin	0	O
disorders	0	O
with	0	O
CD4	1	B
lymphocyte	0	O
counts	0	O
in	0	O
patients	0	O
with	0	O
HIV	1	O
/	0	O
AIDS	1	O
.	0	O


Treatment	1	O
of	0	O
recurrent	0	O
FSGS	1	O
has	0	O
included	0	O
high	0	O
-	0	O
dose	0	O
steroids	0	O
,	0	O
high	0	O
-	0	O
dose	0	O
cyclosporine	0	O
(	0	O
CSA	0	O
),	0	O
plasmapheresis	0	O
,	0	O
and	0	O
ACE	1	B
inhibitors	0	O
with	0	O
mixed	0	O
results	0	O
.	0	O


The	0	O
Saccharomyces	1	B
cerevisiae	0	I
RAD30	0	I
gene	0	I
,	0	O
a	0	O
homologue	0	B
of	0	I
Escherichia	1	I
coli	0	I
dinB	0	I
and	0	O
umuC	0	B
,	0	O
is	0	O
DNA	1	O
damage	0	O
inducible	0	O
and	0	O
functions	0	O
in	0	O
a	0	O
novel	0	O
error	0	O
-	0	O
free	0	O
postreplication	0	O
repair	0	O
mechanism	0	O
.	0	O


Enhanced	0	O
hepatic	0	O
portal	0	O
blood	0	O
flow	0	O
induced	0	O
by	0	O
prostaglandin	0	O
E1	1	O
following	0	O
liver	0	O
transplantation	0	O
in	0	O
pigs	0	O
.	0	O


The	0	O
mean	0	O
body	0	O
mass	0	O
index	0	O
(	0	O
BMI	1	O
)	0	O
was	0	O
31	0	O
.	0	O
8	0	O
+/-	0	O
6	0	O
.	0	O
3	0	O
kg	0	O
/	0	O
m2	0	O
and	0	O
28	0	O
.	0	O
5	0	O
+/-	0	O
6	0	O
.	0	O
3	0	O
kg	0	O
/	0	O
m2	0	O
in	0	O
women	0	O
and	0	O
men	0	O
,	0	O
respectively	0	O
.	0	O


Enterococcus	1	O
faecium	0	O
strains	0	O
with	0	O
vanA	1	O
-	0	O
mediated	0	O
glycopeptide	0	O
resistance	0	O
were	0	O
isolated	0	O
by	0	O
enrichment	0	O
culture	0	O
from	0	O
the	0	O
intestines	0	O
and	0	O
feces	0	O
of	0	O
several	0	O
animal	0	O
species	0	O
,	0	O
mainly	0	O
horses	0	O
and	0	O
dogs	0	O
(	0	O
8	0	O
%	0	O
positive	0	O
),	0	O
chickens	0	O
(	0	O
7	0	O
%	0	O
positive	0	O
),	0	O
and	0	O
pigs	0	O
(	0	O
6	0	O
%	0	O
positive	0	O
).	0	O


In	1	O
our	0	O
previous	0	O
studies	0	O
,	0	O
transcriptional	0	O
activation	0	O
was	0	O
shown	0	O
to	0	O
correlate	0	O
with	0	O
IEP86	0	B
binding	0	O
to	0	O
both	0	O
the	0	O
TATA	0	B
-	0	I
box	0	I
binding	0	I
protein	0	I
(	0	O
TBP	1	B
)	0	O
and	0	O
the	0	O
transcription	0	O
factor	0	O
bound	0	O
upstream	0	O
.	0	O


Bullous	1	O
keratopathy	0	O
was	0	O
usually	0	O
aphakic	0	O
in	0	O
origin	0	O
in	0	O
1982	0	O
,	0	O
but	0	O
after	0	O
1983	0	O
pseudophakic	0	O
bullous	0	O
keratopathy	0	O
(	0	O
PBK	0	O
)	0	O
was	0	O
the	0	O
most	0	O
common	0	O
cause	0	O
of	0	O
bullous	0	O
keratopathy	0	O
.	0	O


Chirality	1	O
-	0	O
glass	0	O
and	0	O
spin	0	O
-	0	O
glass	0	O
correlations	0	O
in	0	O
the	0	O
two	0	O
-	0	O
dimensional	0	O
random	0	O
-	0	O
bond	0	O
XY	0	O
model	0	O
.	0	O


However	0	O
,	0	O
the	0	O
history	0	O
of	0	O
acute	0	O
severe	0	O
complications	0	O
from	0	O
otitis	0	O
media	0	O
revealed	0	O
a	0	O
higher	0	O
frequency	0	O
in	0	O
those	0	O
individuals	0	O
with	0	O
alpha	0	B
1	0	I
-	0	I
antitrypsin	0	I
deficiency	0	O
as	0	O
compared	0	O
to	0	O
normals	0	O
.	0	O


Snail	1	B
family	0	I
proteins	0	I
are	0	O
zinc	0	O
finger	0	O
transcriptional	0	O
regulators	0	O
first	0	O
identified	0	O
in	0	O
Drosophila	1	O
which	0	O
play	0	O
critical	0	O
roles	0	O
in	0	O
cell	0	O
fate	0	O
determination	0	O
.	0	O


The	0	O
finding	0	O
that	0	O
the	0	O
chimeric	0	B
TdT	1	I
::	0	O
Pol	0	B
beta	0	I
protein	0	I
possessed	0	O
significant	0	O
template	0	O
-	0	O
dependent	0	O
polymerase	0	O
activity	0	O
suggests	0	O
that	0	O
aa	0	O
1	0	O
-	0	O
60	0	O
of	0	O
Pol	0	B
beta	0	I
are	0	O
involved	0	O
in	0	O
template	0	O
utilization	0	O
during	0	O
the	0	O
polymerization	0	O
reaction	0	O
,	0	O
as	0	O
suggested	0	O
by	0	O
the	0	O
previous	0	O
finding	0	O
that	0	O
the	0	O
8	0	O
-	0	O
kDa	1	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
Pol	0	B
beta	0	I
possesses	0	O
ssDNA	1	O
-	0	O
binding	0	O
activity	0	O
[	0	O
Kumar	0	O
et	0	O
al	0	O
.,	0	O
J	1	O
.	0	O


Arsenic	1	O
contents	0	O
in	0	O
native	0	O
copper	0	O


Articles	0	O
addressing	0	O
valvular	0	O
heart	0	O
disease	0	O
or	0	O
heart	0	O
failure	0	O
secondary	0	O
to	0	O
acute	0	O
myocardial	0	O
infarction	0	O
or	0	O
Chagas	0	O
'	0	O
disease	0	O
were	0	O
excluded	0	O
.	0	O


2000	0	O
update	0	O
of	0	O
recommendations	0	O
for	0	O
the	0	O
use	0	O
of	0	O
hematopoietic	0	B
colony	0	I
-	0	I
stimulating	0	I
factors	0	I
:	0	O
evidence	0	O
-	0	O
based	0	O
,	0	O
clinical	0	O
practice	0	O
guidelines	0	O
.	0	O


The	0	O
uncomplicated	0	O
cases	0	O
of	0	O
typhoid	0	O
fever	0	O
were	0	O
found	0	O
to	0	O
have	0	O
an	0	O
intact	0	O
CMIR	0	O
as	0	O
compared	0	O
to	0	O
the	0	O
complicated	0	O
cases	0	O
.	0	O


The	0	O
measurement	0	O
of	0	O
the	0	O
areas	0	O
of	0	O
fibrin	0	B
,	0	O
of	0	O
tissue	0	O
and	0	O
fibrinolysis	0	O
,	0	O
at	0	O
the	0	O
above	0	O
mentioned	0	O
times	0	O
,	0	O
has	0	O
been	0	O
effected	0	O
at	0	O
standard	0	O
magnification	0	O
(	0	O
15	0	O
X	1	O
)	0	O
by	0	O
an	0	O
image	0	O
analyser	0	O
(	0	O
Videoplan	0	O
)	0	O
scale	0	O
1	0	O
:	0	O
8	0	O
.	0	O


Trial	1	O
treatment	0	O
of	0	O
schizophrenia	0	O
with	0	O
des	0	B
-	0	I
Tyr	1	I
-	0	I
gamma	0	I
-	0	I
endorphin	0	I


Our	0	O
observations	0	O
suggest	0	O
that	0	O
members	0	O
of	0	O
the	0	O
HMG	1	B
-	0	I
I	1	I
family	0	I
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
SRF	1	B
-	0	O
dependent	0	O
transcription	0	O
and	0	O
that	0	O
their	0	O
effect	0	O
is	0	O
mediated	0	O
primarily	0	O
by	0	O
a	0	O
protein	0	O
-	0	O
protein	0	O
interaction	0	O
.	0	O


The	0	O
symptoms	0	O
and	0	O
objective	0	O
findings	0	O
were	0	O
caused	0	O
by	0	O
a	0	O
malignant	0	O
lymphoma	0	O
,	0	O
and	0	O
the	0	O
diagnosis	0	O
was	0	O
established	0	O
from	0	O
a	0	O
drill	0	O
biopsy	0	O
.	0	O


Approximately	0	O
20	0	O
%	0	O
of	0	O
ALCLs	0	O
that	0	O
express	0	O
ALK	0	B
do	0	O
not	0	O
contain	0	O
the	0	O
t	0	O
(	0	O
2	0	O
;	0	O
5	0	O
),	0	O
suggesting	0	O
that	0	O
other	0	O
genetic	0	O
abnormalities	0	O
can	0	O
result	0	O
in	0	O
aberrant	0	O
ALK	0	B
expression	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
in	0	O
vitro	0	O
mutagenesis	0	O
of	0	O
both	0	O
Engrailed	0	B
and	0	O
Pbx1	0	B
sites	0	I
indicated	0	O
that	0	O
other	0	O
unidentified	0	O
sites	0	O
are	0	O
responsible	0	O
for	0	O
the	0	O
transcriptional	0	O
enhancement	0	O
observed	0	O
with	0	O
the	0	O
intronic	0	O
fragment	0	O
.	0	O


These	0	O
tumors	0	O
were	0	O
classified	0	O
into	0	O
three	0	O
broad	0	O
groups	0	O
:	0	O
I	1	O
,	0	O
cystadenoma	0	O
;	0	O
II	0	O
,	0	O
cystadenocarcinoma	0	O
;	0	O
and	0	O
III	0	O
,	0	O
adenocarcinoma	0	O
with	0	O
mucin	0	B
production	0	O
or	0	O
an	0	O
associated	0	O
cyst	0	O
.	0	O


Pigmentary	1	O
rhythms	0	O
as	0	O
indicators	0	O
of	0	O
neurosecretion	0	O
.	0	O


The	0	O
14	0	B
.	0	I
1	0	I
(	0	I
IGLL1	0	I
)	0	I
gene	0	I
is	0	O
expressed	0	O
in	0	O
a	0	O
lineage	0	O
-	0	O
and	0	O
stage	0	O
-	0	O
restricted	0	O
manner	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
CD69	0	B
gene	0	I
revealed	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
potential	0	O
TATA	0	O
element	0	O
30	0	O
base	0	O
pairs	0	O
upstream	0	O
of	0	O
the	0	O
major	0	O
transcription	0	O
initiation	0	O
site	0	O
and	0	O
several	0	O
putative	0	O
binding	0	O
sequences	0	O
for	0	O
inducible	0	O
transcription	0	O
factors	0	O
(	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
,	0	O
Egr	0	B
-	0	I
1	0	I
,	0	O
AP	1	B
-	0	I
1	0	I
),	0	O
which	0	O
might	0	O
mediate	0	O
the	0	O
inducible	0	O
expression	0	O
of	0	O
this	0	O
gene	0	O
.	0	O


These	0	O
effects	0	O
were	0	O
abrogated	0	O
by	0	O
co	0	O
-	0	O
expression	0	O
of	0	O
kinase	0	B
-	0	I
deficient	0	I
PKC	0	I
zeta	0	I
and	0	O
inhibition	0	O
of	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
p85alpha	0	I
-	0	O
p110	0	B
by	0	O
wortmannin	0	O
,	0	O
LY294002	0	O
and	0	O
a	0	O
dominant	0	O
-	0	O
negative	0	O
mutant	0	O
of	0	O
p85alpha	0	B
.	0	O


This	0	O
proposed	0	O
method	0	O
is	0	O
similar	0	O
in	0	O
principle	0	O
to	0	O
the	0	O
sets	0	O
technique	0	O
but	0	O
is	0	O
shown	0	O
to	0	O
have	0	O
much	0	O
better	0	O
expected	0	O
time	0	O
to	0	O
alarm	0	O
properties	0	O
.	0	O


Evaluation	1	O
of	0	O
myocardial	0	O
perfusion	0	O
by	0	O
99mTc	0	O
-	0	O
tetrofosmin	0	O
SPECT	1	O
before	0	O
and	0	O
after	0	O
emergent	0	O
percutaneous	0	O
transluminal	0	O
coronary	0	O
angioplasty	0	O
for	0	O
acute	0	O
myocardial	0	O
infarction	0	O


Obstruction	1	O
of	0	O
the	0	O
ERF	0	B
repressor	0	I
function	0	O
by	0	O
the	0	O
transactivating	0	O
members	0	O
of	0	O
the	0	O
ets	0	B
family	0	I
of	0	O
genes	0	O
(	0	O
i	0	O
.	0	O
e	0	O
.	0	O
gag	0	B
-	0	O
myb	0	B
-	0	O
ets	0	B
)	0	O
may	0	O
be	0	O
essential	0	O
for	0	O
the	0	O
control	0	O
of	0	O
genes	0	O
involved	0	O
in	0	O
cell	0	O
proliferation	0	O
and	0	O
may	0	O
also	0	O
underlie	0	O
their	0	O
tumorigenic	0	O
effects	0	O
.	0	O


Comparative	0	O
DNA	1	O
sequence	0	O
analysis	0	O
showed	0	O
the	0	O
Genethon	0	O
microsatellite	0	B
D19S596	0	I
lies	0	O
2	0	O
.	0	O
2	0	O
kb	0	O
downstream	0	O
of	0	O
the	0	O
coding	0	O
region	0	O
of	0	O
FUT1	0	B
,	0	O
indicating	0	O
that	0	O
the	0	O
cluster	0	O
comprising	0	O
the	0	O
closely	0	O
linked	0	O
FUT1	0	B
and	0	O
FUT2	0	B
genes	0	I
is	0	O
located	0	O
4	0	O
cM	1	O
distal	0	O
to	0	O
D19S412	0	B
(	0	O
lod	0	O
score	0	O
13	0	O
.	0	O
7	0	O
)	0	O
and	0	O
9	0	O
cM	1	O
proximal	0	O
to	0	O
D19S571	0	B
(	0	O
lod	0	O
score	0	O
11	0	O
.	0	O
7	0	O
).	0	O


We	0	O
have	0	O
found	0	O
that	0	O
the	0	O
expression	0	O
of	0	O
GTPase	1	B
-	0	O
deficient	0	O
mutants	0	O
of	0	O
alpha	0	B
12	0	I
(	0	O
alpha	0	B
12Q229L	0	I
)	0	O
or	0	O
alpha	0	B
13	0	I
(	0	O
alpha	0	B
13Q226L	0	I
)	0	O
leads	0	O
to	0	O
robust	0	O
activation	0	O
of	0	O
the	0	O
Jun	1	B
kinase	0	I
/	0	O
stress	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
(	0	O
JNK	0	B
/	0	O
SAPK	0	B
)	0	O
pathway	0	O
.	0	O


Epstein	0	B
-	0	I
Barr	0	I
virus	0	I
(	0	I
EBV	1	I
)	0	I
latent	0	I
membrane	0	I
protein	0	I
1	0	I
(	0	O
LMP1	0	B
)	0	O
is	0	O
essential	0	O
for	0	O
EBV	1	O
-	0	O
mediated	0	O
transformation	0	O
of	0	O
primary	0	O
B	1	O
lymphocytes	0	O
.	0	O


Ki	1	B
-	0	I
ras4BVal	0	I
-	0	I
12	0	I
transfectant	0	O
cells	0	O
expressed	0	O
2	0	O
-	0	O
fold	0	O
elevated	0	O
protein	0	O
levels	0	O
of	0	O
the	0	O
lysosomal	0	B
cysteine	0	I
protease	0	I
cathepsin	0	I
B	1	I
but	0	O
did	0	O
not	0	O
up	0	O
-	0	O
regulate	0	O
cathepsin	0	B
B	1	I
mRNA	1	I
expression	0	O
.	0	O


Determination	1	O
of	0	O
aortic	0	O
distensibility	0	O
and	0	O
its	0	O
variations	0	O
in	0	O
arterial	0	O
hypertension	0	O
.	0	O


All	1	O
three	0	O
genes	0	O
have	0	O
been	0	O
mapped	0	O
precisely	0	O
to	0	O
a	0	O
small	0	O
region	0	O
on	0	O
human	0	O
chromosome	0	O
16p12	0	O
.	0	O
1	0	O
-	0	O
p11	0	O
.	0	O
2	0	O
(	0	O
homologous	0	O
to	0	O
mouse	0	O
chromosome	0	O
7	0	O
),	0	O
using	0	O
somatic	0	O
cell	0	O
hybrids	0	O
and	0	O
cosmid	0	O
clones	0	O
.	0	O


It	1	O
is	0	O
related	0	O
to	0	O
a	0	O
variety	0	O
of	0	O
mammalian	0	O
Golgi	0	O
-	0	O
associated	0	O
proteins	0	O
and	0	O
to	0	O
the	0	O
yeast	0	O
Uso1p	0	B
,	0	O
an	0	O
essential	0	O
protein	0	O
involved	0	O
in	0	O
docking	0	O
of	0	O
endoplasmic	0	O
reticulum	0	O
-	0	O
derived	0	O
vesicles	0	O
to	0	O
the	0	O
cis	0	O
-	0	O
Golgi	0	O
.	0	O


An	1	O
11	0	O
-	0	O
month	0	O
-	0	O
old	0	O
girl	0	O
suffering	0	O
from	0	O
Dandy	0	O
-	0	O
Walker	1	O
malformation	0	O
(	0	O
DWM	0	O
)	0	O
associated	0	O
with	0	O
tetralogy	0	O
of	0	O
Fallot	0	O
(	0	O
TOF	1	O
)	0	O
is	0	O
presented	0	O
.	0	O


The	0	O
results	0	O
confirm	0	O
that	0	O
a	0	O
single	0	O
base	0	O
change	0	O
in	0	O
the	0	O
branchpoint	0	O
consensus	0	O
sequence	0	O
of	0	O
an	0	O
intron	0	O
can	0	O
cause	0	O
human	0	O
disease	0	O
although	0	O
this	0	O
sequence	0	O
is	0	O
poorly	0	O
conserved	0	O
in	0	O
mammals	0	O
.	0	O


Ras	1	B
-	0	I
and	0	I
ultra	0	I
-	0	I
violet	0	I
-	0	I
responsive	0	I
protein	0	I
kinases	0	I
that	0	O
phosphorylate	0	O
c	0	B
-	0	I
Jun	1	I
on	0	O
serine	0	O
residues	0	O
at	0	O
positions	0	O
63	0	O
and	0	O
73	0	O
and	0	O
stimulate	0	O
its	0	O
transcriptional	0	O
activity	0	O
have	0	O
been	0	O
identified	0	O
.	0	O


Induction	1	O
was	0	O
reversed	0	O
by	0	O
coexpression	0	O
of	0	O
A	1	B
-	0	I
Fos	1	I
,	0	O
a	0	O
dominant	0	O
negative	0	O
to	0	O
AP	1	B
-	0	I
1	0	I
.	0	O


The	0	O
extended	0	O
rat	0	B
SP	1	I
-	0	I
A	1	I
isoforms	0	I
were	0	O
enriched	0	O
in	0	O
the	0	O
more	0	O
fully	0	O
glycosylated	0	O
and	0	O
multimeric	0	O
SP	1	B
-	0	I
A	1	I
species	0	O
separated	0	O
on	0	O
SDS	1	O
-	0	O
PAGE	1	O
gels	0	O
.	0	O


Sixty	0	O
months	0	O
after	0	O
the	0	O
initial	0	O
vaccination	0	O
,	0	O
all	0	O
vaccinees	0	O
who	0	O
received	0	O
annual	0	O
follow	0	O
-	0	O
up	0	O
still	0	O
had	0	O
protective	0	O
levels	0	O
of	0	O
anti	0	B
-	0	I
HAV	1	I
.	0	O


Comparison	0	O
of	0	O
Tc	1	O
-	0	O
99m	0	O
sestamibi	0	O
perfusion	0	O
imaging	0	O
and	0	O
echocardiography	0	O
using	0	O
an	0	O
arbutamine	0	O
infusion	0	O
for	0	O
the	0	O
detection	0	O
of	0	O
coronary	0	O
artery	0	O
disease	0	O
.	0	O


Stimulation	1	O
of	0	O
[	0	O
3H	0	O
]	0	O
PA	1	O
production	0	O
upon	0	O
CD3	0	B
cross	0	O
-	0	O
linking	0	O
was	0	O
77	0	O
%	0	O
lower	0	O
in	0	O
permeabilized	0	O
CD45	0	B
-	0	I
cells	0	O
than	0	O
in	0	O
CD45	0	B
+	0	I
cells	0	O
,	0	O
consistent	0	O
with	0	O
the	0	O
reduced	0	O
activity	0	O
of	0	O
p59fyn	0	B
in	0	O
CD45	0	B
-	0	I
cells	0	O
.	0	O


In	1	O
addition	0	O
a	0	O
significant	0	O
Treatment	1	O
X	1	O
Strain	1	O
interaction	0	O
was	0	O
due	0	O
to	0	O
the	0	O
larger	0	O
defecation	0	O
numbers	0	O
displayed	0	O
by	0	O
the	0	O
taurine	0	O
-	0	O
injected	0	O
MR	1	O
rats	0	O
relative	0	O
to	0	O
the	0	O
saline	0	O
-	0	O
injected	0	O
MR	1	O
rats	0	O
.	0	O


Age	1	O
and	0	O
sex	0	O
structure	0	O
of	0	O
the	0	O
natural	0	O
population	0	O
of	0	O
Ornithodoros	1	O
tatarovski	0	O
Ol	1	O
.	0	O


Primary	1	O
adrenal	0	O
hypersensitivity	0	O
to	0	O
ACTH	1	B
drive	0	O
in	0	O
obesity	0	O
has	0	O
also	0	O
been	0	O
suggested	0	O
.	0	O


However	0	O
,	0	O
only	0	O
complete	0	B
DnaJ	0	I
can	0	O
cooperate	0	O
with	0	O
DnaK	0	B
and	0	O
a	0	O
third	0	O
protein	0	O
,	0	O
GrpE	0	B
,	0	O
in	0	O
refolding	0	O
denatured	0	B
firefly	0	I
luciferase	0	I
.	0	O


The	0	O
mustard	0	B
chloroplast	0	I
gene	0	I
rps16	0	I
is	0	O
split	0	O
by	0	O
an	0	O
887	0	O
bp	0	O
group	0	O
II	0	O
(	0	O
or	0	O
III	0	O
)	0	O
intron	0	O
.	0	O


No	1	O
significant	0	O
differences	0	O
between	0	O
the	0	O
substituted	0	O
and	0	O
wild	0	O
type	0	O
peptides	0	O
were	0	O
observed	0	O
,	0	O
suggesting	0	O
that	0	O
this	0	O
substitution	0	O
in	0	O
the	0	O
intact	0	O
protein	0	O
may	0	O
cause	0	O
disruption	0	O
of	0	O
global	0	O
rather	0	O
than	0	O
local	0	O
structures	0	O
.	0	O


Homozygous	1	O
individuals	0	O
usually	0	O
develop	0	O
purpura	0	O
fulminans	0	O
as	0	O
newborns	0	O
;	0	O
heterozygous	0	O
protein	0	B
C	1	I
-	0	O
deficient	0	O
individuals	0	O
are	0	O
at	0	O
increased	0	O
risk	0	O
for	0	O
venous	0	O
thrombosis	0	O
and	0	O
pulmonary	0	O
embolism	0	O
.	0	O


Sci	1	O
.	0	O


Ulcer	1	O
appeared	0	O
on	0	O
the	0	O
angulus	0	O
of	0	O
the	0	O
stomach	0	O
at	0	O
the	0	O
28th	0	O
week	0	O
and	0	O
resulted	0	O
in	0	O
ulcer	0	O
scar	0	O
at	0	O
the	0	O
42nd	0	O
week	0	O
.	0	O


Therefore	0	O
,	0	O
magnetic	0	O
resonance	0	O
imaging	0	O
was	0	O
used	0	O
to	0	O
determine	0	O
liver	0	O
volume	0	O
in	0	O
pediatric	0	O
and	0	O
adolescent	0	O
patients	0	O
,	0	O
in	0	O
whom	0	O
systemic	0	O
clearance	0	O
of	0	O
three	0	O
model	0	O
substrates	0	O
[	0	O
lorazepam	0	O
(	0	O
0	0	O
.	0	O
03	0	O
mg	0	O
/	0	O
kg	0	O
),	0	O
antipyrine	0	O
(	0	O
10	0	O
mg	0	O
/	0	O
kg	0	O
),	0	O
and	0	O
indocyanine	0	O
green	0	O
(	0	O
ICG	0	O
;	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
)]	0	O
was	0	O
also	0	O
determined	0	O
.	0	O


Unexpectedly	0	O
,	0	O
ALK7	0	B
signaling	0	O
produced	0	O
a	0	O
remarkable	0	O
change	0	O
in	0	O
cell	0	O
morphology	0	O
characterized	0	O
by	0	O
cell	0	O
flattening	0	O
and	0	O
elaboration	0	O
of	0	O
blunt	0	O
,	0	O
short	0	O
cell	0	O
processes	0	O
.	0	O


Reverse	0	B
transcriptase	0	I
-	0	O
polymerase	0	O
chain	0	O
reaction	0	O
(	0	O
RT	1	B
-	0	O
PCR	1	O
)	0	O
was	0	O
performed	0	O
using	0	O
eyestalk	0	O
complementary	0	O
DNA	1	O
of	0	O
the	0	O
sand	0	O
shrimp	0	O
Metapenaeus	0	O
ensis	0	O
.	0	O


Effect	1	O
of	0	O
ingestion	0	O
of	0	O
Norbiogest	0	O
during	0	O
the	0	O
quiescent	0	O
period	0	O
of	0	O
the	0	O
genital	0	O
organs	0	O


This	0	O
fraction	0	O
is	0	O
resistant	0	O
to	0	O
digestions	0	O
by	0	O
DNase	1	B
I	1	I
and	0	O
RNase	1	B
T1	1	I
and	0	O
disappears	0	O
completely	0	O
upon	0	O
alkali	0	O
hydrolysis	0	O
.	0	O


Nineteen	0	O
patients	0	O
with	0	O
non	0	O
-	0	O
visualized	0	O
gallbladder	0	O
with	0	O
OCG	0	O
subsequently	0	O
had	0	O
Tc	1	O
-	0	O
99m	0	O
-	0	O
PyG	0	O
cholescintigraphy	0	O
performed	0	O
.	0	O


Cognate	0	O
promoter	0	O
elements	0	O
implicated	0	O
in	0	O
glucocorticoid	0	O
-	0	O
and	0	O
cAMP	1	O
-	0	O
mediated	0	O
regulation	0	O
as	0	O
well	0	O
as	0	O
in	0	O
liver	0	O
-,	0	O
myeloid	0	O
-,	0	O
and	0	O
lymphocyte	0	O
-	0	O
specific	0	O
expression	0	O
are	0	O
located	0	O
within	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
sequence	0	O
.	0	O


Human	1	O
ESP1	0	B
/	0	O
CRP2	0	B
protein	0	O
has	0	O
two	0	O
LIM	0	B
domains	0	O
,	0	O
and	0	O
each	0	O
shares	0	O
35	0	O
.	0	O
1	0	O
%	0	O
and	0	O
77	0	O
or	0	O
79	0	O
%	0	O
identical	0	O
residues	0	O
with	0	O
human	0	B
cysteine	0	I
-	0	I
rich	0	I
protein	0	I
(	0	O
CRP	1	B
)	0	O
and	0	O
rat	0	B
CRIP	0	I
,	0	O
respectively	0	O
.	0	O


After	0	O
i	0	O
.	0	O
v	0	O
.	0	O


2	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
negative	0	O
transcriptional	0	O
effect	0	O
of	0	O
COUP	1	B
-	0	I
TFs	0	I
is	0	O
dominant	0	O
over	0	O
the	0	O
activating	0	O
effect	0	O
of	0	O
the	0	O
Oct4	0	B
embryonic	0	I
stem	0	I
cell	0	I
-	0	I
specific	0	I
enhancer	0	I
.	0	O


The	0	O
average	0	O
birth	0	O
mass	0	O
of	0	O
these	0	O
newborns	0	O
was	0	O
3491	0	O
.	0	O
9	0	O
+/-	0	O
2	0	O
SD	1	O
780	0	O
.	0	O
5	0	O
g	0	O
and	0	O
that	0	O
in	0	O
the	0	O
control	0	O
group	0	O
3	0	O
,	0	O
767	0	O
.	0	O
5	0	O
+/-	0	O
2	0	O
SD	1	O
824	0	O
.	0	O
2	0	O
g	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Therefore	0	O
the	0	O
binding	0	O
sites	0	O
for	0	O
liver	0	O
-	0	O
enriched	0	O
factors	0	O
,	0	O
present	0	O
in	0	O
the	0	O
hamster	0	B
CYP7A1	0	I
proximal	0	I
promoter	0	I
in	0	O
close	0	O
vicinity	0	O
and	0	O
conserved	0	O
between	0	O
species	0	O
,	0	O
constitute	0	O
a	0	O
regulatory	0	O
unit	0	O
important	0	O
for	0	O
basal	0	O
hepatic	0	O
expression	0	O
and	0	O
tissue	0	O
restriction	0	O
of	0	O
the	0	O
action	0	O
of	0	O
hormones	0	O
such	0	O
as	0	O
insulin	0	B
.	0	O


7	0	O
.	0	O


Although	0	O
p48	0	B
gene	0	I
induction	0	O
is	0	O
dependent	0	O
on	0	O
STAT1	0	B
and	0	O
JAK1	0	B
,	0	O
activated	0	O
STAT1	0	B
does	0	O
not	0	O
bind	0	O
to	0	O
GATE	1	B
.	0	O


Such	0	O
an	0	O
hemoglobin	0	B
solution	0	O
was	0	O
shown	0	O
to	0	O
exhibit	0	O
a	0	O
high	0	O
affinity	0	O
for	0	O
oxygen	0	O
and	0	O
a	0	O
low	0	O
Bohr	0	O
effect	0	O
(	0	O
assessed	0	O
from	0	O
the	0	O
delta	0	O
log	0	O
Po2	1	O
/	0	O
delta	0	O
pH	1	O
ratio	0	O
).	0	O


Multiresistant	0	O
strains	0	O
isolated	0	O
from	0	O
humans	0	O
in	0	O
enteral	0	O
toxico	0	O
-	0	O
infections	0	O
kill	0	O
orally	0	O
infected	0	O
mice	0	O
more	0	O
frequently	0	O
than	0	O
strains	0	O
isolated	0	O
in	0	O
hospital	0	O
infections	0	O
.	0	O


The	0	O
overall	0	O
incidence	0	O
of	0	O
SIDS	1	O
was	0	O
1	0	O
.	0	O
43	0	O
per	0	O
1	0	O
,	0	O
000	0	O
live	0	O
births	0	O
.	0	O


CO2	1	O
assimilation	0	O
by	0	O
chloroplasts	0	O
illuminated	0	O
on	0	O
filter	0	O
paper	0	O
.	0	O


Testing	1	O
gravity	0	O
to	0	O
second	0	O
post	0	O
-	0	O
Newtonian	0	O
order	0	O
:	0	O
A	1	O
field	0	O
-	0	O
theory	0	O
approach	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
hydrostatic	0	O
pressure	0	O
on	0	O
the	0	O
swimming	0	O
activity	0	O
of	0	O
three	0	O
hyponeustonic	0	O
crustacea	0	O
,	0	O
Anomalocera	0	O
patersoni	0	O
,	0	O
Pontella	0	O
mediterranea	0	O
,	0	O
Labidocera	0	O
wollastoni	0	O


On	1	O
Days	0	O
1	0	O
and	0	O
14	0	O
,	0	O
most	0	O
young	0	O
and	0	O
elderly	0	O
subjects	0	O
exhibited	0	O
monoexponential	0	O
decline	0	O
in	0	O
bevantolol	0	O
plasma	0	O
concentrations	0	O
after	0	O
absorption	0	O
phase	0	O
.	0	O


The	0	O
mode	0	O
of	0	O
resistance	0	O
to	0	O
quinupristin	0	O
/	0	O
dalfopristin	0	O
was	0	O
not	0	O
evident	0	O
(	0	O
sat	0	O
A	1	O
-	0	O
negative	0	O
by	0	O
PCR	1	O
);	0	O
and	0	O
these	0	O
cases	0	O
illustrate	0	O
the	0	O
existence	0	O
of	0	O
streptogramin	0	O
-	0	O
resistant	0	O
isolates	0	O
before	0	O
the	0	O
introduction	0	O
of	0	O
this	0	O
antimicrobial	0	O
class	0	O
into	0	O
human	0	O
clinical	0	O
practice	0	O
.	0	O


All	1	O
13	0	O
patients	0	O
showed	0	O
endoscopic	0	O
evidence	0	O
of	0	O
oesophagitis	0	O
,	0	O
moderate	0	O
in	0	O
4	0	O
and	0	O
severe	0	O
in	0	O
9	0	O
.	0	O


Correlating	0	O
with	0	O
the	0	O
previous	0	O
observation	0	O
that	0	O
CBF	1	B
binding	0	O
to	0	O
the	0	O
78C1	0	O
site	0	O
is	0	O
enhanced	0	O
by	0	O
EGTA	1	O
and	0	O
EDTA	1	O
,	0	O
these	0	O
divalent	0	O
cation	0	O
chelators	0	O
specifically	0	O
stimulate	0	O
78C1	0	O
-	0	O
directed	0	O
transcription	0	O
.	0	O


This	0	O
mutation	0	O
also	0	O
results	0	O
in	0	O
markedly	0	O
decreased	0	O
levels	0	O
of	0	O
CAD	1	B
mRNA	1	I
and	0	O
protein	0	O
in	0	O
the	0	O
mutant	0	O
.	0	O


The	0	O
diagnosis	0	O
of	0	O
miliary	0	O
tuberculosis	0	O
should	0	O
be	0	O
systematically	0	O
considered	0	O
in	0	O
ARDS	1	O
of	0	O
unknown	0	O
origin	0	O
.	0	O


Chem	0	O
.	0	O


Previous	0	O
studies	0	O
indicated	0	O
that	0	O
the	0	O
20S	0	B
proteasome	0	I
is	0	O
a	0	O
catalytic	0	O
core	0	O
of	0	O
the	0	O
26S	0	B
proteolytic	0	I
complex	0	I
that	0	O
possesses	0	O
a	0	O
latent	0	O
multicatalytic	0	O
proteinase	0	O
activity	0	O
and	0	O
catalyzes	0	O
an	0	O
ATP	1	O
-	0	O
dependent	0	O
,	0	O
selective	0	O
breakdown	0	O
of	0	O
proteins	0	O
ligated	0	O
to	0	O
ubiquitin	0	B
.	0	O


Petko	0	O
,	0	O
and	0	O
S	1	O
.	0	O


Signal	1	O
transduction	0	O
via	0	O
modulation	0	O
of	0	O
phosphorylation	0	O
after	0	O
selective	0	O
inhibition	0	O
of	0	O
protein	0	B
phosphatase	0	I
(	0	I
PP	1	I
)	0	I
1	0	I
and	0	O
/	0	O
or	0	O
PP2A	0	B
appears	0	O
to	0	O
play	0	O
a	0	O
role	0	O
in	0	O
okadaic	0	O
acid	0	O
(	0	O
OA	1	O
)-	0	O
mediated	0	O
effects	0	O
.	0	O


Collectively	0	O
,	0	O
these	0	O
data	0	O
indicate	0	O
that	0	O
HIP	1	B
is	0	O
a	0	O
membrane	0	O
-	0	O
associated	0	O
HP	1	B
-	0	I
binding	0	I
protein	0	I
expressed	0	O
on	0	O
the	0	O
surface	0	O
of	0	O
normal	0	O
human	0	O
uterine	0	O
epithelia	0	O
and	0	O
uterine	0	O
epithelial	0	O
cell	0	O
lines	0	O
.	0	O


The	0	O
enzyme	0	O
displays	0	O
optimal	0	O
activity	0	O
at	0	O
about	0	O
0	0	O
.	0	O
5	0	O
mM	1	O
pantoate	0	O
(	0	O
k	0	O
(	0	O
cat	0	O
)	0	O
0	0	O
.	0	O
63	0	O
s	0	O
(-	0	O
1	0	O
))	0	O
and	0	O
at	0	O
pH	1	O
7	0	O
.	0	O
8	0	O
.	0	O


Acquired	1	O
factor	0	B
VIII	0	I
inhibitor	0	O
in	0	O
non	0	O
-	0	O
hemophilic	0	O
patients	0	O


Among	0	O
known	0	O
flea	0	O
larvae	0	O
,	0	O
the	0	O
genus	0	O
Anomiopsyllus	0	O
(	0	O
Anomiopsyllinae	0	O
,	0	O
Anomiopsyllini	0	O
)	0	O
is	0	O
as	0	O
distinctive	0	O
in	0	O
larval	0	O
form	0	O
as	0	O
are	0	O
the	0	O
adults	0	O
.	0	O


A	1	O
cdc33	0	B
-	0	I
1	0	I
strain	0	O
expressing	0	O
either	0	O
stable	0	O
Cln3p	0	B
(	0	O
Cln3	0	B
-	0	I
1p	0	I
)	0	O
or	0	O
a	0	O
hybrid	0	O
UBI4	0	B
5	0	I
'-	0	I
CLN3	0	I
mRNA	1	O
,	0	O
whose	0	O
translation	0	O
displays	0	O
decreased	0	O
dependence	0	O
on	0	O
eIF4E	0	B
,	0	O
arrested	0	O
randomly	0	O
in	0	O
the	0	O
cell	0	O
cycle	0	O
.	0	O


Nonsynonymous	0	O
substitution	0	O
in	0	O
abalone	0	O
sperm	0	O
fertilization	0	O
genes	0	O
exceeds	0	O
substitution	0	O
in	0	O
introns	0	O
and	0	O
mitochondrial	0	O
DNA	1	O
.	0	O


The	0	O
limits	0	O
of	0	O
agreement	0	O
between	0	O
DBS	1	O
and	0	O
TOF	1	O
responses	0	O
were	0	O
so	0	O
wide	0	O
that	0	O
they	0	O
cannot	0	O
be	0	O
used	0	O
interchangeably	0	O
.	0	O


We	0	O
also	0	O
examined	0	O
the	0	O
effect	0	O
of	0	O
proteolytic	0	O
processing	0	O
in	0	O
the	0	O
MVE	0	O
nonstructural	0	O
polyprotein	0	O
segment	0	O
mediated	0	O
by	0	O
the	0	O
viral	0	B
proteinase	0	I
NS3	0	I
on	0	O
antigen	0	O
processing	0	O
and	0	O
presentation	0	O
of	0	O
the	0	O
MVE	0	O
H	1	O
-	0	O
2Kk	0	O
-	0	O
restricted	0	O
T	1	O
cell	0	O
determinant	0	O
.	0	O


Fourteen	0	O
healthy	0	O
male	0	O
volunteers	0	O
completed	0	O
the	0	O
study	0	O
.	0	O


The	0	O
preferential	0	O
serum	0	B
IgA	1	I
response	0	O
observed	0	O
in	0	O
the	0	O
patient	0	O
population	0	O
suggests	0	O
that	0	O
bronchial	0	O
associated	0	O
lymphoid	0	O
tissue	0	O
in	0	O
the	0	O
diseased	0	O
lung	0	O
is	0	O
an	0	O
important	0	O
source	0	O
of	0	O
circulating	0	O
IgA	1	B
.	0	O


Sequence	1	O
determination	0	O
of	0	O
isolated	0	O
peptides	0	O
suggested	0	O
that	0	O
Asn120	0	O
is	0	O
glycosylated	0	O
,	0	O
Asn65	0	O
and	0	O
Asn109	0	O
glycosylated	0	O
in	0	O
some	0	O
molecules	0	O
but	0	O
not	0	O
in	0	O
others	0	O
,	0	O
and	0	O
Asn72	0	O
not	0	O
glycosylated	0	O
.	0	O


In	1	O
similar	0	O
transient	0	O
transfection	0	O
experiments	0	O
in	0	O
HeLa	0	O
cells	0	O
,	0	O
overexpression	0	O
of	0	O
the	0	O
wt	0	B
human	0	I
retinoblastoma	0	I
susceptibility	0	I
gene	0	I
product	0	I
,	0	O
RB	1	B
,	0	O
was	0	O
found	0	O
to	0	O
repress	0	O
the	0	O
serum	0	O
-	0	O
induced	0	O
IL	1	B
-	0	I
6	0	I
(-	0	O
225	0	O
to	0	O
+	0	O
13	0	O
),	0	O
c	0	B
-	0	I
fos	0	I
(-	0	O
711	0	O
to	0	O
+	0	O
42	0	O
),	0	O
and	0	O
beta	0	B
-	0	I
actin	0	I
(-	0	O
3400	0	O
to	0	O
+	0	O
912	0	O
)	0	O
promoters	0	O
but	0	O
not	0	O
the	0	O
PRV	0	O
-	0	O
induced	0	O
IL	1	B
-	0	I
6	0	I
(-	0	O
110	0	O
to	0	O
+	0	O
13	0	O
)	0	O
or	0	O
the	0	O
serum	0	O
-	0	O
induced	0	O
MHC	1	B
(-	0	O
528	0	O
to	0	O
-	0	O
38	0	O
)	0	O
promoters	0	O
.	0	O


Finally	0	O
,	0	O
the	0	O
mechanism	0	O
of	0	O
ASK1	0	B
activation	0	O
involves	0	O
,	0	O
in	0	O
part	0	O
,	0	O
homo	0	O
-	0	O
oligomerization	0	O
.	0	O


In	1	O
the	0	O
work	0	O
reported	0	O
here	0	O
,	0	O
we	0	O
used	0	O
peptide	0	O
mapping	0	O
,	0	O
mass	0	O
spectrometry	0	O
,	0	O
and	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
to	0	O
identify	0	O
two	0	O
sets	0	O
of	0	O
pAP	1	B
phosphorylation	0	O
sites	0	O
.	0	O


Several	0	O
cDNAs	0	O
corresponding	0	O
to	0	O
the	0	O
human	0	B
PWP2	0	I
gene	0	I
were	0	O
identified	0	O
and	0	O
partially	0	O
sequenced	0	O
.	0	O


Coenzyme	1	O
Q10	1	O
:	0	O
blood	0	O
levels	0	O
and	0	O
metabolic	0	O
demand	0	O
.	0	O


In	1	O
order	0	O
to	0	O
investigate	0	O
the	0	O
blood	0	O
compatibility	0	O
of	0	O
autogenous	0	O
vein	0	O
graft	0	O
(	0	O
AVG	0	O
),	0	O
changes	0	O
in	0	O
prostacyclin	0	O
(	0	O
PGI2	0	O
)	0	O
production	0	O
following	0	O
harvesting	0	O
and	0	O
arterial	0	O
implantation	0	O
were	0	O
studied	0	O
experimentally	0	O
.	0	O


Sequence	1	O
analysis	0	O
reveals	0	O
that	0	O
the	0	O
newly	0	O
discovered	0	O
oasA2	0	B
gene	0	I
represents	0	O
a	0	O
pseudogene	0	O
that	0	O
is	0	O
still	0	O
transcribed	0	O
,	0	O
but	0	O
is	0	O
not	0	O
functionally	0	O
translated	0	O
.	0	O


Generally	0	O
,	0	O
a	0	O
correlation	0	O
was	0	O
observed	0	O
between	0	O
highest	0	O
concentrations	0	O
of	0	O
CSF	1	B
immunoglobulins	0	I
and	0	O
degree	0	O
of	0	O
meningeal	0	O
inflammatory	0	O
response	0	O
,	0	O
even	0	O
if	0	O
this	0	O
was	0	O
a	0	O
component	0	O
of	0	O
other	0	O
neurological	0	O
diseases	0	O
.	0	O


Of	0	O
the	0	O
53	0	O
units	0	O
tested	0	O
during	0	O
sinusoidal	0	O
motion	0	O
at	0	O
0	0	O
.	0	O
05	0	O
Hz	1	O
(	0	O
9	0	O
.	0	O
1	0	O
cm	0	O
/	0	O
s	0	O
),	0	O
1	0	O
(	0	O
1	0	O
.	0	O
9	0	O
%)	0	O
was	0	O
responsive	0	O
to	0	O
the	0	O
otolith	0	O
input	0	O
only	0	O
,	0	O
13	0	O
(	0	O
24	0	O
.	0	O
5	0	O
%)	0	O
were	0	O
influenced	0	O
by	0	O
the	0	O
visual	0	O
input	0	O
only	0	O
and	0	O
23	0	O
(	0	O
43	0	O
.	0	O
4	0	O
%)	0	O
responded	0	O
to	0	O
both	0	O
modalities	0	O
.	0	O


On	1	O
the	0	O
trail	0	O
of	0	O
Dr	1	O
.	0	O


The	0	O
C	1	O
terminus	0	O
of	0	O
TRBP	0	B
binds	0	O
to	0	O
CBP	0	B
/	0	O
p300	0	B
and	0	O
DRIP130	0	B
,	0	O
a	0	O
component	0	O
of	0	O
the	0	O
DRIP	1	B
/	0	O
TRAP	1	B
/	0	O
ARC	1	B
complex	0	O
,	0	O
which	0	O
suggests	0	O
that	0	O
TRBP	0	B
may	0	O
activate	0	O
transcription	0	O
by	0	O
means	0	O
of	0	O
such	0	O
interactions	0	O
.	0	O


This	0	O
technique	0	O
was	0	O
employed	0	O
in	0	O
12	0	O
patients	0	O
with	0	O
a	0	O
unicameral	0	O
bone	0	O
cyst	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
the	0	O
opiate	0	O
antagonist	0	O
naloxone	0	O
was	0	O
evaluated	0	O
in	0	O
11	0	O
unselected	0	O
patients	0	O
with	0	O
cerebral	0	O
ischemia	0	O
.	0	O


The	0	O
real	0	O
challenge	0	O
for	0	O
the	0	O
future	0	O
will	0	O
be	0	O
the	0	O
management	0	O
of	0	O
patients	0	O
who	0	O
do	0	O
not	0	O
respond	0	O
to	0	O
first	0	O
-	0	O
line	0	O
treatment	0	O
.	0	O


Examination	1	O
of	0	O
the	0	O
immediate	0	O
sequence	0	O
5	0	O
'	0	O
to	0	O
the	0	O
mRNA	1	O
start	0	O
site	0	O
reveals	0	O
no	0	O
TATA	0	O
box	0	O
and	0	O
multiple	0	O
known	0	O
enhancer	0	O
sequences	0	O
.	0	O


Despite	0	O
the	0	O
presence	0	O
of	0	O
one	0	O
additional	0	O
ribonucleotide	0	B
reductase	0	I
,	0	O
the	0	O
nrdAB	0	B
-	0	I
encoded	0	I
enzyme	0	I
is	0	O
essential	0	O
to	0	O
the	0	O
aerobic	0	O
growth	0	O
of	0	O
the	0	O
cell	0	O
because	0	O
nrdAB	0	B
-	0	I
defective	0	I
mutants	0	I
of	0	O
both	0	O
species	0	O
are	0	O
not	0	O
viable	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
oxygen	0	O
.	0	O


We	0	O
show	0	O
here	0	O
that	0	O
v	0	B
-	0	I
Rel	0	I
specifically	0	O
increased	0	O
expression	0	O
from	0	O
a	0	O
reporter	0	O
plasmid	0	O
containing	0	O
multiple	0	O
Sp1	0	B
binding	0	I
sites	0	I
approximately	0	O
sixfold	0	O
in	0	O
chicken	0	O
embryo	0	O
fibroblasts	0	O
(	0	O
CEFs	0	O
),	0	O
even	0	O
though	0	O
v	0	B
-	0	I
Rel	0	I
did	0	O
not	0	O
bind	0	O
directly	0	O
to	0	O
these	0	O
sites	0	O
.	0	O
v	0	B
-	0	I
Rel	0	I
also	0	O
increased	0	O
expression	0	O
from	0	O
a	0	O
reporter	0	O
plasmid	0	O
containing	0	O
a	0	O
human	0	B
immunodeficiency	0	I
virus	0	I
type	0	I
1	0	I
(	0	I
HIV	1	I
-	0	I
1	0	I
)	0	I
long	0	I
terminal	0	I
repeat	0	I
(	0	O
LTR	1	O
)	0	O
in	0	O
which	0	O
the	0	O
kappa	0	B
B	1	I
binding	0	I
sites	0	I
were	0	O
mutated	0	O
but	0	O
which	0	O
still	0	O
contained	0	O
intact	0	O
Sp1	0	B
binding	0	I
sites	0	I
.	0	O


Increased	0	O
plasma	0	O
IgE	1	B
was	0	O
also	0	O
confirmed	0	O
in	0	O
the	0	O
NC	0	O
mice	0	O
,	0	O
and	0	O
treatment	0	O
with	0	O
FK506	0	O
ointment	0	O
reduced	0	O
the	0	O
plasma	0	O
IgE	1	B
level	0	O
.	0	O


The	0	O
expression	0	O
of	0	O
the	0	O
putative	0	O
operon	0	O
bglPH	0	B
of	0	O
Bacillus	1	O
subtilis	0	O
was	0	O
studied	0	O
by	0	O
using	0	O
bglP	0	O
'-	0	O
lacZ	0	B
transcriptional	0	O
fusions	0	O
.	0	O


In	1	O
the	0	O
first	0	O
part	0	O
of	0	O
our	0	O
study	0	O
,	0	O
the	0	O
highest	0	O
mutagenicity	0	O
was	0	O
revealed	0	O
by	0	O
TA98	0	O
strain	0	O
without	0	O
enzymatic	0	O
activation	0	O
,	0	O
suggesting	0	O
a	0	O
direct	0	O
-	0	O
acting	0	O
mutagenicity	0	O
prevalence	0	O
in	0	O
diesel	0	O
particulate	0	O
.	0	O


The	0	O
emerging	0	O
view	0	O
based	0	O
on	0	O
studies	0	O
in	0	O
yeast	0	O
is	0	O
that	0	O
each	0	O
class	0	O
of	0	O
snoRNPs	0	O
is	0	O
composed	0	O
of	0	O
a	0	O
unique	0	O
set	0	O
of	0	O
proteins	0	O
.	0	O


U4	0	B
/	0	O
U6	0	B
snRNP	1	O
is	0	O
one	0	O
of	0	O
four	0	O
essential	0	O
small	0	O
nuclear	0	O
ribonucleoprotein	0	O
(	0	O
snRNP	1	O
)	0	O
particles	0	O
(	0	O
U1	0	B
,	0	O
U2	0	B
,	0	O
U5	0	B
and	0	O
U4	0	B
/	0	O
U6	0	B
)	0	O
present	0	O
in	0	O
the	0	O
spliceosome	0	O
.	0	O


Northern	0	O
and	0	O
RT	1	O
-	0	O
PCR	1	O
analysis	0	O
of	0	O
Ube3a	0	B
expression	0	O
in	0	O
mouse	0	O
tissues	0	O
from	0	O
animals	0	O
with	0	O
segmental	0	O
,	0	O
paternal	0	O
uniparental	0	O
disomy	0	O
failed	0	O
to	0	O
detect	0	O
substantially	0	O
reduced	0	O
or	0	O
absent	0	O
expression	0	O
compared	0	O
to	0	O
control	0	O
animals	0	O
,	0	O
failing	0	O
to	0	O
provide	0	O
any	0	O
evidence	0	O
for	0	O
maternal	0	O
-	0	O
specific	0	O
expression	0	O
from	0	O
this	0	O
locus	0	O
.	0	O


The	0	O
recombinant	0	O
contains	0	O
the	0	O
normal	0	O
beta	0	B
A	1	I
-	0	I
globin	0	I
gene	0	I
,	0	O
the	0	O
mutant	0	O
gene	0	O
and	0	O
Ylp	0	O
vector	0	O
sequences	0	O
between	0	O
the	0	O
two	0	O
copies	0	O
.	0	O


To	1	O
examine	0	O
the	0	O
basis	0	O
for	0	O
the	0	O
apparent	0	O
differences	0	O
in	0	O
postsegregational	0	O
killing	0	O
between	0	O
the	0	O
two	0	O
E	1	O
.	0	O
coli	0	O
strains	0	O
,	0	O
transformation	0	O
assays	0	O
were	0	O
carried	0	O
out	0	O
to	0	O
determine	0	O
the	0	O
relative	0	O
sensitivities	0	O
of	0	O
the	0	O
strains	0	O
to	0	O
the	0	O
ParE	0	B
toxin	0	I
protein	0	I
.	0	O


These	0	O
losses	0	O
account	0	O
for	0	O
the	0	O
resistance	0	O
of	0	O
EDS	0	O
-	0	O
IV	1	O
collagen	0	B
to	0	O
cyanogen	0	O
bromide	0	O
and	0	O
mammalian	0	B
collagenase	0	I
digestion	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
gene	0	O
also	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
multiple	0	O
TATA	0	O
and	0	O
CAAT	0	O
sequences	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
on	0	O
the	0	O
Cohler	0	O
'	0	O
s	0	O
maternal	0	O
scale	0	O
,	0	O
Korean	0	O
mothers	0	O
were	0	O
found	0	O
to	0	O
view	0	O
their	0	O
infants	0	O
as	0	O
more	0	O
passive	0	O
and	0	O
dependent	0	O
than	0	O
American	0	O
mothers	0	O
did	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
00	0	O
).	0	O


Thromboxane	1	O
B2	0	O
increased	0	O
(	0	O
97	0	O
+/-	0	O
105	0	O
versus	0	O
40	0	O
+/-	0	O
26	0	O
pg	0	O
/	0	O
ml	0	O
)	0	O
and	0	O
was	0	O
significantly	0	O
higher	0	O
during	0	O
heparin	0	O
free	0	O
hemodialysis	0	O
than	0	O
during	0	O
hemodialysis	0	O
with	0	O
heparin	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
01	0	O
,	0	O
Wilcoxon	0	O
matched	0	O
pairs	0	O
signed	0	O
rank	0	O
test	0	O
).	0	O


Long	0	O
-	0	O
range	0	O
mapping	0	O
of	0	O
the	0	O
11q23	0	O
region	0	O
involved	0	O
in	0	O
chromosome	0	O
aberrations	0	O
in	0	O
human	0	O
tumors	0	O
by	0	O
pulsed	0	O
-	0	O
field	0	O
gel	0	O
electrophoresis	0	O
with	0	O
a	0	O
yeast	0	O
artificial	0	O
chromosome	0	O
.	0	O


Further	0	O
,	0	O
mutational	0	O
analysis	0	O
of	0	O
NS5A	0	B
assigned	0	O
the	0	O
SH3	0	B
-	0	I
binding	0	I
region	0	I
to	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
motif	0	O
that	0	O
is	0	O
highly	0	O
conserved	0	O
among	0	O
HCV	1	O
genotypes	0	O
.	0	O


However	0	O
,	0	O
when	0	O
,	0	O
where	0	O
and	0	O
how	0	O
the	0	O
DSPP	0	B
is	0	O
cleaved	0	O
into	0	O
DSP	0	B
and	0	O
DPP	0	B
is	0	O
not	0	O
clear	0	O
.	0	O


A	1	O
role	0	O
for	0	O
RalGDS	0	B
and	0	O
a	0	O
novel	0	O
Ras	1	B
effector	0	O
in	0	O
the	0	O
Ras	1	B
-	0	O
mediated	0	O
inhibition	0	O
of	0	O
skeletal	0	O
myogenesis	0	O
.	0	O


Furthermore	0	O
,	0	O
this	0	O
element	0	O
confers	0	O
p53	0	B
induction	0	O
to	0	O
the	0	O
otherwise	0	O
nonresponsive	0	O
adenovirus	0	O
major	0	O
late	0	O
promoter	0	O
.	0	O


Two	0	O
activities	0	O
of	0	O
the	0	O
D	1	B
protein	0	I
of	0	O
the	0	O
miniF	0	O
plasmid	0	O
have	0	O
been	0	O
found	0	O
.	0	O


The	0	O
collection	0	O
of	0	O
mutants	0	O
displaying	0	O
TGN	1	O
sorting	0	O
defects	0	O
includes	0	O
members	0	O
with	0	O
mutations	0	O
in	0	O
previously	0	O
identified	0	O
vacuolar	0	B
protein	0	I
sorting	0	I
genes	0	I
(	0	O
VPS	0	B
),	0	O
including	0	O
the	0	O
dynamin	0	B
family	0	O
member	0	O
VPS1	0	B
.	0	O


Upon	0	O
analysis	0	O
of	0	O
various	0	O
deletion	0	O
and	0	O
point	0	O
-	0	O
mutated	0	O
variants	0	O
of	0	O
the	0	O
human	0	B
IL	1	I
-	0	I
6	0	I
gene	0	I
promoter	0	I
coupled	0	O
to	0	O
a	0	O
reporter	0	O
gene	0	O
,	0	O
we	0	O
screened	0	O
for	0	O
possible	0	O
cooperating	0	O
transcription	0	O
factors	0	O
.	0	O


In	1	O
vitro	0	O
transcription	0	O
results	0	O
indicate	0	O
that	0	O
this	0	O
5	0	O
'	0	O
structure	0	O
functions	0	O
in	0	O
the	0	O
attenuation	0	O
mechanism	0	O
,	0	O
since	0	O
deletion	0	O
of	0	O
the	0	O
stem	0	O
-	0	O
loop	0	O
caused	0	O
an	0	O
increase	0	O
in	0	O
transcription	0	O
readthrough	0	O
.	0	O


Expansins	0	B
are	0	O
a	0	O
family	0	O
of	0	O
proteins	0	O
that	0	O
catalyse	0	O
long	0	O
-	0	O
term	0	O
extension	0	O
of	0	O
isolated	0	O
plant	0	O
cell	0	O
walls	0	O
due	0	O
to	0	O
an	0	O
as	0	O
yet	0	O
unknown	0	O
biochemical	0	O
mechanism	0	O
.	0	O


Marked	0	O
elevation	0	O
of	0	O
creatine	0	B
kinase	0	I
was	0	O
observed	0	O
while	0	O
serum	0	O
albumin	0	B
,	0	O
immunoglobulin	0	B
,	0	O
and	0	O
complement	0	O
were	0	O
decreased	0	O
.	0	O


The	0	O
Aie1	0	B
locus	0	I
was	0	O
mapped	0	O
to	0	O
mouse	0	O
chromosome	0	O
7A2	0	O
-	0	O
A3	0	O
by	0	O
fluorescent	0	O
in	0	O
situ	0	O
hybridization	0	O
.	0	O


Furthermore	0	O
,	0	O
a	0	O
pTyr317	0	B
Shc	0	I
phosphopeptide	0	I
selectively	0	O
recognized	0	O
Grb2	0	B
,	0	O
Sos1	0	B
,	0	O
SHIP	0	B
,	0	O
and	0	O
the	0	O
p85	0	B
subunit	0	I
of	0	O
phosphatidylinositol	0	B
3	0	I
'	0	I
kinase	0	I
from	0	O
mast	0	O
cells	0	O
,	0	O
as	0	O
characterized	0	O
by	0	O
mass	0	O
spectrometry	0	O
.	0	O


A	1	O
transparent	0	O
overlay	0	O
for	0	O
assessing	0	O
amplitude	0	O
of	0	O
ECG	1	O
wave	0	O
forms	0	O
.	0	O


Previous	0	O
studies	0	O
have	0	O
suggested	0	O
that	0	O
the	0	O
616	0	O
amino	0	O
acid	0	O
,	0	O
70	0	B
-	0	I
kDa	1	I
subunit	0	I
of	0	I
RPA	0	I
(	0	O
RPA	0	B
70	0	I
)	0	O
is	0	O
composed	0	O
of	0	O
multiple	0	O
structural	0	O
/	0	O
functional	0	O
domains	0	O
.	0	O


The	0	O
gene	0	O
for	0	O
the	0	O
RNA	1	B
-	0	I
dependent	0	I
eIF	0	I
-	0	I
2	0	I
alpha	0	I
protein	0	I
kinase	0	I
(	0	O
PKR	0	B
)	0	O
was	0	O
isolated	0	O
from	0	O
mouse	0	O
genomic	0	O
DNA	1	O
and	0	O
characterized	0	O
.	0	O


Northern	0	O
blot	0	O
analysis	0	O
demonstrated	0	O
the	0	O
ubiquitous	0	O
expression	0	O
of	0	O
2	0	O
.	0	O
9	0	O
kb	0	O
and	0	O
3	0	O
.	0	O


The	0	O
levels	0	O
of	0	O
NSE	0	B
and	0	O
MBP	1	B
in	0	O
the	0	O
IJVB	0	O
were	0	O
compared	0	O
to	0	O
those	0	O
in	0	O
the	0	O
PVB	1	O
.	0	O


However	0	O
,	0	O
artificially	0	O
ventilated	0	O
rats	0	O
,	0	O
pretreated	0	O
with	0	O
MK	1	O
-	0	O
801	0	O
,	0	O
were	0	O
more	0	O
sensitive	0	O
(	0	O
lethal	0	O
cocaine	0	O
dose	0	O
,	0	O
76	0	O
.	0	O
6	0	O
+/-	0	O
8	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
,	0	O
n	0	O
=	0	O
5	0	O
)	0	O
than	0	O
vehicle	0	O
pretreated	0	O
rats	0	O
(	0	O
129	0	O
.	0	O
4	0	O
+/-	0	O
15	0	O
.	0	O
8	0	O
mg	0	O
/	0	O
kg	0	O
,	0	O
n	0	O
=	0	O
6	0	O
),	0	O
indicating	0	O
that	0	O
MK	1	O
-	0	O
801	0	O
may	0	O
increase	0	O
both	0	O
the	0	O
respiratory	0	O
and	0	O
the	0	O
cardiac	0	O
toxicity	0	O
of	0	O
cocaine	0	O
in	0	O
urethane	0	O
anesthetized	0	O
rats	0	O
.	0	O


Among	0	O
100	0	O
cases	0	O
of	0	O
post	0	O
-	0	O
transfusion	0	O
hepatitis	0	O
,	0	O
10	0	O
are	0	O
due	0	O
to	0	O
the	0	O
hepatitis	0	O
B	1	O
virus	0	O
(	0	O
despite	0	O
systematic	0	O
search	0	O
for	0	O
HBs	1	B
Ag	1	I
),	0	O
89	0	O
are	0	O
due	0	O
to	0	O
one	0	O
of	0	O
the	0	O
non	0	O
-	0	O
A	1	O
non	0	O
-	0	O
B	1	O
viruses	0	O
(	0	O
not	0	O
detectable	0	O
by	0	O
specific	0	O
serological	0	O
tests	0	O
)	0	O
and	0	O
1	0	O
to	0	O
several	0	O
viruses	0	O
,	0	O
specially	0	O
CMV	1	O
.	0	O


Our	0	O
data	0	O
demonstrate	0	O
directly	0	O
that	0	O
Rpm1r	0	B
is	0	O
transcribed	0	O
with	0	O
its	0	O
substrates	0	O
,	0	O
tRNA	1	B
met	0	I
f	0	I
and	0	O
tRNAPro	0	B
,	0	O
from	0	O
a	0	O
promoter	0	O
located	0	O
upstream	0	O
of	0	O
the	0	O
tRNA	1	B
met	0	I
f	0	I
gene	0	I
and	0	O
suggest	0	O
that	0	O
a	0	O
portion	0	O
also	0	O
originates	0	O
from	0	O
a	0	O
second	0	O
promoter	0	O
,	0	O
located	0	O
between	0	O
the	0	O
tRNA	1	B
met	0	I
f	0	I
gene	0	I
and	0	O
RPM1	0	B
.	0	O


19	0	O
-	0	O
32	0	O
.	0	O


Cerebral	1	O
flow	0	O
and	0	O
resistance	0	O
showed	0	O
minor	0	O
reductions	0	O
with	0	O
HD	1	O
.	0	O


Amiodarone	1	O
,	0	O
seldom	0	O
used	0	O
as	0	O
first	0	O
-	0	O
line	0	O
treatment	0	O
,	0	O
appears	0	O
to	0	O
be	0	O
the	0	O
most	0	O
effective	0	O
drug	0	O
.	0	O


Radiation	1	O
therapy	0	O
was	0	O
effective	0	O
in	0	O
controlling	0	O
symptomatic	0	O
metastasis	0	O
in	0	O
all	0	O
three	0	O
patients	0	O
.	0	O


Use	0	O
of	0	O
serum	0	O
thyroglobulin	0	B
determination	0	O
in	0	O
the	0	O
follow	0	O
-	0	O
up	0	O
of	0	O
differentiated	0	O
carcinomas	0	O
of	0	O
the	0	O
thyroid	0	O


Cosmid	1	O
clones	0	O
containing	0	O
both	0	O
VNTR	1	O
sequences	0	O
were	0	O
identified	0	O
,	0	O
and	0	O
restriction	0	O
mapping	0	O
showed	0	O
them	0	O
to	0	O
be	0	O
less	0	O
than	0	O
15	0	O
kb	0	O
apart	0	O
.	0	O


Cryopreservation	1	O
straws	0	O
filled	0	O
with	0	O
media	0	O
plus	0	O
additive	0	O
are	0	O
emersed	0	O
below	0	O
the	0	O
surface	0	O
of	0	O
an	0	O
unprocessed	0	O
donor	0	O
ejaculate	0	O
.	0	O


25	0	O
-	0	O
OH	0	O
-	0	O
D3	0	O
did	0	O
not	0	O
adversely	0	O
affect	0	O
animal	0	O
health	0	O
at	0	O
the	0	O
proposed	0	O
use	0	O
level	0	O
of	0	O
99	0	O
micrograms	0	O
/	0	O
kg	0	O
feed	0	O
when	0	O
replacing	0	O
vitamin	0	O
D3	0	O
in	0	O
turkey	0	O
rations	0	O
.	0	O


Myocardial	0	O
SPET	0	O
imaging	0	O
with	0	O
99Tcm	0	O
-	0	O
tetrofosmin	0	O
in	0	O
clinical	0	O
practice	0	O
:	0	O
comparison	0	O
of	0	O
a	0	O
1	0	O
day	0	O
and	0	O
a	0	O
2	0	O
day	0	O
imaging	0	O
protocol	0	O
.	0	O


Disruption	1	O
of	0	O
any	0	O
one	0	O
of	0	O
the	0	O
four	0	O
genes	0	O
encoding	0	O
the	0	O
newly	0	O
identified	0	O
SRP	0	B
proteins	0	I
results	0	O
in	0	O
slow	0	O
cell	0	O
growth	0	O
and	0	O
inefficient	0	O
protein	0	O
translocation	0	O
across	0	O
the	0	O
ER	1	O
membrane	0	O
.	0	O


This	0	O
indicates	0	O
that	0	O
the	0	O
mechanism	0	O
by	0	O
which	0	O
CX	1	O
blocks	0	O
rapid	0	O
degradation	0	O
of	0	O
tubulin	0	B
mRNA	1	I
in	0	O
vivo	0	O
is	0	O
not	0	O
simply	0	O
by	0	O
preventing	0	O
its	0	O
translation	0	O
and	0	O
suggests	0	O
the	0	O
involvement	0	O
of	0	O
an	0	O
altered	0	O
trans	0	O
-	0	O
factor	0	O
.	0	O


Amino	1	O
acid	0	O
sequence	0	O
of	0	O
one	0	O
human	0	O
liver	0	O
clone	0	O
(	0	O
HL	1	O
-	0	O
14	0	O
)	0	O
was	0	O
identical	0	O
to	0	O
the	0	O
rabbit	0	B
skeletal	0	I
muscle	0	I
phosphatase	0	I
2A	0	I
cDNA	1	I
(	0	O
with	0	O
97	0	O
%	0	O
nucleotide	0	O
identity	0	O
).	0	O


The	0	O
final	0	O
predicted	0	O
structure	0	O
has	0	O
an	0	O
overall	0	O
backbone	0	O
deviation	0	O
of	0	O
0	0	O
.	0	O
7	0	O
A	1	O
from	0	O
that	0	O
of	0	O
ras	0	B
-	0	O
p21	0	B
.	0	O


Using	0	O
Southern	0	O
blot	0	O
analysis	0	O
and	0	O
restriction	0	O
mapping	0	O
of	0	O
genomic	0	O
YAC	1	O
(	0	O
yeast	0	O
artificial	0	O
chromosome	0	O
)	0	O
and	0	O
cosmid	0	O
clones	0	O
,	0	O
we	0	O
located	0	O
the	0	O
human	0	B
RIL	0	I
gene	0	I
240	0	O
-	0	O
260	0	O
kb	0	O
telomeric	0	O
to	0	O
the	0	O
IRF1	0	B
gene	0	I
and	0	O
characterized	0	O
its	0	O
genomic	0	O
structure	0	O
.	0	O


Identification	1	O
of	0	O
p40x	0	O
-	0	O
responsive	0	O
regulatory	0	O
sequences	0	O
within	0	O
the	0	O
human	0	O
T	1	O
-	0	O
cell	0	O
leukemia	0	O
virus	0	O
type	0	O
I	1	O
long	0	O
terminal	0	O
repeat	0	O
.	0	O


Competition	1	O
experiments	0	O
demonstrate	0	O
a	0	O
negative	0	O
allosteric	0	O
relationship	0	O
between	0	O
these	0	O
RGD	0	O
recognition	0	O
sites	0	O
.	0	O


The	0	O
intron	0	O
8	0	O
enhancer	0	O
region	0	O
was	0	O
not	0	O
activated	0	O
by	0	O
GATA	0	B
-	0	I
1	0	I
together	0	O
with	0	O
Sp1	0	B
in	0	O
transactivation	0	O
experiments	0	O
in	0	O
COS	1	O
-	0	O
1	0	O
cells	0	O
indicating	0	O
the	0	O
involvement	0	O
of	0	O
a	0	O
related	0	O
Sp1	0	B
protein	0	I
or	0	O
of	0	O
another	0	O
unidentified	0	O
erythroid	0	O
factor	0	O
.	0	O


However	0	O
,	0	O
five	0	O
new	0	O
mutation	0	O
sites	0	O
(	0	O
S61	0	B
,	0	O
SL1	0	B
,	0	O
S29	0	B
,	0	O
SL11	0	B
,	0	O
SL196	0	B
and	0	O
SL126	0	B
)	0	O
are	0	O
unique	0	O
to	0	O
the	0	O
nrdB	0	B
intron	0	O
and	0	O
disrupt	0	O
self	0	O
-	0	O
splicing	0	O
.	0	O


Discrepant	0	O
results	0	O
with	0	O
a	0	O
latex	0	O
agglutination	0	O
test	0	O
in	0	O
the	0	O
assessment	0	O
of	0	O
cytomegalovirus	0	O
antibody	0	O
status	0	O
of	0	O
cardiac	0	O
transplant	0	O
donors	0	O
.	0	O


Using	0	O
a	0	O
previously	0	O
published	0	O
two	0	O
-	0	O
frequency	0	O
(	0	O
AC	1	O
excitation	0	O
)	0	O
three	0	O
-	0	O
electrode	0	O
method	0	O
,	0	O
the	0	O
admittance	0	O
locus	0	O
plot	0	O
(	0	O
ALP	1	O
)	0	O
in	0	O
the	0	O
low	0	O
-	0	O
frequency	0	O
region	0	O
(<	0	O
1000	0	O
Hz	1	O
)	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
very	0	O
well	0	O
approximated	0	O
by	0	O
a	0	O
straight	0	O
line	0	O
and	0	O
can	0	O
be	0	O
described	0	O
with	0	O
frequency	0	O
-	0	O
independent	0	O
parameters	0	O
;	0	O
phase	0	O
angle	0	O
alpha	0	O
pi	0	O
/	0	O
2	0	O
,	0	O
conductance	0	O
at	0	O
extrapolated	0	O
zero	0	O
frequency	0	O
G0	0	O
=	0	O
1	0	O
/	0	O
R0	1	O
,	0	O
and	0	O
ion	0	O
relaxation	0	O
time	0	O
tau	0	O
.	0	O


In	1	O
MCCP	0	O
functions	0	O
of	0	O
the	0	O
source	0	O
emission	0	O
,	0	O
surface	0	O
reflection	0	O
,	0	O
photoacceptor	0	O
sensitivity	0	O
are	0	O
approximated	0	O
by	0	O
the	0	O
normal	0	O
distribution	0	O
curves	0	O
.	0	O


Steroidogenic	1	B
factor	0	I
1	0	I
,	0	O
an	0	O
orphan	0	B
nuclear	0	I
receptor	0	I
,	0	O
regulates	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
rat	0	B
aromatase	0	I
gene	0	I
in	0	O
gonadal	0	O
tissues	0	O
.	0	O


Transient	1	O
expression	0	O
of	0	O
VSF	0	B
-	0	I
1	0	I
in	0	O
protoplasts	0	O
stimulated	0	O
vs	0	B
-	0	I
1	0	I
dependent	0	O
activation	0	O
of	0	O
the	0	O
-	0	B
76	0	I
/	0	I
grp1	0	I
.	0	I
8	0	I
minimal	0	I
promoter	0	I
.	0	O


No	1	O
homology	0	O
was	0	O
found	0	O
between	0	O
RNA14	0	B
and	0	O
RNA15	0	B
or	0	O
between	0	O
RNA14	0	B
and	0	O
other	0	O
proteins	0	O
contained	0	O
in	0	O
data	0	O
banks	0	O
.	0	O


Cardiac	1	O
preservation	0	O
.	0	O


SAECG	0	O
,	0	O
echocardiography	0	O
and	0	O
thallium	0	O
-	0	O
201	0	O
imaging	0	O
were	0	O
performed	0	O
before	0	O
and	0	O
1	0	O
month	0	O
after	0	O
attempted	0	O
angioplasty	0	O
.	0	O


Multiple	1	O
single	0	O
-	0	O
stranded	0	O
cis	0	O
elements	0	O
are	0	O
associated	0	O
with	0	O
activated	0	O
chromatin	0	O
of	0	O
the	0	O
human	0	B
c	0	I
-	0	I
myc	0	I
gene	0	I
in	0	O
vivo	0	O
.	0	O


A	1	O
further	0	O
subdivision	0	O
of	0	O
Category	0	O
pN1	0	O
into	0	O
pN1a	0	O
(	0	O
metastasis	0	O
in	0	O
single	0	O
node	0	O
)	0	O
and	0	O
pN1b	0	O
(	0	O
two	0	O
or	0	O
more	0	O
nodes	0	O
)	0	O
is	0	O
recommended	0	O
.	0	O


Mechanisms	0	O
of	0	O
tachyphylaxis	0	O
in	0	O
regional	0	O
anesthesia	0	O
of	0	O
long	0	O
duration	0	O


In	1	O
the	0	O
first	0	O
group	0	O
,	0	O
0	0	O
.	0	O
02	0	O
%	0	O
Prazosin	0	O
(	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
was	0	O
administered	0	O
intravenously	0	O
for	0	O
1	0	O
.	0	O
5	0	O
hours	0	O
before	0	O
the	0	O
application	0	O
of	0	O
Oxy	0	O
-	0	O
Hb	1	O
or	0	O
PGF2	0	O
alpha	0	O
.	0	O


The	0	O
DRF	0	B
-	0	I
2	0	I
nuclear	0	I
protein	0	I
has	0	O
characteristics	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
the	0	O
muscle	0	O
-	0	O
specific	0	O
regulatory	0	O
factor	0	O
,	0	O
MEF	0	B
-	0	I
2	0	I
(	0	O
Buskin	0	O
and	0	O
Hauschka	0	O
1989	0	O
;	0	O
Gossett	0	O
et	0	O
al	0	O
.,	0	O
1989	0	O
).	0	O


Videonystagmoscopy	0	O
has	0	O
been	0	O
used	0	O
to	0	O
subjectively	0	O
observe	0	O
the	0	O
responses	0	O
of	0	O
the	0	O
vestibular	0	O
system	0	O
in	0	O
a	0	O
population	0	O
of	0	O
patients	0	O
with	0	O
vestibular	0	O
deficits	0	O
.	0	O


They	0	O
also	0	O
discuss	0	O
the	0	O
existing	0	O
nomenclature	0	O
.	0	O


Tyrosine	1	O
phosphorylation	0	O
of	0	O
cellular	0	O
proteins	0	O
is	0	O
the	0	O
earliest	0	O
identifiable	0	O
event	0	O
following	0	O
T	1	B
-	0	I
cell	0	I
antigen	0	I
receptor	0	I
(	0	O
TCR	1	B
)	0	O
stimulation	0	O
and	0	O
is	0	O
essential	0	O
for	0	O
activating	0	O
downstream	0	O
signaling	0	O
machinery	0	O
.	0	O


Fibrinogen	1	B
determination	0	O
using	0	O
the	0	O
KZM	0	O
-	0	O
1	0	O
meter	0	O


Tristetraprolin	0	B
(	0	O
TTP	0	B
)	0	O
is	0	O
the	0	O
prototype	0	O
of	0	O
a	0	O
group	0	O
of	0	O
potential	0	O
transcription	0	O
factors	0	O
that	0	O
contain	0	O
two	0	O
or	0	O
more	0	O
unusual	0	O
CCCH	0	O
zinc	0	O
fingers	0	O
.	0	O


The	0	O
adenovirus	0	B
E1A	0	I
gene	0	I
encodes	0	O
a	0	O
protein	0	O
that	0	O
transcriptionally	0	O
activates	0	O
viral	0	B
early	0	I
genes	0	I
.	0	O


Atrial	1	O
fibrillation	0	O
and	0	O
the	0	O
autonomic	0	O
nervous	0	O
system	0	O


Among	0	O
non	0	O
-	0	O
cirrhotics	0	O
,	0	O
lack	0	O
of	0	O
portal	0	O
vein	0	O
visualisation	0	O
had	0	O
a	0	O
90	0	O
%	0	O
sensitivity	0	O
,	0	O
88	0	O
%	0	O
specificity	0	O
,	0	O
94	0	O
%	0	O
negative	0	O
predictive	0	O
value	0	O
,	0	O
and	0	O
83	0	O
%	0	O
positive	0	O
predictive	0	O
value	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
pre	0	O
-	0	O
sinusoidal	0	O
portal	0	O
hypertension	0	O
.	0	O


Oligonucleotide	1	O
mutagenesis	0	O
of	0	O
these	0	O
binding	0	O
domains	0	O
indicated	0	O
their	0	O
importance	0	O
in	0	O
the	0	O
transcriptional	0	O
regulation	0	O
of	0	O
the	0	O
E3	1	B
promoter	0	I
in	0	O
yeast	0	O
cells	0	O
.	0	O


A	1	O
range	0	O
of	0	O
normal	0	O
ventricular	0	O
measurements	0	O
for	0	O
the	0	O
EMI	0	O
scan	0	O
is	0	O
suggested	0	O
.	0	O


The	0	O
role	0	O
of	0	O
transport	0	O
by	0	O
sea	0	O
ice	0	O
from	0	O
the	0	O
Kara	0	O
Sea	1	O
into	0	O
the	0	O
Arctic	0	O
Ocean	0	O
was	0	O
assessed	0	O
by	0	O
a	0	O
small	0	O
subgroup	0	O
at	0	O
GEOMAR	0	O
.	0	O


Control	1	O
examination	0	O
was	0	O
performed	0	O
at	0	O
the	0	O
end	0	O
of	0	O
each	0	O
period	0	O
.	0	O


Secondly	0	O
,	0	O
an	0	O
ethanol	0	O
repression	0	O
autoregulation	0	O
(	0	O
ERA	0	O
)/	0	O
twelve	0	O
-	0	O
fold	0	O
TA	1	O
repeat	0	O
(	0	O
TAB	0	O
)	0	O
repressor	0	O
element	0	O
was	0	O
identified	0	O
within	0	O
the	0	O
promoter	0	O
region	0	O
of	0	O
the	0	O
GLK1	0	B
gene	0	I
.	0	O


Calcitriol	1	O
therapy	0	O
was	0	O
associated	0	O
with	0	O
a	0	O
decrease	0	O
in	0	O
serum	0	O
iPTH	0	B
levels	0	O
(	0	O
701	0	O
+/-	0	O
103	0	O
.	0	O
9	0	O
vs	0	O
.	0	O


In	1	O
the	0	O
former	0	O
instance	0	O
,	0	O
in	0	O
addition	0	O
to	0	O
serum	0	O
calcium	0	O
and	0	O
phosphorous	0	O
ion	0	O
concentrations	0	O
,	0	O
tissue	0	O
pH	1	O
,	0	O
blood	0	O
supply	0	O
,	0	O
hormones	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
vitamin	0	O
D	1	O
,	0	O
vitamin	0	O
A	1	O
,	0	O
and	0	O
various	0	O
enzymes	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
alkaline	0	B
phosphatase	0	I
and	0	O
pyrophosphatase	0	B
)	0	O
may	0	O
all	0	O
play	0	O
significant	0	O
,	0	O
ancillary	0	O
,	0	O
time	0	O
-	0	O
dependent	0	O
,	0	O
but	0	O
as	0	O
yet	0	O
undetermined	0	O
roles	0	O
.	0	O


Intron	1	O
1	0	O
is	0	O
6	0	O
.	0	O
5	0	O
kb	0	O
long	0	O
,	0	O
and	0	O
the	0	O
minimal	0	O
sizes	0	O
of	0	O
introns	0	O
2	0	O
and	0	O
3	0	O
are	0	O
estimated	0	O
to	0	O
be	0	O
32	0	O
kb	0	O
each	0	O
.	0	O


Thus	0	O
,	0	O
we	0	O
have	0	O
separated	0	O
the	0	O
signal	0	O
function	0	O
from	0	O
the	0	O
anchor	0	O
function	0	O
of	0	O
the	0	O
6	0	O
.	0	O
7K	0	O
SA	1	O
domain	0	O
.	0	O


Lysosomal	1	O
enzymes	0	O
that	0	O
degrade	0	O
cartilage	0	O
are	0	O
released	0	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
binding	0	O
of	0	O
CBF	1	B
/	0	O
NF	1	B
-	0	I
Y	1	I
to	0	O
the	0	O
inverted	0	O
CCAAT	0	O
box	0	O
is	0	O
responsible	0	O
for	0	O
transcriptional	0	O
activation	0	O
of	0	O
the	0	O
nTPH	0	B
gene	0	I
.	0	O


Three	0	O
experiments	0	O
contrasted	0	O
the	0	O
effects	0	O
of	0	O
6	0	O
-	0	O
hydroxydopamine	0	O
-	0	O
induced	0	O
lesions	0	O
of	0	O
the	0	O
ventral	0	O
noradrenergic	0	O
and	0	O
dorsal	0	O
noradrenergic	0	O
projections	0	O
,	0	O
predominantly	0	O
to	0	O
hypothalamus	0	O
and	0	O
cortex	0	O
,	0	O
respectively	0	O
,	0	O
upon	0	O
body	0	O
weight	0	O
changes	0	O
and	0	O
food	0	O
-	0	O
related	0	O
behaviour	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


A	1	O
mouse	0	B
brain	0	I
beta	0	I
-	0	I
spectrin	0	I
of	0	O
cDNA	1	O
was	0	O
identified	0	O
within	0	O
a	0	O
lambda	0	O
Gt11	0	O
expression	0	O
library	0	O
using	0	O
an	0	O
antibody	0	O
which	0	O
specifically	0	O
binds	0	O
with	0	O
the	0	O
235	0	B
kDa	1	I
spectrin	0	I
beta	0	I
-	0	I
subunit	0	I
.	0	O


This	0	O
is	0	O
consistent	0	O
with	0	O
a	0	O
model	0	O
proposing	0	O
that	0	O
SSV	0	O
was	0	O
generated	0	O
by	0	O
recombination	0	O
between	0	O
proviral	0	O
DNA	1	O
of	0	O
a	0	O
simian	0	O
sarcoma	0	O
associated	0	O
virus	0	O
and	0	O
proto	0	B
-	0	I
sis	0	I
and	0	O
that	0	O
introns	0	O
were	0	O
spliced	0	O
out	0	O
subsequently	0	O
from	0	O
a	0	O
fused	0	O
viral	0	B
-	0	I
sis	0	I
messenger	0	I
RNA	1	I
.	0	O


This	0	O
is	0	O
in	0	O
contrast	0	O
to	0	O
PPARgamma2	0	B
,	0	O
which	0	O
was	0	O
previously	0	O
shown	0	O
to	0	O
be	0	O
phosphorylated	0	O
at	0	O
a	0	O
single	0	O
site	0	O
in	0	O
a	0	O
motif	0	O
that	0	O
is	0	O
not	0	O
homologous	0	O
to	0	O
the	0	O
sites	0	O
now	0	O
described	0	O
in	0	O
PPARalpha	0	B
.	0	O


Consistent	0	O
with	0	O
ErbB	0	B
-	0	I
2	0	I
being	0	O
a	0	O
shared	0	O
receptor	0	O
subunit	0	O
,	0	O
its	0	O
tyrosine	0	O
phosphorylation	0	O
was	0	O
increased	0	O
by	0	O
both	0	O
heterologous	0	O
ligands	0	O
and	0	O
it	0	O
mediated	0	O
a	0	O
trans	0	O
-	0	O
inhibitory	0	O
effect	0	O
of	0	O
NDF	0	B
on	0	O
EGF	1	B
binding	0	O
.	0	O


In	1	O
some	0	O
cases	0	O
,	0	O
factor	0	O
-	0	O
induced	0	O
Rac	0	B
activation	0	O
results	0	O
in	0	O
Rho	1	B
activation	0	O
,	0	O
and	0	O
factor	0	O
-	0	O
induced	0	O
Cdc42	0	B
activation	0	O
leads	0	O
to	0	O
Rac	0	B
activation	0	O
,	0	O
as	0	O
determined	0	O
by	0	O
specific	0	O
morphological	0	O
changes	0	O
.	0	O


During	0	O
treatment	0	O
,	0	O
the	0	O
phosphorylation	0	O
state	0	O
of	0	O
Rb	1	B
shifted	0	O
to	0	O
a	0	O
hypophosphorylated	0	O
form	0	O
.	0	O
mRNA	1	O
for	0	O
the	0	O
HPV	1	O
E6	0	B
/	0	O
E7	0	B
genes	0	O
decreased	0	O
;	0	O
however	0	O
,	0	O
significant	0	O
changes	0	O
in	0	O
the	0	O
E7	0	B
protein	0	I
were	0	O
not	0	O
observed	0	O
,	0	O
while	0	O
increased	0	O
levels	0	O
of	0	O
Rb	1	B
immunoprecipitated	0	O
with	0	O
anti	0	B
-	0	I
E7	0	I
antibodies	0	I
were	0	O
observed	0	O
.	0	O


A	1	O
consensus	0	O
sequence	0	O
indicates	0	O
a	0	O
highly	0	O
conserved	0	O
lysine	0	O
residue	0	O
,	0	O
K120	0	O
of	0	O
endonuclease	0	B
III	0	I
or	0	O
K241	0	O
of	0	O
Ogg1	0	B
,	0	O
respectively	0	O
.	0	O


A	1	O
bovine	0	O
abomasum	0	O
lambda	0	O
gt11	0	O
cDNA	1	O
library	0	O
was	0	O
screened	0	O
with	0	O
a	0	O
monoclonal	0	O
antibody	0	O
raised	0	O
against	0	O
the	0	O
rabbit	0	B
H	1	I
,	0	I
K	1	I
-	0	I
ATPase	1	I
beta	0	I
subunit	0	I
.	0	O


Integrin	1	B
adhesion	0	I
receptors	0	I
transduce	0	O
signals	0	O
that	0	O
control	0	O
complex	0	O
cell	0	O
functions	0	O
which	0	O
require	0	O
the	0	O
regulation	0	O
of	0	O
gene	0	O
expression	0	O
,	0	O
such	0	O
as	0	O
proliferation	0	O
,	0	O
differentiation	0	O
and	0	O
survival	0	O
.	0	O


Cyclin	1	B
A	1	I
expression	0	O
is	0	O
repressed	0	O
in	0	O
quiescent	0	O
cells	0	O
by	0	O
E2F	0	B
acting	0	O
in	0	O
conjunction	0	O
with	0	O
its	0	O
pocket	0	O
protein	0	O
partners	0	O
Rb	1	B
,	0	O
p107	0	B
,	0	O
and	0	O
p130	0	B
;	0	O
however	0	O
,	0	O
v	0	B
-	0	I
Jun	1	I
overrides	0	O
this	0	O
control	0	O
,	0	O
causing	0	O
phosphorylated	0	O
Rb	1	B
and	0	O
proliferation	0	O
-	0	O
specific	0	O
E2F	0	B
-	0	O
p107	0	B
complexes	0	O
to	0	O
persist	0	O
after	0	O
mitogen	0	O
withdrawal	0	O
.	0	O


Adrenergic	1	O
system	0	O
activation	0	O
,	0	O
indicated	0	O
by	0	O
metanephrine	0	O
/	0	O
epinephrine	0	O
ratio	0	O
,	0	O
increased	0	O
with	0	O
time	0	O
in	0	O
losing	0	O
males	0	O
,	0	O
except	0	O
that	0	O
after	0	O
one	0	O
month	0	O
of	0	O
cohabitation	0	O
,	0	O
turnover	0	O
returned	0	O
to	0	O
levels	0	O
that	0	O
equaled	0	O
those	0	O
of	0	O
control	0	O
animals	0	O
.	0	O


Genomic	1	O
and	0	O
functional	0	O
characterization	0	O
of	0	O
the	0	O
oas	0	B
gene	0	I
family	0	I
encoding	0	O
O	1	B
-	0	I
acetylserine	0	I
(	0	I
thiol	0	I
)	0	I
lyases	0	I
,	0	O
enzymes	0	O
catalyzing	0	O
the	0	O
final	0	O
step	0	O
in	0	O
cysteine	0	O
biosynthesis	0	O
in	0	O
Arabidopsis	0	O
thaliana	0	O
.	0	O


Jkappa	0	B
DNA	1	I
-	0	I
binding	0	I
sites	0	I
were	0	O
not	0	O
required	0	O
for	0	O
this	0	O
activation	0	O
,	0	O
and	0	O
a	0	O
mutant	0	B
EBNA	0	I
-	0	I
3C	0	I
protein	0	I
unable	0	O
to	0	O
bind	0	O
Jkappa	0	B
activated	0	O
transcription	0	O
as	0	O
efficiently	0	O
as	0	O
wild	0	B
-	0	I
type	0	I
EBNA	0	I
-	0	I
3C	0	I
,	0	O
indicating	0	O
that	0	O
EBNA	0	B
-	0	I
3C	0	I
can	0	O
regulate	0	O
transcription	0	O
through	0	O
a	0	O
mechanism	0	O
that	0	O
is	0	O
independent	0	O
of	0	O
Jkappa	0	B
.	0	O


We	0	O
previously	0	O
showed	0	O
that	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
portion	0	O
common	0	O
to	0	O
various	0	O
chimeric	0	B
MLL	1	I
products	0	I
,	0	O
as	0	O
well	0	O
as	0	O
to	0	O
MLL	1	B
-	0	I
LTG9	0	I
and	0	O
MLL	1	B
-	0	I
LTG19	0	I
,	0	O
localizes	0	O
in	0	O
the	0	O
nuclei	0	O
,	0	O
and	0	O
therefore	0	O
suggested	0	O
that	0	O
it	0	O
might	0	O
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
leukemogenesis	0	O
.	0	O


Lowering	1	O
of	0	O
the	0	O
renal	0	O
blood	0	O
flow	0	O
alters	0	O
the	0	O
glomerular	0	O
and	0	O
tubular	0	O
excretion	0	O
processes	0	O
.	0	O


When	0	O
data	0	O
were	0	O
expressed	0	O
in	0	O
a	0	O
cumulative	0	O
manner	0	O
,	0	O
the	0	O
response	0	O
to	0	O
intravenous	0	O
adenosine	0	O
3	0	O
mg	0	O
,	0	O
6	0	O
mg	0	O
,	0	O
9	0	O
mg	0	O
and	0	O
12	0	O
mg	0	O
in	0	O
the	0	O
24	0	O
episodes	0	O
of	0	O
PSVT	1	O
were	0	O
5	0	O
episodes	0	O
(	0	O
21	0	O
%),	0	O
16	0	O
episodes	0	O
(	0	O
67	0	O
%),	0	O
20	0	O
episodes	0	O
(	0	O
83	0	O
%)	0	O
and	0	O
20	0	O
episodes	0	O
(	0	O
83	0	O
%)	0	O
respectively	0	O
.	0	O


This	0	O
indicates	0	O
that	0	O
recruitment	0	O
of	0	O
large	0	B
T	1	I
antigen	0	I
to	0	O
the	0	O
rRNA	1	O
promoter	0	O
by	0	O
SL1	0	B
constitutes	0	O
a	0	O
crucial	0	O
step	0	O
in	0	O
the	0	O
activation	0	O
process	0	O
.	0	O


Diltiazem	1	O
caused	0	O
significant	0	O
decrease	0	O
in	0	O
the	0	O
ventricular	0	O
response	0	O
without	0	O
conversion	0	O
to	0	O
sinus	0	O
rhythm	0	O
.	0	O


Furthermore	0	O
,	0	O
synergistic	0	O
activation	0	O
of	0	O
ERK2	0	B
occurred	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
changes	0	O
in	0	O
intracellular	0	O
Ca2	1	O
+,	0	O
and	0	O
was	0	O
not	0	O
blocked	0	O
by	0	O
inhibition	0	O
of	0	O
protein	0	B
kinase	0	I
C	1	I
activity	0	O
and	0	O
represents	0	O
a	0	O
separate	0	O
pathway	0	O
by	0	O
which	0	O
CD19	0	B
regulates	0	O
B	1	O
cell	0	O
function	0	O
.	0	O


Two	0	O
sterol	0	O
regulatory	0	O
element	0	O
-	0	O
like	0	O
sequences	0	O
mediate	0	O
up	0	O
-	0	O
regulation	0	O
of	0	O
caveolin	0	B
gene	0	I
transcription	0	O
in	0	O
response	0	O
to	0	O
low	0	B
density	0	I
lipoprotein	0	I
free	0	O
cholesterol	0	O
.	0	O


To	1	O
determine	0	O
which	0	O
sequences	0	O
in	0	O
the	0	O
rat	0	B
P450c17	0	I
promoter	0	I
may	0	O
be	0	O
responsible	0	O
for	0	O
basal	0	O
and	0	O
cAMP	1	O
-	0	O
stimulated	0	O
gene	0	O
transcription	0	O
,	0	O
deletion	0	O
constructs	0	O
containing	0	O
between	0	O
-	0	O
1	0	O
,	0	O
560	0	O
and	0	O
-	0	O
53	0	O
base	0	O
pairs	0	O
of	0	O
5	0	O
'-	0	O
flanking	0	O
DNA	1	O
from	0	O
the	0	O
rat	0	B
P450c17	0	I
gene	0	I
were	0	O
ligated	0	O
to	0	O
plasmids	0	O
expressing	0	O
the	0	O
reporter	0	O
gene	0	O
luciferase	0	B
and	0	O
transfected	0	O
into	0	O
two	0	O
mouse	0	O
cell	0	O
lines	0	O
,	0	O
adrenal	0	O
Y	1	O
-	0	O
1	0	O
cells	0	O
,	0	O
and	0	O
testicular	0	O
Leydig	0	O
MA	1	O
-	0	O
10	0	O
cells	0	O
.	0	O


Despite	0	O
significant	0	O
lethality	0	O
and	0	O
cardiovascular	0	O
dysfunction	0	O
,	0	O
in	0	O
the	0	O
septic	0	O
group	0	O
on	0	O
Days	0	O
1	0	O
and	0	O
2	0	O
,	0	O
septic	0	O
versus	0	O
control	0	O
animals	0	O
had	0	O
no	0	O
significant	0	O
differences	0	O
in	0	O
mean	0	O
metabolic	0	O
cart	0	O
measured	0	O
(	0	O
Vo2DIR	0	O
,	0	O
ml	0	O
/	0	O
kg	0	O
/	0	O
min	0	O
;	0	O
Day	1	O
1	0	O
:	0	O
11	0	O
.	0	O
9	0	O
versus	0	O
12	0	O
.	0	O
4	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
81	0	O
;	0	O
Day	1	O
2	0	O
:	0	O
14	0	O
.	0	O
2	0	O
versus	0	O
13	0	O
.	0	O
5	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
72	0	O
,	0	O
respectively	0	O
)	0	O
and	0	O
intravascular	0	O
catheter	0	O
calculated	0	O
(	0	O
Vo2INDIR	0	O
,	0	O
ml	0	O
/	0	O
kg	0	O
/	0	O
min	0	O
;	0	O
Day	1	O
1	0	O
:	0	O
11	0	O
.	0	O
2	0	O
versus	0	O
11	0	O
.	0	O
2	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
99	0	O
;	0	O
Day	1	O
2	0	O
:	0	O
12	0	O
.	0	O
8	0	O
versus	0	O
15	0	O
.	0	O
4	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
49	0	O
,	0	O
respectively	0	O
).	0	O


No	1	O
homology	0	O
was	0	O
found	0	O
between	0	O
the	0	O
36K	0	O
protein	0	O
and	0	O
known	0	O
structures	0	O
of	0	O
proteins	0	O
.	0	O


In	1	O
the	0	O
intact	0	O
animal	0	O
,	0	O
postextrasystolic	0	O
potentiation	0	O
depended	0	O
on	0	O
the	0	O
basic	0	O
pacing	0	O
interval	0	O
,	0	O
t0	0	O
,	0	O
and	0	O
the	0	O
timing	0	O
of	0	O
the	0	O
extrasystole	0	O
,	0	O
t1	0	O
:	0	O
when	0	O
t0	0	O
was	0	O
held	0	O
constant	0	O
and	0	O
t1	0	O
was	0	O
increased	0	O
,	0	O
potentiation	0	O
decreased	0	O
;	0	O
when	0	O
t1	0	O
was	0	O
held	0	O
constant	0	O
and	0	O
t0	0	O
was	0	O
increased	0	O
,	0	O
potentiation	0	O
increased	0	O
.	0	O


This	0	O
phenomenon	0	O
did	0	O
not	0	O
require	0	O
DNA	1	O
binding	0	O
by	0	O
the	0	O
"	0	O
interfering	0	O
"	0	O
receptor	0	O
but	0	O
required	0	O
it	0	O
to	0	O
be	0	O
hormone	0	O
-	0	O
bound	0	O
,	0	O
indicating	0	O
that	0	O
a	0	O
transcriptionally	0	O
active	0	O
form	0	O
of	0	O
the	0	O
interfering	0	O
receptor	0	O
is	0	O
essential	0	O
for	0	O
the	0	O
interfering	0	O
effect	0	O
.	0	O


CONCLUSION	0	O
:	0	O
A	1	O
valve	0	O
-	0	O
like	0	O
mechanism	0	O
formed	0	O
by	0	O
the	0	O
capsulorhexis	0	O
rim	0	O
partially	0	O
adhered	0	O
to	0	O
the	0	O
IOL	1	O
optic	0	O
can	0	O
occur	0	O
postoperatively	0	O
.	0	O


The	0	O
sense	0	O
of	0	O
self	0	O
.	0	O


The	0	O
spermicide	0	O
nonoxynol	0	O
-	0	O
9	0	O
is	0	O
a	0	O
member	0	O
of	0	O
a	0	O
homologous	0	O
series	0	O
of	0	O
alkylphenol	0	O
-	0	O
ethoxylates	0	O
(	0	O
polyethoxyethanols	0	O
)	0	O
of	0	O
general	0	O
formula	0	O
C9H19	0	O
-	0	O
C6H6	1	O
-	0	O
O	1	O
-(	0	O
CH2CH2O	0	O
)	0	O
n	0	O
-	0	O
1	0	O
CH2CH2OH	0	O
.	0	O


We	0	O
established	0	O
that	0	O
the	0	O
2	0	O
.	0	O
6	0	O
kb	0	O
mRNA	1	O
V	1	O
-	0	O
1	0	O
and	0	O
the	0	O
2	0	O
.	0	O
3	0	O
kb	0	O
GGT	1	B
mRNA	1	O
V	1	O
-	0	O
2	0	O
derive	0	O
,	0	O
by	0	O
alternate	0	O
splicing	0	O
,	0	O
from	0	O
a	0	O
primary	0	O
transcript	0	O
initiated	0	O
on	0	O
a	0	O
distal	0	O
promoter	0	O
on	0	O
the	0	O
rat	0	B
GGT	1	I
gene	0	I
.	0	O


Position	1	O
22	0	O
is	0	O
an	0	O
isoleucine	0	O
in	0	O
the	0	O
complete	0	B
SsoL12	0	I
protein	0	I
sequence	0	I
,	0	O
coded	0	O
by	0	O
an	0	O
AUA	1	O
codon	0	O
.	0	O


Transfection	1	O
experiments	0	O
using	0	O
preformed	0	O
triplexes	0	O
with	0	O
a	0	O
reporter	0	O
plasmid	0	O
containing	0	O
the	0	O
collagen	0	B
promoter	0	I
sequence	0	I
showed	0	O
significant	0	O
inhibition	0	O
of	0	O
transcription	0	O
when	0	O
compared	0	O
with	0	O
a	0	O
control	0	O
phosphorothioate	0	O
ODN	0	O
.	0	O


The	0	O
two	0	O
larger	0	O
peptides	0	O
,	0	O
one	0	O
containing	0	O
amino	0	O
acids	0	O
1	0	O
-	0	O
228	0	O
and	0	O
the	0	O
other	0	O
containing	0	O
amino	0	O
acids	0	O
85	0	O
-	0	O
228	0	O
,	0	O
formed	0	O
dimers	0	O
in	0	O
solution	0	O
and	0	O
bound	0	O
DNA	1	O
specifically	0	O
as	0	O
a	0	O
dimer	0	O
.	0	O


The	0	O
system	0	O
consisted	0	O
of	0	O
the	0	O
intact	0	O
canine	0	O
heart	0	O
connected	0	O
to	0	O
a	0	O
microcomputer	0	O
that	0	O
operated	0	O
as	0	O
the	0	O
modulated	0	O
parasystolic	0	O
pacemaker	0	O
.	0	O


A	1	O
group	0	O
of	0	O
66	0	O
DSM	1	O
-	0	O
IV	1	O
paranoid	0	O
schizophrenic	0	O
in	0	O
-	0	O
patients	0	O
were	0	O
assessed	0	O
three	0	O
times	0	O
using	0	O
the	0	O
SAPS	1	O
,	0	O
SANS	0	O
,	0	O
BPRS	1	O
and	0	O
PAS	1	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
-	0	O
119	0	O
to	0	O
-	0	O
81	0	O
fragment	0	O
of	0	O
the	0	O
CCK	1	B
promoter	0	I
contains	0	O
a	0	O
transcriptional	0	O
enhancer	0	O
that	0	O
potentiates	0	O
the	0	O
transcription	0	O
from	0	O
the	0	O
herpes	0	O
simplex	0	O
virus	0	O
thymidine	0	B
kinase	0	I
promoter	0	I
in	0	O
a	0	O
position	0	O
-	0	O
and	0	O
orientation	0	O
-	0	O
independent	0	O
manner	0	O
.	0	O


Mean	1	O
corpuscular	0	B
hemoglobin	0	I
concentrations	0	O
remained	0	O
normal	0	O
for	0	O
48	0	O
h	0	O
and	0	O
then	0	O
decreased	0	O
in	0	O
both	0	O
groups	0	O
,	0	O
the	0	O
CO2	1	O
group	0	O
showing	0	O
the	0	O
larger	0	O
decrease	0	O
.	0	O


Six	0	O
putative	0	O
MDV	0	O
genome	0	O
products	0	O
,	0	O
including	0	O
one	0	O
Rep	1	B
and	0	O
five	0	O
non	0	O
-	0	O
Rep	1	B
proteins	0	O
,	0	O
show	0	O
high	0	O
(	0	O
70	0	O
.	0	O
4	0	O
-	0	O
90	0	O
.	0	O
9	0	O
%)	0	O
amino	0	O
acid	0	O
identity	0	O
to	0	O
the	0	O
corresponding	0	O
six	0	O
FBNYV	0	B
proteins	0	I
,	0	O
whereas	0	O
two	0	O
other	0	O
Rep	1	B
proteins	0	I
encoded	0	O
by	0	O
MDV	0	B
-	0	I
C2	1	I
and	0	O
C3	1	B
are	0	O
82	0	O
.	0	O
3	0	O
%	0	O
and	0	O
73	0	O
.	0	O
0	0	O
%	0	O
identical	0	O
to	0	O
those	0	O
encoded	0	O
by	0	O
SCSV	0	B
-	0	I
C2	1	I
and	0	O
C6	1	B
,	0	O
respectively	0	O
.	0	O


The	0	O
NIT2	0	B
protein	0	I
is	0	O
localised	0	O
in	0	O
nuclei	0	O
and	0	O
could	0	O
not	0	O
be	0	O
detected	0	O
in	0	O
the	0	O
cytoplasmic	0	O
fraction	0	O
of	0	O
cells	0	O
subjected	0	O
to	0	O
nitrogen	0	O
derepression	0	O
or	0	O
nitrogen	0	O
repression	0	O
,	0	O
indicating	0	O
that	0	O
the	0	O
nuclear	0	O
import	0	O
of	0	O
NIT2	0	B
is	0	O
not	0	O
regulated	0	O
.	0	O


Lethal	1	O
Tachmalcor	0	O
(	0	O
4	0	O
-(	0	O
3	0	O
'-	0	O
diethylamino	0	O
-	0	O
2	0	O
'-	0	O
hydroxypropyl	0	O
)-	0	O
ajmaline	0	O
)	0	O
poisoning	0	O
in	0	O
childhood	0	O


RT	1	O
-	0	O
PCR	1	O
was	0	O
performed	0	O
using	0	O
previously	0	O
reported	0	O
degenerate	0	O
oligonucleotide	0	O
primers	0	O
to	0	O
the	0	O
ligand	0	O
binding	0	O
domain	0	O
(	0	O
LBD	0	O
)	0	O
of	0	O
known	0	O
beta	0	B
integrin	0	I
subunits	0	I
and	0	O
Bge	0	B
cDNA	1	I
.	0	O


Factors	0	O
associated	0	O
with	0	O
afterdrop	0	O
included	0	O
age	0	O
,	0	O
end	0	O
-	0	O
of	0	O
-	0	O
surgery	0	O
temperature	0	O
(	0	O
both	0	O
positively	0	O
)	0	O
and	0	O
body	0	O
mass	0	O
(	0	O
negatively	0	O
).	0	O


A	1	O
full	0	B
-	0	I
length	0	I
human	0	I
pim	0	I
-	0	I
1	0	I
cDNA	1	I
was	0	O
subcloned	0	O
into	0	O
the	0	O
bacterial	0	O
vector	0	O
pGEX	0	O
-	0	O
2T	0	O
and	0	O
the	0	O
Pim	0	B
-	0	I
1	0	I
protein	0	I
expressed	0	O
as	0	O
a	0	O
fusion	0	O
product	0	O
with	0	O
bacterial	0	B
glutathione	0	I
S	1	I
-	0	I
transferase	0	I
(	0	O
GST	0	B
).	0	O


Hybridization	1	O
signals	0	O
were	0	O
also	0	O
detected	0	O
with	0	O
total	0	O
DNAs	0	O
of	0	O
Rhizobium	1	O
leguminosarum	0	O
bv	0	O
.	0	O
phaseoli	0	O
,	0	O
Rhodobacter	0	O
capsulatus	0	O
and	0	O
Escherichia	1	O
coli	0	O
,	0	O
but	0	O
not	0	O
those	0	O
of	0	O
Xanthomonas	1	O
campestris	0	O
pv	0	O
.	0	O
campestris	0	O
and	0	O
Pseudomonas	1	O
putida	0	O
.	0	O


Patients	0	O
who	0	O
have	0	O
undergone	0	O
thyroidectomy	0	O
for	0	O
thyroid	0	O
carcinoma	0	O
are	0	O
frequently	0	O
subjected	0	O
to	0	O
periods	0	O
of	0	O
induced	0	O
severe	0	O
hypothyroidism	0	O
in	0	O
preparation	0	O
for	0	O
131I	0	O
whole	0	O
body	0	O
scanning	0	O
and	0	O
measurement	0	O
of	0	O
serum	0	O
TG	1	B
.	0	O


We	0	O
concluded	0	O
that	0	O
Ga	1	O
-	0	O
fbg	0	O
scintigraphy	0	O
is	0	O
a	0	O
very	0	O
simple	0	O
method	0	O
and	0	O
sufficiently	0	O
useful	0	O
for	0	O
detecting	0	O
active	0	O
left	0	O
ventricular	0	O
thrombi	0	O
and	0	O
for	0	O
monitoring	0	O
the	0	O
effect	0	O
of	0	O
anticoagulant	0	O
therapy	0	O
.	0	O


Through	0	O
Southern	0	O
blot	0	O
analyses	0	O
of	0	O
DNA	1	O
from	0	O
backcross	0	O
and	0	O
cogenic	0	O
mice	0	O
,	0	O
recombinant	0	O
inbred	0	O
strains	0	O
,	0	O
and	0	O
somatic	0	O
cell	0	O
hybrids	0	O
,	0	O
the	0	O
genetic	0	O
loci	0	O
that	0	O
produce	0	O
the	0	O
cyclin	0	B
B1	0	I
-	0	I
related	0	I
sequences	0	I
(	0	O
designated	0	O
loci	0	B
Cycb1	0	I
-	0	I
rs1	0	I
to	0	O
Cycb1	0	B
-	0	I
rs9	0	I
)	0	O
were	0	O
mapped	0	O
on	0	O
mouse	0	O
chromosomes	0	O
5	0	O
,	0	O
1	0	O
,	0	O
17	0	O
,	0	O
4	0	O
,	0	O
14	0	O
,	0	O
13	0	O
,	0	O
7	0	O
,	0	O
X	1	O
,	0	O
and	0	O
8	0	O
,	0	O
respectively	0	O
.	0	O


Local	1	O
graft	0	O
irradiation	0	O
as	0	O
an	0	O
adjunct	0	O
to	0	O
pharmacologic	0	O
immunosuppression	0	O
.	0	O


Haplotype	1	O
mapping	0	O
and	0	O
sequence	0	O
analysis	0	O
of	0	O
the	0	O
mouse	0	O
Nramp	0	B
gene	0	I
predict	0	O
susceptibility	0	O
to	0	O
infection	0	O
with	0	O
intracellular	0	O
parasites	0	O
.	0	O


Thus	0	O
,	0	O
patients	0	O
with	0	O
metastatic	0	O
melanoma	0	O
are	0	O
not	0	O
tolerant	0	O
to	0	O
gp100	0	B
Ag	1	I
based	0	O
on	0	O
the	0	O
detection	0	O
of	0	O
CD8	0	B
+	0	I
T	1	O
cells	0	O
specific	0	O
for	0	O
multiple	0	O
HLA	1	B
-	0	I
A	1	I
*	0	I
0201	0	I
-	0	O
restricted	0	O
,	0	O
gp100	0	B
-	0	O
derived	0	O
epitopes	0	O
.	0	O


Cellular	1	B
Csk	0	I
was	0	O
associated	0	O
with	0	O
several	0	O
phosphoproteins	0	O
,	0	O
some	0	O
of	0	O
which	0	O
were	0	O
interacting	0	O
with	0	O
the	0	O
Csk	0	B
SH2	0	I
domain	0	I
.	0	O


Removal	0	O
of	0	O
thick	0	O
,	0	O
permanently	0	O
altered	0	O
mucoas	0	O
is	0	O
recommended	0	O
even	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
squamous	0	O
epithelium	0	O
.	0	O


Vancomycin	0	O
data	0	O
were	0	O
analyzed	0	O
according	0	O
to	0	O
a	0	O
one	0	O
-	0	O
compartment	0	O
open	0	O
model	0	O
with	0	O
use	0	O
of	0	O
NONMEM	0	O
population	0	O
pharmacokinetic	0	O
software	0	O
.	0	O


Similarly	0	O
,	0	O
actuarial	0	O
interpretations	0	O
for	0	O
the	0	O
second	0	O
protocols	0	O
were	0	O
not	0	O
more	0	O
frequently	0	O
selected	0	O
by	0	O
therapists	0	O
as	0	O
more	0	O
valid	0	O
,	0	O
regardless	0	O
of	0	O
treatment	0	O
condition	0	O
and	0	O
elevation	0	O
of	0	O
the	0	O
F	1	O
and	0	O
F	1	O
-	0	O
K	1	O
indices	0	O
on	0	O
the	0	O
first	0	O
MMPI	1	O
profile	0	O
.	0	O


In	1	O
biopsies	0	O
CK	1	B
-	0	I
MB	1	I
fraction	0	O
of	0	O
total	0	O
myocardial	0	O
CPK	1	B
was	0	O
37	0	O
%,	0	O
the	0	O
total	0	B
-	0	I
CPK	1	I
activity	0	O
of	0	O
human	0	O
skeletal	0	O
muscles	0	O
still	0	O
shows	0	O
a	0	O
5	0	O
%	0	O
fraction	0	O
of	0	O
CK	1	B
-	0	I
MB	1	I
.	0	O


Subsequently	0	O
,	0	O
HD	1	O
inhibited	0	O
healing	0	O
because	0	O
it	0	O
significantly	0	O
delayed	0	O
epithelialization	0	O
and	0	O
caused	0	O
protracted	0	O
inflammation	0	O
.	0	O


It	1	O
is	0	O
possible	0	O
that	0	O
the	0	O
patch	0	O
determines	0	O
the	0	O
proper	0	O
conformation	0	O
of	0	O
the	0	O
site	0	O
and	0	O
thereby	0	O
contributes	0	O
to	0	O
recognition	0	O
indirectly	0	O
.	0	O


A	1	O
cAMP	1	O
response	0	O
element	0	O
(	0	O
CRE	0	O
)	0	O
consensus	0	O
signal	0	O
was	0	O
identified	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
noncoding	0	O
region	0	O
.	0	O
cAMP	1	O
regulates	0	O
the	0	O
expression	0	O
of	0	O
Kv1	0	B
.	0	I
5	0	I
gene	0	I
in	0	O
a	0	O
cell	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


Measurement	0	O
of	0	O
the	0	O
time	0	O
constant	0	O
of	0	O
VO2	1	O
and	0	O
oxygen	0	O
pulse	0	O
during	0	O
constant	0	O
work	0	O
rate	0	O
exercise	0	O
are	0	O
useful	0	O
for	0	O
the	0	O
objective	0	O
evaluation	0	O
of	0	O
the	0	O
training	0	O
effect	0	O
of	0	O
patients	0	O
with	0	O
COPD	1	O
.	0	O


CONCLUSION	0	O
:	0	O
SPT	0	O
is	0	O
more	0	O
useful	0	O
than	0	O
WST	0	O
in	0	O
differentiating	0	O
patients	0	O
predisposed	0	O
to	0	O
aspiration	0	O
.	0	O


After	0	O
1	0	O
.	0	O
5	0	O
years	0	O
of	0	O
such	0	O
photoperiodic	0	O
control	0	O
,	0	O
all	0	O
ewes	0	O
were	0	O
blinded	0	O
by	0	O
bilateral	0	O
orbital	0	O
enucleation	0	O
.	0	O


Another	0	O
ORF	1	O
,	0	O
dda	0	B
.	0	I
2	0	I
located	0	O
between	0	O
modA	0	B
and	0	O
dda	0	B
,	0	O
shares	0	O
sequence	0	O
similarity	0	O
with	0	O
sigma70	0	B
,	0	O
and	0	O
we	0	O
call	0	O
it	0	O
srd	0	B
.	0	O


The	0	O
JS78	0	O
mutation	0	O
changes	0	O
Gln243	0	O
in	0	O
gp0	0	O
.	0	O
7	0	O
to	0	O
an	0	O
amber	0	O
codon	0	O
,	0	O
which	0	O
explains	0	O
the	0	O
production	0	O
of	0	O
the	0	O
truncated	0	O
,	0	O
30	0	B
-	0	I
kDa	1	I
gp0	0	I
.	0	I
7	0	I
-	0	I
related	0	I
polypeptide	0	I
,	0	O
and	0	O
implicates	0	O
the	0	O
11	0	O
-	0	O
kDa	1	O
C	1	O
-	0	O
terminal	0	O
domain	0	O
in	0	O
host	0	O
transcription	0	O
shut	0	O
-	0	O
off	0	O
.	0	O


Myocardial	0	O
antioxidant	0	O
enzymes	0	O
,	0	O
catalase	0	B
,	0	O
glutathione	0	B
peroxidase	0	I
and	0	O
superoxide	0	B
dismutase	0	I
,	0	O
in	0	O
the	0	O
MCT	1	O
-	0	O
treated	0	O
rats	0	O
were	0	O
not	0	O
different	0	O
compared	0	O
to	0	O
control	0	O
rats	0	O
.	0	O


The	0	O
present	0	O
investigation	0	O
has	0	O
revealed	0	O
that	0	O
the	0	O
distribution	0	O
of	0	O
the	0	O
main	0	O
fatty	0	O
acids	0	O
in	0	O
Leptospira	1	O
phospholipids	0	O
is	0	O
similar	0	O
to	0	O
their	0	O
distribution	0	O
in	0	O
Leptospira	1	O
neutral	0	O
lipids	0	O
with	0	O
the	0	O
exception	0	O
of	0	O
unsaturated	0	O
fatty	0	O
acid	0	O
with	0	O
14	0	O
carbon	0	O
atoms	0	O
,	0	O
occurring	0	O
mainly	0	O
in	0	O
phospholipids	0	O
.	0	O


The	0	O
complement	0	B
C3a	1	I
anaphylatoxin	0	I
receptor	0	I
(	0	O
C3aR	0	B
)	0	O
is	0	O
a	0	O
seven	0	B
-	0	I
transmembrane	0	I
G	1	I
-	0	I
protein	0	I
coupled	0	I
chemoattractant	0	I
receptor	0	I
that	0	O
on	0	O
binding	0	O
the	0	O
C3a	1	B
peptide	0	I
ligand	0	I
mediates	0	O
numerous	0	O
cellular	0	O
responses	0	O
,	0	O
including	0	O
histamine	0	O
release	0	O
from	0	O
mast	0	O
cells	0	O
.	0	O
smooth	0	O
muscle	0	O
contraction	0	O
,	0	O
and	0	O
the	0	O
directed	0	O
migration	0	O
of	0	O
eosinophils	0	O
.	0	O


The	0	O
first	0	O
identification	0	O
of	0	O
the	0	O
active	0	O
37LRP	0	B
/	0	O
p40	0	B
gene	0	O
presented	0	O
in	0	O
this	0	O
study	0	O
is	0	O
a	0	O
critical	0	O
step	0	O
toward	0	O
the	0	O
isolation	0	O
of	0	O
the	0	O
corresponding	0	O
human	0	O
gene	0	O
and	0	O
the	0	O
understanding	0	O
of	0	O
the	0	O
molecular	0	O
mechanisms	0	O
involved	0	O
in	0	O
the	0	O
up	0	O
-	0	O
regulation	0	O
of	0	O
its	0	O
expression	0	O
during	0	O
tumor	0	O
invasion	0	O
and	0	O
metastasis	0	O
.	0	O


Ligation	1	O
of	0	O
CD40	0	B
rescues	0	O
Ramos	0	O
-	0	O
Burkitt	0	O
lymphoma	0	O
B	1	O
cells	0	O
from	0	O
calcium	0	O
ionophore	0	O
-	0	O
and	0	O
antigen	0	O
receptor	0	O
-	0	O
triggered	0	O
apoptosis	0	O
by	0	O
inhibiting	0	O
activation	0	O
of	0	O
the	0	O
cysteine	0	B
protease	0	I
CPP32	0	I
/	0	O
Yama	0	B
and	0	O
cleavage	0	O
of	0	O
its	0	O
substrate	0	O
PARP	0	B
.	0	O


Transcription	1	O
of	0	O
the	0	O
metH	0	B
gene	0	I
in	0	I
Salmonella	1	I
typhimurium	0	I
and	0	I
Escherichia	1	I
coli	0	I
is	0	O
positively	0	O
regulated	0	O
by	0	O
the	0	O
metR	0	B
gene	0	I
product	0	I
,	0	O
a	0	O
DNA	1	O
binding	0	O
protein	0	O
.	0	O


Moreover	0	O
,	0	O
in	0	O
transient	0	O
transfection	0	O
assays	0	O
,	0	O
PU	1	B
.	0	I
1	0	I
alone	0	O
activated	0	O
reporter	0	O
constructs	0	O
containing	0	O
the	0	O
JB	0	O
cis	0	O
-	0	O
element	0	O
,	0	O
and	0	O
the	0	O
activation	0	O
was	0	O
shown	0	O
to	0	O
be	0	O
dependent	0	O
on	0	O
a	0	O
glutamine	0	O
-	0	O
rich	0	O
sequence	0	O
in	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
portion	0	O
of	0	O
PU	1	B
.	0	I
1	0	I
.	0	O


Furthermore	0	O
,	0	O
strains	0	O
with	0	O
mutant	0	B
RPM1	0	I
genes	0	I
also	0	O
accumulate	0	O
precursor	0	B
Rpm1r	0	I
,	0	O
suggesting	0	O
that	0	O
mutations	0	O
in	0	O
either	0	O
gene	0	O
can	0	O
lead	0	O
to	0	O
similar	0	O
biogenesis	0	O
defects	0	O
.	0	O


The	0	O
chloramphenicol	0	B
-	0	I
resistance	0	I
transposon	0	I
Tn4451	0	I
undergoes	0	O
precise	0	O
conjugative	0	O
deletion	0	O
from	0	O
its	0	O
parent	0	O
plasmid	0	O
plP401	0	O
in	0	O
Clostridium	1	O
perfringens	0	O
and	0	O
precise	0	O
spontaneous	0	O
excision	0	O
from	0	O
multicopy	0	O
plasmids	0	O
in	0	O
Escherichia	1	O
coli	0	O
.	0	O


Genomic	1	O
libraries	0	O
were	0	O
stored	0	O
as	0	O
frozen	0	O
cultures	0	O
in	0	O
a	0	O
96	0	O
-	0	O
well	0	O
format	0	O
,	0	O
each	0	O
well	0	O
containing	0	O
approximately	0	O
300	0	O
-	0	O
600	0	O
colonies	0	O
(	0	O
12	0	O
plates	0	O
for	0	O
small	0	O
library	0	O
,	0	O
four	0	O
for	0	O
medium	0	O
-	0	O
size	0	O
library	0	O
and	0	O
four	0	O
for	0	O
large	0	O
library	0	O
).	0	O


The	0	O
derivatives	0	O
of	0	O
the	0	O
latter	0	O
two	0	O
cell	0	O
lines	0	O
showed	0	O
increased	0	O
expression	0	O
of	0	O
the	0	O
p27Kip1	0	B
protein	0	I
and	0	O
inhibition	0	O
of	0	O
cell	0	O
growth	0	O
.	0	O


Among	0	O
the	0	O
patients	0	O
grades	0	O
1	0	O
-	0	O
2	0	O
-	0	O
3	0	O
,	0	O
81	0	O
%	0	O
had	0	O
a	0	O
good	0	O
out	0	O
come	0	O
without	0	O
any	0	O
neurological	0	O
abnormality	0	O
,	0	O
among	0	O
the	0	O
patients	0	O
graded	0	O
4	0	O
-	0	O
5	0	O
,	0	O
only	0	O
27	0	O
%	0	O
had	0	O
a	0	O
fair	0	O
out	0	O
come	0	O
.	0	O


It	1	O
contains	0	O
binding	0	O
sites	0	O
for	0	O
several	0	O
transcription	0	O
factors	0	O
,	0	O
for	0	O
example	0	O
:	0	O
(	0	O
i	0	O
)	0	O
a	0	O
well	0	O
-	0	O
characterized	0	O
binding	0	O
site	0	O
for	0	O
rel	0	B
/	0	O
NF	1	B
-	0	I
kappaB	0	I
transcription	0	O
factors	0	O
in	0	O
its	0	O
3	0	O
'-	0	O
end	0	O
(	0	O
the	0	O
H2TF1	0	B
or	0	O
kappaB1	0	B
element	0	I
),	0	O
(	0	O
ii	0	O
)	0	O
a	0	O
second	0	O
kappaB	0	B
site	0	I
(	0	O
the	0	O
kappaB2	0	B
element	0	I
),	0	O
which	0	O
is	0	O
located	0	O
immediately	0	O
adjacent	0	O
5	0	O
'	0	O
to	0	O
the	0	O
H2TF1	0	B
element	0	I
and	0	O
which	0	O
is	0	O
recognized	0	O
by	0	O
p65	0	B
/	0	O
relA	0	B
in	0	O
the	0	O
human	0	B
HLA	1	I
system	0	O
,	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
an	0	O
AP	1	B
-	0	I
1	0	I
/	0	O
ATF	0	B
recognition	0	O
sequence	0	O
in	0	O
the	0	O
5	0	O
'	0	O
end	0	O
(	0	O
EnA	1	B
-	0	I
TRE	0	I
).	0	O


Common	1	O
foot	0	O
pathologies	0	O
are	0	O
heel	0	O
pain	0	O
,	0	O
metatarsalgia	0	O
,	0	O
hammertoes	0	O
and	0	O
clawtoes	0	O
,	0	O
bunions	0	O
,	0	O
hallux	0	O
rigidus	0	O
,	0	O
corns	0	O
and	0	O
calluses	0	O
,	0	O
nail	0	O
pathologies	0	O
,	0	O
arthritis	0	O
,	0	O
and	0	O
neuropathies	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
The	0	O
study	0	O
was	0	O
designed	0	O
to	0	O
investigate	0	O
the	0	O
frequency	0	O
of	0	O
alterations	0	O
in	0	O
serum	0	O
creatinine	0	O
in	0	O
patients	0	O
with	0	O
psoriasis	0	O
receiving	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
of	0	O
cyclosporine	0	O
.	0	O


However	0	O
,	0	O
overexpression	0	O
of	0	O
both	0	O
the	0	O
STE4	0	B
and	0	O
STE18	0	B
proteins	0	I
did	0	O
not	0	O
generate	0	O
a	0	O
stronger	0	O
pheromone	0	O
response	0	O
than	0	O
overexpression	0	O
of	0	O
STE4	0	B
in	0	O
the	0	O
presence	0	O
of	0	O
wild	0	O
-	0	O
type	0	O
levels	0	O
of	0	O
STE18	0	B
.	0	O


TEMTU	0	O
and	0	O
DPTU	0	O
were	0	O
the	0	O
most	0	O
potent	0	O
teratogens	0	O
.	0	O


Static	1	O
orthoses	0	O
for	0	O
the	0	O
management	0	O
of	0	O
microstomia	0	O
.	0	O


Proteasomes	0	O
are	0	O
the	0	O
multisubunit	0	O
protease	0	O
involved	0	O
in	0	O
the	0	O
generation	0	O
of	0	O
peptides	0	O
presented	0	O
by	0	O
MHC	1	B
class	0	I
I	1	I
molecules	0	I
.	0	O


The	0	O
Dax	0	B
-	0	I
1	0	I
gene	0	I
encodes	0	O
a	0	O
protein	0	O
that	0	O
is	0	O
structurally	0	O
related	0	O
to	0	O
members	0	O
of	0	O
the	0	O
orphan	0	B
nuclear	0	I
receptor	0	I
superfamily	0	I
.	0	O


Induction	1	O
of	0	O
correctly	0	O
spliced	0	O
germline	0	O
transcripts	0	O
is	0	O
necessary	0	O
to	0	O
target	0	O
a	0	O
switch	0	O
region	0	O
for	0	O
recombination	0	O
and	0	O
switching	0	O
.	0	O


These	0	O
mutants	0	O
grow	0	O
normally	0	O
in	0	O
3T6	0	O
mouse	0	O
fibroblast	0	O
cells	0	O
,	0	O
and	0	O
they	0	O
do	0	O
not	0	O
complement	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
virus	0	O
in	0	O
coinfection	0	O
experiments	0	O
of	0	O
C2	1	O
myoblasts	0	O
.	0	O


The	0	O
US	1	O
National	0	O
Institute	0	O
on	0	O
Alcohol	1	O
Abuse	1	O
and	0	O
Alcoholism	1	O
(	0	O
NIAAA	1	O
)	0	O
recognizes	0	O
two	0	O
forms	0	O
of	0	O
problematic	0	O
drinking	0	O
:	0	O
'	0	O
willful	0	O
alcohol	0	O
abuse	0	O
',	0	O
a	0	O
behavioural	0	O
problem	0	O
,	0	O
and	0	O
'	0	O
alcohol	0	O
dependence	0	O
',	0	O
a	0	O
true	0	O
medical	0	O
disorder	0	O
,	0	O
which	0	O
includes	0	O
a	0	O
genetic	0	O
component	0	O
,	0	O
that	0	O
can	0	O
be	0	O
scientifically	0	O
understood	0	O
and	0	O
medically	0	O
treated	0	O
.	0	O


In	1	O
support	0	O
of	0	O
clinical	0	O
antianginal	0	O
studies	0	O
,	0	O
the	0	O
vasodilator	0	O
nicorandil	0	O
(	0	O
NIC	0	O
)	0	O
was	0	O
combined	0	O
with	0	O
the	0	O
beta	0	B
-	0	I
adrenergic	0	I
receptor	0	I
antagonists	0	O
propranolol	0	O
(	0	O
PRO	1	O
)	0	O
and	0	O
atenolol	0	O
(	0	O
ATN	1	O
)	0	O
and	0	O
with	0	O
the	0	O
calcium	0	O
channel	0	O
blocker	0	O
diltiazem	0	O
(	0	O
DTZ	0	O
)	0	O
to	0	O
determine	0	O
their	0	O
cardiovascular	0	O
and	0	O
pharmacokinetic	0	O
interactions	0	O
.	0	O


A	1	O
330	0	O
-	0	O
kb	0	O
YAC	1	O
,	0	O
A148A7	0	O
,	0	O
spanned	0	O
from	0	O
the	0	O
HLA	1	B
-	0	O
DQA1	0	B
locus	0	O
through	0	O
the	0	O
Y3	0	B
/	0	O
Ring	1	B
4	0	I
locus	0	O
and	0	O
extended	0	O
at	0	O
least	0	O
130	0	O
kb	0	O
centromeric	0	O
of	0	O
YAC	1	O
B1D12	0	O
.	0	O


PURPOSE	0	O
:	0	O
To	1	O
evaluate	0	O
the	0	O
kinetics	0	O
of	0	O
erythropoietin	0	B
(	0	O
EPO	0	B
)	0	O
production	0	O
and	0	O
address	0	O
the	0	O
pathogenesis	0	O
of	0	O
anemia	0	O
of	0	O
prematurity	0	O
,	0	O
we	0	O
measured	0	O
EPO	0	B
levels	0	O
in	0	O
infants	0	O
during	0	O
the	0	O
first	0	O
year	0	O
of	0	O
life	0	O
.	0	O


The	0	O
prevalence	0	O
of	0	O
hepatitis	0	B
B	1	I
surface	0	I
antigen	0	I
(	0	O
HBsAg	1	B
)	0	O
and	0	O
anti	0	B
-	0	I
HBs	1	I
was	0	O
determined	0	O
by	0	O
a	0	O
sensitive	0	O
double	0	O
-	0	O
antibody	0	O
radio	0	O
-	0	O
immunoassay	0	O
technique	0	O
in	0	O
a	0	O
series	0	O
of	0	O
patients	0	O
with	0	O
chronic	0	O
liver	0	O
diseases	0	O
.	0	O


MK	1	O
-	0	O
927	0	O
:	0	O
a	0	O
topically	0	O
active	0	O
ocular	0	O
hypotensive	0	O
carbonic	0	B
anhydrase	0	I
inhibitor	0	O
.	0	O


(	0	O
i	0	O
)	0	O
Complete	0	O
Grb10	0	B
expression	0	O
from	0	O
cDNA	1	O
with	0	O
an	0	O
ecdysone	0	O
-	0	O
regulated	0	O
transient	0	O
expression	0	O
system	0	O
stimulated	0	O
PDGF	0	B
-	0	I
BB	0	I
-,	0	O
IGF	1	B
-	0	I
I	1	I
,	0	O
and	0	O
insulin	0	B
-	0	O
but	0	O
not	0	O
epidermal	0	B
growth	0	I
factor	0	I
(	0	O
EGF	1	B
)-	0	O
induced	0	O
DNA	1	O
synthesis	0	O
in	0	O
an	0	O
ecdysone	0	O
dose	0	O
-	0	O
responsive	0	O
fashion	0	O
.	0	O


Consistent	0	O
with	0	O
the	0	O
protein	0	O
expression	0	O
data	0	O
,	0	O
V	1	B
beta	0	I
8	0	I
.	0	I
3	0	I
gene	0	I
transcripts	0	I
were	0	O
found	0	O
only	0	O
in	0	O
the	0	O
transgenic	0	O
lines	0	O
with	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
promoter	0	O
.	0	O


This	0	O
establishes	0	O
Rad3	0	B
/	0	O
Mec1	0	B
as	0	O
the	0	O
only	0	O
conserved	0	O
protein	0	O
which	0	O
is	0	O
required	0	O
for	0	O
all	0	O
the	0	O
DNA	1	O
structure	0	O
checkpoints	0	O
in	0	O
both	0	O
yeast	0	O
model	0	O
systems	0	O
.	0	O


Lacrimal	1	O
secretion	0	O
in	0	O
hyperthyroidism	0	O


Addition	1	O
of	0	O
phalloidin	0	O
-	0	O
stabilized	0	O
F	1	B
-	0	I
actin	0	I
nuclei	0	O
and	0	O
phalloidin	0	O
restored	0	O
L266D	0	O
actin	0	B
'	0	O
s	0	O
ability	0	O
to	0	O
polymerize	0	O
at	0	O
4	0	O
degrees	0	O
C	1	O
.	0	O


We	0	O
describe	0	O
a	0	O
novel	0	O
zinc	0	B
finger	0	I
protein	0	I
,	0	O
dsRBP	0	B
-	0	I
ZFa	0	I
,	0	O
isolated	0	O
by	0	O
screening	0	O
an	0	O
expression	0	O
library	0	O
with	0	O
dsRNA	1	O
.	0	O


In	1	O
the	0	O
absence	0	O
of	0	O
Mg2	0	O
+,	0	O
a	0	O
hydrophobic	0	O
exonuclease	0	O
site	0	O
dominates	0	O
over	0	O
the	0	O
polymerase	0	O
site	0	O
for	0	O
possession	0	O
of	0	O
the	0	O
primer	0	O
terminus	0	O
.	0	O


When	0	O
10	0	O
fields	0	O
were	0	O
analysed	0	O
,	0	O
a	0	O
strong	0	O
relationship	0	O
was	0	O
found	0	O
between	0	O
the	0	O
presence	0	O
of	0	O
bacteria	0	O
on	0	O
Gram	1	O
staining	0	O
and	0	O
the	0	O
final	0	O
diagnosis	0	O
of	0	O
VAP	0	O
(	0	O
for	0	O
PSB	0	O
and	0	O
PTC	1	O
respectively	0	O
:	0	O
sensitivity	0	O
74	0	O
and	0	O
81	0	O
%,	0	O
specificity	0	O
94	0	O
and	0	O
100	0	O
%,	0	O
positive	0	O
predictive	0	O
value	0	O
91	0	O
and	0	O
100	0	O
%,	0	O
negative	0	O
predictive	0	O
value	0	O
82	0	O
and	0	O
88	0	O
%).	0	O


Previous	0	O
studies	0	O
have	0	O
shown	0	O
that	0	O
the	0	O
pro	0	O
-	0	O
inflammatory	0	O
cytokines	0	O
tumor	0	B
necrosis	0	I
factor	0	I
alpha	0	I
and	0	O
interferon	0	B
gamma	0	I
reduce	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
cystic	0	B
fibrosis	0	I
transmembrane	0	I
conductance	0	I
regulator	0	I
(	0	O
CFTR	1	B
)	0	O
gene	0	O
(	0	O
CFTR	1	B
)	0	O
in	0	O
HT	1	O
-	0	O
29	0	O
and	0	O
T84	0	O
cells	0	O
by	0	O
acting	0	O
post	0	O
-	0	O
transcriptionally	0	O
.	0	O


Both	0	O
increasing	0	O
basal	0	O
FSH	1	B
and	0	O
age	0	O
were	0	O
associated	0	O
significantly	0	O
with	0	O
increased	0	O
total	0	O
gonadotrophin	0	B
dose	0	O
,	0	O
and	0	O
reduced	0	O
number	0	O
of	0	O
oocytes	0	O
collected	0	O
and	0	O
pregnancy	0	O
rate	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
The	0	O
largest	0	O
value	0	O
of	0	O
the	0	O
joint	0	O
space	0	O
may	0	O
be	0	O
used	0	O
when	0	O
evaluating	0	O
rheumatoid	0	O
AC	1	O
joint	0	O
space	0	O
.	0	O


A	1	O
vector	0	O
containing	0	O
a	0	O
transcriptionally	0	O
inactive	0	O
neomycin	0	B
phosphotransferase	0	I
II	0	I
gene	0	I
was	0	O
used	0	O
to	0	O
select	0	O
promoter	0	O
sequences	0	O
from	0	O
a	0	O
pool	0	O
of	0	O
random	0	O
genomic	0	O
DNA	1	O
fragments	0	O
.	0	O


One	0	O
of	0	O
the	0	O
sequelae	0	O
of	0	O
the	0	O
antiphospholipid	0	O
-	0	O
antibodies	0	O
is	0	O
an	0	O
impaired	0	O
uteroplacental	0	O
circulation	0	O
.	0	O


Postcoital	1	O
contraception	0	O
:	0	O
a	0	O
family	0	O
planning	0	O
study	0	O
.	0	O


Comparison	0	O
of	0	O
1	0	O
.	0	O
5	0	O
Tesla	1	O
and	0	O
0	0	O
.	0	O
35	0	O
Tesla	1	O
field	0	O
strength	0	O
magnetic	0	O
resonance	0	O
imaging	0	O
scans	0	O
in	0	O
the	0	O
morphometric	0	O
evaluation	0	O
of	0	O
the	0	O
lumbar	0	O
intervertebral	0	O
foramina	0	O
.	0	O


Accurate	0	O
evaluation	0	O
of	0	O
the	0	O
treatment	0	O
results	0	O
in	0	O
unresectable	0	O
lung	0	O
cancer	0	O
patients	0	O
must	0	O
take	0	O
the	0	O
strong	0	O
prognostic	0	O
factors	0	O
into	0	O
account	0	O
.	0	O


SIN	0	O
-	0	O
1	0	O
had	0	O
no	0	O
influence	0	O
on	0	O
either	0	O
the	0	O
ischemic	0	O
parameters	0	O
in	0	O
the	0	O
surface	0	O
electrocardiogram	0	O
(	0	O
ECG	1	O
)	0	O
or	0	O
the	0	O
intracoronary	0	O
ECG	1	O
.	0	O


A	1	O
rat	0	O
cDNA	1	O
that	0	O
encodes	0	O
eIF	0	B
-	0	I
5	0	I
has	0	O
been	0	O
isolated	0	O
and	0	O
expressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
to	0	O
yield	0	O
a	0	O
catalytically	0	O
active	0	O
eIF	0	B
-	0	I
5	0	I
protein	0	I
.	0	O


Among	0	O
82	0	O
superficial	0	O
lesions	0	O
34	0	O
were	0	O
classified	0	O
as	0	O
showing	0	O
CR	1	O
and	0	O
another	0	O
23	0	O
as	0	O
showing	0	O
PR	1	O
,	0	O
with	0	O
a	0	O
response	0	O
rate	0	O
of	0	O
69	0	O
.	0	O
5	0	O
%.	0	O


Albumin	1	B
dialysis	0	O
:	0	O
effective	0	O
removal	0	O
of	0	O
copper	0	O
in	0	O
a	0	O
patient	0	O
with	0	O
fulminant	0	O
Wilson	0	O
disease	0	O
and	0	O
successful	0	O
bridging	0	O
to	0	O
liver	0	O
transplantation	0	O
:	0	O
a	0	O
new	0	O
possibility	0	O
for	0	O
the	0	O
elimination	0	O
of	0	O
protein	0	O
-	0	O
bound	0	O
toxins	0	O
.	0	O


The	0	O
bactericidal	0	O
activity	0	O
of	0	O
six	0	O
new	0	O
rifamycin	0	O
derivatives	0	O
--	0	O
rifabutin	0	O
(	0	O
RBU	0	O
),	0	O
FCE	0	O
22250	0	O
(	0	O
F22	0	O
),	0	O
rifapentine	0	O
(	0	O
RPE	1	O
),	0	O
CGP	0	O
29861	0	O
(	0	O
C29	0	O
),	0	O
CGP	0	O
7040	0	O
(	0	O
C70	0	O
)	0	O
and	0	O
CGP	0	O
27557	0	O
(	0	O
C27	0	O
)	0	O
and	0	O
rifampicin	0	O
(	0	O
RMP	1	O
)--	0	O
have	0	O
been	0	O
measured	0	O
against	0	O
log	0	O
phase	0	O
and	0	O
,	0	O
as	0	O
a	0	O
better	0	O
test	0	O
of	0	O
sterilising	0	O
activity	0	O
,	0	O
against	0	O
stationary	0	O
phase	0	O
cultures	0	O
of	0	O
Mycobacterium	1	O
tuberculosis	0	O
,	0	O
H37Rv	0	O
.	0	O


You	0	O
make	0	O
the	0	O
diagnosis	0	O
.	0	O


This	0	O
association	0	O
appears	0	O
to	0	O
be	0	O
mediated	0	O
by	0	O
Src	1	B
-	0	O
SH2	0	B
domain	0	O
,	0	O
because	0	O
PECAM	0	B
-	0	I
1	0	I
can	0	O
be	0	O
precipitated	0	O
by	0	O
a	0	O
GST	0	B
-	0	O
Src	1	B
-	0	O
SH2	0	B
affinity	0	O
matrix	0	O
.	0	O


Furthermore	0	O
,	0	O
Zelen	0	O
'	0	O
s	0	O
method	0	O
is	0	O
used	0	O
to	0	O
balance	0	O
the	0	O
number	0	O
of	0	O
patients	0	O
allocated	0	O
to	0	O
the	0	O
two	0	O
groups	0	O
within	0	O
each	0	O
institution	0	O
(	0	O
M	1	O
.	0	O


RNA	1	B
polymerase	0	I
IIA	0	I
was	0	O
recovered	0	O
in	0	O
transcriptionally	0	O
active	0	O
complexes	0	O
in	0	O
reactions	0	O
in	0	O
which	0	O
the	0	O
input	0	O
enzyme	0	O
was	0	O
RNA	1	B
polymerase	0	I
IIA	0	I
.	0	O


Either	0	O
a	0	O
UV	1	O
detector	0	O
set	0	O
at	0	O
268	0	O
nm	0	O
or	0	O
an	0	O
electrochemical	0	O
(	0	O
EC	1	O
)	0	O
detector	0	O
set	0	O
at	0	O
a	0	O
potential	0	O
of	0	O
+	0	O
0	0	O
.	0	O
9	0	O
V	1	O
(	0	O
versus	0	O
Ag	1	O
/	0	O
AgCl	1	O
/	0	O
3	0	O
M	1	O
NaCl	1	O
)	0	O
was	0	O
used	0	O
to	0	O
monitor	0	O
the	0	O
drug	0	O
.	0	O


Because	0	O
the	0	O
deletion	0	O
included	0	O
the	0	O
TK	1	B
gene	0	I
,	0	O
selection	0	O
with	0	O
gancyclovir	0	O
against	0	O
cells	0	O
not	0	O
having	0	O
undergone	0	O
recombination	0	O
was	0	O
possible	0	O
.	0	O


The	0	O
construction	0	O
of	0	O
a	0	O
small	0	O
library	0	O
of	0	O
mouse	0	O
repetitive	0	O
DNA	1	O
has	0	O
been	0	O
previously	0	O
reported	0	O
(	0	O
Pietras	0	O
et	0	O
al	0	O
.,	0	O
Nucleic	0	O
Acids	0	O
Res	1	O
.	0	O


In	1	O
both	0	O
shoots	0	O
and	0	O
roots	0	O
,	0	O
GT	1	B
-	0	I
2	0	I
protein	0	I
is	0	O
undetectable	0	O
in	0	O
meristematic	0	O
tissue	0	O
but	0	O
becomes	0	O
expressed	0	O
at	0	O
later	0	O
stages	0	O
of	0	O
cellular	0	O
development	0	O
,	0	O
consistent	0	O
with	0	O
a	0	O
role	0	O
in	0	O
contributing	0	O
to	0	O
the	0	O
pattern	0	O
of	0	O
phytochrome	0	B
A	1	I
gene	0	I
expression	0	O
.	0	O


Perfusion	1	O
washout	0	O
:	0	O
increasing	0	O
a	0	O
microvascular	0	O
free	0	O
flap	0	O
tolerance	0	O
to	0	O
ischemia	0	O
.	0	O


A	1	O
new	0	O
DNA	1	B
repair	0	I
gene	0	I
from	0	O
Schizosaccharomyces	0	O
pombe	0	O
with	0	O
homology	0	O
to	0	O
RecA	0	B
was	0	O
identified	0	O
and	0	O
characterized	0	O
.	0	O


Hops	1	O
,	0	O
and	0	O
L	1	O
.	0	O


HBx	0	B
strongly	0	O
elevates	0	O
levels	0	O
of	0	O
GTP	1	O
-	0	O
bound	0	O
Ras	1	B
,	0	O
activated	0	O
and	0	O
phosphorylated	0	O
Raf	0	B
,	0	O
and	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
and	0	O
activated	0	O
MAP	1	B
kinase	0	I
.	0	O


In	1	O
general	0	O
,	0	O
however	0	O
,	0	O
this	0	O
study	0	O
provided	0	O
little	0	O
evidence	0	O
of	0	O
any	0	O
effect	0	O
of	0	O
supplementation	0	O
to	0	O
athletic	0	O
performance	0	O
for	0	O
athletes	0	O
consuming	0	O
the	0	O
dietary	0	O
RDIs	0	O
.	0	O


Many	0	O
children	0	O
with	0	O
BGC	0	O
are	0	O
delayed	0	O
in	0	O
their	0	O
development	0	O
,	0	O
but	0	O
calcifications	0	O
are	0	O
not	0	O
directly	0	O
related	0	O
to	0	O
specific	0	O
forms	0	O
of	0	O
neurologic	0	O
dysfunction	0	O
.	0	O


Gel	1	O
retardation	0	O
assays	0	O
combined	0	O
with	0	O
DNase	1	B
I	1	I
footprinting	0	O
and	0	O
diethyl	0	O
pyrocarbonate	0	O
interference	0	O
showed	0	O
that	0	O
a	0	O
nuclear	0	O
factor	0	O
from	0	O
differentiated	0	O
C2	1	O
myotubes	0	O
and	0	O
BC3H1	0	O
myocytes	0	O
recognized	0	O
a	0	O
conserved	0	O
A	1	O
+	0	O
T	1	O
-	0	O
rich	0	O
sequence	0	O
within	0	O
the	0	O
peripheral	0	O
activating	0	O
region	0	O
.	0	O


As	1	O
a	0	O
consequence	0	O
of	0	O
dark	0	O
rearing	0	O
,	0	O
the	0	O
numerical	0	O
density	0	O
of	0	O
cortical	0	O
neurons	0	O
in	0	O
area	0	O
17	0	O
amounted	0	O
to	0	O
about	0	O
double	0	O
of	0	O
the	0	O
value	0	O
observed	0	O
in	0	O
normally	0	O
reared	0	O
kittens	0	O
and	0	O
was	0	O
also	0	O
significantly	0	O
higher	0	O
in	0	O
area	0	O
18	0	O
.	0	O


Human	1	B
papillomavirus	0	I
type	0	I
31b	0	I
late	0	I
gene	0	I
expression	0	O
is	0	O
regulated	0	O
through	0	O
protein	0	B
kinase	0	I
C	1	I
-	0	O
mediated	0	O
changes	0	O
in	0	O
RNA	1	O
processing	0	O
.	0	O


Two	0	O
potential	0	O
regulatory	0	O
sequences	0	O
for	0	O
DNA	1	O
binding	0	O
proteins	0	O
were	0	O
found	0	O
in	0	O
the	0	O
non	0	O
-	0	O
coding	0	O
5	0	O
'	0	O
region	0	O
:	0	O
a	0	O
HAP2	0	B
/	0	O
HAP3	0	B
consensus	0	O
recognition	0	O
sequence	0	O
at	0	O
nucleotide	0	O
-	0	O
154	0	O
and	0	O
a	0	O
BAF1	0	B
consensus	0	I
recognition	0	I
sequence	0	I
at	0	O
nucleotide	0	O
-	0	O
136	0	O
.	0	O


The	0	O
single	0	O
-	0	O
stranded	0	O
DNA	1	O
Pur	0	B
alpha	0	I
recognition	0	I
element	0	I
disrupts	0	O
these	0	O
complexes	0	O
.	0	O


In	1	O
rlf2	0	B
mutants	0	I
,	0	O
telomeric	0	O
chromatin	0	O
is	0	O
perturbed	0	O
:	0	O
Telomeric	1	O
silencing	0	O
is	0	O
reduced	0	O
and	0	O
Rap1p	0	B
localization	0	O
is	0	O
altered	0	O
.	0	O


An	1	O
egg	0	O
protein	0	O
,	0	O
lysozyme	0	B
,	0	O
is	0	O
a	0	O
still	0	O
unlabeled	0	O
additive	0	O
currently	0	O
used	0	O
in	0	O
cheese	0	O
preparation	0	O
.	0	O


These	0	O
studies	0	O
suggest	0	O
that	0	O
MAPK	1	B
acts	0	O
by	0	O
stimulating	0	O
AP	1	B
-	0	I
1	0	I
and	0	O
a	0	O
subsequent	0	O
physical	0	O
and	0	O
functional	0	O
interaction	0	O
of	0	O
AP	1	B
-	0	I
1	0	I
with	0	O
NF	1	B
-	0	I
kappaB	0	I
,	0	O
resulting	0	O
in	0	O
a	0	O
complex	0	O
that	0	O
synergistically	0	O
transactivates	0	O
the	0	O
HIV	1	B
-	0	I
1	0	I
LTR	1	I
.	0	O


This	0	O
is	0	O
the	0	O
first	0	O
report	0	O
of	0	O
the	0	O
successful	0	O
resection	0	O
of	0	O
a	0	O
MFH	0	O
originating	0	O
in	0	O
the	0	O
renal	0	O
capsular	0	O
tissue	0	O
and	0	O
extending	0	O
into	0	O
the	0	O
inferior	0	O
vena	0	O
cava	0	O
.	0	O


Therefore	0	O
,	0	O
Mxi1	0	B
and	0	O
Mad	1	B
might	0	O
antagonize	0	O
Myc	0	B
function	0	O
and	0	O
are	0	O
candidate	0	O
tumor	0	O
suppressor	0	O
genes	0	O
.	0	O


Risk	1	O
of	0	O
HTLV	0	O
infection	0	O
in	0	O
patients	0	O
on	0	O
haemodialysis	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
PCNA	1	B
gene	0	I
is	0	O
a	0	O
likely	0	O
target	0	O
gene	0	O
of	0	O
E2F	0	B
.	0	O


However	0	O
,	0	O
both	0	O
TPN	1	O
groups	0	O
showed	0	O
a	0	O
marked	0	O
increase	0	O
in	0	O
activities	0	O
of	0	O
liver	0	O
lysosomal	0	B
enzymes	0	I
.	0	O


A	1	O
role	0	O
for	0	O
glycogen	0	B
synthase	0	I
kinase	0	I
-	0	I
3	0	I
in	0	O
the	0	O
control	0	O
of	0	O
gene	0	O
expression	0	O
.	0	O


Type	1	O
I	1	O
cysts	0	O
(	0	O
with	0	O
a	0	O
high	0	O
K	1	O
+/	0	O
Na	1	O
+	0	O
ratio	0	O
)	0	O
tend	0	O
to	0	O
have	0	O
higher	0	O
total	0	O
PSA	1	B
than	0	O
Type	1	O
II	0	O
cysts	0	O
.	0	O


We	0	O
also	0	O
found	0	O
an	0	O
eIF	0	B
-	0	I
4A	0	I
intronless	0	O
retroposon	0	O
which	0	O
,	0	O
when	0	O
compared	0	O
to	0	O
the	0	O
cDNA	1	O
,	0	O
contains	0	O
a	0	O
single	0	O
nucleotide	0	O
difference	0	O
.	0	O


In	1	O
visible	0	O
tumours	0	O
the	0	O
best	0	O
results	0	O
were	0	O
obtained	0	O
with	0	O
FB	0	O
(	0	O
85	0	O
%)	0	O
while	0	O
TBN	0	O
was	0	O
positive	0	O
in	0	O
65	0	O
%.	0	O


We	0	O
observed	0	O
that	0	O
dephosphorylation	0	O
severely	0	O
inhibits	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
ability	0	O
of	0	O
C	1	B
/	0	I
EBP	1	I
-	0	I
delta	0	I
and	0	O
its	0	O
transactivating	0	O
potential	0	O
increases	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
cellular	0	O
phosphatase	0	O
inhibitors	0	O
,	0	O
such	0	O
as	0	O
okadaic	0	O
acid	0	O
and	0	O
sodium	0	O
orthovanadate	0	O
.	0	O


These	0	O
indications	0	O
of	0	O
deregulated	0	O
signalling	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
tyrosine	0	O
118	0	O
were	0	O
substantiated	0	O
by	0	O
sustained	0	O
activation	0	O
of	0	O
STAT3	0	B
.	0	O


Next	0	O
,	0	O
we	0	O
show	0	O
that	0	O
two	0	O
EMS	1	O
-	0	O
induced	0	O
mutations	0	O
,	0	O
previously	0	O
shown	0	O
to	0	O
interact	0	O
genetically	0	O
with	0	O
zipper	0	O
(	0	O
Ebr	0	B
),	0	O
disrupt	0	O
the	0	O
RhoA	0	B
locus	0	I
.	0	O


These	0	O
cells	0	O
produce	0	O
a	0	O
low	0	O
level	0	O
of	0	O
IL	1	B
-	0	I
5	0	I
when	0	O
stimulated	0	O
with	0	O
PMA	0	O
alone	0	O
;	0	O
however	0	O
,	0	O
N6	0	O
,	0	O
O2	1	O
-	0	O
dibutyryl	0	O
cAMP	1	O
(	0	O
Bt2cAMP	0	O
),	0	O
in	0	O
combination	0	O
with	0	O
PMA	0	O
,	0	O
augmented	0	O
by	0	O
more	0	O
than	0	O
tenfold	0	O
the	0	O
IL	1	B
-	0	I
5	0	I
production	0	O
at	0	O
the	0	O
mRNA	1	O
and	0	O
the	0	O
protein	0	O
levels	0	O
.	0	O


Analysis	1	O
of	0	O
lacZ	0	B
transcriptional	0	I
fusions	0	I
shows	0	O
that	0	O
the	0	O
KdgR	0	B
-	0	I
binding	0	I
sites	0	I
negatively	0	O
affect	0	O
the	0	O
expression	0	O
of	0	O
rsmB	0	B
.	0	O


Serum	1	O
antibody	0	O
titre	0	O
was	0	O
not	0	O
significantly	0	O
associated	0	O
with	0	O
the	0	O
recurrence	0	O
rate	0	O
or	0	O
the	0	O
duration	0	O
of	0	O
infection	0	O
.	0	O


Protein	1	O
splicing	0	O
:	0	O
evidence	0	O
for	0	O
an	0	O
N	1	O
-	0	O
O	1	O
acyl	0	O
rearrangement	0	O
as	0	O
the	0	O
initial	0	O
step	0	O
in	0	O
the	0	O
splicing	0	O
process	0	O
.	0	O


The	0	O
purified	0	O
recombinant	0	O
protein	0	O
was	0	O
assayed	0	O
for	0	O
its	0	O
enzyme	0	O
activity	0	O
by	0	O
monitoring	0	O
transfer	0	O
of	0	O
[	0	O
3H	0	O
]	0	O
methyl	0	O
groups	0	O
from	0	O
the	0	O
substrate	0	O
DNA	1	O
to	0	O
the	0	O
MGMT	0	B
protein	0	I
;	0	O
the	0	O
activity	0	O
was	0	O
found	0	O
to	0	O
be	0	O
stable	0	O
at	0	O
90	0	O
degrees	0	O
C	1	O
for	0	O
at	0	O
least	0	O
30	0	O
min	0	O
.	0	O


Doppler	1	O
echo	0	O
in	0	O
evaluating	0	O
arteriovenous	0	O
fistulae	0	O
for	0	O
dialysis	0	O


Binding	0	O
activity	0	O
in	0	O
rat	0	O
liver	0	O
nuclear	0	O
extracts	0	O
includes	0	O
these	0	O
orphan	0	O
receptors	0	O
as	0	O
judged	0	O
from	0	O
electromobility	0	O
supershift	0	O
experiments	0	O
and	0	O
from	0	O
results	0	O
obtained	0	O
with	0	O
expressed	0	O
receptors	0	O
,	0	O
although	0	O
the	0	O
element	0	O
in	0	O
CYP2C11	0	B
did	0	O
not	0	O
bind	0	O
HNF	1	B
-	0	I
4	0	I
.	0	O


We	0	O
have	0	O
investigated	0	O
the	0	O
contribution	0	O
of	0	O
specific	0	O
TATA	0	B
-	0	I
binding	0	I
protein	0	I
(	0	O
TBP	1	B
)-	0	O
TATA	0	O
interactions	0	O
to	0	O
the	0	O
promoter	0	O
activity	0	O
of	0	O
a	0	O
constitutively	0	O
expressed	0	O
silkworm	0	B
tRNA	1	I
(	0	I
C	1	I
)(	0	I
Ala	1	I
)	0	I
gene	0	I
and	0	O
have	0	O
also	0	O
asked	0	O
whether	0	O
the	0	O
lack	0	O
of	0	O
similar	0	O
interactions	0	O
accounts	0	O
for	0	O
the	0	O
low	0	O
promoter	0	O
activity	0	O
of	0	O
a	0	O
silk	0	B
gland	0	I
-	0	I
specific	0	I
tRNA	1	I
(	0	I
SG	0	I
)(	0	I
Ala	1	I
)	0	I
gene	0	I
.	0	O


The	0	O
equilibrium	0	O
dissociation	0	O
binding	0	O
constant	0	O
for	0	O
the	0	O
interaction	0	O
of	0	O
TnrA	0	B
with	0	O
the	0	O
nrgAB	0	B
promoter	0	I
fragment	0	I
was	0	O
7	0	O
.	0	O
7	0	O
nM	1	O
under	0	O
the	0	O
conditions	0	O
used	0	O
here	0	O
.	0	O


As	1	O
extensively	0	O
examined	0	O
with	0	O
the	0	O
myogenin	0	B
promoter	0	I
,	0	O
presence	0	O
of	0	O
one	0	O
or	0	O
multiple	0	O
copies	0	O
of	0	O
Me	1	B
in	0	O
the	0	O
vectors	0	O
elevated	0	O
the	0	O
expression	0	O
activity	0	O
in	0	O
myotubes	0	O
by	0	O
4	0	O
.	0	O
5	0	O
-	0	O
to	0	O
19	0	O
-	0	O
fold	0	O
over	0	O
those	0	O
without	0	O
Me	1	B
,	0	O
but	0	O
not	0	O
significantly	0	O
in	0	O
myoblasts	0	O
.	0	O


Cdk2	0	B
and	0	O
MAPK	1	B
precipitates	0	O
from	0	O
untreated	0	O
tumor	0	O
lysates	0	O
phosphorylated	0	O
recombinant	0	B
wild	0	I
-	0	I
type	0	I
p27	0	I
but	0	O
not	0	O
the	0	O
T187A	0	O
mutant	0	O
in	0	O
vitro	0	O
.	0	O


Retinoid	1	O
-	0	O
dependent	0	O
activation	0	O
of	0	O
the	0	O
tissue	0	B
transglutaminase	0	I
promoter	0	I
depends	0	O
on	0	O
both	0	O
a	0	O
proximal	0	O
regulatory	0	O
region	0	O
containing	0	O
sequences	0	O
highly	0	O
conserved	0	O
between	0	O
the	0	O
human	0	O
and	0	O
the	0	O
mouse	0	B
tissue	0	I
transglutaminase	0	I
promoters	0	I
and	0	O
a	0	O
distal	0	O
region	0	O
that	0	O
includes	0	O
a	0	O
30	0	O
-	0	O
base	0	O
pair	0	O
retinoid	0	O
response	0	O
element	0	O
(	0	O
mTGRRE1	0	O
).	0	O
mTGRRE1	0	O
contains	0	O
three	0	O
hexanucleotide	0	O
half	0	O
-	0	O
sites	0	O
(	0	O
two	0	O
canonical	0	O
and	0	O
one	0	O
non	0	O
-	0	O
canonical	0	O
)	0	O
in	0	O
a	0	O
DR7	0	B
/	0	O
DR5	0	B
motif	0	O
that	0	O
bind	0	O
both	0	O
RAR	0	B
*	0	O
RXR	0	B
heterodimers	0	O
and	0	O
RXR	0	B
homodimers	0	I
.	0	O


A	1	O
Y	1	B
.	0	I
lipolytica	0	I
Kar2p	0	I
mutant	0	I
was	0	O
isolated	0	O
that	0	O
restored	0	O
interaction	0	O
with	0	O
an	0	O
Sls1p	0	B
mutant	0	I
,	0	O
suggesting	0	O
that	0	O
the	0	O
interaction	0	O
with	0	O
Sls1p	0	B
could	0	O
be	0	O
nucleotide	0	O
and	0	O
/	0	O
or	0	O
conformation	0	O
dependent	0	O
.	0	O


An	1	O
immunoperoxidase	0	B
reaction	0	O
,	0	O
PAP	1	B
method	0	O
,	0	O
with	0	O
the	0	O
antiserum	0	O
of	0	O
Factor	1	B
VIII	0	I
as	0	O
the	0	O
primary	0	O
antibody	0	O
,	0	O
was	0	O
carried	0	O
out	0	O
in	0	O
the	0	O
endometrial	0	O
biopsies	0	O
to	0	O
detect	0	O
the	0	O
Factor	1	B
VIII	0	I
activity	0	O
in	0	O
the	0	O
endometrial	0	O
endothelium	0	O
before	0	O
and	0	O
after	0	O
insertion	0	O
of	0	O
LNG	1	O
-	0	O
IUD	1	O
-	0	O
20	0	O
.	0	O


The	0	O
polyubiquitin	0	B
gene	0	I
was	0	O
transcribed	0	O
throughout	0	O
the	0	O
Volvox	0	O
life	0	O
cycle	0	O
with	0	O
peaks	0	O
in	0	O
the	0	O
1	0	O
.	0	O
6	0	O
-	0	O
kb	0	O
mRNA	1	O
levels	0	O
during	0	O
pre	0	O
-	0	O
cleavage	0	O
,	0	O
cleavage	0	O
,	0	O
and	0	O
post	0	O
-	0	O
inversion	0	O
.	0	O


Elimination	1	O
of	0	O
bagassosis	0	O
in	0	O
Louisiana	0	O
paper	0	O
manufacturing	0	O
plant	0	O
workers	0	O
.	0	O


Surgical	1	O
treatment	0	O
of	0	O
pathologic	0	O
scars	0	O
of	0	O
myocardial	0	O
infarct	0	O


The	0	O
average	0	O
annual	0	O
cost	0	O
per	0	O
head	0	O
of	0	O
population	0	O
was	0	O
US	1	O
+	0	O
0	0	O
X	1	O
46	0	O
.	0	O


We	0	O
also	0	O
provide	0	O
evidence	0	O
that	0	O
neither	0	O
the	0	O
lambda	0	B
O	1	I
and	0	O
P	1	B
initiators	0	I
nor	0	O
the	0	O
E	1	B
.	0	I
coli	0	I
DnaJ	0	I
and	0	O
DnaK	0	B
heat	0	O
shock	0	O
proteins	0	O
play	0	O
a	0	O
direct	0	O
role	0	O
in	0	O
the	0	O
propagation	0	O
of	0	O
lambda	0	O
replication	0	O
forks	0	O
in	0	O
vitro	0	O
.	0	O


Using	0	O
mutagenesis	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
two	0	O
mutations	0	O
of	0	O
the	0	O
second	0	O
actin	0	B
-	0	I
binding	0	I
domain	0	I
that	0	O
can	0	O
also	0	O
suppress	0	O
the	0	O
act1	0	B
mutations	0	O
of	0	O
interest	0	O
.	0	O


None	0	O
of	0	O
the	0	O
patients	0	O
was	0	O
obese	0	O
.	0	O


After	0	O
acclimation	0	O
,	0	O
resting	0	O
supine	0	O
and	0	O
sitting	0	O
DPB	0	O
decreased	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
by	0	O
6	0	O
and	0	O
9	0	O
mmHg	0	O
,	0	O
respectively	0	O
.	0	O


SAM	0	O
-	0	O
TR	1	O
-	0	O
68	0	O
-	0	O
54	0	O
.	0	O


The	0	O
ratio	0	O
of	0	O
radioactivity	0	O
in	0	O
tumour	0	O
compared	0	O
with	0	O
normal	0	O
tissue	0	O
(	0	O
T	1	O
:	0	O
N	1	O
ratio	0	O
)	0	O
was	0	O
determined	0	O
after	0	O
simultaneously	0	O
injecting	0	O
microspheres	0	O
into	0	O
the	0	O
portal	0	O
and	0	O
arterial	0	O
circulation	0	O
of	0	O
each	0	O
animal	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
upstream	0	O
untranslated	0	O
region	0	O
of	0	O
CHL15	0	B
revealed	0	O
the	0	O
presence	0	O
of	0	O
the	0	O
hexamer	0	O
element	0	O
,	0	O
ACGCGT	0	O
(	0	O
an	0	O
MluI	0	B
restriction	0	I
site	0	I
)	0	O
controlling	0	O
both	0	O
the	0	O
periodic	0	O
expression	0	O
and	0	O
coordinate	0	O
regulation	0	O
of	0	O
the	0	O
DNA	1	O
synthesis	0	O
genes	0	O
in	0	O
budding	0	O
yeast	0	O
.	0	O


Many	0	O
canonical	0	O
TATA	0	O
sequences	0	O
are	0	O
present	0	O
upstream	0	O
from	0	O
these	0	O
VZV	0	O
transcriptional	0	O
start	0	O
sites	0	O
but	0	O
,	0	O
apparently	0	O
,	0	O
are	0	O
not	0	O
used	0	O
.	0	O


The	0	O
mutant	0	O
allele	0	O
of	0	O
the	0	O
alpha	0	B
1	0	I
-	0	I
tubulin	0	I
gene	0	I
was	0	O
designated	0	O
tua1	0	B
-	0	I
1	0	I
.	0	O


We	0	O
report	0	O
the	0	O
identification	0	O
and	0	O
characterization	0	O
of	0	O
myr	0	B
4	0	I
(	0	O
myosin	0	B
from	0	I
rat	0	I
),	0	O
the	0	O
first	0	O
mammalian	0	B
myosin	0	I
I	1	I
that	0	O
is	0	O
not	0	O
closely	0	O
related	0	O
to	0	O
brush	0	O
border	0	O
myosin	0	B
I	1	I
.	0	O


Deletion	1	O
and	0	O
mutational	0	O
analyses	0	O
revealed	0	O
two	0	O
positive	0	O
cis	0	O
-	0	O
regulatory	0	O
elements	0	O
in	0	O
this	0	O
region	0	O
that	0	O
are	0	O
essential	0	O
for	0	O
CSX1	0	B
expression	0	O
in	0	O
cardiomyocytes	0	O
.	0	O


Fluorometric	0	O
methods	0	O
can	0	O
also	0	O
provide	0	O
information	0	O
about	0	O
porphyrin	0	O
binding	0	O
sites	0	O
that	0	O
is	0	O
useful	0	O
in	0	O
understanding	0	O
porphyrin	0	O
transport	0	O
and	0	O
clearance	0	O
.	0	O


The	0	O
first	0	O
contains	0	O
ATF	0	B
/	0	O
CRE	0	O
and	0	O
TBP	1	B
/	0	O
TATA	0	O
sequence	0	O
motifs	0	O
within	0	O
an	0	O
87	0	O
-	0	O
bp	0	O
region	0	O
.	0	O


Range	1	O
,	0	O
variations	0	O
and	0	O
neoplastic	0	O
potential	0	O
.	0	O


SEA	1	O
was	0	O
recorded	0	O
with	0	O
bidirectional	0	O
filters	0	O
at	0	O
25	0	O
-	0	O
250	0	O
HZ	1	O
and	0	O
40	0	O
-	0	O
250	0	O
Hz	1	O
using	0	O
Simson	0	O
method	0	O
.	0	O


Recipients	0	O
with	0	O
acute	0	O
leukaemia	0	O
in	0	O
first	0	O
remission	0	O
or	0	O
chronic	0	O
myeloid	0	O
leukaemia	0	O
in	0	O
first	0	O
chronic	0	O
phase	0	O
were	0	O
analysed	0	O
as	0	O
good	0	O
risk	0	O
,	0	O
and	0	O
those	0	O
beyond	0	O
these	0	O
stages	0	O
,	0	O
as	0	O
poor	0	O
risk	0	O
patients	0	O
.	0	O


A	1	O
variety	0	O
of	0	O
nuclear	0	O
ribonucleoproteins	0	O
are	0	O
believed	0	O
to	0	O
associate	0	O
directly	0	O
with	0	O
nascent	0	O
RNA	1	B
polymerase	0	I
II	0	I
transcripts	0	I
and	0	O
remain	0	O
associated	0	O
during	0	O
subsequent	0	O
nuclear	0	O
RNA	1	O
processing	0	O
reactions	0	O
,	0	O
including	0	O
pre	0	O
-	0	O
mRNA	1	O
polyadenylation	0	O
and	0	O
splicing	0	O
as	0	O
well	0	O
as	0	O
nucleocytoplasmic	0	O
mRNA	1	O
transport	0	O
.	0	O


The	0	O
C2C	0	B
-	0	O
Prx	0	B
is	0	O
encoded	0	O
as	0	O
a	0	O
preprotein	0	O
of	0	O
273	0	O
amino	0	O
acids	0	O
containing	0	O
a	0	O
putative	0	O
chloroplast	0	O
-	0	O
targeting	0	O
signal	0	O
of	0	O
65	0	O
amino	0	O
acids	0	O
at	0	O
its	0	O
N	1	O
-	0	O
terminus	0	O
.	0	O


Insulin	1	B
regulation	0	O
of	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
kinase	0	I
(	0	O
MEK	0	B
),	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
and	0	O
casein	0	B
kinase	0	I
in	0	O
the	0	O
cell	0	O
nucleus	0	O
:	0	O
a	0	O
possible	0	O
role	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
gene	0	O
expression	0	O
.	0	O


Although	0	O
the	0	O
E	1	O
-	0	O
box	0	O
consensus	0	O
is	0	O
minimally	0	O
defined	0	O
as	0	O
CANNTG	0	O
,	0	O
the	0	O
adjacent	0	O
nucleotides	0	O
of	0	O
functional	0	O
E	1	O
-	0	O
boxes	0	O
are	0	O
variable	0	O
for	0	O
genes	0	O
regulated	0	O
by	0	O
the	0	O
bHLH	0	B
proteins	0	I
.	0	O


A	1	O
human	0	O
recombinant	0	O
cDNA	1	O
clone	0	O
that	0	O
encoded	0	O
253	0	O
amino	0	O
acids	0	O
residues	0	O
of	0	O
a	0	O
zinc	0	B
-	0	I
finger	0	I
protein	0	I
(	0	O
THZif	0	B
-	0	I
1	0	I
)	0	O
was	0	O
cloned	0	O
by	0	O
screening	0	O
a	0	O
cDNA	1	O
library	0	O
prepared	0	O
from	0	O
human	0	O
promyelocytic	0	O
leukemia	0	O
HL60	0	O
cells	0	O
with	0	O
synthetic	0	O
oligodeoxynucleotide	0	O
probes	0	O
that	0	O
corresponded	0	O
to	0	O
the	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
tryptic	0	O
peptides	0	O
derived	0	O
from	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
protein	0	O
specific	0	O
for	0	O
the	0	O
nuclease	0	B
-	0	I
hypersensitive	0	I
element	0	I
(	0	O
NHE	0	B
)	0	O
of	0	O
the	0	O
human	0	B
c	0	I
-	0	I
myc	0	I
gene	0	I
.	0	O


Since	0	O
only	0	O
58	0	O
%	0	O
of	0	O
our	0	O
sample	0	O
could	0	O
be	0	O
adequately	0	O
classified	0	O
with	0	O
one	0	O
diagnosis	0	O
,	0	O
we	0	O
expect	0	O
that	0	O
the	0	O
ASDC	0	O
nosology	0	O
will	0	O
need	0	O
to	0	O
evolve	0	O
further	0	O
.	0	O


Construction	0	O
of	0	O
human	0	O
cell	0	O
lines	0	O
which	0	O
contain	0	O
and	0	O
express	0	O
the	0	O
adenovirus	0	O
DNA	1	O
binding	0	O
protein	0	O
gene	0	O
by	0	O
cotransformation	0	O
with	0	O
the	0	O
HSV	1	B
-	0	I
1	0	I
tk	0	I
gene	0	I
.	0	O


Marked	0	O
hemolysis	0	O
significantly	0	O
increased	0	O
plasma	0	O
values	0	O
of	0	O
potassium	0	O
,	0	O
phosphorus	0	O
,	0	O
total	0	O
protein	0	O
,	0	O
and	0	O
aspartate	0	B
aminotransferase	0	I
.	0	O


In	1	O
addition	0	O
a	0	O
greater	0	O
proportion	0	O
of	0	O
women	0	O
in	0	O
the	0	O
sweeping	0	O
group	0	O
had	0	O
a	0	O
cervical	0	O
dilatation	0	O
of	0	O
4	0	O
cm	0	O
or	0	O
more	0	O
at	0	O
the	0	O
first	0	O
vaginal	0	O
examination	0	O
in	0	O
the	0	O
labour	0	O
ward	0	O
(	0	O
16	0	O
/	0	O
33	0	O
(	0	O
49	0	O
%)	0	O
vs	0	O
5	0	O
/	0	O
32	0	O
(	0	O
16	0	O
%);	0	O
OR	1	O
4	0	O
.	0	O
39	0	O
;	0	O
95	0	O
%	0	O
CI	1	O
1	0	O
.	0	O
56	0	O
to	0	O
12	0	O
.	0	O
32	0	O
;	0	O
P	1	O
=	0	O
0	0	O
.	0	O
005	0	O
).	0	O


Association	1	O
with	0	O
HL	1	B
-	0	I
A	1	I
W	1	I
-	0	I
27	0	I
.	0	O


Seventy	0	O
-	0	O
five	0	O
percent	0	O
of	0	O
children	0	O
who	0	O
received	0	O
a	0	O
second	0	O
transplant	0	O
for	0	O
HCV	1	O
hepatitis	0	O
had	0	O
early	0	O
histologic	0	O
recurrence	0	O
that	0	O
led	0	O
to	0	O
liver	0	O
failure	0	O
and	0	O
death	0	O
.	0	O


Spatial	1	O
accuracy	0	O
of	0	O
primary	0	O
and	0	O
secondary	0	O
memory	0	O
-	0	O
guided	0	O
saccades	0	O
in	0	O
schizophrenic	0	O
patients	0	O
.	0	O


The	0	O
negative	0	O
predictive	0	O
value	0	O
is	0	O
92	0	O
%,	0	O
vs	0	O
80	0	O
%	0	O
for	0	O
the	0	O
NCEP	0	O
I	1	O
.	0	O


Here	0	O
we	0	O
demonstrate	0	O
that	0	O
Hh	0	B
and	0	O
Patched	0	B
(	0	O
Ptc	1	B
)	0	O
act	0	O
through	0	O
those	0	O
Ci	1	B
binding	0	O
sites	0	O
to	0	O
modulate	0	O
the	0	O
level	0	O
of	0	O
Ci	1	B
-	0	O
dependent	0	O
transcriptional	0	O
activation	0	O
in	0	O
S2	1	O
cells	0	O
.	0	O


However	0	O
,	0	O
division	0	O
of	0	O
the	0	O
chest	0	O
wall	0	O
muscles	0	O
,	0	O
usually	0	O
with	0	O
diathermy	0	O
,	0	O
contributes	0	O
to	0	O
prolonged	0	O
pain	0	O
and	0	O
morbidity	0	O
.	0	O


Analysis	1	O
of	0	O
corticosteroids	0	O
.	0	O


The	0	O
end	0	O
-	0	O
stage	0	O
or	0	O
involutional	0	O
phase	0	O
of	0	O
proliferative	0	O
diabetic	0	O
retinopathy	0	O
may	0	O
result	0	O
in	0	O
stabilization	0	O
of	0	O
vision	0	O
for	0	O
long	0	O
periods	0	O
of	0	O
time	0	O
.	0	O


After	0	O
the	0	O
meal	0	O
containing	0	O
potato	0	O
,	0	O
plasma	0	O
glucose	0	O
levels	0	O
rose	0	O
sharply	0	O
,	0	O
peaked	0	O
at	0	O
30	0	O
-	0	O
45	0	O
min	0	O
and	0	O
fell	0	O
below	0	O
initial	0	O
levels	0	O
2	0	O
to	0	O
3	0	O
h	0	O
later	0	O
.	0	O


Specific	1	O
binding	0	O
was	0	O
not	0	O
observed	0	O
with	0	O
either	0	O
the	0	O
orthologous	0	O
rat	0	O
or	0	O
mouse	0	O
fragments	0	O
using	0	O
human	0	O
or	0	O
rodent	0	O
extracts	0	O
.	0	O


Both	0	O
strains	0	O
grew	0	O
very	0	O
poorly	0	O
,	0	O
or	0	O
not	0	O
at	0	O
all	0	O
,	0	O
on	0	O
nonfermentable	0	O
carbon	0	O
sources	0	O
and	0	O
exhibited	0	O
,	0	O
at	0	O
most	0	O
,	0	O
only	0	O
5	0	O
%	0	O
of	0	O
wild	0	B
-	0	I
type	0	I
ubiquinol	0	I
-	0	I
cytochrome	0	I
c	0	I
oxidoreductase	0	I
activity	0	O
.	0	O


We	0	O
speculate	0	O
that	0	O
the	0	O
human	0	O
papillomavirus	0	O
late	0	O
mRNAs	0	O
,	0	O
produced	0	O
from	0	O
several	0	O
hundred	0	O
copies	0	O
of	0	O
the	0	O
virus	0	O
genome	0	O
present	0	O
in	0	O
infected	0	O
cells	0	O
,	0	O
compete	0	O
with	0	O
the	0	O
c	0	B
-	0	I
fos	0	I
mRNAs	0	I
for	0	O
destabilizing	0	O
cellular	0	O
factors	0	O
and	0	O
that	0	O
this	0	O
may	0	O
lead	0	O
to	0	O
elevated	0	O
Fos	1	B
protein	0	I
levels	0	O
in	0	O
human	0	O
papillomavirus	0	O
infected	0	O
cells	0	O
.	0	O


Using	0	O
himA	0	B
mutants	0	I
,	0	O
we	0	O
confirmed	0	O
that	0	O
IHF	0	B
plays	0	O
a	0	O
role	0	O
in	0	O
the	0	O
molybdate	0	O
-	0	O
dependent	0	O
regulation	0	O
of	0	O
dmsA	1	B
-	0	O
lacZ	0	B
expression	0	O
in	0	O
vivo	0	O
.	0	O


Amikacin	1	O
was	0	O
used	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
56	0	O
serious	0	O
gram	0	O
-	0	O
negative	0	O
infections	0	O
in	0	O
54	0	O
patients	0	O
of	0	O
whom	0	O
47	0	O
survived	0	O
.	0	O


Treatment	1	O
of	0	O
suppurative	0	O
peritonitis	0	O


Unlike	0	O
the	0	O
typical	0	O
enhancer	0	O
element	0	O
,	0	O
this	0	O
region	0	O
functions	0	O
in	0	O
an	0	O
orientation	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


The	0	O
observed	0	O
sequence	0	O
variation	0	O
disrupts	0	O
the	0	O
first	0	O
ORF	1	O
in	0	O
many	0	O
Y	1	B
'	0	O
s	0	O
while	0	O
most	0	O
of	0	O
the	0	O
second	0	O
ORF	1	O
including	0	O
the	0	O
putative	0	O
helicase	0	B
region	0	I
is	0	O
unaffected	0	O
.	0	O


Patients	0	O
receiving	0	O
VPA	0	O
showed	0	O
differences	0	O
in	0	O
attention	0	O
,	0	O
visuomotor	0	O
performance	0	O
,	0	O
verbal	0	O
span	0	O
and	0	O
sensory	0	O
discrimination	0	O
tasks	0	O
at	0	O
T1	1	O
,	0	O
in	0	O
visuomotor	0	O
performance	0	O
at	0	O
T2	0	O
and	0	O
in	0	O
spatial	0	O
span	0	O
at	0	O
T3	1	O
,	0	O
whereas	0	O
no	0	O
differences	0	O
were	0	O
detected	0	O
at	0	O
T4	1	O
.	0	O


Unlike	0	O
the	0	O
introns	0	O
of	0	O
other	0	O
duplicated	0	O
ribosomal	0	B
protein	0	I
genes	0	I
which	0	O
are	0	O
highly	0	O
diverged	0	O
,	0	O
the	0	O
duplicated	0	O
S13	0	B
genes	0	I
have	0	O
two	0	O
nearly	0	O
identical	0	O
DNA	1	O
sequences	0	O
of	0	O
25	0	O
and	0	O
31	0	O
bp	0	O
in	0	O
length	0	O
within	0	O
their	0	O
introns	0	O
.	0	O


Isolation	1	O
and	0	O
characterization	0	O
of	0	O
a	0	O
vinculin	0	B
cDNA	1	I
from	0	I
chick	0	I
-	0	I
embryo	0	I
fibroblasts	0	I
.	0	O


One	0	O
of	0	O
these	0	O
,	0	O
the	0	O
origin	0	O
core	0	O
,	0	O
is	0	O
required	0	O
only	0	O
for	0	O
DNA	1	O
replication	0	O
.	0	O


Tumor	1	O
cells	0	O
were	0	O
focally	0	O
immunoreactive	0	O
for	0	O
neuron	0	B
-	0	I
specific	0	I
enolase	0	I
,	0	O
insulin	0	B
,	0	O
glucagon	0	B
and	0	O
VIP	1	B
.	0	O


Purified	0	O
CarP	1	B
binds	0	O
in	0	O
vitro	0	O
to	0	O
the	0	O
carAB	0	B
control	0	I
region	0	I
and	0	O
protects	0	O
against	0	O
DNase	1	B
I	1	I
two	0	O
approximately	0	O
25	0	O
bp	0	O
long	0	O
stretches	0	O
,	0	O
one	0	O
of	0	O
which	0	O
is	0	O
located	0	O
just	0	O
downstream	0	O
of	0	O
the	0	O
GATC	0	O
sequence	0	O
.	0	O


Furthermore	0	O
,	0	O
transfection	0	O
of	0	O
cells	0	O
with	0	O
the	0	O
spacer	0	O
-	0	O
RING	1	O
domain	0	O
alone	0	O
suppressed	0	O
the	0	O
antiapoptotic	0	O
function	0	O
of	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
BIR	0	B
domain	0	O
of	0	O
c	0	B
-	0	I
IAP1	0	I
and	0	O
induced	0	O
apoptosis	0	O
.	0	O


The	0	O
molecular	0	O
mechanism	0	O
by	0	O
which	0	O
Gle2p	0	B
and	0	O
the	0	O
Gle2p	0	B
-	0	O
Nup116p	0	B
interaction	0	O
function	0	O
in	0	O
mRNA	1	O
export	0	O
is	0	O
unknown	0	O
.	0	O


In	1	O
this	0	O
study	0	O
we	0	O
have	0	O
investigated	0	O
the	0	O
role	0	O
of	0	O
C	1	B
/	0	I
EBP	1	I
beta	0	I
in	0	O
initiating	0	O
the	0	O
adipogenic	0	O
program	0	O
by	0	O
overexpressing	0	O
C	1	B
/	0	I
EBP	1	I
beta	0	I
in	0	O
multipotential	0	O
NIH	1	O
-	0	O
3T3	0	O
fibroblasts	0	O
.	0	O


Thirty	0	O
isolates	0	O
of	0	O
Haemophilus	1	O
influenzae	0	O
type	0	O
b	0	O
were	0	O
obtained	0	O
during	0	O
an	0	O
outbreak	0	O
of	0	O
invasive	0	O
H	1	O
.	0	O
influenzae	0	O
type	0	O
b	0	O
disease	0	O
and	0	O
were	0	O
classified	0	O
by	0	O
the	0	O
electrophoretic	0	O
profile	0	O
of	0	O
their	0	O
lipopolysaccharide	0	O
(	0	O
LPS	1	O
).	0	O


In	1	O
girls	0	O
prolactin	0	B
levels	0	O
rise	0	O
at	0	O
stage	0	O
2	0	O
,	0	O
and	0	O
are	0	O
higher	0	O
after	0	O
menarche	0	O
;	0	O
in	0	O
boys	0	O
there	0	O
is	0	O
no	0	O
change	0	O
in	0	O
prolactin	0	B
levels	0	O
.	0	O


This	0	O
technique	0	O
has	0	O
a	0	O
sensitivity	0	O
and	0	O
a	0	O
specificity	0	O
of	0	O
almost	0	O
100	0	O
%,	0	O
and	0	O
is	0	O
currently	0	O
the	0	O
best	0	O
way	0	O
to	0	O
diagnose	0	O
nodal	0	O
involvement	0	O
,	0	O
apart	0	O
from	0	O
laparotomy	0	O
.	0	O


When	0	O
the	0	O
high	0	O
affinity	0	O
hnRNP	1	B
A1	0	I
binding	0	I
site	0	I
was	0	O
inserted	0	O
into	0	O
the	0	O
beta	0	B
-	0	I
globin	0	I
reporter	0	I
,	0	O
Rev	0	B
was	0	O
able	0	O
to	0	O
increase	0	O
the	0	O
cytoplasmic	0	O
levels	0	O
of	0	O
unspliced	0	O
mRNAs	0	O
to	0	O
14	0	O
%.	0	O


Radiolabeled	1	O
recombinant	0	B
TARC	0	I
specifically	0	O
bound	0	O
to	0	O
T	1	O
cell	0	O
lines	0	O
and	0	O
peripheral	0	O
T	1	O
cells	0	O
but	0	O
not	0	O
to	0	O
monocytes	0	O
or	0	O
granulocytes	0	O
.	0	O


Transfection	1	O
of	0	O
HepG2	0	O
and	0	O
SK	1	O
-	0	O
N	1	O
-	0	O
MC	1	O
cells	0	O
with	0	O
constructs	0	O
deleted	0	O
of	0	O
additional	0	O
5	0	O
'-	0	O
flanking	0	O
fragments	0	O
permitted	0	O
the	0	O
definition	0	O
of	0	O
a	0	O
minimal	0	O
200	0	O
bp	0	O
promoter	0	O
fragment	0	O
containing	0	O
the	0	O
pseudo	0	O
-	0	O
TATA	0	O
box	0	O
and	0	O
two	0	O
putative	0	O
SP1	0	B
-	0	I
binding	0	I
sites	0	I
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
expression	0	O
of	0	O
Cktsf1b1	0	B
,	0	O
a	0	O
gene	0	O
associated	0	O
with	0	O
early	0	O
development	0	O
and	0	O
cell	0	O
transformation	0	O
,	0	O
is	0	O
sensitive	0	O
to	0	O
MKK	0	B
levels	0	O
and	0	O
may	0	O
be	0	O
regulated	0	O
via	0	O
multiple	0	O
transcription	0	O
factor	0	O
complexes	0	O
.	0	O


One	0	O
unit	0	O
encodes	0	O
traA	0	B
,	0	O
traF	0	B
,	0	O
and	0	O
traB	1	B
,	0	O
while	0	O
the	0	O
second	0	O
encodes	0	O
traC	0	B
,	0	O
traD	0	B
,	0	O
and	0	O
traG	0	B
.	0	O


Imaging	1	O
of	0	O
D2	0	B
dopamine	0	I
receptor	0	I


Erythrocyte	1	O
AA	1	O
in	0	O
FO	0	O
+	0	O
EPO	0	B
-	0	O
supplemented	0	O
infants	0	O
remained	0	O
low	0	O
and	0	O
below	0	O
breast	0	O
-	0	O
and	0	O
placebo	0	O
formula	0	O
-	0	O
fed	0	O
levels	0	O
.	0	O


Clinical	1	O
applications	0	O
of	0	O
inhibition	0	O
of	0	O
beta	0	B
-	0	I
adrenergic	0	I
receptors	0	I
with	0	O
propranolol	0	O
.	0	O


During	0	O
chronic	0	O
treatment	0	O
,	0	O
when	0	O
plasma	0	O
concentrations	0	O
fluctuated	0	O
between	0	O
23	0	O
.	0	O
5	0	O
ng	0	O
.	0	O
ml	0	O
-	0	O
1	0	O
at	0	O
8	0	O
h	0	O
and	0	O
14	0	O
ng	0	O
.	0	O
ml	0	O
-	0	O
1	0	O
at	0	O
24	0	O
h	0	O
post	0	O
-	0	O
dosing	0	O
,	0	O
ST	1	O
segment	0	O
depression	0	O
at	0	O
an	0	O
individually	0	O
comparable	0	O
workload	0	O
was	0	O
significantly	0	O
decreased	0	O
by	0	O
28	0	O
%	0	O
compared	0	O
with	0	O
placebo	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
005	0	O
)	0	O
at	0	O
both	0	O
points	0	O
in	0	O
time	0	O
.	0	O


PhoP	0	B
-	0	O
PhoQ	0	B
homologues	0	O
in	0	O
Pseudomonas	1	O
aeruginosa	0	O
regulate	0	O
expression	0	O
of	0	O
the	0	O
outer	0	B
-	0	I
membrane	0	I
protein	0	I
OprH	0	I
and	0	O
polymyxin	0	O
B	1	O
resistance	0	O
.	0	O


Since	0	O
the	0	O
ETS	1	B
domain	0	I
,	0	O
which	0	O
is	0	O
localized	0	O
in	0	O
the	0	O
carboxy	0	O
terminal	0	O
region	0	O
of	0	O
the	0	O
encoded	0	O
protein	0	O
,	0	O
is	0	O
95	0	O
%	0	O
and	0	O
96	0	O
%	0	O
identical	0	O
to	0	O
that	0	O
of	0	O
PEA3	0	B
and	0	O
ER81	0	B
,	0	O
respectively	0	O
,	0	O
we	0	O
named	0	O
this	0	O
new	0	O
member	0	O
'	0	B
Ets	1	I
Related	0	I
Molecule	1	I
PEA3	0	I
-	0	I
like	0	I
'	0	I
(	0	O
ERM	1	B
).	0	O


The	0	O
pharmacology	0	O
of	0	O
carnitine	0	O
.	0	O


This	0	O
effect	0	O
and	0	O
the	0	O
fact	0	O
that	0	O
all	0	O
three	0	O
doses	0	O
were	0	O
toxic	0	O
to	0	O
the	0	O
dams	0	O
dictated	0	O
that	0	O
a	0	O
second	0	O
experiment	0	O
be	0	O
carried	0	O
out	0	O
at	0	O
lower	0	O
doses	0	O
.	0	O


The	0	O
recovered	0	O
calves	0	O
were	0	O
tested	0	O
for	0	O
immunity	0	O
to	0	O
homologous	0	O
severe	0	O
challenge	0	O
,	0	O
50	0	O
or	0	O
73	0	O
days	0	O
after	0	O
the	0	O
first	0	O
infection	0	O
.	0	O


AB004534	0	B
.	0	O


Mechanism	1	O
of	0	O
the	0	O
t	0	O
(	0	O
14	0	O
;	0	O
18	0	O
)	0	O
chromosomal	0	O
translocation	0	O
:	0	O
structural	0	O
analysis	0	O
of	0	O
both	0	O
derivative	0	O
14	0	O
and	0	O
18	0	O
reciprocal	0	O
partners	0	O
.	0	O


The	0	O
p34	0	B
.	0	I
8	0	I
gene	0	I
has	0	O
a	0	O
strong	0	O
codon	0	O
usage	0	O
bias	0	O
which	0	O
is	0	O
strikingly	0	O
different	0	O
from	0	O
that	0	O
of	0	O
the	0	O
polyhedrin	0	B
gene	0	I
.	0	O


The	0	O
localization	0	O
of	0	O
this	0	O
proteoglycan	0	O
locus	0	O
in	0	O
the	0	O
human	0	O
genome	0	O
and	0	O
the	0	O
availability	0	O
of	0	O
new	0	O
RFLPs	0	O
provide	0	O
the	0	O
tools	0	O
for	0	O
future	0	O
studies	0	O
of	0	O
human	0	O
diseases	0	O
where	0	O
the	0	O
HSPG2	0	B
proteoglycan	0	I
gene	0	I
is	0	O
suspected	0	O
to	0	O
be	0	O
involved	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
despite	0	O
external	0	O
radiation	0	O
therapy	0	O
,	0	O
brain	0	O
metastases	0	O
proved	0	O
fatal	0	O
.	0	O


These	0	O
same	0	O
regions	0	O
showed	0	O
remarkable	0	O
homology	0	O
to	0	O
two	0	O
invertebrate	0	O
proteins	0	O
,	0	O
CNC	0	B
and	0	O
skin	0	B
-	0	I
1	0	I
,	0	O
postulated	0	O
to	0	O
regulate	0	O
embryonic	0	O
development	0	O
in	0	O
Drosophila	1	O
melanogaster	0	O
and	0	O
Caenorhabditis	0	O
elegans	0	O
,	0	O
respectively	0	O
.	0	O


Mapping	1	O
of	0	O
the	0	O
DNA	1	O
binding	0	O
domain	0	O
of	0	O
the	0	O
copper	0	O
-	0	O
responsive	0	O
transcription	0	O
factor	0	O
Mac1	0	B
from	0	I
Saccharomyces	1	I
cerevisiae	0	I
.	0	O


The	0	O
purpose	0	O
of	0	O
this	0	O
study	0	O
is	0	O
twofold	0	O
:	0	O
(	0	O
1	0	O
)	0	O
to	0	O
present	0	O
a	0	O
parallel	0	O
form	0	O
of	0	O
the	0	O
Gudjonsson	0	O
Suggestibility	1	O
Scale	1	O
(	0	O
GSS	1	O
,	0	O
Form	1	O
1	0	O
);	0	O
(	0	O
2	0	O
)	0	O
to	0	O
study	0	O
test	0	O
-	0	O
retest	0	O
reliabilities	0	O
of	0	O
interrogative	0	O
suggestibility	0	O
.	0	O


2	0	O
cases	0	O
of	0	O
type	0	O
II	0	O
tyrosinosis	0	O
(	0	O
Richner	0	O
-	0	O
Hanhart	0	O
syndrome	0	O
)	0	O


Our	0	O
mapping	0	O
results	0	O
did	0	O
not	0	O
suggest	0	O
involvement	0	O
of	0	O
this	0	O
gene	0	O
in	0	O
previously	0	O
mapped	0	O
genetic	0	O
disorders	0	O
or	0	O
in	0	O
known	0	O
neoplasia	0	O
-	0	O
associated	0	O
translocation	0	O
breakpoints	0	O
.	0	O


The	0	O
financial	0	O
impact	0	O
of	0	O
childhood	0	O
asthma	0	O
has	0	O
not	0	O
been	0	O
assessed	0	O
since	0	O
Vance	0	O
and	0	O
Taylor	0	O
reported	0	O
their	0	O
data	0	O
in	0	O
Annals	0	O
of	0	O
Allergy	1	O
13	0	O
years	0	O
ago	0	O
.	0	O


IgG	1	B
and	0	O
IgM	1	B
antibody	0	O
activity	0	O
was	0	O
determined	0	O
by	0	O
adding	0	O
a	0	O
1	0	O
:	0	O
100	0	O
dilution	0	O
of	0	O
serum	0	O
to	0	O
plates	0	O
coated	0	O
with	0	O
A60	0	B
antigen	0	I
.	0	O


In	1	O
a	0	O
reconstituted	0	O
human	0	O
DNA	1	O
repair	0	O
system	0	O
containing	0	O
DNA	1	B
polymerase	0	I
beta	0	I
and	0	O
DNA	1	B
ligase	0	I
III	0	I
-	0	O
XRCC1	0	B
,	0	O
accurate	0	O
rejoining	0	O
of	0	O
a	0	O
3	0	O
'	0	O
mismatched	0	O
base	0	O
residue	0	O
at	0	O
a	0	O
single	0	O
-	0	O
strand	0	O
break	0	O
is	0	O
dependent	0	O
on	0	O
addition	0	O
of	0	O
the	0	O
exonuclease	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Our	0	O
findings	0	O
suggest	0	O
that	0	O
pre	0	O
-	0	O
treatment	0	O
with	0	O
coenzyme	0	O
Q10	1	O
may	0	O
play	0	O
a	0	O
protective	0	O
role	0	O
during	0	O
routine	0	O
vascular	0	O
procedures	0	O
requiring	0	O
abdominal	0	O
aortic	0	O
cross	0	O
clamping	0	O
by	0	O
attenuating	0	O
the	0	O
degree	0	O
of	0	O
peroxidative	0	O
damage	0	O
.	0	O


An	1	O
examination	0	O
was	0	O
performed	0	O
in	0	O
15	0	O
patients	0	O
who	0	O
had	0	O
developed	0	O
pronounced	0	O
osteomalacia	0	O
following	0	O
gastric	0	O
resection	0	O
.	0	O


We	0	O
have	0	O
utilized	0	O
the	0	O
human	0	B
4F2	0	I
heavy	0	I
chain	0	I
(	0	O
4F2HC	0	B
)	0	O
gene	0	O
as	0	O
a	0	O
model	0	O
system	0	O
in	0	O
studies	0	O
designed	0	O
to	0	O
elucidate	0	O
the	0	O
molecular	0	O
events	0	O
involved	0	O
in	0	O
regulating	0	O
inducible	0	O
gene	0	O
expression	0	O
during	0	O
normal	0	O
human	0	O
T	1	O
-	0	O
cell	0	O
activation	0	O
.	0	O


Sequence	1	O
of	0	O
10q24	0	B
locus	0	I
surrounding	0	O
the	0	O
HOX11	0	B
oncogene	0	I
reveals	0	O
a	0	O
new	0	O
gene	0	O
HUG1	0	B
expressed	0	O
in	0	O
a	0	O
T	1	O
-	0	O
ALL	1	O
cell	0	O
line	0	O
.	0	O


4	0	O
)	0	O
PU	1	B
and	0	O
PD	1	B
lacked	0	O
the	0	O
canonical	0	O
TATA	0	O
or	0	O
CAAT	0	O
motifs	0	O
,	0	O
and	0	O
are	0	O
AT	1	O
-	0	O
rich	0	O
.	0	O


The	0	O
sequence	0	O
up	0	O
to	0	O
-	0	O
267	0	O
bp	0	O
relative	0	O
to	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
was	0	O
sufficient	0	O
to	0	O
enhance	0	O
reporter	0	O
gene	0	O
expression	0	O
depending	0	O
on	0	O
the	0	O
mesodermal	0	O
differentiation	0	O
of	0	O
P19	0	O
cells	0	O
.	0	O


Tec	0	B
kinase	0	I
signaling	0	O
in	0	O
T	1	O
cells	0	O
is	0	O
regulated	0	O
by	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
and	0	O
the	0	O
Tec	0	B
pleckstrin	0	I
homology	0	I
domain	0	I
.	0	O


Intraventricular	1	O
injection	0	O
of	0	O
(	0	O
2S	0	O
,	0	O
1	0	O
'	0	O
R	1	O
,	0	O
2	0	O
'	0	O
R	1	O
,	0	O
3	0	O
'	0	O
R	1	O
)-	0	O
2	0	O
-(	0	O
2	0	O
,	0	O
3	0	O
-	0	O
dicarboxycyclopropyl	0	O
)	0	O
glycine	0	O
(	0	O
DCG	0	O
-	0	O
IV	1	O
),	0	O
a	0	O
potent	0	O
agonist	0	O
for	0	O
metabotropic	0	O
glutamate	0	B
receptors	0	I
,	0	O
to	0	O
rats	0	O
retarded	0	O
dose	0	O
-	0	O
dependently	0	O
the	0	O
recovery	0	O
from	0	O
halothane	0	O
anesthesia	0	O
at	0	O
a	0	O
dose	0	O
range	0	O
from	0	O
30	0	O
to	0	O
300	0	O
pmol	0	O
/	0	O
rat	0	O
.	0	O


The	0	O
reconstituted	0	O
RNA	1	B
polymerases	0	I
containing	0	O
the	0	O
mutant	0	O
alpha	0	O
subunits	0	O
were	0	O
examined	0	O
for	0	O
their	0	O
response	0	O
to	0	O
transcription	0	O
activation	0	O
by	0	O
cAMP	1	B
-	0	I
CRP	1	I
and	0	O
the	0	O
rrnBP1	0	B
UP	0	I
element	0	I
.	0	O


The	0	O
ERH	0	B
expression	0	O
profile	0	O
is	0	O
similar	0	O
,	0	O
to	0	O
that	0	O
of	0	O
An3	0	B
,	0	O
which	0	O
localizes	0	O
to	0	O
the	0	O
animal	0	O
hemisphere	0	O
of	0	O
oocytes	0	O
and	0	O
is	0	O
abundantly	0	O
expressed	0	O
in	0	O
the	0	O
embryo	0	O
.	0	O


Magnetic	1	O
trapping	0	O
of	0	O
spin	0	O
-	0	O
polarized	0	O
atomic	0	O
hydrogen	0	O
.	0	O


Stromelysin	1	B
-	0	I
1	0	I
,	0	O
matrix	0	B
metalloproteinase	0	I
-	0	I
3	0	I
(	0	O
MMP	1	B
-	0	I
3	0	I
),	0	O
is	0	O
an	0	O
important	0	O
endopeptidase	0	O
selectively	0	O
expressed	0	O
by	0	O
somatic	0	O
cells	0	O
in	0	O
organ	0	O
tissues	0	O
.	0	O


We	0	O
showed	0	O
previously	0	O
that	0	O
a	0	O
fusion	0	O
protein	0	O
(	0	O
GAL4	0	B
-	0	O
p40	0	B
)	0	O
containing	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
of	0	O
GAL4	0	B
and	0	O
sequences	0	O
of	0	O
chicken	0	B
l	0	I
kappa	0	I
B	1	I
-	0	I
alpha	0	I
(	0	O
p40	0	B
)	0	O
inhibits	0	O
growth	0	O
in	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Moreover	0	O
,	0	O
promoters	0	O
containing	0	O
a	0	O
TATA	0	O
box	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
Sp1	0	B
sites	0	I
or	0	O
Sp1	0	B
sites	0	I
in	0	O
the	0	O
absence	0	O
of	0	O
a	0	O
TATA	0	O
box	0	O
were	0	O
equally	0	O
inducible	0	O
in	0	O
vitro	0	O
,	0	O
as	0	O
was	0	O
an	0	O
RNA	1	B
polymerase	0	I
III	0	I
promoter	0	I
.	0	O


Anti	0	B
-	0	I
B	1	I
.	0	I
burgdorferi	0	I
,	0	O
anti	0	B
-	0	I
B	1	I
.	0	I
turicatae	0	I
and	0	O
anti	0	B
-	0	I
B	1	I
.	0	I
parkeri	0	I
antibodies	0	I
,	0	O
tested	0	O
by	0	O
the	0	O
indirect	0	O
immunofluorescent	0	O
assay	0	O
(	0	O
IFA	1	O
),	0	O
were	0	O
detected	0	O
in	0	O
10	0	O
.	0	O
8	0	O
,	0	O
16	0	O
.	0	O
1	0	O
and	0	O
8	0	O
.	0	O
2	0	O
%	0	O
of	0	O
the	0	O
serum	0	O
samples	0	O
tested	0	O
,	0	O
and	0	O
confirmed	0	O
by	0	O
IFA	1	O
-	0	O
ABS	1	O
in	0	O
1	0	O
.	0	O
3	0	O
,	0	O
1	0	O
.	0	O
3	0	O
and	0	O
1	0	O
.	0	O
0	0	O
%,	0	O
respectively	0	O
.	0	O


These	0	O
and	0	O
other	0	O
data	0	O
presented	0	O
suggest	0	O
that	0	O
TAg	1	B
'	0	O
re	0	O
-	0	O
models	0	O
'	0	O
host	0	O
cell	0	O
transcription	0	O
factors	0	O
that	0	O
are	0	O
used	0	O
early	0	O
in	0	O
viral	0	O
infection	0	O
,	0	O
and	0	O
thereby	0	O
mimics	0	O
an	0	O
event	0	O
that	0	O
naturally	0	O
occurs	0	O
during	0	O
transformation	0	O
.	0	O


Together	0	O
,	0	O
these	0	O
results	0	O
suggest	0	O
that	0	O
EGF	1	B
/	0	O
Ras	1	B
/	0	O
Raf	0	B
induces	0	O
transcription	0	O
via	0	O
combined	0	O
activation	0	O
of	0	O
ATF3	0	B
/	0	O
c	0	B
-	0	I
Jun	1	I
and	0	O
a	0	O
52	0	O
-	0	O
kDa	1	O
nuclear	0	O
factor	0	O
,	0	O
whereas	0	O
JunD	0	B
acts	0	O
as	0	O
a	0	O
repressor	0	O
of	0	O
this	0	O
response	0	O
.	0	O


These	0	O
results	0	O
would	0	O
suggest	0	O
that	0	O
a	0	O
high	0	O
UV	1	O
sensitivity	0	O
is	0	O
associated	0	O
with	0	O
high	0	O
phaeomelanin	0	O
and	0	O
low	0	O
eumelanin	0	O
levels	0	O
,	0	O
and	0	O
point	0	O
to	0	O
the	0	O
eumelanin	0	O
/	0	O
phaeomelanin	0	O
ratio	0	O
as	0	O
a	0	O
novel	0	O
chemical	0	O
parameter	0	O
that	0	O
could	0	O
be	0	O
used	0	O
for	0	O
predicting	0	O
individuals	0	O
at	0	O
high	0	O
risk	0	O
for	0	O
skin	0	O
cancer	0	O
and	0	O
melanoma	0	O
.	0	O


A	1	O
second	0	O
,	0	O
novel	0	O
C	1	O
subunit	0	O
(	0	O
CeCAT	0	O
alpha	0	O
',	0	O
374	0	O
residues	0	O
)	0	O
has	0	O
a	0	O
unique	0	O
56	0	O
-	0	O
residue	0	O
carboxyl	0	O
-	0	O
terminal	0	O
region	0	O
that	0	O
is	0	O
generated	0	O
by	0	O
the	0	O
alternative	0	O
splicing	0	O
of	0	O
the	0	O
C	1	B
pre	0	I
-	0	I
mRNA	1	I
.	0	O


The	0	O
author	0	O
analyzes	0	O
extensive	0	O
own	0	O
data	0	O
based	0	O
on	0	O
study	0	O
into	0	O
particular	0	O
features	0	O
of	0	O
cardiovascular	0	O
disorders	0	O
in	0	O
chronic	0	O
renal	0	O
impairement	0	O
with	0	O
making	0	O
use	0	O
of	0	O
modern	0	O
diagnostic	0	O
tools	0	O
.	0	O


Structure	1	O
and	0	O
localization	0	O
of	0	O
the	0	O
human	0	O
gene	0	O
encoding	0	O
SR	1	B
-	0	I
BI	1	I
/	0	O
CLA	0	B
-	0	I
1	0	I
.	0	O


In	1	O
only	0	O
two	0	O
patients	0	O
were	0	O
we	0	O
able	0	O
to	0	O
demonstrate	0	O
changes	0	O
suggestive	0	O
of	0	O
pulmonary	0	O
metastases	0	O
any	0	O
earlier	0	O
with	0	O
a	0	O
99mTc	0	O
-	0	O
EHDP	1	O
scan	0	O
than	0	O
with	0	O
chest	0	O
radiographs	0	O
and	0	O
one	0	O
of	0	O
these	0	O
resolved	0	O
spontaneously	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
and	0	O
functionally	0	O
characterized	0	O
the	0	O
mouse	0	O
gene	0	O
for	0	O
the	0	O
C2	1	O
subunit	0	O
of	0	O
the	0	O
20S	0	B
proteasome	0	I
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
sulfhydryl	0	O
group	0	O
of	0	O
certain	0	O
angiotensin	0	B
converting	0	I
enzyme	0	I
inhibitors	0	O
can	0	O
potentiate	0	O
their	0	O
effect	0	O
on	0	O
the	0	O
endogenous	0	O
nitrovasodilator	0	O
EDRF	1	B
.	0	O


Regulation	1	O
of	0	O
yeast	0	B
LEU2	0	I
.	0	O


Further	0	O
,	0	O
Tax	0	B
-	0	O
mediated	0	O
apoptosis	0	O
was	0	O
effectively	0	O
prevented	0	O
by	0	O
ectopic	0	O
expression	0	O
of	0	O
the	0	O
p300	0	B
coactivator	0	I
.	0	O


Type	1	O
II	0	O
could	0	O
be	0	O
divided	0	O
further	0	O
into	0	O
two	0	O
forms	0	O
(	0	O
IIA	0	O
and	0	O
IIB	0	O
)	0	O
that	0	O
may	0	O
represent	0	O
two	0	O
underscribed	0	O
species	0	O
or	0	O
developmental	0	O
stages	0	O
of	0	O
the	0	O
same	0	O
species	0	O
.	0	O


The	0	O
method	0	O
has	0	O
been	0	O
routinely	0	O
used	0	O
in	0	O
our	0	O
laboratory	0	O
for	0	O
1	0	O
year	0	O
and	0	O
has	0	O
proven	0	O
to	0	O
be	0	O
a	0	O
reliable	0	O
procedure	0	O
for	0	O
the	0	O
biological	0	O
control	0	O
of	0	O
occupational	0	O
exposure	0	O
to	0	O
toluene	0	O
and	0	O
/	0	O
or	0	O
xylene	0	O
.	0	O


Our	0	O
laboratory	0	O
has	0	O
recently	0	O
identified	0	O
two	0	O
phosducin	0	B
-	0	I
like	0	I
orphan	0	I
proteins	0	I
(	0	O
PhLOP1	0	B
and	0	O
PhLOP2	0	B
)	0	O
that	0	O
lack	0	O
the	0	O
ability	0	O
to	0	O
interact	0	O
with	0	O
Gbetagamma	0	B
.	0	O


Two	0	O
scintigraphic	0	O
methods	0	O
,	0	O
resting	0	O
dipyridamole	0	O
and	0	O
exercise	0	O
thallium	0	O
-	0	O
201	0	O
myocardial	0	O
perfusion	0	O
imaging	0	O
,	0	O
to	0	O
detect	0	O
and	0	O
localize	0	O
coronary	0	O
artery	0	O
stenosis	0	O
were	0	O
compared	0	O
in	0	O
32	0	O
patients	0	O
suffering	0	O
from	0	O
coronary	0	O
artery	0	O
disease	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
intact	0	O
hGH	1	B
gene	0	I
or	0	O
hGH	1	B
5	0	I
'-	0	I
flanking	0	I
DNA	1	I
(	0	I
5	0	I
'-	0	I
FR	1	I
)	0	I
coupled	0	O
to	0	O
the	0	O
hGh	1	B
cDNA	1	I
or	0	O
chloramphenicol	0	B
acetyltransferase	0	I
or	0	O
luciferase	0	B
genes	0	I
,	0	O
indicated	0	O
that	0	O
cAMP	1	O
primarily	0	O
stimulated	0	O
hGH	1	B
promoter	0	I
activity	0	O
.	0	O


False	0	O
positive	0	O
amniotic	0	B
fluid	0	I
alpha	0	I
fetoprotein	0	I
levels	0	O
resulting	0	O
from	0	O
contamination	0	O
with	0	O
fetal	0	O
blood	0	O
:	0	O
results	0	O
of	0	O
an	0	O
experiment	0	O
.	0	O


The	0	O
genes	0	O
at	0	O
each	0	O
locus	0	O
are	0	O
divergently	0	O
transcribed	0	O
and	0	O
the	0	O
coding	0	O
sequences	0	O
are	0	O
separated	0	O
by	0	O
646	0	O
base	0	O
-	0	O
pairs	0	O
at	0	O
one	0	O
locus	0	O
and	0	O
676	0	O
base	0	O
-	0	O
pairs	0	O
at	0	O
the	0	O
other	0	O
.	0	O


Moreover	0	O
,	0	O
in	0	O
rats	0	O
allowed	0	O
to	0	O
choose	0	O
in	0	O
a	0	O
T	1	O
-	0	O
maze	0	O
between	0	O
immediate	0	O
-	0	O
but	0	O
-	0	O
small	0	O
vs	0	O
.	0	O
delayed	0	O
-	0	O
but	0	O
-	0	O
large	0	O
reward	0	O
,	0	O
BZP	0	O
significantly	0	O
decreased	0	O
the	0	O
frequency	0	O
with	0	O
which	0	O
the	0	O
delayed	0	O
reward	0	O
was	0	O
chosen	0	O
,	0	O
with	0	O
5	0	O
-	0	O
HT	1	O
uptake	0	O
blockers	0	O
producing	0	O
opposite	0	O
effects	0	O
.	0	O


Following	1	O
chondroitinase	0	B
AC	1	I
and	0	I
ABC	1	I
digestion	0	O
,	0	O
staining	0	O
reactions	0	O
suggested	0	O
that	0	O
the	0	O
highest	0	O
levels	0	O
of	0	O
dermatan	0	O
sulfate	0	O
were	0	O
in	0	O
the	0	O
diabetes	0	O
resistant	0	O
group	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
compared	0	O
to	0	O
diabetic	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
compared	0	O
to	0	O
diabetes	0	O
prone	0	O
)	0	O
and	0	O
the	0	O
highest	0	O
levels	0	O
of	0	O
chondroitin	0	O
sulfates	0	O
were	0	O
in	0	O
the	0	O
diabetes	0	O
prone	0	O
group	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


Analysis	1	O
of	0	O
the	0	O
consensus	0	O
binding	0	O
sequence	0	O
and	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
of	0	O
ZF5	0	B
.	0	O


MICs	0	O
of	0	O
four	0	O
antifungal	0	O
agents	0	O
(	0	O
5	0	O
-	0	O
fluorocytosine	0	O
,	0	O
miconazole	0	O
,	0	O
ketoconazole	0	O
,	0	O
and	0	O
amphotericin	0	O
B	1	O
)	0	O
for	0	O
84	0	O
clinical	0	O
isolates	0	O
of	0	O
various	0	O
Candida	1	O
species	0	O
were	0	O
then	0	O
determined	0	O
with	0	O
both	0	O
media	0	O
in	0	O
agar	0	O
dilution	0	O
and	0	O
microtiter	0	O
broth	0	O
dilution	0	O
systems	0	O
.	0	O


Students	0	O
,	0	O
parents	0	O
,	0	O
teachers	0	O
and	0	O
hearing	0	O
disorders	0	O


3	0	O
-(	0	O
N	1	O
-	0	O
Alkyl	1	O
-	0	O
N	1	O
-	0	O
2	0	O
-	0	O
chloroethylaminomethyl	0	O
)-	0	O
5	0	O
-	0	O
or	0	O
7	0	O
-	0	O
halogenobenzo	0	O
[	0	O
b	0	O
]	0	O
thiophen	0	O
hydrochlorides	0	O
.	0	O


Biochemical	1	O
analysis	0	O
shows	0	O
that	0	O
Ssm1p	0	B
is	0	O
a	0	O
structural	0	O
protein	0	O
that	0	O
forms	0	O
part	0	O
of	0	O
the	0	O
largest	0	O
60S	0	B
ribosomal	0	I
subunit	0	I
,	0	O
which	0	O
does	0	O
not	0	O
exist	0	O
in	0	O
a	0	O
pool	0	O
of	0	O
free	0	O
proteins	0	O
.	0	O


The	0	O
regions	0	O
of	0	O
the	0	O
tooth	0	O
fracture	0	O
are	0	O
determined	0	O
.	0	O


To	1	O
identify	0	O
structural	0	O
features	0	O
of	0	O
residues	0	O
flanking	0	O
the	0	O
c	0	O
-	0	O
region	0	O
that	0	O
influence	0	O
the	0	O
fidelity	0	O
and	0	O
efficiency	0	O
of	0	O
signal	0	O
peptidase	0	O
cleavage	0	O
as	0	O
well	0	O
as	0	O
co	0	O
-	0	O
translational	0	O
translocation	0	O
,	0	O
we	0	O
introduced	0	O
six	0	O
amino	0	O
acid	0	O
substitutions	0	O
into	0	O
the	0	O
COOH	0	O
terminus	0	O
of	0	O
the	0	O
hydrophobic	0	O
core	0	O
and	0	O
seven	0	O
substitutions	0	O
at	0	O
the	0	O
NH2	0	O
terminus	0	O
of	0	O
the	0	O
mature	0	O
region	0	O
(	0	O
the	0	O
+	0	O
1	0	O
position	0	O
)	0	O
of	0	O
a	0	O
model	0	O
eukaryotic	0	B
preprotein	0	I
-	0	I
human	0	I
pre	0	I
(	0	I
delta	0	I
pro	0	I
)	0	I
apoA	0	I
-	0	I
II	0	I
.	0	O


PRH75	0	B
,	0	O
a	0	O
new	0	O
nucleus	0	O
-	0	O
localized	0	O
member	0	O
of	0	O
the	0	O
DEAD	1	B
-	0	I
box	0	I
protein	0	I
family	0	I
from	0	O
higher	0	O
plants	0	O
.	0	O


The	0	O
addition	0	O
of	0	O
zidovudine	0	O
did	0	O
not	0	O
influence	0	O
this	0	O
transfer	0	O
.	0	O


The	0	O
expression	0	O
of	0	O
the	0	O
first	0	O
two	0	O
genes	0	O
located	0	O
in	0	O
this	0	O
unit	0	O
(	0	O
c	0	B
-	0	I
gvpD	0	I
and	0	O
c	0	B
-	0	I
gvpE	0	I
)	0	O
was	0	O
also	0	O
monitored	0	O
by	0	O
Western	0	O
blot	0	O
(	0	O
immunoblot	0	O
)	0	O
analyses	0	O
using	0	O
antisera	0	O
raised	0	O
against	0	O
these	0	O
proteins	0	O
synthesized	0	O
in	0	O
Escherichia	1	O
coli	0	O
.	0	O


Measurement	0	O
of	0	O
anti	0	B
-	0	I
HCV	1	I
IgM	1	I
antibodies	0	I
with	0	O
an	0	O
experimental	0	O
kit	0	O


Two	0	O
copies	0	O
of	0	O
the	0	O
72	0	O
-	0	O
bp	0	O
repeat	0	O
provided	0	O
efficient	0	O
activation	0	O
of	0	O
gene	0	O
expression	0	O
.	0	O


This	0	O
expression	0	O
assumes	0	O
:	0	O
(	0	O
1	0	O
)	0	O
a	0	O
laminar	0	O
flow	0	O
regimen	0	O
during	0	O
expiration	0	O
,	0	O
and	0	O
(	0	O
2	0	O
)	0	O
a	0	O
constant	0	O
CT	1	O
value	0	O
over	0	O
the	0	O
range	0	O
of	0	O
VT	1	O
.	0	O


Insulin	1	B
-	0	I
like	0	I
growth	0	I
factor	0	I
-	0	I
binding	0	I
protein	0	I
-	0	I
2	0	I
(	0	O
IGF	1	B
-	0	I
BP	1	I
-	0	I
2	0	I
)	0	O
transcription	0	O
in	0	O
rat	0	O
liver	0	O
varies	0	O
with	0	O
developmental	0	O
age	0	O
and	0	O
fasting	0	O
.	0	O


The	0	O
MPS1	0	B
open	0	I
reading	0	I
frame	0	I
has	0	O
been	0	O
fused	0	O
to	0	O
those	0	O
that	0	O
encode	0	O
the	0	O
LexA	0	B
protein	0	I
or	0	O
the	0	O
GST	0	B
protein	0	I
and	0	O
both	0	O
of	0	O
these	0	O
constructs	0	O
function	0	O
in	0	O
yeast	0	O
.	0	O


Effects	0	O
of	0	O
cisapride	0	O
on	0	O
upper	0	O
-	0	O
gastrointestinal	0	O
motility	0	O
and	0	O
digestive	0	O
hormones	0	O


Perturbation	1	O
of	0	O
dNTP	0	O
pools	0	O
also	0	O
affected	0	O
the	0	O
frameshift	0	O
fidelity	0	O
of	0	O
the	0	O
replicative	0	O
yeast	0	B
DNA	1	I
polymerase	0	I
alpha	0	I
.	0	O


This	0	O
region	0	O
,	0	O
however	0	O
,	0	O
contains	0	O
a	0	O
CCAATC	0	O
box	0	O
in	0	O
the	0	O
reverse	0	O
complement	0	O
and	0	O
several	0	O
GC	1	O
boxes	0	O
that	0	O
are	0	O
recognition	0	O
sites	0	O
for	0	O
SP1	0	B
.	0	O


Two	0	O
variant	0	O
PRP	1	B
-	0	I
precursor	0	I
alleles	0	I
occur	0	O
which	0	O
slightly	0	O
differ	0	O
in	0	O
the	0	O
number	0	O
of	0	O
repeats	0	O
in	0	O
domain	0	O
C	1	O
.	0	O


However	0	O
,	0	O
each	0	O
promoter	0	O
activated	0	O
by	0	O
IEP86	0	B
was	0	O
synergistically	0	O
affected	0	O
by	0	O
the	0	O
addition	0	O
of	0	O
IEP72	0	B
.	0	O


Germ	1	O
-	0	O
free	0	O
rabbits	0	O
given	0	O
mouse	0	O
CRF	1	O
-	0	O
flora	0	O
showed	0	O
values	0	O
quite	0	O
different	0	O
from	0	O
control	0	O
animals	0	O
for	0	O
most	0	O
parameters	0	O
,	0	O
indicating	0	O
unsuitability	0	O
of	0	O
mouse	0	O
CRF	1	O
flora	0	O
to	0	O
'	0	O
normalize	0	O
'	0	O
rabbits	0	O
.	0	O


These	0	O
results	0	O
suggested	0	O
that	0	O
NfxB	0	B
negatively	0	O
autoregulates	0	O
the	0	O
expression	0	O
of	0	O
nfxB	0	B
itself	0	O
.	0	O


Landsberg	0	O
(	0	O
La	1	O
-	0	O
O	1	O
)	0	O
and	0	O
cv	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
serological	0	O
studies	0	O
,	0	O
the	0	O
highly	0	O
conserved	0	O
A	1	O
domain	0	O
of	0	O
HspA	0	B
was	0	O
found	0	O
to	0	O
be	0	O
the	0	O
immunodominant	0	O
domain	0	O
.	0	O


D	1	O
.	0	O


The	0	O
purposes	0	O
of	0	O
this	0	O
study	0	O
were	0	O
1	0	O
)	0	O
to	0	O
examine	0	O
the	0	O
effect	0	O
of	0	O
high	0	O
intensity	0	O
,	0	O
low	0	O
frequency	0	O
transcutaneous	0	O
electrical	0	O
nerve	0	O
stimulation	0	O
at	0	O
auricular	0	O
acupuncture	0	O
points	0	O
on	0	O
experimental	0	O
pain	0	O
threshold	0	O
measured	0	O
at	0	O
the	0	O
wrist	0	O
and	0	O
2	0	O
)	0	O
to	0	O
determine	0	O
the	0	O
changes	0	O
in	0	O
effect	0	O
over	0	O
time	0	O
.	0	O


To	1	O
determine	0	O
if	0	O
the	0	O
NF	1	B
(	0	I
H	1	I
)	0	I
promoter	0	I
can	0	O
be	0	O
activated	0	O
in	0	O
a	0	O
tissue	0	O
specific	0	O
manner	0	O
during	0	O
development	0	O
transgenic	0	O
mice	0	O
containing	0	O
the	0	O
promoter	0	O
region	0	O
linked	0	O
to	0	O
a	0	O
beta	0	B
-	0	I
galactosidase	0	I
reporter	0	I
gene	0	I
were	0	O
generated	0	O
.	0	O


Identification	1	O
of	0	O
a	0	O
novel	0	O
E2F3	0	B
product	0	I
suggests	0	O
a	0	O
mechanism	0	O
for	0	O
determining	0	O
specificity	0	O
of	0	O
repression	0	O
by	0	O
Rb	1	B
proteins	0	I
.	0	O


By	0	O
using	0	O
total	0	O
-	0	O
protein	0	O
extracts	0	O
from	0	O
mycelia	0	O
grown	0	O
under	0	O
penicillin	0	O
producing	0	O
conditions	0	O
we	0	O
have	0	O
detected	0	O
a	0	O
DNA	1	O
-	0	O
binding	0	O
activity	0	O
that	0	O
specifically	0	O
shifts	0	O
a	0	O
promoter	0	O
fragment	0	O
located	0	O
between	0	O
-	0	O
654	0	O
and	0	O
-	0	O
455	0	O
(	0	O
relative	0	O
to	0	O
IPNS	0	B
tsp	0	I
).	0	O


By	0	O
150	0	O
minutes	0	O
after	0	O
Cr2O3	0	O
inhalation	0	O
,	0	O
FEV1	1	O
.	0	O
0	0	O
had	0	O
decreased	0	O
by	0	O
32	0	O
%.	0	O


Output	1	O
of	0	O
99mTcO	0	O
-	0	O
4	0	O
by	0	O
the	0	O
parotid	0	O
gland	0	O
closely	0	O
mimicked	0	O
fluctuations	0	O
in	0	O
parotid	0	O
saliva	0	O
flow	0	O
rate	0	O
.	0	O


(	0	O
5	0	O
)	0	O
No	1	O
changes	0	O
were	0	O
observed	0	O
in	0	O
the	0	O
gastric	0	O
venous	0	O
blood	0	O
flow	0	O
by	0	O
continuous	0	O
intravenous	0	O
injection	0	O
of	0	O
cimetidine	0	O
,	0	O
but	0	O
by	0	O
rapid	0	O
injection	0	O
both	0	O
the	0	O
flow	0	O
was	0	O
augmented	0	O
and	0	O
the	0	O
systemic	0	O
blood	0	O
pressure	0	O
decreased	0	O
transiently	0	O
.	0	O


Weight	1	O
loss	0	O
reduces	0	O
arterial	0	O
pressure	0	O
by	0	O
a	0	O
decrease	0	O
in	0	O
intravascular	0	O
volume	0	O
and	0	O
cardiac	0	O
output	0	O
associated	0	O
with	0	O
a	0	O
fall	0	O
in	0	O
sympathetic	0	O
activity	0	O
.	0	O


Renal	1	O
clearance	0	O
fell	0	O
from	0	O
19	0	O
.	0	O
0	0	O
+/-	0	O
4	0	O
.	0	O
9	0	O
ml	0	O
/	0	O
min	0	O
/	0	O
1	0	O
.	0	O
73	0	O
m2	0	O
(	0	O
group	0	O
I	1	O
)	0	O
to	0	O
1	0	O
.	0	O
0	0	O
+/-	0	O
0	0	O
.	0	O
4	0	O
ml	0	O
/	0	O
min	0	O
/	0	O
1	0	O
.	0	O
73	0	O
m2	0	O
(	0	O
group	0	O
IV	1	O
).	0	O


Assay	1	O
of	0	O
serum	0	B
immunoreactive	0	I
trypsin	0	I
in	0	O
dried	0	O
blood	0	O
spots	0	O
and	0	O
the	0	O
early	0	O
detection	0	O
of	0	O
cystic	0	O
fibrosis	0	O
.	0	O


Regulatory	1	O
motifs	0	O
for	0	O
gene	0	O
expression	0	O
such	0	O
as	0	O
nuclear	0	B
-	0	I
factor	0	I
-	0	I
kappaB	0	I
-	0	I
binding	0	I
-	0	I
site	0	I
-	0	I
like	0	I
sequence	0	I
(	0	O
kappaB	0	B
site	0	I
)	0	O
and	0	O
nuclear	0	B
-	0	I
factor	0	I
-	0	I
interleukin	0	I
-	0	I
6	0	I
-	0	I
binding	0	I
-	0	I
site	0	I
-	0	I
like	0	I
sequence	0	I
(	0	O
NF	1	B
-	0	I
IL	1	I
-	0	I
6	0	I
site	0	I
)	0	O
were	0	O
found	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
upstream	0	O
regulatory	0	O
region	0	O
.	0	O


(	0	O
Emeritus	0	O
)	0	O
John	0	O
Henri	0	O
Roosegaarde	0	O
Bisschop	0	O


Thirty	0	O
-	0	O
two	0	O
rats	0	O
were	0	O
divided	0	O
into	0	O
four	0	O
groups	0	O
.	0	O


Altogether	0	O
these	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
Syn	0	B
5	0	I
locus	0	I
segregates	0	O
from	0	O
the	0	O
gene	0	O
specifying	0	O
gH	1	B
,	0	O
to	0	O
a	0	O
region	0	O
encompassing	0	O
portions	0	O
of	0	O
the	0	O
TK	1	B
and	0	O
UL	0	B
24	0	I
genes	0	I
,	0	O
and	0	O
that	0	O
the	0	O
syn	0	B
mutation	0	I
does	0	O
not	0	O
affect	0	O
the	0	O
expression	0	O
or	0	O
activity	0	O
of	0	O
TK	1	B
.	0	O


The	0	O
current	0	O
study	0	O
demonstrates	0	O
that	0	O
T3	1	O
-	0	O
activated	0	O
transcription	0	O
of	0	O
the	0	O
NADPH	1	B
:	0	I
cytochrome	0	I
P450	0	I
oxidoreductase	0	I
(	0	O
P450R	0	B
)	0	O
gene	0	O
is	0	O
dependent	0	O
on	0	O
the	0	O
thyroid	0	O
hormonal	0	O
status	0	O
of	0	O
the	0	O
animal	0	O
,	0	O
with	0	O
both	0	O
transcriptional	0	O
and	0	O
post	0	O
-	0	O
transcriptional	0	O
pathways	0	O
being	0	O
important	0	O
in	0	O
regulating	0	O
the	0	O
cellular	0	O
P450R	0	B
mRNA	1	O
level	0	O
.	0	O


The	0	O
used	0	O
expression	0	O
system	0	O
could	0	O
allow	0	O
to	0	O
produce	0	O
mutated	0	O
forms	0	O
of	0	O
SsEF	0	B
-	0	I
2	0	I
obtained	0	O
by	0	O
mutagenesis	0	O
of	0	O
the	0	O
corresponding	0	O
gene	0	O
.	0	O


These	0	O
results	0	O
may	0	O
suggest	0	O
involvement	0	O
of	0	O
peripheral	0	O
enkephalins	0	O
in	0	O
pain	0	O
modulation	0	O
in	0	O
patients	0	O
with	0	O
episodic	0	O
cluster	0	O
headache	0	O
.	0	O


These	0	O
articles	0	O
both	0	O
report	0	O
the	0	O
results	0	O
of	0	O
multi	0	O
-	0	O
institutional	0	O
,	0	O
randomized	0	O
,	0	O
phase	0	O
3	0	O
trials	0	O
for	0	O
the	0	O
treatment	0	O
of	0	O
patients	0	O
with	0	O
localized	0	O
(	0	O
T1	1	O
-	0	O
3	0	O
N0	0	O
-	0	O
1	0	O
M0	1	O
)	0	O
esophageal	0	O
squamous	0	O
cell	0	O
carcinoma	0	O
(	0	O
SCC	0	O
)	0	O
or	0	O
esophageal	0	O
adenocarcinoma	0	O
.	0	O


49	0	O
,	0	O
XXXXY	0	O
chromosome	0	O
anomaly	0	O
:	0	O
an	0	O
unusual	0	O
variant	0	O
of	0	O
Klinefelter	0	O
'	0	O
s	0	O
syndrome	0	O
.	0	O


Cell	1	O
adhesion	0	O
and	0	O
migration	0	O
assays	0	O
demonstrate	0	O
that	0	O
alpha	0	B
6	0	I
beta	0	I
1	0	I
is	0	O
the	0	O
major	0	O
laminin	0	B
receptor	0	I
in	0	O
undifferentiated	0	O
F9	0	O
cells	0	O
as	0	O
well	0	O
as	0	O
F9	0	O
-	0	O
derived	0	O
PE	1	O
cells	0	O
.	0	O


We	0	O
examined	0	O
the	0	O
effects	0	O
of	0	O
long	0	O
-	0	O
term	0	O
perfusion	0	O
with	0	O
pyridoxalated	0	O
hemoglobin	0	B
polyoxyethylene	0	O
conjugate	0	O
(	0	O
PHP	1	O
)	0	O
solution	0	O
on	0	O
cardiac	0	O
function	0	O
of	0	O
isolated	0	O
rat	0	O
hearts	0	O
.	0	O


Skeletal	1	O
muscle	0	O
metaboreceptor	0	O
responses	0	O
are	0	O
impaired	0	O
in	0	O
heart	0	O
failure	0	O
.	0	O


This	0	O
cluster	0	O
consisted	0	O
of	0	O
four	0	O
apparently	0	O
unrelated	0	O
ESTs	0	O
and	0	O
two	0	O
genes	0	O
,	0	O
pregnancy	0	B
-	0	I
associated	0	I
plasma	0	I
protein	0	I
-	0	I
A	1	I
(	0	O
PAPP	0	B
-	0	I
A	1	I
)	0	O
and	0	O
a	0	O
novel	0	O
gene	0	O
(	0	O
tentatively	0	O
named	0	O
EST	1	B
-	0	I
YD1	0	I
).	0	O


Biol	0	O
.	0	O


Agonist	1	O
-	0	O
induced	0	O
receptor	0	O
internalization	0	O
,	0	O
determined	0	O
as	0	O
the	0	O
percent	0	O
of	0	O
total	0	O
[	0	O
125I	0	O
]	0	O
Tyr0	0	B
-	0	I
oCRF	0	I
bound	0	O
located	0	O
in	0	O
the	0	O
acid	0	O
-	0	O
resistant	0	O
fraction	0	O
of	0	O
transfected	0	O
Cos	1	O
7	0	O
cells	0	O
,	0	O
increased	0	O
with	0	O
time	0	O
(	0	O
0	0	O
-	0	O
60	0	O
min	0	O
at	0	O
37	0	O
degrees	0	O
C	1	O
)	0	O
for	0	O
both	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
variant	0	O
oCRF1	0	B
.	0	O


An	1	O
evolutionary	0	O
comparison	0	O
of	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
34	0	O
HSP70	0	B
proteins	0	I
from	0	O
17	0	O
species	0	O
suggests	0	O
that	0	O
BiP	0	B
genes	0	I
share	0	O
a	0	O
common	0	O
ancestor	0	O
,	0	O
which	0	O
diverged	0	O
from	0	O
other	0	O
HSP70	0	B
genes	0	I
near	0	O
the	0	O
time	0	O
when	0	O
eukaryotes	0	O
first	0	O
appeared	0	O
.	0	O


In	1	O
the	0	O
matched	0	O
control	0	O
group	0	O
the	0	O
acquisition	0	O
-	0	O
rate	0	O
of	0	O
both	0	O
symptomatic	0	O
and	0	O
asymptomatic	0	O
0acteriuria	0	O
was	0	O
over	0	O
12	0	O
%,	0	O
a	0	O
figure	0	O
similar	0	O
to	0	O
the	0	O
percentage	0	O
of	0	O
women	0	O
present	0	O
in	0	O
the	0	O
practice	0	O
population	0	O
during	0	O
one	0	O
year	0	O
with	0	O
transient	0	O
,	0	O
symptomatic	0	O
,	0	O
and	0	O
persistent	0	O
A	1	O
.	0	O
B	1	O
.	0	O


Polypeptides	0	O
of	0	O
the	0	O
same	0	O
apparent	0	O
sizes	0	O
are	0	O
detected	0	O
in	0	O
spores	0	O
of	0	O
a	0	O
cotE	0	B
null	0	O
mutant	0	O
,	0	O
on	0	O
which	0	O
basis	0	O
we	0	O
infer	0	O
that	0	O
the	0	O
products	0	O
of	0	O
the	0	O
cotJ	0	B
operon	0	I
are	0	O
required	0	O
for	0	O
the	0	O
normal	0	O
formation	0	O
of	0	O
the	0	O
inner	0	O
layers	0	O
of	0	O
the	0	O
coat	0	O
or	0	O
are	0	O
themselves	0	O
structural	0	O
components	0	O
of	0	O
the	0	O
coat	0	O
.	0	O


Immunologic	1	O
mechanisms	0	O
in	0	O
chronic	0	O
brucellosis	0	O
in	0	O
humans	0	O
.	0	O


Although	0	O
differences	0	O
were	0	O
not	0	O
significant	0	O
,	0	O
infants	0	O
in	0	O
the	0	O
experimental	0	O
group	0	O
had	0	O
more	0	O
changes	0	O
in	0	O
the	0	O
intermittent	0	O
mandatory	0	O
ventilation	0	O
(	0	O
IMV	1	O
)	0	O
settings	0	O
during	0	O
transport	0	O
,	0	O
and	0	O
more	0	O
such	0	O
infants	0	O
arrived	0	O
at	0	O
the	0	O
receiving	0	O
hospital	0	O
with	0	O
acceptable	0	O
pH	1	O
and	0	O
PCO2	1	O
values	0	O
.	0	O


By	0	O
contrast	0	O
,	0	O
deletion	0	O
of	0	O
this	0	O
Ras	1	B
-	0	I
binding	0	I
site	0	I
did	0	O
not	0	O
diminish	0	O
activation	0	O
of	0	O
Raf	0	B
-	0	I
1	0	I
kinase	0	I
by	0	O
Src	1	B
,	0	O
implying	0	O
that	0	O
Src	1	B
and	0	O
Ras	1	B
can	0	O
activate	0	O
Raf	0	B
-	0	I
1	0	I
through	0	O
independent	0	O
mechanisms	0	O
.	0	O


Approximately	0	O
50	0	O
%	0	O
of	0	O
the	0	O
residues	0	O
are	0	O
conserved	0	O
among	0	O
all	0	O
three	0	O
sequences	0	O
,	0	O
yet	0	O
all	0	O
three	0	O
viruses	0	O
have	0	O
retained	0	O
response	0	O
elements	0	O
for	0	O
glucocorticoids	0	O
,	0	O
two	0	O
positionally	0	O
conserved	0	O
CCAAT	0	O
boxes	0	O
,	0	O
and	0	O
positionally	0	O
conserved	0	O
TATA	0	O
boxes	0	O
.	0	O


One	0	O
extract	0	O
with	0	O
the	0	O
lowest	0	O
PCA	1	O
content	0	O
was	0	O
non	0	O
-	0	O
carcinogenic	0	O
.	0	O


Cytogenetic	1	O
studies	0	O
were	0	O
performed	0	O
in	0	O
lymphocytes	0	O
from	0	O
hospital	0	O
workers	0	O
exposed	0	O
to	0	O
low	0	O
doses	0	O
of	0	O
radiation	0	O
(	0	O
1	0	O
.	0	O
6	0	O
-	0	O
42	0	O
.	0	O
71	0	O
mSv	1	O
).	0	O


Fluid	1	O
(	0	O
AVLF	0	O
)	0	O
31	0	O
.	0	O


Both	0	O
quantitative	0	O
and	0	O
qualitative	0	O
analysis	0	O
of	0	O
individual	0	O
cytoarchitectonic	0	O
peculiarities	0	O
of	0	O
Meynart	0	O
'	0	O
s	0	O
nucleus	0	O
as	0	O
well	0	O
as	0	O
of	0	O
external	0	O
part	0	O
of	0	O
dorsomedial	0	O
nucleus	0	O
of	0	O
thalamus	0	O
was	0	O
performed	0	O
in	0	O
mentally	0	O
normal	0	O
individuals	0	O
.	0	O


Sudomoina	0	O
,	0	O
A	1	O
.	0	O


LON	0	O
-	0	O
72	0	O
(	0	O
34	0	O
isolates	0	O
),	0	O
LON	0	O
-	0	O
73	0	O
(	0	O
1	0	O
),	0	O
LON	0	O
-	0	O
71	0	O
(	0	O
2	0	O
)	0	O
and	0	O
LON	0	O
-	0	O
10	0	O
(	0	O
2	0	O
)	0	O
were	0	O
found	0	O
at	0	O
altitudes	0	O
around	0	O
2000	0	O
m	0	O
,	0	O
3	0	O
of	0	O
them	0	O
in	0	O
a	0	O
single	0	O
village	0	O
.	0	O


Sequencing	1	O
of	0	O
the	0	O
16p	0	O
11	0	O
.	0	O
1	0	O
/	0	O
Xq28	0	O
duplication	0	O
breakpoints	0	O
has	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
repetitive	0	O
immunoglobulin	0	B
-	0	I
like	0	I
CAGGG	0	I
pentamer	0	I
sequences	0	I
at	0	O
or	0	O
near	0	O
the	0	O
paralogy	0	O
boundaries	0	O
.	0	O


About	0	O
20	0	O
%	0	O
of	0	O
single	0	O
-	0	O
stranded	0	O
DNA	1	O
binding	0	O
was	0	O
observed	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
MgdTDP	0	O
,	0	O
but	0	O
none	0	O
was	0	O
detectable	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
nucleotides	0	O
.	0	O


Concomitantly	0	O
,	0	O
p34CDC2	0	B
histone	0	I
H1	1	I
kinase	0	O
activity	0	O
increases	0	O
in	0	O
the	0	O
former	0	O
,	0	O
but	0	O
not	0	O
in	0	O
the	0	O
latter	0	O
cell	0	O
lines	0	O
,	0	O
hence	0	O
suggesting	0	O
a	0	O
role	0	O
for	0	O
this	0	O
protein	0	O
in	0	O
radiation	0	O
-	0	O
induced	0	O
cell	0	O
death	0	O
.	0	O


Recently	0	O
,	0	O
we	0	O
have	0	O
reported	0	O
the	0	O
cloning	0	O
of	0	O
the	0	O
germ	0	O
cell	0	O
-	0	O
specific	0	O
,	0	O
nuclear	0	O
orphan	0	O
receptor	0	O
germ	0	B
cell	0	I
nuclear	0	I
factor	0	I
(	0	O
GCNF	0	B
)/	0	O
RTR	0	B
.	0	O


Electrophoretic	1	O
mobility	0	O
shift	0	O
assays	0	O
using	0	O
crude	0	O
extracts	0	O
from	0	O
FREJ4	0	O
cells	0	O
revealed	0	O
the	0	O
binding	0	O
of	0	O
a	0	O
member	0	O
(	0	O
s	0	O
)	0	O
of	0	O
the	0	O
Ets	1	B
family	0	I
of	0	I
transcription	0	I
factors	0	I
to	0	O
the	0	O
P4	0	B
EBS	0	I
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
interaction	0	O
of	0	O
two	0	O
members	0	O
of	0	O
the	0	O
Sp1	0	B
family	0	I
,	0	O
Sp1	0	B
and	0	O
Sp3	0	B
,	0	O
with	0	O
the	0	O
adjacent	0	O
GC	1	O
box	0	O
.	0	O


Wild	1	O
-	0	O
type	0	O
and	0	O
mutant	0	O
MyoD	0	B
were	0	O
introduced	0	O
into	0	O
cells	0	O
using	0	O
an	0	O
E1	1	B
,	0	O
E3	1	B
-	0	O
deleted	0	O
adenoviral	0	O
vector	0	O
.	0	O


Pathological	1	O
processes	0	O
in	0	O
the	0	O
cervix	0	O
uteri	0	O


Initiation	1	O
of	0	O
translation	0	O
of	0	O
the	0	O
human	0	O
hepatitis	0	O
C	1	O
virus	0	O
(	0	O
HCV	1	O
)	0	O
RNA	1	O
genome	0	O
occurs	0	O
by	0	O
internal	0	O
ribosome	0	O
entry	0	O
into	0	O
the	0	O
5	0	O
'	0	O
noncoding	0	O
region	0	O
(	0	O
5	0	O
'	0	O
NCR	0	O
)	0	O
in	0	O
a	0	O
cap	0	O
-	0	O
independent	0	O
manner	0	O
.	0	O


Aortic	1	O
diameters	0	O
in	0	O
infants	0	O
and	0	O
young	0	O
children	0	O
:	0	O
normative	0	O
angiographic	0	O
data	0	O
.	0	O


Blood	1	O
flow	0	O
and	0	O
velocity	0	O
(	0	O
measured	0	O
using	0	O
Doppler	1	O
ultrasound	0	O
)	0	O
gradually	0	O
decreased	0	O
during	0	O
diastole	0	O
and	0	O
ultimately	0	O
reversed	0	O
in	0	O
direction	0	O
as	0	O
cotyledon	0	O
resistance	0	O
was	0	O
increased	0	O
up	0	O
to	0	O
14	0	O
fold	0	O
.	0	O


Daily	0	O
and	0	O
seasonal	0	O
rhythmicity	0	O
in	0	O
the	0	O
methylation	0	O
of	0	O
pineal	0	O
indolic	0	O
compounds	0	O
in	0	O
adult	0	O
male	0	O
golden	0	O
hamsters	0	O
,	0	O
kept	0	O
under	0	O
natural	0	O
conditions	0	O
.	0	O


A	1	O
Dictyostelium	0	O
transformant	0	O
overexpressing	0	O
DdPTPa	0	B
does	0	O
not	0	O
develop	0	O
normally	0	O
.	0	O


No	1	O
apparent	0	O
clinical	0	O
signs	0	O
indicative	0	O
of	0	O
systemic	0	O
toxicity	0	O
were	0	O
observed	0	O
in	0	O
the	0	O
F0	0	O
and	0	O
F1	0	O
animals	0	O
of	0	O
either	0	O
sex	0	O
.	0	O


Cooperative	0	O
roles	0	O
of	0	O
Bozozok	0	B
/	0	O
Dharma	0	B
and	0	O
Nodal	1	B
-	0	I
related	0	I
proteins	0	I
in	0	O
the	0	O
formation	0	O
of	0	O
the	0	O
dorsal	0	O
organizer	0	O
in	0	O
zebrafish	0	O
.	0	O


A	1	O
total	0	O
of	0	O
7	0	O
(	0	O
4	0	O
males	0	O
and	0	O
3	0	O
females	0	O
)	0	O
patients	0	O
were	0	O
included	0	O
in	0	O
this	0	O
retrospective	0	O
study	0	O
to	0	O
determine	0	O
the	0	O
sensitivity	0	O
of	0	O
radioimmunoscintigraphy	0	O
with	0	O
I	1	O
-	0	O
131	0	O
labeled	0	O
anti	0	B
CEA	1	I
/	0	O
CA	1	B
19	0	I
-	0	I
9	0	I
monoclonal	0	O
antibodies	0	O
.	0	O


Benztropine	0	O
for	0	O
venlafaxine	0	O
-	0	O
induced	0	O
night	0	O
sweats	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
insertion	0	O
of	0	O
the	0	O
ColE1	0	B
cer	0	I
site	0	I
into	0	O
the	0	O
RK2	0	O
plasmid	0	O
deleted	0	O
for	0	O
the	0	O
par	0	O
region	0	O
failed	0	O
to	0	O
stabilize	0	O
the	0	O
plasmid	0	O
in	0	O
the	0	O
MC1061K	0	O
strain	0	O
,	0	O
indicating	0	O
that	0	O
the	0	O
multimer	0	O
resolution	0	O
activity	0	O
encoded	0	O
by	0	O
parCBA	0	B
is	0	O
not	0	O
by	0	O
itself	0	O
responsible	0	O
for	0	O
the	0	O
stabilization	0	O
activity	0	O
observed	0	O
for	0	O
this	0	O
operon	0	O
.	0	O


Regulation	1	O
of	0	O
parathyroid	0	B
hormone	0	I
-	0	I
related	0	I
protein	0	I
(	0	O
PTHrP	0	B
)	0	O
gene	0	O
expression	0	O
.	0	O


Several	0	O
artifacts	0	O
occurred	0	O
that	0	O
interfered	0	O
with	0	O
visualization	0	O
of	0	O
the	0	O
diaphragm	0	O
.	0	O


The	0	O
iron	0	O
dependence	0	O
of	0	O
transcription	0	O
and	0	O
expression	0	O
of	0	O
cvaA	0	B
,	0	O
which	0	O
encodes	0	O
a	0	O
transporter	0	O
accessory	0	O
protein	0	O
,	0	O
and	0	O
cvi	0	B
,	0	O
encoding	0	O
the	0	O
colicin	0	B
V	1	I
immunity	0	I
protein	0	I
,	0	O
was	0	O
assessed	0	O
under	0	O
conditions	0	O
of	0	O
iron	0	O
excess	0	O
or	0	O
depletion	0	O
.	0	O


Transfecting	0	O
the	0	O
cloned	0	O
bovine	0	O
PBR	0	B
/	0	O
IBP	0	B
cDNA	1	O
into	0	O
COS	1	O
-	0	O
7	0	O
cells	0	O
resulted	0	O
in	0	O
an	0	O
11	0	O
-	0	O
fold	0	O
increase	0	O
in	0	O
the	0	O
density	0	O
of	0	O
high	0	O
affinity	0	O
[	0	O
3H	0	O
]	0	O
PK	1	O
11195	0	O
binding	0	O
sites	0	O
which	0	O
had	0	O
only	0	O
low	0	O
affinity	0	O
for	0	O
Ro5	0	O
-	0	O
4864	0	O
.	0	O


Immunoblotting	0	O
of	0	O
expressed	0	O
recombinant	0	O
proteins	0	O
with	0	O
the	0	O
monoclonal	0	B
08L	0	I
antibody	0	I
localized	0	O
the	0	O
08L	0	B
epitope	0	O
to	0	O
the	0	O
carboxyl	0	O
end	0	O
of	0	O
the	0	O
protein	0	O
.	0	O


The	0	O
EPO	0	B
levels	0	O
were	0	O
distinctly	0	O
increased	0	O
before	0	O
transfusion	0	O
;	0	O
they	0	O
did	0	O
not	0	O
significantly	0	O
change	0	O
just	0	O
after	0	O
transfusion	0	O
,	0	O
but	0	O
subsequently	0	O
decreased	0	O
.	0	O


Since	0	O
1948	0	O
,	0	O
the	0	O
use	0	O
of	0	O
saline	0	O
-	0	O
washed	0	O
red	0	O
cells	0	O
(	0	O
WRBCs	0	O
)	0	O
has	0	O
been	0	O
advocated	0	O
to	0	O
minimize	0	O
hemolysis	0	O
after	0	O
transfusion	0	O
to	0	O
patients	0	O
with	0	O
PNH	1	O
.	0	O


There	0	O
were	0	O
3	0	O
/	0	O
32	0	O
(	0	O
9	0	O
.	0	O
4	0	O
per	0	O
cent	0	O
)	0	O
adverse	0	O
reactions	0	O
(	0	O
ADRs	0	O
),	0	O
and	0	O
one	0	O
case	0	O
each	0	O
of	0	O
nausea	0	O
,	0	O
dizziness	0	O
and	0	O
increased	0	O
menstrual	0	O
flow	0	O
.	0	O


Drosophila	1	B
UbcD1	0	I
encodes	0	O
a	0	O
highly	0	O
conserved	0	O
ubiquitin	0	B
-	0	O
conjugating	0	O
enzyme	0	O
involved	0	O
in	0	O
selective	0	O
protein	0	O
degradation	0	O
.	0	O


The	0	O
virus	0	O
-	0	O
associated	0	O
VAI	0	B
RNA	1	O
of	0	O
adenovirus	0	O
is	0	O
a	0	O
small	0	O
highly	0	O
structured	0	O
RNA	1	O
that	0	O
is	0	O
required	0	O
for	0	O
the	0	O
efficient	0	O
translation	0	O
of	0	O
cellular	0	O
and	0	O
viral	0	O
mRNAs	0	O
at	0	O
late	0	O
times	0	O
after	0	O
infection	0	O
.	0	O


Assays	0	O
of	0	O
total	0	O
cholesterol	0	O
as	0	O
well	0	O
as	0	O
the	0	O
HDL	1	B
,	0	O
HDL2	1	B
,	0	O
LDL	1	B
,	0	O
triglycerides	0	O
,	0	O
endothelin	0	B
-	0	I
1	0	I
,	0	O
lipoprotein	0	O
(	0	O
a	0	O
),	0	O
estradiol	0	O
and	0	O
FSH	1	B
were	0	O
also	0	O
obtained	0	O
at	0	O
baseline	0	O
before	0	O
receiving	0	O
ERT	1	O
and	0	O
after	0	O
3	0	O
months	0	O
of	0	O
ERT	1	O
.	0	O


The	0	O
basal	0	O
promoter	0	O
elements	0	O
of	0	O
murine	0	B
cytochrome	0	I
c	0	I
oxidase	0	I
subunit	0	I
IV	1	I
gene	0	I
consist	0	O
of	0	O
tandemly	0	O
duplicated	0	O
ets	0	B
motifs	0	O
that	0	O
bind	0	O
to	0	O
GABP	0	B
-	0	I
related	0	I
transcription	0	I
factors	0	I
.	0	O


The	0	O
possible	0	O
mechanisms	0	O
underlying	0	O
differences	0	O
in	0	O
post	0	O
-	0	O
tetanic	0	O
effects	0	O
from	0	O
muscle	0	O
and	0	O
cutaneous	0	O
afferents	0	O
in	0	O
adults	0	O
and	0	O
neonates	0	O
are	0	O
discussed	0	O
.	0	O


The	0	O
recombinant	0	B
vaccinia	0	I
virus	0	I
-	0	I
expressed	0	I
mutant	0	I
P1	1	I
polyproteins	0	I
were	0	O
analyzed	0	O
for	0	O
proteolytic	0	O
processing	0	O
defects	0	O
in	0	O
cells	0	O
coinfected	0	O
with	0	O
a	0	O
recombinant	0	O
vaccinia	0	O
virus	0	O
(	0	O
VVP3	0	O
)	0	O
that	0	O
expresses	0	O
the	0	O
poliovirus	0	B
3CD	0	I
protease	0	I
and	0	O
for	0	O
processing	0	O
and	0	O
assembly	0	O
defects	0	O
by	0	O
using	0	O
a	0	O
trans	0	O
complementation	0	O
system	0	O
in	0	O
which	0	O
P1	1	B
-	0	O
expressing	0	O
recombinant	0	O
vaccinia	0	O
viruses	0	O
provide	0	O
capsid	0	B
precursor	0	I
to	0	O
a	0	O
defective	0	O
poliovirus	0	O
genome	0	O
that	0	O
does	0	O
not	0	O
express	0	O
functional	0	O
capsid	0	B
proteins	0	I
(	0	O
D	1	O
.	0	O


Ime1	0	B
plays	0	O
a	0	O
pivotal	0	O
role	0	O
in	0	O
the	0	O
initiation	0	O
of	0	O
meiosis	0	O
in	0	O
a	0	O
/	0	O
alpha	0	O
diploid	0	O
cells	0	O
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Histone	1	B
acetylation	0	O
levels	0	O
in	0	O
cells	0	O
result	0	O
from	0	O
a	0	O
dynamic	0	O
equilibrium	0	O
between	0	O
competing	0	O
histone	0	B
acetylases	0	I
and	0	I
deacetylases	0	I
.	0	O


Microdetermination	1	O
of	0	O
adrenocortical	0	O
steroids	0	O
by	0	O
double	0	O
isotope	0	O
method	0	O
.	0	O


In	1	O
a	0	O
series	0	O
of	0	O
402	0	O
consecutive	0	O
autopsies	0	O
,	0	O
parietal	0	O
pleural	0	O
plaques	0	O
(	0	O
PP	1	O
)	0	O
were	0	O
found	0	O
in	0	O
68	0	O
individuals	0	O
above	0	O
40	0	O
years	0	O
of	0	O
age	0	O
.	0	O


Two	0	O
points	0	O
are	0	O
indicated	0	O
:	0	O
first	0	O
,	0	O
the	0	O
photosensitized	0	O
damage	0	O
of	0	O
YHPD	0	O
is	0	O
interrelated	0	O
to	0	O
not	0	O
only	0	O
1O2	0	O
,	0	O
but	0	O
also	0	O
free	0	O
radicals	0	O
(	0	O
O2	1	O
-.	0	O
.	0	O
OH	0	O
and	0	O
YHPD	0	O
-.);	0	O
second	0	O
,	0	O
although	0	O
the	0	O
photosensitized	0	O
damage	0	O
of	0	O
YHPD	0	O
is	0	O
stronger	0	O
than	0	O
that	0	O
of	0	O
BHPD	0	O
,	0	O
yet	0	O
the	0	O
photosensitized	0	O
damage	0	O
is	0	O
negatively	0	O
correlated	0	O
to	0	O
the	0	O
yield	0	O
of	0	O
1O2	0	O
but	0	O
positively	0	O
correlated	0	O
to	0	O
those	0	O
of	0	O
O2	1	O
-.	0	O
and	0	O
OH	0	O
.	0	O


The	0	O
phosphotransferase	0	O
system	0	O
(	0	O
PTS	1	O
)	0	O
of	0	O
Streptomyces	1	O
coelicolor	0	O
identification	0	O
and	0	O
biochemical	0	O
analysis	0	O
of	0	O
a	0	O
histidine	0	B
phosphocarrier	0	I
protein	0	I
HPr	0	I
encoded	0	O
by	0	O
the	0	O
gene	0	O
ptsH	0	B
.	0	O


In	1	O
a	0	O
retrospective	0	O
analysis	0	O
of	0	O
data	0	O
from	0	O
35	0	O
cases	0	O
with	0	O
malignant	0	O
lymphoma	0	O
from	0	O
a	0	O
cohort	0	O
of	0	O
2017	0	O
HIV	1	O
-	0	O
infected	0	O
patients	0	O
,	0	O
the	0	O
stage	0	O
of	0	O
HIV	1	O
-	0	O
disease	0	O
,	0	O
the	0	O
CD4	1	B
counts	0	O
at	0	O
the	0	O
time	0	O
of	0	O
diagnosis	0	O
,	0	O
and	0	O
the	0	O
use	0	O
of	0	O
antineoplastic	0	O
agents	0	O
or	0	O
radiotherapy	0	O
were	0	O
correlated	0	O
with	0	O
outcome	0	O
.	0	O


Induced	1	O
gamma	0	O
-	0	O
ray	0	O
spectroscopy	0	O


Although	0	O
the	0	O
terminase	0	B
apparently	0	O
interacts	0	O
with	0	O
this	0	O
gp20	0	B
portal	0	I
peptide	0	I
,	0	O
polyclonal	0	O
antibody	0	O
against	0	O
the	0	O
portal	0	O
peptide	0	O
appears	0	O
unable	0	O
to	0	O
access	0	O
it	0	O
in	0	O
the	0	O
native	0	O
structure	0	O
,	0	O
suggesting	0	O
intimate	0	O
association	0	O
of	0	O
gp20	0	B
and	0	O
gp17	0	B
possibly	0	O
internalizes	0	O
terminase	0	B
regions	0	I
within	0	O
the	0	O
portal	0	O
in	0	O
the	0	O
packasome	0	O
complex	0	O
.	0	O


Localization	1	O
of	0	O
the	0	O
insertion	0	O
locus	0	O
in	0	O
the	0	O
yeast	0	O
genome	0	O
and	0	O
complementation	0	O
studies	0	O
with	0	O
the	0	O
temperature	0	O
-	0	O
sensitive	0	O
mutant	0	O
indicate	0	O
that	0	O
the	0	O
two	0	O
mutations	0	O
are	0	O
allelic	0	O
.	0	O


Mutations	0	O
within	0	O
human	0	O
UTR1	0	O
modulate	0	O
NRF	0	B
-	0	I
1	0	I
expression	0	O
by	0	O
interfering	0	O
with	0	O
mRNA	1	O
translational	0	O
efficiency	0	O
in	0	O
transfected	0	O
cells	0	O
and	0	O
in	0	O
an	0	O
in	0	O
vitro	0	O
translation	0	O
system	0	O
.	0	O


We	0	O
have	0	O
demonstrated	0	O
that	0	O
the	0	O
activity	0	O
of	0	O
ILK	0	B
is	0	O
constitutively	0	O
elevated	0	O
in	0	O
PTEN	0	B
mutant	0	I
cells	0	O
.	0	O


Interleukin	1	B
-	0	I
6	0	I
may	0	O
possibly	0	O
potentiate	0	O
metastasis	0	O
of	0	O
cardiac	0	O
myxoma	0	O
.	0	O


Only	0	O
two	0	O
patients	0	O
(	0	O
0	0	O
.	0	O
3	0	O
%)	0	O
had	0	O
a	0	O
CA	1	B
125	0	I
response	0	O
at	0	O
the	0	O
time	0	O
of	0	O
clinical	0	O
progression	0	O
.	0	O


First	0	O
,	0	O
the	0	O
finding	0	O
of	0	O
a	0	O
monomeric	0	O
Alu	0	B
family	0	O
repeat	0	O
at	0	O
the	0	O
junction	0	O
between	0	O
nonhomology	0	O
block	0	O
I	1	O
and	0	O
homology	0	O
block	0	O
Y	1	O
of	0	O
the	0	O
alpha	0	B
2	0	I
gene	0	I
-	0	I
containing	0	I
unit	0	I
in	0	I
rhesus	0	I
macaque	0	I
suggests	0	O
that	0	O
the	0	O
dimeric	0	O
Alu	0	B
family	0	O
repeat	0	O
,	0	O
Alu	0	B
3	0	I
,	0	O
at	0	O
the	0	O
orthologous	0	O
position	0	O
in	0	O
human	0	O
was	0	O
generated	0	O
by	0	O
insertion	0	O
of	0	O
a	0	O
monomeric	0	O
Alu	0	B
family	0	O
repeat	0	O
into	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
another	0	O
preexisting	0	O
Alu	0	B
family	0	O
repeat	0	O
.	0	O


60	0	O
patients	0	O
were	0	O
entered	0	O
into	0	O
a	0	O
randomised	0	O
study	0	O
comparing	0	O
vindesine	0	O
(	0	O
3	0	O
mg	0	O
/	0	O
m2	0	O
/	0	O
week	0	O
)	0	O
plus	0	O
interferon	0	B
-	0	I
alpha	0	I
2b	0	I
(	0	O
6	0	O
U	1	O
/	0	O
m2	0	O
3	0	O
times	0	O
per	0	O
week	0	O
)	0	O
to	0	O
vindesine	0	O
alone	0	O
or	0	O
to	0	O
interferon	0	B
alone	0	O
for	0	O
the	0	O
treatment	0	O
of	0	O
metastatic	0	O
malignant	0	O
melanoma	0	O
.	0	O


Routine	1	O
isotope	0	O
cystography	0	O
using	0	O
99M	0	O
Tc	1	O
sulfur	0	O
colloid	0	O
for	0	O
detection	0	O
and	0	O
follow	0	O
-	0	O
up	0	O
of	0	O
vesico	0	O
-	0	O
ureteral	0	O
reflux	0	O


Evidence	1	O
is	0	O
presented	0	O
that	0	O
Leber	0	O
'	0	O
s	0	O
military	0	O
aneurysm	0	O
retinitis	0	O
is	0	O
not	0	O
a	0	O
separate	0	O
entity	0	O
but	0	O
a	0	O
special	0	O
form	0	O
of	0	O
Coats	0	O
'	0	O
disease	0	O
.	0	O


An	1	O
undilated	0	O
type	0	O
of	0	O
APBD	0	O
is	0	O
frequently	0	O
associated	0	O
with	0	O
AMT	1	O
and	0	O
we	0	O
believe	0	O
,	0	O
therefore	0	O
,	0	O
that	0	O
clinicians	0	O
should	0	O
be	0	O
aware	0	O
of	0	O
a	0	O
possible	0	O
coexistence	0	O
of	0	O
APBD	0	O
and	0	O
AMT	1	O
.	0	O


There	0	O
is	0	O
now	0	O
a	0	O
significative	0	O
difference	0	O
between	0	O
age	0	O
group	0	O
1	0	O
-	0	O
5	0	O
and	0	O
the	0	O
others	0	O
(	0	O
p	0	O
Less	0	O
Than	0	O
0	0	O
,	0	O
02	0	O
).	0	O


Kinetics	1	O
of	0	O
the	0	O
inhibition	0	O
indicated	0	O
that	0	O
this	0	O
polymerase	0	O
domain	0	O
can	0	O
inhibit	0	O
viral	0	O
replication	0	O
only	0	O
during	0	O
the	0	O
preinitiation	0	O
stage	0	O
.	0	O


Lung	1	O
and	0	O
multi	0	O
-	0	O
system	0	O
damage	0	O
were	0	O
early	0	O
indicators	0	O
of	0	O
poor	0	O
outcome	0	O
in	0	O
severe	0	O
non	0	O
-	0	O
fatal	0	O
disease	0	O
.	0	O


Demonstration	0	O
of	0	O
tissue	0	O
lesions	0	O
after	0	O
intramuscular	0	O
injection	0	O
by	0	O
determination	0	O
of	0	O
creatine	0	B
kinase	0	I
in	0	O
blood	0	O


Felodipine	1	O
did	0	O
not	0	O
alter	0	O
the	0	O
baseline	0	O
FEV1	1	O
,	0	O
but	0	O
showed	0	O
a	0	O
small	0	O
significant	0	O
inhibitory	0	O
effect	0	O
upon	0	O
histamine	0	O
and	0	O
AMP	1	O
induced	0	O
bronchoconstriction	0	O
.	0	O


Both	0	O
examinations	0	O
are	0	O
sensitive	0	O
indicators	0	O
of	0	O
CNS	1	O
abnormalities	0	O
associated	0	O
with	0	O
bacterial	0	O
meningeal	0	O
infections	0	O
and	0	O
are	0	O
important	0	O
determinants	0	O
of	0	O
the	0	O
therapy	0	O
and	0	O
ultimate	0	O
prognosis	0	O
of	0	O
such	0	O
complications	0	O
.	0	O


To	1	O
understand	0	O
the	0	O
regulatory	0	O
mechanism	0	O
controlling	0	O
its	0	O
expression	0	O
at	0	O
low	0	O
temperature	0	O
,	0	O
the	0	O
promoter	0	O
region	0	O
has	0	O
been	0	O
characterized	0	O
.	0	O


Their	0	O
use	0	O
resulted	0	O
in	0	O
a	0	O
sensitivity	0	O
of	0	O
73	0	O
%	0	O
and	0	O
a	0	O
specificity	0	O
of	0	O
74	0	O
%	0	O
with	0	O
regard	0	O
to	0	O
predictability	0	O
of	0	O
ALT	1	B
levels	0	O
increasing	0	O
during	0	O
the	0	O
trial	0	O
.	0	O


Mature	1	O
and	0	O
old	0	O
B6AF1	0	O
and	0	O
B6D2F1	0	O
mice	0	O
were	0	O
given	0	O
acidified	0	O
tap	0	O
water	0	O
or	0	O
promethazine	0	O
HCl	1	O
(	0	O
a	0	O
phenothiazine	0	O
with	0	O
H1	1	B
receptor	0	I
blocking	0	O
activity	0	O
),	0	O
chlorpheniramine	0	O
(	0	O
an	0	O
H1	1	B
blocker	0	O
)	0	O
or	0	O
trifluoperazine	0	O
(	0	O
a	0	O
phenothiazine	0	O
with	0	O
no	0	O
H1	1	B
blocking	0	O
activity	0	O
)	0	O
in	0	O
their	0	O
drinking	0	O
water	0	O
,	0	O
and	0	O
the	0	O
effects	0	O
of	0	O
these	0	O
agents	0	O
on	0	O
bone	0	O
mineral	0	O
content	0	O
were	0	O
assessed	0	O
by	0	O
intermittently	0	O
measuring	0	O
the	0	O
24	0	O
-	0	O
h	0	O
whole	0	O
body	0	O
retention	0	O
of	0	O
Tc	1	O
99m	0	O
methylene	0	O
diphosphonate	0	O
(	0	O
Tc	1	O
99m	0	O
MDP	1	O
,	0	O
an	0	O
indicator	0	O
of	0	O
bone	0	O
metabolism	0	O
)	0	O
and	0	O
at	0	O
the	0	O
end	0	O
of	0	O
the	0	O
studies	0	O
by	0	O
determining	0	O
ash	0	O
weights	0	O
of	0	O
femur	0	O
,	0	O
ilium	0	O
and	0	O
sacrum	0	O
.	0	O


Similarly	0	O
,	0	O
in	0	O
mammalian	0	O
cells	0	O
PBP74	0	B
is	0	O
synthesized	0	O
as	0	O
a	0	O
pre	0	O
-	0	O
protein	0	O
that	0	O
requires	0	O
membrane	0	O
potential	0	O
-	0	O
dependent	0	O
import	0	O
into	0	O
mitochondria	0	O
for	0	O
its	0	O
maturation	0	O
.	0	O


Nitric	1	O
oxide	0	O
inhalation	0	O
selectively	0	O
reduces	0	O
pulmonary	0	O
hypertension	0	O
in	0	O
porcine	0	O
endotoxin	0	O
shock	0	O
and	0	O
improves	0	O
arterial	0	O
oxygenation	0	O
and	0	O
pH	1	O
with	0	O
a	0	O
marked	0	O
attenuation	0	O
of	0	O
sympathetic	0	O
activation	0	O
.	0	O


Digestion	1	O
of	0	O
NF	1	B
-	0	I
IL6	0	I
with	0	O
endoprotease	0	B
Asp	1	I
-	0	I
N	1	I
produced	0	O
a	0	O
domain	0	O
smaller	0	O
than	0	O
the	0	O
TCD	0	B
(	0	O
NF	1	B
-	0	I
IL6	0	I
bZIP	0	I
domains	0	I
(	0	O
NFBD	0	B
)	0	O
(	0	O
272	0	O
-	0	O
345	0	O
)),	0	O
a	0	O
domain	0	O
identified	0	O
either	0	O
in	0	O
the	0	O
absence	0	O
or	0	O
the	0	O
presence	0	O
of	0	O
DNA	1	O
.	0	O


Analysis	1	O
by	0	O
cell	0	O
surface	0	O
immunofluorescence	0	O
showed	0	O
that	0	O
the	0	O
UL28	0	B
gene	0	I
is	0	O
not	0	O
required	0	O
for	0	O
expression	0	O
of	0	O
viral	0	O
glycoproteins	0	O
on	0	O
the	0	O
surface	0	O
of	0	O
infected	0	O
cells	0	O
.	0	O


A	1	O
point	0	O
mutation	0	O
in	0	O
Galphao	0	B
and	0	O
Galphai1	0	B
blocks	0	O
interaction	0	O
with	0	O
regulator	0	O
of	0	O
G	1	B
protein	0	I
signaling	0	O
proteins	0	O
.	0	O


The	0	O
carboxyl	0	O
-	0	O
terminal	0	O
transactivation	0	O
domain	0	O
of	0	O
heat	0	B
shock	0	I
factor	0	I
1	0	I
is	0	O
negatively	0	O
regulated	0	O
and	0	O
stress	0	O
responsive	0	O
.	0	O


With	0	O
regard	0	O
to	0	O
the	0	O
optimal	0	O
threshold	0	O
values	0	O
,	0	O
sensitivity	0	O
and	0	O
specificity	0	O
were	0	O
100	0	O
%/	0	O
97	0	O
%	0	O
and	0	O
95	0	O
%/	0	O
95	0	O
%	0	O
with	0	O
FDG	1	O
PET	1	O
,	0	O
compared	0	O
to	0	O
86	0	O
%/	0	O
92	0	O
%	0	O
and	0	O
77	0	O
%/	0	O
82	0	O
%	0	O
with	0	O
IS	1	O
,	0	O
respectively	0	O
.	0	O


In	1	O
the	0	O
10	0	O
patients	0	O
with	0	O
a	0	O
more	0	O
severe	0	O
degree	0	O
of	0	O
steatorrhea	0	O
the	0	O
decrease	0	O
in	0	O
fat	0	O
loss	0	O
approached	0	O
20	0	O
%	0	O
and	0	O
a	0	O
close	0	O
relationship	0	O
was	0	O
found	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
84	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
)	0	O
between	0	O
the	0	O
extent	0	O
of	0	O
the	0	O
fatty	0	O
acid	0	O
loss	0	O
on	0	O
placebo	0	O
and	0	O
the	0	O
decrease	0	O
of	0	O
this	0	O
loss	0	O
on	0	O
taurine	0	O
.	0	O


Analysis	1	O
of	0	O
strains	0	O
harboring	0	O
an	0	O
mds1	0	B
null	0	I
mutation	0	I
demonstrates	0	O
that	0	O
MDS1	0	B
is	0	O
not	0	O
essential	0	O
during	0	O
normal	0	O
vegetative	0	O
growth	0	O
but	0	O
appears	0	O
to	0	O
be	0	O
required	0	O
for	0	O
meiosis	0	O
.	0	O


Interestingly	0	O
,	0	O
the	0	O
interaction	0	O
of	0	O
ZAP	0	B
-	0	I
70	0	I
with	0	O
the	0	O
motif	0	O
was	0	O
dependent	0	O
on	0	O
the	0	O
presence	0	O
of	0	O
both	0	O
ZAP	0	B
-	0	I
70	0	I
SH2	0	I
domains	0	I
and	0	O
both	0	O
of	0	O
the	0	O
tyrosine	0	O
residues	0	O
in	0	O
the	0	O
motif	0	O
,	0	O
suggesting	0	O
that	0	O
ZAP	0	B
-	0	I
70	0	I
interacts	0	O
with	0	O
two	0	O
phosphotyrosine	0	O
residues	0	O
and	0	O
that	0	O
the	0	O
binding	0	O
of	0	O
the	0	O
two	0	O
SH2	0	B
domains	0	I
is	0	O
cooperative	0	O
.	0	O


On	1	O
a	0	O
separate	0	O
occasion	0	O
the	0	O
T1	1	O
weighted	0	O
and	0	O
T2	0	O
weighted	0	O
sagittal	0	O
and	0	O
T2	0	O
weighted	0	O
axial	0	O
sequences	0	O
were	0	O
reported	0	O
blind	0	O
in	0	O
relation	0	O
to	0	O
the	0	O
initial	0	O
assessment	0	O
.	0	O


The	0	O
standard	0	O
method	0	O
for	0	O
calculating	0	O
the	0	O
composite	0	O
score	0	O
on	0	O
the	0	O
S	1	O
-	0	O
B	1	O
IV	1	O
excludes	0	O
subtests	0	O
with	0	O
a	0	O
raw	0	O
score	0	O
of	0	O
0	0	O
,	0	O
which	0	O
overestimates	0	O
cognitive	0	O
functioning	0	O
in	0	O
young	0	O
biologically	0	O
high	0	O
risk	0	O
children	0	O
.	0	O


Structural	1	O
and	0	O
evolutionary	0	O
studies	0	O
on	0	O
sterol	0	B
14	0	I
-	0	I
demethylase	0	I
P450	0	I
(	0	O
CYP51	0	B
),	0	O
the	0	O
most	0	O
conserved	0	O
P450	0	B
monooxygenase	0	I
:	0	O
I	1	O
.	0	O


As	1	O
high	0	O
-	0	O
speed	0	O
,	0	O
volumetric	0	O
imaging	0	O
,	0	O
computed	0	O
tomographic	0	O
scan	0	O
machines	0	O
such	0	O
as	0	O
the	0	O
Dynamic	1	O
Spatial	1	O
Reconstructor	0	O
become	0	O
available	0	O
with	0	O
higher	0	O
density	0	O
resolution	0	O
,	0	O
perhaps	0	O
a	0	O
single	0	O
injection	0	O
of	0	O
contrast	0	O
agent	0	O
into	0	O
the	0	O
right	0	O
atrium	0	O
or	0	O
even	0	O
a	0	O
peripheral	0	O
vein	0	O
may	0	O
be	0	O
adequate	0	O
to	0	O
obtain	0	O
all	0	O
these	0	O
measurements	0	O
.	0	O


With	0	O
Sair	0	O
and	0	O
So2	0	O
,	0	O
mean	0	O
vital	0	O
capacity	0	O
was	0	O
reduced	0	O
by	0	O
44	0	O
%	0	O
from	0	O
control	0	O
.	0	O


The	0	O
known	0	O
B1	0	O
-	0	O
deficiency	0	O
reaches	0	O
excessive	0	O
high	0	O
values	0	O
with	0	O
light	0	O
exercise	0	O
.	0	O


The	0	O
upTRE	0	O
binds	0	O
more	0	O
T3R	0	B
homodimers	0	I
and	0	O
less	0	O
T3R	0	B
-	0	O
RXR	0	B
heterodimers	0	O
than	0	O
the	0	O
dnTRE	0	O
,	0	O
and	0	O
T3	1	O
more	0	O
readily	0	O
facilitates	0	O
heterodimer	0	O
binding	0	O
to	0	O
the	0	O
dn	0	O
-	0	O
than	0	O
to	0	O
the	0	O
upTRE	0	O
.	0	O


In	1	O
eukaryotic	0	O
cells	0	O
,	0	O
premature	0	O
termination	0	O
of	0	O
translation	0	O
at	0	O
nonsense	0	O
codons	0	O
has	0	O
been	0	O
implicated	0	O
as	0	O
the	0	O
cause	0	O
of	0	O
a	0	O
variety	0	O
of	0	O
posttranscriptional	0	O
events	0	O
,	0	O
including	0	O
rapid	0	O
mRNA	1	O
decay	0	O
in	0	O
the	0	O
cytoplasm	0	O
or	0	O
the	0	O
nucleus	0	O
,	0	O
altered	0	O
splice	0	O
site	0	O
selection	0	O
,	0	O
and	0	O
exon	0	O
skipping	0	O
.	0	O


Here	0	O
we	0	O
demonstrate	0	O
genetically	0	O
that	0	O
plus	0	O
-	0	O
strand	0	O
DNA	1	O
synthesis	0	O
of	0	O
the	0	O
yeast	0	B
Ty1	0	I
element	0	I
is	0	O
initiated	0	O
at	0	O
two	0	O
sites	0	O
located	0	O
at	0	O
the	0	O
5	0	O
'	0	O
boundary	0	O
of	0	O
the	0	O
3	0	O
'	0	O
long	0	O
terminal	0	O
repeat	0	O
(	0	O
PPT1	0	B
)	0	O
and	0	O
near	0	O
the	0	O
middle	0	O
of	0	O
the	0	O
pol	0	B
gene	0	I
in	0	O
the	0	O
integrase	0	B
coding	0	I
sequence	0	I
(	0	O
PPT2	0	B
).	0	O


RESULTS	0	O
:	0	O
Each	0	O
year	0	O
,	0	O
on	0	O
average	0	O
39	0	O
%	0	O
of	0	O
cases	0	O
seen	0	O
in	0	O
Sardinia	0	O
are	0	O
notified	0	O
;	0	O
646	0	O
(	0	O
40	0	O
%)	0	O
of	0	O
the	0	O
1591	0	O
patients	0	O
notified	0	O
during	0	O
the	0	O
study	0	O
period	0	O
were	0	O
never	0	O
seen	0	O
by	0	O
regional	0	O
medical	0	O
centres	0	O
.	0	O


Plasma	1	B
histaminase	0	I
in	0	O
patients	0	O
of	0	O
bronchial	0	O
asthma	0	O
and	0	O
the	0	O
effect	0	O
of	0	O
prednisolone	0	O
administration	0	O
on	0	O
it	0	O
.	0	O


Gap1	0	O
(	0	O
IP4BP	0	O
),	0	O
one	0	O
of	0	O
a	0	O
member	0	O
of	0	O
Ras	1	B
GTPase	1	I
-	0	I
activating	0	I
proteins	0	I
,	0	O
has	0	O
been	0	O
identified	0	O
as	0	O
a	0	O
specific	0	O
inositol	0	B
1	0	I
,	0	I
3	0	I
,	0	I
4	0	I
,	0	I
5	0	I
-	0	I
tetrakisphosphate	0	I
(	0	I
IP4	0	I
)-	0	I
binding	0	I
protein	0	I
(	0	O
Cullen	0	O
,	0	O
P	1	O
.	0	O


The	0	O
maximum	0	O
period	0	O
of	0	O
treatment	0	O
was	0	O
73	0	O
(	0	O
oral	0	O
),	0	O
73	0	O
(	0	O
intraperitoneal	0	O
)	0	O
or	0	O
75	0	O
(	0	O
dermal	0	O
)	0	O
weeks	0	O
.	0	O


EMBO	0	O
J	1	O
.	0	O


Thirty	0	O
-	0	O
five	0	O
strains	0	O
of	0	O
Legionnaires	0	O
'	0	O
disease	0	O
bacteria	0	O
were	0	O
shown	0	O
to	0	O
belong	0	O
in	0	O
four	0	O
distinct	0	O
serologic	0	O
groups	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
findings	0	O
obtained	0	O
with	0	O
direct	0	O
fluorescent	0	O
antibody	0	O
testing	0	O
.	0	O


A	1	O
quantitative	0	O
analysis	0	O
of	0	O
the	0	O
diffraction	0	O
intensity	0	O
as	0	O
function	0	O
of	0	O
the	0	O
accumulated	0	O
electron	0	O
dose	0	O
suggests	0	O
the	0	O
possibility	0	O
of	0	O
recording	0	O
up	0	O
to	0	O
250	0	O
diffraction	0	O
patterns	0	O
with	0	O
3	0	O
.	0	O
5	0	O
A	1	O
resolution	0	O
from	0	O
a	0	O
single	0	O
crotoxin	0	O
complex	0	O
crystal	0	O
128	0	O
A	1	O
thick	0	O
.	0	O


Moreover	0	O
,	0	O
Lck	0	B
was	0	O
reversibly	0	O
co	0	O
-	0	O
immunoprecipitated	0	O
with	0	O
p95Vav	0	B
,	0	O
and	0	O
the	0	O
stoichiometry	0	O
of	0	O
binding	0	O
increased	0	O
in	0	O
anti	0	B
-	0	I
CD3	0	I
-	0	O
treated	0	O
Jurkat	0	O
cells	0	O
.	0	O


Two	0	O
studies	0	O
assessed	0	O
two	0	O
types	0	O
of	0	O
reliability	0	O
of	0	O
the	0	O
student	0	O
Jenkins	0	O
Activity	1	O
Survey	1	O
(	0	O
JAS	0	O
;	0	O
a	0	O
questionnaire	0	O
measure	0	O
of	0	O
Type	1	O
A	1	O
behavior	0	O
).	0	O


No	1	O
positive	0	O
family	0	O
history	0	O
was	0	O
obtained	0	O
.	0	O


Identity	1	O
elements	0	O
in	0	O
tRNA	1	O
for	0	O
mono	0	O
-	0	O
and	0	O
dimethylation	0	O
reactions	0	O
by	0	O
the	0	O
recombinant	0	B
pfTrm1p	0	I
were	0	O
identified	0	O
using	0	O
in	0	O
vitro	0	O
T7	0	O
transcripts	0	O
of	0	O
33	0	O
variants	0	O
of	0	O
tRNA	1	B
(	0	I
Asp	1	I
)	0	I
and	0	O
tRNA	1	B
(	0	I
Phe	1	I
)	0	I
from	0	O
yeast	0	O
.	0	O


Molecule	1	O
(	0	O
s	0	O
)	0	O
secreted	0	O
by	0	O
neuronal	0	O
cultures	0	O
contribute	0	O
to	0	O
this	0	O
induction	0	O
of	0	O
GLT	0	B
-	0	I
1	0	I
,	0	O
but	0	O
little	0	O
is	0	O
known	0	O
about	0	O
the	0	O
signaling	0	O
pathways	0	O
mediating	0	O
this	0	O
regulation	0	O
.	0	O


51	0	O
.	0	O
9	0	O
%	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
0006	0	O
)	0	O
in	0	O
the	0	O
MMF	1	O
versus	0	O
the	0	O
AZA	0	O
groups	0	O
,	0	O
respectively	0	O
.	0	O


Leukocyte	1	O
enzyme	0	O
activity	0	O
and	0	O
blood	0	O
lymphocyte	0	O
blast	0	O
transformation	0	O
in	0	O
chronic	0	O
bronchitis	0	O


Group	1	O
A	1	O
(	0	O
68	0	O
.	0	O
7	0	O
+/-	0	O
2	0	O
.	0	O
7	0	O
years	0	O
)	0	O
consisted	0	O
of	0	O
patients	0	O
with	0	O
0	0	O
or	0	O
1	0	O
risk	0	O
factors	0	O
;	0	O
B	1	O
(	0	O
68	0	O
.	0	O
3	0	O
+/-	0	O
4	0	O
.	0	O
2	0	O
years	0	O
)	0	O
those	0	O
with	0	O
2	0	O
risk	0	O
factors	0	O
;	0	O
and	0	O
C	1	O
(	0	O
69	0	O
.	0	O
2	0	O
+/-	0	O
3	0	O
.	0	O
6	0	O
years	0	O
)	0	O
those	0	O
with	0	O
3	0	O
or	0	O
more	0	O
risk	0	O
factors	0	O
.	0	O


METHODS	0	O
:	0	O
109	0	O
suspected	0	O
cases	0	O
with	0	O
SS	1	O
underwent	0	O
the	0	O
biopsies	0	O
.	0	O


Symptomatic	1	O
hyperventilators	0	O
had	0	O
a	0	O
larger	0	O
number	0	O
of	0	O
sighs	0	O
and	0	O
abnormally	0	O
wide	0	O
fluctuations	0	O
in	0	O
baseline	0	O
for	0	O
inspiratory	0	O
time	0	O
,	0	O
expiratory	0	O
time	0	O
,	0	O
and	0	O
PETCO2	1	O
.	0	O


The	0	O
malate	0	B
synthase	0	I
gene	0	I
,	0	O
MLS1	0	B
,	0	O
of	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
is	0	O
transcriptionally	0	O
regulated	0	O
by	0	O
the	0	O
carbon	0	O
source	0	O
in	0	O
the	0	O
growth	0	O
medium	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
genomes	0	O
of	0	O
PMTV	0	O
,	0	O
BNYVV	0	O
,	0	O
and	0	O
SBWMV	0	O
shows	0	O
that	0	O
furoviruses	0	O
exhibit	0	O
considerable	0	O
heterogeneity	0	O
in	0	O
genome	0	O
organization	0	O
.	0	O


Effects	0	O
of	0	O
cortisone	0	O
,	0	O
starvation	0	O
,	0	O
and	0	O
rickets	0	O
on	0	O
oxidative	0	O
enzyme	0	O
activities	0	O
of	0	O
epiphyseal	0	O
cartilage	0	O
from	0	O
rats	0	O
.	0	O


Transcription	1	O
of	0	O
the	0	O
gene	0	O
for	0	O
ivanolysin	0	B
O	1	I
and	0	O
expression	0	O
of	0	O
other	0	O
genes	0	O
of	0	O
the	0	O
virulence	0	B
gene	0	I
cluster	0	I
in	0	I
L	1	I
.	0	I
ivanovii	0	I
were	0	O
dependent	0	O
on	0	O
PrfA	0	B
.	0	O


However	0	O
,	0	O
the	0	O
signaling	0	O
cascade	0	O
utilized	0	O
by	0	O
the	0	O
urokinase	0	B
receptor	0	I
is	0	O
only	0	O
incompletely	0	O
understood	0	O
.	0	O


The	0	O
Y	1	O
-	0	O
type	0	O
structural	0	O
motif	0	O
is	0	O
also	0	O
conserved	0	O
among	0	O
a	0	O
number	0	O
of	0	O
divergent	0	O
BiP	0	B
mRNAs	0	I
.	0	O


The	0	O
first	0	O
one	0	O
is	0	O
a	0	O
TPA	1	O
-	0	O
responsive	0	O
element	0	O
that	0	O
controls	0	O
the	0	O
base	0	O
-	0	O
line	0	O
ST3	0	B
promoter	0	I
activity	0	O
but	0	O
is	0	O
not	0	O
required	0	O
for	0	O
its	0	O
activation	0	O
.	0	O


Statistics	1	O
of	0	O
the	0	O
past	0	O
5	0	O
years	0	O


POU	0	B
-	0	I
domain	0	I
proteins	0	I
,	0	O
such	0	O
as	0	O
the	0	O
pituitary	0	B
-	0	I
specific	0	I
factor	0	I
Pit	1	I
-	0	I
1	0	I
,	0	O
are	0	O
members	0	O
of	0	O
the	0	O
homeodomain	0	B
family	0	I
of	0	O
proteins	0	O
which	0	O
are	0	O
important	0	O
in	0	O
development	0	O
and	0	O
homeostasis	0	O
,	0	O
acting	0	O
constitutively	0	O
or	0	O
in	0	O
response	0	O
to	0	O
signal	0	O
-	0	O
transduction	0	O
pathways	0	O
to	0	O
either	0	O
repress	0	O
or	0	O
activate	0	O
the	0	O
expression	0	O
of	0	O
specific	0	O
genes	0	O
.	0	O


Re	1	O
:	0	O
"	0	O
Assessing	0	O
the	0	O
direction	0	O
of	0	O
causality	0	O
in	0	O
cross	0	O
-	0	O
sectional	0	O
studies	0	O
".	0	O


The	0	O
HGF	1	B
-	0	O
induced	0	O
cell	0	O
motility	0	O
was	0	O
mimicked	0	O
by	0	O
12	0	O
-	0	O
0	0	O
-	0	O
tetradecanoyl	0	O
-	0	O
phorbol	0	O
-	0	O
13	0	O
-	0	O
acetate	0	O
,	0	O
a	0	O
protein	0	B
kinase	0	I
C	1	I
-	0	O
activating	0	O
phorbol	0	O
ester	0	O
,	0	O
but	0	O
not	0	O
by	0	O
Ca2	1	O
+	0	O
ionophore	0	O
.	0	O


Apart	0	O
from	0	O
two	0	O
proline	0	O
-	0	O
rich	0	O
regions	0	O
(	0	O
amino	0	O
acids	0	O
1	0	O
-	0	O
117	0	O
and	0	O
239	0	O
-	0	O
270	0	O
),	0	O
p230	0	B
contains	0	O
a	0	O
very	0	O
high	0	O
frequency	0	O
of	0	O
heptad	0	O
repeats	0	O
,	0	O
characteristic	0	O
of	0	O
alpha	0	O
-	0	O
helices	0	O
that	0	O
form	0	O
dimeric	0	O
coiled	0	O
-	0	O
coil	0	O
structures	0	O
.	0	O
p230	0	B
also	0	O
includes	0	O
the	0	O
sequence	0	O
ESLALEELEL	0	O
(	0	O
amino	0	O
acids	0	O
538	0	O
-	0	O
546	0	O
),	0	O
a	0	O
motif	0	O
found	0	O
in	0	O
the	0	O
granin	0	B
family	0	I
of	0	O
acidic	0	O
proteins	0	O
present	0	O
in	0	O
secretory	0	O
granules	0	O
of	0	O
neuroendocrine	0	O
cells	0	O
.	0	O


Therefore	0	O
,	0	O
we	0	O
propose	0	O
that	0	O
p27	0	B
represents	0	O
a	0	O
crucial	0	O
molecule	0	O
in	0	O
HMBA	0	O
signaling	0	O
that	0	O
cannot	0	O
be	0	O
replaced	0	O
by	0	O
p21	0	B
.	0	O


Stroop	0	O
interference	0	O
:	0	O
aging	0	O
effects	0	O
assessed	0	O
with	0	O
the	0	O
Stroop	0	O
Color	1	O
-	0	O
Word	0	O
Test	1	O
.	0	O


Variation	1	O
in	0	O
the	0	O
temporal	0	O
-	0	O
spatial	0	O
distribution	0	O
of	0	O
228Ra	0	O
and	0	O
224Ra	0	O
in	0	O
the	0	O
RES	1	O
and	0	O
marrow	0	O
-	0	O
free	0	O
skeleton	0	O
after	0	O
incorporation	0	O
of	0	O
colloidal	0	O
ThO2	0	O


After	0	O
one	0	O
accommodation	0	O
night	0	O
,	0	O
sleep	0	O
EEG	1	O
recordings	0	O
were	0	O
performed	0	O
during	0	O
three	0	O
consecutive	0	O
nights	0	O
in	0	O
ten	0	O
drug	0	O
-	0	O
free	0	O
inpatients	0	O
presenting	0	O
generalized	0	O
anxiety	0	O
disorder	0	O
(	0	O
GAD	1	O
)	0	O
with	0	O
significant	0	O
depression	0	O
,	0	O
compared	0	O
with	0	O
a	0	O
age	0	O
-	0	O
and	0	O
sex	0	O
-	0	O
matched	0	O
group	0	O
of	0	O
patients	0	O
with	0	O
GAD	1	O
and	0	O
a	0	O
group	0	O
of	0	O
primary	0	O
major	0	O
depressive	0	O
disorder	0	O
(	0	O
MDD	0	O
)	0	O
patients	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
differentiation	0	O
of	0	O
neoplastically	0	O
transformed	0	O
cells	0	O
does	0	O
not	0	O
repress	0	O
mitogenic	0	O
responsiveness	0	O
or	0	O
junB	0	B
or	0	O
c	0	B
-	0	I
fos	0	I
inducibility	0	O
.	0	O


Serum	1	B
gamma	0	I
glutamyltransferase	0	I
in	0	O
the	0	O
diagnosis	0	O
of	0	O
liver	0	O
disease	0	O
in	0	O
cattle	0	O
.	0	O


The	0	O
two	0	O
genes	0	O
code	0	O
for	0	O
polypeptides	0	B
of	0	I
420	0	I
amino	0	I
acids	0	I
(	0	I
M	1	I
.	0	I
HgiCI	0	I
)	0	I
and	0	O
345	0	O
amino	0	O
acids	0	O
(	0	O
R	1	O
.	0	O
HgiCI	0	O
).	0	O


In	1	O
two	0	O
-	0	O
field	0	O
nodal	0	O
dissection	0	O
,	0	O
two	0	O
components	0	O
are	0	O
included	0	O
with	0	O
(	0	O
modern	0	O
two	0	O
-	0	O
field	0	O
)	0	O
or	0	O
without	0	O
(	0	O
traditional	0	O
two	0	O
-	0	O
field	0	O
)	0	O
nodal	0	O
dissection	0	O
around	0	O
both	0	O
recurrent	0	O
laryngeal	0	O
nerve	0	O
chains	0	O
in	0	O
the	0	O
upper	0	O
mediastinum	0	O
.	0	O


Polyprotein	1	O
processing	0	O
in	0	O
Southampton	0	O
virus	0	O
:	0	O
identification	0	O
of	0	O
3C	0	B
-	0	I
like	0	I
protease	0	I
cleavage	0	O
sites	0	O
by	0	O
in	0	O
vitro	0	O
mutagenesis	0	O
.	0	O


Vacuum	1	O
Rabi	0	O
splitting	0	O
as	0	O
a	0	O
feature	0	O
of	0	O
linear	0	O
-	0	O
dispersion	0	O
theory	0	O
:	0	O
Analysis	1	O
and	0	O
experimental	0	O
observations	0	O
.	0	O


Cloning	1	O
and	0	O
sequencing	0	O
of	0	O
the	0	O
corresponding	0	O
cDNAs	0	O
indicates	0	O
that	0	O
,	0	O
via	0	O
alternative	0	O
splicing	0	O
,	0	O
the	0	O
rearranged	0	O
gene	0	O
codes	0	O
for	0	O
two	0	O
proteins	0	O
of	0	O
84	0	O
and	0	O
85	0	O
kD	1	O
(	0	O
p84	0	B
/	0	I
85	0	I
)	0	O
which	0	O
retain	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
rel	0	B
domain	0	I
and	0	O
the	0	O
first	0	O
five	0	O
ankyrin	0	B
repeats	0	O
,	0	O
but	0	O
have	0	O
lost	0	O
their	0	O
carboxy	0	O
-	0	O
terminus	0	O
including	0	O
the	0	O
seventh	0	O
ankyrin	0	B
repeat	0	O
.	0	O


Penicillinase	1	B
production	0	O
in	0	O
Staphylococcus	1	O
aureus	0	O
strains	0	O
of	0	O
clinical	0	O
importance	0	O
.	0	O


Fatal	1	O
encephalitis	0	O
in	0	O
a	0	O
patient	0	O
with	0	O
chronic	0	O
graft	0	O
-	0	O
versus	0	O
-	0	O
host	0	O
disease	0	O
.	0	O


Is	1	O
radical	0	O
trachelectomy	0	O
a	0	O
safe	0	O
alternative	0	O
to	0	O
radical	0	O
hysterectomy	0	O
for	0	O
patients	0	O
with	0	O
stage	0	O
IA	1	O
-	0	O
B	1	O
carcinoma	0	O
of	0	O
the	0	O
cervix	0	O
?	0	O
BACKGROUND	0	O
:	0	O
The	0	O
prognosis	0	O
associated	0	O
with	0	O
lymph	0	O
node	0	O
negative	0	O
,	0	O
early	0	O
stage	0	O
carcinoma	0	O
of	0	O
the	0	O
cervix	0	O
is	0	O
excellent	0	O
,	0	O
with	0	O
5	0	O
-	0	O
year	0	O
survival	0	O
rates	0	O
greater	0	O
than	0	O
90	0	O
%.	0	O


Mutations	0	O
in	0	O
the	0	O
nuclear	0	B
gene	0	I
CBP1	0	I
of	0	I
Saccharomyces	1	I
cerevisiae	0	I
result	0	O
in	0	O
degradation	0	O
of	0	O
mitochondrially	0	B
encoded	0	I
cytochrome	0	I
b	0	I
(	0	O
cob	0	B
)	0	O
RNA	1	O
;	0	O
thus	0	O
,	0	O
the	0	O
cells	0	O
are	0	O
unable	0	O
to	0	O
respire	0	O
.	0	O


Far	0	O
from	0	O
this	0	O
being	0	O
the	0	O
case	0	O
,	0	O
however	0	O
,	0	O
the	0	O
measurement	0	O
of	0	O
apo	0	B
B	1	I
has	0	O
met	0	O
every	0	O
reasonable	0	O
standard	0	O
of	0	O
laboratory	0	O
precision	0	O
and	0	O
reliability	0	O
to	0	O
allow	0	O
its	0	O
widespread	0	O
introduction	0	O
in	0	O
clinical	0	O
laboratories	0	O
.	0	O


60th	0	O
birthday	0	O
of	0	O
colonel	0	O
prof	0	O
.	0	O
e	0	O
.	0	O
cerny	0	O
m	0	O
.	0	O
d	0	O
.	0	O


The	0	O
role	0	O
of	0	O
protein	0	B
kinase	0	I
C	1	I
signaling	0	O
in	0	O
activated	0	O
DRA	0	B
transcription	0	O
.	0	O


Two	0	O
splice	0	O
variants	0	O
of	0	O
ALF1	0	B
cDNA	1	I
have	0	O
been	0	O
found	0	O
,	0	O
differing	0	O
by	0	O
a	0	O
72	0	O
-	0	O
bp	0	O
insertion	0	O
,	0	O
coding	0	O
for	0	O
putative	0	O
proteins	0	O
of	0	O
682	0	O
and	0	O
706	0	O
amino	0	O
acids	0	O
.	0	O


The	0	O
general	0	O
recombination	0	O
at	0	O
a	0	O
polarizing	0	O
voltage	0	O
of	0	O
300	0	O
V	1	O
is	0	O
less	0	O
than	0	O
2	0	O
%	0	O
for	0	O
dose	0	O
-	0	O
rates	0	O
up	0	O
to	0	O
about	0	O
100	0	O
mGy	0	O
min	0	O
-	0	O
1	0	O
.	0	O


To	1	O
characterize	0	O
the	0	O
O7	0	B
-	0	I
LPS	1	I
region	0	I
,	0	O
the	0	O
recombinant	0	O
cosmids	0	O
pJHCV31	0	O
and	0	O
pJHCV32	0	O
were	0	O
mutagenized	0	O
by	0	O
transposon	0	O
mutagenesis	0	O
with	0	O
Tn3HoHo1	0	B
,	0	O
which	0	O
carries	0	O
a	0	O
promoterless	0	O
lac	0	B
operon	0	I
and	0	O
can	0	O
therefore	0	O
generate	0	O
lacZ	0	B
transcriptional	0	O
fusions	0	O
with	0	O
target	0	O
DNA	1	O
sequences	0	O
.	0	O


While	0	O
these	0	O
findings	0	O
may	0	O
reflect	0	O
the	0	O
sensitivity	0	O
of	0	O
a	0	O
thick	0	O
myocardial	0	O
wall	0	O
to	0	O
ischaemia	0	O
during	0	O
surgery	0	O
,	0	O
the	0	O
postoperative	0	O
recovery	0	O
was	0	O
not	0	O
related	0	O
to	0	O
the	0	O
serum	0	B
CK	1	I
-	0	I
MB	1	I
level	0	O
.	0	O


A	1	O
contiguous	0	O
and	0	O
sequentially	0	O
occupied	0	O
secondary	0	O
Fur	0	B
-	0	I
binding	0	I
site	0	I
in	0	O
entC	0	B
was	0	O
protected	0	O
at	0	O
higher	0	O
Fur	0	B
concentrations	0	O
,	0	O
extending	0	O
the	0	O
protected	0	O
region	0	O
to	0	O
+	0	O
49	0	O
,	0	O
and	0	O
sequestering	0	O
the	0	O
putative	0	O
Shine	0	O
-	0	O
Dalgarno	0	O
sequence	0	O
.	0	O


In	1	O
several	0	O
studies	0	O
the	0	O
RDFS	0	O
has	0	O
shown	0	O
evidence	0	O
of	0	O
reliability	0	O
and	0	O
validity	0	O
.	0	O


A	1	O
385	0	O
bp	0	O
Glucocorticoid	1	O
Response	1	O
Unit	1	O
(	0	O
GRU	0	O
)	0	O
was	0	O
identified	0	O
whose	0	O
glucocorticoid	0	O
induction	0	O
was	0	O
enhanced	0	O
by	0	O
dibutyryl	0	O
-	0	O
cAMP	1	O
and	0	O
reduced	0	O
by	0	O
phorbol	0	O
esters	0	O
.	0	O


Ischemia	1	O
-	0	O
induced	0	O
biphasic	0	O
arrhythmias	0	O
were	0	O
suppressed	0	O
in	0	O
both	0	O
zatebradine	0	O
and	0	O
propranolol	0	O
groups	0	O
.	0	O


Cephradine	1	O
250	0	O
mg	0	O
at	0	O
night	0	O
for	0	O
12	0	O
months	0	O
was	0	O
given	0	O
as	0	O
a	0	O
prophylactic	0	O
measure	0	O
to	0	O
33	0	O
female	0	O
patients	0	O
of	0	O
mean	0	O
age	0	O
41	0	O
.	0	O
6	0	O
years	0	O
,	0	O
who	0	O
had	0	O
a	0	O
history	0	O
in	0	O
the	0	O
preceding	0	O
12	0	O
months	0	O
of	0	O
between	0	O
three	0	O
and	0	O
24	0	O
(	0	O
median	0	O
=	0	O
7	0	O
)	0	O
episodes	0	O
of	0	O
frequency	0	O
and	0	O
/	0	O
or	0	O
dysuria	0	O
.	0	O


One	0	O
RNA	1	O
construct	0	O
which	0	O
consisted	0	O
of	0	O
112	0	O
nucleotides	0	O
(	0	O
nt	0	O
)	0	O
from	0	O
nt	0	O
639	0	O
to	0	O
nt	0	O
750	0	O
formed	0	O
a	0	O
heterodimeric	0	O
complex	0	O
with	0	O
the	0	O
RNA	1	O
which	0	O
consisted	0	O
of	0	O
200	0	O
nucleotides	0	O
from	0	O
nt	0	O
551	0	O
to	0	O
nt	0	O
750	0	O
.	0	O


These	0	O
data	0	O
demonstrate	0	O
that	0	O
the	0	O
STR	1	B
family	0	I
of	0	O
genes	0	O
is	0	O
represented	0	O
in	0	O
a	0	O
nematode	0	O
whose	0	O
ancestor	0	O
appeared	0	O
well	0	O
before	0	O
the	0	O
branching	0	O
that	0	O
gave	0	O
rise	0	O
to	0	O
the	0	O
Arthropoda	1	O
and	0	O
Chordata	1	O
.	0	O


The	0	O
small	0	O
size	0	O
and	0	O
placement	0	O
of	0	O
the	0	O
mutagenesis	0	O
marker	0	O
(	0	O
the	0	O
supF	0	B
suppressor	0	I
tRNA	1	I
gene	0	I
from	0	I
Escherichia	1	I
coli	0	I
)	0	O
within	0	O
the	0	O
vector	0	O
substantially	0	O
reduced	0	O
the	0	O
frequency	0	O
of	0	O
spontaneous	0	O
mutations	0	O
normally	0	O
observed	0	O
after	0	O
transfection	0	O
of	0	O
mammalian	0	O
cells	0	O
with	0	O
plasmid	0	O
DNA	1	O
;	0	O
hence	0	O
,	0	O
UV	1	O
-	0	O
induced	0	O
mutations	0	O
were	0	O
easily	0	O
identified	0	O
above	0	O
the	0	O
spontaneous	0	O
background	0	O
.	0	O


A	1	O
genetic	0	O
and	0	O
molecular	0	O
analysis	0	O
of	0	O
non	0	O
-	0	O
inducible	0	O
qutA	0	B
mutants	0	I
showed	0	O
that	0	O
all	0	O
23	0	O
mutations	0	O
analysed	0	O
map	0	O
within	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
half	0	O
of	0	O
the	0	O
encoded	0	O
QUTA	0	B
protein	0	I
.	0	O


This	0	O
5	0	O
'	0	O
splice	0	O
site	0	O
sequence	0	O
was	0	O
required	0	O
for	0	O
enhanced	0	O
polyadenylation	0	O
and	0	O
was	0	O
recognized	0	O
by	0	O
both	0	O
U1	0	B
small	0	I
nuclear	0	I
ribonucleoproteins	0	I
(	0	O
snRNPs	0	O
)	0	O
and	0	O
alternative	0	B
splicing	0	I
factor	0	I
/	0	O
splicing	0	B
factor	0	I
2	0	I
(	0	O
ASF	1	B
/	0	O
SF2	0	B
).	0	O


Ang	0	B
II	0	I
significantly	0	O
induced	0	O
Ang2	0	B
mRNA	1	I
accumulations	0	O
without	0	O
affecting	0	O
Ang1	0	B
or	0	O
Tie2	0	B
expression	0	O
,	0	O
which	0	O
was	0	O
inhibited	0	O
by	0	O
protein	0	B
kinase	0	I
C	1	I
inhibitors	0	O
and	0	O
by	0	O
intracellular	0	O
Ca	1	O
(	0	O
2	0	O
+)	0	O
chelating	0	O
agents	0	O
.	0	O


The	0	O
concentrations	0	O
of	0	O
vitamin	0	O
A	1	O
precursors	0	O
and	0	O
vitamin	0	O
E	1	O
in	0	O
the	0	O
hay	0	O
were	0	O
below	0	O
currently	0	O
recommended	0	O
dietary	0	O
levels	0	O
for	0	O
llamas	0	O
,	0	O
and	0	O
alfalfa	0	O
hay	0	O
appears	0	O
to	0	O
provide	0	O
an	0	O
unreliable	0	O
source	0	O
of	0	O
vitamins	0	O
A	1	O
and	0	O
E	1	O
in	0	O
this	0	O
species	0	O
.	0	O


The	0	O
models	0	O
were	0	O
tested	0	O
by	0	O
studying	0	O
their	0	O
response	0	O
to	0	O
disturbances	0	O
of	0	O
the	0	O
afferent	0	O
signal	0	O
from	0	O
the	0	O
bladder	0	O
.	0	O


Timing	0	O
of	0	O
symptoms	0	O
and	0	O
oocyst	0	O
excretion	0	O
in	0	O
human	0	O
cryptosporidiosis	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
describe	0	O
directional	0	O
chromosome	0	O
walking	0	O
studies	0	O
starting	0	O
from	0	O
D8S260	0	B
as	0	O
well	0	O
as	0	O
D8S285	0	B
.	0	O


These	0	O
components	0	O
both	0	O
had	0	O
a	0	O
median	0	O
R2	0	O
of	0	O
0	0	O
.	0	O
84	0	O
,	0	O
compared	0	O
to	0	O
median	0	O
R2s	0	O
ranging	0	O
from	0	O
0	0	O
.	0	O
37	0	O
to	0	O
0	0	O
.	0	O
83	0	O
for	0	O
five	0	O
commonly	0	O
used	0	O
ad	0	O
hoc	0	O
EEG	1	O
components	0	O
.	0	O


This	0	O
study	0	O
indicates	0	O
that	0	O
the	0	O
phenotype	0	O
of	0	O
myofibrillar	0	O
disarray	0	O
seen	0	O
in	0	O
HCM	1	O
patients	0	O
which	0	O
harbor	0	O
either	0	O
of	0	O
these	0	O
two	0	O
mutations	0	O
may	0	O
not	0	O
be	0	O
directly	0	O
due	0	O
to	0	O
the	0	O
failure	0	O
of	0	O
the	0	O
mutant	0	B
myosin	0	I
heavy	0	I
chain	0	I
protein	0	I
to	0	O
assemble	0	O
and	0	O
form	0	O
normal	0	O
sarcomeres	0	O
,	0	O
but	0	O
may	0	O
rather	0	O
be	0	O
a	0	O
secondary	0	O
effect	0	O
possibly	0	O
resulting	0	O
from	0	O
the	0	O
chronic	0	O
stress	0	O
of	0	O
decreased	0	O
beta	0	B
MHC	1	I
function	0	O
.	0	O


In	1	O
AcMNPV	0	O
-	0	O
infected	0	O
Sf9	0	O
cells	0	O
,	0	O
late	0	O
transcription	0	O
initiation	0	O
is	0	O
detected	0	O
from	0	O
only	0	O
two	0	O
upstream	0	O
TAAG	0	O
sites	0	O
and	0	O
not	0	O
from	0	O
three	0	O
downstream	0	O
TAAG	0	O
sites	0	O
.	0	O


According	0	O
to	0	O
the	0	O
published	0	O
sequence	0	O
of	0	O
the	0	O
CHS1	0	B
gene	0	I
,	0	O
this	0	O
fragment	0	O
contains	0	O
four	0	O
repeats	0	O
of	0	O
a	0	O
TGAAACA	0	O
consensus	0	O
sequence	0	O
previously	0	O
identified	0	O
in	0	O
the	0	O
alpha	0	B
-	0	I
factor	0	I
-	0	O
inducible	0	O
BAR1	0	B
promoter	0	I
[	0	O
Kronstad	0	O
,	0	O
J	1	O
.	0	O


Twenty	0	O
-	0	O
nine	0	O
days	0	O
after	0	O
injection	0	O
of	0	O
5	0	O
.	0	O
8	0	O
mCi	1	O
of	0	O
Tc	1	O
-	0	O
99m	0	O
,	0	O
which	0	O
gives	0	O
28	0	O
rads	0	O
to	0	O
the	0	O
testis	0	O
,	0	O
the	0	O
number	0	O
of	0	O
sperm	0	O
hads	0	O
decreased	0	O
to	0	O
70	0	O
%	0	O
of	0	O
control	0	O
.	0	O


The	0	O
muscles	0	O
from	0	O
the	0	O
ischemic	0	O
group	0	O
had	0	O
significantly	0	O
lower	0	O
(	0	O
P	1	O
less	0	O
than	0	O
.	0	O
05	0	O
)	0	O
values	0	O
for	0	O
capillary	0	O
density	0	O
and	0	O
capillary	0	O
to	0	O
fiber	0	O
ratio	0	O
and	0	O
significantly	0	O
higher	0	O
intercapillary	0	O
distance	0	O
than	0	O
those	0	O
from	0	O
the	0	O
normal	0	O
group	0	O
.	0	O


Proteins	0	O
immunoprecipitated	0	O
from	0	O
lysates	0	O
of	0	O
control	0	O
-	0	O
and	0	O
VEGF	1	B
-	0	O
stimulated	0	O
BAEC	0	O
with	0	O
antisera	0	O
to	0	O
phospholipase	0	B
C	1	I
-	0	I
gamma	0	I
(	0	O
PLC	0	B
-	0	I
gamma	0	I
)	0	O
were	0	O
fractionated	0	O
by	0	O
SDS	1	O
-	0	O
polyacrylamide	0	O
gel	0	O
electrophoresis	0	O
and	0	O
transferred	0	O
to	0	O
Immobilon	0	O
-	0	O
P	1	O
.	0	O


Specialist	1	O
in	0	O
family	0	O
practice	0	O
--	0	O
prototype	0	O
of	0	O
a	0	O
doctor	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
P	1	O
.	0	O
aeruginosa	0	O
orfX	0	O
and	0	O
vfr	0	B
promoters	0	I
are	0	O
arranged	0	O
in	0	O
a	0	O
back	0	O
-	0	O
to	0	O
-	0	O
back	0	O
orientation	0	O
rather	0	O
than	0	O
the	0	O
face	0	O
-	0	O
to	0	O
-	0	O
face	0	O
orientation	0	O
of	0	O
the	0	O
dorf	0	O
and	0	O
crp	0	B
promoters	0	I
.	0	O


However	0	O
,	0	O
vancomycin	0	O
and	0	O
fosfomycin	0	O
,	0	O
which	0	O
revealed	0	O
suboptimal	0	O
in	0	O
vitro	0	O
bactericidal	0	O
activity	0	O
,	0	O
proved	0	O
as	0	O
efficacious	0	O
as	0	O
penicillin	0	O
G	1	O
and	0	O
imipenem	0	O
in	0	O
an	0	O
experimental	0	O
mode	0	O
of	0	O
murine	0	O
gas	0	O
gangrene	0	O
.	0	O


In	1	O
this	0	O
study	0	O
we	0	O
describe	0	O
that	0	O
platelet	0	B
-	0	I
derived	0	I
growth	0	I
factor	0	I
(	0	O
PDGF	0	B
),	0	O
12	0	O
-	0	O
O	1	O
-	0	O
tetradecanoyl	0	O
-	0	O
phorbol	0	O
-	0	O
acetate	0	O
(	0	O
TPA	1	O
),	0	O
and	0	O
forskolin	0	O
induced	0	O
CREB	0	B
(	0	O
cAMP	1	B
-	0	I
responsive	0	I
element	0	I
-	0	I
binding	0	I
protein	0	I
)	0	O
Ser	1	O
-	0	O
133	0	O
phosphorylation	0	O
with	0	O
comparable	0	O
magnitude	0	O
and	0	O
kinetics	0	O
in	0	O
NIH	1	O
3T3	0	O
cells	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
antithrombotic	0	O
drugs	0	O
in	0	O
patients	0	O
with	0	O
left	0	O
ventricular	0	O
thrombi	0	O
:	0	O
assessment	0	O
with	0	O
indium	0	O
-	0	O
111	0	O
platelet	0	O
imaging	0	O
and	0	O
two	0	O
-	0	O
dimensional	0	O
echocardiography	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
identification	0	O
of	0	O
a	0	O
Dr1	0	B
-	0	I
like	0	I
protein	0	I
in	0	O
A	1	O
.	0	O
thaliana	0	O
strongly	0	O
argues	0	O
for	0	O
the	0	O
ubiquity	0	O
of	0	O
this	0	O
protein	0	O
among	0	O
eukaryotic	0	O
genera	0	O
and	0	O
for	0	O
a	0	O
conserved	0	O
mechanism	0	O
to	0	O
regulate	0	O
transcription	0	O
initiation	0	O
that	0	O
involves	0	O
Dr1	0	B
.	0	O


A	1	O
new	0	O
UASH	0	O
consensus	0	O
sequence	0	O
derived	0	O
from	0	O
this	0	O
mutational	0	O
analysis	0	O
closely	0	O
matches	0	O
a	0	O
consensus	0	O
Abf1	0	B
binding	0	I
site	0	I
.	0	O


The	0	O
highest	0	O
decrease	0	O
in	0	O
mutagenic	0	O
activity	0	O
was	0	O
observed	0	O
when	0	O
enzymatic	0	O
bleaching	0	O
was	0	O
used	0	O
together	0	O
with	0	O
chlorine	0	O
.	0	O


We	0	O
have	0	O
previously	0	O
mapped	0	O
the	0	O
defect	0	O
in	0	O
RIIIS	0	O
/	0	O
J	1	O
to	0	O
distal	0	O
mouse	0	O
Chr	1	O
11	0	O
,	0	O
distinct	0	O
from	0	O
the	0	O
Vwf	1	B
locus	0	I
on	0	O
Chr	1	O
6	0	O
.	0	O


Therefore	0	O
,	0	O
it	0	O
was	0	O
concluded	0	O
that	0	O
thrombotic	0	O
tendency	0	O
certainly	0	O
existed	0	O
in	0	O
patients	0	O
with	0	O
MS	1	O
compared	0	O
to	0	O
those	0	O
with	0	O
non	0	O
RHD	0	O
and	0	O
that	0	O
it	0	O
was	0	O
one	0	O
of	0	O
the	0	O
causes	0	O
of	0	O
the	0	O
significantly	0	O
high	0	O
incidence	0	O
of	0	O
thromboembolism	0	O
in	0	O
comparison	0	O
with	0	O
non	0	O
RHD	0	O
.	0	O


An	1	O
analysis	0	O
of	0	O
the	0	O
steady	0	O
state	0	O
RNA	1	O
levels	0	O
in	0	O
T	1	O
-	0	O
lymphoid	0	O
cell	0	O
lines	0	O
showed	0	O
that	0	O
at	0	O
least	0	O
three	0	O
different	0	O
incomplete	0	O
proviral	0	O
transcripts	0	O
and	0	O
their	0	O
spliced	0	O
products	0	O
made	0	O
up	0	O
the	0	O
majority	0	O
of	0	O
expressed	0	O
RD	1	B
-	0	I
114	0	I
mRNA	1	I
,	0	O
and	0	O
further	0	O
demonstrated	0	O
that	0	O
partially	0	O
deleted	0	O
proviral	0	O
loci	0	O
have	0	O
the	0	O
potential	0	O
to	0	O
be	0	O
transcriptionally	0	O
vigorous	0	O
in	0	O
certain	0	O
feline	0	O
cell	0	O
types	0	O
.	0	O


The	0	O
present	0	O
findings	0	O
revealed	0	O
that	0	O
the	0	O
rib	0	B
-	0	I
2	0	I
protein	0	I
was	0	O
a	0	O
unique	0	O
alpha1	0	B
,	0	I
4	0	I
-	0	I
N	1	I
-	0	I
acetylglucosaminyltransferase	0	I
involved	0	O
in	0	O
the	0	O
biosynthetic	0	O
initiation	0	O
and	0	O
elongation	0	O
of	0	O
heparan	0	O
sulfate	0	O
.	0	O


The	0	O
amplitude	0	O
of	0	O
detrusor	0	O
contractions	0	O
at	0	O
6	0	O
,	0	O
12	0	O
,	0	O
and	0	O
24	0	O
hours	0	O
showed	0	O
no	0	O
significant	0	O
difference	0	O
from	0	O
that	0	O
in	0	O
the	0	O
controls	0	O
.	0	O


In	1	O
infected	0	O
mammalian	0	O
cells	0	O
,	0	O
the	0	O
ARV	0	B
G	1	I
and	0	O
GNS	0	B
genes	0	I
are	0	O
transcribed	0	O
primarily	0	O
as	0	O
a	0	O
polycistronic	0	O
mRNA	1	O
which	0	O
appears	0	O
to	0	O
extend	0	O
from	0	O
the	0	O
consensus	0	O
sequence	0	O
(	0	O
AACAG	0	O
)	0	O
at	0	O
the	0	O
start	0	O
of	0	O
the	0	O
G	1	B
gene	0	I
to	0	O
the	0	O
next	0	O
recognized	0	O
polyadenylation	0	O
signal	0	O
(	0	O
CATG	0	O
[	0	O
A	1	O
]	0	O
7	0	O
)	0	O
located	0	O
697	0	O
nucleotides	0	O
downstream	0	O
of	0	O
the	0	O
GNS	0	B
protein	0	I
termination	0	O
codon	0	O
.	0	O


The	0	O
promoter	0	O
of	0	O
the	0	O
rat	0	O
pgp2	0	B
/	0	O
mdr1b	0	B
gene	0	O
has	0	O
a	0	O
GC	1	O
-	0	O
rich	0	O
region	0	O
(	0	O
pgp2GC	0	B
)	0	O
that	0	O
is	0	O
highly	0	O
conserved	0	O
in	0	O
mdr	0	B
genes	0	I
and	0	O
contains	0	O
an	0	O
consensus	0	O
Sp1	0	B
site	0	I
.	0	O


W	1	O
.	0	O


However	0	O
,	0	O
addition	0	O
of	0	O
core	0	B
DNA	1	I
polymerase	0	I
III	0	I
to	0	O
preinitiation	0	O
complex	0	O
,	0	O
fully	0	O
reconstituting	0	O
holoenzyme	0	O
resulted	0	O
in	0	O
replacement	0	O
of	0	O
gamma	0	O
by	0	O
alpha	0	O
at	0	O
the	0	O
primer	0	O
terminus	0	O
.	0	O


Genetic	1	O
and	0	O
molecular	0	O
data	0	O
indicate	0	O
that	0	O
wild	0	B
-	0	I
type	0	I
Pan	1	I
and	0	O
CiD	1	B
compete	0	O
for	0	O
binding	0	O
to	0	O
Arm	1	B
,	0	O
leading	0	O
to	0	O
a	0	O
compromised	0	O
transduction	0	O
of	0	O
the	0	O
Wg	0	B
signal	0	O
in	0	O
heterozygous	0	O
ciD	1	B
/+	0	I
animals	0	O
and	0	O
to	0	O
a	0	O
dramatic	0	O
enhancement	0	O
of	0	O
the	0	O
gain	0	O
-	0	O
of	0	O
-	0	O
function	0	O
activity	0	O
of	0	O
CiD	1	B
in	0	O
homozygous	0	O
mutants	0	O
.	0	O


In	1	O
the	0	O
Center	1	O
for	0	O
Human	1	O
Genetics	1	O
in	0	O
Leuven	0	O
,	0	O
predictive	0	O
DNA	1	O
-	0	O
testing	0	O
for	0	O
Huntington	0	O
'	0	O
s	0	O
disease	0	O
is	0	O
available	0	O
as	0	O
a	0	O
clinical	0	O
service	0	O
since	0	O
November	0	O
1987	0	O
,	0	O
initially	0	O
by	0	O
DNA	1	O
-	0	O
linkage	0	O
and	0	O
since	0	O
mid	0	O
1993	0	O
by	0	O
direct	0	O
mutation	0	O
analysis	0	O
.	0	O


Separation	1	O
of	0	O
ninhydrin	0	O
-	0	O
positive	0	O
compounds	0	O
in	0	O
urine	0	O
by	0	O
the	0	O
combined	0	O
methods	0	O
of	0	O
medium	0	O
-	0	O
tension	0	O
intophoresis	0	O
and	0	O
partition	0	O
chromatography	0	O


Near	0	O
term	0	O
,	0	O
under	0	O
experimental	0	O
conditions	0	O
,	0	O
maternal	0	O
and	0	O
fetal	0	O
blood	0	O
gases	0	O
,	0	O
pH	1	O
,	0	O
uterine	0	O
and	0	O
umbilical	0	O
blood	0	O
flows	0	O
were	0	O
measured	0	O
or	0	O
calculated	0	O
.	0	O


Transcriptional	1	O
repression	0	O
mediated	0	O
by	0	O
LysR	0	B
-	0	I
type	0	I
regulator	0	I
CatR	0	I
bound	0	O
at	0	O
multiple	0	O
binding	0	O
sites	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
full	0	B
-	0	I
length	0	I
E2F	0	I
-	0	I
3	0	I
,	0	O
which	0	O
is	0	O
expressed	0	O
only	0	O
at	0	O
the	0	O
G1	0	O
/	0	O
S	1	O
boundary	0	O
,	0	O
E2F	0	B
-	0	I
3B	0	I
is	0	O
detected	0	O
throughout	0	O
the	0	O
cell	0	O
cycle	0	O
with	0	O
peak	0	O
levels	0	O
in	0	O
GO	0	O
where	0	O
it	0	O
is	0	O
associated	0	O
with	0	O
Rb	1	B
.	0	O


The	0	O
main	0	O
aim	0	O
of	0	O
the	0	O
contribution	0	O
,	0	O
which	0	O
opens	0	O
an	0	O
arena	0	O
for	0	O
discussion	0	O
on	0	O
the	0	O
Rivista	0	O
dell	0	O
'	0	O
Infermiere	0	O
is	0	O
to	0	O
critically	0	O
appraise	0	O
published	0	O
research	0	O
works	0	O
focusing	0	O
both	0	O
on	0	O
strengths	0	O
and	0	O
novelty	0	O
and	0	O
weaknesses	0	O
in	0	O
the	0	O
hypothesis	0	O
formulation	0	O
,	0	O
methods	0	O
and	0	O
instruments	0	O
used	0	O
,	0	O
discussion	0	O
of	0	O
results	0	O
.	0	O


Enhanced	0	O
period	0	O
-	0	O
peak	0	O
analysis	0	O
of	0	O
electro	0	O
-	0	O
encephalograms	0	O
using	0	O
a	0	O
fast	0	O
sinc	0	O
function	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
kinase	0	O
-	0	O
dead	0	O
but	0	O
not	0	O
wild	0	O
-	0	O
type	0	O
forms	0	O
of	0	O
Fyn	0	B
,	0	O
Lck	0	B
,	0	O
and	0	O
ZAP	0	B
-	0	I
70	0	I
block	0	O
70Z	0	O
Cbl	1	B
-	0	O
mediated	0	O
NFAT	0	B
activation	0	O
.	0	O


One	0	O
such	0	O
mutant	0	O
also	0	O
affects	0	O
the	0	O
overlapping	0	O
-	0	O
10	0	O
hexamer	0	O
of	0	O
PR	1	O
and	0	O
results	0	O
in	0	O
reduced	0	O
occupancy	0	O
by	0	O
both	0	O
MerR	0	B
and	0	O
RNA	1	B
polymerase	0	I
,	0	O
likely	0	O
as	0	O
a	0	O
result	0	O
of	0	O
inefficient	0	O
transcriptional	0	O
initiation	0	O
of	0	O
merR	0	B
mRNA	1	I
.	0	O


This	0	O
study	0	O
allows	0	O
us	0	O
to	0	O
draw	0	O
conclusions	0	O
about	0	O
the	0	O
identity	0	O
of	0	O
proteins	0	O
required	0	O
for	0	O
the	0	O
development	0	O
of	0	O
the	0	O
nervous	0	O
system	0	O
in	0	O
Drosophila	1	O
and	0	O
provides	0	O
an	0	O
example	0	O
of	0	O
a	0	O
molecular	0	O
approach	0	O
to	0	O
characterize	0	O
en	0	O
masse	0	O
transposon	0	O
-	0	O
tagged	0	O
mutations	0	O
identified	0	O
in	0	O
genetic	0	O
screens	0	O
.	0	O


If	1	O
facilities	0	O
for	0	O
measurements	0	O
of	0	O
O2	1	O
consumption	0	O
and	0	O
hence	0	O
metabolic	0	O
rate	0	O
are	0	O
available	0	O
,	0	O
these	0	O
should	0	O
be	0	O
utilized	0	O
.	0	O


These	0	O
CTD	1	B
kinases	0	I
,	0	O
designated	0	O
CTDK1	0	B
and	0	O
CTDK2	0	B
,	0	O
are	0	O
fractionated	0	O
by	0	O
chromatography	0	O
on	0	O
Mono	1	O
Q	1	O
.	0	O


Wild	1	B
-	0	I
type	0	I
AT1A	0	I
receptors	0	I
,	0	O
expressed	0	O
in	0	O
Chinese	0	O
hamster	0	O
ovary	0	O
cells	0	O
,	0	O
rapidly	0	O
internalized	0	O
after	0	O
Ang	0	B
II	0	I
stimulation	0	O
[	0	O
t1	0	O
/	0	O
2	0	O
2	0	O
.	0	O
3	0	O
min	0	O
;	0	O
maximal	0	O
level	0	O
of	0	O
internalization	0	O
(	0	O
Ymax	0	O
)	0	O
78	0	O
.	0	O
2	0	O
%],	0	O
as	0	O
did	0	O
mutant	0	O
receptors	0	O
carrying	0	O
single	0	O
acidic	0	O
substitutions	0	O
(	0	O
T332E	0	O
,	0	O
t1	0	O
/	0	O
2	0	O
2	0	O
.	0	O
7	0	O
min	0	O
,	0	O
Ymax	0	O
76	0	O
.	0	O
3	0	O
%;	0	O
S335D	0	O
,	0	O
t1	0	O
/	0	O
2	0	O
2	0	O
.	0	O
4	0	O
min	0	O
,	0	O
Ymax	0	O
76	0	O
.	0	O
7	0	O
%;	0	O
T336E	0	O
,	0	O
t1	0	O
/	0	O
2	0	O
2	0	O
.	0	O
5	0	O
min	0	O
,	0	O
Ymax	0	O
78	0	O
.	0	O
2	0	O
%;	0	O
S338D	0	O
,	0	O
t1	0	O
/	0	O
2	0	O
2	0	O
.	0	O
6	0	O
min	0	O
,	0	O
Ymax	0	O
78	0	O
.	0	O
4	0	O
%).	0	O


When	0	O
tested	0	O
with	0	O
wild	0	O
-	0	O
type	0	O
(	0	O
DBA	1	O
/	0	O
2	0	O
)	0	O
p16	0	B
,	0	O
both	0	O
A134C	0	O
and	0	O
G232A	0	O
BALB	0	O
/	0	O
c	0	O
-	0	O
specific	0	O
variants	0	O
of	0	O
p16	0	B
were	0	O
inefficient	0	O
in	0	O
their	0	O
ability	0	O
to	0	O
inhibit	0	O
the	0	O
activity	0	O
of	0	O
cyclin	0	B
D2	0	I
/	0	O
CDK4	0	B
in	0	O
kinase	0	O
assays	0	O
with	0	O
retinoblastoma	0	B
protein	0	I
,	0	O
suggesting	0	O
this	0	O
defective	0	O
,	0	O
inherited	0	O
allele	0	O
plays	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
genetic	0	O
susceptibility	0	O
of	0	O
BALB	0	O
/	0	O
c	0	O
mice	0	O
for	0	O
plasmacytoma	0	O
induction	0	O
and	0	O
that	0	O
p16	0	B
(	0	O
INK4a	0	B
)	0	O
is	0	O
a	0	O
strong	0	O
candidate	0	O
for	0	O
the	0	O
Pctr1	0	B
locus	0	I
.	0	O


We	0	O
purified	0	O
both	0	O
proteins	0	O
from	0	O
human	0	O
platelet	0	O
membranes	0	O
using	0	O
DEAE	0	O
-	0	O
Sepharose	0	O
chromatography	0	O
followed	0	O
by	0	O
mAb	0	B
F11	0	I
affinity	0	O
chromatography	0	O
.	0	O


Plasma	1	O
ion	0	O
changes	0	O
in	0	O
venous	0	O
blood	0	O
incubated	0	O
with	0	O
beta	0	B
receptor	0	I
blockers	0	O
and	0	O
subjected	0	O
to	0	O
tonometry	0	O
in	0	O
vitro	0	O
.	0	O


The	0	O
in	0	O
vitro	0	O
antibacterial	0	O
potency	0	O
is	0	O
greatest	0	O
when	0	O
the	0	O
1	0	O
-	0	O
substituent	0	O
is	0	O
2	0	O
,	0	O
4	0	O
-	0	O
difluorophenyl	0	O
and	0	O
the	0	O
7	0	O
-	0	O
substituent	0	O
is	0	O
a	0	O
3	0	O
-	0	O
amino	0	O
-	0	O
1	0	O
-	0	O
pyrrolidinyl	0	O
group	0	O
.	0	O


The	0	O
ectopic	0	O
expression	0	O
of	0	O
Oct	1	B
-	0	I
3	0	I
/	0	I
4	0	I
in	0	O
hybrid	0	O
cells	0	O
under	0	O
a	0	O
constitutive	0	O
promoter	0	O
is	0	O
sufficient	0	O
for	0	O
transcriptional	0	O
activation	0	O
of	0	O
an	0	O
octamer	0	O
-	0	O
dependent	0	O
promoter	0	O
.	0	O


Thus	0	O
,	0	O
quantitative	0	O
analysis	0	O
of	0	O
thallium	0	O
-	0	O
201	0	O
uptake	0	O
and	0	O
washout	0	O
provided	0	O
objective	0	O
evidence	0	O
for	0	O
improved	0	O
myocardial	0	O
perfusion	0	O
after	0	O
coronary	0	O
angioplasty	0	O
.	0	O


The	0	O
recovery	0	O
rates	0	O
for	0	O
the	0	O
MB	1	O
/	0	O
BacT	0	O
,	0	O
MGIT	0	O
960	0	O
,	0	O
and	0	O
solid	0	O
media	0	O
were	0	O
91	0	O
.	0	O
6	0	O
,	0	O
87	0	O
.	0	O
4	0	O
,	0	O
and	0	O
54	0	O
.	0	O
7	0	O
%,	0	O
respectively	0	O
,	0	O
for	0	O
all	0	O
mycobacteria	0	O
;	0	O
the	0	O
recovery	0	O
rates	0	O
were	0	O
93	0	O
.	0	O
6	0	O
,	0	O
88	0	O
.	0	O
9	0	O
,	0	O
and	0	O
63	0	O
.	0	O
4	0	O
%,	0	O
respectively	0	O
,	0	O
for	0	O
M	1	O
.	0	O
tuberculosis	0	O
complex	0	O
alone	0	O
,	0	O
and	0	O
87	0	O
.	0	O
5	0	O
,	0	O
84	0	O
.	0	O
4	0	O
,	0	O
and	0	O
37	0	O
.	0	O
5	0	O
%,	0	O
respectively	0	O
,	0	O
for	0	O
all	0	O
nontuberculous	0	O
mycobacteria	0	O
.	0	O


Here	0	O
the	0	O
conventional	0	O
tests	0	O
clearly	0	O
pointed	0	O
to	0	O
the	0	O
presence	0	O
of	0	O
retrocochlear	0	O
disease	0	O
.	0	O


With	0	O
respect	0	O
to	0	O
effective	0	O
diffusivity	0	O
of	0	O
platelets	0	O
(	0	O
De	0	O
)	0	O
and	0	O
the	0	O
surface	0	O
reactivity	0	O
constant	0	O
(	0	O
K	1	O
),	0	O
less	0	O
significant	0	O
differences	0	O
were	0	O
found	0	O
among	0	O
artificial	0	O
materials	0	O
.	0	O


Our	0	O
study	0	O
shows	0	O
that	0	O
the	0	O
area	0	O
of	0	O
Alcoy	0	O
is	0	O
a	0	O
medium	0	O
MS	1	O
risk	0	O
region	0	O
according	0	O
to	0	O
the	0	O
thesis	0	O
of	0	O
Kurzke	0	O
,	0	O
although	0	O
high	0	O
MS	1	O
areas	0	O
may	0	O
be	0	O
found	0	O
,	0	O
thus	0	O
confirming	0	O
that	0	O
MS	1	O
distribution	0	O
in	0	O
southern	0	O
Europe	0	O
is	0	O
not	0	O
uniform	0	O
.	0	O


The	0	O
lethal	0	O
toxicity	0	O
of	0	O
inorganic	0	O
(	0	O
HgCl2	1	O
)	0	O
and	0	O
organic	0	O
(	0	O
CH3HgCl	0	O
)	0	O
mercury	0	O
chloride	0	O
was	0	O
compared	0	O
for	0	O
Coturnix	1	O
(	0	O
Japanese	0	O
quail	0	O
,	0	O
Coturnix	1	O
japonica	0	O
)	0	O
of	0	O
different	0	O
ages	0	O
from	0	O
hatch	0	O
through	0	O
adulthood	0	O
by	0	O
single	0	O
-	0	O
dose	0	O
acute	0	O
oral	0	O
and	0	O
intramuscular	0	O
injections	0	O
and	0	O
by	0	O
a	0	O
5	0	O
-	0	O
d	0	O
dietary	0	O
trial	0	O
.	0	O


Individuals	0	O
attending	0	O
the	0	O
GUM	1	O
Department	1	O
in	0	O
the	0	O
Royal	0	O
Infirmary	1	O
of	0	O
Edinburgh	0	O
between	0	O
1990	0	O
and	0	O
1994	0	O
with	0	O
the	0	O
diagnosis	0	O
of	0	O
HIV	1	O
infection	0	O
,	0	O
genital	0	O
warts	0	O
,	0	O
genital	0	O
herpes	0	O
,	0	O
non	0	O
-	0	O
specific	0	O
genital	0	O
infection	0	O
(	0	O
NSGI	0	O
),	0	O
gonorrhoea	0	O
and	0	O
syphilis	0	O
were	0	O
included	0	O
in	0	O
the	0	O
study	0	O
.	0	O


Surprisingly	0	O
,	0	O
a	0	O
C	1	O
to	0	O
G	1	O
transversion	0	O
at	0	O
the	0	O
first	0	O
residue	0	O
of	0	O
the	0	O
CAT	1	B
pentanucleotide	0	I
,	0	O
which	0	O
severely	0	O
impairs	0	O
the	0	O
activity	0	O
of	0	O
both	0	O
promoters	0	O
,	0	O
appears	0	O
to	0	O
increase	0	O
affinity	0	O
of	0	O
the	0	O
CAT	1	B
binding	0	I
protein	0	I
.	0	O


The	0	O
Nmd3	0	B
protein	0	I
sequence	0	I
does	0	O
not	0	O
contain	0	O
readily	0	O
recognizable	0	O
motifs	0	O
of	0	O
known	0	O
function	0	O
.	0	O


Experimental	0	O
data	0	O
showed	0	O
that	0	O
these	0	O
abnormal	0	O
proteins	0	O
are	0	O
constitutively	0	O
localized	0	O
in	0	O
the	0	O
nucleus	0	O
,	0	O
have	0	O
lost	0	O
the	0	O
transcriptional	0	O
repressor	0	O
functions	0	O
typical	0	O
of	0	O
normal	0	O
NF	1	B
-	0	I
kappa	0	I
B2p52	0	I
and	0	O
may	0	O
be	0	O
capable	0	O
of	0	O
transactivation	0	O
activity	0	O
.	0	O


The	0	O
mammalian	0	B
phosphoinositide	0	I
3	0	I
-	0	I
kinases	0	I
(	0	O
PI3Ks	0	B
)	0	O
p110alpha	0	B
,	0	I
beta	0	I
,	0	I
and	0	I
delta	0	I
form	0	O
heterodimers	0	O
with	0	O
Src	1	B
homology	0	I
2	0	I
(	0	O
SH2	0	B
)	0	O
domain	0	O
-	0	O
containing	0	O
adaptors	0	O
such	0	O
as	0	O
p85alpha	0	B
or	0	O
p55	0	B
(	0	O
PIK	0	B
).	0	O


Viable	1	O
flap	0	O
areas	0	O
were	0	O
established	0	O
following	0	O
vascular	0	O
pedicle	0	O
ligation	0	O
(	0	O
both	0	O
vessels	0	O
or	0	O
only	0	O
artery	0	O
or	0	O
vein	0	O
),	0	O
on	0	O
the	0	O
third	0	O
day	0	O
after	0	O
flap	0	O
replantation	0	O
in	0	O
both	0	O
island	0	O
and	0	O
free	0	O
flaps	0	O
.	0	O


We	0	O
show	0	O
that	0	O
the	0	O
5	0	O
'	0	O
UTR	0	O
characteristic	0	O
of	0	O
testis	0	B
-	0	I
specific	0	I
c	0	I
-	0	I
mos	0	I
mRNA	1	I
strongly	0	O
represses	0	O
translation	0	O
relative	0	O
to	0	O
the	0	O
translation	0	O
of	0	O
transcripts	0	O
that	0	O
contain	0	O
a	0	O
5	0	O
'	0	O
UTR	0	O
derived	0	O
from	0	O
beta	0	B
-	0	I
globin	0	I
mRNA	1	I
,	0	O
and	0	O
this	0	O
is	0	O
mainly	0	O
due	0	O
to	0	O
the	0	O
four	0	O
uORFs	0	O
.	0	O


Six	0	O
distinct	0	O
Ets	1	B
mRNAs	0	I
were	0	O
identified	0	O
:	0	O
Ets2	0	B
,	0	O
Fli1	0	B
,	0	O
GABPalpha	0	B
,	0	O
SAP1	0	B
,	0	O
Elk1	0	B
,	0	O
and	0	O
PE1	0	B
.	0	O


A	1	O
genomic	0	O
clone	0	O
was	0	O
isolated	0	O
that	0	O
contained	0	O
12	0	O
.	0	O
5	0	O
kb	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
and	0	O
the	0	O
first	0	O
exon	0	O
of	0	O
the	0	O
p69	0	B
/	0	I
71	0	I
2	0	I
-	0	I
5A	0	I
synthetase	0	I
gene	0	I
.	0	O


Clinical	1	O
and	0	O
haematological	0	O
signs	0	O
are	0	O
not	0	O
specific	0	O
in	0	O
this	0	O
setting	0	O
,	0	O
and	0	O
the	0	O
diagnosis	0	O
relies	0	O
on	0	O
histological	0	O
features	0	O
,	0	O
mainly	0	O
bone	0	O
marrow	0	O
examination	0	O
.	0	O


A	1	O
protein	0	O
footprint	0	O
also	0	O
was	0	O
identified	0	O
for	0	O
a	0	O
GC	1	O
box	0	O
element	0	O
at	0	O
nucleotides	0	O
-	0	O
59	0	O
to	0	O
-	0	O
45	0	O
.	0	O


To	1	O
identify	0	O
the	0	O
precise	0	O
location	0	O
of	0	O
the	0	O
phosphorylation	0	O
site	0	O
on	0	O
the	0	O
64	0	O
-	0	O
kDa	1	O
protein	0	O
,	0	O
a	0	O
step	0	O
-	0	O
by	0	O
-	0	O
step	0	O
mutagenesis	0	O
procedures	0	O
was	0	O
followed	0	O
.	0	O


Although	0	O
there	0	O
is	0	O
little	0	O
evidence	0	O
that	0	O
diet	0	O
composition	0	O
plays	0	O
a	0	O
clinically	0	O
important	0	O
role	0	O
in	0	O
the	0	O
absorption	0	O
or	0	O
expenditure	0	O
of	0	O
energy	0	O
,	0	O
it	0	O
does	0	O
appear	0	O
to	0	O
play	0	O
a	0	O
role	0	O
in	0	O
food	0	O
intake	0	O
.	0	O


The	0	O
GafChromic	0	O
method	0	O
has	0	O
proven	0	O
to	0	O
be	0	O
an	0	O
accurate	0	O
and	0	O
rapid	0	O
method	0	O
of	0	O
analysis	0	O
and	0	O
could	0	O
be	0	O
easily	0	O
incorporated	0	O
into	0	O
a	0	O
quality	0	O
assurance	0	O
program	0	O
.	0	O


In	1	O
nine	0	O
patients	0	O
with	0	O
renal	0	O
failure	0	O
routine	0	O
haemodialysis	0	O
was	0	O
accompanied	0	O
by	0	O
a	0	O
30	0	O
per	0	O
cent	0	O
reduction	0	O
in	0	O
plasma	0	O
ANP	1	B
concentration	0	O
.	0	O


Isolation	1	O
of	0	O
cDNAs	0	B
encoding	0	I
gibbon	0	I
and	0	I
monkey	0	I
platelet	0	I
and	0	I
T	1	I
cell	0	I
activation	0	I
antigen	0	I
1	0	I
(	0	O
PTA1	0	B
).	0	O


Transcripts	0	O
characterized	0	O
include	0	O
(	0	O
i	0	O
)	0	O
abundant	0	O
monocistronic	0	O
L11e	0	B
and	0	O
tricistronic	0	O
L1e	0	B
-	0	O
L10e	0	B
-	0	O
L12e	0	B
transcripts	0	O
;	0	O
(	0	O
ii	0	O
)	0	O
less	0	O
abundant	0	O
bicistronic	0	O
NAB	0	B
-	0	O
L11e	0	B
and	0	O
monocistronic	0	O
NAB	0	B
transcripts	0	I
and	0	O
(	0	O
iii	0	O
)	0	O
a	0	O
very	0	O
rare	0	O
ORF	1	O
monocistronic	0	O
transcript	0	O
.	0	O


The	0	O
critical	0	O
mutations	0	O
were	0	O
likely	0	O
to	0	O
have	0	O
been	0	O
multiple	0	O
and	0	O
dispersed	0	O
,	0	O
including	0	O
elongation	0	O
of	0	O
the	0	O
TM	1	O
and	0	O
Nef	0	B
coding	0	I
sequences	0	I
;	0	O
changes	0	O
in	0	O
RNA	1	O
splice	0	O
donor	0	O
and	0	O
acceptor	0	O
sites	0	O
,	0	O
TATA	0	O
box	0	O
sites	0	O
,	0	O
and	0	O
Sp1	0	B
sites	0	I
;	0	O
multiple	0	O
changes	0	O
in	0	O
the	0	O
V2	0	B
region	0	O
of	0	O
SU	0	B
,	0	O
including	0	O
a	0	O
consensus	0	O
neutralization	0	O
epitope	0	O
;	0	O
and	0	O
five	0	O
new	0	O
N	1	O
-	0	O
linked	0	O
glycosylation	0	O
sites	0	O
in	0	O
SU	0	B
.	0	O


These	0	O
contain	0	O
a	0	O
single	0	O
1977	0	O
-	0	O
bp	0	O
exon	0	O
that	0	O
encodes	0	O
900	0	O
bp	0	O
of	0	O
the	0	O
5	0	O
'	0	O
and	0	O
3	0	O
'	0	O
untranslated	0	O
sequences	0	O
in	0	O
addition	0	O
to	0	O
a	0	O
1077	0	O
-	0	O
bp	0	O
open	0	O
reading	0	O
frame	0	O
identical	0	O
to	0	O
that	0	O
found	0	O
in	0	O
vascular	0	B
smooth	0	I
muscle	0	I
cell	0	I
AT1a	0	I
receptor	0	I
cDNAs	0	I
.	0	O


Sequencing	1	O
of	0	O
the	0	O
facB	1	B
gene	0	I
revealed	0	O
that	0	O
it	0	O
encodes	0	O
a	0	O
protein	0	O
that	0	O
contains	0	O
an	0	O
N	1	O
-	0	O
terminal	0	O
GAL4	0	B
-	0	O
like	0	O
Zn	1	O
(	0	O
II	0	O
)	0	O
2Cys6	0	O
(	0	O
or	0	O
C6	1	O
zinc	0	O
)	0	O
binuclear	0	O
cluster	0	O
for	0	O
DNA	1	O
binding	0	O
,	0	O
leucine	0	O
zipper	0	O
-	0	O
like	0	O
heptad	0	O
repeat	0	O
motifs	0	O
and	0	O
central	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
acidic	0	O
alpha	0	O
-	0	O
helical	0	O
regions	0	O
,	0	O
consistent	0	O
with	0	O
a	0	O
function	0	O
as	0	O
a	0	O
DNA	1	O
-	0	O
binding	0	O
transcriptional	0	O
activator	0	O
.	0	O


A	1	O
new	0	O
variant	0	O
of	0	O
the	0	O
EMG	1	O
-	0	O
BFB	0	O
method	0	O
(	0	O
multichannel	0	O
)	0	O
is	0	O
offered	0	O
which	0	O
has	0	O
made	0	O
it	0	O
possible	0	O
to	0	O
use	0	O
the	0	O
method	0	O
not	0	O
only	0	O
for	0	O
training	0	O
weakened	0	O
muscles	0	O
and	0	O
reducing	0	O
spasticity	0	O
in	0	O
their	0	O
antagonists	0	O
but	0	O
also	0	O
for	0	O
improving	0	O
motor	0	O
coordination	0	O
.	0	O


We	0	O
have	0	O
identified	0	O
and	0	O
characterized	0	O
a	0	O
vitamin	0	O
D	1	O
response	0	O
element	0	O
(	0	O
VDRE	0	O
)	0	O
in	0	O
the	0	O
promoter	0	O
of	0	O
c	0	B
-	0	I
fos	0	I
.	0	O


Microwave	1	O
hyperthermia	0	O
-	0	O
induced	0	O
blood	0	O
-	0	O
brain	0	O
barrier	0	O
alterations	0	O
.	0	O


The	0	O
new	0	O
algorithm	0	O
,	0	O
called	0	O
RBI	0	O
-	0	O
MAP	1	O
,	0	O
is	0	O
based	0	O
on	0	O
the	0	O
rescaled	0	O
block	0	O
iterative	0	O
EM	1	O
(	0	O
RBI	0	O
-	0	O
EM	1	O
)	0	O
algorithm	0	O
.	0	O


The	0	O
observation	0	O
of	0	O
late	0	O
effects	0	O
after	0	O
irradiations	0	O
or	0	O
after	0	O
space	0	O
flights	0	O
show	0	O
the	0	O
difficulties	0	O
encountered	0	O
in	0	O
assessing	0	O
radiative	0	O
risks	0	O
during	0	O
long	0	O
duration	0	O
space	0	O
flights	0	O
.	0	O


Structure	1	O
and	0	O
expression	0	O
of	0	O
the	0	O
mouse	0	B
growth	0	I
hormone	0	I
receptor	0	I
/	0	O
growth	0	B
hormone	0	I
binding	0	I
protein	0	I
gene	0	I
.	0	O


Polysome	1	O
analyses	0	O
in	0	O
a	0	O
temperature	0	O
-	0	O
sensitive	0	O
fal1	0	B
-	0	I
1	0	I
mutant	0	I
and	0	O
a	0	O
Fal1p	0	B
-	0	O
depleted	0	O
strain	0	O
reveal	0	O
a	0	O
decrease	0	O
in	0	O
the	0	O
number	0	O
of	0	O
40S	0	B
ribosomal	0	I
subunits	0	I
.	0	O


The	0	O
glomerular	0	O
filtration	0	O
rate	0	O
and	0	O
effective	0	O
renal	0	O
plasma	0	O
flow	0	O
were	0	O
determined	0	O
by	0	O
a	0	O
standard	0	O
clearance	0	O
method	0	O
,	0	O
employing	0	O
continuous	0	O
infusion	0	O
of	0	O
inulin	0	O
and	0	O
para	0	O
-	0	O
aminohippuric	0	O
acid	0	O
.	0	O


However	0	O
,	0	O
by	0	O
immobilized	0	O
metal	0	O
affinity	0	O
chromatography	0	O
assay	0	O
,	0	O
self	0	O
-	0	O
association	0	O
of	0	O
PR	1	B
-	0	I
A	1	I
was	0	O
3	0	O
.	0	O
5	0	O
-	0	O
fold	0	O
more	0	O
efficient	0	O
than	0	O
that	0	O
of	0	O
either	0	O
the	0	O
DhLBD	0	O
or	0	O
hLBD	0	O
constructs	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
a	0	O
microsatellite	0	O
repeat	0	O
polymorphism	0	O
with	0	O
a	0	O
heterozygosity	0	O
of	0	O
71	0	O
%	0	O
at	0	O
the	0	O
RET	0	B
locus	0	I
and	0	O
a	0	O
restriction	0	O
fragment	0	O
length	0	O
polymorphism	0	O
with	0	O
a	0	O
heterozygosity	0	O
of	0	O
42	0	O
%	0	O
detected	0	O
by	0	O
a	0	O
lambda	0	O
clone	0	O
from	0	O
the	0	O
D10S94	0	B
locus	0	I
have	0	O
been	0	O
developed	0	O
for	0	O
high	0	O
-	0	O
resolution	0	O
genetic	0	O
linkage	0	O
mapping	0	O
and	0	O
predictive	0	O
diagnostic	0	O
testing	0	O
.	0	O


The	0	O
pigment	0	O
intensity	0	O
of	0	O
both	0	O
melanized	0	O
colonies	0	O
and	0	O
appressoria	0	O
of	0	O
CAL	1	O
transformants	0	O
was	0	O
weaker	0	O
than	0	O
that	0	O
of	0	O
the	0	O
wild	0	O
type	0	O
.	0	O


Hypomagnesemia	1	O
was	0	O
due	0	O
to	0	O
magnesium	0	O
wasting	0	O
by	0	O
the	0	O
kidney	0	O
.	0	O


Recombinant	1	B
soluble	0	I
pMCP	0	I
that	0	O
lacked	0	O
transmembrane	0	O
and	0	O
cytoplasmic	0	O
domains	0	O
had	0	O
factor	0	B
I	1	I
cofactor	0	I
activity	0	O
in	0	O
C3b	1	B
cleavage	0	O
,	0	O
indicating	0	O
that	0	O
it	0	O
is	0	O
functionally	0	O
,	0	O
as	0	O
well	0	O
as	0	O
structurally	0	O
homologous	0	O
to	0	O
MCP	1	B
.	0	O


Single	1	O
photon	0	O
emission	0	O
computerized	0	O
tomography	0	O
(	0	O
SPECT	1	O
),	0	O
by	0	O
providing	0	O
three	0	O
-	0	O
dimensional	0	O
representation	0	O
of	0	O
myocardial	0	O
Tl	1	O
-	0	O
201	0	O
,	0	O
offers	0	O
promise	0	O
for	0	O
improved	0	O
localization	0	O
of	0	O
CAD	1	O
.	0	O


Glomerular	1	O
mesangial	0	O
cells	0	O
expressed	0	O
an	0	O
abundant	0	O
1	0	O
.	0	O
1	0	O
kb	0	O
mRNA	1	O
transcript	0	O
for	0	O
Id1	0	B
,	0	O
but	0	O
in	0	O
contrast	0	O
to	0	O
other	0	O
cell	0	O
types	0	O
Id1	0	B
mRNA	1	I
was	0	O
expressed	0	O
in	0	O
both	0	O
randomly	0	O
cycling	0	O
cells	0	O
and	0	O
in	0	O
serum	0	O
-	0	O
deprived	0	O
,	0	O
quiescent	0	O
cultures	0	O
.	0	O


Per	1	O
kg	0	O
FFM	0	O
SMR	1	O
was	0	O
almost	0	O
restored	0	O
to	0	O
baseline	0	O
values	0	O
for	0	O
the	0	O
EX	0	O
group	0	O
,	0	O
whereas	0	O
the	0	O
non	0	O
-	0	O
exercising	0	O
subjects	0	O
still	0	O
showed	0	O
depressed	0	O
values	0	O
(	0	O
EX	0	O
3	0	O
.	0	O
7	0	O
per	0	O
cent	0	O
and	0	O
D	1	O
+	0	O
DE	0	O
15	0	O
.	0	O
8	0	O
per	0	O
cent	0	O
lower	0	O
than	0	O
before	0	O
treatment	0	O
;	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


COUP	1	B
transcription	0	I
factor	0	I
is	0	O
a	0	O
member	0	O
of	0	O
the	0	O
steroid	0	B
receptor	0	I
superfamily	0	I
.	0	O


As	1	O
hypothesized	0	O
,	0	O
believers	0	O
showed	0	O
relatively	0	O
higher	0	O
right	0	O
hemispheric	0	O
activation	0	O
and	0	O
reduced	0	O
hemispheric	0	O
asymmetry	0	O
of	0	O
functional	0	O
complexity	0	O
.	0	O


Upon	0	O
tyrosine	0	O
phosphorylation	0	O
at	0	O
the	0	O
ITIMs	0	O
,	0	O
these	0	O
molecules	0	O
recruit	0	O
SH2	0	B
domain	0	O
-	0	O
containing	0	O
phosphatases	0	O
such	0	O
as	0	O
SH2	0	B
-	0	O
containing	0	O
tyrosine	0	B
phosphatase	0	I
-	0	I
1	0	I
and	0	O
negatively	0	O
regulate	0	O
cell	0	O
activity	0	O
.	0	O


Several	0	O
mutations	0	O
disrupted	0	O
the	0	O
endonuclease	0	O
and	0	O
helicase	0	B
activities	0	O
;	0	O
however	0	O
,	0	O
only	0	O
one	0	O
amino	0	B
-	0	I
terminal	0	I
-	0	I
charge	0	I
cluster	0	I
mutant	0	I
protein	0	I
(	0	O
D40A	0	O
-	0	O
D42A	0	O
-	0	O
D44A	0	O
)	0	O
completely	0	O
lost	0	O
AAV	1	O
hairpin	0	O
DNA	1	O
binding	0	O
activity	0	O
.	0	O


A	1	O
prospectively	0	O
gated	0	O
2D	0	O
axial	0	O
sequence	0	O
with	0	O
velocity	0	O
encoding	0	O
in	0	O
the	0	O
craniocaudal	0	O
direction	0	O
in	0	O
the	0	O
cervical	0	O
region	0	O
was	0	O
set	0	O
at	0	O
a	0	O
velocity	0	O
of	0	O
+/-	0	O
10	0	O
cm	0	O
/	0	O
s	0	O
.	0	O


The	0	O
response	0	O
chain	0	O
in	0	O
each	0	O
component	0	O
was	0	O
maintained	0	O
by	0	O
food	0	O
presentation	0	O
under	0	O
a	0	O
fixed	0	O
-	0	O
ratio	0	O
schedule	0	O
.	0	O


Alternatively	0	O
,	0	O
the	0	O
similarity	0	O
in	0	O
apparent	0	O
regulatory	0	O
action	0	O
of	0	O
the	0	O
genes	0	O
may	0	O
indicate	0	O
allelic	0	O
differences	0	O
wherein	0	O
the	0	O
IS1112C	0	B
Rf3	0	I
allele	0	I
may	0	O
differ	0	O
from	0	O
alleles	0	O
of	0	O
maintainer	0	O
lines	0	O
by	0	O
the	0	O
capability	0	O
to	0	O
regulate	0	O
both	0	O
orf107	0	B
and	0	O
urf209	0	B
processing	0	O
activities	0	O
.	0	O


Aberrant	1	O
protein	0	O
phosphorylation	0	O
at	0	O
tyrosine	0	O
is	0	O
responsible	0	O
for	0	O
the	0	O
growth	0	O
-	0	O
inhibitory	0	O
action	0	O
of	0	O
pp60v	0	B
-	0	I
src	0	I
expressed	0	O
in	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Native	1	O
human	0	B
fibrinogen	0	I
was	0	O
brought	0	O
to	0	O
coagulation	0	O
by	0	O
adding	0	O
thrombin	0	B
.	0	O


Amikacin	1	O
was	0	O
the	0	O
most	0	O
stable	0	O
and	0	O
tobramycin	0	O
was	0	O
the	0	O
least	0	O
stable	0	O
aminoglycoside	0	O
under	0	O
the	0	O
conditions	0	O
tested	0	O
.	0	O


Telomeres	0	O
prevent	0	O
end	0	O
-	0	O
to	0	O
-	0	O
end	0	O
fusions	0	O
and	0	O
exonucleolytic	0	O
degradation	0	O
,	0	O
enable	0	O
the	0	O
end	0	O
of	0	O
the	0	O
linear	0	O
DNA	1	O
molecule	0	O
to	0	O
replicate	0	O
,	0	O
and	0	O
function	0	O
in	0	O
cell	0	O
division	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Some	0	O
Gulf	0	O
War	0	O
veterans	0	O
may	0	O
have	0	O
delayed	0	O
,	0	O
chronic	0	O
neurotoxic	0	O
syndromes	0	O
from	0	O
wartime	0	O
exposure	0	O
to	0	O
combinations	0	O
of	0	O
chemicals	0	O
that	0	O
inhibit	0	O
butyrylcholinesterase	0	B
and	0	O
neuropathy	0	B
target	0	I
esterase	0	I
.	0	O


Regulation	1	O
of	0	O
urokinase	0	B
plasminogen	0	I
activator	0	I
gene	0	I
transcription	0	O
in	0	O
the	0	O
RAW264	0	O
murine	0	O
macrophage	0	O
cell	0	O
line	0	O
by	0	O
macrophage	0	B
colony	0	I
-	0	I
stimulating	0	I
factor	0	I
(	0	O
CSF	1	B
-	0	I
1	0	I
)	0	O
is	0	O
dependent	0	O
upon	0	O
the	0	O
level	0	O
of	0	O
cell	0	O
-	0	O
surface	0	O
receptor	0	O
.	0	O


In	1	O
this	0	O
way	0	O
it	0	O
is	0	O
possible	0	O
to	0	O
simulate	0	O
the	0	O
growth	0	O
function	0	O
of	0	O
the	0	O
embryofetal	0	O
curve	0	O
of	0	O
the	0	O
length	0	O
'	0	O
increase	0	O
of	0	O
man	0	O
and	0	O
the	0	O
curve	0	O
of	0	O
the	0	O
mass	0	O
'	0	O
increase	0	O
of	0	O
rat	0	O
.	0	O


Liquid	1	O
chromatographic	0	O
method	0	O
for	0	O
analysis	0	O
of	0	O
all	0	O
-	0	O
rac	0	O
-	0	O
alpha	0	O
-	0	O
tocopheryl	0	O
acetate	0	O
and	0	O
retinyl	0	O
palmitate	0	O
in	0	O
milk	0	O
-	0	O
based	0	O
infant	0	O
formula	0	O
using	0	O
matrix	0	O
solid	0	O
-	0	O
phase	0	O
dispersion	0	O
.	0	O


The	0	O
mean	0	O
transfer	0	O
ratios	0	O
of	0	O
the	0	O
drug	0	O
into	0	O
the	0	O
genital	0	O
tissues	0	O
to	0	O
the	0	O
concentration	0	O
in	0	O
the	0	O
uterine	0	O
arterial	0	O
blood	0	O
were	0	O
such	0	O
that	0	O
the	0	O
transfer	0	O
ratio	0	O
into	0	O
the	0	O
portio	0	O
vaginalis	0	O
was	0	O
the	0	O
highest	0	O
,	0	O
followed	0	O
by	0	O
the	0	O
uterine	0	O
cervix	0	O
and	0	O
the	0	O
myometrium	0	O
,	0	O
and	0	O
that	0	O
into	0	O
the	0	O
oviduct	0	O
was	0	O
the	0	O
lowest	0	O
with	0	O
about	0	O
1	0	O
/	0	O
2	0	O
that	0	O
into	0	O
the	0	O
portio	0	O
vaginalis	0	O
.	0	O


Linear	1	O
regression	0	O
analysis	0	O
was	0	O
performed	0	O
and	0	O
the	0	O
following	0	O
result	0	O
was	0	O
obtained	0	O
:	0	O
clearance	0	O
(	0	O
HMPAO	1	O
)	0	O
=	0	O
0	0	O
.	0	O
07	0	O
+	0	O
0	0	O
.	0	O
43	0	O
.	0	O
rCBF	1	O
with	0	O
a	0	O
high	0	O
significance	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


Five	0	O
of	0	O
10	0	O
scars	0	O
studied	0	O
decreased	0	O
at	0	O
least	0	O
50	0	O
%	0	O
in	0	O
linear	0	O
dimensions	0	O
.	0	O


The	0	O
reduced	0	O
rate	0	O
of	0	O
F	1	O
absorption	0	O
and	0	O
slower	0	O
rise	0	O
in	0	O
plasma	0	O
F	1	O
concentration	0	O
accompanying	0	O
delayed	0	O
gastric	0	O
emptying	0	O
indicate	0	O
that	0	O
passage	0	O
of	0	O
F	1	O
into	0	O
the	0	O
small	0	O
intestine	0	O
is	0	O
the	0	O
major	0	O
factor	0	O
in	0	O
rapid	0	O
F	1	O
absorption	0	O
.	0	O


Disruption	1	O
demonstrates	0	O
that	0	O
CDC14	0	B
is	0	O
an	0	O
essential	0	O
gene	0	O
.	0	O


SL1	0	B
trans	0	O
-	0	O
splicing	0	O
specified	0	O
by	0	O
AU	1	O
-	0	O
rich	0	O
synthetic	0	O
RNA	1	O
inserted	0	O
at	0	O
the	0	O
5	0	O
'	0	O
end	0	O
of	0	O
Caenorhabditis	0	O
elegans	0	O
pre	0	O
-	0	O
mRNA	1	O
.	0	O


Total	0	O
PGE	0	O
levels	0	O
in	0	O
synovial	0	O
fluid	0	O
remained	0	O
significantly	0	O
depressed	0	O
in	0	O
the	0	O
patient	0	O
group	0	O
for	0	O
24	0	O
hours	0	O
after	0	O
the	0	O
400	0	O
-	0	O
mg	0	O
test	0	O
dose	0	O
of	0	O
tolmetin	0	O
on	0	O
day	0	O
8	0	O
.	0	O


During	0	O
the	0	O
first	0	O
3	0	O
min	0	O
of	0	O
recovery	0	O
,	0	O
plasma	0	O
potassium	0	O
fell	0	O
rapidly	0	O
in	0	O
spite	0	O
of	0	O
nearly	0	O
unchanged	0	O
blood	0	O
acidosis	0	O
and	0	O
significantly	0	O
decreasing	0	O
bicarbonate	0	O
concentration	0	O
.	0	O


Effect	1	O
of	0	O
alcohol	0	O
on	0	O
minimal	0	O
effective	0	O
nCPAP	1	O
pressure	0	O


The	0	O
two	0	O
main	0	O
experimental	0	O
variables	0	O
were	0	O
the	0	O
attended	0	O
hemifield	0	O
(	0	O
left	0	O
or	0	O
right	0	O
)	0	O
and	0	O
the	0	O
proportion	0	O
of	0	O
trials	0	O
requiring	0	O
a	0	O
shift	0	O
within	0	O
that	0	O
hemifield	0	O
(	0	O
20	0	O
%	0	O
or	0	O
80	0	O
%).	0	O


To	1	O
minimize	0	O
reflux	0	O
into	0	O
the	0	O
blind	0	O
loop	0	O
,	0	O
a	0	O
number	0	O
of	0	O
technical	0	O
steps	0	O
are	0	O
considered	0	O
indispensable	0	O
:	0	O
1	0	O
)	0	O
fluted	0	O
section	0	O
of	0	O
the	0	O
jejunal	0	O
stump	0	O
;	0	O
2	0	O
)	0	O
isoperistaltic	0	O
construction	0	O
of	0	O
the	0	O
anastomosis	0	O
and	0	O
,	0	O
particularly	0	O
,	0	O
3	0	O
)	0	O
the	0	O
creation	0	O
of	0	O
a	0	O
single	0	O
or	0	O
double	0	O
valve	0	O
system	0	O
upstream	0	O
from	0	O
the	0	O
anastomosis	0	O
by	0	O
spiral	0	O
introflexion	0	O
of	0	O
the	0	O
mucosa	0	O
using	0	O
seroserous	0	O
stitches	0	O
parallel	0	O
and	0	O
perpendicular	0	O
to	0	O
the	0	O
ileal	0	O
lumen	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
both	0	O
transcription	0	O
activators	0	O
depend	0	O
on	0	O
or	0	O
interact	0	O
with	0	O
different	0	O
subunits	0	O
of	0	O
RNA	1	B
polymerase	0	I
,	0	O
although	0	O
their	0	O
role	0	O
in	0	O
formation	0	O
of	0	O
proper	0	O
DNA	1	O
geometry	0	O
may	0	O
also	0	O
be	0	O
crucial	0	O
.	0	O


Management	1	O
of	0	O
hypertension	0	O
in	0	O
the	0	O
elderly	0	O
.	0	O


The	0	O
nonconsensus	0	O
TATA	0	O
box	0	O
in	0	O
promoter	0	O
B	1	O
plays	0	O
a	0	O
more	0	O
important	0	O
role	0	O
in	0	O
promoter	0	O
activity	0	O
than	0	O
the	0	O
TATA	0	O
box	0	O
in	0	O
promoter	0	O
A	1	O
.	0	O


It	1	O
consists	0	O
of	0	O
2185	0	O
amino	0	O
acid	0	O
residues	0	O
encoded	0	O
by	0	O
a	0	O
9	0	O
-	0	O
kilobase	0	O
pair	0	O
mRNA	1	O
;	0	O
several	0	O
splice	0	O
variants	0	O
have	0	O
been	0	O
detected	0	O
in	0	O
human	0	O
and	0	O
rat	0	O
cDNA	1	O
libraries	0	O
.	0	O


188	0	O
patients	0	O
received	0	O
cimetidine	0	O
400	0	O
mg	0	O
q	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.	0	O
intravenously	0	O
and	0	O
1	0	O
,	0	O
000	0	O
mg	0	O
daily	0	O
orally	0	O
in	0	O
divided	0	O
doses	0	O
.	0	O


Group	1	O
6	0	O
was	0	O
given	0	O
physostigmine	0	O
,	0	O
0	0	O
.	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.,	0	O
known	0	O
to	0	O
inhibit	0	O
cholinesterase	0	B
degradation	0	O
,	0	O
5	0	O
min	0	O
before	0	O
bupivacaine	0	O
administration	0	O
,	0	O
and	0	O
Group	1	O
7	0	O
received	0	O
a	0	O
combination	0	O
of	0	O
physostigmine	0	O
pretreatment	0	O
and	0	O
electrical	0	O
vagal	0	O
stimulation	0	O
.	0	O


Studies	0	O
have	0	O
substantiated	0	O
the	0	O
involvement	0	O
of	0	O
numerous	0	O
loci	0	O
on	0	O
certain	0	O
chromosomes	0	O
;	0	O
in	0	O
excess	0	O
of	0	O
10	0	O
chromosomes	0	O
are	0	O
thought	0	O
to	0	O
be	0	O
involved	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
,	0	O
purified	0	O
Dlk	0	B
phosphorylated	0	O
core	0	O
histones	0	B
H3	0	I
,	0	O
H2A	0	B
and	0	O
H4	0	B
as	0	O
exogenous	0	O
substrates	0	O
and	0	O
endogenous	0	O
histone	0	B
H3	0	I
in	0	O
kinase	0	O
assays	0	O
with	0	O
nuclear	0	O
extracts	0	O
.	0	O


Retrograde	1	O
filling	0	O
consists	0	O
in	0	O
sealing	0	O
endodontics	0	O
system	0	O
directly	0	O
at	0	O
the	0	O
apical	0	O
zone	0	O
after	0	O
surgical	0	O
approach	0	O
.	0	O


Plasma	1	O
and	0	O
erthrocyte	0	O
lipid	0	O
profile	0	O
and	0	O
lipoprotein	0	B
lipase	0	I
activity	0	O
in	0	O
postheparin	0	O
plasma	0	O
on	0	O
vasectomized	0	O
rabbits	0	O
were	0	O
studied	0	O
and	0	O
also	0	O
the	0	O
incidence	0	O
of	0	O
atherosclerosis	0	O
in	0	O
different	0	O
arterial	0	O
beds	0	O
.	0	O


Corticostriatal	0	O
and	0	O
corticosubthalamic	0	O
input	0	O
zones	0	O
from	0	O
the	0	O
presupplementary	0	O
motor	0	O
area	0	O
in	0	O
the	0	O
macaque	0	O
monkey	0	O
:	0	O
comparison	0	O
with	0	O
the	0	O
input	0	O
zones	0	O
from	0	O
the	0	O
supplementary	0	O
motor	0	O
area	0	O
.	0	O


The	0	O
simultaneous	0	O
recording	0	O
of	0	O
electrical	0	O
activity	0	O
from	0	O
the	0	O
surface	0	O
electrocardiogram	0	O
,	0	O
right	0	O
ventricular	0	O
apex	0	O
,	0	O
His	1	O
bundle	0	O
,	0	O
high	0	O
right	0	O
atrium	0	O
,	0	O
coronary	0	O
sinus	0	O
,	0	O
with	0	O
or	0	O
without	0	O
a	0	O
roving	0	O
mapping	0	O
catheter	0	O
,	0	O
enables	0	O
us	0	O
to	0	O
precisely	0	O
map	0	O
the	0	O
electrical	0	O
activation	0	O
sequence	0	O
in	0	O
the	0	O
heart	0	O
.	0	O


Many	0	O
cytokine	0	O
receptors	0	O
employ	0	O
Janus	0	B
protein	0	I
tyrosine	0	I
kinases	0	I
(	0	O
Jaks	0	B
)	0	O
and	0	O
signal	0	B
transducers	0	I
and	0	I
activators	0	I
of	0	I
transcription	0	I
(	0	O
Stats	0	B
)	0	O
for	0	O
nuclear	0	O
signaling	0	O
.	0	O


Proposals	0	O
on	0	O
authorization	0	O
;	0	O
by	0	O
a	0	O
group	0	O
of	0	O
nurses	0	O
from	0	O
psychiatric	0	O
hospitals	0	O


We	0	O
specially	0	O
devised	0	O
3	0	O
types	0	O
of	0	O
turbo	0	O
pumps	0	O
,	0	O
a	0	O
centrifugal	0	O
pump	0	O
(	0	O
CFP	1	O
),	0	O
a	0	O
mixed	0	O
flow	0	O
pump	0	O
(	0	O
MFP	0	O
),	0	O
and	0	O
an	0	O
axial	0	O
flow	0	O
pump	0	O
(	0	O
AFP	1	O
),	0	O
and	0	O
analyzed	0	O
their	0	O
in	0	O
vitro	0	O
performance	0	O
.	0	O


MATERIAL	1	O
AND	0	O
METHODS	0	O
:	0	O
The	0	O
authors	0	O
analyzed	0	O
41	0	O
persons	0	O
formerly	0	O
submitted	0	O
to	0	O
surgery	0	O
(	0	O
after	0	O
8	0	O
years	0	O
and	0	O
4	0	O
months	0	O
,	0	O
as	0	O
a	0	O
mean	0	O
),	0	O
31	0	O
to	0	O
highly	0	O
selective	0	O
vagotomy	0	O
,	0	O
and	0	O
10	0	O
to	0	O
truncal	0	O
or	0	O
selective	0	O
vagotomy	0	O
plus	0	O
gastroduodenal	0	O
drainage	0	O
.	0	O


The	0	O
most	0	O
important	0	O
one	0	O
among	0	O
them	0	O
is	0	O
Cyclosporin	0	O
A	1	O
,	0	O
which	0	O
is	0	O
a	0	O
selective	0	O
immunosuppressive	0	O
drug	0	O
.	0	O


A	1	O
comparison	0	O
of	0	O
the	0	O
promoters	0	O
for	0	O
muMIP	0	B
-	0	I
1	0	I
beta	0	I
and	0	O
muMIP	0	B
-	0	I
1	0	I
alpha	0	I
reveals	0	O
a	0	O
conserved	0	O
CK	1	O
-	0	O
1	0	O
element	0	O
,	0	O
but	0	O
transient	0	O
expression	0	O
studies	0	O
in	0	O
RAW	1	O
264	0	O
.	0	O
7	0	O
macrophages	0	O
with	0	O
proximal	0	O
fragments	0	O
of	0	O
either	0	O
the	0	O
muMIP	0	B
-	0	I
1	0	I
beta	0	I
or	0	O
the	0	O
muMIP	0	B
-	0	I
1	0	I
alpha	0	I
5	0	I
'	0	I
promoter	0	I
fused	0	O
to	0	O
a	0	O
human	0	B
growth	0	I
hormone	0	I
reporter	0	I
gene	0	I
link	0	O
LPS	1	O
-	0	O
inducibility	0	O
in	0	O
both	0	O
to	0	O
promoter	0	O
segments	0	O
near	0	O
to	0	O
,	0	O
but	0	O
not	0	O
identical	0	O
with	0	O
,	0	O
the	0	O
consensus	0	O
CK	1	O
-	0	O
1	0	O
sequence	0	O
.	0	O


Breitbart	0	O
,	0	O
L	1	O
.	0	O


FAK	0	B
localizes	0	O
to	0	O
sites	0	O
of	0	O
transmembrane	0	B
integrin	0	I
receptor	0	I
clustering	0	O
and	0	O
facilitates	0	O
intracellular	0	O
signaling	0	O
events	0	O
.	0	O


Physiology	1	O
and	0	O
Physiopathology	1	O


It	1	O
is	0	O
suggested	0	O
that	0	O
these	0	O
results	0	O
may	0	O
raise	0	O
the	0	O
interesting	0	O
possibility	0	O
of	0	O
providing	0	O
a	0	O
means	0	O
of	0	O
identifying	0	O
greater	0	O
or	0	O
lesser	0	O
susceptibility	0	O
to	0	O
the	0	O
coronary	0	O
effects	0	O
of	0	O
Type	1	O
A	1	O
behavior	0	O
.	0	O


Their	0	O
studies	0	O
have	0	O
revealed	0	O
a	0	O
considerable	0	O
increase	0	O
of	0	O
CSF	1	B
AP	1	I
activity	0	O
in	0	O
purulent	0	O
meningitides	0	O
whereas	0	O
in	0	O
serous	0	O
meningitides	0	O
it	0	O
grows	0	O
negligibly	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
L655	0	O
,	0	O
240	0	O
,	0	O
a	0	O
selective	0	O
thromboxane	0	O
and	0	O
prostaglandin	0	O
endoperoxide	0	O
antagonist	0	O
,	0	O
on	0	O
ischemia	0	O
-	0	O
and	0	O
reperfusion	0	O
-	0	O
induced	0	O
cardiac	0	O
arrhythmias	0	O
.	0	O


It	1	O
is	0	O
now	0	O
recognized	0	O
that	0	O
essentially	0	O
all	0	O
eukaryotic	0	O
and	0	O
prokaryotic	0	O
genes	0	O
whose	0	O
5	0	O
'-	0	O
flanking	0	O
regions	0	O
are	0	O
known	0	O
and	0	O
that	0	O
encode	0	O
barbiturate	0	O
-	0	O
inducible	0	O
proteins	0	O
contain	0	O
the	0	O
Barbie	0	O
box	0	O
element	0	O
.	0	O


The	0	O
amino	0	O
acid	0	O
sequence	0	O
was	0	O
determined	0	O
to	0	O
be	0	O
residues	0	O
716	0	O
-	0	O
724	0	O
and	0	O
hence	0	O
lysine	0	O
residue	0	O
721	0	O
is	0	O
located	0	O
within	0	O
the	0	O
ATP	1	O
-	0	O
binding	0	O
site	0	O
.	0	O


Moreover	0	O
,	0	O
it	0	O
also	0	O
discusses	0	O
the	0	O
effects	0	O
of	0	O
antihypertensive	0	O
drugs	0	O
currently	0	O
regarded	0	O
as	0	O
first	0	O
-	0	O
choice	0	O
agents	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
calcium	0	O
antagonists	0	O
and	0	O
the	0	O
angiotensin	0	B
converting	0	I
enzyme	0	I
inhibitors	0	O
,	0	O
on	0	O
intrarenal	0	O
hemodynamics	0	O
.	0	O


Laboratory	1	O
exam	0	O
:	0	O
IDR	0	O
of	0	O
the	0	O
tuberculin	0	B
was	0	O
high	0	O
positive	0	O
,	0	O
chest	0	O
radiography	0	O
shows	0	O
hilar	0	O
bilateral	0	O
calcifications	0	O
,	0	O
ORL	0	O
exam	0	O
shows	0	O
a	0	O
tumor	0	O
at	0	O
the	0	O
foot	0	O
of	0	O
the	0	O
epiglottis	0	O
and	0	O
anatomopathological	0	O
exam	0	O
shows	0	O
low	0	O
differentiated	0	O
epidermoid	0	O
carcinoma	0	O
.	0	O


Although	0	O
methods	0	O
to	0	O
align	0	O
the	0	O
control	0	O
and	0	O
activation	0	O
fMR	0	O
images	0	O
may	0	O
correct	0	O
for	0	O
some	0	O
of	0	O
this	0	O
motional	0	O
error	0	O
,	0	O
they	0	O
will	0	O
be	0	O
incomplete	0	O
in	0	O
correcting	0	O
for	0	O
those	0	O
that	0	O
depend	0	O
on	0	O
spatial	0	O
orientation	0	O
.	0	O


Me	1	O
(	0	O
2	0	O
)	0	O
SO	1	O
-	0	O
induced	0	O
neuronal	0	O
differentiation	0	O
of	0	O
N1E	0	O
-	0	O
115	0	O
neuroblastoma	0	O
cells	0	O
increased	0	O
both	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
endogenous	0	B
Ntr	0	I
-	0	I
1	0	I
gene	0	I
and	0	O
reporter	0	O
genes	0	O
driven	0	O
by	0	O
NTR	0	B
-	0	I
1	0	I
promoter	0	I
sequences	0	I
by	0	O
3	0	O
-	0	O
4	0	O
-	0	O
fold	0	O
.	0	O


The	0	O
mMIWC1	0	B
promoter	0	I
was	0	O
identified	0	O
and	0	O
contained	0	O
TATA	0	O
,	0	O
CAAT	0	O
,	0	O
GATA	0	O
,	0	O
and	0	O
AP	1	B
-	0	I
2	0	I
elements	0	I
;	0	O
primer	0	O
extension	0	O
revealed	0	O
mMIWC	0	B
transcription	0	O
initiation	0	O
at	0	O
621	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
mMIWC1	0	B
translational	0	O
initiation	0	O
site	0	O
.	0	O


Southern	0	O
blot	0	O
analysis	0	O
of	0	O
endonuclease	0	O
-	0	O
digested	0	O
genomic	0	O
DNA	1	O
from	0	O
primary	0	O
chick	0	O
embryo	0	O
fibroblasts	0	O
(	0	O
CEF	0	O
)	0	O
suggested	0	O
that	0	O
MEK2	0	B
is	0	O
a	0	O
single	0	O
-	0	O
copy	0	O
gene	0	O
in	0	O
this	0	O
vertebrate	0	O
species	0	O
.	0	O


Stat	1	B
activation	0	O
in	0	O
response	0	O
to	0	O
GH	1	B
and	0	O
IL	1	B
-	0	I
6	0	I
was	0	O
determined	0	O
by	0	O
reporter	0	O
gene	0	O
induction	0	O
.	0	O


The	0	O
AD	1	O
components	0	O
were	0	O
markedly	0	O
more	0	O
dependent	0	O
on	0	O
the	0	O
affective	0	O
state	0	O
of	0	O
the	0	O
rat	0	O
then	0	O
was	0	O
the	0	O
V1	0	O
component	0	O
.	0	O


The	0	O
Wilms	0	B
'	0	I
tumour	0	I
suppressor	0	I
protein	0	I
(	0	O
WT1	0	B
)	0	O
is	0	O
a	0	O
putative	0	O
transcriptional	0	O
regulatory	0	O
protein	0	O
with	0	O
four	0	O
zinc	0	O
fingers	0	O
,	0	O
the	0	O
last	0	O
three	0	O
of	0	O
which	0	O
have	0	O
extensive	0	O
sequence	0	O
homology	0	O
to	0	O
the	0	O
early	0	B
growth	0	I
response	0	I
-	0	I
1	0	I
(	0	O
EGR	0	B
-	0	I
1	0	I
)	0	O
protein	0	O
.	0	O


Moreover	0	O
,	0	O
we	0	O
observed	0	O
that	0	O
the	0	O
function	0	O
of	0	O
T3R	0	B
-	0	O
RXR	0	B
heterodimers	0	O
on	0	O
response	0	O
elements	0	O
composed	0	O
of	0	O
two	0	O
half	0	O
-	0	O
sites	0	O
in	0	O
a	0	O
directly	0	O
repeated	0	O
orientation	0	O
spaced	0	O
by	0	O
4	0	O
nucleotides	0	O
is	0	O
determined	0	O
in	0	O
major	0	O
parts	0	O
by	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
sequence	0	O
of	0	O
the	0	O
upstream	0	O
half	0	O
-	0	O
site	0	O
.	0	O


The	0	O
absence	0	O
of	0	O
other	0	O
regions	0	O
of	0	O
hybridization	0	O
suggests	0	O
that	0	O
there	0	O
are	0	O
no	0	O
closely	0	O
related	0	O
sequences	0	O
(	0	O
e	0	O
.	0	O
g	0	O
.,	0	O
reverse	0	O
transcribed	0	O
pseudogenes	0	O
)	0	O
scattered	0	O
throughout	0	O
the	0	O
genome	0	O
and	0	O
that	0	O
if	0	O
there	0	O
are	0	O
closely	0	O
related	0	O
genes	0	O
,	0	O
they	0	O
must	0	O
be	0	O
clustered	0	O
near	0	O
GSTT2	0	B
.	0	O


Dynamic	1	O
and	0	O
static	0	O
scintigrams	0	O
,	0	O
using	0	O
99mtechnetium	0	O
methylene	0	O
diphosphonate	0	O
,	0	O
were	0	O
obtained	0	O
at	0	O
zero	0	O
,	0	O
six	0	O
,	0	O
and	0	O
12	0	O
weeks	0	O
after	0	O
fracture	0	O
.	0	O


Bioplastique	0	O
granuloma	0	O
presents	0	O
with	0	O
irregularly	0	O
shaped	0	O
cystic	0	O
spaces	0	O
of	0	O
varying	0	O
size	0	O
containing	0	O
jagged	0	O
,	0	O
translucent	0	O
,	0	O
nonbirefringent	0	O
foreign	0	O
bodies	0	O
whereas	0	O
Artecoll	0	O
granuloma	0	O
shows	0	O
numerous	0	O
round	0	O
vacuoles	0	O
nearly	0	O
identical	0	O
in	0	O
size	0	O
and	0	O
shape	0	O
enclosing	0	O
round	0	O
and	0	O
sharply	0	O
circumscribed	0	O
,	0	O
translucent	0	O
,	0	O
nonbirefringent	0	O
foreign	0	O
bodies	0	O
.	0	O


A	1	O
population	0	O
pharmacokinetic	0	O
study	0	O
of	0	O
cyclosporin	0	O
in	0	O
organ	0	O
transplant	0	O
patients	0	O
,	0	O
including	0	O
elderly	0	O
allograft	0	O
recipients	0	O
up	0	O
to	0	O
75	0	O
years	0	O
of	0	O
age	0	O
,	0	O
did	0	O
not	0	O
identify	0	O
age	0	O
as	0	O
a	0	O
covariable	0	O
influencing	0	O
cyclosporin	0	O
pharmacokinetics	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
the	0	O
RPO1	0	B
polypeptides	0	I
of	0	I
IIV6	0	I
,	0	I
LCDV	0	I
,	0	I
and	0	I
MCV	1	I
-	0	I
1	0	I
with	0	O
the	0	O
corresponding	0	O
prokaryotic	0	O
,	0	O
eukaryotic	0	O
,	0	O
and	0	O
viral	0	O
proteins	0	O
revealed	0	O
differences	0	O
in	0	O
amino	0	O
acid	0	O
similarity	0	O
and	0	O
phylogenetic	0	O
relationships	0	O
.	0	O


We	0	O
did	0	O
not	0	O
detect	0	O
p50	0	B
in	0	O
association	0	O
with	0	O
native	0	B
glucocorticoid	0	I
receptor	0	I
in	0	O
L	1	O
cells	0	O
or	0	O
with	0	O
the	0	O
overexpressed	0	O
glucocorticoid	0	B
receptor	0	I
in	0	O
Chinese	0	O
hamster	0	O
ovary	0	O
cells	0	O
.	0	O


Both	0	O
mu	0	B
and	0	I
gamma	0	I
2b	0	I
heavy	0	I
chain	0	I
genes	0	I
cause	0	O
this	0	O
feedback	0	O
inhibition	0	O
of	0	O
heavy	0	O
chain	0	O
gene	0	O
rearrangement	0	O
.	0	O


A	1	O
number	0	O
of	0	O
serological	0	O
tests	0	O
measuring	0	O
the	0	O
presence	0	O
of	0	O
Helicobacter	1	O
pylori	0	O
-	0	O
specific	0	O
serum	0	O
immunoglobulin	0	B
G	1	I
(	0	O
IgG	1	B
)	0	O
are	0	O
now	0	O
commercially	0	O
available	0	O
.	0	O


A	1	O
limiting	0	O
factor	0	O
were	0	O
disturbances	0	O
in	0	O
the	0	O
system	0	O
of	0	O
energy	0	O
transport	0	O
(	0	O
creatine	0	O
phosphate	0	O
,	0	O
creatine	0	B
phosphokinase	0	I
)	0	O
and	0	O
of	0	O
the	0	O
calcium	0	O
pump	0	O
(	0	O
Ca	1	B
++-	0	I
ATPase	1	I
of	0	O
the	0	O
sarcoplasmic	0	O
reticulum	0	O
,	0	O
SPR	0	O
),	0	O
which	0	O
evidently	0	O
led	0	O
to	0	O
a	0	O
decrease	0	O
of	0	O
the	0	O
inotropic	0	O
properties	0	O
of	0	O
the	0	O
myocardium	0	O
at	0	O
70	0	O
%	0	O
restriction	0	O
of	0	O
coronary	0	O
blood	0	O
flow	0	O
.	0	O


Conserved	0	O
and	0	O
distinct	0	O
roles	0	O
of	0	O
kreisler	0	B
in	0	O
regulation	0	O
of	0	O
the	0	O
paralogous	0	O
Hoxa3	0	B
and	0	O
Hoxb3	0	B
genes	0	I
.	0	O


Such	0	O
a	0	O
concept	0	O
is	0	O
crucial	0	O
to	0	O
our	0	O
understanding	0	O
of	0	O
the	0	O
pathology	0	O
of	0	O
ageing	0	O
in	0	O
general	0	O
.	0	O


We	0	O
also	0	O
review	0	O
the	0	O
role	0	O
of	0	O
grains	0	O
in	0	O
the	0	O
formation	0	O
of	0	O
complex	0	O
molecules	0	O
in	0	O
interstellar	0	O
molecular	0	O
clouds	0	O
.	0	O


Moreover	0	O
,	0	O
we	0	O
found	0	O
that	0	O
cyclin	0	B
E	1	I
,	0	O
in	0	O
contrast	0	O
to	0	O
cyclin	0	B
D1	1	I
,	0	O
was	0	O
required	0	O
for	0	O
the	0	O
G1	0	O
/	0	O
S	1	O
transition	0	O
even	0	O
in	0	O
cells	0	O
lacking	0	O
retinoblastoma	0	B
protein	0	I
function	0	O
.	0	O


SECONDARY	1	O
OUTCOME	1	O
MEASURE	1	O
--	0	O
Double	1	O
-	0	O
blind	0	O
caffeine	0	O
-	0	O
withdrawal	0	O
evaluation	0	O
.	0	O


A	1	O
yeast	0	O
DNA	1	O
fragment	0	O
carrying	0	O
the	0	O
gene	0	B
CP	1	I
A1	0	I
encoding	0	O
the	0	O
small	0	O
subunit	0	O
of	0	O
the	0	O
arginine	0	O
pathway	0	O
carbamoyl	0	B
-	0	I
phosphate	0	I
synthetase	0	I
has	0	O
been	0	O
sequenced	0	O
.	0	O


The	0	O
usefulness	0	O
of	0	O
the	0	O
lambda	0	O
PG15	0	O
and	0	O
the	0	O
lambda	0	O
AD5	0	O
cloning	0	O
vectors	0	O
was	0	O
demonstrated	0	O
by	0	O
constructing	0	O
large	0	O
Neurospora	1	O
crassa	0	O
cDNA	1	O
libraries	0	O
.	0	O


RESULTS	0	O
:	0	O
The	0	O
cardiac	0	O
index	0	O
significantly	0	O
changed	0	O
with	0	O
varying	0	O
PaCO2	1	O
levels	0	O
(	0	O
hypocapnia	0	O
,	0	O
-	0	O
9	0	O
%;	0	O
hypercapnia	0	O
,	0	O
13	0	O
%).	0	O


Renin	1	B
secretion	0	O
in	0	O
essential	0	O
and	0	O
accelerated	0	O
hypertension	0	O
.	0	O


The	0	O
hit1	0	B
-	0	I
1	0	I
mutation	0	O
caused	0	O
a	0	O
defect	0	O
in	0	O
synthesis	0	O
of	0	O
a	0	O
74	0	B
-	0	I
kD	1	I
heat	0	I
shock	0	I
protein	0	I
.	0	O


73	0	O
:	0	O
658	0	O
-	0	O
666	0	O
,	0	O
1999	0	O
).	0	O


Treatment	1	O
with	0	O
heparin	0	O
,	0	O
plasminogen	0	B
activators	0	O
and	0	O
fibrinogenolytic	0	O
agents	0	O
was	0	O
disappointing	0	O
although	0	O
renal	0	O
function	0	O
has	0	O
stabilized	0	O
in	0	O
one	0	O
patient	0	O
on	0	O
long	0	O
term	0	O
oral	0	O
anticoagulant	0	O
therapy	0	O
.	0	O


These	0	O
results	0	O
demonstrate	0	O
that	0	O
endogenous	0	O
N	1	O
-	0	O
methylation	0	O
of	0	O
salsolinol	0	O
into	0	O
N	1	O
-	0	O
methylsalsolinol	0	O
occurs	0	O
in	0	O
the	0	O
brain	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
efficacy	0	O
of	0	O
quantitative	0	O
and	0	O
qualitative	0	O
chloride	0	O
titrators	0	O
in	0	O
the	0	O
estimation	0	O
of	0	O
human	0	O
salt	0	O
intake	0	O
.	0	O


Rather	0	O
,	0	O
complete	0	O
skipping	0	O
of	0	O
exon	0	O
V	1	O
and	0	O
subsequent	0	O
joining	0	O
of	0	O
exon	0	O
IV	1	O
to	0	O
exon	0	O
VI	0	O
caused	0	O
a	0	O
shift	0	O
in	0	O
the	0	O
open	0	O
reading	0	O
frame	0	O
,	0	O
which	0	O
remodeled	0	O
GPHe	0	B
(	0	I
P2	1	I
)	0	I
with	0	O
an	0	O
elongated	0	O
new	0	O
hydrophobic	0	O
sequence	0	O
for	0	O
membrane	0	O
anchoring	0	O
.	0	O


TH	1	B
-	0	O
SH3	0	B
binding	0	O
in	0	O
vitro	0	O
is	0	O
abolished	0	O
by	0	O
specific	0	O
,	0	O
single	0	O
amino	0	O
acid	0	O
substitutions	0	O
within	0	O
the	0	O
Btk	1	B
TH	1	I
domain	0	I
or	0	O
the	0	O
Fyn	0	B
SH3	0	I
domain	0	I
.	0	O


A	1	O
haemolytic	0	O
enterotoxigenic	0	O
strain	0	O
of	0	O
E	1	O
.	0	O
coli	0	O
(	0	O
O149	0	O
:	0	O
K88	0	O
:	0	O
H10	0	O
)	0	O
was	0	O
regularly	0	O
recovered	0	O
from	0	O
piglets	0	O
with	0	O
PWD	0	O
while	0	O
rotavirus	0	O
was	0	O
demonstrated	0	O
on	0	O
a	0	O
number	0	O
of	0	O
occasions	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
have	0	O
cloned	0	O
the	0	O
human	0	B
DSG3	0	I
gene	0	I
and	0	O
examined	0	O
the	0	O
transcriptional	0	O
regulation	0	O
of	0	O
its	0	O
expression	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
these	0	O
regions	0	O
showed	0	O
a	0	O
CAAT	0	O
box	0	O
upstream	0	O
of	0	O
exon	0	O
1a	0	O
and	0	O
high	0	O
G	1	O
-	0	O
C	1	O
content	0	O
regions	0	O
within	0	O
both	0	O
P1	1	O
and	0	O
P2	1	O
.	0	O


SF	1	B
-	0	I
1	0	I
does	0	O
not	0	O
have	0	O
an	0	O
N	1	O
-	0	O
terminal	0	O
AF1	0	O
domain	0	O
.	0	O


Electrocardiographic	0	O
QRS	0	O
complexes	0	O
and	0	O
vectorcardiographic	0	O
QRS	0	O
loop	0	O


However	0	O
,	0	O
alterations	0	O
in	0	O
electrostatic	0	O
and	0	O
hydrophobic	0	O
interactions	0	O
created	0	O
by	0	O
the	0	O
three	0	O
amino	0	O
acid	0	O
substitutions	0	O
prevent	0	O
the	0	O
conformational	0	O
change	0	O
in	0	O
the	0	O
enzyme	0	O
usually	0	O
produced	0	O
by	0	O
calmodulin	0	B
binding	0	O
.	0	O


It	1	O
was	0	O
not	0	O
possible	0	O
to	0	O
study	0	O
the	0	O
basis	0	O
for	0	O
tissue	0	O
-	0	O
specific	0	O
expression	0	O
of	0	O
this	0	O
gene	0	O
,	0	O
because	0	O
the	0	O
beta	0	B
3	0	I
gene	0	I
promoter	0	I
had	0	O
not	0	O
been	0	O
isolated	0	O
previously	0	O
.	0	O


Among	0	O
953	0	O
infants	0	O
in	0	O
22	0	O
neonatal	0	O
care	0	O
units	0	O
studied	0	O
,	0	O
23	0	O
%	0	O
(	0	O
median	0	O
value	0	O
,	0	O
range	0	O
0	0	O
-	0	O
78	0	O
)	0	O
were	0	O
found	0	O
to	0	O
be	0	O
faecally	0	O
colonized	0	O
with	0	O
one	0	O
of	0	O
21	0	O
distinct	0	O
nosocomial	0	O
strains	0	O
of	0	O
Escherichia	1	O
coli	0	O
,	0	O
Klebsiella	1	O
or	0	O
Enterobacter	1	O
spp	0	O
.	0	O


Despite	0	O
its	0	O
requirement	0	O
for	0	O
enhancer	0	O
-	0	O
dependent	0	O
splicing	0	O
activity	0	O
in	0	O
vitro	0	O
,	0	O
the	0	O
dU2AF38	0	B
RS	1	I
domain	0	I
was	0	O
also	0	O
inessential	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
cis	0	O
-	0	O
acting	0	O
element	0	O
,	0	O
identified	0	O
as	0	O
CACGTGACCCG	0	O
,	0	O
is	0	O
located	0	O
34	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
transcription	0	O
initiation	0	O
site	0	O
,	0	O
and	0	O
contains	0	O
the	0	O
core	0	O
sequence	0	O
of	0	O
the	0	O
upstream	0	O
promoter	0	O
sequence	0	O
of	0	O
Ad2MLP	0	B
.	0	O


We	0	O
conclude	0	O
that	0	O
the	0	O
alpha	0	O
-	0	O
subunit	0	O
of	0	O
the	0	O
telomere	0	B
-	0	I
binding	0	I
protein	0	I
,	0	O
like	0	O
many	0	O
transcription	0	O
factors	0	O
,	0	O
has	0	O
separable	0	O
DNA	1	O
-	0	O
binding	0	O
and	0	O
protein	0	O
-	0	O
protein	0	O
interaction	0	O
domains	0	O
.	0	O


Interferon	1	B
-	0	I
alpha	0	I
may	0	O
exacerbate	0	O
cryoblobulinemia	0	O
-	0	O
related	0	O
ischemic	0	O
manifestations	0	O
:	0	O
an	0	O
adverse	0	O
effect	0	O
potentially	0	O
related	0	O
to	0	O
its	0	O
anti	0	O
-	0	O
angiogenic	0	O
activity	0	O
.	0	O


Immunelectrophoretic	0	O
pattern	0	O
of	0	O
Wassermann	0	O
reagin	0	O
and	0	O
comparison	0	O
of	0	O
the	0	O
appearance	0	O
time	0	O
between	0	O
RPCF	0	B
and	0	O
FTA	0	B
antibodies	0	I


Chlamydia	1	O
trachomatis	0	O
and	0	O
Chlamydia	1	O
psittaci	0	O
were	0	O
not	0	O
affected	0	O
by	0	O
methanol	0	O
fixation	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
SLK	0	B
displays	0	O
high	0	O
homology	0	O
to	0	O
microtubule	0	B
and	0	I
nuclear	0	I
associated	0	I
protein	0	I
(	0	O
M	1	B
-	0	I
NAP	1	I
)	0	O
and	0	O
AT1	0	B
-	0	I
46	0	I
,	0	O
both	0	O
of	0	O
unknown	0	O
function	0	O
.	0	O


Functional	1	O
flow	0	O
was	0	O
evaluated	0	O
using	0	O
laser	0	O
Doppler	1	O
flowmetry	0	O
(	0	O
LDF	0	O
),	0	O
for	0	O
which	0	O
the	0	O
output	0	O
signal	0	O
,	0	O
blood	0	O
cell	0	O
flux	0	O
(	0	O
BCF	1	O
),	0	O
is	0	O
expressed	0	O
in	0	O
terms	0	O
of	0	O
volts	0	O
.	0	O


Cbf3	0	B
contains	0	O
three	0	O
proteins	0	O
,	0	O
Cbf3a	0	B
,	0	O
Cbf3b	0	B
and	0	O
Cbf3c	0	B
.	0	O


The	0	O
addition	0	O
of	0	O
diatrizoate	0	O
to	0	O
the	0	O
IPRK	0	O
led	0	O
to	0	O
a	0	O
dose	0	O
-	0	O
dependent	0	O
biphasic	0	O
change	0	O
in	0	O
RPF	1	O
and	0	O
GFR	1	O
characterized	0	O
by	0	O
an	0	O
initial	0	O
transient	0	O
increase	0	O
followed	0	O
by	0	O
a	0	O
marked	0	O
and	0	O
sustained	0	O
decrease	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
other	0	O
Ras	1	B
effectors	0	I
can	0	O
collaborate	0	O
with	0	O
PI	1	B
3	0	I
-	0	I
kinase	0	I
and	0	O
with	0	O
each	0	O
other	0	O
to	0	O
activate	0	O
Pak	0	B
.	0	O


The	0	O
growth	0	B
factor	0	I
receptor	0	I
-	0	I
bound	0	I
protein	0	I
2	0	I
(	0	O
Grb2	0	B
)	0	O
adaptor	0	O
when	0	O
complexed	0	O
with	0	O
Sos	0	B
(	0	O
Son	0	B
of	0	I
sevenless	0	I
),	0	O
the	0	O
exchange	0	O
factor	0	O
of	0	O
Ras	1	B
,	0	O
conveys	0	O
the	0	O
signal	0	O
induced	0	O
by	0	O
tyrosine	0	B
kinase	0	I
-	0	I
activated	0	I
receptor	0	I
to	0	O
Ras	1	B
by	0	O
recruiting	0	O
Sos	0	B
to	0	O
the	0	O
membrane	0	O
,	0	O
allowing	0	O
activation	0	O
of	0	O
Ras	1	B
.	0	O


The	0	O
TUP1	0	B
gene	0	I
was	0	O
isolated	0	O
in	0	O
a	0	O
screen	0	O
for	0	O
genes	0	O
that	0	O
regulate	0	O
mating	0	O
type	0	O
(	0	O
V	1	O
.	0	O
L	1	O
.	0	O


Plasma	1	B
renin	0	I
concentration	0	O
is	0	O
significantly	0	O
higher	0	O
in	0	O
the	0	O
subcapsular	0	O
venous	0	O
outflow	0	O
,	0	O
which	0	O
drains	0	O
the	0	O
superficial	0	O
cortex	0	O
,	0	O
than	0	O
in	0	O
the	0	O
deep	0	O
venous	0	O
outflow	0	O
,	0	O
which	0	O
drains	0	O
the	0	O
inner	0	O
half	0	O
of	0	O
the	0	O
cortex	0	O
and	0	O
medulla	0	O
of	0	O
the	0	O
cat	0	O
kidney	0	O
.	0	O


We	0	O
used	0	O
oligonucleotide	0	O
-	0	O
directed	0	O
mutagenesis	0	O
to	0	O
alter	0	O
a	0	O
site	0	O
in	0	O
MucA	0	B
homologous	0	O
to	0	O
the	0	O
Ala	1	O
-	0	O
Gly	1	O
cleavage	0	O
site	0	O
of	0	O
LexA	0	B
.	0	O


The	0	O
Drosophila	1	O
clathrin	0	B
heavy	0	I
chain	0	I
gene	0	O
:	0	O
clathrin	0	B
function	0	O
is	0	O
essential	0	O
in	0	O
a	0	O
multicellular	0	O
organism	0	O
.	0	O


Very	0	O
small	0	O
deletions	0	O
within	0	O
the	0	O
conserved	0	O
region	0	O
completely	0	O
abolished	0	O
transforming	0	O
activity	0	O
of	0	O
dbl	0	B
,	0	O
while	0	O
extensive	0	O
deletion	0	O
outside	0	O
of	0	O
this	0	O
region	0	O
had	0	O
no	0	O
effect	0	O
.	0	O


It	1	O
contains	0	O
25	0	O
exons	0	O
coding	0	O
for	0	O
a	0	O
4	0	O
.	0	O
7kb	0	O
transcript	0	O
including	0	O
large	0	O
5	0	O
'-	0	O
and	0	O
3	0	O
'-	0	O
(	0	O
1218bp	0	O
and	0	O
701bp	0	O
,	0	O
respectively	0	O
)	0	O
untranslated	0	O
regions	0	O
(	0	O
UTRs	0	O
).	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
hrpRS	0	B
and	0	O
hrpL	0	B
are	0	O
part	0	O
of	0	O
a	0	O
regulatory	0	O
cascade	0	O
in	0	O
which	0	O
HrpR	0	B
and	0	O
HrpS	0	B
activate	0	O
expression	0	O
of	0	O
hrpL	0	B
and	0	O
HrpL	0	B
,	0	O
a	0	O
putative	0	O
sigma	0	B
factor	0	I
,	0	O
induces	0	O
expression	0	O
of	0	O
HrpL	0	B
-	0	I
responsive	0	I
genes	0	I
.	0	O


G	1	O
.,	0	O
and	0	O
Hyde	0	O
,	0	O
C	1	O
.	0	O


The	0	O
variability	0	O
is	0	O
most	0	O
likely	0	O
a	0	O
result	0	O
of	0	O
alternative	0	O
splicing	0	O
of	0	O
exons	0	O
from	0	O
the	0	O
primary	0	O
elastin	0	B
transcripts	0	I
.	0	O


In	1	O
study	0	O
2	0	O
,	0	O
the	0	O
correlation	0	O
coefficients	0	O
between	0	O
the	0	O
ISO2	0	O
measurements	0	O
obtained	0	O
at	0	O
the	0	O
ulcer	0	O
margin	0	O
and	0	O
at	0	O
the	0	O
adjacent	0	O
normal	0	O
mucosa	0	O
,	0	O
and	0	O
delta	0	O
ISO2	0	O
obtained	0	O
by	0	O
the	0	O
experienced	0	O
observer	0	O
and	0	O
one	0	O
of	0	O
the	0	O
three	0	O
learners	0	O
were	0	O
0	0	O
.	0	O
94	0	O
,	0	O
0	0	O
.	0	O
97	0	O
,	0	O
and	0	O
0	0	O
.	0	O
94	0	O
,	0	O
respectively	0	O
.	0	O


Retransformation	0	O
of	0	O
uvsH77	0	B
mutants	0	I
with	0	O
the	0	O
rescued	0	O
cosmids	0	O
from	0	O
the	0	O
MMS	0	O
-	0	O
resistant	0	O
transformants	0	O
resulted	0	O
in	0	O
restoration	0	O
of	0	O
both	0	O
UV	1	O
and	0	O
MMS	0	O
resistance	0	O
to	0	O
wild	0	O
-	0	O
type	0	O
levels	0	O
.	0	O


Essentially	0	O
,	0	O
2	0	O
'-	0	O
O	1	O
-	0	O
methyl	0	O
oligoribonucleotides	0	O
(	0	O
2	0	O
'	0	O
OMeRNA	0	O
)	0	O
were	0	O
delivered	0	O
to	0	O
the	0	O
nuclei	0	O
of	0	O
primary	0	O
mdx	0	O
myoblasts	0	O
in	0	O
culture	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
AP	1	B
-	0	I
A	1	I
may	0	O
be	0	O
potentially	0	O
useful	0	O
in	0	O
the	0	O
management	0	O
of	0	O
heart	0	O
failure	0	O
.	0	O


Manifest	1	O
anxiety	0	O
of	0	O
Vietnam	0	O
returnees	0	O
and	0	O
undergraduates	0	O
.	0	O


Non	0	O
-	0	O
complement	0	O
-	0	O
dependent	0	O
sperm	0	O
-	0	O
immobilizing	0	O
activity	0	O
was	0	O
also	0	O
detected	0	O
in	0	O
the	0	O
cervical	0	O
mucus	0	O
of	0	O
several	0	O
patients	0	O
.	0	O


The	0	O
pJR	0	O
vectors	0	O
differ	0	O
among	0	O
them	0	O
in	0	O
:	0	O
(	0	O
a	0	O
)	0	O
the	0	O
selectable	0	O
marker	0	O
(	0	O
Saccharomyces	1	O
cerevisiae	0	O
LEU	1	B
2	0	I
gene	0	I
,	0	O
which	0	O
complements	0	O
S	1	B
.	0	I
pombe	0	I
leu1	0	I
-	0	I
gene	0	I
and	0	O
S	1	O
.	0	O
pombe	0	O
ura4	0	B
+	0	I
and	0	O
his3	0	B
+	0	I
genes	0	I
);	0	O
(	0	O
b	0	O
)	0	O
the	0	O
thiamine	0	O
-	0	O
repressible	0	O
nmt1	0	B
promoter	0	I
(	0	O
3X	0	O
,	0	O
41X	0	O
and	0	O
81X	0	O
with	0	O
extremely	0	O
high	0	O
,	0	O
moderate	0	O
or	0	O
low	0	O
transcription	0	O
efficiency	0	O
,	0	O
respectively	0	O
);	0	O
and	0	O
(	0	O
c	0	O
)	0	O
the	0	O
multiple	0	O
cloning	0	O
site	0	O
(	0	O
two	0	O
multiple	0	O
cloning	0	O
sites	0	O
,	0	O
with	0	O
12	0	O
restriction	0	O
sites	0	O
each	0	O
).	0	O


One	0	O
of	0	O
its	0	O
unique	0	O
features	0	O
appears	0	O
to	0	O
be	0	O
the	0	O
unusually	0	O
short	0	O
5	0	O
'-	0	O
untranslated	0	O
regions	0	O
(	0	O
UTR	0	O
)	0	O
(	0	O
1	0	O
-	0	O
6	0	O
nucleotides	0	O
(	0	O
nts	0	O
))	0	O
and	0	O
the	0	O
apparent	0	O
absence	0	O
of	0	O
5	0	O
'-	0	O
cap	0	O
structures	0	O
from	0	O
its	0	O
mRNAs	0	O
.	0	O


Effects	0	O
of	0	O
point	0	O
defects	0	O
on	0	O
lattice	0	O
parameters	0	O
of	0	O
semiconductors	0	O
.	0	O


Natural	1	O
Haemophilus	1	O
influenzae	0	O
type	0	O
b	0	O
capsular	0	O
polysaccharide	0	O
antibodies	0	O
in	0	O
412	0	O
infants	0	O
and	0	O
children	0	O
from	0	O
West	0	O
Africa	0	O
(	0	O
Burkina	0	O
-	0	O
Faso	0	O
)	0	O
and	0	O
France	0	O
:	0	O
a	0	O
cross	0	O
-	0	O
sectional	0	O
serosurvey	0	O
.	0	O


We	0	O
have	0	O
recently	0	O
identified	0	O
a	0	O
mouse	0	O
enzyme	0	O
termed	0	O
gamma	0	B
-	0	I
glutamyl	0	I
leukotrienase	0	I
(	0	O
GGL	0	B
)	0	O
that	0	O
converts	0	O
leukotriene	0	O
C4	1	O
(	0	O
LTC4	0	O
)	0	O
to	0	O
leukotriene	0	O
D4	0	O
(	0	O
LTD4	0	O
).	0	O


In	1	O
some	0	O
early	0	O
B	1	O
cells	0	O
and	0	O
Abelson	0	O
murine	0	O
leukemia	0	O
virus	0	O
-	0	O
transformed	0	O
pre	0	O
-	0	O
B	1	O
-	0	O
cell	0	O
lines	0	O
,	0	O
LT	1	B
mRNA	1	I
is	0	O
constitutively	0	O
expressed	0	O
.	0	O


C	1	B
/	0	I
EBP	1	I
beta	0	I
V	1	I
>	0	O
A	1	O
selectively	0	O
binds	0	O
only	0	O
the	0	O
subset	0	O
of	0	O
C	1	B
/	0	I
EBP	1	I
sites	0	I
that	0	O
are	0	O
also	0	O
DBP	0	B
sites	0	I
,	0	O
both	0	O
as	0	O
oligonucleotides	0	O
and	0	O
within	0	O
the	0	O
natural	0	O
contexts	0	O
of	0	O
the	0	O
albumin	0	B
and	0	O
cholesterol	0	B
hydroxylase	0	I
promoters	0	I
.	0	O


Both	0	O
NUP98	0	B
-	0	O
HOXA9	0	B
chimeras	0	O
transformed	0	O
NIH	1	O
3T3	0	O
fibroblasts	0	O
,	0	O
and	0	O
this	0	O
transformation	0	O
required	0	O
the	0	O
HOXA9	0	B
domains	0	I
for	0	O
DNA	1	O
binding	0	O
and	0	O
PBX	0	B
interaction	0	O
.	0	O


Their	0	O
conduction	0	O
velocity	0	O
ranged	0	O
from	0	O
0	0	O
.	0	O
23	0	O
to	0	O
0	0	O
.	0	O
98	0	O
m	0	O
/	0	O
sec	0	O
(	0	O
group	0	O
C	1	O
).	0	O


Progressive	1	O
100	0	O
-	0	O
mmHg	0	O
stepwise	0	O
decreases	0	O
in	0	O
superfusate	0	O
oxygen	0	O
partial	0	O
pressure	0	O
(	0	O
PO2	1	O
)	0	O
from	0	O
control	0	O
(	0	O
95	0	O
%	0	O
O2	1	O
aeration	0	O
,	0	O
PO2	1	O
,	0	O
620	0	O
-	0	O
650	0	O
mmHg	0	O
)	0	O
were	0	O
produced	0	O
,	0	O
and	0	O
subsequent	0	O
changes	0	O
in	0	O
isometric	0	O
active	0	O
and	0	O
resting	0	O
tension	0	O
were	0	O
measured	0	O
.	0	O


The	0	O
role	0	O
of	0	O
'	0	O
scientific	0	O
psychiatry	0	O
'	0	O
in	0	O
understanding	0	O
patients	0	O
with	0	O
chronic	0	O
schizophrenia	0	O
or	0	O
severe	0	O
personality	0	O
disorder	0	O
.	0	O


Using	0	O
the	0	O
balloon	0	O
-	0	O
gas	0	O
procedure	0	O
with	0	O
a	0	O
single	0	O
gas	0	O
injection	0	O
,	0	O
a	0	O
bubble	0	O
was	0	O
obtained	0	O
that	0	O
was	0	O
large	0	O
enough	0	O
to	0	O
tamponade	0	O
a	0	O
giant	0	O
tear	0	O
without	0	O
prior	0	O
drainage	0	O
of	0	O
subretinal	0	O
fluid	0	O
or	0	O
vitrectomy	0	O
.	0	O


Caries	1	O
prevention	0	O
in	0	O
the	0	O
dental	0	O
office	0	O
.	0	O


The	0	O
two	0	O
methods	0	O
identify	0	O
the	0	O
same	0	O
patients	0	O
only	0	O
if	0	O
micturitional	0	O
pressures	0	O
are	0	O
normal	0	O
(	0	O
40	0	O
to	0	O
60	0	O
cmH2O	0	O
)	0	O
to	0	O
high	0	O
(	0	O
over	0	O
60	0	O
cmH2O	0	O
)	0	O
and	0	O
the	0	O
Sussett	0	O
formula	0	O
is	0	O
used	0	O
with	0	O
a	0	O
higher	0	O
(	0	O
95th	0	O
centile	0	O
)	0	O
cutoff	0	O
.	0	O


These	0	O
regions	0	O
overlap	0	O
with	0	O
the	0	O
HIT	1	B
protein	0	I
similarity	0	I
regions	0	I
.	0	O


METHODS	0	O
:	0	O
A	1	O
population	0	O
survey	0	O
was	0	O
undertaken	0	O
in	0	O
10	0	O
,	0	O
148	0	O
individuals	0	O
to	0	O
measure	0	O
the	0	O
prevalence	0	O
and	0	O
identify	0	O
the	0	O
causes	0	O
of	0	O
blindness	0	O
in	0	O
Lebanon	0	O
.	0	O


Modulation	1	O
of	0	O
AUUUA	0	O
response	0	O
element	0	O
binding	0	O
by	0	O
heterogeneous	0	B
nuclear	0	I
ribonucleoprotein	0	I
A1	0	I
in	0	O
human	0	O
T	1	O
lymphocytes	0	O
.	0	O


Routine	1	O
psychometric	0	O
screening	0	O
of	0	O
IHD	1	O
patients	0	O
may	0	O
provide	0	O
a	0	O
cost	0	O
-	0	O
effective	0	O
means	0	O
of	0	O
alerting	0	O
cardiologists	0	O
and	0	O
internists	0	O
to	0	O
the	0	O
relatively	0	O
high	0	O
levels	0	O
of	0	O
distress	0	O
among	0	O
their	0	O
patients	0	O
.	0	O


Salient	1	O
applications	0	O
of	0	O
PB	1	O
-	0	O
PK	1	O
modeling	0	O
to	0	O
toxicological	0	O
problems	0	O
are	0	O
illustrated	0	O
with	0	O
examples	0	O
.	0	O


To	1	O
evaluate	0	O
the	0	O
gas	0	O
chromatographic	0	O
electron	0	O
capture	0	O
detection	0	O
method	0	O
described	0	O
earlier	0	O
,	0	O
23	0	O
plasma	0	O
samples	0	O
have	0	O
been	0	O
analysed	0	O
by	0	O
both	0	O
techniques	0	O
.	0	O


Pathol	0	O
.	0	O


In	1	O
subjects	0	O
(	0	O
n	0	O
=	0	O
5	0	O
)	0	O
with	0	O
quadriplegia	0	O
and	0	O
reduced	0	O
sympathetic	0	O
tone	0	O
secondary	0	O
to	0	O
cervical	0	O
cord	0	O
trauma	0	O
,	0	O
TcpO2	0	O
at	0	O
42	0	O
degrees	0	O
C	1	O
and	0	O
vasodilation	0	O
index	0	O
were	0	O
increased	0	O
(	0	O
45	0	O
.	0	O
0	0	O
mmHg	0	O
and	0	O
0	0	O
.	0	O
61	0	O
);	0	O
TcpO2	0	O
at	0	O
45	0	O
degrees	0	O
C	1	O
did	0	O
not	0	O
change	0	O
.	0	O


Lys	1	O
(	0	O
193	0	O
)	0	O
and	0	O
Arg	1	O
(	0	O
194	0	O
),	0	O
located	0	O
at	0	O
the	0	O
COOH	0	O
-	0	O
terminal	0	O
end	0	O
of	0	O
HD	1	B
,	0	O
are	0	O
essential	0	O
for	0	O
dimerization	0	O
.	0	O


The	0	O
27	0	O
-	0	O
base	0	O
element	0	O
interacts	0	O
with	0	O
a	0	O
PDGF	0	B
-	0	O
activated	0	O
serine	0	O
/	0	O
threonine	0	O
phosphoprotein	0	O
that	0	O
is	0	O
detected	0	O
only	0	O
within	0	O
the	0	O
nucleus	0	O
of	0	O
PDGF	0	O
-	0	O
treated	0	O
3T3	0	O
cells	0	O
.	0	O


The	0	O
complete	0	O
cDNA	1	O
sequence	0	O
of	0	O
human	0	B
betaV	0	I
spectrin	0	I
is	0	O
available	0	O
from	0	O
GenBank	0	O
(	0	O
TM	1	O
)	0	O
as	0	O
accession	0	O
number	0	O
.	0	O


The	0	O
pharmacokinetics	0	O
of	0	O
each	0	O
tetracycline	0	O
in	0	O
serum	0	O
and	0	O
dermal	0	O
,	0	O
suction	0	O
blister	0	O
fluid	0	O
were	0	O
determined	0	O
after	0	O
oral	0	O
doses	0	O
of	0	O
300	0	O
mg	0	O
lymecycline	0	O
or	0	O
100	0	O
mg	0	O
doxycycline	0	O
on	0	O
the	0	O
3rd	0	O
day	0	O
.	0	O


Perhaps	0	O
in	0	O
addition	0	O
to	0	O
,	0	O
or	0	O
as	0	O
part	0	O
of	0	O
,	0	O
its	0	O
essential	0	O
function	0	O
in	0	O
late	0	O
mitosis	0	O
,	0	O
MOB1	0	B
is	0	O
required	0	O
for	0	O
a	0	O
cell	0	O
cycle	0	O
reset	0	O
function	0	O
necessary	0	O
for	0	O
the	0	O
initiation	0	O
of	0	O
the	0	O
spindle	0	O
pole	0	O
body	0	O
duplication	0	O
.	0	O


The	0	O
dying	0	O
tTG	0	B
-	0	O
transfected	0	O
cells	0	O
exhibit	0	O
both	0	O
cytoplasmic	0	O
and	0	O
nuclear	0	O
changes	0	O
characteristic	0	O
of	0	O
cells	0	O
undergoing	0	O
apoptosis	0	O
.	0	O


Enzyme	1	B
I	1	I
of	0	O
the	0	O
phosphoenolpyruvate	0	B
:	0	I
sugar	0	I
phosphotransferase	0	I
system	0	O
.	0	O


PIP2	1	O
,	0	O
when	0	O
incorporated	0	O
into	0	O
phosphatidylcholine	0	O
carrier	0	O
vesicles	0	O
,	0	O
binds	0	O
tightly	0	O
to	0	O
the	0	O
guanine	0	O
nucleotide	0	O
-	0	O
depleted	0	O
form	0	O
of	0	O
Cdc42Hs	0	B
and	0	O
weakly	0	O
to	0	O
the	0	O
GDP	1	O
-	0	O
bound	0	O
form	0	O
of	0	O
the	0	O
GTP	1	B
-	0	I
binding	0	I
protein	0	I
but	0	O
does	0	O
not	0	O
bind	0	O
to	0	O
GTP	1	O
-	0	O
bound	0	O
Cdc42Hs	0	B
,	0	O
similar	0	O
to	0	O
what	0	O
was	0	O
observed	0	O
for	0	O
the	0	O
Dbl	0	B
oncoprotein	0	I
.	0	O


The	0	O
central	0	O
globular	0	O
domain	0	O
is	0	O
highly	0	O
similar	0	O
to	0	O
those	0	O
regions	0	O
from	0	O
other	0	O
H1	1	B
molecules	0	I
,	0	O
and	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
domain	0	O
contains	0	O
a	0	O
repeating	0	O
hexapeptide	0	O
motif	0	O
,	0	O
variants	0	O
of	0	O
which	0	O
are	0	O
conserved	0	O
among	0	O
H1	1	B
molecules	0	I
.	0	O


Rad6	0	B
mutants	0	I
display	0	O
a	0	O
remarkably	0	O
pleiotropic	0	O
phenotype	0	O
,	0	O
implicating	0	O
the	0	O
protein	0	O
in	0	O
DNA	1	O
damage	0	O
-	0	O
induced	0	O
mutagenesis	0	O
,	0	O
postreplication	0	O
repair	0	O
,	0	O
repression	0	O
of	0	O
retrotransposition	0	O
,	0	O
and	0	O
sporulation	0	O
.	0	O


Substitution	1	O
of	0	O
the	0	O
DR1	0	B
beta	0	I
chain	0	I
with	0	O
H	1	B
-	0	I
2E	0	I
beta	0	I
k	0	I
led	0	O
to	0	O
a	0	O
dramatic	0	O
loss	0	O
of	0	O
recognition	0	O
;	0	O
alpha	0	O
chain	0	O
substitution	0	O
had	0	O
a	0	O
less	0	O
marked	0	O
effect	0	O
.	0	O


Binding	0	O
affinities	0	O
of	0	O
different	0	O
nucleotide	0	O
mono	0	O
-,	0	O
di	0	O
-	0	O
and	0	O
triphosphates	0	O
and	0	O
non	0	O
-	0	O
hydrolyzable	0	O
analogs	0	O
indicate	0	O
that	0	O
the	0	O
beta	0	O
-	0	O
phosphate	0	O
moiety	0	O
is	0	O
required	0	O
for	0	O
substrate	0	O
binding	0	O
.	0	O


Most	0	O
strains	0	O
(	0	O
95	0	O
%)	0	O
of	0	O
S	1	O
.	0	O
lugdunensis	0	O
produced	0	O
a	0	O
delta	0	B
hemolysin	0	I
like	0	O
that	0	O
seen	0	O
with	0	O
nine	0	O
other	0	O
species	0	O
of	0	O
CNS	1	O
.	0	O


Here	0	O
,	0	O
a	0	O
case	0	O
of	0	O
Sjogren	0	O
'	0	O
s	0	O
syndrome	0	O
is	0	O
presented	0	O
that	0	O
was	0	O
initially	0	O
diagnosed	0	O
because	0	O
of	0	O
dental	0	O
complaints	0	O
,	0	O
and	0	O
long	0	O
-	0	O
term	0	O
treatment	0	O
of	0	O
Sjogren	0	O
'	0	O
s	0	O
patients	0	O
is	0	O
discussed	0	O
.	0	O


Lysozyme	1	B
activity	0	O
was	0	O
evidently	0	O
increased	0	O
as	0	O
well	0	O
in	0	O
undiluted	0	O
as	0	O
in	0	O
diluted	0	O
sera	0	O
in	0	O
all	0	O
our	0	O
tested	0	O
patients	0	O
.	0	O


Cotransfection	1	O
of	0	O
the	0	O
helicase	0	B
-	0	O
primase	0	B
proteins	0	O
,	0	O
one	0	O
of	0	O
which	0	O
was	0	O
fused	0	O
to	0	O
a	0	O
heterologous	0	O
activation	0	O
domain	0	O
,	0	O
led	0	O
to	0	O
Zta	0	B
-	0	O
dependent	0	O
superactivation	0	O
of	0	O
CAT	1	B
expression	0	O
.	0	O


I	1	O
.	0	O


HANYS	0	O
criticizes	0	O
laparoscopic	0	O
gall	0	O
bladder	0	O
guidelines	0	O
.	0	O


By	0	O
contrast	0	O
,	0	O
their	0	O
basal	0	O
adrenal	0	O
androgen	0	O
levels	0	O
were	0	O
significantly	0	O
decreased	0	O
compared	0	O
to	0	O
those	0	O
in	0	O
normal	0	O
subjects	0	O
on	0	O
both	0	O
the	0	O
day	0	O
on	0	O
and	0	O
the	0	O
day	0	O
off	0	O
prednisone	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Monospecific	1	O
antibodies	0	O
raised	0	O
against	0	O
rat	0	B
cytochrome	0	I
P	1	I
-	0	I
450	0	I
1A1	0	I
recognized	0	O
a	0	O
protein	0	O
in	0	O
the	0	O
hepatic	0	O
microsomes	0	O
of	0	O
the	0	O
double	0	O
-	0	O
crested	0	O
cormorant	0	O
,	0	O
and	0	O
also	0	O
in	0	O
those	0	O
of	0	O
the	0	O
great	0	O
blue	0	O
heron	0	O
(	0	O
Ardea	0	O
herodias	0	O
),	0	O
using	0	O
immunoblotting	0	O
.	0	O


A	1	O
simple	0	O
method	0	O
for	0	O
measuring	0	O
urinary	0	O
iron	0	O
following	0	O
the	0	O
administration	0	O
of	0	O
desferrioxamine	0	O
(	0	O
DF	0	O
)	0	O
is	0	O
described	0	O
.	0	O


This	0	O
revealed	0	O
a	0	O
minimum	0	O
of	0	O
six	0	O
novel	0	O
OSBP	0	B
-	0	I
related	0	I
proteins	0	I
,	0	O
designated	0	O
ORP	0	B
-	0	I
1	0	I
to	0	O
ORP	0	B
-	0	I
6	0	I
.	0	O


Rice	1	B
dwarf	0	I
phytoreovirus	0	I
segment	0	I
S12	0	I
transcript	0	I
is	0	O
tricistronic	0	O
in	0	O
vitro	0	O
.	0	O


The	0	O
hydropathy	0	O
plot	0	O
revealed	0	O
a	0	O
rather	0	O
hydrophilic	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
and	0	O
the	0	O
absence	0	O
of	0	O
a	0	O
hydrophobic	0	O
signal	0	O
peptide	0	O
.	0	O


In	1	O
the	0	O
PMR	1	O
target	0	O
area	0	O
but	0	O
not	0	O
in	0	O
the	0	O
nontreated	0	O
area	0	O
an	0	O
improvement	0	O
in	0	O
regional	0	O
myocardial	0	O
flow	0	O
reserve	0	O
occurs	0	O
in	0	O
wall	0	O
segments	0	O
with	0	O
initially	0	O
severely	0	O
or	0	O
moderately	0	O
reduced	0	O
stress	0	O
perfusion	0	O
.	0	O


Genesis	1	O
of	0	O
foam	0	O
cells	0	O
:	0	O
study	0	O
in	0	O
rats	0	O
after	0	O
administration	0	O
of	0	O
Cloforex	0	O
.	0	O


Further	0	O
research	0	O
is	0	O
required	0	O
to	0	O
better	0	O
measure	0	O
treatment	0	O
effects	0	O
,	0	O
modification	0	O
of	0	O
MS	1	O
natural	0	O
history	0	O
,	0	O
and	0	O
net	0	O
societal	0	O
costs	0	O
of	0	O
IFN	1	B
beta	0	I
-	0	I
1b	0	I
in	0	O
RRMS	0	O
.	0	O


In	1	O
30	0	O
dogs	0	O
the	0	O
left	0	O
limb	0	O
(	0	O
tail	0	O
)	0	O
of	0	O
the	0	O
pancreas	0	O
was	0	O
removed	0	O
but	0	O
left	0	O
in	0	O
the	0	O
abdominal	0	O
cavity	0	O
after	0	O
cessation	0	O
of	0	O
blood	0	O
flow	0	O
to	0	O
produce	0	O
warm	0	O
ischemia	0	O
for	0	O
30	0	O
,	0	O
60	0	O
,	0	O
and	0	O
120	0	O
min	0	O
(	0	O
10	0	O
dogs	0	O
at	0	O
each	0	O
time	0	O
point	0	O
),	0	O
and	0	O
then	0	O
was	0	O
flushed	0	O
with	0	O
cold	0	O
Ringers	0	O
'	0	O
lactate	0	O
and	0	O
transplanted	0	O
to	0	O
the	0	O
iliac	0	O
vessels	0	O
.	0	O


Recent	0	O
molecular	0	O
analysis	0	O
has	0	O
revealed	0	O
that	0	O
the	0	O
S	1	B
locus	0	I
is	0	O
highly	0	O
polymorphic	0	O
and	0	O
contains	0	O
several	0	O
genes	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
SLG	0	B
,	0	O
SRK	0	B
,	0	O
the	0	O
as	0	O
-	0	O
yet	0	O
-	0	O
unidentified	0	O
pollen	0	O
S	1	O
gene	0	O
(	0	O
s	0	O
),	0	O
and	0	O
other	0	O
linked	0	O
genes	0	O
.	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
such	0	O
lesions	0	O
in	0	O
two	0	O
cases	0	O
were	0	O
evaluated	0	O
by	0	O
ultrasonography	0	O
.	0	O


Protein	1	B
tyrosine	0	I
kinases	0	I
(	0	O
PTKs	0	B
)	0	O
are	0	O
implicated	0	O
in	0	O
the	0	O
control	0	O
of	0	O
cell	0	O
growth	0	O
by	0	O
virtue	0	O
of	0	O
their	0	O
frequent	0	O
appearance	0	O
as	0	O
products	0	O
of	0	O
retroviral	0	O
oncogenes	0	O
,	0	O
as	0	O
intracellular	0	O
signal	0	O
transducers	0	O
,	0	O
and	0	O
as	0	O
growth	0	B
factor	0	I
receptors	0	I
or	0	O
components	0	O
thereof	0	O
.	0	O


Various	0	O
treatment	0	O
modalities	0	O
are	0	O
reviewed	0	O
in	0	O
the	0	O
context	0	O
of	0	O
the	0	O
psychology	0	O
as	0	O
well	0	O
as	0	O
the	0	O
physiology	0	O
of	0	O
severe	0	O
intractable	0	O
pain	0	O
.	0	O


Tissue	1	O
-	0	O
specific	0	O
expression	0	O
of	0	O
the	0	O
diazepam	0	B
-	0	I
binding	0	I
inhibitor	0	I
in	0	O
Drosophila	1	O
melanogaster	0	O
:	0	O
cloning	0	O
,	0	O
structure	0	O
,	0	O
and	0	O
localization	0	O
of	0	O
the	0	O
gene	0	O
.	0	O


However	0	O
,	0	O
mechanisms	0	O
underlying	0	O
HIV	1	O
-	0	O
1	0	O
gene	0	O
expression	0	O
in	0	O
the	0	O
CNS	1	O
are	0	O
poorly	0	O
understood	0	O
.	0	O


Although	0	O
human	0	O
infections	0	O
with	0	O
bacteraemia	0	O
due	0	O
to	0	O
Pasteurella	1	O
multocida	0	O
are	0	O
not	0	O
uncommon	0	O
,	0	O
endocarditis	0	O
associated	0	O
with	0	O
P	1	O
.	0	O
haemolytica	0	O
is	0	O
rare	0	O
.	0	O


MK	1	O
-	0	O
801	0	O
administration	0	O
resulted	0	O
in	0	O
a	0	O
biphasic	0	O
response	0	O
in	0	O
seizure	0	O
latency	0	O
.	0	O


Except	0	O
for	0	O
nonperfusion	0	O
of	0	O
neurosensory	0	O
retinal	0	O
vessels	0	O
at	0	O
a	0	O
light	0	O
dose	0	O
of	0	O
150	0	O
J	1	O
/	0	O
cm2	0	O
,	0	O
no	0	O
other	0	O
adverse	0	O
events	0	O
were	0	O
of	0	O
concern	0	O
.	0	O


Site	1	O
-	0	O
directed	0	O
mutagenesis	0	O
of	0	O
the	0	O
R2	0	B
protein	0	I
was	0	O
used	0	O
to	0	O
provide	0	O
evidence	0	O
that	0	O
this	0	O
motif	0	O
is	0	O
also	0	O
part	0	O
of	0	O
the	0	O
active	0	O
site	0	O
of	0	O
the	0	O
endonuclease	0	O
encoded	0	O
by	0	O
this	0	O
element	0	O
.	0	O


W	1	O
.	0	O


The	0	O
authors	0	O
evaluated	0	O
the	0	O
potential	0	O
for	0	O
thrombotic	0	O
complications	0	O
arising	0	O
from	0	O
implantation	0	O
of	0	O
a	0	O
ventricular	0	O
assist	0	O
device	0	O
(	0	O
Sarns	0	O
/	0	O
3M	0	O
-	0	O
VAD	1	O
)	0	O
in	0	O
four	0	O
calves	0	O
.	0	O


The	0	O
major	0	O
PKC	0	B
beta	0	I
transcription	0	O
initiation	0	O
site	0	O
was	0	O
identified	0	O
by	0	O
primer	0	O
extension	0	O
and	0	O
S1	1	B
nuclease	0	I
protection	0	O
.	0	O


We	0	O
have	0	O
been	0	O
studying	0	O
the	0	O
interaction	0	O
of	0	O
the	0	O
oncogenic	0	O
human	0	O
polyomavirus	0	O
BK	1	O
(	0	O
BKV	0	O
)	0	O
with	0	O
the	0	O
tumor	0	B
-	0	I
suppressor	0	I
protein	0	I
p53	0	I
to	0	O
understand	0	O
the	0	O
biology	0	O
of	0	O
this	0	O
virus	0	O
as	0	O
well	0	O
as	0	O
to	0	O
understand	0	O
the	0	O
basic	0	O
mechanisms	0	O
of	0	O
p53	0	B
transactivation	0	O
.	0	O


Preliminary	0	O
report	0	O
.	0	O


We	0	O
find	0	O
that	0	O
3T1	0	O
-	0	O
3T2	0	O
mixing	0	O
has	0	O
a	0	O
pronounced	0	O
effect	0	O
on	0	O
the	0	O
line	0	O
shape	0	O
and	0	O
radiative	0	O
decay	0	O
rate	0	O
of	0	O
emission	0	O
from	0	O
the	0	O
3T2	0	O
state	0	O
and	0	O
that	0	O
the	0	O
extent	0	O
of	0	O
mixing	0	O
depends	0	O
critically	0	O
on	0	O
the	0	O
magnitude	0	O
of	0	O
nontetrahedral	0	O
distortions	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
computer	0	O
analysis	0	O
suggests	0	O
that	0	O
sequences	0	O
similar	0	O
to	0	O
the	0	O
A	1	O
stem	0	O
element	0	O
are	0	O
present	0	O
within	0	O
the	0	O
three	0	O
AAV	1	B
promoter	0	I
regions	0	O
.	0	O


In	1	O
cells	0	O
limited	0	O
for	0	O
His	1	O
,	0	O
increased	0	O
expression	0	O
of	0	O
arg	0	B
-	0	I
2	0	I
and	0	O
cpc	0	B
-	0	I
1	0	I
,	0	O
and	0	O
decreased	0	O
expression	0	O
of	0	O
cox	0	B
-	0	I
5	0	I
,	0	O
also	0	O
had	0	O
translational	0	O
and	0	O
transcriptional	0	O
components	0	O
.	0	O


Eighty	0	O
patients	0	O
presenting	0	O
to	0	O
HGGM	0	O
with	0	O
non	0	O
-	0	O
Hodgkin	0	O
'	0	O
s	0	O
lymphomas	0	O
between	0	O
1962	0	O
and	0	O
1986	0	O
,	0	O
were	0	O
reviewed	0	O
.	0	O


This	0	O
sequence	0	O
possessed	0	O
homology	0	O
with	0	O
a	0	O
methylation	0	O
-	0	O
sensitive	0	O
promoter	0	O
element	0	O
,	0	O
Enh2	0	O
,	0	O
present	0	O
in	0	O
the	0	O
LTR	1	O
of	0	O
mouse	0	O
intractisternal	0	O
A	1	O
-	0	O
particles	0	O
.	0	O


The	0	O
enzymic	0	O
hydrolysis	0	O
of	0	O
urea	0	O
produces	0	O
ammonia	0	O
which	0	O
causes	0	O
a	0	O
vivid	0	O
yellow	0	O
to	0	O
purple	0	O
colour	0	O
change	0	O
in	0	O
the	0	O
pH	1	O
indicator	0	O
.	0	O


Codon	1	O
optimization	0	O
for	0	O
high	0	O
-	0	O
level	0	O
expression	0	O
of	0	O
human	0	B
erythropoietin	0	I
(	0	O
EPO	0	B
)	0	O
in	0	O
mammalian	0	O
cells	0	O
.	0	O


RegA	0	B
is	0	O
a	0	O
positive	0	O
yet	0	O
nonessential	0	O
regulator	0	O
of	0	O
tol	0	B
-	0	O
oprL	0	B
expression	0	O
.	0	O


Blood	1	O
flow	0	O
velocity	0	O
waveforms	0	O
were	0	O
recorded	0	O
by	0	O
pulsed	0	O
Doppler	1	O
examination	0	O
of	0	O
the	0	O
fetal	0	O
internal	0	O
carotid	0	O
and	0	O
middle	0	O
cerebral	0	O
arteries	0	O
using	0	O
the	0	O
established	0	O
transabdominal	0	O
route	0	O
as	0	O
well	0	O
as	0	O
a	0	O
new	0	O
transvaginal	0	O
approach	0	O
.	0	O


Small	0	O
-	0	O
molecule	0	O
control	0	O
of	0	O
insulin	0	B
and	0	O
PDGF	0	B
receptor	0	I
signaling	0	O
and	0	O
the	0	O
role	0	O
of	0	O
membrane	0	O
attachment	0	O
.	0	O


The	0	O
distributed	0	O
current	0	O
density	0	O
J	1	O
is	0	O
calculated	0	O
within	0	O
the	0	O
volume	0	O
defined	0	O
by	0	O
the	0	O
motor	0	O
unit	0	O
.	0	O


Over	0	O
a	0	O
period	0	O
of	0	O
15	0	O
days	0	O
16	0	O
%	0	O
of	0	O
the	0	O
dose	0	O
administered	0	O
was	0	O
excreted	0	O
with	0	O
faeces	0	O
and	0	O
0	0	O
.	0	O
9	0	O
%	0	O
in	0	O
the	0	O
urine	0	O
.	0	O


E	1	O
.,	0	O
Hession	0	O
,	0	O
C	1	O
.,	0	O
Goff	0	O
,	0	O
D	1	O
.,	0	O
Griffiths	0	O
,	0	O
B	1	O
.,	0	O
Tizard	0	O
,	0	O
R	1	O
.,	0	O
Newman	0	O
,	0	O
B	1	O
.,	0	O
Chi	1	O
-	0	O
Rosso	0	O
,	0	O
G	1	O
.,	0	O
and	0	O
Lobb	0	O
,	0	O
R	1	O
.,	0	O
(	0	O
1990	0	O
)	0	O
Cell	1	O
63	0	O
,	0	O
1349	0	O
-	0	O
1356	0	O
).	0	O


The	0	O
histologic	0	O
grade	0	O
for	0	O
the	0	O
same	0	O
anatomic	0	O
site	0	O
varied	0	O
among	0	O
hearts	0	O
and	0	O
among	0	O
different	0	O
anatomic	0	O
sites	0	O
in	0	O
the	0	O
same	0	O
heart	0	O
.	0	O


The	0	O
median	0	O
post	0	O
-	0	O
treatment	0	O
,	0	O
pre	0	O
-	0	O
operative	0	O
serum	0	B
PSA	1	I
was	0	O
0	0	O
.	0	O
4	0	O
ng	0	O
/	0	O
ml	0	O
.	0	O


Three	0	O
separate	0	O
activation	0	O
subdomains	0	O
,	0	O
and	0	O
one	0	O
negative	0	O
-	0	O
acting	0	O
region	0	O
,	0	O
which	0	O
function	0	O
in	0	O
yeast	0	O
were	0	O
located	0	O
in	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
region	0	O
of	0	O
NIT4	0	B
.	0	O


The	0	O
regurgitation	0	O
of	0	O
large	0	O
vitreous	0	O
injections	0	O
.	0	O


To	1	O
investigate	0	O
the	0	O
effects	0	O
of	0	O
isotretinoin	0	O
on	0	O
HDL	1	B
,	0	O
we	0	O
measured	0	O
HDL	1	B
-	0	I
C	1	I
,	0	O
HDL	1	B
phospholipids	0	O
(	0	O
HDL	1	B
-	0	I
PL	0	I
),	0	O
apoprotein	0	B
A1	0	I
(	0	O
apo	0	B
A	1	I
-	0	I
1	0	I
),	0	O
and	0	O
HDL	1	B
-	0	I
C	1	I
subfractions	0	O
(	0	O
HDL2	1	B
-	0	I
C	1	I
and	0	O
HDL3	1	B
-	0	I
C	1	I
)	0	O
in	0	O
24	0	O
healthy	0	O
,	0	O
male	0	O
patients	0	O
receiving	0	O
a	0	O
16	0	O
-	0	O
week	0	O
course	0	O
of	0	O
isotretinoin	0	O
(	0	O
1	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
)	0	O
for	0	O
treatment	0	O
of	0	O
severe	0	O
acne	0	O
vulgaris	0	O
.	0	O


This	0	O
regulation	0	O
could	0	O
not	0	O
be	0	O
appreciably	0	O
modified	0	O
by	0	O
enhanced	0	O
expression	0	O
of	0	O
STAT	1	B
proteins	0	I
.	0	O


All	1	O
our	0	O
patients	0	O
had	0	O
polyps	0	O
,	0	O
23	0	O
(	0	O
54	0	O
%)	0	O
had	0	O
asthma	0	O
,	0	O
12	0	O
(	0	O
27	0	O
%)	0	O
had	0	O
aspirin	0	O
sensitivity	0	O
,	0	O
20	0	O
(	0	O
65	0	O
%)	0	O
had	0	O
eosinophilia	0	O
,	0	O
and	0	O
9	0	O
(	0	O
69	0	O
%)	0	O
had	0	O
increased	0	O
total	0	O
IgE	1	B
levels	0	O
.	0	O


Our	0	O
results	0	O
suggest	0	O
that	0	O
protein	0	O
binding	0	O
to	0	O
the	0	O
E2F	0	B
-	0	I
like	0	I
sequences	0	I
may	0	O
act	0	O
to	0	O
reduce	0	O
expression	0	O
.	0	O


The	0	O
length	0	O
scales	0	O
of	0	O
the	0	O
turbulence	0	O
were	0	O
also	0	O
estimated	0	O
:	0	O
at	0	O
a	0	O
Reynolds	0	O
number	0	O
near	0	O
4	0	O
,	0	O
000	0	O
the	0	O
macroscale	0	O
is	0	O
about	0	O
1	0	O
.	0	O
25	0	O
mm	0	O
,	0	O
the	0	O
Taylor	0	O
microscale	0	O
is	0	O
about	0	O
0	0	O
.	0	O
85	0	O
mm	0	O
,	0	O
and	0	O
the	0	O
Kolmogoroff	0	O
scale	0	O
is	0	O
near	0	O
0	0	O
.	0	O
075	0	O
mm	0	O
.	0	O


The	0	O
location	0	O
and	0	O
approximate	0	O
length	0	O
of	0	O
the	0	O
intron	0	O
are	0	O
conserved	0	O
in	0	O
both	0	O
the	0	O
tomato	0	O
and	0	O
Arabidopsis	0	O
genes	0	O
,	0	O
with	0	O
the	0	O
intron	0	O
separating	0	O
the	0	O
'	0	O
nose	0	O
'	0	O
region	0	O
(	0	O
encoded	0	O
by	0	O
exon	0	O
1	0	O
)	0	O
from	0	O
the	0	O
central	0	O
globular	0	O
domain	0	O
(	0	O
exon	0	O
2	0	O
).	0	O


Expression	1	O
of	0	O
thiamin	0	O
biosynthetic	0	O
genes	0	O
(	0	O
thiCOGE	0	B
)	0	O
and	0	O
production	0	O
of	0	O
symbiotic	0	B
terminal	0	I
oxidase	0	I
cbb3	0	I
in	0	O
Rhizobium	1	O
etli	0	O
.	0	O


Although	0	O
a	0	O
great	0	O
deal	0	O
is	0	O
understood	0	O
about	0	O
how	0	O
bHLH	0	B
factors	0	I
activate	0	O
gene	0	O
transcription	0	O
via	0	O
E	1	O
-	0	O
box	0	O
DNA	1	O
consensus	0	O
sequences	0	O
,	0	O
studies	0	O
of	0	O
bHLH	0	B
factor	0	I
function	0	O
in	0	O
higher	0	O
eukaryotes	0	O
often	0	O
have	0	O
been	0	O
hindered	0	O
by	0	O
the	0	O
presence	0	O
of	0	O
multiple	0	O
family	0	O
members	0	O
.	0	O


Both	0	O
mutations	0	O
completely	0	O
abolished	0	O
binding	0	O
of	0	O
the	0	O
Abl	0	B
SH3	0	I
domain	0	O
to	0	O
proline	0	O
-	0	O
rich	0	O
target	0	O
proteins	0	O
in	0	O
a	0	O
filter	0	O
-	0	O
binding	0	O
assay	0	O
.	0	O


Our	0	O
results	0	O
suggest	0	O
that	0	O
Lrp	0	B
binds	0	O
a	0	O
central	0	O
palindromic	0	O
site	0	O
,	0	O
interacting	0	O
predominantly	0	O
with	0	O
the	0	O
major	0	O
groove	0	O
of	0	O
its	0	O
DNA	1	O
target	0	O
,	0	O
and	0	O
that	0	O
additional	0	O
dimers	0	O
bind	0	O
to	0	O
flanking	0	O
sites	0	O
to	0	O
form	0	O
a	0	O
nucleoprotein	0	O
activation	0	O
complex	0	O
.	0	O


Previous	0	O
work	0	O
showed	0	O
that	0	O
repA	0	B
(	0	O
initiator	0	O
protein	0	O
)	0	O
expression	0	O
requires	0	O
tap	0	B
(	0	O
leader	0	O
peptide	0	O
)	0	O
translation	0	O
.	0	O


For	0	O
colostral	0	O
milk	0	O
there	0	O
was	0	O
a	0	O
significant	0	O
correlation	0	O
of	0	O
vitamin	0	O
K1	0	O
to	0	O
cholesterol	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
62	0	O
)	0	O
but	0	O
not	0	O
to	0	O
total	0	O
lipid	0	O
or	0	O
phospholipid	0	O
suggesting	0	O
a	0	O
role	0	O
for	0	O
cholesterol	0	O
in	0	O
the	0	O
secretion	0	O
of	0	O
vitamin	0	O
K1	0	O
into	0	O
colostral	0	O
milk	0	O
.	0	O


We	0	O
determined	0	O
how	0	O
DNA	1	O
repair	0	O
is	0	O
affected	0	O
by	0	O
TFA1	0	B
conditional	0	O
mutations	0	O
.	0	O


In	1	O
view	0	O
of	0	O
these	0	O
results	0	O
,	0	O
simultaneous	0	O
pancreas	0	O
-	0	O
kidney	0	O
transplantation	0	O
appears	0	O
to	0	O
be	0	O
the	0	O
treatment	0	O
of	0	O
choice	0	O
for	0	O
Type	1	O
I	1	O
diabetic	0	O
patients	0	O
.	0	O


Radioimmunoassay	1	O
of	0	O
serum	0	O
creatine	0	B
kinase	0	I
B	1	I
isoenzyme	0	I
in	0	O
the	0	O
diagnosis	0	O
of	0	O
acute	0	O
myocardial	0	O
infarction	0	O
.	0	O


Reperfusion	1	O
with	0	O
normal	0	O
blood	0	O
in	0	O
the	0	O
beating	0	O
,	0	O
working	0	O
hearts	0	O
caused	0	O
extensive	0	O
structural	0	O
damage	0	O
,	0	O
reduced	0	O
reflow	0	O
,	0	O
and	0	O
failed	0	O
to	0	O
restore	0	O
contractility	0	O
in	0	O
any	0	O
instance	0	O
(-	0	O
27	0	O
%	0	O
systolic	0	O
shortening	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


The	0	O
first	0	O
transfusion	0	O
resulted	0	O
in	0	O
a	0	O
platelet	0	O
increment	0	O
to	0	O
32	0	O
Gpt	1	O
/	0	O
l	0	O
(	0	O
CCI	0	O
11	0	O
).	0	O


The	0	O
synthetic	0	O
DNA	1	O
sequence	0	O
was	0	O
constructed	0	O
to	0	O
achieve	0	O
efficient	0	O
base	0	O
pairing	0	O
with	0	O
Escherichia	1	B
coli	0	I
16S	0	I
ribosomal	0	I
RNA	1	I
,	0	O
avoidance	0	O
of	0	O
internal	0	O
secondary	0	O
structure	0	O
,	0	O
and	0	O
optimal	0	O
codon	0	O
usage	0	O
for	0	O
high	0	O
-	0	O
level	0	O
protein	0	O
expression	0	O
in	0	O
accord	0	O
with	0	O
the	0	O
known	0	O
preferences	0	O
in	0	O
E	1	O
.	0	O
coli	0	O
.	0	O


Rip1p	0	B
is	0	O
inessential	0	O
,	0	O
associated	0	O
with	0	O
nuclear	0	O
pore	0	O
complexes	0	O
,	0	O
and	0	O
structurally	0	O
related	0	O
to	0	O
the	0	O
FG	1	B
-	0	I
nucleoporin	0	I
family	0	I
of	0	O
pore	0	O
proteins	0	O
.	0	O


Argatroban	1	O
may	0	O
be	0	O
more	0	O
effective	0	O
under	0	O
low	0	O
HC	1	B
II	0	I
conditions	0	O
because	0	O
of	0	O
its	0	O
potent	0	O
inhibition	0	O
of	0	O
thrombin	0	B
activity	0	O
at	0	O
sites	0	O
of	0	O
vascular	0	O
wall	0	O
damage	0	O
.	0	O


Petrous	1	O
meningioma	0	O
en	0	O
plaque	0	O
presenting	0	O
as	0	O
a	0	O
right	0	O
middle	0	O
ear	0	O
tumor	0	O
.	0	O


Endoscopic	1	O
examinations	0	O
,	0	O
peripheral	0	O
white	0	O
blood	0	O
cell	0	O
(	0	O
WBC	1	O
)	0	O
counts	0	O
,	0	O
and	0	O
assays	0	O
of	0	O
myeloperoxidase	0	B
activity	0	O
(	0	O
MPO	1	B
)	0	O
in	0	O
homogenates	0	O
of	0	O
colon	0	O
mucosa	0	O
were	0	O
performed	0	O
after	0	O
one	0	O
week	0	O
(	0	O
4	0	O
%	0	O
DSS	0	O
model	0	O
)	0	O
and	0	O
eight	0	O
weeks	0	O
(	0	O
1	0	O
%	0	O
DSS	0	O
model	0	O
).	0	O


The	0	O
other	0	O
two	0	O
clones	0	O
,	0	O
Ash	1	B
-	0	I
m	0	I
and	0	I
-	0	I
s	0	I
,	0	O
had	0	O
nucleotide	0	O
sequences	0	O
identical	0	O
with	0	O
Ash	1	B
-	0	I
l	0	I
cDNA	1	O
in	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
region	0	O
.	0	O


In	1	O
this	0	O
article	0	O
,	0	O
the	0	O
clinical	0	O
actions	0	O
of	0	O
the	0	O
principal	0	O
dopamine	0	B
receptor	0	I
stimulating	0	O
agents	0	O
(	0	O
apomorphine	0	O
and	0	O
its	0	O
derivatives	0	O
;	0	O
piribedil	0	O
,	0	O
rye	0	O
-	0	O
ergot	0	O
derivatives	0	O
)	0	O
are	0	O
discussed	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
their	0	O
biochemical	0	O
and	0	O
pharmacological	0	O
properties	0	O
.	0	O


Examination	1	O
of	0	O
nuclear	0	O
magnetic	0	O
resonance	0	O
(	0	O
NMR	1	O
)	0	O
spectra	0	O
of	0	O
a	0	O
series	0	O
of	0	O
N	1	B
-	0	I
terminally	0	I
truncated	0	I
MIP	1	I
-	0	I
1	0	I
beta	0	I
variants	0	I
reveals	0	O
that	0	O
these	0	O
proteins	0	O
possess	0	O
a	0	O
range	0	O
of	0	O
ability	0	O
to	0	O
dimerize	0	O
.	0	O


Hydroxypropyl	0	O
methacrylate	0	O
,	0	O
a	0	O
new	0	O
water	0	O
-	0	O
miscible	0	O
embedding	0	O
medium	0	O
for	0	O
electron	0	O
microscopy	0	O
.	0	O


These	0	O
results	0	O
show	0	O
that	0	O
targeting	0	O
of	0	O
Ras	1	B
-	0	O
GAP	1	B
could	0	O
represent	0	O
a	0	O
novel	0	O
anticancer	0	O
approach	0	O
.	0	O


The	0	O
COOH	0	O
-	0	O
terminal	0	O
46	0	O
codons	0	O
of	0	O
slyD	0	B
encode	0	O
a	0	O
remarkable	0	O
histidine	0	O
-	0	O
rich	0	O
peptide	0	O
sequence	0	O
which	0	O
is	0	O
at	0	O
least	0	O
partly	0	O
dispensable	0	O
for	0	O
slyD	0	B
function	0	O
in	0	O
E	1	B
-	0	O
mediated	0	O
lysis	0	O
.	0	O


USA	0	O
80	0	O
,	0	O
3618	0	O
-	0	O
3622	0	O
)	0	O
The	0	O
two	0	O
proteins	0	O
show	0	O
36	0	O
%	0	O
identities	0	O
in	0	O
their	0	O
amino	0	O
acid	0	O
sequence	0	O
,	0	O
in	0	O
an	0	O
alignment	0	O
requiring	0	O
six	0	O
gaps	0	O
.	0	O


After	0	O
nitric	0	O
oxide	0	O
inhalation	0	O
,	0	O
the	0	O
results	0	O
showed	0	O
moderate	0	O
increases	0	O
in	0	O
PaO2	1	O
and	0	O
SaO2	1	O
(	0	O
P	1	O
>	0	O
0	0	O
.	0	O
05	0	O
)	0	O
and	0	O
a	0	O
significant	0	O
decrease	0	O
in	0	O
Qs	0	O
/	0	O
Q	1	O
tau	0	O
ratio	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Southern	0	O
blotting	0	O
and	0	O
single	0	O
strand	0	O
conformation	0	O
polymorphism	0	O
analyses	0	O
did	0	O
not	0	O
show	0	O
tumor	0	O
-	0	O
specific	0	O
alterations	0	O
of	0	O
this	0	O
gene	0	O
in	0	O
gliomas	0	O
and	0	O
RT	1	O
-	0	O
PCR	1	O
studies	0	O
showed	0	O
expression	0	O
in	0	O
glioma	0	O
cell	0	O
lines	0	O
,	0	O
suggesting	0	O
that	0	O
ANOVA	1	B
is	0	O
not	0	O
the	0	O
chromosome	0	O
19q	0	O
glioma	0	O
tumor	0	O
suppressor	0	O
gene	0	O
.	0	O


The	0	O
first	0	O
involved	0	O
complementation	0	O
of	0	O
a	0	O
nonphotosynthetic	0	O
mutant	0	O
of	0	O
Chlamydomonas	0	O
,	0	O
CC	1	O
-	0	O
2341	0	O
(	0	O
ac	0	O
-	0	O
u	0	O
-	0	O
g	0	O
-	0	O
2	0	O
.	0	O
3	0	O
),	0	O
which	0	O
has	0	O
a	0	O
frameshift	0	O
mutation	0	O
in	0	O
the	0	O
psaB	0	B
gene	0	I
,	0	O
and	0	O
selection	0	O
of	0	O
photosynthetic	0	O
transformants	0	O
on	0	O
minimal	0	O
medium	0	O
.	0	O


Southern	0	O
blotting	0	O
analysis	0	O
implied	0	O
the	0	O
occurrence	0	O
of	0	O
multiple	0	O
COXVb	0	B
genes	0	I
in	0	O
the	0	O
rat	0	O
genome	0	O
.	0	O


Human	1	B
MGP	0	I
is	0	O
a	0	O
10	0	B
-	0	I
kD	1	I
skeletal	0	I
extracellular	0	I
matrix	0	I
(	0	I
ECM	1	I
)	0	I
protein	0	I
that	0	O
consists	0	O
of	0	O
an	0	O
84	0	O
-	0	O
aa	0	O
mature	0	O
protein	0	O
and	0	O
a	0	O
19	0	O
-	0	O
aa	0	O
transmembrane	0	O
signal	0	O
peptide	0	O
.	0	O


Similarities	0	O
between	0	O
the	0	O
hIGFBP	0	B
-	0	I
1	0	I
and	0	O
phosphoenolpyruvate	0	B
kinase	0	I
(	0	O
PEPCK	0	B
)	0	O
promoters	0	O
,	0	O
including	0	O
regions	0	O
conferring	0	O
insulin	0	B
,	0	O
glucocorticoid	0	O
,	0	O
and	0	O
cyclic	0	O
adenosine	0	O
-	0	O
monophosphate	0	O
responses	0	O
,	0	O
are	0	O
consistent	0	O
with	0	O
our	0	O
previous	0	O
hypothesis	0	O
that	0	O
IGFBP	0	B
-	0	I
1	0	I
is	0	O
involved	0	O
in	0	O
regulation	0	O
of	0	O
glucose	0	O
metabolism	0	O
.	0	O


In	1	O
line	0	O
with	0	O
the	0	O
small	0	O
values	0	O
for	0	O
QS	0	O
/	0	O
QC	0	O
,	0	O
our	0	O
results	0	O
further	0	O
indicate	0	O
that	0	O
even	0	O
large	0	O
,	0	O
well	0	O
-	0	O
perfused	0	O
,	0	O
occluded	0	O
air	0	O
spaces	0	O
in	0	O
the	0	O
lung	0	O
will	0	O
hardly	0	O
affect	0	O
the	0	O
recovered	0	O
ventilation	0	O
/	0	O
perfusion	0	O
distribution	0	O
obtained	0	O
from	0	O
inert	0	O
gas	0	O
data	0	O
when	0	O
CDCSF6	0	O
exceeds	0	O
0	0	O
.	0	O
1	0	O
ml	0	O
.	0	O
min	0	O
-	0	O
1	0	O
.	0	O
mmHg	0	O
-	0	O
1	0	O
.	0	O


Disorders	0	O
of	0	O
platelet	0	O
function	0	O
in	0	O
chronic	0	O
myeloid	0	O
leukemias	0	O


Plasma	1	O
,	0	O
LDL	1	B
and	0	O
liver	0	O
cholesterol	0	O
concentrations	0	O
were	0	O
higher	0	O
in	0	O
the	0	O
hyperlipidemic	0	O
control	0	O
than	0	O
the	0	O
nonhyperlipidemic	0	O
control	0	O
and	0	O
lower	0	O
in	0	O
the	0	O
groups	0	O
fed	0	O
diets	0	O
containing	0	O
pectin	0	B
or	0	O
prune	0	O
fiber	0	O
than	0	O
in	0	O
the	0	O
hyperlipidemic	0	O
control	0	O
group	0	O
.	0	O


Although	0	O
the	0	O
gene	0	O
is	0	O
substantially	0	O
smaller	0	O
than	0	O
the	0	O
human	0	O
genes	0	O
for	0	O
other	0	O
mitochondrial	0	O
enzymes	0	O
,	0	O
its	0	O
intron	0	O
/	0	O
exon	0	O
organization	0	O
is	0	O
very	0	O
similar	0	O
,	0	O
especially	0	O
to	0	O
that	0	O
of	0	O
P450scc	1	B
.	0	O


In	1	O
sixteen	0	O
patients	0	O
with	0	O
moderate	0	O
essential	0	O
hypertension	0	O
the	0	O
effects	0	O
of	0	O
10	0	O
-	0	O
day	0	O
nifedipine	0	O
treatment	0	O
on	0	O
serum	0	O
uric	0	O
acid	0	O
and	0	O
renal	0	O
excretion	0	O
of	0	O
uric	0	O
acid	0	O
were	0	O
evaluated	0	O
.	0	O


Sprague	0	O
-	0	O
Dawley	0	O
newborn	0	O
rats	0	O
(	0	O
n	0	O
=	0	O
85	0	O
)	0	O
breathed	0	O
100	0	O
%	0	O
oxygen	0	O
(	0	O
O2	1	O
)	0	O
or	0	O
room	0	O
air	0	O
(	0	O
RA	1	O
)	0	O
during	0	O
the	0	O
first	0	O
8	0	O
days	0	O
of	0	O
life	0	O
,	0	O
and	0	O
then	0	O
RA	1	O
.	0	O


Animal	1	O
studies	0	O
showed	0	O
that	0	O
beam	0	O
equalization	0	O
significantly	0	O
improved	0	O
fluoroscopic	0	O
and	0	O
angiographic	0	O
image	0	O
quality	0	O
.	0	O


CONCLUSION	0	O
:	0	O
These	0	O
findings	0	O
imply	0	O
that	0	O
eotaxin	0	O
either	0	O
is	0	O
mechanistically	0	O
involved	0	O
in	0	O
acute	0	O
asthma	0	O
or	0	O
serves	0	O
as	0	O
a	0	O
biomarker	0	O
for	0	O
activity	0	O
of	0	O
the	0	O
CCR3	0	B
receptor	0	I
ligand	0	I
system	0	O
,	0	O
which	0	O
is	0	O
functionally	0	O
linked	0	O
to	0	O
asthma	0	O
.	0	O


Histological	1	O
examination	0	O
revealed	0	O
a	0	O
small	0	O
simple	0	O
renal	0	O
cyst	0	O
associated	0	O
with	0	O
renal	0	O
cell	0	O
carcinoma	0	O
.	0	O


Feed	0	O
intake	0	O
was	0	O
not	0	O
affected	0	O
by	0	O
dietary	0	O
KCl	1	O
or	0	O
NaHCO3	1	O
supplementation	0	O
,	0	O
but	0	O
average	0	O
daily	0	O
gain	0	O
increased	0	O
with	0	O
increased	0	O
K	1	O
and	0	O
tended	0	O
to	0	O
be	0	O
reduced	0	O
by	0	O
dietary	0	O
NaHCO3	1	O
.	0	O


Expression	1	O
and	0	O
characterization	0	O
of	0	O
recombinant	0	B
single	0	I
-	0	I
chain	0	I
Fv	0	I
and	0	O
Fv	0	B
fragments	0	I
derived	0	O
from	0	O
a	0	O
set	0	O
of	0	O
catalytic	0	O
antibodies	0	O
.	0	O


Downstream	1	O
of	0	O
the	0	O
G	1	O
-	0	O
A	1	O
anastomosis	0	O
,	0	O
the	0	O
RD	1	O
,	0	O
CC	1	O
,	0	O
E	1	O
(	0	O
p	0	O
)	0	O
and	0	O
loop	0	O
areas	0	O
were	0	O
significantly	0	O
different	0	O
from	0	O
REF	0	O
,	0	O
but	0	O
significantly	0	O
different	0	O
from	0	O
A	1	O
-	0	O
A	1	O
.	0	O


Pharmacological	1	O
desympathization	0	O
leads	0	O
to	0	O
the	0	O
development	0	O
of	0	O
hyper	0	O
-	0	O
reactivity	0	O
of	0	O
the	0	O
true	0	O
pacemakers	0	O
to	0	O
noradrenaline	0	O
and	0	O
dopamine	0	O
and	0	O
triggers	0	O
off	0	O
changes	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
the	0	O
electric	0	O
activity	0	O
of	0	O
these	0	O
cells	0	O
by	0	O
catecholamines	0	O
.	0	O


The	0	O
positive	0	O
-	0	O
acting	0	O
global	0	O
sulfur	0	O
regulatory	0	O
protein	0	O
,	0	O
CYS3	0	B
,	0	O
of	0	O
Neurospora	1	O
crassa	0	O
turns	0	O
on	0	O
the	0	O
expression	0	O
of	0	O
a	0	O
family	0	O
of	0	O
unlinked	0	O
structural	0	O
genes	0	O
that	0	O
encode	0	O
enzymes	0	O
of	0	O
sulfur	0	O
catabolism	0	O
.	0	O


We	0	O
have	0	O
screened	0	O
the	0	O
mouse	0	O
cDNA	1	O
library	0	O
of	0	O
an	0	O
MIN6	0	O
cell	0	O
line	0	O
,	0	O
derived	0	O
from	0	O
pancreatic	0	O
beta	0	O
cells	0	O
,	0	O
for	0	O
its	0	O
novel	0	O
isoform	0	O
and	0	O
have	0	O
identified	0	O
a	0	O
cDNA	1	O
encoding	0	O
a	0	O
593	0	O
-	0	O
amino	0	O
acid	0	O
protein	0	O
having	0	O
63	0	O
,	0	O
53	0	O
,	0	O
and	0	O
30	0	O
%	0	O
identity	0	O
with	0	O
munc	0	B
-	0	I
18	0	I
/	0	I
n	0	I
-	0	I
Sec1	0	I
/	0	I
rbSec1	0	I
,	0	O
Caenorhabditis	0	B
elegans	0	I
unc18	0	I
,	0	O
and	0	O
Saccharomyces	1	B
cerevisiae	0	I
Sec1p	0	I
,	0	O
respectively	0	O
.	0	O


Homologous	1	O
recombination	0	O
between	0	O
the	0	O
Autographa	0	O
californica	0	O
nuclear	0	O
polyhedrosis	0	O
virus	0	O
(	0	O
AcNPV	0	O
)	0	O
genome	0	O
and	0	O
a	0	O
0	0	O
.	0	O
6	0	O
-	0	O
kbp	0	O
-	0	O
long	0	O
DNA	1	O
fragment	0	O
derived	0	O
from	0	O
the	0	O
putative	0	O
DNA	1	B
helicase	0	I
gene	0	I
of	0	I
Bombyx	1	I
mori	0	I
nuclear	0	I
polyhedrosis	0	I
virus	0	I
generates	0	O
eh2	0	O
-	0	O
AcNPV	0	O
,	0	O
an	0	O
expanded	0	O
-	0	O
host	0	O
-	0	O
range	0	O
AcNPV	0	O
mutant	0	O
(	0	O
S	1	O
.	0	O


Not	0	O
even	0	O
extensive	0	O
pancreatic	0	O
resection	0	O
could	0	O
prevent	0	O
pancreatic	0	O
remnant	0	O
infection	0	O
.	0	O


The	0	O
seco	0	O
-	0	O
steroid	0	O
hormone	0	O
1	0	O
,	0	O
25	0	O
-	0	O
dihydroxyvitamin	0	O
D3	0	O
is	0	O
known	0	O
to	0	O
induce	0	O
the	0	O
expression	0	O
of	0	O
a	0	O
calcium	0	O
binding	0	O
protein	0	O
termed	0	O
calbindin	0	B
-	0	I
D28K	0	I
in	0	O
a	0	O
variety	0	O
of	0	O
target	0	O
tissues	0	O
.	0	O


RNA	1	B
polymerase	0	I
bound	0	O
to	0	O
the	0	O
+	0	O
10A	0	O
promoter	0	O
partially	0	O
protects	0	O
a	0	O
20	0	O
base	0	O
-	0	O
pair	0	O
sequence	0	O
from	0	O
DNase	1	B
I	1	I
digestion	0	O
upstream	0	O
of	0	O
the	0	O
start	0	O
site	0	O
.	0	O


Type	1	B
2	0	I
deiodinase	0	I
(	0	O
D2	0	B
)	0	O
catalyzes	0	O
the	0	O
5	0	O
'-	0	O
deiodination	0	O
of	0	O
thyroxine	0	O
to	0	O
form	0	O
3	0	O
,	0	O
5	0	O
,	0	O
3	0	O
'-	0	O
triiodothyronine	0	O
.	0	O


However	0	O
,	0	O
when	0	O
combined	0	O
with	0	O
mitomycin	0	O
C	1	O
given	0	O
with	0	O
1	0	O
to	0	O
5	0	O
-	0	O
days	0	O
interval	0	O
,	0	O
the	0	O
concurrent	0	O
administration	0	O
of	0	O
SPG	0	O
prolonged	0	O
significantly	0	O
the	0	O
life	0	O
-	0	O
span	0	O
of	0	O
the	0	O
tumor	0	O
-	0	O
bearing	0	O
mice	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
the	0	O
promoter	0	O
region	0	O
showed	0	O
no	0	O
TATA	0	O
box	0	O
but	0	O
identified	0	O
consensus	0	O
binding	0	O
motifs	0	O
for	0	O
Sp1	0	B
,	0	O
CREB	0	B
,	0	O
and	0	O
half	0	O
sites	0	O
of	0	O
the	0	O
estrogen	0	B
receptor	0	I
binding	0	I
site	0	I
.	0	O


Brucellosis	1	O
--	0	O
1990	0	O


We	0	O
report	0	O
here	0	O
the	0	O
identification	0	O
of	0	O
a	0	O
cDNA	1	O
that	0	O
encodes	0	O
a	0	O
new	0	O
member	0	O
of	0	O
the	0	O
GTPase	1	B
-	0	I
activating	0	I
protein	0	I
(	0	O
GAP	1	B
)	0	O
family	0	O
of	0	O
GTPase	1	B
regulators	0	O
.	0	O


Furthermore	0	O
,	0	O
we	0	O
showed	0	O
that	0	O
the	0	O
IL	1	B
-	0	I
6	0	I
/	0	O
interferon	0	B
gamma	0	I
(	0	O
IFN	1	B
gamma	0	I
)	0	O
response	0	O
element	0	O
in	0	O
the	0	O
IRF	1	B
-	0	I
1	0	I
promoter	0	I
(	0	O
IR	1	B
/	0	O
IRF	1	B
-	0	I
1	0	I
),	0	O
which	0	O
contains	0	O
a	0	O
Stat	1	B
-	0	I
binding	0	I
site	0	I
and	0	O
an	0	O
adjacent	0	O
CRE	0	O
-	0	O
like	0	O
site	0	O
,	0	O
also	0	O
makes	0	O
IL	1	B
-	0	I
6	0	I
-	0	O
induced	0	O
binding	0	O
complexes	0	O
similar	0	O
to	0	O
JRE	0	O
-	0	O
IL6	0	B
-	0	O
BCs	0	O
.	0	O


However	0	O
,	0	O
mandibular	0	O
position	0	O
(	0	O
S	1	O
-	0	O
N	1	O
-	0	O
B	1	O
and	0	O
S	1	O
-	0	O
N	1	O
-	0	O
Pog	0	O
)	0	O
was	0	O
found	0	O
to	0	O
be	0	O
significantly	0	O
more	0	O
retrusive	0	O
in	0	O
Class	1	O
II	0	O
when	0	O
compared	0	O
with	0	O
Class	1	O
I	1	O
subjects	0	O
.	0	O


In	1	O
addition	0	O
to	0	O
the	0	O
significant	0	O
reduction	0	O
in	0	O
blood	0	O
pressure	0	O
,	0	O
the	0	O
angiotensin	0	B
converting	0	I
enzyme	0	I
(	0	O
ACE	1	B
)	0	O
inhibitor	0	O
ramipril	0	O
caused	0	O
a	0	O
significant	0	O
regression	0	O
of	0	O
pathologic	0	O
left	0	O
ventricular	0	O
hypertrophy	0	O
demonstrated	0	O
by	0	O
magnetic	0	O
resonance	0	O
imaging	0	O
and	0	O
echocardiography	0	O
.	0	O


The	0	O
transverse	0	O
magnetization	0	O
decays	0	O
mentioned	0	O
above	0	O
exhibited	0	O
two	0	O
components	0	O
,	0	O
a	0	O
T2	0	O
fast	0	O
(	0	O
T2f	0	O
)	0	O
and	0	O
a	0	O
T2	0	O
slow	0	O
(	0	O
T2s	0	O
)	0	O
component	0	O
.	0	O


Thus	0	O
,	0	O
depending	0	O
on	0	O
their	0	O
location	0	O
,	0	O
psoralen	0	O
cross	0	O
-	0	O
links	0	O
affected	0	O
different	0	O
steps	0	O
in	0	O
the	0	O
initiation	0	O
process	0	O
.	0	O


METHODS	0	O
:	0	O
T2	0	O
*-	0	O
weighted	0	O
,	0	O
three	0	O
-	0	O
dimensional	0	O
gradient	0	O
-	0	O
echo	0	O
images	0	O
were	0	O
acquired	0	O
by	0	O
exploiting	0	O
the	0	O
magnetic	0	O
susceptibility	0	O
difference	0	O
between	0	O
oxygenated	0	O
and	0	O
deoxygenated	0	O
hemoglobin	0	B
in	0	O
the	0	O
vasculature	0	O
and	0	O
microvasculature	0	O
.	0	O


Our	0	O
results	0	O
support	0	O
a	0	O
model	0	O
where	0	O
both	0	O
E2F	0	B
-	0	O
and	0	O
CDE	1	O
-	0	O
mediated	0	O
repression	0	O
,	0	O
acting	0	O
at	0	O
different	0	O
stages	0	O
in	0	O
the	0	O
cell	0	O
cycle	0	O
,	0	O
are	0	O
dependent	0	O
on	0	O
promoter	0	O
-	0	O
specific	0	O
CHR	1	O
elements	0	O
.	0	O


D	1	O
.	0	O


To	1	O
map	0	O
this	0	O
regulatory	0	O
serine	0	O
phosphorylation	0	O
site	0	O
we	0	O
developed	0	O
a	0	O
baculovirus	0	O
-	0	O
mediated	0	O
expression	0	O
system	0	O
for	0	O
wild	0	B
-	0	I
type	0	I
annexin	0	I
II	0	I
and	0	O
for	0	O
a	0	O
series	0	O
of	0	O
annexin	0	B
II	0	I
mutants	0	I
which	0	O
contained	0	O
substitutions	0	O
in	0	O
one	0	O
or	0	O
more	0	O
serine	0	O
residues	0	O
present	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
.	0	O


The	0	O
hBRAG	0	B
gene	0	I
was	0	O
localized	0	O
to	0	O
the	0	O
long	0	O
arm	0	O
of	0	O
chromosome	0	O
10	0	O
(	0	O
10q26	0	O
).	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
affinities	0	O
of	0	O
CBF2	0	B
for	0	O
binding	0	O
to	0	O
the	0	O
LMP	1	B
-	0	I
1	0	I
,	0	O
LMP	1	B
-	0	I
2	0	I
,	0	O
and	0	O
CD23	0	B
promoters	0	I
were	0	O
also	0	O
measured	0	O
.	0	O


We	0	O
have	0	O
cloned	0	O
and	0	O
sequenced	0	O
a	0	O
3574	0	O
-	0	O
bp	0	O
Bacillus	1	O
subtilis	0	O
(	0	O
Bs	1	O
)	0	O
DNA	1	O
fragment	0	O
located	0	O
between	0	O
the	0	O
nrdA	0	B
and	0	O
citB	0	B
genes	0	I
at	0	O
about	0	O
169	0	O
degrees	0	O
on	0	O
the	0	O
chromosome	0	O
.	0	O


Deletion	1	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
-	0	O
321	0	O
/+	0	O
41	0	O
sequence	0	O
was	0	O
sufficient	0	O
for	0	O
both	0	O
the	0	O
constitutive	0	O
promoter	0	O
activity	0	O
and	0	O
auto	0	O
-	0	O
activation	0	O
and	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assays	0	O
identified	0	O
the	0	O
interaction	0	O
of	0	O
C	1	B
/	0	I
EBPs	0	I
and	0	O
Sp1	0	B
to	0	O
this	0	O
region	0	O
.	0	O


Therapeutic	1	O
use	0	O
of	0	O
continuous	0	O
subcutaneous	0	O
infusion	0	O
of	0	O
recombinant	0	B
human	0	I
erythropoietin	0	I
in	0	O
malnourished	0	O
predialysis	0	O
anemic	0	O
patients	0	O
with	0	O
diabetic	0	O
nephropathy	0	O
.	0	O


We	0	O
evaluated	0	O
regional	0	O
right	0	O
ventricular	0	O
wall	0	O
motion	0	O
during	0	O
systole	0	O
in	0	O
patients	0	O
with	0	O
surgically	0	O
repaired	0	O
tetralogy	0	O
of	0	O
Fallot	0	O
(	0	O
TOF	1	O
)	0	O
using	0	O
color	0	O
kinesis	0	O
imaging	0	O
.	0	O


The	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
exhibited	0	O
70	0	O
%	0	O
identity	0	O
to	0	O
that	0	O
of	0	O
Bacillus	1	B
stearothermophilus	0	I
TyrTS	0	I
and	0	O
55	0	O
%	0	O
identity	0	O
to	0	O
that	0	O
of	0	O
E	1	B
.	0	I
coli	0	I
TyrTS	0	I
,	0	O
while	0	O
identity	0	O
to	0	O
a	0	O
second	0	O
cryptic	0	O
B	1	B
.	0	I
subtilis	0	I
TyrTS	0	I
gene	0	I
,	0	O
designated	0	O
tyrZ	0	B
,	0	O
was	0	O
only	0	O
27	0	O
%.	0	O


Comparison	0	O
with	0	O
the	0	O
bovine	0	O
gene	0	O
showed	0	O
that	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
hATP1	0	B
gene	0	I
has	0	O
an	0	O
unconserved	0	O
guanine	0	O
-	0	O
cytosine	0	O
(	0	O
GC	1	O
)	0	O
rich	0	O
region	0	O
,	0	O
including	0	O
several	0	O
binding	0	O
motifs	0	O
of	0	O
transcriptional	0	O
factors	0	O
,	0	O
such	0	O
as	0	O
Sp1	0	B
,	0	O
AP	1	B
-	0	I
2	0	I
,	0	O
and	0	O
GCF	0	B
.	0	O


The	0	O
coordinated	0	O
expression	0	O
of	0	O
CD4	1	B
and	0	O
CD8	0	B
during	0	O
T	1	O
-	0	O
cell	0	O
development	0	O
is	0	O
tightly	0	O
coupled	0	O
with	0	O
the	0	O
maturation	0	O
state	0	O
of	0	O
the	0	O
T	1	O
cell	0	O
.	0	O


However	0	O
,	0	O
F	1	B
-	0	I
SRC	1	I
-	0	I
1	0	I
mutant	0	I
lacking	0	O
CBP	0	B
-	0	I
interacting	0	I
domain	0	I
still	0	O
preserved	0	O
enhancing	0	O
activity	0	O
.	0	O


Internal	1	O
amino	0	O
acid	0	O
sequence	0	O
has	0	O
now	0	O
been	0	O
obtained	0	O
from	0	O
this	0	O
protein	0	O
which	0	O
shares	0	O
50	0	O
-	0	O
100	0	O
%	0	O
sequence	0	O
identity	0	O
with	0	O
sequences	0	O
encoded	0	O
by	0	O
mammalian	0	B
G	1	I
alpha	0	I
11	0	I
and	0	O
G	1	B
alpha	0	I
q	0	I
cDNAs	0	I
.	0	O


Clinical	1	O
and	0	O
anatomical	0	O
considerations	0	O


The	0	O
close	0	O
proximity	0	O
of	0	O
the	0	O
two	0	O
neuropeptide	0	B
Y	1	I
receptor	0	I
genes	0	I
suggests	0	O
that	0	O
they	0	O
have	0	O
evolved	0	O
from	0	O
a	0	O
gene	0	O
duplication	0	O
event	0	O
with	0	O
the	0	O
small	0	O
intron	0	O
interrupting	0	O
the	0	O
coding	0	O
sequence	0	O
of	0	O
the	0	O
y1	0	B
gene	0	I
being	0	O
converted	0	O
into	0	O
a	0	O
functional	0	O
sequence	0	O
within	0	O
the	0	O
y5	0	B
gene	0	I
,	0	O
while	0	O
the	0	O
reverse	0	O
complementary	0	O
sequence	0	O
was	0	O
utilized	0	O
as	0	O
an	0	O
alternatively	0	O
spliced	0	O
5	0	O
'	0	O
exon	0	O
for	0	O
the	0	O
y1	0	B
gene	0	I
.	0	O


Human	1	B
neuronal	0	I
Elav	0	I
-	0	I
like	0	I
proteins	0	I
contain	0	O
three	0	O
RNP	1	O
-	0	O
type	0	O
RNA	1	O
recognition	0	O
motifs	0	O
(	0	O
RRMs	0	O
).	0	O


Pulmonary	1	O
vascular	0	O
resistance	0	O
was	0	O
not	0	O
altered	0	O
,	0	O
ejection	0	O
fraction	0	O
remained	0	O
unchanged	0	O
and	0	O
isovolumic	0	O
relaxation	0	O
period	0	O
was	0	O
lengthened	0	O
(	0	O
119	0	O
+/-	0	O
20	0	O
.	0	O
1	0	O
to	0	O
147	0	O
.	0	O
39	0	O
+/-	0	O
21	0	O
.	0	O
15	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Further	0	O
,	0	O
they	0	O
are	0	O
consistent	0	O
with	0	O
the	0	O
suggestion	0	O
that	0	O
sites	0	O
homologous	0	O
to	0	O
the	0	O
CAR1	0	B
URS	0	I
may	0	O
be	0	O
situated	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
regions	0	O
of	0	O
multiple	0	O
unrelated	0	O
yeast	0	O
genes	0	O
.	0	O


High	0	O
values	0	O
of	0	O
both	0	O
retinol	0	O
and	0	O
beta	0	O
-	0	O
carotene	0	O
were	0	O
found	0	O
in	0	O
full	0	O
fat	0	O
cheeses	0	O
and	0	O
whipping	0	O
cream	0	O
:	0	O
from	0	O
179	0	O
.	0	O
0	0	O
(	0	O
cheese	0	O
,	0	O
Edam	0	O
-	0	O
type	0	O
)	0	O
to	0	O
318	0	O
.	0	O
7	0	O
micrograms	0	O
/	0	O
100	0	O
g	0	O
(	0	O
whipping	0	O
cream	0	O
)	0	O
and	0	O
from	0	O
86	0	O
.	0	O
7	0	O
(	0	O
cheese	0	O
,	0	O
Edam	0	O
-	0	O
type	0	O
)	0	O
to	0	O
186	0	O
.	0	O
5	0	O
micrograms	0	O
/	0	O
100	0	O
g	0	O
(	0	O
whipping	0	O
cream	0	O
)	0	O
for	0	O
all	0	O
-	0	O
trans	0	O
retinol	0	O
and	0	O
total	0	O
beta	0	O
-	0	O
carotene	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
mean	0	O
value	0	O
of	0	O
the	0	O
CD79b	0	B
to	0	O
the	0	O
CD79b	0	B
internally	0	O
deleted	0	O
ratio	0	O
was	0	O
0	0	O
.	0	O
64	0	O
+/-	0	O
0	0	O
.	0	O
20	0	O
SD	1	O
in	0	O
normal	0	O
donors	0	O
and	0	O
0	0	O
.	0	O
44	0	O
+/-	0	O
0	0	O
.	0	O
27	0	O
SD	1	O
in	0	O
B	1	O
-	0	O
CLL	1	O
(	0	O
P	1	O
=.	0	O
01	0	O
).	0	O


Naturally	0	O
acquired	0	O
antibodies	0	O
were	0	O
demonstrated	0	O
in	0	O
some	0	O
rabbits	0	O
kept	0	O
on	0	O
commercial	0	O
farms	0	O
.	0	O


Computer	0	O
analysis	0	O
included	0	O
digital	0	O
averaging	0	O
,	0	O
followed	0	O
by	0	O
digital	0	O
filtering	0	O
in	0	O
different	0	O
frequency	0	O
bands	0	O
in	0	O
order	0	O
to	0	O
determine	0	O
the	0	O
frequency	0	O
range	0	O
corresponding	0	O
to	0	O
notches	0	O
and	0	O
slurs	0	O
.	0	O


After	0	O
a	0	O
baseline	0	O
study	0	O
,	0	O
WPW	0	O
syndrome	0	O
was	0	O
simulated	0	O
by	0	O
stimulation	0	O
at	0	O
seven	0	O
different	0	O
sites	0	O
around	0	O
the	0	O
base	0	O
of	0	O
the	0	O
ventricles	0	O
,	0	O
and	0	O
RNV	0	O
'	0	O
s	0	O
were	0	O
obtained	0	O
.	0	O


The	0	O
normal	0	O
cell	0	O
cycle	0	O
is	0	O
regulated	0	O
by	0	O
several	0	O
molecules	0	O
,	0	O
such	0	O
as	0	O
the	0	O
tumor	0	B
-	0	I
suppressor	0	I
protein	0	I
pRb	0	I
,	0	O
the	0	O
G1	0	B
cyclins	0	I
,	0	O
the	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinases	0	I
,	0	O
and	0	O
their	0	O
inhibitors	0	O
.	0	O


Chronic	1	O
administration	0	O
of	0	O
sodium	0	O
cyanate	0	O
decreases	0	O
O2	1	O
extraction	0	O
ratio	0	O
in	0	O
dogs	0	O
.	0	O


Mibefradil	0	O
(	0	O
Ro	0	O
40	0	O
-	0	O
5967	0	O
)	0	O
is	0	O
a	0	O
novel	0	O
calcium	0	O
antagonist	0	O
from	0	O
a	0	O
new	0	O
chemical	0	O
class	0	O
and	0	O
is	0	O
the	0	O
first	0	O
that	0	O
selectively	0	O
blocks	0	O
the	0	O
T	1	O
-	0	O
type	0	O
calcium	0	O
channel	0	O
.	0	O


Degenerate	1	O
primers	0	O
homologous	0	O
to	0	O
highly	0	O
conserved	0	O
regions	0	O
of	0	O
known	0	O
CYP3A	0	B
sequences	0	I
were	0	O
used	0	O
for	0	O
initial	0	O
RT	1	O
-	0	O
PCRs	0	O
.	0	O


Effects	0	O
of	0	O
estradiol	0	O
on	0	O
worm	0	O
burden	0	O
and	0	O
peripheral	0	O
leukocytes	0	O
in	0	O
Parastrongylus	1	O
malaysiensis	0	O
-	0	O
infected	0	O
rats	0	O
.	0	O


Opposite	0	O
effects	0	O
of	0	O
CYP1	0	B
are	0	O
observed	0	O
in	0	O
aerobic	0	O
,	0	O
heme	0	O
-	0	O
sufficient	0	O
cells	0	O
.	0	O


There	0	O
occurred	0	O
a	0	O
linear	0	O
relationship	0	O
between	0	O
the	0	O
drop	0	O
in	0	O
glucose	0	B
-	0	I
6	0	I
-	0	I
phosphatase	0	I
dehydrogenase	0	I
activity	0	O
and	0	O
in	0	O
vitamin	0	O
E	1	O
level	0	O
,	0	O
on	0	O
one	0	O
hand	0	O
,	0	O
and	0	O
the	0	O
duration	0	O
of	0	O
poisoning	0	O
with	0	O
sodium	0	O
nitrite	0	O
.	0	O


The	0	O
STAT	1	B
protein	0	I
accumulation	0	O
resulting	0	O
from	0	O
C	1	B
/	0	I
EBP	1	I
expression	0	O
was	0	O
tightly	0	O
coupled	0	O
to	0	O
the	0	O
morphological	0	O
conversion	0	O
of	0	O
fibroblasts	0	O
to	0	O
adipocytes	0	O
and	0	O
represents	0	O
an	0	O
expression	0	O
profile	0	O
identical	0	O
to	0	O
that	0	O
reported	0	O
for	0	O
mature	0	O
adipocytes	0	O
in	0	O
vivo	0	O
.	0	O


The	0	O
levels	0	O
of	0	O
transactivation	0	O
are	0	O
correlated	0	O
with	0	O
the	0	O
respective	0	O
binding	0	O
affinities	0	O
of	0	O
the	0	O
response	0	O
elements	0	O
(	0	O
IRper	0	O
-	0	O
1	0	O
>	0	O
DR	1	O
-	0	O
4	0	O
>	0	O
IRhsp	0	O
-	0	O
1	0	O
).	0	O


Previous	0	O
studies	0	O
have	0	O
shown	0	O
[	0	O
Hisanaga	0	O
,	0	O
S	1	O
.,	0	O
Kusubata	0	O
,	0	O
M	1	O
.,	0	O
Okumura	0	O
,	0	O
E	1	O
.	0	O
&	0	O
Kishimoto	0	O
,	0	O
T	1	O
.	0	O


Kss1	0	B
binds	0	O
specifically	0	O
to	0	O
a	0	O
GST	0	B
-	0	O
Dig1	0	B
fusion	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
any	0	O
other	0	O
yeast	0	O
protein	0	O
.	0	O


Furthermore	0	O
,	0	O
binding	0	O
of	0	O
recombinant	0	B
Myb	0	I
and	0	O
Ets	1	B
-	0	I
2	0	I
protein	0	I
to	0	O
these	0	O
fragments	0	O
could	0	O
be	0	O
competed	0	O
with	0	O
an	0	O
excess	0	O
of	0	O
double	0	O
stranded	0	O
oligodeoxynucleotides	0	O
containing	0	O
canonical	0	O
,	0	O
but	0	O
not	0	O
mutated	0	O
,	0	O
Myb	0	B
-	0	O
or	0	O
Ets	1	B
-	0	I
binding	0	I
sites	0	I
.	0	O


As	1	O
such	0	O
the	0	O
findings	0	O
support	0	O
existing	0	O
studies	0	O
that	0	O
have	0	O
identified	0	O
given	0	O
social	0	O
characteristics	0	O
of	0	O
drink	0	O
drivers	0	O
.	0	O


A	1	O
transcription	0	O
factor	0	O
exclusion	0	O
assay	0	O
was	0	O
used	0	O
to	0	O
show	0	O
that	0	O
the	0	O
PCF1	0	B
mutation	0	I
affects	0	O
two	0	O
distinct	0	O
stages	0	O
in	0	O
transcription	0	O
:	0	O
one	0	O
prior	0	O
to	0	O
and	0	O
one	0	O
after	0	O
stable	0	O
complex	0	O
formation	0	O
;	0	O
and	0	O
that	0	O
these	0	O
effects	0	O
are	0	O
mediated	0	O
by	0	O
a	0	O
component	0	O
of	0	O
the	0	O
stable	0	O
complex	0	O
.	0	O


DNase	1	B
I	1	I
footprinting	0	O
with	0	O
rat	0	O
liver	0	O
nuclear	0	O
extracts	0	O
identified	0	O
7	0	O
major	0	O
protein	0	O
-	0	O
binding	0	O
domains	0	O
termed	0	O
P1	1	O
through	0	O
P7	0	O
in	0	O
a	0	O
796	0	O
base	0	O
pair	0	O
DNA	1	O
fragment	0	O
(	0	O
base	0	O
pairs	0	O
-	0	O
763	0	O
to	0	O
+	0	O
33	0	O
).	0	O


Of	0	O
these	0	O
patients	0	O
,	0	O
46	0	O
,	0	O
164	0	O
were	0	O
placed	0	O
on	0	O
a	0	O
waiting	0	O
list	0	O
for	0	O
transplantation	0	O
,	0	O
23	0	O
,	0	O
275	0	O
of	0	O
whom	0	O
received	0	O
a	0	O
first	0	O
cadaveric	0	O
transplant	0	O
between	0	O
1991	0	O
and	0	O
1997	0	O
.	0	O


METHODS	0	O
:	0	O
All	1	O
these	0	O
30	0	O
non	0	O
-	0	O
responders	0	O
received	0	O
an	0	O
extra	0	O
dose	0	O
of	0	O
the	0	O
same	0	O
vaccine	0	O
2	0	O
months	0	O
after	0	O
primary	0	O
immunization	0	O
and	0	O
a	0	O
booster	0	O
dose	0	O
with	0	O
a	0	O
yeast	0	O
-	0	O
derived	0	O
vaccine	0	O
6	0	O
years	0	O
later	0	O
.	0	O


We	0	O
demonstrate	0	O
that	0	O
both	0	O
R	1	B
and	0	O
Z	1	B
activate	0	O
the	0	O
cellular	0	O
stress	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
(	0	I
MAP	1	I
)	0	I
kinases	0	I
,	0	O
p38	0	B
and	0	O
JNK	0	B
,	0	O
resulting	0	O
in	0	O
phosphorylation	0	O
(	0	O
and	0	O
activation	0	O
)	0	O
of	0	O
the	0	O
cellular	0	B
transcription	0	I
factor	0	I
ATF2	0	I
.	0	O


The	0	O
resulting	0	O
R	1	B
protein	0	I
terminates	0	O
five	0	O
codons	0	O
downstream	0	O
of	0	O
the	0	O
frameshift	0	O
site	0	O
at	0	O
the	0	O
V	1	B
protein	0	I
stop	0	O
codon	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
c	0	B
-	0	I
met	0	I
gene	0	I
is	0	O
also	0	O
a	0	O
target	0	O
of	0	O
p53	0	B
gene	0	I
regulation	0	O
.	0	O


Soluble	1	O
FasR	0	B
ligand	0	O
-	0	O
binding	0	O
domain	0	O
:	0	O
high	0	O
-	0	O
yield	0	O
production	0	O
of	0	O
active	0	O
fusion	0	O
and	0	O
non	0	O
-	0	O
fusion	0	O
recombinant	0	O
proteins	0	O
using	0	O
the	0	O
baculovirus	0	O
/	0	O
insect	0	O
cell	0	O
system	0	O
.	0	O


Flurazepam	0	O
thus	0	O
appears	0	O
to	0	O
be	0	O
an	0	O
effective	0	O
hypnotic	0	O
drug	0	O
with	0	O
the	0	O
optimum	0	O
dose	0	O
for	0	O
use	0	O
in	0	O
general	0	O
practice	0	O
being	0	O
15	0	O
mg	0	O
at	0	O
night	0	O
.	0	O


TATA	0	O
and	0	O
CCAAT	0	O
boxes	0	O
are	0	O
located	0	O
34	0	O
-	0	O
bp	0	O
and	0	O
68	0	O
-	0	O
bp	0	O
,	0	O
respectively	0	O
,	0	O
upstream	0	O
of	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
,	0	O
the	0	O
5	0	O
'-	0	O
untranslated	0	O
leader	0	O
is	0	O
78	0	O
nucleotides	0	O
long	0	O
,	0	O
and	0	O
the	0	O
intronless	0	O
gene	0	O
has	0	O
at	0	O
least	0	O
two	0	O
different	0	O
polyadenylation	0	O
sites	0	O
.	0	O


In	1	O
an	0	O
in	0	O
vitro	0	O
study	0	O
,	0	O
10	0	O
/	0	O
0	0	O
nylon	0	O
was	0	O
found	0	O
to	0	O
require	0	O
a	0	O
significantly	0	O
lower	0	O
laser	0	O
energy	0	O
density	0	O
to	0	O
produce	0	O
suture	0	O
lysis	0	O
following	0	O
a	0	O
single	0	O
shot	0	O
than	0	O
either	0	O
10	0	O
/	0	O
0	0	O
Dacron	1	O
or	0	O
10	0	O
/	0	O
0	0	O
prolene	0	O
.	0	O


Evaluation	1	O
of	0	O
left	0	O
ventricular	0	O
function	0	O
using	0	O
gated	0	O
planar	0	O
myocardial	0	O
imaging	0	O
with	0	O
Tc	1	O
-	0	O
99m	0	O
-	0	O
MIBI	1	O


The	0	O
1	0	O
,	0	O
2	0	O
,	0	O
3	0	O
and	0	O
4	0	O
year	0	O
survival	0	O
rates	0	O
were	0	O
94	0	O
%,	0	O
84	0	O
%,	0	O
76	0	O
%	0	O
and	0	O
63	0	O
%,	0	O
respectively	0	O
.	0	O


Furthermore	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
a	0	O
soluble	0	O
form	0	O
of	0	O
ERp57	0	B
/	0	O
GRP58	0	B
by	0	O
Western	0	O
blotting	0	O
and	0	O
biosynthetic	0	O
labeling	0	O
.	0	O


Selected	0	O
parameters	0	O
:	0	O
heart	0	O
rate	0	O
(	0	O
HR	1	O
),	0	O
arterial	0	O
blood	0	O
pressure	0	O
(	0	O
ABP	1	O
)	0	O
and	0	O
arterial	0	O
O2	1	O
saturation	0	O
(	0	O
SaO2	1	O
)	0	O
monitored	0	O
by	0	O
pulsoximetry	0	O
were	0	O
measured	0	O
during	0	O
the	0	O
procedure	0	O
.	0	O


Canine	1	O
reproduction	0	O
:	0	O
effects	0	O
of	0	O
a	0	O
single	0	O
injection	0	O
of	0	O
medroxyprogesterone	0	O
acetate	0	O
on	0	O
the	0	O
reproductive	0	O
organs	0	O
of	0	O
the	0	O
bitch	0	O
.	0	O


Gene	1	O
silencing	0	O
associated	0	O
with	0	O
repeated	0	O
DNA	1	O
sequences	0	O
has	0	O
been	0	O
reported	0	O
for	0	O
many	0	O
eukaryotes	0	O
,	0	O
including	0	O
plants	0	O
.	0	O


Next	0	O
,	0	O
with	0	O
carcinoma	0	O
presenting	0	O
a	0	O
leather	0	O
bottle	0	O
(	0	O
linitis	0	O
plastica	0	O
type	0	O
)	0	O
of	0	O
the	0	O
stomach	0	O
itself	0	O
,	0	O
the	0	O
II	0	O
c	0	O
portion	0	O
of	0	O
the	0	O
stomach	0	O
consisted	0	O
of	0	O
fundic	0	O
glands	0	O
(	0	O
undifferentiated	0	O
carcinoma	0	O
)	0	O
shall	0	O
become	0	O
the	0	O
primary	0	O
focus	0	O
supporting	0	O
Nakamura	0	O
'	0	O
s	0	O
theory	0	O
.	0	O


Mutations	0	O
at	0	O
the	0	O
extreme	0	O
C	1	O
-	0	O
terminus	0	O
of	0	O
EIAV	0	B
Tat	1	I
impaired	0	O
both	0	O
RNA	1	O
binding	0	O
and	0	O
activation	0	O
domain	0	O
functions	0	O
,	0	O
suggesting	0	O
effects	0	O
on	0	O
secondary	0	O
or	0	O
tertiary	0	O
structure	0	O
.	0	O


Mobility	1	O
and	0	O
supershift	0	O
assays	0	O
demonstrated	0	O
that	0	O
upstream	0	B
stimulatory	0	I
factor	0	I
(	0	O
USF	0	B
)	0	O
and	0	O
Sp1	0	B
bind	0	O
to	0	O
the	0	O
former	0	O
elements	0	O
and	0	O
competition	0	O
experiments	0	O
confirmed	0	O
that	0	O
CREB	0	B
/	0	O
ATF	0	B
and	0	O
AP	1	B
-	0	I
1	0	I
bind	0	O
to	0	O
the	0	O
CRE	0	O
/	0	O
TRE	0	O
element	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
reverse	0	O
transcribed	0	O
,	0	O
amplified	0	O
cDNA	1	O
generated	0	O
from	0	O
total	0	O
RNA	1	O
isolated	0	O
from	0	O
transfected	0	O
cells	0	O
demonstrated	0	O
the	0	O
presence	0	O
of	0	O
abnormally	0	O
spliced	0	O
products	0	O
containing	0	O
13	0	O
and	0	O
78	0	O
additional	0	O
bases	0	O
as	0	O
well	0	O
as	0	O
the	0	O
accumulation	0	O
of	0	O
unspliced	0	O
mRNA	1	O
.	0	O


Whereas	0	O
MARTA1	0	B
is	0	O
clearly	0	O
detectable	0	O
in	0	O
crude	0	O
lysates	0	O
,	0	O
cytosolic	0	O
and	0	O
ribosomal	0	O
salt	0	O
-	0	O
wash	0	O
fractions	0	O
,	0	O
and	0	O
in	0	O
nuclear	0	O
extracts	0	O
,	0	O
MARTA2	0	B
is	0	O
preferentially	0	O
found	0	O
in	0	O
the	0	O
ribosomal	0	O
salt	0	O
-	0	O
wash	0	O
preparation	0	O
.	0	O


The	0	O
QT	1	O
interval	0	O
was	0	O
related	0	O
to	0	O
various	0	O
components	0	O
of	0	O
the	0	O
insulin	0	B
resistance	0	O
syndrome	0	O
,	0	O
including	0	O
BP	1	O
and	0	O
insulin	0	B
sensitivity	0	O
.	0	O


Findings	0	O
of	0	O
positive	0	O
potentials	0	O
showed	0	O
that	0	O
N1	0	O
originated	0	O
in	0	O
the	0	O
area	0	O
of	0	O
ventral	0	O
gray	0	O
matter	0	O
through	0	O
the	0	O
ventro	0	O
-	0	O
lateral	0	O
column	0	O
and	0	O
N2	0	O
through	0	O
the	0	O
dorsal	0	O
column	0	O
.	0	O


9	0	O
,	0	O
11	0	O
-	0	O
Seco	0	O
steroids	0	O
derived	0	O
from	0	O
estradiol	0	O
3	0	O
-	0	O
methyl	0	O
ether	0	O
.	0	O


Liu	0	O
,	0	O
B	1	O
.	0	O


The	0	O
calcium	0	O
requirement	0	O
for	0	O
hypothermic	0	O
storage	0	O
of	0	O
the	0	O
cardiac	0	O
explant	0	O
.	0	O


The	0	O
structure	0	O
of	0	O
these	0	O
genes	0	O
suggests	0	O
a	0	O
common	0	O
ancestor	0	O
for	0	O
all	0	O
viperid	0	B
PLA2	0	I
genes	0	I
.	0	O


Here	0	O
,	0	O
we	0	O
evidence	0	O
that	0	O
the	0	O
developmental	0	O
functions	0	O
of	0	O
the	0	O
family	0	O
of	0	O
transcription	0	O
factors	0	O
characterized	0	O
by	0	O
the	0	O
POU	0	B
DNA	1	I
binding	0	I
motif	0	I
exerts	0	O
roles	0	O
in	0	O
mammalian	0	O
development	0	O
.	0	O


In	1	O
19	0	O
patients	0	O
vagotomy	0	O
not	0	O
only	0	O
curbed	0	O
the	0	O
bleeding	0	O
but	0	O
provided	0	O
definitive	0	O
therapy	0	O
(	0	O
Visick	0	O
I	1	O
-	0	O
II	0	O
);	0	O
4	0	O
patients	0	O
died	0	O
(	0	O
mortality	0	O
rate	0	O
16	0	O
%).	0	O


The	0	O
pathophysiology	0	O
and	0	O
clinical	0	O
management	0	O
of	0	O
acute	0	O
brain	0	O
injury	0	O
in	0	O
infancy	0	O
and	0	O
childhood	0	O
are	0	O
presented	0	O
using	0	O
acute	0	O
traumatic	0	O
brain	0	O
injury	0	O
as	0	O
a	0	O
model	0	O
.	0	O


Plasma	1	B
lactoferrin	0	I
and	0	O
the	0	O
blood	0	O
count	0	O
of	0	O
polynuclear	0	O
neutrophils	0	O


E1A	0	B
autoactivation	0	O
mediated	0	O
by	0	O
these	0	O
sites	0	O
was	0	O
about	0	O
twofold	0	O
compared	0	O
with	0	O
a	0	O
ninefold	0	O
activation	0	O
described	0	O
for	0	O
the	0	O
complete	0	O
E1A	0	B
promoter	0	I
.	0	O


We	0	O
have	0	O
investigated	0	O
the	0	O
requirements	0	O
of	0	O
the	0	O
CH	1	B
gene	0	I
switch	0	O
by	0	O
characterizing	0	O
two	0	O
rearranged	0	B
gamma	0	I
2b	0	I
genes	0	I
from	0	O
a	0	O
gamma	0	B
2b	0	I
producing	0	O
mouse	0	O
myeloma	0	O
(	0	O
MPC	0	O
-	0	O
11	0	O
).	0	O


Eukaryotic	1	B
initiation	0	I
factor	0	I
3	0	I
(	0	O
eIF3	0	B
)	0	O
is	0	O
a	0	O
large	0	O
multisubunit	0	O
complex	0	O
that	0	O
stabilizes	0	O
the	0	O
ternary	0	O
complex	0	O
,	0	O
eIF2	0	B
x	0	O
GTP	1	O
x	0	O
tRNA	1	B
(	0	I
Met	1	I
)	0	I
i	0	I
and	0	O
promotes	0	O
mRNA	1	O
binding	0	O
to	0	O
the	0	O
40	0	B
S	1	I
ribosomal	0	I
subunit	0	I
.	0	O
eIF3	0	B
also	0	O
functions	0	O
as	0	O
a	0	O
ribosome	0	O
subunit	0	O
anti	0	O
-	0	O
association	0	O
factor	0	O
.	0	O


The	0	O
consequences	0	O
of	0	O
intensive	0	O
swine	0	O
production	0	O
on	0	O
the	0	O
environment	0	O
and	0	O
possible	0	O
solutions	0	O
by	0	O
means	0	O
of	0	O
nutrition	0	O
are	0	O
outlined	0	O
.	0	O


This	0	O
finding	0	O
suggested	0	O
that	0	O
the	0	O
PI3K	0	B
-	0	O
Akt	0	B
activation	0	O
pathway	0	O
plays	0	O
some	0	O
role	0	O
in	0	O
the	0	O
antiapoptotic	0	O
effect	0	O
of	0	O
EPO	0	B
.	0	O


In	1	O
contrast	0	O
,	0	O
in	0	O
LL	0	O
patients	0	O
during	0	O
ENL	0	O
the	0	O
ConA	1	B
-	0	O
induced	0	O
suppressor	0	O
response	0	O
was	0	O
markedly	0	O
reduced	0	O
.	0	O


There	0	O
was	0	O
either	0	O
no	0	O
change	0	O
or	0	O
an	0	O
improvement	0	O
in	0	O
renographic	0	O
findings	0	O
(	0	O
t1	0	O
/	0	O
2	0	O
time	0	O
and	0	O
/	0	O
or	0	O
split	0	O
function	0	O
)	0	O
in	0	O
40	0	O
patients	0	O
(	0	O
93	0	O
%).	0	O


Following	1	O
retransfusion	0	O
,	0	O
the	0	O
affected	0	O
epithelial	0	O
lining	0	O
appeared	0	O
greatly	0	O
distended	0	O
over	0	O
the	0	O
oedematous	0	O
lamina	0	O
propria	0	O
,	0	O
with	0	O
almost	0	O
complete	0	O
loss	0	O
of	0	O
structural	0	O
detail	0	O
.	0	O


Cleidocranial	1	O
dysostosis	0	O


The	0	O
early	0	O
lethality	0	O
of	0	O
the	0	O
left	0	O
-	0	O
sided	0	O
resectio	0	O
was	0	O
0	0	O
%	0	O
and	0	O
the	0	O
postoperative	0	O
survival	0	O
--	0	O
5	0	O
-	0	O
10	0	O
months	0	O
.	0	O


In	1	O
vitro	0	O
DNase	1	B
I	1	I
footprinting	0	O
of	0	O
the	0	O
200	0	O
-	0	O
bp	0	O
proximal	0	O
region	0	O
of	0	O
the	0	O
promoter	0	O
with	0	O
a	0	O
murine	0	O
Hepa	0	O
1	0	O
-	0	O
6	0	O
cell	0	O
nuclear	0	O
extract	0	O
revealed	0	O
a	0	O
clear	0	O
footprint	0	O
of	0	O
a	0	O
region	0	O
corresponding	0	O
to	0	O
-	0	O
80	0	O
to	0	O
-	0	O
28	0	O
bp	0	O
of	0	O
the	0	O
murine	0	B
fVII	0	I
gene	0	I
,	0	O
suggesting	0	O
that	0	O
liver	0	O
factors	0	O
interact	0	O
with	0	O
this	0	O
region	0	O
of	0	O
the	0	O
DNA	1	O
.	0	O


The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
determine	0	O
the	0	O
risk	0	O
factors	0	O
for	0	O
background	0	O
diabetic	0	O
retinopathy	0	O
(	0	O
BDR	0	O
)	0	O
and	0	O
PDR	1	O
by	0	O
following	0	O
394	0	O
Japanese	0	O
patients	0	O
with	0	O
early	0	O
-	0	O
onset	0	O
type	0	O
2	0	O
diabetes	0	O
diagnosed	0	O
before	0	O
30	0	O
years	0	O
of	0	O
age	0	O
(	0	O
mean	0	O
age	0	O
27	0	O
,	0	O
mean	0	O
blood	0	O
pressure	0	O
at	0	O
entry	0	O
116	0	O
/	0	O
73	0	O
mm	0	O
Hg	1	O
).	0	O


We	0	O
propose	0	O
that	0	O
epigenetic	0	O
features	0	O
of	0	O
tissue	0	O
-	0	O
specific	0	O
control	0	O
and	0	O
of	0	O
the	0	O
control	0	O
of	0	O
allelic	0	O
expression	0	O
are	0	O
intricately	0	O
linked	0	O
.	0	O


Incidence	1	O
rate	0	O
ranging	0	O
between	0	O
122	0	O
/	0	O
100	0	O
,	0	O
000	0	O
/	0	O
year	0	O
and	0	O
190	0	O
/	0	O
100	0	O
,	0	O
000	0	O
/	0	O
year	0	O
were	0	O
found	0	O
(	0	O
minimum	0	O
,	0	O
estimated	0	O
and	0	O
raw	0	O
datasets	0	O
).	0	O


Alveolar	1	O
growth	0	O
,	0	O
contemporary	0	O
with	0	O
dental	0	O
eruption	0	O
,	0	O
is	0	O
sufficient	0	O
to	0	O
compensate	0	O
possible	0	O
hypotrophy	0	O
of	0	O
maxillary	0	O
bone	0	O
bases	0	O
.	0	O


We	0	O
have	0	O
identified	0	O
SWI5	0	B
'	0	O
s	0	O
nuclear	0	O
localization	0	O
signal	0	O
(	0	O
NLS	0	O
)	0	O
and	0	O
show	0	O
that	0	O
it	0	O
can	0	O
confer	0	O
cell	0	O
cycle	0	O
-	0	O
dependent	0	O
nuclear	0	O
entry	0	O
to	0	O
a	0	O
heterologous	0	O
protein	0	O
.	0	O


The	0	O
Y	1	O
.	0	O
lipolytica	0	O
genomic	0	O
POT1	0	B
gene	0	O
was	0	O
disrupted	0	O
by	0	O
replacing	0	O
120	0	O
bp	0	O
of	0	O
its	0	O
coding	0	O
sequence	0	O
with	0	O
2	0	O
.	0	O
7	0	O
kbp	0	O
of	0	O
DNA	1	O
including	0	O
the	0	O
Y	1	O
.	0	O
lipolytica	0	O
LEU2	0	B
gene	0	I
.	0	O


This	0	O
analysis	0	O
,	0	O
together	0	O
with	0	O
a	0	O
consideration	0	O
of	0	O
the	0	O
SCBs	0	O
found	0	O
upstream	0	O
of	0	O
known	0	O
SWI4	0	B
,	0	I
6	0	I
-	0	O
dependent	0	O
genes	0	O
,	0	O
leads	0	O
to	0	O
the	0	O
proposal	0	O
of	0	O
a	0	O
revised	0	O
consensus	0	O
sequence	0	O
for	0	O
this	0	O
important	0	O
regulatory	0	O
element	0	O
.	0	O


Identification	1	O
of	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
sequence	0	O
in	0	O
the	0	O
CD2	1	B
cytoplasmic	0	I
domain	0	I
critical	0	O
for	0	O
regulation	0	O
of	0	O
integrin	0	B
-	0	O
mediated	0	O
adhesion	0	O
and	0	O
activation	0	O
of	0	O
phosphoinositide	0	B
3	0	I
-	0	I
kinase	0	I
.	0	O


Localization	1	O
of	0	O
67	0	O
exons	0	O
on	0	O
a	0	O
YAC	1	O
contig	0	O
spanning	0	O
1	0	O
.	0	O
5	0	O
Mb	1	O
around	0	O
the	0	O
multidrug	0	B
resistance	0	I
gene	0	I
region	0	I
of	0	O
human	0	O
chromosome	0	O
7q21	0	O
.	0	O
1	0	O
.	0	O


APETALA3	0	B
transcripts	0	I
are	0	O
first	0	O
detected	0	O
in	0	O
a	0	O
meristematic	0	O
region	0	O
that	0	O
will	0	O
give	0	O
rise	0	O
to	0	O
the	0	O
petal	0	O
and	0	O
stamen	0	O
primordia	0	O
,	0	O
and	0	O
expression	0	O
is	0	O
maintained	0	O
in	0	O
this	0	O
region	0	O
during	0	O
subsequent	0	O
development	0	O
of	0	O
these	0	O
organs	0	O
.	0	O


Diuresis	1	O
was	0	O
induced	0	O
by	0	O
scheduled	0	O
drinking	0	O
of	0	O
tea	0	O
(	0	O
150	0	O
ml	0	O
/	0	O
h	0	O
).	0	O


In	1	O
transient	0	O
cotransfections	0	O
E1A	0	B
could	0	O
induce	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
p53	0	B
promoter	0	I
to	0	O
a	0	O
high	0	O
level	0	O
;	0	O
12S	0	B
E1A	0	I
was	0	O
threefold	0	O
as	0	O
efficient	0	O
as	0	O
13S	0	B
E1A	0	I
in	0	O
this	0	O
activity	0	O
,	0	O
and	0	O
YY1	0	B
bound	0	O
to	0	O
the	0	O
composite	0	O
element	0	O
was	0	O
shown	0	O
to	0	O
mediate	0	O
55	0	O
%	0	O
of	0	O
this	0	O
induction	0	O
.	0	O


A	1	O
fluoroimmunoassay	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
serum	0	O
of	0	O
plasma	0	O
levels	0	O
of	0	O
propranolol	0	O
was	0	O
developed	0	O
using	0	O
antibodies	0	O
to	0	O
propranolol	0	O
coupled	0	O
to	0	O
magnetizable	0	O
solid	0	O
-	0	O
phase	0	O
particles	0	O
and	0	O
fluorescein	0	O
-	0	O
labeled	0	O
propranolol	0	O
as	0	O
tracer	0	O
.	0	O


Biopsies	0	O
of	0	O
the	0	O
jejunal	0	O
mucosa	0	O
have	0	O
shown	0	O
abnormal	0	O
enzyme	0	O
activity	0	O
or	0	O
deficiencies	0	O
in	0	O
transport	0	O
mechanisms	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
during	0	O
pregnancy	0	O
there	0	O
are	0	O
increases	0	O
in	0	O
bone	0	O
formation	0	O
rates	0	O
contributing	0	O
to	0	O
the	0	O
increases	0	O
in	0	O
skeletal	0	O
mass	0	O
.	0	O


Histological	1	O
observations	0	O
on	0	O
the	0	O
decidua	0	O
in	0	O
the	0	O
second	0	O
half	0	O
of	0	O
pregnancy	0	O


Residual	1	O
amphotericin	0	O
B	1	O
was	0	O
detected	0	O
in	0	O
the	0	O
feces	0	O
of	0	O
the	0	O
mice	0	O
only	0	O
while	0	O
they	0	O
were	0	O
receiving	0	O
the	0	O
0	0	O
.	0	O
3	0	O
mg	0	O
/	0	O
ml	0	O
dose	0	O
level	0	O
.	0	O


Visual	1	O
averaged	0	O
evoked	0	O
responses	0	O
and	0	O
platelet	0	B
monoamine	0	I
oxidase	0	I
in	0	O
patients	0	O
suffering	0	O
from	0	O
alcoholism	0	O
.	0	O


Immunofluoresence	0	O
data	0	O
indicated	0	O
that	0	O
once	0	O
bound	0	O
to	0	O
the	0	O
mutant	0	O
receptor	0	O
,	0	O
fluorescent	0	O
-	0	O
labeled	0	O
RAP	0	B
co	0	O
-	0	O
localized	0	O
with	0	O
markers	0	O
of	0	O
the	0	O
endosomal	0	O
pathway	0	O
,	0	O
whereas	0	O
,	0	O
in	0	O
cells	0	O
expressing	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
receptor	0	O
,	0	O
RAP	0	B
fluorescence	0	O
co	0	O
-	0	O
localized	0	O
with	0	O
lysosomal	0	O
markers	0	O
.	0	O


We	0	O
further	0	O
found	0	O
that	0	O
KmMig1p	0	B
is	0	O
fully	0	O
functional	0	O
when	0	O
expressed	0	O
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
.	0	O


Here	0	O
we	0	O
describe	0	O
and	0	O
map	0	O
two	0	O
more	0	O
new	0	O
genes	0	O
identified	0	O
as	0	O
allele	0	O
-	0	O
specific	0	O
suppressors	0	O
that	0	O
compensate	0	O
for	0	O
carboxy	0	O
-	0	O
terminal	0	O
truncation	0	O
of	0	O
PET122	0	B
.	0	O


Disruption	1	O
of	0	O
re	0	O
-	0	O
replication	0	O
control	0	O
by	0	O
overexpression	0	O
of	0	O
human	0	B
ORC1	0	I
in	0	O
fission	0	O
yeast	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
sequence	0	O
upstream	0	O
of	0	O
this	0	O
initiation	0	O
codon	0	O
reveals	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
promotor	0	O
sequence	0	O
.	0	O


However	0	O
,	0	O
the	0	O
element	0	O
proximal	0	O
to	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
is	0	O
dependent	0	O
on	0	O
the	0	O
SRE	0	O
-	0	O
1	0	O
.	0	O


Here	0	O
the	0	O
cloning	0	O
and	0	O
molecular	0	O
analysis	0	O
of	0	O
the	0	O
Zm	0	B
-	0	I
ERabp1	0	I
,	0	O
Zm	0	B
-	0	I
ERabp4	0	I
,	0	O
and	0	O
Zm	0	B
-	0	I
ERabp5	0	I
genes	0	I
is	0	O
presented	0	O
.	0	O


J	1	O
.	0	O


Mutation	1	O
of	0	O
the	0	O
C	1	B
/	0	I
EBP	1	I
binding	0	I
sites	0	I
in	0	O
the	0	O
Rous	0	B
sarcoma	0	I
virus	0	I
long	0	I
terminal	0	I
repeat	0	I
and	0	O
gag	0	B
enhancers	0	I
.	0	O


The	0	O
infected	0	B
cell	0	I
protein	0	I
no	0	I
.	0	I
0	0	I
(	0	O
ICP0	0	B
)	0	O
of	0	O
herpes	0	O
simplex	0	O
virus	0	O
1	0	O
is	0	O
a	0	O
promiscuous	0	O
transactivator	0	O
shown	0	O
to	0	O
enhance	0	O
the	0	O
expression	0	O
of	0	O
genes	0	O
introducted	0	O
into	0	O
cells	0	O
by	0	O
infection	0	O
or	0	O
transfection	0	O
.	0	O


One	0	O
such	0	O
element	0	O
,	0	O
1P	0	O
,	0	O
was	0	O
employed	0	O
to	0	O
clone	0	O
from	0	O
a	0	O
rat	0	O
pituitary	0	O
cDNA	1	O
expression	0	O
library	0	O
a	0	O
novel	0	O
417	0	B
-	0	I
amino	0	I
acid	0	I
WD	0	I
protein	0	I
,	0	O
designated	0	O
PREB	0	B
(	0	I
PRL	1	I
regulatory	0	I
element	0	I
binding	0	I
)	0	I
protein	0	I
.	0	O


On	1	O
the	0	O
third	0	O
occasion	0	O
water	0	O
(	0	O
W	1	O
)	0	O
was	0	O
ingested	0	O
throughout	0	O
the	0	O
run	0	O
.	0	O


The	0	O
expressed	0	O
G1	0	B
-	0	O
G2	0	B
bound	0	O
to	0	O
both	0	O
hyaluronan	0	O
and	0	O
link	0	B
protein	0	I
indicating	0	O
that	0	O
the	0	O
immunoglobulin	0	B
-	0	I
fold	0	I
motif	0	I
and	0	O
proteoglycan	0	O
tandem	0	O
repeat	0	O
loops	0	O
of	0	O
the	0	O
G1	0	B
domain	0	I
were	0	O
correctly	0	O
folded	0	O
.	0	O


In	1	O
gel	0	O
mobility	0	O
shift	0	O
assays	0	O
,	0	O
low	0	O
binding	0	O
activity	0	O
of	0	O
CBF	1	B
to	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
AtpC	0	I
promoter	0	I
sequence	0	I
was	0	O
observed	0	O
with	0	O
nuclear	0	O
extracts	0	O
from	0	O
tissue	0	O
with	0	O
low	0	O
AtpC	0	B
expression	0	O
levels	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
extracts	0	O
from	0	O
etiolated	0	O
and	0	O
photobleached	0	O
seedlings	0	O
,	0	O
whereas	0	O
high	0	O
binding	0	O
activity	0	O
was	0	O
detectable	0	O
with	0	O
extracts	0	O
from	0	O
tissues	0	O
with	0	O
high	0	O
AtpC	0	B
expression	0	O
levels	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
extracts	0	O
from	0	O
light	0	O
-	0	O
grown	0	O
seedlings	0	O
and	0	O
etiolated	0	O
seedlings	0	O
treated	0	O
with	0	O
cytokinin	0	B
.	0	O


Ischemic	1	O
heart	0	O
disease	0	O
,	0	O
age	0	O
of	0	O
more	0	O
than	0	O
75	0	O
years	0	O
,	0	O
and	0	O
the	0	O
fact	0	O
that	0	O
the	0	O
patient	0	O
was	0	O
a	0	O
woman	0	O
were	0	O
independent	0	O
predictors	0	O
of	0	O
poor	0	O
cardiac	0	O
function	0	O
.	0	O


A	1	O
progressive	0	O
growth	0	O
of	0	O
blood	0	O
erythrocyte	0	O
membrane	0	O
injury	0	O
has	0	O
been	0	O
demonstrated	0	O
after	0	O
rats	0	O
were	0	O
exposed	0	O
to	0	O
gamma	0	O
-	0	O
irradiaton	0	O
at	0	O
a	0	O
dose	0	O
of	0	O
100	0	O
to	0	O
500	0	O
Gy	1	O
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
anthraquinone	0	O
sennoside	0	O
B	1	O
and	0	O
rhein	0	O
are	0	O
weakly	0	O
genotoxic	0	O
.	0	O


However	0	O
,	0	O
while	0	O
IL	1	B
-	0	I
1beta	0	I
and	0	O
TNF	1	B
-	0	I
alpha	0	I
both	0	O
induced	0	O
nuclear	0	O
binding	0	O
of	0	O
the	0	O
Rel	0	B
proteins	0	I
p50	0	I
and	0	O
p65	0	B
to	0	O
an	0	O
NF	1	B
-	0	I
kappaB	0	I
consensus	0	I
oligonucleotide	0	I
in	0	O
gel	0	O
shift	0	O
assays	0	O
and	0	O
caused	0	O
transient	0	O
degradation	0	O
of	0	O
inhibitor	0	B
of	0	I
NF	1	I
-	0	I
kappaB	0	I
-	0	I
alpha	0	I
(	0	O
IkappaB	0	B
-	0	I
alpha	0	I
)	0	O
in	0	O
the	0	O
cytoplasm	0	O
of	0	O
myofibroblasts	0	O
,	0	O
only	0	O
IL	1	B
-	0	I
1beta	0	I
upregulated	0	O
PDGF	0	B
-	0	I
Ralpha	0	I
.	0	O


The	0	O
high	0	O
degree	0	O
of	0	O
conservation	0	O
between	0	O
NQO2	0	B
and	0	O
NQO1	0	B
gene	0	I
organization	0	O
and	0	O
sequence	0	O
confirmed	0	O
that	0	O
NQO2	0	B
gene	0	I
encodes	0	O
for	0	O
a	0	O
second	0	O
member	0	O
of	0	O
the	0	O
NQO	0	B
gene	0	I
family	0	I
in	0	O
human	0	O
.	0	O


Movement	1	O
time	0	O
and	0	O
kinematic	0	O
characteristics	0	O
were	0	O
analyzed	0	O
together	0	O
with	0	O
the	0	O
magnitude	0	O
of	0	O
cerebral	0	O
blood	0	O
flow	0	O
to	0	O
identify	0	O
areas	0	O
of	0	O
brain	0	O
activity	0	O
proportionate	0	O
to	0	O
task	0	O
and	0	O
movement	0	O
variables	0	O
.	0	O


Epstein	0	B
-	0	I
Barr	0	I
virus	0	I
nuclear	0	I
protein	0	I
2	0	I
(	0	O
EBNA2	0	B
)	0	O
binds	0	O
to	0	O
a	0	O
component	0	O
of	0	O
the	0	O
human	0	O
SNF	1	B
-	0	O
SWI	0	B
complex	0	O
,	0	O
hSNF5	0	B
/	0	O
Ini1	0	B
.	0	O


Thyreoliberin	0	B
VUFB	0	O
in	0	O
thyroid	0	O
gammagraphy	0	O


Point	1	O
mutations	0	O
that	0	O
suppressed	0	O
the	0	O
in	0	O
vitro	0	O
binding	0	O
of	0	O
NF	1	B
-	0	I
Y	1	I
to	0	O
the	0	O
internal	0	O
palindromic	0	O
arm	0	O
reduced	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
resident	0	O
P4	0	O
promoter	0	O
,	0	O
while	0	O
those	0	O
preventing	0	O
complex	0	O
formation	0	O
with	0	O
USF	0	B
did	0	O
not	0	O
,	0	O
as	0	O
determined	0	O
by	0	O
transient	0	O
expression	0	O
assays	0	O
using	0	O
the	0	O
luciferase	0	B
reporter	0	O
gene	0	O
.	0	O


In	1	O
summary	0	O
,	0	O
the	0	O
no	0	O
-	0	O
adverse	0	O
-	0	O
effect	0	O
-	0	O
level	0	O
for	0	O
this	0	O
study	0	O
was	0	O
determined	0	O
to	0	O
be	0	O
1000	0	O
ppm	0	O
,	0	O
based	0	O
on	0	O
decreased	0	O
weight	0	O
gain	0	O
in	0	O
female	0	O
rats	0	O
,	0	O
and	0	O
on	0	O
slight	0	O
organ	0	O
weight	0	O
changes	0	O
in	0	O
both	0	O
sexes	0	O
at	0	O
3000	0	O
ppm	0	O
.	0	O


This	0	O
motif	0	O
,	0	O
first	0	O
described	0	O
for	0	O
the	0	O
Drosophila	1	B
homeobox	0	I
activator	0	I
DEAF	1	I
-	0	I
1	0	I
,	0	O
identifies	0	O
an	0	O
emerging	0	O
group	0	O
of	0	O
metazoan	0	O
transcriptional	0	O
modulators	0	O
.	0	O


A	1	O
second	0	O
important	0	O
molecule	0	O
in	0	O
TCR	1	B
signal	0	O
transduction	0	O
is	0	O
the	0	O
guanine	0	B
nucleotide	0	I
binding	0	I
protein	0	I
,	0	O
p21ras	0	B
,	0	O
which	0	O
is	0	O
coupled	0	O
to	0	O
the	0	O
TCR	1	B
by	0	O
a	0	O
protein	0	B
tyrosine	0	I
kinase	0	I
dependent	0	O
mechanism	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
a	0	O
cDNA	1	O
encoding	0	O
human	0	B
MEKK3	0	I
.	0	O


CsA	0	O
alone	0	O
resulted	0	O
in	0	O
elevated	0	O
bone	0	O
turnover	0	O
.	0	O


METHODS	0	O
:	0	O
Fifty	0	O
-	0	O
eight	0	O
patients	0	O
who	0	O
underwent	0	O
a	0	O
curative	0	O
hepatic	0	O
resection	0	O
for	0	O
HCC	0	O
and	0	O
whose	0	O
preoperative	0	O
AFP	1	B
levels	0	O
were	0	O
>	0	O
100	0	O
ng	0	O
/	0	O
ml	0	O
,	0	O
were	0	O
selected	0	O
for	0	O
this	0	O
study	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
significant	0	O
pulmonary	0	O
metabolism	0	O
of	0	O
5	0	O
-	0	O
HT	1	O
followed	0	O
by	0	O
efflux	0	O
of	0	O
5	0	O
-	0	O
HIAA	0	O
into	0	O
venous	0	O
output	0	O
occurs	0	O
during	0	O
single	0	O
-	0	O
pass	0	O
circulation	0	O
.	0	O


Double	1	O
-	0	O
blind	0	O
,	0	O
placebo	0	O
-	0	O
controlled	0	O
trial	0	O
.	0	O


Northern	0	O
analysis	0	O
of	0	O
RNA	1	O
samples	0	O
isolated	0	O
from	0	O
ammonium	0	O
-	0	O
grown	0	O
cultures	0	O
of	0	O
the	0	O
ntcA	0	B
mutant	0	I
showed	0	O
reduced	0	O
amounts	0	O
of	0	O
glnA	0	B
message	0	I
and	0	O
the	0	O
absence	0	O
of	0	O
a	0	O
1	0	O
.	0	O
7	0	O
-	0	O
kb	0	O
transcript	0	O
.	0	O


Practical	0	O
interest	0	O
of	0	O
such	0	O
studies	0	O
is	0	O
limited	0	O
since	0	O
the	0	O
pharmacokinetic	0	O
parameters	0	O
are	0	O
systematically	0	O
evaluated	0	O
in	0	O
man	0	O
during	0	O
phase	0	O
I	1	O
trials	0	O
.	0	O


The	0	O
lack	0	O
of	0	O
the	0	O
C2	1	B
domain	0	O
of	0	O
the	0	O
Ca	1	B
(	0	I
2	0	I
+)-	0	I
dependent	0	I
PKCs	0	I
and	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
unique	0	O
NH2	0	O
-	0	O
terminal	0	O
sequence	0	O
with	0	O
a	0	O
potential	0	O
signal	0	O
peptide	0	O
and	0	O
a	0	O
transmembrane	0	O
domain	0	O
suggest	0	O
that	0	O
PKC	0	B
mu	0	I
is	0	O
a	0	O
novel	0	O
member	0	O
of	0	O
the	0	O
subgroup	0	O
of	0	O
atypical	0	O
PKCs	0	B
.	0	O


The	0	O
expression	0	O
of	0	O
the	0	O
gene	0	O
encoding	0	O
the	0	O
enzyme	0	O
(	0	O
CYP19	0	B
)	0	O
is	0	O
regulated	0	O
,	0	O
in	0	O
part	0	O
,	0	O
by	0	O
tissue	0	O
-	0	O
specific	0	O
promoters	0	O
through	0	O
the	0	O
use	0	O
of	0	O
alternative	0	O
-	0	O
splicing	0	O
mechanisms	0	O
.	0	O


These	0	O
risk	0	O
factors	0	O
can	0	O
be	0	O
divided	0	O
into	0	O
2	0	O
groups	0	O
:	0	O
local	0	O
vessel	0	O
wall	0	O
-	0	O
related	0	O
factors	0	O
,	0	O
and	0	O
local	0	O
(	0	O
focal	0	O
action	0	O
)	0	O
systemic	0	O
factors	0	O
.	0	O


The	0	O
Fyn	0	B
NH2	0	I
terminus	0	I
was	0	O
necessary	0	O
but	0	O
not	0	O
sufficient	0	O
for	0	O
interaction	0	O
with	0	O
zeta	0	O
and	0	O
both	0	O
Fyn	0	B
kinase	0	I
and	0	O
SH2	0	B
domains	0	I
were	0	O
required	0	O
,	0	O
directing	0	O
phosphorylation	0	O
of	0	O
zeta	0	B
ITAM	0	I
tyrosines	0	O
and	0	O
binding	0	O
to	0	O
zeta	0	B
ITAM	0	I
phosphotyrosines	0	O
.	0	O


A	1	O
case	0	O
of	0	O
Goodpasture	0	O
'	0	O
s	0	O
syndrome	0	O
.	0	O


Pol32Delta	0	B
strains	0	O
are	0	O
weak	0	O
antimutators	0	O
and	0	O
are	0	O
defective	0	O
for	0	O
damage	0	O
-	0	O
induced	0	O
mutagenesis	0	O
.	0	O


However	0	O
,	0	O
the	0	O
range	0	O
of	0	O
values	0	O
observed	0	O
is	0	O
suggestive	0	O
of	0	O
the	0	O
need	0	O
to	0	O
investigate	0	O
districts	0	O
with	0	O
contrasting	0	O
values	0	O
of	0	O
SYPLR	0	O
with	0	O
respect	0	O
to	0	O
the	0	O
inter	0	O
-	0	O
relationships	0	O
between	0	O
sociodemographic	0	O
characteristics	0	O
,	0	O
duration	0	O
of	0	O
symptoms	0	O
,	0	O
clinical	0	O
presentation	0	O
and	0	O
treatment	0	O
efficacy	0	O
.	0	O


In	1	O
a	0	O
randomised	0	O
double	0	O
-	0	O
blind	0	O
study	0	O
,	0	O
46	0	O
first	0	O
episode	0	O
schizophrenics	0	O
were	0	O
given	0	O
pimozide	0	O
or	0	O
flupenthixol	0	O
for	0	O
up	0	O
to	0	O
5	0	O
weeks	0	O
;	0	O
the	0	O
mean	0	O
daily	0	O
dose	0	O
at	0	O
the	0	O
end	0	O
was	0	O
18	0	O
.	0	O
8	0	O
mg	0	O
pimozide	0	O
and	0	O
20	0	O
mg	0	O
flupenthixol	0	O
.	0	O


DESIGN	0	O
AND	0	O
METHODS	0	O
:	0	O
Case	1	O
study	0	O
.	0	O


The	0	O
algorithm	0	O
also	0	O
limited	0	O
TG	1	O
to	0	O
20	0	O
and	0	O
64	0	O
%,	0	O
apoB	0	B
to	0	O
6	0	O
and	0	O
20	0	O
%,	0	O
and	0	O
Lp	1	B
(	0	I
a	0	I
)	0	I
to	0	O
15	0	O
and	0	O
56	0	O
%,	0	O
of	0	O
low	0	O
-	0	O
and	0	O
high	0	O
-	0	O
risk	0	O
groups	0	O
,	0	O
respectively	0	O
.	0	O


TPBF	0	B
has	0	O
two	0	O
potential	0	O
coiled	0	O
-	0	O
coil	0	O
regions	0	O
,	0	O
a	0	O
basic	0	O
region	0	O
,	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
region	0	O
,	0	O
a	0	O
histidine	0	O
-	0	O
rich	0	O
N	1	O
terminus	0	O
,	0	O
and	0	O
a	0	O
nuclear	0	O
targeting	0	O
sequence	0	O
.	0	O


This	0	O
alternatively	0	O
spliced	0	O
transcript	0	O
contained	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
extending	0	O
from	0	O
the	0	O
upstream	0	O
J	1	O
alpha	0	O
11	0	O
-	0	O
2	0	O
region	0	O
to	0	O
82	0	O
nucleotides	0	O
downstream	0	O
of	0	O
the	0	O
beginning	0	O
of	0	O
the	0	O
TCR	1	B
C	1	I
alpha	0	I
region	0	I
,	0	O
and	0	O
potentially	0	O
encoded	0	O
a	0	O
36	0	O
amino	0	O
acid	0	O
polypeptide	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
In	1	O
healthy	0	O
individuals	0	O
,	0	O
whole	0	O
body	0	O
insulin	0	B
sensitivity	0	O
is	0	O
related	0	O
,	0	O
or	0	O
"	0	O
coupled	0	O
,	0	O
"	0	O
to	0	O
the	0	O
anaerobic	0	O
threshold	0	O
.	0	O


ORFA	0	O
and	0	O
ccdA	0	B
were	0	O
constitutively	0	O
cotranscribed	0	O
as	0	O
determined	0	O
by	0	O
primer	0	O
extension	0	O
analysis	0	O
.	0	O


We	0	O
recently	0	O
found	0	O
that	0	O
the	0	O
p72syk	0	B
protein	0	I
tyrosine	0	I
kinase	0	I
is	0	O
physically	0	O
associated	0	O
with	0	O
the	0	O
TCR	1	B
/	0	O
CD3	0	B
complex	0	O
and	0	O
is	0	O
rapidly	0	O
tyrosine	0	O
phosphorylated	0	O
and	0	O
activated	0	O
by	0	O
receptor	0	O
triggering	0	O
also	0	O
in	0	O
T	1	O
cells	0	O
lacking	0	O
p56lck	0	B
.	0	O


Furthermore	0	O
,	0	O
expression	0	O
of	0	O
the	0	O
promoter	0	O
in	0	O
embryonic	0	O
Drosophila	1	O
melanogaster	0	O
cells	0	O
that	0	O
lack	0	O
MyoD1	0	B
and	0	O
Sp1	0	B
is	0	O
strictly	0	O
dependent	0	O
on	0	O
all	0	O
three	0	O
sites	0	O
remaining	0	O
intact	0	O
and	0	O
on	0	O
the	0	O
presence	0	O
of	0	O
exogenously	0	O
supplied	0	O
Sp1	0	B
and	0	O
MyoD1	0	B
.	0	O


The	0	O
identity	0	O
between	0	O
hnRNPs	0	B
H	1	I
and	0	O
H	1	B
'	0	I
is	0	O
96	0	O
%,	0	O
between	0	O
H	1	B
and	0	O
F	1	B
78	0	O
%,	0	O
and	0	O
between	0	O
H	1	B
'	0	I
and	0	O
F	1	B
75	0	O
%,	0	O
respectively	0	O
.	0	O


This	0	O
newly	0	O
described	0	O
organism	0	O
was	0	O
difficult	0	O
to	0	O
identify	0	O
due	0	O
to	0	O
discrepancies	0	O
between	0	O
the	0	O
Vitek	0	O
and	0	O
API	0	O
20E	0	O
identification	0	O
systems	0	O
.	0	O


Deletions	0	O
were	0	O
examined	0	O
in	0	O
the	0	O
LYS2	0	B
gene	0	I
,	0	O
using	0	O
a	0	O
set	0	O
of	0	O
31	0	O
-	0	O
to	0	O
156	0	O
-	0	O
bp	0	O
inserts	0	O
that	0	O
included	0	O
inserts	0	O
with	0	O
no	0	O
apparent	0	O
potential	0	O
for	0	O
secondary	0	O
structure	0	O
as	0	O
well	0	O
as	0	O
two	0	O
quasipalindromes	0	O
.	0	O


Sequencing	1	O
analysis	0	O
has	0	O
shown	0	O
that	0	O
each	0	O
rap1t	0	B
allele	0	I
contains	0	O
a	0	O
nonsense	0	O
mutation	0	O
within	0	O
a	0	O
discrete	0	O
region	0	O
between	0	O
amino	0	O
acids	0	O
663	0	O
and	0	O
684	0	O
.	0	O


These	0	O
two	0	O
repeat	0	O
motifs	0	O
are	0	O
organized	0	O
in	0	O
an	0	O
extremely	0	O
well	0	O
-	0	O
ordered	0	O
pattern	0	O
in	0	O
each	0	O
domain	0	O
,	0	O
which	0	O
suggests	0	O
that	0	O
SbHRGP3	0	B
belongs	0	O
to	0	O
a	0	O
new	0	O
group	0	O
of	0	O
proteins	0	O
having	0	O
the	0	O
repeat	0	O
motifs	0	O
of	0	O
two	0	O
distinct	0	O
groups	0	O
of	0	O
dicot	0	B
extensins	0	I
.	0	O


The	0	O
downstream	0	O
,	0	O
TATA	0	O
-	0	O
less	0	O
promoter	0	O
has	0	O
high	0	O
G	1	O
+	0	O
C	1	O
content	0	O
,	0	O
and	0	O
exon	0	O
1b	0	O
predominates	0	O
among	0	O
abundantly	0	O
expressed	0	O
mRNA	1	O
species	0	O
.	0	O


Overproduction	1	O
of	0	O
HrcA	0	B
protein	0	I
from	0	O
a	0	O
second	0	O
copy	0	O
of	0	O
hrcA	0	B
derived	0	O
from	0	O
a	0	O
plasmid	0	O
(	0	O
phrcA	0	B
+)	0	O
in	0	O
B	1	O
.	0	O
subtilis	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
delta	0	O
hrcA	0	B
strains	0	O
prevented	0	O
heat	0	O
shock	0	O
induction	0	O
of	0	O
the	0	O
dnaK	0	B
and	0	O
groE	0	B
operons	0	I
at	0	O
the	0	O
level	0	O
of	0	O
transcription	0	O
almost	0	O
completely	0	O
and	0	O
strongly	0	O
reduced	0	O
the	0	O
amounts	0	O
of	0	O
mRNA	1	O
at	0	O
a	0	O
low	0	O
temperature	0	O
as	0	O
well	0	O
.	0	O


Compound	1	O
1	0	O
is	0	O
either	0	O
21	0	O
-	0	O
O	1	O
-	0	O
angeloyl	0	O
,	0	O
22	0	O
-	0	O
O	1	O
-	0	O
tigloyl	0	O
R1	0	O
-	0	O
barrigenol	0	O
,	0	O
or	0	O
21	0	O
-	0	O
O	1	O
-	0	O
tigloyl	0	O
,	0	O
22	0	O
-	0	O
O	1	O
-	0	O
angeloyl	0	O
R1	0	O
-	0	O
barrigenol	0	O
.	0	O


A	1	O
soluble	0	O
62	0	O
-	0	O
kDa	1	O
protein	0	O
was	0	O
produced	0	O
without	0	O
the	0	O
proteolytic	0	O
processing	0	O
by	0	O
inserting	0	O
the	0	O
coding	0	O
sequence	0	O
of	0	O
amino	0	O
acids	0	O
112	0	O
to	0	O
660	0	O
of	0	O
ORF	1	O
-	0	O
2	0	O
in	0	O
a	0	O
baculovirus	0	O
expression	0	O
vector	0	O
and	0	O
using	0	O
the	0	O
corresponding	0	O
virus	0	O
to	0	O
infect	0	O
Sf9	0	O
cells	0	O
.	0	O


The	0	O
purpose	0	O
of	0	O
the	0	O
study	0	O
reported	0	O
here	0	O
was	0	O
to	0	O
investigate	0	O
whether	0	O
differences	0	O
in	0	O
T1	1	O
and	0	O
T2	0	O
between	0	O
tumors	0	O
are	0	O
mainly	0	O
a	0	O
consequence	0	O
of	0	O
differences	0	O
in	0	O
the	0	O
fractional	0	O
volume	0	O
of	0	O
the	0	O
extracellular	0	O
compartment	0	O
.	0	O


The	0	O
future	0	O
of	0	O
research	0	O
with	0	O
interferon	0	B
may	0	O
be	0	O
divided	0	O
into	0	O
three	0	O
areas	0	O
:	0	O
Efforts	0	O
must	0	O
be	0	O
made	0	O
to	0	O
determine	0	O
how	0	O
best	0	O
to	0	O
translate	0	O
the	0	O
in	0	O
vitro	0	O
synergy	0	O
into	0	O
clinically	0	O
meaningful	0	O
terms	0	O
;	0	O
in	0	O
order	0	O
to	0	O
exploit	0	O
the	0	O
fullest	0	O
potential	0	O
of	0	O
IFN	1	B
,	0	O
research	0	O
is	0	O
moving	0	O
toward	0	O
using	0	O
this	0	O
agent	0	O
earlier	0	O
in	0	O
disease	0	O
either	0	O
as	0	O
an	0	O
adjuvant	0	O
after	0	O
tumor	0	O
debulking	0	O
or	0	O
after	0	O
initial	0	O
diagnosis	0	O
;	0	O
the	0	O
medical	0	O
community	0	O
must	0	O
rethink	0	O
the	0	O
natural	0	O
history	0	O
of	0	O
some	0	O
diseases	0	O
,	0	O
because	0	O
the	0	O
fullest	0	O
potential	0	O
of	0	O
the	0	O
biologic	0	O
agents	0	O
will	0	O
most	0	O
likely	0	O
manifest	0	O
itself	0	O
when	0	O
these	0	O
agents	0	O
are	0	O
used	0	O
together	0	O
.	0	O


The	0	O
predicted	0	O
Pay4p	0	B
sequence	0	I
contains	0	O
two	0	O
putative	0	O
ATP	1	O
-	0	O
binding	0	O
domains	0	O
and	0	O
shows	0	O
structural	0	O
relationships	0	O
to	0	O
other	0	O
potential	0	O
ATP	1	B
-	0	I
binding	0	I
proteins	0	I
involved	0	O
in	0	O
biological	0	O
processes	0	O
as	0	O
diverse	0	O
as	0	O
peroxisome	0	O
biogenesis	0	O
,	0	O
vesicle	0	O
-	0	O
mediated	0	O
protein	0	O
transport	0	O
,	0	O
cell	0	O
cycle	0	O
control	0	O
,	0	O
and	0	O
transcriptional	0	O
regulation	0	O
.	0	O


However	0	O
,	0	O
a	0	O
strongly	0	O
increased	0	O
frequency	0	O
of	0	O
CpG	0	O
dinucleotides	0	O
was	0	O
found	0	O
.	0	O


An	1	O
alternative	0	O
method	0	O
of	0	O
UKM	0	O
is	0	O
proposed	0	O
based	0	O
on	0	O
collecting	0	O
a	0	O
small	0	O
fraction	0	O
of	0	O
spent	0	O
dialysate	0	O
flow	0	O
for	0	O
3	0	O
consecutive	0	O
dialyses	0	O
.	0	O


Vitrectomy	1	O
in	0	O
ocular	0	O
traumatology	0	O


Characterization	0	O
of	0	O
fus1	0	B
of	0	O
Schizosaccharomyces	0	O
pombe	0	O
:	0	O
a	0	O
developmentally	0	O
controlled	0	O
function	0	O
needed	0	O
for	0	O
conjugation	0	O
.	0	O


The	0	O
results	0	O
obtained	0	O
tend	0	O
to	0	O
prove	0	O
that	0	O
the	0	O
reticuloendothelial	0	O
system	0	O
mainly	0	O
participated	0	O
in	0	O
beryllium	0	O
retention	0	O
.	0	O


The	0	O
aims	0	O
of	0	O
this	0	O
study	0	O
were	0	O
to	0	O
determine	0	O
and	0	O
rank	0	O
the	0	O
frequency	0	O
of	0	O
self	0	O
reported	0	O
visual	0	O
disability	0	O
in	0	O
daily	0	O
tasks	0	O
performed	0	O
by	0	O
glaucoma	0	O
patients	0	O
;	0	O
to	0	O
examine	0	O
the	0	O
interrelation	0	O
between	0	O
disabilities	0	O
using	0	O
factor	0	O
analysis	0	O
;	0	O
to	0	O
study	0	O
the	0	O
relation	0	O
between	0	O
perceived	0	O
visual	0	O
difficulty	0	O
and	0	O
a	0	O
measure	0	O
of	0	O
the	0	O
severity	0	O
of	0	O
visual	0	O
field	0	O
loss	0	O
;	0	O
to	0	O
develop	0	O
a	0	O
glaucoma	0	O
specific	0	O
subgroup	0	O
of	0	O
questions	0	O
;	0	O
and	0	O
examine	0	O
the	0	O
validity	0	O
and	0	O
reliability	0	O
of	0	O
this	0	O
subgroup	0	O
of	0	O
questions	0	O
.	0	O


Morphological	1	O
and	0	O
functional	0	O
alterations	0	O
noted	0	O
after	0	O
baboon	0	O
renal	0	O
allotransplantation	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
local	0	O
abnormalities	0	O
in	0	O
both	0	O
patients	0	O
can	0	O
support	0	O
the	0	O
hypothesis	0	O
that	0	O
the	0	O
cortex	0	O
,	0	O
especially	0	O
of	0	O
the	0	O
temporal	0	O
anterior	0	O
lobe	0	O
,	0	O
is	0	O
involved	0	O
in	0	O
the	0	O
origin	0	O
of	0	O
the	0	O
laughing	0	O
seizures	0	O
.	0	O


Co	1	O
-	0	O
administration	0	O
of	0	O
5FU	0	O
,	0	O
angiotensin	0	B
II	0	I
and	0	O
microspheres	0	O
via	0	O
the	0	O
hepatic	0	O
artery	0	O
may	0	O
reduce	0	O
drug	0	O
exposure	0	O
in	0	O
the	0	O
systemic	0	O
compartment	0	O
and	0	O
therefore	0	O
may	0	O
increase	0	O
the	0	O
therapeutic	0	O
ratio	0	O
of	0	O
5FU	0	O
administration	0	O
via	0	O
the	0	O
hepatic	0	O
artery	0	O
.	0	O


The	0	O
PSD2	0	B
gene	0	I
was	0	O
heterologously	0	O
expressed	0	O
by	0	O
infection	0	O
of	0	O
Sf	1	O
-	0	O
9	0	O
insect	0	O
cells	0	O
with	0	O
recombinant	0	O
baculovirus	0	O
,	0	O
resulting	0	O
in	0	O
a	0	O
10	0	O
-	0	O
fold	0	O
increase	0	O
in	0	O
PSD	0	B
activity	0	O
.	0	O


Elevation	1	O
of	0	O
intracellular	0	O
Ca	1	O
(	0	O
2	0	O
+)	0	O
levels	0	O
are	0	O
also	0	O
involved	0	O
because	0	O
treatment	0	O
with	0	O
receptor	0	O
-	0	O
associated	0	O
protein	0	O
,	0	O
nifedipine	0	O
,	0	O
MK801	0	O
,	0	O
removal	0	O
of	0	O
Ca	1	O
(	0	O
2	0	O
+)	0	O
from	0	O
the	0	O
medium	0	O
and	0	O
dantrolene	0	O
all	0	O
served	0	O
to	0	O
inhibit	0	O
calcium	0	O
elevation	0	O
and	0	O
attenuate	0	O
the	0	O
activation	0	O
of	0	O
CREB	0	B
.	0	O


GAL4	0	B
-	0	O
VP16	0	B
-	0	O
mediated	0	O
antirepression	0	O
required	0	O
an	0	O
auxiliary	0	O
factor	0	O
,	0	O
denoted	0	O
as	0	O
a	0	O
co	0	O
-	0	O
antirepressor	0	O
,	0	O
which	0	O
was	0	O
partially	0	O
purified	0	O
from	0	O
Drosophila	1	O
embryos	0	O
.	0	O


The	0	O
plant	0	O
hormone	0	O
auxin	0	O
transcriptionally	0	O
activates	0	O
early	0	B
genes	0	I
.	0	O


Clb2	0	B
/	0	O
Cdc28	0	B
kinase	0	O
is	0	O
not	0	O
required	0	O
for	0	O
the	0	O
repression	0	O
of	0	O
MCB	0	B
-	0	I
binding	0	I
factor	0	I
transcriptional	0	O
activity	0	O
in	0	O
G2	0	O
and	0	O
M	1	O
phase	0	O
.	0	O


Enzyme	1	O
histochemical	0	O
findings	0	O
in	0	O
the	0	O
ultimobranchial	0	O
body	0	O
of	0	O
the	0	O
horse	0	O


Prominent	0	O
findings	0	O
were	0	O
chronic	0	O
pancreatitis	0	O
with	0	O
acinar	0	O
and	0	O
ductal	0	O
plugs	0	O
,	0	O
granulomatous	0	O
and	0	O
necrotizing	0	O
peripancreatic	0	O
steatitis	0	O
,	0	O
degenerative	0	O
myopathy	0	O
,	0	O
testicular	0	O
atrophy	0	O
,	0	O
candidiasis	0	O
and	0	O
bacterial	0	O
necrotizing	0	O
glossitis	0	O
.	0	O


In	1	O
11	0	O
eyes	0	O
that	0	O
had	0	O
been	0	O
selected	0	O
at	0	O
random	0	O
10	0	O
micrograms	0	O
of	0	O
recombinant	0	B
tissue	0	I
plasminogen	0	I
activator	0	I
were	0	O
injected	0	O
midvitreally	0	O
24	0	O
hrs	0	O
later	0	O
.	0	O


The	0	O
medium	0	O
chains	0	O
of	0	O
these	0	O
complexes	0	O
,	0	O
mu1	0	B
and	0	O
mu2	0	B
,	0	O
have	0	O
been	0	O
implicated	0	O
in	0	O
two	0	O
types	0	O
of	0	O
interaction	0	O
:	0	O
assembly	0	O
with	0	O
the	0	O
beta1	0	B
and	0	I
beta2	0	I
chains	0	I
of	0	O
the	0	O
corresponding	0	O
complexes	0	O
and	0	O
recognition	0	O
of	0	O
tyrosine	0	O
-	0	O
based	0	O
sorting	0	O
signals	0	O
.	0	O


The	0	O
JTc	0	O
delta	0	O
among	0	O
the	0	O
three	0	O
groups	0	O
did	0	O
not	0	O
differ	0	O
as	0	O
well	0	O
:	0	O
JTc	0	O
delta	0	O
of	0	O
the	0	O
VT	1	O
group	0	O
was	0	O
70	0	O
ms	0	O
+/-	0	O
30	0	O
ms	0	O
,	0	O
the	0	O
JTc	0	O
delta	0	O
of	0	O
the	0	O
PVC	1	O
group	0	O
was	0	O
60	0	O
msec	0	O
+/-	0	O
25	0	O
msec	0	O
,	0	O
and	0	O
the	0	O
JTc	0	O
delta	0	O
of	0	O
the	0	O
control	0	O
group	0	O
was	0	O
70	0	O
ms	0	O
+/-	0	O
30	0	O
ms	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
The	0	O
special	0	O
clinical	0	O
presentation	0	O
of	0	O
our	0	O
case	0	O
of	0	O
possible	0	O
Gardner	0	O
'	0	O
s	0	O
syndrome	0	O
is	0	O
discussed	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
investigated	0	O
the	0	O
molecular	0	O
mechanisms	0	O
underlying	0	O
the	0	O
inducible	0	O
expression	0	O
of	0	O
the	0	O
flt	0	B
-	0	I
1	0	I
gene	0	I
during	0	O
the	0	O
activation	0	O
of	0	O
THP	0	O
-	0	O
1	0	O
cells	0	O
.	0	O


We	0	O
have	0	O
used	0	O
mutation	0	O
-	0	O
directed	0	O
chemical	0	O
cross	0	O
-	0	O
linking	0	O
with	0	O
bis	0	O
(	0	O
sulfosuccinimidyl	0	O
)	0	O
suberate	0	O
(	0	O
BS3	0	O
)	0	O
to	0	O
investigate	0	O
the	0	O
architecture	0	O
of	0	O
the	0	O
gp41	0	B
oligomer	0	I
.	0	O


The	0	O
characteristic	0	O
feature	0	O
of	0	O
liver	0	O
and	0	O
spleen	0	O
MP	1	O
function	0	O
in	0	O
patients	0	O
with	0	O
VHA	0	O
associated	0	O
with	0	O
HBsAg	1	B
carriership	0	O
consisted	0	O
in	0	O
the	0	O
lack	0	O
of	0	O
the	0	O
compensatory	0	O
reaction	0	O
on	0	O
the	0	O
part	0	O
of	0	O
spleen	0	O
MP	1	O
,	0	O
which	0	O
was	0	O
likely	0	O
to	0	O
be	0	O
connected	0	O
with	0	O
overstrain	0	O
of	0	O
long	0	O
standing	0	O
and	0	O
depletion	0	O
of	0	O
the	0	O
MP	1	O
system	0	O
due	0	O
to	0	O
permanent	0	O
antigenic	0	O
stimulation	0	O
of	0	O
HBsAg	1	B
.	0	O


Family	1	O
planning	0	O
continues	0	O
to	0	O
play	0	O
a	0	O
minor	0	O
role	0	O
,	0	O
and	0	O
only	0	O
25	0	O
.	0	O
3	0	O
per	0	O
cent	0	O
of	0	O
all	0	O
patients	0	O
reviewed	0	O
took	0	O
to	0	O
oral	0	O
contraceptives	0	O
for	0	O
shorter	0	O
or	0	O
longer	0	O
periods	0	O
of	0	O
time	0	O
.	0	O
-	0	O
The	0	O
percentages	0	O
of	0	O
primiparae	0	O
and	0	O
secundiparae	0	O
in	0	O
all	0	O
births	0	O
as	0	O
well	0	O
as	0	O
the	0	O
high	0	O
percentage	0	O
of	0	O
multigravidity	0	O
are	0	O
parameters	0	O
by	0	O
which	0	O
the	0	O
approach	0	O
to	0	O
reproduction	0	O
differs	0	O
substantively	0	O
from	0	O
behaviour	0	O
patterns	0	O
in	0	O
Europe	0	O
.	0	O


Batch	0	O
cultures	0	O
of	0	O
S	1	O
.	0	O
mutans	0	O
serotype	0	O
a	0	O
demonstrated	0	O
no	0	O
growth	0	O
on	0	O
MSB	0	O
agar	0	O
.	0	O


Bacillus	1	O
cereus	0	O
cross	0	O
-	0	O
infection	0	O
in	0	O
a	0	O
maternity	0	O
-	0	O
unit	0	O
.	0	O


Phosphate	1	B
glucose	0	I
dehydrogenase	0	I
deficiency	0	O
causing	0	O
hyperbilirubinemia	0	O
in	0	O
the	0	O
newborn	0	O


Administration	1	O
of	0	O
adrenaline	0	O
resulted	0	O
in	0	O
a	0	O
large	0	O
overestimation	0	O
of	0	O
the	0	O
SaO2	1	O
in	0	O
6	0	O
of	0	O
the	0	O
7	0	O
measurements	0	O
.	0	O


A	1	O
canonical	0	O
TATA	0	O
box	0	O
was	0	O
not	0	O
detected	0	O
.	0	O


Normal	1	O
baseline	0	O
(	0	O
day	0	O
-	0	O
8	0	O
)	0	O
PC	1	O
levels	0	O
(	0	O
86	0	O
and	0	O
89	0	O
%)	0	O
were	0	O
markedly	0	O
reduced	0	O
in	0	O
both	0	O
patients	0	O
at	0	O
the	0	O
time	0	O
of	0	O
VOD	0	O
manifestation	0	O
on	0	O
day	0	O
20	0	O
and	0	O
40	0	O
,	0	O
respectively	0	O
(	0	O
26	0	O
and	0	O
31	0	O
%).	0	O


In	1	O
contrast	0	O
,	0	O
H	1	B
-	0	I
NS	1	I
negative	0	O
regulation	0	O
operated	0	O
only	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
Fur	0	B
.	0	O


To	1	O
further	0	O
characterize	0	O
the	0	O
structure	0	O
and	0	O
evolutionary	0	O
synthesis	0	O
of	0	O
the	0	O
CMT1A	0	O
-	0	O
REP	1	O
repeat	0	O
,	0	O
fluorescent	0	O
in	0	O
situ	0	O
hybridization	0	O
(	0	O
FISH	1	O
)	0	O
analysis	0	O
and	0	O
heterologous	0	O
PCR	1	O
-	0	O
based	0	O
assays	0	O
were	0	O
carried	0	O
out	0	O
for	0	O
a	0	O
series	0	O
of	0	O
primates	0	O
.	0	O


The	0	O
results	0	O
of	0	O
supershift	0	O
analysis	0	O
using	0	O
specific	0	O
antibodies	0	O
against	0	O
transcription	0	O
factors	0	O
suggested	0	O
that	0	O
both	0	O
binding	0	O
complexes	0	O
contained	0	O
the	0	O
NF	1	B
-	0	I
kappaB	0	I
components	0	O
p50	0	B
and	0	O
p65	0	B
,	0	O
and	0	O
did	0	O
not	0	O
contain	0	O
other	0	O
NF	1	B
-	0	I
kappaB	0	I
proteins	0	I
(	0	O
p52	0	B
,	0	O
c	0	B
-	0	I
Rel	0	I
,	0	O
Rel	0	B
B	1	I
),	0	O
AP	1	B
-	0	I
1	0	I
proteins	0	I
(	0	O
c	0	B
-	0	I
Fos	1	I
,	0	O
C	1	B
-	0	I
Jun	1	I
),	0	O
CREB	0	B
or	0	O
C	1	B
/	0	I
EBPbeta	0	I
(	0	O
NF	1	B
-	0	I
IL6	0	I
).	0	O


However	0	O
,	0	O
experiments	0	O
with	0	O
S1	1	B
mapping	0	O
of	0	O
in	0	O
vivo	0	O
transcripts	0	O
,	0	O
gene	0	O
disruptions	0	O
in	0	O
the	0	O
alpha	0	O
region	0	O
,	0	O
and	0	O
a	0	O
single	0	O
-	0	O
copy	0	O
transcriptional	0	O
fusion	0	O
vector	0	O
all	0	O
suggested	0	O
that	0	O
these	0	O
possible	0	O
promoters	0	O
were	0	O
largely	0	O
inactive	0	O
during	0	O
logarithmic	0	O
growth	0	O
,	0	O
that	0	O
the	0	O
major	0	O
promoter	0	O
for	0	O
the	0	O
alpha	0	O
operon	0	O
lay	0	O
upstream	0	O
from	0	O
the	0	O
region	0	O
cloned	0	O
,	0	O
and	0	O
that	0	O
the	0	O
genes	0	O
in	0	O
the	0	O
IF1	0	B
to	0	O
L17	0	B
interval	0	O
were	0	O
cotranscribed	0	O
.	0	O


A	1	O
previous	0	O
report	0	O
described	0	O
that	0	O
a	0	O
548	0	O
-	0	O
bp	0	O
BglII	0	B
-	0	O
SmaI	0	B
fragment	0	O
has	0	O
an	0	O
SSO	0	O
activity	0	O
(	0	O
ori2	0	O
;	0	O
Kataoka	0	O
et	0	O
al	0	O
.,	0	O
Mol	1	O
.	0	O


Assuming	0	O
O2	1	O
consumption	0	O
of	0	O
the	0	O
isolated	0	O
skin	0	O
to	0	O
be	0	O
same	0	O
as	0	O
in	0	O
situ	0	O
,	0	O
calculations	0	O
showed	0	O
that	0	O
when	0	O
water	0	O
PO2	1	O
was	0	O
high	0	O
(	0	O
150	0	O
mm	0	O
Hg	1	O
),	0	O
about	0	O
40	0	O
%	0	O
of	0	O
total	0	O
cutaneous	0	O
O2	1	O
uptake	0	O
was	0	O
consumed	0	O
by	0	O
the	0	O
skin	0	O
.	0	O


Thus	0	O
,	0	O
elongin	0	B
C	1	I
is	0	O
found	0	O
to	0	O
oligomerize	0	O
in	0	O
solution	0	O
and	0	O
to	0	O
undergo	0	O
significant	0	O
structural	0	O
rearrangements	0	O
upon	0	O
binding	0	O
of	0	O
two	0	O
different	0	O
partner	0	O
proteins	0	O
.	0	O


As	1	O
the	0	O
high	0	O
-	0	O
affinity	0	O
Mg2	0	O
+	0	O
binding	0	O
sites	0	O
are	0	O
filled	0	O
,	0	O
the	0	O
primer	0	O
terminus	0	O
migrates	0	O
from	0	O
the	0	O
exonuclease	0	O
site	0	O
to	0	O
a	0	O
highly	0	O
based	0	O
stacked	0	O
polymerase	0	O
active	0	O
site	0	O
.	0	O


These	0	O
residues	0	O
,	0	O
Ile244	0	O
at	0	O
the	0	O
extracellular	0	O
end	0	O
of	0	O
transmembrane	0	O
helix	0	O
3	0	O
,	0	O
and	0	O
Tyr318	0	O
at	0	O
the	0	O
COOH	0	O
-	0	O
terminal	0	O
portion	0	O
of	0	O
extracellular	0	O
loop	0	O
2	0	O
,	0	O
are	0	O
replaced	0	O
by	0	O
Leu	1	O
and	0	O
Ile	1	O
in	0	O
the	0	O
PTH	1	B
-	0	I
1	0	I
receptor	0	I
,	0	O
respectively	0	O
.	0	O


Among	0	O
mammalian	0	B
HSFs	0	I
,	0	O
HSF1	0	B
has	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
important	0	O
for	0	O
regulation	0	O
of	0	O
the	0	O
heat	0	O
-	0	O
induced	0	O
stress	0	O
gene	0	O
expression	0	O
,	0	O
whereas	0	O
the	0	O
function	0	O
of	0	O
HSF2	0	B
in	0	O
stress	0	O
response	0	O
is	0	O
unclear	0	O
.	0	O


A	1	O
diagnosis	0	O
of	0	O
MS	1	O
was	0	O
made	0	O
based	0	O
on	0	O
subtle	0	O
neurologic	0	O
signs	0	O
,	0	O
spinal	0	O
fluid	0	O
gamma	0	B
globulin	0	I
elevations	0	O
,	0	O
and	0	O
abnormalities	0	O
in	0	O
neuropsychological	0	O
testing	0	O
.	0	O


The	0	O
authors	0	O
evaluate	0	O
the	0	O
clinical	0	O
efficacy	0	O
of	0	O
EMB	1	O
AZS	0	O
in	0	O
recurrent	0	O
ulcer	0	O
after	0	O
operation	0	O
on	0	O
the	0	O
stomach	0	O
caused	0	O
by	0	O
a	0	O
high	0	O
level	0	O
of	0	O
acid	0	O
production	0	O
and	0	O
ulcerative	0	O
gastroduodenal	0	O
bleeding	0	O
.	0	O


Self	1	O
-	0	O
emasculation	0	O
is	0	O
the	0	O
end	0	O
result	0	O
of	0	O
an	0	O
unusual	0	O
psychiatric	0	O
disorder	0	O
,	0	O
which	0	O
initially	0	O
requires	0	O
surgical	0	O
treatment	0	O
.	0	O


Repression	1	O
is	0	O
alleviated	0	O
when	0	O
the	0	O
two	0	O
(	0	O
for	0	O
E2	1	B
)	0	O
or	0	O
three	0	O
(	0	O
for	0	O
E2	1	B
-	0	I
C	1	I
)	0	O
promoter	0	O
-	0	O
proximal	0	O
copies	0	O
of	0	O
E2	1	B
-	0	O
RS	1	O
are	0	O
mutated	0	O
.	0	O


Protein	1	O
phosphatases	0	O
play	0	O
a	0	O
critical	0	O
role	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
the	0	O
eukaryotic	0	O
cell	0	O
cycle	0	O
and	0	O
signal	0	O
transduction	0	O
.	0	O


Here	0	O
we	0	O
have	0	O
investigated	0	O
the	0	O
structural	0	O
requirements	0	O
and	0	O
consequences	0	O
of	0	O
regulatory	0	O
phosphorylation	0	O
for	0	O
the	0	O
interaction	0	O
between	0	O
c	0	B
-	0	I
Jun	1	I
and	0	O
JNK	0	B
in	0	O
vivo	0	O
.	0	O


The	0	O
hypertension	0	O
with	0	O
elevated	0	O
PRA	1	O
,	0	O
however	0	O
,	0	O
was	0	O
resistant	0	O
to	0	O
the	0	O
angiotensin	0	B
II	0	I
(	0	O
AII	1	B
)	0	O
analog	0	O
[	0	O
Sar1	0	O
,	0	O
Ile8	0	O
]	0	O
ALL	1	O
.	0	O


By	0	O
sequence	0	O
comparison	0	O
,	0	O
42	0	O
blocks	0	O
of	0	O
homology	0	O
are	0	O
defined	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
terminal	0	O
region	0	O
,	0	O
of	0	O
which	0	O
36	0	O
appear	0	O
in	0	O
the	0	O
CpG	0	O
island	0	O
and	0	O
contain	0	O
numerous	0	O
conserved	0	O
CpG	0	O
dinucleotides	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
The	0	O
myocardial	0	O
uptake	0	O
of	0	O
99mTc	0	O
sestamibi	0	O
in	0	O
normal	0	O
subjects	0	O
and	0	O
patients	0	O
with	0	O
coronary	0	O
artery	0	O
disease	0	O
is	0	O
comparable	0	O
after	0	O
exercise	0	O
,	0	O
dipyridamole	0	O
,	0	O
and	0	O
adenosine	0	O
stress	0	O
.	0	O


A	1	O
rare	0	O
chronic	0	O
course	0	O
of	0	O
Budd	0	O
-	0	O
Chiari	0	O
syndrome	0	O
associated	0	O
with	0	O
thrombosis	0	O
of	0	O
the	0	O
portal	0	O
vein	0	O
was	0	O
observed	0	O
in	0	O
a	0	O
30	0	O
-	0	O
year	0	O
-	0	O
old	0	O
male	0	O
patient	0	O
suffering	0	O
from	0	O
postmyocarditic	0	O
cardiosclerosis	0	O
.	0	O


UAS1	0	O
is	0	O
the	0	O
binding	0	O
site	0	O
for	0	O
the	0	O
transcriptional	0	O
regulator	0	O
Adr1p	0	B
.	0	O


MATERIAL	1	O
AND	0	O
METHODS	0	O
:	0	O
Of	0	O
the	0	O
17	0	O
men	0	O
and	0	O
17	0	O
women	0	O
,	0	O
who	0	O
were	0	O
21	0	O
to	0	O
80	0	O
years	0	O
of	0	O
age	0	O
,	0	O
27	0	O
had	0	O
hereditary	0	O
motor	0	O
and	0	O
sensory	0	O
neuropathy	0	O
type	0	O
I	1	O
and	0	O
7	0	O
had	0	O
acquired	0	O
demyelinating	0	O
polyneuropathy	0	O
.	0	O


When	0	O
expressed	0	O
alone	0	O
in	0	O
test	0	O
cells	0	O
,	0	O
Atr	0	B
-	0	I
I	1	I
is	0	O
unable	0	O
to	0	O
bind	0	O
TGF	1	B
-	0	I
beta	0	I
,	0	O
activin	0	B
,	0	O
or	0	O
bone	0	B
morphogenetic	0	I
protein	0	I
2	0	I
.	0	O


In	1	O
4	0	O
spinalized	0	O
cats	0	O
,	0	O
the	0	O
effects	0	O
of	0	O
afferent	0	O
inputs	0	O
from	0	O
hindlimb	0	O
cutaneous	0	O
nerves	0	O
(	0	O
sural	0	O
cutaneous	0	O
nerve	0	O
:	0	O
Sur	0	O
)	0	O
on	0	O
mono	0	O
-	0	O
and	0	O
poly	0	O
-	0	O
synaptic	0	O
reflex	0	O
recorded	0	O
from	0	O
tail	0	O
muscle	0	O
motoneurons	0	O
were	0	O
studied	0	O
before	0	O
and	0	O
after	0	O
spinal	0	O
lesioning	0	O
at	0	O
S2	1	O
-	0	O
3	0	O
level	0	O
.	0	O


Comparisons	0	O
with	0	O
other	0	O
known	0	O
germins	0	B
and	0	O
germin	0	B
-	0	I
like	0	I
proteins	0	I
indicate	0	O
that	0	O
these	0	O
Arabidopsis	0	O
GLP	1	B
subfamilies	0	O
are	0	O
unique	0	O
from	0	O
wheat	0	O
germin	0	B
.	0	O


Lauciello	0	O
describes	0	O
a	0	O
technique	0	O
for	0	O
the	0	O
placement	0	O
of	0	O
functionally	0	O
generated	0	O
amalgam	0	O
stops	0	O
as	0	O
restorations	0	O
within	0	O
mandibular	0	O
acrylic	0	O
teeth	0	O
.	0	O


Effect	1	O
of	0	O
tracheal	0	O
insufflation	0	O
of	0	O
deferoxamine	0	O
on	0	O
acute	0	O
ozone	0	O
toxicity	0	O
in	0	O
rats	0	O
.	0	O


A	1	O
3	0	O
-	0	O
yr	0	O
retrospective	0	O
review	0	O
is	0	O
effective	0	O
and	0	O
detects	0	O
94	0	O
%	0	O
of	0	O
the	0	O
undercalls	0	O
.	0	O


Use	0	O
of	0	O
Selenastrum	0	O
capricornutum	0	O
and	0	O
Microfeast	0	O
as	0	O
food	0	O
for	0	O
Daphnia	1	O
pulex	0	O
.	0	O


Below	0	O
50	0	O
%	0	O
decrease	0	O
of	0	O
PaO2	1	O
,	0	O
NADH	1	O
was	0	O
reduced	0	O
largely	0	O
.	0	O


The	0	O
cis	0	O
-	0	O
acting	0	O
element	0	O
mediating	0	O
glucocorticoid	0	O
inducibility	0	O
of	0	O
the	0	O
chicken	0	B
glutamine	0	I
synthetase	0	I
gene	0	I
has	0	O
been	0	O
identified	0	O
.	0	O


In	1	O
endemic	0	O
BL	0	O
,	0	O
the	0	O
RB2	0	B
/	0	O
p130	0	B
gene	0	O
is	0	O
mutated	0	O
in	0	O
most	0	O
of	0	O
the	0	O
cases	0	O
,	0	O
and	0	O
the	0	O
protein	0	O
is	0	O
restricted	0	O
to	0	O
the	0	O
cytoplasm	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
Cdc42p	0	B
is	0	O
in	0	O
fact	0	O
required	0	O
for	0	O
pheromone	0	O
response	0	O
and	0	O
that	0	O
interaction	0	O
with	0	O
the	0	O
PAK	0	B
Ste20p	0	I
is	0	O
critical	0	O
for	0	O
that	0	O
role	0	O
.	0	O


Distinguishing	0	O
roles	0	O
of	0	O
the	0	O
membrane	0	O
-	0	O
cytoskeleton	0	O
and	0	O
cadherin	0	B
mediated	0	O
cell	0	O
-	0	O
cell	0	O
adhesion	0	O
in	0	O
generating	0	O
different	0	O
Na	1	B
+,	0	I
K	1	I
(+)-	0	I
ATPase	1	I
distributions	0	O
in	0	O
polarized	0	O
epithelia	0	O
.	0	O


More	0	O
mRNA	1	O
corresponding	0	O
to	0	O
nagB	0	B
and	0	O
nagA	0	B
is	0	O
detected	0	O
than	0	O
that	0	O
corresponding	0	O
to	0	O
the	0	O
distal	0	O
genes	0	O
,	0	O
nagC	0	B
and	0	O
nagD	0	B
.	0	O


Though	0	O
hepatomegaly	0	O
and	0	O
mild	0	O
elevation	0	O
of	0	O
enzymes	0	O
can	0	O
be	0	O
observed	0	O
in	0	O
a	0	O
significant	0	O
proportion	0	O
of	0	O
patients	0	O
,	0	O
involvement	0	O
of	0	O
liver	0	O
leading	0	O
to	0	O
acute	0	O
hepatitis	0	O
or	0	O
liver	0	O
cell	0	O
necrosis	0	O
is	0	O
a	0	O
relatively	0	O
uncommon	0	O
complication	0	O
in	0	O
P	1	O
.	0	O
falciparum	0	O
malaria	0	O
.	0	O


High	0	O
dosages	0	O
of	0	O
D	1	O
-	0	O
penicillamine	0	O
in	0	O
pulmonary	0	O
fibroses	0	O


Mitogen	1	B
-	0	I
activated	0	I
protein	0	I
(	0	I
MAP	1	I
)	0	I
kinase	0	I
phosphatase	0	I
-	0	I
3	0	I
(	0	O
MKP	0	B
-	0	I
3	0	I
)	0	O
is	0	O
a	0	O
dual	0	O
specificity	0	O
phosphatase	0	O
that	0	O
inactivates	0	O
extracellular	0	B
signal	0	I
-	0	I
regulated	0	I
kinase	0	I
(	0	O
ERK	0	B
)	0	O
MAP	1	B
kinases	0	I
.	0	O


If	1	O
we	0	O
apply	0	O
the	0	O
finding	0	O
of	0	O
non	0	O
-	0	O
visualization	0	O
of	0	O
the	0	O
GB	1	O
at	0	O
4	0	O
h	0	O
post	0	O
injection	0	O
as	0	O
the	0	O
criterion	0	O
for	0	O
the	0	O
diagnosis	0	O
of	0	O
AC	1	O
,	0	O
the	0	O
diagnostic	0	O
accuracy	0	O
was	0	O
only	0	O
40	0	O
.	0	O
7	0	O
%	0	O
(	0	O
11	0	O
/	0	O
27	0	O
).	0	O


In	1	O
76	0	O
%	0	O
of	0	O
59	0	O
lead	0	O
-	0	O
toxic	0	O
children	0	O
,	0	O
bone	0	O
lead	0	O
values	0	O
measured	0	O
by	0	O
LXRF	0	O
were	0	O
equal	0	O
to	0	O
or	0	O
greater	0	O
than	0	O
those	0	O
measured	0	O
in	0	O
normal	0	O
and	0	O
industrially	0	O
exposed	0	O
adults	0	O
.	0	O


In	1	O
all	0	O
cases	0	O
the	0	O
antigenemia	0	O
was	0	O
transient	0	O
and	0	O
cleared	0	O
by	0	O
28th	0	O
day	0	O
post	0	O
-	0	O
vaccination	0	O
.	0	O


No	1	O
causal	0	O
relations	0	O
may	0	O
be	0	O
inferred	0	O
from	0	O
the	0	O
correlation	0	O
between	0	O
the	0	O
level	0	O
of	0	O
trapezius	0	O
activity	0	O
and	0	O
complaints	0	O
,	0	O
though	0	O
it	0	O
indicates	0	O
that	0	O
individual	0	O
,	0	O
inexpedient	0	O
muscle	0	O
activity	0	O
patterns	0	O
may	0	O
constitute	0	O
an	0	O
important	0	O
risk	0	O
factor	0	O
for	0	O
development	0	O
of	0	O
musculo	0	O
-	0	O
skeletal	0	O
complaints	0	O
.	0	O


Much	0	O
evidence	0	O
indicates	0	O
that	0	O
p38	0	B
is	0	O
an	0	O
activator	0	O
of	0	O
MyoD	0	B
:	0	O
(	0	O
i	0	O
)	0	O
p38	0	B
kinase	0	I
activity	0	O
is	0	O
required	0	O
for	0	O
the	0	O
expression	0	O
of	0	O
MyoD	0	B
-	0	O
responsive	0	O
genes	0	O
,	0	O
(	0	O
ii	0	O
)	0	O
enforced	0	O
induction	0	O
of	0	O
p38	0	B
stimulates	0	O
the	0	O
transcriptional	0	O
activity	0	O
of	0	O
a	0	O
Gal4	0	B
-	0	O
MyoD	0	B
fusion	0	O
protein	0	O
and	0	O
allows	0	O
efficient	0	O
activation	0	O
of	0	O
chromatin	0	O
-	0	O
integrated	0	O
reporters	0	O
by	0	O
MyoD	0	B
,	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
MyoD	0	B
-	0	O
dependent	0	O
myogenic	0	O
conversion	0	O
is	0	O
reduced	0	O
in	0	O
mouse	0	O
embryonic	0	O
fibroblasts	0	O
derived	0	O
from	0	O
p38alpha	0	B
(-/-)	0	I
embryos	0	O
.	0	O


Thirty	0	O
-	0	O
five	0	O
patients	0	O
were	0	O
included	0	O
.	0	O


18F	0	O
and	0	O
85Sr	0	O
scintimetry	0	O
in	0	O
the	0	O
study	0	O
of	0	O
primary	0	O
arthropathies	0	O
.	0	O


The	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
organization	0	O
of	0	O
functional	0	O
units	0	O
of	0	O
the	0	O
72	0	O
-	0	O
bp	0	O
repeat	0	O
required	0	O
for	0	O
transcriptional	0	O
enhancement	0	O
of	0	O
the	0	O
early	0	O
promoter	0	O
is	0	O
different	0	O
from	0	O
that	0	O
required	0	O
for	0	O
late	0	O
promoter	0	O
function	0	O
.	0	O


Evoked	0	O
potential	0	O
and	0	O
single	0	O
unit	0	O
responses	0	O
to	0	O
olfactory	0	O
nerve	0	O
volleys	0	O
in	0	O
the	0	O
isolated	0	O
turtle	0	O
olfactory	0	O
bulb	0	O
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
,	0	O
we	0	O
identified	0	O
a	0	O
strong	0	O
positive	0	O
cis	0	O
-	0	O
regulatory	0	O
element	0	O
at	0	O
-	0	O
70	0	O
bp	0	O
to	0	O
-	0	O
75	0	O
bp	0	O
in	0	O
the	0	O
LpS1	0	B
beta	0	I
promoter	0	I
with	0	O
the	0	O
sequence	0	O
(	0	O
G	1	O
)	0	O
6	0	O
and	0	O
a	0	O
similar	0	O
,	0	O
more	0	O
distal	0	O
cis	0	O
-	0	O
element	0	O
at	0	O
-	0	O
721	0	O
bp	0	O
to	0	O
-	0	O
726	0	O
bp	0	O
.	0	O


Update	0	O
on	0	O
maternal	0	O
-	0	O
fetal	0	O
infections	0	O
by	0	O
hepatitis	0	O
C	1	O
,	0	O
HIV	1	O
and	0	O
cytomegalovirus	0	O


The	0	O
influence	0	O
of	0	O
a	0	O
high	0	O
ionic	0	O
strength	0	O
on	0	O
the	0	O
resolution	0	O
was	0	O
clearly	0	O
shown	0	O
.	0	O


The	0	O
activity	0	O
of	0	O
the	0	O
coat	0	B
protein	0	I
promoter	0	I
of	0	O
chloris	0	O
striate	0	O
mosaic	0	O
virus	0	O
is	0	O
enhanced	0	O
by	0	O
its	0	O
own	0	O
and	0	O
C1	1	B
-	0	O
C2	1	B
gene	0	O
products	0	O
.	0	O


Of	0	O
the	0	O
cases	0	O
with	0	O
PLD	0	O
,	0	O
50	0	O
%	0	O
had	0	O
associated	0	O
renal	0	O
cysts	0	O
and	0	O
10	0	O
%	0	O
of	0	O
the	0	O
cases	0	O
with	0	O
APCD	0	O
had	0	O
associated	0	O
liver	0	O
cysts	0	O
.	0	O


The	0	O
sequence	0	O
was	0	O
determined	0	O
for	0	O
a	0	O
4024	0	O
-	0	O
base	0	O
pair	0	O
(	0	O
bp	0	O
)	0	O
segment	0	O
that	0	O
extends	0	O
from	0	O
149	0	O
bp	0	O
5	0	O
'	0	O
to	0	O
the	0	O
cap	0	O
site	0	O
of	0	O
alpha	0	B
1	0	I
to	0	O
207	0	O
bp	0	O
3	0	O
'	0	O
to	0	O
psi	0	B
alpha	0	I
.	0	O


Molecular	1	O
cloning	0	O
and	0	O
sequencing	0	O
of	0	O
a	0	O
cDNA	1	O
encoding	0	O
SR	1	B
beta	0	I
revealed	0	O
that	0	O
SR	1	B
beta	0	I
is	0	O
a	0	O
transmembrane	0	O
protein	0	O
and	0	O
,	0	O
like	0	O
SR	1	B
alpha	0	I
and	0	O
SRP54	0	B
,	0	O
is	0	O
a	0	O
member	0	O
of	0	O
the	0	O
GTPase	1	B
superfamily	0	I
.	0	O


The	0	O
effects	0	O
of	0	O
high	0	O
intensity	0	O
light	0	O
emissions	0	O
,	0	O
produced	0	O
by	0	O
a	0	O
novel	0	O
pulsed	0	O
power	0	O
energization	0	O
technique	0	O
(	0	O
PPET	0	O
),	0	O
on	0	O
the	0	O
survival	0	O
of	0	O
bacterial	0	O
populations	0	O
of	0	O
verocytotoxigenic	0	O
Escherichia	1	O
coli	0	O
(	0	O
serotype	0	O
0157	0	O
:	0	O
H7	0	O
)	0	O
and	0	O
Listeria	1	O
monocytogenes	0	O
(	0	O
serotype	0	O
4b	0	O
)	0	O
were	0	O
investigated	0	O
.	0	O


The	0	O
reduction	0	O
in	0	O
saturated	0	O
fatty	0	O
acids	0	O
intake	0	O
led	0	O
to	0	O
modest	0	O
(	0	O
but	0	O
in	0	O
group	0	O
1	0	O
significant	0	O
)	0	O
0	0	O
.	0	O
15	0	O
mmol	0	O
/	0	O
l	0	O
(	0	O
2	0	O
.	0	O
5	0	O
%)	0	O
reduction	0	O
in	0	O
total	0	O
serum	0	O
cholesterol	0	O
level	0	O
.	0	O


The	0	O
other	0	O
element	0	O
bound	0	O
RBP	1	B
-	0	I
J	1	I
kappa	0	I
with	0	O
low	0	O
affinity	0	O
.	0	O


QBMDs	0	O
for	0	O
a	0	O
5	0	O
%	0	O
change	0	O
in	0	O
response	0	O
(	0	O
QBMD05	0	O
)	0	O
were	0	O
6	0	O
-	0	O
fold	0	O
lower	0	O
,	0	O
on	0	O
average	0	O
,	0	O
than	0	O
the	0	O
corresponding	0	O
NOAEL	1	O
.	0	O


Surprisingly	0	O
,	0	O
Northern	0	O
(	0	O
RNA	1	O
)	0	O
blot	0	O
analysis	0	O
and	0	O
reverse	0	B
transcriptase	0	I
-	0	O
PCRs	0	O
performed	0	O
after	0	O
transfection	0	O
of	0	O
COS	1	O
-	0	O
7	0	O
or	0	O
HeLa	0	O
cells	0	O
with	0	O
these	0	O
viral	0	O
RNAs	0	O
revealed	0	O
that	0	O
Y88S	0	B
and	0	O
Y88L	0	B
RNAs	0	I
replicated	0	O
at	0	O
only	0	O
very	0	O
low	0	O
levels	0	O
.	0	O


Functional	1	O
characterization	0	O
of	0	O
a	0	O
fraction	0	O
identified	0	O
by	0	O
its	0	O
activity	0	O
in	0	O
a	0	O
second	0	O
template	0	O
rescue	0	O
assay	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
TRP1	0	B
RI	1	O
Circle	1	O
DNA	1	O
is	0	O
organized	0	O
into	0	O
nucleosomes	0	O
whose	0	O
size	0	O
and	0	O
spacing	0	O
are	0	O
indistinguishable	0	O
from	0	O
that	0	O
of	0	O
bulk	0	O
yeast	0	O
chromatin	0	O
.	0	O


Tl	1	O
-	0	O
201	0	O
uptake	0	O
ratio	0	O
of	0	O
the	0	O
right	0	O
ventricle	0	O
,	0	O
which	0	O
represents	0	O
the	0	O
ratio	0	O
of	0	O
total	0	O
counts	0	O
of	0	O
the	0	O
right	0	O
ventricle	0	O
to	0	O
counts	0	O
of	0	O
the	0	O
administered	0	O
dose	0	O
of	0	O
Tl	1	O
-	0	O
201	0	O
,	0	O
was	0	O
higher	0	O
in	0	O
COPD	1	O
,	0	O
especially	0	O
in	0	O
pulmonary	0	O
emphysema	0	O
and	0	O
B	1	O
type	0	O
COPD	1	O
by	0	O
Burrows	0	O
classification	0	O
than	0	O
in	0	O
controls	0	O
.	0	O


Thus	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
a	0	O
GRE	0	O
sufficient	0	O
to	0	O
account	0	O
for	0	O
full	0	O
glucocorticoid	0	O
inducibility	0	O
and	0	O
an	0	O
HNF	1	B
-	0	I
1	0	I
site	0	I
close	0	O
to	0	O
the	0	O
promoter	0	O
that	0	O
are	0	O
major	0	O
determinants	0	O
of	0	O
transcriptional	0	O
control	0	O
of	0	O
the	0	O
Xenopus	1	B
fibrinogen	0	I
B	1	I
beta	0	I
subunit	0	I
gene	0	I
in	0	O
cells	0	O
from	0	O
normal	0	O
liver	0	O
tissue	0	O
.	0	O


Viral	1	O
cell	0	O
-	0	O
to	0	O
-	0	O
cell	0	O
movement	0	O
of	0	O
PVX	0	B
CP	1	I
mutant	0	I
was	0	O
complemented	0	O
in	0	O
Nicotiana	1	O
tabacum	0	O
cv	0	O
.	0	O


Interestingly	0	O
,	0	O
this	0	O
amino	0	O
-	0	O
terminal	0	O
determinant	0	O
appears	0	O
not	0	O
to	0	O
reside	0	O
in	0	O
the	0	O
HSV	1	O
-	0	O
alpha	0	B
TIF	0	I
,	0	O
which	0	O
displays	0	O
no	0	O
independent	0	O
amino	0	O
-	0	O
terminal	0	O
activity	0	O
.	0	O


Within	0	O
a	0	O
135	0	O
-	0	O
bp	0	O
core	0	O
homology	0	O
region	0	O
,	0	O
the	0	O
human	0	B
HS12	0	I
enhancers	0	I
are	0	O
approximately	0	O
90	0	O
%	0	O
identical	0	O
to	0	O
the	0	O
murine	0	O
homolog	0	O
and	0	O
include	0	O
several	0	O
motifs	0	O
previously	0	O
demonstrated	0	O
to	0	O
be	0	O
important	0	O
for	0	O
function	0	O
of	0	O
the	0	O
murine	0	O
enhancer	0	O
;	0	O
additional	0	O
segments	0	O
of	0	O
high	0	O
sequence	0	O
conservation	0	O
suggest	0	O
the	0	O
possibility	0	O
of	0	O
previously	0	O
unrecognized	0	O
functional	0	O
motifs	0	O
.	0	O


A	1	O
drug	0	O
with	0	O
ISA	1	O
"	0	O
down	0	O
regulates	0	O
"	0	O
beta	0	B
receptors	0	I
;	0	O
thus	0	O
,	0	O
when	0	O
the	0	O
drug	0	O
is	0	O
withdrawn	0	O
there	0	O
is	0	O
no	0	O
post	0	O
-	0	O
beta	0	O
-	0	O
blocking	0	O
drug	0	O
hypersensitivity	0	O
in	0	O
contrast	0	O
to	0	O
agents	0	O
without	0	O
ISA	1	O
.	0	O


Incidental	0	O
findings	0	O
in	0	O
the	0	O
epidermis	0	O
and	0	O
in	0	O
the	0	O
intraepidermal	0	O
eccrine	0	O
sweat	0	O
duct	0	O
units	0	O
.	0	O


In	1	O
a	0	O
retrospective	0	O
analysis	0	O
of	0	O
first	0	O
-	0	O
time	0	O
total	0	O
colonoscopies	0	O
in	0	O
685	0	O
patients	0	O
,	0	O
we	0	O
investigated	0	O
the	0	O
relationship	0	O
between	0	O
hyperplastic	0	O
and	0	O
adenomatous	0	O
polyps	0	O
.	0	O


Significant	1	O
correlations	0	O
between	0	O
mental	0	O
status	0	O
as	0	O
measured	0	O
by	0	O
the	0	O
Mini	0	O
-	0	O
Mental	1	O
State	1	O
Examination	1	O
and	0	O
NA	1	O
/	0	O
mI	1	O
,	0	O
mI	1	O
/	0	O
Cr	1	O
and	0	O
NA	1	O
were	0	O
found	0	O
.	0	O


The	0	O
transcriptional	0	O
activities	0	O
of	0	O
the	0	O
full	0	O
-	0	O
length	0	O
promoter	0	O
(-	0	O
295	0	O
to	0	O
+	0	O
85	0	O
)	0	O
and	0	O
of	0	O
three	0	O
deletion	0	O
constructs	0	O
(-	0	O
197	0	O
,	0	O
-	0	O
154	0	O
and	0	O
-	0	O
74	0	O
to	0	O
+	0	O
85	0	O
)	0	O
were	0	O
significantly	0	O
down	0	O
-	0	O
regulated	0	O
in	0	O
resistant	0	O
cells	0	O
.	0	O


The	0	O
endodontal	0	O
treatment	0	O
need	0	O
has	0	O
been	0	O
forming	0	O
a	0	O
clinical	0	O
order	0	O
of	0	O
magnitude	0	O
.	0	O


Exon	1	O
-	0	O
intron	0	O
junctions	0	O
in	0	O
the	0	O
human	0	O
and	0	O
rat	0	B
AdoMet	0	I
decarboxylase	0	I
genes	0	I
were	0	O
in	0	O
identical	0	O
positions	0	O
except	0	O
that	0	O
exons	0	O
6	0	O
and	0	O
7	0	O
of	0	O
the	0	O
human	0	O
gene	0	O
formed	0	O
a	0	O
single	0	O
exon	0	O
in	0	O
the	0	O
rat	0	O
gene	0	O
.	0	O


HupI	0	B
showed	0	O
strong	0	O
identity	0	O
to	0	O
rubredoxin	0	B
and	0	O
rubredoxin	0	B
-	0	I
like	0	I
proteins	0	I
from	0	O
many	0	O
other	0	O
bacteria	0	O
.	0	O


Difficulties	0	O
bound	0	O
to	0	O
measuring	0	O
of	0	O
sputum	0	O
viscosity	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
ketamine	0	O
-	0	O
treated	0	O
rats	0	O
had	0	O
more	0	O
neurons	0	O
and	0	O
glial	0	O
cells	0	O
surrounding	0	O
the	0	O
ventricles	0	O
.	0	O


Chem	0	O
.	0	O


Using	0	O
GST	0	B
-	0	O
PKR	0	B
fusion	0	O
chromatography	0	O
,	0	O
direct	0	O
physical	0	O
interaction	0	O
between	0	O
the	0	O
mouse	0	O
and	0	O
human	0	B
PKR	0	I
homologs	0	I
was	0	O
established	0	O
.	0	O


Primer	1	O
extension	0	O
and	0	O
cDNA	1	O
cloning	0	O
were	0	O
used	0	O
to	0	O
isolate	0	O
the	0	O
complete	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
Nramp1	0	B
mRNA	1	I
.	0	O


AMY	0	B
-	0	I
1	0	I
was	0	O
localized	0	O
in	0	O
the	0	O
cytoplasm	0	O
in	0	O
cells	0	O
expressing	0	O
c	0	B
-	0	I
myc	0	I
at	0	O
low	0	O
levels	0	O
,	0	O
but	0	O
in	0	O
the	0	O
nucleus	0	O
in	0	O
the	0	O
cells	0	O
of	0	O
a	0	O
high	0	O
c	0	B
-	0	I
myc	0	I
expression	0	O
in	0	O
transiently	0	O
transfected	0	O
cells	0	O
.	0	O


At	1	O
a	0	O
systolic	0	O
blood	0	O
pressure	0	O
(	0	O
BP	1	O
)	0	O
of	0	O
60	0	O
mmHg	0	O
,	0	O
C02	0	O
responsiveness	0	O
was	0	O
abolished	0	O
,	0	O
but	0	O
was	0	O
maintained	0	O
at	0	O
higher	0	O
levels	0	O
of	0	O
BP	1	O
.	0	O


Northern	0	O
analysis	0	O
of	0	O
the	0	O
3	0	B
.	0	I
1	0	I
-	0	I
kb	0	I
PWP2H	0	I
cDNA	1	I
revealed	0	O
that	0	O
a	0	O
3	0	O
.	0	O
3	0	O
-	0	O
kb	0	O
major	0	O
transcript	0	O
is	0	O
ubiquitously	0	O
expressed	0	O
in	0	O
human	0	O
adult	0	O
tissues	0	O
.	0	O


Upon	0	O
UV	1	O
damage	0	O
,	0	O
Crb2	0	B
is	0	O
transiently	0	O
modified	0	O
,	0	O
probably	0	O
phosphorylated	0	O
,	0	O
with	0	O
a	0	O
similar	0	O
timing	0	O
of	0	O
phosphorylation	0	O
in	0	O
Chk1	0	B
kinase	0	I
,	0	O
which	0	O
is	0	O
reported	0	O
to	0	O
restrain	0	O
Cdc2	0	B
activation	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
yeast	0	B
CEG1	0	I
demonstrated	0	O
that	0	O
four	0	O
of	0	O
the	0	O
five	0	O
conserved	0	O
motifs	0	O
are	0	O
essential	0	O
for	0	O
capping	0	B
enzyme	0	I
function	0	O
in	0	O
vivo	0	O
.	0	O


We	0	O
also	0	O
report	0	O
here	0	O
the	0	O
complete	0	O
structural	0	O
organization	0	O
of	0	O
the	0	O
goat	0	B
alpha	0	I
s1	0	I
-	0	I
casein	0	I
transcription	0	I
unit	0	I
,	0	O
deduced	0	O
from	0	O
polymerase	0	O
chain	0	O
reaction	0	O
experiments	0	O
.	0	O


1	0	O
("	0	O
long	0	O
method	0	O
")	0	O
and	0	O
the	0	O
HML	0	O
method	0	O
.	0	O


SCID	1	O
V	1	B
(	0	O
D	1	B
)	0	O
J	1	B
recombination	0	O
can	0	O
be	0	O
partly	0	O
rescued	0	O
in	0	O
T	1	O
-	0	O
lymphocytes	0	O
by	0	O
either	0	O
DNA	1	O
-	0	O
damaging	0	O
agents	0	O
(	0	O
gamma	0	O
-	0	O
irradiation	0	O
and	0	O
bieomycin	0	O
)	0	O
or	0	O
a	0	O
null	0	O
mutation	0	O
of	0	O
the	0	O
p53	0	B
gene	0	I
,	0	O
possibly	0	O
because	0	O
of	0	O
transiently	0	O
elevated	0	O
DNA	1	O
repair	0	O
activity	0	O
in	0	O
response	0	O
to	0	O
DNA	1	O
damage	0	O
or	0	O
to	0	O
delayed	0	O
apoptosis	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
p53	0	B
.	0	O


Measurements	0	O
were	0	O
compared	0	O
with	0	O
two	0	O
computerised	0	O
treatment	0	O
planning	0	O
systems	0	O
--	0	O
Theraplan	0	O
VO5B	0	O
and	0	O
ADAC	0	O
Pinnacle3	0	O
V4	0	O
.	0	O
0b	0	O
.	0	O


The	0	O
Cox	1	O
proportional	0	O
hazards	0	O
model	0	O
was	0	O
applied	0	O
to	0	O
the	0	O
data	0	O
in	0	O
order	0	O
to	0	O
determine	0	O
the	0	O
prognostic	0	O
factors	0	O
for	0	O
long	0	O
-	0	O
term	0	O
survival	0	O
.	0	O


Serum	1	B
insulin	0	I
-	0	I
like	0	I
growth	0	I
factor	0	I
I	1	I
(	0	O
IGF	1	B
-	0	I
I	1	I
)	0	O
SD	1	O
score	0	O
increased	0	O
from	0	O
-	0	O
2	0	O
.	0	O
2	0	O
and	0	O
-	0	O
4	0	O
.	0	O
2	0	O
in	0	O
men	0	O
and	0	O
women	0	O
,	0	O
respectively	0	O
,	0	O
to	0	O
1	0	O
.	0	O
8	0	O
and	0	O
-	0	O
0	0	O
.	0	O
9	0	O
at	0	O
6	0	O
months	0	O
and	0	O
0	0	O
.	0	O
8	0	O
and	0	O
-	0	O
0	0	O
.	0	O
7	0	O
at	0	O
12	0	O
months	0	O
.	0	O


This	0	O
region	0	O
includes	0	O
verA	0	B
,	0	O
a	0	O
structural	0	O
gene	0	O
previously	0	O
shown	0	O
to	0	O
be	0	O
required	0	O
for	0	O
ST	1	O
biosynthesis	0	O
,	0	O
and	0	O
24	0	O
additional	0	O
closely	0	O
spaced	0	O
transcripts	0	O
ranging	0	O
in	0	O
size	0	O
from	0	O
0	0	O
.	0	O
6	0	O
to	0	O
7	0	O
.	0	O
2	0	O
kb	0	O
that	0	O
are	0	O
coordinately	0	O
induced	0	O
only	0	O
under	0	O
ST	1	O
-	0	O
producing	0	O
conditions	0	O
.	0	O


The	0	O
binding	0	O
of	0	O
transcription	0	O
factor	0	O
AP	1	B
-	0	I
1	0	I
and	0	O
vitamin	0	B
D	1	I
receptor	0	I
(	0	O
VDR	0	B
)	0	O
to	0	O
the	0	O
composite	0	O
AP	1	B
-	0	I
1	0	I
plus	0	I
vitamin	0	I
-	0	I
D	1	I
-	0	I
responsive	0	I
promoter	0	I
region	0	O
(	0	O
AP	1	B
-	0	I
1	0	I
+	0	I
VDRE	0	I
)	0	O
of	0	O
the	0	O
human	0	B
osteocalcin	0	I
gene	0	I
was	0	O
characterized	0	O
in	0	O
osteocalcin	0	B
-	0	O
producing	0	O
(	0	O
MG	1	O
-	0	O
63	0	O
)	0	O
and	0	O
non	0	O
-	0	O
producing	0	O
(	0	O
U2	0	O
-	0	O
Os	1	O
,	0	O
SaOs	0	O
-	0	O
2	0	O
)	0	O
human	0	O
osteosarcoma	0	O
cell	0	O
lines	0	O
.	0	O


Despite	0	O
the	0	O
high	0	O
frequency	0	O
of	0	O
natural	0	O
infection	0	O
,	0	O
the	0	O
seropositive	0	O
rates	0	O
of	0	O
JEV	0	O
antibody	0	O
still	0	O
correlated	0	O
well	0	O
with	0	O
the	0	O
dose	0	O
of	0	O
vaccine	0	O
received	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
67	0	O
%	0	O
(	0	O
1122	0	O
/	0	O
1664	0	O
),	0	O
66	0	O
%	0	O
(	0	O
65	0	O
/	0	O
97	0	O
),	0	O
33	0	O
%	0	O
(	0	O
4	0	O
/	0	O
12	0	O
)	0	O
and	0	O
40	0	O
%	0	O
(	0	O
19	0	O
/	0	O
47	0	O
)	0	O
for	0	O
children	0	O
receiving	0	O
3	0	O
,	0	O
2	0	O
,	0	O
1	0	O
,	0	O
and	0	O
0	0	O
dose	0	O
of	0	O
JE	1	O
vaccines	0	O
,	0	O
respectively	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
0001	0	O
Chi	1	O
-	0	O
square	0	O
for	0	O
trend	0	O
test	0	O
).	0	O


Chemotherapy	1	O
of	0	O
metastasizing	0	O
breast	0	O
cancer	0	O


The	0	O
rad9	0	B
.	0	I
192	0	I
DNA	1	I
repair	0	I
mutant	0	I
from	0	I
the	0	I
fission	0	I
yeast	0	I
,	0	I
Schizosaccharomyces	0	I
pombe	0	I
,	0	O
is	0	O
sensitive	0	O
to	0	O
both	0	O
UV	1	O
and	0	O
ionising	0	O
radiation	0	O
.	0	O


Regionalization	0	O
of	0	O
drug	0	O
delivery	0	O
is	0	O
a	0	O
potential	0	O
method	0	O
to	0	O
avoid	0	O
this	0	O
problem	0	O
.	0	O


Radionuclide	1	O
study	0	O
and	0	O
endomyocardial	0	O
biopsy	0	O
revealed	0	O
remarkable	0	O
degeneration	0	O
of	0	O
myocardium	0	O
.	0	O


The	0	O
2	0	O
cDNAs	0	O
differed	0	O
in	0	O
the	0	O
length	0	O
of	0	O
their	0	O
respective	0	O
3	0	O
'	0	O
untranslated	0	O
regions	0	O
,	0	O
of	0	O
577	0	O
bp	0	O
in	0	O
Cp	1	B
.	0	I
F6	0	I
and	0	O
72	0	O
bp	0	O
in	0	O
Cp	1	B
.	0	I
F10	0	I
,	0	O
in	0	O
both	0	O
of	0	O
which	0	O
a	0	O
putative	0	O
polyadenylation	0	O
signal	0	O
was	0	O
identified	0	O
.	0	O


Clinically	0	O
meaningful	0	O
decreases	0	O
due	0	O
to	0	O
alkalinization	0	O
alone	0	O
within	0	O
30	0	O
minutes	0	O
are	0	O
unlikely	0	O
.	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
destrin	0	B
is	0	O
165	0	O
residues	0	O
long	0	O
and	0	O
is	0	O
very	0	O
similar	0	O
(	0	O
71	0	O
%	0	O
identical	0	O
)	0	O
to	0	O
that	0	O
of	0	O
cofilin	0	B
,	0	O
a	0	O
widely	0	O
distributed	0	O
,	0	O
pH	1	O
-	0	O
sensitive	0	O
actin	0	B
-	0	O
modulating	0	O
protein	0	O
.	0	O


Myelomatous	0	O
pleural	0	O
effusion	0	O
as	0	O
presentation	0	O
form	0	O
of	0	O
multiple	0	O
myeloma	0	O


The	0	O
5	0	O
'	0	O
ends	0	O
of	0	O
F3R	0	B
late	0	O
transcripts	0	O
were	0	O
located	0	O
to	0	O
an	0	O
A	1	O
within	0	O
the	0	O
sequence	0	O
5	0	O
'-	0	O
TAAAG	0	O
,	0	O
41	0	O
nt	0	O
downstream	0	O
from	0	O
the	0	O
early	0	O
promoter	0	O
and	0	O
17	0	O
nt	0	O
upstream	0	O
from	0	O
the	0	O
initiation	0	O
codon	0	O
.	0	O


D3S1261	0	B
is	0	O
physically	0	O
located	0	O
at	0	O
or	0	O
near	0	O
the	0	O
MITF	0	B
locus	0	I
,	0	O
while	0	O
D3S2465	0	B
and	0	O
D3S1766	0	B
are	0	O
flanking	0	O
the	0	O
locus	0	O
at	0	O
about	0	O
17	0	O
.	0	O
5	0	O
cM	1	O
genetic	0	O
distance	0	O
each	0	O
side	0	O
.	0	O


A	1	O
human	0	O
SPT3	0	B
-	0	O
TAFII31	0	B
-	0	O
GCN5	0	B
-	0	O
L	1	B
acetylase	0	I
complex	0	O
distinct	0	O
from	0	O
transcription	0	B
factor	0	I
IID	0	I
.	0	O


It	1	O
was	0	O
also	0	O
found	0	O
that	0	O
there	0	O
is	0	O
no	0	O
significant	0	O
difference	0	O
between	0	O
the	0	O
prevalence	0	O
of	0	O
nasal	0	O
carriage	0	O
of	0	O
S	1	O
.	0	O
aureus	0	O
amongst	0	O
the	0	O
hospital	0	O
staff	0	O
and	0	O
the	0	O
patients	0	O
.	0	O


During	0	O
skeletal	0	O
muscle	0	O
development	0	O
,	0	O
different	0	O
types	0	O
of	0	O
muscle	0	O
fibers	0	O
are	0	O
generated	0	O
,	0	O
which	0	O
express	0	O
different	0	O
combinations	0	O
of	0	O
muscle	0	O
-	0	O
specific	0	O
gene	0	O
products	0	O
.	0	O


However	0	O
,	0	O
the	0	O
relative	0	O
binding	0	O
affinity	0	O
for	0	O
the	0	O
motifs	0	O
is	0	O
different	0	O
.	0	O


The	0	O
natural	0	O
history	0	O
of	0	O
these	0	O
lesions	0	O
,	0	O
locoregional	0	O
efficiency	0	O
of	0	O
the	0	O
different	0	O
treatments	0	O
used	0	O
,	0	O
the	0	O
part	0	O
played	0	O
by	0	O
chemotherapy	0	O
,	0	O
survival	0	O
,	0	O
causes	0	O
of	0	O
death	0	O
and	0	O
therapeutic	0	O
modalities	0	O
used	0	O
as	0	O
a	0	O
last	0	O
measure	0	O
,	0	O
have	0	O
been	0	O
analysed	0	O
.	0	O


Ly	1	B
-	0	I
49	0	I
is	0	O
a	0	O
family	0	B
type	0	I
II	0	I
transmembrane	0	I
proteins	0	I
encoded	0	O
by	0	O
a	0	O
gene	0	O
cluster	0	O
on	0	O
murine	0	O
chromosome	0	O
6	0	O
.	0	O


ULKs	0	B
and	0	O
UNC	0	B
-	0	I
51	0	I
share	0	O
a	0	O
typical	0	O
domain	0	O
structure	0	O
of	0	O
an	0	O
amino	0	O
-	0	O
terminal	0	O
kinase	0	O
domain	0	O
,	0	O
a	0	O
central	0	O
proline	0	O
/	0	O
serine	0	O
rich	0	O
(	0	O
PS	1	O
)	0	O
domain	0	O
,	0	O
and	0	O
a	0	O
carboxy	0	O
-	0	O
terminal	0	O
(	0	O
C	1	O
)	0	O
domain	0	O
.	0	O


The	0	O
rate	0	O
-	0	O
decreasing	0	O
effects	0	O
of	0	O
morphine	0	O
and	0	O
U50488	0	O
were	0	O
reversed	0	O
completely	0	O
by	0	O
a	0	O
0	0	O
.	0	O
01	0	O
and	0	O
1	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
dose	0	O
of	0	O
naloxone	0	O
,	0	O
respectively	0	O
.	0	O


No	1	O
previous	0	O
studies	0	O
have	0	O
determined	0	O
the	0	O
pharmaco	0	O
-	0	O
dynamics	0	O
of	0	O
intravenous	0	O
procainamide	0	O
when	0	O
administered	0	O
in	0	O
a	0	O
dose	0	O
of	0	O
15	0	O
mg	0	O
/	0	O
kg	0	O
and	0	O
at	0	O
a	0	O
rate	0	O
of	0	O
50	0	O
mg	0	O
/	0	O
min	0	O
,	0	O
as	0	O
is	0	O
common	0	O
practice	0	O
during	0	O
electropharmacologic	0	O
testing	0	O
.	0	O


The	0	O
mean	0	O
duration	0	O
of	0	O
pain	0	O
relief	0	O
was	0	O
4	0	O
-	0	O
6	0	O
weeks	0	O
.	0	O


However	0	O
,	0	O
the	0	O
increase	0	O
in	0	O
biliary	0	O
excretion	0	O
did	0	O
not	0	O
compensate	0	O
for	0	O
the	0	O
reduced	0	O
elimination	0	O
of	0	O
bretylium	0	O
and	0	O
hexylsalicylic	0	O
acid	0	O
via	0	O
the	0	O
kidney	0	O
.	0	O


It	1	O
is	0	O
the	0	O
human	0	O
homolog	0	O
of	0	O
the	0	O
mouse	0	B
Mx	1	I
protein	0	I
involved	0	O
in	0	O
resistance	0	O
to	0	O
influenza	0	O
virus	0	O
.	0	O


DESIGN	0	O
:	0	O
Comparison	0	O
of	0	O
number	0	O
of	0	O
women	0	O
with	0	O
PKU	1	O
aged	0	O
15	0	O
-	0	O
44	0	O
years	0	O
on	0	O
the	0	O
NSW	0	O
PKU	1	O
database	0	O
(	0	O
observed	0	O
number	0	O
)	0	O
with	0	O
expected	0	O
number	0	O
derived	0	O
from	0	O
population	0	O
data	0	O
.	0	O


Performance	1	O
on	0	O
two	0	O
verbal	0	O
measures	0	O
-	0	O
the	0	O
National	0	O
Adult	1	O
Reading	1	O
Test	1	O
-	0	O
Revised	0	O
(	0	O
NART	0	O
-	0	O
R	1	O
)	0	O
and	0	O
the	0	O
Vocabulary	0	O
subtest	0	O
from	0	O
the	0	O
Wechsler	0	O
Adult	1	O
Intelligence	1	O
Scale	1	O
-	0	O
Revised	0	O
(	0	O
WAIS	1	O
-	0	O
R	1	O
)-	0	O
showed	0	O
strong	0	O
correlations	0	O
with	0	O
level	0	O
of	0	O
education	0	O
.	0	O


Purification	1	O
and	0	O
cloning	0	O
of	0	O
a	0	O
novel	0	O
serine	0	B
protease	0	I
,	0	O
RNK	0	B
-	0	I
Met	1	I
-	0	I
1	0	I
,	0	O
from	0	O
the	0	O
granules	0	O
of	0	O
a	0	O
rat	0	O
natural	0	O
killer	0	O
cell	0	O
leukemia	0	O
.	0	O


The	0	O
genome	0	O
of	0	O
all	0	O
retroviruses	0	O
consists	0	O
of	0	O
two	0	O
identical	0	O
RNAs	0	O
noncovalently	0	O
linked	0	O
near	0	O
their	0	O
5	0	O
'	0	O
end	0	O
.	0	O


Our	0	O
study	0	O
also	0	O
demonstrated	0	O
significant	0	O
increases	0	O
in	0	O
the	0	O
number	0	O
of	0	O
larger	0	O
myelinated	0	O
fibers	0	O
crossing	0	O
the	0	O
repair	0	O
site	0	O
in	0	O
comparison	0	O
with	0	O
the	0	O
neonatal	0	O
and	0	O
adult	0	O
groups	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
04	0	O
).	0	O


The	0	O
study	0	O
included	0	O
139	0	O
eyes	0	O
with	0	O
presumed	0	O
ocular	0	O
histoplasmosis	0	O
syndrome	0	O
(	0	O
POHS	0	O
)	0	O
and	0	O
age	0	O
-	0	O
related	0	O
macular	0	O
degeneration	0	O
(	0	O
AMD	0	O
).	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
we	0	O
report	0	O
a	0	O
detailed	0	O
study	0	O
of	0	O
the	0	O
structure	0	O
and	0	O
the	0	O
functional	0	O
role	0	O
of	0	O
the	0	O
MalT	1	B
binding	0	I
sites	0	I
located	0	O
in	0	O
the	0	O
adjacent	0	O
and	0	O
divergent	0	O
pulAp	0	B
and	0	O
pulCp	0	B
promoters	0	I
.	0	O


No	1	O
consistent	0	O
correlation	0	O
between	0	O
blood	0	O
pressure	0	O
change	0	O
and	0	O
SCR	1	O
-	0	O
change	0	O
was	0	O
seen	0	O
.	0	O


The	0	O
euglobulin	0	B
clot	0	O
lysis	0	O
time	0	O
was	0	O
slightly	0	O
longer	0	O
in	0	O
the	0	O
smokers	0	O
than	0	O
in	0	O
the	0	O
non	0	O
-	0	O
smokers	0	O
in	0	O
all	0	O
three	0	O
experimental	0	O
situations	0	O
,	0	O
but	0	O
the	0	O
differences	0	O
were	0	O
not	0	O
significant	0	O
.	0	O


As	1	O
stands	0	O
shifted	0	O
in	0	O
dominance	0	O
from	0	O
pine	0	O
to	0	O
fir	0	O
with	0	O
age	0	O
,	0	O
subalpine	0	O
fir	0	O
appeared	0	O
to	0	O
maintain	0	O
gradually	0	O
increasing	0	O
rates	0	O
of	0	O
whole	0	O
-	0	O
forest	0	O
productivity	0	O
until	0	O
stands	0	O
were	0	O
approximately	0	O
400	0	O
years	0	O
old	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
the	0	O
47	0	B
-	0	I
kilodalton	0	I
major	0	I
integral	0	I
membrane	0	I
immunogen	0	I
of	0	I
Treponema	1	I
pallidum	0	I
.	0	O


A	1	O
mutation	0	O
which	0	O
abrogates	0	O
the	0	O
binding	0	O
of	0	O
these	0	O
factors	0	O
reduces	0	O
Wp	1	B
reporter	0	I
activity	0	O
specifically	0	O
in	0	O
B	1	O
cell	0	O
lines	0	O
,	0	O
whereas	0	O
a	0	O
mutation	0	O
which	0	O
converts	0	O
the	0	O
site	0	O
to	0	O
a	0	O
consensus	0	O
CREB	0	B
-	0	I
binding	0	I
sequence	0	I
maintains	0	O
wild	0	O
-	0	O
type	0	O
promoter	0	O
function	0	O
.	0	O


E1A	0	B
represses	0	O
apolipoprotein	0	B
AI	1	I
enhancer	0	I
activity	0	O
in	0	O
liver	0	O
cells	0	O
through	0	O
a	0	O
pRb	0	B
-	0	O
and	0	O
CBP	0	B
-	0	O
independent	0	O
pathway	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
independent	0	O
predictors	0	O
on	0	O
survival	0	O
was	0	O
examined	0	O
in	0	O
a	0	O
Cox	1	O
regression	0	O
model	0	O
with	0	O
adjustment	0	O
for	0	O
existing	0	O
illnesses	0	O
.	0	O


Herpes	1	O
virus	0	O
infection	0	O
was	0	O
characterized	0	O
by	0	O
inversion	0	O
of	0	O
the	0	O
T4	1	O
/	0	O
T8	0	O
ratio	0	O
below	0	O
1	0	O
.	0	O
0	0	O
(	0	O
sensitivity	0	O
90	0	O
%,	0	O
specificity	0	O
88	0	O
%),	0	O
caused	0	O
by	0	O
proliferation	0	O
of	0	O
the	0	O
T8	0	O
subpopulation	0	O
,	0	O
which	0	O
--	0	O
compared	0	O
with	0	O
the	0	O
findings	0	O
in	0	O
patients	0	O
with	0	O
rejection	0	O
crises	0	O
--	0	O
was	0	O
significantly	0	O
raised	0	O
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


cDNA	1	O
clones	0	O
encoding	0	O
Arabidopsis	0	O
thaliana	0	O
and	0	O
Zea	1	B
mays	0	I
mitochondrial	0	I
chaperonin	0	I
HSP60	0	I
and	0	O
gene	0	O
expression	0	O
during	0	O
seed	0	O
germination	0	O
and	0	O
heat	0	O
shock	0	O
.	0	O


The	0	O
glucose	0	O
areas	0	O
following	0	O
the	0	O
ingestion	0	O
of	0	O
the	0	O
foods	0	O
were	0	O
:	0	O
Study	1	O
1	0	O
:	0	O
glucose	0	O
11	0	O
.	0	O
7	0	O
,	0	O
orange	0	O
juice	0	O
7	0	O
.	0	O
3	0	O
,	0	O
sucrose	0	O
5	0	O
.	0	O
2	0	O
,	0	O
glucose	0	O
+	0	O
fructose	0	O
6	0	O
.	0	O
3	0	O
,	0	O
and	0	O
fructose	0	O
0	0	O
.	0	O
7	0	O
mmol	0	O
X	1	O
h	0	O
/	0	O
l	0	O
;	0	O
Study	1	O
2	0	O
:	0	O
glucose	0	O
14	0	O
.	0	O
6	0	O
,	0	O
orange	0	O
juice	0	O
7	0	O
.	0	O
3	0	O
,	0	O
apples	0	O
5	0	O
.	0	O
5	0	O
,	0	O
and	0	O
apple	0	O
juice	0	O
4	0	O
.	0	O
7	0	O
mmol	0	O
X	1	O
h	0	O
/	0	O
l	0	O
;	0	O
Study	1	O
3	0	O
:	0	O
glucose	0	O
12	0	O
.	0	O
6	0	O
,	0	O
ice	0	O
cream	0	O
8	0	O
.	0	O
1	0	O
,	0	O
milk	0	O
3	0	O
.	0	O
7	0	O
,	0	O
and	0	O
lactose	0	O
4	0	O
.	0	O
1	0	O
mmol	0	O
X	1	O
h	0	O
/	0	O
l	0	O
.	0	O


The	0	O
distal	0	O
portion	0	O
of	0	O
the	0	O
rat	0	B
insulin	0	I
I	1	I
gene	0	I
5	0	I
'-	0	I
flanking	0	I
DNA	1	I
contains	0	O
two	0	O
sequence	0	O
elements	0	O
,	0	O
the	0	O
Far	0	O
and	0	O
FLAT	1	O
elements	0	O
,	0	O
that	0	O
can	0	O
function	0	O
in	0	O
combination	0	O
,	0	O
but	0	O
not	0	O
separately	0	O
,	0	O
as	0	O
a	0	O
beta	0	O
-	0	O
cell	0	O
-	0	O
specific	0	O
transcriptional	0	O
enhancer	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
report	0	O
that	0	O
swa5	0	B
-	0	I
1	0	I
is	0	O
a	0	O
new	0	O
temperature	0	O
-	0	O
sensitive	0	O
allele	0	O
of	0	O
the	0	O
clathrin	0	B
heavy	0	I
chain	0	I
gene	0	I
(	0	O
chc1	0	B
-	0	I
5	0	I
),	0	O
which	0	O
carries	0	O
a	0	O
frameshift	0	O
mutation	0	O
near	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
CHC1	0	B
open	0	O
reading	0	O
frame	0	O
.	0	O


Each	0	O
mRNA	1	O
contained	0	O
five	0	O
or	0	O
six	0	O
internal	0	O
uridine	0	O
residues	0	O
,	0	O
which	0	O
were	0	O
transcribed	0	O
using	0	O
a	0	O
mixture	0	O
of	0	O
UTP	1	O
and	0	O
thio	0	O
-	0	O
UTP	1	O
.	0	O


Thus	0	O
,	0	O
IHHNV	0	O
is	0	O
closely	0	O
related	0	O
to	0	O
densoviruses	0	O
of	0	O
the	0	O
genus	0	O
Brevidensovirus	0	O
in	0	O
the	0	O
family	0	O
Parvoviridae	1	O
,	0	O
and	0	O
we	0	O
therefore	0	O
propose	0	O
to	0	O
rename	0	O
this	0	O
virus	0	O
Penaeus	0	O
stylirostris	0	O
densovirus	0	O
(	0	O
PstDNV	0	O
).	0	O


Characterization	0	O
of	0	O
the	0	O
3	0	O
'	0	O
ends	0	O
of	0	O
the	0	O
plus	0	O
-	0	O
strand	0	O
DNA	1	O
fragments	0	O
reveals	0	O
(	0	O
1	0	O
)	0	O
that	0	O
the	0	O
upstream	0	O
fragment	0	O
is	0	O
elongated	0	O
beyond	0	O
PPT2	0	B
creating	0	O
a	0	O
plus	0	O
-	0	O
strand	0	O
overlap	0	O
and	0	O
(	0	O
2	0	O
)	0	O
that	0	O
the	0	O
majority	0	O
of	0	O
plus	0	O
-	0	O
strand	0	O
strong	0	O
-	0	O
stop	0	O
DNA	1	O
fragments	0	O
bear	0	O
a	0	O
copy	0	O
of	0	O
the	0	O
minus	0	O
-	0	O
strand	0	O
primer	0	O
binding	0	O
site	0	O
in	0	O
agreement	0	O
with	0	O
the	0	O
accepted	0	O
model	0	O
of	0	O
retroviral	0	O
genomic	0	O
RNA	1	O
reverse	0	O
transcription	0	O
.	0	O


Blocked	0	O
shift	0	O
/	0	O
supershift	0	O
analysis	0	O
indicates	0	O
that	0	O
Fos	1	B
family	0	I
member	0	O
proteins	0	O
especially	0	O
Fra	0	B
-	0	I
1	0	I
and	0	O
Fra	0	B
-	0	I
2	0	I
are	0	O
related	0	O
to	0	O
progression	0	O
and	0	O
no	0	O
changes	0	O
found	0	O
in	0	O
the	0	O
Jun	1	B
family	0	I
member	0	O
proteins	0	O
although	0	O
they	0	O
are	0	O
present	0	O
in	0	O
the	0	O
AP	1	B
-	0	I
1	0	I
/	0	I
DNA	1	I
binding	0	I
complex	0	I
.	0	O


Following	1	O
treatment	0	O
,	0	O
serum	0	O
estradiol	0	O
levels	0	O
were	0	O
higher	0	O
in	0	O
groups	0	O
E	1	O
+	0	O
T	1	O
and	0	O
E	1	O
than	0	O
in	0	O
group	0	O
C	1	O
.	0	O


It	1	O
is	0	O
possible	0	O
that	0	O
cyclic	0	O
variations	0	O
in	0	O
heme	0	O
turnover	0	O
are	0	O
related	0	O
to	0	O
changes	0	O
in	0	O
erythrocyte	0	O
characteristics	0	O
during	0	O
the	0	O
progesterone	0	O
phase	0	O
.	0	O


Modifications	0	O
of	0	O
the	0	O
involuntary	0	O
postcontraction	0	O
in	0	O
diseased	0	O
people	0	O
.	0	O


Analysis	1	O
of	0	O
functional	0	O
domains	0	O
of	0	O
Arix	0	B
reveals	0	O
an	0	O
N	1	O
-	0	O
terminal	0	O
activation	0	O
domain	0	O
and	0	O
a	0	O
C	1	O
-	0	O
terminal	0	O
repression	0	O
domain	0	O
.	0	O


It	1	O
contained	0	O
seven	0	O
extra	0	O
amino	0	O
acids	0	O
of	0	O
FVVLNLQ	0	O
;	0	O
this	0	O
short	0	O
stretch	0	O
of	0	O
extra	0	O
sequence	0	O
was	0	O
found	0	O
between	0	O
Gln	1	O
(	0	O
421	0	O
)	0	O
and	0	O
Phe	1	O
(	0	O
422	0	O
)	0	O
within	0	O
the	0	O
SET	1	B
(	0	O
Suvar3	0	B
-	0	I
9	0	I
,	0	O
Enhancer	1	B
-	0	I
of	0	I
-	0	I
zeste	0	I
,	0	O
Trithorax	0	B
)	0	O
interacting	0	O
domain	0	O
(	0	O
SID	1	O
)	0	O
of	0	O
rMTM	0	B
.	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
CT	1	O
should	0	O
be	0	O
routinely	0	O
employed	0	O
in	0	O
patients	0	O
with	0	O
N1	0	O
-	0	O
N3	0	O
neck	0	O
disease	0	O
to	0	O
determine	0	O
the	0	O
proper	0	O
electron	0	O
-	0	O
energy	0	O
prescription	0	O
.	0	O


The	0	O
gene	0	B
encoding	0	I
human	0	I
tissue	0	I
-	0	I
type	0	I
plasminogen	0	I
activator	0	I
(	0	O
t	0	B
-	0	I
PA	1	I
)	0	O
is	0	O
regulated	0	O
in	0	O
a	0	O
cell	0	O
-	0	O
type	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


These	0	O
results	0	O
demonstrate	0	O
that	0	O
tip	0	B
acts	0	O
at	0	O
an	0	O
early	0	O
stage	0	O
of	0	O
the	0	O
T	1	O
-	0	O
cell	0	O
signal	0	O
transduction	0	O
cascade	0	O
by	0	O
associating	0	O
with	0	O
Lck	0	B
and	0	O
downregulating	0	O
Lck	0	O
-	0	O
mediated	0	O
activation	0	O
.	0	O


A	1	O
total	0	O
of	0	O
112	0	O
patients	0	O
received	0	O
anistreplase	0	O
and	0	O
119	0	O
received	0	O
heparin	0	O
within	0	O
a	0	O
mean	0	O
period	0	O
of	0	O
188	0	O
+/-	0	O
62	0	O
min	0	O
following	0	O
the	0	O
onset	0	O
of	0	O
symptoms	0	O
.	0	O


Elimination	1	O
of	0	O
natural	0	O
antibodies	0	O
in	0	O
discordant	0	O
xenografts	0	O


Mutational	1	O
analysis	0	O
of	0	O
the	0	O
L1	0	B
binding	0	I
site	0	I
of	0	O
23S	0	B
rRNA	1	I
in	0	I
Escherichia	1	I
coli	0	I
.	0	O


Prospects	0	O
for	0	O
controlled	0	O
-	0	O
delivery	0	O
systems	0	O
.	0	O


Synthesis	1	O
of	0	O
(+)-	0	O
lysergic	0	O
acid	0	O
diethylamide	0	O
tartrate	0	O


Hisako	0	O
Minowa	0	O
who	0	O
has	0	O
worked	0	O
as	0	O
a	0	O
psychiatric	0	O
counsellor	0	O
in	0	O
industry	0	O
for	0	O
the	0	O
past	0	O
20	0	O
years	0	O


The	0	O
ESEM	0	O
differs	0	O
from	0	O
conventional	0	O
SEM	0	O
in	0	O
that	0	O
no	0	O
sample	0	O
preparation	0	O
is	0	O
needed	0	O
,	0	O
eliminating	0	O
artifactual	0	O
changes	0	O
.	0	O


This	0	O
report	0	O
describes	0	O
a	0	O
patient	0	O
with	0	O
a	0	O
previous	0	O
inferior	0	O
acute	0	O
myocardial	0	O
infarction	0	O
who	0	O
developed	0	O
right	0	O
ventricular	0	O
infarction	0	O
with	0	O
significant	0	O
anterior	0	O
lead	0	O
ST	1	O
segment	0	O
elevation	0	O
(	0	O
V1	0	O
-	0	O
V4	0	O
)	0	O
caused	0	O
by	0	O
the	0	O
loss	0	O
of	0	O
two	0	O
large	0	O
right	0	O
ventricular	0	O
branches	0	O
during	0	O
a	0	O
coronary	0	O
angioplasty	0	O
of	0	O
the	0	O
right	0	O
coronary	0	O
artery	0	O
.	0	O


Far	0	O
-	0	O
infrared	0	O
hopping	0	O
conductivity	0	O
in	0	O
the	0	O
CuO	0	O
chains	0	O
of	0	O
a	0	O
single	0	O
-	0	O
domain	0	O
YBa2Cu3O7	0	O
-	0	O
delta	0	O
crystal	0	O
.	0	O


Introduction	0	O
of	0	O
v	0	B
-	0	I
fms	0	I
into	0	O
a	0	O
CSF	1	B
-	0	I
1	0	I
dependent	0	O
murine	0	O
macrophage	0	O
cell	0	O
line	0	O
induced	0	O
factor	0	O
independence	0	O
and	0	O
tumorigenicity	0	O
by	0	O
a	0	O
nonautocrine	0	O
mechanism	0	O
.	0	O


The	0	O
interferon	0	B
-	0	O
inducible	0	O
protein	0	B
kinase	0	I
PKR	0	I
modulates	0	O
the	0	O
transcriptional	0	O
activation	0	O
of	0	O
immunoglobulin	0	B
kappa	0	I
gene	0	I
.	0	O


In	1	O
wild	0	O
-	0	O
type	0	O
cells	0	O
,	0	O
SSM1b	0	B
transcripts	0	I
accumulate	0	O
to	0	O
twice	0	O
the	0	O
level	0	O
of	0	O
SSM1a	0	B
transcripts	0	I
,	0	O
suggesting	0	O
that	0	O
SSM1b	0	B
is	0	O
responsible	0	O
for	0	O
the	0	O
majority	0	O
of	0	O
the	0	O
Ssm1p	0	B
pool	0	O
.	0	O


In	1	O
assays	0	O
with	0	O
purified	0	O
enzymes	0	O
,	0	O
wild	0	O
-	0	O
type	0	O
but	0	O
not	0	O
PTPS	1	B
-	0	O
S19A	0	B
was	0	O
a	0	O
specific	0	O
substrate	0	O
for	0	O
the	0	O
cGMP	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	I
cGK	0	I
)	0	I
type	0	I
I	1	I
and	0	I
II	0	I
.	0	O


The	0	O
therapeutic	0	O
protocole	0	O
used	0	O
at	0	O
the	0	O
Gustave	0	O
Roussy	0	O
Institute	0	O
for	0	O
invasive	0	O
epithelioma	0	O
of	0	O
the	0	O
uterine	0	O
cervix	0	O
rests	0	O
,	0	O
for	0	O
limited	0	O
forms	0	O
(	0	O
T1B	0	O
-	0	O
T2	0	O
proximal	0	O
),	0	O
on	0	O
combined	0	O
radiology	0	O
and	0	O
surgery	0	O
.	0	O


Gemfibrozil	1	O
in	0	O
hyperlipidaemic	0	O
patients	0	O
with	0	O
peripheral	0	O
arterial	0	O
disease	0	O
:	0	O
some	0	O
undiscovered	0	O
actions	0	O
.	0	O


Choice	0	O
of	0	O
vessel	0	O
.	0	O


This	0	O
approach	0	O
enables	0	O
the	0	O
sources	0	O
of	0	O
error	0	O
in	0	O
the	0	O
calculation	0	O
of	0	O
nutrient	0	O
utilization	0	O
to	0	O
be	0	O
readily	0	O
identified	0	O
,	0	O
and	0	O
their	0	O
effect	0	O
on	0	O
precision	0	O
to	0	O
be	0	O
assessed	0	O
in	0	O
different	0	O
nutritional	0	O
and	0	O
metabolic	0	O
states	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
finding	0	O
,	0	O
beta	0	B
-	0	I
catenin	0	I
interacted	0	O
directly	0	O
with	0	O
the	0	O
RA	1	B
receptor	0	I
(	0	O
RAR	0	B
)	0	O
in	0	O
a	0	O
retinoid	0	O
-	0	O
dependent	0	O
manner	0	O
,	0	O
but	0	O
not	0	O
with	0	O
the	0	O
retinoid	0	B
X	1	I
receptor	0	I
(	0	O
RXR	0	B
),	0	O
and	0	O
RAR	0	B
competed	0	O
with	0	O
TCF	0	B
for	0	O
beta	0	B
-	0	I
catenin	0	I
binding	0	O
.	0	O


Role	1	O
of	0	O
the	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
of	0	O
baculovirus	0	B
p10	0	I
mRNA	1	I
in	0	O
high	0	O
-	0	O
level	0	O
expression	0	O
of	0	O
foreign	0	O
genes	0	O
.	0	O


Here	0	O
,	0	O
it	0	O
is	0	O
shown	0	O
that	0	O
TAFII250	0	B
,	0	O
the	0	O
largest	0	O
subunit	0	O
of	0	O
TFIID	0	B
,	0	O
contains	0	O
two	0	O
tandem	0	O
bromodomain	0	O
modules	0	O
that	0	O
bind	0	O
selectively	0	O
to	0	O
multiply	0	O
acetylated	0	O
histone	0	B
H4	0	I
peptides	0	I
.	0	O


The	0	O
method	0	O
involves	0	O
preliminary	0	O
isolation	0	O
of	0	O
oxiracetam	0	O
and	0	O
internal	0	O
standard	0	O
from	0	O
plasma	0	O
by	0	O
solid	0	O
-	0	O
phase	0	O
extraction	0	O
prior	0	O
to	0	O
the	0	O
formation	0	O
of	0	O
their	0	O
n	0	O
-	0	O
propyl	0	O
carbamate	0	O
derivatives	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
a	0	O
DNA	1	O
sequence	0	O
involved	0	O
in	0	O
linking	0	O
gene	0	O
expression	0	O
to	0	O
the	0	O
cell	0	O
cycle	0	O
.	0	O


Significantly	0	O
greater	0	O
improvement	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
in	0	O
the	0	O
sertraline	0	O
group	0	O
first	0	O
became	0	O
apparent	0	O
by	0	O
the	0	O
end	0	O
of	0	O
week	0	O
3	0	O
on	0	O
the	0	O
Y	1	O
-	0	O
BOCS	0	O
and	0	O
the	0	O
CGI	0	O
Improvement	0	O
scale	0	O
,	0	O
and	0	O
by	0	O
the	0	O
end	0	O
of	0	O
weeks	0	O
6	0	O
and	0	O
8	0	O
,	0	O
respectively	0	O
,	0	O
on	0	O
the	0	O
NIMH	1	O
and	0	O
CGI	0	O
Severity	0	O
scale	0	O
.	0	O


Using	0	O
the	0	O
sequence	0	O
data	0	O
obtained	0	O
from	0	O
the	0	O
human	0	O
TCRAC	0	B
/	0	O
TCRDC	0	B
region	0	O
,	0	O
we	0	O
have	0	O
extended	0	O
a	0	O
polymerase	0	O
chain	0	O
reaction	0	O
-	0	O
based	0	O
assay	0	O
to	0	O
test	0	O
for	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
individual	0	O
TCRAJ	0	B
gene	0	I
segments	0	I
.	0	O


The	0	O
data	0	O
normally	0	O
available	0	O
are	0	O
insufficient	0	O
and	0	O
take	0	O
no	0	O
account	0	O
of	0	O
the	0	O
direction	0	O
of	0	O
recirculation	0	O
,	0	O
which	0	O
may	0	O
be	0	O
a	0	O
determining	0	O
factor	0	O
.	0	O


Northern	0	O
blot	0	O
hybridization	0	O
demonstrated	0	O
that	0	O
HEP	1	B
-	0	O
COP	1	B
was	0	O
expressed	0	O
in	0	O
a	0	O
wide	0	O
range	0	O
of	0	O
human	0	O
adult	0	O
and	0	O
fetal	0	O
tissues	0	O
.	0	O


Furthermore	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
transcription	0	O
from	0	O
the	0	O
MMTV	0	B
5	0	I
'	0	I
LTR	1	I
is	0	O
highly	0	O
active	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
Stat5a	0	B
,	0	O
a	0	O
transcription	0	O
factor	0	O
that	0	O
had	0	O
been	0	O
shown	0	O
previously	0	O
to	0	O
be	0	O
required	0	O
for	0	O
transcription	0	O
from	0	O
the	0	O
MMTV	0	B
LTR	1	I
.	0	O


Psychological	1	O
disturbance	0	O
was	0	O
greater	0	O
in	0	O
the	0	O
high	0	O
life	0	O
stress	0	O
group	0	O
as	0	O
indicated	0	O
by	0	O
significant	0	O
elevations	0	O
on	0	O
the	0	O
global	0	O
severity	0	O
index	0	O
of	0	O
the	0	O
Symptom	1	O
Checklist	0	O
-	0	O
90	0	O
and	0	O
elevations	0	O
on	0	O
somatization	0	O
,	0	O
obsessive	0	O
compulsive	0	O
,	0	O
interpersonal	0	O
sensitivity	0	O
,	0	O
depression	0	O
,	0	O
anxiety	0	O
and	0	O
psychoticism	0	O
subscales	0	O
.	0	O


Vascular	1	B
endothelial	0	I
growth	0	I
factor	0	I
(	0	O
VEGF	1	B
),	0	O
a	0	O
potent	0	O
agonist	0	O
secreted	0	O
by	0	O
virtually	0	O
all	0	O
cells	0	O
,	0	O
controls	0	O
migration	0	O
and	0	O
division	0	O
of	0	O
vascular	0	O
endothelial	0	O
cells	0	O
.	0	O


The	0	O
content	0	O
of	0	O
glucosamine	0	O
and	0	O
galactosamine	0	O
in	0	O
tartar	0	O


However	0	O
,	0	O
it	0	O
was	0	O
synthesized	0	O
at	0	O
both	0	O
temperatures	0	O
after	0	O
addition	0	O
of	0	O
A23187	0	O
.	0	O


Moreover	0	O
,	0	O
by	0	O
complementation	0	O
of	0	O
the	0	O
WA	0	B
fyuA	0	I
mutant	0	I
by	0	O
the	0	O
cloned	0	O
fyuA	0	B
gene	0	I
,	0	O
yersiniabactin	0	O
uptake	0	O
and	0	O
mouse	0	O
virulence	0	O
were	0	O
restored	0	O
.	0	O


G	1	O
-	0	O
DNA	1	O
is	0	O
a	0	O
four	0	O
-	0	O
stranded	0	O
DNA	1	O
structure	0	O
with	0	O
diverse	0	O
putative	0	O
biological	0	O
roles	0	O
.	0	O


Exploratory	1	O
-	0	O
motor	0	O
task	0	O
to	0	O
evaluate	0	O
right	0	O
frontal	0	O
lobe	0	O
damage	0	O
.	0	O


Molecular	1	O
and	0	O
functional	0	O
characterization	0	O
of	0	O
the	0	O
promoter	0	O
of	0	O
ETS2	0	B
,	0	O
the	0	O
human	0	O
c	0	B
-	0	I
ets	0	I
-	0	I
2	0	I
gene	0	O
.	0	O


The	0	O
odds	0	O
ratio	0	O
for	0	O
CHD	1	O
was	0	O
1	0	O
.	0	O
21	0	O
(	0	O
95	0	O
%	0	O
confidence	0	O
interval	0	O
,	0	O
0	0	O
.	0	O
84	0	O
-	0	O
1	0	O
.	0	O
75	0	O
)	0	O
given	0	O
a	0	O
positive	0	O
serostatus	0	O
of	0	O
specific	0	O
IgG	1	B
antibodies	0	O
after	0	O
adjustment	0	O
for	0	O
covariates	0	O
.	0	O


The	0	O
average	0	O
coefficients	0	O
of	0	O
correlation	0	O
were	0	O
0	0	O
.	0	O
9998	0	O
and	0	O
0	0	O
.	0	O
9993	0	O
for	0	O
the	0	O
QMF	0	O
and	0	O
the	0	O
QIT	0	O
system	0	O
,	0	O
respectively	0	O
.	0	O


In	1	O
the	0	O
predicted	0	O
transmembrane	0	O
domain	0	O
,	0	O
Casr	0	B
-	0	I
rs2	0	I
and	0	O
Casr	0	B
-	0	I
rs3	0	I
are	0	O
95	0	O
%	0	O
identical	0	O
to	0	O
Casr	0	B
-	0	I
rs1	0	I
.	0	O


A	1	O
.,	0	O
Bowers	0	O
,	0	O
K	1	O
.	0	O
E	1	O
,	0	O
and	0	O
Matthews	0	O
,	0	O
C	1	O
.	0	O


Other	0	O
parameters	0	O
of	0	O
iron	0	O
metabolism	0	O
,	0	O
including	0	O
ferritin	0	B
,	0	O
were	0	O
not	0	O
found	0	O
to	0	O
contribute	0	O
to	0	O
the	0	O
risk	0	O
.	0	O


Although	0	O
olfactory	0	O
associative	0	O
conditioning	0	O
in	0	O
newborn	0	O
rats	0	O
produces	0	O
marked	0	O
structural	0	O
and	0	O
functional	0	O
changes	0	O
in	0	O
the	0	O
olfactory	0	O
bulb	0	O
,	0	O
recent	0	O
evidence	0	O
suggests	0	O
that	0	O
extrabulbar	0	O
circuits	0	O
must	0	O
be	0	O
involved	0	O
in	0	O
storing	0	O
these	0	O
early	0	O
memories	0	O
.	0	O


CONCLUSION	0	O
:	0	O
In	1	O
women	0	O
who	0	O
want	0	O
or	0	O
require	0	O
conservative	0	O
management	0	O
of	0	O
grade	0	O
4	0	O
prolapse	0	O
and	0	O
are	0	O
unable	0	O
to	0	O
retain	0	O
a	0	O
single	0	O
pessary	0	O
,	0	O
the	0	O
placement	0	O
of	0	O
two	0	O
pessaries	0	O
often	0	O
will	0	O
be	0	O
successful	0	O
.	0	O


Lens	1	B
aldose	0	I
reductase	0	I
in	0	O
diabetic	0	O
and	0	O
galactosemic	0	O
cataracts	0	O
.	0	O


We	0	O
suggest	0	O
that	0	O
FlgN	0	B
and	0	O
FliT	0	B
are	0	O
substrate	0	O
-	0	O
specific	0	O
flagellar	0	O
chaperones	0	O
that	0	O
prevent	0	O
oligomerization	0	O
of	0	O
the	0	O
HAPs	0	B
by	0	O
binding	0	O
to	0	O
their	0	O
helical	0	O
domains	0	O
before	0	O
export	0	O
.	0	O


3600	0	O
-	0	O
fold	0	O
to	0	O
apparent	0	O
homogeneity	0	O
with	0	O
a	0	O
41	0	O
%	0	O
yield	0	O
by	0	O
affinity	0	O
chromatography	0	O
utilizing	0	O
DNA	1	O
-	0	O
cellulose	0	O
;	0	O
the	0	O
purity	0	O
of	0	O
the	0	O
final	0	O
preparation	0	O
was	0	O
assessed	0	O
by	0	O
SDS	1	O
/	0	O
PAGE	1	O
,	0	O
lack	0	O
of	0	O
contamination	0	O
by	0	O
other	0	O
nucleases	0	O
and	0	O
production	0	O
of	0	O
a	0	O
monospecific	0	O
antibody	0	O
against	0	O
the	0	O
enzyme	0	O
.	0	O


Directives	0	O
concerning	0	O
medical	0	O
care	0	O


In	1	O
particular	0	O
,	0	O
Western	0	O
,	0	O
supershift	0	O
,	0	O
and	0	O
promoter	0	O
deletion	0	O
analyses	0	O
suggested	0	O
a	0	O
role	0	O
for	0	O
CCAAT	0	B
/	0	I
enhancer	0	I
-	0	I
binding	0	I
protein	0	I
-	0	I
beta	0	I
(	0	O
C	1	B
/	0	I
EBP	1	I
-	0	I
beta	0	I
)	0	O
binding	0	O
site	0	O
between	0	O
-	0	O
2010	0	O
and	0	O
-	0	O
1954	0	O
in	0	O
regulating	0	O
transcription	0	O
of	0	O
collagenase	0	B
-	0	I
1	0	I
in	0	O
monocytic	0	O
cells	0	O
.	0	O


The	0	O
87K	0	O
protein	0	O
,	0	O
together	0	O
with	0	O
proteins	0	O
of	0	O
105	0	O
,	0	O
000	0	O
and	0	O
75	0	O
,	0	O
000	0	O
daltons	0	O
,	0	O
are	0	O
translated	0	O
from	0	O
leftward	0	O
transcribed	0	O
(	0	O
1	0	O
-	0	O
strand	0	O
)	0	O
messenger	0	O
RNAs	0	O
that	0	O
are	0	O
complementary	0	O
to	0	O
the	0	O
viral	0	O
genome	0	O
between	0	O
positions	0	O
11	0	O
.	0	O
2	0	O
and	0	O
31	0	O
.	0	O
5	0	O
.	0	O


The	0	O
model	0	O
also	0	O
predicts	0	O
that	0	O
blood	0	O
flow	0	O
shunt	0	O
fraction	0	O
(	0	O
Qs	0	O
/	0	O
QT	1	O
)	0	O
is	0	O
directly	0	O
related	0	O
to	0	O
the	0	O
oxygen	0	O
sine	0	O
-	0	O
wave	0	O
amplitude	0	O
perturbations	0	O
transmitted	0	O
to	0	O
end	0	O
-	0	O
expired	0	O
air	0	O
and	0	O
arterial	0	O
and	0	O
mixed	0	O
-	0	O
venous	0	O
blood	0	O
through	0	O
two	0	O
simple	0	O
equations	0	O
.	0	O


RESULTS	0	O
:	0	O
Among	0	O
women	0	O
,	0	O
the	0	O
age	0	O
-	0	O
related	0	O
decline	0	O
in	0	O
BMD	1	O
at	0	O
all	0	O
non	0	O
-	0	O
spine	0	O
skeletal	0	O
sites	0	O
was	0	O
significantly	0	O
different	0	O
from	0	O
zero	0	O
,	0	O
with	0	O
the	0	O
largest	0	O
decline	0	O
seen	0	O
at	0	O
the	0	O
femoral	0	O
neck	0	O
(-.	0	O
0038	0	O
g	0	O
/	0	O
cm2	0	O
/	0	O
y	0	O
,	0	O
p	0	O
<	0	O
.	0	O
001	0	O
)	0	O
and	0	O
the	0	O
smallest	0	O
at	0	O
the	0	O
trochanter	0	O
of	0	O
the	0	O
hip	0	O
(-.	0	O
0023	0	O
g	0	O
/	0	O
cm2	0	O
/	0	O
y	0	O
,	0	O
p	0	O
=	0	O
.	0	O
03	0	O
).	0	O


Two	0	O
rare	0	O
novel	0	O
mutations	0	O
,	0	O
D811N	0	O
in	0	O
exon	0	O
20	0	O
and	0	O
R835C	0	O
in	0	O
exon	0	O
21	0	O
,	0	O
were	0	O
identified	0	O
in	0	O
the	0	O
first	0	O
nucleotide	0	O
-	0	O
binding	0	O
fold	0	O
(	0	O
NBF	0	O
),	0	O
a	0	O
functionally	0	O
important	0	O
region	0	O
of	0	O
SUR1	0	B
,	0	O
in	0	O
one	0	O
patient	0	O
each	0	O
,	0	O
both	0	O
heterozygotes	0	O
.	0	O


These	0	O
modifications	0	O
may	0	O
improve	0	O
the	0	O
interlaboratory	0	O
reproducibility	0	O
of	0	O
CD34	1	B
determinations	0	O
due	0	O
to	0	O
the	0	O
reduction	0	O
in	0	O
sample	0	O
handling	0	O
and	0	O
calculation	0	O
of	0	O
results	0	O
.	0	O


SRFDelta5	0	B
acts	0	O
as	0	O
a	0	O
naturally	0	O
occurring	0	O
dominant	0	O
negative	0	O
regulatory	0	O
mutant	0	O
that	0	O
blocks	0	O
SRF	1	B
-	0	O
dependent	0	O
skeletal	0	B
alpha	0	I
-	0	I
actin	0	I
,	0	O
cardiac	0	B
alpha	0	I
-	0	I
actin	0	I
,	0	O
smooth	0	B
alpha	0	I
-	0	I
actin	0	I
,	0	O
SM22alpha	0	B
,	0	O
and	0	O
SRF	1	B
promoter	0	O
-	0	O
luciferase	0	B
reporter	0	O
activities	0	O
.	0	O


The	0	O
detection	0	O
success	0	O
rate	0	O
was	0	O
determined	0	O
for	0	O
different	0	O
markers	0	O
using	0	O
this	0	O
MEK	0	B
.	0	O


Altogether	0	O
,	0	O
these	0	O
data	0	O
suggest	0	O
that	0	O
Ypt51p	0	B
,	0	O
Ypt52p	0	B
,	0	O
and	0	O
Ypt53p	0	B
are	0	O
required	0	O
for	0	O
transport	0	O
in	0	O
the	0	O
endocytic	0	O
pathway	0	O
and	0	O
for	0	O
correct	0	O
sorting	0	O
of	0	O
vacuolar	0	B
hydrolases	0	I
suggesting	0	O
a	0	O
possible	0	O
intersection	0	O
of	0	O
the	0	O
endocytic	0	O
with	0	O
the	0	O
vacuolar	0	O
sorting	0	O
pathway	0	O
.	0	O


A	1	O
key	0	O
event	0	O
in	0	O
this	0	O
process	0	O
is	0	O
the	0	O
selective	0	O
recognition	0	O
of	0	O
the	0	O
target	0	O
membrane	0	O
by	0	O
the	0	O
vesicle	0	O
and	0	O
the	0	O
current	0	O
view	0	O
is	0	O
that	0	O
SNARE	1	B
protein	0	I
interactions	0	O
likely	0	O
play	0	O
a	0	O
central	0	O
role	0	O
in	0	O
vesicle	0	O
-	0	O
target	0	O
recognition	0	O
and	0	O
or	0	O
membrane	0	O
fusion	0	O
.	0	O


Thirty	0	O
of	0	O
the	0	O
clones	0	O
contained	0	O
a	0	O
complete	0	O
340	0	O
base	0	O
-	0	O
pair	0	O
dimer	0	O
unit	0	O
of	0	O
the	0	O
repeat	0	O
.	0	O


The	0	O
IA4	0	B
mAb	0	I
was	0	O
identified	0	O
among	0	O
a	0	O
series	0	O
of	0	O
antibodies	0	O
raised	0	O
in	0	O
BALB	0	O
/	0	O
c	0	O
mice	0	O
after	0	O
immunization	0	O
against	0	O
a	0	O
HLA	1	B
class	0	O
I	1	O
-	0	O
deficient	0	O
,	0	O
lymphokine	0	O
-	0	O
activated	0	O
killer	0	O
(	0	O
LAK	0	O
)-	0	O
susceptible	0	O
EBV	1	O
-	0	O
B	1	O
lymphocyte	0	O
line	0	O
.	0	O


In	1	O
the	0	O
Arithmetic	0	O
subtest	0	O
one	0	O
of	0	O
the	0	O
items	0	O
would	0	O
not	0	O
meet	0	O
the	0	O
difficulty	0	O
grading	0	O
shown	0	O
while	0	O
the	0	O
last	0	O
two	0	O
items	0	O
offer	0	O
very	0	O
little	0	O
possibility	0	O
of	0	O
success	0	O
for	0	O
all	0	O
subjects	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Although	0	O
linker	0	O
regions	0	O
in	0	O
transcription	0	O
factors	0	O
are	0	O
known	0	O
to	0	O
modulate	0	O
DNA	1	O
binding	0	O
specificity	0	O
,	0	O
our	0	O
studies	0	O
suggest	0	O
that	0	O
the	0	O
human	0	B
HSF1	0	I
linker	0	O
plays	0	O
no	0	O
role	0	O
in	0	O
determining	0	O
HSF1	0	B
binding	0	O
preferences	0	O
in	0	O
vivo	0	O
but	0	O
is	0	O
a	0	O
critical	0	O
determinant	0	O
in	0	O
regulating	0	O
the	0	O
HSF1	0	B
monomer	0	I
-	0	I
trimer	0	I
equilibrium	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
lexical	0	O
priming	0	O
was	0	O
examined	0	O
by	0	O
presenting	0	O
an	0	O
identity	0	O
prime	0	O
earlier	0	O
in	0	O
the	0	O
text	0	O
.	0	O


There	0	O
is	0	O
no	0	O
TATA	0	O
box	0	O
around	0	O
the	0	O
transcriptional	0	O
start	0	O
points	0	O
(	0	O
tsp	0	O
),	0	O
as	0	O
determined	0	O
by	0	O
primer	0	O
extension	0	O
analysis	0	O
.	0	O


Specifically	0	O
,	0	O
by	0	O
the	0	O
type	0	O
of	0	O
adjuvant	0	O
therapy	0	O
,	0	O
the	0	O
median	0	O
disease	0	O
-	0	O
free	0	O
interval	0	O
and	0	O
survival	0	O
from	0	O
stage	0	O
IVA	0	O
for	0	O
23	0	O
patients	0	O
receiving	0	O
Corynebacterium	1	O
parvum	0	O
were	0	O
6	0	O
.	0	O
9	0	O
and	0	O
19	0	O
months	0	O
;	0	O
for	0	O
39	0	O
patients	0	O
receiving	0	O
BCG	1	O
,	0	O
eight	0	O
months	0	O
and	0	O
26	0	O
months	0	O
;	0	O
for	0	O
24	0	O
patients	0	O
receiving	0	O
BCG	1	O
+	0	O
DTIC	1	O
,	0	O
eight	0	O
and	0	O
17	0	O
.	0	O
4	0	O
months	0	O
;	0	O
and	0	O
for	0	O
all	0	O
51	0	O
DTIC	1	O
treated	0	O
patients	0	O
6	0	O
.	0	O
3	0	O
and	0	O
17	0	O
.	0	O
8	0	O
months	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
gcd2	0	B
-	0	I
503	0	I
mutation	0	O
also	0	O
results	0	O
in	0	O
polysome	0	O
runoff	0	O
,	0	O
accumulation	0	O
of	0	O
inactive	0	O
80S	0	B
ribosomal	0	I
couples	0	I
,	0	O
and	0	O
accumulation	0	O
of	0	O
at	0	O
least	0	O
one	0	O
of	0	O
the	0	O
subunits	0	O
of	0	O
the	0	O
general	0	B
translation	0	I
initiation	0	I
factor	0	I
2	0	I
(	0	O
eIF	0	B
-	0	I
2	0	I
alpha	0	I
)	0	O
in	0	O
43S	0	B
-	0	O
48S	0	B
particles	0	O
following	0	O
a	0	O
shift	0	O
to	0	O
the	0	O
restrictive	0	O
temperature	0	O
.	0	O


The	0	O
uteroglobin	0	B
promoter	0	I
contains	0	O
a	0	O
noncanonical	0	O
estrogen	0	O
responsive	0	O
element	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
purified	0	O
and	0	O
characterized	0	O
the	0	O
recombinant	0	B
furin	0	I
from	0	O
the	0	O
conditioned	0	O
medium	0	O
of	0	O
these	0	O
cells	0	O
.	0	O


We	0	O
then	0	O
studied	0	O
four	0	O
unrelated	0	O
Japanese	0	O
families	0	O
with	0	O
GSD	0	O
-	0	O
Ib	1	O
,	0	O
and	0	O
found	0	O
three	0	O
novel	0	O
mutations	0	O
:	0	O
a	0	O
four	0	O
-	0	O
base	0	O
deletion	0	O
/	0	O
two	0	O
-	0	O
base	0	O
insertion	0	O
,	0	O
a	0	O
point	0	O
mutation	0	O
within	0	O
a	0	O
consensus	0	O
splicing	0	O
donor	0	O
site	0	O
,	0	O
and	0	O
a	0	O
missense	0	O
mutation	0	O
(	0	O
W118R	0	O
).	0	O


The	0	O
CHARGE	1	O
association	0	O
is	0	O
a	0	O
collection	0	O
of	0	O
multisystem	0	O
congenital	0	O
anomalies	0	O
including	0	O
choanal	0	O
atresia	0	O
.	0	O


Letter	0	O
:	0	O
Aryl	1	B
hydrocarbon	0	I
hydroxylase	0	I
and	0	O
smoking	0	O
.	0	O


MBP	1	B
-	0	O
Rep68	0	B
delta	0	I
-	0	O
mediated	0	O
DNA	1	O
-	0	O
RNA	1	O
helicase	0	O
activity	0	O
required	0	O
ATP	1	O
hydrolysis	0	O
and	0	O
the	0	O
presence	0	O
of	0	O
Mg2	0	O
+	0	O
ions	0	O
and	0	O
was	0	O
inhibited	0	O
by	0	O
high	0	O
ionic	0	O
strength	0	O
.	0	O


The	0	O
cAMP	1	O
-	0	O
dependent	0	O
mitogenic	0	O
pathway	0	O
is	0	O
unique	0	O
as	0	O
it	0	O
is	0	O
independent	0	O
of	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
activation	0	O
and	0	O
differs	0	O
from	0	O
growth	0	O
factor	0	O
-	0	O
dependent	0	O
pathways	0	O
at	0	O
the	0	O
level	0	O
of	0	O
the	0	O
expression	0	O
of	0	O
several	0	O
protooncogenes	0	O
/	0	O
transcription	0	O
factors	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
calcitonin	0	B
,	0	O
a	0	O
large	0	O
amount	0	O
of	0	O
calcium	0	O
given	0	O
orally	0	O
,	0	O
pentagastrin	0	O
and	0	O
glucagon	0	B
on	0	O
plasma	0	O
47Ca	0	O
radioactivity	0	O
curves	0	O
in	0	O
subjects	0	O
pretreated	0	O
with	0	O
47Ca	0	O
was	0	O
examined	0	O
.	0	O


Sterol	1	O
-	0	O
mediated	0	O
suppression	0	O
of	0	O
cleavage	0	O
of	0	O
SREBP	0	B
-	0	I
1	0	I
was	0	O
found	0	O
to	0	O
be	0	O
dependent	0	O
on	0	O
the	0	O
extreme	0	O
COOH	0	O
-	0	O
terminal	0	O
region	0	O
(	0	O
residue	0	O
1034	0	O
to	0	O
the	0	O
COOH	0	O
terminus	0	O
),	0	O
which	0	O
exists	0	O
in	0	O
two	0	O
forms	0	O
as	0	O
a	0	O
result	0	O
of	0	O
alternative	0	O
splicing	0	O
.	0	O


FISH	1	O
using	0	O
a	0	O
whole	0	O
chromosome	0	O
4	0	O
paint	0	O
demonstrated	0	O
multiple	0	O
rearrangements	0	O
involving	0	O
chromosome	0	O
4	0	O
in	0	O
MCF	1	O
-	0	O
7	0	O
AdVp3000	0	O
and	0	O
MCF	1	O
-	0	O
7	0	O
MX	1	O
,	0	O
while	0	O
S1	1	O
-	0	O
M1	1	O
-	0	O
80	0	O
contained	0	O
only	0	O
a	0	O
simple	0	O
reciprocal	0	O
translocation	0	O
.	0	O


We	0	O
used	0	O
deletion	0	O
analysis	0	O
and	0	O
transfection	0	O
assays	0	O
with	0	O
reporter	0	O
gene	0	O
constructs	0	O
to	0	O
examine	0	O
the	0	O
transcription	0	O
control	0	O
elements	0	O
in	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
human	0	B
EpoR	0	I
gene	0	I
.	0	O


TcPO2	0	O
measurement	0	O
appears	0	O
to	0	O
be	0	O
a	0	O
reliable	0	O
technique	0	O
that	0	O
can	0	O
influence	0	O
ischaemic	0	O
ulcer	0	O
management	0	O
.	0	O


The	0	O
partial	0	O
ORF	1	O
was	0	O
found	0	O
to	0	O
be	0	O
identical	0	O
to	0	O
the	0	O
C	1	O
terminus	0	O
of	0	O
HrpJ2	0	B
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
overall	0	O
chance	0	O
that	0	O
a	0	O
patient	0	O
would	0	O
undergo	0	O
ET	1	O
was	0	O
greater	0	O
in	0	O
a	0	O
cycle	0	O
in	0	O
which	0	O
more	0	O
than	0	O
one	0	O
follicle	0	O
20	0	O
mm	0	O
or	0	O
larger	0	O
was	0	O
developing	0	O
than	0	O
in	0	O
a	0	O
cycle	0	O
in	0	O
which	0	O
a	0	O
single	0	O
large	0	O
follicle	0	O
was	0	O
developing	0	O
.	0	O


Gastric	1	O
CO2	1	O
/	0	O
HCO3	0	O
was	0	O
determined	0	O
in	0	O
absence	0	O
of	0	O
simultaneous	0	O
inhibition	0	O
of	0	O
acid	0	O
secretion	0	O
by	0	O
intra	0	O
-	0	O
and	0	O
extragastric	0	O
pCO2	1	O
/	0	O
pH	1	O
measurements	0	O
in	0	O
23	0	O
persons	0	O
and	0	O
calculated	0	O
using	0	O
the	0	O
equation	0	O
of	0	O
Henderson	0	O
-	0	O
Hasselbalch	0	O
.	0	O
pCO2	1	O
was	0	O
measured	0	O
with	0	O
use	0	O
of	0	O
a	0	O
new	0	O
electrode	0	O
.	0	O


In	1	O
the	0	O
cell	0	O
-	0	O
free	0	O
import	0	O
assay	0	O
,	0	O
beta	0	B
-	0	I
catenin	0	I
rapidly	0	O
migrates	0	O
into	0	O
the	0	O
nucleus	0	O
without	0	O
the	0	O
exogenous	0	O
addition	0	O
of	0	O
cytosol	0	O
,	0	O
Ran	0	B
,	0	O
or	0	O
ATP	1	O
/	0	O
GTP	1	O
.	0	O


Low	0	O
PbrO2	0	O
readings	0	O
,	0	O
however	0	O
,	0	O
could	0	O
be	0	O
caused	0	O
by	0	O
local	0	O
microhemorrhages	0	O
,	0	O
undetectable	0	O
on	0	O
CT	1	O
or	0	O
MRI	1	O
.	0	O


The	0	O
cysteine	0	O
-	0	O
rich	0	O
region	0	O
of	0	O
raf	0	B
-	0	I
1	0	I
kinase	0	I
contains	0	O
zinc	0	O
,	0	O
translocates	0	O
to	0	O
liposomes	0	O
,	0	O
and	0	O
is	0	O
adjacent	0	O
to	0	O
a	0	O
segment	0	O
that	0	O
binds	0	O
GTP	1	B
-	0	I
ras	0	I
.	0	O


Using	0	O
a	0	O
series	0	O
of	0	O
mutant	0	O
proteins	0	O
,	0	O
we	0	O
have	0	O
characterized	0	O
domains	0	O
responsible	0	O
for	0	O
activation	0	O
or	0	O
repression	0	O
.	0	O


G	1	O
-	0	O
box	0	O
-	0	O
directed	0	O
expression	0	O
in	0	O
leaves	0	O
required	0	O
the	0	O
presence	0	O
of	0	O
an	0	O
enhancer	0	O
region	0	O
from	0	O
the	0	O
cauliflower	0	O
mosaic	0	O
virus	0	O
(	0	O
CaMV	0	O
)	0	O
35S	0	B
promoter	0	I
.	0	O


Several	0	O
authors	0	O
have	0	O
recently	0	O
reported	0	O
interference	0	O
in	0	O
theophylline	0	O
analysis	0	O
by	0	O
paraxanthine	0	O
(	0	O
1	0	O
,	0	O
7	0	O
-	0	O
dimethylxanthine	0	O
),	0	O
an	0	O
important	0	O
metabolite	0	O
of	0	O
caffeine	0	O
.	0	O


This	0	O
intron	0	O
occupies	0	O
a	0	O
conserved	0	O
position	0	O
corresponding	0	O
to	0	O
that	0	O
of	0	O
intron	0	O
1	0	O
in	0	O
the	0	O
transit	0	O
peptide	0	O
region	0	O
of	0	O
chloroplast	0	B
GAPDH	0	I
genes	0	I
(	0	O
GapA	0	B
and	0	O
GapB	0	B
)	0	O
of	0	O
higher	0	O
plants	0	O
.	0	O


Oligonucleotide	1	O
probes	0	O
corresponding	0	O
to	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
mutant	0	O
EpRE	0	O
sequences	0	O
were	0	O
used	0	O
in	0	O
gel	0	O
-	0	O
shift	0	O
and	0	O
super	0	O
-	0	O
shift	0	O
analyses	0	O
to	0	O
identify	0	O
proteins	0	O
binding	0	O
.	0	O


Fructokinase	1	B
activity	0	O
is	0	O
elevated	0	O
up	0	O
to	0	O
twofold	0	O
when	0	O
Z	1	O
.	0	O
mobilis	0	O
was	0	O
grown	0	O
on	0	O
fructose	0	O
instead	0	O
of	0	O
glucose	0	O
,	0	O
and	0	O
there	0	O
was	0	O
a	0	O
parallel	0	O
increase	0	O
in	0	O
frk	0	B
mRNA	1	I
levels	0	O
.	0	O


In	1	O
patients	0	O
with	0	O
type	0	O
II	0	O
tumors	0	O
,	0	O
the	0	O
pattern	0	O
of	0	O
lymphatic	0	O
spread	0	O
was	0	O
primarily	0	O
directed	0	O
toward	0	O
the	0	O
paracardial	0	O
,	0	O
lesser	0	O
curvature	0	O
,	0	O
and	0	O
left	0	O
gastric	0	O
artery	0	O
nodes	0	O
;	0	O
esophagectomy	0	O
offered	0	O
no	0	O
survival	0	O
benefit	0	O
over	0	O
extended	0	O
gastrectomy	0	O
in	0	O
these	0	O
patients	0	O
.	0	O


The	0	O
nucleotide	0	O
sequence	0	O
directly	0	O
upstream	0	O
of	0	O
fimA	0	B
contains	0	O
two	0	O
open	0	O
reading	0	O
frames	0	O
,	0	O
ORF5	0	O
and	0	O
ORF1	0	O
,	0	O
whose	0	O
deduced	0	O
protein	0	O
products	0	O
are	0	O
homologous	0	O
to	0	O
members	0	O
of	0	O
a	0	O
superfamily	0	O
of	0	O
ATP	1	B
-	0	I
binding	0	I
cassette	0	I
membrane	0	I
transport	0	I
proteins	0	I
,	0	O
including	0	O
both	0	O
prokaryotic	0	O
and	0	O
eukaryotic	0	O
uptake	0	O
and	0	O
export	0	O
systems	0	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
minimal	0	O
requirements	0	O
for	0	O
induction	0	O
of	0	O
PEPCK	0	B
by	0	O
PKA	1	B
and	0	O
inhibition	0	O
by	0	O
insulin	0	B
include	0	O
:	0	O
1	0	O
)	0	O
the	0	O
CREB	0	B
activation	0	I
domain	0	I
,	0	O
2	0	O
)	0	O
the	0	O
PEPCK	0	B
TATA	0	I
sequence	0	I
,	0	O
and	0	O
3	0	O
)	0	O
insulin	0	B
-	0	O
responsive	0	O
hepatoma	0	O
cells	0	O
.	0	O


Site	1	O
-	0	O
directed	0	O
mutagenesis	0	O
of	0	O
residues	0	O
in	0	O
this	0	O
domain	0	O
(	0	O
R82A	0	O
,	0	O
K85A	0	O
,	0	O
K88A	0	O
,	0	O
and	0	O
V89A	0	O
)	0	O
resulted	0	O
in	0	O
proteins	0	O
which	0	O
failed	0	O
to	0	O
transactivate	0	O
from	0	O
the	0	O
HTLV	0	B
-	0	I
1	0	I
LTR	1	I
in	0	O
vivo	0	O
.	0	O


The	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
role	0	O
of	0	O
S	1	O
.	0	O
argyrostoma	0	O
in	0	O
the	0	O
dissemination	0	O
of	0	O
Trichinella	1	O
larvae	0	O
in	0	O
nature	0	O
is	0	O
limited	0	O
in	0	O
comparison	0	O
to	0	O
the	0	O
role	0	O
played	0	O
by	0	O
mammals	0	O
with	0	O
scavenger	0	O
and	0	O
cannibalistic	0	O
behavior	0	O
.	0	O


The	0	O
target	0	O
contained	0	O
between	0	O
positions	0	O
-	0	O
403	0	O
and	0	O
-	0	O
125	0	O
acts	0	O
independently	0	O
of	0	O
orientation	0	O
,	0	O
in	0	O
different	0	O
cell	0	O
types	0	O
and	0	O
species	0	O
,	0	O
and	0	O
in	0	O
the	0	O
context	0	O
of	0	O
a	0	O
heterologous	0	O
promoter	0	O
.	0	O


An	1	O
experiment	0	O
was	0	O
carried	0	O
on	0	O
133	0	O
grown	0	O
up	0	O
fowls	0	O
and	0	O
broilers	0	O
from	0	O
4	0	O
industrial	0	O
farms	0	O
,	0	O
vaccinated	0	O
with	0	O
spray	0	O
lento	0	O
and	0	O
mesogenic	0	O
vaccines	0	O
for	0	O
straining	0	O
the	0	O
immunity	0	O
against	0	O
pseodopest	0	O
through	0	O
RIHA	0	O
and	0	O
provoking	0	O
pseudoplague	0	O
with	0	O
a	0	O
pathogenic	0	O
virus	0	O
.	0	O


A	1	O
9	0	O
.	0	O
5	0	O
-	0	O
kb	0	O
KpnI	0	B
-	0	O
SalI	0	B
fragment	0	O
,	0	O
where	0	O
all	0	O
the	0	O
DNA	1	O
changes	0	O
associated	0	O
with	0	O
su	0	B
(	0	I
Hw	0	I
)	0	I
mutations	0	I
were	0	O
mapped	0	O
,	0	O
was	0	O
able	0	O
to	0	O
rescue	0	O
the	0	O
su	0	B
(	0	I
Hw	0	I
)	0	I
mutant	0	I
phenotype	0	O
after	0	O
P	1	O
-	0	O
element	0	O
-	0	O
mediated	0	O
germ	0	O
-	0	O
line	0	O
transformation	0	O
.	0	O


The	0	O
unique	0	O
nature	0	O
and	0	O
arrangement	0	O
of	0	O
the	0	O
ANT1	0	B
transcriptional	0	I
control	0	I
elements	0	I
may	0	O
account	0	O
for	0	O
this	0	O
differential	0	O
expression	0	O
.	0	O


Mutating	0	O
the	0	O
E	1	O
-	0	O
box	0	O
in	0	O
the	0	O
context	0	O
of	0	O
the	0	O
3	0	O
'-	0	O
flanking	0	O
region	0	O
confirmed	0	O
that	0	O
it	0	O
contributes	0	O
to	0	O
the	0	O
enhancement	0	O
of	0	O
transcriptional	0	O
activity	0	O
of	0	O
the	0	O
alpha1	0	B
(	0	I
I	1	I
)	0	I
collagen	0	I
gene	0	I
promoter	0	I
.	0	O


Forty	0	O
-	0	O
five	0	O
patients	0	O
with	0	O
pleural	0	O
lesions	0	O
identified	0	O
on	0	O
CT	1	O
scans	0	O
were	0	O
subsequently	0	O
examined	0	O
by	0	O
MR	1	O
imaging	0	O
at	0	O
0	0	O
.	0	O
5	0	O
T	1	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
mammalian	0	O
erythroid	0	O
alpha	0	B
-	0	I
spectrin	0	I
evolved	0	O
by	0	O
duplication	0	O
and	0	O
rapid	0	O
divergence	0	O
from	0	O
an	0	O
ancestral	0	O
alpha	0	B
-	0	I
fodrin	0	I
-	0	I
like	0	I
gene	0	I
.	0	O


In	1	O
human	0	O
proliferative	0	O
cells	0	O
,	0	O
the	0	O
NADP	1	O
-	0	O
dependent	0	O
ME	1	B
activity	0	O
is	0	O
poorly	0	O
expressed	0	O
and	0	O
barely	0	O
inducible	0	O
by	0	O
thyroid	0	O
hormones	0	O
.	0	O


Value	1	O
of	0	O
the	0	O
method	0	O
of	0	O
passive	0	O
hemagglutination	0	O
with	0	O
polysaccharide	0	O
C	1	O
in	0	O
detecting	0	O
C	1	B
-	0	I
reactive	0	I
protein	0	I
as	0	O
compared	0	O
to	0	O
precipitation	0	O
in	0	O
capillaries	0	O
and	0	O
slide	0	O
latex	0	O
test	0	O
with	0	O
anti	0	B
-	0	I
CRP	1	I
serum	0	O


Alternatively	0	O
,	0	O
loss	0	O
-	0	O
of	0	O
-	0	O
function	0	O
alleles	0	O
of	0	O
genes	0	O
that	0	O
inhibit	0	O
cAPK	0	B
lead	0	O
to	0	O
the	0	O
inability	0	O
to	0	O
undergo	0	O
sexual	0	O
differentiation	0	O
.	0	O


Nevertheless	0	O
,	0	O
inactivation	0	O
of	0	O
the	0	O
cyclin	0	B
E	1	I
-	0	O
Cdk2	0	B
complex	0	O
in	0	O
response	0	O
to	0	O
mitogen	0	O
starvation	0	O
occurs	0	O
normally	0	O
in	0	O
MEFs	0	O
that	0	O
have	0	O
a	0	O
homozygous	0	O
deletion	0	O
of	0	O
the	0	O
p27	0	B
gene	0	I
.	0	O


TCR	1	B
alpha	0	I
and	0	I
beta	0	I
gene	0	I
expression	0	O
may	0	O
be	0	O
regulated	0	O
by	0	O
a	0	O
common	0	O
set	0	O
of	0	O
T	1	B
-	0	I
cell	0	I
nuclear	0	I
proteins	0	I
in	0	O
that	0	O
the	0	O
T	1	B
beta	0	I
2	0	I
element	0	I
binding	0	O
a	0	O
set	0	O
of	0	O
cyclic	0	B
AMP	1	I
response	0	I
element	0	I
-	0	I
binding	0	I
proteins	0	I
that	0	O
are	0	O
also	0	O
bound	0	O
by	0	O
the	0	O
T	1	B
alpha	0	I
1	0	I
element	0	I
of	0	O
the	0	O
human	0	O
TCR	1	B
alpha	0	I
enhancer	0	O
and	0	O
the	0	O
decamer	0	O
element	0	O
present	0	O
in	0	O
a	0	O
large	0	O
number	0	O
of	0	O
human	0	O
and	0	O
murine	0	O
TCR	1	B
beta	0	I
promoters	0	O
.	0	O


Gel	1	O
-	0	O
shift	0	O
assays	0	O
with	0	O
nuclear	0	O
extracts	0	O
and	0	O
oligonucleotide	0	O
sequences	0	O
spanning	0	O
the	0	O
0	0	O
.	0	O
125	0	O
-	0	O
kb	0	O
promoter	0	O
region	0	O
detected	0	O
an	0	O
ETS	1	B
-	0	O
immunoreactive	0	O
complex	0	O
,	0	O
present	0	O
most	0	O
abundantly	0	O
in	0	O
cells	0	O
overexpressing	0	O
HER2	1	B
,	0	O
whose	0	O
high	0	O
-	0	O
affinity	0	O
binding	0	O
depended	0	O
on	0	O
the	0	O
GAGGAA	0	O
response	0	O
element	0	O
.	0	O


The	0	O
8	0	O
patients	0	O
receiving	0	O
Ir192	0	O
implant	0	O
in	0	O
addition	0	O
to	0	O
external	0	O
radiation	0	O
showed	0	O
improved	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
06	0	O
)	0	O
survival	0	O
compared	0	O
to	0	O
the	0	O
9	0	O
receiving	0	O
external	0	O
only	0	O
:	0	O
median	0	O
15	0	O
months	0	O
(	0	O
range	0	O
1	0	O
.	0	O
5	0	O
-	0	O
34	0	O
+	0	O
months	0	O
)	0	O
versus	0	O
7	0	O
months	0	O
(	0	O
range	0	O
2	0	O
.	0	O
5	0	O
-	0	O
21	0	O
months	0	O
).	0	O


Dorsal	1	O
foot	0	O
TcpO2	0	O
was	0	O
measured	0	O
by	0	O
using	0	O
oxygen	0	O
-	0	O
sensing	0	O
electrodes	0	O
with	0	O
surface	0	O
temperatures	0	O
of	0	O
42	0	O
degrees	0	O
C	1	O
and	0	O
45	0	O
degrees	0	O
C	1	O
;	0	O
in	0	O
theory	0	O
,	0	O
changes	0	O
in	0	O
sympathetic	0	O
activity	0	O
should	0	O
affect	0	O
vasomotor	0	O
tone	0	O
and	0	O
TcpO2	0	O
in	0	O
skin	0	O
beneath	0	O
an	0	O
electrode	0	O
at	0	O
42	0	O
degrees	0	O
C	1	O
(	0	O
submaximal	0	O
vasodilation	0	O
),	0	O
but	0	O
not	0	O
at	0	O
45	0	O
degrees	0	O
C	1	O
(	0	O
maximal	0	O
vasodilation	0	O
).	0	O


Mutations	0	O
at	0	O
two	0	O
neighboring	0	O
sites	0	O
,	0	O
serine	0	O
242	0	O
and	0	O
threonine	0	O
255	0	O
,	0	O
exacerbated	0	O
the	0	O
effect	0	O
.	0	O


IdB	0	O
1031	0	O
was	0	O
first	0	O
extracted	0	O
by	0	O
liquid	0	O
-	0	O
solid	0	O
partition	0	O
and	0	O
the	0	O
extracts	0	O
were	0	O
evaporated	0	O
and	0	O
analysed	0	O
on	0	O
a	0	O
reversed	0	O
-	0	O
phase	0	O
column	0	O
under	0	O
isocratic	0	O
conditions	0	O
,	0	O
using	0	O
either	0	O
an	0	O
electrochemical	0	O
or	0	O
a	0	O
UV	1	O
detector	0	O
.	0	O


These	0	O
results	0	O
confirming	0	O
the	0	O
high	0	O
validity	0	O
of	0	O
NOM	1	O
inhibiting	0	O
test	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
tumoural	0	O
hyperprolactinemic	0	O
states	0	O
,	0	O
reveal	0	O
contradictory	0	O
responses	0	O
to	0	O
CD	1	O
/	0	O
LD	1	O
,	0	O
LD	1	O
and	0	O
DOM	1	O
,	0	O
with	0	O
sustain	0	O
the	0	O
existence	0	O
of	0	O
2	0	O
sub	0	O
-	0	O
group	0	O
of	0	O
Prolactinomas	0	O
:	0	O
with	0	O
or	0	O
without	0	O
a	0	O
maintained	0	O
DA	1	O
central	0	O
tonus	0	O
supporting	0	O
the	0	O
possibility	0	O
of	0	O
different	0	O
etiopathogenetical	0	O
factors	0	O
in	0	O
inducing	0	O
a	0	O
tumoural	0	O
hyperprolactinemic	0	O
states	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
In	1	O
our	0	O
patients	0	O
and	0	O
within	0	O
the	0	O
range	0	O
of	0	O
treatment	0	O
variables	0	O
studied	0	O
,	0	O
age	0	O
,	0	O
Karnofsky	0	O
index	0	O
,	0	O
and	0	O
graft	0	O
-	0	O
versus	0	O
-	0	O
host	0	O
disease	0	O
are	0	O
the	0	O
most	0	O
important	0	O
factors	0	O
related	0	O
with	0	O
early	0	O
mortality	0	O
.	0	O


The	0	O
development	0	O
of	0	O
a	0	O
data	0	O
base	0	O
is	0	O
described	0	O
which	0	O
can	0	O
be	0	O
used	0	O
as	0	O
common	0	O
reference	0	O
for	0	O
ECG	1	O
computer	0	O
programs	0	O
analyzing	0	O
12	0	O
or	0	O
15	0	O
simultaneously	0	O
recorded	0	O
leads	0	O
.	0	O


NKX2	0	B
.	0	I
1	0	I
is	0	O
a	0	O
member	0	O
of	0	O
the	0	O
NK2	0	B
family	0	I
of	0	O
homeodomain	0	B
-	0	I
containing	0	I
transcription	0	I
factors	0	I
whose	0	O
targeted	0	O
disruption	0	O
in	0	O
mouse	0	O
results	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
thyroid	0	O
tissue	0	O
and	0	O
a	0	O
severely	0	O
abnormal	0	O
lung	0	O
phenotype	0	O
.	0	O


Five	0	O
cell	0	O
strains	0	O
of	0	O
human	0	O
dermal	0	O
fibroblasts	0	O
were	0	O
each	0	O
treated	0	O
with	0	O
three	0	O
samples	0	O
of	0	O
burn	0	O
blister	0	O
fluid	0	O
and	0	O
the	0	O
effect	0	O
compared	0	O
with	0	O
the	0	O
rate	0	O
of	0	O
contraction	0	O
of	0	O
free	0	O
floating	0	O
fibroblast	0	O
populated	0	O
collagen	0	B
lattices	0	O
(	0	O
FPCL	0	O
).	0	O


Investigation	0	O
on	0	O
the	0	O
exchange	0	O
of	0	O
Ca45	0	O
in	0	O
intact	0	O
and	0	O
burned	0	O
rats	0	O
by	0	O
the	0	O
kinetic	0	O
analysis	0	O
method	0	O


Up	0	O
to	0	O
95	0	O
%	0	O
of	0	O
the	0	O
total	0	O
UV	1	O
exposure	0	O
received	0	O
is	0	O
in	0	O
the	0	O
UV	1	O
-	0	O
A	1	O
waveband	0	O
(	0	O
320	0	O
-	0	O
400	0	O
nm	0	O
).	0	O


Studies	0	O
on	0	O
powdered	0	O
preparations	0	O
.	0	O


Two	0	O
patients	0	O
had	0	O
immediate	0	O
adverse	0	O
effects	0	O
from	0	O
NMF	0	O
;	0	O
one	0	O
had	0	O
a	0	O
grand	0	O
mal	0	O
seizure	0	O
and	0	O
the	0	O
other	0	O
developed	0	O
severe	0	O
abdominal	0	O
pain	0	O
.	0	O


There	0	O
was	0	O
a	0	O
trend	0	O
toward	0	O
an	0	O
association	0	O
between	0	O
IENF	0	O
and	0	O
sural	0	O
nerve	0	O
unmyelinated	0	O
fiber	0	O
densities	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
32	0	O
,	0	O
p	0	O
=	0	O
0	0	O
.	0	O
054	0	O
).	0	O


A	1	O
significant	0	O
correlation	0	O
between	0	O
a	0	O
number	0	O
of	0	O
functional	0	O
parameters	0	O
of	0	O
gastric	0	O
secretion	0	O
,	0	O
incretion	0	O
and	0	O
histological	0	O
changes	0	O
of	0	O
gastric	0	O
mucosa	0	O
was	0	O
found	0	O
in	0	O
patients	0	O
with	0	O
chronic	0	O
gastritis	0	O
.	0	O


Furthermore	0	O
,	0	O
a	0	O
p21X	0	B
protein	0	I
lacking	0	O
the	0	O
N	1	O
-	0	O
terminus	0	O
of	0	O
Rex1	0	B
was	0	O
expressed	0	O
at	0	O
high	0	O
levels	0	O
;	0	O
our	0	O
data	0	O
indicate	0	O
that	0	O
p21X	0	B
is	0	O
translated	0	O
from	0	O
the	0	O
1	0	O
.	0	O
6	0	O
-	0	O
kb	0	O
mRNA	1	O
which	0	O
is	0	O
derived	0	O
primarily	0	O
from	0	O
deleted	0	O
proviruses	0	O
.	0	O


Three	0	O
ORFs	0	O
(	0	O
9765orfR002	0	O
,	0	O
9765orfR011	0	O
and	0	O
9765orfR013	0	O
)	0	O
were	0	O
found	0	O
to	0	O
be	0	O
homologous	0	O
with	0	O
Schizosaccharomyces	0	O
pombe	0	O
polyadenylate	0	B
binding	0	I
protein	0	I
,	0	O
Escherichia	1	O
coli	0	O
hypothetical	0	O
38	0	O
.	0	O
1	0	O
-	0	O
kDa	1	O
protein	0	O
in	0	O
the	0	O
BCR	0	B
5	0	O
'	0	O
region	0	O
,	0	O
and	0	O
transcription	0	O
regulatory	0	O
protein	0	O
Swi3	0	B
,	0	O
respectively	0	O
.	0	O


Generally	0	O
the	0	O
differences	0	O
between	0	O
short	0	O
gut	0	O
and	0	O
sham	0	O
operation	0	O
animals	0	O
disappeared	0	O
when	0	O
the	0	O
data	0	O
were	0	O
normalised	0	O
for	0	O
mucosal	0	O
weight	0	O
.	0	O


Total	0	O
serum	0	O
calcium	0	O
was	0	O
7	0	O
.	0	O
8	0	O
+/-	0	O
0	0	O
.	0	O
8	0	O
mg	0	O
/	0	O
dl	0	O
,	0	O
whereas	0	O
ionized	0	O
calcium	0	O
was	0	O
5	0	O
.	0	O
7	0	O
+/-	0	O
0	0	O
.	0	O
7	0	O
mg	0	O
/	0	O
dl	0	O
,	0	O
phosphorus	0	O
3	0	O
.	0	O
2	0	O
+/-	0	O
1	0	O
.	0	O
2	0	O
mg	0	O
/	0	O
dl	0	O
,	0	O
and	0	O
alkaline	0	B
phosphatase	0	I
149	0	O
+/-	0	O
48	0	O
.	0	O
6	0	O
U	1	O
/	0	O
liter	0	O
.	0	O


Recognition	1	O
of	0	O
emphysema	0	O
was	0	O
poor	0	O
when	0	O
radiographs	0	O
of	0	O
inadequate	0	O
quality	0	O
were	0	O
included	0	O
(	0	O
anteroposterior	0	O
films	0	O
or	0	O
films	0	O
from	0	O
patients	0	O
with	0	O
acute	0	O
or	0	O
chronic	0	O
lung	0	O
disease	0	O
).	0	O


Tumor	1	B
necrosis	0	I
factor	0	I
signaling	0	O
to	0	O
stress	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
(	0	O
SAPK	0	B
)/	0	O
Jun	1	B
NH2	0	I
-	0	I
terminal	0	I
kinase	0	I
(	0	O
JNK	0	B
)	0	O
and	0	O
p38	0	B
.	0	O


The	0	O
effect	0	O
of	0	O
a	0	O
constant	0	O
magnetic	0	O
field	0	O
on	0	O
the	0	O
phagocytic	0	O
activity	0	O
of	0	O
Paramecia	1	O


To	1	O
the	0	O
problem	0	O
of	0	O
the	0	O
stimulation	0	O
of	0	O
the	0	O
growth	0	O
of	0	O
transplantable	0	O
tumors	0	O
of	0	O
animals	0	O
previously	0	O
treated	0	O
with	0	O
antineoplastic	0	O
antibiotics	0	O


On	1	O
the	0	O
comparison	0	O
of	0	O
correlated	0	O
proportions	0	O
for	0	O
clustered	0	O
data	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
report	0	O
the	0	O
characterization	0	O
of	0	O
an	0	O
alternatively	0	O
processed	0	O
form	0	O
of	0	O
AFAP	0	B
-	0	I
110	0	I
that	0	O
encodes	0	O
an	0	O
additional	0	O
258	0	O
base	0	O
pair	0	O
(	0	O
bp	0	O
)	0	O
of	0	O
open	0	O
reading	0	O
frame	0	O
.	0	O


Metformin	1	O
plasma	0	O
concentrations	0	O
remained	0	O
unchanged	0	O
except	0	O
for	0	O
patients	0	O
transferred	0	O
from	0	O
1	0	O
.	0	O
5	0	O
to	0	O
2	0	O
.	0	O
0	0	O
g	0	O
daily	0	O
to	0	O
850	0	O
mg	0	O
twice	0	O
daily	0	O
;	0	O
in	0	O
these	0	O
patients	0	O
plasma	0	O
concentrations	0	O
increased	0	O
from	0	O
1	0	O
.	0	O
83	0	O
+/-	0	O
0	0	O
.	0	O
87	0	O
to	0	O
2	0	O
.	0	O
50	0	O
+/-	0	O
0	0	O
.	0	O
89	0	O
micrograms	0	O
/	0	O
l	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


Furthermore	0	O
,	0	O
we	0	O
have	0	O
identified	0	O
a	0	O
43	0	O
-	0	O
bp	0	O
region	0	O
of	0	O
the	0	O
24p3	0	B
promoter	0	I
required	0	O
for	0	O
the	0	O
Dex	0	O
responsiveness	0	O
.	0	O


Further	0	O
,	0	O
the	0	O
ability	0	O
of	0	O
recombinant	0	O
beta	0	O
and	0	O
/	0	O
or	0	O
gamma	0	O
chains	0	O
to	0	O
function	0	O
in	0	O
defined	0	O
biochemical	0	O
assays	0	O
of	0	O
beta	0	O
gamma	0	O
activity	0	O
was	0	O
assessed	0	O
for	0	O
membrane	0	O
extracts	0	O
and	0	O
supernatant	0	O
fractions	0	O
from	0	O
infected	0	O
Sf9	0	O
cells	0	O
.	0	O


As	1	O
it	0	O
had	0	O
been	0	O
previously	0	O
reported	0	O
that	0	O
the	0	O
18	0	O
-	0	O
bp	0	O
palindrome	0	O
contains	0	O
sufficient	0	O
nucleotide	0	O
sequence	0	O
information	0	O
for	0	O
E1	1	B
binding	0	O
,	0	O
we	0	O
speculate	0	O
that	0	O
a	0	O
minimal	0	O
E1	1	B
recognition	0	O
motif	0	O
is	0	O
presented	0	O
in	0	O
each	0	O
half	0	O
site	0	O
.	0	O


After	0	O
treatment	0	O
with	0	O
tunicamycin	0	O
,	0	O
the	0	O
transfectants	0	O
secreted	0	O
unglycosylated	0	O
18	0	O
-	0	O
kDa	1	O
polypeptides	0	O
which	0	O
could	0	O
also	0	O
bind	0	O
IgE	1	B
.	0	O


SETTING	0	O
:	0	O
A	1	O
division	0	O
of	0	O
a	0	O
large	0	O
tea	0	O
plantation	0	O
in	0	O
Kandy	0	O
.	0	O


OBJECTIVES	0	O
:	0	O
To	1	O
assess	0	O
the	0	O
ability	0	O
of	0	O
pretreatment	0	O
and	0	O
post	0	O
-	0	O
treatment	0	O
prostate	0	B
-	0	I
specific	0	I
antigen	0	I
(	0	O
PSA	1	B
)	0	O
measurements	0	O
,	0	O
clinical	0	O
tumor	0	O
stage	0	O
,	0	O
tumor	0	O
grade	0	O
,	0	O
Gleason	0	O
sum	0	O
,	0	O
race	0	O
,	0	O
age	0	O
,	0	O
and	0	O
radiation	0	O
dose	0	O
to	0	O
predict	0	O
the	0	O
recurrence	0	O
of	0	O
prostate	0	O
cancer	0	O
following	0	O
external	0	O
beam	0	O
radiation	0	O
therapy	0	O
(	0	O
XRT	1	O
)	0	O
since	0	O
the	0	O
introduction	0	O
of	0	O
PSA	1	B
as	0	O
a	0	O
tumor	0	O
marker	0	O
at	0	O
one	0	O
tertiary	0	O
care	0	O
center	0	O
.	0	O


Transfection	1	O
of	0	O
non	0	O
-	0	O
deleted	0	O
expression	0	O
vector	0	O
into	0	O
NIH3T3	0	O
cells	0	O
results	0	O
in	0	O
acquisition	0	O
of	0	O
focus	0	O
-	0	O
forming	0	O
activity	0	O
while	0	O
a	0	O
deleted	0	O
form	0	O
of	0	O
expression	0	O
vector	0	O
fails	0	O
to	0	O
show	0	O
this	0	O
activity	0	O
even	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
basic	0	B
FGF	0	I
.	0	O


The	0	O
etiology	0	O
,	0	O
pathology	0	O
,	0	O
brain	0	O
CT	1	O
scan	0	O
features	0	O
,	0	O
clinical	0	O
manifestations	0	O
and	0	O
treatment	0	O
of	0	O
these	0	O
accidents	0	O
were	0	O
discussed	0	O
.	0	O


Prostaglandins	0	O
F	1	O
(	0	O
PGF	0	O
)	0	O
were	0	O
measured	0	O
in	0	O
uterine	0	O
vein	0	O
,	0	O
ovarian	0	O
artery	0	O
,	0	O
and	0	O
jugular	0	O
vein	0	O
plasma	0	O
and	0	O
in	0	O
the	0	O
endometrial	0	O
tissues	0	O
at	0	O
various	0	O
times	0	O
during	0	O
the	0	O
bovine	0	O
estrous	0	O
cycle	0	O
,	0	O
and	0	O
were	0	O
compared	0	O
to	0	O
peripheral	0	O
plasma	0	O
progesterone	0	O
levels	0	O
.	0	O


The	0	O
small	0	B
monomeric	0	I
GTP	1	I
-	0	I
binding	0	I
proteins	0	I
of	0	O
the	0	O
RAB	0	B
subfamily	0	I
are	0	O
key	0	O
regulatory	0	O
elements	0	O
of	0	O
the	0	O
machinery	0	O
that	0	O
controls	0	O
membrane	0	O
traffic	0	O
in	0	O
eukaryotic	0	O
cells	0	O
.	0	O


Mapping	1	O
of	0	O
intracellular	0	O
localization	0	O
domains	0	O
and	0	O
evidence	0	O
for	0	O
colocalization	0	O
interactions	0	O
between	0	O
the	0	O
IE110	0	B
and	0	O
IE175	0	B
nuclear	0	O
transactivator	0	O
proteins	0	O
of	0	O
herpes	0	O
simplex	0	O
virus	0	O
.	0	O


Hexsyn	0	O
is	0	O
the	0	O
Goodyear	0	O
Tire	1	O
and	0	O
Rubber	1	O
Company	0	O
tradename	0	O
for	0	O
a	0	O
polyolefin	0	O
rubber	0	O
synthesized	0	O
from	0	O
1	0	O
-	0	O
hexene	0	O
with	0	O
3	0	O
-	0	O
5	0	O
%	0	O
methylhexadiene	0	O
as	0	O
the	0	O
source	0	O
of	0	O
residual	0	O
double	0	O
bonds	0	O
for	0	O
vulcanization	0	O
.	0	O


Cross	1	O
reactivity	0	O
in	0	O
theophylline	0	O
RIA	1	O
kit	0	O
decreased	0	O
.	0	O


The	0	O
mouse	0	B
M	1	I
-	0	I
lysozyme	0	I
downstream	0	I
enhancer	0	I
has	0	O
been	0	O
previously	0	O
characterized	0	O
on	0	O
several	0	O
levels	0	O
of	0	O
gene	0	O
regulation	0	O
.	0	O


The	0	O
pexB	0	B
upstream	0	I
region	0	I
contained	0	O
245	0	O
nucleotides	0	O
within	0	O
which	0	O
sequences	0	O
approximating	0	O
the	0	O
consensus	0	O
for	0	O
cyclic	0	B
AMP	1	I
receptor	0	I
protein	0	I
and	0	O
integration	0	B
host	0	I
factor	0	I
binding	0	O
sites	0	O
were	0	O
discernible	0	O
.	0	O


Beta	1	B
1	0	I
integrin	0	I
-	0	O
and	0	O
proteoglycan	0	O
-	0	O
mediated	0	O
stimulation	0	O
of	0	O
T	1	O
lymphoma	0	O
cell	0	O
adhesion	0	O
and	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
signaling	0	O
by	0	O
thrombospondin	0	B
-	0	I
1	0	I
and	0	O
thrombospondin	0	B
-	0	I
1	0	I
peptides	0	I
.	0	O


A	1	O
cis	0	O
-	0	O
acting	0	O
DNA	1	O
element	0	O
located	0	O
between	0	O
TATA	0	O
box	0	O
and	0	O
transcription	0	O
initiation	0	O
site	0	O
is	0	O
critical	0	O
in	0	O
response	0	O
to	0	O
regulatory	0	O
sequences	0	O
in	0	O
human	0	O
angiotensinogen	0	B
gene	0	I
.	0	O


Deletion	1	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
NF	1	B
-	0	I
4FA	0	I
,	0	O
NF	1	B
-	0	I
4FB	0	I
,	0	O
and	0	O
AP	1	B
-	0	I
1	0	I
sequences	0	O
are	0	O
each	0	O
necessary	0	O
for	0	O
full	0	O
enhancer	0	O
activity	0	O
.	0	O


Scmh1	0	B
maps	0	O
to	0	O
4D1	0	O
-	0	O
D2	0	O
.	0	O
1	0	O
in	0	O
mice	0	O
.	0	O


Comparison	0	O
of	0	O
transmembrane	0	O
and	0	O
cytoplasmic	0	O
domains	0	O
to	0	O
a	0	O
third	0	O
cell	0	O
-	0	O
surface	0	O
proteoglycan	0	O
,	0	O
48K5	0	B
from	0	O
human	0	O
lung	0	O
fibroblasts	0	O
(	0	O
Marynen	0	O
,	0	O
P	1	O
.,	0	O
Zhang	0	O
,	0	O
J	1	O
.,	0	O
Cassiman	0	O
,	0	O
J	1	O
.,	0	O
Vanden	0	O
Berghe	0	O
,	0	O
H	1	O
.,	0	O
and	0	O
David	0	O
,	0	O
C	1	O
.	0	O


Salivary	1	O
estradiol	0	O
17	0	O
beta	0	O
(	0	O
E2	1	O
-	0	O
17	0	O
beta	0	O
)	0	O
and	0	O
progesterone	0	O
(	0	O
P	1	O
)	0	O
were	0	O
determined	0	O
by	0	O
using	0	O
radioimmunoassay	0	O
techniques	0	O
in	0	O
30	0	O
pregnant	0	O
females	0	O
in	0	O
the	0	O
first	0	O
,	0	O
second	0	O
and	0	O
third	0	O
trimesters	0	O
as	0	O
well	0	O
as	0	O
in	0	O
10	0	O
non	0	O
-	0	O
pregnant	0	O
controls	0	O
during	0	O
the	0	O
luteal	0	O
phase	0	O
of	0	O
the	0	O
menstrual	0	O
cycle	0	O
.	0	O


Nine	0	O
new	0	O
naphthalene	0	O
related	0	O
compounds	0	O
(	0	O
I	1	O
,	0	O
IV	1	O
,	0	O
V	1	O
,	0	O
VII	0	O
-	0	O
XII	0	O
)	0	O
together	0	O
with	0	O
four	0	O
known	0	O
compounds	0	O
(	0	O
II	0	O
,	0	O
III	0	O
,	0	O
VI	0	O
,	0	O
XIII	0	O
)	0	O
were	0	O
isolated	0	O
from	0	O
the	0	O
root	0	O
bark	0	O
of	0	O
Oroxylum	0	O
indicum	0	O
Vent	1	O
.	0	O


Comparison	0	O
of	0	O
data	0	O
obtained	0	O
with	0	O
the	0	O
results	0	O
of	0	O
chronic	0	O
treatment	0	O
with	0	O
the	0	O
opioid	0	O
antagonist	0	O
permits	0	O
to	0	O
conclude	0	O
that	0	O
the	0	O
chronic	0	O
blockade	0	O
increases	0	O
the	0	O
fatiguability	0	O
to	0	O
a	0	O
great	0	O
extent	0	O
than	0	O
chronic	0	O
activation	0	O
of	0	O
opioid	0	O
system	0	O
.	0	O


Buflomedil	0	O
(	0	O
i	0	O
.	0	O
v	0	O
.)	0	O
induced	0	O
a	0	O
dose	0	O
-	0	O
dependent	0	O
increase	0	O
of	0	O
cardiac	0	O
output	0	O
at	0	O
0	0	O
.	0	O
16	0	O
-	0	O
0	0	O
.	0	O
64	0	O
mg	0	O
/	0	O
kg	0	O
,	0	O
biphasic	0	O
changes	0	O
at	0	O
1	0	O
.	0	O
28	0	O
and	0	O
2	0	O
.	0	O
56	0	O
mg	0	O
/	0	O
kg	0	O
and	0	O
a	0	O
marked	0	O
decrease	0	O
and	0	O
subsequent	0	O
slight	0	O
increase	0	O
at	0	O
a	0	O
large	0	O
dose	0	O
of	0	O
5	0	O
.	0	O
12	0	O
mg	0	O
/	0	O
kg	0	O
.	0	O


Rapid	0	O
detection	0	O
of	0	O
radioisotopically	0	O
contaminated	0	O
test	0	O
serum	0	O
before	0	O
radioassay	0	O
of	0	O
vitamin	0	O
B12	0	O
.	0	O


Comparative	0	O
mapping	0	O
of	0	O
the	0	O
Brassica	1	B
S	1	I
locus	0	I
region	0	I
and	0	O
its	0	O
homeolog	0	O
in	0	O
Arabidopsis	0	O
.	0	O


We	0	O
have	0	O
therefore	0	O
studied	0	O
the	0	O
molecular	0	O
mechanisms	0	O
of	0	O
TGF	1	B
-	0	I
beta1	0	I
action	0	O
on	0	O
thyroglobulin	0	B
(	0	O
TG	1	B
)	0	O
gene	0	O
expression	0	O
by	0	O
focusing	0	O
our	0	O
attention	0	O
on	0	O
TGF	1	B
-	0	I
beta1	0	I
regulation	0	O
of	0	O
thyroid	0	O
-	0	O
specific	0	O
transcription	0	O
factors	0	O
.	0	O


Effect	1	O
of	0	O
bromazepam	0	O
on	0	O
growth	0	B
hormone	0	I
and	0	O
prolactin	0	B
secretion	0	O
in	0	O
normal	0	O
subjects	0	O
.	0	O


Courses	0	O
were	0	O
repeated	0	O
every	0	O
four	0	O
weeks	0	O
.	0	O


The	0	O
induced	0	O
respiratory	0	O
burst	0	O
was	0	O
investigated	0	O
by	0	O
the	0	O
intracellular	0	O
oxidative	0	O
transformation	0	O
of	0	O
dihydrorhodamine	0	O
123	0	O
to	0	O
the	0	O
fluorescent	0	O
dye	0	O
rhodamine	0	O
123	0	O
via	0	O
flow	0	O
cytometry	0	O
.	0	O


The	0	O
RNA	1	O
-	0	O
binding	0	O
and	0	O
RNA	1	B
-	0	I
DNA	1	I
helicase	0	I
activities	0	O
of	0	O
the	0	O
Escherichia	1	B
coli	0	I
transcription	0	I
termination	0	I
factor	0	I
rho	0	I
have	0	O
been	0	O
investigated	0	O
using	0	O
natural	0	O
RNA	1	O
molecules	0	O
that	0	O
are	0	O
255	0	O
and	0	O
391	0	O
nucleotide	0	O
residues	0	O
in	0	O
length	0	O
and	0	O
that	0	O
contain	0	O
the	0	O
trp	0	B
t	0	I
'	0	I
rho	0	I
-	0	I
dependent	0	I
termination	0	I
sequence	0	I
of	0	O
E	1	O
.	0	O
coli	0	O
.	0	O


BACKGROUND	0	O
:	0	O
The	0	O
c	0	B
-	0	I
myc	0	I
proto	0	I
-	0	I
oncogene	0	I
has	0	O
been	0	O
suggested	0	O
to	0	O
play	0	O
key	0	O
roles	0	O
in	0	O
cell	0	O
proliferation	0	O
,	0	O
differentiation	0	O
,	0	O
transformation	0	O
and	0	O
apoptosis	0	O
.	0	O


155	0	O
aa	0	O
,	0	O
shares	0	O
78	0	O
%	0	O
identity	0	O
with	0	O
the	0	O
analogous	0	O
region	0	O
of	0	O
Xenopus	1	O
laevis	0	O
FGF3	0	B
and	0	O
72	0	O
%	0	O
identity	0	O
with	0	O
the	0	O
product	0	O
of	0	O
the	0	O
more	0	O
distantly	0	O
related	0	O
human	0	O
gene	0	O
.	0	O


Clinical	1	O
evaluation	0	O
of	0	O
the	0	O
Allergan	0	O
Humphrey	0	O
500	0	O
autorefractor	0	O
and	0	O
the	0	O
Nidek	0	O
AR	1	O
-	0	O
1000	0	O
autorefractor	0	O
.	0	O


Its	0	O
clinical	0	O
and	0	O
histopathologic	0	O
characteristics	0	O
.	0	O


Three	0	O
of	0	O
the	0	O
short	0	O
ORFs	0	O
in	0	O
the	0	O
central	0	O
region	0	O
of	0	O
BIV	0	O
have	0	O
been	0	O
identified	0	O
by	0	O
location	0	O
and	0	O
structural	0	O
similarity	0	O
to	0	O
the	0	O
nonstructural	0	O
/	0	O
regulatory	0	O
genes	0	O
(	0	O
vif	0	B
,	0	O
tat	0	B
,	0	O
and	0	O
rev	0	B
)	0	O
of	0	O
other	0	O
lentiviruses	0	O
;	0	O
we	0	O
also	0	O
discovered	0	O
two	0	O
unique	0	O
ORFs	0	O
,	0	O
termed	0	O
W	1	O
and	0	O
Y	1	O
,	0	O
which	0	O
may	0	O
serve	0	O
as	0	O
exons	0	O
for	0	O
novel	0	O
genes	0	O
.	0	O


Similar	0	O
observations	0	O
have	0	O
been	0	O
made	0	O
previously	0	O
for	0	O
other	0	O
genes	0	O
.	0	O


The	0	O
risk	0	O
for	0	O
these	0	O
complications	0	O
is	0	O
increased	0	O
by	0	O
the	0	O
following	0	O
factors	0	O
:	0	O
multiple	0	O
gestation	0	O
,	0	O
the	0	O
combination	0	O
of	0	O
magnesium	0	O
sulfate	0	O
and	0	O
beta	0	O
-	0	O
adrenergic	0	O
agonist	0	O
,	0	O
and	0	O
the	0	O
use	0	O
of	0	O
adrenocortico	0	O
-	0	O
steroids	0	O
to	0	O
hasten	0	O
fetal	0	O
pulmonary	0	O
maturity	0	O
.	0	O


86	0	O
:	0	O
3199	0	O
-	0	O
3203	0	O
)	0	O
or	0	O
G1	0	O
to	0	O
S	1	O
phase	0	O
(	0	O
Reilly	0	O
,	0	O
C	1	O
.	0	O


The	0	O
pattern	0	O
for	0	O
catalytic	0	O
zinc	0	O
sites	0	O
included	0	O
two	0	O
ligands	0	O
close	0	O
in	0	O
sequence	0	O
,	0	O
a	0	O
sequence	0	O
-	0	O
distant	0	O
ligand	0	O
,	0	O
and	0	O
a	0	O
main	0	O
-	0	O
chain	0	O
hydrogen	0	O
bond	0	O
joining	0	O
two	0	O
ligands	0	O
.	0	O


A	1	O
decrease	0	O
of	0	O
erythrocyte	0	O
Mn	1	O
with	0	O
age	0	O
,	0	O
expressed	0	O
in	0	O
nmol	0	O
/	0	O
L	1	O
,	0	O
was	0	O
noted	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
02	0	O
).	0	O


The	0	O
evolution	0	O
of	0	O
the	0	O
CCR5	0	B
cis	0	I
-	0	I
regulatory	0	I
region	0	I
versus	0	O
the	0	O
open	0	O
reading	0	O
frame	0	O
as	0	O
well	0	O
as	0	O
among	0	O
different	0	O
domains	0	O
of	0	O
the	0	O
open	0	O
reading	0	O
frame	0	O
differed	0	O
from	0	O
one	0	O
another	0	O
.	0	O


Site	1	O
-	0	O
directed	0	O
mutagenesis	0	O
revealed	0	O
that	0	O
two	0	O
clusters	0	O
of	0	O
basic	0	O
amino	0	O
acids	0	O
within	0	O
a	0	O
conserved	0	O
basic	0	O
region	0	O
and	0	O
two	0	O
amphipathic	0	O
helices	0	O
within	0	O
the	0	O
adjacent	0	O
HLH	0	O
domain	0	O
are	0	O
essential	0	O
for	0	O
sequence	0	O
-	0	O
specific	0	O
DNA	1	O
binding	0	O
and	0	O
hetero	0	O
-	0	O
oligomerization	0	O
,	0	O
respectively	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
,	0	O
in	0	O
AIDS	1	O
patients	0	O
with	0	O
cryptococcosis	0	O
,	0	O
tolerance	0	O
to	0	O
ILd	1	O
-	0	O
AmB	0	O
was	0	O
acceptable	0	O
when	0	O
the	0	O
daily	0	O
dosage	0	O
did	0	O
not	0	O
exceed	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
,	0	O
but	0	O
the	0	O
higher	0	O
1	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
daily	0	O
dosage	0	O
was	0	O
associated	0	O
with	0	O
an	0	O
unacceptable	0	O
rate	0	O
of	0	O
nephrotoxicity	0	O
.	0	O


Acoust	0	O
.	0	O


100	0	O
and	0	O
14	0	O
p	0	O
.	0	O


Pharmacokinetic	0	O
profile	0	O
of	0	O
clonazepam	0	O
in	0	O
rhesus	0	O
monkeys	0	O
.	0	O


While	0	O
blood	0	O
pressure	0	O
and	0	O
noradrenergic	0	O
activity	0	O
,	0	O
assessed	0	O
as	0	O
changes	0	O
in	0	O
the	0	O
plasma	0	O
levels	0	O
and	0	O
urinary	0	O
excretion	0	O
of	0	O
norepinephrine	0	O
,	0	O
remained	0	O
unaffected	0	O
in	0	O
the	0	O
Pl	0	O
group	0	O
,	0	O
a	0	O
significant	0	O
drop	0	O
in	0	O
the	0	O
supine	0	O
systolic	0	O
and	0	O
diastolic	0	O
blood	0	O
pressures	0	O
,	0	O
as	0	O
well	0	O
as	0	O
in	0	O
the	0	O
resting	0	O
venous	0	O
norepinephrine	0	O
level	0	O
and	0	O
in	0	O
urinary	0	O
norepinephrine	0	O
excretion	0	O
was	0	O
found	0	O
after	0	O
the	0	O
first	0	O
month	0	O
of	0	O
dF	0	O
administration	0	O
.	0	O


Using	0	O
Scheffe	0	O
'	0	O
s	0	O
procedure	0	O
as	0	O
an	0	O
illustration	0	O
,	0	O
comparisons	0	O
are	0	O
made	0	O
to	0	O
usual	0	O
sample	0	O
size	0	O
methods	0	O
that	0	O
incorrectly	0	O
ignore	0	O
the	0	O
stochastic	0	O
nature	0	O
of	0	O
S2p	0	O
.	0	O


There	0	O
was	0	O
no	0	O
correlation	0	O
between	0	O
secretor	0	O
status	0	O
and	0	O
clinical	0	O
status	0	O
,	0	O
spirometry	0	O
measurements	0	O
,	0	O
salivary	0	O
and	0	O
serum	0	B
lysozyme	0	I
levels	0	O
or	0	O
rates	0	O
of	0	O
respiratory	0	O
tract	0	O
colonization	0	O
with	0	O
P	1	O
.	0	O
aeruginosa	0	O
and	0	O
S	1	O
.	0	O
aureus	0	O
.	0	O


The	0	O
human	0	O
pathogenic	0	O
bacterium	0	O
group	0	O
A	1	O
Streptococcus	1	O
produces	0	O
an	0	O
extracellular	0	O
cysteine	0	B
protease	0	I
[	0	O
streptococcal	0	B
pyrogenic	0	I
exotoxin	0	I
B	1	I
(	0	O
SpeB	0	B
)]	0	O
that	0	O
is	0	O
a	0	O
critical	0	O
virulence	0	O
factor	0	O
for	0	O
invasive	0	O
disease	0	O
episodes	0	O
.	0	O


Nucleotide	1	O
sequences	0	O
between	0	O
the	0	O
env	0	B
gene	0	I
and	0	O
the	0	O
LTR	1	B
of	0	I
SFV	0	I
-	0	I
1	0	I
were	0	O
determined	0	O
.	0	O


A	1	O
poor	0	O
correlation	0	O
was	0	O
found	0	O
between	0	O
a	0	O
mildly	0	O
-	0	O
atypical	0	O
(	0	O
inflammatory	0	O
)	0	O
cytological	0	O
result	0	O
(	0	O
class	0	O
2	0	O
)	0	O
and	0	O
a	0	O
benign	0	O
histological	0	O
diagnosis	0	O
:	0	O
48	0	O
%	0	O
of	0	O
class	0	O
-	0	O
2	0	O
smears	0	O
were	0	O
diagnosed	0	O
histologically	0	O
as	0	O
dysplasia	0	O
or	0	O
worse	0	O
.	0	O


If	1	O
hnRNP	1	B
K	1	I
is	0	O
a	0	O
transcription	0	O
factor	0	O
,	0	O
then	0	O
interactions	0	O
with	0	O
the	0	O
RNA	1	B
polymerase	0	I
II	0	I
transcription	0	O
apparatus	0	O
are	0	O
predicted	0	O
.	0	O


Thus	0	O
,	0	O
it	0	O
was	0	O
confirmed	0	O
that	0	O
the	0	O
sodium	0	O
lauryl	0	O
sulfate	0	O
method	0	O
of	0	O
estimating	0	O
hemoglobin	0	B
concentration	0	O
is	0	O
an	0	O
appropriate	0	O
alternative	0	O
to	0	O
the	0	O
cyanmethemoglobin	0	B
method	0	O
and	0	O
avoids	0	O
the	0	O
generation	0	O
of	0	O
toxic	0	O
wastes	0	O
.	0	O


Here	0	O
we	0	O
describe	0	O
the	0	O
cloning	0	O
,	0	O
tissue	0	O
-	0	O
specific	0	O
expression	0	O
pattern	0	O
,	0	O
and	0	O
functional	0	O
characterization	0	O
of	0	O
two	0	O
novel	0	O
TEF	0	B
-	0	I
1	0	I
isoforms	0	I
,	0	O
TEF	0	B
-	0	I
1beta	0	I
and	0	O
TEF	0	B
-	0	I
1gamma	0	I
.	0	O


The	0	O
determination	0	O
of	0	O
the	0	O
double	0	O
bounds	0	O
in	0	O
blood	0	O
serum	0	O
lipids	0	O
by	0	O
titration	0	O
with	0	O
ozone	0	O
:	0	O
the	0	O
pathophysiology	0	O
and	0	O
diagnostic	0	O
significance	0	O
]	0	O
In	1	O
this	0	O
article	0	O
the	0	O
method	0	O
of	0	O
definition	0	O
of	0	O
double	0	O
binders	0	O
in	0	O
lipids	0	O
of	0	O
blood	0	O
serum	0	O
in	0	O
patients	0	O
with	0	O
different	0	O
diseases	0	O
basically	0	O
atherosclerosis	0	O
and	0	O
ischemic	0	O
heart	0	O
disease	0	O
,	0	O
with	0	O
use	0	O
titration	0	O
by	0	O
ozone	0	O
is	0	O
given	0	O
.	0	O


Next	0	O
,	0	O
to	0	O
identify	0	O
regions	0	O
of	0	O
the	0	O
promoter	0	O
involved	0	O
,	0	O
we	0	O
examined	0	O
a	0	O
series	0	O
of	0	O
tenascin	0	B
-	0	I
C	1	I
promoter	0	I
constructs	0	I
with	0	O
5	0	O
'	0	O
deletions	0	O
and	0	O
showed	0	O
that	0	O
denatured	0	O
collagen	0	B
-	0	I
dependent	0	I
promoter	0	I
activity	0	O
was	0	O
retained	0	O
by	0	O
a	0	O
122	0	O
-	0	O
base	0	O
pair	0	O
element	0	O
,	0	O
located	0	O
-	0	O
43	0	O
to	0	O
-	0	O
165	0	O
bp	0	O
upstream	0	O
of	0	O
the	0	O
RNA	1	O
start	0	O
site	0	O
.	0	O


Avian	1	O
reproductive	0	O
system	0	O
:	0	O
daily	0	O
variations	0	O
in	0	O
responses	0	O
to	0	O
hormones	0	O
.	0	O


Catheter	1	O
transit	0	O
slows	0	O
the	0	O
response	0	O
to	0	O
a	0	O
step	0	O
increase	0	O
in	0	O
concentration	0	O
by	0	O
about	0	O
0	0	O
.	0	O
13	0	O
s	0	O
(	0	O
from	0	O
10	0	O
per	0	O
cent	0	O
-	0	O
90	0	O
per	0	O
cent	0	O
)	0	O
and	0	O
prolongs	0	O
the	0	O
transit	0	O
time	0	O
through	0	O
the	0	O
catheter	0	O
for	0	O
a	0	O
volatile	0	O
anesthetic	0	O
by	0	O
about	0	O
0	0	O
.	0	O
04	0	O
s	0	O
more	0	O
than	0	O
N2	0	O
.	0	O


The	0	O
median	0	O
survival	0	O
is	0	O
not	0	O
reached	0	O
with	0	O
a	0	O
median	0	O
follow	0	O
-	0	O
up	0	O
time	0	O
of	0	O
9	0	O
.	0	O
6	0	O
years	0	O
.	0	O


The	0	O
PAI	1	B
-	0	I
2	0	I
gene	0	I
is	0	O
one	0	O
of	0	O
the	0	O
most	0	O
TNF	1	B
-	0	I
responsive	0	I
genes	0	I
known	0	O
and	0	O
is	0	O
also	0	O
highly	0	O
induced	0	O
by	0	O
the	0	O
phorbol	0	O
ester	0	O
phorbol	0	O
12	0	O
-	0	O
myristate	0	O
13	0	O
-	0	O
acetate	0	O
(	0	O
PMA	0	O
)	0	O
and	0	O
the	0	O
phosphatase	0	O
inhibitor	0	O
,	0	O
okadaic	0	O
acid	0	O
,	0	O
in	0	O
both	0	O
HT	1	O
-	0	O
1080	0	O
fibrosarcoma	0	O
and	0	O
U	1	O
-	0	O
937	0	O
histiocytic	0	O
cells	0	O
.	0	O


Nucleotide	1	O
sequence	0	O
analysis	0	O
of	0	O
the	0	O
Pseudomonas	1	B
putida	0	I
PpG7	0	I
salicylate	0	I
hydroxylase	0	I
gene	0	I
(	0	O
nahG	0	B
)	0	O
and	0	O
its	0	O
3	0	O
'-	0	O
flanking	0	O
region	0	O
.	0	O


This	0	O
domain	0	O
,	0	O
although	0	O
adjacent	0	O
to	0	O
the	0	O
5	0	O
'	0	O
edge	0	O
of	0	O
the	0	O
SD	1	O
sequence	0	O
,	0	O
does	0	O
not	0	O
inhibit	0	O
ribosome	0	O
binding	0	O
as	0	O
long	0	O
as	0	O
the	0	O
single	0	O
-	0	O
stranded	0	O
region	0	O
of	0	O
domain	0	O
3	0	O
is	0	O
present	0	O
.	0	O


Potential	1	O
consensus	0	O
sequences	0	O
for	0	O
early	0	O
and	0	O
late	0	O
regulatory	0	O
elements	0	O
were	0	O
identified	0	O
.	0	O


Linearized	0	O
overall	0	O
infection	0	O
rates	0	O
(	0	O
events	0	O
/	0	O
100	0	O
patient	0	O
-	0	O
days	0	O
)	0	O
were	0	O
2	0	O
.	0	O
05	0	O
+/-	0	O
0	0	O
.	0	O
33	0	O
(	0	O
heart	0	O
-	0	O
lung	0	O
)	0	O
and	0	O
2	0	O
.	0	O
34	0	O
+/-	0	O
0	0	O
.	0	O
34	0	O
(	0	O
double	0	O
-	0	O
lung	0	O
;	0	O
P	1	O
=	0	O
NS	1	O
)	0	O
at	0	O
3	0	O
months	0	O
.	0	O


When	0	O
transiently	0	O
transfected	0	O
into	0	O
K562	0	O
cells	0	O
,	0	O
this	0	O
Lg	0	B
genomic	0	O
clone	0	O
is	0	O
actively	0	O
transcribed	0	O
,	0	O
suggesting	0	O
that	0	O
,	0	O
although	0	O
it	0	O
possesses	0	O
the	0	O
characteristics	0	O
of	0	O
a	0	O
processed	0	O
pseudogene	0	O
,	0	O
it	0	O
is	0	O
likely	0	O
to	0	O
correspond	0	O
to	0	O
the	0	O
gene	0	O
encoding	0	O
this	0	O
new	0	O
ferritin	0	B
subunit	0	I
.	0	O


Vaccinia	1	O
virus	0	O
(	0	O
VV	1	O
)	0	O
is	0	O
a	0	O
potent	0	O
immunogen	0	O
,	0	O
but	0	O
the	0	O
nature	0	O
of	0	O
VV	1	O
proteins	0	O
involved	0	O
in	0	O
the	0	O
activation	0	O
of	0	O
the	0	O
immune	0	O
response	0	O
of	0	O
the	0	O
host	0	O
is	0	O
not	0	O
yet	0	O
known	0	O
.	0	O


The	0	O
c	0	B
-	0	I
Ets	1	I
-	0	I
1	0	I
oncoprotein	0	I
is	0	O
a	0	O
transcription	0	O
activator	0	O
that	0	O
specifically	0	O
binds	0	O
to	0	O
DNA	1	O
.	0	O


Northern	0	O
blot	0	O
analysis	0	O
,	0	O
using	0	O
the	0	O
Ltp4	0	B
-	0	O
specific	0	O
probe	0	O
,	0	O
indicated	0	O
that	0	O
Xanthomonas	1	O
campestris	0	O
pv	0	O
.	0	O
translucens	0	O
induced	0	O
an	0	O
increase	0	O
over	0	O
basal	0	O
levels	0	O
of	0	O
Ltp4	0	B
mRNA	1	I
,	0	O
while	0	O
Pseudomonas	1	O
syringae	0	O
pv	0	O
.	0	O
japonica	0	O
caused	0	O
a	0	O
decrease	0	O
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
KRAB	0	B
domain	0	I
present	0	O
in	0	O
the	0	O
non	0	O
-	0	O
finger	0	O
region	0	O
of	0	O
many	0	O
ZFP	0	B
genes	0	I
quenches	0	O
transcription	0	O
possibly	0	O
due	0	O
to	0	O
specific	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
between	0	O
the	0	O
KRAB	0	B
-	0	I
A	1	I
domain	0	I
and	0	O
components	0	O
of	0	O
the	0	O
proximal	0	O
transcriptional	0	O
apparatus	0	O
.	0	O


Protein	1	B
kinase	0	I
A	1	I
-	0	I
Ialpha	0	I
subunit	0	O
-	0	O
directed	0	O
antisense	0	O
inhibition	0	O
of	0	O
ovarian	0	O
cancer	0	O
cell	0	O
growth	0	O
:	0	O
crosstalk	0	O
with	0	O
tyrosine	0	B
kinase	0	I
signaling	0	O
pathway	0	O
.	0	O


Structural	1	O
features	0	O
of	0	O
the	0	O
minimal	0	O
DNA	1	O
binding	0	O
domain	0	O
(	0	O
M98	0	O
-	0	O
F219	0	O
)	0	O
of	0	O
human	0	B
nucleotide	0	I
excision	0	I
repair	0	I
protein	0	I
XPA	0	I
.	0	O


The	0	O
Saccharomyces	1	B
cerevisiae	0	I
14DM	0	I
gene	0	I
,	0	O
encoding	0	O
cytochrome	0	B
P450	0	I
lanosterol	0	I
14	0	I
alpha	0	I
-	0	I
demethylase	0	I
(	0	O
14DM	0	B
),	0	O
was	0	O
overexpressed	0	O
in	0	O
various	0	O
S	1	O
.	0	O
cerevisiae	0	O
strains	0	O
under	0	O
the	0	O
control	0	O
of	0	O
three	0	O
strong	0	O
heterologous	0	O
yeast	0	O
transcription	0	O
promoters	0	O
(	0	O
pADC1	0	B
,	0	O
pGPD	0	B
,	0	O
pPHO5	0	B
)	0	O
and	0	O
under	0	O
the	0	O
control	0	O
of	0	O
its	0	O
own	0	O
promoter	0	O
.	0	O


The	0	O
AL	1	O
-	0	O
R8	0	O
SI	1	O
:	0	O
the	0	O
next	0	O
generation	0	O
staging	0	O
container	0	O
for	0	O
plutonium	0	O
pits	0	O
at	0	O
the	0	O
USDOE	0	O
Pantex	0	O
Plant	1	O
.	0	O


Defects	0	O
in	0	O
the	0	O
Schizosaccharomyces	0	O
pombe	0	O
(	0	O
Sp	1	O
)	0	O
cell	0	O
cycle	0	O
-	0	O
controlling	0	O
genes	0	O
prevent	0	O
the	0	O
cell	0	O
cycle	0	O
progression	0	O
.	0	O


A	1	O
decrease	0	O
in	0	O
insulin	0	B
-	0	O
induced	0	O
receptor	0	O
kinase	0	O
activity	0	O
was	0	O
observed	0	O
for	0	O
solubilized	0	O
chimeric	0	O
receptors	0	O
.	0	O


The	0	O
levels	0	O
of	0	O
both	0	O
MAP1	0	B
-	0	I
specific	0	I
and	0	I
MAP2	0	I
-	0	I
specific	0	I
mRNAs	0	I
decline	0	O
in	0	O
the	0	O
postnatal	0	O
developing	0	O
brain	0	O
;	0	O
the	0	O
level	0	O
of	0	O
MAP1	0	B
-	0	I
specific	0	I
mRNA	1	I
also	0	O
increases	0	O
slightly	0	O
in	0	O
rat	0	O
PC12	0	O
cells	0	O
upon	0	O
exposure	0	O
to	0	O
nerve	0	B
growth	0	I
factor	0	I
.	0	O


Interestingly	0	O
,	0	O
a	0	O
portion	0	O
of	0	O
the	0	O
tail	0	O
domain	0	O
(	0	O
aa	0	O
,	0	O
1	0	O
,	0	O
094	0	O
-	0	O
1	0	O
,	0	O
830	0	O
)	0	O
shares	0	O
58	0	O
%	0	O
amino	0	O
acid	0	O
sequence	0	O
identity	0	O
with	0	O
a	0	O
723	0	O
-	0	O
aa	0	O
protein	0	O
from	0	O
mouse	0	O
brain	0	O
reported	0	O
to	0	O
be	0	O
a	0	O
glutamic	0	B
acid	0	I
decarboxylase	0	I
.	0	O


The	0	O
nuclear	0	O
proteins	0	O
encoded	0	O
by	0	O
the	0	O
c	0	B
-	0	I
fos	0	I
and	0	O
c	0	B
-	0	I
jun	0	I
protooncogenes	0	I
are	0	O
expressed	0	O
during	0	O
the	0	O
proliferation	0	O
period	0	O
of	0	O
osteoblast	0	O
phenotype	0	O
development	0	O
.	0	O


The	0	O
crystal	0	O
structure	0	O
of	0	O
the	0	O
VP16	0	B
core	0	I
has	0	O
been	0	O
determined	0	O
at	0	O
2	0	O
.	0	O
1	0	O
A	1	O
resolution	0	O
.	0	O


Liver	1	O
transplantation	0	O
in	0	O
one	0	O
patient	0	O
resolved	0	O
metabolic	0	O
complications	0	O
but	0	O
did	0	O
not	0	O
improve	0	O
PMN	1	O
count	0	O
or	0	O
the	0	O
infectious	0	O
status	0	O
,	0	O
while	0	O
neutropenia	0	O
was	0	O
corrected	0	O
by	0	O
G	1	B
-	0	I
CSF	1	I
.	0	O


Thus	0	O
,	0	O
although	0	O
multiple	0	O
senescence	0	O
pathways	0	O
are	0	O
activated	0	O
in	0	O
response	0	O
to	0	O
a	0	O
ras	0	B
oncogene	0	I
,	0	O
inactivation	0	O
of	0	O
TGFbeta1	0	B
secretion	0	O
or	0	O
response	0	O
is	0	O
sufficient	0	O
to	0	O
block	0	O
the	0	O
senescence	0	O
program	0	O
.	0	O


The	0	O
accumulation	0	O
of	0	O
both	0	O
LHA4	0	B
and	0	O
LHA2	0	B
mRNAs	0	I
is	0	O
induced	0	O
by	0	O
the	0	O
addition	0	O
of	0	O
exogenous	0	O
sugars	0	O
and	0	O
this	0	O
induction	0	O
appears	0	O
to	0	O
be	0	O
dependent	0	O
on	0	O
sugar	0	O
uptake	0	O
and	0	O
metabolism	0	O
,	0	O
because	0	O
mannitol	0	O
and	0	O
3	0	O
-	0	O
O	1	O
-	0	O
methylglucose	0	O
do	0	O
not	0	O
stimulate	0	O
mRNA	1	O
accumulation	0	O
.	0	O


Angina	1	O
haemorrhagica	0	O
bullosa	0	O
causing	0	O
respiratory	0	O
obstruction	0	O
postoperatively	0	O
.	0	O


An	1	O
intravenous	0	O
preparation	0	O
of	0	O
doxycycline	0	O
(	0	O
DOTC	0	O
,	0	O
Vibramycin	1	O
'	0	O
Pfizer	0	O
'),	0	O
a	0	O
long	0	O
-	0	O
lasting	0	O
tetracycline	0	O
,	0	O
was	0	O
administered	0	O
mainly	0	O
by	0	O
drip	0	O
infusion	0	O
for	0	O
a	0	O
series	0	O
of	0	O
study	0	O
in	0	O
the	0	O
pediatrics	0	O
field	0	O
,	0	O
and	0	O
the	0	O
results	0	O
were	0	O
as	0	O
follows	0	O
:	0	O
1	0	O
)	0	O
DOTC	0	O
(	0	O
100	0	O
mg	0	O
)	0	O
was	0	O
dissolved	0	O
in	0	O
a	0	O
100	0	O
ml	0	O
of	0	O
glucose	0	O
solution	0	O
and	0	O
2	0	O
--	0	O
3	0	O
mg	0	O
/	0	O
kg	0	O
was	0	O
administered	0	O
intravenously	0	O
.	0	O


The	0	O
52	0	O
-	0	O
protein	0	O
subunit	0	O
of	0	O
T4	1	B
DNA	1	I
topoisomerase	0	I
is	0	O
homologous	0	O
to	0	O
the	0	O
gyrA	0	B
-	0	I
protein	0	I
of	0	O
gyrase	0	B
.	0	O


Urinary	1	O
excretion	0	O
of	0	O
oestrone	0	O
,	0	O
oestradiol	0	O
-	0	O
17	0	O
beta	0	O
and	0	O
oestriol	0	O
in	0	O
pregnancies	0	O
complicated	0	O
by	0	O
steroid	0	B
sulphatase	0	I
deficiency	0	O
.	0	O


Phylogenetic	1	O
analyses	0	O
of	0	O
19	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
6	0	O
related	0	O
protein	0	O
types	0	O
indicate	0	O
that	0	O
actin	0	B
-	0	O
associated	0	O
proteins	0	O
related	0	O
to	0	O
gelsolin	0	B
are	0	O
monophyletic	0	O
to	0	O
a	0	O
common	0	O
ancestor	0	O
and	0	O
include	0	O
flightless	0	B
proteins	0	I
.	0	O


Expression	1	O
,	0	O
cellular	0	O
localization	0	O
and	0	O
in	0	O
vitro	0	O
transcription	0	O
studies	0	O
establish	0	O
that	0	O
cloned	0	B
hUBF	0	I
encodes	0	O
a	0	O
nucleolar	0	O
factor	0	O
that	0	O
binds	0	O
specifically	0	O
to	0	O
the	0	O
upstream	0	O
control	0	O
element	0	O
and	0	O
core	0	O
of	0	O
the	0	O
rRNA	1	O
gene	0	O
promoter	0	O
to	0	O
activate	0	O
transcription	0	O
in	0	O
a	0	O
binding	0	O
site	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


Either	0	O
20	0	O
mg	0	O
mitomycin	0	O
/	0	O
20	0	O
ml	0	O
distilled	0	O
water	0	O
or	0	O
40	0	O
mg	0	O
/	0	O
40	0	O
ml	0	O
distilled	0	O
water	0	O
was	0	O
locally	0	O
instilled	0	O
into	0	O
the	0	O
bladder	0	O
with	0	O
a	0	O
catheter	0	O
after	0	O
emptying	0	O
it	0	O
and	0	O
was	0	O
left	0	O
for	0	O
about	0	O
25	0	O
-	0	O
l20	0	O
min	0	O
.	0	O


Deletion	1	O
mutagenesis	0	O
demonstrated	0	O
that	0	O
these	0	O
two	0	O
elements	0	O
are	0	O
involved	0	O
in	0	O
the	0	O
positive	0	O
regulation	0	O
of	0	O
MLC	1	B
-	0	I
2	0	I
gene	0	I
transcription	0	O
.	0	O


Raf	0	B
is	0	O
a	0	O
key	0	O
serine	0	B
-	0	I
threonine	0	I
protein	0	I
kinase	0	I
which	0	O
participates	0	O
in	0	O
the	0	O
transmission	0	O
of	0	O
growth	0	O
,	0	O
anti	0	O
-	0	O
apoptotic	0	O
and	0	O
differentiation	0	O
messages	0	O
.	0	O


Of	0	O
202	0	O
initially	0	O
seronegative	0	O
caretakers	0	O
(	0	O
observed	0	O
for	0	O
an	0	O
average	0	O
of	0	O
305	0	O
days	0	O
per	0	O
woman	0	O
),	0	O
19	0	O
seroconverted	0	O
,	0	O
for	0	O
an	0	O
annual	0	O
seroconversion	0	O
rate	0	O
of	0	O
11	0	O
percent	0	O
.	0	O


Human	1	B
alpha	0	I
-	0	I
galactosidase	0	I
A	1	I
:	0	O
nucleotide	0	O
sequence	0	O
of	0	O
a	0	O
cDNA	1	O
clone	0	O
encoding	0	O
the	0	O
mature	0	O
enzyme	0	O
.	0	O


Polyvinyl	1	O
alcohol	0	O
as	0	O
a	0	O
solution	0	O
mediator	0	O


The	0	O
results	0	O
raise	0	O
the	0	O
possibility	0	O
that	0	O
pH	1	O
induced	0	O
post	0	O
-	0	O
translational	0	O
modifications	0	O
of	0	O
DdRPA	0	B
are	0	O
involved	0	O
in	0	O
events	0	O
that	0	O
halt	0	O
cell	0	O
proliferation	0	O
and	0	O
induce	0	O
differentiation	0	O
in	0	O
Dictyostelium	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
dietary	0	O
zinc	0	O
deficiency	0	O
on	0	O
the	0	O
mossy	0	O
fiber	0	O
zinc	0	O
content	0	O
of	0	O
the	0	O
rat	0	O
hippocampus	0	O
.	0	O


Mean	1	O
fluorosis	0	O
scores	0	O
,	0	O
however	0	O
,	0	O
were	0	O
similar	0	O
.	0	O


Deletion	1	O
analyses	0	O
of	0	O
the	0	O
construct	0	O
revealed	0	O
that	0	O
the	0	O
transcription	0	O
of	0	O
BOXF1	0	B
gene	0	I
is	0	O
regulated	0	O
by	0	O
BOX	1	O
DNA	1	O
,	0	O
preferentially	0	O
in	0	O
undifferentiated	0	O
EC	1	O
cells	0	O
versus	0	O
differentiated	0	O
cells	0	O
.	0	O


Simian	1	O
parainfluenza	0	O
virus	0	O
5	0	O
(	0	O
SV5	0	O
)	0	O
is	0	O
a	0	O
prototype	0	O
of	0	O
the	0	O
Paramyxoviridae	1	O
family	0	O
of	0	O
nonsegmented	0	O
negative	0	O
-	0	O
sense	0	O
RNA	1	O
viruses	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
data	0	O
suggest	0	O
that	0	O
the	0	O
Mif2	0	B
protein	0	I
interacts	0	O
with	0	O
Cep1p	0	B
at	0	O
the	0	O
centromere	0	O
and	0	O
that	0	O
the	0	O
yeast	0	O
centromere	0	O
indeed	0	O
exists	0	O
as	0	O
a	0	O
higher	0	O
order	0	O
protein	0	O
-	0	O
DNA	1	O
complex	0	O
.	0	O


Later	0	O
in	0	O
development	0	O
,	0	O
Tbx6	0	B
expression	0	O
is	0	O
restricted	0	O
to	0	O
presomitic	0	O
,	0	O
paraxial	0	O
mesoderm	0	O
and	0	O
to	0	O
the	0	O
tail	0	O
bud	0	O
,	0	O
which	0	O
replaces	0	O
the	0	O
streak	0	O
as	0	O
the	0	O
source	0	O
of	0	O
mesoderm	0	O
.	0	O


During	0	O
the	0	O
years	0	O
1980	0	O
-	0	O
87	0	O
a	0	O
total	0	O
of	0	O
287	0	O
persons	0	O
received	0	O
disability	0	O
pensions	0	O
in	0	O
the	0	O
municipality	0	O
of	0	O
Nordreisa	0	O
in	0	O
northern	0	O
Norway	0	O
.	0	O


Oral	1	O
candidiasis	0	O


Long	0	O
-	0	O
term	0	O
effects	0	O
of	0	O
clofibrate	0	O
(	0	O
Atromid	0	O
-	0	O
S	1	O
)	0	O
on	0	O
serum	0	O
lipids	0	O
in	0	O
man	0	O
.	0	O


Epigenetic	1	O
switching	0	O
of	0	O
transcriptional	0	O
states	0	O
:	0	O
cis	0	O
-	0	O
and	0	O
trans	0	O
-	0	O
acting	0	O
factors	0	O
affecting	0	O
establishment	0	O
of	0	O
silencing	0	O
at	0	O
the	0	O
HMR	0	B
locus	0	I
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Like	0	O
Epo	0	B
,	0	O
HNF	1	B
-	0	I
4	0	I
is	0	O
expressed	0	O
in	0	O
kidney	0	O
,	0	O
liver	0	O
,	0	O
and	0	O
Hep3B	0	O
cells	0	O
but	0	O
not	0	O
in	0	O
HeLa	0	O
cells	0	O
.	0	O


At	1	O
60	0	O
days	0	O
the	0	O
amount	0	O
of	0	O
gangliosides	0	O
was	0	O
on	0	O
average	0	O
lower	0	O
in	0	O
females	0	O
than	0	O
in	0	O
males	0	O
,	0	O
even	0	O
if	0	O
with	0	O
some	0	O
exception	0	O
.	0	O


T	1	O
.,	0	O
Patel	0	O
,	0	O
S	1	O
.	0	O


Value	1	O
of	0	O
urine	0	O
glucose	0	O
tests	0	O
in	0	O
the	0	O
management	0	O
of	0	O
type	0	O
II	0	O
diabetes	0	O
mellitus	0	O
.	0	O


The	0	O
3	0	O
-	0	O
hour	0	O
test	0	O
iodine	0	O
(	0	O
I	1	O
-	0	O
132	0	O
)	0	O
uptake	0	O
by	0	O
the	0	O
thyroid	0	O
in	0	O
children	0	O
with	0	O
growth	0	O
deficiency	0	O


Regulation	1	O
of	0	O
RhoA	0	B
is	0	O
required	0	O
to	0	O
maintain	0	O
adhesion	0	O
in	0	O
stationary	0	O
cells	0	O
,	0	O
but	0	O
is	0	O
also	0	O
critical	0	O
for	0	O
cell	0	O
spreading	0	O
and	0	O
migration	0	O
[	0	O
3	0	O
].	0	O


Anatomy	1	O
of	0	O
the	0	O
RNA	1	O
and	0	O
gene	0	O
products	0	O
of	0	O
MC29	0	O
and	0	O
MH2	0	O
,	0	O
two	0	O
defective	0	O
avian	0	O
tumor	0	O
viruses	0	O
causing	0	O
acute	0	O
leukemia	0	O
and	0	O
carcinoma	0	O
:	0	O
evidence	0	O
for	0	O
a	0	O
new	0	O
class	0	O
of	0	O
transforming	0	O
genes	0	O
.	0	O


Ecthyma	1	O
,	0	O
a	0	O
known	0	O
disease	0	O
,	0	O
of	0	O
which	0	O
little	0	O
is	0	O
known	0	O


In	1	O
addition	0	O
to	0	O
protein	0	O
binding	0	O
at	0	O
sequences	0	O
known	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
transcription	0	O
,	0	O
genomic	0	O
footprinting	0	O
of	0	O
the	0	O
entire	0	O
promoter	0	O
region	0	O
also	0	O
showed	0	O
that	0	O
a	0	O
protein	0	O
factor	0	O
is	0	O
constitutively	0	O
bound	0	O
to	0	O
the	0	O
first	0	O
intron	0	O
of	0	O
the	0	O
rep3	0	B
gene	0	I
.	0	O


Activation	1	O
of	0	O
c	0	B
-	0	I
fos	0	I
gene	0	I
expression	0	O
by	0	O
a	0	O
kinase	0	O
-	0	O
deficient	0	O
epidermal	0	B
growth	0	I
factor	0	I
receptor	0	I
.	0	O


Continued	1	O
absorption	0	O
of	0	O
amino	0	O
acids	0	O
by	0	O
the	0	O
NBB	0	O
carrier	0	O
(	0	O
for	0	O
neutral	0	O
amino	0	O
acids	0	O
),	0	O
the	0	O
Y	1	O
+	0	O
system	0	O
(	0	O
for	0	O
dibasic	0	O
amino	0	O
acids	0	O
),	0	O
and	0	O
the	0	O
PHE	1	O
carrier	0	O
were	0	O
operative	0	O
even	0	O
during	0	O
the	0	O
actively	0	O
purging	0	O
stage	0	O
of	0	O
watery	0	O
diarrhoea	0	O
due	0	O
to	0	O
cholera	0	O
.	0	O


AIDS	1	O
-	0	O
related	0	O
disseminated	0	O
histoplasmosis	0	O
in	0	O
San	0	O
Francisco	0	O
,	0	O
California	0	O
.	0	O


Particles	0	O
resembling	0	O
microbodies	0	O
in	0	O
normal	0	O
and	0	O
neoplastic	0	O
perianal	0	O
glands	0	O
of	0	O
dogs	0	O
.	0	O


NDRF	0	B
/	0	O
NeuroD2	0	B
was	0	O
co	0	O
-	0	O
precipitated	0	O
with	0	O
PKN	0	B
from	0	O
the	0	O
lysate	0	O
of	0	O
COS	1	O
-	0	O
7	0	O
cells	0	O
transfected	0	O
with	0	O
both	0	O
expression	0	O
constructs	0	O
for	0	O
NDRF	0	B
/	0	O
NeuroD2	0	B
and	0	O
PKN	0	B
.	0	O


Stringent	0	O
hybridization	0	O
of	0	O
EHS	0	B
-	0	I
1	0	I
back	0	O
to	0	O
primate	0	O
genomic	0	O
DNA	1	O
indicates	0	O
two	0	O
distinct	0	O
EHS	0	B
-	0	I
1	0	I
loci	0	I
in	0	O
normal	0	O
human	0	O
DNA	1	O
,	0	O
an	0	O
identical	0	O
band	0	O
pattern	0	O
in	0	O
chimpanzee	0	O
DNA	1	O
,	0	O
and	0	O
a	0	O
single	0	O
locus	0	O
in	0	O
rhesus	0	O
monkey	0	O
DNA	1	O
.	0	O


The	0	O
determination	0	O
of	0	O
immunoglobulin	0	B
E	1	I
(	0	O
IgE	1	B
)	0	O
antibodies	0	O
by	0	O
one	0	O
of	0	O
several	0	O
laboratory	0	O
tests	0	O
,	0	O
by	0	O
skin	0	O
-	0	O
prick	0	O
tests	0	O
or	0	O
by	0	O
appropriate	0	O
challenge	0	O
procedures	0	O
is	0	O
useful	0	O
either	0	O
to	0	O
identify	0	O
atopic	0	O
individuals	0	O
or	0	O
as	0	O
outcome	0	O
predictors	0	O
in	0	O
wheezy	0	O
children	0	O
.	0	O


Subjects	0	O
were	0	O
16	0	O
male	0	O
chronic	0	O
schizophrenics	0	O
consisting	0	O
of	0	O
8	0	O
DST	0	O
suppressors	0	O
and	0	O
8	0	O
nonsuppressors	0	O
.	0	O


Biol	0	O
.	0	O


A	1	O
protein	0	O
lacking	0	O
the	0	O
SH2	0	B
and	0	O
RING	1	O
finger	0	O
domains	0	O
has	0	O
no	0	O
activity	0	O
,	0	O
but	0	O
a	0	O
chimeric	0	O
protein	0	O
with	0	O
the	0	O
SH2	0	B
and	0	O
RING	1	O
finger	0	O
domains	0	O
of	0	O
SLI	0	B
-	0	I
1	0	I
replaced	0	O
by	0	O
the	0	O
equivalent	0	O
domains	0	O
of	0	O
c	0	B
-	0	I
Cbl	1	I
has	0	O
activity	0	O
.	0	O


In	1	O
the	0	O
second	0	O
case	0	O
,	0	O
an	0	O
epidermal	0	O
cyst	0	O
was	0	O
diagnosed	0	O
.	0	O


Analysis	1	O
of	0	O
one	0	O
cDNA	1	O
revealed	0	O
an	0	O
unusual	0	O
splicing	0	O
event	0	O
involving	0	O
EZH1	0	B
and	0	O
a	0	O
tandemly	0	O
linked	0	O
gene	0	O
GPR2	0	B
and	0	O
suggests	0	O
a	0	O
potential	0	O
mechanism	0	O
for	0	O
modifying	0	O
the	0	O
EZH1	0	B
protein	0	I
in	0	O
the	0	O
conserved	0	O
C	1	O
-	0	O
terminal	0	O
domain	0	O
.	0	O


Pet	1	B
-	0	I
1	0	I
can	0	O
bind	0	O
specifically	0	O
to	0	O
a	0	O
PEA3	0	B
ETS	1	I
DNA	1	O
-	0	O
binding	0	O
motif	0	O
and	0	O
can	0	O
modulate	0	O
transcription	0	O
of	0	O
synthetic	0	O
promoter	0	O
constructs	0	O
in	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Left	1	O
ventricular	0	O
hypertrophy	0	O
is	0	O
a	0	O
heterogeneous	0	O
disorder	0	O
with	0	O
distinct	0	O
morphologies	0	O
.	0	O


These	0	O
studies	0	O
indicate	0	O
that	0	O
the	0	O
acidimetric	0	O
test	0	O
was	0	O
less	0	O
sensitive	0	O
than	0	O
the	0	O
chromogenic	0	O
cephalosporin	0	O
substrates	0	O
and	0	O
that	0	O
nitrocefin	0	O
and	0	O
S1	1	O
could	0	O
be	0	O
used	0	O
to	0	O
screen	0	O
for	0	O
beta	0	B
-	0	I
lactamase	0	I
production	0	O
in	0	O
these	0	O
tested	0	O
species	0	O
.	0	O


The	0	O
defect	0	O
in	0	O
these	0	O
proteins	0	O
was	0	O
also	0	O
uniformly	0	O
suppressed	0	O
by	0	O
either	0	O
Mn2	0	O
+,	0	O
or	0	O
the	0	O
Mu	1	B
B	1	I
protein	0	I
in	0	O
the	0	O
presence	0	O
of	0	O
ATP	1	O
and	0	O
target	0	O
DNA	1	O
.	0	O


Tracheal	1	O
transsection	0	O
combined	0	O
with	0	O
hilar	0	O
ligation	0	O
(	0	O
TL	1	O
&	0	O
PL	0	O
)	0	O
effected	0	O
a	0	O
reduction	0	O
of	0	O
19	0	O
.	0	O
9	0	O
%	0	O
(	0	O
n	0	O
.	0	O
s	0	O
.).	0	O


A	1	O
leucine	0	O
zipper	0	O
domain	0	O
of	0	O
the	0	O
suppressor	0	B
of	0	I
Hairy	1	I
-	0	I
wing	0	I
protein	0	I
mediates	0	O
its	0	O
repressive	0	O
effect	0	O
on	0	O
enhancer	0	O
function	0	O
.	0	O


A	1	O
gas	0	O
-	0	O
liquid	0	O
chromatographic	0	O
method	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
p	0	O
-	0	O
chlorophenoxyisobutyric	0	O
(	0	O
CPIB	0	O
)	0	O
acid	0	O
in	0	O
blood	0	O
plasma	0	O
is	0	O
described	0	O
.	0	O


Human	1	B
cytomegalovirus	0	I
immediate	0	I
-	0	I
early	0	I
protein	0	I
IE2	0	I
tethers	0	O
a	0	O
transcriptional	0	O
repression	0	O
domain	0	O
to	0	O
p53	0	B
.	0	O


Transvenous	1	O
serial	0	O
xeroradiography	0	O
.	0	O


In	1	O
Rat	1	O
1a	0	O
cells	0	O
,	0	O
m1R	0	B
stimulation	0	O
of	0	O
phospholipase	0	B
C	1	I
beta	0	I
and	0	O
the	0	O
marked	0	O
rise	0	O
in	0	O
intracellular	0	O
calcium	0	O
stimulated	0	O
cyclic	0	O
AMP	1	O
(	0	O
cAMP	1	O
)	0	O
synthesis	0	O
,	0	O
resulting	0	O
in	0	O
the	0	O
activation	0	O
of	0	O
protein	0	B
kinase	0	I
A	1	I
.	0	O


Ultrasonography	1	O
provides	0	O
excellent	0	O
intraoperative	0	O
evaluation	0	O
of	0	O
spinal	0	O
cord	0	O
injury	0	O
.	0	O


Similar	0	O
to	0	O
the	0	O
mouse	0	O
gene	0	O
,	0	O
the	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
human	0	B
CD79	0	I
alpha	0	I
lacks	0	O
a	0	O
TATA	0	O
box	0	O
;	0	O
however	0	O
,	0	O
unlike	0	O
mouse	0	B
CD79	0	I
alpha	0	I
,	0	O
a	0	O
classical	0	O
octamer	0	O
motif	0	O
could	0	O
not	0	O
be	0	O
identified	0	O
in	0	O
the	0	O
human	0	O
gene	0	O
.	0	O


The	0	O
BAL	1	O
concentrations	0	O
of	0	O
the	0	O
nine	0	O
cytokines	0	O
evaluated	0	O
for	0	O
the	0	O
more	0	O
and	0	O
less	0	O
affected	0	O
lungs	0	O
were	0	O
compared	0	O
:	0	O
interleukin	0	B
-	0	I
6	0	I
(	0	O
IL	1	B
-	0	I
6	0	I
),	0	O
IL	1	B
-	0	I
8	0	I
,	0	O
IL	1	B
-	0	I
12	0	I
,	0	O
tumor	0	B
necrosis	0	I
factor	0	I
-	0	I
alpha	0	I
(	0	O
TNF	1	B
-	0	I
alpha	0	I
),	0	O
and	0	O
interferon	0	B
gamma	0	I
(	0	O
IFN	1	B
-	0	I
gamma	0	I
)	0	O
showed	0	O
significant	0	O
differences	0	O
(	0	O
p	0	O
ranged	0	O
between	0	O
0	0	O
.	0	O


Removal	0	O
of	0	O
the	0	O
GST	0	B
domain	0	I
from	0	O
GST	0	B
-	0	O
Tax	0	B
by	0	O
thrombin	0	B
restores	0	O
Tax	0	B
'	0	O
s	0	O
ability	0	O
to	0	O
assemble	0	O
a	0	O
ternary	0	O
Tax	0	B
-	0	O
CREB	0	B
-	0	O
21	0	O
-	0	O
bp	0	O
-	0	O
repeat	0	O
complex	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
400	0	O
WORDS	0	O
)	0	O


Recent	0	O
literature	0	O
has	0	O
suggested	0	O
that	0	O
beta	0	B
-	0	I
2	0	I
transferrin	0	I
can	0	O
also	0	O
be	0	O
used	0	O
as	0	O
a	0	O
clinical	0	O
marker	0	O
for	0	O
perilymph	0	O
.	0	O


Several	0	O
7SL	0	B
RNA	1	I
-	0	I
encoding	0	I
sequences	0	I
and	0	O
various	0	O
intergenic	0	O
spacers	0	O
were	0	O
amplified	0	O
from	0	O
the	0	O
individual	0	O
HindIII	0	B
fragments	0	I
of	0	O
about	0	O
1	0	O
.	0	O
3	0	O
and	0	O
2	0	O
.	0	O
8	0	O
kb	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
COUP	1	B
-	0	I
TF	1	I
alone	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
repCRS2	0	O
-	0	O
dependent	0	O
reporter	0	O
gene	0	O
activity	0	O
.	0	O


Results	0	O
of	0	O
the	0	O
official	0	O
inspection	0	O
of	0	O
the	0	O
commercial	0	O
anti	0	O
-	0	O
inflammatory	0	O
enzyme	0	O
preparations	0	O
containing	0	O
chymotrypsin	0	B
and	0	O
trypsin	0	B
by	0	O
means	0	O
of	0	O
modified	0	O
NF	1	O
13	0	O
methods	0	O


Correlation	1	O
coefficients	0	O
between	0	O
the	0	O
reference	0	O
methods	0	O
and	0	O
NIT	1	O
were	0	O
>	0	O
or	0	O
=	0	O
0	0	O
.	0	O
95	0	O
for	0	O
water	0	O
,	0	O
fat	0	O
,	0	O
crude	0	O
protein	0	O
and	0	O
connective	0	O
-	0	O
tissue	0	O
-	0	O
protein	0	O
frei	0	O
meat	0	O
protein	0	O
,	0	O
and	0	O
>	0	O
or	0	O
=	0	O
0	0	O
.	0	O
86	0	O
for	0	O
connective	0	O
-	0	O
tissue	0	O
-	0	O
protein	0	O
.	0	O


The	0	O
protein	0	O
product	0	O
of	0	O
orfD	0	B
,	0	O
which	0	O
is	0	O
probably	0	O
a	0	O
new	0	O
tra	0	B
gene	0	I
(	0	O
named	0	O
traX	0	B
),	0	O
contains	0	O
65	0	O
%	0	O
hydrophobic	0	O
amino	0	O
acids	0	O
,	0	O
especially	0	O
rich	0	O
in	0	O
alanine	0	O
and	0	O
leucine	0	O
.	0	O


The	0	O
gene	0	O
is	0	O
essential	0	O
for	0	O
yeast	0	O
vegetative	0	O
growth	0	O
.	0	O


Coronary	1	O
T1	1	O
and	0	O
T2	0	O
weighted	0	O
images	0	O
were	0	O
obtained	0	O
.	0	O


This	0	O
sequence	0	O
also	0	O
confers	0	O
VDR	0	B
and	0	O
vitamin	0	O
D	1	O
responsiveness	0	O
to	0	O
a	0	O
heterologous	0	O
promoter	0	O
.	0	O


Treatment	1	O
with	0	O
MK	1	O
-	0	O
801	0	O
induced	0	O
a	0	O
burst	0	O
suppression	0	O
in	0	O
the	0	O
EEG	1	O
and	0	O
a	0	O
transient	0	O
drop	0	O
(	0	O
11	0	O
.	0	O
4	0	O
+/-	0	O
6	0	O
.	0	O
5	0	O
mm	0	O
Hg	1	O
)	0	O
in	0	O
the	0	O
mean	0	O
arterial	0	O
pressure	0	O
.	0	O


Klebsiella	1	O
oxytoca	0	O
can	0	O
assimilate	0	O
nitrate	0	O
and	0	O
nitrite	0	O
by	0	O
using	0	O
enzymes	0	O
encoded	0	O
by	0	O
the	0	O
nasFEDCBA	0	B
operon	0	I
.	0	O


Unitary	1	O
-	0	O
group	0	O
approach	0	O
to	0	O
spin	0	O
-	0	O
dependent	0	O
operators	0	O
.	0	O


The	0	O
95	0	O
%	0	O
confidence	0	O
values	0	O
(	0	O
2SD	0	O
)	0	O
for	0	O
the	0	O
change	0	O
in	0	O
Ros	1	O
required	0	O
to	0	O
exclude	0	O
natural	0	O
variability	0	O
were	0	O
0	0	O
.	0	O
39	0	O
,	0	O
0	0	O
.	0	O
50	0	O
and	0	O
0	0	O
.	0	O
53	0	O
cmH2O	0	O
l	0	O
-	0	O
1	0	O
s	0	O
,	0	O
respectively	0	O
.	0	O


Each	0	O
of	0	O
these	0	O
genes	0	O
contains	0	O
a	0	O
putative	0	O
upstream	0	O
ORF	1	O
,	0	O
while	0	O
STA2	0	B
has	0	O
two	0	O
additional	0	O
in	0	O
-	0	O
frame	0	O
AUG	0	O
codons	0	O
5	0	O
'	0	O
to	0	O
the	0	O
major	0	O
cistron	0	O
.	0	O


RESULTS	0	O
:	0	O
Of	0	O
the	0	O
patients	0	O
with	0	O
IS	1	O
,	0	O
67	0	O
%	0	O
had	0	O
significantly	0	O
greater	0	O
values	0	O
of	0	O
directional	0	O
preponderance	0	O
on	0	O
the	0	O
OVAR	0	O
test	0	O
(	0	O
a	0	O
measure	0	O
of	0	O
otolith	0	O
system	0	O
imbalance	0	O
)	0	O
compared	0	O
with	0	O
control	0	O
subjects	0	O
.	0	O


We	0	O
describe	0	O
a	0	O
case	0	O
of	0	O
a	0	O
perinephric	0	O
abscess	0	O
treated	0	O
with	0	O
amphotericin	0	O
B	1	O
and	0	O
nephrectomy	0	O
.	0	O


Deletion	1	O
from	0	O
either	0	O
the	0	O
N	1	O
-	0	O
or	0	O
C	1	O
-	0	O
terminal	0	O
ends	0	O
of	0	O
repA	0	B
(	0	O
28	0	O
and	0	O
69	0	O
codons	0	O
,	0	O
respectively	0	O
,	0	O
out	0	O
of	0	O
the	0	O
286	0	O
-	0	O
codon	0	O
open	0	O
reading	0	O
frame	0	O
)	0	O
affected	0	O
the	0	O
initiator	0	O
but	0	O
not	0	O
the	0	O
inhibitory	0	O
activity	0	O
.	0	O


The	0	O
promoter	0	O
activity	0	O
of	0	O
the	0	O
gene	0	B
encoding	0	I
Alzheimer	0	I
beta	0	I
-	0	I
amyloid	0	I
precursor	0	I
protein	0	I
(	0	O
APP	1	B
)	0	O
is	0	O
regulated	0	O
by	0	O
two	0	O
blocks	0	O
of	0	O
upstream	0	O
sequences	0	O
.	0	O


Tyrosine	1	O
1356	0	O
forms	0	O
a	0	O
multisubstrate	0	O
binding	0	O
site	0	O
for	0	O
the	0	O
Grb2	0	B
and	0	O
Shc	0	B
adaptor	0	I
proteins	0	I
,	0	O
the	0	O
p85	0	B
subunit	0	I
of	0	O
phosphatidylinositol	0	B
3	0	I
'-	0	I
kinase	0	I
,	0	O
phospholipase	0	B
Cgamma	0	I
,	0	O
and	0	O
a	0	O
phosphatase	0	O
,	0	O
SHP2	0	B
.	0	O


For	0	O
replication	0	O
reporter	0	O
constructs	0	O
where	0	O
E1	1	B
and	0	O
E2	1	B
are	0	O
supplied	0	O
in	0	O
trans	0	O
by	0	O
the	0	O
respective	0	O
expression	0	O
vectors	0	O
,	0	O
distance	0	O
between	0	O
the	0	O
half	0	O
sites	0	O
seems	0	O
to	0	O
play	0	O
a	0	O
major	0	O
role	0	O
,	0	O
yet	0	O
the	0	O
phasing	0	O
relationships	0	O
are	0	O
measurable	0	O
.	0	O


Plasma	1	O
vitamin	0	O
E	1	O
,	0	O
total	0	O
lipids	0	O
and	0	O
myeloperoxidase	0	B
levels	0	O
during	0	O
spinal	0	O
surgery	0	O
.	0	O


In	1	O
order	0	O
to	0	O
study	0	O
the	0	O
influence	0	O
of	0	O
iron	0	O
overload	0	O
on	0	O
the	0	O
polymorphonuclear	0	O
leucocyte	0	O
(	0	O
PMN	1	O
)	0	O
metabolism	0	O
of	0	O
patients	0	O
on	0	O
chronic	0	O
hemodialysis	0	O
,	0	O
generation	0	O
of	0	O
superoxide	0	O
anion	0	O
(	0	O
O2	1	O
-)	0	O
by	0	O
PMN	1	O
in	0	O
whole	0	O
blood	0	O
was	0	O
compared	0	O
in	0	O
two	0	O
groups	0	O
of	0	O
hemodialyzed	0	O
patients	0	O
:	0	O
group	0	O
A	1	O
consisted	0	O
of	0	O
twenty	0	O
-	0	O
one	0	O
individuals	0	O
with	0	O
serum	0	O
ferritin	0	B
levels	0	O
above	0	O
1000	0	O
ng	0	O
/	0	O
ml	0	O
and	0	O
group	0	O
B	1	O
of	0	O
nineteen	0	O
individuals	0	O
with	0	O
serum	0	O
ferritin	0	B
levels	0	O
below	0	O
1000	0	O
ng	0	O
/	0	O
ml	0	O
.	0	O


We	0	O
propose	0	O
that	0	O
plasmids	0	O
of	0	O
the	0	O
pLS1	0	O
family	0	O
(	0	O
pE194	0	O
,	0	O
pADB201	0	O
,	0	O
and	0	O
pLB4	0	O
)	0	O
share	0	O
functional	0	O
and	0	O
structural	0	O
characteristics	0	O
for	0	O
the	0	O
regulation	0	O
of	0	O
their	0	O
copy	0	O
numbers	0	O
.	0	O


Gag	1	B
protein	0	O
sequence	0	O
motifs	0	O
of	0	O
the	0	O
NC	0	B
domain	0	I
of	0	O
primate	0	O
foamy	0	O
viruses	0	O
assumed	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
genome	0	O
encapsidation	0	O
are	0	O
not	0	O
conserved	0	O
in	0	O
FeFV	0	O
.	0	O


We	0	O
now	0	O
show	0	O
that	0	O
the	0	O
BAT1	0	B
translation	0	I
product	0	I
is	0	O
the	0	O
homolog	0	O
of	0	O
the	0	O
rat	0	B
p47	0	I
nuclear	0	I
protein	0	I
,	0	O
the	0	O
WM6	0	B
Drosophila	1	I
gene	0	I
product	0	I
,	0	O
and	0	O
probably	0	O
also	0	O
Ce08102	0	B
of	0	O
Caenorhabditis	0	O
elegans	0	O
,	0	O
all	0	O
members	0	O
of	0	O
the	0	O
DEAD	1	B
protein	0	I
family	0	I
of	0	O
ATP	1	B
-	0	I
dependent	0	I
RNA	1	I
helicases	0	I
.	0	O


Subretinal	1	O
fluid	0	O
was	0	O
punctured	0	O
on	0	O
the	0	O
poorer	0	O
eye	0	O
in	0	O
19	0	O
eyes	0	O
(	0	O
52	0	O
.	0	O
7	0	O
%)	0	O
and	0	O
on	0	O
the	0	O
better	0	O
eye	0	O
in	0	O
7	0	O
eyes	0	O
(	0	O
19	0	O
.	0	O
4	0	O
%).	0	O


The	0	O
ParaSight	0	O
-	0	O
F	1	O
test	0	O
alone	0	O
was	0	O
used	0	O
to	0	O
monitor	0	O
serum	0	O
antigen	0	O
levels	0	O
after	0	O
treatment	0	O
in	0	O
24	0	O
patients	0	O
.	0	O


Shape	1	O
factor	0	O
correlated	0	O
well	0	O
with	0	O
hemodynamic	0	O
data	0	O
for	0	O
RV	1	O
/	0	O
LV	1	O
systolic	0	O
pressure	0	O
ratios	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
93	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
)	0	O
for	0	O
normalized	0	O
interventricular	0	O
pressure	0	O
differences	0	O
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
95	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


Tcn1p	0	B
/	0	O
Crz1p	0	B
,	0	O
a	0	O
calcineurin	0	O
-	0	O
dependent	0	O
transcription	0	O
factor	0	O
that	0	O
differentially	0	O
regulates	0	O
gene	0	O
expression	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


These	0	O
genes	0	O
are	0	O
expressed	0	O
within	0	O
a	0	O
few	0	O
hours	0	O
of	0	O
the	0	O
initiation	0	O
of	0	O
development	0	O
;	0	O
their	0	O
mRNAs	0	O
accumulate	0	O
to	0	O
a	0	O
peak	0	O
at	0	O
12	0	O
hr	0	O
and	0	O
persist	0	O
until	0	O
culmination	0	O
.	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
a	0	O
comparison	0	O
between	0	O
the	0	O
number	0	O
and	0	O
shape	0	O
of	0	O
corneal	0	O
endothelial	0	O
cells	0	O
has	0	O
been	0	O
performed	0	O
in	0	O
25	0	O
patients	0	O
before	0	O
and	0	O
6	0	O
months	0	O
after	0	O
PRK	1	O
.	0	O


Forty	0	O
-	0	O
five	0	O
cases	0	O
were	0	O
surgically	0	O
by	0	O
direct	0	O
approach	0	O
to	0	O
the	0	O
tumour	0	O
,	0	O
while	0	O
two	0	O
cases	0	O
were	0	O
treated	0	O
only	0	O
with	0	O
a	0	O
shunt	0	O
.	0	O


Cross	1	O
-	0	O
talking	0	O
among	0	O
Drosophila	1	O
nuclear	0	O
receptors	0	O
at	0	O
the	0	O
promiscuous	0	O
response	0	O
element	0	O
of	0	O
the	0	O
ng	0	B
-	0	I
1	0	I
and	0	O
ng	0	B
-	0	I
2	0	I
intermolt	0	I
genes	0	I
.	0	O


The	0	O
Aa	1	B
-	0	I
Pri2	0	I
gene	0	I
,	0	O
specifically	0	O
expressed	0	O
during	0	O
basidiocarp	0	O
differentiation	0	O
of	0	O
the	0	O
mushroom	0	O
Agrocybe	0	O
aegerita	0	O
,	0	O
was	0	O
cloned	0	O
.	0	O


Selection	1	O
of	0	O
the	0	O
22	0	O
items	0	O
of	0	O
the	0	O
Clinical	1	O
Institute	0	O
Withdrawal	1	O
Assessment	1	O
-	0	O
Benzodiazepines	0	O
(	0	O
CIWA	0	O
-	0	O
B	1	O
)	0	O
was	0	O
based	0	O
on	0	O
statistically	0	O
significant	0	O
differences	0	O
between	0	O
baseline	0	O
and	0	O
critical	0	O
withdrawal	0	O
periods	0	O
in	0	O
high	0	O
-	0	O
dose	0	O
subjects	0	O
and	0	O
between	0	O
symptoms	0	O
associated	0	O
with	0	O
placebo	0	O
and	0	O
diazepam	0	O
in	0	O
low	0	O
-	0	O
dose	0	O
subjects	0	O
,	0	O
using	0	O
contingency	0	O
tables	0	O
and	0	O
logistic	0	O
regression	0	O
analysis	0	O
.	0	O


Diminished	0	O
forearm	0	O
arteriolar	0	O
dilator	0	O
capacity	0	O
produced	0	O
by	0	O
mineralocorticoid	0	O
-	0	O
induced	0	O
salt	0	O
retention	0	O
in	0	O
man	0	O
.	0	O


Both	0	O
variants	0	O
display	0	O
the	0	O
seven	0	O
-	0	O
transmembrane	0	O
topology	0	O
that	0	O
is	0	O
typical	0	O
for	0	O
G	1	B
protein	0	I
-	0	I
coupled	0	I
receptors	0	I
.	0	O


Transcriptional	1	O
regulation	0	O
of	0	O
the	0	O
mouse	0	B
cytosolic	0	I
chaperonin	0	I
subunit	0	I
gene	0	I
Ccta	1	I
/	0	I
t	0	I
-	0	I
complex	0	I
polypeptide	0	I
1	0	I
by	0	O
selenocysteine	0	B
tRNA	1	I
gene	0	I
transcription	0	I
activating	0	I
factor	0	I
family	0	I
zinc	0	I
finger	0	I
proteins	0	I
.	0	O


Analysis	1	O
of	0	O
glucocorticoid	0	O
unresponsive	0	O
cell	0	O
variants	0	O
using	0	O
a	0	O
mouse	0	B
glucocorticoid	0	I
receptor	0	I
complementary	0	O
DNA	1	O
clone	0	O
.	0	O


These	0	O
findings	0	O
and	0	O
the	0	O
differential	0	O
tissue	0	O
distribution	0	O
of	0	O
p54	0	B
suggest	0	O
that	0	O
this	0	O
novel	0	O
SR	1	B
protein	0	I
may	0	O
participate	0	O
in	0	O
regulation	0	O
of	0	O
alternative	0	O
splicing	0	O
in	0	O
a	0	O
tissue	0	O
-	0	O
and	0	O
substrate	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


Reproducing	0	O
populations	0	O
of	0	O
this	0	O
aphid	0	O
were	0	O
first	0	O
detected	0	O
in	0	O
Puerto	0	O
Rico	0	O
in	0	O
April	0	O
1992	0	O
.	0	O


Influence	0	O
of	0	O
metoprolol	0	O
treatment	0	O
on	0	O
sympatho	0	O
-	0	O
adrenal	0	O
activation	0	O
of	0	O
fibrinolysis	0	O
.	0	O


In	1	O
6	0	O
of	0	O
24	0	O
infants	0	O
studied	0	O
(	0	O
27th	0	O
-	0	O
40th	0	O
weeks	0	O
of	0	O
gestation	0	O
),	0	O
acquired	0	O
and	0	O
congenital	0	O
structural	0	O
anomalies	0	O
of	0	O
the	0	O
airways	0	O
were	0	O
detected	0	O
with	0	O
an	0	O
ultrathin	0	O
flexible	0	O
fiberscope	0	O
(	0	O
Olympus	0	O
PF18	0	O
S	1	O
,	0	O
1	0	O
.	0	O
8	0	O
mm	0	O
).	0	O


Plasmids	0	O
pAMS12	0	O
,	0	O
pAMS13	0	O
and	0	O
pAMS14	0	O
were	0	O
transformed	0	O
into	0	O
a	0	O
laboratory	0	O
strain	0	O
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
,	0	O
whereas	0	O
pAMS15	0	O
was	0	O
stably	0	O
introduced	0	O
into	0	O
two	0	O
commercial	0	O
wine	0	O
yeast	0	O
strains	0	O
.	0	O


Purple	1	O
photosynthetic	0	O
bacteria	0	O
are	0	O
capable	0	O
of	0	O
generating	0	O
cellular	0	O
energy	0	O
from	0	O
several	0	O
sources	0	O
,	0	O
including	0	O
photosynthesis	0	O
,	0	O
respiration	0	O
,	0	O
and	0	O
H	1	O
(	0	O
2	0	O
)	0	O
oxidation	0	O
.	0	O


Both	0	O
receptors	0	O
utilize	0	O
protein	0	B
tyrosine	0	I
kinases	0	I
(	0	O
PTKs	0	B
)	0	O
for	0	O
the	0	O
phosphorylation	0	O
of	0	O
various	0	O
signaling	0	O
molecules	0	O
,	0	O
a	0	O
process	0	O
that	0	O
is	0	O
critical	0	O
for	0	O
the	0	O
function	0	O
of	0	O
both	0	O
receptors	0	O
.	0	O


Apropos	0	O
of	0	O
a	0	O
case	0	O


The	0	O
human	0	O
cDNA	1	O
clone	0	O
NFBD1	0	O
(	0	O
previously	0	O
designated	0	O
KIAA0170	0	O
)	0	O
encodes	0	O
a	0	O
novel	0	O
protein	0	O
(	0	O
2089	0	O
amino	0	O
acids	0	O
in	0	O
length	0	O
;	0	O
calculated	0	O
molecular	0	O
mass	0	O
226	0	O
,	0	O
440	0	O
D	1	O
)	0	O
with	0	O
possible	0	O
BRCT	0	B
domains	0	I
at	0	O
its	0	O
carboxy	0	O
terminus	0	O
(	0	O
amino	0	O
acid	0	O
residues	0	O
1894	0	O
-	0	O
2089	0	O
).	0	O


We	0	O
present	0	O
evidence	0	O
that	0	O
DNA	1	B
polymerase	0	I
delta	0	I
of	0	I
Saccharomyces	1	I
cerevisiae	0	I
,	0	O
an	0	O
enzyme	0	O
that	0	O
is	0	O
essential	0	O
for	0	O
viability	0	O
and	0	O
chromosomal	0	O
replication	0	O
,	0	O
is	0	O
also	0	O
required	0	O
for	0	O
base	0	O
excision	0	O
repair	0	O
of	0	O
exogenous	0	O
DNA	1	O
methylation	0	O
damage	0	O
.	0	O


Activity	1	O
of	0	O
palgD	0	B
in	0	O
the	0	O
cysB	0	B
mutant	0	I
,	0	O
in	0	O
CHA	0	O
and	0	O
in	0	O
the	0	O
non	0	O
-	0	O
mucoid	0	O
strain	0	O
PAO	1	O
was	0	O
assessed	0	O
by	0	O
the	0	O
use	0	O
of	0	O
a	0	O
transcriptional	0	O
algD	0	B
-	0	O
xylE	0	B
fusion	0	O
.	0	O


We	0	O
previously	0	O
showed	0	O
that	0	O
the	0	O
upstream	0	O
promoter	0	O
element	0	O
of	0	O
the	0	O
yeast	0	B
RP39A	0	I
gene	0	I
consists	0	O
of	0	O
these	0	O
identical	0	O
sequence	0	O
motifs	0	O
.	0	O


Commonly	0	O
used	0	O
stressors	0	O
are	0	O
mental	0	O
arithmetics	0	O
,	0	O
speech	0	O
tasks	0	O
,	0	O
the	0	O
Stroop	0	O
test	0	O
,	0	O
videogame	0	O
playing	0	O
,	0	O
films	0	O
or	0	O
videotapes	0	O
and	0	O
interviews	0	O
.	0	O


Overexpressing	0	O
the	0	O
coactivator	0	O
,	0	O
SRC1a	0	B
or	0	O
GRIP1	1	B
,	0	O
further	0	O
enhances	0	O
ERRalpha1	0	B
-	0	O
induced	0	O
transcriptional	0	O
activity	0	O
.	0	O


The	0	O
Sp1	0	B
region	0	I
,	0	O
however	0	O
,	0	O
is	0	O
converted	0	O
to	0	O
a	0	O
functionally	0	O
strong	0	O
TRE	0	O
by	0	O
the	0	O
viral	0	B
tat	0	I
factor	0	I
.	0	O


SGPT	1	B
,	0	O
SGOT	1	B
,	0	O
and	0	O
alkaline	0	B
phosphatase	0	I
concentrations	0	O
were	0	O
essentially	0	O
normal	0	O
in	0	O
all	0	O
subjects	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
c	0	B
-	0	I
Abl	0	I
activates	0	O
c	0	B
-	0	I
myc	0	I
transcription	0	O
indirectly	0	O
with	0	O
no	0	O
requirement	0	O
for	0	O
DNA	1	O
binding	0	O
by	0	O
c	0	B
-	0	I
Abl	0	I
.	0	O


The	0	O
DNA	1	O
sequence	0	O
adjacent	0	O
to	0	O
the	0	O
lacZ	0	B
gene	0	I
has	0	O
been	0	O
determined	0	O
for	0	O
91	0	O
vegetative	0	O
fusion	0	O
genes	0	O
whose	0	O
products	0	O
have	0	O
been	0	O
localized	0	O
and	0	O
for	0	O
43	0	O
meiotically	0	O
induced	0	O
fusions	0	O
.	0	O


16	0	O
percent	0	O
,	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
),	0	O
and	0	O
sustained	0	O
normalization	0	O
of	0	O
serum	0	B
alanine	0	I
aminotransferase	0	I
levels	0	O
(	0	O
41	0	O
percent	0	O
vs	0	O
.	0	O


3	0	O
activities	0	O
of	0	O
the	0	O
factor	0	B
II	0	I
molecule	0	O
in	0	O
the	0	O
newborn	0	O
infant	0	O
at	0	O
term	0	O


Accurate	0	O
pathologic	0	O
staging	0	O
identifies	0	O
patients	0	O
who	0	O
are	0	O
potentially	0	O
curable	0	O
with	0	O
radiotherapy	0	O
.	0	O


Effects	0	O
of	0	O
aging	0	O
and	0	O
beta	0	O
-	0	O
adrenergic	0	O
-	0	O
blockade	0	O
on	0	O
standing	0	O
-	0	O
induced	0	O
QT	1	O
/	0	O
QS2	1	O
changes	0	O
.	0	O


Preceptorship	1	O
of	0	O
CNS	1	O
students	0	O
:	0	O
an	0	O
exploratory	0	O
study	0	O
.	0	O


A	1	O
stable	0	O
interface	0	O
depends	0	O
on	0	O
overall	0	O
stress	0	O
and	0	O
microstress	0	O
distribution	0	O
on	0	O
the	0	O
bone	0	O
,	0	O
particularly	0	O
trabecular	0	O
bone	0	O
.	0	O


Definite	0	O
JPsA	0	O
(	0	O
24	0	O
patients	0	O
)	0	O
was	0	O
defined	0	O
as	0	O
arthritis	0	O
associated	0	O
,	0	O
but	0	O
not	0	O
necessarily	0	O
coincident	0	O
,	0	O
with	0	O
a	0	O
typical	0	O
psoriatic	0	O
rash	0	O
,	0	O
or	0	O
arthritis	0	O
plus	0	O
at	0	O
least	0	O
3	0	O
of	0	O
4	0	O
minor	0	O
criteria	0	O
:	0	O
dactylitis	0	O
,	0	O
nail	0	O
pitting	0	O
,	0	O
psoriasis	0	O
-	0	O
like	0	O
rash	0	O
,	0	O
or	0	O
family	0	O
history	0	O
of	0	O
psoriasis	0	O
.	0	O


We	0	O
suggest	0	O
that	0	O
CT	1	O
scan	0	O
be	0	O
preferable	0	O
in	0	O
diagnosis	0	O
of	0	O
tumors	0	O
in	0	O
that	0	O
area	0	O
.	0	O


Alternative	0	O
splicing	0	O
of	0	O
RNA	1	O
transcripts	0	O
encoded	0	O
by	0	O
the	0	O
murine	0	O
p105	0	B
NF	1	I
-	0	I
kappa	0	I
B	1	I
gene	0	O
generates	0	O
I	1	B
kappa	0	I
B	1	I
gamma	0	I
isoforms	0	I
with	0	O
different	0	O
inhibitory	0	O
activities	0	O
.	0	O


This	0	O
model	0	O
is	0	O
further	0	O
supported	0	O
by	0	O
binding	0	O
of	0	O
the	0	O
Fos	1	B
-	0	O
Jun	1	B
complex	0	O
at	0	O
an	0	O
AP	1	B
-	0	I
1	0	I
site	0	I
in	0	O
the	0	O
type	0	B
alpha	0	I
I	1	I
collagen	0	I
promoter	0	I
that	0	O
is	0	O
contiguous	0	O
with	0	O
,	0	O
but	0	O
not	0	O
overlapping	0	O
,	0	O
the	0	O
VDRE	0	O
.	0	O


A	1	O
beta2	0	B
RARE	0	I
reporter	0	I
construct	0	I
in	0	O
which	0	O
the	0	O
methylation	0	O
-	0	O
susceptible	0	O
cytosines	0	O
in	0	O
the	0	O
sense	0	O
strand	0	O
were	0	O
replaced	0	O
by	0	O
thymine	0	O
displayed	0	O
marked	0	O
loss	0	O
of	0	O
activity	0	O
in	0	O
a	0	O
replicated	0	O
chromatin	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


This	0	O
E	1	O
box	0	O
sequence	0	O
(	0	O
CACGTG	0	O
)	0	O
is	0	O
identical	0	O
to	0	O
the	0	O
binding	0	O
element	0	O
for	0	O
USF	0	B
(	0	O
upstream	0	B
stimulatory	0	I
factor	0	I
),	0	O
a	0	O
member	0	O
of	0	O
the	0	O
helix	0	B
-	0	I
loop	0	I
-	0	I
helix	0	I
family	0	I
of	0	I
transcription	0	I
factors	0	I
.	0	O


In	1	O
addition	0	O
,	0	O
marked	0	O
hypertension	0	O
accompanied	0	O
this	0	O
disorder	0	O
and	0	O
all	0	O
abnormalities	0	O
,	0	O
including	0	O
the	0	O
hypertension	0	O
,	0	O
responded	0	O
to	0	O
1	0	B
-	0	I
desamino	0	I
-	0	I
8	0	I
-	0	I
D	1	I
-	0	I
arginine	0	I
vasopressin	0	I
therapy	0	O
.	0	O


Two	0	O
of	0	O
the	0	O
ORFs	0	O
are	0	O
completely	0	O
internal	0	O
to	0	O
longer	0	O
ones	0	O
and	0	O
a	0	O
third	0	O
is	0	O
partially	0	O
embedded	0	O
in	0	O
G2850	0	B
.	0	O


Nucleotide	1	O
sequence	0	O
analysis	0	O
of	0	O
R	1	O
has	0	O
revealed	0	O
similarities	0	O
to	0	O
the	0	O
R1	0	O
plasmid	0	O
found	0	O
in	0	O
some	0	O
South	0	O
American	0	O
maize	0	O
races	0	O
with	0	O
RU	1	O
cytoplasm	0	O
,	0	O
to	0	O
the	0	O
M1	1	O
plasmid	0	O
found	0	O
in	0	O
one	0	O
source	0	O
of	0	O
Zea	1	O
luxurians	0	O
teosinte	0	O
,	0	O
to	0	O
the	0	O
atp9	0	B
mitochondrial	0	I
gene	0	I
and	0	O
its	0	O
3	0	O
'	0	O
flanking	0	O
sequence	0	O
,	0	O
and	0	O
also	0	O
to	0	O
a	0	O
region	0	O
3	0	O
'	0	O
to	0	O
the	0	O
orf221	0	B
gene	0	I
.	0	O


Twenty	0	O
-	0	O
four	0	O
hours	0	O
later	0	O
,	0	O
the	0	O
animals	0	O
were	0	O
randomized	0	O
to	0	O
subretinal	0	O
treatment	0	O
with	0	O
2	0	O
.	0	O
5	0	O
micrograms	0	O
of	0	O
tissue	0	B
plasminogen	0	I
activator	0	I
or	0	O
a	0	O
similar	0	O
volume	0	O
of	0	O
physiologic	0	O
saline	0	O
.	0	O


Molecular	1	O
cloning	0	O
of	0	O
rat	0	B
SH2	0	I
-	0	I
containing	0	I
inositol	0	I
phosphatase	0	I
2	0	I
(	0	O
SHIP2	0	B
)	0	O
and	0	O
its	0	O
role	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
insulin	0	B
signaling	0	O
.	0	O


Atcys1	0	B
,	0	O
Athyp1	0	B
,	0	O
AKin10	0	B
and	0	O
the	0	O
ORF	1	O
are	0	O
very	0	O
close	0	O
to	0	O
each	0	O
other	0	O
and	0	O
organized	0	O
in	0	O
the	0	O
same	0	O
polarity	0	O
;	0	O
hence	0	O
,	0	O
the	0	O
intergenic	0	O
regions	0	O
probably	0	O
contain	0	O
,	0	O
within	0	O
less	0	O
than	0	O
0	0	O
.	0	O
5	0	O
kb	0	O
,	0	O
all	0	O
the	0	O
regulatory	0	O
elements	0	O
necessary	0	O
to	0	O
govern	0	O
initiation	0	O
and	0	O
termination	0	O
of	0	O
transcription	0	O
.	0	O


Pituitary	1	O
adenylate	0	B
cyclase	0	I
-	0	I
activating	0	I
polypeptide	0	I
regulates	0	O
prolactin	0	B
promoter	0	I
activity	0	O
via	0	O
a	0	O
protein	0	B
kinase	0	I
A	1	I
-	0	O
mediated	0	O
pathway	0	O
that	0	O
is	0	O
independent	0	O
of	0	O
the	0	O
transcriptional	0	O
pathway	0	O
employed	0	O
by	0	O
thyrotropin	0	B
-	0	I
releasing	0	I
hormone	0	I
.	0	O


The	0	O
objectives	0	O
of	0	O
the	0	O
present	0	O
study	0	O
were	0	O
to	0	O
evaluate	0	O
the	0	O
effects	0	O
of	0	O
adding	0	O
Equex	0	O
to	0	O
a	0	O
TRIS	1	O
-	0	O
extender	0	O
,	0	O
diluting	0	O
the	0	O
semen	0	O
in	0	O
1	0	O
or	0	O
2	0	O
steps	0	O
,	0	O
freezing	0	O
according	0	O
to	0	O
2	0	O
methods	0	O
,	0	O
thawing	0	O
at	0	O
2	0	O
rates	0	O
,	0	O
and	0	O
the	0	O
interactions	0	O
between	0	O
these	0	O
treatments	0	O
,	0	O
on	0	O
the	0	O
post	0	O
-	0	O
thaw	0	O
survival	0	O
of	0	O
dog	0	O
spermatozoa	0	O
at	0	O
38	0	O
degrees	0	O
C	1	O
.	0	O


The	0	O
effects	0	O
of	0	O
intracisternal	0	O
injection	0	O
(	0	O
i	0	O
.	0	O
c	0	O
.	0	O
i	0	O
.)	0	O
of	0	O
clonidine	0	O
(	0	O
1	0	O
microgram	0	O
kg	0	O
-	0	O
1	0	O
)	0	O
on	0	O
blood	0	O
pressure	0	O
and	0	O
heart	0	O
rate	0	O
were	0	O
studied	0	O
in	0	O
conscious	0	O
rabbits	0	O
with	0	O
an	0	O
implanted	0	O
catheter	0	O
in	0	O
the	0	O
cisterna	0	O
magna	0	O
.	0	O


Adjustment	1	O
for	0	O
age	0	O
,	0	O
total	0	O
cholesterol	0	O
,	0	O
HDL	1	B
cholesterol	0	I
,	0	O
triglycerides	0	O
,	0	O
current	0	O
smoking	0	O
,	0	O
and	0	O
systolic	0	O
pressure	0	O
slightly	0	O
reduced	0	O
the	0	O
association	0	O
between	0	O
fibrinogen	0	B
and	0	O
atherosclerosis	0	O
.	0	O


Using	0	O
an	0	O
ELISA	1	O
,	0	O
we	0	O
found	0	O
that	0	O
surfactant	0	B
protein	0	I
A	1	I
(	0	O
SP	1	B
-	0	I
A	1	I
)	0	O
was	0	O
markedly	0	O
elevated	0	O
in	0	O
the	0	O
pneumonia	0	O
patients	0	O
.	0	O


Recombinant	1	B
FVIIa	0	I
was	0	O
stable	0	O
in	0	O
the	0	O
infusion	0	O
pump	0	O
for	0	O
several	0	O
days	0	O
at	0	O
room	0	O
temperature	0	O
and	0	O
for	0	O
24	0	O
h	0	O
at	0	O
body	0	O
temperature	0	O
.	0	O


A	1	O
16	0	O
-	0	O
year	0	O
follow	0	O
-	0	O
up	0	O
study	0	O
of	0	O
69	0	O
paraplegics	0	O
with	0	O
complete	0	O
lesions	0	O
from	0	O
T1	1	O
-	0	O
L3	0	O
is	0	O
presented	0	O
.	0	O


In	1	O
the	0	O
ultramarathon	0	O
runner	0	O
the	0	O
testosterone	0	O
levels	0	O
sharply	0	O
rose	0	O
at	0	O
the	0	O
beginning	0	O
of	0	O
the	0	O
training	0	O
session	0	O
(	0	O
from	0	O
the	0	O
7	0	O
,	0	O
20	0	O
ng	0	O
/	0	O
ml	0	O
to	0	O
11	0	O
,	0	O
50	0	O
ng	0	O
/	0	O
ml	0	O
after	0	O
20	0	O
'	0	O
training	0	O
),	0	O
and	0	O
subsequently	0	O
decrease	0	O
after	0	O
3	0	O
hours	0	O
(	0	O
9	0	O
,	0	O
20	0	O
ng	0	O
/	0	O
ml	0	O
)	0	O
and	0	O
at	0	O
the	0	O
end	0	O
of	0	O
the	0	O
6	0	O
hours	0	O
training	0	O
(	0	O
4	0	O
,	0	O
60	0	O
ng	0	O
/	0	O
ml	0	O
).	0	O


Overall	0	O
,	0	O
these	0	O
findings	0	O
demonstrate	0	O
that	0	O
mutations	0	O
E768D	0	O
and	0	O
V804L	0	O
are	0	O
gain	0	O
-	0	O
of	0	O
-	0	O
function	0	O
mutations	0	O
that	0	O
confer	0	O
to	0	O
the	0	O
long	0	B
RET	0	I
isoform	0	I
the	0	O
capacity	0	O
to	0	O
exert	0	O
a	0	O
biological	0	O
effect	0	O
,	0	O
although	0	O
these	0	O
mutations	0	O
are	0	O
more	0	O
weakly	0	O
activating	0	O
than	0	O
the	0	O
MEN2A	0	B
and	0	O
MEN2B	0	B
mutations	0	O
.	0	O


The	0	O
extraction	0	O
was	0	O
subsequently	0	O
rated	0	O
as	0	O
'	0	O
easy	0	O
'	0	O
or	0	O
'	0	O
difficult	0	O
'.	0	O
Taking	0	O
Pell	0	O
-	0	O
Gregory	0	O
class	0	O
C	1	O
as	0	O
a	0	O
predictor	0	O
of	0	O
a	0	O
'	0	O
difficult	0	O
'	0	O
extraction	0	O
,	0	O
specificity	0	O
was	0	O
88	0	O
%	0	O
but	0	O
sensitivity	0	O
was	0	O
low	0	O
at	0	O
15	0	O
%.	0	O


Taken	0	O
together	0	O
,	0	O
our	0	O
results	0	O
indicate	0	O
that	0	O
thrombin	0	B
-	0	O
stimulated	0	O
vascular	0	O
smooth	0	O
muscle	0	O
proliferation	0	O
is	0	O
delayed	0	O
and	0	O
requires	0	O
the	0	O
de	0	O
novo	0	O
expression	0	O
of	0	O
one	0	O
or	0	O
more	0	O
autocrine	0	O
mitogens	0	O
.	0	O


The	0	O
5	0	O
'	0	O
and	0	O
3	0	O
'	0	O
untranslated	0	O
sequences	0	O
contain	0	O
characteristic	0	O
sequences	0	O
that	0	O
are	0	O
involved	0	O
in	0	O
the	0	O
initiation	0	O
and	0	O
termination	0	O
of	0	O
transcription	0	O
,	0	O
including	0	O
two	0	O
possible	0	O
promoters	0	O
,	0	O
one	0	O
of	0	O
which	0	O
may	0	O
contain	0	O
two	0	O
overlapping	0	O
-	0	O
10	0	O
sequences	0	O
.	0	O


SPECT	1	O
examination	0	O
of	0	O
the	0	O
TMJ	1	O
using	0	O
99m	0	O
Tc	1	O
-	0	O
MDP	1	O
was	0	O
performed	0	O
in	0	O
43	0	O
patients	0	O
with	0	O
arthrographically	0	O
proven	0	O
anterior	0	O
dislocation	0	O
of	0	O
the	0	O
disc	0	O
and	0	O
in	0	O
30	0	O
normals	0	O
.	0	O


Serum	1	B
response	0	I
factor	0	I
(	0	O
SRF	1	B
),	0	O
a	0	O
member	0	O
of	0	O
an	0	O
ancient	0	O
family	0	O
of	0	O
DNA	1	O
-	0	O
binding	0	O
proteins	0	O
,	0	O
is	0	O
generally	0	O
assumed	0	O
to	0	O
be	0	O
a	0	O
ubiquitous	0	O
transcription	0	O
factor	0	O
involved	0	O
in	0	O
regulating	0	O
growth	0	O
factor	0	O
-	0	O
responsive	0	O
genes	0	O
.	0	O


No	1	O
significant	0	O
differences	0	O
could	0	O
be	0	O
seen	0	O
in	0	O
response	0	O
rates	0	O
according	0	O
to	0	O
the	0	O
concentration	0	O
of	0	O
estrogen	0	B
receptors	0	I
or	0	O
presence	0	O
of	0	O
progesteron	0	B
receptors	0	I
in	0	O
this	0	O
group	0	O
of	0	O
patients	0	O
.	0	O


We	0	O
found	0	O
strand	0	O
selective	0	O
repair	0	O
in	0	O
DNA	1	O
fragments	0	O
within	0	O
two	0	O
active	0	O
genes	0	O
,	0	O
DHFR	1	B
and	0	O
an	0	O
unknown	0	O
gene	0	O
adjacent	0	O
to	0	O
DHFR	1	B
.	0	O


Characterization	0	O
of	0	O
the	0	O
promoter	0	O
for	0	O
the	0	O
human	0	B
85	0	I
kDa	1	I
cytosolic	0	I
phospholipase	0	I
A2	1	I
gene	0	I
.	0	O


Abrogation	0	O
of	0	O
p53	0	B
function	0	O
by	0	O
E6	0	B
resulted	0	O
in	0	O
an	0	O
increase	0	O
in	0	O
the	0	O
spontaneous	0	O
mutation	0	O
frequencies	0	O
at	0	O
the	0	O
heterozygous	0	O
thymidine	0	B
kinase	0	I
(	0	O
TK	1	B
)	0	O
locus	0	O
but	0	O
not	0	O
at	0	O
the	0	O
hemizygous	0	O
hypoxanthine	0	B
phosphoribosyl	0	I
transferase	0	I
(	0	O
HPRT	1	B
)	0	O
locus	0	O
.	0	O


Regulated	0	O
activity	0	O
of	0	O
the	0	O
distal	0	O
promoter	0	O
-	0	O
like	0	O
element	0	O
of	0	O
the	0	O
human	0	B
corticotropin	0	I
-	0	I
releasing	0	I
hormone	0	I
gene	0	I
and	0	O
secondary	0	O
structural	0	O
features	0	O
of	0	O
its	0	O
corresponding	0	O
transcripts	0	O
.	0	O


Induction	1	O
of	0	O
anaesthesia	0	O
was	0	O
standardised	0	O
:	0	O
fentanyl	0	O
(	0	O
3	0	O
micrograms	0	O
/	0	O
kg	0	O
),	0	O
thiopentone	0	O
(	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
),	0	O
atracurium	0	O
(	0	O
0	0	O
.	0	O
4	0	O
mg	0	O
/	0	O
kg	0	O
).	0	O


Oligonucleotide	1	O
-	0	O
directed	0	O
mutagenesis	0	O
was	0	O
used	0	O
to	0	O
create	0	O
an	0	O
NdeI	0	B
restriction	0	I
site	0	I
at	0	O
the	0	O
natural	0	O
ATG	1	O
of	0	O
the	0	O
yeast	0	O
R	1	O
.	0	O


The	0	O
introduction	0	O
of	0	O
hARF4	0	B
to	0	O
the	0	O
cells	0	O
maintained	0	O
the	0	O
balance	0	O
between	0	O
cytosolic	0	O
and	0	O
membrane	0	O
-	0	O
associated	0	O
Sec7p	0	B
pools	0	O
.	0	O


Nuclear	1	O
receptors	0	O
(	0	O
NRs	0	O
)	0	O
can	0	O
function	0	O
as	0	O
ligandinducible	0	O
transregulators	0	O
in	0	O
both	0	O
mammalian	0	O
and	0	O
yeast	0	O
cells	0	O
,	0	O
indicating	0	O
that	0	O
important	0	O
features	0	O
of	0	O
transcriptional	0	O
control	0	O
have	0	O
been	0	O
conserved	0	O
throughout	0	O
evolution	0	O
.	0	O


The	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
m	0	B
-	0	I
Staf	0	I
is	0	O
highly	0	O
homologous	0	O
to	0	O
that	0	O
of	0	O
Staf	0	B
,	0	O
another	0	O
selenocysteine	0	B
tRNA	1	I
gene	0	I
transcription	0	I
activating	0	I
factor	0	I
of	0	O
Xenopus	1	O
laevis	0	O
.	0	O


Suppressive	1	O
therapy	0	O
for	0	O
thyroid	0	O
nodules	0	O
.	0	O


While	0	O
this	0	O
Saccharomyces	1	O
cerevisiae	0	O
SIN4	0	B
gene	0	I
product	0	I
is	0	O
a	0	O
component	0	O
of	0	O
a	0	O
mediator	0	O
complex	0	O
associated	0	O
with	0	O
RNA	1	B
polymerase	0	I
II	0	I
,	0	O
various	0	O
studies	0	O
suggest	0	O
the	0	O
involvement	0	O
of	0	O
Sin4	0	B
in	0	O
the	0	O
alteration	0	O
of	0	O
higher	0	O
-	0	O
order	0	O
chromatin	0	O
structure	0	O
.	0	O


The	0	O
nature	0	O
of	0	O
the	0	O
process	0	O
formed	0	O
by	0	O
the	0	O
successive	0	O
occurrences	0	O
of	0	O
this	0	O
arrhythmia	0	O
was	0	O
studied	0	O
in	0	O
8	0	O
patients	0	O
with	0	O
a	0	O
history	0	O
of	0	O
symptomatic	0	O
paroxysmal	0	O
AF	1	O
.	0	O


J	1	O
.	0	O


Functional	1	O
disorders	0	O
of	0	O
the	0	O
ureter	0	O
following	0	O
gynecologic	0	O
surgery	0	O


The	0	O
other	0	O
hypoglycaemic	0	O
patient	0	O
showed	0	O
an	0	O
exaggerated	0	O
insulin	0	B
release	0	O
in	0	O
response	0	O
to	0	O
tolbutamide	0	O
.	0	O


These	0	O
results	0	O
strongly	0	O
suggested	0	O
that	0	O
similar	0	O
,	0	O
if	0	O
not	0	O
identical	0	O
,	0	O
the	0	O
CArG	0	B
box	0	I
binding	0	I
proteins	0	I
interact	0	O
with	0	O
the	0	O
functionally	0	O
different	0	O
promoter	0	O
element	0	O
in	0	O
the	0	O
VLC1	0	B
,	0	O
cardiac	0	B
alpha	0	I
-	0	I
actin	0	I
,	0	O
and	0	O
c	0	B
-	0	I
fos	0	I
genes	0	I
.	0	O


Precision	1	O
measurement	0	O
of	0	O
the	0	O
pion	0	O
mass	0	O
difference	0	O
m	0	O
pi	0	O
--	0	O
m	0	O
pi	0	O
0	0	O
.	0	O


Biliary	1	O
-	0	O
enteric	0	O
fistulas	0	O


Role	1	O
of	0	O
histoclinical	0	O
studies	0	O
in	0	O
the	0	O
prophylaxis	0	O
of	0	O
spontaneous	0	O
abortions	0	O


Digitalis	1	O
glycosides	0	O
or	0	O
beta	0	B
-	0	I
receptor	0	I
antagonists	0	O
are	0	O
not	0	O
helpful	0	O
in	0	O
the	0	O
therapy	0	O
of	0	O
this	0	O
form	0	O
of	0	O
atrial	0	O
fibrillation	0	O
whereas	0	O
class	0	O
I	1	O
antiarrhythmic	0	O
drugs	0	O
have	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
more	0	O
effective	0	O
.	0	O


All	1	O
subjects	0	O
were	0	O
submitted	0	O
to	0	O
ECG	1	O
and	0	O
arterial	0	O
blood	0	O
pressure	0	O
determination	0	O
and	0	O
were	0	O
assayed	0	O
for	0	O
TSH	1	B
,	0	O
thyroid	0	O
hormone	0	O
,	0	O
PRL	1	B
,	0	O
glucose	0	O
,	0	O
creatinine	0	O
,	0	O
nitrogen	0	O
,	0	O
glutamine	0	B
transaminase	0	I
,	0	O
cholesterol	0	O
and	0	O
triglycerides	0	O
plasma	0	O
levels	0	O
before	0	O
therapy	0	O
(	0	O
T0	0	O
),	0	O
after	0	O
30	0	O
treatment	0	O
days	0	O
(	0	O
T30	0	O
)	0	O
and	0	O
after	0	O
a	0	O
15	0	O
days	0	O
washout	0	O
(	0	O
T45	0	O
).	0	O


However	0	O
,	0	O
rapamycin	0	O
inhibited	0	O
proliferation	0	O
of	0	O
Ba	1	O
/	0	O
F3	0	O
-	0	O
EpoRgp55	0	O
but	0	O
not	0	O
of	0	O
MEL	1	O
cells	0	O
despite	0	O
inhibition	0	O
of	0	O
p70	0	B
S6	0	I
kinase	0	I
activity	0	O
in	0	O
both	0	O
cells	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
same	0	O
mutations	0	O
alter	0	O
the	0	O
structure	0	O
of	0	O
junB	0	B
5	0	O
'	0	O
flanking	0	O
DNA	1	O
within	0	O
chromatin	0	O
.	0	O


The	0	O
cDNA	1	O
sequence	0	O
has	0	O
an	0	O
813	0	O
-	0	O
bp	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
ORF	1	O
)	0	O
whose	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
is	0	O
97	0	O
.	0	O
6	0	O
%	0	O
identical	0	O
to	0	O
the	0	O
272	0	O
carboxy	0	O
-	0	O
terminal	0	O
amino	0	O
acids	0	O
of	0	O
the	0	O
human	0	B
ets	0	I
-	0	I
1	0	I
protein	0	I
.	0	O


Although	0	O
the	0	O
binding	0	O
of	0	O
IE2	0	B
86	0	I
to	0	O
nonphosphorylated	0	O
full	0	B
-	0	I
length	0	I
CREB	0	I
or	0	O
deltaCREB	0	B
is	0	O
minimal	0	O
,	0	O
IE2	0	B
86	0	I
does	0	O
form	0	O
complexes	0	O
with	0	O
p300	0	B
and	0	O
the	0	O
CREB	0	B
-	0	I
binding	0	I
protein	0	I
(	0	O
CBP	0	B
),	0	O
which	0	O
in	0	O
turn	0	O
bind	0	O
to	0	O
CREB	0	B
and	0	O
can	0	O
serve	0	O
as	0	O
adaptor	0	O
proteins	0	O
for	0	O
CREB	0	B
function	0	O
.	0	O


Among	0	O
a	0	O
population	0	O
of	0	O
18	0	O
,	0	O
175	0	O
children	0	O
below	0	O
7	0	O
years	0	O
of	0	O
age	0	O
in	0	O
medium	0	O
sized	0	O
towns	0	O
and	0	O
rural	0	O
areas	0	O
in	0	O
south	0	O
-	0	O
western	0	O
Germany	0	O
552	0	O
(	0	O
3	0	O
.	0	O
03	0	O
%)	0	O
cases	0	O
of	0	O
croup	0	O
were	0	O
registered	0	O
during	0	O
a	0	O
12	0	O
months	0	O
period	0	O
in	0	O
1984	0	O
-	0	O
85	0	O
by	0	O
their	0	O
physicians	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
major	0	O
site	0	O
of	0	O
transcriptional	0	O
initiation	0	O
,	0	O
which	0	O
was	0	O
localized	0	O
by	0	O
primer	0	O
extension	0	O
250	0	O
bp	0	O
upstream	0	O
of	0	O
the	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
Ets	1	B
-	0	I
1	0	I
cDNA	1	I
clone	0	I
,	0	O
was	0	O
shown	0	O
to	0	O
be	0	O
identical	0	O
in	0	O
normal	0	O
cells	0	O
and	0	O
tumors	0	O
carrying	0	O
a	0	O
provirus	0	O
in	0	O
the	0	O
Tpl	0	B
-	0	I
1	0	I
locus	0	I
.	0	O


To	1	O
determine	0	O
whether	0	O
mononuclear	0	O
cell	0	O
secretory	0	O
products	0	O
contribute	0	O
to	0	O
the	0	O
changes	0	O
in	0	O
bone	0	O
turnover	0	O
that	0	O
characterize	0	O
the	0	O
development	0	O
of	0	O
postmenopausal	0	O
osteoporosis	0	O
,	0	O
we	0	O
evaluated	0	O
the	0	O
effects	0	O
of	0	O
oophorectomy	0	O
and	0	O
subsequent	0	O
estrogen	0	O
replacement	0	O
on	0	O
the	0	O
spontaneous	0	O
secretion	0	O
of	0	O
interleukin	0	B
1	0	I
(	0	O
IL	1	B
-	0	I
1	0	I
)	0	O
and	0	O
tumor	0	B
necrosis	0	I
factor	0	I
alpha	0	I
(	0	O
TNF	1	B
-	0	I
alpha	0	I
)	0	O
and	0	O
on	0	O
the	0	O
phytohemagglutinin	0	B
A	1	I
-	0	O
induced	0	O
secretion	0	O
of	0	O
granulocyte	0	B
-	0	I
macrophage	0	I
colony	0	I
-	0	I
stimulating	0	I
factor	0	I
(	0	O
GM	1	B
-	0	I
CSF	1	I
)	0	O
from	0	O
peripheral	0	O
blood	0	O
mononuclear	0	O
cells	0	O
.	0	O


The	0	O
Mig1	0	B
repressor	0	I
is	0	O
a	0	O
zinc	0	B
finger	0	I
protein	0	I
that	0	O
mediates	0	O
glucose	0	O
repression	0	O
in	0	O
yeast	0	O
.	0	O


CONCLUSION	0	O
:	0	O
More	0	O
than	0	O
50	0	O
%	0	O
of	0	O
patients	0	O
with	0	O
perennial	0	O
rhinitis	0	O
and	0	O
CRS	0	O
do	0	O
not	0	O
improve	0	O
after	0	O
surgery	0	O
,	0	O
a	0	O
response	0	O
that	0	O
may	0	O
be	0	O
predicted	0	O
by	0	O
more	0	O
cells	0	O
expressing	0	O
IL	1	B
-	0	I
5	0	I
mRNA	1	I
in	0	O
the	0	O
ethmoid	0	O
sinuses	0	O
.	0	O


Sodium	1	O
restriction	0	O
in	0	O
cardiac	0	O
failure	0	O
.	0	O


Veterinary	1	O
certification	0	O
for	0	O
livestock	0	O
export	0	O
.	0	O


Electrophoretic	1	O
characteriaztion	0	O
of	0	O
virus	0	O
-	0	O
induced	0	O
interferon	0	B
of	0	O
the	0	O
blood	0	O
and	0	O
urine	0	O
in	0	O
rabbits	0	O


The	0	O
unexpected	0	O
presence	0	O
of	0	O
the	0	O
tRNA	1	B
(	0	I
trp	0	I
)(	0	I
CCA	1	I
)-	0	I
gene	0	I
transcript	0	I
in	0	I
mitochondria	0	I
is	0	O
also	0	O
reported	0	O
.	0	O


A	1	O
case	0	O
of	0	O
manifest	0	O
latent	0	O
nystagmus	0	O
of	0	O
late	0	O
onset	0	O
in	0	O
a	0	O
13	0	O
-	0	O
year	0	O
-	0	O
old	0	O
girl	0	O
is	0	O
reported	0	O
.	0	O


Demographic	1	O
and	0	O
clinical	0	O
data	0	O
were	0	O
compared	0	O
with	0	O
a	0	O
control	0	O
group	0	O
of	0	O
339	0	O
healthy	0	O
age	0	O
-	0	O
matched	0	O
women	0	O
and	0	O
with	0	O
a	0	O
sample	0	O
of	0	O
224	0	O
women	0	O
with	0	O
wrist	0	O
fracture	0	O
.	0	O


The	0	O
lymph	0	O
nodes	0	O
from	0	O
two	0	O
of	0	O
the	0	O
patients	0	O
with	0	O
rheumatoid	0	O
arthritis	0	O
contained	0	O
numerous	0	O
sarcoid	0	O
like	0	O
granulomata	0	O
,	0	O
further	0	O
indicating	0	O
a	0	O
possible	0	O
association	0	O
between	0	O
sarcoidosis	0	O
and	0	O
rheumatoid	0	O
arthritis	0	O
.	0	O


A	1	O
recombinant	0	O
derivative	0	O
harboring	0	O
the	0	O
pMJ101	0	O
replication	0	O
region	0	O
proved	0	O
to	0	O
be	0	O
compatible	0	O
with	0	O
pJM1	0	O
,	0	O
a	0	O
plasmid	0	O
containing	0	O
the	0	O
iron	0	O
acquisition	0	O
system	0	O
required	0	O
for	0	O
the	0	O
virulence	0	O
of	0	O
V	1	O
.	0	O
anguillarum	0	O
775	0	O
,	0	O
another	0	O
important	0	O
pathogen	0	O
that	0	O
causes	0	O
vibriosis	0	O
.	0	O


During	0	O
the	0	O
1980	0	O
'	0	O
s	0	O
,	0	O
quantifications	0	O
of	0	O
immunoserological	0	O
testings	0	O
,	0	O
especially	0	O
C	1	B
reactive	0	I
protein	0	I
,	0	O
rheumatoid	0	B
factor	0	I
and	0	O
antistreptolysin	0	B
O	1	I
,	0	O
progressed	0	O
rapidly	0	O
.	0	O


In	1	O
ICU	1	O
patients	0	O
,	0	O
the	0	O
LIS	0	O
related	0	O
to	0	O
the	0	O
postoperative	0	O
rise	0	O
in	0	O
IL	1	B
-	0	I
6	0	I
level	0	O
only	0	O
,	0	O
even	0	O
though	0	O
the	0	O
rise	0	O
in	0	O
plasma	0	O
concentrations	0	O
of	0	O
cytokines	0	O
interrelated	0	O
.	0	O


Members	0	O
of	0	O
the	0	O
C	1	B
/	0	I
EBP	1	I
family	0	I
of	0	O
basic	0	B
-	0	I
leucine	0	I
zipper	0	I
(	0	I
bZip	0	I
)	0	I
transcription	0	I
factors	0	I
form	0	O
heterodimers	0	O
and	0	O
bind	0	O
to	0	O
the	0	O
CAAT	0	O
box	0	O
and	0	O
other	0	O
sequence	0	O
-	0	O
related	0	O
enhancer	0	O
motifs	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
nematode	0	O
genes	0	O
could	0	O
be	0	O
the	0	O
homologs	0	B
of	0	I
Hh	0	I
molecules	0	I
in	0	O
other	0	O
phyla	0	O
.	0	O


The	0	O
patient	0	O
with	0	O
a	0	O
prolonged	0	O
fever	0	O
caused	0	O
by	0	O
dissecting	0	O
aneurysm	0	O
of	0	O
the	0	O
aorta	0	O
in	0	O
whom	0	O
pleuropneumonia	0	O
masked	0	O
the	0	O
real	0	O
diseases	0	O
has	0	O
been	0	O
presented	0	O
.	0	O


When	0	O
used	0	O
subcutaneously	0	O
or	0	O
intravenously	0	O
in	0	O
maximum	0	O
tolerated	0	O
doses	0	O
the	0	O
antibiotic	0	O
inhibited	0	O
the	0	O
development	0	O
of	0	O
lymphadenosis	0	O
NK	1	O
/	0	O
Li	1	O
by	0	O
90	0	O
and	0	O
70	0	O
per	0	O
cent	0	O
respectively	0	O
.	0	O


The	0	O
genomic	0	O
fragments	0	O
were	0	O
fused	0	O
upstream	0	O
of	0	O
the	0	O
luciferase	0	B
reporter	0	I
gene	0	I
.	0	O


A	1	O
1	0	O
.	0	O
8	0	O
-	0	O
kb	0	O
cDNA	1	O
clone	0	O
(	0	O
designed	0	O
hKID	0	B
,	0	O
gene	0	B
symbol	0	I
AQP2L	0	I
)	0	O
with	0	O
homology	0	O
to	0	O
the	0	O
aquaporins	0	B
was	0	O
isolated	0	O
from	0	O
a	0	O
human	0	O
kidney	0	O
cDNA	1	O
library	0	O
.	0	O


Within	0	O
the	0	O
compartment	0	O
or	0	O
dimension	0	O
of	0	O
severity	0	O
of	0	O
depression	0	O
a	0	O
subscale	0	O
of	0	O
the	0	O
Hamilton	0	O
Depression	1	O
Scale	1	O
(	0	O
or	0	O
the	0	O
Melancholia	1	O
Scale	1	O
)	0	O
was	0	O
shown	0	O
to	0	O
have	0	O
reached	0	O
an	0	O
instrumental	0	O
perfection	0	O
,	0	O
e	0	O
.	0	O
g	0	O
.	0	O
as	0	O
an	0	O
outcome	0	O
measure	0	O
of	0	O
antidepressant	0	O
treatment	0	O
.	0	O


Influence	0	O
of	0	O
oil	0	O
emulsions	0	O
and	0	O
diphenyl	0	O
on	0	O
post	0	O
-	0	O
harvest	0	O
physiconutritional	0	O
changes	0	O
in	0	O
Kagzi	0	O
limes	0	O
(	0	O
Citrus	1	O
aurantifolia	0	O
)	0	O
was	0	O
studied	0	O
.	0	O


The	0	O
319	0	O
base	0	O
pair	0	O
region	0	O
immediately	0	O
upstream	0	O
of	0	O
the	0	O
CAP	1	O
site	0	O
is	0	O
characterized	0	O
by	0	O
the	0	O
lack	0	O
of	0	O
a	0	O
proximal	0	O
TATA	0	O
box	0	O
and	0	O
the	0	O
presence	0	O
of	0	O
sequences	0	O
similar	0	O
to	0	O
GC	1	O
boxes	0	O
,	0	O
CACCC	0	O
boxes	0	O
,	0	O
CCAAT	0	O
boxes	0	O
,	0	O
activator	0	B
protein	0	I
2	0	I
(	0	O
Ap	1	B
-	0	I
2	0	I
)	0	O
sites	0	O
,	0	O
partial	0	O
glucocorticoid	0	O
response	0	O
elements	0	O
(	0	O
GREs	0	O
),	0	O
and	0	O
partial	0	O
cyclic	0	O
AMP	1	O
response	0	O
elements	0	O
(	0	O
CREs	0	O
).	0	O


Efficient	0	O
phosphorylation	0	O
of	0	O
BRDG1	0	B
by	0	O
Tec	0	B
required	0	O
the	0	O
PH	1	B
and	0	O
SH2	0	B
domains	0	I
as	0	O
well	0	O
as	0	O
the	0	O
kinase	0	O
domain	0	O
of	0	O
the	0	O
latter	0	O
.	0	O


We	0	O
used	0	O
two	0	O
approaches	0	O
to	0	O
ascertain	0	O
whether	0	O
CDP	1	B
/	0	O
cut	0	B
serves	0	O
as	0	O
a	0	O
repressor	0	O
of	0	O
gp91	0	B
-	0	O
phox	0	B
gene	0	O
expression	0	O
.	0	O


This	0	O
dominant	0	O
-	0	O
negative	0	O
effect	0	O
of	0	O
FRNK	0	B
was	0	O
reversed	0	O
by	0	O
a	0	O
point	0	O
mutation	0	O
(	0	O
Leu	1	O
-	0	O
1034	0	O
to	0	O
Ser	1	O
)	0	O
which	0	O
prevented	0	O
FRNK	0	B
localization	0	O
to	0	O
focal	0	O
contact	0	O
sites	0	O
.	0	O


Autoimmune	1	O
neutropenia	0	O
(	0	O
AIN	0	O
)	0	O
is	0	O
a	0	O
frequent	0	O
cause	0	O
of	0	O
chronic	0	O
neutropenia	0	O
especially	0	O
in	0	O
youngest	0	O
children	0	O
.	0	O


On	1	O
line	0	O
calculation	0	O
of	0	O
steroid	0	O
concentrations	0	O
by	0	O
radioimmunoassay	0	O


This	0	O
review	0	O
summarizes	0	O
the	0	O
clinical	0	O
evidence	0	O
to	0	O
support	0	O
current	0	O
therapies	0	O
in	0	O
irritable	0	O
bowel	0	O
syndrome	0	O
(	0	O
IBS	1	O
).	0	O


The	0	O
4	0	O
days	0	O
dexamethasone	0	O
suppression	0	O
test	0	O
showed	0	O
more	0	O
than	0	O
80	0	O
%	0	O
suppression	0	O
of	0	O
dehydroepiandrosterone	0	O
-	0	O
sulphate	0	O
and	0	O
a	0	O
variable	0	O
(	0	O
40	0	O
-	0	O
60	0	O
%)	0	O
reduction	0	O
of	0	O
testosterone	0	O
and	0	O
androstenedione	0	O
levels	0	O
.	0	O


Among	0	O
these	0	O
360	0	O
ZFPs	0	B
,	0	O
a	0	O
novel	0	O
ZFP	0	B
cDNA	1	I
named	0	O
HFHZ	0	B
(	0	O
human	0	B
fetal	0	I
heart	0	I
ZFP	0	I
)	0	O
with	0	O
sequence	0	O
homology	0	O
to	0	O
a	0	O
Kruppel	0	B
-	0	I
associated	0	I
box	0	I
(	0	O
KRAB	0	B
)	0	O
was	0	O
identified	0	O
.	0	O


Encapsidation	1	O
of	0	O
poliovirus	0	O
replicons	0	O
encoding	0	O
the	0	O
complete	0	O
human	0	B
immunodeficiency	0	I
virus	0	I
type	0	I
1	0	I
gag	0	I
gene	0	I
by	0	O
using	0	O
a	0	O
complementation	0	O
system	0	O
which	0	O
provides	0	O
the	0	O
P1	1	B
capsid	0	I
protein	0	I
in	0	O
trans	0	O
.	0	O


Constitutive	1	O
function	0	O
of	0	O
a	0	O
positively	0	O
regulated	0	O
promoter	0	O
reveals	0	O
new	0	O
sequences	0	O
essential	0	O
for	0	O
activity	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
investigate	0	O
the	0	O
incidence	0	O
and	0	O
presentation	0	O
of	0	O
acute	0	O
pernicious	0	O
or	0	O
fulminating	0	O
beriberi	0	O
in	0	O
a	0	O
general	0	O
district	0	O
hospital	0	O
.	0	O


Ovarian	1	O
tumors	0	O
in	0	O
pregnancy	0	O
.	0	O


e	0	O
.	0	O


Interestingly	0	O
,	0	O
the	0	O
RXRalphaF318A	0	B
constitutive	0	O
activity	0	O
generated	0	O
within	0	O
heterodimers	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
BMS614	0	O
requires	0	O
the	0	O
integrity	0	O
of	0	O
both	0	O
RXR	0	B
and	0	O
RAR	0	B
AF	1	O
-	0	O
2	0	O
domains	0	O
.	0	O


Five	0	O
experiments	0	O
examined	0	O
the	0	O
influence	0	O
of	0	O
opiate	0	O
antagonists	0	O
on	0	O
both	0	O
the	0	O
short	0	O
-	0	O
term	0	O
analgesic	0	O
reaction	0	O
resulting	0	O
30	0	O
min	0	O
after	0	O
exposure	0	O
to	0	O
inescapable	0	O
shock	0	O
and	0	O
the	0	O
long	0	O
-	0	O
term	0	O
analgesic	0	O
reaction	0	O
resulting	0	O
after	0	O
reexposure	0	O
to	0	O
shock	0	O
24	0	O
hr	0	O
after	0	O
inescapable	0	O
shock	0	O
exposure	0	O
.	0	O


In	1	O
summary	0	O
,	0	O
p56	0	B
(	0	O
lck	0	B
)	0	O
activity	0	O
stimulates	0	O
G1	0	O
/	0	O
S	1	O
transition	0	O
in	0	O
immature	0	O
thymoblasts	0	O
and	0	O
maintains	0	O
cell	0	O
viability	0	O
via	0	O
transduction	0	O
of	0	O
constitutive	0	O
activation	0	O
signals	0	O
downstream	0	O
to	0	O
components	0	O
of	0	O
the	0	O
Ras	1	B
/	0	O
Raf	0	B
/	0	O
MAPK	1	B
pathway	0	O
.	0	O


Dangers	0	O
in	0	O
use	0	O
of	0	O
live	0	O
-	0	O
virus	0	O
vaccines	0	O
.	0	O


A	1	O
segmental	0	O
analysis	0	O
of	0	O
the	0	O
key	0	O
regions	0	O
of	0	O
HLA	1	B
-	0	I
DR1	0	I
that	0	O
control	0	O
T	1	O
cell	0	O
allorecognition	0	O
was	0	O
performed	0	O
by	0	O
using	0	O
a	0	O
series	0	O
of	0	O
transfected	0	O
cell	0	O
lines	0	O
expressing	0	O
the	0	O
products	0	O
of	0	O
recombinant	0	O
DRB	0	B
/	0	O
H	1	B
-	0	I
2Eb	0	I
genes	0	O
,	0	O
paired	0	O
with	0	O
either	0	O
DR	1	B
alpha	0	I
or	0	O
H	1	B
-	0	I
2E	0	I
alpha	0	I
.	0	O


We	0	O
screened	0	O
a	0	O
K562	0	O
cDNA	1	O
library	0	O
and	0	O
identified	0	O
novel	0	O
transcripts	0	O
,	0	O
MZF1B	0	B
and	0	O
MZF1C	0	B
.	0	O


The	0	O
clinical	0	O
stage	0	O
was	0	O
I	1	O
(	0	O
T1N0M0	0	O
),	0	O
and	0	O
S2	1	O
sleeve	0	O
segmentectomy	0	O
with	0	O
lymph	0	O
node	0	O
dissection	0	O
(	0	O
R	1	O
2	0	O
b	0	O
)	0	O
was	0	O
performed	0	O
.	0	O


Strikingly	0	O
,	0	O
these	0	O
cells	0	O
contain	0	O
a	0	O
missense	0	O
mutation	0	O
of	0	O
the	0	O
p53	0	B
gene	0	I
at	0	O
codon	0	O
242	0	O
(	0	O
p53	0	B
(	0	O
242	0	O
)),	0	O
which	0	O
substitutes	0	O
alanine	0	O
for	0	O
glycine	0	O
.	0	O


Clinical	1	O
differentiation	0	O
of	0	O
patients	0	O
with	0	O
mild	0	O
diplegic	0	O
cerebral	0	O
palsy	0	O
(	0	O
CP	1	O
)	0	O
and	0	O
idiopathic	0	O
toe	0	O
walking	0	O
(	0	O
ITW	0	O
)	0	O
can	0	O
be	0	O
difficult	0	O
.	0	O


In	1	O
our	0	O
opinion	0	O
,	0	O
the	0	O
SM	1	O
-	0	O
CMA	1	O
system	0	O
is	0	O
,	0	O
despite	0	O
some	0	O
shortcomings	0	O
in	0	O
its	0	O
user	0	O
-	0	O
interface	0	O
,	0	O
a	0	O
useful	0	O
and	0	O
versatile	0	O
instrument	0	O
for	0	O
examination	0	O
of	0	O
human	0	O
semen	0	O
samples	0	O
,	0	O
with	0	O
desirable	0	O
features	0	O
.	0	O


Chagas	0	O
'	0	O
disease	0	O
,	0	O
visceral	0	O
leishmaniasis	0	O
,	0	O
anti	0	B
-	0	I
nuclear	0	I
factor	0	I
,	0	O
schistosomiasis	0	O
,	0	O
rheumatoid	0	B
factor	0	I
and	0	O
normal	0	O
controls	0	O
.	0	O


Cleavage	1	O
and	0	O
DNA	1	O
joining	0	O
reactions	0	O
,	0	O
carried	0	O
out	0	O
by	0	O
human	0	B
immunodeficiency	0	I
virus	0	I
type	0	I
1	0	I
(	0	I
HIV	1	I
-	0	I
1	0	I
)	0	I
integrase	0	I
,	0	O
are	0	O
necessary	0	O
to	0	O
effect	0	O
the	0	O
covalent	0	O
insertion	0	O
of	0	O
HIV	1	O
-	0	O
1	0	O
DNA	1	O
into	0	O
the	0	O
host	0	O
genome	0	O
.	0	O


These	0	O
data	0	O
show	0	O
that	0	O
the	0	O
spv	0	B
virulence	0	I
genes	0	I
belong	0	O
simultaneously	0	O
to	0	O
several	0	O
regulons	0	O
in	0	O
the	0	O
cell	0	O
,	0	O
raising	0	O
the	0	O
possibility	0	O
that	0	O
spv	0	B
expression	0	O
can	0	O
be	0	O
fine	0	O
-	0	O
tuned	0	O
in	0	O
response	0	O
to	0	O
multiple	0	O
environmental	0	O
inputs	0	O
.	0	O


The	0	O
elements	0	O
responsible	0	O
for	0	O
glucocorticoid	0	O
stimulation	0	O
of	0	O
ADH	1	B
gene	0	I
transcription	0	O
appear	0	O
to	0	O
reside	0	O
outside	0	O
of	0	O
this	0	O
region	0	O
.	0	O


The	0	O
P69	0	O
cell	0	O
line	0	O
was	0	O
derived	0	O
by	0	O
immortalization	0	O
of	0	O
human	0	O
primary	0	O
prostate	0	O
epithelial	0	O
cells	0	O
with	0	O
simian	0	B
virus	0	I
-	0	I
40	0	I
T	1	I
antigen	0	I
and	0	O
is	0	O
rarely	0	O
tumorigenic	0	O
.	0	O


It	1	O
is	0	O
now	0	O
estimated	0	O
that	0	O
inactivation	0	O
mutants	0	O
of	0	O
PTEN	0	B
exist	0	O
in	0	O
60	0	O
%	0	O
of	0	O
all	0	O
forms	0	O
of	0	O
solid	0	O
tumors	0	O
.	0	O


Heat	1	O
-	0	O
labile	0	O
-	0	O
like	0	O
enterotoxin	0	O
(	0	O
LT	1	B
)	0	O
was	0	O
produced	0	O
by	0	O
26	0	O
of	0	O
42	0	O
stool	0	O
isolates	0	O
(	0	O
62	0	O
%),	0	O
while	0	O
only	0	O
1	0	O
of	0	O
the	0	O
42	0	O
isolates	0	O
(	0	O
2	0	O
%)	0	O
produced	0	O
enterotoxinlike	0	O
activity	0	O
in	0	O
suckling	0	O
mice	0	O
;	0	O
65	0	O
%	0	O
of	0	O
the	0	O
cytotoxin	0	O
-	0	O
producing	0	O
strains	0	O
also	0	O
produced	0	O
an	0	O
LT	1	B
-	0	I
like	0	I
material	0	O
.	0	O


The	0	O
roxithromycin	0	O
doses	0	O
that	0	O
were	0	O
chosen	0	O
for	0	O
these	0	O
studies	0	O
were	0	O
less	0	O
than	0	O
achievable	0	O
blood	0	O
levels	0	O
.	0	O


Transcriptional	1	O
regulation	0	O
of	0	O
SUP35	0	B
and	0	O
SUP45	0	B
in	0	I
Saccharomyces	1	I
cerevisiae	0	I
.	0	O


Alternative	0	O
splicing	0	O
of	0	O
the	0	O
cytoplasmic	0	O
tail	0	O
appears	0	O
to	0	O
generate	0	O
multiple	0	O
PECAM	0	B
-	0	I
1	0	I
isoforms	0	I
that	0	O
may	0	O
regulate	0	O
phosphorylation	0	O
,	0	O
cytoskeletal	0	O
association	0	O
,	0	O
and	0	O
affinity	0	O
modulation	0	O
of	0	O
the	0	O
mature	0	O
protein	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
ICRF	0	O
-	0	O
187	0	O
on	0	O
the	0	O
antitumor	0	O
response	0	O
induced	0	O
by	0	O
the	0	O
combination	0	O
of	0	O
ADR	1	O
and	0	O
WBH	0	O
was	0	O
also	0	O
investigated	0	O
in	0	O
order	0	O
to	0	O
assess	0	O
alterations	0	O
in	0	O
the	0	O
therapeutic	0	O
index	0	O
of	0	O
this	0	O
combined	0	O
therapeutic	0	O
modality	0	O
treatment	0	O
.	0	O


Phenotypic	1	O
changes	0	O
induced	0	O
by	0	O
wild	0	B
type	0	I
and	0	I
variant	0	I
c	0	I
-	0	I
src	0	I
genes	0	I
carrying	0	O
C	1	O
-	0	O
terminal	0	O
sequence	0	O
alterations	0	O
.	0	O


Endonuclease	1	B
III	0	I
(	0	O
Nth	1	B
)	0	O
of	0	O
Escherichia	1	O
coli	0	O
is	0	O
a	0	O
DNA	1	B
glycosylase	0	I
essential	0	O
for	0	O
the	0	O
removal	0	O
of	0	O
oxidised	0	O
pyrimidine	0	O
base	0	O
residues	0	O
from	0	O
DNA	1	O
.	0	O


The	0	O
tumorigenic	0	O
E1A	0	B
+	0	O
cHa	0	B
-	0	I
ras	0	I
cells	0	O
are	0	O
characterized	0	O
by	0	O
high	0	O
and	0	O
constitutive	0	O
DNA	1	O
binding	0	O
activities	0	O
of	0	O
AP	1	B
-	0	I
1	0	I
,	0	O
in	0	O
contrast	0	O
to	0	O
nontransformed	0	O
cells	0	O
and	0	O
the	0	O
E1A	0	B
cells	0	O
.	0	O


This	0	O
hypothesis	0	O
is	0	O
consistent	0	O
with	0	O
the	0	O
occurrence	0	O
of	0	O
PEA3	0	B
binding	0	I
sites	0	I
in	0	O
the	0	O
PEA3	0	B
promoter	0	I
and	0	O
with	0	O
the	0	O
ability	0	O
of	0	O
PEA3	0	B
to	0	O
transactivate	0	O
this	0	O
promoter	0	O
.	0	O


Using	0	O
an	0	O
interspecific	0	O
backcross	0	O
panel	0	O
,	0	O
we	0	O
localized	0	O
both	0	O
Gng3	0	B
and	0	O
Gng3lg	0	B
to	0	O
the	0	O
same	0	O
locus	0	O
on	0	O
chromosome	0	O
19	0	O
.	0	O


We	0	O
were	0	O
interested	0	O
in	0	O
studying	0	O
the	0	O
relationship	0	O
between	0	O
the	0	O
circadian	0	O
rhythm	0	O
in	0	O
body	0	O
temperature	0	O
and	0	O
24	0	O
-	0	O
h	0	O
variations	0	O
in	0	O
plasma	0	O
concentrations	0	O
of	0	O
iron	0	O
,	0	O
zinc	0	O
,	0	O
circulating	0	O
leukocyte	0	O
counts	0	O
,	0	O
and	0	O
plasma	0	O
interleukin	0	B
1	0	I
(	0	O
IL	1	B
-	0	I
1	0	I
)	0	O
activity	0	O
.	0	O


An	1	O
end	0	O
to	0	O
the	0	O
lottery	0	O
.	0	O


Genes	0	O
for	0	O
ocs	0	B
element	0	I
binding	0	I
factors	0	I
(	0	O
OBFs	0	B
),	0	O
belonging	0	O
to	0	O
a	0	O
specific	0	O
class	0	O
of	0	O
basic	0	B
-	0	I
region	0	I
leucine	0	I
zipper	0	I
(	0	I
bZIP	0	I
)	0	I
transcription	0	I
factors	0	I
,	0	O
have	0	O
been	0	O
isolated	0	O
in	0	O
a	0	O
number	0	O
of	0	O
plants	0	O
.	0	O


The	0	O
other	0	O
is	0	O
located	0	O
at	0	O
-	0	O
1335	0	O
,	0	O
outside	0	O
this	0	O
highly	0	O
conserved	0	O
region	0	O
.	0	O


Anterior	1	O
body	0	O
pattern	0	O
in	0	O
Drosophila	1	O
is	0	O
specified	0	O
by	0	O
the	0	O
graded	0	O
distribution	0	O
of	0	O
the	0	O
bicoid	0	B
protein	0	I
(	0	O
bcd	0	B
),	0	O
which	0	O
activates	0	O
subordinate	0	O
genes	0	O
in	0	O
distinct	0	O
anterior	0	O
domains	0	O
.	0	O


Examination	1	O
of	0	O
the	0	O
sequence	0	O
of	0	O
the	0	O
Punta	0	B
Toro	0	I
M	1	I
gene	0	I
product	0	I
reveals	0	O
the	0	O
presence	0	O
of	0	O
multiple	0	O
hydrophobic	0	O
sequences	0	O
including	0	O
a	0	O
19	0	O
-	0	O
amino	0	O
acid	0	O
,	0	O
carboxy	0	O
-	0	O
proximal	0	O
,	0	O
hydrophobic	0	O
region	0	O
(	0	O
G2	0	O
).	0	O


Results	0	O
showed	0	O
that	0	O
the	0	O
mean	0	O
bond	0	O
strength	0	O
of	0	O
H	1	O
.	0	O
T	1	O
.	0	O
V	1	O
.	0	O
specimens	0	O
ranged	0	O
from	0	O
9	0	O
.	0	O
6	0	O
to	0	O
13	0	O
.	0	O
12	0	O
kg	0	O
/	0	O
cm2	0	O
,	0	O
while	0	O
the	0	O
mean	0	O
bond	0	O
strength	0	O
of	0	O
R	1	O
.	0	O
T	1	O
.	0	O
V	1	O
.	0	O
specimens	0	O
ranged	0	O
from	0	O
0	0	O
.	0	O
36	0	O
to	0	O
1	0	O
.	0	O
75	0	O
kg	0	O
/	0	O
cm2	0	O
.	0	O


Transcripts	0	O
of	0	O
the	0	O
immunoglobulin	0	B
C	1	I
mu	0	I
gene	0	I
vary	0	O
in	0	O
structure	0	O
and	0	O
splicing	0	O
during	0	O
lymphoid	0	O
development	0	O
.	0	O


At	1	O
the	0	O
genomic	0	O
level	0	O
,	0	O
the	0	O
sequences	0	O
of	0	O
two	0	O
members	0	O
of	0	O
this	0	O
family	0	O
are	0	O
known	0	O
in	0	O
the	0	O
rat	0	O
Rattus	1	O
norvegicus	0	O
:	0	O
the	0	O
VCSA1	0	B
gene	0	I
,	0	O
encoding	0	O
the	0	O
prohormone	0	B
-	0	I
like	0	I
polypeptide	0	I
SMR1	0	I
,	0	O
and	0	O
the	0	O
VCSB1	0	B
gene	0	I
,	0	O
encoding	0	O
a	0	O
salivary	0	O
Pro	1	O
-	0	O
rich	0	O
polypeptide	0	O
.	0	O


The	0	O
recombinant	0	O
purified	0	O
protein	0	O
expressed	0	O
in	0	O
the	0	O
baculovirus	0	O
system	0	O
had	0	O
an	0	O
approximate	0	O
molecular	0	O
size	0	O
20	0	O
kDa	1	O
with	0	O
amino	0	O
-	0	O
terminal	0	O
sequence	0	O
of	0	O
AVQGP	0	O
.	0	O


A	1	O
limited	0	O
sampling	0	O
strategy	0	O
was	0	O
used	0	O
based	0	O
on	0	O
a	0	O
bayesian	0	O
parameter	0	O
estimation	0	O
algorithm	0	O
that	0	O
is	0	O
part	0	O
of	0	O
the	0	O
ADAPT	0	O
II	0	O
software	0	O
package	0	O
.	0	O


In	1	O
C	1	O
.	0	O
albicans	0	O
,	0	O
HST6	0	B
is	0	O
expressed	0	O
constitutively	0	O
at	0	O
high	0	O
levels	0	O
in	0	O
the	0	O
different	0	O
cell	0	O
types	0	O
analysed	0	O
(	0	O
yeast	0	O
,	0	O
hyphae	0	O
,	0	O
white	0	O
and	0	O
opaque	0	O
),	0	O
demonstrating	0	O
that	0	O
HST6	0	B
transcription	0	O
is	0	O
not	0	O
repressed	0	O
in	0	O
this	0	O
diploid	0	O
yeast	0	O
,	0	O
unlike	0	O
in	0	O
diploid	0	O
S	1	O
.	0	O
cerevisiae	0	O
,	0	O
and	0	O
suggesting	0	O
a	0	O
basic	0	O
biological	0	O
function	0	O
for	0	O
the	0	O
Hst6p	0	B
transporter	0	O
in	0	O
C	1	O
.	0	O
albicans	0	O
.	0	O


The	0	O
maintenance	0	O
of	0	O
increased	0	O
myocardial	0	O
capillary	0	O
density	0	O
required	0	O
a	0	O
similar	0	O
amount	0	O
of	0	O
exercise	0	O
,	0	O
and	0	O
at	0	O
least	0	O
1	0	O
h	0	O
of	0	O
exercise	0	O
once	0	O
a	0	O
week	0	O
was	0	O
necessary	0	O
to	0	O
maintain	0	O
the	0	O
enlargement	0	O
of	0	O
ECA	0	O
.	0	O
20	0	O


The	0	O
unfolded	0	O
protein	0	O
response	0	O
regulates	0	O
multiple	0	O
aspects	0	O
of	0	O
secretory	0	O
and	0	O
membrane	0	O
protein	0	O
biogenesis	0	O
and	0	O
endoplasmic	0	O
reticulum	0	O
quality	0	O
control	0	O
.	0	O


Immunohistochemical	0	O
staining	0	O
with	0	O
MIB	0	B
-	0	I
1	0	I
and	0	O
p53	0	B
antibodies	0	I
showed	0	O
low	0	O
(<	0	O
1	0	O
%)	0	O
and	0	O
negative	0	O
reaction	0	O
.	0	O


Male	1	B
-	0	I
enhanced	0	I
antigen	0	I
gene	0	I
is	0	O
phylogenetically	0	O
conserved	0	O
and	0	O
expressed	0	O
at	0	O
late	0	O
stages	0	O
of	0	O
spermatogenesis	0	O
.	0	O


Coimmunoprecipitation	0	O
experiments	0	O
performed	0	O
in	0	O
transfected	0	O
cells	0	O
showed	0	O
that	0	O
BCMA	0	B
associates	0	O
with	0	O
TNFR	0	B
-	0	I
associated	0	I
factor	0	I
(	0	I
TRAF	0	I
)	0	I
1	0	I
,	0	O
TRAF2	0	B
,	0	O
and	0	O
TRAF3	0	B
adaptor	0	I
proteins	0	I
.	0	O


Nuclear	1	B
protein	0	I
phosphatase	0	I
2A	0	I
dephosphorylates	0	O
protein	0	B
kinase	0	I
A	1	I
-	0	O
phosphorylated	0	O
CREB	0	B
and	0	O
regulates	0	O
CREB	0	B
transcriptional	0	O
stimulation	0	O
.	0	O


Calves	0	O
fed	0	O
MCT	1	O
-	0	O
milk	0	O
had	0	O
significantly	0	O
lower	0	O
blood	0	O
cholesterol	0	O
than	0	O
calves	0	O
fed	0	O
T	1	O
-	0	O
or	0	O
SBO	0	O
-	0	O
milk	0	O
.	0	O


Other	0	O
assays	0	O
also	0	O
distinguished	0	O
the	0	O
processive	0	O
replication	0	O
of	0	O
pNeo	0	O
.	0	O
Myc	0	O
-	0	O
2	0	O
.	0	O
4	0	O
from	0	O
the	0	O
dispersive	0	O
labeling	0	O
of	0	O
control	0	O
plasmids	0	O
.	0	O


Thus	0	O
,	0	O
diamide	0	O
treatment	0	O
of	0	O
nuclear	0	O
extracts	0	O
strongly	0	O
reduces	0	O
the	0	O
binding	0	O
of	0	O
NFI	0	B
proteins	0	I
,	0	O
and	0	O
the	0	O
addition	0	O
of	0	O
higher	0	O
concentrations	0	O
of	0	O
dithiothreitol	0	O
to	0	O
nuclear	0	O
extracts	0	O
from	0	O
TG	1	B
-	0	O
treated	0	O
cells	0	O
restores	0	O
NFI	0	B
-	0	I
DNA	1	I
binding	0	O
to	0	O
levels	0	O
in	0	O
extracts	0	O
from	0	O
untreated	0	O
cells	0	O
.	0	O


Human	1	B
immunodeficiency	0	I
virus	0	I
type	0	I
1	0	I
Vpr	0	I
is	0	O
a	0	O
virion	0	O
-	0	O
associated	0	O
,	0	O
regulatory	0	O
protein	0	O
that	0	O
is	0	O
required	0	O
for	0	O
efficient	0	O
viral	0	O
replication	0	O
in	0	O
monocytes	0	O
/	0	O
macrophages	0	O
.	0	O


Constantly	0	O
rectilinear	0	O
pressure	0	O
curves	0	O
without	0	O
uterine	0	O
activities	0	O
are	0	O
interpreted	0	O
as	0	O
characteristic	0	O
tocographic	0	O
criteria	0	O
of	0	O
an	0	O
advanced	0	O
ectopic	0	O
gravidity	0	O
.	0	O


After	0	O
that	0	O
report	0	O
,	0	O
carboxypeptidase	0	B
D	1	I
(	0	O
CPD	1	B
)	0	O
was	0	O
subsequently	0	O
purified	0	O
from	0	O
bovine	0	O
pituitary	0	O
and	0	O
characterized	0	O
as	0	O
a	0	O
novel	0	O
carboxypeptidase	0	B
E	1	I
(	0	O
CPE	0	B
)-	0	O
like	0	O
enzyme	0	O
,	0	O
with	0	O
many	0	O
characteristics	0	O
in	0	O
common	0	O
with	0	O
duck	0	O
gp180	0	B
(	0	O
Song	0	O
,	0	O
L	1	O
.,	0	O
Fricker	0	O
,	0	O
L	1	O
.	0	O
D	1	O
.,	0	O
1995	0	O
.	0	O


Temporal	1	O
control	0	O
of	0	O
GUS	0	B
expression	0	O
was	0	O
found	0	O
to	0	O
involve	0	O
two	0	O
negative	0	O
regulatory	0	O
sequences	0	O
,	0	O
NRS1	0	O
(-	0	O
391	0	O
to	0	O
-	0	O
295	0	O
)	0	O
and	0	O
NRS2	0	O
(-	0	O
518	0	O
to	0	O
-	0	O
418	0	O
),	0	O
as	0	O
well	0	O
as	0	O
the	0	O
positive	0	O
domain	0	O
UAS1	0	O
.	0	O


Bullous	1	O
angiolymphoid	0	O
hyperplasia	0	O
with	0	O
eosinophilia	0	O


The	0	O
CT	1	O
characteristics	0	O
are	0	O
discussed	0	O
and	0	O
the	0	O
recent	0	O
literature	0	O
is	0	O
reviewed	0	O
.	0	O


These	0	O
clones	0	O
were	0	O
found	0	O
to	0	O
share	0	O
a	0	O
common	0	O
domain	0	O
encoded	0	O
by	0	O
p	0	O
(	0	O
CA	1	O
)	0	O
n	0	O
repeats	0	O
;	0	O
a	0	O
simple	0	O
sequence	0	O
length	0	O
polymorphism	0	O
(	0	O
SSLP	0	O
).	0	O


Creatine	1	B
kinase	0	I
release	0	O
after	0	O
hepatic	0	O
artery	0	O
embolization	0	O
in	0	O
patients	0	O
with	0	O
carcinoid	0	O
tumors	0	O
.	0	O


Human	1	O
ZFM1	0	B
protein	0	I
is	0	O
a	0	O
transcriptional	0	O
repressor	0	O
that	0	O
interacts	0	O
with	0	O
the	0	O
transcription	0	B
activation	0	I
domain	0	I
of	0	I
stage	0	I
-	0	I
specific	0	I
activator	0	I
protein	0	I
.	0	O


The	0	O
presence	0	O
of	0	O
type	0	O
I	1	O
hypersensitivity	0	O
in	0	O
a	0	O
subgroup	0	O
of	0	O
aspergillomas	0	O
suggests	0	O
an	0	O
immunoallergic	0	O
component	0	O
to	0	O
this	0	O
disease	0	O
which	0	O
could	0	O
contribute	0	O
to	0	O
a	0	O
chronic	0	O
inflammatory	0	O
response	0	O
to	0	O
Aspergillus	1	O
in	0	O
some	0	O
aspergillomas	0	O
.	0	O


T	1	O
cells	0	O
express	0	O
two	0	O
isoforms	0	O
of	0	O
S6k1	0	B
:	0	O
a	0	O
70	0	O
kDa	1	O
cytoplasmic	0	O
kinase	0	O
and	0	O
an	0	O
85	0	O
kDa	1	O
isoform	0	O
that	0	O
has	0	O
a	0	O
classic	0	O
nuclear	0	O
localisation	0	O
.	0	O


The	0	O
corn	0	O
and	0	O
mineral	0	O
oil	0	O
emulsions	0	O
were	0	O
almost	0	O
as	0	O
effective	0	O
as	0	O
milk	0	O
but	0	O
less	0	O
effective	0	O
than	0	O
sucrose	0	O
(	0	O
0	0	O
.	0	O
3M	0	O
)	0	O
in	0	O
stimulating	0	O
ingestion	0	O
.	0	O


CodY	0	B
does	0	O
not	0	O
have	0	O
any	0	O
homologues	0	O
in	0	O
the	0	O
data	0	O
-	0	O
bases	0	O
.	0	O


Value	1	O
of	0	O
Normotest	0	O
and	0	O
antithrombin	0	B
3	0	I
in	0	O
the	0	O
assessment	0	O
of	0	O
liver	0	O
function	0	O
.	0	O


Teratological	0	O
study	0	O
of	0	O
etoperidone	0	O
in	0	O
the	0	O
rat	0	O
and	0	O
rabbit	0	O
.	0	O


Evoked	0	O
electromyographic	0	O
response	0	O
to	0	O
indirect	0	O
supramaximal	0	O
stimulation	0	O
at	0	O
1	0	O
Hz	1	O
was	0	O
monitored	0	O
in	0	O
ten	0	O
adult	0	O
goats	0	O
under	0	O
thiopentone	0	O
-	0	O
halothane	0	O
anaesthesia	0	O
.	0	O


Despite	0	O
the	0	O
reported	0	O
detrimental	0	O
effects	0	O
on	0	O
CNS	1	O
development	0	O
,	0	O
a	0	O
number	0	O
of	0	O
animal	0	O
studies	0	O
have	0	O
shown	0	O
that	0	O
pretreatment	0	O
with	0	O
corticosteroids	0	O
nevertheless	0	O
protect	0	O
the	0	O
brain	0	O
from	0	O
hypoxia	0	O
-	0	O
ischemic	0	O
injury	0	O
;	0	O
however	0	O
,	0	O
clinically	0	O
such	0	O
treatment	0	O
is	0	O
no	0	O
longer	0	O
favored	0	O
.	0	O


NF	1	B
kappa	0	I
B	1	I
was	0	O
activated	0	O
to	0	O
a	0	O
much	0	O
greater	0	O
extent	0	O
by	0	O
roscovitine	0	O
in	0	O
the	0	O
WT	1	O
cells	0	O
than	0	O
in	0	O
Y8	0	O
cells	0	O
.	0	O


All	1	O
members	0	O
are	0	O
also	0	O
capable	0	O
of	0	O
activating	0	O
in	0	O
vivo	0	O
transcription	0	O
from	0	O
promoters	0	O
that	0	O
contain	0	O
a	0	O
C	1	B
/	0	I
EBP	1	I
-	0	I
binding	0	I
site	0	I
.	0	O


Cotransfection	1	O
of	0	O
the	0	O
coactivator	0	O
CREB	0	B
-	0	I
binding	0	I
protein	0	I
relieved	0	O
the	0	O
transcriptional	0	O
repression	0	O
of	0	O
PPARalphawt	0	B
by	0	O
PPARalphatr	0	B
,	0	O
suggesting	0	O
that	0	O
the	0	O
dominant	0	O
negative	0	O
effect	0	O
of	0	O
PPARalphatr	0	B
might	0	O
occur	0	O
through	0	O
competition	0	O
for	0	O
essential	0	O
coactivators	0	O
.	0	O


Until	0	O
such	0	O
investigations	0	O
are	0	O
performed	0	O
,	0	O
we	0	O
conclude	0	O
that	0	O
the	0	O
role	0	O
for	0	O
adjuvant	0	O
treatment	0	O
is	0	O
questionable	0	O
and	0	O
that	0	O
TME	1	O
surgery	0	O
is	0	O
preferred	0	O
as	0	O
the	0	O
treatment	0	O
option	0	O
for	0	O
Stage	1	O
T1	1	O
-	0	O
T3	1	O
rectal	0	O
cancers	0	O
.	0	O


Exons	0	O
A1a	0	O
and	0	O
A1b	0	O
are	0	O
separated	0	O
from	0	O
each	0	O
other	0	O
by	0	O
a	0	O
124	0	O
-	0	O
nucleotide	0	O
intron	0	O
.	0	O


Greater	0	O
rupture	0	O
force	0	O
was	0	O
required	0	O
in	0	O
the	0	O
adult	0	O
pigs	0	O
than	0	O
in	0	O
the	0	O
young	0	O
pigs	0	O
.	0	O


Blood	1	O
GSH	1	B
-	0	I
Px	0	I
activity	0	O
was	0	O
measured	0	O
with	0	O
a	0	O
spectrophotometer	0	O
,	0	O
using	0	O
a	0	O
modification	0	O
of	0	O
a	0	O
previously	0	O
described	0	O
assay	0	O
.	0	O


To	1	O
understand	0	O
whether	0	O
Shc	0	B
localization	0	O
in	0	O
membrane	0	O
rafts	0	O
is	0	O
sufficient	0	O
to	0	O
regulate	0	O
Shc	0	B
function	0	O
,	0	O
we	0	O
constructed	0	O
a	0	O
Shc	0	B
chimera	0	I
containing	0	O
the	0	O
Ras	1	B
membrane	0	I
localization	0	I
motif	0	I
at	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
.	0	O


The	0	O
possible	0	O
origin	0	O
and	0	O
role	0	O
of	0	O
CSF	1	B
prolactin	0	I
are	0	O
discussed	0	O
.	0	O


Morphofunctional	0	O
status	0	O
of	0	O
the	0	O
formed	0	O
elements	0	O
of	0	O
the	0	O
blood	0	O
in	0	O
rats	0	O
subjected	0	O
to	0	O
different	0	O
variants	0	O
of	0	O
combined	0	O
and	0	O
isolated	0	O
exposure	0	O
to	0	O
BR	1	O
-	0	O
1	0	O
benzene	0	O


This	0	O
transition	0	O
is	0	O
regulated	0	O
positively	0	O
by	0	O
G1	0	B
-	0	I
specific	0	I
cyclin	0	I
-	0	I
dependent	0	I
kinases	0	I
(	0	O
cdks	0	B
)	0	O
and	0	O
negatively	0	O
by	0	O
the	0	O
product	0	O
of	0	O
the	0	O
retinoblastoma	0	B
tumour	0	I
suppressor	0	I
gene	0	I
,	0	O
pRb	0	B
.	0	O


One	0	O
complex	0	O
appears	0	O
to	0	O
be	0	O
ubiquitous	0	O
but	0	O
enriched	0	O
in	0	O
lymphoid	0	O
cells	0	O
and	0	O
represents	0	O
the	0	O
binding	0	O
of	0	O
a	0	O
potentially	0	O
novel	0	O
factor	0	O
with	0	O
an	0	O
apparent	0	O
molecular	0	O
mass	0	O
of	0	O
approximately	0	O
50	0	O
kDa	1	O
.	0	O


Acute	1	O
experiments	0	O
on	0	O
nembutal	0	O
-	0	O
anesthetized	0	O
cats	0	O
(	0	O
50	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
were	0	O
employed	0	O
to	0	O
investigate	0	O
the	0	O
effect	0	O
of	0	O
1	0	O
T	1	O
pulsating	0	O
magnetic	0	O
field	0	O
(	0	O
PMF	0	O
)	0	O
on	0	O
neuromuscular	0	O
system	0	O
of	0	O
the	0	O
leg	0	O
.	0	O


The	0	O
beta	0	O
subunit	0	O
of	0	O
the	0	O
heterotrimeric	0	B
G	1	I
proteins	0	I
that	0	O
transduce	0	O
signals	0	O
across	0	O
the	0	O
plasma	0	O
membrane	0	O
is	0	O
made	0	O
up	0	O
of	0	O
an	0	O
amino	0	O
-	0	O
terminal	0	O
alpha	0	O
-	0	O
helical	0	O
segment	0	O
followed	0	O
by	0	O
seven	0	O
repeating	0	O
units	0	O
called	0	O
WD	0	O
(	0	O
Trp	1	O
-	0	O
Asp	1	O
)	0	O
repeats	0	O
that	0	O
occur	0	O
in	0	O
about	0	O
140	0	O
different	0	O
proteins	0	O
.	0	O


RESULTS	0	O
AND	0	O
CONCLUSIONS	0	O
:	0	O
Brandt	0	O
'	0	O
s	0	O
double	0	O
cuff	0	O
-	0	O
tubes	0	O
(	0	O
G2	0	O
)	0	O
succeed	0	O
in	0	O
avoiding	0	O
uncontrolled	0	O
increase	0	O
of	0	O
cuff	0	O
-	0	O
pressure	0	O
during	0	O
anaesthesia	0	O
with	0	O
N2O	1	O
.	0	O


I	1	O
.	0	O


Cyclosporine	1	O
treatment	0	O
for	0	O
intractable	0	O
polymyositis	0	O
.	0	O


Determined	0	O
as	0	O
migration	0	O
differentials	0	O
,	0	O
chemotactic	0	O
and	0	O
chemokinetic	0	O
responsiveness	0	O
tended	0	O
to	0	O
be	0	O
higher	0	O
in	0	O
the	0	O
neutropenic	0	O
group	0	O
.	0	O


IV	1	O
.	0	O


Analysis	1	O
of	0	O
disassociation	0	O
rates	0	O
indicates	0	O
that	0	O
the	0	O
Grf10	0	B
-	0	O
Swi5	0	B
-	0	O
DNA	1	O
complex	0	O
has	0	O
a	0	O
longer	0	O
half	0	O
-	0	O
life	0	O
than	0	O
protein	0	O
-	0	O
DNA	1	O
complexes	0	O
that	0	O
contain	0	O
only	0	O
Swi5	0	B
or	0	O
Grf10	0	B
.	0	O


Thus	0	O
,	0	O
an	0	O
increase	0	O
in	0	O
plasma	0	B
TBG	1	I
and	0	O
a	0	O
shift	0	O
from	0	O
adrenal	0	O
androgen	0	O
and	0	O
mineralocorticoid	0	O
steroid	0	O
secretion	0	O
towards	0	O
cortisol	0	O
secretion	0	O
may	0	O
be	0	O
endocrine	0	O
markers	0	O
for	0	O
progression	0	O
of	0	O
the	0	O
disease	0	O
in	0	O
patients	0	O
with	0	O
HIV	1	O
-	0	O
infection	0	O
.	0	O


The	0	O
apparent	0	O
Kd	1	O
of	0	O
the	0	O
MetRS	0	B
/	0	I
CAU	0	I
operator	0	I
complex	0	I
is	0	O
one	0	O
order	0	O
magnitude	0	O
higher	0	O
than	0	O
that	0	O
of	0	O
the	0	O
ThrRS	0	B
/	0	I
CGU	0	I
operator	0	I
complex	0	I
.	0	O


Sp1	0	B
binds	0	O
the	0	O
CTC	0	O
repeat	0	O
with	0	O
an	0	O
affinity	0	O
,	0	O
KD	1	O
=	0	O
0	0	O
.	0	O
37	0	O
nM	1	O
,	0	O
at	0	O
least	0	O
as	0	O
high	0	O
as	0	O
the	0	O
consensus	0	O
GC	1	O
box	0	O
.	0	O


Deletion	1	O
analysis	0	O
revealed	0	O
that	0	O
the	0	O
essential	0	O
domain	0	O
of	0	O
this	0	O
promoter	0	O
,	0	O
termed	0	O
the	0	O
ORF5	0	B
/	0	I
deltaX	0	I
transcript	0	I
promoter	0	I
,	0	O
mapped	0	O
to	0	O
nucleotides	0	O
1525	0	O
-	0	O
1625	0	O
.	0	O


Initial	1	O
experience	0	O
with	0	O
the	0	O
new	0	O
technology	0	O
indicates	0	O
that	0	O
SieScape	0	O
is	0	O
an	0	O
alternative	0	O
to	0	O
other	0	O
methods	0	O
such	0	O
as	0	O
CT	1	O
and	0	O
MRI	1	O
.	0	O


Myocardial	0	O
interstitial	0	O
edema	0	O
is	0	O
more	0	O
likely	0	O
a	0	O
potential	0	O
mechanism	0	O
of	0	O
diastolic	0	O
dysfunction	0	O
after	0	O
DC	1	O
shocks	0	O
.	0	O


The	0	O
vigilance	0	O
task	0	O
and	0	O
the	0	O
measurement	0	O
of	0	O
attentional	0	O
deficits	0	O
.	0	O


An	1	O
experiment	0	O
on	0	O
the	0	O
return	0	O
-	0	O
of	0	O
-	0	O
fear	0	O
(	0	O
ROF	0	O
)	0	O
was	0	O
carried	0	O
out	0	O
on	0	O
40	0	O
snake	0	O
-	0	O
or	0	O
spider	0	O
-	0	O
phobic	0	O
subjects	0	O
in	0	O
order	0	O
to	0	O
determine	0	O
whether	0	O
an	0	O
arousing	0	O
event	0	O
that	0	O
occurs	0	O
shortly	0	O
before	0	O
retest	0	O
influences	0	O
the	0	O
magnitude	0	O
of	0	O
the	0	O
ROF	0	O
.	0	O


However	0	O
,	0	O
an	0	O
intrinsic	0	O
DNA	1	O
-	0	O
binding	0	O
subunit	0	O
for	0	O
HiNF	0	B
-	0	I
D	1	I
was	0	O
not	0	O
identified	0	O
.	0	O


The	0	O
inhibition	0	O
of	0	O
StAR	1	B
gene	0	I
transcription	0	O
by	0	O
DAX	0	B
-	0	I
1	0	I
was	0	O
dose	0	O
-	0	O
dependent	0	O
reducing	0	O
transcription	0	O
to	0	O
6	0	O
%	0	O
of	0	O
control	0	O
levels	0	O
.	0	O


Growth	1	O
factors	0	O
induce	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
immediate	0	B
early	0	I
gene	0	I
products	0	I
MAP	1	I
kinase	0	I
phosphatase	0	I
-	0	I
1	0	I
(	0	O
MKP	0	B
-	0	I
1	0	I
),	0	O
c	0	B
-	0	I
Fos	1	I
and	0	O
c	0	B
-	0	I
Jun	1	I
.	0	O


RESULTS	0	O
:	0	O
At	1	O
the	0	O
beginning	0	O
of	0	O
the	0	O
QA	1	O
/	0	O
QI	1	O
process	0	O
,	0	O
monitoring	0	O
of	0	O
blood	0	O
administration	0	O
practices	0	O
revealed	0	O
that	0	O
a	0	O
variance	0	O
from	0	O
institutional	0	O
blood	0	O
administration	0	O
policy	0	O
occurred	0	O
during	0	O
50	0	O
percent	0	O
of	0	O
blood	0	O
and	0	O
component	0	O
transfusions	0	O
.	0	O


However	0	O
,	0	O
the	0	O
lens	0	O
dose	0	O
(	0	O
3	0	O
.	0	O
6	0	O
Gy	1	O
/	0	O
25	0	O
fractions	0	O
)	0	O
was	0	O
higher	0	O
compared	0	O
to	0	O
the	0	O
other	0	O
techniques	0	O
.	0	O


A	1	O
114	0	O
-	0	O
base	0	O
pair	0	O
sequence	0	O
of	0	O
predominantly	0	O
repeating	0	O
purine	0	O
-	0	O
pyrimidine	0	O
nucleotides	0	O
separates	0	O
these	0	O
two	0	O
d	0	O
(	0	O
AC	1	O
)	0	O
repeats	0	O
.	0	O


After	0	O
cells	0	O
were	0	O
stably	0	O
transfected	0	O
with	0	O
CIITA	0	B
,	0	O
endogenous	0	O
MHC	1	B
class	0	I
II	0	I
genes	0	I
were	0	O
constitutively	0	O
expressed	0	O
,	0	O
and	0	O
MHC	1	B
class	0	I
II	0	I
promoters	0	I
,	0	O
delivered	0	O
by	0	O
transfection	0	O
,	0	O
were	0	O
actively	0	O
transcribed	0	O
in	0	O
CIITA	0	B
-	0	O
expressing	0	O
cells	0	O
.	0	O


Fecal	1	O
samples	0	O
were	0	O
collected	0	O
at	0	O
the	0	O
beginning	0	O
and	0	O
end	0	O
of	0	O
each	0	O
trial	0	O
period	0	O
and	0	O
were	0	O
analyzed	0	O
for	0	O
gastrointestinal	0	O
nematode	0	O
eggs	0	O
and	0	O
Giardia	1	O
cyst	0	O
.	0	O


Studies	0	O
on	0	O
swine	0	O
enteroviruses	0	O
.	0	O


Molecular	1	O
dissection	0	O
of	0	O
the	0	O
multimeric	0	O
CD3	0	B
-	0	O
TCR	1	B
complex	0	O
revealed	0	O
that	0	O
at	0	O
least	0	O
two	0	O
associated	0	O
polypeptides	0	O
,	0	O
CD3	0	B
zeta	0	I
and	0	O
CD3	0	B
epsilon	0	I
,	0	O
autonomously	0	O
couple	0	O
antigenic	0	O
recognition	0	O
event	0	O
to	0	O
early	0	O
and	0	O
late	0	O
events	0	O
of	0	O
the	0	O
intracytoplasmic	0	O
activation	0	O
cascade	0	O
.	0	O


The	0	O
human	0	B
papillomavirus	0	I
type	0	I
16	0	I
E7	0	I
protein	0	I
complements	0	O
adenovirus	0	B
type	0	I
5	0	I
E1A	0	I
amino	0	O
-	0	O
terminus	0	O
-	0	O
dependent	0	O
transactivation	0	O
of	0	O
adenovirus	0	B
type	0	I
5	0	I
early	0	I
genes	0	I
and	0	O
increases	0	O
ATF	0	B
and	0	O
Oct	1	B
-	0	I
1	0	I
DNA	1	O
binding	0	O
activity	0	O
.	0	O


The	0	O
up	0	O
-	0	O
regulation	0	O
of	0	O
E	1	B
-	0	I
selectin	0	I
,	0	O
one	0	O
of	0	O
the	0	O
adhesion	0	O
molecules	0	O
on	0	O
the	0	O
endothelium	0	O
,	0	O
is	0	O
an	0	O
important	0	O
event	0	O
in	0	O
the	0	O
mediation	0	O
of	0	O
the	0	O
inflammatory	0	O
response	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
its	0	O
bZIP	0	O
structural	0	O
homology	0	O
,	0	O
meq	0	B
is	0	O
perhaps	0	O
the	0	O
only	0	O
member	0	O
of	0	O
the	0	O
jun	0	B
-	0	O
fos	0	B
gene	0	O
family	0	O
completely	0	O
viral	0	O
in	0	O
origin	0	O
.	0	O


Cotransfections	0	O
with	0	O
ATF	0	B
-	0	I
2	0	I
and	0	O
HNF	1	B
-	0	I
4	0	I
expression	0	O
plasmids	0	O
resulted	0	O
in	0	O
additive	0	O
transactivation	0	O
of	0	O
the	0	O
apoCIII	0	B
promoter	0	I
.	0	O


A	1	O
randomised	0	O
,	0	O
controlled	0	O
trial	0	O
was	0	O
undertaken	0	O
in	0	O
40	0	O
patients	0	O
with	0	O
active	0	O
Crohn	0	O
'	0	O
s	0	O
disease	0	O
to	0	O
evaluate	0	O
clinical	0	O
and	0	O
nutritional	0	O
outcomes	0	O
after	0	O
an	0	O
amino	0	O
acid	0	O
based	0	O
diet	0	O
containing	0	O
3	0	O
%	0	O
fat	0	O
was	0	O
given	0	O
by	0	O
a	0	O
feeding	0	O
tube	0	O
compared	0	O
with	0	O
a	0	O
peptide	0	O
based	0	O
diet	0	O
containing	0	O
33	0	O
%	0	O
fat	0	O
.	0	O


A	1	O
novel	0	O
pleckstrin	0	B
homology	0	I
-	0	I
related	0	I
gene	0	I
family	0	I
defined	0	O
by	0	O
Ipl	1	B
/	0	O
Tssc3	0	B
,	0	O
TDAG51	0	B
,	0	O
and	0	O
Tih1	0	B
:	0	O
tissue	0	O
-	0	O
specific	0	O
expression	0	O
,	0	O
chromosomal	0	O
location	0	O
,	0	O
and	0	O
parental	0	O
imprinting	0	O
.	0	O


Intensive	1	O
synthesis	0	O
of	0	O
PNA	1	B
in	0	O
the	0	O
cells	0	O
of	0	O
microvascular	0	O
wall	0	O
evidenced	0	O
of	0	O
their	0	O
high	0	O
functional	0	O
activity	0	O
,	0	O
and	0	O
the	0	O
synthesis	0	O
of	0	O
DNA	1	O
in	0	O
them	0	O
showed	0	O
their	0	O
ability	0	O
for	0	O
proliferation	0	O
,	0	O
i	0	O
.	0	O
g	0	O
.--	0	O
for	0	O
growth	0	O
.	0	O


The	0	O
results	0	O
indicate	0	O
considerable	0	O
flexibility	0	O
in	0	O
the	0	O
spacing	0	O
between	0	O
DH	1	B
regulatory	0	O
sites	0	O
.	0	O


There	0	O
was	0	O
a	0	O
significant	0	O
correlation	0	O
between	0	O
tubular	0	O
diameter	0	O
and	0	O
spg	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
68	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
)	0	O
suggesting	0	O
that	0	O
tubular	0	O
diameter	0	O
measurements	0	O
in	0	O
histological	0	O
sections	0	O
could	0	O
be	0	O
used	0	O
to	0	O
predict	0	O
sperm	0	O
production	0	O
.	0	O


Branch	1	O
occlusion	0	O
of	0	O
Heubner	0	O
'	0	O
s	0	O
artery	0	O
,	0	O
or	0	O
perforators	0	O
from	0	O
the	0	O
proximal	0	O
anterior	0	O
or	0	O
middle	0	O
cerebral	0	O
arteries	0	O
were	0	O
the	0	O
posited	0	O
mechanism	0	O
of	0	O
infarction	0	O
.	0	O


A511	0	O
is	0	O
a	0	O
broad	0	O
-	0	O
host	0	O
-	0	O
range	0	O
,	0	O
virulent	0	O
myovirus	0	O
for	0	O
Listeria	1	O
monocytogenes	0	O
.	0	O


Certain	0	O
transcript	0	O
patterns	0	O
in	0	O
Epifagus	0	O
plastids	0	O
are	0	O
highly	0	O
complex	0	O
and	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
tobacco	0	O
operons	0	O
.	0	O


The	0	O
changes	0	O
after	0	O
treatment	0	O
were	0	O
observed	0	O
chiefly	0	O
by	0	O
electromyography	0	O
while	0	O
sensory	0	O
and	0	O
motor	0	O
improvement	0	O
were	0	O
also	0	O
recorded	0	O
as	0	O
auxiliary	0	O
indicators	0	O
.	0	O


After	0	O
termination	0	O
of	0	O
medication	0	O
the	0	O
animals	0	O
were	0	O
kindled	0	O
electrically	0	O
in	0	O
the	0	O
nucleus	0	O
amygdala	0	O
.	0	O


The	0	O
SH2	0	B
domain	0	I
-	0	I
containing	0	I
inositol	0	I
5	0	I
'-	0	I
phosphatase	0	I
(	0	O
SHIP	0	B
)	0	O
recruits	0	O
the	0	O
p85	0	B
subunit	0	I
of	0	O
phosphoinositide	0	B
3	0	I
-	0	I
kinase	0	I
during	0	O
FcgammaRIIb1	0	B
-	0	O
mediated	0	O
inhibition	0	O
of	0	O
B	1	B
cell	0	I
receptor	0	I
signaling	0	O
.	0	O


The	0	O
C	1	B
-	0	I
terminal	0	I
Cdk2	0	I
truncations	0	O
,	0	O
however	0	O
,	0	O
were	0	O
non	0	O
-	0	O
functional	0	O
in	0	O
these	0	O
strains	0	O
and	0	O
thus	0	O
dependent	0	O
for	0	O
activity	0	O
on	0	O
the	0	O
pho85	0	B
coding	0	I
region	0	I
which	0	O
remained	0	O
in	0	O
the	0	O
mutant	0	B
pho85	0	I
::	0	O
HIS3	0	B
chromosomal	0	I
locus	0	I
.	0	O


We	0	O
concluded	0	O
that	0	O
activation	0	O
of	0	O
c	0	B
-	0	I
fosER	0	I
mediated	0	O
transcriptional	0	O
inhibition	0	O
of	0	O
p21	0	B
(	0	O
Cip1	0	B
/	0	O
WAF1	0	B
)	0	O
through	0	O
a	0	O
previously	0	O
uncharacterized	0	O
AP	1	B
-	0	I
1	0	I
site	0	I
,	0	O
revealing	0	O
an	0	O
important	0	O
role	0	O
for	0	O
c	0	B
-	0	I
fos	0	I
in	0	O
negative	0	O
control	0	O
of	0	O
cell	0	O
cycle	0	O
regulatory	0	O
genes	0	O
.	0	O


These	0	O
observations	0	O
establish	0	O
that	0	O
RsmC	0	B
negatively	0	O
regulates	0	O
rsmB	0	B
transcription	0	O
but	0	O
positively	0	O
affects	0	O
RsmA	0	B
production	0	O
.	0	O


Marrow	1	O
dysplasia	0	O
is	0	O
a	0	O
major	0	O
characteristic	0	O
of	0	O
patients	0	O
with	0	O
myelodysplastic	0	O
syndrome	0	O
(	0	O
MDS	1	O
),	0	O
along	0	O
with	0	O
marrow	0	O
blastosis	0	O
,	0	O
cytopenia	0	O
and	0	O
cytogenetic	0	O
anomalies	0	O
.	0	O


This	0	O
dimer	0	O
interface	0	O
is	0	O
likely	0	O
important	0	O
for	0	O
increasing	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
specificity	0	O
and	0	O
affinity	0	O
of	0	O
the	0	O
trimeric	0	O
form	0	O
of	0	O
HSF	0	B
,	0	O
as	0	O
well	0	O
as	0	O
for	0	O
increasing	0	O
cooperativity	0	O
between	0	O
adjacent	0	O
trimers	0	O
.	0	O


Similar	0	O
synergistic	0	O
activation	0	O
was	0	O
observed	0	O
in	0	O
the	0	O
IL	1	B
-	0	I
8	0	I
promoter	0	I
,	0	O
which	0	O
also	0	O
contains	0	O
both	0	O
NF	1	B
-	0	I
IL6	0	I
and	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
binding	0	I
sites	0	I
.	0	O


Leads	0	O
from	0	O
the	0	O
MMWR	1	O
.	0	O


Whereas	0	O
,	0	O
in	0	O
the	0	O
single	0	O
-	0	O
chambered	0	O
body	0	O
box	0	O
,	0	O
PenH	0	O
units	0	O
(	0	O
Enhanced	0	O
Pause	1	O
)	0	O
reflect	0	O
"	0	O
effort	0	O
of	0	O
breathing	0	O
."	0	O
This	0	O
is	0	O
measured	0	O
as	0	O
the	0	O
pause	0	O
between	0	O
inspiration	0	O
and	0	O
expiration	0	O
.	0	O


Letter	0	O
:	0	O
Salmonella	1	O
detection	0	O


In	1	O
the	0	O
current	0	O
study	0	O
,	0	O
the	0	O
roles	0	O
of	0	O
two	0	O
putative	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
within	0	O
the	0	O
-	0	O
73	0	O
to	0	O
+	0	O
44	0	O
region	0	O
in	0	O
basal	0	O
exon	0	O
2	0	O
promoter	0	O
activity	0	O
were	0	O
evaluated	0	O
using	0	O
mutagenesis	0	O
and	0	O
nuclear	0	O
protein	0	O
-	0	O
DNA	1	O
binding	0	O
assays	0	O
.	0	O


RESULTS	0	O
:	0	O
Of	0	O
the	0	O
29	0	O
patients	0	O
who	0	O
received	0	O
concurrent	0	O
chemotherapy	0	O
and	0	O
G	1	B
-	0	I
CSF	1	I
,	0	O
ten	0	O
(	0	O
34	0	O
%;	0	O
95	0	O
%	0	O
confidence	0	O
interval	0	O
[	0	O
CI	1	O
],	0	O
17	0	O
.	0	O
9	0	O
to	0	O
54	0	O
.	0	O
3	0	O
%)	0	O
were	0	O
believed	0	O
to	0	O
have	0	O
clinically	0	O
significant	0	O
bleomycin	0	O
toxicity	0	O
.	0	O


Chemical	1	O
histologic	0	O
and	0	O
immunologic	0	O
responses	0	O
in	0	O
rats	0	O
to	0	O
CC1	0	O
-	0	O
4	0	O
by	0	O
different	0	O
routes	0	O
of	0	O
administration	0	O
.	0	O


With	0	O
steady	0	O
illumination	0	O
,	0	O
outer	0	O
retinal	0	O
(	0	O
photoreceptor	0	O
)	0	O
QO2	1	O
decreased	0	O
to	0	O
1	0	O
.	0	O
4	0	O
+/-	0	O
0	0	O
.	0	O
9	0	O
ml	0	O
O2	1	O
/(	0	O
100	0	O
g	0	O
.	0	O
min	0	O
),	0	O
but	0	O
inner	0	O
retinal	0	O
QO2	1	O
remained	0	O
unchanged	0	O
at	0	O
3	0	O
.	0	O
7	0	O
+/-	0	O
1	0	O
.	0	O
5	0	O
ml	0	O
O2	1	O
/(	0	O
100	0	O
g	0	O
.	0	O
min	0	O
)	0	O
(	0	O
5	0	O
cats	0	O
).	0	O


The	0	O
Scales	0	O
of	0	O
Cognitive	1	O
Impairment	1	O
Rated	0	O
From	0	O
Institutional	0	O
Records	0	O
(	0	O
SCIRFIR	0	O
),	0	O
a	0	O
battery	0	O
based	0	O
on	0	O
commonly	0	O
used	0	O
dementia	0	O
rating	0	O
instruments	0	O
,	0	O
was	0	O
tested	0	O
on	0	O
the	0	O
records	0	O
of	0	O
26	0	O
chronically	0	O
institutionalized	0	O
,	0	O
elderly	0	O
schizophrenia	0	O
patients	0	O
,	0	O
for	0	O
the	0	O
purpose	0	O
of	0	O
retrospectively	0	O
evaluating	0	O
the	0	O
long	0	O
-	0	O
term	0	O
course	0	O
of	0	O
cognitive	0	O
change	0	O
in	0	O
schizophrenia	0	O
and	0	O
relating	0	O
it	0	O
to	0	O
available	0	O
autopsy	0	O
materials	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
c	0	B
-	0	I
myc	0	I
were	0	O
further	0	O
dissected	0	O
by	0	O
showing	0	O
that	0	O
c	0	B
-	0	I
myc	0	I
can	0	O
inhibit	0	O
differentiation	0	O
independently	0	O
of	0	O
Id	1	B
,	0	O
a	0	O
negative	0	O
regulator	0	O
of	0	O
muscle	0	O
differentiation	0	O
.	0	O


The	0	O
cDNA	1	O
encoded	0	O
a	0	O
mature	0	O
protein	0	O
of	0	O
240	0	O
amino	0	O
acids	0	O
,	0	O
including	0	O
a	0	O
29	0	O
-	0	O
amino	0	O
acid	0	O
signal	0	O
sequence	0	O
.	0	O


Subunit	1	O
composition	0	O
and	0	O
domain	0	O
structure	0	O
of	0	O
the	0	O
Spo0A	0	B
sporulation	0	I
transcription	0	I
factor	0	I
of	0	I
Bacillus	1	I
subtilis	0	I
.	0	O


Amongst	0	O
other	0	O
qualities	0	O
,	0	O
the	0	O
book	0	O
'	0	O
s	0	O
importance	0	O
lies	0	O
in	0	O
the	0	O
fact	0	O
that	0	O
it	0	O
associates	0	O
an	0	O
elaborate	0	O
theoretical	0	O
construction	0	O
with	0	O
the	0	O
empirical	0	O
data	0	O
,	0	O
working	0	O
within	0	O
the	0	O
possibilities	0	O
provided	0	O
by	0	O
late	0	O
19th	0	O
-	0	O
century	0	O
moral	0	O
statistics	0	O
.	0	O


We	0	O
analyzed	0	O
an	0	O
EBV	1	O
B	1	O
-	0	O
cell	0	O
clone	0	O
,	0	O
E29	0	O
.	0	O
1	0	O
,	0	O
derived	0	O
from	0	O
an	0	O
11	0	O
week	0	O
-	0	O
old	0	O
embryo	0	O
,	0	O
and	0	O
secreting	0	O
both	0	O
IgM	1	B
kappa	0	I
and	0	O
IgM	1	B
lambda	0	I
.	0	O


If	1	O
this	0	O
is	0	O
the	0	O
case	0	O
,	0	O
identification	0	O
and	0	O
characterization	0	O
of	0	O
transcripts	0	O
from	0	O
the	0	O
Ig	1	B
loci	0	I
should	0	O
permit	0	O
a	0	O
better	0	O
understanding	0	O
of	0	O
the	0	O
gene	0	O
rearrangement	0	O
process	0	O
.	0	O


Tumor	1	B
necrosis	0	I
factor	0	I
alpha	0	I
,	0	O
the	0	O
cytokine	0	O
that	0	O
participates	0	O
in	0	O
the	0	O
autocrine	0	O
growth	0	O
control	0	O
of	0	O
hairy	0	O
cell	0	O
leukemia	0	O
has	0	O
strong	0	O
bone	0	O
resorptive	0	O
properties	0	O
.	0	O


The	0	O
recovery	0	O
value	0	O
of	0	O
systolic	0	O
pressure	0	O
was	0	O
higher	0	O
than	0	O
diastolic	0	O
pressure	0	O
and	0	O
pulse	0	O
pressure	0	O
increased	0	O
.	0	O


The	0	O
dynamic	0	O
properties	0	O
of	0	O
this	0	O
protein	0	O
fragment	0	O
were	0	O
measured	0	O
and	0	O
analyzed	0	O
using	0	O
both	0	O
isotropic	0	O
and	0	O
anisotropic	0	O
models	0	O
of	0	O
molecular	0	O
motion	0	O
.	0	O


Postglucose	0	O
serum	0	B
insulin	0	I
levels	0	O
showed	0	O
no	0	O
significant	0	O
correlations	0	O
with	0	O
systolic	0	O
or	0	O
diastolic	0	O
blood	0	O
pressure	0	O
levels	0	O
in	0	O
men	0	O
,	0	O
but	0	O
in	0	O
female	0	O
diabetic	0	O
and	0	O
non	0	O
-	0	O
diabetic	0	O
subjects	0	O
significant	0	O
correlations	0	O
were	0	O
found	0	O
in	0	O
particular	0	O
with	0	O
systolic	0	O
blood	0	O
pressure	0	O
level	0	O
.	0	O


Inherent	1	O
hematology	0	O
of	0	O
old	0	O
age	0	O


A	1	O
cytosolic	0	O
variant	0	O
of	0	O
the	0	O
protein	0	O
underwent	0	O
efficient	0	O
transphosphorylation	0	O
,	0	O
yet	0	O
failed	0	O
to	0	O
activate	0	O
appreciably	0	O
either	0	O
p70	0	B
(	0	O
S6k	0	B
)	0	O
or	0	O
MAP	1	B
kinase	0	I
following	0	O
treatment	0	O
with	0	O
FK1012	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Serum	1	O
levels	0	O
of	0	O
S	1	B
-	0	I
100beta	0	I
are	0	O
reliable	0	O
markers	0	O
for	0	O
adverse	0	O
neurologic	0	O
outcomes	0	O
after	0	O
cardiac	0	O
surgery	0	O
.	0	O


RESULTS	0	O
:	0	O
Basal	1	O
plasma	0	B
IGF	1	I
-	0	I
I	1	I
levels	0	O
as	0	O
well	0	O
as	0	O
body	0	O
mass	0	O
index	0	O
(	0	O
BMI	1	O
)	0	O
were	0	O
lower	0	O
in	0	O
amenorrheic	0	O
patients	0	O
than	0	O
in	0	O
healthy	0	O
controls	0	O
.	0	O


For	0	O
smaller	0	O
vessels	0	O
up	0	O
to	0	O
a	0	O
diameter	0	O
of	0	O
0	0	O
.	0	O
5	0	O
mm	0	O
,	0	O
treatments	0	O
at	0	O
16	0	O
and	0	O
18	0	O
J	1	O
/	0	O
cm2	0	O
showed	0	O
good	0	O
results	0	O
in	0	O
60	0	O
and	0	O
82	0	O
%	0	O
respectively	0	O
;	0	O
for	0	O
vessels	0	O
up	0	O
to	0	O
1	0	O
mm	0	O
in	0	O
27	0	O
and	0	O
33	0	O
%.	0	O


Effect	1	O
of	0	O
phenformin	0	O
on	0	O
gluconeogenesis	0	O
in	0	O
perfused	0	O
rat	0	O
liver	0	O
.	0	O


Functional	1	O
recognition	0	O
of	0	O
5	0	O
'	0	O
splice	0	O
site	0	O
by	0	O
U4	0	B
/	0	O
U6	0	B
.	0	O
U5	0	B
tri	0	O
-	0	O
snRNP	1	O
defines	0	O
a	0	O
novel	0	O
ATP	1	O
-	0	O
dependent	0	O
step	0	O
in	0	O
early	0	O
spliceosome	0	O
assembly	0	O
.	0	O


Entry	1	O
of	0	O
yeast	0	O
cells	0	O
into	0	O
the	0	O
mitotic	0	O
cell	0	O
cycle	0	O
(	0	O
Start	0	O
)	0	O
involves	0	O
a	0	O
form	0	O
of	0	O
the	0	O
CDC28	0	B
kinase	0	I
that	0	O
associates	0	O
with	0	O
G1	0	O
-	0	O
specific	0	O
cyclins	0	B
encoded	0	O
by	0	O
CLN1	0	B
and	0	O
CLN2	0	B
(	0	O
ref	0	O
.	0	O


These	0	O
human	0	O
IFN	1	B
-	0	I
beta	0	I
-	0	O
transformed	0	O
cell	0	O
populations	0	O
have	0	O
acquired	0	O
a	0	O
low	0	O
,	0	O
constitutive	0	O
production	0	O
of	0	O
human	0	B
IFN	1	I
,	0	O
while	0	O
replicating	0	O
at	0	O
a	0	O
rate	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
untransformed	0	O
cells	0	O
and	0	O
of	0	O
cells	0	O
transformed	0	O
with	0	O
the	0	O
control	0	O
vector	0	O
carrying	0	O
a	0	O
human	0	B
IFN	1	I
-	0	I
beta	0	I
sequence	0	I
encoding	0	O
an	0	O
inactive	0	O
,	0	O
mutated	0	O
protein	0	O
.	0	O


By	0	O
electrophoresis	0	O
mobility	0	O
shift	0	O
assays	0	O
using	0	O
probes	0	O
corresponding	0	O
to	0	O
different	0	O
segments	0	O
of	0	O
the	0	O
putative	0	O
human	0	B
c	0	I
-	0	I
myb	0	I
intron	0	I
1	0	I
transcription	0	I
pause	0	I
region	0	I
and	0	O
nuclear	0	O
extracts	0	O
from	0	O
myeloid	0	O
leukemia	0	O
HL	1	O
60	0	O
and	0	O
fibroblast	0	O
WI	0	O
38	0	O
cells	0	O
,	0	O
we	0	O
detected	0	O
a	0	O
HL	1	O
-	0	O
60	0	O
-	0	O
specific	0	O
DNA	1	O
-	0	O
protein	0	O
complex	0	O
with	0	O
a	0	O
123	0	O
-	0	O
bp	0	O
fragment	0	O
containing	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
interferon	0	B
regulatory	0	I
factors	0	I
(	0	O
IRFs	0	B
)	0	O
nuclear	0	O
proteins	0	O
.	0	O


Although	0	O
inactive	0	O
in	0	O
cells	0	O
under	0	O
normal	0	O
conditions	0	O
,	0	O
the	0	O
CHOP	1	B
gene	0	I
is	0	O
markedly	0	O
induced	0	O
by	0	O
a	0	O
variety	0	O
of	0	O
cellular	0	O
stresses	0	O
,	0	O
including	0	O
nutrient	0	O
deprivation	0	O
and	0	O
metabolic	0	O
perturbations	0	O
.	0	O


The	0	O
incidence	0	O
of	0	O
hepatitis	0	B
B	1	I
antigen	0	I
following	0	O
transfusion	0	O
was	0	O
about	0	O
2	0	O
.	0	O
8	0	O
per	0	O
cent	0	O
.	0	O


Invertases	0	B
are	0	O
responsible	0	O
for	0	O
the	0	O
breakdown	0	O
of	0	O
sucrose	0	O
to	0	O
fructose	0	O
and	0	O
glucose	0	O
.	0	O


Based	0	O
on	0	O
16S	0	B
rRNA	1	I
gene	0	I
sequence	0	I
analysis	0	O
,	0	O
the	0	O
11	0	O
species	0	O
having	0	O
two	0	O
tuf	0	B
genes	0	I
all	0	O
have	0	O
a	0	O
common	0	O
ancestor	0	O
,	0	O
while	0	O
the	0	O
six	0	O
species	0	O
having	0	O
only	0	O
one	0	O
copy	0	O
diverged	0	O
from	0	O
the	0	O
enterococcal	0	O
lineage	0	O
before	0	O
that	0	O
common	0	O
ancestor	0	O
.	0	O


To	1	O
examine	0	O
whether	0	O
thiamine	0	O
(	0	O
vitamin	0	O
B1	0	O
)	0	O
deficiency	0	O
is	0	O
associated	0	O
with	0	O
recurrent	0	O
aphthous	0	O
stomatitis	0	O
,	0	O
we	0	O
studied	0	O
vitamin	0	O
B1	0	O
levels	0	O
in	0	O
70	0	O
patients	0	O
with	0	O
recurrent	0	O
aphthous	0	O
stomatitis	0	O
and	0	O
in	0	O
50	0	O
members	0	O
of	0	O
a	0	O
control	0	O
group	0	O
.	0	O


Like	0	O
DNA	1	O
binding	0	O
,	0	O
transcriptional	0	O
enhancement	0	O
required	0	O
amino	0	O
-	0	O
terminally	0	O
located	0	O
basic	0	O
amino	0	O
acid	0	O
residues	0	O
but	0	O
not	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
portion	0	O
of	0	O
Hap46	0	B
known	0	O
to	0	O
participate	0	O
in	0	O
hsp70	0	B
interaction	0	O
.	0	O


Titration	1	O
of	0	O
the	0	O
human	0	O
and	0	O
porcine	0	O
proteins	0	O
with	0	O
2	0	O
-	0	O
nitro	0	O
-	0	O
5	0	O
-	0	O
thiosulfabenzoate	0	O
indicates	0	O
that	0	O
membrane	0	B
dipeptidase	0	I
additionally	0	O
possesses	0	O
two	0	O
intrachain	0	O
disulfide	0	O
bonds	0	O
.	0	O


Pentazocine	1	O
analgesia	0	O
:	0	O
is	0	O
there	0	O
a	0	O
niche	0	O
for	0	O
Talwin	1	O
Nx	0	O
?	0	O
Pentazocine	1	O
can	0	O
be	0	O
a	0	O
useful	0	O
analgesic	0	O
agent	0	O
for	0	O
the	0	O
management	0	O
of	0	O
acute	0	O
dental	0	O
pain	0	O
.	0	O


This	0	O
enabled	0	O
the	0	O
formation	0	O
of	0	O
stem	0	O
-	0	O
loop	0	O
templates	0	O
with	0	O
the	0	O
fusion	0	O
point	0	O
of	0	O
the	0	O
chimeric	0	O
transcript	0	O
in	0	O
the	0	O
loop	0	O
and	0	O
the	0	O
use	0	O
of	0	O
MLL	1	B
primers	0	O
in	0	O
two	0	O
-	0	O
sided	0	O
PCR	1	O
.	0	O


What	0	O
young	0	O
people	0	O
think	0	O
and	0	O
do	0	O
when	0	O
the	0	O
option	0	O
for	0	O
cystic	0	O
fibrosis	0	O
carrier	0	O
testing	0	O
is	0	O
available	0	O
.	0	O


In	1	O
an	0	O
attempt	0	O
to	0	O
reduce	0	O
the	0	O
incidence	0	O
of	0	O
NSAID	1	O
-	0	O
induced	0	O
gastrointestinal	0	O
lesions	0	O
,	0	O
the	0	O
following	0	O
approaches	0	O
have	0	O
been	0	O
proposed	0	O
:	0	O
(	0	O
i	0	O
)	0	O
use	0	O
of	0	O
the	0	O
prostaglandin	0	O
analogue	0	O
misoprostol	0	O
,	0	O
which	0	O
is	0	O
an	0	O
antiulcer	0	O
drug	0	O
which	0	O
has	0	O
been	0	O
proven	0	O
to	0	O
be	0	O
as	0	O
effective	0	O
in	0	O
the	0	O
prevention	0	O
of	0	O
NSAID	1	O
-	0	O
induced	0	O
gastric	0	O
and	0	O
duodenal	0	O
ulcers	0	O
as	0	O
in	0	O
the	0	O
reduction	0	O
of	0	O
serious	0	O
upper	0	O
gastrointestinal	0	O
complications	0	O
;	0	O
(	0	O
ii	0	O
)	0	O
histamine	0	B
H2	0	I
receptor	0	I
antagonists	0	O
(	0	O
H2	0	O
antagonists	0	O
),	0	O
e	0	O
.	0	O
g	0	O
.	0	O
ranitidine	0	O
,	0	O
cimetidine	0	O
and	0	O
famotidine	0	O
,	0	O
which	0	O
are	0	O
useful	0	O
in	0	O
the	0	O
prevention	0	O
of	0	O
NSAID	1	O
-	0	O
induced	0	O
duodenal	0	O
ulcers	0	O
during	0	O
long	0	O
term	0	O
treatment	0	O
,	0	O
but	0	O
not	0	O
in	0	O
the	0	O
prevention	0	O
of	0	O
NSAID	1	O
-	0	O
induced	0	O
gastric	0	O
ulcers	0	O
;	0	O
(	0	O
iii	0	O
)	0	O
proton	0	O
pump	0	O
inhibitors	0	O
,	0	O
e	0	O
.	0	O
g	0	O
omeprazole	0	O
,	0	O
and	0	O
pantoprazole	0	O
,	0	O
whose	0	O
efficacy	0	O
in	0	O
preventing	0	O
NSAID	1	O
-	0	O
associated	0	O
ulcers	0	O
has	0	O
been	0	O
recently	0	O
demonstrated	0	O
;	0	O
and	0	O
(	0	O
iv	0	O
)	0	O
barrier	0	O
agents	0	O
,	0	O
e	0	O
.	0	O
g	0	O
.	0	O
sucralfate	0	O
,	0	O
which	0	O
cannot	0	O
be	0	O
recommended	0	O
as	0	O
prophylactic	0	O
agents	0	O
to	0	O
prevent	0	O
NSAID	1	O
-	0	O
induced	0	O
gastropathy	0	O
.	0	O


A	1	O
comparison	0	O
of	0	O
the	0	O
Flavobacterium	1	O
glycosylasparaginase	0	B
with	0	O
a	0	O
mammalian	0	O
glycosylasparaginase	0	B
revealed	0	O
30	0	O
%	0	O
structural	0	O
identity	0	O
and	0	O
60	0	O
%	0	O
overall	0	O
similarity	0	O
between	0	O
the	0	O
prokaryotic	0	O
and	0	O
eukaryotic	0	O
forms	0	O
of	0	O
the	0	O
enzyme	0	O
.	0	O


This	0	O
element	0	O
,	0	O
termed	0	O
CREsp	0	O
-	0	O
a	0	O
(	0	O
TGACCTCA	0	O
),	0	O
differs	0	O
by	0	O
one	0	O
nucleotide	0	O
from	0	O
a	0	O
palindromic	0	O
CRE	0	O
(	0	O
CREpal	0	O
,	0	O
TGACGTCA	0	O
),	0	O
which	0	O
is	0	O
known	0	O
to	0	O
bind	0	O
CREB	0	B
as	0	O
a	0	O
homodimer	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
deletion	0	O
of	0	O
bcp	0	B
from	0	O
the	0	O
chromosome	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
gcv	0	B
-	0	O
lacZ	0	B
expression	0	O
.	0	O


Increases	0	O
in	0	O
the	0	O
perfusate	0	O
PCO2	1	O
but	0	O
not	0	O
in	0	O
the	0	O
perfusate	0	O
H	1	O
+	0	O
were	0	O
highly	0	O
correlated	0	O
with	0	O
decreases	0	O
in	0	O
both	0	O
myocardial	0	O
contractility	0	O
and	0	O
oxygen	0	O
consumption	0	O
(	0	O
r2	0	O
=	0	O
.	0	O
88	0	O
).	0	O


The	0	O
P	1	B
-	0	I
wr	0	I
and	0	O
P	1	B
-	0	I
rr	0	I
cDNA	1	I
sequences	0	I
are	0	O
very	0	O
similar	0	O
in	0	O
their	0	O
5	0	O
'	0	O
regions	0	O
.	0	O


A	1	O
chimeric	0	O
VP16	0	B
-	0	O
Tat	1	B
construct	0	O
containing	0	O
the	0	O
leucine	0	O
mutations	0	O
showed	0	O
no	0	O
increased	0	O
AP	1	B
-	0	I
1	0	I
responsiveness	0	O
in	0	O
comparison	0	O
with	0	O
that	0	O
of	0	O
the	0	O
VP16	0	B
activation	0	I
domain	0	I
alone	0	O
.	0	O


Activities	0	O
of	0	O
hepatic	0	O
cytochrome	0	B
P	1	I
-	0	I
450	0	I
-	0	O
dependent	0	O
metabolizing	0	O
enzymes	0	O
such	0	O
as	0	O
aminopyrine	0	B
-	0	I
and	0	I
TMO	0	I
N	1	I
-	0	I
demethylase	0	I
and	0	O
aniline	0	B
hydroxylase	0	I
activity	0	O
were	0	O
decreased	0	O
by	0	O
pretreatment	0	O
of	0	O
rats	0	O
with	0	O
cimetidine	0	O
,	0	O
whereas	0	O
in	0	O
the	0	O
rats	0	O
pretreated	0	O
with	0	O
ranitidine	0	O
,	0	O
these	0	O
enzyme	0	O
activities	0	O
were	0	O
not	0	O
changed	0	O
.	0	O


Chloroplast	1	B
mutator	0	I
(	0	O
chm	0	B
)	0	O
of	0	O
Arabidopsis	0	O
is	0	O
a	0	O
recessive	0	O
nuclear	0	O
mutation	0	O
that	0	O
causes	0	O
green	0	O
and	0	O
white	0	O
variegation	0	O
in	0	O
leaves	0	O
and	0	O
is	0	O
inherited	0	O
in	0	O
a	0	O
non	0	O
-	0	O
Mendelian	1	O
fashion	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
an	0	O
additional	0	O
sequence	0	O
of	0	O
nucleotides	0	O
145	0	O
-	0	O
165	0	O
from	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
RNA3	0	B
enhanced	0	O
template	0	O
recognition	0	O
by	0	O
RdRp	0	B
in	0	O
vitro	0	O
and	0	O
accumulation	0	O
of	0	O
RNA3	0	B
in	0	O
vivo	0	O
to	0	O
wild	0	O
-	0	O
type	0	O
levels	0	O
.	0	O


Linear	1	O
extrapolation	0	O
is	0	O
used	0	O
below	0	O
the	0	O
experimental	0	O
data	0	O
range	0	O
to	0	O
establish	0	O
an	0	O
upper	0	O
bound	0	O
on	0	O
carcinogenic	0	O
risk	0	O
at	0	O
low	0	O
doses	0	O
.	0	O


Distal	1	O
lower	0	O
motor	0	O
neuron	0	O
syndrome	0	O
with	0	O
high	0	O
-	0	O
titer	0	O
serum	0	B
IgM	1	I
anti	0	I
-	0	I
GM1	0	I
antibodies	0	I
:	0	O
improvement	0	O
following	0	O
immunotherapy	0	O
with	0	O
monthly	0	O
plasma	0	O
exchange	0	O
and	0	O
intravenous	0	O
cyclophosphamide	0	O
.	0	O


The	0	O
rrd1	0	B
,	0	I
2delta	0	I
mutant	0	I
was	0	O
partially	0	O
rescued	0	O
by	0	O
inactivation	0	O
of	0	O
HOG1	0	B
or	0	O
PBS2	0	B
,	0	O
suggesting	0	O
an	0	O
interaction	0	O
between	0	O
the	0	O
RRD	0	B
genes	0	I
and	0	O
the	0	O
Hog1p	0	B
signal	0	I
transduction	0	I
pathway	0	I
.	0	O


A	1	O
MEK	0	B
-	0	O
specific	0	O
inhibitor	0	O
(	0	O
PD098059	0	O
)	0	O
(	0	O
Dudley	0	O
,	0	O
D	1	O
.	0	O


In	1	O
situ	0	O
copper	0	O
-	0	O
phenanthroline	0	O
footprinting	0	O
of	0	O
individual	0	O
gel	0	O
shift	0	O
assembly	0	O
intermediates	0	O
shows	0	O
that	0	O
on	0	O
the	0	O
302	0	O
-	0	O
nucleotide	0	O
G4oric	0	O
,	0	O
the	0	O
first	0	O
two	0	O
SSB	0	B
tetramers	0	I
assemble	0	O
at	0	O
random	0	O
,	0	O
but	0	O
the	0	O
addition	0	O
of	0	O
more	0	O
SSB	0	B
tetramers	0	I
results	0	O
in	0	O
formation	0	O
of	0	O
a	0	O
unique	0	O
structure	0	O
.	0	O


The	0	O
novel	0	O
Notch	1	B
homologue	0	I
mouse	0	I
Notch	1	I
3	0	I
lacks	0	O
specific	0	O
epidermal	0	B
growth	0	I
factor	0	I
-	0	I
repeats	0	I
and	0	O
is	0	O
expressed	0	O
in	0	O
proliferating	0	O
neuroepithelium	0	O
.	0	O


Iodine	1	O
-	0	O
123	0	O
was	0	O
satisfactorily	0	O
imaged	0	O
only	0	O
with	0	O
the	0	O
MEC	0	O
and	0	O
pinhole	0	O
collimators	0	O
,	0	O
which	0	O
in	0	O
turn	0	O
yielded	0	O
MTF	0	O
values	0	O
comparable	0	O
to	0	O
those	0	O
measured	0	O
for	0	O
99mTc	0	O
.	0	O


A	1	O
diagnosis	0	O
of	0	O
IgA	1	B
lambda	0	I
multiple	0	O
myeloma	0	O
with	0	O
peritoneal	0	O
involvement	0	O
was	0	O
made	0	O
.	0	O


Primary	1	O
amenorrhoea	0	O
in	0	O
a	0	O
phenotypically	0	O
female	0	O
individual	0	O
with	0	O
a	0	O
karyotype	0	O
46	0	O
,	0	O
xy	0	O
and	0	O
bilateral	0	O
gonadoblastoma	0	O


Expression	1	O
of	0	O
a	0	O
hybrid	0	O
protein	0	O
containing	0	O
the	0	O
cytoplasmic	0	O
C	1	O
-	0	O
terminal	0	O
half	0	O
of	0	O
UhpB	0	B
fused	0	O
to	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
(	0	O
GST	0	B
)	0	O
also	0	O
interfered	0	O
with	0	O
Uhp	0	B
signaling	0	O
.	0	O


Patients	0	O
underwent	0	O
pretreatment	0	O
cystoscopy	0	O
and	0	O
detailed	0	O
tumor	0	O
mapping	0	O
,	0	O
and	0	O
were	0	O
treated	0	O
with	0	O
75	0	O
mg	0	O
.	0	O
/	0	O
m	0	O
.	0	O
2	0	O
cisplatin	0	O
on	0	O
day	0	O
1	0	O
and	0	O
1	0	O
gm	0	O
./	0	O
m	0	O
.	0	O
2	0	O
daily	0	O
,	0	O
5	0	O
-	0	O
fluorouracil	0	O
on	0	O
days	0	O
1	0	O
to	0	O
4	0	O
and	0	O
definitive	0	O
radiotherapy	0	O
.	0	O


Likewise	0	O
,	0	O
rad6	0	B
-	0	I
delta	0	I
reduces	0	O
silencing	0	O
of	0	O
the	0	O
telomere	0	B
-	0	I
located	0	I
RNAP	0	I
II	0	I
-	0	I
transcribed	0	I
genes	0	I
URA3	0	I
and	0	O
ADE2	0	B
.	0	O


The	0	O
extent	0	O
of	0	O
the	0	O
fbpA	0	O
operator	0	O
sequence	0	O
(	0	O
42	0	O
bp	0	O
),	0	O
as	0	O
defined	0	O
by	0	O
our	0	O
footprinting	0	O
analysis	0	O
,	0	O
would	0	O
suggest	0	O
the	0	O
binding	0	O
of	0	O
two	0	O
Fur	0	B
repressor	0	I
dimers	0	I
.	0	O


For	0	O
the	0	O
first	0	O
group	0	O
,	0	O
the	0	O
maximal	0	O
decrease	0	O
in	0	O
plasma	0	O
potassium	0	O
elicited	0	O
by	0	O
salbutamol	0	O
was	0	O
0	0	O
.	0	O
80	0	O
+/-	0	O
0	0	O
.	0	O
19	0	O
,	0	O
0	0	O
.	0	O
48	0	O
+/-	0	O
0	0	O
.	0	O
22	0	O
,	0	O
and	0	O
0	0	O
.	0	O
78	0	O
+/-	0	O
0	0	O
.	0	O
46	0	O
mmol	0	O
/	0	O
l	0	O
,	0	O
and	0	O
for	0	O
the	0	O
second	0	O
group	0	O
,	0	O
maximal	0	O
decrement	0	O
was	0	O
1	0	O
.	0	O
31	0	O
+/-	0	O
0	0	O
.	0	O
37	0	O
,	0	O
0	0	O
.	0	O
70	0	O
+/-	0	O
0	0	O
.	0	O
24	0	O
,	0	O
and	0	O
0	0	O
.	0	O
84	0	O
+/-	0	O
0	0	O
.	0	O
17	0	O
mmol	0	O
/	0	O
l	0	O
for	0	O
the	0	O
iv	0	O
,	0	O
po	0	O
,	0	O
and	0	O
it	0	O
routes	0	O
,	0	O
respectively	0	O
.	0	O


Chronic	1	O
endotoxemia	0	O
appears	0	O
to	0	O
be	0	O
associated	0	O
with	0	O
an	0	O
elevated	0	O
pulmonary	0	O
microvascular	0	O
permeability	0	O
and	0	O
a	0	O
tendency	0	O
toward	0	O
a	0	O
hyperdynamic	0	O
circulation	0	O
but	0	O
with	0	O
an	0	O
appreciable	0	O
degree	0	O
of	0	O
refractoriness	0	O
associated	0	O
with	0	O
regional	0	O
hemodynamics	0	O
and	0	O
eicosanoid	0	O
biosynthesis	0	O
.	0	O


The	0	O
serine	0	B
-	0	I
threonine	0	I
kinase	0	I
gene	0	I
is	0	O
likely	0	O
functional	0	O
,	0	O
whereas	0	O
the	0	O
zinc	0	O
finger	0	O
motif	0	O
is	0	O
likely	0	O
nonfunctional	0	O
.	0	O


The	0	O
DSF	0	O
regimen	0	O
appears	0	O
to	0	O
have	0	O
significant	0	O
activity	0	O
in	0	O
patients	0	O
who	0	O
have	0	O
metastatic	0	O
pancreatic	0	O
islet	0	O
-	0	O
cell	0	O
carcinoma	0	O
,	0	O
and	0	O
patient	0	O
tolerance	0	O
of	0	O
the	0	O
regimen	0	O
is	0	O
excellent	0	O
,	0	O
thus	0	O
warranting	0	O
further	0	O
investigation	0	O
.	0	O


Northern	0	O
blot	0	O
analysis	0	O
of	0	O
total	0	O
cellular	0	O
RNA	1	O
indicated	0	O
that	0	O
xylP	0	B
encodes	0	O
a	0	O
1	0	O
.	0	O
3	0	O
-	0	O
kb	0	O
transcript	0	O
which	0	O
is	0	O
induced	0	O
by	0	O
xylan	0	O
.	0	O


We	0	O
present	0	O
a	0	O
case	0	O
of	0	O
carcinoma	0	O
of	0	O
the	0	O
breast	0	O
presenting	0	O
concurrently	0	O
with	0	O
SSc	0	O
that	0	O
subsequently	0	O
progressed	0	O
to	0	O
dialysis	0	O
-	0	O
dependent	0	O
renal	0	O
failure	0	O
in	0	O
just	0	O
1	0	O
month	0	O
.	0	O


Female	1	O
Wistar	0	O
rats	0	O
were	0	O
fed	0	O
a	0	O
liquid	0	O
diet	0	O
,	0	O
Sustacal	0	O
,	0	O
which	0	O
contained	0	O
ethanol	0	O
(	0	O
40	0	O
%	0	O
of	0	O
calories	0	O
)	0	O
or	0	O
isocaloric	0	O
sucrose	0	O
.	0	O


Computer	0	O
software	0	O
assisted	0	O
ordering	0	O
(	0	O
CSAO	0	O
)	0	O
was	0	O
developed	0	O
to	0	O
integrate	0	O
PN	0	O
Ca	1	O
:	0	O
P	1	O
solubility	0	O
with	0	O
clinical	0	O
data	0	O
to	0	O
improve	0	O
parenteral	0	O
Ca	1	O
and	0	O
P	1	O
administration	0	O
.	0	O


Toxicity	1	O
was	0	O
mild	0	O
,	0	O
mainly	0	O
consisting	0	O
of	0	O
emesis	0	O
(	0	O
81	0	O
%	0	O
of	0	O
the	0	O
patients	0	O
;	0	O
66	0	O
%	0	O
of	0	O
the	0	O
courses	0	O
),	0	O
leukopenia	0	O
of	0	O
World	0	O
Health	1	O
Organization	1	O
(	0	O
WHO	1	O
)	0	O
grade	0	O
1	0	O
to	0	O
2	0	O
(	0	O
47	0	O
%	0	O
of	0	O
the	0	O
patients	0	O
;	0	O
18	0	O
%	0	O
of	0	O
the	0	O
courses	0	O
),	0	O
and	0	O
thrombocytopenia	0	O
(	0	O
12	0	O
%	0	O
of	0	O
the	0	O
patients	0	O
;	0	O
3	0	O
%	0	O
of	0	O
the	0	O
courses	0	O
).	0	O


A	1	O
study	0	O
was	0	O
conducted	0	O
of	0	O
a	0	O
human	0	O
male	0	O
who	0	O
had	0	O
inhaled	0	O
a	0	O
mixture	0	O
of	0	O
241Am	0	O
and	0	O
Pu	1	O
.	0	O


Resistance	1	O
pattern	0	O
of	0	O
Mycobacterium	1	O
tuberculosis	0	O
(	0	O
H	1	O
37	0	O
Rv	1	O
)	0	O
to	0	O
a	0	O
new	0	O
antibiotic	0	O
,	0	O
lividomycin	0	O


Here	0	O
,	0	O
the	0	O
cloning	0	O
and	0	O
characterization	0	O
of	0	O
S	1	B
-	0	I
RNase	1	I
genes	0	I
from	0	O
two	0	O
species	0	O
of	0	O
Rosaceae	1	O
,	0	O
apple	0	O
(	0	O
Malus	1	O
x	0	O
domestica	0	O
)	0	O
and	0	O
Japanese	0	O
pear	0	O
(	0	O
Pyrus	0	O
serotina	0	O
)	0	O
is	0	O
described	0	O
and	0	O
these	0	O
sequences	0	O
are	0	O
compared	0	O
with	0	O
those	0	O
of	0	O
other	0	O
T2	0	B
-	0	I
type	0	I
RNases	0	I
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
indoramin	0	O
may	0	O
have	0	O
Class	1	O
III	0	O
antiarrhythmic	0	O
activity	0	O
.	0	O


Its	0	O
clearance	0	O
has	0	O
been	0	O
found	0	O
to	0	O
be	0	O
decreased	0	O
(	0	O
typically	0	O
by	0	O
around	0	O
25	0	O
%,	0	O
but	0	O
often	0	O
by	0	O
far	0	O
more	0	O
)	0	O
by	0	O
erythromycin	0	O
,	0	O
troleandomycin	0	O
(	0	O
triacetyloleandomycin	0	O
),	0	O
roxithromycin	0	O
,	0	O
enoxacin	0	O
,	0	O
ciprofloxacin	0	O
,	0	O
pefloxacin	0	O
,	0	O
norfloxacin	0	O
,	0	O
ofloxacin	0	O
,	0	O
fluoroquinolone	0	O
T	1	O
-	0	O
3262	0	O
,	0	O
pipemidic	0	O
acid	0	O
,	0	O
cimetidine	0	O
,	0	O
etintidine	0	O
,	0	O
propranolol	0	O
,	0	O
verapamil	0	O
,	0	O
diltiazem	0	O
,	0	O
nifedipine	0	O
,	0	O
furosemide	0	O
(	0	O
frusemide	0	O
),	0	O
at	0	O
least	0	O
some	0	O
anovulent	0	O
agents	0	O
,	0	O
viloxazine	0	O
,	0	O
allopurinol	0	O
,	0	O
ticlopidine	0	O
,	0	O
idrocilamide	0	O
,	0	O
thiabendazole	0	O
,	0	O
disulfiram	0	O
,	0	O
influenza	0	O
-	0	O
and	0	O
BCG	1	O
-	0	O
vaccination	0	O
,	0	O
interferon	0	B
,	0	O
and	0	O
caffeine	0	O
(	0	O
half	0	O
-	0	O
life	0	O
increase	0	O
).	0	O


Phosphoamino	0	O
acid	0	O
analysis	0	O
of	0	O
radiolabeled	0	O
ASGPR	0	B
subunits	0	I
identified	0	O
Ser	1	O
(	0	O
P	1	O
)	0	O
as	0	O
the	0	O
predominant	0	O
(	0	O
approximately	0	O
95	0	O
%)	0	O
and	0	O
Thr	1	O
(	0	O
P	1	O
)	0	O
as	0	O
a	0	O
minor	0	O
(	0	O
approximately	0	O
5	0	O
%)	0	O
phosphoamino	0	O
acid	0	O
in	0	O
each	0	O
polypeptide	0	O
and	0	O
confirmed	0	O
the	0	O
presence	0	O
of	0	O
Tyr	1	O
(	0	O
P	1	O
)	0	O
(	0	O
approximately	0	O
1	0	O
%)	0	O
in	0	O
RHL1	0	B
.	0	O


The	0	O
enteric	0	O
route	0	O
is	0	O
the	0	O
principal	0	O
mode	0	O
of	0	O
transmission	0	O
for	0	O
hepatitis	0	O
A	1	O
,	0	O
but	0	O
maximal	0	O
levels	0	O
of	0	O
hepatitis	0	O
A	1	O
virus	0	O
excretion	0	O
occur	0	O
before	0	O
the	0	O
onset	0	O
of	0	O
jaundice	0	O
.	0	O


Managing	0	O
dysphagia	0	O
in	0	O
a	0	O
chronic	0	O
care	0	O
setting	0	O
:	0	O
an	0	O
introduction	0	O
.	0	O


The	0	O
mean	0	O
(+/-	0	O
sd	0	O
)	0	O
intra	0	O
-	0	O
vesicular	0	O
pressure	0	O
(	0	O
IVP	1	O
)	0	O
and	0	O
maximal	0	O
urethral	0	O
closure	0	O
pressures	0	O
(	0	O
MUCP	0	O
)	0	O
were	0	O
10	0	O
.	0	O
3	0	O
(+/-	0	O
1	0	O
.	0	O
7	0	O
)	0	O
and	0	O
129	0	O
.	0	O
8	0	O
(+/-	0	O
19	0	O
.	0	O
6	0	O
)	0	O
cmH2O	0	O
,	0	O
respectively	0	O
,	0	O
and	0	O
the	0	O
ratio	0	O
between	0	O
MUCP	0	O
and	0	O
IVP	1	O
was	0	O
13	0	O
.	0	O
2	0	O
(+/-	0	O
2	0	O
.	0	O
5	0	O
).	0	O


A	1	O
retrospective	0	O
epidemiological	0	O
study	0	O
is	0	O
reported	0	O
concerning	0	O
burn	0	O
injuries	0	O
in	0	O
775	0	O
children	0	O
hospitalized	0	O
at	0	O
the	0	O
unit	0	O
of	0	O
burn	0	O
care	0	O
of	0	O
Casablanca	0	O
between	0	O
1985	0	O
and	0	O
1993	0	O
.	0	O


Effects	0	O
of	0	O
dioxins	0	O
on	0	O
thyroid	0	O
function	0	O
in	0	O
newborn	0	O
babies	0	O
.	0	O


Only	0	O
one	0	O
gene	0	O
,	0	O
fibronectin	0	B
(	0	O
FN	0	B
),	0	O
was	0	O
highly	0	O
overexpressed	0	O
(>	0	O
60	0	O
-	0	O
fold	0	O
)	0	O
in	0	O
LNCaP	0	O
-	0	O
r	0	O
cells	0	O
,	0	O
consistent	0	O
with	0	O
previously	0	O
reported	0	O
overexpression	0	O
of	0	O
FN	0	B
in	0	O
prostate	0	O
cancer	0	O
.	0	O


The	0	O
initial	0	O
patients	0	O
treated	0	O
with	0	O
AZQ	1	O
and	0	O
mitroxantrone	0	O
experienced	0	O
prolonged	0	O
bone	0	O
marrow	0	O
suppression	0	O
and	0	O
,	0	O
therefore	0	O
,	0	O
subsequent	0	O
cohorts	0	O
were	0	O
treated	0	O
with	0	O
G	1	B
-	0	I
CSF	1	I
,	0	O
5	0	O
micrograms	0	O
/	0	O
kg	0	O
,	0	O
beginning	0	O
the	0	O
day	0	O
after	0	O
completion	0	O
of	0	O
the	0	O
third	0	O
cycle	0	O
of	0	O
chemotherapy	0	O
.	0	O


Thus	0	O
,	0	O
Hex	0	B
expression	0	O
marks	0	O
the	0	O
earliest	0	O
unequivocal	0	O
molecular	0	O
anteroposterior	0	O
asymmetry	0	O
in	0	O
the	0	O
mouse	0	O
embryo	0	O
and	0	O
indicates	0	O
that	0	O
the	0	O
anteroposterior	0	O
axis	0	O
of	0	O
the	0	O
embryo	0	O
develops	0	O
from	0	O
conversion	0	O
of	0	O
a	0	O
proximodistal	0	O
asymmetry	0	O
established	0	O
in	0	O
the	0	O
primitive	0	O
endoderm	0	O
lineage	0	O
.	0	O


Consistent	0	O
with	0	O
effects	0	O
on	0	O
STAT	1	B
activation	0	O
,	0	O
altered	0	O
SHP	0	B
-	0	I
1	0	I
expression	0	O
also	0	O
affected	0	O
EGF	1	B
-	0	O
induced	0	O
activation	0	O
of	0	O
the	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
pathway	0	O
;	0	O
expression	0	O
of	0	O
SHP	0	B
-	0	I
1	0	I
-(	0	I
Cys	1	I
-->	0	I
Ser	1	I
)	0	I
inhibited	0	O
activity	0	O
of	0	O
MEK	0	B
by	0	O
approximately	0	O
25	0	O
%,	0	O
whereas	0	O
expression	0	O
of	0	O
SHP	0	B
-	0	I
1	0	I
resulted	0	O
in	0	O
a	0	O
approximately	0	O
25	0	O
%	0	O
increase	0	O
.	0	O


The	0	O
data	0	O
suggest	0	O
that	0	O
like	0	O
in	0	O
yeast	0	O
,	0	O
in	0	O
plants	0	O
a	0	O
certain	0	O
subfamily	0	O
of	0	O
UBC	0	B
is	0	O
specifically	0	O
involved	0	O
in	0	O
the	0	O
proteolytic	0	O
degradation	0	O
of	0	O
abnormal	0	O
proteins	0	O
as	0	O
result	0	O
of	0	O
stress	0	O
.	0	O


N	1	O
-	0	O
terminal	0	O
sequence	0	O
analysis	0	O
and	0	O
NMR	1	O
measurements	0	O
revealed	0	O
that	0	O
this	0	O
fragment	0	O
originates	0	O
from	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
80	0	O
residues	0	O
of	0	O
MBF1	0	B
and	0	O
form	0	O
a	0	O
well	0	O
structured	0	O
C	1	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
MBF1	0	B
,	0	O
MBF1CTD	0	B
.	0	O


Transient	1	O
transfection	0	O
analysis	0	O
with	0	O
these	0	O
mutations	0	O
revealed	0	O
that	0	O
only	0	O
a	0	O
10	0	O
-	0	O
bp	0	O
region	0	O
,	0	O
containing	0	O
precisely	0	O
the	0	O
Ets	1	B
and	0	O
proximal	0	O
LyF	0	B
-	0	I
1	0	I
binding	0	I
sites	0	I
,	0	O
was	0	O
needed	0	O
for	0	O
D	1	O
'	0	O
activity	0	O
.	0	O


axl	0	O
,	0	O
a	0	O
transforming	0	O
gene	0	O
isolated	0	O
from	0	O
primary	0	O
human	0	O
myeloid	0	O
leukemia	0	O
cells	0	O
,	0	O
encodes	0	O
a	0	O
novel	0	O
receptor	0	B
tyrosine	0	I
kinase	0	I
.	0	O


When	0	O
extracorporeal	0	O
CO2	1	O
removal	0	O
approximated	0	O
CO2	1	O
production	0	O
(	0	O
VCO2	0	O
),	0	O
alveolar	0	O
ventilation	0	O
almost	0	O
ceased	0	O
.	0	O


Significance	0	O
of	0	O
cytokine	0	O
production	0	O
and	0	O
adhesion	0	O
molecules	0	O
in	0	O
malarial	0	O
immunopathology	0	O
.	0	O


These	0	O
equilibrium	0	O
solutions	0	O
are	0	O
then	0	O
shown	0	O
to	0	O
arise	0	O
from	0	O
the	0	O
vertices	0	O
of	0	O
a	0	O
particular	0	O
convex	0	O
polyhedron	0	O
.	0	O


We	0	O
report	0	O
a	0	O
prevalence	0	O
study	0	O
of	0	O
the	0	O
best	0	O
visual	0	O
acuity	0	O
in	0	O
the	0	O
affected	0	O
eye	0	O
of	0	O
100	0	O
selected	0	O
patients	0	O
with	0	O
herpetic	0	O
keratitis	0	O
seen	0	O
during	0	O
a	0	O
two	0	O
-	0	O
year	0	O
period	0	O
.	0	O


An	1	O
unexpected	0	O
finding	0	O
was	0	O
the	0	O
presence	0	O
at	0	O
position	0	O
-	0	O
403	0	O
to	0	O
-	0	O
385	0	O
of	0	O
a	0	O
putative	0	O
dioxin	0	O
responsive	0	O
element	0	O
,	0	O
a	0	O
sequence	0	O
found	0	O
to	0	O
be	0	O
responsible	0	O
for	0	O
the	0	O
induction	0	O
of	0	O
transcription	0	O
of	0	O
the	0	O
cytochrome	0	B
P450IA1	0	I
gene	0	I
(	0	O
CYPIA1	0	B
)	0	O
and	0	O
other	0	O
genes	0	O
involved	0	O
in	0	O
detoxification	0	O
/	0	O
activation	0	O
of	0	O
polycyclic	0	O
aromatic	0	O
hydrocarbons	0	O
.	0	O


All	1	O
ABFI	0	B
-	0	I
binding	0	I
sites	0	I
,	0	O
regardless	0	O
of	0	O
origin	0	O
,	0	O
provided	0	O
weak	0	O
UAS	0	O
function	0	O
in	0	O
vivo	0	O
when	0	O
examined	0	O
in	0	O
test	0	O
plasmids	0	O
.	0	O


Histopathologic	0	O
observations	0	O
showed	0	O
that	0	O
both	0	O
somatostatin	0	B
and	0	O
triamcinolone	0	O
acetonide	0	O
reduced	0	O
the	0	O
inflammatory	0	O
signs	0	O
in	0	O
the	0	O
joint	0	O
structures	0	O
,	0	O
although	0	O
triamcinolone	0	O
acetonide	0	O
appeared	0	O
to	0	O
be	0	O
more	0	O
effective	0	O
.	0	O


4	0	O
.	0	O


The	0	O
conserved	0	O
ninth	0	O
C	1	O
-	0	O
terminal	0	O
heptad	0	O
in	0	O
thyroid	0	O
hormone	0	O
and	0	O
retinoic	0	B
acid	0	I
receptors	0	I
mediates	0	O
diverse	0	O
responses	0	O
by	0	O
affecting	0	O
heterodimer	0	O
but	0	O
not	0	O
homodimer	0	O
formation	0	O
.	0	O


Whereas	0	O
both	0	O
MAP	1	O
and	0	O
MSNA	0	O
increase	0	O
during	0	O
SHG	0	O
,	0	O
the	0	O
transition	0	O
from	0	O
SHG	0	O
to	0	O
PHI	1	O
is	0	O
characterized	0	O
by	0	O
a	0	O
transient	0	O
reduction	0	O
in	0	O
MAP	1	O
but	0	O
sustained	0	O
elevation	0	O
in	0	O
MSNA	0	O
,	0	O
facilitating	0	O
separation	0	O
of	0	O
these	0	O
factors	0	O
in	0	O
vivo	0	O
.	0	O


Basal	1	O
components	0	O
of	0	O
the	0	O
transcription	0	O
apparatus	0	O
(	0	O
RNA	1	B
polymerase	0	I
II	0	I
,	0	O
TATA	0	B
-	0	I
binding	0	I
protein	0	I
)	0	O
contain	0	O
activation	0	O
domains	0	O
:	0	O
is	0	O
the	0	O
repetitive	0	O
C	1	O
-	0	O
terminal	0	O
domain	0	O
(	0	O
CTD	1	O
)	0	O
of	0	O
RNA	1	B
polymerase	0	I
II	0	I
a	0	O
"	0	O
portable	0	O
enhancer	0	O
domain	0	O
"?	0	O
Regions	0	O
rich	0	O
in	0	O
serine	0	O
,	0	O
threonine	0	O
,	0	O
and	0	O
proline	0	O
residues	0	O
can	0	O
be	0	O
found	0	O
in	0	O
transcriptional	0	O
activation	0	O
domains	0	O
,	0	O
as	0	O
well	0	O
as	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
parts	0	O
of	0	O
mammalian	0	B
TATA	0	I
-	0	I
binding	0	I
proteins	0	I
,	0	O
where	0	O
they	0	O
are	0	O
interrupted	0	O
by	0	O
polyglutamine	0	O
stretches	0	O
.	0	O


Through	0	O
a	0	O
stretch	0	O
of	0	O
56	0	O
amino	0	O
acids	0	O
,	0	O
constituting	0	O
the	0	O
MADS	0	B
domain	0	I
,	0	O
the	0	O
two	0	O
proteins	0	O
are	0	O
identical	0	O
except	0	O
for	0	O
two	0	O
conservative	0	O
amino	0	O
acid	0	O
substitutions	0	O
.	0	O


Serum	1	O
lipids	0	O
and	0	O
lipoproteins	0	O
of	0	O
29	0	O
insulin	0	B
dependent	0	O
diabetic	0	O
children	0	O
have	0	O
been	0	O
determined	0	O
and	0	O
related	0	O
to	0	O
the	0	O
metabolic	0	O
status	0	O
of	0	O
the	0	O
patients	0	O
.	0	O


Since	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
this	0	O
gene	0	O
is	0	O
likely	0	O
involved	0	O
in	0	O
hormonal	0	O
regulation	0	O
of	0	O
its	0	O
expression	0	O
,	0	O
we	0	O
have	0	O
isolated	0	O
and	0	O
partially	0	O
characterized	0	O
an	0	O
avian	0	O
fatty	0	B
acid	0	I
synthase	0	I
gene	0	O
.	0	O


A	1	O
study	0	O
of	0	O
the	0	O
E	1	O
.	0	O
O	1	O
.	0	O
R	1	O
.	0	O
T	1	O
.	0	O
C	1	O
.	0	O


Mechanism	1	O
of	0	O
interferon	0	B
action	0	O
:	0	O
identification	0	O
of	0	O
essential	0	O
positions	0	O
within	0	O
the	0	O
novel	0	O
15	0	B
-	0	I
base	0	I
-	0	I
pair	0	I
KCS	0	I
element	0	I
required	0	O
for	0	O
transcriptional	0	O
activation	0	O
of	0	O
the	0	O
RNA	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
pkr	0	I
gene	0	I
.	0	O


DNA	1	O
methylation	0	O
,	0	O
especially	0	O
of	0	O
either	0	O
one	0	O
or	0	O
both	0	O
of	0	O
the	0	O
deoxyadenosines	0	O
at	0	O
the	0	O
two	0	O
GATC	0	O
motifs	0	O
(	0	O
one	0	O
in	0	O
the	0	O
first	0	O
exon	0	O
and	0	O
the	0	O
other	0	O
in	0	O
the	0	O
first	0	O
intron	0	O
of	0	O
the	0	O
rice	0	O
CatA	0	B
gene	0	I
),	0	O
appeared	0	O
to	0	O
be	0	O
responsible	0	O
for	0	O
the	0	O
CatA	0	B
promoter	0	I
activity	0	O
identified	0	O
in	0	O
the	0	O
transient	0	O
assay	0	O
.	0	O


After	0	O
a	0	O
survey	0	O
of	0	O
the	0	O
anatomical	0	O
and	0	O
physiological	0	O
basis	0	O
of	0	O
operative	0	O
treatment	0	O
of	0	O
behaviour	0	O
disorders	0	O
by	0	O
stereotactic	0	O
lesions	0	O
in	0	O
the	0	O
amygdala	0	O
and	0	O
the	0	O
posterior	0	O
medial	0	O
hypothalamus	0	O
the	0	O
author	0	O
describes	0	O
his	0	O
own	0	O
experiences	0	O
with	0	O
603	0	O
operations	0	O
for	0	O
control	0	O
of	0	O
conservatively	0	O
untreatable	0	O
aggressiveness	0	O
.	0	O


Analysis	1	O
of	0	O
Msy2	0	B
mRNA	1	I
expression	0	O
in	0	O
prepubertal	0	O
and	0	O
adult	0	O
mouse	0	O
testes	0	O
,	0	O
and	0	O
in	0	O
isolated	0	O
populations	0	O
of	0	O
germ	0	O
cells	0	O
,	0	O
reveals	0	O
maximal	0	O
expression	0	O
in	0	O
postmeiotic	0	O
round	0	O
spermatids	0	O
,	0	O
a	0	O
cell	0	O
type	0	O
with	0	O
abundant	0	O
amounts	0	O
of	0	O
stored	0	O
messenger	0	O
ribonucleoproteins	0	O
.	0	O


METHOD	1	O
:	0	O
50	0	O
consecutive	0	O
children	0	O
aged	0	O
from	0	O
6	0	O
months	0	O
to	0	O
17	0	O
years	0	O
were	0	O
included	0	O
into	0	O
the	0	O
study	0	O
which	0	O
comprised	0	O
questionnaires	0	O
of	0	O
patient	0	O
and	0	O
family	0	O
histories	0	O
,	0	O
serological	0	O
screening	0	O
tests	0	O
for	0	O
common	0	O
inhalational	0	O
allergens	0	O
(	0	O
CAP	1	O
SX1	0	O
),	0	O
and	0	O
determination	0	O
of	0	O
total	0	O
serum	0	B
immunoglobulin	0	I
E	1	I
(	0	O
IgE	1	B
)	0	O
and	0	O
of	0	O
latex	0	O
-	0	O
specific	0	O
serum	0	B
IgE	1	I
by	0	O
solid	0	O
-	0	O
phase	0	O
immunoassays	0	O
.	0	O


Following	1	O
the	0	O
satisfactory	0	O
results	0	O
and	0	O
taking	0	O
into	0	O
account	0	O
that	0	O
the	0	O
complications	0	O
had	0	O
reduced	0	O
to	0	O
a	0	O
very	0	O
low	0	O
rate	0	O
(	0	O
in	0	O
2	0	O
cases	0	O
lead	0	O
tip	0	O
displacement	0	O
and	0	O
pouch	0	O
haematoma	0	O
occurred	0	O
respectively	0	O
),	0	O
the	0	O
Authors	0	O
consider	0	O
the	0	O
adopted	0	O
method	0	O
an	0	O
useful	0	O
approach	0	O
for	0	O
PMK	0	O
implantation	0	O
particularly	0	O
when	0	O
the	0	O
use	0	O
of	0	O
the	0	O
vena	0	O
cephalica	0	O
is	0	O
deemed	0	O
impossible	0	O
.	0	O


In	1	O
experiment	0	O
2	0	O
the	0	O
rats	0	O
had	0	O
free	0	O
access	0	O
to	0	O
two	0	O
bottles	0	O
,	0	O
one	0	O
of	0	O
which	0	O
contained	0	O
tap	0	O
water	0	O
,	0	O
and	0	O
the	0	O
other	0	O
contained	0	O
either	0	O
an	0	O
ethanol	0	O
(	0	O
6	0	O
%)	0	O
or	0	O
a	0	O
sucrose	0	O
(	0	O
5	0	O
%)	0	O
solution	0	O
.	0	O


At	1	O
least	0	O
one	0	O
clone	0	O
,	0	O
lambda	0	O
HHG	0	O
41	0	O
,	0	O
contains	0	O
,	0	O
in	0	O
addition	0	O
to	0	O
the	0	O
histone	0	B
genes	0	I
,	0	O
a	0	O
region	0	O
that	0	O
hybridizes	0	O
with	0	O
a	0	O
cytoplasmic	0	O
RNA	1	O
approximately	0	O
330	0	O
nucleotides	0	O
in	0	O
length	0	O
.	0	O


In	1	O
an	0	O
attempt	0	O
to	0	O
investigate	0	O
whether	0	O
the	0	O
intergenic	0	O
region	0	O
between	0	O
the	0	O
oleosin	0	B
and	0	O
a	0	O
second	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
ORFII	0	O
)	0	O
in	0	O
Brassica	1	O
napus	0	O
(	0	O
L	1	O
.)	0	O
is	0	O
a	0	O
divergent	0	O
promoter	0	O
,	0	O
and	0	O
also	0	O
to	0	O
characterize	0	O
the	0	O
ORFII	0	B
,	0	O
cDNA	1	B
clones	0	I
homologous	0	I
to	0	I
ORFII	0	I
were	0	O
isolated	0	O
from	0	O
a	0	O
leaf	0	O
cDNA	1	O
library	0	O
.	0	O


The	0	O
VirR	0	B
response	0	I
regulator	0	I
from	0	O
Clostridium	1	O
perfringens	0	O
binds	0	O
independently	0	O
to	0	O
two	0	O
imperfect	0	O
direct	0	O
repeats	0	O
located	0	O
upstream	0	O
of	0	O
the	0	O
pfoA	0	B
promoter	0	I
.	0	O


This	0	O
site	0	O
acts	0	O
as	0	O
a	0	O
negative	0	O
element	0	O
when	0	O
transferred	0	O
to	0	O
the	0	O
thymidine	0	B
kinase	0	I
promoter	0	I
,	0	O
but	0	O
does	0	O
not	0	O
confer	0	O
inducibility	0	O
.	0	O


In	1	O
earlier	0	O
studies	0	O
we	0	O
identified	0	O
several	0	O
regulatory	0	O
elements	0	O
that	0	O
control	0	O
transcriptional	0	O
activation	0	O
and	0	O
aerobic	0	O
repression	0	O
of	0	O
one	0	O
of	0	O
these	0	O
genes	0	O
,	0	O
COX5b	0	B
.	0	O


In	1	O
64	0	O
%	0	O
a	0	O
small	0	O
cardiac	0	O
vein	0	O
does	0	O
not	0	O
exist	0	O
,	0	O
but	0	O
its	0	O
origin	0	O
,	0	O
the	0	O
right	0	O
marginal	0	O
vein	0	O
,	0	O
joins	0	O
the	0	O
system	0	O
of	0	O
anterior	0	O
cardiac	0	O
veins	0	O
.	0	O


As	1	O
a	0	O
last	0	O
resort	0	O
,	0	O
it	0	O
may	0	O
be	0	O
possible	0	O
to	0	O
maintain	0	O
a	0	O
patient	0	O
on	0	O
dialysis	0	O
in	0	O
reasonable	0	O
health	0	O
with	0	O
a	0	O
DiaTAP	0	O
button	0	O
graft	0	O
complex	0	O
infected	0	O
with	0	O
Staphylococcus	1	O
epidermidis	0	O
and	0	O
intermittent	0	O
positive	0	O
blood	0	O
cultures	0	O
using	0	O
long	0	O
term	0	O
vancomycin	0	O
therapy	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
an	0	O
internal	0	O
short	0	O
element	0	O
located	0	O
at	0	O
the	0	O
very	0	O
5	0	O
'	0	O
terminal	0	O
of	0	O
L1	0	B
sequence	0	I
and	0	O
the	0	O
nuclear	0	O
factor	0	O
binding	0	O
to	0	O
the	0	O
element	0	O
play	0	O
a	0	O
crucial	0	O
role	0	O
in	0	O
the	0	O
transcription	0	O
of	0	O
human	0	B
L1	0	I
.	0	O


Recent	0	O
investigations	0	O
have	0	O
shown	0	O
that	0	O
Grenz	1	O
rays	0	O
can	0	O
suppress	0	O
the	0	O
allergic	0	O
contact	0	O
dermatitis	0	O
reaction	0	O
completely	0	O
and	0	O
that	0	O
Langerhans	0	O
cells	0	O
,	0	O
identified	0	O
by	0	O
OKT6	0	B
antibodies	0	I
and	0	O
electron	0	O
microscopy	0	O
,	0	O
disappear	0	O
from	0	O
the	0	O
epidermis	0	O
at	0	O
the	0	O
same	0	O
time	0	O
.	0	O


One	0	O
was	0	O
allowed	0	O
fresh	0	O
drinking	0	O
water	0	O
ad	0	O
libitum	0	O
whilst	0	O
the	0	O
other	0	O
received	0	O
Aludrox	1	O
in	0	O
their	0	O
drinking	0	O
water	0	O
.	0	O


The	0	O
effectiveness	0	O
of	0	O
NRT	0	O
appears	0	O
to	0	O
be	0	O
largely	0	O
independent	0	O
of	0	O
the	0	O
intensity	0	O
of	0	O
additional	0	O
support	0	O
provided	0	O
to	0	O
the	0	O
smoker	0	O
.	0	O


The	0	O
complete	0	O
response	0	O
(	0	O
CR	1	O
)	0	O
rate	0	O
was	0	O
34	0	O
%	0	O
in	0	O
the	0	O
CODE	1	O
with	0	O
rhG	0	B
-	0	I
CSF	1	I
group	0	O
and	0	O
23	0	O
%	0	O
in	0	O
the	0	O
CODE	1	O
alone	0	O
group	0	O
;	0	O
the	0	O
median	0	O
survival	0	O
was	0	O
59	0	O
and	0	O
32	0	O
weeks	0	O
,	0	O
respectively	0	O
,	0	O
in	0	O
these	0	O
groups	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
004	0	O
).	0	O


However	0	O
,	0	O
despite	0	O
its	0	O
relationship	0	O
to	0	O
the	0	O
TR	1	B
,	0	O
Rev	0	B
-	0	O
Erb	0	B
bound	0	O
poorly	0	O
to	0	O
TR	1	B
binding	0	I
sites	0	I
.	0	O


Mutation	1	O
of	0	O
either	0	O
the	0	O
AP	1	B
-	0	I
1	0	I
or	0	O
the	0	O
ets	0	B
component	0	O
of	0	O
this	0	O
site	0	O
also	0	O
prevented	0	O
promoter	0	O
activity	0	O
in	0	O
SMCs	0	O
.	0	O


Responsibility	1	O
matters	0	O
--	0	O
this	0	O
is	0	O
a	0	O
scientific	0	O
council	0	O


The	0	O
gene	0	O
pairs	0	O
psbB	0	B
-	0	O
psbT	0	B
and	0	O
psbH	0	B
-	0	O
psbN	0	B
are	0	O
cotranscribed	0	O
from	0	O
opposite	0	O
strands	0	O
.	0	O


Just	0	O
before	0	O
inserting	0	O
on	0	O
the	0	O
anterior	0	O
margin	0	O
and	0	O
apex	0	O
of	0	O
the	0	O
iliac	0	O
crest	0	O
it	0	O
widens	0	O
,	0	O
assuming	0	O
the	0	O
aspect	0	O
of	0	O
a	0	O
small	0	O
cone	0	O
.	0	O


The	0	O
hexanucleotide	0	O
5	0	O
'-	0	O
TGTCCT	0	O
-	0	O
3	0	O
',	0	O
thought	0	O
to	0	O
be	0	O
important	0	O
for	0	O
GRE	0	O
activity	0	O
,	0	O
not	0	O
only	0	O
was	0	O
found	0	O
in	0	O
this	0	O
sequence	0	O
and	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
,	0	O
but	0	O
also	0	O
was	0	O
present	0	O
twice	0	O
in	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
gene	0	O
that	0	O
did	0	O
not	0	O
show	0	O
specific	0	O
receptor	0	O
binding	0	O
.	0	O


Comparison	0	O
of	0	O
frequencies	0	O
of	0	O
atrial	0	O
fibrillation	0	O
after	0	O
coronary	0	O
artery	0	O
bypass	0	O
grafting	0	O
with	0	O
and	0	O
without	0	O
the	0	O
use	0	O
of	0	O
cardiopulmonary	0	O
bypass	0	O
.	0	O


In	1	O
fus3	0	B
mutants	0	I
,	0	O
the	0	O
levels	0	O
of	0	O
Ty1	0	B
RNA	1	I
,	0	O
protein	0	O
synthesis	0	O
,	0	O
and	0	O
proteolytic	0	O
processing	0	O
were	0	O
not	0	O
altered	0	O
relative	0	O
to	0	O
those	0	O
in	0	O
FUS3	0	B
strains	0	O
but	0	O
steady	0	O
-	0	O
state	0	O
levels	0	O
of	0	O
TyA	0	B
,	0	O
integrase	0	B
,	0	O
and	0	O
reverse	0	B
transcriptase	0	I
proteins	0	O
and	0	O
Ty1	0	B
cDNA	1	I
were	0	O
all	0	O
increased	0	O
.	0	O


The	0	O
development	0	O
and	0	O
histostructural	0	O
organization	0	O
of	0	O
intrahepatic	0	O
biliary	0	O
ducts	0	O
were	0	O
studied	0	O
on	0	O
a	0	O
human	0	O
embryofetal	0	O
material	0	O
6	0	O
to	0	O
32	0	O
weeks	0	O
old	0	O
.	0	O


1	0	O
.	0	O


Additionally	0	O
,	0	O
MIP	1	B
-	0	I
2A	0	I
antagonizes	0	O
cell	0	O
growth	0	O
regulatory	0	O
role	0	O
of	0	O
MBP	1	B
-	0	I
1	0	I
.	0	O


Pancreatic	1	O
and	0	O
biliary	0	O
secretion	0	O
and	0	O
gastric	0	O
emptying	0	O
rates	0	O
of	0	O
a	0	O
liquid	0	O
test	0	O
meal	0	O
(	0	O
LTM	0	O
)	0	O
were	0	O
determined	0	O
in	0	O
normal	0	O
persons	0	O
,	0	O
in	0	O
patients	0	O
with	0	O
subtotal	0	O
gastrectomy	0	O
with	0	O
gastroduodenostomy	0	O
(	0	O
STG	0	O
-	0	O
BI	1	O
)	0	O
or	0	O
with	0	O
gastrojejunostomy	0	O
(	0	O
STG	0	O
-	0	O
BII	0	O
),	0	O
and	0	O
in	0	O
patients	0	O
with	0	O
truncal	0	O
vagotomy	0	O
and	0	O
pyloroplasty	0	O
(	0	O
V	1	O
&	0	O
P	1	O
).	0	O


Molecular	1	O
characterization	0	O
of	0	O
type	0	O
-	0	O
specific	0	O
capsular	0	O
polysaccharide	0	O
biosynthesis	0	O
genes	0	O
of	0	O
Streptococcus	1	O
agalactiae	0	O
type	0	O
Ia	1	O
.	0	O


TG	1	O
-	0	O
day	0	O
and	0	O
TG	1	O
-	0	O
night	0	O
were	0	O
19	0	O
.	0	O
4	0	O
+/-	0	O
6	0	O
.	0	O
1	0	O
%,	0	O
26	0	O
.	0	O
6	0	O
+/-	0	O
5	0	O
.	0	O
3	0	O
%,	0	O
(	0	O
750	0	O
mm3	0	O
<	0	O
T	1	O
.	0	O


Partial	0	O
engorgement	0	O
was	0	O
higher	0	O
in	0	O
the	0	O
treatments	0	O
.	0	O


Estimated	0	O
nucleic	0	O
acid	0	O
N	1	O
absorption	0	O
is	0	O
7	0	O
-	0	O
8	0	O
%	0	O
of	0	O
N	1	O
intake	0	O
.	0	O


Therefore	0	O
,	0	O
the	0	O
strD	0	B
and	0	O
strE	0	B
genes	0	I
could	0	O
serve	0	O
as	0	O
universal	0	O
probes	0	O
indicative	0	O
of	0	O
the	0	O
presence	0	O
of	0	O
biosynthetic	0	O
capacity	0	O
for	0	O
6	0	O
-	0	O
deoxyhexose	0	O
moieties	0	O
.	0	O


Despite	0	O
resolution	0	O
of	0	O
the	0	O
solid	0	O
portion	0	O
of	0	O
the	0	O
tumor	0	O
,	0	O
serial	0	O
MRI	1	O
showed	0	O
enlargement	0	O
of	0	O
a	0	O
bilobar	0	O
tumor	0	O
cyst	0	O
3	0	O
years	0	O
after	0	O
the	0	O
original	0	O
diagnosis	0	O
.	0	O


Identical	1	O
components	0	O
of	0	O
yeast	0	O
transcription	0	B
factor	0	I
IIIB	0	I
are	0	O
required	0	O
and	0	O
sufficient	0	O
for	0	O
transcription	0	O
of	0	O
TATA	0	O
box	0	O
-	0	O
containing	0	O
and	0	O
TATA	0	O
-	0	O
less	0	O
genes	0	O
.	0	O


These	0	O
HPV16	0	O
E6	0	B
/	0	O
E7	0	B
cDNAs	0	O
were	0	O
cloned	0	O
under	0	O
the	0	O
SV40	1	B
enhancer	0	I
/	0	I
promoter	0	I
and	0	O
the	0	O
MMTV	0	B
LTR	1	I
to	0	O
examine	0	O
the	0	O
activities	0	O
of	0	O
ras	0	B
-	0	O
collaborative	0	O
transformation	0	O
and	0	O
induction	0	O
of	0	O
cellular	0	O
DNA	1	O
synthesis	0	O
,	0	O
both	0	O
of	0	O
which	0	O
depend	0	O
on	0	O
the	0	O
E7	0	B
gene	0	I
product	0	O
.	0	O


The	0	O
site	0	O
-	0	O
directed	0	O
mutation	0	O
of	0	O
the	0	O
kappa	0	B
B	1	I
motif	0	I
in	0	O
IL	1	B
-	0	I
6	0	I
/	0	O
CAT	1	B
plasmid	0	O
resulted	0	O
in	0	O
the	0	O
complete	0	O
abrogation	0	O
of	0	O
IL	1	B
-	0	I
6	0	I
promoter	0	I
activity	0	O
in	0	O
these	0	O
cells	0	O
.	0	O


The	0	O
carcinoma	0	O
was	0	O
restricted	0	O
within	0	O
the	0	O
epithelium	0	O
in	0	O
one	0	O
,	0	O
the	0	O
mucosal	0	O
layer	0	O
in	0	O
five	0	O
,	0	O
and	0	O
the	0	O
submucosal	0	O
layer	0	O
in	0	O
two	0	O
.	0	O


11	0	O
-	0	O
Aminoundecanoyl	0	O
-	0	O
SK	1	O
-	0	O
NH2	0	O
and	0	O
11	0	O
-	0	O
aminoundecanoyl	0	O
-	0	O
SH	1	O
-	0	O
NH2	0	O
establish	0	O
that	0	O
a	0	O
simple	0	O
alkyl	0	O
backbone	0	O
can	0	O
maintain	0	O
an	0	O
appropriate	0	O
distance	0	O
between	0	O
three	0	O
elements	0	O
critical	0	O
for	0	O
recognition	0	O
by	0	O
the	0	O
fungal	0	O
enzyme	0	O
'	0	O
s	0	O
peptide	0	O
-	0	O
binding	0	O
site	0	O
:	0	O
a	0	O
simple	0	O
omega	0	O
-	0	O
terminal	0	O
amino	0	O
group	0	O
,	0	O
a	0	O
beta	0	O
-	0	O
hydroxyl	0	O
,	0	O
and	0	O
an	0	O
epsilon	0	O
-	0	O
amino	0	O
group	0	O
or	0	O
an	0	O
imidazole	0	O
.	0	O


There	0	O
was	0	O
evidence	0	O
of	0	O
attenuated	0	O
regression	0	O
slopes	0	O
relating	0	O
recalled	0	O
to	0	O
observed	0	O
portion	0	O
sizes	0	O
for	0	O
4	0	O
of	0	O
the	0	O
10	0	O
food	0	O
groups	0	O
;	0	O
adjusted	0	O
r2	0	O
values	0	O
for	0	O
the	0	O
recalled	0	O
portion	0	O
sizes	0	O
ranged	0	O
from	0	O
0	0	O
.	0	O
02	0	O
to	0	O
0	0	O
.	0	O
94	0	O
.	0	O


Sequencing	1	O
revealed	0	O
one	0	O
large	0	O
open	0	O
reading	0	O
frame	0	O
encoding	0	O
a	0	O
39	0	O
-	0	O
kDa	1	O
protein	0	O
.	0	O


Inhibition	1	O
of	0	O
histalog	0	O
-	0	O
stimulated	0	O
gastric	0	O
secretion	0	O
by	0	O
40	0	O
749	0	O
RP	1	O
,	0	O
a	0	O
new	0	O
long	0	O
-	0	O
acting	0	O
gastric	0	O
antisecretory	0	O
agent	0	O
.	0	O


Mg	1	B
-	0	I
chelatase	0	I
of	0	O
tobacco	0	O
:	0	O
identification	0	O
of	0	O
a	0	O
Chl	1	B
D	1	I
cDNA	1	I
sequence	0	I
encoding	0	O
a	0	O
third	0	O
subunit	0	O
,	0	O
analysis	0	O
of	0	O
the	0	O
interaction	0	O
of	0	O
the	0	O
three	0	O
subunits	0	O
with	0	O
the	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
system	0	O
,	0	O
and	0	O
reconstitution	0	O
of	0	O
the	0	O
enzyme	0	O
activity	0	O
by	0	O
co	0	O
-	0	O
expression	0	O
of	0	O
recombinant	0	B
CHL	1	I
D	1	I
,	0	O
CHL	1	B
H	1	I
and	0	O
CHL	1	B
I	1	I
.	0	O


JNK	0	B
is	0	O
additionally	0	O
regulated	0	O
by	0	O
the	0	O
Ras	1	B
-	0	O
related	0	O
G	1	B
proteins	0	I
Rac	0	I
and	0	O
Cdc42	0	B
.	0	O


Another	0	O
element	0	O
necessary	0	O
for	0	O
augmenting	0	O
the	0	O
amplitude	0	O
of	0	O
the	0	O
oscillation	0	O
lies	0	O
between	0	O
-	0	O
178	0	O
and	0	O
-	0	O
264	0	O
.	0	O


We	0	O
have	0	O
previously	0	O
demonstrated	0	O
that	0	O
expression	0	O
of	0	O
the	0	O
gene	0	O
for	0	O
the	0	O
reproductive	0	O
neuropeptide	0	O
,	0	O
GnRH	0	B
,	0	O
is	0	O
repressed	0	O
by	0	O
the	0	O
glutamate	0	O
/	0	O
NO	1	O
/	0	O
cyclic	0	O
GMP	1	O
(	0	O
cGMP	1	O
)	0	O
signal	0	O
transduction	0	O
pathway	0	O
through	0	O
cGMP	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
in	0	O
the	0	O
hypothalamic	0	O
GnRH	0	B
-	0	O
secreting	0	O
neuronal	0	O
cell	0	O
line	0	O
GT1	0	O
-	0	O
7	0	O
.	0	O


Effect	1	O
of	0	O
acute	0	O
and	0	O
chronic	0	O
psychogenic	0	O
stress	0	O
on	0	O
corticoadrenal	0	O
and	0	O
pituitary	0	B
-	0	I
thyroid	0	I
hormones	0	I
in	0	O
male	0	O
rats	0	O
.	0	O


Additionally	0	O
,	0	O
a	0	O
variety	0	O
of	0	O
regulatory	0	O
schemes	0	O
contribute	0	O
temporal	0	O
and	0	O
/	0	O
or	0	O
spatial	0	O
restriction	0	O
to	0	O
TGF	1	B
-	0	I
beta	0	I
responses	0	O
.	0	O


This	0	O
is	0	O
the	0	O
first	0	O
determination	0	O
of	0	O
the	0	O
complete	0	O
secondary	0	O
structure	0	O
of	0	O
an	0	O
RNA	1	O
spliced	0	O
in	0	O
a	0	O
spliceosome	0	O
.	0	O


The	0	O
gene	0	O
encoding	0	O
the	0	O
receptor	0	O
for	0	O
macrophage	0	B
colony	0	I
-	0	I
stimulating	0	I
factor	0	I
1	0	I
(	0	O
CSF	1	B
-	0	I
1	0	I
),	0	O
the	0	O
c	0	B
-	0	I
fms	0	I
protooncogene	0	I
,	0	O
is	0	O
selectively	0	O
expressed	0	O
in	0	O
immature	0	O
and	0	O
mature	0	O
mononuclear	0	O
phagocytes	0	O
and	0	O
trophoblasts	0	O
.	0	O


These	0	O
"	0	O
nucleocapsid	0	O
-	0	O
like	0	O
"	0	O
structures	0	O
were	0	O
readily	0	O
purified	0	O
by	0	O
density	0	O
gradient	0	O
centrifugation	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Diazepam	1	O
,	0	O
one	0	O
of	0	O
the	0	O
benzodiazepine	0	O
group	0	O
of	0	O
tranquilizers	0	O
,	0	O
is	0	O
used	0	O
as	0	O
an	0	O
adjunctive	0	O
drug	0	O
for	0	O
sedation	0	O
and	0	O
for	0	O
relief	0	O
of	0	O
anxiety	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
epilepsy	0	O
.	0	O


We	0	O
also	0	O
mapped	0	O
a	0	O
3	0	O
'-	0	O
polyadenylation	0	O
site	0	O
504bp	0	O
downstream	0	O
of	0	O
the	0	O
TGA	0	O
stop	0	O
codon	0	O
,	0	O
consistent	0	O
with	0	O
the	0	O
2	0	O
.	0	O
5kb	0	O
transcript	0	O
size	0	O
.	0	O


Pseudomonas	1	B
aeruginosa	0	I
exotoxin	0	I
A	1	I
:	0	O
its	0	O
role	0	O
in	0	O
retardation	0	O
of	0	O
wound	0	O
healing	0	O
:	0	O
the	0	O
1992	0	O
Lindberg	0	O
Award	1	O
.	0	O


Clone	1	O
4c	0	O
(	0	O
2681	0	O
bp	0	O
)	0	O
had	0	O
a	0	O
coding	0	O
region	0	O
identical	0	O
to	0	O
that	0	O
of	0	O
clone	0	O
22c	0	O
but	0	O
it	0	O
included	0	O
a	0	O
putative	0	O
intron	0	O
of	0	O
959	0	O
bp	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
this	0	O
kinase	0	O
is	0	O
well	0	O
conserved	0	O
evolutionarily	0	O
,	0	O
ubiquitously	0	O
expressed	0	O
,	0	O
and	0	O
its	0	O
genes	0	O
map	0	O
to	0	O
a	0	O
position	0	O
on	0	O
human	0	O
chromosome	0	O
1	0	O
frequently	0	O
deleted	0	O
in	0	O
the	0	O
late	0	O
stages	0	O
of	0	O
tumorigenesis	0	O
.	0	O


Short	0	O
-	0	O
course	0	O
amphotericin	0	O
B	1	O
therapy	0	O
for	0	O
candidemia	0	O
in	0	O
pediatric	0	O
patients	0	O
.	0	O


Green	1	O
pepper	0	O
significantly	0	O
inhibited	0	O
N	1	O
-	0	O
nitrosothiazolidine	0	O
-	0	O
carboxylic	0	O
acid	0	O
formation	0	O
relative	0	O
to	0	O
ascorbic	0	O
acid	0	O
alone	0	O
.	0	O


However	0	O
,	0	O
the	0	O
action	0	O
of	0	O
each	0	O
cognate	0	O
ligand	0	O
and	0	O
the	0	O
accessory	0	O
cellular	0	O
factors	0	O
that	0	O
can	0	O
differentially	0	O
regulate	0	O
the	0	O
transcriptional	0	O
responses	0	O
of	0	O
a	0	O
heterodimer	0	O
-	0	O
DNA	1	O
complex	0	O
are	0	O
not	0	O
well	0	O
understood	0	O
.	0	O


BACKGROUND	0	O
:	0	O
To	1	O
determine	0	O
the	0	O
predictors	0	O
of	0	O
desipramine	0	O
-	0	O
refractory	0	O
depression	0	O
,	0	O
the	0	O
authors	0	O
examined	0	O
the	0	O
outcome	0	O
in	0	O
patients	0	O
with	0	O
major	0	O
depression	0	O
who	0	O
were	0	O
admitted	0	O
to	0	O
a	0	O
general	0	O
hospital	0	O
and	0	O
treated	0	O
with	0	O
desipramine	0	O
adjusted	0	O
to	0	O
an	0	O
adequate	0	O
blood	0	O
level	0	O
.	0	O


Man	1	O
and	0	O
insect	0	O
,	0	O
past	0	O
,	0	O
present	0	O
,	0	O
future	0	O


TaV	0	O
particles	0	O
have	0	O
a	0	O
buoyant	0	O
density	0	O
of	0	O
1	0	O
.	0	O
296	0	O
g	0	O
/	0	O
cm3	0	O
in	0	O
CsCl	0	O
and	0	O
consist	0	O
of	0	O
two	0	O
capsid	0	B
proteins	0	I
of	0	O
56	0	O
and	0	O
6	0	O
kDa	1	O
.	0	O


It	1	O
was	0	O
found	0	O
that	0	O
the	0	O
primary	0	O
visual	0	O
cortex	0	O
of	0	O
the	0	O
rat	0	O
is	0	O
asymmetrical	0	O
in	0	O
volume	0	O
,	0	O
and	0	O
that	0	O
the	0	O
asymmetry	0	O
reflects	0	O
side	0	O
differences	0	O
in	0	O
the	0	O
number	0	O
of	0	O
neurons	0	O
.	0	O


The	0	O
frequency	0	O
of	0	O
lactase	0	B
phenotypes	0	I
in	0	O
Aymara	0	O
children	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
plant	0	O
nuclear	0	O
tRNA	1	O
3	0	O
'	0	O
processing	0	O
enzyme	0	O
with	0	O
the	0	O
plant	0	O
mitochondrial	0	O
one	0	O
suggests	0	O
that	0	O
both	0	O
activities	0	O
are	0	O
different	0	O
enzymes	0	O
.	0	O


Plastic	1	O
solution	0	O
of	0	O
elbow	0	O
joint	0	O
ankylosis	0	O
with	0	O
a	0	O
decorticated	0	O
cylindrical	0	O
flap	0	O


RESULTS	0	O
:	0	O
Auditory	1	O
thresholds	0	O
collected	0	O
during	0	O
audiometric	0	O
tests	0	O
increased	0	O
gradually	0	O
in	0	O
proportion	0	O
with	0	O
age	0	O
,	0	O
especially	0	O
in	0	O
the	0	O
hypertensive	0	O
group	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Mapping	1	O
of	0	O
the	0	O
human	0	B
Voltage	1	I
-	0	I
Dependent	1	I
Anion	1	I
Channel	1	I
isoforms	0	I
1	0	I
and	0	I
2	0	I
reconsidered	0	O
.	0	O


In	1	O
particular	0	O
,	0	O
changes	0	O
in	0	O
intracellular	0	O
Ca2	1	O
+	0	O
have	0	O
the	0	O
potential	0	O
to	0	O
either	0	O
inhibit	0	O
or	0	O
augment	0	O
the	0	O
ability	0	O
of	0	O
cAMP	1	O
to	0	O
stimulate	0	O
transcription	0	O
,	0	O
depending	0	O
on	0	O
the	0	O
presence	0	O
of	0	O
specific	0	O
forms	0	O
of	0	O
Ca2	1	B
+/	0	I
calmodulin	0	I
-	0	I
dependent	0	I
protein	0	I
kinases	0	I
.	0	O


Clones	0	O
33F	0	O
and	0	O
34B	0	O
encoded	0	O
identical	0	O
aromatase	0	B
proteins	0	I
of	0	O
503	0	O
amino	0	O
acids	0	O
,	0	O
but	0	O
differed	0	O
in	0	O
size	0	O
due	0	O
to	0	O
alternative	0	O
polyadenylation	0	O
signal	0	O
usage	0	O
for	0	O
the	0	O
corresponding	0	O
mRNAs	0	O
.	0	O


Methysergide	1	O
is	0	O
a	0	O
serotonin	0	O
antagonist	0	O
and	0	O
has	0	O
been	0	O
demonstrated	0	O
to	0	O
reduce	0	O
wound	0	O
blood	0	O
flow	0	O
and	0	O
edema	0	O
formation	0	O
.	0	O


It	1	O
seems	0	O
that	0	O
the	0	O
way	0	O
in	0	O
which	0	O
drugs	0	O
modify	0	O
a	0	O
patient	0	O
'	0	O
s	0	O
serum	0	O
chemistry	0	O
may	0	O
be	0	O
used	0	O
to	0	O
assess	0	O
the	0	O
efficacy	0	O
with	0	O
which	0	O
they	0	O
control	0	O
the	0	O
inflammatory	0	O
process	0	O
.	0	O


This	0	O
study	0	O
evaluates	0	O
the	0	O
feasibility	0	O
of	0	O
indirect	0	O
mesenteric	0	O
lymphangiography	0	O
as	0	O
a	0	O
colonoscopic	0	O
technique	0	O
in	0	O
a	0	O
canine	0	O
model	0	O
.	0	O


No	1	O
definite	0	O
conclusions	0	O
are	0	O
possible	0	O
because	0	O
of	0	O
the	0	O
small	0	O
number	0	O
of	0	O
patients	0	O
involved	0	O
in	0	O
this	0	O
phase	0	O
II	0	O
trial	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
MIB	0	O
on	0	O
the	0	O
dose	0	O
-	0	O
response	0	O
curve	0	O
of	0	O
externally	0	O
applied	0	O
noradrenaline	0	O
was	0	O
also	0	O
studied	0	O
.	0	O


Disruption	1	O
of	0	O
microtubules	0	O
did	0	O
not	0	O
affect	0	O
the	0	O
fidelity	0	O
or	0	O
kinetics	0	O
of	0	O
vacuolar	0	O
protein	0	O
sorting	0	O
,	0	O
indicating	0	O
that	0	O
Vps1p	0	B
function	0	O
is	0	O
not	0	O
dependent	0	O
on	0	O
microtubules	0	O
.	0	O


Among	0	O
9	0	O
group	0	O
I	1	O
patients	0	O
with	0	O
a	0	O
positive	0	O
result	0	O
on	0	O
head	0	O
-	0	O
up	0	O
tilt	0	O
-	0	O
table	0	O
testing	0	O
and	0	O
no	0	O
evidence	0	O
of	0	O
structural	0	O
heart	0	O
disease	0	O
(	0	O
mean	0	O
follow	0	O
-	0	O
up	0	O
4	0	O
.	0	O
3	0	O
years	0	O
),	0	O
7	0	O
are	0	O
without	0	O
further	0	O
episodes	0	O
of	0	O
syncope	0	O
;	0	O
3	0	O
have	0	O
discontinued	0	O
medication	0	O
and	0	O
5	0	O
have	0	O
resumed	0	O
at	0	O
least	0	O
limited	0	O
exercise	0	O
.	0	O


Assembly	0	O
of	0	O
a	0	O
complex	0	O
between	0	O
FAK	0	B
and	0	O
Src	1	B
kinases	0	I
may	0	O
serve	0	O
to	0	O
regulate	0	O
the	0	O
subcellular	0	O
localization	0	O
and	0	O
the	0	O
enzymatic	0	O
activity	0	O
of	0	O
members	0	O
of	0	O
the	0	O
Src	1	B
family	0	I
of	0	O
kinases	0	O
.	0	O


A	1	O
Drosophila	1	B
shc	0	I
gene	0	I
product	0	I
is	0	O
implicated	0	O
in	0	O
signaling	0	O
by	0	O
the	0	O
DER	0	B
receptor	0	I
tyrosine	0	I
kinase	0	I
.	0	O


The	0	O
expression	0	O
of	0	O
ERV3	0	B
env	0	I
mRNA	1	I
was	0	O
found	0	O
to	0	O
be	0	O
differentiation	0	O
-	0	O
associated	0	O
,	0	O
with	0	O
high	0	O
expression	0	O
detected	0	O
in	0	O
the	0	O
late	0	O
stages	0	O
of	0	O
monocytic	0	O
development	0	O
.	0	O


Respiratory	1	O
adaptation	0	O
to	0	O
chronic	0	O
hypoxia	0	O
in	0	O
newborn	0	O
rats	0	O
.	0	O


We	0	O
report	0	O
an	0	O
example	0	O
of	0	O
an	0	O
MDV	0	O
-	0	O
transformed	0	O
T	1	O
-	0	O
lymphoblastoid	0	O
cell	0	O
line	0	O
(	0	O
T9	0	O
)	0	O
expressing	0	O
high	0	O
levels	0	O
of	0	O
a	0	O
truncated	0	B
C	1	I
-	0	I
MYB	0	I
protein	0	I
as	0	O
a	0	O
result	0	O
of	0	O
RAV	1	O
integration	0	O
within	0	O
one	0	O
c	0	B
-	0	I
myb	0	I
allele	0	I
.	0	O


A	1	O
clinically	0	O
useful	0	O
diagnostic	0	O
method	0	O
has	0	O
been	0	O
developed	0	O
for	0	O
detecting	0	O
and	0	O
quantitating	0	O
periods	0	O
of	0	O
apnea	0	O
in	0	O
pediatric	0	O
patients	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
anabolic	0	O
implants	0	O
on	0	O
rate	0	O
,	0	O
composition	0	O
and	0	O
energetic	0	O
efficiency	0	O
of	0	O
growth	0	O
were	0	O
determined	0	O
in	0	O
steers	0	O
fed	0	O
diets	0	O
varying	0	O
in	0	O
forage	0	O
and	0	O
grain	0	O
content	0	O
.	0	O


Moreover	0	O
,	0	O
LD50	1	O
in	0	O
mice	0	O
of	0	O
RP	1	O
-	0	O
170	0	O
(	0	O
4	0	O
.	0	O
3	0	O
g	0	O
/	0	O
kg	0	O
on	0	O
i	0	O
.	0	O
v	0	O
.)	0	O
was	0	O
increased	0	O
to	0	O
5	0	O
.	0	O
2	0	O
g	0	O
/	0	O
kg	0	O
by	0	O
oral	0	O
administration	0	O
.	0	O


Qualitatively	1	O
,	0	O
the	0	O
results	0	O
are	0	O
similar	0	O
for	0	O
the	0	O
two	0	O
species	0	O
:	0	O
Both	0	O
rhesus	0	O
monkey	0	O
and	0	O
man	0	O
have	0	O
photopic	0	O
and	0	O
scotopic	0	O
branches	0	O
,	0	O
which	0	O
cross	0	O
at	0	O
approximately	0	O
the	0	O
same	0	O
time	0	O
in	0	O
the	0	O
dark	0	O
and	0	O
at	0	O
approximately	0	O
the	0	O
same	0	O
background	0	O
luminance	0	O
.	0	O


Polyadenylation	1	O
of	0	O
B4	0	B
RNA	1	I
,	0	O
which	0	O
occurs	0	O
very	0	O
early	0	O
during	0	O
maturation	0	O
,	0	O
is	0	O
limited	0	O
to	0	O
150	0	O
residues	0	O
,	0	O
and	0	O
it	0	O
is	0	O
this	0	O
number	0	O
that	0	O
is	0	O
required	0	O
for	0	O
polysomal	0	O
recruitment	0	O
.	0	O


IVOX	0	O
was	0	O
named	0	O
as	0	O
an	0	O
acronym	0	O
for	0	O
intravascular	0	O
oxygenator	0	O
.	0	O


Lck	0	B
has	0	O
been	0	O
postulated	0	O
to	0	O
dimerize	0	O
through	0	O
the	0	O
SH2	0	B
and	0	O
SH3	0	B
domains	0	I
.	0	O


Assay	1	O
of	0	O
urea	0	O
by	0	O
immobilized	0	O
urease	0	B
coupled	0	O
to	0	O
a	0	O
differential	0	O
pH	1	O
-	0	O
meter	0	O
.	0	O


Transactivation	1	O
of	0	O
naturally	0	O
occurring	0	O
HIV	1	B
-	0	I
1	0	I
long	0	I
terminal	0	I
repeats	0	I
by	0	O
the	0	O
JNK	0	B
signaling	0	O
pathway	0	O
.	0	O


Three	0	O
monopolar	0	O
electrodes	0	O
were	0	O
inserted	0	O
into	0	O
the	0	O
left	0	O
and	0	O
right	0	O
lateral	0	O
vestibulospinal	0	O
tract	0	O
(	0	O
LVST	0	O
)	0	O
and	0	O
medial	0	O
vestibulospinal	0	O
tract	0	O
(	0	O
MVST	0	O
)	0	O
of	0	O
the	0	O
C1	1	O
segment	0	O
,	0	O
to	0	O
determine	0	O
the	0	O
pathway	0	O
of	0	O
axons	0	O
.	0	O


Pyk2	0	B
phosphorylation	0	O
increased	0	O
upon	0	O
adherence	0	O
of	0	O
FLG	0	O
29	0	O
.	0	O
1	0	O
cells	0	O
to	0	O
fibronectin	0	B
and	0	O
to	0	O
ST2	0	O
stromal	0	O
cells	0	O
.	0	O


An	1	O
NF1	1	B
-	0	I
related	0	I
vitellogenin	0	I
activator	0	I
element	0	I
mediates	0	O
transcription	0	O
from	0	O
the	0	O
estrogen	0	O
-	0	O
regulated	0	O
Xenopus	1	B
laevis	0	I
vitellogenin	0	I
promoter	0	I
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
investigated	0	O
the	0	O
signal	0	O
transduction	0	O
pathways	0	O
that	0	O
are	0	O
involved	0	O
in	0	O
OM	1	B
-	0	O
induced	0	O
LDLR	0	B
transcription	0	O
.	0	O


We	0	O
show	0	O
that	0	O
these	0	O
three	0	O
gain	0	O
-	0	O
of	0	O
-	0	O
function	0	O
mutants	0	O
differ	0	O
considerably	0	O
in	0	O
their	0	O
ability	0	O
to	0	O
bypass	0	O
the	0	O
sex	0	O
determination	0	O
signal	0	O
,	0	O
with	0	O
SxlM4	0	B
being	0	O
the	0	O
strongest	0	O
and	0	O
SxlM1	0	B
the	0	O
weakest	0	O
.	0	O


Effects	0	O
of	0	O
ionizing	0	O
radiation	0	O
in	0	O
the	0	O
human	0	O
oral	0	O
cavity	0	O
and	0	O
oropharynx	0	O
:	0	O
results	0	O
of	0	O
a	0	O
survey	0	O
.	0	O


Evidence	1	O
for	0	O
such	0	O
peak	0	O
shifts	0	O
has	0	O
been	0	O
found	0	O
in	0	O
the	0	O
responses	0	O
of	0	O
auditory	0	O
nerve	0	O
fibers	0	O
,	0	O
cochlear	0	O
microphonics	0	O
,	0	O
and	0	O
the	0	O
responses	0	O
of	0	O
outer	0	O
hair	0	O
cells	0	O
and	0	O
supporting	0	O
cells	0	O
in	0	O
the	0	O
cochlea	0	O
,	0	O
as	0	O
well	0	O
as	0	O
in	0	O
basilar	0	O
membrane	0	O
vibration	0	O
measurements	0	O
,	0	O
and	0	O
indirectly	0	O
,	0	O
in	0	O
psychophysical	0	O
data	0	O
.	0	O


A	1	O
subset	0	O
of	0	O
these	0	O
DMP1	0	B
recognition	0	I
sequences	0	I
containing	0	O
a	0	O
GGA	0	O
trinucleotide	0	O
core	0	O
can	0	O
also	0	O
function	0	O
as	0	O
Ets	1	B
-	0	I
responsive	0	I
elements	0	I
.	0	O


In	1	O
the	0	O
3	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
27	0	B
kDa	1	I
zein	0	I
gene	0	I
,	0	O
several	0	O
AATAAA	0	O
-	0	O
like	0	O
sequences	0	O
and	0	O
a	0	O
sequence	0	O
resembling	0	O
the	0	O
mammalian	0	O
GT	1	O
-	0	O
rich	0	O
sequence	0	O
are	0	O
present	0	O
around	0	O
the	0	O
polyadenylation	0	O
sites	0	O
.	0	O


Effects	0	O
of	0	O
Trypanosoma	1	O
vivax	0	O
on	0	O
pregnancy	0	O
of	0	O
Yankasa	0	O
sheep	0	O
and	0	O
the	0	O
results	0	O
of	0	O
homidum	0	O
chloride	0	O
chemotherapy	0	O
.	0	O


The	0	O
electrocardiogram	0	O
.	0	O


BCL6	0	B
encodes	0	O
a	0	O
POZ	0	B
/	0	I
Zn	1	I
finger	0	I
protein	0	I
,	0	O
a	0	O
structure	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
many	0	O
Drosophila	1	O
developmental	0	O
regulators	0	O
and	0	O
to	0	O
another	0	O
protein	0	O
involved	0	O
in	0	O
a	0	O
human	0	O
hematopoietic	0	O
malignancy	0	O
,	0	O
PLZF	0	B
.	0	O


Variables	0	O
evaluated	0	O
were	0	O
number	0	O
of	0	O
weekly	0	O
anginal	0	O
events	0	O
,	0	O
data	0	O
from	0	O
ergometric	0	O
exercise	0	O
testing	0	O
with	0	O
simultaneous	0	O
electrocardiographic	0	O
registration	0	O
,	0	O
semiquantitative	0	O
evaluation	0	O
of	0	O
Tc	1	O
-	0	O
99m	0	O
2	0	O
-	0	O
methoxy	0	O
isobutyl	0	O
isonitrile	0	O
(	0	O
MIBI	1	O
)	0	O
scans	0	O
and	0	O
rheologic	0	O
variables	0	O
.	0	O


Its	0	O
transcription	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
induced	0	O
40	0	O
-	0	O
50	0	O
-	0	O
fold	0	O
in	0	O
response	0	O
to	0	O
oxygen	0	O
or	0	O
heme	0	O
deficiency	0	O
,	0	O
in	0	O
part	0	O
through	0	O
relief	0	O
of	0	O
repression	0	O
exerted	0	O
by	0	O
Rox1p	0	B
and	0	O
in	0	O
part	0	O
by	0	O
activation	0	O
mediated	0	O
by	0	O
an	0	O
upstream	0	O
activation	0	O
sequence	0	O
(	0	O
UAS	0	O
).	0	O


The	0	O
insulin	0	B
therapy	0	O
regimen	0	O
did	0	O
not	0	O
affect	0	O
the	0	O
evolution	0	O
of	0	O
the	0	O
patients	0	O
and	0	O
no	0	O
significant	0	O
relationship	0	O
existed	0	O
between	0	O
the	0	O
age	0	O
at	0	O
diagnosis	0	O
,	0	O
duration	0	O
of	0	O
diabetes	0	O
,	0	O
daily	0	O
insulin	0	B
dosage	0	O
or	0	O
metabolic	0	O
control	0	O
and	0	O
height	0	O
or	0	O
BMI	1	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
ATF	0	B
-	0	I
2	0	I
plays	0	O
a	0	O
central	0	O
role	0	O
in	0	O
TGF	1	B
-	0	I
beta	0	I
signaling	0	O
by	0	O
acting	0	O
as	0	O
a	0	O
common	0	O
nuclear	0	O
target	0	O
of	0	O
both	0	O
Smad	0	B
and	0	O
TAK1	0	B
pathways	0	O
.	0	O


Zn	1	O
(	0	O
II	0	O
)	0	O
coordination	0	O
domain	0	O
mutants	0	O
of	0	O
T4	1	B
gene	0	I
32	0	I
protein	0	I
.	0	O


This	0	O
study	0	O
was	0	O
carried	0	O
out	0	O
to	0	O
analyze	0	O
PRL	1	B
secretion	0	O
in	0	O
metastatic	0	O
prostate	0	O
cancer	0	O
patients	0	O
both	0	O
at	0	O
basal	0	O
conditions	0	O
and	0	O
in	0	O
response	0	O
to	0	O
L	1	O
-	0	O
Dopa	1	O
and	0	O
metoclopramide	0	O
,	0	O
which	0	O
represents	0	O
the	0	O
most	0	O
classical	0	O
inhibitory	0	O
and	0	O
stimulatory	0	O
tests	0	O
for	0	O
PRL	1	B
secretion	0	O
,	0	O
respectively	0	O
.	0	O


A	1	O
favourable	0	O
response	0	O
was	0	O
achieved	0	O
with	0	O
a	0	O
combination	0	O
of	0	O
amphotericin	0	O
B	1	O
and	0	O
cotrimoxazole	0	O
.	0	O


Is	1	O
leishmaniasis	0	O
endemic	0	O
on	0	O
the	0	O
island	0	O
of	0	O
Minorca	0	O
(	0	O
Spain	0	O
)?	0	O
A	1	O
human	0	O
visceral	0	O
case	0	O
after	0	O
living	0	O
13	0	O
years	0	O
in	0	O
Minorca	0	O
.	0	O


In	1	O
the	0	O
latter	0	O
category	0	O
particular	0	O
emphasis	0	O
is	0	O
being	0	O
placed	0	O
on	0	O
new	0	O
anthracycline	0	O
analogues	0	O
of	0	O
doxorubicin	0	O
and	0	O
analogues	0	O
of	0	O
cisplatinum	0	O
diammine	0	O
dichloride	0	O
.	0	O


Hepatitis	1	O
B	1	O
vaccine	0	O
:	0	O
still	0	O
has	0	O
its	0	O
problems	0	O
.	0	O


The	0	O
diabetic	0	O
state	0	O
was	0	O
characterized	0	O
by	0	O
mild	0	O
insulin	0	B
deficiency	0	O
,	0	O
plasma	0	O
levels	0	O
being	0	O
73	0	O
%	0	O
of	0	O
controls	0	O
,	0	O
and	0	O
mild	0	O
hyperglycemia	0	O
,	0	O
with	0	O
nonfasting	0	O
plasma	0	O
glucose	0	O
levels	0	O
of	0	O
1	0	O
.	0	O
5	0	O
times	0	O
normal	0	O
.	0	O


Moreover	0	O
,	0	O
exons	0	O
2a	0	O
and	0	O
2b	0	O
share	0	O
the	0	O
same	0	O
5	0	O
'	0	O
sequence	0	O
but	0	O
differ	0	O
from	0	O
each	0	O
other	0	O
by	0	O
the	0	O
use	0	O
of	0	O
two	0	O
distinct	0	O
donor	0	O
splice	0	O
sites	0	O
171	0	O
bp	0	O
apart	0	O
in	0	O
the	0	O
gene	0	O
.	0	O


In	1	O
this	0	O
study	0	O
the	0	O
splenectomized	0	O
captive	0	O
born	0	O
cynomolgus	0	O
appeared	0	O
to	0	O
be	0	O
capable	0	O
of	0	O
supplementing	0	O
rhesus	0	O
as	0	O
an	0	O
antimalarial	0	O
drug	0	O
testing	0	O
model	0	O
.	0	O


Seven	0	O
clones	0	O
encoding	0	O
interferon	0	B
response	0	I
element	0	I
binding	0	I
factors	0	I
have	0	O
been	0	O
isolated	0	O
from	0	O
a	0	O
mouse	0	O
fibroblast	0	O
lambda	0	O
gt11	0	O
cDNA	1	O
library	0	O
by	0	O
using	0	O
a	0	O
32P	0	O
end	0	O
-	0	O
labeled	0	O
tandem	0	O
trimer	0	O
of	0	O
the	0	O
mouse	0	B
(	0	I
2	0	I
'-	0	I
5	0	I
')	0	I
oligoadenylate	0	I
synthetase	0	I
gene	0	I
interferon	0	O
response	0	O
element	0	O
as	0	O
a	0	O
probe	0	O
.	0	O


2	0	O
.	0	O


Delta	1	O
-	0	O
aminolevulinic	0	O
acid	0	O
in	0	O
physiological	0	O
conditions	0	O
and	0	O
some	0	O
diseases	0	O
in	0	O
children	0	O


Fufang	0	O
wuzi	0	O
yanzong	0	O
pills	0	O
have	0	O
strong	0	O
leukogenic	0	O
effect	0	O
on	0	O
cyclophosphamide	0	O
induced	0	O
leukopenia	0	O
in	0	O
mice	0	O
.	0	O


Despite	0	O
the	0	O
favourable	0	O
natural	0	O
history	0	O
of	0	O
acute	0	O
BI	1	O
,	0	O
mild	0	O
,	0	O
moderate	0	O
,	0	O
and	0	O
severe	0	O
posttraumatic	0	O
changes	0	O
were	0	O
shown	0	O
to	0	O
appear	0	O
as	0	O
cicatricial	0	O
-	0	O
adhesive	0	O
and	0	O
atrophic	0	O
processes	0	O
,	0	O
intracerebral	0	O
cysts	0	O
,	0	O
porencephaly	0	O
,	0	O
which	0	O
result	0	O
in	0	O
posttraumatic	0	O
epilepsy	0	O
,	0	O
hydrocephalus	0	O
,	0	O
etc	0	O
.	0	O


However	0	O
,	0	O
whether	0	O
or	0	O
not	0	O
nonsense	0	O
codon	0	O
recognition	0	O
within	0	O
TPI	0	B
transcripts	0	I
takes	0	O
place	0	O
prior	0	O
to	0	O
or	0	O
after	0	O
splicing	0	O
remained	0	O
unresolved	0	O
.	0	O


The	0	O
results	0	O
corroborate	0	O
the	0	O
idea	0	O
that	0	O
the	0	O
structure	0	O
of	0	O
relaxation	0	O
curves	0	O
contains	0	O
information	0	O
on	0	O
the	0	O
distance	0	O
scale	0	O
and	0	O
on	0	O
the	0	O
architecture	0	O
of	0	O
the	0	O
pore	0	O
space	0	O
,	0	O
even	0	O
if	0	O
it	0	O
is	0	O
difficult	0	O
to	0	O
extract	0	O
it	0	O
without	0	O
ambiguities	0	O
.	0	O


We	0	O
describe	0	O
here	0	O
a	0	O
Drosophila	1	B
melanogaster	0	I
FAK	0	I
homologue	0	I
,	0	O
DFak56	0	B
,	0	O
which	0	O
maps	0	O
to	0	O
band	0	O
56D	0	O
on	0	O
the	0	O
right	0	O
arm	0	O
of	0	O
the	0	O
second	0	O
chromosome	0	O
.	0	O


The	0	O
accuracies	0	O
of	0	O
presence	0	O
or	0	O
absence	0	O
of	0	O
neuroblastoma	0	O
were	0	O
compared	0	O
between	0	O
131I	0	O
-	0	O
MIBG	1	O
imaging	0	O
and	0	O
several	0	O
tumor	0	O
markers	0	O
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
pooling	0	O
requirements	0	O
are	0	O
task	0	O
dependent	0	O
.	0	O


Concomitantly	0	O
,	0	O
the	0	O
total	0	O
cellular	0	O
level	0	O
of	0	O
p21	0	B
increased	0	O
severalfold	0	O
via	0	O
a	0	O
posttranscriptional	0	O
mechanism	0	O
.	0	O


Statement	0	O
on	0	O
the	0	O
development	0	O
of	0	O
guidelines	0	O
for	0	O
the	0	O
prevention	0	O
of	0	O
AIDS	1	O
transmission	0	O
in	0	O
the	0	O
workplace	0	O
.	0	O


The	0	O
region	0	O
between	0	O
DXS52	0	B
and	0	O
Factor	1	B
VIII	0	I
gene	0	I
in	0	O
the	0	O
human	0	O
Xq28	0	O
chromosomal	0	O
band	0	O
contains	0	O
a	0	O
G	1	O
+	0	O
C	1	O
-	0	O
rich	0	O
isochore	0	O
to	0	O
which	0	O
many	0	O
genes	0	O
have	0	O
been	0	O
mapped	0	O
.	0	O


The	0	O
survival	0	O
in	0	O
the	0	O
case	0	O
of	0	O
these	0	O
patients	0	O
was	0	O
studied	0	O
five	0	O
years	0	O
later	0	O
.	0	O


Insulin	1	B
-	0	O
regulated	0	O
events	0	O
,	0	O
however	0	O
,	0	O
occur	0	O
in	0	O
all	0	O
cells	0	O
.	0	O


(	0	O
1998	0	O
)	0	O
J	1	O
.	0	O


Electrocardiograms	0	O
of	0	O
the	0	O
month	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
IgM	1	B
class	0	O
CIC	0	O
is	0	O
the	0	O
predominant	0	O
CIC	0	O
in	0	O
acute	0	O
hepatitis	0	O
A	1	O
and	0	O
correlated	0	O
with	0	O
disease	0	O
activity	0	O
.	0	O


TCR	1	B
alpha	0	I
(	0	O
TCRA	0	B
)	0	O
expression	0	O
was	0	O
examined	0	O
in	0	O
RNA	1	O
samples	0	O
from	0	O
PBMC	0	O
and	0	O
isolated	0	O
populations	0	O
of	0	O
CD4	1	O
+,	0	O
CD8	0	O
+,	0	O
and	0	O
DN	1	O
T	1	O
cells	0	O
from	0	O
15	0	O
healthy	0	O
individuals	0	O
.	0	O


Striking	0	O
sequence	0	O
similarities	0	O
(	0	O
57	0	O
and	0	O
53	0	O
%)	0	O
were	0	O
observed	0	O
with	0	O
yeast	0	O
mitochondrial	0	O
proteins	0	O
,	0	O
SMF1	0	B
and	0	O
SMF2	0	B
,	0	O
especially	0	O
within	0	O
putative	0	O
functional	0	O
domains	0	O
:	0	O
exon	0	O
6	0	O
encoding	0	O
the	0	O
second	0	O
transmembrane	0	O
spanning	0	O
domain	0	O
,	0	O
site	0	O
of	0	O
the	0	O
murine	0	B
susceptibility	0	I
mutation	0	O
;	0	O
and	0	O
exon	0	O
11	0	O
encoding	0	O
a	0	O
conserved	0	O
transport	0	O
motif	0	O
.	0	O


Recombinant	1	B
I	1	I
-	0	I
kappa	0	I
B	1	I
alpha	0	I
inhibited	0	O
kappa	0	B
B	1	I
motif	0	I
binding	0	O
by	0	O
nuclear	0	B
factor	0	I
-	0	I
kappa	0	I
B1	0	I
,	0	O
RelA	0	B
,	0	O
and	0	O
c	0	B
-	0	I
Rel	0	I
as	0	O
indicated	0	O
by	0	O
studies	0	O
using	0	O
UV	1	O
radiation	0	O
-	0	O
induced	0	O
covalent	0	O
cross	0	O
-	0	O
linking	0	O
to	0	O
a	0	O
bromodeoxyuridine	0	O
-	0	O
substituted	0	O
kappa	0	B
B	1	I
oligonucleotide	0	I
.	0	O


The	0	O
psaD	0	B
,	0	O
psaF	0	B
,	0	O
psaH	0	B
,	0	O
and	0	O
psaL	0	B
products	0	I
have	0	O
two	0	O
isoforms	0	O
each	0	O
that	0	O
are	0	O
distinguished	0	O
by	0	O
different	0	O
mobilities	0	O
in	0	O
polyacrylamide	0	O
gel	0	O
electrophoresis	0	O
,	0	O
and	0	O
the	0	O
psaE	0	B
product	0	I
has	0	O
four	0	O
isoforms	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
double	0	O
mutants	0	O
with	0	O
either	0	O
dim1	0	B
-	0	I
delta	0	I
or	0	O
dim2	0	B
-	0	I
1	0	I
and	0	O
the	0	O
endocytosis	0	O
mutants	0	B
end4	0	I
-	0	I
1	0	I
or	0	O
act1	0	B
-	0	I
1	0	I
displayed	0	O
synthetic	0	O
growth	0	O
defects	0	O
,	0	O
indicating	0	O
that	0	O
the	0	O
DIM	0	B
gene	0	I
products	0	I
function	0	O
in	0	O
a	0	O
common	0	O
or	0	O
parallel	0	O
endocytic	0	O
pathway	0	O
.	0	O


(	0	O
1995	0	O
)	0	O
J	1	O
.	0	O


However	0	O
,	0	O
multiple	0	O
alanine	0	O
substitutions	0	O
or	0	O
proline	0	O
(	0	O
helix	0	O
-	0	O
destabilizing	0	O
)	0	O
substitutions	0	O
disrupted	0	O
both	0	O
oligomerization	0	O
and	0	O
transport	0	O
of	0	O
GP64	0	B
EFP	0	I
.	0	O


Addition	1	O
of	0	O
soluble	0	O
recombinant	0	B
human	0	I
SLF	0	I
to	0	O
SI4	0	O
-	0	O
h220	0	O
cultures	0	O
enhanced	0	O
reduction	0	O
of	0	O
cell	0	O
-	0	O
surface	0	O
c	0	B
-	0	I
kit	0	I
expression	0	O
and	0	O
its	0	O
protein	0	O
degradation	0	O
.	0	O


Stably	0	O
transfected	0	O
human	0	O
kidney	0	O
293	0	O
cells	0	O
expressing	0	O
the	0	O
wild	0	B
type	0	I
rat	0	I
LH	1	I
/	0	I
CG	1	I
receptor	0	I
(	0	O
rLHR	0	B
)	0	O
or	0	O
receptors	0	O
with	0	O
C	1	O
-	0	O
terminal	0	O
tails	0	O
truncated	0	O
at	0	O
residues	0	O
653	0	O
,	0	O
631	0	O
,	0	O
or	0	O
628	0	O
(	0	O
designated	0	O
rLHR	0	B
-	0	I
t653	0	I
,	0	O
rLHR	0	B
-	0	I
t631	0	I
,	0	O
and	0	O
rLHR	0	B
-	0	I
t628	0	I
)	0	O
were	0	O
used	0	O
to	0	O
probe	0	O
the	0	O
importance	0	O
of	0	O
this	0	O
region	0	O
on	0	O
the	0	O
regulation	0	O
of	0	O
hormonal	0	O
responsiveness	0	O
.	0	O


G	1	B
-	0	I
CSF	1	I
activates	0	O
multiple	0	O
signaling	0	O
molecules	0	O
,	0	O
including	0	O
the	0	O
JAK1	0	B
and	0	O
JAK2	0	B
kinases	0	I
and	0	O
the	0	O
STAT	1	B
transcription	0	O
factors	0	O
.	0	O


Intriguingly	0	O
,	0	O
three	0	O
hypomorphic	0	O
Scm	1	B
mutations	0	O
,	0	O
which	0	O
map	0	O
within	0	O
an	0	O
mbt	0	B
repeat	0	I
,	0	O
interact	0	O
with	0	O
PcG	1	B
mutations	0	I
more	0	O
strongly	0	O
than	0	O
do	0	O
Scm	1	B
null	0	O
alleles	0	O
.	0	O


In	1	O
order	0	O
to	0	O
screen	0	O
for	0	O
such	0	O
cofactors	0	O
,	0	O
we	0	O
have	0	O
used	0	O
a	0	O
transcriptionally	0	O
inactive	0	O
mutant	0	O
of	0	O
Xenopus	1	B
MEF2D	0	I
in	0	O
a	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
screen	0	O
.	0	O


The	0	O
carboxyl	0	O
-	0	O
terminal	0	O
portion	0	O
of	0	O
UKLF	0	B
contains	0	O
three	0	O
zinc	0	O
fingers	0	O
of	0	O
the	0	O
Cys2	0	O
-	0	O
His2	0	O
type	0	O
and	0	O
binds	0	O
in	0	O
vitro	0	O
to	0	O
the	0	O
CACCC	0	O
motif	0	O
of	0	O
the	0	O
beta	0	B
-	0	I
globin	0	I
promoter	0	I
and	0	O
to	0	O
the	0	O
Sp1	0	B
recognition	0	I
sequence	0	I
.	0	O


Two	0	O
of	0	O
the	0	O
three	0	O
groups	0	O
were	0	O
administered	0	O
dauricine	0	O
,	0	O
as	0	O
a	0	O
new	0	O
calcium	0	O
channel	0	O
blocker	0	O
,	0	O
and	0	O
verapamil	0	O
,	0	O
as	0	O
a	0	O
generally	0	O
recognized	0	O
calcium	0	O
channel	0	O
blocker	0	O
,	0	O
respectively	0	O
,	0	O
from	0	O
15	0	O
minutes	0	O
pre	0	O
-	0	O
bypass	0	O
to	0	O
the	0	O
end	0	O
of	0	O
the	0	O
bypass	0	O
procedure	0	O
(	0	O
a	0	O
period	0	O
of	0	O
95	0	O
minutes	0	O
).	0	O


Oligonucleotide	1	O
competitors	0	O
were	0	O
used	0	O
to	0	O
evaluate	0	O
the	0	O
accessibility	0	O
of	0	O
the	0	O
TATA	0	O
-	0	O
binding	0	O
site	0	O
in	0	O
TIF	0	B
-	0	I
IB	1	I
,	0	O
TFIID	0	B
,	0	O
and	0	O
TFIIIB	0	B
.	0	O


Interestingly	0	O
,	0	O
the	0	O
avirulent	0	O
strain	0	O
H37Ra	0	O
showed	0	O
weak	0	O
hybridization	0	O
with	0	O
these	0	O
two	0	O
probes	0	O
,	0	O
suggesting	0	O
that	0	O
these	0	O
genes	0	O
might	0	O
have	0	O
been	0	O
deleted	0	O
in	0	O
the	0	O
avirulent	0	O
strain	0	O
or	0	O
are	0	O
present	0	O
in	0	O
limited	0	O
copy	0	O
numbers	0	O
as	0	O
opposed	0	O
to	0	O
those	0	O
in	0	O
the	0	O
virulent	0	O
strain	0	O
H37Rv	0	O
.	0	O


The	0	O
number	0	O
of	0	O
crystalline	0	O
deposits	0	O
is	0	O
less	0	O
in	0	O
the	0	O
advanced	0	O
atrophic	0	O
areas	0	O
of	0	O
the	0	O
RPE	1	O
-	0	O
choriocapillaris	0	O
complex	0	O
.	0	O


A	1	O
tyrosine	0	O
-	0	O
based	0	O
sorting	0	O
signal	0	O
in	0	O
the	0	O
beta2	0	B
integrin	0	I
cytoplasmic	0	I
domain	0	I
mediates	0	O
its	0	O
recycling	0	O
to	0	O
the	0	O
plasma	0	O
membrane	0	O
and	0	O
is	0	O
required	0	O
for	0	O
ligand	0	O
-	0	O
supported	0	O
migration	0	O
.	0	O


Although	0	O
the	0	O
effects	0	O
of	0	O
the	0	O
calcium	0	O
supplement	0	O
or	0	O
calcium	0	O
antagonist	0	O
alone	0	O
were	0	O
significant	0	O
,	0	O
such	0	O
hypotensive	0	O
responses	0	O
were	0	O
not	0	O
optimal	0	O
or	0	O
predictable	0	O
or	0	O
clearly	0	O
dose	0	O
-	0	O
dependent	0	O
.	0	O


The	0	O
vaccine	0	O
used	0	O
was	0	O
known	0	O
to	0	O
be	0	O
immunogenic	0	O
for	0	O
older	0	O
children	0	O
and	0	O
adults	0	O
.	0	O


Using	0	O
an	0	O
RNase	1	B
H	1	I
protection	0	O
assay	0	O
and	0	O
specific	0	O
blocking	0	O
oligonucleotides	0	O
,	0	O
we	0	O
find	0	O
that	0	O
recognition	0	O
of	0	O
the	0	O
5	0	O
'	0	O
splice	0	O
-	0	O
site	0	O
(	0	O
5	0	O
'	0	O
ss	0	O
)	0	O
and	0	O
branchpoint	0	O
sequence	0	O
(	0	O
BPS	0	O
)	0	O
elements	0	O
by	0	O
U11	0	B
and	0	O
U12	0	B
snRNPs	0	I
,	0	O
respectively	0	O
,	0	O
displays	0	O
strong	0	O
cooperativity	0	O
,	0	O
requiring	0	O
both	0	O
sites	0	O
in	0	O
the	0	O
pre	0	O
-	0	O
mRNA	1	O
substrate	0	O
for	0	O
efficient	0	O
complex	0	O
formation	0	O
.	0	O


When	0	O
comparing	0	O
the	0	O
barley	0	B
PSI	1	I
-	0	I
K	1	I
and	0	O
PSI	1	B
-	0	I
G	1	I
with	0	O
the	0	O
reported	0	O
PSI	1	B
-	0	I
K	1	I
sequence	0	I
from	0	I
Synechococcus	0	I
vulcanus	0	I
,	0	O
the	0	O
degree	0	O
of	0	O
similarity	0	O
is	0	O
equal	0	O
,	0	O
suggesting	0	O
that	0	O
an	0	O
ancestral	0	O
gene	0	O
has	0	O
been	0	O
duplicated	0	O
in	0	O
a	0	O
chloroplast	0	O
progenitor	0	O
but	0	O
not	0	O
in	0	O
a	0	O
cyanobacterial	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
carp	0	B
JAK1	0	I
shows	0	O
higher	0	O
sequence	0	O
homology	0	O
to	0	O
mammalian	0	B
JAK1	0	I
in	0	O
both	0	O
the	0	O
kinase	0	O
-	0	O
like	0	O
(	0	O
JH2	0	B
)	0	O
and	0	O
kinase	0	O
(	0	O
JH1	0	B
)	0	O
domains	0	O
(	0	O
approximately	0	O
70	0	O
%	0	O
identity	0	O
).	0	O


The	0	O
elevations	0	O
achieved	0	O
by	0	O
LDEE	0	O
given	0	O
s	0	O
.	0	O
c	0	O
.	0	O
were	0	O
higher	0	O
than	0	O
those	0	O
achieved	0	O
after	0	O
i	0	O
.	0	O
p	0	O
.	0	O
administration	0	O
and	0	O
lasted	0	O
for	0	O
longer	0	O
periods	0	O
.	0	O


Interlimb	0	O
coordination	0	O
during	0	O
fictive	0	O
locomotion	0	O
in	0	O
the	0	O
thalamic	0	O
cat	0	O
.	0	O


We	0	O
have	0	O
identified	0	O
in	0	O
the	0	O
5	0	O
'	0	O
untranslated	0	O
region	0	O
of	0	O
the	0	O
Drosophila	1	B
copia	0	I
retrotransposon	0	I
,	0	O
3	0	O
'	0	O
to	0	O
the	0	O
left	0	O
LTR	1	O
,	0	O
a	0	O
sequence	0	O
for	0	O
transcriptional	0	O
regulation	0	O
by	0	O
homeoproteins	0	O
.	0	O


These	0	O
features	0	O
were	0	O
considered	0	O
consistent	0	O
with	0	O
a	0	O
diagnosis	0	O
of	0	O
Rothmund	0	O
-	0	O
Thomson	0	O
syndrome	0	O
.	0	O


However	0	O
,	0	O
subcutaneously	0	O
administered	0	O
pneumococci	0	O
gave	0	O
a	0	O
lower	0	O
mortality	0	O
than	0	O
pneumococci	0	O
given	0	O
intravenously	0	O
or	0	O
intraperitoneally	0	O
.	0	O


The	0	O
addition	0	O
of	0	O
culture	0	O
to	0	O
the	0	O
CC	1	O
and	0	O
CC	1	O
:	0	O
SW	0	O
by	0	O
-	0	O
products	0	O
resulted	0	O
in	0	O
pH	1	O
values	0	O
lower	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
than	0	O
those	0	O
without	0	O
culture	0	O
on	0	O
Day	1	O
21	0	O
,	0	O
and	0	O
the	0	O
15	0	O
%	0	O
carbohydrate	0	O
treatment	0	O
significantly	0	O
reduced	0	O
pH	1	O
beyond	0	O
the	0	O
5	0	O
%	0	O
carbohydrate	0	O
.	0	O


Dopamine	1	O
SERS	0	O
spectra	0	O
from	0	O
these	0	O
electrodes	0	O
are	0	O
similar	0	O
to	0	O
those	0	O
obtained	0	O
at	0	O
uncoated	0	O
electrodes	0	O
.	0	O


The	0	O
structural	0	O
changes	0	O
in	0	O
intra	0	O
-	0	O
acinar	0	O
artery	0	O
manifested	0	O
mainly	0	O
by	0	O
an	0	O
increase	0	O
in	0	O
number	0	O
of	0	O
muscular	0	O
artery	0	O
resulting	0	O
from	0	O
muscularization	0	O
of	0	O
precursor	0	O
cells	0	O
(	0	O
pericytes	0	O
and	0	O
intermediate	0	O
cells	0	O
)	0	O
located	0	O
within	0	O
partially	0	O
muscular	0	O
and	0	O
nonmuscular	0	O
arterial	0	O
wall	0	O
to	0	O
smooth	0	O
muscle	0	O
cell	0	O
,	0	O
and	0	O
by	0	O
the	0	O
medial	0	O
wall	0	O
thickened	0	O
due	0	O
to	0	O
hypertrophy	0	O
and	0	O
hyperplasia	0	O
of	0	O
smooth	0	O
muscle	0	O
cells	0	O
as	0	O
well	0	O
as	0	O
accumulation	0	O
of	0	O
a	0	O
large	0	O
amount	0	O
of	0	O
collagen	0	B
,	0	O
especially	0	O
the	0	O
type	0	B
1	0	I
collagen	0	I
.	0	O


The	0	O
data	0	O
support	0	O
the	0	O
notion	0	O
that	0	O
suppression	0	O
of	0	O
images	0	O
during	0	O
binocular	0	O
rivalry	0	O
is	0	O
independent	0	O
in	0	O
both	0	O
eyes	0	O
.	0	O


A	1	O
probe	0	O
evoked	0	O
potentials	0	O
procedure	0	O
was	0	O
used	0	O
to	0	O
assess	0	O
the	0	O
relative	0	O
engagement	0	O
of	0	O
both	0	O
cerebral	0	O
hemispheres	0	O
during	0	O
a	0	O
language	0	O
task	0	O
in	0	O
the	0	O
following	0	O
four	0	O
groups	0	O
of	0	O
dextral	0	O
adults	0	O
:	0	O
left	0	O
hemisphere	0	O
(	0	O
LH	1	O
)-	0	O
damaged	0	O
aphasics	0	O
recovering	0	O
from	0	O
stroke	0	O
,	0	O
dysarthrics	0	O
,	0	O
right	0	O
hemisphere	0	O
(	0	O
RH	1	O
)-	0	O
damaged	0	O
nonaphasic	0	O
patients	0	O
,	0	O
and	0	O
normal	0	O
control	0	O
subjects	0	O
.	0	O


Cerebro	0	O
-	0	O
oculo	0	O
-	0	O
facioskeletal	0	O
syndrome	0	O
(	0	O
Pena	0	O
-	0	O
Shokeir	0	O
syndrome	0	O
II	0	O
)	0	O


In	1	O
E	1	O
.	0	O
coli	0	O
,	0	O
CheW	0	B
mediates	0	O
the	0	O
physical	0	O
coupling	0	O
of	0	O
the	0	O
receptors	0	O
to	0	O
the	0	O
kinase	0	O
CheA	0	B
.	0	O


The	0	O
timing	0	O
of	0	O
fla	0	B
gene	0	I
expression	0	O
in	0	O
the	0	O
cell	0	O
cycle	0	O
is	0	O
determined	0	O
by	0	O
specialized	0	O
forms	0	O
of	0	O
RNA	1	B
polymerase	0	I
and	0	O
the	0	O
appearance	0	O
and	0	O
/	0	O
or	0	O
activation	0	O
of	0	O
regulatory	0	O
proteins	0	O
.	0	O


These	0	O
changes	0	O
at	0	O
the	0	O
site	0	O
of	0	O
injection	0	O
consist	0	O
of	0	O
a	0	O
focal	0	O
abnormality	0	O
characterized	0	O
by	0	O
a	0	O
slight	0	O
increase	0	O
in	0	O
signal	0	O
intensity	0	O
on	0	O
T1	1	O
weighted	0	O
images	0	O
and	0	O
markedly	0	O
increased	0	O
signal	0	O
intensity	0	O
on	0	O
T2	0	O
weighted	0	O
images	0	O
.	0	O


Thus	0	O
,	0	O
in	0	O
normal	0	O
intestinal	0	O
epithelial	0	O
goblet	0	O
cells	0	O
,	0	O
TbetaRI	0	B
and	0	O
TbetaRII	0	B
can	0	O
respond	0	O
to	0	O
autocrine	0	O
but	0	O
not	0	O
exogenous	0	O
TGF	1	B
-	0	I
beta	0	I
without	0	O
the	0	O
participation	0	O
of	0	O
TbetaRIII	0	B
.	0	O


Interdigitated	0	O
residues	0	O
within	0	O
a	0	O
small	0	O
region	0	O
of	0	O
VP16	0	B
interact	0	O
with	0	O
Oct	1	B
-	0	I
1	0	I
,	0	O
HCF	0	B
,	0	O
and	0	O
DNA	1	O
.	0	O


CONCLUSIONS	0	O
:	0	O
EBCT	1	O
technology	0	O
allows	0	O
minimally	0	O
invasive	0	O
evaluation	0	O
of	0	O
intramyocardial	0	O
microcirculatory	0	O
function	0	O
and	0	O
permits	0	O
assessment	0	O
of	0	O
microvascular	0	O
BV	1	O
distribution	0	O
in	0	O
different	0	O
functional	0	O
components	0	O
.	0	O


The	0	O
previously	0	O
described	0	O
enhanced	0	O
translation	0	O
of	0	O
spinach	0	O
L12	0	B
mRNA	1	I
from	0	O
its	0	O
two	0	O
tandem	0	O
AUG	0	O
codons	0	O
and	0	O
the	0	O
two	0	O
functional	0	O
rpl12	0	B
genes	0	I
in	0	O
Arabidopsis	0	O
probably	0	O
provide	0	O
two	0	O
mechanisms	0	O
for	0	O
generating	0	O
the	0	O
four	0	O
copies	0	O
of	0	O
L12	0	B
/	0	I
chloroplast	0	I
ribosome	0	I
,	0	O
qualitatively	0	O
different	0	O
from	0	O
those	0	O
attempted	0	O
in	0	O
eubacteria	0	O
.	0	O


We	0	O
report	0	O
here	0	O
that	0	O
in	0	O
cultured	0	O
Jurkat	0	O
T	1	O
cells	0	O
,	0	O
Cbl	1	B
is	0	O
coprecipitated	0	O
with	0	O
antibody	0	O
against	0	O
the	0	O
adapter	0	B
protein	0	I
Grb2	0	I
.	0	O


The	0	O
mean	0	O
jitter	0	O
and	0	O
the	0	O
fiber	0	O
density	0	O
did	0	O
not	0	O
change	0	O
significantly	0	O
from	0	O
day	0	O
0	0	O
(	0	O
30	0	O
.	0	O
1	0	O
+/-	0	O
3	0	O
.	0	O
6	0	O
microseconds	0	O
;	0	O
1	0	O
.	0	O
4	0	O
+/-	0	O
0	0	O
.	0	O
07	0	O
)	0	O
to	0	O
day	0	O
30	0	O
(	0	O
34	0	O
.	0	O
5	0	O
+/-	0	O
2	0	O
.	0	O
7	0	O
microseconds	0	O
;	0	O
1	0	O
.	0	O
6	0	O
+/-	0	O
0	0	O
.	0	O
13	0	O
).	0	O


This	0	O
prospective	0	O
study	0	O
compared	0	O
the	0	O
measured	0	O
energy	0	O
expenditures	0	O
of	0	O
30	0	O
patients	0	O
using	0	O
indirect	0	O
calorimetry	0	O
with	0	O
their	0	O
predicted	0	O
basal	0	O
energy	0	O
expenditure	0	O
according	0	O
to	0	O
the	0	O
Harris	0	O
-	0	O
Benedict	0	O
equation	0	O
,	0	O
or	0	O
their	0	O
calculated	0	O
energy	0	O
expenditure	0	O
derived	0	O
from	0	O
basal	0	O
energy	0	O
expenditure	0	O
times	0	O
,	0	O
an	0	O
activity	0	O
factor	0	O
,	0	O
and	0	O
a	0	O
stress	0	O
factor	0	O
.	0	O


The	0	O
product	0	O
of	0	O
rat	0	B
gene	0	I
33	0	I
was	0	O
identified	0	O
as	0	O
an	0	O
ErbB	0	B
-	0	I
2	0	I
-	0	I
interacting	0	I
protein	0	I
in	0	O
a	0	O
two	0	O
-	0	O
hybrid	0	O
screen	0	O
employing	0	O
the	0	O
ErbB	0	B
-	0	I
2	0	I
juxtamembrane	0	I
and	0	I
kinase	0	I
domains	0	I
as	0	O
bait	0	O
.	0	O


Stable	1	O
transfection	0	O
of	0	O
the	0	O
BL	0	O
cell	0	O
line	0	O
Raji	0	O
with	0	O
constructs	0	O
containing	0	O
core	0	O
promoter	0	O
mutations	0	O
confirmed	0	O
that	0	O
the	0	O
proximal	0	O
Sp1	0	B
site	0	I
and	0	O
the	0	O
TATA	0	O
box	0	O
are	0	O
essential	0	O
for	0	O
the	0	O
activation	0	O
of	0	O
promoter	0	O
P1	1	O
by	0	O
the	0	O
Ig	1	B
kappa	0	I
enhancers	0	I
.	0	O


Mastocytosis	1	O
.	0	O


The	0	O
low	0	O
molecular	0	O
mass	0	O
polypeptide	0	O
complex	0	O
is	0	O
assumed	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
antigen	0	O
presentation	0	O
,	0	O
generating	0	O
peptides	0	O
from	0	O
cytosolic	0	O
protein	0	O
antigens	0	O
,	0	O
which	0	O
are	0	O
subsequently	0	O
presented	0	O
to	0	O
cytotoxic	0	O
T	1	O
-	0	O
lymphocytes	0	O
on	0	O
the	0	O
cell	0	O
surface	0	O
.	0	O


Derepression	1	O
of	0	O
gene	0	O
expression	0	O
mediated	0	O
by	0	O
the	0	O
5	0	O
'	0	O
upstream	0	O
region	0	O
of	0	O
the	0	O
isocitrate	0	B
lyase	0	I
gene	0	I
of	0	I
Candida	1	I
tropicalis	0	I
is	0	O
controlled	0	O
by	0	O
two	0	O
distinct	0	O
regulatory	0	O
pathways	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


The	0	O
progression	0	O
of	0	O
non	0	O
-	0	O
A	1	O
,	0	O
non	0	O
-	0	O
B	1	O
hepatitis	0	O
to	0	O
chronic	0	O
diseases	0	O
,	0	O
and	0	O
the	0	O
transformation	0	O
to	0	O
hepatocellular	0	O
carcinoma	0	O


Two	0	O
hundred	0	O
sixty	0	O
-	0	O
four	0	O
patients	0	O
scheduled	0	O
for	0	O
DCBM	0	O
were	0	O
randomized	0	O
to	0	O
receive	0	O
intravenously	0	O
geG	0	O
0	0	O
.	0	O
25	0	O
mg	0	O
(	0	O
geG	0	O
-	0	O
25	0	O
),	0	O
or	0	O
geG	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
(	0	O
geG	0	O
-	0	O
50	0	O
),	0	O
or	0	O
HBB	0	O
20	0	O
mg	0	O
as	0	O
hypotonic	0	O
agent	0	O
.	0	O


The	0	O
Euglena	0	B
ribosomal	0	I
protein	0	I
gene	0	I
cluster	0	I
resembles	0	O
the	0	O
S	1	B
-	0	I
10	0	I
ribosomal	0	I
protein	0	I
operon	0	I
of	0	I
Escherichia	1	I
coli	0	I
in	0	O
gene	0	O
organization	0	O
and	0	O
follows	0	O
the	0	O
exact	0	O
linear	0	O
order	0	O
of	0	O
the	0	O
analogous	0	O
genes	0	O
in	0	O
the	0	O
tobacco	0	O
and	0	O
liverwort	0	O
chloroplast	0	O
genomes	0	O
.	0	O


Canalith	1	O
repositioning	0	O
is	0	O
the	0	O
mainstay	0	O
of	0	O
treatment	0	O
.	0	O


Surprisingly	0	O
,	0	O
TFIIIC	0	B
alpha	0	I
has	0	O
no	0	O
homology	0	O
to	0	O
any	0	O
of	0	O
the	0	O
yeast	0	B
TFIIIC	0	I
subunits	0	I
already	0	O
cloned	0	O
,	0	O
suggesting	0	O
a	0	O
significant	0	O
degree	0	O
of	0	O
evolutionary	0	O
divergence	0	O
for	0	O
RNA	1	B
polymerase	0	I
III	0	I
factors	0	I
.	0	O


Thus	0	O
,	0	O
the	0	O
class	0	B
C	1	I
-	0	O
Vps	0	B
complex	0	O
directs	0	O
multiple	0	O
reactions	0	O
during	0	O
the	0	O
docking	0	O
and	0	O
fusion	0	O
of	0	O
vesicles	0	O
with	0	O
the	0	O
vacuole	0	O
,	0	O
each	0	O
of	0	O
which	0	O
contributes	0	O
to	0	O
the	0	O
overall	0	O
specificity	0	O
and	0	O
efficiency	0	O
of	0	O
this	0	O
transport	0	O
process	0	O
.	0	O


Diet	1	O
and	0	O
atopic	0	O
eczema	0	O
.	0	O


Disturbances	0	O
of	0	O
placental	0	O
maturation	0	O
,	0	O
2	0	O
.	0	O


Dissolution	1	O
of	0	O
the	0	O
Pt	1	O
-	0	O
30	0	O
%	0	O
Ir	1	O
microelectrode	0	O
tip	0	O
was	0	O
observed	0	O
by	0	O
scanning	0	O
electron	0	O
microscopy	0	O
at	0	O
charge	0	O
densities	0	O
as	0	O
low	0	O
as	0	O
200	0	O
microC	0	O
/	0	O
cm2	0	O
X	1	O
ph	0	O
(	0	O
1	0	O
A	1	O
/	0	O
cm2	0	O
),	0	O
whereas	0	O
erosion	0	O
of	0	O
activated	0	O
iridium	0	O
microelectrodes	0	O
occurred	0	O
only	0	O
at	0	O
the	0	O
highest	0	O
charge	0	O
and	0	O
current	0	O
densities	0	O
(	0	O
3200	0	O
microC	0	O
/	0	O
cm2	0	O
X	1	O
ph	0	O
,	0	O
16	0	O
A	1	O
/	0	O
cm2	0	O
).	0	O


Neither	0	O
the	0	O
reaction	0	O
of	0	O
monosaccharides	0	O
nor	0	O
the	0	O
disaccharides	0	O
with	0	O
beta	0	O
-	0	O
alanine	0	O
resulted	0	O
in	0	O
the	0	O
formation	0	O
of	0	O
maltol	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
R206S	0	B
HSF	0	I
substitution	0	O
exhibits	0	O
constitutive	0	O
transcriptional	0	O
activation	0	O
from	0	O
a	0	O
consensus	0	O
HSE	0	O
(	0	O
HSE2	0	O
).	0	O


Heterogeneous	1	O
electron	0	O
transfer	0	O
of	0	O
cytochrome	0	B
c	0	I
facilitated	0	O
by	0	O
polypyrrole	0	O
and	0	O
methylene	0	O
blue	0	O
polypyrrole	0	O
film	0	O
modified	0	O
electrodes	0	O
.	0	O


The	0	O
C	1	O
/	0	O
D	1	O
ratio	0	O
was	0	O
equal	0	O
to	0	O
or	0	O
over	0	O
0	0	O
.	0	O
6	0	O
in	0	O
9	0	O
cases	0	O
(	0	O
16	0	O
eyes	0	O
),	0	O
and	0	O
the	0	O
values	0	O
were	0	O
inconsistent	0	O
between	0	O
both	0	O
eyes	0	O
in	0	O
55	0	O
%	0	O
of	0	O
the	0	O
patients	0	O
.	0	O


Mutation	1	O
of	0	O
Enh4	0	B
,	0	O
an	0	O
essential	0	O
GT	1	B
-	0	I
IIC	0	I
-	0	I
like	0	I
enhanson	0	I
in	0	O
the	0	O
context	0	O
of	0	O
the	0	O
intact	0	O
enhancer	0	O
,	0	O
abolishes	0	O
silencer	0	O
activity	0	O
,	0	O
and	0	O
multimerized	0	O
GT	1	B
-	0	I
IIC	0	I
enhansons	0	I
mimic	0	O
the	0	O
intact	0	O
CSEn	0	B
enhancer	0	I
/	0	I
silencer	0	I
activities	0	O
in	0	O
BeWo	0	O
and	0	O
GC	1	O
cells	0	O
,	0	O
respectively	0	O
.	0	O


Reporter	1	O
constructs	0	O
function	0	O
in	0	O
a	0	O
parallel	0	O
manner	0	O
,	0	O
demonstrating	0	O
the	0	O
key	0	O
role	0	O
of	0	O
the	0	O
AhR	0	B
in	0	O
constitutive	0	O
as	0	O
well	0	O
as	0	O
TCDD	1	O
-	0	O
induced	0	O
expression	0	O
of	0	O
Cyp1B1	0	B
in	0	O
mouse	0	O
embryo	0	O
fibroblasts	0	O
.	0	O


That	0	O
sequence	0	O
strongly	0	O
promoted	0	O
the	0	O
transcription	0	O
of	0	O
the	0	O
promotorless	0	O
chloramphenicol	0	B
acetyltranferase	0	I
(	0	O
CAT	1	B
)	0	O
gene	0	O
in	0	O
cells	0	O
of	0	O
pancreatic	0	O
origin	0	O
(	0	O
AR	1	O
-	0	O
42J	0	O
)	0	O
but	0	O
not	0	O
in	0	O
cells	0	O
of	0	O
non	0	O
-	0	O
pancreatic	0	O
origin	0	O
(	0	O
Rat	1	O
2	0	O
and	0	O
IEC	0	O
6	0	O
).	0	O


RXR	0	B
-	0	I
gamma	0	I
expression	0	O
produced	0	O
significant	0	O
reduction	0	O
in	0	O
levels	0	O
of	0	O
RA	1	O
-	0	O
responsive	0	O
genes	0	O
including	0	O
the	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinase	0	I
inhibitors	0	O
p21Cip1	0	B
/	0	O
WAF1	0	B
and	0	O
p27Kip1	0	B
,	0	O
resulting	0	O
in	0	O
increased	0	O
cdc2	0	B
and	0	O
cdk2	0	B
kinase	0	I
activity	0	O
and	0	O
RB	1	B
phosphorylation	0	O
.	0	O


Morphology	1	O
of	0	O
bacteriophages	0	O
of	0	O
Klebsiella	1	O
bacilli	0	O
.	0	O


Two	0	O
basic	0	O
patterns	0	O
of	0	O
locomotor	0	O
behavior	0	O
and	0	O
corresponding	0	O
torso	0	O
morphology	0	O
exist	0	O
among	0	O
extant	0	O
anthropoids	0	O
.	0	O


Thus	0	O
,	0	O
multiple	0	O
myogenic	0	O
factors	0	O
that	0	O
vary	0	O
qualitatively	0	O
and	0	O
quantitatively	0	O
may	0	O
be	0	O
responsible	0	O
for	0	O
the	0	O
different	0	O
and	0	O
complex	0	O
modulatory	0	O
programs	0	O
of	0	O
actin	0	B
gene	0	I
expression	0	O
observed	0	O
during	0	O
in	0	O
vivo	0	O
muscle	0	O
differentiation	0	O
.	0	O


Reactivities	0	O
to	0	O
horse	0	B
anti	0	I
-	0	I
lymphocyte	0	I
globulin	0	I
.	0	O


All	1	O
33	0	O
subjects	0	O
were	0	O
given	0	O
psychometric	0	O
instruments	0	O
for	0	O
measuring	0	O
various	0	O
components	0	O
of	0	O
anger	0	O
and	0	O
anxiety	0	O
:	0	O
Spielberger	0	O
'	0	O
s	0	O
State	1	O
-	0	O
Trait	1	O
Personality	1	O
Inventory	1	O
,	0	O
the	0	O
Anger	1	O
Expression	1	O
Scale	1	O
,	0	O
and	0	O
the	0	O
State	1	O
Anger	1	O
Reaction	1	O
Scale	1	O
.	0	O


Arachnoid	1	O
cyst	0	O
.	0	O


A	1	O
0	0	O
.	0	O
5	0	O
rating	0	O
was	0	O
intended	0	O
to	0	O
characterize	0	O
subjects	0	O
in	0	O
whom	0	O
mild	0	O
cognitive	0	O
impairment	0	O
due	0	O
to	0	O
senile	0	O
dementia	0	O
of	0	O
the	0	O
Alzheimer	0	O
type	0	O
was	0	O
suspected	0	O
but	0	O
was	0	O
insufficient	0	O
in	0	O
degree	0	O
to	0	O
warrant	0	O
a	0	O
diagnosis	0	O
of	0	O
definite	0	O
dementia	0	O
.	0	O


The	0	O
report	0	O
highlights	0	O
the	0	O
possible	0	O
contribution	0	O
of	0	O
stress	0	O
factors	0	O
in	0	O
the	0	O
context	0	O
of	0	O
therapy	0	O
resistant	0	O
periodontal	0	O
disease	0	O
,	0	O
and	0	O
the	0	O
results	0	O
seem	0	O
to	0	O
be	0	O
understandable	0	O
within	0	O
the	0	O
context	0	O
of	0	O
a	0	O
stress	0	O
system	0	O
disorder	0	O
perspective	0	O
.	0	O


The	0	O
nmr	0	B
gene	0	I
is	0	O
the	0	O
major	0	O
negative	0	O
regulatory	0	O
gene	0	O
in	0	O
the	0	O
nitrogen	0	O
control	0	O
circuit	0	O
of	0	O
Neurospora	1	O
crassa	0	O
,	0	O
which	0	O
,	0	O
together	0	O
with	0	O
positive	0	O
regulatory	0	O
genes	0	O
,	0	O
governs	0	O
the	0	O
expression	0	O
of	0	O
multiple	0	O
unlinked	0	O
structural	0	O
genes	0	O
of	0	O
the	0	O
circuit	0	O
.	0	O


Preliminary	0	O
experiments	0	O
demonstrated	0	O
that	0	O
it	0	O
was	0	O
possible	0	O
to	0	O
produce	0	O
fasD	0	B
mutants	0	I
,	0	O
whose	0	O
products	0	O
remain	0	O
functional	0	O
for	0	O
fimbrial	0	O
export	0	O
and	0	O
assembly	0	O
.	0	O


Once	0	O
the	0	O
proliferation	0	O
of	0	O
fibroblasts	0	O
and	0	O
collagen	0	B
synthesis	0	O
had	0	O
led	0	O
to	0	O
an	0	O
increase	0	O
of	0	O
mechanical	0	O
strength	0	O
,	0	O
no	0	O
negative	0	O
effect	0	O
on	0	O
wound	0	O
healing	0	O
could	0	O
be	0	O
detected	0	O
applying	0	O
the	0	O
same	0	O
chemotherapeutic	0	O
agents	0	O
.	0	O


No	1	O
differences	0	O
in	0	O
fixation	0	O
quality	0	O
were	0	O
observed	0	O
between	0	O
cochleas	0	O
fixed	0	O
by	0	O
intravascular	0	O
perfusion	0	O
and	0	O
cochleas	0	O
fixed	0	O
by	0	O
intralabyrinthine	0	O
perfusion	0	O
.	0	O


Quantitative	1	O
computed	0	O
tomography	0	O
for	0	O
measuring	0	O
vertebral	0	O
bone	0	O
mineral	0	O
content	0	O
offers	0	O
high	0	O
sensitivity	0	O
and	0	O
reproducibility	0	O
.	0	O


The	0	O
combination	0	O
of	0	O
hydralazine	0	O
hydrochloride	0	O
and	0	O
isosorbide	0	O
dinitrate	0	O
also	0	O
improves	0	O
survival	0	O
,	0	O
but	0	O
direct	0	O
comparison	0	O
of	0	O
both	0	O
regimens	0	O
provided	0	O
evidence	0	O
for	0	O
a	0	O
less	0	O
favourable	0	O
effect	0	O
than	0	O
that	0	O
of	0	O
the	0	O
ACE	1	B
inhibitors	0	O
.	0	O


We	0	O
show	0	O
that	0	O
stimulation	0	O
of	0	O
resting	0	O
splenic	0	O
B	1	O
cells	0	O
with	0	O
CD40L	0	B
-	0	O
expressing	0	O
Sf9	0	O
cells	0	O
induces	0	O
germ	0	O
-	0	O
line	0	O
gamma	0	O
1	0	O
and	0	O
epsilon	0	O
transcripts	0	O
independently	0	O
of	0	O
cytokines	0	O
.	0	O


Partial	0	O
correction	0	O
of	0	O
anemia	0	O
with	0	O
recombinant	0	B
human	0	I
erythropoietin	0	I
likely	0	O
reduces	0	O
left	0	O
ventricular	0	O
mass	0	O
and	0	O
volume	0	O
.	0	O


Primer	1	O
extension	0	O
analysis	0	O
and	0	O
RNA	1	O
sequencing	0	O
demonstrates	0	O
that	0	O
the	0	O
transcription	0	O
start	0	O
point	0	O
of	0	O
rat	0	B
ODC	1	I
mRNA	1	I
is	0	O
located	0	O
303	0	O
nt	0	O
upstream	0	O
from	0	O
the	0	O
A	1	O
residue	0	O
in	0	O
the	0	O
start	0	O
codon	0	O
.	0	O


Cloning	1	O
,	0	O
sequencing	0	O
and	0	O
expression	0	O
of	0	O
the	0	O
3	0	B
-	0	I
phosphoglycerate	0	I
kinase	0	I
gene	0	I
of	0	O
Pyrococcus	0	O
woesei	0	O
in	0	O
Escherichia	1	O
coli	0	O
and	0	O
characterization	0	O
of	0	O
the	0	O
protein	0	O
.	0	O


Expression	1	O
of	0	O
a	0	O
dominant	0	B
negative	0	I
Smad2	0	I
significantly	0	O
reduces	0	O
the	0	O
level	0	O
of	0	O
luciferase	0	B
reporter	0	I
activity	0	O
induced	0	O
by	0	O
nodal	0	O
treatment	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
nitric	0	B
oxide	0	I
synthase	0	I
inhibitor	0	O
on	0	O
reperfusion	0	O
injury	0	O
of	0	O
the	0	O
brain	0	O
under	0	O
hypothermic	0	O
circulatory	0	O
arrest	0	O
.	0	O


5	0	O
.	0	O


Nickel	1	O
is	0	O
the	0	O
most	0	O
common	0	O
cause	0	O
of	0	O
allergic	0	O
contact	0	O
dermatitis	0	O
in	0	O
Singapore	0	O
,	0	O
resulting	0	O
in	0	O
positive	0	O
reactions	0	O
in	0	O
patch	0	O
tests	0	O
between	0	O
7	0	O
and	0	O
14	0	O
%.	0	O


Nasal	1	O
absorption	0	O
was	0	O
rapid	0	O
,	0	O
nasal	0	O
bioavailability	0	O
was	0	O
43	0	O
%,	0	O
and	0	O
the	0	O
iv	0	O
and	0	O
nasal	0	O
elimination	0	O
profiles	0	O
were	0	O
similar	0	O
.	0	O


To	1	O
evaluate	0	O
the	0	O
cost	0	O
and	0	O
benefits	0	O
of	0	O
screening	0	O
tests	0	O
for	0	O
Chlamydia	1	O
trachomatis	0	O
in	0	O
adolescent	0	O
males	0	O
,	0	O
we	0	O
developed	0	O
a	0	O
decision	0	O
analysis	0	O
model	0	O
and	0	O
compared	0	O
the	0	O
leukocyte	0	B
esterase	0	I
urine	0	O
dipstick	0	O
test	0	O
with	0	O
culture	0	O
,	0	O
with	0	O
direct	0	O
-	0	O
smear	0	O
fluorescent	0	O
antibody	0	O
(	0	O
DFA	1	O
),	0	O
and	0	O
with	0	O
the	0	O
option	0	O
of	0	O
no	0	O
screening	0	O
(	0	O
no	0	O
treatment	0	O
).	0	O


The	0	O
men	0	O
self	0	O
-	0	O
selected	0	O
a	0	O
prescribed	0	O
diet	0	O
at	0	O
home	0	O
emphasizing	0	O
saturated	0	O
fat	0	O
as	0	O
the	0	O
visible	0	O
fat	0	O
for	0	O
1	0	O
week	0	O
.	0	O


The	0	O
gene	0	B
ccpA	0	I
encoding	0	O
the	0	O
catabolite	0	B
control	0	I
protein	0	I
CcpA	0	I
of	0	O
Staphylococcus	1	O
xylosus	0	O
has	0	O
been	0	O
cloned	0	O
and	0	O
characterized	0	O
.	0	O


A	1	O
region	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
of	0	O
adenovirus	0	B
2	0	I
/	0	I
5	0	I
E1a	0	I
protein	0	I
is	0	O
required	0	O
for	0	O
association	0	O
with	0	O
a	0	O
cellular	0	O
phosphoprotein	0	O
and	0	O
important	0	O
for	0	O
the	0	O
negative	0	O
modulation	0	O
of	0	O
T24	0	O
-	0	O
ras	0	B
mediated	0	O
transformation	0	O
,	0	O
tumorigenesis	0	O
and	0	O
metastasis	0	O
.	0	O


Quinone	1	O
-	0	O
binding	0	O
domain	0	O
and	0	O
amino	0	O
acid	0	O
residues	0	O
involved	0	O
in	0	O
quinone	0	O
binding	0	O
.	0	O


LysR	0	B
proteins	0	I
have	0	O
been	0	O
shown	0	O
to	0	O
regulate	0	O
urease	0	B
in	0	I
Klebsiella	1	I
aerogenes	0	I
(	0	O
NAC	0	B
),	0	O
and	0	O
catalase	0	B
in	0	I
Escherichia	1	I
coli	0	I
(	0	O
OxyR	0	B
),	0	O
which	0	O
offers	0	O
the	0	O
intracellular	0	O
bacterium	0	O
protection	0	O
from	0	O
phagolysosome	0	O
damage	0	O
.	0	O


In	1	O
comparison	0	O
of	0	O
cDNA	1	O
and	0	O
genomic	0	O
sequences	0	O
four	0	O
RNA	1	O
editing	0	O
events	0	O
were	0	O
found	0	O
in	0	O
both	0	O
atp9	0	B
genes	0	I
.	0	O


Full	0	O
thyroid	0	O
function	0	O
testing	0	O
was	0	O
performed	0	O
on	0	O
600	0	O
randomly	0	O
selected	0	O
samples	0	O
with	0	O
normal	0	O
TSH	1	B
values	0	O
and	0	O
also	0	O
on	0	O
subjects	0	O
with	0	O
abnormal	0	O
TSH	1	B
levels	0	O
.	0	O


Auditory	1	O
clicks	0	O
were	0	O
given	0	O
at	0	O
a	0	O
rate	0	O
of	0	O
20	0	O
s	0	O
(-	0	O
1	0	O
).	0	O


1	0	O
-(	0	O
m	0	O
-	0	O
Chlorophenyl	0	O
)	0	O
piperazine	0	O
(	0	O
mCPP	0	O
,	0	O
0	0	O
.	0	O
1	0	O
-	0	O
3	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
)	0	O
and	0	O
1	0	O
-(	0	O
m	0	O
-	0	O
trifluoromethylphenyl	0	O
)	0	O
piperazine	0	O
(	0	O
TFMPP	0	O
,	0	O
0	0	O
.	0	O
1	0	O
-	0	O
3	0	O
.	0	O
0	0	O
mg	0	O
/	0	O
kg	0	O
),	0	O
both	0	O
thought	0	O
to	0	O
act	0	O
primarily	0	O
at	0	O
5	0	B
-	0	I
HT1	0	I
sites	0	I
,	0	O
also	0	O
decreased	0	O
responding	0	O
and	0	O
this	0	O
effect	0	O
was	0	O
blocked	0	O
by	0	O
methysergide	0	O
and	0	O
by	0	O
1	0	O
-	0	O
NP	1	O
,	0	O
but	0	O
not	0	O
by	0	O
ketanserin	0	O
.	0	O


Furthermore	0	O
,	0	O
in	0	O
vivo	0	O
and	0	O
in	0	O
vitro	0	O
protein	0	O
-	0	O
protein	0	O
interaction	0	O
experiments	0	O
have	0	O
shown	0	O
that	0	O
SR33	0	B
protein	0	I
interacts	0	O
with	0	O
itself	0	O
and	0	O
with	0	O
SR45	0	B
protein	0	I
but	0	O
not	0	O
with	0	O
two	0	O
other	0	O
members	0	O
(	0	O
SRZ21	0	B
and	0	O
SRZ22	0	B
)	0	O
of	0	O
the	0	O
SR	1	B
family	0	I
that	0	O
are	0	O
known	0	O
to	0	O
interact	0	O
with	0	O
the	0	O
Arabidopsis	0	O
full	0	O
-	0	O
length	0	O
U	1	B
-	0	I
70K	0	I
only	0	O
.	0	O


Dominant	1	O
negative	0	O
Sos	0	B
did	0	O
not	0	O
affect	0	O
carbachol	0	O
stimulation	0	O
of	0	O
HA	1	B
-	0	O
ERK2	0	B
but	0	O
inhibited	0	O
the	0	O
stimulatory	0	O
effect	0	O
of	0	O
EGF	1	B
by	0	O
60	0	O
%.	0	O


We	0	O
have	0	O
previously	0	O
reported	0	O
that	0	O
high	0	O
level	0	O
human	0	B
desmin	0	I
expression	0	O
depends	0	O
on	0	O
a	0	O
280	0	O
-	0	O
base	0	O
pair	0	O
muscle	0	O
-	0	O
specific	0	O
enhancer	0	O
which	0	O
can	0	O
function	0	O
not	0	O
only	0	O
in	0	O
myotubes	0	O
,	0	O
but	0	O
can	0	O
also	0	O
activate	0	O
gene	0	O
expression	0	O
in	0	O
myoblasts	0	O
.	0	O


The	0	O
logistic	0	O
regression	0	O
analysis	0	O
of	0	O
the	0	O
manual	0	O
method	0	O
(	0	O
percentage	0	O
normal	0	O
morphology	0	O
)	0	O
and	0	O
IVOS	0	O
indicated	0	O
that	0	O
both	0	O
were	0	O
predictors	0	O
of	0	O
fertilization	0	O
.	0	O


These	0	O
results	0	O
strongly	0	O
suggest	0	O
that	0	O
locally	0	O
-	0	O
applied	0	O
TTC	0	O
in	0	O
combination	0	O
with	0	O
FDBA	0	O
enhances	0	O
new	0	O
bone	0	O
formation	0	O
in	0	O
experimental	0	O
alveolar	0	O
bone	0	O
defects	0	O
.	0	O


The	0	O
data	0	O
imply	0	O
that	0	O
JAK	1	B
/	0	O
STAT	1	B
signaling	0	O
has	0	O
a	0	O
role	0	O
in	0	O
EBV	1	O
-	0	O
associated	0	O
malignancies	0	O
.	0	O


The	0	O
East	0	O
African	0	O
dik	0	O
-	0	O
dik	0	O
antelope	0	O
represents	0	O
a	0	O
miniature	0	O
model	0	O
ruminant	0	O
for	0	O
comparative	0	O
studies	0	O
.	0	O


Of	0	O
the	0	O
153	0	O
patients	0	O
studied	0	O
,	0	O
CK	1	B
-	0	I
MB	1	I
results	0	O
were	0	O
positive	0	O
in	0	O
91	0	O
(	0	O
59	0	O
%)	0	O
patients	0	O
;	0	O
ECG	1	O
revealed	0	O
AMI	1	O
in	0	O
72	0	O
(	0	O
47	0	O
%)	0	O
patients	0	O
.	0	O


The	0	O
course	0	O
of	0	O
endotoxin	0	O
fever	0	O
remained	0	O
uninfluenced	0	O
by	0	O
ALS	1	O
.	0	O


The	0	O
fragments	0	O
are	0	O
separated	0	O
and	0	O
directly	0	O
sized	0	O
by	0	O
agarose	0	O
gel	0	O
electrophoresis	0	O
.	0	O


In	1	O
general	0	O
,	0	O
the	0	O
filtration	0	O
rate	0	O
in	0	O
relevant	0	O
areas	0	O
appears	0	O
to	0	O
be	0	O
an	0	O
integrative	0	O
and	0	O
easily	0	O
determined	0	O
parameter	0	O
,	0	O
reflecting	0	O
hormonal	0	O
and	0	O
neurogenic	0	O
vascular	0	O
as	0	O
well	0	O
as	0	O
local	0	O
interstitial	0	O
control	0	O
of	0	O
the	0	O
Starling	0	O
forces	0	O
.	0	O


The	0	O
cDNAs	0	O
cross	0	O
-	0	O
hybridize	0	O
with	0	O
genomic	0	O
sequences	0	O
in	0	O
rat	0	O
,	0	O
human	0	O
,	0	O
and	0	O
chicken	0	O
DNA	1	O
,	0	O
but	0	O
not	0	O
with	0	O
DNA	1	O
from	0	O
frog	0	O
,	0	O
Drosophila	1	O
,	0	O
or	0	O
sea	0	O
urchin	0	O
.	0	O


It	1	O
was	0	O
suggested	0	O
that	0	O
the	0	O
absence	0	O
of	0	O
pronounced	0	O
differences	0	O
between	0	O
conditions	0	O
may	0	O
have	0	O
been	0	O
due	0	O
to	0	O
the	0	O
complexity	0	O
of	0	O
the	0	O
task	0	O
or	0	O
the	0	O
type	0	O
of	0	O
prompts	0	O
employed	0	O
.	0	O


Initial	1	O
estimates	0	O
indicate	0	O
that	0	O
27	0	O
,	0	O
193	0	O
people	0	O
are	0	O
either	0	O
in	0	O
receipt	0	O
of	0	O
or	0	O
in	0	O
need	0	O
of	0	O
mental	0	O
handicap	0	O
services	0	O
.	0	O


II	0	O
.	0	O


Rats	0	O
treated	0	O
with	0	O
8	0	O
-	0	O
OH	0	O
-	0	O
DPAT	0	O
were	0	O
not	0	O
impaired	0	O
in	0	O
their	0	O
ability	0	O
to	0	O
learn	0	O
a	0	O
visual	0	O
discrimination	0	O
in	0	O
a	0	O
water	0	O
maze	0	O
.	0	O


The	0	O
predicted	0	O
domain	0	O
structures	0	O
of	0	O
FkbB	0	B
and	0	O
FkbC	0	B
are	0	O
analogous	0	O
to	0	O
that	0	O
of	0	O
FkbA	0	B
and	0	O
comprise	0	O
30	0	O
fatty	0	B
-	0	I
acid	0	I
-	0	I
synthase	0	I
(	0	O
FAS	1	B
)-	0	O
like	0	O
domains	0	O
arranged	0	O
in	0	O
6	0	O
modules	0	O
.	0	O


Among	0	O
the	0	O
total	0	O
CDSs	0	O
,	0	O
8	0	O
.	0	O
8	0	O
%	0	O
match	0	O
sequences	0	O
of	0	O
proteins	0	O
found	0	O
only	0	O
in	0	O
Bacillus	1	O
subtilis	0	O
and	0	O
66	0	O
.	0	O
7	0	O
%	0	O
are	0	O
widely	0	O
conserved	0	O
in	0	O
comparison	0	O
with	0	O
the	0	O
proteins	0	O
of	0	O
various	0	O
organisms	0	O
,	0	O
including	0	O
B	1	O
.	0	O
subtilis	0	O
.	0	O


Serum	1	B
IgM	1	I
and	0	O
IgE	1	B
concentrations	0	O
,	0	O
allergen	0	B
-	0	I
specific	0	I
IgE	1	I
scores	0	O
,	0	O
and	0	O
the	0	O
tumor	0	O
E2R	0	B
status	0	O
were	0	O
combined	0	O
to	0	O
construct	0	O
a	0	O
three	0	O
-	0	O
level	0	O
risk	0	O
classification	0	O
that	0	O
was	0	O
more	0	O
prognostic	0	O
than	0	O
any	0	O
of	0	O
the	0	O
individual	0	O
components	0	O
.	0	O


Postnatal	1	O
volumetric	0	O
development	0	O
of	0	O
the	0	O
prefrontal	0	O
cortex	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


These	0	O
women	0	O
should	0	O
not	0	O
be	0	O
given	0	O
the	0	O
current	0	O
estrogen	0	O
PPI	1	O
,	0	O
which	0	O
was	0	O
designed	0	O
to	0	O
warn	0	O
women	0	O
of	0	O
the	0	O
risks	0	O
of	0	O
long	0	O
-	0	O
term	0	O
estrogen	0	O
use	0	O
;	0	O
a	0	O
PPI	1	O
should	0	O
be	0	O
written	0	O
specifically	0	O
for	0	O
patients	0	O
receiving	0	O
short	0	O
courses	0	O
.	0	O


Hoeben	0	O
,	0	O
F	1	O
.	0	O
J	1	O
.	0	O


Effects	0	O
of	0	O
methiothepin	0	O
and	0	O
lysergic	0	O
acid	0	O
diethylamide	0	O
on	0	O
serotonin	0	O
release	0	O
in	0	O
vitro	0	O
and	0	O
serotonin	0	O
synthesis	0	O
in	0	O
vivo	0	O
:	0	O
possible	0	O
relation	0	O
to	0	O
serotonin	0	B
autoreceptor	0	I
function	0	O
.	0	O


Tissue	1	O
necrosis	0	O
was	0	O
evaluated	0	O
using	0	O
triphenyltetrazolium	0	O
staining	0	O
and	0	O
was	0	O
related	0	O
to	0	O
two	0	O
major	0	O
baseline	0	O
predictors	0	O
of	0	O
infarct	0	O
size	0	O
:	0	O
anatomic	0	O
risk	0	O
zone	0	O
size	0	O
and	0	O
coronary	0	O
collateral	0	O
flow	0	O
.	0	O


Effects	0	O
of	0	O
chronic	0	O
descending	0	O
tractotomy	0	O
on	0	O
the	0	O
response	0	O
patterns	0	O
of	0	O
neurons	0	O
in	0	O
the	0	O
trigeminal	0	O
nuclei	0	O
principalis	0	O
and	0	O
oralis	0	O
.	0	O


These	0	O
intron	0	O
chimeras	0	O
show	0	O
that	0	O
peripheral	0	O
sequences	0	O
and	0	O
the	0	O
elements	0	O
that	0	O
define	0	O
the	0	O
splice	0	O
sites	0	O
are	0	O
adequate	0	O
for	0	O
self	0	O
-	0	O
splicing	0	O
activity	0	O
but	0	O
that	0	O
the	0	O
central	0	O
portions	0	O
containing	0	O
the	0	O
catalytic	0	O
cores	0	O
of	0	O
ai4	0	B
and	0	O
bi4	0	B
are	0	O
deficient	0	O
;	0	O
these	0	O
cores	0	O
are	0	O
the	0	O
likely	0	O
targets	0	O
of	0	O
the	0	O
splicing	0	O
proteins	0	O
.	0	O


Suppressors	0	O
of	0	O
defective	0	O
silencing	0	O
in	0	O
yeast	0	O
:	0	O
effects	0	O
on	0	O
transcriptional	0	O
repression	0	O
at	0	O
the	0	O
HMR	0	B
locus	0	I
,	0	O
cell	0	O
growth	0	O
and	0	O
telomere	0	O
structure	0	O
.	0	O


Thus	0	O
,	0	O
TRAF2	0	B
initiates	0	O
SAPK	0	B
and	0	O
p38	0	B
activation	0	O
by	0	O
binding	0	O
two	0	O
proximal	0	O
protein	0	O
kinases	0	O
:	0	O
GCK	0	B
and	0	O
RIP	0	B
.	0	O


After	0	O
7	0	O
days	0	O
,	0	O
a	0	O
spontaneous	0	O
regression	0	O
of	0	O
the	0	O
morphologic	0	O
alterations	0	O
caused	0	O
by	0	O
caerulein	0	O
-	0	O
induced	0	O
acute	0	O
pancreatitis	0	O
occurs	0	O
;	0	O
however	0	O
,	0	O
recovery	0	O
of	0	O
the	0	O
secretory	0	O
function	0	O
of	0	O
the	0	O
pancreas	0	O
was	0	O
only	0	O
reached	0	O
after	0	O
this	0	O
period	0	O
of	0	O
time	0	O
when	0	O
L	1	O
-	0	O
364	0	O
,	0	O
718	0	O
was	0	O
administered	0	O
therapeutically	0	O
(	0	O
0	0	O
.	0	O
1	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
).	0	O


We	0	O
have	0	O
partially	0	O
sequenced	0	O
the	0	O
RAP74	0	B
protein	0	I
from	0	O
purified	0	O
HeLa	0	O
cells	0	O
,	0	O
cloned	0	O
its	0	O
complementary	0	O
DNA	1	O
and	0	O
shown	0	O
that	0	O
its	0	O
translation	0	O
product	0	O
can	0	O
interact	0	O
with	0	O
RAP30	0	B
in	0	O
vitro	0	O
as	0	O
well	0	O
as	0	O
in	0	O
vivo	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
determine	0	O
whether	0	O
administration	0	O
of	0	O
misoprostol	0	O
prevents	0	O
gastric	0	O
hemorrhage	0	O
in	0	O
healthy	0	O
dogs	0	O
treated	0	O
with	0	O
high	0	O
doses	0	O
of	0	O
methylprednisolone	0	O
sodium	0	O
succinate	0	O
(	0	O
MPSS	0	O
).	0	O


In	1	O
adult	0	O
tissues	0	O
,	0	O
it	0	O
was	0	O
less	0	O
restricted	0	O
,	0	O
indicating	0	O
that	0	O
RAFTK	0	B
expression	0	O
is	0	O
developmentally	0	O
up	0	O
-	0	O
regulated	0	O
.	0	O


Plasma	1	O
lipid	0	O
and	0	O
lipoprotein	0	O
profiles	0	O
were	0	O
compared	0	O
in	0	O
elderly	0	O
female	0	O
runners	0	O
(	0	O
RU	1	O
:	0	O
n	0	O
=	0	O
15	0	O
,	0	O
aged	0	O
66	0	O
+/-	0	O
5	0	O
years	0	O
,	0	O
body	0	O
fat	0	O
20	0	O
+/-	0	O
4	0	O
%,	0	O
training	0	O
distance	0	O
35	0	O
+/-	0	O
15	0	O
km	0	O
week	0	O
-	0	O
1	0	O
,	0	O
VO2max	0	O
36	0	O
+/-	0	O
4	0	O
ml	0	O
kg	0	O
-	0	O
1	0	O
min	0	O
-	0	O
1	0	O
,	0	O
mean	0	O
+/-	0	O
SD	1	O
)	0	O
and	0	O
age	0	O
-	0	O
matched	0	O
untrained	0	O
women	0	O
(	0	O
UT	0	O
:	0	O
n	0	O
=	0	O
28	0	O
,	0	O
66	0	O
+/-	0	O
4	0	O
years	0	O
,	0	O
body	0	O
fat	0	O
26	0	O
+/-	0	O
6	0	O
%,	0	O
VO2max	0	O
26	0	O
+/-	0	O
3	0	O
ml	0	O
kg	0	O
-	0	O
1	0	O
min	0	O
-	0	O
1	0	O
).	0	O


SELECTION	1	O
CRITERIA	1	O
:	0	O
Randomised	0	O
and	0	O
possibly	0	O
randomised	0	O
trials	0	O
using	0	O
acupuncture	0	O
to	0	O
treat	0	O
asthma	0	O
and	0	O
asthma	0	O
-	0	O
like	0	O
symptoms	0	O
.	0	O


This	0	O
negative	0	O
regulatory	0	O
pathway	0	O
may	0	O
be	0	O
important	0	O
for	0	O
determining	0	O
cell	0	O
fate	0	O
or	0	O
maintaining	0	O
an	0	O
inducible	0	O
state	0	O
in	0	O
the	0	O
ventroposterior	0	O
region	0	O
of	0	O
the	0	O
embryo	0	O
.	0	O


Therapeutic	1	O
use	0	O
of	0	O
cannabis	0	O
.	0	O


Displacement	1	O
thresholds	0	O
of	0	O
peripheral	0	O
sites	0	O
in	0	O
monocular	0	O
human	0	O
vision	0	O
were	0	O
obtained	0	O
.	0	O


The	0	O
authors	0	O
conclude	0	O
that	0	O
nonspecificity	0	O
of	0	O
low	0	O
platelet	0	B
MAO	1	I
as	0	O
a	0	O
possible	0	O
correlate	0	O
of	0	O
bipolar	0	O
affective	0	O
disorder	0	O
,	0	O
as	0	O
well	0	O
as	0	O
schizophrenia	0	O
,	0	O
increases	0	O
the	0	O
burden	0	O
of	0	O
proof	0	O
necessary	0	O
before	0	O
findings	0	O
of	0	O
low	0	O
platelet	0	B
MAO	1	I
can	0	O
be	0	O
accepted	0	O
as	0	O
primary	0	O
.	0	O


The	0	O
integrity	0	O
of	0	O
the	0	O
cDNA	1	O
sequence	0	O
was	0	O
confirmed	0	O
by	0	O
analysis	0	O
of	0	O
several	0	O
overlapping	0	O
genomic	0	O
clones	0	O
that	0	O
span	0	O
the	0	O
GAR1	0	B
gene	0	I
.	0	O


Serum	1	O
-	0	O
ferritin	0	B
in	0	O
diagnosis	0	O
of	0	O
haemochromatosis	0	O
.	0	O


The	0	O
statistical	0	O
analysis	0	O
of	0	O
data	0	O
of	0	O
TRH	1	B
test	0	O
on	0	O
a	0	O
sample	0	O
of	0	O
57	0	O
healthy	0	O
volunteers	0	O
has	0	O
permitted	0	O
an	0	O
evaluation	0	O
of	0	O
the	0	O
upper	0	O
limits	0	O
of	0	O
the	0	O
normal	0	O
thyrotropin	0	B
response	0	O
;	0	O
the	0	O
secretory	0	O
area	0	O
(	0	O
As	1	O
)	0	O
was	0	O
shown	0	O
to	0	O
be	0	O
more	0	O
discriminating	0	O
.	0	O


This	0	O
transcriptional	0	O
regulation	0	O
occurs	0	O
through	0	O
modulation	0	O
of	0	O
the	0	O
forkhead	0	B
transcription	0	I
factor	0	I
FKHR	0	I
-	0	I
L1	0	I
,	0	O
and	0	O
IL	1	B
-	0	I
3	0	I
inhibited	0	O
FKHR	0	B
-	0	I
L1	0	I
activity	0	O
in	0	O
a	0	O
PI3K	0	B
-	0	O
dependent	0	O
manner	0	O
.	0	O


In	1	O
the	0	O
group	0	O
of	0	O
asthmatics	0	O
statistically	0	O
significant	0	O
correlation	0	O
was	0	O
found	0	O
between	0	O
PC20	0	O
PGF2	0	O
alpha	0	O
and	0	O
histamine	0	O
values	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
538	0	O
,	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


EEG	1	O
theta	0	O
waves	0	O
and	0	O
psychological	0	O
phenomena	0	O
:	0	O
a	0	O
review	0	O
and	0	O
analysis	0	O
.	0	O


We	0	O
demonstrate	0	O
that	0	O
the	0	O
protein	0	O
is	0	O
a	0	O
murine	0	B
homologue	0	I
of	0	I
SAF	0	I
-	0	I
A	1	I
which	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
bind	0	O
selectively	0	O
to	0	O
MARs	1	O
and	0	O
is	0	O
responsible	0	O
for	0	O
the	0	O
satMa	0	B
-	0	O
binding	0	O
activity	0	O
in	0	O
the	0	O
chromatographic	0	O
fractions	0	O
.	0	O


A	1	O
case	0	O
of	0	O
a	0	O
dense	0	O
epidermoid	0	O
cyst	0	O
of	0	O
the	0	O
suprasellar	0	O
cistern	0	O
is	0	O
presented	0	O
.	0	O


Tonometry	1	O
of	0	O
blood	0	O
samples	0	O
from	0	O
patients	0	O
may	0	O
also	0	O
be	0	O
used	0	O
in	0	O
the	0	O
determination	0	O
of	0	O
acid	0	O
-	0	O
base	0	O
quantities	0	O
and	0	O
hemoglobin	0	B
-	0	O
oxygen	0	O
affinity	0	O
e	0	O
.	0	O
g	0	O
.	0	O
p50	0	O
.	0	O


IFI16	0	B
consists	0	O
of	0	O
ten	0	O
exons	0	O
and	0	O
nine	0	O
intervening	0	O
introns	0	O
spanning	0	O
at	0	O
least	0	O
28	0	O
kilobases	0	O
(	0	O
kb	0	O
)	0	O
of	0	O
DNA	1	O
.	0	O


Multi	0	O
drug	0	O
regimens	0	O
like	0	O
C	1	O
-	0	O
MOPP	1	O
,	0	O
CHOP	1	O
and	0	O
BACOP	1	O
led	0	O
to	0	O
high	0	O
remission	0	O
rates	0	O
and	0	O
in	0	O
some	0	O
cases	0	O
probably	0	O
also	0	O
to	0	O
a	0	O
cure	0	O
of	0	O
the	0	O
disease	0	O
.	0	O


Influence	0	O
of	0	O
cyclo	0	B
-	0	I
oxygenase	0	I
inhibition	0	O
and	0	O
of	0	O
leukotriene	0	B
receptor	0	I
blockade	0	O
on	0	O
pulmonary	0	O
vascular	0	O
pressure	0	O
/	0	O
cardiac	0	O
index	0	O
relationships	0	O
in	0	O
hyperoxic	0	O
and	0	O
in	0	O
hypoxic	0	O
dogs	0	O
.	0	O


In	1	O
vitro	0	O
transcription	0	O
assays	0	O
demonstrate	0	O
that	0	O
the	0	O
TCA	1	O
-	0	O
cycle	0	O
intermediate	0	O
,	0	O
fumarate	0	O
,	0	O
directly	0	O
and	0	O
specifically	0	O
inhibits	0	O
the	0	O
formation	0	O
of	0	O
the	0	O
clcA	0	B
transcript	0	I
.	0	O


Since	0	O
GAGs	0	O
are	0	O
the	0	O
components	0	O
of	0	O
cartilage	0	O
matrix	0	O
,	0	O
the	0	O
depletion	0	O
of	0	O
which	0	O
is	0	O
associated	0	O
with	0	O
osteoarthrosis	0	O
,	0	O
a	0	O
method	0	O
for	0	O
measuring	0	O
sulphated	0	O
GAG	1	O
synthesis	0	O
in	0	O
culture	0	O
has	0	O
been	0	O
investigated	0	O
.	0	O


These	0	O
findings	0	O
demonstrate	0	O
that	0	O
signature	0	O
-	0	O
tagged	0	O
mutagenesis	0	O
is	0	O
a	0	O
viable	0	O
approach	0	O
to	0	O
identify	0	O
bacterial	0	O
genes	0	O
associated	0	O
with	0	O
the	0	O
ability	0	O
to	0	O
infect	0	O
the	0	O
urinary	0	O
tract	0	O
.	0	O


To	1	O
define	0	O
the	0	O
mechanism	0	O
responsible	0	O
for	0	O
the	0	O
loss	0	O
of	0	O
transcription	0	O
elongation	0	O
blockage	0	O
and	0	O
resulting	0	O
c	0	B
-	0	I
myc	0	I
deregulation	0	O
in	0	O
Burkitt	0	O
'	0	O
s	0	O
lymphoma	0	O
,	0	O
we	0	O
analyzed	0	O
transcription	0	O
patterns	0	O
after	0	O
transfer	0	O
of	0	O
normal	0	O
and	0	O
Burkitt	0	O
'	0	O
s	0	O
lymphoma	0	O
c	0	B
-	0	I
myc	0	I
alleles	0	O
into	0	O
murine	0	O
cells	0	O
and	0	O
Xenopus	1	O
oocyte	0	O
germinal	0	O
vesicles	0	O
.	0	O


Analysis	1	O
of	0	O
clearance	0	O
curve	0	O
of	0	O
rose	0	O
bengal	0	O
-	0	O
I	1	O
-	0	O
131	0	O


It	1	O
is	0	O
,	0	O
however	0	O
,	0	O
extremely	0	O
homologous	0	O
to	0	O
a	0	O
third	0	O
'	0	O
non	0	O
-	0	O
classical	0	O
'	0	O
gene	0	O
,	0	O
HLA	1	B
-	0	I
5	0	I
.	0	I
4	0	I
,	0	O
and	0	O
to	0	O
the	0	O
chimpanzee	0	O
gene	0	O
,	0	O
Ch28	0	B
.	0	O


No	1	O
other	0	O
changes	0	O
in	0	O
hematopoietic	0	O
differentiation	0	O
status	0	O
were	0	O
observed	0	O
in	0	O
association	0	O
with	0	O
Id	1	B
-	0	I
SCL	0	I
expression	0	O
.	0	O


Construction	0	O
of	0	O
a	0	O
RIP1	0	B
deletion	0	O
strain	0	O
and	0	O
isolation	0	O
of	0	O
temperature	0	O
-	0	O
sensitive	0	O
mutants	0	O
.	0	O


A	1	O
follow	0	O
-	0	O
up	0	O
study	0	O
of	0	O
22	0	O
patients	0	O
with	0	O
Ebstein	0	O
'	0	O
s	0	O
anomaly	0	O
has	0	O
been	0	O
performed	0	O
.	0	O


The	0	O
altered	0	O
amino	0	O
acid	0	O
residues	0	O
of	0	O
the	0	O
seven	0	O
mutant	0	B
9ORF1	0	I
polypeptides	0	I
clustered	0	O
within	0	O
three	0	O
separate	0	O
regions	0	O
referred	0	O
to	0	O
as	0	O
region	0	O
I	1	O
(	0	O
residues	0	O
34	0	O
to	0	O
41	0	O
),	0	O
region	0	O
II	0	O
(	0	O
residues	0	O
89	0	O
to	0	O
91	0	O
),	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
III	0	O
(	0	O
residues	0	O
122	0	O
to	0	O
125	0	O
).	0	O


Examination	1	O
of	0	O
immediate	0	B
-	0	I
early	0	I
transcription	0	I
factor	0	I
expression	0	O
during	0	O
the	0	O
MDI	1	O
regimen	0	O
revealed	0	O
that	0	O
RA	1	O
mediated	0	O
an	0	O
elevated	0	O
,	0	O
prolonged	0	O
expression	0	O
of	0	O
c	0	B
-	0	I
Jun	1	I
mRNA	1	I
accompanied	0	O
by	0	O
diminished	0	O
expression	0	O
of	0	O
c	0	B
-	0	I
Fos	1	I
and	0	O
Jun	1	B
-	0	I
B	1	I
mRNAs	0	I
.	0	O


The	0	O
most	0	O
likely	0	O
explanation	0	O
for	0	O
this	0	O
is	0	O
that	0	O
gold	0	O
principally	0	O
accumulates	0	O
in	0	O
the	0	O
Kupffer	0	O
cells	0	O
and	0	O
renal	0	O
cortex	0	O
and	0	O
these	0	O
cells	0	O
do	0	O
not	0	O
express	0	O
Type	1	B
I	1	I
deiodinase	0	I
.	0	O


This	0	O
organization	0	O
suggests	0	O
that	0	O
duplication	0	O
events	0	O
that	0	O
have	0	O
generated	0	O
the	0	O
primate	0	O
FUT3	0	B
-	0	O
FUT5	0	B
-	0	O
FUT6	0	B
cluster	0	O
might	0	O
have	0	O
occurred	0	O
through	0	O
a	0	O
long	0	O
-	0	O
interspersed	0	O
-	0	O
nuclear	0	O
-	0	O
element	0	O
-	0	O
based	0	O
mechanism	0	O
of	0	O
unequal	0	O
crossing	0	O
over	0	O
,	0	O
as	0	O
described	0	O
for	0	O
the	0	O
globin	0	B
cluster	0	I
.	0	O


The	0	O
predicted	0	O
L	1	B
mRNA	1	I
was	0	O
6398	0	O
nucleotides	0	O
long	0	O
and	0	O
contained	0	O
a	0	O
single	0	O
open	0	O
reading	0	O
frame	0	O
corresponding	0	O
to	0	O
an	0	O
L	1	B
protein	0	I
encompassing	0	I
2109	0	I
amino	0	I
acids	0	I
with	0	O
a	0	O
MW	1	O
of	0	O
241	0	O
,	0	O
546	0	O
.	0	O


Isolation	1	O
and	0	O
identification	0	O
of	0	O
genes	0	O
activating	0	O
UAS2	0	B
-	0	I
dependent	0	I
ADH2	0	I
expression	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Rigid	1	O
point	0	O
feature	0	O
registration	0	O
using	0	O
mutual	0	O
information	0	O
.	0	O


Based	0	O
on	0	O
a	0	O
type	0	O
I	1	O
error	0	O
of	0	O
0	0	O
.	0	O
05	0	O
,	0	O
our	0	O
study	0	O
had	0	O
a	0	O
power	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
75	0	O
%	0	O
to	0	O
detect	0	O
group	0	O
differences	0	O
in	0	O
treatment	0	O
effect	0	O
of	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
15	0	O
%	0	O
to	0	O
20	0	O
%.	0	O


What	0	O
'	0	O
s	0	O
new	0	O
in	0	O
gynecologic	0	O
and	0	O
obstetrical	0	O
surgery	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
show	0	O
that	0	O
IRF	1	B
-	0	I
1	0	I
is	0	O
degraded	0	O
via	0	O
the	0	O
ubiquitin	0	B
-	0	O
proteasome	0	O
pathway	0	O
.	0	O


Poliomyelitis	1	O
from	0	O
a	0	O
vaccine	0	O
.	0	O


VirD2	0	B
is	0	O
one	0	O
of	0	O
the	0	O
key	0	O
Agrobacterium	1	O
tumefaciens	0	O
proteins	0	O
involved	0	O
in	0	O
T	1	O
-	0	O
DNA	1	O
processing	0	O
and	0	O
transfer	0	O
.	0	O


In	1	O
all	0	O
instances	0	O
the	0	O
apparent	0	O
alcohol	0	O
responses	0	O
were	0	O
very	0	O
small	0	O
and	0	O
never	0	O
exceeded	0	O
a	0	O
reading	0	O
of	0	O
1	0	O
microgram	0	O
/	0	O
100ml	0	O
for	0	O
breath	0	O
samples	0	O
more	0	O
than	0	O
10min	0	O
post	0	O
-	0	O
exposure	0	O
.	0	O


The	0	O
history	0	O
of	0	O
exposure	0	O
and	0	O
carboxyhemoglobin	0	B
levels	0	O
should	0	O
alert	0	O
the	0	O
physician	0	O
to	0	O
this	0	O
diagnosis	0	O
.	0	O


The	0	O
N	1	O
-	0	O
terminal	0	O
small	0	O
segment	0	O
of	0	O
yeast	0	B
TAF145	0	I
(	0	O
yTAF145	0	B
)	0	O
binds	0	O
to	0	O
TBP	1	B
and	0	O
thereby	0	O
inhibits	0	O
TBP	1	B
function	0	O
.	0	O


Critical	1	O
residues	0	O
required	0	O
for	0	O
repression	0	O
are	0	O
located	0	O
within	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
27	0	O
amino	0	O
acids	0	O
of	0	O
c	0	B
-	0	I
Fos	1	I
,	0	O
since	0	O
v	0	B
-	0	I
Fos	1	I
and	0	O
C	1	O
-	0	O
terminal	0	O
truncations	0	O
of	0	O
c	0	B
-	0	I
Fos	1	I
did	0	O
not	0	O
down	0	O
regulate	0	O
.	0	O


Relationship	0	O
between	0	O
gross	0	O
lesions	0	O
and	0	O
Escherichia	1	O
coli	0	O
serotypes	0	O
in	0	O
chronic	0	O
respiratory	0	O
disease	0	O
(	0	O
CRD	0	O
)	0	O
of	0	O
poultry	0	O
.	0	O


Hailey	0	O
-	0	O
Hailey	0	O
disease	0	O
is	0	O
caused	0	O
by	0	O
mutations	0	O
in	0	O
ATP2C1	0	B
encoding	0	O
a	0	O
novel	0	O
Ca	1	O
(	0	O
2	0	O
+)	0	O
pump	0	O
.	0	O


A	1	O
sequence	0	O
homology	0	O
analysis	0	O
between	0	O
human	0	B
nm23	0	I
-	0	I
H1	1	I
and	0	O
the	0	O
homolog	0	O
gene	0	O
of	0	O
the	0	O
rat	0	O
(	0	O
NDP	0	B
-	0	I
K	1	I
beta	0	I
)	0	O
shows	0	O
that	0	O
exon	0	O
-	0	O
intron	0	O
boundaries	0	O
are	0	O
well	0	O
conserved	0	O
between	0	O
these	0	O
two	0	O
species	0	O
.	0	O


Two	0	O
patients	0	O
were	0	O
treated	0	O
successfully	0	O
with	0	O
a	0	O
combination	0	O
of	0	O
metronidazole	0	O
(	0	O
a	0	O
tissue	0	O
amoebicide	0	O
)	0	O
and	0	O
diloxanide	0	O
(	0	O
a	0	O
lumenal	0	O
amoebicide	0	O
).	0	O


5	0	O
)	0	O
We	0	O
'	0	O
ve	0	O
noticed	0	O
that	0	O
the	0	O
mean	0	O
value	0	O
of	0	O
the	0	O
cost	0	O
for	0	O
episode	0	O
of	0	O
pnx	0	O
s	0	O
.	0	O
in	0	O
class	0	O
A	1	O
was	0	O
more	0	O
than	0	O
15	0	O
%	0	O
compared	0	O
to	0	O
class	0	O
B	1	O
and	0	O
the	0	O
cost	0	O
for	0	O
patient	0	O
in	0	O
class	0	O
A	1	O
was	0	O
nearly	0	O
double	0	O
than	0	O
in	0	O
class	0	O
B	1	O
.	0	O


I	1	O
.	0	O


Acquired	1	O
bile	0	O
duct	0	O
blockage	0	O
:	0	O
entry	0	O
of	0	O
hepatobiliary	0	O
agent	0	O
into	0	O
an	0	O
intrahepatic	0	O
abscess	0	O
.	0	O


Recurrent	1	O
acute	0	O
rhinosinusitis	0	O
was	0	O
common	0	O
in	0	O
both	0	O
groups	0	O
of	0	O
patients	0	O
,	0	O
but	0	O
the	0	O
development	0	O
of	0	O
chronic	0	O
rhinosinusitis	0	O
was	0	O
only	0	O
found	0	O
in	0	O
patients	0	O
with	0	O
CVID	1	O
,	0	O
indicating	0	O
the	0	O
more	0	O
severe	0	O
nature	0	O
of	0	O
this	0	O
condition	0	O
compared	0	O
with	0	O
selective	0	O
IgA	1	B
deficiency	0	O
.	0	O


Potency	1	O
of	0	O
enflurane	0	O
in	0	O
dogs	0	O
:	0	O
comparison	0	O
with	0	O
halothane	0	O
and	0	O
isoflurane	0	O
.	0	O


Animals	0	O
were	0	O
put	0	O
to	0	O
death	0	O
8	0	O
weeks	0	O
later	0	O
and	0	O
the	0	O
grafts	0	O
were	0	O
sterilely	0	O
explanted	0	O
and	0	O
analyzed	0	O
via	0	O
microbiologic	0	O
culture	0	O
and	0	O
standard	0	O
histologic	0	O
procedures	0	O
for	0	O
evidence	0	O
of	0	O
infection	0	O
.	0	O


Liver	1	O
TG	1	O
and	0	O
serum	0	O
NEFA	1	O
concentrations	0	O
were	0	O
positively	0	O
correlated	0	O
.	0	O


Competitive	0	O
reverse	0	O
transcription	0	O
-	0	O
polymerase	0	O
chain	0	O
reaction	0	O
and	0	O
HPLC	1	O
analysis	0	O
showed	0	O
that	0	O
RUSH	1	B
-	0	I
1alpha	0	I
is	0	O
the	0	O
progesterone	0	O
-	0	O
dependent	0	O
splice	0	O
variant	0	O
.	0	O


The	0	O
perifascicular	0	O
connective	0	O
tissue	0	O
sheath	0	O
is	0	O
important	0	O
in	0	O
organising	0	O
the	0	O
contraction	0	O
of	0	O
the	0	O
myocardium	0	O
by	0	O
preventing	0	O
lateral	0	O
spread	0	O
of	0	O
conduction	0	O
and	0	O
by	0	O
permitting	0	O
transmission	0	O
of	0	O
the	0	O
impulse	0	O
only	0	O
at	0	O
the	0	O
termination	0	O
of	0	O
the	0	O
purkinje	0	O
fibre	0	O
.	0	O


An	1	O
unusual	0	O
complication	0	O
in	0	O
an	0	O
unsuitable	0	O
patient	0	O
.	0	O


Further	0	O
,	0	O
the	0	O
ORFs	0	O
of	0	O
components	0	O
3	0	O
and	0	O
5	0	O
potentially	0	O
encoded	0	O
proteins	0	O
of	0	O
about	0	O
20	0	O
kDa	1	O
,	0	O
the	0	O
size	0	O
of	0	O
the	0	O
BBTV	0	B
coat	0	I
protein	0	I
.	0	O


Furthermore	0	O
it	0	O
was	0	O
suggested	0	O
that	0	O
FK506	0	O
plasma	0	O
levels	0	O
were	0	O
concerned	0	O
with	0	O
the	0	O
appearance	0	O
of	0	O
side	0	O
effect	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
the	0	O
general	0	O
clinical	0	O
criteria	0	O
for	0	O
inhalation	0	O
injury	0	O
--	0	O
presence	0	O
of	0	O
facial	0	O
or	0	O
oropharyngeal	0	O
burns	0	O
,	0	O
carboxyhemoglobin	0	B
levels	0	O
,	0	O
carbonaceous	0	O
sputum	0	O
,	0	O
or	0	O
closed	0	O
space	0	O
injury	0	O
--	0	O
did	0	O
not	0	O
differentiate	0	O
patients	0	O
with	0	O
airway	0	O
injury	0	O
only	0	O
from	0	O
those	0	O
with	0	O
parenchymal	0	O
injury	0	O
.	0	O


Most	0	O
of	0	O
the	0	O
expressed	0	O
human	0	B
E3	1	I
polypeptides	0	I
(	0	O
five	0	O
bands	0	O
)	0	O
were	0	O
found	0	O
in	0	O
the	0	O
insoluble	0	O
pellet	0	O
while	0	O
primarily	0	O
full	0	B
-	0	I
length	0	I
mature	0	I
E3	1	I
was	0	O
found	0	O
in	0	O
the	0	O
soluble	0	O
fraction	0	O
.	0	O


The	0	O
upstream	0	O
promoter	0	O
is	0	O
located	0	O
within	0	O
the	0	O
coding	0	O
sequence	0	O
of	0	O
a	0	O
divergent	0	O
gene	0	O
expressing	0	O
a	0	O
protein	0	O
of	0	O
Mr	1	O
39	0	O
kDa	1	O
of	0	O
unknown	0	O
function	0	O
.	0	O


Relations	0	O
between	0	O
adrenergic	0	O
mechanisms	0	O
and	0	O
analgesic	0	O
effects	0	O


A	1	O
raised	0	O
amplitude	0	O
of	0	O
the	0	O
aggregation	0	O
of	0	O
plates	0	O
and	0	O
a	0	O
decrease	0	O
in	0	O
the	0	O
threshold	0	O
of	0	O
their	0	O
sensitivity	0	O
to	0	O
ADP	1	O
were	0	O
established	0	O
in	0	O
the	0	O
persons	0	O
with	0	O
types	0	O
IIa	0	O
and	0	O
IIb	0	O
HLP	0	O
and	0	O
in	0	O
CHD	1	O
without	0	O
HLP	0	O
.	0	O


When	0	O
the	0	O
blood	0	O
pressure	0	O
increase	0	O
in	0	O
response	0	O
to	0	O
smoking	0	O
was	0	O
blunted	0	O
by	0	O
nitroprusside	0	O
infusion	0	O
,	0	O
there	0	O
was	0	O
a	0	O
striking	0	O
increase	0	O
in	0	O
muscle	0	O
SNA	0	O
.	0	O


Synthetic	1	O
oligonucleotides	0	O
representing	0	O
the	0	O
19	0	O
bp	0	O
repeat	0	O
unit	0	O
strongly	0	O
reduced	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
IE1	0	B
/	0	I
2	0	I
enhancer	0	I
/	0	I
promoter	0	I
in	0	O
cotransfection	0	O
assays	0	O
after	0	O
transient	0	O
expression	0	O
.	0	O


Serotonin	1	B
5	0	I
-	0	I
HT2	0	I
receptor	0	I
binding	0	O
on	0	O
blood	0	O
platelets	0	O
as	0	O
a	0	O
state	0	O
dependent	0	O
marker	0	O
in	0	O
major	0	O
affective	0	O
disorder	0	O
.	0	O


Although	0	O
Micrococcus	1	B
luteus	0	I
UV	1	I
endonuclease	0	I
has	0	O
been	0	O
reported	0	O
to	0	O
be	0	O
an	0	O
18	0	O
-	0	O
kDa	1	O
enzyme	0	O
with	0	O
possible	0	O
homology	0	O
to	0	O
the	0	O
16	0	B
-	0	I
kDa	1	I
endonuclease	0	I
V	1	I
from	0	I
bacteriophage	0	I
T4	1	I
(	0	O
Gordon	0	O
,	0	O
L	1	O
.	0	O


Interestingly	0	O
,	0	O
following	0	O
induction	0	O
of	0	O
stress	0	O
by	0	O
heat	0	O
shock	0	O
,	0	O
high	0	O
salt	0	O
,	0	O
or	0	O
ethanol	0	O
,	0	O
conditions	0	O
under	0	O
which	0	O
most	0	O
mRNA	1	O
export	0	O
is	0	O
blocked	0	O
,	0	O
Npl3p	0	B
is	0	O
still	0	O
exported	0	O
from	0	O
the	0	O
nucleus	0	O
.	0	O


Cluster	1	O
formation	0	O
of	0	O
E	1	B
-	0	I
cadherin	0	I
on	0	O
the	0	O
cell	0	O
surface	0	O
is	0	O
believed	0	O
to	0	O
be	0	O
of	0	O
major	0	O
importance	0	O
for	0	O
cell	0	O
-	0	O
cell	0	O
adhesion	0	O
.	0	O


Initially	0	O
,	0	O
we	0	O
observed	0	O
that	0	O
unmutated	0	O
p53	0	B
is	0	O
strongly	0	O
expressed	0	O
in	0	O
premalignant	0	O
mammary	0	O
glands	0	O
and	0	O
in	0	O
mammary	0	O
tumors	0	O
derived	0	O
from	0	O
the	0	O
MMTV	0	O
-	0	O
c	0	B
-	0	I
myc	0	I
strain	0	O
.	0	O


To	1	O
study	0	O
the	0	O
significance	0	O
of	0	O
these	0	O
domains	0	O
and	0	O
the	0	O
overall	0	O
evolutionary	0	O
conservation	0	O
of	0	O
the	0	O
gene	0	O
,	0	O
the	0	O
homolog	0	O
from	0	O
Drosophila	1	O
melanogaster	0	O
was	0	O
isolated	0	O
by	0	O
low	0	O
stringency	0	O
hybridizations	0	O
using	0	O
two	0	O
flanking	0	O
probes	0	O
of	0	O
the	0	O
human	0	B
ERCC3	0	I
cDNA	1	I
.	0	O


Improving	0	O
fissure	0	O
sealant	0	O
quality	0	O
:	0	O
mechanical	0	O
preparation	0	O
and	0	O
filling	0	O
level	0	O
.	0	O


Pathogens	0	O
(	0	O
Staphylococcus	1	O
aureus	0	O
or	0	O
Gram	1	O
-	0	O
negative	0	O
bacilli	0	O
)	0	O
were	0	O
isolated	0	O
from	0	O
only	0	O
one	0	O
member	0	O
of	0	O
staff	0	O
in	0	O
small	0	O
numbers	0	O
and	0	O
irregularly	0	O
and	0	O
rarely	0	O
in	0	O
large	0	O
numbers	0	O
from	0	O
patients	0	O
.	0	O


The	0	O
authors	0	O
concluded	0	O
that	0	O
ultrasonic	0	O
Doppler	1	O
-	0	O
cardiography	0	O
can	0	O
be	0	O
used	0	O
for	0	O
measuring	0	O
the	0	O
relative	0	O
changes	0	O
in	0	O
the	0	O
stroke	0	O
volume	0	O
.	0	O


Survival	1	O
was	0	O
calculated	0	O
both	0	O
from	0	O
the	0	O
date	0	O
of	0	O
onset	0	O
and	0	O
from	0	O
the	0	O
date	0	O
of	0	O
diagnosis	0	O
.	0	O


Sex	1	O
ratio	0	O
at	0	O
birth	0	O
.	0	O


Of	0	O
the	0	O
remaining	0	O
seven	0	O
,	0	O
five	0	O
reacted	0	O
either	0	O
with	0	O
immediate	0	O
and	0	O
strong	0	O
symptoms	0	O
or	0	O
had	0	O
spontaneously	0	O
reduced	0	O
gluten	0	B
intake	0	O
,	0	O
or	0	O
had	0	O
an	0	O
acquired	0	O
IgA	1	B
deficiency	0	O
.	0	O


In	1	O
Group	1	O
V	1	O
,	0	O
the	0	O
salvaged	0	O
tissue	0	O
was	0	O
primarily	0	O
subepicardial	0	O
with	0	O
virtually	0	O
no	0	O
lateral	0	O
zone	0	O
of	0	O
salvaged	0	O
tissue	0	O
(	0	O
ratio	0	O
of	0	O
salvaged	0	O
subepicardium	0	O
to	0	O
salvaged	0	O
subendocardium	0	O
14	0	O
.	0	O
8	0	O
+/-	0	O
1	0	O
.	0	O
9	0	O
to	0	O
1	0	O
).	0	O


When	0	O
this	0	O
DNA	1	O
fragment	0	O
was	0	O
placed	0	O
upstream	0	O
of	0	O
the	0	O
chloramphenicol	0	B
acetyltransferase	0	I
(	0	O
CAT	1	B
)	0	O
reporter	0	O
gene	0	O
and	0	O
transfected	0	O
into	0	O
a	0	O
carp	0	O
CF	1	O
cell	0	O
line	0	O
,	0	O
it	0	O
could	0	O
drive	0	O
the	0	O
synthesis	0	O
of	0	O
CAT	1	B
enzyme	0	I
16	0	O
times	0	O
more	0	O
efficiently	0	O
than	0	O
the	0	O
promoterless	0	O
pCAT	0	B
-	0	I
Basic	1	I
.	0	O


We	0	O
thus	0	O
conclude	0	O
that	0	O
the	0	O
NFAT	0	B
RIR	0	I
plays	0	O
an	0	O
essential	0	O
dual	0	O
role	0	O
in	0	O
DNA	1	O
recognition	0	O
and	0	O
cooperative	0	O
binding	0	O
to	0	O
AP	1	B
-	0	I
1	0	I
family	0	I
transcription	0	I
factors	0	I
.	0	O


This	0	O
brief	0	O
review	0	O
analyses	0	O
these	0	O
interactions	0	O
and	0	O
defines	0	O
clinical	0	O
settings	0	O
where	0	O
antibiotic	0	O
-	0	O
induced	0	O
endotoxin	0	O
release	0	O
may	0	O
prove	0	O
to	0	O
be	0	O
clinically	0	O
relevant	0	O
.	0	O


Phenazone	1	O
potentiates	0	O
the	0	O
local	0	O
anaesthetic	0	O
effect	0	O
of	0	O
lidocaine	0	O
in	0	O
mice	0	O
.	0	O


Characterization	0	O
of	0	O
the	0	O
transcription	0	B
factor	0	I
MTF	0	I
-	0	I
1	0	I
from	0	O
the	0	O
Japanese	0	O
pufferfish	0	O
(	0	O
Fugu	1	O
rubripes	0	O
)	0	O
reveals	0	O
evolutionary	0	O
conservation	0	O
of	0	O
heavy	0	O
metal	0	O
stress	0	O
response	0	O
.	0	O


Plasma	1	B
renin	0	I
activity	0	O
does	0	O
not	0	O
predict	0	O
the	0	O
antihypertensive	0	O
efficacy	0	O
of	0	O
chlorthalidone	0	O
.	0	O


Combined	0	O
expression	0	O
of	0	O
c	0	B
-	0	I
Jun	1	I
and	0	O
p65	0	B
induced	0	O
vigorous	0	O
transcription	0	O
of	0	O
IL	1	B
-	0	I
2	0	I
promoter	0	O
-	0	O
and	0	O
CD28RE	0	B
-	0	I
driven	0	I
reporter	0	I
constructs	0	I
in	0	O
both	0	O
LFA	1	B
-	0	I
3	0	I
-	0	O
and	0	O
B7	0	B
-	0	I
1	0	I
-	0	O
costimulated	0	O
Jurkat	0	O
cells	0	O
.	0	O


The	0	O
nucleosomal	0	O
arrays	0	O
detected	0	O
by	0	O
MPE	0	O
X	1	O
Fe	1	O
(	0	O
II	0	O
)	0	O
were	0	O
characterized	0	O
by	0	O
a	0	O
considerable	0	O
loss	0	O
of	0	O
detail	0	O
and	0	O
significantly	0	O
enhanced	0	O
accessibility	0	O
,	0	O
the	0	O
extent	0	O
of	0	O
which	0	O
probably	0	O
reflected	0	O
the	0	O
relative	0	O
transcription	0	O
rate	0	O
of	0	O
each	0	O
gene	0	O
.	0	O


Analysis	1	O
of	0	O
its	0	O
genomic	0	O
region	0	O
revealed	0	O
that	0	O
the	0	O
13	0	O
-	0	O
kb	0	O
Cdc6	0	B
gene	0	I
is	0	O
divided	0	O
into	0	O
12	0	O
exons	0	O
by	0	O
11	0	O
introns	0	O
.	0	O


Mn2	0	O
+	0	O
increased	0	O
both	0	O
the	0	O
junction	0	O
binding	0	O
and	0	O
cleaving	0	O
activities	0	O
of	0	O
the	0	O
mutant	0	O
proteins	0	O
.	0	O


Risk	1	O
factors	0	O
associated	0	O
with	0	O
a	0	O
high	0	O
seroprevalence	0	O
of	0	O
hepatitis	0	O
C	1	O
virus	0	O
infection	0	O
in	0	O
Egyptian	0	O
blood	0	O
donors	0	O
.	0	O


Both	0	O
reduced	0	O
spontaneous	0	O
locomotor	0	O
activity	0	O
in	0	O
mice	0	O
,	0	O
protected	0	O
them	0	O
from	0	O
death	0	O
from	0	O
amphetamine	0	O
induced	0	O
toxicity	0	O
,	0	O
prolonged	0	O
hexobarbitone	0	O
sleeping	0	O
time	0	O
and	0	O
caused	0	O
a	0	O
depletion	0	O
of	0	O
catecholamines	0	O
from	0	O
various	0	O
organs	0	O
of	0	O
the	0	O
rat	0	O
.	0	O


Differential	1	O
screening	0	O
of	0	O
mitochondrial	0	O
cDNA	1	O
libraries	0	O
from	0	O
male	0	O
-	0	O
fertile	0	O
and	0	O
cytoplasmic	0	O
male	0	O
-	0	O
sterile	0	O
sugar	0	O
-	0	O
beet	0	O
reveals	0	O
genome	0	O
rearrangements	0	O
at	0	O
atp6	0	B
and	0	O
atpA	0	B
loci	0	I
.	0	O


Moreover	0	O
,	0	O
the	0	O
effect	0	O
exerted	0	O
by	0	O
TIS1	0	B
appeared	0	O
to	0	O
be	0	O
selective	0	O
for	0	O
the	0	O
MCK	0	B
promoter	0	I
.	0	O


The	0	O
unphosphorylated	0	O
form	0	O
of	0	O
RNA	1	B
polymerase	0	I
II	0	I
is	0	O
designated	0	O
IIA	0	O
,	0	O
whereas	0	O
the	0	O
phosphorylated	0	O
form	0	O
is	0	O
designated	0	O
IIO	0	O
.	0	O


Rabbit	1	O
eyes	0	O
were	0	O
removed	0	O
and	0	O
held	0	O
in	0	O
temperature	0	O
-	0	O
regulated	0	O
chambers	0	O
and	0	O
irrigated	0	O
with	0	O
saline	0	O
.	0	O


Cowpox	1	O
virus	0	O
contains	0	O
two	0	O
copies	0	O
of	0	O
an	0	O
early	0	B
gene	0	I
encoding	0	O
a	0	O
soluble	0	O
secreted	0	O
form	0	O
of	0	O
the	0	O
type	0	B
II	0	I
TNF	1	I
receptor	0	I
.	0	O


Information	1	O
about	0	O
immunologic	0	O
drug	0	O
interactions	0	O
is	0	O
needed	0	O
by	0	O
pharmacists	0	O
to	0	O
make	0	O
rational	0	O
drug	0	O
-	0	O
use	0	O
decisions	0	O
.	0	O


The	0	O
carboxyl	0	O
-	0	O
terminal	0	O
CCCC	0	O
module	0	O
is	0	O
structurally	0	O
related	0	O
to	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
domain	0	O
of	0	O
the	0	O
erythroid	0	B
transcription	0	I
factor	0	I
GATA	0	I
-	0	I
1	0	I
.	0	O


Expression	1	O
of	0	O
p130	0	B
(	0	O
Cas	1	B
)	0	O
(	0	O
Cas	1	B
),	0	O
a	0	O
major	0	O
binding	0	O
protein	0	O
for	0	O
the	0	O
Crk	0	B
SH2	0	I
-	0	I
domain	0	I
,	0	O
also	0	O
induced	0	O
JNK	0	B
activation	0	O
,	0	O
which	0	O
was	0	O
blocked	0	O
by	0	O
the	0	O
SH2	0	B
-	0	I
mutant	0	I
of	0	O
Crk	0	B
.	0	O


Here	0	O
we	0	O
report	0	O
that	0	O
in	0	O
cultured	0	O
cells	0	O
from	0	O
Drosophila	1	O
melanogaster	0	O
human	0	B
Sp1	0	I
efficiently	0	O
activates	0	O
transcription	0	O
from	0	O
synthetic	0	O
promoters	0	O
containing	0	O
TATA	0	O
boxes	0	O
,	0	O
but	0	O
not	0	O
from	0	O
promoters	0	O
that	0	O
contain	0	O
an	0	O
initiator	0	O
instead	0	O
of	0	O
a	0	O
TATA	0	O
box	0	O
.	0	O


The	0	O
relationship	0	O
of	0	O
human	0	O
umbilical	0	O
arterial	0	O
and	0	O
venous	0	O
plasma	0	O
levels	0	O
of	0	O
corticosteroids	0	O
to	0	O
gestational	0	O
age	0	O
.	0	O


This	0	O
repression	0	O
does	0	O
not	0	O
require	0	O
the	0	O
PU	1	B
.	0	I
1	0	I
transactivation	0	O
or	0	O
PEST	1	O
domains	0	O
and	0	O
cannot	0	O
be	0	O
reversed	0	O
by	0	O
p300	0	B
expression	0	O
.	0	O


Recently	0	O
,	0	O
a	0	O
human	0	B
transcription	0	I
elongation	0	I
factor	0	I
P	1	I
-	0	I
TEFb	0	I
,	0	O
consisting	0	O
of	0	O
CDK9	0	B
kinase	0	I
,	0	O
cyclin	0	B
T	1	I
and	0	O
other	0	O
associated	0	O
factors	0	O
,	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
interact	0	O
with	0	O
Tat	1	B
to	0	O
restore	0	O
Tat	1	B
activation	0	O
in	0	O
HeLa	0	O
nuclear	0	O
extract	0	O
depleted	0	O
of	0	O
P	1	B
-	0	I
TEFb	0	I
.	0	O


The	0	O
substrates	0	O
for	0	O
glycan	0	O
synthesis	0	O
in	0	O
the	0	O
lumen	0	O
of	0	O
the	0	O
Golgi	0	O
are	0	O
nucleotide	0	O
sugars	0	O
that	0	O
must	0	O
be	0	O
transported	0	O
from	0	O
the	0	O
cytosol	0	O
by	0	O
specific	0	O
membrane	0	O
-	0	O
bound	0	O
transporters	0	O
.	0	O


As	1	O
expected	0	O
,	0	O
the	0	O
insulin	0	B
effect	0	O
to	0	O
increase	0	O
ras	0	B
GTP	1	I
formation	0	O
and	0	O
MAP	1	B
kinase	0	I
activity	0	O
was	0	O
negligible	0	O
in	0	O
A	1	O
/	0	O
K1018	0	O
cells	0	O
but	0	O
normal	0	O
,	0	O
or	0	O
supernormal	0	O
,	0	O
in	0	O
Y	1	O
/	0	O
F2	0	O
cells	0	O
.	0	O


Eucaryotic	1	O
transcription	0	O
factors	0	O
that	0	O
stimulate	0	O
RNA	1	B
polymerase	0	I
II	0	I
by	0	O
increasing	0	O
the	0	O
efficiency	0	O
of	0	O
elongation	0	O
of	0	O
specifically	0	O
or	0	O
randomly	0	O
initiated	0	O
RNA	1	O
chains	0	O
have	0	O
been	0	O
isolated	0	O
and	0	O
characterized	0	O
.	0	O


Cryoglobulinemia	1	O
in	0	O
Raynaud	0	O
'	0	O
s	0	O
syndrome	0	O


Peripheral	1	O
vitreochorioretinal	0	O
dystrophies	0	O
in	0	O
myopia	0	O
patients	0	O


Mutations	0	O
of	0	O
the	0	O
AP	1	B
-	0	I
1	0	I
site	0	I
of	0	O
the	0	O
TIMP	0	B
-	0	I
1	0	I
promoter	0	I
that	0	O
prevented	0	O
formation	0	O
of	0	O
HMAP	0	B
-	0	I
1	0	I
caused	0	O
a	0	O
70	0	O
%	0	O
loss	0	O
of	0	O
activity	0	O
in	0	O
transfected	0	O
activated	0	O
HSCs	0	O
.	0	O


The	0	O
basal	0	O
promoter	0	O
strength	0	O
of	0	O
constructs	0	O
that	0	O
contained	0	O
deletions	0	O
in	0	O
the	0	O
U5	0	B
region	0	I
of	0	O
the	0	O
LTR	1	O
was	0	O
analyzed	0	O
by	0	O
chloramphenicol	0	B
acetyltransferase	0	I
(	0	O
CAT	1	B
)	0	O
assays	0	O
following	0	O
transfection	0	O
of	0	O
HeLa	0	O
cells	0	O
or	0	O
Jurkat	0	O
T	1	O
-	0	O
cells	0	O
in	0	O
the	0	O
presence	0	O
or	0	O
absence	0	O
of	0	O
viral	0	O
transactivator	0	O
tax	0	B
protein	0	O
.	0	O


Results	0	O
have	0	O
surprisingly	0	O
revealed	0	O
the	0	O
presence	0	O
of	0	O
three	0	O
U14	0	B
snRNA	1	I
-	0	I
homologous	0	I
regions	0	I
positioned	0	O
within	0	O
introns	0	O
5	0	O
,	0	O
6	0	O
,	0	O
and	0	O
8	0	O
of	0	O
the	0	O
mouse	0	O
cognate	0	O
hsc70	0	B
heat	0	O
shock	0	O
gene	0	O
.	0	O


In	1	O
such	0	O
a	0	O
manner	0	O
,	0	O
activated	0	O
PKR	0	B
inhibits	0	O
cell	0	O
growth	0	O
and	0	O
induces	0	O
apoptosis	0	O
,	0	O
whereas	0	O
disruption	0	O
of	0	O
normal	0	O
PKR	0	B
signaling	0	O
results	0	O
in	0	O
unregulated	0	O
cell	0	O
growth	0	O
.	0	O


Mature	1	O
mRNA	1	O
for	0	O
cytosolic	0	B
phosphoenolpyruvate	0	I
carboxykinase	0	I
of	0	I
the	0	I
chicken	0	I
is	0	O
2	0	O
.	0	O
8	0	O
kilobases	0	O
in	0	O
length	0	O
,	0	O
similar	0	O
to	0	O
that	0	O
previously	0	O
noted	0	O
for	0	O
mRNA	1	O
coding	0	O
for	0	O
the	0	O
same	0	O
enzyme	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


When	0	O
given	0	O
the	0	O
choice	0	O
between	0	O
an	0	O
estrous	0	O
female	0	O
and	0	O
a	0	O
sexually	0	O
active	0	O
male	0	O
in	0	O
the	0	O
AOF	0	O
,	0	O
flutamide	0	O
females	0	O
,	0	O
as	0	O
well	0	O
as	0	O
controls	0	O
,	0	O
preferred	0	O
the	0	O
male	0	O
partner	0	O
.	0	O


Thin	0	O
-	0	O
layer	0	O
chromatographic	0	O
methods	0	O
were	0	O
up	0	O
-	0	O
dated	0	O
for	0	O
pharmacokinetic	0	O
studies	0	O
of	0	O
imipramine	0	O
in	0	O
plasma	0	O
and	0	O
urine	0	O
.	0	O


Furthermore	0	O
,	0	O
ICER	0	B
negatively	0	O
autoregulates	0	O
the	0	O
alternative	0	O
promoter	0	O
,	0	O
thus	0	O
generating	0	O
a	0	O
feedback	0	O
loop	0	O
.	0	O


Histiocytic	0	O
panniculitis	0	O
was	0	O
observed	0	O
in	0	O
biopsy	0	O
specimens	0	O
with	0	O
cytophagocytosis	0	O
.	0	O


From	0	O
all	0	O
clinically	0	O
important	0	O
yeasts	0	O
species	0	O
,	0	O
a	0	O
total	0	O
of	0	O
96	0	O
%	0	O
were	0	O
identified	0	O
by	0	O
ATB	0	O
method	0	O
according	0	O
to	0	O
conventional	0	O
methods	0	O
.	0	O


Recently	0	O
,	0	O
an	0	O
electrical	0	O
-	0	O
mechanical	0	O
analog	0	O
model	0	O
of	0	O
heat	0	O
flow	0	O
within	0	O
the	0	O
brain	0	O
has	0	O
been	0	O
developed	0	O
from	0	O
which	0	O
an	0	O
expression	0	O
for	0	O
CBF	1	O
has	0	O
been	0	O
derived	0	O
:	0	O
CBF	1	O
=	0	O
Cb	1	O
/(	0	O
tau	0	O
rho	0	O
c	0	O
)	0	O
where	0	O
tau	0	O
is	0	O
the	0	O
thermal	0	O
decay	0	O
constant	0	O
,	0	O
rho	0	O
is	0	O
the	0	O
density	0	O
of	0	O
blood	0	O
,	0	O
and	0	O
c	0	O
is	0	O
its	0	O
specific	0	O
heat	0	O
.	0	O


The	0	O
antilog	0	O
transformation	0	O
of	0	O
pH	1	O
did	0	O
not	0	O
improve	0	O
the	0	O
results	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
social	0	O
isolation	0	O
on	0	O
morphine	0	O
-	0	O
induced	0	O
locomotor	0	O
activity	0	O
were	0	O
compared	0	O
in	0	O
:	0	O
(	0	O
i	0	O
)	0	O
animals	0	O
with	0	O
an	0	O
intact	0	O
hypothalamo	0	O
-	0	O
pituitary	0	O
-	0	O
adrenal	0	O
(	0	O
HPA	1	O
)	0	O
axis	0	O
;	0	O
(	0	O
ii	0	O
)	0	O
animals	0	O
in	0	O
which	0	O
stress	0	O
-	0	O
induced	0	O
corticosterone	0	O
secretion	0	O
was	0	O
blocked	0	O
by	0	O
adrenalectomy	0	O
.	0	O


The	0	O
hepatitis	0	B
A	1	I
virus	0	I
antibody	0	I
(	0	O
anti	0	B
-	0	I
HAV	1	I
)	0	O
in	0	O
chronic	0	O
diffuse	0	O
liver	0	O
diseases	0	O


We	0	O
report	0	O
here	0	O
the	0	O
cloning	0	O
of	0	O
the	0	O
human	0	B
goosecoid	0	I
gene	0	I
(	0	O
GSC	1	B
)	0	O
from	0	O
a	0	O
genomic	0	O
library	0	O
and	0	O
the	0	O
sequence	0	O
of	0	O
its	0	O
encoded	0	O
protein	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
our	0	O
results	0	O
demonstrate	0	O
that	0	O
CAP1	0	B
is	0	O
involved	0	O
in	0	O
multidrug	0	O
resistance	0	O
and	0	O
oxidative	0	O
stress	0	O
response	0	O
in	0	O
C	1	O
.	0	O
albicans	0	O
.	0	O


Of	0	O
these	0	O
sites	0	O
,	0	O
PEA3	0	B
and	0	O
STAT	1	B
contributed	0	O
specifically	0	O
to	0	O
induction	0	O
by	0	O
v	0	B
-	0	I
src	0	I
,	0	O
whereas	0	O
the	0	O
remaining	0	O
elements	0	O
were	0	O
also	0	O
involved	0	O
in	0	O
induction	0	O
by	0	O
the	0	O
phorbol	0	O
ester	0	O
phorbol	0	O
myristate	0	O
acetate	0	O
(	0	O
PMA	0	O
).	0	O


Damage	1	O
to	0	O
the	0	O
BBB	1	O
was	0	O
judged	0	O
by	0	O
extravasation	0	O
of	0	O
Evans	0	O
Blue	1	O
(	0	O
EB	1	O
)	0	O
dye	0	O
,	0	O
which	0	O
was	0	O
administered	0	O
either	0	O
2	0	O
,	0	O
3	0	O
,	0	O
24	0	O
or	0	O
48	0	O
h	0	O
after	0	O
onset	0	O
of	0	O
MCAo	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
mass	0	O
estimated	0	O
with	0	O
the	0	O
QCM	0	O
response	0	O
through	0	O
the	0	O
Sauerbrey	0	O
equation	0	O
and	0	O
the	0	O
mass	0	O
which	0	O
can	0	O
be	0	O
measured	0	O
thanks	0	O
to	0	O
other	0	O
analytical	0	O
techniques	0	O
,	0	O
in	0	O
our	0	O
case	0	O
an	0	O
enzymatic	0	O
assay	0	O
,	0	O
are	0	O
different	0	O
:	0	O
the	0	O
deposited	0	O
mass	0	O
is	0	O
generally	0	O
overestimated	0	O
by	0	O
the	0	O
QCM	0	O
.	0	O


The	0	O
Og4C3	0	B
enzyme	0	O
-	0	O
linked	0	O
immunosorbent	0	O
assay	0	O
(	0	O
ELISA	1	O
)	0	O
to	0	O
detect	0	O
circulating	0	O
Wuchereria	1	B
bancrofti	0	I
antigen	0	I
uses	0	O
50	0	O
microL	1	O
of	0	O
serum	0	O
.	0	O


The	0	O
227	0	O
-	0	O
to	0	O
-	0	O
239	0	O
region	0	O
blocked	0	O
ADR1	0	B
activity	0	O
independently	0	O
of	0	O
the	0	O
TAD	1	B
present	0	O
on	0	O
ADR1	0	B
,	0	O
ADR1	0	B
DNA	1	O
binding	0	O
,	0	O
and	0	O
specific	0	O
ADH2	0	B
promoter	0	I
sequences	0	I
.	0	O


METHODS	0	O
:	0	O
IgG	1	B
antibodies	0	I
vs	0	O
HHV	0	O
-	0	O
6	0	O
(	0	O
anti	0	B
-	0	I
HHV	0	I
-	0	I
6	0	I
-	0	I
IgG	1	I
)	0	O
were	0	O
determined	0	O
by	0	O
indirect	0	O
immunofluorescence	0	O
in	0	O
100	0	O
IVDA	0	O
(	0	O
29	0	O
seronegative	0	O
and	0	O
71	0	O
seropositive	0	O
for	0	O
HIV	1	O
-	0	O
1	0	O
of	0	O
which	0	O
45	0	O
were	0	O
in	0	O
stage	0	O
II	0	O
and	0	O
26	0	O
in	0	O
IV	1	O
-	0	O
C1	1	O
of	0	O
CDC	1	O
)	0	O
as	0	O
well	0	O
as	0	O
in	0	O
100	0	O
healthy	0	O
subjects	0	O
of	0	O
a	0	O
similar	0	O
age	0	O
(	0	O
control	0	O
group	0	O
).	0	O


Herein	0	O
,	0	O
we	0	O
show	0	O
that	0	O
Smad3	0	B
physically	0	O
interacts	0	O
with	0	O
the	0	O
HMG	1	B
box	0	O
domain	0	O
of	0	O
LEF1	0	B
and	0	O
that	0	O
TGFbeta	0	B
and	0	O
Wnt	0	B
pathways	0	O
synergize	0	O
to	0	O
activate	0	O
transcription	0	O
of	0	O
the	0	O
Xenopus	1	O
homeobox	0	O
gene	0	O
twin	0	B
(	0	O
Xtwn	0	B
).	0	O


The	0	O
smaller	0	O
uptake	0	O
rate	0	O
and	0	O
faster	0	O
clearance	0	O
rate	0	O
resulted	0	O
in	0	O
the	0	O
lower	0	O
BCF	1	O
for	0	O
SWA	0	O
killifish	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
5	0	O
KE	1	O
X	1	O
3	0	O
/	0	O
W	1	O
may	0	O
be	0	O
the	0	O
optimal	0	O
regimen	0	O
to	0	O
augment	0	O
the	0	O
antitumor	0	O
immunity	0	O
of	0	O
RNL	0	O
.	0	O


Intraoperatively	0	O
the	0	O
complement	0	B
factor	0	I
C3c	0	I
decreased	0	O
by	0	O
20	0	O
%,	0	O
while	0	O
alpha	0	B
1	0	I
-	0	I
antitrypsin	0	I
showed	0	O
postoperatively	0	O
an	0	O
increase	0	O
by	0	O
30	0	O
%.	0	O


Recently	0	O
we	0	O
have	0	O
performed	0	O
a	0	O
detailed	0	O
analysis	0	O
of	0	O
specific	0	O
neuronal	0	O
populations	0	O
affected	0	O
by	0	O
the	0	O
mutation	0	O
which	0	O
shed	0	O
new	0	O
light	0	O
on	0	O
the	0	O
role	0	O
of	0	O
Krox	0	B
-	0	I
20	0	I
in	0	O
the	0	O
segmentation	0	O
and	0	O
on	0	O
the	0	O
physiological	0	O
consequences	0	O
of	0	O
its	0	O
inactivation	0	O
.	0	O


Previously	0	O
,	0	O
we	0	O
showed	0	O
that	0	O
SNF2	0	B
,	0	O
SNF5	0	B
,	0	O
and	0	O
SNF6	0	B
function	0	O
interdependently	0	O
in	0	O
transcriptional	0	O
activation	0	O
,	0	O
possibly	0	O
forming	0	O
a	0	O
heteromeric	0	O
complex	0	O
.	0	O


Sp1	0	B
binds	0	O
two	0	O
sites	0	O
in	0	O
the	0	O
CD11c	0	B
promoter	0	I
in	0	O
vivo	0	O
specifically	0	O
in	0	O
myeloid	0	O
cells	0	O
and	0	O
cooperates	0	O
with	0	O
AP1	0	B
to	0	O
activate	0	O
transcription	0	O
.	0	O


Caries	1	O
and	0	O
parodontitis	0	O
have	0	O
been	0	O
one	0	O
of	0	O
the	0	O
most	0	O
spread	0	O
diseases	0	O
of	0	O
mankind	0	O
.	0	O


Preventive	1	O
effect	0	O
of	0	O
ONO	0	O
-	0	O
3708	0	O
on	0	O
thrombosis	0	O
and	0	O
vasospasms	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
.	0	O


An	1	O
IgG	1	B
monoclonal	0	O
gammopathy	0	O
was	0	O
present	0	O
in	0	O
the	0	O
serum	0	O
of	0	O
4	0	O
patients	0	O
and	0	O
Bence	0	O
-	0	O
Joanes	0	O
proteinuria	0	O
was	0	O
found	0	O
in	0	O
1	0	O
patient	0	O
.	0	O


Chicken	0	O
sterol	0	B
carrier	0	I
protein	0	I
2	0	I
/	0	O
sterol	0	B
carrier	0	I
protein	0	I
x	0	I
:	0	O
cDNA	1	O
cloning	0	O
reveals	0	O
evolutionary	0	O
conservation	0	O
of	0	O
structure	0	O
and	0	O
regulated	0	O
expression	0	O
.	0	O


The	0	O
cycle	0	O
length	0	O
of	0	O
induced	0	O
VT	1	O
(	0	O
n	0	O
=	0	O
10	0	O
VTs	0	O
)	0	O
was	0	O
380	0	O
+/-	0	O
41	0	O
msec	0	O
.	0	O


The	0	O
role	0	O
of	0	O
HIV	1	B
tat	0	I
,	0	O
which	0	O
is	0	O
the	0	O
main	0	O
enhancing	0	O
factor	0	O
for	0	O
viral	0	B
LTR	1	I
,	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
IL	1	B
-	0	I
2	0	I
gene	0	I
transcription	0	O
has	0	O
been	0	O
studied	0	O
following	0	O
transient	0	O
expression	0	O
of	0	O
the	0	O
tat	0	B
gene	0	I
in	0	O
phorbol	0	O
ester	0	O
and	0	O
calcium	0	O
ionophore	0	O
-	0	O
activated	0	O
Jurkat	0	O
cells	0	O
transfected	0	O
with	0	O
IL	1	B
-	0	I
2	0	I
promoter	0	O
-	0	O
chloramphenicol	0	B
acetyltransferase	0	I
reporter	0	O
constructs	0	O
.	0	O


This	0	O
distribution	0	O
parallels	0	O
that	0	O
of	0	O
the	0	O
neurotransmitters	0	O
glutamate	0	O
and	0	O
aspartate	0	O
;	0	O
however	0	O
,	0	O
neither	0	O
of	0	O
these	0	O
excitatory	0	O
amino	0	O
acids	0	O
is	0	O
a	0	O
substrate	0	O
for	0	O
transport	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
both	0	O
N	1	O
-	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
mutations	0	O
are	0	O
required	0	O
to	0	O
inhibit	0	O
transrepression	0	O
by	0	O
FBR	0	B
protein	0	I
and	0	O
that	0	O
multiple	0	O
structural	0	O
mutations	0	O
accompanied	0	O
by	0	O
posttranslational	0	O
protein	0	O
modification	0	O
alter	0	O
gene	0	O
regulation	0	O
by	0	O
FBR	0	B
protein	0	I
.	0	O


The	0	O
activity	0	O
of	0	O
the	0	O
transcription	0	B
factor	0	I
CREB	0	I
is	0	O
regulated	0	O
by	0	O
extracellular	0	O
stimuli	0	O
that	0	O
result	0	O
in	0	O
its	0	O
phosphorylation	0	O
at	0	O
a	0	O
critical	0	O
serine	0	O
residue	0	O
,	0	O
Ser133	0	O
.	0	O


Echinostomiasis	1	O
is	0	O
aggravated	0	O
by	0	O
socioeconomic	0	O
factors	0	O
such	0	O
as	0	O
poverty	0	O
,	0	O
malnutrition	0	O
,	0	O
an	0	O
explosively	0	O
growing	0	O
free	0	O
-	0	O
food	0	O
market	0	O
,	0	O
a	0	O
lack	0	O
of	0	O
supervised	0	O
food	0	O
inspection	0	O
,	0	O
poor	0	O
or	0	O
insufficient	0	O
sanitation	0	O
,	0	O
other	0	O
helminthiases	0	O
,	0	O
and	0	O
declining	0	O
economic	0	O
conditions	0	O
.	0	O


A	1	O
new	0	O
instrument	0	O
has	0	O
been	0	O
designed	0	O
for	0	O
freeze	0	O
-	0	O
fracturing	0	O
of	0	O
biological	0	O
material	0	O
in	0	O
ultra	0	O
high	0	O
vacuum	0	O
.	0	O


From	0	O
these	0	O
results	0	O
,	0	O
CBF	1	B
-	0	I
A	1	I
is	0	O
a	0	O
novel	0	O
CArG	0	O
box	0	O
-,	0	O
ssDNA	1	B
-	0	I
and	0	I
RNA	1	I
-	0	I
binding	0	I
protein	0	I
,	0	O
as	0	O
well	0	O
as	0	O
a	0	O
repressive	0	O
transcriptional	0	O
factor	0	O
.	0	O


In	1	O
this	0	O
report	0	O
,	0	O
we	0	O
investigate	0	O
the	0	O
mechanism	0	O
underlying	0	O
Ras	1	B
activation	0	O
upon	0	O
stimulation	0	O
of	0	O
these	0	O
two	0	O
types	0	O
of	0	O
receptors	0	O
in	0	O
hematopoietic	0	O
cells	0	O
.	0	O


The	0	O
solitary	0	O
kidney	0	O
:	0	O
a	0	O
model	0	O
of	0	O
chronic	0	O
hyperfiltration	0	O
in	0	O
humans	0	O
.	0	O


Two	0	O
other	0	O
peptides	0	O
,	0	O
either	0	O
partially	0	O
or	0	O
totally	0	O
lacking	0	O
the	0	O
basic	0	O
region	0	O
,	0	O
but	0	O
containing	0	O
the	0	O
intact	0	O
leucine	0	O
zipper	0	O
domain	0	O
,	0	O
readily	0	O
form	0	O
dimers	0	O
but	0	O
do	0	O
not	0	O
bind	0	O
to	0	O
the	0	O
CRE	0	O
.	0	O


Heat	1	O
-	0	O
inducible	0	O
CAT	1	B
activity	0	O
was	0	O
detectable	0	O
when	0	O
additional	0	O
sequences	0	O
from	0	O
the	0	O
native	0	O
promoter	0	O
containing	0	O
three	0	O
CCAAT	0	O
boxes	0	O
and	0	O
a	0	O
single	0	O
HSE	0	O
were	0	O
present	0	O
in	0	O
the	0	O
constructions	0	O
.	0	O


ECM	1	O
disruption	0	O
in	0	O
Lytechinus	0	O
embryos	0	O
caused	0	O
a	0	O
relative	0	O
drop	0	O
in	0	O
USF	0	B
RNA	1	I
accumulation	0	O
levels	0	O
to	0	O
approximately	0	O
60	0	O
%	0	O
of	0	O
control	0	O
embryos	0	O
,	0	O
while	0	O
LpS1	0	B
RNA	1	I
accumulation	0	O
levels	0	O
dropped	0	O
to	0	O
less	0	O
than	0	O
5	0	O
%.	0	O


Mesial	1	O
temporal	0	O
sclerosis	0	O
was	0	O
characterized	0	O
by	0	O
severe	0	O
neuronal	0	O
loss	0	O
accompanied	0	O
by	0	O
gliosis	0	O
occurring	0	O
in	0	O
the	0	O
CA1	0	O
/	0	O
prosubiculum	0	O
(	0	O
27	0	O
patients	0	O
,	0	O
100	0	O
%),	0	O
focally	0	O
in	0	O
the	0	O
dentate	0	O
gyrus	0	O
(	0	O
12	0	O
patients	0	O
,	0	O
44	0	O
%),	0	O
and	0	O
in	0	O
the	0	O
CA4	0	O
region	0	O
(	0	O
11	0	O
patients	0	O
,	0	O
41	0	O
%).	0	O


Acylation	1	O
with	0	O
the	0	O
palmitate	0	O
analog	0	O
was	0	O
prevented	0	O
when	0	O
Gly	1	O
-	0	O
2	0	O
was	0	O
mutated	0	O
to	0	O
alanine	0	O
,	0	O
implying	0	O
that	0	O
N	1	O
-	0	O
myristylation	0	O
is	0	O
required	0	O
for	0	O
palmitylation	0	O
,	0	O
and	0	O
when	0	O
either	0	O
Cys	1	O
-	0	O
3	0	O
or	0	O
Cys	1	O
-	0	O
6	0	O
was	0	O
mutated	0	O
to	0	O
serine	0	O
.	0	O


Modification	1	O
of	0	O
the	0	O
growth	0	O
of	0	O
Tetrahymena	1	O
by	0	O
compounds	0	O
which	0	O
affect	0	O
the	0	O
adrenergic	0	O
mechanism	0	O
.	0	O


The	0	O
13	0	O
,	0	O
14	0	O
-	0	O
dihydro	0	O
-	0	O
15	0	O
-	0	O
keto	0	O
-	0	O
metabolites	0	O
of	0	O
PGE2	0	O
and	0	O
PGF2	0	O
alpha	0	O
had	0	O
no	0	O
statistically	0	O
significant	0	O
antiarrhythmic	0	O
effect	0	O
.	0	O


A	1	O
case	0	O
of	0	O
anterior	0	O
cleavage	0	O
syndrome	0	O
in	0	O
a	0	O
27	0	O
-	0	O
year	0	O
-	0	O
old	0	O
female	0	O
patient	0	O
is	0	O
described	0	O
.	0	O


From	0	O
day	0	O
10	0	O
,	0	O
a	0	O
significant	0	O
increase	0	O
in	0	O
platelet	0	O
count	0	O
was	0	O
observed	0	O
in	0	O
eight	0	O
of	0	O
the	0	O
ten	0	O
patients	0	O
treated	0	O
with	0	O
heparin	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
),	0	O
with	0	O
return	0	O
to	0	O
the	0	O
initial	0	O
value	0	O
after	0	O
heparin	0	O
cessation	0	O
in	0	O
six	0	O
of	0	O
the	0	O
responders	0	O
.	0	O


In	1	O
patients	0	O
with	0	O
myalgia	0	O
,	0	O
Raynaud	0	O
'	0	O
s	0	O
syndrome	0	O
,	0	O
skin	0	O
vasculitis	0	O
and	0	O
vascular	0	O
diseases	0	O
WFAg	0	B
concentrations	0	O
were	0	O
higher	0	O
than	0	O
in	0	O
patients	0	O
without	0	O
them	0	O
.	0	O


Sequence	1	O
and	0	O
genetic	0	O
organization	0	O
of	0	O
a	0	O
Zymomonas	0	O
mobilis	0	O
gene	0	O
cluster	0	O
that	0	O
encodes	0	O
several	0	O
enzymes	0	O
of	0	O
glucose	0	O
metabolism	0	O
.	0	O


It	1	O
is	0	O
concluded	0	O
that	0	O
fludarabine	0	O
is	0	O
a	0	O
highly	0	O
useful	0	O
agent	0	O
in	0	O
CLL	1	O
.	0	O


An	1	O
inactive	0	O
analog	0	O
of	0	O
wortmannin	0	O
,	0	O
WM12	0	O
,	0	O
did	0	O
not	0	O
affect	0	O
TCR	1	B
/	0	O
CD3	0	B
-	0	O
induced	0	O
Erk2	0	B
activation	0	O
,	0	O
and	0	O
wortmannin	0	O
had	0	O
no	0	O
effect	0	O
on	0	O
the	0	O
activity	0	O
of	0	O
Erk2	0	B
when	0	O
added	0	O
directly	0	O
to	0	O
the	0	O
in	0	O
vitro	0	O
assays	0	O
.	0	O


Another	0	O
tentative	0	O
hotspot	0	O
mutation	0	O
in	0	O
the	0	O
third	0	O
patient	0	O
,	0	O
a	0	O
frame	0	O
shift	0	O
caused	0	O
by	0	O
a	0	O
G	1	O
nucleotide	0	O
insertion	0	O
in	0	O
a	0	O
monotonous	0	O
repeat	0	O
of	0	O
six	0	O
Gs	0	O
in	0	O
HPRT	1	B
exon	0	I
3	0	I
,	0	O
has	0	O
been	0	O
reported	0	O
previously	0	O
in	0	O
three	0	O
other	0	O
LN	1	O
patients	0	O
.	0	O


The	0	O
biology	0	O
of	0	O
Hyostrongylus	1	O
ruidus	0	O
.	0	O


Collaborative	0	O
study	0	O
of	0	O
Japanese	0	O
Pharmacopoeia	1	O
Heparin	1	O
Sodium	1	O
Reference	1	O
Standard	1	O


Analysis	1	O
of	0	O
Bcl	0	B
-	0	I
2	0	I
/	0	O
Bcl	0	B
-	0	I
2	0	I
homodimerization	0	O
using	0	O
both	0	O
in	0	O
vitro	0	O
binding	0	O
assays	0	O
as	0	O
well	0	O
as	0	O
a	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
method	0	O
provided	0	O
evidence	0	O
in	0	O
support	0	O
of	0	O
a	0	O
head	0	O
-	0	O
to	0	O
-	0	O
tail	0	O
model	0	O
for	0	O
Bcl	0	B
-	0	I
2	0	I
/	0	O
Bcl	0	B
-	0	I
2	0	I
homodimerization	0	O
and	0	O
revealed	0	O
that	0	O
sequences	0	O
within	0	O
the	0	O
NH2	0	O
-	0	O
terminal	0	O
A	1	O
domain	0	O
interact	0	O
with	0	O
a	0	O
structure	0	O
that	0	O
requires	0	O
the	0	O
presence	0	O
of	0	O
both	0	O
the	0	O
carboxyl	0	O
B	1	O
and	0	O
C	1	O
domains	0	O
in	0	O
combination	0	O
.	0	O


The	0	O
bcl	0	B
-	0	I
2	0	I
gene	0	I
can	0	O
potentially	0	O
encode	0	O
26	0	O
-	0	O
and	0	O
22	0	O
-	0	O
kDa	1	O
proteins	0	O
that	0	O
differ	0	O
only	0	O
in	0	O
their	0	O
carboxyl	0	O
tails	0	O
because	0	O
of	0	O
an	0	O
alternative	0	O
splicing	0	O
mechanism	0	O
.	0	O


Antibiotic	1	O
effect	0	O
of	0	O
the	0	O
mud	0	O
from	0	O
heviz	0	O


PCNA	1	B
mRNA	1	I
has	0	O
a	0	O
3	0	O
'	0	O
UTR	0	O
antisense	0	O
to	0	O
yellow	0	O
crescent	0	O
RNA	1	O
and	0	O
is	0	O
localized	0	O
in	0	O
ascidian	0	O
eggs	0	O
and	0	O
embryos	0	O
.	0	O


The	0	O
arginyl	0	O
peptide	0	O
bonds	0	O
that	0	O
are	0	O
cleaved	0	O
in	0	O
the	0	O
conversion	0	O
of	0	O
human	0	B
factor	0	I
IX	0	I
to	0	O
factor	0	B
IXa	0	I
by	0	O
factor	0	B
XIa	0	I
were	0	O
identified	0	O
as	0	O
Arg145	0	O
-	0	O
Ala146	0	O
and	0	O
Arg180	0	O
-	0	O
Val181	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
found	0	O
that	0	O
cell	0	O
-	0	O
specific	0	O
suppression	0	O
of	0	O
RA	1	O
-	0	O
stimulated	0	O
zif268	0	B
gene	0	I
expression	0	O
can	0	O
be	0	O
attributed	0	O
to	0	O
a	0	O
29	0	O
base	0	O
pair	0	O
nucleotide	0	O
sequence	0	O
,	0	O
located	0	O
downstream	0	O
of	0	O
the	0	O
RA	1	O
-	0	O
responsive	0	O
region	0	O
in	0	O
the	0	O
zif268	0	B
gene	0	I
.	0	O


Depleted	0	O
and	0	O
enriched	0	O
U3O8	0	O
standard	0	O
reference	0	O
materials	0	O
were	0	O
used	0	O
to	0	O
calibrate	0	O
the	0	O
system	0	O
.	0	O


The	0	O
stereoselectivity	0	O
of	0	O
drug	0	O
action	0	O
.	0	O


Gng3lg	0	B
transcripts	0	I
are	0	O
expressed	0	O
in	0	O
a	0	O
variety	0	O
of	0	O
tissues	0	O
including	0	O
both	0	O
brain	0	O
and	0	O
testes	0	O
.	0	O


The	0	O
ipsilateral	0	O
breast	0	O
tumor	0	O
relapse	0	O
rate	0	O
was	0	O
similar	0	O
between	0	O
the	0	O
PALP	0	O
and	0	O
MGDET	0	O
groups	0	O
.	0	O


Perceptual	0	O
learning	0	O
for	0	O
a	0	O
pattern	0	O
discrimination	0	O
task	0	O
.	0	O


Increase	0	O
in	0	O
blood	0	O
NEFA	1	O
was	0	O
further	0	O
augmented	0	O
by	0	O
fat	0	O
plus	0	O
AA	1	O
supplementation	0	O
,	0	O
but	0	O
no	0	O
changes	0	O
in	0	O
concentrations	0	O
of	0	O
Lys	1	O
or	0	O
Met	1	O
in	0	O
blood	0	O
were	0	O
found	0	O
.	0	O


These	0	O
observations	0	O
,	0	O
together	0	O
with	0	O
the	0	O
occurrence	0	O
of	0	O
putative	0	O
4	0	O
'-	0	O
phosphopantetheine	0	O
-	0	O
attachment	0	O
sites	0	O
and	0	O
a	0	O
putative	0	O
thioesterase	0	B
site	0	I
,	0	O
are	0	O
discussed	0	O
with	0	O
reference	0	O
to	0	O
the	0	O
reaction	0	O
sequence	0	O
leading	0	O
to	0	O
production	0	O
of	0	O
the	0	O
ACV	0	B
tripeptide	0	I
.	0	O


DNA	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	O
DNA	1	B
-	0	I
PK	1	I
)	0	O
consists	0	O
of	0	O
a	0	O
heterodimeric	0	O
protein	0	O
(	0	O
Ku	0	B
)	0	O
and	0	O
a	0	O
large	0	O
catalytic	0	O
subunit	0	O
(	0	O
DNA	1	B
-	0	I
PKcs	0	I
).	0	O


The	0	O
variable	0	O
regions	0	O
of	0	O
vertebrate	0	O
striated	0	O
TnT	1	B
isoforms	0	I
reflect	0	O
the	0	O
subsequent	0	O
addition	0	O
and	0	O
modification	0	O
of	0	O
genomic	0	O
sequences	0	O
to	0	O
give	0	O
rise	0	O
to	0	O
members	0	O
of	0	O
the	0	O
TnT	1	B
multigene	0	I
family	0	I
.	0	O


Overall	0	O
,	0	O
lesions	0	O
infiltrating	0	O
the	0	O
deep	0	O
lamina	0	O
propria	0	O
do	0	O
not	0	O
exhibit	0	O
a	0	O
reduced	0	O
frequency	0	O
of	0	O
occurrence	0	O
compared	0	O
to	0	O
lesions	0	O
infiltrating	0	O
the	0	O
skeletal	0	O
muscle	0	O
;	0	O
however	0	O
,	0	O
carcinomas	0	O
affecting	0	O
other	0	O
oral	0	O
sites	0	O
showed	0	O
a	0	O
reduced	0	O
frequency	0	O
of	0	O
deeply	0	O
infiltrating	0	O
lesions	0	O
in	0	O
comparison	0	O
to	0	O
more	0	O
superficial	0	O
lesions	0	O
.	0	O


Furthermore	0	O
,	0	O
experiments	0	O
with	0	O
32D	0	O
temperature	0	O
-	0	O
sensitive	0	O
p53	0	B
cells	0	O
indicate	0	O
that	0	O
aberrant	0	O
tal	0	B
-	0	I
1	0	I
expression	0	O
at	0	O
the	0	O
permissive	0	O
temperature	0	O
does	0	O
not	0	O
exert	0	O
a	0	O
proliferative	0	O
effect	0	O
but	0	O
causes	0	O
p53	0	B
-	0	O
mediated	0	O
apoptosis	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
the	0	O
tal	0	B
-	0	I
1	0	I
proliferative	0	O
effect	0	O
depends	0	O
on	0	O
the	0	O
integrity	0	O
of	0	O
the	0	O
cell	0	O
cycle	0	O
checkpoints	0	O
of	0	O
the	0	O
host	0	O
cell	0	O
,	0	O
as	0	O
observed	0	O
for	0	O
c	0	B
-	0	I
myc	0	I
and	0	O
other	0	O
oncogenes	0	O
.	0	O
tal	0	B
-	0	I
1	0	I
mutant	0	I
experiments	0	O
indicate	0	O
that	0	O
ectopic	0	O
tal	0	B
-	0	I
1	0	I
effects	0	O
are	0	O
mediated	0	O
by	0	O
both	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
and	0	O
the	0	O
heterodimerization	0	O
domains	0	O
,	0	O
while	0	O
the	0	O
N	1	B
-	0	I
terminally	0	I
truncated	0	I
tal	0	I
-	0	I
1	0	I
variant	0	I
(	0	O
M3	1	B
)	0	O
expressed	0	O
in	0	O
T	1	O
-	0	O
ALL	1	O
malignant	0	O
cells	0	O
mimics	0	O
the	0	O
effects	0	O
of	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
protein	0	O
.	0	O


Dose	1	O
of	0	O
20	0	O
ig	0	O
were	0	O
administered	0	O
within	0	O
a	0	O
scheme	0	O
from	0	O
0	0	O
.	0	O
1	0	O
to	0	O
6	0	O
months	0	O
in	0	O
order	0	O
to	0	O
study	0	O
its	0	O
immunogenicity	0	O
,	0	O
which	0	O
was	0	O
evaluated	0	O
at	0	O
2	0	O
,	0	O
7	0	O
,	0	O
and	0	O
12	0	O
months	0	O
after	0	O
the	0	O
first	0	O
dose	0	O
.	0	O


Endocytosis	1	O
and	0	O
lysosomal	0	O
targeting	0	O
of	0	O
epidermal	0	B
growth	0	I
factor	0	I
receptors	0	I
are	0	O
mediated	0	O
by	0	O
distinct	0	O
sequences	0	O
independent	0	O
of	0	O
the	0	O
tyrosine	0	B
kinase	0	I
domain	0	I
.	0	O


These	0	O
changes	0	O
weren	0	O
'	0	O
t	0	O
so	0	O
significant	0	O
in	0	O
the	0	O
group	0	O
of	0	O
obese	0	O
children	0	O
who	0	O
didn	0	O
'	0	O
t	0	O
lose	0	O
weight	0	O
.	0	O


Negative	1	O
-	0	O
staining	0	O
,	0	O
refractile	0	O
mycobacteria	0	O
in	0	O
Romanowsky	0	O
-	0	O
stained	0	O
smears	0	O
.	0	O


Selenium	1	O
status	0	O
of	0	O
thoroughbreds	0	O
in	0	O
the	0	O
United	0	O
Kingdom	1	O
.	0	O


Chlamydial	1	O
agents	0	O
were	0	O
isolated	0	O
from	0	O
the	0	O
semen	0	O
near	0	O
the	0	O
end	0	O
of	0	O
the	0	O
chlamydemic	0	O
phase	0	O
.	0	O


Two	0	O
experiments	0	O
were	0	O
conducted	0	O
to	0	O
study	0	O
the	0	O
vacuous	0	O
jaw	0	O
movements	0	O
induced	0	O
in	0	O
rats	0	O
by	0	O
acute	0	O
administration	0	O
of	0	O
the	0	O
monoamine	0	O
-	0	O
depleting	0	O
agent	0	O
reserpine	0	O
.	0	O


Validity	1	O
of	0	O
NIR	0	O
spectroscopy	0	O
for	0	O
quantitatively	0	O
measuring	0	O
muscle	0	O
oxidative	0	O
metabolic	0	O
rate	0	O
in	0	O
exercise	0	O
.	0	O


RACK1	0	B
,	0	O
a	0	O
receptor	0	O
for	0	O
activated	0	B
C	1	I
kinase	0	I
and	0	O
a	0	O
homolog	0	O
of	0	O
the	0	O
beta	0	O
subunit	0	O
of	0	O
G	1	B
proteins	0	I
,	0	O
inhibits	0	O
activity	0	O
of	0	O
src	0	B
tyrosine	0	I
kinases	0	I
and	0	O
growth	0	O
of	0	O
NIH	1	O
3T3	0	O
cells	0	O
.	0	O


Secondary	1	O
pancreatic	0	O
involvement	0	O
of	0	O
mycosis	0	O
fungoides	0	O
detected	0	O
by	0	O
a	0	O
clinically	0	O
palpable	0	O
mass	0	O
.	0	O


Terbutaline	0	O
;	0	O
a	0	O
beta2	0	O
-	0	O
adrenergic	0	O
agonist	0	O
,	0	O
and	0	O
aminophyllin	0	O
,	0	O
a	0	O
phosphodiesterase	0	O
inhibitor	0	O
,	0	O
were	0	O
given	0	O
separately	0	O
,	0	O
or	0	O
in	0	O
combination	0	O
,	0	O
to	0	O
rabbit	0	O
fetuses	0	O
on	0	O
the	0	O
28th	0	O
day	0	O
of	0	O
gestation	0	O
.	0	O


In	1	O
11	0	O
patients	0	O
with	0	O
Horton	0	O
'	0	O
s	0	O
headache	0	O
morphological	0	O
investigations	0	O
(	0	O
differential	0	O
white	0	O
blood	0	O
cell	0	O
count	0	O
),	0	O
cytoenzymatic	0	O
determinations	0	O
(	0	O
alkaline	0	B
and	0	I
acid	0	I
phosphatase	0	I
,	0	O
non	0	B
-	0	I
specific	0	I
esterase	0	I
)	0	O
and	0	O
cytoimmunological	0	O
tests	0	O
(	0	O
IgM	1	B
and	0	O
IgG	1	B
binding	0	O
)	0	O
were	0	O
carried	0	O
out	0	O
on	0	O
capillary	0	O
blood	0	O
neutrophils	0	O
obtained	0	O
from	0	O
the	0	O
area	0	O
of	0	O
pain	0	O
,	0	O
non	0	O
-	0	O
painful	0	O
area	0	O
of	0	O
the	0	O
skin	0	O
on	0	O
the	0	O
head	0	O
on	0	O
the	0	O
contralateral	0	O
side	0	O
,	0	O
and	0	O
from	0	O
the	0	O
finger	0	O
.	0	O


Our	0	O
results	0	O
suggested	0	O
that	0	O
the	0	O
hexamer	0	O
and	0	O
the	0	O
octamer	0	O
motifs	0	O
may	0	O
play	0	O
important	0	O
role	0	O
(	0	O
s	0	O
)	0	O
in	0	O
regulation	0	O
of	0	O
replication	0	O
-	0	O
dependent	0	O
but	0	O
not	0	O
of	0	O
replication	0	O
-	0	O
independent	0	O
expression	0	O
of	0	O
the	0	O
wheat	0	B
histone	0	I
H3	0	I
gene	0	I
.	0	O


Ruddell	0	O
,	0	O
M	1	O
.	0	O


It	1	O
may	0	O
also	0	O
be	0	O
suggested	0	O
that	0	O
particular	0	O
care	0	O
should	0	O
be	0	O
taken	0	O
when	0	O
such	0	O
a	0	O
trans	0	O
-	0	O
dominant	0	O
Rev	0	B
mutant	0	I
is	0	O
considered	0	O
to	0	O
be	0	O
used	0	O
as	0	O
a	0	O
genetic	0	O
therapy	0	O
against	0	O
HIV	1	O
-	0	O
I	1	O
infection	0	O
,	0	O
in	0	O
individuals	0	O
infected	0	O
with	0	O
both	0	O
HIV	1	O
-	0	O
I	1	O
and	0	O
HTLV	0	O
-	0	O
1	0	O
.	0	O


The	0	O
Man9	0	B
-	0	I
mannosidase	0	I
specificity	0	O
of	0	O
the	0	O
cDNA	1	O
construct	0	O
was	0	O
verified	0	O
by	0	O
the	0	O
observation	0	O
that	0	O
all	0	O
peptide	0	O
sequences	0	O
derived	0	O
from	0	O
a	0	O
previously	0	O
purified	0	O
,	0	O
catalytically	0	O
active	0	O
49	0	O
-	0	O
kDa	1	O
fragment	0	O
were	0	O
found	0	O
within	0	O
the	0	O
coding	0	O
region	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
differences	0	O
in	0	O
signaling	0	O
and	0	O
tissue	0	O
expression	0	O
suggest	0	O
that	0	O
the	0	O
human	0	B
intermediate	0	I
PRLr	0	I
differs	0	O
from	0	O
the	0	O
long	0	B
PRLr	0	I
in	0	O
physiological	0	O
function	0	O
.	0	O


Analysis	1	O
of	0	O
electrically	0	O
evoked	0	O
response	0	O
(	0	O
EER	0	O
)	0	O
in	0	O
relation	0	O
to	0	O
the	0	O
central	0	O
visual	0	O
pathway	0	O
of	0	O
the	0	O
cat	0	O
(	0	O
1	0	O
).	0	O


All	1	O
runners	0	O
drank	0	O
a	0	O
total	0	O
of	0	O
1	0	O
.	0	O
4	0	O
L	1	O
of	0	O
water	0	O
during	0	O
the	0	O
race	0	O
.	0	O


Bisoprolol	0	O
was	0	O
found	0	O
to	0	O
be	0	O
an	0	O
effective	0	O
beta	0	B
-	0	I
adrenoceptor	0	I
antagonist	0	O
,	0	O
the	0	O
pA2	0	O
values	0	O
determined	0	O
against	0	O
isoprenaline	0	O
in	0	O
guinea	0	O
pig	0	O
atria	0	O
and	0	O
tracheal	0	O
muscle	0	O
being	0	O
7	0	O
.	0	O
45	0	O
and	0	O
6	0	O
.	0	O
41	0	O
,	0	O
respectively	0	O
.	0	O


We	0	O
detected	0	O
no	0	O
effect	0	O
of	0	O
deleting	0	O
YCL024W	0	B
,	0	O
either	0	O
alone	0	O
or	0	O
in	0	O
combination	0	O
with	0	O
deletion	0	O
of	0	O
GIN4	0	B
.	0	O


These	0	O
results	0	O
were	0	O
corroborated	0	O
in	0	O
a	0	O
subsequent	0	O
study	0	O
in	0	O
which	0	O
30	0	O
hypogonadal	0	O
men	0	O
were	0	O
supplemented	0	O
with	0	O
SLT	1	O
5	0	O
mg	0	O
three	0	O
times	0	O
daily	0	O
for	0	O
6	0	O
months	0	O
.	0	O


These	0	O
IgG	1	B
antibodies	0	I
in	0	O
the	0	O
babies	0	O
diminished	0	O
rapidly	0	O
after	0	O
delivery	0	O
,	0	O
and	0	O
were	0	O
detectable	0	O
only	0	O
in	0	O
3	0	O
cases	0	O
at	0	O
2	0	O
,	0	O
3	0	O
,	0	O
and	0	O
5	0	O
months	0	O
of	0	O
ages	0	O
out	0	O
of	0	O
38	0	O
babies	0	O
up	0	O
to	0	O
21	0	O
months	0	O
.	0	O


This	0	O
night	0	O
-	0	O
day	0	O
oscillation	0	O
is	0	O
driven	0	O
by	0	O
the	0	O
endogenous	0	O
clock	0	O
(	0	O
located	0	O
in	0	O
the	0	O
suprachiasmatic	0	O
nucleus	0	O
,	0	O
SCN	0	O
).	0	O


Extraction	1	O
procedure	0	O
for	0	O
the	0	O
measurement	0	O
of	0	O
butyltin	0	O
compounds	0	O
in	0	O
biological	0	O
tissues	0	O
using	0	O
toluene	0	O
,	0	O
HBr	0	O
,	0	O
and	0	O
tropolone	0	O
.	0	O


All	1	O
numbers	0	O
refer	0	O
to	0	O
nucleotide	0	O
positions	0	O
on	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
HIV	1	O
-	0	O
1	0	O
transcript	0	O
.	0	O


Echosismography	0	O
enables	0	O
to	0	O
improve	0	O
the	0	O
diagnosis	0	O
when	0	O
compared	0	O
with	0	O
classical	0	O
sonography	0	O
in	0	O
about	0	O
20	0	O
%	0	O
of	0	O
cases	0	O
.	0	O


Dermal	1	O
toxicity	0	O
and	0	O
carcinogenicity	0	O
of	0	O
4	0	O
-	0	O
vinyl	0	O
-	0	O
1	0	O
-	0	O
cyclohexene	0	O
diepoxide	0	O
in	0	O
Fischer	0	O
rats	0	O
and	0	O
B6C3F1	0	O
mice	0	O
.	0	O


Selected	0	O
topics	0	O
in	0	O
laboratory	0	O
animal	0	O
medicine	0	O
.	0	O


Furthermore	0	O
,	0	O
no	0	O
transcripts	0	O
of	0	O
the	0	O
same	0	O
size	0	O
and	0	O
having	0	O
the	0	O
same	0	O
developmental	0	O
profile	0	O
as	0	O
those	0	O
generated	0	O
by	0	O
the	0	O
wild	0	B
-	0	I
type	0	I
E10	0	I
fragment	0	I
were	0	O
identified	0	O
by	0	O
probes	0	O
covering	0	O
the	0	O
remainder	0	O
of	0	O
the	0	O
cloned	0	O
region	0	O
.	0	O


In	1	O
order	0	O
to	0	O
investigate	0	O
how	0	O
these	0	O
expression	0	O
patterns	0	O
are	0	O
established	0	O
,	0	O
we	0	O
fused	0	O
promoter	0	O
regions	0	O
of	0	O
an	0	O
acidic	0	O
and	0	O
a	0	O
basic	0	O
glucanase	0	B
gene	0	I
to	0	O
the	0	O
beta	0	B
-	0	I
glucuronidase	0	I
(	0	O
GUS	0	B
)	0	O
reporter	0	O
gene	0	O
and	0	O
examined	0	O
expression	0	O
of	0	O
these	0	O
constructs	0	O
in	0	O
transgenic	0	O
tobacco	0	O
plants	0	O
.	0	O


Double	1	O
mutant	0	O
analysis	0	O
suggests	0	O
that	0	O
Rad54p	0	B
and	0	O
Mus81p	0	B
act	0	O
in	0	O
one	0	O
pathway	0	O
for	0	O
the	0	O
repair	0	O
of	0	O
,	0	O
or	0	O
tolerance	0	O
to	0	O
,	0	O
UV	1	O
-	0	O
induced	0	O
DNA	1	O
damage	0	O
.	0	O


Attitudes	0	O
were	0	O
found	0	O
to	0	O
be	0	O
multidimensional	0	O
,	0	O
with	0	O
similar	0	O
dimensions	0	O
being	0	O
identified	0	O
in	0	O
both	0	O
samples	0	O
.	0	O


The	0	O
cases	0	O
included	0	O
35	0	O
de	0	O
novo	0	O
diffuse	0	O
aggressive	0	O
lymphomas	0	O
(	0	O
DAL	0	O
;	0	O
19	0	O
large	0	O
-	0	O
cell	0	O
,	0	O
4	0	O
mixed	0	O
-	0	O
cell	0	O
,	0	O
and	0	O
12	0	O
large	0	O
-	0	O
cell	0	O
immunoblastic	0	O
),	0	O
52	0	O
transformed	0	O
aggressive	0	O
lymphomas	0	O
derived	0	O
from	0	O
follicular	0	O
lymphomas	0	O
(	0	O
TFL	0	O
),	0	O
42	0	O
indolent	0	O
follicular	0	O
lymphomas	0	O
(	0	O
FL	1	O
),	0	O
14	0	O
mantle	0	O
cell	0	O
lymphomas	0	O
(	0	O
MCL	0	O
),	0	O
and	0	O
27	0	O
small	0	O
noncleaved	0	O
cell	0	O
lymphomas	0	O
(	0	O
SNCL	0	O
).	0	O


Effect	1	O
of	0	O
a	0	O
high	0	O
-	0	O
intensity	0	O
SHF	0	O
field	0	O
on	0	O
the	0	O
blood	0	O
coagulation	0	O
system	0	O


To	1	O
improve	0	O
test	0	O
efficiency	0	O
,	0	O
we	0	O
modified	0	O
our	0	O
previously	0	O
introduced	0	O
contrast	0	O
/	0	O
color	0	O
card	0	O
test	0	O
by	0	O
including	0	O
a	0	O
patterned	0	O
test	0	O
stimulus	0	O
and	0	O
reducing	0	O
the	0	O
number	0	O
of	0	O
stimuli	0	O
in	0	O
both	0	O
experimental	0	O
phases	0	O
.	0	O


Changes	0	O
in	0	O
stimulation	0	O
levels	0	O
over	0	O
time	0	O
in	0	O
nucleus	0	O
22	0	O
cochlear	0	O
implant	0	O
users	0	O
.	0	O


We	0	O
demonstrate	0	O
that	0	O
Ddc1p	0	B
interacts	0	O
physically	0	O
in	0	O
vivo	0	O
with	0	O
Mec3p	0	B
,	0	O
and	0	O
this	0	O
interaction	0	O
requires	0	O
Rad17p	0	B
.	0	O


Effects	0	O
of	0	O
a	0	O
new	0	O
antihypertensive	0	O
agent	0	O
,	0	O
SGB	0	O
-	0	O
1534	0	O
,	0	O
on	0	O
rat	0	O
platelet	0	O
aggregation	0	O
.	0	O


Changes	0	O
in	0	O
ionic	0	O
content	0	O
of	0	O
the	0	O
mucous	0	O
suggest	0	O
that	0	O
cholinergic	0	O
mechanisms	0	O
affect	0	O
pressure	0	O
in	0	O
the	0	O
excretory	0	O
duct	0	O
of	0	O
the	0	O
gland	0	O
.	0	O


In	1	O
the	0	O
case	0	O
of	0	O
congenital	0	O
protein	0	B
C	1	I
deficiency	0	O
,	0	O
vitamin	0	O
K	1	O
antagonists	0	O
must	0	O
be	0	O
started	0	O
cautiously	0	O
due	0	O
to	0	O
the	0	O
risk	0	O
of	0	O
skin	0	O
necrosis	0	O
.	0	O


The	0	O
STAT	1	B
-	0	I
1	0	I
signaling	0	O
pathway	0	O
provides	0	O
at	0	O
least	0	O
one	0	O
mechanism	0	O
for	0	O
activation	0	O
of	0	O
the	0	O
CAEV	0	B
LTR	1	I
by	0	O
IFN	1	B
-	0	I
gamma	0	I
in	0	O
monocytes	0	O
.	0	O


Polycythemia	1	O
-	0	O
1973	0	O
.	0	O


Static	1	O
and	0	O
dynamic	0	O
compliance	0	O
was	0	O
measured	0	O
after	0	O
induction	0	O
of	0	O
anesthesia	0	O
,	0	O
before	0	O
and	0	O
immediately	0	O
after	0	O
filtration	0	O
in	0	O
the	0	O
operating	0	O
theater	0	O
,	0	O
1	0	O
hour	0	O
after	0	O
return	0	O
to	0	O
the	0	O
pediatric	0	O
intensive	0	O
care	0	O
unit	0	O
,	0	O
and	0	O
24	0	O
hours	0	O
after	0	O
the	0	O
operation	0	O
.	0	O


The	0	O
rate	0	O
of	0	O
decrement	0	O
in	0	O
DPOAE	0	O
amplitude	0	O
over	0	O
a	0	O
prescribed	0	O
time	0	O
period	0	O
was	0	O
utilized	0	O
as	0	O
a	0	O
measure	0	O
of	0	O
susceptibility	0	O
to	0	O
the	0	O
acoustic	0	O
trauma	0	O
.	0	O


These	0	O
experiments	0	O
confirm	0	O
that	0	O
the	0	O
6	0	O
-	0	O
S	1	O
liganded	0	O
form	0	O
of	0	O
the	0	O
receptor	0	O
identified	0	O
in	0	O
nuclear	0	O
extracts	0	O
of	0	O
cells	0	O
treated	0	O
with	0	O
2	0	O
,	0	O
3	0	O
,	0	O
7	0	O
,	0	O
8	0	O
-	0	O
tetrachlorodibenzo	0	O
-	0	O
p	0	O
-	0	O
dioxin	0	O
(	0	O
TCDD	1	O
)	0	O
contains	0	O
the	0	O
Ah	1	B
receptor	0	I
protein	0	I
and	0	O
ARNT	0	B
but	0	O
not	0	O
the	0	O
90	0	B
-	0	I
kDa	1	I
heat	0	I
shock	0	I
protein	0	I
.	0	O


Climatic	0	O
treatment	0	O
of	0	O
children	0	O
with	0	O
respiratory	0	O
allergy	0	O


Holger	0	O
v	0	O
.	0	O


Bimodal	1	O
cochlear	0	O
response	0	O
curves	0	O
in	0	O
rodents	0	O
.	0	O


In	1	O
PAV	0	O
-	0	O
3	0	O
,	0	O
the	0	O
E1A	0	B
region	0	I
is	0	O
located	0	O
between	0	O
1	0	O
.	0	O
5	0	O
and	0	O
3	0	O
.	0	O
8	0	O
map	0	O
units	0	O
.	0	O


Cross	1	O
-	0	O
linking	0	O
the	0	O
B	1	B
cell	0	I
Ag	1	I
receptor	0	I
(	0	O
BCR	0	B
)	0	O
to	0	O
surface	0	B
Fc	1	I
receptors	0	I
for	0	O
IgG	1	B
(	0	O
Fc	1	B
gamma	0	I
R	1	I
)	0	O
inhibits	0	O
G1	0	O
-	0	O
to	0	O
-	0	O
S	1	O
progression	0	O
;	0	O
the	0	O
mechanism	0	O
by	0	O
which	0	O
this	0	O
occurs	0	O
is	0	O
not	0	O
completely	0	O
known	0	O
.	0	O


Evolution	1	O
of	0	O
lesions	0	O
did	0	O
not	0	O
necessarily	0	O
follow	0	O
a	0	O
regular	0	O
progression	0	O
through	0	O
the	0	O
later	0	O
stages	0	O
of	0	O
the	0	O
vitelliform	0	O
classification	0	O
.	0	O


Studies	0	O
on	0	O
immunoglobulin	0	B
E	1	I
:	0	O
the	0	O
impact	0	O
of	0	O
a	0	O
sojourn	0	O
with	0	O
Professor	0	O
Dan	0	O
H	1	O
.	0	O


There	0	O
were	0	O
9	0	O
patients	0	O
in	0	O
NYHA	1	O
class	0	O
III	0	O
and	0	O
8	0	O
in	0	O
class	0	O
IV	1	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


We	0	O
now	0	O
show	0	O
that	0	O
gp200	0	B
-	0	O
MR6	0	B
ligation	0	O
can	0	O
also	0	O
mimic	0	O
IL	1	B
-	0	I
4	0	I
and	0	O
have	0	O
an	0	O
anti	0	O
-	0	O
proliferative	0	O
pro	0	O
-	0	O
maturational	0	O
influence	0	O
within	0	O
the	0	O
immune	0	O
system	0	O
,	0	O
causing	0	O
up	0	O
-	0	O
regulation	0	O
of	0	O
co	0	O
-	0	O
stimulatory	0	O
molecules	0	O
on	0	O
B	1	O
lymphocytes	0	O
.	0	O


Isolation	1	O
of	0	O
a	0	O
novel	0	O
TP53	0	B
target	0	I
gene	0	I
from	0	O
a	0	O
colon	0	O
cancer	0	O
cell	0	O
line	0	O
carrying	0	O
a	0	O
highly	0	O
regulated	0	O
wild	0	B
-	0	I
type	0	I
TP53	0	I
expression	0	O
system	0	O
.	0	O


Administration	1	O
of	0	O
dexamethasone	0	O
was	0	O
associated	0	O
with	0	O
progressive	0	O
rises	0	O
in	0	O
plasma	0	O
17	0	O
alpha	0	O
OH	0	O
progesterone	0	O
,	0	O
11	0	O
beta	0	O
-	0	O
desoxycortisol	0	O
,	0	O
DHEA	1	O
sulphate	0	O
,	0	O
androstenedione	0	O
and	0	O
testosterone	0	O
,	0	O
together	0	O
with	0	O
increased	0	O
urinary	0	O
excretion	0	O
of	0	O
androsterone	0	O
,	0	O
11	0	O
beta	0	O
OH	0	O
androsterone	0	O
,	0	O
etiocholanolone	0	O
,	0	O
DHEA	1	O
,	0	O
and	0	O
16	0	O
alpha	0	O
OH	0	O
DHEA	1	O
.	0	O


Once	0	O
NGF	1	B
administration	0	O
is	0	O
proven	0	O
effective	0	O
it	0	O
will	0	O
be	0	O
possible	0	O
to	0	O
develop	0	O
alternative	0	O
ways	0	O
of	0	O
NGF	1	B
administration	0	O
.	0	O


A	1	O
complementary	0	O
study	0	O
,	0	O
showing	0	O
a	0	O
good	0	O
agreement	0	O
between	0	O
surface	0	O
and	0	O
oesophageal	0	O
EMGd	0	O
seems	0	O
to	0	O
confirm	0	O
that	0	O
surface	0	O
EMGd	0	O
is	0	O
a	0	O
useful	0	O
and	0	O
promising	0	O
tool	0	O
for	0	O
clinical	0	O
investigation	0	O
.	0	O


Cytoskeletal	0	O
polarization	0	O
of	0	O
T	1	O
cells	0	O
is	0	O
regulated	0	O
by	0	O
an	0	O
immunoreceptor	0	O
tyrosine	0	O
-	0	O
based	0	O
activation	0	O
motif	0	O
-	0	O
dependent	0	O
mechanism	0	O
.	0	O


A	1	O
further	0	O
study	0	O
on	0	O
plasminogen	0	B
activator	0	I
release	0	O
by	0	O
vasoactive	0	O
agents	0	O
in	0	O
the	0	O
isolated	0	O
perfused	0	O
dog	0	O
leg	0	O
.	0	O


Peripheral	1	O
visual	0	O
stimuli	0	O
and	0	O
monoaural	0	O
auditory	0	O
stimuli	0	O
were	0	O
used	0	O
as	0	O
targets	0	O
.	0	O


Two	0	O
additional	0	O
cis	0	O
-	0	O
acting	0	O
sequences	0	O
,	0	O
conserved	0	O
in	0	O
both	0	O
the	0	O
region	0	O
1	0	O
and	0	O
3	0	O
promoters	0	O
,	0	O
were	0	O
identified	0	O
,	0	O
suggesting	0	O
a	0	O
role	0	O
for	0	O
these	0	O
sequences	0	O
in	0	O
the	0	O
coordinate	0	O
regulation	0	O
of	0	O
transcription	0	O
from	0	O
these	0	O
promoters	0	O
.	0	O


Within	0	O
their	0	O
polypeptide	0	O
chain	0	O
,	0	O
they	0	O
all	0	O
contain	0	O
those	0	O
conserved	0	O
features	0	O
that	0	O
define	0	O
a	0	O
plant	0	O
CDPK	0	B
;	0	O
kinase	0	O
catalytic	0	O
sequences	0	O
are	0	O
linked	0	O
to	0	O
a	0	O
calmodulin	0	B
-	0	I
like	0	I
regulatory	0	I
domain	0	I
through	0	O
a	0	O
junction	0	O
region	0	O
.	0	O


Both	0	O
promoters	0	O
lack	0	O
a	0	O
TATA	0	O
box	0	O
,	0	O
and	0	O
Pint	1	B
belongs	0	O
to	0	O
the	0	O
MED	1	B
-	0	I
1	0	I
class	0	O
of	0	O
promoters	0	O
,	0	O
which	0	O
initiate	0	O
transcription	0	O
at	0	O
multiple	0	O
sites	0	O
.	0	O


LDL	1	B
cholesterol	0	I
decreased	0	O
from	0	O
4	0	O
.	0	O
74	0	O
+/-	0	O
0	0	O
.	0	O
87	0	O
to	0	O
3	0	O
.	0	O
78	0	O
+/-	0	O
0	0	O
.	0	O
78	0	O
mmol	0	O
/	0	O
l	0	O
after	0	O
8	0	O
weeks	0	O
on	0	O
simvastatin	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
),	0	O
and	0	O
apo	0	B
B	1	I
fell	0	O
from	0	O
142	0	O
+/-	0	O
31	0	O
to	0	O
112	0	O
+/-	0	O
22	0	O
mg	0	O
/	0	O
dl	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
).	0	O


The	0	O
two	0	O
cysteine	0	O
residues	0	O
located	0	O
in	0	O
this	0	O
additional	0	O
region	0	O
may	0	O
be	0	O
involved	0	O
in	0	O
the	0	O
formation	0	O
of	0	O
a	0	O
disulfide	0	O
bridge	0	O
associated	0	O
with	0	O
the	0	O
activation	0	O
process	0	O
of	0	O
the	0	O
catalytic	0	O
activity	0	O
.	0	O


(	0	O
2	0	O
)	0	O
The	0	O
inappropriateness	0	O
of	0	O
adaptive	0	O
segmentation	0	O
for	0	O
the	0	O
isolation	0	O
of	0	O
spikes	0	O
and	0	O
sharp	0	O
waves	0	O
,	0	O
which	0	O
had	0	O
been	0	O
anticipated	0	O
in	0	O
view	0	O
of	0	O
the	0	O
short	0	O
duration	0	O
of	0	O
such	0	O
transients	0	O
in	0	O
relation	0	O
to	0	O
the	0	O
length	0	O
of	0	O
the	0	O
window	0	O
(	0	O
1	0	O
.	0	O
2	0	O
sec	0	O
)	0	O
used	0	O
for	0	O
the	0	O
autocorrelation	0	O
functions	0	O
employed	0	O
in	0	O
the	0	O
segmentation	0	O
algorithm	0	O
,	0	O
was	0	O
confirmed	0	O
.	0	O


Vitrectomy	1	O
was	0	O
still	0	O
a	0	O
significant	0	O
risk	0	O
factor	0	O
when	0	O
macular	0	O
holes	0	O
were	0	O
excluded	0	O
.	0	O


We	0	O
report	0	O
the	0	O
construction	0	O
of	0	O
an	0	O
approximately	0	O
1	0	O
.	0	O
7	0	O
-	0	O
Mb	1	O
sequence	0	O
-	0	O
ready	0	O
YAC	1	O
/	0	O
BAC	1	O
clone	0	O
contig	0	O
of	0	O
8p22	0	O
-	0	O
p23	0	O
.	0	O


However	0	O
,	0	O
the	0	O
mouse	0	O
has	0	O
previously	0	O
been	0	O
shown	0	O
to	0	O
possess	0	O
only	0	O
three	0	O
forms	0	O
of	0	O
ADH	1	B
.	0	O


IA	1	O
-	0	O
CT	1	O
with	0	O
cisplatin	0	O
50	0	O
mg	0	O
and	0	O
doxorubicin	0	O
30	0	O
mg	0	O
was	0	O
administered	0	O
by	0	O
one	0	O
shot	0	O
method	0	O
in	0	O
bilateral	0	O
internal	0	O
iliac	0	O
arteries	0	O
.	0	O


Microvessels	0	O
were	0	O
counted	0	O
in	0	O
a	0	O
x200	0	O
field	0	O
(	0	O
0	0	O
.	0	O
754	0	O
mm2	0	O
)	0	O
in	0	O
the	0	O
area	0	O
of	0	O
maximal	0	O
angiogenesis	0	O
.	0	O


MRI	1	O
disclosed	0	O
one	0	O
or	0	O
more	0	O
of	0	O
the	0	O
following	0	O
abnormalities	0	O
in	0	O
24	0	O
(	0	O
63	0	O
%)	0	O
of	0	O
38	0	O
treated	0	O
kidneys	0	O
:	0	O
(	0	O
1	0	O
)	0	O
loss	0	O
of	0	O
corticomedullary	0	O
differentiation	0	O
,	0	O
(	0	O
2	0	O
)	0	O
perirenal	0	O
fluid	0	O
,	0	O
(	0	O
3	0	O
)	0	O
subcapsular	0	O
hematoma	0	O
,	0	O
(	0	O
4	0	O
)	0	O
hemorrhage	0	O
into	0	O
a	0	O
renal	0	O
cyst	0	O
,	0	O
and	0	O
(	0	O
5	0	O
)	0	O
unexplained	0	O
abnormalities	0	O
.	0	O


This	0	O
gene	0	O
joins	0	O
the	0	O
group	0	O
of	0	O
genes	0	O
whose	0	O
members	0	O
are	0	O
rapidly	0	O
transcribed	0	O
in	0	O
response	0	O
to	0	O
insulin	0	B
and	0	O
other	0	O
mitogens	0	O
.	0	O


The	0	O
sequence	0	O
and	0	O
isolated	0	O
cDNAs	0	O
will	0	O
provide	0	O
useful	0	O
reagents	0	O
for	0	O
studying	0	O
the	0	O
expression	0	O
of	0	O
Brca1	0	B
in	0	O
the	0	O
mouse	0	O
,	0	O
and	0	O
for	0	O
testing	0	O
the	0	O
importance	0	O
of	0	O
the	0	O
evolutionarily	0	O
conserved	0	O
domains	0	O
.	0	O


Recommendations	0	O
to	0	O
deal	0	O
with	0	O
these	0	O
and	0	O
related	0	O
issues	0	O
are	0	O
presented	0	O
.	0	O


Activation	1	O
mediated	0	O
by	0	O
Cat8p	0	B
was	0	O
no	0	O
longer	0	O
detectable	0	O
in	0	O
a	0	O
cat1	0	B
mutant	0	I
.	0	O


Our	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
retroplasmid	0	O
reverse	0	B
transcriptase	0	I
is	0	O
uniquely	0	O
adapted	0	O
to	0	O
initiate	0	O
cDNA	1	O
synthesis	0	O
by	0	O
recognizing	0	O
a	0	O
3	0	O
'	0	O
CCA	1	O
sequence	0	O
.	0	O


Regional	1	O
CBF	1	O
was	0	O
determined	0	O
by	0	O
clearance	0	O
of	0	O
xenon	0	O
133	0	O
in	0	O
67	0	O
patients	0	O
undergoing	0	O
coronary	0	O
bypass	0	O
grafting	0	O
procedures	0	O
.	0	O


Thus	0	O
,	0	O
sgRNA2	0	B
has	0	O
the	0	O
3	0	O
'	0	O
TE	1	O
in	0	O
its	0	O
5	0	O
'	0	O
UTR	0	O
.	0	O


MOP5	0	B
contained	0	O
the	0	O
characteristic	0	O
PAS	1	B
domain	0	O
and	0	O
a	0	O
variable	0	O
C	1	O
terminus	0	O
;	0	O
it	0	O
is	0	O
possible	0	O
that	0	O
the	0	O
cDNA	1	O
contains	0	O
a	0	O
bHLH	0	O
domain	0	O
,	0	O
but	0	O
the	0	O
entire	0	O
open	0	O
reading	0	O
frame	0	O
has	0	O
yet	0	O
to	0	O
be	0	O
completed	0	O
.	0	O


The	0	O
computer	0	O
-	0	O
programmed	0	O
cytocentrifuge	0	O
is	0	O
currently	0	O
most	0	O
popular	0	O
.	0	O


Hprp3p	0	B
is	0	O
a	0	O
77	0	O
kDa	1	O
protein	0	O
,	0	O
which	0	O
is	0	O
homologous	0	O
to	0	O
the	0	O
Saccharomyces	1	B
cerevisiae	0	I
splicing	0	I
factor	0	I
Prp3p	0	I
.	0	O


In	1	O
Salmo	0	O
gairdneri	0	O
,	0	O
no	0	O
specialized	0	O
system	0	O
of	0	O
portal	0	O
vessels	0	O
appears	0	O
to	0	O
exist	0	O
between	0	O
the	0	O
pineal	0	O
organ	0	O
and	0	O
other	0	O
portions	0	O
of	0	O
the	0	O
brain	0	O
.	0	O


Streptococcal	1	O
preparation	0	O
(	0	O
OK	0	O
-	0	O
432	0	O
),	0	O
a	0	O
new	0	O
type	0	O
of	0	O
anti	0	O
-	0	O
cancer	0	O
agent	0	O
,	0	O
was	0	O
given	0	O
to	0	O
the	0	O
patients	0	O
with	0	O
advanced	0	O
cancer	0	O
in	0	O
combination	0	O
with	0	O
Mitomycin	1	O
-	0	O
C	1	O
,	0	O
5	0	O
-	0	O
FU	0	O
and	0	O
Cytosine	1	O
arabinoside	0	O
.	0	O


Three	0	O
missense	0	O
mutants	0	O
in	0	O
subunit	0	O
a	0	O
of	0	O
the	0	O
Escherichia	1	B
coli	0	I
F1F0	0	I
-	0	I
ATPase	1	I
were	0	O
isolated	0	O
and	0	O
characterized	0	O
after	0	O
hydroxylamine	0	O
mutagenesis	0	O
of	0	O
a	0	O
plasmid	0	O
carrying	0	O
the	0	O
uncB	0	B
(	0	I
subunit	0	I
a	0	I
)	0	I
gene	0	I
.	0	O


Male	1	O
Japanese	0	O
quail	0	O
were	0	O
chronically	0	O
exposed	0	O
to	0	O
5000	0	O
ppm	0	O
manganese	0	O
(	0	O
Mn	1	O
)	0	O
as	0	O
particulate	0	O
manganese	0	O
oxide	0	O
(	0	O
Mn3O4	0	O
)	0	O
in	0	O
their	0	O
diet	0	O
from	0	O
hatching	0	O
to	0	O
75	0	O
days	0	O
of	0	O
age	0	O
.	0	O


Residual	1	O
urinary	0	O
abnormalities	0	O
were	0	O
significantly	0	O
more	0	O
frequent	0	O
in	0	O
patients	0	O
with	0	O
type	0	O
III	0	O
than	0	O
type	0	O
I	1	O
MPGN	0	O
.	0	O


The	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
the	0	O
predicted	0	O
RfbA	0	B
and	0	O
RfbB	0	B
homologs	0	I
showed	0	O
identities	0	O
of	0	O
75	0	O
.	0	O
7	0	O
%	0	O
(	0	O
87	0	O
.	0	O
9	0	O
%	0	O
total	0	O
similarity	0	O
)	0	O
and	0	O
78	0	O
.	0	O
0	0	O
%	0	O
(	0	O
86	0	O
.	0	O
5	0	O
%	0	O
total	0	O
similarity	0	O
),	0	O
respectively	0	O
.	0	O


The	0	O
in	0	O
vivo	0	O
profile	0	O
of	0	O
ZFH	0	B
-	0	I
2	0	I
in	0	O
the	0	O
larval	0	O
CNS	1	O
shows	0	O
intriguing	0	O
overlap	0	O
with	0	O
DDC	1	B
in	0	O
specific	0	O
serotonin	0	O
and	0	O
dopamine	0	O
neurons	0	O
.	0	O


Rabbit	1	B
skeletal	0	I
muscle	0	I
glycogenin	0	I
.	0	O


RESULTS	0	O
:	0	O
During	0	O
the	0	O
7	0	O
-	0	O
year	0	O
period	0	O
,	0	O
10	0	O
,	0	O
331	0	O
symptomatic	0	O
duodenal	0	O
ulcer	0	O
diseases	0	O
were	0	O
diagnosed	0	O
.	0	O


These	0	O
primers	0	O
yielded	0	O
a	0	O
PCR	1	O
product	0	O
of	0	O
a	0	O
characteristic	0	O
length	0	O
within	0	O
most	0	O
Xanthomonas	1	O
species	0	O
and	0	O
pathovars	0	O
tested	0	O
.	0	O


Furthermore	0	O
,	0	O
deletion	0	O
and	0	O
mutation	0	O
analyses	0	O
of	0	O
the	0	O
VCAM	0	B
-	0	I
1	0	I
promoter	0	I
performed	0	O
with	0	O
chloramphenicol	0	B
acetyltransferase	0	I
constructs	0	I
revealed	0	O
that	0	O
Tax	0	B
was	0	O
trans	0	O
activating	0	O
the	0	O
VCAM	0	B
-	0	I
1	0	I
promoter	0	I
via	0	O
two	0	O
NF	1	B
-	0	I
kappaB	0	I
sites	0	I
present	0	O
at	0	O
bp	0	O
-	0	O
72	0	O
and	0	O
-	0	O
57	0	O
in	0	O
the	0	O
VCAM	0	B
-	0	I
1	0	I
gene	0	I
promoter	0	I
,	0	O
with	0	O
both	0	O
of	0	O
them	0	O
being	0	O
required	0	O
for	0	O
the	0	O
Tax	0	B
-	0	O
induced	0	O
expression	0	O
of	0	O
this	0	O
adhesion	0	O
molecule	0	O
.	0	O


A	1	O
rate	0	O
-	0	O
decreasing	0	O
dose	0	O
of	0	O
physostigmine	0	O
,	0	O
an	0	O
acetylcholinesterase	0	B
inhibitor	0	O
,	0	O
was	0	O
studied	0	O
in	0	O
combination	0	O
with	0	O
the	0	O
range	0	O
of	0	O
atropine	0	O
doses	0	O
.	0	O


Cell	1	O
factor	0	O
-	0	O
mediated	0	O
regulatory	0	O
interactions	0	O
are	0	O
involved	0	O
in	0	O
regulating	0	O
the	0	O
restricted	0	O
expression	0	O
of	0	O
the	0	O
HCMV	0	B
major	0	I
immediate	0	I
-	0	I
early	0	I
(	0	I
IE	1	I
)	0	I
gene	0	I
(	0	O
J	1	O
.	0	O


In	1	O
analyses	0	O
with	0	O
control	0	O
for	0	O
multiple	0	O
variables	0	O
,	0	O
relative	0	O
risk	0	O
for	0	O
microalbuminuria	0	O
(	0	O
urinary	0	O
albumin	0	B
excretion	0	O
,	0	O
20	0	O
-	0	O
199	0	O
microg	0	O
/	0	O
min	0	O
)	0	O
in	0	O
men	0	O
and	0	O
women	0	O
was	0	O
2	0	O
.	0	O
51	0	O
and	0	O
1	0	O
.	0	O
62	0	O
,	0	O
respectively	0	O
,	0	O
with	0	O
18	0	O
mm	0	O
Hg	1	O
higher	0	O
(	0	O
1	0	O
SD	1	O
)	0	O
systolic	0	O
blood	0	O
pressure	0	O
;	0	O
2	0	O
.	0	O
25	0	O
and	0	O
2	0	O
.	0	O
10	0	O
,	0	O
respectively	0	O
,	0	O
with	0	O
1	0	O
.	0	O
0	0	O
-	0	O
mmol	0	O
/	0	O
L	1	O
(	0	O
40	0	O
mg	0	O
/	0	O
dL	1	O
)	0	O
higher	0	O
plasma	0	O
cholesterol	0	O
level	0	O
;	0	O
1	0	O
.	0	O
99	0	O
and	0	O
1	0	O
.	0	O
91	0	O
,	0	O
respectively	0	O
,	0	O
for	0	O
smokers	0	O
vs	0	O
nonsmokers	0	O
;	0	O
and	0	O
1	0	O
.	0	O
83	0	O
and	0	O
1	0	O
.	0	O
33	0	O
,	0	O
respectively	0	O
,	0	O
with	0	O
4	0	O
kg	0	O
/	0	O
m2	0	O
higher	0	O
body	0	O
mass	0	O
index	0	O
.	0	O


The	0	O
novel	0	O
protein	0	O
kinases	0	O
,	0	O
c	0	B
-	0	I
Jun	1	I
NH2	0	I
-	0	I
terminal	0	I
kinases	0	I
(	0	O
JNKs	0	B
)/	0	O
stress	0	B
-	0	I
activated	0	I
protein	0	I
kinases	0	I
,	0	O
are	0	O
also	0	O
activated	0	O
by	0	O
TNF	1	B
-	0	I
alpha	0	I
,	0	O
IL	1	B
-	0	I
1	0	I
,	0	O
and	0	O
CD28	0	B
costimulation	0	O
.	0	O


S	1	O
.,	0	O
Kim	0	O
,	0	O
S	1	O
.	0	O


Concordance	1	O
of	0	O
IBDQ	0	O
scores	0	O
was	0	O
tested	0	O
in	0	O
280	0	O
stable	0	O
subjects	0	O
.	0	O


Pseudocontact	0	O
shifts	0	O
arise	0	O
from	0	O
the	0	O
isotropic	0	O
reorientational	0	O
average	0	O
of	0	O
the	0	O
dipolar	0	O
coupling	0	O
between	0	O
unpaired	0	O
electron	0	O
and	0	O
nuclei	0	O
,	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
magnetic	0	O
susceptibility	0	O
anisotropy	0	O
.	0	O


The	0	O
prevalence	0	O
and	0	O
incidence	0	O
of	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
types	0	O
1	0	O
and	0	O
2	0	O
(	0	O
HIV	1	O
-	0	O
1	0	O
,	0	O
HIV	1	O
-	0	O
2	0	O
),	0	O
human	0	O
T	1	O
-	0	O
lymphotropic	0	O
virus	0	O
types	0	O
I	1	O
and	0	O
II	0	O
(	0	O
HTLV	0	O
-	0	O
I	1	O
/	0	O
II	0	O
),	0	O
and	0	O
syphilitic	0	O
infections	0	O
and	0	O
the	0	O
association	0	O
between	0	O
these	0	O
infections	0	O
were	0	O
determined	0	O
in	0	O
a	0	O
cohort	0	O
of	0	O
police	0	O
officers	0	O
in	0	O
Guinea	0	O
-	0	O
Bissau	0	O
.	0	O


All	1	O
8	0	O
(	0	O
100	0	O
%)	0	O
patients	0	O
with	0	O
fulminant	0	O
hepatic	0	O
failure	0	O
who	0	O
received	0	O
grafts	0	O
survived	0	O
,	0	O
including	0	O
3	0	O
who	0	O
received	0	O
ABO	0	O
-	0	O
incompatible	0	O
grafts	0	O
,	0	O
though	0	O
2	0	O
of	0	O
these	0	O
subsequently	0	O
required	0	O
retransplantation	0	O
.	0	O


Standard	1	O
reference	0	O
sources	0	O
indicate	0	O
that	0	O
an	0	O
able	0	O
-	0	O
bodied	0	O
11	0	O
-	0	O
year	0	O
-	0	O
old	0	O
child	0	O
of	0	O
comparable	0	O
height	0	O
requires	0	O
1	0	O
,	0	O
493	0	O
kcal	0	O
/	0	O
d	0	O
for	0	O
support	0	O
of	0	O
basal	0	O
metabolic	0	O
functions	0	O
.	0	O


Activation	1	O
was	0	O
biphasic	0	O
;	0	O
peaking	0	O
at	0	O
5	0	O
-	0	O
10	0	O
min	0	O
and	0	O
24	0	O
h	0	O
after	0	O
treatment	0	O
.	0	O


Considering	0	O
these	0	O
sources	0	O
of	0	O
error	0	O
some	0	O
of	0	O
the	0	O
variability	0	O
in	0	O
the	0	O
present	0	O
investigation	0	O
might	0	O
be	0	O
avoided	0	O
by	0	O
systematic	0	O
instructions	0	O
.	0	O


This	0	O
interaction	0	O
inhibits	0	O
the	0	O
histone	0	B
acetyltransferase	0	I
activity	0	O
of	0	O
p300	0	B
,	0	O
resulting	0	O
in	0	O
drastic	0	O
reduction	0	O
of	0	O
nucleosomal	0	O
histone	0	B
acetylation	0	O
and	0	O
alteration	0	O
of	0	O
chromatin	0	O
structure	0	O
.	0	O


Each	0	O
type	0	O
was	0	O
divided	0	O
into	0	O
two	0	O
subgroups	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
whether	0	O
the	0	O
body	0	O
and	0	O
tail	0	O
of	0	O
the	0	O
pancreas	0	O
showed	0	O
intense	0	O
fatty	0	O
replacement	0	O
(	0	O
type	0	O
a	0	O
=	0	O
negative	0	O
for	0	O
intense	0	O
fatty	0	O
replacement	0	O
,	0	O
type	0	O
b	0	O
=	0	O
positive	0	O
for	0	O
intense	0	O
fatty	0	O
replacement	0	O
).	0	O


Abstracts	0	O
.	0	O


UbiA	0	B
is	0	O
also	0	O
unique	0	O
among	0	O
known	0	O
polyubiquitin	0	B
genes	0	I
in	0	O
containing	0	O
four	0	O
cis	0	O
-	0	O
spliced	0	O
introns	0	O
within	0	O
its	0	O
coding	0	O
sequence	0	O
.	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
CBP90	0	B
had	0	O
no	0	O
significant	0	O
similarity	0	O
to	0	O
any	0	O
other	0	O
protein	0	O
,	0	O
but	0	O
it	0	O
had	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
domain	0	O
at	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
.	0	O


These	0	O
differences	0	O
are	0	O
smaller	0	O
than	0	O
those	0	O
described	0	O
in	0	O
standard	0	O
textbooks	0	O
.	0	O


The	0	O
gene	0	O
encoding	0	O
IFN	1	B
-	0	I
gamma	0	I
was	0	O
previously	0	O
found	0	O
to	0	O
contain	0	O
an	0	O
intronic	0	O
enhancer	0	O
element	0	O
that	0	O
was	0	O
not	0	O
tissue	0	O
-	0	O
specific	0	O
in	0	O
its	0	O
activity	0	O
,	0	O
despite	0	O
the	0	O
restricted	0	O
expression	0	O
of	0	O
the	0	O
intact	0	O
IFN	1	B
-	0	I
gamma	0	I
-	0	I
encoding	0	I
gene	0	I
.	0	O


The	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
relationship	0	O
between	0	O
comprehension	0	O
and	0	O
production	0	O
is	0	O
different	0	O
at	0	O
different	0	O
stages	0	O
in	0	O
development	0	O
.	0	O


As	1	O
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
,	0	O
the	0	O
sequence	0	O
of	0	O
rhp51	0	B
+	0	I
showed	0	O
two	0	O
MluI	0	B
cell	0	I
-	0	I
cycle	0	I
boxes	0	I
and	0	O
a	0	O
putative	0	O
DNA	1	O
damage	0	O
-	0	O
responsive	0	O
element	0	O
in	0	O
its	0	O
upstream	0	O
region	0	O
.	0	O


It	1	O
contains	0	O
three	0	O
putative	0	O
TATA	0	O
boxes	0	O
far	0	O
upstream	0	O
of	0	O
the	0	O
main	0	O
start	0	O
sites	0	O
region	0	O
,	0	O
one	0	O
AP	1	B
-	0	I
1	0	I
box	0	I
,	0	O
one	0	O
AP	1	B
-	0	I
2	0	I
box	0	I
,	0	O
one	0	O
Malt	1	B
box	0	I
,	0	O
one	0	O
GAGA	0	O
box	0	O
,	0	O
one	0	O
half	0	O
serum	0	O
-	0	O
responsive	0	O
element	0	O
,	0	O
and	0	O
putative	0	O
binding	0	O
sites	0	O
for	0	O
Sp1	0	B
(	0	O
five	0	O
),	0	O
GC	1	B
-	0	I
rich	0	I
binding	0	I
factor	0	I
(	0	O
five	0	O
),	0	O
CTF	0	B
-	0	I
NF1	1	I
(	0	O
one	0	O
),	0	O
Myb	0	B
(	0	O
one	0	O
),	0	O
p53	0	B
(	0	O
two	0	O
),	0	O
Ets	1	B
-	0	I
1	0	I
(	0	O
one	0	O
),	0	O
NF	1	B
-	0	I
IL6	0	I
(	0	O
two	0	O
),	0	O
MyoD	0	B
(	0	O
two	0	O
),	0	O
Zeste	0	B
(	0	O
one	0	O
),	0	O
and	0	O
hepatocyte	0	B
nuclear	0	I
factor	0	I
-	0	I
5	0	I
(	0	O
one	0	O
).	0	O


The	0	O
two	0	O
bases	0	O
immediately	0	O
flanking	0	O
the	0	O
5	0	O
'	0	O
end	0	O
of	0	O
the	0	O
element	0	O
proved	0	O
to	0	O
be	0	O
very	0	O
important	0	O
to	0	O
its	0	O
function	0	O
as	0	O
a	0	O
UAS	0	O
element	0	O
as	0	O
did	0	O
the	0	O
two	0	O
bases	0	O
immediately	0	O
3	0	O
'	0	O
of	0	O
the	0	O
bHLH	0	O
core	0	O
motif	0	O
.	0	O


CTF1alpha	0	B
,	0	O
expressed	0	O
in	0	O
Escherichia	1	O
coli	0	O
,	0	O
showed	0	O
specific	0	O
binding	0	O
to	0	O
the	0	O
palindrome	0	O
2	0	O
DNA	1	O
fragment	0	O
but	0	O
not	0	O
to	0	O
palindrome	0	O
1	0	O
or	0	O
mutant	0	O
palindrome	0	O
2	0	O
DNA	1	O
fragments	0	O
,	0	O
suggesting	0	O
specific	0	O
binding	0	O
of	0	O
CTF1alpha	0	B
to	0	O
palindrome	0	O
2	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
protein	0	O
sequences	0	O
of	0	O
these	0	O
two	0	O
replicases	0	B
,	0	O
together	0	O
with	0	O
previously	0	O
characterized	0	O
H	1	B
.	0	I
pylori	0	I
plasmid	0	I
replication	0	I
proteins	0	I
,	0	O
supports	0	O
the	0	O
formation	0	O
of	0	O
a	0	O
distinct	0	O
class	0	O
of	0	O
H	1	B
.	0	I
pylori	0	I
plasmid	0	I
proteins	0	I
.	0	O


A	1	O
case	0	O
of	0	O
AIDS	1	O
-	0	O
related	0	O
complex	0	O
(	0	O
ARC	1	O
/	0	O
LAS	1	O
)	0	O
in	0	O
a	0	O
health	0	O
worker	0	O


The	0	O
immunophilin	0	B
,	0	O
which	0	O
can	0	O
be	0	O
of	0	O
the	0	O
FK506	0	O
-	0	O
or	0	O
cyclosporin	0	O
A	1	O
-	0	O
binding	0	O
class	0	O
,	0	O
binds	0	O
to	0	O
hsp90	0	B
via	0	O
its	0	O
tetratricopeptide	0	O
repeat	0	O
(	0	O
TPR	1	O
)	0	O
domain	0	O
,	0	O
and	0	O
different	0	O
receptor	0	O
heterocomplexes	0	O
exist	0	O
depending	0	O
upon	0	O
which	0	O
immunophilin	0	B
occupies	0	O
the	0	O
TPR	1	O
-	0	O
binding	0	O
region	0	O
of	0	O
hsp90	0	B
.	0	O


Present	1	O
results	0	O
reveal	0	O
a	0	O
frequency	0	O
-	0	O
dependent	0	O
inhibition	0	O
of	0	O
ganglionic	0	O
transmission	0	O
by	0	O
diltiazem	0	O
,	0	O
and	0	O
suggest	0	O
that	0	O
diltiazem	0	O
may	0	O
depress	0	O
excessive	0	O
sympathetic	0	O
activity	0	O
without	0	O
affecting	0	O
normal	0	O
ganglionic	0	O
transmission	0	O
.	0	O


Acoustic	1	O
transmission	0	O
spectra	0	O
in	0	O
the	0	O
Penrose	0	O
lattice	0	O
.	0	O


At	1	O
the	0	O
same	0	O
time	0	O
,	0	O
the	0	O
results	0	O
indicate	0	O
that	0	O
p53	0	B
plays	0	O
a	0	O
defensive	0	O
role	0	O
against	0	O
HBV	1	O
by	0	O
transcriptionally	0	O
repressing	0	O
the	0	O
HBV	1	B
core	0	I
promoter	0	I
through	0	O
liver	0	B
-	0	I
specific	0	I
enhancer	0	I
II	0	I
and	0	O
HBx	0	B
is	0	O
required	0	O
to	0	O
counteract	0	O
this	0	O
inhibitory	0	O
function	0	O
of	0	O
p53	0	B
.	0	O


During	0	O
the	0	O
cloning	0	O
by	0	O
reverse	0	B
transcriptase	0	I
-	0	O
polymerase	0	O
chain	0	O
reaction	0	O
of	0	O
the	0	O
human	0	B
HIF	0	I
-	0	I
1alpha	0	I
subunit	0	I
,	0	O
we	0	O
isolated	0	O
two	0	O
cDNA	1	O
clones	0	O
which	0	O
corresponded	0	O
to	0	O
alternative	0	O
splicing	0	O
of	0	O
the	0	O
HIF	0	B
-	0	I
1alpha	0	I
gene	0	I
.	0	O


We	0	O
conclude	0	O
that	0	O
the	0	O
SIMV	1	O
is	0	O
useful	0	O
in	0	O
weaning	0	O
neonates	0	O
from	0	O
the	0	O
ventilator	0	O
.	0	O


Two	0	O
experiments	0	O
investigating	0	O
the	0	O
effects	0	O
of	0	O
short	0	O
-	0	O
term	0	O
spaceflight	0	O
on	0	O
cancellous	0	O
bone	0	O
turnover	0	O
were	0	O
carried	0	O
out	0	O
:	0	O
Physiological	1	O
Systems	0	O
Experiment	1	O
-	0	O
1	0	O
(	0	O
PSE	1	O
-	0	O
1	0	O
)	0	O
(	0	O
a	0	O
4	0	O
-	0	O
d	0	O
orbital	0	O
spaceflight	0	O
)	0	O
and	0	O
PSE	1	O
-	0	O
2	0	O
(	0	O
a	0	O
10	0	O
-	0	O
d	0	O
flight	0	O
).	0	O


In	1	O
a	0	O
stepwise	0	O
logistic	0	O
regression	0	O
analysis	0	O
of	0	O
SPT	0	O
and	0	O
RAST	1	O
data	0	O
,	0	O
the	0	O
occurrence	0	O
of	0	O
serum	0	B
IgE	1	I
antibodies	0	I
to	0	I
P	1	I
.	0	I
orbiculare	0	I
had	0	O
the	0	O
highest	0	O
explanatory	0	O
value	0	O
for	0	O
current	0	O
eczema	0	O
.	0	O


Binding	0	O
to	0	O
sulphatides	0	O
and	0	O
the	0	O
alpha	0	B
-	0	I
dystroglycan	0	I
receptor	0	I
was	0	O
much	0	O
stronger	0	O
and	0	O
required	0	O
at	0	O
least	0	O
two	0	O
LG	0	B
modules	0	I
.	0	O


In	1	O
some	0	O
instances	0	O
,	0	O
this	0	O
is	0	O
partly	0	O
mediated	0	O
by	0	O
the	0	O
expression	0	O
of	0	O
virally	0	O
encoded	0	O
proteases	0	O
which	0	O
lead	0	O
to	0	O
the	0	O
cleavage	0	O
of	0	O
initiation	0	B
factor	0	I
eIF4G	0	I
.	0	O


High	0	O
-	0	O
resolution	0	O
computed	0	O
tomography	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
miliary	0	O
tuberculosis	0	O
.	0	O


The	0	O
proteins	0	O
are	0	O
more	0	O
than	0	O
90	0	O
%	0	O
identical	0	O
to	0	O
each	0	O
other	0	O
within	0	O
the	0	O
protein	0	O
kinase	0	O
domain	0	O
but	0	O
only	0	O
51	0	O
-	0	O
59	0	O
%	0	O
identical	0	O
to	0	O
other	0	O
casein	0	B
kinase	0	I
I	1	I
isoforms	0	I
within	0	O
this	0	O
region	0	O
.	0	O


The	0	O
cleavage	0	O
of	0	O
Fak	0	B
by	0	O
caspases	0	B
may	0	O
thus	0	O
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
execution	0	O
of	0	O
the	0	O
suicide	0	O
program	0	O
by	0	O
disabling	0	O
the	0	O
anti	0	O
-	0	O
apoptotic	0	O
function	0	O
of	0	O
Fak	0	B
.	0	O


Here	0	O
,	0	O
we	0	O
show	0	O
that	0	O
the	0	O
zinc	0	B
finger	0	I
protein	0	I
Gis1	0	I
acts	0	O
as	0	O
a	0	O
dosage	0	O
-	0	O
dependent	0	O
suppressor	0	O
of	0	O
the	0	O
rim15Delta	0	B
defect	0	O
in	0	O
nutrient	0	O
limitation	0	O
-	0	O
induced	0	O
transcriptional	0	O
derepression	0	O
of	0	O
SSA3	0	B
.	0	O


Isoelectric	1	O
focusing	0	O
of	0	O
tryptic	0	O
peptides	0	O
generated	0	O
from	0	O
MHC	1	B
-	0	I
B	1	I
phosphorylated	0	O
with	0	O
cdc2	0	B
kinase	0	I
revealed	0	O
one	0	O
major	0	O
phosphopeptide	0	O
that	0	O
was	0	O
purified	0	O
by	0	O
reverse	0	O
-	0	O
phase	0	O
high	0	O
performance	0	O
liquid	0	O
chromatography	0	O
and	0	O
sequenced	0	O
.	0	O


Co	1	O
-	0	O
transfection	0	O
of	0	O
expression	0	O
vectors	0	O
for	0	O
CCAAT	0	B
/	0	I
enhancer	0	I
binding	0	I
protein	0	I
(	0	I
C	1	I
/	0	I
EBP	1	I
)	0	I
alpha	0	I
and	0	O
C	1	B
/	0	I
EBP	1	I
beta	0	I
trans	0	O
-	0	O
activated	0	O
the	0	O
rat	0	B
uncoupling	0	I
protein	0	I
gene	0	I
promoter	0	I
due	0	O
to	0	O
sequences	0	O
in	0	O
the	0	O
5	0	O
'	0	O
proximal	0	O
region	0	O
.	0	O


Beg2	0	B
and	0	O
Beg1	0	B
are	0	O
regulated	0	O
differently	0	O
which	0	O
may	0	O
indicate	0	O
variation	0	O
in	0	O
storage	0	O
or	0	O
utilization	0	O
properties	0	O
among	0	O
the	0	O
barley	0	B
globulins	0	I
.	0	O


METHOD	1	O
:	0	O
The	0	O
sample	0	O
of	0	O
subjects	0	O
was	0	O
drawn	0	O
from	0	O
the	0	O
Suffolk	0	O
County	0	O
Mental	1	O
Health	1	O
Project	1	O
,	0	O
a	0	O
longitudinal	0	O
epidemiologic	0	O
study	0	O
of	0	O
first	0	O
-	0	O
hospitalized	0	O
subjects	0	O
with	0	O
psychotic	0	O
disorders	0	O
;	0	O
the	0	O
present	0	O
study	0	O
focused	0	O
on	0	O
patients	0	O
with	0	O
schizophrenic	0	O
disorders	0	O
.	0	O


Two	0	O
differentially	0	O
expressed	0	O
LNX	0	B
messages	0	I
encode	0	O
overlapping	0	O
proteins	0	O
with	0	O
predicted	0	O
molecular	0	O
masses	0	O
of	0	O
80	0	B
kDa	1	I
(	0	I
LNX	0	I
)	0	I
and	0	O
70	0	O
kDa	1	O
(	0	O
LNX	0	O
-	0	O
b	0	O
).	0	O


The	0	O
prophylactic	0	O
use	0	O
of	0	O
new	0	O
medication	0	O
for	0	O
patients	0	O
between	0	O
the	0	O
first	0	O
and	0	O
second	0	O
cycle	0	O
of	0	O
chemotherapy	0	O
,	0	O
in	0	O
agreement	0	O
with	0	O
the	0	O
estimates	0	O
calculated	0	O
,	0	O
does	0	O
not	0	O
save	0	O
health	0	O
care	0	O
costs	0	O
but	0	O
may	0	O
improve	0	O
the	0	O
quality	0	O
of	0	O
life	0	O
in	0	O
these	0	O
patients	0	O
and	0	O
permit	0	O
the	0	O
continuation	0	O
of	0	O
a	0	O
therapeutic	0	O
schedule	0	O
without	0	O
interruption	0	O
which	0	O
may	0	O
improve	0	O
the	0	O
life	0	O
expectancy	0	O
of	0	O
the	0	O
patient	0	O
.	0	O


Bulbar	1	O
pouches	0	O
were	0	O
perfused	0	O
with	0	O
solutions	0	O
of	0	O
0	0	O
.	0	O
9	0	O
%	0	O
Na	1	O
C1	1	O
,	0	O
0	0	O
.	0	O
1	0	O
N	1	O
HC1	0	O
,	0	O
40	0	O
%	0	O
glucose	0	O
,	0	O
40	0	O
%	0	O
NaC1	0	O
,	0	O
and	0	O
40	0	O
%	0	O
peptone	0	O
or	0	O
with	0	O
0	0	O
.	0	O
1	0	O
%	0	O
solutions	0	O
of	0	O
acetylcholine	0	O
chloride	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
the	0	O
corresponding	0	O
mature	0	O
mRNA	1	O
transcripts	0	O
(	0	O
3	0	O
.	0	O
2	0	O
-	0	O
3	0	O
.	0	O
5	0	O
kilobase	0	O
pairs	0	O
(	0	O
kb	0	O
]	0	O
in	0	O
human	0	O
fibroblasts	0	O
was	0	O
shown	0	O
by	0	O
Northern	0	O
blot	0	O
hybridization	0	O
,	0	O
S1	1	B
nuclease	0	I
protection	0	O
assay	0	O
,	0	O
and	0	O
the	0	O
polymerase	0	O
chain	0	O
reaction	0	O
.	0	O


Nuclear	1	B
beta	0	I
II	0	I
PKC	0	I
,	0	O
like	0	O
p34cdc2	0	B
kinase	0	I
,	0	O
may	0	O
function	0	O
to	0	O
regulate	0	O
nuclear	0	O
lamina	0	O
structural	0	O
stability	0	O
during	0	O
cell	0	O
cycle	0	O
.	0	O


Computerized	0	O
detection	0	O
of	0	O
abnormal	0	O
asymmetry	0	O
in	0	O
digital	0	O
chest	0	O
radiographs	0	O
.	0	O


Covalent	1	O
modification	0	O
of	0	O
the	0	O
transactivator	0	O
protein	0	O
IE2	0	B
-	0	O
p86	0	B
of	0	O
human	0	O
cytomegalovirus	0	O
by	0	O
conjugation	0	O
to	0	O
the	0	O
ubiquitin	0	B
-	0	I
homologous	0	I
proteins	0	I
SUMO	0	I
-	0	I
1	0	I
and	0	O
hSMT3b	0	B
.	0	O


Groups	0	O
of	0	O
male	0	O
and	0	O
female	0	O
Fischer	0	O
344	0	O
rats	0	O
,	0	O
B6C3F1	0	O
mice	0	O
,	0	O
and	0	O
Hartley	0	O
guinea	0	O
pigs	0	O
were	0	O
exposed	0	O
once	0	O
for	0	O
6	0	O
hr	0	O
to	0	O
mean	0	O
concentrations	0	O
of	0	O
10	0	O
.	0	O
5	0	O
,	0	O
5	0	O
.	0	O
4	0	O
,	0	O
2	0	O
.	0	O
4	0	O
,	0	O
1	0	O
.	0	O
0	0	O
,	0	O
or	0	O
0	0	O
(	0	O
control	0	O
)	0	O
ppm	0	O
of	0	O
methyl	0	O
isocyanate	0	O
(	0	O
MIC	1	O
)	0	O
vapor	0	O
.	0	O


Low	0	O
-	0	O
grade	0	O
glioma	0	O
.	0	O


The	0	O
number	0	O
of	0	O
fecal	0	O
pellets	0	O
ingested	0	O
peaked	0	O
at	0	O
5	0	O
to	0	O
6	0	O
weeks	0	O
old	0	O
(	0	O
13	0	O
pellets	0	O
/	0	O
day	0	O
)	0	O
and	0	O
gradually	0	O
decreased	0	O
,	0	O
thereafter	0	O
(	0	O
2	0	O
.	0	O
1	0	O
pellets	0	O
at	0	O
78	0	O
weeks	0	O
old	0	O
,	0	O
1	0	O
.	0	O
5	0	O
pellets	0	O
at	0	O
104	0	O
weeks	0	O
old	0	O
).	0	O


In	1	O
the	0	O
tissues	0	O
tested	0	O
,	0	O
except	0	O
brain	0	O
,	0	O
the	0	O
message	0	O
for	0	O
CLIP	1	B
-	0	I
170	0	I
was	0	O
more	0	O
abundant	0	O
than	0	O
that	0	O
for	0	O
Restin	0	B
.	0	O


In	1	O
the	0	O
first	0	O
series	0	O
of	0	O
experiments	0	O
,	0	O
Sprague	0	O
-	0	O
Dawley	0	O
male	0	O
rats	0	O
were	0	O
implanted	0	O
unilaterally	0	O
with	0	O
guide	0	O
cannulas	0	O
aimed	0	O
at	0	O
the	0	O
lateral	0	O
ventricle	0	O
.	0	O


Using	0	O
the	0	O
polymerase	0	O
chain	0	O
reaction	0	O
,	0	O
we	0	O
analyzed	0	O
the	0	O
U6	0	B
RNA	1	I
genes	0	I
of	0	O
52	0	O
organisms	0	O
.	0	O


The	0	O
currently	0	O
proposed	0	O
extended	0	O
arch	0	O
repair	0	O
should	0	O
be	0	O
reserved	0	O
for	0	O
the	0	O
small	0	O
group	0	O
of	0	O
infants	0	O
with	0	O
transverse	0	O
aortic	0	O
arch	0	O
to	0	O
ascending	0	O
aorta	0	O
diameter	0	O
ratios	0	O
(	0	O
arch	0	O
indices	0	O
)	0	O
of	0	O
less	0	O
than	0	O
0	0	O
.	0	O
25	0	O
.	0	O


Htra2	0	B
-	0	I
beta3	0	I
is	0	O
developmentally	0	O
regulated	0	O
and	0	O
expressed	0	O
predominantly	0	O
in	0	O
brain	0	O
,	0	O
liver	0	O
testis	0	O
,	0	O
and	0	O
weakly	0	O
in	0	O
kidney	0	O
.	0	O


Serotonin	1	O
concentration	0	O
in	0	O
the	0	O
blood	0	O
of	0	O
patients	0	O
with	0	O
hemorrhagic	0	O
fever	0	O
with	0	O
renal	0	O
syndrome	0	O


Because	0	O
the	0	O
high	0	B
-	0	I
density	0	I
lipoprotein	0	I
receptor	0	I
(	0	O
HDL	1	B
-	0	I
R	1	I
)	0	O
is	0	O
a	0	O
key	0	O
element	0	O
in	0	O
cholesterol	0	O
homeostasis	0	O
and	0	O
a	0	O
potential	0	O
therapeutic	0	O
target	0	O
for	0	O
hypercholesterolemic	0	O
drugs	0	O
,	0	O
an	0	O
understanding	0	O
of	0	O
HDL	1	B
-	0	I
R	1	I
regulation	0	O
is	0	O
essential	0	O
.	0	O


Review	0	O
:	0	O
deterioration	0	O
of	0	O
glucose	0	O
tolerance	0	O
with	0	O
age	0	O
:	0	O
the	0	O
role	0	O
of	0	O
insulin	0	B
resistance	0	O
.	0	O


Screening	1	O
,	0	O
counseling	0	O
,	0	O
and	0	O
treatment	0	O
for	0	O
alcohol	0	O
and	0	O
illicit	0	O
drug	0	O
use	0	O
should	0	O
be	0	O
essential	0	O
components	0	O
in	0	O
comprehensive	0	O
HBP	0	O
care	0	O
.	0	O


Similarly	0	O
,	0	O
we	0	O
observed	0	O
synthetic	0	O
phenotypes	0	O
between	0	O
mutations	0	O
in	0	O
MIF2	0	B
and	0	O
trans	0	O
-	0	O
acting	0	O
mutations	0	O
in	0	O
three	0	O
known	0	O
yeast	0	O
centromere	0	O
protein	0	O
genes	0	O
-	0	O
CEP1	0	B
/	0	O
CBF1	0	B
/	0	O
CPF1	0	B
,	0	O
NDC10	0	B
/	0	O
CBF2	0	B
,	0	O
and	0	O
CEP3	0	B
/	0	O
CBF3B	0	B
.	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
observe	0	O
that	0	O
the	0	O
hUBF	0	B
-	0	I
promoter	0	I
interaction	0	O
is	0	O
highly	0	O
sensitive	0	O
to	0	O
the	0	O
antagonistic	0	O
effects	0	O
of	0	O
cisplatin	0	O
-	0	O
DNA	1	O
adducts	0	O
.	0	O


The	0	O
combination	0	O
of	0	O
F1	0	O
and	0	O
F2	0	O
which	0	O
was	0	O
the	0	O
best	0	O
predictor	0	O
of	0	O
CHD	1	O
in	0	O
this	0	O
population	0	O
(	0	O
G1	0	O
)	0	O
might	0	O
be	0	O
interpreted	0	O
as	0	O
reflecting	0	O
trunk	0	O
adiposity	0	O
mainly	0	O
abdominal	0	O
.	0	O


The	0	O
reduced	0	O
efficiency	0	O
in	0	O
the	0	O
glycosylase	0	B
activity	0	O
is	0	O
also	0	O
reflected	0	O
in	0	O
a	0	O
reduced	0	O
ability	0	O
of	0	O
S120K	0	B
MutY	0	I
to	0	O
prevent	0	O
DNA	1	O
mutations	0	O
in	0	O
vivo	0	O
.	0	O


Cataract	1	O
extraction	0	O
in	0	O
primary	0	O
glaucoma	0	O


Renal	1	O
excretion	0	O
of	0	O
sulphadimidine	0	O
in	0	O
normal	0	O
and	0	O
uraemic	0	O
subjects	0	O
.	0	O


Cytogenetic	1	O
analysis	0	O
of	0	O
LOH	1	O
mutants	0	O
by	0	O
chromosome	0	O
painting	0	O
indicated	0	O
a	0	O
mosaic	0	O
of	0	O
chromosomal	0	O
aberrations	0	O
involving	0	O
chromosome	0	O
17	0	O
,	0	O
in	0	O
which	0	O
partial	0	O
chromosome	0	O
deletions	0	O
,	0	O
amplifications	0	O
,	0	O
and	0	O
multiple	0	O
translocations	0	O
appeared	0	O
heterogeneously	0	O
in	0	O
a	0	O
single	0	O
mutant	0	O
.	0	O


Some	0	O
strains	0	O
of	0	O
A	1	O
.	0	O
parasiticus	0	O
produced	0	O
all	0	O
four	0	O
aflatoxins	0	O
B1	0	O
B2	0	O
G1	0	O
G2	0	O
,	0	O
while	0	O
the	0	O
other	0	O
ones	0	O
produced	0	O
AF	1	O
B1	0	O
+	0	O
G1	0	O
only	0	O
,	0	O
with	0	O
concentrations	0	O
of	0	O
aflatoxins	0	O
from	0	O
0	0	O
.	0	O
1	0	O
to	0	O
450	0	O
mg	0	O
/	0	O
kg	0	O
.	0	O


The	0	O
protein	0	B
-	0	I
tyrosine	0	I
kinase	0	I
fer	0	I
associates	0	O
with	0	O
signaling	0	O
complexes	0	O
containing	0	O
insulin	0	B
receptor	0	I
substrate	0	I
-	0	I
1	0	I
and	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
.	0	O


Recovery	1	O
of	0	O
carbimazole	0	O
-	0	O
induced	0	O
agranulocytosis	0	O
following	0	O
recombinant	0	B
granulocyte	0	I
-	0	I
macrophage	0	I
colony	0	I
stimulating	0	I
factor	0	I
(	0	O
rhGM	0	B
-	0	I
CSF	1	I
)	0	O
administration	0	O
.	0	O


Although	0	O
increased	0	O
expression	0	O
of	0	O
the	0	O
HMG	1	B
-	0	I
I	1	I
/	0	I
Y	1	I
proteins	0	I
is	0	O
associated	0	O
with	0	O
cellular	0	O
proliferation	0	O
,	0	O
neoplastic	0	O
transformation	0	O
,	0	O
and	0	O
several	0	O
human	0	O
cancers	0	O
,	0	O
the	0	O
role	0	O
of	0	O
these	0	O
proteins	0	O
in	0	O
the	0	O
pathogenesis	0	O
of	0	O
malignancy	0	O
remains	0	O
unclear	0	O
.	0	O


The	0	O
inhibition	0	O
of	0	O
focus	0	O
formation	0	O
observed	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
C3G	0	B
was	0	O
not	0	O
due	0	O
to	0	O
toxic	0	O
effects	0	O
on	0	O
cell	0	O
viability	0	O
,	0	O
since	0	O
transfected	0	O
C3G	0	B
cells	0	O
exhibited	0	O
the	0	O
same	0	O
survival	0	O
and	0	O
growth	0	O
rates	0	O
as	0	O
untransfected	0	O
NIH3T3	0	O
cells	0	O
or	0	O
cells	0	O
transfected	0	O
with	0	O
plasmid	0	O
vector	0	O
alone	0	O
.	0	O


Fundus	1	O
changes	0	O
in	0	O
(	0	O
type	0	O
II	0	O
)	0	O
mesangiocapillary	0	O
glomerulonephritis	0	O
simulating	0	O
drusen	0	O
:	0	O
a	0	O
histopathological	0	O
report	0	O
.	0	O


Observation	0	O
of	0	O
dipolar	0	O
interactions	0	O
between	0	O
Pb0	0	O
defects	0	O
at	0	O
the	0	O
(	0	O
111	0	O
)	0	O
Si	1	O
/	0	O
SiO2	1	O
interface	0	O
.	0	O


Urinary	1	B
N	1	I
-	0	I
acetylglucosaminidase	0	I
activity	0	O
per	0	O
mg	0	O
creatinine	0	O
did	0	O
not	0	O
differ	0	O
significantly	0	O
between	0	O
groups	0	O
.	0	O


The	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
the	0	O
yeast	0	O
and	0	O
mammalian	0	O
mitochondrial	0	O
targeting	0	O
sequences	0	O
are	0	O
similar	0	O
but	0	O
less	0	O
related	0	O
than	0	O
the	0	O
mature	0	O
polypeptides	0	O
.	0	O


ANIMALS	0	O
:	0	O
Fifty	0	O
dogs	0	O
with	0	O
naturally	0	O
developing	0	O
DM	1	O
.	0	O


No	1	O
difference	0	O
in	0	O
percentage	0	O
of	0	O
males	0	O
in	0	O
semen	0	O
production	0	O
was	0	O
noted	0	O
between	0	O
strains	0	O
,	0	O
CP	1	O
levels	0	O
,	0	O
or	0	O
feeding	0	O
regimens	0	O
.	0	O


To	1	O
facilitate	0	O
the	0	O
investigation	0	O
of	0	O
parameters	0	O
that	0	O
govern	0	O
selective	0	O
export	0	O
in	0	O
adenovirus	0	O
-	0	O
infected	0	O
cells	0	O
,	0	O
we	0	O
constructed	0	O
a	0	O
marked	0	O
human	0	O
beta	0	B
-	0	I
actin	0	I
minigene	0	I
under	0	O
the	0	O
control	0	O
of	0	O
the	0	O
glucocorticoid	0	B
-	0	I
inducible	0	I
enhancer	0	I
-	0	I
promoter	0	I
of	0	O
mouse	0	O
mammary	0	O
tumor	0	O
virus	0	O
and	0	O
introduced	0	O
it	0	O
into	0	O
the	0	O
left	0	O
end	0	O
of	0	O
the	0	O
adenovirus	0	O
type	0	O
5	0	O
(	0	O
Ad5	0	O
)	0	O
genome	0	O
.	0	O


1	0	O
in	0	O
Ho	1	O
Chi	1	O
Minh	0	O
City	0	O
was	0	O
studied	0	O
by	0	O
culture	0	O
and	0	O
latex	0	O
agglutination	0	O
of	0	O
blood	0	O
,	0	O
cerebrospinal	0	O
fluid	0	O
,	0	O
urine	0	O
and	0	O
pleural	0	O
fluid	0	O
.	0	O


Hepatic	1	O
oxygen	0	O
supply	0	O
and	0	O
selected	0	O
blood	0	O
parameters	0	O
were	0	O
recorded	0	O
in	0	O
fasted	0	O
male	0	O
rates	0	O
given	0	O
20	0	O
--	0	O
30	0	O
mg	0	O
/	0	O
kg	0	O
Escherichia	1	B
coli	0	I
endotoxin	0	I
intraperitoneally	0	O
.	0	O


The	0	O
predicted	0	O
receptor	0	O
structure	0	O
includes	0	O
a	0	O
cysteine	0	O
-	0	O
rich	0	O
extracellular	0	O
domain	0	O
,	0	O
a	0	O
single	0	O
hydrophobic	0	O
transmembrane	0	O
domain	0	O
,	0	O
and	0	O
a	0	O
predicted	0	O
cytoplasmic	0	B
serine	0	I
/	0	I
threonine	0	I
kinase	0	I
domain	0	I
.	0	O


RESULTS	0	O
:	0	O
The	0	O
bilinear	0	O
model	0	O
provided	0	O
a	0	O
significantly	0	O
better	0	O
fit	0	O
to	0	O
the	0	O
acuity	0	O
outcome	0	O
data	0	O
.	0	O


In	1	O
26	0	O
patients	0	O
with	0	O
angina	0	O
pectoris	0	O
,	0	O
the	0	O
changes	0	O
of	0	O
LVEF	0	O
,	0	O
LVESV	0	O
and	0	O
PSP	1	O
/	0	O
LVESV	0	O
were	0	O
more	0	O
sensitive	0	O
for	0	O
the	0	O
detection	0	O
of	0	O
exercise	0	O
-	0	O
induced	0	O
ischemia	0	O
than	0	O
the	0	O
appearance	0	O
of	0	O
chest	0	O
pain	0	O
and	0	O
the	0	O
changes	0	O
of	0	O
ECG	1	O
.	0	O


Ste18p	0	B
was	0	O
targeted	0	O
to	0	O
the	0	O
plasma	0	O
membrane	0	O
even	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
prenylation	0	O
or	0	O
thioacylation	0	O
.	0	O


Biol	0	O
.	0	O


It	1	O
has	0	O
been	0	O
shown	0	O
in	0	O
experiments	0	O
in	0	O
vitro	0	O
that	0	O
the	0	O
hepatotrophic	0	O
organic	0	O
anions	0	O
,	0	O
the	0	O
radiographic	0	O
contrast	0	O
agent	0	O
(	0	O
RCA	1	O
)	0	O
bilignost	0	O
used	0	O
in	0	O
cholecystography	0	O
and	0	O
Bengal	0	O
pink	0	O
,	0	O
have	0	O
an	0	O
affinity	0	O
,	0	O
unlike	0	O
the	0	O
urographic	0	O
RCA	1	O
triombrin	0	O
and	0	O
renotrophic	0	O
dye	0	O
indigo	0	O
-	0	O
carmine	0	O
,	0	O
for	0	O
the	0	O
plasmatic	0	O
membranes	0	O
(	0	O
PM	1	O
)	0	O
of	0	O
liver	0	O
cells	0	O
.	0	O


In	1	O
untransformed	0	O
cells	0	O
,	0	O
three	0	O
major	0	O
proteins	0	O
coprecipitated	0	O
with	0	O
CRKL	0	B
,	0	O
identified	0	O
as	0	O
C3G	0	B
,	0	O
SOS	0	B
and	0	O
c	0	B
-	0	I
ABL	0	I
.	0	O


The	0	O
calculated	0	O
values	0	O
of	0	O
lambda	0	O
tb	0	O
at	0	O
37	0	O
degrees	0	O
C	1	O
and	0	O
50	0	O
per	0	O
cent	0	O
haematocrit	0	O
were	0	O
0	0	O
.	0	O
650	0	O
for	0	O
the	0	O
pulp	0	O
,	0	O
0	0	O
.	0	O
674	0	O
for	0	O
the	0	O
tongue	0	O
,	0	O
0	0	O
.	0	O
828	0	O
for	0	O
the	0	O
submandibular	0	O
gland	0	O
and	0	O
0	0	O
.	0	O
881	0	O
for	0	O
the	0	O
gingiva	0	O
of	0	O
the	0	O
dog	0	O
.	0	O
lambda	0	O
cp	0	O
increased	0	O
and	0	O
lambda	0	O
tp	0	O
decreased	0	O
as	0	O
the	0	O
temperature	0	O
was	0	O
reduced	0	O
from	0	O
37	0	O
to	0	O
4	0	O
degrees	0	O
C	1	O
.	0	O


Members	0	O
of	0	O
the	0	O
MAPK	1	B
family	0	I
include	0	O
the	0	O
extracellular	0	B
response	0	I
kinases	0	I
(	0	O
ERKs	0	B
or	0	O
p42	0	B
/	0	I
44	0	I
(	0	O
MAPK	1	B
)),	0	O
the	0	O
c	0	B
-	0	I
Jun	1	I
amino	0	I
-	0	I
terminal	0	I
kinases	0	I
(	0	O
JNKs	0	B
),	0	O
and	0	O
the	0	O
p38	0	B
/	0	O
Hog	0	B
1	0	I
protein	0	O
kinases	0	O
.	0	O


RNase	1	B
protection	0	O
assays	0	O
revealed	0	O
a	0	O
correlation	0	O
between	0	O
the	0	O
levels	0	O
of	0	O
dorsal	0	O
and	0	O
ventral	0	O
skin	0	O
expression	0	O
with	0	O
pigmentation	0	O
/	0	O
phaeomelanin	0	O
phenotypes	0	O
.	0	O


However	0	O
,	0	O
at	0	O
18	0	O
months	0	O
of	0	O
age	0	O
,	0	O
significantly	0	O
higher	0	O
levels	0	O
of	0	O
IgG1	0	B
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
and	0	O
of	0	O
IgG4	0	B
(	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
)	0	O
were	0	O
found	0	O
in	0	O
infants	0	O
with	0	O
an	0	O
elevated	0	O
IgE	1	B
(	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
8	0	O
.	0	O
0	0	O
kU	0	O
/	0	O
l	0	O
)	0	O
than	0	O
in	0	O
those	0	O
with	0	O
a	0	O
lower	0	O
level	0	O
.	0	O


Inverse	1	O
relation	0	O
between	0	O
serum	0	O
IgG	1	B
concentration	0	O
and	0	O
glucose	0	O
and	0	O
xylose	0	O
absorption	0	O
in	0	O
Zambian	0	O
African	0	O
adults	0	O
.	0	O


The	0	O
second	0	O
mutation	0	O
present	0	O
in	0	O
the	0	O
original	0	O
mutant	0	O
proved	0	O
to	0	O
be	0	O
an	0	O
allele	0	O
of	0	O
a	0	O
known	0	O
gene	0	O
,	0	O
PBS2	0	B
,	0	O
which	0	O
encodes	0	O
a	0	O
putative	0	O
protein	0	O
kinase	0	O
that	0	O
functions	0	O
in	0	O
the	0	O
high	0	O
osmolarity	0	O
stress	0	O
pathway	0	O
.	0	O


In	1	O
a	0	O
prospective	0	O
,	0	O
multicentre	0	O
trial	0	O
the	0	O
efficacy	0	O
of	0	O
an	0	O
Vitex	1	O
agnus	0	O
castus	0	O
L	1	O
extract	0	O
Ze	0	O
440	0	O
was	0	O
investigated	0	O
in	0	O
50	0	O
patients	0	O
with	0	O
pre	0	O
-	0	O
menstrual	0	O
syndrome	0	O
(	0	O
PMS	1	O
).	0	O


Furthermore	0	O
,	0	O
phosphatidylinositol	0	O
(	0	O
3	0	O
,	0	O
4	0	O
,	0	O
5	0	O
)	0	O
trisphosphate	0	O
specifically	0	O
stimulates	0	O
the	0	O
activity	0	O
of	0	O
ILK	0	B
in	0	O
vitro	0	O
,	0	O
and	0	O
in	0	O
addition	0	O
,	0	O
membrane	0	O
targetted	0	O
constitutively	0	O
active	0	O
Pi	1	B
(	0	I
3	0	I
)	0	I
K	1	I
activates	0	O
ILK	0	B
in	0	O
vivo	0	O
.	0	O


While	0	O
no	0	O
obvious	0	O
transmembrane	0	O
regions	0	O
were	0	O
identified	0	O
,	0	O
several	0	O
short	0	O
hydrophobic	0	O
amino	0	O
acid	0	O
stretches	0	O
were	0	O
found	0	O
to	0	O
be	0	O
localized	0	O
in	0	O
and	0	O
around	0	O
the	0	O
Pro	1	O
II	0	O
region	0	O
,	0	O
and	0	O
these	0	O
may	0	O
be	0	O
responsible	0	O
for	0	O
attachment	0	O
of	0	O
precursors	0	O
to	0	O
membranes	0	O
.	0	O


Epstein	0	B
-	0	I
Barr	0	I
virus	0	I
-	0	I
encoded	0	I
latent	0	I
membrane	0	I
protein	0	I
1	0	I
activates	0	O
the	0	O
JNK	0	B
pathway	0	O
through	0	O
its	0	O
extreme	0	O
C	1	O
terminus	0	O
via	0	O
a	0	O
mechanism	0	O
involving	0	O
TRADD	0	B
and	0	O
TRAF2	0	B
.	0	O


Maternal	1	O
seizures	0	O
had	0	O
occurred	0	O
during	0	O
pregnancy	0	O
in	0	O
52	0	O
per	0	O
cent	0	O
.	0	O


A	1	O
striking	0	O
finding	0	O
in	0	O
all	0	O
of	0	O
the	0	O
studies	0	O
was	0	O
a	0	O
positive	0	O
correlation	0	O
between	0	O
PI	1	O
ACTH	1	B
and	0	O
MSH	1	B
contents	0	O
.	0	O


The	0	O
CVA16	0	B
.	0	I
4	0	I
proteolipid	0	I
transcript	0	I
is	0	O
the	0	O
most	0	O
prevalent	0	O
of	0	O
the	0	O
two	0	O
proteolipid	0	O
messages	0	O
in	0	O
expanding	0	O
ovules	0	O
harvested	0	O
10	0	O
d	0	O
post	0	O
-	0	O
anthesis	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Congenital	1	O
horizontal	0	O
tarsal	0	O
kink	0	O
is	0	O
rare	0	O
and	0	O
its	0	O
cause	0	O
is	0	O
unknown	0	O
.	0	O


Analysis	1	O
of	0	O
the	0	O
mouse	0	B
STAP	0	I
gene	0	I
isolated	0	O
from	0	O
the	0	O
genomic	0	O
library	0	O
revealed	0	O
that	0	O
the	0	O
STAP	0	B
gene	0	I
spans	0	O
a	0	O
region	0	O
of	0	O
over	0	O
11	0	O
kb	0	O
and	0	O
comprises	0	O
eight	0	O
exons	0	O
.	0	O


A	1	O
larger	0	O
region	0	O
upstream	0	O
of	0	O
human	0	B
CMV	1	I
dbp	0	I
also	0	O
mediated	0	O
replication	0	O
in	0	O
transient	0	O
assays	0	O
.	0	O


In	1	O
particular	0	O
,	0	O
the	0	O
highly	0	O
expressed	0	O
ADH1	0	B
gene	0	I
is	0	O
represented	0	O
in	0	O
this	0	O
database	0	O
by	0	O
no	0	O
less	0	O
than	0	O
20	0	O
EST	1	O
sequences	0	O
.	0	O


Multiparity	1	O
had	0	O
a	0	O
protective	0	O
effect	0	O
with	0	O
0	0	O
.	0	O
66	0	O
less	0	O
risk	0	O
(	0	O
95	0	O
%	0	O
CI	1	O
0	0	O
.	0	O
44	0	O
-	0	O
0	0	O
.	0	O
99	0	O
).	0	O


Rat	1	B
kidney	0	I
carboxylesterase	0	I
.	0	O


The	0	O
growth	0	O
defect	0	O
of	0	O
a	0	O
reg1	0	B
reg2	0	I
double	0	I
mutant	0	I
is	0	O
alleviated	0	O
by	0	O
a	0	O
loss	0	O
-	0	O
of	0	O
-	0	O
function	0	O
mutation	0	O
in	0	O
the	0	O
SNF1	0	B
-	0	I
encoded	0	I
protein	0	I
kinase	0	I
.	0	O


Upstream	1	O
of	0	O
-	0	O
37	0	O
,	0	O
the	0	O
5	0	O
'	0	O
untranslated	0	O
sequences	0	O
of	0	O
the	0	O
isolates	0	O
differ	0	O
in	0	O
both	0	O
length	0	O
and	0	O
sequence	0	O
.	0	O


Statement	0	O
of	0	O
the	0	O
American	0	O
Academy	0	O
of	0	O
Implant	1	O
Dentistry	1	O
.	0	O


In	1	O
cellular	0	O
supernatant	0	O
fraction	0	O
,	0	O
SHRSP	0	O
showed	0	O
a	0	O
decrease	0	O
of	0	O
magnesium	0	O
in	0	O
many	0	O
tissues	0	O
and	0	O
an	0	O
elevation	0	O
of	0	O
the	0	O
calcium	0	O
to	0	O
magnesium	0	O
ratio	0	O
when	0	O
compared	0	O
to	0	O
age	0	O
-	0	O
matched	0	O
WKY	0	O
and	0	O
SHRSR	0	O
.	0	O


Plots	0	O
of	0	O
RV	1	O
,	0	O
LV	1	O
+	0	O
S	1	O
and	0	O
2A	0	O
weight	0	O
vs	0	O
real	0	O
hematocrit	0	O
showed	0	O
sharp	0	O
upward	0	O
inflections	0	O
at	0	O
real	0	O
hematocrit	0	O
65	0	O
%,	0	O
suggesting	0	O
a	0	O
possible	0	O
role	0	O
of	0	O
increased	0	O
viscosity	0	O
in	0	O
CO	1	O
cardiomegaly	0	O
at	0	O
the	0	O
higher	0	O
hematocrit	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
class	0	O
I	1	O
cytologic	0	O
smears	0	O
with	0	O
moderate	0	O
to	0	O
severe	0	O
inflammation	0	O
may	0	O
be	0	O
associated	0	O
with	0	O
findings	0	O
of	0	O
condylomata	0	O
and	0	O
cervical	0	O
dysplasia	0	O
.	0	O


Using	0	O
a	0	O
natural	0	O
dominant	0	O
negative	0	O
for	0	O
AP	1	B
-	0	I
1	0	I
transcriptional	0	O
activity	0	O
in	0	O
ROS	1	O
17	0	O
/	0	O
2	0	O
.	0	O
8	0	O
cells	0	O
,	0	O
we	0	O
then	0	O
showed	0	O
that	0	O
AP	1	B
-	0	I
1	0	I
transcription	0	I
factors	0	I
mediated	0	O
TGF	1	B
-	0	I
beta1	0	I
-	0	O
and	0	O
BMP	1	B
-	0	I
2	0	I
-	0	O
regulated	0	O
expression	0	O
of	0	O
the	0	O
(	0	B
alpha1	0	I
)	0	I
collagen	0	I
I	1	I
gene	0	I
as	0	O
well	0	O
as	0	O
TGF	1	B
-	0	I
beta1	0	I
-	0	O
regulated	0	O
expression	0	O
of	0	O
the	0	O
parathyroid	0	B
hormone	0	I
(	0	O
PTH	1	B
)/	0	O
PTH	1	B
-	0	I
related	0	I
peptide	0	I
(	0	I
PTHrP	0	I
)	0	I
receptor	0	I
.	0	O


Only	0	O
two	0	O
of	0	O
the	0	O
isoforms	0	O
possess	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
zinc	0	O
finger	0	O
domain	0	O
that	0	O
is	0	O
necessary	0	O
and	0	O
sufficient	0	O
for	0	O
TdT	1	B
promoter	0	I
binding	0	O
.	0	O


If	1	O
delay	0	O
has	0	O
occurred	0	O
between	0	O
centrifugation	0	O
and	0	O
the	0	O
measurement	0	O
,	0	O
causing	0	O
substantial	0	O
loss	0	O
of	0	O
CO2	1	O
,	0	O
equilibration	0	O
of	0	O
the	0	O
sample	0	O
with	0	O
a	0	O
gas	0	O
mixture	0	O
corresponding	0	O
to	0	O
PCO2	1	O
=	0	O
5	0	O
.	0	O
3	0	O
kPa	0	O
prior	0	O
to	0	O
the	0	O
measurement	0	O
is	0	O
recommended	0	O
.	0	O


The	0	O
pyramidal	0	O
tract	0	O
and	0	O
Mesencephalic	1	O
Reticular	1	O
Formation	1	O
(	0	O
MRF	0	O
)	0	O
were	0	O
stimulated	0	O
before	0	O
and	0	O
after	0	O
the	0	O
transection	0	O
.	0	O


To	1	O
study	0	O
the	0	O
structure	0	O
-	0	O
function	0	O
of	0	O
the	0	O
gene	0	B
5	0	I
product	0	I
,	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
mutant	0	O
forms	0	O
of	0	O
NS53	0	B
were	0	O
produced	0	O
by	0	O
using	0	O
a	0	O
recombinant	0	O
baculovirus	0	O
expression	0	O
system	0	O
and	0	O
a	0	O
recombinant	0	O
vaccinia	0	O
virus	0	O
/	0	O
T7	0	O
(	0	O
vTF7	0	O
-	0	O
3	0	O
)	0	O
expression	0	O
system	0	O
.	0	O


Use	0	O
of	0	O
subcutaneous	0	O
deferoxamine	0	O
in	0	O
a	0	O
child	0	O
with	0	O
hemochromatosis	0	O
associated	0	O
with	0	O
congenital	0	O
dyserythropoietic	0	O
anemia	0	O
,	0	O
type	0	O
I	1	O
.	0	O


The	0	O
ability	0	O
of	0	O
spt2	0	B
mutations	0	I
to	0	O
suppress	0	O
the	0	O
transcriptional	0	O
interference	0	O
caused	0	O
by	0	O
the	0	O
delta	0	B
promoter	0	I
insertion	0	I
his	0	I
-	0	I
4	0	I
-	0	I
912	0	I
delta	0	I
correlates	0	O
with	0	O
an	0	O
increase	0	O
in	0	O
wild	0	B
-	0	I
type	0	I
HIS4	0	I
mRNA	1	I
levels	0	O
.	0	O


Strontium	1	O
nitrate	0	O
mixed	0	O
with	0	O
glycolic	0	O
acid	0	O
,	0	O
in	0	O
comparison	0	O
with	0	O
glycolic	0	O
acid	0	O
alone	0	O
,	0	O
markedly	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
)	0	O
shortened	0	O
the	0	O
duration	0	O
of	0	O
the	0	O
irritation	0	O
sensation	0	O
from	0	O
24	0	O
.	0	O
4	0	O
+/-	0	O
4	0	O
.	0	O
1	0	O
(	0	O
mean	0	O
+/-	0	O
SEM	0	O
)	0	O
min	0	O
to	0	O
8	0	O
.	0	O
9	0	O
+/-	0	O
3	0	O
.	0	O
7	0	O
(	0	O
mean	0	O
+/-	0	O
SEM	0	O
)	0	O
min	0	O
,	0	O
and	0	O
significantly	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
reduced	0	O
the	0	O
mean	0	O
magnitude	0	O
of	0	O
the	0	O
irritation	0	O
sensation	0	O
at	0	O
all	0	O
time	0	O
points	0	O
(	0	O
overall	0	O
).	0	O


The	0	O
coating	0	O
materials	0	O
were	0	O
poloxamine	0	O
904	0	O
,	0	O
poloxamine	0	O
908	0	O
,	0	O
poloxamine	0	O
1508	0	O
,	0	O
poloxamer	0	O
338	0	O
,	0	O
and	0	O
Brij	0	O
35	0	O
.	0	O


Evaluation	1	O
of	0	O
automatic	0	O
blood	0	O
cell	0	O
counters	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
our	0	O
data	0	O
suggest	0	O
that	0	O
Dbf8p	0	B
plays	0	O
an	0	O
essential	0	O
role	0	O
in	0	O
chromosome	0	O
segregation	0	O
.	0	O


A	1	O
genomic	0	O
DNA	1	O
clone	0	O
encoding	0	O
oryzacystatin	0	B
(	0	O
Oc	1	B
),	0	O
a	0	O
cysteine	0	B
proteinase	0	I
inhibitor	0	O
(	0	O
cystatin	0	B
)	0	O
of	0	O
rice	0	O
,	0	O
was	0	O
isolated	0	O
from	0	O
a	0	O
lambda	0	O
EMBL3	0	O
phage	0	O
library	0	O
constructed	0	O
with	0	O
Sau3AI	0	B
partial	0	O
digests	0	O
of	0	O
rice	0	O
chromosomal	0	O
DNA	1	O
,	0	O
by	0	O
screening	0	O
with	0	O
an	0	O
oc	0	B
cDNA	1	I
as	0	O
a	0	O
probe	0	O
.	0	O


Reactive	1	O
lymphoid	0	O
hyperplasia	0	O
was	0	O
found	0	O
in	0	O
15	0	O
cases	0	O
,	0	O
2	0	O
cases	0	O
had	0	O
angiofollicular	0	O
lymphoid	0	O
hyperplasia	0	O
or	0	O
Castleman	0	O
'	0	O
s	0	O
disease	0	O
,	0	O
atypical	0	O
lymphoid	0	O
hyperplasia	0	O
suggestive	0	O
of	0	O
malignant	0	O
lymphoma	0	O
was	0	O
observed	0	O
in	0	O
3	0	O
cases	0	O
,	0	O
and	0	O
malignant	0	O
lymphoma	0	O
was	0	O
diagnosed	0	O
in	0	O
the	0	O
remaining	0	O
4	0	O
cases	0	O
.	0	O


To	1	O
investigate	0	O
the	0	O
activity	0	O
of	0	O
TCF11	0	B
through	0	O
this	0	O
selected	0	O
site	0	O
,	0	O
both	0	O
alone	0	O
and	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
MafG	0	B
,	0	O
we	0	O
have	0	O
used	0	O
a	0	O
transient	0	O
transfection	0	O
assay	0	O
.	0	O


Hepatitis	1	O
B	1	O
and	0	O
liver	0	O
transplantation	0	O
.	0	O


End	1	O
points	0	O
measured	0	O
were	0	O
perioperative	0	O
(	0	O
30	0	O
-	0	O
day	0	O
)	0	O
myocardial	0	O
infarction	0	O
(	0	O
MI	1	O
)	0	O
rate	0	O
and	0	O
death	0	O
.	0	O


Northern	0	O
blot	0	O
analysis	0	O
revealed	0	O
the	0	O
expression	0	O
of	0	O
LIMK	0	B
-	0	I
1	0	I
mRNA	1	I
predominantly	0	O
in	0	O
the	0	O
brain	0	O
and	0	O
the	0	O
expression	0	O
of	0	O
LIMK	0	B
-	0	I
2	0	I
mRNA	1	I
in	0	O
various	0	O
tissues	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


Detection	1	O
of	0	O
exercise	0	O
-	0	O
induced	0	O
asynergy	0	O
by	0	O
M	1	O
-	0	O
mode	0	O
echocardiography	0	O
.	0	O


A	1	O
significant	0	O
direct	0	O
relationship	0	O
was	0	O
observed	0	O
between	0	O
the	0	O
percent	0	O
area	0	O
density	0	O
of	0	O
smooth	0	O
muscle	0	O
and	0	O
the	0	O
percent	0	O
change	0	O
in	0	O
peak	0	O
urinary	0	O
flow	0	O
rate	0	O
.	0	O


A	1	O
new	0	O
hypothesis	0	O
on	0	O
mechanisms	0	O
for	0	O
inhibiting	0	O
catalytic	0	O
subunits	0	O
by	0	O
gamma	0	O
-	0	O
subunits	0	O
and	0	O
activation	0	O
of	0	O
a	0	O
holoenzyme	0	O
by	0	O
transducin	0	B


The	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
state	0	O
of	0	O
CAK	0	B
beta	0	I
was	0	O
not	0	O
reduced	0	O
on	0	O
trypsinization	0	O
,	0	O
nor	0	O
enhanced	0	O
in	0	O
response	0	O
to	0	O
plating	0	O
3Y1	0	O
cells	0	O
onto	0	O
fibronectin	0	B
.	0	O


It	1	O
is	0	O
clear	0	O
that	0	O
subclinical	0	O
and	0	O
silent	0	O
CD	1	O
exist	0	O
in	0	O
a	0	O
large	0	O
subgroup	0	O
of	0	O
the	0	O
celiac	0	O
population	0	O
.	0	O


The	0	O
treatments	0	O
were	0	O
60	0	O
mg	0	O
t	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.	0	O
and	0	O
120	0	O
mg	0	O
t	0	O
.	0	O
i	0	O
.	0	O
d	0	O
.	0	O
during	0	O
14	0	O
days	0	O
'	0	O
treatment	0	O
,	0	O
with	0	O
the	0	O
last	0	O
dose	0	O
pulsed	0	O
with	0	O
1	0	O
.	0	O
85	0	O
MBq	1	O
[	0	O
14C	0	O
]	0	O
diltiazem	0	O
.	0	O


Moreover	0	O
,	0	O
a	0	O
recombinant	0	O
Ad	1	O
expressing	0	O
Ad5	0	B
E4orf6	0	I
/	0	I
7	0	I
induced	0	O
apoptosis	0	O
in	0	O
rat	0	O
cells	0	O
when	0	O
coinfected	0	O
with	0	O
wild	0	O
-	0	O
type	0	O
p53	0	B
-	0	O
expressing	0	O
Ad	1	O
.	0	O


A	1	O
potential	0	O
binding	0	O
site	0	O
for	0	O
the	0	O
dShc	0	B
PTB	0	O
domain	0	O
is	0	O
located	0	O
at	0	O
Tyr	1	O
-	0	O
1228	0	O
of	0	O
DER	0	B
.	0	O


Induction	1	O
requires	0	O
the	0	O
ACE1	0	B
gene	0	I
product	0	I
,	0	O
which	0	O
binds	0	O
to	0	O
specific	0	O
sites	0	O
in	0	O
the	0	O
promoter	0	O
region	0	O
of	0	O
the	0	O
CUP1	0	B
gene	0	I
.	0	O


Thus	0	O
analysis	0	O
indicated	0	O
no	0	O
reliable	0	O
evidence	0	O
that	0	O
conscious	0	O
presleep	0	O
suggestions	0	O
become	0	O
incorporated	0	O
into	0	O
dream	0	O
content	0	O
.	0	O


Regression	1	O
line	0	O
slopes	0	O
of	0	O
IBDQ	0	O
scores	0	O
were	0	O
significantly	0	O
different	0	O
in	0	O
patients	0	O
who	0	O
deteriorated	0	O
from	0	O
those	0	O
who	0	O
remained	0	O
stable	0	O
([	0	O
b	0	O
]	0	O
<	0	O
0	0	O
.	0	O
15	0	O
;	0	O
P	1	O
<	0	O
0	0	O
.	0	O
0001	0	O
).	0	O


Effect	1	O
of	0	O
indoramin	0	O
in	0	O
small	0	O
doses	0	O
on	0	O
the	0	O
central	0	O
vasomotor	0	O
loci	0	O
has	0	O
been	0	O
studied	0	O
in	0	O
chloralose	0	O
anesthetized	0	O
cats	0	O
by	0	O
localizing	0	O
it	0	O
to	0	O
the	0	O
central	0	O
sites	0	O
.	0	O


Presently	0	O
four	0	O
unique	0	O
variants	0	O
carrying	0	O
distinct	0	O
GAF	1	B
sequences	0	I
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
region	0	O
have	0	O
been	0	O
identified	0	O
.	0	O


This	0	O
analysis	0	O
revealed	0	O
that	0	O
SAP	1	B
145	0	I
,	0	O
together	0	O
with	0	O
four	0	O
other	0	O
SF3a	0	B
/	0	O
SF3b	0	B
subunits	0	O
,	0	O
UV	1	O
cross	0	O
-	0	O
links	0	O
to	0	O
pre	0	O
-	0	O
mRNA	1	O
in	0	O
a	0	O
20	0	O
-	0	O
nucleotide	0	O
region	0	O
upstream	0	O
of	0	O
the	0	O
BPS	0	O
.	0	O


A	1	O
G22V	0	B
mutant	0	I
of	0	O
M	1	B
-	0	I
Ras	1	I
was	0	O
constitutively	0	O
active	0	O
and	0	O
its	0	O
expression	0	O
in	0	O
an	0	O
interleukin	0	B
-	0	I
3	0	I
(	0	O
IL	1	B
-	0	I
3	0	I
)-	0	O
dependent	0	O
mast	0	O
cell	0	O
/	0	O
megakaryocyte	0	O
cell	0	O
line	0	O
resulted	0	O
in	0	O
increased	0	O
survival	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
IL	1	B
-	0	I
3	0	I
,	0	O
increased	0	O
growth	0	O
in	0	O
IL	1	B
-	0	I
4	0	I
,	0	O
and	0	O
,	0	O
at	0	O
high	0	O
expression	0	O
levels	0	O
,	0	O
in	0	O
factor	0	O
-	0	O
independent	0	O
growth	0	O
.	0	O


The	0	O
ubiquitously	0	O
expressed	0	O
E12	0	B
bHLH	0	I
protein	0	I
dimerizes	0	O
with	0	O
numerous	0	O
cell	0	O
-	0	O
specific	0	O
bHLH	0	B
factors	0	I
.	0	O


However	0	O
,	0	O
a	0	O
similar	0	O
mutation	0	O
of	0	O
a	0	O
leucine	0	O
residue	0	O
to	0	O
arginine	0	O
at	0	O
position	0	O
422	0	O
showed	0	O
no	0	O
alteration	0	O
of	0	O
heterodimerization	0	O
,	0	O
DNA	1	O
binding	0	O
,	0	O
or	0	O
transcriptional	0	O
activation	0	O
.	0	O


In	1	O
human	0	O
brain	0	O
,	0	O
contactin	0	B
was	0	O
first	0	O
identified	0	O
by	0	O
amino	0	O
terminal	0	O
and	0	O
peptide	0	O
sequencing	0	O
of	0	O
the	0	O
lentil	0	B
-	0	I
lectin	0	I
-	0	I
binding	0	I
glycoprotein	0	I
Gp135	0	I
.	0	O


In	1	O
all	0	O
other	0	O
cases	0	O
,	0	O
vestibular	0	O
neurectomy	0	O
or	0	O
chemical	0	O
vestibular	0	O
labyrinthectomy	0	O
,	0	O
by	0	O
means	0	O
of	0	O
intratympanic	0	O
low	0	O
concentration	0	O
gentamicin	0	O
(	0	O
20	0	O
mg	0	O
/	0	O
mL	1	O
),	0	O
are	0	O
indicated	0	O
.	0	O


Role	1	O
of	0	O
g2	0	O
in	0	O
relating	0	O
the	0	O
Schwinger	0	O
and	0	O
Gerasimov	0	O
-	0	O
Drell	0	O
-	0	O
Hearn	0	O
sum	0	O
rules	0	O
.	0	O


Therefore	0	O
,	0	O
we	0	O
studied	0	O
ninety	0	O
coagulopathic	0	O
patients	0	O
with	0	O
the	0	O
aim	0	O
of	0	O
determining	0	O
the	0	O
prevalence	0	O
of	0	O
hepatitis	0	B
C	1	I
virus	0	I
(	0	I
HCV	1	I
)	0	I
antibodies	0	I
using	0	O
the	0	O
ELISA	1	O
and	0	O
RIBA	0	O
methods	0	O
.	0	O


Chronic	1	O
hypophosphatemia	0	O
is	0	O
the	0	O
most	0	O
common	0	O
type	0	O
of	0	O
"	0	O
resistant	0	O
"	0	O
rickets	0	O
.	0	O


However	0	O
,	0	O
further	0	O
analyses	0	O
of	0	O
the	0	O
data	0	O
indicate	0	O
that	0	O
increasing	0	O
VO2	1	O
AT	1	O
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
63	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
rather	0	O
than	0	O
VO2max	0	O
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
15	0	O
)	0	O
could	0	O
result	0	O
in	0	O
improving	0	O
the	0	O
10	0	O
,	0	O
000	0	O
m	0	O
race	0	O
performance	0	O
to	0	O
a	0	O
larger	0	O
extent	0	O
,	0	O
and	0	O
that	0	O
the	0	O
absolute	0	O
amount	0	O
of	0	O
change	0	O
(	0	O
delta	0	O
)	0	O
in	0	O
the	0	O
10	0	O
,	0	O
000	0	O
m	0	O
run	0	O
time	0	O
is	0	O
best	0	O
accounted	0	O
for	0	O
by	0	O
a	0	O
combination	0	O
of	0	O
delta	0	O
VO2	1	O
AT	1	O
and	0	O
delta	0	O
5	0	O
,	0	O
000	0	O
m	0	O
run	0	O
time	0	O
.	0	O


The	0	O
Caenorhabditis	0	B
elegans	0	I
vitellogenin	0	I
genes	0	I
are	0	O
subject	0	O
to	0	O
sex	0	O
-,	0	O
stage	0	O
-,	0	O
and	0	O
tissue	0	O
-	0	O
specific	0	O
regulation	0	O
:	0	O
they	0	O
are	0	O
expressed	0	O
solely	0	O
in	0	O
the	0	O
adult	0	O
hermaphrodite	0	O
intestine	0	O
.	0	O


The	0	O
patient	0	O
underwent	0	O
two	0	O
intracytoplasmic	0	O
sperm	0	O
injection	0	O
cycles	0	O
with	0	O
thawed	0	O
epididymal	0	O
spermatozoa	0	O
,	0	O
in	0	O
which	0	O
,	0	O
due	0	O
to	0	O
a	0	O
pharmacist	0	O
'	0	O
s	0	O
mistake	0	O
,	0	O
ovarian	0	O
stimulation	0	O
was	0	O
carried	0	O
out	0	O
by	0	O
a	0	O
combination	0	O
of	0	O
long	0	O
-	0	O
acting	0	O
gonadotrophin	0	B
-	0	I
releasing	0	I
hormone	0	I
agonist	0	O
(	0	O
leuprolide	0	O
depot	0	O
)	0	O
and	0	O
gonadotrophins	0	B
.	0	O


Pulmonary	1	O
arterial	0	O
pressure	0	O
and	0	O
structure	0	O
in	0	O
the	0	O
patas	0	O
monkey	0	O
after	0	O
prolonged	0	O
administration	0	O
of	0	O
aminorex	0	O
fumarate	0	O
.	0	O


The	0	O
cDNA	1	O
segment	0	O
is	0	O
flanked	0	O
by	0	O
the	0	O
immunoglobulin	0	B
gene	0	I
recombination	0	I
signal	0	I
sequences	0	I
so	0	O
that	0	O
the	0	O
cDNA	1	O
segment	0	O
can	0	O
invert	0	O
and	0	O
the	0	O
human	0	B
IL	1	I
-	0	I
2R	0	I
L	1	I
chain	0	I
is	0	O
subsequently	0	O
expressed	0	O
under	0	O
the	0	O
control	0	O
of	0	O
the	0	O
SV40	1	B
promoter	0	I
.	0	O


The	0	O
relationship	0	O
between	0	O
the	0	O
rare	0	O
complications	0	O
mentioned	0	O
above	0	O
and	0	O
the	0	O
pathophysiology	0	O
of	0	O
Bartter	0	O
'	0	O
s	0	O
syndrome	0	O
is	0	O
still	0	O
obscure	0	O
.	0	O


Furthermore	0	O
,	0	O
using	0	O
transgenic	0	O
mouse	0	O
technology	0	O
we	0	O
localized	0	O
independent	0	O
cis	0	O
-	0	O
regulatory	0	O
elements	0	O
controlling	0	O
the	0	O
tissue	0	O
-	0	O
specific	0	O
expression	0	O
of	0	O
Pax6	0	B
.	0	O


Studies	0	O
were	0	O
performed	0	O
on	0	O
several	0	O
superficial	0	O
veins	0	O
from	0	O
the	0	O
rabbit	0	O
face	0	O
to	0	O
examine	0	O
the	0	O
relationship	0	O
between	0	O
beta	0	B
adrenoceptor	0	I
subtype	0	I
distribution	0	O
,	0	O
intrinsic	0	O
myogenic	0	O
tone	0	O
and	0	O
sympathetic	0	O
nerve	0	O
innervation	0	O
.	0	O


Inclusion	1	O
in	0	O
this	0	O
family	0	O
of	0	O
proteins	0	O
suggests	0	O
that	0	O
FliQ	0	B
and	0	O
FliR	0	B
may	0	O
participate	0	O
in	0	O
an	0	O
export	0	O
pathway	0	O
required	0	O
for	0	O
flagellum	0	O
assembly	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
the	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
a	0	O
second	0	O
family	0	O
(	0	O
ART5	0	B
)	0	O
of	0	O
transferases	0	O
,	0	O
cloned	0	O
from	0	O
murine	0	O
lymphoma	0	O
cells	0	O
and	0	O
expressed	0	O
in	0	O
high	0	O
abundance	0	O
in	0	O
testis	0	O
,	0	O
displays	0	O
a	0	O
hydrophobic	0	O
amino	0	O
terminus	0	O
,	0	O
consistent	0	O
with	0	O
a	0	O
signal	0	O
sequence	0	O
,	0	O
but	0	O
lacks	0	O
a	0	O
hydrophobic	0	O
signal	0	O
sequence	0	O
at	0	O
its	0	O
carboxyl	0	O
terminus	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
protein	0	O
is	0	O
destined	0	O
for	0	O
export	0	O
.	0	O


Regulation	1	O
of	0	O
irgA	0	B
by	0	O
iron	0	O
in	0	O
V	1	O
.	0	O
cholerae	0	O
occurs	0	O
at	0	O
the	0	O
transcriptional	0	O
level	0	O
,	0	O
and	0	O
there	0	O
is	0	O
an	0	O
interrupted	0	O
dyad	0	O
symmetric	0	O
sequence	0	O
in	0	O
the	0	O
vicinity	0	O
of	0	O
the	0	O
promoter	0	O
that	0	O
is	0	O
homologous	0	O
to	0	O
Fur	0	B
binding	0	I
sites	0	I
of	0	O
E	1	O
.	0	O
coli	0	O
.	0	O


Demispan	0	O
is	0	O
a	0	O
reliable	0	O
and	0	O
reproducible	0	O
measure	0	O
of	0	O
stature	0	O
in	0	O
the	0	O
elderly	0	O
.	0	O


A	1	O
sequence	0	O
representing	0	O
about	0	O
50	0	O
%	0	O
of	0	O
the	0	O
expected	0	O
complete	0	O
sequence	0	O
was	0	O
obtained	0	O
by	0	O
translation	0	O
of	0	O
the	0	O
two	0	O
open	0	O
reading	0	O
frames	0	O
present	0	O
on	0	O
a	0	O
1	0	O
.	0	O
6	0	O
kb	0	O
DNA	1	O
genomic	0	O
fragment	0	O
.	0	O


Serum	1	O
levels	0	O
of	0	O
testosterone	0	O
also	0	O
showed	0	O
no	0	O
significant	0	O
changes	0	O
by	0	O
exposure	0	O
to	0	O
p	0	O
,	0	O
p	0	O
'-	0	O
DDE	0	O
under	0	O
the	0	O
conditions	0	O
of	0	O
this	0	O
study	0	O
.	0	O


Mesial	1	O
temporal	0	O
sclerosis	0	O
.	0	O


Because	0	O
the	0	O
adrenergic	0	O
nervous	0	O
system	0	O
influences	0	O
cardiac	0	O
arrhythmias	0	O
and	0	O
myocardial	0	O
infarction	0	O
can	0	O
directly	0	O
affect	0	O
sympathetic	0	O
innervation	0	O
in	0	O
the	0	O
heart	0	O
,	0	O
we	0	O
investigated	0	O
the	0	O
role	0	O
of	0	O
the	0	O
sympathetic	0	O
nervous	0	O
system	0	O
on	0	O
reentry	0	O
in	0	O
the	0	O
canine	0	O
heart	0	O
4	0	O
days	0	O
after	0	O
infarction	0	O
.	0	O


In	1	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assays	0	O
,	0	O
the	0	O
PERE	0	B
formed	0	O
three	0	O
major	0	O
complexes	0	O
(	0	O
P1	1	O
,	0	O
P2	1	O
and	0	O
P3	0	O
)	0	O
with	0	O
proteins	0	O
in	0	O
nuclear	0	O
extracts	0	O
from	0	O
HeLa	0	O
or	0	O
293	0	O
cells	0	O
.	0	O


A	1	O
comparison	0	O
of	0	O
the	0	O
predicted	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
the	0	O
two	0	O
human	0	B
PKC	0	I
-	0	I
delta	0	I
clones	0	O
with	0	O
the	0	O
rat	0	O
and	0	O
mouse	0	O
homologues	0	O
indicated	0	O
a	0	O
greater	0	O
degree	0	O
of	0	O
sequence	0	O
divergence	0	O
(	0	O
89	0	O
-	0	O
90	0	O
%	0	O
homology	0	O
)	0	O
compared	0	O
to	0	O
the	0	O
high	0	O
degree	0	O
of	0	O
sequence	0	O
conservation	0	O
observed	0	O
with	0	O
other	0	O
human	0	B
PKC	0	I
family	0	I
members	0	I
and	0	O
their	0	O
mammalian	0	O
counterparts	0	O
.	0	O


The	0	O
phi	0	B
AP3	0	I
factor	0	I
is	0	O
a	0	O
nuclear	0	O
phosphoprotein	0	O
;	0	O
the	0	O
extent	0	O
of	0	O
its	0	O
phosphorylation	0	O
is	0	O
regulated	0	O
during	0	O
the	0	O
cell	0	O
cycle	0	O
.	0	O


These	0	O
observations	0	O
indicate	0	O
that	0	O
there	0	O
are	0	O
multiple	0	O
mechanisms	0	O
by	0	O
which	0	O
an	0	O
individual	0	O
transcript	0	O
can	0	O
be	0	O
degraded	0	O
following	0	O
deadenylation	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
regulatory	0	O
sequences	0	O
for	0	O
the	0	O
binding	0	O
of	0	O
transcription	0	O
factors	0	O
such	0	O
as	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
and	0	O
AP	1	B
-	0	I
2	0	I
,	0	O
whose	0	O
activation	0	O
is	0	O
associated	0	O
with	0	O
the	0	O
immediate	0	O
response	0	O
of	0	O
the	0	O
cell	0	O
to	0	O
an	0	O
injury	0	O
,	0	O
may	0	O
be	0	O
an	0	O
indication	0	O
of	0	O
the	0	O
important	0	O
role	0	O
which	0	O
HO	1	B
-	0	I
1	0	I
may	0	O
play	0	O
in	0	O
defense	0	O
mechanisms	0	O
against	0	O
tissue	0	O
injury	0	O
.	0	O


Here	0	O
we	0	O
report	0	O
the	0	O
purification	0	O
of	0	O
this	0	O
larger	0	O
form	0	O
as	0	O
an	0	O
approximately	0	O
320	0	O
-	0	O
kDa	1	O
particle	0	O
that	0	O
contains	0	O
mRNP3	0	B
+	0	I
4	0	I
and	0	O
nine	0	O
additional	0	O
polypeptides	0	O
,	0	O
including	0	O
mRNA	1	O
-	0	O
binding	0	O
polypeptides	0	O
of	0	O
34	0	O
and	0	O
36	0	O
kDa	1	O
and	0	O
a	0	O
doublet	0	O
of	0	O
110	0	O
/	0	O
105	0	O
kDa	1	O
that	0	O
proved	0	O
to	0	O
be	0	O
nucleolin	0	B
.	0	O


A	1	O
randomized	0	O
clinical	0	O
trial	0	O
in	0	O
sixty	0	O
-	0	O
two	0	O
adult	0	O
patients	0	O
suffering	0	O
from	0	O
typhoid	0	O
fever	0	O
,	0	O
proved	0	O
by	0	O
blood	0	O
and	0	O
marrow	0	O
culture	0	O
,	0	O
showed	0	O
that	0	O
amoxycillin	0	O
in	0	O
a	0	O
dosage	0	O
schedule	0	O
of	0	O
1	0	O
g	0	O
8	0	O
-	0	O
hourly	0	O
orally	0	O
for	0	O
fourteen	0	O
days	0	O
was	0	O
better	0	O
than	0	O
chloramphenicol	0	O
with	0	O
regard	0	O
to	0	O
clinical	0	O
and	0	O
temperature	0	O
response	0	O
and	0	O
in	0	O
respect	0	O
of	0	O
carriers	0	O
and	0	O
relapse	0	O
rates	0	O
.	0	O


It	1	O
is	0	O
believed	0	O
that	0	O
these	0	O
domains	0	O
are	0	O
important	0	O
for	0	O
directing	0	O
specific	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
necessary	0	O
for	0	O
the	0	O
proper	0	O
functioning	0	O
of	0	O
Src	1	B
.	0	O


In	1	O
about	0	O
one	0	O
third	0	O
of	0	O
the	0	O
cases	0	O
this	0	O
operation	0	O
results	0	O
in	0	O
tonal	0	O
and	0	O
vocal	0	O
improvement	0	O
for	0	O
patients	0	O
suffering	0	O
from	0	O
progressive	0	O
perceptive	0	O
deafness	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
chromosomal	0	O
segment	0	O
64AB	0	O
,	0	O
a	0	O
region	0	O
containing	0	O
the	0	O
glutamic	0	B
acid	0	I
decarboxylase	0	I
gene	0	I
.	0	O


The	0	O
consensus	0	O
gene	0	O
order	0	O
deduced	0	O
by	0	O
combining	0	O
data	0	O
from	0	O
both	0	O
crosses	0	O
is	0	O
D2Mit1	0	B
-(	0	O
Dbh	0	B
,	0	O
Notch1	0	B
)-(	0	O
Col5a1	0	B
,	0	O
Rxra	0	B
)-	0	O
Spna2	0	B
-	0	O
Ab	1	B
l	0	I
-(	0	O
Ak1	0	B
,	0	O
Fpgs	0	B
)-	0	O
(	0	O
Grp78	0	B
,	0	O
Pbx3	0	B
)-(	0	O
Epb7	0	B
.	0	I
2	0	I
,	0	I
Hc	1	I
,	0	I
Gsn	0	I
)-	0	O
Acra	0	B
.	0	O


The	0	O
binding	0	O
specificity	0	O
of	0	O
this	0	O
protein	0	O
was	0	O
compared	0	O
to	0	O
that	0	O
of	0	O
human	0	B
E2F	0	I
using	0	O
a	0	O
number	0	O
of	0	O
mutant	0	B
E2F	0	I
sites	0	I
as	0	O
competitors	0	O
.	0	O


To	1	O
determine	0	O
whether	0	O
vanadate	0	O
could	0	O
inhibit	0	O
PEPCK	0	B
gene	0	I
transcription	0	O
,	0	O
a	0	O
series	0	O
of	0	O
chimeric	0	O
genes	0	O
containing	0	O
several	0	O
deletions	0	O
in	0	O
the	0	O
P	1	B
-	0	I
enolypyruvate	0	I
carboxykinase	0	I
promoter	0	I
between	0	O
-	0	O
550	0	O
and	0	O
-	0	O
68	0	O
was	0	O
linked	0	O
to	0	O
the	0	O
structural	0	O
genes	0	O
for	0	O
either	0	O
amino	0	B
-	0	I
3	0	I
-	0	I
glycosyl	0	I
phosphotransferase	0	I
(	0	O
neo	0	B
)	0	O
or	0	O
chloramphenicol	0	B
acetyltransferase	0	I
and	0	O
introduced	0	O
into	0	O
hepatoma	0	O
cells	0	O
using	0	O
three	0	O
methods	0	O
:	0	O
(	0	O
a	0	O
)	0	O
infection	0	O
with	0	O
a	0	O
Moloney	0	O
murine	0	O
leukemia	0	O
virus	0	O
-	0	O
based	0	O
retrovirus	0	O
,	0	O
(	0	O
b	0	O
)	0	O
transfection	0	O
and	0	O
stable	0	O
selection	0	O
for	0	O
neo	0	B
expression	0	O
,	0	O
or	0	O
(	0	O
c	0	O
)	0	O
transient	0	O
expression	0	O
of	0	O
chloroamphenicol	0	B
acetyltransferase	0	I
.	0	O


An	1	O
increase	0	O
in	0	O
the	0	O
level	0	O
of	0	O
serum	0	O
enzymes	0	O
,	0	O
such	0	O
as	0	O
aspartate	0	B
transaminase	0	I
,	0	O
alkaline	0	B
phosphatase	0	I
,	0	O
creatine	0	B
phosphokinase	0	I
,	0	O
lactate	0	B
dehydrogenase	0	I
after	0	O
D	1	O
.	0	O
russelli	0	O
venom	0	O
injection	0	O
in	0	O
albino	0	O
rats	0	O
is	0	O
indicative	0	O
of	0	O
cell	0	O
or	0	O
tissue	0	O
damage	0	O
.	0	O


Since	0	O
electrical	0	O
stimulation	0	O
of	0	O
neurones	0	O
may	0	O
activate	0	O
not	0	O
only	0	O
cell	0	O
bodies	0	O
but	0	O
also	0	O
neuronal	0	O
fibres	0	O
,	0	O
this	0	O
study	0	O
aimed	0	O
to	0	O
test	0	O
a	0	O
selectively	0	O
cholinergic	0	O
neurochemical	0	O
stimulation	0	O
of	0	O
the	0	O
rat	0	O
substantia	0	O
innominata	0	O
(	0	O
SI	1	O
)	0	O
by	0	O
the	0	O
local	0	O
microinjection	0	O
of	0	O
carbachol	0	O
;	0	O
the	0	O
effects	0	O
of	0	O
this	0	O
acetylcholine	0	O
agonist	0	O
were	0	O
compared	0	O
with	0	O
glutamate	0	O
.	0	O


Thus	0	O
,	0	O
SOX8	0	B
is	0	O
a	0	O
good	0	O
candidate	0	O
gene	0	O
contributing	0	O
to	0	O
the	0	O
mental	0	O
retardation	0	O
phenotype	0	O
seen	0	O
in	0	O
ATR	0	O
-	0	O
16	0	O
patients	0	O
.	0	O


Bronchial	1	O
mucosa	0	O
tattooing	0	O
in	0	O
persons	0	O
exposed	0	O
to	0	O
different	0	O
industrial	0	O
aerosols	0	O
did	0	O
not	0	O
depend	0	O
on	0	O
the	0	O
forms	0	O
of	0	O
PC	1	O
,	0	O
DB	1	O
and	0	O
the	0	O
diseases	0	O
'	0	O
stages	0	O
.	0	O


With	0	O
a	0	O
cutoff	0	O
level	0	O
for	0	O
TSST	0	B
-	0	I
1	0	I
of	0	O
less	0	O
than	0	O
100	0	O
pg	0	O
/	0	O
ml	0	O
,	0	O
28	0	O
samples	0	O
obtained	0	O
from	0	O
12	0	O
patients	0	O
were	0	O
positive	0	O
for	0	O
TSST	0	B
-	0	I
1	0	I
.	0	O


No	1	O
symptoms	0	O
other	0	O
than	0	O
hot	0	O
flush	0	O
showed	0	O
such	0	O
significant	0	O
correlation	0	O
with	0	O
plasma	0	O
epinephrine	0	O
or	0	O
norepinephrine	0	O
levels	0	O
.	0	O


Two	0	O
classes	0	O
of	0	O
mutations	0	O
were	0	O
obtained	0	O
:	0	O
(	0	O
i	0	O
)	0	O
those	0	O
that	0	O
altered	0	O
the	0	O
coding	0	O
region	0	O
of	0	O
HOL1	0	B
,	0	O
conferring	0	O
the	0	O
ability	0	O
to	0	O
take	0	O
up	0	O
histidinol	0	O
;	0	O
and	0	O
(	0	O
ii	0	O
)	0	O
cis	0	O
-	0	O
acting	0	O
mutations	0	O
(	0	O
selected	0	O
in	0	O
a	0	O
mutant	0	O
HOL1	0	B
-	0	I
1	0	I
background	0	O
)	0	O
that	0	O
increased	0	O
expression	0	O
of	0	O
the	0	O
Hol1	0	B
protein	0	I
.	0	O


PrpB	0	B
showed	0	O
homology	0	O
to	0	O
carboxyphosphonoenolpyruvate	0	B
phosphonomutase	0	I
of	0	I
Streptomyces	1	I
hygroscopicus	0	I
and	0	O
to	0	O
its	0	O
homolog	0	O
in	0	O
the	0	O
carnation	0	O
Dianthus	0	O
caryophyllus	0	O
;	0	O
PrpC	0	B
was	0	O
homologous	0	O
to	0	O
both	0	O
archaeal	0	B
and	0	I
bacterial	0	I
citrate	0	I
synthases	0	I
;	0	O
PrpD	0	B
showed	0	O
homology	0	O
to	0	O
yeast	0	O
and	0	O
Bacillus	1	O
subtilis	0	O
proteins	0	O
of	0	O
unknown	0	O
function	0	O
;	0	O
PrpE	0	B
showed	0	O
homology	0	O
to	0	O
acetyl	0	B
coenzyme	0	I
A	1	I
synthetases	0	I
.	0	O


One	0	O
of	0	O
these	0	O
SEBPs	0	B
,	0	O
SEBP2	0	B
,	0	O
was	0	O
shown	0	O
to	0	O
be	0	O
the	0	O
product	0	O
of	0	O
the	0	O
homeotic	0	B
gene	0	I
fork	0	I
head	0	I
.	0	O


These	0	O
results	0	O
show	0	O
that	0	O
the	0	O
neonate	0	O
differs	0	O
from	0	O
the	0	O
adult	0	O
in	0	O
respect	0	O
of	0	O
both	0	O
the	0	O
nature	0	O
of	0	O
effects	0	O
of	0	O
the	0	O
drug	0	O
and	0	O
sensitivity	0	O
to	0	O
it	0	O
.	0	O


Protease	1	O
activities	0	O
in	0	O
cultures	0	O
of	0	O
the	0	O
streptococcal	0	O
strains	0	O
were	0	O
associated	0	O
with	0	O
species	0	O
of	0	O
different	0	O
molecular	0	O
masses	0	O
ranging	0	O
from	0	O
130	0	O
to	0	O
200	0	O
kDa	1	O
,	0	O
suggesting	0	O
posttranslational	0	O
processing	0	O
possibly	0	O
as	0	O
a	0	O
result	0	O
of	0	O
autoproteolysis	0	O
at	0	O
post	0	O
-	0	O
proline	0	O
peptide	0	O
bonds	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
parts	0	O
of	0	O
the	0	O
molecules	0	O
.	0	O


Clinical	1	O
aspects	0	O
of	0	O
early	0	O
increase	0	O
in	0	O
serum	0	O
gamma	0	B
-	0	I
glutamyl	0	I
transferase	0	I
in	0	O
cerebral	0	O
infarction	0	O
.	0	O


All	1	O
four	0	O
domains	0	O
were	0	O
linked	0	O
via	0	O
proline	0	O
-	0	O
threonine	0	O
-	0	O
rich	0	O
peptides	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
decreased	0	O
class	0	O
I	1	O
enhancer	0	O
activity	0	O
in	0	O
Ad12	0	O
-	0	O
transformed	0	O
cells	0	O
may	0	O
,	0	O
at	0	O
least	0	O
in	0	O
part	0	O
,	0	O
be	0	O
due	0	O
to	0	O
the	0	O
higher	0	O
levels	0	O
of	0	O
an	0	O
enhancer	0	O
-	0	O
specific	0	O
factor	0	O
,	0	O
possibly	0	O
acting	0	O
as	0	O
a	0	O
repressor	0	O
.	0	O


Most	0	O
kinases	0	O
are	0	O
not	0	O
significantly	0	O
inhibited	0	O
by	0	O
roscovitine	0	O
.	0	O
cdc2	0	B
/	0	O
cyclin	0	B
B	1	I
,	0	O
cdk2	0	B
/	0	O
cyclin	0	B
A	1	I
,	0	O
cdk2	0	B
/	0	O
cyclin	0	B
E	1	I
and	0	O
cdk5	0	B
/	0	O
p35	0	B
only	0	O
are	0	O
substantially	0	O
inhibited	0	O
(	0	O
IC50	0	O
values	0	O
of	0	O
0	0	O
.	0	O
65	0	O
,	0	O
0	0	O
.	0	O
7	0	O
,	0	O
0	0	O
.	0	O
7	0	O
and	0	O
0	0	O
.	0	O
2	0	O
microM	0	O
,	0	O
respectively	0	O
).	0	O
cdk4	0	B
/	0	O
cyclin	0	B
D1	1	I
and	0	O
cdk6	0	B
/	0	O
cyclin	0	B
D2	0	I
are	0	O
very	0	O
poorly	0	O
inhibited	0	O
by	0	O
roscovitine	0	O
(	0	O
IC50	0	O
>	0	O
100	0	O
microM	0	O
).	0	O


A	1	O
cause	0	O
of	0	O
increase	0	O
of	0	O
alkaline	0	B
phosphatase	0	I
in	0	O
children	0	O


These	0	O
discoloration	0	O
'	0	O
s	0	O
can	0	O
be	0	O
treated	0	O
in	0	O
several	0	O
ways	0	O
but	0	O
up	0	O
to	0	O
lately	0	O
tooth	0	O
structure	0	O
had	0	O
to	0	O
be	0	O
removed	0	O
in	0	O
an	0	O
irreversible	0	O
manner	0	O
in	0	O
order	0	O
to	0	O
provide	0	O
sufficient	0	O
bulk	0	O
for	0	O
the	0	O
new	0	O
restorative	0	O
material	0	O
.	0	O


Serum	1	O
magnesium	0	O
in	0	O
79	0	O
patients	0	O
of	0	O
gynecologic	0	O
neoplasms	0	O
treated	0	O
with	0	O
cisplatin	0	O
and	0	O
their	0	O
controls	0	O
was	0	O
measured	0	O
.	0	O


Facts	0	O
on	0	O
the	0	O
Economic	0	O
Recovery	1	O
Tax	0	O
Act	1	O
of	0	O
1981	0	O
for	0	O
speech	0	O
-	0	O
language	0	O
pathologists	0	O
and	0	O
audiologists	0	O
.	0	O


Retroviral	1	O
replication	0	O
requires	0	O
that	0	O
a	0	O
portion	0	O
of	0	O
the	0	O
primary	0	O
transcripts	0	O
generated	0	O
from	0	O
proviral	0	O
DNA	1	O
be	0	O
spliced	0	O
to	0	O
serve	0	O
as	0	O
mRNA	1	O
for	0	O
the	0	O
envelope	0	B
protein	0	I
and	0	O
in	0	O
Rous	0	O
sarcoma	0	O
virus	0	O
as	0	O
src	0	B
mRNA	1	I
.	0	O


In	1	O
contrast	0	O
,	0	O
deletion	0	O
of	0	O
the	0	O
upstream	0	O
portion	0	O
of	0	O
the	0	O
delta	0	O
promoter	0	O
led	0	O
to	0	O
a	0	O
10	0	O
fold	0	O
decrease	0	O
in	0	O
expression	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
these	0	O
mutations	0	O
on	0	O
RNA	1	B
polymerase	0	I
II	0	I
activity	0	O
were	0	O
assayed	0	O
by	0	O
measuring	0	O
the	0	O
ability	0	O
of	0	O
mutant	0	O
genes	0	O
to	0	O
confer	0	O
alpha	0	B
-	0	I
amanitin	0	I
resistance	0	O
after	0	O
transfection	0	O
of	0	O
susceptible	0	O
rodent	0	O
cells	0	O
.	0	O


The	0	O
RNA	1	B
polymerase	0	I
III	0	I
-	0	I
recruiting	0	I
factor	0	I
TFIIIB	0	I
induces	0	O
a	0	O
DNA	1	O
bend	0	O
between	0	O
the	0	O
TATA	0	O
box	0	O
and	0	O
the	0	O
transcriptional	0	O
start	0	O
site	0	O
.	0	O


At	1	O
1	0	O
,	0	O
5	0	O
,	0	O
and	0	O
9	0	O
months	0	O
after	0	O
initial	0	O
isolation	0	O
of	0	O
C	1	O
.	0	O
kutscheri	0	O
from	0	O
the	0	O
oral	0	O
cavity	0	O
,	0	O
hamsters	0	O
were	0	O
euthanatized	0	O
,	0	O
and	0	O
attempts	0	O
were	0	O
made	0	O
to	0	O
culture	0	O
C	1	O
.	0	O
kutscheri	0	O
from	0	O
13	0	O
additional	0	O
sites	0	O
.	0	O


Conversely	0	O
,	0	O
treatment	0	O
of	0	O
human	0	B
protein	0	I
-	0	I
tyrosine	0	I
phosphatase	0	I
alpha	0	I
-	0	O
overexpressing	0	O
cells	0	O
with	0	O
phenylarsine	0	O
oxide	0	O
led	0	O
to	0	O
a	0	O
loss	0	O
of	0	O
the	0	O
constitutive	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
activity	0	O
.	0	O


Krox	0	B
-	0	I
24	0	I
is	0	O
therefore	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
transcriptional	0	O
activator	0	O
.	0	O


Expression	1	O
plasmids	0	O
harboring	0	O
full	0	O
-	0	O
length	0	O
or	0	O
kinase	0	O
domain	0	O
of	0	O
PKC	0	B
alpha	0	I
and	0	O
PKC	0	B
delta	0	I
(	0	O
PKC	0	B
alpha	0	I
K	1	I
and	0	O
PKC	0	B
delta	0	I
K	1	I
)	0	O
were	0	O
constructed	0	O
.	0	O


Exogenous	1	O
LHRH	1	B
is	0	O
also	0	O
known	0	O
to	0	O
facilitate	0	O
mating	0	O
behavior	0	O
in	0	O
several	0	O
species	0	O
.	0	O


Systemic	1	O
impact	0	O
of	0	O
risk	0	O
-	0	O
sharing	0	O
arrangements	0	O
.	0	O


Early	0	O
infection	0	O
was	0	O
detected	0	O
in	0	O
one	0	O
of	0	O
50	0	O
control	0	O
women	0	O
who	0	O
gave	0	O
birth	0	O
to	0	O
a	0	O
healthy	0	O
infant	0	O
.	0	O


Erythrocyte	1	B
delta	0	I
-	0	I
aminolevulinic	0	I
acid	0	I
dehydratase	0	I
(	0	O
ALAD	0	B
)	0	O
activity	0	O
,	0	O
erythrocyte	0	O
zinc	0	O
protoporphyrin	0	O
(	0	O
ZPP	0	O
)/	0	O
heme	0	O
ratio	0	O
,	0	O
and	0	O
urinary	0	O
coproporphyrin	0	O
(	0	O
UC	0	O
)	0	O
concentration	0	O
have	0	O
been	0	O
employed	0	O
as	0	O
biological	0	O
indicators	0	O
of	0	O
moderate	0	O
-	0	O
to	0	O
high	0	O
-	0	O
level	0	O
lead	0	O
exposure	0	O
,	0	O
corresponding	0	O
to	0	O
blood	0	O
levels	0	O
in	0	O
excess	0	O
of	0	O
50	0	O
micrograms	0	O
/	0	O
dl	0	O
,	0	O
in	0	O
human	0	O
subjects	0	O
.	0	O


Both	0	O
methods	0	O
were	0	O
employed	0	O
for	0	O
various	0	O
focal	0	O
-	0	O
film	0	O
distances	0	O
,	0	O
image	0	O
intensifier	0	O
tube	0	O
modes	0	O
and	0	O
laser	0	O
printer	0	O
formats	0	O
.	0	O


Purified	0	B
P7	0	I
could	0	O
be	0	O
assembled	0	O
onto	0	O
particles	0	O
lacking	0	O
P7	0	B
and	0	O
particles	0	O
lacking	0	O
both	0	O
P2	1	B
(	0	O
RNA	1	B
polymerase	0	I
)	0	O
and	0	O
P7	0	B
.	0	O


Furthermore	0	O
,	0	O
freezing	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
bovine	0	B
lactalbumin	0	I
resulted	0	O
in	0	O
a	0	O
good	0	O
maintenance	0	O
of	0	O
the	0	O
cellular	0	O
viability	0	O
and	0	O
of	0	O
the	0	O
CCCD	0	O
heterogeneity	0	O
in	0	O
respect	0	O
to	0	O
fresh	0	O
cells	0	O
.	0	O


Antibodies	0	O
specific	0	O
to	0	O
rE12	0	B
and	0	O
rNFIL	0	B
-	0	I
6	0	I
disrupt	0	O
nucleoprotein	0	O
complexes	0	O
with	0	O
these	0	O
DNA	1	O
-	0	O
binding	0	O
sites	0	O
,	0	O
confirming	0	O
the	0	O
interaction	0	O
of	0	O
native	0	O
in	0	O
vivo	0	O
factors	0	O
.	0	O


Deep	1	O
tans	0	O
were	0	O
induced	0	O
over	0	O
the	0	O
backs	0	O
of	0	O
volunteers	0	O
with	0	O
repeated	0	O
exposure	0	O
to	0	O
longwave	0	O
ultraviolet	0	O
radiation	0	O
(	0	O
UV	1	O
-	0	O
A	1	O
).	0	O


The	0	O
presence	0	O
of	0	O
the	0	O
RV	1	O
5	0	O
'(+)	0	O
SL	1	O
sequence	0	O
had	0	O
the	0	O
primary	0	O
enhancing	0	O
effect	0	O
on	0	O
translation	0	O
.	0	O


The	0	O
DNA	1	O
helix	0	O
at	0	O
the	0	O
tandemly	0	O
repeated	0	O
,	0	O
13mer	0	O
sequence	0	O
is	0	O
thermodynamically	0	O
unstable	0	O
,	0	O
as	0	O
evidenced	0	O
by	0	O
hypersensitivity	0	O
to	0	O
single	0	B
-	0	I
strand	0	I
-	0	I
specific	0	I
nuclease	0	I
in	0	O
a	0	O
negatively	0	O
supercoiled	0	O
plasmid	0	O
,	0	O
and	0	O
demonstrated	0	O
by	0	O
stable	0	O
DNA	1	O
unwinding	0	O
seen	0	O
after	0	O
two	0	O
-	0	O
dimensional	0	O
gel	0	O
electrophoresis	0	O
of	0	O
topoisomers	0	O
.	0	O


Northern	0	O
blotting	0	O
analysis	0	O
indicates	0	O
that	0	O
expression	0	O
of	0	O
the	0	O
genes	0	O
corresponding	0	O
to	0	O
these	0	O
clones	0	O
is	0	O
confined	0	O
to	0	O
pollen	0	O
tissue	0	O
.	0	O


Vitiligo	1	O
in	0	O
diabetes	0	O
mellitus	0	O
.	0	O


Both	0	O
P5CDh	0	B
cDNA	1	I
clones	0	O
detect	0	O
a	0	O
single	0	O
3	0	O
.	0	O
2	0	O
-	0	O
kb	0	O
transcript	0	O
on	0	O
Northern	0	O
blots	0	O
of	0	O
multiple	0	O
human	0	O
tissues	0	O
,	0	O
indicating	0	O
the	0	O
long	0	O
cDNA	1	O
containing	0	O
the	0	O
3	0	O
'-	0	O
untranslated	0	O
intron	0	O
represents	0	O
the	0	O
predominant	0	O
transcript	0	O
.	0	O


Substantial	0	O
amounts	0	O
of	0	O
liposomal	0	O
ampicillin	0	O
were	0	O
recovered	0	O
from	0	O
isolated	0	O
Kupffer	0	O
cells	0	O
,	0	O
the	0	O
target	0	O
cells	0	O
of	0	O
L	1	O
.	0	O
monocytogenes	0	O
after	0	O
intravenous	0	O
inoculation	0	O
.	0	O


Mutagenesis	1	O
of	0	O
each	0	O
NRF	0	B
-	0	I
1	0	I
motif	0	I
in	0	O
the	0	O
ALAS	1	B
promoter	0	I
gave	0	O
substantially	0	O
lowered	0	O
levels	0	O
of	0	O
chloramphenicol	0	B
acetyltransferase	0	I
expression	0	O
,	0	O
whereas	0	O
mutagenesis	0	O
of	0	O
both	0	O
NRF	0	B
-	0	I
1	0	I
motifs	0	I
resulted	0	O
in	0	O
the	0	O
almost	0	O
complete	0	O
loss	0	O
of	0	O
expression	0	O
.	0	O


To	1	O
analyze	0	O
the	0	O
VH	1	O
regions	0	O
of	0	O
polyreactive	0	O
antibodies	0	O
,	0	O
with	0	O
particular	0	O
attention	0	O
at	0	O
their	0	O
somatically	0	O
mutated	0	O
status	0	O
,	0	O
we	0	O
generated	0	O
five	0	O
IgG	1	B
(	0	O
three	0	O
IgG1	0	B
and	0	O
two	0	O
IgG3	0	B
)	0	O
mAb	0	O
(	0	O
using	0	O
B	1	O
cells	0	O
from	0	O
a	0	O
healthy	0	O
subject	0	O
,	0	O
a	0	O
patient	0	O
with	0	O
insulin	0	B
-	0	O
dependent	0	O
diabetes	0	O
mellitus	0	O
and	0	O
a	0	O
patient	0	O
with	0	O
SLE	1	O
),	0	O
which	0	O
bound	0	O
with	0	O
various	0	O
efficiencies	0	O
a	0	O
number	0	O
of	0	O
different	0	O
self	0	O
and	0	O
foreign	0	O
Ag	1	O
.	0	O


12	0	O
-	0	O
O	1	O
-	0	O
Tetradecanoylphorbol	0	O
13	0	O
-	0	O
acetate	0	O
was	0	O
found	0	O
to	0	O
inhibit	0	O
rapidly	0	O
and	0	O
potently	0	O
the	0	O
expression	0	O
of	0	O
mRNAs	0	O
coding	0	O
for	0	O
the	0	O
myogenic	0	O
regulators	0	O
CMD1	0	B
and	0	O
myogenin	0	B
.	0	O


Our	0	O
data	0	O
suggest	0	O
that	0	O
it	0	O
may	0	O
be	0	O
possible	0	O
to	0	O
individualize	0	O
hCG	1	B
administration	0	O
at	0	O
midcycle	0	O
by	0	O
determining	0	O
the	0	O
number	0	O
of	0	O
follicles	0	O
greater	0	O
than	0	O
1	0	O
cm	0	O
by	0	O
ultrasound	0	O
on	0	O
cycle	0	O
day	0	O
12	0	O
or	0	O
13	0	O
and	0	O
giving	0	O
hCG	1	B
when	0	O
serum	0	O
E2	1	O
levels	0	O
reach	0	O
1100	0	O
to	0	O
1200	0	O
pmol	0	O
/	0	O
l	0	O
per	0	O
follicle	0	O
.	0	O


Radiotherapy	1	O
and	0	O
early	0	O
orchiectomy	0	O
in	0	O
stage	0	O
D1	1	O
prostatic	0	O
carcinoma	0	O


The	0	O
decrease	0	O
in	0	O
HDL	1	B
-	0	I
cholesterol	0	I
with	0	O
increasing	0	O
VLDL	1	B
-	0	I
triglycerides	0	I
was	0	O
relatively	0	O
much	0	O
larger	0	O
than	0	O
the	0	O
concomitant	0	O
decrease	0	O
in	0	O
apo	0	B
A	1	I
-	0	I
I	1	I
.	0	O


Possibility	0	O
of	0	O
a	0	O
TSH	1	B
-	0	O
Screening	1	O
method	0	O
for	0	O
detection	0	O
of	0	O
hypothyroidism	0	O
in	0	O
the	0	O
newborn	0	O


We	0	O
report	0	O
the	0	O
molecular	0	O
cloning	0	O
and	0	O
functional	0	O
characterization	0	O
of	0	O
USF2	0	B
isoforms	0	I
,	0	O
corresponding	0	O
to	0	O
a	0	O
44	0	O
-	0	O
kDa	1	O
subunit	0	O
,	0	O
USF2a	0	B
,	0	O
and	0	O
a	0	O
new	0	O
38	0	O
-	0	O
kDa	1	O
subunit	0	O
,	0	O
USF2b	0	B
,	0	O
generated	0	O
by	0	O
differential	0	O
splicing	0	O
.	0	O


By	0	O
order	0	O
of	0	O
decreasing	0	O
rate	0	O
,	0	O
finger	0	O
flexors	0	O
,	0	O
jaw	0	O
,	0	O
crossed	0	O
adductors	0	O
,	0	O
and	0	O
triceps	0	O
reflexes	0	O
were	0	O
less	0	O
frequently	0	O
elicited	0	O
in	0	O
both	0	O
groups	0	O
.	0	O


In	1	O
a	0	O
control	0	O
group	0	O
both	0	O
common	0	O
carotid	0	O
arteries	0	O
(	0	O
CCA	1	O
)	0	O
were	0	O
ligated	0	O
.	0	O


Plethysmographic	0	O
technique	0	O
and	0	O
indirect	0	O
blood	0	O
pressure	0	O
recordings	0	O
were	0	O
used	0	O
.	0	O


The	0	O
ZNF274	0	B
gene	0	I
is	0	O
mapped	0	O
distal	0	O
to	0	O
marker	0	O
RP	1	O
S28	0	O
1	0	O
in	0	O
the	0	O
human	0	O
chromosome	0	O
19qter	0	O
region	0	O
,	0	O
by	0	O
RH	1	O
mapping	0	O
.	0	O


A	1	O
medical	0	O
-	0	O
geographical	0	O
review	0	O


At	1	O
both	0	O
water	0	O
temperatures	0	O
,	0	O
VO2	1	O
increased	0	O
linearly	0	O
with	0	O
increasing	0	O
swimming	0	O
velocity	0	O
.	0	O


These	0	O
early	0	O
structural	0	O
processes	0	O
are	0	O
assumed	0	O
to	0	O
be	0	O
subserved	0	O
by	0	O
the	0	O
anterior	0	O
parts	0	O
of	0	O
the	0	O
left	0	O
hemisphere	0	O
,	0	O
as	0	O
event	0	O
-	0	O
related	0	O
brain	0	O
potentials	0	O
show	0	O
this	0	O
area	0	O
to	0	O
be	0	O
maximally	0	O
activated	0	O
when	0	O
phrase	0	O
structure	0	O
violations	0	O
are	0	O
processed	0	O
and	0	O
as	0	O
circumscribed	0	O
lesions	0	O
in	0	O
this	0	O
area	0	O
lead	0	O
to	0	O
an	0	O
impairment	0	O
of	0	O
the	0	O
on	0	O
-	0	O
line	0	O
structural	0	O
assignment	0	O
.	0	O


Scalp	1	O
flaps	0	O
can	0	O
be	0	O
expanded	0	O
just	0	O
to	0	O
the	0	O
point	0	O
of	0	O
becoming	0	O
noticeable	0	O
over	0	O
4	0	O
to	0	O
6	0	O
weeks	0	O
followed	0	O
by	0	O
scalp	0	O
flap	0	O
transposition	0	O
and	0	O
easy	0	O
closure	0	O
of	0	O
the	0	O
donor	0	O
site	0	O
.	0	O


Contributions	0	O
from	0	O
pairs	0	O
of	0	O
source	0	O
and	0	O
target	0	O
volume	0	O
elements	0	O
are	0	O
summed	0	O
for	0	O
the	0	O
S	1	O
values	0	O
between	0	O
the	0	O
tumor	0	O
and	0	O
itself	0	O
,	0	O
between	0	O
the	0	O
remaining	0	O
healthy	0	O
host	0	O
organ	0	O
and	0	O
itself	0	O
,	0	O
and	0	O
between	0	O
the	0	O
tumor	0	O
and	0	O
the	0	O
remaining	0	O
healthy	0	O
host	0	O
organ	0	O
,	0	O
with	0	O
the	0	O
reciprocity	0	O
theorem	0	O
assumed	0	O
for	0	O
the	0	O
last	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
S1	1	B
nuclease	0	I
protection	0	O
analysis	0	O
of	0	O
RNA	1	O
preparations	0	O
from	0	O
several	0	O
mouse	0	O
tissues	0	O
,	0	O
both	0	O
dhfr	0	B
and	0	O
divergent	0	O
genes	0	O
showed	0	O
similar	0	O
levels	0	O
of	0	O
expression	0	O
but	0	O
did	0	O
show	0	O
some	0	O
specificity	0	O
in	0	O
start	0	O
site	0	O
utilization	0	O
.	0	O


In	1	O
this	0	O
animal	0	O
,	0	O
infected	0	O
with	0	O
what	0	O
was	0	O
judged	0	O
previously	0	O
to	0	O
be	0	O
the	0	O
less	0	O
virulent	0	O
of	0	O
the	0	O
two	0	O
T	1	O
.	0	O
cruzi	0	O
stocks	0	O
used	0	O
('	0	O
strain	0	O
7	0	O
'),	0	O
there	0	O
was	0	O
severe	0	O
myocarditis	0	O
,	0	O
with	0	O
myofibre	0	O
degeneration	0	O
,	0	O
and	0	O
lesions	0	O
of	0	O
the	0	O
oesophagus	0	O
.	0	O


Antivitamin	1	O
K	1	O
agents	0	O


Testing	1	O
blood	0	O
donors	0	O
for	0	O
non	0	O
-	0	O
A	1	O
,	0	O
non	0	O
-	0	O
B	1	O
hepatitis	0	O
:	0	O
irrational	0	O
,	0	O
perhaps	0	O
,	0	O
but	0	O
inescapable	0	O
.	0	O


BACKGROUND	0	O
:	0	O
The	0	O
MAZE	1	O
-	0	O
III	0	O
is	0	O
the	0	O
surgical	0	O
treatment	0	O
of	0	O
choice	0	O
for	0	O
medically	0	O
refractory	0	O
atrial	0	O
fibrillation	0	O
.	0	O


nos	0	B
-	0	I
1	0	I
and	0	O
nos	0	B
-	0	I
2	0	I
,	0	O
two	0	O
genes	0	O
related	0	O
to	0	O
Drosophila	1	B
nanos	0	I
,	0	O
regulate	0	O
primordial	0	O
germ	0	O
cell	0	O
development	0	O
and	0	O
survival	0	O
in	0	O
Caenorhabditis	0	O
elegans	0	O
.	0	O


On	1	O
an	0	O
antithrombin	0	B
unit	0	O
basis	0	O
,	0	O
CY	1	O
216	0	O
and	0	O
CY	1	O
222	0	O
were	0	O
equivalent	0	O
and	0	O
more	0	O
potent	0	O
than	0	O
UH	0	O
.	0	O


Although	0	O
the	0	O
consumption	0	O
of	0	O
myoglobin	0	B
-	0	O
bound	0	O
O2	1	O
(	0	O
MbO2	0	O
)	0	O
stores	0	O
in	0	O
seal	0	O
muscles	0	O
has	0	O
been	0	O
demonstrated	0	O
in	0	O
seal	0	O
muscles	0	O
during	0	O
laboratory	0	O
simulations	0	O
of	0	O
diving	0	O
,	0	O
this	0	O
may	0	O
not	0	O
be	0	O
a	0	O
feature	0	O
of	0	O
normal	0	O
field	0	O
diving	0	O
in	0	O
which	0	O
measurements	0	O
of	0	O
heart	0	O
rate	0	O
and	0	O
lactate	0	O
production	0	O
show	0	O
marked	0	O
differences	0	O
from	0	O
the	0	O
profound	0	O
diving	0	O
response	0	O
induced	0	O
by	0	O
forced	0	O
immersion	0	O
.	0	O


The	0	O
translation	0	O
products	0	O
of	0	O
both	0	O
clones	0	O
are	0	O
highly	0	O
homologous	0	O
to	0	O
APS1	0	B
(	0	O
66	0	O
and	0	O
86	0	O
%	0	O
identity	0	O
,	0	O
respectively	0	O
)	0	O
over	0	O
their	0	O
entire	0	O
lengths	0	O
,	0	O
including	0	O
amino	0	O
terminal	0	O
sequences	0	O
resembling	0	O
transit	0	O
peptides	0	O
for	0	O
plastid	0	O
localization	0	O
.	0	O


Monitoring	0	O
patients	0	O
with	0	O
acute	0	O
leukemia	0	O
for	0	O
IL	1	B
-	0	I
1	0	I
and	0	O
TNF	1	B
levels	0	O
throughout	0	O
the	0	O
clinical	0	O
course	0	O
of	0	O
disease	0	O
may	0	O
help	0	O
clarify	0	O
the	0	O
causes	0	O
of	0	O
febrile	0	O
episodes	0	O
.	0	O


Additionally	0	O
,	0	O
although	0	O
c	0	B
-	0	I
fos	0	I
and	0	O
egr	0	B
-	0	I
1	0	I
mRNAs	0	I
are	0	O
expressed	0	O
at	0	O
elevated	0	O
levels	0	O
in	0	O
stimulated	0	O
liver	0	O
cells	0	O
,	0	O
fos	0	B
-	0	I
B	1	I
,	0	O
fra	0	B
-	0	I
1	0	I
,	0	O
and	0	O
egr	0	B
-	0	I
2	0	I
are	0	O
not	0	O
,	0	O
which	0	O
suggests	0	O
that	0	O
factors	0	O
in	0	O
addition	0	O
to	0	O
the	0	O
serum	0	B
response	0	I
factor	0	I
participate	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
immediate	0	B
-	0	I
early	0	I
gene	0	I
induction	0	O
.	0	O


Implications	0	O
of	0	O
this	0	O
observation	0	O
for	0	O
pediatrics	0	O
are	0	O
discussed	0	O
.	0	O


This	0	O
mutant	0	O
was	0	O
identified	0	O
by	0	O
screening	0	O
with	0	O
a	0	O
TGF	1	B
-	0	I
beta	0	I
-	0	O
inducible	0	O
vector	0	O
a	0	O
series	0	O
of	0	O
mink	0	O
lung	0	O
epithelial	0	O
cell	0	O
clones	0	O
that	0	O
have	0	O
normal	0	O
TGF	1	B
-	0	I
beta	0	I
binding	0	O
activity	0	O
but	0	O
have	0	O
lost	0	O
antiproliferative	0	O
and	0	O
transcriptional	0	O
responses	0	O
to	0	O
TGF	1	B
-	0	I
beta	0	I
.	0	O


Characterization	0	O
of	0	O
these	0	O
R	1	O
subunits	0	O
by	0	O
their	0	O
8	0	O
-	0	O
azido	0	O
-	0	O
cAMP	1	O
photoaffinity	0	O
labeling	0	O
and	0	O
immunoreactivity	0	O
,	0	O
as	0	O
well	0	O
as	0	O
by	0	O
a	0	O
phosphorylation	0	O
-	0	O
dependent	0	O
mobility	0	O
shift	0	O
on	0	O
sodium	0	O
dodecyl	0	O
sulfate	0	O
-	0	O
polyacrylamide	0	O
gel	0	O
electrophoresis	0	O
(	0	O
SDS	1	O
-	0	O
PAGE	1	O
),	0	O
indicated	0	O
subunit	0	O
sizes	0	O
of	0	O
RII	0	B
beta	0	I
(	0	O
53	0	O
kDa	1	O
)	0	O
greater	0	O
than	0	O
RII	0	B
alpha	0	I
dephosphoform	0	O
(	0	O
51	0	O
kDa	1	O
)	0	O
greater	0	O
than	0	O
RI	1	B
alpha	0	I
(	0	O
49	0	O
kDa	1	O
).	0	O


The	0	O
levels	0	O
of	0	O
fibrinogen	0	B
as	0	O
well	0	O
as	0	O
antithrombin	0	B
III	0	I
(	0	O
ATIII	0	B
)	0	O
and	0	O
heparin	0	B
cofactor	0	I
II	0	I
(	0	O
HCII	0	B
)	0	O
activities	0	O
were	0	O
steadily	0	O
increased	0	O
in	0	O
loop	0	O
-	0	O
bearing	0	O
animals	0	O
.	0	O


But	0	O
,	0	O
as	0	O
Theriault	0	O
explains	0	O
,	0	O
improvements	0	O
in	0	O
assessing	0	O
exposure	0	O
have	0	O
not	0	O
yet	0	O
translated	0	O
into	0	O
clear	0	O
and	0	O
consistent	0	O
findings	0	O
.	0	O


Thus	0	O
,	0	O
transcriptional	0	O
regulation	0	O
,	0	O
splicing	0	O
,	0	O
kinase	0	O
interaction	0	O
sites	0	O
,	0	O
and	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
the	0	O
LMP2A	0	B
homologs	0	I
have	0	O
been	0	O
conserved	0	O
despite	0	O
significant	0	O
sequences	0	O
heterogeneity	0	O
in	0	O
the	0	O
preterminal	0	O
repeat	0	O
regions	0	O
of	0	O
these	0	O
human	0	O
and	0	O
nonhuman	0	O
primate	0	O
EBVs	0	O
.	0	O


Paracrine	1	O
activation	0	O
of	0	O
the	0	O
HIV	1	B
-	0	I
1	0	I
LTR	1	I
promoter	0	I
by	0	O
the	0	O
viral	0	B
Tat	1	I
protein	0	I
is	0	O
mechanistically	0	O
similar	0	O
to	0	O
trans	0	O
-	0	O
activation	0	O
within	0	O
a	0	O
cell	0	O
.	0	O


The	0	O
ns2	0	B
gene	0	I
comprises	0	O
an	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
ORF	1	O
)	0	O
encoding	0	O
a	0	O
putative	0	O
nonstructural	0	O
(	0	O
ns	0	O
)	0	O
protein	0	O
of	0	O
279	0	O
amino	0	O
acids	0	O
with	0	O
a	0	O
predicted	0	O
molecular	0	O
mass	0	O
of	0	O
32	0	O
-	0	O
kDa	1	O
.	0	O


The	0	O
gene	0	O
encoding	0	O
the	0	O
105	0	B
-	0	I
kDa	1	I
protein	0	I
(	0	I
p105	0	I
)	0	I
precursor	0	I
of	0	O
the	0	O
p50	0	B
subunit	0	I
of	0	O
transcription	0	O
factor	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
also	0	O
encodes	0	O
a	0	O
p70	0	B
I	1	I
kappa	0	I
B	1	I
protein	0	I
,	0	O
I	1	B
kappa	0	I
B	1	I
gamma	0	I
,	0	O
which	0	O
is	0	O
identical	0	O
to	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
607	0	O
amino	0	O
acids	0	O
of	0	O
p105	0	B
.	0	O


Six	0	O
tandem	0	O
repeats	0	O
of	0	O
the	0	O
P	1	B
element	0	I
linked	0	O
to	0	O
the	0	O
SV40	1	B
promoter	0	I
responded	0	O
to	0	O
phorbol	0	O
12	0	O
-	0	O
myristate	0	O
13	0	O
-	0	O
acetate	0	O
,	0	O
while	0	O
that	0	O
of	0	O
other	0	O
elements	0	O
did	0	O
not	0	O
.	0	O


We	0	O
report	0	O
the	0	O
isolation	0	O
of	0	O
genomic	0	O
and	0	O
cDNA	1	O
clones	0	O
of	0	O
the	0	O
light	0	O
-	0	O
independent	0	O
Sn	1	B
:	0	I
bol3	0	I
allele	0	I
.	0	O


The	0	O
mean	0	O
plasma	0	O
sodium	0	O
concentration	0	O
which	0	O
was	0	O
135	0	O
.	0	O
95	0	O
(+/-	0	O
SD	1	O
4	0	O
.	0	O
14	0	O
)	0	O
mEq	1	O
/	0	O
kg	0	O
before	0	O
diuretic	0	O
treatment	0	O
was	0	O
significantly	0	O
decreased	0	O
during	0	O
treatment	0	O
to	0	O
129	0	O
.	0	O
19	0	O
(+/-	0	O
SD	1	O
2	0	O
.	0	O
77	0	O
)	0	O
mEq	1	O
/	0	O
kg	0	O
,	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
.	0	O


This	0	O
result	0	O
supports	0	O
the	0	O
argument	0	O
that	0	O
the	0	O
beta	0	O
'	0	O
subunit	0	O
plays	0	O
an	0	O
essential	0	O
role	0	O
in	0	O
determining	0	O
the	0	O
progress	0	O
of	0	O
transcription	0	O
elongation	0	O
.	0	O


The	0	O
program	0	O
has	0	O
been	0	O
written	0	O
in	0	O
a	0	O
generic	0	O
BASIC	1	O
in	0	O
order	0	O
to	0	O
make	0	O
the	0	O
procedure	0	O
user	0	O
-	0	O
friendly	0	O
.	0	O


Molecular	1	O
cloning	0	O
of	0	O
Elk	0	B
-	0	I
3	0	I
,	0	O
a	0	O
new	0	O
member	0	O
of	0	O
the	0	O
Ets	1	B
family	0	I
expressed	0	O
during	0	O
mouse	0	O
embryogenesis	0	O
and	0	O
analysis	0	O
of	0	O
its	0	O
transcriptional	0	O
repression	0	O
activity	0	O
.	0	O


The	0	O
xylose	0	B
isomerase	0	I
-	0	I
encoding	0	I
gene	0	I
(	0	O
xylA	0	B
)	0	O
of	0	O
Clostridium	1	O
thermosaccharolyticum	0	O
:	0	O
cloning	0	O
,	0	O
sequencing	0	O
and	0	O
phylogeny	0	O
of	0	O
XylA	0	B
enzymes	0	I
.	0	O


It	1	O
has	0	O
been	0	O
proposed	0	O
that	0	O
the	0	O
parCBA	0	B
operon	0	I
encodes	0	O
a	0	O
plasmid	0	O
partitioning	0	O
system	0	O
(	0	O
M	1	O
.	0	O


Such	0	O
an	0	O
interaction	0	O
could	0	O
be	0	O
detected	0	O
using	0	O
a	0	O
GST	0	B
-	0	O
POU	0	B
fusion	0	O
protein	0	O
bound	0	O
to	0	O
glutathione	0	O
-	0	O
agarose	0	O
beads	0	O
.	0	O


In	1	O
a	0	O
previous	0	O
study	0	O
(	0	O
Brandl	0	O
,	0	O
C	1	O
.	0	O


In	1	O
contrast	0	O
,	0	O
transiently	0	O
transfected	0	O
cells	0	O
expressing	0	O
EBNA	0	B
-	0	I
3	0	I
revealed	0	O
a	0	O
sixfold	0	O
increase	0	O
in	0	O
EBNA	0	B
-	0	I
3	0	I
protein	0	I
expression	0	O
from	0	O
the	0	O
genomic	0	O
EBNA	0	B
-	0	I
3	0	I
gene	0	I
compared	0	O
to	0	O
EBNA	0	B
-	0	I
3	0	I
cDNA	1	I
.	0	O


The	0	O
effect	0	O
of	0	O
the	0	O
thromboxane	0	B
A2	1	I
(	0	I
TXA2	1	I
)/	0	I
prostaglandin	0	I
endoperoxide	0	I
receptor	0	I
antagonist	0	O
,	0	O
SQ	1	O
29	0	O
,	0	O
548	0	O
on	0	O
pacing	0	O
-	0	O
induced	0	O
ischemia	0	O
was	0	O
determined	0	O
in	0	O
anesthetized	0	O
open	0	O
-	0	O
chest	0	O
dogs	0	O
.	0	O


Comparison	0	O
of	0	O
the	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
M	1	B
RNA	1	I
product	0	I
of	0	I
Uukuniemi	0	I
virus	0	I
with	0	O
that	0	O
of	0	O
Punta	0	O
Toro	0	O
and	0	O
Rift	0	O
Valley	0	O
fever	0	O
viruses	0	O
showed	0	O
in	0	O
both	0	O
cases	0	O
a	0	O
weak	0	O
homology	0	O
that	0	O
was	0	O
more	0	O
pronounced	0	O
for	0	O
the	0	O
proteins	0	O
located	0	O
at	0	O
the	0	O
COOH	0	O
-	0	O
terminal	0	O
end	0	O
of	0	O
the	0	O
precursor	0	O
.	0	O


The	0	O
beta	0	O
subunit	0	O
of	0	O
the	0	O
Fc	1	B
epsilon	0	I
R1	0	I
is	0	O
a	0	O
33	0	O
-	0	O
kDa	1	O
tyrosine	0	O
phosphoprotein	0	O
,	0	O
but	0	O
the	0	O
p33	0	B
Grb2	0	I
-	0	I
binding	0	I
protein	0	I
described	0	O
in	0	O
the	0	O
present	0	O
report	0	O
is	0	O
not	0	O
the	0	O
Fc	1	B
epsilon	0	I
R1	0	I
beta	0	I
chain	0	I
and	0	O
its	0	O
identity	0	O
is	0	O
unknown	0	O
.	0	O


Antibodies	0	O
affinity	0	O
-	0	O
purified	0	O
using	0	O
the	0	O
bacterially	0	O
expressed	0	O
recombinant	0	O
protein	0	O
recognized	0	O
the	0	O
56K	0	B
autoantigen	0	I
in	0	O
a	0	O
HeLa	0	O
cell	0	O
extract	0	O
.	0	O
cDNA	1	O
sequencing	0	O
revealed	0	O
that	0	O
the	0	O
56K	0	B
cDNA	1	I
shares	0	O
a	0	O
high	0	O
degree	0	O
of	0	O
homology	0	O
in	0	O
both	0	O
nucleotide	0	O
(	0	O
87	0	O
%)	0	O
and	0	O
amino	0	O
acid	0	O
sequence	0	O
(	0	O
92	0	O
.	0	O
5	0	O
%)	0	O
with	0	O
bovine	0	B
annexin	0	I
XI	1	I
,	0	O
indicating	0	O
that	0	O
the	0	O
56K	0	B
cDNA	1	I
encodes	0	O
the	0	O
human	0	B
homologue	0	I
of	0	I
annexin	0	I
XI	1	I
,	0	O
a	0	O
member	0	O
of	0	O
the	0	O
Ca	1	B
(	0	I
2	0	I
+)-	0	I
dependent	0	I
phospholipid	0	I
binding	0	I
protein	0	I
family	0	I
.	0	O


Specific	1	O
requirements	0	O
for	0	O
branched	0	O
-	0	O
chain	0	O
amino	0	O
acids	0	O
,	0	O
glutamine	0	O
,	0	O
and	0	O
arginine	0	O
are	0	O
evaluated	0	O
.	0	O


The	0	O
author	0	O
provides	0	O
a	0	O
rationale	0	O
for	0	O
an	0	O
interactional	0	O
view	0	O
and	0	O
presents	0	O
a	0	O
case	0	O
in	0	O
which	0	O
post	0	O
-	0	O
surgical	0	O
hiccups	0	O
were	0	O
successfully	0	O
treated	0	O
,	0	O
using	0	O
principles	0	O
developed	0	O
by	0	O
the	0	O
Mental	1	O
Research	1	O
Institute	0	O
.	0	O


However	0	O
,	0	O
reoperation	0	O
for	0	O
bulky	0	O
cervical	0	O
disease	0	O
(	0	O
group	0	O
3	0	O
)	0	O
rarely	0	O
results	0	O
in	0	O
normal	0	O
calcitonin	0	B
levels	0	O
and	0	O
is	0	O
associated	0	O
with	0	O
a	0	O
high	0	O
incidence	0	O
of	0	O
permanent	0	O
hypoparathyroidism	0	O
.	0	O


A	1	O
.	0	O


Using	0	O
purified	0	O
recombinant	0	B
HMG	1	I
I	1	I
,	0	O
we	0	O
have	0	O
identified	0	O
several	0	O
high	0	O
-	0	O
affinity	0	O
binding	0	O
sites	0	O
which	0	O
overlap	0	O
important	0	O
transcription	0	O
factor	0	O
binding	0	O
sites	0	O
.	0	O


The	0	O
molecular	0	O
weight	0	O
of	0	O
in	0	O
vivo	0	O
-	0	O
labeled	0	O
proteins	0	O
was	0	O
increased	0	O
relative	0	O
to	0	O
that	0	O
of	0	O
in	0	O
vitro	0	O
-	0	O
translated	0	O
proteins	0	O
,	0	O
indicating	0	O
that	0	O
a	0	O
posttranslational	0	O
modification	0	O
had	0	O
occurred	0	O
.	0	O


The	0	O
amino	0	O
acid	0	O
sequences	0	O
of	0	O
the	0	O
known	0	O
largest	0	O
subunits	0	O
of	0	O
DdRPs	0	B
from	0	O
different	0	O
species	0	O
contain	0	O
highly	0	O
conserved	0	O
regions	0	O
.	0	O


Vertebrate	1	B
synapsins	0	I
constitute	0	O
a	0	O
family	0	O
of	0	O
synaptic	0	O
proteins	0	O
that	0	O
participate	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
neurotransmitter	0	O
release	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
mitochondrial	0	O
presequences	0	O
interact	0	O
with	0	O
the	0	O
mt	0	B
-	0	I
hsp70	0	I
during	0	O
or	0	O
after	0	O
mitochondrial	0	O
protein	0	O
import	0	O
.	0	O


The	0	O
conservation	0	O
of	0	O
both	0	O
the	0	O
G	1	O
-	0	O
box	0	O
and	0	O
H	1	O
-	0	O
box	0	O
in	0	O
different	0	O
CHS	1	B
promoters	0	I
emphasizes	0	O
their	0	O
importance	0	O
as	0	O
regulatory	0	O
motifs	0	O
.	0	O


ME1a1	0	B
,	0	O
a	0	O
16	0	O
-	0	O
base	0	O
-	0	O
pair	0	O
nuclear	0	O
factor	0	O
binding	0	O
site	0	O
residing	0	O
between	0	O
the	0	O
c	0	B
-	0	I
MYC	0	I
P1	1	I
and	0	I
P2	1	I
transcription	0	I
initiation	0	I
sites	0	I
,	0	O
is	0	O
required	0	O
for	0	O
P2	1	O
activity	0	O
.	0	O


Higher	0	O
fasting	0	O
serum	0	O
gastrin	0	B
concentration	0	O
(	0	O
102	0	O
.	0	O
0	0	O
+/-	0	O
21	0	O
.	0	O
1	0	O
vs	0	O
63	0	O
.	0	O
3	0	O
+/-	0	O
8	0	O
.	0	O
3	0	O
ng	0	O
.	0	O
l	0	O
-	0	O
1	0	O
),	0	O
and	0	O
greater	0	O
postprandial	0	O
gastrin	0	B
release	0	O
(	0	O
AUC0	0	O
-	0	O
120	0	O
:	0	O
16690	0	O
+/-	0	O
2648	0	O
vs	0	O
10654	0	O
+/-	0	O
1283	0	O
ng	0	O
.	0	O
l	0	O
-	0	O
1	0	O
min	0	O
)	0	O
were	0	O
observed	0	O
after	0	O
VTP	0	O
-	0	O
HM	1	O
than	0	O
after	0	O
VTP	0	O
-	0	O
Cas	1	O
.	0	O


A	1	O
needs	0	O
assessment	0	O
of	0	O
these	0	O
families	0	O
was	0	O
also	0	O
done	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
In	1	O
essential	0	O
hypertension	0	O
an	0	O
acute	0	O
protein	0	O
load	0	O
induces	0	O
a	0	O
decrease	0	O
in	0	O
GFR	1	O
that	0	O
may	0	O
normalize	0	O
under	0	O
antihypertensive	0	O
treatment	0	O
.	0	O


The	0	O
bioavailability	0	O
of	0	O
etodolac	0	O
from	0	O
capsules	0	O
exposed	0	O
to	0	O
stressed	0	O
conditions	0	O
was	0	O
compared	0	O
in	0	O
both	0	O
dogs	0	O
and	0	O
humans	0	O
to	0	O
capsules	0	O
stored	0	O
at	0	O
RT	1	O
conditions	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
osmotic	0	O
flow	0	O
on	0	O
the	0	O
distribution	0	O
of	0	O
horseradish	0	B
peroxidase	0	I
within	0	O
the	0	O
intercellular	0	O
spaces	0	O
of	0	O
toad	0	O
bladder	0	O
epithelium	0	O
.	0	O


A	1	O
synergistic	0	O
effect	0	O
on	0	O
HCK	0	B
promoter	0	I
activity	0	O
was	0	O
observed	0	O
at	0	O
high	0	O
concentrations	0	O
of	0	O
Sp1	0	B
.	0	O


Several	0	O
demographic	0	O
indices	0	O
of	0	O
isolated	0	O
populations	0	O
in	0	O
Uzbekistan	0	O


TBP	1	B
can	0	O
be	0	O
phosphorylated	0	O
in	0	O
vitro	0	O
by	0	O
extracts	0	O
of	0	O
U937	0	O
cells	0	O
or	0	O
by	0	O
bacterially	0	O
expressed	0	O
activated	0	O
ERK2	0	B
;	0	O
the	0	O
phosphorylation	0	O
sites	0	O
were	0	O
mapped	0	O
to	0	O
ERK	0	B
kinase	0	I
consensus	0	I
sites	0	I
in	0	O
the	0	O
TBP	1	B
amino	0	I
-	0	I
terminal	0	I
domain	0	I
.	0	O


Intravenous	1	O
versus	0	O
oral	0	O
administration	0	O
of	0	O
amitriptyline	0	O
in	0	O
patients	0	O
with	0	O
major	0	O
depression	0	O
.	0	O


Physiol	0	O
.	0	O


EGFR	1	B
levels	0	O
were	0	O
found	0	O
to	0	O
be	0	O
elevated	0	O
5	0	O
-,	0	O
3	0	O
.	0	O


Studying	0	O
intracellular	0	O
signaling	0	O
pathways	0	O
,	0	O
which	0	O
may	0	O
be	0	O
involved	0	O
in	0	O
malignant	0	O
transformation	0	O
of	0	O
Ret	0	B
-	0	I
9bp	0	I
expressing	0	O
NIH3T3	0	O
cells	0	O
,	0	O
we	0	O
could	0	O
demonstrate	0	O
Ret	0	B
-	0	I
9bp	0	I
dependent	0	O
phosphorylation	0	O
of	0	O
insulin	0	B
receptor	0	I
substrate	0	I
-	0	I
2	0	I
(	0	O
IRS	0	B
-	0	I
2	0	I
)	0	O
with	0	O
consecutive	0	O
activation	0	O
of	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
(	0	O
PI	1	B
3	0	I
-	0	I
kinase	0	I
)	0	O
and	0	O
protein	0	B
kinase	0	I
B	1	I
(	0	O
PKB	0	B
/	0	O
AKT	0	B
).	0	O


A	1	O
genomic	0	O
clone	0	O
for	0	O
the	0	O
cyc07	0	B
gene	0	I
,	0	O
which	0	O
is	0	O
expressed	0	O
specifically	0	O
at	0	O
the	0	O
S	1	O
phase	0	O
during	0	O
the	0	O
cell	0	O
cycle	0	O
in	0	O
synchronous	0	O
cultures	0	O
of	0	O
periwinkle	0	O
(	0	O
Catharanthus	0	O
roseus	0	O
)	0	O
cells	0	O
,	0	O
was	0	O
isolated	0	O
.	0	O


These	0	O
results	0	O
continue	0	O
to	0	O
support	0	O
the	0	O
hypothesis	0	O
that	0	O
HS2	0	O
,	0	O
HS3	0	O
,	0	O
and	0	O
HS4	0	O
act	0	O
as	0	O
a	0	O
single	0	O
,	0	O
integral	0	O
unit	0	O
to	0	O
regulate	0	O
human	0	B
globin	0	I
gene	0	I
transcription	0	O
as	0	O
a	0	O
holocomplex	0	O
,	0	O
but	0	O
they	0	O
can	0	O
also	0	O
be	0	O
interpreted	0	O
to	0	O
say	0	O
that	0	O
formation	0	O
of	0	O
a	0	O
DNase	1	B
I	1	I
hypersensitive	0	O
holocomplex	0	O
alone	0	O
is	0	O
not	0	O
sufficient	0	O
for	0	O
mediating	0	O
high	0	O
-	0	O
level	0	O
globin	0	B
gene	0	I
transcription	0	O
.	0	O


The	0	O
gene	0	O
product	0	O
of	0	O
cotS	0	B
was	0	O
confirmed	0	O
to	0	O
be	0	O
identical	0	O
to	0	O
Cot40	0	B
-	0	I
2	0	I
by	0	O
SDS	1	O
-	0	O
PAGE	1	O
and	0	O
immunoblotting	0	O
from	0	O
Escherichia	1	O
coli	0	O
transformed	0	O
with	0	O
a	0	O
plasmid	0	O
containing	0	O
the	0	O
cotS	0	B
region	0	I
.	0	O


The	0	O
primary	0	O
structure	0	O
of	0	O
the	0	O
GAL7	0	B
5	0	I
'	0	I
flanking	0	I
region	0	I
has	0	O
many	0	O
features	0	O
common	0	O
to	0	O
those	0	O
of	0	O
multicellular	0	O
eukaryotic	0	O
genes	0	O
.	0	O


To	1	O
confirm	0	O
the	0	O
GapIII	0	B
protein	0	I
activity	0	O
,	0	O
constructs	0	O
containing	0	O
different	0	O
GapIII	0	B
-	0	O
GRD	0	B
domains	0	O
were	0	O
transformed	0	O
into	0	O
iral	0	B
mutant	0	O
yeast	0	O
to	0	O
determine	0	O
their	0	O
relative	0	O
ability	0	O
to	0	O
replace	0	O
IRA1	0	B
functionally	0	O
.	0	O


Role	1	O
of	0	O
estrogen	0	B
receptor	0	I
ligand	0	O
and	0	O
estrogen	0	O
response	0	O
element	0	O
sequence	0	O
on	0	O
interaction	0	O
with	0	O
chicken	0	B
ovalbumin	0	I
upstream	0	I
promoter	0	I
transcription	0	I
factor	0	I
(	0	O
COUP	1	B
-	0	I
TF	1	I
).	0	O


A	1	O
single	0	O
MEF	0	B
-	0	I
2	0	I
site	0	I
is	0	O
a	0	O
major	0	O
positive	0	O
regulatory	0	O
element	0	O
required	0	O
for	0	O
transcription	0	O
of	0	O
the	0	O
muscle	0	O
-	0	O
specific	0	O
subunit	0	O
of	0	O
the	0	O
human	0	B
phosphoglycerate	0	I
mutase	0	I
gene	0	I
in	0	O
skeletal	0	O
and	0	O
cardiac	0	O
muscle	0	O
cells	0	O
.	0	O


Therefore	0	O
,	0	O
the	0	O
results	0	O
indicate	0	O
that	0	O
repeated	0	O
exposure	0	O
to	0	O
amphetamine	0	O
or	0	O
apomorphine	0	O
overcomes	0	O
the	0	O
context	0	O
-	0	O
dependent	0	O
component	0	O
of	0	O
sensitization	0	O
of	0	O
amphetamine	0	O
-	0	O
or	0	O
apomorphine	0	O
-	0	O
induced	0	O
stereotyped	0	O
behavior	0	O
.	0	O


Using	0	O
16	0	O
strains	0	O
of	0	O
C	1	O
.	0	O
trachomatis	0	O
in	0	O
triplicate	0	O
assays	0	O
,	0	O
we	0	O
found	0	O
the	0	O
RT	1	O
-	0	O
PCR	1	O
method	0	O
consistently	0	O
more	0	O
sensitive	0	O
than	0	O
the	0	O
conventional	0	O
technique	0	O
for	0	O
all	0	O
eight	0	O
antimicrobials	0	O
tested	0	O
,	0	O
with	0	O
resultant	0	O
MICs	0	O
determined	0	O
by	0	O
RT	1	O
-	0	O
PCR	1	O
ranging	0	O
from	0	O
1	0	O
.	0	O
6	0	O
-	0	O
fold	0	O
higher	0	O
(	0	O
erythromycin	0	O
)	0	O
to	0	O
>/=	0	O
195	0	O
-	0	O
fold	0	O
higher	0	O
(	0	O
amoxicillin	0	O
).	0	O


These	0	O
alternative	0	O
splice	0	O
variants	0	O
were	0	O
detected	0	O
in	0	O
RNA	1	O
isolated	0	O
from	0	O
several	0	O
sources	0	O
,	0	O
including	0	O
primary	0	O
leptomeningeal	0	O
tissue	0	O
and	0	O
an	0	O
established	0	O
line	0	O
of	0	O
leptomeningeal	0	O
cells	0	O
(	0	O
LMC	0	O
).	0	O


Abnormalities	0	O
of	0	O
plasma	0	B
cholecystokinin	0	I
were	0	O
observed	0	O
only	0	O
in	0	O
patients	0	O
with	0	O
delayed	0	O
gastric	0	O
emptying	0	O
.	0	O


Prognosis	1	O
of	0	O
asymptomatic	0	O
multiple	0	O
myeloma	0	O
.	0	O


The	0	O
coordinate	0	O
increase	0	O
in	0	O
cyclin	0	B
D1	1	I
and	0	O
p21	0	B
had	0	O
the	0	O
effect	0	O
of	0	O
decreasing	0	O
the	0	O
specific	0	O
but	0	O
not	0	O
absolute	0	O
activity	0	O
of	0	O
cyclin	0	B
D1	1	I
/	0	O
cdk4	0	B
.	0	O
p53	0	B
was	0	O
not	0	O
involved	0	O
since	0	O
CSF	1	B
-	0	I
1	0	I
induction	0	O
of	0	O
p21	0	B
was	0	O
unaffected	0	O
by	0	O
dominant	0	B
-	0	I
negative	0	I
p53	0	I
expression	0	O
.	0	O


The	0	O
detectability	0	O
of	0	O
the	0	O
defects	0	O
in	0	O
RCA	1	O
or	0	O
LAD	1	O
region	0	O
was	0	O
80	0	O
%	0	O
in	0	O
single	0	O
-	0	O
position	0	O
scans	0	O
in	0	O
stress	0	O
studies	0	O
.	0	O


Serum	1	O
IgG	1	B
was	0	O
initially	0	O
elevated	0	O
in	0	O
6	0	O
patients	0	O
.	0	O


These	0	O
data	0	O
show	0	O
that	0	O
heterologous	0	O
virus	0	O
RNAs	0	O
(	0	O
BSMV	0	O
)	0	O
can	0	O
serve	0	O
as	0	O
primer	0	O
donors	0	O
for	0	O
MStV	0	O
mRNA	1	O
capped	0	O
RNA	1	O
-	0	O
primed	0	O
transcription	0	O
in	0	O
doubly	0	O
infected	0	O
plants	0	O
.	0	O


A	1	O
large	0	O
increase	0	O
of	0	O
serum	0	O
ketones	0	O
occurred	0	O
under	0	O
all	0	O
conditions	0	O
,	0	O
and	0	O
the	0	O
exercise	0	O
respiratory	0	O
quotient	0	O
suggested	0	O
some	0	O
increase	0	O
of	0	O
fat	0	O
utilization	0	O
,	0	O
WW	0	O
(	0	O
0	0	O
.	0	O
85	0	O
)	0	O
through	0	O
CW	0	O
(	0	O
0	0	O
.	0	O
84	0	O
)	0	O
to	0	O
CC	1	O
(	0	O
0	0	O
.	0	O
83	0	O
).	0	O


Recent	0	O
developments	0	O
in	0	O
drugs	0	O
antagonistic	0	O
to	0	O
factors	0	O
causing	0	O
peptic	0	O
ulcer	0	O
--	0	O
clinical	0	O
efficacy	0	O
and	0	O
problems	0	O
;	0	O
gastrin	0	B
receptor	0	I
blockaders	0	O


Documentation	1	O
of	0	O
a	0	O
successful	0	O
intrauterine	0	O
fertilization	0	O
with	0	O
delivery	0	O
of	0	O
a	0	O
term	0	O
baby	0	O
supports	0	O
the	0	O
theoretical	0	O
feasibility	0	O
of	0	O
the	0	O
EP	1	O
;	0	O
however	0	O
,	0	O
anovulation	0	O
incurred	0	O
by	0	O
our	0	O
procedure	0	O
appears	0	O
to	0	O
be	0	O
the	0	O
major	0	O
drawback	0	O
.	0	O


The	0	O
highly	0	O
amyloidogenic	0	O
42	0	O
-	0	O
residue	0	O
form	0	O
of	0	O
Abeta	0	B
(	0	O
Abeta42	1	B
)	0	O
is	0	O
the	0	O
first	0	O
species	0	O
to	0	O
be	0	O
deposited	0	O
in	0	O
both	0	O
sporadic	0	O
and	0	O
familial	0	O
AD	1	O
.	0	O


Regional	1	O
insertional	0	O
mutagenesis	0	O
of	0	O
specific	0	O
genes	0	O
on	0	O
the	0	O
CIC5F11	0	B
/	0	O
CIC2B9	0	B
locus	0	O
of	0	O
Arabidopsis	0	O
thaliana	0	O
chromosome	0	O
5	0	O
using	0	O
the	0	O
Ac	1	B
/	0	O
Ds	1	B
transposon	0	O
in	0	O
combination	0	O
with	0	O
the	0	O
cDNA	1	O
scanning	0	O
method	0	O
.	0	O


The	0	O
analysis	0	O
of	0	O
the	0	O
prevalence	0	O
values	0	O
shows	0	O
clearly	0	O
that	0	O
the	0	O
global	0	O
MS	1	O
-	0	O
frequency	0	O
is	0	O
closer	0	O
related	0	O
to	0	O
the	0	O
geomagnetic	0	O
than	0	O
to	0	O
the	0	O
geographic	0	O
latitude	0	O
.	0	O


Very	0	O
good	0	O
accuracy	0	O
(	0	O
r	0	O
greater	0	O
than	0	O
0	0	O
.	0	O
9	0	O
)	0	O
was	0	O
found	0	O
when	0	O
except	0	O
comparing	0	O
H	1	O
*	0	O
2	0	O
with	0	O
the	0	O
other	0	O
machine	0	O
and	0	O
the	0	O
reference	0	O
methods	0	O
,	0	O
except	0	O
for	0	O
MCHCH	0	O
and	0	O
basophil	0	O
count	0	O
.	0	O


We	0	O
detected	0	O
mos	0	B
transcripts	0	I
by	0	O
Northern	0	O
(	0	O
RNA	1	O
)	0	O
analyses	0	O
in	0	O
RNA	1	O
prepared	0	O
from	0	O
chicken	0	O
and	0	O
quail	0	O
ovaries	0	O
and	0	O
testes	0	O
.	0	O


An	1	O
N	1	O
-	0	O
terminal	0	O
arm	0	O
from	0	O
each	0	O
subunit	0	O
wraps	0	O
around	0	O
the	0	O
dinucleotide	0	O
-	0	O
binding	0	O
domain	0	O
of	0	O
an	0	O
adjacent	0	O
subunit	0	O
,	0	O
covering	0	O
the	0	O
adenine	0	O
ring	0	O
of	0	O
NADP	1	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
the	0	O
G	1	B
-	0	I
protein	0	I
gene	0	I
family	0	I
may	0	O
be	0	O
distributed	0	O
over	0	O
at	0	O
least	0	O
two	0	O
human	0	O
chromosomes	0	O
.	0	O


Alternative	0	O
transcript	0	O
of	0	O
the	0	O
nonselective	0	O
-	0	O
type	0	O
endothelin	0	B
receptor	0	I
from	0	O
rat	0	O
brain	0	O
.	0	O


The	0	O
RAP74	0	B
subunit	0	I
of	0	O
TFIIF	0	B
alone	0	O
contained	0	O
the	0	O
stimulatory	0	O
activity	0	O
and	0	O
the	0	O
minimal	0	O
region	0	O
sufficient	0	O
for	0	O
stimulation	0	O
corresponds	0	O
to	0	O
COOH	0	O
-	0	O
terminal	0	O
residues	0	O
358	0	O
-	0	O
517	0	O
.	0	O


One	0	O
of	0	O
these	0	O
factors	0	O
,	0	O
HRF	1	B
-	0	I
1	0	I
,	0	O
recognizes	0	O
a	0	O
cis	0	O
element	0	O
consisting	0	O
of	0	O
an	0	O
inverted	0	O
palindromic	0	O
motif	0	O
.	0	O


Further	0	O
,	0	O
the	0	O
PIP2	1	O
content	0	O
of	0	O
the	0	O
85	0	O
-	0	O
90	0	O
kDa	1	O
protein	0	O
appeared	0	O
to	0	O
decrease	0	O
with	0	O
CSF	1	B
-	0	I
1	0	I
treatment	0	O
.	0	O


With	0	O
0	0	O
.	0	O
5	0	O
vol	0	O
.-%,	0	O
the	0	O
corresponding	0	O
values	0	O
were	0	O
345	0	O
mumol	0	O
/	0	O
1	0	O
(	0	O
5	0	O
.	0	O
72	0	O
mg	0	O
/	0	O
100	0	O
ml	0	O
)	0	O
and	0	O
137	0	O
mumol	0	O
/	0	O
1	0	O
(	0	O
2	0	O
.	0	O
25	0	O
mg	0	O
/	0	O
100	0	O
ml	0	O
)	0	O
respectively	0	O
.	0	O


While	0	O
all	0	O
deletions	0	O
within	0	O
the	0	O
sequence	0	O
coding	0	O
for	0	O
the	0	O
mature	0	O
tRNA	1	O
led	0	O
to	0	O
inactivity	0	O
of	0	O
the	0	O
mutated	0	O
genes	0	O
,	0	O
substitution	0	O
of	0	O
the	0	O
central	0	O
portion	0	O
by	0	O
concatenated	0	B
Hind	0	I
III	0	I
linkers	0	I
produced	0	O
gene	0	O
units	0	O
active	0	O
in	0	O
transcription	0	O
.	0	O


Inspired	0	O
CO2	1	O
causing	0	O
changes	0	O
from	0	O
hypo	0	O
-	0	O
to	0	O
normocapnia	0	O
has	0	O
previously	0	O
been	0	O
shown	0	O
to	0	O
improve	0	O
arterial	0	O
O2	1	O
tension	0	O
(	0	O
PaO2	1	O
)	0	O
and	0	O
to	0	O
reduce	0	O
alveolar	0	O
-	0	O
arterial	0	O
O2	1	O
difference	0	O
.	0	O


Moreover	0	O
,	0	O
expression	0	O
of	0	O
CBF1	0	B
in	0	O
yeast	0	O
was	0	O
found	0	O
to	0	O
activate	0	O
transcription	0	O
of	0	O
reporter	0	O
genes	0	O
containing	0	O
the	0	O
C	1	O
-	0	O
repeat	0	O
/	0	O
DRE	1	O
as	0	O
an	0	O
upstream	0	O
activator	0	O
sequence	0	O
but	0	O
not	0	O
mutant	0	O
versions	0	O
of	0	O
the	0	O
DNA	1	O
element	0	O
.	0	O


Estimated	0	O
daily	0	O
intakes	0	O
(	0	O
EDIs	0	O
)	0	O
per	0	O
person	0	O
were	0	O
0	0	O
.	0	O
56	0	O
microgram	0	O
for	0	O
total	0	O
HCH	0	O
,	0	O
0	0	O
.	0	O
20	0	O
microgram	0	O
for	0	O
gamma	0	O
-	0	O
HCH	0	O
,	0	O
0	0	O
.	0	O
09	0	O
microgram	0	O
for	0	O
dieldrin	0	O
,	0	O
1	0	O
.	0	O
42	0	O
micrograms	0	O
for	0	O
total	0	O
DDT	1	O
,	0	O
and	0	O
0	0	O
.	0	O
15	0	O
microgram	0	O
for	0	O
HCB	0	O
.	0	O


VII	0	O
.	0	O


The	0	O
complete	0	O
gene	0	O
organization	0	O
was	0	O
obtained	0	O
by	0	O
combining	0	O
the	0	O
results	0	O
of	0	O
the	0	O
sequence	0	O
of	0	O
these	0	O
clones	0	O
and	0	O
those	0	O
of	0	O
the	0	O
characterization	0	O
of	0	O
polymerase	0	O
chain	0	O
reaction	0	O
-	0	O
amplified	0	O
genomic	0	O
segments	0	O
.	0	O


Our	0	O
results	0	O
suggest	0	O
that	0	O
a	0	O
sequence	0	O
match	0	O
between	0	O
enhancers	0	O
and	0	O
certain	0	O
promoter	0	O
elements	0	O
is	0	O
critical	0	O
.	0	O


Recombination	1	O
and	0	O
transcription	0	O
of	0	O
the	0	O
endogenous	0	B
Ig	1	I
heavy	0	I
chain	0	I
locus	0	I
is	0	O
effected	0	O
by	0	O
the	0	O
Ig	1	B
heavy	0	I
chain	0	I
intronic	0	I
enhancer	0	I
core	0	I
region	0	I
in	0	O
the	0	O
absence	0	O
of	0	O
the	0	O
matrix	0	O
attachment	0	O
regions	0	O
.	0	O


According	0	O
to	0	O
the	0	O
investigation	0	O
,	0	O
the	0	O
recent	0	O
burst	0	O
of	0	O
pseudoterranovosis	0	O
in	0	O
this	0	O
area	0	O
can	0	O
be	0	O
attributed	0	O
to	0	O
the	0	O
increased	0	O
presence	0	O
of	0	O
sea	0	O
lions	0	O
,	0	O
which	0	O
proliferate	0	O
in	0	O
the	0	O
Arctic	0	O
region	0	O
,	0	O
then	0	O
migrate	0	O
to	0	O
the	0	O
northern	0	O
Japan	0	O
Sea	1	O
and	0	O
eat	0	O
the	0	O
intermediate	0	O
host	0	O
fish	0	O
.	0	O


Mycoplasma	1	O
hominis	0	O
infections	0	O
are	0	O
easily	0	O
missed	0	O
because	0	O
conventional	0	O
methods	0	O
for	0	O
bacterial	0	O
detection	0	O
may	0	O
fail	0	O
.	0	O


To	1	O
understand	0	O
the	0	O
function	0	O
of	0	O
receptor	0	B
-	0	I
linked	0	I
tyrosine	0	I
phosphatases	0	I
in	0	O
neural	0	O
development	0	O
,	0	O
we	0	O
sought	0	O
to	0	O
identify	0	O
LAR	0	B
isoforms	0	I
preferentially	0	O
expressed	0	O
in	0	O
the	0	O
nervous	0	O
system	0	O
and	0	O
cellular	0	O
processes	0	O
regulating	0	O
LAR	0	B
alternative	0	O
splicing	0	O
.	0	O


One	0	O
group	0	O
(	0	O
n	0	O
=	0	O
9	0	O
)	0	O
was	0	O
premedicated	0	O
with	0	O
midazolam	0	O
,	0	O
0	0	O
.	0	O
1	0	O
mg	0	O
kg	0	O
-	0	O
1	0	O
,	0	O
and	0	O
atropine	0	O
0	0	O
.	0	O
2	0	O
-	0	O
0	0	O
.	0	O
4	0	O
mg	0	O
i	0	O
.	0	O
m	0	O
.	0	O


Component	1	O
P100	0	O
was	0	O
associated	0	O
with	0	O
a	0	O
frontal	0	O
negativity	0	O
of	0	O
similar	0	O
latency	0	O
favoring	0	O
the	0	O
hypothesis	0	O
of	0	O
a	0	O
dipolar	0	O
occipital	0	O
generator	0	O
.	0	O


By	0	O
introducing	0	O
a	0	O
series	0	O
of	0	O
deletions	0	O
in	0	O
the	0	O
vimentin	0	B
promoter	0	O
,	0	O
we	0	O
further	0	O
restrict	0	O
these	0	O
sequences	0	O
to	0	O
30	0	O
base	0	O
pairs	0	O
,	0	O
located	0	O
between	0	O
241	0	O
and	0	O
210	0	O
base	0	O
pairs	0	O
upstream	0	O
of	0	O
the	0	O
mRNA	1	O
cap	0	O
site	0	O
.	0	O


The	0	O
progression	0	O
of	0	O
acute	0	O
bronchitis	0	O
is	0	O
associated	0	O
with	0	O
elevated	0	O
blood	0	O
concentrations	0	O
of	0	O
acute	0	O
-	0	O
phase	0	O
proteins	0	O
,	0	O
KKS	0	B
activation	0	O
in	0	O
the	0	O
blood	0	O
and	0	O
high	0	O
serotonin	0	O
and	0	O
lactic	0	O
acid	0	O
content	0	O
in	0	O
the	0	O
humor	0	O
condensated	0	O
from	0	O
the	0	O
exhaled	0	O
air	0	O
.	0	O


In	1	O
agreement	0	O
with	0	O
this	0	O
southern	0	O
blotting	0	O
of	0	O
mouse	0	O
DNA	1	O
with	0	O
SmN	0	B
probes	0	O
reveals	0	O
bands	0	O
,	0	O
additional	0	O
to	0	O
those	0	O
derived	0	O
from	0	O
the	0	O
pseudogene	0	O
,	0	O
which	0	O
are	0	O
characteristic	0	O
of	0	O
an	0	O
intron	0	O
-	0	O
containing	0	O
SmN	0	B
gene	0	I
.	0	O


Technetium	1	O
-	0	O
99m	0	O
stannous	0	O
pyrophosphate	0	O
myocardial	0	O
scintigrams	0	O
were	0	O
obtained	0	O
in	0	O
138	0	O
clinically	0	O
stable	0	O
patients	0	O
32	0	O
.	0	O
7	0	O
+/-	0	O
47	0	O
.	0	O
3	0	O
weeks	0	O
(	0	O
range	0	O
6	0	O
to	0	O
260	0	O
)	0	O
after	0	O
acute	0	O
myocardial	0	O
infarction	0	O
.	0	O


In	1	O
the	0	O
absence	0	O
of	0	O
other	0	O
stabilizers	0	O
,	0	O
increased	0	O
sucrose	0	O
can	0	O
provide	0	O
increased	0	O
thermoresistance	0	O
to	0	O
the	0	O
virus	0	O
in	0	O
2	0	O
.	0	O
5	0	O
%	0	O
albumin	0	B
.	0	O


Infectious	1	O
mutant	0	O
virus	0	O
progeny	0	O
was	0	O
obtained	0	O
only	0	O
on	0	O
complementing	0	O
gK	0	B
-	0	O
expressing	0	O
cells	0	O
,	0	O
suggesting	0	O
that	0	O
gK	0	B
has	0	O
an	0	O
important	0	O
function	0	O
in	0	O
the	0	O
replication	0	O
cycle	0	O
.	0	O


A	1	O
single	0	O
protease	0	O
-	0	O
resistant	0	O
structure	0	O
formed	0	O
by	0	O
the	0	O
entirety	0	O
of	0	O
both	0	O
PDZ	0	B
repeats	0	I
1	0	I
and	0	I
2	0	I
(	0	O
PDZ1	0	B
-	0	I
2	0	I
)	0	O
contains	0	O
the	0	O
protein	0	B
4	0	I
.	0	I
1	0	I
-	0	I
binding	0	I
site	0	I
.	0	O


Identification	1	O
and	0	O
structure	0	O
of	0	O
the	0	O
Marek	0	B
'	0	I
s	0	I
disease	0	I
virus	0	I
serotype	0	I
2	0	I
glycoprotein	0	I
M	1	I
gene	0	I
:	0	O
comparison	0	O
with	0	O
glycoprotein	0	B
M	1	I
genes	0	I
of	0	O
Herpesviridae	1	O
family	0	O
.	0	O


GN101	0	O
,	0	O
YC819	0	O
-	0	O
9	0	O
,	0	O
and	0	O
SB3	0	O
.	0	O


BACKGROUND	0	O
:	0	O
The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
determine	0	O
the	0	O
response	0	O
rates	0	O
and	0	O
toxicity	0	O
of	0	O
two	0	O
regimens	0	O
containing	0	O
granulocyte	0	B
-	0	I
macrophage	0	I
-	0	I
colony	0	I
stimulating	0	I
factor	0	I
(	0	O
GM	1	B
-	0	I
CSF	1	I
)	0	O
in	0	O
combination	0	O
with	0	O
interleukin	0	B
-	0	I
2	0	I
(	0	O
IL	1	B
-	0	I
2	0	I
)	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
patients	0	O
with	0	O
metastatic	0	O
renal	0	O
cell	0	O
carcinoma	0	O
.	0	O


A	1	O
normal	0	O
systemic	0	O
response	0	O
was	0	O
obtained	0	O
after	0	O
IF	1	O
,	0	O
indicating	0	O
that	0	O
rhG	0	B
-	0	I
CSF	1	I
retains	0	O
activity	0	O
in	0	O
the	0	O
solid	0	O
state	0	O
.	0	O


Analysis	1	O
of	0	O
cell	0	O
cycle	0	O
regulation	0	O
in	0	O
the	0	O
budding	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
has	0	O
shown	0	O
that	0	O
a	0	O
central	0	O
regulatory	0	O
protein	0	O
kinase	0	O
,	0	O
Cdc28	0	B
,	0	O
undergoes	0	O
changes	0	O
in	0	O
activity	0	O
through	0	O
the	0	O
cell	0	O
cycle	0	O
by	0	O
associating	0	O
with	0	O
distinct	0	O
groups	0	O
of	0	O
cyclins	0	B
that	0	O
accumulate	0	O
at	0	O
different	0	O
times	0	O
.	0	O


Focused	0	O
beams	0	O
of	0	O
classical	0	O
light	0	O
ablate	0	O
elements	0	O
of	0	O
the	0	O
cell	0	O
division	0	O
machinery	0	O
and	0	O
switch	0	O
the	0	O
beating	0	O
of	0	O
hearts	0	O
on	0	O
a	0	O
cellular	0	O
basis	0	O
.	0	O


RNase	1	B
protection	0	O
experiments	0	O
confirmed	0	O
the	0	O
presence	0	O
of	0	O
the	0	O
GHR1	0	B
-	0	I
279	0	I
variant	0	I
in	0	O
IM	1	O
-	0	O
9	0	O
cells	0	O
and	0	O
human	0	O
liver	0	O
.	0	O


Gas6	0	B
contains	0	O
an	0	O
NH2	0	O
-	0	O
terminal	0	O
Gla	0	O
domain	0	O
followed	0	O
by	0	O
four	0	O
epidermal	0	B
growth	0	I
factor	0	I
-	0	I
like	0	I
repeats	0	I
and	0	O
tandem	0	O
globular	0	O
(	0	O
G	1	O
)	0	O
domains	0	O
.	0	O


With	0	O
chemical	0	O
shift	0	O
imaging	0	O
,	0	O
the	0	O
signal	0	O
intensity	0	O
decreased	0	O
on	0	O
the	0	O
out	0	O
-	0	O
of	0	O
-	0	O
phase	0	O
images	0	O
in	0	O
six	0	O
of	0	O
seven	0	O
(	0	O
86	0	O
%)	0	O
patients	0	O
with	0	O
APA	1	O
and	0	O
in	0	O
eight	0	O
of	0	O
nine	0	O
(	0	O
89	0	O
%)	0	O
patients	0	O
with	0	O
BAH	0	O
.	0	O


Deletion	1	O
analysis	0	O
of	0	O
rOC	0	B
promoter	0	I
-	0	O
chloramphenicol	0	B
acetyltransferase	0	I
constructs	0	O
demonstrates	0	O
that	0	O
an	0	O
AML	1	B
-	0	I
1	0	I
-	0	I
binding	0	I
sequence	0	I
within	0	O
the	0	O
proximal	0	O
promoter	0	O
(-	0	O
138	0	O
to	0	O
-	0	O
130	0	O
nt	0	O
)	0	O
contributes	0	O
to	0	O
75	0	O
%	0	O
of	0	O
the	0	O
level	0	O
of	0	O
osteocalcin	0	B
gene	0	I
expression	0	O
.	0	O


In	1	O
Arabidopsis	0	O
,	0	O
the	0	O
induction	0	O
of	0	O
a	0	O
dehydration	0	O
-	0	O
responsive	0	O
gene	0	O
,	0	O
rd22	0	B
,	0	O
is	0	O
mediated	0	O
by	0	O
abscisic	0	O
acid	0	O
(	0	O
ABA	0	O
)	0	O
and	0	O
requires	0	O
protein	0	O
biosynthesis	0	O
for	0	O
ABA	0	O
-	0	O
dependent	0	O
gene	0	O
expression	0	O
.	0	O


Effect	1	O
of	0	O
nitrous	0	O
oxide	0	O
(	0	O
N2O	1	O
)	0	O
on	0	O
the	0	O
somatosympathetic	0	O
A	1	O
-	0	O
and	0	O
C	1	O
-	0	O
reflexes	0	O
was	0	O
investigated	0	O
using	0	O
artificially	0	O
ventilated	0	O
rats	0	O
anesthetized	0	O
with	0	O
alpha	0	O
-	0	O
chloralose	0	O
and	0	O
urethane	0	O
.	0	O


[	0	O
82Br	0	O
]	0	O
MISO	0	O
was	0	O
prepared	0	O
by	0	O
irradiating	0	O
samples	0	O
of	0	O
Br	1	O
-	0	O
MISO	0	O
in	0	O
a	0	O
SLOWPOKE	0	O
reactor	0	O
for	0	O
2	0	O
h	0	O
at	0	O
a	0	O
thermal	0	O
neutron	0	O
flux	0	O
of	0	O
10	0	O
(	0	O
12	0	O
)	0	O
n	0	O
cm	0	O
-	0	O
2	0	O
s	0	O
-	0	O
1	0	O
.	0	O


Significant	1	O
immunoglobulinuria	0	O
developed	0	O
prior	0	O
to	0	O
the	0	O
development	0	O
of	0	O
azotemia	0	O
,	0	O
significantly	0	O
decreased	0	O
creatinine	0	O
clearance	0	O
,	0	O
significant	0	O
proteinuria	0	O
(	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
3	0	O
+	0	O
dipstick	0	O
or	0	O
greater	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
5	0	O
gm	0	O
per	0	O
24	0	O
-	0	O
hour	0	O
urine	0	O
collection	0	O
),	0	O
or	0	O
oliguria	0	O
.	0	O


RESULTS	0	O
:	0	O
The	0	O
overall	0	O
FNF	0	O
for	0	O
1992	0	O
was	0	O
12	0	O
.	0	O
3	0	O
%	0	O
and	0	O
was	0	O
19	0	O
.	0	O
1	0	O
%,	0	O
22	0	O
.	0	O
2	0	O
%,	0	O
3	0	O
.	0	O
8	0	O
%	0	O
and	0	O
6	0	O
.	0	O
1	0	O
%	0	O
per	0	O
successive	0	O
quarters	0	O
in	0	O
1992	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
striking	0	O
ability	0	O
of	0	O
polyoma	0	B
middle	0	I
T	1	I
antigens	0	I
to	0	O
promote	0	O
retinoic	0	O
acid	0	O
-	0	O
induced	0	O
differentiation	0	O
appears	0	O
to	0	O
utilize	0	O
ERK	0	B
,	0	O
but	0	O
not	0	O
JNK	0	B
/	0	O
SPK	0	B
or	0	O
p38	0	B
signaling	0	O
.	0	O


Peripheral	1	O
polyneuropathy	0	O
associated	0	O
with	0	O
multiple	0	O
myeloma	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
over	0	O
-	0	O
replication	0	O
phenotype	0	O
produced	0	O
by	0	O
this	0	O
mutant	0	B
p65cdc18	0	I
is	0	O
resistant	0	O
to	0	O
increased	0	O
mitotic	0	O
cyclin	0	B
/	0	O
CDK	1	B
activity	0	O
,	0	O
a	0	O
known	0	O
inhibitor	0	O
of	0	O
over	0	O
-	0	O
replication	0	O
.	0	O


We	0	O
have	0	O
used	0	O
a	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
approach	0	O
to	0	O
examine	0	O
how	0	O
the	0	O
Xaa	0	O
and	0	O
hydroxy	0	O
(	0	O
Ser	1	O
/	0	O
Thr	1	O
)	0	O
amino	0	O
acid	0	O
residues	0	O
in	0	O
sequons	0	O
influence	0	O
core	0	O
-	0	O
glycosylation	0	O
efficiency	0	O
.	0	O


Demonstration	0	O
of	0	O
the	0	O
agent	0	O
was	0	O
performed	0	O
from	0	O
the	0	O
6th	0	O
to	0	O
the	0	O
11th	0	O
day	0	O
p	0	O
.	0	O
i	0	O
.	0	O
by	0	O
direct	0	O
microscopic	0	O
methods	0	O
(	0	O
Stamp	0	O
and	0	O
auramine	0	O
staining	0	O
,	0	O
fluorescent	0	O
antibody	0	O
technique	0	O
);	0	O
the	0	O
Coxiella	1	O
content	0	O
was	0	O
determined	0	O
by	0	O
titration	0	O
in	0	O
embryonated	0	O
hen	0	O
'	0	O
s	0	O
eggs	0	O
.	0	O


The	0	O
M	1	B
reading	0	I
frame	0	I
differed	0	O
from	0	O
the	0	O
reported	0	O
sequence	0	O
by	0	O
a	0	O
single	0	O
nucleotide	0	O
corresponding	0	O
to	0	O
a	0	O
conservative	0	O
lysine	0	O
to	0	O
arginine	0	O
amino	0	O
acid	0	O
substitution	0	O
near	0	O
the	0	O
carboxy	0	O
-	0	O
terminus	0	O
conserved	0	O
among	0	O
the	0	O
M	1	B
proteins	0	I
of	0	O
paramyxoviruses	0	O
.	0	O


The	0	O
MICs	0	O
of	0	O
this	0	O
compound	0	O
against	0	O
90	0	O
%	0	O
of	0	O
these	0	O
organisms	0	O
,	0	O
except	0	O
for	0	O
methicillin	0	O
-	0	O
resistant	0	O
S	1	O
.	0	O
aureus	0	O
,	0	O
ranged	0	O
from	0	O
less	0	O
than	0	O
or	0	O
equal	0	O
to	0	O
0	0	O
.	0	O
006	0	O
to	0	O
3	0	O
.	0	O
13	0	O
micrograms	0	O
/	0	O
ml	0	O
.	0	O


Diethylene	0	O
benzene	0	O


Drag	1	O
reduction	0	O
in	0	O
turbulent	0	O
flows	0	O
by	0	O
polymers	0	O
.	0	O


The	0	O
use	0	O
of	0	O
the	0	O
PLCgamma	0	B
inhibitory	0	I
peptide	0	I
,	0	O
neomycin	0	O
and	0	O
the	0	O
calcium	0	O
chelator	0	O
BAPTA	0	O
-	0	O
AM	1	O
on	0	O
oocytes	0	O
expressing	0	O
FGFR1	0	B
or	0	O
the	0	O
stimulation	0	O
by	0	O
PDGF	0	B
-	0	I
BB	0	I
of	0	O
oocytes	0	O
expressing	0	O
PDGFR	0	B
-	0	O
FGFR1	0	B
mutated	0	O
on	0	O
the	0	O
PLCgamma	0	B
binding	0	I
site	0	I
,	0	O
prevented	0	O
GVBD	0	O
and	0	O
ERK2	0	B
phosphorylation	0	O
.	0	O


Human	1	B
bcl3	0	I
protein	0	I
specifically	0	O
displaces	0	O
(	0	B
p50	0	I
)	0	I
2	0	I
-	0	I
DNA	1	I
complexes	0	I
.	0	O


Proceedings	0	O
:	0	O
Barrels	0	O
and	0	O
somatotopy	0	O
in	0	O
S	1	O
I	1	O
neocortex	0	O
of	0	O
the	0	O
brush	0	O
-	0	O
tailed	0	O
possum	0	O
.	0	O


Importance	0	O
of	0	O
determining	0	O
the	0	O
blood	0	O
sulfhydryl	0	O
groups	0	O
in	0	O
fractures	0	O
of	0	O
the	0	O
long	0	O
tubular	0	O
bones	0	O
complicated	0	O
by	0	O
infection	0	O


In	1	O
addition	0	O
,	0	O
insulin	0	B
induced	0	O
AP	1	B
-	0	I
1	0	I
DNA	1	O
binding	0	O
activity	0	O
,	0	O
this	0	O
effect	0	O
being	0	O
totally	0	O
prevented	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
MEK	0	B
-	0	I
1	0	I
inhibitor	0	O
.	0	O


Transplantation	1	O
of	0	O
kidneys	0	O
of	0	O
juvenile	0	O
donors	0	O
in	0	O
adult	0	O
recipients	0	O
.	0	O


Furthermore	0	O
,	0	O
the	0	O
PH	1	B
and	0	O
PTB	0	O
domains	0	O
are	0	O
highly	0	O
homologous	0	O
(	0	O
at	0	O
least	0	O
40	0	O
%	0	O
identical	0	O
)	0	O
to	0	O
those	0	O
found	0	O
in	0	O
insulin	0	B
receptor	0	I
substrates	0	I
1	0	I
,	0	I
2	0	I
,	0	I
and	0	I
3	0	I
(	0	O
IRS	0	B
-	0	I
1	0	I
,	0	O
IRS	0	B
-	0	I
2	0	I
,	0	O
and	0	O
IRS	0	B
-	0	I
3	0	I
).	0	O


NSCL	0	B
-	0	I
1	0	I
is	0	O
expressed	0	O
in	0	O
a	0	O
larger	0	O
number	0	O
of	0	O
these	0	O
cell	0	O
lines	0	O
.	0	O


Two	0	O
independent	0	O
promoters	0	O
as	0	O
well	0	O
as	0	O
5	0	O
'	0	O
untranslated	0	O
regions	0	O
regulate	0	O
Dd	0	B
ras	0	I
expression	0	O
in	0	O
Dictyostelium	0	O
.	0	O


In	1	O
15	0	O
ventilator	0	O
-	0	O
dependent	0	O
,	0	O
SB	1	O
,	0	O
and	0	O
actively	0	O
expiring	0	O
patients	0	O
,	0	O
we	0	O
found	0	O
that	0	O
the	0	O
difference	0	O
PEEP	1	O
(	0	O
i	0	O
),	0	O
dyn	0	O
-	0	O
Pga	1	O
,	0	O
total	0	O
decay	0	O
(	0	O
mean	0	O
+/-	0	O
SD	1	O
,	0	O
5	0	O
.	0	O
7	0	O
+/-	0	O
1	0	O
.	0	O
9	0	O
cm	0	O
H	1	O
(	0	O
2	0	O
)	0	O
O	1	O
)	0	O
was	0	O
quite	0	O
similar	0	O
to	0	O
PEEP	1	O
(	0	O
i	0	O
),	0	O
dyn	0	O
ref	0	O
(	0	O
5	0	O
.	0	O
3	0	O
+/-	0	O
1	0	O
.	0	O
9	0	O
cm	0	O
H	1	O
(	0	O
2	0	O
)	0	O
O	1	O
).	0	O


These	0	O
findings	0	O
suggest	0	O
that	0	O
both	0	O
in	0	O
the	0	O
early	0	O
stages	0	O
(	0	O
0T	0	O
,	0	O
0N	0	O
)	0	O
and	0	O
in	0	O
more	0	O
severe	0	O
stages	0	O
of	0	O
VWF	1	O
(	0	O
stages	0	O
1	0	O
-	0	O
2	0	O
)	0	O
cold	0	O
induced	0	O
hyperreactivity	0	O
in	0	O
the	0	O
digital	0	O
vessels	0	O
and	0	O
Raynaud	0	O
'	0	O
s	0	O
syndrome	0	O
are	0	O
vascular	0	O
disorders	0	O
of	0	O
functional	0	O
origin	0	O
occurring	0	O
without	0	O
any	0	O
prethrombotic	0	O
alterations	0	O
.	0	O


A	1	O
new	0	O
non	0	O
-	0	O
LTR	1	O
retrotransposon	0	O
provides	0	O
evidence	0	O
for	0	O
multiple	0	O
distinct	0	O
site	0	O
-	0	O
specific	0	O
elements	0	O
in	0	O
Crithidia	1	O
fasciculata	0	O
miniexon	0	O
arrays	0	O
.	0	O


All	1	O
of	0	O
the	0	O
newly	0	O
acquired	0	O
proviruses	0	O
identified	0	O
in	0	O
mosaic	0	O
founder	0	O
SWR	0	O
/	0	O
J	1	O
-	0	O
RF	1	O
/	0	O
J	1	O
mice	0	O
that	0	O
could	0	O
be	0	O
transmitted	0	O
through	0	O
the	0	O
germ	0	O
line	0	O
were	0	O
also	0	O
present	0	O
in	0	O
somatic	0	O
tissues	0	O
,	0	O
demonstrating	0	O
that	0	O
viral	0	O
integration	0	O
occurred	0	O
before	0	O
the	0	O
germ	0	O
line	0	O
was	0	O
set	0	O
aside	0	O
from	0	O
the	0	O
somatic	0	O
lineages	0	O
.	0	O


Transfer	1	O
RNA	1	O
genes	0	O
from	0	O
Dictyostelium	0	O
discoideum	0	O
are	0	O
frequently	0	O
associated	0	O
with	0	O
repetitive	0	O
elements	0	O
and	0	O
contain	0	O
consensus	0	O
boxes	0	O
in	0	O
their	0	O
5	0	O
'	0	O
and	0	O
3	0	O
'-	0	O
flanking	0	O
regions	0	O
.	0	O


The	0	O
hybrid	0	O
viruses	0	O
were	0	O
found	0	O
to	0	O
accumulate	0	O
to	0	O
high	0	O
levels	0	O
in	0	O
infected	0	O
plants	0	O
,	0	O
to	0	O
form	0	O
stable	0	O
virions	0	O
,	0	O
and	0	O
to	0	O
be	0	O
mechanically	0	O
transmissible	0	O
.	0	O


An	1	O
aromatic	0	O
stacking	0	O
interaction	0	O
between	0	O
subunits	0	O
helps	0	O
mediate	0	O
DNA	1	O
sequence	0	O
specificity	0	O
:	0	O
operator	0	O
site	0	O
discrimination	0	O
by	0	O
phage	0	B
lambda	0	I
cI	1	I
repressor	0	I
.	0	O


Because	0	O
of	0	O
the	0	O
potential	0	O
implications	0	O
of	0	O
these	0	O
findings	0	O
in	0	O
human	0	O
physiology	0	O
,	0	O
we	0	O
cloned	0	O
the	0	O
hPACAP	0	B
-	0	I
R	1	I
gene	0	I
.	0	O


CONCLUSION	0	O
:	0	O
Treatment	1	O
of	0	O
sepsis	0	O
with	0	O
the	0	O
platelet	0	B
-	0	I
activating	0	I
factor	0	I
antagonist	0	O
BB	0	O
-	0	O
882	0	O
offers	0	O
no	0	O
advantage	0	O
over	0	O
placebo	0	O
on	0	O
survival	0	O
,	0	O
hemodynamic	0	O
status	0	O
,	0	O
respiratory	0	O
function	0	O
,	0	O
or	0	O
organ	0	O
failure	0	O
scores	0	O
.	0	O


Six	0	O
hours	0	O
after	0	O
the	0	O
last	0	O
administration	0	O
,	0	O
uterus	0	O
of	0	O
Gf	0	O
and	0	O
Cv	1	O
mice	0	O
were	0	O
weight	0	O
337	0	O
.	0	O
6	0	O
mg	0	O
%	0	O
and	0	O
423	0	O
.	0	O
5	0	O
mg	0	O
%	0	O
respectively	0	O
,	0	O
the	0	O
difference	0	O
was	0	O
statistically	0	O
significant	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


In	1	O
addition	0	O
,	0	O
we	0	O
demonstrate	0	O
that	0	O
the	0	O
production	0	O
of	0	O
active	0	B
recombinant	0	I
telomerase	0	I
requires	0	O
a	0	O
factor	0	O
in	0	O
rabbit	0	O
reticulocyte	0	O
lysate	0	O
that	0	O
promotes	0	O
ribonucleoprotein	0	O
assembly	0	O
.	0	O


Evaluation	1	O
of	0	O
thyroid	0	O
function	0	O
.	0	O


These	0	O
are	0	O
two	0	O
regions	0	O
of	0	O
known	0	O
conserved	0	O
synteny	0	O
,	0	O
providing	0	O
further	0	O
evidence	0	O
that	0	O
the	0	O
human	0	B
STEP	1	I
is	0	O
a	0	O
true	0	O
homolog	0	O
of	0	O
the	0	O
murine	0	B
STEP	1	I
gene	0	I
.	0	O


Relaxation	1	O
of	0	O
catch	0	O
in	0	O
a	0	O
molluscan	0	O
smooth	0	O
muscle	0	O
.	0	O


A	1	O
soap	0	O
and	0	O
water	0	O
(	0	O
1	0	O
:	0	O
1	0	O
,	0	O
v	0	O
/	0	O
v	0	O
)	0	O
solution	0	O
effectively	0	O
decontaminated	0	O
powdered	0	O
stratum	0	O
corneum	0	O
.	0	O


An	1	O
extensive	0	O
inverted	0	O
repeat	0	O
is	0	O
present	0	O
3	0	O
'	0	O
of	0	O
rpeA	0	B
;	0	O
inverted	0	O
repeats	0	O
are	0	O
found	0	O
downstream	0	O
of	0	O
all	0	O
PE	1	B
operons	0	I
sequenced	0	O
to	0	O
date	0	O
,	0	O
although	0	O
the	0	O
sequence	0	O
is	0	O
not	0	O
conserved	0	O
.	0	O


It	1	O
was	0	O
subsequently	0	O
shown	0	O
that	0	O
Tip60	0	B
had	0	O
histone	0	B
acetyltransferase	0	I
(	0	O
HAT	1	B
)	0	O
activity	0	O
.	0	O


The	0	O
amplification	0	O
was	0	O
achieved	0	O
using	0	O
two	0	O
primers	0	O
which	0	O
correspond	0	O
to	0	O
TRH	1	B
progenitor	0	I
sequence	0	I
(	0	O
Lys	1	O
/	0	O
Arg	1	O
-	0	O
Arg	1	O
-	0	O
Gln	1	O
-	0	O
His	1	O
-	0	O
Pro	1	O
-	0	O
Gly	1	O
-	0	O
Lys	1	O
/	0	O
Arg	1	O
-	0	O
Arg	1	O
).	0	O


However	0	O
,	0	O
unlike	0	O
the	0	O
SIN3	0	B
gene	0	I
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
,	0	O
pst1	0	B
(+)	0	I
is	0	O
essential	0	O
for	0	O
cell	0	O
viability	0	O
.	0	O


Position	1	O
-	0	O
independent	0	O
expression	0	O
of	0	O
a	0	O
human	0	O
nerve	0	B
growth	0	I
factor	0	I
-	0	O
luciferase	0	B
reporter	0	O
gene	0	O
cloned	0	O
on	0	O
a	0	O
yeast	0	O
artificial	0	O
chromosome	0	O
vector	0	O
.	0	O


Rex	0	B
-	0	I
1	0	I
,	0	O
a	0	O
gene	0	O
encoding	0	O
a	0	O
transcription	0	O
factor	0	O
expressed	0	O
in	0	O
the	0	O
early	0	O
embryo	0	O
,	0	O
is	0	O
regulated	0	O
via	0	O
Oct	1	B
-	0	I
3	0	I
/	0	I
4	0	I
and	0	O
Oct	1	B
-	0	I
6	0	I
binding	0	O
to	0	O
an	0	O
octamer	0	O
site	0	O
and	0	O
a	0	O
novel	0	O
protein	0	O
,	0	O
Rox	0	B
-	0	I
1	0	I
,	0	O
binding	0	O
to	0	O
an	0	O
adjacent	0	O
site	0	O
.	0	O


Serotonin	1	O
levels	0	O
in	0	O
infant	0	O
hypothyroidism	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
the	0	O
QLMI	0	O
questionnaire	0	O
has	0	O
good	0	O
potential	0	O
as	0	O
an	0	O
instrument	0	O
for	0	O
assessing	0	O
QL	0	O
in	0	O
post	0	O
-	0	O
AMI	1	O
patients	0	O
and	0	O
that	0	O
it	0	O
can	0	O
be	0	O
successfully	0	O
self	0	O
-	0	O
administered	0	O
.	0	O


Each	0	O
parent	0	O
interacted	0	O
with	0	O
their	0	O
4	0	O
-	0	O
or	0	O
5	0	O
-	0	O
year	0	O
-	0	O
old	0	O
son	0	O
or	0	O
daughter	0	O
in	0	O
each	0	O
of	0	O
two	0	O
conversations	0	O
--	0	O
unstructured	0	O
(	0	O
social	0	O
conversation	0	O
)	0	O
and	0	O
structured	0	O
(	0	O
task	0	O
activity	0	O
).	0	O


The	0	O
first	0	O
open	0	O
reading	0	O
frame	0	O
of	0	O
the	0	O
blueberry	0	O
scorch	0	O
carlavirus	0	O
(	0	O
BBScV	0	O
)	0	O
genome	0	O
encodes	0	O
a	0	O
putative	0	O
replication	0	O
-	0	O
associated	0	O
protein	0	O
of	0	O
223	0	O
kDa	1	O
(	0	O
p223	0	B
).	0	O


Therefore	0	O
,	0	O
analogs	0	O
of	0	O
vitamin	0	O
D3	0	O
have	0	O
been	0	O
investigated	0	O
in	0	O
a	0	O
number	0	O
of	0	O
trials	0	O
showing	0	O
improvement	0	O
of	0	O
psoriasis	0	O
.	0	O


Strategies	0	O
for	0	O
blood	0	O
screening	0	O
for	0	O
the	0	O
hepatitis	0	O
C	1	O
virus	0	O
and	0	O
for	0	O
the	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
in	0	O
high	0	O
risk	0	O
groups	0	O
.	0	O


This	0	O
site	0	O
is	0	O
upstream	0	O
from	0	O
the	0	O
TATA	0	O
box	0	O
used	0	O
in	0	O
somatic	0	O
cells	0	O
.	0	O


The	0	O
structural	0	O
gene	0	O
for	0	O
copper	0	B
-	0	I
and	0	I
topa	0	I
quinone	0	I
-	0	I
containing	0	I
monoamine	0	I
oxidase	0	I
(	0	O
maoA	0	B
)	0	O
and	0	O
an	0	O
unknown	0	O
amine	0	B
oxidase	0	I
gene	0	I
have	0	O
been	0	O
located	0	O
at	0	O
30	0	O
.	0	O
9	0	O
min	0	O
on	0	O
the	0	O
Escherichia	1	O
coli	0	O
chromosome	0	O
.	0	O


Isolation	1	O
and	0	O
characterization	0	O
of	0	O
the	0	O
rat	0	O
chromosomal	0	O
gene	0	O
for	0	O
a	0	O
polypeptide	0	O
(	0	O
pS1	0	B
)	0	O
antigenically	0	O
related	0	O
to	0	O
statin	0	B
.	0	O


The	0	O
December	0	O
armed	0	O
revolt	0	O
in	0	O
Moscow	0	O
and	0	O
the	0	O
paramedical	0	O
personnel	0	O


SCA	0	B
was	0	O
resistant	0	O
to	0	O
inhibitors	0	O
of	0	O
serine	0	O
,	0	O
aspartyl	0	O
,	0	O
and	0	O
metalloproteases	0	B
,	0	O
but	0	O
it	0	O
was	0	O
sensitive	0	O
to	0	O
N	1	O
-	0	O
ethylmaleimide	0	O
.	0	O


The	0	O
intranodal	0	O
mesothelial	0	O
cells	0	O
occupied	0	O
the	0	O
sinusoids	0	O
of	0	O
the	0	O
lymph	0	O
nodes	0	O
and	0	O
were	0	O
initially	0	O
suspected	0	O
of	0	O
being	0	O
metastatic	0	O
from	0	O
the	0	O
ovarian	0	O
tumor	0	O
in	0	O
each	0	O
case	0	O
.	0	O


Platelet	1	O
number	0	O
and	0	O
life	0	O
span	0	O
were	0	O
determined	0	O
in	0	O
the	0	O
last	0	O
trimester	0	O
of	0	O
pregnancy	0	O
in	0	O
22	0	O
women	0	O
who	0	O
were	0	O
delivered	0	O
of	0	O
small	0	O
-	0	O
for	0	O
-	0	O
gestational	0	O
age	0	O
(	0	O
SGA	1	O
)	0	O
infants	0	O
and	0	O
in	0	O
21	0	O
women	0	O
with	0	O
infants	0	O
having	0	O
normal	0	O
birth	0	O
weights	0	O
.	0	O


Neuronal	1	O
mechanisms	0	O
underlying	0	O
stimulus	0	O
-	0	O
response	0	O
(	0	O
S	1	O
-	0	O
R	1	O
)	0	O
associations	0	O
in	0	O
S	1	O
-	0	O
R	1	O
compatibility	0	O
tasks	0	O
were	0	O
identified	0	O
in	0	O
2	0	O
experiments	0	O
with	0	O
monkeys	0	O
.	0	O


Moreover	0	O
,	0	O
this	0	O
enhancement	0	O
of	0	O
transcriptional	0	O
activation	0	O
by	0	O
COUP	1	B
-	0	I
TFI	0	I
requires	0	O
specifically	0	O
the	0	O
AF	1	O
-	0	O
1	0	O
transactivation	0	O
function	0	O
of	0	O
ER	1	B
and	0	O
can	0	O
be	0	O
observed	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
E2	1	O
or	0	O
4	0	O
-	0	O
hydroxytamoxifen	0	O
but	0	O
not	0	O
ICI	0	O
164384	0	O
.	0	O


Symptoms	0	O
due	0	O
to	0	O
the	0	O
action	0	O
of	0	O
mastocyte	0	O
mediators	0	O
were	0	O
observed	0	O
.	0	O


One	0	O
month	0	O
after	0	O
the	0	O
DTaP	1	O
booster	0	O
vaccination	0	O
,	0	O
both	0	O
groups	0	O
had	0	O
6	0	O
-	0	O
to	0	O
40	0	O
-	0	O
fold	0	O
increases	0	O
in	0	O
serum	0	O
antibody	0	O
concentrations	0	O
to	0	O
all	0	O
antigens	0	O
tested	0	O
;	0	O
the	0	O
concentrations	0	O
against	0	O
the	0	O
three	0	O
pertussis	0	B
antigens	0	I
were	0	O
higher	0	O
in	0	O
the	0	O
DTaP	1	O
-	0	O
primed	0	O
children	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Our	0	O
results	0	O
confirm	0	O
the	0	O
participation	0	O
of	0	O
intron	0	O
1	0	O
in	0	O
transcriptional	0	O
regulation	0	O
of	0	O
the	0	O
c	0	B
-	0	I
myb	0	I
gene	0	I
(	0	O
in	0	O
mouse	0	O
and	0	O
human	0	O
)	0	O
and	0	O
implicate	0	O
multiple	0	O
and	0	O
complex	0	O
regulatory	0	O
mechanisms	0	O
of	0	O
activation	0	O
during	0	O
myelomonocytic	0	O
differentiation	0	O
and	0	O
leukemic	0	O
cell	0	O
growth	0	O
control	0	O
.	0	O


Atomic	1	O
absorption	0	O
spectrophotometry	0	O
applied	0	O
to	0	O
bacterially	0	O
expressed	0	O
E1A	0	B
proteins	0	I
revealed	0	O
that	0	O
the	0	O
289	0	O
-	0	O
amino	0	O
acid	0	O
protein	0	O
binds	0	O
one	0	O
zinc	0	O
ion	0	O
,	0	O
whereas	0	O
the	0	O
243	0	O
-	0	O
amino	0	O
acid	0	O
protein	0	O
binds	0	O
no	0	O
zinc	0	O
.	0	O


Large	0	O
strain	0	O
differences	0	O
were	0	O
found	0	O
for	0	O
all	0	O
variables	0	O
recorded	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.,	0	O
the	0	O
proportion	0	O
of	0	O
attacking	0	O
males	0	O
,	0	O
the	0	O
time	0	O
spent	0	O
in	0	O
the	0	O
brightly	0	O
lit	0	O
box	0	O
,	0	O
and	0	O
the	0	O
number	0	O
of	0	O
transitions	0	O
between	0	O
the	0	O
lit	0	O
and	0	O
the	0	O
dark	0	O
boxes	0	O
.	0	O


Band	1	O
structure	0	O
effects	0	O
of	0	O
transport	0	O
properties	0	O
in	0	O
icosahedral	0	O
quasicrystals	0	O
.	0	O


Furthermore	0	O
,	0	O
loss	0	O
of	0	O
methylation	0	O
also	0	O
greatly	0	O
reduced	0	O
the	0	O
association	0	O
of	0	O
another	0	O
yeast	0	O
B	1	O
-	0	O
type	0	O
subunit	0	O
,	0	O
Rts1p	0	B
.	0	O


Derivatives	0	O
of	0	O
boswellic	0	O
acids	0	O
.	0	O


Bound	1	O
-	0	O
exciton	0	O
transfer	0	O
and	0	O
photoluminescence	0	O
undulation	0	O
spectra	0	O
for	0	O
acceptors	0	O
in	0	O
ZnTe	0	O
.	0	O


Electromobility	0	O
shift	0	O
and	0	O
cotransfection	0	O
assays	0	O
demonstrated	0	O
that	0	O
HNF1alpha	0	B
,	0	O
but	0	O
not	0	O
HNF4	0	B
,	0	O
bound	0	O
to	0	O
its	0	O
cognate	0	O
site	0	O
and	0	O
transactivated	0	O
G6Pase	0	B
gene	0	I
expression	0	O
.	0	O


The	0	O
full	0	O
length	0	O
cDNA	1	O
sequence	0	O
of	0	O
a	0	O
Type	1	B
I	1	I
transforming	0	I
growth	0	I
factor	0	I
-	0	I
beta	0	I
(	0	I
TGF	1	I
-	0	I
beta	0	I
)	0	I
receptor	0	I
has	0	O
been	0	O
isolated	0	O
from	0	O
the	0	O
filarial	0	O
parasitic	0	O
nematode	0	O
Brugia	1	O
pahangi	0	O
.	0	O


Comments	0	O
are	0	O
given	0	O
on	0	O
the	0	O
present	0	O
status	0	O
of	0	O
regulations	0	O
concerning	0	O
water	0	O
in	0	O
swimming	0	O
pools	0	O
and	0	O
baths	0	O
--	0	O
1991	0	O
--(	0	O
in	0	O
connection	0	O
with	0	O
the	0	O
KOK	0	O
regulations	0	O
--	0	O
1972	0	O
--	0	O
and	0	O
the	0	O
Federal	0	O
German	0	O
standard	0	O
[	0	O
DIN	0	O
]	0	O
No	1	O
.	0	O


Refractory	1	O
periods	0	O
of	0	O
the	0	O
AV	1	O
junction	0	O
were	0	O
altered	0	O
in	0	O
a	0	O
comparable	0	O
fashion	0	O
to	0	O
conduction	0	O
through	0	O
the	0	O
AV	1	O
node	0	O
.	0	O


The	0	O
amino	0	O
-	0	O
terminal	0	O
half	0	O
of	0	O
1a	0	B
is	0	O
a	0	O
distant	0	O
homolog	0	B
of	0	I
alphavirus	0	I
nonstructural	0	I
protein	0	I
nsP1	0	I
,	0	O
which	0	O
has	0	O
been	0	O
implicated	0	O
in	0	O
capping	0	O
viral	0	O
RNAs	0	O
.	0	O


Interestingly	0	O
,	0	O
Csx	0	B
/	0	O
Nkx2	0	B
.	0	O


Electron	1	O
microscopic	0	O
and	0	O
enzymatic	0	O
analyses	0	O
revealed	0	O
that	0	O
the	0	O
A118	0	O
genome	0	O
is	0	O
a	0	O
linear	0	O
,	0	O
circularly	0	O
permuted	0	O
,	0	O
terminally	0	O
redundant	0	O
collection	0	O
of	0	O
double	0	O
-	0	O
stranded	0	O
DNA	1	O
molecules	0	O
.	0	O


We	0	O
have	0	O
recently	0	O
discovered	0	O
that	0	O
CCAAAT	0	B
/	0	I
enhancer	0	I
-	0	I
binding	0	I
protein	0	I
-	0	I
beta	0	I
(	0	O
C	1	B
/	0	I
EBP	1	I
-	0	I
beta	0	I
)	0	O
induces	0	O
gene	0	O
transcription	0	O
through	0	O
a	0	O
novel	0	O
IFN	1	B
response	0	I
element	0	I
called	0	O
the	0	O
gamma	0	B
-	0	I
IFN	1	I
-	0	I
activated	0	I
transcriptional	0	I
element	0	I


These	0	O
cells	0	O
were	0	O
able	0	O
to	0	O
present	0	O
influenza	0	O
virus	0	O
particles	0	O
to	0	O
HLA	1	B
-	0	I
DR1	0	I
-	0	O
restricted	0	O
T	1	O
cell	0	O
clones	0	O
.	0	O


Twenty	0	O
-	0	O
one	0	O
ELISA	1	O
-	0	O
positive	0	O
sera	0	O
were	0	O
tested	0	O
and	0	O
confirmed	0	O
positive	0	O
by	0	O
plaque	0	O
reduction	0	O
neutralization	0	O
testing	0	O
.	0	O


Strikingly	0	O
,	0	O
stoichiometric	0	O
association	0	O
of	0	O
p107	0	B
or	0	O
p130	0	B
with	0	O
either	0	O
cyclin	0	B
E	1	I
-	0	O
cdk2	0	B
or	0	O
cyclin	0	B
A	1	I
-	0	O
cdk2	0	B
negated	0	O
the	0	O
activities	0	O
of	0	O
these	0	O
kinases	0	O
.	0	O


Eight	0	O
of	0	O
the	0	O
non	0	O
-	0	O
acceptable	0	O
inlays	0	O
/	0	O
onlays	0	O
and	0	O
five	0	O
of	0	O
the	0	O
direct	0	O
restorations	0	O
were	0	O
replaced	0	O
,	0	O
while	0	O
the	0	O
other	0	O
ones	0	O
were	0	O
repaired	0	O
with	0	O
resin	0	O
composite	0	O
.	0	O


After	0	O
age	0	O
30	0	O
,	0	O
mean	0	O
hemoglobin	0	B
levels	0	O
for	0	O
men	0	O
gradually	0	O
declined	0	O
,	0	O
while	0	O
those	0	O
in	0	O
women	0	O
rose	0	O
,	0	O
so	0	O
that	0	O
the	0	O
sex	0	O
difference	0	O
diminished	0	O
after	0	O
60	0	O
years	0	O
of	0	O
age	0	O
.	0	O


EMSA	0	O
showed	0	O
that	0	O
nuclear	0	O
proteins	0	O
from	0	O
PC12	0	O
but	0	O
not	0	O
C6	1	O
or	0	O
Rat2	0	O
cells	0	O
bind	0	O
the	0	O
CRE	0	O
as	0	O
a	0	O
complex	0	O
containing	0	O
activating	0	B
transcription	0	I
factor	0	I
(	0	I
ATF	0	I
)-	0	I
4	0	I
and	0	O
CCAAT	0	B
enhancer	0	I
-	0	I
binding	0	I
protein	0	I
beta	0	I
,	0	O
while	0	O
both	0	O
PC12	0	O
and	0	O
C6	1	O
cell	0	O
nuclear	0	O
extracts	0	O
were	0	O
recruited	0	O
by	0	O
the	0	O
CCAAT	0	O
-	0	O
box	0	O
as	0	O
a	0	O
complex	0	O
containing	0	O
nuclear	0	B
factor	0	I
Y	1	I
.	0	O


Sterol	1	O
analysis	0	O
of	0	O
the	0	O
disrupted	0	O
mutant	0	O
demonstrated	0	O
the	0	O
accumulation	0	O
of	0	O
ignosterol	0	O
,	0	O
indicating	0	O
a	0	O
loss	0	O
of	0	O
Erg24p	0	B
activity	0	O
.	0	O


Point	1	O
mutations	0	O
of	0	O
the	0	O
site	0	O
that	0	O
suppressed	0	O
Pit	1	B
-	0	I
1	0	I
binding	0	O
in	0	O
vitro	0	O
restored	0	O
full	0	O
tiGH	0	B
promoter	0	I
activity	0	O
.	0	O


A	1	O
small	0	O
amount	0	O
of	0	O
HSP81	0	B
-	0	I
1	0	I
mRNA	1	I
was	0	O
detected	0	O
only	0	O
in	0	O
roots	0	O
.	0	O


Since	0	O
sildenafil	0	O
came	0	O
on	0	O
the	0	O
market	0	O
,	0	O
it	0	O
seems	0	O
that	0	O
the	0	O
place	0	O
of	0	O
MUSE	1	O
is	0	O
reduced	0	O
because	0	O
comparative	0	O
studies	0	O
give	0	O
better	0	O
results	0	O
for	0	O
sildenafil	0	O
than	0	O
MUSE	1	O
(	0	O
70	0	O
%	0	O
vs	0	O
40	0	O
%)	0	O
and	0	O
of	0	O
course	0	O
with	0	O
a	0	O
better	0	O
acceptance	0	O
.	0	O


STUDY	1	O
DESIGN	0	O
.	0	O


Intravenous	1	O
amine	0	O
pressor	0	O
tests	0	O
in	0	O
healthy	0	O
volunteers	0	O
.	0	O


Finally	0	O
,	0	O
antibody	0	O
binding	0	O
to	0	O
site	0	O
IIIa	0	O
on	0	O
the	0	O
hCG	1	B
-	0	I
ectodomain	0	I
complex	0	I
was	0	O
also	0	O
hindered	0	O
by	0	O
an	0	O
anti	0	O
-	0	O
peptide	0	O
mAb	0	O
directed	0	O
against	0	O
a	0	O
peptide	0	O
encoded	0	O
by	0	O
the	0	O
eighth	0	O
exon	0	O
(	0	O
pE	1	O
x	0	O
8	0	O
)	0	O
of	0	O
the	0	O
LHR	0	B
.	0	O


(	0	O
anti	0	B
-	0	I
IIa	0	I
)	0	O
and	0	O
Holmer	0	O
et	0	O
al	0	O
.	0	O


The	0	O
dnaK	0	B
operon	0	I
of	0	I
Bacillus	1	I
subtilis	0	I
is	0	O
heptacistronic	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
three	0	O
mutant	0	O
alleles	0	O
of	0	O
CDC4	0	B
(	0	O
cdc4	0	B
-	0	I
10	0	I
,	0	O
cdc4	0	B
-	0	I
11	0	I
,	0	O
and	0	O
cdc4	0	B
-	0	I
16	0	I
)	0	O
which	0	O
suppress	0	O
the	0	O
nuclear	0	O
division	0	O
defect	0	O
of	0	O
cdc20	0	B
-	0	I
1	0	I
cells	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
capsid	0	B
proteins	0	I
derived	0	O
from	0	O
the	0	O
P1	1	B
precursor	0	I
with	0	O
a	0	O
valine	0	O
substitution	0	O
at	0	O
the	0	O
amino	0	O
terminus	0	O
of	0	O
VP1	0	B
(	0	O
VP1	0	B
-	0	I
G001V	0	I
)	0	O
assembled	0	O
empty	0	O
capsid	0	O
particles	0	O
but	0	O
were	0	O
deficient	0	O
in	0	O
assembling	0	O
RNA	1	O
-	0	O
containing	0	O
virions	0	O
.	0	O


Heart	1	O
rate	0	O
(	0	O
HR	1	O
),	0	O
rectal	0	O
temperature	0	O
(	0	O
Tre	0	O
),	0	O
blood	0	O
pressure	0	O
,	0	O
temperature	0	O
and	0	O
relative	0	O
humidity	0	O
changes	0	O
inside	0	O
clothing	0	O
were	0	O
measured	0	O
on	0	O
18	0	O
professional	0	O
firemen	0	O
(	0	O
mean	0	O
age	0	O
29	0	O
.	0	O
4	0	O
+/-	0	O
7	0	O
.	0	O
4	0	O
yr	0	O
,	0	O
VO2	1	O
max	0	O
41	0	O
.	0	O
4	0	O
+	0	O
8	0	O
.	0	O
8	0	O
ml	0	O
kg	0	O
-	0	O
1	0	O
min	0	O
-	0	O
1	0	O
)	0	O
wearing	0	O
fire	0	O
fighter	0	O
'	0	O
s	0	O
uniforms	0	O
(	0	O
SU	0	O
)	0	O
or	0	O
aluminized	0	O
,	0	O
fire	0	O
resistant	0	O
,	0	O
impermeable	0	O
clothing	0	O
with	0	O
self	0	O
contained	0	O
breathing	0	O
apparatus	0	O
(	0	O
FE	1	O
).	0	O


No	1	O
direct	0	O
repeats	0	O
flank	0	O
the	0	O
pseudogene	0	O
in	0	O
the	0	O
U2	0	B
/	0	I
4	0	I
locus	0	I
.	0	O


The	0	O
experimentally	0	O
mapped	0	O
regions	0	O
of	0	O
RPB5	0	B
involved	0	O
in	0	O
these	0	O
interactions	0	O
correspond	0	O
to	0	O
distinct	0	O
and	0	O
surface	0	O
-	0	O
exposed	0	O
alpha	0	O
-	0	O
helical	0	O
structures	0	O
.	0	O


Finger	1	B
associated	0	I
box	0	I
-	0	I
zinc	0	I
finger	0	I
proteins	0	I
(	0	O
FAX	0	B
-	0	I
ZFPs	0	I
)	0	O
constitute	0	O
a	0	O
subfamily	0	O
of	0	O
the	0	O
many	0	O
C2H2	1	B
type	0	I
ZFPs	0	I
in	0	O
Xenopus	1	O
laevis	0	O
.	0	O


We	0	O
suggest	0	O
that	0	O
MotA	0	B
and	0	O
AsiA	1	B
may	0	O
function	0	O
like	0	O
certain	0	O
eukaryotic	0	B
TAFs	0	I
(	0	O
TATA	0	B
binding	0	I
protein	0	I
(	0	I
TBP	1	I
)	0	I
associated	0	I
factors	0	I
)	0	O
whose	0	O
binding	0	O
to	0	O
TBP	1	B
results	0	O
in	0	O
transcription	0	O
from	0	O
new	0	O
core	0	O
promoter	0	O
sequences	0	O
.	0	O


After	0	O
90	0	O
d	0	O
a	0	O
subsurface	0	O
,	0	O
radiolucent	0	O
caries	0	O
-	0	O
like	0	O
lesion	0	O
was	0	O
observed	0	O
in	0	O
two	0	O
specimens	0	O
only	0	O
.	0	O


This	0	O
suggests	0	O
roles	0	O
for	0	O
both	0	O
the	0	O
CE1	0	O
and	0	O
CE2	0	O
elements	0	O
in	0	O
regulating	0	O
Hoxb1	0	B
gene	0	I
expression	0	O
during	0	O
development	0	O
.	0	O


Sequencing	1	O
the	0	O
gene	0	O
for	0	O
an	0	O
imipenem	0	O
-	0	O
cefoxitin	0	O
-	0	O
hydrolyzing	0	O
enzyme	0	O
(	0	O
CfiA	0	B
)	0	O
from	0	O
Bacteroides	1	O
fragilis	0	O
TAL2480	0	O
reveals	0	O
strong	0	O
similarity	0	O
between	0	O
CfiA	0	B
and	0	O
Bacillus	1	B
cereus	0	I
beta	0	I
-	0	I
lactamase	0	I
II	0	I
.	0	O


The	0	O
DNA	1	O
binding	0	O
domain	0	O
of	0	O
NirA	0	B
was	0	O
expressed	0	O
as	0	O
a	0	O
fusion	0	O
protein	0	O
with	0	O
the	0	O
glutathione	0	B
S	1	I
-	0	I
transferase	0	I
of	0	O
Schistosoma	1	O
japonicum	0	O
.	0	O


The	0	O
front	0	O
(	0	O
F	1	O
)	0	O
interaction	0	O
occurs	0	O
ahead	0	O
of	0	O
the	0	O
growing	0	O
end	0	O
of	0	O
RNA	1	O
.	0	O


At	1	O
the	0	O
end	0	O
of	0	O
the	0	O
experiment	0	O
the	0	O
urinary	0	O
porphyrin	0	O
excretion	0	O
and	0	O
the	0	O
porphyrin	0	O
content	0	O
in	0	O
lijver	0	O
and	0	O
skin	0	O
were	0	O
diminished	0	O
in	0	O
HCB	0	O
-	0	O
CQ	0	O
-	0	O
treated	0	O
animals	0	O
by	0	O
about	0	O
50	0	O
%	0	O
compared	0	O
to	0	O
the	0	O
HCB	0	O
controls	0	O
.	0	O


Lengthy	0	O
and	0	O
repeated	0	O
hemodialyses	0	O
were	0	O
required	0	O
to	0	O
lower	0	O
lithemia	0	O
to	0	O
nontoxic	0	O
ranges	0	O
.	0	O


Also	0	O
,	0	O
the	0	O
amplitude	0	O
of	0	O
the	0	O
oscillatory	0	O
potentials	0	O
(	0	O
O1	0	O
+	0	O
O2	1	O
+	0	O
O3	1	O
+	0	O
O4	0	O
)	0	O
was	0	O
significantly	0	O
reduced	0	O
in	0	O
the	0	O
early	0	O
postoperative	0	O
period	0	O
.	0	O


For	0	O
this	0	O
purpose	0	O
,	0	O
we	0	O
used	0	O
a	0	O
series	0	O
of	0	O
plasmid	0	O
constructs	0	O
encoding	0	O
different	0	O
forms	0	O
of	0	O
the	0	O
envelope	0	B
glycoprotein	0	I
E	1	I
of	0	I
the	0	I
flavivirus	0	I
tick	0	I
-	0	I
borne	0	I
encephalitis	0	I
virus	0	I
.	0	O


These	0	O
results	0	O
suggest	0	O
KCC3	0	B
is	0	O
a	0	O
new	0	O
member	0	O
of	0	O
the	0	O
KCC	0	B
family	0	I
that	0	O
is	0	O
under	0	O
distinct	0	O
regulation	0	O
from	0	O
KCC1	0	B
.	0	O


Maternal	1	O
lactation	0	O


The	0	O
tissue	0	O
-	0	O
specific	0	O
expression	0	O
of	0	O
DP	1	B
family	0	I
members	0	I
suggests	0	O
that	0	O
the	0	O
combination	0	O
of	0	O
DP	1	B
/	0	O
E2F	0	B
heterodimers	0	O
that	0	O
constitute	0	O
DRTF1	0	B
/	0	O
E2F	0	B
is	0	O
influenced	0	O
by	0	O
the	0	O
phenotype	0	O
of	0	O
the	0	O
cell	0	O
.	0	O


One	0	O
of	0	O
these	0	O
small	0	B
inteins	0	I
might	0	O
be	0	O
inactive	0	O
or	0	O
a	0	O
"	0	B
pseudo	0	I
intein	0	I
."	0	I
The	0	O
results	0	O
suggest	0	O
a	0	O
modular	0	O
architecture	0	O
for	0	O
inteins	0	B
,	0	O
clarify	0	O
their	0	O
origin	0	O
and	0	O
relationship	0	O
to	0	O
other	0	O
protein	0	O
families	0	O
,	0	O
and	0	O
extend	0	O
recent	0	O
experimental	0	O
findings	0	O
on	0	O
the	0	O
functional	0	O
roles	0	O
of	0	O
intein	0	B
N	1	I
,	0	I
C	1	I
,	0	I
and	0	I
EN	0	I
motifs	0	I
.	0	O


Removal	0	O
of	0	O
each	0	O
of	0	O
three	0	O
contiguous	0	O
segments	0	O
from	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
half	0	O
specifically	0	O
inhibits	0	O
the	0	O
formation	0	O
of	0	O
5	0	B
.	0	I
8Ss	0	I
rRNA	1	I
,	0	O
whereas	0	O
deleting	0	O
part	0	O
of	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
of	0	O
the	0	O
protein	0	O
only	0	O
blocks	0	O
the	0	O
production	0	O
of	0	O
18S	0	B
rRNA	1	I
.	0	O


Tih1	0	B
maps	0	O
to	0	O
distal	0	O
mouse	0	O
Chr	1	O
1	0	O
and	0	O
human	0	O
Chr	1	O
1q31	0	O
,	0	O
chromosomal	0	O
regions	0	O
that	0	O
have	0	O
not	0	O
shown	0	O
evidence	0	O
for	0	O
imprinting	0	O
and	0	O
,	0	O
in	0	O
contrast	0	O
to	0	O
Ipl	1	B
,	0	O
Tih1	0	B
is	0	O
expressed	0	O
equally	0	O
from	0	O
both	0	O
parental	0	O
alleles	0	O
.	0	O


Enhancers	0	O
containing	0	O
disrupted	0	O
Ets	1	B
-	0	I
1	0	I
binding	0	I
sites	0	I
were	0	O
tested	0	O
in	0	O
transient	0	O
expression	0	O
assays	0	O
in	0	O
the	0	O
murine	0	O
T	1	O
-	0	O
cell	0	O
line	0	O
EL4	0	O
.	0	O
E1	1	O
;	0	O
alterations	0	O
in	0	O
the	0	O
LVb	0	O
element	0	O
affected	0	O
constitutive	0	O
enhancer	0	O
activity	0	O
,	0	O
while	0	O
mutation	0	O
of	0	O
either	0	O
the	0	O
LVb	0	O
or	0	O
LVc	0	O
element	0	O
disrupted	0	O
phorbol	0	O
ester	0	O
-	0	O
induced	0	O
enhancer	0	O
activity	0	O
.	0	O


Electrochemical	1	O
detection	0	O
of	0	O
depressed	0	O
circulating	0	O
levels	0	O
of	0	O
vitamin	0	O
K1	0	O
in	0	O
osteoporosis	0	O
.	0	O


All	1	O
patients	0	O
diagnosed	0	O
of	0	O
H	1	O
.	0	O
influenza	0	O
type	0	O
b	0	O
meningitis	0	O
were	0	O
less	0	O
than	0	O
3	0	O
years	0	O
old	0	O
.	0	O


One	0	O
chimpanzee	0	O
reliably	0	O
selected	0	O
the	0	O
larger	0	O
numeral	0	O
4	0	O
during	0	O
testing	0	O
with	0	O
a	0	O
nonadjacent	0	O
pair	0	O
(	0	O
2	0	O
-	0	O
4	0	O
),	0	O
and	0	O
2	0	O
chimps	0	O
showed	0	O
no	0	O
preference	0	O
.	0	O


Deleting	0	O
SNF1	0	B
repressed	0	O
meiosis	0	O
at	0	O
the	0	O
same	0	O
three	0	O
steps	0	O
that	0	O
were	0	O
inhibited	0	O
by	0	O
glucose	0	O
,	0	O
suggesting	0	O
that	0	O
glucose	0	O
blocks	0	O
meiosis	0	O
by	0	O
inhibiting	0	O
Snf1	0	B
.	0	O


There	0	O
are	0	O
regions	0	O
with	0	O
long	0	O
runs	0	O
of	0	O
up	0	O
to	0	O
45	0	O
%	0	O
C	1	O
or	0	O
35	0	O
%	0	O
G	1	O
residues	0	O
.	0	O


Levels	0	O
of	0	O
both	0	O
PGF	0	O
and	0	O
PGFM	0	O
were	0	O
significantly	0	O
higher	0	O
during	0	O
early	0	O
spontaneous	0	O
labour	0	O
,	0	O
at	0	O
a	0	O
cervical	0	O
dilatation	0	O
of	0	O
less	0	O
than	0	O
4	0	O
cm	0	O
,	0	O
than	0	O
before	0	O
the	0	O
onset	0	O
of	0	O
labour	0	O
.	0	O


To	1	O
explore	0	O
the	0	O
mechanism	0	O
of	0	O
RSK	0	B
activation	0	O
,	0	O
a	0	O
cloned	0	O
human	0	O
RSK	0	B
cDNA	1	O
(	0	O
RSK3	0	B
)	0	O
was	0	O
used	0	O
to	0	O
generate	0	O
and	0	O
characterize	0	O
several	0	O
site	0	O
-	0	O
directed	0	O
RSK	0	B
mutants	0	I
;	0	O
K91A	0	O
(	0	O
N	1	O
-	0	O
Lys	1	O
,	0	O
NH2	0	O
-	0	O
terminal	0	O
ATP	1	O
-	0	O
binding	0	O
mutant	0	O
),	0	O
K444A	0	O
(	0	O
C	1	O
-	0	O
Lys	1	O
,	0	O
COOH	0	O
-	0	O
terminal	0	O
ATP	1	O
-	0	O
binding	0	O
mutant	0	O
),	0	O
N	1	O
/	0	O
C	1	O
-	0	O
Lys	1	O
(	0	O
double	0	O
ATP	1	O
-	0	O
binding	0	O
mutant	0	O
)	0	O
T570A	0	O
(	0	O
C	1	O
-	0	O
Thr	1	O
,	0	O
mutant	0	O
of	0	O
the	0	O
putative	0	O
MAPK	1	B
phosphorylation	0	O
site	0	O
in	0	O
subdomain	0	O
VIII	0	O
of	0	O
the	0	O
C	1	O
-	0	O
domain	0	O
),	0	O
S218A	0	O
(	0	O
N	1	O
-	0	O
Ser	1	O
,	0	O
mutant	0	O
of	0	O
the	0	O
corresponding	0	O
NH2	0	O
-	0	O
terminal	0	O
residue	0	O
).	0	O


The	0	O
approach	0	O
derives	0	O
from	0	O
a	0	O
recently	0	O
described	0	O
strategy	0	O
for	0	O
making	0	O
recombinants	0	O
from	0	O
five	0	O
overlapping	0	O
EBV	1	O
cosmid	0	O
-	0	O
cloned	0	O
DNAs	0	O
(	0	O
B	1	O
.	0	O


One	0	O
hundred	0	O
units	0	O
/	0	O
kg	0	O
of	0	O
recombinant	0	B
human	0	I
erythropoietin	0	I
(	0	O
rhEPO	0	B
)	0	O
was	0	O
given	0	O
subcutaneously	0	O
3	0	O
times	0	O
a	0	O
week	0	O
for	0	O
3	0	O
weeks	0	O
.	0	O


Unrecognized	0	O
amnionitis	0	O
and	0	O
prematurity	0	O
:	0	O
a	0	O
preliminary	0	O
report	0	O
.	0	O


RESULTS	0	O
:	0	O
An	1	O
herpetic	0	O
seroconversion	0	O
is	0	O
observed	0	O
with	0	O
presence	0	O
of	0	O
type	0	O
I	1	O
herpes	0	O
simplex	0	O
virus	0	O
(	0	O
HSV	1	O
I	1	O
)	0	O
nucleic	0	O
acids	0	O
in	0	O
the	0	O
recipient	0	O
'	0	O
s	0	O
aqueous	0	O
humor	0	O
.	0	O


Subsequent	0	O
experiments	0	O
showed	0	O
that	0	O
motoric	0	O
tasks	0	O
rather	0	O
than	0	O
cognitive	0	O
aspects	0	O
of	0	O
the	0	O
COWA	0	O
task	0	O
were	0	O
critical	0	O
in	0	O
potentiating	0	O
finger	0	O
-	0	O
tapping	0	O
performance	0	O
.	0	O


The	0	O
capacity	0	O
to	0	O
repair	0	O
8	0	O
-	0	O
OxoG	0	O
has	0	O
been	0	O
measured	0	O
in	0	O
cell	0	O
-	0	O
free	0	O
extracts	0	O
of	0	O
wild	0	O
-	0	O
type	0	O
and	0	O
ogg1	0	B
strains	0	O
using	0	O
a	0	O
34mer	0	O
DNA	1	O
fragment	0	O
containing	0	O
a	0	O
single	0	O
8	0	O
-	0	O
OxoG	0	O
residue	0	O
paired	0	O
with	0	O
a	0	O
cytosine	0	O
(	0	O
8	0	O
-	0	O
OxoG	0	O
/	0	O
C	1	O
)	0	O
as	0	O
a	0	O
substrate	0	O
.	0	O


An	1	O
evolutionary	0	O
conserved	0	O
element	0	O
is	0	O
essential	0	O
for	0	O
somite	0	O
and	0	O
adjacent	0	O
mesenchymal	0	O
expression	0	O
of	0	O
the	0	O
Hoxa1	0	B
gene	0	I
.	0	O


The	0	O
drug	0	O
-	0	O
resistant	0	O
cell	0	O
lines	0	O
P388	0	O
/	0	O
ADR	1	O
/	0	O
3	0	O
and	0	O
P388	0	O
/	0	O
ADR	1	O
/	0	O
7	0	O
express	0	O
a	0	O
shortened	0	O
topo	0	B
II	0	I
alpha	0	I
mRNA	1	I
transcript	0	I
in	0	O
addition	0	O
to	0	O
the	0	O
native	0	O
transcript	0	O
present	0	O
in	0	O
the	0	O
drug	0	O
-	0	O
sensitive	0	O
P388	0	O
/	0	O
4	0	O
cell	0	O
line	0	O
.	0	O


In	1	O
vitro	0	O
,	0	O
Arix	0	B
and	0	O
NBPhox	0	B
form	0	O
DNA	1	O
-	0	O
independent	0	O
multimers	0	O
and	0	O
exhibit	0	O
cooperative	0	O
binding	0	O
to	0	O
the	0	O
DB1	0	B
regulatory	0	I
element	0	I
,	0	O
which	0	O
contains	0	O
two	0	O
homeodomain	0	B
recognition	0	I
sites	0	I
.	0	O


The	0	O
method	0	O
was	0	O
adapted	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
nadolol	0	O
racemate	0	O
A	1	O
by	0	O
a	0	O
change	0	O
in	0	O
mobile	0	O
phase	0	O
composition	0	O
.	0	O


After	0	O
28	0	O
days	0	O
of	0	O
haloperidol	0	O
treatment	0	O
,	0	O
similar	0	O
changes	0	O
were	0	O
observed	0	O
for	0	O
delta	0	O
,	0	O
together	0	O
with	0	O
an	0	O
increase	0	O
of	0	O
alpha	0	O
1	0	O
,	0	O
and	0	O
a	0	O
decrease	0	O
of	0	O
fast	0	O
beta	0	O
.	0	O


The	0	O
phenotypes	0	O
of	0	O
the	0	O
ICP0	0	B
nonsense	0	O
mutants	0	O
were	0	O
intermediate	0	O
between	0	O
those	0	O
of	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
virus	0	O
and	0	O
7134	0	O
in	0	O
that	0	O
the	0	O
more	0	O
ICP0	0	B
-	0	I
coding	0	I
sequence	0	I
expressed	0	O
by	0	O
a	0	O
given	0	O
nonsense	0	O
mutant	0	O
,	0	O
the	0	O
more	0	O
wild	0	O
type	0	O
-	0	O
like	0	O
was	0	O
its	0	O
phenotype	0	O
.	0	O


The	0	O
sequences	0	O
showed	0	O
extensive	0	O
homologies	0	O
with	0	O
squalene	0	B
synthase	0	I
genes	0	I
and	0	O
enzymes	0	O
from	0	O
a	0	O
number	0	O
of	0	O
other	0	O
organisms	0	O
and	0	O
extreme	0	O
amino	0	O
acid	0	O
conservation	0	O
within	0	O
the	0	O
binding	0	O
and	0	O
catalytic	0	O
domains	0	O
.	0	O


The	0	O
results	0	O
strongly	0	O
support	0	O
the	0	O
notion	0	O
that	0	O
the	0	O
OBF1	0	B
-	0	I
binding	0	I
sites	0	I
and	0	O
the	0	O
OBF1	0	B
protein	0	I
are	0	O
important	0	O
for	0	O
normal	0	O
ARS	1	O
function	0	O
as	0	O
an	0	O
origin	0	O
of	0	O
replication	0	O
.	0	O


Furthermore	0	O
,	0	O
competitor	0	O
containing	0	O
the	0	O
YY1	0	B
consensus	0	I
sequence	0	I
competed	0	O
for	0	O
protein	0	B
B	1	I
binding	0	O
,	0	O
whereas	0	O
competitor	0	O
containing	0	O
a	0	O
perfect	0	O
yeast	0	B
ABF	0	I
-	0	I
1	0	I
consensus	0	I
sequence	0	I
did	0	O
not	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
400	0	O
WORDS	0	O
)	0	O


During	0	O
IC	1	O
breaths	0	O
and	0	O
following	0	O
EC	1	O
and	0	O
VC	1	O
breaths	0	O
at	0	O
rest	0	O
,	0	O
end	0	O
-	0	O
tidal	0	O
CO2	1	O
pressure	0	O
(	0	O
PET	1	O
,	0	O
CO2	1	O
)	0	O
fell	0	O
by	0	O
7	0	O
.	0	O
5	0	O
,	0	O
8	0	O
.	0	O
5	0	O
and	0	O
9	0	O
.	0	O
5	0	O
mmHg	0	O
,	0	O
respectively	0	O
.	0	O


Point	1	O
mutations	0	O
of	0	O
the	0	O
five	0	O
tyrosine	0	O
residues	0	O
in	0	O
the	0	O
cytoplasmic	0	O
domain	0	O
of	0	O
the	0	O
receptor	0	O
were	0	O
subsequently	0	O
used	0	O
to	0	O
confirm	0	O
our	0	O
conclusions	0	O
.	0	O


The	0	O
BAL	1	O
-	0	O
to	0	O
-	0	O
plasma	0	O
specific	0	O
activity	0	O
of	0	O
urea	0	O
was	0	O
about	0	O
twice	0	O
that	0	O
of	0	O
Na	1	O
+,	0	O
indicating	0	O
that	0	O
urea	0	O
diffused	0	O
into	0	O
the	0	O
ELF	0	O
more	0	O
rapidly	0	O
than	0	O
Na	1	O
+	0	O
during	0	O
the	0	O
70	0	O
s	0	O
that	0	O
elapsed	0	O
between	0	O
the	0	O
time	0	O
the	0	O
radioactive	0	O
urea	0	O
and	0	O
Na	1	O
+	0	O
were	0	O
injected	0	O
into	0	O
the	0	O
circulation	0	O
and	0	O
the	0	O
time	0	O
when	0	O
lavage	0	O
was	0	O
complete	0	O
.	0	O


RESULTS	0	O
:	0	O
In	1	O
the	0	O
AGA	1	O
group	0	O
,	0	O
both	0	O
fetal	0	O
and	0	O
maternal	0	O
serum	0	O
prolactin	0	B
concentration	0	O
increased	0	O
significantly	0	O
with	0	O
gestation	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
and	0	O
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
,	0	O
respectively	0	O
).	0	O


Indeed	0	O
,	0	O
A	1	O
-	0	O
MuLV	0	O
pseudotyped	0	O
with	0	O
some	0	O
viruses	0	O
,	0	O
such	0	O
as	0	O
the	0	O
Moloney	0	O
MuLV	0	O
,	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
highly	0	O
lymphogenic	0	O
,	0	O
whereas	0	O
A	1	O
-	0	O
MuLV	0	O
pseudotyped	0	O
with	0	O
other	0	O
viruses	0	O
,	0	O
such	0	O
as	0	O
the	0	O
BALB	0	O
/	0	O
c	0	O
endogenous	0	O
N	1	O
-	0	O
tropic	0	O
MuLV	0	O
,	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
be	0	O
devoid	0	O
of	0	O
lymphogenic	0	O
potential	0	O
(	0	O
N	1	O
.	0	O


Five	0	O
families	0	O
of	0	O
Ashkenazi	0	O
Jewish	0	O
descent	0	O
carried	0	O
the	0	O
185delAG	0	O
mutation	0	O
and	0	O
shared	0	O
the	0	O
same	0	O
haplotype	0	O
at	0	O
eight	0	O
polymorphic	0	O
markers	0	O
spanning	0	O
approximately	0	O
850	0	O
kb	0	O
at	0	O
BRCA1	0	B
.	0	O


Therefore	0	O
,	0	O
we	0	O
have	0	O
named	0	O
this	0	O
gene	0	O
UBP43	0	B
.	0	O


Immunostaining	1	O
of	0	O
cells	0	O
transfected	0	O
with	0	O
these	0	O
constructs	0	O
revealed	0	O
that	0	O
both	0	O
the	0	O
myristoylated	0	O
and	0	O
nonmyristoylated	0	O
mutants	0	O
were	0	O
localized	0	O
in	0	O
nuclei	0	O
,	0	O
whereas	0	O
wild	0	B
-	0	I
type	0	I
PKC	0	I
alpha	0	I
was	0	O
primarily	0	O
cytoplasmic	0	O
and	0	O
perinuclear	0	O
.	0	O


The	0	O
cop	0	B
region	0	I
also	0	O
harbors	0	O
a	0	O
region	0	O
of	0	O
plasmid	0	O
incompatibility	0	O
,	0	O
inc	0	B
,	0	O
encompassing	0	O
a	0	O
stem	0	O
-	0	O
loop	0	O
structure	0	O
,	0	O
the	0	O
repA	0	B
promoter	0	I
,	0	O
Prep	1	B
,	0	O
as	0	O
well	0	O
as	0	O
two	0	O
distinct	0	O
RepA	0	B
binding	0	I
sites	0	I
,	0	O
BD	1	O
-	0	O
1	0	O
and	0	O
BD	1	O
-	0	O
2	0	O
.	0	O


This	0	O
information	0	O
,	0	O
together	0	O
with	0	O
estimation	0	O
of	0	O
the	0	O
size	0	O
of	0	O
the	0	O
deglycosylated	0	O
A	1	O
subunit	0	O
relative	0	O
to	0	O
a	0	O
series	0	O
of	0	O
C	1	B
-	0	I
terminal	0	I
truncated	0	I
TSHR	0	I
ectodomain	0	I
variants	0	I
,	0	O
places	0	O
cleavage	0	O
Site	1	O
1	0	O
in	0	O
the	0	O
vicinity	0	O
of	0	O
,	0	O
or	0	O
closely	0	O
upstream	0	O
to	0	O
,	0	O
residue	0	O
317	0	O
.	0	O


The	0	O
role	0	O
of	0	O
ascorbic	0	O
acid	0	O
in	0	O
the	0	O
prevention	0	O
of	0	O
bladder	0	O
tumor	0	O
formation	0	O
.	0	O


(	0	O
LH	1	B
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
,	0	O
LH	1	B
/	0	O
FSH	1	B
P	1	O
<	0	O
0	0	O
.	0	O
01	0	O
).	0	O


We	0	O
have	0	O
addressed	0	O
these	0	O
issues	0	O
by	0	O
reconstituting	0	O
and	0	O
characterizing	0	O
the	0	O
KRAB	0	B
:	0	O
KAP	0	B
-	0	I
1	0	I
-	0	O
RBCC	0	B
interaction	0	O
using	0	O
purified	0	O
components	0	O
.	0	O


Chemical	1	O
constituents	0	O
of	0	O
the	0	O
gentianaceae	0	O
V	1	O
:	0	O
tetraoxygenated	0	O
xanthones	0	O
of	0	O
Swertia	0	O
chirata	0	O
Buch	0	O
.-	0	O
Ham	1	O
.	0	O


Montelukast	1	O
reduces	0	O
airway	0	O
eosinophilic	0	O
inflammation	0	O
in	0	O
asthma	0	O
:	0	O
a	0	O
randomized	0	O
,	0	O
controlled	0	O
trial	0	O
.	0	O


We	0	O
have	0	O
obtained	0	O
the	0	O
human	0	B
EP4	0	I
receptor	0	I
gene	0	I
sequence	0	I
and	0	O
determined	0	O
its	0	O
structure	0	O
relative	0	O
to	0	O
EP4R	0	B
cDNA	1	I
synthesized	0	O
from	0	O
peripheral	0	O
blood	0	O
lymphocytes	0	O
.	0	O


Protein	1	B
cHMGI	0	I
binds	0	O
preferentially	0	O
to	0	O
AT	1	O
-	0	O
rich	0	O
DNA	1	O
with	0	O
a	0	O
half	0	O
-	0	O
saturation	0	O
value	0	O
of	0	O
1	0	O
.	0	O
1	0	O
nM	1	O
.	0	O


Surprisingly	0	O
,	0	O
the	0	O
results	0	O
of	0	O
several	0	O
experiments	0	O
suggest	0	O
that	0	O
the	0	O
TSF	1	B
genes	0	I
encode	0	O
global	0	O
regulatory	0	O
factors	0	O
.	0	O
tsf1	0	B
to	0	O
tsf6	0	B
mutations	0	O
derepressed	0	O
expression	0	O
from	0	O
yeast	0	O
CYC	1	B
-	0	O
GAL	0	B
hybrid	0	O
promoters	0	O
(	0	O
fused	0	O
to	0	O
lacZ	0	B
)	0	O
that	0	O
harbor	0	O
a	0	O
variety	0	O
of	0	O
operator	0	O
sequences	0	O
,	0	O
and	0	O
caused	0	O
pleiotropic	0	O
defects	0	O
in	0	O
cell	0	O
growth	0	O
,	0	O
mating	0	O
,	0	O
and	0	O
sporulation	0	O
.	0	O


KEY	1	O
WORDS	0	O
:	0	O
Melaleuca	1	O
;	0	O
Lake	1	O
Okeechobee	0	O
;	0	O
Littoral	1	O
zone	0	O
;	0	O
Water	1	O
level	0	O
;	0	O
Regulation	1	O
schedule	0	O


These	0	O
six	0	O
districts	0	O
have	0	O
an	0	O
area	0	O
of	0	O
34	0	O
,	0	O
000	0	O
km2	0	O
and	0	O
hold	0	O
a	0	O
population	0	O
of	0	O
30	0	O
million	0	O
.	0	O


Widening	0	O
of	0	O
the	0	O
abdominal	0	O
aortic	0	O
wall	0	O
on	0	O
an	0	O
ultrasound	0	O
examination	0	O
was	0	O
the	0	O
key	0	O
to	0	O
the	0	O
incidental	0	O
diagnosis	0	O
of	0	O
a	0	O
clinically	0	O
unsuspected	0	O
type	0	O
B	1	O
dissection	0	O
.	0	O


The	0	O
patient	0	O
was	0	O
a	0	O
78	0	O
-	0	O
year	0	O
-	0	O
old	0	O
male	0	O
in	0	O
whom	0	O
skin	0	O
lesions	0	O
preceded	0	O
the	0	O
diagnosis	0	O
of	0	O
myelofibrosis	0	O
.	0	O


At	1	O
cuticular	0	O
positions	0	O
exhibiting	0	O
the	0	O
Brd	0	B
bristle	0	I
loss	0	I
phenotype	0	I
,	0	O
we	0	O
have	0	O
found	0	O
that	0	O
the	0	O
progeny	0	O
of	0	O
the	0	O
multiplied	0	O
SOPs	0	O
develop	0	O
aberrantly	0	O
,	0	O
in	0	O
that	0	O
neurons	0	O
and	0	O
thecogen	0	O
(	0	O
sheath	0	O
)	0	O
cells	0	O
appear	0	O
but	0	O
not	0	O
trichogen	0	O
(	0	O
shaft	0	O
)	0	O
and	0	O
tormogen	0	O
(	0	O
socket	0	O
)	0	O
cells	0	O
.	0	O


Marrow	1	O
cell	0	O
necrosis	0	O
in	0	O
anorexia	0	O
nervosa	0	O
and	0	O
involuntary	0	O
starvation	0	O
.	0	O


Results	0	O
for	0	O
men	0	O
who	0	O
drank	0	O
up	0	O
to	0	O
two	0	O
drinks	0	O
per	0	O
day	0	O
suggest	0	O
that	0	O
if	0	O
the	0	O
dependence	0	O
criteria	0	O
were	0	O
invalid	0	O
,	0	O
reductions	0	O
in	0	O
the	0	O
prevalence	0	O
of	0	O
specific	0	O
indicators	0	O
of	0	O
alcohol	0	O
dependence	0	O
would	0	O
range	0	O
from	0	O
0	0	O
.	0	O
3	0	O
%	0	O
to	0	O
5	0	O
.	0	O
2	0	O
%.	0	O


265	0	O
,	0	O
1102	0	O
-	0	O
1110	0	O
).	0	O


Detailed	0	O
analysis	0	O
of	0	O
alpha1	0	B
,	0	I
3GT	0	I
transcripts	0	I
revealed	0	O
two	0	O
major	0	O
alternative	0	O
splicing	0	O
patterns	0	O
in	0	O
the	0	O
5	0	O
'-	0	O
untranslated	0	O
region	0	O
(	0	O
5	0	O
'-	0	O
UTR	0	O
)	0	O
and	0	O
evidence	0	O
for	0	O
minor	0	O
splicing	0	O
activity	0	O
that	0	O
occurs	0	O
in	0	O
a	0	O
tissue	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


To	1	O
address	0	O
mechanisms	0	O
that	0	O
define	0	O
interactions	0	O
of	0	O
Site	1	B
II	0	I
regulatory	0	I
factors	0	I
with	0	O
this	0	O
cell	0	O
cycle	0	O
control	0	O
element	0	O
,	0	O
we	0	O
have	0	O
investigated	0	O
these	0	O
determinants	0	O
of	0	O
transcriptional	0	O
regulation	0	O
at	0	O
the	0	O
G1	0	O
/	0	O
S	1	O
phase	0	O
transition	0	O
in	0	O
FDC	0	O
-	0	O
P1	1	O
hematopoietic	0	O
progenitor	0	O
cells	0	O
.	0	O


After	0	O
6	0	O
h	0	O
of	0	O
reperfusion	0	O
,	0	O
PO2	1	O
/	0	O
FlO2	0	O
ratio	0	O
was	0	O
significantly	0	O
better	0	O
after	0	O
Combined	0	O
Therapy	1	O
(	0	O
372	0	O
+/-	0	O
52	0	O
mm	0	O
Hg	1	O
)	0	O
than	0	O
in	0	O
the	0	O
Recipient	1	O
Instilled	0	O
(	0	O
117	0	O
+/-	0	O
47	0	O
mm	0	O
Hg	1	O
)	0	O
and	0	O
Control	1	O
groups	0	O
(	0	O
87	0	O
+/-	0	O
26	0	O
mm	0	O
Hg	1	O
),	0	O
with	0	O
intermediate	0	O
values	0	O
in	0	O
Donor	1	O
Aerosol	1	O
dogs	0	O
(	0	O
232	0	O
+/-	0	O
64	0	O
mm	0	O
Hg	1	O
).	0	O


Although	0	O
the	0	O
Src	1	B
tyrosine	0	I
kinase	0	I
induces	0	O
constitutive	0	O
Stat3	0	B
phosphorylation	0	O
on	0	O
tyrosine	0	O
,	0	O
activation	0	O
of	0	O
Stat3	0	B
-	0	O
mediated	0	O
gene	0	O
regulation	0	O
requires	0	O
both	0	O
tyrosine	0	O
and	0	O
serine	0	O
phosphorylation	0	O
of	0	O
Stat3	0	B
.	0	O


We	0	O
conclude	0	O
that	0	O
sequences	0	O
outside	0	O
of	0	O
the	0	O
hLEF	0	B
HMG	1	I
box	0	I
mediate	0	O
cell	0	O
-	0	O
and	0	O
context	0	O
-	0	O
specific	0	O
activation	0	O
of	0	O
the	0	O
TCR	1	B
alpha	0	I
enhancer	0	I
and	0	O
may	0	O
facilitate	0	O
interactions	0	O
between	0	O
hLEF	0	B
and	0	O
other	0	O
T	1	O
-	0	O
cell	0	O
-	0	O
specific	0	O
factors	0	O
recruited	0	O
to	0	O
the	0	O
enhancer	0	O
.	0	O


The	0	O
ratio	0	O
of	0	O
P	1	O
-	0	O
31	0	O
NMR	1	O
-	0	O
S	1	O
derived	0	O
inorganic	0	O
phosphates	0	O
[	0	O
Pi	1	O
]	0	O
to	0	O
phosphocreatine	0	O
[	0	O
PCr	1	O
]	0	O
was	0	O
significantly	0	O
greater	0	O
at	0	O
rest	0	O
in	0	O
LVH	1	O
baboons	0	O
[	0	O
0	0	O
.	0	O
53	0	O
+/-	0	O
0	0	O
.	0	O
06	0	O
versus	0	O
controls	0	O
=	0	O
0	0	O
.	0	O
41	0	O
+/-	0	O
0	0	O
.	0	O
17	0	O
;	0	O
P	1	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
].	0	O


The	0	O
gene	0	B
cat	0	I
-	0	I
86	0	I
,	0	O
specifying	0	O
chloramphenicol	0	B
-	0	I
inducible	0	I
chloramphenicol	0	I
acetyltransferase	0	I
,	0	O
is	0	O
located	0	O
on	0	O
the	0	O
1	0	O
.	0	O
1	0	O
-	0	O
kilobase	0	O
cloned	0	O
DNA	1	O
.	0	O


NPT	1	B
II	0	I
synthesis	0	O
,	0	O
measured	0	O
by	0	O
agar	0	O
plate	0	O
assays	0	O
of	0	O
kanamycin	0	O
resistance	0	O
and	0	O
by	0	O
immunoprecipitation	0	O
of	0	O
the	0	O
NPT	1	B
II	0	I
protein	0	I
,	0	O
was	0	O
repressed	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
cysteine	0	O
and	0	O
derepressed	0	O
in	0	O
its	0	O
absence	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
results	0	O
demonstrate	0	O
that	0	O
the	0	O
RP	1	B
,	0	O
like	0	O
the	0	O
20S	0	B
proteasome	0	I
,	0	O
is	0	O
functionally	0	O
and	0	O
structurally	0	O
conserved	0	O
among	0	O
eukaryotes	0	O
and	0	O
indicate	0	O
that	0	O
the	0	O
plant	0	B
RPT	0	I
subunits	0	I
,	0	O
like	0	O
their	0	O
yeast	0	O
counterparts	0	O
,	0	O
have	0	O
non	0	O
-	0	O
redundant	0	O
functions	0	O
.	0	O


Labial	1	O
bar	0	O
.	0	O


There	0	O
is	0	O
no	0	O
TATA	0	O
box	0	O
appropriately	0	O
spaced	0	O
upstream	0	O
from	0	O
the	0	O
transcription	0	O
initiation	0	O
site	0	O
.	0	O


IL	1	B
-	0	I
1	0	I
and	0	O
TNF	1	B
increase	0	O
AND	0	B
-	0	I
34	0	I
transcript	0	I
levels	0	O
in	0	O
thymic	0	O
cortical	0	O
reticular	0	O
,	0	O
thymic	0	O
nurse	0	O
,	0	O
and	0	O
fibroblast	0	O
cell	0	O
lines	0	O
.	0	O


Four	0	O
transcription	0	O
initiation	0	O
sites	0	O
have	0	O
been	0	O
identified	0	O
by	0	O
full	0	O
-	0	O
length	0	O
RNA	1	B
ligase	0	I
-	0	O
mediated	0	O
rapid	0	O
amplification	0	O
of	0	O
cDNA	1	O
ends	0	O
(	0	O
RLM	0	O
-	0	O
RACE	1	O
)	0	O
between	0	O
-	0	O
61	0	O
and	0	O
-	0	O
32	0	O
bp	0	O
from	0	O
the	0	O
translation	0	O
initiation	0	O
codon	0	O
.	0	O
Reverse	0	O
transcription	0	O
-	0	O
PCR	1	O
analysis	0	O
revealed	0	O
that	0	O
PFK	0	B
-	0	I
A	1	I
,	0	O
PFK	0	B
-	0	I
B	1	I
and	0	O
PFK	0	B
-	0	I
C	1	I
genes	0	I
were	0	O
expressed	0	O
,	0	O
in	0	O
all	0	O
mouse	0	O
tissues	0	O
tested	0	O
,	0	O
at	0	O
varying	0	O
levels	0	O
.	0	O


Their	0	O
use	0	O
established	0	O
that	0	O
the	0	O
BrAAP	0	O
activity	0	O
catalyzed	0	O
both	0	O
a	0	O
postproline	0	O
and	0	O
a	0	O
postglutamate	0	O
cleavage	0	O
and	0	O
therefore	0	O
has	0	O
a	0	O
broader	0	O
specificity	0	O
than	0	O
previously	0	O
recognized	0	O
.	0	O


I	1	O
.	0	O


A	1	O
region	0	O
of	0	O
the	0	O
deduced	0	O
protein	0	O
shares	0	O
extensive	0	O
homology	0	O
with	0	O
a	0	O
catalytic	0	O
region	0	O
of	0	O
Raf	0	B
kinases	0	I
,	0	O
a	0	O
feature	0	O
shared	0	O
only	0	O
with	0	O
TFIIE	0	B
among	0	O
transcription	0	O
factors	0	O
.	0	O


The	0	O
promoter	0	O
region	0	O
(	0	O
P1	1	O
)	0	O
corresponding	0	O
to	0	O
the	0	O
main	0	O
group	0	O
of	0	O
transcription	0	O
initiation	0	O
sites	0	O
is	0	O
devoid	0	O
of	0	O
TATA	0	O
and	0	O
CAAT	0	O
boxes	0	O
but	0	O
has	0	O
putative	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
transcription	0	B
factor	0	I
SP1	0	I
and	0	O
is	0	O
embedded	0	O
in	0	O
a	0	O
large	0	O
G	1	O
+	0	O
C	1	O
-	0	O
rich	0	O
domain	0	O
of	0	O
a	0	O
CpG	0	O
island	0	O
,	0	O
features	0	O
shared	0	O
by	0	O
the	0	O
promoters	0	O
of	0	O
constitutively	0	O
expressed	0	O
housekeeping	0	O
genes	0	O
.	0	O


A	1	O
13	0	O
base	0	O
-	0	O
pair	0	O
oligonucleotide	0	O
spanning	0	O
nucleotides	0	O
+	0	O
80	0	O
to	0	O
+	0	O
92	0	O
of	0	O
the	0	O
5	0	B
S	1	I
RNA	1	I
gene	0	I
retained	0	O
specific	0	O
and	0	O
high	0	O
-	0	O
affinity	0	O
binding	0	O
,	0	O
although	0	O
the	0	O
latter	0	O
was	0	O
reduced	0	O
sixfold	0	O
relative	0	O
to	0	O
longer	0	O
DNA	1	O
fragments	0	O
.	0	O


The	0	O
relations	0	O
between	0	O
type	0	O
A	1	O
behavior	0	O
,	0	O
clinically	0	O
relevant	0	O
behavior	0	O
,	0	O
academic	0	O
achievement	0	O
,	0	O
and	0	O
IQ	1	O
in	0	O
children	0	O
.	0	O


In	1	O
view	0	O
of	0	O
the	0	O
presence	0	O
of	0	O
SECIS	0	O
elements	0	O
in	0	O
the	0	O
open	0	O
reading	0	O
frames	0	O
(	0	O
ORFs	0	O
)	0	O
of	0	O
bacterial	0	B
selenoproteins	0	I
,	0	O
we	0	O
examine	0	O
the	0	O
effects	0	O
in	0	O
the	0	O
type	0	B
1	0	I
deiodinase	0	I
of	0	O
extending	0	O
the	0	O
ORF	1	O
into	0	O
the	0	O
SECIS	0	O
element	0	O
,	0	O
and	0	O
find	0	O
that	0	O
this	0	O
dramatically	0	O
inhibits	0	O
SECIS	0	O
function	0	O
.	0	O


The	0	O
RF	1	O
values	0	O
correlated	0	O
well	0	O
with	0	O
the	0	O
angiographic	0	O
semiquantitative	0	O
scale	0	O
of	0	O
severity	0	O
of	0	O
aortal	0	O
insufficiency	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
805	0	O
;	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
),	0	O
although	0	O
they	0	O
enabled	0	O
the	0	O
authors	0	O
only	0	O
to	0	O
make	0	O
a	0	O
partial	0	O
differentiation	0	O
of	0	O
haemodynamically	0	O
severe	0	O
regurgitations	0	O
and	0	O
mild	0	O
or	0	O
insignificant	0	O
ones	0	O
.	0	O


From	0	O
life	0	O
-	0	O
table	0	O
analyses	0	O
of	0	O
these	0	O
patients	0	O
,	0	O
we	0	O
estimated	0	O
that	0	O
the	0	O
incidence	0	O
of	0	O
secondary	0	O
chondrosarcoma	0	O
in	0	O
patients	0	O
who	0	O
have	0	O
Ollier	0	O
disease	0	O
is	0	O
about	0	O
25	0	O
per	0	O
cent	0	O
at	0	O
the	0	O
age	0	O
of	0	O
forty	0	O
years	0	O
,	0	O
and	0	O
that	0	O
malignant	0	O
degeneration	0	O
is	0	O
almost	0	O
a	0	O
certainty	0	O
in	0	O
patients	0	O
who	0	O
have	0	O
Maffucci	0	O
syndrome	0	O
.	0	O


Each	0	O
patient	0	O
had	0	O
measurable	0	O
LH	1	B
and	0	O
FSH	1	B
levels	0	O
,	0	O
with	0	O
pulsed	0	O
nocturnal	0	O
secretion	0	O
,	0	O
and	0	O
pubertal	0	O
LH	1	B
and	0	O
FSH	1	B
responses	0	O
to	0	O
LRH	0	B
.	0	O


Proceedings	0	O
:	0	O
Reversible	1	O
complete	0	O
heart	0	O
block	0	O
following	0	O
surgery	0	O
of	0	O
congenital	0	O
heart	0	O
defects	0	O


This	0	O
rapid	0	O
and	0	O
extensive	0	O
penetration	0	O
of	0	O
intrathecally	0	O
administered	0	O
chemotherapy	0	O
may	0	O
offer	0	O
insight	0	O
into	0	O
the	0	O
myelopathy	0	O
observed	0	O
with	0	O
these	0	O
treatments	0	O
.	0	O


The	0	O
mechanisms	0	O
that	0	O
govern	0	O
the	0	O
activation	0	O
or	0	O
suppression	0	O
of	0	O
the	0	O
CD8	0	B
gene	0	I
are	0	O
likely	0	O
to	0	O
be	0	O
central	0	O
to	0	O
the	0	O
T	1	O
cell	0	O
development	0	O
program	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
and	0	O
sequenced	0	O
the	0	O
gene	0	O
encoding	0	O
the	0	O
human	0	B
U1	0	I
-	0	I
70K	0	I
snRNP	1	I
protein	0	I
.	0	O


Surprisingly	0	O
,	0	O
however	0	O
,	0	O
TCR	1	B
-	0	O
mediated	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
phospholipase	0	B
C	1	I
gamma	0	I
1	0	I
remains	0	O
intact	0	O
in	0	O
the	0	O
Jurkat	0	O
cells	0	O
expressing	0	O
the	0	O
A2	1	B
/	0	O
HCP	1	B
chimera	0	O
.	0	O


The	0	O
double	0	O
-	0	O
stranded	0	O
RNA	1	O
binding	0	O
domain	0	O
(	0	O
dsRBD	0	O
)	0	O
is	0	O
an	0	O
approximately	0	O
65	0	O
amino	0	O
acid	0	O
motif	0	O
that	0	O
is	0	O
found	0	O
in	0	O
a	0	O
variety	0	O
of	0	O
proteins	0	O
that	0	O
interact	0	O
with	0	O
double	0	O
-	0	O
stranded	0	O
(	0	O
ds	0	O
)	0	O
RNA	1	O
,	0	O
such	0	O
as	0	O
Escherichia	1	O
coli	0	O
RNase	1	B
III	0	I
and	0	O
the	0	O
dsRNA	1	B
-	0	I
dependent	0	I
kinase	0	I
,	0	O
PKR	0	B
.	0	O


They	0	O
also	0	O
interact	0	O
with	0	O
GTPase	1	B
activating	0	I
proteins	0	I
encoded	0	O
by	0	O
IRA1	0	B
and	0	O
IRA2	0	B
.	0	O


During	0	O
surgery	0	O
bone	0	O
cysts	0	O
were	0	O
excised	0	O
and	0	O
filled	0	O
by	0	O
bone	0	O
grafts	0	O
.	0	O


Several	0	O
studies	0	O
have	0	O
characterized	0	O
the	0	O
upstream	0	O
regulatory	0	O
region	0	O
of	0	O
c	0	B
-	0	I
fos	0	I
,	0	O
and	0	O
identified	0	O
cis	0	O
-	0	O
acting	0	O
elements	0	O
termed	0	O
the	0	O
cyclic	0	O
AMP	1	O
(	0	O
cAMP	1	O
)	0	O
response	0	O
elements	0	O
(	0	O
CREs	0	O
)	0	O
that	0	O
are	0	O
critical	0	O
for	0	O
c	0	B
-	0	I
fos	0	I
transcription	0	O
in	0	O
response	0	O
to	0	O
a	0	O
variety	0	O
of	0	O
extracellular	0	O
stimuli	0	O
.	0	O


No	1	O
differences	0	O
in	0	O
total	0	O
cholesterol	0	O
levels	0	O
were	0	O
observed	0	O
between	0	O
mapuches	0	O
and	0	O
aymaras	0	O
.	0	O


The	0	O
second	0	O
complex	0	O
,	0	O
when	0	O
purified	0	O
,	0	O
contained	0	O
four	0	O
protein	0	O
components	0	O
including	0	O
the	0	O
36	0	O
-	0	O
kDa	1	O
protein	0	O
.	0	O


We	0	O
characterized	0	O
three	0	O
Arabidopsis	0	O
thaliana	0	O
cDNA	1	O
clones	0	O
that	0	O
could	0	O
rescue	0	O
the	0	O
sterile	0	O
phenotype	0	O
of	0	O
the	0	O
Schizosaccharomyces	0	B
pombe	0	I
pde1	0	I
mutant	0	I
,	0	O
which	0	O
is	0	O
defective	0	O
in	0	O
cAMP	1	B
phosphodiesterase	0	I
.	0	O


These	0	O
latter	0	O
results	0	O
showed	0	O
that	0	O
the	0	O
ABFI	0	B
protein	0	I
,	0	O
like	0	O
the	0	O
RAP1	0	B
protein	0	I
,	0	O
bound	0	O
sequences	0	O
required	0	O
for	0	O
positive	0	O
as	0	O
well	0	O
as	0	O
negative	0	O
regulation	0	O
of	0	O
gene	0	O
expression	0	O
.	0	O


A	1	O
-	0	O
69	0	O
-	0	O
year	0	O
-	0	O
old	0	O
patient	0	O
with	0	O
postoperative	0	O
small	0	O
-	0	O
bowel	0	O
obstruction	0	O
underwent	0	O
laparotomy	0	O
three	0	O
times	0	O
.	0	O


The	0	O
C5	1	B
alpha	0	I
-	0	I
chain	0	I
was	0	O
encoded	0	O
by	0	O
49	0	O
kilobases	0	O
containing	0	O
26	0	O
exons	0	O
;	0	O
the	0	O
beta	0	O
-	0	O
chain	0	O
was	0	O
encoded	0	O
by	0	O
29	0	O
kilobases	0	O
containing	0	O
16	0	O
exons	0	O
.	0	O


The	0	O
atp	0	B
1	0	I
and	0	O
atp	0	B
2	0	I
types	0	O
of	0	O
cDNA	1	O
sequences	0	O
were	0	O
the	0	O
most	0	O
redundant	0	O
among	0	O
the	0	O
28	0	O
different	0	O
isoperoxidases	0	B
identified	0	O
among	0	O
about	0	O
200	0	O
peroxidase	0	B
encoding	0	I
ESTs	0	I
.	0	O


Praziquantel	1	O
and	0	O
Albendazole	1	O
were	0	O
found	0	O
effective	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
neurocysticercosis	0	O
,	0	O
but	0	O
because	0	O
of	0	O
serious	0	O
side	0	O
effects	0	O
encountered	0	O
in	0	O
some	0	O
cases	0	O
,	0	O
the	0	O
drugs	0	O
should	0	O
be	0	O
used	0	O
cautiously	0	O
in	0	O
selected	0	O
cases	0	O
only	0	O
.	0	O


E3	1	B
/	0	I
19K	0	I
resides	0	O
in	0	O
the	0	O
endoplasmic	0	O
reticulum	0	O
where	0	O
it	0	O
binds	0	O
to	0	O
MHC	1	B
class	0	I
I	1	I
molecules	0	I
,	0	O
thereby	0	O
preventing	0	O
their	0	O
transport	0	O
to	0	O
the	0	O
cell	0	O
surface	0	O
.	0	O


Wild	1	O
-	0	O
type	0	O
protein	0	O
bound	0	O
azido	0	O
-	0	O
ATP	1	O
well	0	O
,	0	O
but	0	O
mutants	0	O
with	0	O
substitutions	0	O
in	0	O
the	0	O
consensus	0	O
amino	0	O
acids	0	O
were	0	O
unable	0	O
to	0	O
bind	0	O
azido	0	O
-	0	O
ATP	1	O
.	0	O


No	1	O
hypotension	0	O
was	0	O
noted	0	O
in	0	O
patients	0	O
with	0	O
toxemia	0	O
and	0	O
only	0	O
2	0	O
ran	0	O
a	0	O
fever	0	O
above	0	O
37	0	O
.	0	O
5	0	O
degrees	0	O
C	1	O
.	0	O


This	0	O
study	0	O
was	0	O
undertaken	0	O
to	0	O
evaluate	0	O
how	0	O
couplers	0	O
and	0	O
their	0	O
placement	0	O
affect	0	O
the	0	O
ALGO2	0	O
click	0	O
spectral	0	O
properties	0	O
.	0	O


We	0	O
are	0	O
reporting	0	O
an	0	O
autopsy	0	O
case	0	O
of	0	O
so	0	O
-	0	O
called	0	O
"	0	O
acute	0	O
multiple	0	O
sclerosis	0	O
"	0	O
that	0	O
was	0	O
difficult	0	O
to	0	O
differentiate	0	O
from	0	O
a	0	O
brain	0	O
tumor	0	O
on	0	O
MRI	1	O
findings	0	O
.	0	O


Similarly	0	O
,	0	O
the	0	O
sequence	0	O
of	0	O
the	0	O
U2	0	B
RNA	1	I
region	0	I
shown	0	O
to	0	O
be	0	O
involved	0	O
in	0	O
pre	0	O
-	0	O
mRNA	1	O
branchpoint	0	O
recognition	0	O
in	0	O
yeast	0	O
,	0	O
and	0	O
exactly	0	O
conserved	0	O
in	0	O
metazoan	0	B
U2	0	I
RNAs	0	I
,	0	O
was	0	O
totally	0	O
divergent	0	O
in	0	O
trypanosomes	0	O
.	0	O


None	0	O
were	0	O
restricted	0	O
from	0	O
clinical	0	O
duties	0	O
,	0	O
were	0	O
given	0	O
varicella	0	B
-	0	I
zoster	0	I
immune	0	I
globulin	0	I
,	0	O
or	0	O
developed	0	O
disease	0	O
.	0	O


The	0	O
transcription	0	O
factor	0	O
E2F	0	B
plays	0	O
an	0	O
important	0	O
role	0	O
in	0	O
G	1	O
(	0	O
1	0	O
)	0	O
to	0	O
S	1	O
phase	0	O
transition	0	O
in	0	O
the	0	O
higher	0	O
eukaryotic	0	O
cell	0	O
cycle	0	O
.	0	O


These	0	O
findings	0	O
suggest	0	O
that	0	O
the	0	O
MAP	1	B
kinase	0	I
activator	0	I
/	0	O
MAP	1	B
kinase	0	I
system	0	O
may	0	O
be	0	O
the	0	O
downstream	0	O
components	0	O
of	0	O
ras	0	B
signal	0	O
transduction	0	O
pathways	0	O
.	0	O


Significance	0	O
of	0	O
the	0	O
biopsy	0	O
site	0	O
of	0	O
the	0	O
latissimus	0	O
dorsi	0	O
muscle	0	O
for	0	O
fiber	0	O
typing	0	O
.	0	O


Oncostatin	0	B
M	1	I
stimulates	0	O
c	0	B
-	0	I
Fos	1	I
to	0	O
bind	0	O
a	0	O
transcriptionally	0	O
responsive	0	O
AP	1	B
-	0	I
1	0	I
element	0	I
within	0	O
the	0	O
tissue	0	B
inhibitor	0	I
of	0	I
metalloproteinase	0	I
-	0	I
1	0	I
promoter	0	I
.	0	O


These	0	O
regions	0	O
may	0	O
be	0	O
differentially	0	O
involved	0	O
in	0	O
tissue	0	O
-	0	O
specificity	0	O
,	0	O
and	0	O
/	0	O
or	0	O
circadian	0	O
regulation	0	O
,	0	O
of	0	O
the	0	O
human	0	B
hPer1	0	I
gene	0	I
transcription	0	O
.	0	O


Sak	1	B
kinase	0	I
gene	0	O
structure	0	O
and	0	O
transcriptional	0	O
regulation	0	O
.	0	O


Injection	1	O
of	0	O
double	0	O
-	0	O
stranded	0	O
RNA	1	O
into	0	O
C	1	O
.	0	O
elegans	0	O
results	0	O
in	0	O
embryonic	0	O
lethality	0	O
;	0	O
thus	0	O
,	0	O
the	0	O
SF1	0	B
gene	0	I
is	0	O
essential	0	O
not	0	O
only	0	O
in	0	O
yeast	0	O
but	0	O
also	0	O
in	0	O
at	0	O
least	0	O
one	0	O
metazoan	0	O
.	0	O


The	0	O
concentrations	0	O
of	0	O
plasma	0	O
ACTH	1	B
and	0	O
cortisol	0	O
increased	0	O
by	0	O
40	0	O
%	0	O
and	0	O
60	0	O
%	0	O
after	0	O
MPTP	0	O
treatment	0	O
,	0	O
respectively	0	O
.	0	O


Active	1	O
lambda	0	B
and	0	I
kappa	0	I
antibody	0	I
gene	0	I
rearrangement	0	O
in	0	O
Abelson	0	O
murine	0	O
leukemia	0	O
virus	0	O
-	0	O
transformed	0	O
pre	0	O
-	0	O
B	1	O
cell	0	O
lines	0	O
.	0	O


In	1	O
conclusion	0	O
,	0	O
our	0	O
data	0	O
do	0	O
not	0	O
support	0	O
a	0	O
role	0	O
for	0	O
IVIg	0	B
in	0	O
the	0	O
remyelination	0	O
of	0	O
stable	0	O
multiple	0	O
sclerosis	0	O
lesions	0	O
as	0	O
measured	0	O
by	0	O
central	0	O
conduction	0	O
time	0	O
.	0	O


FZD4	0	B
is	0	O
homologous	0	O
to	0	O
FZD9	0	B
and	0	O
FZD10	0	B
,	0	O
and	0	O
overall	0	O
amino	0	O
acid	0	O
identity	0	O
is	0	O
as	0	O
follows	0	O
:	0	O
FZD4	0	B
vs	0	O
FZD9	0	B
,	0	O
51	0	O
.	0	O
6	0	O
%;	0	O
FZD4	0	B
vs	0	O
FZD10	0	B
,	0	O
51	0	O
.	0	O
2	0	O
%;	0	O
FZD9	0	B
vs	0	O
FZD10	0	B
,	0	O
65	0	O
.	0	O
7	0	O
%.	0	O


The	0	O
physicians	0	O
in	0	O
charge	0	O
of	0	O
all	0	O
patients	0	O
with	0	O
evidence	0	O
of	0	O
acute	0	O
Q	1	O
fever	0	O
(	0	O
seroconversion	0	O
and	0	O
/	0	O
or	0	O
presence	0	O
of	0	O
IgM	1	B
)	0	O
or	0	O
chronic	0	O
Q	1	O
fever	0	O
(	0	O
prolonged	0	O
disease	0	O
and	0	O
/	0	O
or	0	O
IgG	1	B
antibody	0	I
titer	0	O
to	0	O
phase	0	O
I	1	O
of	0	O
Coxiella	1	O
burnetii	0	O
>	0	O
or	0	O
=	0	O
800	0	O
)	0	O
were	0	O
asked	0	O
to	0	O
complete	0	O
a	0	O
questionnaire	0	O
,	0	O
which	0	O
was	0	O
computerized	0	O
.	0	O


In	1	O
a	0	O
recent	0	O
measles	0	O
epidemic	0	O
in	0	O
El	0	O
Paso	0	O
,	0	O
TX	0	O
,	0	O
120	0	O
,	0	O
000	0	O
records	0	O
were	0	O
screened	0	O
using	0	O
these	0	O
criteria	0	O
,	0	O
and	0	O
as	0	O
a	0	O
result	0	O
13	0	O
,	0	O
000	0	O
students	0	O
were	0	O
vaccinated	0	O
.	0	O


The	0	O
prognosis	0	O
of	0	O
seven	0	O
patients	0	O
who	0	O
received	0	O
ABSCT	0	O
was	0	O
significantly	0	O
better	0	O
than	0	O
that	0	O
of	0	O
13	0	O
patients	0	O
who	0	O
received	0	O
conventional	0	O
therapy	0	O
alone	0	O
.	0	O


ATP	1	O
-	0	O
dependent	0	O
assembly	0	O
of	0	O
a	0	O
ternary	0	O
complex	0	O
consisting	0	O
of	0	O
a	0	O
DNA	1	O
mismatch	0	O
and	0	O
the	0	O
yeast	0	O
MSH2	0	B
-	0	O
MSH6	0	B
and	0	O
MLH1	0	B
-	0	O
PMS1	0	B
protein	0	O
complexes	0	O
.	0	O


Evaluation	1	O
of	0	O
human	0	O
and	0	O
bovine	0	O
modified	0	O
-	0	O
hemoglobin	0	B
solution	0	O
as	0	O
oxygen	0	O
-	0	O
carrying	0	O
fluid	0	O
for	0	O
blood	0	O
volume	0	O
replacement	0	O
.	0	O


On	1	O
the	0	O
other	0	O
hand	0	O
,	0	O
subjects	0	O
with	0	O
air	0	O
trapping	0	O
(	0	O
residual	0	O
volume	0	O
(	0	O
RV	1	O
)/	0	O
total	0	O
lung	0	O
capacity	0	O
(	0	O
TLC	1	O
)	0	O
>	0	O
37	0	O
%)	0	O
disclosed	0	O
not	0	O
only	0	O
a	0	O
higher	0	O
n	0	O
(	0	O
mit	0	O
)	0	O
(	0	O
0	0	O
.	0	O
63	0	O
+/-	0	O
0	0	O
.	0	O
17	0	O
versus	0	O
0	0	O
.	0	O
43	0	O
+/-	0	O
0	0	O
.	0	O
07	0	O
mt	0	O
x	0	O
microm	0	O
(-	0	O
2	0	O
),	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
)	0	O
but	0	O
shorter	0	O
sarcomeres	0	O
(	0	O
L	1	O
(	0	O
sar	0	O
))	0	O
than	0	O
subjects	0	O
without	0	O
this	0	O
functional	0	O
abnormality	0	O
(	0	O
2	0	O
.	0	O
08	0	O
+/-	0	O
0	0	O
.	0	O
16	0	O
to	0	O
2	0	O
.	0	O
27	0	O
+/-	0	O
0	0	O
.	0	O
15	0	O
microm	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Large	0	B
T	1	I
antigen	0	I
was	0	O
coimmunoprecipitated	0	O
by	0	O
antibodies	0	O
to	0	O
epitope	0	O
-	0	O
tagged	0	O
TBP	1	B
,	0	O
endogenous	0	O
TBP	1	B
,	0	O
hTAF	0	B
(	0	I
II	0	I
)	0	I
100	0	I
,	0	O
hTAF	0	B
(	0	I
II	0	I
)	0	I
130	0	I
,	0	O
and	0	O
hTAF	0	B
(	0	I
II	0	I
)	0	I
250	0	I
,	0	O
under	0	O
conditions	0	O
where	0	O
holo	0	B
-	0	I
TFIID	0	I
would	0	O
be	0	O
precipitated	0	O
.	0	O


The	0	O
well	0	O
-	0	O
known	0	O
Rel	0	B
/	0	O
NF	1	B
-	0	I
kappaB	0	I
family	0	O
of	0	O
vertebrate	0	O
transcription	0	O
factors	0	O
comprises	0	O
a	0	O
number	0	O
of	0	O
structurally	0	O
related	0	O
,	0	O
interacting	0	O
proteins	0	O
that	0	O
bind	0	O
DNA	1	O
as	0	O
dimers	0	O
and	0	O
whose	0	O
activity	0	O
is	0	O
regulated	0	O
by	0	O
subcellular	0	O
location	0	O
.	0	O


Effect	1	O
of	0	O
enteral	0	O
nutritional	0	O
products	0	O
differing	0	O
in	0	O
carbohydrate	0	O
and	0	O
fat	0	O
on	0	O
indices	0	O
of	0	O
carbohydrate	0	O
and	0	O
lipid	0	O
metabolism	0	O
in	0	O
patients	0	O
with	0	O
NIDDM	1	O
.	0	O


Inhibition	1	O
appears	0	O
to	0	O
result	0	O
from	0	O
titration	0	O
of	0	O
general	0	O
transcription	0	O
factors	0	O
because	0	O
MDM2	0	B
overexpression	0	O
inhibits	0	O
c	0	B
-	0	I
fos	0	I
as	0	O
well	0	O
as	0	O
other	0	O
promoters	0	O
in	0	O
vivo	0	O
and	0	O
basal	0	O
transcription	0	O
in	0	O
vitro	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
(	0	O
a	0	O
)	0	O
the	0	O
likelihood	0	O
of	0	O
detecting	0	O
carcinoma	0	O
or	0	O
atypical	0	O
hyperplasia	0	O
exclusively	0	O
in	0	O
the	0	O
adipose	0	O
tissue	0	O
component	0	O
of	0	O
grossly	0	O
benign	0	O
breast	0	O
biopsies	0	O
is	0	O
extremely	0	O
low	0	O
,	0	O
and	0	O
(	0	O
b	0	O
)	0	O
a	0	O
possible	0	O
cost	0	O
-	0	O
effective	0	O
method	0	O
of	0	O
sampling	0	O
grossly	0	O
benign	0	O
breast	0	O
biopsies	0	O
consists	0	O
of	0	O
initially	0	O
submitting	0	O
a	0	O
maximum	0	O
of	0	O
10	0	O
blocks	0	O
of	0	O
fibrous	0	O
parenchyma	0	O
for	0	O
each	0	O
case	0	O
,	0	O
then	0	O
examining	0	O
the	0	O
remaining	0	O
tissue	0	O
histologically	0	O
only	0	O
if	0	O
carcinoma	0	O
or	0	O
atypical	0	O
hyperplasia	0	O
is	0	O
found	0	O
among	0	O
these	0	O
blocks	0	O
.	0	O


We	0	O
have	0	O
designated	0	O
the	0	O
protein	0	O
"	0	B
cellular	0	I
NBP	0	I
"	0	I
(	0	O
CNBP	0	B
).	0	O


Immunophenotyping	1	O
in	0	O
four	0	O
cases	0	O
,	0	O
demonstrated	0	O
non	0	O
-	0	O
B	1	O
,	0	O
non	0	O
-	0	O
T	1	O
cell	0	O
origin	0	O
in	0	O
three	0	O
and	0	O
pre	0	O
-	0	O
B	1	O
cell	0	O
origin	0	O
in	0	O
one	0	O
.	0	O


Haploid	1	O
cells	0	O
of	0	O
mating	0	O
type	0	O
A	1	O
of	0	O
the	0	O
basidiomycetous	0	O
yeast	0	O
Rhodosporidium	0	O
toruloides	0	O
secrete	0	O
a	0	O
mating	0	O
pheromone	0	O
,	0	O
rhodotorucine	0	B
A	1	I
,	0	O
which	0	O
is	0	O
an	0	O
undecapeptide	0	O
containing	0	O
S	1	O
-	0	O
farnesyl	0	O
cysteine	0	O
at	0	O
its	0	O
carboxy	0	O
terminus	0	O
.	0	O


Factors	0	O
influencing	0	O
the	0	O
bond	0	O
strength	0	O
between	0	O
glass	0	O
polyalkenoate	0	O
(	0	O
ionomer	0	O
)	0	O
cements	0	O
and	0	O
dentine	0	O
.	0	O


The	0	O
git1	0	B
,	0	O
git3	0	B
,	0	O
git5	0	B
,	0	O
git7	0	B
,	0	O
git8	0	B
and	0	O
git10	0	B
genes	0	I
act	0	O
upstream	0	O
of	0	O
adenylate	0	B
cyclase	0	I
,	0	O
presumably	0	O
encoding	0	O
an	0	O
adenylate	0	B
cyclase	0	I
activation	0	O
pathway	0	O
.	0	O


A	1	O
preoperative	0	O
teaching	0	O
booklet	0	O
for	0	O
pediatric	0	O
patients	0	O
.	0	O


The	0	O
differential	0	O
diagnosis	0	O
of	0	O
both	0	O
affections	0	O
is	0	O
based	0	O
on	0	O
the	0	O
clinical	0	O
course	0	O
,	0	O
sialography	0	O
and	0	O
CT	1	O
examination	0	O
which	0	O
along	0	O
with	0	O
modern	0	O
ATB	0	O
treatment	0	O
significantly	0	O
modify	0	O
hitherto	0	O
used	0	O
surgical	0	O
therapy	0	O
.	0	O


The	0	O
most	0	O
common	0	O
types	0	O
of	0	O
malformations	0	O
were	0	O
eye	0	O
defects	0	O
and	0	O
open	0	O
coeloms	0	O
.	0	O


However	0	O
,	0	O
a	0	O
>	0	O
10	0	O
-	0	O
fold	0	O
increase	0	O
in	0	O
ERK3	0	B
activity	0	O
in	0	O
each	0	O
PKC	0	B
beta	0	I
transfectant	0	O
was	0	O
shown	0	O
by	0	O
immunoprecipitation	0	O
with	0	O
anti	0	B
-	0	I
ERK3	0	I
monoclonal	0	I
antibody	0	I
followed	0	O
by	0	O
either	0	O
immune	0	O
complex	0	O
kinase	0	O
assay	0	O
or	0	O
by	0	O
in	0	O
gel	0	O
kinase	0	O
assay	0	O
.	0	O


This	0	O
resulted	0	O
in	0	O
a	0	O
complete	0	O
inhibition	0	O
of	0	O
Site	1	O
-	0	O
1	0	O
cleavage	0	O
that	0	O
was	0	O
restored	0	O
by	0	O
concomitant	0	O
overexpression	0	O
of	0	O
full	0	O
-	0	O
length	0	O
SCAP	0	B
.	0	O


Uroflowmetry	1	O
can	0	O
detect	0	O
dysuria	0	O
,	0	O
which	0	O
may	0	O
be	0	O
poorly	0	O
perceived	0	O
or	0	O
even	0	O
unknown	0	O
to	0	O
the	0	O
subjects	0	O
themselves	0	O
.	0	O


BACKGROUND	0	O
/	0	O
PURPOSE	0	O
:	0	O
Anomalous	1	O
arrangement	0	O
of	0	O
the	0	O
pancreaticobiliary	0	O
duct	0	O
(	0	O
AAPBD	0	O
)	0	O
is	0	O
closely	0	O
related	0	O
to	0	O
congenital	0	O
biliary	0	O
dilatation	0	O
and	0	O
frequently	0	O
associated	0	O
with	0	O
biliary	0	O
tract	0	O
malignancy	0	O
.	0	O


They	0	O
contrast	0	O
trends	0	O
in	0	O
fertility	0	O
,	0	O
life	0	O
expectancy	0	O
ratios	0	O
,	0	O
and	0	O
gender	0	O
differences	0	O
in	0	O
these	0	O
countries	0	O
with	0	O
the	0	O
Hispanic	0	O
population	0	O
of	0	O
the	0	O
United	0	O
States	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
antilymphocyte	0	O
sera	0	O
on	0	O
formation	0	O
of	0	O
transplantation	0	O
and	0	O
anti	0	O
-	0	O
infection	0	O
immunity	0	O
in	0	O
mice	0	O


This	0	O
study	0	O
demonstrated	0	O
that	0	O
the	0	O
PFA	0	O
-	0	O
100	0	O
analyzer	0	O
can	0	O
accurately	0	O
assess	0	O
vWF	1	B
-	0	O
dependent	0	O
platelet	0	O
function	0	O
and	0	O
detect	0	O
other	0	O
platelet	0	O
defects	0	O
under	0	O
high	0	O
shear	0	O
stress	0	O
in	0	O
complex	0	O
patient	0	O
populations	0	O
.	0	O


The	0	O
5	0	O
'	0	O
flanking	0	O
region	0	O
of	0	O
the	0	O
CD1	0	B
gene	0	I
contained	0	O
the	0	O
binding	0	O
motifs	0	O
for	0	O
two	0	O
cytokine	0	O
-	0	O
inducible	0	O
transcription	0	O
factors	0	O
,	0	O
NF	1	B
-	0	I
IL2	0	I
-	0	I
A	1	I
and	0	O
NF	1	B
-	0	I
IL6	0	I
.	0	O


Validation	1	O
of	0	O
the	0	O
survey	0	O
of	0	O
work	0	O
styles	0	O
:	0	O
a	0	O
profile	0	O
measure	0	O
of	0	O
the	0	O
type	0	O
A	1	O
behaviour	0	O
pattern	0	O
.	0	O


While	0	O
interactions	0	O
of	0	O
WT	1	O
and	0	O
variant	0	O
TGF	1	B
-	0	I
alpha	0	I
with	0	O
the	0	O
ErbBs	0	B
all	0	O
result	0	O
in	0	O
ErbB2	0	B
activation	0	O
,	0	O
they	0	O
produce	0	O
different	0	O
biological	0	O
consequences	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
various	0	O
TGF	1	B
-	0	I
alpha	0	I
precursors	0	I
differentially	0	O
modulate	0	O
ErbB	0	B
signaling	0	O
.	0	O


The	0	O
first	0	O
follow	0	O
-	0	O
up	0	O
was	0	O
at	0	O
a	0	O
nearly	0	O
constant	0	O
interval	0	O
of	0	O
5	0	O
.	0	O
1	0	O
years	0	O
in	0	O
Caerphilly	0	O
and	0	O
3	0	O
.	0	O
2	0	O
years	0	O
in	0	O
Speedwell	0	O
;	0	O
251	0	O
major	0	O
IHD	1	O
events	0	O
had	0	O
occurred	0	O
.	0	O


Serum	1	O
ferritin	0	B
concentration	0	O
and	0	O
bone	0	O
marrow	0	O
iron	0	O
stores	0	O
.	0	O


Proprotein	1	O
processing	0	O
occurs	0	O
intracellularly	0	O
.	0	O


Stereotactic	1	O
radiofrequency	0	O
lesioning	0	O
of	0	O
the	0	O
hamartoma	0	O
resulted	0	O
in	0	O
seizure	0	O
remission	0	O
without	0	O
complications	0	O
20	0	O
months	0	O
after	0	O
surgery	0	O
.	0	O


Cortisol	1	O
excretion	0	O
,	0	O
appeared	0	O
to	0	O
be	0	O
markedly	0	O
affected	0	O
by	0	O
the	0	O
season	0	O
although	0	O
other	0	O
factors	0	O
such	0	O
as	0	O
social	0	O
and	0	O
environmental	0	O
stress	0	O
cannot	0	O
be	0	O
discounted	0	O
.	0	O


A	1	O
comparative	0	O
study	0	O
by	0	O
holographic	0	O
interferometry	0	O
of	0	O
ten	0	O
porcine	0	O
bioprosthetic	0	O
valves	0	O
(	0	O
seven	0	O
Carpentier	0	O
-	0	O
Edwards	0	O
SAV	0	O
,	0	O
two	0	O
BioImplant	1	O
and	0	O
one	0	O
Valcor	0	O
)	0	O
with	0	O
five	0	O
human	0	O
aortic	0	O
valves	0	O
before	0	O
and	0	O
after	0	O
glutaraldehyde	0	O
treatment	0	O
is	0	O
presented	0	O
.	0	O


The	0	O
hIGF	0	B
-	0	I
I	1	I
gene	0	I
has	0	O
two	0	O
promoters	0	O
,	0	O
P1	1	O
and	0	O
P2	1	O
.	0	O


Sustained	0	O
ventricular	0	O
tachycardia	0	O
and	0	O
its	0	O
successful	0	O
prophylaxis	0	O
during	0	O
high	0	O
-	0	O
dose	0	O
bolus	0	O
interleukin	0	B
-	0	I
2	0	I
therapy	0	O
for	0	O
metastatic	0	O
renal	0	O
cell	0	O
carcinoma	0	O
.	0	O


Abnormal	1	O
urinary	0	O
coproporphyrin	0	O
levels	0	O
in	0	O
patients	0	O
infected	0	O
by	0	O
hepatitis	0	O
C	1	O
virus	0	O
with	0	O
or	0	O
without	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
.	0	O


Here	0	O
we	0	O
investigate	0	O
the	0	O
role	0	O
of	0	O
c	0	B
-	0	I
Cbl	1	I
in	0	O
development	0	O
and	0	O
homeostasis	0	O
in	0	O
mice	0	O
by	0	O
targeted	0	O
disruption	0	O
of	0	O
the	0	O
c	0	B
-	0	I
Cbl	1	I
locus	0	I
.	0	O
c	0	B
-	0	I
Cbl	1	I
-	0	O
deficient	0	O
mice	0	O
were	0	O
viable	0	O
,	0	O
fertile	0	O
,	0	O
and	0	O
outwardly	0	O
normal	0	O
in	0	O
appearance	0	O
.	0	O


Reporter	1	O
gene	0	O
expression	0	O
analyses	0	O
indicate	0	O
that	0	O
both	0	O
WASP	1	B
promoters	0	I
show	0	O
high	0	O
levels	0	O
of	0	O
expression	0	O
in	0	O
different	0	O
hematopoietic	0	O
cell	0	O
lines	0	O
.	0	O


Hepatitis	1	O
B	1	O
virus	0	O
and	0	O
hepatoma	0	O
.	0	O


Contraction	1	O
of	0	O
the	0	O
tracheal	0	O
muscle	0	O
and	0	O
the	0	O
activity	0	O
of	0	O
stretch	0	O
receptors	0	O
in	0	O
the	0	O
trachea	0	O


CASE	1	O
REPORT	1	O
:	0	O
We	0	O
observed	0	O
a	0	O
congenital	0	O
skin	0	O
defect	0	O
located	0	O
exclusively	0	O
on	0	O
the	0	O
trunk	0	O
.	0	O


Adjuvant	1	O
therapy	0	O
for	0	O
colon	0	O
cancer	0	O
]	0	O
Surgery	1	O
alone	0	O
may	0	O
fail	0	O
to	0	O
cure	0	O
a	0	O
considerable	0	O
number	0	O
of	0	O
locally	0	O
advanced	0	O
colon	0	O
cancers	0	O
.	0	O


(	0	O
1998	0	O
)	0	O
FASEB	0	O
J	1	O
.	0	O


Examples	0	O
of	0	O
its	0	O
use	0	O
in	0	O
the	0	O
intensive	0	O
therapy	0	O
unit	0	O
are	0	O
described	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
cis	0	O
-	0	O
regulatory	0	O
elements	0	O
required	0	O
for	0	O
developmental	0	O
control	0	O
of	0	O
the	0	O
HaG3	0	B
-	0	I
A	1	I
helianthinin	0	I
gene	0	I
are	0	O
located	0	O
in	0	O
a	0	O
2	0	O
.	0	O
4	0	O
kb	0	O
upstream	0	O
region	0	O
of	0	O
this	0	O
gene	0	O
.	0	O


Five	0	O
concensus	0	O
poly	0	O
A	1	O
addition	0	O
sites	0	O
are	0	O
located	0	O
in	0	O
the	0	O
350	0	O
base	0	O
pairs	0	O
immediately	0	O
following	0	O
the	0	O
protein	0	B
IX	0	I
coding	0	O
region	0	O
.	0	O


We	0	O
report	0	O
herein	0	O
the	0	O
case	0	O
of	0	O
a	0	O
30	0	O
-	0	O
year	0	O
-	0	O
old	0	O
man	0	O
in	0	O
whom	0	O
ectopic	0	O
mediastinal	0	O
parathyroid	0	O
adenoma	0	O
was	0	O
detected	0	O
by	0	O
99mTc	0	O
-	0	O
methoxyisobutylisonitrile	0	O
scintigraphy	0	O
(	0	O
99mTc	0	O
-	0	O
MIBI	1	O
).	0	O


1	0	O
A	1	O
colonic	0	O
delivery	0	O
system	0	O
is	0	O
described	0	O
to	0	O
deliver	0	O
orally	0	O
ingested	0	O
drugs	0	O
to	0	O
the	0	O
colon	0	O
and	0	O
release	0	O
them	0	O
at	0	O
that	0	O
site	0	O
by	0	O
coating	0	O
with	0	O
an	0	O
acrylic	0	O
based	0	O
resin	0	O
(	0	O
Eudragit	0	O
S	1	O
).	0	O


A	1	O
total	0	O
of	0	O
194	0	O
STSs	0	O
map	0	O
to	0	O
this	0	O
interval	0	O
of	0	O
3	0	O
Mb	1	O
,	0	O
giving	0	O
an	0	O
average	0	O
marker	0	O
resolution	0	O
of	0	O
approximately	0	O
one	0	O
per	0	O
15	0	O
kb	0	O
.	0	O


BACKGROUND	0	O
:	0	O
The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
determine	0	O
and	0	O
compare	0	O
interleukin	0	B
-	0	I
6	0	I
(	0	O
IL	1	B
-	0	I
6	0	I
)	0	O
levels	0	O
in	0	O
gingival	0	O
crevicular	0	O
fluid	0	O
(	0	O
GCF	0	O
)	0	O
and	0	O
clinical	0	O
periodontal	0	O
findings	0	O
in	0	O
patients	0	O
with	0	O
rheumatoid	0	O
arthritis	0	O
(	0	O
RA	1	O
)	0	O
and	0	O
adult	0	O
periodontitis	0	O
(	0	O
AP	1	O
).	0	O


Assessment	1	O
of	0	O
nutrient	0	O
media	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
diptheria	0	O


Two	0	O
members	0	O
of	0	O
the	0	O
Cbl	1	B
family	0	I
have	0	O
since	0	O
been	0	O
defined	0	O
in	0	O
mammals	0	O
(	0	O
c	0	B
-	0	I
Cbl	1	I
and	0	O
Cbl	1	B
-	0	I
b	0	I
),	0	O
one	0	O
in	0	O
C	1	O
.	0	O
elegans	0	O
(	0	O
Sli	0	B
-	0	I
1	0	I
)	0	O
and	0	O
one	0	O
in	0	O
Drosophila	1	O
(	0	O
D	1	B
-	0	I
Cbl	1	I
).	0	O


More	0	O
generally	0	O
,	0	O
Ets1	0	B
and	0	O
Ets2	0	B
could	0	O
regulate	0	O
transcription	0	O
of	0	O
cellular	0	O
genes	0	O
.	0	O


We	0	O
now	0	O
show	0	O
that	0	O
RNU2	0	B
fragility	0	O
can	0	O
be	0	O
induced	0	O
by	0	O
transfection	0	O
with	0	O
an	0	O
expression	0	O
vector	0	O
encoding	0	O
Ad12	0	B
E1B	0	I
55	0	O
kDa	1	O
alone	0	O
but	0	O
not	0	O
by	0	O
an	0	O
E1	1	B
vector	0	O
encoding	0	O
all	0	O
E1	1	B
products	0	I
(	0	O
3	0	O
E1A	0	B
proteins	0	I
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
E1B	0	B
19	0	O
kDa	1	O
and	0	O
55	0	O
kDa	1	O
proteins	0	O
).	0	O


Nuclear	1	O
spin	0	O
of	0	O
249Bk	0	O
from	0	O
the	0	O
hyperfine	0	O
structure	0	O
in	0	O
its	0	O
emission	0	O
spectrum	0	O
.	0	O


Positron	1	O
emission	0	O
tomography	0	O
radioligands	0	O
for	0	O
dopamine	0	B
transporters	0	I
and	0	O
studies	0	O
in	0	O
human	0	O
and	0	O
nonhuman	0	O
primates	0	O
.	0	O


Twenty	0	O
-	0	O
two	0	O
of	0	O
the	0	O
24	0	O
patients	0	O
had	0	O
a	0	O
rise	0	O
in	0	O
the	0	O
total	0	O
serum	0	O
amylase	0	B
following	0	O
ERCP	1	O
.	0	O


Changes	0	O
in	0	O
tissue	0	O
PCO2	1	O
were	0	O
less	0	O
dramatic	0	O
and	0	O
did	0	O
not	0	O
vary	0	O
significantly	0	O
from	0	O
those	0	O
recorded	0	O
in	0	O
venous	0	O
blood	0	O
.	0	O


We	0	O
compared	0	O
the	0	O
inhibitory	0	O
effect	0	O
of	0	O
naturally	0	O
occurring	0	O
mutant	0	B
hTR	0	I
beta	0	I
1	0	I
,	0	O
artificially	0	O
created	0	O
hTR	0	B
alpha	0	I
1	0	I
mutants	0	I
,	0	O
c	0	B
-	0	I
erbA	0	I
alpha	0	I
2	0	I
and	0	O
the	0	O
human	0	B
peroxisome	0	I
proliferator	0	I
-	0	I
activated	0	I
receptor	0	I
(	0	O
hPPAR	0	B
)	0	O
on	0	O
three	0	O
prototypic	0	O
T3	1	O
-	0	O
response	0	O
elements	0	O
(	0	O
TREs	0	O
),	0	O
TRE	0	O
-	0	O
PAL	1	O
,	0	O
DR	1	O
+	0	O
4	0	O
and	0	O
TRE	0	O
-	0	O
LAP	1	O
.	0	O


Deletion	1	O
and	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
localized	0	O
a	0	O
novel	0	O
SF	1	B
-	0	I
1	0	I
regulatory	0	I
element	0	I
(	0	O
TCA	1	O
GGGCCA	0	O
;	0	O
-	0	O
137	0	O
to	0	O
-	0	O
129	0	O
)	0	O
adjacent	0	O
to	0	O
a	0	O
variant	0	O
cAMP	1	O
-	0	O
response	0	O
element	0	O
(	0	O
CRE	0	O
;	0	O
-	0	O
120	0	O
to	0	O
-	0	O
114	0	O
).	0	O


A	1	O
genetic	0	O
system	0	O
was	0	O
devised	0	O
to	0	O
select	0	O
for	0	O
pi	0	B
protein	0	I
mutants	0	I
which	0	O
discriminate	0	O
between	0	O
IR	1	O
and	0	O
DR	1	O
(	0	O
York	0	O
et	0	O
al	0	O
.,	0	O
Gene	1	O
(	0	O
Amst	0	O
.)	0	O
116	0	O
,	0	O
7	0	O
-	0	O
12	0	O
,	0	O
1992	0	O
;	0	O
York	0	O
and	0	O
Filutowicz	0	O
,	0	O
J	1	O
.	0	O


Symposium	0	O
on	0	O
presenile	0	O
spongy	0	O
encephalopathies	0	O
.	0	O


The	0	O
mechanistic	0	O
implications	0	O
of	0	O
aromatic	0	O
non	0	O
-	0	O
responsiveness	0	O
of	0	O
autonomously	0	O
expressed	0	O
A	1	O
-	0	O
domain	0	O
,	0	O
despite	0	O
its	0	O
demonstrated	0	O
ability	0	O
to	0	O
bind	0	O
phenol	0	O
,	0	O
are	0	O
discussed	0	O
.	0	O


Regulation	1	O
of	0	O
pituitary	0	O
vasopressin	0	B
V1b	0	I
receptors	0	I
plays	0	O
a	0	O
critical	0	O
role	0	O
in	0	O
regulating	0	O
pituitary	0	B
adrenocorticotropic	0	I
hormone	0	I
(	0	O
ACTH	1	B
)	0	O
secretion	0	O
during	0	O
adaptation	0	O
to	0	O
stress	0	O
.	0	O


The	0	O
state	0	O
of	0	O
the	0	O
liver	0	O
in	0	O
generalized	0	O
forms	0	O
of	0	O
meningococcal	0	O
infection	0	O


The	0	O
hepatocyte	0	B
nuclear	0	I
factor	0	I
-	0	I
3	0	I
(	0	O
HNF	1	B
-	0	I
3	0	I
)/	0	O
forkhead	0	B
(	0	O
fkh	0	B
)	0	O
proteins	0	O
consist	0	O
of	0	O
an	0	O
extensive	0	O
family	0	O
of	0	O
tissue	0	O
-	0	O
specific	0	O
and	0	O
developmental	0	O
gene	0	O
regulators	0	O
which	0	O
share	0	O
homology	0	O
within	0	O
the	0	O
winged	0	O
helix	0	O
DNA	1	O
binding	0	O
motif	0	O
.	0	O


To	1	O
isolate	0	O
this	0	O
gene	0	O
,	0	O
a	0	O
P	1	O
-	0	O
1	0	O
artificial	0	O
chromosome	0	O
(	0	O
PAC	1	O
)	0	O
library	0	O
was	0	O
screened	0	O
with	0	O
a	0	O
full	0	B
length	0	I
UGT2B7	0	I
probe	0	O
and	0	O
a	0	O
clone	0	O
of	0	O
approximately	0	O
100	0	O
kb	0	O
in	0	O
length	0	O
was	0	O
isolated	0	O
.	0	O


The	0	O
major	0	O
transcription	0	O
factors	0	O
controlling	0	O
arginine	0	O
metabolism	0	O
in	0	O
Escherichia	1	O
coli	0	O
and	0	O
Bacillus	1	O
subtilis	0	O
,	0	O
ArgR	0	B
and	0	O
AhrC	0	B
,	0	O
respectively	0	O
,	0	O
are	0	O
homologous	0	O
multimeric	0	O
proteins	0	O
that	0	O
form	0	O
l	0	O
-	0	O
arginine	0	O
-	0	O
dependent	0	O
DNA	1	O
-	0	O
binding	0	O
complexes	0	O
capable	0	O
of	0	O
repressing	0	O
transcription	0	O
of	0	O
the	0	O
biosynthetic	0	O
genes	0	O
(	0	O
both	0	O
),	0	O
activating	0	O
transcription	0	O
of	0	O
catabolic	0	O
genes	0	O
(	0	O
AhrC	0	B
only	0	O
)	0	O
or	0	O
facilitating	0	O
plasmid	0	O
dimer	0	O
resolution	0	O
(	0	O
both	0	O
).	0	O


Enoxacin	1	O
appears	0	O
to	0	O
be	0	O
well	0	O
suited	0	O
for	0	O
the	0	O
treatment	0	O
of	0	O
complicated	0	O
UTI	1	O
.	0	O


References	0	O
for	0	O
occupational	0	O
fitness	0	O
of	0	O
adolescents	0	O
with	0	O
diseases	0	O
of	0	O
the	0	O
respiratory	0	O
tract	0	O
and	0	O
lungs	0	O


The	0	O
minimal	0	O
promoter	0	O
of	0	O
the	0	O
RII	0	B
beta	0	I
gene	0	I
was	0	O
composed	0	O
of	0	O
two	0	O
adjacent	0	O
functional	0	O
elements	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
there	0	O
was	0	O
a	0	O
significant	0	O
increase	0	O
in	0	O
postdexamethasone	0	O
cortical	0	O
concentrations	0	O
with	0	O
age	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
;	0	O
r	0	O
=	0	O
0	0	O
.	0	O
31	0	O
).	0	O


Structural	1	O
analysis	0	O
and	0	O
characterization	0	O
of	0	O
tissue	0	O
and	0	O
hormonal	0	O
responsive	0	O
expression	0	O
of	0	O
the	0	O
avian	0	B
bone	0	I
sialoprotein	0	I
(	0	O
BSP	0	B
)	0	O
gene	0	O
.	0	O


Serum	1	O
Fibrin	1	B
Degradation	1	I
Products	0	I
(	0	O
FDP	1	B
)	0	O
were	0	O
determined	0	O
in	0	O
50	0	O
oral	0	O
cancer	0	O
patients	0	O
and	0	O
50	0	O
normal	0	O
individuals	0	O
prior	0	O
to	0	O
any	0	O
kind	0	O
of	0	O
treatment	0	O
.	0	O


Recombinant	1	O
unr	0	B
acts	0	O
synergistically	0	O
with	0	O
recombinant	0	O
PTB	0	B
to	0	O
stimulate	0	O
translation	0	O
dependent	0	O
on	0	O
the	0	O
rhinovirus	0	O
IRES	0	O
.	0	O


Polarised	0	O
expression	0	O
of	0	O
human	0	O
intestinal	0	O
N	1	B
-	0	I
benzoyl	0	I
-	0	I
L	1	I
-	0	I
tyrosyl	0	I
-	0	I
p	0	I
-	0	I
aminobenzoic	0	I
acid	0	I
hydrolase	0	I
(	0	O
human	0	B
meprin	0	I
)	0	O
alpha	0	O
and	0	O
beta	0	O
subunits	0	O
in	0	O
Madin	0	O
-	0	O
Darby	0	O
canine	0	O
kidney	0	O
cells	0	O
.	0	O


Jerseys	0	O
had	0	O
higher	0	O
hepatic	0	O
Cu	1	O
concentrations	0	O
than	0	O
did	0	O
Holsteins	0	O
on	0	O
d	0	O
60	0	O
(	0	O
346	0	O
vs	0	O
.	0	O


The	0	O
results	0	O
of	0	O
these	0	O
experiments	0	O
indicate	0	O
that	0	O
at	0	O
least	0	O
two	0	O
upstream	0	O
activator	0	O
sequences	0	O
(	0	O
UAS	0	O
)	0	O
mediate	0	O
maximum	0	O
induction	0	O
by	0	O
galactose	0	O
.	0	O


By	0	O
site	0	O
-	0	O
specific	0	O
mutagenesis	0	O
,	0	O
we	0	O
also	0	O
show	0	O
that	0	O
individual	0	O
ICP27	0	B
C	1	I
-	0	I
terminal	0	I
amino	0	I
acid	0	I
residues	0	I
that	0	O
are	0	O
positionally	0	O
conserved	0	O
in	0	O
ICP27	0	B
homologs	0	I
in	0	O
other	0	O
herpesviruses	0	O
(	0	O
D	1	O
-	0	O
357	0	O
,	0	O
E	1	O
-	0	O
358	0	O
,	0	O
H	1	O
-	0	O
479	0	O
,	0	O
C	1	O
-	0	O
400	0	O
,	0	O
C	1	O
-	0	O
483	0	O
,	0	O
and	0	O
C	1	O
-	0	O
488	0	O
)	0	O
are	0	O
critical	0	O
for	0	O
trans	0	O
-	0	O
regulatory	0	O
activity	0	O
.	0	O


Taken	0	O
together	0	O
,	0	O
these	0	O
observations	0	O
indicate	0	O
that	0	O
inhibition	0	O
of	0	O
p27	0	B
(	0	O
KIP1	0	B
)	0	O
transcription	0	O
through	0	O
PI3K	0	B
-	0	O
induced	0	O
FKHR	0	B
-	0	I
L1	0	I
phosphorylation	0	O
provides	0	O
a	0	O
novel	0	O
mechanism	0	O
of	0	O
regulating	0	O
cytokine	0	O
-	0	O
mediated	0	O
survival	0	O
and	0	O
proliferation	0	O
.	0	O


Efficacy	1	O
and	0	O
field	0	O
evaluation	0	O
of	0	O
Bacillus	1	O
thuringiensis	0	O
(	0	O
H	1	O
-	0	O
14	0	O
)	0	O
and	0	O
B	1	O
.	0	O
sphaericus	0	O
against	0	O
floodwater	0	O
mosquitoes	0	O
in	0	O
California	0	O
.	0	O


A	1	O
murine	0	O
expressed	0	O
sequence	0	O
tag	0	O
(	0	O
EST	1	O
)	0	O
showing	0	O
homology	0	O
with	0	O
erythropoietin	0	B
receptor	0	I
(	0	O
EPOR	0	B
)	0	O
was	0	O
identified	0	O
in	0	O
the	0	O
EST	1	O
database	0	O
.	0	O


Furthermore	0	O
,	0	O
this	0	O
study	0	O
demonstrates	0	O
that	0	O
reduced	0	O
inotropy	0	O
with	0	O
timolol	0	O
helped	0	O
uniform	0	O
local	0	O
contraction	0	O
as	0	O
estimated	0	O
by	0	O
the	0	O
increased	0	O
LONG	0	O
/	0	O
CIRC	0	O
ratio	0	O
,	0	O
a	0	O
transition	0	O
that	0	O
could	0	O
improve	0	O
contraction	0	O
efficacy	0	O
.	0	O


Furthermore	0	O
,	0	O
formation	0	O
of	0	O
foci	0	O
of	0	O
transformed	0	O
RECs	0	O
by	0	O
the	0	O
c	0	B
-	0	I
jun	0	I
/	0	O
ras	0	B
combination	0	O
was	0	O
augmented	0	O
3	0	O
-	0	O
fold	0	O
by	0	O
the	0	O
tumor	0	O
promoter	0	O
phorbol	0	O
12	0	O
-	0	O
tetradecanoate	0	O
13	0	O
-	0	O
acetate	0	O
.	0	O


Some	0	O
users	0	O
will	0	O
willingly	0	O
comply	0	O
with	0	O
management	0	O
measures	0	O
,	0	O
other	0	O
users	0	O
will	0	O
comply	0	O
in	0	O
response	0	O
to	0	O
education	0	O
,	0	O
but	0	O
there	0	O
will	0	O
be	0	O
another	0	O
group	0	O
who	0	O
will	0	O
only	0	O
respond	0	O
to	0	O
enforcement	0	O
activities	0	O
.	0	O


Trinipatch	0	O
is	0	O
a	0	O
small	0	O
,	0	O
transparent	0	O
,	0	O
matricial	0	O
,	0	O
monolayer	0	O
patch	0	O
with	0	O
an	0	O
absorption	0	O
promoter	0	O
,	0	O
marketed	0	O
in	0	O
two	0	O
dose	0	O
-	0	O
strengths	0	O
(	0	O
5	0	O
mg	0	O
/	0	O
24	0	O
h	0	O
and	0	O
10	0	O
mg	0	O
/	0	O
24	0	O
h	0	O
)	0	O
by	0	O
Laboratoires	0	O
Synthelabo	0	O
.	0	O


Four	0	O
possible	0	O
isoforms	0	O
(	0	O
hGli2	0	B
alpha	0	I
,	0	I
beta	0	I
,	0	I
gamma	0	I
,	0	I
and	0	I
delta	0	I
)	0	O
are	0	O
formed	0	O
by	0	O
combinations	0	O
of	0	O
two	0	O
independent	0	O
alternative	0	O
splicings	0	O
,	0	O
and	0	O
all	0	O
the	0	O
isoforms	0	O
could	0	O
bind	0	O
to	0	O
a	0	O
DNA	1	O
motif	0	O
,	0	O
TRE2S	0	O
,	0	O
in	0	O
the	0	O
LTR	1	O
.	0	O


Chaotic	1	O
electron	0	O
dynamics	0	O
around	0	O
a	0	O
single	0	O
elliptically	0	O
shaped	0	O
antidot	0	O
.	0	O


Based	0	O
on	0	O
peptide	0	O
map	0	O
similarities	0	O
,	0	O
partial	0	O
amino	0	O
-	0	O
terminal	0	O
sequence	0	O
data	0	O
,	0	O
and	0	O
common	0	O
genetic	0	O
origin	0	O
,	0	O
it	0	O
is	0	O
suggested	0	O
that	0	O
p60	0	B
and	0	O
p62	0	B
have	0	O
identical	0	O
amino	0	O
acid	0	O
sequences	0	O
carboxy	0	O
-	0	O
terminal	0	O
to	0	O
the	0	O
p60	0	B
initiator	0	O
methionine	0	O
(	0	O
residue	0	O
21	0	O
of	0	O
p62	0	B
).	0	O


The	0	O
virus	0	O
encodes	0	O
a	0	O
40	0	O
-	0	O
kDa	1	O
protein	0	O
,	0	O
tax	0	B
,	0	O
that	0	O
is	0	O
important	0	O
for	0	O
the	0	O
immortalization	0	O
of	0	O
T	1	O
cells	0	O
.	0	O


Finally	0	O
,	0	O
over	0	O
a	0	O
similar	0	O
range	0	O
of	0	O
QO2	1	O
,	0	O
oxygen	0	O
extraction	0	O
was	0	O
greater	0	O
in	0	O
patients	0	O
with	0	O
ARDS	1	O
compared	0	O
to	0	O
patients	0	O
with	0	O
non	0	O
-	0	O
ARDS	1	O
respiratory	0	O
failure	0	O
(	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
67	0	O
and	0	O
slope	0	O
=	0	O
-	0	O
0	0	O
.	0	O
62	0	O
vs	0	O
r	0	O
=	0	O
-	0	O
0	0	O
.	0	O
45	0	O
and	0	O
slope	0	O
=	0	O
-	0	O
0	0	O
.	0	O
35	0	O
;	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
).	0	O


We	0	O
have	0	O
measured	0	O
the	0	O
kinetics	0	O
of	0	O
the	0	O
recovery	0	O
of	0	O
mRNA	1	O
synthesis	0	O
in	0	O
the	0	O
inducible	0	O
GAL10	0	B
and	0	O
RNR3	0	B
genes	0	I
after	0	O
exposure	0	O
of	0	O
yeast	0	O
cells	0	O
to	0	O
ultraviolet	0	O
(	0	O
UV	1	O
)	0	O
radiation	0	O
.	0	O


The	0	O
Southern	0	O
technique	0	O
allowed	0	O
a	0	O
further	0	O
localization	0	O
of	0	O
the	0	O
region	0	O
of	0	O
most	0	O
extensive	0	O
transcription	0	O
to	0	O
a	0	O
1	0	O
.	0	O
8	0	O
kb	0	O
HindIII	0	B
-	0	O
EcoRI	0	B
fragment	0	O
.	0	O


The	0	O
sequenced	0	O
genomic	0	O
region	0	O
thus	0	O
accounts	0	O
for	0	O
essentially	0	O
all	0	O
of	0	O
the	0	O
longest	0	O
known	0	O
transcript	0	O
(	0	O
4	0	O
.	0	O
5	0	O
kb	0	O
),	0	O
although	0	O
the	0	O
precise	0	O
ends	0	O
of	0	O
this	0	O
transcript	0	O
have	0	O
not	0	O
been	0	O
defined	0	O
.	0	O


In	1	O
the	0	O
whole	0	O
group	0	O
of	0	O
infected	0	O
children	0	O
,	0	O
an	0	O
age	0	O
-	0	O
specific	0	O
z	0	O
score	0	O
<	0	O
-	0	O
2	0	O
for	0	O
weight	0	O
and	0	O
for	0	O
FFM	0	O
was	0	O
significantly	0	O
associated	0	O
with	0	O
an	0	O
increased	0	O
risk	0	O
of	0	O
death	0	O
[	0	O
relative	0	O
risk	0	O
(	0	O
95	0	O
%	0	O
CI	1	O
)	0	O
=	0	O
11	0	O
.	0	O
4	0	O
(	0	O
3	0	O
.	0	O
1	0	O
,	0	O
41	0	O
.	0	O
0	0	O
)	0	O
and	0	O
5	0	O
.	0	O
1	0	O
(	0	O
1	0	O
.	0	O
5	0	O
,	0	O
18	0	O
.	0	O
2	0	O
),	0	O
respectively	0	O
];	0	O
when	0	O
only	0	O
children	0	O
with	0	O
more	0	O
severe	0	O
disease	0	O
were	0	O
considered	0	O
,	0	O
only	0	O
z	0	O
score	0	O
for	0	O
weight	0	O
was	0	O
significantly	0	O
associated	0	O
with	0	O
an	0	O
increased	0	O
risk	0	O
[	0	O
4	0	O
.	0	O
6	0	O
(	0	O
1	0	O
.	0	O
4	0	O
,	0	O
14	0	O
.	0	O
9	0	O
)].	0	O


A	1	O
DNA	1	O
motif	0	O
related	0	O
to	0	O
the	0	O
cAMP	1	O
-	0	O
responsive	0	O
element	0	O
and	0	O
an	0	O
exon	0	B
-	0	I
located	0	I
activator	0	I
protein	0	I
-	0	I
2	0	I
binding	0	I
site	0	I
in	0	O
the	0	O
human	0	B
tissue	0	I
-	0	I
type	0	I
plasminogen	0	I
activator	0	I
gene	0	I
promoter	0	I
cooperate	0	O
in	0	O
basal	0	O
expression	0	O
and	0	O
convey	0	O
activation	0	O
by	0	O
phorbol	0	O
ester	0	O
and	0	O
cAMP	1	O
.	0	O


Ventilatory	1	O
management	0	O
casebook	0	O
.	0	O


Differential	1	O
signaling	0	O
and	0	O
immediate	0	B
-	0	I
early	0	I
gene	0	I
activation	0	O
by	0	O
four	0	O
splice	0	O
variants	0	O
of	0	O
the	0	O
human	0	B
pituitary	0	I
adenylate	0	I
cyclase	0	I
-	0	I
activating	0	I
polypeptide	0	I
receptor	0	I
(	0	O
hPACAP	0	B
-	0	I
R	1	I
).	0	O


Sequence	1	O
analysis	0	O
revealed	0	O
:	0	O
1	0	O
)	0	O
a	0	O
kinase	0	O
catalytic	0	O
domain	0	O
most	0	O
characteristic	0	O
of	0	O
serine	0	B
/	0	I
threonine	0	I
kinases	0	I
but	0	O
hybrid	0	O
between	0	O
members	0	O
of	0	O
the	0	O
family	0	O
of	0	O
microtubule	0	B
-	0	I
associated	0	I
protein	0	I
kinase	0	I
kinase	0	I
kinases	0	I
and	0	O
the	0	O
fibroblast	0	B
growth	0	I
factor	0	I
receptor	0	I
family	0	I
;	0	O
2	0	O
)	0	O
two	0	O
putative	0	O
alpha	0	O
-	0	O
helical	0	O
leucine	0	O
zipper	0	O
motifs	0	O
separated	0	O
by	0	O
a	0	O
25	0	O
-	0	O
amino	0	O
acid	0	O
charged	0	O
intermediate	0	O
segment	0	O
but	0	O
lacking	0	O
an	0	O
NH2	0	O
-	0	O
terminal	0	O
basic	0	O
domain	0	O
;	0	O
and	0	O
3	0	O
)	0	O
COOH	0	O
-	0	O
terminal	0	O
and	0	O
NH2	0	O
-	0	O
terminal	0	O
proline	0	O
-	0	O
rich	0	O
domains	0	O
suggestive	0	O
of	0	O
src	0	B
homology	0	I
3	0	I
(	0	O
SH3	0	B
)	0	O
domain	0	O
binding	0	O
regions	0	O
.	0	O


These	0	O
data	0	O
may	0	O
also	0	O
aid	0	O
in	0	O
the	0	O
localization	0	O
of	0	O
other	0	O
disease	0	O
loci	0	O
mapped	0	O
to	0	O
this	0	O
region	0	O
,	0	O
including	0	O
the	0	O
gene	0	O
for	0	O
tricho	0	O
-	0	O
dento	0	O
-	0	O
osseous	0	O
syndrome	0	O
and	0	O
a	0	O
murine	0	O
locus	0	O
for	0	O
susceptibility	0	O
to	0	O
ozone	0	O
-	0	O
induced	0	O
acute	0	O
lung	0	O
injury	0	O
.	0	O


Frequent	0	O
loss	0	O
of	0	O
heterozygosity	0	O
(	0	O
LOH	1	O
)	0	O
of	0	O
>	0	O
30	0	O
%	0	O
of	0	O
the	0	O
informative	0	O
cases	0	O
was	0	O
observed	0	O
on	0	O
chromosomes	0	O
3p	0	O
(	0	O
41	0	O
.	0	O
1	0	O
%),	0	O
5q	0	O
(	0	O
52	0	O
.	0	O
6	0	O
%),	0	O
6p	0	O
(	0	O
30	0	O
.	0	O
4	0	O
%),	0	O
8p	0	O
(	0	O
33	0	O
.	0	O
3	0	O
%),	0	O
9p	0	O
(	0	O
35	0	O
.	0	O
7	0	O
%),	0	O
9q	0	O
(	0	O
30	0	O
.	0	O
8	0	O
%),	0	O
11p	0	O
(	0	O
32	0	O
.	0	O
4	0	O
%),	0	O
13q	0	O
(	0	O
52	0	O
.	0	O
7	0	O
%),	0	O
17p	0	O
(	0	O
55	0	O
.	0	O
2	0	O
%),	0	O
17q	0	O
(	0	O
33	0	O
.	0	O
3	0	O
%),	0	O
18q	0	O
(	0	O
45	0	O
.	0	O
7	0	O
%),	0	O
and	0	O
19q	0	O
(	0	O
30	0	O
.	0	O
4	0	O
%).	0	O


This	0	O
test	0	O
should	0	O
provide	0	O
another	0	O
practical	0	O
means	0	O
to	0	O
study	0	O
leprosy	0	O
.	0	O


Eight	0	O
induced	0	O
cDNA	1	O
sequences	0	O
were	0	O
identified	0	O
and	0	O
designated	0	O
message	0	B
up	0	I
-	0	I
regulated	0	I
during	0	I
death	0	I
(	0	I
mud	0	I
)-	0	I
1	0	I
-	0	I
8	0	I
.	0	O


Each	0	O
recombinant	0	O
product	0	O
was	0	O
a	0	O
fusion	0	O
protein	0	O
with	0	O
a	0	O
B	1	O
domain	0	O
of	0	O
Staphylococcal	1	B
protein	0	I
A	1	I
(	0	O
SPA	1	B
).	0	O


To	1	O
analyze	0	O
the	0	O
mechanism	0	O
of	0	O
fos	0	B
/	0	O
jun	0	B
activation	0	O
by	0	O
TCDD	1	O
we	0	O
have	0	O
used	0	O
electrophoretic	0	O
mobility	0	O
shift	0	O
and	0	O
transient	0	O
expression	0	O
assays	0	O
of	0	O
reporter	0	O
gene	0	O
constructs	0	O
containing	0	O
response	0	O
elements	0	O
for	0	O
12	0	O
-	0	O
O	1	O
-	0	O
tetradecanoyl	0	O
-	0	O
phorbol	0	O
-	0	O
13	0	O
-	0	O
acetate	0	O
(	0	O
TRE	0	O
),	0	O
serum	0	O
(	0	O
SRE	0	O
),	0	O
cAMP	1	O
(	0	O
CRE	0	O
),	0	O
and	0	O
aromatic	0	O
hydrocarbons	0	O
(	0	O
AhRE	0	O
)	0	O
from	0	O
the	0	O
fos	0	B
and	0	O
jun	0	B
genes	0	I
fused	0	O
to	0	O
the	0	O
firefly	0	B
luciferase	0	I
gene	0	I
under	0	O
the	0	O
control	0	O
of	0	O
the	0	O
SV40	1	B
minimal	0	I
promoter	0	I
.	0	O


The	0	O
major	0	O
neurological	0	O
manifestations	0	O
of	0	O
brain	0	O
injury	0	O
in	0	O
these	0	O
babies	0	O
are	0	O
spastic	0	O
motor	0	O
deficits	0	O
.	0	O


Similarly	0	O
,	0	O
we	0	O
examined	0	O
whether	0	O
the	0	O
ELK1	0	B
,	0	O
SAP1a	0	B
,	0	O
FLI1	0	B
,	0	O
EWS	1	B
-	0	O
FLI1	0	B
,	0	O
ETS1	0	B
,	0	O
ETS2	0	B
,	0	O
PEA3	0	B
and	0	O
PU	1	B
.	0	I
1	0	I
proteins	0	I
can	0	O
form	0	O
ternary	0	O
complexes	0	O
with	0	O
SRF	1	B
on	0	O
the	0	O
Egr1	0	B
SREI	0	I
and	0	I
II	0	I
.	0	O


In	1	O
a	0	O
screen	0	O
for	0	O
genes	0	O
with	0	O
oncogenic	0	O
potential	0	O
expressed	0	O
by	0	O
the	0	O
murine	0	O
B6SUtA1	0	O
myeloid	0	O
progenitor	0	O
cell	0	O
line	0	O
,	0	O
we	0	O
isolated	0	O
a	0	O
2	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
leader	0	O
-	0	O
mRNA	1	O
fusion	0	O
in	0	O
coronavirus	0	O
transcription	0	O
does	0	O
not	0	O
require	0	O
direct	0	O
RNA	1	O
-	0	O
RNA	1	O
interaction	0	O
between	0	O
complementary	0	O
sequences	0	O
.	0	O


A	1	O
neonatal	0	O
alloimmune	0	O
thrombocytopenia	0	O
with	0	O
an	0	O
HPA	1	B
-	0	I
3a	0	I
(	0	O
Baka	0	O
)	0	O
incompatibility	0	O
was	0	O
confirmed	0	O
.	0	O


The	0	O
alpha	0	B
4	0	I
gene	0	I
5	0	O
'	0	O
flanking	0	O
region	0	O
acted	0	O
as	0	O
a	0	O
promoter	0	O
in	0	O
transfection	0	O
assays	0	O
.	0	O


Second	1	O
,	0	O
nitrate	0	O
induction	0	O
of	0	O
aeg	0	B
-	0	I
46	0	I
.	0	I
5	0	I
operon	0	I
expression	0	O
is	0	O
substantially	0	O
enhanced	0	O
in	0	O
narL	0	B
null	0	O
strains	0	O
(	0	O
M	1	O
.	0	O
H	1	O
.	0	O


Novel	0	O
multigene	0	O
families	0	O
encoding	0	O
highly	0	O
repetitive	0	O
peptide	0	O
sequences	0	O
.	0	O


Several	0	O
of	0	O
the	0	O
exon	0	O
boundaries	0	O
correspond	0	O
to	0	O
the	0	O
boundaries	0	O
of	0	O
functional	0	O
domains	0	O
in	0	O
the	0	O
p55	0	B
protein	0	I
.	0	O


Immunologically	0	O
reactive	0	O
insulin	0	B
levels	0	O
were	0	O
determined	0	O
in	0	O
freely	0	O
-	0	O
moving	0	O
normal	0	O
rats	0	O
offered	0	O
three	0	O
different	0	O
test	0	O
-	0	O
meals	0	O
.	0	O


To	1	O
study	0	O
the	0	O
retinal	0	O
surface	0	O
in	0	O
the	0	O
human	0	O
eye	0	O
in	0	O
normal	0	O
and	0	O
diseased	0	O
states	0	O
we	0	O
used	0	O
laser	0	O
scanning	0	O
tomography	0	O
.	0	O


Nuclear	1	O
localization	0	O
and	0	O
protein	0	O
sequence	0	O
similarities	0	O
suggested	0	O
that	0	O
the	0	O
SPT2	0	B
/	0	O
SIN1	0	B
protein	0	O
may	0	O
be	0	O
related	0	O
to	0	O
the	0	O
nonhistone	0	B
chromosomal	0	I
protein	0	I
HMG1	0	I
.	0	O


Cocaine	1	O
-	0	O
treated	0	O
rats	0	O
acquired	0	O
a	0	O
preference	0	O
for	0	O
cocaine	0	O
-	0	O
associated	0	O
contextual	0	O
stimuli	0	O
(	0	O
CS	1	O
)	0	O
relative	0	O
to	0	O
saline	0	O
-	0	O
injected	0	O
control	0	O
rats	0	O
.	0	O


Interestingly	0	O
,	0	O
EGF	1	B
,	0	O
but	0	O
not	0	O
insulin	0	B
,	0	O
stimulated	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
c	0	B
-	0	I
cbl	0	I
and	0	O
its	0	O
association	0	O
with	0	O
Crk	0	B
-	0	I
II	0	I
.	0	O


To	1	O
examine	0	O
the	0	O
biochemical	0	O
basis	0	O
of	0	O
the	0	O
end	0	O
joining	0	O
,	0	O
nuclear	0	O
extracts	0	O
were	0	O
prepared	0	O
from	0	O
a	0	O
wide	0	O
variety	0	O
of	0	O
mammalian	0	O
cell	0	O
lines	0	O
and	0	O
tested	0	O
for	0	O
their	0	O
ability	0	O
to	0	O
join	0	O
test	0	O
plasmid	0	O
substrates	0	O
.	0	O


Sustained	0	O
activation	0	O
of	0	O
p21	0	B
expression	0	O
is	0	O
proposed	0	O
to	0	O
be	0	O
a	0	O
distinguishing	0	O
feature	0	O
of	0	O
the	0	O
activity	0	O
of	0	O
NGF	1	B
that	0	O
contributes	0	O
to	0	O
PC12	0	O
growth	0	O
arrest	0	O
during	0	O
differentiation	0	O


Moreover	0	O
,	0	O
an	0	O
in	0	O
vitro	0	O
pull	0	O
-	0	O
down	0	O
assay	0	O
showed	0	O
that	0	O
Os	1	B
;	0	I
CycH	0	I
;	0	I
1	0	I
specifically	0	O
bound	0	O
to	0	O
R2	0	B
but	0	O
not	0	O
to	0	O
other	0	O
rice	0	B
CDKs	0	I
.	0	O


To	1	O
see	0	O
if	0	O
a	0	O
pulse	0	O
oximeter	0	O
can	0	O
monitor	0	O
the	0	O
fetus	0	O
during	0	O
labour	0	O
we	0	O
recruited	0	O
100	0	O
Caucasian	1	O
women	0	O
in	0	O
normal	0	O
uncomplicated	0	O
labour	0	O
.	0	O


The	0	O
mechanism	0	O
whereby	0	O
zeta	0	B
PKC	0	I
regulates	0	O
NF	1	B
-	0	I
kappa	0	I
B	1	I
most	0	O
probably	0	O
involves	0	O
the	0	O
activation	0	O
of	0	O
a	0	O
putative	0	O
I	1	B
kappa	0	I
B	1	I
kinase	0	I
of	0	O
molecular	0	O
mass	0	O
approximately	0	O
50	0	O
kDa	1	O
,	0	O
which	0	O
phosphorylates	0	O
and	0	O
inactivates	0	O
I	1	B
kappa	0	I
B	1	I
.	0	O


The	0	O
detection	0	O
ratio	0	O
peaked	0	O
at	0	O
ages	0	O
30	0	O
to	0	O
34	0	O
and	0	O
decreased	0	O
heavily	0	O
during	0	O
the	0	O
next	0	O
15	0	O
years	0	O
of	0	O
age	0	O
.	0	O


METHODS	0	O
:	0	O
A	1	O
total	0	O
of	0	O
15	0	O
pigs	0	O
were	0	O
randomised	0	O
to	0	O
ligation	0	O
of	0	O
left	0	O
marginal	0	O
arteries	0	O
(	0	O
infarction	0	O
group	0	O
,	0	O
n	0	O
=	0	O
5	0	O
),	0	O
to	0	O
TMLR	0	O
of	0	O
the	0	O
left	0	O
lateral	0	O
wall	0	O
using	0	O
a	0	O
holmium	0	O
:	0	O
yttrium	0	O
-	0	O
aluminium	0	O
garnet	0	O
(	0	O
Ho	1	O
:	0	O
YAG	0	O
)	0	O
laser	0	O
(	0	O
laser	0	O
group	0	O
,	0	O
n	0	O
=	0	O
5	0	O
),	0	O
and	0	O
to	0	O
both	0	O
(	0	O
laser	0	O
-	0	O
infarction	0	O
group	0	O
,	0	O
n	0	O
=	0	O
5	0	O
).	0	O


Shoulder	1	O
forearm	0	O
support	0	O
for	0	O
the	0	O
subluxed	0	O
shoulder	0	O
.	0	O


The	0	O
cytogenetic	0	O
expression	0	O
of	0	O
the	0	O
folate	0	O
sensitive	0	O
fragile	0	O
site	0	O
,	0	O
FRAXE	0	B
,	0	O
is	0	O
due	0	O
to	0	O
the	0	O
expansion	0	O
of	0	O
a	0	O
GCC	0	O
repeat	0	O
in	0	O
proximal	0	O
Xq28	0	O
of	0	O
the	0	O
human	0	O
X	1	O
chromosome	0	O
and	0	O
is	0	O
associated	0	O
with	0	O
a	0	O
mild	0	O
form	0	O
of	0	O
mental	0	O
handicap	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Human	1	O
preterm	0	O
birth	0	O
is	0	O
associated	0	O
with	0	O
significantly	0	O
lower	0	O
progesterone	0	O
/	0	O
17	0	O
beta	0	O
-	0	O
estradiol	0	O
ratios	0	O
than	0	O
those	0	O
of	0	O
women	0	O
with	0	O
preterm	0	O
labor	0	O
delivered	0	O
at	0	O
term	0	O
.	0	O


The	0	O
heterogeneous	0	O
nuclear	0	B
ribonucleoprotein	0	I
C	1	I
protein	0	I
tetramer	0	I
binds	0	O
U1	0	B
,	0	O
U2	0	B
,	0	O
and	0	O
U6	0	B
snRNAs	0	I
through	0	O
its	0	O
high	0	O
affinity	0	O
RNA	1	O
binding	0	O
domain	0	O
(	0	O
the	0	O
bZIP	0	O
-	0	O
like	0	O
motif	0	O
).	0	O


The	0	O
N	1	O
-	0	O
terminus	0	O
of	0	O
another	0	O
open	0	O
reading	0	O
frame	0	O
was	0	O
found	0	O
3	0	O
'	0	O
from	0	O
nifA	0	B
and	0	O
tentatively	0	O
identified	0	O
as	0	O
nifB	0	B
by	0	O
amino	0	O
acid	0	O
sequence	0	O
comparison	0	O
.	0	O


A	1	O
new	0	O
hemagglutination	0	O
test	0	O
for	0	O
the	0	O
on	0	O
-	0	O
slide	0	O
assay	0	O
of	0	O
rheumatoid	0	B
factor	0	I


Probable	0	O
progressive	0	O
multifocal	0	O
leukoencephalopathy	0	O
(	0	O
PML	1	O
)	0	O
was	0	O
diagnosed	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
clinical	0	O
picture	0	O
and	0	O
magnetic	0	O
resonance	0	O
imaging	0	O
in	0	O
a	0	O
63	0	O
-	0	O
year	0	O
-	0	O
old	0	O
man	0	O
with	0	O
a	0	O
complete	0	O
remission	0	O
of	0	O
a	0	O
non	0	O
-	0	O
Hodgkin	0	O
'	0	O
s	0	O
lymphoma	0	O
.	0	O


The	0	O
goal	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
identify	0	O
neuronal	0	O
cell	0	O
cultures	0	O
that	0	O
express	0	O
RC3	0	B
/	0	O
neurogranin	0	B
,	0	O
to	0	O
check	0	O
whether	0	O
they	0	O
are	0	O
sensitive	0	O
to	0	O
T3	1	O
,	0	O
and	0	O
to	0	O
examine	0	O
the	0	O
mechanism	0	O
of	0	O
regulation	0	O
.	0	O


A	1	O
deproteinization	0	O
procedure	0	O
was	0	O
coupled	0	O
with	0	O
a	0	O
reversed	0	O
-	0	O
phase	0	O
HPLC	1	O
separation	0	O
using	0	O
a	0	O
250x4	0	O
.	0	O
6	0	O
mm	0	O
I	1	O
.	0	O
D	1	O
.	0	O


Interaction	1	O
of	0	O
HRI	0	B
with	0	O
Hsc70	0	B
was	0	O
required	0	O
for	0	O
the	0	O
transformation	0	O
of	0	O
HRI	0	B
,	0	O
as	0	O
the	0	O
Hsc70	0	B
antagonist	0	O
clofibric	0	O
acid	0	O
inhibited	0	O
the	0	O
folding	0	O
of	0	O
HRI	0	B
into	0	O
a	0	O
mature	0	O
-	0	O
competent	0	O
conformation	0	O
.	0	O


Resolution	1	O
of	0	O
thermographic	0	O
asymmetry	0	O
and	0	O
/	0	O
or	0	O
decrease	0	O
in	0	O
Delta	1	O
T	1	O
was	0	O
demonstrated	0	O
in	0	O
approximately	0	O
81	0	O
%	0	O
of	0	O
the	0	O
post	0	O
-	0	O
treatment	0	O
population	0	O
.	0	O


Consistent	0	O
with	0	O
this	0	O
finding	0	O
,	0	O
wild	0	B
-	0	I
type	0	I
SAGA	0	I
inhibits	0	O
TBP	1	B
binding	0	O
to	0	O
the	0	O
HIS3	0	B
promoter	0	I
in	0	O
vitro	0	O
,	0	O
while	0	O
SAGA	0	B
lacking	0	O
Spt3	0	B
or	0	O
Spt8	0	B
is	0	O
not	0	O
inhibitory	0	O
.	0	O


Induction	1	O
of	0	O
Fas	1	B
ligand	0	I
expression	0	O
by	0	O
HIV	1	O
involves	0	O
the	0	O
interaction	0	O
of	0	O
Nef	0	B
with	0	O
the	0	O
T	1	B
cell	0	I
receptor	0	I
zeta	0	I
chain	0	I
.	0	O


The	0	O
conditions	0	O
for	0	O
obtaining	0	O
titanium	0	O
dioxide	0	O
from	0	O
the	0	O
substrates	0	O
titanium	0	O
tetrachloride	0	O
and	0	O
oxygen	0	O
and	0	O
applying	0	O
this	0	O
to	0	O
a	0	O
surgical	0	O
stainless	0	O
steel	0	O
of	0	O
the	0	O
type	0	O
316L	0	O
by	0	O
the	0	O
plasma	0	O
assisted	0	O
chemical	0	O
vapour	0	O
deposition	0	O
method	0	O
have	0	O
been	0	O
determined	0	O
.	0	O


We	0	O
found	0	O
a	0	O
direct	0	O
correlation	0	O
between	0	O
the	0	O
levels	0	O
of	0	O
transcription	0	O
of	0	O
the	0	O
acc	0	B
genes	0	I
and	0	O
the	0	O
rate	0	O
of	0	O
cellular	0	O
growth	0	O
.	0	O


This	0	O
virus	0	O
is	0	O
not	0	O
merely	0	O
a	0	O
South	0	O
African	0	O
strain	0	O
of	0	O
passion	0	O
fruit	0	O
woodiness	0	O
virus	0	O
(	0	O
PWV	0	O
):	0	O
the	0	O
deduced	0	O
CP	1	B
sequence	0	I
is	0	O
only	0	O
distantly	0	O
related	0	O
to	0	O
CPs	1	B
of	0	O
other	0	O
sequenced	0	O
strains	0	O
of	0	O
PWV	0	O
,	0	O
although	0	O
it	0	O
is	0	O
part	0	O
of	0	O
a	0	O
distinct	0	O
subgroup	0	O
of	0	O
potyviruses	0	O
related	0	O
to	0	O
PWV	0	O
.	0	O


Mutational	1	O
analysis	0	O
of	0	O
potential	0	O
activating	0	O
phosphorylation	0	O
sites	0	O
found	0	O
in	0	O
NIMA	0	B
,	0	O
NIM	0	B
-	0	I
1	0	I
,	0	O
and	0	O
related	0	O
protein	0	O
kinases	0	O
was	0	O
performed	0	O
on	0	O
NIMA	0	B
.	0	O


GAP	1	O
JUNCTIONS	0	O
IN	1	O
THE	0	O
BRAIN	1	O
:	0	O
PREFACE	0	O
.	0	O


Although	0	O
large	0	O
epidemiologic	0	O
studies	0	O
are	0	O
best	0	O
able	0	O
to	0	O
identify	0	O
the	0	O
relative	0	O
contributions	0	O
of	0	O
specific	0	O
risk	0	O
factors	0	O
while	0	O
controlling	0	O
for	0	O
other	0	O
risk	0	O
factors	0	O
,	0	O
new	0	O
studies	0	O
need	0	O
to	0	O
focus	0	O
on	0	O
important	0	O
unresolved	0	O
questions	0	O
.	0	O


Moreover	0	O
,	0	O
following	0	O
a	0	O
single	0	O
intravenous	0	O
injection	0	O
of	0	O
the	0	O
bicistronic	0	O
vector	0	O
complexed	0	O
to	0	O
cationic	0	O
liposomes	0	O
into	0	O
recipient	0	O
mice	0	O
,	0	O
delivery	0	O
of	0	O
MDR1	0	B
and	0	O
GC	1	B
cDNAs	0	I
was	0	O
achieved	0	O
in	0	O
all	0	O
the	0	O
organs	0	O
we	0	O
tested	0	O
.	0	O


It	1	O
was	0	O
found	0	O
that	0	O
under	0	O
the	0	O
selected	0	O
conditions	0	O
a	0	O
linear	0	O
dependence	0	O
exists	0	O
between	0	O
the	0	O
betaI	0	O
%	0	O
value	0	O
and	0	O
lgC	0	O
within	0	O
the	0	O
range	0	O
of	0	O
0	0	O
.	0	O
5	0	O
--	0	O
10	0	O
mug	0	O
ruscogenin	0	O
.	0	O


Activation	1	O
of	0	O
PKA	1	B
by	0	O
8	0	O
-	0	O
bromo	0	O
-	0	O
cyclic	0	O
AMP	1	O
or	0	O
forskolin	0	O
,	0	O
and	0	O
inhibition	0	O
of	0	O
PKC	0	B
by	0	O
calphostin	0	O
C	1	O
,	0	O
resulted	0	O
in	0	O
a	0	O
significant	0	O
decrease	0	O
in	0	O
3TP	0	B
activity	0	O
as	0	O
well	0	O
as	0	O
in	0	O
vitro	0	O
ERK	0	B
kinase	0	I
activity	0	O
in	0	O
CRAC	0	O
.	0	O


A	1	O
cDNA	1	O
clone	0	O
was	0	O
isolated	0	O
from	0	O
a	0	O
chicken	0	O
embryo	0	O
cDNA	1	O
library	0	O
employing	0	O
a	0	O
PCR	1	O
-	0	O
generated	0	O
radiolabeled	0	O
probe	0	O
specific	0	O
for	0	O
the	0	O
U3	0	B
region	0	I
of	0	O
the	0	O
Rous	0	B
sarcoma	0	I
virus	0	I
LTR	1	I
.	0	O


As	1	O
regards	0	O
lipid	0	O
metabolism	0	O
,	0	O
the	0	O
mean	0	O
values	0	O
for	0	O
total	0	O
triglycerides	0	O
,	0	O
cholesterol	0	O
,	0	O
LDL	1	B
-	0	I
cholesterol	0	I
and	0	O
HDL	1	B
-	0	I
cholesterol	0	I
seen	0	O
at	0	O
the	0	O
end	0	O
of	0	O
five	0	O
years	0	O
of	0	O
Norplant	1	O
-	0	O
2	0	O
rod	0	O
use	0	O
and	0	O
six	0	O
months	0	O
postremoval	0	O
were	0	O
similar	0	O
to	0	O
the	0	O
preinsertion	0	O
mean	0	O
.	0	O


The	0	O
metabolic	0	O
clearance	0	O
rate	0	O
of	0	O
progesterone	0	O
was	0	O
295	0	O
+/-	0	O
49	0	O
(	0	O
S	1	O
.	0	O
E	1	O
.)	0	O
1	0	O
/	0	O
day	0	O
.	0	O


Transformation	1	O
of	0	O
the	0	O
sconC3	0	B
mutant	0	I
with	0	O
sconB	0	B
+	0	I
restores	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
phenotype	0	O
.	0	O


The	0	O
exonic	0	O
sequence	0	O
encodes	0	O
a	0	O
protein	0	O
of	0	O
495	0	O
amino	0	O
acids	0	O
that	0	O
is	0	O
nearly	0	O
identical	0	O
to	0	O
the	0	O
previously	0	O
reported	0	O
protein	0	O
sequence	0	O
of	0	O
human	0	B
GPT	1	I
-	0	I
1	0	I
.	0	O


The	0	O
MVV	1	O
-	0	O
value	0	O
is	0	O
under	0	O
the	0	O
predicted	0	O
level	0	O
in	0	O
the	0	O
case	0	O
of	0	O
67	0	O
-	0	O
76	0	O
percent	0	O
.	0	O


In	1	O
this	0	O
study	0	O
26	0	O
patients	0	O
(	0	O
20	0	O
females	0	O
and	0	O
6	0	O
males	0	O
)	0	O
were	0	O
evaluated	0	O
.	0	O


Somatostatin	1	B
-	0	O
producing	0	O
endocrine	0	O
pancreatic	0	O
tumor	0	O
in	0	O
Recklinghausen	0	O
'	0	O
s	0	O
neurofibromatosis	0	O
.	0	O


Transcription	1	O
of	0	O
the	0	O
first	0	O
operon	0	O
coding	0	O
for	0	O
m	0	O
-	0	O
xylene	0	O
-	0	O
degrading	0	O
enzymes	0	O
on	0	O
the	0	O
TOL	0	O
plasmid	0	O
of	0	O
Pseudomonas	1	O
putida	0	O
is	0	O
activated	0	O
by	0	O
the	0	O
xylR	0	B
gene	0	I
product	0	I
in	0	O
the	0	O
presence	0	O
of	0	O
m	0	O
-	0	O
xylene	0	O
.	0	O


Smoking	0	O
was	0	O
regarded	0	O
as	0	O
the	0	O
major	0	O
contribution	0	O
to	0	O
pulmonary	0	O
dysfunction	0	O
.	0	O


The	0	O
ubiquitous	0	O
transcription	0	O
factor	0	O
Oct	1	B
-	0	I
1	0	I
forms	0	O
complexes	0	O
with	0	O
an	0	O
octamer	0	O
motif	0	O
present	0	O
within	0	O
FPIV	0	O
by	0	O
gel	0	O
shift	0	O
analysis	0	O
with	0	O
liver	0	O
and	0	O
kidney	0	O
extracts	0	O
,	0	O
making	0	O
Oct	1	B
-	0	I
1	0	I
an	0	O
intriguing	0	O
candidate	0	O
for	0	O
partnership	0	O
in	0	O
androgen	0	O
regulation	0	O
.	0	O


Laboratory	1	O
evaluation	0	O
was	0	O
normal	0	O
,	0	O
and	0	O
neuroimaging	0	O
failed	0	O
to	0	O
confirm	0	O
obstruction	0	O
of	0	O
venous	0	O
or	0	O
lymphatic	0	O
drainage	0	O
.	0	O


In	1	O
the	0	O
course	0	O
of	0	O
investigating	0	O
the	0	O
mechanisms	0	O
by	0	O
which	0	O
OF5	0	B
and	0	O
OF3	0	B
regulated	0	O
CYP11A1	0	B
transcription	0	O
,	0	O
we	0	O
found	0	O
that	0	O
OF5	0	B
and	0	O
OF3	0	B
bound	0	O
Sp1	0	B
and	0	O
Sp3	0	B
in	0	O
JEG	0	O
-	0	O
3	0	O
cells	0	O
.	0	O


The	0	O
present	0	O
studies	0	O
compare	0	O
the	0	O
biochemical	0	O
characteristics	0	O
,	0	O
Kanagawa	0	O
hemolysin	0	B
reactions	0	O
,	0	O
and	0	O
plasmid	0	O
profiles	0	O
of	0	O
13	0	O
patient	0	O
and	0	O
221	0	O
environmental	0	O
isolates	0	O
of	0	O
the	0	O
organism	0	O
.	0	O


Diffuse	1	O
white	0	O
matter	0	O
injury	0	O
can	0	O
be	0	O
attributed	0	O
to	0	O
radiation	0	O
and	0	O
associated	0	O
with	0	O
neurological	0	O
deficits	0	O
,	0	O
but	0	O
leukoencephalopathy	0	O
is	0	O
rarely	0	O
observed	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
chemotherapy	0	O
.	0	O


Epithelial	1	O
damage	0	O
was	0	O
not	0	O
observed	0	O
in	0	O
any	0	O
controls	0	O
but	0	O
was	0	O
in	0	O
all	0	O
tissues	0	O
exposed	0	O
to	0	O
SO2	0	O
.	0	O


Gel	1	O
route	0	O
preparation	0	O
of	0	O
low	0	O
fusing	0	O
dental	0	O
porcelain	0	O
frit	0	O
.	0	O


Together	0	O
,	0	O
our	0	O
results	0	O
show	0	O
that	0	O
tinman	0	B
is	0	O
controlled	0	O
by	0	O
an	0	O
array	0	O
of	0	O
discrete	0	O
enhancer	0	O
elements	0	O
that	0	O
are	0	O
activated	0	O
successively	0	O
by	0	O
differential	0	O
genetic	0	O
inputs	0	O
,	0	O
as	0	O
well	0	O
as	0	O
by	0	O
closely	0	O
linked	0	O
activator	0	O
and	0	O
repressor	0	O
binding	0	O
sites	0	O
within	0	O
an	0	O
early	0	O
-	0	O
acting	0	O
enhancer	0	O
,	0	O
which	0	O
restrict	0	O
twist	0	B
activity	0	O
to	0	O
specific	0	O
areas	0	O
within	0	O
the	0	O
twist	0	B
expression	0	I
domain	0	I
.	0	O


In	1	O
canrenoate	0	O
-	0	O
treated	0	O
rats	0	O
,	0	O
ANP	1	B
infusion	0	O
caused	0	O
greater	0	O
increases	0	O
in	0	O
sodium	0	O
excretion	0	O
(	0	O
FENA	1	O
from	0	O
3	0	O
.	0	O
05	0	O
+/-	0	O
0	0	O
.	0	O
71	0	O
to	0	O
7	0	O
.	0	O
21	0	O
+/-	0	O
0	0	O
.	0	O
45	0	O
%;	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
;	0	O
n	0	O
=	0	O
8	0	O
)	0	O
than	0	O
saline	0	O
infusion	0	O
(	0	O
FENA	1	O
from	0	O
4	0	O
.	0	O
16	0	O
+/-	0	O
1	0	O
.	0	O
11	0	O
to	0	O
5	0	O
.	0	O
47	0	O
+/-	0	O
0	0	O
.	0	O
66	0	O
%;	0	O
n	0	O
=	0	O
6	0	O
),	0	O
despite	0	O
the	0	O
hypocapnia	0	O
.	0	O


A	1	O
total	0	O
of	0	O
117	0	O
EVS	0	O
treatments	0	O
were	0	O
performed	0	O
on	0	O
34	0	O
patients	0	O
.	0	O


A	1	O
gene	0	O
homologous	0	O
to	0	O
the	0	O
Escherichia	1	B
coli	0	I
dnaA	0	I
gene	0	I
was	0	O
isolated	0	O
from	0	O
Pseudomonas	1	O
putida	0	O
and	0	O
its	0	O
transcription	0	O
was	0	O
investigated	0	O
in	0	O
E	1	O
.	0	O
coli	0	O
as	0	O
well	0	O
as	0	O
in	0	O
P	1	O
.	0	O
putida	0	O
.	0	O


Unlike	0	O
p59v	0	B
-	0	O
rel	0	B
,	0	O
which	0	O
is	0	O
a	0	O
nuclear	0	O
protein	0	O
in	0	O
CEF	0	O
,	0	O
indirect	0	O
immunofluorescence	0	O
showed	0	O
that	0	O
p68c	0	B
-	0	O
rel	0	B
in	0	O
JD214c	0	O
-	0	O
rel	0	O
infected	0	O
CEF	0	O
is	0	O
located	0	O
exclusively	0	O
in	0	O
the	0	O
cytoplasm	0	O
of	0	O
these	0	O
cells	0	O
,	0	O
even	0	O
though	0	O
the	0	O
sequence	0	O
of	0	O
p68c	0	B
-	0	O
rel	0	B
showed	0	O
that	0	O
it	0	O
contains	0	O
a	0	O
nuclear	0	O
localizing	0	O
sequence	0	O
identical	0	O
to	0	O
the	0	O
one	0	O
previously	0	O
identified	0	O
in	0	O
p59v	0	B
-	0	O
rel	0	B
.	0	O


The	0	O
various	0	O
available	0	O
data	0	O
strongly	0	O
suggesting	0	O
an	0	O
environmental	0	O
toxic	0	O
origin	0	O
for	0	O
the	0	O
"	0	O
sperm	0	O
fall	0	O
"	0	O
will	0	O
be	0	O
presented	0	O
as	0	O
well	0	O
as	0	O
the	0	O
most	0	O
frequently	0	O
suspected	0	O
class	0	O
of	0	O
substances	0	O
,	0	O
the	0	O
xenoestrogens	0	O
.	0	O


Genomic	1	O
clones	0	O
encompassing	0	O
the	0	O
human	0	B
ETS1	0	I
gene	0	I
were	0	O
isolated	0	O
and	0	O
utilized	0	O
to	0	O
define	0	O
its	0	O
molecular	0	O
organization	0	O
.	0	O


This	0	O
emphasizes	0	O
the	0	O
conclusion	0	O
that	0	O
CDF	1	B
-	0	I
1	0	I
is	0	O
not	0	O
an	0	O
E2F	0	B
family	0	I
member	0	I
and	0	O
points	0	O
to	0	O
profound	0	O
differences	0	O
in	0	O
the	0	O
cell	0	O
cycle	0	O
regulation	0	O
of	0	O
CDF	1	B
-	0	I
1	0	I
and	0	O
E2F	0	B
.	0	O


What	0	O
to	0	O
look	0	O
for	0	O
during	0	O
a	0	O
compliance	0	O
review	0	O
:	0	O
10	0	O
common	0	O
mistakes	0	O
made	0	O
by	0	O
SNFs	0	O
.	0	O


Clinical	1	O
course	0	O
and	0	O
nursing	0	O
care	0	O
of	0	O
patients	0	O
with	0	O
decubitus	0	O
ulcer	0	O
--	0	O
use	0	O
of	0	O
pillows	0	O
stuffed	0	O
with	0	O
buckwheat	0	O
chaff	0	O


Both	0	O
neural	0	O
and	0	O
hormonal	0	O
pathways	0	O
and	0	O
both	0	O
opiate	0	O
and	0	O
nonopiate	0	O
substances	0	O
play	0	O
roles	0	O
in	0	O
the	0	O
complex	0	O
modulation	0	O
of	0	O
pain	0	O
transmission	0	O
.	0	O


However	0	O
,	0	O
mean	0	O
food	0	O
intake	0	O
in	0	O
the	0	O
40	0	O
%	0	O
group	0	O
was	0	O
half	0	O
that	0	O
of	0	O
the	0	O
ACT	1	O
group	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
and	0	O
significantly	0	O
less	0	O
(	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
)	0	O
than	0	O
the	0	O
SEP	1	O
group	0	O
,	0	O
which	0	O
consumed	0	O
amounts	0	O
equivalent	0	O
to	0	O
65	0	O
%	0	O
of	0	O
daily	0	O
requirement	0	O
.	0	O


There	0	O
were	0	O
no	0	O
significant	0	O
differences	0	O
in	0	O
graft	0	O
survival	0	O
between	0	O
groups	0	O
with	0	O
early	0	O
graft	0	O
function	0	O
(	0	O
EGF	1	O
)	0	O
and	0	O
DGF	0	O
,	0	O
either	0	O
in	0	O
first	0	O
transplantations	0	O
or	0	O
retransplantations	0	O
.	0	O


The	0	O
bovine	0	B
papillomavirus	0	I
E2	1	I
protein	0	I
can	0	O
inhibit	0	O
the	0	O
proliferation	0	O
of	0	O
HT	1	O
-	0	O
3	0	O
cells	0	O
,	0	O
a	0	O
p53	0	B
-	0	O
negative	0	O
cervical	0	O
carcinoma	0	O
cell	0	O
line	0	O
containing	0	O
integrated	0	O
human	0	O
papillomavirus	0	O
type	0	O
30	0	O
DNA	1	O
.	0	O


After	0	O
10	0	O
months	0	O
of	0	O
treatment	0	O
with	0	O
the	0	O
conjugated	0	O
estrogen	0	O
,	0	O
both	0	O
his	0	O
height	0	O
and	0	O
weight	0	O
showed	0	O
improvement	0	O
,	0	O
while	0	O
his	0	O
bone	0	O
mineral	0	O
density	0	O
and	0	O
bone	0	O
age	0	O
were	0	O
increased	0	O
.	0	O


However	0	O
,	0	O
the	0	O
relative	0	O
positions	0	O
of	0	O
the	0	O
VV	1	O
genes	0	O
(	0	O
genus	0	O
Orthopoxvirus	1	O
)	0	O
are	0	O
different	0	O
than	0	O
those	0	O
of	0	O
the	0	O
corresponding	0	O
ORFs	0	O
in	0	O
SFV	0	O
(	0	O
genus	0	O
Leporipoxvirus	1	O
),	0	O
indicating	0	O
complex	0	O
rearrangements	0	O
of	0	O
DNA	1	O
in	0	O
the	0	O
genome	0	O
of	0	O
one	0	O
or	0	O
both	0	O
of	0	O
these	0	O
viruses	0	O
subsequent	0	O
to	0	O
their	0	O
divergence	0	O
from	0	O
a	0	O
common	0	O
ancestor	0	O
.	0	O


DIBA	0	O
was	0	O
more	0	O
sensitive	0	O
and	0	O
had	0	O
a	0	O
better	0	O
negative	0	O
predictive	0	O
value	0	O
and	0	O
a	0	O
lower	0	O
false	0	O
negative	0	O
percentage	0	O
than	0	O
DFAT	0	O
.	0	O


Functional	1	O
domains	0	O
of	0	O
c	0	B
-	0	I
myc	0	I
promoter	0	I
binding	0	I
protein	0	I
1	0	I
involved	0	O
in	0	O
transcriptional	0	O
repression	0	O
and	0	O
cell	0	O
growth	0	O
regulation	0	O
.	0	O


The	0	O
serine	0	B
/	0	I
threonine	0	I
kinase	0	I
Raf	0	I
-	0	I
1	0	I
functions	0	O
downstream	0	O
of	0	O
Rats	0	B
in	0	O
a	0	O
signal	0	O
transduction	0	O
cascade	0	O
which	0	O
transmits	0	O
mitogenic	0	O
stimuli	0	O
from	0	O
the	0	O
plasma	0	O
membrane	0	O
to	0	O
the	0	O
nucleus	0	O
.	0	O


In	1	O
10	0	O
patients	0	O
with	0	O
subacute	0	O
cardiac	0	O
tamponade	0	O
,	0	O
pulmonary	0	O
wedge	0	O
pressure	0	O
(	0	O
PWP	0	O
),	0	O
RAP	0	O
,	0	O
and	0	O
IPP	0	O
were	0	O
measured	0	O
along	0	O
with	0	O
indexes	0	O
of	0	O
systolic	0	O
function	0	O
.	0	O


The	0	O
overall	0	O
prevalence	0	O
of	0	O
HBV	1	O
markers	0	O
was	0	O
higher	0	O
among	0	O
staff	0	O
members	0	O
than	0	O
in	0	O
the	0	O
blood	0	O
donors	0	O
of	0	O
our	0	O
area	0	O
.	0	O


A	1	O
controlled	0	O
trial	0	O
of	0	O
recombinant	0	B
human	0	I
granulocyte	0	I
-	0	I
macrophage	0	I
colony	0	I
-	0	I
stimulating	0	I
factor	0	I
after	0	O
total	0	O
body	0	O
irradiation	0	O
,	0	O
high	0	O
-	0	O
dose	0	O
chemotherapy	0	O
,	0	O
and	0	O
autologous	0	O
bone	0	O
marrow	0	O
transplantation	0	O
for	0	O
acute	0	O
lymphoblastic	0	O
leukemia	0	O
or	0	O
malignant	0	O
lymphoma	0	O
.	0	O


It	1	O
encodes	0	O
a	0	O
protein	0	O
with	0	O
three	0	O
zinc	0	O
fingers	0	O
similar	0	O
to	0	O
those	0	O
of	0	O
the	0	O
transcription	0	B
factor	0	I
Sp1	0	I
.	0	O


This	0	O
would	0	O
have	0	O
had	0	O
the	0	O
effect	0	O
of	0	O
positioning	0	O
the	0	O
genes	0	O
currently	0	O
on	0	O
the	0	O
long	0	O
arm	0	O
adjacent	0	O
to	0	O
the	0	O
centromeric	0	O
heterochromatin	0	O
,	0	O
perhaps	0	O
resulting	0	O
in	0	O
a	0	O
"	0	O
position	0	O
effect	0	O
"	0	O
on	0	O
transcription	0	O
of	0	O
these	0	O
genes	0	O
.	0	O


The	0	O
Escherichia	1	B
coli	0	I
tet	0	I
-	0	I
repressor	0	I
(	0	O
TetR	0	B
)	0	O
operator	0	O
system	0	O
was	0	O
used	0	O
to	0	O
develop	0	O
a	0	O
variation	0	O
of	0	O
the	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
assay	0	O
in	0	O
which	0	O
disruptions	0	O
of	0	O
protein	0	O
-	0	O
protein	0	O
interactions	0	O
can	0	O
be	0	O
identified	0	O
by	0	O
a	0	O
positive	0	O
selection	0	O
.	0	O


The	0	O
concentrations	0	O
of	0	O
C4	1	B
and	0	O
C1	1	B
-	0	I
INH	1	I
increased	0	O
with	0	O
advancing	0	O
stage	0	O
of	0	O
disease	0	O
and	0	O
were	0	O
above	0	O
normal	0	O
mean	0	O
values	0	O
in	0	O
all	0	O
stages	0	O
.	0	O


DAF	1	B
is	0	O
a	0	O
70	0	O
kD	1	O
glycoprotein	0	O
containing	0	O
complement	0	O
regulatory	0	O
short	0	O
consensus	0	O
repeats	0	O
(	0	O
SCRs	0	O
);	0	O
its	0	O
gene	0	O
is	0	O
located	0	O
in	0	O
the	0	O
regulation	0	B
of	0	I
complement	0	I
activation	0	I
(	0	O
RCA	1	B
)	0	O
gene	0	O
cluster	0	O
on	0	O
chromosome	0	O
1	0	O
and	0	O
is	0	O
about	0	O
40	0	O
kb	0	O
in	0	O
size	0	O
.	0	O


Ras	1	B
-	0	O
GRF1	0	B
transiently	0	O
expressed	0	O
with	0	O
v	0	B
-	0	I
Src	1	I
was	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
and	0	O
showed	0	O
significant	0	O
GEF	0	B
activity	0	O
toward	0	O
Rac	0	B
,	0	O
but	0	O
not	0	O
Rho	1	B
and	0	O
Cdc42	0	B
,	0	O
which	0	O
was	0	O
comparable	0	O
with	0	O
that	0	O
induced	0	O
by	0	O
Gbetagamma	0	B
.	0	O


This	0	O
sequence	0	O
is	0	O
almost	0	O
identical	0	O
with	0	O
that	0	O
of	0	O
human	0	B
luteinizing	0	I
hormone	0	I
(	0	O
Sairam	0	O
,	0	O
M	1	O
.	0	O


However	0	O
,	0	O
by	0	O
an	0	O
NS35	0	B
-	0	I
specific	0	I
RNA	1	I
capture	0	O
assay	0	O
,	0	O
the	0	O
multimers	0	O
were	0	O
shown	0	O
to	0	O
possess	0	O
the	0	O
RNA	1	O
-	0	O
binding	0	O
activity	0	O
previously	0	O
demonstrated	0	O
for	0	O
NS35	0	B
.	0	O


Mammalian	0	O
Ras	1	B
GTPase	1	I
-	0	I
activating	0	I
protein	0	I
(	0	O
GAP	1	B
),	0	O
p120	0	B
Ras	1	I
-	0	O
GAP	1	B
,	0	O
has	0	O
been	0	O
implicated	0	O
as	0	O
both	0	O
a	0	O
downregulator	0	O
and	0	O
effector	0	O
of	0	O
Ras	1	B
proteins	0	I
,	0	O
but	0	O
its	0	O
precise	0	O
role	0	O
in	0	O
Ras	1	B
-	0	O
mediated	0	O
signal	0	O
transduction	0	O
pathways	0	O
is	0	O
unclear	0	O
.	0	O


A	1	O
prerequisite	0	O
for	0	O
the	0	O
synthesis	0	O
of	0	O
sialylated	0	O
glycoconjugates	0	O
is	0	O
the	0	O
activated	0	O
sugar	0	O
-	0	O
nucleotide	0	O
cytidine	0	O
5	0	O
'-	0	O
monophosphate	0	O
N	1	O
-	0	O
acetylneuraminic	0	O
acid	0	O
(	0	O
CMP	1	O
-	0	O
Neu5Ac	0	O
),	0	O
which	0	O
provides	0	O
a	0	O
substrate	0	O
for	0	O
Golgi	0	B
sialyltransferases	0	I
.	0	O


In	1	O
contrast	0	O
to	0	O
hemodynamic	0	O
and	0	O
histopathological	0	O
predictors	0	O
of	0	O
survival	0	O
,	0	O
vWF	1	B
:	0	O
Ag	1	O
does	0	O
not	0	O
require	0	O
invasive	0	O
techniques	0	O
to	0	O
be	0	O
determined	0	O
.	0	O


Occupational	1	O
asthma	0	O
and	0	O
rhinoconjunctivitis	0	O
from	0	O
inhalation	0	O
of	0	O
crystalline	0	O
bovine	0	B
serum	0	I
albumin	0	I
powder	0	O
.	0	O


Our	0	O
results	0	O
favor	0	O
the	0	O
possibility	0	O
that	0	O
the	0	O
Drosophila	1	B
EGF	1	I
receptor	0	I
DER	0	I
/	0	O
Egfr	1	B
expressed	0	O
by	0	O
the	0	O
EMA	1	O
cells	0	O
functions	0	O
as	0	O
a	0	O
receptor	0	O
for	0	O
Vein	1	B
.	0	O


We	0	O
also	0	O
recovered	0	O
mutations	0	O
in	0	O
the	0	O
60A	0	B
gene	0	I
which	0	O
encodes	0	O
another	0	O
TGF	1	B
-	0	I
beta	0	I
-	0	I
related	0	I
factor	0	I
in	0	O
Drosophila	1	O
.	0	O


Letter	0	O
:	0	O
Perspectives	0	O
in	0	O
bone	0	O
marrow	0	O
transplantation	0	O
.	0	O


The	0	O
antioxidant	0	O
agent	0	O
pyrrolidine	0	O
dithiocarbamate	0	O
(	0	O
PDTC	0	O
)	0	O
has	0	O
been	0	O
shown	0	O
to	0	O
protect	0	O
endothelial	0	O
cells	0	O
(	0	O
EC	1	O
)	0	O
from	0	O
pro	0	O
-	0	O
inflammatory	0	O
-	0	O
induced	0	O
and	0	O
pro	0	O
-	0	O
oxidant	0	O
-	0	O
induced	0	O
NF	1	B
-	0	I
kappaB	0	I
activation	0	O
.	0	O


These	0	O
patients	0	O
appear	0	O
to	0	O
have	0	O
slightly	0	O
better	0	O
pulmonary	0	O
function	0	O
and	0	O
nutritional	0	O
status	0	O
;	0	O
yet	0	O
,	0	O
they	0	O
seem	0	O
to	0	O
have	0	O
a	0	O
higher	0	O
degree	0	O
of	0	O
health	0	O
care	0	O
utilization	0	O
.	0	O


There	0	O
are	0	O
,	0	O
however	0	O
,	0	O
several	0	O
differences	0	O
between	0	O
the	0	O
two	0	O
new	0	O
ars	0	O
sequences	0	O
.	0	O


TFEC	0	B
,	0	O
a	0	O
basic	0	B
helix	0	I
-	0	I
loop	0	I
-	0	I
helix	0	I
protein	0	I
,	0	O
forms	0	O
heterodimers	0	O
with	0	O
TFE3	0	B
and	0	O
inhibits	0	O
TFE3	0	B
-	0	O
dependent	0	O
transcription	0	O
activation	0	O
.	0	O


We	0	O
have	0	O
carried	0	O
out	0	O
a	0	O
comprehensive	0	O
and	0	O
systematic	0	O
mutagenesis	0	O
of	0	O
the	0	O
Cse4p	0	B
N	1	I
terminus	0	I
to	0	O
analyze	0	O
its	0	O
function	0	O
.	0	O


Analyses	1	O
of	0	O
tyrosine	0	O
residue	0	O
-	0	O
mutated	0	O
PDGF	0	B
receptors	0	I
show	0	O
that	0	O
Src	1	B
homology	0	I
2	0	I
domain	0	I
-	0	I
containing	0	I
proteins	0	I
including	0	O
Src	1	B
family	0	I
kinases	0	I
,	0	O
phosphatidylinositol	0	B
3	0	I
-	0	I
kinase	0	I
,	0	O
the	0	O
GTPase	1	B
-	0	I
activating	0	I
protein	0	I
of	0	O
Ras	1	B
,	0	O
the	0	O
Src	1	B
homology	0	I
2	0	I
domain	0	I
-	0	I
containing	0	I
phosphatase	0	I
SHP	0	I
-	0	I
2	0	I
,	0	O
phospholipase	0	B
C	1	I
-	0	I
gamma	0	I
,	0	O
and	0	O
Crk	0	B
do	0	O
not	0	O
play	0	O
a	0	O
major	0	O
role	0	O
in	0	O
mediating	0	O
the	0	O
PDGF	0	B
-	0	O
induced	0	O
activation	0	O
of	0	O
p38	0	B
.	0	O


Isolation	1	O
and	0	O
characterization	0	O
of	0	O
SRF	1	B
accessory	0	I
proteins	0	I
.	0	O


CONCLUSION	0	O
(	0	O
S	1	O
):	0	O
Measuring	0	O
urinary	0	O
LH	1	B
levels	0	O
is	0	O
an	0	O
excellent	0	O
method	0	O
for	0	O
determining	0	O
ovulation	0	O
.	0	O


Multiple	1	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
signaling	0	O
pathways	0	O
connect	0	O
the	0	O
cot	0	B
oncoprotein	0	I
to	0	O
the	0	O
c	0	B
-	0	I
jun	0	I
promoter	0	I
and	0	O
to	0	O
cellular	0	O
transformation	0	O
.	0	O


Functional	1	O
effects	0	O
following	0	O
subacute	0	O
administration	0	O
.	0	O


W	1	O
.	0	O


Northern	0	O
blot	0	O
and	0	O
in	0	O
situ	0	O
hybridization	0	O
analyses	0	O
revealed	0	O
GPR34	0	B
mRNA	1	I
transcripts	0	I
in	0	O
several	0	O
human	0	O
and	0	O
rat	0	O
brain	0	O
regions	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
human	0	B
D1A	0	I
gene	0	I
belongs	0	O
to	0	O
the	0	O
category	0	O
of	0	O
tissue	0	O
-	0	O
specific	0	O
,	0	O
regulated	0	O
genes	0	O
that	0	O
have	0	O
housekeeping	0	O
-	0	O
type	0	O
promoters	0	O
.	0	O


With	0	O
each	0	O
of	0	O
the	0	O
three	0	O
pairs	0	O
of	0	O
isolates	0	O
(	0	O
case	0	O
and	0	O
suspicious	0	O
case	0	O
),	0	O
identical	0	O
IS6110	0	O
banding	0	O
patterns	0	O
were	0	O
found	0	O
suggesting	0	O
identical	0	O
MTB	0	O
strains	0	O
.	0	O


A	1	O
second	0	O
domain	0	O
,	0	O
located	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
437	0	O
amino	0	O
acids	0	O
of	0	O
IE1	0	B
,	0	O
is	0	O
required	0	O
for	0	O
inhibitory	0	O
and	0	O
DNA	1	O
-	0	O
binding	0	O
activities	0	O
.	0	O


Four	0	O
CsA	0	O
-	0	O
treated	0	O
patients	0	O
developed	0	O
persistently	0	O
elevated	0	O
UAER	0	O
>	0	O
30	0	O
mg	0	O
/	0	O
24	0	O
h	0	O
(	0	O
n	0	O
=	0	O
3	0	O
with	0	O
microalbuminuria	0	O
),	0	O
whereas	0	O
all	0	O
the	0	O
17	0	O
placebo	0	O
-	0	O
treated	0	O
patients	0	O
had	0	O
normal	0	O
UAER	0	O
(<	0	O
30	0	O
mg	0	O
/	0	O
24	0	O
h	0	O
)	0	O
after	0	O
7	0	O
years	0	O
of	0	O
follow	0	O
-	0	O
up	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
ibopamine	0	O
and	0	O
furosemide	0	O
in	0	O
130	0	O
patients	0	O
with	0	O
NYHA	1	O
Class	1	O
I	1	O
and	0	O
II	0	O
heart	0	O
failure	0	O
were	0	O
studied	0	O
in	0	O
a	0	O
parallel	0	O
,	0	O
double	0	O
-	0	O
blind	0	O
,	0	O
randomized	0	O
placebo	0	O
-	0	O
controlled	0	O
multi	0	O
-	0	O
centre	0	O
trial	0	O
.	0	O


The	0	O
SH2	0	O
-	0	O
containing	0	O
adapter	0	O
protein	0	O
GRB10	0	B
interacts	0	O
with	0	O
BCR	0	B
-	0	O
ABL	0	B
.	0	O


Candidate	0	O
tumor	0	O
suppressor	0	O
genes	0	O
,	0	O
Mts1	0	B
(	0	O
p16INK4a	0	B
)	0	O
and	0	O
Mts2	0	B
(	0	O
p15INK4b	0	B
),	0	O
have	0	O
been	0	O
mapped	0	O
to	0	O
this	0	O
region	0	O
,	0	O
but	0	O
by	0	O
Southern	0	O
blot	0	O
analysis	0	O
,	0	O
no	0	O
homozygous	0	O
deletions	0	O
were	0	O
detected	0	O
in	0	O
either	0	O
gene	0	O
.	0	O


Escherichia	1	O
of	0	O
a	0	O
single	0	O
sero	0	O
-	0	O
anzymatic	0	O
type	0	O
(	0	O
06a6b	0	O
:	0	O
K13	0	O
:	0	O
H1	1	O
)	0	O
were	0	O
isolated	0	O
in	0	O
a	0	O
group	0	O
affection	0	O
.	0	O


These	0	O
data	0	O
indicate	0	O
that	0	O
the	0	O
interaction	0	O
of	0	O
eIF4A	0	B
with	0	O
the	0	O
middle	0	O
region	0	O
of	0	O
eIF4GI	0	B
is	0	O
necessary	0	O
for	0	O
translation	0	O
,	0	O
whereas	0	O
the	0	O
interaction	0	O
of	0	O
eIF4A	0	B
with	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
plays	0	O
a	0	O
modulatory	0	O
role	0	O
.	0	O


The	0	O
FAS	1	B
promoter	0	I
was	0	O
up	0	O
-	0	O
regulated	0	O
by	0	O
insulin	0	B
through	0	O
the	0	O
proximal	0	O
insulin	0	B
response	0	I
sequence	0	I
containing	0	O
an	0	O
E	1	O
-	0	O
box	0	O
motif	0	O
at	0	O
the	0	O
-	0	O
65	0	O
-	0	O
base	0	O
pair	0	O
position	0	O
.	0	O


255	0	O
-	0	O
61	0	O
.	0	O


CD4	1	B
lymphocyte	0	O
and	0	O
viral	0	O
load	0	O
levels	0	O
suggested	0	O
an	0	O
optimal	0	O
response	0	O
to	0	O
ARV	0	O
therapy	0	O
at	0	O
the	0	O
time	0	O
LD	1	O
developed	0	O
.	0	O


The	0	O
relationships	0	O
among	0	O
four	0	O
descriptors	0	O
of	0	O
lactate	0	O
increase	0	O
:	0	O
lactate	0	O
threshold	0	O
(	0	O
LT	1	O
)	0	O
(	0	O
the	0	O
VO2	1	O
at	0	O
which	0	O
blood	0	O
lactate	0	O
concentration	0	O
begins	0	O
to	0	O
increase	0	O
above	0	O
the	0	O
resting	0	O
level	0	O
during	0	O
an	0	O
incremental	0	O
exercise	0	O
test	0	O
),	0	O
LT1	0	O
(	0	O
the	0	O
VO2	1	O
at	0	O
which	0	O
blood	0	O
lactate	0	O
increases	0	O
1	0	O
mM	1	O
above	0	O
the	0	O
resting	0	O
level	0	O
),	0	O
LT2	0	O
(	0	O
the	0	O
VO2	1	O
at	0	O
which	0	O
blood	0	O
lactate	0	O
concentration	0	O
reaches	0	O
a	0	O
fixed	0	O
value	0	O
of	0	O
2	0	O
mM	1	O
),	0	O
onset	0	O
of	0	O
blood	0	O
lactate	0	O
accumulation	0	O
(	0	O
OBLA	0	O
;	0	O
the	0	O
VO2	1	O
at	0	O
which	0	O
blood	0	O
lactate	0	O
reaches	0	O
a	0	O
concentration	0	O
of	0	O
4	0	O
mM	1	O
),	0	O
were	0	O
compared	0	O
with	0	O
aerobic	0	O
capacity	0	O
(	0	O
VO2max	0	O
)	0	O
and	0	O
12	0	O
min	0	O
running	0	O
performance	0	O
in	0	O
19	0	O
untrained	0	O
female	0	O
students	0	O
.	0	O


In	1	O
contrast	0	O
,	0	O
high	0	O
COUP	1	B
-	0	I
TFI	0	I
expression	0	O
impeded	0	O
the	0	O
neuronal	0	O
differentiation	0	O
of	0	O
P19	0	O
cells	0	O
induced	0	O
with	0	O
RA	1	O
,	0	O
resulting	0	O
in	0	O
cell	0	O
cultures	0	O
lacking	0	O
neurons	0	O
.	0	O


It	1	O
is	0	O
now	0	O
well	0	O
accepted	0	O
that	0	O
the	0	O
p53	0	B
C	1	I
-	0	I
terminus	0	I
plays	0	O
a	0	O
central	0	O
role	0	O
in	0	O
controlling	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
molecule	0	O
.	0	O


The	0	O
eukaryotic	0	O
cell	0	O
cycle	0	O
is	0	O
governed	0	O
in	0	O
part	0	O
by	0	O
the	0	O
periodic	0	O
transcription	0	O
of	0	O
cyclin	0	B
genes	0	I
,	0	O
whose	0	O
protein	0	O
products	0	O
associate	0	O
with	0	O
and	0	O
positively	0	O
regulate	0	O
the	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinases	0	I
.	0	O


High	0	O
-	0	O
affinity	0	O
site	0	O
-	0	O
specific	0	O
DNA	1	O
binding	0	O
by	0	O
POU	0	B
domain	0	I
transcription	0	I
factors	0	I
requires	0	O
both	0	O
the	0	O
POU	0	B
-	0	I
specific	0	I
and	0	O
the	0	O
POU	0	B
-	0	I
homeodomain	0	I
.	0	O


FN	0	B
-	0	O
stimulated	0	O
c	0	B
-	0	I
Src	1	I
PTK	0	I
activity	0	O
was	0	O
enhanced	0	O
by	0	O
wild	0	O
type	0	O
FAK	0	B
expression	0	O
,	0	O
whereas	0	O
FN	0	B
-	0	O
stimulated	0	O
activation	0	O
of	0	O
ERK2	0	B
was	0	O
blocked	0	O
by	0	O
expression	0	O
of	0	O
the	0	O
c	0	B
-	0	I
Src	1	I
binding	0	I
site	0	I
Phe	1	I
-	0	I
397	0	I
mutant	0	I
of	0	O
FAK	0	B
.	0	O


Current	1	O
evidence	0	O
for	0	O
this	0	O
type	0	O
of	0	O
DNA	1	O
supercoiling	0	O
-	0	O
dependent	0	O
transcriptional	0	O
coupling	0	O
,	0	O
based	0	O
largely	0	O
on	0	O
the	0	O
in	0	O
vivo	0	O
activities	0	O
of	0	O
promoters	0	O
contained	0	O
in	0	O
engineered	0	O
DNA	1	O
constructs	0	O
,	0	O
suggests	0	O
that	0	O
the	0	O
transcription	0	O
complex	0	O
must	0	O
be	0	O
physically	0	O
hindered	0	O
to	0	O
generate	0	O
DNA	1	O
supercoils	0	O
and	0	O
to	0	O
prevent	0	O
their	0	O
diffusion	0	O
throughout	0	O
the	0	O
DNA	1	O
duplex	0	O
.	0	O


Aedes	1	O
aegypti	0	O
(	0	O
L	1	O
.)	0	O
and	0	O
Aedes	1	O
albopictus	0	O
(	0	O
Skuse	0	O
)	0	O
in	0	O
Singapore	0	O
City	0	O
.	0	O


The	0	O
use	0	O
of	0	O
an	0	O
appropriate	0	O
solution	0	O
of	0	O
methylene	0	O
blue	0	O
(	0	O
0	0	O
.	0	O
2	0	O
%	0	O
in	0	O
0	0	O
.	0	O
9	0	O
M	1	O
NaCl	1	O
for	0	O
15	0	O
min	0	O
)	0	O
permits	0	O
the	0	O
staining	0	O
of	0	O
premalignant	0	O
areas	0	O
and	0	O
CIS	1	O
,	0	O
and	0	O
their	0	O
early	0	O
diagnosis	0	O
.	0	O


A	1	O
two	0	O
phase	0	O
slug	0	O
flow	0	O
tubular	0	O
heat	0	O
exchanger	0	O
was	0	O
used	0	O
for	0	O
the	0	O
thermal	0	O
inactivation	0	O
of	0	O
Listeria	1	O
monocytogenes	0	O
in	0	O
natural	0	O
infected	0	O
milk	0	O
from	0	O
seven	0	O
cows	0	O
.	0	O


Lithium	1	O
phthalocyanine	0	O
(	0	O
LiPc	0	O
)	0	O
is	0	O
a	0	O
prototype	0	O
of	0	O
another	0	O
generation	0	O
of	0	O
synthetic	0	O
,	0	O
metallic	0	O
-	0	O
organic	0	O
,	0	O
paramagnetic	0	O
crystallites	0	O
that	0	O
appear	0	O
very	0	O
useful	0	O
for	0	O
in	0	O
vitro	0	O
and	0	O
in	0	O
vivo	0	O
electron	0	O
paramagnetic	0	O
resonance	0	O
oximetry	0	O
.	0	O


We	0	O
have	0	O
determined	0	O
the	0	O
molecular	0	O
lesions	0	O
of	0	O
nine	0	O
Scm	1	B
mutant	0	I
alleles	0	I
,	0	O
which	0	O
identify	0	O
functional	0	O
requirements	0	O
for	0	O
specific	0	O
domains	0	O
.	0	O


Randomised	0	O
comparison	0	O
of	0	O
addition	0	O
of	0	O
autologous	0	O
bone	0	O
-	0	O
marrow	0	O
transplantation	0	O
to	0	O
intensive	0	O
chemotherapy	0	O
for	0	O
acute	0	O
myeloid	0	O
leukaemia	0	O
in	0	O
first	0	O
remission	0	O
:	0	O
results	0	O
of	0	O
MRC	1	O
AML	1	O
10	0	O
trial	0	O
.	0	O


METHODS	0	O
:	0	O
Forty	0	O
-	0	O
nine	0	O
cases	0	O
with	0	O
intrahepatic	0	O
multiple	0	O
nodules	0	O
of	0	O
HCC	0	O
,	0	O
by	0	O
gross	0	O
examination	0	O
,	0	O
among	0	O
184	0	O
consecutive	0	O
resected	0	O
HCCs	0	O
were	0	O
examined	0	O
clinicopathologically	0	O
.	0	O


E2	1	B
point	0	O
mutants	0	O
unable	0	O
to	0	O
inhibit	0	O
cell	0	O
growth	0	O
did	0	O
not	0	O
repress	0	O
cdc25A	0	B
and	0	O
cdc25B	0	B
expression	0	O
,	0	O
nor	0	O
did	0	O
the	0	O
cell	0	O
cycle	0	O
inhibitors	0	O
hydroxyurea	0	O
and	0	O
mimosine	0	O
.	0	O


Sensory	1	O
kindling	0	O
:	0	O
implications	0	O
for	0	O
development	0	O
of	0	O
sensory	0	O
prostheses	0	O
.	0	O


We	0	O
found	0	O
that	0	O
the	0	O
gene	0	O
segment	0	O
containing	0	O
the	0	O
mu	0	O
m	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
signals	0	O
,	0	O
along	0	O
with	0	O
536	0	O
bp	0	O
of	0	O
downstream	0	O
flanking	0	O
sequence	0	O
,	0	O
acted	0	O
as	0	O
a	0	O
transcription	0	O
terminator	0	O
in	0	O
both	0	O
myeloma	0	O
cells	0	O
and	0	O
L	1	O
cell	0	O
fibroblasts	0	O
.	0	O


These	0	O
striations	0	O
were	0	O
caused	0	O
by	0	O
contact	0	O
between	0	O
the	0	O
sharp	0	O
edge	0	O
of	0	O
the	0	O
upper	0	O
canine	0	O
and	0	O
the	0	O
P3	0	O
during	0	O
honing	0	O
(	0	O
canine	0	O
/	0	O
premolar	0	O
complex	0	O
).	0	O


BACKGROUND	0	O
:	0	O
We	0	O
conducted	0	O
a	0	O
phase	0	O
I	1	O
study	0	O
with	0	O
MDL	0	O
73	0	O
,	0	O
147EF	0	O
,	0	O
a	0	O
new	0	O
5	0	B
hydroxytryptamine	0	I
3	0	I
(	0	I
5	0	I
-	0	I
HT3	0	I
)	0	I
receptor	0	I
antagonist	0	O
,	0	O
in	0	O
25	0	O
patients	0	O
requiring	0	O
emetogenic	0	O
chemotherapy	0	O
.	0	O


Here	0	O
we	0	O
demonstrate	0	O
that	0	O
THOV	0	B
NP	1	I
contains	0	O
a	0	O
motif	0	O
(	0	O
KRxxxxxxxxxKTKK	0	O
)	0	O
at	0	O
amino	0	O
acid	0	O
positions	0	O
179	0	O
-	0	O
193	0	O
that	0	O
represents	0	O
a	0	O
classical	0	O
bipartite	0	O
nuclear	0	O
localization	0	O
signal	0	O
(	0	O
NLS	0	O
).	0	O


The	0	O
tumor	0	O
suppressor	0	O
and	0	O
transcriptional	0	O
factor	0	O
p53	0	B
is	0	O
a	0	O
phosphorylated	0	O
protein	0	O
.	0	O


CyIIa	0	B
transcription	0	O
follows	0	O
,	0	O
and	0	O
is	0	O
therefore	0	O
downstream	0	O
of	0	O
,	0	O
the	0	O
initial	0	O
specification	0	O
of	0	O
these	0	O
embryonic	0	O
domains	0	O
.	0	O


However	0	O
,	0	O
conversions	0	O
of	0	O
12	0	O
mm	0	O
or	0	O
more	0	O
from	0	O
a	0	O
documented	0	O
negative	0	O
result	0	O
indicated	0	O
spread	0	O
of	0	O
infection	0	O
.	0	O


The	0	O
incidence	0	O
of	0	O
HSV	1	O
-	0	O
2	0	O
positive	0	O
subjects	0	O
(	0	O
HSV	1	B
-	0	I
2	0	I
/	0	I
HSV	1	I
-	0	I
1	0	I
antibody	0	I
ratio	0	O
>	0	O
or	0	O
=	0	O
1	0	O
)	0	O
was	0	O
low	0	O
in	0	O
the	0	O
Jewish	0	O
Israeli	0	O
population	0	O
,	0	O
compared	0	O
to	0	O
other	0	O
demographic	0	O
areas	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
the	0	O
fatty	0	B
acid	0	I
cyclo	0	I
-	0	I
oxygenase	0	I
inhibitor	0	O
indomethacin	0	O
on	0	O
cerebral	0	O
blood	0	O
flow	0	O
(	0	O
CBF	1	O
)	0	O
and	0	O
the	0	O
metabolic	0	O
rate	0	O
for	0	O
oxygen	0	O
(	0	O
CMRO2	0	O
)	0	O
was	0	O
studied	0	O
in	0	O
paralyzed	0	O
and	0	O
artificially	0	O
ventilated	0	O
rats	0	O
.	0	O


Retroviral	1	B
nucleocapsid	0	I
proteins	0	I
(	0	O
NCPs	0	B
)	0	O
are	0	O
CCHC	0	B
-	0	I
type	0	I
zinc	0	I
finger	0	I
proteins	0	I
that	0	O
mediate	0	O
virion	0	O
RNA	1	O
binding	0	O
activities	0	O
associated	0	O
with	0	O
retrovirus	0	O
assembly	0	O
and	0	O
genomic	0	O
RNA	1	O
encapsidation	0	O
.	0	O


The	0	O
presence	0	O
of	0	O
the	0	O
foreign	0	O
gene	0	O
was	0	O
confirmed	0	O
by	0	O
Southern	0	O
analysis	0	O
.	0	O


Hair	1	O
and	0	O
blood	0	O
samples	0	O
were	0	O
taken	0	O
before	0	O
vitamin	0	O
C	1	O
or	0	O
placebo	0	O
supplementation	0	O
was	0	O
started	0	O
and	0	O
at	0	O
monthly	0	O
intervals	0	O
thereafter	0	O
for	0	O
three	0	O
months	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Chronic	1	O
alcohol	0	O
consumption	0	O
has	0	O
been	0	O
demonstrated	0	O
to	0	O
be	0	O
deleterious	0	O
to	0	O
bone	0	O
health	0	O
.	0	O


Nipponbare	0	O
as	0	O
well	0	O
as	0	O
O	1	O
.	0	O
australiensis	0	O
.	0	O


The	0	O
following	0	O
markers	0	O
were	0	O
looked	0	O
for	0	O
in	0	O
the	0	O
serum	0	O
,	0	O
skin	0	O
and	0	O
liver	0	O
of	0	O
all	0	O
patients	0	O
with	0	O
chronic	0	O
hepatitis	0	O
:	0	O
HBV	1	O
(	0	O
HBs	1	B
Ag	1	I
and	0	O
HBe	1	B
Ag	1	I
,	0	O
anti	0	B
-	0	I
HBs	1	I
,	0	O
anti	0	B
-	0	I
HBe	1	I
and	0	O
anti	0	B
-	0	I
HBc	1	I
in	0	O
the	0	O
serum	0	O
,	0	O
HBs	1	B
and	0	I
HBc	1	I
Ag	1	I
in	0	O
the	0	O
liver	0	O
);	0	O
non	0	B
-	0	I
A	1	I
non	0	I
-	0	I
B	1	I
(	0	O
non	0	B
-	0	I
A	1	I
,	0	I
non	0	I
-	0	I
B	1	I
Ag	1	I
and	0	I
antibody	0	I
,	0	O
anti	0	B
non	0	I
-	0	I
A	1	I
non	0	I
-	0	I
Bc	1	I
in	0	O
the	0	O
serum	0	O
,	0	O
non	0	B
-	0	I
A	1	I
,	0	I
non	0	I
-	0	I
Bc	1	I
Ag	1	I
in	0	O
the	0	O
liver	0	O
).	0	O


The	0	O
phosphorylation	0	O
efficiency	0	O
is	0	O
improved	0	O
by	0	O
increasing	0	O
the	0	O
number	0	O
of	0	O
N	1	O
-	0	O
terminal	0	O
arginine	0	O
residues	0	O
and	0	O
by	0	O
moving	0	O
the	0	O
arginyl	0	O
cluster	0	O
one	0	O
residue	0	O
further	0	O
away	0	O
from	0	O
the	0	O
serine	0	O
,	0	O
the	0	O
nonapeptide	0	O
(	0	O
Arg	1	O
)	0	O
4	0	O
-	0	O
Ala	1	O
-	0	O
Ala	1	O
-	0	O
Ser	1	O
-	0	O
Val	1	O
-	0	O
Ala	1	O
being	0	O
the	0	O
best	0	O
substrate	0	O
among	0	O
all	0	O
the	0	O
short	0	O
peptides	0	O
tested	0	O
(	0	O
Km	1	O
=	0	O
15	0	O
microM	0	O
).	0	O


A	1	O
developmentally	0	O
modulated	0	O
chromatin	0	O
structure	0	O
at	0	O
the	0	O
mouse	0	B
immunoglobulin	0	I
kappa	0	I
3	0	I
'	0	I
enhancer	0	I
.	0	O


Interaction	1	O
of	0	O
Ets	1	B
-	0	I
1	0	I
and	0	O
the	0	O
POU	0	B
-	0	I
homeodomain	0	I
protein	0	I
GHF	0	I
-	0	I
1	0	I
/	0	O
Pit	1	B
-	0	I
1	0	I
reconstitutes	0	O
pituitary	0	O
-	0	O
specific	0	O
gene	0	O
expression	0	O
.	0	O


CKbeta4GT	0	B
-	0	I
II	0	I
is	0	O
predicted	0	O
to	0	O
encode	0	O
a	0	O
type	0	B
II	0	I
transmembrane	0	I
glycoprotein	0	I
of	0	O
43	0	O
kDa	1	O
with	0	O
five	0	O
potential	0	O
N	1	O
-	0	O
linked	0	O
glycosylation	0	O
sites	0	O
.	0	O


We	0	O
studied	0	O
the	0	O
human	0	O
vestibulo	0	O
-	0	O
ocular	0	O
reflex	0	O
(	0	O
VOR	0	O
)	0	O
in	0	O
response	0	O
to	0	O
head	0	O
'	0	O
impulses	0	O
':	0	O
brief	0	O
,	0	O
unpredictable	0	O
,	0	O
passive	0	O
,	0	O
high	0	O
-	0	O
acceleration	0	O
(	0	O
up	0	O
to	0	O
4000	0	O
degrees	0	O
/	0	O
s2	0	O
),	0	O
low	0	O
-	0	O
amplitude	0	O
(	0	O
20	0	O
-	0	O
30	0	O
degrees	0	O
)	0	O
head	0	O
rotations	0	O
.	0	O


How	0	O
plants	0	O
respond	0	O
to	0	O
attack	0	O
by	0	O
the	0	O
range	0	O
of	0	O
herbivores	0	O
and	0	O
pathogens	0	O
that	0	O
confront	0	O
them	0	O
in	0	O
the	0	O
field	0	O
is	0	O
the	0	O
subject	0	O
of	0	O
considerable	0	O
research	0	O
by	0	O
both	0	O
molecular	0	O
biologists	0	O
and	0	O
ecologists	0	O
.	0	O


O2	1	O
and	0	O
CO2	1	O
in	0	O
the	0	O
tracheostomy	0	O
tube	0	O
were	0	O
continuously	0	O
monitored	0	O
by	0	O
mass	0	O
spectrometry	0	O
using	0	O
a	0	O
special	0	O
sample	0	O
-	0	O
hold	0	O
phase	0	O
-	0	O
locked	0	O
sampling	0	O
technique	0	O
.	0	O


The	0	O
functional	0	O
mature	0	O
domain	0	O
of	0	O
pediocin	0	B
AcH	1	I
(	0	I
Lys	1	I
+	0	I
1	0	I
to	0	I
Cys	1	I
+	0	I
44	0	I
)	0	I
is	0	O
targeted	0	O
into	0	O
the	0	O
E	1	O
.	0	O
coli	0	O
sec	0	O
machinery	0	O
and	0	O
secreted	0	O
to	0	O
the	0	O
periplasm	0	O
in	0	O
active	0	O
form	0	O
when	0	O
fused	0	O
in	0	O
frame	0	O
to	0	O
the	0	O
COOH	0	O
terminus	0	O
of	0	O
the	0	O
secretory	0	B
protein	0	I
maltose	0	I
-	0	I
binding	0	I
protein	0	I
(	0	O
MBP	1	B
).	0	O


Sixteen	0	O
patients	0	O
were	0	O
studied	0	O
within	0	O
24	0	O
hours	0	O
of	0	O
resuscitation	0	O
and	0	O
all	0	O
showed	0	O
depressed	0	O
right	0	O
ventricular	0	O
ejection	0	O
(	0	O
RVEF	0	O
)	0	O
and	0	O
/	0	O
or	0	O
an	0	O
increased	0	O
end	0	O
-	0	O
diastolic	0	O
volume	0	O
(	0	O
RVEDVI	0	O
).	0	O


ASL	1	O
-	0	O
8123	0	O
demonstrated	0	O
weak	0	O
competitive	0	O
beta	0	B
-	0	I
adrenoreceptor	0	I
blocking	0	O
activity	0	O
in	0	O
isolated	0	O
guinea	0	O
pig	0	O
right	0	O
atria	0	O
with	0	O
a	0	O
pA2	0	O
of	0	O
3	0	O
.	0	O
73	0	O
+/-	0	O
0	0	O
.	0	O
07	0	O
;	0	O
no	0	O
agonist	0	O
-	0	O
like	0	O
activity	0	O
was	0	O
observed	0	O
in	0	O
this	0	O
tissue	0	O
at	0	O
concentrations	0	O
of	0	O
ASL	1	O
-	0	O
8123	0	O
from	0	O
3	0	O
X	1	O
10	0	O
(-	0	O
5	0	O
)	0	O
to	0	O
1	0	O
X	1	O
10	0	O
(-	0	O
2	0	O
)	0	O
M	1	O
.	0	O


Radiolabelled	0	O
palmitate	0	O
was	0	O
not	0	O
incorporated	0	O
into	0	O
the	0	O
mutated	0	O
protein	0	O
,	0	O
showing	0	O
that	0	O
lipid	0	O
modification	0	O
occurs	0	O
at	0	O
the	0	O
Cys	1	O
-	0	O
22	0	O
residue	0	O
.	0	O


Porcelain	1	O
to	0	O
dentin	0	O
bond	0	O
strength	0	O
with	0	O
a	0	O
dentin	0	O
adhesive	0	O
.	0	O


Glomerular	1	O
hemodynamics	0	O
during	0	O
abortion	0	O
induced	0	O
by	0	O
RU	1	O
486	0	O
and	0	O
sepsis	0	O
in	0	O
rats	0	O
.	0	O


The	0	O
spleen	0	O
rate	0	O
of	0	O
about	0	O
600	0	O
villagers	0	O
of	0	O
RK	0	O
I	1	O
examined	0	O
was	0	O
54	0	O
.	0	O
3	0	O
%	0	O
and	0	O
the	0	O
parasite	0	O
rate	0	O
13	0	O
.	0	O
2	0	O
%	0	O
before	0	O
the	0	O
drug	0	O
intervention	0	O
.	0	O


For	0	O
signal	0	O
durations	0	O
less	0	O
than	0	O
10	0	O
ms	0	O
,	0	O
however	0	O
,	0	O
the	0	O
SoNo	0	O
and	0	O
S	1	O
pi	0	O
No	1	O
threshold	0	O
functions	0	O
converged	0	O
and	0	O
the	0	O
masking	0	O
-	0	O
level	0	O
difference	0	O
decreased	0	O
.	0	O


Northern	0	O
analysis	0	O
indicated	0	O
differential	0	O
expression	0	O
by	0	O
tissue	0	O
with	0	O
highest	0	O
expression	0	O
in	0	O
the	0	O
heart	0	O
.	0	O


Factor	1	O
V	1	O
Leiden	0	O
is	0	O
a	0	O
genetic	0	O
disorder	0	O
associated	0	O
with	0	O
an	0	O
increased	0	O
risk	0	O
of	0	O
venous	0	O
thrombosis	0	O
.	0	O


Current	1	O
status	0	O
of	0	O
telepathology	0	O
.	0	O


This	0	O
correlated	0	O
with	0	O
reduced	0	O
levels	0	O
of	0	O
secreted	0	O
hepatitis	0	B
B	1	I
e	0	I
antigen	0	I
and	0	O
increased	0	O
intracellular	0	O
levels	0	O
of	0	O
core	0	B
and	0	O
Pol	0	B
proteins	0	I
and	0	O
replicative	0	O
HBV	1	O
DNA	1	O
intermediates	0	O
.	0	O


Late	0	O
complications	0	O
of	0	O
catheterisation	0	O
for	0	O
intravenous	0	O
nutrition	0	O
.	0	O


In	1	O
this	0	O
report	0	O
,	0	O
almost	0	O
6	0	O
kb	0	O
of	0	O
DNA	1	O
sequence	0	O
is	0	O
presented	0	O
,	0	O
including	0	O
1251	0	O
bp	0	O
5	0	O
'	0	O
to	0	O
the	0	O
gene	0	O
,	0	O
over	0	O
4	0	O
kb	0	O
of	0	O
exon	0	O
and	0	O
exon	0	O
-	0	O
intron	0	O
junctions	0	O
,	0	O
and	0	O
583	0	O
bp	0	O
3	0	O
'	0	O
to	0	O
the	0	O
gene	0	O
.	0	O


The	0	O
results	0	O
showed	0	O
that	0	O
the	0	O
sensitivity	0	O
of	0	O
the	0	O
3	0	O
given	0	O
guinea	0	O
pig	0	O
strains	0	O
was	0	O
comparable	0	O
.	0	O


Myosin	1	B
light	0	I
chain	0	I
kinase	0	I
functions	0	O
downstream	0	O
of	0	O
Ras	1	B
/	0	O
ERK	0	B
to	0	O
promote	0	O
migration	0	O
of	0	O
urokinase	0	B
-	0	I
type	0	I
plasminogen	0	I
activator	0	I
-	0	O
stimulated	0	O
cells	0	O
in	0	O
an	0	O
integrin	0	B
-	0	O
selective	0	O
manner	0	O
.	0	O


Gamma	1	B
glutamyl	0	I
transpeptidase	0	I
(	0	O
GGTP	0	B
)	0	O
activity	0	O
in	0	O
the	0	O
seminal	0	O
fluid	0	O


Thus	0	O
,	0	O
phosphodiesterase	0	O
inhibitors	0	O
that	0	O
produce	0	O
an	0	O
opiate	0	O
quasi	0	O
-	0	O
withdrawal	0	O
syndrome	0	O
potentiate	0	O
interoceptive	0	O
stimuli	0	O
and	0	O
weight	0	O
loss	0	O
associated	0	O
with	0	O
the	0	O
withdrawal	0	O
syndrome	0	O
precipitated	0	O
by	0	O
naltrexone	0	O
in	0	O
morphine	0	O
-	0	O
dependent	0	O
rats	0	O
.	0	O


Visual	1	O
response	0	O
properties	0	O
of	0	O
neurons	0	O
in	0	O
four	0	O
extrastriate	0	O
visual	0	O
areas	0	O
of	0	O
the	0	O
owl	0	O
monkey	0	O
(	0	O
Aotus	0	O
trivirgatus	0	O
):	0	O
a	0	O
quantitative	0	O
comparison	0	O
of	0	O
medial	0	O
,	0	O
dorsomedial	0	O
,	0	O
dorsolateral	0	O
,	0	O
and	0	O
middle	0	O
temporal	0	O
areas	0	O
.	0	O


Lung	1	O
mesenchyme	0	O
serves	0	O
as	0	O
a	0	O
'	0	O
compleat	0	O
'	0	O
inducer	0	O
of	0	O
lung	0	O
morphogenesis	0	O
by	0	O
secreting	0	O
soluble	0	O
peptide	0	O
growth	0	O
factors	0	O
.	0	O


The	0	O
genetic	0	O
basis	0	O
for	0	O
the	0	O
expression	0	O
of	0	O
a	0	O
latent	0	O
VH	1	B
allotype	0	I
in	0	O
the	0	O
rabbit	0	O
was	0	O
investigated	0	O
.	0	O


We	0	O
have	0	O
improved	0	O
our	0	O
system	0	O
for	0	O
nuclear	0	O
contour	0	O
digitization	0	O
and	0	O
determined	0	O
its	0	O
theoretical	0	O
limitations	0	O
by	0	O
digitizing	0	O
standardized	0	O
objects	0	O
.	0	O


It	1	O
is	0	O
possible	0	O
that	0	O
the	0	O
telomeres	0	O
of	0	O
the	0	O
two	0	O
nuclei	0	O
have	0	O
different	0	O
functions	0	O
.	0	O


The	0	O
need	0	O
for	0	O
including	0	O
forensic	0	O
medical	0	O
expertise	0	O
in	0	O
the	0	O
list	0	O
of	0	O
urgent	0	O
criminal	0	O
investigative	0	O
actions	0	O


Gel	1	O
electrophoresis	0	O
and	0	O
Western	0	O
immunoblot	0	O
analyses	0	O
of	0	O
intracellular	0	O
fractions	0	O
derived	0	O
from	0	O
infected	0	O
cells	0	O
revealed	0	O
that	0	O
large	0	O
amounts	0	O
of	0	O
NS53	0	B
were	0	O
present	0	O
in	0	O
the	0	O
cytosol	0	O
and	0	O
in	0	O
association	0	O
with	0	O
the	0	O
cytoskeletal	0	O
matrix	0	O
.	0	O


Initial	1	O
screening	0	O
of	0	O
a	0	O
rat	0	O
liver	0	O
cDNA	1	O
library	0	O
with	0	O
an	0	O
oligonucleotide	0	O
probe	0	O
derived	0	O
from	0	O
the	0	O
rat	0	O
SCP2	0	B
protein	0	O
sequence	0	O
revealed	0	O
an	0	O
825	0	O
-	0	O
base	0	O
pair	0	O
cDNA	1	O
clone	0	O
coding	0	O
for	0	O
the	0	O
complete	0	O
SCP2	0	B
protein	0	O
sequence	0	O
.	0	O


Terazosin	0	O
,	0	O
a	0	O
structural	0	O
analog	0	O
of	0	O
prazosin	0	O
,	0	O
also	0	O
inhibits	0	O
alpha	0	B
1	0	I
adrenoceptors	0	I
and	0	O
is	0	O
recommended	0	O
as	0	O
once	0	O
or	0	O
twice	0	O
-	0	O
daily	0	O
therapy	0	O
.	0	O


The	0	O
debate	0	O
over	0	O
electives	0	O
--	0	O
1899	0	O
.	0	O


The	0	O
human	0	B
gp39	0	I
promoter	0	I
.	0	O


All	1	O
patients	0	O
had	0	O
elevated	0	O
levels	0	O
of	0	O
serum	0	B
IgE	1	I
antibodies	0	I
to	0	O
the	0	O
crude	0	O
soybean	0	O
extract	0	O
;	0	O
binding	0	O
values	0	O
ranged	0	O
from	0	O
2	0	O
.	0	O
3	0	O
to	0	O
28	0	O
.	0	O
1	0	O
times	0	O
that	0	O
of	0	O
a	0	O
negative	0	O
control	0	O
serum	0	O
.	0	O


The	0	O
receptor	0	B
for	0	I
hyaluronan	0	I
mediated	0	I
motility	0	I
(	0	I
RHAMM	0	I
)	0	I
gene	0	I
expression	0	O
is	0	O
markedly	0	O
elevated	0	O
in	0	O
fibrosarcomas	0	O
exposed	0	O
to	0	O
transforming	0	B
growth	0	I
factor	0	I
-	0	I
beta1	0	I
(	0	O
TGF	1	B
-	0	I
beta1	0	I
).	0	O


One	0	O
of	0	O
its	0	O
lysine	0	O
residues	0	O
is	0	O
modified	0	O
by	0	O
spermidine	0	O
to	0	O
form	0	O
hypusine	0	O
,	0	O
a	0	O
posttranslational	0	O
modification	0	O
unique	0	O
to	0	O
eIF	0	B
-	0	I
5A	0	I
.	0	O


TNF	1	B
Treatment	1	O
of	0	O
cell	0	O
activated	0	O
the	0	O
p38	0	B
MAP	1	I
kinase	0	I
pathway	0	O
,	0	O
as	0	O
revealed	0	O
by	0	O
increased	0	O
phosphorylation	0	O
of	0	O
p38	0	B
MAP	1	I
kinase	0	I
itself	0	O
,	0	O
activation	0	O
of	0	O
the	0	O
substrate	0	O
protein	0	O
MAPKAP	0	B
kinase	0	I
-	0	I
2	0	I
,	0	O
and	0	O
culminating	0	O
in	0	O
the	0	O
phosphorylation	0	O
of	0	O
the	0	O
heat	0	B
shock	0	I
protein	0	I
27	0	I
(	0	O
hsp27	0	B
).	0	O


In	1	O
addition	0	O
,	0	O
an	0	O
mck1	0	B
mds1	0	I
mrk1	0	I
triple	0	O
disruptant	0	O
was	0	O
viable	0	O
.	0	O


No	1	O
such	0	O
benefits	0	O
were	0	O
seen	0	O
for	0	O
children	0	O
with	0	O
CD4	1	B
+	0	I
counts	0	O
below	0	O
0	0	O
.	0	O
2	0	O
x	0	O
10	0	O
(	0	O
9	0	O
)	0	O
per	0	O
liter	0	O
at	0	O
entry	0	O
.	0	O


In	1	O
the	0	O
unclipped	0	O
group	0	O
arterial	0	O
pressure	0	O
decreased	0	O
50	0	O
mmHg	0	O
to	0	O
normal	0	O
by	0	O
24	0	O
h	0	O
and	0	O
was	0	O
associated	0	O
with	0	O
increased	0	O
diuresis	0	O
and	0	O
a	0	O
small	0	O
decrease	0	O
in	0	O
blood	0	O
volume	0	O
(	0	O
9	0	O
.	0	O
8	0	O
%).	0	O


Secretory	1	B
IgA	1	I
and	0	O
serum	0	B
immunoglobulins	0	I
as	0	O
indices	0	O
of	0	O
the	0	O
local	0	O
immunity	0	O
of	0	O
the	0	O
intestinal	0	O
mucosa	0	O
in	0	O
acute	0	O
leukemias	0	O


PPD	1	B
-	0	O
specific	0	O
IgG	1	B
subclass	0	O
responses	0	O
were	0	O
evident	0	O
to	0	O
all	0	O
four	0	O
IgG	1	B
subclasses	0	O
.	0	O


Optical	1	O
CD	1	O
,	0	O
and	0	O
spectral	0	O
and	0	O
activity	0	O
analyses	0	O
were	0	O
used	0	O
to	0	O
examine	0	O
reactivity	0	O
of	0	O
HO	1	B
isozymes	0	I
with	0	O
NO	1	O
species	0	O
produced	0	O
by	0	O
NO	1	O
donors	0	O
.	0	O


Defects	0	O
of	0	O
fibrillin	0	B
(	0	O
FBN1	0	B
),	0	O
a	0	O
glycoprotein	0	O
component	0	O
of	0	O
the	0	O
extracellular	0	O
microfibril	0	O
,	0	O
cause	0	O
Marfan	0	O
syndrome	0	O
.	0	O


Apoptosis	1	O
of	0	O
small	0	O
cells	0	O
is	0	O
still	0	O
observed	0	O
after	0	O
co	0	O
-	0	O
transfection	0	O
of	0	O
JBD	0	B
and	0	O
LMP1	0	B
but	0	O
in	0	O
addition	0	O
a	0	O
few	0	O
apoptotic	0	O
HD	1	O
-	0	O
MyZ	0	O
cells	0	O
with	0	O
large	0	O
fused	0	O
nuclear	0	O
masses	0	O
are	0	O
identified	0	O
suggesting	0	O
that	0	O
specific	0	O
inhibition	0	O
of	0	O
JNK	0	B
leads	0	O
also	0	O
to	0	O
apoptosis	0	O
of	0	O
LMP1	0	B
induced	0	O
RS	1	O
cells	0	O
.	0	O


Three	0	O
FGF	0	B
-	0	I
AS	1	I
cDNAs	0	I
were	0	O
isolated	0	O
;	0	O
the	0	O
full	0	B
-	0	I
length	0	I
FGF	0	I
-	0	I
AS	1	I
mRNA	1	I
and	0	O
two	0	O
alternative	0	O
splice	0	O
variants	0	O
lacking	0	O
exon	0	O
2	0	O
or	0	O
exons	0	O
2	0	O
and	0	O
3	0	O
of	0	O
the	0	O
FGF	0	B
-	0	I
AS	1	I
sequence	0	I
.	0	O


Within	0	O
the	0	O
human	0	O
enhancer	0	O
,	0	O
these	0	O
two	0	O
sites	0	O
are	0	O
located	0	O
within	0	O
the	0	O
previously	0	O
defined	0	O
DNase	1	B
I	1	I
footprints	0	I
,	0	O
NFAT	0	B
-	0	I
1	0	I
and	0	O
NFIL	0	B
-	0	I
2B	0	I
,	0	O
respectively	0	O
.	0	O


The	0	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
approximately	0	O
70	0	O
kDa	1	O
exhibits	0	O
11	0	O
imperfect	0	O
amino	0	O
acid	0	O
repeats	0	O
that	0	O
show	0	O
some	0	O
homology	0	O
to	0	O
promastigote	0	O
surface	0	O
glycoproteins	0	O
of	0	O
the	0	O
psa2	0	B
/	0	O
gp46	0	B
complex	0	O
.	0	O


In	1	O
the	0	O
rat	0	B
rnu	0	I
allele	0	I
described	0	O
here	0	O
,	0	O
a	0	O
nonsense	0	O
mutation	0	O
in	0	O
exon	0	O
8	0	O
of	0	O
the	0	O
whn	0	B
gene	0	I
was	0	O
identified	0	O
.	0	O


Electronic	1	O
structure	0	O
of	0	O
delta	0	O
-	0	O
plutonium	0	O
and	0	O
of	0	O
single	0	O
Al	1	O
,	0	O
Ga	1	O
,	0	O
and	0	O
Sc	1	O
impurities	0	O
in	0	O
delta	0	O
-	0	O
plutonium	0	O
.	0	O


CSF	1	O
adenosine	0	B
deaminase	0	I
activity	0	O
(	0	O
ADA	1	O
)	0	O
was	0	O
measured	0	O
at	0	O
the	0	O
same	0	O
time	0	O
.	0	O


The	0	O
tissue	0	O
specificity	0	O
of	0	O
gene	0	O
expression	0	O
was	0	O
identical	0	O
to	0	O
that	0	O
described	0	O
previously	0	O
for	0	O
the	0	O
CaMV	0	B
35S	0	I
domain	0	I
B	1	I
enhancer	0	I
element	0	I
.	0	O


The	0	O
alterations	0	O
in	0	O
differentiation	0	O
of	0	O
osteoprogenitor	0	O
cells	0	O
,	0	O
together	0	O
with	0	O
the	0	O
failure	0	O
of	0	O
mineralization	0	O
,	0	O
resulted	0	O
in	0	O
significantly	0	O
lower	0	O
rates	0	O
of	0	O
bone	0	O
formation	0	O
(	0	O
as	0	O
measured	0	O
by	0	O
fluorochrome	0	O
labeling	0	O
)	0	O
in	0	O
the	0	O
magnesium	0	O
-	0	O
deficient	0	O
rats	0	O
.	0	O


Anoxia	1	O
was	0	O
introduced	0	O
by	0	O
perfusing	0	O
the	0	O
gill	0	O
with	0	O
water	0	O
deprived	0	O
of	0	O
oxygen	0	O
or	0	O
by	0	O
halting	0	O
the	0	O
water	0	O
flow	0	O
to	0	O
the	0	O
gill	0	O
.	0	O


In	1	O
the	0	O
control	0	O
preparation	0	O
before	0	O
weight	0	O
was	0	O
allowed	0	O
to	0	O
increase	0	O
,	0	O
isogravimetric	0	O
capillary	0	O
pressure	0	O
(	0	O
Pci	1	O
)	0	O
averaged	0	O
8	0	O
mmHg	0	O
lower	0	O
than	0	O
colloid	0	O
osmotic	0	O
pressure	0	O
of	0	O
the	0	O
plasma	0	O
(	0	O
IIp	0	O
).	0	O


During	0	O
the	0	O
CR	1	O
/	0	O
PP	1	O
diet	0	O
only	0	O
the	0	O
HS	1	O
subjects	0	O
did	0	O
not	0	O
show	0	O
the	0	O
stress	0	O
-	0	O
induced	0	O
rise	0	O
in	0	O
depression	0	O
,	0	O
decline	0	O
in	0	O
vigour	0	O
and	0	O
cortisol	0	O
elevation	0	O
that	0	O
they	0	O
showed	0	O
after	0	O
the	0	O
PR	1	O
/	0	O
CP	1	O
diet	0	O
.	0	O


The	0	O
DNA	1	O
sequence	0	O
conferring	0	O
AP	1	B
-	0	I
1	0	I
activity	0	O
was	0	O
located	0	O
in	0	O
the	0	O
proximal	0	O
promoter	0	O
region	0	O
.	0	O


Deflunia	0	O
was	0	O
well	0	O
tolerated	0	O
by	0	O
25	0	O
patients	0	O
,	0	O
very	0	O
well	0	O
tolerated	0	O
by	0	O
2	0	O
.	0	O


DMI	0	O
and	0	O
2	0	O
-	0	O
OH	0	O
-	0	O
DMI	0	O
concentrations	0	O
were	0	O
determined	0	O
in	0	O
a	0	O
similar	0	O
group	0	O
of	0	O
61	0	O
DMI	0	O
-	0	O
treated	0	O
patients	0	O
.	0	O


The	0	O
DAP5	0	B
/	0	O
p86	0	B
apoptotic	0	O
form	0	O
was	0	O
more	0	O
potent	0	O
than	0	O
DAP5	0	B
/	0	O
p97	0	B
in	0	O
these	0	O
functional	0	O
assays	0	O
.	0	O


Its	0	O
neuromuscular	0	O
effects	0	O
are	0	O
similar	0	O
to	0	O
a	0	O
single	0	O
ED90	0	O
dose	0	O
of	0	O
vecuronium	0	O
.	0	O


Three	0	O
large	0	O
field	0	O
placement	0	O
errors	0	O
(	0	O
two	0	O
patients	0	O
with	0	O
11	0	O
.	0	O
5	0	O
and	0	O
16	0	O
.	0	O
0	0	O
mm	0	O
distances	0	O
of	0	O
the	0	O
planned	0	O
versus	0	O
simulated	0	O
isocenter	0	O
,	0	O
respectively	0	O
and	0	O
one	0	O
patient	0	O
with	0	O
a	0	O
7	0	O
degree	0	O
rotational	0	O
error	0	O
)	0	O
were	0	O
detected	0	O
and	0	O
,	0	O
as	0	O
with	0	O
the	0	O
smaller	0	O
errors	0	O
,	0	O
were	0	O
immediately	0	O
corrected	0	O
.	0	O


A	1	O
variety	0	O
of	0	O
professional	0	O
and	0	O
self	0	O
-	0	O
applied	0	O
fluoride	0	O
products	0	O
are	0	O
available	0	O
and	0	O
new	0	O
fluoride	0	O
delivery	0	O
systems	0	O
have	0	O
recently	0	O
entered	0	O
the	0	O
market	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
UBP41	0	B
may	0	O
play	0	O
an	0	O
important	0	O
role	0	O
in	0	O
the	0	O
recycling	0	O
of	0	O
ubiquitin	0	B
by	0	O
hydrolysis	0	O
of	0	O
branched	0	B
poly	0	I
-	0	I
ubiquitin	0	I
chains	0	I
generated	0	O
by	0	O
the	0	O
action	0	O
of	0	O
26	0	B
S	1	I
proteasome	0	I
on	0	O
poly	0	O
-	0	O
ubiquitinated	0	O
protein	0	O
substrates	0	O
,	0	O
as	0	O
well	0	O
as	0	O
in	0	O
the	0	O
production	0	O
of	0	O
free	0	O
ubiquitin	0	B
from	0	O
linear	0	B
poly	0	I
-	0	I
ubiquitin	0	I
chains	0	I
and	0	O
of	0	O
certain	0	O
ribosomal	0	O
proteins	0	O
from	0	O
ubiquitin	0	B
fusion	0	I
proteins	0	I
.	0	O


The	0	O
Drosophila	1	B
insulin	0	I
receptor	0	I
homolog	0	I
:	0	O
a	0	O
gene	0	O
essential	0	O
for	0	O
embryonic	0	O
development	0	O
encodes	0	O
two	0	O
receptor	0	O
isoforms	0	O
with	0	O
different	0	O
signaling	0	O
potential	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
the	0	O
combined	0	O
treatment	0	O
with	0	O
a	0	O
thromboxane	0	B
synthetase	0	I
inhibitor	0	O
and	0	O
a	0	O
thromboxane	0	B
receptor	0	I
antagonist	0	O
provides	0	O
a	0	O
better	0	O
protection	0	O
against	0	O
digoxin	0	O
intoxication	0	O
than	0	O
with	0	O
either	0	O
agent	0	O
alone	0	O
.	0	O


Confirming	0	O
measures	0	O
made	0	O
by	0	O
nurses	0	O
and	0	O
additionally	0	O
,	0	O
ABPM	1	O
for	0	O
women	0	O
,	0	O
seem	0	O
to	0	O
lessen	0	O
this	0	O
effect	0	O
.	0	O


FEV1	1	O
did	0	O
not	0	O
fall	0	O
significantly	0	O
in	0	O
patients	0	O
without	0	O
acute	0	O
or	0	O
chronic	0	O
GVHD	1	O
and	0	O
recovered	0	O
earlier	0	O
than	0	O
in	0	O
patients	0	O
without	0	O
posttransplant	0	O
pulmonary	0	O
infection	0	O
.	0	O


PKNbeta	0	B
had	0	O
high	0	O
sequence	0	O
homology	0	O
with	0	O
PKNalpha	0	B
,	0	O
originally	0	O
isolated	0	O
PKN	0	B
,	0	O
especially	0	O
in	0	O
the	0	O
repeats	0	O
of	0	O
charged	0	O
amino	0	O
acid	0	O
-	0	O
rich	0	O
region	0	O
with	0	O
leucine	0	O
-	0	O
zipper	0	O
like	0	O
sequences	0	O
(	0	O
CZ	1	O
region	0	O
/	0	O
HR1	0	O
),	0	O
in	0	O
the	0	O
carboxyl	0	O
-	0	O
terminal	0	O
catalytic	0	O
domain	0	O
,	0	O
and	0	O
in	0	O
approximately	0	O
130	0	O
amino	0	O
acid	0	O
stretch	0	O
(	0	O
D	1	O
region	0	O
/	0	O
HR2	0	O
),	0	O
located	0	O
between	0	O
CZ	1	O
region	0	O
/	0	O
HR1	0	O
and	0	O
the	0	O
catalytic	0	O
domain	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
a	0	O
patient	0	O
'	0	O
s	0	O
report	0	O
of	0	O
one	0	O
inaccurate	0	O
Clinitemp	0	O
,	0	O
we	0	O
undertook	0	O
to	0	O
investigate	0	O
the	0	O
accuracy	0	O
of	0	O
this	0	O
thermometer	0	O
.	0	O


There	0	O
was	0	O
no	0	O
correlation	0	O
between	0	O
secretor	0	O
status	0	O
and	0	O
clinical	0	O
status	0	O
,	0	O
spirometry	0	O
measurements	0	O
,	0	O
salivary	0	B
and	0	I
serum	0	I
lysozyme	0	I
levels	0	O
or	0	O
rates	0	O
of	0	O
respiratory	0	O
tract	0	O
colonization	0	O
with	0	O
P	1	O
.	0	O
aeruginosa	0	O
and	0	O
S	1	O
.	0	O
aureus	0	O
.	0	O


The	0	O
limit	0	O
between	0	O
the	0	O
cecum	0	O
and	0	O
the	0	O
ascending	0	O
colon	0	O
was	0	O
externally	0	O
marked	0	O
by	0	O
the	0	O
sulcus	0	O
cecocolicus	0	O
dorsalis	0	O
and	0	O
ventralis	0	O
.	0	O


YAC	1	O
and	0	O
cosmid	0	O
contigs	0	O
spanning	0	O
the	0	O
BRCA1	0	B
region	0	I
were	0	O
used	0	O
to	0	O
select	0	O
cDNA	1	O
clones	0	O
from	0	O
pools	0	O
of	0	O
cDNAs	0	O
derived	0	O
from	0	O
human	0	O
placenta	0	O
,	0	O
HeLa	0	O
cells	0	O
,	0	O
activated	0	O
T	1	O
cells	0	O
,	0	O
and	0	O
fetal	0	O
head	0	O
.	0	O


Clear	1	O
and	0	O
evidenced	0	O
-	0	O
based	0	O
information	0	O
should	0	O
be	0	O
provided	0	O
to	0	O
patients	0	O
as	0	O
to	0	O
the	0	O
means	0	O
of	0	O
prevention	0	O
with	0	O
special	0	O
attention	0	O
to	0	O
individual	0	O
risk	0	O
groups	0	O
such	0	O
as	0	O
IV	1	O
drug	0	O
abusers	0	O
.	0	O


The	0	O
coding	0	O
sequences	0	O
of	0	O
the	0	O
Crry	0	B
gene	0	I
encompass	0	O
over	0	O
25	0	O
kb	0	O
of	0	O
DNA	1	O
,	0	O
whereas	0	O
the	0	O
Crry	0	B
-	0	O
ps	0	B
sequences	0	O
are	0	O
included	0	O
within	0	O
a	0	O
single	0	O
5	0	B
.	0	I
6	0	I
-	0	I
kb	0	I
Eco	0	I
-	0	I
R1	0	I
fragment	0	I
.	0	O


The	0	O
immunosuppressant	0	O
FK506	0	O
inhibits	0	O
amino	0	O
acid	0	O
import	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


This	0	O
distribution	0	O
implies	0	O
that	0	O
the	0	O
polycistronic	0	O
precursor	0	O
is	0	O
imported	0	O
into	0	O
the	0	O
nucleolus	0	O
for	0	O
processing	0	O
to	0	O
the	0	O
mature	0	O
snoRNAs	0	O
,	0	O
and	0	O
that	0	O
the	0	O
import	0	O
or	0	O
processing	0	O
pathway	0	O
involves	0	O
coiled	0	O
bodies	0	O
.	0	O


A	1	O
note	0	O
on	0	O
the	0	O
phase	0	O
-	0	O
plane	0	O
technique	0	O
representation	0	O
of	0	O
cardiac	0	O
action	0	O
potentials	0	O
.	0	O


CONCLUSIONS	0	O
:	0	O
Translocation	1	O
of	0	O
bacteria	0	O
or	0	O
endotoxin	0	O
from	0	O
the	0	O
gastrointestinal	0	O
tract	0	O
into	0	O
the	0	O
bloodstream	0	O
has	0	O
been	0	O
noted	0	O
in	0	O
animal	0	O
experiments	0	O
;	0	O
however	0	O
,	0	O
translocation	0	O
was	0	O
not	0	O
detected	0	O
in	0	O
our	0	O
patients	0	O
with	0	O
hemorrhagic	0	O
shock	0	O
.	0	O


Prostate	1	B
-	0	I
specific	0	I
antigen	0	I
(	0	O
PSA	1	B
)	0	O
promoter	0	O
-	0	O
driven	0	O
androgen	0	O
-	0	O
inducible	0	O
expression	0	O
of	0	O
sodium	0	B
iodide	0	I
symporter	0	I
in	0	O
prostate	0	O
cancer	0	O
cell	0	O
lines	0	O
.	0	O


Within	0	O
each	0	O
lobe	0	O
,	0	O
the	0	O
PA	1	O
dispersion	0	O
was	0	O
up	0	O
to	0	O
10	0	O
cmH2O	0	O
at	0	O
CFV	0	O
of	0	O
90	0	O
l	0	O
/	0	O
min	0	O
;	0	O
when	0	O
flow	0	O
decreased	0	O
,	0	O
PA	1	O
at	0	O
all	0	O
sites	0	O
decreased	0	O
,	0	O
as	0	O
did	0	O
the	0	O
intralobar	0	O
dispersion	0	O
.	0	O


The	0	O
daily	0	O
administration	0	O
of	0	O
betamethasone	0	O
for	0	O
three	0	O
weeks	0	O
markedly	0	O
reduced	0	O
the	0	O
absorption	0	O
of	0	O
calcium	0	O
and	0	O
phosphate	0	O
as	0	O
well	0	O
as	0	O
the	0	O
growth	0	O
rate	0	O
.	0	O


METHODS	0	O
AND	0	O
RESULTS	0	O
:	0	O
Studies	0	O
were	0	O
undertaken	0	O
in	0	O
9	0	O
isolated	0	O
guinea	0	O
pig	0	O
hearts	0	O
,	0	O
which	0	O
demonstrated	0	O
reverse	0	O
use	0	O
-	0	O
dependent	0	O
prolongation	0	O
of	0	O
cardiac	0	O
repolarization	0	O
by	0	O
100	0	O
nmol	0	O
/	0	O
L	1	O
domperidone	0	O
.	0	O


This	0	O
complex	0	O
interacts	0	O
at	0	O
the	0	O
GTPase	1	B
domain	0	I
in	0	O
the	0	O
large	0	O
subunit	0	O
rRNA	1	O
,	0	O
overlapping	0	O
the	0	O
binding	0	O
site	0	O
of	0	O
the	0	O
protein	0	B
L11	0	I
-	0	I
like	0	I
eukaryotic	0	I
counterpart	0	I
(	0	O
Saccharomyces	1	B
cerevisiae	0	I
protein	0	I
L15	0	I
and	0	O
mammalian	0	B
protein	0	I
L12	0	I
).	0	O


It	1	O
could	0	O
also	0	O
inhibit	0	O
C1q	1	B
-	0	O
dependent	0	O
haemolysis	0	O
of	0	O
both	0	O
IgG	1	B
-	0	O
and	0	O
IgM	1	B
-	0	O
sensitized	0	O
erythrocytes	0	O
.	0	O


Postoperative	1	O
serum	0	O
ACTH	1	B
levels	0	O
were	0	O
normal	0	O
.	0	O


Isolation	1	O
of	0	O
Aeromonas	1	O
from	0	O
faeces	0	O
.	0	O


Since	0	O
glutathione	0	B
peroxidase	0	I
(	0	O
GPX	0	B
)	0	O
and	0	O
superoxide	0	B
dismutase	0	I
(	0	O
SOD	0	B
)	0	O
play	0	O
a	0	O
significant	0	O
role	0	O
in	0	O
erythrocyte	0	O
antioxidative	0	O
defence	0	O
,	0	O
it	0	O
is	0	O
very	0	O
important	0	O
to	0	O
determine	0	O
their	0	O
activity	0	O
in	0	O
occupationally	0	O
exposed	0	O
workers	0	O
.	0	O


This	0	O
short	0	O
communication	0	O
compares	0	O
a	0	O
novel	0	O
fluorimetric	0	O
microplate	0	O
enzyme	0	O
immunoassay	0	O
(	0	O
FEIA	0	O
)	0	O
with	0	O
a	0	O
commercial	0	O
time	0	O
-	0	O
resolved	0	O
fluoroimmunoassay	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
thyrotropin	0	B
in	0	O
dried	0	O
blood	0	O
spots	0	O
.	0	O


Endogenous	1	O
release	0	O
of	0	O
neuronal	0	O
serotonin	0	O
and	0	O
5	0	O
-	0	O
hydroxyindoleacetic	0	O
acid	0	O
in	0	O
the	0	O
caudate	0	O
-	0	O
putamen	0	O
of	0	O
the	0	O
rat	0	O
as	0	O
revealed	0	O
by	0	O
intracerebral	0	O
dialysis	0	O
coupled	0	O
to	0	O
high	0	O
-	0	O
performance	0	O
liquid	0	O
chromatography	0	O
with	0	O
fluorimetric	0	O
detection	0	O
.	0	O


A	1	O
xylE	0	B
transcriptional	0	I
fusion	0	I
to	0	O
the	0	O
putative	0	O
mxbD	0	B
promoter	0	I
showed	0	O
low	0	O
-	0	O
level	0	O
expression	0	O
in	0	O
wild	0	O
-	0	O
type	0	O
cells	0	O
grown	0	O
on	0	O
one	0	O
-	0	O
carbon	0	O
(	0	O
C1	1	O
)	0	O
compounds	0	O
and	0	O
no	0	O
detectable	0	O
expression	0	O
in	0	O
cells	0	O
grown	0	O
on	0	O
succinate	0	O
.	0	O


In	1	O
the	0	O
absence	0	O
of	0	O
Swi4	0	B
and	0	O
Swi6	0	B
cell	0	O
viability	0	O
is	0	O
lost	0	O
,	0	O
but	0	O
can	0	O
be	0	O
regained	0	O
by	0	O
ectopic	0	O
expression	0	O
of	0	O
the	0	O
G1	0	B
cyclin	0	I
encoding	0	I
genes	0	I
,	0	O
CLN1	0	B
or	0	O
CLN2	0	B
.	0	O


This	0	O
suggested	0	O
that	0	O
baboon	0	B
liver	0	I
class	0	I
I	1	I
ADH	1	I
is	0	O
of	0	O
the	0	O
same	0	O
ancestral	0	O
lineage	0	O
as	0	O
the	0	O
human	0	B
ADH	1	I
-	0	I
beta	0	I
.	0	O


DNase	1	B
I	1	I
footprinting	0	O
analysis	0	O
indicated	0	O
that	0	O
DREF	0	B
binds	0	O
to	0	O
the	0	O
24	0	O
-	0	O
bp	0	O
DRE	1	O
region	0	O
of	0	O
the	0	O
DNA	1	B
polymerase	0	I
alpha	0	I
gene	0	I
in	0	O
which	0	O
8	0	O
-	0	O
bp	0	O
palindromic	0	O
sequences	0	O
are	0	O
centered	0	O
.	0	O


Effects	0	O
of	0	O
ketamine	0	O
on	0	O
the	0	O
circulatory	0	O
functions	0	O
and	0	O
body	0	O
tissue	0	O
oxygenation	0	O
in	0	O
dogs	0	O
under	0	O
normal	0	O
and	0	O
hypovolemic	0	O
conditions	0	O
.	0	O


The	0	O
cytoprotective	0	O
and	0	O
antiulcer	0	O
activities	0	O
of	0	O
the	0	O
antacid	0	O
magaldrate	0	O
(	0	O
ES	1	O
Riopan	0	O
)	0	O
as	0	O
well	0	O
as	0	O
its	0	O
effects	0	O
on	0	O
gastric	0	O
mucosal	0	O
blood	0	O
flow	0	O
and	0	O
mucus	0	O
secretions	0	O
,	0	O
were	0	O
determined	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


Sample	1	O
treatment	0	O
was	0	O
optimized	0	O
in	0	O
order	0	O
to	0	O
achieve	0	O
a	0	O
complete	0	O
extraction	0	O
of	0	O
labetalol	0	O
diastereoisomers	0	O
and	0	O
to	0	O
avoid	0	O
racemization	0	O
during	0	O
extraction	0	O
.	0	O


STP1	0	B
is	0	O
an	0	O
unessential	0	O
yeast	0	O
gene	0	O
involved	0	O
in	0	O
the	0	O
removal	0	O
of	0	O
intervening	0	O
sequences	0	O
from	0	O
some	0	O
,	0	O
but	0	O
not	0	O
all	0	O
,	0	O
families	0	O
of	0	O
intervening	0	O
sequence	0	O
-	0	O
containing	0	O
pre	0	O
-	0	O
tRNAs	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
dietary	0	O
safflower	0	O
phospholipids	0	O
may	0	O
be	0	O
a	0	O
valuable	0	O
ingredient	0	O
to	0	O
layers	0	O
for	0	O
reducing	0	O
liver	0	O
triglycerides	0	O
and	0	O
serum	0	O
cholesterol	0	O
without	0	O
any	0	O
adverse	0	O
effects	0	O
.	0	O


Inhibition	1	O
of	0	O
the	0	O
apolipoprotein	0	B
B	1	I
mRNA	1	I
editing	0	O
enzyme	0	O
-	0	O
complex	0	O
by	0	O
hnRNP	1	B
C1	1	I
protein	0	I
and	0	O
40S	0	B
hnRNP	1	I
complexes	0	I
.	0	O


Based	0	O
on	0	O
the	0	O
estimated	0	O
values	0	O
of	0	O
divergence	0	O
of	0	O
apobec1	0	B
sequences	0	I
in	0	O
terms	0	O
of	0	O
the	0	O
numbers	0	O
of	0	O
synonymous	0	O
and	0	O
non	0	O
-	0	O
synonymous	0	O
suhstitutions	0	O
per	0	O
site	0	O
,	0	O
we	0	O
found	0	O
that	0	O
apobec1	0	B
is	0	O
a	0	O
fairly	0	O
rapidly	0	O
evolving	0	O
protein	0	O
.	0	O


Structural	1	O
organization	0	O
of	0	O
the	0	O
gene	0	O
encoding	0	O
the	0	O
human	0	B
lipocalin	0	I
tear	0	I
prealbumin	0	I
and	0	O
synthesis	0	O
of	0	O
the	0	O
recombinant	0	O
protein	0	O
in	0	O
Escherichia	1	O
coli	0	O
.	0	O


Microcirculatory	1	O
oxygenation	0	O
and	0	O
shunting	0	O
in	0	O
sepsis	0	O
and	0	O
shock	0	O
.	0	O


Using	0	O
various	0	O
techniques	0	O
,	0	O
we	0	O
have	0	O
undertaken	0	O
a	0	O
systematic	0	O
analysis	0	O
of	0	O
the	0	O
natural	0	O
TATA	0	O
-	0	O
less	0	O
human	0	B
DNA	1	I
polymerase	0	I
beta	0	I
(	0	O
beta	0	B
-	0	I
pol	0	I
)	0	O
gene	0	O
promoter	0	O
.	0	O


Adduction	1	O
of	0	O
the	0	O
human	0	B
N	1	I
-	0	I
ras	0	I
codon	0	I
61	0	I
sequence	0	I
with	0	O
(-)-(	0	O
7S	0	O
,	0	O
8R	0	O
,	0	O
9R	0	O
,	0	O
10S	0	O
)-	0	O
7	0	O
,	0	O
8	0	O
-	0	O
dihydroxy	0	O
-	0	O
9	0	O
,	0	O
10	0	O
-	0	O
epoxy	0	O
-	0	O
7	0	O
,	0	O
8	0	O
,	0	O
9	0	O
,	0	O
10	0	O
-	0	O
tetrahydrobenzo	0	O
[	0	O
a	0	O
]	0	O
pyrene	0	O
:	0	O
structural	0	O
refinement	0	O
of	0	O
the	0	O
intercalated	0	O
SRSR	0	O
(	0	O
61	0	O
,	0	O
2	0	O
)	0	O
(-)-(	0	O
7S	0	O
,	0	O
8R	0	O
,	0	O
9S	0	O
,	0	O
10R	0	O
)-	0	O
N6	0	O
-[	0	O
10	0	O
-(	0	O
7	0	O
,	0	O
8	0	O
,	0	O
9	0	O
,	0	O
10	0	O
-	0	O
tetrahydrobenzo	0	O
[	0	O
a	0	O
]	0	O
pyrenyl	0	O
)]-	0	O
2	0	O
'-	0	O
deoxyadenosyl	0	O
adduct	0	O
from	0	O
1H	0	O
NMR	1	O
.	0	O


Patients	0	O
with	0	O
an	0	O
enzymatic	0	O
activity	0	O
below	0	O
X	1	O
--	0	O
1	0	O
manifested	0	O
a	0	O
decrease	0	O
of	0	O
the	0	O
content	0	O
of	0	O
IgA	1	B
,	0	O
IgG	1	B
,	0	O
IgM	1	B
,	0	O
T	1	O
and	0	O
B	1	O
lymphocytes	0	O
,	0	O
and	0	O
of	0	O
phagocytic	0	O
activity	0	O
of	0	O
neutrophils	0	O
as	0	O
compared	0	O
to	0	O
patients	0	O
exhibiting	0	O
a	0	O
high	0	O
enzymatic	0	O
activity	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
the	0	O
selective	0	O
expression	0	O
of	0	O
the	0	O
receptor	0	O
,	0	O
FL	1	B
expression	0	O
was	0	O
detected	0	O
in	0	O
90	0	O
-	0	O
100	0	O
%	0	O
of	0	O
the	0	O
various	0	O
cell	0	O
types	0	O
of	0	O
leukemia	0	O
cell	0	O
lines	0	O
from	0	O
all	0	O
hematopoietic	0	O
cell	0	O
lineages	0	O
.	0	O


Relationships	0	O
with	0	O
the	0	O
acquired	0	O
immune	0	O
deficiency	0	O
syndrome	0	O
.	0	O


Evolutive	0	O
morphology	0	O
of	0	O
the	0	O
olfactory	0	O
bulb	0	O
in	0	O
man	0	O
and	0	O
certain	0	O
non	0	O
-	0	O
human	0	O
mammals	0	O


The	0	O
sequence	0	O
similarity	0	O
has	0	O
suggested	0	O
that	0	O
SCG10	0	B
and	0	O
stathmin	0	B
have	0	O
been	0	O
derived	0	O
from	0	O
structurally	0	O
and	0	O
evolutionarily	0	O
related	0	O
genes	0	O
.	0	O


While	0	O
fusion	0	O
to	0	O
the	0	O
N	1	O
-	0	O
terminus	0	O
required	0	O
a	0	O
linker	0	O
to	0	O
become	0	O
surface	0	O
accessible	0	O
,	0	O
both	0	O
fusion	0	O
to	0	O
the	0	O
N	1	O
-	0	O
terminus	0	O
and	0	O
to	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
was	0	O
compatible	0	O
with	0	O
particle	0	O
assembly	0	O
and	0	O
preserved	0	O
the	0	O
native	0	O
antigenicity	0	O
and	0	O
immunogenicity	0	O
of	0	O
HBcAg	1	B
.	0	O


We	0	O
have	0	O
determined	0	O
the	0	O
structure	0	O
of	0	O
the	0	O
WNT	0	B
-	0	I
2B	0	I
gene	0	I
.	0	O


Thus	0	O
,	0	O
hGRbeta	0	B
potentially	0	O
functions	0	O
as	0	O
a	0	O
dominant	0	O
negative	0	O
inhibitor	0	O
of	0	O
hGRalpha	0	B
activity	0	O
.	0	O


Methoxyflurane	1	O
and	0	O
renal	0	O
function	0	O


However	0	O
,	0	O
we	0	O
did	0	O
not	0	O
observe	0	O
a	0	O
correlation	0	O
between	0	O
serum	0	O
and	0	O
seminal	0	B
plasma	0	I
PSA	1	I
levels	0	O
.	0	O


Seven	0	O
of	0	O
these	0	O
had	0	O
counterparts	0	O
in	0	O
the	0	O
US	1	O
of	0	O
herpes	0	O
simplex	0	O
type	0	O
1	0	O
(	0	O
HSV	1	O
-	0	O
1	0	O
),	0	O
pseudorabies	0	O
virus	0	O
(	0	O
PRV	0	O
),	0	O
and	0	O
equine	0	O
herpesvirus	0	O
type	0	O
1	0	O
(	0	O
EHV	0	O
-	0	O
1	0	O
).	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
hypocitraturia	0	O
in	0	O
type	0	O
I	1	O
renal	0	O
tubular	0	O
acidosis	0	O
may	0	O
be	0	O
due	0	O
to	0	O
a	0	O
defect	0	O
in	0	O
proximal	0	O
tubule	0	O
function	0	O
.	0	O


Diagnosis	1	O
and	0	O
treatment	0	O
of	0	O
insulin	0	B
-	0	O
secreting	0	O
tumours	0	O
.	0	O


The	0	O
same	0	O
trend	0	O
was	0	O
noted	0	O
between	0	O
YG	0	O
4	0	O
.	0	O
5	0	O
heifers	0	O
and	0	O
YG	0	O
5	0	O
.	0	O
5	0	O
steers	0	O
,	0	O
indicating	0	O
a	0	O
sex	0	O
-	0	O
related	0	O
deposition	0	O
of	0	O
seam	0	O
fat	0	O
in	0	O
fed	0	O
cattle	0	O
.	0	O


Ab	1	O
-	0	O
MLV	0	O
strains	0	O
expressing	0	O
P70	0	B
/	0	O
S2	1	B
failed	0	O
to	0	O
transform	0	O
NIH	1	O
3T3	0	O
cells	0	O
and	0	O
demonstrated	0	O
a	0	O
greatly	0	O
reduced	0	O
capacity	0	O
to	0	O
mediate	0	O
signaling	0	O
events	0	O
associated	0	O
with	0	O
the	0	O
Ras	1	B
-	0	O
dependent	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
(	0	I
MAP	1	I
)	0	I
kinase	0	I
pathway	0	O
.	0	O


It	1	O
is	0	O
considered	0	O
that	0	O
the	0	O
recurrent	0	O
annular	0	O
erythema	0	O
is	0	O
a	0	O
specific	0	O
skin	0	O
manifestation	0	O
of	0	O
SjS	0	O
with	0	O
anti	0	B
SS	1	I
-	0	I
A	1	I
/	0	O
SS	1	B
-	0	I
B	1	I
antibodies	0	I
.	0	O


Methisergide	0	O
(	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
/	0	O
kg	0	O
,	0	O
i	0	O
.	0	O
p	0	O
.),	0	O
a	0	O
blocker	0	O
of	0	O
serotonin	0	B
receptors	0	I
,	0	O
prevented	0	O
the	0	O
development	0	O
of	0	O
the	0	O
antinociceptive	0	O
effect	0	O
of	0	O
serotonin	0	O
.	0	O


Primary	1	O
and	0	O
secondary	0	O
structural	0	O
elements	0	O
required	0	O
for	0	O
synthesis	0	O
of	0	O
barley	0	O
yellow	0	O
dwarf	0	O
virus	0	O
subgenomic	0	O
RNA1	0	O
.	0	O


Regressing	0	O
microaneurysms	0	O
in	0	O
5	0	O
cases	0	O
of	0	O
hepatitis	0	O
B	1	O
virus	0	O
related	0	O
polyarteritis	0	O
nodosa	0	O
.	0	O


Expense	0	O
limits	0	O
the	0	O
use	0	O
of	0	O
hepatitis	0	O
B	1	O
vaccines	0	O
,	0	O
but	0	O
low	0	O
-	0	O
dose	0	O
intradermal	0	O
immunization	0	O
has	0	O
been	0	O
evaluated	0	O
as	0	O
a	0	O
cost	0	O
-	0	O
saving	0	O
strategy	0	O
in	0	O
numerous	0	O
studies	0	O
.	0	O


Two	0	O
patients	0	O
withdrew	0	O
from	0	O
therapy	0	O
,	0	O
one	0	O
for	0	O
personal	0	O
reasons	0	O
and	0	O
one	0	O
because	0	O
a	0	O
paraspinal	0	O
mass	0	O
developed	0	O
.	0	O


Somatostatin	1	B
gene	0	I
expression	0	O
in	0	O
pancreatic	0	O
islet	0	O
cells	0	O
is	0	O
directed	0	O
by	0	O
cell	0	O
-	0	O
specific	0	O
DNA	1	O
control	0	O
elements	0	O
and	0	O
DNA	1	O
-	0	O
binding	0	O
proteins	0	O
.	0	O


Using	0	O
PRL	1	B
-	0	I
R	1	I
tagged	0	O
both	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
or	0	O
C	1	O
-	0	O
terminal	0	O
regions	0	O
of	0	O
the	0	O
mature	0	O
receptor	0	O
excludes	0	O
the	0	O
possibility	0	O
of	0	O
a	0	O
cleaved	0	O
fragment	0	O
which	0	O
could	0	O
have	0	O
been	0	O
subsequently	0	O
imported	0	O
into	0	O
the	0	O
nucleus	0	O
.	0	O


The	0	O
Dox	0	B
-	0	I
A2	1	I
ORF	1	I
driven	0	O
by	0	O
the	0	O
TDH3	0	B
promoter	0	I
complemented	0	O
the	0	O
phenotype	0	O
of	0	O
a	0	O
strain	0	O
deleted	0	O
for	0	O
sun2	0	B
.	0	O


Thus	0	O
,	0	O
blocks	0	O
in	0	O
the	0	O
RARalpha	0	B
-	0	O
specific	0	O
pathway	0	O
of	0	O
retinoid	0	O
-	0	O
induced	0	O
differentiation	0	O
may	0	O
be	0	O
bypassed	0	O
during	0	O
retinoid	0	O
induction	0	O
of	0	O
FR	1	B
-	0	I
beta	0	I
expression	0	O
.	0	O


Hippocampal	1	O
stimulation	0	O
overlapping	0	O
conditioned	0	O
stimulus	0	O
preexposure	0	O
produced	0	O
attenuation	0	O
of	0	O
latent	0	O
inhibition	0	O
,	0	O
as	0	O
did	0	O
stimulation	0	O
presented	0	O
during	0	O
conditioning	0	O
after	0	O
preexposure	0	O
.	0	O


Electrophoretic	1	O
mobility	0	O
shift	0	O
assays	0	O
revealed	0	O
that	0	O
Sp1	0	B
binds	0	O
to	0	O
two	0	O
different	0	O
regions	0	O
in	0	O
the	0	O
proximal	0	O
promoter	0	O
,	0	O
a	0	O
typical	0	O
Sp1	0	B
site	0	I
located	0	O
at	0	O
(-	0	O
38	0	O
;	0	O
-	0	O
33	0	O
)	0	O
and	0	O
a	0	O
G	1	O
/	0	O
C	1	O
-	0	O
rich	0	O
region	0	O
between	0	O
(-	0	O
67	0	O
;	0	O
-	0	O
62	0	O
).	0	O


Abdominal	1	O
tumors	0	O
in	0	O
childhood	0	O
.	0	O


Capnography	1	O
curves	0	O
of	0	O
40	0	O
HVS	0	O
patients	0	O
,	0	O
40	0	O
non	0	O
-	0	O
HVS	0	O
patients	0	O
with	0	O
psycho	0	O
-	0	O
somatic	0	O
complaints	0	O
and	0	O
26	0	O
healthy	0	O
controls	0	O
were	0	O
analyzed	0	O
.	0	O


Methanesulfonyl	0	O
fluoride	0	O
(	0	O
MSF	0	O
):	0	O
a	0	O
double	0	O
-	0	O
blind	0	O
,	0	O
placebo	0	O
-	0	O
controlled	0	O
study	0	O
of	0	O
safety	0	O
and	0	O
efficacy	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
senile	0	O
dementia	0	O
of	0	O
the	0	O
Alzheimer	0	O
type	0	O
.	0	O


Superoxide	1	B
dismutase	0	I
(	0	O
SOD	0	B
)	0	O
activity	0	O
decreased	0	O
significantly	0	O
in	0	O
sperm	0	O
subjected	0	O
to	0	O
direct	0	O
electric	0	O
current	0	O
in	0	O
comparison	0	O
to	0	O
the	0	O
control	0	O
or	0	O
the	0	O
sample	0	O
incubated	0	O
with	0	O
electrolyzed	0	O
medium	0	O
.	0	O


To	1	O
evaluate	0	O
the	0	O
comparative	0	O
safety	0	O
of	0	O
U	1	O
-	0	O
P	1	O
and	0	O
D	1	O
&	0	O
E	1	O
,	0	O
we	0	O
analyzed	0	O
2	0	O
,	0	O
805	0	O
U	1	O
-	0	O
P	1	O
and	0	O
9	0	O
,	0	O
572	0	O
D	1	O
&	0	O
E	1	O
abortions	0	O
at	0	O
13	0	O
to	0	O
24	0	O
menstrual	0	O
weeks	0	O
'	0	O
gestation	0	O
.	0	O


In	1	O
the	0	O
present	0	O
study	0	O
,	0	O
we	0	O
sought	0	O
to	0	O
investigate	0	O
whether	0	O
constitutive	0	O
NF	1	B
-	0	I
kappaB	0	I
activity	0	O
in	0	O
chronically	0	O
HIV	1	O
-	0	O
1	0	O
-	0	O
infected	0	O
promonocytic	0	O
U937	0	O
(	0	O
U9	0	O
-	0	O
IIIB	0	O
)	0	O
and	0	O
myeloblastic	0	O
PLB	0	O
-	0	O
985	0	O
(	0	O
PLB	0	O
-	0	O
IIIB	0	O
)	0	O
cells	0	O
affects	0	O
apoptotic	0	O
signaling	0	O
.	0	O


Neonatal	1	O
Chagas	0	O
disease	0	O
:	0	O
laboratory	0	O
diagnosis	0	O
during	0	O
the	0	O
first	0	O
year	0	O
of	0	O
life	0	O


George	0	O
T	1	O
.	0	O


There	0	O
was	0	O
also	0	O
a	0	O
highly	0	O
significant	0	O
correlation	0	O
between	0	O
total	0	O
selenium	0	O
intake	0	O
and	0	O
liver	0	O
selenium	0	O
concentration	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
99	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
)	0	O
after	0	O
1	0	O
mo	0	O
of	0	O
treatment	0	O
,	0	O
but	0	O
this	0	O
time	0	O
liver	0	O
selenium	0	O
did	0	O
not	0	O
change	0	O
with	0	O
time	0	O
,	0	O
and	0	O
the	0	O
correlation	0	O
remained	0	O
highly	0	O
significant	0	O
throughout	0	O
the	0	O
investigation	0	O
.	0	O


The	0	O
differences	0	O
among	0	O
subgenera	0	O
of	0	O
the	0	O
genus	0	O
Dermacentor	1	O
are	0	O
more	0	O
significant	0	O
.	0	O


The	0	O
size	0	O
of	0	O
the	0	O
group	0	O
allocated	0	O
to	0	O
the	0	O
good	0	O
compliance	0	O
category	0	O
by	0	O
the	0	O
use	0	O
of	0	O
the	0	O
digoxin	0	O
marker	0	O
was	0	O
equivalent	0	O
in	0	O
size	0	O
to	0	O
a	0	O
group	0	O
of	0	O
patients	0	O
who	0	O
had	0	O
returned	0	O
less	0	O
than	0	O
15	0	O
%	0	O
of	0	O
their	0	O
prescribed	0	O
dose	0	O
or	0	O
reported	0	O
a	0	O
deviation	0	O
of	0	O
less	0	O
than	0	O
6	0	O
%	0	O
from	0	O
their	0	O
prescription	0	O
.	0	O


The	0	O
relative	0	O
toxicity	0	O
of	0	O
nickel	0	O
oxide	0	O
(	0	O
NiO	0	O
),	0	O
nickel	0	O
sulfate	0	O
hexahydrate	0	O
(	0	O
NiSO4	0	O
.	0	O
6H2O	0	O
),	0	O
and	0	O
nickel	0	O
subsulfide	0	O
(	0	O
Ni3S2	0	O
)	0	O
was	0	O
studied	0	O
in	0	O
F344	0	O
/	0	O
N	1	O
rats	0	O
and	0	O
B6C3F1	0	O
mice	0	O
after	0	O
inhalation	0	O
exposure	0	O
for	0	O
6	0	O
hr	0	O
/	0	O
day	0	O
,	0	O
5	0	O
days	0	O
/	0	O
week	0	O
,	0	O
for	0	O
13	0	O
weeks	0	O
.	0	O


Phylogenetic	1	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
ToLCV	0	O
isolates	0	O
from	0	O
Bangalore	0	O
constitute	0	O
a	0	O
group	0	O
of	0	O
viruses	0	O
separated	0	O
from	0	O
those	0	O
of	0	O
Northern	0	O
India	0	O
.	0	O


As	1	O
the	0	O
half	0	O
-	0	O
life	0	O
of	0	O
the	0	O
compound	0	O
did	0	O
never	0	O
exceed	0	O
8	0	O
-	0	O
9	0	O
h	0	O
,	0	O
the	0	O
data	0	O
do	0	O
not	0	O
support	0	O
any	0	O
change	0	O
of	0	O
pidotimod	0	O
administration	0	O
schedule	0	O
(	0	O
every	0	O
24	0	O
-	0	O
12	0	O
h	0	O
).	0	O


We	0	O
conclude	0	O
from	0	O
this	0	O
study	0	O
that	0	O
Arix	0	B
and	0	O
NBPhox	0	B
exhibit	0	O
indistinguishable	0	O
and	0	O
independent	0	O
transcriptional	0	O
regulatory	0	O
properties	0	O
on	0	O
the	0	O
DBH	0	B
promoter	0	I
.	0	O


Erythromycin	1	O
and	0	O
clindamycin	0	O
resistance	0	O
in	0	O
Corynebacterium	1	O
diphtheriae	0	O
from	0	O
skin	0	O
lesions	0	O
.	0	O


Phosphorylation	1	O
analyses	0	O
indicated	0	O
that	0	O
inhibition	0	O
of	0	O
ERK	0	B
-	0	I
1	0	I
/	0	I
2	0	I
decreased	0	O
okadaic	0	O
acid	0	O
-	0	O
elevated	0	O
phosphorylation	0	O
of	0	O
JunD	0	B
and	0	O
FosB	0	B
.	0	O


ID	1	O
-	0	O
PaGIA	0	O
diphtheria	0	B
toxin	0	I
polymer	0	O
particle	0	O
diagnostic	0	O
agent	0	O
manufactured	0	O
by	0	O
DiaMed	0	O
AG	1	O
,	0	O
Switzerland	0	O
,	0	O
was	0	O
tried	0	O
at	0	O
bacteriological	0	O
laboratory	0	O
of	0	O
Institute	0	O
of	0	O
Childhood	1	O
Infections	0	O
in	0	O
St	1	O
.	0	O


Despite	0	O
this	0	O
DNA	1	O
binding	0	O
activity	0	O
,	0	O
AP	1	B
-	0	I
1	0	I
reporter	0	I
activity	0	O
was	0	O
suppressed	0	O
in	0	O
these	0	O
cells	0	O
.	0	O


The	0	O
factor	0	O
which	0	O
binds	0	O
to	0	O
the	0	O
TR	1	B
promoter	0	I
co	0	O
-	0	O
sedimented	0	O
with	0	O
SV40	1	O
chromosomes	0	O
extracted	0	O
late	0	O
in	0	O
infection	0	O
.	0	O


Increasing	0	O
the	0	O
extracellular	0	O
calcium	0	O
concentration	0	O
enhanced	0	O
detrusor	0	O
contractility	0	O
in	0	O
a	0	O
dose	0	O
-	0	O
dependent	0	O
manner	0	O
in	0	O
both	0	O
control	0	O
and	0	O
obstructed	0	O
bladders	0	O
.	0	O


4	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
experiments	0	O
show	0	O
that	0	O
either	0	O
one	0	O
of	0	O
the	0	O
two	0	O
MADS	0	B
domains	0	I
of	0	O
a	0	O
dimer	0	O
can	0	O
be	0	O
sufficient	0	O
to	0	O
confer	0	O
a	0	O
particular	0	O
DNA	1	O
-	0	O
binding	0	O
specificity	0	O
to	0	O
the	0	O
complex	0	O
and	0	O
that	0	O
sequences	0	O
outside	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
basic	0	O
region	0	O
of	0	O
the	0	O
MADS	0	B
domain	0	O
can	0	O
,	0	O
in	0	O
some	0	O
cases	0	O
,	0	O
contribute	0	O
to	0	O
the	0	O
DNA	1	O
-	0	O
binding	0	O
specificity	0	O
of	0	O
the	0	O
proteins	0	O
.	0	O


On	1	O
the	0	O
other	0	O
side	0	O
,	0	O
when	0	O
the	0	O
aortic	0	O
ring	0	O
was	0	O
perfused	0	O
with	0	O
L	1	O
-	0	O
NNA	0	O
(	0	O
NO	1	O
-	0	O
synthesis	0	O
inhibitor	0	O
)	0	O
or	0	O
methylene	0	O
blue	0	O
(	0	O
soluble	0	O
cGMPase	0	B
inhibitor	0	O
),	0	O
the	0	O
changes	0	O
could	0	O
be	0	O
attenuated	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
,	0	O
in	0	O
comparison	0	O
to	0	O
reports	0	O
from	0	O
other	0	O
regions	0	O
,	0	O
Scandinavian	0	O
renal	0	O
transplant	0	O
recipients	0	O
are	0	O
at	0	O
high	0	O
risk	0	O
of	0	O
dying	0	O
of	0	O
IHD	1	O
.	0	O


Mean	1	O
growth	0	O
changes	0	O
in	0	O
this	0	O
Class	1	O
II	0	O
sample	0	O
were	0	O
comparable	0	O
to	0	O
those	0	O
previously	0	O
reported	0	O
for	0	O
male	0	O
subjects	0	O
with	0	O
Class	1	O
I	1	O
malocclusions	0	O
over	0	O
the	0	O
same	0	O
age	0	O
period	0	O
,	0	O
suggesting	0	O
a	0	O
similarity	0	O
in	0	O
postpubertal	0	O
development	0	O
between	0	O
these	0	O
two	0	O
groups	0	O
.	0	O


Fundamental	1	O
and	0	O
clinical	0	O
evaluation	0	O
of	0	O
equilibrium	0	O
dialysis	0	O
--	0	O
radioimmunoassay	0	O
system	0	O
for	0	O
measurement	0	O
of	0	O
serum	0	O
free	0	O
thyroxine	0	O


KFC	0	B
,	0	O
a	0	O
Ste20	0	B
-	0	I
like	0	I
kinase	0	I
with	0	O
mitogenic	0	O
potential	0	O
and	0	O
capability	0	O
to	0	O
activate	0	O
the	0	O
SAPK	0	B
/	0	O
JNK	0	B
pathway	0	O
.	0	O


The	0	O
study	0	O
was	0	O
repeated	0	O
after	0	O
administration	0	O
of	0	O
oral	0	O
amiodarone	0	O
,	0	O
50	0	O
mg	0	O
/	0	O
kg	0	O
/	0	O
day	0	O
for	0	O
2	0	O
days	0	O
in	0	O
8	0	O
divided	0	O
doses	0	O
(	0	O
mean	0	O
dose	0	O
6	0	O
.	0	O
9	0	O
+/-	0	O
0	0	O
.	0	O
4	0	O
g	0	O
).	0	O


Sleep	1	O
was	0	O
determined	0	O
again	0	O
for	0	O
an	0	O
additional	0	O
3	0	O
days	0	O
and	0	O
6	0	O
hours	0	O
.	0	O


These	0	O
observations	0	O
link	0	O
actin	0	B
plaque	0	O
assembly	0	O
to	0	O
increased	0	O
cell	0	O
substrate	0	O
adhesion	0	O
.	0	O


JCAHO	1	O
asks	0	O
for	0	O
hospitals	0	O
'	0	O
patience	0	O
.	0	O


Effects	0	O
of	0	O
thromboxane	0	B
synthetase	0	I
inhibition	0	O
on	0	O
postburn	0	O
mesenteric	0	O
vascular	0	O
resistance	0	O
and	0	O
the	0	O
rate	0	O
of	0	O
bacterial	0	O
translocation	0	O
in	0	O
a	0	O
chronic	0	O
porcine	0	O
model	0	O
.	0	O


To	1	O
study	0	O
the	0	O
regulation	0	O
of	0	O
its	0	O
expression	0	O
,	0	O
the	0	O
human	0	B
aldehyde	0	I
reductase	0	I
gene	0	I
and	0	O
promoter	0	O
were	0	O
cloned	0	O
and	0	O
characterized	0	O
.	0	O


In	1	O
concept	0	O
II	0	O
62	0	O
patients	0	O
were	0	O
treated	0	O
with	0	O
selective	0	O
vagotomy	0	O
and	0	O
pyloroplasty	0	O
.	0	O


These	0	O
results	0	O
are	0	O
consistent	0	O
with	0	O
the	0	O
roles	0	O
that	0	O
CCK	1	B
and	0	O
trypsin	0	B
inhibitors	0	O
are	0	O
believed	0	O
to	0	O
play	0	O
in	0	O
the	0	O
negative	0	O
feedback	0	O
control	0	O
of	0	O
pancreatic	0	O
exocrine	0	O
function	0	O
.	0	O


EsaR	0	B
can	0	O
repress	0	O
its	0	O
own	0	O
expression	0	O
but	0	O
seems	0	O
not	0	O
to	0	O
regulate	0	O
the	0	O
expression	0	O
of	0	O
esaI	0	B
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
FK	0	O
506	0	O
is	0	O
a	0	O
useful	0	O
immunosuppressive	0	O
agent	0	O
in	0	O
kidney	0	O
transplantation	0	O
.	0	O


I	1	O
.	0	O


Inhibition	1	O
of	0	O
Fusarium	1	O
moniliforme	0	O
var	0	O
.	0	O
subglutinans	0	O
,	0	O
the	0	O
causal	0	O
agent	0	O
of	0	O
pine	0	O
pitch	0	O
canker	0	O
,	0	O
by	0	O
the	0	O
soil	0	O
bacterium	0	O
Arthrobacter	1	O
sp	0	O
.	0	O


The	0	O
hp55	0	B
gamma	0	I
protein	0	I
interacts	0	O
strongly	0	O
with	0	O
the	0	O
activated	0	O
IGFIR	0	B
but	0	O
not	0	O
with	0	O
the	0	O
kinase	0	O
-	0	O
negative	0	O
mutant	0	O
receptor	0	O
.	0	O
hp55	0	B
gamma	0	I
also	0	O
interacts	0	O
with	0	O
the	0	O
insulin	0	B
receptor	0	I
(	0	O
IR	1	B
)	0	O
in	0	O
the	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
system	0	O
.	0	O


A	1	O
region	0	O
approximately	0	O
100	0	O
bp	0	O
upstream	0	O
from	0	O
the	0	O
transcription	0	O
start	0	O
point	0	O
of	0	O
virB	0	B
was	0	O
identified	0	O
as	0	O
being	0	O
necessary	0	O
for	0	O
full	0	O
activation	0	O
of	0	O
this	0	O
promoter	0	O
by	0	O
VirF	0	B
.	0	O


A	1	O
chaotropic	0	O
detergent	0	O
,	0	O
0	0	O
.	0	O
1	0	O
%	0	O
Nonidet	0	O
P	1	O
-	0	O
40	0	O
,	0	O
also	0	O
abolished	0	O
the	0	O
interaction	0	O
,	0	O
further	0	O
supporting	0	O
the	0	O
hydrophobic	0	O
nature	0	O
of	0	O
the	0	O
interaction	0	O
.	0	O


A	1	O
.	0	O


Potscoital	0	O
test	0	O


Statistics	1	O
for	0	O
nurse	0	O
managers	0	O
--	0	O
3	0	O
.	0	O


Weak	1	O
promoter	0	O
activity	0	O
was	0	O
observed	0	O
for	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
C1	1	B
and	0	O
C2	1	B
ORFs	0	O
(	0	O
C1	1	B
-	0	O
C2	1	B
gene	0	O
)	0	O
and	0	O
for	0	O
the	0	O
promoter	0	O
of	0	O
the	0	O
V1	0	B
ORF	1	I
.	0	O


Retrogradely	0	O
labelled	0	O
neurons	0	O
significantly	0	O
prevailed	0	O
in	0	O
the	0	O
ipsilateral	0	O
substantia	0	O
nigra	0	O
pars	0	O
compacta	0	O
.	0	O


Polypyrimidine	0	O
and	0	O
ssDNA	1	O
binding	0	O
by	0	O
the	0	O
isolated	0	O
VH	1	B
domain	0	I
of	0	O
immunization	0	O
-	0	O
induced	0	O
anti	0	O
-	0	O
Z	1	O
-	0	O
DNA	1	O
Ab	1	O
resembles	0	O
the	0	O
activity	0	O
of	0	O
natural	0	O
autoantibodies	0	O
and	0	O
suggests	0	O
that	0	O
VH	1	B
-	0	O
dependent	0	O
binding	0	O
to	0	O
a	0	O
ligand	0	O
mimicked	0	O
by	0	O
polypyrimidines	0	O
may	0	O
play	0	O
a	0	O
role	0	O
in	0	O
B	1	O
cell	0	O
selection	0	O
before	0	O
immunization	0	O
with	0	O
Z	1	O
-	0	O
DNA	1	O
.	0	O


The	0	O
relationship	0	O
between	0	O
estrogenic	0	O
properties	0	O
of	0	O
Tamoxifen	0	O
and	0	O
breast	0	O
cancer	0	O
management	0	O
is	0	O
discussed	0	O
.	0	O


Changes	0	O
in	0	O
prognosis	0	O
of	0	O
twin	0	O
births	0	O
over	0	O
20	0	O
years	0	O
.	0	O


Thalamotomy	1	O
aiming	0	O
at	0	O
the	0	O
CM	1	O
-	0	O
Pf	1	O
complex	0	O
and	0	O
using	0	O
stereotactic	0	O
gamma	0	O
irradiation	0	O
has	0	O
been	0	O
performed	0	O
in	0	O
a	0	O
series	0	O
of	0	O
52	0	O
patients	0	O
with	0	O
severe	0	O
pain	0	O
due	0	O
to	0	O
malignancy	0	O
.	0	O


Truncated	0	O
forms	0	O
of	0	O
a	0	O
novel	0	O
yeast	0	O
protein	0	O
suppress	0	O
the	0	O
lethality	0	O
of	0	O
a	0	O
G	1	B
protein	0	I
alpha	0	I
subunit	0	I
deficiency	0	O
by	0	O
interacting	0	O
with	0	O
the	0	O
beta	0	O
subunit	0	O
.	0	O


13	0	O
men	0	O
with	0	O
a	0	O
history	0	O
of	0	O
recurrent	0	O
genital	0	O
herpes	0	O
simplex	0	O
virus	0	O
type	0	O
2	0	O
(	0	O
HSV	1	O
-	0	O
2	0	O
)	0	O
infection	0	O
were	0	O
followed	0	O
daily	0	O
for	0	O
4	0	O
weeks	0	O
with	0	O
samples	0	O
taken	0	O
from	0	O
the	0	O
urethra	0	O
for	0	O
virus	0	O
isolation	0	O
.	0	O


Psychiatry	1	O
and	0	O
the	0	O
skin	0	O
.	0	O


A	1	O
cluster	0	O
of	0	O
basic	0	O
amino	0	O
acids	0	O
,	0	O
KKKR	0	O
,	0	O
generated	0	O
by	0	O
joining	0	O
of	0	O
the	0	O
sequences	0	O
encoded	0	O
by	0	O
the	0	O
constitutive	0	O
exon	0	O
13	0	O
and	0	O
the	0	O
alternative	0	O
exon	0	O
16	0	O
,	0	O
is	0	O
necessary	0	O
for	0	O
the	0	O
nuclear	0	O
targeting	0	O
of	0	O
4	0	B
.	0	I
1H	0	I
,	0	O
as	0	O
demonstrated	0	O
by	0	O
site	0	O
-	0	O
directed	0	O
mutagenesis	0	O
analysis	0	O
.	0	O


A	1	O
study	0	O
of	0	O
human	0	O
genes	0	O
coding	0	O
for	0	O
U4	0	B
small	0	I
nuclear	0	I
RNA	1	I
is	0	O
presented	0	O
.	0	O


We	0	O
have	0	O
performed	0	O
toeprinting	0	O
analyses	0	O
on	0	O
repA	0	B
mRNA	1	I
of	0	O
plasmid	0	O
R1	0	O
,	0	O
both	0	O
free	0	O
and	0	O
in	0	O
duplex	0	O
with	0	O
the	0	O
antisense	0	O
RNA	1	O
,	0	O
CopA	1	B
.	0	O


Mutually	0	O
exclusive	0	O
interaction	0	O
of	0	O
the	0	O
adenovirus	0	B
E4	1	I
-	0	I
6	0	I
/	0	I
7	0	I
protein	0	I
and	0	O
the	0	O
retinoblastoma	0	B
gene	0	I
product	0	I
with	0	O
internal	0	O
domains	0	O
of	0	O
E2F	0	B
-	0	I
1	0	I
and	0	O
DP	1	B
-	0	I
1	0	I
.	0	O


Ultrastructure	1	O
of	0	O
the	0	O
heart	0	O
muscle	0	O
in	0	O
experimental	0	O
myocardial	0	O
infarct	0	O
following	0	O
physical	0	O
training	0	O


The	0	O
effects	0	O
of	0	O
a	0	O
1	0	O
-	0	O
or	0	O
24	0	O
-	0	O
hour	0	O
pretreatment	0	O
regimen	0	O
with	0	O
monophosphoryl	0	O
lipid	0	O
A	1	O
(	0	O
MLA	1	O
,	0	O
35	0	O
micrograms	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.)	0	O
on	0	O
myocardial	0	O
stunning	0	O
produced	0	O
by	0	O
repetitive	0	O
coronary	0	O
occlusions	0	O
were	0	O
studied	0	O
in	0	O
barbital	0	O
-	0	O
anesthetized	0	O
dogs	0	O
.	0	O


From	0	O
sequence	0	O
alignments	0	O
with	0	O
phylogenetically	0	O
related	0	O
viruses	0	O
,	0	O
including	0	O
tymoviruses	0	O
,	0	O
we	0	O
predicted	0	O
that	0	O
p223	0	B
contained	0	O
a	0	O
papain	0	B
-	0	I
like	0	I
proteinase	0	I
domain	0	I
with	0	O
a	0	O
putative	0	O
catalytic	0	O
cysteine994	0	O
and	0	O
histidine1075	0	O
.	0	O


A	1	O
17	0	O
-	0	O
mer	0	O
oligodeoxynucleotide	0	O
,	0	O
corresponding	0	O
to	0	O
a	0	O
region	0	O
of	0	O
the	0	O
VtHb	0	B
amino	0	I
acid	0	I
sequence	0	I
was	0	O
used	0	O
as	0	O
a	0	O
hybridization	0	O
probe	0	O
to	0	O
screen	0	O
a	0	O
Vitreoscilla	0	O
genomic	0	O
library	0	O
constructed	0	O
in	0	O
broad	0	O
-	0	O
host	0	O
-	0	O
range	0	O
cosmid	0	O
vector	0	O
pVK102	0	O
.	0	O


Infants	0	O
who	0	O
died	0	O
in	0	O
the	0	O
first	0	O
12	0	O
hours	0	O
from	0	O
'	0	O
IVH	0	O
only	0	O
'	0	O
had	0	O
suffered	0	O
severe	0	O
birth	0	O
asphyxia	0	O
but	0	O
in	0	O
those	0	O
who	0	O
died	0	O
later	0	O
the	0	O
main	0	O
symptom	0	O
was	0	O
recurrent	0	O
apnoea	0	O
.	0	O


In	1	O
vitro	0	O
interaction	0	O
studies	0	O
,	0	O
using	0	O
proteins	0	O
fused	0	O
to	0	O
glutathione	0	B
-	0	I
S	1	I
-	0	I
transferase	0	I
,	0	O
showed	0	O
that	0	O
RBP	1	B
-	0	I
J	1	I
kappa	0	I
and	0	O
Su	0	B
(	0	I
H	1	I
)	0	I
bind	0	O
directly	0	O
to	0	O
the	0	O
RAM23	0	B
regions	0	I
of	0	O
mouse	0	B
Notch1	0	I
and	0	O
Drosophila	1	B
Notch	1	I
,	0	O
respectively	0	O
.	0	O


At	1	O
the	0	O
very	0	O
high	0	O
dose	0	O
levels	0	O
used	0	O
,	0	O
sodium	0	O
saccharin	0	O
and	0	O
sodium	0	O
cyclamate	0	O
were	0	O
weak	0	O
solitary	0	O
carcinogens	0	O
producing	0	O
4	0	O
/	0	O
253	0	O
and	0	O
3	0	O
/	0	O
228	0	O
bladder	0	O
tumours	0	O
respectively	0	O
,	0	O
and	0	O
the	0	O
first	0	O
of	0	O
these	0	O
tumours	0	O
did	0	O
not	0	O
appear	0	O
for	0	O
more	0	O
than	0	O
80	0	O
weeks	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Twice	0	O
daily	0	O
treatment	0	O
with	0	O
inhaled	0	O
fluticasone	0	O
propionate	0	O
50	0	O
micrograms	0	O
or	0	O
100	0	O
micrograms	0	O
was	0	O
significantly	0	O
more	0	O
effective	0	O
than	0	O
theophylline	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
mild	0	O
-	0	O
to	0	O
-	0	O
moderate	0	O
asthma	0	O
.	0	O


The	0	O
same	0	O
-	0	O
sized	0	O
EBNA	0	B
protein	0	I
(	0	I
approximately	0	I
78	0	I
,	0	I
000	0	I
)	0	I
was	0	O
made	0	O
after	0	O
transfection	0	O
with	0	O
BamHI	0	B
-	0	I
K	1	I
(	0	I
5	0	I
.	0	I
2	0	I
kilobase	0	I
pairs	0	I
[	0	I
kbp	0	I
])	0	I
or	0	O
the	0	O
I1f	0	O
subfragment	0	O
(	0	O
2	0	O
.	0	O
9	0	O
kbp	0	O
).	0	O


Low	0	O
NA	1	O
and	0	O
A	1	O
may	0	O
participate	0	O
in	0	O
lowering	0	O
the	0	O
plasma	0	B
renin	0	I
activity	0	O
which	0	O
in	0	O
PA	1	O
in	0	O
suppressed	0	O
,	0	O
sometimes	0	O
disproportionately	0	O
to	0	O
the	0	O
actual	0	O
body	0	O
sodium	0	O
content	0	O
.	0	O


Current	1	O
clinical	0	O
trials	0	O
should	0	O
answer	0	O
the	0	O
question	0	O
of	0	O
which	0	O
of	0	O
the	0	O
therapeutic	0	O
options	0	O
impairs	0	O
quality	0	O
of	0	O
life	0	O
less	0	O
.	0	O


The	0	O
molecular	0	O
basis	0	O
for	0	O
commitment	0	O
of	0	O
progenitors	0	O
to	0	O
the	0	O
eosinophil	0	O
lineage	0	O
and	0	O
mechanisms	0	O
by	0	O
which	0	O
eosinophil	0	O
-	0	O
specific	0	O
genes	0	O
are	0	O
expressed	0	O
and	0	O
regulated	0	O
during	0	O
differentiation	0	O
is	0	O
unknown	0	O
.	0	O


In	1	O
contrast	0	O
to	0	O
T	1	O
cells	0	O
,	0	O
in	0	O
fibroblasts	0	O
PILOT	0	B
gene	0	I
expression	0	O
requires	0	O
only	0	O
one	0	O
signal	0	O
(	0	O
PMA	0	O
)	0	O
and	0	O
is	0	O
not	0	O
affected	0	O
by	0	O
CyA	0	O
.	0	O


First	0	O
,	0	O
human	0	O
erythroid	0	O
K562	0	O
cells	0	O
stably	0	O
integrated	0	O
with	0	O
various	0	O
HS	1	B
-	0	I
40	0	I
mutants	0	I
cis	0	O
linked	0	O
to	0	O
a	0	O
human	0	B
alpha	0	I
-	0	I
globin	0	I
promoter	0	I
-	0	O
growth	0	B
hormone	0	I
hybrid	0	O
gene	0	O
were	0	O
analyzed	0	O
by	0	O
genomic	0	O
footprinting	0	O
and	0	O
expression	0	O
analysis	0	O
.	0	O


We	0	O
report	0	O
here	0	O
the	0	O
cloning	0	O
of	0	O
the	0	O
murine	0	O
p44	0	B
MAP	1	I
kinase	0	I
(	0	O
extracellular	0	B
signal	0	I
-	0	I
regulated	0	I
kinase	0	I
1	0	I
)	0	O
gene	0	O
,	0	O
the	0	O
determination	0	O
of	0	O
its	0	O
intron	0	O
/	0	O
exon	0	O
boundaries	0	O
,	0	O
and	0	O
the	0	O
characterization	0	O
of	0	O
its	0	O
promoter	0	O
.	0	O


In	1	O
these	0	O
cells	0	O
,	0	O
E2	1	B
proteins	0	I
had	0	O
little	0	O
or	0	O
no	0	O
stimulatory	0	O
effect	0	O
on	0	O
the	0	O
transcriptional	0	O
activity	0	O
of	0	O
the	0	O
HPV	1	B
-	0	I
11	0	I
enhancer	0	I
-	0	O
SV40	1	B
promoter	0	I
.	0	O


Increasing	0	O
the	0	O
cut	0	O
-	0	O
off	0	O
point	0	O
to	0	O
3	0	O
positive	0	O
responses	0	O
decreased	0	O
the	0	O
sensitivity	0	O
to	0	O
81	0	O
%	0	O
and	0	O
increased	0	O
the	0	O
specificity	0	O
to	0	O
94	0	O
%.	0	O


Here	0	O
we	0	O
examine	0	O
the	0	O
potential	0	O
for	0	O
VP16	0	B
protein	0	O
-	0	O
protein	0	O
interactions	0	O
specific	0	O
to	0	O
virus	0	O
-	0	O
infected	0	O
cells	0	O
and	0	O
show	0	O
that	0	O
VP16	0	B
copurifies	0	O
in	0	O
a	0	O
highly	0	O
enriched	0	O
fraction	0	O
with	0	O
a	0	O
single	0	O
major	0	O
polypeptide	0	O
which	0	O
we	0	O
identify	0	O
as	0	O
the	0	O
virus	0	O
-	0	O
encoded	0	O
structural	0	O
protein	0	O
VP22	0	B
.	0	O


Instead	0	O
,	0	O
it	0	O
contained	0	O
two	0	O
tandem	0	O
kappaB	0	B
elements	0	I
and	0	O
a	0	O
variant	0	O
activating	0	B
transcription	0	I
factor	0	I
/	0	I
cAMP	1	I
response	0	I
element	0	I
site	0	O
,	0	O
which	0	O
closely	0	O
resembled	0	O
sites	0	O
in	0	O
the	0	O
E	1	B
-	0	I
selectin	0	I
gene	0	I
that	0	O
are	0	O
required	0	O
for	0	O
TNF	1	B
-	0	I
alpha	0	I
-	0	O
or	0	O
LPS	1	O
-	0	O
inducible	0	O
expression	0	O
.	0	O


Alanine	1	B
aminotransferase	0	I
in	0	O
clinical	0	O
practice	0	O
.	0	O


We	0	O
have	0	O
cloned	0	O
a	0	O
novel	0	O
100	0	O
-	0	O
kDa	1	O
mammalian	0	O
protein	0	O
,	0	O
which	0	O
was	0	O
recognized	0	O
by	0	O
an	0	O
anti	0	O
-	0	O
peptide	0	O
antibody	0	O
against	0	O
an	0	O
epitope	0	O
-	0	O
containing	0	O
nuclear	0	O
localization	0	O
signal	0	O
of	0	O
NF	1	B
-	0	I
kappaB	0	I
p65	0	I
subunit	0	I
.	0	O


The	0	O
role	0	O
of	0	O
intraoperative	0	O
echocardiography	0	O
in	0	O
surgery	0	O
of	0	O
the	0	O
heart	0	O
and	0	O
large	0	O
vessels	0	O


CONCLUSION	0	O
:	0	O
The	0	O
study	0	O
demonstrates	0	O
that	0	O
transvaginal	0	O
ultrasonography	0	O
has	0	O
an	0	O
efficiency	0	O
of	0	O
88	0	O
%	0	O
in	0	O
differentiating	0	O
endometriomas	0	O
from	0	O
other	0	O
ovarian	0	O
masses	0	O
with	0	O
a	0	O
specificity	0	O
of	0	O
90	0	O
%.	0	O


Structural	1	O
organization	0	O
and	0	O
expression	0	O
of	0	O
the	0	O
mouse	0	B
estrogen	0	I
receptor	0	I
.	0	O


We	0	O
constructed	0	O
a	0	O
yeast	0	O
reporter	0	O
strain	0	O
containing	0	O
the	0	O
lacZ	0	B
gene	0	I
under	0	O
the	0	O
control	0	O
of	0	O
the	0	O
CYC1	0	B
promoter	0	I
associated	0	O
with	0	O
three	0	O
copies	0	O
of	0	O
TRE	0	B
-	0	I
1	0	I
.	0	O


The	0	O
enhanced	0	O
cysteine	0	O
formation	0	O
in	0	O
a	0	O
pCSK4F	0	O
plant	0	O
responding	0	O
to	0	O
sulfite	0	O
was	0	O
also	0	O
observed	0	O
in	0	O
leaf	0	O
discs	0	O
.	0	O


Although	0	O
popular	0	O
this	0	O
hypothesis	0	O
is	0	O
far	0	O
from	0	O
explaining	0	O
all	0	O
the	0	O
clinical	0	O
facts	0	O
,	0	O
namely	0	O
that	0	O
rigidity	0	O
is	0	O
equal	0	O
in	0	O
extensor	0	O
and	0	O
flexor	0	O
,	0	O
proximal	0	O
and	0	O
distal	0	O
muscles	0	O
.	0	O


CM	1	O
reduced	0	O
the	0	O
nuclear	0	O
binding	0	O
activity	0	O
of	0	O
transcription	0	B
factor	0	I
AP	1	I
-	0	I
1	0	I
.	0	O


We	0	O
have	0	O
used	0	O
these	0	O
modified	0	O
assay	0	O
conditions	0	O
to	0	O
extend	0	O
studies	0	O
on	0	O
the	0	O
transposition	0	O
pathway	0	O
.	0	O


Change	1	O
in	0	O
plasma	0	B
cystyl	0	I
aminopeptidase	0	I
(	0	O
oxytocinase	0	B
)	0	O
between	0	O
30	0	O
-	0	O
34	0	O
weeks	0	O
'	0	O
gestation	0	O
as	0	O
a	0	O
predictor	0	O
of	0	O
pregnancy	0	O
-	0	O
induced	0	O
hypertension	0	O
.	0	O


The	0	O
bronchial	0	O
epithelia	0	O
of	0	O
all	0	O
smoke	0	O
-	0	O
exposed	0	O
animals	0	O
were	0	O
hyperplastic	0	O
,	0	O
and	0	O
their	0	O
ultrastructure	0	O
showed	0	O
invaginations	0	O
,	0	O
tilt	0	O
of	0	O
nuclear	0	O
axes	0	O
,	0	O
an	0	O
increase	0	O
in	0	O
the	0	O
number	0	O
and	0	O
size	0	O
of	0	O
lysosomes	0	O
and	0	O
multivesiculated	0	O
bodies	0	O
,	0	O
and	0	O
increased	0	O
numbers	0	O
of	0	O
enlarged	0	O
intramitochondrial	0	O
granules	0	O
.	0	O


The	0	O
sequence	0	O
of	0	O
the	0	O
HIR1	0	B
gene	0	I
predicts	0	O
an	0	O
88	0	O
-	0	O
kDa	1	O
protein	0	O
with	0	O
three	0	O
repeats	0	O
of	0	O
a	0	O
motif	0	O
found	0	O
in	0	O
the	0	O
G	1	B
beta	0	I
subunit	0	I
of	0	O
retinal	0	B
transducin	0	I
and	0	O
in	0	O
a	0	O
yeast	0	O
transcriptional	0	O
repressor	0	O
,	0	O
Tup1	0	B
.	0	O


Holliday	0	B
junction	0	I
resolvase	0	I
in	0	O
Schizosaccharomyces	0	O
pombe	0	O
has	0	O
identical	0	O
endonuclease	0	O
activity	0	O
to	0	O
the	0	O
CCE1	0	B
homologue	0	O
YDC2	0	B
.	0	O


OBJECTIVE	1	O
--	0	O
To	1	O
assess	0	O
the	0	O
risk	0	O
of	0	O
hepatitis	0	O
A	1	O
in	0	O
international	0	O
travelers	0	O
and	0	O
to	0	O
recommend	0	O
preventive	0	O
measures	0	O
.	0	O


The	0	O
open	0	O
reading	0	O
frames	0	O
of	0	O
rbsD	0	B
,	0	O
rbsA	0	B
,	0	O
and	0	O
rbsC	0	B
encode	0	O
proteins	0	O
of	0	O
139	0	O
,	0	O
501	0	O
,	0	O
and	0	O
321	0	O
amino	0	O
acid	0	O
residues	0	O
,	0	O
respectively	0	O
.	0	O


The	0	O
only	0	O
abundant	0	O
viral	0	O
transcript	0	O
expressed	0	O
during	0	O
latency	0	O
is	0	O
the	0	O
latency	0	B
-	0	I
related	0	I
(	0	O
LR	1	B
)	0	O
RNA	1	O
.	0	O


Mammalian	0	O
sperm	0	O
motility	0	O
is	0	O
regulated	0	O
by	0	O
a	0	O
cascade	0	O
of	0	O
cAMP	1	O
-	0	O
dependent	0	O
protein	0	O
phosphorylation	0	O
events	0	O
mediated	0	O
by	0	O
protein	0	B
kinase	0	I
A	1	I
.	0	O


The	0	O
marker	0	O
orders	0	O
from	0	O
the	0	O
genetic	0	O
and	0	O
RH	1	O
maps	0	O
were	0	O
consistent	0	O
.	0	O


These	0	O
findings	0	O
suggest	0	O
a	0	O
functional	0	O
cross	0	O
-	0	O
talk	0	O
between	0	O
RB	1	B
protein	0	I
and	0	O
p21ras	0	B
,	0	O
which	0	O
balances	0	O
the	0	O
cell	0	O
phenotype	0	O
between	0	O
normal	0	O
and	0	O
transformed	0	O
states	0	O
.	0	O


Increased	0	O
blood	0	O
pressure	0	O
during	0	O
CyA	0	O
treatment	0	O
was	0	O
independent	0	O
of	0	O
circulating	0	O
ET	1	B
-	0	I
1	0	I
levels	0	O
.	0	O


Mutations	0	O
at	0	O
the	0	O
suf12	0	B
locus	0	I
were	0	O
isolated	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
as	0	O
extragenic	0	O
suppressors	0	O
of	0	O
+	0	O
1	0	O
frameshift	0	O
mutations	0	O
in	0	O
glycine	0	O
(	0	O
GGX	0	O
)	0	O
and	0	O
proline	0	O
(	0	O
CCX	0	O
)	0	O
codons	0	O
,	0	O
as	0	O
well	0	O
as	0	O
UGA	0	O
and	0	O
UAG	0	O
nonsense	0	O
mutations	0	O
.	0	O


Additionally	0	O
,	0	O
deletion	0	O
analysis	0	O
of	0	O
the	0	O
UCP2	0	B
promoter	0	O
-	0	O
PLAP	1	B
constructs	0	O
indicated	0	O
that	0	O
the	0	O
minimal	0	O
region	0	O
exhibiting	0	O
the	0	O
promoter	0	O
activity	0	O
was	0	O
located	0	O
between	0	O
nt	0	O
-	0	O
33	0	O
and	0	O
+	0	O
100	0	O
,	0	O
and	0	O
that	0	O
a	0	O
strong	0	O
enhancer	0	O
was	0	O
present	0	O
within	0	O
601	0	O
bp	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
promoter	0	O
region	0	O
.	0	O


At	1	O
the	0	O
basal	0	O
unstimulated	0	O
condition	0	O
,	0	O
Ren1d	0	B
5	0	I
'	0	I
flanking	0	I
sequence	0	I
in	0	O
the	0	O
sense	0	O
orientation	0	O
inhibited	0	O
basal	0	O
CAT	1	B
expression	0	O
from	0	O
the	0	O
TK	1	B
promoter	0	I
of	0	O
pUTKAT1	0	O
,	0	O
whereas	0	O
the	0	O
same	0	O
sequence	0	O
in	0	O
the	0	O
antisense	0	O
orientation	0	O
did	0	O
not	0	O
.	0	O


Insulin	1	B
-	0	O
stimulated	0	O
glucose	0	O
transport	0	O
in	0	O
adipocytes	0	O
is	0	O
mediated	0	O
by	0	O
the	0	O
insulin	0	B
receptor	0	I
.	0	O


After	0	O
MOPP	1	O
therapy	0	O
,	0	O
complete	0	O
remission	0	O
of	0	O
Hodgkin	0	O
'	0	O
s	0	O
disease	0	O
was	0	O
accompanied	0	O
by	0	O
normalization	0	O
of	0	O
the	0	O
glucocerebrosidase	0	B
level	0	O
and	0	O
disappearance	0	O
of	0	O
Gaucher	0	O
'	0	O
s	0	O
cells	0	O
.	0	O


Ozagrel	0	O
,	0	O
ifenprodil	0	O
,	0	O
cinnarizine	0	O
and	0	O
dilazep	0	O
were	0	O
more	0	O
effective	0	O
than	0	O
pentoxifylline	0	O
in	0	O
increasing	0	O
rCBF	1	O
at	0	O
the	0	O
HPC	0	O
.	0	O


The	0	O
addition	0	O
of	0	O
a	0	O
Paf	1	B
-	0	O
containing	0	O
extract	0	O
does	0	O
not	0	O
lead	0	O
to	0	O
significant	0	O
protein	0	O
binding	0	O
to	0	O
these	0	O
two	0	O
hly	0	B
target	0	I
sequences	0	I
in	0	O
the	0	O
absence	0	O
of	0	O
PrfA	0	B
but	0	O
converts	0	O
the	0	O
complex	0	O
(	0	O
CIII	0	O
)	0	O
consisting	0	O
of	0	O
PrfA	0	B
and	0	O
the	0	O
109	0	B
bp	0	I
hly	0	I
DNA	1	I
fragment	0	I
to	0	O
a	0	O
slower	0	O
migrating	0	O
PrfA	0	B
-	0	O
Paf	1	B
-	0	O
DNA	1	O
complex	0	O
(	0	O
CI	1	O
).	0	O


In	1	O
3	0	O
treatments	0	O
the	0	O
diet	0	O
was	0	O
supplemented	0	O
with	0	O
0	0	O
,	0	O
100	0	O
and	0	O
150	0	O
mg	0	O
probiotic	0	O
/	0	O
kg	0	O
food	0	O
.	0	O


All	1	O
patients	0	O
had	0	O
abnormal	0	O
von	0	B
Willebrand	0	I
factor	0	I
(	0	O
vWF	1	B
)	0	O
fragmentation	0	O
as	0	O
reflected	0	O
by	0	O
decreased	0	O
high	0	O
molecular	0	O
weight	0	O
and	0	O
increased	0	O
low	0	O
molecular	0	O
weight	0	O
vWF	1	B
multimers	0	I
in	0	O
the	0	O
circulation	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
Hansel	0	O
'	0	O
s	0	O
stain	0	O
substantially	0	O
improves	0	O
the	0	O
recognition	0	O
of	0	O
eosinophiluria	0	O
as	0	O
compared	0	O
with	0	O
Wright	0	O
'	0	O
s	0	O
stain	0	O
.	0	O


Analysis	1	O
of	0	O
nucleotide	0	O
sequence	0	O
of	0	O
the	0	O
rightmost	0	O
43	0	O
kbp	0	O
of	0	O
herpesvirus	0	O
saimiri	0	O
(	0	O
HVS	0	O
)	0	O
L	1	O
-	0	O
DNA	1	O
:	0	O
general	0	O
conservation	0	O
of	0	O
genetic	0	O
organization	0	O
between	0	O
HVS	0	O
and	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
.	0	O


The	0	O
clinical	0	O
relevance	0	O
of	0	O
these	0	O
findings	0	O
is	0	O
strengthened	0	O
by	0	O
the	0	O
observation	0	O
that	0	O
similar	0	O
results	0	O
were	0	O
obtained	0	O
when	0	O
P	1	O
.	0	O
HCl	1	O
was	0	O
given	0	O
by	0	O
the	0	O
intravenous	0	O
route	0	O
.	0	O


The	0	O
B	1	B
.	0	I
germanica	0	I
cyclophilin	0	I
amino	0	I
acid	0	I
sequence	0	I
shares	0	O
83	0	O
%	0	O
identity	0	O
with	0	O
the	0	O
cytosolic	0	B
cyclophilin	0	I
isoform	0	I
from	0	I
Drosophila	1	I
melanogaster	0	I
(	0	O
Cyp	1	B
-	0	I
1	0	I
).	0	O


So	1	O
far	0	O
no	0	O
problems	0	O
with	0	O
multiply	0	O
resistant	0	O
strains	0	O
have	0	O
developed	0	O
.	0	O


The	0	O
frequency	0	O
of	0	O
SPs	1	O
for	0	O
both	0	O
the	0	O
moderate	0	O
and	0	O
severe	0	O
groups	0	O
was	0	O
significantly	0	O
higher	0	O
than	0	O
that	0	O
in	0	O
patients	0	O
with	0	O
a	0	O
normal	0	O
MMFCV	0	O
(	0	O
p	0	O
<	0	O
.	0	O
01	0	O
);	0	O
of	0	O
154	0	O
arms	0	O
with	0	O
a	0	O
normal	0	O
MMFCV	0	O
,	0	O
only	0	O
9	0	O
(	0	O
6	0	O
%)	0	O
had	0	O
an	0	O
SP	1	O
.	0	O


Quantitative	1	O
analysis	0	O
of	0	O
DNA	1	O
using	0	O
flow	0	O
cytometry	0	O
and	0	O
immunocytochemical	0	O
findings	0	O
in	0	O
16	0	O
cases	0	O
of	0	O
cardiac	0	O
myxomas	0	O


Thereafter	0	O
,	0	O
the	0	O
aggregation	0	O
rose	0	O
to	0	O
the	0	O
initial	0	O
100	0	O
%	0	O
value	0	O
4	0	O
h	0	O
after	0	O
drug	0	O
application	0	O
and	0	O
remained	0	O
at	0	O
this	0	O
level	0	O
during	0	O
the	0	O
observation	0	O
period	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


ERV1	0	B
is	0	O
involved	0	O
in	0	O
the	0	O
cell	0	O
-	0	O
division	0	O
cycle	0	O
and	0	O
the	0	O
maintenance	0	O
of	0	O
mitochondrial	0	O
genomes	0	O
in	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


Diabetes	1	O
care	0	O
:	0	O
a	0	O
guideline	0	O
to	0	O
the	0	O
facilities	0	O
needed	0	O
to	0	O
support	0	O
internationally	0	O
endorsed	0	O
standards	0	O
.	0	O


Furthermore	0	O
,	0	O
heparin	0	B
lyase	0	I
treatment	0	O
of	0	O
extracts	0	O
of	0	O
cells	0	O
expressing	0	O
recombinant	0	B
YD	0	I
-	0	I
repeat	0	I
protein	0	I
releases	0	O
this	0	O
protein	0	O
from	0	O
high	0	O
molecular	0	O
mass	0	O
aggregates	0	O
.	0	O


Utilizing	0	O
transient	0	O
transfection	0	O
studies	0	O
in	0	O
HepG2	0	O
cells	0	O
,	0	O
we	0	O
have	0	O
shown	0	O
that	0	O
deletion	0	O
of	0	O
the	0	O
factor	0	B
VIII	0	I
promoter	0	I
sequences	0	I
distal	0	O
to	0	O
nucleotide	0	O
-	0	O
44	0	O
results	0	O
in	0	O
a	0	O
significant	0	O
but	0	O
small	0	O
increase	0	O
in	0	O
promoter	0	O
activity	0	O
.	0	O


The	0	O
results	0	O
of	0	O
these	0	O
analyses	0	O
indicate	0	O
that	0	O
the	0	O
proteinase	0	O
cleaves	0	O
at	0	O
amino	0	O
acid	0	O
residues	0	O
E960	0	O
-	0	O
A961	0	O
,	0	O
E1071	0	O
-	0	O
S1072	0	O
,	0	O
E1345	0	O
-	0	O
T1346	0	O
,	0	O
and	0	O
E1419	0	O
-	0	O
G1420	0	O
;	0	O
however	0	O
,	0	O
the	0	O
cleavage	0	O
efficiency	0	O
is	0	O
varied	0	O
.	0	O


Carcinoembryonic	1	B
antigen	0	I
(	0	O
CEA	1	B
)	0	O
procedures	0	O
and	0	O
clinical	0	O
evaluation	0	O
.	0	O


BACKGROUND	0	O
:	0	O
Defensins	0	B
,	0	O
also	0	O
known	0	O
as	0	O
human	0	B
neutrophil	0	I
peptides	0	I
,	0	O
are	0	O
antimicrobial	0	O
peptides	0	O
present	0	O
in	0	O
the	0	O
azurophil	0	O
granules	0	O
of	0	O
neutrophils	0	O
.	0	O


Factors	0	O
influencing	0	O
direct	0	O
-	0	O
immersion	0	O
(	0	O
DI	0	O
)-	0	O
SPME	0	O
process	0	O
were	0	O
also	0	O
checked	0	O
and	0	O
chosen	0	O
experimentally	0	O
.	0	O


Inhibition	1	O
of	0	O
phosphatidylinositol	0	B
-	0	I
3	0	I
kinase	0	I
did	0	O
not	0	O
have	0	O
a	0	O
significant	0	O
effect	0	O
on	0	O
p53	0	B
conformation	0	O
but	0	O
did	0	O
have	0	O
a	0	O
weak	0	O
but	0	O
significant	0	O
effect	0	O
on	0	O
Tpo	0	B
-	0	O
enhanced	0	O
viability	0	O
.	0	O


Measurements	0	O
included	0	O
bone	0	O
mineral	0	O
density	0	O
of	0	O
the	0	O
lumbar	0	O
spine	0	O
and	0	O
proximal	0	O
femur	0	O
(	0	O
by	0	O
dual	0	O
-	0	O
energy	0	O
X	1	O
-	0	O
ray	0	O
absorptiometry	0	O
)	0	O
and	0	O
biochemical	0	O
markers	0	O
of	0	O
bone	0	O
remodeling	0	O
(	0	O
serum	0	O
bone	0	O
-	0	O
specific	0	O
alkaline	0	B
phosphatase	0	I
by	0	O
immunoassay	0	O
and	0	O
urine	0	O
deoxypyridinoline	0	O
by	0	O
high	0	O
-	0	O
pressure	0	O
liquid	0	O
chromatography	0	O
).	0	O


The	0	O
general	0	O
transcription	0	B
factor	0	I
IIA	0	I
(	0	O
TFIIA	0	B
)	0	O
interacts	0	O
with	0	O
the	0	O
TATA	0	B
binding	0	I
protein	0	I
(	0	O
TBP	1	B
)	0	O
and	0	O
promoter	0	O
DNA	1	O
to	0	O
mediate	0	O
transcription	0	O
activation	0	O
in	0	O
vitro	0	O
.	0	O


Survival	1	O
after	0	O
development	0	O
of	0	O
symptomatic	0	O
infection	0	O
(	0	O
P	1	O
-	0	O
2	0	O
)	0	O
did	0	O
not	0	O
differ	0	O
by	0	O
transmission	0	O
mode	0	O
.	0	O


PRDII	0	B
-	0	I
BF1	0	I
-	0	I
derived	0	I
cDNAs	0	I
did	0	O
not	0	O
result	0	O
in	0	O
stimulation	0	O
of	0	O
either	0	O
basal	0	O
or	0	O
tat	0	B
-	0	O
induced	0	O
activated	0	O
gene	0	O
expression	0	O
.	0	O


Because	0	O
the	0	O
human	0	B
Antp	0	I
TATAA	0	I
binding	0	I
protein	0	I
is	0	O
expressed	0	O
in	0	O
both	0	O
lymphoid	0	O
and	0	O
non	0	O
-	0	O
lymphoid	0	O
cells	0	O
,	0	O
we	0	O
suggest	0	O
that	0	O
this	0	O
homeobox	0	B
gene	0	I
has	0	O
evolved	0	O
a	0	O
more	0	O
general	0	O
transcriptional	0	O
regulatory	0	O
function	0	O
in	0	O
higher	0	O
eukaryotic	0	O
cells	0	O
.	0	O


Losses	0	O
during	0	O
the	0	O
complete	0	O
procedure	0	O
are	0	O
corrected	0	O
for	0	O
using	0	O
radioactive	0	O
estrogen	0	O
conjugates	0	O
during	0	O
the	0	O
first	0	O
steps	0	O
and	0	O
later	0	O
by	0	O
adding	0	O
deuterated	0	O
internal	0	O
standards	0	O
of	0	O
all	0	O
compounds	0	O
measured	0	O
(	0	O
matairesinol	0	O
,	0	O
enterodiol	0	O
,	0	O
enterolactone	0	O
,	0	O
daidzein	0	O
,	0	O
O	1	O
-	0	O
desmethylangolensin	0	O
,	0	O
equol	0	O
,	0	O
and	0	O
genistein	0	O
).	0	O


We	0	O
show	0	O
that	0	O
LexA	0	B
-	0	O
GAL4	0	B
and	0	O
LexA	0	B
-	0	O
Bicoid	0	B
fusion	0	O
proteins	0	O
are	0	O
both	0	O
dependent	0	O
on	0	O
SNF2	0	B
,	0	O
SNF5	0	B
,	0	O
and	0	O
SNF6	0	B
for	0	O
activation	0	O
of	0	O
target	0	O
genes	0	O
containing	0	O
one	0	O
or	0	O
multiple	0	O
lexA	0	B
operators	0	I
.	0	O


Similarly	0	O
,	0	O
comparison	0	O
of	0	O
percentage	0	O
reductions	0	O
of	0	O
heart	0	O
rate	0	O
at	0	O
supine	0	O
,	0	O
sitting	0	O
and	0	O
exercise	0	O
by	0	O
repeated	0	O
measure	0	O
analysis	0	O
showed	0	O
the	0	O
Malays	0	O
to	0	O
have	0	O
significantly	0	O
higher	0	O
change	0	O
compared	0	O
to	0	O
the	0	O
Chinese	0	O
(	0	O
p	0	O
=	0	O
0	0	O
.	0	O
040	0	O
).	0	O


The	0	O
recovery	0	O
of	0	O
labelled	0	O
methoxydextrane	0	O
is	0	O
98	0	O
+/-	0	O
7	0	O
%.	0	O


Recombinant	1	B
prenylcysteine	0	I
lyase	0	I
was	0	O
produced	0	O
in	0	O
a	0	O
baculovirus	0	O
-	0	O
Sf9	0	O
expression	0	O
system	0	O
.	0	O


Modern	0	O
cancer	0	O
therapy	0	O
has	0	O
included	0	O
surgery	0	O
,	0	O
radiotherapy	0	O
,	0	O
chemotherapy	0	O
,	0	O
and	0	O
most	0	O
recently	0	O
,	0	O
immunotherapy	0	O
and	0	O
hyperthermia	0	O
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
the	0	O
effect	0	O
of	0	O
the	0	O
isomers	0	O
of	0	O
pentobarbital	0	O
and	0	O
secobarbital	0	O
on	0	O
mult	0	O
FR30	0	O
FI600	0	O
responding	0	O
and	0	O
on	0	O
suppressed	0	O
responding	0	O
are	0	O
qualitatively	0	O
similar	0	O
.(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


I	1	O
.	0	O


Structure	1	O
determination	0	O
of	0	O
an	0	O
adsorbate	0	O
-	0	O
induced	0	O
multilayer	0	O
reconstruction	0	O
:	0	O
(	0	O
1	0	O
x	0	O
2	0	O
)-	0	O
H	1	O
/	0	O
Ni	1	O
(	0	O
110	0	O
).	0	O


The	0	O
effect	0	O
of	0	O
Rho	1	B
on	0	O
AP	1	B
-	0	I
1	0	I
is	0	O
independent	0	O
of	0	O
the	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
pathway	0	O
,	0	O
as	0	O
a	0	O
dominant	0	B
-	0	I
negative	0	I
MEK	0	I
and	0	O
a	0	O
MEK	0	B
inhibitor	0	O
(	0	O
PD98059	0	O
)	0	O
did	0	O
not	0	O
affect	0	O
Rho	1	B
-	0	O
induced	0	O
AP	1	B
-	0	I
1	0	I
activity	0	O
.	0	O


The	0	O
nerve	0	B
growth	0	I
factor	0	I
beta	0	I
gene	0	I
(	0	O
NGFB	0	B
)	0	O
belongs	0	O
to	0	O
a	0	O
conserved	0	O
syntenic	0	O
group	0	O
on	0	O
human	0	O
chromosome	0	O
1	0	O
and	0	O
mouse	0	O
Chromosome	1	O
3	0	O
.	0	O


If	1	O
the	0	O
haemoglobin	0	B
concentration	0	O
(	0	O
Hb	1	B
)	0	O
was	0	O
less	0	O
than	0	O
12	0	O
g	0	O
dL	1	O
-	0	O
1	0	O
they	0	O
were	0	O
given	0	O
a	0	O
four	0	O
week	0	O
course	0	O
of	0	O
ferrous	0	O
sulphate	0	O
.	0	O


The	0	O
subjects	0	O
received	0	O
a	0	O
single	0	O
500	0	O
mg	0	O
dose	0	O
of	0	O
acetaminophen	0	O
i	0	O
.	0	O
v	0	O
.	0	O
and	0	O
concentrations	0	O
in	0	O
plasma	0	O
were	0	O
measured	0	O
for	0	O
360	0	O
minutes	0	O
and	0	O
in	0	O
urine	0	O
for	0	O
24	0	O
h	0	O
in	0	O
order	0	O
to	0	O
estimate	0	O
the	0	O
production	0	O
of	0	O
metabolites	0	O
.	0	O


However	0	O
,	0	O
in	0	O
TF	1	O
-	0	O
1	0	O
cells	0	O
grown	0	O
on	0	O
GM	1	B
-	0	I
CSF	1	I
before	0	O
starvation	0	O
,	0	O
CREB	0	B
phosphorylation	0	O
was	0	O
observed	0	O
10	0	O
minutes	0	O
after	0	O
PIXY321	0	B
stimulation	0	O
.	0	O


CONCLUSION	0	O
:	0	O
Chronic	1	O
administration	0	O
of	0	O
misoprostol	0	O
may	0	O
have	0	O
caused	0	O
a	0	O
negative	0	O
natriuretic	0	O
effect	0	O
in	0	O
cirrhotic	0	O
patients	0	O
with	0	O
ascites	0	O
.	0	O


Molecular	1	O
analysis	0	O
of	0	O
a	0	O
novel	0	O
schizosaccharomyces	0	O
pombe	0	O
gene	0	O
containing	0	O
two	0	O
RNP	1	O
consensus	0	O
-	0	O
sequence	0	O
RNA	1	O
-	0	O
binding	0	O
domains	0	O
.	0	O


Recently	0	O
,	0	O
the	0	O
3	0	B
.	0	I
6	0	I
-	0	I
kb	0	I
full	0	I
-	0	I
length	0	I
alpha	0	I
-	0	I
GalNAc	1	I
cDNA	1	I
sequence	0	I
was	0	O
isolated	0	O
and	0	O
found	0	O
to	0	O
have	0	O
remarkable	0	O
nucleotide	0	O
and	0	O
predicted	0	O
amino	0	O
acid	0	O
homology	0	O
(	0	O
55	0	O
.	0	O
8	0	O
and	0	O
46	0	O
.	0	O
9	0	O
%,	0	O
respectively	0	O
)	0	O
with	0	O
the	0	O
human	0	B
alpha	0	I
-	0	I
galactosidase	0	I
A	1	I
(	0	O
alpha	0	B
-	0	I
Gal	0	I
A	1	I
)	0	O
cDNA	1	O
.	0	O


After	0	O
an	0	O
initial	0	O
titration	0	O
period	0	O
and	0	O
adjustment	0	O
of	0	O
the	0	O
therapeutic	0	O
dose	0	O
,	0	O
the	0	O
individual	0	O
doses	0	O
were	0	O
from	0	O
21	0	O
to	0	O
500	0	O
micrograms	0	O
/	0	O
24	0	O
hrs	0	O
(	0	O
mean	0	O
160	0	O
micrograms	0	O
/	0	O
24	0	O
hrs	0	O
).	0	O


This	0	O
may	0	O
explain	0	O
in	0	O
part	0	O
a	0	O
secular	0	O
trend	0	O
towards	0	O
reduced	0	O
birthweight	0	O
for	0	O
gestation	0	O
in	0	O
preterm	0	O
infants	0	O
.	0	O


A	1	O
case	0	O
of	0	O
M	1	O
hemoglobinosis	0	O


In	1	O
mitogen	0	O
-	0	O
stimulated	0	O
splenocytes	0	O
,	0	O
Gfi	0	B
-	0	I
1	0	I
expression	0	O
begins	0	O
to	0	O
rise	0	O
at	0	O
12	0	O
h	0	O
after	0	O
stimulation	0	O
and	0	O
reaches	0	O
very	0	O
high	0	O
levels	0	O
after	0	O
50	0	O
h	0	O
,	0	O
suggesting	0	O
that	0	O
it	0	O
may	0	O
be	0	O
functionally	0	O
involved	0	O
in	0	O
events	0	O
occurring	0	O
after	0	O
the	0	O
interaction	0	O
of	0	O
IL	1	B
-	0	I
2	0	I
with	0	O
its	0	O
receptor	0	O
,	0	O
perhaps	0	O
during	0	O
the	0	O
transition	0	O
from	0	O
the	0	O
G1	0	O
to	0	O
the	0	O
S	1	O
phase	0	O
of	0	O
the	0	O
cell	0	O
cycle	0	O
.	0	O


The	0	O
transcription	0	O
factor	0	O
CHOP	1	B
/	0	O
GADD153	0	B
gene	0	O
is	0	O
induced	0	O
by	0	O
cellular	0	O
stress	0	O
and	0	O
is	0	O
involved	0	O
in	0	O
mediating	0	O
apoptosis	0	O
.	0	O


They	0	O
generated	0	O
ca	0	O
.	0	O


Experimental	0	O
chlorpromazine	0	O
cataracts	0	O
.	0	O


Evaluation	1	O
of	0	O
the	0	O
new	0	O
Gravigard	0	O
IUCD	1	O
inserter	0	O
.	0	O


Fragments	0	O
containing	0	O
the	0	O
21	0	O
-	0	O
base	0	O
-	0	O
pair	0	O
repeat	0	O
region	0	O
,	0	O
the	0	O
enhancer	0	B
of	0	I
simian	0	I
virus	0	I
40	0	I
or	0	O
both	0	O
strongly	0	O
stimulated	0	O
beta	0	B
-	0	I
galactosidase	0	I
synthesis	0	O
,	0	O
and	0	O
three	0	O
fragments	0	O
from	0	O
the	0	O
polyomavirus	0	B
enhancer	0	I
region	0	I
stimulated	0	O
moderate	0	O
levels	0	O
.	0	O


Human	1	B
PDK1	0	I
is	0	O
homologous	0	O
to	0	O
the	0	O
Drosophila	1	B
protein	0	I
kinase	0	I
DSTPK61	0	I
,	0	O
which	0	O
has	0	O
been	0	O
implicated	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
sex	0	O
differentiation	0	O
,	0	O
oogenesis	0	O
and	0	O
spermatogenesis	0	O
.	0	O


Escherichia	1	O
coli	0	O
JRG582	0	O
is	0	O
an	0	O
ampD	0	B
ampE	0	I
deletion	0	O
derivative	0	O
of	0	O
strain	0	O
HfrH	0	O
and	0	O
accordingly	0	O
it	0	O
is	0	O
derepressed	0	O
for	0	O
expression	0	O
of	0	O
the	0	O
cloned	0	O
inducible	0	O
beta	0	B
-	0	I
lactamase	0	I
gene	0	I
of	0	O
Citrobacter	1	O
freundii	0	O
,	0	O
carried	0	O
on	0	O
plasmid	0	O
pNU305	0	O
.	0	O


Histological	1	O
evaluation	0	O
revealed	0	O
a	0	O
more	0	O
than	0	O
twofold	0	O
increase	0	O
in	0	O
the	0	O
number	0	O
of	0	O
interepithelial	0	O
mononuclear	0	O
cells	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
005	0	O
),	0	O
while	0	O
the	0	O
number	0	O
of	0	O
epithelial	0	O
cells	0	O
/	0	O
100	0	O
microns	0	O
of	0	O
villous	0	O
mucosa	0	O
and	0	O
the	0	O
mean	0	O
height	0	O
of	0	O
the	0	O
epithelial	0	O
cells	0	O
were	0	O
comparable	0	O
in	0	O
both	0	O
groups	0	O
.	0	O


Although	0	O
noninhibitory	0	O
fluid	0	O
had	0	O
higher	0	O
mean	0	O
concentrations	0	O
of	0	O
phosphorus	0	O
and	0	O
zinc	0	O
,	0	O
these	0	O
differences	0	O
did	0	O
not	0	O
hold	0	O
after	0	O
meconium	0	O
-	0	O
stained	0	O
samples	0	O
were	0	O
excluded	0	O
.	0	O


It	1	O
has	0	O
been	0	O
demonstrated	0	O
previously	0	O
that	0	O
Pax	0	B
-	0	I
6	0	I
,	0	O
a	0	O
paired	0	B
domain	0	I
(	0	O
PD	1	B
)/	0	O
homeodomain	0	B
(	0	O
HD	1	B
)	0	O
transcription	0	O
factor	0	O
critical	0	O
for	0	O
eye	0	O
development	0	O
,	0	O
contributes	0	O
to	0	O
the	0	O
activation	0	O
of	0	O
the	0	O
alphaB	0	B
-,	0	I
alphaA	0	I
-,	0	I
delta1	0	I
-,	0	I
and	0	I
zeta	0	I
-	0	I
crystallin	0	I
genes	0	O
in	0	O
the	0	O
lens	0	O
.	0	O


PURPOSE	0	O
:	0	O
To	1	O
determine	0	O
the	0	O
effects	0	O
of	0	O
hypercholesterolemia	0	O
and	0	O
atherosclerosis	0	O
-	0	O
induced	0	O
chronic	0	O
cavernosal	0	O
arterial	0	O
insufficiency	0	O
on	0	O
cavernosal	0	O
smooth	0	O
muscle	0	O
tone	0	O
,	0	O
nitric	0	B
oxide	0	I
synthase	0	I
(	0	O
NOS	1	B
)	0	O
activity	0	O
and	0	O
cavernosal	0	O
tissue	0	O
synthesis	0	O
of	0	O
constrictor	0	O
eicosanoids	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
Rho	1	B
family	0	I
protein	0	I
Cdc42	0	I
,	0	O
a	0	O
conserved	0	O
morphogenetic	0	B
G	1	I
protein	0	I
,	0	O
is	0	O
also	0	O
a	0	O
potent	0	O
regulator	0	O
of	0	O
filamentous	0	O
growth	0	O
and	0	O
FG	1	B
(	0	O
TyA	0	B
)::	0	O
lacZ	0	B
expression	0	O
in	0	O
S	1	O
.	0	O
cerevisiae	0	O
.	0	O


In	1	O
these	0	O
vectors	0	O
the	0	O
chimeric	0	B
long	0	I
terminal	0	I
repeat	0	I
(	0	O
chLTR	0	B
)	0	O
drives	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
chloramphenicol	0	B
acetyl	0	I
transferase	0	I
(	0	O
CAT	1	B
)	0	O
reporter	0	O
gene	0	O
that	0	O
is	0	O
followed	0	O
by	0	O
an	0	O
internal	0	O
SV40	1	B
virus	0	I
early	0	I
region	0	I
promoter	0	I
linked	0	O
to	0	O
the	0	O
neomycin	0	B
phosphotransferase	0	I
II	0	I
(	0	O
NEO	0	B
)	0	O
gene	0	O
.	0	O


A	1	O
proportion	0	O
of	0	O
APC	1	B
wild	0	O
-	0	O
type	0	O
colon	0	O
carcinomas	0	O
and	0	O
melanomas	0	O
also	0	O
contains	0	O
constitutive	0	O
nuclear	0	O
Tcf	0	B
-	0	I
4	0	I
/	0	O
beta	0	B
-	0	I
catenin	0	I
complexes	0	O
as	0	O
a	0	O
result	0	O
of	0	O
dominant	0	O
mutations	0	O
in	0	O
the	0	O
N	1	O
terminus	0	O
of	0	O
beta	0	B
-	0	I
catenin	0	I
that	0	O
render	0	O
it	0	O
insensitive	0	O
to	0	O
downregulation	0	O
by	0	O
APC	1	B
,	0	O
GSK3	0	B
beta	0	I
,	0	O
and	0	O
Axin	0	B
/	0	O
Conductin	0	B
.	0	O


Identification	1	O
of	0	O
five	0	O
new	0	O
genes	0	O
,	0	O
closely	0	O
related	0	O
to	0	O
the	0	O
interleukin	0	B
-	0	I
1beta	0	I
converting	0	I
enzyme	0	I
gene	0	I
,	0	O
that	0	O
do	0	O
not	0	O
encode	0	O
functional	0	O
proteases	0	O
.	0	O


These	0	O
data	0	O
are	0	O
consistent	0	O
with	0	O
a	0	O
model	0	O
in	0	O
which	0	O
GATA	0	B
-	0	I
5	0	I
performs	0	O
a	0	O
unique	0	O
temporally	0	O
and	0	O
spatially	0	O
restricted	0	O
function	0	O
in	0	O
the	0	O
embryonic	0	O
heart	0	O
and	0	O
lung	0	O
.	0	O


DESIGN	0	O
--	0	O
A	1	O
randomised	0	O
study	0	O
was	0	O
conducted	0	O
in	0	O
all	0	O
women	0	O
aged	0	O
50	0	O
-	0	O
70	0	O
years	0	O
who	0	O
were	0	O
eligible	0	O
for	0	O
breast	0	O
cancer	0	O
screening	0	O
and	0	O
living	0	O
in	0	O
the	0	O
city	0	O
of	0	O
Utrecht	0	O
.	0	O


Persistence	1	O
of	0	O
toxaphene	0	O
in	0	O
treated	0	O
lakes	0	O
.	0	O


Functional	1	O
analysis	0	O
of	0	O
promoter	0	O
activity	0	O
of	0	O
the	0	O
5	0	O
'-	0	O
flanking	0	O
region	0	O
of	0	O
cyclin	0	B
D2	0	I
suggested	0	O
that	0	O
the	0	O
region	0	O
-	0	O
1	0	O
,	0	O
100	0	O
to	0	O
-	0	O
805	0	O
including	0	O
C	1	B
/	0	I
EBP	1	I
,	0	O
PEA3	0	B
,	0	O
AP2	0	B
,	0	O
NF	1	B
-	0	I
Y	1	I
,	0	O
c	0	B
-	0	I
Myc	0	I
,	0	O
and	0	O
Sp1	0	B
may	0	O
have	0	O
a	0	O
major	0	O
positive	0	O
regulatory	0	O
activity	0	O
for	0	O
expression	0	O
of	0	O
cyclin	0	B
D2	0	I
.	0	O


A	1	O
patient	0	O
with	0	O
an	0	O
infected	0	O
wound	0	O
or	0	O
one	0	O
on	0	O
a	0	O
primary	0	O
area	0	O
(	0	O
hands	0	O
,	0	O
feet	0	O
,	0	O
face	0	O
,	0	O
or	0	O
perineum	0	O
)	0	O
may	0	O
have	0	O
to	0	O
be	0	O
hospitalized	0	O
to	0	O
ensure	0	O
proper	0	O
care	0	O
.	0	O


A	1	O
v	0	B
-	0	I
erbB	0	I
-	0	I
related	0	I
protooncogene	0	I
,	0	O
c	0	B
-	0	I
erbB	0	I
-	0	I
2	0	I
,	0	O
is	0	O
distinct	0	O
from	0	O
the	0	O
c	0	B
-	0	I
erbB	0	I
-	0	I
1	0	I
/	0	O
epidermal	0	B
growth	0	I
factor	0	I
-	0	I
receptor	0	I
gene	0	O
and	0	O
is	0	O
amplified	0	O
in	0	O
a	0	O
human	0	O
salivary	0	O
gland	0	O
adenocarcinoma	0	O
.	0	O


The	0	O
major	0	O
RNase	1	B
E	1	I
cleavage	0	O
product	0	O
(	0	O
denoted	0	O
pSok	0	B
-	0	I
6	0	I
)	0	O
is	0	O
rapidly	0	O
degraded	0	O
by	0	O
polynucleotide	0	B
phosphorylase	0	I
(	0	O
PNPase	0	B
).	0	O


Serum	1	O
levels	0	O
of	0	O
albumin	0	B
,	0	O
globulin	0	B
,	0	O
and	0	O
coagulation	0	B
protein	0	I
activity	0	O
were	0	O
measured	0	O
preshock	0	O
,	0	O
postshock	0	O
,	0	O
and	0	O
daily	0	O
for	0	O
3	0	O
days	0	O
;	0	O
skin	0	O
lymph	0	O
levels	0	O
were	0	O
measured	0	O
on	0	O
Day	1	O
3	0	O
.	0	O


MZF	0	B
-	0	I
1	0	I
represses	0	O
CAT	1	B
reporter	0	I
gene	0	I
expression	0	O
via	0	O
GAL4	0	B
binding	0	I
sites	0	I
in	0	O
the	0	O
nonhematopoietic	0	O
cell	0	O
lines	0	O
NIH	1	O
3T3	0	O
and	0	O
293	0	O
.	0	O


Multivariate	1	O
logistic	0	O
regression	0	O
analysis	0	O
indicated	0	O
that	0	O
seropositivity	0	O
was	0	O
strongly	0	O
associated	0	O
with	0	O
the	0	O
prevalence	0	O
of	0	O
hepatitis	0	O
B	1	O
in	0	O
an	0	O
employee	0	O
'	0	O
s	0	O
country	0	O
of	0	O
birth	0	O
and	0	O
with	0	O
age	0	O
.	0	O


PAS1	0	B
,	0	O
a	0	O
yeast	0	O
gene	0	O
required	0	O
for	0	O
peroxisome	0	O
biogenesis	0	O
,	0	O
encodes	0	O
a	0	O
member	0	O
of	0	O
a	0	O
novel	0	O
family	0	O
of	0	O
putative	0	O
ATPases	0	B
.	0	O


2	0	O
-	0	O
AP	1	O
induced	0	O
marked	0	O
,	0	O
steady	0	O
rises	0	O
in	0	O
mRNA	1	O
accumulation	0	O
from	0	O
both	0	O
transfected	0	O
and	0	O
chromosomally	0	O
integrated	0	O
HIV	1	O
-	0	O
1	0	O
constructs	0	O
but	0	O
no	0	O
increases	0	O
from	0	O
an	0	O
endogenous	0	O
gene	0	O
encoding	0	O
gamma	0	B
-	0	I
actin	0	I
or	0	O
glucose	0	B
6	0	I
-	0	I
phosphate	0	I
dehydrogenase	0	I
.	0	O


Synovial	1	O
cysts	0	O
of	0	O
the	0	O
hip	0	O
joint	0	O


As	1	O
the	0	O
length	0	O
of	0	O
the	0	O
fatty	0	O
acid	0	O
decreased	0	O
,	0	O
the	0	O
binding	0	O
affinity	0	O
was	0	O
reduced	0	O
;	0	O
myristic	0	O
acid	0	O
(	0	O
14	0	O
:	0	O
0	0	O
)	0	O
bound	0	O
with	0	O
a	0	O
K	1	O
(	0	O
d	0	O
)	0	O
of	0	O
1409	0	O
+/-	0	O
423	0	O
nM	1	O
,	0	O
but	0	O
medium	0	O
-	0	O
chain	0	O
(	0	O
decanoic	0	O
acid	0	O
,	0	O
10	0	O
:	0	O
0	0	O
)	0	O
and	0	O
short	0	O
-	0	O
chain	0	O
(	0	O
octanoic	0	O
acid	0	O
,	0	O
8	0	O
:	0	O
0	0	O
)	0	O
lipids	0	O
were	0	O
not	0	O
bound	0	O
at	0	O
all	0	O
.	0	O


Escalation	0	O
to	0	O
180	0	O
mg	0	O
/	0	O
m2	0	O
was	0	O
to	0	O
be	0	O
carried	0	O
out	0	O
if	0	O
white	0	O
blood	0	O
cell	0	O
nadir	0	O
count	0	O
was	0	O
>	0	O
2	0	O
.	0	O
0	0	O
x	0	O
10	0	O
(	0	O
9	0	O
)/	0	O
l	0	O
and	0	O
platelet	0	O
nadir	0	O
count	0	O
was	0	O
>	0	O
75	0	O
x	0	O
10	0	O
(	0	O
9	0	O
)/	0	O
l	0	O
.	0	O


Isolation	1	O
of	0	O
tha	0	O
avian	0	O
reticuloendothelial	0	O
virus	0	O
(	0	O
strain	0	O
T	1	O
).	0	O


Absorption	1	O
was	0	O
rapid	0	O
,	0	O
with	0	O
a	0	O
mean	0	O
time	0	O
to	0	O
peak	0	O
of	0	O
39	0	O
min	0	O
.	0	O


CPT	1	O
-	0	O
11	0	O
was	0	O
administered	0	O
as	0	O
a	0	O
30	0	O
-	0	O
minute	0	O
i	0	O
.	0	O
v	0	O
.	0	O
infusion	0	O
at	0	O
a	0	O
dose	0	O
of	0	O
350	0	O
mg	0	O
/	0	O
m2	0	O
diluted	0	O
in	0	O
250	0	O
ml	0	O
normal	0	O
saline	0	O
every	0	O
3	0	O
weeks	0	O
.	0	O


Topics	0	O
reviewed	0	O
here	0	O
include	0	O
:	0	O
data	0	O
supporting	0	O
the	0	O
association	0	O
of	0	O
myositis	0	O
with	0	O
cancer	0	O
and	0	O
the	0	O
appropriate	0	O
evaluations	0	O
for	0	O
malignancy	0	O
in	0	O
a	0	O
myositis	0	O
patient	0	O
;	0	O
an	0	O
approach	0	O
to	0	O
the	0	O
assessment	0	O
of	0	O
patients	0	O
with	0	O
dermatomyositis	0	O
sine	0	O
myositis	0	O
;	0	O
the	0	O
usefulness	0	O
of	0	O
the	0	O
clinicopathological	0	O
and	0	O
serological	0	O
classifications	0	O
;	0	O
a	0	O
discussion	0	O
of	0	O
whether	0	O
childhood	0	O
and	0	O
adult	0	O
myositis	0	O
are	0	O
the	0	O
same	0	O
or	0	O
different	0	O
entities	0	O
;	0	O
a	0	O
review	0	O
of	0	O
those	0	O
prognostic	0	O
factors	0	O
to	0	O
consider	0	O
in	0	O
the	0	O
clinical	0	O
management	0	O
of	0	O
myositis	0	O
patients	0	O
;	0	O
current	0	O
approaches	0	O
and	0	O
their	0	O
limitations	0	O
for	0	O
assessing	0	O
disease	0	O
activity	0	O
and	0	O
damage	0	O
.	0	O


Essential	1	O
features	0	O
of	0	O
this	0	O
model	0	O
are	0	O
bending	0	O
of	0	O
the	0	O
DNA	1	O
double	0	O
helix	0	O
and	0	O
contact	0	O
of	0	O
operator	0	O
sites	0	O
with	0	O
repressor	0	O
domains	0	O
bearing	0	O
sequence	0	O
homologies	0	O
with	0	O
the	0	O
helix	0	O
-	0	O
turn	0	O
-	0	O
helix	0	O
(	0	O
HTH	0	O
)	0	O
motifs	0	O
of	0	O
other	0	O
DNA	1	O
-	0	O
binding	0	O
proteins	0	O
.	0	O


These	0	O
data	0	O
show	0	O
that	0	O
the	0	O
alpha	0	O
-	0	O
helix	0	O
domain	0	O
of	0	O
p57	0	B
(	0	O
Kip2	0	B
),	0	O
which	0	O
is	0	O
conserved	0	O
in	0	O
the	0	O
Cip	1	B
/	0	O
Kip	0	B
proteins	0	O
,	0	O
is	0	O
implicated	0	O
in	0	O
protein	0	O
-	0	O
protein	0	O
interaction	0	O
and	0	O
confers	0	O
a	0	O
specific	0	O
regulatory	0	O
mechanism	0	O
,	0	O
outside	0	O
of	0	O
their	0	O
Cdk	1	B
-	0	O
inhibitory	0	O
activity	0	O
,	0	O
by	0	O
which	0	O
the	0	O
p57	0	B
(	0	O
Kip2	0	B
)	0	O
family	0	O
members	0	O
positively	0	O
act	0	O
on	0	O
myogenic	0	O
differentiation	0	O
.	0	O


The	0	O
reduced	0	O
NO	1	O
production	0	O
in	0	O
these	0	O
cells	0	O
was	0	O
associated	0	O
with	0	O
low	0	O
levels	0	O
of	0	O
mRNA	1	O
of	0	O
inducible	0	B
NO	1	I
synthetase	0	I
.	0	O


This	0	O
study	0	O
demonstrates	0	O
that	0	O
alteration	0	O
of	0	O
CDKN2	0	B
is	0	O
one	0	O
of	0	O
the	0	O
most	0	O
frequent	0	O
genetic	0	O
abnormalities	0	O
in	0	O
prostate	0	O
cancer	0	O
and	0	O
may	0	O
contribute	0	O
to	0	O
prostate	0	O
carcinogenesis	0	O
.	0	O


The	0	O
major	0	O
findings	0	O
of	0	O
our	0	O
studies	0	O
are	0	O
as	0	O
follows	0	O
:	0	O
1	0	O
)	0	O
There	0	O
are	0	O
no	0	O
detectable	0	O
signals	0	O
around	0	O
GDF	0	B
-	0	I
9	0	I
-	0	O
deficient	0	O
follicles	0	O
for	0	O
several	0	O
theca	0	O
cell	0	O
layer	0	O
markers	0	O
[	0	O
i	0	O
.	0	O
e	0	O
.	0	O


Poor	0	O
response	0	O
when	0	O
laboratory	0	O
recommended	0	O
range	0	O
for	0	O
serum	0	O
lithium	0	O
is	0	O
changed	0	O
.	0	O


The	0	O
integration	0	O
at	0	O
the	0	O
VIP	1	B
CyRE	0	I
of	0	O
the	0	O
Jak	1	B
-	0	O
Stat	1	B
and	0	O
AP	1	B
-	0	I
1	0	I
signaling	0	O
pathways	0	O
with	0	O
other	0	O
pre	0	O
-	0	O
existing	0	O
proteins	0	O
provides	0	O
a	0	O
cellular	0	O
mechanism	0	O
for	0	O
cell	0	O
-	0	O
and	0	O
cytokine	0	O
-	0	O
specific	0	O
signaling	0	O
.	0	O


Moreover	0	O
,	0	O
the	0	O
hypoxia	0	O
-	0	O
induced	0	O
expression	0	O
of	0	O
the	0	O
endogenous	0	O
Epo	0	B
gene	0	I
was	0	O
significantly	0	O
inhibited	0	O
in	0	O
Hep3B	0	O
cells	0	O
stably	0	O
transfected	0	O
with	0	O
HNF	1	B
-	0	I
4	0	I
delta	0	I
C	1	I
.	0	O


The	0	O
RFLP	1	O
patterns	0	O
of	0	O
the	0	O
isolates	0	O
from	0	O
six	0	O
of	0	O
these	0	O
patients	0	O
remained	0	O
essentially	0	O
unchanged	0	O
(	0	O
two	0	O
strains	0	O
showed	0	O
one	0	O
additional	0	O
band	0	O
)	0	O
despite	0	O
the	0	O
development	0	O
of	0	O
drug	0	O
resistance	0	O
.	0	O


65	0	O
-	0	O
kilodalton	0	O
protein	0	O
phosphorylated	0	O
by	0	O
interleukin	0	B
2	0	I
stimulation	0	O
bears	0	O
two	0	O
putative	0	O
actin	0	B
-	0	I
binding	0	I
sites	0	I
and	0	O
two	0	O
calcium	0	O
-	0	O
binding	0	O
sites	0	O
.	0	O


Alanine	1	O
substitution	0	O
mutations	0	O
in	0	O
the	0	O
Zta	0	B
activation	0	I
domain	0	I
which	0	O
eliminate	0	O
the	0	O
ability	0	O
of	0	O
Zta	0	B
to	0	O
stimulate	0	O
the	0	O
D	1	B
-	0	I
A	1	I
complex	0	I
were	0	O
examined	0	O
.	0	O


Ten	0	O
patients	0	O
with	0	O
advanced	0	O
,	0	O
diffuse	0	O
Hodgkin	0	O
'	0	O
s	0	O
and	0	O
non	0	O
-	0	O
Hodgkin	0	O
'	0	O
s	0	O
lymphomas	0	O
responding	0	O
poorly	0	O
to	0	O
the	0	O
most	0	O
widely	0	O
employed	0	O
primary	0	O
chemotherapy	0	O
regimens	0	O
were	0	O
treated	0	O
with	0	O
a	0	O
high	0	O
-	0	O
dose	0	O
chemotherapy	0	O
(	0	O
HDC	0	O
)	0	O
followed	0	O
by	0	O
rescue	0	O
with	0	O
non	0	O
-	0	O
frozen	0	O
autologous	0	O
bone	0	O
marrow	0	O
infusion	0	O
(	0	O
ABMT	1	O
).	0	O


Iodine	1	O
deficiency	0	O
disorders	0	O
in	0	O
Bangladesh	0	O
.	0	O


This	0	O
agent	0	O
,	0	O
isolated	0	O
from	0	O
the	0	O
fungus	0	O
Streptomyces	1	O
tsukubaensis	0	O
,	0	O
has	0	O
a	0	O
mechanism	0	O
of	0	O
action	0	O
similar	0	O
to	0	O
that	0	O
of	0	O
cyclosporine	0	O
.	0	O


On	1	O
admission	0	O
to	0	O
our	0	O
department	0	O
in	0	O
September	0	O
,	0	O
1987	0	O
,	0	O
the	0	O
patient	0	O
was	0	O
alert	0	O
and	0	O
had	0	O
spastic	0	O
paraparesis	0	O
,	0	O
the	0	O
impairment	0	O
of	0	O
all	0	O
sensory	0	O
modalities	0	O
below	0	O
the	0	O
level	0	O
of	0	O
Th	1	O
10	0	O
and	0	O
urinary	0	O
disturbance	0	O
.	0	O


The	0	O
relation	0	O
between	0	O
myocardial	0	B
beta	0	I
-	0	I
adrenergic	0	I
receptor	0	I
and	0	O
left	0	O
ventricular	0	O
(	0	O
LV	1	O
)	0	O
function	0	O
was	0	O
studied	0	O
in	0	O
10	0	O
patients	0	O
,	0	O
aged	0	O
41	0	O
to	0	O
61	0	O
years	0	O
(	0	O
average	0	O
51	0	O
),	0	O
with	0	O
LV	1	O
volume	0	O
overload	0	O
mainly	0	O
due	0	O
to	0	O
chronic	0	O
mitral	0	O
regurgitation	0	O
.	0	O


Volume	1	O
of	0	O
distribution	0	O
of	0	O
total	0	O
DMDZ	0	O
(	0	O
range	0	O
,	0	O
1	0	O
.	0	O
33	0	O
to	0	O
6	0	O
.	0	O
30	0	O
l	0	O
/	0	O
kg	0	O
)	0	O
and	0	O
of	0	O
unbound	0	O
DMDZ	0	O
after	0	O
correction	0	O
for	0	O
protein	0	O
binding	0	O
(	0	O
range	0	O
,	0	O
43	0	O
to	0	O
243	0	O
l	0	O
/	0	O
kg	0	O
)	0	O
was	0	O
larger	0	O
in	0	O
women	0	O
than	0	O
in	0	O
men	0	O
of	0	O
all	0	O
ages	0	O
,	0	O
and	0	O
in	0	O
the	0	O
elderly	0	O
as	0	O
opposed	0	O
to	0	O
the	0	O
young	0	O
.	0	O


The	0	O
rci	0	B
gene	0	I
was	0	O
fused	0	O
with	0	O
lacZ	0	B
and	0	O
its	0	O
gene	0	O
product	0	O
was	0	O
identified	0	O
by	0	O
Western	0	O
blot	0	O
analysis	0	O
.	0	O


Blood	1	O
variables	0	O
measured	0	O
at	0	O
eight	0	O
intervals	0	O
before	0	O
,	0	O
during	0	O
,	0	O
and	0	O
after	0	O
operation	0	O
were	0	O
as	0	O
follows	0	O
:	0	O
seven	0	O
plasma	0	O
proteins	0	O
,	0	O
free	0	O
hemoglobin	0	B
,	0	O
formed	0	O
elements	0	O
,	0	O
and	0	O
clotting	0	O
functions	0	O
.	0	O


Like	0	O
their	0	O
yeast	0	O
counterpart	0	O
,	0	O
the	0	O
mouse	0	O
GCN2	0	B
isoforms	0	O
contain	0	O
HisRS	0	B
-	0	I
related	0	I
sequences	0	I
juxtaposed	0	O
to	0	O
the	0	O
kinase	0	O
catalytic	0	O
domain	0	O
.	0	O


Localized	1	O
fluorescence	0	O
was	0	O
detectable	0	O
only	0	O
in	0	O
cells	0	O
containing	0	O
a	0	O
visible	0	O
midcell	0	O
constriction	0	O
,	0	O
suggesting	0	O
that	0	O
FtsK	0	B
targeting	0	O
normally	0	O
occurs	0	O
only	0	O
at	0	O
a	0	O
late	0	O
stage	0	O
of	0	O
septation	0	O
.	0	O


Deletion	1	O
mapping	0	O
experiments	0	O
determined	0	O
that	0	O
the	0	O
sequences	0	O
required	0	O
for	0	O
full	0	O
activity	0	O
in	0	O
MSC	0	O
-	0	O
1	0	O
cells	0	O
were	0	O
included	0	O
within	0	O
619	0	O
bp	0	O
of	0	O
the	0	O
start	0	O
site	0	O
and	0	O
identified	0	O
several	0	O
regions	0	O
that	0	O
demonstrated	0	O
increased	0	O
luciferase	0	B
activity	0	O
:	0	O
the	0	O
-	0	O
583	0	O
bp	0	O
to	0	O
-	0	O
564	0	O
bp	0	O
,	0	O
-	0	O
503	0	O
bp	0	O
to	0	O
-	0	O
484	0	O
bp	0	O
,	0	O
and	0	O
-	0	O
114	0	O
bp	0	O
to	0	O
-	0	O
65	0	O
regions	0	O
.	0	O


Thus	0	O
,	0	O
both	0	O
the	0	O
hyperplasia	0	O
and	0	O
thrombotic	0	O
complications	0	O
which	0	O
often	0	O
follow	0	O
stenting	0	O
might	0	O
be	0	O
minimized	0	O
by	0	O
employing	0	O
gold	0	O
stents	0	O
,	0	O
which	0	O
have	0	O
a	0	O
greater	0	O
capacity	0	O
than	0	O
steel	0	O
in	0	O
supporting	0	O
a	0	O
functional	0	O
neo	0	O
-	0	O
endothelium	0	O
.	0	O


Human	1	B
MN	1	I
/	0	I
CA9	0	I
gene	0	I
,	0	O
a	0	O
novel	0	O
member	0	O
of	0	O
the	0	O
carbonic	0	B
anhydrase	0	I
family	0	I
:	0	O
structure	0	O
and	0	O
exon	0	O
to	0	O
protein	0	O
domain	0	O
relationships	0	O
.	0	O


Incorporation	1	O
of	0	O
the	0	O
polyene	0	O
antibiotic	0	O
amphotericin	0	O
B	1	O
(	0	O
AMB	0	O
)	0	O
in	0	O
liposomes	0	O
results	0	O
in	0	O
a	0	O
marked	0	O
reduction	0	O
in	0	O
drug	0	O
toxicity	0	O
with	0	O
no	0	O
loss	0	O
of	0	O
antifungal	0	O
potency	0	O
.	0	O


When	0	O
two	0	O
determinations	0	O
were	0	O
performed	0	O
on	0	O
12	0	O
samples	0	O
of	0	O
plasma	0	O
taken	0	O
from	0	O
normal	0	O
adults	0	O
in	0	O
October	0	O
,	0	O
the	0	O
values	0	O
were	0	O
22	0	O
.	0	O
6	0	O
+/-	0	O
4	0	O
.	0	O
8	0	O
and	0	O
21	0	O
.	0	O
0	0	O
+/-	0	O
3	0	O
.	0	O
6	0	O
(	0	O
mean	0	O
+/-	0	O
SD	1	O
)	0	O
ng	0	O
/	0	O
ml	0	O
,	0	O
respectively	0	O
.	0	O


Similarly	0	O
,	0	O
PCDFs	0	O
/	0	O
PCDDs	0	O
ratio	0	O
in	0	O
ESP	1	O
ash	0	O
was	0	O
lower	0	O
than	0	O
that	0	O
in	0	O
boiler	0	O
ash	0	O
.	0	O


All	1	O
the	0	O
women	0	O
received	0	O
13	0	O
.	0	O
5	0	O
mg	0	O
plain	0	O
bupivacaine	0	O
via	0	O
subarachnoid	0	O
injection	0	O
at	0	O
the	0	O
L2	0	O
-	0	O
3	0	O
interspace	0	O
.	0	O


Changes	0	O
in	0	O
muscarinic	0	B
acetylcholine	0	I
receptors	0	I
in	0	O
guinea	0	O
-	0	O
pig	0	O
lung	0	O
:	0	O
effects	0	O
of	0	O
aging	0	O
,	0	O
inhalation	0	O
of	0	O
an	0	O
allergen	0	O
,	0	O
administration	0	O
of	0	O
drugs	0	O
,	0	O
and	0	O
vagotomy	0	O
.	0	O


Familial	1	O
juvenile	0	O
nephronophthisis	0	O


RESULTS	0	O
:	0	O
Circulating	0	O
leptin	0	B
concentrations	0	O
in	0	O
AN	1	O
were	0	O
3	0	O
.	0	O
5	0	O
+/-	0	O
0	0	O
.	0	O
5	0	O
versus	0	O
7	0	O
.	0	O
6	0	O
+/-	0	O
1	0	O
.	0	O
2	0	O
ng	0	O
/	0	O
ml	0	O
in	0	O
control	0	O
subjects	0	O
.	0	O


In	1	O
two	0	O
experiments	0	O
,	0	O
neonatal	0	O
female	0	O
BALB	0	O
/	0	O
cCrgl	0	O
or	0	O
BALB	0	O
/	0	O
cfC3HCrgl	0	O
mice	0	O
were	0	O
given	0	O
subcutaneous	0	O
injections	0	O
of	0	O
5	0	O
micrograms	0	O
17	0	O
beta	0	O
-	0	O
estradiol	0	O
or	0	O
sesame	0	O
oil	0	O
for	0	O
the	0	O
first	0	O
3	0	O
days	0	O
of	0	O
life	0	O
and	0	O
were	0	O
ovariectomized	0	O
at	0	O
60	0	O
days	0	O
of	0	O
age	0	O
,	0	O
at	0	O
which	0	O
time	0	O
vaginal	0	O
concretions	0	O
(	0	O
Experiments	0	O
I	1	O
and	0	O
II	0	O
)	0	O
or	0	O
silica	0	O
(	0	O
Experiment	1	O
II	0	O
)	0	O
were	0	O
implanted	0	O
intravaginally	0	O
.	0	O


Toxicity	1	O
was	0	O
very	0	O
mild	0	O
with	0	O
both	0	O
regimens	0	O
,	0	O
although	0	O
sedation	0	O
was	0	O
significantly	0	O
higher	0	O
in	0	O
arm	0	O
B	1	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
001	0	O
).	0	O


Serum	1	B
IgE	1	I
levels	0	O
in	0	O
Tauranga	0	O
children	0	O
.	0	O


Northern	0	O
blot	0	O
analyses	0	O
demonstrate	0	O
that	0	O
3	0	O
.	0	O
9	0	O
-	0	O
and	0	O
5	0	O
-	0	O
kilobase	0	O
mRNAs	0	O
corresponding	0	O
to	0	O
the	0	O
cDNA	1	O
were	0	O
present	0	O
in	0	O
all	0	O
tissues	0	O
examined	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
protein	0	O
it	0	O
encodes	0	O
performs	0	O
a	0	O
housekeeping	0	O
function	0	O
.	0	O


Compared	0	O
to	0	O
its	0	O
counterpart	0	O
in	0	O
the	0	O
GPB	0	B
gene	0	I
,	0	O
exon	0	O
3	0	O
of	0	O
the	0	O
GPE	0	B
gene	0	I
contains	0	O
several	0	O
point	0	O
mutations	0	O
,	0	O
an	0	O
insertion	0	O
of	0	O
24	0	O
bp	0	O
,	0	O
and	0	O
a	0	O
stop	0	O
codon	0	O
which	0	O
shortens	0	O
the	0	O
reading	0	O
frame	0	O
.	0	O


The	0	O
analysis	0	O
of	0	O
two	0	O
distinct	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
pathways	0	O
shows	0	O
that	0	O
stress	0	B
-	0	I
activated	0	I
protein	0	I
kinase	0	I
-	0	O
Jun	1	B
N	1	I
-	0	I
terminal	0	I
kinase	0	I
activation	0	O
,	0	O
resulting	0	O
in	0	O
the	0	O
phosphorylation	0	O
of	0	O
ATF	0	B
-	0	I
2	0	I
,	0	O
c	0	B
-	0	I
Jun	1	I
,	0	O
and	0	O
JunD	0	B
,	0	O
is	0	O
required	0	O
not	0	O
only	0	O
for	0	O
the	0	O
IL	1	B
-	0	I
1	0	I
-	0	O
but	0	O
also	0	O
for	0	O
the	0	O
TPA	1	O
-	0	O
dependent	0	O
induction	0	O
,	0	O
while	0	O
the	0	O
extracellular	0	B
signal	0	I
-	0	I
related	0	I
kinase	0	I
1	0	I
(	0	O
ERK	0	B
-	0	I
1	0	I
)	0	O
and	0	O
ERK	0	B
-	0	I
2	0	I
activation	0	O
is	0	O
involved	0	O
in	0	O
the	0	O
TPA	1	O
-	0	O
but	0	O
not	0	O
in	0	O
the	0	O
IL	1	B
-	0	I
1	0	I
-	0	O
dependent	0	O
stimulation	0	O
of	0	O
the	0	O
uPA	0	B
enhancer	0	I
.	0	O


Selection	1	O
using	0	O
SC	1	O
EPD	0	O
was	0	O
more	0	O
effective	0	O
than	0	O
phenotypic	0	O
selection	0	O
in	0	O
reducing	0	O
age	0	O
at	0	O
puberty	0	O
in	0	O
daughters	0	O
.	0	O


These	0	O
data	0	O
indicate	0	O
that	0	O
phosphorylation	0	O
of	0	O
M	1	B
protein	0	I
at	0	O
the	0	O
major	0	O
in	0	O
vivo	0	O
sites	0	O
is	0	O
not	0	O
essential	0	O
for	0	O
virus	0	O
assembly	0	O
.	0	O


The	0	O
circadian	0	O
rhythm	0	O
,	0	O
however	0	O
,	0	O
was	0	O
not	0	O
affected	0	O
and	0	O
the	0	O
difference	0	O
between	0	O
minimum	0	O
(	0	O
12	0	O
.	0	O
00	0	O
h	0	O
)	0	O
and	0	O
maximum	0	O
(	0	O
18	0	O
.	0	O
50	0	O
h	0	O
)	0	O
serum	0	O
concentrations	0	O
was	0	O
31	0	O
.	0	O
3	0	O
%.	0	O


In	1	O
accordance	0	O
with	0	O
clinical	0	O
improvement	0	O
we	0	O
found	0	O
a	0	O
decrease	0	O
of	0	O
laboratory	0	O
indicators	0	O
of	0	O
inflammation	0	O
(	0	O
C	1	B
-	0	I
reactive	0	I
protein	0	I
,	0	O
alpha	0	B
2	0	I
-	0	I
globuline	0	I
,	0	O
prostaglandin	0	O
E2	1	O
).	0	O


We	0	O
report	0	O
a	0	O
patient	0	O
developing	0	O
factor	0	B
VII	0	I
inhibitor	0	I
possibly	0	O
as	0	O
a	0	O
reaction	0	O
to	0	O
penicillin	0	O
administration	0	O
;	0	O
it	0	O
gave	0	O
rise	0	O
to	0	O
fatal	0	O
haemorrhage	0	O
.	0	O


In	1	O
some	0	O
cases	0	O
,	0	O
the	0	O
aberrant	0	O
methylation	0	O
of	0	O
CpGs	0	O
within	0	O
5	0	O
'	0	O
regulatory	0	O
regions	0	O
has	0	O
led	0	O
to	0	O
suppression	0	O
of	0	O
gene	0	O
activity	0	O
.	0	O


The	0	O
development	0	O
and	0	O
distribution	0	O
of	0	O
Trypanosoma	1	O
congolense	0	O
,	0	O
T	1	O
vivax	0	O
and	0	O
T	1	O
brucei	0	O
in	0	O
the	0	O
skin	0	O
of	0	O
goats	0	O
was	0	O
examined	0	O
after	0	O
the	0	O
animals	0	O
were	0	O
bitten	0	O
by	0	O
infected	0	O
Glossina	1	O
morsitans	0	O
centralis	0	O
.	0	O


Analysis	1	O
of	0	O
cell	0	O
cycle	0	O
proteins	0	O
showed	0	O
that	0	O
24	0	O
h	0	O
of	0	O
lovastatin	0	O
treatment	0	O
in	0	O
the	0	O
control	0	O
cells	0	O
caused	0	O
an	0	O
elevation	0	O
in	0	O
the	0	O
levels	0	O
of	0	O
the	0	O
cyclin	0	B
-	0	I
dependent	0	I
kinase	0	I
inhibitor	0	O
p27	0	B
(	0	O
kip1	0	B
),	0	O
inhibition	0	O
of	0	O
both	0	O
cyclin	0	B
E	1	I
-	0	I
and	0	I
cyclin	0	I
A	1	I
-	0	I
dependent	0	I
kinase	0	I
activity	0	O
,	0	O
and	0	O
decreased	0	O
levels	0	O
of	0	O
hyperphosphorylated	0	O
retinoblastoma	0	B
protein	0	I
(	0	O
pRb	0	B
).	0	O


By	0	O
stepwise	0	O
linear	0	O
multiple	0	O
regression	0	O
analysis	0	O
,	0	O
ionized	0	O
magnesium	0	O
was	0	O
significantly	0	O
related	0	O
to	0	O
cyclosporin	0	O
trough	0	O
level	0	O
and	0	O
total	0	O
cholesterol	0	O
but	0	O
not	0	O
to	0	O
serum	0	O
creatinine	0	O
,	0	O
time	0	O
after	0	O
transplant	0	O
or	0	O
the	0	O
dose	0	O
of	0	O
cyclosporin	0	O
.	0	O


Following	1	O
conditioning	0	O
,	0	O
a	0	O
single	0	O
coat	0	O
of	0	O
adhesive	0	O
was	0	O
applied	0	O
and	0	O
light	0	O
-	0	O
cured	0	O
.	0	O


A	1	O
technique	0	O
for	0	O
thermal	0	O
imaging	0	O
of	0	O
the	0	O
animal	0	O
and	0	O
human	0	O
brain	0	O
cortex	0	O
using	0	O
an	0	O
infrared	0	O
optical	0	O
system	0	O
is	0	O
described	0	O
.	0	O


Determination	1	O
of	0	O
transaminases	0	O
with	0	O
an	0	O
autoanalyzer	0	O


A	1	O
larval	0	B
albumin	0	I
-	0	I
like	0	I
protein	0	I
was	0	O
not	0	O
detectable	0	O
by	0	O
silver	0	O
staining	0	O
in	0	O
serum	0	O
of	0	O
tadpoles	0	O
before	0	O
the	0	O
beginning	0	O
of	0	O
metamorphosis	0	O
at	0	O
stage	0	O
48	0	O
.	0	O


The	0	O
protooncogene	0	O
c	0	B
-	0	I
myb	0	I
encodes	0	O
a	0	O
nuclear	0	O
transcription	0	O
factor	0	O
that	0	O
binds	0	O
to	0	O
DNA	1	O
in	0	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
manner	0	O
and	0	O
transactivates	0	O
transcription	0	O
of	0	O
several	0	O
viral	0	O
and	0	O
cellular	0	O
genes	0	O
.	0	O


Insulin	1	B
-	0	I
like	0	I
growth	0	I
factor	0	I
-	0	I
I	1	I
induces	0	O
bcl	0	B
-	0	I
2	0	I
promoter	0	I
through	0	O
the	0	O
transcription	0	O
factor	0	O
cAMP	1	B
-	0	I
response	0	I
element	0	I
-	0	I
binding	0	I
protein	0	I
.	0	O


This	0	O
report	0	O
expands	0	O
on	0	O
previous	0	O
work	0	O
with	0	O
interferon	0	B
alfa	0	I
-	0	I
2b	0	I
(	0	I
Intron	1	I
A	1	I
;	0	I
Schering	0	I
-	0	I
Plough	0	I
)	0	I
in	0	O
the	0	O
treatment	0	O
of	0	O
hairy	0	O
cell	0	O
leukemia	0	O
(	0	O
HCL	1	O
).	0	O


I	1	O
hypothesize	0	O
that	0	O
white	0	B
gene	0	I
expression	0	O
from	0	O
P	1	B
[	0	I
en	0	I
]	0	I
is	0	O
repressed	0	O
by	0	O
the	0	O
formation	0	O
of	0	O
a	0	O
protein	0	O
complex	0	O
which	0	O
is	0	O
initiated	0	O
at	0	O
the	0	O
engrailed	0	B
PS	1	I
sites	0	I
and	0	O
also	0	O
requires	0	O
interactions	0	O
with	0	O
flanking	0	O
genomic	0	O
DNA	1	O
.	0	O


The	0	O
requirement	0	O
of	0	O
PilE	1	B
in	0	O
pilus	0	O
biogenesis	0	O
was	0	O
confirmed	0	O
by	0	O
demonstrating	0	O
that	0	O
chromosomal	0	B
pilE	1	I
insertion	0	I
mutants	0	I
were	0	O
pilus	0	O
-	0	O
and	0	O
twitching	0	O
-	0	O
motility	0	O
deficient	0	O
.	0	O


The	0	O
relationship	0	O
between	0	O
primary	0	O
malignant	0	O
lymphoma	0	O
of	0	O
the	0	O
thyroid	0	O
and	0	O
chronic	0	O
thyroiditis	0	O
is	0	O
discussed	0	O
.	0	O


We	0	O
present	0	O
evidence	0	O
that	0	O
the	0	O
upstream	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
uORF	0	O
)	0	O
represses	0	O
the	0	O
translation	0	O
of	0	O
the	0	O
downstream	0	O
major	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
mORF	0	O
).	0	O


To	1	O
determine	0	O
the	0	O
effects	0	O
on	0	O
the	0	O
pulmonary	0	O
barrier	0	O
of	0	O
several	0	O
surface	0	O
active	0	O
agents	0	O
,	0	O
a	0	O
series	0	O
of	0	O
metered	0	O
dose	0	O
inhalers	0	O
(	0	O
MDIs	0	O
)	0	O
was	0	O
prepared	0	O
and	0	O
used	0	O
to	0	O
dose	0	O
aerosolized	0	O
surfactant	0	O
to	0	O
the	0	O
airways	0	O
of	0	O
isolated	0	O
perfused	0	O
rat	0	O
lungs	0	O
.	0	O


Selective	1	O
stimulation	0	O
of	0	O
central	0	O
alpha	0	B
-	0	I
autoreceptors	0	I
following	0	O
treatment	0	O
with	0	O
alpha	0	O
-	0	O
methyldopa	0	O
and	0	O
FLA	1	O
136	0	O
.	0	O


The	0	O
GPI	0	O
anchor	0	O
moiety	0	O
is	0	O
either	0	O
absent	0	O
or	0	O
present	0	O
at	0	O
a	0	O
very	0	O
low	0	O
level	0	O
in	0	O
the	0	O
polypeptide	0	O
expressed	0	O
from	0	O
the	0	O
cDNA	1	O
that	0	O
contained	0	O
both	0	O
the	0	O
signal	0	O
peptide	0	O
and	0	O
GPI	0	O
signal	0	O
sequences	0	O
.	0	O


The	0	O
recommendation	0	O
is	0	O
made	0	O
that	0	O
specific	0	O
sub	0	O
-	0	O
groups	0	O
of	0	O
attempters	0	O
need	0	O
to	0	O
be	0	O
identified	0	O
and	0	O
may	0	O
warrant	0	O
specialized	0	O
intervention	0	O
strategies	0	O
.	0	O


A	1	O
set	0	O
of	0	O
peptides	0	O
corresponding	0	O
to	0	O
the	0	O
individual	0	O
elements	0	O
of	0	O
secondary	0	O
structure	0	O
derived	0	O
from	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
the	0	O
ribosomal	0	B
protein	0	I
L9	0	I
have	0	O
been	0	O
synthesized	0	O
.	0	O


These	0	O
results	0	O
are	0	O
consistent	0	O
with	0	O
the	0	O
well	0	O
established	0	O
polarity	0	O
of	0	O
RXR	0	B
heterodimer	0	O
binding	0	O
to	0	O
bipartite	0	O
hormone	0	O
response	0	O
elements	0	O
,	0	O
with	0	O
the	0	O
VDR	0	B
recognizing	0	O
the	0	O
3	0	O
'-	0	O
half	0	O
-	0	O
element	0	O
.	0	O


During	0	O
this	0	O
time	0	O
,	0	O
the	0	O
patients	0	O
all	0	O
had	0	O
the	0	O
characteristic	0	O
plasma	0	O
thyroid	0	O
hormone	0	O
changes	0	O
associated	0	O
with	0	O
amiodarone	0	O
therapy	0	O
,	0	O
i	0	O
.	0	O
e	0	O
.	0	O
increased	0	O
T4	1	O
,	0	O
free	0	O
T4	1	O
,	0	O
and	0	O
rT3	0	O
and	0	O
decreased	0	O
T3	1	O
,	0	O
while	0	O
remaining	0	O
clinically	0	O
euthyroid	0	O
.	0	O


Iron	1	O
and	0	O
folate	0	O
deficiency	0	O
in	0	O
pregnancy	0	O


Alternating	1	O
proline	0	O
/	0	O
alanine	0	O
sequence	0	O
of	0	O
beta	0	B
B1	0	I
subunit	0	I
originates	0	O
from	0	O
a	0	O
repetitive	0	O
DNA	1	O
sequence	0	O
.	0	O


The	0	O
Nostoc	0	O
petBD	0	B
genes	0	I
are	0	O
not	0	O
closely	0	O
linked	0	O
to	0	O
the	0	O
psbB	0	B
gene	0	I
(	0	O
encoding	0	O
the	0	O
51	0	O
-	0	O
kDa	1	O
photosystem	0	B
II	0	I
polypeptide	0	I
)	0	O
and	0	O
do	0	O
not	0	O
contain	0	O
introns	0	O
as	0	O
do	0	O
the	0	O
closely	0	O
related	0	O
chloroplast	0	O
genes	0	O
.	0	O


Concerted	0	O
action	0	O
of	0	O
three	0	O
distinct	0	O
domains	0	O
in	0	O
the	0	O
DNA	1	O
cleaving	0	O
-	0	O
joining	0	O
reaction	0	O
catalyzed	0	O
by	0	O
relaxase	0	B
(	0	O
TraI	0	B
)	0	O
of	0	O
conjugative	0	O
plasmid	0	O
RP4	0	O
.	0	O


MEKs	0	B
and	0	O
ERKs	0	B
inhibited	0	O
IL	1	B
-	0	I
6	0	I
activation	0	O
of	0	O
Stat3	0	B
harboring	0	O
a	0	O
mutation	0	O
at	0	O
serine	0	O
-	0	O
727	0	O
,	0	O
the	0	O
major	0	O
site	0	O
for	0	O
serine	0	O
phosphorylation	0	O
,	0	O
similar	0	O
to	0	O
inhibition	0	O
of	0	O
wild	0	B
-	0	I
type	0	I
Stat3	0	I
,	0	O
and	0	O
inhibited	0	O
Janus	0	B
kinases	0	I
Jak1	0	I
and	0	O
Jak2	0	B
upstream	0	O
of	0	O
Stat3	0	B
in	0	O
the	0	O
Jak	1	B
-	0	O
STAT	1	B
-	0	O
signaling	0	O
pathway	0	O
.	0	O


Both	0	O
inserts	0	O
are	0	O
larger	0	O
than	0	O
their	0	O
homologues	0	O
in	0	O
eIF	0	B
-	0	I
2alpha	0	I
kinases	0	I
.	0	O


Cutis	1	O
aplasia	0	O
.	0	O


To	1	O
test	0	O
the	0	O
role	0	O
of	0	O
ML	1	O
in	0	O
human	0	O
reproductive	0	O
axis	0	O
,	0	O
128	0	O
healthy	0	O
children	0	O
,	0	O
68	0	O
boys	0	O
and	0	O
60	0	O
girls	0	O
,	0	O
were	0	O
studied	0	O
.	0	O


T1	1	O
-	0	O
weighted	0	O
MRI	1	O
on	0	O
the	0	O
49th	0	O
postoperative	0	O
day	0	O
demonstrated	0	O
bilateral	0	O
and	0	O
symmetrical	0	O
hyperintense	0	O
lesions	0	O
in	0	O
the	0	O
globus	0	O
pallidus	0	O
.	0	O


We	0	O
conclude	0	O
that	0	O
solidification	0	O
could	0	O
occur	0	O
in	0	O
all	0	O
feeds	0	O
containing	0	O
casein	0	B
and	0	O
that	0	O
alternative	0	O
feeds	0	O
should	0	O
be	0	O
considered	0	O
in	0	O
patients	0	O
with	0	O
increased	0	O
gastric	0	O
acidity	0	O
.	0	O


The	0	O
17	0	O
-	0	O
kDa	1	O
protein	0	O
is	0	O
required	0	O
for	0	O
the	0	O
systemic	0	O
infection	0	O
of	0	O
plants	0	O
.	0	O


Fifty	0	O
min	0	O
after	0	O
release	0	O
from	0	O
stress	0	O
,	0	O
increases	0	O
in	0	O
plasma	0	O
corticosterone	0	O
levels	0	O
induced	0	O
by	0	O
stress	0	O
recovered	0	O
in	0	O
the	0	O
biting	0	O
group	0	O
but	0	O
remained	0	O
high	0	O
in	0	O
the	0	O
non	0	O
-	0	O
biting	0	O
group	0	O
.	0	O


59	0	O
cases	0	O
of	0	O
surgically	0	O
resectable	0	O
cancers	0	O
(	0	O
T1	1	O
,	0	O
T2	0	O
,	0	O
T3	1	O
,	0	O
N0	0	O
,	0	O
N1	0	O
)	0	O
had	0	O
a	0	O
minimum	0	O
followup	0	O
of	0	O
two	0	O
years	0	O
(	0	O
average	0	O
4	0	O
years	0	O
+/-	0	O
3	0	O
months	0	O
).	0	O


U24	0	B
has	0	O
two	0	O
separate	0	O
12	0	O
nt	0	O
long	0	O
complementarities	0	O
to	0	O
a	0	O
highly	0	O
conserved	0	O
tract	0	O
of	0	O
28S	0	B
rRNA	1	I
.	0	O


Overexpression	1	O
of	0	O
ICBP90	0	B
in	0	O
COS	1	O
-	0	O
1	0	O
-	0	O
transfected	0	O
cells	0	O
induced	0	O
an	0	O
enhanced	0	O
expression	0	O
of	0	O
endogenous	0	B
topoisomerase	0	I
IIalpha	0	I
.	0	O


Although	0	O
it	0	O
has	0	O
two	0	O
potential	0	O
binding	0	O
sites	0	O
,	0	O
the	0	O
purified	0	O
MerR	0	B
homodimer	0	I
binds	0	O
only	0	O
one	0	O
Hg	1	O
(	0	O
II	0	O
)	0	O
ion	0	O
,	0	O
employing	0	O
Cys82	0	O
from	0	O
one	0	O
monomer	0	O
and	0	O
Cys117	0	O
and	0	O
Cys126	0	O
from	0	O
the	0	O
other	0	O
.	0	O


Treatment	1	O
of	0	O
PCC4	0	O
.	0	O
aza1R	0	O
cells	0	O
with	0	O
an	0	O
RAR	0	B
-	0	O
selective	0	O
agonist	0	O
also	0	O
repressed	0	O
the	0	O
expression	0	O
of	0	O
EC	1	B
-	0	I
1	0	I
mRNA	1	I
while	0	O
treatment	0	O
with	0	O
an	0	O
RXR	0	B
-	0	O
selective	0	O
agonist	0	O
reduced	0	O
EC	1	B
-	0	I
1	0	I
expression	0	O
slightly	0	O
.	0	O


The	0	O
predicted	0	O
protein	0	O
,	0	O
Seb1p	0	B
,	0	O
consists	0	O
of	0	O
82	0	O
amino	0	O
acids	0	O
and	0	O
contains	0	O
one	0	O
potential	0	O
membrane	0	O
-	0	O
spanning	0	O
region	0	O
at	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
but	0	O
no	0	O
N	1	O
-	0	O
terminal	0	O
signal	0	O
sequence	0	O
.	0	O


Several	0	O
Src	1	B
SH3	0	I
-	0	I
binding	0	I
proteins	0	I
were	0	O
phosphorylated	0	O
in	0	O
Src	1	B
-	0	O
transformed	0	O
cells	0	O
.	0	O


It	1	O
is	0	O
also	0	O
homologous	0	O
to	0	O
other	0	O
sugar	0	O
carriers	0	O
from	0	O
human	0	O
,	0	O
mouse	0	O
and	0	O
Escherichia	1	O
coli	0	O
.	0	O


During	0	O
this	0	O
period	0	O
,	0	O
administration	0	O
of	0	O
additional	0	O
exogenous	0	B
PRL	1	I
did	0	O
not	0	O
stimulate	0	O
further	0	O
activation	0	O
(	0	O
binding	0	O
)	0	O
of	0	O
the	0	O
Stat	1	B
factors	0	I
.	0	O


Western	0	O
blot	0	O
analysis	0	O
of	0	O
various	0	O
bovine	0	O
tissues	0	O
with	0	O
human	0	O
NMT	0	B
peptide	0	I
antibody	0	I
indicated	0	O
a	0	O
common	0	O
prominent	0	O
immunoreactive	0	O
band	0	O
with	0	O
an	0	O
apparent	0	O
molecular	0	O
mass	0	O
of	0	O
48	0	O
.	0	O
5	0	O
-	0	O
50	0	O
kDa	1	O
in	0	O
all	0	O
tissues	0	O
.	0	O


Improving	0	O
the	0	O
evidence	0	O
base	0	O
for	0	O
anaesthesia	0	O
.	0	O


The	0	O
roll	0	O
-	0	O
over	0	O
test	0	O
to	0	O
predict	0	O
toxemia	0	O
in	0	O
pregnancy	0	O
.	0	O


Routine	1	O
clinical	0	O
analysis	0	O
revealed	0	O
lower	0	O
hematocrit	0	O
and	0	O
hemoglobin	0	B
,	0	O
and	0	O
elevated	0	O
BUN	1	O
and	0	O
alkaline	0	B
phosphatase	0	I
in	0	O
the	0	O
treated	0	O
group	0	O
.	0	O


Six	0	O
out	0	O
of	0	O
ten	0	O
hearts	0	O
from	0	O
macerated	0	O
stillborn	0	O
infants	0	O
showed	0	O
varying	0	O
degrees	0	O
of	0	O
positive	0	O
staining	0	O
.	0	O


Persistent	0	O
activation	0	O
of	0	O
mitogen	0	B
-	0	I
activated	0	I
protein	0	I
kinases	0	I
p42	0	I
and	0	O
p44	0	B
and	0	O
ets	0	B
-	0	I
2	0	I
phosphorylation	0	O
in	0	O
response	0	O
to	0	O
colony	0	B
-	0	I
stimulating	0	I
factor	0	I
1	0	I
/	0	O
c	0	B
-	0	I
fms	0	I
signaling	0	O
.	0	O


METHODS	0	O
:	0	O
We	0	O
studied	0	O
20	0	O
symptomatic	0	O
patients	0	O
with	0	O
HOCM	1	O
(	0	O
12	0	O
men	0	O
),	0	O
mean	0	O
age	0	O
52	0	O
+/-	0	O
17	0	O
years	0	O
,	0	O
before	0	O
and	0	O
after	0	O
septal	0	O
reduction	0	O
using	0	O
echocardiography	0	O
and	0	O
electrocardiogram	0	O
(	0	O
ECG	1	O
).	0	O


Since	0	O
CENP	0	B
-	0	I
B	1	I
gene	0	I
is	0	O
conserved	0	O
in	0	O
mammalian	0	O
species	0	O
and	0	O
CENP	0	B
-	0	I
B	1	I
boxes	0	I
are	0	O
found	0	O
also	0	O
in	0	O
mouse	0	O
centromere	0	O
satellite	0	O
DNA	1	O
(	0	O
minor	0	O
satellite	0	O
),	0	O
this	0	O
sequence	0	O
-	0	O
specific	0	O
DNA	1	O
-	0	O
protein	0	O
interaction	0	O
may	0	O
be	0	O
important	0	O
for	0	O
some	0	O
kind	0	O
of	0	O
common	0	O
centromere	0	O
function	0	O
.	0	O


We	0	O
propose	0	O
that	0	O
Mnt	0	B
:	0	O
Max	0	B
:	0	O
Sin3	0	B
complexes	0	O
normally	0	O
function	0	O
to	0	O
restrict	0	O
Myc	0	B
:	0	O
Max	0	B
activities	0	O
associated	0	O
with	0	O
cell	0	O
proliferation	0	O
.	0	O


Effects	0	O
of	0	O
long	0	O
-	0	O
term	0	O
parenteral	0	O
nutrition	0	O
on	0	O
gastrin	0	B
release	0	O
in	0	O
dogs	0	O
.	0	O


An	1	O
increase	0	O
in	0	O
hypothalamic	0	O
expression	0	O
of	0	O
at	0	O
least	0	O
two	0	O
of	0	O
the	0	O
erbB	0	B
receptors	0	I
is	0	O
initiated	0	O
before	0	O
the	0	O
pubertal	0	O
augmentation	0	O
of	0	O
gonadal	0	O
steroid	0	O
secretion	0	O
and	0	O
is	0	O
completed	0	O
on	0	O
the	0	O
day	0	O
of	0	O
the	0	O
first	0	O
preovulatory	0	O
surge	0	O
of	0	O
gonadotropins	0	B
.	0	O


Sixty	0	O
-	0	O
nine	0	O
(	0	O
44	0	O
%)	0	O
patients	0	O
were	0	O
administered	0	O
250	0	O
MBq	1	O
(	0	O
7	0	O
mCi	1	O
)	0	O
99Tcm	0	O
-	0	O
tetrofosmin	0	O
at	0	O
rest	0	O
followed	0	O
4	0	O
h	0	O
later	0	O
by	0	O
750	0	O
MBq	1	O
(	0	O
21	0	O
mCi	1	O
)	0	O
during	0	O
stress	0	O
(	0	O
the	0	O
1	0	O
day	0	O
protocol	0	O
),	0	O
whereas	0	O
88	0	O
(	0	O
56	0	O
%)	0	O
patients	0	O
had	0	O
rest	0	O
and	0	O
stress	0	O
imaging	0	O
studies	0	O
on	0	O
two	0	O
separate	0	O
days	0	O
,	0	O
receiving	0	O
a	0	O
500	0	O
MBq	1	O
(	0	O
14	0	O
mCi	1	O
)	0	O
dose	0	O
of	0	O
99Tcm	0	O
-	0	O
tetrofosmin	0	O
on	0	O
each	0	O
occasion	0	O
(	0	O
the	0	O
2	0	O
day	0	O
protocol	0	O
).	0	O


SIM1	0	B
and	0	O
SIM2	0	B
do	0	O
not	0	O
form	0	O
homodimers	0	O
,	0	O
and	0	O
they	0	O
do	0	O
not	0	O
interact	0	O
with	0	O
AHR	0	B
.	0	O


ROCK	0	B
-	0	I
I	1	I
,	0	O
Kinectin	0	B
,	0	O
and	0	O
mDia2	0	B
can	0	O
bind	0	O
the	0	O
wild	0	O
type	0	O
forms	0	O
of	0	O
both	0	O
RhoA	0	B
and	0	O
Cdc42	0	B
in	0	O
a	0	O
GTP	1	O
-	0	O
dependent	0	O
manner	0	O
in	0	O
vitro	0	O
.	0	O


5	0	O
)	0	O
Before	0	O
and	0	O
ten	0	O
days	0	O
after	0	O
DOTC	0	O
infusion	0	O
,	0	O
laboratory	0	O
tests	0	O
for	0	O
liver	0	O
and	0	O
renal	0	O
functions	0	O
and	0	O
blood	0	O
were	0	O
performed	0	O
.	0	O


Stress	1	O
effects	0	O
on	0	O
affiliation	0	O
preferences	0	O
among	0	O
subjects	0	O
possessing	0	O
the	0	O
type	0	O
A	1	O
coronary	0	O
-	0	O
prone	0	O
behavior	0	O
pattern	0	O
.	0	O


KRN2391	0	O
and	0	O
cromakalim	0	O
produced	0	O
a	0	O
dose	0	O
-	0	O
dependent	0	O
increase	0	O
in	0	O
aortic	0	O
and	0	O
coronary	0	O
blood	0	O
flow	0	O
.	0	O


Junctions	0	O
between	0	O
cells	0	O
of	0	O
the	0	O
human	0	O
enamel	0	O
organ	0	O
.	0	O


A	1	O
new	0	O
generation	0	O
of	0	O
information	0	O
retrieval	0	O
tools	0	O
for	0	O
biologists	0	O
:	0	O
the	0	O
example	0	O
of	0	O
the	0	O
ExPASy	0	O
WWW	0	O
server	0	O
.	0	O


Adding	0	O
phytase	0	B
and	0	O
nP	1	O
improved	0	O
the	0	O
orderliness	0	O
of	0	O
development	0	O
,	0	O
mineralization	0	O
and	0	O
arrangement	0	O
of	0	O
cartilage	0	O
and	0	O
bone	0	O
cells	0	O
,	0	O
and	0	O
alleviated	0	O
the	0	O
effects	0	O
of	0	O
P	1	O
deficiency	0	O
on	0	O
the	0	O
histological	0	O
and	0	O
gross	0	O
structure	0	O
of	0	O
the	0	O
tibias	0	O
.	0	O


The	0	O
partial	0	O
ORF	1	O
was	0	O
found	0	O
to	0	O
be	0	O
identical	0	O
to	0	O
the	0	O
C	1	O
terminus	0	O
of	0	O
HrpJ2	0	B
.	0	O


Chronotherapeutics	0	O
in	0	O
cardiovascular	0	O
disease	0	O
.	0	O


Influence	0	O
of	0	O
neural	0	O
regulation	0	O
on	0	O
anti	0	O
-	0	O
arrhythmic	0	O
effects	0	O
of	0	O
GABA	1	O
in	0	O
rats	0	O


Skn	0	B
-	0	I
1a	0	I
lacking	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
region	0	O
completely	0	O
lost	0	O
transactivation	0	O
ability	0	O
,	0	O
irrespective	0	O
of	0	O
the	0	O
promoter	0	O
tested	0	O
,	0	O
and	0	O
was	0	O
able	0	O
to	0	O
block	0	O
transactivation	0	O
by	0	O
normal	0	O
Skn	0	B
-	0	I
1a	0	I
in	0	O
competition	0	O
assays	0	O
.	0	O


A	1	O
series	0	O
of	0	O
amino	0	O
terminal	0	O
deletion	0	O
mutants	0	O
(	0	O
d10	0	O
,	0	O
d20	0	O
,	0	O
d27	0	O
,	0	O
d31	0	O
,	0	O
d40	0	O
,	0	O
d44	0	O
,	0	O
and	0	O
d73	0	O
)	0	O
were	0	O
compared	0	O
for	0	O
processing	0	O
,	0	O
cell	0	O
surface	0	O
expression	0	O
,	0	O
and	0	O
maintenance	0	O
of	0	O
their	0	O
biological	0	O
attributes	0	O
by	0	O
recombinant	0	O
expression	0	O
of	0	O
mutant	0	O
genes	0	O
using	0	O
a	0	O
plasmid	0	O
vector	0	O
(	0	O
pcDL	0	O
-	0	O
SR	1	O
alpha	0	O
-	0	O
296	0	O
)	0	O
in	0	O
CV	1	O
-	0	O
1	0	O
and	0	O
HeLa	0	O
cells	0	O
.	0	O


In	1	O
transformed	0	O
E	1	O
.	0	O
coli	0	O
,	0	O
constitutive	0	B
CAT	1	I
expression	0	O
is	0	O
maintained	0	O
when	0	O
as	0	O
little	0	O
as	0	O
0	0	O
.	0	O
3	0	O
kilobase	0	O
of	0	O
DNA	1	O
from	0	O
the	0	O
3	0	O
'	0	O
end	0	O
of	0	O
the	0	O
1	0	O
.	0	O
6	0	O
-	0	O
kilobase	0	O
segment	0	O
is	0	O
inserted	0	O
in	0	O
the	0	O
correct	0	O
orientation	0	O
in	0	O
front	0	O
of	0	O
the	0	O
CAT	1	B
gene	0	I
.	0	O


The	0	O
gene	0	O
contains	0	O
six	0	O
exons	0	O
separated	0	O
by	0	O
1	0	O
.	0	O
1	0	O
-	0	O
5	0	O
.	0	O
8	0	O
kb	0	O
introns	0	O
and	0	O
has	0	O
been	0	O
localized	0	O
to	0	O
the	0	O
murine	0	O
chromosome	0	O
2	0	O
by	0	O
linkage	0	O
analysis	0	O
.	0	O


Other	0	O
than	0	O
d	0	O
7	0	O
,	0	O
there	0	O
was	0	O
no	0	O
significant	0	O
effect	0	O
on	0	O
the	0	O
number	0	O
of	0	O
implants	0	O
.	0	O


An	1	O
epidemiological	0	O
survey	0	O
of	0	O
rheumatic	0	O
valve	0	O
disease	0	O
and	0	O
rheumatic	0	O
fever	0	O
in	0	O
primary	0	O
and	0	O
secondary	0	O
school	0	O
students	0	O
in	0	O
Jiangxi	0	O
Province	0	O


Activation	1	O
of	0	O
ERK1	0	B
/	0	I
2	0	I
is	0	O
correlated	0	O
with	0	O
induction	0	O
of	0	O
the	0	O
immediate	0	B
-	0	I
early	0	I
response	0	I
genes	0	I
.	0	O


62	0	O
:	0	O
2491	0	O
-	0	O
2499	0	O
,	0	O
1987	0	O
).	0	O


Sixteen	0	O
other	0	O
normal	0	O
subjects	0	O
with	0	O
2	0	O
g	0	O
of	0	O
Metyrapone	1	O
are	0	O
best	0	O
responses	0	O
.	0	O


Echo	1	O
modulation	0	O
in	0	O
Pr3	0	O
+:	0	O
YAlO3	0	O
.	0	O


J	1	O
.	0	O


In	1	O
this	0	O
paper	0	O
,	0	O
the	0	O
current	0	O
status	0	O
of	0	O
the	0	O
understanding	0	O
of	0	O
the	0	O
interaction	0	O
mechanisms	0	O
of	0	O
ultrasound	0	O
with	0	O
biological	0	O
media	0	O
and	0	O
the	0	O
factors	0	O
that	0	O
govern	0	O
different	0	O
biological	0	O
effects	0	O
are	0	O
surveyed	0	O
.	0	O


A	1	O
survey	0	O
is	0	O
given	0	O
of	0	O
the	0	O
pharmacological	0	O
backgrounds	0	O
that	0	O
are	0	O
relevant	0	O
for	0	O
the	0	O
drug	0	O
treatment	0	O
of	0	O
essential	0	O
hypertension	0	O
in	0	O
the	0	O
elderly	0	O
.	0	O


This	0	O
new	0	O
knowledge	0	O
has	0	O
contributed	0	O
to	0	O
the	0	O
development	0	O
of	0	O
a	0	O
successful	0	O
immunoprophylactic	0	O
strategy	0	O
for	0	O
eliminating	0	O
Hib	1	O
disease	0	O
.	0	O


Furthermore	0	O
,	0	O
this	0	O
study	0	O
looks	0	O
at	0	O
the	0	O
impact	0	O
of	0	O
synthesis	0	O
conditions	0	O
on	0	O
block	0	O
length	0	O
and	0	O
crystallinity	0	O
,	0	O
and	0	O
the	0	O
impact	0	O
of	0	O
the	0	O
blocking	0	O
on	0	O
both	0	O
,	0	O
crystallinity	0	O
and	0	O
solubility	0	O
of	0	O
the	0	O
polymers	0	O
.	0	O


A	1	O
comparative	0	O
study	0	O
of	0	O
the	0	O
total	0	O
protein	0	O
profiles	0	O
of	0	O
wild	0	O
-	0	O
type	0	O
S	1	O
.	0	O
entomophila	0	O
UC9	0	O
and	0	O
mutant	0	O
UC21	0	O
revealed	0	O
that	0	O
the	0	O
mutant	0	O
lacked	0	O
an	0	O
approximately	0	O
44	0	O
-	0	O
kDa	1	O
protein	0	O
and	0	O
overexpressed	0	O
an	0	O
approximately	0	O
20	0	O
-	0	O
kDa	1	O
protein	0	O
.	0	O


S6K2	0	B
is	0	O
highly	0	O
homologous	0	O
to	0	O
S6K1	0	B
in	0	O
the	0	O
core	0	O
kinase	0	O
and	0	O
linker	0	O
regulatory	0	O
domains	0	O
but	0	O
differs	0	O
from	0	O
S6K1	0	B
in	0	O
the	0	O
N	1	O
-	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
regions	0	O
and	0	O
is	0	O
differently	0	O
localized	0	O
primarily	0	O
to	0	O
the	0	O
nucleus	0	O
because	0	O
of	0	O
a	0	O
C	1	O
-	0	O
terminal	0	O
nuclear	0	O
localization	0	O
signal	0	O
unique	0	O
to	0	O
S6K2	0	B
.	0	O


We	0	O
further	0	O
show	0	O
that	0	O
proteolytic	0	O
targeting	0	O
by	0	O
calpain	0	B
II	0	I
and	0	O
the	0	O
proteasome	0	O
involves	0	O
different	0	O
structural	0	O
elements	0	O
of	0	O
YY1	0	B
.	0	O


Southern	0	O
analysis	0	O
on	0	O
genomic	0	O
DNA	1	O
isolated	0	O
from	0	O
tissues	0	O
and	0	O
cell	0	O
lines	0	O
from	0	O
several	0	O
mouse	0	O
strains	0	O
using	0	O
mCD22	0	B
cDNA	1	I
demonstrated	0	O
that	0	O
the	0	O
Cd22	0	B
locus	0	I
encoding	0	O
mCD22	0	B
is	0	O
a	0	O
single	0	O
copy	0	O
gene	0	O
of	0	O
<	0	O
or	0	O
=	0	O
30	0	O
kb	0	O
.	0	O


Deletion	1	O
analysis	0	O
of	0	O
the	0	O
ICL1	0	B
promoter	0	I
led	0	O
to	0	O
the	0	O
identification	0	O
of	0	O
an	0	O
upstream	0	O
activating	0	O
sequence	0	O
element	0	O
,	0	O
UASICL1	0	O
(	0	O
5	0	O
'	0	O
CATTCATCCG	0	O
3	0	O
'),	0	O
necessary	0	O
and	0	O
sufficient	0	O
for	0	O
conferring	0	O
carbon	0	O
source	0	O
-	0	O
dependent	0	O
regulation	0	O
on	0	O
a	0	O
heterologous	0	O
reporter	0	O
gene	0	O
.	0	O


Unlike	0	O
the	0	O
mammalian	0	O
proteins	0	O
,	0	O
XFGF3	0	B
is	0	O
efficiently	0	O
secreted	0	O
as	0	O
a	0	O
Mr	1	O
31	0	O
,	0	O
000	0	O
glycoprotein	0	O
,	0	O
gp31	0	B
,	0	O
which	0	O
undergoes	0	O
proteolytic	0	O
cleavage	0	O
to	0	O
produce	0	O
an	0	O
NH2	0	O
-	0	O
terminally	0	O
truncated	0	O
product	0	O
,	0	O
gp27	0	B
.	0	O


The	0	O
SH3	0	B
domains	0	I
of	0	O
Grb2	0	B
bound	0	O
in	0	O
vitro	0	O
to	0	O
specific	0	O
proline	0	O
-	0	O
rich	0	O
motifs	0	O
in	0	O
the	0	O
HPK1	0	B
tail	0	O
and	0	O
functioned	0	O
synergistically	0	O
to	0	O
direct	0	O
the	0	O
stable	0	O
binding	0	O
of	0	O
Grb2	0	B
to	0	O
HPK1	0	B
in	0	O
transfected	0	O
Cos1	0	O
cells	0	O
.	0	O


A	1	O
22K	0	O
polypeptide	0	O
was	0	O
detected	0	O
as	0	O
a	0	O
translation	0	O
product	0	O
of	0	O
late	0	O
RNA	1	O
that	0	O
hybridized	0	O
to	0	O
this	0	O
DNA	1	O
fragment	0	O
.	0	O


Cut	1	O
-	0	O
off	0	O
levels	0	O
that	0	O
define	0	O
abnormality	0	O
are	0	O
rather	0	O
arbitrary	0	O
and	0	O
this	0	O
decreases	0	O
the	0	O
specificity	0	O
of	0	O
the	0	O
test	0	O
in	0	O
apparently	0	O
healthy	0	O
patients	0	O
.	0	O


Rather	0	O
,	0	O
usp	0	B
is	0	O
required	0	O
in	0	O
late	0	O
third	0	O
instar	0	O
larvae	0	O
for	0	O
appropriate	0	O
developmental	0	O
and	0	O
transcriptional	0	O
responses	0	O
to	0	O
the	0	O
ecdysone	0	O
pulse	0	O
that	0	O
triggers	0	O
puparium	0	O
formation	0	O
.	0	O


Expression	1	O
in	0	O
established	0	O
LCLs	0	O
,	0	O
occurring	0	O
irrespective	0	O
of	0	O
virus	0	O
producer	0	O
status	0	O
,	0	O
was	0	O
not	0	O
a	0	O
consequence	0	O
of	0	O
continued	0	O
in	0	O
vitro	0	O
passage	0	O
;	0	O
thus	0	O
,	0	O
appropriately	0	O
spliced	0	O
BamHI	0	B
-	0	I
A	1	I
transcripts	0	I
could	0	O
be	0	O
amplified	0	O
from	0	O
normal	0	O
B	1	O
cells	0	O
within	0	O
1	0	O
day	0	O
of	0	O
their	0	O
experimental	0	O
infection	0	O
in	0	O
vitro	0	O
,	0	O
along	0	O
with	0	O
BamHI	0	B
-	0	I
C	1	I
/	0	I
W	1	I
promoter	0	O
-	0	O
initiated	0	O
but	0	O
not	0	O
BamHI	0	B
-	0	I
F	1	I
promoter	0	I
-	0	I
initiated	0	I
mRNAs	0	I
.	0	O


We	0	O
show	0	O
that	0	O
CBF	1	B
-	0	I
A	1	I
and	0	O
CBF	1	B
-	0	I
C	1	I
interact	0	O
with	0	O
each	0	O
other	0	O
to	0	O
form	0	O
a	0	O
CBF	1	B
-	0	I
A	1	I
-	0	O
CBF	1	B
-	0	I
C	1	I
complex	0	O
and	0	O
that	0	O
CBF	1	B
-	0	I
B	1	I
does	0	O
not	0	O
interact	0	O
with	0	O
CBF	1	B
-	0	I
A	1	I
or	0	O
CBF	1	B
-	0	I
C	1	I
individually	0	O
but	0	O
that	0	O
it	0	O
associates	0	O
with	0	O
the	0	O
CBF	1	B
-	0	I
A	1	I
-	0	O
CBF	1	B
-	0	I
C	1	I
complex	0	O
.	0	O


Using	0	O
an	0	O
audiotape	0	O
cassette	0	O
and	0	O
headphones	0	O
the	0	O
duration	0	O
of	0	O
the	0	O
hallucinations	0	O
decreased	0	O
significantly	0	O
.	0	O


The	0	O
single	0	O
most	0	O
important	0	O
element	0	O
,	0	O
by	0	O
linker	0	O
-	0	O
scanning	0	O
analysis	0	O
,	0	O
is	0	O
a	0	O
10	0	O
-	0	O
bp	0	O
region	0	O
that	0	O
contains	0	O
a	0	O
CCAAT	0	O
motif	0	O
.	0	O


In	1	O
summary	0	O
,	0	O
at	0	O
equianesthetic	0	O
concentrations	0	O
,	0	O
desflurane	0	O
and	0	O
isoflurane	0	O
produced	0	O
similar	0	O
hemodynamic	0	O
effects	0	O
;	0	O
however	0	O
,	0	O
in	0	O
the	0	O
absence	0	O
of	0	O
drugs	0	O
that	0	O
inhibit	0	O
autonomic	0	O
reflexes	0	O
,	0	O
desflurane	0	O
had	0	O
less	0	O
negative	0	O
inotropic	0	O
activity	0	O
and	0	O
produced	0	O
less	0	O
decrease	0	O
in	0	O
arterial	0	O
pressure	0	O
.	0	O


These	0	O
data	0	O
suggest	0	O
that	0	O
the	0	O
function	0	O
of	0	O
the	0	O
DS2	0	B
may	0	O
be	0	O
the	0	O
protection	0	O
of	0	O
the	0	O
nuclear	0	O
DNA	1	O
from	0	O
desiccation	0	O
.	0	O


The	0	O
workup	0	O
included	0	O
skin	0	O
tests	0	O
(	0	O
up	0	O
to	0	O
1	0	O
microgram	0	O
/	0	O
ml	0	O
,	0	O
Pharmacia	0	O
),	0	O
measurement	0	O
of	0	O
specific	0	O
serum	0	O
IgE	1	B
with	0	O
RAST	1	O
-	0	O
CAP	1	O
(	0	O
Pharmacia	0	O
),	0	O
and	0	O
CAST	1	O
with	0	O
three	0	O
concentrations	0	O
of	0	O
bee	0	O
(	0	O
Apis	1	O
mellifera	0	O
)	0	O
and	0	O
wasp	0	O
(	0	O
Vespula	1	O
spec	0	O
.)	0	O
venom	0	O
(	0	O
Aquagen	0	O
ALK	0	O
).	0	O


Since	0	O
the	0	O
RINX	0	B
gene	0	I
is	0	O
likely	0	O
an	0	O
ortholog	0	O
of	0	O
the	0	O
goldfish	0	B
Vsx1	0	I
gene	0	I
,	0	O
it	0	O
has	0	O
been	0	O
named	0	O
VSX1	0	B
by	0	O
the	0	O
Human	1	O
Gene	1	O
Nomenclature	1	O
Committee	0	O
.	0	O


We	0	O
found	0	O
14	0	O
protein	0	O
binding	0	O
sites	0	O
that	0	O
were	0	O
occupied	0	O
in	0	O
vivo	0	O
.	0	O


We	0	O
purified	0	O
a	0	O
Ca2	1	B
+/	0	I
calmodulin	0	I
(	0	I
CaM	1	I
)-	0	I
dependent	0	I
protein	0	I
kinase	0	I
(	0	O
CaM	1	B
kinase	0	I
)	0	O
from	0	O
the	0	O
yeast	0	O
Saccharomyces	1	O
cerevisiae	0	O
with	0	O
properties	0	O
similar	0	O
to	0	O
mammalian	0	B
type	0	I
II	0	I
CaM	1	I
kinases	0	I
.	0	O


Induction	1	O
of	0	O
B	1	O
cell	0	O
apoptosis	0	O
by	0	O
co	0	O
-	0	O
cross	0	O
-	0	O
linking	0	O
CD23	0	B
and	0	O
sIg	1	B
involves	0	O
aberrant	0	O
regulation	0	O
of	0	O
c	0	B
-	0	I
myc	0	I
and	0	O
is	0	O
inhibited	0	O
by	0	O
bcl	0	B
-	0	I
2	0	I
.	0	O


Sterols	0	O
in	0	O
pollen	0	O
.	0	O


METHODS	0	O
--	0	O
16	0	O
volunteered	0	O
for	0	O
spirometry	0	O
with	0	O
methacholine	0	O
provocation	0	O
test	0	O
including	0	O
a	0	O
test	0	O
for	0	O
small	0	O
airways	0	O
function	0	O
by	0	O
volume	0	O
of	0	O
trapped	0	O
gas	0	O
(	0	O
VTG	0	O
).	0	O


At	1	O
the	0	O
same	0	O
time	0	O
we	0	O
obtained	0	O
easily	0	O
understandable	0	O
EEG	1	O
-	0	O
information	0	O
which	0	O
has	0	O
never	0	O
previously	0	O
been	0	O
available	0	O
to	0	O
us	0	O
.	0	O


These	0	O
adverse	0	O
effects	0	O
usually	0	O
abate	0	O
with	0	O
time	0	O
.	0	O


A	1	O
second	0	O
study	0	O
group	0	O
,	0	O
with	0	O
intact	0	O
cardiac	0	O
innervation	0	O
,	0	O
consisted	0	O
of	0	O
19	0	O
patients	0	O
with	0	O
stable	0	O
angina	0	O
pectoris	0	O
class	0	O
I	1	O
to	0	O
III	0	O
.	0	O


Members	0	O
of	0	O
the	0	O
JAK	1	B
/	0	O
Tyk	0	B
family	0	O
of	0	O
tyrosine	0	B
kinases	0	I
mediate	0	O
phosphorylation	0	O
of	0	O
STAT3	0	B
at	0	O
Tyr705	0	O
during	0	O
CNTF	0	B
signaling	0	O
;	0	O
however	0	O
,	0	O
the	0	O
kinase	0	O
responsible	0	O
for	0	O
phosphorylation	0	O
at	0	O
STAT3	0	B
Tyr727	0	O
appears	0	O
to	0	O
depend	0	O
on	0	O
both	0	O
the	0	O
extracellular	0	O
stimulus	0	O
and	0	O
the	0	O
cellular	0	O
context	0	O
.	0	O


In	1	O
Trial	1	O
1	0	O
,	0	O
eight	0	O
sows	0	O
were	0	O
allowed	0	O
to	0	O
farrow	0	O
naturally	0	O
(	0	O
d	0	O
114	0	O
,	0	O
NF	1	O
sows	0	O
)	0	O
and	0	O
eight	0	O
sows	0	O
were	0	O
induced	0	O
to	0	O
farrow	0	O
(	0	O
IF	1	O
sows	0	O
)	0	O
prematurely	0	O
by	0	O
injection	0	O
of	0	O
prostaglandin	0	O
F2	0	O
alpha	0	O
on	0	O
d	0	O
112	0	O
of	0	O
gestation	0	O
.	0	O


METHODS	0	O
:	0	O
Fibrotic	1	O
changes	0	O
involving	0	O
bone	0	O
marrow	0	O
were	0	O
evaluated	0	O
histologically	0	O
semiquantitatively	0	O
using	0	O
reticulin	0	B
fiber	0	O
impregnation	0	O
(	0	O
method	0	O
of	0	O
Gomori	0	O
).	0	O


When	0	O
a	0	O
tumour	0	O
is	0	O
present	0	O
nipple	0	O
discharge	0	O
is	0	O
of	0	O
little	0	O
importance	0	O
for	0	O
the	0	O
diagnosis	0	O
and	0	O
treatment	0	O
.	0	O


Rep63A	0	O
(	0	O
513	0	O
amino	0	O
acids	0	O
[	0	O
aa	0	O
]),	0	O
encoded	0	O
by	0	O
the	0	O
largest	0	O
ORF	1	O
,	0	O
displayed	0	O
strong	0	O
similarity	0	O
(	0	O
40	0	O
%	0	O
identity	0	O
)	0	O
to	0	O
the	0	O
replication	0	O
proteins	0	O
from	0	O
plasmids	0	O
pAMbeta1	0	O
,	0	O
pIP501	0	O
,	0	O
and	0	O
pSM19035	0	O
,	0	O
indicating	0	O
that	0	O
the	0	O
pAW63	0	O
replicon	0	O
belongs	0	O
to	0	O
the	0	O
pAMbeta1	0	O
family	0	O
of	0	O
gram	0	O
-	0	O
positive	0	O
theta	0	O
-	0	O
replicating	0	O
plasmids	0	O
.	0	O


Potential	1	O
translational	0	O
start	0	O
signals	0	O
are	0	O
upstream	0	O
of	0	O
ORF1	0	O
and	0	O
ORF2	0	O
.	0	O


We	0	O
have	0	O
found	0	O
out	0	O
that	0	O
one	0	O
-	0	O
year	0	O
-	0	O
old	0	O
carps	0	O
are	0	O
extremely	0	O
sensitive	0	O
to	0	O
ichthiomycin	0	O
in	0	O
concentrations	0	O
between	0	O
25	0	O
-	0	O
125	0	O
micrograms	0	O
/	0	O
dm3	0	O
.	0	O


The	0	O
physical	0	O
linkage	0	O
of	0	O
the	0	O
FHR2	0	B
and	0	O
the	0	O
factor	0	B
H	1	I
genes	0	I
provides	0	O
additional	0	O
evidence	0	O
for	0	O
a	0	O
close	0	O
relatedness	0	O
of	0	O
complement	0	B
factor	0	I
H	1	I
and	0	O
the	0	O
factor	0	B
H	1	I
-	0	I
related	0	I
proteins	0	I
.	0	O


The	0	O
C	1	O
-	0	O
terminal	0	O
approximately	0	O
50	0	O
amino	0	O
acids	0	O
of	0	O
Bel	1	B
-	0	I
1	0	I
are	0	O
shown	0	O
to	0	O
be	0	O
essential	0	O
for	0	O
Bel	1	B
-	0	I
1	0	I
activity	0	O
but	0	O
can	0	O
be	0	O
effectively	0	O
substituted	0	O
by	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
activation	0	O
domain	0	O
of	0	O
VP16	0	B
.	0	O


Study	1	O
of	0	O
antinuclear	0	O
autoantibodies	0	O
by	0	O
immunofluorescence	0	O
technic	0	O
in	0	O
collagen	0	B
diseases	0	O


At	1	O
the	0	O
MTD	1	O
(	0	O
8	0	O
mg	0	O
/	0	O
m2	0	O
/	0	O
day	0	O
),	0	O
the	0	O
dose	0	O
-	0	O
limiting	0	O
toxicity	0	O
of	0	O
this	0	O
agent	0	O
is	0	O
myelosuppression	0	O
.	0	O


UF	0	O
-	0	O
021	0	O
ophthalmic	0	O
solution	0	O
(	0	O
0	0	O
.	0	O
03	0	O
to	0	O
0	0	O
.	0	O
24	0	O
%),	0	O
when	0	O
topically	0	O
applied	0	O
to	0	O
the	0	O
eyes	0	O
of	0	O
rabbits	0	O
,	0	O
caused	0	O
dose	0	O
-	0	O
dependent	0	O
IOP	1	O
reduction	0	O
(	0	O
2	0	O
.	0	O
8	0	O
to	0	O
5	0	O
.	0	O
2	0	O
mmHg	0	O
),	0	O
without	0	O
transient	0	O
IOP	1	O
rise	0	O
.	0	O


In	1	O
ICE	1	B
gamma	0	I
,	0	O
most	0	O
of	0	O
the	0	O
propeptide	0	O
(	0	O
amino	0	O
acids	0	O
20	0	O
-	0	O
112	0	O
)	0	O
is	0	O
deleted	0	O
,	0	O
which	0	O
suggests	0	O
that	0	O
it	0	O
may	0	O
function	0	O
as	0	O
a	0	O
catalyst	0	O
for	0	O
ICE	1	B
autoprocessing	0	O
in	0	O
vivo	0	O
.	0	O


A	1	O
total	0	O
of	0	O
174	0	O
primer	0	O
pairs	0	O
gave	0	O
interpretable	0	O
banding	0	O
patterns	0	O
,	0	O
137	0	O
(	0	O
79	0	O
%)	0	O
of	0	O
which	0	O
revealed	0	O
at	0	O
least	0	O
two	0	O
alleles	0	O
on	0	O
native	0	O
polyacrylamide	0	O
gels	0	O
.	0	O


We	0	O
now	0	O
show	0	O
that	0	O
regulation	0	O
of	0	O
flaN	0	B
transcription	0	O
in	0	O
vivo	0	O
depends	0	O
on	0	O
a	0	O
sigma	0	B
54	0	I
promoter	0	I
and	0	O
two	0	O
ftr	0	O
elements	0	O
located	0	O
downstream	0	O
of	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
at	0	O
+	0	O
86	0	O
(	0	O
ftr2	0	O
)	0	O
and	0	O
+	0	O
120	0	O
(	0	O
ftr3	0	O
).	0	O


Since	0	O
very	0	O
recent	0	O
scanning	0	O
-	0	O
deletion	0	O
analysis	0	O
indicates	0	O
that	0	O
there	0	O
is	0	O
a	0	O
critical	0	O
region	0	O
for	0	O
activity	0	O
near	0	O
Cys	1	O
-	0	O
118	0	O
and	0	O
that	0	O
Cys	1	O
-	0	O
118	0	O
is	0	O
necessary	0	O
for	0	O
maximal	0	O
activity	0	O
,	0	O
we	0	O
conclude	0	O
that	0	O
the	0	O
Cys	1	O
-	0	O
118	0	O
residue	0	O
is	0	O
necessary	0	O
for	0	O
proper	0	O
glycosylation	0	O
and	0	O
maximal	0	O
biologic	0	O
activity	0	O
of	0	O
GM	1	B
-	0	I
CSF	1	I
.	0	O


The	0	O
nucleotide	0	O
sequence	0	O
consists	0	O
of	0	O
48	0	O
bp	0	O
of	0	O
5	0	O
'-	0	O
end	0	O
non	0	O
-	0	O
coding	0	O
region	0	O
,	0	O
1695	0	O
bp	0	O
of	0	O
coding	0	O
region	0	O
and	0	O
212	0	O
bp	0	O
of	0	O
3	0	O
'-	0	O
end	0	O
non	0	O
-	0	O
coding	0	O
region	0	O
including	0	O
a	0	O
20	0	O
bp	0	O
poly	0	O
(	0	O
A	1	O
)	0	O
tail	0	O
.	0	O


Nuclear	1	B
-	0	I
encoded	0	I
chloroplast	0	I
ribosomal	0	I
protein	0	I
L12	0	I
of	0	I
Nicotiana	1	I
tabacum	0	I
:	0	O
characterization	0	O
of	0	O
mature	0	O
protein	0	O
and	0	O
isolation	0	O
and	0	O
sequence	0	O
analysis	0	O
of	0	O
cDNA	1	O
clones	0	O
encoding	0	O
its	0	O
cytoplasmic	0	O
precursor	0	O
.	0	O


We	0	O
show	0	O
here	0	O
that	0	O
this	0	O
difference	0	O
is	0	O
due	0	O
to	0	O
the	0	O
presence	0	O
of	0	O
a	0	O
Mot3	0	B
binding	0	I
site	0	I
in	0	O
OpA	1	B
.	0	O


DATA	1	O
SOURCES	0	O
:	0	O
Epidemiologic	1	O
studies	0	O
,	0	O
research	0	O
studies	0	O
,	0	O
review	0	O
articles	0	O
,	0	O
and	0	O
government	0	O
reports	0	O
pertaining	0	O
to	0	O
epidemiology	0	O
of	0	O
lung	0	O
cancer	0	O
.	0	O


Some	0	O
mutations	0	O
affected	0	O
Dhfr	1	B
in	0	O
a	0	O
qualitative	0	O
manner	0	O
,	0	O
such	0	O
as	0	O
by	0	O
changing	0	O
the	0	O
startpoint	0	O
of	0	O
one	0	O
of	0	O
the	0	O
major	0	O
Dhfr	1	B
transcripts	0	I
or	0	O
changing	0	O
the	0	O
relative	0	O
abundance	0	O
of	0	O
the	0	O
two	0	O
major	0	O
Dhfr	1	B
transcripts	0	I
.	0	O


RVR	0	B
'	0	O
loss	0	O
of	0	O
function	0	O
'	0	O
studies	0	O
by	0	O
constitutive	0	O
over	0	O
-	0	O
expression	0	O
of	0	O
a	0	O
dominant	0	O
negative	0	O
RVR	0	B
delta	0	I
E	1	I
resulted	0	O
in	0	O
increased	0	O
levels	0	O
of	0	O
p21Cip1	0	B
/	0	O
Waf1	0	B
and	0	O
myogenin	0	B
mRNAs	0	I
after	0	O
serum	0	O
withdrawal	0	O
.	0	O


Substituting	0	O
a	0	O
Ser	1	O
for	0	O
Gly69	0	O
or	0	O
a	0	O
Glu	1	O
for	0	O
Lys	1	O
71	0	O
in	0	O
the	0	O
conserved	0	O
TGEK	0	B
tetrapeptide	0	I
in	0	O
finger	0	O
II	0	O
of	0	O
TFIIIA	0	B
resulted	0	O
in	0	O
the	0	O
loss	0	O
of	0	O
DNA	1	O
binding	0	O
.	0	O


Two	0	O
separate	0	O
NF1	1	B
-	0	I
binding	0	I
loci	0	I
were	0	O
also	0	O
found	0	O
in	0	O
the	0	O
equivalent	0	O
IE68	0	B
gene	0	I
of	0	O
HCMV	0	O
(	0	O
Towne	0	O
)	0	O
DNA	1	O
,	0	O
but	0	O
in	0	O
this	0	O
case	0	O
the	0	O
DNA	1	O
sequence	0	O
and	0	O
competition	0	O
filter	0	O
binding	0	O
experiments	0	O
indicated	0	O
a	0	O
maximum	0	O
of	0	O
only	0	O
four	0	O
to	0	O
five	0	O
consensus	0	O
binding	0	O
sites	0	O
encompassing	0	O
the	0	O
promoter	0	O
-	0	O
enhancer	0	O
region	0	O
.	0	O


Delineating	0	O
the	0	O
molecular	0	O
basis	0	O
for	0	O
agonist	0	O
-	0	O
induced	0	O
destabilization	0	O
of	0	O
mRNA	1	O
of	0	O
G	1	B
-	0	I
protein	0	I
-	0	I
linked	0	I
receptors	0	I
that	0	O
contributes	0	O
to	0	O
receptor	0	O
down	0	O
-	0	O
regulation	0	O
is	0	O
fundamental	0	O
to	0	O
our	0	O
understanding	0	O
of	0	O
long	0	O
-	0	O
term	0	O
regulation	0	O
of	0	O
receptors	0	O
by	0	O
agonist	0	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
evaluate	0	O
the	0	O
accuracy	0	O
of	0	O
working	0	O
casts	0	O
for	0	O
crown	0	O
and	0	O
bridge	0	O
restorations	0	O
made	0	O
from	0	O
twin	0	O
mix	0	O
putty	0	O
/	0	O
wash	0	O
silicone	0	O
elastomeric	0	O
impression	0	O
materials	0	O
using	0	O
different	0	O
types	0	O
of	0	O
stock	0	O
tray	0	O
.	0	O


Identification	1	O
of	0	O
Ste4	0	B
as	0	O
a	0	O
potential	0	O
regulator	0	O
of	0	O
Byr2	0	B
in	0	O
the	0	O
sexual	0	O
response	0	O
pathway	0	O
of	0	O
Schizosaccharomyces	0	O
pombe	0	O
.	0	O


The	0	O
plasma	0	O
half	0	O
-	0	O
life	0	O
of	0	O
slow	0	O
disposition	0	O
phase	0	O
t1	0	O
/	0	O
2	0	O
beta	0	O
,	0	O
increases	0	O
from	0	O
0	0	O
.	0	O
26	0	O
hour	0	O
in	0	O
rabbits	0	O
with	0	O
normal	0	O
renal	0	O
function	0	O
to	0	O
5	0	O
.	0	O
41	0	O
hours	0	O
in	0	O
rabbits	0	O
with	0	O
severe	0	O
renal	0	O
impairment	0	O
.	0	O


(	0	O
ii	0	O
)	0	O
opening	0	O
of	0	O
KATP	0	O
attenuates	0	O
,	0	O
inhibition	0	O
of	0	O
the	0	O
channel	0	O
exacerbates	0	O
functional	0	O
consequences	0	O
of	0	O
coronary	0	O
occlusion	0	O
,	0	O
and	0	O
(	0	O
iii	0	O
)	0	O
KATP	0	O
opening	0	O
attenuates	0	O
reperfusion	0	O
-	0	O
induced	0	O
VF	1	O
,	0	O
but	0	O
it	0	O
triggers	0	O
ischemia	0	O
-	0	O
induced	0	O
VF	1	O
.	0	O


To	1	O
accomplish	0	O
this	0	O
,	0	O
actin	0	B
cables	0	O
and	0	O
patches	0	O
are	0	O
redistributed	0	O
during	0	O
the	0	O
cell	0	O
cycle	0	O
to	0	O
direct	0	O
secretory	0	O
components	0	O
to	0	O
appropriate	0	O
sites	0	O
for	0	O
cell	0	O
growth	0	O
.	0	O


Disrupted	0	O
vaccines	0	O
and	0	O
whole	0	O
-	0	O
virus	0	O
vaccines	0	O
containing	0	O
type	0	B
B	1	I
antigen	0	I
only	0	O
did	0	O
not	0	O
cause	0	O
significant	0	O
reactivity	0	O
.	0	O


Therefore	0	O
,	0	O
in	0	O
order	0	O
to	0	O
search	0	O
for	0	O
the	0	O
latent	0	O
genes	0	O
,	0	O
we	0	O
used	0	O
allotype	0	O
-	0	O
specific	0	O
oligonucleotides	0	O
for	0	O
b5	0	O
,	0	O
b6	0	O
and	0	O
b9	0	O
to	0	O
probe	0	O
DNAs	0	O
from	0	O
both	0	O
normal	0	O
and	0	O
T	1	O
.	0	O
brucei	0	O
-	0	O
infected	0	O
rabbits	0	O
by	0	O
Southern	0	O
blotting	0	O
.	0	O


Our	0	O
study	0	O
was	0	O
addressed	0	O
to	0	O
the	0	O
synthesis	0	O
of	0	O
some	0	O
derivatives	0	O
of	0	O
this	0	O
sequence	0	O
in	0	O
order	0	O
to	0	O
obtain	0	O
both	0	O
peptide	0	O
substrates	0	O
suitable	0	O
for	0	O
the	0	O
detection	0	O
of	0	O
the	0	O
Src	1	B
-	0	O
like	0	O
tyrosine	0	B
kinase	0	I
activity	0	O
and	0	O
active	0	O
site	0	O
-	0	O
directed	0	O
inhibitors	0	O
specific	0	O
for	0	O
this	0	O
class	0	O
of	0	O
enzymes	0	O
.	0	O


Two	0	O
mutants	0	O
,	0	O
each	0	O
representative	0	O
of	0	O
a	0	O
separate	0	O
pet	0	B
complementation	0	O
group	0	O
,	0	O
have	0	O
been	0	O
analyzed	0	O
.	0	O


Separation	1	O
of	0	O
malaria	0	O
-	0	O
infected	0	O
erythrocytes	0	O
from	0	O
whole	0	O
blood	0	O
:	0	O
use	0	O
of	0	O
a	0	O
selective	0	O
high	0	O
-	0	O
gradient	0	O
magnetic	0	O
separation	0	O
technique	0	O
.	0	O


Prevention	1	O
of	0	O
transfusion	0	O
reactions	0	O
by	0	O
the	0	O
use	0	O
of	0	O
saline	0	O
washed	0	O
red	0	O
blood	0	O
cells	0	O
.	0	O


We	0	O
demonstrate	0	O
here	0	O
that	0	O
the	0	O
-	0	O
DEDDDL	0	O
sequence	0	O
stabilizes	0	O
GDP	1	O
binding	0	O
to	0	O
Ran	0	B
,	0	O
and	0	O
that	0	O
the	0	O
domain	0	O
is	0	O
required	0	O
for	0	O
high	0	O
affinity	0	O
interaction	0	O
with	0	O
a	0	O
Ran	0	B
-	0	I
binding	0	I
protein	0	I
,	0	O
HTF9A	0	B
/	0	O
RanBP1	0	B
.	0	O


Strains	0	O
bearing	0	O
the	0	O
drs2	0	B
mutation	0	I
process	0	O
the	0	O
20S	0	B
precursor	0	I
of	0	O
the	0	O
mature	0	B
18S	0	I
rRNA	1	I
slowly	0	O
and	0	O
are	0	O
deficient	0	O
in	0	O
40S	0	B
ribosomal	0	I
subunits	0	I
.	0	O


Anti	0	B
-	0	I
CRK	0	I
antibodies	0	I
detect	0	O
a	0	O
53kDa	0	O
protein	0	O
in	0	O
extracts	0	O
of	0	O
C	1	O
.	0	O
fasciculata	0	O
in	0	O
agreement	0	O
with	0	O
the	0	O
size	0	O
predicted	0	O
from	0	O
the	0	O
nucleotide	0	O
sequence	0	O
of	0	O
the	0	O
cloned	0	O
gene	0	O
.	0	O


A	1	O
Golgi	0	O
study	0	O
of	0	O
the	0	O
sixth	0	O
layer	0	O
of	0	O
the	0	O
cerebral	0	O
cortex	0	O
.	0	O


Normal	1	O
values	0	O
for	0	O
the	0	O
peripheral	0	O
blood	0	O
and	0	O
bone	0	O
marrow	0	O
of	0	O
the	0	O
grey	0	O
(	0	O
Armenian	0	O
)	0	O
hamster	0	O


In	1	O
synchronized	0	O
HeLa	0	O
cells	0	O
,	0	O
expression	0	O
of	0	O
luciferase	0	B
activity	0	O
was	0	O
induced	0	O
at	0	O
the	0	O
beginning	0	O
of	0	O
DNA	1	O
synthesis	0	O
and	0	O
was	0	O
dependent	0	O
on	0	O
the	0	O
presence	0	O
of	0	O
an	0	O
E2F	0	B
-	0	I
binding	0	I
site	0	I
in	0	O
the	0	O
H2A	0	B
.	0	I
1	0	I
promoter	0	I
.	0	O


Simultaneously	0	O
a	0	O
greater	0	O
NA	1	O
was	0	O
found	0	O
with	0	O
no	0	O
change	0	O
in	0	O
plasma	0	O
epinephrine	0	O
response	0	O
.	0	O


Phenylephrine	1	O
is	0	O
a	0	O
pure	0	O
alpha	0	B
-	0	I
1	0	I
adrenoreceptor	0	I
agonist	0	O
known	0	O
to	0	O
produce	0	O
marked	0	O
systemic	0	O
vasoconstriction	0	O
and	0	O
associated	0	O
hypertension	0	O
with	0	O
occasional	0	O
profound	0	O
reflex	0	O
bradycardia	0	O
.	0	O


HA	1	O
resulted	0	O
in	0	O
decreased	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
Tre	0	O
(	0	O
0	0	O
.	0	O
4	0	O
degrees	0	O
C	1	O
)	0	O
and	0	O
HR	1	O
(	0	O
17	0	O
b	0	O
X	1	O
min	0	O
-	0	O
1	0	O
),	0	O
and	0	O
increased	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
Msw	0	O
(	0	O
16	0	O
g	0	O
X	1	O
m	0	O
-	0	O
2	0	O
X	1	O
h	0	O
-	0	O
1	0	O
)	0	O
during	0	O
the	0	O
saline	0	O
experiments	0	O
.	0	O


In	1	O
the	0	O
case	0	O
of	0	O
the	0	O
unspliceable	0	O
intron	0	O
,	0	O
repression	0	O
of	0	O
luciferase	0	B
expression	0	O
likely	0	O
involved	0	O
two	0	O
AUF1	0	B
-	0	I
binding	0	I
sequences	0	I
,	0	O
since	0	O
luciferase	0	B
expression	0	O
was	0	O
increased	0	O
by	0	O
deletion	0	O
of	0	O
these	0	O
sites	0	O
.	0	O


A	1	O
cDNA	1	O
encoding	0	O
a	0	O
new	0	O
human	0	O
lymphocyte	0	O
cell	0	O
surface	0	O
molecule	0	O
has	0	O
been	0	O
isolated	0	O
and	0	O
shown	0	O
to	0	O
identify	0	O
a	0	O
fourth	0	O
member	0	O
of	0	O
a	0	O
recently	0	O
discovered	0	O
family	0	O
of	0	O
adhesion	0	O
proteins	0	O
.	0	O


Uses	0	O
of	0	O
orthoclone	0	O
OKT3	1	O
for	0	O
prophylaxis	0	O
of	0	O
rejection	0	O
and	0	O
induction	0	O
in	0	O
initial	0	O
nonfunction	0	O
in	0	O
kidney	0	O
transplantation	0	O
.	0	O


There	0	O
was	0	O
no	0	O
evidence	0	O
of	0	O
any	0	O
persistent	0	O
oscillation	0	O
within	0	O
the	0	O
ULF	0	O
band	0	O
.	0	O


PURPOSE	0	O
:	0	O
To	1	O
evaluate	0	O
the	0	O
disease	0	O
-	0	O
free	0	O
survival	0	O
(	0	O
DFS	0	O
)	0	O
and	0	O
overall	0	O
survival	0	O
(	0	O
OS	1	O
),	0	O
prognostic	0	O
factors	0	O
,	0	O
and	0	O
treatment	0	O
-	0	O
related	0	O
mortality	0	O
of	0	O
women	0	O
with	0	O
stage	0	O
IIIB	0	O
inflammatory	0	O
breast	0	O
cancer	0	O
(	0	O
IBC	1	O
)	0	O
treated	0	O
with	0	O
combined	0	O
modality	0	O
therapy	0	O
(	0	O
CMT	1	O
)	0	O
and	0	O
high	0	O
-	0	O
dose	0	O
chemotherapy	0	O
(	0	O
HDCT	0	O
)	0	O
with	0	O
autologous	0	O
stem	0	O
-	0	O
cell	0	O
transplantation	0	O
.	0	O


High	0	O
-	0	O
frequency	0	O
electrical	0	O
stimulation	0	O
in	0	O
the	0	O
hippocampus	0	O
leads	0	O
to	0	O
an	0	O
increase	0	O
in	0	O
synaptic	0	O
efficacy	0	O
that	0	O
lasts	0	O
for	0	O
many	0	O
hours	0	O
.	0	O


Unlike	0	O
class	0	O
II	0	O
-	0	O
and	0	O
III	0	O
-	0	O
specific	0	O
TBP	1	B
-	0	O
TAF	0	B
complexes	0	O
,	0	O
the	0	O
corresponding	0	O
murine	0	O
and	0	O
human	0	O
class	0	O
I	1	O
-	0	O
specific	0	O
transcription	0	O
initiation	0	O
factor	0	O
TIF	0	B
-	0	I
IB	1	I
/	0	O
SL1	0	B
exhibits	0	O
a	0	O
pronounced	0	O
selectivity	0	O
for	0	O
its	0	O
homologous	0	O
promoter	0	O
.	0	O


Roles	0	O
of	0	O
the	0	O
Candida	1	B
albicans	0	I
mitogen	0	I
-	0	I
activated	0	I
protein	0	I
kinase	0	I
homolog	0	I
,	0	O
Cek1p	0	B
,	0	O
in	0	O
hyphal	0	O
development	0	O
and	0	O
systemic	0	O
candidiasis	0	O
.	0	O


In	1	O
vitro	0	O
penetration	0	O
tests	0	O
of	0	O
human	0	O
sperm	0	O
into	0	O
cervical	0	O
mucus	0	O
were	0	O
introduced	0	O
in	0	O
order	0	O
to	0	O
study	0	O
the	0	O
interaction	0	O
between	0	O
sperm	0	O
and	0	O
cervical	0	O
mucus	0	O
.	0	O


The	0	O
elevation	0	O
of	0	O
cyclic	0	O
AMP	1	O
(	0	O
cAMP	1	O
)	0	O
levels	0	O
in	0	O
the	0	O
cell	0	O
downregulates	0	O
the	0	O
activity	0	O
of	0	O
the	0	O
Raf	0	B
-	0	I
1	0	I
kinase	0	I
.	0	O


Army	0	O
veterans	0	O
given	0	O
yellow	0	O
fever	0	O
vaccine	0	O
contaminated	0	O
with	0	O
hepatitis	0	O
B	1	O
virus	0	O
in	0	O
1942	0	O
and	0	O
controls	0	O
and	0	O
(	0	O
b	0	O
)	0	O
a	0	O
case	0	O
-	0	O
control	0	O
study	0	O
comparing	0	O
veterans	0	O
with	0	O
hepatocellular	0	O
carcinoma	0	O
in	0	O
Veterans	0	O
Affairs	0	O
hospitals	0	O
with	0	O
matched	0	O
controls	0	O
with	0	O
respect	0	O
to	0	O
receipt	0	O
of	0	O
contaminated	0	O
vaccine	0	O
in	0	O
1942	0	O
.	0	O


Asymptomatic	1	O
bacteriospermia	0	O
and	0	O
fertility	0	O


The	0	O
large	0	O
subfamily	0	O
of	0	O
receptor	0	B
tyrosine	0	I
kinases	0	I
(	0	O
RTKs	0	B
)	0	O
for	0	O
which	0	O
EPH	0	B
is	0	O
the	0	O
prototype	0	O
have	0	O
likely	0	O
roles	0	O
in	0	O
intercellular	0	O
communication	0	O
during	0	O
normal	0	O
mammalian	0	O
development	0	O
,	0	O
but	0	O
the	0	O
biochemical	0	O
signalling	0	O
pathways	0	O
utilised	0	O
by	0	O
this	0	O
family	0	O
are	0	O
poorly	0	O
characterised	0	O
.	0	O


Approximately	0	O
65	0	O
%	0	O
of	0	O
the	0	O
total	0	O
cAMP	1	B
-	0	I
dependent	0	I
phosphotransferase	0	I
activity	0	O
is	0	O
recovered	0	O
in	0	O
particulate	0	O
fractions	0	O
of	0	O
homogenates	0	O
prepared	0	O
from	0	O
asynchronous	0	O
populations	0	O
of	0	O
C	1	O
.	0	O
elegans	0	O
.	0	O


Following	1	O
seizure	0	O
induction	0	O
,	0	O
MABP	0	O
increased	0	O
to	0	O
105	0	O
mm	0	O
Hg	1	O
and	0	O
brain	0	O
pHi	1	O
fell	0	O
to	0	O
6	0	O
.	0	O
79	0	O
+/-	0	O
0	0	O
.	0	O
03	0	O
within	0	O
15	0	O
min	0	O
and	0	O
remained	0	O
at	0	O
this	0	O
level	0	O
for	0	O
1	0	O
h	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
).	0	O


However	0	O
,	0	O
a	0	O
correlation	0	O
was	0	O
observed	0	O
between	0	O
SF	1	O
levels	0	O
of	0	O
IL	1	B
-	0	I
8	0	I
with	0	O
those	0	O
of	0	O
lactate	0	O
,	0	O
LDH	1	B
,	0	O
beta	0	B
2	0	I
-	0	I
microglobulin	0	I
and	0	O
glucose	0	O
.	0	O


Expression	1	O
of	0	O
herpes	0	O
simplex	0	O
virus	0	O
beta	0	O
and	0	O
gamma	0	O
genes	0	O
integrated	0	O
in	0	O
mammalian	0	O
cells	0	O
and	0	O
their	0	O
induction	0	O
by	0	O
an	0	O
alpha	0	O
gene	0	O
product	0	O
.	0	O


P	1	O
.,	0	O
Peyron	0	O
,	0	O
J	1	O
.	0	O


Because	0	O
ATF	0	B
-	0	I
1	0	I
and	0	O
CREM	0	B
are	0	O
known	0	O
to	0	O
bind	0	O
to	0	O
cAMP	1	O
response	0	O
elements	0	O
(	0	O
CRE	0	O
),	0	O
this	0	O
functional	0	O
sequence	0	O
was	0	O
named	0	O
the	0	O
kappa	0	O
E3	1	O
'-	0	O
CRE	0	O
.	0	O


Characterization	0	O
of	0	O
the	0	O
regulatory	0	O
regions	0	O
of	0	O
the	0	O
human	0	B
aromatase	0	I
(	0	O
P450arom	0	B
)	0	O
gene	0	O
involved	0	O
in	0	O
placenta	0	O
-	0	O
specific	0	O
expression	0	O
.	0	O


Plasmids	0	O
were	0	O
constructed	0	O
with	0	O
the	0	O
mouse	0	O
promoter	0	O
region	0	O
linked	0	O
to	0	O
the	0	O
reporter	0	B
gene	0	I
chloramphenicol	0	I
acetyltransferase	0	I
(	0	O
CAT	1	B
),	0	O
and	0	O
transiently	0	O
and	0	O
stably	0	O
transfected	0	O
in	0	O
the	0	O
INS	0	O
-	0	O
1	0	O
cells	0	O
.	0	O


A	1	O
32P	0	O
-	0	O
labeled	0	O
LAP	1	B
DNA	1	O
-	0	O
binding	0	O
and	0	O
dimerization	0	O
domain	0	O
"	0	O
zipper	0	O
probe	0	O
"	0	O
was	0	O
used	0	O
to	0	O
isolate	0	O
a	0	O
clone	0	O
that	0	O
encodes	0	O
a	0	O
new	0	O
C	1	B
/	0	I
EBP	1	I
-	0	I
homologous	0	I
protein	0	I
:	0	O
CHOP	1	B
-	0	I
10	0	I
.	0	O


The	0	O
coding	0	O
region	0	O
of	0	O
2385	0	O
nucleotides	0	O
corresponds	0	O
to	0	O
a	0	O
polypeptide	0	O
chain	0	O
of	0	O
795	0	O
amino	0	O
acids	0	O
,	0	O
giving	0	O
a	0	O
molecular	0	O
weight	0	O
of	0	O
91	0	O
,	0	O
555	0	O
for	0	O
the	0	O
hsp108	0	B
protein	0	I
.	0	O


Gonadal	1	O
dysfunction	0	O
in	0	O
patients	0	O
with	0	O
ataxia	0	O
telangiectasia	0	O
.	0	O


The	0	O
specificity	0	O
of	0	O
action	0	O
of	0	O
C	1	B
/	0	I
EBP	1	I
family	0	I
members	0	I
may	0	O
be	0	O
derived	0	O
from	0	O
the	0	O
characteristics	0	O
of	0	O
each	0	O
factor	0	O
,	0	O
including	0	O
the	0	O
expression	0	O
profiles	0	O
,	0	O
the	0	O
DNA	1	O
binding	0	O
affinities	0	O
,	0	O
the	0	O
cofactors	0	O
,	0	O
and	0	O
so	0	O
on	0	O
,	0	O
in	0	O
addition	0	O
to	0	O
the	0	O
DNA	1	O
binding	0	O
specificities	0	O
.	0	O


These	0	O
results	0	O
demonstrate	0	O
that	0	O
N	1	O
-	0	O
glycans	0	O
flanking	0	O
the	0	O
receptor	0	O
-	0	O
binding	0	O
site	0	O
of	0	O
the	0	O
HA	1	B
molecule	0	I
are	0	O
potent	0	O
regulators	0	O
of	0	O
influenza	0	O
virus	0	O
growth	0	O
,	0	O
with	0	O
the	0	O
glycan	0	O
at	0	O
Asn149	0	O
being	0	O
dominant	0	O
and	0	O
that	0	O
at	0	O
Asn123	0	O
being	0	O
less	0	O
effective	0	O
.	0	O


Under	0	O
the	0	O
same	0	O
hematocrit	0	O
and	0	O
flow	0	O
conditions	0	O
,	0	O
the	0	O
rate	0	O
of	0	O
oxygen	0	O
saturation	0	O
decrease	0	O
was	0	O
significantly	0	O
higher	0	O
for	0	O
the	0	O
sickle	0	O
cells	0	O
than	0	O
for	0	O
normal	0	O
cells	0	O
.	0	O


Transcriptional	1	O
activation	0	O
of	0	O
the	0	O
chicken	0	B
lysozyme	0	I
gene	0	I
by	0	O
NF	1	B
-	0	I
kappa	0	I
Bp65	0	I
(	0	O
RelA	0	B
)	0	O
and	0	O
c	0	B
-	0	I
Rel	0	I
,	0	O
but	0	O
not	0	O
by	0	O
NF	1	B
-	0	I
kappa	0	I
Bp50	0	I
.	0	O


Colorectal	1	O
polyps	0	O
should	0	O
be	0	O
removed	0	O
endoscopically	0	O
whenever	0	O
possible	0	O
.	0	O


The	0	O
alpha	0	O
-	0	O
subunit	0	O
by	0	O
itself	0	O
binds	0	O
to	0	O
telomeric	0	O
DNA	1	O
.	0	O


Myogenic	1	O
differentiation	0	O
can	0	O
be	0	O
inhibited	0	O
by	0	O
the	0	O
adenovirus	0	O
E1a	0	B
protein	0	I
in	0	O
the	0	O
rat	0	O
L6	0	O
muscle	0	O
cell	0	O
line	0	O
.	0	O


The	0	O
different	0	O
holoenzyme	0	B
RNA	1	I
polymerases	0	I
generated	0	O
upon	0	O
reconstituting	0	O
these	0	O
mutants	0	O
independently	0	O
with	0	O
core	0	B
RNA	1	I
polymerase	0	I
(	0	O
alpha2beta	0	O
beta	0	O
')	0	O
have	0	O
shown	0	O
reduced	0	O
transcriptional	0	O
activity	0	O
in	0	O
comparison	0	O
to	0	O
the	0	O
enzyme	0	O
containing	0	O
wild	0	B
-	0	I
type	0	I
sigma	0	I
factor	0	I
.	0	O


Growth	1	O
,	0	O
4	0	O
-	0	O
PA	1	O
and	0	O
14C	0	O
turnover	0	O
data	0	O
indicated	0	O
that	0	O
WB	1	O
contributed	0	O
to	0	O
B	1	O
-	0	O
6	0	O
intake	0	O
of	0	O
these	0	O
rats	0	O
.	0	O


Transgenic	1	O
tobacco	0	O
plants	0	O
(	0	O
ppa	0	B
-	0	I
1	0	I
)	0	O
constitutively	0	O
expressing	0	O
Escherichia	1	B
coli	0	I
pyrophosphatase	0	I
behind	0	O
the	0	O
35S	0	B
CaMV	0	I
promoter	0	I
accumulate	0	O
high	0	O
levels	0	O
of	0	O
soluble	0	O
sugars	0	O
in	0	O
their	0	O
leaves	0	O
[	0	O
27	0	O
].	0	O


The	0	O
intracoronary	0	O
administration	0	O
of	0	O
both	0	O
drugs	0	O
markedly	0	O
reduced	0	O
the	0	O
incidence	0	O
of	0	O
VF	1	O
induced	0	O
by	0	O
the	0	O
release	0	O
of	0	O
a	0	O
40	0	O
-	0	O
min	0	O
coronary	0	O
artery	0	O
occlusion	0	O
.	0	O


This	0	O
region	0	O
does	0	O
not	0	O
contain	0	O
an	0	O
identifiable	0	O
TATA	0	O
element	0	O
,	0	O
indicating	0	O
that	0	O
transcription	0	O
of	0	O
the	0	O
glutaminase	0	B
gene	0	I
is	0	O
driven	0	O
by	0	O
a	0	O
TATA	0	O
-	0	O
less	0	O
promoter	0	O
.	0	O


We	0	O
have	0	O
tested	0	O
this	0	O
proposal	0	O
by	0	O
carrying	0	O
out	0	O
circular	0	O
dichroism	0	O
(	0	O
CD	1	O
)	0	O
and	0	O
NMR	1	O
experiments	0	O
on	0	O
the	0	O
Skn	0	B
domain	0	I
and	0	O
five	0	O
truncated	0	O
proteins	0	O
.	0	O


Using	0	O
fluorescence	0	O
in	0	O
situ	0	O
hybridization	0	O
,	0	O
we	0	O
mapped	0	O
the	0	O
chromosome	0	O
-	0	O
17	0	O
breakpoint	0	O
in	0	O
a	0	O
patient	0	O
with	0	O
acampomelic	0	O
CMPD	0	O
and	0	O
sex	0	O
reversal	0	O
,	0	O
who	0	O
carries	0	O
a	0	O
de	0	O
novo	0	O
constitutional	0	O
t	0	O
(	0	O
12	0	O
;	0	O
17	0	O
)	0	O
translocation	0	O
,	0	O
between	0	O
two	0	O
known	0	O
cosmid	0	O
markers	0	O
in	0	O
the	0	O
17q24	0	O
-	0	O
q25	0	O
region	0	O
.	0	O


One	0	O
member	0	O
of	0	O
this	0	O
multigene	0	O
family	0	O
,	0	O
GATA	0	B
-	0	I
3	0	I
,	0	O
is	0	O
most	0	O
abundantly	0	O
expressed	0	O
in	0	O
T	1	O
lymphocytes	0	O
,	0	O
a	0	O
cellular	0	O
target	0	O
for	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
type	0	O
1	0	O
(	0	O
HIV	1	O
-	0	O
1	0	O
)	0	O
infection	0	O
and	0	O
replication	0	O
.	0	O


Information	1	O
on	0	O
conserved	0	O
noncoding	0	O
sequences	0	O
will	0	O
help	0	O
in	0	O
studies	0	O
on	0	O
the	0	O
regulation	0	O
of	0	O
the	0	O
pro	0	B
alpha	0	I
1	0	I
(	0	I
II	0	I
)	0	I
collagen	0	I
gene	0	I
.	0	O


Study	1	O
of	0	O
the	0	O
alterations	0	O
of	0	O
intestinal	0	O
absorption	0	O
,	0	O
by	0	O
means	0	O
of	0	O
I	1	O
-	0	O
131	0	O
-	0	O
triolein	0	O
,	0	O
in	0	O
the	0	O
whole	0	O
body	0	O
irradiated	0	O
rat	0	O


A	1	O
general	0	O
model	0	O
for	0	O
ARE	0	O
-	0	O
mediated	0	O
mRNA	1	O
degradation	0	O
involving	0	O
a	0	O
potential	0	O
role	0	O
for	0	O
certain	0	O
heterogeneous	0	O
nuclear	0	O
ribonucleoproteins	0	O
and	0	O
ARE	0	B
-	0	I
binding	0	I
proteins	0	I
is	0	O
proposed	0	O
.	0	O


Ca2	1	O
+	0	O
decreased	0	O
Zn2	0	O
+	0	O
binding	0	O
in	0	O
S100	0	B
beta	0	I
but	0	O
it	0	O
did	0	O
not	0	O
influence	0	O
binding	0	O
to	0	O
MRP14	0	B
,	0	O
suggesting	0	O
that	0	O
the	0	O
Zn2	0	O
+	0	O
binding	0	O
site	0	O
was	0	O
distinct	0	O
from	0	O
and	0	O
independent	0	O
of	0	O
the	0	O
two	0	O
Ca2	1	O
+	0	O
binding	0	O
domains	0	O
.	0	O


Patients	0	O
and	0	O
their	0	O
relatives	0	O
must	0	O
be	0	O
informed	0	O
about	0	O
the	0	O
available	0	O
effective	0	O
treatment	0	O
possibilities	0	O
and	0	O
about	0	O
the	0	O
right	0	O
moment	0	O
for	0	O
their	0	O
application	0	O
in	0	O
an	0	O
individual	0	O
patient	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
consensus	0	O
sequences	0	O
for	0	O
phosphatase	0	O
regulation	0	O
are	0	O
5	0	O
'-	0	O
GCACGTGGG	0	O
-	0	O
3	0	O
'	0	O
and	0	O
5	0	O
'-	0	O
GCACGTTTT	0	O
-	0	O
3	0	O
'	0	O
which	0	O
differ	0	O
from	0	O
the	0	O
binding	0	O
sequences	0	O
for	0	O
the	0	O
Cpflp	0	B
protein	0	O
required	0	O
for	0	O
transcription	0	O
of	0	O
the	0	O
genes	0	O
in	0	O
methionine	0	O
biosynthesis	0	O
and	0	O
for	0	O
centromere	0	O
function	0	O
.	0	O


These	0	O
data	0	O
support	0	O
the	0	O
idea	0	O
that	0	O
the	0	O
repression	0	O
activity	0	O
of	0	O
NRSF	1	B
/	0	O
REST	1	B
depends	0	O
upon	0	O
the	0	O
species	0	O
of	0	O
promoter	0	O
to	0	O
which	0	O
it	0	O
is	0	O
linked	0	O
and	0	O
upon	0	O
the	0	O
proteins	0	O
that	0	O
bind	0	O
to	0	O
those	0	O
promoters	0	O
.	0	O


In	1	O
general	0	O
,	0	O
two	0	O
separate	0	O
high	0	O
-	0	O
performance	0	O
liquid	0	O
chromatographic	0	O
runs	0	O
were	0	O
performed	0	O
,	0	O
one	0	O
for	0	O
the	0	O
gamma	0	O
-	0	O
aminobutyric	0	O
acid	0	O
determination	0	O
and	0	O
one	0	O
for	0	O
the	0	O
determination	0	O
of	0	O
the	0	O
monoamines	0	O
.	0	O


We	0	O
show	0	O
that	0	O
Rlm1	0	B
and	0	O
Smp1	0	B
have	0	O
MEF2	0	B
-	0	O
related	0	O
DNA	1	O
-	0	O
binding	0	O
specificities	0	O
:	0	O
Rlm1	0	B
binds	0	O
with	0	O
the	0	O
same	0	O
specificity	0	O
as	0	O
MEF2	0	B
,	0	O
CTA	1	B
(	0	I
T	1	I
/	0	I
A	1	I
)	0	I
4TAG	0	I
,	0	O
while	0	O
SMP1	0	B
binds	0	O
a	0	O
more	0	O
extended	0	O
consensus	0	O
sequence	0	O
,	0	O
ACTACTA	0	O
(	0	O
T	1	O
/	0	O
A	1	O
)	0	O
4TAG	0	O
.	0	O


Morphine	1	O
produced	0	O
a	0	O
dose	0	O
-	0	O
dependent	0	O
bradycardia	0	O
followed	0	O
by	0	O
tachycardia	0	O
.	0	O


Replication	1	O
of	0	O
bovine	0	O
papillomavirus	0	O
-	0	O
1	0	O
(	0	O
BPV	1	O
-	0	O
1	0	O
)	0	O
DNA	1	O
requires	0	O
two	0	O
viral	0	O
gene	0	O
products	0	O
,	0	O
the	0	O
E1	1	B
protein	0	I
and	0	O
the	0	O
full	0	B
-	0	I
length	0	I
E2	1	I
protein	0	I
.	0	O


Alpha	1	B
-	0	I
1	0	I
antitrypsin	0	I
and	0	O
Indian	0	O
childhood	0	O
cirrhosis	0	O
.	0	O


We	0	O
produced	0	O
transgenic	0	O
plants	0	O
expressing	0	O
the	0	O
antisense	0	B
Arabidopsis	0	I
HD	1	I
(	0	O
AtHD1	0	B
)	0	O
gene	0	O
.	0	O


A	1	O
low	0	O
aspirin	0	B
esterase	0	I
activity	0	O
may	0	O
be	0	O
a	0	O
contributory	0	O
factor	0	O
in	0	O
precipitating	0	O
these	0	O
aspirin	0	O
sensitive	0	O
reactions	0	O
.	0	O


We	0	O
have	0	O
isolated	0	O
a	0	O
new	0	O
,	0	O
larger	0	O
rat	0	B
B	1	I
-	0	I
myc	0	I
genomic	0	I
clone	0	I
.	0	O


The	0	O
MCAD	0	B
nuclear	0	I
receptor	0	I
response	0	I
element	0	I
1	0	I
(	0	O
NRRE	0	B
-	0	I
1	0	I
)	0	O
interacts	0	O
in	0	O
vitro	0	O
with	0	O
ERR	0	B
alpha	0	I
expressed	0	O
in	0	O
COS	1	O
-	0	O
7	0	O
cells	0	O
.	0	O


Active	1	O
complexes	0	O
eluted	0	O
at	0	O
a	0	O
higher	0	O
molecular	0	O
weight	0	O
than	0	O
inactive	0	O
complexes	0	O
,	0	O
were	0	O
relatively	0	O
deficient	0	O
in	0	O
both	0	O
p21	0	B
and	0	O
p27	0	B
,	0	O
and	0	O
contained	0	O
Cdk2	0	B
with	0	O
increased	0	O
threonine	0	O
160	0	O
phosphorylation	0	O
,	0	O
consistent	0	O
with	0	O
a	0	O
mechanism	0	O
of	0	O
activation	0	O
of	0	O
cyclin	0	B
E	1	I
-	0	O
Cdk2	0	B
involving	0	O
both	0	O
reduced	0	O
CDK	1	B
inhibitor	0	O
association	0	O
and	0	O
CDK	1	B
-	0	I
activating	0	I
kinase	0	I
-	0	O
mediated	0	O
phosphorylation	0	O
of	0	O
Cdk2	0	B
.	0	O


The	0	O
GHR	0	B
mRNA	1	I
:	0	O
GHBP	0	B
mRNA	1	I
ratio	0	O
was	0	O
1	0	O
.	0	O
1	0	O
+/-	0	O
0	0	O
.	0	O
12	0	O
and	0	O
remained	0	O
unchanged	0	O
during	0	O
differentiation	0	O
.	0	O


Exons	0	O
III	0	O
to	0	O
VIII	0	O
,	0	O
which	0	O
cover	0	O
the	0	O
coding	0	O
region	0	O
and	0	O
the	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
,	0	O
are	0	O
almost	0	O
identical	0	O
in	0	O
all	0	O
types	0	O
of	0	O
PST	0	B
or	0	O
AST	1	B
cDNAs	0	I
.	0	O


Using	0	O
backcross	0	O
analysis	0	O
,	0	O
both	0	O
exons	0	O
1	0	O
and	0	O
4	0	O
mapped	0	O
to	0	O
a	0	O
proximal	0	O
region	0	O
of	0	O
murine	0	O
Chromosome	1	O
4	0	O
indistinguishable	0	O
from	0	O
the	0	O
vacillans	0	B
gene	0	I
.	0	O


Transient	1	O
transfection	0	O
assays	0	O
using	0	O
reporter	0	O
gene	0	O
constructs	0	O
containing	0	O
various	0	O
lengths	0	O
of	0	O
the	0	O
5	0	B
'	0	I
mdr1b	0	I
sequences	0	I
revealed	0	O
that	0	O
the	0	O
sequence	0	O
located	0	O
between	0	O
-	0	O
247	0	O
to	0	O
-	0	O
126	0	O
bp	0	O
was	0	O
important	0	O
for	0	O
the	0	O
expression	0	O
of	0	O
the	0	O
reporter	0	O
gene	0	O
in	0	O
many	0	O
different	0	O
cell	0	O
lines	0	O
.	0	O


The	0	O
full	0	O
protocol	0	O
was	0	O
completed	0	O
by	0	O
33	0	O
patients	0	O
(	0	O
45	0	O
%	0	O
of	0	O
original	0	O
cohort	0	O
).	0	O


Isolation	1	O
of	0	O
Weeksella	1	O
virosa	0	O
(	0	O
formerly	0	O
CDC	1	O
group	0	O
IIf	0	O
)	0	O
from	0	O
a	0	O
vaginal	0	O
sample	0	O
.	0	O


The	0	O
effects	0	O
of	0	O
glutaraldehyde	0	O
on	0	O
dimensions	0	O
and	0	O
ultrastructure	0	O
of	0	O
microvascular	0	O
beds	0	O
in	0	O
rat	0	O
mesentery	0	O
were	0	O
studied	0	O
in	0	O
two	0	O
kinds	0	O
of	0	O
experiment	0	O
,	0	O
administering	0	O
the	0	O
fixative	0	O
by	0	O
intra	0	O
-	0	O
arterial	0	O
perfusion	0	O
at	0	O
a	0	O
pressure	0	O
of	0	O
80	0	O
mm	0	O
Hg	1	O
and	0	O
by	0	O
superfusion	0	O
of	0	O
the	0	O
exteriorized	0	O
mesenteric	0	O
membrane	0	O
.	0	O


The	0	O
detector	0	O
has	0	O
the	0	O
advantage	0	O
of	0	O
finding	0	O
both	0	O
ST	1	O
segment	0	O
deviations	0	O
and	0	O
entire	0	O
ST	1	O
-	0	O
T	1	O
complex	0	O
changes	0	O
thereby	0	O
providing	0	O
a	0	O
wider	0	O
characterization	0	O
of	0	O
the	0	O
potential	0	O
ischemic	0	O
events	0	O
.	0	O


The	0	O
mouse	0	B
beta	0	I
2	0	I
-	0	I
syntrophin	0	I
gene	0	I
(	0	O
>	0	O
33	0	O
kilobases	0	O
)	0	O
contains	0	O
seven	0	O
exons	0	O
,	0	O
all	0	O
of	0	O
which	0	O
have	0	O
homologues	0	O
at	0	O
the	0	O
corresponding	0	O
position	0	O
in	0	O
the	0	O
alpha	0	B
1	0	I
-	0	I
syntrophin	0	I
gene	0	I
.	0	O


The	0	O
effects	0	O
of	0	O
mean	0	O
luminance	0	O
were	0	O
also	0	O
measured	0	O
and	0	O
a	0	O
general	0	O
expression	0	O
that	0	O
would	0	O
take	0	O
them	0	O
into	0	O
account	0	O
was	0	O
derived	0	O
.	0	O


SBF	0	B
binds	0	O
to	0	O
the	0	O
promoter	0	O
prior	0	O
to	0	O
the	0	O
activation	0	O
of	0	O
transcription	0	O
in	0	O
late	0	O
G1	0	O
,	0	O
suggesting	0	O
that	0	O
Cln	0	B
/	0	O
Cdc28	0	B
kinase	0	O
regulates	0	O
the	0	O
ability	0	O
of	0	O
previously	0	O
bound	0	O
SBF	0	B
to	0	O
activate	0	O
transcription	0	O
.	0	O


Their	0	O
biosynthesis	0	O
proceeds	0	O
via	0	O
linear	0	O
precursors	0	O
that	0	O
become	0	O
branched	0	O
by	0	O
beta1	0	B
,	0	I
6	0	I
-	0	I
GlcNAc	1	I
transferases	0	I
(	0	O
IGnT6	0	O
,	0	O
GlcNAc	1	O
to	0	O
Gal	0	O
).	0	O


An	1	O
approximately	0	O
37	0	O
-	0	O
kDa	1	O
cytoplasmic	0	O
protein	0	O
is	0	O
rapidly	0	O
tyrosine	0	O
-	0	O
phosphorylated	0	O
in	0	O
the	0	O
response	0	O
of	0	O
mouse	0	O
BAC1	0	O
.	0	O
2F5	0	O
macrophages	0	O
to	0	O
colony	0	B
stimulating	0	I
factor	0	I
-	0	I
1	0	I
(	0	O
CSF	1	B
-	0	I
1	0	I
).	0	O
pp37	0	B
was	0	O
purified	0	O
from	0	O
the	0	O
cytosolic	0	O
fraction	0	O
by	0	O
anti	0	B
-	0	I
Tyr	1	I
(	0	I
P	1	I
)	0	I
affinity	0	O
chromatography	0	O
,	0	O
size	0	O
exclusion	0	O
chromatography	0	O
,	0	O
and	0	O
C4	1	O
reverse	0	O
phase	0	O
high	0	O
pressure	0	O
liquid	0	O
chromatography	0	O
.	0	O


Intensification	1	O
of	0	O
human	0	O
myocardial	0	O
contractile	0	O
activity	0	O
as	0	O
affected	0	O
by	0	O
blood	0	O
serum	0	O


The	0	O
subjects	0	O
were	0	O
diagnosed	0	O
on	0	O
the	0	O
basis	0	O
of	0	O
DSM	1	O
-	0	O
IV	1	O
pathological	0	O
gambling	0	O
criteria	0	O
and	0	O
completed	0	O
the	0	O
Turkish	0	O
Version	1	O
of	0	O
South	0	O
Oaks	0	O
Gambling	1	O
Screen	1	O
(	0	O
SOGS	0	O
).	0	O


A	1	O
36	0	O
-	0	O
kDa	1	O
protein	0	O
that	0	O
was	0	O
localized	0	O
to	0	O
the	0	O
membrane	0	O
fraction	0	O
was	0	O
detected	0	O
in	0	O
minicells	0	O
containing	0	O
plasmids	0	O
with	0	O
the	0	O
ftsN	0	B
gene	0	I
,	0	O
confirming	0	O
that	0	O
FtsN	0	B
was	0	O
a	0	O
membrane	0	O
protein	0	O
.	0	O


Serotonin	1	B
receptors	0	I
in	0	O
suicide	0	O
victims	0	O
with	0	O
major	0	O
depression	0	O
.	0	O


Closure	1	O
of	0	O
an	0	O
open	0	O
high	0	O
below	0	O
-	0	O
knee	0	O
guillotine	0	O
amputation	0	O
wound	0	O
using	0	O
a	0	O
skin	0	O
-	0	O
stretching	0	O
device	0	O
.	0	O


Prevalence	1	O
of	0	O
rheumatoid	0	O
arthritis	0	O
and	0	O
rheumatoid	0	B
factor	0	I
in	0	O
women	0	O
:	0	O
evidence	0	O
for	0	O
a	0	O
secular	0	O
decline	0	O
.	0	O


Pax	0	B
-	0	I
3	0	I
is	0	O
a	0	O
paired	0	B
-	0	I
type	0	I
homeobox	0	I
gene	0	I
that	0	O
is	0	O
specifically	0	O
expressed	0	O
in	0	O
the	0	O
dorsal	0	O
and	0	O
posterior	0	O
neural	0	O
tube	0	O
.	0	O


Effect	1	O
of	0	O
chronic	0	O
undernutrition	0	O
on	0	O
susceptibility	0	O
to	0	O
cold	0	O
stress	0	O
in	0	O
young	0	O
adult	0	O
and	0	O
aged	0	O
rats	0	O
.	0	O


Does	0	O
afferent	0	O
loop	0	O
syndrome	0	O
exist	0	O
?]	0	O
It	1	O
is	0	O
the	0	O
author	0	O
'	0	O
s	0	O
opinion	0	O
that	0	O
diagnosis	0	O
of	0	O
the	0	O
"	0	O
adducent	0	O
loop	0	O
syndrome	0	O
"	0	O
is	0	O
unlikely	0	O
to	0	O
be	0	O
correct	0	O
in	0	O
patients	0	O
subjected	0	O
to	0	O
Billroth	0	O
-	0	O
II	0	O
gastrectomy	0	O
.	0	O


These	0	O
results	0	O
confirmed	0	O
that	0	O
cleavage	0	O
of	0	O
the	0	O
leader	0	O
peptide	0	O
is	0	O
the	0	O
last	0	O
step	0	O
in	0	O
nisin	0	B
maturation	0	O
and	0	O
is	0	O
necessary	0	O
to	0	O
generate	0	O
a	0	O
biologically	0	O
active	0	O
peptide	0	O
.	0	O


The	0	O
zona	0	O
pellucida	0	O
(	0	O
ZP	0	O
),	0	O
the	0	O
extracellular	0	O
glycocalyx	0	O
that	0	O
surrounds	0	O
the	0	O
oocyte	0	O
,	0	O
is	0	O
well	0	O
known	0	O
to	0	O
mediate	0	O
homologous	0	O
gamete	0	O
interaction	0	O
.	0	O


Role	1	O
of	0	O
superoxide	0	B
dismutase	0	I
in	0	O
cellular	0	O
oxidative	0	O
processes	0	O
and	0	O
method	0	O
of	0	O
its	0	O
determination	0	O
in	0	O
biological	0	O
materials	0	O


The	0	O
salient	0	O
clinical	0	O
features	0	O
,	0	O
the	0	O
problems	0	O
of	0	O
management	0	O
and	0	O
the	0	O
modern	0	O
approaches	0	O
to	0	O
the	0	O
reconstruction	0	O
of	0	O
facial	0	O
deformities	0	O
seen	0	O
in	0	O
this	0	O
disease	0	O
are	0	O
described	0	O
.	0	O


Mutations	0	O
in	0	O
the	0	O
VPS45	0	B
gene	0	I
,	0	O
a	0	O
SEC1	0	B
homologue	0	O
,	0	O
result	0	O
in	0	O
vacuolar	0	O
protein	0	O
sorting	0	O
defects	0	O
and	0	O
accumulation	0	O
of	0	O
membrane	0	O
vesicles	0	O
.	0	O


To	1	O
determine	0	O
the	0	O
signal	0	B
recognition	0	I
particle	0	I
(	0	O
SRP	0	B
)-	0	O
SRP	0	B
receptor	0	I
(	0	O
Srb	0	B
)	0	O
system	0	O
in	0	O
Bacillus	1	O
subtilis	0	O
(	0	O
Bs	1	O
),	0	O
we	0	O
cloned	0	O
the	0	O
Bs	1	B
srb	0	I
gene	0	I
,	0	O
which	0	O
encodes	0	O
a	0	O
homologue	0	O
of	0	O
the	0	O
mammalian	0	B
SRP	0	I
receptor	0	I
alpha	0	I
-	0	I
subunit	0	I
[	0	O
Oguro	0	O
et	0	O
al	0	O
.,	0	O
DNA	1	O
Res	1	O
.	0	O


Analysis	1	O
of	0	O
an	0	O
autopsy	0	O
population	0	O
.	0	O


The	0	O
promoter	0	O
segment	0	O
was	0	O
inactive	0	O
when	0	O
introduced	0	O
into	0	O
the	0	O
rat	0	O
glioma	0	O
cell	0	O
line	0	O
C6B4	0	O
,	0	O
the	0	O
rat	0	O
submandibular	0	O
cell	0	O
line	0	O
RSMT	0	O
-	0	O
A5	0	O
,	0	O
and	0	O
the	0	O
rat	0	O
pancreatic	0	O
beta	0	O
cell	0	O
line	0	O
RIN	0	O
-	0	O
5AH	0	O
,	0	O
all	0	O
of	0	O
which	0	O
do	0	O
not	0	O
express	0	O
the	0	O
endogenous	0	O
alpha2c	0	B
-	0	I
AR	1	I
gene	0	I
.	0	O


Pharmacokinetic	0	O
parameters	0	O
were	0	O
similar	0	O
to	0	O
values	0	O
given	0	O
in	0	O
the	0	O
literature	0	O
for	0	O
intravenous	0	O
(	0	O
IV	1	O
)	0	O
or	0	O
intraarterial	0	O
(	0	O
IA	1	O
)	0	O
bolus	0	O
MMC	0	O
injections	0	O
(	0	O
Tmax	1	O
=	0	O
7	0	O
.	0	O
0	0	O
min	0	O
following	0	O
the	0	O
beginning	0	O
of	0	O
MMC	0	O
infusion	0	O
,	0	O
Vss	0	O
=	0	O
0	0	O
.	0	O
57	0	O
1	0	O
/	0	O
kg	0	O
,	0	O
C1	1	O
=	0	O
8	0	O
.	0	O
9	0	O
ml	0	O
/	0	O
min	0	O
.	0	O
kg	0	O
,	0	O
T1	1	O
/	0	O
2	0	O
alpha	0	O
=	0	O
8	0	O
.	0	O
3	0	O
min	0	O
,	0	O
T1	1	O
/	0	O
2	0	O
beta	0	O
=	0	O
58	0	O
.	0	O
6	0	O
min	0	O
).	0	O


The	0	O
goal	0	O
of	0	O
the	0	O
present	0	O
study	0	O
was	0	O
to	0	O
determine	0	O
the	0	O
feasibility	0	O
of	0	O
retrovirus	0	O
mediated	0	O
expression	0	O
of	0	O
rp47phox	0	B
in	0	O
the	0	O
HL60	0	O
and	0	O
U937	0	O
human	0	O
hematopoietic	0	O
cell	0	O
lines	0	O
,	0	O
and	0	O
in	0	O
an	0	O
Epstein	0	O
-	0	O
Barr	0	O
virus	0	O
transformed	0	O
B	1	O
-	0	O
lymphocyte	0	O
cell	0	O
line	0	O
(	0	O
EBV	1	O
-	0	O
BCL	0	O
)	0	O
derived	0	O
from	0	O
a	0	O
p47phox	0	B
-	0	O
deficient	0	O
CGD	1	O
patient	0	O
.	0	O


As	1	O
well	0	O
,	0	O
further	0	O
deletion	0	O
of	0	O
the	0	O
promoter	0	O
region	0	O
to	0	O
nucleotide	0	O
-	0	O
110	0	O
,	0	O
which	0	O
contains	0	O
only	0	O
one	0	O
SF	1	B
-	0	I
1	0	I
binding	0	I
site	0	I
,	0	O
still	0	O
retained	0	O
the	0	O
ability	0	O
to	0	O
respond	0	O
to	0	O
exogenous	0	O
SF	1	B
-	0	I
1	0	I
.	0	O


In	1	O
metabolic	0	O
acidosis	0	O
there	0	O
was	0	O
a	0	O
marked	0	O
stimulation	0	O
when	0	O
clamped	0	O
at	0	O
-	0	O
10	0	O
to	0	O
-	0	O
100	0	O
mV	1	O
.	0	O


Erythema	1	O
exsudativum	0	O
multiforme	0	O
induced	0	O
by	0	O
granulocyte	0	B
colony	0	I
-	0	I
stimulating	0	I
factor	0	I
in	0	O
an	0	O
allogeneic	0	O
peripheral	0	O
blood	0	O
stem	0	O
cell	0	O
donor	0	O
.	0	O


Hierarchy	1	O
of	0	O
protein	0	B
tyrosine	0	I
kinases	0	I
in	0	O
interleukin	0	B
-	0	I
2	0	I
(	0	O
IL	1	B
-	0	I
2	0	I
)	0	O
signaling	0	O
:	0	O
activation	0	O
of	0	O
syk	0	B
depends	0	O
on	0	O
Jak3	0	B
;	0	O
however	0	O
,	0	O
neither	0	O
Syk	0	B
nor	0	O
Lck	0	B
is	0	O
required	0	O
for	0	O
IL	1	B
-	0	I
2	0	I
-	0	O
mediated	0	O
STAT	1	B
activation	0	O
.	0	O


Weaned	0	O
rats	0	O
were	0	O
fed	0	O
a	0	O
normal	0	O
diet	0	O
or	0	O
a	0	O
low	0	O
-	0	O
protein	0	O
,	0	O
low	0	O
-	0	O
energy	0	O
diet	0	O
,	0	O
and	0	O
injected	0	O
with	0	O
saline	0	O
or	0	O
thyroxine	0	O
(	0	O
5	0	O
micrograms	0	O
/	0	O
100	0	O
g	0	O
BW	1	O
)	0	O
for	0	O
22	0	O
days	0	O
.	0	O


In	1	O
addition	0	O
,	0	O
the	0	O
gcd1	0	B
-	0	I
101	0	I
mutation	0	I
suppressed	0	O
the	0	O
low	0	O
translational	0	O
efficiency	0	O
of	0	O
GCN4	0	B
-	0	O
lacZ	0	B
mRNA	1	O
observed	0	O
in	0	O
gcn2	0	B
-	0	I
and	0	O
gcn3	0	B
-	0	I
cells	0	O
.	0	O


Spontaneous	1	O
recovery	0	O
occurs	0	O
within	0	O
30	0	O
min	0	O
to	0	O
2	0	O
hrs	0	O
.	0	O


The	0	O
results	0	O
show	0	O
that	0	O
both	0	O
the	0	O
amino	0	O
and	0	O
carboxy	0	O
termini	0	O
of	0	O
the	0	O
NS1	0	B
protein	0	I
molecule	0	I
and	0	O
the	0	O
cysteines	0	O
at	0	O
residues	0	O
337	0	O
and	0	O
340	0	O
are	0	O
essential	0	O
for	0	O
tubule	0	O
formation	0	O
.	0	O


This	0	O
and	0	O
previous	0	O
results	0	O
suggest	0	O
that	0	O
the	0	O
CRE	0	O
and	0	O
Sp1	0	B
site	0	I
may	0	O
synergistically	0	O
activate	0	O
TH	1	B
transcription	0	O
in	0	O
a	0	O
promoter	0	O
context	0	O
-	0	O
dependent	0	O
manner	0	O
.	0	O


Furthermore	0	O
,	0	O
no	0	O
Shine	0	O
-	0	O
Dalgarno	0	O
sequences	0	O
are	0	O
present	0	O
upstream	0	O
of	0	O
the	0	O
presumed	0	O
translational	0	O
start	0	O
codons	0	O
.	0	O


Current	1	O
diagnostic	0	O
uses	0	O
of	0	O
computerized	0	O
tomography	0	O
in	0	O
clinical	0	O
medicine	0	O
.	0	O


In	1	O
patients	0	O
with	0	O
limited	0	O
disease	0	O
,	0	O
the	0	O
survival	0	O
in	0	O
the	0	O
alternating	0	O
arm	0	O
was	0	O
significantly	0	O
superior	0	O
to	0	O
the	0	O
survival	0	O
in	0	O
the	0	O
CAV	1	O
arm	0	O
(	0	O
P	1	O
=	0	O
.	0	O
014	0	O
)	0	O
or	0	O
the	0	O
survival	0	O
in	0	O
the	0	O
PE	1	O
arm	0	O
(	0	O
P	1	O
=	0	O
.	0	O
023	0	O
).	0	O


After	0	O
a	0	O
year	0	O
of	0	O
planning	0	O
in	0	O
the	0	O
Laboratory	1	O
Assistants	0	O
'	0	O
School	0	O
in	0	O
Stockholm	0	O
:	0	O
new	0	O
education	0	O
for	0	O
laboratory	0	O
assistants	0	O
is	0	O
now	0	O
arranged	0	O


Sings	0	O
which	0	O
are	0	O
indicative	0	O
of	0	O
metaplastic	0	O
erythropoiesis	0	O
are	0	O
absent	0	O
.	0	O


Ras	1	B
is	0	O
not	0	O
associated	0	O
with	0	O
the	0	O
tegument	0	O
.	0	O


I	1	O
.	0	O


To	1	O
study	0	O
the	0	O
mechanisms	0	O
as	0	O
well	0	O
as	0	O
magnitude	0	O
of	0	O
the	0	O
transmembrane	0	O
transfer	0	O
of	0	O
bacterial	0	O
products	0	O
from	0	O
the	0	O
dialysate	0	O
,	0	O
we	0	O
developed	0	O
a	0	O
computerized	0	O
in	0	O
vitro	0	O
dialysis	0	O
model	0	O
which	0	O
provides	0	O
continuous	0	O
pressure	0	O
recording	0	O
from	0	O
the	0	O
arterial	0	O
,	0	O
venous	0	O
,	0	O
dialysate	0	O
inflow	0	O
and	0	O
outflow	0	O
ports	0	O
.	0	O


Recent	0	O
studies	0	O
have	0	O
shown	0	O
the	0	O
rat	0	O
larynx	0	O
to	0	O
be	0	O
an	0	O
important	0	O
organ	0	O
in	0	O
the	0	O
evaluation	0	O
of	0	O
irritancy	0	O
of	0	O
inhaled	0	O
materials	0	O
.	0	O


In	1	O
an	0	O
attempt	0	O
to	0	O
understand	0	O
Wee1	0	B
regulation	0	O
during	0	O
cell	0	O
cycle	0	O
,	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
screening	0	O
was	0	O
used	0	O
to	0	O
identify	0	O
Wee1	0	O
-	0	O
binding	0	O
protein	0	O
(	0	O
s	0	O
).	0	O


Lymphocytes	0	O
from	0	O
all	0	O
3	0	O
species	0	O
yielded	0	O
maximum	0	O
responses	0	O
with	0	O
a	0	O
48	0	O
-	0	O
hour	0	O
prelabel	0	O
and	0	O
12	0	O
-	0	O
to	0	O
-	0	O
16	0	O
hour	0	O
postlabel	0	O
incubation	0	O
period	0	O
at	0	O
41	0	O
C	1	O
and	0	O
1	0	O
:	0	O
20	0	O
blood	0	O
dilution	0	O
.	0	O


Elimination	1	O
of	0	O
the	0	O
inducible	0	O
response	0	O
requires	0	O
simultaneous	0	O
mutation	0	O
of	0	O
both	0	O
sequences	0	O
,	0	O
however	0	O
,	0	O
in	0	O
the	0	O
presence	0	O
of	0	O
an	0	O
intact	0	O
EpRE	0	O
the	0	O
upstream	0	O
AP	1	B
-	0	I
1	0	I
site	0	I
is	0	O
irrelevant	0	O
to	0	O
induction	0	O
.	0	O


The	0	O
cloned	0	O
HindIII	0	B
fragment	0	I
,	0	O
which	0	O
was	0	O
shown	0	O
by	0	O
DNA	1	O
sequence	0	O
analysis	0	O
to	0	O
encode	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
half	0	O
of	0	O
the	0	O
B	1	B
.	0	I
subtilis	0	I
IF2	0	I
protein	0	I
and	0	O
0	0	O
.	0	O
2	0	O
kb	0	O
of	0	O
upstream	0	O
flanking	0	O
sequence	0	O
,	0	O
was	0	O
utilized	0	O
as	0	O
a	0	O
homologous	0	O
probe	0	O
to	0	O
clone	0	O
an	0	O
overlapping	0	O
2	0	B
.	0	I
76	0	I
-	0	I
kb	0	I
ClaI	0	I
chromosomal	0	I
fragment	0	I
containing	0	O
the	0	O
entire	0	B
IF2	0	I
structural	0	I
gene	0	I
.	0	O


Studies	0	O
using	0	O
an	0	O
inhibitor	0	O
or	0	O
a	0	O
mutant	0	B
Lb	1	I
proteinase	0	I
indicated	0	O
that	0	O
stimulation	0	O
of	0	O
IRES	0	O
-	0	O
driven	0	O
translation	0	O
is	0	O
mediated	0	O
via	0	O
proteolysis	0	O
of	0	O
some	0	O
cellular	0	O
component	0	O
(	0	O
s	0	O
).	0	O


The	0	O
Ras	1	B
guanine	0	I
nucleotide	0	I
-	0	I
binding	0	I
protein	0	I
functions	0	O
as	0	O
a	0	O
molecular	0	O
switch	0	O
in	0	O
signalling	0	O
downstream	0	O
of	0	O
protein	0	B
-	0	I
tyrosine	0	I
kinases	0	I
.	0	O


Of	0	O
the	0	O
compounds	0	O
tested	0	O
,	0	O
alpha	0	O
-(	0	O
3	0	O
-	0	O
methyl	0	O
-	0	O
2	0	O
-	0	O
quinoxalinyl	0	O
)-	0	O
N	1	O
-	0	O
methylnitrone	0	O
1	0	O
,	0	O
4	0	O
-	0	O
dioxide	0	O
(	0	O
2	0	O
)	0	O
was	0	O
the	0	O
most	0	O
active	0	O
agent	0	O
in	0	O
vivo	0	O
against	0	O
the	0	O
gram	0	O
-	0	O
negative	0	O
and	0	O
the	0	O
gram	0	O
-	0	O
positive	0	O
organisms	0	O
.	0	O


The	0	O
subunit	0	O
protein	0	O
of	0	O
curli	0	B
was	0	O
highly	0	O
homologous	0	O
at	0	O
its	0	O
amino	0	O
terminus	0	O
to	0	O
SEF	0	B
-	0	I
17	0	I
,	0	O
the	0	O
subunit	0	O
protein	0	O
of	0	O
thin	0	O
,	0	O
aggregative	0	O
fimbriae	0	O
of	0	O
Salmonella	1	O
enteritidis	0	O
27655	0	O
strain	0	O
3b	0	O
,	0	O
suggesting	0	O
that	0	O
these	0	O
fibres	0	O
form	0	O
a	0	O
novel	0	O
class	0	O
of	0	O
surface	0	O
organelles	0	O
on	0	O
enterobacteria	0	O
.	0	O


The	0	O
mature	0	O
AP	1	B
-	0	I
2	0	I
mRNA	1	I
is	0	O
spliced	0	O
from	0	O
7	0	O
exons	0	O
distributed	0	O
over	0	O
a	0	O
region	0	O
of	0	O
18	0	O
kb	0	O
genomic	0	O
DNA	1	O
.	0	O


The	0	O
major	0	O
pathological	0	O
findings	0	O
of	0	O
the	0	O
placenta	0	O
were	0	O
prematuration	0	O
and	0	O
hypoplasia	0	O
.	0	O


Neither	0	O
verapamil	0	O
nor	0	O
nifedipine	0	O
changed	0	O
collateral	0	O
myocardial	0	O
blood	0	O
flow	0	O
from	0	O
0	0	O
.	0	O
10	0	O
+/-	0	O
0	0	O
.	0	O
02	0	O
in	0	O
the	0	O
subendocardium	0	O
and	0	O
0	0	O
.	0	O
17	0	O
+/-	0	O
0	0	O
.	0	O
03	0	O
ml	0	O
/	0	O
min	0	O
/	0	O
g	0	O
in	0	O
the	0	O
subepicardium	0	O
.	0	O


Experiments	0	O
showed	0	O
that	0	O
temporary	0	O
arrest	0	O
of	0	O
pulmonary	0	O
circulation	0	O
under	0	O
conditions	0	O
of	0	O
extracorporeal	0	O
circulation	0	O
is	0	O
attended	0	O
by	0	O
the	0	O
development	0	O
of	0	O
ischemia	0	O
of	0	O
the	0	O
respiratory	0	O
pulmonary	0	O
tissue	0	O
.	0	O


The	0	O
yeast	0	O
silent	0	B
information	0	I
regulator	0	I
Sir4p	0	I
anchors	0	O
and	0	O
partitions	0	O
plasmids	0	O
.	0	O


Splice	1	O
-	0	O
junction	0	O
elements	0	O
and	0	O
intronic	0	O
sequences	0	O
regulate	0	O
alternative	0	O
splicing	0	O
of	0	O
the	0	O
Drosophila	1	O
myosin	0	B
heavy	0	I
chain	0	I
gene	0	I
transcript	0	O
.	0	O


Competitionsupershift	0	O
EMSA	0	O
assays	0	O
revealed	0	O
that	0	O
multiple	0	O
proteins	0	O
were	0	O
involved	0	O
in	0	O
bandshift	0	O
complex	0	O
formation	0	O
with	0	O
KCS	0	B
,	0	O
one	0	O
of	0	O
which	0	O
was	0	O
identified	0	O
as	0	O
factor	0	O
Sp1	0	O
.	0	O


Some	0	O
of	0	O
them	0	O
produce	0	O
gigantic	0	O
sperm	0	O
several	0	O
times	0	O
the	0	O
total	0	O
male	0	O
body	0	O
length	0	O
.	0	O


The	0	O
Scm	1	B
and	0	O
ph	0	B
proteins	0	O
share	0	O
a	0	O
homology	0	O
domain	0	O
with	0	O
38	0	O
%	0	O
identity	0	O
over	0	O
a	0	O
length	0	O
of	0	O
65	0	O
amino	0	O
acids	0	O
,	0	O
termed	0	O
the	0	O
SPM	0	O
domain	0	O
,	0	O
that	0	O
is	0	O
located	0	O
at	0	O
their	0	O
respective	0	O
C	1	O
termini	0	O
.	0	O


The	0	O
deduced	0	O
amino	0	O
acid	0	O
sequence	0	O
of	0	O
the	0	O
gene	0	O
has	0	O
significant	0	O
homology	0	O
to	0	O
the	0	O
interferon	0	B
regulatory	0	I
factors	0	I
(	0	O
IRFs	0	B
).	0	O


(	0	O
1992	0	O
)	0	O
Biochemistry	1	O
31	0	O
,	0	O
3351	0	O
-	0	O
3358	0	O
].	0	O


Replacement	1	O
of	0	O
residues	0	O
in	0	O
positions	0	O
+	0	O
3	0	O
(	0	O
His128Asn	0	O
)	0	O
and	0	O
+	0	O
2	0	O
(	0	O
Gln155Lys	0	O
)	0	O
of	0	O
the	0	O
reading	0	O
helices	0	O
of	0	O
fingers	0	O
2	0	O
and	0	O
3	0	O
,	0	O
respectively	0	O
,	0	O
prevented	0	O
binding	0	O
.	0	O


We	0	O
isolated	0	O
a	0	O
ribosomal	0	B
protein	0	I
L18	0	I
by	0	O
interaction	0	O
with	0	O
PKR	0	B
.	0	O


Esophageal	1	O
brush	0	O
cytological	0	O
screening	0	O
was	0	O
undertaken	0	O
and	0	O
blood	0	O
concentrations	0	O
of	0	O
micronutrients	0	O
(	0	O
vitamin	0	O
A	1	O
,	0	O
E	1	O
,	0	O
B12	0	O
,	0	O
folic	0	O
acid	0	O
and	0	O
methionine	0	O
)	0	O
determined	0	O
from	0	O
adults	0	O
at	0	O
risk	0	O
for	0	O
esophageal	0	O
carcinoma	0	O
(	0	O
EC	1	O
)	0	O
in	0	O
Transkei	0	O
and	0	O
Ciskei	0	O
,	0	O
Southern	0	O
Africa	0	O
.	0	O


Overexpression	1	O
of	0	O
BAG	1	B
-	0	I
1	0	I
also	0	O
protected	0	O
certain	0	O
cell	0	O
lines	0	O
from	0	O
heat	0	O
shock	0	O
-	0	O
induced	0	O
cell	0	O
death	0	O
.	0	O


These	0	O
data	0	O
strongly	0	O
implicate	0	O
the	0	O
normal	0	O
product	0	O
of	0	O
the	0	O
int	0	B
-	0	I
2	0	I
gene	0	I
,	0	O
which	0	O
is	0	O
related	0	O
to	0	O
the	0	O
fibroblast	0	B
growth	0	I
factor	0	I
family	0	I
,	0	O
as	0	O
a	0	O
contributory	0	O
factor	0	O
in	0	O
virally	0	O
induced	0	O
mammary	0	O
tumors	0	O
.	0	O


The	0	O
only	0	O
isolate	0	O
of	0	O
Aeromonas	1	O
hydrophila	0	O
produced	0	O
cytotoxic	0	O
enterotoxin	0	O
and	0	O
was	0	O
invasive	0	O
.	0	O


Selenium	1	O
,	0	O
as	0	O
a	0	O
constituent	0	O
of	0	O
glutathione	0	B
peroxidase	0	I
,	0	O
plays	0	O
a	0	O
role	0	O
in	0	O
the	0	O
antioxidant	0	O
defense	0	O
systems	0	O
of	0	O
the	0	O
body	0	O
,	0	O
but	0	O
other	0	O
metabolic	0	O
roles	0	O
for	0	O
selenium	0	O
may	0	O
yet	0	O
be	0	O
discovered	0	O
.	0	O


PNRC	0	B
:	0	O
a	0	O
proline	0	O
-	0	O
rich	0	O
nuclear	0	O
receptor	0	O
coregulatory	0	O
protein	0	O
that	0	O
modulates	0	O
transcriptional	0	O
activation	0	O
of	0	O
multiple	0	O
nuclear	0	O
receptors	0	O
including	0	O
orphan	0	O
receptors	0	O
SF1	0	B
(	0	O
steroidogenic	0	B
factor	0	I
1	0	I
)	0	O
and	0	O
ERRalpha1	0	B
(	0	O
estrogen	0	B
related	0	I
receptor	0	I
alpha	0	I
-	0	I
1	0	I
).	0	O


Thus	0	O
,	0	O
the	0	O
active	0	O
-	0	O
site	0	O
mutation	0	O
prevents	0	O
the	0	O
wild	0	O
-	0	O
type	0	O
processing	0	O
of	0	O
the	0	O
N	1	O
-	0	O
glycosylated	0	O
73	0	O
-	0	O
kDa	1	O
precursor	0	O
of	0	O
PrB	0	B
to	0	O
the	0	O
41	0	B
.	0	I
5	0	I
kDa	1	I
pro	0	I
-	0	I
PrB	0	I
in	0	O
the	0	O
endoplasmic	0	O
reticulum	0	O
.	0	O


DNA	1	O
sequence	0	O
analysis	0	O
revealed	0	O
that	0	O
these	0	O
clones	0	O
encode	0	O
two	0	O
distinct	0	O
forms	0	O
of	0	O
translocase	0	B
.	0	O


Sterile	1	O
mutants	0	O
of	0	O
Saccharomyces	1	O
cerevisiae	0	O
were	0	O
isolated	0	O
from	0	O
alpha	0	O
*	0	O
cells	0	O
having	0	O
the	0	O
a	0	B
/	0	I
alpha	0	I
aar1	0	I
-	0	I
6	0	I
genotype	0	O
(	0	O
exhibiting	0	O
alpha	0	O
mating	0	O
ability	0	O
and	0	O
weak	0	O
a	0	O
mating	0	O
ability	0	O
as	0	O
a	0	O
result	0	O
of	0	O
a	0	O
defect	0	O
in	0	O
a1	0	B
-	0	I
alpha	0	I
2	0	I
repression	0	O
).	0	O


The	0	O
monoexponential	0	O
rate	0	O
of	0	O
clearance	0	O
of	0	O
tracer	0	O
--	0	O
obtained	0	O
from	0	O
the	0	O
portion	0	O
of	0	O
the	0	O
residue	0	O
-	0	O
detection	0	O
curve	0	O
reflecting	0	O
metabolism	0	O
of	0	O
fatty	0	O
acid	0	O
incorporated	0	O
into	0	O
neutral	0	O
lipids	0	O
--	0	O
correlated	0	O
directly	0	O
with	0	O
induced	0	O
changes	0	O
in	0	O
tension	0	O
-	0	O
time	0	O
index	0	O
after	0	O
injections	0	O
into	0	O
the	0	O
left	0	O
atrium	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
96	0	O
,	0	O
n	0	O
=	0	O
12	0	O
),	0	O
right	0	O
atrium	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
86	0	O
,	0	O
n	0	O
=	0	O
14	0	O
),	0	O
and	0	O
ear	0	O
vein	0	O
(	0	O
r	0	O
=	0	O
0	0	O
.	0	O
93	0	O
,	0	O
n	0	O
=	0	O
14	0	O
).	0	O


In	1	O
contrast	0	O
,	0	O
rats	0	O
receiving	0	O
U74500A	0	O
(	0	O
2	0	O
mg	0	O
/	0	O
kg	0	O
i	0	O
.	0	O
v	0	O
.	0	O
infusion	0	O
commencing	0	O
30	0	O
min	0	O
prior	0	O
to	0	O
revascularisation	0	O
)	0	O
exhibited	0	O
enhanced	0	O
GMBF	0	O
throughout	0	O
reperfusion	0	O
[	0	O
PI	1	O
10	0	O
min	0	O
:	0	O
3	0	O
.	0	O
26	0	O
(	0	O
2	0	O
.	0	O
56	0	O
-	0	O
3	0	O
.	0	O
63	0	O
);	0	O
120	0	O
min	0	O
:	0	O
2	0	O
.	0	O
03	0	O
(	0	O
1	0	O
.	0	O
73	0	O
-	0	O
2	0	O
.	0	O
25	0	O
);	0	O
240	0	O
min	0	O
:	0	O
2	0	O
.	0	O
13	0	O
(	0	O
1	0	O
.	0	O
75	0	O
-	0	O
2	0	O
.	0	O
44	0	O
),	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
vs	0	O
.	0	O
controls	0	O
and	0	O
normals	0	O
]	0	O
with	0	O
complete	0	O
muscle	0	O
salvage	0	O
[	0	O
GMV	0	O
100	0	O
%	0	O
in	0	O
all	0	O
reperfused	0	O
muscles	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
vs	0	O
.	0	O
controls	0	O
,	0	O
not	0	O
significant	0	O
(	0	O
NS	1	O
)	0	O
vs	0	O
.	0	O
normals	0	O
and	0	O
6	0	O
h	0	O
ischaemia	0	O
].(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


Cerebral	1	O
vasculitis	0	O
secondary	0	O
to	0	O
Crohn	0	O
'	0	O
s	0	O
disease	0	O
seems	0	O
to	0	O
be	0	O
a	0	O
very	0	O
rare	0	O
phenomenon	0	O
.	0	O


We	0	O
have	0	O
applied	0	O
the	0	O
mRNA	1	O
differential	0	O
display	0	O
method	0	O
to	0	O
compare	0	O
and	0	O
analyze	0	O
mRNAs	0	O
prepared	0	O
from	0	O
five	0	O
normal	0	O
nasopharyngeal	0	O
epithelial	0	O
cell	0	O
cultures	0	O
and	0	O
five	0	O
nasopharyngeal	0	O
carcinoma	0	O
cell	0	O
lines	0	O
.	0	O


Patients	0	O
were	0	O
randomly	0	O
assigned	0	O
to	0	O
treatment	0	O
with	0	O
the	0	O
ACE	1	B
inhibitor	0	O
perindopril	0	O
(	0	O
and	0	O
the	0	O
diuretic	0	O
indapamide	0	O
for	0	O
those	0	O
with	0	O
no	0	O
definite	0	O
indication	0	O
for	0	O
or	0	O
contraindication	0	O
to	0	O
treatment	0	O
with	0	O
a	0	O
diuretic	0	O
)	0	O
or	0	O
matching	0	O
placebo	0	O
(	0	O
s	0	O
).	0	O


At	1	O
least	0	O
some	0	O
of	0	O
the	0	O
difference	0	O
in	0	O
stability	0	O
of	0	O
the	0	O
two	0	O
kinds	0	O
of	0	O
complexes	0	O
was	0	O
due	0	O
to	0	O
the	0	O
fact	0	O
that	0	O
the	0	O
dissociation	0	O
rate	0	O
of	0	O
the	0	O
A	1	O
stem	0	O
substrate	0	O
from	0	O
the	0	O
protein	0	O
-	0	O
DNA	1	O
complexes	0	O
was	0	O
approximately	0	O
fourfold	0	O
faster	0	O
than	0	O
that	0	O
of	0	O
the	0	O
complete	0	O
TR	1	B
.	0	O


In	1	O
these	0	O
cells	0	O
,	0	O
ras	0	B
-	0	O
induced	0	O
transition	0	O
is	0	O
accompanied	0	O
by	0	O
a	0	O
strong	0	O
induction	0	O
of	0	O
AP	1	B
-	0	I
1	0	I
-	0	O
binding	0	O
activity	0	O
along	0	O
with	0	O
increased	0	O
expression	0	O
of	0	O
CD44	0	B
mRNA	1	I
and	0	O
protein	0	O
.	0	O


The	0	O
1	0	O
.	0	O
1	0	O
-	0	O
and	0	O
1	0	O
.	0	O
3	0	O
-	0	O
kb	0	O
mRNA	1	O
species	0	O
were	0	O
found	0	O
only	0	O
in	0	O
the	0	O
heart	0	O
,	0	O
and	0	O
the	0	O
2	0	O
.	0	O
6	0	O
-	0	O
kb	0	O
species	0	O
was	0	O
found	0	O
in	0	O
the	0	O
heart	0	O
,	0	O
kidney	0	O
and	0	O
brain	0	O
,	0	O
but	0	O
not	0	O
in	0	O
skeletal	0	O
muscle	0	O
or	0	O
liver	0	O
.	0	O


Hypothalamic	0	O
control	0	O
of	0	O
coronary	0	O
circulation	0	O
in	0	O
the	0	O
dog	0	O
.	0	O


The	0	O
'	0	O
field	0	O
of	0	O
stress	0	O
'	0	O
of	0	O
the	0	O
supervisory	0	O
nurse	0	O


During	0	O
exercise	0	O
,	0	O
the	0	O
Pes	1	O
-	0	O
Ves	0	O
relation	0	O
was	0	O
shifted	0	O
toward	0	O
the	0	O
left	0	O
and	0	O
the	0	O
slope	0	O
[	0	O
end	0	O
-	0	O
systolic	0	O
elastance	0	O
(	0	O
Ees	0	O
)]	0	O
increased	0	O
from	0	O
7	0	O
.	0	O
7	0	O
+/-	0	O
2	0	O
.	0	O
8	0	O
to	0	O
12	0	O
.	0	O
7	0	O
+/-	0	O
4	0	O
.	0	O
2	0	O
(	0	O
SD	1	O
)	0	O
mmHg	0	O
/	0	O
ml	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Alterations	0	O
of	0	O
the	0	O
5q23	0	O
-	0	O
q31	0	O
interval	0	O
are	0	O
frequently	0	O
observed	0	O
in	0	O
myelodysplasia	0	O
and	0	O
myeloid	0	O
leukemia	0	O
.	0	O


Replacement	1	O
of	0	O
the	0	O
spacer	0	O
sequence	0	O
between	0	O
the	0	O
two	0	O
ARMs	0	O
with	0	O
a	0	O
shorter	0	O
stretch	0	O
of	0	O
sequence	0	O
also	0	O
reduced	0	O
RNA	1	O
binding	0	O
in	0	O
vitro	0	O
.	0	O


When	0	O
the	0	O
CO2	1	O
content	0	O
reached	0	O
9	0	O
Vol	1	O
%	0	O
the	0	O
animals	0	O
became	0	O
apathic	0	O
and	0	O
lost	0	O
body	0	O
weight	0	O
.	0	O


Skin	1	O
and	0	O
bowel	0	O
TPO2	0	O
varied	0	O
with	0	O
DO2	0	O
and	0	O
each	0	O
other	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
05	0	O
).	0	O


Diver	0	O
respiratory	0	O
responses	0	O
to	0	O
a	0	O
tunable	0	O
closed	0	O
-	0	O
circuit	0	O
breathing	0	O
apparatus	0	O
.	0	O


Instead	0	O
,	0	O
some	0	O
small	0	O
negative	0	O
effects	0	O
are	0	O
observed	0	O
,	0	O
particularly	0	O
involving	0	O
effects	0	O
of	0	O
husbands	0	O
'	0	O
retirement	0	O
on	0	O
the	0	O
marital	0	O
satisfaction	0	O
of	0	O
employed	0	O
wives	0	O
.	0	O


The	0	O
partial	0	O
sequence	0	O
of	0	O
the	0	O
62	0	B
-	0	I
kDa	1	I
nuclear	0	I
pore	0	I
glycoprotein	0	I
shows	0	O
little	0	O
similarity	0	O
to	0	O
other	0	O
characterized	0	O
proteins	0	O
and	0	O
elucidates	0	O
structural	0	O
features	0	O
of	0	O
a	0	O
member	0	O
of	0	O
the	0	O
family	0	O
of	0	O
nuclear	0	B
pore	0	I
glycoproteins	0	I
.	0	O


Magnetic	1	O
resonance	0	O
spectroscopy	0	O
(	0	O
MRS	0	O
)	0	O
and	0	O
imaging	0	O
(	0	O
MRI	1	O
)	0	O
are	0	O
now	0	O
well	0	O
established	0	O
techniques	0	O
for	0	O
the	0	O
study	0	O
of	0	O
cellular	0	O
metabolism	0	O
and	0	O
gross	0	O
structure	0	O
of	0	O
muscle	0	O
.	0	O


There	0	O
were	0	O
27	0	O
men	0	O
and	0	O
156	0	O
women	0	O
.	0	O


Diltiazem	1	O
decreased	0	O
the	0	O
total	0	O
body	0	O
clearance	0	O
from	0	O
34	0	O
.	0	O
0	0	O
+/-	0	O
8	0	O
.	0	O
0	0	O
to	0	O
28	0	O
.	0	O
6	0	O
+/-	0	O
6	0	O
.	0	O
1	0	O
mL	1	O
/	0	O
min	0	O
(	0	O
P	1	O
less	0	O
than	0	O
.	0	O
01	0	O
),	0	O
and	0	O
prolonged	0	O
the	0	O
elimination	0	O
half	0	O
-	0	O
life	0	O
from	0	O
12	0	O
.	0	O
6	0	O
+/-	0	O
3	0	O
.	0	O
0	0	O
to	0	O
14	0	O
.	0	O
3	0	O
+/-	0	O
2	0	O
.	0	O
5	0	O
hours	0	O
(	0	O
P	1	O
less	0	O
than	0	O
.	0	O
01	0	O
)	0	O
of	0	O
antipyrine	0	O
without	0	O
any	0	O
changes	0	O
in	0	O
volume	0	O
of	0	O
distribution	0	O
.	0	O


ZEBRA	0	B
and	0	O
cellular	0	O
AP	1	B
-	0	I
1	0	I
bZip	0	I
activators	0	I
,	0	O
such	0	O
as	0	O
c	0	B
-	0	I
Fos	1	I
,	0	O
have	0	O
homologous	0	O
DNA	1	O
-	0	O
binding	0	O
domains	0	O
,	0	O
and	0	O
their	0	O
DNA	1	O
-	0	O
binding	0	O
specificities	0	O
overlap	0	O
.	0	O


Equine	1	O
amnion	0	O
and	0	O
live	0	O
yeast	0	O
cell	0	O
derivative	0	O
were	0	O
evaluated	0	O
as	0	O
a	0	O
biological	0	O
dressing	0	O
and	0	O
as	0	O
a	0	O
topical	0	O
wound	0	O
medicament	0	O
respectively	0	O
,	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
granulating	0	O
wounds	0	O
of	0	O
the	0	O
distal	0	O
portion	0	O
of	0	O
the	0	O
limbs	0	O
of	0	O
horses	0	O
.	0	O


Of	0	O
110	0	O
previously	0	O
untreated	0	O
patients	0	O
who	0	O
had	0	O
entered	0	O
the	0	O
study	0	O
of	0	O
protocol	0	O
TCL821	0	O
,	0	O
96	0	O
were	0	O
evaluable	0	O
.	0	O


The	0	O
hemodynamics	0	O
of	0	O
isoproterenol	0	O
-	0	O
induced	0	O
cardiac	0	O
failure	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


The	0	O
physical	0	O
and	0	O
chemical	0	O
stability	0	O
of	0	O
a	0	O
combination	0	O
of	0	O
drugs	0	O
commonly	0	O
administered	0	O
into	0	O
the	0	O
epidural	0	O
or	0	O
intrathecal	0	O
space	0	O
for	0	O
the	0	O
treatment	0	O
of	0	O
chronic	0	O
pain	0	O
was	0	O
investigated	0	O
.	0	O


Human	1	O
T	1	O
-	0	O
cell	0	O
leukemia	0	O
virus	0	O
type	0	O
I	1	O
(	0	O
HTLV	0	O
-	0	O
I	1	O
)	0	O
encodes	0	O
a	0	O
40	0	O
-	0	O
kDa	1	O
nuclear	0	O
protein	0	O
,	0	O
Tax	0	B
,	0	O
which	0	O
stimulates	0	O
transcription	0	O
from	0	O
three	0	O
21	0	O
-	0	O
base	0	O
pair	0	O
(	0	O
bp	0	O
)	0	O
repeats	0	O
in	0	O
its	0	O
U3	0	O
region	0	O
.	0	O


c	0	B
-	0	I
Fos	1	I
transcriptional	0	O
activity	0	O
stimulated	0	O
by	0	O
H	1	B
-	0	I
Ras	1	I
-	0	I
activated	0	I
protein	0	I
kinase	0	I
distinct	0	O
from	0	O
JNK	0	B
and	0	O
ERK	0	B
.	0	O


Using	0	O
this	0	O
method	0	O
,	0	O
VLPs	0	O
were	0	O
obtained	0	O
in	0	O
quantities	0	O
sufficient	0	O
for	0	O
further	0	O
characterization	0	O
.	0	O


Bupropion	1	O
to	0	O
aid	0	O
smoking	0	O
cessation	0	O
.	0	O


In	1	O
this	0	O
article	0	O
we	0	O
propose	0	O
to	0	O
find	0	O
out	0	O
the	0	O
percentage	0	O
of	0	O
normal	0	O
occlusion	0	O
and	0	O
the	0	O
distribution	0	O
of	0	O
maloclusions	0	O
,	0	O
according	0	O
to	0	O
the	0	O
anteroposterior	0	O
relationship	0	O
between	0	O
the	0	O
dental	0	O
archs	0	O
(	0	O
following	0	O
the	0	O
ANGLE3	0	O
classification	0	O
).	0	O


Pilot	0	O
study	0	O
of	0	O
blood	0	O
coagulation	0	O
in	0	O
gout	0	O
patients	0	O
.	0	O


Since	0	O
we	0	O
have	0	O
observed	0	O
effects	0	O
of	0	O
growth	0	O
factors	0	O
and	0	O
cAMP	1	O
as	0	O
well	0	O
as	0	O
estradiol	0	O
(	0	O
E2	1	O
)	0	O
on	0	O
regulation	0	O
of	0	O
expression	0	O
of	0	O
some	0	O
genes	0	O
stimulated	0	O
by	0	O
the	0	O
estrogen	0	B
receptor	0	I
(	0	O
ER	1	B
),	0	O
we	0	O
have	0	O
undertaken	0	O
studies	0	O
to	0	O
examine	0	O
directly	0	O
whether	0	O
activators	0	O
of	0	O
protein	0	O
kinases	0	O
can	0	O
modulate	0	O
transcriptional	0	O
activity	0	O
of	0	O
the	0	O
ER	1	B
.	0	O


Investigation	0	O
of	0	O
the	0	O
control	0	O
of	0	O
coronavirus	0	O
subgenomic	0	O
mRNA	1	O
transcription	0	O
by	0	O
using	0	O
T7	0	O
-	0	O
generated	0	O
negative	0	O
-	0	O
sense	0	O
RNA	1	O
transcripts	0	O
.	0	O


For	0	O
228	0	O
of	0	O
425	0	O
deaths	0	O
(	0	O
54	0	O
%)	0	O
occurring	0	O
among	0	O
26	0	O
100	0	O
people	0	O
of	0	O
known	0	O
age	0	O
in	0	O
the	0	O
Malumfashi	0	O
area	0	O
of	0	O
northern	0	O
Nigeria	0	O
,	0	O
data	0	O
were	0	O
collected	0	O
on	0	O
symptoms	0	O
present	0	O
prior	0	O
to	0	O
death	0	O
.	0	O


The	0	O
relative	0	O
importance	0	O
of	0	O
these	0	O
two	0	O
mechanisms	0	O
differed	0	O
in	0	O
a	0	O
response	0	O
element	0	O
-	0	O
specific	0	O
manner	0	O
.	0	O


Body	1	O
temperature	0	O
and	0	O
overall	0	O
conductance	0	O
in	0	O
the	0	O
cold	0	O
appear	0	O
to	0	O
be	0	O
more	0	O
variable	0	O
in	0	O
P	1	O
.	0	O
s	0	O
.	0	O
campbelli	0	O
than	0	O
in	0	O
nominative	0	O
sp	0	O
.	0	O


RESULTS	0	O
:	0	O
Prevalence	1	O
of	0	O
obesity	0	O
(	0	O
BMI	1	O
SDS	1	O
>	0	O
2	0	O
.	0	O
0	0	O
)	0	O
was	0	O
<	0	O
2	0	O
%	0	O
at	0	O
diagnosis	0	O
,	0	O
but	0	O
increased	0	O
to	0	O
16	0	O
%	0	O
at	0	O
3y	0	O
.	0	O


Using	0	O
a	0	O
v	0	B
-	0	I
erbA	0	I
probe	0	O
,	0	O
we	0	O
obtained	0	O
a	0	O
cDNA	1	O
which	0	O
encodes	0	O
a	0	O
novel	0	O
445	0	O
-	0	O
amino	0	O
-	0	O
acid	0	O
protein	0	O
,	0	O
RLD	0	B
-	0	I
1	0	I
,	0	O
that	0	O
contains	0	O
the	0	O
characteristic	0	O
domains	0	O
of	0	O
nuclear	0	O
receptors	0	O
.	0	O


Variations	0	O
of	0	O
the	0	O
timing	0	O
of	0	O
deflections	0	O
in	0	O
the	0	O
His	1	O
bundle	0	O
recordings	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
food	0	O
on	0	O
procainamide	0	O
absorption	0	O
.	0	O


On	1	O
the	0	O
other	0	O
hand	0	O
,	0	O
knowledge	0	O
of	0	O
the	0	O
epidemiology	0	O
of	0	O
Parkinson	0	O
'	0	O
s	0	O
disease	0	O
is	0	O
necessary	0	O
in	0	O
creating	0	O
etiological	0	O
hypotheses	0	O
,	0	O
since	0	O
only	0	O
hypotheses	0	O
consistent	0	O
with	0	O
the	0	O
epidemiological	0	O
profile	0	O
deserve	0	O
careful	0	O
testing	0	O
.	0	O


A	1	O
cDNA	1	O
clone	0	O
was	0	O
identified	0	O
encoding	0	O
a	0	O
second	0	O
GHS	0	B
-	0	I
R	1	I
-	0	I
related	0	I
gene	0	I
(	0	O
GPR39	0	B
).	0	O


The	0	O
chromosomal	0	O
localization	0	O
on	0	O
distal	0	O
chromosome	0	O
7	0	O
places	0	O
it	0	O
in	0	O
a	0	O
cluster	0	O
of	0	O
imprinted	0	O
genes	0	O
,	0	O
flanked	0	O
by	0	O
the	0	O
previously	0	O
described	0	O
Tapa1	0	B
and	0	O
Kcnq1	0	B
genes	0	I
.	0	O


The	0	O
protein	0	O
encoded	0	O
by	0	O
the	0	O
fruA	0	B
transcript	0	I
is	0	O
well	0	O
conserved	0	O
with	0	O
the	0	O
D	1	B
.	0	I
melanogaster	0	I
type	0	I
A	1	I
protein	0	I
,	0	O
particularly	0	O
the	0	O
BTB	0	B
protein	0	I
-	0	O
protein	0	O
-	0	O
binding	0	O
domain	0	O
,	0	O
which	0	O
is	0	O
encoded	0	O
by	0	O
exons	0	O
I	1	O
and	0	O
II	0	O
and	0	O
is	0	O
100	0	O
%	0	O
conserved	0	O
.	0	O


To	1	O
explore	0	O
the	0	O
functional	0	O
properties	0	O
of	0	O
the	0	O
protein	0	O
encoded	0	O
by	0	O
neu	0	B
,	0	O
we	0	O
created	0	O
a	0	O
fusion	0	O
gene	0	O
that	0	O
joins	0	O
the	0	O
cytoplasmic	0	O
domain	0	O
of	0	O
neu	0	B
to	0	O
the	0	O
extracellular	0	O
portion	0	O
of	0	O
an	0	O
immunoglobulin	0	B
heavy	0	I
chain	0	I
.	0	O


In	1	O
this	0	O
respect	0	O
C	1	B
reactive	0	I
protein	0	I
concentrations	0	O
are	0	O
superior	0	O
to	0	O
white	0	O
cell	0	O
count	0	O
,	0	O
erythrocyte	0	O
sedimentation	0	O
rate	0	O
,	0	O
and	0	O
temperature	0	O
and	0	O
the	0	O
concentrations	0	O
of	0	O
antiproteases	0	O
.	0	O


A	1	O
comparative	0	O
study	0	O
of	0	O
the	0	O
cortical	0	O
end	0	O
of	0	O
the	0	O
auditory	0	O
analyzer	0	O
during	0	O
postnatal	0	O
ontogenesis	0	O
in	0	O
lower	0	O
monkeys	0	O
and	0	O
man	0	O


The	0	O
cpc	0	B
-	0	I
1	0	I
-	0	I
encoded	0	I
transcript	0	I
contains	0	O
three	0	O
open	0	O
reading	0	O
frames	0	O
,	0	O
two	0	O
of	0	O
which	0	O
are	0	O
located	0	O
in	0	O
the	0	O
720	0	O
-	0	O
nucleotide	0	O
leader	0	O
segment	0	O
preceding	0	O
the	0	O
cpc	0	B
-	0	I
1	0	I
coding	0	I
region	0	I
.	0	O


Volunteers	0	O
were	0	O
irradiated	0	O
on	0	O
their	0	O
backs	0	O
with	0	O
suberythemal	0	O
UV	1	O
daily	0	O
for	0	O
5	0	O
d	0	O
after	0	O
application	0	O
of	0	O
the	0	O
sunscreens	0	O
and	0	O
their	0	O
base	0	O
lotion	0	O
to	0	O
different	0	O
sites	0	O
.	0	O


With	0	O
respect	0	O
to	0	O
the	0	O
distribution	0	O
of	0	O
active	0	O
MREs	0	O
over	0	O
the	0	O
promoter	0	O
region	0	O
,	0	O
the	0	O
hMT	0	B
-	0	I
IIA	0	I
gene	0	I
is	0	O
largely	0	O
different	0	O
from	0	O
the	0	O
mouse	0	O
metallothionein	0	B
-	0	I
I	1	I
gene	0	I
,	0	O
suggesting	0	O
that	0	O
MRE	0	O
arrangement	0	O
is	0	O
not	0	O
an	0	O
important	0	O
factor	0	O
for	0	O
metal	0	O
regulation	0	O
.	0	O


The	0	O
need	0	O
in	0	O
the	0	O
small	0	O
hospital	0	O
.	0	O


Fifty	0	O
-	0	O
eight	0	O
RMI	0	O
'	0	O
s	0	O
occurred	0	O
in	0	O
the	0	O
placebo	0	O
group	0	O
as	0	O
compared	0	O
to	0	O
only	0	O
twenty	0	O
in	0	O
the	0	O
AC	1	O
group	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
01	0	O
).	0	O


According	0	O
to	0	O
their	0	O
functional	0	O
properties	0	O
the	0	O
latter	0	O
neurons	0	O
were	0	O
subdivided	0	O
into	0	O
:	0	O
(	0	O
a	0	O
)	0	O
neurons	0	O
responding	0	O
to	0	O
stimuli	0	O
near	0	O
the	0	O
eyes	0	O
;	0	O
(	0	O
b	0	O
)	0	O
neurons	0	O
triggered	0	O
by	0	O
complex	0	O
visual	0	O
stimuli	0	O
;	0	O
(	0	O
c	0	O
)	0	O
neurons	0	O
inhibited	0	O
by	0	O
visual	0	O
stimuli	0	O
.	0	O


Examination	1	O
of	0	O
the	0	O
mitochondrial	0	B
bc1	0	I
complex	0	I
crystal	0	I
structure	0	I
[	0	O
Zhang	0	O
,	0	O
Z	1	O
.,	0	O
Huang	0	O
,	0	O
L	1	O
.,	0	O
Shulmeister	0	O
,	0	O
V	1	O
.	0	O


Plasma	1	O
concentrations	0	O
of	0	O
atracurium	0	O
and	0	O
laudanosine	0	O
were	0	O
0	0	O
.	0	O
73	0	O
-	0	O
3	0	O
.	0	O
11	0	O
micrograms	0	O
ml	0	O
-	0	O
1	0	O
and	0	O
0	0	O
.	0	O
48	0	O
-	0	O
8	0	O
.	0	O
65	0	O
micrograms	0	O
ml	0	O
-	0	O
1	0	O
,	0	O
respectively	0	O
;	0	O
CSF	1	O
concentration	0	O
of	0	O
laudanosine	0	O
was	0	O
70	0	O
-	0	O
440	0	O
ng	0	O
ml	0	O
-	0	O
1	0	O
.	0	O


Further	0	O
research	0	O
is	0	O
recommended	0	O
to	0	O
identify	0	O
the	0	O
coping	0	O
styles	0	O
associated	0	O
with	0	O
the	0	O
high	0	O
EE	1	O
/	0	O
low	0	O
EE	1	O
research	0	O
classification	0	O
.	0	O


The	0	O
revertant	0	O
TATA	0	O
boxes	0	O
accelerated	0	O
the	0	O
kinetics	0	O
of	0	O
HIV	1	O
replication	0	O
when	0	O
present	0	O
in	0	O
the	0	O
context	0	O
of	0	O
an	0	O
LTR	1	O
containing	0	O
a	0	O
Sp1	0	B
mutation	0	O
(	0	O
deletion	0	O
or	0	O
site	0	O
specific	0	O
);	0	O
no	0	O
effect	0	O
was	0	O
observed	0	O
on	0	O
the	0	O
infectivity	0	O
of	0	O
wild	0	O
-	0	O
type	0	O
HIV	1	O
.	0	O


In	1	O
addition	0	O
,	0	O
our	0	O
results	0	O
show	0	O
that	0	O
ERKs	0	B
and	0	O
PI3Ks	0	B
can	0	O
synergise	0	O
to	0	O
convert	0	O
ectoderm	0	O
into	0	O
mesoderm	0	O
.	0	O


This	0	O
machinery	0	O
involves	0	O
a	0	O
secondary	0	O
structure	0	O
,	0	O
SECIS	0	O
element	0	O
,	0	O
in	0	O
the	0	O
selenoprotein	0	B
-	0	O
encoding	0	O
mRNA	1	O
,	0	O
directing	0	O
selenocysteine	0	O
insertion	0	O
at	0	O
the	0	O
position	0	O
of	0	O
an	0	O
opal	0	O
(	0	O
UGA	0	O
)	0	O
codon	0	O
,	0	O
normally	0	O
conferring	0	O
termination	0	O
of	0	O
translation	0	O
.	0	O


Biological	1	O
properties	0	O
of	0	O
sumithion	0	O
.	0	O


The	0	O
IE0	0	B
gene	0	I
product	0	O
also	0	O
transactivated	0	O
the	0	O
IE1	0	B
promoter	0	I
but	0	O
did	0	O
not	0	O
affect	0	O
expression	0	O
from	0	O
its	0	O
own	0	O
promoter	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
sodium	0	O
18	0	O
beta	0	O
-	0	O
glycyrrhetate	0	O
(	0	O
SGA	1	O
)	0	O
on	0	O
experimental	0	O
arrhythmia	0	O
was	0	O
investigated	0	O
.	0	O


In	1	O
this	0	O
study	0	O
,	0	O
we	0	O
identified	0	O
four	0	O
distinct	0	O
E2F	0	B
complexes	0	I
present	0	O
in	0	O
aged	0	O
and	0	O
senescent	0	O
normal	0	O
,	0	O
human	0	O
diploid	0	O
fibroblasts	0	O
.	0	O


However	0	O
,	0	O
we	0	O
did	0	O
detect	0	O
lot	0	O
-	0	O
to	0	O
-	0	O
lot	0	O
variation	0	O
and	0	O
differences	0	O
in	0	O
performance	0	O
between	0	O
narrow	0	O
bandpass	0	O
and	0	O
wide	0	O
bandpass	0	O
spectrophotometers	0	O
.	0	O


Furthermore	0	O
,	0	O
DNA	1	O
-	0	O
bound	0	O
LAZ3	0	B
/	0	O
BCL6	0	B
recruits	0	O
SMRT	0	B
in	0	O
vivo	0	O
,	0	O
and	0	O
both	0	O
overexpressed	0	O
proteins	0	O
completely	0	O
colocalize	0	O
in	0	O
nuclear	0	O
dots	0	O
.	0	O


The	0	O
effect	0	O
of	0	O
feeding	0	O
patterns	0	O
on	0	O
fat	0	O
deposition	0	O
in	0	O
mice	0	O
.	0	O


The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
find	0	O
out	0	O
whether	0	O
it	0	O
was	0	O
possible	0	O
to	0	O
detect	0	O
normal	0	O
lymph	0	O
nodes	0	O
by	0	O
high	0	O
-	0	O
resolution	0	O
mediastinal	0	O
US	1	O
.	0	O


Diagnostic	1	O
value	0	O
of	0	O
adenosine	0	B
deaminase	0	I
activity	0	O
in	0	O
tuberculous	0	O
effusions	0	O
.	0	O


Indoor	0	O
concentrations	0	O
were	0	O
only	0	O
weakly	0	O
correlated	0	O
with	0	O
outdoor	0	O
concentrations	0	O
,	0	O
however	0	O
,	0	O
and	0	O
personal	0	O
exposures	0	O
were	0	O
even	0	O
more	0	O
poorly	0	O
correlated	0	O
with	0	O
outdoor	0	O
concentrations	0	O
.	0	O


As	1	O
expected	0	O
,	0	O
glycosylation	0	O
of	0	O
Env	0	B
produced	0	O
from	0	O
mutants	0	O
was	0	O
affected	0	O
but	0	O
,	0	O
irrespective	0	O
of	0	O
the	0	O
glycosylation	0	O
phenotype	0	O
,	0	O
(	0	O
i	0	O
)	0	O
similar	0	O
quantities	0	O
of	0	O
Env	0	B
were	0	O
synthesized	0	O
,	0	O
(	0	O
ii	0	O
)	0	O
the	0	O
immunoreactivity	0	O
of	0	O
V3	0	B
was	0	O
similar	0	O
,	0	O
(	0	O
iii	0	O
)	0	O
gp160	0	B
was	0	O
efficiently	0	O
cleaved	0	O
into	0	O
gp120	0	B
and	0	O
gp41	0	B
,	0	O
(	0	O
vi	0	O
)	0	O
Env	0	B
was	0	O
exposed	0	O
at	0	O
the	0	O
cell	0	O
membrane	0	O
,	0	O
(	0	O
v	0	O
)	0	O
secreted	0	O
gp120	0	B
bound	0	O
CD4	1	B
,	0	O
and	0	O
(	0	O
vi	0	O
)	0	O
membrane	0	O
gp41	0	B
was	0	O
able	0	O
to	0	O
induce	0	O
membrane	0	O
fusion	0	O
with	0	O
CD4	1	B
+	0	I
cells	0	O
.	0	O


1	0	O
The	0	O
effects	0	O
in	0	O
normal	0	O
subjects	0	O
of	0	O
a	0	O
single	0	O
oral	0	O
dose	0	O
of	0	O
Motival	0	O
(	0	O
one	0	O
tablet	0	O
,	0	O
containing	0	O
fluphenazine	0	O
0	0	O
.	0	O
5	0	O
mg	0	O
and	0	O
nortriptyline	0	O
10	0	O
mg	0	O
)	0	O
on	0	O
the	0	O
contingent	0	O
negative	0	O
variation	0	O
(	0	O
CNV	1	O
),	0	O
reaction	0	O
time	0	O
,	0	O
heart	0	O
rate	0	O
,	0	O
blood	0	O
pressure	0	O
and	0	O
self	0	O
-	0	O
rating	0	O
scales	0	O
for	0	O
alertness	0	O
,	0	O
anxiety	0	O
,	0	O
tension	0	O
,	0	O
detachment	0	O
and	0	O
depression	0	O
were	0	O
compared	0	O
with	0	O
those	0	O
of	0	O
diazepam	0	O
(	0	O
5	0	O
mg	0	O
and	0	O
7	0	O
.	0	O
5	0	O
mg	0	O
)	0	O
and	0	O
placebo	0	O
or	0	O
propranolol	0	O
(	0	O
60	0	O
mg	0	O
).	0	O


MSSP	0	B
-	0	I
1	0	I
produced	0	O
in	0	O
E	1	O
.	0	O
coli	0	O
as	0	O
a	0	O
fusion	0	O
protein	0	O
with	0	O
GST	0	B
specifically	0	O
interacted	0	O
with	0	O
single	0	O
-	0	O
stranded	0	O
TCTTAT	0	O
(	0	O
plus	0	O
myc	0	B
(	0	O
H	1	O
-	0	O
P	1	O
)	0	O
21	0	O
)	0	O
and	0	O
ACT	1	O
-	0	O
ATT	0	O
(	0	O
in	0	O
minus	0	O
myc	0	B
(	0	O
H	1	O
-	0	O
P	1	O
)	0	O
21	0	O
),	0	O
the	0	O
consensus	0	O
of	0	O
which	0	O
can	0	O
be	0	O
referred	0	O
to	0	O
as	0	O
A	1	O
/	0	O
TCTA	0	O
/	0	O
TA	1	O
/	0	O
TT	1	O
.	0	O


Our	0	O
results	0	O
showed	0	O
that	0	O
compared	0	O
to	0	O
the	0	O
primary	0	O
photon	0	O
fluence	0	O
,	0	O
the	0	O
extra	0	O
-	0	O
focal	0	O
photon	0	O
fluence	0	O
from	0	O
the	0	O
primary	0	O
collimator	0	O
and	0	O
the	0	O
flattening	0	O
filter	0	O
was	0	O
11	0	O
%-	0	O
16	0	O
%	0	O
at	0	O
the	0	O
isocenter	0	O
,	0	O
among	0	O
which	0	O
70	0	O
%	0	O
was	0	O
contributed	0	O
by	0	O
the	0	O
flattening	0	O
filter	0	O
.	0	O


The	0	O
therapeutic	0	O
action	0	O
of	0	O
cyclosporin	0	O
A	1	O
(	0	O
Sandimmun	0	O
):	0	O
its	0	O
application	0	O
in	0	O
rheumatoid	0	O
arthritis	0	O
.	0	O


After	0	O
PTCA	1	O
,	0	O
ejection	0	O
fraction	0	O
increased	0	O
from	0	O
54	0	O
+/-	0	O
8	0	O
%	0	O
to	0	O
59	0	O
+/-	0	O
8	0	O
%	0	O
(	0	O
p	0	O
less	0	O
than	0	O
0	0	O
.	0	O
05	0	O
)	0	O
and	0	O
regional	0	O
function	0	O
improved	0	O
significantly	0	O
(	0	O
maximal	0	O
standard	0	O
deviation	0	O
before	0	O
PTCA	1	O
:	0	O
2	0	O
.	0	O
8	0	O
+/-	0	O
0	0	O
.	0	O
8	0	O
;	0	O
after	0	O
PTCA	1	O
:	0	O
1	0	O
.	0	O
9	0	O
+/-	0	O
0	0	O
.	0	O
9	0	O
-	0	O
segments	0	O
below	0	O
the	0	O
first	0	O
standard	0	O
deviation	0	O
before	0	O
PTCA	1	O
:	0	O
31	0	O
+/-	0	O
16	0	O
;	0	O
after	0	O
PTCA	1	O
:	0	O
19	0	O
+/-	0	O
17	0	O
).	0	O


TMBr	0	B
-	0	I
1	0	I
is	0	O
identical	0	O
to	0	O
striated	0	B
muscle	0	I
alpha	0	I
-	0	I
tropomyosin	0	I
from	0	O
amino	0	O
acids	0	O
1	0	O
through	0	O
258	0	O
but	0	O
contains	0	O
a	0	O
novel	0	O
COOH	0	O
-	0	O
terminal	0	O
region	0	O
from	0	O
amino	0	O
acids	0	O
259	0	O
through	0	O
281	0	O
.	0	O


Results	0	O
of	0	O
this	0	O
study	0	O
indicate	0	O
that	0	O
GLC	1	O
of	0	O
short	0	O
chain	0	O
fatty	0	O
acids	0	O
produced	0	O
on	0	O
agar	0	O
medium	0	O
by	0	O
anaerobes	0	O
,	0	O
combined	0	O
with	0	O
simple	0	O
tests	0	O
such	0	O
as	0	O
Gram	1	O
'	0	O
s	0	O
stain	0	O
and	0	O
colonial	0	O
morphology	0	O
,	0	O
may	0	O
allow	0	O
fir	0	O
direct	0	O
presumptive	0	O
genus	0	O
identification	0	O
from	0	O
an	0	O
initial	0	O
pure	0	O
agar	0	O
culture	0	O
.	0	O


Investigations	0	O
using	0	O
hippocampal	0	O
slices	0	O
maintained	0	O
in	0	O
vitro	0	O
have	0	O
demonstrated	0	O
that	0	O
bursts	0	O
of	0	O
oscillatory	0	O
field	0	O
potentials	0	O
in	0	O
the	0	O
gamma	0	O
frequency	0	O
range	0	O
(	0	O
30	0	O
-	0	O
80	0	O
Hz	1	O
)	0	O
are	0	O
followed	0	O
by	0	O
a	0	O
slower	0	O
oscillation	0	O
in	0	O
the	0	O
beta	0	O
1	0	O
range	0	O
(	0	O
12	0	O
-	0	O
20	0	O
Hz	1	O
).	0	O


CONCLUSION	0	O
:	0	O
In	1	O
our	0	O
animal	0	O
model	0	O
,	0	O
blood	0	O
-	0	O
brain	0	O
barrier	0	O
disruption	0	O
was	0	O
a	0	O
reproducible	0	O
,	0	O
integral	0	O
finding	0	O
of	0	O
single	0	O
-	0	O
fraction	0	O
,	0	O
high	0	O
-	0	O
dose	0	O
irradiation	0	O
injury	0	O
.	0	O


The	0	O
construct	0	O
was	0	O
introduced	0	O
into	0	O
BW2001	0	O
(	0	O
xth	0	O
-	0	O
11	0	O
,	0	O
nfo	0	O
-	0	O
2	0	O
)	0	O
strain	0	O
cells	0	O
of	0	O
Escherichia	1	O
coli	0	O
.	0	O


Repair	1	O
of	0	O
a	0	O
cosmetic	0	O
defect	0	O
of	0	O
the	0	O
lower	0	O
leg	0	O
with	0	O
a	0	O
myocutaneous	0	O
free	0	O
flap	0	O
.	0	O


However	0	O
,	0	O
the	0	O
BCH	0	O
group	0	O
showed	0	O
inferior	0	O
gross	0	O
motor	0	O
performance	0	O
on	0	O
the	0	O
Bruininks	0	O
-	0	O
Oseretsky	0	O
Test	1	O
of	0	O
Motor	1	O
Proficiency	1	O
(	0	O
Bruininks	0	O
1978	0	O
).	0	O


A	1	O
prospective	0	O
observational	0	O
study	0	O
was	0	O
conducted	0	O
to	0	O
identify	0	O
early	0	O
indicators	0	O
of	0	O
acute	0	O
dengue	0	O
virus	0	O
infection	0	O
.	0	O


In	1	O
group	0	O
I	1	O
adults	0	O
both	0	O
of	0	O
these	0	O
variables	0	O
increased	0	O
.	0	O


2	0	O
:	0	O
121	0	O
-	0	O
133	0	O
,	0	O
1988	0	O
).	0	O


In	1	O
HeLa	0	O
x	0	O
fibroblast	0	O
cell	0	O
hybrids	0	O
its	0	O
expression	0	O
correlates	0	O
with	0	O
tumorigenicity	0	O
.	0	O


Discrimination	1	O
between	0	O
HIV	1	O
-	0	O
1	0	O
and	0	O
HIV	1	O
-	0	O
2	0	O
showed	0	O
evidence	0	O
for	0	O
the	0	O
presence	0	O
of	0	O
HIV	1	O
-	0	O
1	0	O
only	0	O
.	0	O


The	0	O
full	0	O
-	0	O
length	0	O
N	1	B
gene	0	I
,	0	O
encoded	0	O
by	0	O
open	0	O
reading	0	O
frame	0	O
7	0	O
,	0	O
was	0	O
cloned	0	O
from	0	O
the	0	O
Canadian	0	O
PRRS	0	O
virus	0	O
,	0	O
PA	1	O
-	0	O
8	0	O
.	0	O


The	0	O
active	0	O
open	0	O
reading	0	O
frame	0	O
in	0	O
the	0	O
clone	0	O
maps	0	O
at	0	O
27	0	O
min	0	O
on	0	O
the	0	O
E	1	O
.	0	O
coli	0	O
chromosome	0	O
and	0	O
is	0	O
identical	0	O
in	0	O
sequence	0	O
to	0	O
a	0	O
wild	0	O
type	0	O
counterpart	0	O
.	0	O


In	1	O
the	0	O
context	0	O
of	0	O
liver	0	O
allograft	0	O
shortage	0	O
,	0	O
our	0	O
results	0	O
suggest	0	O
that	0	O
an	0	O
ELT	0	O
should	0	O
not	0	O
be	0	O
performed	0	O
in	0	O
patients	0	O
with	0	O
cardiac	0	O
failure	0	O
,	0	O
more	0	O
than	0	O
two	0	O
OSF	0	O
,	0	O
or	0	O
an	0	O
APACHE	0	O
II	0	O
score	0	O
higher	0	O
than	0	O
30	0	O
.	0	O


How	0	O
do	0	O
graduates	0	O
of	0	O
different	0	O
types	0	O
of	0	O
programs	0	O
perform	0	O
on	0	O
state	0	O
boards	0	O
?	0	O


3	0	O
cases	0	O


In	1	O
addition	0	O
,	0	O
CaMig1	0	B
formed	0	O
specific	0	O
complexes	0	O
with	0	O
the	0	O
URS1	0	O
region	0	O
of	0	O
the	0	O
S	1	B
.	0	I
cerevisiae	0	I
FBP1	0	I
gene	0	I
.	0	O


Baseline	1	O
data	0	O
were	0	O
obtained	0	O
from	0	O
10	0	O
adults	0	O
.	0	O


Interpersonal	1	O
style	0	O
differences	0	O
among	0	O
drug	0	O
abusers	0	O
were	0	O
explored	0	O
using	0	O
Ryan	0	O
'	0	O
s	0	O
(	0	O
1977	0	O
)	0	O
typological	0	O
system	0	O
of	0	O
FIRO	0	O
-	0	O
B	1	O
interpretation	0	O
.	0	O


Glycemic	1	O
response	0	O
to	0	O
malted	0	O
,	0	O
popped	0	O
and	0	O
roller	0	O
dried	0	O
wheat	0	O
-	0	O
legume	0	O
based	0	O
foods	0	O
in	0	O
normal	0	O
subjects	0	O
.	0	O


Antibodies	0	O
raised	0	O
against	0	O
GST	0	B
mSH2	0	I
-	0	I
B	1	I
identified	0	O
a	0	O
cellular	0	O
protein	0	O
of	0	O
92	0	O
kDa	1	O
that	0	O
was	0	O
not	0	O
found	0	O
to	0	O
be	0	O
phosphorylated	0	O
on	0	O
Tyr	1	O
.	0	O


In	1	O
the	0	O
past	0	O
,	0	O
immunology	0	O
in	0	O
Singapore	0	O
was	0	O
mainly	0	O
confined	0	O
to	0	O
serology	0	O
for	0	O
the	0	O
diagnosis	0	O
of	0	O
certain	0	O
infectious	0	O
diseases	0	O
.	0	O


Like	0	O
the	0	O
p190	0	B
-	0	I
B	1	I
exon	0	O
,	0	O
the	0	O
first	0	O
exon	0	O
of	0	O
p190	0	B
-	0	I
A	1	I
is	0	O
extremely	0	O
large	0	O
(	0	O
3	0	O
.	0	O
7	0	O
kb	0	O
in	0	O
length	0	O
),	0	O
encoding	0	O
both	0	O
the	0	O
GTPase	1	B
and	0	O
middle	0	O
domains	0	O
(	0	O
residues	0	O
1	0	O
-	0	O
1228	0	O
),	0	O
but	0	O
not	0	O
the	0	O
remaining	0	O
GAP	1	B
domain	0	I
,	0	O
suggesting	0	O
a	0	O
high	0	O
conservation	0	O
of	0	O
genomic	0	O
structure	0	O
between	0	O
two	0	O
p190	0	B
genes	0	I
.	0	O


A	1	O
secondary	0	O
phosphorylation	0	O
of	0	O
CREB341	0	B
at	0	O
Ser129	0	O
is	0	O
required	0	O
for	0	O
the	0	O
cAMP	1	O
-	0	O
mediated	0	O
control	0	O
of	0	O
gene	0	O
expression	0	O
.	0	O


Antibodies	0	O
directed	0	O
against	0	O
the	0	O
SNM1	0	B
protein	0	I
immunoprecipitated	0	O
RNase	1	B
MRP	0	I
RNA	1	I
from	0	O
whole	0	O
-	0	O
cell	0	O
extracts	0	O
without	0	O
precipitating	0	O
the	0	O
structurally	0	O
and	0	O
functionally	0	O
related	0	O
RNase	1	B
P	1	I
RNA	1	I
.	0	O


There	0	O
was	0	O
no	0	O
difference	0	O
in	0	O
the	0	O
hormone	0	O
receptor	0	O
status	0	O
between	0	O
the	0	O
cases	0	O
without	0	O
lymph	0	O
node	0	O
metastases	0	O
and	0	O
with	0	O
lymph	0	O
node	0	O
metastases	0	O
,	0	O
'	0	O
clandestine	0	O
'	0	O
or	0	O
macrometastases	0	O
.	0	O


Sequence	1	O
analysis	0	O
of	0	O
these	0	O
genes	0	O
and	0	O
their	0	O
surrounding	0	O
sequences	0	O
are	0	O
presented	0	O
and	0	O
compared	0	O
with	0	O
other	0	O
known	0	O
tRNA	1	O
genes	0	O
from	0	O
plant	0	O
mitochondria	0	O
.	0	O


Naloxone	0	O
(	0	O
2	0	O
mg	0	O
/	0	O
kg	0	O
bolus	0	O
+	0	O
2	0	O
mg	0	O
X	1	O
kg	0	O
-	0	O
1	0	O
X	1	O
h	0	O
-	0	O
1	0	O
)	0	O
was	0	O
given	0	O
with	0	O
one	0	O
of	0	O
the	0	O
two	0	O
doses	0	O
of	0	O
the	0	O
lipopolysaccharide	0	O
.	0	O


Pargyline	0	O
,	0	O
a	0	O
monoamine	0	B
oxidase	0	I
inhibitor	0	O
,	0	O
reduces	0	O
peak	0	O
3	0	O
transiently	0	O
(	0	O
max	0	O
.	0	O


RAS2val19	0	B
,	0	O
a	0	O
dominant	0	O
activated	0	O
form	0	O
of	0	O
Saccharomyces	1	B
cerevisiae	0	I
Ras2	1	I
,	0	O
stimulates	0	O
both	0	O
filamentous	0	O
growth	0	O
and	0	O
expression	0	O
of	0	O
a	0	O
transcriptional	0	O
reporter	0	O
FG	1	B
(	0	O
TyA	0	B
)::	0	O
lacZ	0	B
but	0	O
does	0	O
not	0	O
induce	0	O
the	0	O
mating	0	B
pathway	0	I
reporter	0	I
FUS1	0	I
::	0	O
lacZ	0	B
.	0	O


Steroid	1	O
glucuronides	0	O
in	0	O
amniotic	0	O
fluid	0	O
at	0	O
term	0	O
.	0	O


NH2	0	O
-	0	O
terminal	0	O
trimming	0	O
of	0	O
Xenopus	1	O
and	0	O
mammalian	0	B
FGF3s	0	I
may	0	O
therefore	0	O
be	0	O
a	0	O
prerequisite	0	O
of	0	O
optimal	0	O
biological	0	O
activity	0	O
.	0	O


When	0	O
the	0	O
downstream	0	O
operator	0	O
was	0	O
altered	0	O
,	0	O
there	0	O
was	0	O
a	0	O
fourfold	0	O
reduction	0	O
in	0	O
reporter	0	O
enzyme	0	O
levels	0	O
.	0	O


The	0	O
GAC1	0	B
gene	0	I
encodes	0	O
the	0	O
regulatory	0	O
subunit	0	O
for	0	O
a	0	O
type	0	B
1	0	I
serine	0	I
/	0	I
threonine	0	I
phosphoprotein	0	I
phosphatase	0	I
,	0	O
Glc7	0	B
.	0	O


Significant	1	O
GMBF	0	O
reductions	0	O
occurred	0	O
in	0	O
early	0	O
shock	0	O
in	0	O
both	0	O
treatment	0	O
groups	0	O
.	0	O


The	0	O
relationships	0	O
between	0	O
the	0	O
partial	0	O
pressures	0	O
of	0	O
O2	1	O
and	0	O
CO2	1	O
as	0	O
well	0	O
as	0	O
between	0	O
their	0	O
gradients	0	O
,	0	O
become	0	O
stronger	0	O
with	0	O
the	0	O
increase	0	O
of	0	O
the	0	O
ventilation	0	O
-	0	O
perfusion	0	O
ratio	0	O
.	0	O


Pneumothorax	1	O
following	0	O
lung	0	O
abscess	0	O
in	0	O
the	0	O
renal	0	O
transplant	0	O
patient	0	O
.	0	O


METHODS	0	O
:	0	O
We	0	O
obtained	0	O
maximal	0	O
inspiratory	0	O
and	0	O
expiratory	0	O
flow	0	O
-	0	O
volume	0	O
curves	0	O
in	0	O
41	0	O
unselected	0	O
patients	0	O
with	0	O
essential	0	O
tremor	0	O
(	0	O
14	0	O
males	0	O
,	0	O
27	0	O
females	0	O
,	0	O
age	0	O
61	0	O
.	0	O
7	0	O
+/-	0	O
2	0	O
.	0	O
14	0	O
years	0	O
).	0	O


An	1	O
electrophoretic	0	O
mobility	0	O
shift	0	O
assay	0	O
was	0	O
performed	0	O
to	0	O
characterize	0	O
the	0	O
binding	0	O
property	0	O
of	0	O
TR2	0	B
and	0	O
its	0	O
truncated	0	O
isoform	0	O
.	0	O


To	1	O
study	0	O
the	0	O
functional	0	O
differences	0	O
between	0	O
cutaneous	0	O
HPV5	0	O
and	0	O
HPV8	0	O
E7s	0	B
and	0	O
genital	0	B
HPV16	0	I
E7	0	I
,	0	O
we	0	O
cloned	0	O
each	0	O
of	0	O
the	0	O
E7	0	B
open	0	O
reading	0	O
frames	0	O
and	0	O
tested	0	O
their	0	O
immortalizing	0	O
and	0	O
transforming	0	O
activities	0	O
,	0	O
the	0	O
binding	0	O
ability	0	O
of	0	O
their	0	O
products	0	O
with	0	O
retinoblastoma	0	B
protein	0	I
(	0	O
RB	1	B
)	0	O
and	0	O
their	0	O
complementation	0	O
activity	0	O
of	0	O
a	0	O
RB	1	B
-	0	I
nonbinding	0	I
adenovirus	0	I
E1A	0	I
mutant	0	I
.	0	O


Studies	0	O
on	0	O
Coxsackie	0	O
B	1	O
Type	1	O
5	0	O
virus	0	O
infections	0	O
.	0	O


The	0	O
induction	0	O
of	0	O
RNKP	0	B
-	0	I
1	0	I
expression	0	O
in	0	O
the	0	O
Con	1	B
A	1	I
-	0	O
cultured	0	O
spleen	0	O
cells	0	O
is	0	O
accompanied	0	O
by	0	O
increases	0	O
in	0	O
both	0	O
NK	1	O
and	0	O
lymphokine	0	O
-	0	O
activated	0	O
killer	0	O
lymphocyte	0	O
activities	0	O
.	0	O


The	0	O
recombinant	0	O
protein	0	O
was	0	O
purified	0	O
to	0	O
homogeneity	0	O
by	0	O
(	0	O
NH4	0	O
)	0	O
2SO4	0	O
-	0	O
precipitation	0	O
and	0	O
affinity	0	O
chromatography	0	O
on	0	O
5	0	O
'	0	O
AMP	1	O
-	0	O
Sepharose	0	O
.	0	O


In	1	O
insects	0	O
,	0	O
arylalkylamine	0	B
N	1	I
-	0	I
acetyltransferases	0	I
(	0	O
AANATs	0	B
)	0	O
have	0	O
been	0	O
implicated	0	O
in	0	O
several	0	O
physiological	0	O
processes	0	O
,	0	O
including	0	O
sclerotization	0	O
,	0	O
inactivation	0	O
of	0	O
certain	0	O
neurotransmitters	0	O
,	0	O
and	0	O
,	0	O
similar	0	O
to	0	O
the	0	O
function	0	O
in	0	O
vertebrates	0	O
,	0	O
catalysis	0	O
of	0	O
the	0	O
rate	0	O
-	0	O
limiting	0	O
step	0	O
in	0	O
melatonin	0	O
biosynthesis	0	O
.	0	O


The	0	O
adeno	0	B
-	0	I
associated	0	I
virus	0	I
(	0	I
AAV	1	I
)	0	I
rep	0	I
gene	0	I
encodes	0	O
four	0	O
proteins	0	O
(	0	O
Rep78	0	B
,	0	O
Rep68	0	B
,	0	O
Rep52	0	B
,	0	O
and	0	O
Rep40	0	B
)	0	O
required	0	O
for	0	O
AAV	1	O
DNA	1	O
replication	0	O
and	0	O
AAV	1	O
gene	0	O
regulation	0	O
.	0	O


In	1	O
control	0	O
patients	0	O
,	0	O
baseline	0	O
images	0	O
presented	0	O
Type	1	O
I	1	O
in	0	O
25	0	O
,	0	O
Type	1	O
II	0	O
in	0	O
7	0	O
,	0	O
and	0	O
the	0	O
Type	1	O
III	0	O
&	0	O
IV	1	O
in	0	O
0	0	O
,	0	O
and	0	O
the	0	O
Type	1	O
after	0	O
loading	0	O
was	0	O
the	0	O
same	0	O
as	0	O
the	0	O
Type	1	O
at	0	O
baseline	0	O
.	0	O


Individual	0	O
alcohol	0	O
reaction	0	O
profiles	0	O
.	0	O


Mammalian	0	B
M	1	I
-	0	I
Ras	1	I
and	0	O
a	0	O
Caenorhabditis	0	O
elegans	0	O
orthologue	0	O
exhibit	0	O
conserved	0	O
structural	0	O
features	0	O
,	0	O
and	0	O
these	0	O
are	0	O
likely	0	O
to	0	O
mediate	0	O
activation	0	O
of	0	O
distinctive	0	O
signaling	0	O
paths	0	O
that	0	O
function	0	O
in	0	O
parallel	0	O
to	0	O
those	0	O
downstream	0	O
of	0	O
p21	0	B
Ras	1	I
.	0	O


After	0	O
overtraining	0	O
on	0	O
the	0	O
original	0	O
discrimination	0	O
,	0	O
the	0	O
controls	0	O
showed	0	O
the	0	O
normal	0	O
difficulty	0	O
in	0	O
learning	0	O
the	0	O
first	0	O
reversal	0	O
.	0	O


In	1	O
unc	0	B
-	0	I
4	0	I
mutants	0	I
,	0	O
VA	1	O
motor	0	O
neurons	0	O
assume	0	O
the	0	O
pattern	0	O
of	0	O
synaptic	0	O
input	0	O
normally	0	O
reserved	0	O
for	0	O
their	0	O
lineal	0	O
sister	0	O
cells	0	O
,	0	O
the	0	O
VB	0	O
motor	0	O
neurons	0	O
;	0	O
the	0	O
loss	0	O
of	0	O
normal	0	O
input	0	O
to	0	O
the	0	O
VAs	1	O
produces	0	O
a	0	O
distinctive	0	O
backward	0	O
movement	0	O
defect	0	O
.	0	O


Other	0	O
hemostatic	0	O
values	0	O
evaluated	0	O
were	0	O
activated	0	O
partial	0	O
thromboplastin	0	B
times	0	O
,	0	O
prothrombin	0	B
times	0	O
,	0	O
thrombin	0	B
times	0	O
,	0	O
fibrinogen	0	B
,	0	O
platelet	0	O
counts	0	O
,	0	O
and	0	O
fibrin	0	B
/	0	O
fibrinogen	0	B
degradation	0	O
products	0	O
.	0	O


Laboratory	1	O
aspects	0	O
with	0	O
particular	0	O
reference	0	O
to	0	O
chemotherapy	0	O
and	0	O
control	0	O
.	0	O


Data	1	O
on	0	O
the	0	O
line	0	O
spread	0	O
function	0	O
(	0	O
LSF	0	O
)	0	O
were	0	O
obtained	0	O
from	0	O
the	0	O
image	0	O
of	0	O
a	0	O
0	0	O
.	0	O
2	0	O
mm	0	O
wide	0	O
slit	0	O
between	0	O
tungsten	0	O
blocks	0	O
that	0	O
were	0	O
positioned	0	O
at	0	O
the	0	O
isocentre	0	O
in	0	O
front	0	O
of	0	O
a	0	O
polystyrene	0	O
phantom	0	O
.	0	O


HuEpo	0	B
-	0	I
R	1	I
Ab	1	I
inhibited	0	O
Epo	0	B
-	0	O
induced	0	O
parental	0	O
UT	0	O
-	0	O
7	0	O
cell	0	O
growth	0	O
,	0	O
but	0	O
not	0	O
that	0	O
of	0	O
cells	0	O
of	0	O
clone	0	O
12	0	O
,	0	O
suggesting	0	O
that	0	O
the	0	O
muEpo	0	B
-	0	I
R	1	I
is	0	O
able	0	O
to	0	O
induce	0	O
human	0	O
UT	0	O
-	0	O
7	0	O
cell	0	O
proliferation	0	O
.	0	O


To	1	O
characterize	0	O
the	0	O
gene	0	O
products	0	O
,	0	O
the	0	O
cvaA	0	B
gene	0	I
was	0	O
subcloned	0	O
and	0	O
expressed	0	O
under	0	O
the	0	O
control	0	O
of	0	O
T7	0	B
RNA	1	I
polymerase	0	I
promoter	0	I
.	0	O


Underlying	0	O
the	0	O
clustering	0	O
of	0	O
these	0	O
risk	0	O
variables	0	O
were	0	O
three	0	O
factors	0	O
.	0	O


Orthop	0	O
.	0	O


The	0	O
specific	0	O
interaction	0	O
between	0	O
a	0	O
defined	0	O
structural	0	O
element	0	O
of	0	O
the	0	O
human	0	O
immunodeficiency	0	O
virus	0	O
mRNA	1	O
(	0	O
RRE	0	B
,	0	O
the	0	O
Rev	0	B
response	0	I
element	0	I
)	0	O
and	0	O
the	0	O
virus	0	B
-	0	I
encoded	0	I
protein	0	I
Rev	0	I
has	0	O
been	0	O
implicated	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
the	0	O
export	0	O
of	0	O
unspliced	0	O
or	0	O
singly	0	O
spliced	0	O
mRNA	1	O
from	0	O
the	0	O
nucleus	0	O
to	0	O
the	0	O
cytoplasm	0	O
.	0	O


Among	0	O
the	0	O
mixed	0	O
race	0	O
persons	0	O
one	0	O
Chukcha	0	O
-	0	O
Eskimo	0	O
had	0	O
AS	1	O
,	0	O
one	0	O
Eskimo	0	O
-	0	O
Russian	0	O
had	0	O
psoriatic	0	O
arthritis	0	O
(	0	O
PsA	1	O
).	0	O


Hydropathy	0	O
analysis	0	O
of	0	O
KCC1	0	B
indicates	0	O
structural	0	O
homology	0	O
to	0	O
NKCC	0	B
,	0	O
including	0	O
12	0	O
transmembrane	0	O
domains	0	O
,	0	O
a	0	O
large	0	O
extracellular	0	O
loop	0	O
with	0	O
potential	0	O
N	1	O
-	0	O
linked	0	O
glycosylation	0	O
sites	0	O
,	0	O
and	0	O
cytoplasmic	0	O
N	1	O
-	0	O
and	0	O
C	1	O
-	0	O
terminal	0	O
regions	0	O
.	0	O


Clinical	1	O
and	0	O
angiographic	0	O
examinations	0	O
in	0	O
occlusion	0	O
disease	0	O
of	0	O
the	0	O
great	0	O
intestinal	0	O
arteries	0	O


The	0	O
homology	0	O
to	0	O
v	0	B
-	0	I
mil	0	I
starts	0	O
within	0	O
the	0	O
coding	0	O
sequence	0	O
of	0	O
exon	0	O
1	0	O
and	0	O
ends	0	O
within	0	O
the	0	O
3	0	O
'	0	O
untranslated	0	O
region	0	O
of	0	O
exon	0	O
11	0	O
,	0	O
12	0	O
nucleotides	0	O
downstream	0	O
from	0	O
the	0	O
nonsense	0	O
codon	0	O
terminating	0	O
the	0	O
large	0	O
open	0	O
reading	0	O
frame	0	O
shared	0	O
between	0	O
c	0	B
-	0	I
mil	0	I
and	0	O
v	0	B
-	0	I
mil	0	I
.	0	O


Transabdominal	1	O
repair	0	O
of	0	O
type	0	O
IV	1	O
thoraco	0	O
-	0	O
abdominal	0	O
aortic	0	O
aneurysms	0	O
.	0	O


The	0	O
pulpal	0	O
tissues	0	O
of	0	O
the	0	O
permanent	0	O
mandibular	0	O
molars	0	O
were	0	O
amputated	0	O
and	0	O
then	0	O
dressed	0	O
with	0	O
calcium	0	O
hydrate	0	O
.	0	O


On	1	O
the	0	O
basis	0	O
of	0	O
size	0	O
,	0	O
the	0	O
CRS	0	O
sequence	0	O
to	0	O
which	0	O
it	0	O
binds	0	O
,	0	O
and	0	O
its	0	O
tentative	0	O
identification	0	O
as	0	O
a	0	O
zinc	0	B
finger	0	I
protein	0	I
,	0	O
Adx	0	B
factor	0	I
has	0	O
been	0	O
identified	0	O
as	0	O
a	0	O
Kruppel	0	B
-	0	I
like	0	I
zinc	0	I
finger	0	I
protein	0	I
(	0	O
a	0	O
mouse	0	B
ZBP	0	I
-	0	I
89	0	I
homologue	0	I
).	0	O


Mnt	0	B
:	0	O
Max	0	B
complexes	0	O
also	0	O
efficiently	0	O
suppress	0	O
Myc	0	B
-	0	O
dependent	0	O
activation	0	O
from	0	O
the	0	O
same	0	O
promoter	0	O
.	0	O


We	0	O
have	0	O
identified	0	O
three	0	O
binding	0	O
sites	0	O
for	0	O
protein	0	O
complexes	0	O
:	0	O
a	0	O
palindrome	0	O
,	0	O
a	0	O
direct	0	O
repeat	0	O
,	0	O
and	0	O
a	0	O
C	1	O
+	0	O
T	1	O
sequence	0	O
that	0	O
corresponds	0	O
to	0	O
seven	0	O
GAGA	0	O
motifs	0	O
on	0	O
the	0	O
transcribed	0	O
strand	0	O
.	0	O


Expression	1	O
of	0	O
the	0	O
human	0	B
papillomavirus	0	I
type	0	I
11	0	I
E5A	0	I
protein	0	I
from	0	O
the	0	O
E1E4	0	B
,	0	I
E5	0	I
transcript	0	I
.	0	O


These	0	O
results	0	O
indicate	0	O
that	0	O
baculovirus	0	O
-	0	O
expressed	0	O
TR	1	B
mediates	0	O
transcriptional	0	O
activation	0	O
and	0	O
repression	0	O
in	0	O
a	0	O
promoter	0	O
-	0	O
specific	0	O
manner	0	O
in	0	O
vitro	0	O
.	0	O


Two	0	O
soybean	0	O
cDNA	1	O
clones	0	O
,	0	O
SPK	0	B
-	0	I
3	0	I
and	0	O
SPK	0	B
-	0	I
4	0	I
,	0	O
encoding	0	O
putative	0	O
protein	0	O
kinases	0	O
were	0	O
isolated	0	O
and	0	O
characterized	0	O
.	0	O


63	0	O
.	0	O
3	0	O
micromol	0	O
/	0	O
1	0	O
,	0	O
p	0	O
<	0	O
0	0	O
.	0	O
01	0	O
)	0	O
and	0	O
area	0	O
under	0	O
the	0	O
plasma	0	O
concentration	0	O
-	0	O
time	0	O
curve	0	O
extrapolated	0	O
to	0	O
infinity	0	O
AUC	1	O
9	0	O
(	0	O
0	0	O
-	0	O
infinity	0	O
)(	0	O
518	0	O
.	0	O
7	0	O
vs	0	O
.	0	O


Structural	1	O
changes	0	O
in	0	O
the	0	O
C	1	O
-	0	O
terminus	0	O
of	0	O
Ca2	1	O
+-	0	O
bound	0	O
rat	0	B
S100B	0	I
(	0	O
beta	0	B
beta	0	I
)	0	O
upon	0	O
binding	0	O
to	0	O
a	0	O
peptide	0	O
derived	0	O
from	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
regulatory	0	O
domain	0	O
of	0	O
p53	0	B
.	0	O


Two	0	O
predominant	0	O
effects	0	O
were	0	O
noted	0	O
:	0	O
(	0	O
i	0	O
)	0	O
the	0	O
Xaa	0	O
residue	0	O
in	0	O
the	0	O
dual	0	O
phosphorylation	0	O
motif	0	O
Thr	1	O
-	0	O
Xaa	0	O
-	0	O
Tyr	1	O
as	0	O
well	0	O
as	0	O
the	0	O
length	0	O
of	0	O
L12	0	O
influence	0	O
p38	0	B
substrate	0	O
specificity	0	O
,	0	O
and	0	O
(	0	O
ii	0	O
)	0	O
the	0	O
length	0	O
of	0	O
L12	0	O
plays	0	O
a	0	O
major	0	O
role	0	O
in	0	O
controlling	0	O
autophosphorylation	0	O
.	0	O


To	1	O
gain	0	O
further	0	O
insight	0	O
into	0	O
the	0	O
pathogenesis	0	O
of	0	O
the	0	O
adult	0	O
respiratory	0	O
distress	0	O
syndrome	0	O
(	0	O
ARDS	1	O
),	0	O
the	0	O
authors	0	O
studied	0	O
possible	0	O
relationships	0	O
among	0	O
the	0	O
activation	0	O
status	0	O
of	0	O
circulating	0	O
polymorphonuclear	0	O
neutrophils	0	O
(	0	O
PMN	1	O
),	0	O
cytokine	0	O
levels	0	O
,	0	O
and	0	O
the	0	O
severity	0	O
of	0	O
lung	0	O
injury	0	O
in	0	O
31	0	O
patients	0	O
:	0	O
15	0	O
with	0	O
ARDS	1	O
,	0	O
9	0	O
with	0	O
severe	0	O
pneumonia	0	O
uncomplicated	0	O
by	0	O
ARDS	1	O
,	0	O
and	0	O
7	0	O
mechanically	0	O
ventilated	0	O
patients	0	O
with	0	O
neither	0	O
ARDS	1	O
nor	0	O
pneumonia	0	O
.	0	O


Deaths	0	O
stopped	0	O
11	0	O
hours	0	O
after	0	O
copper	0	O
concentrations	0	O
decreased	0	O
below	0	O
0	0	O
.	0	O
2	0	O
ppm	0	O
and	0	O
signs	0	O
of	0	O
distress	0	O
stopped	0	O
in	0	O
surviving	0	O
pinfish	0	O
by	0	O
approximately	0	O
6	0	O
hours	0	O
after	0	O
the	0	O
last	0	O
death	0	O
.	0	O


The	0	O
results	0	O
show	0	O
that	0	O
the	0	O
structure	0	O
of	0	O
the	0	O
decorin	0	B
gene	0	I
promoter	0	I
is	0	O
different	0	O
from	0	O
that	0	O
of	0	O
any	0	O
other	0	O
proteoglycan	0	O
promoter	0	O
characterized	0	O
so	0	O
far	0	O
and	0	O
indicate	0	O
that	0	O
the	0	O
pur	0	O
/	0	O
pyr	0	O
segment	0	O
plays	0	O
a	0	O
role	0	O
in	0	O
the	0	O
regulation	0	O
of	0	O
gene	0	O
transcription	0	O
.	0	O


The	0	O
genome	0	O
organization	0	O
of	0	O
the	0	O
mite	0	O
-	0	O
transmitted	0	O
wheat	0	O
streak	0	O
mosaic	0	O
virus	0	O
(	0	O
WSMV	0	O
)	0	O
appears	0	O
to	0	O
parallel	0	O
that	0	O
of	0	O
members	0	O
of	0	O
the	0	O
Potyviridae	0	O
with	0	O
monopartite	0	O
genomes	0	O
,	0	O
but	0	O
there	0	O
are	0	O
substantial	0	O
amino	0	O
acid	0	O
dissimilarities	0	O
with	0	O
other	0	O
potyviral	0	O
polyproteins	0	O
.	0	O


Acute	1	O
inhalation	0	O
toxicity	0	O
of	0	O
T	1	O
-	0	O
2	0	O
mycotoxin	0	O
in	0	O
mice	0	O
.	0	O


Here	0	O
,	0	O
we	0	O
present	0	O
evidence	0	O
that	0	O
exposure	0	O
of	0	O
DT40	0	O
lymphoma	0	O
B	1	O
cells	0	O
to	0	O
low	0	O
energy	0	O
electromagnetic	0	O
field	0	O
(	0	O
EMF	1	O
)	0	O
results	0	O
in	0	O
a	0	O
tyrosine	0	B
kinase	0	I
-	0	O
dependent	0	O
activation	0	O
of	0	O
phospholipase	0	B
Cgamma2	0	I
(	0	O
PLC	0	B
-	0	I
gamma2	0	I
)	0	O
leading	0	O
to	0	O
increased	0	O
inositol	0	O
phospholipid	0	O
turnover	0	O
.	0	O


The	0	O
increase	0	O
in	0	O
amplitudes	0	O
of	0	O
the	0	O
b	0	O
-	0	O
wave	0	O
during	0	O
the	0	O
adaptation	0	O
period	0	O
was	0	O
more	0	O
prominent	0	O
in	0	O
lead	0	O
-	0	O
exposed	0	O
subjects	0	O
than	0	O
in	0	O
controls	0	O
.	0	O


Forty	0	O
patients	0	O
,	0	O
divided	0	O
according	0	O
to	0	O
their	0	O
initial	0	O
total	0	O
gastrointestinal	0	O
transit	0	O
times	0	O
and	0	O
presenting	0	O
symptoms	0	O
,	0	O
were	0	O
treated	0	O
with	0	O
cimetropium	0	O
bromide	0	O
50	0	O
mg	0	O
t	0	O
.	0	O
d	0	O
.	0	O
s	0	O
.	0	O
or	0	O
placebo	0	O
for	0	O
1	0	O
month	0	O
according	0	O
to	0	O
a	0	O
double	0	O
-	0	O
blind	0	O
,	0	O
parallel	0	O
group	0	O
design	0	O
.	0	O


Schnell	0	O
,	0	O
J	1	O
.	0	O


The	0	O
most	0	O
common	0	O
characteristics	0	O
of	0	O
VRE	1	O
patients	0	O
were	0	O
recent	0	O
prior	0	O
vancomycin	0	O
use	0	O
,	0	O
recent	0	O
prior	0	O
susceptible	0	O
enterococcal	0	O
infection	0	O
,	0	O
coinfection	0	O
with	0	O
other	0	O
microbial	0	O
pathogens	0	O
,	0	O
and	0	O
concurrent	0	O
fungal	0	O
infection	0	O
.	0	O


This	0	O
repression	0	O
was	0	O
reversed	0	O
agonists	0	O
of	0	O
either	0	O
receptor	0	O
demonstrating	0	O
a	0	O
functional	0	O
interaction	0	O
between	0	O
NCoR	0	B
and	0	O
PPARalpha	0	B
.	0	O
RXRalpha	0	B
heterodimeric	0	O
complexes	0	O
in	0	O
mammalian	0	O
cells	0	O
.	0	O


Next	0	O
,	0	O
we	0	O
stably	0	O
overexpressed	0	O
wild	0	B
-	0	I
type	0	I
Shc	0	I
or	0	O
Y317F	0	B
mutant	0	I
Shc	0	I
into	0	O
HIRc	0	O
cells	0	O
.	0	O


Mean	1	O
total	0	O
lung	0	O
capacity	0	O
,	0	O
functional	0	O
residual	0	O
capacity	0	O
,	0	O
and	0	O
residual	0	O
volume	0	O
increased	0	O
significantly	0	O
,	0	O
and	0	O
the	0	O
mean	0	O
closing	0	O
volume	0	O
,	0	O
the	0	O
lung	0	O
volume	0	O
above	0	O
residual	0	O
volume	0	O
at	0	O
which	0	O
phase	0	O
IV	1	O
begins	0	O
,	0	O
decreased	0	O
significantly	0	O
with	0	O
11	0	O
cm	0	O
H20	0	O
continuous	0	O
positive	0	O
airway	0	O
pressure	0	O
;	0	O
differences	0	O
at	0	O
5	0	O
cm	0	O
H20	0	O
were	0	O
not	0	O
significant	0	O
.	0	O


Research	1	O
was	0	O
carried	0	O
out	0	O
on	0	O
the	0	O
rheumatoid	0	B
factors	0	I
in	0	O
the	0	O
serum	0	O
of	0	O
917	0	O
patients	0	O
by	0	O
means	0	O
of	0	O
two	0	O
tests	0	O
(	0	O
one	0	O
using	0	O
polystyrene	0	O
and	0	O
one	0	O
with	0	O
erythrocytes	0	O
)	0	O
and	0	O
the	0	O
results	0	O
obtained	0	O
were	0	O
compared	0	O
using	0	O
a	0	O
method	0	O
of	0	O
reference	0	O
.	0	O


Re	1	O
-	0	O
evaluation	0	O
of	0	O
the	0	O
biopsy	0	O
specimen	0	O
from	0	O
the	0	O
right	0	O
hip	0	O
taken	0	O
at	0	O
the	0	O
time	0	O
of	0	O
the	0	O
initial	0	O
operation	0	O
showed	0	O
areas	0	O
of	0	O
chondrosarcoma	0	O
arising	0	O
in	0	O
the	0	O
background	0	O
of	0	O
synovial	0	O
chondromatosis	0	O
.	0	O


Secretory	1	O
function	0	O
of	0	O
the	0	O
prostate	0	O
gland	0	O
.	0	O


Latexin	0	B
,	0	O
a	0	O
carboxypeptidase	0	B
A	1	I
inhibitor	0	O
,	0	O
is	0	O
expressed	0	O
in	0	O
a	0	O
cell	0	O
type	0	O
-	0	O
specific	0	O
manner	0	O
in	0	O
both	0	O
central	0	O
and	0	O
peripheral	0	O
nervous	0	O
systems	0	O
in	0	O
the	0	O
rat	0	O
.	0	O


In	1	O
yeast	0	O
,	0	O
the	0	O
products	0	O
of	0	O
the	0	O
UPF1	0	B
and	0	O
UPF3	0	B
genes	0	I
are	0	O
required	0	O
for	0	O
this	0	O
decay	0	O
pathway	0	O
,	0	O
and	0	O
in	0	O
this	0	O
report	0	O
we	0	O
focus	0	O
on	0	O
the	0	O
identification	0	O
and	0	O
characterization	0	O
of	0	O
additional	0	O
factors	0	O
required	0	O
for	0	O
rapid	0	O
decay	0	O
of	0	O
nonsense	0	O
-	0	O
containing	0	O
mRNAs	0	O
.	0	O


Anti	0	B
-	0	I
PTB	0	I
antibodies	0	I
did	0	O
not	0	O
inhibit	0	O
the	0	O
binding	0	O
of	0	O
PTB	0	B
to	0	O
RNA	1	O
because	0	O
they	0	O
were	0	O
able	0	O
to	0	O
supershift	0	O
RNA	1	B
-	0	I
PTB	0	I
complexes	0	I
.	0	O


The	0	O
major	0	B
49	0	I
-	0	I
kDa	1	I
core	0	I
protein	0	I
in	0	O
the	0	O
liver	0	O
HSPG	0	B
preparation	0	O
was	0	O
found	0	O
to	0	O
be	0	O
reactive	0	O
to	0	O
an	0	O
antibody	0	O
that	0	O
specifically	0	O
recognizes	0	O
the	0	O
cytoplasmic	0	O
domain	0	O
of	0	O
fibroglycan	0	B
.	0	O


The	0	O
structure	0	O
of	0	O
the	0	O
calcineurin	0	B
A	1	I
gene	0	I
was	0	O
determined	0	O
by	0	O
comparison	0	O
of	0	O
the	0	O
genomic	0	O
and	0	O
cDNA	1	O
sequences	0	O
.	0	O


Benefits	0	O
of	0	O
obtaining	0	O
board	0	O
certification	0	O
in	0	O
pharmacotherapy	0	O
.	0	O


These	0	O
results	0	O
suggest	0	O
that	0	O
members	0	O
of	0	O
the	0	O
ATF	0	B
family	0	I
are	0	O
involved	0	O
in	0	O
mediating	0	O
the	0	O
transcriptional	0	O
regulation	0	O
of	0	O
the	0	O
KGF	0	B
gene	0	I
in	0	O
response	0	O
to	0	O
extracellular	0	O
stimuli	0	O
via	0	O
a	0	O
novel	0	O
CRE	0	O
regulatory	0	O
element	0	O
.	0	O


Successful	0	O
treatment	0	O
of	0	O
candidiasis	0	O
with	0	O
transfer	0	B
factor	0	I
.	0	O


The	0	O
fatigue	0	O
exercise	0	O
showed	0	O
relatively	0	O
high	0	O
blood	0	O
lactate	0	O
concentration	0	O
[	0	O
12	0	O
.	0	O
5	0	O
(	0	O
SD	1	O
2	0	O
.	0	O
6	0	O
)	0	O
mmol	0	O
x	0	O
l	0	O
(-	0	O
1	0	O
)]	0	O
and	0	O
an	0	O
increase	0	O
of	0	O
serum	0	B
creatine	0	I
kinase	0	I
(	0	O
CK	1	B
)	0	O
activity	0	O
delayed	0	O
by	0	O
2	0	O
days	0	O
[	0	O
540	0	O
(	0	O
SD	1	O
407	0	O
)	0	O
U	1	O
x	0	O
l	0	O
(-	0	O
1	0	O
)].	0	O


These	0	O
results	0	O
were	0	O
superior	0	O
to	0	O
those	0	O
in	0	O
24	0	O
patients	0	O
with	0	O
conventional	0	O
end	0	O
-	0	O
to	0	O
-	0	O
end	0	O
sutures	0	O
on	0	O
clinical	0	O
testing	0	O
.	0	O


Production	1	O
costs	0	O
included	0	O
feed	0	O
,	0	O
non	0	O
-	0	O
feed	0	O
operating	0	O
,	0	O
fixed	0	O
,	0	O
and	0	O
replacement	0	O
stock	0	O
costs	0	O
.	0	O


There	0	O
is	0	O
a	0	O
national	0	O
effort	0	O
to	0	O
begin	0	O
to	0	O
ask	0	O
all	0	O
female	0	O
patients	0	O
about	0	O
family	0	O
violence	0	O
.	0	O


An	1	O
intact	0	O
5	0	O
.	0	O
7	0	O
-	0	O
kb	0	O
provirus	0	O
of	0	O
the	0	O
avian	0	O
erythroblastosis	0	O
virus	0	O
E26	0	O
has	0	O
been	0	O
molecularly	0	O
cloned	0	O
for	0	O
comparisons	0	O
with	0	O
avian	0	O
myeloblastosis	0	O
virus	0	O
(	0	O
AMV	0	O
)	0	O
and	0	O
other	0	O
avian	0	O
tumor	0	O
viruses	0	O
.	0	O


Two	0	O
related	0	O
cDNAs	0	O
were	0	O
isolated	0	O
that	0	O
encode	0	O
proteins	0	O
that	0	O
recognize	0	O
the	0	O
XMyoDa	0	B
TATA	0	I
motif	0	I
.	0	O


Compensatory	1	O
renal	0	O
hypertrophy	0	O
in	0	O
parabiotic	0	O
rats	0	O
.	0	O


In	1	O
the	0	O
former	0	O
cells	0	O
,	0	O
ets	0	B
-	0	I
2	0	I
was	0	O
a	0	O
CSF	1	B
-	0	I
1	0	I
immediate	0	O
-	0	O
early	0	O
response	0	O
gene	0	O
,	0	O
and	0	O
phosphorylated	0	O
ets	0	B
-	0	I
2	0	I
was	0	O
detected	0	O
after	0	O
2	0	O
to	0	O
4	0	O
h	0	O
,	0	O
coincident	0	O
with	0	O
expression	0	O
of	0	O
ets	0	B
-	0	I
2	0	I
protein	0	I
.	0	O


However	0	O
,	0	O
serial	0	O
passages	0	O
of	0	O
fetal	0	O
lamb	0	O
kidney	0	O
(	0	O
FLK	0	O
)	0	O
cells	0	O
,	0	O
which	0	O
are	0	O
sensitive	0	O
to	0	O
infection	0	O
with	0	O
BLV	0	O
,	0	O
after	0	O
transient	0	O
transfection	0	O
revealed	0	O
that	0	O
mutation	0	O
of	0	O
a	0	O
second	0	O
tyrosine	0	O
residue	0	O
in	0	O
the	0	O
N	1	O
-	0	O
terminal	0	O
motif	0	O
completely	0	O
prevented	0	O
the	0	O
propagation	0	O
of	0	O
the	0	O
virus	0	O
.	0	O


Cytoprotection	1	O
with	0	O
amifostine	0	O
in	0	O
radiotherapy	0	O
or	0	O
radio	0	O
-	0	O
chemotherapy	0	O
of	0	O
head	0	O
and	0	O
neck	0	O
tumors	0	O


After	0	O
measuring	0	O
baseline	0	O
Vmca	0	O
at	0	O
a	0	O
partial	0	O
pressure	0	O
of	0	O
carbon	0	O
dioxide	0	O
in	0	O
arterial	0	O
blood	0	O
(	0	O
PaCO2	1	O
)	0	O
of	0	O
37	0	O
.	0	O
7	0	O
+/-	0	O
4	0	O
.	0	O
5	0	O
mmHg	0	O
(	0	O
mean	0	O
+/-	0	O
SD	1	O
),	0	O
measurements	0	O
were	0	O
repeated	0	O
at	0	O
a	0	O
PaCO	0	O
of	0	O
44	0	O
.	0	O
2	0	O
+/-	0	O
3	0	O
.	0	O
8	0	O
mmHg	0	O
,	0	O
and	0	O
the	0	O
carbon	0	O
dioxide	0	O
reactivity	0	O
(	0	O
absolute	0	O
value	0	O
:	0	O
cm	0	O
x	0	O
s	0	O
(-	0	O
1	0	O
)	0	O
x	0	O
mmHg	0	O
(-	0	O
1	0	O
);	0	O
relative	0	O
value	0	O
:	0	O
percentage	0	O
of	0	O
baseline	0	O
Vmca	0	O
/	0	O
mmHg	0	O
)	0	O
was	0	O
calculated	0	O
.	0	O


Ultrastructural	0	O
study	0	O
of	0	O
polyarteritis	0	O


Five	0	O
patients	0	O
with	0	O
type	0	O
III	0	O
musculoskeletal	0	O
infection	0	O
from	0	O
nongonococcal	0	O
Neisseria	1	O
species	0	O
were	0	O
examined	0	O
during	0	O
a	0	O
13	0	O
-	0	O
month	0	O
period	0	O
.	0	O


Sequence	1	O
comparison	0	O
between	0	O
the	0	O
translated	0	O
ORF	1	O
and	0	O
a	0	O
protein	0	O
database	0	O
reveal	0	O
between	0	O
26	0	O
.	0	O
5	0	O
and	0	O
23	0	O
.	0	O
4	0	O
%	0	O
aa	0	O
sequence	0	O
homology	0	O
to	0	O
bacterial	0	B
transmembrane	0	I
(	0	I
TM	1	I
)	0	I
proteins	0	I
including	0	O
those	0	O
mediating	0	O
chloramphenicol	0	O
(	0	O
Cm	1	O
)	0	O
and	0	O
tetracycline	0	O
(	0	O
Tc	1	O
)	0	O
resistance	0	O
and	0	O
an	0	O
arabinose	0	O
-	0	O
proton	0	O
symport	0	O
protein	0	O
.	0	O


Story	0	O
of	0	O
a	0	O
hospital	0	O
that	0	O
filmed	0	O
its	0	O
employee	0	O
orientation	0	O
program	0	O
.	0	O


With	0	O
the	0	O
increasing	0	O
use	0	O
of	0	O
ACE	1	B
inhibitors	0	O
,	0	O
the	0	O
incidence	0	O
of	0	O
rare	0	O
adverse	0	O
effects	0	O
such	0	O
as	0	O
potentially	0	O
lethal	0	O
pancreatitis	0	O
is	0	O
likely	0	O
to	0	O
increase	0	O
.	0	O


Two	0	O
-	0	O
dimensional	0	O
gel	0	O
electrophoresis	0	O
of	0	O
anti	0	B
-	0	I
p59fyn	0	I
immunoprecipitates	0	O
obtained	0	O
from	0	O
non	0	O
-	0	O
transformed	0	O
resting	0	O
human	0	O
T	1	O
lymphocytes	0	O
resulted	0	O
in	0	O
the	0	O
identification	0	O
of	0	O
an	0	O
oligomeric	0	O
protein	0	O
complex	0	O
which	0	O
is	0	O
constitutively	0	O
formed	0	O
between	0	O
Fyn	0	B
and	0	O
several	0	O
additional	0	O
phosphoproteins	0	O
(	0	O
pp43	0	B
,	0	O
pp72	0	B
,	0	O
pp85	0	B
,	0	O
the	0	O
protein	0	B
tyrosine	0	I
kinase	0	I
Pyk2	0	I
,	0	O
as	0	O
well	0	O
as	0	O
the	0	O
two	0	O
recently	0	O
cloned	0	O
adaptor	0	O
proteins	0	O
,	0	O
SKAP55	0	B
and	0	O
SLAP	0	B
-	0	I
130	0	I
).	0	O


Since	0	O
the	0	O
-	0	O
172	0	O
/-	0	O
148	0	O
element	0	O
also	0	O
conferred	0	O
estrogen	0	O
and	0	O
thyroid	0	O
hormone	0	O
responsiveness	0	O
,	0	O
it	0	O
can	0	O
be	0	O
considered	0	O
a	0	O
composite	0	O
hormone	0	O
response	0	O
element	0	O
.	0	O


The	0	O
native	0	O
enzyme	0	O
purified	0	O
from	0	O
protease	0	B
-	0	I
B	1	I
-	0	O
deficient	0	O
URA2	0	B
-	0	O
transformed	0	O
cells	0	O
,	0	O
was	0	O
phosphorylated	0	O
in	0	O
vitro	0	O
using	0	O
catalytic	0	O
subunits	0	O
of	0	O
pure	0	O
cAMP	1	B
-	0	I
dependent	0	I
protein	0	I
kinase	0	I
.	0	O


Adriamycin	1	O
:	0	O
comparison	0	O
of	0	O
a	0	O
5	0	O
-	0	O
week	0	O
schedule	0	O
with	0	O
a	0	O
3	0	O
-	0	O
week	0	O
schedule	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
breast	0	O
cancer	0	O
.	0	O


We	0	O
have	0	O
also	0	O
tested	0	O
Src	1	B
SH2	0	I
mutants	0	O
for	0	O
their	0	O
binding	0	O
properties	0	O
and	0	O
have	0	O
interpreted	0	O
our	0	O
results	0	O
in	0	O
light	0	O
of	0	O
the	0	O
recent	0	O
crystal	0	O
structure	0	O
solution	0	O
for	0	O
the	0	O
Src	1	B
SH2	0	I
domain	0	O
.	0	O


Three	0	O
patients	0	O
had	0	O
well	0	O
-,	0	O
6	0	O
patients	0	O
had	0	O
moderately	0	O
-,	0	O
and	0	O
5	0	O
patients	0	O
had	0	O
poorly	0	O
-	0	O
differentiated	0	O
adenocarcinoma	0	O
of	0	O
the	0	O
prostate	0	O
.	0	O


The	0	O
transcription	0	O
initiation	0	O
site	0	O
was	0	O
determined	0	O
to	0	O
occur	0	O
66	0	O
bp	0	O
upstream	0	O
of	0	O
the	0	O
initiating	0	O
Met	1	O
.	0	O


Moreover	0	O
,	0	O
a	0	O
high	0	O
proportion	0	O
of	0	O
blood	0	O
samples	0	O
from	0	O
a	0	O
random	0	O
sample	0	O
of	0	O
the	0	O
rest	0	O
of	0	O
the	0	O
suspects	0	O
tested	0	O
positive	0	O
for	0	O
trypanosome	0	O
-	0	O
specific	0	O
DNA	1	O
by	0	O
PCR	1	O
(	0	O
79	0	O
.	0	O
9	0	O
%	0	O
for	0	O
T	1	O
.	0	O
b	0	O
.	0	O
gambiense	0	O
and	0	O
13	0	O
.	0	O
9	0	O
%	0	O
for	0	O
T	1	O
.	0	O
b	0	O
.	0	O
rhodesiense	0	O
).	0	O


As	1	O
control	0	O
,	0	O
the	0	O
cells	0	O
were	0	O
transfected	0	O
with	0	O
DNA	1	O
mixtures	0	O
containing	0	O
vector	0	O
mU6	0	O
-	0	O
C1	1	O
or	0	O
mU6	0	O
-	0	O
C2	1	O
.	0	O


If	1	O
E	1	O
.	0	O
coli	0	O
is	0	O
present	0	O
in	0	O
any	0	O
source	0	O
water	0	O
sample	0	O
,	0	O
the	0	O
borehole	0	O
and	0	O
any	0	O
directly	0	O
connected	0	O
borehole	0	O
should	0	O
be	0	O
embargoed	0	O
.	0	O


In	1	O
order	0	O
to	0	O
gain	0	O
deeper	0	O
insight	0	O
into	0	O
the	0	O
role	0	O
of	0	O
the	0	O
amino	0	O
-	0	O
terminal	0	O
domain	0	O
of	0	O
the	0	O
p24	0	B
(	0	O
CA	1	B
)	0	O
protein	0	O
during	0	O
viral	0	O
replication	0	O
,	0	O
eight	0	O
highly	0	O
conserved	0	O
proline	0	O
residues	0	O
known	0	O
to	0	O
promote	0	O
turns	0	O
and	0	O
to	0	O
terminate	0	O
alpha	0	O
-	0	O
helices	0	O
within	0	O
the	0	O
p24	0	B
tertiary	0	O
structure	0	O
were	0	O
replaced	0	O
by	0	O
a	0	O
leucine	0	O
residue	0	O
(	0	O
P	1	O
-	0	O
position	0	O
-	0	O
L	1	O
).	0	O


Then	0	O
,	0	O
pure	0	O
pancreatic	0	O
juice	0	O
was	0	O
infused	0	O
into	0	O
the	0	O
duodenum	0	O
.	0	O


The	0	O
IE13	0	O
.	0	O
1	0	O
cell	0	O
line	0	O
was	0	O
able	0	O
to	0	O
complement	0	O
a	0	O
recombinant	0	O
virus	0	O
in	0	O
which	0	O
both	0	O
copies	0	O
of	0	O
the	0	O
IE	1	B
gene	0	I
were	0	O
replaced	0	O
by	0	O
insertion	0	O
of	0	O
the	0	O
Escherichia	1	B
coli	0	I
lacZ	0	I
gene	0	I
.	0	O


An	1	O
immunologically	0	O
related	0	O
protein	0	O
was	0	O
detected	0	O
in	0	O
ribosome	0	O
and	0	O
membrane	0	O
fractions	0	O
of	0	O
mitochondria	0	O
from	0	O
Saccharomyces	1	O
cerevisiae	0	O
.	0	O


The	0	O
predicted	0	O
amino	0	O
acid	0	O
sequence	0	O
contains	0	O
regions	0	O
identical	0	O
to	0	O
the	0	O
sequences	0	O
of	0	O
peptides	0	O
derived	0	O
from	0	O
bovine	0	B
liver	0	I
eIF	0	I
-	0	I
2B	0	I
alpha	0	I
subunit	0	I
.	0	O


We	0	O
have	0	O
isolated	0	O
a	0	O
binding	0	O
partner	0	O
for	0	O
the	0	O
Fanconi	0	B
anemia	0	I
group	0	I
C	1	I
protein	0	I
(	0	O
FANCC	0	B
)	0	O
by	0	O
yeast	0	O
two	0	O
-	0	O
hybrid	0	O
screening	0	O
.	0	O


USF	0	B
synthesized	0	O
in	0	O
an	0	O
in	0	O
vitro	0	O
transcription	0	O
and	0	O
translation	0	O
system	0	O
also	0	O
binds	0	O
to	0	O
the	0	O
ADH	1	B
promoter	0	I
as	0	O
well	0	O
as	0	O
to	0	O
the	0	O
MLP	1	O
.	0	O


HYPOTHESIS	1	O
:	0	O
The	0	O
aim	0	O
of	0	O
this	0	O
study	0	O
was	0	O
to	0	O
investigate	0	O
the	0	O
oxidative	0	O
susceptibility	0	O
of	0	O
apolipoprotein	0	B
B	1	I
-	0	I
containing	0	I
lipoproteins	0	I
and	0	O
antioxidant	0	O
status	0	O
in	0	O
patients	0	O
with	0	O
acute	0	O
coronary	0	O
syndromes	0	O
and	0	O
chronic	0	O
stable	0	O
angina	0	O
pectoris	0	O
.	0	O


O	1	B
.	0	I
novo	0	I
-	0	I
ulmi	0	I
RNA	1	I
-	0	I
7	0	I
,	0	O
previously	0	O
believed	0	O
to	0	O
be	0	O
a	0	O
satellite	0	O
-	0	O
like	0	O
RNA	1	O
,	0	O
is	0	O
shown	0	O
to	0	O
be	0	O
a	0	O
defective	0	O
RNA	1	O
,	0	O
derived	0	O
from	0	O
OnuMV4	0	B
-	0	I
Ld	1	I
RNA	1	I
by	0	O
multiple	0	O
internal	0	O
deletions	0	O
.	0	O


A	1	O
fine	0	O
-	0	O
structure	0	O
deletion	0	O
map	0	O
of	0	O
human	0	O
chromosome	0	O
11p	0	O
:	0	O
analysis	0	O
of	0	O
J1	0	O
series	0	O
hybrids	0	O
.	0	O


SPECT	1	O
is	0	O
an	0	O
important	0	O
aid	0	O
in	0	O
the	0	O
diagnosis	0	O
of	0	O
AIDS	1	O
dementia	0	O
complex	0	O
and	0	O
contributes	0	O
to	0	O
the	0	O
understanding	0	O
of	0	O
the	0	O
pathophysiological	0	O
mechanisms	0	O
of	0	O
this	0	O
disorder	0	O
.	0	O


There	0	O
are	0	O
four	0	O
polyglutamine	0	O
motifs	0	O
interspersed	0	O
with	0	O
histidine	0	O
-	0	O
rich	0	O
regions	0	O
.	0	O


The	0	O
distinguishing	0	O
features	0	O
involved	0	O
eight	0	O
amino	0	O
acid	0	O
changes	0	O
,	0	O
including	0	O
a	0	O
single	0	O
lysine	0	O
deletion	0	O
relative	0	O
to	0	O
a	0	O
primate	0	O
consensus	0	O
sequence	0	O
in	0	O
the	0	O
first	0	O
complementary	0	O
-	0	O
determing	0	O
region	0	O
of	0	O
V1J1	0	B
.	0	O


The	0	O
minimum	0	O
inhibitory	0	O
concentrations	0	O
(	0	O
MICs	0	O
)	0	O
of	0	O
ketoconazole	0	O
,	0	O
miconazole	0	O
,	0	O
itraconazole	0	O
,	0	O
fluconazole	0	O
,	0	O
and	0	O
amphotericin	0	O
B	1	O
were	0	O
significantly	0	O
influenced	0	O
by	0	O
the	0	O
inoculum	0	O
size	0	O
,	0	O
regardless	0	O
of	0	O
the	0	O
techniques	0	O
used	0	O
.	0	O


The	0	O
product	0	O
of	0	O
the	0	O
vpr	0	B
open	0	I
reading	0	I
frame	0	I
of	0	I
human	0	I
immunodeficiency	0	I
virus	0	I
type	0	I
1	0	I
(	0	I
HIV	1	I
-	0	I
1	0	I
)	0	I
is	0	O
a	0	O
15	0	O
-	0	O
kDa	1	O
,	0	O
arginine	0	O
-	0	O
rich	0	O
protein	0	O
that	0	O
is	0	O
present	0	O
in	0	O
virions	0	O
in	0	O
molar	0	O
quantities	0	O
equivalent	0	O
to	0	O
that	0	O
of	0	O
Gag	1	B
.	0	O


Blood	1	O
glucose	0	O
and	0	O
plasma	0	O
insulin	0	B
were	0	O
measured	0	O
at	0	O
zero	0	O
time	0	O
and	0	O
then	0	O
at	0	O
15	0	O
,	0	O
30	0	O
,	0	O
60	0	O
,	0	O
90	0	O
and	0	O
120	0	O
min	0	O
after	0	O
ingestion	0	O
of	0	O
25	0	O
g	0	O
glucose	0	O
,	0	O
fructose	0	O
or	0	O
lactose	0	O
,	0	O
or	0	O
30	0	O
g	0	O
honey	0	O
,	0	O
50	0	O
g	0	O
white	0	O
bread	0	O
,	0	O
125	0	O
g	0	O
white	0	O
rice	0	O
or	0	O
potatoes	0	O
,	0	O
150	0	O
g	0	O
apples	0	O
or	0	O
260	0	O
g	0	O
carrots	0	O
.	0	O


Sodium	1	O
-	0	O
taurocholate	0	O
-	0	O
induced	0	O
acute	0	O
necrotizing	0	O
pancreatitis	0	O
does	0	O
not	0	O
affect	0	O
jejunal	0	O
oxygenation	0	O
in	0	O
pigs	0	O
.	0	O


Duch	0	O
,	0	O
and	0	O
F	1	O
.	0	O


Based	0	O
on	0	O
our	0	O
observations	0	O
,	0	O
we	0	O
propose	0	O
a	0	O
model	0	O
whereby	0	O
inactive	0	O
precursor	0	O
molecules	0	O
produced	0	O
from	0	O
the	0	O
PEP4	0	B
gene	0	I
self	0	O
-	0	O
activate	0	O
within	0	O
the	0	O
yeast	0	O
vacuole	0	O
and	0	O
subsequently	0	O
activate	0	O
other	0	O
vacuolar	0	B
hydrolases	0	I
.	0	O


Consistent	0	O
with	0	O
a	0	O
possible	0	O
role	0	O
in	0	O
transcription	0	O
,	0	O
Paf1p	0	B
is	0	O
localized	0	O
to	0	O
the	0	O
nucleus	0	O
.	0	O


Tests	0	O
of	0	O
the	0	O
method	0	O
indicate	0	O
(	0	O
1	0	O
)	0	O
the	0	O
Mossbauer	0	O
source	0	O
can	0	O
be	0	O
placed	0	O
on	0	O
the	0	O
basilar	0	O
membrane	0	O
without	0	O
altering	0	O
the	0	O
signal	0	O
-	0	O
transmission	0	O
properties	0	O
of	0	O
the	0	O
cochlea	0	O
,	0	O
and	0	O
(	0	O
2	0	O
)	0	O
the	0	O
source	0	O
adheres	0	O
to	0	O
the	0	O
basilar	0	O
membrane	0	O
.	0	O


Gene	1	O
and	0	O
pseudogene	0	O
of	0	O
the	0	O
mouse	0	O
cation	0	O
-	0	O
dependent	0	O
mannose	0	B
6	0	I
-	0	I
phosphate	0	I
receptor	0	I
.	0	O


Effect	1	O
of	0	O
proteolytic	0	O
enzymes	0	O
and	0	O
polypeptides	0	O
on	0	O
the	0	O
antacid	0	O
activity	0	O
of	0	O
almagate	0	O
and	0	O
other	0	O
antacids	0	O
.	0	O


The	0	O
protein	0	O
mixtures	0	O
of	0	O
sesame	0	O
flour	0	O
and	0	O
soybean	0	O
flour	0	O
were	0	O
well	0	O
accepted	0	O
.	0	O


By	0	O
using	0	O
a	0	O
DNA	1	O
sequence	0	O
selected	0	O
for	0	O
its	0	O
ability	0	O
to	0	O
bind	0	O
recombinant	0	B
BCL	0	I
-	0	I
6	0	I
in	0	O
vitro	0	O
,	0	O
we	0	O
show	0	O
here	0	O
that	0	O
BCL	0	B
-	0	I
6	0	I
is	0	O
present	0	O
in	0	O
DNA	1	O
-	0	O
binding	0	O
complexes	0	O
in	0	O
nuclear	0	O
extracts	0	O
from	0	O
various	0	O
B	1	O
-	0	O
cell	0	O
lines	0	O
.	0	O


Switching	0	O
FDC	0	O
-	0	O
P1	1	O
/	0	O
MAC	1	O
cells	0	O
from	0	O
growth	0	O
in	0	O
M	1	B
-	0	I
CSF	1	I
to	0	O
GM	1	B
-	0	I
CSF	1	I
caused	0	O
the	0	O
selective	0	O
degradation	0	O
of	0	O
c	0	B
-	0	I
fms	0	I
mRNA	1	I
within	0	O
6	0	O
h	0	O
after	0	O
factor	0	O
switching	0	O
.	0	O


It	1	O
has	0	O
come	0	O
out	0	O
that	0	O
CAEC	0	O
is	0	O
between	0	O
CC	1	O
and	0	O
CIEC	0	O
and	0	O
that	0	O
attacks	0	O
of	0	O
biliary	0	O
fever	0	O
and	0	O
high	0	O
levels	0	O
of	0	O
alkaline	0	B
phosphatase	0	I
and	0	O
transaminases	0	O
in	0	O
the	0	O
serum	0	O
are	0	O
the	0	O
helpful	0	O
findings	0	O
for	0	O
preoperative	0	O
diagnosis	0	O
.	0	O


Vibrio	1	O
cholerae	0	O
O139	0	O
in	0	O
Calcutta	0	O
.	0	O


Reaction	1	O
time	0	O
(	0	O
RT	1	O
)	0	O
and	0	O
P300	0	O
were	0	O
collected	0	O
simultaneously	0	O
.	0	O


A	1	O
concentration	0	O
of	0	O
12	0	O
.	0	O
5	0	O
ppm	0	O
SO2	0	O
induced	0	O
a	0	O
decrease	0	O
from	0	O
baseline	0	O
values	0	O
of	0	O
approximately	0	O
80	0	O
%	0	O
in	0	O
mean	0	O
MCA	1	O
and	0	O
of	0	O
roughly	0	O
70	0	O
%	0	O
in	0	O
mean	0	O
CBF	1	O
.	0	O


OBJECTIVE	1	O
:	0	O
To	1	O
evaluate	0	O
the	0	O
overall	0	O
performance	0	O
of	0	O
a	0	O
new	0	O
oscillometric	0	O
wrist	0	O
blood	0	O
pressure	0	O
monitor	0	O
(	0	O
Braun	0	O
PrecisionSensor	0	O
,	0	O
Braun	0	O
GmbH	0	O
,	0	O
Kronberg	0	O
,	0	O
Germany	0	O
)	0	O
as	0	O
defined	0	O
by	0	O
the	0	O
ANSI	1	O
/	0	O
AAMI	1	O
SP10	0	O
-	0	O
1992	0	O
guidelines	0	O
,	0	O
and	0	O
to	0	O
analyze	0	O
the	0	O
data	0	O
for	0	O
the	0	O
optimized	0	O
selection	0	O
of	0	O
the	0	O
algorithm	0	O
that	0	O
derives	0	O
the	0	O
blood	0	O
pressure	0	O
values	0	O
from	0	O
the	0	O
oscillometric	0	O
blood	0	O
pressure	0	O
curves	0	O
.	0	O


Further	0	O
,	0	O
we	0	O
show	0	O
that	0	O
this	0	O
EIA	1	B
-	0	O
inducible	0	O
CBF	1	O
/	0	O
cdc2	0	B
is	0	O
related	0	O
to	0	O
the	0	O
CBF	1	B
which	0	O
was	0	O
shown	0	O
to	0	O
activate	0	O
the	0	O
heat	0	B
shock	0	I
protein	0	I
70	0	I
promoter	0	I
.	0	O


Martin	0	O
Luther	0	O
and	0	O
his	0	O
physicians	0	O
.	0	O


Syndromes	0	O
of	0	O
abnormal	0	O
fat	0	O
redistribution	0	O
and	0	O
metabolic	0	O
complications	0	O
in	0	O
HIV	1	O
-	0	O
infected	0	O
patients	0	O
.	0	O


Macroscopic	1	O
researches	0	O
on	0	O
heart	0	O
vascularization	0	O
have	0	O
indicated	0	O
that	0	O
the	0	O
angioarchitecture	0	O
of	0	O
the	0	O
conducting	0	O
system	0	O
differs	0	O
from	0	O
that	0	O
of	0	O
the	0	O
normal	0	O
myocardium	0	O
.	0	O


This	0	O
sensitivity	0	O
analysis	0	O
showed	0	O
that	0	O
the	0	O
practical	0	O
limits	0	O
of	0	O
the	0	O
accuracy	0	O
of	0	O
the	0	O
used	0	O
screening	0	O
test	0	O
jeopardize	0	O
the	0	O
estimation	0	O
of	0	O
the	0	O
true	0	O
herd	0	O
prevalence	0	O
within	0	O
reasonable	0	O
confidence	0	O
limits	0	O
,	0	O
because	0	O
the	0	O
within	0	O
-	0	O
herd	0	O
PTB	0	O
true	0	O
prevalence	0	O
was	0	O
low	0	O
.	0	O
For	0	O
this	0	O
reason	0	O
we	0	O
augmented	0	O
the	0	O
herd	0	O
specificity	0	O
for	0	O
herds	0	O
with	0	O
larger	0	O
adult	0	O
herd	0	O
size	0	O
(>	0	O
5	0	O
).	0	O


During	0	O
V	1	O
-	0	O
A	1	O
bypass	0	O
,	0	O
hemodynamics	0	O
were	0	O
stable	0	O
.	0	O


Female	1	O
subjects	0	O
,	0	O
including	0	O
both	0	O
normal	0	O
subjects	0	O
and	0	O
idiopathic	0	O
calcium	0	O
stone	0	O
-	0	O
formers	0	O
,	0	O
have	0	O
higher	0	O
urinary	0	O
cyclic	0	O
AMP	1	O
levels	0	O
than	0	O
their	0	O
male	0	O
counterparts	0	O
,	0	O
and	0	O
this	0	O
difference	0	O
is	0	O
significant	0	O
when	0	O
urinary	0	O
cyclic	0	O
AMP	1	O
is	0	O
expressed	0	O
in	0	O
the	0	O
units	0	O
mumol	0	O
/	0	O
g	0	O
of	0	O
creatinine	0	O
.	0	O


Future	0	O
analysis	0	O
of	0	O
long	0	O
-	0	O
term	0	O
outcome	0	O
measures	0	O
of	0	O
performance	0	O
with	0	O
the	0	O
implant	0	O
will	0	O
confirm	0	O
or	0	O
dispute	0	O
the	0	O
benefit	0	O
of	0	O
ear	0	O
selection	0	O
using	0	O
the	0	O
Prom	1	O
-	0	O
EABR	0	O
.	0	O


Prediction	1	O
of	0	O
the	0	O
times	0	O
of	0	O
sandfly	0	O
development	0	O


Exposure	1	O
to	0	O
higher	0	O
TPA	1	O
concentrations	0	O
decreased	0	O
the	0	O
content	0	O
of	0	O
these	0	O
transcripts	0	O
.	0	O


Re	1	O
:	0	O
A	1	O
modified	0	O
method	0	O
for	0	O
the	0	O
in	0	O
vivo	0	O
labeling	0	O
of	0	O
red	0	O
blood	0	O
cells	0	O
with	0	O
Tc	1	O
-	0	O
99m	0	O
.	0	O


We	0	O
had	0	O
previously	0	O
analyzed	0	O
repair	0	O
rates	0	O
of	0	O
cyclobutane	0	O
pyrimidine	0	O
dimers	0	O
at	0	O
nucleotide	0	O
resolution	0	O
along	0	O
the	0	O
human	0	B
JUN	1	I
gene	0	I
in	0	O
normal	0	O
fibroblasts	0	O
and	0	O
found	0	O
very	0	O
efficient	0	O
repair	0	O
of	0	O
sequences	0	O
near	0	O
the	0	O
transcription	0	O
initiation	0	O
site	0	O
but	0	O
slow	0	O
repair	0	O
along	0	O
the	0	O
promoter	0	O
.	0	O


Following	1	O
intravenous	0	O
administration	0	O
,	0	O
the	0	O
myocardial	0	O
concentration	0	O
of	0	O
tracer	0	O
thallium	0	O
-	0	O
201	0	O
,	0	O
potassium	0	O
-	0	O
43	0	O
,	0	O
and	0	O
rubidium	0	O
-	0	O
81	0	O
were	0	O
determined	0	O
in	0	O
mice	0	O
;	0	O
thallium	0	O
was	0	O
present	0	O
in	0	O
the	0	O
greatest	0	O
concentration	0	O
in	0	O
the	0	O
myocardium	0	O
(	0	O
2	0	O
.	0	O
08	0	O
%	0	O
compared	0	O
1	0	O
.	0	O
25	0	O
%	0	O
for	0	O
potassium	0	O
and	0	O
1	0	O
.	0	O
15	0	O
%	0	O
for	0	O
rubidium	0	O
at	0	O
10	0	O
minutes	0	O
).	0	O


Despite	0	O
continuous	0	O
compliance	0	O
,	0	O
unexplained	0	O
resurgence	0	O
of	0	O
serum	0	O
ferritin	0	B
levels	0	O
occurred	0	O
in	0	O
4	0	O
/	0	O
7	0	O
patients	0	O
of	0	O
the	0	O
'	0	O
veteran	0	O
'	0	O
group	0	O
after	0	O
4	0	O
-	0	O
5	0	O
years	0	O
on	0	O
L1	0	O
.	0	O


As	1	O
a	0	O
sequence	0	O
-	0	O
specific	0	O
DNA	1	O
binding	0	O
transcription	0	O
factor	0	O
,	0	O
p53	0	B
specifically	0	O
binds	0	O
to	0	O
a	0	O
20	0	O
-	0	O
bp	0	O
consensus	0	O
motif	0	O
5	0	O
'-	0	O
PuPuPuC	0	O
(	0	O
A	1	O
/	0	O
T	1	O
)	0	O
(	0	O
T	1	O
/	0	O
A	1	O
)	0	O
GPyPyPyPuPuPuC	0	O
(	0	O
A	1	O
/	0	O
T	1	O
)(	0	O
T	1	O
/	0	O
A	1	O
)	0	O
GPyPyPy	0	O
-	0	O
3	0	O
'.	0	O


In	1	O
addition	0	O
,	0	O
and	0	O
in	0	O
support	0	O
of	0	O
a	0	O
mediating	0	O
role	0	O
of	0	O
STATs	0	B
in	0	O
the	0	O
activation	0	O
of	0	O
the	0	O
p21	0	B
promoter	0	I
,	0	O
overexpression	0	O
of	0	O
Stat3	0	B
potentiated	0	O
the	0	O
cytokine	0	O
effect	0	O
on	0	O
the	0	O
p21	0	B
promoter	0	I
;	0	O
whereas	0	O
a	0	O
dominant	0	B
negative	0	I
Stat3	0	I
,	0	O
or	0	O
a	0	O
mutation	0	O
of	0	O
the	0	O
STAT	1	B
response	0	I
element	0	I
on	0	O
the	0	O
promoter	0	O
,	0	O
significantly	0	O
reduced	0	O
the	0	O
cytokine	0	O
effect	0	O
.	0	O


Role	1	O
of	0	O
the	0	O
transcription	0	O
start	0	O
site	0	O
core	0	O
region	0	O
and	0	O
transcription	0	B
factor	0	I
YY1	0	I
in	0	O
Rous	0	B
sarcoma	0	I
virus	0	I
long	0	I
terminal	0	I
repeat	0	I
promoter	0	I
activity	0	O
.	0	O


Detection	1	O
of	0	O
hemophilia	0	O
A	1	O
carriers	0	O
.	0	O


An	1	O
alternatively	0	O
spliced	0	O
MAdCAM	0	B
-	0	I
1	0	I
variant	0	O
was	0	O
identified	0	O
that	0	O
lacks	0	O
exon	0	O
4	0	O
encoding	0	O
the	0	O
mucin	0	B
domain	0	O
,	0	O
and	0	O
may	0	O
mediate	0	O
leukocyte	0	O
adhesion	0	O
to	0	O
LPAM	0	B
-	0	I
1	0	I
without	0	O
adhesion	0	O
to	0	O
the	0	O
alternate	0	O
receptor	0	O
,	0	O
L	1	B
-	0	I
selectin	0	I
.	0	O


Subcloning	0	O
of	0	O
DNA	1	O
fragments	0	O
from	0	O
the	0	O
8	0	O
.	0	O
5	0	O
-	0	O
kilobase	0	O
(	0	O
kb	0	O
)	0	O
insert	0	O
of	0	O
pAVO4	0	O
defined	0	O
a	0	O
4	0	O
-	0	O
kb	0	O
DNA	1	O
fragment	0	O
which	0	O
contained	0	O
the	0	O
functional	0	B
FBP	0	I
+	0	I
gene	0	I
and	0	O
its	0	O
regulatory	0	O
region	0	O
.	0	O


All	1	O
ribosomal	0	B
protein	0	I
(	0	O
rp	0	B
)	0	O
gene	0	O
promoters	0	O
from	0	O
Saccharomyces	1	O
cerevisiae	0	O
studied	0	O
so	0	O
far	0	O
contain	0	O
either	0	O
(	0	O
usually	0	O
two	0	O
)	0	O
binding	0	O
sites	0	O
for	0	O
the	0	O
global	0	O
gene	0	O
regulator	0	O
Rap1p	0	B
or	0	O
one	0	O
binding	0	O
site	0	O
for	0	O
another	0	O
global	0	O
factor	0	O
,	0	O
Abf1p	0	B
.	0	O


The	0	O
concentrations	0	O
of	0	O
apo	0	B
A	1	I
-	0	I
I	1	I
and	0	O
apo	0	B
A	1	I
-	0	I
II	0	I
of	0	O
abstainers	0	O
decreased	0	O
significantly	0	O
compared	0	O
with	0	O
the	0	O
corresponding	0	O
changes	0	O
in	0	O
controls	0	O
.	0	O


Leukocyte	1	O
cultures	0	O
,	0	O
prepared	0	O
from	0	O
blood	0	O
drawn	0	O
from	0	O
these	0	O
18	0	O
children	0	O
at	0	O
6	0	O
months	0	O
of	0	O
age	0	O
,	0	O
produced	0	O
lower	0	O
yields	0	O
of	0	O
IFN	1	B
than	0	O
those	0	O
of	0	O
the	0	O
remaining	0	O
53	0	O
children	0	O
,	0	O
when	0	O
stimulated	0	O
with	0	O
adenovirus	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
),	0	O
coronavirus	0	O
(	0	O
P	1	O
<	0	O
0	0	O
.	0	O
001	0	O
)	0	O
or	0	O
rhinovirus	0	O
(	0	O
P	1	O
=	0	O
0	0	O
.	0	O
002	0	O
).	0	O


Tobramycin	1	O
60	0	O
mg	0	O
did	0	O
not	0	O
show	0	O
any	0	O
remarkable	0	O
effect	0	O
,	0	O
but	0	O
dibecacin	0	O
100	0	O
mg	0	O
produced	0	O
a	0	O
slight	0	O
potentiating	0	O
effect	0	O
on	0	O
the	0	O
action	0	O
of	0	O
d	0	O
-	0	O
tubocurarine	0	O
.	0	O


Diagnosis	1	O
of	0	O
phenylalanine	0	B
hydroxylase	0	I
deficiency	0	O
(	0	O
phenylketonuria	0	O
).	0	O


We	0	O
have	0	O
cloned	0	O
a	0	O
kinase	0	O
,	0	O
Nlk	0	B
,	0	O
that	0	O
is	0	O
a	0	O
murine	0	B
homolog	0	I
of	0	I
the	0	I
Drosophila	1	I
nemo	0	I
(	0	O
nmo	0	B
)	0	O
gene	0	O
.	0	O


Summers	0	O
,	0	O
Virology	1	O
89	0	O
:	0	O
517	0	O
-	0	O
527	0	O
,	0	O
1978	0	O
).	0	O


A	1	O
comparison	0	O
of	0	O
the	0	O
nucleotide	0	O
sequence	0	O
of	0	O
the	0	O
p54	0	B
gene	0	I
carried	0	O
by	0	O
two	0	O
virulent	0	O
ASFV	0	O
strains	0	O
(	0	O
E70	0	O
and	0	O
E75	0	O
)	0	O
with	0	O
that	0	O
obtained	0	O
from	0	O
virus	0	O
Ba71V	0	O
showed	0	O
100	0	O
%	0	O
similarity	0	O
.	0	O


A	1	O
single	0	O
case	0	O
of	0	O
an	0	O
adenocarcinoma	0	O
,	0	O
arising	0	O
in	0	O
a	0	O
retroperitoneal	0	O
enterogenous	0	O
cyst	0	O
and	0	O
which	0	O
presented	0	O
as	0	O
a	0	O
left	0	O
renal	0	O
cyst	0	O
,	0	O
is	0	O
reported	0	O
.	0	O


V	1	O
.	0	O


The	0	O
low	0	O
number	0	O
of	0	O
false	0	O
positives	0	O
indicates	0	O
that	0	O
our	0	O
scheme	0	O
would	0	O
not	0	O
confuse	0	O
the	0	O
radiologist	0	O
by	0	O
suggesting	0	O
normal	0	O
regions	0	O
as	0	O
suspicious	0	O
.	0	O


Insulin	1	B
-	0	I
like	0	I
growth	0	I
factor	0	I
1	0	I
(	0	O
IGF	1	B
-	0	I
1	0	I
)	0	O
in	0	O
burn	0	O
patients	0	O
.	0	O


The	0	O
results	0	O
also	0	O
imply	0	O
that	0	O
the	0	O
absence	0	O
of	0	O
perforin	0	B
expression	0	O
in	0	O
non	0	O
-	0	O
cytotoxic	0	O
cells	0	O
may	0	O
be	0	O
due	0	O
to	0	O
the	0	O
suppression	0	O
of	0	O
the	0	O
induction	0	O
of	0	O
the	0	O
killer	0	O
-	0	O
cell	0	O
-	0	O
specific	0	O
trans	0	O
-	0	O
acting	0	O
factor	0	O
NF	1	B
-	0	I
P2	1	I
.	0	O


Gel	1	O
mobility	0	O
shift	0	O
and	0	O
super	0	O
-	0	O
shift	0	O
assays	0	O
using	0	O
liver	0	O
nuclear	0	O
extracts	0	O
from	0	O
either	0	O
rat	0	O
liver	0	O
or	0	O
DDT1MF	0	O
-	0	O
2	0	O
cells	0	O
demonstrated	0	O
that	0	O
the	0	O
CRE	0	O
in	0	O
the	0	O
alpha	0	B
1B	0	I
-	0	I
AR	1	I
gene	0	I
bound	0	O
CRE	0	B
binding	0	I
protein	0	I
.	0	O


Factors	0	O
that	0	O
showed	0	O
significant	0	O
correlation	0	O
to	0	O
elevated	0	O
CIC	0	O
'	0	O
s	0	O
in	0	O
the	0	O
highly	0	O
elevated	0	O
portion	0	O
of	0	O
our	0	O
CIC	0	O
population	0	O
were	0	O
poor	0	O
NIH	1	O
score	0	O
,	0	O
increased	0	O
patient	0	O
age	0	O
,	0	O
low	0	O
peak	0	O
expiratory	0	O
flow	0	O
rate	0	O
,	0	O
and	0	O
elevated	0	O
total	0	O
serum	0	B
IgG	1	I
.	0	O


Plasma	1	O
fibrinogen	0	B
was	0	O
measured	0	O
by	0	O
the	0	O
turbidimetric	0	O
method	0	O
in	0	O
timol	0	O
turbidimetric	0	O
units	0	O
.	0	O


The	0	O
significance	0	O
of	0	O
the	0	O
phenolphthalein	0	B
sulphatase	0	I
test	0	O
for	0	O
the	0	O
differentiation	0	O
and	0	O
identification	0	O
of	0	O
Nocardia	1	O
species	0	O
.	0	O


NF	1	B
-	0	I
kappaB	0	I
plays	0	O
a	0	O
critical	0	O
role	0	O
in	0	O
activation	0	O
of	0	O
HIV	1	O
-	0	O
1	0	O
gene	0	O
expression	0	O
by	0	O
cytokines	0	O
and	0	O
other	0	O
stimuli	0	O
,	0	O
but	0	O
the	0	O
signal	0	O
transduction	0	O
pathways	0	O
that	0	O
regulate	0	O
the	0	O
switch	0	O
from	0	O
latent	0	O
to	0	O
productive	0	O
infection	0	O
have	0	O
not	0	O
been	0	O
defined	0	O
.	0	O


The	0	O
German	0	O
Society	0	O
of	0	O
Pediatric	1	O
Oncology	1	O
in	0	O
1981	0	O
initiated	0	O
the	0	O
Cooperative	0	O
Ewing	0	O
'	0	O
s	0	O
Sarcoma	1	O
Study	1	O
(	0	O
CESS	0	O
81	0	O
)	0	O
using	0	O
a	0	O
four	0	O
-	0	O
drug	0	O
combination	0	O
of	0	O
chemotherapy	0	O
prior	0	O
to	0	O
definitive	0	O
local	0	O
control	0	O
with	0	O
surgery	0	O
and	0	O
/	0	O
or	0	O
radiation	0	O
.	0	O


Finally	0	O
,	0	O
three	0	O
new	0	O
missense	0	O
mutations	0	O
,	0	O
E138V	0	O
,	0	O
R254G	0	O
,	0	O
and	0	O
P362R	0	O
,	0	O
were	0	O
identified	0	O
in	0	O
the	0	O
human	0	B
AC	1	I
gene	0	I
from	0	O
FD	1	O
patients	0	O
.	0	O


We	0	O
propose	0	O
that	0	O
the	0	O
technique	0	O
of	0	O
low	0	O
-	0	O
frequency	0	O
kindling	0	O
is	0	O
a	0	O
useful	0	O
experimental	0	O
model	0	O
in	0	O
assessing	0	O
the	0	O
effects	0	O
of	0	O
antipsychotic	0	O
or	0	O
antiepileptic	0	O
drugs	0	O
on	0	O
the	0	O
excitability	0	O
of	0	O
the	0	O
limbic	0	O
regions	0	O
.	0	O


The	0	O
antibody	0	O
titer	0	O
of	0	O
202	0	O
chickens	0	O
to	0	O
SA	1	O
-	0	O
11	0	O
rotavirus	0	O
was	0	O
determined	0	O
by	0	O
enzyme	0	O
-	0	O
linked	0	O
immunosorbent	0	O
blocking	0	O
assay	0	O
.	0	O


The	0	O
level	0	O
of	0	O
subclinical	0	O
infection	0	O
was	0	O
75	0	O
%	0	O
among	0	O
seropositive	0	O
dogs	0	O
.	0	O


The	0	O
mean	0	O
serum	0	O
creatinine	0	O
levels	0	O
were	0	O
similar	0	O
at	0	O
one	0	O
year	0	O
(	0	O
SPK	0	O
1	0	O
.	0	O
8	0	O
,	0	O
KTA	0	O
1	0	O
.	0	O
9	0	O
mg	0	O
/	0	O
d	0	O
).(	0	O
ABSTRACT	1	O
TRUNCATED	0	O
AT	1	O
250	0	O
WORDS	0	O
)	0	O


The	0	O
ability	0	O
of	0	O
A20	0	B
to	0	O
block	0	O
NF	1	B
-	0	I
kappaB	0	I
activation	0	O
was	0	O
mapped	0	O
to	0	O
its	0	O
C	1	O
-	0	O
terminal	0	O
zinc	0	O
finger	0	O
domain	0	O
.	0	O


Hodgkin	0	O
'	0	O
s	0	O
disease	0	O
.	0	O


The	0	O
enhancer	0	O
region	0	O
of	0	O
Akv	0	O
murine	0	O
leukemia	0	O
virus	0	O
contains	0	O
the	0	O
sequence	0	O
motif	0	O
ACAGATGG	0	O
.	0	O


BIM	0	O
130	0	O
.	0	O


Comparison	0	O
was	0	O
made	0	O
with	0	O
other	0	O
neuroradiological	0	O
imaging	0	O
modalities	0	O
including	0	O
CT	1	O
,	0	O
myelography	0	O
,	0	O
CT	1	O
ventriculography	0	O
,	0	O
and	0	O
CT	1	O
myelocisternography	0	O
.	0	O


DNA	1	O
sequence	0	O
analysis	0	O
reveals	0	O
that	0	O
the	0	O
gene	0	O
encodes	0	O
a	0	O
protein	0	O
highly	0	O
homologous	0	O
to	0	O
rat	0	B
CRP1	0	I
.	0	O


Analysis	1	O
of	0	O
chromosomal	0	O
DNA	1	O
sequence	0	O
immediately	0	O
downstream	0	O
of	0	O
the	0	O
transposon	0	O
insertion	0	O
identified	0	O
two	0	O
open	0	O
reading	0	O
frames	0	O
,	0	O
designated	0	O
csrR	0	B
and	0	O
csrS	0	B
,	0	O
which	0	O
exhibited	0	O
sequence	0	O
similarity	0	O
to	0	O
bacterial	0	O
two	0	O
-	0	O
component	0	O
regulatory	0	O
systems	0	O
.	0	O


The	0	O
rational	0	O
for	0	O
the	0	O
prophylactic	0	O
treatment	0	O
,	0	O
the	0	O
therapy	0	O
of	0	O
the	0	O
meningopathy	0	O
and	0	O
AIL	0	O
-	0	O
AIEOP	0	O
protocols	0	O
are	0	O
exposed	0	O
.	0	O


The	0	O
operation	0	O
recommended	0	O
is	0	O
excision	0	O
of	0	O
3	0	O
mm	0	O
of	0	O
central	0	O
slip	0	O
followed	0	O
by	0	O
end	0	O
-	0	O
to	0	O
-	0	O
end	0	O
repair	0	O
of	0	O
the	0	O
tendon	0	O
.	0	O


The	0	O
priming	0	O
activity	0	O
of	0	O
DNA	1	O
incised	0	O
by	0	O
either	0	O
of	0	O
the	0	O
Drosophila	1	O
enzymes	0	O
can	0	O
be	0	O
enhanced	0	O
,	0	O
however	0	O
,	0	O
by	0	O
an	0	O
additional	0	O
incubation	0	O
with	0	O
E	1	B
.	0	I
coli	0	I
endonuclease	0	I
IV	1	I
,	0	O
which	0	O
is	0	O
known	0	O
to	0	O
cleave	0	O
depurinated	0	O
DNA	1	O
on	0	O
the	0	O
5	0	O
'-	0	O
side	0	O
of	0	O
an	0	O
apurinic	0	O
site	0	O
.	0	O


The	0	O
PEPCK	0	B
promoter	0	O
fragment	0	O
was	0	O
introduced	0	O
either	0	O
in	0	O
the	0	O
proper	0	O
orientation	0	O
for	0	O
transcription	0	O
of	0	O
the	0	O
TK	1	B
gene	0	I
or	0	O
in	0	O
the	0	O
opposite	0	O
orientation	0	O
.	0	O


The	0	O
main	0	O
issues	0	O
are	0	O
the	0	O
need	0	O
to	0	O
explain	0	O
a	0	O
number	0	O
of	0	O
still	0	O
unknown	0	O
mechanisms	0	O
,	0	O
to	0	O
determine	0	O
which	0	O
"	0	O
natural	0	O
diet	0	O
"	0	O
carries	0	O
the	0	O
minimum	0	O
coronary	0	O
risk	0	O
and	0	O
whether	0	O
"	0	O
new	0	O
"	0	O
foods	0	O
produced	0	O
by	0	O
modern	0	O
technology	0	O
are	0	O
really	0	O
needed	0	O
to	0	O
contrast	0	O
this	0	O
epidemic	0	O
.	0	O


A	1	O
new	0	O
physiopathological	0	O
treatment	0	O
of	0	O
HBV	1	O
-	0	O
related	0	O
polyarteritis	0	O
inspired	0	O
by	0	O
advances	0	O
in	0	O
the	0	O
treatment	0	O
of	0	O
chronic	0	O
active	0	O
hepatitis	0	O
B	1	O
was	0	O
tested	0	O
in	0	O
7	0	O
patients	0	O
.	0	O


In	1	O
vitro	0	O
translation	0	O
of	0	O
RNA	1	O
synthesized	0	O
from	0	O
the	0	O
cloned	0	O
cDNAs	0	O
predicts	0	O
that	0	O
P0	0	B
transcripts	0	I
are	0	O
translated	0	O
into	0	O
a	0	O
novel	0	O
12	0	O
.	0	O
5	0	O
-	0	O
kilodalton	0	O
protein	0	O
corresponding	0	O
to	0	O
the	0	O
first	0	O
open	0	O
reading	0	O
frame	0	O
.	0	O


Molecular	1	O
cloning	0	O
and	0	O
expression	0	O
of	0	O
human	0	B
UDP	1	I
-	0	I
d	0	I
-	0	I
Xylose	1	I
:	0	I
proteoglycan	0	I
core	0	I
protein	0	I
beta	0	I
-	0	I
d	0	I
-	0	I
xylosyltransferase	0	I
and	0	O
its	0	O
first	0	O
isoform	0	B
XT	0	I
-	0	I
II	0	I
.	0	O


In	1	O
contrast	0	O
,	0	O
c	0	B
-	0	I
Src	1	I
activated	0	O
by	0	O
isoproterenol	0	O
led	0	O
to	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
Shc	0	B
and	0	O
subsequent	0	O
Erk	0	B
activation	0	O
,	0	O
but	0	O
not	0	O
tyrosine	0	O
phosphorylation	0	O
of	0	O
cortactin	0	B
or	0	O
Stat3	0	B
.	0	O


Airflow	1	O
through	0	O
the	0	O
dust	0	O
trap	0	O
was	0	O
controlled	0	O
with	0	O
a	0	O
vacuum	0	O
pump	0	O
.	0	O


Reverse	0	O
transcription	0	O
-	0	O
PCR	1	O
was	0	O
then	0	O
used	0	O
to	0	O
clone	0	O
from	0	O
human	0	O
poly	0	O
(	0	O
A	1	O
)+	0	O
RNA	1	O
the	0	O
cDNA	1	O
corresponding	0	O
to	0	O
the	0	O
expressed	0	O
homolog	0	O
of	0	O
psi	0	B
ARF	1	I
4	0	I
,	0	O
referred	0	O
to	0	O
as	0	O
human	0	B
ARF	1	I
4	0	I
.	0	O


Expression	1	O
of	0	O
the	0	O
CYP11A1	0	B
gene	0	I
is	0	O
increased	0	O
by	0	O
hormones	0	O
,	0	O
such	0	O
as	0	O
adrenocorticotropin	0	B
and	0	O
luteinizing	0	B
hormone	0	I
,	0	O
as	0	O
well	0	O
as	0	O
by	0	O
a	0	O
number	0	O
of	0	O
growth	0	O
factors	0	O
,	0	O
suggesting	0	O
that	0	O
its	0	O
promoter	0	O
may	0	O
contain	0	O
regulatory	0	O
elements	0	O
that	0	O
respond	0	O
to	0	O
multiple	0	O
signal	0	O
transduction	0	O
pathways	0	O
.	0	O


BYV	0	O
,	0	O
citrus	0	O
tristeza	0	O
virus	0	O
(	0	O
CTV	0	O
),	0	O
beet	0	O
yellow	0	O
stunt	0	O
virus	0	O
(	0	O
BYSV	0	O
)	0	O
and	0	O
carnation	0	O
necrotic	0	O
fleck	0	O
virus	0	O
templates	0	O
produced	0	O
1	0	O
kb	0	O
amplification	0	O
products	0	O
,	0	O
which	0	O
were	0	O
shown	0	O
by	0	O
sequencing	0	O
to	0	O
represent	0	O
fragments	0	O
of	0	O
the	0	O
respective	0	O
HSP70	0	B
genes	0	I
.	0	O


The	0	O
purpose	0	O
of	0	O
this	0	O
article	0	O
is	0	O
to	0	O
discuss	0	O
the	0	O
factors	0	O
involved	0	O
in	0	O
the	0	O
selection	0	O
of	0	O
antibodies	0	O
,	0	O
radionuclides	0	O
and	0	O
labeling	0	O
methods	0	O
in	0	O
the	0	O
development	0	O
of	0	O
radioimmunotherapy	0	O
(	0	O
RIT	0	O
)	0	O
for	0	O
non	0	O
-	0	O
Hodgkin	0	O
'	0	O
s	0	O
lymphoma	0	O
(	0	O
NHL	1	O
)	0	O
from	0	O
a	0	O
single	0	O
clinical	0	O
study	0	O
site	0	O
through	0	O
multicenter	0	O
trials	0	O
and	0	O
commercialization	0	O
.	0	O


Lymphatics	0	O
in	0	O
the	0	O
aorta	0	O
of	0	O
rats	0	O
treated	0	O
with	0	O
a	0	O
soy	0	O
-	0	O
bean	0	O
oil	0	O
extract	0	O
(	0	O
lipofundin	0	O
).	0	O


There	0	O
was	0	O
no	0	O
further	0	O
increase	0	O
in	0	O
oxygen	0	O
consumption	0	O
when	0	O
these	0	O
subjects	0	O
breathed	0	O
with	0	O
inspiratory	0	O
pressures	0	O
above	0	O
SIP	1	O
.	0	O


Foreign	1	O
profiles	0	O
in	0	O
air	0	O
pollution	0	O
control	0	O
activities	0	O
.	0	O


Hybrid	1	O
-	0	O
selection	0	O
experiments	0	O
against	0	O
total	0	O
PB	1	O
-	0	O
inducible	0	O
RNA	1	O
were	0	O
performed	0	O
with	0	O
plasmid	0	O
DNA	1	O
derived	0	O
from	0	O
clones	0	O
enriched	0	O
in	0	O
PB	1	O
-	0	O
inducible	0	O
information	0	O
.	0	O


The	0	O
micturition	0	O
pressure	0	O
was	0	O
significantly	0	O
decreased	0	O
only	0	O
after	0	O
injection	0	O
with	0	O
BUP	0	O
-	0	O
4	0	O
in	0	O
both	0	O
normal	0	O
and	0	O
obstructed	0	O
rats	0	O
.	0	O


All	1	O
pigs	0	O
had	0	O
significant	0	O
regional	0	O
LV	1	O
dysfunction	0	O
and	0	O
reduced	0	O
LV	1	O
ejection	0	O
fraction	0	O
(	0	O
41	0	O
+/-	0	O
11	0	O
%).	0	O


Primer	1	O
extension	0	O
experiments	0	O
revealed	0	O
a	0	O
strong	0	O
transcription	0	O
initiation	0	O
site	0	O
102	0	O
bp	0	O
upstream	0	O
of	0	O
the	0	O
translational	0	O
start	0	O
site	0	O
.	0	O


This	0	O
mutation	0	O
no	0	O
longer	0	O
repressed	0	O
the	0	O
HPV	1	O
-	0	O
11	0	O
upstream	0	O
regulatory	0	O
region	0	O
-	0	O
controlled	0	O
reporter	0	O
expression	0	O
.	0	O


There	0	O
are	0	O
no	0	O
introns	0	O
within	0	O
the	0	O
gene	0	O
,	0	O
which	0	O
contains	0	O
a	0	O
9360	0	O
-	0	O
bp	0	O
open	0	O
reading	0	O
frame	0	O
and	0	O
encodes	0	O
a	0	O
377	0	O
-	0	O
kDa	1	O
protein	0	O
.	0	O


T	1	O
.,	0	O
Mahasneh	0	O
,	0	O
A	1	O
.,	0	O
and	0	O
Cote	0	O
,	0	O
G	1	O
.	0	O


Previous	0	O
transactivation	0	O
experiments	0	O
indicated	0	O
that	0	O
three	0	O
amino	0	O
acids	0	O
residing	0	O
in	0	O
this	0	O
region	0	O
,	0	O
Gly	1	O
,	0	O
Ser	1	O
and	0	O
Val	1	O
,	0	O
appear	0	O
to	0	O
be	0	O
critical	0	O
for	0	O
target	0	O
-	0	O
site	0	O
discrimination	0	O
.	0	O


RESULTS	0	O
:	0	O
CK	1	B
-	0	O
MB	1	B
elevation	0	O
was	0	O
detected	0	O
in	0	O
313	0	O
patients	0	O
(	0	O
18	0	O
.	0	O
7	0	O
%),	0	O
with	0	O
1	0	O
-	0	O
3x	0	O
in	0	O
12	0	O
.	0	O
8	0	O
%,	0	O
3	0	O
-	0	O
5x	0	O
in	0	O
3	0	O
.	0	O
5	0	O
%	0	O
and	0	O
>	0	O
5x	0	O
normal	0	O
in	0	O
2	0	O
.	0	O
4	0	O
%	0	O
of	0	O
patients	0	O
.	0	O


Chem	0	O
.	0	O


A	1	O
short	0	O
open	0	O
reading	0	O
frame	0	O
(	0	O
ORF2	0	O
),	0	O
of	0	O
unknown	0	O
function	0	O
,	0	O
is	0	O
present	0	O
in	0	O
all	0	O
FIV	1	O
isolates	0	O
.	0	O


Thus	0	O
,	0	O
the	0	O
characterization	0	O
of	0	O
the	0	O
promoter	0	O
region	0	O
should	0	O
help	0	O
to	0	O
define	0	O
regulatory	0	O
elements	0	O
that	0	O
control	0	O
neuron	0	O
-	0	O
specific	0	O
and	0	O
developmental	0	O
expression	0	O
of	0	O
the	0	O
MAP1B	0	B
gene	0	I
.	0	O


In	1	O
vitro	0	O
precipitation	0	O
with	0	O
a	0	O
glutathione	0	B
-	0	I
S	1	I
-	0	I
transferase	0	I
-	0	I
fusion	0	I
protein	0	I
containing	0	O
the	0	O
C	1	O
-	0	O
terminal	0	O
transactivation	0	O
domain	0	O
of	0	O
STAT5a	0	B
showed	0	O
GH	1	B
-	0	O
regulated	0	O
association	0	O
of	0	O
ERK1	0	B
/	0	I
2	0	I
with	0	O
the	0	O
fusion	0	O
protein	0	O
,	0	O
while	0	O
this	0	O
was	0	O
not	0	O
seen	0	O
when	0	O
serine	0	O
780	0	O
in	0	O
STAT5a	0	B
was	0	O
changed	0	O
to	0	O
alanine	0	O
.	0	O


The	0	O
assembly	0	O
of	0	O
sequence	0	O
ready	0	O
,	0	O
high	0	O
-	0	O
resolution	0	O
physical	0	O
maps	0	O
and	0	O
construction	0	O
of	0	O
minimally	0	O
overlapping	0	O
contigs	0	O
for	0	O
the	0	O
human	0	O
as	0	O
well	0	O
as	0	O
model	0	O
genomes	0	O
requires	0	O
accurate	0	O
determination	0	O
of	0	O
the	0	O
extent	0	O
of	0	O
overlap	0	O
between	0	O
adjacent	0	O
clones	0	O
as	0	O
well	0	O
as	0	O
their	0	O
relative	0	O
orientation	0	O
.	0	O


As	1	O
in	0	O
the	0	O
other	0	O
three	0	O
members	0	O
whose	0	O
gene	0	O
expression	0	O
is	0	O
altered	0	O
during	0	O
tumorigenesis	0	O
,	0	O
PI12	0	B
expression	0	O
was	0	O
found	0	O
to	0	O
be	0	O
down	0	O
-	0	O
regulated	0	O
in	0	O
tumor	0	O
brain	0	O
tissues	0	O
and	0	O
in	0	O
two	0	O
brain	0	O
cancer	0	O
cell	0	O
lines	0	O
:	0	O
U	1	O
-	0	O
87	0	O
MG	1	O
and	0	O
H4	0	O
.	0	O


Isomers	0	O
were	0	O
differentiated	0	O
based	0	O
on	0	O
the	0	O
MS	1	O
-	0	O
MS	1	O
data	0	O
of	0	O
the	0	O
trofluoroacetyl	0	O
-	0	O
biphenylol	0	O
derivatives	0	O
.	0	O


Mutations	0	O
within	0	O
the	0	O
C	1	O
terminus	0	O
of	0	O
c	0	B
-	0	I
fos	0	I
at	0	O
serine	0	O
residues	0	O
that	0	O
are	0	O
phosphorylation	0	O
targets	0	O
for	0	O
growth	0	O
factors	0	O
and	0	O
MAP	1	B
kinase	0	I
completely	0	O
abrogate	0	O
transactivation	0	O
and	0	O
block	0	O
potentiation	0	O
by	0	O
MAP	1	B
kinase	0	I
.	0	O


NF	1	B
-	0	I
kappa	0	I
B	1	I
/	0	O
Rel	0	B
transcription	0	O
factors	0	O
participate	0	O
in	0	O
the	0	O
activation	0	O
of	0	O
numerous	0	O
genes	0	O
involved	0	O
in	0	O
immune	0	O
regulation	0	O
/	0	O
inflammation	0	O
including	0	O
cytokines	0	O
,	0	O
cell	0	O
surface	0	O
receptors	0	O
,	0	O
adhesion	0	O
molecules	0	O
,	0	O
and	0	O
acute	0	O
phase	0	O
proteins	0	O
.	0	O


